

APPROVED DRUG PRODUCTS

WITH

**THERAPEUTIC
EQUIVALENCE
EVALUATIONS**

41st EDITION

**THE PRODUCTS IN THIS LIST HAVE BEEN APPROVED UNDER
SECTION 505 OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT.**

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
OFFICE OF MEDICAL PRODUCTS AND TOBACCO
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF GENERIC DRUGS
OFFICE OF GENERIC DRUG POLICY**

2021

APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS

The products in this list have been approved under section 505 of the Federal Food, Drug, and Cosmetic Act. This volume is current through December 31, 2020.

41st EDITION



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
OFFICE OF MEDICAL PRODUCTS AND TOBACCO
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF GENERIC DRUGS
OFFICE OF GENERIC DRUG POLICY

2021

**FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH**

**APPROVED DRUG PRODUCTS
With
Therapeutic Equivalence Evaluations**

CONTENTS

	<i>PAGE</i>
PREFACE TO FORTY FIRST EDITION.....	iv
1.0 INTRODUCTION.....	vi
1.1 Content and Exclusion.....	vi
1.2 Therapeutic Equivalence-Related Terms.....	vii
1.3 Further Guidance on Bioequivalence.....	ix
1.4 Reference Listed Drug and Reference Standard.....	x
1.5 General Policies and Legal Status.....	xi
1.6 Practitioner/User Responsibilities.....	xi
1.7 Therapeutic Equivalence Evaluations Codes.....	xii
1.8 Description of Certain Special Situations.....	xx
1.9 Therapeutic Equivalence Code Change for a Drug Entity.....	xxiii
1.10 Change of the Therapeutic Equivalence Evaluation for a Single Product.....	xxiv
1.11 Discontinued Section.....	xxiv
1.12 Changes to the Orange Book.....	xxiv
1.13 Availability of the Edition.....	xxv
2.0 HOW TO USE THE DRUG PRODUCTS LISTS.....	2-1
2.1 Key Sections for Using the Drug Product Lists.....	2-1
2.2 Drug Product Illustration.....	2-3
2.3 Therapeutic Equivalence Evaluations Illustration.....	2-4
DRUG PRODUCT LISTS	
Prescription Drug Product List.....	3-1
OTC Drug Product List.....	4-1
Drug Products with Approval under Section 505 of the FD&C Act Administered by the Center for Biologics Evaluation and Research List.....	5-1
Discontinued Drug Product List.....	6-1
Orphan Products Designations and Approvals List.....	7-1
Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution.....	8-1
APPENDICES	
A. Product Name Index.....	A-1
B. Product Name Index Listed by Applicant.....	B-1
C. Uniform Terms.....	C-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM.....	AD1
A. Patent and Exclusivity Lists.....	ADA1
B. Patent and Exclusivity Terms.....	ADB1

**FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH**

**APPROVED DRUG PRODUCTS
With
Therapeutic Equivalence Evaluations**

PREFACE TO FORTY FIRST EDITION

The publication, *Approved Drug Products With Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book), identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (the FD&C Act). The main criterion for the inclusion of any product is that the product is the subject of an application with an approval that has not been withdrawn for safety or efficacy reasons. Inclusion of products in the Orange Book is independent of any current regulatory action being taken administratively or judicially against a drug product. In addition, the Orange Book contains therapeutic equivalence evaluations for approved multisource prescription drug products. These evaluations have been prepared to serve as public information and advice to state health agencies, prescribers, and pharmacists to promote public education in the area of drug product selection and to foster containment of health care costs. Therapeutic equivalence evaluations in this publication are not official FDA actions affecting the legal status of products under the FD&C Act.

Background of the Publication. To contain drug costs, virtually every state has adopted laws and/or regulations that encourage the substitution of drug products. These state laws generally require either that substitution be limited to drugs on a specific list (the positive formulary approach) or that it be permitted for all drugs except those prohibited by a particular list (the negative formulary approach). Because of the number of requests in the late 1970s for FDA assistance in preparing both positive and negative formularies, it became apparent that FDA could not serve the needs of each state on an individual basis. The Agency also recognized that providing a single list based on common criteria would be preferable to evaluating drug products on the basis of differing definitions and criteria in various state laws. As a result, on May 31, 1978, the Commissioner of the Food and Drug Administration sent a letter to officials of each state announcing FDA's intent to provide a list of all prescription drug products that are approved by FDA for safety and effectiveness, along with therapeutic equivalence determinations for multisource prescription products.

The Orange Book was distributed as a proposal in January 1979. It included only currently marketed prescription drug products approved by FDA through new drug applications (NDAs) and abbreviated new drug applications (ANDAs) under the provisions of Section 505 of the FD&C Act and FDA regulations at that time.

The therapeutic equivalence evaluations in the Orange Book reflect FDA's application of specific criteria to the multisource prescription drug products listed in the Orange Book and approved under Section 505 of the FD&C Act. These evaluations are presented in the form of code letters that indicate the basis for the evaluation made. An explanation of the codes appears in the *Introduction*.

A complete discussion of the background and basis of FDA's therapeutic equivalence evaluation policy was published in the *Federal Register* on January 12, 1979 (44 FR 2932). The final rule, which includes FDA's responses to the public comments on the proposal, was published in the *Federal Register* on October 31, 1980 (45 FR 72582). The first publication of the Orange Book in October 1980, concurrent with finalization of the rule, incorporated appropriate corrections and additions. Each subsequent edition has included new approvals and made appropriate changes in data.

On September 24, 1984, the President signed into law the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Amendments). The Hatch-Waxman Amendments amended the FD&C Act to establish, among other things, the 505(b)(2) and 505(j) approval pathways. The Hatch-Waxman Amendments require that FDA, among other things, make publicly available a list of approved drug products with monthly supplements. The Orange Book and its monthly Cumulative Supplements satisfy this requirement. The *Addendum* to this publication identifies drugs that have qualified under the FD&C Act for periods of exclusivity and provides patent information concerning the approved drug products in the Orange Book. The *Addendum* also provides additional information that may be helpful to those submitting an NDA under section 505(b) of the FD&C Act or an abbreviated new drug application (ANDA) under section 505(j) of the FD&C Act to the Agency.

The Agency intends to use this publication to further its objective of obtaining input and comment on the publication itself and related Agency procedures. Therefore, if you have comments on how the publication can be improved, please send them to the Central Document Room, Attn: Director, Division of Legal and Regulatory Support, Office of Generic Drug Policy, Center for Drug Evaluation and Research, Food and Drug Administration, 5901-B Ammendale Rd., Beltsville, MD 20705-1266. Comments received are publicly available to the extent allowable under the Freedom of Information Act and FDA regulations.

1.0 INTRODUCTION

1.1 Content and Exclusion

The Orange Book is composed of four parts: (1) approved prescription drug products with therapeutic equivalence evaluations; (2) approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; (3) drug products with approval under Section 505 of the FD&C Act administered by the Center for Biologics Evaluation and Research; and (4) a cumulative list of approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn from sale for safety or effectiveness reasons, or have had their approvals withdrawn for other than safety or efficacy reasons subsequent to being discontinued from marketing.¹ This publication also includes indices of prescription and OTC drug products by proprietary name (brand name or trade name) or, if no proprietary name exists, established name of the active ingredient and by applicant name, which have been abbreviated for this publication. Established names for active ingredients generally conform to compendial names or *United States Adopted Names* (USAN) as described in 21 CFR 299.4(e). A list of uniform terms is provided in Appendix C.

The *Addendum* contains patent and exclusivity information for the Prescription, OTC, Discontinued Drug Product Lists, and for the Drug Products with Approval under Section 505 of the FD&C Act Administered by the Center for Biologics Evaluation and Research. The publication may include additional information that the Agency deems appropriate to disseminate.

Prior to the 6th Edition, the publication had excluded OTC drug products and drug products with approval under Section 505 of the FD&C Act administered by the Center for Biologics Evaluation and Research. The Hatch-Waxman Amendments required the Agency to begin publishing an up-to-date list of all marketed drug products, OTC as well as prescription, that have been approved for safety and efficacy and for which new drug applications are required.

Under the FD&C Act, some drug products are given tentative approvals. The Agency will not include drug products with tentative approvals in the Orange Book because a drug product that is granted tentative approval is not an approved drug product. Tentative approval lists by month are available on FDA's website Drugs@FDA. When the tentative approval becomes a final approval through a subsequent action letter to the applicant, the Agency will list the drug product and the date of approval in the appropriate approved drug product list. In addition, we note that Section 505(x) of the FD&C Act affects the date of approval for certain drug products subject to scheduling under the Controlled Substances Act. The Agency will list the drug product in the Orange Book and the date of approval as determined under Section 505(x).

The Orange Book identifies the application holder of a drug product and does not identify distributors or repackagers.

¹ Generally, newly approved products are added to the Active Section of the Orange Book (i.e., the Prescription Drug Product List or the Over-the-Counter Drug Product List), depending on the dispensing requirements (prescription or OTC) or approval authority, unless the Orange Book staff is otherwise notified before publication. See Section 1.12.

1.2 Therapeutic Equivalence-Related Terms

Pharmaceutical Equivalents. Pharmaceutical equivalents are drug products in identical dosage forms and route(s) of administration that contain identical amounts of the identical active drug ingredient, i.e., the same salt or ester of the same therapeutic moiety, or, in the case of modified-release dosage forms that require a reservoir or overage or such forms as prefilled syringes where the residual volume may vary, that deliver identical amounts of the active drug ingredient over the identical dosing period; do not necessarily contain the same inactive ingredients; and meet the identical compendial or other applicable standard of identity, strength, quality, and purity, including potency and, where applicable, content uniformity, disintegration times, and/or dissolution rates.² They may differ in characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time, and, within certain limits, labeling.

Pharmaceutical Alternatives. Pharmaceutical alternatives are drug products that contain the identical therapeutic moiety, or its precursor, but not necessarily in the same amount or dosage form, or the same salt or ester (e.g., tetracycline hydrochloride, 250mg capsules vs. tetracycline phosphate complex, 250mg capsules; quinidine sulfate, 200mg tablets vs. quinidine sulfate, 200mg capsules).³ Each such drug product individually meets either the identical or its own respective compendial or other applicable standard of identity, strength, quality, and purity, including potency and, where applicable, content uniformity, disintegration times, and/or dissolution rates.⁴ Different dosage forms and strengths within a product line by a single manufacturer are pharmaceutical alternatives, as are extended-release products when compared with immediate-release or standard-release formulations of the same active ingredient.

Therapeutic Equivalents. Approved drug products are considered to be therapeutic equivalents if they are pharmaceutical equivalents for which bioequivalence has been demonstrated, and they can be expected to have the same clinical effect and safety profile when administered to patients under the conditions specified in the labeling.⁵

FDA classifies as therapeutically equivalent those drug products that meet the following general criteria: (1) they are approved as safe and effective; (2) they are pharmaceutical equivalents in that they (a) contain identical amounts of the identical active drug ingredient in the identical dosage form and route of administration, and (b) meet compendial or other applicable standards of strength, quality, purity, and identity; (3) they are bioequivalent in that (a) they do not present a known or potential bioequivalence problem, and they meet an acceptable *in vitro* standard, or (b) if they do present such a known or potential problem, they are shown to meet an appropriate bioequivalence standard; (4) they are adequately labeled; and (5) they are manufactured in compliance with Current Good Manufacturing Practice regulations. The concept of therapeutic equivalence applies only to drug products containing the identical active ingredient(s) and does not encompass a comparison of different therapeutic agents used for the same condition (e.g., meperidine hydrochloride vs. morphine sulfate for the treatment of pain). Any drug product in the Orange Book repackaged and/or distributed by other than the applicant is considered to be therapeutically equivalent to the applicant's drug product even if the applicant's drug

² 21 CFR 314.3(b).

³ See 21 CFR 314.3(b).

⁴ 21 CFR 314.3(b).

⁵ 21 CFR 314.3(b).

product is single source or coded as non-equivalent (e.g., **BN**). Distributors or repackagers of an applicant's drug product are not identified in the Orange Book.

FDA considers drug products to be therapeutically equivalent if they meet the criteria outlined above, even though they may differ in certain other characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time, certain aspects of labeling (e.g., the presence of specific pharmacokinetic information), and storage conditions. When such differences are important in the care of a particular patient, it may be appropriate for the prescribing physician to require that a specific product be dispensed as a medical necessity. With this limitation, however, FDA believes that products classified as therapeutically equivalent can be substituted with the full expectation that the substituted product can be expected to have the same clinical effect and safety profile as the prescribed product when administered to patients under the conditions specified in the labeling.

Strength. Strength refers to the amount of drug substance contained in, delivered, or deliverable from a drug product, which includes: (1) (a) the total quantity of drug substance in mass or units of activity in a dosage unit or container closure (e.g., weight/unit dose, weight/volume or weight/weight in a container closure, or units/volume or units/weight in a container closure); and/or, as applicable, (b) the concentration of the drug substance in mass or units of activity per unit volume or mass (e.g., weight/weight, weight/volume, or units/volume); or (2) such other criteria the Agency establishes for determining the amount of drug substance contained in, delivered, or deliverable from a drug product if the weights and measures described in clause (1) (a) do not apply (e.g., certain drug-device combination products for which the amount of drug substance is emitted per use or unit time).⁶ Note that if the criteria the Agency establishes for determining and expressing the amount of drug substance in a product evolves over time, the Agency generally does not intend to revise the expressions of strength for drug products already included in the Orange Book, but rather intends to apply the criteria prospectively to drug products added to the Orange Book.

Although the strength of drug products in the Orange Book is generally expressed in terms of the amount of drug substance (active ingredient) in the drug product, it is sometimes expressed in terms of the amount of the active moiety. For example, certain drug products included in the Orange Book include a designation of "EQ" next to their expression of strength. This "EQ" designation generally is used in connection with salt drug products to indicate that the strength of such drug product is being expressed in terms of the equivalent strength of the active moiety (e.g., "EQ 200MG BASE"), rather than in terms of the strength of the active ingredient.

Bioavailability. Bioavailability is the rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of drug action. For drug products that are not intended to be absorbed into the bloodstream, bioavailability may be assessed by scientifically valid measurements intended to reflect the rate and extent to which the active ingredient or active moiety becomes available at the site of drug action.⁷

⁶ 21 CFR 314.3(b).

⁷ 21 CFR 314.3(b).

Bioequivalence. Bioequivalence is the absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study.⁸ Section 505(j)(8)(B) of the FD&C Act describes certain conditions under which a test drug and reference listed drug (see Section 1.4) shall be considered bioequivalent:

- (i) the rate and extent of absorption of the [test] drug do not show a significant difference from the rate and extent of absorption of the [reference] listed drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses; or
- (ii) the extent of absorption of the [test] drug does not show a significant difference from the extent of absorption of the [reference] listed drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses and the difference from the [reference] listed drug in the rate of absorption of the drug is intentional, is reflected in its proposed labeling, is not essential to the attainment of effective body drug concentrations on chronic use, and is considered medically insignificant for the drug.

Where these above methods are not applicable (e.g., for drug products that are not intended to be absorbed into the bloodstream), other scientifically valid *in vivo* or *in vitro* test methods to demonstrate bioequivalence may be appropriate.

For example, bioequivalence may sometimes be demonstrated using an *in vitro* bioequivalence standard, especially when such an *in vitro* test has been correlated with human *in vivo* bioavailability data. In other situations, bioequivalence may sometimes be demonstrated through comparative clinical trials or pharmacodynamic studies.⁹

1.3 Further Guidance on Bioequivalence

FDA's regulations and guidance documents provide additional information regarding bioequivalence and bioavailability, including methodologies and statistical criteria used to establish the bioequivalence of drug products.¹⁰

⁸ 21 CFR 314.3(b).

⁹ 21 CFR 320.24.

¹⁰ We note that prior to the 36th edition of the Orange Book, the Preface to the Orange Book included a section entitled "Statistical Criteria for Bioequivalence." Please see FDA's regulations and guidance documents for additional information regarding bioequivalence and bioavailability. See generally 21 CFR part 320. See FDA Drugs guidance Web page at <https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs> and FDA Drugs guidance (Product-Specific Guidances for Generic Drug Development) Web page at <https://www.fda.gov/drugs/guidances-drugs/product-specific-guidances-generic-drug-development>.

1.4 Reference Listed Drug and Reference Standard

A reference listed drug is the listed drug¹¹ identified by FDA as the drug product upon which an applicant relies in seeking approval of its ANDA.¹² Generally, a reference listed drug is a drug product approved in a new drug application under Section 505(c) of the FD&C Act based on full reports of investigations of safety and effectiveness. For an ANDA based on an approved suitability petition (a petitioned ANDA), the reference listed drug generally is the listed drug referenced in the approved suitability petition.¹³

A reference standard is the drug product selected by FDA that an applicant seeking approval of an ANDA must use in conducting an *in vivo* bioequivalence study required for approval.¹⁴ FDA generally selects a single reference standard that ANDA applicants must use in *in vivo* bioequivalence testing. Ordinarily, FDA will select the reference listed drug as the reference standard. However, in some instances, the reference listed drug and the reference standard may be different. For example, where the reference listed drug has been withdrawn from sale FDA may select an ANDA as the reference standard.

FDA identifies reference listed drugs in the Prescription Drug Product, OTC Drug Product, and Discontinued Drug Product Lists. Listed drugs identified as reference listed drugs represent drug products upon which an applicant can rely in seeking approval of an ANDA. FDA intends to update periodically the reference listed drugs identified in the Prescription Drug Product, OTC Drug Product, and Discontinued Drug Product Lists, as appropriate.

In some instances when FDA has not designated a listed drug as a reference listed drug, such listed drug may be shielded from generic competition. If FDA has not designated a reference listed drug for a drug product the applicant intends to duplicate, the potential applicant may submit a controlled correspondence to the Office of Generic Drugs to ask FDA to designate a reference listed drug for that drug product. Section 1.7, *Therapeutic Equivalence Evaluations Codes (products meeting necessary bioequivalence requirements)* explains the character coding system (e.g., **AB**, **AB1**, **AB2**, **AB3**...) for multisource drug products listed under the same heading with two or more reference listed drugs.

FDA also identifies reference standards in the Prescription Drug Product and OTC Drug Product Lists. Listed drugs identified as reference standards represent FDA's best judgment at this time as to the appropriate comparator for purposes of conducting any *in vivo* bioequivalence studies required for approval.

A potential applicant should consult Agency guidance related to referencing approved drug products in ANDA submissions for information on submitting a request for selection of a reference standard. FDA may, on its own initiative, select a new reference standard when doing so will help to ensure that applications for generic drugs may be submitted and evaluated,

¹¹ A "listed drug" is a new drug product that has been approved under section 505(c) of the FD&C Act for safety and effectiveness or under section 505(j) of the FD&C Act, which has not been withdrawn or suspended under section 505(e) (1) through (5) or section 505(j) (6) of the FD&C Act, and which has not been withdrawn from sale for what FDA has determined are reasons of safety or effectiveness. Listed drug status is evidenced by the drug product's identification in the current edition of FDA's "Approved Drug Products With Therapeutic Equivalence Evaluations" (the list) as an approved drug. A drug product is deemed to be a listed drug on the date of approval for the NDA or ANDA for that drug product (21 CFR 314.3(b)).

¹² 21 CFR 314.3(b).

¹³ 21 CFR 314.94(a) (3) (i).

¹⁴ 21 CFR 314.3(b).

e.g., in the event that the listed drug currently selected as the reference standard has been withdrawn from sale

If an applicant has a question related to the appropriate reference standard, it is recommended that an applicant planning to conduct an *in vivo* bioequivalence study submit a controlled correspondence to the Office of Generic Drugs.

1.5 General Policies and Legal Status

The Orange Book contains public information and advice. It does not mandate the drug products that are purchased, prescribed, dispensed, or substituted for one another, nor does it, conversely, mandate the products that should be avoided. To the extent that the Orange Book sets forth FDA's evaluations of the therapeutic equivalence of drug products that have been approved, it contains FDA's advice to the public, to practitioners, and to the states regarding drug product selection. These evaluations do not constitute determinations that any product is in violation of the FD&C Act or that any product is preferable to any other. Therapeutic equivalence evaluations are a scientific judgment based upon evidence, while generic substitution may involve social and economic policy administered by the states, e.g., reducing the cost of drugs to consumers. To the extent that the Orange Book identifies drug products approved under Section 505 of the FD&C Act, it sets forth information that the Agency is required to publish and that the public is entitled to under the Freedom of Information Act. Exclusion of a drug product from the Orange Book does not necessarily mean that the drug product is in violation of Section 505 of the FD&C Act, that such a product is not safe or effective, or that such a product is not therapeutically equivalent to other drug products. Rather, the exclusion may be based on the fact that FDA has not evaluated the safety, effectiveness, and quality of the drug product.

1.6 Practitioner/User Responsibilities

Professional care and judgment should be exercised in using the Orange Book. Evaluations of therapeutic equivalence for prescription drugs are based on scientific and medical evaluations by FDA. Products evaluated as therapeutically equivalent can be expected, in the judgment of FDA, to have the same clinical effect and safety profile when administered to patients under the conditions specified in the labeling. However, these products may differ in other characteristics that are not required by statute or regulation to be the same, such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time, and, in some instances, labeling. If products with such differences are substituted for each other, there is a potential for patient confusion, e.g., due to differences in color or shape of tablets, inability to provide a given dose using a partial tablet if the proper scoring configuration is not available, or decreased patient acceptance of certain products because of flavor. There may also be patient-specific allergic reactions in rare cases due to a coloring or a preservative ingredient.

FDA evaluation of therapeutic equivalence in no way relieves practitioners of their professional responsibilities in prescribing and dispensing such products with due care and with appropriate information to individual patients. In those circumstances where the characteristics of a specific product, other than its active ingredient, are important in the therapy of a particular patient, the practitioner's prescribing of that product may be appropriate. Pharmacists must also be familiar with the different

characteristics of therapeutically equivalent products, e.g., expiration dates/times and labeling directions for storage of the different products (particularly for reconstituted products), so they can properly advise patients when one product is substituted for another.

Multisource and single-source drug products. In the Orange Book, FDA has evaluated for therapeutic equivalence only multisource prescription drug products approved under Section 505 of the FD&C Act, which in most instances means those pharmaceutical equivalents available from more than one manufacturer. For such products, a therapeutic equivalence code generally is included and product information is highlighted in bold face and underlined. Those products with approved applications that are single-source (i.e., there is only one approved product available for that active ingredient, dosage form, route of administration, and strength) are also included in the Orange Book, but no therapeutic equivalence code is included with such products. Any drug product in the Orange Book repackaged and/or distributed by the applicant or some other person authorized by the applicant (e.g., an authorized generic) is considered to be therapeutically equivalent to the applicant's drug product even if the applicant's drug product is single source or coded as non-equivalent (e.g., **BN**). Distributors or repackagers of an applicant's drug product are not identified in the Orange Book. The details of therapeutic equivalence codes and the policies underlying them are discussed in Section 1.7, *Therapeutic Equivalence Evaluations Codes*.

Products in the Orange Book are identified by the names of the holders of approved applications (applicants) who may not necessarily be the manufacturer of the product. There are numerous entities other than the applicant that may be involved in the development, manufacturing, and/or marketing of a product. Products listed in the Orange Book are identified by the applicant's name (firm name on the Form FDA 356h in the application). Where the applicant's name does not appear on the label, a person wishing to relate a specific product to the applicant name in the Orange Book may refer to FDA's NDC Directory¹⁵ and match its search terms to information on the label, such as the NDC Code if available.

Every product in the Orange Book is subject at all times to regulatory action. From time to time, approved products may be found in violation of one or more provisions of the FD&C Act. In such circumstances, the Agency may commence appropriate enforcement action to correct the violation, if necessary, by securing removal of the product from the market by voluntary recall, seizure, or other enforcement actions. Such regulatory actions are, however, independent of the inclusion of a product in the Orange Book. The main criterion for inclusion of a product is that it has an NDA or ANDA that has been approved and that has not been withdrawn for safety or efficacy reasons. FDA believes that retention of a violative product in the Orange Book will not have any significant adverse health consequences, because other legal mechanisms are available to the Agency to prevent the product's actual marketing. FDA may, however, change a product's therapeutic equivalence rating if the circumstances giving rise to the violation change or otherwise call into question the Agency's assessment of whether a product meets the criteria for therapeutic equivalence.

1.7 Therapeutic Equivalence Evaluations Codes

Generally, drug products that the Agency considers multisource have been assigned a therapeutic equivalence code. The coding system for therapeutic equivalence evaluations is designed to allow users to determine quickly

¹⁵ <https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory>.

whether the Agency has evaluated a particular approved product (e.g., a particular strength of an approved drug) as therapeutically equivalent to other pharmaceutically equivalent products (first letter) and to provide additional information on the basis of FDA's evaluations (second letter). With some exceptions (e.g., therapeutic equivalence evaluations for certain 505(b)(2) applications), the therapeutic equivalence evaluation date is the same as the approval date.

The two basic categories into which multisource drugs have been placed are indicated by the first letter of the relevant therapeutic equivalence code as follows:

A Drug products that FDA considers to be therapeutically equivalent to other pharmaceutically equivalent products, i.e., drug products for which:

- (1) there are no known or suspected bioequivalence problems. These are designated **AA, AN, AO, AP, or AT**, depending on the dosage form; or
- (2) actual or potential bioequivalence problems have been resolved with adequate *in vivo* and/or *in vitro* evidence supporting bioequivalence. These are designated **AB**.

B Drug products that FDA at this time, considers not to be therapeutically equivalent to other pharmaceutically equivalent products, i.e.,

drug products for which actual or potential bioequivalence problems have not been resolved by adequate evidence of bioequivalence. Often the problem is with specific dosage forms rather than with the active ingredients. These are designated **BC, BD, BE, BN, BP, BR, BS, BT, BX, or B***.

Individual drug products have been evaluated as therapeutically equivalent to the reference product in accordance with the definitions and policies outlined below:

"A" CODES

Drug products that are considered to be therapeutically equivalent to other pharmaceutically equivalent products.

"A" products are those for which there are no known or suspected bioequivalence problems or for which actual or potential bioequivalence problems have been resolved with adequate *in vivo* and/or *in vitro* evidence supporting bioequivalence. Drug products designated with an "A" code fall under one of two main policies:

- (1) for those active ingredients or dosage forms for which no *in vivo* bioequivalence issue is known or suspected, the information necessary to show bioequivalence between pharmaceutically equivalent products is either presumed and considered self-evident (based on other information in the application for some dosage forms (e.g., solutions)), or satisfied by a showing that an acceptable *in vitro* approach is met. A therapeutically equivalent rating is assigned such products so long as they are manufactured in accordance with Current Good Manufacturing Practice regulations and meet the other requirements of their approved applications (these are designated **AA, AN, AO, AP, or AT**, depending on the dosage form, as described below); or

- (2) for those Drug Efficacy Study Implementation (DESI) drug products containing active ingredients or dosage forms that have been identified by FDA as having actual or potential bioequivalence problems, and for post-1962 drug products presenting a potential bioequivalence problem, an evaluation of therapeutic equivalence is assigned to pharmaceutical equivalents only if the approved application contains adequate scientific evidence establishing through *in vivo* and/or *in vitro* studies the bioequivalence of the product to a selected reference product (these products are designated as **AB**).

There are some general principles that may affect the substitution of pharmaceutically equivalent products in specific cases. Prescribers and dispensers of drugs should be alert to these principles so as to deal appropriately with situations that require professional judgment and discretion.

There may be labeling differences among pharmaceutically equivalent products that require attention on the part of the health professional (e.g., pharmaceutically equivalent powders to be reconstituted for administration as oral or injectable liquids may vary with respect to their expiration time or storage conditions after reconstitution). FDA's determination that such products are therapeutically equivalent is applicable only when each product is reconstituted, stored, and used under the conditions specified in its labeling.

The Agency may use notes in this publication to point out special situations, such as potential differences between two drug products that have been evaluated as bioequivalent and otherwise therapeutically equivalent, when they should be brought to the attention of health professionals. These notes are contained in Section 1.8, *Description of Certain Special Situations*. For example, in certain instances, there may be variations among therapeutically equivalent products in their use or in conditions of administration. When such variations may, in the Agency's opinion, affect prescribing or substitution decisions by health professionals, a note may be added to Section 1.8.

For example, occasionally a situation may arise in which changes in a listed drug product after its approval (for example, a change in dosing interval) may have an impact on the substitutability of already approved generic versions of that product that were rated by the Agency as therapeutically equivalent to the listed product. When such changes in the listed drug product are considered by the Agency to have a significant impact on therapeutic equivalence, the Agency will change the therapeutic equivalence ratings for other versions of the drug product unless the manufacturers of those other versions of the product provide additional information to assure equivalence under the changed conditions. Pending receipt of the additional data, the Agency may add a note to Section 1.8, or, in rare cases, may even change the therapeutic equivalence rating.

In some cases (e.g., Isolyte® S w/ Dextrose 5% in Plastic Container and Plasma-Lyte® 148 and Dextrose 5% in Plastic Container), closely related products are listed as containing the same active ingredients, but in somewhat different amounts. In determining which of these products are pharmaceutically equivalent, generally the Agency has considered products to be pharmaceutically equivalent with labeled strengths of an ingredient that do not vary by more than 1%.

Different salts, esters or other noncovalent derivatives (such as a complex, chelate, or clathrate) of the same active moiety are regarded as different active ingredients. For the purpose of this publication, products containing such different active ingredients are considered pharmaceutical

alternatives and, thus, not therapeutically equivalent. Anhydrous and hydrated entities, as well as different polymorphs, are considered to be the same active ingredient and are expected to meet the same standards for identity to be considered pharmaceutical equivalents and therapeutic equivalents.

The codes in this book are not intended to preclude health care professionals from converting pharmaceutically different concentrations into pharmaceutical equivalents using accepted professional practice.

Where package size variations have therapeutic implications, products so packaged have not been considered pharmaceutically equivalent. For example, some oral contraceptives are supplied in 21-tablet and 28-tablet packets; the 28-tablet packets contain 7 placebo or iron tablets. These two packaging configurations are not regarded as pharmaceutically equivalent; thus, they are not designated as therapeutically equivalent.

Preservatives and other inactive ingredients may differ among some therapeutically equivalent drug products. These differences do not affect FDA's evaluation of therapeutic equivalence except in cases where these components may influence bioequivalence or routes of administration.

The specific sub-codes for those drugs evaluated as therapeutically equivalent and the policies underlying these sub-codes follow:

AA Products in conventional dosage forms not presenting bioequivalence problems

Multisource drug products coded as **AA** contain active ingredients and are in dosage forms that are not regarded as presenting either actual or potential bioequivalence problems or drug quality or standards issues. However, all oral dosage forms must, nonetheless, meet an appropriate *in vitro* bioequivalence standard that is acceptable to the Agency in order to be approved.

AB, AB1, AB2, AB3... Products meeting necessary bioequivalence requirements

Multisource drug products listed under the same heading (i.e., identical active ingredient(s), dosage form, and route(s) of administration) and having the same strength (see Section 1.2, *Therapeutic Equivalence-Related Terms, Strength*) generally will be coded **AB** if data and information are submitted demonstrating bioequivalence.

In certain instances, a number is added to the end of the **AB** code to make a three character code (i.e., **AB1, AB2, AB3, etc.**). Three-character codes generally are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. If a study is submitted that demonstrates bioequivalence to a reference listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against. For example, Adalat® CC and Procardia XL®, extended-release tablets, are listed under the active ingredient nifedipine. These drug products, listed under the same heading, are not bioequivalent to each other. Adalat® CC and Procardia XL® have been assigned ratings of **AB1** and **AB2**, respectively. Generic drug products deemed by FDA to be bioequivalent to Adalat® CC and Procardia XL® have been approved. As a result, the generic drug products bioequivalent to Adalat® CC have been assigned a rating of **AB1** and those bioequivalent to Procardia XL® have been assigned a rating of **AB2**. (The assignment of an **AB1** or **AB2** rating to a specific product does not imply product preference.) Even though drug products of distributors and/or repackagers are not included in the Orange Book, they are considered

therapeutically equivalent to the applicant's drug product if the applicant's drug product is rated either with an **AB** or three-character code or is single source in the Orange Book. Drugs coded as **AB** under a heading are considered therapeutically equivalent only to other drugs coded as **AB** under that heading. Drugs coded with a three-character code under a heading are considered therapeutically equivalent only to other drugs coded with the same three-character code under that heading.

AN Solutions and powders for aerosolization

Uncertainty regarding the therapeutic equivalence of aerosolized products arises primarily because of differences in the drug delivery system. Solutions and powders intended for aerosolization that are marketed for use in general-use delivery systems are considered to be pharmaceutically and therapeutically equivalent and are coded **AN**. Those products that are compatible only with a specific delivery system or those products that are packaged in and with a specific delivery system are coded **BN**, unless they have met an appropriate bioequivalence standard and are otherwise determined to be therapeutically equivalent. Solutions or suspensions in a specific delivery system will be coded **AN** if the bioequivalence standard is based upon *in vitro* methodology, if bioequivalence needs to be demonstrated by *in vivo* methodology then the drug products will be coded **AB**.

AO Injectable oil solutions

The absorption of drugs in injectable (parenteral) oil solutions may vary substantially with the type of oil employed as a vehicle and the concentration of the active ingredient. Injectable oil solutions are therefore considered to be pharmaceutically and therapeutically equivalent only when the active ingredient, its concentration, and the type of oil used as a vehicle are all identical.

AP Injectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions

It should be noted that even though injectable (parenteral) products under a specific listing may be evaluated as therapeutically equivalent, there may be important differences among the products in the general category, Injectable; Injection. For example, historically some injectable products that are rated therapeutically equivalent are labeled for different routes of administration. In addition, some products evaluated as therapeutically equivalent may have different preservatives or no preservatives at all. Injectable products available as dry powders for reconstitution, concentrated sterile solutions for dilution, or sterile solutions ready for injection are pharmaceutical alternative drug products. They are not rated as therapeutically equivalent (AP) to each other even if these pharmaceutical alternative drug products are designed to produce the same concentration prior to injection and are similarly labeled. Consistent with accepted professional practice, it is the responsibility of the prescriber, dispenser, or individual administering the product to be familiar with a product's labeling to assure that it is given only by the route(s) of administration stated in the labeling.

Certain commonly used large volume intravenous products in glass containers are not included in the Orange Book (e.g., dextrose injection 5%, dextrose injection 10%, sodium chloride injection 0.9%) since these

products are on the market without FDA approval and FDA has not published conditions for marketing such parenteral products under approved NDAs. When packaged in plastic containers, however, FDA regulations require approved applications prior to marketing. Approval then depends on, among other things, the extent of the available safety data involving the specific plastic component of the product. All large volume parenteral products are manufactured under similar standards, regardless of whether they are packaged in glass or plastic. Thus, FDA has no reason to believe that the packaging container of large volume parenteral drug products that are pharmaceutically equivalent would have any effect on their therapeutic equivalence.

Consistent with the definition of strength included in Section 1.2, *Therapeutic Equivalence-Related Terms*, the strength of parenteral drug products generally is identified by both the total drug content and the concentration of drug substance in a container approved by FDA.¹⁶ In the past, the strength of liquid parenteral drug products in the Orange Book has not been fully displayed. Rather, the strength of liquid parenteral drug products in the Orange Book has been displayed in terms of concentration, expressed as x mg/mL. Generally, the amount of dry powder or lyophilized powder in a container is identified as the strength, expressed as x mg/vial.

However, FDA subsequently realized that the format of the Orange Book with respect to parenteral solutions should be changed to reflect that each strength of a drug is considered to be a separate listed drug. The Orange Book displays the strength of all new approvals of parenteral solutions. Previously (i.e., prior to 2003), we would have displayed only the concentration of an approved parenteral solution, e.g. 50 mg/mL. For example, if this application had a 20 mL and 60 mL container approved, we would now display two product strengths, listing both total drug content and concentration of drug substance in the relevant approved container, e.g. 1 gm/20 mL (50 mg/mL) and 3 gm/60 mL (50 mg/mL).

AT Topical products

There are a variety of topical dosage forms available for dermatologic, ophthalmic, otic, rectal, and vaginal administration, including creams, gels, lotions, oils, ointments, pastes, solutions, sprays, suppositories, and inserts. Even though different topical dosage forms may contain the same active ingredient and potency, these dosage forms are not considered pharmaceutically equivalent. Therefore, they are not considered therapeutically equivalent. All solutions and DESI drug products containing the same active ingredient in the same topical dosage form for which a waiver of *in vivo* bioequivalence has been granted, or the application contains adequate scientific evidence establishing through an *in vitro* approach the bioequivalence of the product to a selected reference product, and for which chemistry and manufacturing processes are adequate to demonstrate bioequivalence, are considered therapeutically equivalent and coded **AT**. Pharmaceutically equivalent topical products that raise questions of bioequivalence and for which a waiver of *in vivo* bioequivalence has not been granted, including all post-1962 non-solution topical drug products, are coded **AB** when supported by adequate *in vivo* bioequivalence data, and **BT** in the absence of such data.

¹⁶ The strengths of certain parenteral drug products, including contrast agents, may be expressed as a percentage.

"B" CODES

Drug products that FDA, at this time, considers not to be therapeutically equivalent to other pharmaceutically equivalent products.

"B" products, for which actual or potential bioequivalence problems have not been resolved by adequate evidence of bioequivalence, often have a problem with specific dosage forms rather than with the active ingredients. Drug products designated with a "B" code fall under one of three main policies:

- (1) the drug products contain active ingredients or are manufactured in dosage forms that have been identified by the Agency as having documented bioequivalence problems or a significant potential for such problems and for which no adequate studies demonstrating bioequivalence have been submitted to FDA; or
- (2) the quality standards are inadequate or FDA has an insufficient basis to determine therapeutic equivalence; or
- (3) the drug products are under regulatory review.

The specific coding definitions and policies for the "B" sub-codes are as follows:

B* Drug products requiring further FDA investigation and review to determine therapeutic equivalence

The code **B*** is assigned to products previously assigned an **A** or **B** code when FDA receives new information that raises a significant question regarding therapeutic equivalence that can be resolved only through further Agency investigation and/or review of data and information submitted by the applicant. The **B*** code signifies that the Agency will take no position regarding the therapeutic equivalence of the product until the Agency completes its investigation and review.

BC Extended-release dosage forms (capsules, injectables and tablets)

Extended-release tablets are formulated in such a manner as to make the contained drug substance available over an extended period of time following ingestion.

Although bioavailability studies have been conducted on these dosage forms, they may be subject to bioavailability differences, primarily because applicants developing extended-release products for the same active ingredient rarely employ the same formulation approach. FDA, therefore, does not consider different extended-release dosage forms containing the same active ingredient in equal strength to be therapeutically equivalent unless equivalence between individual products in both rate and extent has been specifically demonstrated through appropriate bioequivalence studies. Extended-release products for which such bioequivalence data have not been submitted are coded **BC**, while those for which such data are available have been coded **AB**.

BD Active ingredients and dosage forms with documented bioequivalence problems

The **BD** code denotes products containing active ingredients with known bioequivalence problems and for which adequate studies have not been

submitted to FDA demonstrating bioequivalence. Where studies showing bioequivalence have been submitted, the product has been coded **AB**.

BE Delayed-release oral dosage forms

Where the drug may be destroyed or inactivated by the gastric juice or where it may irritate the gastric mucosa, the use of "enteric" coatings is indicated. Such coatings are intended to delay the release of the medication until the tablet has passed through the stomach. Drug products in delayed-release dosage forms containing the same active ingredients are subject to significant differences in absorption. Unless otherwise specifically noted, the Agency considers different delayed-release products containing the same active ingredients as presenting a potential bioequivalence problem and codes these products **BE** in the absence of *in vivo* studies showing bioequivalence. If adequate *in vivo* studies have demonstrated the bioequivalence of specific delayed-release products, such products are coded **AB**.

BN Products in aerosol-nebulizer drug delivery systems

This code applies to drug solutions or powders that are marketed only as a component of, or as compatible with, a specific drug delivery system. There may, for example, be significant differences in the dose of drug and particle size delivered by different products of this type. Therefore, the Agency does not consider different metered aerosol dosage forms containing the same active ingredient(s) in equal strengths to be therapeutically equivalent unless the drug products meet an appropriate bioequivalence standard; such products are coded **AB**.

BP Active ingredients and dosage forms with potential bioequivalence problems

FDA's bioequivalence regulations (21 CFR 320.33) contain criteria and procedures for determining whether a specific active ingredient in a specific dosage form has a potential for causing a bioequivalence problem. It is FDA's policy to consider an ingredient meeting these criteria as having a potential bioequivalence problem even in the absence of positive data demonstrating inequivalence. Pharmaceutically equivalent products containing these ingredients in oral dosage forms are coded **BP** until adequate bioequivalence data are submitted, after which such products are coded **AB**. Injectable suspensions containing an active ingredient suspended in an aqueous or oleaginous vehicle have also been coded **BP**. Injectable suspensions are subject to bioequivalence problems because differences in particle size, polymorphic structure of the suspended active ingredient, or the suspension formulation can significantly affect the rate of release and absorption. FDA does not consider pharmaceutical equivalents of these products bioequivalent without adequate evidence of bioequivalence; such products would be coded **AB**.

BR Suppositories or enemas that deliver drugs for systemic absorption

The absorption of active ingredients from suppositories or enemas that are intended to have a systemic effect (as distinct from suppositories administered for local effect) can vary significantly from product to product. Therefore, FDA considers pharmaceutically equivalent systemic suppositories or enemas bioequivalent only if *in vivo* evidence of bioequivalence is available. In those cases where *in vivo* evidence is

available, the products are coded **AB**. If such evidence is not available, the products are coded **BR**.

BS Products having drug standard deficiencies

If the drug standards for an active ingredient in a particular dosage form are found by FDA to be deficient so as to prevent an FDA evaluation of either pharmaceutical or therapeutic equivalence, all drug products containing that active ingredient in that dosage form are coded **BS**. For example, if the standards permit a wide variation in pharmacologically active components of the active ingredient such that pharmaceutical equivalence is in question, all products containing that active ingredient in that dosage form are coded **BS**.

BT Topical products with bioequivalence issues

This code applies mainly to post-1962 dermatologic, ophthalmic, otic, rectal, and vaginal products for topical administration, including creams, gels, lotions, oils, ointments, pastes, solutions, sprays, suppositories, and inserts not intended for systemic drug absorption. Topical products evaluated as having acceptable clinical performance, but that are not bioequivalent to other pharmaceutically equivalent products or that lack sufficient evidence of bioequivalence, will be coded **BT**.

BX Drug products for which the data are insufficient to determine therapeutic equivalence

The code **BX** is assigned to specific drug products for which the data that have been reviewed by the Agency are insufficient to determine therapeutic equivalence under the policies stated in this document. In these situations, the drug products are presumed to be therapeutically inequivalent until the Agency has determined that there is adequate information to make a full evaluation of therapeutic equivalence.

1.8 Description of Certain Special Situations

Certain drugs listed in the Orange Book present special situations that merit further discussion. The following are descriptions of certain examples of those special situations:

Amino Acid and Protein Hydrolysate Injections. These products differ in the amount and kinds of amino acids they contain and, therefore, are not considered pharmaceutical equivalents. For this reason, these products are not considered therapeutically equivalent. At the same time, the Agency believes that it is appropriate to point out that where nitrogen balance is the sole therapeutic objective and individual amino acid content is not a consideration, pharmaceutical alternatives with the same total amount of nitrogen content may be expected to have the same clinical effect and safety profile when administered to patients under the conditions specified in the labeling.

Gaviscon®. Gaviscon® is an OTC product that has been marketed since September 1970. The active ingredients in this product, aluminum hydroxide and magnesium trisilicate, were reviewed by the Agency's OTC Antacid Panel and were considered to be safe and effective ingredients (Category I) by that Panel. However, the tablet failed to pass the antacid test that is required of all antacid products. The Agency, therefore, placed the tablet in Category III for lack of effectiveness. A full NDA with clinical studies was

submitted by Marion Laboratories, Inc., and approved by FDA on December 9, 1983. Gaviscon®'s activity in treating reflux acidity is made possible by the physical-chemical properties of the inactive ingredients, sodium bicarbonate and alginic acid. Therefore, *all ANDAs that cite Gaviscon® tablets as the reference listed drug must contain the inactive ingredients sodium bicarbonate and alginic acid.* A full NDA will be required to support the effectiveness of the drug product if different inactive ingredients are to be substituted for sodium bicarbonate or alginic acid or if different proportions of these ingredients are to be used.

Levothyroxine Sodium.¹⁷ Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.¹⁸

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS

¹⁷ In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

¹⁸ The chart is current as of the date of publication of the annual edition. See the most current monthly cumulative supplement for updates to this information available at <https://www.fda.gov/media/72973/download>. Please consult the Active Section for information on other strengths.

AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN GROUP HOLDINGS 4 LLC	0.3MG	N021116	RLD	-
AB4	LEVOTHYROXINE SODIUM ¹⁹	MYLAN	0.3MG	A076187	-	RS

Patent Certification(s) and Reference Standard for ANDAs Duplicating a Drug Product Approved in a Petitioned ANDA. To submit an ANDA for a generic drug that is not the same as its reference listed drug because it has one different active ingredient in a fixed-combination drug product, or has a different route of administration, dosage form, or strength than that of the reference listed drug, an applicant first must obtain permission from FDA through what is known as a suitability petition pursuant to Section 505(j) (2) (C) of the FD&C Act. A petitioned ANDA relies on the reference listed drug described in the suitability petition. An ANDA seeking approval of a drug that is the same as a drug product approved in a petitioned ANDA should use as its reference listed drug, the reference listed drug that served as the basis for the approved suitability petition, and use the drug product approved in the petitioned ANDA as its reference standard for conducting an *in vivo* bioequivalence study required for approval. However, the reference listed drug for any such ANDA is generally the listed drug referenced in the approved suitability petition. The ANDA must include appropriate patent certification(s) and an exclusivity statement with respect to the reference listed drug that served as the basis for the approved suitability petition.²⁰ (This concept also generally applies to an ANDA applicant that utilizes a reference standard that is not a reference listed drug, as such an application must include appropriate patent certification(s) and an exclusivity statement with respect to the reference listed drug.)

Waived exclusivity. If an NDA submitted under Section 505(b) of the FD&C Act qualifies for exclusivity under the FD&C Act, the exclusivity is generally listed in the Patent and Exclusivity Section of the Orange Book. If a drug product has received this exclusivity, FDA will not accept for review and/or will not approve a 505(b) (2) application or an ANDA under Section 505(j) of the FD&C Act, as applicable, in accordance with the relevant exclusivity.²¹ If the listed drug is also protected by one or more

¹⁹ Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levotheroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

²⁰ If after approval of a suitability petition and before approval of an ANDA submitted pursuant to the approved petition, a drug product is approved in an NDA for the change described in the petition, the suitability petition and the listed drug identified in the petition can no longer be the basis of submission for such ANDA. Under these circumstances, an applicant seeking approval for a drug product with the change approved in the suitability petition must submit a new ANDA that identifies the drug product approved under such NDA as the RLD and comply with applicable regulatory requirements. See 21 CFR 314.93(f) (2).

²¹ See Patent and Exclusivity Information Addendum in the Orange Book.

patents, the approval date for the ANDA or 505(b)(2) application will be determined based on an analysis of the applicant's patent certification(s) or statement(s) for each relevant patent and the effect of relevant exclusivity listed in the Orange Book. However, the holder of the NDA may waive its exclusivity as to any or all ANDAs and 505(b)(2) applications that might otherwise be blocked by such exclusivity. If an NDA sponsor waives its exclusivity, qualified ANDAs or 505(b)(2) applications may be accepted for review and/or approved, as applicable. An NDA for which the holder has waived its exclusivity as to all ANDAs and 505(b)(2) applications will be coded with a "W" in the Patent and Exclusivity Section of the Orange Book. The applicant whose product might otherwise be blocked by this exclusivity should indicate in the exclusivity statement in its application that the holder of the listed drug has waived its exclusivity.

1.9 Therapeutic Equivalence Code Change for a Category of Multisource Drug Products

The Agency will use the following procedures when, in response to a petition or on its own initiative, it is considering a change in the therapeutic equivalence code for approved multisource drug products. Such changes will generally occur when the Agency becomes aware of new scientific information affecting the therapeutic equivalence of an entire category of multisource drug products in the Orange Book (e.g., information concerning the active ingredient or the dosage form), rather than information concerning a single drug product within the category. These procedures will be used when a change in therapeutic equivalence code is under consideration for all drug products found in the Prescription Drug Product List under a specific active ingredient and dosage form. The change may be from the code signifying that the drug does not present a bioequivalence problem (e.g., **AA**) to a code signifying an actual or potential bioequivalence problem (e.g., **BP**), or vice versa. This procedure does not apply to a change of a particular product code (e.g., a change from **BP** to **AB** or from **AB** to **BX**).

Before making a change in a therapeutic equivalence code for an entire category of multisource drug products as described above, the Agency will announce in the *Introduction* to the Cumulative Supplement that it is considering the change and will invite comments. Comments, along with scientific data, may be sent to the Director, Office of Bioequivalence, Office of Generic Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Central Document Room, 5901-B Ammendale Rd., Beltsville, MD 20705-1266.

The comment period will generally be 60 days in length, and the closing date for comments will be listed in the description of the proposed change for each drug entity.

The most useful type of scientific data submitted to support comments is generally an *in vivo* bioavailability/bioequivalence study conducted on batches of the subject drug products. Comments including scientific data from an *in vivo* bioavailability/bioequivalence study should present a full description of the analytical procedures and equipment used, a validation of the analytical methodology, including the standard curve, a description of the method of calculating results, and a description of the pharmacokinetic and statistical models used in analyzing the data. Anecdotal or testimonial information is the least useful to the Agency, and submission of comments based on such information is discouraged. However, when there is supporting published or unpublished scientific literature, copies should be submitted with comments.

1.10 Change of the Therapeutic Equivalence Evaluation for a Single Product

The procedure described in Section 1.9 does not apply to a change in a single drug product code. For example, a change in a single drug product's code from **BP** to **AB** as a result of the submission of an acceptable bioequivalence study ordinarily will not be the subject of notice and comment in the Cumulative Supplement. Likewise, a change in a single drug product's code from **AB** to **BX** (e.g., as a result of new information raising a significant question as to bioequivalence) does not require notice and comment. The Agency's responsibility to provide the public with the Agency's most current information related to therapeutic equivalence may require a change in a drug product's code prior to any formal notice and opportunity for the applicant to be heard. The publication in the *Federal Register* of a proposal to withdraw approval of a drug product will ordinarily result in a change in a product's code from **AB** to **BX** if this action has not already been taken.

We recognize that certain drug products approved in 505(b)(2) applications may not have therapeutic equivalence codes, and that FDA may undertake therapeutic equivalence evaluations with respect to such drug products. A person seeking to have a therapeutic equivalence rating for a drug product approved in a 505(b)(2) application may petition the Agency through the citizen petition procedure (see 21 CFR 10.25(a) and 21 CFR 10.30).

1.11 Discontinued Section

Those drug products in the discontinued section of the Orange Book (Discontinued Drug Product List) for which a determination has been made that the products were not withdrawn for safety or effectiveness reasons have been annotated with a footnote following the product strength: "***Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**". The determinations listed in the Orange Book are only reflective of determinations made since 1995 and published in the Federal Register. The identification of these drug products in the Discontinued Drug Product List should avoid the submission of multiple citizen petitions requesting a determination for the same drug product.

Generally, approved products are added to the Discontinued Drug Product List when the applicant notifies the Orange Book staff of the products' not-marketed status. Products may also be added to the Discontinued Drug Product List if annual reports or other submissions to the Agency indicate the product is not being marketed or as a result of other Agency administrative actions.²² Changes to the Orange Book are not affected by the drug registration and listing requirements of Section 510 of the FD&C Act.

1.12 Changes to the Orange Book

Every effort is made to ensure the Annual Edition is current and accurate. Applicants are requested to inform the FDA Orange Book Staff of any changes or corrections, including any change in ownership or a product's marketing status that would result in the product being moved to the Discontinued Drug Product List. FDA notes that under Section 506I(a) of the FD&C Act, applicants must notify the Agency in writing 180 days prior to withdrawing a drug product from sale, or if 180 days is not practicable, not later than the date of withdrawal from sale. Furthermore, Section 506I(b) of the FD&C Act requires that applicants notify the Agency in writing within 180

²² See, e.g., Section 506I(d) of the FD&C Act.

days of approval of a drug product if such drug product will not be available for sale within 180 days of approval. A request to include a newly approved product in the Discontinued Drug Product List, rather than parts 1 or 2 of the Orange Book (as discussed in Section 1.1), must be submitted to the Orange Book staff by the end of the month in which the product is approved to ensure that the product is not included in the "active" portions of the next published Orange Book update.

In addition, the FDA Orange Book Staff generally will act on requests to change a proprietary name for a listed drug only after approval of a supplement for the relevant change in proprietary name. To the extent that conventions for describing product identification information (i.e., active ingredients, dosage forms, routes of administration, product names, applicants, strengths) evolve over time, the Agency generally does not intend to revise such information for drug products already listed in the Orange Book, but rather intends to apply the change prospectively to drug products as they are added to the Orange Book.

You can contact the Orange Book Staff by email at orangebook@fda.hhs.gov.

1.13 Availability of the Edition

The Annual Edition and current monthly Cumulative Supplement are available in a Portable Document Format (PDF) at the [Orange Book](#) home page by clicking on Publications. An annual subscription of the PDF format may be obtained from the U.S. Government Publishing Office, <https://www.gpo.gov/>.

2.0 HOW TO USE THE DRUG PRODUCT LISTS

2.1 Key Sections for Using the Drug Product Lists

This publication contains illustrations, along with Drug Product Lists, indices, and lists of abbreviations and terms which facilitate their use.

Illustrations. The annotated *Drug Product Illustration*, see Section 2.2, and the *Therapeutic Equivalence Evaluations Illustration*, see Section 2.3, are offered to provide further clarification. These depict the format found in the Prescription Drug Product List (the only list in which therapeutic equivalence evaluation codes are displayed).

Drug Product Lists. The Prescription and OTC Drug Product Lists, arranged alphabetically by active ingredient(s), contain product identification information (active ingredients, dosage forms, routes of administration, product names, applicants, strengths) for single and multiple ingredient drug products. Also shown are the application number and drug product number (FDA internal computer data use only) and approval dates for those drug products approved on or after January 1, 1982. The application number preceded by "N" is a New Drug Application (NDA or commonly the innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or commonly the generic).

The Discontinued Drug Product List, arranged alphabetically by active ingredient(s), contains product identification information (dosage form, product name, strength, and application number).

If a prescription drug product is available from more than one source (multisource), a therapeutic equivalence code will appear in front of the applicant's name. If a product is therapeutically equivalent to one or more products or to an appropriate reference, it will be designated with a code beginning with "A" and the entry will be underlined and printed in bold font for emphasis.

Active ingredient headings for multiple ingredient (combination) drug products are arranged alphabetically. For purposes of this publication, this alphabetical sort takes precedence over United States Pharmacopeia official monograph order (i.e., Reserpine, Hydralazine Hydrochloride, Hydrochlorothiazide). For example, product information labeled as Reserpine, Hydrochlorothiazide and Hydralazine Hydrochloride appears under the active ingredient heading *Hydralazine Hydrochloride; Hydrochlorothiazide; Reserpine*. A cross-reference to the product information (for prescription and OTC products) appears for each additional active ingredient in the product. For combination drug products, the ingredient strengths are separated by semicolons and appear in the same relative sequence as the ingredients in the heading. Available strengths of the dosage form from an applicant appear on separate lines.

To use the Drug Product Lists, determine by alphabetical order the ingredient under which the product information is listed, using the Product Name Index, if necessary. Then, find the ingredient in the applicable Drug Product List. Proceed to the dosage form and route of administration and compare products within that ingredient heading only. Therapeutic equivalence or inequivalence for prescription products is determined on the basis of the therapeutic equivalence codes provided within that specific dosage form and route heading. The OTC Drug Product List, Discontinued Drug Product List, and

Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List have their data arranged similarly.

The Discontinued Drug Product List contains approved products that have never been marketed, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, are for military use, or have had their approvals withdrawn for other than safety or efficacy reasons subsequent to being discontinued from marketing. All products having a "@" in the December Cumulative Supplement of the previous Edition List have been added to the Discontinued Drug Product List appearing in this Edition. In addition, approved drug products that are not in the commercial distribution channel e.g., approved drug products in applications for export only are also listed in the Discontinued Drug Product List.

Product Name Index (*Prescription and OTC Drug Product Lists*). This is an index of drug products by trade name or established name of the active ingredient, if no trade name exists. The second term of each entry indicates the active ingredient name under which product information can be found in the appropriate Drug Product List. For those drug products with multiple active ingredients, only the first active ingredient (in alphabetical order) will appear. OTC products are so designated.

Product Name Index Listed by Applicant (*Prescription and OTC Drug Product Lists*). This is an index that cross-references applicants to drug products. The bolded and underlined entry represents the applicant name abbreviation used in this publication. Each complete applicant name that is represented by the abbreviated name is marked with an asterisk (*). Listed under each complete applicant name is the first alphabetically arranged ingredient under which product information can be found in the appropriate Drug Product List. OTC products are so designated. To use the Drug Product Lists, determine by alphabetical order the ingredient under which the product information is listed, using the Product Name Index, if appropriate.

Uniform Terms. To improve readability, uniform terms are used to designate dosage forms, routes of administration, and abbreviations used to express strengths. These terms are listed in Appendix C. In some cases, the terms used may differ from those used in product labels and other labeling.

2.2 DRUG PRODUCT ILLUSTRATION

SINGLE INGREDIENT

ACTIVE INGREDIENT	→	<u>MEPERIDINE HYDROCHLORIDE</u>					
DOSAGE FORM; ROUTE OF ADMINISTRATION	→	INJECTABLE; INJECTION					
TRADE OR GENERIC NAMES	→	<u>HEXANON</u>					
REFERENCE LISTED DRUG* (+)	→	<u>AP</u> +!	PAGE PHARMA	<u>25MG/ML</u>	<u>N013111</u>	<u>001</u>	AUG 22, 1983
REFERENCE STANDARD * (!)	→	<u>AP</u> +!		<u>50MG/ML</u>	<u>N013111</u>	<u>002</u>	AUG 22, 1983
		<u>AP</u> +!		<u>75MG/ML</u>	<u>N013111</u>	<u>003</u>	AUG 22, 1983
		<u>AP</u> +!		<u>100MG/ML</u>	<u>N013111</u>	<u>004</u>	JAN 04, 1989
		<u>MEPERIDINE HCL</u>					
THERAPEUTIC EQUIVALENCE (TE)	→	<u>AP</u>	GREENBERG PHARM	<u>25MG/ML</u>	<u>A064890</u>	001	FEB 29, 1987
CODE FOR MULTISOURCE PRODUCT	→	<u>AP</u>		<u>50MG/ML</u>	<u>A064890</u>	002	FEB 29, 1987
		<u>AP</u>		<u>75MG/ML</u>	<u>A064890</u>	003	FEB 29, 1987
		<u>AP</u>		<u>100MG/ML</u>	<u>A064890</u>	004	MAR 08, 1992
SINGLE SOURCE PRODUCT (NO TE CODE)			! TIMOKIM LLC	10MG/ML	A099225	001	DEC 12, 1995
		<u>AP</u>	JOHNSON MED	<u>25MG/ML</u>	<u>A099226</u>	<u>001</u>	NOV 27, 1993
			! KENDRA PHARM	150MG/ML	A079444	001	OCT 31, 1999
APPLICANT	→						
AVAILABLE STRENGTH(S) OF A PRODUCT	→						
APPLICATION NUMBER AND PRODUCT NUMBER	→						
PRODUCT NUMBER IS FOR FDA INTERNAL COMPUTER DATA USE ONLY	→						
APPROVAL DATE	→						

*NOTE: REFERENCE LISTED DRUG AND REFERENCE STANDARD ARE DISCUSSED IN THE PREFACE SECTION 1.4

MULTIPLE INGREDIENTS WITH PRODUCT INFORMATION

ALPHABETICALLY SORTED BY	→	<u>HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE</u>																							
PRODUCT INFORMATION	→	<table border="0"> <tr> <td>TABLET; ORAL</td> <td colspan="5"></td> </tr> <tr> <td>HYDROCHLOROTHIAZIDE, RESERPINE AND HYDRALAZINE HCL</td> <td colspan="5"></td> </tr> <tr> <td>REINWALD LABS</td> <td>25MG; 15MG; 0.1MG</td> <td>A069808</td> <td>001</td> <td>JAN 18, 1982</td> <td></td> </tr> </table>						TABLET; ORAL						HYDROCHLOROTHIAZIDE, RESERPINE AND HYDRALAZINE HCL						REINWALD LABS	25MG; 15MG; 0.1MG	A069808	001	JAN 18, 1982	
TABLET; ORAL																									
HYDROCHLOROTHIAZIDE, RESERPINE AND HYDRALAZINE HCL																									
REINWALD LABS	25MG; 15MG; 0.1MG	A069808	001	JAN 18, 1982																					

THIS EXAMPLE IS FOR PURPOSE OF ILLUSTRATION ONLY. IT DOES NOT REPRESENT ACTUAL PRODUCTS FROM THE PRESCRIPTION DRUG PRODUCT LIST.

2.3 THERAPEUTIC EQUIVALENCE EVALUATIONS ILLUSTRATION

DRUG PRODUCTS CODED **AB** (OR ANY CODE BEGINNING WITH AN "A") UNDER AN INGREDIENT AND DOSAGE FORM HEADING ARE CONSIDERED THERAPEUTICALLY EQUIVALENT ONLY TO OTHER PRODUCTS CODED **AB** (OR ANY CODE BEGINNING WITH AN "A") AND **NOT** TO THOSE CODED **BP** (OR ANY CODE BEGINNING WITH "B") AND ANY PRODUCTS NOT LISTED. DRUG PRODUCTS CODED **BP** (OR ANY CODE BEGINNING WITH A "B") ARE **NOT** CONSIDERED THERAPEUTICALLY EQUIVALENT TO ANY OTHER PRODUCT. FOR A COMPLETE EXPLANATION OF THE **TE** CODES REFER TO SECTION 1.7 OF THE *INTRODUCTION*.

SULFASALAZINE

TABLET; ORAL

FAZINE

AB PARKLAND **500MG** **A042999** **001**

SULAZINE

AB URSA **500MG** **A042222** **001**

SULFASALAZINE

BP BROWN 500MG A041297 001

SULFASALAZINE

TABLET; ORAL

FAZINE


AB PARKLAND **500MG** **A042999** **001**

SULFASALAZINE

BP BROWN 500MG A041297 001

SOUTH 500MG A067627 001

PRODUCTS CONSIDERED THERAPEUTICALLY EQUIVALENT TO EACH OTHER



PRODUCTS CONSIDERED **NOT** THERAPEUTICALLY EQUIVALENT TO ANY OTHER PRODUCTS LISTED

PRODUCTS CONSIDERED **NOT** THERAPEUTICALLY EQUIVALENT TO EACH OTHER



NOTE: BOLD FONT AND UNDERLINING DENOTES MULTISOURCE PRODUCTS WHICH ARE CONSIDERED THERAPEUTICALLY EQUIVALENT.

THIS EXAMPLE IS FOR PURPOSES OF ILLUSTRATION ONLY. IT DOES NOT REPRESENT ACTUAL PRODUCTS FROM THE PRESCRIPTION DRUG PRODUCT LIST.

PRESCRIPTION DRUG PRODUCT LIST

ABACAVIR SULFATE

SOLUTION;ORAL

ABACAVIR SULFATE

AA	AUROBINDO PHARMA LTD	EQ 20MG BASE/ML	A077950 001	Mar 14, 2018
AA	HETERO LABS LTD III	EQ 20MG BASE/ML	A201107 001	Sep 26, 2016

ZIAGEN

AA	+! VIIV HLTHCARE	EQ 20MG BASE/ML	N020978 001	Dec 17, 1998
-----------	------------------	------------------------	--------------------	--------------

TABLET;ORAL

ABACAVIR SULFATE

AB	AUROBINDO PHARMA LTD	EQ 300MG BASE	A077844 001	Dec 17, 2012
AB	CIPLA	EQ 300MG BASE	A078119 001	Nov 21, 2017
AB	HETERO LABS LTD III	EQ 300MG BASE	A091560 001	Sep 13, 2013
AB	MYLAN PHARMS INC	EQ 300MG BASE	A091294 001	Jun 18, 2012
AB	STRIDES PHARMA	EQ 300MG BASE	A091050 001	Oct 28, 2016

ZIAGEN

AB	+! VIIV HLTHCARE	EQ 300MG BASE	N020977 001	Dec 17, 1998
-----------	------------------	----------------------	--------------------	--------------

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

TABLET;ORAL

TRIUMEQ

+!	VIIV HLTHCARE	EQ 600MG BASE;EQ 50MG BASE;300MG	N205551 001	Aug 22, 2014
----	---------------	----------------------------------	-------------	--------------

ABACAVIR SULFATE; LAMIVUDINE

TABLET;ORAL

ABACAVIR SULFATE AND LAMIVUDINE

AB	AUROBINDO PHARMA LTD	EQ 600MG BASE;300MG	A090159 001	Nov 15, 2018
AB		EQ 600MG BASE;300MG	A206151 001	Mar 28, 2017
AB	CIPLA	EQ 600MG BASE;300MG	A091144 001	Mar 28, 2017
AB	LUPIN LTD	EQ 600MG BASE;300MG	A204990 001	Mar 28, 2017
AB	TEVA PHARMS USA	EQ 600MG BASE;300MG	A079246 001	Sep 29, 2016

EPZICOM

AB	+! VIIV HLTHCARE	EQ 600MG BASE;300MG	N021652 001	Aug 02, 2004
-----------	------------------	----------------------------	--------------------	--------------

ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL

ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE

AB	LUPIN LTD	EQ 300MG BASE;150MG;300MG	A202912 001	Dec 05, 2013
AB	+! VIIV HLTHCARE	EQ 300MG BASE;150MG;300MG	N021205 001	Nov 14, 2000

ABALOPARATIDE

SOLUTION;SUBCUTANEOUS

TYMLOS

+!	RADIUS HEALTH INC	3.12MG/1.56ML (2MG/ML)	N208743 001	Apr 28, 2017
----	-------------------	------------------------	-------------	--------------

ABEMACICLIB

TABLET;ORAL

VERZENIO

+	ELI LILLY AND CO	50MG	N208716 001	Sep 28, 2017
+		100MG	N208716 002	Sep 28, 2017
+		150MG	N208716 003	Sep 28, 2017
+!		200MG	N208716 004	Sep 28, 2017

ABIRATERONE ACETATE

TABLET;ORAL

ABIRATERONE ACETATE

AB	AMNEAL PHARMS	250MG	A208327 001	Jan 07, 2019
AB	APOTEX	250MG	A208453 001	Oct 31, 2018
AB	DR REDDYS LABS LTD	250MG	A208416 001	May 18, 2020
AB	GLENMARK PHARMS	250MG	A209227 001	Oct 16, 2019
AB	HIKMA	250MG	A208339 001	Oct 31, 2018
AB	MSN	250MG	A210686 001	Jul 10, 2019
AB	MYLAN	250MG	A208446 001	Oct 31, 2018
AB		500MG	A208446 002	Dec 14, 2020
AB	QILU	250MG	A212462 001	Sep 27, 2019
AB	RISING	250MG	A208371 001	Feb 25, 2019
AB	TEVA PHARMS USA	250MG	A208432 001	Oct 31, 2018
AB	WOCKHARDT BIO AG	250MG	A208380 001	Feb 27, 2019

ZYTIGA

AB	+ JANSSEN BIOTECH	250MG	N202379 001	Apr 28, 2011
AB	+!	500MG	N202379 002	Apr 14, 2017

PRESCRIPTION DRUG PRODUCT LIST

ABIRATERONE ACETATE

TABLET; ORAL

YONSA

+! SUN PHARMA GLOBAL 125MG N210308 001 May 22, 2018

ACALABRUTINIB

CAPSULE; ORAL

CALQUENCE

+! ASTRAZENECA 100MG N210259 001 Oct 31, 2017

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE; ORAL

ACAMPROSATE CALCIUM

AB	!	GLENMARK GENERICS	333MG	A202229	001	Jul 16, 2013
AB		MYLAN	333MG	A200142	001	Mar 11, 2014
AB		ZYDUS PHARMS	333MG	A205995	001	May 26, 2017

ACARBOSE

TABLET; ORAL

ACARBOSE

AB		HANGZHOU ZHONGMEI	25MG	A213821	001	Aug 18, 2020
AB			50MG	A213821	002	Aug 18, 2020
AB			100MG	A213821	003	Aug 18, 2020
AB		HIKMA	25MG	A078470	001	May 07, 2008
AB			50MG	A078470	002	May 07, 2008
AB			100MG	A078470	003	May 07, 2008
AB		IMPAX LABS	25MG	A078441	001	May 14, 2009
AB			50MG	A078441	002	May 14, 2009
AB			100MG	A078441	003	May 14, 2009
AB	!	STRIDES PHARMA	25MG	A090912	001	Jul 27, 2011
AB			50MG	A090912	002	Jul 27, 2011
AB			100MG	A090912	003	Jul 27, 2011
AB		VIRTUS PHARM	25MG	A091343	001	Oct 17, 2013
AB			50MG	A091343	002	Oct 17, 2013
AB			100MG	A091343	003	Oct 17, 2013
AB		WATSON LABS	25MG	A077532	001	May 07, 2008
AB			50MG	A077532	002	May 07, 2008
AB			100MG	A077532	003	May 07, 2008

ACEBUTOLOL HYDROCHLORIDE

CAPSULE; ORAL

ACEBUTOLOL HYDROCHLORIDE

AB	!	AMNEAL PHARM	EQ 200MG BASE	A075047	001	Dec 30, 1999
AB	!		EQ 400MG BASE	A075047	002	Dec 30, 1999
AB		MYLAN	EQ 200MG BASE	A074288	001	Apr 24, 1995
AB			EQ 400MG BASE	A074288	002	Apr 24, 1995

ACETAMINOPHEN

SOLUTION; INTRAVENOUS

ACETAMINOPHEN

AP		AUROBINDO PHARMA LTD	1GM/100ML (10MG/ML)	A210969	001	Oct 21, 2020
AP		CUSTOPHARM INC	1GM/100ML (10MG/ML)	A202605	001	Jun 13, 2016
AP		MYLAN	1GM/100ML (10MG/ML)	A213255	001	Aug 07, 2020
AP		SANDOZ INC	1GM/100ML (10MG/ML)	A204052	001	Mar 22, 2016
OFIRMEV						
AP	+!	MALLINCKRODT HOSP	1GM/100ML (10MG/ML)	N022450	001	Nov 02, 2010
		ACETAMINOPHEN				
		FRESENIUS KABI USA	1GM/100ML (10MG/ML)	N204767	001	Oct 28, 2015

ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE

TABLET; ORAL

APADAZ

+	KVK TECH INC	325MG;EQ 4.08MG BASE	N208653	002	Jan 04, 2019
+		325MG;EQ 6.12MG BASE	N208653	001	Feb 23, 2018
+	!	325MG;EQ 8.16MG BASE	N208653	003	Jan 04, 2019

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL

BUTALBITAL AND ACETAMINOPHEN

AA		GRANULES PHARMS	300MG;50MG	A213115	001	Nov 22, 2019
AA	!	MAYNE PHARMA INC	300MG;50MG	A207313	001	Dec 27, 2017

TABLET; ORAL

BUTALBITAL AND ACETAMINOPHEN

AA		CNTY LINE PHARMS	300MG;50MG	A207635	001	Jun 05, 2017
AA			325MG;50MG	A205120	001	Oct 30, 2015

PRESCRIPTION DRUG PRODUCT LIST

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL

BUTALBITAL AND ACETAMINOPHEN

<u>AA</u>	LARKEN LABS INC	<u>325MG; 50MG</u>	<u>A203484 002</u>	Dec 04, 2015
<u>AA</u>	! LGM PHARMA	<u>300MG; 50MG</u>	<u>A090956 001</u>	Aug 23, 2011
<u>AA</u>	MIKART	<u>300MG; 50MG</u>	<u>A207386 001</u>	Nov 15, 2016

BUTAPAP

<u>AA</u>	! MIKART	<u>325MG; 50MG</u>	<u>A089987 001</u>	Oct 26, 1992
	ALLZITAL			
	! LARKEN LABS INC	325MG; 25MG	A203484 001	Dec 04, 2015

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

<u>AA</u>	AUROLIFE PHARMA LLC	<u>325MG; 50MG; 40MG</u>	<u>A204733 001</u>	Sep 26, 2018
<u>AA</u>	GRANULES PHARMS	<u>300MG; 50MG; 40MG</u>	<u>A213321 001</u>	Apr 08, 2020
<u>AA</u>	LANNETT CO INC	<u>300MG; 50MG; 40MG</u>	<u>A212082 001</u>	Dec 17, 2019
<u>AA</u>		<u>325MG; 50MG; 40MG</u>	<u>A212083 001</u>	Dec 17, 2019
<u>AA</u>	! LGM PHARMA	<u>300MG; 50MG; 40MG</u>	<u>A040885 001</u>	Nov 16, 2009
<u>AA</u>	MAYNE PHARMA INC	<u>300MG; 50MG; 40MG</u>	<u>A210817 001</u>	Dec 17, 2019
<u>AA</u>	!	<u>325MG; 50MG; 40MG</u>	<u>A089007 001</u>	Mar 17, 1986
<u>AA</u>	NUVO PHARMS INC	<u>300MG; 50MG; 40MG</u>	<u>A207118 001</u>	Oct 28, 2016
<u>AA</u>	TARO PHARM INDS LTD	<u>300MG; 50MG; 40MG</u>	<u>A213046 001</u>	Jul 01, 2020
<u>AA</u>	WRASER PHARMS LLC	<u>300MG; 50MG; 40MG</u>	<u>A206615 001</u>	Aug 04, 2017

SOLUTION; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

!	MIKART	325MG/15ML; 50MG/15ML; 40MG/15ML	A040387 001	Jan 31, 2003
---	--------	----------------------------------	-------------	--------------

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

<u>AA</u>	ABHAI LLC	<u>325MG; 50MG; 40MG</u>	<u>A211106 001</u>	Sep 26, 2018
<u>AA</u>	ACTAVIS LABS UT INC	<u>325MG; 50MG; 40MG</u>	<u>A088616 001</u>	Nov 09, 1984
<u>AA</u>	CNTY LINE PHARMS	<u>325MG; 50MG; 40MG</u>	<u>A204984 001</u>	Jan 10, 2017
<u>AA</u>	LANNETT CO INC	<u>325MG; 50MG; 40MG</u>	<u>A200243 001</u>	Sep 13, 2012
<u>AA</u>	LGM PHARMA	<u>325MG; 50MG; 40MG</u>	<u>A209587 001</u>	Oct 31, 2018
<u>AA</u>	MIKART	<u>325MG; 50MG; 40MG</u>	<u>A089175 001</u>	Jan 21, 1987
<u>AA</u>	NESHER PHARMS	<u>325MG; 50MG; 40MG</u>	<u>A211543 001</u>	Jul 17, 2020
<u>AA</u>	STRIDES PHARMA	<u>325MG; 50MG; 40MG</u>	<u>A203647 001</u>	Sep 21, 2020
<u>AA</u>	! VINTAGE PHARMS	<u>325MG; 50MG; 40MG</u>	<u>A040511 001</u>	Aug 27, 2003

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

<u>AB</u>	LGM PHARMA	<u>325MG; 50MG; 40MG; 30MG</u>	<u>A076560 001</u>	Jun 10, 2004
<u>AB</u>	STRIDES PHARMA	<u>325MG; 50MG; 40MG; 30MG</u>	<u>A204649 001</u>	Jul 08, 2020
<u>AB</u>	VINTAGE PHARMS	<u>325MG; 50MG; 40MG; 30MG</u>	<u>A075929 001</u>	Apr 22, 2002
	<u>FIORICET W/ CODEINE</u>			
<u>AB</u>	+! ACTAVIS LABS UT INC	<u>325MG; 50MG; 40MG; 30MG</u>	<u>N020232 001</u>	Jul 30, 1992
	BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE			
	LGM PHARMA	300MG; 50MG; 40MG; 30MG	A076560 002	Jul 19, 2012

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

TREZIX

	WRASER PHARMS LLC	320.5MG; 30MG; 16MG	A204785 001	Nov 26, 2014
--	-------------------	---------------------	-------------	--------------

TABLET; ORAL

ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE

	LARKEN LABS INC	325MG; 30MG; 16MG	A204209 001	Sep 30, 2016
--	-----------------	-------------------	-------------	--------------

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

<u>AA</u>	AKORN	<u>120MG/5ML; 12MG/5ML</u>	<u>A040119 001</u>	Apr 26, 1996
<u>AA</u>	ANDA REPOSITORY	<u>120MG/5ML; 12MG/5ML</u>	<u>A089450 001</u>	Oct 27, 1992
<u>AA</u>	! PHARM ASSOC	<u>120MG/5ML; 12MG/5ML</u>	<u>A087508 001</u>	

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

<u>AA</u>	AMNEAL PHARMS NY	<u>300MG; 30MG</u>	<u>A040779 001</u>	May 29, 2008
<u>AA</u>	AUROLIFE PHARMA LLC	<u>300MG; 15MG</u>	<u>A202800 001</u>	Apr 15, 2013
<u>AA</u>		<u>300MG; 30MG</u>	<u>A202800 002</u>	Apr 15, 2013
<u>AA</u>		<u>300MG; 60MG</u>	<u>A202800 003</u>	Apr 15, 2013
<u>AA</u>	ELITE LABS INC	<u>300MG; 15MG</u>	<u>A212418 001</u>	Sep 10, 2019
<u>AA</u>		<u>300MG; 30MG</u>	<u>A212418 002</u>	Sep 10, 2019
<u>AA</u>		<u>300MG; 60MG</u>	<u>A212418 003</u>	Sep 10, 2019
<u>AA</u>	EYWA	<u>300MG; 15MG</u>	<u>A211610 001</u>	Jun 27, 2019

PRESCRIPTION DRUG PRODUCT LIST

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

<u>AA</u>		<u>300MG;30MG</u>	<u>A211610 002</u>	Jun 27, 2019
<u>AA</u>		<u>300MG;60MG</u>	<u>A211610 003</u>	Jun 27, 2019
<u>AA</u>	NOSTRUM LABS INC	<u>300MG;15MG</u>	<u>A088627 001</u>	Mar 06, 1985
<u>AA</u>		<u>300MG;30MG</u>	<u>A088628 001</u>	Mar 06, 1985
<u>AA</u>	!	<u>300MG;60MG</u>	<u>A088629 001</u>	Mar 06, 1985
<u>AA</u>	!	<u>300MG;15MG</u>	<u>A040419 001</u>	May 31, 2001
<u>AA</u>	!	<u>300MG;30MG</u>	<u>A040419 002</u>	May 31, 2001
<u>AA</u>		<u>300MG;60MG</u>	<u>A040419 003</u>	May 31, 2001
<u>AA</u>	SUN PHARM INDS LTD	<u>300MG;30MG</u>	<u>A085868 001</u>	
<u>AA</u>		<u>300MG;60MG</u>	<u>A087083 001</u>	
<u>AA</u>	VINTAGE	<u>300MG;15MG</u>	<u>A089990 001</u>	Sep 30, 1988
<u>AA</u>		<u>300MG;30MG</u>	<u>A089805 001</u>	Sep 30, 1988
<u>AA</u>	VINTAGE PHARMS	<u>300MG;60MG</u>	<u>A089828 001</u>	Sep 30, 1988

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

<u>AA</u>	!	ANDA REPOSITORY	<u>325MG/15ML;7.5MG/15ML</u>	<u>A040482 001</u>	Sep 25, 2003
<u>AA</u>		GENUS	<u>325MG/15ML;7.5MG/15ML</u>	<u>A040894 001</u>	Jul 19, 2011
<u>AA</u>		PHARM ASSOC	<u>325MG/15ML;7.5MG/15ML</u>	<u>A040838 001</u>	May 10, 2013
<u>AA</u>		VISTAPHARM	<u>325MG/15ML;7.5MG/15ML</u>	<u>A200343 001</u>	Jan 25, 2012
<u>AA</u>		WES PHARMA INC	<u>325MG/15ML;7.5MG/15ML</u>	<u>A211023 001</u>	Mar 08, 2019
<u>AA</u>	!	MIKART	300MG/15ML;10MG/15ML	A040881	Feb 25, 2010
<u>AA</u>	!	PHARM ASSOC	325MG/15ML;10MG/15ML	A040834	Apr 18, 2008

TABLET;ORAL

ANEXSIA 5/325

<u>AA</u>		SPECGX LLC	<u>325MG;5MG</u>	<u>A040409 001</u>	Oct 20, 2000
-----------	--	------------	------------------	--------------------	--------------

ANEXSIA 7.5/325

<u>AA</u>		SPECGX LLC	<u>325MG;7.5MG</u>	<u>A040405 001</u>	Sep 08, 2000
-----------	--	------------	--------------------	--------------------	--------------

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

<u>AA</u>		ABHAI LLC	<u>300MG;5MG</u>	<u>A209036 001</u>	Jun 21, 2017
<u>AA</u>			<u>300MG;7.5MG</u>	<u>A209036 002</u>	Jun 21, 2017
<u>AA</u>			<u>300MG;10MG</u>	<u>A209036 003</u>	Jun 21, 2017
<u>AA</u>			<u>325MG;5MG</u>	<u>A209037 001</u>	Jun 21, 2017
<u>AA</u>			<u>325MG;7.5MG</u>	<u>A209037 002</u>	Jun 21, 2017
<u>AA</u>			<u>325MG;10MG</u>	<u>A209037 003</u>	Jun 21, 2017
<u>AA</u>		AMNEAL PHARMS	<u>300MG;10MG</u>	<u>A207137 001</u>	Nov 29, 2016
<u>AA</u>		AMNEAL PHARMS NY	<u>300MG;5MG</u>	<u>A206869 001</u>	Jun 23, 2017
<u>AA</u>			<u>325MG;5MG</u>	<u>A040736 001</u>	Aug 25, 2006
<u>AA</u>			<u>325MG;7.5MG</u>	<u>A040746 002</u>	May 10, 2016
<u>AA</u>			<u>325MG;10MG</u>	<u>A040746 001</u>	Aug 25, 2006
<u>AA</u>	!	ANDA REPOSITORY	<u>325MG;2.5MG</u>	<u>A040846 001</u>	Jun 09, 2010
<u>AA</u>			<u>325MG;7.5MG</u>	<u>A040432 001</u>	Jan 22, 2003
<u>AA</u>		ASCENT PHARMS INC	<u>325MG;2.5MG</u>	<u>A211487 001</u>	Nov 07, 2018
<u>AA</u>			<u>325MG;5MG</u>	<u>A211487 002</u>	Nov 07, 2018
<u>AA</u>			<u>325MG;7.5MG</u>	<u>A211487 003</u>	Nov 07, 2018
<u>AA</u>			<u>325MG;10MG</u>	<u>A211487 004</u>	Nov 07, 2018
<u>AA</u>		AUROLIFE PHARMA LLC	<u>300MG;5MG</u>	<u>A207709 001</u>	Sep 13, 2018
<u>AA</u>			<u>300MG;7.5MG</u>	<u>A207709 002</u>	Sep 13, 2018
<u>AA</u>			<u>300MG;10MG</u>	<u>A207709 003</u>	Sep 13, 2018
<u>AA</u>			<u>325MG;5MG</u>	<u>A201013 001</u>	Apr 11, 2012
<u>AA</u>			<u>325MG;7.5MG</u>	<u>A201013 002</u>	Apr 11, 2012
<u>AA</u>			<u>325MG;10MG</u>	<u>A201013 003</u>	Apr 11, 2012
<u>AA</u>		EPIC PHARMA LLC	<u>325MG;5MG</u>	<u>A203863 001</u>	Mar 30, 2018
<u>AA</u>			<u>325MG;7.5MG</u>	<u>A203863 002</u>	Mar 30, 2018
<u>AA</u>			<u>325MG;10MG</u>	<u>A203863 003</u>	Mar 30, 2018
<u>AA</u>	!	MIKART	<u>300MG;5MG</u>	<u>A040658 001</u>	Jan 19, 2006
<u>AA</u>	!		<u>300MG;7.5MG</u>	<u>A040658 002</u>	Mar 24, 2006
<u>AA</u>	!		<u>300MG;10MG</u>	<u>A040658 003</u>	Jun 23, 2004
<u>AA</u>		NOVEL LABS INC	<u>300MG;5MG</u>	<u>A206142 001</u>	Nov 14, 2016
<u>AA</u>			<u>300MG;7.5MG</u>	<u>A206142 002</u>	Nov 14, 2016
<u>AA</u>			<u>300MG;10MG</u>	<u>A206142 003</u>	Nov 14, 2016
<u>AA</u>			<u>325MG;5MG</u>	<u>A206245 001</u>	Dec 01, 2016
<u>AA</u>			<u>325MG;7.5MG</u>	<u>A206245 002</u>	Dec 01, 2016
<u>AA</u>			<u>325MG;10MG</u>	<u>A206245 003</u>	Dec 01, 2016
<u>AA</u>		PAR PHARM	<u>325MG;5MG</u>	<u>A202935 002</u>	Jun 15, 2016
<u>AA</u>			<u>325MG;7.5MG</u>	<u>A202935 003</u>	Jun 15, 2016
<u>AA</u>			<u>325MG;10MG</u>	<u>A202935 004</u>	Jun 15, 2016
<u>AA</u>		RHODES PHARMS	<u>300MG;5MG</u>	<u>A207808 001</u>	Mar 30, 2018
<u>AA</u>			<u>300MG;7.5MG</u>	<u>A207808 002</u>	Mar 30, 2018

PRESCRIPTION DRUG PRODUCT LIST

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

<u>AA</u>		<u>300MG;10MG</u>	<u>A207808</u>	<u>003</u>	Mar 30, 2018
<u>AA</u>		<u>325MG;5MG</u>	<u>A202991</u>	<u>001</u>	Apr 12, 2016
<u>AA</u>		<u>325MG;7.5MG</u>	<u>A202991</u>	<u>002</u>	Apr 12, 2016
<u>AA</u>		<u>325MG;10MG</u>	<u>A202991</u>	<u>003</u>	Apr 12, 2016
<u>AA</u>	SPECGX LLC	<u>300MG;5MG</u>	<u>A206718</u>	<u>001</u>	Mar 31, 2017
<u>AA</u>		<u>300MG;7.5MG</u>	<u>A206718</u>	<u>002</u>	Mar 31, 2017
<u>AA</u>		<u>300MG;10MG</u>	<u>A206718</u>	<u>003</u>	Mar 31, 2017
<u>AA</u>		<u>325MG;10MG</u>	<u>A040400</u>	<u>001</u>	Jul 26, 2000
<u>AA</u>	SUN PHARM INDS INC	<u>325MG;5MG</u>	<u>A090118</u>	<u>001</u>	Dec 23, 2008
<u>AA</u>		<u>325MG;7.5MG</u>	<u>A090118</u>	<u>002</u>	Dec 23, 2008
<u>AA</u>		<u>325MG;10MG</u>	<u>A090118</u>	<u>003</u>	Dec 23, 2008
<u>AA</u>	TRIS PHARMA INC	<u>300MG;5MG</u>	<u>A202214</u>	<u>004</u>	Mar 15, 2016
<u>AA</u>		<u>300MG;7.5MG</u>	<u>A202214</u>	<u>005</u>	Mar 15, 2016
<u>AA</u>		<u>300MG;10MG</u>	<u>A202214</u>	<u>006</u>	Mar 15, 2016
<u>AA</u>		<u>325MG;5MG</u>	<u>A202214</u>	<u>001</u>	Mar 27, 2013
<u>AA</u>		<u>325MG;7.5MG</u>	<u>A202214</u>	<u>002</u>	Mar 27, 2013
<u>AA</u>		<u>325MG;10MG</u>	<u>A202214</u>	<u>003</u>	Mar 27, 2013
<u>AA</u>	VINTAGE PHARMS	<u>325MG;5MG</u>	<u>A040655</u>	<u>001</u>	Jan 19, 2006
<u>AA</u>		<u>325MG;7.5MG</u>	<u>A040656</u>	<u>001</u>	Jan 19, 2006
<u>AA</u>		<u>325MG;10MG</u>	<u>A040355</u>	<u>001</u>	May 31, 2000
<u>AA</u>	WES PHARMA INC	<u>300MG;5MG</u>	<u>A207509</u>	<u>001</u>	Oct 29, 2018
<u>AA</u>		<u>300MG;7.5MG</u>	<u>A207509</u>	<u>002</u>	Oct 29, 2018
<u>AA</u>		<u>300MG;10MG</u>	<u>A207509</u>	<u>003</u>	Oct 29, 2018
<u>AA</u>		<u>325MG;5MG</u>	<u>A210211</u>	<u>001</u>	Oct 30, 2017
<u>AA</u>		<u>325MG;7.5MG</u>	<u>A210211</u>	<u>002</u>	Oct 30, 2017
<u>AA</u>		<u>325MG;10MG</u>	<u>A210211</u>	<u>003</u>	Oct 30, 2017

NORCO

<u>AA</u>	APIL	<u>325MG;2.5MG</u>	<u>A040148</u>	<u>004</u>	Jul 07, 2014
<u>AA</u>	!	<u>325MG;5MG</u>	<u>A040099</u>	<u>001</u>	Jun 25, 1997
<u>AA</u>		<u>325MG;5MG</u>	<u>A040148</u>	<u>005</u>	Jul 07, 2014
<u>AA</u>	!	<u>325MG;7.5MG</u>	<u>A040148</u>	<u>003</u>	Sep 12, 2000
<u>AA</u>	!	<u>325MG;10MG</u>	<u>A040148</u>	<u>001</u>	Feb 14, 1997

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION; ORAL

OXYCODONE AND ACETAMINOPHEN

!	ABHAI LLC	325MG/5ML; 5MG/5ML	A211499	001	Dec 31, 2018
	MIKART INC	300MG/5ML; 10MG/5ML	A202142	001	Nov 27, 2018

TABLET; ORAL

OXYCET

<u>AA</u>	SPECGX LLC	<u>325MG;5MG</u>	<u>A087463</u>	<u>001</u>	Dec 07, 1983
-----------	------------	------------------	----------------	------------	--------------

OXYCODONE AND ACETAMINOPHEN

<u>AA</u>	ABHAI LLC	<u>325MG;2.5MG</u>	<u>A210644</u>	<u>001</u>	Feb 09, 2018
<u>AA</u>		<u>325MG;5MG</u>	<u>A210644</u>	<u>002</u>	Feb 09, 2018
<u>AA</u>		<u>325MG;7.5MG</u>	<u>A210644</u>	<u>003</u>	Feb 09, 2018
<u>AA</u>		<u>325MG;10MG</u>	<u>A210644</u>	<u>004</u>	Feb 09, 2018
<u>AA</u>	ACTAVIS ELIZABETH	<u>325MG;2.5MG</u>	<u>A201447</u>	<u>001</u>	Apr 12, 2013
<u>AA</u>		<u>325MG;5MG</u>	<u>A201447</u>	<u>002</u>	Apr 12, 2013
<u>AA</u>		<u>325MG;7.5MG</u>	<u>A201447</u>	<u>003</u>	Apr 12, 2013
<u>AA</u>		<u>325MG;10MG</u>	<u>A201447</u>	<u>004</u>	Apr 12, 2013
<u>AA</u>	ALVOGEN	<u>325MG;5MG</u>	<u>A202677</u>	<u>003</u>	Mar 08, 2016
<u>AA</u>		<u>325MG;7.5MG</u>	<u>A202677</u>	<u>001</u>	Jul 26, 2012
<u>AA</u>		<u>325MG;10MG</u>	<u>A202677</u>	<u>002</u>	Jul 26, 2012
<u>AA</u>	AMNEAL PHARMS	<u>325MG;5MG</u>	<u>A040777</u>	<u>001</u>	Nov 27, 2007
<u>AA</u>	AMNEAL PHARMS NY	<u>325MG;7.5MG</u>	<u>A040778</u>	<u>002</u>	Jun 27, 2014
<u>AA</u>		<u>325MG;10MG</u>	<u>A040778</u>	<u>001</u>	Nov 27, 2007
<u>AA</u>	ANDA REPOSITORY	<u>325MG;5MG</u>	<u>A207834</u>	<u>001</u>	Aug 15, 2019
<u>AA</u>		<u>325MG;7.5MG</u>	<u>A207834</u>	<u>002</u>	Aug 15, 2019
<u>AA</u>		<u>325MG;10MG</u>	<u>A207834</u>	<u>003</u>	Aug 15, 2019
<u>AA</u>	ASCENT PHARMS INC	<u>325MG;2.5MG</u>	<u>A207419</u>	<u>001</u>	Mar 22, 2017
<u>AA</u>		<u>325MG;5MG</u>	<u>A207419</u>	<u>002</u>	Mar 22, 2017
<u>AA</u>		<u>325MG;7.5MG</u>	<u>A207419</u>	<u>003</u>	Mar 22, 2017
<u>AA</u>		<u>325MG;10MG</u>	<u>A207419</u>	<u>004</u>	Mar 22, 2017
<u>AA</u>	AUROLIFE PHARMA LLC	<u>325MG;2.5MG</u>	<u>A201972</u>	<u>001</u>	Jul 15, 2013
<u>AA</u>		<u>325MG;5MG</u>	<u>A201972</u>	<u>002</u>	Jul 15, 2013
<u>AA</u>		<u>325MG;7.5MG</u>	<u>A201972</u>	<u>003</u>	Jul 15, 2013
<u>AA</u>		<u>325MG;10MG</u>	<u>A201972</u>	<u>004</u>	Jul 15, 2013
<u>AA</u>	EPIC PHARMA LLC	<u>325MG;5MG</u>	<u>A203864</u>	<u>001</u>	Jul 02, 2018
<u>AA</u>		<u>325MG;7.5MG</u>	<u>A203864</u>	<u>002</u>	Jul 02, 2018
<u>AA</u>		<u>325MG;10MG</u>	<u>A203864</u>	<u>003</u>	Jul 02, 2018

PRESCRIPTION DRUG PRODUCT LIST

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

<u>AA</u>	MAYNE PHARMA INC	<u>325MG; 2.5MG</u>	<u>A090177 001</u>	Oct 20, 2008
<u>AA</u>		<u>325MG; 5MG</u>	<u>A090177 002</u>	Oct 20, 2008
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A090177 003</u>	Oct 20, 2008
<u>AA</u>		<u>325MG; 10MG</u>	<u>A090177 004</u>	Oct 20, 2008
<u>AA</u>	NESHER PHARMS	<u>325MG; 2.5MG</u>	<u>A210079 001</u>	Dec 28, 2017
<u>AA</u>		<u>325MG; 5MG</u>	<u>A210079 002</u>	Dec 28, 2017
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A210079 003</u>	Dec 28, 2017
<u>AA</u>		<u>325MG; 10MG</u>	<u>A210079 004</u>	Dec 28, 2017
<u>AA</u>	NOVEL LABS INC	<u>325MG; 2.5MG</u>	<u>A204407 001</u>	Feb 24, 2017
<u>AA</u>		<u>325MG; 5MG</u>	<u>A204407 002</u>	Feb 24, 2017
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A204407 003</u>	Feb 24, 2017
<u>AA</u>		<u>325MG; 10MG</u>	<u>A204407 004</u>	Feb 24, 2017
<u>AA</u>	RHODES PHARMS	<u>325MG; 5MG</u>	<u>A201278 001</u>	Aug 28, 2014
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A201278 002</u>	Aug 28, 2014
<u>AA</u>		<u>325MG; 10MG</u>	<u>A201278 003</u>	Aug 28, 2014
<u>AA</u>	SPECGX LLC	<u>325MG; 7.5MG</u>	<u>A040545 001</u>	Jun 30, 2004
<u>AA</u>		<u>325MG; 10MG</u>	<u>A040545 002</u>	Jun 30, 2004
<u>AA</u>	SUN PHARM INDS INC	<u>325MG; 2.5MG</u>	<u>A090535 001</u>	Dec 26, 2013
<u>AA</u>		<u>325MG; 5MG</u>	<u>A090535 002</u>	Dec 26, 2013
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A090535 003</u>	Dec 26, 2013
<u>AA</u>		<u>325MG; 10MG</u>	<u>A090535 004</u>	Dec 26, 2013
<u>AA</u>	VINTAGE PHARMS	<u>325MG; 2.5MG</u>	<u>A090733 001</u>	Jul 11, 2013
<u>AA</u>		<u>325MG; 5MG</u>	<u>A040105 001</u>	Jul 30, 1996
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A090734 001</u>	Jul 11, 2013
<u>AA</u>		<u>325MG; 10MG</u>	<u>A090734 002</u>	Jul 11, 2013
<u>AA</u>	WES PHARMA INC	<u>325MG; 5MG</u>	<u>A207510 001</u>	Mar 21, 2018
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A207510 002</u>	Mar 21, 2018
<u>AA</u>		<u>325MG; 10MG</u>	<u>A207510 003</u>	Mar 21, 2018

PERCOCET

<u>AA</u>	! VINTAGE PHARMS LLC	<u>325MG; 2.5MG</u>	<u>A040330 001</u>	Jun 25, 1999
<u>AA</u>	!	<u>325MG; 5MG</u>	<u>A040330 002</u>	Jun 25, 1999
<u>AA</u>	!	<u>325MG; 7.5MG</u>	<u>A040330 003</u>	Nov 23, 2001
<u>AA</u>	!	<u>325MG; 10MG</u>	<u>A040330 004</u>	Nov 23, 2001

ROXICET

<u>AA</u>	HIKMA	<u>325MG; 5MG</u>	<u>A087003 001</u>	
	OXYCODONE AND ACETAMINOPHEN			
	! MIKART	<u>300MG; 2.5MG</u>	<u>A040608 001</u>	Dec 30, 2005
	!	<u>300MG; 5MG</u>	<u>A040608 002</u>	Dec 30, 2005
	!	<u>300MG; 7.5MG</u>	<u>A040608 003</u>	Dec 30, 2005
	!	<u>300MG; 10MG</u>	<u>A040608 004</u>	Dec 30, 2005

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

<u>AB</u>	ALKEM LABS LTD	<u>325MG; 37.5MG</u>	<u>A202076 001</u>	Mar 30, 2012
<u>AB</u>	AMNEAL PHARMS	<u>325MG; 37.5MG</u>	<u>A090485 001</u>	Dec 09, 2009
<u>AB</u>	AUROBINDO PHARMA LTD	<u>325MG; 37.5MG</u>	<u>A207152 001</u>	Mar 22, 2017
<u>AB</u>	MICRO LABS LTD INDIA	<u>325MG; 37.5MG</u>	<u>A201952 001</u>	Dec 14, 2012
<u>AB</u>	MYLAN	<u>325MG; 37.5MG</u>	<u>A077858 001</u>	Sep 26, 2008
<u>AB</u>	SUN PHARM INDS INC	<u>325MG; 37.5MG</u>	<u>A077184 001</u>	Dec 16, 2005
<u>AB</u>	ZYDUS PHARMS USA INC	<u>325MG; 37.5MG</u>	<u>A090460 001</u>	Sep 06, 2012

ULTRACET

<u>AB</u>	+! JANSSEN PHARMS	<u>325MG; 37.5MG</u>	<u>N021123 001</u>	Aug 15, 2001
-----------	-------------------	----------------------	--------------------	--------------

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL

ACETAZOLAMIDE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>500MG</u>	<u>A210423 001</u>	Feb 19, 2019
<u>AB</u>	CADILA	<u>500MG</u>	<u>A205301 001</u>	Jan 16, 2019
<u>AB</u>	HERITAGE PHARMA	<u>500MG</u>	<u>A040904 001</u>	Dec 10, 2008
<u>AB</u>	! HERITAGE PHARMS INC	<u>500MG</u>	<u>A090779 001</u>	Jul 14, 2011
<u>AB</u>	MICRO LABS LTD INDIA	<u>500MG</u>	<u>A207401 001</u>	Oct 01, 2020
<u>AB</u>	NOSTRUM LABS INC	<u>500MG</u>	<u>A204691 001</u>	Mar 29, 2016
<u>AB</u>	NOVAST LABS	<u>500MG</u>	<u>A203434 001</u>	Sep 30, 2016

TABLET; ORAL

ACETAZOLAMIDE

<u>AB</u>	BRECKENRIDGE	<u>125MG</u>	<u>A207503 001</u>	Apr 30, 2020
-----------	--------------	--------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ACETAZOLAMIDE

TABLET; ORAL

ACETAZOLAMIDE

<u>AB</u>		<u>250MG</u>	<u>A207503 002</u>	Apr 30, 2020
<u>AB</u>	EYWA PHARMA	<u>125MG</u>	<u>A211556 001</u>	Oct 18, 2019
<u>AB</u>		<u>250MG</u>	<u>A211556 002</u>	Oct 18, 2019
<u>AB</u>	HERITAGE PHARMA	<u>125MG</u>	<u>A205530 001</u>	Oct 27, 2016
<u>AB</u>		<u>250MG</u>	<u>A205530 002</u>	Oct 27, 2016
<u>AB</u>	LANNETT	<u>250MG</u>	<u>A084840 001</u>	
<u>AB</u>	MANKIND PHARMA	<u>125MG</u>	<u>A214282 001</u>	Oct 07, 2020
<u>AB</u>		<u>250MG</u>	<u>A214282 002</u>	Oct 07, 2020
<u>AB</u>	NOVITIUM PHARMA	<u>125MG</u>	<u>A210588 001</u>	Oct 17, 2019
<u>AB</u>		<u>250MG</u>	<u>A210588 002</u>	Oct 17, 2019
<u>AB</u>	STRIDES PHARMA	<u>125MG</u>	<u>A209734 001</u>	Nov 20, 2017
<u>AB</u>		<u>250MG</u>	<u>A209734 002</u>	Nov 20, 2017
<u>AB</u>	TARO	<u>125MG</u>	<u>A040195 001</u>	May 28, 1997
<u>AB</u>	!	<u>250MG</u>	<u>A040195 002</u>	May 28, 1997

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

<u>AP</u>	MYLAN ASI	<u>EQ 500MG BASE/VIAL</u>	<u>A200880 001</u>	May 09, 2012
<u>AP</u>	WEST-WARD PHARMS INT	<u>EQ 500MG BASE/VIAL</u>	<u>A040089 001</u>	Feb 28, 1995
<u>AP</u>	! XGEN PHARMS	<u>EQ 500MG BASE/VIAL</u>	<u>A040784 001</u>	Dec 10, 2008
<u>AP</u>	ZYDUS PHARMS	<u>EQ 500MG BASE/VIAL</u>	<u>A206533 001</u>	Apr 15, 2019

ACETIC ACID, GLACIAL

SOLUTION; IRRIGATION, URETHRAL

ACETIC ACID 0.25% IN PLASTIC CONTAINER

<u>AT</u>	B BRAUN	<u>250MG/100ML</u>	<u>N018161 001</u>	
<u>AT</u>	BAXTER HLTHCARE	<u>250MG/100ML</u>	<u>N018523 001</u>	Feb 19, 1982
<u>AT</u>	+! ICU MEDICAL INC	<u>250MG/100ML</u>	<u>N017656 001</u>	

SOLUTION/DROPS; OTIC

ACETIC ACID

<u>AT</u>	RISING	<u>2%</u>	<u>A207280 001</u>	Mar 09, 2018
<u>AT</u>	SAPTALIS PHARMS	<u>2%</u>	<u>A040607 001</u>	Feb 24, 2005
<u>AT</u>	TARO	<u>2%</u>	<u>A088638 001</u>	Sep 06, 1984
<u>AT</u>	! WOCKHARDT BIO AG	<u>2%</u>	<u>A040166 001</u>	Jul 26, 1996

VOSOL

<u>AT</u>	AKORN	<u>2%</u>	<u>N012179 001</u>	
-----------	-------	-----------	--------------------	--

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC

HYDROCORTISONE AND ACETIC ACID

<u>AT</u>	COSETTE	<u>2%:1%</u>	<u>A040609 001</u>	Feb 06, 2006
<u>AT</u>	TARO PHARM INDS LTD	<u>2%:1%</u>	<u>A088759 001</u>	Mar 04, 1985

VOSOL HC

<u>AT</u>	+! AKORN	<u>2%:1%</u>	<u>N012770 001</u>	
-----------	----------	--------------	--------------------	--

ACETOHYDROXAMIC ACID

TABLET; ORAL

LITHOSTAT

+!	MISSION PHARMA	250MG	N018749 001	May 31, 1983
----	----------------	-------	-------------	--------------

ACETYLCHOLINE CHLORIDE

FOR SOLUTION; OPHTHALMIC

MIOCHOL-E

+!	BAUSCH AND LOMB	20MG/VIAL	N020213 001	Sep 22, 1993
----	-----------------	-----------	-------------	--------------

ACETYLCYSTEINE

INJECTABLE; INTRAVENOUS

ACETADOTE

<u>AP</u>	+! CUMBERLAND PHARMS	<u>6GM/30ML (200MG/ML)</u>	<u>N021539 001</u>	Jan 23, 2004
-----------	----------------------	----------------------------	--------------------	--------------

ACETYLCYSTEINE

<u>AP</u>	AKORN	<u>6GM/30ML (200MG/ML)</u>	<u>A203173 001</u>	Mar 24, 2015
<u>AP</u>	AUROBINDO PHARMA LTD	<u>6GM/30ML (200MG/ML)</u>	<u>A207358 001</u>	Feb 29, 2016
<u>AP</u>	FRESENIUS KABI USA	<u>6GM/30ML (200MG/ML)</u>	<u>A200644 001</u>	Nov 07, 2012
<u>AP</u>	SAGENT PHARMS INC	<u>6GM/30ML (200MG/ML)</u>	<u>A091684 001</u>	Oct 31, 2017
<u>AP</u>	ZYDUS PHARMS	<u>6GM/30ML (200MG/ML)</u>	<u>A208166 001</u>	Jul 20, 2018

SOLUTION; INHALATION, ORAL

ACETYLCYSTEINE

<u>AN</u>	ALVOGEN	<u>10%</u>	<u>A204674 001</u>	Feb 11, 2014
<u>AN</u>		<u>20%</u>	<u>A203853 001</u>	Jun 21, 2012
<u>AN</u>	! AM REGENT	<u>10%</u>	<u>A072489 001</u>	Jul 28, 1995

PRESCRIPTION DRUG PRODUCT LIST

ACETYL CYSTEINE

SOLUTION; INHALATION, ORAL

ACETYL CYSTEINE

<u>AN</u>	!		<u>20%</u>	<u>A072547</u>	<u>001</u>	Jul 28, 1995
<u>AN</u>		HOSPIRA	<u>10%</u>	<u>A073664</u>	<u>001</u>	Aug 30, 1994
<u>AN</u>			<u>20%</u>	<u>A074037</u>	<u>001</u>	Aug 30, 1994

ACITRETIN

CAPSULE; ORAL

ACITRETIN

<u>AB</u>		BARR LABS INC	<u>10MG</u>	<u>A091455</u>	<u>001</u>	Apr 04, 2013
<u>AB</u>			<u>25MG</u>	<u>A091455</u>	<u>002</u>	Apr 04, 2013
<u>AB</u>		IMPAX LABS INC	<u>10MG</u>	<u>A202552</u>	<u>001</u>	Dec 23, 2015
<u>AB</u>			<u>17.5MG</u>	<u>A202552</u>	<u>002</u>	Dec 23, 2015
<u>AB</u>			<u>22.5MG</u>	<u>A202552</u>	<u>003</u>	Dec 23, 2015
<u>AB</u>			<u>25MG</u>	<u>A202552</u>	<u>004</u>	Dec 23, 2015
<u>AB</u>		MYLAN	<u>10MG</u>	<u>A202148</u>	<u>001</u>	Sep 10, 2015
<u>AB</u>			<u>25MG</u>	<u>A202148</u>	<u>002</u>	Sep 10, 2015
<u>AB</u>		SIGMAPHARM LABS LLC	<u>10MG</u>	<u>A204633</u>	<u>001</u>	May 22, 2015
<u>AB</u>			<u>17.5MG</u>	<u>A204633</u>	<u>002</u>	May 22, 2015
<u>AB</u>			<u>22.5MG</u>	<u>A204633</u>	<u>003</u>	May 22, 2015
<u>AB</u>			<u>25MG</u>	<u>A204633</u>	<u>004</u>	May 22, 2015
<u>AB</u>		TEVA PHARMS USA	<u>17.5MG</u>	<u>A202897</u>	<u>001</u>	Apr 04, 2013
<u>AB</u>			<u>22.5MG</u>	<u>A202897</u>	<u>002</u>	Apr 04, 2013

SORIATANE

<u>AB</u>	+	STIEFEL LABS INC	<u>10MG</u>	<u>N019821</u>	<u>001</u>	Oct 28, 1996
<u>AB</u>	+	!	<u>25MG</u>	<u>N019821</u>	<u>002</u>	Oct 28, 1996

ACOLIDINIUM BROMIDE

POWDER, METERED; INHALATION

TUDORZA PRESSAIR

+! CIRCASSIA

0.4MG/INH

N202450 001 Jul 23, 2012

ACOLIDINIUM BROMIDE; FORMOTEROL FUMARATE

POWDER, METERED; INHALATION

DUAKLIR PRESSAIR

CIRCASSIA

0.4MG/INH; 0.012MG/INH

N210595 001 Mar 29, 2019

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

<u>AB</u>	!	APOTEX	<u>200MG</u>	<u>A075677</u>	<u>001</u>	Sep 28, 2005
<u>AB</u>		CADILA	<u>200MG</u>	<u>A204313</u>	<u>001</u>	Mar 25, 2016
<u>AB</u>		CADILA PHARMS LTD	<u>200MG</u>	<u>A201445</u>	<u>001</u>	Mar 06, 2014
<u>AB</u>		CARLSBAD TECHNOLOGY	<u>200MG</u>	<u>A206261</u>	<u>001</u>	Aug 16, 2017
<u>AB</u>		HERITAGE PHARMS INC	<u>200MG</u>	<u>A074889</u>	<u>001</u>	Oct 31, 1997
<u>AB</u>		KENTON	<u>200MG</u>	<u>A075090</u>	<u>001</u>	Jan 26, 1999
<u>AB</u>		TEVA	<u>200MG</u>	<u>A074578</u>	<u>001</u>	Apr 22, 1997
<u>AB</u>		YILING	<u>200MG</u>	<u>A212173</u>	<u>001</u>	Sep 14, 2020

CREAM; TOPICAL

ACYCLOVIR

<u>AB</u>		AMNEAL	<u>5%</u>	<u>A208766</u>	<u>001</u>	Nov 09, 2020
<u>AB</u>	!	PERRIGO UK FINCO	<u>5%</u>	<u>A208702</u>	<u>001</u>	Feb 04, 2019

ZOVIRAX

<u>AB</u>	+	BAUSCH	<u>5%</u>	<u>N021478</u>	<u>001</u>	Dec 30, 2002
-----------	---	--------	-----------	----------------	------------	--------------

OINTMENT; TOPICAL

ACYCLOVIR

<u>AB</u>		ALEMBIC PHARMS LTD	<u>5%</u>	<u>A209000</u>	<u>001</u>	Apr 06, 2018
<u>AB</u>		AMNEAL PHARMS	<u>5%</u>	<u>A204605</u>	<u>001</u>	Jun 18, 2014
<u>AB</u>		ANDA REPOSITORY	<u>5%</u>	<u>A206437</u>	<u>001</u>	Jul 31, 2017
<u>AB</u>		APOTEX	<u>5%</u>	<u>A210774</u>	<u>001</u>	Sep 06, 2019
<u>AB</u>		CADILA	<u>5%</u>	<u>A205974</u>	<u>001</u>	Mar 15, 2019
<u>AB</u>		CIPLA	<u>5%</u>	<u>A211794</u>	<u>001</u>	Jan 18, 2019
<u>AB</u>		COSETTE	<u>5%</u>	<u>A205591</u>	<u>001</u>	Nov 13, 2017
<u>AB</u>		FOUGERA PHARMS INC	<u>5%</u>	<u>A206633</u>	<u>001</u>	May 11, 2016
<u>AB</u>		GLENMARK PHARMS SA	<u>5%</u>	<u>A205510</u>	<u>001</u>	Jul 31, 2017
<u>AB</u>		MYLAN PHARMS INC	<u>5%</u>	<u>A202459</u>	<u>001</u>	Apr 03, 2013
<u>AB</u>		SOLARIS PHARMA CORP	<u>5%</u>	<u>A212495</u>	<u>001</u>	Apr 07, 2020
<u>AB</u>		TARO	<u>5%</u>	<u>A205469</u>	<u>001</u>	Dec 21, 2016
<u>AB</u>		TORRENT	<u>5%</u>	<u>A209971</u>	<u>001</u>	Jan 11, 2019
<u>AB</u>		XIROMED	<u>5%</u>	<u>A201501</u>	<u>001</u>	Jan 29, 2020

ZOVIRAX

<u>AB</u>	+	!	BAUSCH	<u>5%</u>	<u>N018604</u>	<u>001</u>	Mar 29, 1982
-----------	---	---	--------	-----------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ACYCLOVIR

SUSPENSION; ORAL

ACYCLOVIR

AB	ACTAVIS MID ATLANTIC	200MG/5ML	A074738 001	Apr 28, 1997
AB	AKORN	200MG/5ML	A077026 001	Jun 07, 2005
AB	HERITAGE PHARMS INC	200MG/5ML	A212718 001	Apr 23, 2020
AB	NOVITIUM PHARMA	200MG/5ML	A212252 001	Jul 10, 2020

ZOVIRAX

AB	+ ! MYLAN	200MG/5ML	N019909 001	Dec 22, 1989
	TABLET; BUCCAL			
	SITAVIG			
	+ ! EPI HLTH	50MG	N203791 001	Apr 12, 2013
	TABLET; ORAL			

ACYCLOVIR

AB	APOTEX INC	400MG	A077309 001	Sep 29, 2005
AB		800MG	A077309 002	Sep 29, 2005
AB	CADILA PHARMS LTD	400MG	A202168 001	Nov 15, 2013
AB		800MG	A202168 002	Nov 15, 2013
AB	CARLSBAD	400MG	A075382 001	Apr 30, 1999
AB		800MG	A075382 002	Apr 30, 1999
AB	DAVA PHARMS INC	400MG	A074946 001	Nov 19, 1997
AB		800MG	A074946 002	Nov 19, 1997
AB	HERITAGE PHARMS INC	400MG	A074891 001	Oct 31, 1997
AB		800MG	A074891 002	Oct 31, 1997
AB	HETERO LABS LTD V	400MG	A203834 001	Oct 29, 2013
AB	!	800MG	A203834 002	Oct 29, 2013
AB	SQUARE PHARMS LTD	400MG	A209366 001	Oct 07, 2019
AB		800MG	A209366 002	Oct 07, 2019
AB	TEVA	400MG	A074556 002	Apr 22, 1997
AB		800MG	A074556 003	Apr 22, 1997
AB	YILING	400MG	A210401 001	Mar 07, 2018
AB		800MG	A210401 002	Mar 07, 2018
AB	ZYDUS PHARMS	400MG	A204314 001	Aug 19, 2014
AB		800MG	A204314 002	Aug 19, 2014

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

AP	AUROBINDO PHARMA LTD	EQ 50MG BASE/ML	A203701 001	Oct 11, 2013
AP	EXELA PHARMA	EQ 50MG BASE/ML	A207919 001	Jun 17, 2020
AP	! FRESENIUS KABI USA	EQ 50MG BASE/ML	A074930 001	May 13, 1998
	! ZYDUS PHARMS	EQ 500MG BASE/VIAL	A206535 001	Aug 31, 2018
	!	EQ 1GM BASE/VIAL	A206535 002	Aug 31, 2018

ACYCLOVIR; HYDROCORTISONE

CREAM; TOPICAL

XERESE

+ !	BAUSCH	5%;1%	N022436 001	Jul 31, 2009
------------	--------	-------	-------------	--------------

ADAPALENE

CREAM; TOPICAL

ADAPALENE

AB	FOUGERA PHARMS	0.1%	A090824 001	Jun 30, 2010
-----------	----------------	-------------	--------------------	--------------

DIFFERIN

AB	+ ! GALDERMA LABS LP	0.1%	N020748 001	May 26, 2000
-----------	-----------------------------	-------------	--------------------	--------------

GEL; TOPICAL

ADAPALENE

AB	ACTAVIS MID ATLANTIC	0.3%	A201000 001	Oct 27, 2014
AB	ALEOR DERMACEUTICALS	0.3%	A213508 001	Jun 18, 2020
AB	TARO	0.3%	A208322 001	Jun 23, 2016
AB	TOLMAR	0.3%	A200298 001	Jun 14, 2012

DIFFERIN

AB	+ ! GALDERMA LABS LP	0.3%	N021753 001	Jun 19, 2007
-----------	-----------------------------	-------------	--------------------	--------------

LOTION; TOPICAL

DIFFERIN

+ !	GALDERMA LABS LP	0.1%	N022502 001	Mar 17, 2010
------------	------------------	------	-------------	--------------

SOLUTION; TOPICAL

ADAPALENE

AB	CALL INC	0.1%	A203981 001	Sep 23, 2016
AB		0.1%	A204593 001	Jan 05, 2016

PRESCRIPTION DRUG PRODUCT LIST

ADAPALENE; BENZOYL PEROXIDE

GEL; TOPICAL

ADAPALENE AND BENZOYL PEROXIDE

<u>AB</u>	ACTAVIS MID ATLANTIC	<u>0.1%;2.5%</u>	<u>A203790 001</u>	Sep 30, 2015
<u>AB</u>	GLENMARK PHARMS LTD	<u>0.1%;2.5%</u>	<u>A208108 001</u>	Nov 08, 2019
<u>AB</u>	PERRIGO UK FINCO	<u>0.1%;2.5%</u>	<u>A205033 001</u>	Jan 23, 2018
<u>AB</u>	TARO	<u>0.1%;2.5%</u>	<u>A206959 001</u>	Jan 24, 2018
<u>AB</u>	TOLMAR	<u>0.1%;2.5%</u>	<u>A206164 001</u>	May 23, 2018

EPIDUO

<u>AB</u>	+! GALDERMA LABS LP	<u>0.1%;2.5%</u>	<u>N022320 001</u>	Dec 08, 2008
-----------	---------------------	------------------	--------------------	--------------

EPIDUO FORTE

<u>AB</u>	+! GALDERMA LABS	<u>0.3%;2.5%</u>	<u>N207917 001</u>	Jul 15, 2015
-----------	------------------	------------------	--------------------	--------------

ADEFOVIR DIPIVOXIL

TABLET; ORAL

ADEFOVIR DIPIVOXIL

<u>AB</u>	APOTEX	<u>10MG</u>	<u>A205459 001</u>	Jul 06, 2018
<u>AB</u>	SIGMAPHARM LABS LLC	<u>10MG</u>	<u>A202051 001</u>	Aug 29, 2013

HEPSERA

<u>AB</u>	+! GILEAD	<u>10MG</u>	<u>N021449 001</u>	Sep 20, 2002
-----------	-----------	-------------	--------------------	--------------

ADENOSINE

INJECTABLE; INJECTION

ADENOSINE

<u>AP</u>	! AKORN	<u>3MG/ML</u>	<u>A078076 001</u>	Oct 31, 2008
<u>AP</u>	FRESENIUS KABI USA	<u>3MG/ML</u>	<u>A077133 001</u>	Apr 27, 2005
<u>AP</u>		<u>3MG/ML</u>	<u>A205568 001</u>	Apr 16, 2018
<u>AP</u>	GLAND PHARMA LTD	<u>3MG/ML</u>	<u>A077283 001</u>	Jun 14, 2007
<u>AP</u>		<u>3MG/ML</u>	<u>A206778 001</u>	Feb 16, 2018
<u>AP</u>	MYLAN LABS LTD	<u>3MG/ML</u>	<u>A078686 001</u>	May 13, 2009
<u>AP</u>	WEST-WARD PHARMS INT	<u>3MG/ML</u>	<u>A076404 001</u>	Jun 16, 2004
<u>AP</u>		<u>3MG/ML</u>	<u>A076500 001</u>	Jun 16, 2004

SOLUTION; INTRAVENOUS

ADENOSINE

<u>AP</u>	AKORN	<u>60MG/20ML (3MG/ML)</u>	<u>A090450 001</u>	Oct 02, 2014
<u>AP</u>		<u>90MG/30ML (3MG/ML)</u>	<u>A090450 002</u>	Oct 02, 2014
<u>AP</u>	AUROBINDO PHARMA LTD	<u>60MG/20ML (3MG/ML)</u>	<u>A205331 001</u>	Nov 02, 2017
<u>AP</u>		<u>90MG/30ML (3MG/ML)</u>	<u>A205331 002</u>	Nov 02, 2017
<u>AP</u>	FRESENIUS KABI USA	<u>60MG/20ML (3MG/ML)</u>	<u>A077897 001</u>	Nov 27, 2017
<u>AP</u>		<u>90MG/30ML (3MG/ML)</u>	<u>A077897 002</u>	Nov 27, 2017
<u>AP</u>	HOSPIRA INC	<u>60MG/20ML (3MG/ML)</u>	<u>A203883 001</u>	Mar 24, 2014
<u>AP</u>		<u>90MG/30ML (3MG/ML)</u>	<u>A203883 002</u>	Mar 24, 2014
<u>AP</u>	MYLAN ASI	<u>60MG/20ML (3MG/ML)</u>	<u>A090212 001</u>	Mar 28, 2014
<u>AP</u>		<u>90MG/30ML (3MG/ML)</u>	<u>A090212 002</u>	Mar 28, 2014
<u>AP</u>	! TEVA PHARMS USA	<u>60MG/20ML (3MG/ML)</u>	<u>A077425 001</u>	Aug 29, 2013
<u>AP</u>	!	<u>90MG/30ML (3MG/ML)</u>	<u>A077425 002</u>	Aug 29, 2013

AFAMELANOTIDE

IMPLANT; SUBCUTANEOUS

SCENESSE

+!	CLIVUNEL INC	16MG	N210797 001	Oct 08, 2019
----	--------------	------	-------------	--------------

AFATINIB DIMALEATE

TABLET; ORAL

GILOTRIF

+	BOEHRINGER INGELHEIM	EQ 20MG BASE	N201292 001	Jul 12, 2013
+		EQ 30MG BASE	N201292 002	Jul 12, 2013
+!		EQ 40MG BASE	N201292 003	Jul 12, 2013

AIR POLYMER-TYPE A

FOAM; INTRAUTERINE

EXEM FOAM KIT

+!	GISKIT	10ML	N212279 001	Nov 07, 2019
----	--------	------	-------------	--------------

ALBENDAZOLE

TABLET; ORAL

ALBENDAZOLE

<u>AB</u>	ACTAVIS ELIZABETH	<u>200MG</u>	<u>A208094 001</u>	May 20, 2019
<u>AB</u>	CIPLA LTD	<u>200MG</u>	<u>A210434 001</u>	Sep 21, 2018
<u>AB</u>	EDENBRIDGE PHARMS	<u>200MG</u>	<u>A211117 001</u>	May 14, 2019
<u>AB</u>	LUPIN LTD	<u>200MG</u>	<u>A211636 001</u>	Jun 10, 2020
<u>AB</u>	STRIDES PHARMA	<u>200MG</u>	<u>A210011 001</u>	Dec 07, 2018

PRESCRIPTION DRUG PRODUCT LIST

ALBENDAZOLE

TABLET; ORAL

ALBENDAZOLE

<u>AB</u>	ZYDUS PHARMS	<u>200MG</u>	<u>A208979 001</u>	Dec 14, 2018
-----------	--------------	--------------	--------------------	--------------

ALBENZA

<u>AB</u>	+! IMPAX LABS INC	<u>200MG</u>	<u>N020666 001</u>	Jun 11, 1996
-----------	-------------------	--------------	--------------------	--------------

ALBUMIN HUMAN

INJECTABLE; INJECTION

OPTISON

+!	GE HEALTHCARE	10MG/ML	N020899 001	Dec 31, 1997
----	---------------	---------	-------------	--------------

ALBUTEROL SULFATE

AEROSOL, METERED; INHALATION

ALBUTEROL SULFATE

<u>AB1</u>	CIPLA	<u>EQ 0.09MG BASE/INH</u>	<u>A209959 001</u>	Apr 08, 2020
------------	-------	---------------------------	--------------------	--------------

PROVENTIL-HFA

<u>AB1</u>	+! KINDEVA	<u>EQ 0.09MG BASE/INH</u>	<u>N020503 001</u>	Aug 15, 1996
------------	------------	---------------------------	--------------------	--------------

ALBUTEROL SULFATE

<u>AB2</u>	LUPIN	<u>EQ 0.09MG BASE/INH</u>	<u>A209954 001</u>	Aug 24, 2020
------------	-------	---------------------------	--------------------	--------------

PROAIR HFA

<u>AB2</u>	+! TEVA BRANDED PHARM	<u>EQ 0.09MG BASE/INH</u>	<u>N021457 001</u>	Oct 29, 2004
------------	-----------------------	---------------------------	--------------------	--------------

VENTOLIN HFA

BX	+! GLAXOSMITHKLINE	EQ 0.09MG BASE/INH	N020983 001	Apr 19, 2001
----	--------------------	--------------------	-------------	--------------

POWDER, METERED; INHALATION

PROAIR DIGIHALER

+	TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N205636 002	Dec 21, 2018
---	--------------------	--------------------	-------------	--------------

PROAIR RESPICLICK

+!	TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N205636 001	Mar 31, 2015
----	--------------------	--------------------	-------------	--------------

SOLUTION; INHALATION

ACCUNEB

<u>AN</u>	+! MYLAN SPECIALITY LP	<u>EQ 0.021% BASE</u>	<u>N020949 002</u>	Apr 30, 2001
-----------	------------------------	-----------------------	--------------------	--------------

<u>AN</u>	+!	<u>EQ 0.042% BASE</u>	<u>N020949 001</u>	Apr 30, 2001
-----------	----	-----------------------	--------------------	--------------

ALBUTEROL SULFATE

<u>AN</u>	AKORN	<u>EQ 0.5% BASE</u>	<u>A074543 001</u>	Jan 15, 1998
-----------	-------	---------------------	--------------------	--------------

<u>AN</u>	AUROBINDO PHARMA LTD	<u>EQ 0.083% BASE</u>	<u>A206224 001</u>	Oct 17, 2017
-----------	----------------------	-----------------------	--------------------	--------------

<u>AN</u>	NEPHRON	<u>EQ 0.021% BASE</u>	<u>A076355 002</u>	Mar 31, 2010
-----------	---------	-----------------------	--------------------	--------------

<u>AN</u>		<u>EQ 0.042% BASE</u>	<u>A076355 001</u>	Jun 28, 2004
-----------	--	-----------------------	--------------------	--------------

<u>AN</u>	!	<u>EQ 0.083% BASE</u>	<u>A074880 001</u>	Sep 17, 1997
-----------	---	-----------------------	--------------------	--------------

<u>AN</u>	!	<u>EQ 0.5% BASE</u>	<u>A075664 001</u>	Jun 26, 2001
-----------	---	---------------------	--------------------	--------------

<u>AN</u>	RITEDOSE CORP	<u>EQ 0.083% BASE</u>	<u>A077839 001</u>	Dec 16, 2008
-----------	---------------	-----------------------	--------------------	--------------

<u>AN</u>	SUN PHARM	<u>EQ 0.083% BASE</u>	<u>A207857 001</u>	Jul 21, 2017
-----------	-----------	-----------------------	--------------------	--------------

<u>AN</u>	WATSON LABS	<u>EQ 0.021% BASE</u>	<u>A077772 001</u>	Sep 25, 2007
-----------	-------------	-----------------------	--------------------	--------------

<u>AN</u>		<u>EQ 0.042% BASE</u>	<u>A077772 002</u>	Sep 25, 2007
-----------	--	-----------------------	--------------------	--------------

SYRUP; ORAL

ALBUTEROL SULFATE

<u>AA</u>	AKORN	<u>EQ 2MG BASE/5ML</u>	<u>A074749 001</u>	Jan 30, 1998
-----------	-------	------------------------	--------------------	--------------

<u>AA</u>	AMNEAL PHARMS	<u>EQ 2MG BASE/5ML</u>	<u>A079241 001</u>	May 12, 2010
-----------	---------------	------------------------	--------------------	--------------

<u>AA</u>	COSETTE	<u>EQ 2MG BASE/5ML</u>	<u>A074454 001</u>	Sep 25, 1995
-----------	---------	------------------------	--------------------	--------------

<u>AA</u>	LANNETT CO INC	<u>EQ 2MG BASE/5ML</u>	<u>A078105 001</u>	Dec 27, 2006
-----------	----------------	------------------------	--------------------	--------------

<u>AA</u>	QUAGEN	<u>EQ 2MG BASE/5ML</u>	<u>A212197 001</u>	Sep 06, 2019
-----------	--------	------------------------	--------------------	--------------

<u>AA</u>	! TEVA	<u>EQ 2MG BASE/5ML</u>	<u>A073419 001</u>	Mar 30, 1992
-----------	--------	------------------------	--------------------	--------------

TABLET; ORAL

ALBUTEROL SULFATE

<u>AB</u>	AMNEAL PHARMS CO	<u>EQ 2MG BASE</u>	<u>A208804 001</u>	May 21, 2018
-----------	------------------	--------------------	--------------------	--------------

<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A208804 002</u>	May 21, 2018
-----------	--	--------------------	--------------------	--------------

<u>AB</u>	EYWA	<u>EQ 2MG BASE</u>	<u>A213524 001</u>	Oct 08, 2020
-----------	------	--------------------	--------------------	--------------

<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A213524 002</u>	Oct 08, 2020
-----------	--	--------------------	--------------------	--------------

<u>AB</u>	MYLAN	<u>EQ 2MG BASE</u>	<u>A072894 002</u>	Jan 17, 1991
-----------	-------	--------------------	--------------------	--------------

<u>AB</u>	!	<u>EQ 4MG BASE</u>	<u>A072894 001</u>	Jan 17, 1991
-----------	---	--------------------	--------------------	--------------

<u>AB</u>	RISING	<u>EQ 2MG BASE</u>	<u>A207046 001</u>	Jun 29, 2018
-----------	--------	--------------------	--------------------	--------------

<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A207046 002</u>	Jun 29, 2018
-----------	--	--------------------	--------------------	--------------

<u>AB</u>	SUN PHARM INDUSTRIES	<u>EQ 2MG BASE</u>	<u>A072637 002</u>	Dec 05, 1989
-----------	----------------------	--------------------	--------------------	--------------

<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A072637 001</u>	Dec 05, 1989
-----------	--	--------------------	--------------------	--------------

<u>AB</u>	VIRTUS PHARM	<u>EQ 2MG BASE</u>	<u>A211397 001</u>	Oct 26, 2018
-----------	--------------	--------------------	--------------------	--------------

<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A211397 002</u>	Oct 26, 2018
-----------	--	--------------------	--------------------	--------------

<u>AB</u>	ZYDUS PHARMS	<u>EQ 2MG BASE</u>	<u>A208884 001</u>	Oct 22, 2020
-----------	--------------	--------------------	--------------------	--------------

<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A208884 002</u>	Oct 22, 2020
-----------	--	--------------------	--------------------	--------------

TABLET, EXTENDED RELEASE; ORAL

ALBUTEROL SULFATE

<u>AB</u>	MYLAN	<u>EQ 4MG BASE</u>	<u>A078092 002</u>	Jan 29, 2007
-----------	-------	--------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ALBUTEROL SULFATE

TABLET, EXTENDED RELEASE;ORAL

YOSPIRE ER

AB	DAVA PHARMS INC	EQ 4MG BASE	A076130 002	Sep 26, 2002
	ALBUTEROL SULFATE			
	! MYLAN	EQ 8MG BASE	A078092 001	Jan 29, 2007

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION;INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

AN	AUROBINDO PHARMA LTD	EQ 0.083% BASE;0.017%	A206532 001	Jul 08, 2020
AN	CIPLA	EQ 0.083% BASE;0.017%	A077559 001	Dec 31, 2007
AN	NEPHRON	EQ 0.083% BASE;0.017%	A076749 001	Dec 31, 2007
AN	RITEDOSE CORP	EQ 0.083% BASE;0.017%	A202496 001	Oct 01, 2012
AN	SUN PHARM	EQ 0.083% BASE;0.017%	A207875 001	Aug 07, 2017
	SPRAY, METERED;INHALATION			
	COMBIVENT RESPIMAT			
	+! BOEHRINGER INGELHEIM	EQ 0.1MG BASE/INH;0.02MG/INH	N021747 001	Oct 07, 2011

ALCAFTADINE

SOLUTION/DROPS;OPHTHALMIC

LASTACFT

	+! ALLERGAN	0.25%	N022134 001	Jul 28, 2010
--	-------------	-------	-------------	--------------

ALCLOMETASONE DIPROPIONATE

CREAM;TOPICAL

ALCLOMETASONE DIPROPIONATE

AB	! FOUGERA PHARMS	0.05%	A076973 001	Jul 12, 2005
AB	GLENMARK GENERICS	0.05%	A079061 001	Jun 23, 2009
AB	TARO	0.05%	A076587 001	Sep 15, 2005

OINTMENT;TOPICAL

ALCLOMETASONE DIPROPIONATE

AB	! FOUGERA PHARMS	0.05%	A076884 001	Jul 18, 2005
AB	GLENMARK GENERICS	0.05%	A079227 001	Jul 30, 2009
AB	TARO	0.05%	A076730 001	Jul 29, 2004

ALCOHOL

SOLUTION;INTRA-ARTERIAL

ABLYSINOL

	+ BELCHER	99% (1ML)	N207987 001	Jun 21, 2018
	+!	99% (5ML)	N207987 002	Jun 21, 2018

ALECTINIB HYDROCHLORIDE

CAPSULE;ORAL

ALECENSA

	+! HOFFMANN-LA ROCHE	EQ 150MG BASE	N208434 001	Dec 11, 2015
--	----------------------	---------------	-------------	--------------

ALENDRONATE SODIUM

SOLUTION;ORAL

ALENDRONATE SODIUM

	! HIKMA	EQ 70MG BASE/75ML	A090520 001	Feb 25, 2013
--	---------	-------------------	-------------	--------------

TABLET;ORAL

ALENDRONATE SODIUM

AB	APOTEX	EQ 5MG BASE	A077982 001	Aug 04, 2008
AB		EQ 10MG BASE	A077982 002	Aug 04, 2008
AB		EQ 35MG BASE	A077982 003	Aug 04, 2008
AB		EQ 70MG BASE	A077982 004	Aug 04, 2008
AB	AUROBINDO PHARMA	EQ 10MG BASE	A090124 001	Aug 04, 2008
AB		EQ 35MG BASE	A090124 002	Aug 04, 2008
AB		EQ 70MG BASE	A090124 003	Aug 04, 2008
AB	CIPLA	EQ 5MG BASE	A076768 001	Aug 04, 2008
AB		EQ 10MG BASE	A076768 002	Aug 04, 2008
AB		EQ 35MG BASE	A076768 003	Aug 04, 2008
AB		EQ 40MG BASE	A076768 004	Aug 04, 2008
AB		EQ 70MG BASE	A076768 005	Aug 04, 2008
AB	HANGZHOU BINJIANG	EQ 5MG BASE	A090258 001	Sep 24, 2009
AB		EQ 10MG BASE	A090258 002	Sep 24, 2009
AB		EQ 35MG BASE	A090258 003	Sep 24, 2009
AB		EQ 70MG BASE	A090258 004	Sep 24, 2009
AB	IMPAX LABS INC	EQ 5MG BASE	A075710 001	Feb 06, 2008
AB		EQ 10MG BASE	A075710 002	Feb 06, 2008
AB		EQ 35MG BASE	A075710 003	Feb 06, 2008
AB		EQ 40MG BASE	A075710 004	Feb 06, 2008
AB		EQ 70MG BASE	A075710 005	Feb 06, 2008

PRESCRIPTION DRUG PRODUCT LIST

ALENDRONATE SODIUM

TABLET; ORAL

ALENDRONATE SODIUM

<u>AB</u>	JUBILANT CADISTA	<u>EQ 5MG BASE</u>	<u>A090557 001</u>	Feb 18, 2010
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090557 002</u>	Feb 18, 2010
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A090557 003</u>	Feb 18, 2010
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A090557 004</u>	Feb 18, 2010
<u>AB</u>	SUN PHARM	<u>EQ 5MG BASE</u>	<u>A090022 001</u>	Sep 10, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090022 002</u>	Sep 10, 2008
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A090022 003</u>	Sep 10, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A090022 004</u>	Sep 10, 2008
<u>AB</u>	WATSON LABS	<u>EQ 35MG BASE</u>	<u>A076984 001</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076984 002</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A076984 003</u>	Aug 04, 2008

FOSAMAX

<u>AB</u>	+! MERCK AND CO INC	<u>EQ 70MG BASE</u>	<u>N020560 005</u>	Oct 20, 2000
	TABLET, EFFERVESCENT; ORAL			
	BINOSTO			
	+! ASCEND THERAPS US	EQ 70MG BASE	N202344 001	Mar 12, 2012

ALENDRONATE SODIUM; CHOLECALCIFEROL

TABLET; ORAL

FOSAMAX PLUS D

+	MERCK	EQ 70MG BASE; 2,800 IU	N021762 001	Apr 07, 2005
+	!	EQ 70MG BASE; 5,600 IU	N021762 002	Apr 26, 2007

ALFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION

ALFENTA

<u>AP</u>	+! AKORN	<u>EQ 0.5MG BASE/ML</u>	<u>N019353 001</u>	Dec 29, 1986
	<u>ALFENTANIL</u>			
<u>AP</u>	HOSPIRA	<u>EQ 0.5MG BASE/ML</u>	<u>A075221 001</u>	Oct 28, 1999

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALFUZOSIN HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>10MG</u>	<u>A079013 001</u>	Jul 18, 2011
<u>AB</u>	AUROBINDO PHARMA LTD	<u>10MG</u>	<u>A079060 001</u>	Aug 30, 2012
<u>AB</u>	INVAGEN PHARMS	<u>10MG</u>	<u>A090284 001</u>	Jan 17, 2012
<u>AB</u>	SUN PHARM	<u>10MG</u>	<u>A079057 001</u>	Jul 18, 2011
<u>AB</u>	UNICHEM	<u>10MG</u>	<u>A203192 001</u>	Jan 28, 2016
	<u>UROXATRAL</u>			
<u>AB</u>	+! CONCORDIA	<u>10MG</u>	<u>N021287 001</u>	Jun 12, 2003

ALISKIREN HEMIFUMARATE

TABLET; ORAL

ALISKIREN HEMIFUMARATE

<u>AB</u>	ANCHEN PHARMS	<u>EQ 150MG BASE</u>	<u>A206665 001</u>	Mar 22, 2019
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A206665 002</u>	Mar 22, 2019
	<u>TEKTURNA</u>			
<u>AB</u>	+ NODEN PHARMA	<u>EQ 150MG BASE</u>	<u>N021985 001</u>	Mar 05, 2007
<u>AB</u>	+!	<u>EQ 300MG BASE</u>	<u>N021985 002</u>	Mar 05, 2007

ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

TEKTURNA HCT

+	NODEN PHARMA	EQ 150MG BASE; 12.5MG	N022107 001	Jan 18, 2008
+		EQ 150MG BASE; 25MG	N022107 002	Jan 18, 2008
+	!	EQ 300MG BASE; 12.5MG	N022107 003	Jan 18, 2008
+	!	EQ 300MG BASE; 25MG	N022107 004	Jan 18, 2008

ALITRETINOIN

GEL; TOPICAL

PANRETIN

+	CONCORDIA	EQ 0.1% BASE	N020886 001	Feb 02, 1999
---	-----------	--------------	-------------	--------------

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

<u>AB</u>	ACCORD HLTHCARE	<u>100MG</u>	<u>A203154 001</u>	May 06, 2013
<u>AB</u>		<u>300MG</u>	<u>A203154 002</u>	May 06, 2013
<u>AB</u>	APOTEX INC	<u>100MG</u>	<u>A077353 001</u>	Sep 08, 2005
<u>AB</u>		<u>300MG</u>	<u>A077353 002</u>	Sep 08, 2005
<u>AB</u>	INDOCO	<u>100MG</u>	<u>A204467 001</u>	Jul 28, 2016
<u>AB</u>		<u>300MG</u>	<u>A204467 002</u>	Jul 28, 2016

PRESCRIPTION DRUG PRODUCT LIST

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

<u>AB</u>	IPCA LABS LTD	<u>100MG</u>	<u>A090637 001</u>	Mar 16, 2011
<u>AB</u>		<u>300MG</u>	<u>A090637 002</u>	Mar 16, 2011
<u>AB</u>	MYLAN	<u>100MG</u>	<u>A018659 001</u>	Oct 24, 1986
<u>AB</u>		<u>300MG</u>	<u>A018659 002</u>	Oct 24, 1986
<u>AB</u>	NORTHSTAR HLTHCARE	<u>100MG</u>	<u>A078253 001</u>	Sep 11, 2007
<u>AB</u>		<u>300MG</u>	<u>A078253 002</u>	Sep 11, 2007
<u>AB</u>	SUN PHARM INDUSTRIES	<u>100MG</u>	<u>A071450 002</u>	Jan 09, 1987
<u>AB</u>		<u>300MG</u>	<u>A071450 001</u>	Jan 09, 1987
<u>AB</u>	UNICHEM	<u>100MG</u>	<u>A211820 001</u>	Mar 12, 2019
<u>AB</u>		<u>300MG</u>	<u>A211820 002</u>	Mar 12, 2019
<u>AB</u>	VINTAGE PHARMS	<u>100MG</u>	<u>A075798 001</u>	Jun 27, 2003
<u>AB</u>		<u>300MG</u>	<u>A075798 002</u>	Jun 27, 2003
<u>AB</u>	WATSON LABS	<u>100MG</u>	<u>N018832 002</u>	Sep 28, 1984
<u>AB</u>		<u>300MG</u>	<u>N018877 001</u>	Sep 28, 1984
<u>AB</u>	ZYDUS PHARMS	<u>100MG</u>	<u>A210117 001</u>	Oct 12, 2017
<u>AB</u>		<u>300MG</u>	<u>A210117 002</u>	Oct 12, 2017

LOPURIN

<u>AB</u>	DR REDDYS LA	<u>100MG</u>	<u>A071586 001</u>	Apr 02, 1987
<u>AB</u>		<u>300MG</u>	<u>A071587 001</u>	Apr 02, 1987

ZYLOPRIM

<u>AB</u>	+ CASPER PHARMA LLC	<u>100MG</u>	<u>N016084 001</u>	
<u>AB</u>	+!	<u>300MG</u>	<u>N016084 002</u>	

ALLOPURINOL SODIUM

INJECTABLE; INJECTION

ALLOPURINOL SODIUM

<u>AP</u>	WEST-WARD PHARMS INT	<u>EQ 500MG BASE/VIAL</u>	<u>A076870 001</u>	Aug 26, 2004
-----------	-------------------------	---------------------------	--------------------	--------------

ALOPRIM

<u>AP</u>	+! MYLAN INSTITUTIONAL	<u>EQ 500MG BASE/VIAL</u>	<u>N020298 001</u>	May 17, 1996
-----------	------------------------	---------------------------	--------------------	--------------

ALMOTRIPTAN MALATE

TABLET; ORAL

ALMOTRIPTAN MALATE

<u>AB</u>	AJANTA PHARMA LTD	<u>EQ 6.25MG BASE</u>	<u>A205523 001</u>	Mar 03, 2016
<u>AB</u>	!	<u>EQ 12.5MG BASE</u>	<u>A205523 002</u>	Mar 03, 2016
<u>AB</u>	MYLAN	<u>EQ 6.25MG BASE</u>	<u>A205171 001</u>	Nov 09, 2015
<u>AB</u>		<u>EQ 12.5MG BASE</u>	<u>A205171 002</u>	Nov 09, 2015
<u>AB</u>	TEVA PHARMS USA	<u>EQ 6.25MG BASE</u>	<u>A078027 001</u>	Jul 07, 2015
<u>AB</u>		<u>EQ 12.5MG BASE</u>	<u>A078027 002</u>	Jul 07, 2015

ALOGLIPTIN BENZOATE

TABLET; ORAL

NESINA

+	TAKEDA PHARMS USA	EQ 6.25MG BASE	N022271 001	Jan 25, 2013
+		EQ 12.5MG BASE	N022271 002	Jan 25, 2013
+	!	EQ 25MG BASE	N022271 003	Jan 25, 2013

ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

KAZANO

+	TAKEDA PHARMS USA	EQ 12.5MG BASE;500MG	N203414 001	Jan 25, 2013
+	!	EQ 12.5MG BASE;1GM	N203414 002	Jan 25, 2013

ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

OSEN

+	TAKEDA PHARMS USA	EQ 12.5MG BASE;EQ 15MG BASE	N022426 004	Jan 25, 2013
+		EQ 12.5MG BASE;EQ 30MG BASE	N022426 005	Jan 25, 2013
+		EQ 12.5MG BASE;EQ 45MG BASE	N022426 006	Jan 25, 2013
+		EQ 25MG BASE;EQ 15MG BASE	N022426 001	Jan 25, 2013
+		EQ 25MG BASE;EQ 30MG BASE	N022426 002	Jan 25, 2013
+	!	EQ 25MG BASE;EQ 45MG BASE	N022426 003	Jan 25, 2013

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

ALOSETRON HYDROCHLORIDE

<u>AB</u>	AMNEAL PHARMS	<u>EQ 0.5MG BASE</u>	<u>A206647 001</u>	Dec 22, 2016
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A206647 002</u>	Dec 22, 2016
<u>AB</u>	HIKMA	<u>EQ 0.5MG BASE</u>	<u>A200652 001</u>	May 04, 2015
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A200652 002</u>	May 04, 2015
<u>AB</u>	MANKIND PHARMA	<u>EQ 0.5MG BASE</u>	<u>A213614 001</u>	Sep 09, 2020

PRESCRIPTION DRUG PRODUCT LIST

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

ALOSETRON HYDROCHLORIDE

<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A213614 002</u>	Sep 09, 2020
<u>AB</u>	PAR PHARM INC	<u>EQ 0.5MG BASE</u>	<u>A206113 001</u>	Feb 23, 2018
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A206113 002</u>	Feb 23, 2018
<u>AB</u>	RISING	<u>EQ 0.5MG BASE</u>	<u>A209180 001</u>	Jan 14, 2019
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A209180 002</u>	Jan 14, 2019

LOTRONEX

<u>AB</u>	+ SEBELA IRELAND LTD	<u>EQ 0.5MG BASE</u>	<u>N021107 002</u>	Dec 23, 2003
<u>AB</u>	+!	<u>EQ 1MG BASE</u>	<u>N021107 001</u>	Feb 09, 2000

ALPELISIB

TABLET; ORAL

PIQRAY

+	NOVARTIS	50MG	N212526 001	May 24, 2019
+		150MG	N212526 002	May 24, 2019
+	!	200MG	N212526 003	May 24, 2019

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

SOLUTION; INTRAVENOUS

INFUVITE ADULT

+	SANDOZ CANADA INC	2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 0.03MG/ML	N021163 001	May 18, 2000
+	!	2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 30MCG/ML	N021163 002	Jun 16, 2003

ALPRAZOLAM

CONCENTRATE; ORAL

ALPRAZOLAM

!	HIKMA	1MG/ML	A074312 001	Oct 31, 1993
---	-------	--------	-------------	--------------

TABLET; ORAL

ALPRAZOLAM

<u>AB</u>	ACTAVIS ELIZABETH	<u>0.25MG</u>	<u>A074342 001</u>	Oct 31, 1993
<u>AB</u>		<u>0.5MG</u>	<u>A074342 002</u>	Oct 31, 1993
<u>AB</u>		<u>1MG</u>	<u>A074342 003</u>	Oct 31, 1993
<u>AB</u>		<u>2MG</u>	<u>A074342 004</u>	Oct 31, 1993
<u>AB</u>	APOTEX INC	<u>0.25MG</u>	<u>A077741 001</u>	Jan 19, 2007
<u>AB</u>		<u>0.5MG</u>	<u>A077741 002</u>	Jan 19, 2007
<u>AB</u>		<u>1MG</u>	<u>A077741 003</u>	Jan 19, 2007
<u>AB</u>		<u>2MG</u>	<u>A077741 004</u>	Jan 19, 2007
<u>AB</u>	AUROBINDO PHARMA LTD	<u>0.25MG</u>	<u>A203346 001</u>	Jul 31, 2015
<u>AB</u>		<u>0.5MG</u>	<u>A203346 002</u>	Jul 31, 2015
<u>AB</u>		<u>1MG</u>	<u>A203346 003</u>	Jul 31, 2015
<u>AB</u>		<u>2MG</u>	<u>A203346 004</u>	Jul 31, 2015
<u>AB</u>	BRECKENRIDGE	<u>0.25MG</u>	<u>A207507 001</u>	Jul 09, 2018
<u>AB</u>		<u>0.5MG</u>	<u>A207507 002</u>	Jul 09, 2018
<u>AB</u>		<u>1MG</u>	<u>A207507 003</u>	Jul 09, 2018
<u>AB</u>		<u>2MG</u>	<u>A207507 004</u>	Jul 09, 2018
<u>AB</u>	MYLAN	<u>0.25MG</u>	<u>A074215 001</u>	Jan 27, 1994
<u>AB</u>		<u>0.5MG</u>	<u>A074215 002</u>	Jan 27, 1994
<u>AB</u>		<u>1MG</u>	<u>A074215 003</u>	Jan 27, 1994
<u>AB</u>		<u>2MG</u>	<u>A074215 004</u>	Jan 27, 1994
<u>AB</u>	NATCO PHARMA LTD	<u>0.25MG</u>	<u>A200739 001</u>	Apr 15, 2015
<u>AB</u>		<u>0.5MG</u>	<u>A200739 002</u>	Apr 15, 2015
<u>AB</u>		<u>1MG</u>	<u>A200739 003</u>	Apr 15, 2015
<u>AB</u>		<u>2MG</u>	<u>A200739 004</u>	Apr 15, 2015
<u>AB</u>	SANDOZ	<u>0.25MG</u>	<u>A074112 001</u>	Dec 29, 1995
<u>AB</u>		<u>0.5MG</u>	<u>A074112 002</u>	Dec 29, 1995
<u>AB</u>		<u>1MG</u>	<u>A074112 003</u>	Dec 29, 1995
<u>AB</u>		<u>2MG</u>	<u>A074909 001</u>	Mar 25, 1998
<u>AB</u>	SUN PHARM	<u>0.25MG</u>	<u>A090082 001</u>	Jun 17, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A090082 002</u>	Jun 17, 2010
<u>AB</u>		<u>1MG</u>	<u>A090082 003</u>	Jun 17, 2010
<u>AB</u>		<u>2MG</u>	<u>A090082 004</u>	Jun 17, 2010
<u>AB</u>	VINTAGE PHARMS	<u>0.25MG</u>	<u>A090248 001</u>	Sep 17, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A090248 002</u>	Sep 17, 2010
<u>AB</u>		<u>1MG</u>	<u>A090248 003</u>	Sep 17, 2010

PRESCRIPTION DRUG PRODUCT LIST

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

<u>AB</u>		<u>2MG</u>	<u>A090248 004</u>	Sep 17, 2010
<u>XANAX</u>				
<u>AB</u>	+	UPJOHN	<u>0.25MG</u>	<u>N018276 001</u>
<u>AB</u>	+		<u>0.5MG</u>	<u>N018276 002</u>
<u>AB</u>	+	!	<u>1MG</u>	<u>N018276 003</u>
<u>AB</u>	+		<u>2MG</u>	<u>N018276 004</u> Nov 27, 1985

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

<u>AB</u>		ACTAVIS ELIZABETH	<u>0.5MG</u>	<u>A078056 001</u>	Feb 13, 2007
<u>AB</u>			<u>1MG</u>	<u>A078056 002</u>	Feb 13, 2007
<u>AB</u>			<u>2MG</u>	<u>A078056 003</u>	Feb 13, 2007
<u>AB</u>			<u>3MG</u>	<u>A078056 004</u>	Feb 13, 2007
<u>AB</u>		AMNEAL PHARMS NY	<u>0.5MG</u>	<u>A078387 001</u>	May 30, 2008
<u>AB</u>			<u>1MG</u>	<u>A078387 002</u>	May 30, 2008
<u>AB</u>			<u>2MG</u>	<u>A078387 003</u>	May 30, 2008
<u>AB</u>			<u>3MG</u>	<u>A078387 004</u>	May 30, 2008
<u>AB</u>		ANCHEN PHARMS	<u>0.5MG</u>	<u>A078469 001</u>	Sep 29, 2011
<u>AB</u>			<u>1MG</u>	<u>A078469 002</u>	Sep 29, 2011
<u>AB</u>			<u>2MG</u>	<u>A078469 003</u>	Sep 29, 2011
<u>AB</u>			<u>3MG</u>	<u>A078469 004</u>	Sep 29, 2011
<u>AB</u>		APOTEX INC	<u>0.5MG</u>	<u>A078449 001</u>	Nov 12, 2008
<u>AB</u>			<u>1MG</u>	<u>A078449 004</u>	Dec 23, 2015
<u>AB</u>			<u>2MG</u>	<u>A078449 002</u>	Nov 12, 2008
<u>AB</u>			<u>3MG</u>	<u>A078449 003</u>	Nov 12, 2008
<u>AB</u>		AUROBINDO PHARMA LTD	<u>0.5MG</u>	<u>A090871 001</u>	Jun 07, 2011
<u>AB</u>			<u>1MG</u>	<u>A090871 002</u>	Jun 07, 2011
<u>AB</u>			<u>2MG</u>	<u>A090871 003</u>	Jun 07, 2011
<u>AB</u>			<u>3MG</u>	<u>A090871 004</u>	Jun 07, 2011

XANAX XR

<u>AB</u>	+	UPJOHN	<u>0.5MG</u>	<u>N021434 001</u>	Jan 17, 2003
<u>AB</u>	+		<u>1MG</u>	<u>N021434 002</u>	Jan 17, 2003
<u>AB</u>	+		<u>2MG</u>	<u>N021434 003</u>	Jan 17, 2003
<u>AB</u>	+	!	<u>3MG</u>	<u>N021434 004</u>	Jan 17, 2003

TABLET, ORALLY DISINTEGRATING; ORAL

ALPRAZOLAM

<u>AB</u>		ACTAVIS ELIZABETH	<u>0.25MG</u>	<u>A078561 001</u>	Mar 16, 2010
<u>AB</u>			<u>0.5MG</u>	<u>A078561 002</u>	Mar 16, 2010
<u>AB</u>			<u>1MG</u>	<u>A078561 003</u>	Mar 16, 2010
<u>AB</u>			<u>2MG</u>	<u>A078561 004</u>	Mar 16, 2010
<u>AB</u>		PAR PHARM	<u>0.25MG</u>	<u>A078088 001</u>	Jan 09, 2009
<u>AB</u>			<u>0.5MG</u>	<u>A078088 002</u>	Jan 09, 2009
<u>AB</u>	!		<u>1MG</u>	<u>A078088 003</u>	Jan 09, 2009
<u>AB</u>			<u>2MG</u>	<u>A078088 004</u>	Jan 09, 2009

ALPROSTADIL

INJECTABLE; INJECTION

ALPROSTADIL

<u>AP</u>		TEVA PHARMS USA	<u>0.5MG/ML</u>	<u>A075196 001</u>	Apr 30, 1999
<u>AP</u>		WEST-WARD PHARMS INT	<u>0.5MG/ML</u>	<u>A074815 001</u>	Jan 20, 1998

CAVERJECT

<u>AP</u>	+	PHARMACIA AND UPJOHN	<u>0.01MG/VIAL</u>	<u>N020379 001</u>	Jul 06, 1995
<u>AP</u>	+	!	<u>0.02MG/VIAL</u>	<u>N020379 002</u>	Jul 06, 1995
<u>AP</u>	+	!	<u>0.04MG/VIAL</u>	<u>N020379 004</u>	May 19, 1997

EDEX

<u>AP</u>	+	AUXILIUM PHARMS LLC	<u>0.01MG/VIAL</u>	<u>N020649 002</u>	Jun 12, 1997
<u>AP</u>	+		<u>0.02MG/VIAL</u>	<u>N020649 003</u>	Jun 12, 1997
<u>AP</u>	+	!	<u>0.04MG/VIAL</u>	<u>N020649 004</u>	Jun 12, 1997

PROSTIN VR PEDIATRIC

<u>AP</u>	+	PHARMACIA AND UPJOHN	<u>0.5MG/ML</u>	<u>N018484 001</u>	
		CAVERJECT IMPULSE			
		PHARMACIA AND UPJOHN	0.01MG/VIAL	N021212 001	Jun 11, 2002
			0.02MG/VIAL	N021212 002	Jun 11, 2002
		EDEX			
	+	!	AUXILIUM PHARMS LLC	0.01MG/VIAL	N020649 005 Jul 30, 1998
	+	!		0.02MG/VIAL	N020649 006 Jul 30, 1998
	+	!		0.04MG/VIAL	N020649 007 Jul 30, 1998

PRESCRIPTION DRUG PRODUCT LIST

ALPROSTADIL

SUPPOSITORY; URETHRAL

MUSE

+	!	MYLAN SPECIALITY LP	0.125MG	N020700	001	Nov 19, 1996
+	!		0.25MG	N020700	002	Nov 19, 1996
+	!		0.5MG	N020700	003	Nov 19, 1996
+	!		1MG	N020700	004	Nov 19, 1996

ALVIMOPAN

CAPSULE; ORAL

ALVIMOPAN

AB		WATSON LABS TEVA	12MG	A208295	001	Dec 19, 2019
-----------	--	------------------	-------------	----------------	------------	--------------

ENTEREG

AB	+	!	CUBIST PHARMS	12MG	N021775	001	May 20, 2008
-----------	---	---	---------------	-------------	----------------	------------	--------------

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

AB		ALEMBIC PHARMS LTD	100MG	A208966	001	Jun 21, 2017
AB	!	BIONPHARMA INC	100MG	A078720	001	May 29, 2008
AB		HERITAGE PHARMA	100MG	A209171	001	Jun 12, 2017
AB		NOVELGENIX THERAPS	100MG	A210129	001	Mar 02, 2020
AB		RUBICON	100MG	A212044	001	May 21, 2020
AB		SANDOZ	100MG	A071293	001	Feb 18, 1987
AB		STRIDES PHARMA	100MG	A209047	001	Jun 07, 2017
AB		UPSHER SMITH LABS	100MG	A070589	001	Aug 05, 1986
AB		WATSON LABS INC	100MG	A208107	001	Dec 06, 2016
AB		ZYDUS PHARMS	100MG	A208278	001	May 31, 2016

CAPSULE, EXTENDED RELEASE; ORAL

GOCOVRI

+		ADAMAS PHARMA	EQ 68.5MG BASE	N208944	001	Aug 24, 2017
+	!		EQ 137MG BASE	N208944	002	Aug 24, 2017

SYRUP; ORAL

AMANTADINE HYDROCHLORIDE

AA	!	AKORN	50MG/5ML	A074170	001	Oct 28, 1994
AA	!	ANDA REPOSITORY	50MG/5ML	A074028	001	Jun 28, 1993
AA	!	CMP PHARMA INC	50MG/5ML	A075819	001	Sep 11, 2002
AA	!	PHARM ASSOC	50MG/5ML	A074509	001	Jul 17, 1995
AA	!	WOCKHARDT BIO AG	50MG/5ML	A075060	001	Dec 24, 1998

TABLET; ORAL

AMANTADINE HYDROCHLORIDE

AB		ALEMBIC PHARMS LTD	100MG	A214284	001	Oct 15, 2020
AB		INVAGEN PHARMS	100MG	A207571	001	Jan 31, 2017
AB		JUBILANT GENERICS	100MG	A210403	001	Feb 07, 2018
AB		NOVELGENIX THERAPS	100MG	A210215	001	Mar 10, 2020
AB		STRIDES PHARMA	100MG	A209035	001	Jun 09, 2017
AB	!	UPSHER SMITH LABS	100MG	A076186	001	Dec 16, 2002
AB		WATSON LABS INC	100MG	A208096	001	Dec 15, 2016

TABLET, EXTENDED RELEASE; ORAL

OSMOLEX ER

+		OSMOTICA PHARM	EQ 129MG BASE	N209410	001	Feb 16, 2018
+			EQ 193MG BASE	N209410	002	Feb 16, 2018
+	!		EQ 258MG BASE	N209410	003	Feb 16, 2018

AMBRISENTAN

TABLET; ORAL

AMBRISENTAN

AB		CIPLA	5MG	A210715	001	Apr 26, 2019
AB			10MG	A210715	002	Apr 26, 2019
AB		MYLAN	5MG	A208441	001	Mar 28, 2019
AB			10MG	A208441	002	Mar 28, 2019
AB		PAR PHARM INC	5MG	A209509	001	Apr 10, 2019
AB			10MG	A209509	002	Apr 10, 2019
AB		SIGMAPHARM LABS LLC	5MG	A208354	001	Apr 10, 2019
AB			10MG	A208354	002	Apr 10, 2019
AB		SUN PHARM	5MG	A210784	001	Mar 28, 2019
AB			10MG	A210784	002	Mar 28, 2019
AB		WATSON LABS INC	5MG	A208252	001	Mar 28, 2019
AB			10MG	A208252	002	Mar 28, 2019
AB		ZYDUS PHARMS	5MG	A210058	001	Mar 28, 2019
AB			10MG	A210058	002	Mar 28, 2019

LETAIRIS

AB	+	GILEAD	5MG	N022081	001	Jun 15, 2007
AB	+	!	10MG	N022081	002	Jun 15, 2007

PRESCRIPTION DRUG PRODUCT LIST

AMCINONIDE

CREAM; TOPICAL

AMCINONIDE

AB	!	FOUGERA PHARMS	0.1%	A076065	001	May 15, 2003
AB		TARO PHARM INDS	0.1%	A076229	001	May 31, 2002

LOTION; TOPICAL

AMCINONIDE

!	FOUGERA PHARMS	0.1%	A076329	001	Nov 06, 2002
---	----------------	------	---------	-----	--------------

OINTMENT; TOPICAL

AMCINONIDE

AB	!	FOUGERA PHARMS	0.1%	A076096	001	Nov 19, 2002
AB		TARO PHARM INDS	0.1%	A076367	001	Mar 19, 2003

AMIFAMPRIDINE

TABLET; ORAL

RUZURGI

+	!	JACOBUS PHARM CO INC	10MG	N209321	001	May 06, 2019
---	---	-------------------------	------	---------	-----	--------------

AMIFAMPRIDINE PHOSPHATE

TABLET; ORAL

FIRDAPSE

+	!	CATALYST PHARMS	EQ 10MG BASE	N208078	001	Nov 28, 2018
---	---	-----------------	--------------	---------	-----	--------------

AMIFOSTINE

INJECTABLE; INJECTION

AMIFOSTINE

AP		SUN PHARM	500MG/VIAL	A077126	001	Mar 14, 2008
-----------	--	-----------	-------------------	----------------	------------	--------------

ETHYOL

AP	+	!	CLINIGEN	500MG/VIAL	N020221	001	Dec 08, 1995
-----------	---	---	----------	-------------------	----------------	------------	--------------

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

AP	!	EMCURE PHARMS LTD	EQ 250MG BASE/ML	A204040	001	Dec 12, 2013
AP		FRESENIUS KABI USA	EQ 50MG BASE/ML	A205605	001	Dec 09, 2015
AP			EQ 250MG BASE/ML	A205604	001	Dec 09, 2015
AP		SAGENT PHARMS INC	EQ 250MG BASE/ML	A203323	001	May 12, 2016
AP		TEVA PHARMS USA	EQ 250MG BASE/ML	A064045	002	Sep 28, 1993
AP	!	WEST-WARD PHARMS INT	EQ 50MG BASE/ML	A063313	001	Apr 11, 1994
AP			EQ 250MG BASE/ML	A063315	001	Apr 11, 1994

SUSPENSION, LIPOSOMAL; INHALATION

ARIKAYCE KIT

+	!	INSMED INC	EQ 590MG BASE/8.4ML	N207356	001	Sep 28, 2018
---	---	------------	---------------------	---------	-----	--------------

AMILORIDE HYDROCHLORIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE

AB		ANDA REPOSITORY	5MG	A204180	001	Aug 07, 2015
AB	!	PAR PHARM	5MG	A070346	001	Jan 22, 1986
AB		SIGMAPHARM LABS LLC	5MG	A079133	001	Jan 30, 2009

MIDAMOR

AB	+	PADDOCK LLC	5MG	N018200	001	
-----------	---	-------------	------------	----------------	------------	--

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB		BARR	EQ 5MG ANHYDROUS; 50MG	A071111	001	May 10, 1988
AB	!	MYLAN	EQ 5MG ANHYDROUS; 50MG	A073209	001	Oct 31, 1991

AMINO ACIDS

INJECTABLE; INJECTION

AMINO ACIDS

B	BRAUN	15% (150GM/1000ML)	A091112	001	Apr 13, 2012
		15% (300GM/2000ML)	A091112	002	Apr 13, 2012

AMINOSYN II 10% IN PLASTIC CONTAINER

ICU	MEDICAL INC	10% (10GM/100ML)	N020015	001	Dec 19, 1991
-----	-------------	------------------	---------	-----	--------------

AMINOSYN II 15% IN PLASTIC CONTAINER

ICU	MEDICAL INC	15% (15GM/100ML)	N020041	001	Dec 19, 1991
-----	-------------	------------------	---------	-----	--------------

AMINOSYN-PF 10%

ICU	MEDICAL INC	10% (10GM/100ML)	N019492	002	Oct 17, 1986
-----	-------------	------------------	---------	-----	--------------

AMINOSYN-PF 7%

ICU	MEDICAL INC	7% (7GM/100ML)	N019398	001	Sep 06, 1985
-----	-------------	----------------	---------	-----	--------------

CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER

BAXTER	HLTHCARE	15% (15GM/100ML)	A020512	001	Aug 30, 1996
--------	----------	------------------	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

AMINO ACIDS

INJECTABLE; INJECTION

FREAMINE HBC 6.9%			
B BRAUN	6.9% (6.9GM/100ML)	N016822 006	May 17, 1983
FREAMINE III 10%			
B BRAUN	10% (10GM/100ML)	N016822 005	
FREAMINE III 8.5%			
B BRAUN	8.5% (8.5GM/100ML)	N016822 004	
HEPATAMINE 8%			
B BRAUN	8% (8GM/100ML)	N018676 001	Aug 03, 1982
NEPHRAMINE 5.4%			
B BRAUN	5.4% (5.4GM/100ML)	N017766 001	
PREMASOL 10% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	10% (10GM/100ML)	A075880 002	Jun 19, 2003
PREMASOL 6% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	6% (6GM/100ML)	A075880 001	Jun 19, 2003
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER			
+! BAXTER HLTHCARE	20% (20GM/100ML)	N020849 001	Aug 26, 1998
TRAVASOL 10% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	10% (10MG/100ML)	N018931 003	Aug 23, 1984
TRAVASOL 5.5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5.5% (5.5GM/100ML)	N018931 001	Aug 23, 1984
TRAVASOL 8.5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	8.5% (8.5GM/100ML)	N018931 002	Aug 23, 1984
TROPHAMINE			
+! B BRAUN	6% (6GM/100ML)	N019018 001	Jul 20, 1984
TROPHAMINE 10%			
+! B BRAUN	10% (10GM/100ML)	N019018 003	Sep 07, 1988

AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PROCALAMINE

B BRAUN	3%;26MG/100ML;3GM/100ML;54MG/100ML;41MG/100ML;150MG/100ML;200MG/100ML;120MG/100ML	N018582 001	May 08, 1982
---------	---	-------------	--------------

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER			
+! BAXTER HLTHCARE	2.75%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;217MG/100ML;112MG/100ML	N020678 002	Mar 26, 1997
CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER			
+! BAXTER HLTHCARE	2.75%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;217MG/100ML;112MG/100ML	N020678 005	Mar 26, 1997
CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER			
+! BAXTER HLTHCARE	2.75%;33MG/100ML;5GM/100ML;51MG/100ML;261MG/100ML;217MG/100ML;112MG/100ML	N020678 001	Mar 26, 1997
CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER			
+! BAXTER HLTHCARE	4.25%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678 009	Mar 26, 1997
CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER			
+! BAXTER HLTHCARE	4.25%;33MG/100ML;20GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678 011	Mar 26, 1997
CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER			
+! BAXTER HLTHCARE	4.25%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678 012	Mar 26, 1997
CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER			
+! BAXTER HLTHCARE	4.25%;33MG/100ML;5GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678 008	Mar 26, 1997
CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER			
+! BAXTER HLTHCARE	5%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678 016	Mar 26, 1997
CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER			
+! BAXTER HLTHCARE	5%;33MG/100ML;15GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678 017	Mar 26, 1997
CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER			
+! BAXTER HLTHCARE	5%;33MG/100ML;20GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678 018	Mar 26, 1997
CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER			
+! BAXTER HLTHCARE	5%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678 019	Mar 26, 1997
CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER			
+! BAXTER HLTHCARE	5%;33MG/100ML;35GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678 021	Mar 26, 1997

PRESCRIPTION DRUG PRODUCT LISTAMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL

EMULSION; INTRAVENOUS

KABIVEN IN PLASTIC CONTAINER

+	FRESENIUS KABI USA	3.3%; 29MG/100ML; 9.8GM/100ML; 96MG/100ML; 174MG/100ML; 239MG/100ML; 147MG/100ML; 3.9GM/100ML (1026ML)	N200656 004	Aug 25, 2014
+		3.3%; 29MG/100ML; 9.8GM/100ML; 96MG/100ML; 174MG/100ML; 239MG/100ML; 147MG/100ML; 3.9GM/100ML (1540ML)	N200656 005	Aug 25, 2014
+		3.3%; 29MG/100ML; 9.8GM/100ML; 96MG/100ML; 174MG/100ML; 239MG/100ML; 147MG/100ML; 3.9GM/100ML (2053ML)	N200656 006	Aug 25, 2014
+		3.3%; 29MG/100ML; 9.8GM/100ML; 96MG/100ML; 174MG/100ML; 239MG/100ML; 147MG/100ML; 3.9GM/100ML (2566ML)	N200656 007	Aug 25, 2014

PERIKABIVEN IN PLASTIC CONTAINER

+	FRESENIUS KABI USA	2.4%; 20MG/100ML; 6.8GM/100ML; 68MG/100ML; 124MG/100ML; 170MG/100ML; 105MG/100ML; 3.5GM/100ML (1440ML)	N200656 001	Aug 25, 2014
+		2.4%; 20MG/100ML; 6.8GM/100ML; 68MG/100ML; 124MG/100ML; 170MG/100ML; 105MG/100ML; 3.5GM/100ML (1920ML)	N200656 002	Aug 25, 2014
+		2.4%; 20MG/100ML; 6.8GM/100ML; 68MG/100ML; 124MG/100ML; 170MG/100ML; 105MG/100ML; 3.5GM/100ML (2400ML)	N200656 003	Aug 25, 2014

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

	CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER			
	BAXTER HLTHCARE	2.75%; 10GM/100ML	N020734 002	Sep 29, 1997
	CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER			
	BAXTER HLTHCARE	2.75%; 25GM/100ML	N020734 005	Sep 29, 1997
	CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER			
	BAXTER HLTHCARE	2.75%; 5GM/100ML	N020734 001	Sep 29, 1997
	CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER			
	BAXTER HLTHCARE	4.25%; 10GM/100ML	N020734 008	Sep 29, 1997
	CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER			
	BAXTER HLTHCARE	4.25%; 20GM/100ML	N020734 010	Sep 29, 1997
	CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER			
	BAXTER HLTHCARE	4.25%; 25GM/100ML	N020734 011	Sep 29, 1997
	CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER			
	BAXTER HLTHCARE	4.25%; 5GM/100ML	N020734 007	Sep 29, 1997
	CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER			
	BAXTER HLTHCARE	5%; 10GM/100ML	N020734 014	Sep 29, 1997
	CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER			
	BAXTER HLTHCARE	5%; 15GM/100ML	N020734 015	Sep 29, 1997
	CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER			
	BAXTER HLTHCARE	5%; 20GM/100ML	N020734 016	Sep 29, 1997
	CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER			
	BAXTER HLTHCARE	5%; 25GM/100ML	N020734 017	Sep 29, 1997
	CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER			
	BAXTER HLTHCARE	5%; 35GM/100ML	N020734 018	Sep 29, 1997

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE; INJECTION

	FREAMINE III 8.5% W/ ELECTROLYTES			
	B BRAUN	8.5%; 110MG/100ML; 230MG/100ML; 10MG/100ML; 440MG/100ML; 690MG/100ML	N016822 007	Jul 01, 1988

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

	FREAMINE III 3% W/ ELECTROLYTES			
	B BRAUN	3%; 54MG/100ML; 40MG/100ML; 150MG/100ML; 200MG/100ML; 120MG/100ML	N016822 003	

AMINOCAPROIC ACID

INJECTABLE; INJECTION

	<u>AMINOCAPROIC ACID</u>			
AP	LUITPOLD	250MG/ML	A071192 001	Dec 01, 1987
	<u>AMINOCAPROIC ACID IN PLASTIC CONTAINER</u>			
AP	HOSPIRA	250MG/ML	A070010 001	Mar 09, 1987
	SYRUP; ORAL			
	<u>AMICAR</u>			
AA	+	AKORN	1.25GM/5ML	N015230 002

PRESCRIPTION DRUG PRODUCT LIST

AMINOCAPROIC ACID

SYRUP; ORAL

AMINOCAPROIC ACID

AA	AMNEAL	1.25GM/5ML	A212780 001	Aug 23, 2019
AA	TULEX PHARMS INC	1.25GM/5ML	A212494 001	Aug 11, 2020
AA	VISTAPHARM	1.25GM/5ML	A212814 001	Feb 26, 2020

TABLET; ORAL

AMICAR

AB	+	AKORN	500MG	N015197 001	
AB	+		1GM	N015197 002	Jun 24, 2004

AMINOCAPROIC ACID

AB		AMNEAL	500MG	A212492 001	Nov 26, 2019
AB		ANI PHARMS INC	500MG	A211629 001	Dec 14, 2020
AB		MSN	500MG	A212938 001	Nov 06, 2020
AB		SUNNY PHARMTECH INC	500MG	A209060 001	Nov 27, 2018
AB	!		1GM	A209060 002	Nov 27, 2018

AMINOLEVULINIC ACID HYDROCHLORIDE

FOR SOLUTION; ORAL

GLEOLAN

+	!	NXDC	1.5GM/VIAL	N208630 001	Jun 06, 2017
---	---	------	------------	-------------	--------------

GEL; TOPICAL

AMELUZ

+	!	BIOFRONTERA	10%	N208081 001	May 10, 2016
---	---	-------------	-----	-------------	--------------

SOLUTION; TOPICAL

LEVULAN

+	!	DUSA	20%	N020965 001	Dec 03, 1999
---	---	------	-----	-------------	--------------

AMINOPHYLLINE

INJECTABLE; INJECTION

AMINOPHYLLINE

!		HOSPIRA	25MG/ML	A087242 001	Oct 26, 1983
---	--	---------	---------	-------------	--------------

AMINOSALICYLIC ACID

GRANULE, DELAYED RELEASE; ORAL

PASER

!		JACOBUS	4GM/PACKET	A074346 001	Jun 30, 1994
---	--	---------	------------	-------------	--------------

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

AP		AUROBINDO PHARMA LTD	50MG/ML	A204550 001	Oct 25, 2017
AP	!	FRESENIUS KABI USA	50MG/ML	A075761 001	Oct 15, 2002
AP	!	GLAND PHARMA LTD	50MG/ML	A077161 001	Apr 20, 2005
AP		HIKMA FARMACEUTICA	50MG/ML	A077234 001	Feb 25, 2008
AP		HOSPIRA INC	50MG/ML	A203884 001	Nov 25, 2013
AP			50MG/ML	A203885 001	Nov 25, 2013
AP	!	MYLAN INSTITUTIONAL	50MG/ML	A076217 001	Oct 15, 2002
AP		WOCKHARDT	50MG/ML	A077610 001	Oct 30, 2008
AP			50MG/ML	A077834 001	Oct 30, 2008

NEXTERONE

+	!	BAXTER HLTHCARE	150MG/100ML (1.5MG/ML)	N022325 002	Nov 16, 2010
---	---	-----------------	------------------------	-------------	--------------

+	!		360MG/200ML (1.8MG/ML)	N022325 003	Nov 16, 2010
---	---	--	------------------------	-------------	--------------

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	200MG	A204742 001	Jun 03, 2016
AB		MAYNE PHARMA INC	100MG	A075389 002	Dec 28, 2017
AB			200MG	A075389 001	Jan 25, 2001
AB			400MG	A075389 003	Dec 28, 2017
AB		MURTY PHARMS	100MG	A077069 003	Oct 04, 2016
AB			200MG	A077069 001	Apr 08, 2005
AB			400MG	A077069 002	Apr 08, 2005
AB		RUBICON	200MG	A078578 001	Nov 06, 2008
AB		TARO	100MG	A075424 002	Dec 18, 2002
AB			200MG	A075424 001	Mar 30, 2001
AB			400MG	A076362 001	Nov 29, 2002
AB		TEVA PHARMS	200MG	A074739 001	Nov 30, 1998
AB		UNICHEM	200MG	A213446 001	Jul 21, 2020
AB	!	UPSHER SMITH LABS	200MG	A075315 001	Dec 23, 1998
AB			400MG	A075315 002	Jun 30, 2000
AB		ZYDUS PHARMS USA INC	200MG	A079029 001	Sep 16, 2008

PRESCRIPTION DRUG PRODUCT LIST

AMIODARONE HYDROCHLORIDE

TABLET; ORAL

PACERONE

<u>AB</u>	UPSHER SMITH LABS	<u>100MG</u>	<u>A075135</u>	<u>002</u>	Apr 12, 2005
<u>AB</u>		<u>200MG</u>	<u>A075135</u>	<u>001</u>	Apr 30, 1998
<u>AB</u>		<u>400MG</u>	<u>A075135</u>	<u>003</u>	Jul 02, 2020
	AMIODARONE HYDROCHLORIDE				
	TARO	300MG	A076362	002	Dec 02, 2003

AMISULPRIDE

SOLUTION; INTRAVENOUS

BARHEMSYS

+	!	ACACIA	5MG/2ML (2.5MG/ML)	N209510	001	Feb 26, 2020
+	!		10MG/4ML (2.5MG/ML)	N209510	002	Sep 01, 2020

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

<u>AB</u>	ACCORD HLTHCARE	<u>10MG</u>	<u>A202446</u>	<u>001</u>	Jun 04, 2014
<u>AB</u>		<u>25MG</u>	<u>A202446</u>	<u>002</u>	Jun 04, 2014
<u>AB</u>		<u>50MG</u>	<u>A202446</u>	<u>003</u>	Jun 04, 2014
<u>AB</u>		<u>75MG</u>	<u>A202446</u>	<u>004</u>	Jun 04, 2014
<u>AB</u>		<u>100MG</u>	<u>A202446</u>	<u>005</u>	Jun 04, 2014
<u>AB</u>		<u>150MG</u>	<u>A202446</u>	<u>006</u>	Jun 04, 2014
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A086009</u>	<u>002</u>	
<u>AB</u>		<u>25MG</u>	<u>A086009</u>	<u>003</u>	
<u>AB</u>		<u>50MG</u>	<u>A086009</u>	<u>001</u>	
<u>AB</u>		<u>75MG</u>	<u>A086009</u>	<u>004</u>	
<u>AB</u>		<u>100MG</u>	<u>A086009</u>	<u>005</u>	
<u>AB</u>		<u>150MG</u>	<u>A086009</u>	<u>006</u>	
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A085968</u>	<u>004</u>	
<u>AB</u>	!	<u>25MG</u>	<u>A085968</u>	<u>002</u>	
<u>AB</u>		<u>50MG</u>	<u>A085968</u>	<u>001</u>	
<u>AB</u>		<u>75MG</u>	<u>A085968</u>	<u>006</u>	
<u>AB</u>		<u>100MG</u>	<u>A085968</u>	<u>003</u>	
<u>AB</u>		<u>150MG</u>	<u>A085968</u>	<u>005</u>	
<u>AB</u>	SUN PHARM INDS INC	<u>10MG</u>	<u>A089399</u>	<u>002</u>	Jul 14, 1987
<u>AB</u>		<u>25MG</u>	<u>A089399</u>	<u>001</u>	Jul 14, 1987
<u>AB</u>		<u>50MG</u>	<u>A089399</u>	<u>003</u>	Jul 14, 1987
<u>AB</u>		<u>75MG</u>	<u>A089399</u>	<u>004</u>	Jul 14, 1987
<u>AB</u>		<u>100MG</u>	<u>A089399</u>	<u>005</u>	Jul 14, 1987
<u>AB</u>		<u>150MG</u>	<u>A089399</u>	<u>006</u>	Jul 14, 1987
<u>AB</u>	VINTAGE PHARMS	<u>10MG</u>	<u>A040218</u>	<u>001</u>	Sep 11, 1997
<u>AB</u>		<u>25MG</u>	<u>A040218</u>	<u>002</u>	Sep 11, 1997
<u>AB</u>		<u>50MG</u>	<u>A040218</u>	<u>003</u>	Sep 11, 1997
<u>AB</u>		<u>75MG</u>	<u>A040218</u>	<u>004</u>	Sep 11, 1997
<u>AB</u>		<u>100MG</u>	<u>A040218</u>	<u>005</u>	Sep 11, 1997
<u>AB</u>		<u>150MG</u>	<u>A040218</u>	<u>006</u>	Sep 11, 1997
<u>AB</u>	ZYDUS PHARMS	<u>10MG</u>	<u>A210086</u>	<u>001</u>	Oct 06, 2017
<u>AB</u>		<u>25MG</u>	<u>A210086</u>	<u>002</u>	Oct 06, 2017
<u>AB</u>		<u>50MG</u>	<u>A210086</u>	<u>003</u>	Oct 06, 2017
<u>AB</u>		<u>75MG</u>	<u>A210086</u>	<u>004</u>	Oct 06, 2017
<u>AB</u>		<u>100MG</u>	<u>A210086</u>	<u>005</u>	Oct 06, 2017
<u>AB</u>		<u>150MG</u>	<u>A210086</u>	<u>006</u>	Oct 06, 2017

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

	MYLAN PHARMS INC	EQ 12.5MG BASE;5MG	A071297	002	Dec 10, 1986
!		EQ 25MG BASE;10MG	A071297	001	Dec 10, 1986

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

	MYLAN	10MG;2MG	A071443	002	Nov 10, 1988
		10MG;4MG	A071443	003	Nov 10, 1988
!		25MG;2MG	A071443	004	Nov 10, 1988
!		25MG;4MG	A071443	005	Nov 10, 1988
!		50MG;4MG	A071443	001	Nov 10, 1988

PRESCRIPTION DRUG PRODUCT LIST

AMLODIPINE BENZOATE

SUSPENSION; ORAL

KATERZIA

+! AZURITY

EQ 1MG BASE/ML

N211340 001 Jul 08, 2019

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 2.5MG BASE</u>	<u>A202553 001</u>	Apr 29, 2013
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A202553 002</u>	Apr 29, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A202553 003</u>	Apr 29, 2013
<u>AB</u>	ALKEM	<u>EQ 2.5MG BASE</u>	<u>A078925 001</u>	May 04, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078925 002</u>	May 04, 2009
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078925 003</u>	May 04, 2009
<u>AB</u>	APOTEX	<u>EQ 2.5MG BASE</u>	<u>A076719 001</u>	May 23, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A076719 002</u>	May 23, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076719 003</u>	May 23, 2007
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 2.5MG BASE</u>	<u>A078021 001</u>	Jul 17, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078021 002</u>	Jul 17, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078021 003</u>	Jul 17, 2007
<u>AB</u>	CHINA RESOURCES	<u>EQ 2.5MG BASE</u>	<u>A090752 003</u>	May 16, 2016
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090752 001</u>	Apr 15, 2011
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090752 002</u>	Apr 15, 2011
<u>AB</u>	CIPLA	<u>EQ 2.5MG BASE</u>	<u>A077073 001</u>	Sep 26, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077073 002</u>	Sep 26, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077073 003</u>	Sep 26, 2007
<u>AB</u>	EPIC PHARMA LLC	<u>EQ 2.5MG BASE</u>	<u>A078552 001</u>	Apr 08, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078552 002</u>	Apr 08, 2009
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078552 003</u>	Apr 08, 2009
<u>AB</u>	INVAGEN PHARMS	<u>EQ 2.5MG BASE</u>	<u>A077955 001</u>	Aug 28, 2007
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A206367 001</u>	Dec 10, 2015
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077955 002</u>	Aug 28, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A206367 002</u>	Dec 10, 2015
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077955 003</u>	Aug 28, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A206367 003</u>	Dec 10, 2015
<u>AB</u>	LUPIN	<u>EQ 2.5MG BASE</u>	<u>A078043 001</u>	Jul 12, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078043 002</u>	Jul 12, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078043 003</u>	Jul 12, 2007
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 2.5MG BASE</u>	<u>A078453 001</u>	Jul 02, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078453 002</u>	Jul 02, 2009
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078453 003</u>	Jul 02, 2009
<u>AB</u>	OXFORD PHARMS	<u>EQ 2.5MG BASE</u>	<u>A078414 001</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078414 002</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078414 003</u>	Apr 07, 2010
<u>AB</u>	POLYGEN PHARMS	<u>EQ 2.5MG BASE</u>	<u>A207821 001</u>	Jul 11, 2016
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A207821 002</u>	Jul 11, 2016
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A207821 003</u>	Jul 11, 2016
<u>AB</u>	STRIDES PHARMA	<u>EQ 2.5MG BASE</u>	<u>A077516 001</u>	Jul 11, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077516 002</u>	Jul 11, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077516 003</u>	Jul 11, 2007
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 2.5MG BASE</u>	<u>A077974 001</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077974 002</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077974 003</u>	Jul 09, 2007
<u>AB</u>	UNICHEM	<u>EQ 2.5MG BASE</u>	<u>A203245 001</u>	Oct 21, 2013
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A203245 002</u>	Oct 21, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A203245 003</u>	Oct 21, 2013
<u>AB</u>	UPSHER SMITH LABS	<u>EQ 2.5MG BASE</u>	<u>A077759 001</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077759 002</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077759 003</u>	Jul 09, 2007
<u>AB</u>	WOCKHARDT	<u>EQ 2.5MG BASE</u>	<u>A078500 001</u>	Sep 06, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078500 002</u>	Sep 06, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078500 003</u>	Sep 06, 2007
<u>AB</u>	YILING	<u>EQ 2.5MG BASE</u>	<u>A076692 001</u>	Jul 20, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A076692 002</u>	Jul 20, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076692 003</u>	Jul 20, 2007
<u>AB</u>	ZYDUS PHARMS USA	<u>EQ 2.5MG BASE</u>	<u>A078226 001</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078226 002</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078226 003</u>	Jul 09, 2007
<u>NORVASC</u>				
<u>AB</u>	+ UPJOHN	<u>EQ 2.5MG BASE</u>	<u>N019787 001</u>	Jul 31, 1992
<u>AB</u>	+	<u>EQ 5MG BASE</u>	<u>N019787 002</u>	Jul 31, 1992
<u>AB</u>	+!	<u>EQ 10MG BASE</u>	<u>N019787 003</u>	Jul 31, 1992

PRESCRIPTION DRUG PRODUCT LIST

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET; ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

<u>AB</u>	APOTEX	<u>EQ 5MG BASE;EQ 10MG BASE</u>	<u>A205199 001</u>	Nov 18, 2019
<u>AB</u>		<u>EQ 5MG BASE;EQ 20MG BASE</u>	<u>A205199 002</u>	Nov 18, 2019
<u>AB</u>		<u>EQ 5MG BASE;EQ 40MG BASE</u>	<u>A205199 003</u>	Nov 18, 2019
<u>AB</u>		<u>EQ 5MG BASE;EQ 80MG BASE</u>	<u>A205199 004</u>	Nov 18, 2019
<u>AB</u>		<u>EQ 10MG BASE;EQ 10MG BASE</u>	<u>A205199 005</u>	Nov 18, 2019
<u>AB</u>		<u>EQ 10MG BASE;EQ 20MG BASE</u>	<u>A205199 006</u>	Nov 18, 2019
<u>AB</u>		<u>EQ 10MG BASE;EQ 40MG BASE</u>	<u>A205199 007</u>	Nov 18, 2019
<u>AB</u>		<u>EQ 10MG BASE;EQ 80MG BASE</u>	<u>A205199 008</u>	Nov 18, 2019
<u>AB</u>	DR REDDYS	<u>EQ 2.5MG BASE;EQ 10MG BASE</u>	<u>A203874 001</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 2.5MG BASE;EQ 20MG BASE</u>	<u>A203874 002</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 2.5MG BASE;EQ 40MG BASE</u>	<u>A203874 003</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 5MG BASE;EQ 10MG BASE</u>	<u>A203874 004</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 5MG BASE;EQ 20MG BASE</u>	<u>A203874 005</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 5MG BASE;EQ 40MG BASE</u>	<u>A203874 006</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 5MG BASE;EQ 80MG BASE</u>	<u>A203874 007</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 10MG BASE;EQ 10MG BASE</u>	<u>A203874 008</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 10MG BASE;EQ 20MG BASE</u>	<u>A203874 009</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 10MG BASE;EQ 40MG BASE</u>	<u>A203874 010</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 10MG BASE;EQ 80MG BASE</u>	<u>A203874 011</u>	Mar 07, 2014
<u>AB</u>	MYLAN	<u>EQ 2.5MG BASE;EQ 10MG BASE</u>	<u>A200465 001</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 2.5MG BASE;EQ 20MG BASE</u>	<u>A200465 002</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 2.5MG BASE;EQ 40MG BASE</u>	<u>A200465 003</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 5MG BASE;EQ 10MG BASE</u>	<u>A200465 004</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 5MG BASE;EQ 20MG BASE</u>	<u>A200465 005</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 5MG BASE;EQ 40MG BASE</u>	<u>A200465 006</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 5MG BASE;EQ 80MG BASE</u>	<u>A200465 007</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 10MG BASE;EQ 10MG BASE</u>	<u>A200465 008</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 10MG BASE;EQ 20MG BASE</u>	<u>A200465 009</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 10MG BASE;EQ 40MG BASE</u>	<u>A200465 010</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 10MG BASE;EQ 80MG BASE</u>	<u>A200465 011</u>	Nov 29, 2013
<u>AB</u>	ZYDUS PHARMS	<u>EQ 2.5MG BASE;EQ 10MG BASE</u>	<u>A207762 001</u>	Jan 11, 2019
<u>AB</u>		<u>EQ 2.5MG BASE;EQ 20MG BASE</u>	<u>A207762 002</u>	Jan 11, 2019
<u>AB</u>		<u>EQ 2.5MG BASE;EQ 40MG BASE</u>	<u>A207762 003</u>	Jan 11, 2019
<u>AB</u>		<u>EQ 5MG BASE;EQ 10MG BASE</u>	<u>A207762 004</u>	Jan 11, 2019
<u>AB</u>		<u>EQ 5MG BASE;EQ 20MG BASE</u>	<u>A207762 005</u>	Jan 11, 2019
<u>AB</u>		<u>EQ 5MG BASE;EQ 40MG BASE</u>	<u>A207762 006</u>	Jan 11, 2019
<u>AB</u>		<u>EQ 5MG BASE;EQ 80MG BASE</u>	<u>A207762 007</u>	Jan 11, 2019
<u>AB</u>		<u>EQ 10MG BASE;EQ 10MG BASE</u>	<u>A207762 008</u>	Jan 11, 2019
<u>AB</u>		<u>EQ 10MG BASE;EQ 20MG BASE</u>	<u>A207762 009</u>	Jan 11, 2019
<u>AB</u>		<u>EQ 10MG BASE;EQ 40MG BASE</u>	<u>A207762 010</u>	Jan 11, 2019
<u>AB</u>		<u>EQ 10MG BASE;EQ 80MG BASE</u>	<u>A207762 011</u>	Jan 11, 2019
<u>CADUET</u>				
<u>AB</u>	+ PHARMACIA	<u>EQ 2.5MG BASE;EQ 10MG BASE</u>	<u>N021540 009</u>	Jul 29, 2004
<u>AB</u>	+	<u>EQ 2.5MG BASE;EQ 20MG BASE</u>	<u>N021540 010</u>	Jul 29, 2004
<u>AB</u>	+	<u>EQ 2.5MG BASE;EQ 40MG BASE</u>	<u>N021540 011</u>	Jul 29, 2004
<u>AB</u>	+	<u>EQ 5MG BASE;EQ 10MG BASE</u>	<u>N021540 001</u>	Jan 30, 2004
<u>AB</u>	+	<u>EQ 5MG BASE;EQ 20MG BASE</u>	<u>N021540 002</u>	Jan 30, 2004
<u>AB</u>	+	<u>EQ 5MG BASE;EQ 40MG BASE</u>	<u>N021540 003</u>	Jan 30, 2004
<u>AB</u>	+	<u>EQ 5MG BASE;EQ 80MG BASE</u>	<u>N021540 004</u>	Jan 30, 2004
<u>AB</u>	+	<u>EQ 10MG BASE;EQ 10MG BASE</u>	<u>N021540 005</u>	Jan 30, 2004
<u>AB</u>	+	<u>EQ 10MG BASE;EQ 20MG BASE</u>	<u>N021540 006</u>	Jan 30, 2004
<u>AB</u>	+	<u>EQ 10MG BASE;EQ 40MG BASE</u>	<u>N021540 007</u>	Jan 30, 2004
<u>AB</u>	+	<u>EQ 10MG BASE;EQ 80MG BASE</u>	<u>N021540 008</u>	Jan 30, 2004

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

<u>AB</u>	APOTEX	<u>EQ 2.5MG BASE;10MG</u>	<u>A091431 001</u>	Dec 30, 2013
<u>AB</u>		<u>EQ 5MG BASE;10MG</u>	<u>A091431 002</u>	Dec 30, 2013
<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>A091431 003</u>	Dec 30, 2013
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A091431 004</u>	Dec 30, 2013
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A091431 005</u>	Dec 30, 2013
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A091431 006</u>	Dec 30, 2013
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 2.5MG BASE;10MG</u>	<u>A202239 001</u>	Sep 05, 2012
<u>AB</u>		<u>EQ 5MG BASE;10MG</u>	<u>A202239 002</u>	Sep 05, 2012
<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>A202239 003</u>	Sep 05, 2012
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A202239 004</u>	Sep 05, 2012
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A202239 005</u>	Sep 05, 2012
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A202239 006</u>	Sep 05, 2012

PRESCRIPTION DRUG PRODUCT LIST

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE;ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

<u>AB</u>	DR REDDYS LABS INC	<u>EQ 2.5MG BASE;10MG</u>	<u>A077183 001</u>	Apr 15, 2010
<u>AB</u>		<u>EQ 5MG BASE;10MG</u>	<u>A077183 002</u>	Apr 15, 2010
<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>A077183 003</u>	Apr 15, 2010
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A090149 001</u>	Jul 05, 2011
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A077183 004</u>	Apr 15, 2010
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A090149 002</u>	Jul 05, 2011
<u>AB</u>	LUPIN PHARMS	<u>EQ 2.5MG BASE;10MG</u>	<u>A078466 001</u>	Feb 05, 2010
<u>AB</u>		<u>EQ 5MG BASE;10MG</u>	<u>A078466 002</u>	Feb 05, 2010
<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>A078466 003</u>	Feb 05, 2010
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A078466 005</u>	Jul 05, 2011
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A078466 004</u>	Feb 05, 2010
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A078466 006</u>	Jul 05, 2011
<u>AB</u>	WATSON LABS	<u>EQ 2.5MG BASE;10MG</u>	<u>A077890 001</u>	Oct 14, 2010
<u>AB</u>		<u>EQ 5MG BASE;10MG</u>	<u>A077890 002</u>	Oct 14, 2010
<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>A077890 003</u>	Oct 14, 2010
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A077890 004</u>	Oct 14, 2010
<u>AB</u>	WATSON LABS INC	<u>EQ 5MG BASE;40MG</u>	<u>A090364 001</u>	Jul 05, 2011
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A090364 002</u>	Jul 05, 2011

LOTREL

<u>AB</u>	+	NOVARTIS	<u>EQ 2.5MG BASE;10MG</u>	<u>N020364 002</u>	Mar 03, 1995
<u>AB</u>	+		<u>EQ 5MG BASE;10MG</u>	<u>N020364 003</u>	Mar 03, 1995
<u>AB</u>	+		<u>EQ 5MG BASE;20MG</u>	<u>N020364 004</u>	Mar 03, 1995
<u>AB</u>	+		<u>EQ 5MG BASE;40MG</u>	<u>N020364 007</u>	Apr 11, 2006
<u>AB</u>	+		<u>EQ 10MG BASE;20MG</u>	<u>N020364 005</u>	Jun 20, 2002
<u>AB</u>	+	!	<u>EQ 10MG BASE;40MG</u>	<u>N020364 006</u>	Apr 11, 2006

AMLODIPINE BESYLATE; CELECOXIB

TABLET;ORAL

CONSENSI

+	COEPTIS	EQ 2.5MG BASE;200MG	N210045 001	May 31, 2018
+		EQ 5MG BASE;200MG	N210045 002	May 31, 2018
+	!	EQ 10MG BASE;200MG	N210045 003	May 31, 2018

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	PAR PHARM INC	<u>EQ 5MG BASE;12.5MG;20MG</u>	<u>A206137 001</u>	Oct 26, 2016
<u>AB</u>		<u>EQ 5MG BASE;12.5MG;40MG</u>	<u>A206137 002</u>	Oct 26, 2016
<u>AB</u>		<u>EQ 5MG BASE;25MG;40MG</u>	<u>A206137 003</u>	Oct 26, 2016
<u>AB</u>		<u>EQ 10MG BASE;12.5MG;40MG</u>	<u>A206137 004</u>	Oct 26, 2016
<u>AB</u>		<u>EQ 10MG BASE;25MG;40MG</u>	<u>A206137 005</u>	Oct 26, 2016
<u>AB</u>	TEVA PHARMS USA	<u>EQ 5MG BASE;12.5MG;20MG</u>	<u>A202491 001</u>	Nov 03, 2016
<u>AB</u>		<u>EQ 5MG BASE;12.5MG;40MG</u>	<u>A202491 002</u>	Nov 03, 2016
<u>AB</u>		<u>EQ 5MG BASE;25MG;40MG</u>	<u>A202491 003</u>	Nov 03, 2016
<u>AB</u>		<u>EQ 10MG BASE;12.5MG;40MG</u>	<u>A202491 004</u>	Nov 03, 2016
<u>AB</u>		<u>EQ 10MG BASE;25MG;40MG</u>	<u>A202491 005</u>	Nov 03, 2016
<u>AB</u>	TORRENT	<u>EQ 5MG BASE;12.5MG;20MG</u>	<u>A203580 001</u>	Oct 26, 2016
<u>AB</u>		<u>EQ 5MG BASE;12.5MG;40MG</u>	<u>A203580 002</u>	Oct 26, 2016
<u>AB</u>		<u>EQ 5MG BASE;25MG;40MG</u>	<u>A203580 003</u>	Oct 26, 2016
<u>AB</u>		<u>EQ 10MG BASE;12.5MG;40MG</u>	<u>A203580 004</u>	Oct 26, 2016
<u>AB</u>		<u>EQ 10MG BASE;25MG;40MG</u>	<u>A203580 005</u>	Oct 26, 2016

TRIBENZOR

<u>AB</u>	+	DAIICHI SANKYO	<u>EQ 5MG BASE;12.5MG;20MG</u>	<u>N200175 001</u>	Jul 23, 2010
<u>AB</u>	+		<u>EQ 5MG BASE;12.5MG;40MG</u>	<u>N200175 002</u>	Jul 23, 2010
<u>AB</u>	+		<u>EQ 5MG BASE;25MG;40MG</u>	<u>N200175 003</u>	Jul 23, 2010
<u>AB</u>	+		<u>EQ 10MG BASE;12.5MG;40MG</u>	<u>N200175 004</u>	Jul 23, 2010
<u>AB</u>	+	!	<u>EQ 10MG BASE;25MG;40MG</u>	<u>N200175 005</u>	Jul 23, 2010

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 5MG BASE;12.5MG;160MG</u>	<u>A206180 001</u>	Dec 19, 2017
<u>AB</u>		<u>EQ 5MG BASE;25MG;160MG</u>	<u>A206180 002</u>	Dec 19, 2017
<u>AB</u>		<u>EQ 10MG BASE;12.5MG;160MG</u>	<u>A206180 003</u>	Dec 19, 2017
<u>AB</u>		<u>EQ 10MG BASE;25MG;160MG</u>	<u>A206180 004</u>	Dec 19, 2017
<u>AB</u>		<u>EQ 10MG BASE;25MG;320MG</u>	<u>A206180 005</u>	Dec 19, 2017
<u>AB</u>	LUPIN LTD	<u>EQ 5MG BASE;12.5MG;160MG</u>	<u>A200797 001</u>	Jun 03, 2015
<u>AB</u>		<u>EQ 5MG BASE;25MG;160MG</u>	<u>A200797 002</u>	Jun 03, 2015
<u>AB</u>		<u>EQ 10MG BASE;12.5MG;160MG</u>	<u>A200797 003</u>	Jun 03, 2015
<u>AB</u>		<u>EQ 10MG BASE;25MG;160MG</u>	<u>A200797 004</u>	Jun 03, 2015

PRESCRIPTION DRUG PRODUCT LIST

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

<u>AB</u>		<u>EQ 10MG BASE;25MG;320MG</u>	<u>A200797 005</u>	Jun 03, 2015
	<u>EXFORGE HCT</u>			
<u>AB</u>	+	<u>EQ 5MG BASE;12.5MG;160MG</u>	<u>N022314 001</u>	Apr 30, 2009
<u>AB</u>	+	<u>EQ 5MG BASE;25MG;160MG</u>	<u>N022314 002</u>	Apr 30, 2009
<u>AB</u>	+	<u>EQ 10MG BASE;12.5MG;160MG</u>	<u>N022314 003</u>	Apr 30, 2009
<u>AB</u>	+	<u>EQ 10MG BASE;25MG;160MG</u>	<u>N022314 004</u>	Apr 30, 2009
<u>AB</u>	+	<u>EQ 10MG BASE;25MG;320MG</u>	<u>N022314 005</u>	Apr 30, 2009

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

<u>AB</u>	AJANTA PHARMA LTD	<u>EQ 5MG BASE;20MG</u>	<u>A207216 001</u>	Oct 28, 2016
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A207216 002</u>	Oct 28, 2016
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A207216 003</u>	Oct 28, 2016
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A207216 004</u>	Oct 28, 2016
<u>AB</u>	ALEMIC PHARMS LTD	<u>EQ 5MG BASE;20MG</u>	<u>A207073 001</u>	Jul 17, 2017
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A207073 002</u>	Jul 17, 2017
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A207073 003</u>	Jul 17, 2017
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A207073 004</u>	Jul 17, 2017
<u>AB</u>	ALKEM LABS LTD	<u>EQ 5MG BASE;20MG</u>	<u>A209042 001</u>	Aug 14, 2017
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A209042 002</u>	Aug 14, 2017
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A209042 003</u>	Aug 14, 2017
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A209042 004</u>	Aug 14, 2017
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 5MG BASE;20MG</u>	<u>A206906 001</u>	May 15, 2017
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A206906 002</u>	May 15, 2017
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A206906 003</u>	May 15, 2017
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A206906 004</u>	May 15, 2017
<u>AB</u>	GLENMARK PHARMS LTD	<u>EQ 5MG BASE;20MG</u>	<u>A207807 001</u>	Jul 05, 2017
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A207807 002</u>	Jul 05, 2017
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A207807 003</u>	Jul 05, 2017
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A207807 004</u>	Jul 05, 2017
<u>AB</u>	JUBILANT GENERICS	<u>EQ 5MG BASE;20MG</u>	<u>A207450 001</u>	May 15, 2017
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A207450 002</u>	May 15, 2017
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A207450 003</u>	May 15, 2017
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A207450 004</u>	May 15, 2017
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 5MG BASE;20MG</u>	<u>A206884 001</u>	Oct 26, 2016
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A206884 003</u>	Oct 26, 2016
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A206884 002</u>	Oct 26, 2016
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A206884 004</u>	Oct 26, 2016
<u>AB</u>	MICRO LABS	<u>EQ 5MG BASE;20MG</u>	<u>A207435 001</u>	Nov 02, 2017
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A207435 002</u>	Nov 02, 2017
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A207435 003</u>	Nov 02, 2017
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A207435 004</u>	Nov 02, 2017
<u>AB</u>	SCIEGEN PHARMS INC	<u>EQ 5MG BASE;20MG</u>	<u>A209010 001</u>	Dec 03, 2018
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A209010 002</u>	Dec 03, 2018
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A209010 003</u>	Dec 03, 2018
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A209010 004</u>	Dec 03, 2018
<u>AB</u>	TORRENT	<u>EQ 5MG BASE;20MG</u>	<u>A202933 001</u>	Nov 25, 2016
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A202933 002</u>	Nov 25, 2016
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A202933 003</u>	Nov 25, 2016
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A202933 004</u>	Nov 25, 2016
<u>AB</u>	ZYDUS PHARMS	<u>EQ 5MG BASE;20MG</u>	<u>A207771 001</u>	Sep 22, 2017
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A207771 002</u>	Sep 22, 2017
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A207771 003</u>	Sep 22, 2017
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A207771 004</u>	Sep 22, 2017
	<u>AZOR</u>			
<u>AB</u>	+	<u>EQ 5MG BASE;20MG</u>	<u>N022100 001</u>	Sep 26, 2007
<u>AB</u>	+	<u>EQ 5MG BASE;40MG</u>	<u>N022100 002</u>	Sep 26, 2007
<u>AB</u>	+	<u>EQ 10MG BASE;20MG</u>	<u>N022100 003</u>	Sep 26, 2007
<u>AB</u>	+	<u>EQ 10MG BASE;40MG</u>	<u>N022100 004</u>	Sep 26, 2007

AMLODIPINE BESYLATE; PERINDOPRIL ARGININE

TABLET;ORAL

PRESTALIA

+	ADHERA	<u>EQ 2.5MG BASE;3.5MG</u>	<u>N205003 001</u>	Jan 21, 2015
+		<u>EQ 5MG BASE;7MG</u>	<u>N205003 002</u>	Jan 21, 2015
+		<u>EQ 10MG BASE;14MG</u>	<u>N205003 003</u>	Jan 21, 2015

PRESCRIPTION DRUG PRODUCT LIST

AMLODIPINE BESYLATE; TELMISARTAN

TABLET; ORAL

TELMISARTAN AND AMLODIPINE

<u>AB</u>	LUPIN LTD	<u>EQ 5MG BASE;40MG</u>	<u>A201586 001</u>	Jan 08, 2014
<u>AB</u>		<u>EQ 5MG BASE;80MG</u>	<u>A201586 003</u>	Jan 08, 2014
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A201586 002</u>	Jan 08, 2014
<u>AB</u>		<u>EQ 10MG BASE;80MG</u>	<u>A201586 004</u>	Jan 08, 2014
<u>AB</u>	MYLAN	<u>EQ 5MG BASE;40MG</u>	<u>A202516 001</u>	Aug 26, 2014
<u>AB</u>		<u>EQ 5MG BASE;80MG</u>	<u>A202516 003</u>	Aug 26, 2014
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A202516 002</u>	Aug 26, 2014
<u>AB</u>		<u>EQ 10MG BASE;80MG</u>	<u>A202516 004</u>	Aug 26, 2014
<u>AB</u>	TORRENT	<u>EQ 5MG BASE;40MG</u>	<u>A202517 001</u>	Jan 08, 2014
<u>AB</u>		<u>EQ 5MG BASE;80MG</u>	<u>A202517 003</u>	Jan 08, 2014
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A202517 002</u>	Jan 08, 2014
<u>AB</u>		<u>EQ 10MG BASE;80MG</u>	<u>A202517 004</u>	Jan 08, 2014
<u>TWYNSTA</u>				
<u>AB</u>	+ BOEHRINGER INGELHEIM	<u>EQ 5MG BASE;40MG</u>	<u>N022401 001</u>	Oct 16, 2009
<u>AB</u>	+	<u>EQ 5MG BASE;80MG</u>	<u>N022401 003</u>	Oct 16, 2009
<u>AB</u>	+	<u>EQ 10MG BASE;40MG</u>	<u>N022401 002</u>	Oct 16, 2009
<u>AB</u>	+	<u>EQ 10MG BASE;80MG</u>	<u>N022401 004</u>	Oct 16, 2009

AMLODIPINE BESYLATE; VALSARTAN

TABLET; ORAL

AMLODIPINE BESYLATE AND VALSARTAN

<u>AB</u>	ALEMBIC PHARMS LTD	<u>EQ 5MG BASE;160MG</u>	<u>A202713 001</u>	Apr 03, 2015
<u>AB</u>		<u>EQ 5MG BASE;320MG</u>	<u>A202713 003</u>	Apr 03, 2015
<u>AB</u>		<u>EQ 10MG BASE;160MG</u>	<u>A202713 002</u>	Apr 03, 2015
<u>AB</u>		<u>EQ 10MG BASE;320MG</u>	<u>A202713 004</u>	Apr 03, 2015
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 5MG BASE;160MG</u>	<u>A206512 001</u>	Apr 22, 2016
<u>AB</u>		<u>EQ 5MG BASE;320MG</u>	<u>A206512 002</u>	Apr 22, 2016
<u>AB</u>		<u>EQ 10MG BASE;160MG</u>	<u>A206512 003</u>	Apr 22, 2016
<u>AB</u>		<u>EQ 10MG BASE;320MG</u>	<u>A206512 004</u>	Apr 22, 2016
<u>AB</u>	INVAGEN PHARMS	<u>EQ 5MG BASE;160MG</u>	<u>A205137 001</u>	Sep 16, 2016
<u>AB</u>		<u>EQ 5MG BASE;320MG</u>	<u>A205137 003</u>	Sep 16, 2016
<u>AB</u>		<u>EQ 10MG BASE;160MG</u>	<u>A205137 002</u>	Sep 16, 2016
<u>AB</u>		<u>EQ 10MG BASE;320MG</u>	<u>A205137 004</u>	Sep 16, 2016
<u>AB</u>	LUPIN	<u>EQ 5MG BASE;160MG</u>	<u>A090245 001</u>	Mar 30, 2015
<u>AB</u>		<u>EQ 5MG BASE;320MG</u>	<u>A090245 003</u>	Mar 30, 2015
<u>AB</u>		<u>EQ 10MG BASE;160MG</u>	<u>A090245 002</u>	Mar 30, 2015
<u>AB</u>		<u>EQ 10MG BASE;320MG</u>	<u>A090245 004</u>	Mar 30, 2015
<u>AB</u>	MYLAN	<u>EQ 5MG BASE;160MG</u>	<u>A090483 001</u>	Mar 30, 2015
<u>AB</u>		<u>EQ 5MG BASE;320MG</u>	<u>A090483 003</u>	Mar 30, 2015
<u>AB</u>		<u>EQ 10MG BASE;160MG</u>	<u>A090483 002</u>	Mar 30, 2015
<u>AB</u>		<u>EQ 10MG BASE;320MG</u>	<u>A090483 004</u>	Mar 30, 2015
<u>AB</u>	NOVEL LABS INC	<u>EQ 5MG BASE;160MG</u>	<u>A202829 001</u>	Mar 30, 2015
<u>AB</u>		<u>EQ 5MG BASE;320MG</u>	<u>A202829 003</u>	Mar 30, 2015
<u>AB</u>		<u>EQ 10MG BASE;160MG</u>	<u>A202829 002</u>	Mar 30, 2015
<u>AB</u>		<u>EQ 10MG BASE;320MG</u>	<u>A202829 004</u>	Mar 30, 2015
<u>EXFORGE</u>				
<u>AB</u>	+ NOVARTIS	<u>EQ 5MG BASE;160MG</u>	<u>N021990 002</u>	Jun 20, 2007
<u>AB</u>	+	<u>EQ 5MG BASE;320MG</u>	<u>N021990 004</u>	Jun 20, 2007
<u>AB</u>	+	<u>EQ 10MG BASE;160MG</u>	<u>N021990 003</u>	Jun 20, 2007
<u>AB</u>	+	<u>EQ 10MG BASE;320MG</u>	<u>N021990 005</u>	Jun 20, 2007

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

<u>AP</u>	3D IMAGING DRUG	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203779 001</u>	Oct 19, 2015
<u>AP</u>	BIOMEDCL RES FDN	<u>48.75mCi-487.5mCi/13ML (3.75-</u> <u>37.5mCi/ML)</u>	<u>A204352 001</u>	May 01, 2015
<u>AP</u>	BRIGHAM WOMENS HOSP	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203783 001</u>	Oct 30, 2014
<u>AP</u>	CARDINAL HLTH 414	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203700 001</u>	Feb 25, 2013
<u>AP</u>	DECATUR	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204465 001</u>	Oct 23, 2014
<u>AP</u>	ESSENTIAL ISOTOPES	<u>3.75mCi-260mCi/ML</u>	<u>A205687 001</u>	Dec 17, 2015
<u>AP</u>	+ FEINSTEIN	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>N022119 001</u>	Aug 23, 2007
<u>AP</u>	GEN HOSP	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A207025 001</u>	Feb 03, 2016
<u>AP</u>	IONETIX	<u>22.5mCi-225mCi/6ML (3.75-37.5mCi/ML)</u>	<u>A210524 001</u>	Dec 21, 2018
<u>AP</u>	JOHNS HOPKINS UNIV	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204514 001</u>	Aug 19, 2014
<u>AP</u>	KREITCHMAN PET CTR	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203938 001</u>	Dec 09, 2013
<u>AP</u>	MCPRF	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203321 001</u>	Feb 25, 2013
<u>AP</u>	MIDWEST MEDCL	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204457 001</u>	Nov 18, 2015
<u>AP</u>	MIPS CRF	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204535 001</u>	Nov 20, 2014

PRESCRIPTION DRUG PRODUCT LIST

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

<u>AP</u>	NCM USA BRONX LLC	<u>3.75mCi-260mCi/ML</u>	<u>A204515</u>	<u>001</u>	Feb 04, 2015
<u>AP</u>	PETNET	<u>30mCi-300mCi (3.75-37.5mCi/ML)</u>	<u>A204510</u>	<u>001</u>	Nov 02, 2015
<u>AP</u>	PRECISION NUCLEAR	<u>3.75mCi-260mCi/ML</u>	<u>A204547</u>	<u>001</u>	Aug 14, 2015
<u>AP</u>	SHERTECH LABS LLC	<u>3.75mCi-260mCi/ML</u>	<u>A204366</u>	<u>001</u>	Sep 19, 2014
<u>AP</u>	SOFIE	<u>18.8mCi-188mCi/5ML (3.75-37.5mCi/ML)</u>	<u>A204667</u>	<u>001</u>	Apr 22, 2015
<u>AP</u>	!	<u>3.75mCi-260mCi/ML</u>	<u>A203543</u>	<u>001</u>	Dec 14, 2012
<u>AP</u>	SPECTRON MRC LLC	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204455</u>	<u>001</u>	Apr 23, 2015
<u>AP</u>	UCLA BIOMEDICAL	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203812</u>	<u>001</u>	Jun 27, 2013
<u>AP</u>	UCSF RODIOPHARM	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204496</u>	<u>001</u>	Mar 28, 2014
<u>AP</u>	UNIV TX SW MEDCTR	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A209507</u>	<u>001</u>	Nov 01, 2019
<u>AP</u>	UNIV WISCONSIN	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A211740</u>	<u>001</u>	Sep 09, 2020
<u>AP</u>	WA UNIV SCH MED	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204506</u>	<u>001</u>	Feb 07, 2014
<u>AP</u>	WISCONSIN	<u>3.75mCi-260mCi/ML</u>	<u>A204356</u>	<u>001</u>	Dec 18, 2014

AMMONIUM CHLORIDE

INJECTABLE; INJECTION

AMMONIUM CHLORIDE IN PLASTIC CONTAINER

! HOSPIRA

5MEQ/ML

A088366 001 Jun 13, 1984

AMMONIUM LACTATE

CREAM; TOPICAL

AMMONIUM LACTATE

<u>AB</u>	!	PERRIGO ISRAEL	<u>EQ 12% BASE</u>	<u>A075774</u>	<u>001</u>	May 01, 2002
<u>AB</u>		TARO	<u>EQ 12% BASE</u>	<u>A075883</u>	<u>001</u>	Apr 10, 2003

LOTION; TOPICAL

AMMONIUM LACTATE

<u>AB</u>	!	PERRIGO ISRAEL	<u>EQ 12% BASE</u>	<u>A075570</u>	<u>001</u>	Jun 23, 2004
<u>AB</u>		TARO	<u>EQ 12% BASE</u>	<u>A076216</u>	<u>001</u>	May 28, 2004

AMOXAPINE

TABLET; ORAL

AMOXAPINE

WATSON LABS

25MG

A072691 002 Aug 28, 1992

50MG

A072691 003 Aug 28, 1992

100MG

A072691 004 Aug 28, 1992

!

150MG

A072691 001 Aug 28, 1992

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

<u>AB</u>		AUROBINDO	<u>250MG</u>	<u>A065271</u>	<u>001</u>	Nov 09, 2005
<u>AB</u>			<u>500MG</u>	<u>A065271</u>	<u>002</u>	Nov 09, 2005
<u>AB</u>		BELCHER PHARMS	<u>250MG</u>	<u>A062058</u>	<u>001</u>	
<u>AB</u>			<u>500MG</u>	<u>A062058</u>	<u>002</u>	
<u>AB</u>		HIKMA PHARMS	<u>250MG</u>	<u>A065291</u>	<u>001</u>	Feb 05, 2007
<u>AB</u>			<u>500MG</u>	<u>A065291</u>	<u>002</u>	Feb 05, 2007
<u>AB</u>		SANDOZ	<u>250MG</u>	<u>A064076</u>	<u>001</u>	Sep 30, 1994
<u>AB</u>			<u>500MG</u>	<u>A064076</u>	<u>002</u>	Sep 30, 1994
<u>AB</u>		TEVA	<u>250MG</u>	<u>A061926</u>	<u>001</u>	
<u>AB</u>	!		<u>500MG</u>	<u>A061926</u>	<u>003</u>	

AMOXIL

<u>AB</u>		NEOPHARMA	<u>250MG</u>	<u>A062216</u>	<u>001</u>	
<u>AB</u>			<u>500MG</u>	<u>A062216</u>	<u>004</u>	

FOR SUSPENSION; ORAL

AMOXICILLIN

<u>AB</u>		AUROBINDO	<u>200MG/5ML</u>	<u>A065334</u>	<u>001</u>	Dec 28, 2006
<u>AB</u>			<u>400MG/5ML</u>	<u>A065334</u>	<u>002</u>	Dec 28, 2006
<u>AB</u>		AUROBINDO PHARMA LTD	<u>125MG/5ML</u>	<u>A204030</u>	<u>001</u>	Sep 15, 2014
<u>AB</u>			<u>250MG/5ML</u>	<u>A204030</u>	<u>002</u>	Sep 15, 2014
<u>AB</u>		DAVA PHARMS INC	<u>125MG/5ML</u>	<u>A062927</u>	<u>001</u>	Nov 25, 1988
<u>AB</u>			<u>250MG/5ML</u>	<u>A062927</u>	<u>002</u>	Nov 25, 1988
<u>AB</u>		HIKMA	<u>125MG/5ML</u>	<u>A065322</u>	<u>002</u>	Jun 19, 2006
<u>AB</u>			<u>200MG/5ML</u>	<u>A065325</u>	<u>002</u>	Jun 19, 2006
<u>AB</u>			<u>250MG/5ML</u>	<u>A065322</u>	<u>001</u>	Jun 19, 2006
<u>AB</u>			<u>400MG/5ML</u>	<u>A065325</u>	<u>001</u>	Jun 19, 2006
<u>AB</u>		SANDOZ	<u>125MG/5ML</u>	<u>A065387</u>	<u>001</u>	Mar 26, 2007
<u>AB</u>			<u>200MG/5ML</u>	<u>A065378</u>	<u>001</u>	Mar 26, 2007
<u>AB</u>			<u>250MG/5ML</u>	<u>A065387</u>	<u>002</u>	Mar 26, 2007
<u>AB</u>			<u>400MG/5ML</u>	<u>A065378</u>	<u>002</u>	Mar 26, 2007
<u>AB</u>		TEVA	<u>200MG/5ML</u>	<u>A065119</u>	<u>001</u>	Dec 04, 2002
<u>AB</u>	!		<u>250MG/5ML</u>	<u>A061931</u>	<u>002</u>	

PRESCRIPTION DRUG PRODUCT LIST

AMOXICILLIN

FOR SUSPENSION;ORAL

AMOXICILLIN

<u>AB</u>	!	<u>400MG/5ML</u>	<u>A065119</u>	<u>002</u>	Dec 04, 2002
<u>AB</u>	WOCKHARDT BIO AG	<u>400MG/5ML</u>	<u>A065319</u>	<u>002</u>	Jun 18, 2007

AMOXICILLIN PEDIATRIC

<u>AB</u>	TEVA	<u>50MG/ML</u>	<u>A061931</u>	<u>003</u>	Dec 01, 1982
-----------	------	----------------	----------------	------------	--------------

AMOXIL

<u>AB</u>	NEOPHARMA	<u>50MG/ML</u>	<u>A062226</u>	<u>005</u>	
<u>AB</u>		<u>125MG/5ML</u>	<u>A062226</u>	<u>001</u>	
<u>AB</u>		<u>250MG/5ML</u>	<u>A062226</u>	<u>002</u>	

LAROTID

<u>AB</u>	NEOPHARMA	<u>125MG/5ML</u>	<u>A062226</u>	<u>003</u>	
<u>AB</u>		<u>250MG/5ML</u>	<u>A062226</u>	<u>004</u>	

TABLET;ORAL

AMOXICILLIN

<u>AB</u>	AUROBINDO	<u>500MG</u>	<u>A065256</u>	<u>001</u>	Nov 09, 2005
<u>AB</u>		<u>875MG</u>	<u>A065256</u>	<u>002</u>	Nov 09, 2005
<u>AB</u>	HIKMA	<u>875MG</u>	<u>A065255</u>	<u>001</u>	Mar 29, 2006
<u>AB</u>	SANDOZ	<u>500MG</u>	<u>A065228</u>	<u>001</u>	Jul 13, 2005
<u>AB</u>		<u>875MG</u>	<u>A065228</u>	<u>002</u>	Jul 13, 2005
<u>AB</u>	TEVA	<u>500MG</u>	<u>A065056</u>	<u>001</u>	Sep 18, 2000
<u>AB</u>	!	<u>875MG</u>	<u>A065056</u>	<u>002</u>	Sep 18, 2000

TABLET, CHEWABLE;ORAL

AMOXICILLIN

<u>AB</u>	HIKMA	<u>125MG</u>	<u>A205274</u>	<u>001</u>	Jun 25, 2020
<u>AB</u>		<u>250MG</u>	<u>A205274</u>	<u>002</u>	Jun 25, 2020
<u>AB</u>	TEVA	<u>125MG</u>	<u>A064013</u>	<u>002</u>	Sep 11, 1995
<u>AB</u>	!	<u>250MG</u>	<u>A064013</u>	<u>001</u>	Dec 22, 1992

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET;ORAL

LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN

<u>AB</u>	!	RISING	<u>500MG,N/A,N/A:N/A,500MG,N/A:N/A,N/A,30MG</u>	<u>A206006</u>	<u>001</u>	Oct 07, 2016
<u>AB</u>	SANDOZ INC		<u>500MG,N/A,N/A:N/A,500MG,N/A:N/A,N/A,30MG</u>	<u>A202588</u>	<u>001</u>	Mar 04, 2014

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED RELEASE;ORAL

OMEPRazole AND CLARITHROMYCIN AND AMOXICILLIN

+	!	CUMBERLAND PHARMS	<u>500MG,N/A,N/A:N/A,500MG,N/A:N/A,N/A,20MG</u>	<u>N050824</u>	<u>001</u>	Feb 08, 2011
---	---	-------------------	---	----------------	------------	--------------

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

<u>AB</u>	AUROBINDO PHARMA LTD	<u>125MG/5ML;EQ 31.25MG BASE/5ML</u>	<u>A209371</u>	<u>001</u>	Apr 19, 2019
<u>AB</u>		<u>200MG/5ML;EQ 28.5MG BASE/5ML</u>	<u>A201090</u>	<u>001</u>	Dec 20, 2011
<u>AB</u>		<u>250MG/5ML;EQ 62.5MG BASE/5ML</u>	<u>A209371</u>	<u>002</u>	Apr 19, 2019
<u>AB</u>		<u>400MG/5ML;EQ 57MG BASE/5ML</u>	<u>A201090</u>	<u>002</u>	Dec 20, 2011
<u>AB</u>		<u>600MG/5ML;EQ 42.9MG BASE/5ML</u>	<u>A201091</u>	<u>001</u>	Dec 20, 2011
<u>AB</u>	HIKMA PHARMS	<u>200MG/5ML;EQ 28.5MG BASE/5ML</u>	<u>A065191</u>	<u>002</u>	Jan 25, 2005
<u>AB</u>		<u>400MG/5ML;EQ 57MG BASE/5ML</u>	<u>A065191</u>	<u>001</u>	Jan 25, 2005
<u>AB</u>		<u>600MG/5ML;EQ 42.9MG BASE/5ML</u>	<u>A065373</u>	<u>001</u>	Nov 09, 2007
<u>AB</u>	SANDOZ	<u>200MG/5ML;EQ 28.5MG BASE/5ML</u>	<u>A065066</u>	<u>001</u>	Jun 05, 2002
<u>AB</u>		<u>400MG/5ML;EQ 57MG BASE/5ML</u>	<u>A065066</u>	<u>002</u>	Jun 05, 2002
<u>AB</u>	SANDOZ INC	<u>200MG/5ML;EQ 28.5MG BASE/5ML</u>	<u>A065098</u>	<u>001</u>	Dec 16, 2002
<u>AB</u>		<u>400MG/5ML;EQ 57MG BASE/5ML</u>	<u>A065098</u>	<u>002</u>	Dec 16, 2002
<u>AB</u>		<u>600MG/5ML;EQ 42.9MG BASE/5ML</u>	<u>A065358</u>	<u>001</u>	Aug 13, 2007
<u>AB</u>	TEVA	<u>200MG/5ML;EQ 28.5MG BASE/5ML</u>	<u>A065089</u>	<u>001</u>	May 25, 2004
<u>AB</u>	!	<u>400MG/5ML;EQ 57MG BASE/5ML</u>	<u>A065089</u>	<u>002</u>	May 25, 2004
<u>AB</u>	!	<u>600MG/5ML;EQ 42.9MG BASE/5ML</u>	<u>A065162</u>	<u>001</u>	Mar 12, 2004
<u>AB</u>	WOCKHARDT BIO AG	<u>250MG/5ML;EQ 62.5MG BASE/5ML</u>	<u>A065431</u>	<u>001</u>	Nov 25, 2008
<u>AB</u>		<u>600MG/5ML;EQ 42.9MG BASE/5ML</u>	<u>A065420</u>	<u>001</u>	Dec 02, 2013
<u>AB</u>	<u>AUGMENTIN '125'</u>				
<u>AB</u>	+ NEOPHARMA	<u>125MG/5ML;EQ 31.25MG BASE/5ML</u>	<u>N050575</u>	<u>001</u>	Aug 06, 1984
<u>AB</u>	<u>AUGMENTIN '250'</u>				
<u>AB</u>	+! NEOPHARMA	<u>250MG/5ML;EQ 62.5MG BASE/5ML</u>	<u>N050575</u>	<u>002</u>	Aug 06, 1984
<u>AB</u>	<u>AUGMENTIN ES-600</u>				
<u>AB</u>	+ NEOPHARMA	<u>600MG/5ML;EQ 42.9MG BASE/5ML</u>	<u>N050755</u>	<u>001</u>	Jun 22, 2001

PRESCRIPTION DRUG PRODUCT LIST

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	AUROBINDO PHARMA LTD	250MG;EQ 125MG BASE	A091569 001	Jan 20, 2012
AB		500MG;EQ 125MG BASE	A091569 002	Jan 20, 2012
AB		875MG;EQ 125MG BASE	A091568 001	Jan 20, 2012
AB	HIKMA PHARMS	875MG;EQ 125MG BASE	A203824 001	Aug 23, 2016
AB	MICRO LABS LTD INDIA	250MG;EQ 125MG BASE	A205707 001	Dec 30, 2016
AB		500MG;EQ 125MG BASE	A205707 002	Dec 30, 2016
AB		875MG;EQ 125MG BASE	A204755 003	Dec 30, 2016
AB	! SANDOZ	250MG;EQ 125MG BASE	A065189 001	Aug 23, 2005
AB		500MG;EQ 125MG BASE	A065064 001	Mar 15, 2002
AB	!	875MG;EQ 125MG BASE	A065063 001	Mar 14, 2002
AB	! SANDOZ INC	500MG;EQ 125MG BASE	A065117 001	Nov 27, 2002
AB		875MG;EQ 125MG BASE	A065093 001	Nov 21, 2002
AB	TEVA	500MG;EQ 125MG BASE	A065101 001	Oct 30, 2002
AB	TEVA PHARMS USA	875MG;EQ 125MG BASE	A065096 001	Oct 29, 2002

AUGMENTIN '875'

AB	+ NEOPHARMA	875MG;EQ 125MG BASE	N050720 001	Feb 13, 1996
-----------	-------------	----------------------------	--------------------	--------------

TABLET, CHEWABLE; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

TEVA

200MG;EQ 28.5MG BASE

A065205 001

Feb 09, 2005

!

400MG;EQ 57MG BASE

A065205 002

Feb 09, 2005

TABLET, EXTENDED RELEASE; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

! SANDOZ

1GM;EQ 62.5MG BASE

A090227 001

Apr 21, 2010

AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN

CAPSULE, DELAYED RELEASE; ORAL

TALICIA

+! REDHILL

250MG;EQ 10MG BASE;12.5MG

N213004 001

Nov 01, 2019

AMPHETAMINE

SUSPENSION, EXTENDED RELEASE; ORAL

ADZENYS ER

+! NEOS THERAPS INC

EQ 1.25MG BASE/ML

N204325 001

Sep 15, 2017

DYANAVEL XR

+! TRIS PHARMA INC

EQ 2.5MG BASE/ML

N208147 001

Oct 19, 2015

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE; ORAL

ADZENYS XR-ODT

+ NEOS THERAPS

EQ 3.1MG BASE

N204326 001

Jan 27, 2016

+

EQ 6.3MG BASE

N204326 002

Jan 27, 2016

+

EQ 9.4MG BASE

N204326 003

Jan 27, 2016

+

EQ 12.5MG BASE

N204326 004

Jan 27, 2016

+

EQ 15.7MG BASE

N204326 005

Jan 27, 2016

+!

EQ 18.8MG BASE

N204326 006

Jan 27, 2016

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

ADDERALL XR 10

AB	+ TAKEDA PHARMS USA	2.5MG;2.5MG;2.5MG;2.5MG	N021303 001	Oct 11, 2001
-----------	---------------------	--------------------------------	--------------------	--------------

ADDERALL XR 15

AB	+ TAKEDA PHARMS USA	3.75MG;3.75MG;3.75MG;3.75MG	N021303 006	May 22, 2002
-----------	---------------------	------------------------------------	--------------------	--------------

ADDERALL XR 20

AB	+ TAKEDA PHARMS USA	5MG;5MG;5MG;5MG	N021303 002	Oct 11, 2001
-----------	---------------------	------------------------	--------------------	--------------

ADDERALL XR 25

AB	+ TAKEDA PHARMS USA	6.25MG;6.25MG;6.25MG;6.25MG	N021303 004	May 22, 2002
-----------	---------------------	------------------------------------	--------------------	--------------

ADDERALL XR 30

AB	+! TAKEDA PHARMS USA	7.5MG;7.5MG;7.5MG;7.5MG	N021303 003	Oct 11, 2001
-----------	----------------------	--------------------------------	--------------------	--------------

ADDERALL XR 5

AB	+ TAKEDA PHARMS USA	1.25MG;1.25MG;1.25MG;1.25MG	N021303 005	May 22, 2002
-----------	---------------------	------------------------------------	--------------------	--------------

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	ACTAVIS ELIZABETH	1.25MG;1.25MG;1.25MG;1.25MG	A077302 001	Jun 22, 2012
AB		2.5MG;2.5MG;2.5MG;2.5MG	A077302 002	Jun 22, 2012
AB		3.75MG;3.75MG;3.75MG;3.75MG	A077302 003	Jun 22, 2012
AB		5MG;5MG;5MG;5MG	A077302 004	Jun 22, 2012
AB		6.25MG;6.25MG;6.25MG;6.25MG	A077302 005	Jun 22, 2012
AB		7.5MG;7.5MG;7.5MG;7.5MG	A077302 006	Jun 22, 2012
AB	ANI PHARMS INC	1.25MG;1.25MG;1.25MG;1.25MG	A205401 001	Jan 22, 2019
AB		2.5MG;2.5MG;2.5MG;2.5MG	A205401 002	Jan 22, 2019
AB		3.75MG;3.75MG;3.75MG;3.75MG	A205401 003	Jan 22, 2019

PRESCRIPTION DRUG PRODUCT LIST

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB		5MG;5MG;5MG;5MG	A205401 004	Jan 22, 2019
AB		6.25MG;6.25MG;6.25MG;6.25MG	A205401 005	Jan 22, 2019
AB		7.5MG;7.5MG;7.5MG;7.5MG	A205401 006	Jan 22, 2019
AB	ELITE LABS INC	1.25MG;1.25MG;1.25MG;1.25MG	A212037 001	Dec 11, 2019
AB		2.5MG;2.5MG;2.5MG;2.5MG	A212037 002	Dec 11, 2019
AB		3.75MG;3.75MG;3.75MG;3.75MG	A212037 003	Dec 11, 2019
AB		5MG;5MG;5MG;5MG	A212037 004	Dec 11, 2019
AB		6.25MG;6.25MG;6.25MG;6.25MG	A212037 005	Dec 11, 2019
AB		7.5MG;7.5MG;7.5MG;7.5MG	A212037 006	Dec 11, 2019
AB	IMPAX LABS	1.25MG;1.25MG;1.25MG;1.25MG	A076852 001	Feb 16, 2016
AB		2.5MG;2.5MG;2.5MG;2.5MG	A076852 002	Feb 16, 2016
AB		3.75MG;3.75MG;3.75MG;3.75MG	A076852 003	Feb 16, 2016
AB		5MG;5MG;5MG;5MG	A076852 004	Feb 16, 2016
AB		6.25MG;6.25MG;6.25MG;6.25MG	A076852 005	Feb 16, 2016
AB		7.5MG;7.5MG;7.5MG;7.5MG	A076852 006	Feb 16, 2016
AB	PAR PHARM INC	1.25MG;1.25MG;1.25MG;1.25MG	A206159 001	May 31, 2019
AB		2.5MG;2.5MG;2.5MG;2.5MG	A206159 002	May 31, 2019
AB		3.75MG;3.75MG;3.75MG;3.75MG	A206159 003	May 31, 2019
AB		5MG;5MG;5MG;5MG	A206159 004	May 31, 2019
AB		6.25MG;6.25MG;6.25MG;6.25MG	A206159 005	May 31, 2019
AB		7.5MG;7.5MG;7.5MG;7.5MG	A206159 006	May 31, 2019
AB	RHODES PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A210651 001	May 17, 2019
AB		2.5MG;2.5MG;2.5MG;2.5MG	A210651 002	May 17, 2019
AB		3.75MG;3.75MG;3.75MG;3.75MG	A210651 003	May 17, 2019
AB		5MG;5MG;5MG;5MG	A210651 004	May 17, 2019
AB		6.25MG;6.25MG;6.25MG;6.25MG	A210651 005	May 17, 2019
AB		7.5MG;7.5MG;7.5MG;7.5MG	A210651 006	May 17, 2019
AB	SPECGX LLC	1.25MG;1.25MG;1.25MG;1.25MG	A211547 001	Apr 22, 2019
AB		2.5MG;2.5MG;2.5MG;2.5MG	A211547 002	Apr 22, 2019
AB		3.75MG;3.75MG;3.75MG;3.75MG	A211547 003	Apr 22, 2019
AB		5MG;5MG;5MG;5MG	A211547 004	Apr 22, 2019
AB		6.25MG;6.25MG;6.25MG;6.25MG	A211547 005	Apr 22, 2019
AB		7.5MG;7.5MG;7.5MG;7.5MG	A211547 006	Apr 22, 2019
AB	SUN PHARM INDUSTRIES	1.25MG;1.25MG;1.25MG;1.25MG	A211715 001	May 17, 2019
AB		2.5MG;2.5MG;2.5MG;2.5MG	A211715 002	May 17, 2019
AB		3.75MG;3.75MG;3.75MG;3.75MG	A211715 003	May 17, 2019
AB		5MG;5MG;5MG;5MG	A211715 004	May 17, 2019
AB		6.25MG;6.25MG;6.25MG;6.25MG	A211715 005	May 17, 2019
AB		7.5MG;7.5MG;7.5MG;7.5MG	A211715 006	May 17, 2019
	MYDAYIS			
	+ TAKEDA PHARMS USA	3.125MG;3.125MG;3.125MG;3.125MG	N022063 001	Jun 20, 2017
		6.25MG;6.25MG;6.25MG;6.25MG	N022063 002	Jun 20, 2017
		9.375MG;9.375MG;9.375MG;9.375MG	N022063 003	Jun 20, 2017
		12.5MG;12.5MG;12.5MG;12.5MG	N022063 004	Jun 20, 2017

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	ACTAVIS ELIZABETH	1.25MG;1.25MG;1.25MG;1.25MG	A206340 001	Feb 05, 2016
AB		1.875MG;1.875MG;1.875MG;1.875MG	A206340 002	Feb 05, 2016
AB		2.5MG;2.5MG;2.5MG;2.5MG	A206340 003	Feb 05, 2016
AB		3.125MG;3.125MG;3.125MG;3.125MG	A206340 004	Feb 05, 2016
AB		3.75MG;3.75MG;3.75MG;3.75MG	A206340 005	Feb 05, 2016
AB		5MG;5MG;5MG;5MG	A206340 006	Feb 05, 2016
AB		7.5MG;7.5MG;7.5MG;7.5MG	A206340 007	Feb 05, 2016
AB	ALVOGEN	1.25MG;1.25MG;1.25MG;1.25MG	A207388 001	Jul 28, 2017
AB		1.875MG;1.875MG;1.875MG;1.875MG	A207388 002	Jul 28, 2017
AB		2.5MG;2.5MG;2.5MG;2.5MG	A207388 003	Jul 28, 2017
AB		3.125MG;3.125MG;3.125MG;3.125MG	A207388 004	Jul 28, 2017
AB		3.75MG;3.75MG;3.75MG;3.75MG	A207388 005	Jul 28, 2017
AB		5MG;5MG;5MG;5MG	A207388 006	Jul 28, 2017
AB		7.5MG;7.5MG;7.5MG;7.5MG	A207388 007	Jul 28, 2017
AB	AUROLIFE PHARMA LLC	1.25MG;1.25MG;1.25MG;1.25MG	A202424 001	Nov 27, 2013
AB		1.875MG;1.875MG;1.875MG;1.875MG	A202424 002	Nov 27, 2013
AB		2.5MG;2.5MG;2.5MG;2.5MG	A202424 003	Nov 27, 2013
AB		3.125MG;3.125MG;3.125MG;3.125MG	A202424 004	Nov 27, 2013
AB		3.75MG;3.75MG;3.75MG;3.75MG	A202424 005	Nov 27, 2013
AB		5MG;5MG;5MG;5MG	A202424 006	Nov 27, 2013
AB		7.5MG;7.5MG;7.5MG;7.5MG	A202424 007	Nov 27, 2013
AB	BARR	1.25MG;1.25MG;1.25MG;1.25MG	A040422 001	Feb 11, 2002

PRESCRIPTION DRUG PRODUCT LIST

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB		<u>1.875MG;1.875MG;1.875MG;1.875MG</u>	<u>A040422 005</u>	Mar 19, 2003
AB		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A040422 002</u>	Feb 11, 2002
AB		<u>3.125MG;3.125MG;3.125MG;3.125MG</u>	<u>A040422 006</u>	Mar 19, 2003
AB		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A040422 007</u>	Mar 19, 2003
AB		<u>5MG;5MG;5MG;5MG</u>	<u>A040422 003</u>	Feb 11, 2002
AB		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A040422 004</u>	Feb 11, 2002
AB	ELITE LABS INC	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A211352 001</u>	Dec 07, 2018
AB		<u>1.875MG;1.875MG;1.875MG;1.875MG</u>	<u>A211352 002</u>	Dec 07, 2018
AB		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A211352 003</u>	Dec 07, 2018
AB		<u>3.125MG;3.125MG;3.125MG;3.125MG</u>	<u>A211352 004</u>	Dec 07, 2018
AB		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A211352 005</u>	Dec 07, 2018
AB		<u>5MG;5MG;5MG;5MG</u>	<u>A211352 006</u>	Dec 07, 2018
AB		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A211352 007</u>	Dec 07, 2018
AB	EPIC PHARMA LLC	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A040444 001</u>	Jun 19, 2002
AB		<u>1.875MG;1.875MG;1.875MG;1.875MG</u>	<u>A040444 005</u>	Nov 03, 2014
AB		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A040444 002</u>	Jun 19, 2002
AB		<u>3.125MG;3.125MG;3.125MG;3.125MG</u>	<u>A040444 006</u>	Nov 03, 2014
AB		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A040444 007</u>	Nov 03, 2014
AB		<u>5MG;5MG;5MG;5MG</u>	<u>A040444 003</u>	Jun 19, 2002
AB		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A040444 004</u>	Jun 19, 2002
AB	MYLAN	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A206721 001</u>	Nov 10, 2015
AB		<u>1.875MG;1.875MG;1.875MG;1.875MG</u>	<u>A206721 002</u>	Nov 10, 2015
AB		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A206721 003</u>	Nov 10, 2015
AB		<u>3.125MG;3.125MG;3.125MG;3.125MG</u>	<u>A206721 004</u>	Nov 10, 2015
AB		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A206721 005</u>	Nov 10, 2015
AB		<u>5MG;5MG;5MG;5MG</u>	<u>A206721 006</u>	Nov 10, 2015
AB		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A206721 007</u>	Nov 10, 2015
AB	NESHER PHARMS	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A207340 001</u>	Oct 31, 2017
AB		<u>1.875MG;1.875MG;1.875MG;1.875MG</u>	<u>A207340 002</u>	Oct 31, 2017
AB		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A207340 003</u>	Oct 31, 2017
AB		<u>3.125MG;3.125MG;3.125MG;3.125MG</u>	<u>A207340 004</u>	Oct 31, 2017
AB		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A207340 005</u>	Oct 31, 2017
AB		<u>5MG;5MG;5MG;5MG</u>	<u>A207340 006</u>	Oct 31, 2017
AB		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A207340 007</u>	Oct 31, 2017
AB	NUVO PHARM	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A209799 001</u>	Dec 28, 2017
AB		<u>1.875MG;1.875MG;1.875MG;1.875MG</u>	<u>A209799 002</u>	Dec 28, 2017
AB		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A209799 003</u>	Dec 28, 2017
AB		<u>3.125MG;3.125MG;3.125MG;3.125MG</u>	<u>A209799 004</u>	Dec 28, 2017
AB		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A209799 005</u>	Dec 28, 2017
AB		<u>5MG;5MG;5MG;5MG</u>	<u>A209799 006</u>	Dec 28, 2017
AB		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A209799 007</u>	Dec 28, 2017
AB	SANDOZ	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A040439 004</u>	Sep 27, 2002
AB		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A040439 001</u>	Jun 14, 2002
AB		<u>5MG;5MG;5MG;5MG</u>	<u>A040439 002</u>	Jun 14, 2002
AB		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A040439 003</u>	Jun 14, 2002
AB	SPECGX LLC	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A040440 001</u>	Oct 07, 2003
AB		<u>1.875MG;1.875MG;1.875MG;1.875MG</u>	<u>A040440 002</u>	Oct 07, 2003
AB		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A040440 003</u>	Oct 07, 2003
AB		<u>3.125MG;3.125MG;3.125MG;3.125MG</u>	<u>A040440 004</u>	Oct 07, 2003
AB		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A040440 005</u>	Oct 07, 2003
AB		<u>5MG;5MG;5MG;5MG</u>	<u>A040440 006</u>	Oct 07, 2003
AB		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A040440 007</u>	Oct 07, 2003
AB	SUN PHARM INDUSTRIES	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A040480 001</u>	Sep 09, 2003
AB		<u>1.875MG;1.875MG;1.875MG;1.875MG</u>	<u>A040480 002</u>	Sep 09, 2003
AB		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A040480 003</u>	Sep 09, 2003
AB		<u>3.125MG;3.125MG;3.125MG;3.125MG</u>	<u>A040480 004</u>	Sep 09, 2003
AB		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A040480 005</u>	Sep 09, 2003
AB		<u>5MG;5MG;5MG;5MG</u>	<u>A040480 006</u>	Sep 09, 2003
AB		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A040480 007</u>	Sep 09, 2003
AB	USPHARMA	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A210293 001</u>	Apr 03, 2020
AB		<u>1.875MG;1.875MG;1.875MG;1.875MG</u>	<u>A210293 002</u>	Apr 03, 2020
AB		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A210293 003</u>	Apr 03, 2020
AB		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A210293 004</u>	Apr 03, 2020
AB		<u>5MG;5MG;5MG;5MG</u>	<u>A210293 005</u>	Apr 03, 2020
AB		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A210293 006</u>	Apr 03, 2020

PRESCRIPTION DRUG PRODUCT LIST

AMPHETAMINE SULFATE

TABLET; ORAL

AMPHETAMINE SULFATE

<u>AA</u>	ALKEM LABS LTD	<u>5MG</u>	<u>A213720 001</u>	Oct 27, 2020
<u>AA</u>		<u>10MG</u>	<u>A213720 002</u>	Oct 27, 2020
<u>AA</u>	AMNEAL PHARMS	<u>5MG</u>	<u>A211139 001</u>	Sep 26, 2018
<u>AA</u>		<u>10MG</u>	<u>A211139 002</u>	Sep 26, 2018
<u>AA</u>	AUROLIFE PHARMA LLC	<u>5MG</u>	<u>A211639 001</u>	Apr 17, 2019
<u>AA</u>		<u>10MG</u>	<u>A211639 002</u>	Apr 17, 2019
<u>AA</u>	BIONPHARMA INC	<u>5MG</u>	<u>A212919 001</u>	Nov 22, 2019
<u>AA</u>		<u>10MG</u>	<u>A212919 002</u>	Nov 22, 2019
<u>AA</u>	CEROVENE INC	<u>5MG</u>	<u>A212582 001</u>	Feb 04, 2020
<u>AA</u>		<u>10MG</u>	<u>A212582 002</u>	Feb 04, 2020
<u>AA</u>	EPIC PHARMA LLC	<u>5MG</u>	<u>A213980 001</u>	Oct 27, 2020
<u>AA</u>		<u>10MG</u>	<u>A213980 002</u>	Oct 27, 2020
<u>AA</u>	GRANULES PHARMS	<u>5MG</u>	<u>A212619 001</u>	Aug 05, 2019
<u>AA</u>		<u>10MG</u>	<u>A212619 002</u>	Aug 05, 2019
<u>AA</u>	HAVIX	<u>5MG</u>	<u>A212901 001</u>	May 22, 2020
<u>AA</u>		<u>10MG</u>	<u>A212901 002</u>	May 22, 2020
<u>AA</u>	MAYNE PHARMA	<u>5MG</u>	<u>A213898 001</u>	Jul 14, 2020
<u>AA</u>		<u>10MG</u>	<u>A213898 002</u>	Jul 14, 2020
<u>AA</u>	NOVAST LABS	<u>5MG</u>	<u>A213763 001</u>	Aug 24, 2020
<u>AA</u>		<u>10MG</u>	<u>A213763 002</u>	Aug 24, 2020
<u>AA</u>	PRINSTON INC	<u>5MG</u>	<u>A211861 001</u>	Mar 11, 2020
<u>AA</u>		<u>10MG</u>	<u>A211861 002</u>	Mar 11, 2020

EVEKEO

<u>AA</u>	ARBOR PHARMS LLC	<u>5MG</u>	<u>A200166 001</u>	Aug 09, 2012
<u>AA</u>	!	<u>10MG</u>	<u>A200166 002</u>	Aug 09, 2012

TABLET, ORALLY DISINTEGRATING; ORAL

EVEKEO ODT

+	ARBOR PHARMS LLC	5MG	N209905 001	Jan 30, 2019
+		10MG	N209905 002	Jan 30, 2019
+		15MG	N209905 003	Jan 30, 2019
+		20MG	N209905 004	Jan 30, 2019

AMPHOTERICIN B

INJECTABLE; INJECTION

AMPHOTERICIN B

!	XGEN PHARMS	50MG/VIAL	A063206 001	Apr 29, 1992
---	-------------	-----------	-------------	--------------

INJECTABLE, LIPID COMPLEX; INJECTION

ABELCET

+	LEADIANT BIOSCI INC	5MG/ML	N050724 001	Nov 20, 1995
---	---------------------	--------	-------------	--------------

INJECTABLE, LIPOSOMAL; INJECTION

AMBISOME

+	ASTELLAS	50MG/VIAL	N050740 001	Aug 11, 1997
---	----------	-----------	-------------	--------------

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

<u>AP</u>	ACS DOBFAR SPA	<u>EQ 10GM BASE/VIAL</u>	<u>A090889 001</u>	Apr 03, 2013
<u>AP</u>	ANTIBIOTICE	<u>EQ 250MG BASE/VIAL</u>	<u>A090354 001</u>	Dec 28, 2009
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A090354 002</u>	Dec 28, 2009
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A090354 003</u>	Dec 28, 2009
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A090354 004</u>	Dec 28, 2009
<u>AP</u>	AUROBINDO PHARMA	<u>EQ 250MG BASE/VIAL</u>	<u>A065499 002</u>	Aug 17, 2010
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065499 003</u>	Aug 17, 2010
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065499 004</u>	Aug 17, 2010
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065499 005</u>	Aug 17, 2010
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065493 001</u>	Aug 17, 2010
<u>AP</u>	HANFORD GC	<u>EQ 250MG BASE/VIAL</u>	<u>A062772 006</u>	Apr 15, 1993
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A062772 007</u>	Apr 15, 1993
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A062772 001</u>	Apr 15, 1993
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A062772 003</u>	Apr 15, 1993
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A063142 001</u>	Apr 15, 1993
<u>AP</u>	ISTITUTO BIO ITA SPA	<u>EQ 10GM BASE/VIAL</u>	<u>A201404 001</u>	Dec 20, 2013
<u>AP</u>		<u>EQ 250MG BASE/VIAL</u>	<u>A062719 001</u>	May 12, 1987
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A062719 003</u>	May 12, 1987
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A062719 002</u>	May 12, 1987
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A062797 002</u>	Jul 12, 1993
<u>AP</u>	MYLAN LABS LTD	<u>EQ 250MG BASE/VIAL</u>	<u>A201025 001</u>	Apr 09, 2014
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A201025 002</u>	Apr 09, 2014
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A201025 003</u>	Apr 09, 2014
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A201025 004</u>	Apr 09, 2014

PRESCRIPTION DRUG PRODUCT LIST

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A202198 001</u>	Apr 07, 2014
<u>AP</u>	SAGENT PHARMS INC	<u>EQ 125MG BASE/VIAL</u>	<u>A090583 001</u>	Nov 27, 2015
<u>AP</u>		<u>EQ 250MG BASE/VIAL</u>	<u>A090583 002</u>	Nov 27, 2015
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A090583 003</u>	Nov 27, 2015
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A090583 004</u>	Nov 27, 2015
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A090583 005</u>	Nov 27, 2015
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A090581 001</u>	Oct 20, 2015
<u>AP</u>	! SANDOZ	<u>EQ 125MG BASE/VIAL</u>	<u>A061395 001</u>	
<u>AP</u>	!	<u>EQ 250MG BASE/VIAL</u>	<u>A061395 002</u>	
<u>AP</u>	!	<u>EQ 500MG BASE/VIAL</u>	<u>A061395 003</u>	
<u>AP</u>	!	<u>EQ 1GM BASE/VIAL</u>	<u>A061395 004</u>	
<u>AP</u>	!	<u>EQ 2GM BASE/VIAL</u>	<u>A061395 005</u>	
<u>AP</u>	!	<u>EQ 10GM BASE/VIAL</u>	<u>A061395 006</u>	

POWDER; INTRAVENOUS

AMPICILLIN SODIUM

<u>AP</u>	! SANDOZ	<u>EQ 1GM BASE/VIAL</u>	<u>A062738 001</u>	Feb 19, 1987
<u>AP</u>	!	<u>EQ 2GM BASE/VIAL</u>	<u>A062738 002</u>	Feb 19, 1987

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

<u>AP</u>	ACS DOBFAR	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065406 001</u>	Dec 22, 2009
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065406 002</u>	Dec 22, 2009
<u>AP</u>		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065403 001</u>	Dec 23, 2009
<u>AP</u>	ANTIBIOTICE	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A201406 001</u>	Dec 07, 2015
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A201406 002</u>	Dec 07, 2015
<u>AP</u>	ASTRAL	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A090579 001</u>	Jan 08, 2016
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A090579 002</u>	Jan 08, 2016
<u>AP</u>		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A090578 001</u>	Jan 11, 2016
<u>AP</u>	AUROBINDO PHARMA	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A090340 001</u>	Sep 20, 2010
<u>AP</u>		<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A090349 001</u>	Sep 20, 2010
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A090340 002</u>	Sep 20, 2010
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A090349 002</u>	Sep 20, 2010
<u>AP</u>		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A090339 001</u>	Sep 20, 2010
<u>AP</u>	HANFORD GC	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065176 001</u>	Nov 30, 2005
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065176 002</u>	Nov 30, 2005
<u>AP</u>		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065188 001</u>	Nov 25, 2005
<u>AP</u>	ISTITUTO BIO ITA SPA	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065222 001</u>	Nov 29, 2005
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065222 002</u>	Nov 29, 2005
<u>AP</u>		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065314 001</u>	Nov 27, 2006
<u>AP</u>	MYLAN LABS LTD	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A201024 001</u>	Apr 07, 2014
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A201024 002</u>	Apr 07, 2014
<u>AP</u>		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A202197 001</u>	Apr 07, 2014
<u>AP</u>	SANDOZ	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065241 001</u>	Jul 25, 2006
<u>AP</u>		<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065310 001</u>	Jul 25, 2006
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065241 002</u>	Jul 25, 2006
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065310 002</u>	Jul 25, 2006
<u>AP</u>		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065240 001</u>	Jul 25, 2006
<u>AP</u>	WEST-WARD PHARMS INT	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065074 001</u>	Mar 19, 2002
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065074 002</u>	Mar 19, 2002
<u>AP</u>		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065076 001</u>	Mar 19, 2002
<u>UNASYN</u>				
<u>AP</u>	! PFIZER	<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A062901 002</u>	Feb 27, 1992
<u>AP</u>	!	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A062901 001</u>	Nov 23, 1988
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>N050608 002</u>	Dec 31, 1986
<u>AP</u>	+	<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>N050608 001</u>	Dec 31, 1986
<u>AP</u>	+	<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>N050608 005</u>	Dec 10, 1993

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

AMPICILLIN TRIHYDRATE

!	SANDOZ	EQ 500MG BASE	A064082 002	Aug 29, 1995
---	--------	---------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

AGRYLIN

AB	TAKEDA PHARMS USA	EQ 0.5MG BASE	N020333 001	Mar 14, 1997
-----------	-------------------	----------------------	--------------------	--------------

ANAGRELIDE HYDROCHLORIDE

AB	IMPAX LABS	EQ 0.5MG BASE	A076910 001	Apr 18, 2005
-----------	------------	----------------------	--------------------	--------------

AB		EQ 1MG BASE	A076910 002	Apr 18, 2005
-----------	--	--------------------	--------------------	--------------

AB	IVAX SUB TEVA PHARMS	EQ 0.5MG BASE	A076468 001	Apr 18, 2005
-----------	----------------------	----------------------	--------------------	--------------

AB	!	EQ 1MG BASE	A076468 002	Apr 18, 2005
-----------	---	--------------------	--------------------	--------------

AB	TORRENT	EQ 0.5MG BASE	A209151 001	Jun 30, 2017
-----------	---------	----------------------	--------------------	--------------

AB		EQ 1MG BASE	A209151 002	Jun 30, 2017
-----------	--	--------------------	--------------------	--------------

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

AB	ACCORD HLTHCARE	1MG	A090568 001	Jun 28, 2010
-----------	-----------------	------------	--------------------	--------------

AB	BEIJING YILING	1MG	A206037 001	Nov 09, 2018
-----------	----------------	------------	--------------------	--------------

AB	CIPLA	1MG	A091164 001	Jun 28, 2010
-----------	-------	------------	--------------------	--------------

AB	EUGIA PHARMA	1MG	A212434 001	Jul 24, 2020
-----------	--------------	------------	--------------------	--------------

AB	FRESENIUS KABI USA	1MG	A090088 001	Jun 28, 2010
-----------	--------------------	------------	--------------------	--------------

AB	KENTON	1MG	A078944 001	Jun 28, 2010
-----------	--------	------------	--------------------	--------------

AB	NATCO PHARMA LTD	1MG	A079220 001	Jun 28, 2010
-----------	------------------	------------	--------------------	--------------

AB	TEVA PHARMS	1MG	A078058 001	Jun 28, 2010
-----------	-------------	------------	--------------------	--------------

AB	ZYDUS PHARMS USA INC	1MG	A078921 001	Jun 28, 2010
-----------	----------------------	------------	--------------------	--------------

ARIMIDEX

AB	+! ANI PHARMS INC	1MG	N020541 001	Dec 27, 1995
-----------	-------------------	------------	--------------------	--------------

ANGIOTENSIN II ACETATE

SOLUTION; INTRAVENOUS

GIAPREZA

+!	LA JOLLA PHARMA	EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	N209360 001	Dec 21, 2017
----	-----------------	-------------------------------------	-------------	--------------

ANIDULAFUNGIN

POWDER; INTRAVENOUS

ERAXIS

+!	VICURON	50MG/VIAL	N021632 001	Feb 17, 2006
----	---------	-----------	-------------	--------------

+!		100MG/VIAL	N021632 002	Nov 14, 2006
----	--	------------	-------------	--------------

APALUTAMIDE

TABLET; ORAL

ERLEADA

+!	JANSSEN BIOTECH	60MG	N210951 001	Feb 14, 2018
----	-----------------	------	-------------	--------------

APIXABAN

TABLET; ORAL

APIXABAN

AB	ACCORD HLTHCARE	2.5MG	A210180 001	Jul 28, 2020
-----------	-----------------	--------------	--------------------	--------------

AB		5MG	A210180 002	Jul 28, 2020
-----------	--	------------	--------------------	--------------

AB	INDOCO	2.5MG	A209898 001	Sep 11, 2020
-----------	--------	--------------	--------------------	--------------

AB		5MG	A209898 002	Sep 11, 2020
-----------	--	------------	--------------------	--------------

ELIQUIS

AB	+ BRISTOL MYERS SQUIBB	2.5MG	N202155 001	Dec 28, 2012
-----------	------------------------	--------------	--------------------	--------------

AB	+!	5MG	N202155 002	Dec 28, 2012
-----------	----	------------	--------------------	--------------

APOMORPHINE HYDROCHLORIDE

FILM; SUBLINGUAL

KYNMOBI

+	SUNOVION PHARMS INC	10MG	N210875 001	May 21, 2020
---	---------------------	------	-------------	--------------

+		15MG	N210875 002	May 21, 2020
---	--	------	-------------	--------------

+		20MG	N210875 003	May 21, 2020
---	--	------	-------------	--------------

+		25MG	N210875 004	May 21, 2020
---	--	------	-------------	--------------

+!		30MG	N210875 005	May 21, 2020
----	--	------	-------------	--------------

INJECTABLE; SUBCUTANEOUS

APOKYN

+!	MDD US	30MG/3ML (10MG/ML)	N021264 002	Apr 20, 2004
----	--------	--------------------	-------------	--------------

APRACLONIDINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

APRACLONIDINE HYDROCHLORIDE

AT	AKORN INC	EQ 0.5% BASE	A077764 001	Mar 12, 2009
-----------	-----------	---------------------	--------------------	--------------

IOPIDINE

AT	+! NOVARTIS	EQ 0.5% BASE	N020258 001	Jul 30, 1993
-----------	-------------	---------------------	--------------------	--------------

+!		EQ 1% BASE	N019779 001	Dec 31, 1987
----	--	------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

APREMILAST

TABLET; ORAL

OTEZLA

+	AMGEN INC	10MG	N205437 001	Mar 21, 2014
+		20MG	N205437 002	Mar 21, 2014
+	!	30MG	N205437 003	Mar 21, 2014

APREPITANT

CAPSULE; ORAL

APREPITANT

AB	GLENMARK PHARMS SA	40MG	A207777 001	Oct 12, 2017
AB		80MG	A207777 002	Oct 12, 2017
AB		125MG	A207777 003	Oct 12, 2017
AB	SANDOZ	40MG	A090999 001	Sep 24, 2012
AB		80MG	A090999 002	Sep 24, 2012
AB		125MG	A090999 003	Sep 24, 2012
AB	TORRENT	40MG	A211835 001	Oct 21, 2020
AB		80MG	A211835 002	Oct 21, 2020
AB		125MG	A211835 003	Oct 21, 2020

EMEND

AB	+	MERCK	80MG	N021549 001	Mar 26, 2003
AB	+	!	125MG	N021549 002	Mar 26, 2003

EMULSION; INTRAVENOUS

CINVANTI

+	HERON THERAPS INC	130MG/18ML (7.2MG/ML)	N209296 001	Nov 09, 2017
---	-------------------	-----------------------	-------------	--------------

FOR SUSPENSION; ORAL

EMEND

+	MSD MERCK CO	125MG/KIT	N207865 001	Dec 17, 2015
---	--------------	-----------	-------------	--------------

ARFORMOTEROL TARTRATE

SOLUTION; INHALATION

BROVANA

+	SUNOVION	EQ 0.015MG BASE/2ML	N021912 001	Oct 06, 2006
---	----------	---------------------	-------------	--------------

ARGATROBAN

INJECTABLE; INJECTION

ARGATROBAN

AP	AMNEAL PHARMS CO	250MG/2.5ML (100MG/ML)	A206698 001	Jan 26, 2018	
AP	FRESENIUS KABI USA	250MG/2.5ML (100MG/ML)	N201811 001	Mar 23, 2015	
AP	+	HIKMA PHARM CO LTD	250MG/2.5ML (100MG/ML)	N203049 001	Jan 05, 2012
AP	HOSPIRA INC	250MG/2.5ML (100MG/ML)	A204120 001	Sep 21, 2016	
AP	MYLAN INSTITUTIONAL	250MG/2.5ML (100MG/ML)	A202626 001	Jun 30, 2014	
AP	+	NOVARTIS	250MG/2.5ML (100MG/ML)	N020883 001	Jun 30, 2000
AP	PAR STERILE PRODUCTS	250MG/2.5ML (100MG/ML)	A091665 001	Jun 30, 2014	
+	HIKMA PHARM CO LTD	50MG/50ML (1MG/ML)	N203049 002	Sep 30, 2016	

INJECTABLE; INTRAVENOUS

ARGATROBAN IN SODIUM CHLORIDE

AP	GLAND PHARMA LTD	125MG/125ML (1MG/ML)	A205570 001	May 22, 2017	
AP	+	SANDOZ	125MG/125ML (1MG/ML)	N022485 001	May 09, 2011
+	EAGLE PHARMS	50MG/50ML (1MG/ML)	N022434 001	Jun 29, 2011	

SOLUTION; INTRAVENOUS

ARGATROBAN IN SODIUM CHLORIDE

AUROBINDO PHARMA LTD	50MG/50ML (1MG/ML)	N209552 001	Nov 27, 2018
----------------------	--------------------	-------------	--------------

ARGININE HYDROCHLORIDE

INJECTABLE; INJECTION

R-GENE 10

+	PHARMACIA AND UPJOHN	10GM/100ML	N016931 001
---	----------------------	------------	-------------

ARIPIPRAZOLE

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

ABILIFY MAINTENA KIT

+	OTSUKA PHARM CO LTD	300MG/VIAL	N202971 001	Feb 28, 2013
+		300MG	N202971 003	Sep 29, 2014
+	!	400MG/VIAL	N202971 002	Feb 28, 2013
+		400MG	N202971 004	Sep 29, 2014

SOLUTION; ORAL

ARIPIPRAZOLE

AA	!	AMNEAL PHARMS	1MG/ML	A203906 001	Aug 14, 2015
AA		APOTEX INC	1MG/ML	A204094 001	Sep 30, 2015
AA		AUROBINDO PHARMA LTD	1MG/ML	A210479 001	Jan 29, 2019
AA		LANNETT CO INC	1MG/ML	A204171 001	Aug 14, 2015

PRESCRIPTION DRUG PRODUCT LIST

ARIPIPIRAZOLE

SOLUTION; ORAL

ARIPIPIRAZOLE

<u>AA</u>	VISTAPHARM	<u>1MG/ML</u>	<u>A212870 001</u>	Dec 26, 2019
-----------	------------	---------------	--------------------	--------------

TABLET; ORAL

ABILIFY

<u>AB</u>	+	OTSUKA	<u>2MG</u>	<u>N021436 006</u>	Nov 15, 2002
<u>AB</u>	+	!	<u>5MG</u>	<u>N021436 005</u>	Nov 15, 2002
<u>AB</u>	+	!	<u>10MG</u>	<u>N021436 001</u>	Nov 15, 2002
<u>AB</u>	+		<u>15MG</u>	<u>N021436 002</u>	Nov 15, 2002
<u>AB</u>	+		<u>20MG</u>	<u>N021436 003</u>	Nov 15, 2002
<u>AB</u>	+		<u>30MG</u>	<u>N021436 004</u>	Nov 15, 2002

ARIPIPIRAZOLE

<u>AB</u>	ACCORD HLTHCARE	<u>2MG</u>	<u>A206251 001</u>	Dec 07, 2016
<u>AB</u>		<u>5MG</u>	<u>A206251 002</u>	Dec 07, 2016
<u>AB</u>		<u>10MG</u>	<u>A206251 003</u>	Dec 07, 2016
<u>AB</u>		<u>15MG</u>	<u>A206251 004</u>	Dec 07, 2016
<u>AB</u>		<u>20MG</u>	<u>A206251 005</u>	Dec 07, 2016
<u>AB</u>		<u>30MG</u>	<u>A206251 006</u>	Dec 07, 2016
<u>AB</u>	AJANTA PHARMA LTD	<u>2MG</u>	<u>A206174 001</u>	Sep 12, 2016
<u>AB</u>		<u>5MG</u>	<u>A206174 002</u>	Sep 12, 2016
<u>AB</u>		<u>10MG</u>	<u>A206174 003</u>	Sep 12, 2016
<u>AB</u>		<u>15MG</u>	<u>A206174 004</u>	Sep 12, 2016
<u>AB</u>		<u>20MG</u>	<u>A206174 005</u>	Sep 12, 2016
<u>AB</u>		<u>30MG</u>	<u>A206174 006</u>	Sep 12, 2016
<u>AB</u>	ALEMBIC PHARMS LTD	<u>2MG</u>	<u>A202101 001</u>	Apr 28, 2015
<u>AB</u>		<u>5MG</u>	<u>A202101 002</u>	Apr 28, 2015
<u>AB</u>		<u>10MG</u>	<u>A202101 003</u>	Apr 28, 2015
<u>AB</u>		<u>15MG</u>	<u>A202101 004</u>	Apr 28, 2015
<u>AB</u>		<u>20MG</u>	<u>A202101 005</u>	Apr 28, 2015
<u>AB</u>		<u>30MG</u>	<u>A202101 006</u>	Apr 28, 2015
<u>AB</u>	ALKEM LABS LTD	<u>2MG</u>	<u>A207105 001</u>	Feb 21, 2019
<u>AB</u>		<u>5MG</u>	<u>A207105 002</u>	Feb 21, 2019
<u>AB</u>		<u>10MG</u>	<u>A207105 003</u>	Feb 21, 2019
<u>AB</u>		<u>15MG</u>	<u>A207105 004</u>	Feb 21, 2019
<u>AB</u>		<u>20MG</u>	<u>A207105 005</u>	Feb 21, 2019
<u>AB</u>		<u>30MG</u>	<u>A207105 006</u>	Feb 21, 2019
<u>AB</u>	AMNEAL PHARMS	<u>2MG</u>	<u>A204838 001</u>	Jun 17, 2016
<u>AB</u>		<u>5MG</u>	<u>A204838 002</u>	Jun 17, 2016
<u>AB</u>		<u>10MG</u>	<u>A204838 003</u>	Jun 17, 2016
<u>AB</u>		<u>15MG</u>	<u>A204838 004</u>	Jun 17, 2016
<u>AB</u>		<u>20MG</u>	<u>A204838 005</u>	Jun 17, 2016
<u>AB</u>		<u>30MG</u>	<u>A204838 006</u>	Jun 17, 2016
<u>AB</u>	APOTEX INC	<u>2MG</u>	<u>A078583 001</u>	Jul 24, 2015
<u>AB</u>		<u>5MG</u>	<u>A078583 002</u>	Jul 24, 2015
<u>AB</u>		<u>10MG</u>	<u>A078583 003</u>	Jul 24, 2015
<u>AB</u>		<u>15MG</u>	<u>A078583 004</u>	Jul 24, 2015
<u>AB</u>		<u>20MG</u>	<u>A078583 005</u>	Jul 24, 2015
<u>AB</u>		<u>30MG</u>	<u>A078583 006</u>	Jul 24, 2015
<u>AB</u>	AUROBINDO PHARMA LTD	<u>2MG</u>	<u>A203908 001</u>	Oct 08, 2015
<u>AB</u>		<u>5MG</u>	<u>A203908 002</u>	Oct 08, 2015
<u>AB</u>		<u>10MG</u>	<u>A203908 003</u>	Oct 08, 2015
<u>AB</u>		<u>15MG</u>	<u>A203908 004</u>	Oct 08, 2015
<u>AB</u>		<u>20MG</u>	<u>A203908 005</u>	Oct 08, 2015
<u>AB</u>		<u>30MG</u>	<u>A203908 006</u>	Oct 08, 2015
<u>AB</u>	BOSCOGEN	<u>2MG</u>	<u>A091279 001</u>	Jan 09, 2017
<u>AB</u>		<u>5MG</u>	<u>A091279 002</u>	Jan 09, 2017
<u>AB</u>		<u>10MG</u>	<u>A091279 003</u>	Jan 09, 2017
<u>AB</u>		<u>15MG</u>	<u>A091279 004</u>	Jan 09, 2017
<u>AB</u>		<u>20MG</u>	<u>A091279 005</u>	Jan 09, 2017
<u>AB</u>		<u>30MG</u>	<u>A091279 006</u>	Jan 09, 2017
<u>AB</u>	HETERO LABS LTD V	<u>2MG</u>	<u>A205064 001</u>	Apr 28, 2015
<u>AB</u>		<u>5MG</u>	<u>A205064 002</u>	Apr 28, 2015
<u>AB</u>		<u>10MG</u>	<u>A205064 003</u>	Apr 28, 2015
<u>AB</u>		<u>15MG</u>	<u>A205064 004</u>	Apr 28, 2015
<u>AB</u>		<u>20MG</u>	<u>A205064 005</u>	Apr 28, 2015
<u>AB</u>		<u>30MG</u>	<u>A205064 006</u>	Apr 28, 2015
<u>AB</u>	MACLEODS PHARMS LTD	<u>2MG</u>	<u>A204111 001</u>	Oct 07, 2016
<u>AB</u>		<u>5MG</u>	<u>A204111 002</u>	Oct 07, 2016
<u>AB</u>		<u>10MG</u>	<u>A204111 003</u>	Oct 07, 2016
<u>AB</u>		<u>15MG</u>	<u>A204111 004</u>	Oct 07, 2016
<u>AB</u>		<u>20MG</u>	<u>A204111 005</u>	Oct 07, 2016

PRESCRIPTION DRUG PRODUCT LIST

ARIPIRAZOLE

TABLET; ORAL

ARIPIRAZOLE

<u>AB</u>		<u>30MG</u>	<u>A204111</u>	<u>006</u>	Oct 07, 2016
<u>AB</u>	ORCHID HLTHCARE	<u>2MG</u>	<u>A202683</u>	<u>001</u>	May 23, 2017
<u>AB</u>		<u>5MG</u>	<u>A202683</u>	<u>002</u>	May 23, 2017
<u>AB</u>		<u>10MG</u>	<u>A202683</u>	<u>003</u>	May 23, 2017
<u>AB</u>		<u>15MG</u>	<u>A202683</u>	<u>004</u>	May 23, 2017
<u>AB</u>		<u>20MG</u>	<u>A202683</u>	<u>005</u>	May 23, 2017
<u>AB</u>		<u>30MG</u>	<u>A202683</u>	<u>006</u>	May 23, 2017
<u>AB</u>	PRINSTON INC	<u>2MG</u>	<u>A205363</u>	<u>001</u>	Dec 04, 2017
<u>AB</u>		<u>5MG</u>	<u>A205363</u>	<u>002</u>	Dec 04, 2017
<u>AB</u>		<u>10MG</u>	<u>A205363</u>	<u>003</u>	Dec 04, 2017
<u>AB</u>		<u>15MG</u>	<u>A205363</u>	<u>004</u>	Dec 04, 2017
<u>AB</u>		<u>20MG</u>	<u>A205363</u>	<u>005</u>	Dec 04, 2017
<u>AB</u>		<u>30MG</u>	<u>A205363</u>	<u>006</u>	Dec 04, 2017
<u>AB</u>	SCIEGEN PHARMS INC	<u>2MG</u>	<u>A206383</u>	<u>001</u>	Sep 29, 2016
<u>AB</u>		<u>5MG</u>	<u>A206383</u>	<u>002</u>	Sep 29, 2016
<u>AB</u>		<u>10MG</u>	<u>A206383</u>	<u>003</u>	Sep 29, 2016
<u>AB</u>		<u>15MG</u>	<u>A206383</u>	<u>004</u>	Sep 29, 2016
<u>AB</u>		<u>20MG</u>	<u>A206383</u>	<u>005</u>	Sep 29, 2016
<u>AB</u>		<u>30MG</u>	<u>A206383</u>	<u>006</u>	Sep 29, 2016
<u>AB</u>	TORRENT	<u>2MG</u>	<u>A201519</u>	<u>001</u>	Apr 28, 2015
<u>AB</u>		<u>10MG</u>	<u>A201519</u>	<u>003</u>	Apr 28, 2015
<u>AB</u>		<u>5MG</u>	<u>A201519</u>	<u>002</u>	Apr 28, 2015
<u>AB</u>		<u>15MG</u>	<u>A201519</u>	<u>004</u>	Apr 28, 2015
<u>AB</u>		<u>20MG</u>	<u>A201519</u>	<u>005</u>	Apr 28, 2015
<u>AB</u>		<u>30MG</u>	<u>A201519</u>	<u>006</u>	Apr 28, 2015

ABILIFY MYCITE KIT

+	OTSUKA	2MG	N207202	001	Nov 13, 2017
+	!	5MG	N207202	002	Nov 13, 2017
+		10MG	N207202	003	Nov 13, 2017
+		15MG	N207202	004	Nov 13, 2017
+		20MG	N207202	005	Nov 13, 2017
+		30MG	N207202	006	Nov 13, 2017

TABLET, ORALLY DISINTEGRATING; ORAL

ARIPIRAZOLE

<u>AB</u>	!	ALEMBIC PHARMS LTD	<u>10MG</u>	<u>A202102</u>	<u>001</u>	Apr 28, 2015
<u>AB</u>			<u>15MG</u>	<u>A202102</u>	<u>002</u>	Apr 28, 2015
<u>AB</u>		ORCHID HLTHCARE	<u>10MG</u>	<u>A202547</u>	<u>001</u>	Dec 11, 2017
<u>AB</u>			<u>15MG</u>	<u>A202547</u>	<u>002</u>	Dec 11, 2017
<u>AB</u>		SCIEGEN PHARMS INC	<u>10MG</u>	<u>A207240</u>	<u>001</u>	Apr 18, 2018
<u>AB</u>			<u>15MG</u>	<u>A207240</u>	<u>002</u>	Apr 18, 2018
<u>AB</u>		ZYDUS PHARMS	<u>10MG</u>	<u>A090165</u>	<u>001</u>	Aug 28, 2018
<u>AB</u>			<u>15MG</u>	<u>A090165</u>	<u>002</u>	Aug 28, 2018
			20MG	A090165	003	Aug 28, 2018
			30MG	A090165	004	Aug 28, 2018

ARIPIRAZOLE LAUROXIL

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

ARISTADA

+	ALKERMES INC	441MG/1.6ML (275.63MG/ML)	N207533	001	Oct 05, 2015
+		662MG/2.4ML (275.83MG/ML)	N207533	002	Oct 05, 2015
+	!	882MG/3.2ML (275.63MG/ML)	N207533	003	Oct 05, 2015
+		1064MG/3.9ML (272.82MG/ML)	N207533	004	Jun 05, 2017

ARISTADA INITIO KIT

+	ALKERMES INC	675MG/2.4ML	N209830	001	Jun 29, 2018
---	--------------	-------------	---------	-----	--------------

ARMODAFINIL

TABLET; ORAL

ARMODAFINIL

<u>AB</u>	AUROBINDO PHARMA LTD	<u>50MG</u>	<u>A206069</u>	<u>001</u>	Mar 06, 2018
<u>AB</u>		<u>150MG</u>	<u>A206069</u>	<u>002</u>	Mar 06, 2018
<u>AB</u>		<u>200MG</u>	<u>A206069</u>	<u>004</u>	Dec 07, 2018
<u>AB</u>		<u>250MG</u>	<u>A206069</u>	<u>003</u>	Mar 06, 2018
<u>AB</u>	LUPIN LTD	<u>50MG</u>	<u>A200751</u>	<u>001</u>	Nov 28, 2016
<u>AB</u>		<u>150MG</u>	<u>A200751</u>	<u>003</u>	Nov 28, 2016
<u>AB</u>		<u>200MG</u>	<u>A200751</u>	<u>004</u>	Nov 28, 2016
<u>AB</u>		<u>250MG</u>	<u>A200751</u>	<u>005</u>	Nov 28, 2016
<u>AB</u>	MYLAN PHARMS INC	<u>50MG</u>	<u>A200043</u>	<u>001</u>	Jun 01, 2012
<u>AB</u>		<u>100MG</u>	<u>A200043</u>	<u>004</u>	May 09, 2019
<u>AB</u>		<u>150MG</u>	<u>A200043</u>	<u>002</u>	Jun 01, 2012
<u>AB</u>		<u>200MG</u>	<u>A200043</u>	<u>005</u>	May 09, 2019

PRESCRIPTION DRUG PRODUCT LIST

ARMODAFINIL

TABLET; ORAL

ARMODAFINIL

<u>AB</u>		<u>250MG</u>	<u>A200043 003</u>	Jun 01, 2012
<u>AB</u>	NATCO PHARMA LTD	<u>50MG</u>	<u>A202768 001</u>	Nov 28, 2016
<u>AB</u>		<u>100MG</u>	<u>A202768 004</u>	Sep 28, 2017
<u>AB</u>		<u>150MG</u>	<u>A202768 002</u>	Nov 28, 2016
<u>AB</u>		<u>200MG</u>	<u>A202768 005</u>	Sep 28, 2017
<u>AB</u>		<u>250MG</u>	<u>A202768 003</u>	Nov 28, 2016

NUVIGIL

<u>AB</u>	+ CEPHALON	<u>50MG</u>	<u>N021875 001</u>	Jun 15, 2007
<u>AB</u>	+	<u>150MG</u>	<u>N021875 003</u>	Jun 15, 2007
<u>AB</u>	+	<u>200MG</u>	<u>N021875 005</u>	Mar 26, 2009
<u>AB</u>	+!	<u>250MG</u>	<u>N021875 004</u>	Jun 15, 2007

ARSENIC TRIOXIDE

INJECTABLE; INJECTION

ARSENIC TRIOXIDE

<u>AP</u>	AMRING PHARMS	<u>1MG/ML</u>	<u>A210802 001</u>	Nov 13, 2018
<u>AP</u>	FRESENIUS KABI USA	<u>1MG/ML</u>	<u>A208231 001</u>	Aug 31, 2018
<u>AP</u>	INGENUS PHARMS LLC	<u>1MG/ML</u>	<u>A209315 001</u>	Nov 15, 2018
<u>AP</u>	NEXUS PHARMS	<u>1MG/ML</u>	<u>A209780 001</u>	Nov 15, 2018
<u>AP</u>	STI PHARMA LLC	<u>1MG/ML</u>	<u>A209873 001</u>	May 06, 2019
<u>AP</u>	ZYDUS PHARMS	<u>1MG/ML</u>	<u>A206228 001</u>	Nov 13, 2018
<u>AP</u>		<u>2MG/ML</u>	<u>A206228 002</u>	Aug 30, 2019

TRISENOX

<u>AP</u>	+! CEPHALON	<u>2MG/ML</u>	<u>N021248 002</u>	Oct 13, 2017
-----------	-------------	---------------	--------------------	--------------

ARTEMETHER; LUMEFANTRINE

TABLET; ORAL

COARTEM

+	NOVARTIS	20MG;120MG	N022268 001	Apr 07, 2009
---	----------	------------	-------------	--------------

ARTESUNATE

POWDER; INTRAVENOUS

ARTESUNATE

+	AMIVAS	110MG/VIAL	N213036 001	May 26, 2020
---	--------	------------	-------------	--------------

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

ORABLOC

+	PIERREL	4%;EQ 0.009MG BASE/1.8ML (EQ 0.005MG BASE/ML)	N022466 001	Feb 26, 2010
+		4%;EQ 0.018MG BASE/1.8ML (EQ 0.01MG BASE/ML)	N022466 002	Feb 26, 2010

SEPTOCAINE

+	DEPROCO	4%; EQ 0.0085MG BASE/1.7ML (4%; EQ 0.005MG BASE/ML)	N020971 002	Mar 30, 2006
+		4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML)	N020971 001	Apr 03, 2000

ASCORBIC ACID

SOLUTION; INTRAVENOUS

ASCOR

+	MCGUFF	25,000MG/50ML (500MG/ML)	N209112 001	Oct 02, 2017
---	--------	--------------------------	-------------	--------------

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; INTRAVENOUS

INFUVITE PEDIATRIC

+	SANDOZ CANADA INC	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N021265 001	Feb 21, 2001
---	-------------------	---	-------------	--------------

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL HYDROCHLORIDE; VITAMIN A; VITAMIN K

INJECTABLE; INTRAVENOUS

INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)

+	SANDOZ CANADA INC	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N021265 002	Jan 29, 2004
---	-------------------	---	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOR SOLUTION; INTRAVENOUS

M.V.I. PEDIATRIC

+	!	HOSPIRA	80MG/VIAL; 0.02MG/VIAL; 0.001MG/VIAL; 5MG/VIAL; 0.01MG/VIAL; 0.14MG/VIAL; 17MG/VIAL; 0.2MG/VIAL; 1MG/VIAL; 1.4MG/VIAL; EQ 1.2MG BASE/VIAL; 0.7MG/VIAL; 7MG/VIAL	N018920 001	Sep 21, 2000
---	---	---------	---	-------------	--------------

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E; VITAMIN K

INJECTABLE; INTRAVENOUS

M.V.I. ADULT

+	!	HOSPIRA	200MG/VIAL; 0.06MG/VIAL; 0.005MG/VIAL; 15MG/VIAL; 0.005MG/VIAL; 0.6MG/VIAL; 40MG/VIAL; 6MG/VIAL; 3.6MG/VIAL; 6MG/VIAL; 1MG/VIAL; 10MG/VIAL; 0.15MG/VIAL	N021625 001	Jan 30, 2004
---	---	---------	---	-------------	--------------

M.V.I. ADULT (PHARMACY BULK PACKAGE)

+	!	HOSPIRA	200MG/5ML; 0.06MG/5ML; 0.005MG/5ML; 15MG/5ML; 0.005MG/5ML; 0.6MG/5ML; 40MG/5ML; 6MG/5ML; 3.6MG/5ML; 6MG/5ML; 1MG/5ML; 10MG/5ML; 0.15MG/5ML	N021643 001	Feb 18, 2004
---	---	---------	--	-------------	--------------

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

MOVIPREP

AA	+	!	SALIX PHARMS	4.7GM; 100GM; 1.015GM; 5.9GM; 2.691GM; 7.5GM	N021881 001	Aug 02, 2006
PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC						
AA			NOVEL LABS INC	4.7GM; 100GM; 1.015GM; 5.9GM; 2.691GM; 7.5GM	A090145 001	Jan 25, 2012
			PLENVU			
	+	!	SALIX	7.54GM; 140GM; 2.2GM; 48.11GM; 5.2GM; 9GM	N209381 001	May 04, 2018

ASENAPINE

SYSTEM; TRANSDERMAL

SECUADO

+		HISAMITSU	3.8MG/24HR	N212268 001	Oct 11, 2019
+			5.7MG/24HR	N212268 002	Oct 11, 2019
+	!		7.6MG/24HR	N212268 003	Oct 11, 2019

ASENAPINE MALEATE

TABLET; SUBLINGUAL

ASENAPINE MALEATE

AB			ALEMBIC PHARMS LTD	EQ 5MG BASE	A206098 001	Dec 10, 2020
AB				EQ 10MG BASE	A206098 002	Dec 10, 2020
AB			BRECKENRIDGE	EQ 2.5MG BASE	A205960 001	Dec 10, 2020
AB				EQ 10MG BASE	A205960 002	Dec 10, 2020
AB			SIGMAPHARM LABS LLC	EQ 5MG BASE	A206107 001	Dec 10, 2020
AB				EQ 10MG BASE	A206107 002	Dec 10, 2020
SAPHRIS						
AB	+		ALLERGAN	EQ 2.5MG BASE	N022117 003	Mar 12, 2015
AB	+			EQ 5MG BASE	N022117 001	Aug 13, 2009
AB	+	!		EQ 10MG BASE	N022117 002	Aug 13, 2009

ASPIRIN

CAPSULE, EXTENDED RELEASE; ORAL

DURLAZA

+	!	ESPERO	162.5MG	N200671 001	Sep 04, 2015
---	---	--------	---------	-------------	--------------

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

FIORINAL

AA	+	!	ALLERGAN	325MG; 50MG; 40MG	N017534 005	Apr 16, 1986
LANORINAL						
AA			LANNETT	325MG; 50MG; 40MG	A086996 002	Oct 11, 1985
TABLET; ORAL						
BUTALBITAL, ASPIRIN AND CAFFEINE						
	!		STRIDES PHARMA	325MG; 50MG; 40MG	A204195 001	Sep 22, 2016

PRESCRIPTION DRUG PRODUCT LIST

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

<u>AB</u>	LGM PHARMA	<u>325MG; 50MG; 40MG; 30MG</u>	<u>A075231 001</u>	Nov 30, 2001
<u>AB</u>	MAYNE PHARMA INC	<u>325MG; 50MG; 40MG; 30MG</u>	<u>A203335 001</u>	Oct 30, 2015
<u>AB</u>	STEVENS J	<u>325MG; 50MG; 40MG; 30MG</u>	<u>A074951 001</u>	Aug 31, 1998

FIORINAL W/CODEINE

<u>AB</u>	+! ALLERGAN	<u>325MG; 50MG; 40MG; 30MG</u>	<u>N019429 003</u>	Oct 26, 1990
-----------	-------------	--------------------------------	--------------------	--------------

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

ORPHENGESIC FORTE

!	GALT PHARMS	770MG; 60MG; 50MG	A075141 002	May 29, 1998
---	-------------	-------------------	-------------	--------------

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

<u>AB</u>	INGENUS PHARMS NJ	<u>325MG; 200MG; 16MG</u>	<u>A040860 001</u>	Jan 07, 2010
<u>AB</u>	! SANDOZ	<u>325MG; 200MG; 16MG</u>	<u>A040118 001</u>	Apr 16, 1996

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE; ORAL

AGGRENOX

<u>AB</u>	+! BOEHRINGER INGELHEIM	<u>25MG; 200MG</u>	<u>N020884 001</u>	Nov 22, 1999
-----------	----------------------------	--------------------	--------------------	--------------

ASPIRIN AND DIPYRIDAMOLE

<u>AB</u>	AMNEAL PHARMS	<u>25MG; 200MG</u>	<u>A206392 001</u>	Mar 08, 2016
<u>AB</u>	BARR	<u>25MG; 200MG</u>	<u>A078804 001</u>	Aug 14, 2009
<u>AB</u>	DR REDDYS	<u>25MG; 200MG</u>	<u>A209048 001</u>	Oct 10, 2018
<u>AB</u>	GLENMARK PHARMS SA	<u>25MG; 200MG</u>	<u>A210318 001</u>	May 24, 2019
<u>AB</u>	LANNETT CO INC	<u>25MG; 200MG</u>	<u>A204552 001</u>	Mar 20, 2019
<u>AB</u>	PAR PHARM INC	<u>25MG; 200MG</u>	<u>A207944 001</u>	Jan 18, 2017
<u>AB</u>	SANDOZ INC	<u>25MG; 200MG</u>	<u>A206739 001</u>	Jan 18, 2017
<u>AB</u>	SUN PHARM	<u>25MG; 200MG</u>	<u>A208572 001</u>	Aug 21, 2018
<u>AB</u>	ZYDUS PHARMS	<u>25MG; 200MG</u>	<u>A206753 001</u>	Aug 29, 2017

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ASPIRIN

<u>AA</u>	EPIC PHARMA LLC	<u>325MG; 4.8355MG</u>	<u>A040910 001</u>	Jul 16, 2020
<u>AA</u>	MAYNE PHARMA INC	<u>325MG; 4.8355MG</u>	<u>A091670 001</u>	Mar 16, 2011

PERCODAN

<u>AA</u>	+! ENDO PHARMS	<u>325MG; 4.8355MG</u>	<u>N007337 007</u>	Aug 05, 2005
-----------	----------------	------------------------	--------------------	--------------

ATAZANAVIR SULFATE

CAPSULE; ORAL

ATAZANAVIR SULFATE

<u>AB</u>	AMNEAL	<u>EQ 150MG BASE</u>	<u>A209717 002</u>	Jun 01, 2020
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A209717 003</u>	Jun 01, 2020
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A209717 004</u>	Jun 01, 2020
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 100MG BASE</u>	<u>A204806 001</u>	Jun 25, 2018
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A204806 002</u>	Jun 25, 2018
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A204806 003</u>	Jun 25, 2018
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A204806 004</u>	Jun 25, 2018
<u>AB</u>	CIPLA	<u>EQ 100MG BASE</u>	<u>A200626 001</u>	Aug 09, 2018
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A200626 002</u>	Aug 09, 2018
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A200626 003</u>	Aug 09, 2018
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A200626 004</u>	Aug 09, 2018
<u>AB</u>	TEVA PHARMS USA	<u>EQ 100MG BASE</u>	<u>A091673 001</u>	Apr 22, 2014
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A091673 002</u>	Apr 22, 2014
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A091673 003</u>	Apr 22, 2014
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A091673 004</u>	Apr 22, 2014
<u>REYATAZ</u>				
<u>AB</u>	+ BRISTOL MYERS SQUIBB	<u>EQ 150MG BASE</u>	<u>N021567 002</u>	Jun 20, 2003
<u>AB</u>	+	<u>EQ 200MG BASE</u>	<u>N021567 003</u>	Jun 20, 2003
<u>AB</u>	+!	<u>EQ 300MG BASE</u>	<u>N021567 004</u>	Oct 16, 2006

POWDER; ORAL

REYATAZ

+	BRISTOL MYERS SQUIBB	EQ 50MG BASE/PACKET	N206352 001	Jun 02, 2014
---	-------------------------	---------------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ATAZANAVIR SULFATE; COBICISTAT

TABLET; ORAL

EVOTAZ

+	!	BRISTOL-MYERS SQUIBB	EQ 300MG BASE;150MG	N206353 001	Jan 29, 2015
---	---	-------------------------	---------------------	-------------	--------------

ATENOLOL

TABLET; ORAL

ATENOLOL

<u>AB</u>		ALVOGEN	<u>25MG</u>	<u>A072304 002</u>	Jul 31, 1992
<u>AB</u>			<u>50MG</u>	<u>A072304 003</u>	Jul 18, 1988
<u>AB</u>			<u>100MG</u>	<u>A072304 001</u>	Jul 15, 1988
<u>AB</u>		AUROBINDO PHARMA	<u>25MG</u>	<u>A078512 001</u>	Oct 31, 2007
<u>AB</u>			<u>50MG</u>	<u>A078512 002</u>	Oct 31, 2007
<u>AB</u>			<u>100MG</u>	<u>A078512 003</u>	Oct 31, 2007
<u>AB</u>		HLTHCARE	<u>25MG</u>	<u>A073026 002</u>	May 01, 1992
<u>AB</u>			<u>50MG</u>	<u>A073026 003</u>	Sep 17, 1991
<u>AB</u>			<u>100MG</u>	<u>A073026 001</u>	Sep 17, 1991
<u>AB</u>		IPCA LABS LTD	<u>25MG</u>	<u>A077877 001</u>	Dec 27, 2006
<u>AB</u>			<u>50MG</u>	<u>A077877 002</u>	Dec 27, 2006
<u>AB</u>			<u>100MG</u>	<u>A077877 003</u>	Dec 27, 2006
<u>AB</u>		MYLAN	<u>25MG</u>	<u>A073457 002</u>	Apr 26, 1999
<u>AB</u>			<u>50MG</u>	<u>A073457 003</u>	Jan 24, 1992
<u>AB</u>			<u>100MG</u>	<u>A073457 001</u>	Jan 24, 1992
<u>AB</u>		TEVA	<u>25MG</u>	<u>A074056 003</u>	Jul 19, 2004
<u>AB</u>			<u>50MG</u>	<u>A074056 001</u>	Jan 18, 1995
<u>AB</u>			<u>100MG</u>	<u>A074056 002</u>	Jan 18, 1995
<u>AB</u>		UNICHEM	<u>25MG</u>	<u>A213136 001</u>	Nov 21, 2019
<u>AB</u>			<u>50MG</u>	<u>A213136 002</u>	Nov 21, 2019
<u>AB</u>			<u>100MG</u>	<u>A213136 003</u>	Nov 21, 2019
<u>AB</u>		UNIQUE PHARM LABS	<u>25MG</u>	<u>A077443 001</u>	Sep 13, 2006
<u>AB</u>			<u>50MG</u>	<u>A077443 002</u>	Sep 13, 2006
<u>AB</u>			<u>100MG</u>	<u>A077443 003</u>	Sep 13, 2006
<u>AB</u>		ZYDUS PHARMS USA	<u>25MG</u>	<u>A076900 001</u>	Jan 28, 2005
<u>AB</u>			<u>50MG</u>	<u>A076900 002</u>	Jan 28, 2005
<u>AB</u>			<u>100MG</u>	<u>A076900 003</u>	Jan 28, 2005
		<u>TENORMIN</u>			
<u>AB</u>	+	ALMATICA	<u>25MG</u>	<u>N018240 004</u>	Apr 09, 1990
<u>AB</u>	+		<u>50MG</u>	<u>N018240 001</u>	
<u>AB</u>	+	!	<u>100MG</u>	<u>N018240 002</u>	

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

ATENOLOL AND CHLORTHALIDONE

<u>AB</u>		ALVOGEN	<u>50MG;25MG</u>	<u>A072302 002</u>	May 31, 1990	
<u>AB</u>			<u>100MG;25MG</u>	<u>A072302 001</u>	May 31, 1990	
<u>AB</u>		UNICHEM	<u>50MG;25MG</u>	<u>A213302 001</u>	Nov 25, 2020	
<u>AB</u>			<u>100MG;25MG</u>	<u>A213302 002</u>	Nov 25, 2020	
<u>AB</u>		WATSON LABS	<u>50MG;25MG</u>	<u>A073665 001</u>	Jul 02, 1992	
<u>AB</u>			<u>100MG;25MG</u>	<u>A073665 002</u>	Jul 02, 1992	
<u>AB</u>		ZYDUS PHARMS	<u>50MG;25MG</u>	<u>A210028 001</u>	Mar 08, 2019	
<u>AB</u>			<u>100MG;25MG</u>	<u>A210028 002</u>	Mar 08, 2019	
		<u>TENORETIC 100</u>				
<u>AB</u>	+	!	<u>ALMATICA</u>	<u>100MG;25MG</u>	<u>N018760 001</u>	Jun 08, 1984
		<u>TENORETIC 50</u>				
<u>AB</u>	+	!	<u>ALMATICA</u>	<u>50MG;25MG</u>	<u>N018760 002</u>	Jun 08, 1984

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

ATOMOXETINE HYDROCHLORIDE

<u>AB</u>		APOTEX	<u>10MG</u>	<u>A078983 001</u>	May 30, 2017
<u>AB</u>			<u>18MG</u>	<u>A078983 002</u>	May 30, 2017
<u>AB</u>			<u>25MG</u>	<u>A078983 003</u>	May 30, 2017
<u>AB</u>			<u>40MG</u>	<u>A078983 004</u>	May 30, 2017
<u>AB</u>			<u>60MG</u>	<u>A078983 005</u>	May 30, 2017
<u>AB</u>			<u>80MG</u>	<u>A078983 006</u>	May 30, 2017
<u>AB</u>			<u>100MG</u>	<u>A078983 007</u>	May 30, 2017
<u>AB</u>		AUROBINDO PHARMA LTD	<u>10MG</u>	<u>A079016 001</u>	May 30, 2017
<u>AB</u>			<u>18MG</u>	<u>A079016 002</u>	May 30, 2017
<u>AB</u>			<u>25MG</u>	<u>A079016 003</u>	May 30, 2017
<u>AB</u>			<u>40MG</u>	<u>A079016 004</u>	May 30, 2017
<u>AB</u>			<u>60MG</u>	<u>A079016 005</u>	May 30, 2017
<u>AB</u>			<u>80MG</u>	<u>A079016 006</u>	May 30, 2017

PRESCRIPTION DRUG PRODUCT LIST

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

ATOMOXETINE HYDROCHLORIDE

<u>AB</u>		<u>100MG</u>	<u>A079016</u>	<u>007</u>	May 30, 2017
<u>AB</u>	DR REDDYS LABS LTD	<u>10MG</u>	<u>A090609</u>	<u>001</u>	Feb 23, 2018
<u>AB</u>		<u>18MG</u>	<u>A090609</u>	<u>002</u>	Feb 23, 2018
<u>AB</u>		<u>25MG</u>	<u>A090609</u>	<u>003</u>	Feb 23, 2018
<u>AB</u>		<u>40MG</u>	<u>A090609</u>	<u>004</u>	Feb 23, 2018
<u>AB</u>		<u>60MG</u>	<u>A090609</u>	<u>005</u>	Feb 23, 2018
<u>AB</u>		<u>80MG</u>	<u>A090609</u>	<u>006</u>	Feb 23, 2018
<u>AB</u>		<u>100MG</u>	<u>A090609</u>	<u>007</u>	Feb 23, 2018
<u>AB</u>	GLENMARK PHARMS LTD	<u>10MG</u>	<u>A079019</u>	<u>001</u>	May 30, 2017
<u>AB</u>		<u>18MG</u>	<u>A079019</u>	<u>002</u>	May 30, 2017
<u>AB</u>		<u>25MG</u>	<u>A079019</u>	<u>003</u>	May 30, 2017
<u>AB</u>		<u>40MG</u>	<u>A079019</u>	<u>004</u>	May 30, 2017
<u>AB</u>		<u>60MG</u>	<u>A079019</u>	<u>005</u>	May 30, 2017
<u>AB</u>		<u>80MG</u>	<u>A079019</u>	<u>006</u>	May 30, 2017
<u>AB</u>		<u>100MG</u>	<u>A079019</u>	<u>007</u>	May 30, 2017
<u>AB</u>	TEVA PHARMS USA	<u>10MG</u>	<u>A079022</u>	<u>001</u>	May 30, 2017
<u>AB</u>		<u>18MG</u>	<u>A079022</u>	<u>002</u>	May 30, 2017
<u>AB</u>		<u>25MG</u>	<u>A079022</u>	<u>003</u>	May 30, 2017
<u>AB</u>		<u>40MG</u>	<u>A079022</u>	<u>004</u>	May 30, 2017
<u>AB</u>		<u>60MG</u>	<u>A079022</u>	<u>005</u>	May 30, 2017
<u>AB</u>		<u>80MG</u>	<u>A079022</u>	<u>006</u>	May 30, 2017
<u>AB</u>		<u>100MG</u>	<u>A079022</u>	<u>007</u>	May 30, 2017
<u>AB</u>	ZYDUS PHARMS USA INC	<u>18MG</u>	<u>A079017</u>	<u>001</u>	Sep 17, 2010
<u>AB</u>		<u>25MG</u>	<u>A079017</u>	<u>002</u>	Sep 17, 2010
<u>AB</u>		<u>40MG</u>	<u>A079017</u>	<u>003</u>	Sep 17, 2010
<u>AB</u>		<u>60MG</u>	<u>A079017</u>	<u>004</u>	Sep 17, 2010
<u>AB</u>		<u>80MG</u>	<u>A079017</u>	<u>005</u>	Sep 17, 2010
<u>AB</u>		<u>100MG</u>	<u>A079017</u>	<u>006</u>	Sep 17, 2010
	<u>STRATTERA</u>				
<u>AB</u>	+ LILLY	<u>10MG</u>	<u>N021411</u>	<u>002</u>	Nov 26, 2002
<u>AB</u>	+	<u>18MG</u>	<u>N021411</u>	<u>003</u>	Nov 26, 2002
<u>AB</u>	+	<u>25MG</u>	<u>N021411</u>	<u>004</u>	Nov 26, 2002
<u>AB</u>	+	<u>40MG</u>	<u>N021411</u>	<u>005</u>	Nov 26, 2002
<u>AB</u>	+!	<u>60MG</u>	<u>N021411</u>	<u>006</u>	Nov 26, 2002
<u>AB</u>	+	<u>80MG</u>	<u>N021411</u>	<u>007</u>	Feb 14, 2005
<u>AB</u>	+	<u>100MG</u>	<u>N021411</u>	<u>008</u>	Feb 14, 2005

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 10MG BASE</u>	<u>A207687</u>	<u>001</u>	Mar 30, 2018
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A207687</u>	<u>002</u>	Mar 30, 2018
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A207687</u>	<u>003</u>	Mar 30, 2018
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A207687</u>	<u>004</u>	Mar 30, 2018
<u>AB</u>	APOTEX INC	<u>EQ 10MG BASE</u>	<u>A090548</u>	<u>001</u>	May 29, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A090548</u>	<u>002</u>	May 29, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A090548</u>	<u>003</u>	May 29, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A090548</u>	<u>004</u>	May 29, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 10MG BASE</u>	<u>A091650</u>	<u>001</u>	Jul 17, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A091650</u>	<u>002</u>	Jul 17, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A091650</u>	<u>003</u>	Jul 17, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A202357</u>	<u>001</u>	Jul 17, 2012
<u>AB</u>	GRAVITI PHARMS	<u>EQ 10MG BASE</u>	<u>A209912</u>	<u>001</u>	Jun 18, 2018
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A209912</u>	<u>002</u>	Jun 18, 2018
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A209912</u>	<u>003</u>	Jun 18, 2018
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A209912</u>	<u>004</u>	Jun 18, 2018
<u>AB</u>	INVAGEN PHARMS	<u>EQ 10MG BASE</u>	<u>A204846</u>	<u>001</u>	Jan 09, 2017
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A204846</u>	<u>002</u>	Jan 09, 2017
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A204846</u>	<u>003</u>	Jan 09, 2017
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A204846</u>	<u>004</u>	Jan 09, 2017
<u>AB</u>	LANNETT CO INC	<u>EQ 10MG BASE</u>	<u>A091624</u>	<u>001</u>	Apr 05, 2013
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A091624</u>	<u>002</u>	Apr 05, 2013
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A091624</u>	<u>003</u>	Apr 05, 2013
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A091624</u>	<u>004</u>	Apr 05, 2013
<u>AB</u>	LUPIN LTD	<u>EQ 10MG BASE</u>	<u>A204991</u>	<u>001</u>	Mar 06, 2019
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A204991</u>	<u>002</u>	Mar 06, 2019
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A204991</u>	<u>003</u>	Mar 06, 2019
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A204991</u>	<u>004</u>	Mar 06, 2019
<u>AB</u>	MICRO LABS LTD	<u>EQ 10MG BASE</u>	<u>A205945</u>	<u>001</u>	Nov 07, 2019

PRESCRIPTION DRUG PRODUCT LIST

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

INDIA

<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A205945 002</u>	Nov 07, 2019
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A205945 003</u>	Nov 07, 2019
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A205945 004</u>	Nov 07, 2019
<u>AB</u>	MSN	<u>EQ 10MG BASE</u>	<u>A211933 001</u>	Feb 08, 2019
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A211933 002</u>	Feb 08, 2019
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A211933 003</u>	Feb 08, 2019
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A211933 004</u>	Feb 08, 2019
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A091226 001</u>	May 29, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A091226 002</u>	May 29, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A091226 003</u>	May 29, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A091226 004</u>	May 29, 2012
<u>AB</u>	SANDOZ INC	<u>EQ 10MG BASE</u>	<u>A077575 001</u>	May 29, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077575 002</u>	May 29, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077575 003</u>	May 29, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A077575 004</u>	May 29, 2012
<u>AB</u>	SCIEGEN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A205519 001</u>	May 19, 2016
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A205519 002</u>	May 19, 2016
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A205519 003</u>	May 19, 2016
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A205519 004</u>	May 19, 2016
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 10MG BASE</u>	<u>A076477 001</u>	Nov 30, 2011
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076477 002</u>	Nov 30, 2011
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076477 003</u>	Nov 30, 2011
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A076477 004</u>	Nov 30, 2011
<u>AB</u>	TEVA PHARMS USA	<u>EQ 10MG BASE</u>	<u>A205300 001</u>	Mar 27, 2017
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A205300 002</u>	Mar 27, 2017
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A205300 003</u>	Mar 27, 2017
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A205300 004</u>	Mar 27, 2017
<u>AB</u>	THEPHARMANETWORK LLC	<u>EQ 10MG BASE</u>	<u>A209288 001</u>	Dec 21, 2018
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A209288 002</u>	Dec 21, 2018
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A209288 003</u>	Dec 21, 2018
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A209288 004</u>	Dec 21, 2018
<u>AB</u>	UMEDICA LABS PVT LTD	<u>EQ 10MG BASE</u>	<u>A213853 001</u>	Aug 19, 2020
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A213853 002</u>	Aug 19, 2020
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A213853 003</u>	Aug 19, 2020
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A213853 004</u>	Aug 19, 2020
<u>AB</u>	ZYDUS PHARMS	<u>EQ 10MG BASE</u>	<u>A206536 001</u>	Nov 20, 2018
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A206536 002</u>	Nov 20, 2018
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A206536 003</u>	Nov 20, 2018
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A206536 004</u>	Nov 20, 2018
<u>LIPITOR</u>				
<u>AB</u>	+ UPJOHN	<u>EQ 10MG BASE</u>	<u>N020702 001</u>	Dec 17, 1996
<u>AB</u>	+	<u>EQ 20MG BASE</u>	<u>N020702 002</u>	Dec 17, 1996
<u>AB</u>	+	<u>EQ 40MG BASE</u>	<u>N020702 003</u>	Dec 17, 1996
<u>AB</u>	+!	<u>EQ 80MG BASE</u>	<u>N020702 004</u>	Apr 07, 2000

ATOVAQUONE

SUSPENSION; ORAL

ATOVAQUONE

<u>AB</u>	ABHAI LLC	<u>750MG/5ML</u>	<u>A210510 001</u>	May 31, 2019
<u>AB</u>	AMNEAL PHARMS	<u>750MG/5ML</u>	<u>A202960 001</u>	Mar 18, 2014
<u>AB</u>	APOTEX	<u>750MG/5ML</u>	<u>A209750 001</u>	Oct 11, 2017
<u>AB</u>	GLENMARK PHARMS	<u>750MG/5ML</u>	<u>A209685 001</u>	Nov 21, 2018
<u>AB</u>	HETERO LABS LTD III	<u>750MG/5ML</u>	<u>A210692 001</u>	Oct 11, 2018
<u>AB</u>	LUPIN LTD	<u>750MG/5ML</u>	<u>A209105 001</u>	Sep 11, 2018
<u>AB</u>	PADDOCK LABS LLC	<u>750MG/5ML</u>	<u>A207833 001</u>	Apr 28, 2017
<u>MEPRON</u>				
<u>AB</u>	+! GLAXOSMITHKLINE LLC	<u>750MG/5ML</u>	<u>N020500 001</u>	Feb 08, 1995

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET; ORAL

ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

<u>AB</u>	GLENMARK GENERICS	<u>62.5MG;25MG</u>	<u>A091211 002</u>	Apr 06, 2015
<u>AB</u>		<u>250MG;100MG</u>	<u>A091211 001</u>	Jan 12, 2011
<u>AB</u>	MYLAN	<u>62.5MG;25MG</u>	<u>A202362 001</u>	May 27, 2014
<u>AB</u>		<u>250MG;100MG</u>	<u>A202362 002</u>	May 27, 2014
<u>MALARONE</u>				
<u>AB</u>	+! GLAXOSMITHKLINE	<u>250MG;100MG</u>	<u>N021078 001</u>	Jul 14, 2000

PRESCRIPTION DRUG PRODUCT LIST

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET; ORAL

MALARONE PEDIATRIC

AB	+	GLAXOSMITHKLINE	62.5MG;25MG	N021078 002	Jul 14, 2000
-----------	---	-----------------	--------------------	--------------------	--------------

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

AP		AUROBINDO PHARMA LTD	10MG/ML	A206011 001	Apr 08, 2015
-----------	--	----------------------	----------------	--------------------	--------------

AP		HOSPIRA INC	10MG/ML	A090761 001	Oct 18, 2012
-----------	--	-------------	----------------	--------------------	--------------

AP		MEITHEAL	10MG/ML	A091489 001	Feb 17, 2012
-----------	--	----------	----------------	--------------------	--------------

AP	!	WEST-WARD PHARMS INT	10MG/ML	A074901 001	Jul 18, 1997
-----------	---	----------------------	----------------	--------------------	--------------

ATRACURIUM BESYLATE PRESERVATIVE FREE

AP		AUROBINDO PHARMA LTD	10MG/ML	A206010 001	Apr 08, 2015
-----------	--	----------------------	----------------	--------------------	--------------

AP		HOSPIRA INC	10MG/ML	A090782 001	Oct 18, 2012
-----------	--	-------------	----------------	--------------------	--------------

AP		MEITHEAL	10MG/ML	A091488 001	Feb 17, 2012
-----------	--	----------	----------------	--------------------	--------------

AP	!	WEST-WARD PHARMS INT	10MG/ML	A074900 001	Jul 18, 1997
-----------	---	----------------------	----------------	--------------------	--------------

ATROPINE

SOLUTION; INTRAMUSCULAR

ATROPEN

+	!	MERIDIAN MEDCL TECHN	EQ 0.25MG SULFATE/0.3ML	N017106 004	Sep 17, 2004
---	---	----------------------	-------------------------	-------------	--------------

+	!		EQ 0.5MG SULFATE/0.7ML	N017106 003	Jun 19, 2003
---	---	--	------------------------	-------------	--------------

+	!		EQ 1MG SULFATE/0.7ML	N017106 002	Jun 19, 2003
---	---	--	----------------------	-------------	--------------

+	!		EQ 2MG SULFATE/0.7ML	N017106 001	
---	---	--	----------------------	-------------	--

ATROPINE SULFATE

SOLUTION; INTRAVENOUS

ATROPINE SULFATE

AA	+	!	HOSPIRA	1MG/10ML (0.1MG/ML)	N021146 005	Aug 17, 2017
-----------	---	---	---------	----------------------------	--------------------	--------------

AA			INTL MEDICATION SYS	1MG/10ML (0.1MG/ML)	A212461 001	Oct 05, 2020
-----------	--	--	---------------------	----------------------------	--------------------	--------------

+	!		ACCORD HLTHCARE	0.4MG/ML (0.4MG/ML)	N214652 001	Sep 29, 2020
---	---	--	-----------------	---------------------	-------------	--------------

+	!			1MG/ML (1MG/ML)	N214652 002	Sep 29, 2020
---	---	--	--	-----------------	-------------	--------------

+	!		HOSPIRA	0.25MG/5ML (0.05MG/ML)	N021146 002	Jul 09, 2001
---	---	--	---------	------------------------	-------------	--------------

+	!			0.5MG/5ML (0.1MG/ML)	N021146 004	Aug 17, 2017
---	---	--	--	----------------------	-------------	--------------

+	!			1MG/10ML (0.1MG/ML)	N021146 003	Jul 09, 2001
---	---	--	--	---------------------	-------------	--------------

SOLUTION; INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, INTRAOSSEOUS, ENDOTRACHEAL

ATROPINE SULFATE

+	!		FRESENIUS KABI USA	8MG/20ML (0.4MG/ML)	N209260 001	Jan 26, 2018
---	---	--	--------------------	---------------------	-------------	--------------

SOLUTION/DROPS; OPHTHALMIC

ATROPINE SULFATE

+	!		AKORN	1%	N206289 001	Jul 18, 2014
---	---	--	-------	----	-------------	--------------

ISOPTO ATROPINE

+	!		ALCON LABS INC	1%	N208151 001	Dec 01, 2016
---	---	--	----------------	----	-------------	--------------

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL

MOTOFEN

+	!		SEBELA IRELAND LTD	0.025MG;1MG	N017744 002	
---	---	--	--------------------	-------------	-------------	--

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

SOLUTION; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

!			HIKMA	0.025MG/5ML; 2.5MG/5ML	A087708 001	May 03, 1982
---	--	--	-------	------------------------	-------------	--------------

TABLET; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

AA			ANI PHARMS INC	0.025MG;2.5MG	A086727 001	
-----------	--	--	----------------	----------------------	--------------------	--

AA			BAYSHORE PHARMS LLC	0.025MG;2.5MG	A210819 001	Nov 13, 2018
-----------	--	--	---------------------	----------------------	--------------------	--------------

AA			ECI PHARMS LLC	0.025MG;2.5MG	A207128 001	Oct 21, 2020
-----------	--	--	----------------	----------------------	--------------------	--------------

AA			LANNETT	0.025MG;2.5MG	A085372 001	
-----------	--	--	---------	----------------------	--------------------	--

AA			LEADING PHARMA LLC	0.025MG;2.5MG	A213413 001	Feb 20, 2020
-----------	--	--	--------------------	----------------------	--------------------	--------------

AA			MAYNE PHARMA INC	0.025MG;2.5MG	A210789 001	Jun 03, 2020
-----------	--	--	------------------	----------------------	--------------------	--------------

AA			MYLAN	0.025MG;2.5MG	A085762 001	
-----------	--	--	-------	----------------------	--------------------	--

AA			SPECGX LLC	0.025MG;2.5MG	A213335 001	Oct 06, 2020
-----------	--	--	------------	----------------------	--------------------	--------------

AA			UPSHER SMITH LABS	0.025MG;2.5MG	A210571 001	Aug 31, 2018
-----------	--	--	-------------------	----------------------	--------------------	--------------

LOMOTIL

AA	+		PFIZER	0.025MG;2.5MG	N012462 001	
-----------	---	--	--------	----------------------	--------------------	--

PRESCRIPTION DRUG PRODUCT LIST

ATROPINE; PRALIDOXIME CHLORIDE

INJECTABLE; INTRAMUSCULAR

DUODOTE

+! MERIDIAN MEDCL 2.1MG/0.7ML; 600MG/2ML N021983 001 Sep 28, 2006

AURANOFIN

CAPSULE; ORAL

RIDAURA

+! SEBELA IRELAND LTD 3MG N018689 001 May 24, 1985

AVANAFIL

TABLET; ORAL

STENDRA

+ METUCHEN PHARMS 50MG N202276 001 Apr 27, 2012

+ 100MG N202276 002 Apr 27, 2012

+! 200MG N202276 003 Apr 27, 2012

AVAPRITINIB

TABLET; ORAL

AYVAKIT

+ BLUEPRINT MEDICINES 100MG N212608 001 Jan 09, 2020

+ 200MG N212608 002 Jan 09, 2020

+! 300MG N212608 003 Jan 09, 2020

AVATROMBOPAG MALEATE

TABLET; ORAL

DOPTELET

+! AKARX INC EQ 20MG BASE N210238 001 May 21, 2018

AVIBACTAM SODIUM; CEFTAZIDIME

POWDER; IV (INFUSION)

AVYCAZ

+! ALLERGAN EQ 0.5GM BASE; 2GM/VIAL N206494 001 Feb 25, 2015

AXITINIB

TABLET; ORAL

INLYTA

+ PF PRISM CV 1MG N202324 001 Jan 27, 2012

+! 5MG N202324 002 Jan 27, 2012

AZACITIDINE

POWDER; INTRAVENOUS, SUBCUTANEOUS

AZACITIDINE

<u>AP</u>	ACCORD HLTHCARE	<u>100MG/VIAL</u>	<u>A207475</u>	<u>001</u>	Jul 02, 2018
<u>AP</u>	ACTAVIS LLC	<u>100MG/VIAL</u>	<u>N208216</u>	<u>001</u>	Apr 29, 2016
<u>AP</u>	CIPLA	<u>100MG/VIAL</u>	<u>A209540</u>	<u>001</u>	May 04, 2018
<u>AP</u>	DR REDDYS	<u>100MG/VIAL</u>	<u>A201537</u>	<u>001</u>	Sep 16, 2013
<u>AP</u>	EUROHLTH INTL SARL	<u>100MG/VIAL</u>	<u>A209337</u>	<u>001</u>	Jun 08, 2020
<u>AP</u>	MEITHEAL	<u>100MG/VIAL</u>	<u>A212128</u>	<u>001</u>	Nov 02, 2020
<u>AP</u>	MYLAN INSTITUTIONAL	<u>100MG/VIAL</u>	<u>A204949</u>	<u>001</u>	Apr 28, 2016
<u>AP</u>	NATCO PHARMA LTD	<u>100MG/VIAL</u>	<u>A207234</u>	<u>001</u>	Jun 23, 2017
<u>AP</u>	SHILPA MEDICARE	<u>100MG/VIAL</u>	<u>A207518</u>	<u>001</u>	Sep 29, 2016

VIDAZAAP +! CELGENE 100MG/VIAL N050794 001 May 19, 2004

TABLET; ORAL

ONUREG

+ CELGENE CORP 200MG N214120 001 Sep 01, 2020

+! 300MG N214120 002 Sep 01, 2020

AZATHIOPRINE

TABLET; ORAL

AZASAN

<u>AB</u>	AAIPHARMA LLC	<u>25MG</u>	<u>A075252</u>	<u>002</u>	Feb 03, 2003
<u>AB</u>		<u>50MG</u>	<u>A075252</u>	<u>001</u>	Jun 07, 1999
<u>AB</u>		<u>75MG</u>	<u>A075252</u>	<u>003</u>	Feb 03, 2003
<u>AB</u>		<u>100MG</u>	<u>A075252</u>	<u>004</u>	Feb 03, 2003

AZATHIOPRINE

<u>AB</u>	ALKEM LABS LTD	<u>25MG</u>	<u>A208687</u>	<u>001</u>	Mar 27, 2020
<u>AB</u>		<u>50MG</u>	<u>A208687</u>	<u>002</u>	Mar 27, 2020
<u>AB</u>		<u>75MG</u>	<u>A208687</u>	<u>003</u>	Mar 27, 2020
<u>AB</u>		<u>100MG</u>	<u>A208687</u>	<u>004</u>	Mar 27, 2020
<u>AB</u>	AMNEAL	<u>50MG</u>	<u>A074069</u>	<u>001</u>	Feb 16, 1996
<u>AB</u>	RISING	<u>50MG</u>	<u>A075568</u>	<u>001</u>	Dec 13, 1999
<u>AB</u>	ZYDUS PHARMS USA	<u>25MG</u>	<u>A077621</u>	<u>002</u>	Sep 05, 2008
<u>AB</u>		<u>50MG</u>	<u>A077621</u>	<u>001</u>	Mar 15, 2007
<u>AB</u>		<u>75MG</u>	<u>A077621</u>	<u>003</u>	Sep 05, 2008

PRESCRIPTION DRUG PRODUCT LIST

AZATHIOPRINE

TABLET;ORAL

AZATHIOPRINE

AB		100MG	A077621 004	Sep 05, 2008
-----------	--	--------------	--------------------	--------------

IMURAN

AB	+ !	SEBELA IRELAND LTD	50MG	N016324 001
-----------	------------	--------------------	-------------	--------------------

AZATHIOPRINE SODIUM

INJECTABLE;INJECTION

AZATHIOPRINE SODIUM

! WEST-WARD PHARMS

INT

EQ 100MG BASE/VIAL

A074419 001 Mar 31, 1995

AZELAIC ACID

AEROSOL, FOAM;TOPICAL

FINACEA

AB	+ !	LEO PHARMA AS	15%	N207071 001	Jul 29, 2015
-----------	------------	---------------	------------	--------------------	--------------

CREAM;TOPICAL

AZELEX

+! ALMIRALL

20%

N020428 001 Sep 13, 1995

GEL;TOPICAL

AZELAIC ACID

AB		ACTAVIS LABS UT INC	15%	A208011 001	Nov 19, 2018
-----------	--	---------------------	------------	--------------------	--------------

AB		GLENMARK PHARMS	15%	A204637 001	Nov 19, 2018
-----------	--	-----------------	------------	--------------------	--------------

AB		TARO	15%	A210549 001	Aug 23, 2019
-----------	--	------	------------	--------------------	--------------

AB		TOLMAR	15%	A208724 001	Nov 19, 2018
-----------	--	--------	------------	--------------------	--------------

FINACEA

AB	+ !	LEO PHARMA AS	15%	N021470 001	Dec 24, 2002
-----------	------------	---------------	------------	--------------------	--------------

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

AZELASTINE HYDROCHLORIDE

AT		AKORN	0.05%	A203660 001	Nov 08, 2016
-----------	--	-------	--------------	--------------------	--------------

AT		ALEMBIC PHARMS LTD	0.05%	A209620 001	Mar 20, 2019
-----------	--	--------------------	--------------	--------------------	--------------

AT		APOTEX INC	0.05%	A078621 001	Aug 03, 2009
-----------	--	------------	--------------	--------------------	--------------

AT		GLAND PHARMA LTD	0.05%	A210092 001	Feb 25, 2020
-----------	--	------------------	--------------	--------------------	--------------

AT	!	SANDOZ INC	0.05%	A202305 001	May 31, 2012
-----------	----------	------------	--------------	--------------------	--------------

AT		SOMERSET THERAPS LLC	0.05%	A207411 001	Mar 29, 2019
-----------	--	-------------------------	--------------	--------------------	--------------

AT		SUN PHARM	0.05%	A078738 001	Jun 21, 2010
-----------	--	-----------	--------------	--------------------	--------------

SPRAY, METERED;NASAL

ASTELIN

AB	+ !	MYLAN SPECIALITY LP	EQ 0.125MG BASE/SPRAY	N020114 001	Nov 01, 1996
-----------	------------	---------------------	------------------------------	--------------------	--------------

ASTEPRO

AB	+ !	MYLAN SPECIALITY LP	EQ 0.1876MG BASE/SPRAY	N022203 002	Aug 31, 2009
-----------	------------	---------------------	-------------------------------	--------------------	--------------

AZELASTINE HYDROCHLORIDE

AB		AKORN	EQ 0.125MG BASE/SPRAY	A207610 001	May 17, 2019
-----------	--	-------	------------------------------	--------------------	--------------

AB			EQ 0.1876MG BASE/SPRAY	A210032 001	Aug 23, 2019
-----------	--	--	-------------------------------	--------------------	--------------

AB		ALKEM LABS LTD	EQ 0.125MG BASE/SPRAY	A208156 001	Aug 18, 2017
-----------	--	----------------	------------------------------	--------------------	--------------

AB		AMNEAL	EQ 0.125MG BASE/SPRAY	A204660 001	Aug 28, 2017
-----------	--	--------	------------------------------	--------------------	--------------

AB			EQ 0.1876MG BASE/SPRAY	A208199 001	Dec 15, 2017
-----------	--	--	-------------------------------	--------------------	--------------

AB		APOTEX INC	EQ 0.125MG BASE/SPRAY	A077954 001	Apr 30, 2009
-----------	--	------------	------------------------------	--------------------	--------------

AB			EQ 0.1876MG BASE/SPRAY	A201846 001	Aug 31, 2012
-----------	--	--	-------------------------------	--------------------	--------------

AB		AUROBINDO PHARMA LTD	EQ 0.125MG BASE/SPRAY	A212289 001	May 08, 2020
-----------	--	-------------------------	------------------------------	--------------------	--------------

AB			EQ 0.1876MG BASE/SPRAY	A212775 001	Nov 12, 2020
-----------	--	--	-------------------------------	--------------------	--------------

AB		BRECKENRIDGE	EQ 0.125MG BASE/SPRAY	A090176 001	Jul 28, 2015
-----------	--	--------------	------------------------------	--------------------	--------------

AB		HIKMA	EQ 0.125MG BASE/SPRAY	A091444 001	Oct 24, 2014
-----------	--	-------	------------------------------	--------------------	--------------

AB			EQ 0.1876MG BASE/SPRAY	A207243 001	Sep 22, 2017
-----------	--	--	-------------------------------	--------------------	--------------

AB		PERRIGO ISRAEL	EQ 0.1876MG BASE/SPRAY	A202743 001	May 08, 2014
-----------	--	----------------	-------------------------------	--------------------	--------------

AB		SUN PHARM	EQ 0.125MG BASE/SPRAY	A090423 001	May 23, 2012
-----------	--	-----------	------------------------------	--------------------	--------------

AB		UPSHER SMITH LABS	EQ 0.125MG BASE/SPRAY	A202609 001	Mar 17, 2017
-----------	--	-------------------	------------------------------	--------------------	--------------

AB		ZYDUS PHARMS	EQ 0.125MG BASE/SPRAY	A091409 001	Aug 14, 2017
-----------	--	--------------	------------------------------	--------------------	--------------

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE

AB		APOTEX	EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY	A207712 001	Apr 28, 2017
-----------	--	--------	---	--------------------	--------------

DYMISTA

AB	+ !	MYLAN SPECIALITY LP	EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY	N202236 001	May 01, 2012
-----------	------------	---------------------	---	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

AZILSARTAN KAMEDOXOMIL

TABLET; ORAL

EDARBI

+	ARBOR PHARMS LLC	EQ 40MG MEDOXOMIL	N200796	001	Feb 25, 2011
+	!	EQ 80MG MEDOXOMIL	N200796	002	Feb 25, 2011

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET; ORAL

EDARBYCLOR

+	ARBOR PHARMS LLC	EQ 40MG MEDOXOMIL;12.5MG	N202331	001	Dec 20, 2011
+	!	EQ 40MG MEDOXOMIL;25MG	N202331	002	Dec 20, 2011

AZITHROMYCIN

FOR SUSPENSION; ORAL

AZITHROMYCIN

<u>AB</u>	AMNEAL	<u>EQ 100MG BASE/5ML</u>	<u>A205666</u>	<u>001</u>	Jul 19, 2018	
<u>AB</u>		<u>EQ 200MG BASE/5ML</u>	<u>A205666</u>	<u>002</u>	Jul 19, 2018	
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 100MG BASE/5ML</u>	<u>A209201</u>	<u>001</u>	Oct 09, 2018	
<u>AB</u>		<u>EQ 200MG BASE/5ML</u>	<u>A209201</u>	<u>002</u>	Oct 09, 2018	
<u>AB</u>	EPIC PHARMA LLC	<u>EQ 100MG BASE/5ML</u>	<u>A207531</u>	<u>001</u>	Apr 09, 2018	
<u>AB</u>		<u>EQ 200MG BASE/5ML</u>	<u>A207531</u>	<u>002</u>	Apr 09, 2018	
<u>AB</u>	PLIVA	<u>EQ 100MG BASE/5ML</u>	<u>A065246</u>	<u>002</u>	Jul 05, 2006	
<u>AB</u>		<u>EQ 200MG BASE/5ML</u>	<u>A065246</u>	<u>001</u>	Jul 05, 2006	
<u>AB</u>	ZYDUS	<u>EQ 100MG BASE/5ML</u>	<u>A211147</u>	<u>001</u>	Jul 31, 2018	
<u>AB</u>		<u>EQ 200MG BASE/5ML</u>	<u>A211147</u>	<u>002</u>	Jul 31, 2018	
<u>ZITHROMAX</u>						
<u>AB</u>	+	PFIZER	<u>EQ 100MG BASE/5ML</u>	<u>N050710</u>	<u>001</u>	Oct 19, 1995
<u>AB</u>	+	!	<u>EQ 200MG BASE/5ML</u>	<u>N050710</u>	<u>002</u>	Oct 19, 1995
		!	EQ 1GM BASE/PACKET	N050693	001	Sep 28, 1994

INJECTABLE; INJECTION

AZITHROMYCIN

<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 500MG BASE/VIAL</u>	<u>A203294</u>	<u>001</u>	Jun 19, 2015
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 500MG BASE/VIAL</u>	<u>A065179</u>	<u>001</u>	Dec 13, 2005
<u>AP</u>	GLAND PHARMA LTD	<u>EQ 500MG BASE/VIAL</u>	<u>A065501</u>	<u>001</u>	Nov 09, 2009
<u>AP</u>	HAINAN POLY PHARM	<u>EQ 500MG BASE/VIAL</u>	<u>A203412</u>	<u>001</u>	Oct 09, 2018
<u>AP</u>	HOSPIRA	<u>EQ 500MG BASE/VIAL</u>	<u>A065500</u>	<u>001</u>	Jun 26, 2009
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065511</u>	<u>001</u>	Jun 26, 2009
<u>AP</u>	MYLAN ASI	<u>EQ 500MG BASE/VIAL</u>	<u>A065506</u>	<u>001</u>	Mar 24, 2009
<u>AP</u>	SUN PHARM INDS LTD	<u>EQ 500MG BASE/VIAL</u>	<u>A090923</u>	<u>001</u>	Apr 02, 2013

ZITHROMAX

<u>AP</u>	+	!	PFIZER	<u>EQ 500MG BASE/VIAL</u>	<u>N050733</u>	<u>001</u>	Jan 30, 1997	
SOLUTION/DROPS; OPHTHALMIC								
AZASITE								
		+	!	AKORN	1%	N050810	001	Apr 27, 2007

TABLET; ORAL

AZITHROMYCIN

<u>AB</u>	ALEMBIC PHARMS LTD	<u>EQ 250MG BASE</u>	<u>A211791</u>	<u>001</u>	Jan 28, 2020
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A211792</u>	<u>001</u>	Jan 28, 2020
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 250MG BASE</u>	<u>A207370</u>	<u>001</u>	Jul 05, 2018
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A207398</u>	<u>001</u>	Jul 05, 2018
<u>AB</u>	BIONPHARMA INC	<u>EQ 250MG BASE</u>	<u>A210000</u>	<u>001</u>	Feb 26, 2019
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A210001</u>	<u>001</u>	Feb 26, 2019
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A209999</u>	<u>001</u>	Dec 26, 2018
<u>AB</u>	CSPC OUYI	<u>EQ 250MG BASE</u>	<u>A208250</u>	<u>001</u>	Apr 17, 2019
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A208249</u>	<u>001</u>	Oct 25, 2018
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A207566</u>	<u>001</u>	Sep 24, 2018
<u>AB</u>	LUPIN LTD	<u>EQ 250MG BASE</u>	<u>A065398</u>	<u>001</u>	May 15, 2015
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065399</u>	<u>001</u>	May 15, 2015
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A065400</u>	<u>001</u>	May 15, 2015
<u>AB</u>	PLIVA	<u>EQ 250MG BASE</u>	<u>A065225</u>	<u>001</u>	Nov 14, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065223</u>	<u>001</u>	Nov 14, 2005
<u>AB</u>	!	<u>EQ 600MG BASE</u>	<u>A065218</u>	<u>001</u>	Nov 14, 2005
<u>AB</u>	SANDOZ	<u>EQ 250MG BASE</u>	<u>A065211</u>	<u>001</u>	Nov 14, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065212</u>	<u>001</u>	Nov 14, 2005
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A065209</u>	<u>001</u>	Nov 14, 2005
<u>AB</u>	SUNSHINE	<u>EQ 250MG BASE</u>	<u>A209045</u>	<u>001</u>	Dec 07, 2018
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A209044</u>	<u>001</u>	Dec 07, 2018
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A209043</u>	<u>001</u>	Dec 06, 2018
<u>AB</u>	TEVA	<u>EQ 500MG BASE</u>	<u>A065193</u>	<u>001</u>	Nov 14, 2005
<u>AB</u>	WOCKHARDT	<u>EQ 250MG BASE</u>	<u>A065404</u>	<u>001</u>	Feb 11, 2008
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065405</u>	<u>001</u>	Feb 11, 2008

PRESCRIPTION DRUG PRODUCT LIST

AZITHROMYCIN

TABLET; ORAL

AZITHROMYCIN

AB		<u>EQ 600MG BASE</u>	<u>A065302 003</u>	Feb 11, 2008
-----------	--	----------------------	--------------------	--------------

ZITHROMAX

AB	+	PFIZER	<u>EQ 250MG BASE</u>	<u>N050711 001</u>	Jul 18, 1996
-----------	---	--------	----------------------	--------------------	--------------

AB	+		<u>EQ 500MG BASE</u>	<u>N050784 001</u>	May 24, 2002
-----------	---	--	----------------------	--------------------	--------------

AZTREONAM

FOR SOLUTION; INHALATION

CAYSTON

+! GILEAD

75MG/VIAL

N050814 001 Feb 22, 2010

INJECTABLE; INJECTION

AZACTAM

AP	+	BRISTOL MYERS SQUIBB	<u>1GM/VIAL</u>	<u>N050580 002</u>	Dec 31, 1986
-----------	---	-------------------------	-----------------	--------------------	--------------

AP	+		<u>2GM/VIAL</u>	<u>N050580 003</u>	Dec 31, 1986
-----------	---	--	-----------------	--------------------	--------------

AZTREONAM

AP		FRESENIUS KABI USA	<u>1GM/VIAL</u>	<u>A065439 002</u>	Jun 18, 2010
-----------	--	--------------------	-----------------	--------------------	--------------

AP			<u>2GM/VIAL</u>	<u>A065439 003</u>	Jun 18, 2010
-----------	--	--	-----------------	--------------------	--------------

			500MG/VIAL	A065439 001	Jun 18, 2010
--	--	--	------------	-------------	--------------

BACITRACIN

INJECTABLE; INJECTION

BACITRACIN

! XELLIA PHARMS APS

50,000 UNITS/VIAL

A203177 001 Aug 25, 2014

OINTMENT; OPHTHALMIC

BACITRACIN

! PERRIGO CO

500 UNITS/GM

A061212 001

TENNESSEE

BACITRACIN ZINC; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

! PERRIGO CO

400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000
UNITS/GM

A062166 002

TENNESSEE

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE

AT		AKORN	<u>400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>A065213 001</u>	Jul 25, 2012
-----------	--	-------	---	--------------------	--------------

AT	!	BAUSCH AND LOMB	<u>400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>A064068 001</u>	Oct 30, 1995
-----------	---	-----------------	---	--------------------	--------------

OINTMENT; TOPICAL

CORTISPORIN

+! MONARCH PHARMS

400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000
UNITS/GM

N050168 002 May 04, 1984

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

LUMI-SPORYN

AT	+	CASPER PHARMA LLC	<u>EQ 400 UNITS/GM;EQ 3.5MG BASE/GM;EQ 10,000 UNITS/GM</u>	<u>N050417 001</u>	
-----------	---	-------------------	--	--------------------	--

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

AT		AKORN	<u>400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>A065088 001</u>	Feb 06, 2004
-----------	--	-------	--	--------------------	--------------

AT	!	BAUSCH AND LOMB	<u>400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>A064064 001</u>	Oct 30, 1995
-----------	---	-----------------	--	--------------------	--------------

AT		PERRIGO CO	<u>400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>A060764 002</u>	
-----------	--	------------	--	--------------------	--

TENNESSEE

--	--	--	--	--	--

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN ZINC AND POLYMYXIN B SULFATE

AT		AKORN	<u>500 UNITS/GM;10,000 UNITS/GM</u>	<u>A064028 001</u>	Jan 30, 1995
-----------	--	-------	-------------------------------------	--------------------	--------------

AT	!	BAUSCH AND LOMB	<u>500 UNITS/GM;10,000 UNITS/GM</u>	<u>A064046 001</u>	Jan 26, 1995
-----------	---	-----------------	-------------------------------------	--------------------	--------------

AT		PERRIGO CO	<u>500 UNITS/GM;10,000 UNITS/GM</u>	<u>A065022 001</u>	Feb 27, 2002
-----------	--	------------	-------------------------------------	--------------------	--------------

TENNESSEE

BACLOFEN

INJECTABLE; INTRATHECAL

BACLOFEN

AP		EMERALD INTL LTD	<u>0.05MG/ML</u>	<u>A091193 001</u>	May 03, 2016
-----------	--	------------------	------------------	--------------------	--------------

AP			<u>0.5MG/ML</u>	<u>A091193 002</u>	May 03, 2016
-----------	--	--	-----------------	--------------------	--------------

AP			<u>2MG/ML</u>	<u>A091193 003</u>	May 03, 2016
-----------	--	--	---------------	--------------------	--------------

AP		MAIA PHARMS INC	<u>1MG/ML</u>	<u>A210315 001</u>	Jul 30, 2019
-----------	--	-----------------	---------------	--------------------	--------------

AP		MYLAN LABS LTD	<u>0.5MG/ML</u>	<u>A209592 001</u>	Mar 21, 2018
-----------	--	----------------	-----------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

BACLOFEN

INJECTABLE; INTRATHECAL

BACLOFEN

<u>AP</u>		<u>1MG/ML</u>	<u>A209594 001</u>	Mar 06, 2018
<u>AP</u>		<u>2MG/ML</u>	<u>A209592 002</u>	Mar 21, 2018

GABLOFEN

<u>AP</u>	PIRAMAL CRITICAL	<u>0.05MG/ML</u>	<u>N022462 001</u>	Nov 19, 2010
<u>AP</u>		<u>0.5MG/ML</u>	<u>N022462 002</u>	Nov 19, 2010
<u>AP</u>	+	<u>1MG/ML</u>	<u>N022462 004</u>	Jun 22, 2012
<u>AP</u>		<u>2MG/ML</u>	<u>N022462 003</u>	Nov 19, 2010

LIORESAL

<u>AP</u>	+	SAOL THERAPS RES LTD	<u>0.05MG/ML</u>	<u>N020075 003</u>	Nov 07, 1996
<u>AP</u>	+		<u>0.5MG/ML</u>	<u>N020075 001</u>	Jun 17, 1992
<u>AP</u>	+		<u>2MG/ML</u>	<u>N020075 002</u>	Jun 17, 1992

SOLUTION; ORAL

OZOBAX

+	METACEL PHARMS LLC	5MG/5ML	N208193 001	Sep 18, 2019
---	--------------------	---------	-------------	--------------

TABLET; ORAL

BACLOFEN

<u>AB</u>	EYWA PHARMA	<u>10MG</u>	<u>A211555 001</u>	Feb 01, 2019
<u>AB</u>		<u>20MG</u>	<u>A211555 002</u>	Feb 01, 2019
<u>AB</u>	IMPAX LABS	<u>10MG</u>	<u>A077971 001</u>	Oct 26, 2007
<u>AB</u>		<u>20MG</u>	<u>A077971 002</u>	Oct 26, 2007
<u>AB</u>	INNOGENIX	<u>10MG</u>	<u>A212378 001</u>	Oct 09, 2020
<u>AB</u>		<u>20MG</u>	<u>A212378 002</u>	Oct 09, 2020
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>10MG</u>	<u>A072234 001</u>	Jul 21, 1988
<u>AB</u>	!	<u>20MG</u>	<u>A072235 001</u>	Jul 21, 1988
<u>AB</u>	LANNETT CO INC	<u>10MG</u>	<u>A077241 002</u>	Jul 06, 2007
<u>AB</u>		<u>20MG</u>	<u>A077241 001</u>	Dec 20, 2005
<u>AB</u>	NORTHSTAR HLTHCARE	<u>10MG</u>	<u>A078401 002</u>	Sep 18, 2009
<u>AB</u>		<u>20MG</u>	<u>A078401 001</u>	Sep 18, 2009
<u>AB</u>	OXFORD PHARMS	<u>10MG</u>	<u>A077088 002</u>	Oct 31, 2007
<u>AB</u>		<u>20MG</u>	<u>A077088 001</u>	Oct 31, 2007
<u>AB</u>	RUBICON	<u>5MG</u>	<u>A209102 001</u>	Nov 28, 2017
<u>AB</u>		<u>10MG</u>	<u>A209102 002</u>	Nov 28, 2017
<u>AB</u>		<u>20MG</u>	<u>A209102 003</u>	Nov 28, 2017
<u>AB</u>	UNICHEM	<u>10MG</u>	<u>A212067 001</u>	Jul 09, 2020
<u>AB</u>		<u>20MG</u>	<u>A212067 002</u>	Jul 09, 2020
<u>AB</u>	UPSHER SMITH LABS	<u>10MG</u>	<u>A074584 001</u>	Aug 19, 1996
<u>AB</u>		<u>20MG</u>	<u>A074584 002</u>	Aug 19, 1996
<u>AB</u>	VINTAGE PHARMS	<u>10MG</u>	<u>A077068 002</u>	Aug 30, 2005
<u>AB</u>		<u>20MG</u>	<u>A077068 001</u>	Aug 30, 2005
<u>AB</u>	ZYDUS	<u>5MG</u>	<u>A211659 003</u>	Apr 17, 2020
<u>AB</u>		<u>10MG</u>	<u>A211659 001</u>	Nov 23, 2018
<u>AB</u>		<u>20MG</u>	<u>A211659 002</u>	Nov 23, 2018

BALOXAVIR MARBOXIL

FOR SUSPENSION; ORAL

XOFLUZA

+	GENENTECH INC	2MG/ML	N214410 001	Nov 23, 2020
---	---------------	--------	-------------	--------------

TABLET; ORAL

XOFLUZA

+	GENENTECH INC	20MG	N210854 001	Oct 24, 2018
+		40MG	N210854 002	Oct 24, 2018

BALSALAZIDE DISODIUM

CAPSULE; ORAL

BALSALAZIDE DISODIUM

<u>AB</u>	APOTEX INC	<u>750MG</u>	<u>A077883 001</u>	Dec 28, 2007
<u>AB</u>	HIKMA	<u>750MG</u>	<u>A077806 001</u>	Dec 28, 2007

COLAZAL

<u>AB</u>	+	VALEANT PHARMS INTL	<u>750MG</u>	<u>N020610 001</u>	Jul 18, 2000
-----------	---	---------------------	--------------	--------------------	--------------

BARICITINIB

TABLET; ORAL

OLUMIANT

+	ELI LILLY AND CO	1MG	N207924 002	Oct 08, 2019
+		2MG	N207924 001	May 31, 2018

PRESCRIPTION DRUG PRODUCT LIST

BARIUM SULFATE

FOR SUSPENSION;ORAL

E-Z-HD

+! BRACCO 98% (334GM/BOT) N208036 001 Jan 11, 2016

E-Z-PAQUE

+! BRACCO 96% (169GM/BOT) N208036 002 Apr 07, 2017

VARIBAR THIN LIQUID

+! BRACCO 81% (120GM/BOT) N208036 004 Apr 30, 2019

PASTE;ORAL

VARIBAR PUDDING

BRACCO 40% N208844 001 Oct 14, 2016

SUSPENSION;ORAL

ENTERO VU 24%

+! BRACCO 24% (144GM/600ML) N208143 008 May 29, 2020

LIQUID E-Z-PAQUE

+! BRACCO 60% (213GM/BOT) N208143 003 Mar 01, 2017

READI-CAT 2

+! BRACCO 2% (9GM/BOT) N208143 001 Jan 15, 2016

READI-CAT 2 SMOOTHIE

+! BRACCO 2% (9GM/BOT) N208143 002 Jan 15, 2016

TAGITOL V

+! BRACCO 40% (8GM/BOT) N208143 005 Aug 04, 2017

VARIBAR HONEY

+! BRACCO 40% (100GM/250ML) N208143 007 Mar 26, 2018

VARIBAR NECTAR

+! BRACCO 40% (96GM/240ML) N208143 004 Jul 07, 2017

VARIBAR THIN HONEY

+! BRACCO 40% (100GM/250ML) N208143 006 Jan 23, 2018

BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED

TABLET;ORAL

DUAVEE

+! WYETH PHARMS EQ 20MG BASE;0.45MG N022247 001 Oct 03, 2013

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED;INHALATION

QVAR REDIHALER

+ NORTON WATERFORD 0.04MG/INH N207921 001 Aug 03, 2017

+ 0.08MG/INH N207921 002 Aug 03, 2017

AEROSOL, METERED;NASAL

QNASL

+ TEVA BRANDED PHARM 0.04MG/ACTUATION N202813 002 Dec 17, 2014

+! 0.08MG/ACTUATION N202813 001 Mar 23, 2012

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED;NASAL

BECONASE AQ

+! GLAXOSMITHKLINE EQ 0.042MG DIPROP/SPRAY N019389 001 Jul 27, 1987

BEDAQUILINE FUMARATE

TABLET;ORAL

SIRTURO

+ JANSSEN THERAP EQ 20MG BASE N204384 002 May 27, 2020

+! EQ 100MG BASE N204384 001 Dec 28, 2012

BELINOSTAT

POWDER;INTRAVENOUS

BELEODAQ

+! ACROTECH 500MG/VIAL N206256 001 Jul 03, 2014

BEMPEDOIC ACID

TABLET;ORAL

NEXLETOL

+! ESPERION THERAPS 180MG N211616 001 Feb 21, 2020

INC

BEMPEDOIC ACID; EZETIMIBE

TABLET;ORAL

NEXLIZET

+! ESPERION THERAPS 180MG;10MG N211617 001 Feb 26, 2020

INC

PRESCRIPTION DRUG PRODUCT LIST

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

<u>AB</u>	AMNEAL PHARMS	<u>5MG</u>	<u>A076820 001</u>	Feb 03, 2006
<u>AB</u>		<u>10MG</u>	<u>A076820 002</u>	Feb 03, 2006
<u>AB</u>		<u>20MG</u>	<u>A076820 003</u>	Feb 03, 2006
<u>AB</u>		<u>40MG</u>	<u>A076820 004</u>	Feb 03, 2006
<u>AB</u>	ANNORA PHARMA	<u>5MG</u>	<u>A077128 001</u>	Mar 08, 2006
<u>AB</u>		<u>10MG</u>	<u>A077128 002</u>	Mar 08, 2006
<u>AB</u>		<u>20MG</u>	<u>A077128 003</u>	Mar 08, 2006
<u>AB</u>		<u>40MG</u>	<u>A077128 004</u>	Mar 08, 2006
<u>AB</u>	AUROBINDO PHARMA	<u>10MG</u>	<u>A078212 001</u>	May 22, 2008
<u>AB</u>		<u>20MG</u>	<u>A078212 002</u>	May 22, 2008
<u>AB</u>		<u>40MG</u>	<u>A078212 003</u>	May 22, 2008
<u>AB</u>	CHARTWELL RX	<u>5MG</u>	<u>A076402 001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076402 002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076402 003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076402 004</u>	Feb 11, 2004
<u>AB</u>	PRINSTON INC	<u>5MG</u>	<u>A076118 001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076118 002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076118 003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076118 004</u>	Feb 11, 2004
<u>AB</u>	SUN PHARM INDS LTD	<u>5MG</u>	<u>A076344 001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076344 002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076344 003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076344 004</u>	Feb 11, 2004
<u>AB</u>	TEVA	<u>5MG</u>	<u>A076211 001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076211 002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076211 003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076211 004</u>	Feb 11, 2004
<u>AB</u>	ZYDUS PHARMS USA	<u>5MG</u>	<u>A078848 001</u>	May 23, 2008
<u>AB</u>		<u>10MG</u>	<u>A078848 002</u>	May 23, 2008
<u>AB</u>		<u>20MG</u>	<u>A078848 003</u>	May 23, 2008
<u>AB</u>		<u>40MG</u>	<u>A078848 004</u>	May 23, 2008
<u>LOTENSIN</u>				
<u>AB</u>	+ US PHARMS HOLDINGS I	<u>5MG</u>	<u>N019851 001</u>	Jun 25, 1991
<u>AB</u>	+	<u>10MG</u>	<u>N019851 002</u>	Jun 25, 1991
<u>AB</u>	+	<u>20MG</u>	<u>N019851 003</u>	Jun 25, 1991
<u>AB</u>	+	<u>40MG</u>	<u>N019851 004</u>	Jun 25, 1991

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	MYLAN	<u>5MG; 6.25MG</u>	<u>A076688 001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>A076688 002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>A076688 003</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 25MG</u>	<u>A076688 004</u>	Feb 11, 2004
<u>AB</u>	SANDOZ	<u>5MG; 6.25MG</u>	<u>A076631 001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>A076631 002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>A076631 003</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 25MG</u>	<u>A076631 004</u>	Feb 11, 2004
<u>LOTENSIN HCT</u>				
<u>AB</u>	+ US PHARMS HOLDINGS I	<u>10MG; 12.5MG</u>	<u>N020033 002</u>	May 19, 1992
<u>AB</u>	+	<u>20MG; 12.5MG</u>	<u>N020033 004</u>	May 19, 1992
<u>AB</u>	+	<u>20MG; 25MG</u>	<u>N020033 003</u>	May 19, 1992

BENDAMUSTINE HYDROCHLORIDE

POWDER; IV (INFUSION)

TRENDA

+! CEPHALON

25MG/VIAL

N022249 002 May 01, 2009

+!

100MG/VIAL

N022249 001 Mar 20, 2008

SOLUTION; IV (INFUSION)

BELRAPZO

+! EAGLE PHARMS

100MG/4ML (25MG/ML)

N205580 001 May 15, 2018

BENDEKA

+! EAGLE PHARMS

100MG/4ML (25MG/ML)

N208194 001 Dec 07, 2015

PRESCRIPTION DRUG PRODUCT LIST

BENDROFLUMETHIAZIDE; NADOLOL

TABLET; ORAL

CORZIDE

AB	+	KING PHARMS LLC	5MG; 40MG	N018647 001	May 25, 1983
AB	+	!	5MG; 80MG	N018647 002	May 25, 1983

NADOLOL AND BENDROFLUMETHIAZIDE

AB		IMPAX LABS	5MG; 40MG	A077833 001	Mar 30, 2007
AB			5MG; 80MG	A077833 002	Mar 30, 2007

BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM

SOLUTION/DROPS; OPHTHALMIC

ALTAFLUOR BENOX

+	!	ALTAIRE PHARMS INC	0.4%; 0.25%	N208582 001	Dec 14, 2017
---	---	--------------------	-------------	-------------	--------------

FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE

+	!	BAUSCH	0.4%; 0.3%	N211039 001	Mar 09, 2020
---	---	--------	------------	-------------	--------------

BENZNIDAZOLE

TABLET; ORAL

BENZNIDAZOLE

+		CHEMO RESEARCH SL	12.5MG	N209570 001	Aug 29, 2017
---	--	-------------------	--------	-------------	--------------

+	!		100MG	N209570 002	Aug 29, 2017
---	---	--	-------	-------------	--------------

BENZONATATE

CAPSULE; ORAL

BENZONATATE

AA		ALEMBIC LABS	100MG	A040682 001	Jul 30, 2007
AA			200MG	A040682 002	Jul 30, 2007
AA		APOTEX INC	100MG	A091310 001	Jan 16, 2015
AA			200MG	A091310 002	Jan 16, 2015
AA		ASCENT PHARMS INC	100MG	A211518 001	Feb 22, 2019
AA			150MG	A211518 002	Feb 22, 2019
AA			200MG	A211518 003	Feb 22, 2019
AA		BIONPHARMA INC	100MG	A081297 001	Jan 29, 1993
AA			200MG	A081297 002	Oct 30, 2007
AA		CSPC-NBP PHARM	100MG	A202765 002	Aug 25, 2017
AA			200MG	A202765 001	Jul 31, 2015
AA		MIKART	100MG	A040851 001	Nov 09, 2009
AA			150MG	A040851 002	Nov 09, 2009
AA			200MG	A040851 003	Nov 09, 2009
AA		PURACAP PHARM LLC	100MG	A206948 001	Dec 19, 2018
AA			200MG	A206948 002	Dec 19, 2018
AA		QINGDAO BAHEAL PHARM	100MG	A210562 001	Nov 09, 2018
AA			150MG	A210562 002	Nov 09, 2018
AA			200MG	A210562 003	Nov 09, 2018
AA		STRIDES PHARMA	100MG	A091133 001	Jul 30, 2015
AA			200MG	A091133 002	Jul 30, 2015
AA	!	THEPHARMANETWORK LLC	100MG	A040627 001	Mar 30, 2007
AA	!		150MG	A201209 001	Sep 24, 2014
AA	!		200MG	A040749 001	Jul 25, 2007
AA		ZYDUS PHARMS USA	100MG	A040597 001	Jun 08, 2007
AA			200MG	A040597 002	Jun 08, 2007

TESSALON

AA	+	PFIZER	100MG	N011210 001	
-----------	---	--------	--------------	--------------------	--

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

ACANYA

AB	+	!	BAUSCH	2.5%; EQ 1.2% BASE	N050819 001	Oct 23, 2008
-----------	---	---	--------	---------------------------	--------------------	--------------

BENZACLIN

AB	+	!	BAUSCH	5%; EQ 1% BASE	N050756 001	Dec 21, 2000
-----------	---	---	--------	-----------------------	--------------------	--------------

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

AB		ACTAVIS LABS UT INC	2.5%; EQ 1.2% BASE	A205128 001	Jun 19, 2015
AB		GLENMARK PHARMS	5%; EQ 1% BASE	A209252 001	Mar 14, 2019
AB		MYLAN PHARMS INC	5%; EQ 1% BASE	A065443 001	Aug 11, 2009
AB		PERRIGO ISRAEL	2.5%; EQ 1.2% BASE	A205397 001	Sep 09, 2019
AB			5%; 1.2%	A090979 001	Jun 26, 2012
AB		PERRIGO UK FINCO	5%; EQ 1% BASE	A202440 001	Sep 21, 2015
AB		TARO	2.5%; EQ 1.2% BASE	A206575 001	Aug 19, 2019
AB			5%; EQ 1% BASE	A208776 001	May 25, 2018
AB		TARO PHARMS	5%; 1.2%	A206218 001	Dec 15, 2017
AB		TOLMAR	5%; EQ 1% BASE	A204087 001	Jun 27, 2017
AB			5%; 1.2%	A203688 001	Aug 25, 2016
AB		ZYDUS PHARMS	5%; 1.2%	A210794 001	Dec 28, 2018

PRESCRIPTION DRUG PRODUCT LIST

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

DUAC

AB	+ !	STIEFEL	5%;1.2%	N050741 001	Aug 26, 2002
		ONEXTON			
	+ !	BAUSCH	3.75%;EQ 1.2% BASE	N050819 002	Nov 24, 2014

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

BENZAMYCIN

AB	+ !	VALEANT INTL	5%;3%	N050557 001	Oct 26, 1984
-----------	------------	--------------	--------------	--------------------	--------------

ERYTHROMYCIN AND BENZOYL PEROXIDE

AB		LYNE	5%;3%	A065385 001	Sep 18, 2015
AB		TOLMAR	5%;3%	A065112 001	Mar 29, 2004

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

AA		ANDA REPOSITORY	50MG	A090473 002	Sep 15, 2010
AA		EPIC PHARMA LLC	50MG	A090346 001	Dec 15, 2015
AA	!	KVK TECH	50MG	A090968 001	Jul 20, 2010
		ANDA REPOSITORY	25MG	A090473 001	Sep 15, 2010

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

BENZTROPINE MESYLATE

AP		FRESENIUS KABI USA	1MG/ML	A090233 001	Jul 28, 2009
AP		HIKMA FARMACEUTICA	1MG/ML	A090287 001	Aug 31, 2009
AP		NAVINTA LLC	1MG/ML	A091525 001	Feb 05, 2013

COGENTIN

AP	+ !	AKORN	1MG/ML	N012015 001	
-----------	------------	-------	---------------	--------------------	--

TABLET; ORAL

BENZTROPINE MESYLATE

AA	!	ASPEN GLOBAL INC	0.5MG	A204713 001	Apr 14, 2015
AA	!		1MG	A204713 002	Apr 14, 2015
AA	!		2MG	A204713 003	Apr 14, 2015
AA		EPIC PHARMA LLC	0.5MG	A072264 001	Feb 27, 1989
AA			1MG	A072265 001	Feb 27, 1989
AA			2MG	A072266 001	Feb 27, 1989
AA		INVAGEN PHARMS	0.5MG	A090294 001	Mar 29, 2010
AA			1MG	A090294 002	Mar 29, 2010
AA			2MG	A090294 003	Mar 29, 2010
AA		LEADING PHARMA LLC	0.5MG	A090168 001	Nov 28, 2012
AA			1MG	A090168 002	Nov 28, 2012
AA			2MG	A090168 003	Nov 28, 2012
AA		PLIVA	0.5MG	A089058 001	Aug 10, 1988
AA			1MG	A089059 001	Aug 10, 1988
AA			2MG	A089060 001	Aug 10, 1988
AA		VINTAGE	0.5MG	A040715 001	Aug 27, 2007
AA			1MG	A040715 002	Aug 27, 2007
AA			2MG	A040715 003	Aug 27, 2007

BENZYL PENICILLOYL POLYLYSINE

INJECTABLE; INJECTION

PRE-PEN

+ !	ALLERQUEST	60UMOLAR	N050114 001	
------------	------------	----------	-------------	--

BEPOTASTINE BESILATE

SOLUTION/DROPS; OPHTHALMIC

BEPREVE

+ !	BAUSCH AND LOMB INC	1.5%	N022288 001	Sep 08, 2009
------------	---------------------	------	-------------	--------------

BEROTRALSTAT HYDROCHLORIDE

CAPSULE; ORAL

ORLADEYO

+	BIOCRIST	EQ 110MG BASE	N214094 001	Dec 03, 2020
+ !		EQ 150MG BASE	N214094 002	Dec 03, 2020

BESIFLOXACIN HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

BESIVANCE

+ !	BAUSCH AND LOMB	EQ 0.6% BASE	N022308 001	May 28, 2009
------------	-----------------	--------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

BETAINE

FOR SOLUTION;ORAL

CYSTADANE

+! ORPHAN EUROPE

1GM/SCOOPFUL

N020576 001 Oct 25, 1996

BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATEAB AM REGENT3MG/ML;EQ 3MG BASE/MLA090747 001 Jul 31, 2009CELESTONE SOLUSPANAB +! MERCK SHARP DOHME3MG/ML;EQ 3MG BASE/MLN014602 001BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL

BETAMETHASONE DIPROPIONATEAB ACTAVIS MIDEQ 0.05% BASEA070885 001 Feb 03, 1987

ATLANTIC

AB COSETTEEQ 0.05% BASEA210217 001 Oct 12, 2018AB +! FOUGERA PHARMSEQ 0.05% BASEN019137 001 Jun 26, 1984AB TAROEQ 0.05% BASEA073552 001 Apr 30, 1992AB ZYDUS PHARMSEQ 0.05% BASEA208885 001 Jan 11, 2019

CREAM, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATEAB FOUGERA PHARMSEQ 0.05% BASEA076215 001 Dec 09, 2003AB ! GLENMARK GENERICSEQ 0.05% BASEA078930 001 Sep 23, 2008AB PERRIGO ISRAELEQ 0.05% BASEA076592 001 Dec 09, 2003AB TAROEQ 0.05% BASEA076543 001 Dec 09, 2003

GEL, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATEAB ! FOUGERA PHARMSEQ 0.05% BASEA075276 001 May 13, 2003AB TAROEQ 0.05% BASEA076508 001 Dec 02, 2003

LOTION; TOPICAL

BETAMETHASONE DIPROPIONATEAB AKORNEQ 0.05% BASEA209896 001 Feb 06, 2018AB COSETTEEQ 0.05% BASEA071467 001 Aug 10, 1987AB ! FOUGERA PHARMS INCEQ 0.05% BASEA070275 001 Aug 12, 1985AB PERRIGO NEW YORKEQ 0.05% BASEA072538 001 Jan 31, 1990

LOTION, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATEAB AKORNEQ 0.05% BASEA208849 001 Oct 11, 2019AB FOUGERA PHARMSEQ 0.05% BASEA077111 001 May 21, 2007AB ! TAROEQ 0.05% BASEA077477 001 May 21, 2007AB TELIGENTEQ 0.05% BASEA206389 001 Feb 13, 2018

OINTMENT; TOPICAL

BETAMETHASONE DIPROPIONATEAB ACTAVIS MIDEQ 0.05% BASEA071012 001 Feb 03, 1987

ATLANTIC

AB CADILAEQ 0.05% BASEA214048 001 Jul 14, 2020AB +! FOUGERA PHARMS INCEQ 0.05% BASEN019141 001 Sep 04, 1984AB TAROEQ 0.05% BASEA074271 001 Sep 15, 1994

OINTMENT, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATEAB ACTAVIS MIDEQ 0.05% BASEA074304 001 Aug 31, 1995

ATLANTIC

AB FOUGERA PHARMSEQ 0.05% BASEA075373 001 Jun 22, 1999AB LUPIN LTDEQ 0.05% BASEA209106 001 Dec 18, 2019AB TAROEQ 0.05% BASEA076753 001 Oct 12, 2004AB TELIGENTEQ 0.05% BASEA206118 001 Nov 09, 2017DIPROLENEAB +! MERCK SHARP DOHMEEQ 0.05% BASEN018741 001 Jul 27, 1983

SPRAY; TOPICAL

SERNIVO

+! ENCORE DERMAT

EQ 0.05% BASE/SPRAY

N208079 001 Feb 05, 2016

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

AEROSOL, FOAM; TOPICAL

ENSTILAR

+! LEO PHARMA AS

0.064%; 0.005%

N207589 001 Oct 16, 2015

CREAM; TOPICAL

WYNZORA

+! MC2

0.064%; 0.005%

N213422 001 Jul 20, 2020

OINTMENT; TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATEAB PERRIGO UK FINCO0.064%; 0.005%A200174 001 Dec 12, 2014

PRESCRIPTION DRUG PRODUCT LIST

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

OINTMENT; TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

AB	TOLMAR	<u>0.064%;0.005%</u>	<u>A201615</u>	<u>001</u>	Jan 14, 2013
-----------	--------	----------------------	----------------	------------	--------------

TACLONEX

AB	+! LEO PHARMA AS	<u>0.064%;0.005%</u>	<u>N021852</u>	<u>001</u>	Jan 09, 2006
-----------	------------------	----------------------	----------------	------------	--------------

SUSPENSION; TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

AB	TARO PHARMS	<u>0.064%;0.005%</u>	<u>A213269</u>	<u>001</u>	Sep 02, 2020
-----------	-------------	----------------------	----------------	------------	--------------

AB	TOLMAR	<u>0.064%;0.005%</u>	<u>A210765</u>	<u>001</u>	May 11, 2020
-----------	--------	----------------------	----------------	------------	--------------

CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE

AB	PERRIGO UK FINCO	<u>0.064%;0.005%</u>	<u>A212367</u>	<u>001</u>	Sep 11, 2020
-----------	------------------	----------------------	----------------	------------	--------------

TACLONEX

AB	+! LEO PHARMA AS	<u>0.064%;0.005%</u>	<u>N022185</u>	<u>001</u>	May 09, 2008
-----------	------------------	----------------------	----------------	------------	--------------

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB	ACTAVIS MID	<u>EQ 0.05% BASE;1%</u>	<u>A076002</u>	<u>001</u>	Aug 02, 2002
-----------	-------------	-------------------------	----------------	------------	--------------

AB	ATLANTIC				
-----------	----------	--	--	--	--

AB	FOUGERA PHARMS	<u>EQ 0.05% BASE;1%</u>	<u>A075502</u>	<u>001</u>	Jun 05, 2001
-----------	----------------	-------------------------	----------------	------------	--------------

AB	GLENMARK PHARMS	<u>EQ 0.05% BASE;1%</u>	<u>A202894</u>	<u>001</u>	Oct 30, 2015
-----------	-----------------	-------------------------	----------------	------------	--------------

AB	TARO	<u>EQ 0.05% BASE;1%</u>	<u>A075673</u>	<u>001</u>	May 29, 2001
-----------	------	-------------------------	----------------	------------	--------------

LOTRISONE

AB	+! MERCK SHARP DOHME	<u>EQ 0.05% BASE;1%</u>	<u>N018827</u>	<u>001</u>	Jul 10, 1984
-----------	----------------------	-------------------------	----------------	------------	--------------

LOTION; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB	FOUGERA PHARMS	<u>EQ 0.05% BASE;1%</u>	<u>A076516</u>	<u>001</u>	Jun 16, 2005
-----------	----------------	-------------------------	----------------	------------	--------------

AB	TARO	<u>EQ 0.05% BASE;1%</u>	<u>A076493</u>	<u>001</u>	Jul 28, 2004
-----------	------	-------------------------	----------------	------------	--------------

LOTRISONE

AB	+! MERCK SHARP DOHME	<u>EQ 0.05% BASE;1%</u>	<u>N020010</u>	<u>001</u>	Dec 08, 2000
-----------	----------------------	-------------------------	----------------	------------	--------------

BETAMETHASONE VALERATE

AEROSOL, FOAM; TOPICAL

BETAMETHASONE VALERATE

AB	PERRIGO UK FINCO	<u>0.12%</u>	<u>A078337</u>	<u>001</u>	Nov 26, 2012
-----------	------------------	--------------	----------------	------------	--------------

AB	RICONPHARMA LLC	<u>0.12%</u>	<u>A207144</u>	<u>001</u>	May 24, 2017
-----------	-----------------	--------------	----------------	------------	--------------

AB	TARO	<u>0.12%</u>	<u>A208204</u>	<u>001</u>	May 24, 2017
-----------	------	--------------	----------------	------------	--------------

LUXIQ

AB	+! MYLAN	<u>0.12%</u>	<u>N020934</u>	<u>001</u>	Feb 28, 1999
-----------	----------	--------------	----------------	------------	--------------

CREAM; TOPICAL

BETA-VAL

AB	COSETTE	<u>EQ 0.1% BASE</u>	<u>N018642</u>	<u>001</u>	Mar 24, 1983
-----------	---------	---------------------	----------------	------------	--------------

BETAMETHASONE VALERATE

AB	+! FOUGERA PHARMS INC	<u>EQ 0.1% BASE</u>	<u>N018861</u>	<u>001</u>	Aug 31, 1983
-----------	-----------------------	---------------------	----------------	------------	--------------

DERMABET

AB	TARO	<u>EQ 0.1% BASE</u>	<u>A072041</u>	<u>001</u>	Jan 06, 1988
-----------	------	---------------------	----------------	------------	--------------

VALNAC

AB	ACTAVIS MID	<u>EQ 0.1% BASE</u>	<u>A070050</u>	<u>001</u>	Oct 10, 1984
-----------	-------------	---------------------	----------------	------------	--------------

ATLANTIC

LOTION; TOPICAL

BETAMETHASONE VALERATE

AB	ANIMA	<u>EQ 0.1% BASE</u>	<u>A070052</u>	<u>001</u>	Jul 31, 1985
-----------	-------	---------------------	----------------	------------	--------------

AB	+! FOUGERA PHARMS INC	<u>EQ 0.1% BASE</u>	<u>N018866</u>	<u>001</u>	Aug 31, 1983
-----------	-----------------------	---------------------	----------------	------------	--------------

OINTMENT; TOPICAL

BETA-VAL

AB	COSETTE	<u>EQ 0.1% BASE</u>	<u>A070069</u>	<u>001</u>	Dec 19, 1985
-----------	---------	---------------------	----------------	------------	--------------

BETAMETHASONE VALERATE

AB	ACTAVIS MID	<u>EQ 0.1% BASE</u>	<u>A070051</u>	<u>001</u>	Oct 10, 1984
-----------	-------------	---------------------	----------------	------------	--------------

ATLANTIC

AB	+! FOUGERA PHARMS INC	<u>EQ 0.1% BASE</u>	<u>N018865</u>	<u>001</u>	Aug 31, 1983
-----------	-----------------------	---------------------	----------------	------------	--------------

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

AT	AKORN	<u>EQ 0.5% BASE</u>	<u>A075386</u>	<u>001</u>	Jun 30, 2000
-----------	-------	---------------------	----------------	------------	--------------

AT	MEDIMETRIKS PHARMS	<u>EQ 0.5% BASE</u>	<u>A075630</u>	<u>001</u>	Apr 12, 2001
-----------	--------------------	---------------------	----------------	------------	--------------

AT	WOCKHARDT	<u>EQ 0.5% BASE</u>	<u>A078694</u>	<u>001</u>	Nov 16, 2009
-----------	-----------	---------------------	----------------	------------	--------------

BETOPTIC

AT	+! SANDOZ INC	<u>EQ 0.5% BASE</u>	<u>N019270</u>	<u>001</u>	Aug 30, 1985
-----------	---------------	---------------------	----------------	------------	--------------

SUSPENSION/DROPS; OPHTHALMIC

BETOPTIC S

	+! NOVARTIS	<u>EQ 0.25% BASE</u>	<u>N019845</u>	<u>001</u>	Dec 29, 1989
--	-------------	----------------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

BETAXOLOL HYDROCHLORIDE

TABLET; ORAL

BETAXOLOL HYDROCHLORIDE

<u>AB</u>	!	EPIC PHARMA	<u>10MG</u>	<u>A075541</u>	<u>001</u>	Oct 22, 1999
<u>AB</u>	!		<u>20MG</u>	<u>A075541</u>	<u>002</u>	Oct 22, 1999
<u>AB</u>		KVK TECH	<u>10MG</u>	<u>A078962</u>	<u>001</u>	Jun 27, 2008
<u>AB</u>			<u>20MG</u>	<u>A078962</u>	<u>002</u>	Jun 27, 2008

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

<u>AA</u>	!	AMNEAL PHARM	<u>5MG</u>	<u>A040855</u>	<u>001</u>	Nov 21, 2007
<u>AA</u>	!		<u>10MG</u>	<u>A040855</u>	<u>002</u>	Nov 21, 2007
<u>AA</u>	!		<u>25MG</u>	<u>A040855</u>	<u>003</u>	Nov 21, 2007
<u>AA</u>	!		<u>50MG</u>	<u>A040855</u>	<u>004</u>	Nov 21, 2007
<u>AA</u>		DISCOVERY THERAP	<u>5MG</u>	<u>A040728</u>	<u>002</u>	Oct 26, 2007
<u>AA</u>			<u>10MG</u>	<u>A040728</u>	<u>003</u>	Oct 26, 2007
<u>AA</u>			<u>25MG</u>	<u>A040728</u>	<u>004</u>	Oct 26, 2007
<u>AA</u>			<u>50MG</u>	<u>A040728</u>	<u>001</u>	Oct 26, 2007
<u>AA</u>		LANNETT CO INC	<u>5MG</u>	<u>A040677</u>	<u>002</u>	Mar 27, 2008
<u>AA</u>			<u>10MG</u>	<u>A040677</u>	<u>003</u>	Mar 27, 2008
<u>AA</u>			<u>25MG</u>	<u>A040677</u>	<u>004</u>	Mar 27, 2008
<u>AA</u>			<u>50MG</u>	<u>A040677</u>	<u>001</u>	Mar 27, 2008
<u>AA</u>		UPSHER SMITH LABS	<u>5MG</u>	<u>A040633</u>	<u>001</u>	Jun 01, 2005
<u>AA</u>			<u>10MG</u>	<u>A040634</u>	<u>001</u>	Jun 01, 2005
<u>AA</u>			<u>25MG</u>	<u>A040635</u>	<u>001</u>	Jun 01, 2005
<u>AA</u>			<u>50MG</u>	<u>A040636</u>	<u>001</u>	Jun 01, 2005
<u>AA</u>		WOCKHARDT	<u>5MG</u>	<u>A040532</u>	<u>001</u>	Sep 29, 2003
<u>AA</u>			<u>50MG</u>	<u>A040518</u>	<u>001</u>	Sep 29, 2003
<u>DUVOID</u>						
<u>AA</u>		CHARTWELL RX	<u>10MG</u>	<u>A086262</u>	<u>001</u>	
<u>AA</u>			<u>25MG</u>	<u>A086263</u>	<u>001</u>	
<u>AA</u>			<u>50MG</u>	<u>A085882</u>	<u>003</u>	

BEXAROTENE

CAPSULE; ORAL

BEXAROTENE

<u>AB</u>		AMNEAL PHARMS NY	<u>75MG</u>	<u>A210105</u>	<u>001</u>	Sep 04, 2018
<u>AB</u>		ANI PHARMS INC	<u>75MG</u>	<u>A209861</u>	<u>001</u>	May 08, 2018
<u>AB</u>		BIONPHARMA INC	<u>75MG</u>	<u>A203174</u>	<u>001</u>	Aug 12, 2014
<u>AB</u>		HIKMA	<u>75MG</u>	<u>A203663</u>	<u>001</u>	Jun 16, 2020
<u>AB</u>		UPSHER SMITH LABS	<u>75MG</u>	<u>A209886</u>	<u>001</u>	Jul 25, 2018

TARGRETIN

<u>AB</u>	+	!	VALEANT LUXEMBOURG	<u>75MG</u>	<u>N021055</u>	<u>001</u>	Dec 29, 1999
GEL; TOPICAL							
TARGRETIN							
	+	!	BAUSCH	1%	N021056	001	Jun 28, 2000

BICALUTAMIDE

TABLET; ORAL

BICALUTAMIDE

<u>AB</u>		ACCORD HLTHCARE	<u>50MG</u>	<u>A078917</u>	<u>001</u>	Jul 06, 2009
<u>AB</u>		APOTEX INC	<u>50MG</u>	<u>A200274</u>	<u>001</u>	May 21, 2015
<u>AB</u>		KENTON	<u>50MG</u>	<u>A091011</u>	<u>001</u>	Jun 10, 2015
<u>AB</u>		SANDOZ	<u>50MG</u>	<u>A078575</u>	<u>001</u>	Jul 06, 2009
<u>AB</u>		SUN PHARM	<u>50MG</u>	<u>A079110</u>	<u>001</u>	Jul 06, 2009
<u>AB</u>		WATSON LABS TEVA	<u>50MG</u>	<u>A078634</u>	<u>001</u>	Aug 28, 2009
<u>AB</u>		ZYDUS PHARMS USA INC	<u>50MG</u>	<u>A079089</u>	<u>001</u>	Jul 06, 2009

CASODEX

<u>AB</u>	+	!	ANI PHARMS INC	<u>50MG</u>	<u>N020498</u>	<u>001</u>	Oct 04, 1995
-----------	---	---	----------------	-------------	----------------	------------	--------------

BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET; ORAL

BIKTARVY

	+	!	GILEAD SCIENCES INC	EQ 50MG BASE; 200MG; EQ 25MG BASE	N210251	001	Feb 07, 2018
--	---	---	---------------------	-----------------------------------	---------	-----	--------------

BIMATOPROST

IMPLANT; OPHTHALMIC

DURYSTA

	+	!	ALLERGAN INC	10MCG	N211911	001	Mar 04, 2020
--	---	---	--------------	-------	---------	-----	--------------

SOLUTION/DROPS; OPHTHALMIC

BIMATOPROST

<u>AT</u>			ALEMBIC PHARMS LTD	<u>0.03%</u>	<u>A210263</u>	<u>001</u>	Apr 12, 2019
<u>AT</u>			APOTEX INC	<u>0.03%</u>	<u>A090449</u>	<u>001</u>	Jul 20, 2015

PRESCRIPTION DRUG PRODUCT LIST

BIMATOPROST

SOLUTION/DROPS;OPHTHALMIC

BIMATOPROST

<u>AT</u>	GLAND PHARMA LTD	<u>0.03%</u>	<u>A210126</u>	<u>001</u>	Mar 22, 2019
<u>AT</u>	! LUPIN LTD	<u>0.03%</u>	<u>A203991</u>	<u>001</u>	Feb 20, 2015
<u>AT</u>	MICRO LABS	<u>0.03%</u>	<u>A202505</u>	<u>001</u>	Sep 08, 2020
<u>AT</u>	SANDOZ INC	<u>0.03%</u>	<u>A202565</u>	<u>001</u>	May 05, 2015
<u>AT</u>	SOMERSET THERAPS LLC	<u>0.03%</u>	<u>A207601</u>	<u>001</u>	Jun 19, 2019

LUMIGAN

+! ALLERGAN

0.01%

N022184 001 Aug 31, 2010

SOLUTION/DROPS;TOPICAL

BIMATOPROST

<u>AT</u>	AKORN	<u>0.03%</u>	<u>A203051</u>	<u>001</u>	Oct 09, 2018
<u>AT</u>	ALEMBIC PHARMS LTD	<u>0.03%</u>	<u>A210515</u>	<u>001</u>	Jan 21, 2020
<u>AT</u>	APOTEX INC	<u>0.03%</u>	<u>A201894</u>	<u>001</u>	Dec 01, 2014
<u>AT</u>	SANDOZ INC	<u>0.03%</u>	<u>A202719</u>	<u>001</u>	Apr 19, 2016

LATISSE

<u>AT</u>	+! ALLERGAN	<u>0.03%</u>	<u>N022369</u>	<u>001</u>	Dec 24, 2008
-----------	-------------	--------------	----------------	------------	--------------

BINIMETINIB

TABLET;ORAL

MEKTOVI

+! ARRAY BIOPHARMA INC 15MG

N210498 001 Jun 27, 2018

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

PYLERA

+! ALLERGAN 140MG;125MG;125MG

N050786 001 Sep 28, 2006

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE;ORAL

BISMUTH SUBSALICYLATE, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE

! AILEX PHARMS LLC 262.4MG, N/A, N/A;N/A, 250MG, N/A;N/A,
N/A, 500MG

A202584 001 Nov 30, 2018

BISOPROLOL FUMARATE

TABLET;ORAL

BISOPROLOL FUMARATE

<u>AB</u>	ALEMBIC LABS	<u>5MG</u>	<u>A204891</u>	<u>001</u>	Jan 11, 2017
<u>AB</u>		<u>10MG</u>	<u>A204891</u>	<u>002</u>	Jan 11, 2017
<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A077910</u>	<u>001</u>	Dec 27, 2006
<u>AB</u>		<u>10MG</u>	<u>A077910</u>	<u>002</u>	Dec 27, 2006
<u>AB</u>	FRONTIDA BIOPHARM	<u>5MG</u>	<u>A075474</u>	<u>001</u>	Oct 25, 2002
<u>AB</u>		<u>10MG</u>	<u>A075474</u>	<u>002</u>	Oct 25, 2002
<u>AB</u>	RUBICON	<u>5MG</u>	<u>A075643</u>	<u>001</u>	Nov 16, 2000
<u>AB</u>		<u>10MG</u>	<u>A075643</u>	<u>002</u>	Nov 16, 2000
<u>AB</u>	UNICHEM PHARMS (USA)	<u>5MG</u>	<u>A078635</u>	<u>001</u>	Aug 18, 2009
<u>AB</u>	!	<u>10MG</u>	<u>A078635</u>	<u>002</u>	Aug 18, 2009

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	EDENBRIDGE PHARMS	<u>2.5MG;6.25MG</u>	<u>A212678</u>	<u>001</u>	Jul 09, 2020
<u>AB</u>		<u>5MG;6.25MG</u>	<u>A212678</u>	<u>002</u>	Jul 09, 2020
<u>AB</u>		<u>10MG;6.25MG</u>	<u>A212678</u>	<u>003</u>	Jul 09, 2020
<u>AB</u>	MYLAN	<u>2.5MG;6.25MG</u>	<u>A075768</u>	<u>001</u>	Sep 25, 2000
<u>AB</u>		<u>5MG;6.25MG</u>	<u>A075768</u>	<u>002</u>	Sep 25, 2000
<u>AB</u>		<u>10MG;6.25MG</u>	<u>A075768</u>	<u>003</u>	Sep 25, 2000
<u>AB</u>	SANDOZ	<u>2.5MG;6.25MG</u>	<u>A075579</u>	<u>001</u>	Sep 25, 2000
<u>AB</u>		<u>5MG;6.25MG</u>	<u>A075579</u>	<u>002</u>	Sep 25, 2000
<u>AB</u>		<u>10MG;6.25MG</u>	<u>A075579</u>	<u>003</u>	Sep 25, 2000
<u>AB</u>	UNICHEM	<u>2.5MG;6.25MG</u>	<u>A079106</u>	<u>001</u>	Jul 28, 2010
<u>AB</u>		<u>5MG;6.25MG</u>	<u>A079106</u>	<u>002</u>	Jul 28, 2010
<u>AB</u>		<u>10MG;6.25MG</u>	<u>A079106</u>	<u>003</u>	Jul 28, 2010

ZIAC

<u>AB</u>	+ TEVA BRANDED PHARM	<u>2.5MG;6.25MG</u>	<u>N020186</u>	<u>003</u>	Mar 26, 1993
<u>AB</u>	+	<u>5MG;6.25MG</u>	<u>N020186</u>	<u>001</u>	Mar 26, 1993
<u>AB</u>	+!	<u>10MG;6.25MG</u>	<u>N020186</u>	<u>002</u>	Mar 26, 1993

PRESCRIPTION DRUG PRODUCT LIST

BIVALIRUDIN

INJECTABLE; INTRAVENOUS

ANGIOMAX

<u>AP</u>	<u>+!</u>	<u>SANDOZ INC</u>	<u>250MG/VIAL</u>	<u>N020873</u>	<u>001</u>	Dec 15, 2000
-----------	-----------	-------------------	-------------------	----------------	------------	--------------

BIVALIRUDIN

<u>AP</u>		<u>ACCORD HLTHCARE</u>	<u>250MG/VIAL</u>	<u>A206551</u>	<u>001</u>	Nov 22, 2017
<u>AP</u>		<u>AUROBINDO PHARMA LTD</u>	<u>250MG/VIAL</u>	<u>A205962</u>	<u>001</u>	Jul 27, 2018
<u>AP</u>		<u>DR REDDYS LABS LTD</u>	<u>250MG/VIAL</u>	<u>A201577</u>	<u>001</u>	May 26, 2017
<u>AP</u>		<u>FRESENIUS KABI USA</u>	<u>250MG/VIAL</u>	<u>A090189</u>	<u>001</u>	Oct 28, 2016
<u>AP</u>		<u>HONG KONG</u>	<u>250MG/VIAL</u>	<u>A091602</u>	<u>001</u>	Jul 16, 2018
<u>AP</u>		<u>HOSPIRA INC</u>	<u>250MG/VIAL</u>	<u>A090811</u>	<u>001</u>	Jul 14, 2015
<u>AP</u>			<u>250MG/VIAL</u>	<u>A090816</u>	<u>001</u>	Jul 14, 2015
<u>AP</u>		<u>MYLAN INSTITUTIONAL</u>	<u>250MG/VIAL</u>	<u>A202471</u>	<u>001</u>	Jun 01, 2018
<u>AP</u>		<u>SHUANGCHENG</u>	<u>250MG/VIAL</u>	<u>A210031</u>	<u>001</u>	Oct 23, 2019

SOLUTION; INTRAVENOUS

ANGIOMAX RTU

<u>+!</u>	<u>MAIA PHARMS INC</u>	<u>250MG/50ML (5MG/ML)</u>	<u>N211215</u>	<u>001</u>	Jul 25, 2019
-----------	------------------------	----------------------------	----------------	------------	--------------

BIVALIRUDIN IN 0.9% SODIUM CHLORIDE

<u>+!</u>	<u>BAXTER HLTHCARE CORP</u>	<u>250MG/50ML (5MG/ML)</u>	<u>N208374</u>	<u>001</u>	Dec 21, 2017
-----------	-----------------------------	----------------------------	----------------	------------	--------------

<u>+!</u>		<u>500MG/100ML (5MG/ML)</u>	<u>N208374</u>	<u>002</u>	Dec 21, 2017
-----------	--	-----------------------------	----------------	------------	--------------

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

BLEOMYCIN SULFATE

<u>AP</u>		<u>CIPLA</u>	<u>EQ 15 UNITS BASE/VIAL</u>	<u>A209439</u>	<u>001</u>	Mar 11, 2019
<u>AP</u>	<u>!</u>	<u>FRESENIUS KABI USA</u>	<u>EQ 15 UNITS BASE/VIAL</u>	<u>A065185</u>	<u>001</u>	Jan 28, 2008
<u>AP</u>	<u>!</u>		<u>EQ 30 UNITS BASE/VIAL</u>	<u>A065185</u>	<u>002</u>	Jan 28, 2008
<u>AP</u>		<u>HOSPIRA</u>	<u>EQ 15 UNITS BASE/VIAL</u>	<u>A065031</u>	<u>001</u>	Mar 10, 2000
<u>AP</u>			<u>EQ 30 UNITS BASE/VIAL</u>	<u>A065031</u>	<u>002</u>	Mar 10, 2000
<u>AP</u>		<u>MEITHEAL</u>	<u>EQ 15 UNITS BASE/VIAL</u>	<u>A205030</u>	<u>001</u>	Apr 20, 2018
<u>AP</u>			<u>EQ 30 UNITS BASE/VIAL</u>	<u>A205030</u>	<u>002</u>	Apr 20, 2018
<u>AP</u>		<u>TEVA PHARMS USA</u>	<u>EQ 15 UNITS BASE/VIAL</u>	<u>A065033</u>	<u>001</u>	Jun 27, 2000
<u>AP</u>			<u>EQ 30 UNITS BASE/VIAL</u>	<u>A065033</u>	<u>002</u>	Jun 27, 2000
<u>AP</u>		<u>WEST-WARD PHARMS INT</u>	<u>EQ 15 UNITS BASE/VIAL</u>	<u>A065042</u>	<u>002</u>	Oct 17, 2001
<u>AP</u>			<u>EQ 30 UNITS BASE/VIAL</u>	<u>A065042</u>	<u>001</u>	Oct 17, 2001

BORTEZOMIB

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

VELCADE

<u>+!</u>	<u>MILLENNIUM PHARMS</u>	<u>3.5MG/VIAL</u>	<u>N021602</u>	<u>001</u>	May 13, 2003
-----------	--------------------------	-------------------	----------------	------------	--------------

POWDER; INTRAVENOUS

BORTEZOMIB

	<u>DR REDDYS LABS LTD</u>	<u>3.5MG/VIAL</u>	<u>N206927</u>	<u>001</u>	Oct 04, 2019
--	---------------------------	-------------------	----------------	------------	--------------

	<u>FRESENIUS KABI USA</u>	<u>3.5MG/VIAL</u>	<u>N205004</u>	<u>001</u>	Nov 06, 2017
--	---------------------------	-------------------	----------------	------------	--------------

BOSENTAN

TABLET; ORAL

BOSENTAN

<u>AB</u>		<u>AMNEAL PHARMS CO</u>	<u>62.5MG</u>	<u>A209742</u>	<u>001</u>	Apr 26, 2019
<u>AB</u>			<u>125MG</u>	<u>A209742</u>	<u>002</u>	Apr 26, 2019
<u>AB</u>		<u>HIKMA</u>	<u>62.5MG</u>	<u>A208695</u>	<u>001</u>	Apr 26, 2019
<u>AB</u>			<u>125MG</u>	<u>A208695</u>	<u>002</u>	Apr 26, 2019
<u>AB</u>		<u>NATCO PHARMA LTD</u>	<u>62.5MG</u>	<u>A206987</u>	<u>001</u>	Apr 26, 2019
<u>AB</u>			<u>125MG</u>	<u>A206987</u>	<u>002</u>	Apr 26, 2019
<u>AB</u>		<u>PAR PHARM INC</u>	<u>62.5MG</u>	<u>A205699</u>	<u>001</u>	Apr 26, 2019
<u>AB</u>			<u>125MG</u>	<u>A205699</u>	<u>002</u>	Apr 26, 2019
<u>AB</u>		<u>SUN PHARM</u>	<u>62.5MG</u>	<u>A209324</u>	<u>001</u>	Apr 26, 2019
<u>AB</u>			<u>125MG</u>	<u>A209324</u>	<u>002</u>	Apr 26, 2019
<u>AB</u>		<u>WATSON LABS INC</u>	<u>62.5MG</u>	<u>A207110</u>	<u>001</u>	Apr 26, 2019
<u>AB</u>			<u>125MG</u>	<u>A207110</u>	<u>002</u>	Apr 26, 2019
<u>AB</u>		<u>ZYDUS PHARMS</u>	<u>62.5MG</u>	<u>A207760</u>	<u>001</u>	Apr 26, 2019
<u>AB</u>			<u>125MG</u>	<u>A207760</u>	<u>002</u>	Apr 26, 2019

TRACLEER

<u>AB</u>	<u>+</u>	<u>ACTELION PHARMS LTD</u>	<u>62.5MG</u>	<u>N021290</u>	<u>001</u>	Nov 20, 2001
<u>AB</u>	<u>+!</u>		<u>125MG</u>	<u>N021290</u>	<u>002</u>	Nov 20, 2001

TABLET, FOR SUSPENSION; ORAL

TRACLEER

<u>+!</u>	<u>ACTELION PHARMS</u>	<u>32MG</u>	<u>N209279</u>	<u>001</u>	Sep 05, 2017
-----------	------------------------	-------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

BOSUTINIB MONOHYDRATE

TABLET; ORAL

BOSULIF

+	!	PF PRISM CV	EQ 100MG BASE	N203341 001	Sep 04, 2012
+			EQ 400MG BASE	N203341 003	Oct 27, 2017
+			EQ 500MG BASE	N203341 002	Sep 04, 2012

BREMELANOTIDE ACETATE

SOLUTION; SUBCUTANEOUS

VYLEESI (AUTOINJECTOR)

+	!	PALATIN TECHNOLOGIES	EQ 1.75MG BASE/0.3ML (EQ 1.75MG BASE/0.3 ML)	N210557 001	Jun 21, 2019
---	---	----------------------	--	-------------	--------------

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE

!		BRECKENRIDGE	50MG/ML	A204386 001	Dec 21, 2018
---	--	--------------	---------	-------------	--------------

BREXANOLONE

SOLUTION; INTRAVENOUS

ZULRESSO

+	!	SAGE THERAP	100MG/20ML (5MG/ML)	N211371 001	Jun 17, 2019
---	---	-------------	---------------------	-------------	--------------

BREXPIPIRAZOLE

TABLET; ORAL

REXULTI

+		OTSUKA PHARM CO LTD	0.25MG	N205422 001	Jul 10, 2015
+			0.5MG	N205422 002	Jul 10, 2015
+			1MG	N205422 003	Jul 10, 2015
+	!		2MG	N205422 004	Jul 10, 2015
+			3MG	N205422 005	Jul 10, 2015
+			4MG	N205422 006	Jul 10, 2015

BRIGATINIB

TABLET; ORAL

ALUNBRIG

+		ARIAD	30MG	N208772 001	Apr 28, 2017
+			90MG	N208772 002	Apr 28, 2017
+	!		180MG	N208772 003	Oct 02, 2017

BRILLIANT BLUE G

SOLUTION; OPHTHALMIC

TISSUEBLUE

+	!	DUTCH OPHTHALMIC	0.025%	N209569 001	Dec 20, 2019
---	---	------------------	--------	-------------	--------------

BRIMONIDINE TARTRATE

GEL; TOPICAL

MIRVASO

+	!	GALDERMA LABS LP	EQ 0.33% BASE	N204708 001	Aug 23, 2013
---	---	------------------	---------------	-------------	--------------

SOLUTION/DROPS; OPHTHALMIC

ALPHAGAN P

AT	+	!	ALLERGAN	0.15%	N021262 001	Mar 16, 2001
-----------	---	---	----------	--------------	--------------------	--------------

BRIMONIDINE TARTRATE

AT			AKORN	0.2%	A076439 001	Mar 14, 2006
-----------	--	--	-------	-------------	--------------------	--------------

AT	!		BAUSCH AND LOMB	0.2%	A076260 001	May 28, 2003
-----------	---	--	-----------------	-------------	--------------------	--------------

AT			INDOCO	0.2%	A091691 001	Nov 18, 2014
-----------	--	--	--------	-------------	--------------------	--------------

AT			SANDOZ INC	0.2%	A076254 001	Sep 16, 2003
-----------	--	--	------------	-------------	--------------------	--------------

AT				0.2%	A078075 001	Jan 30, 2008
-----------	--	--	--	-------------	--------------------	--------------

AT			SOMERSET THERAPS LLC	0.2%	A208992 001	Mar 11, 2019
-----------	--	--	----------------------	-------------	--------------------	--------------

QOLIANA

AT	+	!	SANDOZ INC	0.15%	N021764 001	May 22, 2006
-----------	---	---	------------	--------------	--------------------	--------------

ALPHAGAN P

+	!	ALLERGAN	0.1%	N021770 001	Aug 19, 2005
---	---	----------	------	-------------	--------------

BRIMONIDINE TARTRATE; BRINZOLAMIDE

SUSPENSION/DROPS; OPHTHALMIC

SIMBRINZA

+	!	NOVARTIS	0.2%; 1%	N204251 001	Apr 19, 2013
---	---	----------	----------	-------------	--------------

BRIMONIDINE TARTRATE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

COMBIGAN

+	!	ALLERGAN	0.2%; EQ 0.5% BASE	N021398 001	Oct 30, 2007
---	---	----------	--------------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

BRINZOLAMIDE

SUSPENSION/DROPS;OPHTHALMIC

AZOPT**AB** +! NOVARTIS **1%** **N020816 001** Apr 01, 1998BRINZOLAMIDE**AB** WATSON LABS INC **1%** **A209406 001** Nov 27, 2020BRIVARACETAM

SOLUTION;INTRAVENOUS

BRIVIACT

+! UCB INC 50MG/5ML (10MG/ML) N205837 001 May 12, 2016

SOLUTION;ORAL

BRIVIACT

+! UCB INC 10MG/ML N205838 001 May 12, 2016

TABLET;ORAL

BRIVIACT

+ UCB INC 10MG N205836 001 May 12, 2016

+ 25MG N205836 002 May 12, 2016

+ 50MG N205836 003 May 12, 2016

+ 75MG N205836 004 May 12, 2016

+! 100MG N205836 005 May 12, 2016

BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC

BROMFENAC SODIUM**AT2** ! AKORN **EQ 0.09% ACID** **A203395 001** Jan 22, 2014**AT2** ALEMBIC PHARMS LTD **EQ 0.09% ACID** **A210560 001** Jun 21, 2019**AT2** GLAND PHARMA LTD **EQ 0.09% ACID** **A211029 001** Mar 17, 2020

BROMSITE

+! SUN PHARMA GLOBAL EQ 0.075% ACID N206911 001 Apr 08, 2016

PROLENSA

+! BAUSCH AND LOMB EQ 0.07% ACID N203168 001 Apr 05, 2013

BROMOCRIPTINE MESYLATE

CAPSULE;ORAL

BROMOCRIPTINE MESYLATE**AB** ! MYLAN **EQ 5MG BASE** **A077226 001** Apr 04, 2005**AB** ZYDUS PHARMS USA **EQ 5MG BASE** **A078899 001** Jul 30, 2008
INCPARLODEL**AB** + US PHARMS HOLDINGS **EQ 5MG BASE** **N017962 002** Mar 01, 1982

I

TABLET;ORAL

BROMOCRIPTINE MESYLATE**AB** ! PADDOCK LLC **EQ 2.5MG BASE** **A077646 001** Oct 01, 2008**AB** SANDOZ INC **EQ 2.5MG BASE** **A074631 001** Jan 13, 1998PARLODEL**AB** + US PHARMS HOLDINGS **EQ 2.5MG BASE** **N017962 001**

I

CYCLOSET

+! VEROSCIENCE EQ 0.8MG BASE N020866 001 May 05, 2009

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP;ORAL

BROMFED-DM**AA** ! WOCKHARDT BIO AG **2MG/5ML;10MG/5ML;30MG/5ML** **A088811 001** Jun 07, 1985BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE**AA** ACELLA **2MG/5ML;10MG/5ML;30MG/5ML** **A203375 001** Sep 20, 2016**AA** ALKEM LABS LTD **2MG/5ML;10MG/5ML;30MG/5ML** **A210647 001** Jul 14, 2020**AA** BRECKENRIDGE **2MG/5ML;10MG/5ML;30MG/5ML** **A203997 001** Sep 30, 2020**AA** EYWA **2MG/5ML;10MG/5ML;30MG/5ML** **A211170 001** Jun 16, 2020**AA** LANNETT CO INC **2MG/5ML;10MG/5ML;30MG/5ML** **A213125 001** Apr 17, 2020**AA** MAYNE PHARMA INC **2MG/5ML;10MG/5ML;30MG/5ML** **A207676 001** Dec 04, 2018**AA** PADDOCK LABS LLC **2MG/5ML;10MG/5ML;30MG/5ML** **A205292 001** Jul 15, 2014**AA** RHODES PHARMS **2MG/5ML;10MG/5ML;30MG/5ML** **A202955 001** Nov 05, 2020**AA** TARO **2MG/5ML;10MG/5ML;30MG/5ML** **A205112 001** Feb 27, 2017BUDESONIDE

AEROSOL, FOAM;RECTAL

UCERIS

+! SALIX 2MG/ACTUATION N205613 001 Oct 07, 2014

CAPSULE;ORAL

BUDESONIDE**AB** AMNEAL PHARMS **3MG** **A206200 001** Jul 31, 2017**AB** BARR LABS DIV TEVA **3MG** **A090379 001** Apr 02, 2014

PRESCRIPTION DRUG PRODUCT LIST

BUDESONIDE

CAPSULE; ORAL

BUDESONIDE

<u>AB</u>	MAYNE PHARMA	<u>3MG</u>	<u>A206623</u>	<u>001</u>	Apr 08, 2016
<u>AB</u>	MYLAN	<u>3MG</u>	<u>A090410</u>	<u>001</u>	May 16, 2011
<u>AB</u>	RISING	<u>3MG</u>	<u>A207367</u>	<u>001</u>	Apr 07, 2017
<u>AB</u>	SCIECURE PHARMA INC	<u>3MG</u>	<u>A209041</u>	<u>001</u>	Sep 28, 2017
<u>AB</u>	ZYDUS PHARMS	<u>3MG</u>	<u>A206134</u>	<u>001</u>	May 04, 2017

ENTOCORT EC

<u>AB</u>	+!	PERRIGO PHARMA INTL	<u>3MG</u>	<u>N021324</u>	<u>001</u>	Oct 02, 2001
-----------	----	---------------------	------------	----------------	------------	--------------

CAPSULE, EXTENDED RELEASE; ORAL

ORTIKOS

	+	SUN PHARMA GLOBAL	6MG	N211929	001	Jun 13, 2019
	+	!	9MG	N211929	002	Jun 13, 2019

POWDER, METERED; INHALATION

PULMICORT FLEXHALER

	+	ASTRAZENECA	0.08MG/INH	N021949	001	Jul 12, 2006
	+	!	0.16MG/INH	N021949	002	Jul 12, 2006

SUSPENSION; INHALATION

BUDESONIDE

<u>AN</u>		CIPLA	<u>0.25MG/2ML</u>	<u>A205710</u>	<u>001</u>	Nov 16, 2017
<u>AN</u>			<u>0.5MG/2ML</u>	<u>A205710</u>	<u>002</u>	Nov 16, 2017
<u>AN</u>			<u>1MG/2ML</u>	<u>A205710</u>	<u>003</u>	Nov 16, 2017
<u>AN</u>		IMPAX LABS INC	<u>0.25MG/2ML</u>	<u>A078404</u>	<u>001</u>	Jul 31, 2012
<u>AN</u>			<u>0.5MG/2ML</u>	<u>A078404</u>	<u>002</u>	Jul 31, 2012
<u>AN</u>		LUPIN	<u>0.5MG/2ML</u>	<u>A210897</u>	<u>001</u>	Nov 09, 2018
<u>AN</u>		NEPHRON	<u>0.25MG/2ML</u>	<u>A078202</u>	<u>001</u>	Mar 30, 2009
<u>AN</u>			<u>0.5MG/2ML</u>	<u>A078202</u>	<u>002</u>	Mar 30, 2009
<u>AN</u>		SANDOZ INC	<u>0.25MG/2ML</u>	<u>A201966</u>	<u>003</u>	Sep 27, 2013
<u>AN</u>			<u>0.5MG/2ML</u>	<u>A201966</u>	<u>002</u>	Sep 27, 2013
<u>AN</u>			<u>1MG/2ML</u>	<u>A201966</u>	<u>001</u>	Sep 27, 2013
<u>AN</u>		TEVA PHARMS	<u>0.25MG/2ML</u>	<u>A077519</u>	<u>001</u>	Nov 18, 2008
<u>AN</u>			<u>0.5MG/2ML</u>	<u>A077519</u>	<u>002</u>	Nov 18, 2008
<u>AN</u>		TEVA PHARMS USA	<u>1MG/2ML</u>	<u>A204548</u>	<u>001</u>	Mar 08, 2016

PULMICORT RESPULES

<u>AN</u>	+	ASTRAZENECA PHARMS	<u>0.25MG/2ML</u>	<u>N020929</u>	<u>001</u>	Aug 08, 2000
<u>AN</u>	+		<u>0.5MG/2ML</u>	<u>N020929</u>	<u>002</u>	Aug 08, 2000
<u>AN</u>	+	!	<u>1MG/2ML</u>	<u>N020929</u>	<u>003</u>	Aug 08, 2000

TABLET, EXTENDED RELEASE; ORAL

BUDESONIDE

<u>AB</u>		ACTAVIS LABS FL INC	<u>9MG</u>	<u>A205457</u>	<u>001</u>	Jul 03, 2018
<u>AB</u>		MYLAN	<u>9MG</u>	<u>A208851</u>	<u>001</u>	Sep 17, 2020

UCERIS

<u>AB</u>	+	!	SALIX	<u>9MG</u>	<u>N203634</u>	<u>001</u>	Jan 14, 2013
-----------	---	---	-------	------------	----------------	------------	--------------

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

AEROSOL, METERED; INHALATION

SYMBICORT

	+	!	ASTRAZENECA	0.08MG/INH; 0.0045MG/INH	N021929	001	Jul 21, 2006
	+	!		0.16MG/INH; 0.0045MG/INH	N021929	002	Jul 21, 2006

BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE

AEROSOL, METERED; INHALATION

BREZTRI AEROSPHERE

	+	!	ASTRAZENECA AB	0.16MG/INH; 0.0048MG/INH; 0.009MG/INH	N212122	001	Jul 23, 2020
--	---	---	----------------	---------------------------------------	---------	-----	--------------

BUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE

<u>AP</u>		HOSPIRA	<u>0.25MG/ML</u>	<u>A074332</u>	<u>001</u>	Oct 31, 1994
<u>AP</u>	!	WEST-WARD PHARMS INT	<u>0.25MG/ML</u>	<u>A079196</u>	<u>001</u>	Apr 30, 2008

TABLET; ORAL

BUMETANIDE

<u>AB</u>		AMNEAL PHARMS CO	<u>0.5MG</u>	<u>A209724</u>	<u>001</u>	Oct 18, 2017
<u>AB</u>			<u>1MG</u>	<u>A209724</u>	<u>002</u>	Oct 18, 2017
<u>AB</u>			<u>2MG</u>	<u>A209724</u>	<u>003</u>	Oct 18, 2017
<u>AB</u>		HERITAGE PHARMA	<u>0.5MG</u>	<u>A074225</u>	<u>001</u>	Apr 24, 1995
<u>AB</u>			<u>1MG</u>	<u>A074225</u>	<u>002</u>	Apr 24, 1995
<u>AB</u>			<u>2MG</u>	<u>A074225</u>	<u>003</u>	Apr 24, 1995
<u>AB</u>		RISING	<u>0.5MG</u>	<u>A212019</u>	<u>001</u>	Dec 12, 2019
<u>AB</u>			<u>1MG</u>	<u>A212019</u>	<u>002</u>	Dec 12, 2019
<u>AB</u>			<u>2MG</u>	<u>A212019</u>	<u>003</u>	Dec 12, 2019
<u>AB</u>		SANDOZ	<u>0.5MG</u>	<u>A074700</u>	<u>001</u>	Nov 21, 1996

PRESCRIPTION DRUG PRODUCT LIST

BUMETANIDE

TABLET; ORAL

BUMETANIDE

<u>AB</u>		<u>1MG</u>	<u>A074700 002</u>	Nov 21, 1996
<u>AB</u>	!	<u>2MG</u>	<u>A074700 003</u>	Nov 21, 1996
<u>AB</u>	UPSHER SMITH LABS	<u>0.5MG</u>	<u>A209916 001</u>	Jan 23, 2018
<u>AB</u>		<u>1MG</u>	<u>A209916 002</u>	Jan 23, 2018
<u>AB</u>		<u>2MG</u>	<u>A209916 003</u>	Jan 23, 2018
<u>AB</u>	ZYDUS PHARMS	<u>0.5MG</u>	<u>A202900 001</u>	Apr 30, 2018
<u>AB</u>		<u>1MG</u>	<u>A202900 002</u>	Apr 30, 2018
<u>AB</u>		<u>2MG</u>	<u>A202900 003</u>	Apr 30, 2018

BUMEX

<u>AB</u>	+	VALIDUS PHARMS	<u>0.5MG</u>	<u>N018225 002</u>	Feb 28, 1983
<u>AB</u>	+		<u>1MG</u>	<u>N018225 001</u>	Feb 28, 1983
<u>AB</u>	+		<u>2MG</u>	<u>N018225 003</u>	Jun 14, 1985

BUPIVACAINE

INJECTABLE, LIPOSOMAL; INJECTION

EXPAREL

+	!	PACIRA PHARMS INC	133MG/10ML (13.3MG/ML)	N022496 001	Oct 28, 2011
+	!		266MG/20ML (13.3MG/ML)	N022496 002	Oct 28, 2011

BUPIVACAINE HYDROCHLORIDE

IMPLANT; IMPLANTATION

XARACOLL

+	!	INNOCOLL PHARMS	100MG	N209511 001	Aug 28, 2020
---	---	-----------------	-------	-------------	--------------

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE

<u>AP</u>		AUROBINDO PHARMA LTD	<u>0.25%</u>	<u>A207183 001</u>	May 13, 2016
<u>AP</u>			<u>0.5%</u>	<u>A207183 002</u>	May 13, 2016
<u>AP</u>		HOSPIRA	<u>0.25%</u>	<u>A070583 001</u>	Feb 17, 1987
<u>AP</u>			<u>0.25%</u>	<u>A070586 001</u>	Mar 03, 1987
<u>AP</u>			<u>0.25%</u>	<u>A070590 001</u>	Feb 17, 1987
<u>AP</u>			<u>0.25%</u>	<u>N018053 002</u>	
<u>AP</u>			<u>0.5%</u>	<u>A070584 001</u>	Feb 17, 1986
<u>AP</u>			<u>0.5%</u>	<u>A070597 001</u>	Mar 03, 1987
<u>AP</u>			<u>0.5%</u>	<u>A070609 001</u>	Mar 03, 1987
<u>AP</u>			<u>0.5%</u>	<u>N018053 001</u>	
<u>AP</u>			<u>0.75%</u>	<u>A070585 001</u>	Mar 03, 1987
<u>AP</u>			<u>0.75%</u>	<u>N018053 003</u>	

BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>		AUROBINDO PHARMA LTD	<u>0.25%</u>	<u>A203895 001</u>	Nov 05, 2013
<u>AP</u>			<u>0.5%</u>	<u>A203895 002</u>	Nov 05, 2013
<u>AP</u>			<u>0.75%</u>	<u>A203895 003</u>	Nov 05, 2013

MARCAINE HYDROCHLORIDE

<u>AP</u>	+	HOSPIRA	<u>0.25%</u>	<u>N016964 001</u>	
<u>AP</u>	+		<u>0.5%</u>	<u>N016964 006</u>	

MARCAINE HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	+	HOSPIRA	<u>0.25%</u>	<u>N016964 012</u>	
<u>AP</u>	+		<u>0.5%</u>	<u>N016964 005</u>	
<u>AP</u>	+		<u>0.75%</u>	<u>N016964 009</u>	

SENSORCAINE

<u>AP</u>		FRESENIUS KABI USA	<u>0.25%</u>	<u>A070552 001</u>	May 21, 1986
<u>AP</u>			<u>0.25%</u>	<u>N018304 001</u>	
<u>AP</u>			<u>0.5%</u>	<u>A070553 001</u>	May 21, 1986
<u>AP</u>			<u>0.5%</u>	<u>N018304 002</u>	
<u>AP</u>			<u>0.75%</u>	<u>A070554 001</u>	May 21, 1986
<u>AP</u>			<u>0.75%</u>	<u>N018304 003</u>	

INJECTABLE; SPINAL

BUPIVACAINE HYDROCHLORIDE

<u>AP</u>		B BRAUN MEDICAL INC	<u>0.75%</u>	<u>A209087 001</u>	Apr 02, 2019
<u>AP</u>		BAXTER HLTHCARE CORP	<u>0.75%</u>	<u>A207266 001</u>	Jul 25, 2016
<u>AP</u>		HOSPIRA	<u>0.75%</u>	<u>A071810 001</u>	Dec 11, 1987
<u>AP</u>		HUONS	<u>0.75%</u>	<u>A212822 001</u>	Dec 30, 2019

MARCAINE

<u>AP</u>	+	HOSPIRA	<u>0.75%</u>	<u>N018692 001</u>	May 04, 1984
-----------	---	---------	--------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

<u>AP</u>	!	HOSPIRA	<u>0.5%;0.005MG/ML</u>	<u>A071168 001</u>	Jun 16, 1988
<u>AP</u>			<u>0.5%;0.005MG/ML</u>	<u>A071170 001</u>	Jun 16, 1988
	!		0.25%;0.005MG/ML	A071165 001	Jun 16, 1988
			0.25%;0.005MG/ML	A071167 001	Jun 16, 1988

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

MARCAINE HYDROCHLORIDE W/ EPINEPHRINE

<u>AP</u>	+	!	HOSPIRA	<u>0.25%;0.0091MG/ML</u>	<u>N016964 004</u>
<u>AP</u>	+	!		<u>0.5%;0.0091MG/ML</u>	<u>N016964 008</u>

MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE

<u>AP</u>	+	!	HOSPIRA	<u>0.25%;0.0091MG/ML</u>	<u>N016964 013</u>
<u>AP</u>	+	!		<u>0.5%;0.0091MG/ML</u>	<u>N016964 007</u>
<u>AP</u>	+	!		<u>0.75%;0.0091MG/ML</u>	<u>N016964 010</u>

SENSORCAINE

<u>AP</u>			FRESENIUS KABI USA	<u>0.25%;0.0091MG/ML</u>	<u>A070966 001</u>	Oct 13, 1987
<u>AP</u>				<u>0.25%;0.0091MG/ML</u>	<u>A070967 001</u>	Oct 13, 1987
<u>AP</u>				<u>0.5%;0.0091MG/ML</u>	<u>A070968 001</u>	Oct 13, 1987
<u>AP</u>				<u>0.5%;0.0091MG/ML</u>	<u>N018304 004</u>	Sep 02, 1983
<u>AP</u>				<u>0.75%;0.0091MG/ML</u>	<u>N018304 005</u>	Sep 02, 1983
			BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE			
	!		SEPTODONT	0.5%;0.0091MG/ML	A077250 001	Sep 27, 2006

BUPRENORPHINE

FILM, EXTENDED RELEASE; TRANSDERMAL

BUPRENORPHINE

<u>AB</u>			AMNEAL	<u>5MCG/HR</u>	<u>A211586 001</u>	Apr 14, 2020
<u>AB</u>				<u>7.5MCG/HR</u>	<u>A211586 002</u>	Apr 14, 2020
<u>AB</u>				<u>10MCG/HR</u>	<u>A211586 003</u>	Apr 14, 2020
<u>AB</u>				<u>15MCG/HR</u>	<u>A211586 004</u>	Apr 14, 2020
<u>AB</u>				<u>20MCG/HR</u>	<u>A211586 005</u>	Apr 14, 2020
<u>AB</u>			WATSON LABS TEVA	<u>5MCG/HR</u>	<u>A204937 001</u>	Nov 20, 2018
<u>AB</u>				<u>10MCG/HR</u>	<u>A204937 002</u>	Nov 20, 2018
<u>AB</u>				<u>15MCG/HR</u>	<u>A204937 003</u>	Nov 20, 2018
<u>AB</u>				<u>20MCG/HR</u>	<u>A204937 004</u>	Nov 20, 2018

BUTRANS

<u>AB</u>	+		PURDUE PHARMA LP	<u>5MCG/HR</u>	<u>N021306 001</u>	Jun 30, 2010
<u>AB</u>	+			<u>7.5MCG/HR</u>	<u>N021306 005</u>	Jun 30, 2014
<u>AB</u>	+			<u>10MCG/HR</u>	<u>N021306 002</u>	Jun 30, 2010
<u>AB</u>	+			<u>15MCG/HR</u>	<u>N021306 004</u>	Jul 25, 2013
<u>AB</u>	+	!		<u>20MCG/HR</u>	<u>N021306 003</u>	Jun 30, 2010

SOLUTION, EXTENDED RELEASE; SUBCUTANEOUS

SUBLOCADE

	+		INDIVIOR INC	100MG/0.5ML (100MG/0.5ML)	N209819 001	Nov 30, 2017
	+	!		300MG/1.5ML (200MG/ML)	N209819 002	Nov 30, 2017

BUPRENORPHINE HYDROCHLORIDE

FILM; BUCCAL

BELBUCA

	+		BDSI	EQ 0.075MG BASE	N207932 001	Oct 23, 2015
	+			EQ 0.15MG BASE	N207932 002	Oct 23, 2015
	+			EQ 0.3MG BASE	N207932 003	Oct 23, 2015
	+			EQ 0.45MG BASE	N207932 004	Oct 23, 2015
	+			EQ 0.6MG BASE	N207932 005	Oct 23, 2015
	+			EQ 0.75MG BASE	N207932 006	Oct 23, 2015
	+	!		EQ 0.9MG BASE	N207932 007	Oct 23, 2015

INJECTABLE; INJECTION

BUPRENEX

<u>AP</u>	+	!	INDIVIOR INC	<u>EQ 0.3MG BASE/ML</u>	<u>N018401 001</u>
-----------	---	---	--------------	-------------------------	--------------------

BUPRENORPHINE HYDROCHLORIDE

<u>AP</u>			AM REGENT	<u>EQ 0.3MG BASE/ML</u>	<u>A078331 001</u>	Mar 27, 2007
<u>AP</u>			HOSPIRA	<u>EQ 0.3MG BASE/ML</u>	<u>A074137 001</u>	Jun 03, 1996
<u>AP</u>			PAR STERILE PRODUCTS	<u>EQ 0.3MG BASE/ML</u>	<u>A206586 001</u>	Jul 28, 2015
<u>AP</u>			WEST-WARD PHARMS INT	<u>EQ 0.3MG BASE/ML</u>	<u>A076931 001</u>	Mar 02, 2005

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

<u>AB</u>			ACTAVIS ELIZABETH	<u>EQ 2MG BASE</u>	<u>A090819 001</u>	Feb 19, 2015
<u>AB</u>				<u>EQ 8MG BASE</u>	<u>A090819 002</u>	Feb 19, 2015
<u>AB</u>			ETHYPHARM	<u>EQ 2MG BASE</u>	<u>A090622 001</u>	Sep 24, 2010

PRESCRIPTION DRUG PRODUCT LIST

BUPRENORPHINE HYDROCHLORIDE

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A090622 002</u>	Sep 24, 2010
<u>AB</u>	HIKMA	<u>EQ 2MG BASE</u>	<u>A078633 001</u>	Oct 08, 2009
<u>AB</u>	!	<u>EQ 8MG BASE</u>	<u>A078633 002</u>	Oct 08, 2009
<u>AB</u>	RHODES PHARMS	<u>EQ 2MG BASE</u>	<u>A207276 001</u>	Mar 27, 2017
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A207276 002</u>	Mar 27, 2017
<u>AB</u>	RUBICON	<u>EQ 2MG BASE</u>	<u>A090279 001</u>	Jun 10, 2015
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A090279 002</u>	Jun 10, 2015
<u>AB</u>	SUN PHARM	<u>EQ 2MG BASE</u>	<u>A201760 001</u>	Jan 29, 2016
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A201760 002</u>	Jan 29, 2016

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM;BUCCAL, SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

<u>AB</u>	ALVOGEN PINE BROOK	<u>EQ 2MG BASE;EQ 0.5MG BASE</u>	<u>A205954 001</u>	Jan 24, 2019
<u>AB</u>		<u>EQ 4MG BASE;EQ 1MG BASE</u>	<u>A205954 002</u>	Jan 24, 2019
<u>AB</u>		<u>EQ 8MG BASE;EQ 2MG BASE</u>	<u>A205954 003</u>	Jan 24, 2019
<u>AB</u>		<u>EQ 12MG BASE;EQ 3MG BASE</u>	<u>A205954 004</u>	Jan 24, 2019
<u>AB</u>	DR REDDYS LABS SA	<u>EQ 2MG BASE;EQ 0.5MG BASE</u>	<u>A205299 001</u>	Jun 14, 2018
<u>AB</u>		<u>EQ 4MG BASE;EQ 1MG BASE</u>	<u>A205806 001</u>	Jun 14, 2018
<u>AB</u>		<u>EQ 8MG BASE;EQ 2MG BASE</u>	<u>A205299 002</u>	Jun 14, 2018
<u>AB</u>		<u>EQ 12MG BASE;EQ 3MG BASE</u>	<u>A205806 002</u>	Jun 14, 2018
<u>AB</u>	MYLAN TECHNOLOGIES	<u>EQ 2MG BASE;EQ 0.5MG BASE</u>	<u>A211785 001</u>	Apr 17, 2020
<u>AB</u>		<u>EQ 4MG BASE;EQ 1MG BASE</u>	<u>A211785 002</u>	Apr 17, 2020
<u>AB</u>		<u>EQ 8MG BASE;EQ 2MG BASE</u>	<u>A207607 001</u>	Jun 14, 2018
<u>AB</u>		<u>EQ 12MG BASE;EQ 3MG BASE</u>	<u>A207607 002</u>	Jun 14, 2018

SUBOXONE

<u>AB</u>	+	INDIVIOR INC	<u>EQ 2MG BASE;EQ 0.5MG BASE</u>	<u>N022410 001</u>	Aug 30, 2010
<u>AB</u>	+		<u>EQ 4MG BASE;EQ 1MG BASE</u>	<u>N022410 003</u>	Aug 10, 2012
<u>AB</u>	+		<u>EQ 8MG BASE;EQ 2MG BASE</u>	<u>N022410 002</u>	Aug 30, 2010
<u>AB</u>	+	!	<u>EQ 12MG BASE;EQ 3MG BASE</u>	<u>N022410 004</u>	Aug 10, 2012

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>EQ 2MG BASE;EQ 0.5MG BASE</u>	<u>A091422 001</u>	Feb 22, 2013
<u>AB</u>	!	<u>EQ 8MG BASE;EQ 2MG BASE</u>	<u>A091422 002</u>	Feb 22, 2013
<u>AB</u>	AMNEAL PHARMS	<u>EQ 2MG BASE;EQ 0.5MG BASE</u>	<u>A203136 001</u>	Feb 22, 2013
<u>AB</u>		<u>EQ 8MG BASE;EQ 2MG BASE</u>	<u>A203136 002</u>	Feb 22, 2013
<u>AB</u>	ETHYPHARM USA CORP	<u>EQ 2MG BASE;EQ 0.5MG BASE</u>	<u>A204431 001</u>	Oct 16, 2015
<u>AB</u>		<u>EQ 8MG BASE;EQ 2MG BASE</u>	<u>A204431 002</u>	Oct 16, 2015
<u>AB</u>	HIKMA	<u>EQ 2MG BASE;EQ 0.5MG BASE</u>	<u>A203326 001</u>	Jun 27, 2014
<u>AB</u>		<u>EQ 8MG BASE;EQ 2MG BASE</u>	<u>A203326 002</u>	Jun 27, 2014
<u>AB</u>	LANNETT CO INC	<u>EQ 2MG BASE;EQ 0.5MG BASE</u>	<u>A205022 001</u>	Sep 19, 2016
<u>AB</u>		<u>EQ 8MG BASE;EQ 2MG BASE</u>	<u>A205022 002</u>	Sep 19, 2016
<u>AB</u>	MAYNE PHARMA INC	<u>EQ 2MG BASE;EQ 0.5MG BASE</u>	<u>A206953 001</u>	Jul 17, 2020
<u>AB</u>		<u>EQ 8MG BASE;EQ 2MG BASE</u>	<u>A206953 002</u>	Jul 17, 2020
<u>AB</u>	SPECGX LLC	<u>EQ 2MG BASE;EQ 0.5MG BASE</u>	<u>A207000 001</u>	Dec 13, 2017
<u>AB</u>		<u>EQ 8MG BASE;EQ 2MG BASE</u>	<u>A207000 002</u>	Dec 13, 2017
<u>AB</u>	SUN PHARM	<u>EQ 2MG BASE;EQ 0.5MG BASE</u>	<u>A201633 001</u>	Aug 05, 2016
<u>AB</u>		<u>EQ 8MG BASE;EQ 2MG BASE</u>	<u>A201633 002</u>	Aug 05, 2016
<u>AB</u>	WES PHARMA INC	<u>EQ 2MG BASE;EQ 0.5MG BASE</u>	<u>A209069 001</u>	Jul 17, 2020
<u>AB</u>		<u>EQ 8MG BASE;EQ 2MG BASE</u>	<u>A209069 002</u>	Jul 17, 2020

ZUBSOLV

+	OREXO US INC	EQ 0.7MG BASE;EQ 0.18MG BASE	N204242 006	Oct 04, 2016
+		EQ 1.4MG BASE;EQ 0.36MG BASE	N204242 001	Jul 03, 2013
+		EQ 2.9MG BASE;EQ 0.71MG BASE	N204242 005	Jun 04, 2015
+		EQ 5.7MG BASE;EQ 1.4MG BASE	N204242 002	Jul 03, 2013
+		EQ 8.6MG BASE;EQ 2.1MG BASE	N204242 003	Dec 11, 2014
+	!	EQ 11.4MG BASE;EQ 2.9MG BASE	N204242 004	Dec 11, 2014

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

APLENZIN

+	VALEANT PHARMS NORTH	174MG	N022108 001	Apr 23, 2008
+		348MG	N022108 002	Apr 23, 2008
+	!	522MG	N022108 003	Apr 23, 2008

PRESCRIPTION DRUG PRODUCT LIST

BUPROPION HYDROCHLORIDE

TABLET; ORAL

BUPROPION HYDROCHLORIDE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>75MG</u>	<u>A203013</u>	<u>001</u>	Jun 08, 2018
<u>AB</u>		<u>100MG</u>	<u>A203013</u>	<u>002</u>	Jun 08, 2018
<u>AB</u>	APNAR PHARMA LP	<u>75MG</u>	<u>A075584</u>	<u>001</u>	Feb 07, 2000
<u>AB</u>		<u>100MG</u>	<u>A075584</u>	<u>002</u>	Feb 07, 2000
<u>AB</u>	APOTEX INC	<u>75MG</u>	<u>A076143</u>	<u>001</u>	Jan 17, 2006
<u>AB</u>	!	<u>100MG</u>	<u>A076143</u>	<u>002</u>	Jan 17, 2006
<u>AB</u>	CADILA PHARMS LTD	<u>75MG</u>	<u>A208606</u>	<u>001</u>	Jan 16, 2020
<u>AB</u>		<u>100MG</u>	<u>A208606</u>	<u>002</u>	Jan 16, 2020
<u>AB</u>	HERITAGE PHARMA	<u>75MG</u>	<u>A206975</u>	<u>001</u>	Aug 19, 2016
<u>AB</u>		<u>100MG</u>	<u>A206975</u>	<u>002</u>	Aug 19, 2016
<u>AB</u>	INVAGEN PHARMS	<u>75MG</u>	<u>A207389</u>	<u>001</u>	Sep 18, 2017
<u>AB</u>		<u>100MG</u>	<u>A207389</u>	<u>002</u>	Sep 18, 2017
<u>AB</u>	MICRO LABS	<u>75MG</u>	<u>A207403</u>	<u>001</u>	Apr 17, 2020
<u>AB</u>		<u>100MG</u>	<u>A207403</u>	<u>002</u>	Apr 17, 2020
<u>AB</u>	MYLAN	<u>75MG</u>	<u>A075491</u>	<u>001</u>	Apr 17, 2000
<u>AB</u>		<u>100MG</u>	<u>A075491</u>	<u>002</u>	Apr 17, 2000

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

<u>AB1</u>	ACTAVIS LABS FL INC	<u>100MG</u>	<u>A079095</u>	<u>001</u>	Mar 24, 2009
<u>AB1</u>		<u>150MG</u>	<u>A079095</u>	<u>002</u>	Mar 24, 2009
<u>AB1</u>		<u>200MG</u>	<u>A079095</u>	<u>003</u>	Mar 24, 2009
<u>AB1</u>	ANCHEN PHARMS	<u>100MG</u>	<u>A091459</u>	<u>001</u>	Jun 09, 2011
<u>AB1</u>		<u>150MG</u>	<u>A091459</u>	<u>002</u>	Jun 09, 2011
<u>AB1</u>		<u>200MG</u>	<u>A091459</u>	<u>003</u>	Jun 09, 2011
<u>AB1</u>	IMPAX LABS	<u>100MG</u>	<u>A075913</u>	<u>001</u>	Jan 28, 2004
<u>AB1</u>		<u>150MG</u>	<u>A075913</u>	<u>002</u>	Mar 22, 2004
<u>AB1</u>		<u>200MG</u>	<u>A076711</u>	<u>001</u>	Dec 03, 2004
<u>AB1</u>	INVAGEN PHARMS	<u>100MG</u>	<u>A206674</u>	<u>001</u>	Feb 09, 2016
<u>AB1</u>		<u>150MG</u>	<u>A206674</u>	<u>002</u>	Feb 09, 2016
<u>AB1</u>		<u>200MG</u>	<u>A206674</u>	<u>003</u>	Feb 09, 2016
<u>AB1</u>	PRINSTON INC	<u>100MG</u>	<u>A202304</u>	<u>001</u>	May 26, 2015
<u>AB1</u>		<u>150MG</u>	<u>A202304</u>	<u>002</u>	May 26, 2015
<u>AB1</u>		<u>200MG</u>	<u>A202304</u>	<u>003</u>	May 26, 2015
<u>AB1</u>	SANDOZ	<u>100MG</u>	<u>A075932</u>	<u>001</u>	Nov 25, 2003
<u>AB1</u>		<u>150MG</u>	<u>A075932</u>	<u>002</u>	Mar 22, 2004
<u>AB1</u>		<u>200MG</u>	<u>A075932</u>	<u>003</u>	Jun 22, 2005
<u>AB1</u>	SCIEGEN PHARMS INC	<u>100MG</u>	<u>A205794</u>	<u>001</u>	Mar 01, 2016
<u>AB1</u>		<u>150MG</u>	<u>A205794</u>	<u>002</u>	Mar 01, 2016
<u>AB1</u>		<u>200MG</u>	<u>A205794</u>	<u>003</u>	Mar 01, 2016
<u>AB1</u>	SUN PHARM	<u>100MG</u>	<u>A078866</u>	<u>001</u>	Apr 06, 2010
<u>AB1</u>		<u>150MG</u>	<u>A078866</u>	<u>002</u>	Apr 06, 2010
<u>AB1</u>		<u>200MG</u>	<u>A078866</u>	<u>003</u>	Apr 06, 2010
<u>AB1</u>	TORRENT	<u>100MG</u>	<u>A203969</u>	<u>001</u>	Oct 31, 2014
<u>AB1</u>		<u>150MG</u>	<u>A203969</u>	<u>002</u>	Oct 31, 2014
<u>AB1</u>		<u>200MG</u>	<u>A203969</u>	<u>003</u>	Oct 31, 2014
<u>AB1</u>	YICHANG HUMANWELL	<u>100MG</u>	<u>A211347</u>	<u>001</u>	Oct 16, 2018
<u>AB1</u>		<u>150MG</u>	<u>A211347</u>	<u>002</u>	Oct 16, 2018
<u>AB1</u>		<u>200MG</u>	<u>A211347</u>	<u>003</u>	Oct 16, 2018

WELLBUTRIN SR

<u>AB1</u>	+	GLAXOSMITHKLINE	<u>100MG</u>	<u>N020358</u>	<u>002</u>	Oct 04, 1996
<u>AB1</u>	+		<u>150MG</u>	<u>N020358</u>	<u>003</u>	Oct 04, 1996
<u>AB1</u>	+	!	<u>200MG</u>	<u>N020358</u>	<u>004</u>	Jun 14, 2002

BUPROPION HYDROCHLORIDE

<u>AB2</u>	!	ACTAVIS LABS FL INC	<u>150MG</u>	<u>A079094</u>	<u>001</u>	Mar 24, 2009
<u>AB2</u>		ANCHEN PHARMS	<u>150MG</u>	<u>A091520</u>	<u>001</u>	Jun 09, 2011
<u>AB2</u>		IMPAX LABS	<u>150MG</u>	<u>A075914</u>	<u>001</u>	May 27, 2004
<u>AB2</u>		SANDOZ INC	<u>150MG</u>	<u>A077475</u>	<u>001</u>	Mar 12, 2008
<u>AB2</u>		SCIEGEN PHARMS INC	<u>150MG</u>	<u>A206122</u>	<u>001</u>	Aug 17, 2016
<u>AB3</u>		ACCORD HLTHCARE	<u>150MG</u>	<u>A210497</u>	<u>001</u>	Oct 31, 2018
<u>AB3</u>			<u>300MG</u>	<u>A210497</u>	<u>002</u>	Oct 31, 2018
<u>AB3</u>		ACTAVIS LABS FL INC	<u>150MG</u>	<u>A077715</u>	<u>001</u>	Nov 26, 2008
<u>AB3</u>		ADAPTIS	<u>150MG</u>	<u>A211020</u>	<u>001</u>	Jan 28, 2019
<u>AB3</u>			<u>300MG</u>	<u>A211020</u>	<u>002</u>	Jan 28, 2019
<u>AB3</u>		ANBISON LAB	<u>150MG</u>	<u>A207224</u>	<u>001</u>	Jun 30, 2017
<u>AB3</u>			<u>300MG</u>	<u>A207224</u>	<u>002</u>	Jun 30, 2017
<u>AB3</u>		ANCHEN PHARMS	<u>150MG</u>	<u>A077284</u>	<u>001</u>	Dec 14, 2006
<u>AB3</u>			<u>300MG</u>	<u>A077284</u>	<u>002</u>	Dec 14, 2006
<u>AB3</u>		IMPAX LABS	<u>150MG</u>	<u>A077415</u>	<u>001</u>	Nov 26, 2008
<u>AB3</u>		INVAGEN PHARMS	<u>150MG</u>	<u>A206556</u>	<u>001</u>	Aug 26, 2016

PRESCRIPTION DRUG PRODUCT LIST

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

<u>AB3</u>		<u>300MG</u>	<u>A206556</u>	<u>002</u>	Aug 26, 2016
<u>AB3</u>	LUPIN LTD	<u>150MG</u>	<u>A090693</u>	<u>001</u>	Apr 06, 2017
<u>AB3</u>		<u>300MG</u>	<u>A090693</u>	<u>002</u>	Apr 06, 2017
<u>AB3</u>	SCIEGEN PHARMS INC	<u>150MG</u>	<u>A207479</u>	<u>001</u>	Apr 12, 2017
<u>AB3</u>		<u>300MG</u>	<u>A207479</u>	<u>002</u>	Apr 12, 2017
<u>AB3</u>	SINOTHERAPEUTICS INC	<u>150MG</u>	<u>A208652</u>	<u>001</u>	Aug 21, 2017
<u>AB3</u>		<u>300MG</u>	<u>A208652</u>	<u>002</u>	Aug 21, 2017
<u>AB3</u>	SUN PHARM	<u>150MG</u>	<u>A200216</u>	<u>001</u>	Nov 30, 2020
<u>AB3</u>		<u>300MG</u>	<u>A203650</u>	<u>001</u>	Dec 31, 2020
<u>AB3</u>	TWI PHARMS	<u>150MG</u>	<u>A210081</u>	<u>001</u>	Nov 03, 2017
<u>AB3</u>		<u>300MG</u>	<u>A210081</u>	<u>002</u>	Nov 03, 2017
<u>AB3</u>	WATSON LABS INC	<u>150MG</u>	<u>A077285</u>	<u>001</u>	Nov 26, 2008
<u>AB3</u>		<u>300MG</u>	<u>A077285</u>	<u>002</u>	Aug 15, 2008
<u>AB3</u>	WOCKHARDT LTD	<u>150MG</u>	<u>A202189</u>	<u>001</u>	Nov 21, 2012
<u>AB3</u>	YICHANG HUMANWELL	<u>150MG</u>	<u>A210015</u>	<u>001</u>	Jun 14, 2018
<u>AB3</u>		<u>300MG</u>	<u>A210015</u>	<u>002</u>	Jun 14, 2018
<u>AB3</u>	ZHEJIANG JUTAI PHARM	<u>150MG</u>	<u>A211200</u>	<u>002</u>	Apr 29, 2020
<u>AB3</u>		<u>300MG</u>	<u>A211200</u>	<u>001</u>	Sep 05, 2019
<u>AB3</u>	ZYDUS PHARMS	<u>150MG</u>	<u>A201567</u>	<u>002</u>	Jul 23, 2018
<u>AB3</u>		<u>300MG</u>	<u>A201567</u>	<u>001</u>	Jan 17, 2014
	<u>WELLBUTRIN XL</u>				
<u>AB3</u>	+ VALEANT INTL	<u>150MG</u>	<u>N021515</u>	<u>001</u>	Aug 28, 2003
<u>AB3</u>	+!	<u>300MG</u>	<u>N021515</u>	<u>002</u>	Aug 28, 2003
	FORFIVO XL				
	+! ALVOGEN	450MG	N022497	001	Nov 10, 2011

BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CONTRAVE

+!	NALPROPION	90MG;8MG	N200063	001	Sep 10, 2014
----	------------	----------	---------	-----	--------------

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

<u>AB</u>	ACCORD HLTHCARE	<u>5MG</u>	<u>A202557</u>	<u>001</u>	Dec 30, 2014
<u>AB</u>		<u>7.5MG</u>	<u>A202557</u>	<u>002</u>	Dec 30, 2014
<u>AB</u>		<u>10MG</u>	<u>A202557</u>	<u>003</u>	Dec 30, 2014
<u>AB</u>		<u>15MG</u>	<u>A202557</u>	<u>004</u>	Dec 30, 2014
<u>AB</u>		<u>30MG</u>	<u>A202557</u>	<u>005</u>	Dec 30, 2014
<u>AB</u>	AMNEAL PHARMS CO	<u>5MG</u>	<u>A208829</u>	<u>001</u>	May 24, 2017
<u>AB</u>		<u>7.5MG</u>	<u>A208829</u>	<u>002</u>	May 24, 2017
<u>AB</u>		<u>10MG</u>	<u>A208829</u>	<u>003</u>	May 24, 2017
<u>AB</u>		<u>15MG</u>	<u>A208829</u>	<u>004</u>	May 24, 2017
<u>AB</u>		<u>30MG</u>	<u>A208829</u>	<u>005</u>	May 24, 2017
<u>AB</u>	AUROBINDO PHARMA LTD	<u>5MG</u>	<u>A078246</u>	<u>001</u>	Feb 27, 2009
<u>AB</u>		<u>7.5MG</u>	<u>A078246</u>	<u>005</u>	Feb 21, 2020
<u>AB</u>		<u>10MG</u>	<u>A078246</u>	<u>002</u>	Feb 27, 2009
<u>AB</u>		<u>15MG</u>	<u>A078246</u>	<u>003</u>	Feb 27, 2009
<u>AB</u>		<u>30MG</u>	<u>A078246</u>	<u>004</u>	Feb 27, 2009
<u>AB</u>	EPIC PHARMA LLC	<u>5MG</u>	<u>A208972</u>	<u>001</u>	Apr 16, 2019
<u>AB</u>		<u>7.5MG</u>	<u>A208972</u>	<u>002</u>	Apr 16, 2019
<u>AB</u>		<u>10MG</u>	<u>A208972</u>	<u>003</u>	Apr 16, 2019
<u>AB</u>		<u>15MG</u>	<u>A208972</u>	<u>004</u>	Apr 16, 2019
<u>AB</u>		<u>30MG</u>	<u>A208972</u>	<u>005</u>	Apr 16, 2019
<u>AB</u>	HERITAGE PHARMA	<u>5MG</u>	<u>A204582</u>	<u>001</u>	Sep 18, 2015
<u>AB</u>		<u>10MG</u>	<u>A204582</u>	<u>002</u>	Sep 18, 2015
<u>AB</u>		<u>15MG</u>	<u>A204582</u>	<u>003</u>	Sep 18, 2015
<u>AB</u>		<u>30MG</u>	<u>A204582</u>	<u>004</u>	Sep 18, 2015
<u>AB</u>	IMPAX LABS INC	<u>5MG</u>	<u>A074253</u>	<u>001</u>	Mar 28, 2001
<u>AB</u>		<u>10MG</u>	<u>A074253</u>	<u>002</u>	Mar 28, 2001
<u>AB</u>		<u>15MG</u>	<u>A074253</u>	<u>003</u>	Mar 13, 2002
<u>AB</u>	INVENTIA HLTHCARE	<u>5MG</u>	<u>A209696</u>	<u>001</u>	May 03, 2018
<u>AB</u>		<u>7.5MG</u>	<u>A209696</u>	<u>002</u>	May 03, 2018
<u>AB</u>		<u>10MG</u>	<u>A209696</u>	<u>003</u>	May 03, 2018
<u>AB</u>		<u>15MG</u>	<u>A209696</u>	<u>004</u>	May 03, 2018
<u>AB</u>		<u>30MG</u>	<u>A209696</u>	<u>005</u>	May 03, 2018
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A076008</u>	<u>003</u>	Mar 01, 2002
<u>AB</u>	!	<u>7.5MG</u>	<u>A075467</u>	<u>002</u>	Mar 28, 2001

PRESCRIPTION DRUG PRODUCT LIST

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

<u>AB</u>		<u>7.5MG</u>	<u>A076008 002</u>	Jul 08, 2013
<u>AB</u>		<u>10MG</u>	<u>A076008 004</u>	Mar 01, 2002
<u>AB</u>		<u>15MG</u>	<u>A076008 005</u>	Mar 28, 2001
<u>AB</u>		<u>30MG</u>	<u>A076008 001</u>	Jun 28, 2001
<u>AB</u>	OXFORD PHARMS	<u>5MG</u>	<u>A075388 001</u>	May 09, 2002
<u>AB</u>		<u>10MG</u>	<u>A075388 002</u>	May 09, 2002
<u>AB</u>		<u>15MG</u>	<u>A075388 003</u>	May 09, 2002
<u>AB</u>		<u>30MG</u>	<u>A078302 001</u>	Dec 17, 2007
<u>AB</u>	STRIDES PHARMA	<u>5MG</u>	<u>A202330 001</u>	Aug 25, 2014
<u>AB</u>		<u>7.5MG</u>	<u>A202330 005</u>	Feb 17, 2017
<u>AB</u>		<u>10MG</u>	<u>A202330 002</u>	Aug 25, 2014
<u>AB</u>		<u>15MG</u>	<u>A202330 003</u>	Aug 25, 2014
<u>AB</u>		<u>30MG</u>	<u>A202330 004</u>	Aug 25, 2014
<u>AB</u>	TEVA	<u>5MG</u>	<u>A075022 001</u>	Feb 28, 2002
<u>AB</u>		<u>10MG</u>	<u>A075022 002</u>	Feb 28, 2002
<u>AB</u>	!	<u>15MG</u>	<u>A075022 003</u>	Feb 28, 2002
<u>AB</u>		<u>30MG</u>	<u>A075022 004</u>	Mar 25, 2004
<u>AB</u>	UNICHEM	<u>5MG</u>	<u>A210907 001</u>	Nov 14, 2019
<u>AB</u>		<u>10MG</u>	<u>A210907 002</u>	Nov 14, 2019
<u>AB</u>		<u>15MG</u>	<u>A210907 003</u>	Nov 14, 2019
<u>AB</u>		<u>30MG</u>	<u>A210907 004</u>	Nov 14, 2019
<u>AB</u>	YILING	<u>5MG</u>	<u>A202087 001</u>	Dec 16, 2015
<u>AB</u>		<u>10MG</u>	<u>A202087 002</u>	Dec 16, 2015
<u>AB</u>		<u>15MG</u>	<u>A202087 003</u>	Dec 16, 2015
<u>AB</u>		<u>30MG</u>	<u>A202087 004</u>	Dec 16, 2015
<u>AB</u>	ZYDUS PHARMS	<u>5MG</u>	<u>A078888 001</u>	Feb 07, 2014
<u>AB</u>		<u>10MG</u>	<u>A078888 002</u>	Feb 07, 2014
<u>AB</u>		<u>15MG</u>	<u>A078888 003</u>	Feb 07, 2014
<u>AB</u>		<u>30MG</u>	<u>A078888 004</u>	Feb 07, 2014

BUSULFAN

INJECTABLE; INJECTION

BUSULFAN

<u>AP</u>	ACCORD HLTHCARE INC	<u>6MG/ML</u>	<u>A210148 001</u>	Feb 22, 2019
<u>AP</u>	AMNEAL	<u>6MG/ML</u>	<u>A209580 001</u>	Dec 18, 2017
<u>AP</u>	APOTEX	<u>6MG/ML</u>	<u>A210448 001</u>	May 07, 2019
<u>AP</u>	ATHENEX INC	<u>6MG/ML</u>	<u>A205106 001</u>	Sep 21, 2018
<u>AP</u>	HOSPIRA INC	<u>6MG/ML</u>	<u>A205672 001</u>	Jul 31, 2018
<u>AP</u>	LUITPOLD	<u>6MG/ML</u>	<u>A202259 001</u>	Dec 22, 2015
<u>AP</u>	MEITHEAL	<u>6MG/ML</u>	<u>A212127 001</u>	Oct 23, 2020
<u>AP</u>	MYLAN INSTITUTIONAL	<u>6MG/ML</u>	<u>A208536 001</u>	Nov 20, 2017
<u>AP</u>	NEXUS PHARMS	<u>6MG/ML</u>	<u>A207794 001</u>	Jan 14, 2019
<u>AP</u>	PHARMASCIENCE INC	<u>6MG/ML</u>	<u>A207050 001</u>	Mar 24, 2017
<u>AP</u>	SHILPA MEDICARE LTD	<u>6MG/ML</u>	<u>A210931 001</u>	Apr 18, 2019

BUSULFEX

<u>AP</u>	+! OTSUKA PHARM	<u>6MG/ML</u>	<u>N020954 001</u>	Feb 04, 1999
-----------	-----------------	---------------	--------------------	--------------

TABLET; ORAL

MYLERAN

+!	ASPEN GLOBAL	2MG	N009386 001	
----	--------------	-----	-------------	--

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL

MENTAX

+!	MYLAN	1%	N020524 001	Oct 18, 1996
----	-------	----	-------------	--------------

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

GYNAZOLE-1

!	PERRIGO ISRAEL	2%	A200923 001	May 18, 2012
---	----------------	----	-------------	--------------

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE

<u>AP</u>	HIKMA FARMACEUTICA	<u>1MG/ML</u>	<u>A078400 001</u>	May 01, 2009
<u>AP</u>		<u>2MG/ML</u>	<u>A078400 002</u>	May 01, 2009
<u>AP</u>	WEST-WARD PHARMS	<u>2MG/ML</u>	<u>A075046 001</u>	Aug 12, 1998

INT

BUTORPHANOL TARTRATE PRESERVATIVE FREE

<u>AP</u>	!	HOSPIRA	<u>1MG/ML</u>	<u>A074626 001</u>	Jan 23, 1997
<u>AP</u>	!		<u>2MG/ML</u>	<u>A074626 002</u>	Jan 23, 1997
<u>AP</u>		WEST-WARD PHARMS	<u>1MG/ML</u>	<u>A075045 001</u>	Aug 12, 1998

INT

PRESCRIPTION DRUG PRODUCT LIST

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE PRESERVATIVE FREE

AP		<u>2MG/ML</u>	A075045 002	Aug 12, 1998
SPRAY, METERED; NASAL				
<u>BUTORPHANOL TARTRATE</u>				
AB	APOTEX INC	<u>1MG/SPRAY</u>	A075499 001	Dec 04, 2002
AB	HIKMA	<u>1MG/SPRAY</u>	A075824 001	Mar 12, 2002
AB	! MYLAN	<u>1MG/SPRAY</u>	A075759 001	Aug 08, 2001

CABAZITAXEL

SOLUTION; INTRAVENOUS

JEVTANA KIT

+	!	SANOFI AVENTIS US	60MG/1.5ML (40MG/ML)	N201023 001	Jun 17, 2010
---	---	-------------------	----------------------	-------------	--------------

CABERGOLINE

TABLET; ORAL

CABERGOLINE

AB	!	INGENUS PHARMS LLC	<u>0.5MG</u>	A204735 001	Aug 01, 2018
AB		IVAX SUB TEVA PHARMS	<u>0.5MG</u>	A077750 001	Mar 07, 2007

CABOZANTINIB S-MALATE

CAPSULE; ORAL

COMETRIQ

+	!	EXELIXIS	EQ 20MG BASE	N203756 001	Nov 29, 2012
+			EQ 80MG BASE	N203756 002	Nov 29, 2012

TABLET; ORAL

CABOMETYX

+		EXELIXIS INC	EQ 20MG BASE	N208692 001	Apr 25, 2016
+			EQ 40MG BASE	N208692 002	Apr 25, 2016
+	!		EQ 60MG BASE	N208692 003	Apr 25, 2016

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS

CAFCIT

AP	+	!	HIKMA	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	N020793 001	Sep 21, 1999
<u>CAFFEINE CITRATE</u>						
AP			AM REGENT	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	A077906 001	May 15, 2007
AP			AUROBINDO PHARMA LTD	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	A205013 001	Sep 22, 2015
AP			EXELA PHARMA SCIENCE	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	A077233 001	Sep 21, 2006
AP			FRESENIUS KABI USA	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	A077997 001	Jul 20, 2007
AP			MICRO LABS	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	A207400 001	Dec 14, 2017
AP			SAGENT PHARMS	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	A090827 001	Aug 29, 2012

SOLUTION; ORAL

CAFCIT

AA	+	!	HIKMA	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	N020793 002	Apr 12, 2000
<u>CAFFEINE CITRATE</u>						
AA			EXELA PHARMA	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	A077304 001	Sep 21, 2006
AA			FRESENIUS KABI USA	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	A078002 001	Jan 31, 2008
AA			MICRO LABS	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	A213202 001	Dec 16, 2019
AA			SAGENT PHARMS	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	A091102 001	Aug 29, 2012
AA			SUN PHARM	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	A090357 001	Sep 30, 2009

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL

MIGERGOT

!		COSETTE	100MG; 2MG	A086557 001	Oct 04, 1983
---	--	---------	------------	-------------	--------------

TABLET; ORAL

CAFERGOT

AA	!	SANDOZ	<u>100MG; 1MG</u>	A084294 001	
<u>ERGOTAMINE TARTRATE AND CAFFEINE</u>					
AA		MIKART	<u>100MG; 1MG</u>	A040590 001	Sep 16, 2005

CALCIFEDIOL

CAPSULE, EXTENDED RELEASE; ORAL

RAYALDEE

+	!	EIRGEN	0.03MG	N208010 001	Jun 17, 2016
---	---	--------	--------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

CALCIPOTRIENE

AEROSOL, FOAM;TOPICAL

SORILUX

+! MAYNE PHARMA

0.005%

N022563 001 Oct 06, 2010

CREAM;TOPICAL

CALCIPOTRIENE**AB** GLENMARK PHARMS**0.005%****A205772 001** Jun 09, 2015**AB** TOLMAR**0.005%****A200935 001** May 30, 2012DOVONEX**AB** +! LEO PHARMA AS**0.005%****N020554 001** Jul 22, 1996

OINTMENT;TOPICAL

CALCIPOTRIENE

! GLENMARK PHARMS INC

0.005%

A090633 001 Mar 24, 2010

SOLUTION;TOPICAL

CALCIPOTRIENE**AT** AKORN**0.005%****A077579 001** Nov 19, 2009**AT** COSETTE**0.005%****A078468 001** Mar 24, 2011**AT** FOUGERA PHARMS**0.005%****A078305 001** May 06, 2008**AT** NOVEL LABS INC**0.005%****A207163 001** Dec 26, 2017**AT** ! TOLMAR**0.005%****A077029 001** Nov 20, 2009CALCITONIN SALMON

INJECTABLE;INJECTION

MIACALCIN

+! MYLAN IRELAND LTD

200 IU/ML

N017808 002 Mar 29, 1991

SPRAY, METERED;NASAL

CALCITONIN-SALMON**AB** ! APOTEX INC**200 IU/SPRAY****A076396 001** Nov 17, 2008**AB** PAR PHARM**200 IU/SPRAY****A076979 001** Jun 08, 2009CALCITRIOL

CAPSULE;ORAL

CALCITRIOL**AB** AMNEAL PHARMS**0.25MCG****A203289 002** Jun 14, 2017**AB****0.5MCG****A203289 001** Jun 14, 2017**AB** BIONPHARMA INC**0.25MCG****A091174 001** May 24, 2013**AB****0.5MCG****A091174 002** May 24, 2013**AB** HIKMA**0.25MCG****A076917 001** Mar 27, 2006**AB** STRIDES PHARMA**0.25MCG****A091356 001** Dec 12, 2014**AB****0.5MCG****A091356 002** Dec 12, 2014**AB** SUN PHARM**0.25MCG****A204556 001** Feb 21, 2019**AB****0.5MCG****A204556 002** Feb 21, 2019**AB** TEVA**0.25MCG****A075765 001** Oct 12, 2001**AB****0.5MCG****A075765 002** Oct 12, 2001ROCALTROL**AB** + VALIDUS PHARMS**0.25MCG****N018044 001****AB** +!**0.5MCG****N018044 002**

INJECTABLE;INJECTION

CALCITRIOL**AP** ! AKORN**0.001MG/ML****A078066 001** Jan 29, 2008**AP** GLAND PHARMA LTD**0.001MG/ML****A211030 001** Feb 03, 2020

OINTMENT;TOPICAL

VECTICAL

+! GALDERMA LABS LP

3MCG/GM

N022087 001 Jan 23, 2009

SOLUTION;ORAL

CALCITRIOL**AA** ELYSIUM**1MCG/ML****A209798 001** Nov 21, 2018**AA** HIKMA**1MCG/ML****A076242 001** Jul 18, 2003ROCALTROL**AA** +! VALIDUS PHARMS**1MCG/ML****N021068 001** Nov 20, 1998CALCIUM ACETATE

CAPSULE;ORAL

CALCIUM ACETATE**AB** AMNEAL PHARMS**667MG****A201658 001** Oct 06, 2014**AB** CHARTWELL RX**667MG****A091312 001** Jun 01, 2012**AB** HERITAGE PHARMS INC**667MG****A202315 001** Jun 29, 2015**AB** HIKMA**667MG****A077728 001** Feb 26, 2008**AB** INVAGEN PHARMS**667MG****A203135 001** Feb 07, 2013**AB** LUPIN LTD**667MG****A202127 001** Jul 09, 2015**AB** NOSTRUM LABS INC**667MG****A203179 001** Oct 26, 2015**AB** SUVEN PHARMS**667MG****A211038 001** Feb 21, 2020

PRESCRIPTION DRUG PRODUCT LIST

CALCIUM ACETATE

CAPSULE; ORAL

PHOSLO GELCAPS

AB	+ !	FRESENIUS MEDCL	667MG	N021160 003	Apr 02, 2001
-----------	------------	-----------------	--------------	--------------------	--------------

SOLUTION; ORAL

PHOSLYRA

	+ !	FRESENIUS MEDCL	667MG/5ML	N022581 001	Apr 18, 2011
--	------------	-----------------	-----------	-------------	--------------

TABLET; ORAL

CALCIUM ACETATE

AB		CHARTWELL MOLECULAR	667MG	A202420 001	Feb 05, 2013
-----------	--	---------------------	--------------	--------------------	--------------

AB		HERITAGE PHARMS INC	667MG	A202885 001	Jan 22, 2015
-----------	--	---------------------	--------------	--------------------	--------------

AB	!	PADDOCK LLC	667MG	A091561 001	Apr 13, 2011
-----------	----------	-------------	--------------	--------------------	--------------

CALCIUM CHLORIDE

INJECTABLE; INJECTION

CALCIUM CHLORIDE 10%

AP		AM REGENT	100MG/ML	A209088 001	Jul 27, 2017
-----------	--	-----------	-----------------	--------------------	--------------

AP		INTL MEDICATION SYS	100MG/ML	A203477 001	May 09, 2018
-----------	--	---------------------	-----------------	--------------------	--------------

AP		MEDEFIL INC	100MG/ML	A211553 001	May 01, 2019
-----------	--	-------------	-----------------	--------------------	--------------

CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER

AP	+ !	HOSPIRA	100MG/ML	N021117 001	Jan 28, 2000
-----------	------------	---------	-----------------	--------------------	--------------

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION

BSS PLUS

	+ !	ALCON	0.154MG/ML; 0.92MG/ML; 0.184MG/ML; 0.2MG/ML; 0.38MG/ML; 2.1MG/ML; 7.14MG/ML; 0.42MG/ML	N018469 001	
--	------------	-------	--	-------------	--

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER

	+ !	BAXTER HLTHCARE CORP	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703 011	Oct 10, 2008
--	------------	----------------------	---	-------------	--------------

PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER

	+ !	BAXTER HLTHCARE CORP	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703 006	Oct 25, 2006
--	------------	----------------------	--	-------------	--------------

PRISMASOL BGK 2/0 IN PLASTIC CONTAINER

	+ !	BAXTER HLTHCARE CORP	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703 002	Oct 25, 2006
--	------------	----------------------	---	-------------	--------------

PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER

	+ !	BAXTER HLTHCARE CORP	5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703 003	Oct 25, 2006
--	------------	----------------------	--	-------------	--------------

PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER

	+ !	BAXTER HLTHCARE CORP	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.44GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703 015	Oct 10, 2008
--	------------	----------------------	---	-------------	--------------

PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER

	+ !	BAXTER HLTHCARE CORP	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703 004	Oct 25, 2006
--	------------	----------------------	--	-------------	--------------

PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER

	+ !	BAXTER HLTHCARE CORP	N/A/1000ML; N/A/1000ML; 5.4GM/1000ML; 2.44GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703 014	Oct 10, 2008
--	------------	----------------------	--	-------------	--------------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DELFLX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	+ !	FRESENIUS MEDCL	25.7MG/100ML; 1.5GM/100ML; 15.2MG/100ML; 5.67MG/100ML; 392MG/100ML	N018883 001	Nov 30, 1984
-----------	------------	-----------------	---	--------------------	--------------

DELFLX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER

AT	+ !	FRESENIUS MEDCL	25.7MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 5.38MG/100ML; 448MG/100ML	N018883 004	Nov 30, 1984
-----------	------------	-----------------	---	--------------------	--------------

DELFLX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT	+ !	FRESENIUS MEDCL	18.4MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 5.38MG/100ML; 448MG/100ML	N020171 001	Aug 19, 1992
-----------	------------	-----------------	---	--------------------	--------------

DELFLX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT	+ !	FRESENIUS MEDCL	25.7MG/100ML; 2.5GM/100ML; 15.2MG/100ML; 5.67MG/100ML; 392MG/100ML	N018883 002	Nov 30, 1984
-----------	------------	-----------------	---	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE SOLUTION; INTRAPERITONEAL

<u>DELFLX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER</u>					
AT	+	FRESENIUS MEDCL	<u>25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;5.38MG/100ML;448MG/100ML</u>	<u>N018883 005</u>	Nov 30, 1984
<u>DELFLX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER</u>					
AT	+	FRESENIUS MEDCL	<u>18.4MG/100ML;2.5GM/100ML;5.08MG/100ML;5.38MG/100ML;448MG/100ML</u>	<u>N020171 002</u>	Aug 19, 1992
<u>DELFLX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER</u>					
AT	+	FRESENIUS MEDCL	<u>25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML</u>	<u>N018883 003</u>	Nov 30, 1984
<u>DELFLX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER</u>					
AT	+	FRESENIUS MEDCL	<u>25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML</u>	<u>N018883 006</u>	Nov 30, 1984
<u>DELFLX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER</u>					
AT	+	FRESENIUS MEDCL	<u>18.4MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML</u>	<u>N020171 003</u>	Aug 19, 1992
<u>DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER</u>					
AT	+	BAXTER HLTHCARE	<u>18.3MG/100ML;1.5GM/100ML;5.08MG/100ML;5.38MG/100ML;448MG/100ML</u>	<u>N020183 001</u>	Dec 04, 1992
<u>DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER</u>					
AT	+	BAXTER HLTHCARE	<u>18.3MG/100ML;2.5GM/100ML;5.08MG/100ML;5.38MG/100ML;448MG/100ML</u>	<u>N020183 002</u>	Dec 04, 1992
<u>DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER</u>					
AT	+	BAXTER HLTHCARE	<u>18.3MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML</u>	<u>N020183 004</u>	Dec 04, 1992
<u>DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER</u>					
AT	+	BAXTER HLTHCARE	<u>18.3MG/100ML;1.5GM/100ML;5.08MG/100ML;5.38MG/100ML;448MG/100ML</u>	<u>N017512 012</u>	Jan 10, 1989
<u>DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER</u>					
AT	+	BAXTER HLTHCARE	<u>18.3MG/100ML;2.5GM/100ML;5.08MG/100ML;5.38MG/100ML;448MG/100ML</u>	<u>N017512 013</u>	Jul 11, 1990
<u>DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER</u>					
AT	+	BAXTER HLTHCARE	<u>18.3MG/100ML;3.5GM/100ML;5.08MG/100ML;5.38MG/100ML;448MG/100ML</u>	<u>N017512 014</u>	Jul 11, 1990
<u>DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER</u>					
AT	+	BAXTER HLTHCARE	<u>18.3MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML</u>	<u>N017512 015</u>	Jul 11, 1990
<u>DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER</u>					
AT	+	BAXTER HLTHCARE	<u>25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;5.38MG/100ML;448MG/100ML</u>	<u>N017512 004</u>	
AT	+		<u>25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;5.38MG/100ML;448MG/100ML</u>	<u>N020163 001</u>	Dec 04, 1992
<u>DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER</u>					
AT	+	BAXTER HLTHCARE	<u>25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;5.38MG/100ML;448MG/100ML</u>	<u>N017512 005</u>	
AT	+		<u>25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;5.38MG/100ML;448MG/100ML</u>	<u>N020163 002</u>	Dec 04, 1992
<u>DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER</u>					
AT	+	BAXTER HLTHCARE	<u>25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML</u>	<u>N017512 006</u>	
AT	+		<u>25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML</u>	<u>N020163 003</u>	Dec 04, 1992

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INTRATHECAL

ELLIOTTS B SOLUTION

+	!	LUKARE MEDICAL LLC	<u>0.2MG/ML;0.8MG/ML;0.3MG/ML;0.3MG/ML;1.9MG/ML;7.3MG/ML;0.2MG/ML</u>	<u>N020577 001</u>	Sep 27, 1996
---	---	--------------------	---	--------------------	--------------

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

<u>DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER</u>					
AP	+	ICU MEDICAL INC	<u>20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML</u>	<u>N017608 001</u>	
<u>DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER</u>					
AP		B BRAUN	<u>20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML</u>	<u>N019634 003</u>	Feb 24, 1988
<u>LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER</u>					
AP		BAXTER HLTHCARE	<u>20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML</u>	<u>N016679 001</u>	
<u>POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER</u>					
AP		BAXTER HLTHCARE	<u>20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML</u>	<u>N019367 006</u>	Apr 05, 1985
<u>POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER</u>					
AP		BAXTER HLTHCARE	<u>20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML</u>	<u>N019367 004</u>	Apr 05, 1985

PRESCRIPTION DRUG PRODUCT LIST

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP		<u>20MG/100ML; 5GM/100ML; 328MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019367 005</u>	Apr 05, 1985
-----------	--	---	--------------------	--------------

AP	+ ICU MEDICAL INC	<u>20MG/100ML; 5GM/100ML; 179MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019685 002</u>	Oct 17, 1988
-----------	-------------------	---	--------------------	--------------

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	<u>20MG/100ML; 5GM/100ML; 254MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019367 007</u>	Apr 05, 1985
-----------	-----------------	---	--------------------	--------------

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	<u>20MG/100ML; 5GM/100ML; 328MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019367 008</u>	Apr 05, 1985
-----------	-----------------	---	--------------------	--------------

DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER

	B BRAUN	10MG/100ML; 2.5GM/100ML; 15MG/100ML; 300MG/100ML; 160MG/100ML	N019634 001	Feb 24, 1988
--	---------	---	-------------	--------------

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

	BAXTER HLTHCARE	20MG/100ML; 5GM/100ML; 105MG/100ML; 600MG/100ML; 310MG/100ML	N019367 002	Apr 05, 1985
--	-----------------	--	-------------	--------------

		20MG/100ML; 5GM/100ML; 179MG/100ML; 600MG/100ML; 310MG/100ML	N019367 003	Apr 05, 1985
--	--	--	-------------	--------------

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

	BAXTER HLTHCARE	20MG/100ML; 5GM/100ML; 105MG/100ML; 600MG/100ML; 310MG/100ML	N019367 001	Apr 05, 1985
--	-----------------	--	-------------	--------------

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TPN ELECTROLYTES IN PLASTIC CONTAINER

	+! HOSPIRA	16.5MG/ML; 25.4MG/ML; 74.6MG/ML; 121MG/ML; 16.1MG/ML	N018895 001	Jul 20, 1984
--	------------	--	-------------	--------------

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SOLUTION; IRRIGATION

BALANCED SALT

AT	AKORN	<u>0.48MG/ML; 0.3MG/ML; 0.75MG/ML; 3.9MG/ML; 6.4MG/ML; 1.7MG/ML</u>	<u>A075503 001</u>	Sep 27, 2006
-----------	-------	---	--------------------	--------------

AT	B BRAUN	<u>0.48MG/ML; 0.3MG/ML; 0.75MG/ML; 3.9MG/ML; 6.4MG/ML; 1.7MG/ML</u>	<u>A091387 001</u>	Feb 03, 2010
-----------	---------	---	--------------------	--------------

BSS

AT	+! ALCON	<u>0.48MG/ML; 0.3MG/ML; 0.75MG/ML; 3.9MG/ML; 6.4MG/ML; 1.7MG/ML</u>	<u>N020742 001</u>	Dec 10, 1997
-----------	----------	---	--------------------	--------------

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE; INJECTION

PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER

	+! BAXTER HLTHCARE CORP	N/A/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 6.95GM/1000ML; 0.187GM/1000ML (5000ML)	N207026 002	Jan 13, 2015
--	-------------------------	--	-------------	--------------

PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER

	+! BAXTER HLTHCARE CORP	3.68GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.34GM/1000ML; 0.187GM/1000ML	N207026 001	Jan 13, 2015
--	-------------------------	--	-------------	--------------

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION; PERFUSION, CARDIAC

CARDIOPLEGIC IN PLASTIC CONTAINER

AT	BAXTER HLTHCARE	<u>17.6MG/100ML; 325.3MG/100ML; 119.3MG/100ML; 643MG/100ML</u>	<u>A075323 001</u>	Apr 21, 2000
-----------	-----------------	--	--------------------	--------------

PLEGISOL IN PLASTIC CONTAINER

AT	+! HOSPIRA	<u>17.6MG/100ML; 325.3MG/100ML; 119.3MG/100ML; 643MG/100ML</u>	<u>N018608 001</u>	Feb 26, 1982
-----------	------------	--	--------------------	--------------

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

RINGER'S IN PLASTIC CONTAINER

AP	B BRAUN	<u>33MG/100ML; 30MG/100ML; 860MG/100ML</u>	<u>N020002 001</u>	Apr 17, 1992
-----------	---------	--	--------------------	--------------

AP	BAXTER HLTHCARE	<u>33MG/100ML; 30MG/100ML; 860MG/100ML</u>	<u>N016693 001</u>	
-----------	-----------------	--	--------------------	--

AP	ICU MEDICAL INC	<u>33MG/100ML; 30MG/100ML; 860MG/100ML</u>	<u>N018251 001</u>	
-----------	-----------------	--	--------------------	--

SOLUTION; IRRIGATION

RINGER'S IN PLASTIC CONTAINER

AT	B BRAUN	<u>33MG/100ML; 30MG/100ML; 860MG/100ML</u>	<u>N018156 001</u>	
-----------	---------	--	--------------------	--

AT	BAXTER HLTHCARE	<u>33MG/100ML; 30MG/100ML; 860MG/100ML</u>	<u>N018495 001</u>	Feb 19, 1982
-----------	-----------------	--	--------------------	--------------

AT	ICU MEDICAL INC	<u>33MG/100ML; 30MG/100ML; 860MG/100ML</u>	<u>N017635 001</u>	
-----------	-----------------	--	--------------------	--

PRESCRIPTION DRUG PRODUCT LIST

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

AP	B BRAUN	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019632 001</u>	Feb 29, 1988
AP	+! BAXTER HLTHCARE	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N016682 001</u>	
AP	FRESENIUS KABI USA	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>A209338 001</u>	Jan 28, 2019
AP	ICU MEDICAL INC	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N017641 001</u>	

SOLUTION; IRRIGATION

LACTATED RINGER'S IN PLASTIC CONTAINER

AT	+! B BRAUN	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N018681 001</u>	Dec 27, 1982
AT	BAXTER HLTHCARE	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N018494 001</u>	Feb 19, 1982
AT	+!	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N018921 001</u>	Apr 03, 1984
AT	+! ICU MEDICAL INC	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019416 001</u>	Jan 17, 1986

CALCIUM GLUCONATE

SOLUTION; INTRAVENOUS

CALCIUM GLUCONATE

+!	FRESENIUS KABI USA	1GM/10ML (100MG/ML)	N208418 001	Jun 15, 2017
+!		5GM/50ML (100MG/ML)	N208418 002	Jun 15, 2017
+!		10GM/100ML (100MG/ML)	N208418 003	Jun 15, 2017

CALCIUM GLUCONATE IN SODIUM CHLORIDE

+!	HQ SPCLT PHARMA	1GM/50ML (20MG/ML)	N210906 001	Oct 29, 2018
+!		2GM/100ML (20MG/ML)	N210906 002	Oct 29, 2018

CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE

SOLUTION; ORAL

XYWAV

+!	JAZZ	0.234GM/ML; 0.096GM/ML; 0.13GM/ML; 0.04GM/ML	N212690 001	Jul 21, 2020
----	------	--	-------------	--------------

CANAGLIFLOZIN

TABLET; ORAL

INVOKANA

+	JANSSEN PHARMS	100MG	N204042 001	Mar 29, 2013
+!		300MG	N204042 002	Mar 29, 2013

CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET; ORAL

INVOKAMET

+	JANSSEN PHARMS	50MG; 500MG	N204353 001	Aug 08, 2014
+		50MG; 1GM	N204353 002	Aug 08, 2014
+		150MG; 500MG	N204353 003	Aug 08, 2014
+!		150MG; 1GM	N204353 004	Aug 08, 2014

TABLET, EXTENDED RELEASE; ORAL

INVOKAMET XR

+	JANSSEN PHARMS	50MG; 500MG	N205879 001	Sep 20, 2016
+		50MG; 1GM	N205879 002	Sep 20, 2016
+		150MG; 500MG	N205879 003	Sep 20, 2016
+!		150MG; 1GM	N205879 004	Sep 20, 2016

CANDESARTAN CILEXETIL

TABLET; ORAL

ATACAND

AB	+	ANI PHARMS INC	<u>4MG</u>	<u>N020838 001</u>	Jun 04, 1998
AB	+		<u>8MG</u>	<u>N020838 002</u>	Jun 04, 1998
AB	+		<u>16MG</u>	<u>N020838 003</u>	Jun 04, 1998
AB	+!		<u>32MG</u>	<u>N020838 004</u>	Jun 04, 1998

CANDESARTAN CILEXETIL

AB	ALEMBIC PHARMS LTD	<u>4MG</u>	<u>A210302 001</u>	Dec 04, 2018
AB		<u>8MG</u>	<u>A210302 002</u>	Dec 04, 2018
AB		<u>16MG</u>	<u>A210302 003</u>	Dec 04, 2018
AB		<u>32MG</u>	<u>A209119 001</u>	Jun 20, 2017
AB	MACLEODS PHARMS LTD	<u>4MG</u>	<u>A203813 001</u>	Dec 05, 2016
AB		<u>8MG</u>	<u>A203813 002</u>	Dec 05, 2016
AB		<u>16MG</u>	<u>A203813 003</u>	Dec 05, 2016
AB		<u>32MG</u>	<u>A203813 004</u>	Dec 05, 2016
AB	MYLAN	<u>4MG</u>	<u>A078702 001</u>	May 03, 2013
AB		<u>8MG</u>	<u>A078702 002</u>	May 03, 2013
AB		<u>16MG</u>	<u>A078702 003</u>	May 03, 2013

PRESCRIPTION DRUG PRODUCT LIST

CANDESARTAN CILEXETIL

TABLET; ORAL

CANDESARTAN CILEXETIL

<u>AB</u>		<u>32MG</u>	<u>A078702</u>	<u>004</u>	May 03, 2013
<u>AB</u>	ZYDUS PHARMS	<u>4MG</u>	<u>A091390</u>	<u>001</u>	Aug 23, 2017
<u>AB</u>		<u>8MG</u>	<u>A091390</u>	<u>002</u>	Aug 23, 2017
<u>AB</u>		<u>16MG</u>	<u>A091390</u>	<u>003</u>	Aug 23, 2017
<u>AB</u>		<u>32MG</u>	<u>A091390</u>	<u>004</u>	Aug 23, 2017

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ATACAND HCT

<u>AB</u>	+	ANI PHARMS INC	<u>16MG;12.5MG</u>	<u>N021093</u>	<u>001</u>	Sep 05, 2000
<u>AB</u>	+		<u>32MG;12.5MG</u>	<u>N021093</u>	<u>002</u>	Sep 05, 2000
<u>AB</u>	+	!	<u>32MG;25MG</u>	<u>N021093</u>	<u>003</u>	May 16, 2008

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

<u>AB</u>		DR REDDYS LABS LTD	<u>16MG;12.5MG</u>	<u>A202965</u>	<u>001</u>	Jun 03, 2013
<u>AB</u>			<u>32MG;12.5MG</u>	<u>A202965</u>	<u>002</u>	Jun 03, 2013
<u>AB</u>			<u>32MG;25MG</u>	<u>A202965</u>	<u>003</u>	Jun 03, 2013
<u>AB</u>		MACLEODS PHARMS LTD	<u>16MG;12.5MG</u>	<u>A204100</u>	<u>001</u>	Feb 27, 2015
<u>AB</u>			<u>32MG;12.5MG</u>	<u>A204100</u>	<u>002</u>	Feb 27, 2015
<u>AB</u>			<u>32MG;25MG</u>	<u>A204100</u>	<u>003</u>	Feb 27, 2015
<u>AB</u>		MYLAN	<u>16MG;12.5MG</u>	<u>A090704</u>	<u>001</u>	Dec 04, 2012
<u>AB</u>			<u>32MG;12.5MG</u>	<u>A090704</u>	<u>002</u>	Dec 04, 2012
<u>AB</u>			<u>32MG;25MG</u>	<u>A090704</u>	<u>003</u>	Dec 04, 2012
<u>AB</u>		PRINSTON INC	<u>16MG;12.5MG</u>	<u>A207455</u>	<u>001</u>	Apr 11, 2018
<u>AB</u>			<u>32MG;12.5MG</u>	<u>A207455</u>	<u>002</u>	Apr 11, 2018
<u>AB</u>			<u>32MG;25MG</u>	<u>A207455</u>	<u>003</u>	Apr 11, 2018
<u>AB</u>		ZYDUS PHARMS	<u>16MG;12.5MG</u>	<u>A203466</u>	<u>001</u>	Nov 27, 2017
<u>AB</u>			<u>32MG;12.5MG</u>	<u>A203466</u>	<u>002</u>	Nov 27, 2017
<u>AB</u>			<u>32MG;25MG</u>	<u>A203466</u>	<u>003</u>	Nov 27, 2017

CANGRELOR

POWDER; INTRAVENOUS

KENGREAL

	+	CHIESI	50MG/VIAL	N204958	001	Jun 22, 2015
--	---	--------	-----------	---------	-----	--------------

CANNABIDIOL

SOLUTION; ORAL

EPIDIOLEX

	+	GW RES LTD	100MG/ML	N210365	001	Sep 28, 2018
--	---	------------	----------	---------	-----	--------------

CAPECITABINE

TABLET; ORAL

CAPECITABINE

<u>AB</u>		ACCORD HLTHCARE	<u>150MG</u>	<u>A202593</u>	<u>001</u>	Apr 23, 2015
<u>AB</u>			<u>500MG</u>	<u>A202593</u>	<u>002</u>	Apr 23, 2015
<u>AB</u>		ALKEM LABS LTD	<u>150MG</u>	<u>A207652</u>	<u>001</u>	Nov 24, 2017
<u>AB</u>			<u>500MG</u>	<u>A207652</u>	<u>002</u>	Nov 24, 2017
<u>AB</u>		AMNEAL PHARMS	<u>150MG</u>	<u>A204741</u>	<u>001</u>	Feb 28, 2017
<u>AB</u>			<u>500MG</u>	<u>A204741</u>	<u>002</u>	Feb 28, 2017
<u>AB</u>		DR REDDYS LABS LTD	<u>150MG</u>	<u>A204345</u>	<u>001</u>	Dec 04, 2020
<u>AB</u>			<u>500MG</u>	<u>A204345</u>	<u>002</u>	Dec 04, 2020
<u>AB</u>		EUGIA PHARMA	<u>150MG</u>	<u>A210604</u>	<u>001</u>	Apr 17, 2018
<u>AB</u>			<u>500MG</u>	<u>A210604</u>	<u>002</u>	Apr 17, 2018
<u>AB</u>		HIKMA	<u>150MG</u>	<u>A200483</u>	<u>001</u>	Jul 14, 2016
<u>AB</u>			<u>500MG</u>	<u>A200483</u>	<u>002</u>	Jul 14, 2016
<u>AB</u>		MSN	<u>150MG</u>	<u>A209365</u>	<u>001</u>	Jul 02, 2018
<u>AB</u>			<u>500MG</u>	<u>A209365</u>	<u>002</u>	Jul 02, 2018
<u>AB</u>		MYLAN	<u>150MG</u>	<u>A090943</u>	<u>001</u>	Aug 08, 2014
<u>AB</u>			<u>500MG</u>	<u>A090943</u>	<u>002</u>	Aug 08, 2014
<u>AB</u>		RELIANCE LIFE	<u>150MG</u>	<u>A211724</u>	<u>001</u>	Apr 27, 2020
<u>AB</u>			<u>500MG</u>	<u>A211724</u>	<u>002</u>	Apr 27, 2020
<u>AB</u>		SHILPA MEDICARE LTD	<u>150MG</u>	<u>A207456</u>	<u>001</u>	Dec 12, 2016
<u>AB</u>			<u>500MG</u>	<u>A207456</u>	<u>002</u>	Dec 12, 2016
<u>AB</u>		SUN PHARM	<u>150MG</u>	<u>A204668</u>	<u>001</u>	Jun 21, 2019
<u>AB</u>			<u>500MG</u>	<u>A204668</u>	<u>002</u>	Jun 21, 2019
<u>AB</u>		TEVA PHARMS USA	<u>150MG</u>	<u>A091649</u>	<u>001</u>	Sep 16, 2013
<u>AB</u>			<u>500MG</u>	<u>A091649</u>	<u>002</u>	Sep 16, 2013

XELODA

<u>AB</u>	+	HOFFMANN LA ROCHE	<u>150MG</u>	<u>N020896</u>	<u>001</u>	Apr 30, 1998
<u>AB</u>	+	!	<u>500MG</u>	<u>N020896</u>	<u>002</u>	Apr 30, 1998

PRESCRIPTION DRUG PRODUCT LIST

CAPMATINIB HYDROCHLORIDE

TABLET; ORAL

TABRECTA

+	NOVARTIS PHARM	EQ 150MG BASE	N213591	001	May 06, 2020
+	!	EQ 200MG BASE	N213591	002	May 06, 2020

CAPREOMYCIN SULFATE

INJECTABLE; INJECTION

CAPASTAT SULFATE

+	AKORN	EQ 1GM BASE/VIAL	N050095	001	
---	-------	------------------	---------	-----	--

CAPSAICIN

PATCH; TOPICAL

QUTENZA

+	AVERITAS	8%	N022395	001	Nov 16, 2009
---	----------	----	---------	-----	--------------

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

AB	AJANTA PHARMA LTD	12.5MG	A212809	001	Dec 13, 2019
AB		25MG	A212809	002	Dec 13, 2019
AB		50MG	A212809	003	Dec 13, 2019
AB		100MG	A212809	004	Dec 13, 2019
AB	BOSCOGEN	12.5MG	A074677	004	May 30, 1997
AB		25MG	A074677	002	May 30, 1997
AB		50MG	A074677	001	May 30, 1997
AB		100MG	A074677	003	May 30, 1997
AB	HIKMA INTL PHARMS	12.5MG	A074505	001	Feb 13, 1996
AB		25MG	A074505	002	Feb 13, 1996
AB		50MG	A074505	003	Feb 13, 1996
AB		100MG	A074505	004	Feb 13, 1996
AB	MYLAN	12.5MG	A074434	001	Feb 13, 1996
AB		25MG	A074434	002	Feb 13, 1996
AB		50MG	A074434	003	Feb 13, 1996
AB	!	100MG	A074434	004	Feb 13, 1996
AB	PRINSTON INC	12.5MG	A074477	001	Feb 13, 1996
AB		25MG	A074477	002	Feb 13, 1996
AB		50MG	A074477	003	Feb 13, 1996
AB		100MG	A074477	004	Feb 13, 1996
AB	WOCKHARDT LTD	12.5MG	A074532	001	Mar 28, 1997
AB		25MG	A074532	002	Mar 28, 1997
AB		50MG	A074532	003	Mar 28, 1997
AB		100MG	A074532	004	Mar 28, 1997

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

	MYLAN	25MG; 15MG	A074896	001	Dec 29, 1997
!		25MG; 25MG	A074896	002	Dec 29, 1997
!		50MG; 15MG	A074896	004	Dec 29, 1997
		50MG; 25MG	A074896	003	Dec 29, 1997

CARBACHOL

SOLUTION; INTRAOCULAR

MIOSTAT

+	ALCON	0.01%	N016968	001	
---	-------	-------	---------	-----	--

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

AB	APOTEX INC	100MG	A078986	001	Nov 25, 2011
AB		200MG	A078986	002	Nov 25, 2011
AB		300MG	A078986	003	Nov 25, 2011
AB	NOSTRUM LABS INC	100MG	A076697	001	May 20, 2011
AB		200MG	A076697	002	May 20, 2011
AB		300MG	A076697	003	May 20, 2011
AB	TARO	100MG	A201106	001	Jun 21, 2013
AB		200MG	A201106	002	Jun 21, 2013
AB		300MG	A201106	003	Jun 21, 2013
AB	TEVA PHARMS	100MG	A078592	001	Sep 20, 2012
AB		200MG	A078592	002	Sep 20, 2012
AB		300MG	A078592	003	Sep 20, 2012

CARBATROL

AB	+	TAKEDA PHARMS USA	100MG	N020712	003	Sep 30, 1997
AB	+		200MG	N020712	001	Sep 30, 1997

PRESCRIPTION DRUG PRODUCT LIST

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE;ORAL

CARBATROL

AB	+!	300MG	N020712 002	Sep 30, 1997
	EQUETRO			
	+ VALIDUS PHARMS	100MG	N021710 001	Dec 10, 2004
	+	200MG	N021710 002	Dec 10, 2004
	+!	300MG	N021710 003	Dec 10, 2004

SUSPENSION;ORAL

CARBAMAZEPINE

AB	WOCKHARDT BIO AG	100MG/5ML	A075714 001	Jun 05, 2002
-----------	------------------	------------------	--------------------	--------------

TEGRETOL

AB	+!	NOVARTIS	100MG/5ML	N018927 001	Dec 18, 1987
-----------	-----------	----------	------------------	--------------------	--------------

TERIL

AB	TARO	100MG/5ML	A076729 001	Sep 20, 2004
-----------	------	------------------	--------------------	--------------

TABLET;ORAL

CARBAMAZEPINE

AB	APOTEX INC	200MG	A075948 001	Feb 27, 2002
AB	TARO	200MG	A074649 001	Oct 03, 1996
AB	TORRENT PHARMS	100MG	A077272 001	Dec 07, 2005
AB		200MG	A077272 002	Dec 07, 2005
AB	UMEDICA LABS PVT LTD	100MG	A207798 001	Apr 15, 2020
AB		200MG	A207798 002	Apr 15, 2020

EPITOL

AB	TEVA	200MG	A070541 001	Sep 17, 1986
-----------	------	--------------	--------------------	--------------

TEGRETOL

AB	+!	NOVARTIS	200MG	N016608 001
	CARBAMAZEPINE			
	TORRENT PHARMS	300MG	A077272 003	Dec 07, 2005
		400MG	A077272 004	Dec 07, 2005

TABLET, CHEWABLE;ORAL

CARBAMAZEPINE

AB	!	TARO PHARM INDS	100MG	A075687 001	Oct 24, 2000
AB		TORRENT PHARMS	100MG	A075712 001	Jul 05, 2001

EPITOL

AB	TEVA	100MG	A073524 001	Jul 29, 1992	
	CARBAMAZEPINE				
	!	TARO PHARM INDS	200MG	A075687 002	Jul 29, 2002

TABLET, EXTENDED RELEASE;ORAL

CARBAMAZEPINE

AB	TARO	100MG	A078115 001	Mar 31, 2009
AB		200MG	A078115 002	Mar 31, 2009
AB		400MG	A078115 003	Mar 31, 2009
AB	UNIQUE PHARM	100MG	A211623 001	Apr 24, 2020
AB		200MG	A211623 002	Apr 24, 2020
AB		400MG	A211623 003	Apr 24, 2020
AB	ZYDUS PHARMS	100MG	A205571 001	Feb 07, 2019
AB		200MG	A205571 002	Feb 07, 2019
AB		400MG	A205571 003	Feb 07, 2019

TEGRETOL-XR

AB	+	NOVARTIS	100MG	N020234 001	Mar 25, 1996
AB	+		200MG	N020234 002	Mar 25, 1996
AB	+!		400MG	N020234 003	Mar 25, 1996

CARBIDOPA

TABLET;ORAL

CARBIDOPA

AB	ALVOGEN	25MG	A204291 001	Jan 08, 2016
AB	ANI PHARMS INC	25MG	A203261 001	Mar 10, 2014
AB	AUROBINDO PHARMA LTD	25MG	A211055 001	Oct 21, 2019
AB	EDENBRIDGE PHARMS	25MG	A205304 001	Feb 17, 2016
AB	NOVEL LABS INC	25MG	A204763 001	Oct 20, 2017
AB	ZYDUS PHARMS	25MG	A209910 001	May 07, 2018

LODOSYN

AB	+!	ATON	25MG	N017830 001
-----------	-----------	------	-------------	--------------------

PRESCRIPTION DRUG PRODUCT LIST

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

AB	SUN PHARM	25MG;200MG;100MG	A079085 001	May 10, 2012
AB		37.5MG;200MG;150MG	A079085 002	May 10, 2012
	STALEVO 100			
AB	+ ORION PHARMA	25MG;200MG;100MG	N021485 002	Jun 11, 2003
	STALEVO 150			
AB	+ ORION PHARMA	37.5MG;200MG;150MG	N021485 003	Jun 11, 2003
	STALEVO 125			
	+ ORION PHARMA	31.25MG;200MG;125MG	N021485 006	Aug 29, 2008
	STALEVO 200			
	+! ORION PHARMA	50MG;200MG;200MG	N021485 004	Aug 02, 2007
	STALEVO 50			
	+! ORION PHARMA	12.5MG;200MG;50MG	N021485 001	Jun 11, 2003
	STALEVO 75			
	+ ORION PHARMA	18.75MG;200MG;75MG	N021485 005	Aug 29, 2008

CARBIDOPA; LEVODOPA

CAPSULE, EXTENDED RELEASE; ORAL

RYTARY

	+ IMPAX LABS INC	23.75MG;95MG	N203312 001	Jan 07, 2015
		36.25MG;145MG	N203312 002	Jan 07, 2015
		48.75MG;195MG	N203312 003	Jan 07, 2015
	+!	61.25MG;245MG	N203312 004	Jan 07, 2015

SUSPENSION; ENTERAL

DUOPA

	+! ABBVIE INC	4.63MG/ML;20MG/ML	N203952 001	Jan 09, 2015
--	---------------	-------------------	-------------	--------------

TABLET; ORAL

CARBIDOPA AND LEVODOPA

AB	ACTAVIS ELIZABETH	10MG;100MG	A074260 001	Sep 03, 1993
AB		25MG;100MG	A074260 002	Sep 03, 1993
AB	!	25MG;250MG	A074260 003	Sep 03, 1993
AB	APOTEX INC	10MG;100MG	A077120 001	Jun 02, 2008
AB		25MG;100MG	A077120 002	Jun 02, 2008
AB		25MG;250MG	A077120 003	Jun 02, 2008
AB	MAYNE PHARMA	10MG;100MG	A073618 001	Aug 28, 1992
AB		25MG;100MG	A073589 001	Aug 28, 1992
AB		25MG;250MG	A073607 001	Aug 28, 1992
AB	MYLAN	10MG;100MG	A090324 001	Sep 28, 2009
AB		25MG;100MG	A090324 002	Sep 28, 2009
AB		25MG;250MG	A090324 003	Sep 28, 2009
AB	SUN PHARM INDS	10MG;100MG	A078536 001	Oct 28, 2008
AB		25MG;100MG	A078536 002	Oct 28, 2008
AB		25MG;250MG	A078536 003	Oct 28, 2008
	SINEMET			
AB	+ MERCK SHARP DOHME	10MG;100MG	N017555 001	
AB		25MG;100MG	N017555 003	
AB		25MG;250MG	N017555 002	

TABLET, EXTENDED RELEASE; ORAL

CARBIDOPA AND LEVODOPA

AB	ACCORD HLTHCARE	25MG;100MG	A202323 001	Feb 08, 2013
AB		50MG;200MG	A202323 002	Feb 08, 2013
AB	ALEMBIC PHARMS LTD	25MG;100MG	A210341 001	Jun 05, 2019
AB		50MG;200MG	A210341 002	Jun 05, 2019
AB	APOTEX	25MG;100MG	A076212 001	Jun 16, 2004
AB		50MG;200MG	A076212 002	Jun 16, 2004
AB	IMPAX LABS	25MG;100MG	A076521 001	May 14, 2004
AB		50MG;200MG	A076521 002	May 14, 2004
AB	MYLAN	25MG;100MG	A075091 002	Apr 21, 2000
AB		50MG;200MG	A075091 001	Sep 30, 1999
AB	SUN PHARM INDS	25MG;100MG	A077828 001	Aug 23, 2007
AB	!	50MG;200MG	A077828 002	Aug 23, 2007

TABLET, ORALLY DISINTEGRATING; ORAL

CARBIDOPA AND LEVODOPA

AB	MYLAN	10MG;100MG	A078893 001	Sep 18, 2008
AB		25MG;100MG	A078893 002	Sep 18, 2008
AB	!	25MG;250MG	A078893 003	Sep 18, 2008
AB	SUN PHARM	10MG;100MG	A078690 001	Jul 31, 2009
AB		25MG;100MG	A078690 002	Jul 31, 2009
AB		25MG;250MG	A078690 003	Jul 31, 2009

PRESCRIPTION DRUG PRODUCT LIST

CARBINOXAMINE MALEATE

SOLUTION;ORAL

CARBINOXAMINE MALEATE

! MIKART

4MG/5ML

A040458 001 Apr 25, 2003

SUSPENSION, EXTENDED RELEASE;ORAL

KARBINAL ER

+! AYTU

4MG/5ML

N022556 001 Mar 28, 2013

TABLET;ORAL

CARBINOXAMINE MALEATE

<u>AA</u>	INVAGEN PHARMS	<u>4MG</u>	<u>A090435</u>	<u>001</u>	Apr 15, 2010
<u>AA</u>	! MIKART	<u>4MG</u>	<u>A040442</u>	<u>001</u>	Mar 19, 2003
<u>AA</u>	MISSION PHARMACAL CO	<u>4MG</u>	<u>A090756</u>	<u>001</u>	May 27, 2011
	! MIKART	6MG	A207484	001	May 31, 2016

CARBOPLATIN

INJECTABLE;INJECTION

CARBOPLATIN

<u>AP</u>	EUGIA PHARMA	<u>600MG/60ML (10MG/ML)</u>	<u>A205487</u>	<u>004</u>	Aug 03, 2020
-----------	--------------	-----------------------------	----------------	------------	--------------

INJECTABLE;INTRAVENOUS

CARBOPLATIN

<u>AP</u>	ACCORD HLTHCARE	<u>50MG/5ML (10MG/ML)</u>	<u>A206775</u>	<u>001</u>	Feb 09, 2017
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A206775</u>	<u>002</u>	Feb 09, 2017
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A206775</u>	<u>003</u>	Feb 09, 2017
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A206775</u>	<u>004</u>	Feb 09, 2017
<u>AP</u>	AKORN	<u>50MG/5ML (10MG/ML)</u>	<u>A090475</u>	<u>001</u>	Jul 29, 2009
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A090475</u>	<u>002</u>	Jul 29, 2009
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A090475</u>	<u>003</u>	Jul 29, 2009
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A091268</u>	<u>002</u>	Jul 28, 2010
<u>AP</u>	CIPLA LTD	<u>50MG/5ML (10MG/ML)</u>	<u>A077861</u>	<u>001</u>	Jan 18, 2007
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077861</u>	<u>002</u>	Jan 18, 2007
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077861</u>	<u>003</u>	Jan 18, 2007
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A077861</u>	<u>004</u>	Jan 18, 2007
<u>AP</u>	EUGIA PHARMA	<u>50MG/5ML (10MG/ML)</u>	<u>A205487</u>	<u>001</u>	Mar 28, 2016
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A205487</u>	<u>002</u>	Mar 28, 2016
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A205487</u>	<u>003</u>	Mar 28, 2016
<u>AP</u>	FRESENIUS KABI USA	<u>450MG/45ML (10MG/ML)</u>	<u>A077247</u>	<u>003</u>	Oct 21, 2004
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077266</u>	<u>003</u>	Feb 15, 2006
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A077266</u>	<u>004</u>	Feb 15, 2006
<u>AP</u>	GLAND PHARMA LTD	<u>150MG/15ML (10MG/ML)</u>	<u>A207324</u>	<u>002</u>	Feb 15, 2017
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A207324</u>	<u>003</u>	Feb 15, 2017
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A207324</u>	<u>004</u>	Feb 15, 2017
<u>AP</u>	HOSPIRA	<u>50MG/5ML (10MG/ML)</u>	<u>A076517</u>	<u>001</u>	Oct 14, 2004
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A076517</u>	<u>002</u>	Oct 14, 2004
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A076517</u>	<u>003</u>	Oct 14, 2004
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A077059</u>	<u>001</u>	Nov 23, 2004
<u>AP</u>	MEITHEAL	<u>50MG/5ML (10MG/ML)</u>	<u>A077096</u>	<u>001</u>	Jun 14, 2005
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077096</u>	<u>002</u>	Jun 14, 2005
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077096</u>	<u>003</u>	Jun 14, 2005
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A077096</u>	<u>004</u>	Jun 03, 2013
<u>AP</u>	NOVAST LABS	<u>50MG/5ML (10MG/ML)</u>	<u>A208487</u>	<u>001</u>	Apr 26, 2017
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A208487</u>	<u>002</u>	Apr 26, 2017
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A208487</u>	<u>003</u>	Apr 26, 2017
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A208487</u>	<u>004</u>	Apr 26, 2017
<u>AP</u>	! PHARMACHEMIE BV	<u>50MG/5ML (10MG/ML)</u>	<u>A077269</u>	<u>001</u>	Oct 14, 2004
<u>AP</u>	!	<u>150MG/15ML (10MG/ML)</u>	<u>A077269</u>	<u>002</u>	Oct 14, 2004
<u>AP</u>	!	<u>450MG/45ML (10MG/ML)</u>	<u>A077269</u>	<u>003</u>	Oct 14, 2004
<u>AP</u>	!	<u>600MG/60ML (10MG/ML)</u>	<u>A077269</u>	<u>004</u>	Dec 28, 2007
<u>AP</u>	SANDOZ INC	<u>50MG/5ML (10MG/ML)</u>	<u>A078280</u>	<u>001</u>	May 08, 2008
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A078280</u>	<u>002</u>	May 08, 2008
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A078280</u>	<u>003</u>	May 08, 2008
<u>AP</u>	SUN PHARM	<u>50MG/5ML (10MG/ML)</u>	<u>A077926</u>	<u>001</u>	Sep 19, 2008
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077926</u>	<u>002</u>	Sep 19, 2008
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077926</u>	<u>003</u>	Sep 19, 2008
<u>AP</u>	WEST-WARD PHARMS INT	<u>50MG/5ML (10MG/ML)</u>	<u>A077244</u>	<u>001</u>	Oct 15, 2004
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077244</u>	<u>002</u>	Oct 15, 2004
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077244</u>	<u>003</u>	Oct 15, 2004
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A077244</u>	<u>004</u>	Jan 20, 2006
	! ACCORD HLTHCARE	1GM/100ML (10MG/ML)	A206775	005	Apr 06, 2020
	INJECTABLE;IV (INFUSION)				
	<u>CARBOPLATIN</u>				
<u>AP</u>	GLAND PHARMA LTD	<u>50MG/5ML (10MG/ML)</u>	<u>A207324</u>	<u>001</u>	Feb 15, 2017

PRESCRIPTION DRUG PRODUCT LIST

CARBOPROST TROMETHAMINE

INJECTABLE; INJECTION

CARBOPROST TROMETHAMINE

AP	DR REDDYS LABS LTD	EQ 0.25MG BASE/ML	A211941 001	Jul 02, 2019
-----------	--------------------	--------------------------	--------------------	--------------

HEMABATE

AP	+	PFIZER	EQ 0.25MG BASE/ML	N017989 001
-----------	---	--------	--------------------------	--------------------

CARFILZOMIB

POWDER; INTRAVENOUS

CARFILZOMIB

AP	DR REDDYS	60MG/VIAL	A209422 001	Sep 09, 2019
-----------	-----------	------------------	--------------------	--------------

KYPROLIS

AP	+	ONYX THERAP	60MG/VIAL	N202714 001	Jul 20, 2012
	+		10MG/VIAL	N202714 003	Jun 07, 2018
	+		30MG/VIAL	N202714 002	Jun 03, 2016

CARGLUMIC ACID

TABLET, FOR SUSPENSION; ORAL

CARBAGLU

+	RECORDATI RARE	200MG	N022562 001	Mar 18, 2010
---	----------------	-------	-------------	--------------

CARIPRAZINE HYDROCHLORIDE

CAPSULE; ORAL

VRAYLAR

+	ALLERGAN	EQ 1.5MG BASE	N204370 001	Sep 17, 2015
---	----------	---------------	-------------	--------------

+		EQ 3MG BASE	N204370 002	Sep 17, 2015
---	--	-------------	-------------	--------------

+		EQ 4.5MG BASE	N204370 003	Sep 17, 2015
---	--	---------------	-------------	--------------

+		EQ 6MG BASE	N204370 004	Sep 17, 2015
---	--	-------------	-------------	--------------

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

AA	ACCELRX LABS	350MG	A040576 001	Jun 07, 2005
-----------	--------------	--------------	--------------------	--------------

AA	ALLIED	350MG	A040245 001	Sep 08, 1997
-----------	--------	--------------	--------------------	--------------

AA	AUROBINDO PHARMA	350MG	A040792 001	Aug 06, 2009
-----------	------------------	--------------	--------------------	--------------

AA	FOSUN PHARMA	350MG	A081025 001	Apr 13, 1989
-----------	--------------	--------------	--------------------	--------------

AA	NATCO PHARMA LTD	350MG	A090988 001	Oct 28, 2014
-----------	------------------	--------------	--------------------	--------------

AA	NOSTRUM LABS INC	350MG	A207237 002	Sep 21, 2020
-----------	------------------	--------------	--------------------	--------------

AA	NOVAST LABS	350MG	A040823 001	Oct 22, 2008
-----------	-------------	--------------	--------------------	--------------

AA	ORIENT PHARMA CO	350MG	A205085 001	Oct 28, 2014
-----------	------------------	--------------	--------------------	--------------

AA	LTD			
-----------	-----	--	--	--

AA	OXFORD PHARMS	350MG	A040188 001	Mar 07, 1997
-----------	---------------	--------------	--------------------	--------------

AA	SCIEGEN PHARMS INC	350MG	A203374 001	Jan 27, 2014
-----------	--------------------	--------------	--------------------	--------------

AA	STRIDES PHARMA	350MG	A205513 002	Nov 12, 2015
-----------	----------------	--------------	--------------------	--------------

AA	WATSON LABS	350MG	A087499 001	Apr 20, 1982
-----------	-------------	--------------	--------------------	--------------

AA	WILSHIRE PHARMS INC	350MG	A205126 002	Jul 08, 2015
-----------	---------------------	--------------	--------------------	--------------

SOMA

AA	+	MYLAN SPECIALITY LP	350MG	N011792 001
-----------	---	---------------------	--------------	--------------------

CARISOPRODOL

AB	AUROBINDO PHARMA	250MG	A040792 002	Nov 08, 2016
-----------	------------------	--------------	--------------------	--------------

AB	NOSTRUM LABS INC	250MG	A207237 001	May 11, 2017
-----------	------------------	--------------	--------------------	--------------

AB	STRIDES PHARMA	250MG	A205513 001	Nov 12, 2015
-----------	----------------	--------------	--------------------	--------------

AB	WILSHIRE PHARMS INC	250MG	A205126 001	Jul 08, 2015
-----------	---------------------	--------------	--------------------	--------------

SOMA

AB	+	MYLAN SPECIALITY LP	250MG	N011792 004	Sep 13, 2007
-----------	---	---------------------	--------------	--------------------	--------------

CARMUSTINE

IMPLANT; INTRACRANIAL

GLIADEL

+	ARBOR PHARMS LLC	7.7MG	N020637 001	Sep 23, 1996
---	------------------	-------	-------------	--------------

INJECTABLE; INJECTION

BICNU

AP	+	EMCURE PHARMS LTD	100MG/VIAL	N017422 001
-----------	---	-------------------	-------------------	--------------------

CARMUSTINE

AP	AMNEAL	100MG/VIAL	A211229 001	Oct 16, 2018
-----------	--------	-------------------	--------------------	--------------

AP	DR REDDYS	100MG/VIAL	A213207 001	Oct 22, 2020
-----------	-----------	-------------------	--------------------	--------------

AP	NAVINTA LLC	100MG/VIAL	A210179 001	Sep 11, 2018
-----------	-------------	-------------------	--------------------	--------------

AP	STI PHARMA LLC	100MG/VIAL	A209278 001	Apr 02, 2019
-----------	----------------	-------------------	--------------------	--------------

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CARTEOLOL HYDROCHLORIDE

!	SANDOZ INC	1%	A075476 001	Jan 03, 2000
---	------------	----	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

CARVEDILOL

TABLET; ORAL

CARVEDILOL

<u>AB</u>	AUROBINDO PHARMA	<u>3.125MG</u>	<u>A078332 001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078332 002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078332 003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A078332 004</u>	Sep 05, 2007
<u>AB</u>	BEXIMCO USA	<u>3.125MG</u>	<u>A078384 001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078384 002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078384 003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A078384 004</u>	Sep 05, 2007
<u>AB</u>	CHARTWELL MOLECULAR	<u>3.125MG</u>	<u>A077474 001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A077474 002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A077474 003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A077474 004</u>	Sep 05, 2007
<u>AB</u>	DR REDDYS LABS LTD	<u>3.125MG</u>	<u>A076649 001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A076649 002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A076649 003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A076649 004</u>	Sep 05, 2007
<u>AB</u>	GLENMARK GENERICS	<u>3.125MG</u>	<u>A078251 001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078251 002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078251 003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A078251 004</u>	Sep 05, 2007
<u>AB</u>	LUPIN	<u>3.125MG</u>	<u>A078217 001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078217 002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078217 003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A078217 004</u>	Sep 05, 2007
<u>AB</u>	MYLAN	<u>3.125MG</u>	<u>A077316 001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A077316 002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A077316 003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A077316 004</u>	Sep 05, 2007
<u>AB</u>	RUBICON	<u>3.125MG</u>	<u>A078165 001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078165 002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078165 003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A078165 004</u>	Sep 05, 2007
<u>AB</u>	SANDOZ	<u>3.125MG</u>	<u>A078227 001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078227 002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078227 003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A078227 004</u>	Sep 05, 2007
<u>AB</u>	SUN PHARM INDS LTD	<u>3.125MG</u>	<u>A076989 001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A076989 002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A076989 003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A076989 004</u>	Sep 05, 2007
<u>AB</u>	TARO	<u>3.125MG</u>	<u>A077780 001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A077780 002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A077780 003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A077780 004</u>	Sep 05, 2007
<u>AB</u>	TEVA	<u>3.125MG</u>	<u>A076373 001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A076373 002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A076373 003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A076373 004</u>	Sep 05, 2007
<u>AB</u>	ZYDUS PHARMS USA INC	<u>3.125MG</u>	<u>A077614 004</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A077614 001</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A077614 002</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A077614 003</u>	Sep 05, 2007
<u>COREG</u>				
<u>AB</u>	+ SMITHKLINE BEECHAM	<u>3.125MG</u>	<u>N020297 004</u>	May 29, 1997
<u>AB</u>	+	<u>6.25MG</u>	<u>N020297 003</u>	Sep 14, 1995
<u>AB</u>	+!	<u>12.5MG</u>	<u>N020297 002</u>	Sep 14, 1995
<u>AB</u>	+	<u>25MG</u>	<u>N020297 001</u>	Sep 14, 1995

CARVEDILOL PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL

CARVEDILOL PHOSPHATE

<u>AB</u>	IMPAX LABS INC	<u>10MG</u>	<u>A204717 001</u>	May 07, 2018
<u>AB</u>		<u>20MG</u>	<u>A204717 002</u>	May 07, 2018
<u>AB</u>		<u>40MG</u>	<u>A204717 003</u>	May 07, 2018
<u>AB</u>		<u>80MG</u>	<u>A204717 004</u>	May 07, 2018
<u>AB</u>	SUN PHARM INDUSTRIES	<u>10MG</u>	<u>A090132 001</u>	Oct 25, 2017
<u>AB</u>		<u>20MG</u>	<u>A090132 002</u>	Oct 25, 2017
<u>AB</u>		<u>40MG</u>	<u>A090132 003</u>	Oct 25, 2017

PRESCRIPTION DRUG PRODUCT LIST

CARVEDILOL PHOSPHATE

CAPSULE, EXTENDED RELEASE;ORAL

CARVEDILOL PHOSPHATE

<u>AB</u>		<u>80MG</u>	<u>A090132</u>	<u>004</u>	Oct 25, 2017	
	<u>COREG CR</u>					
<u>AB</u>	+	SMITHKLINE BEECHAM	<u>10MG</u>	<u>N022012</u>	<u>001</u>	Oct 20, 2006
<u>AB</u>	+		<u>20MG</u>	<u>N022012</u>	<u>002</u>	Oct 20, 2006
<u>AB</u>	+	!	<u>40MG</u>	<u>N022012</u>	<u>003</u>	Oct 20, 2006
<u>AB</u>	+		<u>80MG</u>	<u>N022012</u>	<u>004</u>	Oct 20, 2006

CASPOFUNGIN ACETATE

POWDER; INTRAVENOUS

CANCIDAS

<u>AP</u>	+	MERCK	<u>50MG/VIAL</u>	<u>N021227</u>	<u>001</u>	Jan 26, 2001
<u>AP</u>	+	!	<u>70MG/VIAL</u>	<u>N021227</u>	<u>002</u>	Jan 26, 2001

CASPOFUNGIN ACETATE

<u>AP</u>		FRESENIUS KABI USA	<u>50MG/VIAL</u>	<u>N206110</u>	<u>001</u>	Dec 30, 2016
<u>AP</u>			<u>70MG/VIAL</u>	<u>N206110</u>	<u>002</u>	Dec 30, 2016
<u>AP</u>		GLAND PHARMA LTD	<u>50MG/VIAL</u>	<u>A207092</u>	<u>001</u>	Sep 29, 2017
<u>AP</u>			<u>70MG/VIAL</u>	<u>A207092</u>	<u>002</u>	Sep 29, 2017
<u>AP</u>		JIANGSU HENGRUI MED	<u>50MG/VIAL</u>	<u>A200833</u>	<u>001</u>	Jun 28, 2018
<u>AP</u>			<u>70MG/VIAL</u>	<u>A200833</u>	<u>002</u>	Jun 28, 2018
<u>AP</u>		MYLAN LABS LTD	<u>50MG/VIAL</u>	<u>A207650</u>	<u>001</u>	Sep 29, 2017
<u>AP</u>		XELLIA PHARMS APS	<u>50MG/VIAL</u>	<u>A205923</u>	<u>001</u>	Jul 02, 2018
<u>AP</u>			<u>70MG/VIAL</u>	<u>A205923</u>	<u>002</u>	Jul 02, 2018

CEDAZURIDINE; DECITABINE

TABLET; ORAL

INQOVI

	+	OTSUKA	100MG; 35MG	N212576	001	Jul 07, 2020
--	---	--------	-------------	---------	-----	--------------

CEFACLOR

CAPSULE; ORAL

CEFACLOR

<u>AB</u>		HIKMA	<u>EQ 250MG BASE</u>	<u>A065350</u>	<u>001</u>	Apr 03, 2007
<u>AB</u>	!		<u>EQ 500MG BASE</u>	<u>A065350</u>	<u>002</u>	Apr 03, 2007
<u>AB</u>		YUNG SHIN PHARM	<u>EQ 250MG BASE</u>	<u>A065146</u>	<u>001</u>	Jan 22, 2004
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A065146</u>	<u>002</u>	Jan 22, 2004

FOR SUSPENSION; ORAL

CEFACLOR

		YUNG SHIN PHARM	EQ 125MG BASE/5ML	A065412	001	Feb 17, 2012
			EQ 187MG BASE/5ML	A065412	002	Feb 17, 2012
			EQ 250MG BASE/5ML	A065412	003	Feb 17, 2012
	!		EQ 375MG BASE/5ML	A065412	004	Feb 17, 2012

TABLET, EXTENDED RELEASE; ORAL

CEFACLOR

		TEVA	EQ 375MG BASE	A065058	001	Sep 04, 2002
	!		EQ 500MG BASE	A065058	002	Sep 04, 2002

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

CEFADROXIL

<u>AB</u>		AUROBINDO PHARMA	<u>EQ 500MG BASE</u>	<u>A065352</u>	<u>001</u>	Jan 25, 2007
<u>AB</u>		HIKMA	<u>EQ 500MG BASE</u>	<u>A065311</u>	<u>001</u>	Feb 07, 2006
<u>AB</u>		LUPIN	<u>EQ 500MG BASE</u>	<u>A065392</u>	<u>001</u>	May 29, 2007
<u>AB</u>		ORCHID HLTHCARE	<u>EQ 500MG BASE</u>	<u>A065309</u>	<u>001</u>	Sep 18, 2006
<u>AB</u>	!	TEVA PHARMS	<u>EQ 500MG BASE</u>	<u>A065282</u>	<u>001</u>	Jan 20, 2006

FOR SUSPENSION; ORAL

CEFADROXIL

<u>AB</u>		AUROBINDO	<u>EQ 250MG BASE/5ML</u>	<u>A065349</u>	<u>001</u>	Apr 25, 2013
<u>AB</u>			<u>EQ 500MG BASE/5ML</u>	<u>A065349</u>	<u>002</u>	Apr 25, 2013
<u>AB</u>		HIKMA PHARMS	<u>EQ 250MG BASE/5ML</u>	<u>A091036</u>	<u>001</u>	Nov 28, 2012
<u>AB</u>			<u>EQ 500MG BASE/5ML</u>	<u>A091036</u>	<u>002</u>	Nov 28, 2012
<u>AB</u>		LUPIN	<u>EQ 250MG BASE/5ML</u>	<u>A065396</u>	<u>001</u>	Feb 21, 2008
<u>AB</u>	!		<u>EQ 500MG BASE/5ML</u>	<u>A065396</u>	<u>002</u>	Feb 21, 2008
<u>AB</u>		ORCHID HLTHCARE	<u>EQ 250MG BASE/5ML</u>	<u>A065307</u>	<u>002</u>	Oct 16, 2006
<u>AB</u>			<u>EQ 500MG BASE/5ML</u>	<u>A065307</u>	<u>003</u>	Oct 16, 2006

TABLET; ORAL

CEFADROXIL

<u>AB</u>		HIKMA	<u>EQ 1GM BASE</u>	<u>A065260</u>	<u>001</u>	Mar 30, 2006
<u>AB</u>		ORCHID HLTHCARE	<u>EQ 1GM BASE</u>	<u>A065301</u>	<u>001</u>	Sep 18, 2006
	!	TEVA PHARMS	EQ 1GM BASE	A062774	001	Apr 08, 1987

PRESCRIPTION DRUG PRODUCT LIST

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

<u>AP</u>	ACS DOBFAR	<u>EQ 500MG BASE/VIAL</u>	<u>A065303 001</u>	Oct 22, 2008
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065303 002</u>	Oct 22, 2008
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065306 001</u>	Oct 22, 2008
<u>AP</u>	! HIKMA FARMACEUTICA	<u>EQ 500MG BASE/VIAL</u>	<u>A065047 001</u>	Sep 18, 2001
<u>AP</u>	!	<u>EQ 1GM BASE/VIAL</u>	<u>A065047 002</u>	Sep 18, 2001
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065143 001</u>	Oct 18, 2004
<u>AP</u>	QILU	<u>EQ 1GM BASE/VIAL</u>	<u>A203661 001</u>	Dec 28, 2015
<u>AP</u>	!	<u>EQ 10GM BASE/VIAL</u>	<u>A209217 001</u>	Oct 17, 2018
<u>AP</u>	SANDOZ	<u>EQ 500MG BASE/VIAL</u>	<u>A062831 001</u>	Dec 09, 1988
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A062831 002</u>	Dec 09, 1988
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065345 001</u>	May 09, 2007
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A062831 003</u>	Sep 25, 1992
	ANCEF IN PLASTIC CONTAINER			
	! BAXTER HLTHCARE	EQ 20MG BASE/ML	A063002 002	Mar 28, 1991
	CEFAZOLIN AND DEXTROSE			
	+! B BRAUN	EQ 1GM BASE/VIAL	N050779 002	Jul 27, 2000
	+	EQ 2GM BASE/VIAL	N050779 003	Jan 13, 2012
	CEFAZOLIN SODIUM			
	! ACS DOBFAR	EQ 20GM BASE/VIAL	A065306 002	Aug 18, 2014
	! SAMSON MEDCL	EQ 100GM BASE/VIAL	A065141 001	Nov 29, 2006
	!	EQ 300GM BASE/VIAL	A065141 002	Nov 29, 2006
	SOLUTION; INTRAVENOUS			
	CEFAZOLIN IN PLASTIC CONTAINER			
	BAXTER HLTHCARE CORP	EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N207131 001	Aug 07, 2015

CEFDINIR

CAPSULE; ORAL

CEFDINIR

<u>AB</u>	AUROBINDO PHARMA	<u>300MG</u>	<u>A065434 001</u>	Jan 07, 2008
<u>AB</u>	LUPIN	<u>300MG</u>	<u>A065264 001</u>	May 19, 2006
<u>AB</u>	ORCHID HLTHCARE	<u>300MG</u>	<u>A065418 001</u>	Jul 18, 2007
<u>AB</u>	! SANDOZ	<u>300MG</u>	<u>A065330 001</u>	Apr 06, 2007
<u>AB</u>	TEVA PHARMS	<u>300MG</u>	<u>A065368 001</u>	May 09, 2007

FOR SUSPENSION; ORAL

CEFDINIR

<u>AB</u>	AUROBINDO PHARMA	<u>125MG/5ML</u>	<u>A065473 001</u>	Dec 14, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065473 002</u>	Dec 14, 2007
<u>AB</u>	LUPIN	<u>125MG/5ML</u>	<u>A065259 001</u>	May 31, 2006
<u>AB</u>		<u>250MG/5ML</u>	<u>A065259 002</u>	May 07, 2007
<u>AB</u>	ORCHID HLTHCARE	<u>125MG/5ML</u>	<u>A065429 001</u>	Jul 18, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065429 002</u>	Jul 18, 2007
<u>AB</u>	SANDOZ	<u>125MG/5ML</u>	<u>A065337 001</u>	Apr 06, 2007
<u>AB</u>	!	<u>250MG/5ML</u>	<u>A065337 002</u>	Apr 06, 2007
<u>AB</u>	TEVA PHARMS	<u>125MG/5ML</u>	<u>A065332 001</u>	May 04, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065332 002</u>	May 04, 2007

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

<u>AP</u>	ACS DOBFAR	<u>EQ 1GM BASE/VIAL</u>	<u>A065441 001</u>	Mar 20, 2008
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065441 002</u>	Mar 20, 2008
<u>AP</u>	ASTRAL	<u>EQ 1GM BASE/VIAL</u>	<u>A212721 001</u>	Jul 21, 2020
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A212721 002</u>	Jul 21, 2020
<u>AP</u>	QILU	<u>EQ 500MG BASE/VIAL</u>	<u>A203704 001</u>	Feb 01, 2016
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A203704 002</u>	Feb 01, 2016
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A203704 003</u>	Feb 01, 2016
<u>AP</u>	SAGENT PHARMS INC	<u>EQ 1GM BASE/VIAL</u>	<u>A091048 001</u>	Jan 04, 2017
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A091048 002</u>	Jan 04, 2017

MAXIPIME

<u>AP</u>	+! HOSPIRA INC	<u>EQ 500MG BASE/VIAL</u>	<u>N050679 001</u>	Jan 18, 1996
<u>AP</u>	+!	<u>EQ 1GM BASE/VIAL</u>	<u>N050679 002</u>	Jan 18, 1996
<u>AP</u>	+!	<u>EQ 2GM BASE/VIAL</u>	<u>N050679 003</u>	Jan 18, 1996

CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER

	B BRAUN	EQ 1GM BASE/VIAL	N050821 001	May 06, 2010
		EQ 2GM BASE/VIAL	N050821 002	May 06, 2010

CEFEPIME IN PLASTIC CONTAINER

	+! BAXTER HLTHCARE	EQ 1GM BASE/50ML (EQ 20MG BASE/ML)	N050817 001	Aug 05, 2008
	+!	EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N050817 002	Aug 05, 2008

PRESCRIPTION DRUG PRODUCT LIST

CEFEPIME HYDROCHLORIDE

POWDER; INTRAVENOUS

CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER

SAMSON MEDCL

EQ 100GM BASE

A209408 001 Aug 21, 2018

CEFIDEROCOL SULFATE TOSYLATE

POWDER; INTRAVENOUS

FETROJA

+! SHIONOGI INC

EQ 1GM BASE/VIAL

N209445 001 Nov 14, 2019

CEFIXIME

CAPSULE; ORAL

CEFIXIME

! ALKEM LABS LTD

400MG

A210574 001 Oct 09, 2018

FOR SUSPENSION; ORAL

CEFIXIME**AB** AUROBINDO PHARMA LTD100MG/5MLA204835 001 Apr 14, 2015**AB** 200MG/5ML A204835 002 Apr 14, 2015**AB** BELCHER 100MG/5ML A206938 001 Feb 06, 2017**AB** 200MG/5ML A206938 002 Feb 06, 2017**AB** 500MG/5ML A206939 001 Feb 06, 2017SUPRAX**AB** +! LUPIN LTD 500MG/5ML N202091 001 Feb 20, 2013**AB** ! LUPIN PHARMS 200MG/5ML A065355 001 Apr 10, 2007

TABLET, CHEWABLE; ORAL

SUPRAX

LUPIN LTD

100MG

A065380 001 Oct 25, 2010

150MG

A065380 002 Oct 25, 2010

!

200MG

A065380 003 Oct 25, 2010

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME

! HIKMA

EQ 500MG BASE/VIAL

A065072 001 Nov 20, 2002

!

EQ 1GM BASE/VIAL

A065072 002 Nov 20, 2002

!

EQ 2GM BASE/VIAL

A065072 003 Nov 20, 2002

!

EQ 10GM BASE/VIAL

A065071 001 Nov 20, 2002

CEFOTETAN DISODIUM

INJECTABLE; INJECTION

CEFOTAN**AP** + TELIGENT EQ 1GM BASE/VIAL N050588 001 Dec 27, 1985**AP** + EQ 2GM BASE/VIAL N050588 002 Dec 27, 1985CEFOTETAN**AP** ! FRESENIUS KABI USA EQ 1GM BASE/VIAL A065374 001 Aug 09, 2007**AP** ! EQ 2GM BASE/VIAL A065374 002 Aug 09, 2007**AP** HIKMA EQ 1GM BASE/VIAL A091031 001 Oct 26, 2011**AP** EQ 2GM BASE/VIAL A091031 002 Oct 26, 2011

CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER

+! B BRAUN

EQ 1GM BASE/VIAL

N065430 001 Aug 09, 2007

+!

EQ 2GM BASE/VIAL

N065430 002 Aug 09, 2007

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN**AP** ! ACS DOBFAR EQ 1GM BASE/VIAL A065414 001 Jun 12, 2009**AP** ! EQ 2GM BASE/VIAL A065414 002 Jun 12, 2009**AP** ! EQ 10GM BASE/VIAL A065415 001 May 19, 2010**AP** HIKMA FARMACEUTICA EQ 1GM BASE/VIAL A065238 001 Mar 12, 2010**AP** EQ 2GM BASE/VIAL A065238 002 Mar 12, 2010**AP** EQ 10GM BASE/VIAL A065239 001 Mar 02, 2010**AP** WEST-WARD PHARMS EQ 1GM BASE/VIAL A065051 001 Sep 11, 2000

INT

AP EQ 2GM BASE/VIAL A065051 002 Sep 11, 2000**AP** EQ 10GM BASE/VIAL A065050 001 Sep 11, 2000CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER**AP** +! B BRAUN EQ 1GM BASE/VIAL N065214 001 Mar 10, 2006**AP** +! EQ 2GM BASE/VIAL N065214 002 Mar 10, 2006

POWDER; INTRAVENOUS

CEFOXITIN IN PLASTIC CONTAINER

SAMSON MEDCL

EQ 100GM BASE

A200938 001 Nov 16, 2015

PRESCRIPTION DRUG PRODUCT LIST

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL

CEFPODOXIME PROXETIL

AUROBINDO PHARMA LTD	EQ 50MG BASE/5ML	A065409 001	Jun 08, 2007
----------------------	------------------	-------------	--------------

!	EQ 100MG BASE/5ML	A065409 002	Jun 08, 2007
---	-------------------	-------------	--------------

TABLET; ORAL

CEFPODOXIME PROXETIL

<u>AB</u>	AUROBINDO PHARMA	<u>EQ 100MG BASE</u>	<u>A065370 001</u>	Jun 11, 2007
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A065370 002</u>	Jun 11, 2007
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 100MG BASE</u>	<u>A065388 001</u>	Nov 14, 2007
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A065388 002</u>	Nov 14, 2007
<u>AB</u>	SANDOZ	<u>EQ 100MG BASE</u>	<u>A065462 001</u>	May 28, 2008
<u>AB</u>	!	<u>EQ 200MG BASE</u>	<u>A065462 002</u>	May 28, 2008

CEFPROZIL

FOR SUSPENSION; ORAL

CEFPROZIL

<u>AB</u>	APOTEX INC	<u>125MG/5ML</u>	<u>A065351 001</u>	Feb 29, 2012
<u>AB</u>		<u>250MG/5ML</u>	<u>A065351 002</u>	Feb 29, 2012
<u>AB</u>	AUROBINDO PHARMA	<u>125MG/5ML</u>	<u>A065381 001</u>	Jan 30, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065381 002</u>	Jan 30, 2007
<u>AB</u>	LUPIN	<u>125MG/5ML</u>	<u>A065261 001</u>	Dec 19, 2005
<u>AB</u>	!	<u>250MG/5ML</u>	<u>A065261 002</u>	Dec 19, 2005
<u>AB</u>	ORCHID HLTHCARE	<u>125MG/5ML</u>	<u>A065284 002</u>	Dec 30, 2005
<u>AB</u>		<u>250MG/5ML</u>	<u>A065284 001</u>	Dec 30, 2005
<u>AB</u>	SANDOZ	<u>125MG/5ML</u>	<u>A065257 001</u>	Dec 08, 2005
<u>AB</u>		<u>250MG/5ML</u>	<u>A065257 002</u>	Dec 08, 2005

TABLET; ORAL

CEFPROZIL

<u>AB</u>	APOTEX INC	<u>250MG</u>	<u>A065327 001</u>	Mar 26, 2008
<u>AB</u>		<u>500MG</u>	<u>A065327 002</u>	Mar 26, 2008
<u>AB</u>	AUROBINDO PHARMA LTD	<u>250MG</u>	<u>A065340 001</u>	May 24, 2007
<u>AB</u>		<u>500MG</u>	<u>A065340 002</u>	May 24, 2007
<u>AB</u>	CHARTWELL RX	<u>250MG</u>	<u>A065235 001</u>	Nov 14, 2005
<u>AB</u>		<u>500MG</u>	<u>A065235 002</u>	Nov 14, 2005
<u>AB</u>	LUPIN	<u>250MG</u>	<u>A065276 001</u>	Dec 08, 2005
<u>AB</u>	!	<u>500MG</u>	<u>A065276 002</u>	Dec 08, 2005
<u>AB</u>	ORCHID HLTHCARE	<u>250MG</u>	<u>A065267 001</u>	Dec 19, 2005
<u>AB</u>		<u>500MG</u>	<u>A065267 002</u>	Dec 19, 2005
<u>AB</u>	TEVA	<u>250MG</u>	<u>A065208 001</u>	Dec 06, 2005
<u>AB</u>		<u>500MG</u>	<u>A065208 002</u>	Dec 06, 2005

CEFTAROLINE FOSAMIL

POWDER; INTRAVENOUS

TEFLARO

+ ALLERGAN	400MG/VIAL	N200327 001	Oct 29, 2010
+!	600MG/VIAL	N200327 002	Oct 29, 2010

CEFTAZIDIME

INJECTABLE; INJECTION

CEFTAZIDIME

<u>AP</u>	ACS DOBFAR	<u>1GM/VIAL</u>	<u>A062640 002</u>	Nov 20, 1985
<u>AP</u>		<u>2GM/VIAL</u>	<u>A062640 003</u>	Nov 20, 1985
<u>AP</u>		<u>6GM/VIAL</u>	<u>A062640 004</u>	Feb 03, 1992

FORTAZ

<u>AP</u>	+! TELIGENT	<u>500MG/VIAL</u>	<u>N050578 001</u>	Jul 19, 1985
<u>AP</u>	+!	<u>1GM/VIAL</u>	<u>N050578 002</u>	Jul 19, 1985
<u>AP</u>	+!	<u>2GM/VIAL</u>	<u>N050578 003</u>	Jul 19, 1985
<u>AP</u>	+!	<u>6GM/VIAL</u>	<u>N050578 004</u>	Jul 19, 1985

TAZICEF

<u>AP</u>	HOSPIRA	<u>500MG/VIAL</u>	<u>A062662 001</u>	Mar 06, 1986
<u>AP</u>		<u>1GM/VIAL</u>	<u>A062662 002</u>	Mar 06, 1986
<u>AP</u>		<u>1GM/VIAL</u>	<u>A064032 001</u>	Oct 31, 1993
<u>AP</u>		<u>2GM/VIAL</u>	<u>A062662 003</u>	Mar 06, 1986
<u>AP</u>		<u>2GM/VIAL</u>	<u>A064032 002</u>	Oct 31, 1993
<u>AP</u>		<u>6GM/VIAL</u>	<u>A062662 004</u>	Mar 06, 1986

CEFTAZIDIME IN DEXTROSE CONTAINER

+ B BRAUN	EQ 1GM BASE	N050823 001	Jun 13, 2011
+!	EQ 2GM BASE	N050823 002	Jun 13, 2011

PRESCRIPTION DRUG PRODUCT LIST

CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM

POWDER; INTRAVENOUS

ZERBAXA

+! CUBIST PHARMS LLC EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL N206829 001 Dec 19, 2014

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION

CEFTRIAXONE

<u>AP</u>	ACS DOBFAR	<u>EQ 500MG BASE/VIAL</u>	<u>A065329 001</u>	Jul 24, 2008
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065329 002</u>	Jul 24, 2008
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065329 003</u>	Jul 24, 2008
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065328 001</u>	Jul 24, 2008
<u>AP</u>	QILU	<u>EQ 10GM BASE/VIAL</u>	<u>A209218 001</u>	Oct 17, 2018
<u>AP</u>	! SANDOZ	<u>EQ 10GM BASE/VIAL</u>	<u>A065168 001</u>	May 17, 2005
<u>AP</u>	! SANDOZ INC	<u>EQ 1GM BASE/VIAL</u>	<u>A065204 001</u>	May 03, 2005
<u>AP</u>	!	<u>EQ 2GM BASE/VIAL</u>	<u>A065204 002</u>	May 03, 2005
<u>AP</u>	WOCKHARDT	<u>EQ 1GM BASE/VIAL</u>	<u>A065180 001</u>	May 12, 2006

CEFTRIAXONE AND DEXTROSE IN DUPLIX CONTAINER

<u>AP</u>	+! B BRAUN	<u>EQ 1GM BASE/VIAL</u>	<u>N050796 001</u>	Apr 20, 2005
<u>AP</u>	+!	<u>EQ 2GM BASE/VIAL</u>	<u>N050796 002</u>	Apr 20, 2005

CEFTRIAXONE SODIUM

<u>AP</u>	ASTRAL	<u>EQ 10GM BASE/VIAL</u>	<u>A091117 001</u>	Jan 20, 2017
<u>AP</u>	HIKMA	<u>EQ 10GM BASE/VIAL</u>	<u>A090701 001</u>	Oct 04, 2017

CEFTRIAXONE

	SAMSON MEDCL	EQ 100GM BASE/VIAL	A090057 001	Apr 25, 2014
--	--------------	--------------------	-------------	--------------

CEFTRIAXONE IN PLASTIC CONTAINER

!	BAXTER HLTHCARE	EQ 20MG BASE/ML	A065224 001	Aug 23, 2005
!		EQ 40MG BASE/ML	A065224 002	Aug 23, 2005

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

CEFTRIAXONE

<u>AP</u>	AKORN INC	<u>EQ 250MG BASE/VIAL</u>	<u>A065305 001</u>	Jan 11, 2008
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065305 002</u>	Jan 11, 2008
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065305 003</u>	Jan 11, 2008
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065305 004</u>	Jan 11, 2008
<u>AP</u>	ASTRAL	<u>EQ 250MG BASE/VIAL</u>	<u>A091049 001</u>	Jun 11, 2018
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A091049 002</u>	Jun 11, 2018
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A091049 003</u>	Jun 11, 2018
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A091049 004</u>	Jun 11, 2018
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 250MG BASE/VIAL</u>	<u>A065342 001</u>	Jan 10, 2008
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065342 002</u>	Jan 10, 2008
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065342 003</u>	Jan 10, 2008
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065342 004</u>	Jan 10, 2008
<u>AP</u>	LUPIN	<u>EQ 250MG BASE/VIAL</u>	<u>A065125 001</u>	Sep 30, 2003
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065125 002</u>	Sep 30, 2003
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065125 003</u>	Sep 30, 2003
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065125 004</u>	Sep 30, 2003
<u>AP</u>	QILU	<u>EQ 250MG BASE/VIAL</u>	<u>A203702 001</u>	Jun 29, 2016
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A203702 002</u>	Jun 29, 2016
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A203702 003</u>	Jun 29, 2016
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A203702 004</u>	Jun 29, 2016
<u>AP</u>	! SANDOZ	<u>EQ 250MG BASE/VIAL</u>	<u>A065169 001</u>	May 09, 2005
<u>AP</u>	!	<u>EQ 500MG BASE/VIAL</u>	<u>A065169 002</u>	May 09, 2005
<u>AP</u>	!	<u>EQ 1GM BASE/VIAL</u>	<u>A065169 003</u>	May 09, 2005
<u>AP</u>	!	<u>EQ 2GM BASE/VIAL</u>	<u>A065169 004</u>	May 09, 2005
<u>AP</u>	WOCKHARDT	<u>EQ 250MG BASE/VIAL</u>	<u>A065391 001</u>	Apr 12, 2007
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065391 002</u>	Apr 12, 2007
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065391 003</u>	Apr 12, 2007

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

<u>AB</u>	ALKEM LABS LTD	<u>EQ 250MG BASE</u>	<u>A065496 001</u>	Jun 07, 2010
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065496 002</u>	Jun 07, 2010
<u>AB</u>	APOTEX	<u>EQ 250MG BASE</u>	<u>A065069 001</u>	Oct 02, 2002
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065069 002</u>	Oct 02, 2002
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 125MG BASE</u>	<u>A065308 001</u>	Mar 29, 2006
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A065308 002</u>	Mar 29, 2006
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065308 003</u>	Mar 29, 2006
<u>AB</u>	LUPIN	<u>EQ 250MG BASE</u>	<u>A065135 001</u>	Jul 25, 2003
<u>AB</u>	!	<u>EQ 500MG BASE</u>	<u>A065135 002</u>	Jul 25, 2003
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 125MG BASE</u>	<u>A065359 001</u>	Feb 15, 2008
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A065359 002</u>	Feb 15, 2008
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065359 003</u>	Feb 15, 2008

PRESCRIPTION DRUG PRODUCT LIST

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

<u>AB</u>	WOCKHARDT	<u>EQ 125MG BASE</u>	<u>A065166 001</u>	Jul 29, 2005
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A065166 002</u>	Jul 29, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065166 003</u>	Jul 29, 2005

CEFUROXIME SODIUM

INJECTABLE; INJECTION

CEFUROXIME AND DEXTROSE IN DUPLIX CONTAINER

<u>AP</u>	+! B BRAUN	<u>EQ 750MG BASE/VIAL</u>	<u>N050780 001</u>	Feb 21, 2001
<u>AP</u>	+!	<u>EQ 1.5GM BASE/VIAL</u>	<u>N050780 002</u>	Feb 21, 2001

CEFUROXIME SODIUM

<u>AP</u>	ACS DOBFAR SPA	<u>EQ 1.5GM BASE/VIAL</u>	<u>A064125 002</u>	May 30, 1997
<u>AP</u>		<u>EQ 7.5GM BASE/VIAL</u>	<u>A064124 001</u>	May 30, 1997
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 1.5GM BASE/VIAL</u>	<u>A065048 002</u>	Jan 09, 2004
<u>AP</u>		<u>EQ 7.5GM BASE/VIAL</u>	<u>A065046 001</u>	Jan 09, 2004

ZINACEF

<u>AP</u>	+! TELIGENT	<u>EQ 1.5GM BASE/VIAL</u>	<u>N050558 003</u>	Oct 19, 1983
<u>AP</u>	+!	<u>EQ 7.5GM BASE/VIAL</u>	<u>N050558 004</u>	Oct 23, 1986

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

CEFUROXIME SODIUM

<u>AB</u>	ACS DOBFAR SPA	<u>EQ 750MG BASE/VIAL</u>	<u>A064125 001</u>	May 30, 1997
<u>AB</u>	HIKMA FARMACEUTICA	<u>EQ 750MG BASE/VIAL</u>	<u>A065048 001</u>	Jan 09, 2004

ZINACEF

<u>AB</u>	+! TELIGENT	<u>EQ 750MG BASE/VIAL</u>	<u>N050558 002</u>	Oct 19, 1983
-----------	-------------	---------------------------	--------------------	--------------

CELECOXIB

CAPSULE; ORAL

CELEBREX

<u>AB</u>	+ GD SEARLE	<u>50MG</u>	<u>N020998 004</u>	Dec 15, 2006
<u>AB</u>	+	<u>100MG</u>	<u>N020998 001</u>	Dec 31, 1998
<u>AB</u>	+	<u>200MG</u>	<u>N020998 002</u>	Dec 31, 1998
<u>AB</u>	+!	<u>400MG</u>	<u>N020998 003</u>	Aug 29, 2002

CELECOXIB

<u>AB</u>	ACIC PHARMS	<u>200MG</u>	<u>A212925 001</u>	Dec 09, 2020
<u>AB</u>		<u>400MG</u>	<u>A212925 002</u>	Dec 09, 2020
<u>AB</u>	ALEMBIC PHARMS LTD	<u>50MG</u>	<u>A204519 001</u>	Aug 21, 2015
<u>AB</u>		<u>100MG</u>	<u>A204519 002</u>	Aug 21, 2015
<u>AB</u>		<u>200MG</u>	<u>A204519 003</u>	Aug 21, 2015
<u>AB</u>		<u>400MG</u>	<u>A204519 004</u>	Aug 21, 2015
<u>AB</u>	AMNEAL PHARMS	<u>50MG</u>	<u>A208833 001</u>	May 31, 2018
<u>AB</u>		<u>100MG</u>	<u>A208833 002</u>	May 31, 2018
<u>AB</u>		<u>200MG</u>	<u>A208833 003</u>	May 31, 2018
<u>AB</u>		<u>400MG</u>	<u>A208833 004</u>	May 31, 2018
<u>AB</u>	APOTEX INC	<u>50MG</u>	<u>A204197 001</u>	Jun 02, 2015
<u>AB</u>		<u>100MG</u>	<u>A204197 002</u>	Jun 02, 2015
<u>AB</u>		<u>200MG</u>	<u>A204197 003</u>	Jun 02, 2015
<u>AB</u>	AUROBINDO PHARMA LTD	<u>50MG</u>	<u>A206827 001</u>	Feb 01, 2016
<u>AB</u>		<u>100MG</u>	<u>A206827 002</u>	Feb 01, 2016
<u>AB</u>		<u>200MG</u>	<u>A206827 003</u>	Feb 01, 2016
<u>AB</u>		<u>400MG</u>	<u>A206827 004</u>	Feb 01, 2016
<u>AB</u>	CADILA PHARMS LTD	<u>50MG</u>	<u>A208701 001</u>	Nov 14, 2019
<u>AB</u>		<u>100MG</u>	<u>A208701 002</u>	Nov 14, 2019
<u>AB</u>		<u>200MG</u>	<u>A208701 003</u>	Nov 14, 2019
<u>AB</u>		<u>400MG</u>	<u>A208701 004</u>	Nov 14, 2019
<u>AB</u>	CIPLA	<u>50MG</u>	<u>A207446 001</u>	Sep 23, 2015
<u>AB</u>		<u>100MG</u>	<u>A207446 002</u>	Sep 23, 2015
<u>AB</u>		<u>200MG</u>	<u>A207446 003</u>	Sep 23, 2015
<u>AB</u>		<u>400MG</u>	<u>A207446 004</u>	Sep 23, 2015
<u>AB</u>	CSPC OUYI	<u>50MG</u>	<u>A210071 001</u>	Jan 23, 2018
<u>AB</u>		<u>100MG</u>	<u>A210071 002</u>	Jan 23, 2018
<u>AB</u>		<u>200MG</u>	<u>A210071 003</u>	Jan 23, 2018
<u>AB</u>	JUBILANT GENERICS	<u>50MG</u>	<u>A207061 001</u>	Apr 04, 2017
<u>AB</u>		<u>100MG</u>	<u>A207061 002</u>	Apr 04, 2017
<u>AB</u>		<u>200MG</u>	<u>A207061 003</u>	Apr 04, 2017
<u>AB</u>		<u>400MG</u>	<u>A207061 004</u>	Apr 04, 2017
<u>AB</u>	LUPIN LTD	<u>50MG</u>	<u>A202240 001</u>	Oct 29, 2014
<u>AB</u>		<u>100MG</u>	<u>A202240 002</u>	Jun 09, 2015
<u>AB</u>		<u>200MG</u>	<u>A202240 003</u>	Jun 09, 2015
<u>AB</u>		<u>400MG</u>	<u>A202240 004</u>	Jun 09, 2015
<u>AB</u>	MACLEODS PHARMS LTD	<u>50MG</u>	<u>A204590 001</u>	Mar 16, 2016
<u>AB</u>		<u>100MG</u>	<u>A204590 002</u>	Mar 16, 2016

PRESCRIPTION DRUG PRODUCT LIST

CELECOXIB

CAPSULE; ORAL

CELECOXIB

<u>AB</u>		<u>200MG</u>	<u>A204590 003</u>	Mar 16, 2016
<u>AB</u>		<u>400MG</u>	<u>A204590 004</u>	Mar 16, 2016
<u>AB</u>	MICRO LABS	<u>50MG</u>	<u>A204776 001</u>	Apr 30, 2018
<u>AB</u>		<u>100MG</u>	<u>A204776 002</u>	Apr 30, 2018
<u>AB</u>		<u>200MG</u>	<u>A204776 003</u>	Apr 30, 2018
<u>AB</u>		<u>400MG</u>	<u>A204776 004</u>	Apr 30, 2018
<u>AB</u>	MYLAN	<u>50MG</u>	<u>A078857 001</u>	May 30, 2014
<u>AB</u>		<u>100MG</u>	<u>A078857 002</u>	Feb 11, 2015
<u>AB</u>		<u>200MG</u>	<u>A078857 003</u>	Feb 11, 2015
<u>AB</u>		<u>400MG</u>	<u>A078857 004</u>	Feb 11, 2015
<u>AB</u>	NANJING	<u>200MG</u>	<u>A213598 001</u>	May 13, 2020
<u>AB</u>	QINGDAO BAHEAL PHARM	<u>50MG</u>	<u>A208856 001</u>	Aug 07, 2019
<u>AB</u>		<u>100MG</u>	<u>A208856 002</u>	Aug 07, 2019
<u>AB</u>		<u>200MG</u>	<u>A208856 003</u>	Aug 07, 2019
<u>AB</u>		<u>400MG</u>	<u>A208856 004</u>	Aug 07, 2019
<u>AB</u>	SCIEGEN PHARMS INC	<u>50MG</u>	<u>A205129 001</u>	Dec 03, 2020
<u>AB</u>		<u>100MG</u>	<u>A205129 002</u>	Dec 03, 2020
<u>AB</u>		<u>200MG</u>	<u>A205129 003</u>	Dec 03, 2020
<u>AB</u>		<u>400MG</u>	<u>A205129 004</u>	Dec 03, 2020
<u>AB</u>	TEVA	<u>50MG</u>	<u>A076898 001</u>	May 30, 2014
<u>AB</u>		<u>100MG</u>	<u>A076898 002</u>	May 30, 2014
<u>AB</u>		<u>200MG</u>	<u>A076898 003</u>	May 30, 2014
<u>AB</u>		<u>400MG</u>	<u>A076898 004</u>	May 30, 2014
<u>AB</u>	TIANJIN TIANYAO	<u>50MG</u>	<u>A207872 001</u>	Feb 25, 2020
<u>AB</u>		<u>100MG</u>	<u>A207872 002</u>	Feb 25, 2020
<u>AB</u>		<u>200MG</u>	<u>A207872 003</u>	Feb 25, 2020
<u>AB</u>		<u>400MG</u>	<u>A207872 004</u>	Feb 25, 2020
<u>AB</u>	TORRENT	<u>50MG</u>	<u>A207677 001</u>	Dec 23, 2015
<u>AB</u>		<u>100MG</u>	<u>A207677 002</u>	Dec 23, 2015
<u>AB</u>		<u>200MG</u>	<u>A207677 003</u>	Dec 23, 2015
<u>AB</u>		<u>400MG</u>	<u>A207677 004</u>	Dec 23, 2015
<u>AB</u>	UMEDICA LABS PVT LTD	<u>50MG</u>	<u>A210628 001</u>	Nov 27, 2019
<u>AB</u>		<u>100MG</u>	<u>A210628 002</u>	Nov 27, 2019
<u>AB</u>		<u>200MG</u>	<u>A210628 003</u>	Nov 27, 2019
<u>AB</u>		<u>400MG</u>	<u>A210628 004</u>	Nov 27, 2019
<u>AB</u>	WATSON LABS INC	<u>50MG</u>	<u>A200562 001</u>	Feb 11, 2015
<u>AB</u>		<u>100MG</u>	<u>A200562 002</u>	Feb 11, 2015
<u>AB</u>		<u>200MG</u>	<u>A200562 003</u>	Feb 11, 2015
<u>AB</u>		<u>400MG</u>	<u>A200562 004</u>	Feb 11, 2015

CENOBAAMATE

TABLET; ORAL

XCOPRI

+	SK LIFE	12.5MG	N212839 001	Mar 10, 2020
+		25MG	N212839 002	Mar 10, 2020
+		50MG	N212839 003	Mar 10, 2020
+		100MG	N212839 004	Mar 10, 2020
+		150MG	N212839 005	Mar 10, 2020
+	!	200MG	N212839 006	Mar 10, 2020

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

<u>AB</u>	ALKEM LABS LTD	<u>EQ 250MG BASE</u>	<u>A090836 001</u>	Dec 20, 2010
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A090836 002</u>	Dec 20, 2010
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A090836 004</u>	Mar 29, 2013
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 250MG BASE</u>	<u>A065253 001</u>	Nov 16, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065253 002</u>	Nov 16, 2005
<u>AB</u>	BELCHER PHARMS	<u>EQ 250MG BASE</u>	<u>A062713 001</u>	Jul 15, 1988
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A062713 002</u>	Jul 15, 1988
<u>AB</u>	HIKMA	<u>EQ 250MG BASE</u>	<u>A065215 001</u>	Jan 24, 2006
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065215 002</u>	Jan 24, 2006
<u>AB</u>	LUPIN	<u>EQ 250MG BASE</u>	<u>A065229 001</u>	Nov 25, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065229 002</u>	Nov 25, 2005
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 250MG BASE</u>	<u>A065248 001</u>	Jun 28, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065248 002</u>	Jun 28, 2005
<u>AB</u>	TEVA	<u>EQ 250MG BASE</u>	<u>A062702 001</u>	Feb 13, 1987
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A062702 002</u>	Feb 13, 1987

PRESCRIPTION DRUG PRODUCT LIST

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

<u>AB</u>	YUNG SHIN PHARM	<u>EQ 250MG BASE</u>	<u>A065152 001</u>	Feb 24, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065152 002</u>	Feb 24, 2005

KEFLEX

<u>AB</u>	+ PRAGMA	<u>EQ 250MG BASE</u>	<u>N050405 002</u>	
<u>AB</u>	+	<u>EQ 500MG BASE</u>	<u>N050405 003</u>	
<u>AB</u>	+	<u>EQ 750MG BASE</u>	<u>N050405 005</u>	May 12, 2006

CEPHALEXIN

ALKEM LABS LTD

FOR SUSPENSION; ORAL

CEPHALEXIN

<u>AB</u>	ALKEM LABS LTD	<u>EQ 125MG BASE/5ML</u>	<u>A210221 001</u>	Mar 26, 2019
<u>AB</u>		<u>EQ 250MG BASE/5ML</u>	<u>A210221 002</u>	Mar 26, 2019
<u>AB</u>	LUPIN	<u>EQ 125MG BASE/5ML</u>	<u>A065234 001</u>	Aug 17, 2005
<u>AB</u>		<u>EQ 250MG BASE/5ML</u>	<u>A065234 002</u>	Aug 17, 2005
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 125MG BASE/5ML</u>	<u>A065326 001</u>	Jul 10, 2006
<u>AB</u>		<u>EQ 250MG BASE/5ML</u>	<u>A065326 002</u>	Jul 10, 2006
<u>AB</u>	TEVA	<u>EQ 125MG BASE/5ML</u>	<u>A062703 001</u>	Feb 13, 1987
<u>AB</u>	!	<u>EQ 250MG BASE/5ML</u>	<u>A062703 002</u>	Feb 13, 1987
<u>AB</u>	YUNG SHIN PHARM	<u>EQ 125MG BASE/5ML</u>	<u>A065336 001</u>	Jul 25, 2007
<u>AB</u>		<u>EQ 250MG BASE/5ML</u>	<u>A065336 002</u>	Jul 25, 2007

TABLET; ORAL

CEPHALEXIN

TEVA

!

EQ 250MG BASE	A063023 001	Jan 12, 1989
EQ 500MG BASE	A063024 001	Jan 12, 1989

CERITINIB

TABLET; ORAL

ZYKADIA

+! NOVARTIS

150MG	N211225 001	Mar 18, 2019
-------	-------------	--------------

CETIRIZINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS

QUZYTIR

+! JDP

10MG/ML (10MG/ML)	N211415 001	Oct 04, 2019
-------------------	-------------	--------------

SOLUTION/DROPS; OPHTHALMIC

ZERVIAE

+! EYEVANCE

EQ 0.24% BASE	N208694 001	May 30, 2017
---------------	-------------	--------------

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

<u>AA</u>	AMNEAL PHARMS	<u>5MG/5ML</u>	<u>A090766 001</u>	Oct 07, 2009
<u>AA</u>	BRECKENRIDGE	<u>5MG/5ML</u>	<u>A078488 001</u>	Oct 06, 2008
<u>AA</u>	LANNETT CO INC	<u>5MG/5ML</u>	<u>A078876 001</u>	May 11, 2012
<u>AA</u>	MLV	<u>5MG/5ML</u>	<u>A090191 001</u>	Nov 12, 2009
<u>AA</u>	! PERRIGO PHARMS CO	<u>5MG/5ML</u>	<u>A078398 001</u>	Jun 17, 2008
<u>AA</u>	TARO	<u>5MG/5ML</u>	<u>A076601 001</u>	Jun 20, 2008
<u>AA</u>	TEVA PHARMS	<u>5MG/5ML</u>	<u>A077279 001</u>	May 27, 2008

CETRORELIX

INJECTABLE; INJECTION

CETROTIDE

+! EMD SERONO INC

EQ 0.25MG BASE/ML	N021197 001	Aug 11, 2000
-------------------	-------------	--------------

CEVIMELINE HYDROCHLORIDE

CAPSULE; ORAL

CEVIMELINE HYDROCHLORIDE

<u>AB</u>	HIKMA	<u>30MG</u>	<u>A091591 001</u>	Jul 08, 2013
<u>AB</u>	NOVEL LABS INC	<u>30MG</u>	<u>A204746 001</u>	Dec 30, 2016
<u>AB</u>	RISING	<u>30MG</u>	<u>A203775 001</u>	Jun 04, 2014

EVOXAC

<u>AB</u>	+! DAIICHI SANKYO INC	<u>30MG</u>	<u>N020989 002</u>	Jan 11, 2000
-----------	-----------------------	-------------	--------------------	--------------

CHENODIOL

TABLET; ORAL

CHENODIOL

! LGM PHARMA

250MG	A091019 001	Oct 22, 2009
-------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

CHLORAMBUCIL

TABLET; ORAL

LEUKERAN

+! ASPEN GLOBAL INC 2MG

N010669 002

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION

CHLORAMPHENICOL SODIUM SUCCINATE

! FRESENIUS KABI USA EQ 1GM BASE/VIAL

A062365 001 Aug 25, 1982

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE**AB** BARR **5MG** **A084768 001****AB** **10MG** **A083116 001****AB** **25MG** **A084769 001**LIBRIUM**AB** VALEANT PHARM INTL **5MG** **A085461 001****AB** **10MG** **A085472 001****AB** ! **25MG** **A085475 001**CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE**AB** ECI PHARMS LLC **5MG;2.5MG** **A213530 001** Oct 20, 2020**AB** MISEMER **5MG;2.5MG** **A210579 001** Jul 29, 2020**AB** NUVO PHARMS INC **5MG;2.5MG** **A211421 001** Jul 07, 2020LIBRAX**AB** +! BAUSCH **5MG;2.5MG** **N012750 001**CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

CHLORHEXIDINE GLUCONATE**AT** AKORN **0.12%** **A074356 001** May 07, 1996**AT** LYNE **0.12%** **A074291 001** Dec 28, 1995**AT** PHARM ASSOC **0.12%** **A074522 001** Dec 15, 1995**AT** WOCKHARDT BIO AG **0.12%** **A075006 001** Mar 03, 2004**AT** XTTRIUM **0.12%** **A077789 001** Jun 18, 2009PAROEX**AT** SUNSTAR AMERICAS **0.12%** **A076434 001** Nov 29, 2005PERIDEX**AT** +! 3M **0.12%** **N019028 001** Aug 13, 1986PERIOGARD**AT** COLGATE PALMOLIVE **0.12%** **A073695 001** Jan 14, 1994

CO

AT COLGATE-PALMOLIVE **0.12%** **A203212 001** Jan 28, 2016

CO

TABLET; DENTAL

PERIOCHIP

+! DEXCEL PHARMA 2.5MG

N020774 001 May 15, 1998

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHLOROPROCAINE HYDROCHLORIDE**AP** HOSPIRA **2%** **A087447 001** Apr 16, 1982**AP** **3%** **A087446 001** Apr 16, 1982**AP** WEST-WARD PHARMS **2%** **A040273 001** Sep 09, 1998

INT

AP **3%** **A040273 002** Sep 09, 1998NESACAINE**AP** + FRESENIUS KABI USA **2%** **N009435 002**NESACAINE-MPF**AP** +! FRESENIUS KABI USA **2%** **N009435 006** May 02, 1996**AP** +! **3%** **N009435 007** May 02, 1996

NESACAINE

+! FRESENIUS KABI USA 1%

N009435 001

SOLUTION; INTRATHECAL

CLOROTEKAL

+ B BRAUN MEDICAL INC 50MG/5ML (10MG/ML)

N208791 001 Sep 26, 2017

PRESCRIPTION DRUG PRODUCT LIST

CHLOROQUINE PHOSPHATE

TABLET; ORAL

CHLOROQUINE PHOSPHATE

AA	IPCA LABS LTD	250MG	A090610 001	Dec 03, 2009
AA		500MG	A090249 001	Dec 03, 2009
AA	! NATCO PHARMA LTD	250MG	A091621 001	Jan 21, 2011
AA	!	500MG	A090612 001	Jan 21, 2011

CHLOROTHIAZIDE

SUSPENSION; ORAL

DIURIL

+! SALIX PHARMS 250MG/5ML N011870 001

CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION

CHLOROTHIAZIDE SODIUM

AP	AM REGENT	EQ 500MG BASE/VIAL	A202561 001	Apr 22, 2013
AP	FRESENIUS KABI USA	EQ 500MG BASE/VIAL	A090896 001	Oct 16, 2009
AP	RK PHARMA	EQ 500MG BASE/VIAL	A202493 001	Jun 18, 2014
AP	SAGENT PHARMS INC	EQ 500MG BASE/VIAL	A202462 001	May 29, 2015
AP	SUN PHARM	EQ 500MG BASE/VIAL	A091546 001	Jul 26, 2011
DIURIL				
AP	+! AKORN	EQ 500MG BASE/VIAL	N011145 005	

CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE

TABLET, EXTENDED RELEASE; ORAL

TUXARIN ER

MAINPOINTE 8MG; 54.3MG N206323 001 Jun 22, 2015

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE
! PADDOCK LABS LLC 4MG/5ML; 5MG/5ML; 60MG/5ML A204627 001 Apr 29, 2014CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

TUZISTRA XR

+! AYTU EQ 2.8MG BASE/5ML; EQ 14.7MG BASE/5ML N207768 001 Apr 30, 2015

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

CAPSULE, EXTENDED RELEASE; ORAL

TUSSICAPS

ECR PHARMA EQ 4MG MALEATE; EQ 5MG BITARTRATE A077273 002 Sep 24, 2007
! EQ 8MG MALEATE; EQ 10MG BITARTRATE A077273 001 Sep 24, 2007

SUSPENSION, EXTENDED RELEASE; ORAL

HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX

AB	TRIS PHARMA INC	EQ 8MG MALEATE/5ML; EQ 10MG BITARTRATE/5ML	A091632 001	Oct 01, 2010
HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX				
AB	! NEOS THERAP INC	EQ 8MG MALEATE/5ML; EQ 10MG BITARTRATE/5ML	A091671 001	Jun 29, 2012

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHLORPROMAZINE HYDROCHLORIDE

AP	AUROBINDO PHARMA LTD	25MG/ML	A211816 001	Jul 07, 2020
AP	! WEST-WARD PHARMS INT	25MG/ML	A083329 001	

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

AB	AMNEAL PHARMS CO	10MG	A209755 001	Sep 10, 2018
AB		25MG	A209755 002	Sep 10, 2018
AB		50MG	A209755 003	Sep 10, 2018
AB		100MG	A209755 004	Sep 10, 2018
AB		200MG	A209755 005	Sep 10, 2018
AB	MAYNE PHARMA	10MG	A213590 001	Aug 31, 2020
AB		25MG	A213590 002	Aug 31, 2020
AB		50MG	A213590 003	Aug 31, 2020
AB		100MG	A213590 004	Aug 31, 2020
AB		200MG	A213590 005	Aug 31, 2020
AB	SUN PHARM	10MG	A214256 001	Oct 26, 2020
AB		25MG	A214256 002	Oct 26, 2020
AB		50MG	A214256 003	Oct 26, 2020
AB		100MG	A214256 004	Oct 26, 2020
AB		200MG	A214256 005	Oct 26, 2020
AB	UPSHER SMITH LABS	10MG	A083386 001	

PRESCRIPTION DRUG PRODUCT LIST

CHLORPROMAZINE HYDROCHLORIDE

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

<u>AB</u>	!	<u>25MG</u>	<u>A084112</u>	<u>001</u>	
<u>AB</u>		<u>50MG</u>	<u>A084113</u>	<u>001</u>	
<u>AB</u>	!	<u>100MG</u>	<u>A084114</u>	<u>001</u>	
<u>AB</u>		<u>200MG</u>	<u>A084115</u>	<u>001</u>	
<u>AB</u>	ZYDUS	<u>10MG</u>	<u>A213368</u>	<u>001</u>	Jan 17, 2020
<u>AB</u>		<u>25MG</u>	<u>A213368</u>	<u>002</u>	Jan 17, 2020
<u>AB</u>		<u>50MG</u>	<u>A213368</u>	<u>003</u>	Jan 17, 2020
<u>AB</u>		<u>100MG</u>	<u>A213368</u>	<u>004</u>	Jan 17, 2020
<u>AB</u>		<u>200MG</u>	<u>A213368</u>	<u>005</u>	Jan 17, 2020

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

<u>AB</u>	AJANTA PHARMA LTD	<u>25MG</u>	<u>A214129</u>	<u>001</u>	Nov 27, 2020
<u>AB</u>		<u>50MG</u>	<u>A214129</u>	<u>002</u>	Nov 27, 2020
<u>AB</u>	ALKEM LABS LTD	<u>25MG</u>	<u>A213412</u>	<u>001</u>	Feb 11, 2020
<u>AB</u>		<u>50MG</u>	<u>A213412</u>	<u>002</u>	Feb 11, 2020
<u>AB</u>	AMNEAL PHARMS CO	<u>25MG</u>	<u>A207204</u>	<u>001</u>	Jul 01, 2019
<u>AB</u>		<u>50MG</u>	<u>A207204</u>	<u>002</u>	Jul 01, 2019
<u>AB</u>	DR REDDYS	<u>25MG</u>	<u>A210742</u>	<u>001</u>	Oct 12, 2018
<u>AB</u>		<u>50MG</u>	<u>A210742</u>	<u>002</u>	Oct 12, 2018
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A086831</u>	<u>002</u>	
<u>AB</u>	!	<u>50MG</u>	<u>A086831</u>	<u>001</u>	
<u>AB</u>	RICONPHARMA LLC	<u>25MG</u>	<u>A206904</u>	<u>001</u>	Mar 30, 2017
<u>AB</u>		<u>50MG</u>	<u>A206904</u>	<u>002</u>	Mar 30, 2017
<u>AB</u>	SUN PHARM INDUSTRIES	<u>25MG</u>	<u>A089286</u>	<u>002</u>	Jul 21, 1986
<u>AB</u>		<u>50MG</u>	<u>A089286</u>	<u>001</u>	Jul 21, 1986
<u>AB</u>	UMEDICA LABS PVT LTD	<u>25MG</u>	<u>A207222</u>	<u>001</u>	May 24, 2018
<u>AB</u>		<u>50MG</u>	<u>A207222</u>	<u>002</u>	May 24, 2018
<u>AB</u>	UNICHEM	<u>25MG</u>	<u>A211627</u>	<u>001</u>	Aug 06, 2019
<u>AB</u>		<u>50MG</u>	<u>A211627</u>	<u>002</u>	Aug 06, 2019
<u>AB</u>	VISTAPHARM	<u>25MG</u>	<u>A211063</u>	<u>001</u>	Feb 26, 2019
<u>AB</u>		<u>50MG</u>	<u>A211063</u>	<u>002</u>	Feb 26, 2019
<u>AB</u>	ZYDUS PHARMS	<u>25MG</u>	<u>A207813</u>	<u>001</u>	May 10, 2019
<u>AB</u>		<u>50MG</u>	<u>A207813</u>	<u>002</u>	May 10, 2019

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

<u>AA</u>	AUROBINDO PHARMA LTD	<u>500MG</u>	<u>A089853</u>	<u>001</u>	May 04, 1988
<u>AA</u>	MAYNE PHARMA	<u>500MG</u>	<u>A211849</u>	<u>002</u>	Jul 21, 2020
<u>AA</u>	NOVITIUM PHARMA	<u>500MG</u>	<u>A212254</u>	<u>001</u>	Sep 12, 2019
<u>AA</u>	!	<u>500MG</u>	<u>A089859</u>	<u>001</u>	May 04, 1988
<u>AB</u>	GLENMARK PHARMS LTD	<u>375MG</u>	<u>A212185</u>	<u>001</u>	May 26, 2020
<u>AB</u>		<u>750MG</u>	<u>A212185</u>	<u>002</u>	May 26, 2020
<u>AB</u>	I3 PHARMS	<u>375MG</u>	<u>A212053</u>	<u>001</u>	Sep 14, 2020
<u>AB</u>		<u>750MG</u>	<u>A212053</u>	<u>002</u>	Sep 14, 2020
<u>AB</u>	MAYNE PHARMA	<u>375MG</u>	<u>A211849</u>	<u>001</u>	Jul 21, 2020
<u>AB</u>		<u>750MG</u>	<u>A211849</u>	<u>003</u>	Jul 21, 2020
<u>AB</u>	!	<u>375MG</u>	<u>A040861</u>	<u>001</u>	Jun 01, 2010
<u>AB</u>	!	<u>750MG</u>	<u>A040861</u>	<u>002</u>	Jun 01, 2010
<u>AB</u>	NOVITIUM PHARMA	<u>375MG</u>	<u>A212253</u>	<u>001</u>	Nov 27, 2019
<u>AB</u>		<u>750MG</u>	<u>A212253</u>	<u>002</u>	Nov 27, 2019
<u>AB</u>	PAR PHARM INC	<u>750MG</u>	<u>A212743</u>	<u>001</u>	Nov 02, 2020
<u>AB</u>	TEVA PHARMS USA INC	<u>375MG</u>	<u>A212898</u>	<u>001</u>	Jun 17, 2020
<u>AB</u>		<u>750MG</u>	<u>A212898</u>	<u>002</u>	Jun 17, 2020
<u>AB</u>	!	<u>250MG</u>	<u>A207483</u>	<u>001</u>	Jun 24, 2016

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE

<u>AB</u>	AJANTA PHARMA LTD	<u>EQ 4GM RESIN/PACKET</u>	<u>A211119</u>	<u>001</u>	Apr 06, 2020
<u>AB</u>		<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>A211119</u>	<u>002</u>	Apr 06, 2020
<u>AB</u>	ANI PHARMS INC	<u>EQ 4GM RESIN/PACKET</u>	<u>A074554</u>	<u>001</u>	Oct 02, 1996
<u>AB</u>		<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>A074554</u>	<u>002</u>	Oct 02, 1996
<u>AB</u>	PAR PHARM	<u>EQ 4GM RESIN/PACKET</u>	<u>A077204</u>	<u>001</u>	Aug 26, 2005
<u>AB</u>		<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>A077204</u>	<u>002</u>	Aug 26, 2005
<u>AB</u>	!	<u>EQ 4GM RESIN/PACKET</u>	<u>A074557</u>	<u>001</u>	Aug 15, 1996

PRESCRIPTION DRUG PRODUCT LIST

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE

<u>AB</u>		<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>A074557 002</u>	Aug 15, 1996
<u>AB</u>	ZYDUS PHARMS	<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>A202901 001</u>	Jul 02, 2018
<u>CHOLESTYRAMINE LIGHT</u>				
<u>AB</u>	PAR PHARM	<u>EQ 4GM RESIN/PACKET</u>	<u>A077203 001</u>	Aug 26, 2005
<u>AB</u>		<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>A077203 002</u>	Aug 26, 2005
<u>AB</u>	! SANDOZ	<u>EQ 4GM RESIN/PACKET</u>	<u>A074558 001</u>	Aug 15, 1996
<u>AB</u>		<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>A074558 002</u>	Aug 15, 1996
<u>AB</u>	TAGI	<u>EQ 4GM RESIN/PACKET</u>	<u>A209599 001</u>	Nov 12, 2020
<u>AB</u>		<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>A209599 002</u>	Nov 12, 2020
<u>AB</u>	ZYDUS PHARMS	<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>A202902 001</u>	Apr 25, 2017
<u>PREVALITE</u>				
<u>AB</u>	UPSHER SMITH LABS	<u>EQ 4GM RESIN/PACKET</u>	<u>A073263 001</u>	Feb 22, 1996
<u>AB</u>		<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>A073263 002</u>	Oct 30, 1997

CHOLIC ACID

CAPSULE; ORAL

CHOLBAM

+	TRAVERE	50MG	N205750 001	Mar 17, 2015
+	!	250MG	N205750 002	Mar 17, 2015

CHOLINE C-11

INJECTABLE; INTRAVENOUS

CHOLINE C-11

<u>AP</u>	DECATUR	<u>4-33.1mCi/ML</u>	<u>A206319 001</u>	Nov 13, 2015
<u>AP</u>	+! MCPRF	<u>4-33.1mCi/ML</u>	<u>N203155 001</u>	Sep 12, 2012
<u>AP</u>	UCSF RODIOPHARM	<u>4-33.1mCi/ML</u>	<u>A208444 001</u>	Nov 20, 2017
<u>AP</u>	WA UNIV SCH MED	<u>4-33.1mCi/ML</u>	<u>A208413 001</u>	Jan 10, 2017
	UNIV TX MD ANDERSON	4-100mCi/ML	A205690 001	Oct 29, 2015

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL

FENOFIBRIC ACID

<u>AB</u>	ACTAVIS ELIZABETH	<u>EQ 45MG FENOFIBRIC ACID</u>	<u>A200920 001</u>	Oct 07, 2015
<u>AB</u>		<u>EQ 135MG FENOFIBRIC ACID</u>	<u>A200920 002</u>	Oct 07, 2015
<u>AB</u>	ALEMBIC PHARMS LTD	<u>EQ 45MG FENOFIBRIC ACID</u>	<u>A208705 001</u>	May 12, 2017
<u>AB</u>		<u>EQ 135MG FENOFIBRIC ACID</u>	<u>A208705 002</u>	May 12, 2017
<u>AB</u>	ANCHEN PHARMS	<u>EQ 45MG FENOFIBRIC ACID</u>	<u>A201573 002</u>	Jul 18, 2013
<u>AB</u>		<u>EQ 135MG FENOFIBRIC ACID</u>	<u>A201573 001</u>	Jul 18, 2013
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 45MG FENOFIBRIC ACID</u>	<u>A212598 001</u>	Jul 25, 2019
<u>AB</u>		<u>EQ 135MG FENOFIBRIC ACID</u>	<u>A212598 002</u>	Jul 25, 2019
<u>AB</u>	GRAVITI PHARMS	<u>EQ 45MG FENOFIBRIC ACID</u>	<u>A211626 001</u>	Jul 18, 2019
<u>AB</u>		<u>EQ 135MG FENOFIBRIC ACID</u>	<u>A211626 002</u>	Jul 18, 2019
<u>AB</u>	IMPAX LABS INC	<u>EQ 45MG FENOFIBRIC ACID</u>	<u>A200264 001</u>	Sep 07, 2016
<u>AB</u>		<u>EQ 135MG FENOFIBRIC ACID</u>	<u>A200264 002</u>	Sep 07, 2016
<u>AB</u>	LUPIN LTD	<u>EQ 45MG FENOFIBRIC ACID</u>	<u>A200750 001</u>	Dec 04, 2013
<u>AB</u>		<u>EQ 135MG FENOFIBRIC ACID</u>	<u>A200750 002</u>	Dec 04, 2013
<u>AB</u>	MICRO LABS	<u>EQ 45MG FENOFIBRIC ACID</u>	<u>A213450 001</u>	Jun 16, 2020
<u>AB</u>		<u>EQ 135MG FENOFIBRIC ACID</u>	<u>A213450 002</u>	Jun 16, 2020
<u>AB</u>	TWI PHARMS	<u>EQ 45MG FENOFIBRIC ACID</u>	<u>A210469 001</u>	Jul 05, 2019
<u>AB</u>		<u>EQ 135MG FENOFIBRIC ACID</u>	<u>A210469 002</u>	Jul 05, 2019
<u>AB</u>	YICHANG HUMANWELL	<u>EQ 45MG FENOFIBRIC ACID</u>	<u>A212562 001</u>	Dec 23, 2020
<u>AB</u>		<u>EQ 135MG FENOFIBRIC ACID</u>	<u>A212562 002</u>	Dec 23, 2020
<u>TRILIPIX</u>				
<u>AB</u>	+ ABBVIE	<u>EQ 45MG FENOFIBRIC ACID</u>	<u>N022224 001</u>	Dec 15, 2008
<u>AB</u>	+!	<u>EQ 135MG FENOFIBRIC ACID</u>	<u>N022224 002</u>	Dec 15, 2008

CHROMIC CHLORIDE

INJECTABLE; INJECTION

CHROMIC CHLORIDE IN PLASTIC CONTAINER

+	HOSPIRA	EQ 0.004MG CHROMIUM/ML	N018961 001	Jun 26, 1986
---	---------	------------------------	-------------	--------------

CICLESONIDE

AEROSOL, METERED; INHALATION

ALVESCO

+	COVIS	0.08MG/INH	N021658 002	Jan 10, 2008
+	!	0.16MG/INH	N021658 003	Jan 10, 2008

AEROSOL, METERED; NASAL

ZETONNA

+	COVIS	0.037MG/INH	N202129 001	Jan 20, 2012
---	-------	-------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

CICLESONIDE

SPRAY, METERED;NASAL

OMNARIS

+! COVIS

0.05MG/INH

N022004 001 Oct 20, 2006

CICLOPIROX

CREAM;TOPICAL

CICLOPIROX

AB	COSETTE	<u>0.77%</u>	<u>A078463</u>	<u>001</u>	Dec 20, 2010
AB	FOUGERA PHARMS	<u>0.77%</u>	<u>A076435</u>	<u>001</u>	Dec 29, 2004
AB	GLENMARK PHARMS	<u>0.77%</u>	<u>A090273</u>	<u>001</u>	Nov 10, 2009
AB	PERRIGO ISRAEL	<u>0.77%</u>	<u>A077364</u>	<u>001</u>	Mar 03, 2006
AB	TARO	<u>0.77%</u>	<u>A076790</u>	<u>001</u>	Apr 12, 2005

LOPROX

AB	+! MEDIMETRIKS PHARMS	<u>0.77%</u>	<u>N018748</u>	<u>001</u>	Dec 30, 1982
-----------	-----------------------	--------------	-----------------------	-------------------	--------------

GEL;TOPICAL

CICLOPIROX

AB	+! CNTY LINE PHARMS	<u>0.77%</u>	<u>N020519</u>	<u>001</u>	Jul 21, 1997
AB	FOUGERA PHARMS	<u>0.77%</u>	<u>A077896</u>	<u>001</u>	Jun 10, 2008
AB	GLENMARK GENERICS	<u>0.77%</u>	<u>A091595</u>	<u>001</u>	Feb 29, 2012
AB	PADDOCK LLC	<u>0.77%</u>	<u>A078266</u>	<u>001</u>	Jan 07, 2009

SHAMPOO;TOPICAL

CICLOPIROX

AT	ACTAVIS MID	<u>1%</u>	<u>A090490</u>	<u>001</u>	Nov 24, 2009
	ATLANTIC				
AT	FOUGERA PHARMS	<u>1%</u>	<u>A090146</u>	<u>001</u>	May 25, 2010
AT	PERRIGO CO	<u>1%</u>	<u>A078594</u>	<u>001</u>	Feb 16, 2010
AT	TARO	<u>1%</u>	<u>A090269</u>	<u>001</u>	Feb 23, 2011
AT	TELIGENT	<u>1%</u>	<u>A209975</u>	<u>001</u>	Apr 05, 2018

LOPROX

AT	+! BAUSCH	<u>1%</u>	<u>N021159</u>	<u>001</u>	Feb 28, 2003
-----------	-----------	-----------	-----------------------	-------------------	--------------

SOLUTION;TOPICAL

CICLOPIROX

AT	ACELLA	<u>8%</u>	<u>A078172</u>	<u>001</u>	Sep 18, 2007
AT	ACTAVIS MID	<u>8%</u>	<u>A078046</u>	<u>001</u>	Sep 18, 2007
	ATLANTIC				
AT	AKORN	<u>8%</u>	<u>A078270</u>	<u>001</u>	Sep 18, 2007
AT		<u>8%</u>	<u>A078975</u>	<u>001</u>	Feb 17, 2010
AT	COSETTE	<u>8%</u>	<u>A078233</u>	<u>001</u>	Sep 18, 2007
AT	NOVAST LABS	<u>8%</u>	<u>A078124</u>	<u>001</u>	Sep 18, 2007
AT	PERRIGO NEW YORK	<u>8%</u>	<u>A077623</u>	<u>001</u>	Sep 18, 2007
AT	TARO PHARM INDS	<u>8%</u>	<u>A078144</u>	<u>001</u>	Sep 18, 2007

PENLAC

AT	+! VALEANT BERMUDA	<u>8%</u>	<u>N021022</u>	<u>001</u>	Dec 17, 1999
-----------	--------------------	-----------	-----------------------	-------------------	--------------

SUSPENSION;TOPICAL

CICLOPIROX

AB	FOUGERA PHARMS	<u>0.77%</u>	<u>A076422</u>	<u>001</u>	Aug 06, 2004
AB	PERRIGO NEW YORK	<u>0.77%</u>	<u>A077676</u>	<u>001</u>	Dec 15, 2006
AB	TARO	<u>0.77%</u>	<u>A077092</u>	<u>001</u>	Aug 10, 2005

LOPROX

AB	+! MEDIMETRIKS PHARMS	<u>0.77%</u>	<u>N019824</u>	<u>001</u>	Dec 30, 1988
-----------	-----------------------	--------------	-----------------------	-------------------	--------------

CIDOFOVIR

INJECTABLE;INJECTION

CIDOFOVIR

AP	EMCURE PHARMS LTD	<u>EQ 75MG BASE/ML</u>	<u>A202501</u>	<u>001</u>	Jul 26, 2012
AP	! MYLAN INSTITUTIONAL	<u>EQ 75MG BASE/ML</u>	<u>A201276</u>	<u>001</u>	Jun 27, 2012

CILASTATIN SODIUM; IMIPENEM

POWDER;INTRAVENOUS

IMIPENEM AND CILASTATIN

AP	ACS DOBFAR	<u>EQ 500MG BASE/VIAL;500MG/VIAL</u>	<u>A090577</u>	<u>002</u>	Dec 21, 2011
AP	HQ SPCLT PHARMA	<u>EQ 500MG BASE/VIAL;500MG/VIAL</u>	<u>A207594</u>	<u>001</u>	Dec 12, 2019

PRIMAXIN

AP	+! MERCK	<u>EQ 500MG BASE/VIAL;500MG/VIAL</u>	<u>N050587</u>	<u>002</u>	Nov 26, 1985
-----------	----------	---	-----------------------	-------------------	--------------

IMIPENEM AND CILASTATIN

! ACS DOBFAR

EQ 250MG BASE/VIAL;250MG/VIAL

A090577 001 Dec 21, 2011

CILASTATIN SODIUM; IMIPENEM; RELEBACTAM

POWDER;INTRAVENOUS

RECARBRIO

+! MSD MERCK CO

EQ 500MG
BASE/VIAL;500MG/VIAL;250MG/VIAL

N212819 001 Jul 16, 2019

PRESCRIPTION DRUG PRODUCT LIST

CILOSTAZOL

TABLET;ORAL

CILOSTAZOL

<u>AB</u>	APOTEX INC	<u>50MG</u>	<u>A077030 001</u>	Dec 10, 2004
<u>AB</u>		<u>100MG</u>	<u>A077030 002</u>	Dec 10, 2004
<u>AB</u>	BRECKENRIDGE PHARM	<u>50MG</u>	<u>A077708 001</u>	Sep 28, 2009
<u>AB</u>		<u>100MG</u>	<u>A077708 002</u>	Sep 28, 2009
<u>AB</u>	CASI PHARMS INC	<u>50MG</u>	<u>A077310 001</u>	Nov 08, 2005
<u>AB</u>		<u>100MG</u>	<u>A077021 001</u>	Nov 23, 2004
<u>AB</u>	CHARTWELL RX	<u>50MG</u>	<u>A077831 002</u>	Sep 24, 2012
<u>AB</u>		<u>100MG</u>	<u>A077831 001</u>	Sep 24, 2012
<u>AB</u>	HIKMA	<u>50MG</u>	<u>A077024 001</u>	May 17, 2005
<u>AB</u>		<u>100MG</u>	<u>A077024 002</u>	May 17, 2005
<u>AB</u>	SLATE	<u>50MG</u>	<u>A077208 002</u>	Mar 29, 2006
<u>AB</u>		<u>100MG</u>	<u>A077208 001</u>	Mar 29, 2006
<u>AB</u>	! TEVA	<u>50MG</u>	<u>A077027 001</u>	Nov 24, 2004
<u>AB</u>	!	<u>100MG</u>	<u>A077027 002</u>	Nov 24, 2004

CIMETIDINE

TABLET;ORAL

CIMETIDINE

<u>AB</u>	MYLAN	<u>200MG</u>	<u>A074246 001</u>	May 17, 1994
<u>AB</u>		<u>300MG</u>	<u>A074246 002</u>	May 17, 1994
<u>AB</u>		<u>400MG</u>	<u>A074246 003</u>	May 17, 1994
<u>AB</u>	!	<u>800MG</u>	<u>A074246 004</u>	May 17, 1994
<u>AB</u>	PLIVA	<u>800MG</u>	<u>A074566 001</u>	Feb 27, 1997
<u>AB</u>	TEVA	<u>200MG</u>	<u>A074151 001</u>	May 17, 1994
<u>AB</u>		<u>300MG</u>	<u>A074151 002</u>	May 17, 1994
<u>AB</u>		<u>400MG</u>	<u>A074151 003</u>	May 17, 1994
<u>AB</u>		<u>800MG</u>	<u>A074463 001</u>	May 17, 1994

CIMETIDINE HYDROCHLORIDE

SOLUTION;ORAL

CIMETIDINE HYDROCHLORIDE

<u>AA</u>	! AKORN	<u>EQ 300MG BASE/5ML</u>	<u>A074664 001</u>	Oct 28, 1997
<u>AA</u>	PHARM ASSOC	<u>EQ 300MG BASE/5ML</u>	<u>A074553 001</u>	Jan 27, 1997
<u>AA</u>	WOCKHARDT BIO AG	<u>EQ 300MG BASE/5ML</u>	<u>A074757 001</u>	Oct 17, 1997

CINACALCET HYDROCHLORIDE

TABLET;ORAL

CINACALCET HYDROCHLORIDE

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 30MG BASE</u>	<u>A211892 001</u>	May 15, 2020
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A211892 002</u>	May 15, 2020
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A211892 003</u>	May 15, 2020
<u>AB</u>	ACME LABS	<u>EQ 30MG BASE</u>	<u>A213325 001</u>	May 18, 2020
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A213325 002</u>	May 18, 2020
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A213325 003</u>	May 18, 2020
<u>AB</u>	ALKEM LABS LTD	<u>EQ 30MG BASE</u>	<u>A210570 001</u>	May 17, 2019
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A210570 002</u>	May 17, 2019
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A210570 003</u>	May 17, 2019
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 30MG BASE</u>	<u>A206125 001</u>	Mar 08, 2018
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A206125 002</u>	Mar 08, 2018
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A206125 003</u>	Mar 08, 2018
<u>AB</u>	CIPLA	<u>EQ 30MG BASE</u>	<u>A208915 001</u>	Mar 08, 2018
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A208915 002</u>	Mar 08, 2018
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A208915 003</u>	Mar 08, 2018
<u>AB</u>	DR REDDYS	<u>EQ 30MG BASE</u>	<u>A208368 001</u>	Sep 18, 2020
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A208368 002</u>	Sep 18, 2020
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A208368 003</u>	Sep 18, 2020
<u>AB</u>	HETERO LABS LTD V	<u>EQ 30MG BASE</u>	<u>A209403 001</u>	Oct 07, 2020
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A209403 002</u>	Oct 07, 2020
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A209403 003</u>	Oct 07, 2020
<u>AB</u>	MYLAN	<u>EQ 30MG BASE</u>	<u>A203422 001</u>	Oct 16, 2018
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A203422 002</u>	Oct 16, 2018
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A203422 003</u>	Oct 16, 2018
<u>AB</u>	PIRAMAL HLTHCARE UK	<u>EQ 30MG BASE</u>	<u>A210207 001</u>	Aug 01, 2018
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A210207 002</u>	Aug 01, 2018
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A210207 003</u>	Aug 01, 2018
<u>AB</u>	STRIDES PHARMA	<u>EQ 30MG BASE</u>	<u>A209226 001</u>	Apr 30, 2018
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A209226 002</u>	Apr 30, 2018
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A209226 003</u>	Apr 30, 2018
<u>AB</u>	SUN PHARM	<u>EQ 30MG BASE</u>	<u>A207008 001</u>	Oct 11, 2018
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A207008 002</u>	Oct 11, 2018

PRESCRIPTION DRUG PRODUCT LIST

CINACALCET HYDROCHLORIDE

TABLET; ORAL

CINACALCET HYDROCHLORIDE

<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A207008 003</u>	Oct 11, 2018
<u>AB</u>	WATSON LABS TEVA	<u>EQ 30MG BASE</u>	<u>A204377 001</u>	Dec 27, 2018
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A204377 002</u>	Dec 27, 2018
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A204377 003</u>	Dec 27, 2018

SENSIPAR

<u>AB</u>	+	AMGEN	<u>EQ 30MG BASE</u>	<u>N021688 001</u>	Mar 08, 2004
<u>AB</u>	+		<u>EQ 60MG BASE</u>	<u>N021688 002</u>	Mar 08, 2004
<u>AB</u>	+	!	<u>EQ 90MG BASE</u>	<u>N021688 003</u>	Mar 08, 2004

CIPROFLOXACIN

FOR SUSPENSION; ORAL

CIPRO

+	BAYER HLTHCARE	250MG/5ML	N020780 001	Sep 26, 1997
+	!	500MG/5ML	N020780 002	Sep 26, 1997

INJECTABLE; INJECTION

CIPROFLOXACIN

<u>AP</u>	!	BAXTER HLTHCARE CORP	<u>200MG/20ML (10MG/ML)</u>	<u>A078062 001</u>	Apr 29, 2008
<u>AP</u>	!		<u>400MG/40ML (10MG/ML)</u>	<u>A078062 002</u>	Apr 29, 2008
<u>AP</u>		HIKMA FARMACEUTICA	<u>200MG/20ML (10MG/ML)</u>	<u>A076717 001</u>	Dec 22, 2009
<u>AP</u>			<u>400MG/40ML (10MG/ML)</u>	<u>A076717 002</u>	Dec 22, 2009
<u>AP</u>		HOSPIRA	<u>200MG/20ML (10MG/ML)</u>	<u>A077245 001</u>	Aug 28, 2006
<u>AP</u>			<u>400MG/40ML (10MG/ML)</u>	<u>A077245 002</u>	Aug 28, 2006

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>		BAXTER HLTHCARE CORP	<u>200MG/100ML</u>	<u>A078024 001</u>	Mar 18, 2008
<u>AP</u>			<u>400MG/200ML</u>	<u>A078024 002</u>	Mar 18, 2008
<u>AP</u>		HIKMA FARMACEUTICA	<u>400MG/200ML</u>	<u>A078431 001</u>	Nov 18, 2009
<u>AP</u>	!	HOSPIRA	<u>200MG/100ML</u>	<u>A077753 001</u>	Mar 18, 2008
<u>AP</u>	!		<u>400MG/200ML</u>	<u>A077753 002</u>	Mar 18, 2008
<u>AP</u>		INFORLIFE	<u>200MG/100ML</u>	<u>A078252 001</u>	Mar 18, 2008
<u>AP</u>			<u>400MG/200ML</u>	<u>A078252 002</u>	Mar 18, 2008

INJECTABLE, SUSPENSION; OTIC

OTIPRIO

+	!	OTONOMY INC	6% (60MG/ML)	N207986 001	Dec 10, 2015
---	---	-------------	--------------	-------------	--------------

CIPROFLOXACIN HYDROCHLORIDE

OINTMENT; OPHTHALMIC

CILOXAN

+	!	NOVARTIS	EQ 0.3% BASE	N020369 001	Mar 30, 1998
---	---	----------	--------------	-------------	--------------

SOLUTION/DROPS; OPHTHALMIC

CILOXAN

<u>AT</u>	+	!	NOVARTIS	<u>EQ 0.3% BASE</u>	<u>N019992 001</u>	Dec 31, 1990
-----------	---	---	----------	---------------------	--------------------	--------------

CIPROFLOXACIN HYDROCHLORIDE

<u>AT</u>		AKORN INC	<u>EQ 0.3% BASE</u>	<u>A076555 001</u>	Dec 11, 2008
<u>AT</u>		ALTAIRE PHARMS INC	<u>EQ 0.3% BASE</u>	<u>A204613 001</u>	May 03, 2018
<u>AT</u>		FDC LTD	<u>EQ 0.3% BASE</u>	<u>A077568 001</u>	Jun 30, 2008
<u>AT</u>		RISING	<u>EQ 0.3% BASE</u>	<u>A077689 001</u>	Dec 13, 2006
<u>AT</u>		TELIGENT	<u>EQ 0.3% BASE</u>	<u>A076754 001</u>	Jun 09, 2004
<u>AT</u>		WATSON LABS INC	<u>EQ 0.3% BASE</u>	<u>A076673 001</u>	Jan 21, 2005

SOLUTION/DROPS; OTIC

CETRALAX

+	!	WRASER PHARMS	EQ 0.2% BASE	N021918 001	May 01, 2009
---	---	---------------	--------------	-------------	--------------

TABLET; ORAL

CIPRO

<u>AB</u>	+	BAYER HLTHCARE	<u>EQ 250MG BASE</u>	<u>N019537 002</u>	Oct 22, 1987
<u>AB</u>	+	!	<u>EQ 500MG BASE</u>	<u>N019537 003</u>	Oct 22, 1987

CIPROFLOXACIN HYDROCHLORIDE

<u>AB</u>		AUROBINDO PHARMA	<u>EQ 250MG BASE</u>	<u>A077859 001</u>	Apr 26, 2007
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A077859 002</u>	Apr 26, 2007
<u>AB</u>			<u>EQ 750MG BASE</u>	<u>A077859 003</u>	Apr 26, 2007
<u>AB</u>		CARLSBAD	<u>EQ 250MG BASE</u>	<u>A076126 002</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A076126 003</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 750MG BASE</u>	<u>A076126 004</u>	Jun 09, 2004
<u>AB</u>		CHARTWELL	<u>EQ 250MG BASE</u>	<u>A076896 001</u>	Nov 04, 2004
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A076896 002</u>	Nov 04, 2004
<u>AB</u>			<u>EQ 750MG BASE</u>	<u>A076896 003</u>	Nov 04, 2004
<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 100MG BASE</u>	<u>A075593 002</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 250MG BASE</u>	<u>A075593 003</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A075593 004</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 750MG BASE</u>	<u>A075593 001</u>	Jun 09, 2004

PRESCRIPTION DRUG PRODUCT LISTCIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

AB	HIKMA	<u>EQ 250MG BASE</u>	<u>A076558 002</u>	Jun 09, 2004
AB		<u>EQ 500MG BASE</u>	<u>A076558 003</u>	Jun 09, 2004
AB		<u>EQ 750MG BASE</u>	<u>A076558 004</u>	Jun 09, 2004
AB	IVAX SUB TEVA PHARMS	<u>EQ 250MG BASE</u>	<u>A076089 002</u>	Jun 09, 2004
AB		<u>EQ 500MG BASE</u>	<u>A076089 003</u>	Jun 09, 2004
AB		<u>EQ 750MG BASE</u>	<u>A076089 004</u>	Jun 09, 2004
AB	MYLAN	<u>EQ 500MG BASE</u>	<u>A075817 003</u>	Jun 09, 2004
AB	TARO	<u>EQ 100MG BASE</u>	<u>A076912 001</u>	Feb 18, 2005
AB		<u>EQ 250MG BASE</u>	<u>A076912 002</u>	Oct 06, 2004
AB		<u>EQ 500MG BASE</u>	<u>A076912 003</u>	Oct 06, 2004
AB		<u>EQ 750MG BASE</u>	<u>A076912 004</u>	Oct 06, 2004
AB	UNIQUE PHARM LABS	<u>EQ 250MG BASE</u>	<u>A076639 001</u>	Sep 10, 2004
AB		<u>EQ 500MG BASE</u>	<u>A076639 002</u>	Sep 10, 2004
AB		<u>EQ 750MG BASE</u>	<u>A076639 003</u>	Sep 10, 2004
AB	WATSON LABS	<u>EQ 100MG BASE</u>	<u>A076794 001</u>	Feb 10, 2005
AB		<u>EQ 250MG BASE</u>	<u>A076794 002</u>	Jun 09, 2004
AB		<u>EQ 500MG BASE</u>	<u>A076794 003</u>	Jun 09, 2004
AB		<u>EQ 750MG BASE</u>	<u>A076794 004</u>	Jun 09, 2004
AB	YILING	<u>EQ 250MG BASE</u>	<u>A208921 001</u>	Jun 22, 2018
AB		<u>EQ 500MG BASE</u>	<u>A208921 002</u>	Jun 22, 2018

CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE

SOLUTION/DROPS; OTIC

OTOVEL

+! LABORATORIOS SALVAT EQ 0.3% BASE; 0.025% N208251 001 Apr 29, 2016

CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE

SUSPENSION/DROPS; OTIC

CIPRO HC

+! NOVARTIS EQ 0.2% BASE; 1% N020805 001 Feb 10, 1998

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPROFLOXACIN EXTENDED RELEASE

AB	! ANCHEN PHARMS	<u>425.2MG; EQ 574.9MG BASE</u>	<u>A078166 001</u>	Nov 27, 2007
AB	DR REDDYS LABS LTD	<u>425.2MG; EQ 574.9MG BASE</u>	<u>A077701 001</u>	Mar 26, 2007
	! ANCHEN PHARMS	<u>212.6MG; EQ 287.5MG BASE</u>	<u>A078166 002</u>	Nov 27, 2007

CIPROFLOXACIN; DEXAMETHASONE

SUSPENSION/DROPS; OTIC

CIPRODEX**AB** +! NOVARTIS **0.3%; 0.1%** **N021537 001** Jul 18, 2003CIPROFLOXACIN AND DEXAMETHASONE**AB** DR REDDYS LABS LTD **0.3%; 0.1%** **A205548 001** Aug 10, 2020CISATRACURIUM BESYLATE

INJECTABLE; INJECTION

CISATRACURIUM BESYLATE

AP	AUROBINDO PHARMA LTD	<u>EQ 2MG BASE/ML</u>	<u>A209144 001</u>	May 08, 2020
AP	FRESENIUS KABI USA	<u>EQ 2MG BASE/ML</u>	<u>A203183 001</u>	Feb 26, 2015
AP	HOSPIRA INC	<u>EQ 2MG BASE/ML</u>	<u>A203236 001</u>	Mar 30, 2018
AP		<u>EQ 2MG BASE/ML</u>	<u>A203238 001</u>	Mar 30, 2018
AP		<u>EQ 10MG BASE/ML</u>	<u>A203236 002</u>	Mar 30, 2018
AP	JIANGSU HENGRUI MED	<u>EQ 2MG BASE/ML</u>	<u>A209334 001</u>	Aug 30, 2017
AP	MEITHEAL	<u>EQ 2MG BASE/ML</u>	<u>A211668 001</u>	Apr 25, 2019
AP		<u>EQ 2MG BASE/ML</u>	<u>A211669 001</u>	Apr 25, 2019
AP		<u>EQ 10MG BASE/ML</u>	<u>A211668 002</u>	Apr 25, 2019
AP	SAGENT PHARMS INC	<u>EQ 2MG BASE/ML</u>	<u>A201836 001</u>	Nov 06, 2020
AP		<u>EQ 2MG BASE/ML</u>	<u>A201851 001</u>	Nov 06, 2020
AP		<u>EQ 10MG BASE/ML</u>	<u>A201836 002</u>	Nov 06, 2020
AP	SANDOZ INC	<u>EQ 2MG BASE/ML</u>	<u>A200159 001</u>	Feb 03, 2012
AP	SOMERSET	<u>EQ 2MG BASE/ML</u>	<u>A209132 001</u>	Apr 24, 2019
AP	ZYDUS PHARMS	<u>EQ 2MG BASE/ML</u>	<u>A212171 001</u>	Nov 04, 2019
AP		<u>EQ 2MG BASE/ML</u>	<u>A213527 001</u>	Aug 31, 2020
AP		<u>EQ 10MG BASE/ML</u>	<u>A212171 002</u>	Nov 04, 2019

CISATRACURIUM BESYLATE PRESERVATIVE FREE

AP	AUROBINDO PHARMA LTD	<u>EQ 2MG BASE/ML</u>	<u>A209665 001</u>	Oct 27, 2020
AP	FRESENIUS KABI USA	<u>EQ 2MG BASE/ML</u>	<u>A203182 001</u>	Feb 26, 2015
AP		<u>EQ 10MG BASE/ML</u>	<u>A203182 002</u>	Feb 26, 2015

PRESCRIPTION DRUG PRODUCT LIST

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION

CISATRACURIUM BESYLATE PRESERVATIVE FREE

<u>AP</u>	JIANGSU HENGRUI MED	<u>EQ 2MG BASE/ML</u>	<u>A204960 001</u>	Jan 27, 2017
<u>AP</u>		<u>EQ 10MG BASE/ML</u>	<u>A204960 002</u>	Sep 19, 2017
<u>AP</u>	SANDOZ INC	<u>EQ 2MG BASE/ML</u>	<u>A200154 001</u>	Feb 03, 2012
<u>AP</u>		<u>EQ 10MG BASE/ML</u>	<u>A200154 002</u>	Feb 03, 2012
<u>AP</u>	SOMERSET THERAPS LLC	<u>EQ 2MG BASE/ML</u>	<u>A206791 001</u>	Feb 20, 2019
<u>AP</u>		<u>EQ 10MG BASE/ML</u>	<u>A206791 002</u>	Feb 20, 2019
<u>NIMBEX</u>				
<u>AP</u>	+! ABBVIE	<u>EQ 2MG BASE/ML</u>	<u>N020551 001</u>	Dec 15, 1995
<u>NIMBEX PRESERVATIVE FREE</u>				
<u>AP</u>	+! ABBVIE	<u>EQ 2MG BASE/ML</u>	<u>N020551 003</u>	Dec 15, 1995
<u>AP</u>	+!	<u>EQ 10MG BASE/ML</u>	<u>N020551 002</u>	Dec 15, 1995

CISPLATIN

INJECTABLE; INJECTION

CISPLATIN

<u>AP</u>	ACCORD HLTHCARE	<u>1MG/ML</u>	<u>A206774 001</u>	Aug 18, 2015
<u>AP</u>	! FRESENIUS KABI USA	<u>1MG/ML</u>	<u>A074735 001</u>	Jul 16, 1999
<u>AP</u>	GLAND PHARMA LTD	<u>1MG/ML</u>	<u>A207323 001</u>	Mar 17, 2017
<u>AP</u>	+ HQ SPCLT PHARMA	<u>1MG/ML</u>	<u>N018057 004</u>	Nov 08, 1988
<u>AP</u>	PHARMACHEMIE BV	<u>1MG/ML</u>	<u>A074656 001</u>	May 16, 2000
<u>AP</u>	WEST-WARD PHARMS INT	<u>1MG/ML</u>	<u>A075036 001</u>	Nov 07, 2000

CITALOPRAM HYDROBROMIDE

SOLUTION; ORAL

CITALOPRAM HYDROBROMIDE

<u>AA</u>	AUROBINDO PHARMA LTD	<u>EQ 10MG BASE/5ML</u>	<u>A077812 001</u>	Aug 28, 2006
<u>AA</u>	HETERO LABS LTD III	<u>EQ 10MG BASE/5ML</u>	<u>A201450 001</u>	Dec 15, 2015
<u>AA</u>	! HIKMA	<u>EQ 10MG BASE/5ML</u>	<u>A077043 001</u>	Dec 13, 2004
<u>AA</u>	LANNETT CO INC	<u>EQ 10MG BASE/5ML</u>	<u>A077629 001</u>	Jun 15, 2006

TABLET; ORAL

CELEXA

<u>AB</u>	+ ALLERGAN	<u>EQ 10MG BASE</u>	<u>N020822 001</u>	Apr 27, 2000
<u>AB</u>	+	<u>EQ 20MG BASE</u>	<u>N020822 002</u>	Jul 17, 1998
<u>AB</u>	+!	<u>EQ 40MG BASE</u>	<u>N020822 003</u>	Jul 17, 1998

CITALOPRAM HYDROBROMIDE

<u>AB</u>	AMNEAL PHARMS NY	<u>EQ 10MG BASE</u>	<u>A077289 001</u>	Nov 30, 2006
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077289 002</u>	Nov 30, 2006
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077289 003</u>	Nov 30, 2006
<u>AB</u>	APOTEX INC	<u>EQ 10MG BASE</u>	<u>A077046 001</u>	Nov 24, 2004
<u>AB</u>	AUROBINDO	<u>EQ 10MG BASE</u>	<u>A077031 001</u>	Oct 28, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077031 002</u>	Oct 28, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077031 003</u>	Oct 28, 2004
<u>AB</u>	CHARTWELL MOLECULAR	<u>EQ 10MG BASE</u>	<u>A077044 001</u>	Nov 05, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077044 002</u>	Nov 05, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077044 003</u>	Nov 05, 2004
<u>AB</u>	COSETTE	<u>EQ 10MG BASE</u>	<u>A077048 001</u>	Nov 16, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077048 002</u>	Nov 16, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077048 003</u>	Nov 16, 2004
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 10MG BASE</u>	<u>A077038 001</u>	Oct 28, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077038 002</u>	Oct 28, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077038 003</u>	Oct 28, 2004
<u>AB</u>	EPIC PHARMA	<u>EQ 10MG BASE</u>	<u>A077045 003</u>	Apr 29, 2005
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077045 002</u>	Apr 29, 2005
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077045 001</u>	Apr 29, 2005
<u>AB</u>	GLENMARK GENERICS	<u>EQ 10MG BASE</u>	<u>A077654 001</u>	Feb 27, 2009
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077654 002</u>	Feb 27, 2009
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077654 003</u>	Feb 27, 2009
<u>AB</u>	INVAGEN PHARMS	<u>EQ 10MG BASE</u>	<u>A077534 001</u>	Oct 03, 2006
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077534 002</u>	Oct 03, 2006
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077534 003</u>	Oct 03, 2006
<u>AB</u>	MYLAN	<u>EQ 10MG BASE</u>	<u>A077042 001</u>	Nov 05, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077042 002</u>	Nov 05, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077042 003</u>	Nov 05, 2004
<u>AB</u>	TORPHARM	<u>EQ 20MG BASE</u>	<u>A077046 002</u>	Nov 24, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077046 003</u>	Nov 24, 2004
<u>AB</u>	TORRENT PHARMS	<u>EQ 10MG BASE</u>	<u>A078216 001</u>	Mar 27, 2007
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A078216 002</u>	Mar 27, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078216 003</u>	Mar 27, 2007

PRESCRIPTION DRUG PRODUCT LIST

CITRIC ACID; GLUCONOLACTONE; MAGNESIUM CARBONATE

SOLUTION; IRRIGATION

RENACIDIN

+! UNITED GUARDIAN 6.602GM/100ML; 198MG/100ML; 3.177GM/100ML N019481 001 Oct 02, 1990

CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE

GEL; VAGINAL

PHEXXI

+! EVOFEM INC 1%; 1.8%; 0.4% N208352 001 May 22, 2020

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

SOLUTION; ORAL

CLENPIQ

+! FERRING PHARMS INC 12GM/BOT; 3.5GM/BOT; 10MG/BOT N209589 001 Nov 28, 2017

CITRIC ACID; UREA C-13

FOR SOLUTION, TABLET, FOR SOLUTION; ORAL

IDKIT:HP

+! EXALENZ BIOSCIENCE N/A, 4GM; 75MG, N/A N021314 001 Dec 17, 2002

CLADRIBINE

INJECTABLE; INJECTION

CLADRIBINE**AP** ! FRESENIUS KABI USA 1MG/ML **A076571 001** Apr 22, 2004**AP** HISUN PHARM 1MG/ML **A210856 001** Nov 25, 2019

HANGZHOU

AP MYLAN LABS LTD 1MG/ML **A200510 001** Oct 06, 2011**AP** WEST-WARD PHARMS 1MG/ML **A075405 001** Feb 28, 2000

INT

TABLET; ORAL

MAVENCLAD

+! EMD SERONO INC 10MG N022561 001 Mar 29, 2019

CLARITHROMYCIN

FOR SUSPENSION; ORAL

CLARITHROMYCIN**AB** SANDOZ 125MG/5ML **A065283 002** Sep 04, 2007**AB** ! 250MG/5ML **A065283 003** Sep 04, 2007

TABLET; ORAL

CLARITHROMYCIN**AB** ! AUROBINDO 250MG **A065489 001** Jul 25, 2012**AB** ! 500MG **A065489 002** Jul 25, 2012**AB** CHARTWELL 250MG **A065384 001** Aug 20, 2007**AB** 500MG **A065384 002** Aug 20, 2007**AB** HEC PHARM 250MG **A203584 001** Sep 28, 2015**AB** 500MG **A203584 002** Sep 28, 2015**AB** SANDOZ 250MG **A065144 001** Oct 18, 2005**AB** 500MG **A065136 001** Aug 25, 2005**AB** STRIDES PHARMA 250MG **A202710 001** Jun 10, 2013**AB** 500MG **A202710 002** Jun 10, 2013**AB** TEVA 250MG **A065155 001** May 31, 2005**AB** 500MG **A065155 002** May 31, 2005**AB** WOCKHARDT 250MG **A065266 001** May 31, 2006**AB** 500MG **A065266 002** May 31, 2006

TABLET, EXTENDED RELEASE; ORAL

CLARITHROMYCIN**AB** ACTAVIS LABS FL INC 500MG **A065145 001** Jun 24, 2004**AB** ! MAYNE PHARMA 500MG **A065154 001** May 18, 2005**AB** SUNSHINE 500MG **A208987 001** Jul 09, 2018CLASCOTERONE

CREAM; TOPICAL

WINLEVI

+! CASSIOPEA SPA 1% N213433 001 Aug 26, 2020

CLEMASTINE FUMARATE

SYRUP; ORAL

CLEMASTINE FUMARATE

! GENUS EQ 0.5MG BASE/5ML A073399 001 Jun 30, 1994

TABLET; ORAL

CLEMASTINE FUMARATE

! TEVA 2.68MG A073283 001 Jan 31, 1992

PRESCRIPTION DRUG PRODUCT LIST

CLEVIDIPINE

EMULSION; INTRAVENOUS

CLEVIPREX

+! CHIESI

25MG/50ML (0.5MG/ML)

N022156 001 Aug 01, 2008

+!

50MG/100ML (0.5MG/ML)

N022156 002 Aug 01, 2008

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLEOCIN HYDROCHLORIDE**AB** + PHARMACIA AND
UPJOHN**EQ 75MG BASE****N050162 001****AB** +**EQ 150MG BASE****N050162 002****AB** +!**EQ 300MG BASE****N050162 003** Apr 14, 1988CLINDAMYCIN HYDROCHLORIDE**AB** AUROBINDO PHARMA**EQ 150MG BASE****A065442 001** Aug 26, 2009**AB****EQ 300MG BASE****A065442 002** Aug 26, 2009**AB** COSETTE**EQ 150MG BASE****A063029 001** Sep 20, 1989**AB****EQ 300MG BASE****A063029 002** Aug 05, 2005**AB** EPIC PHARMA LLC**EQ 150MG BASE****A065194 001** Mar 22, 2004**AB****EQ 300MG BASE****A065194 002** Mar 22, 2004**AB** LANNETT CO INC**EQ 75MG BASE****A065243 002** Aug 12, 2005**AB** MICRO LABS**EQ 75MG BASE****A207402 001** Nov 05, 2018**AB****EQ 150MG BASE****A207402 002** Nov 05, 2018**AB****EQ 300MG BASE****A207402 003** Nov 05, 2018**AB** SUN PHARM INDS LTD**EQ 150MG BASE****A065061 001** Feb 02, 2001**AB****EQ 300MG BASE****A065061 002** Feb 02, 2001**AB** WATSON LABS**EQ 150MG BASE****A063083 001** Jul 31, 1991**AB****EQ 300MG BASE****A063083 002** Mar 18, 2003**AB** ZYDUS PHARMS USA**EQ 75MG BASE****A065217 001** Jan 31, 2005**AB****EQ 150MG BASE****A065217 002** Jan 31, 2005**AB****EQ 300MG BASE****A065217 003** Jan 31, 2005CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL

CLEOCIN**AA** ! PHARMACIA AND
UPJOHN**EQ 75MG BASE/5ML****A062644 001** Apr 07, 1986CLINDAMYCIN PALMITATE HYDROCHLORIDE**AA** ALEMIC LABS**EQ 75MG BASE/5ML****A206958 001** May 05, 2017**AA** AMNEAL PHARMS**EQ 75MG BASE/5ML****A203513 001** Mar 13, 2014**AA** AUROBINDO PHARMA**EQ 75MG BASE/5ML****A202409 001** Apr 30, 2013**AA** LTD**AA** HERITAGE PHARMS INC**EQ 75MG BASE/5ML****A207047 001** May 11, 2018**AA** LYNE**EQ 75MG BASE/5ML****A201821 001** Aug 28, 2012**AA** PADDOCK LABS LLC**EQ 75MG BASE/5ML****A090902 001** Jul 07, 2010CLINDAMYCIN PHOSPHATE

AEROSOL, FOAM; TOPICAL

CLINDAMYCIN PHOSPHATE**AT** PERRIGO UK FINCO**1%****A090785 001** Mar 31, 2010EVOCLIN**AT** +! MYLAN**1%****N050801 001** Oct 22, 2004

CREAM; VAGINAL

CLEOCIN**AB** +! PHARMACIA AND
UPJOHN**EQ 2% BASE****N050680 002** Mar 02, 1998CLINDAMYCIN PHOSPHATE**AB** FOUGERA PHARMS**EQ 2% BASE****A065139 001** Dec 27, 2004

CLINDESSE

+! PERRIGO PHARMA INTL

EQ 2% BASE

N050793 001 Nov 30, 2004

GEL; TOPICAL

CLEOCIN T**AB** +! PHARMACIA AND
UPJOHN**EQ 1% BASE****N050615 001** Jan 07, 1987CLINDAMYCIN PHOSPHATE**AB** FOUGERA PHARMS**EQ 1% BASE****A064160 001** Jan 28, 2000**AB** GAGE DEVELOPMENT**EQ 1% BASE****A212104 001** Dec 31, 2020**AB** SOLARIS PHARMA CORP**EQ 1% BASE****A211872 001** Jul 29, 2020**AB** TARO PHARMS**EQ 1% BASE****A214052 001** Nov 10, 2020

CLINDAGEL

BT +! BAUSCH

EQ 1% BASE

N050782 001 Nov 27, 2000

INJECTABLE; INJECTION

CLEOCIN PHOSPHATE**AP** PHARMACIA AND
UPJOHN**EQ 150MG BASE/ML****A062803 001** Oct 16, 1987

PRESCRIPTION DRUG PRODUCT LIST

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLEOCIN PHOSPHATE

<u>AP</u>	<u>+!</u>		<u>EQ 150MG BASE/ML</u>	<u>N050441 001</u>	
		<u>CLINDAMYCIN PHOSPHATE</u>			
<u>AP</u>		ALVOGEN	<u>EQ 150MG BASE/ML</u>	<u>A062800 001</u>	Jul 24, 1987
<u>AP</u>			<u>EQ 150MG BASE/ML</u>	<u>A062943 001</u>	Sep 29, 1988
<u>AP</u>		FRESENIUS KABI USA	<u>EQ 150MG BASE/ML</u>	<u>A065346 001</u>	Mar 29, 2007
<u>AP</u>			<u>EQ 150MG BASE/ML</u>	<u>A065347 001</u>	May 09, 2007
<u>AP</u>		MYLAN LABS LTD	<u>EQ 150MG BASE/ML</u>	<u>A204748 001</u>	Oct 10, 2017
<u>AP</u>		SAGENT PHARMS INC	<u>EQ 150MG BASE/ML</u>	<u>A090108 001</u>	Sep 30, 2011
<u>AP</u>			<u>EQ 150MG BASE/ML</u>	<u>A090109 001</u>	Sep 30, 2011
<u>AP</u>		WEST-WARD PHARMS INT	<u>EQ 150MG BASE/ML</u>	<u>A062889 001</u>	Apr 25, 1988
<u>AP</u>			<u>EQ 150MG BASE/ML</u>	<u>A065206 001</u>	Sep 24, 2004
		<u>CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER</u>			
<u>AP</u>		AKORN INC	<u>EQ 6MG BASE/ML</u>	<u>A203048 001</u>	Apr 04, 2013
<u>AP</u>			<u>EQ 12MG BASE/ML</u>	<u>A203048 002</u>	Apr 04, 2013
<u>AP</u>			<u>EQ 18MG BASE/ML</u>	<u>A203048 003</u>	Apr 04, 2013
<u>AP</u>		BAXTER HLTHCARE CORP	<u>EQ 6MG BASE/ML</u>	<u>A208084 001</u>	Jun 28, 2017
<u>AP</u>			<u>EQ 12MG BASE/ML</u>	<u>A208084 002</u>	Jun 28, 2017
<u>AP</u>			<u>EQ 18MG BASE/ML</u>	<u>A208084 003</u>	Jun 28, 2017
<u>AP</u>	<u>!</u>	SANDOZ INC	<u>EQ 6MG BASE/ML</u>	<u>A201692 001</u>	May 31, 2012
<u>AP</u>	<u>!</u>		<u>EQ 12MG BASE/ML</u>	<u>A201692 002</u>	May 31, 2012
<u>AP</u>	<u>!</u>		<u>EQ 18MG BASE/ML</u>	<u>A201692 003</u>	May 31, 2012
		CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% <u>+!</u> ABRAXIS PHARM	EQ 900MG BASE/100ML	N050635 001	Dec 22, 1989
		LOTION; TOPICAL			
		<u>CLEOCIN T</u>			
<u>AB</u>	<u>+!</u>	PHARMACIA AND UPJOHN	<u>EQ 1% BASE</u>	<u>N050600 001</u>	May 31, 1989
		<u>CLINDAMYCIN PHOSPHATE</u>			
<u>AB</u>		FOUGERA PHARMS	<u>EQ 1% BASE</u>	<u>A065067 001</u>	Jan 31, 2002
		SOLUTION; INTRAVENOUS			
		CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE <u>+!</u> BAXTER HLTHCARE CORP	EQ 300MG BASE/50ML (EQ 6MG BASE/ML)	N208083 001	Apr 20, 2017
		<u>+!</u>	EQ 600MG BASE/50ML (EQ 12MG BASE/ML)	N208083 002	Apr 20, 2017
		<u>+!</u>	EQ 900MG BASE/50ML (EQ 18MG BASE/ML)	N208083 003	Apr 20, 2017
		SOLUTION; TOPICAL			
		<u>CLEOCIN T</u>			
<u>AT</u>	<u>+!</u>	PHARMACIA AND UPJOHN	<u>EQ 1% BASE</u>	<u>N050537 001</u>	
		<u>CLINDA-DERM</u>			
<u>AT</u>		PADDOCK LLC	<u>EQ 1% BASE</u>	<u>A063329 001</u>	Sep 30, 1992
		<u>CLINDAMYCIN PHOSPHATE</u>			
<u>AT</u>		CADILA	<u>EQ 1% BASE</u>	<u>A208767 001</u>	Jul 16, 2018
<u>AT</u>		ENCUBE ETHICALS	<u>EQ 1% BASE</u>	<u>A209914 001</u>	Jan 28, 2019
<u>AT</u>		FOUGERA PHARMS INC	<u>EQ 1% BASE</u>	<u>A064159 001</u>	Jun 05, 1997
<u>AT</u>		GLASSHOUSE PHARMS	<u>EQ 1% BASE</u>	<u>A209846 001</u>	Feb 08, 2018
<u>AT</u>		PERRIGO NEW YORK	<u>EQ 1% BASE</u>	<u>A064050 001</u>	Nov 30, 1995
<u>AT</u>		TARO PHARM INDS	<u>EQ 1% BASE</u>	<u>A065184 001</u>	Mar 31, 2004
<u>AT</u>		TELIGENT	<u>EQ 1% BASE</u>	<u>A206945 001</u>	Dec 30, 2016
		SUPPOSITORY; VAGINAL			
		CLEOCIN <u>+!</u> PHARMACIA AND UPJOHN	100MG	N050767 001	Aug 13, 1999
		SWAB; TOPICAL			
		<u>CLEOCIN</u>			
<u>AT</u>	<u>+!</u>	PHARMACIA AND UPJOHN	<u>EQ 1% BASE</u>	<u>N050537 002</u>	Feb 22, 1994
		<u>CLINDAMYCIN PHOSPHATE</u>			
<u>AT</u>		AKORN	<u>EQ 1% BASE</u>	<u>A065513 001</u>	Jun 17, 2010
<u>AT</u>		PERRIGO NEW YORK	<u>EQ 1% BASE</u>	<u>A065049 001</u>	May 25, 2000
		<u>CLINDETS</u>			
<u>AT</u>		PERRIGO CO	<u>EQ 1% BASE</u>	<u>A064136 001</u>	Sep 30, 1996

PRESCRIPTION DRUG PRODUCT LIST

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL; TOPICAL

CLINDAMYCIN PHOSPHATE AND TRETINOIN

AB	ACTAVIS MID ATLANTIC	1.2%;0.025%	A202564 001	Jun 12, 2015
-----------	----------------------	--------------------	--------------------	--------------

ZIANA

AB	+! MEDICIS	1.2%;0.025%	N050802 001	Nov 07, 2006
BX	+! ALMIRALL	1.2%;0.025%	N050803 001	Jul 16, 2010

CLOBAZAM

FILM; ORAL

SYMPAZAN

+	AQUESTIVE THERAP	5MG	N210833 001	Nov 01, 2018
+		10MG	N210833 002	Nov 01, 2018
+!		20MG	N210833 003	Nov 01, 2018

SUSPENSION; ORAL

CLOBAZAM

AB	AMNEAL	2.5MG/ML	A210039 001	Oct 22, 2018
AB	BIONPHARMA INC	2.5MG/ML	A208819 001	Oct 22, 2018
AB	HETERO LABS LTD III	2.5MG/ML	A209796 001	Feb 24, 2020
AB	HIKMA	2.5MG/ML	A209715 001	Oct 22, 2018
AB	LANNETT CO INC	2.5MG/ML	A213110 001	Apr 24, 2020
AB	LUPIN LTD	2.5MG/ML	A210546 001	Dec 28, 2018
AB	MYLAN	2.5MG/ML	A211259 001	Oct 22, 2018
AB	UPSHER SMITH LABS	2.5MG/ML	A210569 001	Oct 22, 2018
AB	VISTAPHARM	2.5MG/ML	A210746 001	Jul 10, 2019
ONFI				
AB	+! LUNDBECK PHARMS LLC	2.5MG/ML	N203993 001	Dec 14, 2012

TABLET; ORAL

CLOBAZAM

AB	ALKEM LABS LTD	10MG	A212714 001	Sep 06, 2019
AB		20MG	A212714 002	Sep 06, 2019
AB	AMNEAL PHARMS CO	10MG	A209718 001	Oct 22, 2018
AB		20MG	A209718 002	Oct 22, 2018
AB	BIONPHARMA INC	10MG	A208825 001	Oct 22, 2018
AB		20MG	A208825 002	Oct 22, 2018
AB	BRECKENRIDGE	10MG	A209308 001	Oct 22, 2018
AB		20MG	A209308 002	Oct 22, 2018
AB	CELLTRION	10MG	A211959 001	Dec 09, 2020
AB		20MG	A211959 002	Dec 09, 2020
AB	HETERO LABS LTD III	10MG	A209795 001	Oct 22, 2018
AB		20MG	A209795 002	Oct 22, 2018
AB	HIKMA	10MG	A208785 001	Oct 22, 2018
AB		20MG	A208785 002	Oct 22, 2018
AB	LANNETT CO INC	10MG	A212092 001	Oct 30, 2019
AB		20MG	A212092 002	Oct 30, 2019
AB	LUPIN LTD	10MG	A210545 001	Dec 14, 2018
AB		20MG	A210545 002	Dec 14, 2018
AB	MICRO LABS	10MG	A211711 001	Jan 30, 2019
AB		20MG	A211711 002	Jan 30, 2019
AB	PIRAMAL HLTHCARE UK	10MG	A209808 001	Oct 22, 2018
AB		20MG	A209808 002	Oct 22, 2018
AB	UPSHER SMITH LABS	10MG	A209687 001	Oct 22, 2018
AB		20MG	A209687 002	Oct 22, 2018
AB	ZYDUS PHARMS	10MG	A211449 001	Oct 22, 2018
AB		20MG	A211449 002	Oct 22, 2018

ONFI

AB	+ LUNDBECK PHARMS LLC	10MG	N202067 002	Oct 21, 2011
AB	+!	20MG	N202067 003	Oct 21, 2011

CLOBAZAM

	ALKEM LABS LTD	5MG	A212714 003	Dec 21, 2020
--	----------------	-----	-------------	--------------

CLOBETASOL PROPIONATE

AEROSOL, FOAM; TOPICAL

CLOBETASOL PROPIONATE

AB1	GLENMARK PHARMS LTD	0.05%	A210809 001	Feb 15, 2019
AB1	INGENUS PHARMS LLC	0.05%	A206805 001	Jul 31, 2017
AB1	PERRIGO ISRAEL	0.05%	A077763 001	Mar 10, 2008
AB1	TARO	0.05%	A208779 001	Oct 04, 2018

OLUX

AB1	+! MYLAN	0.05%	N021142 001	May 26, 2000
------------	----------	--------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

CLOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL

CLOBETASOL PROPIONATE

AB2	GLENMARK PHARMS LTD	<u>0.05%</u>	<u>A211450</u>	<u>001</u>	Sep 09, 2019
AB2	PERRIGO UK FINCO	<u>0.05%</u>	<u>A201402</u>	<u>001</u>	Aug 14, 2012

OLUX E

AB2	+ ! MYLAN	<u>0.05%</u>	<u>N022013</u>	<u>001</u>	Jan 12, 2007
------------	------------------	--------------	-----------------------	-------------------	--------------

CREAM;TOPICAL

CLOBETASOL PROPIONATE

AB1	ALEOR	<u>0.05%</u>	<u>A213291</u>	<u>001</u>	Jan 27, 2020
	DERMACEUTICALS				
AB1	AMNEAL	<u>0.05%</u>	<u>A211256</u>	<u>001</u>	Dec 26, 2018
AB1	COSETTE	<u>0.05%</u>	<u>A074139</u>	<u>001</u>	Aug 03, 1994
AB1	ENCUBE	<u>0.05%</u>	<u>A212982</u>	<u>001</u>	Aug 28, 2020
AB1	FOUGERA PHARMS INC	<u>0.05%</u>	<u>A074392</u>	<u>001</u>	Sep 30, 1996
AB1	GLENMARK PHARMS	<u>0.05%</u>	<u>A209095</u>	<u>001</u>	May 10, 2018
AB1	LUPIN LTD	<u>0.05%</u>	<u>A210208</u>	<u>001</u>	Jan 30, 2018
AB1	MYLAN	<u>0.05%</u>	<u>A075338</u>	<u>001</u>	Feb 09, 2001
AB1	RISING	<u>0.05%</u>	<u>A211401</u>	<u>001</u>	Jan 11, 2019
AB1	TARO	<u>0.05%</u>	<u>A074249</u>	<u>001</u>	Jul 08, 1996
AB1	TELIGENT	<u>0.05%</u>	<u>A209974</u>	<u>001</u>	Apr 17, 2018
AB1	TORRENT	<u>0.05%</u>	<u>A211836</u>	<u>001</u>	Dec 30, 2019
AB1	XIROMED	<u>0.05%</u>	<u>A210034</u>	<u>001</u>	Jun 15, 2018
AB1	ZYDUS PHARMS	<u>0.05%</u>	<u>A211074</u>	<u>001</u>	Oct 15, 2018

CORMAX

AB1	! AKORN	<u>0.05%</u>	<u>A074220</u>	<u>001</u>	May 16, 1997
------------	----------------	--------------	-----------------------	-------------------	--------------

CLOBETASOL PROPIONATE (EMOLLIENT)

AB2	ANI PHARMS INC	<u>0.05%</u>	<u>A075733</u>	<u>001</u>	Aug 22, 2001
AB2	! FOUGERA PHARMS	<u>0.05%</u>	<u>A075430</u>	<u>001</u>	May 26, 1999
AB2	TARO	<u>0.05%</u>	<u>A075633</u>	<u>001</u>	May 17, 2000
AB2	TELIGENT	<u>0.05%</u>	<u>A209411</u>	<u>001</u>	Aug 21, 2017

EMBELINE E

AB2	AKORN	<u>0.05%</u>	<u>A075325</u>	<u>001</u>	Dec 24, 1998
	IMPOYZ				
	+ ! ENCORE DERMAT	<u>0.025%</u>	<u>N209483</u>	<u>001</u>	Nov 28, 2017

GEL;TOPICAL

CLOBETASOL PROPIONATE

AB	! FOUGERA PHARMS	<u>0.05%</u>	<u>A075368</u>	<u>001</u>	Feb 15, 2000
AB	PERRIGO CO	<u>0.05%</u>	<u>A075027</u>	<u>001</u>	Oct 31, 1997
AB	TARO	<u>0.05%</u>	<u>A075279</u>	<u>001</u>	May 28, 1999
AB	TELIGENT	<u>0.05%</u>	<u>A208881</u>	<u>001</u>	Mar 06, 2017

EMBELINE

AB	AKORN	<u>0.05%</u>	<u>A076141</u>	<u>001</u>	Apr 12, 2002
-----------	-------	--------------	-----------------------	-------------------	--------------

LOTION;TOPICAL

CLOBETASOL PROPIONATE

AB	ACTAVIS MID	<u>0.05%</u>	<u>A078223</u>	<u>001</u>	Dec 04, 2008
	ATLANTIC				
AB	CADILA	<u>0.05%</u>	<u>A205249</u>	<u>001</u>	Sep 24, 2019
AB	LUPIN LTD	<u>0.05%</u>	<u>A209147</u>	<u>001</u>	Sep 22, 2017
AB	TARO	<u>0.05%</u>	<u>A200302</u>	<u>001</u>	Jul 02, 2012
AB	TELIGENT	<u>0.05%</u>	<u>A208667</u>	<u>001</u>	Nov 29, 2016

CLOBEX

AB	+ ! GALDERMA LABS LP	<u>0.05%</u>	<u>N021535</u>	<u>001</u>	Jul 24, 2003
	IMPEKLO				
	+ ! MYLAN	<u>0.05%</u>	<u>N213691</u>	<u>001</u>	May 19, 2020

OINTMENT;TOPICAL

CLOBETASOL PROPIONATE

AB	ALEOR	<u>0.05%</u>	<u>A211800</u>	<u>001</u>	Mar 04, 2019
	DERMACEUTICALS				
AB	COSETTE	<u>0.05%</u>	<u>A074089</u>	<u>001</u>	Feb 16, 1994
AB	ENCUBE	<u>0.05%</u>	<u>A211295</u>	<u>001</u>	Nov 15, 2019
AB	! FOUGERA PHARMS	<u>0.05%</u>	<u>A074407</u>	<u>001</u>	Feb 23, 1996
AB	GLENMARK PHARMS	<u>0.05%</u>	<u>A208933</u>	<u>001</u>	Mar 20, 2017
AB	MYLAN	<u>0.05%</u>	<u>A075057</u>	<u>001</u>	Aug 12, 1998
AB	NOVEL LABS INC	<u>0.05%</u>	<u>A208841</u>	<u>001</u>	May 04, 2018
AB	TARO	<u>0.05%</u>	<u>A074248</u>	<u>001</u>	Jul 12, 1996
AB	TELIGENT	<u>0.05%</u>	<u>A208589</u>	<u>001</u>	Jan 23, 2019
AB	TORRENT	<u>0.05%</u>	<u>A212926</u>	<u>001</u>	Oct 25, 2019
AB	XIROMED	<u>0.05%</u>	<u>A209701</u>	<u>001</u>	Apr 17, 2018
AB	ZYDUS PHARMS	<u>0.05%</u>	<u>A210199</u>	<u>001</u>	Oct 27, 2017

EMBELINE

AB	AKORN	<u>0.05%</u>	<u>A074221</u>	<u>001</u>	Mar 31, 1995
-----------	-------	--------------	-----------------------	-------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

CLOBETASOL PROPIONATE

SHAMPOO; TOPICAL

CLOBETASOL PROPIONATE

AB	ACTAVIS MID ATLANTIC	0.05%	A078854 001	Jun 07, 2011
AB	AKORN	0.05%	A209871 001	Oct 27, 2017
AB	ALEOR DERMACEUTICALS	0.05%	A213290 001	May 18, 2020
AB	PERRIGO ISRAEL	0.05%	A090974 001	Aug 09, 2012

CLOBEX

AB	+! GALDERMA LABS	0.05%	N021644 001	Feb 05, 2004
-----------	------------------	--------------	--------------------	--------------

SOLUTION; TOPICAL

CLOBETASOL PROPIONATE

AT	ALEOR DERMACEUTICALS	0.05%	A212881 001	Oct 21, 2019
AT	COSETTE	0.05%	A074331 001	Dec 15, 1995
AT	FOUGERA PHARMS	0.05%	A075391 001	Feb 08, 1999
AT	GLENMARK PHARMS LTD	0.05%	A210190 001	Apr 18, 2018
AT	MACLEODS PHARMS LTD	0.05%	A209361 001	Oct 25, 2017
AT	NOVEL LABS INC	0.05%	A206075 001	Nov 23, 2015
AT	SAPTALIS PHARMS	0.05%	A211494 001	Oct 02, 2019
AT	TARO	0.05%	A075224 001	Nov 16, 1998
AT		0.05%	A075363 001	Dec 29, 2000
AT	TOLMAR	0.05%	A076977 001	Aug 05, 2005
AT	WOCKHARDT BIO AG	0.05%	A075205 001	Nov 13, 1998

EMBELINE

AT	! AKORN	0.05%	A074222 001	Dec 06, 1995
-----------	---------	--------------	--------------------	--------------

SPRAY; TOPICAL

CLOBETASOL PROPIONATE

AT	AKORN	0.05%	A207218 001	Apr 28, 2017
AT	ALEOR DERMACEUTICALS	0.05%	A211191 001	Oct 02, 2019
AT	GLENMARK PHARMS	0.05%	A209004 001	Mar 26, 2018
AT	LUPIN LTD	0.05%	A208125 001	Mar 26, 2018
AT	PADDOCK LLC	0.05%	A090898 001	Jun 16, 2011
AT	TARO	0.05%	A208842 001	Mar 26, 2018
AT	ZYDUS PHARMS	0.05%	A206378 001	Feb 16, 2017

CLOBEX

AT	+! GALDERMA LABS LP	0.05%	N021835 001	Oct 27, 2005
-----------	---------------------	--------------	--------------------	--------------

CLOCORTOLONE PIVALATE

CREAM; TOPICAL

CLODERM

+!	EPI HLTH	0.1%	N017765 001	
----	----------	------	-------------	--

CLOFARABINE

SOLUTION; INTRAVENOUS

CLOFARABINE

AP	ABON PHARMS LLC	20MG/20ML (1MG/ML)	A204029 001	May 09, 2017
AP	ACCORD HLTHCARE	20MG/20ML (1MG/ML)	A212034 001	Feb 22, 2019
AP	AMNEAL	20MG/20ML (1MG/ML)	A208857 001	Nov 06, 2017
AP	DR REDDYS LABS LTD	20MG/20ML (1MG/ML)	A205375 001	Nov 06, 2017
AP	GLAND PHARMA LTD	20MG/20ML (1MG/ML)	A207831 001	Oct 31, 2018
AP	HONG KONG	20MG/20ML (1MG/ML)	A213461 001	Oct 23, 2020
AP	MSN	20MG/20ML (1MG/ML)	A209775 001	Dec 06, 2017
AP	MYLAN LABS LTD	20MG/20ML (1MG/ML)	A208860 001	Nov 06, 2017
AP	NOVAST LABS	20MG/20ML (1MG/ML)	A210270 001	Sep 14, 2018

CLOLAR

AP	+! GENZYME	20MG/20ML (1MG/ML)	N021673 001	Dec 28, 2004
-----------	------------	---------------------------	--------------------	--------------

CLOMIPHENE CITRATE

TABLET; ORAL

CLOMIPHENE CITRATE

!	PAR PHARM	50MG	A075528 001	Aug 30, 1999
---	-----------	------	-------------	--------------

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

ANAFRANIL

AB	+! SPECGX LLC	25MG	N019906 001	Dec 29, 1989
AB	+	50MG	N019906 002	Dec 29, 1989
AB	+	75MG	N019906 003	Dec 29, 1989

CLOMIPRAMINE HYDROCHLORIDE

AB	AJANTA PHARMA LTD	25MG	A213897 001	Oct 02, 2020
AB		50MG	A213897 002	Oct 02, 2020
AB		75MG	A213897 003	Oct 02, 2020

PRESCRIPTION DRUG PRODUCT LIST

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL

CLOMIPRAMINE HYDROCHLORIDE

<u>AB</u>	AMNEAL PHARMS CO	<u>25MG</u>	<u>A208632</u>	<u>001</u>	Oct 31, 2018
<u>AB</u>		<u>50MG</u>	<u>A208632</u>	<u>002</u>	Oct 31, 2018
<u>AB</u>		<u>75MG</u>	<u>A208632</u>	<u>003</u>	Oct 31, 2018
<u>AB</u>	JUBILANT CADISTA	<u>25MG</u>	<u>A212218</u>	<u>001</u>	Oct 21, 2019
<u>AB</u>		<u>50MG</u>	<u>A212218</u>	<u>002</u>	Oct 21, 2019
<u>AB</u>		<u>75MG</u>	<u>A212218</u>	<u>003</u>	Oct 21, 2019
<u>AB</u>	LEADING PHARMA LLC	<u>25MG</u>	<u>A211364</u>	<u>001</u>	Feb 07, 2020
<u>AB</u>		<u>50MG</u>	<u>A211364</u>	<u>002</u>	Feb 07, 2020
<u>AB</u>		<u>75MG</u>	<u>A211364</u>	<u>003</u>	Feb 07, 2020
<u>AB</u>	LUPIN LTD	<u>25MG</u>	<u>A209294</u>	<u>001</u>	Nov 21, 2018
<u>AB</u>		<u>50MG</u>	<u>A209294</u>	<u>002</u>	Nov 21, 2018
<u>AB</u>		<u>75MG</u>	<u>A209294</u>	<u>003</u>	Nov 21, 2018
<u>AB</u>	MANKIND PHARMA	<u>25MG</u>	<u>A211767</u>	<u>001</u>	Apr 08, 2019
<u>AB</u>		<u>50MG</u>	<u>A211767</u>	<u>002</u>	Apr 08, 2019
<u>AB</u>		<u>75MG</u>	<u>A211767</u>	<u>003</u>	Apr 08, 2019
<u>AB</u>	MICRO LABS	<u>25MG</u>	<u>A213219</u>	<u>001</u>	Jun 22, 2020
<u>AB</u>		<u>50MG</u>	<u>A213219</u>	<u>002</u>	Jun 22, 2020
<u>AB</u>		<u>75MG</u>	<u>A213219</u>	<u>003</u>	Jun 22, 2020
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A074947</u>	<u>001</u>	Apr 30, 1998
<u>AB</u>		<u>50MG</u>	<u>A074947</u>	<u>002</u>	Apr 30, 1998
<u>AB</u>		<u>75MG</u>	<u>A074947</u>	<u>003</u>	Apr 30, 1998
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A074364</u>	<u>001</u>	Mar 29, 1996
<u>AB</u>		<u>25MG</u>	<u>A074953</u>	<u>001</u>	Jun 25, 1997
<u>AB</u>		<u>50MG</u>	<u>A074364</u>	<u>002</u>	Mar 29, 1996
<u>AB</u>		<u>50MG</u>	<u>A074953</u>	<u>002</u>	Jun 25, 1997
<u>AB</u>		<u>75MG</u>	<u>A074364</u>	<u>003</u>	Mar 29, 1996
<u>AB</u>		<u>75MG</u>	<u>A074953</u>	<u>003</u>	Jun 25, 1997
<u>AB</u>	TARO	<u>25MG</u>	<u>A074694</u>	<u>001</u>	Dec 31, 1996
<u>AB</u>		<u>50MG</u>	<u>A074694</u>	<u>002</u>	Dec 31, 1996
<u>AB</u>		<u>75MG</u>	<u>A074694</u>	<u>003</u>	Dec 31, 1996
<u>AB</u>	TULEX PHARMS INC	<u>25MG</u>	<u>A210653</u>	<u>001</u>	Apr 03, 2020
<u>AB</u>		<u>50MG</u>	<u>A210653</u>	<u>002</u>	Apr 03, 2020
<u>AB</u>		<u>75MG</u>	<u>A210653</u>	<u>003</u>	Apr 03, 2020
<u>AB</u>	UNIQUE PHARM LABS	<u>25MG</u>	<u>A212285</u>	<u>001</u>	Aug 07, 2020
<u>AB</u>		<u>50MG</u>	<u>A212285</u>	<u>002</u>	Aug 07, 2020
<u>AB</u>		<u>75MG</u>	<u>A212285</u>	<u>003</u>	Aug 07, 2020
<u>AB</u>	ZYDUS PHARMS	<u>25MG</u>	<u>A208961</u>	<u>001</u>	Dec 27, 2017
<u>AB</u>		<u>50MG</u>	<u>A208961</u>	<u>002</u>	Dec 27, 2017
<u>AB</u>		<u>75MG</u>	<u>A208961</u>	<u>003</u>	Dec 27, 2017

CLONAZEPAM

TABLET;ORAL

CLONAZEPAM

<u>AB</u>	ACCORD HLTHCARE	<u>0.5MG</u>	<u>A077147</u>	<u>001</u>	May 02, 2005
<u>AB</u>		<u>1MG</u>	<u>A077147</u>	<u>002</u>	May 02, 2005
<u>AB</u>		<u>2MG</u>	<u>A077147</u>	<u>003</u>	May 02, 2005
<u>AB</u>	ACTAVIS ELIZABETH	<u>0.5MG</u>	<u>A074869</u>	<u>001</u>	Oct 31, 1996
<u>AB</u>		<u>1MG</u>	<u>A074869</u>	<u>002</u>	Oct 31, 1996
<u>AB</u>		<u>2MG</u>	<u>A074869</u>	<u>003</u>	Oct 31, 1996
<u>AB</u>	PRINSTON INC	<u>0.5MG</u>	<u>A077856</u>	<u>001</u>	Jun 28, 2006
<u>AB</u>		<u>1MG</u>	<u>A077856</u>	<u>002</u>	Jun 28, 2006
<u>AB</u>		<u>2MG</u>	<u>A077856</u>	<u>003</u>	Jun 28, 2006
<u>AB</u>	SANDOZ	<u>0.5MG</u>	<u>A074979</u>	<u>001</u>	Aug 29, 1997
<u>AB</u>		<u>1MG</u>	<u>A074979</u>	<u>002</u>	Aug 29, 1997
<u>AB</u>		<u>2MG</u>	<u>A074979</u>	<u>003</u>	Aug 29, 1997
<u>AB</u>	TEVA	<u>0.5MG</u>	<u>A074569</u>	<u>001</u>	Sep 10, 1996
<u>AB</u>		<u>1MG</u>	<u>A074569</u>	<u>002</u>	Sep 10, 1996
<u>AB</u>		<u>2MG</u>	<u>A074569</u>	<u>003</u>	Sep 10, 1996
<u>AB</u>	WATSON LABS	<u>0.5MG</u>	<u>A074964</u>	<u>001</u>	Dec 30, 1997
<u>AB</u>		<u>1MG</u>	<u>A074964</u>	<u>002</u>	Dec 30, 1997
<u>AB</u>		<u>2MG</u>	<u>A074964</u>	<u>003</u>	Dec 30, 1997

KLONOPIN

<u>AB</u>	+ ROCHE	<u>0.5MG</u>	<u>N017533</u>	<u>001</u>	
<u>AB</u>	+!	<u>1MG</u>	<u>N017533</u>	<u>002</u>	
<u>AB</u>	+	<u>2MG</u>	<u>N017533</u>	<u>003</u>	

TABLET, ORALLY DISINTEGRATING;ORAL

CLONAZEPAM

<u>AB</u>	ALEMBIC PHARMS LTD	<u>0.125MG</u>	<u>A211033</u>	<u>001</u>	Jun 28, 2019
<u>AB</u>		<u>0.25MG</u>	<u>A211033</u>	<u>002</u>	Jun 28, 2019
<u>AB</u>		<u>0.5MG</u>	<u>A211033</u>	<u>003</u>	Jun 28, 2019

PRESCRIPTION DRUG PRODUCT LIST

CLONAZEPAM

TABLET, ORALLY DISINTEGRATING;ORAL

CLONAZEPAM

<u>AB</u>		<u>1MG</u>	<u>A211033 004</u>	Jun 28, 2019
<u>AB</u>		<u>2MG</u>	<u>A211033 005</u>	Jun 28, 2019
<u>AB</u>	BARR	<u>0.125MG</u>	<u>A077194 001</u>	Aug 10, 2005
<u>AB</u>		<u>0.25MG</u>	<u>A077194 002</u>	Aug 10, 2005
<u>AB</u>		<u>0.5MG</u>	<u>A077194 003</u>	Aug 10, 2005
<u>AB</u>		<u>1MG</u>	<u>A077194 004</u>	Aug 10, 2005
<u>AB</u>		<u>2MG</u>	<u>A077194 005</u>	Aug 10, 2005
<u>AB</u>	PAR PHARM	<u>0.125MG</u>	<u>A077171 001</u>	Aug 03, 2005
<u>AB</u>		<u>0.25MG</u>	<u>A077171 002</u>	Aug 03, 2005
<u>AB</u>		<u>0.5MG</u>	<u>A077171 003</u>	Aug 03, 2005
<u>AB</u>	!	<u>1MG</u>	<u>A077171 004</u>	Aug 03, 2005
<u>AB</u>		<u>2MG</u>	<u>A077171 005</u>	Aug 03, 2005
<u>AB</u>	SUN PHARM INDS INC	<u>0.125MG</u>	<u>A078654 001</u>	Aug 27, 2014
<u>AB</u>		<u>0.25MG</u>	<u>A078654 002</u>	Aug 27, 2014
<u>AB</u>		<u>0.5MG</u>	<u>A078654 003</u>	Aug 27, 2014
<u>AB</u>		<u>1MG</u>	<u>A078654 004</u>	Aug 27, 2014
<u>AB</u>		<u>2MG</u>	<u>A078654 005</u>	Aug 27, 2014

CLONIDINE

SYSTEM; TRANSDERMAL

CATAPRES-TTS-1

<u>AB</u>	+	BOEHRINGER INGELHEIM	<u>0.1MG/24HR</u>	<u>N018891 001</u>	Oct 10, 1984
-----------	---	-------------------------	-------------------	--------------------	--------------

CATAPRES-TTS-2

<u>AB</u>	+	BOEHRINGER INGELHEIM	<u>0.2MG/24HR</u>	<u>N018891 002</u>	Oct 10, 1984
-----------	---	-------------------------	-------------------	--------------------	--------------

CATAPRES-TTS-3

<u>AB</u>	+	BOEHRINGER INGELHEIM	<u>0.3MG/24HR</u>	<u>N018891 003</u>	Oct 10, 1984
-----------	---	-------------------------	-------------------	--------------------	--------------

CLONIDINE

<u>AB</u>		ACTAVIS LABS UT INC	<u>0.1MG/24HR</u>	<u>A090873 001</u>	May 06, 2014
<u>AB</u>			<u>0.2MG/24HR</u>	<u>A090873 002</u>	May 06, 2014
<u>AB</u>			<u>0.3MG/24HR</u>	<u>A090873 003</u>	May 06, 2014
<u>AB</u>		AVEVA	<u>0.1MG/24HR</u>	<u>A076157 001</u>	Aug 18, 2009
<u>AB</u>			<u>0.2MG/24HR</u>	<u>A076157 002</u>	Aug 18, 2009
<u>AB</u>			<u>0.3MG/24HR</u>	<u>A076157 003</u>	Aug 18, 2009
<u>AB</u>		MAYNE PHARMA	<u>0.1MG/24HR</u>	<u>A079090 001</u>	Aug 20, 2010
<u>AB</u>			<u>0.2MG/24HR</u>	<u>A079090 002</u>	Aug 20, 2010
<u>AB</u>			<u>0.3MG/24HR</u>	<u>A079090 003</u>	Aug 20, 2010
<u>AB</u>		MYLAN TECHNOLOGIES	<u>0.1MG/24HR</u>	<u>A076166 001</u>	Jul 16, 2010
<u>AB</u>			<u>0.2MG/24HR</u>	<u>A076166 002</u>	Jul 16, 2010
<u>AB</u>			<u>0.3MG/24HR</u>	<u>A076166 003</u>	Jul 16, 2010

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CLONIDINE HYDROCHLORIDE

<u>AP</u>		FRESENIUS KABI USA	<u>1MG/10ML (0.1MG/ML)</u>	<u>A200673 001</u>	Jul 08, 2011
<u>AP</u>			<u>5MG/10ML (0.5MG/ML)</u>	<u>A200673 002</u>	Jul 08, 2011
<u>AP</u>		HIKMA FARMACEUTICA	<u>1MG/10ML (0.1MG/ML)</u>	<u>A200300 001</u>	Jan 26, 2011
<u>AP</u>			<u>5MG/10ML (0.5MG/ML)</u>	<u>A200300 002</u>	Jan 26, 2011
<u>AP</u>		XGEN PHARMS	<u>1MG/10ML (0.1MG/ML)</u>	<u>A203167 001</u>	Oct 29, 2013
<u>AP</u>			<u>5MG/10ML (0.5MG/ML)</u>	<u>A203167 002</u>	Oct 29, 2013
<u>AP</u>		ZYDUS PHARMS	<u>1MG/10ML (0.1MG/ML)</u>	<u>A202601 001</u>	Feb 20, 2014
<u>AP</u>			<u>5MG/10ML (0.5MG/ML)</u>	<u>A202601 002</u>	Feb 20, 2014

DURACLON

<u>AP</u>	+	MYLAN INSTITUTIONAL	<u>1MG/10ML (0.1MG/ML)</u>	<u>N020615 001</u>	Oct 02, 1996
<u>AP</u>	+		<u>5MG/10ML (0.5MG/ML)</u>	<u>N020615 002</u>	Apr 27, 1999

TABLET; ORAL

CATAPRES

<u>AB</u>	+	BOEHRINGER INGELHEIM	<u>0.1MG</u>	<u>N017407 001</u>	
<u>AB</u>	+		<u>0.2MG</u>	<u>N017407 002</u>	
<u>AB</u>	+		<u>0.3MG</u>	<u>N017407 003</u>	

CLONIDINE HYDROCHLORIDE

<u>AB</u>		ACTAVIS ELIZABETH	<u>0.1MG</u>	<u>A070974 001</u>	Dec 16, 1986
<u>AB</u>			<u>0.2MG</u>	<u>A070975 001</u>	Dec 16, 1986
<u>AB</u>			<u>0.3MG</u>	<u>A070976 001</u>	Dec 16, 1986
<u>AB</u>		ALEMBIC PHARMS LTD	<u>0.1MG</u>	<u>A091368 001</u>	Dec 06, 2011
<u>AB</u>			<u>0.2MG</u>	<u>A091368 002</u>	Dec 06, 2011
<u>AB</u>			<u>0.3MG</u>	<u>A091368 003</u>	Dec 06, 2011
<u>AB</u>		FRONTIDA BIOPHARM	<u>0.1MG</u>	<u>A070923 003</u>	Sep 04, 1987

PRESCRIPTION DRUG PRODUCT LIST

CLONIDINE HYDROCHLORIDE

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

<u>AB</u>		<u>0.2MG</u>	<u>A070923 002</u>	Sep 04, 1987
<u>AB</u>		<u>0.3MG</u>	<u>A070923 001</u>	Sep 04, 1987
<u>AB</u>	IMPAX LABS	<u>0.1MG</u>	<u>A078099 001</u>	Aug 27, 2009
<u>AB</u>		<u>0.2MG</u>	<u>A078099 002</u>	Aug 27, 2009
<u>AB</u>		<u>0.3MG</u>	<u>A078099 003</u>	Aug 27, 2009
<u>AB</u>	PRINSTON INC	<u>0.1MG</u>	<u>A077901 001</u>	Mar 09, 2007
<u>AB</u>		<u>0.2MG</u>	<u>A077901 002</u>	Mar 09, 2007
<u>AB</u>		<u>0.3MG</u>	<u>A077901 003</u>	Mar 09, 2007
<u>AB</u>	UNICHEM	<u>0.1MG</u>	<u>A078895 001</u>	Aug 26, 2009
<u>AB</u>		<u>0.2MG</u>	<u>A078895 002</u>	Aug 26, 2009
<u>AB</u>		<u>0.3MG</u>	<u>A078895 003</u>	Aug 26, 2009
<u>AB</u>	YUNG SHIN PHARM	<u>0.1MG</u>	<u>A202297 001</u>	Jun 13, 2013
<u>AB</u>		<u>0.2MG</u>	<u>A202297 002</u>	Jun 13, 2013
<u>AB</u>		<u>0.3MG</u>	<u>A202297 003</u>	Jun 13, 2013

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

<u>AB1</u>	ACTAVIS ELIZABETH	<u>0.1MG</u>	<u>A203320 001</u>	May 15, 2015
<u>AB1</u>	AJANTA PHARMA LTD	<u>0.1MG</u>	<u>A209686 001</u>	Nov 20, 2017
<u>AB1</u>	AMNEAL PHARMS NY	<u>0.1MG</u>	<u>A210052 001</u>	Nov 20, 2017
<u>AB1</u>	ANCHEN PHARMS	<u>0.1MG</u>	<u>A202984 001</u>	Sep 30, 2013
<u>AB1</u>	JUBILANT GENERICS	<u>0.1MG</u>	<u>A210338 001</u>	Jan 29, 2018
<u>AB1</u>	LUPIN LTD	<u>0.1MG</u>	<u>A209285 001</u>	Oct 23, 2017
<u>AB1</u>	MAYNE PHARMA INC	<u>0.1MG</u>	<u>A210680 001</u>	Apr 30, 2018
<u>AB1</u>	NOVAST LABS	<u>0.1MG</u>	<u>A209675 001</u>	Mar 05, 2019
<u>AB1</u>	UPSHER SMITH LABS	<u>0.1MG</u>	<u>A211433 001</u>	Oct 12, 2018
<u>AB1</u>	XIAMEN LP PHARM CO	<u>0.1MG</u>	<u>A209757 001</u>	Nov 20, 2017

KAPVAY

<u>AB1</u>	+!	CONCORDIA PHARMS	<u>0.1MG</u>	<u>N022331 003</u>	Sep 28, 2010
------------	----	------------------	--------------	--------------------	--------------

CLONIDINE HYDROCHLORIDE

<u>AB2</u>		ACTAVIS ELIZABETH	<u>0.1MG</u>	<u>A202792 001</u>	May 15, 2015
------------	--	-------------------	--------------	--------------------	--------------

CLOPIDOGREL BISULFATE

TABLET;ORAL

CLOPIDOGREL BISULFATE

<u>AB</u>		ACCORD HLTHCARE	<u>EQ 75MG BASE</u>	<u>A202925 001</u>	Mar 27, 2013
<u>AB</u>			<u>EQ 300MG BASE</u>	<u>A202925 002</u>	Mar 27, 2013
<u>AB</u>		ACME LABS	<u>EQ 75MG BASE</u>	<u>A078004 001</u>	May 17, 2012
<u>AB</u>		ADAPTIS	<u>EQ 75MG BASE</u>	<u>A204359 001</u>	Feb 02, 2017
<u>AB</u>		AMNEAL PHARMS	<u>EQ 75MG BASE</u>	<u>A203751 001</u>	Apr 11, 2014
<u>AB</u>		APOTEX INC	<u>EQ 75MG BASE</u>	<u>A076274 001</u>	May 17, 2012
<u>AB</u>	!		<u>EQ 300MG BASE</u>	<u>A076274 002</u>	Mar 04, 2014
<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 75MG BASE</u>	<u>A090540 001</u>	May 17, 2012
<u>AB</u>		DR REDDYS LABS INC	<u>EQ 75MG BASE</u>	<u>A076273 001</u>	Jan 14, 2008
<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 300MG BASE</u>	<u>A091023 001</u>	May 17, 2012
<u>AB</u>		MACLEODS PHARMS LTD	<u>EQ 75MG BASE</u>	<u>A202928 001</u>	Feb 10, 2014
<u>AB</u>		PRINSTON INC	<u>EQ 75MG BASE</u>	<u>A206376 001</u>	May 07, 2018
<u>AB</u>			<u>EQ 300MG BASE</u>	<u>A206376 002</u>	May 07, 2018
<u>AB</u>		SCIEGEN PHARMS INC	<u>EQ 75MG BASE</u>	<u>A204165 001</u>	Sep 15, 2014
<u>AB</u>			<u>EQ 300MG BASE</u>	<u>A204165 002</u>	Sep 15, 2014
<u>AB</u>		SUN PHARM	<u>EQ 75MG BASE</u>	<u>A090494 001</u>	May 17, 2012
<u>AB</u>		TEVA	<u>EQ 75MG BASE</u>	<u>A076999 001</u>	May 17, 2012
<u>AB</u>		TORRENT PHARMS LTD	<u>EQ 75MG BASE</u>	<u>A090844 001</u>	May 17, 2012
		<u>PLAVIX</u>			
<u>AB</u>	+	SANOFI AVENTIS US	<u>EQ 75MG BASE</u>	<u>N020839 001</u>	Nov 17, 1997
<u>AB</u>	+		<u>EQ 300MG BASE</u>	<u>N020839 002</u>	Sep 20, 2007

CLORAZEPATE DIPOTASSIUM

TABLET;ORAL

CLORAZEPATE DIPOTASSIUM

<u>AB</u>		MYLAN	<u>3.75MG</u>	<u>A071858 002</u>	Jul 17, 1987
<u>AB</u>			<u>7.5MG</u>	<u>A071858 003</u>	Jul 17, 1987
<u>AB</u>	!		<u>15MG</u>	<u>A071858 001</u>	Jul 17, 1987
<u>AB</u>		TARO	<u>3.75MG</u>	<u>A075731 003</u>	Apr 27, 2000
<u>AB</u>			<u>7.5MG</u>	<u>A075731 002</u>	Apr 27, 2000
<u>AB</u>			<u>15MG</u>	<u>A075731 001</u>	Apr 27, 2000
		<u>GEN-XENE</u>			
<u>AB</u>		ALRA	<u>3.75MG</u>	<u>A071787 001</u>	Apr 26, 1988
<u>AB</u>			<u>7.5MG</u>	<u>A071788 001</u>	Apr 26, 1988
<u>AB</u>			<u>15MG</u>	<u>A071789 001</u>	Apr 26, 1988

PRESCRIPTION DRUG PRODUCT LIST

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL

TRANXENE

AB	+	RECORDATI RARE	7.5MG	N017105	007	
-----------	---	----------------	--------------	----------------	------------	--

CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE

AB		FOUGERA PHARMS	1%	A078338	001	Sep 02, 2008
AB		GLENMARK PHARMS	1%	A090219	001	Aug 03, 2010
AB	!	TARO	1%	A072640	001	Aug 31, 1993

SOLUTION; TOPICAL

CLOTRIMAZOLE

AT		NOVITIUM PHARMA	1%	A209815	001	Feb 14, 2019
AT	!	TARO	1%	A074580	001	Jul 29, 1996
AT		TASMAN PHARMA	1%	A212281	001	Jul 25, 2019
AT		TEVA	1%	A073306	001	Feb 28, 1995

TROCHE/LOZENGE; ORAL

CLOTRIMAZOLE

AB	!	HIKMA	10MG	A076387	001	Jul 29, 2004
AB		PADDOCK LLC	10MG	A076763	001	Oct 28, 2005

CLOZAPINE

SUSPENSION; ORAL

VERSACLOZ

+	!	TASMAN PHARMA	50MG/ML	N203479	001	Feb 06, 2013
---	---	---------------	---------	---------	-----	--------------

TABLET; ORAL

CLOZAPINE

AB		ACCORD HLTHCARE	25MG	A202873	001	Nov 25, 2015
AB			100MG	A202873	002	Nov 25, 2015
AB		AUROBINDO PHARMA LTD	25MG	A206433	001	Nov 29, 2016
AB			50MG	A206433	002	Nov 29, 2016
AB			100MG	A206433	003	Nov 29, 2016
AB			200MG	A206433	004	Nov 29, 2016
AB		IVAX SUB TEVA PHARMS	25MG	A074949	001	Nov 26, 1997
AB			50MG	A074949	004	Apr 25, 2005
AB			50MG	A076809	003	Dec 16, 2005
AB			100MG	A074949	002	Nov 26, 1997
AB			100MG	A076809	002	Dec 16, 2005
AB			200MG	A076809	001	Dec 16, 2005
AB		MAYNE PHARMA	25MG	A203807	001	Sep 17, 2015
AB			50MG	A203807	003	Aug 22, 2017
AB			100MG	A203807	002	Sep 17, 2015
AB			200MG	A203807	004	Aug 22, 2017
AB		MYLAN	25MG	A075417	001	May 27, 1999
AB			50MG	A075417	004	Apr 15, 2010
AB			100MG	A075417	002	May 27, 1999
AB			200MG	A075417	005	Apr 15, 2010
AB		SUN PHARM INDS INC	25MG	A075713	001	Nov 15, 2002
AB			50MG	A075713	003	Aug 19, 2005
AB			100MG	A075713	002	Nov 15, 2002
AB			200MG	A075713	004	Nov 07, 2017

CLOZARIL

AB	+	HERITAGE LIFE	25MG	N019758	001	Sep 26, 1989
AB	+		50MG	N019758	003	May 20, 2019
AB	+	!	100MG	N019758	002	Sep 26, 1989
AB	+		200MG	N019758	004	May 20, 2019

CLOZAPINE

		IVAX SUB TEVA PHARMS	12.5MG	A074949	003	Jul 31, 2003
--	--	----------------------	--------	---------	-----	--------------

TABLET, ORALLY DISINTEGRATING; ORAL

CLOZAPINE

AB		BARR LABS INC	25MG	A090308	001	Nov 25, 2015
AB	!		100MG	A090308	002	Nov 25, 2015
AB		MYLAN	25MG	A201824	002	Sep 15, 2015
AB			100MG	A201824	003	Sep 15, 2015
		BARR LABS INC	12.5MG	A090308	003	Apr 09, 2018
		TEVA PHARMS USA	150MG	A203039	001	Nov 25, 2015
			200MG	A203039	002	Nov 25, 2015

PRESCRIPTION DRUG PRODUCT LIST

COBICISTAT

TABLET;ORAL

TYBOST

+! GILEAD SCIENCES INC 150MG N203094 001 Sep 24, 2014

COBICISTAT; DARUNAVIR

TABLET;ORAL

PREZCOBIX

+! JANSSEN PRODS 150MG;800MG N205395 001 Jan 29, 2015

COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL

SYMITUZA

+! JANSSEN PRODS 150MG;800MG;200MG;EQ 10MG BASE N210455 001 Jul 17, 2018

COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL

GENVOYA

+! GILEAD SCIENCES INC 150MG;150MG;200MG;EQ 10MG BASE N207561 001 Nov 05, 2015

COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

STRIBILD

+! GILEAD SCIENCES INC 150MG;150MG;200MG;300MG N203100 001 Aug 27, 2012

COBIMETINIB FUMARATE

TABLET;ORAL

COTELLIC

+! GENENTECH INC EQ 20MG BASE N206192 001 Nov 10, 2015

COCAINE HYDROCHLORIDE

SOLUTION;NASAL

GOPRELTO

+! GENUS LIFESCIENCES 4% N209963 001 Dec 14, 2017

NUMBRINO

+! CODY LABS INC 4% N209575 001 Jan 10, 2020

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETH HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE**AA** PHARM ASSOC 10MG/5ML; 5MG/5ML; 6.25MG/5ML **A040660 001** Dec 07, 2006PROMETH VC W/ CODEINE**AA** ! NOSTRUM LABS INC 10MG/5ML; 5MG/5ML; 6.25MG/5ML **A088764 001** Oct 31, 1984PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE**AA** HI-TECH PHARMA CO 10MG/5ML; 5MG/5ML; 6.25MG/5ML **A040674 001** Dec 23, 2014PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE**AA** AMNEAL PHARMS 10MG/5ML; 5MG/5ML; 6.25MG/5ML **A200963 001** Aug 26, 2015CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE**AA** ! ACTAVIS MID 10MG/5ML; 6.25MG/5ML **A088763 001** Oct 31, 1984

ATLANTIC

AA AKORN 10MG/5ML; 6.25MG/5ML **A040151 001** Aug 26, 1997**AA** AMNEAL PHARMS 10MG/5ML; 6.25MG/5ML **A200894 001** Apr 24, 2013**AA** NOSTRUM LABS INC 10MG/5ML; 6.25MG/5ML **A090180 001** Mar 17, 2010**AA** QUAGEN 10MG/5ML; 6.25MG/5ML **A214238 001** Oct 08, 2020**AA** TRIS PHARMA INC 10MG/5ML; 6.25MG/5ML **A200386 001** Jun 29, 2012**AA** WOCKHARDT BIO AG 10MG/5ML; 6.25MG/5ML **A088875 001** Dec 17, 1984PROMETHAZINE WITH CODEINE**AA** PHARM ASSOC 10MG/5ML; 6.25MG/5ML **A040650 001** Jan 31, 2006CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP;ORAL

TRIACIN-C

! STI PHARMA LLC 10MG/5ML; 30MG/5ML; 1.25MG/5ML A088704 001 Mar 22, 1985

CODEINE SULFATE

TABLET;ORAL

CODEINE SULFATE**AB** + HIKMA 15MG **N022402 001** Jul 16, 2009**AB** + 30MG **N022402 002** Jul 16, 2009**AB** +! 60MG **N022402 003** Jul 16, 2009**AB** LANNETT CO INC 15MG **A203046 001** Jun 13, 2014**AB** 30MG **A203046 002** Jun 13, 2014**AB** 60MG **A203046 003** Jun 13, 2014

PRESCRIPTION DRUG PRODUCT LIST

COLCHICINE

CAPSULE; ORAL

MITIGARE

+! HIKMA INTL PHARMS 0.6MG N204820 001 Sep 26, 2014

SOLUTION; ORAL

GLOPERBA

+! AVION PHARMS 0.6MG/5ML N210942 001 Jan 30, 2019

TABLET; ORAL

COLCHICINE

AB	ALKEM LABS LTD	<u>0.6MG</u>	<u>A211250 001</u>	Feb 08, 2019
AB	AMNEAL PHARMS	<u>0.6MG</u>	<u>A204711 001</u>	Sep 28, 2016
AB	DR REDDYS	<u>0.6MG</u>	<u>A209876 001</u>	Sep 06, 2019
AB	GRANULES PHARMS	<u>0.6MG</u>	<u>A210425 001</u>	Feb 05, 2020
AB	MYLAN	<u>0.6MG</u>	<u>A209470 001</u>	Sep 16, 2019
AB	WATSON LABS INC	<u>0.6MG</u>	<u>A204461 001</u>	Jul 31, 2019
AB	ZYDUS PHARMS	<u>0.6MG</u>	<u>A211519 001</u>	Feb 19, 2019

COLCRYS

AB	+! TAKEDA PHARMS USA	<u>0.6MG</u>	<u>N022352 001</u>	Jul 29, 2009
	COLCHICINE			
	ZYDUS PHARMS	0.3MG	A211519 002	Nov 14, 2019

COLCHICINE; PROBENECID

TABLET; ORAL

COL-PROBENECID

AB	! WATSON LABS	<u>0.5MG; 500MG</u>	<u>A084279 001</u>	
	<u>PROBENECID AND COLCHICINE</u>			
AB	NOVAST LABS	<u>0.5MG; 500MG</u>	<u>A040618 001</u>	May 13, 2008

COLESEVELAM HYDROCHLORIDE

FOR SUSPENSION; ORAL

COLESEVELAM HYDROCHLORIDE

AB	ALKEM LABS LTD	<u>3.75GM/PACKET</u>	<u>A210316 001</u>	May 06, 2019
AB	GLENMARK PHARMS LTD	<u>1.875GM/PACKET</u>	<u>A202190 001</u>	Jul 16, 2018
AB		<u>3.75GM/PACKET</u>	<u>A202190 002</u>	Jul 16, 2018
AB	WATSON LABS INC	<u>1.875GM/PACKET</u>	<u>A202178 001</u>	Sep 01, 2020
AB		<u>3.75GM/PACKET</u>	<u>A202178 002</u>	Sep 01, 2020

WELCHOL

AB	+! DAIICHI SANKYO	<u>3.75GM/PACKET</u>	<u>N022362 002</u>	Oct 02, 2009
-----------	-------------------	----------------------	--------------------	--------------

TABLET; ORAL

COLESEVELAM HYDROCHLORIDE

AB	ALKEM LABS LTD	<u>625MG</u>	<u>A209038 001</u>	Oct 05, 2018
AB	BIONPHARMA INC	<u>625MG</u>	<u>A208670 001</u>	Sep 13, 2019
AB	DR REDDYS	<u>625MG</u>	<u>A210889 001</u>	Oct 05, 2018
AB	GLENMARK PHARMS LTD	<u>625MG</u>	<u>A203480 001</u>	May 18, 2018
AB	IMPAX LABS INC	<u>625MG</u>	<u>A091600 001</u>	May 16, 2018
AB	INVENTIA	<u>625MG</u>	<u>A212050 001</u>	Dec 04, 2020
AB	LUPIN LTD	<u>625MG</u>	<u>A201354 001</u>	Dec 17, 2020
AB	WATSON LABS INC	<u>625MG</u>	<u>A200830 001</u>	Sep 02, 2020
AB	ZHEJIANG JINGXIN	<u>625MG</u>	<u>A209946 001</u>	Jul 15, 2020
AB	ZYDUS PHARMS	<u>625MG</u>	<u>A207765 001</u>	Oct 07, 2019

WELCHOL

AB	+! DAIICHI SANKYO	<u>625MG</u>	<u>N021176 001</u>	May 26, 2000
-----------	-------------------	--------------	--------------------	--------------

COLESTIPOL HYDROCHLORIDE

GRANULE; ORAL

COLESTID

AB	+ PHARMACIA UPJOHN	<u>5GM/SCOOPFUL</u>	<u>N017563 003</u>	Sep 22, 1995
AB	+!	<u>5GM/PACKET</u>	<u>N017563 004</u>	Sep 22, 1995

COLESTIPOL HYDROCHLORIDE

AB	IMPAX LABS	<u>5GM/SCOOPFUL</u>	<u>A077277 001</u>	May 02, 2006
AB		<u>5GM/PACKET</u>	<u>A077277 002</u>	May 02, 2006

FLAVORED COLESTID

+ PHARMACIA UPJOHN 5GM/PACKET N017563 001

+ 5GM/SCOOPFUL N017563 002

TABLET; ORAL

COLESTID

AB	+! PHARMACIA UPJOHN	<u>1GM</u>	<u>N020222 001</u>	Jul 19, 1994
-----------	---------------------	------------	--------------------	--------------

COLESTIPOL HYDROCHLORIDE

AB	IMPAX LABS	<u>1GM</u>	<u>A077510 001</u>	Oct 24, 2006
-----------	------------	------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

COLISTIMETHATE SODIUM

AP	FRESENIUS KABI USA	<u>EQ 150MG BASE/VIAL</u>	<u>A065364 001</u>	Apr 17, 2008
AP	NEXUS PHARMS	<u>EQ 150MG BASE/VIAL</u>	<u>A065177 001</u>	Mar 19, 2004
AP	SAGENT PHARMS INC	<u>EQ 150MG BASE/VIAL</u>	<u>A201365 001</u>	Feb 19, 2014
AP	XELLIA PHARMS APS	<u>EQ 150MG BASE/VIAL</u>	<u>A205356 001</u>	May 29, 2015
AP	XGEN PHARMS	<u>EQ 150MG BASE/VIAL</u>	<u>A064216 001</u>	Feb 26, 1999

COLY-MYCIN M

AP	+ ! PAR STERILE PRODUCTS	<u>EQ 150MG BASE/VIAL</u>	<u>N050108 002</u>	
-----------	---------------------------------	----------------------------------	---------------------------	--

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

SUSPENSION/DROPS; OTIC

COLY-MYCIN S

+ !	ENDO PHARMS INC	EQ 3MG BASE/ML; 10MG/ML; EQ 3.3MG BASE/ML; 0.5MG/ML	N050356 001	
------------	-----------------	---	-------------	--

CONIVAPTAN HYDROCHLORIDE

INJECTABLE; INTRAVENOUS

VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

+ !	CUMBERLAND PHARMS	20MG/100ML (0.2MG/ML)	N021697 002	Oct 08, 2008
------------	-------------------	-----------------------	-------------	--------------

COPANLISIB DIHYDROCHLORIDE

POWDER; INTRAVENOUS

ALIQOPA

+ !	BAYER HEALTHCARE	60MG/VIAL	N209936 001	Sep 14, 2017
------------	------------------	-----------	-------------	--------------

COPPER

INTRAUTERINE DEVICE; INTRAUTERINE

PARAGARD T 380A

+ !	COOPERSURGICAL	309MG/COPPER	N018680 001	Nov 15, 1984
------------	----------------	--------------	-------------	--------------

COPPER DOTATATE CU-64

SOLUTION; INTRAVENOUS

DETECTNET

+ !	RADIOMEDIX	4mL (1mCi/ML)	N213227 001	Sep 03, 2020
------------	------------	---------------	-------------	--------------

CORTICOTROPIN

INJECTABLE; INJECTION

H.P. ACTHAR GEL

+ !	MALLINCKRODT ARD	80 UNITS/ML	N008372 008	
------------	------------------	-------------	-------------	--

CORTISONE ACETATE

TABLET; ORAL

CORTISONE ACETATE

!	HIKMA INTL PHARMS	25MG	A080776 002	
----------	-------------------	------	-------------	--

COSYNTROPIN

INJECTABLE; INJECTION

CORTROSYN

AP	+ ! AMPHASTAR PHARMS INC	<u>0.25MG/VIAL</u>	<u>N016750 001</u>	
-----------	---------------------------------	---------------------------	---------------------------	--

COSYNTROPIN

AP	MYLAN INSTITUTIONAL	<u>0.25MG/VIAL</u>	<u>A090574 001</u>	Dec 17, 2009
AP	SANDOZ	<u>0.25MG/VIAL</u>	<u>A202147 001</u>	Jun 29, 2012

CRISABOROLE

OINTMENT; TOPICAL

EUCRISA

+ !	ANACOR PHARMS INC	2%	N207695 001	Dec 14, 2016
------------	-------------------	----	-------------	--------------

CRIZOTINIB

CAPSULE; ORAL

XALKORI

+	PF PRISM CV	200MG	N202570 001	Aug 26, 2011
+ !		250MG	N202570 002	Aug 26, 2011

CROFLEMER

TABLET, DELAYED RELEASE; ORAL

MYTESI

+ !	NAPO PHARMS INC	125MG	N202292 001	Dec 31, 2012
------------	-----------------	-------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

CROMOLYN SODIUM

CONCENTRATE; ORAL

CROMOLYN SODIUM

AA	AILEX PHARMS LLC	100MG/5ML	A209264 001	Oct 16, 2017
AA	MICRO LABS LTD INDIA	100MG/5ML	A202745 001	Apr 04, 2013
AA	RISING	100MG/5ML	A202583 001	Oct 27, 2011

GASTROCROM

AA	+! MYLAN SPECIALITY LP	100MG/5ML	N020479 001	Feb 29, 1996
-----------	------------------------	------------------	--------------------	--------------

SOLUTION; INHALATION

CROMOLYN SODIUM

AN	AILEX PHARMS LLC	10MG/ML	A209453 001	Oct 16, 2017
AN	! TEVA PHARMS	10MG/ML	A075271 001	Jan 18, 2000
AN	WOCKHARDT BIO AG	10MG/ML	A075346 001	Oct 25, 1999

SOLUTION/DROPS; OPHTHALMIC

CROMOLYN SODIUM

AT	! AKORN	4%	A074706 001	Apr 29, 1998
AT	SANDOZ INC	4%	A075282 001	Jun 16, 1999

CROTAMITON

LOTION; TOPICAL

CROTAN

AT	MARNEL PHARMS	10%	A087204 001	
AT	+! SUN PHARM INDS INC	10%	N009112 003	

EURAXCUPRIC CHLORIDE

INJECTABLE; INJECTION

CUPRIC CHLORIDE IN PLASTIC CONTAINER

+!	HOSPIRA	EQ 0.4MG COPPER/ML	N018960 001	Jun 26, 1986
----	---------	--------------------	-------------	--------------

CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE

SOLUTION; INTRAVENOUS

TRALEMENT

+!	AM REGENT	EQ 0.3MG COPPER/ML; EQ 55MCG BASE/ML; EQ 60MCG BASE/ML; EQ 3MG BASE/ML	N209376 001	Jul 02, 2020
----	-----------	--	-------------	--------------

CYANOCOBALAMIN

INJECTABLE; INJECTION

CYANOCOBALAMIN

AP	+! AM REGENT	1MG/ML	A080737 001	
AP	AUROBINDO PHARMA LTD	1MG/ML	A213874 001	Dec 08, 2020
AP	GLAND PHARMA LTD	1MG/ML	A214390 001	Sep 24, 2020
AP	MYLAN LABS LTD	1MG/ML	A204829 001	Jun 05, 2017
AP	SANDOZ INC	1MG/ML	A212915 001	Jan 04, 2021
AP	SOMERSET THERAPS LLC	1MG/ML	A206503 001	Dec 11, 2015
AP		1MG/ML	A209429 001	Dec 18, 2018
AP	VITRUVIAS THERAP	1MG/ML	A209255 001	Dec 18, 2018
AP	WEST-WARD PHARMS INT	1MG/ML	A080515 002	

VIBISONNE

AP	! FRESENIUS KABI USA	1MG/ML	A080557 003	
-----------	----------------------	---------------	--------------------	--

SPRAY, METERED; NASAL
NASCOBAL

+!	ENDO PHARMS INC	0.5MG/SPRAY	N021642 001	Jan 31, 2005
----	-----------------	-------------	-------------	--------------

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

AMRIX

AB	+ TEVA PHARMS INTL	15MG	N021777 001	Feb 01, 2007
AB	+!	30MG	N021777 002	Feb 01, 2007

CYCLOBENZAPRINE HYDROCHLORIDE

AB	APOTEX	15MG	A206703 001	Jul 24, 2018
AB		30MG	A206703 002	Jul 24, 2018
AB	TWI PHARMS INC	15MG	A091281 001	Jan 31, 2013
AB		30MG	A091281 002	Jan 31, 2013

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB	ACTAVIS LABS FL INC	5MG	A071611 002	Feb 03, 2006
AB		7.5MG	A071611 003	Feb 03, 2006
AB		10MG	A071611 001	May 03, 1989
AB	ALEMBIC LABS	5MG	A078218 002	Jun 19, 2015
AB		7.5MG	A078218 003	Nov 03, 2020
AB		10MG	A078218 001	Apr 18, 2008

PRESCRIPTION DRUG PRODUCT LIST

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

<u>AB</u>	ANDA REPOSITORY	<u>5MG</u>	<u>A073541 002</u>	Apr 06, 2006
<u>AB</u>		<u>10MG</u>	<u>A073541 001</u>	May 23, 1995
<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A078643 001</u>	Sep 26, 2008
<u>AB</u>		<u>10MG</u>	<u>A078643 002</u>	Sep 26, 2008
<u>AB</u>	INVAGEN PHARMS	<u>5MG</u>	<u>A090478 001</u>	Jul 23, 2010
<u>AB</u>		<u>10MG</u>	<u>A090478 002</u>	Jul 23, 2010
<u>AB</u>	JUBILANT CADISTA	<u>5MG</u>	<u>A077563 001</u>	Apr 19, 2006
<u>AB</u>		<u>7.5MG</u>	<u>A077563 003</u>	Aug 25, 2017
<u>AB</u>		<u>10MG</u>	<u>A077563 002</u>	Apr 19, 2006
<u>AB</u>	KVK TECH	<u>5MG</u>	<u>A078048 001</u>	Feb 28, 2011
<u>AB</u>		<u>10MG</u>	<u>A078048 002</u>	Feb 28, 2011
<u>AB</u>	MYLAN PHARMS INC	<u>5MG</u>	<u>A073144 002</u>	Feb 03, 2006
<u>AB</u>		<u>7.5MG</u>	<u>A073144 003</u>	Mar 25, 2013
<u>AB</u>		<u>10MG</u>	<u>A073144 001</u>	May 30, 1991
<u>AB</u>	OXFORD PHARMS	<u>5MG</u>	<u>A077209 002</u>	Feb 03, 2006
<u>AB</u>		<u>10MG</u>	<u>A077209 001</u>	Oct 04, 2005
<u>AB</u>	PLIVA	<u>10MG</u>	<u>A074421 001</u>	Sep 29, 1995
<u>AB</u>	PRINSTON INC	<u>5MG</u>	<u>A077797 001</u>	Feb 28, 2007
<u>AB</u>		<u>10MG</u>	<u>A077797 002</u>	Feb 28, 2007
<u>AB</u>	RUBICON	<u>5MG</u>	<u>A208170 001</u>	May 31, 2017
<u>AB</u>		<u>7.5MG</u>	<u>A208170 002</u>	May 31, 2017
<u>AB</u>	!	<u>10MG</u>	<u>A208170 003</u>	May 31, 2017
<u>AB</u>	SUN PHARM INDS LTD	<u>5MG</u>	<u>A078722 001</u>	May 12, 2008
<u>AB</u>		<u>7.5MG</u>	<u>A078722 002</u>	May 12, 2008
<u>AB</u>		<u>10MG</u>	<u>A078722 003</u>	May 12, 2008
<u>AB</u>	UNICHEM	<u>5MG</u>	<u>A213324 001</u>	Jul 06, 2020
<u>AB</u>		<u>7.5MG</u>	<u>A213324 002</u>	Jul 06, 2020
<u>AB</u>		<u>10MG</u>	<u>A213324 003</u>	Jul 05, 2020

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AKPENTOLATE

<u>AT</u>	AKORN	<u>1%</u>	<u>A040164 001</u>	Jan 13, 1997
-----------	-------	-----------	--------------------	--------------

CYCLOGYL

<u>AT</u>	!	ALCON LABS INC	<u>0.5%</u>	<u>A084109 001</u>
<u>AT</u>	!		<u>1%</u>	<u>A084110 001</u>

CYCLOPENTOLATE HYDROCHLORIDE

<u>AT</u>	AKORN INC	<u>0.5%</u>	<u>A205937 001</u>	Dec 09, 2015
-----------	-----------	-------------	--------------------	--------------

PENTOLAIR

<u>AT</u>	BAUSCH AND LOMB	<u>1%</u>	<u>A040075 001</u>	Apr 29, 1994
-----------	-----------------	-----------	--------------------	--------------

CYCLOGYL

!	ALCON LABS INC	<u>2%</u>	A084108	001
---	----------------	-----------	---------	-----

CYCLOPENTOLATE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CYCLOMYDRIL

!	ALCON LABS INC	<u>0.2%;1%</u>	A084300	001
---	----------------	----------------	---------	-----

CYCLOPHOSPHAMIDE

CAPSULE; ORAL

CYCLOPHOSPHAMIDE

<u>AB</u>	ANI PHARMS INC	<u>25MG</u>	<u>A207014 001</u>	Mar 19, 2018	
<u>AB</u>		<u>50MG</u>	<u>A207014 002</u>	Mar 19, 2018	
<u>AB</u>	CIPLA	<u>25MG</u>	<u>A211608 001</u>	Jan 18, 2019	
<u>AB</u>		<u>50MG</u>	<u>A211608 002</u>	Jan 18, 2019	
<u>AB</u>	+	HIKMA	<u>25MG</u>	<u>N203856 001</u>	Sep 16, 2013
<u>AB</u>	+	!	<u>50MG</u>	<u>N203856 002</u>	Sep 16, 2013
<u>AB</u>	STI PHARMA LLC	<u>25MG</u>	<u>A209872 001</u>	May 07, 2018	
<u>AB</u>		<u>50MG</u>	<u>A209872 002</u>	May 07, 2018	

INJECTABLE; INJECTION

CYCLOPHOSPHAMIDE

<u>AP</u>	AMNEAL	<u>500MG/VIAL</u>	<u>A210046 001</u>	May 25, 2018	
<u>AP</u>		<u>1GM/VIAL</u>	<u>A210046 002</u>	May 25, 2018	
<u>AP</u>		<u>2GM/VIAL</u>	<u>A210046 003</u>	May 25, 2018	
<u>AP</u>	!	BAXTER HLTHCARE	<u>500MG/VIAL</u>	<u>A040745 001</u>	May 21, 2008
<u>AP</u>	!		<u>1GM/VIAL</u>	<u>A040745 002</u>	May 21, 2008
<u>AP</u>	!		<u>2GM/VIAL</u>	<u>A040745 003</u>	May 21, 2008
<u>AP</u>	JIANGSU HENGRUI MED	<u>500MG/VIAL</u>	<u>A204555 001</u>	Oct 31, 2014	
<u>AP</u>		<u>1GM/VIAL</u>	<u>A204555 002</u>	Oct 31, 2014	
<u>AP</u>		<u>2GM/VIAL</u>	<u>A204555 003</u>	Oct 31, 2014	

PRESCRIPTION DRUG PRODUCT LIST

CYCLOPHOSPHAMIDE

SOLUTION;INTRAVENOUS

CYCLOPHOSPHAMIDE

+! INGENUS PHARMS LLC 500MG/2.5ML (200MG/ML)
 +! 1GM/5ML (200MG/ML)

N212501 001 Jul 30, 2020
 N212501 002 Jul 30, 2020

TABLET;ORAL

CYTOXAN

+ BAXTER HLTHCARE 25MG
 +! 50MG

N012141 002
 N012141 001

CYCLOSERINE

CAPSULE;ORAL

SEROMYCIN

! PURDUE 250MG

A060593 001

CYCLOSPORINE

CAPSULE;ORAL

CYCLOSPORINE

<u>AB1</u>	APOTEX	<u>25MG</u>	<u>A210721 001</u>	Jul 10, 2019
<u>AB1</u>		<u>50MG</u>	<u>A210721 002</u>	Jul 10, 2019
<u>AB1</u>		<u>100MG</u>	<u>A210721 003</u>	Jul 10, 2019
<u>AB1</u>	IVAX SUB TEVA PHARMS	<u>25MG</u>	<u>A065110 003</u>	Mar 29, 2005
<u>AB1</u>		<u>50MG</u>	<u>A065110 001</u>	Mar 29, 2005
<u>AB1</u>		<u>100MG</u>	<u>A065110 002</u>	Mar 29, 2005
<u>AB1</u>	MAYNE PHARMA	<u>25MG</u>	<u>A065044 002</u>	Dec 20, 2000
<u>AB1</u>		<u>100MG</u>	<u>A065044 001</u>	Dec 20, 2000
<u>AB1</u>	SANDOZ	<u>25MG</u>	<u>A065017 002</u>	Jan 13, 2000
<u>AB1</u>		<u>100MG</u>	<u>A065017 001</u>	Jan 13, 2000

GENGRAF

<u>AB1</u>	ABBVIE	<u>25MG</u>	<u>A065003 001</u>	May 12, 2000
<u>AB1</u>		<u>100MG</u>	<u>A065003 003</u>	May 12, 2000

NEORAL

<u>AB1</u>	+ NOVARTIS	<u>25MG</u>	<u>N050715 001</u>	Jul 14, 1995
<u>AB1</u>	+!	<u>100MG</u>	<u>N050715 002</u>	Jul 14, 1995

CYCLOSPORINE

<u>AB2</u>	APOTEX	<u>25MG</u>	<u>A065040 001</u>	May 09, 2002
<u>AB2</u>		<u>100MG</u>	<u>A065040 002</u>	May 09, 2002

SANDIMMUNE

<u>AB2</u>	+ NOVARTIS	<u>25MG</u>	<u>N050625 001</u>	Mar 02, 1990
<u>AB2</u>	+!	<u>100MG</u>	<u>N050625 002</u>	Mar 02, 1990
BX	+	50MG	N050625 003	Nov 23, 1992

EMULSION;OPHTHALMIC

RESTASIS

+! ALLERGAN 0.05%

N050790 001 Dec 23, 2002

RESTASIS MULTIDOSE

+! ALLERGAN 0.05%

N050790 002 Oct 27, 2016

INJECTABLE;INJECTION

CYCLOSPORINE

<u>AP</u>	PADDOCK LABS LLC	<u>50MG/ML</u>	<u>A065151 001</u>	Oct 07, 2003
<u>AP</u>	WEST-WARD PHARMS INT	<u>50MG/ML</u>	<u>A065004 001</u>	Oct 29, 1999

SANDIMMUNE

<u>AP</u>	+! NOVARTIS	<u>50MG/ML</u>	<u>N050573 001</u>	Nov 14, 1983
SOLUTION;OPHTHALMIC				
CEQUA				
	+! SUN PHARMA GLOBAL	0.09%	N210913 001	Aug 14, 2018

SOLUTION;ORAL

CYCLOSPORINE

<u>AB1</u>	ABBVIE	<u>100MG/ML</u>	<u>A065025 001</u>	Mar 03, 2000
<u>AB1</u>	IVAX SUB TEVA PHARMS	<u>100MG/ML</u>	<u>A065078 001</u>	Mar 25, 2005
<u>AB1</u>	MAYNE PHARMA	<u>100MG/ML</u>	<u>A065054 001</u>	Dec 18, 2001

NEORAL

<u>AB1</u>	+! NOVARTIS	<u>100MG/ML</u>	<u>N050716 001</u>	Jul 14, 1995
------------	-------------	-----------------	--------------------	--------------

CYCLOSPORINE

<u>AB2</u>	WOCKHARDT BIO AG	<u>100MG/ML</u>	<u>A065133 001</u>	Sep 17, 2004
------------	------------------	-----------------	--------------------	--------------

SANDIMMUNE

<u>AB2</u>	+! NOVARTIS	<u>100MG/ML</u>	<u>N050574 001</u>	Nov 14, 1983
------------	-------------	-----------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

CYPROHEPTADINE HYDROCHLORIDE

<u>AA</u>	ANDA REPOSITORY	<u>2MG/5ML</u>	<u>A204823</u>	<u>001</u>	Dec 27, 2016
<u>AA</u>	ELYSIUM	<u>2MG/5ML</u>	<u>A209108</u>	<u>001</u>	Oct 16, 2018
<u>AA</u>	LANNETT CO INC	<u>2MG/5ML</u>	<u>A203191</u>	<u>001</u>	Jul 13, 2017
<u>AA</u>	! LYNE	<u>2MG/5ML</u>	<u>A040668</u>	<u>001</u>	Jun 28, 2006
<u>AA</u>	PHARM ASSOC	<u>2MG/5ML</u>	<u>A091295</u>	<u>001</u>	Mar 28, 2013
<u>AA</u>	QUAGEN	<u>2MG/5ML</u>	<u>A212423</u>	<u>001</u>	May 22, 2019

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

<u>AA</u>	APPCO	<u>4MG</u>	<u>A206553</u>	<u>001</u>	Nov 29, 2016
<u>AA</u>	BEXIMCO PHARMS USA	<u>4MG</u>	<u>A206676</u>	<u>001</u>	Apr 12, 2019
<u>AA</u>	BOSCOGEN	<u>4MG</u>	<u>A040644</u>	<u>001</u>	May 30, 2006
<u>AA</u>	ELYSIUM	<u>4MG</u>	<u>A207555</u>	<u>001</u>	Jan 31, 2017
<u>AA</u>	! HERITAGE PHARMA	<u>4MG</u>	<u>A087056</u>	<u>001</u>	
<u>AA</u>	MOUNTAIN	<u>4MG</u>	<u>A040537</u>	<u>001</u>	Sep 30, 2003
<u>AA</u>	NOVAST LABS	<u>4MG</u>	<u>A205087</u>	<u>001</u>	Sep 23, 2015
<u>AA</u>	RISING	<u>4MG</u>	<u>A207783</u>	<u>001</u>	Dec 29, 2016
<u>AA</u>	STRIDES PHARMA	<u>4MG</u>	<u>A209172</u>	<u>001</u>	Apr 11, 2018
<u>AA</u>	ZYDUS PHARMS	<u>4MG</u>	<u>A208938</u>	<u>001</u>	May 19, 2017

CYSTEAMINE BITARTRATE

CAPSULE; ORAL

CYSTAGON

+	MYLAN	EQ 50MG BASE	N020392	001	Aug 15, 1994
+	!	EQ 150MG BASE	N020392	002	Aug 15, 1994

CAPSULE, DELAYED RELEASE; ORAL

PROCYSBI

+	HORIZON PHARMA USA	EQ 25MG BASE	N203389	001	Apr 30, 2013
+	!	EQ 75MG BASE	N203389	002	Apr 30, 2013

GRANULE, DELAYED RELEASE; ORAL

PROCYSBI

+	HORIZON PHARMA USA	EQ 75MG BASE/PACKET	N213491	001	Feb 14, 2020
+	!	EQ 300MG BASE/PACKET	N213491	002	Feb 14, 2020

CYSTEAMINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CYSTADROPS

+	! RECORDATI RARE	EQ 0.37% BASE	N211302	001	Aug 19, 2020
+	! LEADIANT BIOSCI INC	EQ 0.44% BASE	N200740	001	Oct 02, 2012

CYSTEINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS

ELCYS

+	! EXELA PHARMA	500MG/10ML (50MG/ML)	N210660	001	Apr 16, 2019
---	----------------	----------------------	---------	-----	--------------

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

<u>AP</u>	! FRESENIUS KABI USA	<u>100MG/ML</u>	<u>A076512</u>	<u>001</u>	Jan 15, 2004
<u>AP</u>	GLAND PHARMA LTD	<u>100MG/VIAL</u>	<u>A211937</u>	<u>001</u>	Dec 23, 2019
<u>AP</u>		<u>2GM/VIAL</u>	<u>A211938</u>	<u>001</u>	Dec 23, 2019
<u>AP</u>	HONG KONG	<u>20MG/ML</u>	<u>A206189</u>	<u>001</u>	Jun 26, 2020
<u>AP</u>	! HOSPIRA	<u>20MG/ML</u>	<u>A071868</u>	<u>001</u>	Jun 04, 1990
<u>AP</u>	!	<u>20MG/ML</u>	<u>A072168</u>	<u>001</u>	Aug 31, 1990
<u>AP</u>	!	<u>20MG/ML</u>	<u>A072945</u>	<u>001</u>	Feb 28, 1994
<u>AP</u>		<u>100MG/ML</u>	<u>A075383</u>	<u>001</u>	Nov 22, 1999
<u>AP</u>	MEITHEAL	<u>20MG/ML</u>	<u>A206190</u>	<u>001</u>	Nov 09, 2017
<u>AP</u>		<u>100MG/ML</u>	<u>A205696</u>	<u>001</u>	Jul 17, 2018
<u>AP</u>	MYLAN LABS LTD	<u>20MG/ML</u>	<u>A200914</u>	<u>001</u>	Dec 13, 2011
<u>AP</u>		<u>20MG/ML</u>	<u>A200915</u>	<u>001</u>	Dec 13, 2011
<u>AP</u>		<u>100MG/ML</u>	<u>A201784</u>	<u>001</u>	Jan 30, 2012
<u>AP</u>	WEST-WARD PHARMS	<u>100MG/VIAL</u>	<u>A071471</u>	<u>001</u>	Aug 02, 1989
<u>AP</u>	INT				
<u>AP</u>	!	<u>2GM/VIAL</u>	<u>A074245</u>	<u>002</u>	Aug 31, 1994
	!	500MG/VIAL	A071472	001	Aug 02, 1989
	!	1GM/VIAL	A074245	001	Aug 31, 1994

PRESCRIPTION DRUG PRODUCT LIST

CYTARABINE; DAUNORUBICIN

POWDER; INTRAVENOUS

VYXEOS

+! CELATOR PHARMS 100MG;44MG

N209401 001 Aug 03, 2017

DABIGATRAN ETEXILATE MESYLATE

CAPSULE; ORAL

DABIGATRAN ETEXILATE MESYLATE

AB ALKEM LABS LTD **EQ 75MG BASE**
AB **EQ 150MG BASE**
AB HETERO LABS LTD III **EQ 75MG BASE**
AB **EQ 150MG BASE**

A208040 001 Mar 11, 2020
A208040 002 Mar 11, 2020
A207961 001 May 06, 2020
A207961 002 May 06, 2020

PRADAXA

AB + BOEHRINGER **EQ 75MG BASE**
 INGELHEIM
AB +! **EQ 150MG BASE**
 + **EQ 110MG BASE**

N022512 001 Oct 19, 2010
N022512 002 Oct 19, 2010
N022512 003 Nov 20, 2015

DABRAFENIB MESYLATE

CAPSULE; ORAL

TAFINLAR

+ NOVARTIS EQ 50MG BASE
 +! EQ 75MG BASE

N202806 001 May 29, 2013
 N202806 002 May 29, 2013

DACARBAZINE

INJECTABLE; INJECTION

DACARBAZINE

AP ! FRESENIUS KABI USA **200MG/VIAL**
AP HOSPIRA **200MG/VIAL**
AP TEVA PHARMS USA **200MG/VIAL**
AP ! **500MG/VIAL**
AP WEST-WARD PHARMS **200MG/VIAL**
 INT
AP **500MG/VIAL**
 ! FRESENIUS KABI USA 100MG/VIAL

A075371 002 Aug 27, 1999
A075940 001 Oct 18, 2001
A075259 002 Aug 27, 1998
A075259 001 Sep 22, 2000
A075812 001 Jun 15, 2001
A075812 002 Oct 31, 2002
 A075371 001 Aug 27, 1999

DACOMITINIB

TABLET; ORAL

VIZIMPRO

+ PFIZER 15MG
 + 30MG
 +! 45MG

N211288 001 Sep 27, 2018
 N211288 002 Sep 27, 2018
 N211288 003 Sep 27, 2018

DACTINOMYCIN

INJECTABLE; INJECTION

COSMEGEN**AP** +! RECORDATI RARE **0.5MG/VIAL****N050682 001**DACTINOMYCIN

AP HISUN PHARM **0.5MG/VIAL**
 HANGZHOU
AP HONG KONG **0.5MG/VIAL**
AP MYLAN LABS LTD **0.5MG/VIAL**
AP XGEN PHARMS **0.5MG/VIAL**

A207232 001 Jul 16, 2019
A213463 001 Nov 13, 2020
A203385 001 Nov 09, 2017
A203999 001 May 20, 2019

DALBAVANCIN HYDROCHLORIDE

POWDER; INTRAVENOUS

DALVANCE

+! ALLERGAN EQ 500MG BASE/VIAL

N021883 001 May 23, 2014

DALFAMPRIDINE

TABLET, EXTENDED RELEASE; ORAL

AMPYRA**AB** +! ACORDA **10MG****N022250 001** Jan 22, 2010DALFAMPRIDINE

AB ACCORD HLTHCARE **10MG**
AB ACTAVIS LABS FL INC **10MG**
AB ALKEM LABS LTD **10MG**
AB AUROBINDO PHARMA **10MG**
 LTD
AB HIKMA **10MG**
AB MICRO LABS **10MG**
AB SUN PHARM **10MG**

A206863 001 Jul 11, 2018
A206836 001 Jan 23, 2017
A206765 001 Jul 30, 2018
A206811 001 Jan 23, 2017
A206646 001 Oct 24, 2018
A210158 001 Mar 11, 2019
A208292 001 May 21, 2019

PRESCRIPTION DRUG PRODUCT LIST

DALFOPRISTIN; QUINUPRISTIN

INJECTABLE; INTRAVENOUS

SYNERCID

+! KING PHARMS

350MG/VIAL; 150MG/VIAL

N050748 001 Sep 21, 1999

DALTEPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

FRAGMIN

+ PFIZER

2,500IU/0.2ML (12,500IU/ML)

N020287 001 Dec 22, 1994

+

5,000IU/0.2ML (25,000IU/ML)

N020287 003 Mar 18, 1996

+

7,500IU/0.3ML (25,000IU/ML)

N020287 005 Apr 04, 2002

+

10,000IU/ML (10,000IU/ML)

N020287 004 Jan 30, 1998

+

12,500IU/0.5ML (25,000IU/ML)

N020287 009 May 01, 2007

+

15,000IU/0.6ML (25,000IU/ML)

N020287 010 May 01, 2007

+

18,000IU/0.72ML (25,000IU/ML)

N020287 011 May 01, 2007

+!

95,000IU/3.8ML (25,000IU/ML)

N020287 006 Apr 04, 2002

DANAZOL

CAPSULE; ORAL

DANAZOLAB BARR50MGA074582 003 May 29, 1998AB100MGA074582 002 May 29, 1998AB !200MGA074582 001 Aug 09, 1996AB LANNETT CO INC50MGA077246 002 Apr 19, 2007AB100MGA077246 003 Apr 19, 2007AB200MGA077246 001 Sep 28, 2005DANTROLENE SODIUM

CAPSULE; ORAL

DANTRIUMAB + PAR STERILE25MGN017443 001

PRODUCTS

AB +50MGN017443 003AB +!100MGN017443 002DANTROLENE SODIUMAB ELITE LABS INC25MGA076686 001 Oct 24, 2005AB50MGA076686 002 Oct 24, 2005AB100MGA076686 003 Oct 24, 2005AB IMPAX LABS25MGA076856 001 Mar 01, 2005AB50MGA076856 002 Mar 01, 2005AB100MGA076856 003 Mar 01, 2005

FOR SUSPENSION; INTRAVENOUS

RYANODEX

+! EAGLE PHARMS

250MG/VIAL

N205579 001 Jul 22, 2014

INJECTABLE; INJECTION

DANTRIUMAP +! PAR STERILE20MG/VIALN018264 001

PRODUCTS

DANTROLENE SODIUMAP HIKMA20MG/VIALA204762 001 Jun 19, 2017REVONTOAP USWM20MG/VIALA078378 001 Jul 24, 2007DAPAGLIFLOZIN

TABLET; ORAL

FARXIGA

+ ASTRAZENECA AB

5MG

N202293 001 Jan 08, 2014

+!

10MG

N202293 002 Jan 08, 2014

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

XIGDUO XR

+ ASTRAZENECA AB

2.5MG; 1GM

N205649 005 Jul 28, 2017

+

5MG; 500MG

N205649 001 Oct 29, 2014

+

5MG; 1GM

N205649 002 Oct 29, 2014

+

10MG; 500MG

N205649 003 Oct 29, 2014

+!

10MG; 1GM

N205649 004 Oct 29, 2014

DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE

TABLET; ORAL

QTERN

+ ASTRAZENECA AB

5MG; EQ 5MG BASE

N209091 002 May 02, 2019

+!

10MG; EQ 5MG BASE

N209091 001 Feb 27, 2017

PRESCRIPTION DRUG PRODUCT LIST

DAPSONE

GEL; TOPICAL

ACZONE

<u>AB</u>	<u>+</u> !	ALLERGAN	<u>5%</u>	<u>N021794</u>	<u>001</u>	Jul 07, 2005
<u>AB</u>	<u>+</u> !	ALMIRALL	<u>7.5%</u>	<u>N207154</u>	<u>001</u>	Feb 24, 2016

DAPSONE

<u>AB</u>		TARO	<u>5%</u>	<u>A209506</u>	<u>001</u>	Oct 16, 2017
<u>AB</u>		TARO PHARMS	<u>7.5%</u>	<u>A210191</u>	<u>001</u>	Jun 26, 2019

TABLET; ORAL

DAPSONE

<u>AB</u>		ACTAVIS LLC	<u>25MG</u>	<u>A204380</u>	<u>001</u>	Mar 23, 2017
<u>AB</u>			<u>100MG</u>	<u>A204380</u>	<u>002</u>	Mar 23, 2017
<u>AB</u>		ALVOGEN	<u>25MG</u>	<u>A205429</u>	<u>001</u>	Jan 07, 2016
<u>AB</u>			<u>100MG</u>	<u>A205429</u>	<u>002</u>	Jan 07, 2016
<u>AB</u>		JACOBUS	<u>25MG</u>	<u>A086841</u>	<u>001</u>	
<u>AB</u>	<u>!</u>		<u>100MG</u>	<u>A086842</u>	<u>001</u>	
<u>AB</u>		NOSTRUM LABS INC	<u>25MG</u>	<u>A203887</u>	<u>001</u>	May 06, 2016
<u>AB</u>			<u>100MG</u>	<u>A203887</u>	<u>002</u>	May 06, 2016
<u>AB</u>		NOVITIUM PHARMA	<u>25MG</u>	<u>A206505</u>	<u>001</u>	Dec 01, 2016
<u>AB</u>			<u>100MG</u>	<u>A206505</u>	<u>002</u>	Dec 01, 2016
<u>AB</u>		RISING	<u>100MG</u>	<u>A207165</u>	<u>001</u>	May 08, 2019
<u>AB</u>		VIRTUS PHARMS	<u>25MG</u>	<u>A204074</u>	<u>001</u>	May 10, 2016
<u>AB</u>			<u>100MG</u>	<u>A204074</u>	<u>002</u>	May 10, 2016

DAPTOMYCIN

POWDER; INTRAVENOUS

CUBICIN

<u>AP</u>	<u>+</u> !	CUBIST PHARMS LLC	<u>500MG/VIAL</u>	<u>N021572</u>	<u>002</u>	Sep 12, 2003
-----------	------------	-------------------	-------------------	----------------	------------	--------------

DAPTOMYCIN

<u>AP</u>		ACCORD HLTHCARE	<u>500MG/VIAL</u>	<u>A211961</u>	<u>001</u>	Jun 24, 2019
<u>AP</u>		BE PHARMS	<u>500MG/VIAL</u>	<u>A212513</u>	<u>001</u>	Jun 26, 2019
<u>AP</u>		DR REDDYS	<u>500MG/VIAL</u>	<u>A208375</u>	<u>001</u>	May 01, 2019
<u>AP</u>		FRESENIUS KABI USA	<u>500MG/VIAL</u>	<u>A206077</u>	<u>001</u>	Apr 11, 2018
<u>AP</u>		HOSPIRA INC	<u>500MG/VIAL</u>	<u>A202857</u>	<u>001</u>	Sep 12, 2014
<u>AP</u>		JIANGSU HENGRUI MED	<u>500MG/VIAL</u>	<u>A212022</u>	<u>001</u>	Aug 22, 2019
<u>AP</u>		MYLAN LABS LTD	<u>500MG/VIAL</u>	<u>A205037</u>	<u>001</u>	Jun 05, 2018
<u>AP</u>		SAGENT PHARMS INC	<u>500MG/VIAL</u>	<u>A207104</u>	<u>001</u>	Nov 15, 2019
<u>AP</u>		TEVA PHARMS USA	<u>500MG/VIAL</u>	<u>A091039</u>	<u>001</u>	Mar 25, 2016
<u>AP</u>		XELLIA PHARMS APS	<u>500MG/VIAL</u>	<u>A206005</u>	<u>001</u>	Jun 15, 2016

CUBICIN RF

<u>+</u> !		CUBIST PHARMS LLC	500MG/VIAL	N021572	003	Jul 06, 2016
------------	--	-------------------	------------	---------	-----	--------------

POWDER; IV (INFUSION)

DAPTOMYCIN

<u>AP</u>		ACCORD HLTHCARE	<u>350MG/VIAL</u>	<u>A212667</u>	<u>001</u>	Jul 12, 2019
<u>AP</u>		BE PHARMS	<u>350MG/VIAL</u>	<u>A213425</u>	<u>001</u>	Aug 20, 2020
<u>AP</u>		DR REDDYS	<u>350MG/VIAL</u>	<u>A211403</u>	<u>001</u>	Aug 31, 2020
<u>AP</u>	<u>+</u> !	SAGENT PHARMS INC	<u>350MG/VIAL</u>	<u>N208385</u>	<u>001</u>	Sep 12, 2017
<u>+</u> !		XELLIA PHARMS APS	350MG/VIAL	N209949	001	Oct 20, 2017

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL

DARIFENACIN

<u>AB</u>		MACLEODS PHARMS LTD	<u>EQ 7.5MG BASE</u>	<u>A207302</u>	<u>001</u>	Jul 28, 2017
<u>AB</u>			<u>EQ 15MG BASE</u>	<u>A207302</u>	<u>002</u>	Jul 28, 2017

DARIFENACIN HYDROBROMIDE

<u>AB</u>		ALEMBIC PHARMS LTD	<u>EQ 7.5MG BASE</u>	<u>A207681</u>	<u>001</u>	Dec 08, 2017
<u>AB</u>			<u>EQ 15MG BASE</u>	<u>A207681</u>	<u>002</u>	Dec 08, 2017
<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 7.5MG BASE</u>	<u>A206743</u>	<u>001</u>	Sep 19, 2016
<u>AB</u>			<u>EQ 15MG BASE</u>	<u>A206743</u>	<u>002</u>	Sep 19, 2016
<u>AB</u>		CIPLA	<u>EQ 7.5MG BASE</u>	<u>A207664</u>	<u>001</u>	Sep 01, 2016
<u>AB</u>			<u>EQ 15MG BASE</u>	<u>A207664</u>	<u>002</u>	Sep 01, 2016
<u>AB</u>		JUBILANT GENERICS	<u>EQ 7.5MG BASE</u>	<u>A205550</u>	<u>001</u>	Oct 12, 2016
<u>AB</u>			<u>EQ 15MG BASE</u>	<u>A205550</u>	<u>002</u>	Oct 12, 2016
<u>AB</u>		POLYGEN PHARMS	<u>EQ 7.5MG BASE</u>	<u>A211045</u>	<u>001</u>	Jan 06, 2020
<u>AB</u>			<u>EQ 15MG BASE</u>	<u>A211045</u>	<u>002</u>	Jan 06, 2020
<u>AB</u>		TORRENT	<u>EQ 7.5MG BASE</u>	<u>A205209</u>	<u>001</u>	Nov 17, 2016
<u>AB</u>			<u>EQ 15MG BASE</u>	<u>A205209</u>	<u>002</u>	Nov 17, 2016
<u>AB</u>		XIROMED	<u>EQ 7.5MG BASE</u>	<u>A209571</u>	<u>002</u>	Oct 22, 2019
<u>AB</u>			<u>EQ 15MG BASE</u>	<u>A209571</u>	<u>001</u>	Oct 22, 2019

ENABLEX

<u>AB</u>	<u>+</u>	APIL	<u>EQ 7.5MG BASE</u>	<u>N021513</u>	<u>001</u>	Dec 22, 2004
<u>AB</u>	<u>+</u> !		<u>EQ 15MG BASE</u>	<u>N021513</u>	<u>002</u>	Dec 22, 2004

PRESCRIPTION DRUG PRODUCT LIST

DAROLUTAMIDE

TABLET; ORAL

NUBEQA

+! BAYER HEALTHCARE 300MG N212099 001 Jul 30, 2019

DARUNAVIR

SUSPENSION; ORAL

PREZISTA

+! JANSSEN PRODS 100MG/ML N202895 001 Dec 16, 2011

TABLET; ORAL

DARUNAVIRAB TEVA PHARMS USA 600MG A202118 001 Nov 21, 2017PREZISTAAB + JANSSEN PRODS 600MG N021976 002 Feb 25, 2008

+ 75MG N021976 004 Dec 18, 2008

+ 150MG N021976 005 Dec 18, 2008

+! 800MG N021976 006 Nov 09, 2012

DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR

TABLET, TABLET; ORAL

VIEKIRA PAK (COPACKAGED)

+! ABBVIE INC 250.0MG; 12.5MG; 75.0MG; EQ 250MG N206619 001 Dec 19, 2014
BASE, N/A, N/A, N/A; N/A, 12.5MG, 75MG, 50MGDASATINIB

TABLET; ORAL

SPRYCEL

+ BRISTOL MYERS 20MG N021986 001 Jun 28, 2006

SQUIBB

+ 50MG N021986 002 Jun 28, 2006

+ 70MG N021986 003 Jun 28, 2006

+ 80MG N021986 005 Oct 28, 2010

+! 100MG N021986 004 May 30, 2008

+ 140MG N021986 006 Oct 28, 2010

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

CERUBIDINEAP ! WEST-WARD PHARMS EQ 20MG BASE/VIAL A064103 001 Feb 03, 1995
INTDAUNORUBICIN HYDROCHLORIDEAP FRESENIUS KABI USA EQ 20MG BASE/VIAL A065000 001 May 25, 1999AP HISUN PHARM EQ 5MG BASE/ML A208759 001 Apr 12, 2019

HANGZHOU

AP TEVA PHARMS USA EQ 5MG BASE/ML A065035 001 Jan 24, 2000AP +! WEST-WARD PHARMS EQ 5MG BASE/ML N050731 001 Jan 30, 1998

INT

FRESENIUS KABI USA EQ 5MG BASE/VIAL A065034 001 Nov 20, 2001

DECITABINE

INJECTABLE; INTRAVENOUS

DACOGENAP +! OTSUKA 50MG/VIAL N021790 001 May 02, 2006DECITABINEAP ACCORD HLTHCARE 50MG/VIAL A203475 001 Feb 27, 2017AP APOTEX 50MG/VIAL A205539 001 Nov 23, 2020AP CHEMI SPA 50MG/VIAL A206033 001 Sep 22, 2017AP CIPLA 50MG/VIAL A208601 001 Nov 16, 2017AP DR REDDYS 50MG/VIAL A203131 001 Jul 11, 2013AP INGENUS PHARMS LLC 50MG/VIAL A210984 001 Sep 16, 2019AP LUPIN LTD 50MG/VIAL A210756 001 Nov 09, 2018AP MSN 50MG/VIAL A212265 001 Aug 28, 2019AP NIVAGEN PHARMS INC 50MG/VIAL A212117 001 Dec 07, 2020AP PHARMASCIENCE INC 50MG/VIAL A204607 001 May 31, 2017AP SAGENT PHARMS INC 50MG/VIAL A207100 001 Mar 16, 2018AP SANDOZ INC 50MG/VIAL A202969 001 Aug 28, 2014AP WOCKHARDT BIO AG 50MG/VIAL A209056 001 Apr 09, 2019

POWDER; INTRAVENOUS

DECITABINE

+! SUN PHARMA GLOBAL 50MG/VIAL N205582 001 Jan 28, 2014

PRESCRIPTION DRUG PRODUCT LIST

DEFERASIROX

GRANULE; ORAL

DEFERASIROX

<u>AB</u>	ALKEM LABS LTD	<u>90MG</u>	<u>A213374 001</u>	Jul 14, 2020
<u>AB</u>		<u>180MG</u>	<u>A213374 002</u>	Jul 14, 2020
<u>AB</u>		<u>360MG</u>	<u>A213374 003</u>	Jul 14, 2020

JADENU SPRINKLE

<u>AB</u>	+ NOVARTIS	<u>90MG</u>	<u>N207968 001</u>	May 18, 2017
<u>AB</u>	+	<u>180MG</u>	<u>N207968 002</u>	May 18, 2017
<u>AB</u>	+!	<u>360MG</u>	<u>N207968 003</u>	May 18, 2017

TABLET; ORAL

DEFERASIROX

<u>AB</u>	ACTAVIS ELIZABETH	<u>90MG</u>	<u>A208697 001</u>	Dec 13, 2019
<u>AB</u>		<u>180MG</u>	<u>A208697 002</u>	Dec 13, 2019
<u>AB</u>		<u>360MG</u>	<u>A208697 003</u>	Dec 13, 2019
<u>AB</u>	ALEMBIC PHARMS LTD	<u>90MG</u>	<u>A211824 001</u>	Nov 20, 2019
<u>AB</u>		<u>180MG</u>	<u>A211824 003</u>	Jun 15, 2020
<u>AB</u>		<u>360MG</u>	<u>A211824 002</u>	Nov 20, 2019
<u>AB</u>	ALKEM LABS LTD	<u>90MG</u>	<u>A210555 001</u>	Mar 30, 2020
<u>AB</u>		<u>180MG</u>	<u>A210555 003</u>	Jul 02, 2020
<u>AB</u>		<u>360MG</u>	<u>A210555 002</u>	Mar 30, 2020
<u>AB</u>	AMNEAL	<u>90MG</u>	<u>A210727 001</u>	Dec 27, 2019
<u>AB</u>		<u>180MG</u>	<u>A210727 003</u>	Jun 15, 2020
<u>AB</u>		<u>360MG</u>	<u>A210727 002</u>	Dec 27, 2019
<u>AB</u>	CIPLA	<u>90MG</u>	<u>A211852 001</u>	Feb 11, 2020
<u>AB</u>		<u>180MG</u>	<u>A211852 003</u>	Jun 15, 2020
<u>AB</u>		<u>360MG</u>	<u>A211852 002</u>	Feb 11, 2020
<u>AB</u>	MSN	<u>90MG</u>	<u>A210945 001</u>	Nov 20, 2019
<u>AB</u>		<u>180MG</u>	<u>A210945 003</u>	Jun 16, 2020
<u>AB</u>		<u>360MG</u>	<u>A210945 002</u>	Nov 20, 2019
<u>AB</u>	PIRAMAL HLTHCARE UK	<u>90MG</u>	<u>A212995 001</u>	Dec 30, 2019
<u>AB</u>		<u>180MG</u>	<u>A212995 003</u>	Jun 15, 2020
<u>AB</u>		<u>360MG</u>	<u>A212995 002</u>	Dec 30, 2019
<u>AB</u>	SUN PHARM	<u>90MG</u>	<u>A211641 001</u>	Jan 02, 2020
<u>AB</u>		<u>180MG</u>	<u>A211641 003</u>	Jun 15, 2020
<u>AB</u>		<u>360MG</u>	<u>A211641 002</u>	Jan 02, 2020
<u>AB</u>	TEVA PHARMS USA	<u>90MG</u>	<u>A209223 001</u>	Nov 25, 2019
<u>AB</u>		<u>180MG</u>	<u>A209223 003</u>	Apr 24, 2020
<u>AB</u>		<u>360MG</u>	<u>A209223 002</u>	Nov 25, 2019
<u>AB</u>	ZYDUS PHARMS	<u>90MG</u>	<u>A211383 001</u>	Nov 20, 2019
<u>AB</u>		<u>180MG</u>	<u>A211383 003</u>	Jun 15, 2020
<u>AB</u>		<u>360MG</u>	<u>A211383 002</u>	Nov 20, 2019

JADENU

<u>AB</u>	+ NOVARTIS PHARMS CORP	<u>90MG</u>	<u>N206910 001</u>	Mar 30, 2015
<u>AB</u>	+	<u>180MG</u>	<u>N206910 002</u>	Mar 30, 2015
<u>AB</u>	+!	<u>360MG</u>	<u>N206910 003</u>	Mar 30, 2015

TABLET, FOR SUSPENSION; ORAL

DEFERASIROX

<u>AB</u>	ACTAVIS ELIZABETH	<u>125MG</u>	<u>A203560 001</u>	Jan 26, 2016
<u>AB</u>		<u>250MG</u>	<u>A203560 002</u>	Jan 26, 2016
<u>AB</u>		<u>500MG</u>	<u>A203560 003</u>	Jan 26, 2016
<u>AB</u>	ALEMBIC PHARMS LTD	<u>125MG</u>	<u>A210060 001</u>	Nov 20, 2019
<u>AB</u>		<u>250MG</u>	<u>A210060 002</u>	Nov 20, 2019
<u>AB</u>		<u>500MG</u>	<u>A210060 003</u>	Nov 20, 2019
<u>AB</u>	ALKEM LABS LTD	<u>125MG</u>	<u>A210519 001</u>	Nov 20, 2019
<u>AB</u>		<u>250MG</u>	<u>A210519 002</u>	Nov 20, 2019
<u>AB</u>		<u>500MG</u>	<u>A210519 003</u>	Nov 20, 2019
<u>AB</u>	BIONPHARMA INC	<u>125MG</u>	<u>A210920 001</u>	Nov 20, 2019
<u>AB</u>		<u>250MG</u>	<u>A210920 002</u>	Nov 20, 2019
<u>AB</u>		<u>500MG</u>	<u>A210920 003</u>	Nov 20, 2019
<u>AB</u>	ICHNOS	<u>125MG</u>	<u>A209433 001</u>	Jan 06, 2020
<u>AB</u>		<u>250MG</u>	<u>A209433 002</u>	Jan 06, 2020
<u>AB</u>		<u>500MG</u>	<u>A209433 003</u>	Jan 06, 2020
<u>AB</u>	MSN	<u>125MG</u>	<u>A209878 001</u>	Nov 20, 2019
<u>AB</u>		<u>250MG</u>	<u>A209878 002</u>	Nov 20, 2019
<u>AB</u>		<u>500MG</u>	<u>A209878 003</u>	Nov 20, 2019
<u>AB</u>	SUN PHARM	<u>125MG</u>	<u>A209782 001</u>	Nov 20, 2019
<u>AB</u>		<u>250MG</u>	<u>A209782 002</u>	Nov 20, 2019
<u>AB</u>		<u>500MG</u>	<u>A209782 003</u>	Nov 20, 2019

EXJADE

<u>AB</u>	+ NOVARTIS	<u>125MG</u>	<u>N021882 001</u>	Nov 02, 2005
<u>AB</u>	+	<u>250MG</u>	<u>N021882 002</u>	Nov 02, 2005

PRESCRIPTION DRUG PRODUCT LIST

DEFERASIROX

TABLET, FOR SUSPENSION;ORAL

EXJADE

AB	+ !	500MG	N021882	003	Nov 02, 2005
-----------	------------	--------------	----------------	------------	--------------

DEFERIPRONE

SOLUTION;ORAL

FERRIPROX

+ CHIESI

80MG/ML

N208030 002 Apr 20, 2018

+!

100MG/ML

N208030 001 Sep 09, 2015

TABLET;ORAL

DEFERIPRONE

AB		TARO PHARM INDS LTD	500MG	A208800	001	Feb 08, 2019
-----------	--	---------------------	--------------	----------------	------------	--------------

FERRIPROX

+! CHIESI

500MG

N021825 001 Oct 14, 2011

+

1GM

N021825 002 Jul 25, 2019

+!

1GM

N212269 001 May 19, 2020

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION

DEFEROXAMINE MESYLATE

AP		FRESENIUS KABI USA	500MG/VIAL	A078718	001	Sep 15, 2009
-----------	--	--------------------	-------------------	----------------	------------	--------------

AP			2GM/VIAL	A078718	002	Sep 15, 2009
-----------	--	--	-----------------	----------------	------------	--------------

AP		GLAND PHARMA LTD	500MG/VIAL	A207384	001	Sep 29, 2017
-----------	--	------------------	-------------------	----------------	------------	--------------

AP			2GM/VIAL	A207384	002	Sep 29, 2017
-----------	--	--	-----------------	----------------	------------	--------------

AP		HOSPIRA	500MG/VIAL	A076019	001	Mar 17, 2004
-----------	--	---------	-------------------	----------------	------------	--------------

AP	!		2GM/VIAL	A076019	002	Mar 17, 2004
-----------	----------	--	-----------------	----------------	------------	--------------

AP		WEST-WARD PHARMS	500MG/VIAL	A078086	001	May 30, 2007
-----------	--	------------------	-------------------	----------------	------------	--------------

INT

AP			2GM/VIAL	A078086	002	May 30, 2007
-----------	--	--	-----------------	----------------	------------	--------------

DESFERAL

AP	+ !	NOVARTIS	500MG/VIAL	N016267	001	
-----------	------------	----------	-------------------	----------------	------------	--

DEFIBROTIDE SODIUM

SOLUTION;INTRAVENOUS

DEFITELIO

+! JAZZ PHARMS INC

200MG/2.5ML (80MG/ML)

N208114 001 Mar 30, 2016

DEFLAZACORT

SUSPENSION;ORAL

EMFLAZA

+! PTC THERAP

22.75MG/ML

N208685 001 Feb 09, 2017

TABLET;ORAL

EMFLAZA

+ PTC THERAP

6MG

N208684 001 Feb 09, 2017

+

18MG

N208684 002 Feb 09, 2017

+

30MG

N208684 003 Feb 09, 2017

+!

36MG

N208684 004 Feb 09, 2017

DEGARELIX ACETATE

POWDER;SUBCUTANEOUS

FIRMAGON

+ FERRING

EQ 80MG BASE/VIAL

N022201 001 Dec 24, 2008

+!

EQ 120MG BASE/VIAL

N022201 002 Dec 24, 2008

DELAFLOXACIN MEGLUMINE

POWDER;INTRAVENOUS

BAXDELA

+! MELINTA

EQ 300MG BASE/VIAL

N208611 001 Jun 19, 2017

TABLET;ORAL

BAXDELA

+! MELINTA

EQ 450MG BASE

N208610 001 Jun 19, 2017

DEMECLOCYCLINE HYDROCHLORIDE

TABLET;ORAL

DEMECLOCYCLINE HYDROCHLORIDE

AB		AKORN	150MG	A065389	001	Dec 01, 2008
-----------	--	-------	--------------	----------------	------------	--------------

AB			300MG	A065389	002	Dec 01, 2008
-----------	--	--	--------------	----------------	------------	--------------

AB		AMNEAL PHARM	150MG	A065425	001	Feb 27, 2008
-----------	--	--------------	--------------	----------------	------------	--------------

AB	!		300MG	A065425	002	Feb 27, 2008
-----------	----------	--	--------------	----------------	------------	--------------

AB		EPIC PHARMA LLC	150MG	A065447	001	Aug 18, 2015
-----------	--	-----------------	--------------	----------------	------------	--------------

AB			300MG	A065447	002	Aug 18, 2015
-----------	--	--	--------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

DEOXYCHOLIC ACID

SOLUTION;SUBCUTANEOUS

KYBELLA

+! KYTHERA BIOPHARMS 20MG/2ML (10MG/ML) N206333 001 Apr 29, 2015

DESFLURANE

LIQUID;INHALATION

DESFLURANE

AN SHANGHAI HENGRUI 100% A208234 001 Feb 26, 2018

SUPRANE

AN +! BAXTER HLTHCARE 100% N020118 001 Sep 18, 1992

DESIPRAMINE HYDROCHLORIDE

TABLET;ORAL

DESIPRAMINE HYDROCHLORIDE

AB ACTAVIS TOTOWA 10MG A074430 001 Feb 09, 1996

AB 25MG A071601 001 Jun 05, 1987

AB 50MG A071588 001 Jun 05, 1987

AB 75MG A071602 001 Oct 05, 1987

AB 100MG A071766 001 Oct 05, 1987

AB 150MG A074430 002 Feb 09, 1996

AB AMNEAL PHARMS CO 10MG A208105 001 Mar 17, 2016

AB 25MG A208105 002 Mar 17, 2016

AB 50MG A208105 003 Mar 17, 2016

AB 75MG A208105 004 Mar 17, 2016

AB 100MG A208105 005 Mar 17, 2016

AB 150MG A208105 006 Mar 17, 2016

AB HERITAGE PHARMS INC 10MG A207433 001 May 05, 2016

AB 25MG A207433 002 May 05, 2016

AB 50MG A207433 003 May 05, 2016

AB 75MG A207433 004 May 05, 2016

AB 100MG A207433 005 May 05, 2016

AB 150MG A207433 006 May 05, 2016

AB NOVAST LABS 10MG A204963 001 Dec 26, 2017

AB 25MG A204963 002 Dec 26, 2017

AB 50MG A204963 003 Dec 26, 2017

AB 75MG A204963 004 Dec 26, 2017

AB 100MG A204963 005 Dec 26, 2017

AB 150MG A204963 006 Dec 26, 2017

AB SANDOZ 10MG A072099 001 May 24, 1988

AB 25MG A072100 001 May 24, 1988

AB 50MG A072101 001 May 24, 1988

AB 75MG A072102 001 Jun 20, 1988

AB 100MG A072103 001 Jun 20, 1988

AB 150MG A072104 001 Jun 20, 1988

NORPRAMIN

AB + US PHARM HOLDINGS 10MG N014399 007 Feb 11, 1982

AB + 25MG N014399 001

AB + 50MG N014399 003

AB + 75MG N014399 004

AB +! 100MG N014399 005

AB + 150MG N014399 006

DESLORATADINE

TABLET;ORAL

CLARINEX

AB +! MERCK SHARP DOHME 5MG N021165 001 Dec 21, 2001

DESLORATADINE

AB BELCHER PHARMS 5MG A078355 001 Apr 19, 2012

AB DR REDDYS LABS LTD 5MG A078365 001 Mar 08, 2011

AB LUPIN PHARMS 5MG A078352 001 Oct 25, 2010

AB ORCHID HLTHCARE 5MG A078357 001 Feb 19, 2010

AB PERRIGO 5MG A078361 001 Dec 22, 2011

AB SANDOZ 5MG A078364 001 Dec 03, 2010

AB SUN PHARM INDS 5MG A078359 001 Nov 16, 2010

TABLET, ORALLY DISINTEGRATING;ORAL

DESLORATADINE

REDDYS 2.5MG A078367 001 Jul 12, 2010

! 5MG A078367 002 Jul 12, 2010

PRESCRIPTION DRUG PRODUCT LIST

DESLORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

CLARINEX-D 12 HOUR

+! MERCK SHARP DOHME 2.5MG;120MG

N021313 001 Feb 01, 2006

DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR

! DR REDDYS LABS LTD 5MG;240MG

A078366 001 Apr 26, 2011

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION

DDAVP**AP** +! FERRING PHARMS INC 0.004MG/ML**N018938 001** Mar 30, 1984DESMOPRESSIN ACETATE**AP** AM REGENT 0.004MG/ML**A091374 001** Feb 14, 2019**AP** SAGENT PHARMS INC 0.004MG/ML**A204695 001** Aug 22, 2017**AP** 0.004MG/ML**A204751 001** Aug 22, 2017**AP** SUN PHARM INDS LTD 0.004MG/ML**A091280 001** Jan 25, 2013**AP** TEVA PHARMS USA 0.004MG/ML**A074888 001** Oct 15, 1997**AP** UBI 0.004MG/ML**A210218 001** Feb 14, 2020**AP** 0.004MG/ML**A210223 001** Sep 17, 2020

SPRAY, METERED;NASAL

DESMOPRESSIN ACETATE**AB** ! BAUSCH AND LOMB 0.01MG/SPRAY**A074830 001** Jan 25, 1999DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION)**AB** APOTEX INC 0.01MG/SPRAY**A076703 001** Jan 27, 2005**AB** ! SUN PHARM 0.01MG/SPRAY**A078271 001** Dec 23, 2013**AB** ZYDUS PHARMS 0.01MG/SPRAY**A091345 001** Oct 03, 2017

TABLET;ORAL

DDAVP**AB** + FERRING PHARMS INC 0.1MG**N019955 001** Sep 06, 1995**AB** +! 0.2MG**N019955 002** Sep 06, 1995DESMOPRESSIN ACETATE**AB** ABHAI LLC 0.1MG**A210371 001** Jan 28, 2019**AB** 0.2MG**A210371 002** Jan 28, 2019**AB** ACTAVIS LABS FL INC 0.1MG**A076470 001** Jul 01, 2005**AB** 0.2MG**A076470 002** Jul 01, 2005**AB** APOTEX INC 0.1MG**A077414 001** Mar 07, 2006**AB** 0.2MG**A077414 002** Mar 07, 2006**AB** GLENMARK PHARMS LTD 0.1MG**A201831 001** May 28, 2015**AB** 0.2MG**A201831 002** May 28, 2015**AB** HERITAGE PHARMA 0.1MG**A207880 001** May 26, 2017**AB** 0.2MG**A207880 002** May 26, 2017**AB** NOVAST LABS 0.1MG**A208357 001** Jun 06, 2019**AB** 0.2MG**A208357 002** Jun 06, 2019

TABLET;SUBLINGUAL

NOCDURNA

+ FERRING PHARMS INC 0.0277MG

N022517 001 Jun 21, 2018

+! 0.0553MG

N022517 002 Jun 21, 2018

DESOGESTREL; ETHINYL ESTRADIOL

TABLET;ORAL-28

BEKYREE**AB** LUPIN LTD 0.15MG,N/A;0.02MG,0.01MG**A202226 001** Aug 12, 2015CYCLESSA**AB** +! ASPEN GLOBAL INC 0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG**N021090 001** Dec 20, 2000DESOGESTREL AND ETHINYL ESTRADIOL**AB** ! DURAMED PHARMS BARR 0.15MG;0.03MG**A075256 002** Aug 12, 1999**AB** MAYNE PHARMA 0.15MG,N/A;0.02MG,0.01MG**A076916 001** Dec 29, 2008**AB** 0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG**A077182 001** Jan 24, 2006**AB** MYLAN LABS LTD 0.15MG,N/A;0.02MG,0.01MG**A202296 001** Aug 30, 2013**AB** NAARI PTE LTD 0.15MG,N/A;0.02MG,0.01MG**A209170 001** Jun 05, 2017**AB** NOVAST LABS 0.15MG;0.03MG**A091234 001** Jul 12, 2013**AB** WATSON LABS 0.15MG;0.03MG**A076915 001** Jul 29, 2005ENSKYCE**AB** LUPIN LTD 0.15MG;0.03MG**A201887 001** Mar 07, 2013ISIBLOOM**AB** XIROMED 0.15MG;0.03MG**A202789 001** Aug 12, 2015KALLIGA**AB** AUROBINDO PHARMA LTD 0.15MG;0.03MG**A207081 001** May 17, 2017KARIVA**AB** ! BARR 0.15MG,N/A;0.02MG,0.01MG**A075863 001** Apr 05, 2002

PRESCRIPTION DRUG PRODUCT LIST

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

KIMIDESS

AB	VINTAGE PHARMS	<u>0.15MG,N/A;0.02MG,0.01MG</u>	<u>A076681 001</u>	Apr 30, 2015
-----------	----------------	---------------------------------	--------------------	--------------

PIMTREA

AB	NOVAST LABS	<u>0.15MG,N/A;0.02MG,0.01MG</u>	<u>A091247 001</u>	Aug 01, 2013
-----------	-------------	---------------------------------	--------------------	--------------

SIMLIYA

AB	AUROBINDO PHARMA LTD	<u>0.15MG,N/A;0.02MG,0.01MG</u>	<u>A206853 001</u>	Mar 22, 2017
-----------	----------------------	---------------------------------	--------------------	--------------

VELIVET

AB	DURAMED PHARMS BARR	<u>0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG</u>	<u>A076455 001</u>	Feb 24, 2004
-----------	---------------------	---	--------------------	--------------

VIORELE

AB	GLENMARK GENERICS	<u>0.15MG,N/A;0.02MG,0.01MG</u>	<u>A091346 001</u>	Apr 02, 2012
-----------	-------------------	---------------------------------	--------------------	--------------

VOLNEA

AB	XIROMED	<u>0.15MG,N/A;0.02MG,0.01MG</u>	<u>A202689 001</u>	Sep 09, 2016
-----------	---------	---------------------------------	--------------------	--------------

DESONIDE

AEROSOL, FOAM; TOPICAL

VERDESO

+! ALMIRALL

0.05%

N021978 001 Sep 19, 2006

CREAM; TOPICAL

DESONIDE

AB	CADILA	<u>0.05%</u>	<u>A210198 001</u>	Nov 20, 2019
-----------	--------	--------------	--------------------	--------------

AB	COSETTE	<u>0.05%</u>	<u>A074027 001</u>	Sep 28, 1992
-----------	---------	--------------	--------------------	--------------

AB	GLENMARK PHARMS	<u>0.05%</u>	<u>A209729 001</u>	Jul 24, 2017
-----------	-----------------	--------------	--------------------	--------------

AB	+! PERRIGO NEW YORK	<u>0.05%</u>	<u>N017010 001</u>	
-----------	---------------------	--------------	--------------------	--

AB	TARO	<u>0.05%</u>	<u>A073548 001</u>	Jun 30, 1992
-----------	------	--------------	--------------------	--------------

DESOWEN

AB	GALDERMA LABS LP	<u>0.05%</u>	<u>N019048 001</u>	Dec 14, 1984
-----------	------------------	--------------	--------------------	--------------

GEL; TOPICAL

DESONATE

AB	+! LEO PHARMA AS	<u>0.05%</u>	<u>N021844 001</u>	Oct 20, 2006
-----------	------------------	--------------	--------------------	--------------

DESONIDE

AB	CINTEX SVCS	<u>0.05%</u>	<u>A202470 001</u>	May 11, 2020
-----------	-------------	--------------	--------------------	--------------

LOTION; TOPICAL

DESONIDE

AB	ALEOR	<u>0.05%</u>	<u>A213632 001</u>	Aug 24, 2020
-----------	-------	--------------	--------------------	--------------

DERMACEUTICALS

AB	FOUGERA PHARMS	<u>0.05%</u>	<u>A075860 001</u>	Mar 19, 2002
-----------	----------------	--------------	--------------------	--------------

AB	GLENMARK PHARMS	<u>0.05%</u>	<u>A209494 001</u>	Sep 26, 2017
-----------	-----------------	--------------	--------------------	--------------

AB	TARO	<u>0.05%</u>	<u>A202161 001</u>	Oct 31, 2014
-----------	------	--------------	--------------------	--------------

AB	TELGENT	<u>0.05%</u>	<u>A207855 001</u>	Sep 28, 2017
-----------	---------	--------------	--------------------	--------------

DESOWEN

AB	! GALDERMA LABS LP	<u>0.05%</u>	<u>A072354 001</u>	Jan 24, 1992
-----------	--------------------	--------------	--------------------	--------------

OINTMENT; TOPICAL

DESONIDE

AB	AKORN	<u>0.05%</u>	<u>A208836 001</u>	Mar 27, 2017
-----------	-------	--------------	--------------------	--------------

AB	ALEOR	<u>0.05%</u>	<u>A212473 001</u>	Oct 23, 2019
-----------	-------	--------------	--------------------	--------------

DERMACEUTICALS

AB	ENCUBE ETHICALS	<u>0.05%</u>	<u>A210998 001</u>	Jan 30, 2019
-----------	-----------------	--------------	--------------------	--------------

AB	FOUGERA PHARMS	<u>0.05%</u>	<u>A075751 001</u>	Mar 12, 2001
-----------	----------------	--------------	--------------------	--------------

AB	GLENMARK PHARMS LTD	<u>0.05%</u>	<u>A209996 001</u>	Sep 15, 2017
-----------	---------------------	--------------	--------------------	--------------

AB	+! PERRIGO NEW YORK	<u>0.05%</u>	<u>N017426 001</u>	
-----------	---------------------	--------------	--------------------	--

AB	TARO	<u>0.05%</u>	<u>A074254 001</u>	Aug 03, 1994
-----------	------	--------------	--------------------	--------------

AB	TELGENT	<u>0.05%</u>	<u>A212002 001</u>	Mar 12, 2019
-----------	---------	--------------	--------------------	--------------

DESOWEN

AB	GALDERMA LABS LP	<u>0.05%</u>	<u>A071425 001</u>	Jun 15, 1988
-----------	------------------	--------------	--------------------	--------------

DESOXIMETASONE

CREAM; TOPICAL

DESOXIMETASONE

AB	ACTAVIS MID ATLANTIC	<u>0.25%</u>	<u>A205082 001</u>	Sep 04, 2015
-----------	----------------------	--------------	--------------------	--------------

AB	AKORN	<u>0.05%</u>	<u>A203787 001</u>	Jan 06, 2017
-----------	-------	--------------	--------------------	--------------

AB		<u>0.25%</u>	<u>A203234 001</u>	Jun 12, 2015
-----------	--	--------------	--------------------	--------------

AB	CADILA	<u>0.25%</u>	<u>A205620 001</u>	Sep 28, 2018
-----------	--------	--------------	--------------------	--------------

AB	COSETTE	<u>0.25%</u>	<u>A209595 001</u>	Mar 04, 2020
-----------	---------	--------------	--------------------	--------------

AB	FOUGERA PHARMS	<u>0.25%</u>	<u>A078369 001</u>	Jun 29, 2010
-----------	----------------	--------------	--------------------	--------------

AB	LUPIN	<u>0.05%</u>	<u>A208163 001</u>	Jan 10, 2017
-----------	-------	--------------	--------------------	--------------

AB		<u>0.25%</u>	<u>A208164 001</u>	Jan 09, 2017
-----------	--	--------------	--------------------	--------------

AB	PERRIGO NEW YORK	<u>0.25%</u>	<u>A076510 001</u>	Jul 01, 2003
-----------	------------------	--------------	--------------------	--------------

AB	RISING	<u>0.05%</u>	<u>A210980 001</u>	Dec 21, 2018
-----------	--------	--------------	--------------------	--------------

AB		<u>0.25%</u>	<u>A205594 001</u>	Jul 02, 2018
-----------	--	--------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

DESOXIMETASONE

CREAM; TOPICAL

TOPICORT

<u>AB</u>	!	TARO PHARM INDS LTD	<u>0.05%</u>	<u>A073210</u>	<u>001</u>	Nov 30, 1990
<u>AB</u>	!		<u>0.25%</u>	<u>A073193</u>	<u>001</u>	Nov 30, 1990

GEL; TOPICAL

DESOXIMETASONE

<u>AB</u>		AKORN	<u>0.05%</u>	<u>A090727</u>	<u>001</u>	Mar 10, 2011
<u>AB</u>		PERRIGO NEW YORK	<u>0.05%</u>	<u>A077552</u>	<u>001</u>	Jan 09, 2006
<u>AB</u>		RISING	<u>0.05%</u>	<u>A204675</u>	<u>001</u>	Aug 12, 2016

TOPICORT

<u>AB</u>	!	TARO PHARM INDS LTD	<u>0.05%</u>	<u>A074904</u>	<u>001</u>	Jul 14, 1998
-----------	---	---------------------	--------------	----------------	------------	--------------

OINTMENT; TOPICAL

DESOXIMETASONE

<u>AB</u>		ACTAVIS MID ATLANTIC	<u>0.25%</u>	<u>A204965</u>	<u>001</u>	Nov 07, 2016
<u>AB</u>		AKORN	<u>0.25%</u>	<u>A201005</u>	<u>001</u>	Apr 24, 2014
<u>AB</u>		CADILA	<u>0.25%</u>	<u>A205206</u>	<u>001</u>	Sep 19, 2017
<u>AB</u>		COSETTE	<u>0.25%</u>	<u>A206740</u>	<u>001</u>	Dec 23, 2016
<u>AB</u>		FOUGERA PHARMS	<u>0.25%</u>	<u>A078657</u>	<u>001</u>	Sep 28, 2012
<u>AB</u>		GLENMARK GENERICS	<u>0.25%</u>	<u>A202838</u>	<u>001</u>	Sep 20, 2013
<u>AB</u>		LUPIN	<u>0.05%</u>	<u>A208044</u>	<u>001</u>	Dec 12, 2016
<u>AB</u>			<u>0.25%</u>	<u>A208104</u>	<u>001</u>	Dec 01, 2016
<u>AB</u>		NOVEL LABS INC	<u>0.25%</u>	<u>A206792</u>	<u>001</u>	May 10, 2016
<u>AB</u>		PERRIGO ISRAEL	<u>0.25%</u>	<u>A077770</u>	<u>001</u>	Apr 20, 2015
<u>AB</u>		RISING	<u>0.25%</u>	<u>A204272</u>	<u>001</u>	Nov 30, 2016
<u>AB</u>		TELIGENT	<u>0.05%</u>	<u>A209973</u>	<u>001</u>	Oct 23, 2018
<u>AB</u>			<u>0.25%</u>	<u>A208101</u>	<u>001</u>	Feb 25, 2016

TOPICORT

<u>AB</u>	+!	TARO PHARM INDS LTD	<u>0.05%</u>	<u>N018594</u>	<u>001</u>	Jan 17, 1985
<u>AB</u>	!		<u>0.25%</u>	<u>A074286</u>	<u>001</u>	Jun 07, 1996

SPRAY; TOPICAL

DESOXIMETASONE

<u>AT</u>		LUPIN	<u>0.25%</u>	<u>A208124</u>	<u>001</u>	Mar 16, 2018
<u>AT</u>		PERRIGO ISRAEL	<u>0.25%</u>	<u>A206441</u>	<u>001</u>	Jan 20, 2017

TOPICORT

<u>AT</u>	+!	TARO PHARMS	<u>0.25%</u>	<u>N204141</u>	<u>001</u>	Apr 11, 2013
-----------	----	-------------	--------------	----------------	------------	--------------

DESVENLAFAXINE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE

+	ALEMBIC PHARMS LTD	50MG	N204150	001	Mar 04, 2013
+	!	100MG	N204150	002	Mar 04, 2013

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE SUCCINATE

<u>AB</u>		ACTAVIS LABS FL	<u>EQ 25MG BASE</u>	<u>A204065</u>	<u>001</u>	Jul 29, 2016
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A204065</u>	<u>002</u>	Jul 29, 2016
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A204065</u>	<u>003</u>	Jul 29, 2016
<u>AB</u>		ALEMBIC PHARMS LTD	<u>EQ 25MG BASE</u>	<u>A204003</u>	<u>003</u>	Sep 14, 2018
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A204003</u>	<u>001</u>	Jun 29, 2015
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A204003</u>	<u>002</u>	Jun 29, 2015
<u>AB</u>		HIKMA	<u>EQ 25MG BASE</u>	<u>A204082</u>	<u>002</u>	Aug 28, 2017
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A204082</u>	<u>001</u>	Feb 16, 2016
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A204083</u>	<u>001</u>	Feb 16, 2016
<u>AB</u>		INTELLIPHARMACEUTIC S	<u>EQ 50MG BASE</u>	<u>A204805</u>	<u>001</u>	May 07, 2019
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A204805</u>	<u>002</u>	May 07, 2019
<u>AB</u>		LUPIN LTD	<u>EQ 50MG BASE</u>	<u>A204172</u>	<u>001</u>	Jun 29, 2015
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A204172</u>	<u>002</u>	Jun 29, 2015
<u>AB</u>		RUBICON	<u>EQ 50MG BASE</u>	<u>A204028</u>	<u>001</u>	Jun 29, 2015
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A204028</u>	<u>002</u>	Jun 29, 2015
<u>AB</u>		YICHANG HUMANWELL	<u>EQ 25MG BASE</u>	<u>A210014</u>	<u>003</u>	Oct 13, 2020
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A210014</u>	<u>001</u>	Oct 01, 2018
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A210014</u>	<u>002</u>	Oct 01, 2018
<u>AB</u>		ZYDUS PHARMS	<u>EQ 50MG BASE</u>	<u>A204020</u>	<u>001</u>	Oct 11, 2017
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A204020</u>	<u>002</u>	Oct 11, 2017

PRISTIQ

<u>AB</u>	+	PF PRISM CV	<u>EQ 25MG BASE</u>	<u>N021992</u>	<u>003</u>	Aug 20, 2014
<u>AB</u>	+		<u>EQ 50MG BASE</u>	<u>N021992</u>	<u>001</u>	Feb 29, 2008
<u>AB</u>	+!		<u>EQ 100MG BASE</u>	<u>N021992</u>	<u>002</u>	Feb 29, 2008

PRESCRIPTION DRUG PRODUCT LIST

DEUTETRABENAZINE

TABLET; ORAL

AUSTEDO

+	TEVA BRANDED PHARM	6MG	N208082	001	Apr 03, 2017
+		9MG	N208082	002	Apr 03, 2017
+	!	12MG	N208082	003	Apr 03, 2017

DEXAMETHASONE

CONCENTRATE; ORAL

DEXAMETHASONE INTENSOL

!	HIKMA	1MG/ML	A088252	001	Sep 01, 1983
---	-------	--------	---------	-----	--------------

ELIXIR; ORAL

DEXAMETHASONE

AA	!	ANIMA	<u>0.5MG/5ML</u>	<u>A084754</u>	<u>001</u>	
AA		LANNETT CO INC	<u>0.5MG/5ML</u>	<u>A091188</u>	<u>001</u>	May 11, 2011
AA		LYNE	<u>0.5MG/5ML</u>	<u>A090891</u>	<u>001</u>	Jul 12, 2011
AA		WOCKHARDT BIO AG	<u>0.5MG/5ML</u>	<u>A088254</u>	<u>001</u>	Jul 27, 1983

IMPLANT; INTRAVITREAL

OZURDEX

+	ALLERGAN	0.7MG	N022315	001	Jun 17, 2009
---	----------	-------	---------	-----	--------------

INSERT; OPHTHALMIC

DEXTENZA

+	OCULAR THERAPEUTIX	0.4MG	N208742	001	Nov 30, 2018
---	--------------------	-------	---------	-----	--------------

SOLUTION; ORAL

DEXAMETHASONE

!	HIKMA	0.5MG/5ML	A088248	001	Sep 01, 1983
---	-------	-----------	---------	-----	--------------

SUSPENSION; INTRAOCULAR

DEXYCU KIT

+	EYEPOINT PHARMS	9%	N208912	001	Feb 09, 2018
---	-----------------	----	---------	-----	--------------

SUSPENSION/DROPS; OPHTHALMIC

MAXIDEX

+	NOVARTIS	0.1%	N013422	001	
---	----------	------	---------	-----	--

TABLET; ORAL

DEXAMETHASONE

AB		ECR	<u>1.5MG</u>	<u>A040700</u>	<u>001</u>	Aug 15, 2008
AB		HIKMA	<u>1.5MG</u>	<u>A084610</u>	<u>001</u>	
AB		LARKEN LABS INC	<u>1.5MG</u>	<u>A201270</u>	<u>001</u>	Jul 17, 2017
BP		FERA PHARMS LLC	0.5MG	A088481	002	Apr 28, 1983
BP			0.75MG	A088481	003	Apr 28, 1983
BP			4MG	A088481	004	Apr 28, 1983
BP			6MG	A088481	001	Nov 28, 1983
BP		HIKMA	0.5MG	A084611	001	
BP			0.75MG	A084613	001	
BP			1MG	A088306	001	Sep 15, 1983
BP			2MG	A087916	001	Aug 26, 1982
BP			4MG	A084612	001	
BP	!		6MG	A088316	001	Sep 15, 1983
BP		XSPIRE PHARMA	1.5MG	A088237	001	Apr 28, 1983
		HEMADY				
	+	DEXCEL PHARMA	20MG	N211379	001	Oct 03, 2019

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

AP		AMNEAL	<u>EQ 4MG PHOSPHATE/ML</u>	<u>A208689</u>	<u>001</u>	Aug 22, 2018
AP		AUROBINDO PHARMA LTD	<u>EQ 4MG PHOSPHATE/ML</u>	<u>A206781</u>	<u>001</u>	Dec 01, 2015
AP			<u>EQ 10MG PHOSPHATE/ML</u>	<u>A210966</u>	<u>001</u>	Jun 05, 2020
AP			<u>EQ 10MG PHOSPHATE/ML</u>	<u>A210967</u>	<u>001</u>	Jun 07, 2019
AP	!	FRESENIUS KABI USA	<u>EQ 4MG PHOSPHATE/ML</u>	<u>A084916</u>	<u>001</u>	
AP			<u>EQ 4MG PHOSPHATE/ML</u>	<u>A203129</u>	<u>001</u>	Sep 30, 2015
AP	!		<u>EQ 10MG PHOSPHATE/ML</u>	<u>A040572</u>	<u>001</u>	Apr 22, 2005
AP			<u>EQ 10MG PHOSPHATE/ML</u>	<u>A209192</u>	<u>001</u>	Jul 06, 2018
AP		MYLAN LABS LTD	<u>EQ 4MG PHOSPHATE/ML</u>	<u>A040803</u>	<u>001</u>	Aug 29, 2008
AP			<u>EQ 10MG PHOSPHATE/ML</u>	<u>A040802</u>	<u>001</u>	Aug 29, 2008
AP		SOMERSET	<u>EQ 4MG PHOSPHATE/ML</u>	<u>A207521</u>	<u>001</u>	Jun 08, 2018
AP		SOMERSET THERAPS LLC	<u>EQ 10MG PHOSPHATE/ML</u>	<u>A211036</u>	<u>001</u>	May 10, 2019
AP		WEST-WARD PHARMS INT	<u>EQ 4MG PHOSPHATE/ML</u>	<u>A084282</u>	<u>001</u>	
AP	!		<u>EQ 10MG PHOSPHATE/ML</u>	<u>A087702</u>	<u>001</u>	Sep 07, 1982
		<u>DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE</u>				
AP		AMNEAL	<u>EQ 10MG PHOSPHATE/ML</u>	<u>A208690</u>	<u>001</u>	Aug 22, 2018
AP	!	FRESENIUS KABI USA	<u>EQ 10MG PHOSPHATE/ML</u>	<u>A040491</u>	<u>001</u>	Apr 11, 2003

PRESCRIPTION DRUG PRODUCT LIST

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE

AP	SOMERSET THERAPS LLC	EQ 10MG PHOSPHATE/ML	A207442 001	Apr 19, 2018
	SOLUTION/DROPS; OPHTHALMIC, OTIC			
	DEXAMETHASONE SODIUM PHOSPHATE			
	! BAUSCH AND LOMB	EQ 0.1% PHOSPHATE	A040069 001	Jul 26, 1996

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

MAXITROL

AT	+! NOVARTIS	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050065 002	
	<u>NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE</u>			
AT	BAUSCH AND LOMB	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A064063 001	Jul 25, 1994
AT	PERRIGO CO TENNESSEE	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062938 001	Jul 31, 1989

SUSPENSION/DROPS; OPHTHALMIC

DEXASPORIN

AT	BAUSCH AND LOMB	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A064135 001	Sep 13, 1995
	<u>MAXITROL</u>			
AT	+! NOVARTIS	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050023 002	
AT	SANDOZ INC	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062341 001	May 22, 1984

DEXAMETHASONE; TOBRAMYCIN

OINTMENT; OPHTHALMIC

TOBRADEX

	+! NOVARTIS	0.1%;0.3%	N050616 001	Sep 28, 1988
	SUSPENSION/DROPS; OPHTHALMIC			

TOBRADEX

AB	+! NOVARTIS	0.1%;0.3%	N050592 001	Aug 18, 1988
	<u>TOBRAMYCIN AND DEXAMETHASONE</u>			
AB	BAUSCH AND LOMB	0.1%;0.3%	A064134 001	Oct 27, 1999
	TOBRADEX ST			
	+! EYEVANCE	0.05%;0.3%	N050818 001	Feb 13, 2009

DEXCHLORPHENIRAMINE MALEATE

SYRUP; ORAL

DEXCHLORPHENIRAMINE MALEATE

AA	! WOCKHARDT BIO AG	2MG/5ML	A088251 001	Mar 23, 1984
	<u>POLMON</u>			
AA	CAPELLON PHARMS LLC	2MG/5ML	A202520 001	Jul 16, 2018

DEXLANSOPRAZOLE

CAPSULE, DELAYED RELEASE; ORAL

DEXILANT

AB	+! TAKEDA PHARMS USA	60MG	N022287 002	Jan 30, 2009
	<u>DEXLANSOPRAZOLE</u>			
AB	PAR PHARM INC	60MG	A202294 001	Apr 19, 2017
	DEXILANT			
	+ TAKEDA PHARMS USA	30MG	N022287 001	Jan 30, 2009

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AP	ACCORD HLTHCARE	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A204023 001	Feb 09, 2016
AP	ACTAVIS INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A204686 001	Oct 17, 2016
AP	AKORN INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A202585 001	Nov 24, 2014
AP	AMNEAL PHARMS CO	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A207551 001	May 20, 2020
AP		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A207551 002	May 20, 2020
AP	AUROBINDO PHARMA LTD	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A205867 001	Mar 17, 2016
AP		EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A210321 001	Dec 07, 2020
AP		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A210321 002	Dec 07, 2020
AP	BAXTER HLTHCARE CORP	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A208532 001	Aug 21, 2018
AP		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A208532 002	Aug 21, 2018
AP	FRESENIUS KABI USA	EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)	A208129 001	Nov 29, 2018
AP		EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A201072 001	Sep 18, 2015
AP		EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A208129 002	Nov 29, 2018
AP		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A208129 003	Nov 29, 2018
AP	GLAND PHARMA LTD	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A209307 001	Jun 03, 2020
AP		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A209307 002	Jun 03, 2020
AP	HIKMA	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A206407 001	Jan 30, 2020
AP		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A206407 002	Jan 30, 2020
AP	JIANGSU HENGRUI MED	EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)	A209065 002	Jun 12, 2020

PRESCRIPTION DRUG PRODUCT LIST

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

<u>AP</u>		<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A209065 001</u>	Sep 19, 2017
<u>AP</u>		<u>EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)</u>	<u>A209065 003</u>	Jun 12, 2020
<u>AP</u>		<u>EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)</u>	<u>A209065 004</u>	Jun 12, 2020
<u>AP</u>	MYLAN INSTITUTIONAL	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A202881 001</u>	Aug 18, 2014
<u>AP</u>	MYLAN LABS LTD	<u>EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)</u>	<u>A212571 001</u>	Aug 27, 2020
<u>AP</u>		<u>EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)</u>	<u>A212571 002</u>	Aug 27, 2020
<u>AP</u>	PAR STERILE PRODUCTS	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A203972 001</u>	Aug 18, 2014
<u>AP</u>		<u>EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)</u>	<u>A208266 001</u>	Sep 15, 2020
<u>AP</u>		<u>EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)</u>	<u>A208266 002</u>	Sep 15, 2020
<u>AP</u>	SANDOZ INC	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A091465 001</u>	Jun 14, 2016
<u>AP</u>	SLAYBACK PHARMA LLC	<u>EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)</u>	<u>A212791 001</u>	Dec 04, 2019
<u>AP</u>		<u>EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)</u>	<u>A212791 002</u>	Dec 04, 2019
<u>AP</u>	SUN PHARM INDS INC	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A202126 001</u>	Aug 20, 2015
<u>AP</u>	TAGI	<u>EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)</u>	<u>A212857 001</u>	Nov 23, 2020
<u>AP</u>		<u>EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)</u>	<u>A212857 002</u>	Nov 23, 2020
<u>AP</u>		<u>EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)</u>	<u>A212857 003</u>	Nov 23, 2020
<u>AP</u>	TEVA PHARMS USA	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A205272 001</u>	Nov 28, 2017
<u>AP</u>	WEST-WARD PHARMS INT	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A205046 001</u>	Apr 26, 2017
<u>AP</u>	ZYDUS PHARMS	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A206798 001</u>	Feb 27, 2018

PRECEDEX

<u>AP</u>	+!	HOSPIRA	<u>EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)</u>	<u>N021038 004</u>	Nov 14, 2014
<u>AP</u>	+!		<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>N021038 001</u>	Dec 17, 1999
<u>AP</u>	+!		<u>EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)</u>	<u>N021038 002</u>	Mar 13, 2013
<u>AP</u>	+!		<u>EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)</u>	<u>N021038 003</u>	Mar 13, 2013
	+!		<u>EQ 1MG BASE/250ML (EQ 4MCG BASE/ML)</u>	<u>N021038 005</u>	Jan 31, 2020

SOLUTION; INTRAVENOUS

DEXMEDETOMIDINE HYDROCHLORIDE

+!	HQ SPCLT PHARMA	<u>EQ 1MG BASE/10ML (EQ 100MCG BASE/ML)</u>	<u>N206628 002</u>	Oct 21, 2015
+		<u>EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)</u>	<u>N206628 003</u>	Jun 22, 2018
+		<u>EQ 400MCG BASE/4ML (EQ 100MCG BASE/ML)</u>	<u>N206628 001</u>	Oct 21, 2015
+		<u>EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)</u>	<u>N206628 004</u>	Jun 22, 2018

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>	ADARE PHARMS INC	<u>5MG</u>	<u>A210279 001</u>	Oct 09, 2018
<u>AB</u>		<u>10MG</u>	<u>A210279 002</u>	Oct 09, 2018
<u>AB</u>		<u>15MG</u>	<u>A210279 003</u>	Oct 09, 2018
<u>AB</u>		<u>20MG</u>	<u>A210279 004</u>	Oct 09, 2018
<u>AB</u>		<u>25MG</u>	<u>A210279 005</u>	Oct 09, 2018
<u>AB</u>		<u>30MG</u>	<u>A210279 006</u>	Oct 09, 2018
<u>AB</u>		<u>35MG</u>	<u>A210279 007</u>	Oct 09, 2018
<u>AB</u>		<u>40MG</u>	<u>A210279 008</u>	Oct 09, 2018
<u>AB</u>	GRANULES PHARMS	<u>5MG</u>	<u>A213813 001</u>	Sep 09, 2020
<u>AB</u>		<u>10MG</u>	<u>A213813 002</u>	Sep 09, 2020
<u>AB</u>		<u>15MG</u>	<u>A213813 003</u>	Sep 09, 2020
<u>AB</u>		<u>20MG</u>	<u>A213813 004</u>	Sep 09, 2020
<u>AB</u>		<u>25MG</u>	<u>A213813 005</u>	Sep 09, 2020
<u>AB</u>		<u>30MG</u>	<u>A213813 006</u>	Sep 09, 2020
<u>AB</u>		<u>35MG</u>	<u>A213813 007</u>	Sep 09, 2020
<u>AB</u>		<u>40MG</u>	<u>A213813 008</u>	Sep 09, 2020
<u>AB</u>	IMPAX LABS INC	<u>5MG</u>	<u>A079108 001</u>	Aug 05, 2015
<u>AB</u>		<u>10MG</u>	<u>A079108 002</u>	Aug 05, 2015
<u>AB</u>		<u>15MG</u>	<u>A079108 003</u>	May 19, 2014
<u>AB</u>		<u>20MG</u>	<u>A079108 004</u>	Dec 21, 2015
<u>AB</u>		<u>25MG</u>	<u>A203614 001</u>	Jul 05, 2017
<u>AB</u>		<u>30MG</u>	<u>A079108 005</u>	Nov 21, 2013
<u>AB</u>		<u>35MG</u>	<u>A203614 002</u>	Jul 05, 2017
<u>AB</u>	INTELLIPHARMACEUTICS	<u>15MG</u>	<u>A078992 003</u>	Nov 18, 2013
<u>AB</u>		<u>30MG</u>	<u>A078992 004</u>	Nov 18, 2013
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A204266 001</u>	Aug 25, 2015
<u>AB</u>		<u>10MG</u>	<u>A204266 002</u>	Aug 25, 2015
<u>AB</u>		<u>15MG</u>	<u>A204266 003</u>	Aug 25, 2015
<u>AB</u>		<u>20MG</u>	<u>A204266 004</u>	Dec 21, 2015
<u>AB</u>		<u>30MG</u>	<u>A202580 001</u>	Aug 28, 2013
<u>AB</u>		<u>40MG</u>	<u>A204266 007</u>	Aug 25, 2015
<u>AB</u>	PAR PHARM INC	<u>5MG</u>	<u>A202842 001</u>	Nov 30, 2016

PRESCRIPTION DRUG PRODUCT LIST

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>		<u>10MG</u>	<u>A202842 002</u>	Nov 30, 2016	
<u>AB</u>		<u>15MG</u>	<u>A202842 003</u>	Nov 30, 2016	
<u>AB</u>		<u>20MG</u>	<u>A202842 004</u>	Nov 30, 2016	
<u>AB</u>		<u>25MG</u>	<u>A202842 005</u>	Nov 30, 2016	
<u>AB</u>		<u>30MG</u>	<u>A202842 006</u>	Nov 30, 2016	
<u>AB</u>		<u>35MG</u>	<u>A202842 007</u>	Nov 30, 2016	
<u>AB</u>		<u>40MG</u>	<u>A202842 008</u>	Nov 30, 2016	
<u>AB</u>	TEVA PHARMS USA	<u>5MG</u>	<u>A078908 001</u>	Nov 19, 2013	
<u>AB</u>		<u>10MG</u>	<u>A078908 002</u>	Nov 19, 2013	
<u>AB</u>		<u>15MG</u>	<u>A078908 004</u>	May 19, 2014	
<u>AB</u>		<u>20MG</u>	<u>A078908 003</u>	Nov 19, 2013	
<u>AB</u>		<u>25MG</u>	<u>A202731 001</u>	Jul 05, 2017	
<u>AB</u>		<u>30MG</u>	<u>A202731 003</u>	May 19, 2014	
<u>AB</u>		<u>35MG</u>	<u>A202731 004</u>	Jul 05, 2017	
<u>AB</u>		<u>40MG</u>	<u>A202731 002</u>	Nov 19, 2013	
<u>FOCALIN XR</u>					
<u>AB</u>	+	NOVARTIS	<u>5MG</u>	<u>N021802 001</u>	May 26, 2005
<u>AB</u>	+		<u>10MG</u>	<u>N021802 002</u>	May 26, 2005
<u>AB</u>	+		<u>15MG</u>	<u>N021802 004</u>	Aug 01, 2006
<u>AB</u>	+		<u>20MG</u>	<u>N021802 003</u>	May 26, 2005
<u>AB</u>	+		<u>25MG</u>	<u>N021802 008</u>	Apr 21, 2011
<u>AB</u>	+		<u>30MG</u>	<u>N021802 005</u>	Oct 23, 2009
<u>AB</u>	+		<u>35MG</u>	<u>N021802 007</u>	Apr 21, 2011
<u>AB</u>	+		<u>40MG</u>	<u>N021802 006</u>	Aug 11, 2010

TABLET;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>	ABHAI INC	<u>2.5MG</u>	<u>A206931 001</u>	Dec 04, 2015	
<u>AB</u>		<u>5MG</u>	<u>A206931 002</u>	Dec 04, 2015	
<u>AB</u>		<u>10MG</u>	<u>A206931 003</u>	Dec 04, 2015	
<u>AB</u>	ALKEM LABS LTD	<u>2.5MG</u>	<u>A212631 001</u>	Jul 19, 2019	
<u>AB</u>		<u>5MG</u>	<u>A212631 002</u>	Jul 19, 2019	
<u>AB</u>		<u>10MG</u>	<u>A212631 003</u>	Jul 19, 2019	
<u>AB</u>	CEDIPROF INC	<u>5MG</u>	<u>A209211 001</u>	Sep 19, 2018	
<u>AB</u>		<u>10MG</u>	<u>A209211 002</u>	Sep 19, 2018	
<u>AB</u>	NOVEL LABS INC	<u>2.5MG</u>	<u>A204534 001</u>	Dec 04, 2015	
<u>AB</u>		<u>5MG</u>	<u>A204534 002</u>	Dec 04, 2015	
<u>AB</u>		<u>10MG</u>	<u>A204534 003</u>	Dec 04, 2015	
<u>AB</u>	RHODES PHARMS	<u>2.5MG</u>	<u>A208756 001</u>	Nov 20, 2017	
<u>AB</u>		<u>5MG</u>	<u>A208756 002</u>	Nov 20, 2017	
<u>AB</u>		<u>10MG</u>	<u>A208756 003</u>	Nov 20, 2017	
<u>AB</u>	SUN PHARM INDUSTRIES	<u>2.5MG</u>	<u>A201231 001</u>	Sep 24, 2015	
<u>AB</u>		<u>5MG</u>	<u>A201231 002</u>	Sep 24, 2015	
<u>AB</u>		<u>10MG</u>	<u>A201231 003</u>	Sep 24, 2015	
<u>AB</u>	TRIS PHARMA INC	<u>2.5MG</u>	<u>A207901 001</u>	Aug 26, 2016	
<u>AB</u>		<u>5MG</u>	<u>A207901 002</u>	Aug 26, 2016	
<u>AB</u>		<u>10MG</u>	<u>A207901 003</u>	Aug 26, 2016	
<u>FOCALIN</u>					
<u>AB</u>	+	NOVARTIS	<u>2.5MG</u>	<u>N021278 001</u>	Nov 13, 2001
<u>AB</u>	+		<u>5MG</u>	<u>N021278 002</u>	Nov 13, 2001
<u>AB</u>	+		<u>10MG</u>	<u>N021278 003</u>	Nov 13, 2001

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE;INJECTION

DEXRAZOXANE HYDROCHLORIDE

<u>AP</u>	GLAND PHARMA LTD	<u>EQ 250MG BASE/VIAL</u>	<u>A207321 002</u>	Dec 16, 2019	
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A207321 001</u>	Nov 28, 2016	
<u>AP</u>	MYLAN INSTITUTIONAL	<u>EQ 250MG BASE/VIAL</u>	<u>A200752 001</u>	Oct 19, 2011	
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A200752 002</u>	Oct 19, 2011	
<u>AP</u>	WEST-WARD PHARMS INT	<u>EQ 250MG BASE/VIAL</u>	<u>A076068 001</u>	Sep 28, 2004	
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A076068 002</u>	Sep 28, 2004	
<u>ZINECARD</u>					
<u>AP</u>	+	PHARMACIA AND UPJOHN	<u>EQ 250MG BASE/VIAL</u>	<u>N020212 001</u>	May 26, 1995
<u>AP</u>	+		<u>EQ 500MG BASE/VIAL</u>	<u>N020212 002</u>	May 26, 1995
TOTECT					
	+	CLINIGEN	<u>EQ 500MG BASE/VIAL</u>	<u>N022025 001</u>	Sep 06, 2007

PRESCRIPTION DRUG PRODUCT LIST

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXEDRINE

<u>AB</u>	+	IMPAX LABS INC	<u>5MG</u>	<u>N017078</u>	<u>001</u>	
<u>AB</u>	+		<u>10MG</u>	<u>N017078</u>	<u>002</u>	
<u>AB</u>	+	!	<u>15MG</u>	<u>N017078</u>	<u>003</u>	

DEXTROAMPHETAMINE SULFATE

<u>AB</u>		ACTAVIS ELIZABETH	<u>5MG</u>	<u>A203901</u>	<u>001</u>	Nov 30, 2012
<u>AB</u>			<u>10MG</u>	<u>A203901</u>	<u>002</u>	Nov 30, 2012
<u>AB</u>			<u>15MG</u>	<u>A203901</u>	<u>003</u>	Nov 30, 2012
<u>AB</u>		MAYNE PHARMA	<u>5MG</u>	<u>A076137</u>	<u>001</u>	Jan 18, 2002
<u>AB</u>			<u>10MG</u>	<u>A076137</u>	<u>002</u>	Jan 18, 2002
<u>AB</u>			<u>15MG</u>	<u>A076137</u>	<u>003</u>	Jan 18, 2002
<u>AB</u>		NESHER PHARMS	<u>5MG</u>	<u>A209111</u>	<u>001</u>	Jun 27, 2017
<u>AB</u>			<u>10MG</u>	<u>A209111</u>	<u>002</u>	Jun 27, 2017
<u>AB</u>			<u>15MG</u>	<u>A209111</u>	<u>003</u>	Jun 27, 2017
<u>AB</u>		SPECGX LLC	<u>5MG</u>	<u>A076353</u>	<u>001</u>	May 06, 2003
<u>AB</u>			<u>10MG</u>	<u>A076353</u>	<u>002</u>	May 06, 2003
<u>AB</u>			<u>15MG</u>	<u>A076353</u>	<u>003</u>	May 06, 2003
<u>AB</u>		VINTAGE PHARMS	<u>5MG</u>	<u>A205673</u>	<u>001</u>	Oct 31, 2017
<u>AB</u>			<u>10MG</u>	<u>A205673</u>	<u>002</u>	Oct 31, 2017
<u>AB</u>			<u>15MG</u>	<u>A205673</u>	<u>003</u>	Oct 31, 2017

SOLUTION;ORAL

DEXTROAMPHETAMINE SULFATE

<u>AA</u>	!	OUTLOOK PHARMS	<u>5MG/5ML</u>	<u>A040776</u>	<u>001</u>	Jan 29, 2008
<u>AA</u>		TRIS PHARMA INC	<u>5MG/5ML</u>	<u>A203644</u>	<u>001</u>	May 29, 2013

TABLET;ORAL

DEXTROAMPHETAMINE SULFATE

<u>AA</u>		ARBOR PHARMS LLC	<u>5MG</u>	<u>A090533</u>	<u>002</u>	Oct 25, 2011
<u>AA</u>			<u>10MG</u>	<u>A090533</u>	<u>004</u>	Oct 25, 2011
<u>AA</u>		AUROLIFE PHARMA LLC	<u>5MG</u>	<u>A202893</u>	<u>001</u>	Jul 31, 2013
<u>AA</u>			<u>10MG</u>	<u>A202893</u>	<u>002</u>	Jul 31, 2013
<u>AA</u>		AVANTHI INC	<u>5MG</u>	<u>A203548</u>	<u>001</u>	Nov 23, 2015
<u>AA</u>			<u>10MG</u>	<u>A203548</u>	<u>002</u>	Nov 23, 2015
<u>AA</u>		BARR	<u>5MG</u>	<u>A040361</u>	<u>001</u>	Jan 31, 2001
<u>AA</u>	!		<u>10MG</u>	<u>A040361</u>	<u>002</u>	Jan 31, 2001
<u>AA</u>		NESHER PHARMS	<u>5MG</u>	<u>A206588</u>	<u>001</u>	Mar 28, 2016
<u>AA</u>			<u>10MG</u>	<u>A206588</u>	<u>002</u>	Mar 28, 2016
<u>AA</u>		NOVEL LABS INC	<u>5MG</u>	<u>A204330</u>	<u>001</u>	Mar 16, 2016
<u>AA</u>			<u>10MG</u>	<u>A204330</u>	<u>002</u>	Mar 16, 2016
<u>AA</u>		NUVO PHARM	<u>5MG</u>	<u>A210059</u>	<u>001</u>	Oct 18, 2017
<u>AA</u>			<u>10MG</u>	<u>A210059</u>	<u>002</u>	Oct 18, 2017
<u>AA</u>		SPECGX LLC	<u>5MG</u>	<u>A040436</u>	<u>001</u>	Jan 29, 2002
<u>AA</u>			<u>10MG</u>	<u>A040436</u>	<u>002</u>	Jan 29, 2002
		ARBOR PHARMS LLC	2.5MG	A090533	001	Oct 25, 2011
			7.5MG	A090533	003	Oct 25, 2011
			15MG	A090533	005	Oct 25, 2011
			20MG	A090533	006	Oct 25, 2011
			30MG	A090533	007	Oct 25, 2011

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE DM

<u>AA</u>	!	SLATE	<u>15MG/5ML;6.25MG/5ML</u>	<u>A040649</u>	<u>001</u>	Feb 14, 2006
-----------	---	-------	----------------------------	----------------	------------	--------------

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

<u>AA</u>		AMNEAL PHARMS	<u>15MG/5ML;6.25MG/5ML</u>	<u>A090575</u>	<u>001</u>	Feb 08, 2011
-----------	--	---------------	----------------------------	----------------	------------	--------------

PROMETHAZINE W/ DEXTROMETHORPHAN

<u>AA</u>		WOCKHARDT BIO AG	<u>15MG/5ML;6.25MG/5ML</u>	<u>A088864</u>	<u>001</u>	Jan 04, 1985
-----------	--	------------------	----------------------------	----------------	------------	--------------

DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE

CAPSULE;ORAL

DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE

<u>AB</u>		ACTAVIS ELIZABETH	<u>20MG;10MG</u>	<u>A202934</u>	<u>001</u>	Oct 10, 2017
-----------	--	-------------------	------------------	----------------	------------	--------------

NUDEXTA

<u>AB</u>	+	AVANIR PHARMS	<u>20MG;10MG</u>	<u>N021879</u>	<u>001</u>	Oct 29, 2010
-----------	---	---------------	------------------	----------------	------------	--------------

DEXTROSE

INJECTABLE;INJECTION

DEXTROSE 10% IN PLASTIC CONTAINER

<u>AP</u>	+	!	B BRAUN	<u>10GM/100ML</u>	<u>N019626</u>	<u>004</u>	Feb 02, 1988
<u>AP</u>	+	!	BAXTER HLTHCARE	<u>10GM/100ML</u>	<u>N016694</u>	<u>001</u>	
<u>AP</u>			FRESENIUS KABI USA	<u>10GM/100ML</u>	<u>A209448</u>	<u>001</u>	Jul 16, 2018
<u>AP</u>	+	!	ICU MEDICAL INC	<u>10GM/100ML</u>	<u>N018080</u>	<u>001</u>	

PRESCRIPTION DRUG PRODUCT LISTDEXTROSE

INJECTABLE; INJECTION

DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+	B BRAUN	<u>50MG/ML</u>	<u>N016730 002</u>	
<u>AP</u>	+		<u>5GM/100ML</u>	<u>N016730 001</u>	
<u>AP</u>	+		<u>5GM/100ML</u>	<u>N019626 002</u>	Feb 02, 1988
<u>AP</u>	+	BAXTER HLTHCARE	<u>50MG/ML</u>	<u>N016673 003</u>	Oct 30, 1985
<u>AP</u>	+		<u>50MG/ML</u>	<u>N020179 002</u>	Dec 07, 1992
<u>AP</u>	+		<u>5GM/100ML</u>	<u>N016673 001</u>	
<u>AP</u>	+		<u>5GM/100ML</u>	<u>N020179 001</u>	Dec 07, 1992
<u>AP</u>		FRESENIUS KABI USA	<u>50MG/ML</u>	<u>A207449 001</u>	Oct 21, 2016
<u>AP</u>	+	HOSPIRA	<u>5GM/100ML</u>	<u>N019466 001</u>	Jul 15, 1985
<u>AP</u>	+		<u>5GM/100ML</u>	<u>N019479 001</u>	Sep 17, 1985
<u>AP</u>	+	ICU MEDICAL INC	<u>50MG/ML</u>	<u>N016367 002</u>	

DEXTROSE 50% IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>50GM/100ML</u>	<u>N020047 001</u>	Jul 02, 1991
<u>AP</u>	+	ICU MEDICAL INC	<u>50GM/100ML</u>	<u>N018563 001</u>	Mar 23, 1982

DEXTROSE 70% IN PLASTIC CONTAINER

<u>AP</u>	+	B BRAUN	<u>70GM/100ML</u>	<u>N019626 005</u>	Feb 18, 2015
<u>AP</u>	+	BAXTER HLTHCARE	<u>70GM/100ML</u>	<u>N020047 003</u>	Jul 02, 1991
<u>AP</u>	+	ICU MEDICAL INC	<u>70GM/100ML</u>	<u>N018561 001</u>	Mar 23, 1982
<u>AP</u>	+		<u>70GM/100ML</u>	<u>N019893 001</u>	Dec 26, 1989

DEXTROSE 20% IN PLASTIC CONTAINER

+! ICU MEDICAL INC 20GM/100ML N018564 001 Mar 23, 1982

DEXTROSE 25%

+! HOSPIRA 250MG/ML N019445 002 Nov 23, 1998

DEXTROSE 30% IN PLASTIC CONTAINER

+! ICU MEDICAL INC 30GM/100ML N019345 001 Jan 26, 1985

DEXTROSE 40% IN PLASTIC CONTAINER

+! ICU MEDICAL INC 40GM/100ML N018562 001 Mar 23, 1982

DEXTROSE 50%

+ HOSPIRA 500MG/ML N019445 003 Sep 03, 2014

DEXTROSE 50% IN PLASTIC CONTAINER

+ HOSPIRA 500MG/ML N019445 001 Jun 03, 1986

DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER

ICU MEDICAL INC 5GM/100ML; 21MG/100ML; 128MG/100ML; 234MG/100ML N017610 001

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE; INJECTION

ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML; 31MG/100ML; 130MG/100ML; 26MG/100ML; 320MG/100ML N019873 001 Jun 10, 1993

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER

BAXTER HLTHCARE 5GM/100ML; 31MG/100ML; 141MG/100ML; 20MG/100ML; 12MG/100ML; 260MG/100ML N017484 001

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE; INJECTION

IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER

ICU MEDICAL INC 5GM/100ML; 30MG/100ML; 141MG/100ML; 15MG/100ML; 260MG/100ML; 25MG/100ML N019513 001 May 08, 1986

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER

ICU MEDICAL INC 5GM/100ML; 30MG/100ML; 37MG/100ML; 222MG/100ML; 526MG/100ML; 502MG/100ML N017609 001

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075%AP FRESENIUS KABI USA 5GM/100ML; 75MG/100ML A212346 001 Sep 10, 2020DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINERAP + BAXTER HLTHCARE 5GM/100ML; 75MG/100ML N017634 004DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15%AP FRESENIUS KABI USA 5GM/100ML; 150MG/100ML A212346 002 Sep 10, 2020

PRESCRIPTION DRUG PRODUCT LIST

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

<u>DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER</u>					
AP	+	BAXTER HLTHCARE	5GM/100ML;150MG/100ML	N017634 001	
<u>DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER</u>					
AP	+	BAXTER HLTHCARE	5GM/100ML;224MG/100ML	N017634 003	
<u>DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER</u>					
AP	+	BAXTER HLTHCARE	5GM/100ML;300MG/100ML	N017634 002	
<u>POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER</u>					
AP		B BRAUN	5GM/100ML;150MG/100ML	N019699 004	Sep 29, 1989
<u>POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER</u>					
AP		B BRAUN	5GM/100ML;300MG/100ML	N019699 006	Sep 29, 1989
		POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER			
		ICU MEDICAL INC	5GM/100ML;149MG/100ML	N018371 001	

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

<u>DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ</u>					
AP		BAXTER HLTHCARE	5GM/100ML;75MG/100ML;200MG/100ML	N018037 006	Apr 13, 1982
AP		BAXTER HLTHCARE	5GM/100ML;150MG/100ML;200MG/100ML	N018037 007	Apr 13, 1982
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K)</u>					
AP		BAXTER HLTHCARE	5GM/100ML;224MG/100ML;200MG/100ML	N018037 004	
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ</u>					
AP		BAXTER HLTHCARE	5GM/100ML;150MG/100ML;200MG/100ML	N018037 008	Apr 13, 1982
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K)</u>					
AP		BAXTER HLTHCARE	5GM/100ML;300MG/100ML;200MG/100ML	N018037 001	
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ</u>					
AP		BAXTER HLTHCARE	5GM/100ML;224MG/100ML;200MG/100ML	N018037 005	Apr 13, 1982
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ</u>					
AP		BAXTER HLTHCARE	5GM/100ML;300MG/100ML;200MG/100ML	N018037 009	Apr 13, 1982
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ</u>					
AP		BAXTER HLTHCARE	5GM/100ML;75MG/100ML;200MG/100ML	N018037 002	
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K)</u>					
AP		BAXTER HLTHCARE	5GM/100ML;150MG/100ML;200MG/100ML	N018037 003	
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER</u>					
AP		BAXTER HLTHCARE	5GM/100ML;75MG/100ML;330MG/100ML	N018629 005	Mar 23, 1982
AP		BAXTER HLTHCARE	5GM/100ML;150MG/100ML;330MG/100ML	N018629 002	Mar 23, 1982
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER</u>					
AP		BAXTER HLTHCARE	5GM/100ML;224MG/100ML;330MG/100ML	N018629 003	Mar 23, 1982
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER</u>					
AP		BAXTER HLTHCARE	5GM/100ML;150MG/100ML;330MG/100ML	N018629 004	Mar 23, 1982
AP		BAXTER HLTHCARE	5GM/100ML;300MG/100ML;330MG/100ML	N018629 006	Mar 23, 1982
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER</u>					
AP		BAXTER HLTHCARE	5GM/100ML;224MG/100ML;330MG/100ML	N018629 007	Mar 23, 1982
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER</u>					
AP		BAXTER HLTHCARE	5GM/100ML;300MG/100ML;330MG/100ML	N018629 008	Mar 23, 1982
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER</u>					
AP		BAXTER HLTHCARE	5GM/100ML;75MG/100ML;330MG/100ML	N018629 001	Mar 23, 1982
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER</u>					
AP		BAXTER HLTHCARE	5GM/100ML;300MG/100ML;450MG/100ML	N018008 010	
<u>POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>					
AP		B BRAUN	5GM/100ML;75MG/100ML;200MG/100ML	N019630 008	Feb 17, 1988
<u>POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>					
AP		B BRAUN	5GM/100ML;75MG/100ML;330MG/100ML	N019630 014	Feb 17, 1988
<u>POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>					
AP		B BRAUN	5GM/100ML;75MG/100ML;450MG/100ML	N019630 020	Feb 17, 1988
<u>POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>					
AP		B BRAUN	5GM/100ML;75MG/100ML;900MG/100ML	N019630 026	Feb 17, 1988
<u>POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>					
AP		B BRAUN	5GM/100ML;150MG/100ML;200MG/100ML	N019630 010	Feb 17, 1988
<u>POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>					
AP		B BRAUN	5GM/100ML;150MG/100ML;330MG/100ML	N019630 016	Feb 17, 1988
<u>POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>					
AP		B BRAUN	5GM/100ML;150MG/100ML;450MG/100ML	N019630 022	Feb 17, 1988
<u>POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>					
AP		B BRAUN	5GM/100ML;150MG/100ML;900MG/100ML	N019630 028	Feb 17, 1988
<u>POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>					
AP		B BRAUN	5GM/100ML;300MG/100ML;200MG/100ML	N019630 012	Feb 17, 1988
<u>POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>					
AP		B BRAUN	5GM/100ML;300MG/100ML;330MG/100ML	N019630 018	Feb 17, 1988
<u>POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>					
AP		B BRAUN	5GM/100ML;300MG/100ML;450MG/100ML	N019630 024	Feb 17, 1988

PRESCRIPTION DRUG PRODUCT LIST

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDEINJECTABLE; INJECTIONPOTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>5GM/100ML;300MG/100ML;900MG/100ML</u>	<u>N019630 030</u>	Feb 17, 1988
-----------	---------	--	--------------------	--------------

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;75MG/100ML;450MG/100ML</u>	<u>N018008 005</u>	Apr 28, 1982
-----------	-----------------	---	--------------------	--------------

<u>AP</u>		<u>5GM/100ML;150MG/100ML;450MG/100ML</u>	<u>N018008 006</u>	Apr 28, 1982
-----------	--	--	--------------------	--------------

<u>AP</u>	+!	ICU MEDICAL INC	<u>5GM/100ML;74.5MG/100ML;450MG/100ML</u>	<u>N018362 009</u>	Jul 05, 1983
-----------	----	-----------------	---	--------------------	--------------

<u>AP</u>	+!		<u>5GM/100ML;149MG/100ML;450MG/100ML</u>	<u>N018362 005</u>	Mar 28, 1988
-----------	----	--	--	--------------------	--------------

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;150MG/100ML;450MG/100ML</u>	<u>N018008 007</u>	Apr 28, 1982
-----------	-----------------	--	--------------------	--------------

<u>AP</u>	+!	ICU MEDICAL INC	<u>5GM/100ML;149MG/100ML;450MG/100ML</u>	<u>N018362 010</u>	Jul 05, 1983
-----------	----	-----------------	--	--------------------	--------------

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;150MG/100ML;900MG/100ML</u>	<u>N019308 005</u>	Apr 05, 1985
-----------	-----------------	--	--------------------	--------------

<u>AP</u>	+!	ICU MEDICAL INC	<u>5GM/100ML;149MG/100ML;900MG/100ML</u>	<u>N019691 005</u>	Mar 24, 1988
-----------	----	-----------------	--	--------------------	--------------

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;224MG/100ML;450MG/100ML</u>	<u>N018008 008</u>	Apr 28, 1982
-----------	-----------------	--	--------------------	--------------

<u>AP</u>	+!	ICU MEDICAL INC	<u>5GM/100ML;224MG/100ML;450MG/100ML</u>	<u>N018362 002</u>	
-----------	----	-----------------	--	--------------------	--

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;300MG/100ML;450MG/100ML</u>	<u>N018008 009</u>	Apr 28, 1982
-----------	-----------------	--	--------------------	--------------

<u>AP</u>	+!	ICU MEDICAL INC	<u>5GM/100ML;298MG/100ML;450MG/100ML</u>	<u>N018362 003</u>	
-----------	----	-----------------	--	--------------------	--

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;300MG/100ML;900MG/100ML</u>	<u>N019308 007</u>	Apr 05, 1985
-----------	-----------------	--	--------------------	--------------

<u>AP</u>	+!	ICU MEDICAL INC	<u>5GM/100ML;298MG/100ML;900MG/100ML</u>	<u>N019691 009</u>	Mar 24, 1988
-----------	----	-----------------	--	--------------------	--------------

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

	B BRAUN	10GM/100ML;37MG/100ML;200MG/100ML	N019630 031	Feb 17, 1988
--	---------	-----------------------------------	-------------	--------------

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	B BRAUN	10GM/100ML;37MG/100ML;450MG/100ML	N019630 037	Feb 17, 1988
--	---------	-----------------------------------	-------------	--------------

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	B BRAUN	10GM/100ML;37MG/100ML;900MG/100ML	N019630 043	Feb 17, 1988
--	---------	-----------------------------------	-------------	--------------

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;37MG/100ML;110MG/100ML	N019630 001	Feb 17, 1988
--	---------	----------------------------------	-------------	--------------

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;37MG/100ML;200MG/100ML	N019630 007	Feb 17, 1988
--	---------	----------------------------------	-------------	--------------

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;37MG/100ML;330MG/100ML	N019630 013	Feb 17, 1988
--	---------	----------------------------------	-------------	--------------

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;37MG/100ML;450MG/100ML	N019630 019	Feb 17, 1988
--	---------	----------------------------------	-------------	--------------

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;37MG/100ML;900MG/100ML	N019630 025	Feb 17, 1988
--	---------	----------------------------------	-------------	--------------

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

	B BRAUN	10GM/100ML;75MG/100ML;200MG/100ML	N019630 032	Feb 17, 1988
--	---------	-----------------------------------	-------------	--------------

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	B BRAUN	10GM/100ML;75MG/100ML;450MG/100ML	N019630 038	Feb 17, 1988
--	---------	-----------------------------------	-------------	--------------

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	B BRAUN	10GM/100ML;75MG/100ML;900MG/100ML	N019630 044	Feb 17, 1988
--	---------	-----------------------------------	-------------	--------------

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	B BRAUN	3.3GM/100ML;75MG/100ML;300MG/100ML	N019630 049	May 07, 1992
--	---------	------------------------------------	-------------	--------------

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;75MG/100ML;110MG/100ML	N019630 002	Feb 17, 1988
--	---------	----------------------------------	-------------	--------------

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

	B BRAUN	10GM/100ML;110MG/100ML;200MG/100ML	N019630 033	Feb 17, 1988
--	---------	------------------------------------	-------------	--------------

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	B BRAUN	10GM/100ML;110MG/100ML;450MG/100ML	N019630 039	Feb 17, 1988
--	---------	------------------------------------	-------------	--------------

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	B BRAUN	10GM/100ML;110MG/100ML;900MG/100ML	N019630 045	Feb 17, 1988
--	---------	------------------------------------	-------------	--------------

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	B BRAUN	3.3GM/100ML;110MG/100ML;300MG/100ML	N019630 050	May 07, 1992
--	---------	-------------------------------------	-------------	--------------

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;110MG/100ML;110MG/100ML	N019630 003	Feb 17, 1988
--	---------	-----------------------------------	-------------	--------------

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;110MG/100ML;200MG/100ML	N019630 009	Feb 17, 1988
--	---------	-----------------------------------	-------------	--------------

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;110MG/100ML;330MG/100ML	N019630 015	Feb 17, 1988
--	---------	-----------------------------------	-------------	--------------

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;110MG/100ML;450MG/100ML	N019630 021	Feb 17, 1988
--	---------	-----------------------------------	-------------	--------------

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;110MG/100ML;900MG/100ML	N019630 027	Feb 17, 1988
--	---------	-----------------------------------	-------------	--------------

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

	B BRAUN	10GM/100ML;150MG/100ML;200MG/100ML	N019630 034	Feb 17, 1988
--	---------	------------------------------------	-------------	--------------

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	B BRAUN	10GM/100ML;150MG/100ML;450MG/100ML	N019630 040	Feb 17, 1988
--	---------	------------------------------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.15% IN	DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN	PLASTIC CONTAINER		
B BRAUN	10GM/100ML;150MG/100ML;900MG/100ML		N019630 046	Feb 17, 1988
POTASSIUM CHLORIDE 0.15% IN	DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN	PLASTIC CONTAINER		
B BRAUN	3.3GM/100ML;150MG/100ML;300MG/100ML		N019630 051	May 07, 1992
POTASSIUM CHLORIDE 0.15% IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN	PLASTIC CONTAINER		
B BRAUN	5GM/100ML;150MG/100ML;110MG/100ML		N019630 004	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN	DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN	PLASTIC CONTAINER		
B BRAUN	10GM/100ML;220MG/100ML;200MG/100ML		N019630 035	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN	DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN	PLASTIC CONTAINER		
B BRAUN	10GM/100ML;220MG/100ML;450MG/100ML		N019630 041	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN	DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN	PLASTIC CONTAINER		
B BRAUN	10GM/100ML;220MG/100ML;900MG/100ML		N019630 047	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN	DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN	PLASTIC CONTAINER		
B BRAUN	3.3GM/100ML;220MG/100ML;300MG/100ML		N019630 052	May 07, 1992
POTASSIUM CHLORIDE 0.22% IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN	PLASTIC CONTAINER		
B BRAUN	5GM/100ML;220MG/100ML;110MG/100ML		N019630 005	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN	PLASTIC CONTAINER		
B BRAUN	5GM/100ML;220MG/100ML;200MG/100ML		N019630 011	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN	PLASTIC CONTAINER		
B BRAUN	5GM/100ML;220MG/100ML;330MG/100ML		N019630 017	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN	PLASTIC CONTAINER		
B BRAUN	5GM/100ML;220MG/100ML;450MG/100ML		N019630 023	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN	PLASTIC CONTAINER		
B BRAUN	5GM/100ML;220MG/100ML;900MG/100ML		N019630 029	Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN	DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN	PLASTIC CONTAINER		
B BRAUN	10GM/100ML;300MG/100ML;200MG/100ML		N019630 036	Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN	DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN	PLASTIC CONTAINER		
B BRAUN	10GM/100ML;300MG/100ML;450MG/100ML		N019630 042	Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN	DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN	PLASTIC CONTAINER		
B BRAUN	10GM/100ML;300MG/100ML;900MG/100ML		N019630 048	Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN	DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN	PLASTIC CONTAINER		
B BRAUN	3.3GM/100ML;300MG/100ML;300MG/100ML		N019630 053	May 07, 1992
POTASSIUM CHLORIDE 0.3% IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN	PLASTIC CONTAINER		
B BRAUN	5GM/100ML;300MG/100ML;110MG/100ML		N019630 006	Feb 17, 1988
POTASSIUM CHLORIDE 10MEQ IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN	PLASTIC CONTAINER		
BAXTER HLTHCARE	5GM/100ML;75MG/100ML;900MG/100ML		N019308 004	Apr 05, 1985
	5GM/100ML;150MG/100ML;900MG/100ML		N019308 002	Apr 05, 1985
POTASSIUM CHLORIDE 20MEQ IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN	PLASTIC CONTAINER		
+ ICU MEDICAL INC	5GM/100ML;149MG/100ML;225MG/100ML		N018365 001	
POTASSIUM CHLORIDE 20MEQ IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN	PLASTIC CONTAINER		
BAXTER HLTHCARE	5GM/100ML;300MG/100ML;900MG/100ML		N019308 003	Apr 05, 1985
POTASSIUM CHLORIDE 30MEQ IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN	PLASTIC CONTAINER		
BAXTER HLTHCARE	5GM/100ML;224MG/100ML;900MG/100ML		N019308 006	Apr 05, 1985
POTASSIUM CHLORIDE 5MEQ IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN	PLASTIC CONTAINER		
BAXTER HLTHCARE	5GM/100ML;150MG/100ML;450MG/100ML		N018008 004	
POTASSIUM CHLORIDE 5MEQ IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN	PLASTIC CONTAINER		
BAXTER HLTHCARE	5GM/100ML;150MG/100ML;900MG/100ML		N019308 001	Apr 05, 1985

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

<u>DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>				
AP	B BRAUN	<u>2.5GM/100ML;450MG/100ML</u>	<u>N019631 004</u>	Feb 24, 1988
AP	+! BAXTER HLTHCARE	<u>2.5GM/100ML;450MG/100ML</u>	<u>N016697 001</u>	
<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>				
AP	B BRAUN	<u>5GM/100ML;200MG/100ML</u>	<u>N019631 007</u>	Feb 24, 1988
<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.225%</u>				
AP	FRESENIUS KABI USA	<u>5GM/100ML;225MG/100ML</u>	<u>A211221 001</u>	Sep 15, 2020
<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER</u>				
AP	+! ICU MEDICAL INC	<u>5GM/100ML;225MG/100ML</u>	<u>N017606 001</u>	
<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER</u>				
AP	FRESENIUS KABI USA	<u>5GM/100ML;300MG/100ML</u>	<u>A211194 001</u>	Aug 26, 2020
AP	+! ICU MEDICAL INC	<u>5GM/100ML;300MG/100ML</u>	<u>N017799 001</u>	
<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>				
AP	B BRAUN	<u>5GM/100ML;330MG/100ML</u>	<u>N019631 008</u>	Feb 24, 1988
<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.45%</u>				
AP	FRESENIUS KABI USA	<u>5GM/100ML;450MG/100ML</u>	<u>A211276 001</u>	Sep 15, 2020
<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>				
AP	B BRAUN	<u>5GM/100ML;450MG/100ML</u>	<u>N019631 009</u>	Feb 24, 1988
AP	+ ICU MEDICAL INC	<u>5GM/100ML;450MG/100ML</u>	<u>N017607 001</u>	

PRESCRIPTION DRUG PRODUCT LIST

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND SODIUM CHLORIDE 0.9%

AP	FRESENIUS KABI USA	<u>5GM/100ML;900MG/100ML</u>	<u>A211211 001</u>	Sep 14, 2020
		<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>		
AP	B BRAUN	<u>5GM/100ML;900MG/100ML</u>	<u>N019631 010</u>	Feb 24, 1988
AP	+! ICU MEDICAL INC	<u>5GM/100ML;900MG/100ML</u>	<u>N017585 001</u>	
		<u>DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>		
AP	BAXTER HLTHCARE	<u>5GM/100ML;200MG/100ML</u>	<u>N016689 001</u>	
		<u>DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>		
AP	BAXTER HLTHCARE	<u>5GM/100ML;330MG/100ML</u>	<u>N016687 001</u>	
		<u>DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>		
AP	BAXTER HLTHCARE	<u>5GM/100ML;450MG/100ML</u>	<u>N016683 001</u>	
		<u>DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>		
AP	BAXTER HLTHCARE	<u>5GM/100ML;900MG/100ML</u>	<u>N016678 001</u>	
		<u>DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER</u>		
	B BRAUN	10GM/100ML;110MG/100ML	N019631 011	Feb 24, 1988
		<u>DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>		
	B BRAUN	10GM/100ML;200MG/100ML	N019631 012	Feb 24, 1988
		<u>DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>		
	B BRAUN	10GM/100ML;330MG/100ML	N019631 013	Feb 24, 1988
		<u>DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>		
	B BRAUN	10GM/100ML;450MG/100ML	N019631 014	Feb 24, 1988
		<u>DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>		
	B BRAUN	10GM/100ML;900MG/100ML	N019631 015	Feb 24, 1988
		<u>DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER</u>		
	B BRAUN	2.5GM/100ML;110MG/100ML	N019631 001	Feb 24, 1988
		<u>DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>		
	B BRAUN	2.5GM/100ML;200MG/100ML	N019631 002	Feb 24, 1988
		<u>DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>		
	B BRAUN	2.5GM/100ML;330MG/100ML	N019631 003	Feb 24, 1988
		<u>DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>		
	B BRAUN	2.5GM/100ML;900MG/100ML	N019631 005	Feb 24, 1988
		<u>DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER</u>		
	B BRAUN	3.3GM/100ML;300MG/100ML	N019631 016	Jan 19, 1990
		<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER</u>		
	B BRAUN	5GM/100ML;110MG/100ML	N019631 006	Feb 24, 1988

DIATRIZOATE MEGLUMINE

SOLUTION; URETHRAL

CYSTOGRAFIN

+ BRACCO 30%

N010040 018

CYSTOGRAFIN DILUTE

+ BRACCO 18%

N010040 022 Nov 09, 1982

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

SOLUTION; ORAL, RECTAL

GASTROGRAFIN**AA** +! BRACCO **66%;10%****N011245 003**MD-GASTROVIEW**AA** LIEBEL-FLARSHEIM **66%;10%****A087388 001**DIAZEPAM

CONCENTRATE; ORAL

DIAZEPAM**AA** LANNETT CO INC **5MG/ML** **A204433 001** Apr 14, 2014DIAZEPAM INTENSOL**AA** ! HIKMA **5MG/ML** **A071415 001** Apr 03, 1987

GEL; RECTAL

DIASTAT

+ BAUSCH 2.5MG/0.5ML (5MG/ML)

N020648 001 Jul 29, 1997

DIASTAT ACUDIAL

+ BAUSCH 10MG/2ML (5MG/ML)

N020648 007 Sep 15, 2005

+! 20MG/4ML (5MG/ML)

N020648 006 Sep 15, 2005

INJECTABLE; INJECTION

DIAZEPAM**AP** BELOTECA INC **50MG/10ML (5MG/ML)** **A211998 001** Dec 26, 2019**AP** HOSPIRA **10MG/2ML (5MG/ML)** **A072079 001** Dec 20, 1988**AP** ! **50MG/10ML (5MG/ML)** **A071583 001** Oct 13, 1987! BELOTECA INC **10MG/2ML (5MG/ML)** **A210363 001** Mar 18, 2019

SOLUTION; ORAL

DIAZEPAM**AA** ! HIKMA **5MG/5ML** **A070928 001** Apr 03, 1987**AA** LANNETT CO INC **5MG/5ML** **A206477 001** Jun 24, 2016

PRESCRIPTION DRUG PRODUCT LIST

DIAZEPAM

SPRAY;NASAL

VALTOCO

+	NEURELIS INC	5MG/SPRAY	N211635 001	Jan 10, 2020
+		7.5MG/SPRAY	N211635 002	Jan 10, 2020
+	!	10MG/SPRAY	N211635 003	Jan 10, 2020

TABLET;ORAL

DIAZEPAM

AB	BARR	2MG	A070152 001	Nov 01, 1985
AB		10MG	A070154 001	Nov 01, 1985
AB	IVAX SUB TEVA PHARMS	2MG	A071307 001	Dec 10, 1986
AB		5MG	A071321 001	Dec 10, 1986
AB		10MG	A071322 001	Dec 10, 1986
AB	MAYNE PHARMA	2MG	A071134 001	Feb 03, 1987
AB		5MG	A071135 001	Feb 03, 1987
AB		10MG	A071136 001	Feb 03, 1987
AB	MYLAN	2MG	A070325 002	Sep 04, 1985
AB		5MG	A070325 003	Sep 04, 1985
AB		10MG	A070325 001	Sep 04, 1985
AB	VINTAGE PHARMS	2MG	A077749 001	Mar 31, 2006
AB		5MG	A077749 002	Mar 31, 2006
AB		10MG	A077749 003	Mar 31, 2006

VALIUM

AB	+	ROCHE	2MG	N013263 002
AB	+		5MG	N013263 004
AB	+	!	10MG	N013263 006

DIAZOXIDE

SUSPENSION;ORAL

DIAZOXIDE

AB	E5 PHARMA INC	50MG/ML	A211050 001	Dec 20, 2019
AB	NOVITIUM PHARMA	50MG/ML	A210799 001	Jul 08, 2020
AB	+	!	TEVA BRANDED PHARM	50MG/ML
				N017453 001

DICHLORPHENAMIDE

TABLET;ORAL

KEVEYIS

+	!	STRONGBRIDGE US	50MG	N011366 002	Aug 07, 2015
---	---	-----------------	------	-------------	--------------

DICLOFENAC

CAPSULE;ORAL

ZORVOLEX

+	!	ZYLA	35MG	N204592 002	Oct 18, 2013
---	---	------	------	-------------	--------------

DICLOFENAC EPOLAMINE

SYSTEM;TOPICAL

FLECTOR

+	!	INST BIOCHEM	1.3%	N021234 001	Jan 31, 2007
---	---	--------------	------	-------------	--------------

LICART

+	!	IBSA INST BIO	1.3%	N206976 001	Dec 19, 2018
---	---	---------------	------	-------------	--------------

DICLOFENAC POTASSIUM

CAPSULE;ORAL

DICLOFENAC POTASSIUM

AB	BIONPHARMA INC	25MG	A204648 001	Feb 23, 2016
-----------	----------------	-------------	--------------------	--------------

ZIPSOR

AB	+	!	ASSERTIO	25MG	N022202 001	Jun 16, 2009
-----------	---	---	----------	-------------	--------------------	--------------

FOR SOLUTION;ORAL

CAMBIA

AB	+	!	ASSERTIO	50MG	N022165 001	Jun 17, 2009
-----------	---	---	----------	-------------	--------------------	--------------

DICLOFENAC POTASSIUM

AB	PAR FORM	50MG	A202964 001	May 02, 2016
-----------	----------	-------------	--------------------	--------------

TABLET;ORAL

DICLOFENAC POTASSIUM

AB	AMICI	50MG	A076561 001	Mar 18, 2004	
AB	!	RK PHARMA	50MG	A075463 001	Jul 26, 1999
AB	RUBICON	50MG	A075229 001	Nov 20, 1998	
AB	TEVA	50MG	A075219 001	Aug 06, 1998	

PRESCRIPTION DRUG PRODUCT LIST

DICLOFENAC SODIUM

GEL; TOPICAL

DICLOFENAC SODIUM

AB	ACTAVIS MID ATLANTIC	3%	A206493 001	Dec 02, 2015
AB	AKORN	1%	A209484 001	Nov 21, 2018
AB	CIPLA	1%	A209903 001	Aug 03, 2018
AB	GLENMARK PHARMS LTD	3%	A208301 001	Sep 13, 2016
AB	PERRIGO UK FINCO	3%	A210893 001	Jul 27, 2018
AB	TARO	3%	A206298 001	Apr 28, 2016
AB	TOLMAR	3%	A200936 001	Oct 28, 2013

SOLARAZE

AB	+! FOUGERA PHARMS	3%	N021005 001	Oct 16, 2000
-----------	-------------------	-----------	--------------------	--------------

SOLUTION; TOPICAL

DICLOFENAC SODIUM

AT	AMNEAL PHARMS	1.5%	A206116 001	Sep 02, 2016
AT	CADILA	1.5%	A206411 001	Apr 17, 2018
AT	LUPIN LTD	1.5%	A204132 001	Aug 20, 2015
AT	NOVEL LABS INC	1.5%	A205878 001	Dec 09, 2015
AT	! TARO	1.5%	A203818 001	Nov 26, 2014
AT	TELIGENT	1.5%	A202769 001	Jul 08, 2015
AT	TWI PHARMS	1.5%	A202393 001	Nov 24, 2014
AT	WATSON LABS INC	1.5%	A202852 001	Nov 24, 2014

PENNSAID

+!	HORIZON	2%	N204623 001	Jan 16, 2014
----	---------	----	-------------	--------------

SOLUTION/DROPS; OPHTHALMIC

DICLOFENAC SODIUM

AT	AKORN	0.1%	A077845 001	Apr 17, 2008
AT	ALTAIRE PHARMS INC	0.1%	A203383 001	Nov 16, 2015
AT	BAUSCH AND LOMB	0.1%	A078792 001	Dec 28, 2007
AT	RISING	0.1%	A078553 001	Dec 28, 2007
AT	SANDOZ INC	0.1%	A078031 001	Feb 06, 2008

VOLTAREN

AT	+! NOVARTIS	0.1%	N020037 001	Mar 28, 1991
-----------	-------------	-------------	--------------------	--------------

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

AB	ACTAVIS ELIZABETH	50MG	A074514 001	Mar 26, 1996
AB		75MG	A074514 002	Mar 26, 1996
AB	CARLSBAD	25MG	A075185 002	Nov 13, 1998
AB		50MG	A075185 003	Nov 13, 1998
AB		75MG	A075185 001	Nov 13, 1998
AB	! UNIQUE PHARM LABS	25MG	A090066 001	Dec 01, 2010
AB	!	50MG	A090066 002	Dec 01, 2010
AB	!	75MG	A077863 003	Jun 08, 2007

TABLET, EXTENDED RELEASE; ORAL

DICLOFENAC SODIUM

AB	! DEXCEL LTD	100MG	A076201 001	Nov 06, 2002
AB	VPNA	100MG	A075492 001	Feb 11, 2000

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE; ORAL

ARTHROTEC

AB	+ PFIZER	50MG; 0.2MG	N020607 001	Dec 24, 1997
AB	+!	75MG; 0.2MG	N020607 002	Dec 24, 1997

DICLOFENAC SODIUM AND MISOPROSTOL

AB	ACTAVIS LABS FL INC	50MG; 0.2MG	A201089 001	Jul 09, 2012
AB		75MG; 0.2MG	A201089 002	Jul 09, 2012
AB	AMNEAL PHARMS	50MG; 0.2MG	A203995 001	Nov 25, 2016
AB		75MG; 0.2MG	A203995 002	Nov 25, 2016
AB	SANDOZ	50MG; 0.2MG	A200158 001	May 09, 2013
AB		75MG; 0.2MG	A200158 002	May 09, 2013
AB	YUNG SHIN PHARM	50MG; 0.2MG	A205143 001	Feb 19, 2020
AB		75MG; 0.2MG	A205143 002	Feb 19, 2020

DICLOXACILLIN SODIUM

CAPSULE; ORAL

DICLOXACILLIN SODIUM

AB	SANDOZ	EQ 250MG BASE	A061454 001	
AB	!	EQ 500MG BASE	A061454 003	
AB	TEVA	EQ 250MG BASE	A062286 001	Jun 03, 1982
AB		EQ 500MG BASE	A062286 002	Jun 03, 1982
	SANDOZ	EQ 125MG BASE	A061454 002	

PRESCRIPTION DRUG PRODUCT LIST

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

DICYCLOMINE HYDROCHLORIDE

<u>AB</u>	!	LANNETT	<u>10MG</u>	<u>A084285</u>	<u>001</u>	
<u>AB</u>		MYLAN	<u>10MG</u>	<u>A040319</u>	<u>001</u>	Sep 07, 1999
<u>AB</u>		WATSON LABS	<u>10MG</u>	<u>A085082</u>	<u>001</u>	Jun 19, 1986
<u>AB</u>		WEST WARD	<u>10MG</u>	<u>A040204</u>	<u>001</u>	Feb 28, 1997

INJECTABLE; INJECTION

BENTYL

<u>AP</u>	+	!	ALLERGAN	<u>10MG/ML</u>	<u>N008370</u>	<u>001</u>	Oct 15, 1984
-----------	---	---	----------	----------------	----------------	------------	--------------

BENTYL PRESERVATIVE FREE

<u>AP</u>	+	!	ALLERGAN	<u>10MG/ML</u>	<u>N008370</u>	<u>002</u>	Oct 15, 1984
-----------	---	---	----------	----------------	----------------	------------	--------------

DICYCLOMINE HYDROCHLORIDE

<u>AP</u>			AKORN INC	<u>10MG/ML</u>	<u>A207084</u>	<u>001</u>	May 04, 2018
<u>AP</u>			AM REGENT	<u>10MG/ML</u>	<u>A208353</u>	<u>001</u>	Feb 17, 2017
<u>AP</u>			CUSTOPHARM INC	<u>10MG/ML</u>	<u>A210788</u>	<u>001</u>	Feb 11, 2019
<u>AP</u>			FOSUN PHARMA	<u>10MG/ML</u>	<u>A210979</u>	<u>001</u>	Jul 02, 2018
<u>AP</u>			FRESENIUS KABI USA	<u>10MG/ML</u>	<u>A210257</u>	<u>001</u>	Jan 25, 2019
<u>AP</u>			NEXUS PHARMS	<u>10MG/ML</u>	<u>A206468</u>	<u>001</u>	Feb 01, 2019
<u>AP</u>			SLATE	<u>10MG/ML</u>	<u>A207076</u>	<u>001</u>	Nov 02, 2018
<u>AP</u>			SUNGEN PHARMA	<u>10MG/ML</u>	<u>A212058</u>	<u>001</u>	Apr 26, 2019

DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE)

<u>AP</u>			WEST-WARD PHARMS	<u>10MG/ML</u>	<u>A040465</u>	<u>001</u>	Jun 30, 2003
-----------	--	--	------------------	----------------	----------------	------------	--------------

SYRUP; ORAL

DICYCLOMINE HYDROCHLORIDE

<u>AA</u>	!		GENERICS	<u>10MG/5ML</u>	<u>A040169</u>	<u>001</u>	Mar 24, 2005
<u>AA</u>			HIKMA	<u>10MG/5ML</u>	<u>A212286</u>	<u>001</u>	May 22, 2020

TABLET; ORAL

DICYCLOMINE HYDROCHLORIDE

<u>AB</u>			HIKMA PHARMS	<u>20MG</u>	<u>A040161</u>	<u>001</u>	Oct 01, 1996
<u>AB</u>			LANNETT	<u>20MG</u>	<u>A040230</u>	<u>001</u>	Feb 26, 1999
<u>AB</u>			MYLAN	<u>20MG</u>	<u>A040317</u>	<u>001</u>	Sep 07, 1999
<u>AB</u>	!		WATSON LABS	<u>20MG</u>	<u>A085223</u>	<u>001</u>	Jul 30, 1986

DIDANOSINE

CAPSULE, DELAYED REL PELLETS; ORAL

DIDANOSINE

			AUROBINDO PHARMA	125MG	A090094	001	Sep 24, 2008
				200MG	A090094	002	Sep 24, 2008
				250MG	A090094	003	Sep 24, 2008
	!			400MG	A090094	004	Sep 24, 2008

DIENOGEST; ESTRADIOL VALERATE

TABLET; ORAL

NATAZIA

	+	!	BAYER HLTHCARE	N/A, 2MG, 3MG, N/A, N/A; 3MG, 2MG, 2MG, 1MG, N/A	N022252	001	May 06, 2010
--	---	---	----------------	--	---------	-----	--------------

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

DIETHYLPROPION HYDROCHLORIDE

<u>AA</u>			AVANTHI INC	<u>25MG</u>	<u>A201212</u>	<u>001</u>	Dec 22, 2010
<u>AA</u>	!		LANNETT CO INC	<u>25MG</u>	<u>A200177</u>	<u>001</u>	Jul 18, 2011

TABLET, EXTENDED RELEASE; ORAL

DIETHYLPROPION HYDROCHLORIDE

<u>AB</u>	!		LANNETT CO INC	<u>75MG</u>	<u>A091680</u>	<u>001</u>	Oct 24, 2011
-----------	---	--	----------------	-------------	----------------	------------	--------------

DIFLORASONE DIACETATE

CREAM; TOPICAL

DIFLORASONE DIACETATE

BX	!		FOUGERA PHARMS	0.05%	A076263	001	Dec 20, 2002
BX	!		TARO	0.05%	A075508	001	Apr 24, 2000

OINTMENT; TOPICAL

DIFLORASONE DIACETATE

<u>AB</u>			AKORN	<u>0.05%</u>	<u>A206572</u>	<u>001</u>	Jul 24, 2015
<u>AB</u>			FOUGERA PHARMS	<u>0.05%</u>	<u>A075374</u>	<u>001</u>	Apr 27, 1999
<u>AB</u>			RISING	<u>0.05%</u>	<u>A207440</u>	<u>001</u>	Feb 27, 2017
<u>AB</u>	!		TARO	<u>0.05%</u>	<u>A075331</u>	<u>001</u>	May 14, 1999
<u>AB</u>			TELIGENT	<u>0.05%</u>	<u>A210753</u>	<u>001</u>	Jun 12, 2018

PRESCRIPTION DRUG PRODUCT LIST

DIFLUNISAL

TABLET; ORAL

DIFLUNISAL

AB	HERITAGE PHARMA	500MG	A202845 001	Mar 08, 2012
AB	! TEVA	500MG	A073673 001	Jul 31, 1992
AB	ZYDUS PHARMS	500MG	A203547 001	Jun 16, 2017

DIFLUPREDNATE

EMULSION; OPHTHALMIC

DUREZOL

+	NOVARTIS	0.05%	N022212 001	Jun 23, 2008
---	----------	-------	-------------	--------------

DIGOXIN

ELIXIR; ORAL

DIGOXIN

AA	! HIKMA	0.05MG/ML	N021648 001	Aug 26, 2004
AA	VISTAPHARM	0.05MG/ML	A213000 001	Oct 04, 2019

INJECTABLE; INJECTION

DIGOXIN

AP	SANDOZ INC	0.25MG/ML	A040481 001	Aug 21, 2003
AP	WEST-WARD PHARMS INT	0.25MG/ML	A083391 001	

LANOXIN

AP	! COVIS	0.25MG/ML	N009330 002	
	LANOXIN PEDIATRIC			
+	COVIS	0.1MG/ML	N009330 004	

TABLET; ORAL

DIGOXIN

AB	HIKMA INTL PHARMS	0.125MG	A077002 002	Oct 30, 2007
AB		0.25MG	A077002 001	Oct 30, 2007
AB	IMPAX LABS	0.125MG	A078556 001	Jul 20, 2009
AB		0.25MG	A078556 002	Jul 20, 2009
AB	MYLAN PHARMS INC	0.125MG	A040282 001	Dec 23, 1999
AB		0.25MG	A040282 002	Dec 23, 1999
AB	STEVENS J	0.125MG	A076268 001	Jul 26, 2002
AB		0.25MG	A076268 002	Jul 26, 2002
AB	SUN PHARM INDS INC	0.125MG	A076363 001	Jan 31, 2003
AB		0.25MG	A076363 002	Jan 31, 2003

LANOXIN

AB	+ CONCORDIA	0.125MG	N020405 002	Sep 30, 1997
AB	+	0.25MG	N020405 004	Sep 30, 1997
		0.0625MG	N020405 001	Sep 30, 1997

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION

D.H.E. 45

AP	! BAUSCH	1MG/ML	N005929 001	
-----------	----------	---------------	--------------------	--

DIHYDROERGOTAMINE MESYLATE

AP	APOLLO	1MG/ML	A212046 001	Jan 07, 2020
AP	HIKMA PHARMS	1MG/ML	A206621 001	Sep 15, 2017
AP	PADDOCK LLC	1MG/ML	A040475 001	Apr 28, 2003
AP	SAGENT PHARMS INC	1MG/ML	A207264 001	Jul 11, 2018
AP	WEST-WARD PHARMS INT	1MG/ML	A040453 001	Jun 09, 2003

SPRAY, METERED; NASAL

DIHYDROERGOTAMINE MESYLATE

AB	CIPLA	0.5MG/SPRAY	A212907 001	May 20, 2020
AB	CUSTOPHARM INC	0.5MG/SPRAY	A211393 001	Feb 28, 2020

MIGRANAL

AB	! BAUSCH	0.5MG/SPRAY	N020148 001	Dec 08, 1997
-----------	----------	--------------------	--------------------	--------------

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILTIAZEM HYDROCHLORIDE

AB2	ACCORD HLTHCARE	120MG	A206997 001	Apr 28, 2020
AB2		180MG	A206997 002	Apr 28, 2020
AB2		240MG	A206997 003	Apr 28, 2020
AB2	APOTEX	120MG	A074943 003	Dec 19, 2000
AB2		180MG	A074943 002	Dec 19, 2000
AB2	!	240MG	A074943 001	Aug 06, 1998

CARDIZEM CD

AB3	+ BAUSCH	120MG	N020062 001	Aug 10, 1992
AB3	+	180MG	N020062 002	Dec 27, 1991
AB3	+	240MG	N020062 003	Dec 27, 1991
AB3	+	300MG	N020062 004	Dec 27, 1991

PRESCRIPTION DRUG PRODUCT LIST

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

CARDIZEM CD

<u>AB3</u>	<u>+!</u>	<u>360MG</u>	<u>N020062</u>	<u>005</u>	Aug 24, 1999
------------	-----------	--------------	----------------	------------	--------------

CARTIA XT

<u>AB3</u>	ACTAVIS LABS FL INC	<u>120MG</u>	<u>A074752</u>	<u>002</u>	Jul 09, 1998
<u>AB3</u>		<u>180MG</u>	<u>A074752</u>	<u>001</u>	Jul 09, 1998
<u>AB3</u>		<u>240MG</u>	<u>A074752</u>	<u>003</u>	Jul 09, 1998
<u>AB3</u>		<u>300MG</u>	<u>A074752</u>	<u>004</u>	Jul 09, 1998

DILTIAZEM HYDROCHLORIDE

<u>AB3</u>	ACTAVIS ELIZABETH	<u>360MG</u>	<u>A202463</u>	<u>001</u>	Dec 07, 2012
<u>AB3</u>	NOVAST LABS	<u>120MG</u>	<u>A208783</u>	<u>001</u>	Jun 14, 2019
<u>AB3</u>		<u>180MG</u>	<u>A208783</u>	<u>002</u>	Jun 14, 2019
<u>AB3</u>		<u>240MG</u>	<u>A208783</u>	<u>003</u>	Jun 14, 2019
<u>AB3</u>		<u>300MG</u>	<u>A208783</u>	<u>004</u>	Jun 14, 2019
<u>AB3</u>		<u>360MG</u>	<u>A208783</u>	<u>005</u>	Jun 14, 2019
<u>AB3</u>	PAR PHARM	<u>120MG</u>	<u>A074984</u>	<u>001</u>	Dec 20, 1999
<u>AB3</u>		<u>180MG</u>	<u>A074984</u>	<u>002</u>	Dec 20, 1999
<u>AB3</u>		<u>240MG</u>	<u>A074984</u>	<u>003</u>	Dec 20, 1999
<u>AB3</u>		<u>300MG</u>	<u>A074984</u>	<u>004</u>	Dec 20, 1999
<u>AB3</u>	SUN PHARM	<u>120MG</u>	<u>A090492</u>	<u>001</u>	Oct 28, 2011
<u>AB3</u>		<u>120MG</u>	<u>A203023</u>	<u>001</u>	Jun 08, 2017
<u>AB3</u>		<u>180MG</u>	<u>A090492</u>	<u>002</u>	Oct 28, 2011
<u>AB3</u>		<u>180MG</u>	<u>A203023</u>	<u>002</u>	Jun 08, 2017
<u>AB3</u>		<u>240MG</u>	<u>A090492</u>	<u>003</u>	Oct 28, 2011
<u>AB3</u>		<u>240MG</u>	<u>A203023</u>	<u>003</u>	Jun 08, 2017
<u>AB3</u>		<u>300MG</u>	<u>A090492</u>	<u>004</u>	Oct 28, 2011
<u>AB3</u>		<u>300MG</u>	<u>A203023</u>	<u>004</u>	Jun 08, 2017
<u>AB3</u>		<u>360MG</u>	<u>A090492</u>	<u>005</u>	Oct 28, 2011
<u>AB3</u>		<u>360MG</u>	<u>A203023</u>	<u>005</u>	Jun 08, 2017
<u>AB3</u>	TWI PHARMS	<u>120MG</u>	<u>A205231</u>	<u>001</u>	Aug 30, 2018
<u>AB3</u>		<u>180MG</u>	<u>A205231</u>	<u>002</u>	Aug 30, 2018
<u>AB3</u>		<u>240MG</u>	<u>A205231</u>	<u>003</u>	Aug 30, 2018
<u>AB3</u>		<u>300MG</u>	<u>A205231</u>	<u>004</u>	Aug 30, 2018
<u>AB3</u>		<u>360MG</u>	<u>A205231</u>	<u>005</u>	Aug 30, 2018
<u>AB3</u>	VALEANT PHARMS NORTH	<u>120MG</u>	<u>A075116</u>	<u>001</u>	Dec 23, 1999
<u>AB3</u>		<u>180MG</u>	<u>A075116</u>	<u>002</u>	Dec 23, 1999
<u>AB3</u>		<u>240MG</u>	<u>A075116</u>	<u>003</u>	Dec 23, 1999
<u>AB3</u>		<u>300MG</u>	<u>A075116</u>	<u>004</u>	Dec 23, 1999
<u>AB3</u>	ZYDUS PHARMS	<u>120MG</u>	<u>A206534</u>	<u>001</u>	Aug 08, 2017
<u>AB3</u>		<u>180MG</u>	<u>A206534</u>	<u>002</u>	Aug 08, 2017
<u>AB3</u>		<u>240MG</u>	<u>A206534</u>	<u>003</u>	Aug 08, 2017
<u>AB3</u>		<u>300MG</u>	<u>A206534</u>	<u>004</u>	Aug 08, 2017
<u>AB3</u>		<u>360MG</u>	<u>A206534</u>	<u>005</u>	Aug 08, 2017
<u>AB4</u>	SANDOZ	<u>120MG</u>	<u>A091022</u>	<u>001</u>	Sep 28, 2012
<u>AB4</u>		<u>180MG</u>	<u>A091022</u>	<u>002</u>	Sep 28, 2012
<u>AB4</u>		<u>240MG</u>	<u>A091022</u>	<u>003</u>	Sep 28, 2012
<u>AB4</u>		<u>300MG</u>	<u>A091022</u>	<u>004</u>	Sep 28, 2012
<u>AB4</u>		<u>360MG</u>	<u>A091022</u>	<u>005</u>	Sep 28, 2012
<u>AB4</u>		<u>420MG</u>	<u>A091022</u>	<u>006</u>	Sep 28, 2012
<u>AB4</u>	SUN PHARM	<u>120MG</u>	<u>A090421</u>	<u>001</u>	Nov 15, 2010
<u>AB4</u>		<u>180MG</u>	<u>A090421</u>	<u>002</u>	Nov 15, 2010
<u>AB4</u>		<u>240MG</u>	<u>A090421</u>	<u>003</u>	Nov 15, 2010
<u>AB4</u>		<u>300MG</u>	<u>A090421</u>	<u>004</u>	Nov 15, 2010
<u>AB4</u>		<u>360MG</u>	<u>A090421</u>	<u>005</u>	Nov 15, 2010
<u>AB4</u>	ZYDUS PHARMS	<u>120MG</u>	<u>A206641</u>	<u>001</u>	Aug 11, 2017
<u>AB4</u>		<u>180MG</u>	<u>A206641</u>	<u>002</u>	Aug 11, 2017
<u>AB4</u>		<u>240MG</u>	<u>A206641</u>	<u>003</u>	Aug 11, 2017
<u>AB4</u>		<u>300MG</u>	<u>A206641</u>	<u>004</u>	Aug 11, 2017
<u>AB4</u>		<u>360MG</u>	<u>A206641</u>	<u>005</u>	Aug 11, 2017
<u>AB4</u>		<u>420MG</u>	<u>A206641</u>	<u>006</u>	Aug 11, 2017

TAZTIA XT

<u>AB4</u>	ACTAVIS LABS FL INC	<u>120MG</u>	<u>A075401</u>	<u>001</u>	Apr 10, 2003
<u>AB4</u>		<u>180MG</u>	<u>A075401</u>	<u>002</u>	Apr 10, 2003
<u>AB4</u>		<u>240MG</u>	<u>A075401</u>	<u>003</u>	Apr 10, 2003
<u>AB4</u>		<u>300MG</u>	<u>A075401</u>	<u>004</u>	Apr 10, 2003
<u>AB4</u>		<u>360MG</u>	<u>A075401</u>	<u>005</u>	Apr 10, 2003

TIAZAC

<u>AB4</u>	<u>+</u>	BAUSCH	<u>120MG</u>	<u>N020401</u>	<u>001</u>	Sep 11, 1995
<u>AB4</u>	<u>+</u>		<u>180MG</u>	<u>N020401</u>	<u>002</u>	Sep 11, 1995
<u>AB4</u>	<u>+</u>		<u>240MG</u>	<u>N020401</u>	<u>003</u>	Sep 11, 1995
<u>AB4</u>	<u>+</u>		<u>300MG</u>	<u>N020401</u>	<u>004</u>	Sep 11, 1995

PRESCRIPTION DRUG PRODUCT LIST

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

TIAZAC

<u>AB4</u>	+		<u>360MG</u>	<u>N020401</u>	<u>005</u>	Sep 11, 1995
<u>AB4</u>	+	!	<u>420MG</u>	<u>N020401</u>	<u>006</u>	Oct 16, 1998
DILTIAZEM HYDROCHLORIDE						
BC	!	MYLAN	120MG	A074910	003	May 02, 1997
			60MG	A074910	001	May 02, 1997
			90MG	A074910	002	May 02, 1997

INJECTABLE; INJECTION

DILTIAZEM HYDROCHLORIDE

<u>AP</u>		AKORN INC	<u>5MG/ML</u>	<u>A075086</u>	<u>001</u>	Apr 09, 1998
<u>AP</u>	!	ATHENEX INC	<u>5MG/ML</u>	<u>A074617</u>	<u>001</u>	Feb 28, 1996
<u>AP</u>		HIKMA FARMACEUTICA	<u>5MG/ML</u>	<u>A202651</u>	<u>001</u>	Aug 09, 2012
<u>AP</u>		HOSPIRA	<u>5MG/ML</u>	<u>A074941</u>	<u>001</u>	Apr 15, 1998
<u>AP</u>		INTL MEDICATION	<u>5MG/ML</u>	<u>A075749</u>	<u>001</u>	Nov 21, 2001
<u>AP</u>		WEST-WARD PHARMS	<u>5MG/ML</u>	<u>A078538</u>	<u>001</u>	Dec 17, 2008
		INT				
	!	HOSPIRA	100MG/VIAL	A075853	001	Dec 17, 2002

TABLET; ORAL

CARDIZEM

<u>AB</u>	+	BAUSCH	<u>30MG</u>	<u>N018602</u>	<u>001</u>	Nov 05, 1982
<u>AB</u>	+		<u>60MG</u>	<u>N018602</u>	<u>002</u>	Nov 05, 1982
<u>AB</u>	+		<u>90MG</u>	<u>N018602</u>	<u>003</u>	Dec 08, 1986
<u>AB</u>	+	!	<u>120MG</u>	<u>N018602</u>	<u>004</u>	Dec 08, 1986

DILTIAZEM HYDROCHLORIDE

<u>AB</u>		EDENBRIDGE PHARMS	<u>30MG</u>	<u>A211596</u>	<u>001</u>	Nov 18, 2019
<u>AB</u>			<u>60MG</u>	<u>A211596</u>	<u>002</u>	Nov 18, 2019
<u>AB</u>			<u>90MG</u>	<u>A211596</u>	<u>003</u>	Nov 18, 2019
<u>AB</u>			<u>120MG</u>	<u>A211596</u>	<u>004</u>	Nov 18, 2019
<u>AB</u>		MYLAN	<u>30MG</u>	<u>A072838</u>	<u>004</u>	Nov 05, 1992
<u>AB</u>			<u>60MG</u>	<u>A072838</u>	<u>003</u>	Nov 05, 1992
<u>AB</u>			<u>90MG</u>	<u>A072838</u>	<u>002</u>	Nov 05, 1992
<u>AB</u>			<u>120MG</u>	<u>A072838</u>	<u>001</u>	Nov 05, 1992
<u>AB</u>		TEVA	<u>30MG</u>	<u>A074185</u>	<u>001</u>	May 31, 1995
<u>AB</u>			<u>60MG</u>	<u>A074185</u>	<u>002</u>	May 31, 1995
<u>AB</u>			<u>90MG</u>	<u>A074185</u>	<u>003</u>	May 31, 1995
<u>AB</u>			<u>120MG</u>	<u>A074185</u>	<u>004</u>	May 31, 1995

TABLET, EXTENDED RELEASE;ORAL

CARDIZEM LA

<u>AB</u>	+	BAUSCH	<u>120MG</u>	<u>N021392</u>	<u>001</u>	Feb 06, 2003
<u>AB</u>	+		<u>180MG</u>	<u>N021392</u>	<u>002</u>	Feb 06, 2003
<u>AB</u>	+		<u>240MG</u>	<u>N021392</u>	<u>003</u>	Feb 06, 2003
<u>AB</u>	+		<u>300MG</u>	<u>N021392</u>	<u>004</u>	Feb 06, 2003
<u>AB</u>	+		<u>360MG</u>	<u>N021392</u>	<u>005</u>	Feb 06, 2003
<u>AB</u>	+	!	<u>420MG</u>	<u>N021392</u>	<u>006</u>	Feb 06, 2003

DILTIAZEM HYDROCHLORIDE

<u>AB</u>		ACTAVIS LABS FL INC	<u>120MG</u>	<u>A077686</u>	<u>006</u>	Mar 15, 2010
<u>AB</u>			<u>180MG</u>	<u>A077686</u>	<u>005</u>	Mar 15, 2010
<u>AB</u>			<u>240MG</u>	<u>A077686</u>	<u>004</u>	Mar 15, 2010
<u>AB</u>			<u>300MG</u>	<u>A077686</u>	<u>003</u>	Mar 15, 2010
<u>AB</u>			<u>360MG</u>	<u>A077686</u>	<u>002</u>	Mar 15, 2010
<u>AB</u>			<u>420MG</u>	<u>A077686</u>	<u>001</u>	Mar 15, 2010

DIMENHYDRINATE

INJECTABLE; INJECTION

DIMENHYDRINATE

!	FRESENIUS KABI USA	50MG/ML	A040519	001	Jun 23, 2004
---	--------------------	---------	---------	-----	--------------

DIMERCAPROL

INJECTABLE; INJECTION

BAL

+	!	AKORN	10%	N005939	001
---	---	-------	-----	---------	-----

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE;ORAL

DIMETHYL FUMARATE

<u>AB</u>		ACCORD HLTHCARE	<u>120MG</u>	<u>A210499</u>	<u>001</u>	Sep 24, 2020
<u>AB</u>			<u>240MG</u>	<u>A210499</u>	<u>002</u>	Sep 24, 2020
<u>AB</u>		ALKEM LABS LTD	<u>120MG</u>	<u>A210440</u>	<u>001</u>	Sep 24, 2020
<u>AB</u>			<u>240MG</u>	<u>A210440</u>	<u>002</u>	Sep 24, 2020
<u>AB</u>		AMNEAL	<u>120MG</u>	<u>A210402</u>	<u>001</u>	Sep 24, 2020
<u>AB</u>			<u>240MG</u>	<u>A210402</u>	<u>002</u>	Sep 24, 2020
<u>AB</u>		CIPLA	<u>120MG</u>	<u>A210305</u>	<u>001</u>	Sep 24, 2020

PRESCRIPTION DRUG PRODUCT LIST

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE;ORAL

DIMETHYL FUMARATE

AB		240MG	A210305 002	Sep 24, 2020
AB	GLENMARK PHARMS LTD	120MG	A210309 001	Oct 06, 2020
AB		240MG	A210309 002	Oct 06, 2020
AB	HETERO LABS LTD III	120MG	A210500 001	Sep 24, 2020
AB		240MG	A210500 002	Sep 24, 2020
AB	LUPIN ATLANTIS	120MG	A210226 001	Oct 05, 2020
AB		240MG	A210226 002	Oct 05, 2020
AB	MSN	120MG	A210460 001	Sep 24, 2020
AB		240MG	A210460 002	Sep 24, 2020
AB	MYLAN	120MG	A210531 001	Aug 17, 2020
AB		240MG	A210531 002	Aug 17, 2020
AB	TWI PHARMS	120MG	A210382 001	Oct 14, 2020
AB		240MG	A210382 002	Oct 14, 2020
AB	ZYDUS PHARMS	120MG	A210538 001	Sep 24, 2020
AB		240MG	A210538 002	Sep 24, 2020

TECFIDERA

AB	+ BIOGEN IDEC INC	120MG	N204063 001	Mar 27, 2013
AB	+!	240MG	N204063 002	Mar 27, 2013

DIMETHYL SULFOXIDE

SOLUTION;INTRAVESICAL

RIMSO-50

+! MYLAN INSTITUTIONAL 50%

N017788 001

DINOPROSTONE

GEL;ENDOCERVICAL

PREPIDIL

+! PHARMACIA AND 0.5MG/3GM

N019617 001 Dec 09, 1992

INSERT, EXTENDED RELEASE;VAGINAL

CERVIDIL

+! FERRING PHARMS INC 10MG

N020411 001 Mar 30, 1995

SUPPOSITORY;VAGINAL

PROSTIN E2

+! PHARMACIA AND 20MG

N017810 001

UPJOHN

DIPHENHYDRAMINE HYDROCHLORIDE

ELIXIR;ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

! PHARM ASSOC 12.5MG/5ML

A087513 001 Feb 10, 1982

INJECTABLE;INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE

AP	APP PHARMS	50MG/ML	A040466 001	May 28, 2002
AP	HOSPIRA	50MG/ML	A040140 001	Nov 20, 1998
AP	MICRO LABS	50MG/ML	A205723 001	Aug 22, 2018
AP	MYLAN INSTITUTIONAL	50MG/ML	A040498 001	Jul 12, 2005
AP	! WEST-WARD PHARMS	50MG/ML	A080817 002	
	INT			

DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

AP	FRESENIUS KABI USA	50MG/ML	A091526 001	Mar 26, 2013
-----------	--------------------	----------------	--------------------	--------------

DIPYRIDAMOLE

INJECTABLE;INJECTION

DIPYRIDAMOLE

AP	! ATHENEX INC	5MG/ML	A074939 001	Apr 13, 1998
AP	FRESENIUS KABI USA	5MG/ML	A074956 001	Sep 30, 1998
AP	WEST-WARD PHARMS	5MG/ML	A074521 001	Oct 18, 1996
	INT			

TABLET;ORAL

DIPYRIDAMOLE

AB	BARR	25MG	A087184 001	Oct 03, 1990
AB		50MG	A087716 001	Oct 03, 1990
AB		75MG	A087717 001	Oct 03, 1990
AB	IMPAX LABS	25MG	A040782 001	Jul 18, 2007
AB		50MG	A040782 002	Jul 18, 2007
AB		75MG	A040782 003	Jul 18, 2007
AB	MURTY PHARMS	25MG	A040733 001	Feb 13, 2007
AB		50MG	A040733 002	Feb 13, 2007
AB		75MG	A040733 003	Feb 13, 2007
AB	ZYDUS PHARMS USA	25MG	A040874 001	Jan 28, 2008
	INC			

PRESCRIPTION DRUG PRODUCT LIST

DIPYRIDAMOLE

TABLET;ORAL

DIPYRIDAMOLE

<u>AB</u>		<u>50MG</u>	<u>A040874 002</u>	Jan 28, 2008
<u>AB</u>		<u>75MG</u>	<u>A040874 003</u>	Jan 28, 2008
<u>PERSANTINE</u>				
<u>AB</u>	+	BOEHRINGER INGELHEIM	<u>25MG</u>	<u>N012836 003</u> Dec 22, 1986
<u>AB</u>	+		<u>50MG</u>	<u>N012836 004</u> Feb 06, 1987
<u>AB</u>	+		<u>75MG</u>	<u>N012836 005</u> Feb 06, 1987

DIROXIMEL FUMARATECAPSULE, DELAYED RELEASE;ORAL
VUMERITY

+! BIOGEN 231MG N211855 001 Oct 29, 2019

DISOPYRAMIDE PHOSPHATE

CAPSULE;ORAL

DISOPYRAMIDE PHOSPHATE

<u>AB</u>		MAYNE PHARMA	<u>EQ 100MG BASE</u>	<u>A070173 001</u> May 31, 1985
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>A070173 002</u> May 31, 1985
<u>AB</u>		TEVA	<u>EQ 100MG BASE</u>	<u>A070101 001</u> Feb 22, 1985
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>A070102 001</u> Feb 22, 1985
<u>NORPACE</u>				
<u>AB</u>	+	PFIZER	<u>EQ 100MG BASE</u>	<u>N017447 001</u>
<u>AB</u>	+		<u>EQ 150MG BASE</u>	<u>N017447 002</u>

CAPSULE, EXTENDED RELEASE;ORAL

NORPACE CR

+ PFIZER EQ 100MG BASE N018655 001 Jul 20, 1982
+! EQ 150MG BASE N018655 002 Jul 20, 1982DISULFIRAM

TABLET;ORAL

ANTABUSE

<u>AB</u>		ODYSSEY PHARMS	<u>250MG</u>	<u>A088482 001</u> Dec 08, 1983
<u>AB</u>	!		<u>500MG</u>	<u>A088483 001</u> Dec 08, 1983

DISULFIRAM

<u>AB</u>		ALVOGEN	<u>250MG</u>	<u>A091681 001</u> Aug 08, 2013
<u>AB</u>		CHARTWELL MOLECULES	<u>250MG</u>	<u>A091563 001</u> Dec 31, 2012
<u>AB</u>			<u>500MG</u>	<u>A091563 002</u> Dec 31, 2012
<u>AB</u>		HIKMA	<u>250MG</u>	<u>A202652 001</u> Feb 05, 2014
<u>AB</u>			<u>500MG</u>	<u>A202652 002</u> Feb 05, 2014
<u>AB</u>		SIGMAPHARM LABS LLC	<u>250MG</u>	<u>A091619 001</u> Mar 28, 2011
<u>AB</u>			<u>500MG</u>	<u>A091619 002</u> Mar 28, 2011

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS;ORAL

DEPAKOTE

<u>AB</u>	+	ABBVIE	<u>EQ 125MG VALPROIC ACID</u>	<u>N019680 001</u> Sep 12, 1989
-----------	---	--------	-------------------------------	---------------------------------

DIVALPROEX SODIUM

<u>AB</u>		AJANTA PHARMA LTD	<u>EQ 125MG VALPROIC ACID</u>	<u>A213181 001</u> Mar 02, 2020
<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 125MG VALPROIC ACID</u>	<u>A078979 001</u> Jan 23, 2009
<u>AB</u>		TEVA PHARMS USA	<u>EQ 125MG VALPROIC ACID</u>	<u>A211505 001</u> Nov 17, 2020
<u>AB</u>		ZYDUS PHARMS USA	<u>EQ 125MG VALPROIC ACID</u>	<u>A078919 001</u> Jan 27, 2009

TABLET, DELAYED RELEASE;ORAL

DEPAKOTE

<u>AB</u>	+	ABBVIE	<u>EQ 125MG VALPROIC ACID</u>	<u>N018723 003</u> Oct 26, 1984
<u>AB</u>	+		<u>EQ 250MG VALPROIC ACID</u>	<u>N018723 001</u> Mar 10, 1983
<u>AB</u>	+		<u>EQ 500MG VALPROIC ACID</u>	<u>N018723 002</u> Mar 10, 1983

DIVALPROEX SODIUM

<u>AB</u>		ACTAVIS LABS FL INC	<u>EQ 500MG VALPROIC ACID</u>	<u>A079080 001</u> Feb 25, 2011
<u>AB</u>		ANCHEN PHARMS	<u>EQ 500MG VALPROIC ACID</u>	<u>A078411 001</u> Nov 03, 2008
<u>AB</u>		APOTEX	<u>EQ 125MG VALPROIC ACID</u>	<u>A077615 003</u> Jul 29, 2008
<u>AB</u>			<u>EQ 250MG VALPROIC ACID</u>	<u>A077615 002</u> Jul 29, 2008
<u>AB</u>			<u>EQ 500MG VALPROIC ACID</u>	<u>A077615 001</u> Jul 29, 2008
<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 125MG VALPROIC ACID</u>	<u>A090554 001</u> Apr 21, 2011
<u>AB</u>			<u>EQ 250MG VALPROIC ACID</u>	<u>A090554 002</u> Apr 21, 2011
<u>AB</u>			<u>EQ 500MG VALPROIC ACID</u>	<u>A090554 003</u> Apr 21, 2011
<u>AB</u>		CELLTRION	<u>EQ 125MG VALPROIC ACID</u>	<u>A077296 001</u> Jul 31, 2008
<u>AB</u>			<u>EQ 250MG VALPROIC ACID</u>	<u>A077296 002</u> Jul 31, 2008
<u>AB</u>			<u>EQ 500MG VALPROIC ACID</u>	<u>A077296 003</u> Jul 31, 2008
<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 125MG VALPROIC ACID</u>	<u>A078755 001</u> Jul 29, 2008
<u>AB</u>			<u>EQ 250MG VALPROIC ACID</u>	<u>A078755 002</u> Jul 29, 2008

PRESCRIPTION DRUG PRODUCT LIST

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE;ORAL

DIVALPROEX SODIUM

<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078755 003</u>	Jul 29, 2008
<u>AB</u>	INVATECH	<u>EQ 125MG VALPROIC ACID</u>	<u>A078290 003</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078290 002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078290 001</u>	Jul 29, 2008
<u>AB</u>	LUPIN	<u>EQ 125MG VALPROIC ACID</u>	<u>A078790 001</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078790 002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078790 003</u>	Jul 29, 2008
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 125MG VALPROIC ACID</u>	<u>A078853 001</u>	Nov 25, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078853 002</u>	Nov 25, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078853 003</u>	Nov 25, 2008
<u>AB</u>	PRINSTON INC	<u>EQ 125MG VALPROIC ACID</u>	<u>A090210 001</u>	Nov 30, 2009
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A090210 002</u>	Nov 30, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A090210 003</u>	Nov 30, 2009
<u>AB</u>	SUN PHARM INDS	<u>EQ 125MG VALPROIC ACID</u>	<u>A078597 001</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078597 002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078597 003</u>	Jul 29, 2008
<u>AB</u>	UNICHEM LABS LTD	<u>EQ 125MG VALPROIC ACID</u>	<u>A079163 001</u>	Apr 05, 2011
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A079163 002</u>	Apr 05, 2011
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A079163 003</u>	Apr 05, 2011
<u>AB</u>	UPSHER SMITH LABS	<u>EQ 125MG VALPROIC ACID</u>	<u>A078182 001</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078182 002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078182 003</u>	Jul 29, 2008
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 125MG VALPROIC ACID</u>	<u>A077100 001</u>	Mar 05, 2009
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A077100 002</u>	Mar 05, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A077100 003</u>	Mar 05, 2009

TABLET, EXTENDED RELEASE;ORAL

DEPAKOTE ER

<u>AB</u>	+	ABEVIE	<u>EQ 250MG VALPROIC ACID</u>	<u>N021168 002</u>	May 31, 2002
<u>AB</u>	+	!	<u>EQ 500MG VALPROIC ACID</u>	<u>N021168 001</u>	Aug 04, 2000

DIVALPROEX SODIUM

<u>AB</u>	AMNEAL PHARMS	<u>EQ 250MG VALPROIC ACID</u>	<u>A203730 001</u>	May 29, 2015
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A203730 002</u>	May 29, 2015
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 250MG VALPROIC ACID</u>	<u>A202419 001</u>	Jun 02, 2014
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A202419 002</u>	Jun 02, 2014
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 250MG VALPROIC ACID</u>	<u>A090161 001</u>	Mar 15, 2012
<u>AB</u>	LUPIN LTD	<u>EQ 250MG VALPROIC ACID</u>	<u>A209286 001</u>	Oct 18, 2019
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A209286 002</u>	Oct 18, 2019
<u>AB</u>	MYLAN	<u>EQ 250MG VALPROIC ACID</u>	<u>A077567 001</u>	Jan 29, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A077567 002</u>	Jan 29, 2009
<u>AB</u>	REDDYS	<u>EQ 500MG VALPROIC ACID</u>	<u>A090070 001</u>	Mar 12, 2012
<u>AB</u>	WOCKHARDT	<u>EQ 250MG VALPROIC ACID</u>	<u>A078705 002</u>	Feb 10, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078705 001</u>	Aug 04, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 250MG VALPROIC ACID</u>	<u>A078239 001</u>	Feb 27, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078239 002</u>	Aug 04, 2009

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOBUTAMINE HYDROCHLORIDE

<u>AP</u>	!	HOSPIRA	<u>EQ 12.5MG BASE/ML</u>	<u>A074086 001</u>	Nov 29, 1993
<u>AP</u>		WEST-WARD PHARMS INT	<u>EQ 12.5MG BASE/ML</u>	<u>A074277 001</u>	Oct 31, 1994

DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>EQ 50MG BASE/100ML</u>	<u>N020255 001</u>	Oct 19, 1993
<u>AP</u>	+		<u>EQ 100MG BASE/100ML</u>	<u>N020255 003</u>	Oct 19, 1993
<u>AP</u>	+		<u>EQ 200MG BASE/100ML</u>	<u>N020255 004</u>	Oct 19, 1993
<u>AP</u>	+		<u>EQ 400MG BASE/100ML</u>	<u>N020255 005</u>	Oct 19, 1993
<u>AP</u>	+	HOSPIRA	<u>EQ 50MG BASE/100ML</u>	<u>N020201 003</u>	Oct 19, 1993
<u>AP</u>	+		<u>EQ 100MG BASE/100ML</u>	<u>N020201 002</u>	Oct 19, 1993
<u>AP</u>	+		<u>EQ 200MG BASE/100ML</u>	<u>N020201 001</u>	Oct 19, 1993
<u>AP</u>	+		<u>EQ 400MG BASE/100ML</u>	<u>N020201 006</u>	Jul 07, 1994

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

<u>AP</u>	+	ACCORD HLTHCARE	<u>20MG/ML (20MG/ML)</u>	<u>N201195 003</u>	Apr 20, 2012
<u>AP</u>	+		<u>80MG/4ML (20MG/ML)</u>	<u>N201195 004</u>	Apr 20, 2012
<u>AP</u>	+		<u>160MG/8ML (20MG/ML)</u>	<u>N201195 005</u>	Apr 20, 2012
<u>AP</u>		ACTAVIS LLC	<u>20MG/ML (20MG/ML)</u>	<u>N203551 001</u>	Apr 12, 2013

PRESCRIPTION DRUG PRODUCT LIST

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

<u>AP</u>		<u>80MG/4ML (20MG/ML)</u>	<u>N203551 002</u>	Apr 12, 2013
<u>AP</u>		<u>160MG/8ML (20MG/ML)</u>	<u>N203551 004</u>	Sep 21, 2015
<u>AP</u>	AMNEAL	<u>20MG/ML (20MG/ML)</u>	<u>A209640 001</u>	Jan 19, 2018
<u>AP</u>		<u>80MG/4ML (20MG/ML)</u>	<u>A209640 002</u>	Jan 19, 2018
<u>AP</u>		<u>160MG/8ML (20MG/ML)</u>	<u>A209640 003</u>	Jan 19, 2018
<u>AP</u>	DFB ONCOLOGY LTD	<u>20MG/ML (20MG/ML)</u>	<u>A206177 001</u>	Jan 20, 2017
<u>AP</u>		<u>80MG/4ML (20MG/ML)</u>	<u>A206177 002</u>	Jan 20, 2017
<u>AP</u>	DR REDDYS LABS LTD	<u>20MG/ML (20MG/ML)</u>	<u>A204193 001</u>	Nov 05, 2014
<u>AP</u>		<u>80MG/4ML (20MG/ML)</u>	<u>A204193 002</u>	Nov 05, 2014
<u>AP</u>	+!	<u>20MG/2ML (10MG/ML)</u>	<u>N022234 001</u>	Mar 08, 2011
<u>AP</u>	+!	<u>80MG/8ML (10MG/ML)</u>	<u>N022234 002</u>	Mar 08, 2011
<u>AP</u>	+!	<u>160MG/16ML (10MG/ML)</u>	<u>N022234 003</u>	Mar 08, 2011
<u>AP</u>	INGENUS PHARMS LLC	<u>20MG/2ML (10MG/ML)</u>	<u>A207563 001</u>	Aug 31, 2017
<u>AP</u>		<u>80MG/8ML (10MG/ML)</u>	<u>A207563 002</u>	Aug 31, 2017
<u>AP</u>		<u>160MG/16ML (10MG/ML)</u>	<u>A207563 003</u>	Aug 31, 2017
<u>AP</u>	JIANGSU HENGRUI MED	<u>20MG/ML (20MG/ML)</u>	<u>A207252 001</u>	Aug 09, 2017
<u>AP</u>		<u>80MG/4ML (20MG/ML)</u>	<u>A207252 002</u>	Aug 09, 2017
<u>AP</u>		<u>160MG/8ML (20MG/ML)</u>	<u>A207252 003</u>	Aug 09, 2017
<u>AP</u>	MYLAN LABS LTD	<u>20MG/2ML (10MG/ML)</u>	<u>A210072 001</u>	Jul 02, 2018
<u>AP</u>		<u>80MG/8ML (10MG/ML)</u>	<u>A210848 001</u>	Jul 06, 2018
<u>AP</u>		<u>160MG/8ML (20MG/ML)</u>	<u>A208137 001</u>	Apr 01, 2019
<u>AP</u>		<u>160MG/16ML (10MG/ML)</u>	<u>A208859 001</u>	Apr 30, 2018
<u>AP</u>	SANDOZ	<u>20MG/2ML (10MG/ML)</u>	<u>N201525 001</u>	Jun 29, 2011
<u>AP</u>		<u>80MG/8ML (10MG/ML)</u>	<u>N201525 002</u>	Jun 29, 2011
<u>AP</u>		<u>160MG/16ML (10MG/ML)</u>	<u>N201525 003</u>	Jun 29, 2011
<u>AP</u>	SHILPA MEDICARE LTD	<u>20MG/ML (20MG/ML)</u>	<u>A210327 001</u>	May 16, 2019
<u>AP</u>		<u>80MG/4ML (20MG/ML)</u>	<u>A210327 002</u>	May 16, 2019
<u>AP</u>		<u>160MG/8ML (20MG/ML)</u>	<u>A210327 003</u>	May 16, 2019
<u>AP</u>	TEIKOKU PHARMA	<u>20MG/ML (20MG/ML)</u>	<u>N205934 001</u>	Dec 22, 2015
<u>AP</u>		<u>80MG/4ML (20MG/ML)</u>	<u>N205934 002</u>	Dec 22, 2015
<u>AP</u>		<u>160MG/8ML (20MG/ML)</u>	<u>N205934 003</u>	Dec 22, 2015

TAXOTERE

<u>AP</u>	+!	<u>20MG/ML (20MG/ML)</u>	<u>N020449 003</u>	Aug 03, 2010
<u>AP</u>	+!	<u>80MG/4ML (20MG/ML)</u>	<u>N020449 004</u>	Aug 02, 2010
<u>AP</u>	+!	<u>160MG/8ML (20MG/ML)</u>	<u>N020449 005</u>	Apr 13, 2012

DOCETAXEL

	ACTAVIS LLC	140MG/7ML (20MG/ML)	N203551 003	Apr 12, 2013
	DFB ONCOLOGY LTD	200MG/10ML (20MG/ML)	A206177 003	Jan 20, 2017
	+ HOSPIRA INC	20MG/ML (20MG/ML)	N022234 004	Jun 23, 2016
	+ HOSPIRA INC	80MG/4ML (20MG/ML)	N022234 005	Jun 23, 2016
	+ HOSPIRA INC	160MG/8ML (20MG/ML)	N022234 007	Jan 24, 2017
	! JIANGSU HENGRUI MED	40MG/ML	A203170 001	Feb 15, 2017

SOLUTION; INTRAVENOUS

DOCETAXEL

<u>AP</u>	SUN PHARMA GLOBAL	<u>20MG/ML (20MG/ML)</u>	<u>N022534 003</u>	Jan 08, 2019
<u>AP</u>		<u>80MG/4ML (20MG/ML)</u>	<u>N022534 004</u>	Jan 08, 2019
<u>AP</u>		<u>160MG/8ML (20MG/ML)</u>	<u>N022534 005</u>	Jan 08, 2019

DOFETILIDE

CAPSULE; ORAL

DOFETILIDE

<u>AB</u>	AUROBINDO PHARMA LTD	<u>0.125MG</u>	<u>A210740 001</u>	Jan 22, 2019
<u>AB</u>		<u>0.25MG</u>	<u>A210740 002</u>	Jan 22, 2019
<u>AB</u>		<u>0.5MG</u>	<u>A210740 003</u>	Jan 22, 2019

DOFETILIDE

<u>AB</u>	ACCORD HLTHCARE	<u>0.125MG</u>	<u>A213338 001</u>	Jun 19, 2020
<u>AB</u>		<u>0.25MG</u>	<u>A213338 002</u>	Jun 19, 2020
<u>AB</u>		<u>0.5MG</u>	<u>A213338 003</u>	Jun 19, 2020
<u>AB</u>	BIONPHARMA INC	<u>0.125MG</u>	<u>A208625 001</u>	Apr 10, 2018
<u>AB</u>		<u>0.25MG</u>	<u>A208625 002</u>	Apr 10, 2018
<u>AB</u>		<u>0.5MG</u>	<u>A208625 003</u>	Apr 10, 2018
<u>AB</u>	MAYNE PHARMA INC	<u>0.125MG</u>	<u>A207058 001</u>	Jun 06, 2016
<u>AB</u>		<u>0.25MG</u>	<u>A207058 002</u>	Jun 06, 2016
<u>AB</u>		<u>0.5MG</u>	<u>A207058 003</u>	Jun 06, 2016
<u>AB</u>	MSN	<u>0.125MG</u>	<u>A213220 001</u>	Jan 29, 2020
<u>AB</u>		<u>0.25MG</u>	<u>A213220 002</u>	Jan 29, 2020
<u>AB</u>		<u>0.5MG</u>	<u>A213220 003</u>	Jan 29, 2020
<u>AB</u>	PAR PHARM INC	<u>0.125MG</u>	<u>A208519 001</u>	Oct 09, 2018
<u>AB</u>		<u>0.25MG</u>	<u>A208519 002</u>	Oct 09, 2018

PRESCRIPTION DRUG PRODUCT LIST

DOFETILIDE

CAPSULE;ORAL

DOFETILIDE

AB		0.5MG	A208519 003	Oct 09, 2018
AB	RICONPHARMA LLC	0.125MG	A212410 001	Dec 27, 2019
AB		0.25MG	A212410 002	Dec 27, 2019
AB		0.5MG	A212410 003	Dec 27, 2019
AB	SIGMAPHARM LABS LLC	0.125MG	A207746 001	Mar 26, 2018
AB		0.25MG	A207746 002	Mar 26, 2018
AB		0.5MG	A207746 003	Mar 26, 2018
AB	SUN PHARM	0.125MG	A210466 001	Oct 09, 2018
AB		0.25MG	A210466 002	Oct 09, 2018
AB		0.5MG	A210466 003	Oct 09, 2018
TIKOSYN				
AB	+ PFIZER	0.125MG	N020931 001	Oct 01, 1999
AB	+	0.25MG	N020931 002	Oct 01, 1999
AB	+	0.5MG	N020931 003	Oct 01, 1999

DOLUTEGRAVIR SODIUM

TABLET;ORAL

TIVICAY

+	VIIV HLTHCARE	EQ 10MG BASE	N204790 002	Jun 09, 2016
+		EQ 25MG BASE	N204790 003	Jun 09, 2016
+	!	EQ 50MG BASE	N204790 001	Aug 12, 2013

TABLET, FOR SUSPENSION;ORAL

TIVICAY PD

+	!	VIIV HLTHCARE	EQ 5MG BASE	N213983 001	Jun 12, 2020
---	---	---------------	-------------	-------------	--------------

DOLUTEGRAVIR SODIUM; LAMIVUDINE

TABLET;ORAL

DOVATO

+	!	VIIV HLTHCARE	EQ 50MG BASE;300MG	N211994 001	Apr 08, 2019
---	---	---------------	--------------------	-------------	--------------

DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE

TABLET;ORAL

JULUCA

+	!	VIIV HLTHCARE	EQ 50MG BASE;EQ 25MG BASE	N210192 001	Nov 21, 2017
---	---	---------------	---------------------------	-------------	--------------

DONEPEZIL HYDROCHLORIDE

TABLET;ORAL

ARICEPT

AB	+	EISAI INC	5MG	N020690 002	Nov 25, 1996
AB	+	!	10MG	N020690 001	Nov 25, 1996
AB	+	!	23MG	N022568 001	Jul 23, 2010

DONEPEZIL HYDROCHLORIDE

AB		ACI HEALTHCARE LTD	5MG	A078662 001	May 31, 2011
AB			10MG	A078662 002	May 31, 2011
AB		ALEMBIC PHARMS LTD	5MG	A201724 001	Feb 25, 2013
AB			10MG	A201724 002	Feb 25, 2013
AB		AUROBINDO	5MG	A090056 001	May 31, 2011
AB			10MG	A090056 002	May 31, 2011
AB		CADILA	5MG	A090100 001	Oct 24, 2012
AB			10MG	A090100 002	Oct 24, 2012
AB		CADILA PHARMS LTD	5MG	A204609 001	Sep 19, 2017
AB			10MG	A204609 002	Sep 19, 2017
AB		CIPLA LTD	5MG	A077518 001	May 31, 2011
AB			10MG	A077518 002	May 31, 2011
AB		DEXCEL PHARMA	23MG	A203713 001	Feb 19, 2016
AB		DR REDDYS	23MG	A202723 001	Jul 24, 2013
AB		DR REDDYS LABS LTD	5MG	A201001 001	May 31, 2011
AB			10MG	A201001 002	May 31, 2011
AB		HETERO LABS LTD V	5MG	A203034 001	Jan 30, 2015
AB			10MG	A203034 002	Jan 30, 2015
AB		INDICUS PHARMA	5MG	A201634 001	Jun 13, 2012
AB			10MG	A201634 002	Jun 13, 2012
AB			23MG	A203419 001	Apr 12, 2016
AB		JUBILANT GENERICS	5MG	A090768 001	May 31, 2011
AB			10MG	A090768 002	May 31, 2011
AB		LUPIN LTD	23MG	A202782 001	Oct 30, 2015
AB		MACLEODS PHARMS LTD	5MG	A201146 001	Aug 17, 2012
AB			10MG	A201146 002	Aug 17, 2012
AB			23MG	A202631 001	Jan 22, 2014
AB		MYLAN	23MG	A202656 001	Oct 22, 2015
AB		PLIVA HRVATSKA DOO	5MG	A090425 001	May 31, 2011

PRESCRIPTION DRUG PRODUCT LIST

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

<u>AB</u>		<u>10MG</u>	<u>A090425</u>	<u>002</u>	May 31, 2011
<u>AB</u>	PRINSTON INC	<u>5MG</u>	<u>A200292</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A200292</u>	<u>002</u>	May 31, 2011
<u>AB</u>	RISING	<u>5MG</u>	<u>A202114</u>	<u>001</u>	Jul 05, 2013
<u>AB</u>		<u>10MG</u>	<u>A202114</u>	<u>002</u>	Jul 05, 2013
<u>AB</u>	SANDOZ	<u>5MG</u>	<u>A090290</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A090290</u>	<u>002</u>	May 31, 2011
<u>AB</u>	SCIEGEN PHARMS INC	<u>5MG</u>	<u>A203907</u>	<u>001</u>	Oct 29, 2014
<u>AB</u>		<u>10MG</u>	<u>A203907</u>	<u>002</u>	Oct 29, 2014
<u>AB</u>	STRIDES PHARMA	<u>5MG</u>	<u>A090551</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A090551</u>	<u>002</u>	May 31, 2011
<u>AB</u>	SUN PHARM INDS	<u>5MG</u>	<u>A090493</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A090493</u>	<u>002</u>	May 31, 2011
<u>AB</u>	TORRENT PHARMS	<u>5MG</u>	<u>A090686</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A090686</u>	<u>002</u>	May 31, 2011
<u>AB</u>	TWI PHARMS	<u>23MG</u>	<u>A203104</u>	<u>001</u>	Oct 29, 2014
<u>AB</u>	ZYDUS PHARMS	<u>23MG</u>	<u>A203162</u>	<u>001</u>	Aug 31, 2017

TABLET, ORALLY DISINTEGRATING; ORAL

DONEPEZIL HYDROCHLORIDE

<u>AB</u>	HISUN PHARM HANGZHOU	<u>5MG</u>	<u>A205269</u>	<u>001</u>	Jul 27, 2018
<u>AB</u>		<u>10MG</u>	<u>A205269</u>	<u>002</u>	Jul 27, 2018
<u>AB</u>	MACLEODS PHARMS LTD	<u>5MG</u>	<u>A201787</u>	<u>001</u>	Dec 14, 2012
<u>AB</u>		<u>10MG</u>	<u>A201787</u>	<u>002</u>	Dec 14, 2012
<u>AB</u>	SANDOZ	<u>5MG</u>	<u>A091198</u>	<u>001</u>	May 10, 2011
<u>AB</u>	!	<u>10MG</u>	<u>A091198</u>	<u>002</u>	May 10, 2011

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

NAMZARIC

+	ALLERGAN	10MG; 7MG	N206439	003	Jul 18, 2016
+		10MG; 14MG	N206439	001	Dec 23, 2014
+		10MG; 21MG	N206439	004	Jul 18, 2016
+	!	10MG; 28MG	N206439	002	Dec 23, 2014

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HYDROCHLORIDE

<u>AP</u>	HIKMA INTL PHARMS	<u>40MG/ML</u>	<u>A207707</u>	<u>001</u>	Apr 11, 2018
<u>AP</u>		<u>80MG/ML</u>	<u>A207707</u>	<u>002</u>	Apr 11, 2018
<u>AP</u>	+! HOSPIRA	<u>40MG/ML</u>	<u>N018132</u>	<u>001</u>	
<u>AP</u>	+!	<u>80MG/100ML</u>	<u>N018132</u>	<u>002</u>	Feb 04, 1982
<u>AP</u>	+!	<u>80MG/ML</u>	<u>N018132</u>	<u>004</u>	Jul 09, 1982
<u>AP</u>	+!	<u>160MG/100ML</u>	<u>N018132</u>	<u>003</u>	Feb 04, 1982

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%

<u>AP</u>	+! B BRAUN	<u>80MG/100ML</u>	<u>N019099</u>	<u>002</u>	Oct 15, 1986
<u>AP</u>	+!	<u>320MG/100ML</u>	<u>N019099</u>	<u>004</u>	Oct 15, 1986

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+! B BRAUN	<u>160MG/100ML</u>	<u>N019099</u>	<u>003</u>	Oct 15, 1986
-----------	------------	--------------------	----------------	------------	--------------

DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+! BAXTER HLTHCARE	<u>80MG/100ML</u>	<u>N019615</u>	<u>001</u>	Mar 27, 1987
<u>AP</u>	+!	<u>160MG/100ML</u>	<u>N019615</u>	<u>002</u>	Mar 27, 1987
<u>AP</u>	+!	<u>320MG/100ML</u>	<u>N019615</u>	<u>003</u>	Mar 27, 1987
<u>AP</u>	+! HOSPIRA	<u>80MG/100ML</u>	<u>N018826</u>	<u>001</u>	Sep 30, 1983
<u>AP</u>	+!	<u>160MG/100ML</u>	<u>N018826</u>	<u>002</u>	Sep 30, 1983
<u>AP</u>	+!	<u>320MG/100ML</u>	<u>N018826</u>	<u>003</u>	Sep 30, 1983

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER

+	B BRAUN	40MG/100ML	N019099	001	Oct 15, 1986
---	---------	------------	---------	-----	--------------

DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	640MG/100ML	N019615	004	Mar 27, 1987
---	-----------------	-------------	---------	-----	--------------

DORAVIRINE

TABLET; ORAL

PIFELTRO

+	MSD MERCK CO	100MG	N210806	001	Aug 30, 2018
---	--------------	-------	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

DELSTRIGO

+! MSD MERCK CO

100MG; 300MG; 300MG

N210807 001 Aug 30, 2018

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

<u>AT</u>	AKORN	<u>EQ 2% BASE</u>	<u>A077846 001</u>	Oct 28, 2008
<u>AT</u>	ALEMBIC PHARMS LTD	<u>EQ 2% BASE</u>	<u>A212639 001</u>	Aug 09, 2019
<u>AT</u>	BAUSCH AND LOMB	<u>EQ 2% BASE</u>	<u>A090143 001</u>	Jun 25, 2009
<u>AT</u>	FDC LTD	<u>EQ 2% BASE</u>	<u>A205294 001</u>	Jan 24, 2019
<u>AT</u>	MICRO LABS	<u>EQ 2% BASE</u>	<u>A204778 001</u>	Nov 08, 2019
<u>AT</u>	SANDOZ INC	<u>EQ 2% BASE</u>	<u>A078748 001</u>	Nov 06, 2008
<u>AT</u>		<u>EQ 2% BASE</u>	<u>A078981 001</u>	Apr 13, 2009

TRUSOPT

<u>AT</u>	+! MERCK	<u>EQ 2% BASE</u>	<u>N020408 001</u>	Dec 09, 1994
-----------	----------	-------------------	--------------------	--------------

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

COSOPT

<u>AT</u>	+! AKORN	<u>EQ 2% BASE; EQ 0.5% BASE</u>	<u>N020869 001</u>	Apr 07, 1998
-----------	----------	---------------------------------	--------------------	--------------

COSOPT PF

<u>AT</u>	+! AKORN	<u>EQ 2% BASE; EQ 0.5% BASE</u>	<u>N202667 001</u>	Feb 01, 2012
-----------	----------	---------------------------------	--------------------	--------------

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

<u>AT</u>	AKORN	<u>EQ 2% BASE; EQ 0.5% BASE</u>	<u>A077847 001</u>	Oct 28, 2008
<u>AT</u>	AKORN INC	<u>EQ 2% BASE; EQ 0.5% BASE</u>	<u>A203058 001</u>	Sep 22, 2014
<u>AT</u>	AUROBINDO PHARMA LTD	<u>EQ 2% BASE; EQ 0.5% BASE</u>	<u>A207630 001</u>	Jul 24, 2018
<u>AT</u>	BAUSCH AND LOMB	<u>EQ 2% BASE; EQ 0.5% BASE</u>	<u>A090037 001</u>	Jul 14, 2009
<u>AT</u>	MICRO LABS	<u>EQ 2.0% BASE; EQ 0.5% BASE</u>	<u>A204777 001</u>	May 28, 2020
<u>AT</u>	SANDOZ	<u>EQ 2% BASE; EQ 0.5% BASE</u>	<u>A078749 001</u>	Nov 06, 2008
<u>AT</u>	SANDOZ INC	<u>EQ 2% BASE; EQ 0.5% BASE</u>	<u>A090604 001</u>	Nov 18, 2009
<u>AT</u>	SOMERSET	<u>EQ 2% BASE; EQ 0.5% BASE</u>	<u>A207523 001</u>	Jun 25, 2019
<u>AT</u>	TEVA PHARMS	<u>EQ 2% BASE; EQ 0.5% BASE</u>	<u>A078704 001</u>	Sep 28, 2009

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION

DOPRAM

<u>AP</u>	+! HIKMA	<u>20MG/ML</u>	<u>N014879 001</u>	
-----------	----------	----------------	--------------------	--

DOXAPRAM HYDROCHLORIDE

<u>AP</u>	ATHENEX INC	<u>20MG/ML</u>	<u>A076266 001</u>	Jan 10, 2003
-----------	-------------	----------------	--------------------	--------------

DOXAZOSIN MESYLATE

TABLET; ORAL

CARDURA

<u>AB</u>	+! UPJOHN	<u>EQ 1MG BASE</u>	<u>N019668 001</u>	Nov 02, 1990
<u>AB</u>	+	<u>EQ 2MG BASE</u>	<u>N019668 002</u>	Nov 02, 1990
<u>AB</u>	+	<u>EQ 4MG BASE</u>	<u>N019668 003</u>	Nov 02, 1990
<u>AB</u>	+	<u>EQ 8MG BASE</u>	<u>N019668 004</u>	Nov 02, 1990

DOXAZOSIN MESYLATE

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 1MG BASE</u>	<u>A202824 001</u>	Jun 11, 2014
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A202824 002</u>	Jun 11, 2014
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A202824 003</u>	Jun 11, 2014
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A202824 004</u>	Jun 11, 2014
<u>AB</u>	APOTEX	<u>EQ 1MG BASE</u>	<u>A075580 001</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075580 002</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A075580 003</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A075580 004</u>	Oct 18, 2000
<u>AB</u>	HERITAGE PHARMA	<u>EQ 1MG BASE</u>	<u>A205210 001</u>	Feb 13, 2018
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A205210 002</u>	Feb 13, 2018
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A205210 003</u>	Feb 13, 2018
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A205210 004</u>	Feb 13, 2018
<u>AB</u>	MYLAN	<u>EQ 1MG BASE</u>	<u>A075509 001</u>	Oct 19, 2000
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075509 002</u>	Oct 19, 2000
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A075509 003</u>	Oct 19, 2000
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A075509 004</u>	Oct 19, 2000
<u>AB</u>	PLIVA	<u>EQ 1MG BASE</u>	<u>A075750 001</u>	Jun 08, 2001
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075750 002</u>	Jun 08, 2001
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A075750 003</u>	Jun 08, 2001
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A075750 004</u>	Jun 08, 2001
<u>AB</u>	TEVA	<u>EQ 1MG BASE</u>	<u>A075536 001</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075536 002</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A075536 003</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A075536 004</u>	Oct 18, 2000

PRESCRIPTION DRUG PRODUCT LIST

DOXAZOSIN MESYLATE

TABLET;ORAL

DOXAZOSIN MESYLATE

<u>AB</u>	UPSHER SMITH LABS	<u>EQ 1MG BASE</u>	<u>A209013 001</u>	Apr 17, 2018
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A209013 002</u>	Apr 17, 2018
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A209013 003</u>	Apr 17, 2018
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A209013 004</u>	Apr 17, 2018
<u>AB</u>	ZYDUS PHARMS	<u>EQ 1MG BASE</u>	<u>A208719 001</u>	Jul 07, 2017
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A208719 002</u>	Jul 07, 2017
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A208719 003</u>	Jul 07, 2017
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A208719 004</u>	Jul 07, 2017

TABLET, EXTENDED RELEASE;ORAL

CARDURA XL

+ UPJOHN

EQ 4MG BASE

N021269 001 Feb 22, 2005

+!

EQ 8MG BASE

N021269 002 Feb 22, 2005

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

<u>AB</u>	AJANTA PHARMA LTD	<u>EQ 10MG BASE</u>	<u>A212624 001</u>	Sep 13, 2019
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A212624 002</u>	Sep 13, 2019
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A212624 003</u>	Sep 13, 2019
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A212624 004</u>	Sep 13, 2019
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A212624 005</u>	Sep 13, 2019
<u>AB</u>	AMNEAL PHARMS CO	<u>EQ 10MG BASE</u>	<u>A207482 001</u>	Jun 28, 2017
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A207482 002</u>	Jun 28, 2017
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A207482 003</u>	Jun 28, 2017
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A207482 004</u>	Jun 28, 2017
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A207482 005</u>	Jun 28, 2017
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 10MG BASE</u>	<u>A211603 001</u>	Mar 27, 2019
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A211603 002</u>	Mar 27, 2019
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A211603 003</u>	Mar 27, 2019
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A211603 004</u>	Mar 27, 2019
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A211603 005</u>	Mar 27, 2019
<u>AB</u>	CONTRACT PHARMACAL	<u>EQ 10MG BASE</u>	<u>A213474 001</u>	Jul 28, 2020
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A213474 002</u>	Jul 28, 2020
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A213474 003</u>	Jul 28, 2020
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A213474 004</u>	Jul 28, 2020
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A213474 005</u>	Jul 28, 2020
<u>AB</u>	EPIC PHARMA LLC	<u>EQ 10MG BASE</u>	<u>A210675 001</u>	Oct 16, 2020
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A210675 002</u>	Oct 16, 2020
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A210675 003</u>	Oct 16, 2020
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A070791 002</u>	May 13, 1986
<u>AB</u>	!	<u>EQ 25MG BASE</u>	<u>A070791 003</u>	May 13, 1986
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A070791 001</u>	May 13, 1986
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A070791 004</u>	May 13, 1986
<u>AB</u>	!	<u>EQ 100MG BASE</u>	<u>A070791 005</u>	May 13, 1986
<u>AB</u>	PAR PHARM	<u>EQ 10MG BASE</u>	<u>A071422 002</u>	Nov 09, 1987
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A071422 003</u>	Nov 09, 1987
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A071422 004</u>	Nov 09, 1987
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A071422 005</u>	Nov 09, 1987
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A071422 001</u>	Nov 09, 1987
<u>AB</u>	TARO PHARM INDS LTD	<u>EQ 10MG BASE</u>	<u>A213063 001</u>	Jul 01, 2020
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A213063 002</u>	Jul 01, 2020
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A213063 003</u>	Jul 01, 2020
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A213063 004</u>	Jul 01, 2020
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A213063 005</u>	Jul 01, 2020
<u>AB</u>	UPSHER SMITH LABS	<u>EQ 10MG BASE</u>	<u>A210268 001</u>	Sep 04, 2020
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A210268 002</u>	Sep 04, 2020
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A210268 003</u>	Sep 04, 2020
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A210268 004</u>	Sep 04, 2020
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A210268 005</u>	Sep 04, 2020
	!	PAR PHARM	EQ 150MG BASE	A071422 006 Nov 09, 1987

CONCENTRATE;ORAL

DOXEPIN HYDROCHLORIDE

<u>AA</u>	!	LANNETT CO INC	<u>EQ 10MG BASE/ML</u>	<u>A074721 001</u>	Dec 29, 1998
<u>AA</u>		WOCKHARDT BIO AG	<u>EQ 10MG BASE/ML</u>	<u>A071918 001</u>	Jul 20, 1988

CREAM;TOPICAL

ZONALON

+! MYLAN

5%

N020126 001 Apr 01, 1994

PRESCRIPTION DRUG PRODUCT LIST

DOXEPIN HYDROCHLORIDE

TABLET; ORAL

DOXEPIN HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>EQ 3MG BASE</u>	<u>A201951 001</u>	Jul 26, 2013
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A201951 002</u>	Jul 26, 2013
<u>AB</u>	MYLAN	<u>EQ 3MG BASE</u>	<u>A202337 001</u>	Jan 20, 2016
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A202337 002</u>	Jan 20, 2016
<u>AB</u>	PAR PHARM INC	<u>EQ 3MG BASE</u>	<u>A202510 001</u>	Jul 24, 2020
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A202510 002</u>	Jul 24, 2020
<u>SILENOR</u>				
<u>AB</u>	+ CURRAX	<u>EQ 3MG BASE</u>	<u>N022036 001</u>	Mar 17, 2010
<u>AB</u>	+!	<u>EQ 6MG BASE</u>	<u>N022036 002</u>	Mar 17, 2010

DOXERCALCIFEROL

CAPSULE; ORAL

DOXERCALCIFEROL

<u>AB</u>	AVET	<u>0.5MCG</u>	<u>A205360 001</u>	Sep 15, 2020
<u>AB</u>		<u>1MCG</u>	<u>A205360 002</u>	Sep 15, 2020
<u>AB</u>		<u>2.5MCG</u>	<u>A205360 003</u>	Sep 15, 2020
<u>AB</u>	RISING	<u>0.5MCG</u>	<u>A201518 001</u>	Sep 09, 2016
<u>AB</u>		<u>1MCG</u>	<u>A201518 002</u>	Sep 09, 2016
<u>AB</u>		<u>2.5MCG</u>	<u>A201518 003</u>	Sep 09, 2016
<u>HECTOROL</u>				
<u>AB</u>	+ SANOFI	<u>0.5MCG</u>	<u>N020862 002</u>	Apr 23, 2004
<u>AB</u>	+!	<u>1MCG</u>	<u>N020862 003</u>	Jul 13, 2009
<u>AB</u>	+!	<u>2.5MCG</u>	<u>N020862 001</u>	Jun 09, 1999

INJECTABLE; INJECTION

DOXERCALCIFEROL

<u>AP</u>	AKORN INC	<u>2MCG/ML (2MCG/ML)</u>	<u>A203929 002</u>	Mar 28, 2016
<u>AP</u>		<u>4MCG/2ML (2MCG/ML)</u>	<u>A203929 001</u>	May 07, 2015
<u>AP</u>	AMNEAL	<u>2MCG/ML (2MCG/ML)</u>	<u>A208974 001</u>	May 24, 2017
<u>AP</u>		<u>4MCG/2ML (2MCG/ML)</u>	<u>A208974 002</u>	May 24, 2017
<u>AP</u>	GLAND PHARMA LTD	<u>4MCG/2ML (2MCG/ML)</u>	<u>A210452 001</u>	Sep 26, 2019
<u>AP</u>	HIKMA	<u>4MCG/2ML (2MCG/ML)</u>	<u>A091101 001</u>	Aug 30, 2013
<u>AP</u>	+ HOSPIRA INC	<u>4MCG/2ML (2MCG/ML)</u>	<u>N208614 001</u>	Jul 24, 2018
<u>AP</u>	LUPIN LTD	<u>4MCG/2ML (2MCG/ML)</u>	<u>A210801 001</u>	Nov 01, 2018
<u>AP</u>	MEITHEAL	<u>4MCG/2ML (2MCG/ML)</u>	<u>A211670 001</u>	Feb 07, 2020
<u>AP</u>	SANDOZ INC	<u>4MCG/2ML (2MCG/ML)</u>	<u>A091333 001</u>	May 05, 2014
<u>AP</u>		<u>4MCG/2ML (2MCG/ML)</u>	<u>A200926 001</u>	Feb 04, 2014
<u>AP</u>	SUN PHARM	<u>2MCG/ML (2MCG/ML)</u>	<u>A203875 001</u>	Nov 14, 2019
<u>AP</u>		<u>4MCG/2ML (2MCG/ML)</u>	<u>A203875 002</u>	Nov 14, 2019
<u>HECTOROL</u>				
<u>AP</u>	+ SANOFI	<u>2MCG/ML (2MCG/ML)</u>	<u>N021027 002</u>	Apr 06, 2000
<u>AP</u>	+!	<u>4MCG/2ML (2MCG/ML)</u>	<u>N021027 001</u>	Apr 06, 2000

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

<u>AP</u>	ACTAVIS INC	<u>2MG/ML</u>	<u>A203622 001</u>	Jun 27, 2014
<u>AP</u>		<u>200MG/100ML</u>	<u>A203622 002</u>	Jun 27, 2014
<u>AP</u>	AMNEAL	<u>20MG/VIAL</u>	<u>A208888 001</u>	Feb 17, 2017
<u>AP</u>		<u>50MG/VIAL</u>	<u>A208888 002</u>	Feb 17, 2017
<u>AP</u>	FRESENIUS KABI USA	<u>2MG/ML</u>	<u>A063277 001</u>	Oct 26, 1995
<u>AP</u>	GLAND PHARMA LTD	<u>2MG/ML</u>	<u>A209825 001</u>	Aug 11, 2017
<u>AP</u>	MYLAN LABS LTD	<u>50MG/VIAL</u>	<u>A200170 002</u>	Oct 28, 2011
<u>AP</u>	+! PFIZER	<u>2MG/ML</u>	<u>N050629 001</u>	Dec 23, 1987
<u>AP</u>	+!	<u>200MG/100ML</u>	<u>N050629 002</u>	May 03, 1988
<u>AP</u>	PHARMACHEMIE BV	<u>2MG/ML</u>	<u>A063336 001</u>	Feb 28, 1995
<u>AP</u>		<u>10MG/VIAL</u>	<u>A063097 001</u>	May 21, 1990
<u>AP</u>		<u>20MG/VIAL</u>	<u>A063097 002</u>	May 21, 1990
<u>AP</u>		<u>50MG/VIAL</u>	<u>A063097 003</u>	May 21, 1990
<u>AP</u>		<u>200MG/100ML</u>	<u>A063336 004</u>	Feb 28, 1995
<u>AP</u>	SAGENT PHARMS	<u>2MG/ML</u>	<u>A091495 001</u>	Mar 18, 2013
<u>AP</u>	SUN PHARM INDS	<u>2MG/ML</u>	<u>A091418 001</u>	Feb 15, 2012
<u>AP</u>	TEVA PHARMS USA	<u>2MG/ML</u>	<u>A064140 001</u>	Jul 28, 1995
<u>AP</u>		<u>200MG/100ML</u>	<u>A064140 002</u>	Jul 28, 1995
<u>AP</u>	WEST-WARD PHARMS INT	<u>2MG/ML</u>	<u>A062975 001</u>	Mar 17, 1989
<u>AP</u>	!	<u>10MG/VIAL</u>	<u>A062921 001</u>	Mar 17, 1989
<u>AP</u>	!	<u>20MG/VIAL</u>	<u>A062921 002</u>	Mar 17, 1989
<u>AP</u>	!	<u>50MG/VIAL</u>	<u>A062921 003</u>	Mar 17, 1989
<u>AP</u>		<u>200MG/100ML</u>	<u>A064097 001</u>	Sep 13, 1994
<u>AP</u>	+ PFIZER	<u>150MG/75ML</u>	<u>N050629 003</u>	Mar 28, 2011

PRESCRIPTION DRUG PRODUCT LIST

DOXORUBICIN HYDROCHLORIDE

INJECTABLE, LIPOSOMAL; INJECTION

DOXIL (LIPOSOMAL)

<u>AB</u>	+	BAXTER HLTHCARE CORP	<u>20MG/10ML (2MG/ML)</u>	<u>N050718 001</u>	Nov 17, 1995
<u>AB</u>	+		<u>50MG/25ML (2MG/ML)</u>	<u>N050718 002</u>	Jun 13, 2000

DOXORUBICIN HYDROCHLORIDE

<u>AB</u>		ZYDUS	<u>20MG/10ML (2MG/ML)</u>	<u>A212299 001</u>	Sep 10, 2020
<u>AB</u>			<u>50MG/25ML (2MG/ML)</u>	<u>A212299 002</u>	Sep 10, 2020

DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

<u>AB</u>		DR REDDYS LABS LTD	<u>20MG/10ML (2MG/ML)</u>	<u>A208657 001</u>	May 15, 2017
<u>AB</u>			<u>50MG/25ML (2MG/ML)</u>	<u>A208657 002</u>	May 15, 2017
<u>AB</u>	!	SUN PHARM	<u>20MG/10ML (2MG/ML)</u>	<u>A203263 001</u>	Feb 04, 2013
<u>AB</u>	!		<u>50MG/25ML (2MG/ML)</u>	<u>A203263 002</u>	Feb 04, 2013

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

<u>AB</u>		ALEMBIC PHARMS LTD	<u>EQ 75MG BASE</u>	<u>A209165 001</u>	Jul 28, 2017
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A209165 002</u>	Jul 28, 2017
<u>AB</u>		COSETTE	<u>EQ 50MG BASE</u>	<u>A204446 001</u>	May 28, 2015
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A204446 002</u>	May 28, 2015
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A204446 003</u>	May 28, 2015
<u>AB</u>		IMPAX LABS INC	<u>EQ 150MG BASE</u>	<u>A200065 001</u>	Feb 17, 2011
<u>AB</u>		LUPIN LTD	<u>EQ 50MG BASE</u>	<u>A204234 001</u>	Mar 05, 2014
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A204234 002</u>	Mar 05, 2014
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A204234 003</u>	Mar 05, 2014
<u>AB</u>		MAYNE PHARMA INC	<u>EQ 50MG BASE</u>	<u>A209396 001</u>	Sep 29, 2017
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A209396 002</u>	Sep 29, 2017
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A209396 003</u>	Sep 29, 2017
<u>AB</u>		PAR PHARM	<u>EQ 50MG BASE</u>	<u>A065055 001</u>	Dec 01, 2000
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A065055 002</u>	Dec 01, 2000
<u>AB</u>	!		<u>EQ 150MG BASE</u>	<u>A065055 003</u>	Jul 15, 2005
<u>AB</u>		SUN PHARM INDS LTD	<u>EQ 50MG BASE</u>	<u>A065053 001</u>	Nov 22, 2000
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A065053 003</u>	Sep 10, 2003
<u>AB</u>	!		<u>EQ 100MG BASE</u>	<u>A065053 002</u>	Nov 22, 2000
<u>AB</u>		ZYDUS PHARMS	<u>EQ 50MG BASE</u>	<u>A205115 001</u>	Feb 18, 2016
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A205115 002</u>	Feb 18, 2016
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A205115 003</u>	Feb 18, 2016

ORACEA

+! GALDERMA LABS LP 40MG

N050805 001 May 26, 2006

FOR SUSPENSION; ORAL

DOXYCYCLINE

<u>AB</u>		CHARTWELL LIFE SCI	<u>EQ 25MG BASE/5ML</u>	<u>A065454 001</u>	Jul 16, 2008
<u>AB</u>		LUPIN LTD	<u>EQ 25MG BASE/5ML</u>	<u>A201678 001</u>	Mar 18, 2013

VIBRAMYCIN

<u>AB</u>	+	PFIZER	<u>EQ 25MG BASE/5ML</u>	<u>N050006 001</u>	
-----------	---	--------	-------------------------	--------------------	--

TABLET; ORAL

DOXYCYCLINE

<u>AB</u>		HERITAGE PHARMS INC	<u>EQ 50MG BASE</u>	<u>A091605 001</u>	Dec 20, 2011
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A091605 002</u>	Dec 20, 2011
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A091605 003</u>	Dec 20, 2011
<u>AB</u>	!		<u>EQ 150MG BASE</u>	<u>A091605 004</u>	Dec 20, 2011
<u>AB</u>		LANNETT CO INC	<u>EQ 50MG BASE</u>	<u>A065285 001</u>	Dec 08, 2005
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A065285 003</u>	Jul 30, 2008
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A065285 002</u>	Dec 08, 2005
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>A065285 004</u>	Jul 30, 2008
<u>AB</u>		SUN PHARM INDS LTD	<u>EQ 50MG BASE</u>	<u>A065356 001</u>	May 31, 2006
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A065356 002</u>	May 31, 2006
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A065356 003</u>	May 31, 2006
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>A065356 004</u>	Jul 29, 2010
<u>AB</u>		ZYDUS PHARMS	<u>EQ 50MG BASE</u>	<u>A209582 001</u>	Sep 28, 2017
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A209582 002</u>	Sep 28, 2017
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A209582 003</u>	Sep 28, 2017
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>A209582 004</u>	Sep 28, 2017

DOXYCYCLINE CALCIUM

SUSPENSION; ORAL

VIBRAMYCIN

+! PFIZER EQ 50MG BASE/5ML

N050480 001

PRESCRIPTION DRUG PRODUCT LIST

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

<u>AB</u>	ACTAVIS LABS FL INC	<u>EQ 50MG BASE</u>	<u>A062031 002</u>	Oct 13, 1982
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A062031 001</u>	
<u>AB</u>	ALEMBIC PHARMS LTD	<u>EQ 50MG BASE</u>	<u>A210527 001</u>	Jun 13, 2018
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A210527 002</u>	Jun 13, 2018
<u>AB</u>	AMNEAL PHARMS	<u>EQ 100MG BASE</u>	<u>A207289 001</u>	Jun 27, 2016
<u>AB</u>	CHANGZHOU PHARM	<u>EQ 100MG BASE</u>	<u>A209402 001</u>	Oct 07, 2019
<u>AB</u>	CHARTWELL LIFE SCI	<u>EQ 50MG BASE</u>	<u>A062500 001</u>	Sep 11, 1984
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A062500 002</u>	Sep 11, 1984
<u>AB</u>	HIKMA INTL PHARMS	<u>EQ 50MG BASE</u>	<u>A062396 002</u>	Nov 07, 1984
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A062396 001</u>	May 07, 1984
<u>AB</u>	NOSTRUM LABS INC	<u>EQ 50MG BASE</u>	<u>A209393 001</u>	Dec 10, 2020
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A209393 002</u>	Dec 10, 2020
<u>AB</u>	SUN PHARM INDUSTRIES	<u>EQ 50MG BASE</u>	<u>A062676 002</u>	Jul 10, 1986
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A062676 001</u>	Jul 10, 1986
<u>AB</u>	ZYDUS PHARMS	<u>EQ 50MG BASE</u>	<u>A207774 001</u>	May 31, 2018
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A207774 002</u>	May 31, 2018

VIBRAMYCINAB +! PFIZEREQ 100MG BASEN050007 002

INJECTABLE; INJECTION

DOXY 100AP ! FRESENIUS KABI USAEQ 100MG BASE/VIALA062475 001 Dec 09, 1983DOXY 200AP ! FRESENIUS KABI USAEQ 200MG BASE/VIALA062475 002 Dec 09, 1983DOXYCYCLINEAP MYLAN LABS LTDEQ 100MG BASE/VIALA091406 001 Aug 21, 2012AP ! WEST-WARD PHARMS
INTEQ 100MG BASE/VIALA062569 001 Mar 09, 1988AP ZYDUS PHARMSEQ 100MG BASE/VIALA207757 001 Sep 28, 2017AP EQ 200MG BASE/VIALA207757 002 Sep 28, 2017

SYSTEM, EXTENDED RELEASE; PERIODONTAL

ATRIDOX

+! DEN-MAT

50MG

N050751 001 Sep 03, 1998

TABLET; ORAL

ACTICLATEAB + ALMIRALLEQ 75MG BASEN205931 001 Jul 25, 2014AB +!EQ 150MG BASEN205931 002 Jul 25, 2014DOXYCYCLINE HYCLATEAB ACELLAEQ 100MG BASEA210664 001 Mar 16, 2020AB ACTAVIS LABS FL INCEQ 100MG BASEA062421 001 Feb 02, 1983AB AJANTA PHARMA LTDEQ 75MG BASEA211584 001 Jun 01, 2020AB EQ 150MG BASEA211584 002 Jun 01, 2020AB ALEMBIC PHARMS LTDEQ 20MG BASEA210537 001 Mar 03, 2020AB EQ 75MG BASEA211744 001 Jun 30, 2020AB EQ 150MG BASEA211744 002 Jun 30, 2020AB AMNEAL PHARMS COEQ 75MG BASEA209372 001 Oct 06, 2017AB EQ 150MG BASEA209372 002 Oct 06, 2017AB APOTEXEQ 75MG BASEA209243 001 Apr 15, 2019AB EQ 150MG BASEA209243 002 Apr 15, 2019AB CADILAEQ 100MG BASEA207773 001 Oct 30, 2017AB ! CARIBE HOLDINGSEQ 100MG BASEA062269 002 Nov 08, 1982AB CHANGZHOU PHARMEQ 100MG BASEA211343 001 Oct 09, 2019AB CHARTWELL LIFE SCIEQ 100MG BASEA062505 001 Sep 11, 1984AB EMCURE PHARMS LTDEQ 100MG BASEA209969 001 Nov 09, 2018AB EPIC PHARMA LLCEQ 20MG BASEA065182 001 May 13, 2005AB EQ 75MG BASEA214207 001 Dec 16, 2020AB EQ 150MG BASEA214207 002 Dec 16, 2020AB HIKMA INTL PHARMSEQ 100MG BASEA065095 001 Jul 02, 2003AB ! LANNETT CO INCEQ 20MG BASEA065277 001 Nov 10, 2005AB LARKEN LABSEQ 20MG BASEA065287 001 Feb 28, 2006AB LUPIN LTDEQ 75MG BASEA208818 001 Sep 27, 2017AB EQ 150MG BASEA208818 002 Sep 27, 2017AB MAYNE PHARMA INCEQ 75MG BASEA208765 001 Jun 14, 2017AB EQ 150MG BASEA208765 002 Jun 14, 2017AB MYLANEQ 100MG BASEA062432 001 Feb 15, 1983AB NOVEL LABS INCEQ 100MG BASEA207558 001 Sep 06, 2017AB SUN PHARMEQ 20MG BASEA065134 001 May 13, 2005AB EQ 100MG BASEA062677 001 Jul 10, 1986

INDUSTRIES

EQ 50MG BASEA062269 003 Oct 05, 1983

PRESCRIPTION DRUG PRODUCT LIST

DOXYCYCLINE HYCLATE

TABLET, DELAYED RELEASE;ORAL

DORYX

<u>AB</u>	+	MAYNE PHARMA	<u>EQ 50MG BASE</u>	<u>N050795 006</u>	Dec 19, 2014
<u>AB</u>	+		<u>EQ 75MG BASE</u>	<u>N050795 001</u>	May 06, 2005
<u>AB</u>	+		<u>EQ 100MG BASE</u>	<u>N050795 002</u>	May 06, 2005
<u>AB</u>	+		<u>EQ 150MG BASE</u>	<u>N050795 003</u>	Jun 20, 2008
<u>AB</u>	+	!	<u>EQ 200MG BASE</u>	<u>N050795 005</u>	Apr 11, 2013

DOXYCYCLINE HYCLATE

<u>AB</u>		ACTAVIS ELIZABETH	<u>EQ 50MG BASE</u>	<u>A090134 003</u>	May 22, 2018	
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A090134 001</u>	Dec 14, 2011	
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A090134 002</u>	Dec 14, 2011	
<u>AB</u>			<u>EQ 200MG BASE</u>	<u>A090134 004</u>	May 22, 2018	
<u>AB</u>		HERITAGE PHARMS INC	<u>EQ 75MG BASE</u>	<u>A200856 001</u>	Apr 30, 2013	
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A200856 002</u>	Apr 30, 2013	
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>A200856 003</u>	Apr 30, 2013	
<u>AB</u>			<u>EQ 200MG BASE</u>	<u>A200856 004</u>	Nov 13, 2018	
<u>AB</u>		MYLAN	<u>EQ 50MG BASE</u>	<u>A090431 003</u>	May 23, 2016	
<u>AB</u>		PRINSTON INC	<u>EQ 50MG BASE</u>	<u>A207494 003</u>	Feb 19, 2019	
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>A207494 001</u>	Nov 15, 2016	
<u>AB</u>			<u>EQ 200MG BASE</u>	<u>A207494 002</u>	Nov 15, 2016	
		DORYX				
		+	MAYNE PHARMA	EQ 80MG BASE	N050795 004 Apr 11, 2013	
			DORYX MPC			
		+	!	MAYNE PHARMA	EQ 120MG BASE	N050795 008 May 20, 2016

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, DELAYED RELEASE;ORAL

DICLEGIS

<u>AB</u>	+	!	DUCHESNAY	<u>10MG;10MG</u>	<u>N021876 001</u>	Apr 08, 2013
-----------	---	---	-----------	------------------	--------------------	--------------

DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE

<u>AB</u>			ACTAVIS LABS FL INC	<u>10MG;10MG</u>	<u>A205811 001</u>	Aug 19, 2016
<u>AB</u>			MYLAN PHARMS INC	<u>10MG;10MG</u>	<u>A207825 001</u>	Jul 06, 2020
<u>AB</u>			PAR PHARM INC	<u>10MG;10MG</u>	<u>A208518 001</u>	Dec 06, 2017

TABLET, EXTENDED RELEASE;ORAL

BONJESTA

		+	!	DUCHESNAY	20MG;20MG	N209661 001 Nov 07, 2016
--	--	---	---	-----------	-----------	--------------------------

DRONABINOL

CAPSULE;ORAL

DRONABINOL

<u>AB</u>			AKORN INC	<u>2.5MG</u>	<u>A079217 001</u>	Jun 20, 2014
<u>AB</u>				<u>5MG</u>	<u>A079217 002</u>	Jun 20, 2014
<u>AB</u>				<u>10MG</u>	<u>A079217 003</u>	Jun 20, 2014
<u>AB</u>			ASCENT PHARMS INC	<u>2.5MG</u>	<u>A207421 001</u>	Feb 07, 2020
<u>AB</u>				<u>5MG</u>	<u>A207421 002</u>	Feb 07, 2020
<u>AB</u>				<u>10MG</u>	<u>A207421 003</u>	Feb 07, 2020
<u>AB</u>			LANNETT CO INC	<u>2.5MG</u>	<u>A201463 001</u>	May 18, 2018
<u>AB</u>				<u>5MG</u>	<u>A201463 002</u>	May 18, 2018
<u>AB</u>				<u>10MG</u>	<u>A201463 003</u>	May 18, 2018
<u>AB</u>			SVC PHARMA	<u>2.5MG</u>	<u>A078292 001</u>	Jun 27, 2008
<u>AB</u>				<u>5MG</u>	<u>A078292 002</u>	Jun 27, 2008
<u>AB</u>				<u>10MG</u>	<u>A078292 003</u>	Jun 27, 2008

MARINOL

<u>AB</u>	+		ALKEM LABS LTD	<u>2.5MG</u>	<u>N018651 001</u>	May 31, 1985
<u>AB</u>	+	!		<u>5MG</u>	<u>N018651 002</u>	May 31, 1985
<u>AB</u>	+			<u>10MG</u>	<u>N018651 003</u>	May 31, 1985

SOLUTION;ORAL

SYNDROS

		+	!	BENUVIA	5MG/ML	N205525 001 Mar 23, 2017
--	--	---	---	---------	--------	--------------------------

DRONEDARONE HYDROCHLORIDE

TABLET;ORAL

MULTAQ

		+	!	SANOFI AVENTIS US	EQ 400MG BASE	N022425 001 Jul 01, 2009
--	--	---	---	-------------------	---------------	--------------------------

DROPERIDOL

INJECTABLE; INJECTION

DROPERIDOL

<u>AP</u>			AM REGENT	<u>2.5MG/ML</u>	<u>A072123 001</u>	Oct 24, 1988
<u>AP</u>			EUROHLTH INTL SARL	<u>2.5MG/ML</u>	<u>A208197 001</u>	Dec 14, 2017
<u>AP</u>			HOSPIRA	<u>2.5MG/ML</u>	<u>A071981 001</u>	Feb 29, 1988

INAPSINE

<u>AP</u>	+	!	AKORN	<u>2.5MG/ML</u>	<u>N016796 001</u>	
-----------	---	---	-------	-----------------	--------------------	--

PRESCRIPTION DRUG PRODUCT LIST

DROSPIRENONE

TABLET;ORAL

SLYND

+! EXELTIS USA INC 4MG

N211367 001 May 23, 2019

DROSPIRENONE; ESTRADIOL

TABLET;ORAL

ANGELIQ

+ BAYER HLTHCARE 0.25MG;0.5MG

N021355 001 Feb 29, 2012

+! 0.5MG;1MG

N021355 002 Sep 28, 2005

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL

AB	ALLIED	<u>3MG;0.02MG</u>	<u>A203291</u>	<u>001</u>	Jul 18, 2017
AB	BARR	<u>3MG;0.02MG</u>	<u>A078515</u>	<u>001</u>	Mar 30, 2009
AB	GLENMARK PHARMS LTD	<u>3MG;0.02MG</u>	<u>A204296</u>	<u>001</u>	Aug 17, 2015
AB	HETERO LABS LTD	<u>3MG;0.02MG</u>	<u>A211944</u>	<u>001</u>	Mar 22, 2019
AB	JUBILANT CADISTA	<u>3MG;0.02MG</u>	<u>A209423</u>	<u>001</u>	Dec 22, 2017
AB	MYLAN LABS LTD	<u>3MG;0.02MG</u>	<u>A202594</u>	<u>001</u>	Oct 22, 2015
AB	WATSON LABS	<u>3MG;0.02MG</u>	<u>A078833</u>	<u>001</u>	Nov 28, 2011
<u>KYRA</u>					
AB	SUN PHARM	<u>3MG;0.02MG</u>	<u>A202318</u>	<u>001</u>	Jul 23, 2019
<u>LO-ZUMANDIMINE</u>					
AB	AUROBINDO PHARMA LTD	<u>3MG;0.02MG</u>	<u>A209632</u>	<u>001</u>	Feb 27, 2018
<u>LORYNA</u>					
AB	XIROMED	<u>3MG;0.02MG</u>	<u>A079221</u>	<u>001</u>	Mar 28, 2011
<u>MELAMISA</u>					
AB	NOVAST LABS	<u>3MG;0.02MG</u>	<u>A202016</u>	<u>001</u>	Jan 26, 2016
<u>NIKKI</u>					
AB	LUPIN LTD	<u>3MG;0.02MG</u>	<u>A201661</u>	<u>001</u>	May 27, 2014
<u>YAZ</u>					
AB	+! BAYER HLTHCARE	<u>3MG;0.02MG</u>	<u>N021676</u>	<u>001</u>	Mar 16, 2006

TABLET;ORAL-28

DROSPIRENONE AND ETHINYL ESTRADIOL

AB	BARR	<u>3MG;0.03MG</u>	<u>A077527</u>	<u>001</u>	May 09, 2008
AB	GLENMARK PHARMS LTD	<u>3MG;0.03MG</u>	<u>A204848</u>	<u>001</u>	Mar 25, 2016
AB	HETERO LABS LTD	<u>3MG;0.03MG</u>	<u>A213034</u>	<u>001</u>	Jan 24, 2020
AB	JUBILANT CADISTA	<u>3MG;0.03MG</u>	<u>A210017</u>	<u>001</u>	Sep 10, 2018
AB	LUPIN LTD	<u>3MG;0.03MG</u>	<u>A201663</u>	<u>001</u>	Dec 18, 2012
AB	MAYNE PHARMA	<u>3MG;0.03MG</u>	<u>A090081</u>	<u>001</u>	Sep 07, 2010
AB	MYLAN LABS LTD	<u>3MG;0.03MG</u>	<u>A202131</u>	<u>001</u>	May 04, 2015
AB	NAARI PTE LTD	<u>3MG;0.03MG</u>	<u>A207245</u>	<u>001</u>	Nov 22, 2016
<u>KEMEYA</u>					
AB	SUN PHARM	<u>3MG;0.03MG</u>	<u>A202138</u>	<u>001</u>	Mar 13, 2019
<u>SYEDA</u>					
AB	XIROMED	<u>3MG;0.03MG</u>	<u>A090114</u>	<u>001</u>	Mar 28, 2011
<u>YAELA</u>					
AB	NOVAST LABS	<u>3MG;0.03MG</u>	<u>A202015</u>	<u>001</u>	Nov 19, 2014
<u>YASMIN</u>					
AB	+! BAYER HLTHCARE	<u>3MG;0.03MG</u>	<u>N021098</u>	<u>001</u>	May 11, 2001
<u>ZUMANDIMINE</u>					
AB	AUROBINDO PHARMA LTD	<u>3MG;0.03MG</u>	<u>A209407</u>	<u>001</u>	Mar 26, 2018

DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM

TABLET;ORAL

BEYAZ

AB	BAYER HLTHCARE	<u>3MG,N/A;0.02MG,N/A;0.451MG,0.451MG</u>	<u>N022532</u>	<u>001</u>	Sep 24, 2010
<u>DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM</u>					
AB	LUPIN LTD	<u>3MG,N/A;0.02MG,N/A;0.451MG,0.451MG</u>	<u>A205947</u>	<u>001</u>	Jun 13, 2018
AB	WATSON LABS INC	<u>3MG,N/A;0.02MG,N/A;0.451MG,0.451MG</u>	<u>A203593</u>	<u>001</u>	Oct 11, 2016
AB		<u>3MG,N/A;0.03MG,N/A;0.451MG,0.451MG</u>	<u>A203594</u>	<u>001</u>	Oct 11, 2016
<u>SAFYRAL</u>					
AB	+! BAYER HLTHCARE	<u>3MG,N/A;0.03MG,N/A;0.451MG,0.451MG</u>	<u>N022574</u>	<u>001</u>	Dec 16, 2010
<u>TYDEMY</u>					
AB	LUPIN LTD	<u>3MG,N/A;0.03MG,N/A;0.451MG,0.451MG</u>	<u>A205948</u>	<u>001</u>	Dec 12, 2017

PRESCRIPTION DRUG PRODUCT LIST

DROXIDOPA

CAPSULE;ORAL

NORTHERA

+	LUNDBECK NA LTD	100MG	N203202 001	Feb 18, 2014
+		200MG	N203202 002	Feb 18, 2014
+		300MG	N203202 003	Feb 18, 2014

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

CYMBALTA

AB	+	LILLY	<u>EQ 20MG BASE</u>	<u>N021427 001</u>	Aug 03, 2004
AB	+		<u>EQ 30MG BASE</u>	<u>N021427 002</u>	Aug 03, 2004
AB	+		<u>EQ 60MG BASE</u>	<u>N021427 004</u>	Aug 03, 2004

DULOXETINE HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	<u>EQ 20MG BASE</u>	<u>A090776 001</u>	Dec 17, 2013
AB			<u>EQ 30MG BASE</u>	<u>A090776 002</u>	Dec 17, 2013
AB			<u>EQ 60MG BASE</u>	<u>A090776 003</u>	Dec 17, 2013
AB		AJANTA PHARMA LTD	<u>EQ 20MG BASE</u>	<u>A208706 001</u>	Jan 06, 2017
AB			<u>EQ 30MG BASE</u>	<u>A208706 002</u>	Jan 06, 2017
AB			<u>EQ 40MG BASE</u>	<u>A208706 004</u>	Mar 11, 2019
AB			<u>EQ 60MG BASE</u>	<u>A208706 003</u>	Jan 06, 2017
AB		ALEMBIC PHARMS LTD	<u>EQ 20MG BASE</u>	<u>A202949 001</u>	Jun 09, 2014
AB			<u>EQ 30MG BASE</u>	<u>A202949 002</u>	Jun 09, 2014
AB			<u>EQ 60MG BASE</u>	<u>A202949 003</u>	Jun 09, 2014
AB		ALKEM LABS LTD	<u>EQ 20MG BASE</u>	<u>A203197 001</u>	Aug 26, 2015
AB			<u>EQ 30MG BASE</u>	<u>A203197 002</u>	Aug 26, 2015
AB			<u>EQ 60MG BASE</u>	<u>A203197 003</u>	Aug 26, 2015
AB		ANCHEN PHARMS	<u>EQ 20MG BASE</u>	<u>A090780 001</u>	Oct 28, 2015
AB			<u>EQ 30MG BASE</u>	<u>A090780 002</u>	Oct 28, 2015
AB			<u>EQ 60MG BASE</u>	<u>A090780 003</u>	Oct 28, 2015
AB		APOTEX	<u>EQ 20MG BASE</u>	<u>A202045 001</u>	Jun 11, 2014
AB			<u>EQ 30MG BASE</u>	<u>A202045 002</u>	Jun 11, 2014
AB			<u>EQ 60MG BASE</u>	<u>A202045 003</u>	Jun 11, 2014
AB		AUROBINDO PHARMA LTD	<u>EQ 20MG BASE</u>	<u>A090778 001</u>	Dec 11, 2013
AB			<u>EQ 30MG BASE</u>	<u>A090778 002</u>	Dec 11, 2013
AB			<u>EQ 60MG BASE</u>	<u>A090778 003</u>	Dec 11, 2013
AB		BRECKENRIDGE	<u>EQ 20MG BASE</u>	<u>A203088 001</u>	Jun 11, 2014
AB			<u>EQ 30MG BASE</u>	<u>A203088 002</u>	Jun 11, 2014
AB			<u>EQ 40MG BASE</u>	<u>A203088 004</u>	May 18, 2018
AB			<u>EQ 60MG BASE</u>	<u>A203088 003</u>	Jun 11, 2014
AB		CSPC OUYI	<u>EQ 20MG BASE</u>	<u>A211310 001</u>	Oct 16, 2018
AB			<u>EQ 30MG BASE</u>	<u>A211310 002</u>	Oct 16, 2018
AB			<u>EQ 60MG BASE</u>	<u>A211310 003</u>	Oct 16, 2018
AB		HETERO LABS LTD III	<u>EQ 20MG BASE</u>	<u>A204343 001</u>	Aug 03, 2016
AB			<u>EQ 30MG BASE</u>	<u>A204343 002</u>	Aug 03, 2016
AB			<u>EQ 60MG BASE</u>	<u>A204343 003</u>	Aug 03, 2016
AB		INVENTIA	<u>EQ 20MG BASE</u>	<u>A202336 001</u>	Oct 28, 2015
AB			<u>EQ 30MG BASE</u>	<u>A202336 002</u>	Oct 28, 2015
AB			<u>EQ 60MG BASE</u>	<u>A202336 003</u>	Oct 28, 2015
AB		LUPIN LTD	<u>EQ 20MG BASE</u>	<u>A090694 001</u>	Dec 11, 2013
AB			<u>EQ 30MG BASE</u>	<u>A090694 002</u>	Dec 11, 2013
AB			<u>EQ 40MG BASE</u>	<u>A090694 003</u>	Dec 11, 2013
AB			<u>EQ 60MG BASE</u>	<u>A090694 004</u>	Dec 11, 2013
AB		MACLEODS PHARMS LTD	<u>EQ 20MG BASE</u>	<u>A204815 001</u>	Mar 23, 2017
AB			<u>EQ 30MG BASE</u>	<u>A204815 002</u>	Mar 23, 2017
AB			<u>EQ 60MG BASE</u>	<u>A204815 003</u>	Mar 23, 2017
AB		MARKSANS PHARMA	<u>EQ 20MG BASE</u>	<u>A090723 001</u>	Dec 11, 2013
AB			<u>EQ 30MG BASE</u>	<u>A090723 002</u>	Dec 11, 2013
AB			<u>EQ 60MG BASE</u>	<u>A090723 003</u>	Dec 11, 2013
AB		PRINSTON INC	<u>EQ 20MG BASE</u>	<u>A206653 001</u>	May 18, 2017
AB			<u>EQ 30MG BASE</u>	<u>A206653 002</u>	May 18, 2017
AB			<u>EQ 60MG BASE</u>	<u>A206653 003</u>	May 18, 2017
AB		QINGDAO BAHEAL PHARM	<u>EQ 20MG BASE</u>	<u>A210599 001</u>	Apr 17, 2019
AB			<u>EQ 30MG BASE</u>	<u>A210599 002</u>	Apr 17, 2019
AB			<u>EQ 60MG BASE</u>	<u>A210599 003</u>	Apr 17, 2019
AB		SUN PHARM	<u>EQ 20MG BASE</u>	<u>A090745 001</u>	Dec 11, 2013
AB			<u>EQ 30MG BASE</u>	<u>A090745 002</u>	Dec 11, 2013
AB			<u>EQ 60MG BASE</u>	<u>A090745 003</u>	Dec 11, 2013
AB		TORRENT	<u>EQ 20MG BASE</u>	<u>A090774 001</u>	Dec 11, 2013
AB			<u>EQ 30MG BASE</u>	<u>A090774 002</u>	Dec 11, 2013
AB			<u>EQ 60MG BASE</u>	<u>A090774 003</u>	Dec 11, 2013

PRESCRIPTION DRUG PRODUCT LIST

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

DULOXETINE HYDROCHLORIDE

AB	ZYDUS HLTHCARE	EQ 20MG BASE	A090739 001	Jan 08, 2014
AB		EQ 30MG BASE	A090739 002	Jan 08, 2014
AB		EQ 60MG BASE	A090739 003	Jan 08, 2014
AB	ZYDUS PHARMS	EQ 20MG BASE	A090728 001	Jan 08, 2014
AB		EQ 30MG BASE	A090728 002	Jan 08, 2014
AB		EQ 60MG BASE	A090728 003	Jan 08, 2014

CAPSULE, DELAYED RELEASE;ORAL

DRIZALMA SPRINKLE

+	SUN PHARMA GLOBAL	EQ 20MG BASE	N212516 001	Jul 19, 2019
+		EQ 30MG BASE	N212516 002	Jul 19, 2019
+		EQ 40MG BASE	N212516 003	Jul 19, 2019
+	!	EQ 60MG BASE	N212516 004	Jul 19, 2019

DUTASTERIDE

CAPSULE;ORAL

AVODART

AB	+	GLAXOSMITHKLINE	0.5MG	N021319 001	Nov 20, 2001
-----------	---	-----------------	--------------	--------------------	--------------

DUTASTERIDE

AB		ACELLA	0.5MG	A206373 001	Mar 17, 2016
AB		AMNEAL PHARMS	0.5MG	A203118 001	Nov 20, 2015
AB		ASCENT PHARMS INC	0.5MG	A206574 001	Oct 21, 2016
AB		AUROBINDO PHARMA LTD	0.5MG	A202660 001	Nov 20, 2015
AB		BARR	0.5MG	A090095 001	Dec 21, 2010
AB		BIONPHARMA INC	0.5MG	A200899 001	Nov 20, 2015
AB		CADILA	0.5MG	A204373 001	Oct 04, 2017
AB		HUMANWELL PURACAP	0.5MG	A209909 001	Nov 21, 2017
AB		MARKSANS PHARMA	0.5MG	A204376 001	Apr 07, 2017
AB		STRIDES PHARMA	0.5MG	A204262 001	Nov 20, 2015
AB		VINTAGE PHARMS LLC	0.5MG	A202421 001	Nov 20, 2015

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE

AB		ANCHEN PHARMS	0.5MG;0.4MG	A202509 001	Feb 26, 2014
AB		ZYDUS PHARMS	0.5MG;0.4MG	A207769 001	May 24, 2018
AB	+	GLAXOSMITHKLINE	0.5MG;0.4MG	N022460 001	Jun 14, 2010

DUVELISIB

CAPSULE;ORAL

COPIKTRA

+	SECURA	15MG	N211155 001	Sep 24, 2018
+	!	25MG	N211155 002	Sep 24, 2018

DYCLONINE HYDROCHLORIDE

SOLUTION;TOPICAL

DYCLOPRO

!	NOVOCOL INC	0.5%	A200480 001	Nov 20, 2018
!		1%	A200480 002	Nov 20, 2018

ECHOTHIOPHATE IODIDE

FOR SOLUTION;OPHTHALMIC

PHOSPHOLINE IODIDE

+	WYETH PHARMS	0.125%	N011963 001	
---	--------------	--------	-------------	--

ECONAZOLE NITRATE

AEROSOL, FOAM;TOPICAL

ECOZA

+	GLENMARK	1%	N205175 001	Oct 24, 2013
---	----------	----	-------------	--------------

CREAM;TOPICAL

ECONAZOLE NITRATE

AB	!	PERRIGO ISRAEL	1%	A076479 001	Jun 23, 2004
AB		TARO	1%	A076005 001	Nov 26, 2002
AB		TELGENT	1%	A076574 001	Dec 17, 2004
AB	+	ALVOGEN	1%	N018751 001	Dec 23, 1982

PRESCRIPTION DRUG PRODUCT LIST

EDARAVONE

SOLUTION; INTRAVENOUS

RADICAVA

+	!	MITSUBISHI TANABE	30MG/100ML (0.3MG/ML)	N209176	001	May 05, 2017
+	!		60MG/100ML (0.6MG/ML)	N209176	002	Nov 15, 2018

EDETATE CALCIUM DISODIUM

INJECTABLE; INJECTION

CALCIUM DISODIUM VERSENATE

+	!	MEDICIS	200MG/ML	N008922	001	
---	---	---------	----------	---------	-----	--

EDOXYBAN TOSYLATE

TABLET; ORAL

SAVAYSA

+		DAIICHI SANKYO INC	EQ 15MG BASE	N206316	001	Jan 08, 2015
+			EQ 30MG BASE	N206316	002	Jan 08, 2015
+	!		EQ 60MG BASE	N206316	003	Jan 08, 2015

EFAVIRENZ

CAPSULE; ORAL

EFAVIRENZ

AB		AUROBINDO PHARMA LTD	50MG	A078064	001	Dec 15, 2017
-----------	--	----------------------	-------------	----------------	------------	--------------

AB			200MG	A078064	003	Dec 15, 2017
-----------	--	--	--------------	----------------	------------	--------------

SUSTIVA

AB	+	BRISTOL MYERS SQUIBB	50MG	N020972	001	Sep 17, 1998
-----------	---	----------------------	-------------	----------------	------------	--------------

AB	+	!	200MG	N020972	003	Sep 17, 1998
-----------	---	---	--------------	----------------	------------	--------------

EFAVIRENZ

		AUROBINDO PHARMA LTD	100MG	A078064	002	Dec 15, 2017
--	--	----------------------	-------	---------	-----	--------------

TABLET; ORAL

EFAVIRENZ

AB		AUROBINDO PHARMA LTD	600MG	A077673	001	Sep 21, 2018
-----------	--	----------------------	--------------	----------------	------------	--------------

AB			600MG	A205322	001	Aug 30, 2018
-----------	--	--	--------------	----------------	------------	--------------

AB		CIPLA	600MG	A204766	001	Jun 15, 2018
-----------	--	-------	--------------	----------------	------------	--------------

AB		HETERO LABS LTD III	600MG	A078886	001	Apr 27, 2018
-----------	--	---------------------	--------------	----------------	------------	--------------

AB		MYLAN	600MG	A091471	001	Feb 17, 2016
-----------	--	-------	--------------	----------------	------------	--------------

AB		STRIDES PHARMA	600MG	A204869	001	Mar 12, 2018
-----------	--	----------------	--------------	----------------	------------	--------------

SUSTIVA

AB	+	!	BRISTOL MYERS SQUIBB	600MG	N021360	002	Feb 01, 2002
-----------	---	---	----------------------	--------------	----------------	-----	--------------

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

ATRIPLA

AB	+	!	GILEAD SCIENCES	600MG; 200MG; 300MG	N021937	001	Jul 12, 2006
-----------	---	---	-----------------	----------------------------	----------------	------------	--------------

EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE

AB		AUROBINDO PHARMA LTD	600MG; 200MG; 300MG	A203041	001	Sep 04, 2018
-----------	--	----------------------	----------------------------	----------------	------------	--------------

AB		CIPLA	600MG; 200MG; 300MG	A206894	001	Jun 03, 2019
-----------	--	-------	----------------------------	----------------	------------	--------------

AB		TEVA PHARMS USA	600MG; 200MG; 300MG	A091215	001	Nov 09, 2018
-----------	--	-----------------	----------------------------	----------------	------------	--------------

EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

AB		LAURUS LABS LTD	400MG; 300MG; 300MG	A213038	001	May 14, 2020
-----------	--	-----------------	----------------------------	----------------	------------	--------------

AB			600MG; 300MG; 300MG	A212786	001	May 14, 2020
-----------	--	--	----------------------------	----------------	------------	--------------

SYMFI

AB	+	!	MYLAN LABS LTD	600MG; 300MG; 300MG	N022142	001	Mar 22, 2018
-----------	---	---	----------------	----------------------------	----------------	------------	--------------

SYMFI LO

AB	+	!	MYLAN	400MG; 300MG; 300MG	N208255	001	Feb 05, 2018
-----------	---	---	-------	----------------------------	----------------	------------	--------------

EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

+	!	AUROBINDO PHARMA LTD	600MG; 300MG; 300MG	N022343	001	Aug 15, 2018
---	---	----------------------	---------------------	---------	-----	--------------

EFINACONAZOLE

SOLUTION; TOPICAL

EFINACONAZOLE

AT		PERRIGO PHARMA INTL	10%	A211851	001	Dec 16, 2020
AT		TEVA PHARMS USA	10%	A211827	001	Dec 16, 2020

JUBLIA

AT	+	!	BAUSCH	10%	N203567	001	Jun 06, 2014
-----------	---	---	--------	------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

EFLORNITHINE HYDROCHLORIDE

CREAM; TOPICAL

VANIQA

+! SKINMEDICA

13.9%

N021145 001 Jul 27, 2000

ELAGOLIX SODIUM

TABLET; ORAL

ORILISSA

+ ABBVIE INC

EQ 150MG BASE

N210450 001 Jul 23, 2018

+!

EQ 200MG BASE

N210450 002 Jul 23, 2018

ELAGOLIX SODIUM, ESTRADIOL, NORETHINDRONE ACETATE; ELAGOLIX SODIUM

CAPSULE; ORAL

ORIAHNN (COPACKAGED)

+! ABBVIE INC

EQ 300MG BASE, 1MG, 0.5MG; EQ 300MG BASE

N213388 001 May 29, 2020

ELBASVIR; GRAZOPREXIN

TABLET; ORAL

ZEPATIER

+! MERCK SHARP DOHME

50MG; 100MG

N208261 001 Jan 28, 2016

ELETRIPTAN HYDROBROMIDE

TABLET; ORAL

ELETRIPTAN HYDROBROMIDE**AB** AJANTA PHARMA LTD**EQ 20MG BASE****A205186 001** Aug 29, 2017**AB****EQ 40MG BASE****A205186 002** Aug 29, 2017**AB** AUROBINDO PHARMA**EQ 20MG BASE****A210708 001** Jan 15, 2019

LTD

AB**EQ 40MG BASE****A210708 002** Jan 15, 2019**AB** MYLAN**EQ 20MG BASE****A205152 001** Aug 11, 2017**AB****EQ 40MG BASE****A205152 002** Aug 11, 2017**AB** TEVA PHARMS USA**EQ 20MG BASE****A202040 001** Jun 27, 2017**AB****EQ 40MG BASE****A202040 002** Jun 27, 2017**AB** ZYDUS PHARMS**EQ 20MG BASE****A206409 001** Jun 16, 2017**AB****EQ 40MG BASE****A206409 002** Jun 16, 2017RELPAK**AB** + UPJOHN**EQ 20MG BASE****N021016 001** Dec 26, 2002**AB** +!**EQ 40MG BASE****N021016 002** Dec 26, 2002ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR

TABLET, TABLET; ORAL

TRIKAFTA (COPACKAGED)

+! VERTEX PHARMS INC

100MG, 75MG, 50MG; N/A, 150MG, N/A

N212273 001 Oct 21, 2019

ELIGLUSTAT TARTRATE

CAPSULE; ORAL

CERDELGA

+! GENZYME CORP

EQ 84MG BASE

N205494 001 Aug 19, 2014

ELTROMBOPAG OLAMINE

FOR SUSPENSION; ORAL

PROMACTA KIT

+ NOVARTIS

EQ 12.5MG ACID/PACKET

N207027 002 Sep 27, 2018

+!

EQ 25MG ACID/PACKET

N207027 001 Aug 24, 2015

TABLET; ORAL

PROMACTA

+ NOVARTIS

EQ 12.5MG ACID

N022291 004 Oct 20, 2011

+

EQ 25MG ACID

N022291 001 Nov 20, 2008

+

EQ 50MG ACID

N022291 002 Nov 20, 2008

+!

EQ 75MG ACID

N022291 003 Sep 08, 2009

ELUXADOLINE

TABLET; ORAL

VIBERZI

+ ALLERGAN HOLDINGS

75MG

N206940 001 May 27, 2015

+!

100MG

N206940 002 May 27, 2015

EMPAGLIFLOZIN

TABLET; ORAL

JARDIANCE

+ BOEHRINGER

10MG

N204629 001 Aug 01, 2014

INGELHEIM

+!

25MG

N204629 002 Aug 01, 2014

PRESCRIPTION DRUG PRODUCT LIST

EMPAGLIFLOZIN; LINAGLIPTIN

TABLET; ORAL

GLYXAMBI

+	BOEHRINGER INGELHEIM	10MG; 5MG	N206073 001	Jan 30, 2015
+	!	25MG; 5MG	N206073 002	Jan 30, 2015

EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

TRIJARDY XR

+	BOEHRINGER INGELHEIM	5MG; 2.5MG; 1GM	N212614 001	Jan 27, 2020
+		10MG; 5MG; 1GM	N212614 002	Jan 27, 2020
+		12.5MG; 2.5MG; 1GM	N212614 003	Jan 27, 2020
+	!	25MG; 5MG; 1GM	N212614 004	Jan 27, 2020

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET; ORAL

SYNJARDY

+	BOEHRINGER INGELHEIM	5MG; 500MG	N206111 001	Aug 26, 2015
+		5MG; 1GM	N206111 002	Aug 26, 2015
+		12.5MG; 500MG	N206111 003	Aug 26, 2015
+	!	12.5MG; 1GM	N206111 004	Aug 26, 2015

TABLET, EXTENDED RELEASE; ORAL

SYNJARDY XR

+	BOEHRINGER INGELHEIM	5MG; 1GM	N208658 001	Dec 09, 2016
+		10MG; 1GM	N208658 002	Dec 09, 2016
+		12.5MG; 1GM	N208658 003	Dec 09, 2016
+	!	25MG; 1GM	N208658 004	Dec 09, 2016

EMTRICITABINE

CAPSULE; ORAL

EMTRICITABINE

AB	CIPLA	200MG	A091168 001	Jul 02, 2018
-----------	-------	--------------	--------------------	--------------

EMTRIVA

AB	+	GILEAD	200MG	N021500 001	Jul 02, 2003
-----------	---	--------	--------------	--------------------	--------------

SOLUTION; ORAL

EMTRIVA

+	!	GILEAD	10MG/ML	N021896 001	Sep 28, 2005
---	---	--------	---------	-------------	--------------

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET; ORAL

ODEFSEY

+	!	GILEAD SCIENCES INC	200MG; EQ 25MG BASE; EQ 25MG BASE	N208351 001	Mar 01, 2016
---	---	---------------------	-----------------------------------	-------------	--------------

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

COMPLERA

+	!	GILEAD SCIENCES INC	200MG; EQ 25MG BASE; 300MG	N202123 001	Aug 10, 2011
---	---	---------------------	----------------------------	-------------	--------------

EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET; ORAL

DESCOVY

+	!	GILEAD SCIENCES INC	200MG; EQ 25MG BASE	N208215 001	Apr 04, 2016
---	---	---------------------	---------------------	-------------	--------------

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

AB		AMNEAL PHARMS CO	100MG; 150MG	A209721 001	Aug 22, 2018
-----------	--	------------------	---------------------	--------------------	--------------

AB			133MG; 200MG	A209721 002	Aug 22, 2018
-----------	--	--	---------------------	--------------------	--------------

AB			167MG; 250MG	A209721 003	Aug 22, 2018
-----------	--	--	---------------------	--------------------	--------------

AB			200MG; 300MG	A209721 004	Aug 22, 2018
-----------	--	--	---------------------	--------------------	--------------

AB		AUROBINDO PHARMA LTD	200MG; 300MG	A090513 001	Jan 26, 2018
-----------	--	----------------------	---------------------	--------------------	--------------

AB		TEVA PHARMS USA	200MG; 300MG	A090894 001	Jun 08, 2017
-----------	--	-----------------	---------------------	--------------------	--------------

AB		ZYDUS PHARMS	200MG; 300MG	A212689 001	Feb 28, 2020
-----------	--	--------------	---------------------	--------------------	--------------

TRUVADA

AB	+	GILEAD	100MG; 150MG	N021752 002	Mar 10, 2016
-----------	---	--------	---------------------	--------------------	--------------

AB	+		133MG; 200MG	N021752 003	Mar 10, 2016
-----------	---	--	---------------------	--------------------	--------------

AB	+		167MG; 250MG	N021752 004	Mar 10, 2016
-----------	---	--	---------------------	--------------------	--------------

AB	+	!	200MG; 300MG	N021752 001	Aug 02, 2004
-----------	---	---	---------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ENALAPRIL MALEATE

SOLUTION;ORAL

EPANED

+! AZURITY

1MG/ML

N208686 001 Sep 20, 2016

TABLET;ORAL

ENALAPRIL MALEATEAB HERITAGE PHARMA2.5MGA075479 001 Aug 22, 2000AB 5MGA075479 002 Aug 22, 2000AB 10MGA075479 003 Aug 22, 2000AB 20MGA075479 004 Aug 22, 2000AB SANDOZ INC2.5MGA075496 001 Aug 22, 2000AB 5MGA075496 002 Aug 22, 2000AB 10MGA075459 001 Aug 22, 2000AB 20MGA075459 002 Aug 22, 2000AB TARO2.5MGA075657 001 Jan 23, 2001AB 5MGA075657 002 Jan 23, 2001AB 10MGA075657 003 Jan 23, 2001AB 20MGA075657 004 Jan 23, 2001AB WOCKHARDT LTD2.5MGA075483 001 Aug 22, 2000AB 5MGA075483 002 Aug 22, 2000AB 10MGA075483 003 Aug 22, 2000AB 20MGA075483 004 Aug 22, 2000VASOTECAB + BAUSCH2.5MGN018998 005 Jul 26, 1988AB + 5MGN018998 001 Dec 24, 1985AB + 10MGN018998 002 Dec 24, 1985AB +! 20MGN018998 003 Dec 24, 1985ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDEAB COSETTE5MG;12.5MGA075727 001 Sep 18, 2001AB 10MG;25MGA075727 002 Sep 18, 2001AB DR REDDYS LABS LTD5MG;12.5MGA075909 001 Oct 15, 2001AB 10MG;25MGA075909 002 Oct 15, 2001AB MYLAN5MG;12.5MGA075624 001 Sep 18, 2001AB 10MG;25MGA075624 002 Sep 18, 2001AB TARO PHARM INDS5MG;12.5MGA075788 001 Sep 18, 2001AB 10MG;25MGA075788 002 Sep 18, 2001VASERETICAB + BAUSCH5MG;12.5MGN019221 003 Jul 12, 1995AB +! 10MG;25MGN019221 001 Oct 31, 1986ENALAPRILAT

INJECTABLE;INJECTION

ENALAPRILATAP ! ATHENEX INC1.25MG/MLA075634 001 Aug 22, 2000AP DR REDDYS1.25MG/MLA075578 001 Aug 22, 2000AP HIKMA FARMACEUTICA1.25MG/MLA078687 001 Dec 23, 2008AP ! HOSPIRA1.25MG/MLA075458 001 Aug 22, 2000ENASIDENIB MESYLATE

TABLET;ORAL

IDHIFA

+ CELGENE CORP

EQ 50MG BASE

N209606 001 Aug 01, 2017

+! EQ 100MG BASE

N209606 002 Aug 01, 2017

ENCORAFENIB

CAPSULE;ORAL

BRAFTOVI

+! ARRAY BIOPHARMA INC 75MG

N210496 002 Jun 27, 2018

ENFUVRTIDE

INJECTABLE;SUBCUTANEOUS

FUZEON

+! ROCHE

90MG/VIAL

N021481 001 Mar 13, 2003

ENOXAPARIN SODIUM

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

ENOXAPARIN SODIUMAB AMPHASTAR PHARMS300MG/3ML (100MG/ML)A208600 001 Mar 14, 2019AB INC

SANDOZ INC

300MG/3ML (100MG/ML)A078660 001 Nov 28, 2011LOVENOXAB + SANOFI AVENTIS US300MG/3ML (100MG/ML)N020164 009 Jan 23, 2003

PRESCRIPTION DRUG PRODUCT LIST

ENOXAPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

ENOXAPARIN SODIUM (PRESERVATIVE FREE)

<u>AP</u>	AMPHASTAR PHARM	<u>30MG/0.3ML (100MG/ML)</u>	<u>A076684 001</u>	Sep 19, 2011
<u>AP</u>		<u>40MG/0.4ML (100MG/ML)</u>	<u>A076684 002</u>	Sep 19, 2011
<u>AP</u>		<u>60MG/0.6ML (100MG/ML)</u>	<u>A076684 003</u>	Sep 19, 2011
<u>AP</u>		<u>80MG/0.8ML (100MG/ML)</u>	<u>A076684 004</u>	Sep 19, 2011
<u>AP</u>		<u>100MG/ML (100MG/ML)</u>	<u>A076684 005</u>	Sep 19, 2011
<u>AP</u>		<u>120MG/0.8ML (150MG/ML)</u>	<u>A076684 006</u>	Sep 19, 2011
<u>AP</u>		<u>150MG/ML (150MG/ML)</u>	<u>A076684 007</u>	Sep 19, 2011
<u>AP</u>	APOTEX INC	<u>30MG/0.3ML (100MG/ML)</u>	<u>A078990 001</u>	Sep 28, 2018
<u>AP</u>		<u>40MG/0.4ML (100MG/ML)</u>	<u>A078990 002</u>	Sep 28, 2018
<u>AP</u>		<u>60MG/0.6ML (100MG/ML)</u>	<u>A078990 003</u>	Sep 28, 2018
<u>AP</u>		<u>80MG/0.8ML (100MG/ML)</u>	<u>A078990 004</u>	Sep 28, 2018
<u>AP</u>		<u>100MG/ML (100MG/ML)</u>	<u>A078990 005</u>	Sep 28, 2018
<u>AP</u>		<u>120MG/0.8ML (150MG/ML)</u>	<u>A078990 006</u>	Sep 28, 2018
<u>AP</u>		<u>150MG/ML (150MG/ML)</u>	<u>A078990 007</u>	Sep 28, 2018
<u>AP</u>	NANJING KING-FRIEND	<u>30MG/0.3ML (100MG/ML)</u>	<u>A206834 001</u>	Nov 29, 2019
<u>AP</u>		<u>40MG/0.4ML (100MG/ML)</u>	<u>A206834 002</u>	Nov 29, 2019
<u>AP</u>		<u>60MG/0.6ML (100MG/ML)</u>	<u>A206834 003</u>	Nov 29, 2019
<u>AP</u>		<u>80MG/0.8ML (100MG/ML)</u>	<u>A206834 004</u>	Nov 29, 2019
<u>AP</u>		<u>100MG/ML (100MG/ML)</u>	<u>A206834 005</u>	Nov 29, 2019
<u>AP</u>		<u>120MG/0.8ML (150MG/ML)</u>	<u>A206834 006</u>	Nov 29, 2019
<u>AP</u>		<u>150MG/ML (150MG/ML)</u>	<u>A206834 007</u>	Nov 29, 2019
<u>AP</u>	SANDOZ	<u>30MG/0.3ML (100MG/ML)</u>	<u>A077857 002</u>	Jul 23, 2010
<u>AP</u>		<u>40MG/0.4ML (100MG/ML)</u>	<u>A077857 003</u>	Jul 23, 2010
<u>AP</u>		<u>60MG/0.6ML (100MG/ML)</u>	<u>A077857 004</u>	Jul 23, 2010
<u>AP</u>		<u>80MG/0.8ML (100MG/ML)</u>	<u>A077857 005</u>	Jul 23, 2010
<u>AP</u>		<u>100MG/ML (100MG/ML)</u>	<u>A077857 001</u>	Jul 23, 2010
<u>AP</u>		<u>120MG/0.8ML (150MG/ML)</u>	<u>A077857 006</u>	Jul 23, 2010
<u>AP</u>		<u>150MG/ML (150MG/ML)</u>	<u>A077857 007</u>	Jul 23, 2010
<u>AP</u>	ZYDUS PHARMS	<u>30MG/0.3ML (100MG/ML)</u>	<u>A076726 001</u>	Jun 23, 2014
<u>AP</u>		<u>40MG/0.4ML (100MG/ML)</u>	<u>A076726 002</u>	Jun 23, 2014
<u>AP</u>		<u>60MG/0.6ML (100MG/ML)</u>	<u>A076726 003</u>	Jun 23, 2014
<u>AP</u>		<u>80MG/0.8ML (100MG/ML)</u>	<u>A076726 004</u>	Jun 23, 2014
<u>AP</u>		<u>100MG/ML (100MG/ML)</u>	<u>A076726 005</u>	Jun 23, 2014
<u>AP</u>		<u>120MG/0.8ML (150MG/ML)</u>	<u>A076726 006</u>	Jun 23, 2014
<u>AP</u>		<u>150MG/ML (150MG/ML)</u>	<u>A076726 007</u>	Jun 23, 2014
<u>LOVENOX (PRESERVATIVE FREE)</u>				
<u>AP</u>	+ SANOFI AVENTIS US	<u>30MG/0.3ML (100MG/ML)</u>	<u>N020164 001</u>	Mar 29, 1993
<u>AP</u>	+	<u>40MG/0.4ML (100MG/ML)</u>	<u>N020164 002</u>	Jan 30, 1998
<u>AP</u>	+	<u>60MG/0.6ML (100MG/ML)</u>	<u>N020164 003</u>	Mar 27, 1998
<u>AP</u>	+	<u>80MG/0.8ML (100MG/ML)</u>	<u>N020164 004</u>	Mar 27, 1998
<u>AP</u>	+	<u>100MG/ML (100MG/ML)</u>	<u>N020164 005</u>	Mar 27, 1998
<u>AP</u>	+	<u>120MG/0.8ML (150MG/ML)</u>	<u>N020164 007</u>	Jun 02, 2000
<u>AP</u>	+	<u>150MG/ML (150MG/ML)</u>	<u>N020164 008</u>	Jun 02, 2000

ENTACAPONE

TABLET; ORAL

COMTAN

<u>AB</u>	+! ORION PHARMA	<u>200MG</u>	<u>N020796 001</u>	Oct 19, 1999
<u>ENTACAPONE</u>				
<u>AB</u>	AJANTA PHARMA LTD	<u>200MG</u>	<u>A205792 001</u>	Aug 31, 2017
<u>AB</u>	ATLANTIDE	<u>200MG</u>	<u>A078941 001</u>	Aug 16, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>200MG</u>	<u>A203437 001</u>	Jun 19, 2015
<u>AB</u>	MACLEODS PHARMS LTD	<u>200MG</u>	<u>A207210 001</u>	Jun 05, 2017
<u>AB</u>	SUN PHARM	<u>200MG</u>	<u>A090690 001</u>	Jul 16, 2012
<u>AB</u>	SUNSHINE	<u>200MG</u>	<u>A206669 001</u>	Oct 03, 2018

ENTECAVIR

SOLUTION; ORAL

BARACLUE

+	BRISTOL MYERS SQUIBB	0.05MG/ML	N021798 001	Mar 29, 2005
---	----------------------	-----------	-------------	--------------

TABLET; ORAL

BARACLUE

<u>AB</u>	+ BRISTOL MYERS SQUIBB	<u>0.5MG</u>	<u>N021797 001</u>	Mar 29, 2005
<u>AB</u>	+	<u>1MG</u>	<u>N021797 002</u>	Mar 29, 2005
<u>ENTECAVIR</u>				
<u>AB</u>	ACCORD HLTHCARE	<u>0.5MG</u>	<u>A205824 001</u>	Aug 25, 2017
<u>AB</u>		<u>1MG</u>	<u>A205824 002</u>	Aug 25, 2017
<u>AB</u>	AMNEAL PHARMS	<u>0.5MG</u>	<u>A206652 001</u>	Nov 12, 2015

PRESCRIPTION DRUG PRODUCT LIST

ENTECAVIR

TABLET; ORAL

ENTECAVIR

<u>AB</u>		<u>1MG</u>	<u>A206652</u>	<u>002</u>	Nov 12, 2015
<u>AB</u>	AUROBINDO PHARMA LTD	<u>0.5MG</u>	<u>A206217</u>	<u>001</u>	Aug 26, 2015
<u>AB</u>		<u>1MG</u>	<u>A206217</u>	<u>002</u>	Aug 26, 2015
<u>AB</u>	BRECKENRIDGE	<u>0.5MG</u>	<u>A208721</u>	<u>001</u>	Mar 15, 2018
<u>AB</u>		<u>1MG</u>	<u>A208721</u>	<u>002</u>	Mar 15, 2018
<u>AB</u>	BRIGHTGENE	<u>0.5MG</u>	<u>A212126</u>	<u>001</u>	Sep 25, 2019
<u>AB</u>		<u>1MG</u>	<u>A212126</u>	<u>002</u>	Sep 25, 2019
<u>AB</u>	CASI PHARMS INC	<u>0.5MG</u>	<u>A206672</u>	<u>001</u>	May 11, 2017
<u>AB</u>		<u>1MG</u>	<u>A206672</u>	<u>002</u>	May 11, 2017
<u>AB</u>	CIPLA	<u>0.5MG</u>	<u>A206872</u>	<u>001</u>	Dec 06, 2016
<u>AB</u>		<u>1MG</u>	<u>A206872</u>	<u>002</u>	Dec 06, 2016
<u>AB</u>	HETERO LABS LTD V	<u>0.5MG</u>	<u>A205740</u>	<u>001</u>	Aug 21, 2015
<u>AB</u>		<u>1MG</u>	<u>A205740</u>	<u>002</u>	Aug 21, 2015
<u>AB</u>	PHARMADAX INC	<u>0.5MG</u>	<u>A212106</u>	<u>001</u>	Aug 10, 2020
<u>AB</u>		<u>1MG</u>	<u>A212106</u>	<u>002</u>	Aug 10, 2020
<u>AB</u>	PRINSTON INC	<u>0.5MG</u>	<u>A208782</u>	<u>001</u>	Oct 10, 2017
<u>AB</u>		<u>1MG</u>	<u>A208782</u>	<u>002</u>	Oct 10, 2017
<u>AB</u>	ZYDUS PHARMS	<u>0.5MG</u>	<u>A206745</u>	<u>001</u>	Jun 23, 2017
<u>AB</u>		<u>1MG</u>	<u>A206745</u>	<u>002</u>	Jun 23, 2017

ENTRECTINIB

CAPSULE; ORAL

ROZLYTREK

+ GENENTECH INC

+!

100MG

200MG

N212725 001 Aug 15, 2019

N212725 002 Aug 15, 2019

ENZALUTAMIDE

CAPSULE; ORAL

XTANDI

+! ASTELLAS

40MG

N203415 001 Aug 31, 2012

TABLET; ORAL

XTANDI

+ ASTELLAS

40MG

N213674 001 Aug 04, 2020

+!

80MG

N213674 002 Aug 04, 2020

EPHEDRINE SULFATE

SOLUTION; INTRAVENOUS

AKOVAZ

<u>AP</u>	+! EXELA PHARMA	<u>50MG/ML (50MG/ML)</u>	<u>N208289</u>	<u>001</u>	Apr 29, 2016
-----------	-----------------	--------------------------	----------------	------------	--------------

CORPHEDRA

<u>AP</u>	PAR STERILE PRODUCTS	<u>50MG/ML (50MG/ML)</u>	<u>N208943</u>	<u>001</u>	Jan 27, 2017
-----------	----------------------	--------------------------	----------------	------------	--------------

EPHEDRINE SULFATE

<u>AP</u>	AKORN	<u>50MG/ML (50MG/ML)</u>	<u>N208609</u>	<u>001</u>	Mar 01, 2017
-----------	-------	--------------------------	----------------	------------	--------------

<u>AP</u>	AMNEAL	<u>50MG/ML (50MG/ML)</u>	<u>A212932</u>	<u>001</u>	Oct 23, 2019
-----------	--------	--------------------------	----------------	------------	--------------

<u>AP</u>	DR REDDYS LABS LTD	<u>50MG/ML (50MG/ML)</u>	<u>A212649</u>	<u>001</u>	Oct 03, 2020
-----------	--------------------	--------------------------	----------------	------------	--------------

<u>AP</u>	FRESENIUS KABI USA	<u>50MG/ML (50MG/ML)</u>	<u>A209646</u>	<u>001</u>	Aug 04, 2020
-----------	--------------------	--------------------------	----------------	------------	--------------

<u>AP</u>	HIKMA	<u>50MG/ML (50MG/ML)</u>	<u>A214334</u>	<u>001</u>	Dec 15, 2020
-----------	-------	--------------------------	----------------	------------	--------------

<u>AP</u>	SANDOZ INC	<u>50MG/ML (50MG/ML)</u>	<u>A209784</u>	<u>001</u>	Aug 23, 2017
-----------	------------	--------------------------	----------------	------------	--------------

EMERPHED

+! NEXUS PHARMS

50MG/10ML (5MG/ML)

N213407 001 Apr 17, 2020

EPHEDRINE SULFATE

+! ENDO VENTURES

50MG/10ML (5MG/ML)

N213994 001 Oct 16, 2020

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

ELESTAT

<u>AT</u>	+! ALLERGAN	<u>0.05%</u>	<u>N021565</u>	<u>001</u>	Oct 16, 2003
-----------	-------------	--------------	----------------	------------	--------------

EPINASTINE HYDROCHLORIDE

<u>AT</u>	AKORN	<u>0.05%</u>	<u>A204055</u>	<u>001</u>	May 05, 2017
-----------	-------	--------------	----------------	------------	--------------

<u>AT</u>	APOTEX	<u>0.05%</u>	<u>A090919</u>	<u>001</u>	Oct 31, 2011
-----------	--------	--------------	----------------	------------	--------------

<u>AT</u>	BRECKENRIDGE	<u>0.05%</u>	<u>A090870</u>	<u>001</u>	Mar 14, 2011
-----------	--------------	--------------	----------------	------------	--------------

<u>AT</u>	SOMERSET THERAPS LLC	<u>0.05%</u>	<u>A090951</u>	<u>001</u>	Oct 31, 2011
-----------	----------------------	--------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

EPINEPHRINE

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

EPINEPHRINE (AUTOINJECTOR)

AB	TEVA PHARMS USA	<u>0.15MG/DELIVERY</u>	<u>A090589 002</u>	Aug 16, 2018
AB		<u>0.3MG/DELIVERY</u>	<u>A090589 001</u>	Aug 16, 2018

EPIPEN

AB	+! MYLAN SPECIALITY LP	<u>0.3MG/DELIVERY</u>	<u>N019430 001</u>	Dec 22, 1987
-----------	------------------------	-----------------------	---------------------------	--------------

EPIPEN JR.

AB	+! MYLAN SPECIALITY LP	<u>0.15MG/DELIVERY</u>	<u>N019430 002</u>	Dec 22, 1987
-----------	------------------------	------------------------	---------------------------	--------------

ADRENACLICK

BX	+! IMPAX	EQ 0.15MG/DELIVERY	N020800 003	Nov 25, 2009
-----------	----------	--------------------	-------------	--------------

BX	+!	EQ 0.3MG/DELIVERY	N020800 004	Nov 25, 2009
-----------	----	-------------------	-------------	--------------

SOLUTION; INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

ADRENALIN

AP	+! PAR STERILE PRODUCTS	<u>EQ 30MG BASE/30ML (EQ 1MG BASE/ML)</u>	<u>N204640 001</u>	Dec 18, 2013
-----------	-------------------------	---	---------------------------	--------------

EPINEPHRINE

AP	INTL MEDICATION SYS	<u>EQ 30MG BASE/30ML (EQ 1MG BASE/ML)</u>	<u>A211880 001</u>	Apr 24, 2020
-----------	---------------------	---	---------------------------	--------------

ADRENALIN

+!	PAR STERILE PRODUCTS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N204200 001	Dec 07, 2012
----	----------------------	---------------------------------	-------------	--------------

SOLUTION; INTRAMUSCULAR, SUBCUTANEOUS

AUVI-Q

BX	+! KALEO INC	EQ 0.15MG/DELIVERY	N201739 002	Aug 10, 2012
-----------	--------------	--------------------	-------------	--------------

BX	+	EQ 0.3MG/DELIVERY	N201739 001	Aug 10, 2012
-----------	---	-------------------	-------------	--------------

+		EQ 0.1MG/DELIVERY	N201739 003	Nov 17, 2017
---	--	-------------------	-------------	--------------

SYMJEPI

+!	ADAMIS PHARMS CORP	0.15MG/0.3ML (0.15MG/0.3ML)	N207534 002	Sep 27, 2018
----	--------------------	-----------------------------	-------------	--------------

+!		0.3MG/0.3ML (0.3MG/0.3ML)	N207534 001	Jun 15, 2017
----	--	---------------------------	-------------	--------------

SOLUTION; INTRAVENOUS

EPINEPHRINE (COPACKAGED)

+!	HOSPIRA INC	1MG/10ML (0.1MG/ML)	N209359 001	Nov 05, 2019
----	-------------	---------------------	-------------	--------------

SOLUTION; INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS

EPINEPHRINE

+!	BELCHER	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N205029 001	Jul 29, 2014
----	---------	---------------------------------	-------------	--------------

EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIGNOSPAN FORTE

!	DEPROCO	EQ 0.02MG BASE/ML; 2%	A088389 001	Jan 22, 1985
---	---------	-----------------------	-------------	--------------

LIGNOSPAN STANDARD

!	DEPROCO	EQ 0.01MG BASE/ML; 2%	A088390 001	Jan 22, 1985
---	---------	-----------------------	-------------	--------------

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST FORTE DENTAL

AP	+! DENTSPLY PHARM	<u>0.005MG/ML; 4%</u>	<u>N021383 001</u>	
-----------	-------------------	-----------------------	---------------------------	--

PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE

AP	SEPTODONT INC	<u>0.005MG/ML; 4%</u>	<u>A078959 001</u>	Aug 30, 2011
-----------	---------------	-----------------------	---------------------------	--------------

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

AP	HOSPIRA	<u>0.005MG/ML; 0.5%</u>	<u>A089635 001</u>	Jun 21, 1988
-----------	---------	-------------------------	---------------------------	--------------

AP		<u>0.005MG/ML; 1.5%</u>	<u>A088571 001</u>	Sep 13, 1985
-----------	--	-------------------------	---------------------------	--------------

AP		<u>0.005MG/ML; 1.5%</u>	<u>A089645 001</u>	Jun 21, 1988
-----------	--	-------------------------	---------------------------	--------------

AP		<u>0.005MG/ML; 2%</u>	<u>A089651 001</u>	Jun 21, 1988
-----------	--	-----------------------	---------------------------	--------------

AP		<u>0.01MG/ML; 1%</u>	<u>A089644 001</u>	Jun 21, 1988
-----------	--	----------------------	---------------------------	--------------

AP	!	<u>0.01MG/ML; 2%</u>	<u>A089646 001</u>	Jun 21, 1988
-----------	---	----------------------	---------------------------	--------------

XYLOCAINE W/ EPINEPHRINE

AP	+! FRESENIUS KABI USA	<u>0.005MG/ML; 0.5%</u>	<u>N006488 012</u>	
-----------	-----------------------	-------------------------	---------------------------	--

AP	+!	<u>0.005MG/ML; 1.5%</u>	<u>N006488 017</u>	
-----------	----	-------------------------	---------------------------	--

AP	+!	<u>0.005MG/ML; 2%</u>	<u>N006488 019</u>	Nov 13, 1986
-----------	----	-----------------------	---------------------------	--------------

AP	+!	<u>0.01MG/ML; 1%</u>	<u>N006488 004</u>	
-----------	----	----------------------	---------------------------	--

AP	+!	<u>0.02MG/ML; 2%</u>	<u>N006488 005</u>	
-----------	----	----------------------	---------------------------	--

+!		0.005MG/ML; 1%	N006488 018	Nov 13, 1986
----	--	----------------	-------------	--------------

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

ELLEENCE

AP	+! PFIZER INC	<u>200MG/100ML (2MG/ML)</u>	<u>N050778 001</u>	Sep 15, 1999
-----------	---------------	-----------------------------	---------------------------	--------------

AP	+	<u>50MG/25ML (2MG/ML)</u>	<u>N050778 002</u>	Sep 15, 1999
-----------	---	---------------------------	---------------------------	--------------

EPIRUBICIN HYDROCHLORIDE

AP	ACTAVIS TOTOWA	<u>50MG/25ML (2MG/ML)</u>	<u>A065445 002</u>	Sep 18, 2008
-----------	----------------	---------------------------	---------------------------	--------------

AP		<u>200MG/100ML (2MG/ML)</u>	<u>A065445 003</u>	Sep 18, 2008
-----------	--	-----------------------------	---------------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE

<u>AP</u>	AKORN INC	<u>50MG/25ML (2MG/ML)</u>	<u>A090163 001</u>	Jun 24, 2009
<u>AP</u>	CIPLA LTD	<u>50MG/25ML (2MG/ML)</u>	<u>A065361 001</u>	Oct 22, 2007
<u>AP</u>		<u>200MG/100ML (2MG/ML)</u>	<u>A065361 002</u>	Oct 22, 2007
<u>AP</u>	FRESENIUS KABI USA	<u>50MG/25ML (2MG/ML)</u>	<u>A065408 002</u>	Oct 15, 2007
<u>AP</u>		<u>200MG/100ML (2MG/ML)</u>	<u>A065408 004</u>	Oct 15, 2007
<u>AP</u>	HISUN PHARM HANGZHOU	<u>50MG/25ML (2MG/ML)</u>	<u>A090075 001</u>	Mar 25, 2010
<u>AP</u>		<u>200MG/100ML (2MG/ML)</u>	<u>A090075 002</u>	Mar 25, 2010
<u>AP</u>	IMPAX LABS INC	<u>50MG/25ML (2MG/ML)</u>	<u>A065331 001</u>	Aug 09, 2007
<u>AP</u>		<u>200MG/100ML (2MG/ML)</u>	<u>A065331 002</u>	Aug 09, 2007
<u>AP</u>	WEST-WARD PHARMS INT	<u>50MG/25ML (2MG/ML)</u>	<u>A065289 001</u>	Jun 27, 2007
<u>AP</u>		<u>200MG/100ML (2MG/ML)</u>	<u>A065289 002</u>	Jun 27, 2007
	FRESENIUS KABI USA	10MG/5ML (2MG/ML)	A065408 001	Oct 15, 2007
		150MG/75ML (2MG/ML)	A065408 003	Oct 15, 2007

EPLERENONE

TABLET; ORAL

EPLERENONE

<u>AB</u>	ACCORD HLTHCARE	<u>25MG</u>	<u>A206922 001</u>	Jul 13, 2017
<u>AB</u>		<u>50MG</u>	<u>A206922 002</u>	Jul 13, 2017
<u>AB</u>	BRECKENRIDGE	<u>25MG</u>	<u>A208283 001</u>	Sep 14, 2018
<u>AB</u>		<u>50MG</u>	<u>A208283 002</u>	Sep 14, 2018
<u>AB</u>	COREPHARMA	<u>25MG</u>	<u>A078482 001</u>	Jul 30, 2008
<u>AB</u>		<u>50MG</u>	<u>A078482 002</u>	Jul 30, 2008
<u>AB</u>	PIRAMAL HLTHCARE UK	<u>25MG</u>	<u>A212765 001</u>	Aug 10, 2020
<u>AB</u>		<u>50MG</u>	<u>A212765 002</u>	Aug 10, 2020
<u>AB</u>	PRASCO	<u>25MG</u>	<u>A203896 001</u>	Feb 02, 2017
<u>AB</u>		<u>50MG</u>	<u>A203896 002</u>	Feb 02, 2017
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A078510 001</u>	Aug 01, 2008
<u>AB</u>		<u>50MG</u>	<u>A078510 002</u>	Aug 01, 2008
	<u>INSPIRA</u>			
<u>AB</u>	+ GD SEARLE LLC	<u>25MG</u>	<u>N021437 001</u>	Sep 27, 2002
<u>AB</u>	+!	<u>50MG</u>	<u>N021437 002</u>	Sep 27, 2002

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION

EPOPROSTENOL SODIUM

<u>AP</u>	TEVA PHARMS USA	<u>EQ 0.5MG BASE/VIAL</u>	<u>A078396 001</u>	Apr 23, 2008
<u>AP</u>		<u>EQ 1.5MG BASE/VIAL</u>	<u>A078396 002</u>	Apr 23, 2008
	<u>FLOLAN</u>			
<u>AP</u>	+! GLAXOSMITHKLINE LLC	<u>EQ 0.5MG BASE/VIAL</u>	<u>N020444 001</u>	Sep 20, 1995
<u>AP</u>	+!	<u>EQ 1.5MG BASE/VIAL</u>	<u>N020444 002</u>	Sep 20, 1995
	<u>VELETRI</u>			
	+ ACTELION PHARMS LTD	EQ 0.5MG BASE/VIAL	N022260 002	Jun 28, 2012
	+!	EQ 1.5MG BASE/VIAL	N022260 001	Jun 27, 2008

EPTIFIBATIDE

INJECTABLE; INJECTION

EPTIFIBATIDE

<u>AP</u>	ACCORD HLTHCARE	<u>2MG/ML</u>	<u>A205557 001</u>	Nov 06, 2017
<u>AP</u>		<u>75MG/100ML</u>	<u>A205557 002</u>	Nov 06, 2017
<u>AP</u>	AKORN	<u>2MG/ML</u>	<u>A204589 001</u>	Apr 18, 2017
<u>AP</u>		<u>75MG/100ML</u>	<u>A204589 002</u>	Apr 18, 2017
<u>AP</u>	AUROBINDO PHARMA LTD	<u>2MG/ML</u>	<u>A206127 001</u>	Dec 08, 2015
<u>AP</u>		<u>75MG/100ML</u>	<u>A206127 002</u>	Dec 08, 2015
<u>AP</u>	BAXTER HLTHCARE CORP	<u>2MG/ML</u>	<u>A208554 001</u>	Nov 23, 2018
<u>AP</u>		<u>75MG/100ML</u>	<u>A208554 002</u>	Nov 23, 2018
<u>AP</u>	HAINAN POLY PHARM	<u>2MG/ML</u>	<u>A209864 001</u>	Jan 25, 2019
<u>AP</u>		<u>75MG/100ML</u>	<u>A209864 002</u>	Jan 25, 2019
<u>AP</u>	MYLAN LABS LTD	<u>2MG/ML</u>	<u>A203258 001</u>	Jul 20, 2018
<u>AP</u>		<u>75MG/100ML</u>	<u>A203258 002</u>	Jul 20, 2018
<u>AP</u>	SAGENT PHARMS INC	<u>2MG/ML</u>	<u>A204693 001</u>	Mar 07, 2018
<u>AP</u>		<u>75MG/100ML</u>	<u>A204693 002</u>	Mar 07, 2018
<u>AP</u>	TEVA PHARMS USA	<u>2MG/ML</u>	<u>A090854 001</u>	Jun 12, 2015
	<u>INTEGRILIN</u>			
<u>AP</u>	+! SCHERING	<u>2MG/ML</u>	<u>N020718 001</u>	May 18, 1998
<u>AP</u>	+!	<u>75MG/100ML</u>	<u>N020718 002</u>	May 18, 1998

PRESCRIPTION DRUG PRODUCT LIST

ERAVACYCLINE DIHYDROCHLORIDE

POWDER; INTRAVENOUS

XERAVA

+	!	TETRAPHASE PHARMS	EQ 50MG BASE/VIAL	N211109	001	Aug 27, 2018
+	!		EQ 100MG BASE/VIAL	N211109	002	Jun 03, 2020

ERDAFITINIB

TABLET; ORAL

BALVERSA

+		JANSSEN BIOTECH	3MG	N212018	001	Apr 12, 2019
+			4MG	N212018	002	Apr 12, 2019
+	!		5MG	N212018	003	Apr 12, 2019

ERGOCALCIFEROL

CAPSULE; ORAL

DRISDOL

AA	+	!	US PHARM HOLDINGS	50,000 IU	N003444	001
-----------	---	---	-------------------	------------------	----------------	------------

ERGOCALCIFEROL

AA			ALEMBIC LABS	50,000 IU	A040833	001	May 20, 2009
AA			PURACAP PHARM LLC	50,000 IU	A204276	001	Dec 07, 2018
AA			SIGMAPHARM LABS LLC	50,000 IU	A091004	001	Jul 14, 2010
AA			STRIDES PHARMA	50,000 IU	A090455	001	Aug 03, 2010
AA			SUN PHARM INDS INC	50,000 IU	A040865	001	Dec 29, 2009

VITAMIN D

AA			BIONPHARMA INC	50,000 IU	A080704	001
-----------	--	--	----------------	------------------	----------------	------------

ERGOLOID MESYLATES

TABLET; ORAL

ERGOLOID MESYLATES

!		SUN PHARM INDUSTRIES	1MG	A081113	001	Oct 31, 1991
---	--	----------------------	-----	---------	-----	--------------

ERGOTAMINE TARTRATE

TABLET; SUBLINGUAL

ERGOMAR

!		TERSERA	2MG	A087693	001	Feb 24, 1983
---	--	---------	-----	---------	-----	--------------

ERIBULIN MESYLATE

SOLUTION; INTRAVENOUS

HALAVEN

+	!	EISAI INC	1MG/2ML (0.5MG/ML)	N201532	001	Nov 15, 2010
---	---	-----------	--------------------	---------	-----	--------------

ERLOTINIB HYDROCHLORIDE

TABLET; ORAL

ERLOTINIB HYDROCHLORIDE

AB			APOTEX	EQ 25MG BASE	A208396	001	Nov 05, 2019
AB				EQ 100MG BASE	A208396	002	Nov 05, 2019
AB				EQ 150MG BASE	A208396	003	Nov 05, 2019
AB			MYLAN	EQ 25MG BASE	A091002	001	Jun 11, 2014
AB				EQ 100MG BASE	A091002	002	Jun 11, 2014
AB				EQ 150MG BASE	A091002	003	Jun 11, 2014
AB			NATCO PHARMA LTD	EQ 25MG BASE	A208488	001	Nov 05, 2019
AB				EQ 100MG BASE	A208488	002	Nov 05, 2019
AB				EQ 150MG BASE	A208488	003	Nov 05, 2019
AB			SHILPA MEDICARE LTD	EQ 25MG BASE	A211960	001	Nov 05, 2019
AB				EQ 100MG BASE	A211960	002	Nov 05, 2019
AB				EQ 150MG BASE	A211960	003	Nov 05, 2019
AB			SUN PHARM	EQ 25MG BASE	A210300	001	Nov 05, 2019
AB				EQ 100MG BASE	A210300	002	Nov 05, 2019
AB				EQ 150MG BASE	A210300	003	Nov 05, 2019
AB			TEVA PHARMS USA INC	EQ 25MG BASE	A091059	001	Nov 09, 2020
AB				EQ 100MG BASE	A091059	002	Aug 28, 2015
AB				EQ 150MG BASE	A091059	003	Aug 28, 2015
AB			ZYDUS PHARMS	EQ 25MG BASE	A213065	001	Apr 16, 2020
AB				EQ 100MG BASE	A213065	002	Apr 16, 2020
AB				EQ 150MG BASE	A213065	003	Apr 16, 2020

TARCEVA

AB	+		OSI PHARMS	EQ 25MG BASE	N021743	001	Nov 18, 2004
AB	+			EQ 100MG BASE	N021743	002	Nov 18, 2004
AB	+	!		EQ 150MG BASE	N021743	003	Nov 18, 2004

PRESCRIPTION DRUG PRODUCT LIST

ERTAPENEM SODIUM

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

ERTAPENEM SODIUM

AP	ACS DOBFAR SPA	EQ 1GM BASE/VIAL	A208790 001	Apr 16, 2018
AP	AUROBINDO PHARMA LTD	EQ 1GM BASE/VIAL	A209133 001	Jun 25, 2018
AP	SAVIOR LIFETEC CORP	EQ 1GM BASE/VIAL	A207647 001	Mar 19, 2019

INVANZ

AP	+! MERCK SHARP DOHME	EQ 1GM BASE/VIAL	N021337 001	Nov 21, 2001
-----------	----------------------	-------------------------	--------------------	--------------

ERTUGLIFLOZIN

TABLET; ORAL

STEGLATRO

+	MERCK SHARP DOHME	5MG	N209803 001	Dec 19, 2017
+	!	15MG	N209803 002	Dec 19, 2017

ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET; ORAL

SEGLUROMET

+	MERCK SHARP DOHME	2.5MG; 500MG	N209806 001	Dec 19, 2017
+		2.5MG; 1GM	N209806 002	Dec 19, 2017
+		7.5MG; 500MG	N209806 003	Dec 19, 2017
+	!	7.5MG; 1GM	N209806 004	Dec 19, 2017

ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE

TABLET; ORAL

STEGLUJAN

+	MERCK SHARP DOHME	5MG; EQ 100MG BASE	N209805 001	Dec 19, 2017
+	!	15MG; EQ 100MG BASE	N209805 002	Dec 19, 2017

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

ERYC

AB	+! MAYNE PHARMA	250MG	N050536 001	
-----------	-----------------	--------------	--------------------	--

ERYTHROMYCIN

AB	ARBOR PHARMS LLC	250MG	A062746 001	Dec 22, 1986
-----------	------------------	--------------	--------------------	--------------

GEL; TOPICAL

ERYGEL

AT	+! MYLAN	2%	N050617 001	Oct 21, 1987
-----------	----------	-----------	--------------------	--------------

ERYTHROMYCIN

AT	FOUGERA PHARMS	2%	A064184 001	Sep 30, 1997
-----------	----------------	-----------	--------------------	--------------

AT	PERRIGO CO	2%	A063211 001	Jan 29, 1993
-----------	------------	-----------	--------------------	--------------

AT	TELGENT	2%	A208154 001	Jul 19, 2017
-----------	---------	-----------	--------------------	--------------

OINTMENT; OPHTHALMIC

ERYTHROMYCIN

AT	AKORN	0.5%	A064030 001	Jul 18, 1996
-----------	-------	-------------	--------------------	--------------

AT	BAUSCH AND LOMB	0.5%	A064067 001	Jul 29, 1994
-----------	-----------------	-------------	--------------------	--------------

AT	! PERRIGO CO TENNESSEE	0.5%	A062447 001	Sep 26, 1983
-----------	---------------------------	-------------	--------------------	--------------

SOLUTION; TOPICAL

ERYTHROMYCIN

AT	! PERRIGO NEW YORK	2%	A063038 001	Jan 11, 1991
-----------	--------------------	-----------	--------------------	--------------

AT	TELGENT	2%	A208100 001	Nov 20, 2017
-----------	---------	-----------	--------------------	--------------

AT	WOCKHARDT BIO AG	2%	A062825 001	Oct 23, 1987
-----------	------------------	-----------	--------------------	--------------

SWAB; TOPICAL

ERYTHROMYCIN

AT	AKORN	2%	A090215 001	May 12, 2010
-----------	-------	-----------	--------------------	--------------

AT	! PERRIGO CO	2%	A064126 001	Jul 03, 1996
-----------	--------------	-----------	--------------------	--------------

TABLET; ORAL

ERYTHROMYCIN

AB	AMNEAL PHARMS CO	250MG	A209720 001	Mar 09, 2018
-----------	------------------	--------------	--------------------	--------------

AB		500MG	A209720 002	Mar 09, 2018
-----------	--	--------------	--------------------	--------------

AB	ARBOR PHARMS LLC	250MG	A061621 001	
-----------	------------------	--------------	--------------------	--

AB	!	500MG	A061621 002	
-----------	---	--------------	--------------------	--

AB	TORRENT	250MG	A212015 001	Jul 06, 2020
-----------	---------	--------------	--------------------	--------------

AB		500MG	A212015 002	Jul 06, 2020
-----------	--	--------------	--------------------	--------------

TABLET, DELAYED RELEASE; ORAL

ERY-TAB

AB	ARBOR PHARMS LLC	250MG	A062298 001	
-----------	------------------	--------------	--------------------	--

AB		333MG	A062298 003	Mar 29, 1982
-----------	--	--------------	--------------------	--------------

AB	!	500MG	A062298 002	
-----------	---	--------------	--------------------	--

ERYTHROMYCIN

AB	AMNEAL PHARMS CO	250MG	A210954 001	Jul 02, 2019
-----------	------------------	--------------	--------------------	--------------

AB		333MG	A210954 002	Jul 02, 2019
-----------	--	--------------	--------------------	--------------

AB		500MG	A210954 003	Jul 02, 2019
-----------	--	--------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE;ORAL

E.E.S.

AB	+	ARBOR PHARMS LLC	<u>EQ 200MG BASE/5ML</u>	<u>N050207</u>	<u>001</u>	
-----------	---	------------------	--------------------------	----------------	------------	--

ERYPED

AB	+	ARBOR PHARMS LLC	<u>EQ 200MG BASE/5ML</u>	<u>N050207</u>	<u>003</u>	Mar 30, 1987
AB	+	!	<u>EQ 400MG BASE/5ML</u>	<u>N050207</u>	<u>002</u>	

ERYTHROMYCIN ETHYLSUCCINATE

AB		AMNEAL PHARMS	<u>EQ 200MG BASE/5ML</u>	<u>A211204</u>	<u>001</u>	Nov 01, 2019
AB			<u>EQ 400MG BASE/5ML</u>	<u>A211204</u>	<u>002</u>	Nov 01, 2019
AB		ANI PHARMS INC	<u>EQ 200MG BASE/5ML</u>	<u>A062055</u>	<u>001</u>	
AB			<u>EQ 200MG BASE/5ML</u>	<u>A062055</u>	<u>003</u>	Nov 02, 2018
AB			<u>EQ 400MG BASE/5ML</u>	<u>A062055</u>	<u>002</u>	Nov 02, 2018
AB		PAR PHARM INC	<u>EQ 200MG BASE/5ML</u>	<u>A211991</u>	<u>001</u>	Oct 23, 2019
AB			<u>EQ 400MG BASE/5ML</u>	<u>A211991</u>	<u>002</u>	Oct 23, 2019

TABLET;ORAL

E.E.S. 400

BX	!	ARBOR PHARMS LLC	<u>EQ 400MG BASE</u>	<u>A061905</u>	<u>002</u>	Aug 12, 1982
		ERYTHROMYCIN ETHYLSUCCINATE				
BX	!	ARBOR PHARMS LLC	<u>EQ 400MG BASE</u>	<u>A061904</u>	<u>001</u>	

ERYTHROMYCIN LACTOBIONATE

INJECTABLE;INJECTION

ERYTHROCIN

AP		HOSPIRA	<u>EQ 500MG BASE/VIAL</u>	<u>A062638</u>	<u>001</u>	Oct 31, 1986
AP		+	<u>EQ 500MG BASE/VIAL</u>	<u>N050609</u>	<u>001</u>	Sep 24, 1986

ERYTHROMYCIN LACTOBIONATE

AP		EXELA PHARMA	<u>EQ 500MG BASE/VIAL</u>	<u>A211086</u>	<u>001</u>	Sep 17, 2020
-----------	--	--------------	---------------------------	----------------	------------	--------------

ERYTHROMYCIN STEARATE

TABLET;ORAL

ERYTHROCIN STEARATE

	!	ARBOR PHARMS LLC	<u>EQ 250MG BASE</u>	<u>A060359</u>	<u>001</u>	
--	---	------------------	----------------------	----------------	------------	--

ESCITALOPRAM OXALATE

SOLUTION;ORAL

ESCITALOPRAM OXALATE

AA		AMNEAL PHARMS	<u>EQ 5MG BASE/5ML</u>	<u>A202227</u>	<u>001</u>	Mar 14, 2012
AA		ANTRIM PHARMS LLC	<u>EQ 5MG BASE/5ML</u>	<u>A203967</u>	<u>001</u>	May 26, 2015
AA		AUROBINDO PHARMA LTD	<u>EQ 5MG BASE/5ML</u>	<u>A079062</u>	<u>001</u>	Apr 02, 2012
AA	!	HETERO LABS LTD III	<u>EQ 5MG BASE/5ML</u>	<u>A202221</u>	<u>001</u>	Jun 12, 2012
AA		LANNETT CO INC	<u>EQ 5MG BASE/5ML</u>	<u>A090477</u>	<u>001</u>	Jun 12, 2013
AA		MACLEODS PHARMS LTD	<u>EQ 5MG BASE/5ML</u>	<u>A202754</u>	<u>001</u>	Mar 31, 2016
AA		TARO	<u>EQ 5MG BASE/5ML</u>	<u>A079121</u>	<u>001</u>	May 03, 2012

TABLET;ORAL

ESCITALOPRAM OXALATE

AB		ACCORD HLTHCARE	<u>EQ 5MG BASE</u>	<u>A202389</u>	<u>001</u>	Sep 11, 2012
AB			<u>EQ 10MG BASE</u>	<u>A202389</u>	<u>002</u>	Sep 11, 2012
AB			<u>EQ 20MG BASE</u>	<u>A202389</u>	<u>003</u>	Sep 11, 2012
AB		AMNEAL PHARMS	<u>EQ 5MG BASE</u>	<u>A205619</u>	<u>001</u>	May 17, 2017
AB			<u>EQ 10MG BASE</u>	<u>A205619</u>	<u>002</u>	May 17, 2017
AB			<u>EQ 20MG BASE</u>	<u>A205619</u>	<u>003</u>	May 17, 2017
AB		AUROBINDO PHARMA LTD	<u>EQ 5MG BASE</u>	<u>A090432</u>	<u>001</u>	Sep 11, 2012
AB			<u>EQ 10MG BASE</u>	<u>A090432</u>	<u>002</u>	Sep 11, 2012
AB			<u>EQ 20MG BASE</u>	<u>A090432</u>	<u>003</u>	Sep 11, 2012
AB		CADILA	<u>EQ 5MG BASE</u>	<u>A077734</u>	<u>001</u>	Sep 11, 2012
AB			<u>EQ 10MG BASE</u>	<u>A077734</u>	<u>002</u>	Sep 11, 2012
AB			<u>EQ 20MG BASE</u>	<u>A077734</u>	<u>003</u>	Sep 11, 2012
AB		INVAGEN PHARMS	<u>EQ 5MG BASE</u>	<u>A078604</u>	<u>001</u>	Sep 11, 2012
AB			<u>EQ 10MG BASE</u>	<u>A078604</u>	<u>002</u>	Sep 11, 2012
AB			<u>EQ 20MG BASE</u>	<u>A078604</u>	<u>003</u>	Sep 11, 2012
AB		JUBILANT GENERICS	<u>EQ 5MG BASE</u>	<u>A202280</u>	<u>001</u>	Sep 12, 2012
AB			<u>EQ 10MG BASE</u>	<u>A202280</u>	<u>002</u>	Sep 12, 2012
AB			<u>EQ 20MG BASE</u>	<u>A202280</u>	<u>003</u>	Sep 12, 2012
AB		LUPIN LTD	<u>EQ 5MG BASE</u>	<u>A078169</u>	<u>001</u>	Sep 11, 2012
AB			<u>EQ 10MG BASE</u>	<u>A078169</u>	<u>002</u>	Sep 11, 2012
AB			<u>EQ 20MG BASE</u>	<u>A078169</u>	<u>003</u>	Sep 11, 2012
AB		PHARM ASSOC	<u>EQ 5MG BASE</u>	<u>A077512</u>	<u>001</u>	Sep 12, 2012
AB			<u>EQ 10MG BASE</u>	<u>A077512</u>	<u>002</u>	Sep 12, 2012
AB			<u>EQ 20MG BASE</u>	<u>A077512</u>	<u>003</u>	Sep 12, 2012
AB		PRINSTON INC	<u>EQ 5MG BASE</u>	<u>A078032</u>	<u>001</u>	Aug 28, 2015
AB			<u>EQ 10MG BASE</u>	<u>A078032</u>	<u>002</u>	Aug 28, 2015

PRESCRIPTION DRUG PRODUCT LIST

ESCITALOPRAM OXALATE

TABLET; ORAL

ESCITALOPRAM OXALATE

<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A078032 003</u>	Aug 28, 2015
<u>AB</u>	RISING	<u>EQ 5MG BASE</u>	<u>A078777 001</u>	Sep 11, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078777 002</u>	Sep 11, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A078777 003</u>	Sep 11, 2012
<u>AB</u>	TEVA PHARMS USA	<u>EQ 5MG BASE</u>	<u>A076765 001</u>	Mar 14, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076765 002</u>	Mar 14, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076765 003</u>	Mar 14, 2012
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 5MG BASE</u>	<u>A090939 001</u>	Sep 11, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090939 002</u>	Sep 11, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A090939 003</u>	Sep 11, 2012
<u>LEXAPRO</u>				
<u>AB</u>	+ ALLERGAN	<u>EQ 5MG BASE</u>	<u>N021323 001</u>	Aug 14, 2002
<u>AB</u>	+	<u>EQ 10MG BASE</u>	<u>N021323 002</u>	Aug 14, 2002
<u>AB</u>	+!	<u>EQ 20MG BASE</u>	<u>N021323 003</u>	Aug 14, 2002

ESKETAMINE HYDROCHLORIDE

SPRAY; NASAL

SPRAVATO

+! JANSSEN PHARMS EQ 28MG BASE N211243 001 Mar 05, 2019

ESLICARBAZEPINE ACETATE

TABLET; ORAL

APTIOM

+	SUNOVION PHARMS INC	200MG	N022416 001	Nov 08, 2013
+		400MG	N022416 002	Nov 08, 2013
+		600MG	N022416 003	Nov 08, 2013
+		800MG	N022416 004	Nov 08, 2013

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

BREVIBLOCAP +! BAXTER HLTHCARE 10MG/ML N019386 006 Feb 25, 2003ESMOLOL HYDROCHLORIDE

<u>AP</u>	AUROBINDO PHARMA LTD	<u>10MG/ML</u>	<u>A205520 001</u>	Jul 23, 2015
<u>AP</u>	FRESENIUS KABI USA	<u>10MG/ML</u>	<u>A076573 001</u>	May 02, 2005
<u>AP</u>	GLAND PHARMA LTD	<u>10MG/ML</u>	<u>A208538 001</u>	Aug 14, 2019
<u>AP</u>	MYLAN INSTITUTIONAL	<u>10MG/ML</u>	<u>A076474 001</u>	May 02, 2005
<u>AP</u>	MYLAN LABS LTD	<u>10MG/ML</u>	<u>A206608 001</u>	Jun 08, 2018
<u>AP</u>		<u>20MG/ML</u>	<u>A206608 002</u>	Jun 08, 2018
<u>AP</u>	SAGENT PHARMS INC	<u>10MG/ML</u>	<u>A207107 001</u>	Jun 08, 2018
<u>AP</u>		<u>20MG/ML</u>	<u>A207107 002</u>	Jun 08, 2018
<u>AP</u>	WEST-WARD PHARMS INT	<u>10MG/ML</u>	<u>A076323 001</u>	Aug 10, 2004

BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER

+! BAXTER HLTHCARE 2GM/100ML N019386 005 Jan 27, 2003

BREVIBLOC IN PLASTIC CONTAINER

+! BAXTER HLTHCARE 1GM/100ML N019386 004 Feb 16, 2001

SOLUTION; INTRAVENOUS

ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER

+! HQ SPCLT PHARMA 2GM/100ML (20MG/ML) N205703 002 Apr 07, 2016

ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER

+! HQ SPCLT PHARMA 2.5GM/250ML (10MG/ML) N205703 001 Apr 07, 2016

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL

ESOMEPRAZOLE MAGNESIUM

<u>AB</u>	ALKEM LABS LTD	<u>EQ 20MG BASE</u>	<u>A208333 001</u>	Oct 20, 2017
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A208333 002</u>	Oct 20, 2017
<u>AB</u>	AMTA	<u>EQ 20MG BASE</u>	<u>A213859 001</u>	Nov 18, 2020
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A213859 002</u>	Nov 18, 2020
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 20MG BASE</u>	<u>A205606 001</u>	Apr 21, 2016
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A205606 002</u>	Apr 21, 2016
<u>AB</u>	CISEN	<u>EQ 20MG BASE</u>	<u>A213158 001</u>	Sep 22, 2020
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A213158 002</u>	Sep 22, 2020
<u>AB</u>	CSPC OUYI	<u>EQ 20MG BASE</u>	<u>A212949 001</u>	Oct 02, 2020
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A212949 002</u>	Oct 02, 2020
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 20MG BASE</u>	<u>A078279 001</u>	Sep 25, 2015
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078279 002</u>	Sep 25, 2015
<u>AB</u>	GLENMARK PHARMS	<u>EQ 20MG BASE</u>	<u>A209495 001</u>	May 10, 2019
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A209495 002</u>	May 10, 2019

PRESCRIPTION DRUG PRODUCT LIST

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL

ESOMEPRAZOLE MAGNESIUM

<u>AB</u>	HETERO LABS LTD III	<u>EQ 20MG BASE</u>	<u>A202784 001</u>	Sep 21, 2015
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A211977 001</u>	Jun 02, 2020
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A202784 002</u>	Sep 21, 2015
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A211977 002</u>	Jun 02, 2020
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 20MG BASE</u>	<u>A078003 001</u>	Jan 26, 2015
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078003 002</u>	Jan 26, 2015
<u>AB</u>	LANNETT CO INC	<u>EQ 20MG BASE</u>	<u>A205563 001</u>	Sep 01, 2017
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A205563 002</u>	Sep 01, 2017
<u>AB</u>	MYLAN	<u>EQ 20MG BASE</u>	<u>A078936 001</u>	Aug 02, 2015
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078936 002</u>	Aug 03, 2015
<u>AB</u>	SUN PHARM	<u>EQ 20MG BASE</u>	<u>A209735 001</u>	Apr 30, 2018
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A209735 002</u>	Apr 30, 2018
<u>AB</u>	TORRENT	<u>EQ 20MG BASE</u>	<u>A203636 001</u>	Oct 19, 2015
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A203636 002</u>	Oct 19, 2015
<u>AB</u>	ZYDUS PHARMS	<u>EQ 20MG BASE</u>	<u>A206296 001</u>	May 22, 2019
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A206296 002</u>	May 22, 2019

NEXIUM

<u>AB</u>	+	ASTRAZENECA PHARMS	<u>EQ 20MG BASE</u>	<u>N021153 001</u>	Feb 20, 2001
<u>AB</u>	+	!	<u>EQ 40MG BASE</u>	<u>N021153 002</u>	Feb 20, 2001

FOR SUSPENSION, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

<u>AB</u>	CIPLA	<u>EQ 10MG BASE/PACKET</u>	<u>A211752 001</u>	Mar 23, 2020
<u>AB</u>		<u>EQ 20MG BASE/PACKET</u>	<u>A211751 001</u>	Mar 23, 2020
<u>AB</u>		<u>EQ 40MG BASE/PACKET</u>	<u>A211751 002</u>	Mar 23, 2020

NEXIUM

<u>AB</u>	+	ASTRAZENECA PHARMS	<u>EQ 10MG BASE/PACKET</u>	<u>N022101 001</u>	Feb 27, 2008
<u>AB</u>	+		<u>EQ 20MG BASE/PACKET</u>	<u>N021957 001</u>	Oct 20, 2006
<u>AB</u>	+	!	<u>EQ 40MG BASE/PACKET</u>	<u>N021957 002</u>	Oct 20, 2006
			EQ 2.5MG BASE/PACKET	N021957 003	Dec 15, 2011
			EQ 5MG BASE/PACKET	N021957 004	Dec 15, 2011

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE;ORAL

NAPROXEN AND ESOMEPRAZOLE MAGNESIUM

<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 20MG BASE;375MG</u>	<u>A204206 001</u>	Feb 18, 2020	
<u>AB</u>		<u>EQ 20MG BASE;500MG</u>	<u>A204206 002</u>	Feb 18, 2020	
<u>AB</u>	+	HORIZON	<u>EQ 20MG BASE;375MG</u>	<u>N022511 002</u>	Apr 30, 2010
<u>AB</u>	+	!	<u>EQ 20MG BASE;500MG</u>	<u>N022511 001</u>	Apr 30, 2010

ESOMEPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS

ESOMEPRAZOLE SODIUM

<u>AP</u>	ACCORD HLTHCARE	<u>EQ 40MG BASE/VIAL</u>	<u>A205379 001</u>	Sep 25, 2015
<u>AP</u>	! AUROBINDO PHARMA LTD	<u>EQ 40MG BASE/VIAL</u>	<u>A204657 002</u>	Aug 10, 2016
<u>AP</u>	DEVA HOLDING AS	<u>EQ 40MG BASE/VIAL</u>	<u>A207181 001</u>	Mar 06, 2017
<u>AP</u>	GLAND PHARMA LTD	<u>EQ 20MG BASE/VIAL</u>	<u>A203349 001</u>	Apr 01, 2020
<u>AP</u>		<u>EQ 40MG BASE/VIAL</u>	<u>A203349 002</u>	Apr 01, 2020
<u>AP</u>	MYLAN LABS LTD	<u>EQ 40MG BASE/VIAL</u>	<u>A202686 002</u>	May 17, 2017
<u>AP</u>	SUN PHARMA GLOBAL	<u>EQ 40MG BASE/VIAL</u>	<u>A200882 002</u>	Mar 18, 2013

NEXIUM IV

<u>AP</u>	+	ASTRAZENECA PHARMS	<u>EQ 40MG BASE/VIAL</u>	<u>N021689 002</u>	Mar 31, 2005
-----------	---	--------------------	--------------------------	--------------------	--------------

ESTAZOLAM

TABLET;ORAL

ESTAZOLAM

<u>AB</u>	MAYNE PHARMA	<u>1MG</u>	<u>A074921 001</u>	Jul 10, 1997
<u>AB</u>	!	<u>2MG</u>	<u>A074921 002</u>	Jul 10, 1997
<u>AB</u>	NOVITIUM PHARMA	<u>1MG</u>	<u>A074826 001</u>	Jul 03, 1997
<u>AB</u>		<u>2MG</u>	<u>A074826 002</u>	Jul 03, 1997
<u>AB</u>	WATSON LABS	<u>1MG</u>	<u>A074818 001</u>	Aug 19, 1997
<u>AB</u>		<u>2MG</u>	<u>A074818 002</u>	Aug 19, 1997

ESTRADIOL

CREAM;VAGINAL

ESTRACE

<u>AB</u>	!	ALLERGAN	<u>0.01%</u>	<u>A086069 001</u>	Jan 31, 1984
-----------	---	----------	--------------	--------------------	--------------

ESTRADIOL

<u>AB</u>		ALVOGEN PINE BROOK	<u>0.01%</u>	<u>A209767 001</u>	Mar 05, 2018
<u>AB</u>		MYLAN	<u>0.01%</u>	<u>A208788 001</u>	Dec 29, 2017

PRESCRIPTION DRUG PRODUCT LIST

ESTRADIOL

CREAM; VAGINAL

ESTRADIOL

<u>AB</u>	PERRIGO UK FINCO	<u>0.01%</u>	<u>A210194</u>	<u>001</u>	Jan 22, 2018
<u>AB</u>	TEVA PHARMS USA	<u>0.01%</u>	<u>A210488</u>	<u>001</u>	Mar 30, 2018

FILM, EXTENDED RELEASE; TRANSDERMAL

CLIMARA

<u>AB</u>	+	BAYER HLTHCARE	<u>0.06MG/24HR</u>	<u>N020375</u>	<u>006</u>	May 27, 2003
-----------	---	----------------	--------------------	----------------	------------	--------------

ESTRADIOL

<u>AB</u>		MYLAN TECHNOLOGIES	<u>0.06MG/24HR</u>	<u>A075182</u>	<u>005</u>	Jul 20, 2006
-----------	--	--------------------	--------------------	----------------	------------	--------------

CLIMARA

<u>AB2</u>	+	BAYER HLTHCARE	<u>0.025MG/24HR</u>	<u>N020375</u>	<u>004</u>	Mar 05, 1999
<u>AB2</u>	+		<u>0.0375MG/24HR</u>	<u>N020375</u>	<u>005</u>	May 27, 2003
<u>AB2</u>	+		<u>0.05MG/24HR</u>	<u>N020375</u>	<u>001</u>	Dec 22, 1994
<u>AB2</u>	+		<u>0.075MG/24HR</u>	<u>N020375</u>	<u>003</u>	Mar 23, 1998
<u>AB2</u>	+		<u>0.1MG/24HR</u>	<u>N020375</u>	<u>002</u>	Dec 22, 1994

ESTRADIOL

<u>AB2</u>		MYLAN TECHNOLOGIES	<u>0.025MG/24HR</u>	<u>A075182</u>	<u>003</u>	Jan 26, 2005
<u>AB2</u>			<u>0.0375MG/24HR</u>	<u>A075182</u>	<u>004</u>	Jul 20, 2006
<u>AB2</u>			<u>0.05MG/24HR</u>	<u>A075182</u>	<u>006</u>	Feb 24, 2000
<u>AB2</u>			<u>0.075MG/24HR</u>	<u>A075182</u>	<u>002</u>	Jan 26, 2005
<u>AB2</u>			<u>0.1MG/24HR</u>	<u>A075182</u>	<u>001</u>	Feb 24, 2000
<u>AB3</u>		AMNEAL	<u>0.025MG/24HR</u>	<u>A211396</u>	<u>001</u>	Sep 28, 2020
<u>AB3</u>			<u>0.0375MG/24HR</u>	<u>A211396</u>	<u>002</u>	Sep 28, 2020
<u>AB3</u>			<u>0.05MG/24HR</u>	<u>A211396</u>	<u>003</u>	Sep 28, 2020
<u>AB3</u>			<u>0.075MG/24HR</u>	<u>A211396</u>	<u>004</u>	Sep 28, 2020
<u>AB3</u>			<u>0.1MG/24HR</u>	<u>A211396</u>	<u>005</u>	Sep 28, 2020
<u>AB3</u>		MYLAN TECHNOLOGIES	<u>0.025MG/24HR</u>	<u>A206685</u>	<u>001</u>	Aug 15, 2018
<u>AB3</u>			<u>0.0375MG/24HR</u>	<u>A206685</u>	<u>002</u>	Aug 15, 2018
<u>AB3</u>			<u>0.05MG/24HR</u>	<u>A206685</u>	<u>003</u>	Aug 15, 2018
<u>AB3</u>			<u>0.075MG/24HR</u>	<u>A206685</u>	<u>004</u>	Aug 15, 2018
<u>AB3</u>			<u>0.1MG/24HR</u>	<u>A206685</u>	<u>005</u>	Aug 15, 2018

MINIVELLE

<u>AB3</u>	+	NOVEN	<u>0.025MG/24HR</u>	<u>N203752</u>	<u>005</u>	Sep 23, 2014
<u>AB3</u>	+		<u>0.0375MG/24HR</u>	<u>N203752</u>	<u>001</u>	Oct 29, 2012
<u>AB3</u>	+		<u>0.05MG/24HR</u>	<u>N203752</u>	<u>003</u>	Oct 29, 2012
<u>AB3</u>	+		<u>0.075MG/24HR</u>	<u>N203752</u>	<u>002</u>	Oct 29, 2012
<u>AB3</u>	+		<u>0.1MG/24HR</u>	<u>N203752</u>	<u>004</u>	Oct 29, 2012

ALORA

BX		ALLERGAN	0.025MG/24HR	N020655	004	Apr 05, 2002
BX			0.05MG/24HR	N020655	001	Dec 20, 1996
BX			0.075MG/24HR	N020655	002	Dec 20, 1996
BX			0.1MG/24HR	N020655	003	Dec 20, 1996

GEL; TRANSDERMAL

DIVIGEL

+	!	VERTICAL PHARMS LLC	0.1%	N022038	001	Jun 04, 2007
---	---	---------------------	------	---------	-----	--------------

GEL, METERED; TRANSDERMAL

ELESTRIN

+	!	MYLAN SPECIALITY LP	0.06% (0.87GM/ACTIVATION)	N021813	001	Dec 15, 2006
---	---	---------------------	---------------------------	---------	-----	--------------

ESTROGEL

+	!	ASCEND THERAPS US	0.06% (1.25GM/ACTIVATION)	N021166	002	Feb 09, 2004
---	---	-------------------	---------------------------	---------	-----	--------------

INSERT; VAGINAL

IMVEXXY

+		THERAPEUTICSMD INC	0.004MG	N208564	001	May 29, 2018
+	!		0.01MG	N208564	002	May 29, 2018

INSERT, EXTENDED RELEASE; VAGINAL

ESTRING

+	!	PHARMACIA AND UPJOHN	0.0075MG/24HR	N020472	001	Apr 26, 1996
---	---	-------------------------	---------------	---------	-----	--------------

SPRAY; TRANSDERMAL

EVAMIST

+	!	PERRIGO PHARMA INTL	1.53MG/SPRAY	N022014	001	Jul 27, 2007
---	---	---------------------	--------------	---------	-----	--------------

SYSTEM; TRANSDERMAL

ESTRADIOL

<u>AB1</u>		AMNEAL	<u>0.025MG/24HR</u>	<u>A211293</u>	<u>001</u>	Feb 04, 2019
<u>AB1</u>			<u>0.0375MG/24HR</u>	<u>A211293</u>	<u>002</u>	Feb 04, 2019
<u>AB1</u>			<u>0.05MG/24HR</u>	<u>A211293</u>	<u>003</u>	Feb 04, 2019
<u>AB1</u>			<u>0.075MG/24HR</u>	<u>A211293</u>	<u>004</u>	Feb 04, 2019
<u>AB1</u>			<u>0.1MG/24HR</u>	<u>A211293</u>	<u>005</u>	Feb 04, 2019
<u>AB1</u>		MYLAN TECHNOLOGIES	<u>0.025MG/24HR</u>	<u>A201675</u>	<u>001</u>	Dec 19, 2014
<u>AB1</u>			<u>0.0375MG/24HR</u>	<u>A201675</u>	<u>002</u>	Dec 19, 2014
<u>AB1</u>			<u>0.05MG/24HR</u>	<u>A201675</u>	<u>003</u>	Dec 19, 2014
<u>AB1</u>			<u>0.075MG/24HR</u>	<u>A201675</u>	<u>004</u>	Dec 19, 2014

PRESCRIPTION DRUG PRODUCT LIST

ESTRADIOL

SYSTEM; TRANSDERMAL

ESTRADIOL

<u>AB1</u>		<u>0.1MG/24HR</u>	<u>A201675 005</u>	Dec 19, 2014
<u>VIVELLE-DOT</u>				
<u>AB1</u>	+	NOVARTIS	<u>0.025MG/24HR</u>	<u>N020538 009</u> May 03, 2002
<u>AB1</u>	+		<u>0.0375MG/24HR</u>	<u>N020538 005</u> Jan 08, 1999
<u>AB1</u>	+		<u>0.05MG/24HR</u>	<u>N020538 006</u> Jan 08, 1999
<u>AB1</u>	+		<u>0.075MG/24HR</u>	<u>N020538 007</u> Jan 08, 1999
<u>AB1</u>	+	!	<u>0.1MG/24HR</u>	<u>N020538 008</u> Jan 08, 1999

MENOSTAR

+! BAYER HLTHCARE

0.014MG/24HR

N021674 001 Jun 08, 2004

TABLET; ORAL

ESTRADIOL

<u>AB</u>		BARR LABS INC	<u>0.5MG</u>	<u>A040197 001</u> Oct 22, 1997
<u>AB</u>			<u>1MG</u>	<u>A040197 002</u> Oct 22, 1997
<u>AB</u>		!	<u>2MG</u>	<u>A040197 003</u> Oct 22, 1997
<u>AB</u>		EPIC PHARMA INC	<u>0.5MG</u>	<u>A040275 001</u> Dec 29, 1998
<u>AB</u>			<u>1MG</u>	<u>A040275 002</u> Dec 29, 1998
<u>AB</u>			<u>2MG</u>	<u>A040275 003</u> Dec 29, 1998
<u>AB</u>		MAYNE PHARMA	<u>0.5MG</u>	<u>A040114 003</u> Mar 14, 1996
<u>AB</u>			<u>1MG</u>	<u>A040114 001</u> Mar 14, 1996
<u>AB</u>			<u>2MG</u>	<u>A040114 002</u> Mar 14, 1996
<u>AB</u>		MYLAN	<u>0.5MG</u>	<u>A040326 001</u> Apr 21, 1999
<u>AB</u>			<u>1MG</u>	<u>A040326 002</u> Apr 21, 1999
<u>AB</u>			<u>2MG</u>	<u>A040326 003</u> Apr 21, 1999

TABLET; VAGINAL

ESTRADIOL

<u>AB</u>		AMNEAL PHARMS	<u>10MCG</u>	<u>A205256 001</u> May 29, 2015
<u>AB</u>		GLENMARK PHARMS LTD	<u>10MCG</u>	<u>A210264 001</u> Sep 14, 2018
<u>AB</u>		TEVA PHARMS USA	<u>10MCG</u>	<u>A206388 001</u> Jul 21, 2017

VAGIFEM

<u>AB</u>	+	!	NOVO NORDISK INC	<u>10MCG</u>	<u>N020908 002</u> Nov 25, 2009
-----------	---	---	------------------	--------------	---------------------------------

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE; VAGINAL

FEMRING

+ MILLICENT

EQ 0.05MG BASE/24HR

N021367 001 Mar 20, 2003

+!

EQ 0.1MG BASE/24HR

N021367 002 Mar 20, 2003

ESTRADIOL CYPIONATE

INJECTABLE; INJECTION

DEPO-ESTRADIOL

! PHARMACIA AND

5MG/ML

A085470 003

UPJOHN

ESTRADIOL VALERATE

INJECTABLE; INJECTION

DELESTROGEN

<u>AO</u>	+	!	PAR STERILE PRODUCTS	<u>10MG/ML</u>	<u>N009402 002</u>
<u>AO</u>	+	!		<u>20MG/ML</u>	<u>N009402 004</u>
<u>AO</u>	+	!		<u>40MG/ML</u>	<u>N009402 003</u>

ESTRADIOL VALERATE

<u>AO</u>		AM REGENT	<u>20MG/ML</u>	<u>A090920 001</u> Jan 19, 2010
<u>AO</u>			<u>40MG/ML</u>	<u>A090920 002</u> Jan 19, 2010
<u>AO</u>		HIKMA	<u>10MG/ML</u>	<u>A203723 001</u> Apr 21, 2020
<u>AO</u>			<u>20MG/ML</u>	<u>A203723 002</u> Apr 21, 2020
<u>AO</u>			<u>40MG/ML</u>	<u>A203723 003</u> Apr 21, 2020

ESTRADIOL; LEVONORGESTREL

FILM, EXTENDED RELEASE; TRANSDERMAL

CLIMARA PRO

+! BAYER HLTHCARE

0.045MG/24HR; 0.015MG/24HR

N021258 001 Nov 21, 2003

ESTRADIOL; NORETHINDRONE ACETATE

FILM, EXTENDED RELEASE; TRANSDERMAL

COMBIPATCH

+ NOVEN PHARMS INC

0.05MG/24HR; 0.14MG/24HR

N020870 001 Aug 07, 1998

+!

0.05MG/24HR; 0.25MG/24HR

N020870 002 Aug 07, 1998

TABLET; ORAL

ACTIVELLA

<u>AB</u>	+	AMNEAL	<u>0.5MG; 0.1MG</u>	<u>N020907 002</u> Dec 28, 2006
<u>AB</u>	+	!	<u>1MG; 0.5MG</u>	<u>N020907 001</u> Nov 18, 1998

PRESCRIPTION DRUG PRODUCT LIST

ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

AMABELZ

AB	LUPIN LTD	0.5MG;0.1MG	A203339 001	Jun 20, 2016
AB		1MG;0.5MG	A203339 002	Jun 20, 2016
<u>ESTRADIOL AND NORETHINDRONE ACETATE</u>				
AB	BARR	1MG;0.5MG	A079193 001	May 11, 2010
AB	BRECKENRIDGE PHARM	0.5MG;0.1MG	A078324 002	Jun 09, 2011
AB		1MG;0.5MG	A078324 001	Apr 17, 2008
AB	MYLAN LABS LTD	0.5MG;0.1MG	A207261 001	Feb 10, 2017
AB		1MG;0.5MG	A207261 002	Feb 10, 2017
AB	NOVAST LABS	0.5MG;0.1MG	A210612 001	Apr 03, 2019
AB		1MG;0.5MG	A210612 002	Apr 03, 2019

ESTRADIOL; NORGESTIMATE

TABLET;ORAL

ESTRADIOL AND NORGESTIMATE

! BARR 1MG,1MG;N/A,0.09MG A076812 001 Apr 29, 2005

ESTRADIOL; PROGESTERONE

CAPSULE;ORAL

BIJUVA

+! THERAPEUTICSMD INC 1MG;100MG N210132 001 Oct 28, 2018

ESTRAMUSTINE PHOSPHATE SODIUM

CAPSULE;ORAL

EMCYT

+! PHARMACIA AND UPJOHN EQ 140MG PHOSPHATE N018045 001

ESTROGENS, CONJUGATED

CREAM;TOPICAL, VAGINAL

PREMARIN

+! WYETH PHARMS 0.625MG/GM N020216 001

INJECTABLE;INJECTION

PREMARIN

+! WYETH PHARMS 25MG/VIAL N010402 001

TABLET;ORAL

PREMARIN

+	WYETH PHARMS	0.3MG	N004782 003	
+		0.45MG	N004782 006	Jul 16, 2003
+	!	0.625MG	N004782 004	
+	!	0.9MG	N004782 005	Jan 26, 1984
+	!	1.25MG	N004782 001	

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET;ORAL-28

PREMPHASE 14/14

+! WYETH PHARMS 0.625MG,0.625MG;N/A,5MG N020527 002 Nov 17, 1995

PREMPRO

+	!	WYETH PHARMS	0.3MG;1.5MG	N020527 005	Jun 04, 2003
+	!		0.45MG;1.5MG	N020527 004	Mar 12, 2003
+	!		0.625MG;2.5MG	N020527 001	Nov 17, 1995
+	!		0.625MG;5MG	N020527 003	Jan 09, 1998

ESTROGENS, ESTERIFIED

TABLET;ORAL

MENEST

	MONARCH PHARMS	0.3MG	A084951 001	
		0.625MG	A084948 001	
		1.25MG	A084950 001	
!		2.5MG	A084949 001	

ESTROPIPATE

TABLET;ORAL

OGEN 5

PHARMACIA AND UPJOHN 6MG A083220 004

ESZOPICLONE

TABLET;ORAL

ESZOPICLONE

AB	AUROBINDO PHARMA LTD	1MG	A208451 001	Sep 15, 2016
AB		2MG	A208451 002	Sep 15, 2016
AB		3MG	A208451 003	Sep 15, 2016
AB	DR REDDYS LABS LTD	1MG	A091024 001	Apr 15, 2014

PRESCRIPTION DRUG PRODUCT LIST

ESZOPICLONE

TABLET; ORAL

ESZOPICLONE

<u>AB</u>		<u>2MG</u>	<u>A091024</u>	<u>002</u>	Apr 15, 2014
<u>AB</u>		<u>3MG</u>	<u>A091024</u>	<u>003</u>	Apr 15, 2014
<u>AB</u>	GLENMARK GENERICS	<u>1MG</u>	<u>A091166</u>	<u>001</u>	Apr 15, 2014
<u>AB</u>		<u>2MG</u>	<u>A091166</u>	<u>002</u>	Apr 15, 2014
<u>AB</u>		<u>3MG</u>	<u>A091166</u>	<u>003</u>	Apr 15, 2014
<u>AB</u>	LUPIN LTD	<u>1MG</u>	<u>A091124</u>	<u>001</u>	Sep 13, 2011
<u>AB</u>		<u>2MG</u>	<u>A091124</u>	<u>002</u>	Sep 13, 2011
<u>AB</u>		<u>3MG</u>	<u>A091124</u>	<u>003</u>	Sep 13, 2011
<u>AB</u>	MACLEODS PHARMS LTD	<u>1MG</u>	<u>A202929</u>	<u>001</u>	Jan 30, 2015
<u>AB</u>		<u>2MG</u>	<u>A202929</u>	<u>002</u>	Jan 30, 2015
<u>AB</u>		<u>3MG</u>	<u>A202929</u>	<u>003</u>	Jan 30, 2015
<u>AB</u>	MYLAN PHARMS INC	<u>1MG</u>	<u>A091151</u>	<u>001</u>	Mar 26, 2013
<u>AB</u>		<u>2MG</u>	<u>A091151</u>	<u>002</u>	Mar 26, 2013
<u>AB</u>		<u>3MG</u>	<u>A091151</u>	<u>003</u>	Mar 26, 2013
<u>AB</u>	ORCHID HLTHCARE	<u>1MG</u>	<u>A091113</u>	<u>001</u>	Jun 10, 2014
<u>AB</u>		<u>2MG</u>	<u>A091113</u>	<u>002</u>	Jun 10, 2014
<u>AB</u>		<u>3MG</u>	<u>A091113</u>	<u>003</u>	Jun 10, 2014
<u>AB</u>	SUN PHARM	<u>1MG</u>	<u>A091103</u>	<u>001</u>	Apr 03, 2013
<u>AB</u>		<u>2MG</u>	<u>A091103</u>	<u>002</u>	Apr 03, 2013
<u>AB</u>		<u>3MG</u>	<u>A091103</u>	<u>003</u>	Apr 03, 2013
<u>AB</u>	TEVA	<u>1MG</u>	<u>A091169</u>	<u>001</u>	May 23, 2011
<u>AB</u>		<u>2MG</u>	<u>A091169</u>	<u>002</u>	May 23, 2011
<u>AB</u>		<u>3MG</u>	<u>A091169</u>	<u>003</u>	May 23, 2011

LUNESTA

<u>AB</u>	+	SUNOVION PHARMS INC	<u>1MG</u>	<u>N021476</u>	<u>001</u>	Dec 15, 2004
<u>AB</u>	+		<u>2MG</u>	<u>N021476</u>	<u>002</u>	Dec 15, 2004
<u>AB</u>	+		<u>3MG</u>	<u>N021476</u>	<u>003</u>	Dec 15, 2004

ETELALCETIDE

SOLUTION; INTRAVENOUS

PARSABIV

+	!	KAI PHARMS INC	2.5MG/0.5ML (2.5MG/0.5ML)	N208325	001	Feb 07, 2017
+	!		5MG/ML (5MG/ML)	N208325	002	Feb 07, 2017
+	!		10MG/2ML (5MG/ML)	N208325	003	Feb 07, 2017

ETEPLIRSEN

SOLUTION; INTRAVENOUS

EXONDYS 51

+	!	SAREPTA THERAPS INC	100MG/2ML (50MG/ML)	N206488	001	Sep 19, 2016
+	!		500MG/10ML (50MG/ML)	N206488	002	Sep 19, 2016

ETHACRYNATE SODIUM

INJECTABLE; INJECTION

EDECRIIN

<u>AP</u>	+	!	BAUSCH	<u>EQ 50MG BASE/VIAL</u>	<u>N016093</u>	<u>001</u>	
<u>AP</u>			MYLAN INSTITUTIONAL	<u>EQ 50MG BASE/VIAL</u>	<u>A204634</u>	<u>001</u>	Aug 23, 2016
<u>AP</u>			PAR STERILE PRODUCTS	<u>EQ 50MG BASE/VIAL</u>	<u>A205473</u>	<u>001</u>	Jul 29, 2015
<u>AP</u>			VPI PHARMS INC	<u>EQ 50MG BASE/VIAL</u>	<u>A208663</u>	<u>001</u>	Jun 09, 2020
<u>AP</u>			ZYDUS PHARMS	<u>EQ 50MG BASE/VIAL</u>	<u>A207758</u>	<u>001</u>	Nov 17, 2017

ETHACRYNIC ACID

TABLET; ORAL

EDECRIIN

<u>AB</u>	+	!	BAUSCH	<u>25MG</u>	<u>N016092</u>	<u>001</u>	
<u>AB</u>			AGNITIO	<u>25MG</u>	<u>A211809</u>	<u>001</u>	Jul 12, 2019
<u>AB</u>			ALVOGEN	<u>25MG</u>	<u>A205709</u>	<u>001</u>	Jul 24, 2018
<u>AB</u>			AMNEAL PHARMS CO	<u>25MG</u>	<u>A208805</u>	<u>001</u>	May 08, 2018
<u>AB</u>			EDENBRIDGE PHARMS	<u>25MG</u>	<u>A205609</u>	<u>001</u>	Jun 30, 2016
<u>AB</u>			HIKMA	<u>25MG</u>	<u>A207262</u>	<u>001</u>	Feb 23, 2017
<u>AB</u>			LUPIN LTD	<u>25MG</u>	<u>A211719</u>	<u>001</u>	Sep 06, 2019
<u>AB</u>			PAR PHARM INC	<u>25MG</u>	<u>A208501</u>	<u>001</u>	Jul 21, 2017
<u>AB</u>			SCIEGEN PHARMS INC	<u>25MG</u>	<u>A211232</u>	<u>001</u>	Aug 27, 2019
<u>AB</u>			STRIDES PHARMA	<u>25MG</u>	<u>A213240</u>	<u>001</u>	Oct 19, 2020
<u>AB</u>			UPSHER SMITH LABS	<u>25MG</u>	<u>A212417</u>	<u>001</u>	Feb 19, 2020

PRESCRIPTION DRUG PRODUCT LIST

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL

ETHAMBUTOL HYDROCHLORIDE

<u>AB</u>	AKORN	<u>100MG</u>	<u>A075095 001</u>	Nov 30, 1999
<u>AB</u>		<u>400MG</u>	<u>A075095 002</u>	Nov 30, 1999
<u>AB</u>	BARR	<u>400MG</u>	<u>A076057 001</u>	Nov 26, 2001
<u>AB</u>	LUPIN	<u>100MG</u>	<u>A078939 001</u>	Jun 17, 2009
<u>AB</u>		<u>400MG</u>	<u>A078939 002</u>	Jun 17, 2009
<u>MYAMBUTOL</u>				
<u>AB</u>	+ STI PHARMA LLC	<u>100MG</u>	<u>N016320 001</u>	
<u>AB</u>	+!	<u>400MG</u>	<u>N016320 003</u>	

ETHANOLAMINE OLEATE

INJECTABLE; INJECTION

ETHAMOLIN

+! QOL MEDCL 50MG/ML N019357 001 Dec 22, 1988

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-28

ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL

<u>AB</u>	MYLAN LABS LTD	<u>0.035MG;1MG</u>	<u>A204703 001</u>	Jul 28, 2016
<u>AB</u>		<u>0.05MG;1MG</u>	<u>A204704 001</u>	Feb 09, 2016
<u>KELNOR</u>				
<u>AB</u>	BARR	<u>0.035MG;1MG</u>	<u>A076785 001</u>	May 23, 2005
<u>LO-MALMOREDE</u>				
<u>AB</u>	NOVAST LABS	<u>0.035MG;1MG</u>	<u>A209548 001</u>	Feb 11, 2019
<u>MALMOREDE</u>				
<u>AB</u>	NOVAST LABS	<u>0.05MG;1MG</u>	<u>A209547 001</u>	Jul 25, 2018
<u>ZOVIA 1/35E-28</u>				
<u>AB</u>	MAYNE PHARMA	<u>0.035MG;1MG</u>	<u>A072721 001</u>	Dec 30, 1991
<u>ZOVIA 1/50E-28</u>				
<u>AB</u>	! WATSON LABS	<u>0.05MG;1MG</u>	<u>A072723 001</u>	Dec 30, 1991

ETHINYL ESTRADIOL; ETNOGESTREL

RING; VAGINAL

ELURYNG

<u>AB</u>	AMNEAL	<u>0.015MG/24HR;0.12MG/24HR</u>	<u>A210830 001</u>	Dec 11, 2019
<u>NUVARING</u>				
<u>AB</u>	+! ORGANON SUB MERCK	<u>0.015MG/24HR;0.12MG/24HR</u>	<u>N021187 001</u>	Oct 03, 2001

ETHINYL ESTRADIOL; LEVONORGESTREL

SYSTEM; TRANSDERMAL

TWIRLA

+! AGILE 0.03MG/24HR;0.12MG/24HR N204017 001 Feb 14, 2020

TABLET; ORAL

ASHLYNA

<u>AB</u>	GLENMARK GENERICS	<u>0.03MG,0.01MG;0.15MG,N/A</u>	<u>A203163 001</u>	Feb 23, 2015
<u>DAYSEE</u>				
<u>AB</u>	LUPIN LTD	<u>0.03MG,0.01MG;0.15MG,N/A</u>	<u>A091467 001</u>	Apr 10, 2013
<u>DOLISHALE</u>				
<u>AB</u>	NOVAST LABS	<u>0.02MG;0.09MG</u>	<u>A091692 001</u>	Oct 22, 2020
<u>ICLEVIA</u>				
<u>AB</u>	AUROBINDO PHARMA LTD	<u>0.03MG;0.15MG</u>	<u>A206850 001</u>	Jun 29, 2018
<u>INTROVALE</u>				
<u>AB</u>	XIROMED	<u>0.03MG;0.15MG</u>	<u>A079064 001</u>	Sep 27, 2010
<u>JAIMIESS</u>				
<u>AB</u>	XIROMED	<u>0.03MG,0.01MG;0.15MG,N/A</u>	<u>A203770 001</u>	Dec 27, 2017
<u>LEVONORGESTREL AND ETHINYL ESTRADIOL</u>				
<u>AB</u>	AMNEAL PHARMS	<u>0.03MG;0.15MG</u>	<u>A203871 001</u>	Nov 13, 2015
<u>AB</u>		<u>0.03MG,0.01MG;0.15MG,N/A</u>	<u>A203872 001</u>	Dec 22, 2015
<u>AB</u>	GLENMARK GENERICS	<u>0.02MG;0.09MG</u>	<u>A202791 001</u>	Apr 09, 2015
<u>AB</u>	GLENMARK PHARMS LTD	<u>0.03MG;0.15MG</u>	<u>A203164 001</u>	Jun 12, 2015
<u>AB</u>	LUPIN LTD	<u>0.03MG;0.15MG</u>	<u>A091440 001</u>	Oct 23, 2012
<u>AB</u>	MYLAN LABS LTD	<u>0.03MG;0.15MG</u>	<u>A200490 001</u>	Apr 21, 2015
<u>AB</u>	! WATSON LABS	<u>0.02MG;0.09MG</u>	<u>A079218 001</u>	Jun 06, 2011
<u>LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL</u>				
<u>AB</u>	LUPIN LTD	<u>0.02MG,0.1MG;0.01MG,N/A</u>	<u>A091674 001</u>	Oct 26, 2011
<u>AB</u>	MAYNE PHARMA	<u>0.02MG,0.1MG;0.01MG,N/A</u>	<u>A200407 001</u>	Oct 25, 2011
<u>AB</u>		<u>0.03MG,0.01MG;0.15MG,N/A</u>	<u>A078834 001</u>	May 31, 2011
<u>AB</u>	MYLAN LABS LTD	<u>0.02MG,0.15MG;</u>	<u>A206053 001</u>	Oct 02, 2017
		<u>0.025MG,0.15MG;0.03MG,0.15MG;</u>		
<u>AB</u>		<u>0.02MG,0.1MG;0.01MG,N/A</u>	<u>A200493 001</u>	Jun 17, 2015
<u>AB</u>		<u>0.03MG,0.01MG;0.15MG,N/A</u>	<u>A200492 001</u>	May 27, 2015
<u>AB</u>	XIROMED	<u>0.02MG,0.1MG;0.01MG,N/A</u>	<u>A205131 001</u>	Dec 14, 2017

PRESCRIPTION DRUG PRODUCT LIST

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

<u>LO SIMPESSE</u>				
AB	AUROBINDO PHARMA LTD	<u>0.02MG,0.1MG;0.01MG,N/A</u>	<u>A206852 001</u>	Apr 28, 2017
<u>LOSEASONIQUE</u>				
AB	TEVA BRANDED PHARM	<u>0.02MG,0.1MG;0.01MG,N/A</u>	<u>N022262 001</u>	Oct 24, 2008
<u>QUARTETTE</u>				
AB	+! TEVA BRANDED PHARM	<u>0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A</u>	<u>N204061 001</u>	Mar 28, 2013
<u>OUASENSE</u>				
AB	WATSON LABS	<u>0.03MG;0.15MG</u>	<u>A077101 001</u>	Sep 06, 2006
<u>SEASONALE</u>				
AB	+! TEVA BRANDED PHARM	<u>0.03MG;0.15MG</u>	<u>N021544 001</u>	Sep 05, 2003
<u>SEASONIQUE</u>				
AB	+! TEVA BRANDED PHARM	<u>0.03MG,0.01MG;0.15MG,N/A</u>	<u>N021840 001</u>	May 25, 2006
<u>SETLAKIN</u>				
AB	NOVAST LABS	<u>0.03MG;0.15MG</u>	<u>A090716 001</u>	Sep 15, 2014
<u>SIMPESSE</u>				
AB	AUROBINDO PHARMA LTD	<u>0.03MG,0.01MG;0.15MG,N/A</u>	<u>A206851 001</u>	Apr 07, 2017
<u>SYLEVIA</u>				
AB	SUN PHARM	<u>0.03MG;0.15MG</u>	<u>A202988 001</u>	Feb 06, 2019
<u>BALCOLTRA</u>				
	+! AVION PHARMS	0.02MG;0.1MG	N208612 001	Jan 09, 2018
<u>TYBLUME</u>				
	+! EXELTIS USA INC	0.02MG;0.1MG	N209405 001	Mar 30, 2020
TABLET; ORAL-28				
<u>ALTAVERA</u>				
AB	XIROMED	<u>0.03MG;0.15MG</u>	<u>A079102 001</u>	Aug 03, 2010
<u>AYUNA</u>				
AB	AUROBINDO PHARMA LTD	<u>0.03MG;0.15MG</u>	<u>A206866 001</u>	Sep 23, 2016
<u>ENPRESSE-28</u>				
AB	DURAMED PHARMS BARR	<u>0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG</u>	<u>A075809 002</u>	Jul 16, 2001
<u>KURVELO</u>				
AB	LUPIN LTD	<u>0.03MG;0.15MG</u>	<u>A091408 001</u>	Oct 17, 2012
<u>LEVONEST</u>				
AB	NOVAST LABS LTD	<u>0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG</u>	<u>A090719 001</u>	Dec 29, 2010
<u>LEVONORGESTREL AND ETHINYL ESTRADIOL</u>				
AB	AMNEAL PHARMS	<u>0.03MG;0.15MG</u>	<u>A201095 001</u>	Dec 08, 2014
AB	LUPIN LTD	<u>0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG</u>	<u>A200248 001</u>	Nov 19, 2015
AB	MYLAN LABS LTD	<u>0.03MG;0.15MG</u>	<u>A091663 001</u>	Dec 21, 2012
AB	NAARI PTE LTD	<u>0.02MG;0.1MG</u>	<u>A207065 001</u>	Aug 17, 2020
AB		<u>0.03MG;0.15MG</u>	<u>A207033 001</u>	Oct 09, 2020
<u>LEVORA 0.15/30-28</u>				
AB	! MAYNE PHARMA	<u>0.03MG;0.15MG</u>	<u>A073594 001</u>	Dec 13, 1993
<u>MARLISSA</u>				
AB	GLENMARK GENERICS	<u>0.03MG;0.15MG</u>	<u>A091452 001</u>	Feb 29, 2012
<u>MYZILRA</u>				
AB	VINTAGE PHARMS LLC	<u>0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG</u>	<u>A077502 001</u>	Nov 23, 2011
<u>PORTIA-28</u>				
AB	BARR	<u>0.03MG;0.15MG</u>	<u>A075866 002</u>	May 23, 2002
<u>TRIVORA-28</u>				
AB	! MAYNE PHARMA	<u>0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG</u>	<u>A074538 002</u>	Dec 18, 1997
<u>AFIRMELLE</u>				
AB1	AUROBINDO PHARMA LTD	<u>0.02MG;0.1MG</u>	<u>A206886 001</u>	Nov 14, 2016
<u>AVIANE-28</u>				
AB1	DURAMED PHARMS BARR	<u>0.02MG;0.1MG</u>	<u>A075796 001</u>	Apr 30, 2001
<u>CERINTA</u>				
AB1	SUN PHARM	<u>0.02MG;0.1MG</u>	<u>A202817 001</u>	Jan 07, 2019
<u>FALMINA</u>				
AB1	NOVAST LABS LTD	<u>0.02MG;0.1MG</u>	<u>A090721 001</u>	Mar 28, 2012
<u>LEVONORGESTREL AND ETHINYL ESTRADIOL</u>				
AB1	AMNEAL PHARMS	<u>0.02MG;0.1MG</u>	<u>A201108 001</u>	Feb 05, 2014
AB1	LUPIN LTD	<u>0.02MG;0.1MG</u>	<u>A091425 001</u>	Jan 18, 2013
AB1	! MAYNE PHARMA	<u>0.02MG;0.1MG</u>	<u>A076625 001</u>	Nov 18, 2004
AB1	MYLAN LABS LTD	<u>0.02MG;0.1MG</u>	<u>A200245 001</u>	Oct 09, 2013

PRESCRIPTION DRUG PRODUCT LIST

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-28

VIENVA

AB1	XIROMED	0.02MG;0.1MG	A201088 001	May 21, 2015
------------	---------	---------------------	--------------------	--------------

LESSINA-28

AB2	BARR	0.02MG;0.1MG	A075803 002	Mar 20, 2002
------------	------	---------------------	--------------------	--------------

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB2	! MAYNE PHARMA	0.02MG;0.1MG	A077681 001	May 31, 2006
------------	----------------	---------------------	--------------------	--------------

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE; TRANSDERMAL

XULANE

!	MYLAN TECHNOLOGIES	0.035MG/24HR;0.15MG/24HR	A200910 001	Apr 16, 2014
---	--------------------	--------------------------	-------------	--------------

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

NORINYL 1+35 21-DAY

AB	ALLERGAN	0.035MG;1MG	N017565 001	
-----------	----------	--------------------	--------------------	--

NORTREL 1/35-21

AB	BARR	0.035MG;1MG	A072693 001	Feb 28, 1992
-----------	------	--------------------	--------------------	--------------

NORTREL 7/7/7

BARR	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A075478 001	Aug 30, 2002
------	--	-------------	--------------

TABLET; ORAL-28

ALYACEN 1/35

AB	GLENMARK GENERICS	0.035MG;1MG	A091634 001	Jan 19, 2012
-----------	-------------------	--------------------	--------------------	--------------

ALYACEN 7/7/7

AB	GLENMARK GENERICS	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A091636 001	Jan 19, 2012
-----------	-------------------	---	--------------------	--------------

ARANELLE

AB	BARR	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG	A076783 001	Sep 29, 2004
-----------	------	--	--------------------	--------------

BALZIVA-28

AB	! BARR	0.035MG;0.4MG	A076238 001	Apr 22, 2004
-----------	--------	----------------------	--------------------	--------------

BRIELLYN

AB	GLENMARK GENERICS	0.035MG;0.4MG	A090538 001	Mar 22, 2011
-----------	-------------------	----------------------	--------------------	--------------

CYCLAFEM 1/35

AB	VINTAGE PHARMS LLC	0.035MG;1MG	A076337 001	Nov 12, 2010
-----------	--------------------	--------------------	--------------------	--------------

CYCLAFEM 7/7/7

AB	VINTAGE PHARMS LLC	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A076338 001	Nov 16, 2010
-----------	--------------------	---	--------------------	--------------

CYONANZ

AB	AUROBINDO PHARMA LTD	0.035MG;0.5MG	A207055 001	Oct 21, 2016
-----------	----------------------	----------------------	--------------------	--------------

DASETTA 1/35

AB	NOVAST LABS LTD	0.035MG;1MG	A090948 001	Dec 22, 2011
-----------	-----------------	--------------------	--------------------	--------------

DASETTA 7/7/7

AB	! NOVAST LABS LTD	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A090946 001	Dec 22, 2011
-----------	-------------------	---	--------------------	--------------

GILDAGIA

AB	VINTAGE PHARMS	0.035MG;0.4MG	A078376 001	Nov 06, 2012
-----------	----------------	----------------------	--------------------	--------------

NORETHINDRONE AND ETHINYL ESTRADIOL

AB	MAYNE PHARMA	0.035MG;0.5MG	A070686 001	Jan 29, 1987
-----------	--------------	----------------------	--------------------	--------------

AB	NAARI PTE LTD	0.035MG;1MG	A206864 001	Apr 28, 2017
-----------	---------------	--------------------	--------------------	--------------

AB	WATSON LABS	0.035MG;0.4MG	A078323 001	Feb 04, 2010
-----------	-------------	----------------------	--------------------	--------------

AB	WATSON LABS TEVA	0.035MG;1MG	A070687 001	Jan 29, 1987
-----------	------------------	--------------------	--------------------	--------------

NORINYL 1+35 28-DAY

AB	ALLERGAN	0.035MG;1MG	N017565 002	
-----------	----------	--------------------	--------------------	--

NORTREL 0.5/35-28

AB	BARR	0.035MG;0.5MG	A072695 001	Feb 28, 1992
-----------	------	----------------------	--------------------	--------------

NORTREL 1/35-28

AB	! BARR	0.035MG;1MG	A072696 001	Feb 28, 1992
-----------	--------	--------------------	--------------------	--------------

NORTREL 7/7/7

AB	BARR	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A075478 002	Aug 30, 2002
-----------	------	---	--------------------	--------------

NYLIA 1/35

AB	AUROBINDO PHARMA LTD	0.035MG;1MG	A207056 001	Oct 21, 2016
-----------	----------------------	--------------------	--------------------	--------------

NYLIA 7/7/7

AB	AUROBINDO PHARMA LTD	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A207054 001	Oct 21, 2016
-----------	----------------------	---	--------------------	--------------

PHILITH

AB	NOVAST LABS LTD	0.035MG;0.4MG	A090947 001	Dec 22, 2011
-----------	-----------------	----------------------	--------------------	--------------

PIRMELLA 1/35

AB	LUPIN LTD	0.035MG;1MG	A201512 001	Apr 24, 2013
-----------	-----------	--------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

PIRMELLA 7/7/7

AB	LUPIN LTD	<u>0.035MG;0.035MG;0.035MG;0.5MG;0.75MG,1MG</u>	<u>A201510 001</u>	Apr 24, 2013
-----------	-----------	---	--------------------	--------------

TRI-NORINYL 28-DAY

AB	+! MAYNE PHARMA	<u>0.035MG;0.035MG;0.035MG;0.5MG,1MG,0.5MG</u>	<u>N018977 002</u>	Apr 13, 1984
-----------	-----------------	--	--------------------	--------------

VYFEMLA

AB	LUPIN LTD	<u>0.035MG;0.4MG</u>	<u>A201886 001</u>	Sep 26, 2013
-----------	-----------	----------------------	--------------------	--------------

WERA

AB	! NOVAST LABS LTD	<u>0.035MG;0.5MG</u>	<u>A091204 001</u>	Mar 27, 2012
-----------	-------------------	----------------------	--------------------	--------------

NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)

WATSON LABS TEVA 0.035MG;0.035MG;0.5MG,1MG

A071044 001 Apr 01, 1988

TABLET, CHEWABLE; ORAL

KAITLIB FE

AB	LUPIN LTD	<u>0.025MG;0.8MG</u>	<u>A203448 001</u>	Dec 17, 2015
-----------	-----------	----------------------	--------------------	--------------

NEXESTA FE

AB	AUROBINDO PHARMA LTD	<u>0.035MG;0.4MG</u>	<u>A207535 001</u>	Feb 02, 2017
-----------	----------------------	----------------------	--------------------	--------------

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB	AMNEAL PHARMS	<u>0.035MG;0.4MG</u>	<u>A078892 001</u>	Sep 26, 2011
-----------	---------------	----------------------	--------------------	--------------

AB	+! APIL	<u>0.025MG;0.8MG</u>	<u>N022573 001</u>	Dec 22, 2010
-----------	---------	----------------------	--------------------	--------------

AB	BARR	<u>0.035MG;0.4MG</u>	<u>A078965 001</u>	Aug 05, 2010
-----------	------	----------------------	--------------------	--------------

AB	LUPIN LTD	<u>0.035MG;0.4MG</u>	<u>A091332 001</u>	Mar 23, 2016
-----------	-----------	----------------------	--------------------	--------------

AB	MYLAN LABS LTD	<u>0.025MG;0.8MG</u>	<u>A203371 001</u>	Apr 23, 2014
-----------	----------------	----------------------	--------------------	--------------

AB	! NAARI PTE LTD	<u>0.035MG;0.4MG</u>	<u>A202086 001</u>	Apr 01, 2015
-----------	-----------------	----------------------	--------------------	--------------

AB	NAARI PTE LTD	<u>0.035MG;0.4MG</u>	<u>A207066 001</u>	Mar 29, 2017
-----------	---------------	----------------------	--------------------	--------------

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

CAPSULE; ORAL

GEMMILY

AB	CHEMO RESEARCH SL	<u>0.02MG;1MG</u>	<u>A213317 001</u>	Nov 09, 2020
-----------	-------------------	-------------------	--------------------	--------------

MERZEE

AB	SLAYBACK PHARMA LLC	<u>0.02MG;1MG</u>	<u>A212706 001</u>	Dec 18, 2020
-----------	---------------------	-------------------	--------------------	--------------

TAYTULLA

AB	+! APIL	<u>0.02MG;1MG</u>	<u>N204426 001</u>	Apr 19, 2013
-----------	---------	-------------------	--------------------	--------------

TABLET; ORAL

AUROVELA 24 FE

AB	AUROBINDO PHARMA LTD	<u>0.02MG;1MG</u>	<u>A207504 001</u>	Jun 15, 2017
-----------	----------------------	-------------------	--------------------	--------------

BLISOVI 24 FE

AB	LUPIN LTD	<u>0.02MG;1MG</u>	<u>A091398 001</u>	Oct 28, 2015
-----------	-----------	-------------------	--------------------	--------------

FEMHRT

AB	APIL	<u>0.0025MG;0.5MG</u>	<u>N021065 001</u>	Jan 14, 2005
-----------	------	-----------------------	--------------------	--------------

FYAVOLV

AB	LUPIN LTD	<u>0.005MG;1MG</u>	<u>A204213 002</u>	Dec 10, 2015
-----------	-----------	--------------------	--------------------	--------------

AB		<u>0.0025MG;0.5MG</u>	<u>A204213 001</u>	Dec 10, 2015
-----------	--	-----------------------	--------------------	--------------

GILDESS 24 FE

AB	VINTAGE PHARMS	<u>0.02MG;1MG</u>	<u>A090293 001</u>	Dec 01, 2014
-----------	----------------	-------------------	--------------------	--------------

LARIN 24 FE

AB	NOVAST LABS	<u>0.02MG;1MG</u>	<u>A202994 001</u>	Feb 18, 2015
-----------	-------------	-------------------	--------------------	--------------

LERIBANE

AB	NOVAST LABS	<u>0.0025MG;0.5MG</u>	<u>A203435 002</u>	Jun 03, 2016
-----------	-------------	-----------------------	--------------------	--------------

AB		<u>0.005MG;1MG</u>	<u>A203435 001</u>	Jun 03, 2016
-----------	--	--------------------	--------------------	--------------

LOESTRIN 24 FE

AB	+ TEVA BRANDED PHARM	<u>0.02MG;1MG</u>	<u>N021871 001</u>	Feb 17, 2006
-----------	----------------------	-------------------	--------------------	--------------

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB	! BARR LABS INC	<u>0.005MG;1MG</u>	<u>A076221 001</u>	Nov 06, 2009
-----------	-----------------	--------------------	--------------------	--------------

AB	GLENMARK GENERICS	<u>0.0025MG;0.5MG</u>	<u>A203038 001</u>	Apr 02, 2015
-----------	-------------------	-----------------------	--------------------	--------------

AB		<u>0.005MG;1MG</u>	<u>A203038 002</u>	Apr 02, 2015
-----------	--	--------------------	--------------------	--------------

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB	! AMNEAL PHARMS	<u>0.02MG;1MG</u>	<u>A078267 001</u>	Sep 01, 2009
-----------	-----------------	-------------------	--------------------	--------------

AB	BARR LABS INC	<u>0.02MG;1MG</u>	<u>A090938 001</u>	Dec 01, 2014
-----------	---------------	-------------------	--------------------	--------------

AB	GLENMARK PHARMS LTD	<u>0.02MG;1MG</u>	<u>A204847 001</u>	Nov 17, 2017
-----------	---------------------	-------------------	--------------------	--------------

LO LOESTRIN FE

+! APIL 0.01MG,0.01MG;1MG,N/A

N022501 001 Oct 21, 2010

TABLET; ORAL-21

AUROVELA 1.5/30

AB	AUROBINDO PHARMA LTD	<u>0.03MG;1.5MG</u>	<u>A207581 001</u>	Jun 26, 2017
-----------	----------------------	---------------------	--------------------	--------------

AUROVELA 1/20

AB	AUROBINDO PHARMA LTD	<u>0.02MG;1MG</u>	<u>A207506 001</u>	Jun 16, 2017
-----------	----------------------	-------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-21

GILDESS 1/20

AB	VINTAGE PHARMS LLC	<u>0.02MG;1MG</u>	<u>A077077 002</u>	Jul 24, 2012
-----------	--------------------	-------------------	--------------------	--------------

HAILEY 1.5/30

AB	GLENMARK PHARMS	<u>0.03MG;1.5MG</u>	<u>A209297 001</u>	Jun 05, 2018
-----------	-----------------	---------------------	--------------------	--------------

JUNEL 1.5/30

AB	BARR	<u>0.03MG;1.5MG</u>	<u>A076381 001</u>	May 30, 2003
-----------	------	---------------------	--------------------	--------------

JUNEL 1/20

AB	BARR	<u>0.02MG;1MG</u>	<u>A076380 001</u>	May 30, 2003
-----------	------	-------------------	--------------------	--------------

LARIN 1.5/30

AB	NOVAST LABS	<u>0.03MG;1.5MG</u>	<u>A202996 001</u>	Mar 20, 2014
-----------	-------------	---------------------	--------------------	--------------

LARIN 1/20

AB	NOVAST LABS	<u>0.02MG;1MG</u>	<u>A202995 001</u>	Dec 04, 2013
-----------	-------------	-------------------	--------------------	--------------

LOESTRIN 21 1.5/30

AB	+ TEVA BRANDED PHARM	<u>0.03MG;1.5MG</u>	<u>N017875 001</u>	
-----------	----------------------	---------------------	--------------------	--

LOESTRIN 21 1/20

AB	+ TEVA BRANDED PHARM	<u>0.02MG;1MG</u>	<u>N017876 001</u>	
-----------	----------------------	-------------------	--------------------	--

LOESTRIN FE 1.5/30

AB	+! TEVA BRANDED PHARM	<u>0.03MG;1.5MG</u>	<u>N017355 001</u>	
-----------	-----------------------	---------------------	--------------------	--

MICROGESTIN 1.5/30

AB	MAYNE PHARMA	<u>0.03MG;1.5MG</u>	<u>A075548 002</u>	Jul 30, 2003
-----------	--------------	---------------------	--------------------	--------------

MICROGESTIN 1/20

AB	MAYNE PHARMA	<u>0.02MG;1MG</u>	<u>A075647 002</u>	Jul 30, 2003
-----------	--------------	-------------------	--------------------	--------------

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB	GLENMARK PHARMS LTD	<u>0.02MG;1MG</u>	<u>A206969 001</u>	Jan 20, 2016
-----------	---------------------	-------------------	--------------------	--------------

AB	MYLAN LABS LTD	<u>0.02MG;1MG</u>	<u>A202771 001</u>	Nov 06, 2013
-----------	----------------	-------------------	--------------------	--------------

AB		<u>0.03MG;1.5MG</u>	<u>A202770 001</u>	Feb 19, 2015
-----------	--	---------------------	--------------------	--------------

TRI-LEGEST 21

BARR

0.02MG, 0.03MG, 0.035MG; 1MG, 1MG, 1MG

A076405 001 Oct 26, 2007

TABLET; ORAL-28

AUROVELA FE 1.5/30

AB	AUROBINDO PHARMA LTD	<u>0.03MG;1.5MG</u>	<u>A207580 001</u>	Jun 15, 2017
-----------	----------------------	---------------------	--------------------	--------------

AUROVELA FE 1/20

AB	AUROBINDO PHARMA LTD	<u>0.02MG;1MG</u>	<u>A207505 001</u>	Jun 16, 2017
-----------	----------------------	-------------------	--------------------	--------------

BLISOVI FE 1.5/30

AB	LUPIN LTD	<u>0.03MG;1.5MG</u>	<u>A201585 001</u>	Nov 18, 2015
-----------	-----------	---------------------	--------------------	--------------

BLISOVI FE 1/20

AB	LUPIN LTD	<u>0.02MG;1MG</u>	<u>A201584 001</u>	Nov 18, 2015
-----------	-----------	-------------------	--------------------	--------------

CHABELINA FE

AB	NOVAST LABS	<u>0.02MG, 0.03MG, 0.035MG; 1MG, 1MG, 1MG</u>	<u>A202962 001</u>	Apr 15, 2020
-----------	-------------	---	--------------------	--------------

ESTROSTEP FE

AB	+! APIL	<u>0.02MG, 0.03MG, 0.035MG; 1MG, 1MG, 1MG</u>	<u>N020130 002</u>	Oct 09, 1996
-----------	---------	---	--------------------	--------------

GILDESS FE 1/20

AB	VINTAGE PHARMS LLC	<u>0.02MG;1MG</u>	<u>A077077 001</u>	May 20, 2005
-----------	--------------------	-------------------	--------------------	--------------

HAILEY FE 1.5/30

AB	GLENMARK PHARMS	<u>0.03MG;1.5MG</u>	<u>A209031 001</u>	Jun 05, 2018
-----------	-----------------	---------------------	--------------------	--------------

HAILEY FE 1/20

AB	GLENMARK PHARMS LTD	<u>0.02MG;1MG</u>	<u>A206597 001</u>	Nov 21, 2017
-----------	---------------------	-------------------	--------------------	--------------

JUNEL FE 1.5/30

AB	BARR	<u>0.03MG;1.5MG</u>	<u>A076064 001</u>	Sep 18, 2003
-----------	------	---------------------	--------------------	--------------

JUNEL FE 1/20

AB	BARR	<u>0.02MG;1MG</u>	<u>A076081 001</u>	Sep 18, 2003
-----------	------	-------------------	--------------------	--------------

LARIN FE 1.5/30

AB	NOVAST LABS	<u>0.03MG;1.5MG</u>	<u>A091453 001</u>	Aug 23, 2013
-----------	-------------	---------------------	--------------------	--------------

LARIN FE 1/20

AB	NOVAST LABS	<u>0.02MG;1MG</u>	<u>A091454 001</u>	Aug 26, 2013
-----------	-------------	-------------------	--------------------	--------------

LOESTRIN FE 1/20

AB	+ TEVA BRANDED PHARM	<u>0.02MG;1MG</u>	<u>N017354 001</u>	
-----------	----------------------	-------------------	--------------------	--

MICROGESTIN FE 1.5/30

AB	MAYNE PHARMA	<u>0.03MG;1.5MG</u>	<u>A075548 001</u>	Feb 05, 2001
-----------	--------------	---------------------	--------------------	--------------

MICROGESTIN FE 1/20

AB	MAYNE PHARMA	<u>0.02MG;1MG</u>	<u>A075647 001</u>	Feb 05, 2001
-----------	--------------	-------------------	--------------------	--------------

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB	MAYNE PHARMA	<u>0.02MG, 0.03MG, 0.035MG; 1MG, 1MG, 1MG</u>	<u>A076629 001</u>	Mar 18, 2010
-----------	--------------	---	--------------------	--------------

AB	MYLAN LABS LTD	<u>0.02MG;1MG</u>	<u>A202772 001</u>	Nov 14, 2013
-----------	----------------	-------------------	--------------------	--------------

AB		<u>0.03MG;1.5MG</u>	<u>A202741 001</u>	Feb 20, 2015
-----------	--	---------------------	--------------------	--------------

TRI-LEGEST FE

BARR

0.02MG, 0.03MG, 0.035MG; 1MG, 1MG, 1MG

A076105 001 Oct 26, 2007

PRESCRIPTION DRUG PRODUCT LIST

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET, CHEWABLE; ORAL

MIBELAS 24 FE

AB	LUPIN	<u>0.02MG;1MG</u>	A206287 001	May 24, 2016
-----------	-------	-------------------	--------------------	--------------

MINASTRIN 24 FE

AB	+! APIL	<u>0.02MG;1MG</u>	N203667 001	May 08, 2013
-----------	---------	-------------------	--------------------	--------------

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB	AMNEAL PHARMS	<u>0.02MG;1MG</u>	A207514 001	Sep 11, 2017
-----------	---------------	-------------------	--------------------	--------------

AB	GLENMARK PHARMS LTD	<u>0.02MG;1MG</u>	A210369 001	Dec 26, 2017
-----------	---------------------	-------------------	--------------------	--------------

AB	XIROMED	<u>0.02MG;1MG</u>	A209609 001	Jul 16, 2018
-----------	---------	-------------------	--------------------	--------------

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

ESTARYLLA

AB	XIROMED	<u>0.035MG;0.25MG</u>	A090794 001	Jan 30, 2013
-----------	---------	-----------------------	--------------------	--------------

MILI

AB	AUROBINDO PHARMA LTD	<u>0.035MG;0.25MG</u>	A205449 001	Jul 07, 2016
-----------	----------------------	-----------------------	--------------------	--------------

MONO-LINYAH

AB	NOVAST LABS LTD	<u>0.035MG;0.25MG</u>	A090523 001	May 23, 2012
-----------	-----------------	-----------------------	--------------------	--------------

NORGESTIMATE AND ETHINYL ESTRADIOL

AB	AMNEAL PHARMS	<u>0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG</u>	A203870 001	Nov 12, 2015
-----------	---------------	--	--------------------	--------------

AB		<u>0.035MG;0.25MG</u>	A203865 001	Oct 27, 2015
-----------	--	-----------------------	--------------------	--------------

AB		<u>0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG</u>	A203873 001	May 12, 2016
-----------	--	--	--------------------	--------------

AB	! GLENMARK GENERICS	<u>0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG</u>	A200494 001	Jun 17, 2011
-----------	---------------------	--	--------------------	--------------

AB		<u>0.035MG;0.25MG</u>	A200538 001	Apr 05, 2012
-----------	--	-----------------------	--------------------	--------------

AB	! GLENMARK PHARMS	<u>0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG</u>	A204057 001	Feb 23, 2016
-----------	-------------------	--	--------------------	--------------

AB	LUPIN LTD	<u>0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG</u>	A205588 001	Apr 26, 2016
-----------	-----------	--	--------------------	--------------

AB		<u>0.035MG;0.25MG</u>	A205630 001	Oct 27, 2016
-----------	--	-----------------------	--------------------	--------------

AB	LUPIN PHARMS	<u>0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG</u>	A200541 001	Jun 25, 2012
-----------	--------------	--	--------------------	--------------

AB	MYLAN LABS LTD	<u>0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG</u>	A201897 001	Jan 27, 2016
-----------	----------------	--	--------------------	--------------

AB		<u>0.035MG;0.25MG</u>	A201896 001	Jan 27, 2016
-----------	--	-----------------------	--------------------	--------------

AB	NAARI PTE LTD	<u>0.035MG,0.035MG;0.035MG;0.18MG;0.215MG;0.25MG</u>	A200383 001	Apr 07, 2015
-----------	---------------	--	--------------------	--------------

AB		<u>0.035MG;0.25MG</u>	A200384 001	Apr 07, 2015
-----------	--	-----------------------	--------------------	--------------

PREVIFEM

AB	VINTAGE PHARMS LLC	<u>0.035MG;0.25MG</u>	A076334 001	Jan 09, 2004
-----------	--------------------	-----------------------	--------------------	--------------

SPRINTEC

AB	! BARR	<u>0.035MG;0.25MG</u>	A075804 001	Sep 25, 2002
-----------	--------	-----------------------	--------------------	--------------

TRI LO SPRINTEC

AB	BARR LABS INC	<u>0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG</u>	A076784 001	Jun 29, 2009
-----------	---------------	--	--------------------	--------------

TRI-ESTARYLLA

AB	XIROMED	<u>0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG</u>	A090793 001	Jan 30, 2013
-----------	---------	--	--------------------	--------------

TRI-LINYAH

AB	NOVAST LABS LTD	<u>0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG</u>	A090524 001	May 30, 2012
-----------	-----------------	--	--------------------	--------------

TRI-LO-ESTARYLLA

AB	XIROMED	<u>0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG</u>	A091232 001	Jun 29, 2015
-----------	---------	--	--------------------	--------------

TRI-LO-MILI

AB	AUROBINDO PHARMA LTD	<u>0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG</u>	A205762 001	Nov 04, 2016
-----------	----------------------	--	--------------------	--------------

TRI-MILI

AB	AUROBINDO PHARMA LTD	<u>0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG</u>	A205441 001	Jul 06, 2016
-----------	----------------------	--	--------------------	--------------

TRI-SPRINTEC

AB	BARR	<u>0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG</u>	A075808 001	Dec 29, 2003
-----------	------	--	--------------------	--------------

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21

CRYSELLE

AB	DURAMED PHARMS BARR	<u>0.03MG;0.3MG</u>	A075840 001	Nov 30, 2001
-----------	---------------------	---------------------	--------------------	--------------

TABLET; ORAL-28

CRYSELLE

AB	DURAMED PHARMS BARR	<u>0.03MG;0.3MG</u>	A075840 002	Nov 30, 2001
-----------	---------------------	---------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ETHINYL ESTRADIOL; NORGESTREL

TABLET;ORAL-28

ELINEST

AB	NOVAST LABS LTD	0.03MG;0.3MG	A091105 001	Mar 28, 2012
-----------	-----------------	---------------------	--------------------	--------------

LOW-OGESTREL-28

AB	MAYNE PHARMA	0.03MG;0.3MG	A075288 002	Jul 28, 1999
-----------	--------------	---------------------	--------------------	--------------

ETHINYL ESTRADIOL; SEGESTERONE ACETATE

RING;VAGINAL

ANNOVERA

+	THERAPEUTICSMD INC	0.013MG/24HR;0.15MG/24HR	N209627 001	Aug 10, 2018
---	--------------------	--------------------------	-------------	--------------

ETHIODIZED OIL

OIL;INTRALYMPHATIC, INTRAUTERINE

LIPIODOL

+	GUERBET	EQ 4.8GM IODINE/10ML (EQ 480MG IODINE/ML)	N009190 001	
---	---------	---	-------------	--

ETHIONAMIDE

TABLET;ORAL

TRECATOR

+	WYETH PHARMS	250MG	N013026 002	
---	--------------	-------	-------------	--

ETHOSUXIMIDE

CAPSULE;ORAL

ETHOSUXIMIDE

AB	AKORN	250MG	A040686 001	May 28, 2008
-----------	-------	--------------	--------------------	--------------

AB	BIONPHARMA INC	250MG	A040430 001	Oct 28, 2002
-----------	----------------	--------------	--------------------	--------------

AB	HERITAGE PHARMS INC	250MG	A200892 001	Sep 25, 2012
-----------	---------------------	--------------	--------------------	--------------

AB	PURACAP PHARM LLC	250MG	A210654 001	Mar 16, 2020
-----------	-------------------	--------------	--------------------	--------------

AB	STRIDES PHARMA	250MG	A211928 001	Feb 19, 2019
-----------	----------------	--------------	--------------------	--------------

ZARONTIN

AB	+	PARKE DAVIS	250MG	N012380 001
-----------	---	-------------	--------------	--------------------

SYRUP;ORAL

ETHOSUXIMIDE

AA	MIKART	250MG/5ML	A040506 001	Dec 22, 2003
-----------	--------	------------------	--------------------	--------------

AA	PHARM ASSOC	250MG/5ML	A040253 001	Nov 22, 2000
-----------	-------------	------------------	--------------------	--------------

ZARONTIN

AA	!	PARKE-DAVIS	250MG/5ML	A080258 001
-----------	---	-------------	------------------	--------------------

ETODOLAC

CAPSULE;ORAL

ETODOLAC

AB	ANI PHARMS INC	200MG	A075126 001	Sep 16, 1999
-----------	----------------	--------------	--------------------	--------------

AB		300MG	A075126 002	Sep 16, 1999
-----------	--	--------------	--------------------	--------------

AB	APOTEX	200MG	A075419 001	Jul 28, 2000
-----------	--------	--------------	--------------------	--------------

AB		300MG	A075419 002	Jul 28, 2000
-----------	--	--------------	--------------------	--------------

AB	TARO	200MG	A075078 001	Apr 30, 1998
-----------	------	--------------	--------------------	--------------

AB	!		A075078 002	Apr 30, 1998
-----------	---	--	--------------------	--------------

TABLET;ORAL

ETODOLAC

AB	AMNEAL PHARMS CO	400MG	A208834 001	Jun 07, 2018
-----------	------------------	--------------	--------------------	--------------

AB		500MG	A208834 002	Jun 07, 2018
-----------	--	--------------	--------------------	--------------

AB	APOTEX INC	400MG	A076004 001	Dec 03, 2002
-----------	------------	--------------	--------------------	--------------

AB		500MG	A076004 002	Dec 03, 2002
-----------	--	--------------	--------------------	--------------

AB	BAYSHORE PHARMS LLC	400MG	A210704 001	Dec 16, 2020
-----------	---------------------	--------------	--------------------	--------------

AB		500MG	A210704 002	Dec 16, 2020
-----------	--	--------------	--------------------	--------------

AB	EDENBRIDGE PHARMS	400MG	A209888 001	Nov 30, 2018
-----------	-------------------	--------------	--------------------	--------------

AB		500MG	A209888 002	Nov 30, 2018
-----------	--	--------------	--------------------	--------------

AB	SANDOZ	400MG	A074903 001	Apr 11, 1997
-----------	--------	--------------	--------------------	--------------

AB		500MG	A074903 002	Apr 19, 1999
-----------	--	--------------	--------------------	--------------

AB	TARO PHARM INDS	400MG	A075074 001	Mar 11, 1998
-----------	-----------------	--------------	--------------------	--------------

AB	!		A075074 002	Apr 25, 2000
-----------	---	--	--------------------	--------------

TABLET, EXTENDED RELEASE;ORAL

ETODOLAC

AB	BAYSHORE PHARMS LLC	400MG	A212263 001	Nov 24, 2020
-----------	---------------------	--------------	--------------------	--------------

AB		500MG	A212263 002	Nov 24, 2020
-----------	--	--------------	--------------------	--------------

AB		600MG	A212263 003	Nov 24, 2020
-----------	--	--------------	--------------------	--------------

AB	TARO	400MG	A076174 001	Mar 13, 2003
-----------	------	--------------	--------------------	--------------

AB		500MG	A076174 002	Mar 13, 2003
-----------	--	--------------	--------------------	--------------

AB		600MG	A076174 003	Mar 13, 2003
-----------	--	--------------	--------------------	--------------

AB	TEVA	400MG	A075665 003	Feb 05, 2001
-----------	------	--------------	--------------------	--------------

AB		500MG	A075665 002	Jul 31, 2000
-----------	--	--------------	--------------------	--------------

AB	!		A075665 001	Jul 31, 2000
-----------	---	--	--------------------	--------------

AB	ZYDUS PHARMS	400MG	A091134 001	Jan 23, 2014
-----------	--------------	--------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ETODOLAC

TABLET, EXTENDED RELEASE;ORAL

ETODOLAC

<u>AB</u>		<u>500MG</u>	<u>A091134</u>	<u>002</u>	Jan 23, 2014
<u>AB</u>		<u>600MG</u>	<u>A091134</u>	<u>003</u>	Jan 23, 2014

ETOMIDATE

INJECTABLE; INJECTION

AMIDATE

<u>AP</u>	<u>+</u> !	HOSPIRA	<u>2MG/ML</u>	<u>N018227</u>	<u>001</u>	Sep 07, 1982
-----------	------------	---------	---------------	----------------	------------	--------------

ETOMIDATE

<u>AP</u>		AUROBINDO PHARMA LTD	<u>2MG/ML</u>	<u>A206126</u>	<u>001</u>	Feb 24, 2017
<u>AP</u>		CAPLIN	<u>2MG/ML</u>	<u>A215028</u>	<u>001</u>	Dec 18, 2020
<u>AP</u>		EMCURE PHARMS LTD	<u>2MG/ML</u>	<u>A204618</u>	<u>001</u>	Aug 13, 2014
<u>AP</u>		GLAND PHARMA LTD	<u>2MG/ML</u>	<u>A209058</u>	<u>001</u>	Apr 18, 2017
<u>AP</u>		HIKMA	<u>2MG/ML</u>	<u>A202354</u>	<u>001</u>	Feb 25, 2016
<u>AP</u>		MYLAN LABS LTD	<u>2MG/ML</u>	<u>A201044</u>	<u>001</u>	Feb 07, 2017
<u>AP</u>		WEST-WARD PHARMS INT	<u>2MG/ML</u>	<u>A074593</u>	<u>001</u>	Nov 04, 1996
<u>AP</u>		ZYDUS PHARMS	<u>2MG/ML</u>	<u>A202360</u>	<u>001</u>	Jul 18, 2014

ETONOGESTREL

IMPLANT; IMPLANTATION

NEXPLANON

<u>+</u> !	ORGANON USA INC	68MG/IMPLANT	<u>N021529</u>	<u>002</u>	May 31, 2011
------------	-----------------	--------------	----------------	------------	--------------

ETOPOSIDE

CAPSULE; ORAL

ETOPOSIDE

<u>!</u>	MYLAN	50MG	<u>A075635</u>	<u>001</u>	Sep 19, 2001
----------	-------	------	----------------	------------	--------------

INJECTABLE; INJECTION

ETOPOSIDE

<u>AP</u>		ACCORD HLTHCARE	<u>20MG/ML</u>	<u>A074513</u>	<u>001</u>	Mar 14, 1996
<u>AP</u>	<u>!</u>	FRESENIUS KABI USA	<u>20MG/ML</u>	<u>A074983</u>	<u>001</u>	Sep 30, 1998
<u>AP</u>		TEVA PHARMS USA	<u>20MG/ML</u>	<u>A074529</u>	<u>001</u>	Jul 24, 1996
<u>AP</u>		WEST-WARD PHARMS INT	<u>20MG/ML</u>	<u>A074290</u>	<u>001</u>	Jul 17, 1995

ETOPOSIDE PHOSPHATE

INJECTABLE; INJECTION

ETOPOPHOS PRESERVATIVE FREE

<u>+</u> !	CHEPLAPHARM	EQ 100MG BASE/VIAL	<u>N020457</u>	<u>001</u>	May 17, 1996
------------	-------------	--------------------	----------------	------------	--------------

ETRAVIRINE

TABLET; ORAL

INTELENCE

<u>+</u>	JANSSEN R AND D	25MG	<u>N022187</u>	<u>003</u>	Mar 26, 2012
<u>+</u>		100MG	<u>N022187</u>	<u>001</u>	Jan 18, 2008
<u>+</u> !		200MG	<u>N022187</u>	<u>002</u>	Dec 22, 2010

EVEROLIMUS

TABLET; ORAL

AFINITOR

<u>AB</u>	<u>+</u>	NOVARTIS	<u>2.5MG</u>	<u>N022334</u>	<u>003</u>	Jul 09, 2010
<u>AB</u>	<u>+</u> !		<u>5MG</u>	<u>N022334</u>	<u>001</u>	Mar 30, 2009
<u>AB</u>	<u>+</u>		<u>7.5MG</u>	<u>N022334</u>	<u>004</u>	Mar 30, 2012

EVEROLIMUS

<u>AB</u>		HIKMA	<u>0.25MG</u>	<u>A206133</u>	<u>001</u>	Apr 12, 2018
<u>AB</u>			<u>0.5MG</u>	<u>A206133</u>	<u>002</u>	Apr 12, 2018
<u>AB</u>			<u>0.75MG</u>	<u>A206133</u>	<u>003</u>	Apr 12, 2018
<u>AB</u>			<u>2.5MG</u>	<u>A207486</u>	<u>001</u>	Jun 08, 2020
<u>AB</u>			<u>5MG</u>	<u>A207486</u>	<u>002</u>	Jun 08, 2020
<u>AB</u>			<u>7.5MG</u>	<u>A207486</u>	<u>003</u>	Jun 08, 2020
<u>AB</u>		MYLAN	<u>2.5MG</u>	<u>A212936</u>	<u>001</u>	Jun 08, 2020
<u>AB</u>			<u>5MG</u>	<u>A212936</u>	<u>002</u>	Jun 08, 2020
<u>AB</u>			<u>7.5MG</u>	<u>A212936</u>	<u>003</u>	Jun 08, 2020
<u>AB</u>		PAR PHARM	<u>2.5MG</u>	<u>A207934</u>	<u>001</u>	Dec 09, 2019
<u>AB</u>			<u>5MG</u>	<u>A207934</u>	<u>002</u>	Dec 09, 2019
<u>AB</u>			<u>7.5MG</u>	<u>A207934</u>	<u>003</u>	Dec 09, 2019
<u>AB</u>			<u>10MG</u>	<u>A207934</u>	<u>004</u>	Dec 09, 2020
<u>AB</u>		TEVA PHARMS USA	<u>2.5MG</u>	<u>A210050</u>	<u>001</u>	Dec 09, 2019
<u>AB</u>			<u>5MG</u>	<u>A210050</u>	<u>002</u>	Dec 09, 2019
<u>AB</u>			<u>7.5MG</u>	<u>A210050</u>	<u>003</u>	Dec 09, 2019

PRESCRIPTION DRUG PRODUCT LIST

EVEROLIMUS

TABLET; ORAL

ZORTRESS

AB	+	NOVARTIS	0.25MG	N021560 001	Apr 20, 2010
AB	+		0.5MG	N021560 002	Apr 20, 2010
AB	+		0.75MG	N021560 003	Apr 20, 2010
AFINITOR					
	+	NOVARTIS	10MG	N022334 002	Mar 30, 2009
ZORTRESS					
	+	NOVARTIS	1MG	N021560 004	Aug 10, 2018
TABLET, FOR SUSPENSION; ORAL					
AFINITOR DISPERZ					
	+	NOVARTIS PHARM	2MG	N203985 001	Aug 29, 2012
	+		3MG	N203985 002	Aug 29, 2012
	+		5MG	N203985 003	Aug 29, 2012

EXEMESTANE

TABLET; ORAL

AROMASIN

AB	+	PHARMACIA AND UPJOHN	25MG	N020753 001	Oct 21, 1999
-----------	---	-------------------------	-------------	--------------------	--------------

EXEMESTANE

AB		ALVOGEN	25MG	A200898 001	Jul 28, 2014
AB		BRECKENRIDGE	25MG	A211031 001	Feb 21, 2019
AB		CIPLA	25MG	A210323 001	Apr 27, 2018
AB		HIKMA	25MG	A077431 001	Apr 01, 2011
AB		MYLAN	25MG	A203315 001	Mar 10, 2017
AB		QILU	25MG	A213547 001	Apr 13, 2020
AB		UPSHER SMITH LABS	25MG	A209208 001	Jul 26, 2017
AB		ZYDUS PHARMS	25MG	A202602 001	Oct 03, 2018

EXENATIDE

SUSPENSION, EXTENDED RELEASE; SUBCUTANEOUS

BYDUREON BCISE

	+	ASTRAZENECA AB	2MG/0.85ML (2MG/0.85ML)	N209210 001	Oct 20, 2017
--	---	----------------	-------------------------	-------------	--------------

EXENATIDE SYNTHETIC

FOR SUSPENSION, EXTENDED RELEASE; SUBCUTANEOUS

BYDUREON

	+	ASTRAZENECA AB	2MG/VIAL	N022200 001	Jan 27, 2012
--	---	----------------	----------	-------------	--------------

BYDUREON PEN

	+	ASTRAZENECA AB	2MG	N022200 002	Feb 28, 2014
--	---	----------------	-----	-------------	--------------

INJECTABLE; SUBCUTANEOUS

BYETTA

	+	ASTRAZENECA AB	300MCG/1.2ML (250MCG/ML)	N021773 001	Apr 28, 2005
--	---	----------------	--------------------------	-------------	--------------

	+		600MCG/2.4ML (250MCG/ML)	N021773 002	Apr 28, 2005
--	---	--	--------------------------	-------------	--------------

EZETIMIBE

TABLET; ORAL

EZETIMIBE

AB		ACCORD HLTHCARE	10MG	A211550 001	Oct 26, 2018
AB		ALKEM LABS LTD	10MG	A209234 001	Dec 21, 2017
AB		AMNEAL PHARMS CO	10MG	A208803 001	Jun 12, 2017
AB		APOTEX	10MG	A208332 001	Jun 12, 2017
AB		AUROBINDO PHARMA LTD	10MG	A209838 001	Aug 25, 2017
AB		GLENMARK PHARMS LTD	10MG	A078560 001	Jun 26, 2015
AB		OHM LABS INC	10MG	A207311 001	Jun 12, 2017
AB		SANDOZ INC	10MG	A203931 001	Jun 12, 2017
AB		SCIEGEN PHARMS INC	10MG	A210673 001	Oct 23, 2020
AB		WATSON LABS INC	10MG	A200831 001	Jun 12, 2017
AB		ZYDUS PHARMS	10MG	A204331 001	Jun 12, 2017
<u>ZETIA</u>					
AB	+	MSD INTL GMBH	10MG	N021445 001	Oct 25, 2002

EZETIMIBE; SIMVASTATIN

TABLET; ORAL

EZETIMIBE AND SIMVASTATIN

AB		ALKEM LABS LTD	10MG; 10MG	A209222 001	Dec 22, 2017
AB			10MG; 20MG	A209222 002	Dec 22, 2017
AB			10MG; 40MG	A209222 003	Dec 22, 2017
AB			10MG; 80MG	A209222 004	Dec 22, 2017
AB		AMNEAL PHARMS CO	10MG; 10MG	A208831 001	Nov 21, 2017
AB			10MG; 20MG	A208831 002	Nov 21, 2017
AB			10MG; 40MG	A208831 003	Nov 21, 2017

PRESCRIPTION DRUG PRODUCT LIST

EZETIMIBE; SIMVASTATIN

TABLET; ORAL

EZETIMIBE AND SIMVASTATIN

<u>AB</u>		<u>10MG; 80MG</u>	<u>A208831 004</u>	Nov 21, 2017
<u>AB</u>	ANI PHARMS INC	<u>10MG; 10MG</u>	<u>A201890 001</u>	Apr 26, 2017
<u>AB</u>		<u>10MG; 20MG</u>	<u>A201890 002</u>	Apr 26, 2017
<u>AB</u>		<u>10MG; 40MG</u>	<u>A201890 003</u>	Apr 26, 2017
<u>AB</u>		<u>10MG; 80MG</u>	<u>A201890 004</u>	Apr 26, 2017
<u>AB</u>	DR REDDYS LABS SA	<u>10MG; 10MG</u>	<u>A200909 001</u>	Apr 26, 2017
<u>AB</u>		<u>10MG; 20MG</u>	<u>A200909 002</u>	Apr 26, 2017
<u>AB</u>		<u>10MG; 40MG</u>	<u>A200909 003</u>	Apr 26, 2017
<u>AB</u>		<u>10MG; 80MG</u>	<u>A200909 004</u>	Apr 26, 2017
<u>AB</u>	GLENMARK PHARMS LTD	<u>10MG; 10MG</u>	<u>A208699 001</u>	Jun 27, 2019
<u>AB</u>		<u>10MG; 20MG</u>	<u>A208699 002</u>	Jun 27, 2019
<u>AB</u>		<u>10MG; 40MG</u>	<u>A208699 003</u>	Jun 27, 2019
<u>AB</u>		<u>10MG; 80MG</u>	<u>A208699 004</u>	Jun 27, 2019
<u>AB</u>	MYLAN	<u>10MG; 10MG</u>	<u>A200082 001</u>	Dec 17, 2020
<u>AB</u>		<u>10MG; 20MG</u>	<u>A200082 002</u>	Dec 17, 2020
<u>AB</u>		<u>10MG; 40MG</u>	<u>A200082 003</u>	Dec 17, 2020
<u>AB</u>		<u>10MG; 80MG</u>	<u>A200082 004</u>	Dec 17, 2020
<u>AB</u>	WATSON LABS INC	<u>10MG; 10MG</u>	<u>A202968 001</u>	Apr 26, 2017
<u>AB</u>		<u>10MG; 20MG</u>	<u>A202968 002</u>	Apr 26, 2017
<u>AB</u>		<u>10MG; 40MG</u>	<u>A202968 003</u>	Apr 26, 2017
<u>AB</u>		<u>10MG; 80MG</u>	<u>A202968 004</u>	Apr 26, 2017
<u>VYTORIN</u>				
<u>AB</u>	+ MSD INTL	<u>10MG; 10MG</u>	<u>N021687 001</u>	Jul 23, 2004
<u>AB</u>	+	<u>10MG; 20MG</u>	<u>N021687 002</u>	Jul 23, 2004
<u>AB</u>	+	<u>10MG; 40MG</u>	<u>N021687 003</u>	Jul 23, 2004
<u>AB</u>	+	<u>10MG; 80MG</u>	<u>N021687 004</u>	Jul 23, 2004

FAMCICLOVIR

TABLET; ORAL

FAMCICLOVIR

<u>AB</u>	APOTEX	<u>125MG</u>	<u>A091480 001</u>	Jul 22, 2011
<u>AB</u>		<u>250MG</u>	<u>A091480 002</u>	Jul 22, 2011
<u>AB</u>		<u>500MG</u>	<u>A091480 003</u>	Jul 22, 2011
<u>AB</u>	AUROBINDO PHARMA LTD	<u>125MG</u>	<u>A091114 001</u>	Mar 21, 2011
<u>AB</u>		<u>250MG</u>	<u>A091114 002</u>	Mar 21, 2011
<u>AB</u>		<u>500MG</u>	<u>A091114 003</u>	Mar 21, 2011
<u>AB</u>	CIPLA	<u>125MG</u>	<u>A078278 001</u>	Mar 21, 2011
<u>AB</u>		<u>250MG</u>	<u>A078278 002</u>	Mar 21, 2011
<u>AB</u>		<u>500MG</u>	<u>A078278 003</u>	Mar 21, 2011
<u>AB</u>	HETERO LABS LTD V	<u>125MG</u>	<u>A202438 001</u>	Sep 10, 2014
<u>AB</u>		<u>250MG</u>	<u>A202438 002</u>	Sep 10, 2014
<u>AB</u>		<u>500MG</u>	<u>A202438 003</u>	Sep 10, 2014
<u>AB</u>	MACLEODS PHARMS LTD	<u>125MG</u>	<u>A201022 001</u>	Jan 12, 2012
<u>AB</u>		<u>250MG</u>	<u>A201022 002</u>	Jan 12, 2012
<u>AB</u>		<u>500MG</u>	<u>A201022 003</u>	Jan 12, 2012
<u>AB</u>	TEVA PHARMS	<u>125MG</u>	<u>A077487 001</u>	Aug 24, 2007
<u>AB</u>		<u>250MG</u>	<u>A077487 002</u>	Aug 24, 2007
<u>AB</u>	!	<u>500MG</u>	<u>A077487 003</u>	Aug 24, 2007

FAMOTIDINE

FOR SUSPENSION; ORAL

FAMOTIDINE

<u>AB</u>	HI-TECH PHARMA CO	<u>40MG/5ML</u>	<u>A201995 001</u>	May 30, 2014
<u>AB</u>	!	<u>40MG/5ML</u>	<u>A090440 001</u>	Jun 29, 2010
<u>AB</u>	NAVINTA LLC	<u>40MG/5ML</u>	<u>A091020 001</u>	May 27, 2010
<u>AB</u>	NOVEL LABS INC	<u>40MG/5ML</u>	<u>A201695 001</u>	Dec 17, 2012

INJECTABLE; INJECTION

FAMOTIDINE

<u>AP</u>	ATHENEX INC	<u>10MG/ML</u>	<u>A075651 001</u>	Apr 16, 2001
<u>AP</u>		<u>10MG/ML</u>	<u>A075684 001</u>	Apr 16, 2001
<u>AP</u>	FRESENIUS KABI USA	<u>10MG/ML</u>	<u>A075709 001</u>	Apr 16, 2001
<u>AP</u>	MYLAN LABS LTD	<u>10MG/ML</u>	<u>A078641 001</u>	Jun 25, 2008
<u>AP</u>	!	<u>10MG/ML</u>	<u>A075488 001</u>	Apr 16, 2001

FAMOTIDINE PRESERVATIVE FREE

<u>AP</u>	ATHENEX INC	<u>10MG/ML</u>	<u>A075622 001</u>	Apr 16, 2001
<u>AP</u>		<u>10MG/ML</u>	<u>A075825 001</u>	Apr 17, 2001
<u>AP</u>	FRESENIUS KABI USA	<u>10MG/ML</u>	<u>A075813 001</u>	Apr 16, 2001
<u>AP</u>	MYLAN LABS LTD	<u>10MG/ML</u>	<u>A078642 001</u>	Jun 25, 2008
<u>AP</u>	!	<u>10MG/ML</u>	<u>A075486 001</u>	Apr 16, 2001

PRESCRIPTION DRUG PRODUCT LIST

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE PRESERVATIVE FREE

INT

FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER

! BAXTER HLTHCARE

0.4MG/ML

A075591 001 May 10, 2001

TABLET; ORAL

FAMOTIDINE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>20MG</u>	<u>A078916</u>	<u>001</u>	May 22, 2009
<u>AB</u>		<u>40MG</u>	<u>A078916</u>	<u>002</u>	May 22, 2009
<u>AB</u>	APOTEX	<u>20MG</u>	<u>A075611</u>	<u>001</u>	Jul 23, 2001
<u>AB</u>		<u>40MG</u>	<u>A075611</u>	<u>002</u>	Jul 23, 2001
<u>AB</u>	AUROBINDO PHARMA LTD	<u>20MG</u>	<u>A206530</u>	<u>001</u>	Dec 22, 2015
<u>AB</u>	!	<u>40MG</u>	<u>A206530</u>	<u>002</u>	Dec 22, 2015
<u>AB</u>	CARLSBAD	<u>20MG</u>	<u>A075805</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075805</u>	<u>002</u>	Apr 16, 2001
<u>AB</u>	CELLTRION	<u>20MG</u>	<u>A075786</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075786</u>	<u>002</u>	Apr 16, 2001
<u>AB</u>	DR REDDYS LABS LTD	<u>20MG</u>	<u>A075718</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075718</u>	<u>002</u>	Apr 16, 2001
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>20MG</u>	<u>A075511</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075511</u>	<u>002</u>	Apr 16, 2001
<u>AB</u>	PERRIGO R AND D	<u>20MG</u>	<u>A077352</u>	<u>002</u>	Jul 27, 2005
<u>AB</u>		<u>40MG</u>	<u>A077352</u>	<u>001</u>	Jul 27, 2005

FAMOTIDINE; IBUPROFEN

TABLET; ORAL

DUEXIS

+! HORIZON

26.6MG; 800MG

N022519 001 Apr 23, 2011

FEBUXOSTAT

TABLET; ORAL

FEBUXOSTAT

<u>AB</u>	ALEMBIC PHARMS LTD	<u>40MG</u>	<u>A205421</u>	<u>001</u>	Jul 01, 2019
<u>AB</u>		<u>80MG</u>	<u>A205421</u>	<u>002</u>	Jul 01, 2019
<u>AB</u>	DR REDDYS LABS LTD	<u>40MG</u>	<u>A205374</u>	<u>001</u>	Oct 22, 2020
<u>AB</u>		<u>80MG</u>	<u>A205374</u>	<u>002</u>	Oct 22, 2020
<u>AB</u>	HIKMA	<u>40MG</u>	<u>A205414</u>	<u>001</u>	Oct 15, 2019
<u>AB</u>		<u>80MG</u>	<u>A205414</u>	<u>002</u>	Oct 15, 2019
<u>AB</u>	INDOCO	<u>40MG</u>	<u>A210292</u>	<u>001</u>	Dec 30, 2019
<u>AB</u>		<u>80MG</u>	<u>A210292</u>	<u>002</u>	Dec 30, 2019
<u>AB</u>	MSN	<u>40MG</u>	<u>A210461</u>	<u>001</u>	Dec 30, 2019
<u>AB</u>		<u>80MG</u>	<u>A210461</u>	<u>002</u>	Dec 30, 2019
<u>AB</u>	MYLAN	<u>40MG</u>	<u>A205385</u>	<u>001</u>	Jul 01, 2019
<u>AB</u>		<u>80MG</u>	<u>A205385</u>	<u>002</u>	Jul 01, 2019
<u>AB</u>	SUN PHARM	<u>40MG</u>	<u>A205467</u>	<u>001</u>	Jul 01, 2019
<u>AB</u>		<u>80MG</u>	<u>A205467</u>	<u>002</u>	Jul 01, 2019
<u>AB</u>	SUNSHINE	<u>40MG</u>	<u>A213069</u>	<u>001</u>	Jun 02, 2020
<u>AB</u>		<u>80MG</u>	<u>A213069</u>	<u>002</u>	Jun 02, 2020

ULORIC

<u>AB</u>	+ TAKEDA PHARMS USA	<u>40MG</u>	<u>N021856</u>	<u>001</u>	Feb 13, 2009
<u>AB</u>	+!	<u>80MG</u>	<u>N021856</u>	<u>002</u>	Feb 13, 2009

FEDRATINIB HYDROCHLORIDE

CAPSULE; ORAL

INREBIC

+! IMPACT

EQ 100MG BASE

N212327 001 Aug 16, 2019

FELBAMATE

SUSPENSION; ORAL

FELBAMATE

<u>AB</u>	AMNEAL PHARMS	<u>600MG/5ML</u>	<u>A202385</u>	<u>001</u>	Dec 16, 2011
<u>AB</u>	TARO	<u>600MG/5ML</u>	<u>A206314</u>	<u>001</u>	Jun 16, 2017
<u>AB</u>	VISTAPHARM	<u>600MG/5ML</u>	<u>A211333</u>	<u>001</u>	May 31, 2019

FELBATOL

<u>AB</u>	+! MYLAN SPECIALITY LP	<u>600MG/5ML</u>	<u>N020189</u>	<u>003</u>	Jul 29, 1993
-----------	------------------------	------------------	----------------	------------	--------------

TABLET; ORAL

FELBAMATE

<u>AB</u>	ALVOGEN	<u>400MG</u>	<u>A204595</u>	<u>001</u>	Jan 11, 2016
<u>AB</u>		<u>600MG</u>	<u>A204595</u>	<u>002</u>	Jan 11, 2016
<u>AB</u>	AMNEAL PHARMS	<u>400MG</u>	<u>A201680</u>	<u>001</u>	Sep 13, 2011
<u>AB</u>		<u>600MG</u>	<u>A201680</u>	<u>002</u>	Sep 13, 2011
<u>AB</u>	ANI PHARMS INC	<u>400MG</u>	<u>A202284</u>	<u>001</u>	Nov 04, 2015

PRESCRIPTION DRUG PRODUCT LIST

FELBAMATE

TABLET;ORAL

FELBAMATE

<u>AB</u>		<u>600MG</u>	<u>A202284</u>	<u>002</u>	Nov 04, 2015	
<u>AB</u>	CADILA	<u>400MG</u>	<u>A208970</u>	<u>001</u>	May 30, 2017	
<u>AB</u>		<u>600MG</u>	<u>A208970</u>	<u>002</u>	May 30, 2017	
<u>AB</u>	TARO	<u>400MG</u>	<u>A207093</u>	<u>001</u>	Apr 20, 2017	
<u>AB</u>		<u>600MG</u>	<u>A207093</u>	<u>002</u>	Apr 20, 2017	
<u>FELBATOL</u>						
<u>AB</u>	+	MYLAN SPECIALITY LP	<u>400MG</u>	<u>N020189</u>	<u>001</u>	Jul 29, 1993
<u>AB</u>	+	!	<u>600MG</u>	<u>N020189</u>	<u>002</u>	Jul 29, 1993

FELODIPINE

TABLET, EXTENDED RELEASE;ORAL

FELODIPINE

<u>AB</u>	AUROBINDO PHARMA LTD	<u>2.5MG</u>	<u>A203417</u>	<u>001</u>	Jan 17, 2013
<u>AB</u>		<u>5MG</u>	<u>A203417</u>	<u>002</u>	Jan 17, 2013
<u>AB</u>		<u>10MG</u>	<u>A203417</u>	<u>003</u>	Jan 17, 2013
<u>AB</u>	GLENMARK GENERICS	<u>2.5MG</u>	<u>A090365</u>	<u>001</u>	Dec 17, 2010
<u>AB</u>		<u>5MG</u>	<u>A090365</u>	<u>002</u>	Dec 17, 2010
<u>AB</u>		<u>10MG</u>	<u>A090365</u>	<u>003</u>	Dec 17, 2010
<u>AB</u>	HERITAGE PHARMS INC	<u>2.5MG</u>	<u>A201964</u>	<u>001</u>	Nov 08, 2013
<u>AB</u>		<u>5MG</u>	<u>A201964</u>	<u>002</u>	Nov 08, 2013
<u>AB</u>		<u>10MG</u>	<u>A201964</u>	<u>003</u>	Nov 08, 2013
<u>AB</u>	JUBILANT GENERICS	<u>2.5MG</u>	<u>A203983</u>	<u>001</u>	Aug 19, 2016
<u>AB</u>		<u>5MG</u>	<u>A203983</u>	<u>002</u>	Aug 19, 2016
<u>AB</u>		<u>10MG</u>	<u>A203983</u>	<u>003</u>	Aug 19, 2016
<u>AB</u>	ORCHID HLTHCARE	<u>2.5MG</u>	<u>A203032</u>	<u>001</u>	May 21, 2015
<u>AB</u>		<u>5MG</u>	<u>A203032</u>	<u>002</u>	May 21, 2015
<u>AB</u>		<u>10MG</u>	<u>A203032</u>	<u>003</u>	May 21, 2015
<u>AB</u>	SUN PHARM INDS LTD	<u>2.5MG</u>	<u>A091200</u>	<u>001</u>	Dec 13, 2013
<u>AB</u>		<u>5MG</u>	<u>A091200</u>	<u>002</u>	Dec 13, 2013
<u>AB</u>		<u>10MG</u>	<u>A091200</u>	<u>003</u>	Dec 13, 2013
<u>AB</u>	SUN PHARM INDUSTRIES	<u>2.5MG</u>	<u>A075896</u>	<u>001</u>	Nov 02, 2004
<u>AB</u>		<u>5MG</u>	<u>A075896</u>	<u>002</u>	Nov 02, 2004
<u>AB</u>		<u>10MG</u>	<u>A075896</u>	<u>003</u>	Nov 02, 2004
<u>AB</u>	TORRENT PHARMS LTD	<u>2.5MG</u>	<u>A202170</u>	<u>001</u>	Nov 28, 2011
<u>AB</u>		<u>5MG</u>	<u>A202170</u>	<u>002</u>	Nov 28, 2011
<u>AB</u>	!	<u>10MG</u>	<u>A202170</u>	<u>003</u>	Nov 28, 2011
<u>AB</u>	VINTAGE PHARMS LLC	<u>2.5MG</u>	<u>A200815</u>	<u>001</u>	Oct 28, 2011
<u>AB</u>		<u>5MG</u>	<u>A200815</u>	<u>002</u>	Oct 28, 2011
<u>AB</u>		<u>10MG</u>	<u>A200815</u>	<u>003</u>	Oct 28, 2011
<u>AB</u>	YILING	<u>2.5MG</u>	<u>A210847</u>	<u>001</u>	Oct 26, 2018
<u>AB</u>		<u>5MG</u>	<u>A210847</u>	<u>002</u>	Oct 26, 2018
<u>AB</u>		<u>10MG</u>	<u>A210847</u>	<u>003</u>	Oct 26, 2018
<u>AB</u>	YUNG SHIN PHARM	<u>2.5MG</u>	<u>A204800</u>	<u>001</u>	Apr 29, 2019
<u>AB</u>		<u>5MG</u>	<u>A204800</u>	<u>002</u>	Apr 29, 2019
<u>AB</u>		<u>10MG</u>	<u>A204800</u>	<u>003</u>	Apr 29, 2019

FENFLURAMINE HYDROCHLORIDE

SOLUTION;ORAL

FINTEPLA

+! ZOGENIX INC

EQ 2.2MG BASE/ML

N212102 001 Jun 25, 2020

FENOFIBRATE

CAPSULE;ORAL

ANTARA (MICRONIZED)

<u>AB</u>	+	LUPIN	<u>43MG</u>	<u>N021695</u>	<u>001</u>	Nov 30, 2004
<u>AB</u>	+	!	<u>130MG</u>	<u>N021695</u>	<u>003</u>	Nov 30, 2004
<u>FENOFIBRATE</u>						
<u>AB</u>		SUN PHARM INDS LTD	<u>43MG</u>	<u>A201748</u>	<u>001</u>	Oct 31, 2014
<u>AB</u>			<u>130MG</u>	<u>A201748</u>	<u>002</u>	Oct 31, 2014
<u>FENOFIBRATE (MICRONIZED)</u>						
<u>AB</u>		AJANTA PHARMA LTD	<u>67MG</u>	<u>A210705</u>	<u>001</u>	Sep 10, 2018
<u>AB</u>			<u>134MG</u>	<u>A210705</u>	<u>002</u>	Sep 10, 2018
<u>AB</u>			<u>200MG</u>	<u>A210705</u>	<u>003</u>	Sep 10, 2018
<u>AB</u>		ALEMBIC PHARMS LTD	<u>67MG</u>	<u>A213842</u>	<u>001</u>	Oct 19, 2020
<u>AB</u>			<u>134MG</u>	<u>A213842</u>	<u>002</u>	Oct 19, 2020
<u>AB</u>			<u>200MG</u>	<u>A213842</u>	<u>003</u>	Oct 19, 2020
<u>AB</u>		ANI PHARMS INC	<u>67MG</u>	<u>A209504</u>	<u>001</u>	Apr 30, 2018
<u>AB</u>			<u>134MG</u>	<u>A209504</u>	<u>002</u>	Apr 30, 2018
<u>AB</u>			<u>200MG</u>	<u>A209504</u>	<u>003</u>	Apr 30, 2018

PRESCRIPTION DRUG PRODUCT LIST

FENOFIBRATE

CAPSULE; ORAL

FENOFIBRATE (MICRONIZED)

AB	APOTEX	43MG	A202252 001	Jul 26, 2013
AB		130MG	A202252 002	Jul 26, 2013
AB	AUSTARPHARMA	67MG	A207805 001	Nov 16, 2017
AB		134MG	A207805 002	Nov 16, 2017
AB		200MG	A207805 003	Nov 16, 2017
AB	DR REDDYS LABS SA	43MG	A090859 001	Mar 01, 2012
AB		130MG	A090859 002	Mar 01, 2012
AB	GLENMARK PHARMS LTD	67MG	A205566 001	Apr 07, 2017
AB		134MG	A205566 002	Apr 07, 2017
AB		200MG	A205566 003	Apr 07, 2017
AB	IMPAX LABS	67MG	A075868 001	Oct 27, 2003
AB		134MG	A075868 002	Oct 27, 2003
AB	!	200MG	A075868 003	Oct 27, 2003
AB	INVAGEN PHARMS	67MG	A207378 001	Mar 28, 2017
AB		134MG	A207378 002	Mar 28, 2017
AB		200MG	A207378 003	Mar 28, 2017
AB	MYLAN PHARMS INC	67MG	A202676 001	Oct 23, 2012
AB		134MG	A202676 002	Oct 23, 2012
AB		200MG	A202676 003	Oct 23, 2012
AB	RHODES PHARMS	67MG	A075753 001	Sep 03, 2002
AB		134MG	A075753 002	Apr 09, 2002
AB		200MG	A075753 003	Apr 09, 2002
AB	TORRENT	67MG	A210782 001	Jun 26, 2018
AB		134MG	A210782 002	Jun 26, 2018
AB		200MG	A210782 003	Jun 26, 2018
ANTARA (MICRONIZED)				
	+ LUPIN	30MG	N021695 004	Oct 18, 2013
	+!	90MG	N021695 005	Oct 18, 2013
LIPOFEN				
	+ CIPHER PHARMS INC	50MG	N021612 001	Jan 11, 2006
	+!	150MG	N021612 003	Jan 11, 2006

TABLET; ORAL

FENOFIBRATE

AB	AJANTA PHARMA LTD	54MG	A210138 001	Jul 23, 2018
AB		160MG	A210138 002	Jul 23, 2018
AB	ALEMBIC LABS	54MG	A209660 001	Feb 11, 2019
AB		160MG	A209660 002	Feb 11, 2019
AB	ALEMBIC PHARMS LTD	48MG	A210476 001	Aug 09, 2019
AB		145MG	A210476 002	Aug 09, 2019
AB	AMNEAL	48MG	A209951 001	Feb 09, 2018
AB		54MG	A209950 001	Mar 19, 2018
AB		145MG	A209951 002	Feb 09, 2018
AB		160MG	A209950 002	Mar 19, 2018
AB	AUROBINDO PHARMA LTD	48MG	A205118 001	May 05, 2016
AB		145MG	A205118 002	May 05, 2016
AB	AUSTARPHARMA	54MG	A207803 001	Dec 19, 2017
AB		160MG	A207803 002	Dec 19, 2017
AB	CIPLA	48MG	A208709 001	Dec 15, 2016
AB		145MG	A208709 002	Dec 15, 2016
AB	DR REDDYS	54MG	A210670 001	Sep 06, 2019
AB		160MG	A210670 002	Sep 06, 2019
AB	GRAVITI PHARMS	48MG	A211122 001	Mar 18, 2020
AB		54MG	A210606 001	Aug 17, 2018
AB		145MG	A211122 002	Mar 18, 2020
AB		160MG	A210606 002	Aug 17, 2018
AB	HETERO LABS LTD III	48MG	A204598 001	Jul 12, 2016
AB		145MG	A204598 002	Jul 12, 2016
AB	IMPAX LABS	54MG	A076509 001	Mar 26, 2008
AB	!	160MG	A076509 002	Mar 26, 2008
AB	LUPIN LTD	48MG	A090856 001	Dec 23, 2011
AB		54MG	A204019 001	Aug 17, 2015
AB		145MG	A090856 002	Dec 23, 2011
AB		160MG	A204019 002	Aug 17, 2015
AB	MANKIND PHARMA	54MG	A213864 001	Jun 12, 2020
AB		160MG	A213864 002	Jun 12, 2020
AB	MYLAN	54MG	A076520 001	Oct 25, 2007
AB		160MG	A076520 003	Oct 25, 2007
AB	MYLAN PHARMS INC	40MG	A204475 001	Jun 23, 2016
AB		48MG	A202856 001	Dec 07, 2012

PRESCRIPTION DRUG PRODUCT LIST

FENOFIBRATE

TABLET; ORAL

FENOFIBRATE

<u>AB</u>		<u>120MG</u>	<u>A204475 002</u>	Jun 23, 2016
<u>AB</u>		<u>145MG</u>	<u>A202856 002</u>	Dec 07, 2012
<u>AB</u>	PRINSTON INC	<u>48MG</u>	<u>A211080 001</u>	Aug 28, 2018
<u>AB</u>		<u>145MG</u>	<u>A211080 002</u>	Aug 28, 2018
<u>AB</u>	RHODES PHARMS	<u>54MG</u>	<u>A076433 001</u>	May 13, 2005
<u>AB</u>		<u>160MG</u>	<u>A076433 002</u>	May 13, 2005
<u>AB</u>	SUN PHARM	<u>48MG</u>	<u>A200884 001</u>	Sep 07, 2017
<u>AB</u>		<u>145MG</u>	<u>A200884 002</u>	Sep 07, 2017
<u>AB</u>	SUN PHARM INDS LTD	<u>54MG</u>	<u>A076635 001</u>	Oct 31, 2005
<u>AB</u>		<u>160MG</u>	<u>A076635 003</u>	Oct 31, 2005
<u>AB</u>	VALEANT PHARMS NORTH	<u>48MG</u>	<u>A090715 001</u>	Apr 05, 2012
<u>AB</u>		<u>145MG</u>	<u>A090715 002</u>	Apr 05, 2012

FENOGLIDE

<u>AB</u>	+ SALIX	<u>40MG</u>	<u>N022118 001</u>	Aug 10, 2007
<u>AB</u>	+!	<u>120MG</u>	<u>N022118 002</u>	Aug 10, 2007

TRICOR

<u>AB</u>	+ ABBVIE	<u>48MG</u>	<u>N021656 001</u>	Nov 05, 2004
<u>AB</u>	+!	<u>145MG</u>	<u>N021656 002</u>	Nov 05, 2004
<u>TRIGLIDE</u>				
BX	+ SKYEPHARMA AG	160MG	N021350 002	May 07, 2005
<u>FENOFIBRATE</u>				
	SUN PHARM INDS LTD	107MG	A076635 002	Oct 31, 2005

FENOFIBRIC ACID

TABLET; ORAL

FIBRICOR

	+! ATHENA	105MG	N022418 002	Aug 14, 2009
--	-----------	-------	-------------	--------------

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION

CORLOPAM

<u>AP</u>	+! HOSPIRA	<u>EQ 10MG BASE/ML</u>	<u>N019922 001</u>	Sep 23, 1997
-----------	------------	------------------------	--------------------	--------------

FENOLDOPAM MESYLATE

<u>AP</u>	SANDOZ INC	<u>EQ 10MG BASE/ML</u>	<u>A077155 001</u>	Feb 15, 2005
<u>AP</u>	WEST-WARD PHARMS INT	<u>EQ 10MG BASE/ML</u>	<u>A076582 001</u>	Oct 12, 2004

FENOPROFEN CALCIUM

CAPSULE; ORAL

NALFON

	+ XSPIRE PHARMA	EQ 200MG BASE	N017604 003	
	+!	EQ 400MG BASE	N017604 004	Jul 21, 2009

TABLET; ORAL

FENOPROFEN CALCIUM

	! XSPIRE PHARMA	EQ 600MG BASE	A072267 001	Aug 17, 1988
--	-----------------	---------------	-------------	--------------

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

DURAGESIC-100

<u>AB</u>	+ JANSSEN PHARMS	<u>100MCG/HR</u>	<u>N019813 001</u>	Aug 07, 1990
-----------	------------------	------------------	--------------------	--------------

DURAGESIC-12

<u>AB</u>	+ JANSSEN PHARMS	<u>12.5MCG/HR</u>	<u>N019813 005</u>	Feb 04, 2005
-----------	------------------	-------------------	--------------------	--------------

DURAGESIC-25

<u>AB</u>	+! JANSSEN PHARMS	<u>25MCG/HR</u>	<u>N019813 004</u>	Aug 07, 1990
-----------	-------------------	-----------------	--------------------	--------------

DURAGESIC-37

<u>AB</u>	+ JANSSEN PHARMS	<u>37.5MCG/HR</u>	<u>N019813 006</u>	Jan 24, 2018
-----------	------------------	-------------------	--------------------	--------------

DURAGESIC-50

<u>AB</u>	+ JANSSEN PHARMS	<u>50MCG/HR</u>	<u>N019813 003</u>	Aug 07, 1990
-----------	------------------	-----------------	--------------------	--------------

DURAGESIC-75

<u>AB</u>	+ JANSSEN PHARMS	<u>75MCG/HR</u>	<u>N019813 002</u>	Aug 07, 1990
-----------	------------------	-----------------	--------------------	--------------

FENTANYL-100

<u>AB</u>	AVEVA	<u>100MCG/HR</u>	<u>A077449 004</u>	Oct 20, 2008
<u>AB</u>	KINDEVA	<u>100MCG/HR</u>	<u>A202097 005</u>	Nov 04, 2016
<u>AB</u>	MYLAN TECHNOLOGIES	<u>100MCG/HR</u>	<u>A076258 004</u>	Jan 28, 2005
<u>AB</u>	SPECGX LLC	<u>100MCG/HR</u>	<u>A077154 004</u>	Feb 09, 2011

FENTANYL-12

<u>AB</u>	AVEVA	<u>12.5MCG/HR</u>	<u>A077449 005</u>	Sep 11, 2015
<u>AB</u>	KINDEVA	<u>12.5MCG/HR</u>	<u>A202097 001</u>	Nov 04, 2016
<u>AB</u>	MYLAN TECHNOLOGIES	<u>12.5MCG/HR</u>	<u>A076258 005</u>	Jan 23, 2007
<u>AB</u>	SPECGX LLC	<u>12.5MCG/HR</u>	<u>A077154 005</u>	Jun 11, 2015

PRESCRIPTION DRUG PRODUCT LIST

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

FENTANYL-25

<u>AB</u>	AVEVA	<u>25MCG/HR</u>	<u>A077449 001</u>	Oct 20, 2008
<u>AB</u>	KINDEVA	<u>25MCG/HR</u>	<u>A202097 002</u>	Nov 04, 2016
<u>AB</u>	MYLAN TECHNOLOGIES	<u>25MCG/HR</u>	<u>A076258 001</u>	Jan 28, 2005
<u>AB</u>	SPECGX LLC	<u>25MCG/HR</u>	<u>A077154 001</u>	Feb 09, 2011

FENTANYL-37

<u>AB</u>	AVEVA	<u>37.5MCG/HR</u>	<u>A077449 006</u>	Dec 06, 2017
<u>AB</u>	MYLAN TECHNOLOGIES	<u>37.5MCG/HR</u>	<u>A076258 006</u>	Dec 29, 2014
<u>AB</u>	SPECGX LLC	<u>37.5MCG/HR</u>	<u>A077154 006</u>	Jan 14, 2020

FENTANYL-50

<u>AB</u>	AVEVA	<u>50MCG/HR</u>	<u>A077449 002</u>	Oct 20, 2008
<u>AB</u>	KINDEVA	<u>50MCG/HR</u>	<u>A202097 003</u>	Nov 04, 2016
<u>AB</u>	MYLAN TECHNOLOGIES	<u>50MCG/HR</u>	<u>A076258 002</u>	Jan 28, 2005
<u>AB</u>	SPECGX LLC	<u>50MCG/HR</u>	<u>A077154 002</u>	Feb 09, 2011

FENTANYL-62

<u>AB</u>	AVEVA	<u>62.5MCG/HR</u>	<u>A077449 007</u>	Dec 06, 2017
<u>AB</u>	MYLAN TECHNOLOGIES	<u>62.5MCG/HR</u>	<u>A076258 007</u>	Dec 29, 2014
<u>AB</u>	SPECGX LLC	<u>62.5MCG/HR</u>	<u>A077154 007</u>	Jan 14, 2020

FENTANYL-75

<u>AB</u>	AVEVA	<u>75MCG/HR</u>	<u>A077449 003</u>	Oct 20, 2008
<u>AB</u>	KINDEVA	<u>75MCG/HR</u>	<u>A202097 004</u>	Nov 04, 2016
<u>AB</u>	MYLAN TECHNOLOGIES	<u>75MCG/HR</u>	<u>A076258 003</u>	Jan 28, 2005
<u>AB</u>	SPECGX LLC	<u>75MCG/HR</u>	<u>A077154 003</u>	Feb 09, 2011

FENTANYL-87

<u>AB</u>	AVEVA	<u>87.5MCG/HR</u>	<u>A077449 008</u>	Dec 06, 2017
<u>AB</u>	MYLAN TECHNOLOGIES	<u>87.5MCG/HR</u>	<u>A076258 008</u>	Dec 29, 2014

SPRAY; SUBLINGUAL

SUBSYS

+	BTCP PHARMA	0.1MG	N202788 001	Jan 04, 2012
+		0.2MG	N202788 002	Jan 04, 2012
+	!	0.4MG	N202788 003	Jan 04, 2012
+		0.6MG	N202788 004	Jan 04, 2012
+		0.8MG	N202788 005	Jan 04, 2012
+		1.2MG	N202788 006	Aug 30, 2012
+		1.6MG	N202788 007	Aug 30, 2012

FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 0.05MG BASE/ML</u>	<u>A212086 001</u>	Sep 01, 2020
<u>AP</u>	HOSPIRA	<u>EQ 0.05MG BASE/ML</u>	<u>N019115 001</u>	Jan 12, 1985

FENTANYL CITRATE PRESERVATIVE FREE

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 0.05MG BASE/ML</u>	<u>A210762 001</u>	May 03, 2019	
<u>AP</u>	+	!	<u>EQ 0.05MG BASE/ML</u>	<u>N019101 001</u>	Jul 11, 1984
<u>AP</u>	HOSPIRA	<u>EQ 0.05MG BASE/ML</u>	<u>A072786 001</u>	Sep 24, 1991	

SUBLIMAZE PRESERVATIVE FREE

<u>AP</u>	+	!	AKORN	<u>EQ 0.05MG BASE/ML</u>	<u>N016619 001</u>
-----------	---	---	-------	--------------------------	--------------------

SPRAY, METERED; NASAL

LAZANDA

+	BTCP PHARMA	EQ 0.1MG BASE	N022569 001	Jun 30, 2011
+	!	EQ 0.4MG BASE	N022569 002	Jun 30, 2011

TABLET; BUCCAL, SUBLINGUAL

FENTORA

+	CEPHALON	EQ 0.1MG BASE	N021947 001	Sep 25, 2006
+		EQ 0.2MG BASE	N021947 002	Sep 25, 2006
+	!	EQ 0.4MG BASE	N021947 003	Sep 25, 2006
+		EQ 0.6MG BASE	N021947 004	Sep 25, 2006
+		EQ 0.8MG BASE	N021947 005	Sep 25, 2006

TROCHE/LOZENGE; TRANSMUCOSAL

ACTIQ

<u>AB</u>	+	CEPHALON	<u>EQ 0.2MG BASE</u>	<u>N020747 001</u>	Nov 04, 1998
<u>AB</u>	+	!	<u>EQ 0.4MG BASE</u>	<u>N020747 002</u>	Nov 04, 1998
<u>AB</u>	+		<u>EQ 0.6MG BASE</u>	<u>N020747 003</u>	Nov 04, 1998
<u>AB</u>	+		<u>EQ 0.8MG BASE</u>	<u>N020747 004</u>	Nov 04, 1998
<u>AB</u>	+		<u>EQ 1.2MG BASE</u>	<u>N020747 005</u>	Nov 04, 1998
<u>AB</u>	+		<u>EQ 1.6MG BASE</u>	<u>N020747 006</u>	Nov 04, 1998

FENTANYL CITRATE

<u>AB</u>	SPECGX LLC	<u>EQ 0.2MG BASE</u>	<u>A078907 001</u>	Oct 30, 2009
<u>AB</u>		<u>EQ 0.4MG BASE</u>	<u>A078907 002</u>	Oct 30, 2009
<u>AB</u>		<u>EQ 0.6MG BASE</u>	<u>A078907 003</u>	Oct 30, 2009
<u>AB</u>		<u>EQ 0.8MG BASE</u>	<u>A078907 004</u>	Oct 30, 2009

PRESCRIPTION DRUG PRODUCT LIST

FENTANYL CITRATE

TROCHE/LOZENGE; TRANSMUCOSAL

FENTANYL CITRATE

AB		EQ 1.2MG BASE	A078907 005	Oct 30, 2009
AB		EQ 1.6MG BASE	A078907 006	Oct 30, 2009

FERRIC CARBOXYMALTOSESOLUTION; INTRAVENOUS
INJECTAFER

+	AM REGENT	750MG IRON/15ML (50MG IRON/ML)	N203565 001	Jul 25, 2013
+		500MG IRON/10ML (50MG IRON/ML)	N203565 002	Oct 08, 2020

FERRIC CITRATE

TABLET; ORAL

AURYXIA

+	KERYX BIOPHARMS	EQ 210MG IRON	N205874 001	Sep 05, 2014
---	-----------------	---------------	-------------	--------------

FERRIC DERISOMALTOSE

SOLUTION; INTRAVENOUS

MONOFERRIC

+	PHARMACOSMOS AS	1GM/10ML (100MG/ML)	N208171 003	Jan 16, 2020
---	-----------------	---------------------	-------------	--------------

FERRIC HEXACYANOFERRATE (II)

CAPSULE; ORAL

RADIOGARDASE (PRUSSIAN BLUE)

+	HEYL CHEMISCH	500MG	N021626 001	Oct 02, 2003
---	---------------	-------	-------------	--------------

FERRIC PYROPHOSPHATE CITRATE

FOR SOLUTION; INTRAVENOUS

TRIFERIC

+	ROCKWELL MEDICAL INC	272MG IRON/PACKET	N208551 001	Apr 25, 2016
---	----------------------	-------------------	-------------	--------------

SOLUTION; INTRAVENOUS

TRIFERIC

+	ROCKWELL MEDICAL INC	27.2MG IRON/5ML (5.44MG IRON/ML)	N206317 001	Jan 23, 2015
---	----------------------	----------------------------------	-------------	--------------

TRIFERIC AVNU

+	ROCKWELL MEDICAL INC	6.75MG IRON/4.5ML (1.5MG IRON/ML)	N212860 001	Mar 27, 2020
---	----------------------	-----------------------------------	-------------	--------------

FERUMOXYTOL

SOLUTION; INTRAVENOUS

FERAHEME

+	AMAG PHARMS INC	EQ 510MG IRON/17ML (EQ 30MG IRON/ML)	N022180 001	Jun 30, 2009
---	-----------------	--------------------------------------	-------------	--------------

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE; ORAL

FESOTERODINE FUMARATE

AB	AUROBINDO PHARMA LTD	4MG	A205007 001	Feb 17, 2017
AB		8MG	A205007 002	Feb 17, 2017
AB	ZYDUS PHARMS	4MG	A204946 001	Oct 03, 2017
AB		8MG	A204946 002	Oct 03, 2017

TOVIAZ

AB	+	PFIZER	4MG	N022030 001	Oct 31, 2008
AB	+		8MG	N022030 002	Oct 31, 2008

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL

FEXOFENADINE HYDROCHLORIDE

AB	DR REDDYS LABS LTD	30MG	A076502 001	Apr 11, 2006
AB		60MG	A076502 002	Apr 11, 2006
AB		180MG	A076502 003	Apr 11, 2006
AB	MYLAN	60MG	A077081 003	Apr 11, 2008
AB		180MG	A077081 001	Apr 16, 2007
AB	TEVA	30MG	A076447 001	Sep 01, 2005
AB		60MG	A076447 002	Sep 01, 2005
AB		180MG	A076447 003	Sep 01, 2005

FIDAXOMICIN

FOR SUSPENSION; ORAL

DIFICID

+	CUBIST PHARMS LLC	40MG/ML	N213138 001	Jan 24, 2020
---	-------------------	---------	-------------	--------------

TABLET; ORAL

DIFICID

+	CUBIST PHARMS LLC	200MG	N201699 001	May 27, 2011
---	-------------------	-------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

FINASTERIDE

TABLET; ORAL

FINASTERIDE

<u>AB</u>	ACCORD HLTHCARE	<u>1MG</u>	<u>A091643</u>	<u>001</u>	Nov 05, 2013
<u>AB</u>		<u>5MG</u>	<u>A090121</u>	<u>001</u>	Feb 23, 2010
<u>AB</u>	ACTAVIS TOTOWA TEVA	<u>5MG</u>	<u>A077914</u>	<u>001</u>	Mar 28, 2007
<u>AB</u>	ALKEM LABS LTD	<u>1MG</u>	<u>A207750</u>	<u>001</u>	Jan 06, 2017
<u>AB</u>		<u>5MG</u>	<u>A204304</u>	<u>001</u>	Jan 05, 2017
<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A078341</u>	<u>001</u>	Oct 30, 2007
<u>AB</u>	AUROBINDO PHARMA LTD	<u>1MG</u>	<u>A203687</u>	<u>001</u>	Nov 05, 2013
<u>AB</u>	CIPLA	<u>1MG</u>	<u>A077335</u>	<u>001</u>	Nov 20, 2014
<u>AB</u>	DR REDDYS LABS INC	<u>1MG</u>	<u>A076436</u>	<u>001</u>	Jul 28, 2006
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A076437</u>	<u>001</u>	Feb 28, 2007
<u>AB</u>	HETERO LABS LTD III	<u>1MG</u>	<u>A090060</u>	<u>001</u>	Jul 01, 2013
<u>AB</u>		<u>5MG</u>	<u>A090061</u>	<u>001</u>	Jun 07, 2010
<u>AB</u>	SUN PHARM	<u>1MG</u>	<u>A090508</u>	<u>001</u>	Jul 01, 2013
<u>AB</u>		<u>5MG</u>	<u>A090507</u>	<u>001</u>	Aug 16, 2011
<u>AB</u>	TEVA	<u>5MG</u>	<u>A076511</u>	<u>001</u>	Dec 15, 2006
<u>AB</u>	ZYDUS PHARMS USA INC	<u>5MG</u>	<u>A078900</u>	<u>001</u>	Dec 28, 2009

PROPECIA

<u>AB</u>	<u>+</u> ! MERCK	<u>1MG</u>	<u>N020788</u>	<u>001</u>	Dec 19, 1997
-----------	------------------	------------	----------------	------------	--------------

PROSCAR

<u>AB</u>	<u>+</u> ! MERCK	<u>5MG</u>	<u>N020180</u>	<u>001</u>	Jun 19, 1992
-----------	------------------	------------	----------------	------------	--------------

FINGOLIMOD HYDROCHLORIDE

CAPSULE; ORAL

FINGOLIMOD HYDROCHLORIDE

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 0.5MG BASE</u>	<u>A207991</u>	<u>001</u>	Oct 28, 2020
<u>AB</u>	ALKEM LABS LTD	<u>EQ 0.5MG BASE</u>	<u>A208004</u>	<u>001</u>	Dec 30, 2020
<u>AB</u>	APOTEX	<u>EQ 0.5MG BASE</u>	<u>A207993</u>	<u>001</u>	Dec 18, 2020
<u>AB</u>	GLENMARK PHARMS LTD	<u>EQ 0.5MG BASE</u>	<u>A207985</u>	<u>001</u>	Jun 18, 2020
<u>AB</u>	HEC PHARM CO LTD	<u>EQ 0.5MG BASE</u>	<u>A207939</u>	<u>001</u>	Dec 04, 2019
<u>AB</u>	HETERO LABS LTD V	<u>EQ 0.5MG BASE</u>	<u>A207933</u>	<u>001</u>	May 18, 2020
<u>AB</u>	STRIDES PHARMA	<u>EQ 0.5MG BASE</u>	<u>A207971</u>	<u>001</u>	Jun 29, 2020
<u>AB</u>	SUN PHARM	<u>EQ 0.5MG BASE</u>	<u>A208014</u>	<u>001</u>	Dec 04, 2019
<u>AB</u>	ZYDUS PHARMS	<u>EQ 0.5MG BASE</u>	<u>A207994</u>	<u>001</u>	Oct 14, 2020

GILENYA

<u>AB</u>	<u>+</u> ! NOVARTIS	<u>EQ 0.5MG BASE</u>	<u>N022527</u>	<u>001</u>	Sep 21, 2010
	<u>+</u>	EQ 0.25MG BASE	N022527	<u>002</u>	May 11, 2018

FISH OIL TRIGLYCERIDES

EMULSION; INTRAVENOUS

OMEGAVEN

<u>+</u> !	FRESENIUS KABI USA	5GM/50ML (0.1GM/ML)	N210589	<u>001</u>	Jul 27, 2018
<u>+</u> !		10GM/100ML (0.1GM/ML)	N210589	<u>002</u>	Jul 27, 2018

FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL

EMULSION; INTRAVENOUS

SMOFLIPID 20%

<u>+</u> !	FRESENIUS KABI USA	3GM/100ML; 6GM/100ML; 5GM/100ML; 6GM/100ML (100ML)	N207648	<u>001</u>	Jul 13, 2016
<u>+</u> !		3GM/100ML; 6GM/100ML; 5GM/100ML; 6GM/100ML (250ML)	N207648	<u>002</u>	Jul 13, 2016
<u>+</u> !		3GM/100ML; 6GM/100ML; 5GM/100ML; 6GM/100ML (500ML)	N207648	<u>003</u>	Jul 13, 2016
<u>+</u> !		3GM/100ML; 6GM/100ML; 5GM/100ML; 6GM/100ML (1000ML)	N207648	<u>004</u>	Aug 10, 2018

FLAVOXATE HYDROCHLORIDE

TABLET; ORAL

FLAVOXATE HYDROCHLORIDE

<u>AB</u>	EPIC PHARMA	<u>100MG</u>	<u>A076835</u>	<u>001</u>	Nov 30, 2005
<u>AB</u>	! PADDOCK LLC	<u>100MG</u>	<u>A076831</u>	<u>001</u>	Dec 16, 2004

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

<u>AB</u>	AMNEAL PHARM	<u>50MG</u>	<u>A075442</u>	<u>001</u>	Jul 31, 2001
<u>AB</u>		<u>100MG</u>	<u>A075442</u>	<u>002</u>	Jul 31, 2001
<u>AB</u>		<u>150MG</u>	<u>A075442</u>	<u>003</u>	Jul 31, 2001
<u>AB</u>	ANI PHARMS INC	<u>50MG</u>	<u>A075882</u>	<u>001</u>	Oct 28, 2002
<u>AB</u>		<u>100MG</u>	<u>A075882</u>	<u>002</u>	Oct 28, 2002
<u>AB</u>		<u>150MG</u>	<u>A075882</u>	<u>003</u>	Oct 28, 2002
<u>AB</u>	AUROBINDO PHARMA	<u>50MG</u>	<u>A202821</u>	<u>001</u>	Nov 03, 2017

PRESCRIPTION DRUG PRODUCT LIST

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

LTD

<u>AB</u>		<u>100MG</u>	<u>A202821 002</u>	Nov 03, 2017
<u>AB</u>		<u>150MG</u>	<u>A202821 003</u>	Nov 03, 2017
<u>AB</u>	BEXIMCO PHARMS USA	<u>50MG</u>	<u>A210683 001</u>	Sep 16, 2020
<u>AB</u>		<u>100MG</u>	<u>A210683 002</u>	Sep 16, 2020
<u>AB</u>		<u>150MG</u>	<u>A210683 003</u>	Sep 16, 2020
<u>AB</u>	HIKMA	<u>50MG</u>	<u>A076278 001</u>	Jan 14, 2003
<u>AB</u>		<u>100MG</u>	<u>A076278 002</u>	Jan 14, 2003
<u>AB</u>	!	<u>150MG</u>	<u>A076278 003</u>	Jan 14, 2003
<u>AB</u>	SUN PHARM INDS LTD	<u>50MG</u>	<u>A076421 001</u>	Mar 28, 2003
<u>AB</u>		<u>100MG</u>	<u>A076421 002</u>	Mar 28, 2003
<u>AB</u>		<u>150MG</u>	<u>A076421 003</u>	Mar 28, 2003
<u>TAMBOCOR</u>				
<u>AB</u>	+	CNTY LINE PHARMS	<u>50MG</u>	<u>N018830 004</u> Aug 23, 1988
<u>AB</u>	+		<u>100MG</u>	<u>N018830 001</u> Oct 31, 1985
<u>AB</u>	+		<u>150MG</u>	<u>N018830 003</u> Jun 03, 1988

FLIBANSERIN

TABLET; ORAL

ADDYI

+! SPROUT PHARMS

100MG

N022526 001 Aug 18, 2015

FLORBETABEN F-18

SOLUTION; INTRAVENOUS

NEURACEQ

+! LIFE MOLECULAR

30ML (1.4-135mCi/ML)

N204677 001 Mar 19, 2014

FLORBETAPIR F-18

SOLUTION; INTRAVENOUS

AMYVID

+! AVID RADIOPHARMS
INC

10-30ML (13.5-51mCi/ML)

N202008 002 Apr 06, 2012

+! 10-50ML (13.5-51mCi/ML)

N202008 003 Apr 06, 2012

FLORTAUCIPIR F-18

SOLUTION; INTRAVENOUS

TAUVID

+! AVID RADIOPHARMS
INC

30ML (8.1-51mCi/ML)

N212123 001 May 28, 2020

+! 50ML (8.1-51mCi/ML)

N212123 002 May 28, 2020

FLOXURIDINE

INJECTABLE; INJECTION

FLOXURIDINE

<u>AP</u>	FRESENIUS KABI USA	<u>500MG/VIAL</u>	<u>A075837 001</u>	Feb 22, 2001
<u>AP</u>	!	WEST-WARD PHARMS INT	<u>500MG/VIAL</u>	<u>A075387 001</u> Apr 16, 2000

FLUCICLOVINE F-18

SOLUTION; INTRAVENOUS

AXUMIN

+! BLUE EARTH

9-221mCi/ML

N208054 001 May 27, 2016

FLUCONAZOLE

FOR SUSPENSION; ORAL

DIFLUCAN

<u>AB</u>	+	PFIZER	<u>50MG/5ML</u>	<u>N020090 001</u> Dec 23, 1993
<u>AB</u>	+	!	<u>200MG/5ML</u>	<u>N020090 002</u> Dec 23, 1993

FLUCONAZOLE

<u>AB</u>	AUROBINDO PHARMA LTD	<u>50MG/5ML</u>	<u>A079150 001</u>	Sep 18, 2009
<u>AB</u>		<u>200MG/5ML</u>	<u>A079150 002</u>	Sep 18, 2009

INJECTABLE; INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

<u>AP</u>	BAXTER HLTHCARE CORP	<u>200MG/100ML (2MG/ML)</u>	<u>A077947 001</u>	May 26, 2010
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A077947 002</u>	May 26, 2010
<u>AP</u>	FRESENIUS KABI USA	<u>200MG/100ML (2MG/ML)</u>	<u>A076145 001</u>	Jul 29, 2004
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A076145 002</u>	Jul 29, 2004
<u>AP</u>	HIKMA FARMACEUTICA	<u>200MG/100ML (2MG/ML)</u>	<u>A076736 001</u>	Aug 23, 2005
<u>AP</u>	WEST-WARD PHARMS INT	<u>200MG/100ML (2MG/ML)</u>	<u>A076087 001</u>	Jul 29, 2004
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A076087 003</u>	Jul 29, 2004

PRESCRIPTION DRUG PRODUCT LIST

FLUCONAZOLE

INJECTABLE; INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>200MG/100ML (2MG/ML)</u>	<u>A076766 001</u>	Jul 29, 2004
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A076766 002</u>	Jul 29, 2004
<u>AP</u>	HIKMA FARMACEUTICA	<u>200MG/100ML (2MG/ML)</u>	<u>A078698 001</u>	Jan 30, 2012
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A078698 002</u>	Jan 30, 2012
<u>AP</u>	HOSPIRA	<u>200MG/100ML (2MG/ML)</u>	<u>A076303 001</u>	Jul 29, 2004
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A076303 002</u>	Jul 29, 2004
<u>AP</u>	! INFORLIFE	<u>200MG/100ML (2MG/ML)</u>	<u>A079104 001</u>	Jul 30, 2009
<u>AP</u>	!	<u>400MG/200ML (2MG/ML)</u>	<u>A079104 002</u>	Jul 30, 2009
<u>AP</u>	WEST-WARD PHARMS INT	<u>200MG/100ML (2MG/ML)</u>	<u>A078107 001</u>	Jul 30, 2008
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A078107 002</u>	Jul 30, 2008
<u>AP</u>	WOODWARD	<u>200MG/100ML (2MG/ML)</u>	<u>A077909 001</u>	May 26, 2010
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A077909 002</u>	May 26, 2010
	FLUCONAZOLE IN SODIUM CHLORIDE 0.9%			
	WEST-WARD PHARMS	100MG/50ML (2MG/ML)	A076087 002	Sep 26, 2008
	INT			
	FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
	WOODWARD	100MG/50ML (2MG/ML)	A077909 003	Apr 20, 2015

TABLET; ORAL

DIFLUCAN

<u>AB</u>	+ PFIZER	<u>50MG</u>	<u>N019949 001</u>	Jan 29, 1990
<u>AB</u>	+	<u>100MG</u>	<u>N019949 002</u>	Jan 29, 1990
<u>AB</u>	+	<u>150MG</u>	<u>N019949 004</u>	Jun 30, 1994
<u>AB</u>	+!	<u>200MG</u>	<u>N019949 003</u>	Jan 29, 1990

FLUCONAZOLE

<u>AB</u>	ANI PHARMS INC	<u>50MG</u>	<u>A078423 001</u>	Mar 07, 2011
<u>AB</u>		<u>100MG</u>	<u>A078423 002</u>	Mar 07, 2011
<u>AB</u>		<u>150MG</u>	<u>A078423 003</u>	Mar 07, 2011
<u>AB</u>		<u>200MG</u>	<u>A078423 004</u>	Mar 07, 2011
<u>AB</u>	AUROBINDO PHARMA	<u>50MG</u>	<u>A077731 001</u>	Oct 07, 2008
<u>AB</u>		<u>100MG</u>	<u>A077731 002</u>	Oct 07, 2008
<u>AB</u>		<u>150MG</u>	<u>A077731 003</u>	Oct 07, 2008
<u>AB</u>		<u>200MG</u>	<u>A077731 004</u>	Oct 07, 2008
<u>AB</u>	CHARTWELL	<u>50MG</u>	<u>A076665 001</u>	Jul 29, 2004
<u>AB</u>		<u>100MG</u>	<u>A076665 002</u>	Jul 29, 2004
<u>AB</u>		<u>150MG</u>	<u>A076665 003</u>	Jul 29, 2004
<u>AB</u>		<u>200MG</u>	<u>A076665 004</u>	Jul 29, 2004
<u>AB</u>	DR REDDYS LABS INC	<u>50MG</u>	<u>A076658 001</u>	Jul 29, 2004
<u>AB</u>		<u>100MG</u>	<u>A076658 002</u>	Jul 29, 2004
<u>AB</u>		<u>150MG</u>	<u>A076658 003</u>	Jul 29, 2004
<u>AB</u>		<u>200MG</u>	<u>A076658 004</u>	Jul 29, 2004
<u>AB</u>	GLENMARK GENERICS	<u>50MG</u>	<u>A077253 001</u>	Jan 25, 2006
<u>AB</u>		<u>100MG</u>	<u>A077253 002</u>	Jan 25, 2006
<u>AB</u>		<u>150MG</u>	<u>A077253 003</u>	Jan 25, 2006
<u>AB</u>		<u>200MG</u>	<u>A077253 004</u>	Jan 25, 2006
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>50MG</u>	<u>A076077 001</u>	Jul 29, 2004
<u>AB</u>		<u>100MG</u>	<u>A076077 002</u>	Jul 29, 2004
<u>AB</u>		<u>150MG</u>	<u>A076077 003</u>	Jul 29, 2004
<u>AB</u>		<u>200MG</u>	<u>A076077 004</u>	Jul 29, 2004
<u>AB</u>	TARO	<u>50MG</u>	<u>A076507 001</u>	Jul 29, 2004
<u>AB</u>		<u>100MG</u>	<u>A076507 002</u>	Jul 29, 2004
<u>AB</u>		<u>150MG</u>	<u>A076507 003</u>	Jul 29, 2004
<u>AB</u>		<u>200MG</u>	<u>A076507 004</u>	Jul 29, 2004
<u>AB</u>	UNIQUE PHARM LABS	<u>50MG</u>	<u>A076957 001</u>	Sep 28, 2005
<u>AB</u>		<u>100MG</u>	<u>A076957 002</u>	Sep 28, 2005
<u>AB</u>		<u>150MG</u>	<u>A076957 004</u>	Feb 27, 2017
<u>AB</u>		<u>200MG</u>	<u>A076957 003</u>	Sep 28, 2005
<u>AB</u>	ZYDUS PHARMS	<u>50MG</u>	<u>A208963 001</u>	Feb 16, 2017
<u>AB</u>		<u>100MG</u>	<u>A208963 002</u>	Feb 16, 2017
<u>AB</u>		<u>150MG</u>	<u>A208963 003</u>	Feb 16, 2017
<u>AB</u>		<u>200MG</u>	<u>A208963 004</u>	Feb 16, 2017

FLUCYTOSINE

CAPSULE; ORAL

ANCOBON

<u>AB</u>	+ BAUSCH	<u>250MG</u>	<u>N017001 001</u>	
<u>AB</u>	+!	<u>500MG</u>	<u>N017001 002</u>	

FLUCYTOSINE

<u>AB</u>	AUROBINDO PHARMA LTD	<u>250MG</u>	<u>A213665 001</u>	May 01, 2020
-----------	-------------------------	--------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

FLUCYTOSINE

CAPSULE; ORAL

FLUCYTOSINE

AB		500MG	A213665 002	May 01, 2020
AB	HIKMA	250MG	A206550 001	Oct 17, 2017
AB		500MG	A206550 002	Oct 17, 2017
AB	NOVEL LABS INC	250MG	A204652 001	Jul 07, 2017
AB		500MG	A204652 002	Jul 07, 2017
AB	SIGMAPHARM LABS LLC	250MG	A201566 001	Jun 28, 2011
AB		500MG	A201566 002	Jun 28, 2011

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARABINE PHOSPHATE

AP	ACTAVIS LLC	50MG/2ML (25MG/ML)	A203738 001	Feb 28, 2017
AP	ACTAVIS TOTOWA	50MG/VIAL	A078610 001	Feb 11, 2009
AP	AREVA PHARMS	50MG/2ML (25MG/ML)	A090724 001	Sep 27, 2010
AP	CUSTOPHARM INC	50MG/VIAL	A076349 001	Aug 28, 2003
AP	! FRESENIUS KABI USA	50MG/2ML (25MG/ML)	A078393 001	Oct 15, 2007
AP		50MG/VIAL	A078544 001	Oct 15, 2007
AP	! HOSPIRA	50MG/VIAL	A077790 001	Apr 06, 2007
AP	SAGENT PHARMS INC	50MG/2ML (25MG/ML)	A076661 001	Apr 28, 2004
AP	+! SANDOZ	50MG/2ML (25MG/ML)	N022137 001	Sep 21, 2007

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP	3D IMAGING DRUG	20-300mCi/ML	A203778 001	Oct 30, 2015
AP	BIOMEDCL RES FDN	20-300mCi/ML	A203710 001	May 01, 2015
AP		20-300mCi/ML	A203837 001	May 01, 2015
AP	BRIGHAM WOMENS	20-300mCi/ML	A203816 001	Oct 30, 2014
AP	CARDINAL HEALTH 414	20-300mCi/ML	A203603 001	Nov 13, 2015
AP	CHILDRENS HOSP MI	20-300mCi/ML	A204385 001	Oct 29, 2014
AP	CPDC	20-300mCi/ML	A204525 001	Oct 29, 2014
AP	DECATUR	20-300mCi/ML	A204463 001	Oct 21, 2014
AP	ESSENTIAL ISOTOPES	20-300mCi/ML	A203946 001	Feb 05, 2014
AP	+! FEINSTEIN	20-400mCi/ML	N021870 002	Nov 21, 2008
AP	JUBILANT DRAXIMAGE	20-300mCi/ML	A203920 001	Jun 23, 2015
AP	KETTERING MEDCTR	4-40mCi/ML	A204759 001	Oct 27, 2015
AP	KREITCHMAN PET CTR	10-100mCi/ML	A203942 001	Apr 11, 2016
AP	LANTHEUS MEDICAL	20-200mCi/ML	A203664 001	Feb 04, 2014
AP	MA GENERAL HOSP	20-300mCi/ML	A204333 001	Sep 25, 2014
AP	MCPRF	20-240mCi/ML	A203612 001	Aug 05, 2013
AP	MEM SLOAN-KETTERING	20-300mCi/ML	A208679 001	Dec 08, 2016
AP	METHODIST HOSP RES	20-300mCi/ML	A203904 001	Apr 23, 2015
AP	MIPS CRF	20-300mCi/ML	A204472 001	Sep 11, 2015
AP	NCM USA BRONX LLC	20-300mCi/ML	A204512 001	Jan 07, 2015
AP	! PETNET	20-200mCi/ML	A079086 001	Feb 25, 2011
AP	! QUEEN HAMAMATSU PET	10-100mCi/ML	A203771 001	Aug 31, 2015
AP	SHERTECH LABS LLC	20-300mCi/ML	A204264 001	Dec 18, 2014
AP	SOFIE	20-300mCi/ML	A203591 001	Aug 31, 2015
AP	! TRUSTEES UNIV PA	20-500mCi/ML	A203665 001	Feb 14, 2013
AP		20-200mCi/ML	A203801 001	Oct 29, 2014
AP	! UCLA BIOMEDICAL	4-40mCi/ML	A203811 001	Jun 27, 2013
AP	UCSF RODIOPHARM	20-300mCi/ML	A203902 001	May 09, 2014
AP	UIHC PET IMAGING	20-300mCi/ML	A203990 001	Aug 06, 2014
AP	UNIV MICHIGAN	20-300mCi/ML	A204531 001	Jul 17, 2015
AP	UNIV SOUTHERN CA	20-300mCi/ML	A209341 001	Dec 16, 2020
AP	UNIV TX MD ANDERSON	20-300mCi/ML	A203246 002	Jan 13, 2014
AP	UNIV UTAH CYCLOTRON	20-300mCi/ML	A204498 001	Jun 23, 2015
AP	WISCONSIN	20-500mCi/ML	A203709 001	Oct 23, 2013
AP	WUSM CYCLOTRON	20-300mCi/ML	A203935 001	Feb 05, 2014
	HOT SHOTS NM LLC	4-500mCi/ML	A203937	001 Oct 30, 2014
	NORTHLAND	4-500mCi/ML	A203994	001 Feb 04, 2015
	PRECISION NUCLEAR	20-500mCi/ML	A204546	001 Apr 07, 2015
	SPECTRON MRC LLC	4-500mCi/ML	A203911	001 Apr 22, 2015
	UNIV TX MD ANDERSON	20-150mCi/ML	A203246	001 Jan 13, 2014

PRESCRIPTION DRUG PRODUCT LIST

FLUDROCORTISONE ACETATE

TABLET; ORAL

FLUDROCORTISONE ACETATE

<u>AB</u>	BARR	<u>0.1MG</u>	<u>A040425</u>	<u>001</u>	Jan 21, 2003
<u>AB</u>	! IMPAX LABS	<u>0.1MG</u>	<u>A040431</u>	<u>001</u>	Mar 18, 2002

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

<u>AP</u>	FRESENIUS KABI USA	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A076955</u>	<u>002</u>	Oct 12, 2004
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A076955</u>	<u>001</u>	Oct 12, 2004
<u>AP</u>	HIKMA FARMACEUTICA	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A078527</u>	<u>001</u>	Mar 23, 2009
<u>AP</u>	!	<u>1MG/10ML (0.1MG/ML)</u>	<u>A078527</u>	<u>002</u>	Mar 23, 2009
<u>AP</u>	MYLAN LABS LTD	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A078595</u>	<u>001</u>	May 13, 2008
<u>AP</u>	SAGENT PHARMS	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A090584</u>	<u>001</u>	Aug 28, 2012
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A090584</u>	<u>002</u>	Aug 28, 2012
<u>AP</u>	SANDOZ INC	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A077071</u>	<u>001</u>	May 03, 2005
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A077071</u>	<u>002</u>	May 03, 2005
<u>AP</u>	WEST-WARD PHARMS INT	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A076256</u>	<u>002</u>	Oct 12, 2004
<u>AP</u>		<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A076787</u>	<u>002</u>	Oct 12, 2004
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A076256</u>	<u>001</u>	Oct 12, 2004
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A076787</u>	<u>001</u>	Oct 12, 2004

FLUNISOLIDE

SPRAY, METERED; NASAL

FLUNISOLIDE

<u>AB</u>	! BAUSCH AND LOMB	<u>0.025MG/SPRAY</u>	<u>A074805</u>	<u>001</u>	Feb 20, 2002
<u>AB</u>	RISING	<u>0.025MG/SPRAY</u>	<u>A077704</u>	<u>001</u>	Aug 03, 2006
	! APOTEX	0.029MG/SPRAY	A077436	001	Aug 09, 2007

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

FLUOCINOLONE ACETONIDE

<u>AT</u>	COSETTE	<u>0.01%</u>	<u>A089526</u>	<u>001</u>	Jul 26, 1988
<u>AT</u>		<u>0.025%</u>	<u>A210747</u>	<u>001</u>	Nov 05, 2018
<u>AT</u>	FOUGERA PHARMS INC	<u>0.01%</u>	<u>A088170</u>	<u>001</u>	Dec 16, 1982
<u>AT</u>		<u>0.025%</u>	<u>A088169</u>	<u>001</u>	Dec 16, 1982
<u>AT</u>	TARO	<u>0.025%</u>	<u>A087104</u>	<u>001</u>	Apr 27, 1982

SYNALAR

<u>AT</u>	+! MEDIMETRIKS PHARMS	<u>0.01%</u>	<u>N012787</u>	<u>004</u>	
<u>AT</u>	+!	<u>0.025%</u>	<u>N012787</u>	<u>002</u>	
<u>AT</u>	+!	<u>0.025%</u>	<u>N012787</u>	<u>005</u>	

IMPLANT; INTRAVITREAL

ILUVIEN

+!	ALIMERA SCIENCES INC	0.19MG	N201923	001	Sep 26, 2014
----	-------------------------	--------	---------	-----	--------------

RETISERT

+!	BAUSCH AND LOMB	0.59MG	N021737	001	Apr 08, 2005
----	-----------------	--------	---------	-----	--------------

YUTIQ

+!	EYEPOINT PHARMS	0.18MG	N210331	001	Oct 12, 2018
----	-----------------	--------	---------	-----	--------------

OIL; TOPICAL

DERMA-SMOOTH/FS

<u>AT</u>	+! HILL DERMAC	<u>0.01%</u>	<u>N019452</u>	<u>001</u>	Feb 03, 1988
<u>AT</u>	+!	<u>0.01%</u>	<u>N019452</u>	<u>002</u>	Nov 09, 2005

FLUCINOLONE ACETONIDE

<u>AT</u>	GLENMARK PHARMS LTD	<u>0.01%</u>	<u>A210556</u>	<u>001</u>	Oct 25, 2018
-----------	---------------------	--------------	----------------	------------	--------------

FLUOCINOLONE ACETONIDE

<u>AT</u>	AKORN	<u>0.01%</u>	<u>A091514</u>	<u>001</u>	Jun 25, 2015
<u>AT</u>	AMNEAL	<u>0.01%</u>	<u>A201759</u>	<u>001</u>	Oct 17, 2011
<u>AT</u>		<u>0.01%</u>	<u>A201764</u>	<u>001</u>	Oct 17, 2011
<u>AT</u>	LYNE	<u>0.01%</u>	<u>A090982</u>	<u>001</u>	Apr 25, 2016
<u>AT</u>		<u>0.01%</u>	<u>A203377</u>	<u>001</u>	Apr 25, 2016
<u>AT</u>	PERRIGO ISRAEL	<u>0.01%</u>	<u>A202847</u>	<u>001</u>	Aug 09, 2013
<u>AT</u>		<u>0.01%</u>	<u>A202848</u>	<u>001</u>	Aug 09, 2013
<u>AT</u>	TARO	<u>0.01%</u>	<u>A202368</u>	<u>001</u>	May 19, 2016
<u>AT</u>		<u>0.01%</u>	<u>A209336</u>	<u>001</u>	May 19, 2016

FLUOCINONIDE ACETONIDE

<u>AT</u>	GLENMARK PHARMS LTD	<u>0.01%</u>	<u>A210539</u>	<u>001</u>	Oct 26, 2018
-----------	---------------------	--------------	----------------	------------	--------------

OIL/DROPS; OTIC

DERMOTIC

<u>AT</u>	+! HILL DERMAC	<u>0.01%</u>	<u>N019452</u>	<u>003</u>	Nov 09, 2005
-----------	----------------	--------------	----------------	------------	--------------

FLAC

<u>AT</u>	ANDA REPOSITORY	<u>0.01%</u>	<u>A210736</u>	<u>001</u>	Apr 11, 2018
-----------	-----------------	--------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

FLUOCINOLONE ACETONIDE

OIL/DROPS;OTIC

FLUOCINOLONE ACETONIDE

AT	AKORN	<u>0.01%</u>	<u>A202705</u>	<u>001</u>	Sep 09, 2016
AT	AMNEAL	<u>0.01%</u>	<u>A091306</u>	<u>001</u>	Oct 17, 2011
AT	LYNE	<u>0.01%</u>	<u>A203378</u>	<u>001</u>	Apr 25, 2016
AT	PERRIGO ISRAEL	<u>0.01%</u>	<u>A202849</u>	<u>001</u>	Jul 17, 2017

FLUOCINONIDE ACETONIDE

AT	GLENMARK PHARMS LTD	<u>0.01%</u>	<u>A211815</u>	<u>001</u>	Dec 14, 2018
-----------	---------------------	--------------	----------------	------------	--------------

OINTMENT;TOPICAL

FLUOCINOLONE ACETONIDE

AT	COSETTE	<u>0.025%</u>	<u>A089524</u>	<u>001</u>	Jul 26, 1988
AT	FOUGERA PHARMS INC	<u>0.025%</u>	<u>A088168</u>	<u>001</u>	Dec 16, 1982
AT	TARO	<u>0.025%</u>	<u>A040041</u>	<u>001</u>	Sep 15, 1994

SYNALAR

AT	+	MEDIMETRIKS PHARMS	<u>0.025%</u>	<u>N013960</u>	<u>001</u>
-----------	---	--------------------	---------------	----------------	------------

SHAMPOO;TOPICAL

CAPEX

+	GALDERMA LABS LP	0.01%	N020001	001	Aug 27, 1990
---	------------------	-------	---------	-----	--------------

SOLUTION;TOPICAL

FLUOCINOLONE ACETONIDE

AT	ENCUBE ETHICALS	<u>0.01%</u>	<u>A209913</u>	<u>001</u>	Feb 13, 2019
AT	FOUGERA PHARMS INC	<u>0.01%</u>	<u>A088167</u>	<u>001</u>	Dec 16, 1982
AT	GLASSHOUSE PHARMS	<u>0.01%</u>	<u>A209596</u>	<u>001</u>	Dec 26, 2017
AT	LUPIN	<u>0.01%</u>	<u>A206422</u>	<u>001</u>	Sep 02, 2015
AT	TARO	<u>0.01%</u>	<u>A089124</u>	<u>001</u>	Sep 11, 1985

SYNALAR

AT	+	MEDIMETRIKS PHARMS	<u>0.01%</u>	<u>N015296</u>	<u>001</u>
-----------	---	--------------------	--------------	----------------	------------

FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN

CREAM;TOPICAL

TRI-LUMA

+	GALDERMA LABS LP	0.01%;4%;0.05%	N021112	001	Jan 18, 2002
---	------------------	----------------	---------	-----	--------------

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE

CREAM;TOPICAL

NEO-SYNALAR

!	MEDIMETRIKS PHARMS	0.025%;EQ 3.5MG BASE/GM	A060700	001	
---	--------------------	-------------------------	---------	-----	--

FLUOCINONIDE

CREAM;TOPICAL

FLUOCINONIDE

AB	AMNEAL	<u>0.1%</u>	<u>A211111</u>	<u>001</u>	Jun 04, 2018
AB	CADILA	<u>0.1%</u>	<u>A208989</u>	<u>001</u>	Feb 10, 2020
AB	FOUGERA PHARMS INC	<u>0.1%</u>	<u>A200735</u>	<u>001</u>	Jul 14, 2014
AB	GLENMARK GENERICS	<u>0.1%</u>	<u>A091282</u>	<u>001</u>	Jul 14, 2014
AB	PERRIGO ISRAEL	<u>0.1%</u>	<u>A090256</u>	<u>001</u>	Jan 14, 2014
AB	TARO	<u>0.1%</u>	<u>A200734</u>	<u>001</u>	Jul 14, 2014
AB	TELGENT	<u>0.1%</u>	<u>A211758</u>	<u>001</u>	Apr 03, 2019

VANOS

AB	+	MEDICIS	<u>0.1%</u>	<u>N021758</u>	<u>001</u>	Feb 11, 2005
-----------	---	---------	-------------	----------------	------------	--------------

FLUOCINONIDE

AB1	AMNEAL	<u>0.05%</u>	<u>A210554</u>	<u>001</u>	Aug 21, 2018
AB1	COSETTE	<u>0.05%</u>	<u>A073085</u>	<u>001</u>	Feb 14, 1992
AB1	FOUGERA PHARMS INC	<u>0.05%</u>	<u>A073030</u>	<u>001</u>	Oct 17, 1994
AB1	TARO	<u>0.05%</u>	<u>A071500</u>	<u>001</u>	Jun 10, 1987
AB1	+		<u>N019117</u>	<u>001</u>	Jun 26, 1984
AB1	TEVA	<u>0.05%</u>	<u>A072488</u>	<u>001</u>	Feb 06, 1989

FLUOCINONIDE EMULSIFIED BASE

AB2	COSETTE	<u>0.05%</u>	<u>A074204</u>	<u>001</u>	Jun 13, 1995	
AB2	FOUGERA PHARMS	<u>0.05%</u>	<u>A076586</u>	<u>001</u>	Jun 23, 2004	
AB2	!	TARO PHARM INDS LTD	<u>0.05%</u>	<u>A072494</u>	<u>001</u>	Jan 19, 1989
AB2	TEVA	<u>0.05%</u>	<u>A072490</u>	<u>001</u>	Feb 07, 1989	

LIDEX-E

AB2	+	CNTY LINE PHARMS	<u>0.05%</u>	<u>N016908</u>	<u>003</u>
------------	---	------------------	--------------	----------------	------------

GEL;TOPICAL

FLUOCINONIDE

AB	+	CNTY LINE PHARMS	<u>0.05%</u>	<u>N017373</u>	<u>001</u>	
AB		COSETTE	<u>0.05%</u>	<u>A072537</u>	<u>001</u>	Feb 07, 1989
AB		FOUGERA PHARMS INC	<u>0.05%</u>	<u>A072933</u>	<u>001</u>	Dec 30, 1994
AB	!	TARO	<u>0.05%</u>	<u>A074935</u>	<u>001</u>	Jul 29, 1997
AB		TELGENT	<u>0.05%</u>	<u>A209030</u>	<u>001</u>	Jun 19, 2018

PRESCRIPTION DRUG PRODUCT LIST

FLUOCINONIDE

OINTMENT; TOPICAL

FLUOCINONIDE

<u>AB</u>	FOUGERA PHARMS	<u>0.05%</u>	<u>A074905 001</u>	Aug 26, 1997
<u>AB</u>	NOVEL LABS INC	<u>0.05%</u>	<u>A207538 001</u>	Jul 31, 2017
<u>AB</u>	! TARO	<u>0.05%</u>	<u>A075008 001</u>	Jun 30, 1999
<u>AB</u>	TELGENT	<u>0.05%</u>	<u>A207680 001</u>	Sep 28, 2018
<u>AB</u>	TEVA	<u>0.05%</u>	<u>A073481 001</u>	Dec 27, 1991
<u>AB</u>	XIROMED	<u>0.05%</u>	<u>A212976 001</u>	Nov 26, 2019

LIDEX

<u>AB</u>	+ CNTY LINE PHARMS	<u>0.05%</u>	<u>N016909 002</u>	
-----------	--------------------	--------------	--------------------	--

SOLUTION; TOPICAL

FLUOCINONIDE

<u>AT</u>	COSETTE	<u>0.05%</u>	<u>A071535 001</u>	Dec 02, 1988
<u>AT</u>	ENCUBE ETHICALS	<u>0.05%</u>	<u>A209699 001</u>	Nov 29, 2018
<u>AT</u>	FOUGERA PHARMS INC	<u>0.05%</u>	<u>A072934 001</u>	Feb 27, 1995
<u>AT</u>	GLASSHOUSE PHARMS	<u>0.05%</u>	<u>A209118 001</u>	Apr 23, 2018
<u>AT</u>	MACLEODS PHARMS LTD	<u>0.05%</u>	<u>A209283 001</u>	Apr 23, 2018
<u>AT</u>	NOVEL LABS INC	<u>0.05%</u>	<u>A206003 001</u>	Jul 21, 2017
<u>AT</u>	! TARO	<u>0.05%</u>	<u>A074799 001</u>	Dec 31, 1996
<u>AT</u>	TELGENT	<u>0.05%</u>	<u>A207554 001</u>	Mar 18, 2019
<u>AT</u>	ZYDUS PHARMS	<u>0.05%</u>	<u>A208948 001</u>	Jul 17, 2018

LIDEX

<u>AT</u>	+ CNTY LINE PHARMS	<u>0.05%</u>	<u>N018849 001</u>	Apr 06, 1984
-----------	--------------------	--------------	--------------------	--------------

FLUORESCEIN SODIUM

INJECTABLE; INTRAVENOUS

AK-FLUOR 10%

<u>AP</u>	+ AKORN	<u>EQ 500MG BASE/5ML (EQ 100MG BASE/ML)</u>	<u>N022186 001</u>	Aug 08, 2008
-----------	---------	---	--------------------	--------------

FLUORESCITE

<u>AP</u>	+! ALCON LABS INC	<u>EQ 500MG BASE/5ML (EQ 100MG BASE/ML)</u>	<u>N021980 001</u>	Mar 28, 2006
	AK-FLUOR 25%			
	+! AKORN	<u>EQ 500MG BASE/2ML (EQ 250MG BASE/ML)</u>	<u>N022186 002</u>	Aug 08, 2008

FLUOROESTRADIOL F-18

SOLUTION; INTRAVENOUS

CERIANNA

+!	ZIONEXA	50ML (4-100mCi/ML)	<u>N212155 001</u>	May 20, 2020
----	---------	--------------------	--------------------	--------------

FLUOROMETHOLONE

OINTMENT; OPHTHALMIC

FML

+!	ALLERGAN	0.1%	<u>N017760 001</u>	Sep 04, 1985
----	----------	------	--------------------	--------------

SUSPENSION/DROPS; OPHTHALMIC

FML

+!	ALLERGAN	0.1%	<u>N016851 002</u>	Jul 28, 1982
----	----------	------	--------------------	--------------

FML FORTE

+!	ALLERGAN	0.25%	<u>N019216 001</u>	Apr 23, 1986
----	----------	-------	--------------------	--------------

FLUOROMETHOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC

FLAREX

+!	EYEVANCE	0.1%	<u>N019079 001</u>	Feb 11, 1986
----	----------	------	--------------------	--------------

FLUOROURACIL

CREAM; TOPICAL

EFUDEX

<u>AB</u>	+! BAUSCH	<u>5%</u>	<u>N016831 003</u>	
-----------	-----------	-----------	--------------------	--

FLUOROURACIL

<u>AB</u>	MAYNE PHARMA	<u>5%</u>	<u>A077524 001</u>	Apr 11, 2008
<u>AB</u>	TARO	<u>5%</u>	<u>A090368 001</u>	Mar 05, 2010
	CARAC			
	+! VALEANT PHARMS NORTH	0.5%	<u>N020985 001</u>	Oct 27, 2000
	FLUOROPLEX			
	+! ALMIRALL	1%	<u>N016988 001</u>	
	TOLAK			
	+! HILL DERMACEUTICALS	4%	<u>N022259 001</u>	Sep 18, 2015

INJECTABLE; INJECTION

FLUOROURACIL

<u>AP</u>	! ACCORD HLTHCARE	<u>500MG/10ML (50MG/ML)</u>	<u>A040743 002</u>	Apr 26, 2007
<u>AP</u>	!	<u>1GM/20ML (50MG/ML)</u>	<u>A040743 001</u>	Apr 26, 2007
<u>AP</u>	!	<u>2.5GM/50ML (50MG/ML)</u>	<u>A040798 002</u>	Apr 26, 2007
<u>AP</u>	!	<u>5GM/100ML (50MG/ML)</u>	<u>A040798 001</u>	Apr 26, 2007
<u>AP</u>	! FRESenius KABI USA	<u>500MG/10ML (50MG/ML)</u>	<u>A040279 002</u>	Sep 30, 1998

PRESCRIPTION DRUG PRODUCT LIST

FLUOROURACIL

INJECTABLE; INJECTION

FLUOROURACIL

<u>AP</u>	!		<u>1GM/20ML (50MG/ML)</u>	<u>A040279 001</u>	Sep 30, 1998
<u>AP</u>	!		<u>2.5GM/50ML (50MG/ML)</u>	<u>A040278 001</u>	Sep 30, 1998
<u>AP</u>	!		<u>5GM/100ML (50MG/ML)</u>	<u>A040278 002</u>	Sep 30, 1998
<u>AP</u>		GLAND PHARMA LTD	<u>500MG/10ML (50MG/ML)</u>	<u>A210123 001</u>	Oct 27, 2017
<u>AP</u>			<u>1GM/20ML (50MG/ML)</u>	<u>A210123 002</u>	Oct 27, 2017
<u>AP</u>			<u>2.5GM/50ML (50MG/ML)</u>	<u>A210124 001</u>	Dec 26, 2017
<u>AP</u>			<u>5GM/100ML (50MG/ML)</u>	<u>A210124 002</u>	Dec 26, 2017
<u>AP</u>		SAGENT PHARMS INC	<u>500MG/10ML (50MG/ML)</u>	<u>A203608 001</u>	May 11, 2017
<u>AP</u>			<u>1GM/20ML (50MG/ML)</u>	<u>A203608 002</u>	May 11, 2017
<u>AP</u>			<u>2.5GM/50ML (50MG/ML)</u>	<u>A203609 001</u>	Feb 17, 2016
<u>AP</u>			<u>5GM/100ML (50MG/ML)</u>	<u>A203609 002</u>	Feb 17, 2016
<u>AP</u>	!	TEVA PHARMS USA	<u>500MG/10ML (50MG/ML)</u>	<u>A040333 001</u>	Jan 27, 2000

SOLUTION; TOPICAL

EFUDEX

<u>AT</u>	+	BAUSCH	<u>2%</u>	<u>N016831 001</u>	
-----------	---	--------	-----------	--------------------	--

FLUOROURACIL

<u>AT</u>		TARO	<u>2%</u>	<u>A076526 001</u>	Nov 05, 2003
	!		<u>5%</u>	<u>A076526 002</u>	Nov 05, 2003

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

<u>AB</u>		ACCORD HLTHCARE	<u>EQ 40MG BASE</u>	<u>A202729 003</u>	Aug 27, 2020
<u>AB</u>		ALEMBIC PHARMS LTD	<u>EQ 40MG BASE</u>	<u>A090223 003</u>	Mar 19, 2009
<u>AB</u>		APNAR PHARMA LP	<u>EQ 40MG BASE</u>	<u>A075049 003</u>	Jan 29, 2002
<u>AB</u>		AUROBINDO PHARMA	<u>EQ 40MG BASE</u>	<u>A078619 003</u>	Jan 31, 2008
<u>AB</u>		CADILA PHARMS LTD	<u>EQ 40MG BASE</u>	<u>A206993 003</u>	May 23, 2019
<u>AB</u>		IVAX SUB TEVA PHARMS	<u>EQ 40MG BASE</u>	<u>A075245 003</u>	Sep 28, 2004
<u>AB</u>		MARKSANS PHARMA	<u>EQ 40MG BASE</u>	<u>A075465 003</u>	Aug 02, 2001
<u>AB</u>		SCIEGEN PHARMS INC	<u>EQ 40MG BASE</u>	<u>A204597 003</u>	Mar 16, 2015
<u>AB</u>		SUN PHARM INDS LTD	<u>EQ 40MG BASE</u>	<u>A076990 001</u>	Dec 13, 2004
<u>AB</u>		TEVA	<u>EQ 40MG BASE</u>	<u>A075452 003</u>	Jan 29, 2002

PROZAC

<u>AB</u>	+	ELI LILLY AND CO	<u>EQ 40MG BASE</u>	<u>N018936 003</u>	Jun 15, 1999
-----------	---	------------------	---------------------	--------------------	--------------

FLUOXETINE HYDROCHLORIDE

<u>AB1</u>		ACCORD HLTHCARE	<u>EQ 10MG BASE</u>	<u>A202729 001</u>	Aug 27, 2020
<u>AB1</u>			<u>EQ 20MG BASE</u>	<u>A202729 002</u>	Aug 27, 2020
<u>AB1</u>		ALEMBIC PHARMS LTD	<u>EQ 10MG BASE</u>	<u>A090223 001</u>	Mar 19, 2009
<u>AB1</u>			<u>EQ 20MG BASE</u>	<u>A090223 002</u>	Mar 19, 2009
<u>AB1</u>		APNAR PHARMA LP	<u>EQ 10MG BASE</u>	<u>A075049 001</u>	Aug 02, 2001
<u>AB1</u>			<u>EQ 20MG BASE</u>	<u>A075049 002</u>	Jan 29, 2002
<u>AB1</u>		AUROBINDO PHARMA	<u>EQ 10MG BASE</u>	<u>A078619 001</u>	Jan 31, 2008
<u>AB1</u>			<u>EQ 20MG BASE</u>	<u>A078619 002</u>	Jan 31, 2008
<u>AB1</u>		CADILA PHARMS LTD	<u>EQ 10MG BASE</u>	<u>A206993 001</u>	May 23, 2019
<u>AB1</u>			<u>EQ 20MG BASE</u>	<u>A206993 002</u>	May 23, 2019
<u>AB1</u>		IVAX SUB TEVA PHARMS	<u>EQ 10MG BASE</u>	<u>A075245 002</u>	Jan 31, 2002
<u>AB1</u>			<u>EQ 20MG BASE</u>	<u>A075245 001</u>	Jan 31, 2002
<u>AB1</u>		LANDELA PHARM	<u>EQ 10MG BASE</u>	<u>A075464 001</u>	Jan 30, 2002
<u>AB1</u>			<u>EQ 20MG BASE</u>	<u>A075464 002</u>	Jan 30, 2002
<u>AB1</u>		MARKSANS PHARMA	<u>EQ 10MG BASE</u>	<u>A075465 001</u>	Jan 29, 2002
<u>AB1</u>			<u>EQ 20MG BASE</u>	<u>A075465 002</u>	Jan 29, 2002
<u>AB1</u>		SCIEGEN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A204597 001</u>	Mar 16, 2015
<u>AB1</u>			<u>EQ 20MG BASE</u>	<u>A204597 002</u>	Mar 16, 2015
<u>AB1</u>		TEVA	<u>EQ 10MG BASE</u>	<u>A075452 001</u>	Jan 29, 2002
<u>AB1</u>			<u>EQ 20MG BASE</u>	<u>A075452 002</u>	Jan 29, 2002
<u>AB1</u>		TEVA PHARMS USA	<u>EQ 10MG BASE</u>	<u>A076001 001</u>	Jan 29, 2002
<u>AB1</u>			<u>EQ 20MG BASE</u>	<u>A076001 002</u>	Jan 29, 2002

PROZAC

<u>AB1</u>	+	ELI LILLY AND CO	<u>EQ 10MG BASE</u>	<u>N018936 006</u>	Dec 23, 1992
<u>AB1</u>	+		<u>EQ 20MG BASE</u>	<u>N018936 001</u>	Dec 29, 1987

CAPSULE, DELAYED REL PELLETS; ORAL

FLUOXETINE HYDROCHLORIDE

!		DR REDDYS LABS LTD	<u>EQ 90MG BASE</u>	<u>A078572 001</u>	Mar 22, 2010
---	--	--------------------	---------------------	--------------------	--------------

SOLUTION; ORAL

FLUOXETINE HYDROCHLORIDE

<u>AA</u>		AUROBINDO PHARMA LTD	<u>EQ 20MG BASE/5ML</u>	<u>A079209 001</u>	Mar 20, 2009
<u>AA</u>		LANNETT CO INC	<u>EQ 20MG BASE/5ML</u>	<u>A077849 001</u>	Feb 09, 2007

PRESCRIPTION DRUG PRODUCT LIST

FLUOXETINE HYDROCHLORIDE

SOLUTION;ORAL

FLUOXETINE HYDROCHLORIDE

<u>AA</u>	!	PHARM ASSOC	<u>EQ 20MG BASE/5ML</u>	<u>A076015</u>	<u>001</u>	Jan 30, 2002
<u>AA</u>		TEVA	<u>EQ 20MG BASE/5ML</u>	<u>A075506</u>	<u>001</u>	Aug 02, 2001
<u>AA</u>		WOCKHARDT BIO AG	<u>EQ 20MG BASE/5ML</u>	<u>A075514</u>	<u>001</u>	Aug 29, 2002

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE

<u>AB</u>		ALEMBIC PHARMS LTD	<u>EQ 10MG BASE</u>	<u>A208698</u>	<u>001</u>	Apr 05, 2017
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A208698</u>	<u>002</u>	Apr 05, 2017
<u>AB</u>	+	ALVOGEN	<u>EQ 60MG BASE</u>	<u>N202133</u>	<u>001</u>	Oct 06, 2011
<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 10MG BASE</u>	<u>A213286</u>	<u>001</u>	Apr 08, 2020
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A213286</u>	<u>002</u>	Apr 08, 2020
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A213265</u>	<u>001</u>	Jun 10, 2020
<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 10MG BASE</u>	<u>A076006</u>	<u>001</u>	Jan 30, 2002
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A076006</u>	<u>002</u>	Apr 23, 2018
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A211721</u>	<u>001</u>	Jan 25, 2019
<u>AB</u>		INVENTIA HLTHCARE	<u>EQ 60MG BASE</u>	<u>A209695</u>	<u>001</u>	Nov 20, 2017
<u>AB</u>		LUPIN LTD	<u>EQ 10MG BASE</u>	<u>A211653</u>	<u>001</u>	Apr 15, 2019
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A211653</u>	<u>002</u>	Apr 15, 2019
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A211632</u>	<u>001</u>	Feb 08, 2019
<u>AB</u>		MYLAN	<u>EQ 10MG BASE</u>	<u>A075755</u>	<u>001</u>	Aug 02, 2001
<u>AB</u>	!		<u>EQ 20MG BASE</u>	<u>A075755</u>	<u>002</u>	Aug 02, 2001
<u>AB</u>		PAR FORM	<u>EQ 10MG BASE</u>	<u>A203836</u>	<u>001</u>	Aug 19, 2016
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A203836</u>	<u>002</u>	Aug 19, 2016
<u>AB</u>		PAR PHARM INC	<u>EQ 60MG BASE</u>	<u>A209419</u>	<u>001</u>	Nov 16, 2017
<u>AB</u>		SCIEGEN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A210935</u>	<u>001</u>	Mar 20, 2019
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A210935</u>	<u>002</u>	Mar 20, 2019
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A211282</u>	<u>001</u>	Jan 10, 2019
<u>AB</u>		TARO	<u>EQ 60MG BASE</u>	<u>A211477</u>	<u>001</u>	Nov 21, 2018
<u>AB</u>		TEVA	<u>EQ 10MG BASE</u>	<u>A075872</u>	<u>001</u>	Jan 29, 2002
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A075872</u>	<u>002</u>	Jan 04, 2019
<u>AB</u>		TEVA PHARMS USA	<u>EQ 60MG BASE</u>	<u>A211051</u>	<u>001</u>	Dec 03, 2018
<u>AB</u>		UPSHER SMITH LABS	<u>EQ 10MG BASE</u>	<u>A211696</u>	<u>001</u>	Jan 30, 2019
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A211696</u>	<u>002</u>	Jan 30, 2019
<u>AB1</u>		TORRENT	<u>EQ 10MG BASE</u>	<u>A206937</u>	<u>001</u>	Oct 21, 2016
<u>AB1</u>			<u>EQ 20MG BASE</u>	<u>A206937</u>	<u>002</u>	Oct 21, 2016
		<u>SARAFEM</u>				
<u>AB1</u>	+	APIL	<u>EQ 10MG BASE</u>	<u>N021860</u>	<u>001</u>	May 19, 2006
<u>AB1</u>	+	!	<u>EQ 20MG BASE</u>	<u>N021860</u>	<u>003</u>	May 19, 2006

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE;ORAL

OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

<u>AB</u>		PAR PHARM	<u>EQ 25MG BASE;EQ 3MG BASE</u>	<u>A077742</u>	<u>001</u>	Nov 02, 2012
<u>AB</u>			<u>EQ 25MG BASE;EQ 6MG BASE</u>	<u>A077742</u>	<u>002</u>	Nov 02, 2012
<u>AB</u>			<u>EQ 25MG BASE;EQ 12MG BASE</u>	<u>A077742</u>	<u>003</u>	Nov 02, 2012
<u>AB</u>			<u>EQ 50MG BASE;EQ 6MG BASE</u>	<u>A077742</u>	<u>004</u>	Nov 02, 2012
<u>AB</u>			<u>EQ 50MG BASE;EQ 12MG BASE</u>	<u>A077742</u>	<u>005</u>	Nov 02, 2012
<u>AB</u>		SANDOZ	<u>EQ 25MG BASE;EQ 3MG BASE</u>	<u>A078901</u>	<u>005</u>	Nov 16, 2012
<u>AB</u>			<u>EQ 25MG BASE;EQ 6MG BASE</u>	<u>A078901</u>	<u>001</u>	Nov 16, 2012
<u>AB</u>			<u>EQ 25MG BASE;EQ 12MG BASE</u>	<u>A078901</u>	<u>003</u>	Nov 16, 2012
<u>AB</u>			<u>EQ 50MG BASE;EQ 6MG BASE</u>	<u>A078901</u>	<u>002</u>	Nov 16, 2012
<u>AB</u>			<u>EQ 50MG BASE;EQ 12MG BASE</u>	<u>A078901</u>	<u>004</u>	Nov 16, 2012
<u>AB</u>		TEVA PHARMS	<u>EQ 25MG BASE;EQ 3MG BASE</u>	<u>A202074</u>	<u>001</u>	Mar 25, 2013
<u>AB</u>			<u>EQ 25MG BASE;EQ 6MG BASE</u>	<u>A077528</u>	<u>001</u>	Jun 19, 2012
<u>AB</u>			<u>EQ 25MG BASE;EQ 12MG BASE</u>	<u>A077528</u>	<u>002</u>	Jun 19, 2012
<u>AB</u>			<u>EQ 50MG BASE;EQ 6MG BASE</u>	<u>A077528</u>	<u>003</u>	Jun 19, 2012
<u>AB</u>			<u>EQ 50MG BASE;EQ 12MG BASE</u>	<u>A077528</u>	<u>004</u>	Jun 19, 2012
		<u>SYMBYAX</u>				
<u>AB</u>	+	LILLY	<u>EQ 25MG BASE;EQ 3MG BASE</u>	<u>N021520</u>	<u>001</u>	Apr 09, 2007
<u>AB</u>	+		<u>EQ 25MG BASE;EQ 6MG BASE</u>	<u>N021520</u>	<u>002</u>	Dec 24, 2003
<u>AB</u>	+		<u>EQ 25MG BASE;EQ 12MG BASE</u>	<u>N021520</u>	<u>004</u>	Dec 24, 2003
<u>AB</u>	+	!	<u>EQ 50MG BASE;EQ 6MG BASE</u>	<u>N021520</u>	<u>003</u>	Dec 24, 2003
<u>AB</u>	+		<u>EQ 50MG BASE;EQ 12MG BASE</u>	<u>N021520</u>	<u>005</u>	Dec 24, 2003

FLUOXYMESTERONE

TABLET;ORAL

FLUOXYMESTERONE

!		UPSHER SMITH LABS	10MG	A088342	001	Oct 21, 1983
---	--	-------------------	------	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

AO	AUROBINDO PHARMA LTD	25MG/ML	A207739 001	Oct 17, 2017
AO	! FRESenius KABI USA	25MG/ML	A071413 001	Jul 14, 1987
AO	MYLAN LABS LTD	25MG/ML	A075918 001	Aug 17, 2001
AO	PAR STERILE PRODUCTS	25MG/ML	A203732 001	Jul 03, 2014
AO	WEST-WARD PHARMS INT	25MG/ML	A074531 001	Aug 30, 1996

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

FLUPHENAZINE HYDROCHLORIDE

! PHARM ASSOC

5MG/ML

A074725 001 Sep 16, 1996

ELIXIR; ORAL

FLUPHENAZINE HYDROCHLORIDE

! PHARM ASSOC

2.5MG/5ML

A040146 001 Aug 21, 1996

INJECTABLE; INJECTION

FLUPHENAZINE HYDROCHLORIDE

! FRESenius KABI USA

2.5MG/ML

A089556 001 Apr 16, 1987

TABLET; ORAL

FLUPHENAZINE HYDROCHLORIDE

AB	AMNEAL	1MG	A213647 001	Jul 09, 2020
AB		2.5MG	A213647 002	Jul 09, 2020
AB		5MG	A213647 003	Jul 09, 2020
AB		10MG	A213647 004	Jul 09, 2020
AB	LANNETT CO INC	1MG	A089743 002	Aug 25, 1988
AB		2.5MG	A089743 003	Aug 25, 1988
AB	!	5MG	A089743 004	Aug 25, 1988
AB		10MG	A089743 001	Aug 25, 1988

FLURANDRENOLIDE

CREAM; TOPICAL

CORDRAN SP

AT	+! ALMIRALL	0.05%	N012806 002	
-----------	-------------	--------------	--------------------	--

FLURANDRENOLIDE

AT	CINTEX SVCS	0.05%	A205342 001	Apr 13, 2016
-----------	-------------	--------------	--------------------	--------------

LOTION; TOPICAL

CORDRAN

AT	+! ALMIRALL	0.05%	N013790 001	
-----------	-------------	--------------	--------------------	--

FLURANDRENOLIDE

AT	CINTEX SVCS	0.05%	A205343 001	Dec 22, 2016
-----------	-------------	--------------	--------------------	--------------

AT	PERRIGO UK FINCO	0.05%	A207133 001	Aug 30, 2016
-----------	------------------	--------------	--------------------	--------------

OINTMENT; TOPICAL

CORDRAN

AT	+! ALMIRALL	0.05%	N012806 001	
-----------	-------------	--------------	--------------------	--

FLURANDRENOLIDE

AT	TELGENT	0.05%	A207851 001	Dec 30, 2016
-----------	---------	--------------	--------------------	--------------

TAPE; TOPICAL

CORDRAN

+! ALMIRALL

0.004MG/SQ CM

N016455 001

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

FLURAZEPAM HYDROCHLORIDE

MYLAN PHARMS INC

15MG

A070345 002 Nov 27, 1985

!

30MG

A070345 001 Nov 27, 1985

FLURBIPROFEN

TABLET; ORAL

FLURBIPROFEN

! TEVA

100MG

A074431 001 May 31, 1995

FLURBIPROFEN SODIUM

SOLUTION/DROPS; OPHTHALMIC

FLURBIPROFEN SODIUM

AT	BAUSCH AND LOMB	0.03%	A074447 001	Jan 04, 1995
-----------	-----------------	--------------	--------------------	--------------

OCUFEN

AT	+! ALLERGAN	0.03%	N019404 001	Dec 31, 1986
-----------	-------------	--------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

FLUTAMIDE

CAPSULE; ORAL

FLUTAMIDE

AB	!	CIPLA	125MG	A075780 001	Sep 19, 2001
AB		PAR PHARM	125MG	A075298 001	Sep 18, 2001

FLUTEMETAMOL F-18

INJECTABLE; INTRAVENOUS

VIZAMYL

+	!	GE HEALTHCARE	121.5mCi/30ML (4.05mCi/ML)	N203137 002	Oct 25, 2013
---	---	---------------	----------------------------	-------------	--------------

FLUTICASON E FUROATE

POWDER; INHALATION

ARNUITY ELLIPTA

+	!	GLAXOSMITHKLINE	0.05MG/INH	N205625 003	May 17, 2018
+	!		0.1MG/INH	N205625 001	Aug 20, 2014
+	!		0.2MG/INH	N205625 002	Aug 20, 2014

FLUTICASON E FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE

POWDER; INHALATION

TRELEGY ELLIPTA

+	!	GLAXOSMITHKLINE	0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH	N209482 001	Sep 18, 2017
+	!		0.2MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH	N209482 002	Sep 09, 2020

FLUTICASON E FUROATE; VILANTEROL TRIFENATATE

POWDER; INHALATION

BREO ELLIPTA

+	!	GLAXO GRP LTD	0.1MG/INH;EQ 0.025MG BASE/INH	N204275 001	May 10, 2013
+	!		0.2MG/INH;EQ 0.025MG BASE/INH	N204275 002	Apr 30, 2015

FLUTICASON E PROPIONATE

AEROSOL, METERED; INHALATION

FLOVENT HFA

+	!	GLAXO GRP LTD	0.044MG/INH	N021433 003	May 14, 2004
+	!		0.11MG/INH	N021433 002	May 14, 2004
+	!		0.22MG/INH	N021433 001	May 14, 2004

CREAM; TOPICAL

FLUTICASON E PROPIONATE

AB		COSETTE	0.05%	A077055 001	Jun 30, 2006
AB		FOUGERA PHARMS	0.05%	A076451 001	May 14, 2004
AB	!	PERRIGO ISRAEL	0.05%	A076793 001	May 14, 2004

LOTION; TOPICAL

CUTIVATE

AB	+	!	FOUGERA PHARMS	0.05%	N021152 001	Mar 31, 2005
-----------	---	---	----------------	--------------	--------------------	--------------

FLUTICASON E PROPIONATE

AB		GLENMARK GENERICS	0.05%	A090759 001	May 02, 2011
AB		PERRIGO ISRAEL	0.05%	A091553 001	Jul 30, 2013

OINTMENT; TOPICAL

FLUTICASON E PROPIONATE

AB		COSETTE	0.005%	A077168 001	Mar 03, 2006
AB	!	PERRIGO NEW YORK	0.005%	A076668 001	May 14, 2004

POWDER; INHALATION

ARMONAIR DIGIHALER

+		TEVA PHARM	0.055MG/INH	N208798 004	Feb 20, 2020
+			0.113MG/INH	N208798 005	Feb 20, 2020
+	!		0.232MG/INH	N208798 006	Feb 20, 2020

FLOVENT DISKUS 100

+	!	GLAXO GRP LTD	0.1MG/INH	N020833 002	Sep 29, 2000
---	---	---------------	-----------	-------------	--------------

FLOVENT DISKUS 250

+	!	GLAXO GRP LTD	0.25MG/INH	N020833 003	Sep 29, 2000
---	---	---------------	------------	-------------	--------------

FLOVENT DISKUS 50

+	!	GLAXO GRP LTD	0.05MG/INH	N020833 001	Sep 29, 2000
---	---	---------------	------------	-------------	--------------

SPRAY, METERED; NASAL

FLUTICASON E PROPIONATE

AB		AKORN	0.05MG/SPRAY	A077570 001	Jan 16, 2008
AB		APOTEX INC	0.05MG/SPRAY	A077538 001	Sep 12, 2007
AB	!	HIKMA	0.05MG/SPRAY	A076504 001	Feb 22, 2006
AB		WOCKHARDT BIO AG	0.05MG/SPRAY	A078492 001	Jan 09, 2012

XHANCE

+	!	OPTINOSE US INC	0.093MG	N209022 001	Sep 18, 2017
---	---	-----------------	---------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

AEROSOL, METERED; INHALATION

ADVAIR HFA

+	GLAXO GRP LTD	0.045MG/INH;EQ 0.021MG BASE/INH	N021254	001	Jun 08, 2006
+		0.115MG/INH;EQ 0.021MG BASE/INH	N021254	002	Jun 08, 2006
+		0.23MG/INH;EQ 0.021MG BASE/INH	N021254	003	Jun 08, 2006

POWDER; INHALATION

ADVAIR DISKUS 100/50

AB	+	GLAXO GRP LTD	<u>0.1MG/INH;EQ 0.05MG BASE/INH</u>	<u>N021077</u>	<u>001</u>	Aug 24, 2000
----	---	---------------	-------------------------------------	----------------	------------	--------------

ADVAIR DISKUS 250/50

AB	+	GLAXO GRP LTD	<u>0.25MG/INH;EQ 0.05MG BASE/INH</u>	<u>N021077</u>	<u>002</u>	Aug 24, 2000
----	---	---------------	--------------------------------------	----------------	------------	--------------

ADVAIR DISKUS 500/50

AB	+	GLAXO GRP LTD	<u>0.5MG/INH;EQ 0.05MG BASE/INH</u>	<u>N021077</u>	<u>003</u>	Aug 24, 2000
----	---	---------------	-------------------------------------	----------------	------------	--------------

FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE

AB		HIKMA	<u>0.1MG/INH;EQ 0.05MG BASE/INH</u>	<u>A203433</u>	<u>001</u>	Dec 17, 2020
----	--	-------	-------------------------------------	----------------	------------	--------------

AB			<u>0.25MG/INH;EQ 0.05MG BASE/INH</u>	<u>A203433</u>	<u>002</u>	Dec 17, 2020
----	--	--	--------------------------------------	----------------	------------	--------------

WIXELA INHUB

AB		MYLAN	<u>0.1MG/INH;EQ 0.05MG BASE/INH</u>	<u>A208891</u>	<u>001</u>	Jan 30, 2019
----	--	-------	-------------------------------------	----------------	------------	--------------

AB			<u>0.25MG/INH;EQ 0.05MG BASE/INH</u>	<u>A208891</u>	<u>002</u>	Jan 30, 2019
----	--	--	--------------------------------------	----------------	------------	--------------

AB			<u>0.5MG/INH;EQ 0.05MG BASE/INH</u>	<u>A208891</u>	<u>003</u>	Jan 30, 2019
----	--	--	-------------------------------------	----------------	------------	--------------

AIRDUO DIGIHALER

+	TEVA PHARM	0.055MG/INH;EQ 0.014MG BASE/INH	N208799	004	Jul 12, 2019
---	------------	---------------------------------	---------	-----	--------------

+		0.113MG/INH;EQ 0.014MG BASE/INH	N208799	005	Jul 12, 2019
---	--	---------------------------------	---------	-----	--------------

+		0.232MG/INH;EQ 0.014MG BASE/INH	N208799	006	Jul 12, 2019
---	--	---------------------------------	---------	-----	--------------

AIRDUO RESPICLICK

+	TEVA PHARM	0.055MG/INH;EQ 0.014MG BASE/INH	N208799	001	Jan 27, 2017
---	------------	---------------------------------	---------	-----	--------------

+		0.113MG/INH;EQ 0.014MG BASE/INH	N208799	002	Jan 27, 2017
---	--	---------------------------------	---------	-----	--------------

+		0.232MG/INH;EQ 0.014MG BASE/INH	N208799	003	Jan 27, 2017
---	--	---------------------------------	---------	-----	--------------

FLUVASTATIN SODIUM

CAPSULE; ORAL

FLUVASTATIN SODIUM

AB		MYLAN PHARMS INC	<u>EQ 20MG BASE</u>	<u>A090595</u>	<u>001</u>	Apr 11, 2012
----	--	------------------	---------------------	----------------	------------	--------------

AB	!		<u>EQ 40MG BASE</u>	<u>A090595</u>	<u>002</u>	Apr 11, 2012
----	---	--	---------------------	----------------	------------	--------------

AB		TEVA PHARMS	<u>EQ 20MG BASE</u>	<u>A078407</u>	<u>001</u>	Jun 12, 2012
----	--	-------------	---------------------	----------------	------------	--------------

AB			<u>EQ 40MG BASE</u>	<u>A078407</u>	<u>002</u>	Jun 12, 2012
----	--	--	---------------------	----------------	------------	--------------

TABLET, EXTENDED RELEASE; ORAL

FLUVASTATIN SODIUM

AB		TEVA PHARMS USA	<u>EQ 80MG BASE</u>	<u>A079011</u>	<u>001</u>	Jan 27, 2016
----	--	-----------------	---------------------	----------------	------------	--------------

LESCOL XL

AB	+	NOVARTIS	<u>EQ 80MG BASE</u>	<u>N021192</u>	<u>001</u>	Oct 06, 2000
----	---	----------	---------------------	----------------	------------	--------------

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

FLUVOXAMINE MALEATE

AB		ACTAVIS ELIZABETH	<u>100MG</u>	<u>A091482</u>	<u>001</u>	Apr 23, 2013
----	--	-------------------	--------------	----------------	------------	--------------

AB	!		<u>150MG</u>	<u>A091482</u>	<u>002</u>	Nov 18, 2013
----	---	--	--------------	----------------	------------	--------------

AB		ANCHEN PHARMS	<u>100MG</u>	<u>A091476</u>	<u>001</u>	Mar 13, 2013
----	--	---------------	--------------	----------------	------------	--------------

AB			<u>150MG</u>	<u>A091476</u>	<u>002</u>	Mar 13, 2013
----	--	--	--------------	----------------	------------	--------------

AB		BIONPHARMA INC	<u>100MG</u>	<u>A212182</u>	<u>002</u>	Sep 16, 2020
----	--	----------------	--------------	----------------	------------	--------------

AB			<u>150MG</u>	<u>A212182</u>	<u>001</u>	May 11, 2020
----	--	--	--------------	----------------	------------	--------------

TABLET; ORAL

FLUVOXAMINE MALEATE

AB		APOTEX	<u>25MG</u>	<u>A075902</u>	<u>001</u>	May 07, 2001
----	--	--------	-------------	----------------	------------	--------------

AB			<u>50MG</u>	<u>A075902</u>	<u>002</u>	May 07, 2001
----	--	--	-------------	----------------	------------	--------------

AB			<u>100MG</u>	<u>A075902</u>	<u>003</u>	May 07, 2001
----	--	--	--------------	----------------	------------	--------------

AB		UPSHER SMITH LABS	<u>25MG</u>	<u>A075888</u>	<u>001</u>	Nov 29, 2000
----	--	-------------------	-------------	----------------	------------	--------------

AB			<u>50MG</u>	<u>A075888</u>	<u>002</u>	Nov 29, 2000
----	--	--	-------------	----------------	------------	--------------

AB	!		<u>100MG</u>	<u>A075888</u>	<u>003</u>	Nov 29, 2000
----	---	--	--------------	----------------	------------	--------------

LUVOX

AB		ANI PHARMS	<u>25MG</u>	<u>N021519</u>	<u>001</u>	Dec 20, 2007
----	--	------------	-------------	----------------	------------	--------------

AB			<u>50MG</u>	<u>N021519</u>	<u>002</u>	Dec 20, 2007
----	--	--	-------------	----------------	------------	--------------

AB			<u>100MG</u>	<u>N021519</u>	<u>003</u>	Dec 20, 2007
----	--	--	--------------	----------------	------------	--------------

FOLIC ACID

INJECTABLE; INJECTION

FOLIC ACID

AP	!	FRESENIUS KABI USA	<u>5MG/ML</u>	<u>A089202</u>	<u>001</u>	Feb 18, 1986
----	---	--------------------	---------------	----------------	------------	--------------

AP		XGEN PHARMS	<u>5MG/ML</u>	<u>A202522</u>	<u>001</u>	Nov 06, 2019
----	--	-------------	---------------	----------------	------------	--------------

TABLET; ORAL

FOLIC ACID

AA	!	AMNEAL PHARM	<u>1MG</u>	<u>A040625</u>	<u>001</u>	Jul 21, 2005
----	---	--------------	------------	----------------	------------	--------------

AA		ATHEM	<u>1MG</u>	<u>A211064</u>	<u>001</u>	Mar 08, 2019
----	--	-------	------------	----------------	------------	--------------

AA		CADILA PHARMS LTD	<u>1MG</u>	<u>A202437</u>	<u>001</u>	Jan 27, 2014
----	--	-------------------	------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

FOLIC ACID

TABLET; ORAL

FOLIC ACID

<u>AA</u>	CHARTWELL MOLECULAR	<u>1MG</u>	<u>A090035</u>	<u>001</u>	Jun 09, 2009
<u>AA</u>	LEADING PHARMA LLC	<u>1MG</u>	<u>A040796</u>	<u>001</u>	Jan 12, 2009
<u>AA</u>	NUVO PHARMS INC	<u>1MG</u>	<u>A204418</u>	<u>001</u>	Jul 28, 2015
<u>AA</u>	QINGDAO BAHEAL PHARM	<u>1MG</u>	<u>A091145</u>	<u>001</u>	Jul 12, 2013
<u>AA</u>	! WATSON LABS	<u>1MG</u>	<u>A080680</u>	<u>001</u>	

FOMEPIZOLE

INJECTABLE; INJECTION

FOMEPIZOLE

<u>AP</u>	AM REGENT	<u>1.5GM/1.5ML (1GM/ML)</u>	<u>A078368</u>	<u>001</u>	Dec 14, 2007
<u>AP</u>	! MYLAN INSTITUTIONAL	<u>1.5GM/1.5ML (1GM/ML)</u>	<u>A078639</u>	<u>001</u>	Mar 03, 2008
<u>AP</u>	NAVINTA LLC	<u>1.5GM/1.5ML (1GM/ML)</u>	<u>A078537</u>	<u>001</u>	Mar 06, 2008

FONDAPARINUX SODIUM

INJECTABLE; SUBCUTANEOUS

ARIXTRA

<u>AP</u>	+! MYLAN IRELAND LTD	<u>2.5MG/0.5ML</u>	<u>N021345</u>	<u>001</u>	Dec 07, 2001
<u>AP</u>	+!	<u>5MG/0.4ML</u>	<u>N021345</u>	<u>002</u>	May 28, 2004
<u>AP</u>	+!	<u>7.5MG/0.6ML</u>	<u>N021345</u>	<u>003</u>	May 28, 2004
<u>AP</u>	+!	<u>10MG/0.8ML</u>	<u>N021345</u>	<u>004</u>	May 28, 2004

FONDAPARINUX SODIUM

<u>AP</u>	AUROBINDO PHARMA LTD	<u>2.5MG/0.5ML</u>	<u>A206918</u>	<u>001</u>	Dec 26, 2017
<u>AP</u>		<u>5MG/0.4ML</u>	<u>A206918</u>	<u>002</u>	Dec 26, 2017
<u>AP</u>		<u>7.5MG/0.6ML</u>	<u>A206918</u>	<u>003</u>	Dec 26, 2017
<u>AP</u>		<u>10MG/0.8ML</u>	<u>A206918</u>	<u>004</u>	Dec 26, 2017
<u>AP</u>	DR REDDYS LABS LTD	<u>2.5MG/0.5ML</u>	<u>A091316</u>	<u>001</u>	Jul 11, 2011
<u>AP</u>		<u>5MG/0.4ML</u>	<u>A091316</u>	<u>002</u>	Jul 11, 2011
<u>AP</u>		<u>7.5MG/0.6ML</u>	<u>A091316</u>	<u>003</u>	Jul 11, 2011
<u>AP</u>		<u>10MG/0.8ML</u>	<u>A091316</u>	<u>004</u>	Jul 11, 2011
<u>AP</u>	JIANGSU HENGRUI MED	<u>2.5MG/0.5ML</u>	<u>A206812</u>	<u>001</u>	May 15, 2018
<u>AP</u>		<u>5MG/0.4ML</u>	<u>A206812</u>	<u>002</u>	May 15, 2018
<u>AP</u>		<u>7.5MG/0.6ML</u>	<u>A206812</u>	<u>003</u>	May 15, 2018
<u>AP</u>		<u>10MG/0.8ML</u>	<u>A206812</u>	<u>004</u>	May 15, 2018
<u>AP</u>	SCINOPHARM TAIWAN	<u>2.5MG/0.5ML</u>	<u>A208615</u>	<u>001</u>	Nov 14, 2018
<u>AP</u>		<u>5MG/0.4ML</u>	<u>A208615</u>	<u>002</u>	Nov 14, 2018
<u>AP</u>		<u>7.5MG/0.6ML</u>	<u>A208615</u>	<u>003</u>	Nov 14, 2018
<u>AP</u>		<u>10MG/0.8ML</u>	<u>A208615</u>	<u>004</u>	Nov 14, 2018

FORMOTEROL FUMARATE

SOLUTION; INHALATION

PERFOROMIST

+!	MYLAN SPECLT	0.02MG/2ML	N022007	001	May 11, 2007
----	--------------	------------	---------	-----	--------------

FORMOTEROL FUMARATE; GLYCOPYRROLATE

AEROSOL, METERED; INHALATION

BEVESPI AEROSPHERE

+!	ASTRAZENECA PHARMS	0.0048MG/INH;0.0090MG/INH	N208294	001	Apr 25, 2016
----	--------------------	---------------------------	---------	-----	--------------

FORMOTEROL FUMARATE; MOMETASONE FUROATE

AEROSOL, METERED; INHALATION

DULERA

+	MERCK SHARP DOHME	0.005MG/INH;0.05MG/INH	N022518	003	Aug 12, 2019
+!		0.005MG/INH;0.1MG/INH	N022518	001	Jun 22, 2010
+!		0.005MG/INH;0.2MG/INH	N022518	002	Jun 22, 2010

FOSAMPRENAVIR CALCIUM

SUSPENSION; ORAL

LEXIVA

+!	VIIV HLTHCARE	EQ 50MG BASE/ML	N022116	001	Jun 14, 2007
----	---------------	-----------------	---------	-----	--------------

TABLET; ORAL

FOSAMPRENAVIR CALCIUM

<u>AB</u>	MYLAN	<u>EQ 700MG BASE</u>	<u>A204060</u>	<u>001</u>	Apr 15, 2016
<u>AB</u>	SUN PHARM	<u>EQ 700MG BASE</u>	<u>A204024</u>	<u>001</u>	Nov 20, 2019
<u>AB</u>	+!	<u>EQ 700MG BASE</u>	<u>N021548</u>	<u>001</u>	Oct 20, 2003

PRESCRIPTION DRUG PRODUCT LIST

FOSAPREPITANT DIMEGLUMINE

POWDER; INTRAVENOUS

EMEND

<u>AP</u>	<u>+!</u>	MERCK AND CO INC	<u>EQ 150MG BASE/VIAL</u>	<u>N022023 002</u>	Nov 12, 2010
<u>FOSAPREPITANT DIMEGLUMINE</u>					
<u>AP</u>		ACCORD HLTHCARE	<u>EQ 150MG BASE/VIAL</u>	<u>A204025 001</u>	Aug 26, 2020
<u>AP</u>		APOTEX	<u>EQ 150MG BASE/VIAL</u>	<u>A205020 001</u>	Sep 05, 2019
<u>AP</u>		BAXTER HLTHCARE CORP	<u>EQ 150MG BASE/VIAL</u>	<u>A211860 001</u>	Sep 05, 2019
<u>AP</u>		BE PHARMS	<u>EQ 150MG BASE/VIAL</u>	<u>A212309 001</u>	Sep 05, 2019
<u>AP</u>		DR REDDYS	<u>EQ 150MG BASE/VIAL</u>	<u>A211160 001</u>	Dec 09, 2020
<u>AP</u>		FRESENIUS KABI USA	<u>EQ 150MG BASE/VIAL</u>	<u>A206197 001</u>	Jun 09, 2016
<u>AP</u>		LUPIN LTD	<u>EQ 150MG BASE/VIAL</u>	<u>A210689 001</u>	Sep 05, 2019
<u>AP</u>		MSN	<u>EQ 150MG BASE/VIAL</u>	<u>A209965 001</u>	Sep 05, 2019
<u>AP</u>		MYLAN LABS LTD	<u>EQ 150MG BASE/VIAL</u>	<u>A204015 002</u>	Sep 05, 2019
<u>AP</u>		NAVINTA LLC	<u>EQ 150MG BASE/VIAL</u>	<u>A212957 002</u>	Aug 20, 2020
<u>AP</u>		QILU	<u>EQ 150MG BASE/VIAL</u>	<u>A213106 001</u>	Sep 08, 2020
<u>AP</u>		SANDOZ INC	<u>EQ 150MG BASE/VIAL</u>	<u>A203939 001</u>	Dec 08, 2020
<u>AP</u>		SUNGEN PHARMA	<u>EQ 150MG BASE/VIAL</u>	<u>A211624 001</u>	Sep 05, 2019
		MYLAN LABS LTD	EQ 115MG BASE/VIAL	A204015 001	Sep 05, 2019
		TEVA PHARMS USA	EQ 150MG BASE/VIAL	N210064 001	Sep 05, 2019

FOSCARNET SODIUM

INJECTABLE; INJECTION

FOSCAVIR

<u>+!</u>	CLINIGEN HLTHCARE	2.4GM/100ML	<u>N020068 001</u>	Sep 27, 1991
-----------	-------------------	-------------	--------------------	--------------

FOSEFOMYCIN TROMETHAMINE

FOR SOLUTION; ORAL

FOSEFOMYCIN TROMETHAMINE

<u>AA</u>		XIROMED	<u>EQ 3GM BASE/PACKET</u>	<u>A212548 001</u>	Oct 06, 2020
<u>MONUROL</u>					
<u>AA</u>	<u>+!</u>	ZAMBON SPA	<u>EQ 3GM BASE/PACKET</u>	<u>N050717 001</u>	Dec 19, 1996

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

<u>AB</u>		APOTEX INC	<u>10MG</u>	<u>A076906 001</u>	May 17, 2005
<u>AB</u>			<u>20MG</u>	<u>A076906 002</u>	May 17, 2005
<u>AB</u>			<u>40MG</u>	<u>A076906 003</u>	May 17, 2005
<u>AB</u>		AUROBINDO PHARMA LTD	<u>10MG</u>	<u>A091163 001</u>	Mar 30, 2011
<u>AB</u>			<u>20MG</u>	<u>A091163 002</u>	Mar 30, 2011
<u>AB</u>			<u>40MG</u>	<u>A091163 003</u>	Mar 30, 2011
<u>AB</u>		INVAGEN PHARMS	<u>10MG</u>	<u>A077222 001</u>	Apr 20, 2005
<u>AB</u>			<u>20MG</u>	<u>A077222 002</u>	Apr 20, 2005
<u>AB</u>			<u>40MG</u>	<u>A077222 003</u>	Apr 20, 2005
<u>AB</u>		PRINSTON INC	<u>10MG</u>	<u>A205670 001</u>	Aug 29, 2016
<u>AB</u>			<u>20MG</u>	<u>A205670 002</u>	Aug 29, 2016
<u>AB</u>			<u>40MG</u>	<u>A205670 003</u>	Aug 29, 2016
<u>AB</u>		TEVA	<u>10MG</u>	<u>A076139 001</u>	Nov 25, 2003
<u>AB</u>			<u>20MG</u>	<u>A076139 002</u>	Nov 25, 2003
<u>AB</u>	<u>!</u>		<u>40MG</u>	<u>A076139 003</u>	Nov 25, 2003
<u>AB</u>		UPSHER SMITH LABS	<u>10MG</u>	<u>A076483 001</u>	Apr 23, 2004
<u>AB</u>			<u>20MG</u>	<u>A076483 002</u>	Apr 23, 2004
<u>AB</u>			<u>40MG</u>	<u>A076483 003</u>	Apr 23, 2004

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

<u>AB</u>		AUROBINDO PHARMA	<u>10MG;12.5MG</u>	<u>A079245 001</u>	Jul 09, 2009
<u>AB</u>	<u>!</u>		<u>20MG;12.5MG</u>	<u>A079245 002</u>	Jul 09, 2009
<u>AB</u>		INVAGEN PHARMS	<u>10MG;12.5MG</u>	<u>A090228 001</u>	Jul 09, 2009
<u>AB</u>			<u>20MG;12.5MG</u>	<u>A090228 002</u>	Jul 09, 2009
<u>AB</u>		SANDOZ	<u>10MG;12.5MG</u>	<u>A076961 001</u>	Sep 28, 2005
<u>AB</u>			<u>20MG;12.5MG</u>	<u>A076961 002</u>	Sep 28, 2005

FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE

POWDER; INTRAVENOUS

AKYNZEO

<u>+!</u>	HELSINN HLTHCARE	EQ 235MG BASE/VIAL;EQ 0.25MG BASE/VIAL	N210493 001	Apr 19, 2018
-----------	------------------	--	-------------	--------------

SOLUTION; INTRAVENOUS

AKYNZEO

<u>+!</u>	HELSINN HLTHCARE	EQ 235MG BASE/20ML (EQ 11.75MG BASE/ML);EQ 0.25MG BASE/20ML (EQ 0.0125)	N210493 002	May 27, 2020
-----------	------------------	--	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE

SOLUTION; INTRAVENOUS

AKYNZEO

MG BASE/ML)

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

CEREBYX**AP** +! PARKE DAVIS **EQ 50MG PHENYTOIN NA/ML** **N020450 001** Aug 05, 1996**FOSPHENYTOIN SODIUM****AP** FRESENIUS KABI USA **EQ 50MG PHENYTOIN NA/ML** **A078052 001** Aug 06, 2007**AP** HIKMA FARMACEUTICA **EQ 50MG PHENYTOIN NA/ML** **A078765 001** Dec 02, 2009**AP** MYLAN LABS LTD **EQ 50MG PHENYTOIN NA/ML** **A078736 001** Jun 08, 2010**AP** SUN PHARM **EQ 50MG PHENYTOIN NA/ML** **A078417 001** Mar 18, 2008**AP** WEST-WARD PHARMS **EQ 50MG PHENYTOIN NA/ML** **A077481 001** Aug 06, 2007

INT

AP **EQ 50MG PHENYTOIN NA/ML** **A077989 001** Aug 06, 2007**AP** WOCKHARDT **EQ 50MG PHENYTOIN NA/ML** **A078137 001** Aug 06, 2007

SOLUTION; INTRAVENOUS

SESQUIENT

+! SEDOR PHARMS LLC EQ 100MG PHENYTOIN NA/2ML (EQ 50MG PHENYTOIN NA/ML) N210864 001 Nov 05, 2020

+! EQ 500MG PHENYTOIN NA/10ML (EQ 50MG PHENYTOIN NA/ML) N210864 002 Nov 05, 2020

FOSTAMATINIB DISODIUM

TABLET; ORAL

TAVALISSE

+ RIGEL PHARMS INC EQ 100MG BASE N209299 001 Apr 17, 2018

+! EQ 150MG BASE N209299 002 Apr 17, 2018

FOSTEMSAVIR TROMETHAMINE

TABLET, EXTENDED RELEASE; ORAL

RUKOBIA

+! VIIV HLTHCARE EQ 600MG BASE N212950 001 Jul 02, 2020

FROVATRIPTAN SUCCINATE

TABLET; ORAL

FROVA**AB** +! ENDO PHARMS **EQ 2.5MG BASE** **N021006 001** Nov 08, 2001**FROVATRIPTAN SUCCINATE****AB** AMNEAL PHARMS CO **EQ 2.5MG BASE** **A211292 001** Nov 06, 2018**AB** GLENMARK PHARMS LTD **EQ 2.5MG BASE** **A204730 001** Mar 11, 2016**AB** MYLAN **EQ 2.5MG BASE** **A202931 001** Aug 28, 2014FULVESTRANT

INJECTABLE; INTRAMUSCULAR

FASLODEX**AO** +! ASTRAZENECA **50MG/ML** **N021344 001** Apr 25, 2002**FULVESTRANT****AO** ACCORD HLTHCARE **50MG/ML** **A211689 001** Nov 17, 2020**AO** AMNEAL **50MG/ML** **A210044 001** Mar 04, 2019**AO** CHIA TAI TIANQING **50MG/ML** **A211422 001** Feb 07, 2020**AO** DR REDDYS **50MG/ML** **A209246 001** Aug 07, 2020**AO** GLENMARK PHARMS INC **50MG/ML** **A207754 001** Aug 22, 2019**AO** HBT LABS INC **50MG/ML** **A209714 001** Nov 21, 2019**AO** MYLAN INSTITUTIONAL **50MG/ML** **A208811 001** Jul 23, 2019**AO** SAGENT PHARMS INC **50MG/ML** **A205871 001** Aug 22, 2019**AO** SANDOZ INC **50MG/ML** **A205935 001** May 14, 2019

SOLUTION; INTRAMUSCULAR

FULVESTRANT

FRESENIUS KABI USA 250MG/5ML (50MG/ML) N210326 001 May 20, 2019

TEVA PHARMS USA INC 250MG/5ML (50MG/ML) N210063 001 Aug 19, 2019

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE**AP** AREVA PHARMS **10MG/ML** **A208435 001** Dec 18, 2020**AP** AUROBINDO PHARMA **10MG/ML** **A212174 001** May 03, 2019

LTD

AP ! BAXTER HLTHCARE **10MG/ML** **A202747 001** Jan 27, 2014

CORP

AP EMCURE PHARMS LTD **10MG/ML** **A203428 001** Aug 26, 2014**AP** FRESENIUS KABI USA **10MG/ML** **N018902 001** May 22, 1984**AP** GLAND PHARMA LTD **10MG/ML** **A213902 001** Jul 01, 2020**AP** HOSPIRA **10MG/ML** **A075241 001** May 28, 1999

PRESCRIPTION DRUG PRODUCT LIST

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

<u>AP</u>		<u>10MG/ML</u>	<u>N018667</u>	<u>001</u>	May 28, 1982
<u>AP</u>	WOCKHARDT	<u>10MG/ML</u>	<u>A077941</u>	<u>001</u>	Mar 22, 2007

SOLUTION; ORAL

FUROSEMIDE

<u>AA</u>	!	HIKMA	<u>10MG/ML</u>	<u>A070434</u>	<u>001</u>	Apr 22, 1987
<u>AA</u>		WOCKHARDT BIO AG	<u>10MG/ML</u>	<u>A070655</u>	<u>001</u>	Oct 02, 1987
		HIKMA	<u>40MG/5ML</u>	<u>A070433</u>	<u>001</u>	Apr 22, 1987

TABLET; ORAL

FUROSEMIDE

<u>AB</u>		HIKMA	<u>20MG</u>	<u>N018823</u>	<u>001</u>	Nov 10, 1983
<u>AB</u>			<u>40MG</u>	<u>N018823</u>	<u>002</u>	Nov 10, 1983
<u>AB</u>			<u>80MG</u>	<u>A070086</u>	<u>001</u>	Jan 24, 1986
<u>AB</u>		IPCA LABS LTD	<u>20MG</u>	<u>A078010</u>	<u>001</u>	Sep 18, 2006
<u>AB</u>			<u>40MG</u>	<u>A078010</u>	<u>002</u>	Sep 18, 2006
<u>AB</u>			<u>80MG</u>	<u>A078010</u>	<u>003</u>	Sep 18, 2006
<u>AB</u>		LEADING PHARMA LLC	<u>20MG</u>	<u>A077293</u>	<u>001</u>	Nov 09, 2005
<u>AB</u>			<u>40MG</u>	<u>A077293</u>	<u>002</u>	Nov 09, 2005
<u>AB</u>			<u>80MG</u>	<u>A077293</u>	<u>003</u>	Nov 09, 2005
<u>AB</u>		MYLAN	<u>20MG</u>	<u>N018487</u>	<u>001</u>	
<u>AB</u>			<u>40MG</u>	<u>N018487</u>	<u>002</u>	
<u>AB</u>			<u>80MG</u>	<u>A070082</u>	<u>001</u>	Oct 29, 1986
<u>AB</u>		PRINSTON INC	<u>20MG</u>	<u>A076796</u>	<u>001</u>	Mar 26, 2004
<u>AB</u>			<u>40MG</u>	<u>A076796</u>	<u>002</u>	Mar 26, 2004
<u>AB</u>			<u>80MG</u>	<u>A076796</u>	<u>003</u>	Mar 26, 2004
<u>AB</u>		SANDOZ	<u>20MG</u>	<u>N018569</u>	<u>002</u>	
<u>AB</u>			<u>40MG</u>	<u>N018569</u>	<u>001</u>	
<u>AB</u>			<u>80MG</u>	<u>N018569</u>	<u>005</u>	Aug 14, 1984

LASIX

<u>AB</u>	+	US PHARM HOLDINGS	<u>20MG</u>	<u>N016273</u>	<u>002</u>	
<u>AB</u>	+		<u>40MG</u>	<u>N016273</u>	<u>001</u>	
<u>AB</u>	+	!	<u>80MG</u>	<u>N016273</u>	<u>003</u>	

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

<u>AB</u>		ACI HEALTHCARE LTD	<u>100MG</u>	<u>A206943</u>	<u>001</u>	May 14, 2018
<u>AB</u>			<u>300MG</u>	<u>A206943</u>	<u>002</u>	May 14, 2018
<u>AB</u>			<u>400MG</u>	<u>A206943</u>	<u>003</u>	May 14, 2018
<u>AB</u>		ACTAVIS ELIZABETH	<u>100MG</u>	<u>A075350</u>	<u>001</u>	Sep 12, 2003
<u>AB</u>			<u>300MG</u>	<u>A075350</u>	<u>002</u>	Sep 12, 2003
<u>AB</u>			<u>400MG</u>	<u>A075350</u>	<u>003</u>	Sep 12, 2003
<u>AB</u>		ALKEM	<u>100MG</u>	<u>A090858</u>	<u>001</u>	Dec 17, 2010
<u>AB</u>			<u>300MG</u>	<u>A090858</u>	<u>002</u>	Dec 17, 2010
<u>AB</u>			<u>400MG</u>	<u>A090858</u>	<u>003</u>	Dec 17, 2010
<u>AB</u>		AMNEAL PHARMS NY	<u>100MG</u>	<u>A078428</u>	<u>001</u>	Jul 25, 2007
<u>AB</u>			<u>300MG</u>	<u>A078428</u>	<u>002</u>	Jul 25, 2007
<u>AB</u>			<u>400MG</u>	<u>A078428</u>	<u>003</u>	Jul 25, 2007
<u>AB</u>		AUROBINDO PHARMA LTD	<u>100MG</u>	<u>A078787</u>	<u>001</u>	Jan 31, 2008
<u>AB</u>			<u>300MG</u>	<u>A078787</u>	<u>002</u>	Jan 31, 2008
<u>AB</u>			<u>400MG</u>	<u>A078787</u>	<u>003</u>	Jan 31, 2008
<u>AB</u>		CSPC OUYI	<u>100MG</u>	<u>A075477</u>	<u>001</u>	Mar 23, 2005
<u>AB</u>			<u>300MG</u>	<u>A075477</u>	<u>002</u>	Mar 23, 2005
<u>AB</u>			<u>400MG</u>	<u>A075477</u>	<u>003</u>	Mar 23, 2005
<u>AB</u>		EPIC PHARMA LLC	<u>100MG</u>	<u>A207099</u>	<u>001</u>	Mar 24, 2017
<u>AB</u>			<u>300MG</u>	<u>A207099</u>	<u>002</u>	Mar 24, 2017
<u>AB</u>			<u>400MG</u>	<u>A207099</u>	<u>003</u>	Mar 24, 2017
<u>AB</u>		GRANULES	<u>100MG</u>	<u>A075360</u>	<u>001</u>	Apr 06, 2005
<u>AB</u>			<u>300MG</u>	<u>A075360</u>	<u>002</u>	Apr 06, 2005
<u>AB</u>			<u>400MG</u>	<u>A075360</u>	<u>003</u>	Apr 06, 2005
<u>AB</u>		INVAGEN PHARMS	<u>100MG</u>	<u>A090705</u>	<u>001</u>	Dec 30, 2009
<u>AB</u>			<u>300MG</u>	<u>A090705</u>	<u>002</u>	Dec 30, 2009
<u>AB</u>			<u>400MG</u>	<u>A090705</u>	<u>003</u>	Dec 30, 2009
<u>AB</u>		MARKSANS PHARMA	<u>100MG</u>	<u>A090007</u>	<u>001</u>	Jul 21, 2011
<u>AB</u>			<u>300MG</u>	<u>A090007</u>	<u>002</u>	Jul 21, 2011
<u>AB</u>			<u>400MG</u>	<u>A090007</u>	<u>003</u>	Jul 21, 2011
<u>AB</u>		SCIEGEN PHARMS INC	<u>100MG</u>	<u>A204989</u>	<u>001</u>	Feb 18, 2016
<u>AB</u>			<u>300MG</u>	<u>A204989</u>	<u>002</u>	Feb 18, 2016
<u>AB</u>			<u>400MG</u>	<u>A204989</u>	<u>003</u>	Feb 18, 2016
<u>AB</u>		STRIDES PHARMA	<u>100MG</u>	<u>A211314</u>	<u>001</u>	Oct 16, 2018

PRESCRIPTION DRUG PRODUCT LIST

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

<u>AB</u>		<u>300MG</u>	<u>A211314 002</u>	Oct 16, 2018
<u>AB</u>		<u>400MG</u>	<u>A211314 003</u>	Oct 16, 2018
<u>AB</u>	SUN PHARM INDS LTD	<u>100MG</u>	<u>A077242 001</u>	Aug 24, 2006
<u>AB</u>		<u>300MG</u>	<u>A077242 002</u>	Aug 24, 2006
<u>AB</u>		<u>400MG</u>	<u>A077242 003</u>	Aug 24, 2006
<u>AB</u>	TARO	<u>100MG</u>	<u>A077261 001</u>	Aug 02, 2013
<u>AB</u>		<u>300MG</u>	<u>A077261 002</u>	Aug 02, 2013
<u>AB</u>		<u>400MG</u>	<u>A077261 003</u>	Aug 02, 2013
<u>AB</u>	ZHEJIANG YONGTAI	<u>100MG</u>	<u>A213603 001</u>	Aug 17, 2020
<u>AB</u>		<u>300MG</u>	<u>A213603 002</u>	Aug 17, 2020
<u>AB</u>		<u>400MG</u>	<u>A213603 003</u>	Aug 17, 2020

NEURONTIN

<u>AB</u>	+ UPJOHN	<u>100MG</u>	<u>N020235 001</u>	Dec 30, 1993
<u>AB</u>	+	<u>300MG</u>	<u>N020235 002</u>	Dec 30, 1993
<u>AB</u>	+	<u>400MG</u>	<u>N020235 003</u>	Dec 30, 1993

SOLUTION; ORAL

GABAPENTIN

<u>AA</u>	ACELLA PHARMS LLC	<u>250MG/5ML</u>	<u>A076403 001</u>	May 01, 2012
<u>AA</u>	AKORN	<u>250MG/5ML</u>	<u>A078974 001</u>	Feb 18, 2011
<u>AA</u>	AMNEAL PHARMS	<u>250MG/5ML</u>	<u>A202024 001</u>	Mar 23, 2012
<u>AA</u>	TARO	<u>250MG/5ML</u>	<u>A076672 001</u>	Jul 03, 2013
<u>AA</u>	TRIS PHARMA INC	<u>250MG/5ML</u>	<u>A091286 001</u>	Mar 14, 2016

NEURONTIN

<u>AA</u>	+	UPJOHN	<u>250MG/5ML</u>	<u>N021129 001</u>	Mar 02, 2000
-----------	---	--------	------------------	--------------------	--------------

TABLET; ORAL

GABAPENTIN

<u>AB</u>	ACI HEALTHCARE LTD	<u>600MG</u>	<u>A203244 002</u>	Jul 12, 2013
<u>AB</u>		<u>800MG</u>	<u>A203244 001</u>	Jul 12, 2013
<u>AB</u>	ACTAVIS ELIZABETH	<u>600MG</u>	<u>A075694 001</u>	Oct 21, 2004
<u>AB</u>		<u>800MG</u>	<u>A075694 002</u>	Oct 21, 2004
<u>AB</u>	ALKEM LABS LTD	<u>600MG</u>	<u>A206402 001</u>	Dec 23, 2015
<u>AB</u>		<u>800MG</u>	<u>A206402 002</u>	Dec 23, 2015
<u>AB</u>	APOTEX INC	<u>100MG</u>	<u>A077894 001</u>	Oct 10, 2006
<u>AB</u>		<u>300MG</u>	<u>A077894 002</u>	Oct 10, 2006
<u>AB</u>		<u>400MG</u>	<u>A077894 003</u>	Oct 10, 2006
<u>AB</u>	AUROBINDO PHARMA LTD	<u>600MG</u>	<u>A200651 001</u>	Oct 06, 2011
<u>AB</u>		<u>800MG</u>	<u>A200651 002</u>	Oct 06, 2011
<u>AB</u>	CSPC OUYI	<u>600MG</u>	<u>A207057 001</u>	Oct 26, 2017
<u>AB</u>		<u>800MG</u>	<u>A207057 002</u>	Oct 26, 2017
<u>AB</u>	GLENMARK PHARMS LTD	<u>600MG</u>	<u>A077662 001</u>	Aug 18, 2006
<u>AB</u>		<u>800MG</u>	<u>A077662 002</u>	Aug 18, 2006
<u>AB</u>	INVAGEN PHARMS	<u>600MG</u>	<u>A202764 001</u>	Oct 16, 2012
<u>AB</u>		<u>800MG</u>	<u>A202764 002</u>	Oct 16, 2012
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>100MG</u>	<u>A076017 001</u>	Apr 28, 2004
<u>AB</u>		<u>300MG</u>	<u>A076017 002</u>	Apr 28, 2004
<u>AB</u>		<u>400MG</u>	<u>A076017 003</u>	Apr 28, 2004
<u>AB</u>	RUBICON	<u>600MG</u>	<u>A077661 004</u>	Sep 13, 2006
<u>AB</u>		<u>800MG</u>	<u>A077661 005</u>	Sep 13, 2006
<u>AB</u>	SCIEGEN PHARMS INC	<u>600MG</u>	<u>A205101 001</u>	Feb 04, 2016
<u>AB</u>		<u>800MG</u>	<u>A205101 002</u>	Feb 04, 2016
<u>AB</u>	SUN PHARM INDS LTD	<u>600MG</u>	<u>A077525 001</u>	Aug 24, 2006
<u>AB</u>		<u>800MG</u>	<u>A077525 002</u>	Aug 24, 2006
<u>AB</u>	ZYDUS PHARMS USA INC	<u>600MG</u>	<u>A078926 001</u>	Feb 11, 2011
<u>AB</u>		<u>800MG</u>	<u>A078926 002</u>	Feb 11, 2011

NEURONTIN

<u>AB</u>	+ UPJOHN	<u>600MG</u>	<u>N020882 001</u>	Oct 09, 1998
<u>AB</u>	+	<u>800MG</u>	<u>N020882 002</u>	Oct 09, 1998

GRALISE

BX	+	ALMATICA	300MG	N022544 001	Jan 28, 2011
BX	+		600MG	N022544 002	Jan 28, 2011

PRESCRIPTION DRUG PRODUCT LIST

GABAPENTIN ENACARBIL

TABLET, EXTENDED RELEASE;ORAL

HORIZANT

+	ARBOR PHARMS LLC	300MG	N022399	002	Dec 13, 2011
+	!	600MG	N022399	001	Apr 06, 2011

GADOBENATE DIMEGLUMINE

INJECTABLE; INTRAVENOUS

MULTIHANCE

+	BRACCO	2.645GM/5ML (529MG/ML)	N021357	001	Nov 23, 2004
+	!	5.29GM/10ML (529MG/ML)	N021357	002	Nov 23, 2004
+	!	7.935GM/15ML (529MG/ML)	N021357	003	Nov 23, 2004
+	!	10.58GM/20ML (529MG/ML)	N021357	004	Nov 23, 2004

MULTIHANCE MULTIPACK

+	BRACCO	26.45GM/50ML (529MG/ML)	N021358	001	Nov 23, 2004
+	!	52.9GM/100ML (529MG/ML)	N021358	002	Nov 23, 2004

GADOBUTROL

SOLUTION; INTRAVENOUS

GADAVIST

+	BAYER HLTHCARE	1.20944GM/2ML (604.72MG/ML)	N201277	006	Dec 18, 2013
+	!	4.5354GM/7.5ML (604.72MG/ML)	N201277	001	Mar 14, 2011
+	!	6.0472GM/10ML (604.72MG/ML)	N201277	002	Mar 14, 2011
+	!	9.0708GM/15ML (604.72MG/ML)	N201277	003	Mar 14, 2011
+	!	18.1416GM/30ML (604.72MG/ML)	N201277	004	Mar 14, 2011
+	!	39.3068GM/65ML (604.72MG/ML)	N201277	005	Mar 14, 2011

GADODIAMIDE

INJECTABLE; INJECTION

OMNISCAN

+	GE HEALTHCARE	287MG/ML	N020123	001	Jan 08, 1993
+	!	28.7GM/100ML (287MG/ML)	N022066	002	Sep 05, 2007

GADOTERATE MEGLUMINE

SOLUTION; INTRAVENOUS

CLARISCAN

<u>AP</u>	GE HEALTHCARE	<u>7.538GM/20ML (376.9MG/ML)</u>	<u>A210016</u>	<u>003</u>	Nov 01, 2019
<u>AP</u>		<u>1.8845GM/5ML (376.9MG/ML)</u>	<u>A210016</u>	<u>005</u>	Nov 24, 2020
<u>AP</u>		<u>3.769GM/10ML (376.9MG/ML)</u>	<u>A210016</u>	<u>001</u>	Nov 01, 2019
<u>AP</u>		<u>5.6535GM/15ML (376.9MG/ML)</u>	<u>A210016</u>	<u>002</u>	Nov 01, 2019
<u>AP</u>		<u>37.69GM/100ML (376.9MG/ML)</u>	<u>A210016</u>	<u>004</u>	Aug 04, 2020

DOTAREM

<u>AP</u>	+	GUERBET	<u>37.69GM/100ML (376.9MG/ML)</u>	<u>N204781</u>	<u>001</u>	Mar 20, 2013
<u>AP</u>	+	!	<u>1.8845GM/5ML (376.9MG/ML)</u>	<u>N204781</u>	<u>005</u>	Mar 31, 2017
<u>AP</u>	+	!	<u>3.769GM/10ML (376.9MG/ML)</u>	<u>N204781</u>	<u>002</u>	Mar 20, 2013
<u>AP</u>	+	!	<u>5.6535GM/15ML (376.9MG/ML)</u>	<u>N204781</u>	<u>003</u>	Mar 20, 2013
<u>AP</u>	+	!	<u>7.538GM/20ML (376.9MG/ML)</u>	<u>N204781</u>	<u>004</u>	Mar 20, 2013

GADOTERIDOL

INJECTABLE; INJECTION

PROHANCE

+	BRACCO	279.3MG/ML	N020131	001	Nov 16, 1992
---	--------	------------	---------	-----	--------------

PROHANCE MULTIPACK

+	BRACCO	279.3MG/ML	N021489	001	Oct 09, 2003
---	--------	------------	---------	-----	--------------

GADOXETATE DISODIUM

SOLUTION; INTRAVENOUS

EOVIST

+	BAYER HLTHCARE	1.8143GM/10ML (181.43MG/ML)	N022090	001	Jul 03, 2008
+	!	2.72145GM/15ML (181.43MG/ML)	N022090	002	Feb 04, 2013

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE;ORAL

GALANTAMINE HYDROBROMIDE

<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 8MG BASE</u>	<u>A204895</u>	<u>001</u>	Aug 05, 2016
<u>AB</u>		<u>EQ 16MG BASE</u>	<u>A204895</u>	<u>002</u>	Aug 05, 2016
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A204895</u>	<u>003</u>	Aug 05, 2016
<u>AB</u>	BARR	<u>EQ 8MG BASE</u>	<u>A078189</u>	<u>001</u>	Sep 15, 2008
<u>AB</u>		<u>EQ 16MG BASE</u>	<u>A078189</u>	<u>002</u>	Sep 15, 2008
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A078189</u>	<u>003</u>	Sep 15, 2008
<u>AB</u>	SUN PHARM	<u>EQ 8MG BASE</u>	<u>A090178</u>	<u>001</u>	Feb 02, 2011
<u>AB</u>		<u>EQ 16MG BASE</u>	<u>A090178</u>	<u>002</u>	Feb 02, 2011
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A090178</u>	<u>003</u>	Feb 02, 2011
<u>AB</u>	WATSON LABS	<u>EQ 8MG BASE</u>	<u>A079028</u>	<u>001</u>	Dec 15, 2008
<u>AB</u>		<u>EQ 16MG BASE</u>	<u>A079028</u>	<u>002</u>	Dec 15, 2008

PRESCRIPTION DRUG PRODUCT LIST

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE;ORAL

GALANTAMINE HYDROBROMIDEAB RAZADYNE ER EQ 24MG BASE A079028 003 Dec 15, 2008RAZADYNE ERAB +! JANSSEN PHARMS EQ 8MG BASE N021615 001 Apr 01, 2005AB + EQ 16MG BASE N021615 002 Apr 01, 2005AB + EQ 24MG BASE N021615 003 Apr 01, 2005

SOLUTION;ORAL

GALANTAMINE HYDROBROMIDE

! HIKMA

4MG/ML

A078185 001 Jan 30, 2009

TABLET;ORAL

GALANTAMINE HYDROBROMIDEAB AUROBINDO PHARMA LTD EQ 4MG BASE A090957 001 Mar 29, 2011AB EQ 8MG BASE A090957 002 Mar 29, 2011AB EQ 12MG BASE A090957 003 Mar 29, 2011AB BARR EQ 4MG BASE A077605 001 Aug 28, 2008AB EQ 8MG BASE A077605 002 Aug 28, 2008AB EQ 12MG BASE A077605 003 Aug 28, 2008AB DR REDDYS LABS LTD EQ 4MG BASE A077593 001 Sep 11, 2008AB EQ 8MG BASE A077593 002 Sep 11, 2008AB EQ 12MG BASE A077593 003 Sep 11, 2008AB SANDOZ EQ 4MG BASE A077589 001 Jun 22, 2009AB EQ 8MG BASE A077589 002 Jun 22, 2009AB EQ 12MG BASE A077589 003 Jun 22, 2009AB YABAO PHARM EQ 4MG BASE A077604 001 Feb 06, 2009AB EQ 8MG BASE A077604 002 Feb 06, 2009AB EQ 12MG BASE A077604 003 Feb 06, 2009AB ZYDUS PHARMS USA EQ 4MG BASE A078898 001 Feb 17, 2011

INC

AB EQ 8MG BASE A078898 002 Feb 17, 2011AB EQ 12MG BASE A078898 003 Feb 17, 2011RAZADYNEAB +! JANSSEN PHARMS EQ 4MG BASE N021169 001 Feb 28, 2001AB + EQ 8MG BASE N021169 002 Feb 28, 2001AB + EQ 12MG BASE N021169 003 Feb 28, 2001GALLIUM CITRATE GA-67

INJECTABLE;INJECTION

GALLIUM CITRATE GA 67

BS CURIUM 2mCi/ML N018058 001

BS LANTHEUS MEDCL 2mCi/ML N017478 001

GALLIUM DOTATATE GA-68

POWDER;INTRAVENOUS

NETSPOT

+! AAA USA INC

2.1-5.5mCi/ML

N208547 001 Jun 01, 2016

GALLIUM DOTATOC GA-68

SOLUTION;INTRAVENOUS

GALLIUM DOTATOC GA 68

+! UIHC PET IMAGING

0.5-4mCi/ML

N210828 001 Aug 21, 2019

GALLIUM GA-68 PSMA-11

SOLUTION;INTRAVENOUS

GALLIUM GA 68 PSMA-11

+! UNIV CA LOS ANGELES

30ML (0.5-5MCI/ML)

N212642 001 Dec 01, 2020

+! UNIV OF CA SAN FRAN

20ML (0.5-5MCI/ML)

N212643 001 Dec 01, 2020

GANCICLOVIR

GEL;OPHTHALMIC

ZIRGAN

+! BAUSCH AND LOMB

0.15%

N022211 001 Sep 15, 2009

SOLUTION;INTRAVENOUS

GANZYK-RTU

+! EXELA PHARMA

500MG/250ML (2MG/ML)

N209347 001 Feb 17, 2017

GANCICLOVIR SODIUM

INJECTABLE;INJECTION

CYTOVENEAP +! CHEPLAPHARM EQ 500MG BASE/VIAL N019661 001 Jun 23, 1989GANCICLOVIR SODIUMAP FRESENIUS KABI USA EQ 500MG BASE/VIAL A090658 001 Jun 21, 2010AP HAINAN POLY PHARM EQ 500MG BASE/VIAL A204204 001 Nov 08, 2018AP PAR STERILE EQ 500MG BASE/VIAL A204950 001 Dec 06, 2016

PRESCRIPTION DRUG PRODUCT LIST

GANCICLOVIR SODIUM

INJECTABLE; INJECTION

GANCICLOVIR SODIUM

PRODUCTS

<u>AP</u>	PHARMASCIENCE INC	<u>EQ 500MG BASE/VIAL</u>	<u>A207645 001</u>	Dec 08, 2017
-----------	-------------------	---------------------------	--------------------	--------------

GANIRELIX ACETATE

INJECTABLE; INJECTION

GANIRELIX ACETATE

<u>AP</u>	<u>+</u> !	ORGANON USA INC	<u>250MCG/0.5ML</u>	<u>N021057 001</u>	Jul 29, 1999
<u>AP</u>		SUN PHARM	<u>250MCG/0.5ML</u>	<u>A204246 001</u>	Nov 30, 2018

GATIFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

GATIFLOXACIN

<u>AT</u>		HI-TECH PHARMA CO	<u>0.5%</u>	<u>A203189 001</u>	Sep 03, 2014
<u>AT</u>		LUPIN LTD	<u>0.5%</u>	<u>A202653 001</u>	Aug 28, 2013
<u>AT</u>		MYLAN	<u>0.5%</u>	<u>A206446 001</u>	Jun 08, 2018
<u>AT</u>		SANDOZ INC	<u>0.5%</u>	<u>A204227 001</u>	Jul 11, 2016

ZYMAXID

<u>AT</u>	<u>+</u> !	ALLERGAN	<u>0.5%</u>	<u>N022548 001</u>	May 18, 2010
		ZYMAR			
	<u>+</u> !	ALLERGAN	0.3%	N021493 001	Mar 28, 2003

GEFITINIB

TABLET; ORAL

IRESSA

	<u>+</u> !	ASTRAZENECA PHARMS	250MG	N206995 001	Jul 13, 2015
--	------------	--------------------	-------	-------------	--------------

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE HYDROCHLORIDE

<u>AP</u>		ACCORD HLTHCARE	<u>EQ 200MG BASE/VIAL</u>	<u>A091594 001</u>	Jul 25, 2011
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A091594 002</u>	Jul 25, 2011
<u>AP</u>			<u>EQ 2GM BASE/VIAL</u>	<u>A091594 003</u>	Jul 25, 2011
<u>AP</u>		CIPLA	<u>EQ 200MG BASE/VIAL</u>	<u>A078759 001</u>	Jul 25, 2011
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A078759 002</u>	Jul 25, 2011
<u>AP</u>		DR REDDYS LABS LTD	<u>EQ 200MG BASE/VIAL</u>	<u>A091365 001</u>	Jul 25, 2011
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A091365 002</u>	Jul 25, 2011
<u>AP</u>			<u>EQ 2GM BASE/VIAL</u>	<u>A202997 001</u>	May 07, 2013
<u>AP</u>		FRESENIUS KABI USA	<u>EQ 200MG BASE/VIAL</u>	<u>A090799 001</u>	Jul 25, 2011
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A090799 002</u>	Jul 25, 2011
<u>AP</u>			<u>EQ 2GM BASE/VIAL</u>	<u>A090242 003</u>	May 16, 2011
<u>AP</u>			<u>EQ 2GM BASE/VIAL</u>	<u>A090799 003</u>	May 16, 2011
<u>AP</u>		GLAND PHARMA LTD	<u>EQ 200MG BASE/VIAL</u>	<u>A204520 001</u>	Jan 05, 2016
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A204520 002</u>	Jan 05, 2016
<u>AP</u>		HOSPIRA	<u>EQ 200MG BASE/VIAL</u>	<u>A078339 001</u>	Jul 25, 2011
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A078339 002</u>	Jul 25, 2011
<u>AP</u>	<u>+</u> !	HOSPIRA INC	<u>200MG/5.26ML (38MG/ML)</u>	<u>N200795 001</u>	Aug 04, 2011
<u>AP</u>	<u>+</u> !		<u>1GM/26.3ML (38MG/ML)</u>	<u>N200795 002</u>	Aug 04, 2011
<u>AP</u>	!		<u>EQ 2GM BASE/VIAL</u>	<u>A079183 001</u>	Nov 15, 2010
<u>AP</u>	<u>+</u> !		<u>2GM/52.6ML (38MG/ML)</u>	<u>N200795 003</u>	Aug 04, 2011
<u>AP</u>		JIANGSU HANSONH PHARM	<u>EQ 200MG BASE/VIAL</u>	<u>A202485 001</u>	May 07, 2013
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A202485 002</u>	May 07, 2013
<u>AP</u>		MYLAN LABS LTD	<u>200MG/5.26ML (38MG/ML)</u>	<u>A205242 001</u>	Dec 06, 2017
<u>AP</u>			<u>1GM/26.3ML (38MG/ML)</u>	<u>A205242 002</u>	Dec 06, 2017
<u>AP</u>			<u>2GM/52.6ML (38MG/ML)</u>	<u>A205242 003</u>	Dec 06, 2017
<u>AP</u>		NANJING KING-FRIEND	<u>200MG/5.26ML (38MG/ML)</u>	<u>A212129 001</u>	Dec 11, 2020
<u>AP</u>			<u>1GM/26.3ML (38MG/ML)</u>	<u>A212129 002</u>	Dec 11, 2020
<u>AP</u>			<u>2GM/52.6ML (38MG/ML)</u>	<u>A212129 003</u>	Dec 11, 2020
<u>AP</u>		SAGENT PHARMS INC	<u>200MG/5.26ML (38MG/ML)</u>	<u>A209077 001</u>	Jul 20, 2018
<u>AP</u>			<u>1GM/26.3ML (38MG/ML)</u>	<u>A209077 002</u>	Jul 20, 2018
<u>AP</u>			<u>2GM/52.6ML (38MG/ML)</u>	<u>A209077 003</u>	Jul 20, 2018
<u>AP</u>		SHILPA MEDICARE LTD	<u>EQ 200MG BASE/VIAL</u>	<u>A207575 001</u>	Feb 22, 2019
<u>AP</u>			<u>200MG/5.26ML (38MG/ML)</u>	<u>A210991 001</u>	Oct 04, 2019
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A207575 002</u>	Feb 22, 2019
<u>AP</u>			<u>1GM/26.3ML (38MG/ML)</u>	<u>A210991 002</u>	Oct 04, 2019
<u>AP</u>			<u>2GM/52.6ML (38MG/ML)</u>	<u>A210991 003</u>	Oct 04, 2019
<u>AP</u>		SUN PHARM	<u>EQ 200MG BASE/VIAL</u>	<u>A078433 001</u>	Jul 25, 2011
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A078433 002</u>	Jul 25, 2011

GEMZAR

<u>AP</u>	<u>+</u> !	LILLY	<u>EQ 200MG BASE/VIAL</u>	<u>N020509 001</u>	May 15, 1996
<u>AP</u>	<u>+</u> !		<u>EQ 1GM BASE/VIAL</u>	<u>N020509 002</u>	May 15, 1996

PRESCRIPTION DRUG PRODUCT LIST

GEMCITABINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS

GEMCITABINE HYDROCHLORIDE

+	!	ACCORD HLTHCARE	1GM/10ML (100MG/ML)	N209604	002	Aug 03, 2017
+	!		1.5GM/15ML (100MG/ML)	N209604	003	Aug 03, 2017
+	!		2GM/20ML (100MG/ML)	N209604	004	Aug 03, 2017
+	!		200MG/2ML (100MG/ML)	N209604	001	Aug 03, 2017

INFUGEM

+	!	SUN PHARM	EQ 1200MG BASE/120ML (EQ 10MG BASE/ML)	N208313	001	Jul 16, 2018
+	!		EQ 1300MG BASE/130ML (EQ 10MG BASE/ML)	N208313	002	Jul 16, 2018
+	!		EQ 1400MG BASE/140ML (EQ 10MG BASE/ML)	N208313	003	Jul 16, 2018
+	!		EQ 1500MG BASE/150ML (EQ 10MG BASE/ML)	N208313	004	Jul 16, 2018
+	!		EQ 1600MG BASE/160ML (EQ 10MG BASE/ML)	N208313	005	Jul 16, 2018
+	!		EQ 1700MG BASE/170ML (EQ 10MG BASE/ML)	N208313	006	Jul 16, 2018
+	!		EQ 1800MG BASE/180ML (EQ 10MG BASE/ML)	N208313	007	Jul 16, 2018
+	!		EQ 1900MG BASE/190ML (EQ 10MG BASE/ML)	N208313	008	Jul 16, 2018
+	!		EQ 2000MG BASE/200ML (EQ 10MG BASE/ML)	N208313	009	Jul 16, 2018
+	!		EQ 2200MG BASE/220ML (EQ 10MG BASE/ML)	N208313	010	Jul 16, 2018

GEMFIBROZIL

TABLET; ORAL

GEMFIBROZIL

AB		APOTEX	600MG	A075034	001	Jul 20, 1998
AB		AUROBINDO PHARMA LTD	600MG	A202726	001	Sep 16, 2015
AB		CADILA	600MG	A204189	001	Aug 28, 2018
AB		CADILA PHARMS LTD	600MG	A203266	001	Jun 17, 2016
AB		CARIBE HOLDINGS	600MG	A078012	001	Mar 26, 2007
AB		CHARTWELL MOLECULES	600MG	A074270	001	Sep 27, 1993
AB		IMPAX PHARMS	600MG	A078207	001	Jun 01, 2007
AB		INVAGEN PHARMS	600MG	A077836	001	Jul 27, 2006
AB		NORTHSTAR HLTHCARE	600MG	A079072	001	Sep 13, 2010

LOPID

AB	+	!	PFIZER PHARMS	600MG	N018422	003	Nov 20, 1986
-----------	---	---	---------------	--------------	----------------	------------	--------------

GEMIFLOXACIN MESYLATE

TABLET; ORAL

FACTIVE

AB	+	!	LG CHEM LTD	EQ 320MG BASE	N021158	001	Apr 04, 2003
AB			ORCHID HLTHCARE	EQ 320MG BASE	A090466	001	Jun 15, 2015

GENTAMICIN SULFATE

CREAM; TOPICAL

GENTAMICIN SULFATE

AT			COSETTE	EQ 0.1% BASE	A064056	001	Apr 29, 1994
AT	!		PERRIGO NEW YORK	EQ 0.1% BASE	A062307	001	
AT			TELIGENT	EQ 0.1% BASE	A209304	001	Oct 18, 2019

INJECTABLE; INJECTION

GENTAMICIN SULFATE

AP	!		FRESENIUS KABI USA	EQ 10MG BASE/ML	A062366	002	Feb 06, 1986
AP	!			EQ 40MG BASE/ML	A062366	001	Aug 04, 1983
AP			HOSPIRA	EQ 10MG BASE/ML	A062420	001	Aug 15, 1983
AP				EQ 40MG BASE/ML	A062420	002	Aug 15, 1983

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP			BAXTER HLTHCARE	EQ 1.2MG BASE/ML	A062373	007	Sep 07, 1982
AP				EQ 1.6MG BASE/ML	A062373	008	Sep 07, 1982
AP				EQ 80MG BASE/100ML	A062373	002	Sep 07, 1982
AP				EQ 100MG BASE/100ML	A062373	005	Sep 07, 1982
AP			HOSPIRA	EQ 1.2MG BASE/ML	A062414	001	Aug 15, 1983
AP				EQ 1.6MG BASE/ML	A062414	003	Aug 15, 1983
AP				EQ 80MG BASE/100ML	A062414	008	Aug 15, 1983
AP				EQ 100MG BASE/100ML	A062414	010	Aug 15, 1983
	!		BAXTER HLTHCARE	EQ 2MG BASE/ML	A062373	009	Sep 07, 1982
	!			EQ 120MG BASE/100ML	A062373	006	Sep 07, 1982

OINTMENT; OPHTHALMIC

GENTAMICIN SULFATE

AT	!		AKORN	EQ 0.3% BASE	A064093	001	Aug 31, 1995
AT			FERA PHARMS LLC	EQ 0.3% BASE	A065024	001	Jul 30, 2004

OINTMENT; TOPICAL

GENTAMICIN SULFATE

AT			COSETTE	EQ 0.1% BASE	A064054	001	Apr 29, 1994
AT			FOUGERA PHARMS INC	EQ 0.1% BASE	A062533	001	Oct 05, 1984
AT	!		PERRIGO NEW YORK	EQ 0.1% BASE	A062351	001	Feb 18, 1982

PRESCRIPTION DRUG PRODUCT LIST

GENTAMICIN SULFATE

OINTMENT; TOPICAL

GENTAMICIN SULFATE

AT	TARO	EQ 0.1% BASE	A062477 001	Dec 23, 1983
AT	TELLIGENT	EQ 0.1% BASE	A209233 001	Dec 31, 2018

SOLUTION/DROPS; OPHTHALMIC

GENOPTIC

AT	! ALLERGAN	EQ 0.3% BASE	A062452 001	Oct 10, 1984
-----------	------------	---------------------	--------------------	--------------

GENTAK

AT	AKORN	EQ 0.3% BASE	A064163 001	Oct 12, 2001
-----------	-------	---------------------	--------------------	--------------

GENTAMICIN SULFATE

AT	AKORN	EQ 0.3% BASE	A062635 001	Jan 08, 1987
AT	BAUSCH AND LOMB	EQ 0.3% BASE	A064048 001	May 11, 1994
AT	PERRIGO CO TENNESSEE	EQ 0.3% BASE	A065121 001	Jan 30, 2004
AT	SANDOZ INC	EQ 0.3% BASE	A062196 001	

GENTAMICIN SULFATE; PREDNISOLONE ACETATE

OINTMENT; OPHTHALMIC

PRED-G

+	! ALLERGAN	EQ 0.3% BASE; 0.6%	N050612 001	Dec 01, 1989
---	------------	---------------------------	--------------------	--------------

SUSPENSION/DROPS; OPHTHALMIC

PRED-G

+	! ALLERGAN	EQ 0.3% BASE; 1%	N050586 001	Jun 10, 1988
---	------------	-------------------------	--------------------	--------------

GILTERITINIB FUMARATE

TABLET; ORAL

XOSPATA

+	! ASTELLAS	EQ 40MG BASE	N211349 001	Nov 28, 2018
---	------------	---------------------	--------------------	--------------

GIVOSIRAN SODIUM

SOLUTION; SUBCUTANEOUS

GIVLAARI

+	! ALNYLAM PHARMS INC	EQ 189MG BASE/ML (EQ 189MG BASE/ML)	N212194 001	Nov 20, 2019
---	----------------------	--	--------------------	--------------

GLASDEGIB MALEATE

TABLET; ORAL

DAURISMO

+	PFIZER	EQ 25MG BASE	N210656 001	Nov 21, 2018
---	--------	---------------------	--------------------	--------------

+	!	EQ 100MG BASE	N210656 002	Nov 21, 2018
---	---	----------------------	--------------------	--------------

GLATIRAMER ACETATE

INJECTABLE; SUBCUTANEOUS

COPAXONE

AP	+	! TEVA PHARMS USA	20MG/ML	N020622 002	Feb 12, 2002
-----------	---	-------------------	----------------	--------------------	--------------

AP	+	!	40MG/ML	N020622 003	Jan 28, 2014
-----------	---	---	----------------	--------------------	--------------

GLATIRAMER ACETATE

AP	MYLAN	20MG/ML	A091646 001	Oct 03, 2017
-----------	-------	----------------	--------------------	--------------

AP		40MG/ML	A206936 001	Oct 03, 2017
-----------	--	----------------	--------------------	--------------

GLATOPIA

AP	SANDOZ INC	20MG/ML	A090218 001	Apr 16, 2015
-----------	------------	----------------	--------------------	--------------

AP		40MG/ML	A206921 001	Feb 12, 2018
-----------	--	----------------	--------------------	--------------

GLECAPREVIR; PIBRENTASVIR

TABLET; ORAL

MAVYRET

+	! ABBVIE INC	100MG; 40MG	N209394 001	Aug 03, 2017
---	--------------	--------------------	--------------------	--------------

GLIMEPIRIDE

TABLET; ORAL

AMARYL

AB	+	! SANOFI AVENTIS US	1MG	N020496 001	Nov 30, 1995
-----------	---	---------------------	------------	--------------------	--------------

AB	+		2MG	N020496 002	Nov 30, 1995
-----------	---	--	------------	--------------------	--------------

AB	+		4MG	N020496 003	Nov 30, 1995
-----------	---	--	------------	--------------------	--------------

GLIMEPIRIDE

AB	ACCORD HLTHCARE	1MG	A078181 001	Aug 23, 2007
-----------	-----------------	------------	--------------------	--------------

AB		2MG	A078181 002	Aug 23, 2007
-----------	--	------------	--------------------	--------------

AB		4MG	A078181 003	Aug 23, 2007
-----------	--	------------	--------------------	--------------

AB	AUROBINDO PHARMA LTD	1MG	A202759 001	Jun 29, 2012
-----------	-------------------------	------------	--------------------	--------------

AB		2MG	A202759 002	Jun 29, 2012
-----------	--	------------	--------------------	--------------

AB		4MG	A202759 003	Jun 29, 2012
-----------	--	------------	--------------------	--------------

AB	CARLSBAD	1MG	A077911 001	Sep 22, 2009
-----------	----------	------------	--------------------	--------------

AB		2MG	A077911 002	Sep 22, 2009
-----------	--	------------	--------------------	--------------

AB		4MG	A077911 003	Sep 22, 2009
-----------	--	------------	--------------------	--------------

AB	DR REDDYS LABS LTD	1MG	A077091 001	Oct 06, 2005
-----------	--------------------	------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

GLIMEPIRIDE

TABLET;ORAL

GLIMEPIRIDE

<u>AB</u>		<u>2MG</u>	<u>A077091 002</u>	Oct 06, 2005
<u>AB</u>		<u>4MG</u>	<u>A077091 003</u>	Oct 06, 2005
<u>AB</u>	INDOCO REMEDIES	<u>1MG</u>	<u>A202112 001</u>	Apr 17, 2013
<u>AB</u>		<u>2MG</u>	<u>A202112 002</u>	Apr 17, 2013
<u>AB</u>		<u>4MG</u>	<u>A202112 003</u>	Apr 17, 2013
<u>AB</u>	INVAGEN PHARMS	<u>1MG</u>	<u>A077295 001</u>	Oct 06, 2005
<u>AB</u>		<u>2MG</u>	<u>A077295 002</u>	Oct 06, 2005
<u>AB</u>		<u>4MG</u>	<u>A077295 003</u>	Oct 06, 2005
<u>AB</u>	MICRO LABS	<u>1MG</u>	<u>A091220 001</u>	Jun 29, 2012
<u>AB</u>		<u>2MG</u>	<u>A091220 002</u>	Jun 29, 2012
<u>AB</u>		<u>4MG</u>	<u>A091220 004</u>	Jun 29, 2012
<u>AB</u>		<u>8MG</u>	<u>A091220 006</u>	Jun 29, 2012
<u>AB</u>	PRINSTON INC	<u>1MG</u>	<u>A077370 001</u>	Dec 23, 2005
<u>AB</u>		<u>2MG</u>	<u>A077370 002</u>	Dec 23, 2005
<u>AB</u>		<u>4MG</u>	<u>A077370 003</u>	Dec 23, 2005
<u>AB</u>		<u>8MG</u>	<u>A077370 004</u>	Dec 23, 2005
	MICRO LABS	3MG	A091220 003	Jun 29, 2012
		6MG	A091220 005	Jun 29, 2012

GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

DUETACT

<u>AB</u>	+	TAKEDA PHARMS USA	<u>2MG;30MG</u>	<u>N021925 001</u>	Jul 28, 2006
<u>AB</u>	+		<u>4MG;30MG</u>	<u>N021925 002</u>	Jul 28, 2006

PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE

<u>AB</u>		SANDOZ	<u>2MG;30MG</u>	<u>A201049 001</u>	Jan 04, 2013
<u>AB</u>			<u>4MG;30MG</u>	<u>A201049 002</u>	Jan 04, 2013

GLIPIZIDE

TABLET;ORAL

GLIPIZIDE

<u>AB</u>		ACCORD HLTHCARE	<u>5MG</u>	<u>A074550 001</u>	Sep 11, 1997
<u>AB</u>			<u>10MG</u>	<u>A074550 002</u>	Sep 11, 1997
<u>AB</u>		APOTEX	<u>5MG</u>	<u>A075795 001</u>	Jun 13, 2001
<u>AB</u>			<u>10MG</u>	<u>A075795 002</u>	Jun 13, 2001
<u>AB</u>		MYLAN	<u>5MG</u>	<u>A074226 001</u>	May 10, 1994
<u>AB</u>			<u>10MG</u>	<u>A074226 002</u>	May 10, 1994
<u>AB</u>		SANDOZ	<u>5MG</u>	<u>A074305 001</u>	Apr 07, 1995
<u>AB</u>			<u>10MG</u>	<u>A074305 002</u>	Apr 07, 1995
<u>AB</u>		SUN PHARM INDS INC	<u>5MG</u>	<u>A077820 001</u>	Jul 11, 2006
<u>AB</u>			<u>10MG</u>	<u>A077820 002</u>	Jul 11, 2006
<u>AB</u>		WATSON LABS TEVA	<u>5MG</u>	<u>A074223 001</u>	Feb 27, 1995
<u>AB</u>			<u>10MG</u>	<u>A074223 002</u>	Feb 27, 1995

GLUCOTROL

<u>AB</u>	+	PFIZER	<u>5MG</u>	<u>N017783 001</u>	May 08, 1984
<u>AB</u>	+		<u>10MG</u>	<u>N017783 002</u>	May 08, 1984

TABLET, EXTENDED RELEASE;ORAL

GLIPIZIDE

<u>AB</u>		AUROBINDO PHARMA LTD	<u>2.5MG</u>	<u>A206928 001</u>	May 12, 2017
<u>AB</u>			<u>5MG</u>	<u>A206928 002</u>	May 12, 2017
<u>AB</u>			<u>10MG</u>	<u>A206928 003</u>	May 12, 2017
<u>AB</u>		PAR PHARM	<u>5MG</u>	<u>A076159 002</u>	Sep 20, 2013
<u>AB</u>			<u>10MG</u>	<u>A076159 001</u>	Sep 20, 2013
<u>AB</u>		UNIQUE PHARM LABS	<u>2.5MG</u>	<u>A204720 001</u>	Dec 29, 2016
<u>AB</u>			<u>5MG</u>	<u>A204720 002</u>	Dec 29, 2016
<u>AB</u>			<u>10MG</u>	<u>A204720 003</u>	Dec 29, 2016
<u>AB</u>		WATSON LABS	<u>2.5MG</u>	<u>A076467 003</u>	Mar 27, 2006
<u>AB</u>			<u>5MG</u>	<u>A076467 001</u>	Sep 08, 2003
<u>AB</u>			<u>10MG</u>	<u>A076467 002</u>	Nov 07, 2003
<u>AB</u>		ZYDUS PHARMS	<u>2.5MG</u>	<u>A203499 001</u>	Jul 16, 2018
<u>AB</u>			<u>5MG</u>	<u>A203499 002</u>	Jul 16, 2018
<u>AB</u>			<u>10MG</u>	<u>A203499 003</u>	Jul 16, 2018

GLUCOTROL XL

<u>AB</u>	+	PFIZER	<u>2.5MG</u>	<u>N020329 003</u>	Aug 10, 1999
<u>AB</u>	+		<u>5MG</u>	<u>N020329 001</u>	Apr 26, 1994
<u>AB</u>	+		<u>10MG</u>	<u>N020329 002</u>	Apr 26, 1994

PRESCRIPTION DRUG PRODUCT LIST

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

AB	EPIC PHARMA LLC	2.5MG;250MG	A077507 001	Oct 27, 2005
AB		2.5MG;500MG	A077507 002	Oct 27, 2005
AB		5MG;500MG	A077507 003	Oct 27, 2005
AB	HERITAGE PHARMS INC	2.5MG;250MG	A078728 001	Jun 23, 2010
AB		2.5MG;500MG	A078728 002	Jun 23, 2010
AB		5MG;500MG	A078728 003	Jun 23, 2010
AB	TEVA PHARMS	2.5MG;250MG	A077270 001	Oct 28, 2005
AB		2.5MG;500MG	A077270 002	Oct 28, 2005
AB	!	5MG;500MG	A077270 003	Oct 28, 2005
AB	ZYDUS PHARMS USA INC	2.5MG;250MG	A078905 001	Jan 31, 2011
AB		2.5MG;500MG	A078905 002	Jan 31, 2011
AB		5MG;500MG	A078905 003	Jan 31, 2011

GLUCAGON

INJECTABLE; INJECTION

GLUCAGON

AP	AMPHASTAR PHARMS INC	1MG/VIAL	A208086 001	Dec 28, 2020
AP	+! LILLY	1MG/VIAL	N020928 001	Sep 11, 1998
	POWDER; NASAL BAQSIMI			
	+! ELI LILLY AND CO	3MG	N210134 001	Jul 24, 2019
	SOLUTION; SUBCUTANEOUS GVOKE HYOPEN			
	+! XERIS	0.5MG/0.1ML (0.5MG/0.1ML)	N212097 003	Sep 10, 2019
	+!	1MG/0.2ML (1MG/0.2ML)	N212097 004	Sep 10, 2019
	GVOKE PFS			
	+! XERIS	0.5MG/0.1ML (0.5MG/0.1ML)	N212097 001	Sep 10, 2019
	+!	1MG/0.2ML (1MG/0.2ML)	N212097 002	Sep 10, 2019

GLUCAGON HYDROCHLORIDE

INJECTABLE; INJECTION

GLUCAGON

	+! NOVO NORDISK	EQ 1MG BASE/VIAL	N020918 001	Jun 22, 1998
	POWDER; INTRAMUSCULAR, INTRAVENOUS GLUCAGON			
	+! FRESENIUS KABI USA	EQ 1MG BASE/VIAL	N201849 001	May 08, 2015

GLYBURIDE

TABLET; ORAL

GLYBURIDE (MICRONIZED)

AB	HIKMA	1.5MG	A075890 001	Jul 31, 2003
AB		3MG	A075890 002	Jul 31, 2003
AB		6MG	A075890 003	Jul 31, 2003
AB	TEVA	1.5MG	A074686 001	Apr 20, 1999
AB		3MG	A074686 002	Apr 20, 1999
AB		6MG	A074686 004	Apr 20, 1999
	<u>GLYNASE</u>			
AB	+ PHARMACIA AND UPJOHN	1.5MG	N020051 001	Mar 04, 1992
AB	+	3MG	N020051 002	Mar 04, 1992
AB	+!	6MG	N020051 004	Sep 24, 1993

GLYBURIDE

AB1	CADILA PHARMS LTD	1.25MG	A203379 001	Jan 04, 2019
AB1		2.5MG	A203379 002	Jan 04, 2019
AB1		5MG	A203379 003	Jan 04, 2019
AB1	EPIC PHARMA LLC	1.25MG	A076257 001	Jun 27, 2002
AB1		2.5MG	A076257 002	Jun 27, 2002
AB1		5MG	A076257 003	Jun 27, 2002
AB1	HERITAGE PHARMS INC	1.25MG	A090937 001	Feb 28, 2011
AB1		2.5MG	A090937 002	Feb 28, 2011
AB1		5MG	A090937 003	Feb 28, 2011
AB1	ORIENT PHARMA CO LTD	1.25MG	A206483 001	Feb 22, 2019
AB1		2.5MG	A206483 002	Feb 22, 2019
AB1		5MG	A206483 003	Feb 22, 2019
AB1	SWISS PHARM	1.25MG	A203581 001	Apr 14, 2016
AB1		2.5MG	A203581 002	Apr 14, 2016
AB1		5MG	A203581 003	Apr 14, 2016
AB1	TEVA	1.25MG	A074388 001	Aug 29, 1995
AB1		2.5MG	A074388 002	Aug 29, 1995

PRESCRIPTION DRUG PRODUCT LIST

GLYBURIDE

TABLET; ORAL

GLYBURIDE

<u>AB1</u>	!		<u>5MG</u>	<u>A074388</u>	<u>003</u>	Aug 29, 1995
<u>AB1</u>		ZYDUS PHARMS	<u>1.25MG</u>	<u>A206749</u>	<u>001</u>	May 10, 2016
<u>AB1</u>			<u>2.5mg</u>	<u>A206749</u>	<u>002</u>	May 10, 2016
<u>AB1</u>			<u>5MG</u>	<u>A206749</u>	<u>003</u>	May 10, 2016

DIABETA

<u>AB2</u>	+	SANOFI AVENTIS US	<u>1.25MG</u>	<u>N017532</u>	<u>001</u>	May 01, 1984
<u>AB2</u>	+		<u>2.5MG</u>	<u>N017532</u>	<u>002</u>	May 01, 1984
<u>AB2</u>	+	!	<u>5MG</u>	<u>N017532</u>	<u>003</u>	May 01, 1984

GLYBURIDE

<u>AB2</u>		IMPAX LABS INC	<u>1.25MG</u>	<u>A206079</u>	<u>001</u>	Sep 30, 2015
<u>AB2</u>			<u>2.5MG</u>	<u>A206079</u>	<u>002</u>	Sep 30, 2015
<u>AB2</u>			<u>5MG</u>	<u>A206079</u>	<u>003</u>	Sep 30, 2015
		GLYBURIDE (MICRONIZED)				
		TEVA	4.5MG	A074686	003	Apr 20, 1999

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

<u>AB</u>		ACTAVIS ELIZABETH	<u>1.25MG;250MG</u>	<u>A076716</u>	<u>001</u>	Jun 28, 2005
<u>AB</u>			<u>2.5MG;500MG</u>	<u>A076716</u>	<u>002</u>	Jun 28, 2005
<u>AB</u>			<u>5MG;500MG</u>	<u>A076716</u>	<u>003</u>	Jun 28, 2005
<u>AB</u>		AUROBINDO PHARMA	<u>1.25MG;250MG</u>	<u>A077870</u>	<u>001</u>	Nov 14, 2007
<u>AB</u>	!		<u>2.5MG;500MG</u>	<u>A077870</u>	<u>002</u>	Nov 14, 2007
<u>AB</u>			<u>5MG;500MG</u>	<u>A077870</u>	<u>003</u>	Nov 14, 2007
<u>AB</u>		IMPAX LABS INC	<u>1.25MG;250MG</u>	<u>A076345</u>	<u>001</u>	Feb 18, 2004
<u>AB</u>			<u>2.5MG;500MG</u>	<u>A076345</u>	<u>002</u>	Feb 18, 2004
<u>AB</u>			<u>5MG;500MG</u>	<u>A076345</u>	<u>003</u>	Feb 18, 2004
<u>AB</u>		ZYDUS PHARMS	<u>1.25MG;250MG</u>	<u>A206748</u>	<u>001</u>	Feb 29, 2016
<u>AB</u>			<u>2.5MG;500MG</u>	<u>A206748</u>	<u>002</u>	Feb 29, 2016
<u>AB</u>			<u>5MG;500MG</u>	<u>A206748</u>	<u>003</u>	Feb 29, 2016

GLYCEROL PHENYLBUTYRATE

LIQUID; ORAL

RAVICTI

	+	HORIZON THERAP	1.1GM/ML	N203284	001	Feb 01, 2013
--	---	----------------	----------	---------	-----	--------------

GLYCINE

SOLUTION; IRRIGATION

AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER

<u>AT</u>	+	BAXTER HLTHCARE	<u>1.5GM/100ML</u>	<u>N017865</u>	<u>001</u>	
-----------	---	-----------------	--------------------	----------------	------------	--

GLYCINE 1.5% IN PLASTIC CONTAINER

<u>AT</u>		B BRAUN	<u>1.5GM/100ML</u>	<u>N016784</u>	<u>001</u>	
<u>AT</u>		ICU MEDICAL INC	<u>1.5GM/100ML</u>	<u>N018315</u>	<u>001</u>	

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

<u>AP</u>		ACCORD HLTHCARE	<u>0.2MG/ML</u>	<u>A213238</u>	<u>001</u>	Jul 08, 2020
<u>AP</u>		AM REGENT	<u>0.2MG/ML</u>	<u>A089335</u>	<u>001</u>	Jul 23, 1986
<u>AP</u>		AMNEAL	<u>0.2MG/ML</u>	<u>A208973</u>	<u>001</u>	Jun 15, 2017
<u>AP</u>		APOTEX	<u>0.2MG/ML</u>	<u>A210246</u>	<u>001</u>	Oct 29, 2019
<u>AP</u>		AUROBINDO PHARMA LTD	<u>0.2MG/ML</u>	<u>A210244</u>	<u>001</u>	Nov 28, 2018
<u>AP</u>		CAPLIN	<u>0.2MG/ML</u>	<u>A211705</u>	<u>001</u>	Mar 20, 2019
<u>AP</u>		FRESENIUS KABI USA	<u>0.2MG/ML</u>	<u>A209024</u>	<u>001</u>	Oct 31, 2018
<u>AP</u>			<u>0.2MG/ML</u>	<u>A209328</u>	<u>001</u>	Oct 27, 2017
<u>AP</u>		GLAND PHARMA LTD	<u>0.2MG/ML</u>	<u>A212612</u>	<u>001</u>	Sep 30, 2019
<u>AP</u>	!	HIKMA FARMACEUTICA	<u>0.2MG/ML</u>	<u>A090963</u>	<u>001</u>	Sep 21, 2011
<u>AP</u>		PIRAMAL CRITICAL	<u>0.2MG/ML</u>	<u>A210842</u>	<u>001</u>	Oct 25, 2018
<u>AP</u>		PRINSON INC	<u>0.2MG/ML</u>	<u>A210927</u>	<u>001</u>	Oct 31, 2018
<u>AP</u>		RICONPHARMA LLC	<u>0.2MG/ML</u>	<u>A210083</u>	<u>001</u>	Feb 21, 2020
<u>AP</u>		SANDOZ INC	<u>0.2MG/ML</u>	<u>A211334</u>	<u>001</u>	May 14, 2019
<u>AP</u>		SOMERSET THERAPS LLC	<u>0.2MG/ML</u>	<u>A207639</u>	<u>001</u>	Jun 23, 2017

SOLUTION; INHALATION

LONHALA MAGNAIR KIT

	+	SUNOVION RESP	25MCG/ML	N208437	001	Dec 05, 2017
--	---	---------------	----------	---------	-----	--------------

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

GLYRX-PF

		EXELA PHARMA	0.2MG/ML (0.2MG/ML)	N210997	001	Jul 11, 2018
			0.4MG/2ML (0.2MG/ML)	N210997	002	Jul 11, 2018
			0.6MG/3ML (0.2MG/ML)	N210997	004	Dec 14, 2020

PRESCRIPTION DRUG PRODUCT LIST

GLYCOPYRROLATE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

GLYRX-PF

1MG/5ML (0.2MG/ML)

N210997 003 Apr 09, 2020

SOLUTION;ORAL

CUVPOSA

+! MERZ PHARMS

1MG/5ML

N022571 001 Jul 28, 2010

TABLET;ORAL

GLYCOPYRROLATE

<u>AA</u>	ALEMBIC LABS	<u>1MG</u>	<u>A203657 001</u>	Nov 30, 2018
<u>AA</u>		<u>2MG</u>	<u>A203657 002</u>	Nov 30, 2018
<u>AA</u>	AUROLIFE PHARMA LLC	<u>1MG</u>	<u>A202675 001</u>	Apr 15, 2013
<u>AA</u>		<u>2MG</u>	<u>A202675 002</u>	Oct 30, 2018
<u>AA</u>	DR REDDYS LABS LTD	<u>1MG</u>	<u>A040847 001</u>	Mar 21, 2008
<u>AA</u>		<u>2MG</u>	<u>A040847 002</u>	Mar 21, 2008
<u>AA</u>	HERITAGE PHARMS INC	<u>1MG</u>	<u>A207201 001</u>	Jan 03, 2017
<u>AA</u>		<u>2MG</u>	<u>A207201 002</u>	Jan 03, 2017
<u>AA</u>	KENTON	<u>1MG</u>	<u>A091182 001</u>	Feb 03, 2014
<u>AA</u>		<u>2MG</u>	<u>A091182 002</u>	Feb 03, 2014
<u>AA</u>	LEADING PHARMA LLC	<u>1MG</u>	<u>A090195 001</u>	Sep 21, 2012
<u>AA</u>		<u>2MG</u>	<u>A090195 002</u>	Sep 21, 2012
<u>AA</u>	NATCO PHARMA LTD	<u>1MG</u>	<u>A091413 001</u>	Jun 20, 2016
<u>AA</u>		<u>2MG</u>	<u>A091413 002</u>	Jun 20, 2016
<u>AA</u>	OXFORD PHARMS	<u>1MG</u>	<u>A090020 001</u>	Oct 19, 2011
<u>AA</u>		<u>2MG</u>	<u>A090020 002</u>	Oct 19, 2011
<u>AA</u>	! PAR PHARM	<u>1MG</u>	<u>A040653 001</u>	Aug 31, 2006
<u>AA</u>	!	<u>2MG</u>	<u>A040653 002</u>	Aug 31, 2006
<u>AA</u>	RISING	<u>1MG</u>	<u>A040821 001</u>	Dec 29, 2008
<u>AA</u>		<u>2MG</u>	<u>A040821 002</u>	Dec 29, 2008
<u>AA</u>	SUN PHARM INDS LTD	<u>1MG</u>	<u>A040844 001</u>	Aug 18, 2009
<u>AA</u>		<u>2MG</u>	<u>A040844 002</u>	Aug 18, 2009
	LGM PHARMA	1.5MG	A091522 001	Mar 12, 2012

GLYCOPYRRONIUM TOSYLATE

CLOTH;TOPICAL

QBREXZA

+! DERMIRA INC

EQ 2.4% BASE

N210361 001 Jun 28, 2018

GOLODIRSEN

SOLUTION;INTRAVENOUS

VYONDYS 53

+! SAREPTA THERAPS INC

100MG/2ML (50MG/ML)

N211970 001 Dec 12, 2019

GOSERELIN ACETATE

IMPLANT;IMPLANTATION

ZOLADEX

+! TERSERA

EQ 3.6MG BASE

N019726 001 Dec 29, 1989

+!

EQ 10.8MG BASE

N020578 001 Jan 11, 1996

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

<u>AT</u>	AMRING PHARMS	<u>0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML</u>	<u>A065187 001</u>	Oct 28, 2005
<u>AT</u>	! BAUSCH AND LOMB	<u>0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML</u>	<u>A064047 001</u>	Jan 31, 1996
	<u>NEOSPORIN</u>			
<u>AT</u>	! MONARCH PHARMS	<u>0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML</u>	<u>A060582 001</u>	

GRANISETRON

FILM, EXTENDED RELEASE;TRANSDERMAL

SANCUSO

+! KYOWA KIRIN

3.1MG/24HR

N022198 001 Sep 12, 2008

INJECTION, EXTENDED RELEASE;SUBCUTANEOUS

SUSTOL

+! HERON THERAPS INC

10MG/0.4ML (10MG/0.4ML)

N022445 001 Aug 09, 2016

GRANISETRON HYDROCHLORIDE

INJECTABLE;INJECTION

GRANISETRON HYDROCHLORIDE

<u>AP</u>	AKORN INC	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A079119 001</u>	Sep 10, 2009
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A079078 001</u>	Sep 14, 2009
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A079078 002</u>	Sep 14, 2009
<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A204238 001</u>	Jul 06, 2016

PRESCRIPTION DRUG PRODUCT LIST

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A204238 002</u>	Jul 06, 2016
<u>AP</u>	BIONPHARMA INC	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078863 001</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078880 001</u>	Jun 30, 2008
<u>AP</u>	! DR REDDYS	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078392 001</u>	Dec 31, 2007
<u>AP</u>	!	<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A077297 001</u>	Jun 30, 2008
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078522 001</u>	Dec 31, 2007
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078090 001</u>	Jun 30, 2008
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078629 001</u>	Dec 23, 2009
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078629 002</u>	Dec 23, 2009
<u>AP</u>	MYLAN ASI	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A091136 001</u>	Apr 09, 2010
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A091136 002</u>	Apr 09, 2010
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A091137 002</u>	Apr 09, 2010
<u>AP</u>	PUNISKA	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078262 001</u>	Dec 31, 2007
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078258 001</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078258 002</u>	Jun 30, 2008
<u>AP</u>	SANDOZ INC	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078534 001</u>	Apr 30, 2009
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078531 001</u>	Apr 30, 2009
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078835 001</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078531 002</u>	Apr 30, 2009
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078835 002</u>	Jun 30, 2008
<u>AP</u>	WEST-WARD PHARMS INT	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A077913 001</u>	Jun 26, 2008
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A077186 001</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A077187 001</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A077177 001</u>	Dec 31, 2007
<u>AP</u>	WOCKHARDT USA	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078566 001</u>	Feb 29, 2008
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078564 001</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078565 001</u>	Jun 30, 2008

GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	BIONPHARMA INC	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078863 002</u>	Jun 30, 2008
<u>AP</u>	! FRESENIUS KABI USA	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078096 001</u>	Jun 30, 2008

TABLET; ORAL

GRANISETRON HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>EQ 1MG BASE</u>	<u>A078843 001</u>	Feb 27, 2008
<u>AB</u>	CHARTWELL MOLECULAR	<u>EQ 1MG BASE</u>	<u>A078037 001</u>	Feb 27, 2008
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 1MG BASE</u>	<u>A078846 001</u>	Feb 27, 2009
<u>AB</u>	! HIKMA	<u>EQ 1MG BASE</u>	<u>A077842 001</u>	Dec 31, 2007
<u>AB</u>	NATCO PHARMA	<u>EQ 1MG BASE</u>	<u>A078969 001</u>	Jun 22, 2009
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 1MG BASE</u>	<u>A078678 001</u>	Feb 13, 2008
<u>AB</u>	TARO	<u>EQ 1MG BASE</u>	<u>A090817 001</u>	May 28, 2010

GRISEOFULVIN, MICROSIZED

SUSPENSION; ORAL

GRISEOFULVIN

<u>AB</u>	! ACTAVIS MID ATLANTIC	<u>125MG/5ML</u>	<u>A065394 001</u>	Jul 06, 2007
<u>AB</u>	CHARTWELL RX	<u>125MG/5ML</u>	<u>A065200 001</u>	Mar 02, 2005
<u>AB</u>	CIPLA	<u>125MG/5ML</u>	<u>A065354 001</u>	Sep 10, 2007
<u>AB</u>	COSETTE	<u>125MG/5ML</u>	<u>A065438 001</u>	Oct 08, 2010

TABLET; ORAL

GRISEOFULVIN

<u>AB</u>	! SANDOZ INC	<u>500MG</u>	<u>A091592 002</u>	Aug 07, 2013
<u>AB</u>	SIGMAPHARM LABS LLC	<u>500MG</u>	<u>A202482 001</u>	Oct 22, 2012
	SANDOZ INC	<u>250MG</u>	<u>A091592 001</u>	Aug 07, 2013

GRISEOFULVIN, ULTRAMICROSIZED

TABLET; ORAL

GRIS-PEG

<u>AB</u>	+ BAUSCH	<u>125MG</u>	<u>N050475 001</u>	
<u>AB</u>	+ BAUSCH	<u>250MG</u>	<u>N050475 002</u>	

GRISEOFULVIN, ULTRAMICROSIZED

<u>AB</u>	MOUNTAIN	<u>125MG</u>	<u>A204371 001</u>	Jan 09, 2014
<u>AB</u>	!	<u>250MG</u>	<u>A204371 002</u>	Jan 09, 2014
<u>AB</u>	SANDOZ INC	<u>125MG</u>	<u>A202805 001</u>	Dec 26, 2018
<u>AB</u>		<u>250MG</u>	<u>A202805 002</u>	Dec 26, 2018

GRISEOFULVIN, ULTRAMICROSIZED

<u>AB</u>	SIGMAPHARM LABS LLC	<u>125MG</u>	<u>A202545 001</u>	Oct 22, 2012
<u>AB</u>		<u>250MG</u>	<u>A202545 002</u>	Oct 22, 2012

PRESCRIPTION DRUG PRODUCT LIST

GUANFACINE HYDROCHLORIDE

TABLET;ORAL

GUANFACINE HYDROCHLORIDE

<u>AB</u>	AMNEAL PHARM	<u>EQ 1MG BASE</u>	<u>A075109 001</u>	Nov 25, 1998
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075109 002</u>	Nov 25, 1998
<u>AB</u>	EPIC PHARMA LLC	<u>EQ 1MG BASE</u>	<u>A074673 001</u>	Feb 28, 1997
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A074673 002</u>	Feb 28, 1997
<u>AB</u>	MYLAN	<u>EQ 1MG BASE</u>	<u>A074796 001</u>	Jan 27, 1997
<u>AB</u>	!	<u>EQ 2MG BASE</u>	<u>A074796 002</u>	Jan 27, 1997
<u>AB</u>	WATSON LABS	<u>EQ 1MG BASE</u>	<u>A074145 001</u>	Oct 17, 1995
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A074145 002</u>	Oct 17, 1995

TABLET, EXTENDED RELEASE;ORAL

GUANFACINE HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>EQ 1MG BASE</u>	<u>A200881 001</u>	Oct 05, 2012
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A200881 002</u>	Oct 05, 2012
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A200881 003</u>	Oct 05, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A200881 004</u>	Oct 05, 2012
<u>AB</u>	APOTEX	<u>EQ 1MG BASE</u>	<u>A205430 001</u>	Jul 25, 2018
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A205430 002</u>	Jul 25, 2018
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A205430 003</u>	Jul 25, 2018
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A205430 004</u>	Jul 25, 2018
<u>AB</u>	SANDOZ INC	<u>EQ 1MG BASE</u>	<u>A202568 001</u>	Jun 03, 2015
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A202568 002</u>	Jun 03, 2015
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A202568 003</u>	Jun 03, 2015
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A202568 004</u>	Jun 03, 2015
<u>AB</u>	SUN PHARM	<u>EQ 1MG BASE</u>	<u>A205689 001</u>	Nov 16, 2017
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A205689 002</u>	Nov 16, 2017
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A205689 003</u>	Nov 16, 2017
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A205689 004</u>	Nov 16, 2017
<u>AB</u>	TEVA PHARMS USA	<u>EQ 1MG BASE</u>	<u>A201382 001</u>	Jun 02, 2015
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A201382 002</u>	Jun 02, 2015
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A201382 003</u>	Jun 02, 2015
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A201382 004</u>	Jun 02, 2015
<u>AB</u>	TWI PHARMS	<u>EQ 1MG BASE</u>	<u>A201408 001</u>	Jun 02, 2015
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A201408 002</u>	Jun 02, 2015
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A201408 003</u>	Jun 02, 2015
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A201408 004</u>	Jun 02, 2015
<u>AB</u>	YICHANG HUMANWELL	<u>EQ 1MG BASE</u>	<u>A213428 001</u>	Nov 25, 2020
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A213428 002</u>	Nov 25, 2020
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A213428 003</u>	Nov 25, 2020
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A213428 004</u>	Nov 25, 2020

INTUNIV

<u>AB</u>	+	TAKEDA PHARMS USA	<u>EQ 1MG BASE</u>	<u>N022037 001</u>	Sep 02, 2009
<u>AB</u>	+		<u>EQ 2MG BASE</u>	<u>N022037 002</u>	Sep 02, 2009
<u>AB</u>	+		<u>EQ 3MG BASE</u>	<u>N022037 003</u>	Sep 02, 2009
<u>AB</u>	+	!	<u>EQ 4MG BASE</u>	<u>N022037 004</u>	Sep 02, 2009

HALCINONIDE

CREAM;TOPICAL

HALCINONIDE

<u>AB</u>	MYLAN	<u>0.1%</u>	<u>A211027 001</u>	Aug 12, 2019
<u>AB</u>	+	!	<u>N017556 001</u>	
	SUN PHARM INDS INC	<u>0.1%</u>		
	ointment;TOPICAL			
	HALOG			
	+	!	N017824	001
	SUN PHARM INDS INC	0.1%		
	SOLUTION;TOPICAL			
	HALOG			
	!	!	N017823	001
	SUN PHARM INDS INC	0.1%		

HALOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL

LEXETTE

+

CREAM;TOPICAL

HALOBETASOL PROPIONATE

<u>AB</u>	!	COSETTE	<u>0.05%</u>	<u>A078162 001</u>	Apr 24, 2007
<u>AB</u>		FOUGERA PHARMS	<u>0.05%</u>	<u>A077001 001</u>	Dec 16, 2004
<u>AB</u>		PERRIGO ISRAEL	<u>0.05%</u>	<u>A077123 001</u>	Dec 16, 2004
<u>AB</u>		TARO	<u>0.05%</u>	<u>A077227 001</u>	Aug 04, 2005
		LOTION;TOPICAL			
		BRYHALI			
	+	!	BAUSCH	0.01%	N209355 001 Nov 06, 2018

PRESCRIPTION DRUG PRODUCT LIST

HALOBETASOL PROPIONATE

LOTION; TOPICAL

ULTRAVATE

+	!	SUN PHARM INDUSTRIES	0.05%	N208183	001	Nov 06, 2015
---	---	----------------------	-------	---------	-----	--------------

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE

<u>AB</u>		COSETTE	<u>0.05%</u>	<u>A077109</u>	<u>001</u>	Jun 14, 2005
<u>AB</u>	!		<u>0.05%</u>	<u>A077721</u>	<u>001</u>	Sep 07, 2006
<u>AB</u>		PERRIGO ISRAEL	<u>0.05%</u>	<u>A076872</u>	<u>001</u>	Dec 16, 2004
<u>AB</u>		QUAGEN	<u>0.05%</u>	<u>A213560</u>	<u>001</u>	Oct 06, 2020
<u>AB</u>		TARO	<u>0.05%</u>	<u>A076994</u>	<u>001</u>	Dec 16, 2004
<u>AB</u>		TELIGENT	<u>0.05%</u>	<u>A209978</u>	<u>001</u>	Mar 20, 2018
<u>ULTRAVATE</u>						
<u>AB</u>	+	SUN PHARM INDS INC	<u>0.05%</u>	<u>N019968</u>	<u>001</u>	Dec 17, 1990

HALOBETASOL PROPIONATE; TAZAROTENE

LOTION; TOPICAL

DUOBRII

+	!	BAUSCH	0.01%;0.045%	N209354	001	Apr 25, 2019
---	---	--------	--------------	---------	-----	--------------

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

<u>AB</u>		INNOGENIX	<u>0.5MG</u>	<u>A071173</u>	<u>002</u>	Jan 02, 1987
<u>AB</u>			<u>1MG</u>	<u>A071173</u>	<u>003</u>	Jan 02, 1987
<u>AB</u>			<u>2MG</u>	<u>A071173</u>	<u>004</u>	Jan 02, 1987
<u>AB</u>			<u>5MG</u>	<u>A071173</u>	<u>005</u>	Jan 07, 1988
<u>AB</u>			<u>10MG</u>	<u>A071173</u>	<u>001</u>	Jan 07, 1988
<u>AB</u>			<u>20MG</u>	<u>A071173</u>	<u>006</u>	Jan 07, 1988
<u>AB</u>		MYLAN	<u>0.5MG</u>	<u>A070278</u>	<u>006</u>	Jun 10, 1986
<u>AB</u>			<u>1MG</u>	<u>A070278</u>	<u>004</u>	Jun 10, 1986
<u>AB</u>	!		<u>2MG</u>	<u>A070278</u>	<u>001</u>	Jun 10, 1986
<u>AB</u>			<u>5MG</u>	<u>A070278</u>	<u>005</u>	Jun 10, 1986
<u>AB</u>			<u>10MG</u>	<u>A070278</u>	<u>002</u>	Jul 16, 2009
<u>AB</u>			<u>20MG</u>	<u>A070278</u>	<u>003</u>	Jul 16, 2009
<u>AB</u>		SANDOZ	<u>0.5MG</u>	<u>A071206</u>	<u>001</u>	Nov 17, 1986
<u>AB</u>			<u>1MG</u>	<u>A071207</u>	<u>001</u>	Nov 17, 1986
<u>AB</u>			<u>5MG</u>	<u>A071209</u>	<u>001</u>	Nov 17, 1986
<u>AB</u>			<u>10MG</u>	<u>A071210</u>	<u>001</u>	Mar 11, 1988
<u>AB</u>			<u>20MG</u>	<u>A071211</u>	<u>001</u>	Mar 11, 1988
<u>AB</u>		UPSHER SMITH LABS	<u>0.5MG</u>	<u>A211061</u>	<u>001</u>	Jan 08, 2020
<u>AB</u>			<u>1MG</u>	<u>A211061</u>	<u>002</u>	Jan 08, 2020
<u>AB</u>			<u>2MG</u>	<u>A211061</u>	<u>003</u>	Jan 08, 2020
<u>AB</u>			<u>5MG</u>	<u>A211061</u>	<u>004</u>	Jan 08, 2020
<u>AB</u>			<u>10MG</u>	<u>A211061</u>	<u>005</u>	Jan 08, 2020
<u>AB</u>			<u>20MG</u>	<u>A211061</u>	<u>006</u>	Jan 08, 2020
<u>AB</u>		ZYDUS PHARMS USA	<u>5MG</u>	<u>A077580</u>	<u>003</u>	Nov 29, 2007
<u>AB</u>			<u>10MG</u>	<u>A077580</u>	<u>004</u>	Nov 29, 2007
<u>AB</u>			<u>20MG</u>	<u>A077580</u>	<u>005</u>	Nov 29, 2007

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALDOL

<u>AO</u>	+	!	JANSSEN PHARMS	<u>EQ 50MG BASE/ML</u>	<u>N018701</u>	<u>001</u>	Jan 14, 1986
<u>AO</u>	+	!		<u>EQ 100MG BASE/ML</u>	<u>N018701</u>	<u>002</u>	Jan 31, 1997

HALOPERIDOL DECANOATE

<u>AO</u>		FRESENIUS KABI USA	<u>EQ 50MG BASE/ML</u>	<u>A074893</u>	<u>001</u>	Dec 19, 1997
<u>AO</u>			<u>EQ 100MG BASE/ML</u>	<u>A074893</u>	<u>002</u>	Dec 19, 1997
<u>AO</u>		GLAND PHARMA LTD	<u>EQ 50MG BASE/ML</u>	<u>A205241</u>	<u>001</u>	May 12, 2017
<u>AO</u>			<u>EQ 100MG BASE/ML</u>	<u>A205241</u>	<u>002</u>	May 12, 2017
<u>AO</u>		MYLAN LABS LTD	<u>EQ 50MG BASE/ML</u>	<u>A075440</u>	<u>001</u>	Feb 28, 2000
<u>AO</u>			<u>EQ 100MG BASE/ML</u>	<u>A075440</u>	<u>002</u>	Feb 28, 2000
<u>AO</u>		SOMERSET THERAPS LLC	<u>EQ 50MG BASE/ML</u>	<u>A209101</u>	<u>001</u>	Jul 03, 2018
<u>AO</u>			<u>EQ 100MG BASE/ML</u>	<u>A209101</u>	<u>002</u>	Jul 03, 2018
<u>AO</u>		TEVA PHARMS USA	<u>EQ 50MG BASE/ML</u>	<u>A075393</u>	<u>001</u>	May 11, 1999
<u>AO</u>			<u>EQ 100MG BASE/ML</u>	<u>A075393</u>	<u>002</u>	May 11, 1999
<u>AO</u>		WEST-WARD PHARMS INT	<u>EQ 50MG BASE/ML</u>	<u>A074811</u>	<u>001</u>	Jan 30, 1998
<u>AO</u>			<u>EQ 100MG BASE/ML</u>	<u>A075305</u>	<u>001</u>	Sep 28, 1998
<u>AO</u>		ZYDUS PHARMS	<u>EQ 50MG BASE/ML</u>	<u>A211180</u>	<u>001</u>	Oct 22, 2019
<u>AO</u>			<u>EQ 100MG BASE/ML</u>	<u>A211180</u>	<u>002</u>	Oct 22, 2019

PRESCRIPTION DRUG PRODUCT LIST

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALOPERIDOL

<u>AA</u>	LANNETT CO INC	<u>EQ 2MG BASE/ML</u>	<u>A073364 001</u>	Sep 28, 1993
<u>AA</u>	! PHARM ASSOC	<u>EQ 2MG BASE/ML</u>	<u>A073037 001</u>	Feb 26, 1993

INJECTABLE; INJECTION

HALOPERIDOL

<u>AP</u>	AKORN	<u>EQ 5MG BASE/ML</u>	<u>A204849 001</u>	Sep 06, 2017
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 5MG BASE/ML</u>	<u>A075689 001</u>	Mar 09, 2001
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A210356 001</u>	Jul 01, 2019
<u>AP</u>	GLAND PHARMA LTD	<u>EQ 5MG BASE/ML</u>	<u>A076774 001</u>	Aug 25, 2004
<u>AP</u>	! MYLAN LABS LTD	<u>EQ 5MG BASE/ML</u>	<u>A078347 001</u>	Sep 14, 2009
<u>AP</u>	SAGENT PHARMS	<u>EQ 5MG BASE/ML</u>	<u>A091637 001</u>	Sep 02, 2011
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A200742 001</u>	Sep 02, 2011
<u>AP</u>	WEST-WARD PHARMS INT	<u>EQ 5MG BASE/ML</u>	<u>A075858 001</u>	Jun 18, 2001

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

<u>AP</u>	BE PHARMS	<u>1,000 UNITS/ML</u>	<u>A214804 001</u>	Dec 29, 2020
<u>AP</u>		<u>10,000 UNITS/ML</u>	<u>A214839 001</u>	Dec 29, 2020
<u>AP</u>	+! FRESENIUS KABI USA	<u>1,000 UNITS/ML</u>	<u>N017029 001</u>	
<u>AP</u>		<u>5,000 UNITS/ML</u>	<u>A206552 001</u>	Jun 10, 2016
<u>AP</u>	+!	<u>5,000 UNITS/ML</u>	<u>N017651 006</u>	
<u>AP</u>	+!	<u>10,000 UNITS/ML</u>	<u>N017029 003</u>	
<u>AP</u>	+!	<u>20,000 UNITS/ML</u>	<u>N017029 004</u>	
<u>AP</u>	GLAND PHARMA LTD	<u>1,000 UNITS/ML</u>	<u>A205323 002</u>	Nov 18, 2019
<u>AP</u>		<u>5,000 UNITS/ML</u>	<u>A205323 001</u>	Feb 06, 2017
<u>AP</u>	+! HIKMA	<u>1,000 UNITS/ML</u>	<u>N017037 001</u>	
<u>AP</u>	+!	<u>5,000 UNITS/ML</u>	<u>N017037 002</u>	
<u>AP</u>	+!	<u>10,000 UNITS/ML</u>	<u>N017037 003</u>	
<u>AP</u>	HOSPIRA INC	<u>1,000 UNITS/ML</u>	<u>A090571 001</u>	Aug 31, 2009
<u>AP</u>		<u>5,000 UNITS/ML</u>	<u>A090571 002</u>	Aug 31, 2009
<u>AP</u>		<u>10,000 UNITS/ML</u>	<u>A090571 003</u>	Aug 31, 2009
<u>AP</u>	MYLAN LABS LTD	<u>1,000 UNITS/ML</u>	<u>A203851 001</u>	Nov 30, 2017
<u>AP</u>		<u>5,000 UNITS/ML</u>	<u>A203851 002</u>	Nov 30, 2017
<u>AP</u>		<u>10,000 UNITS/ML</u>	<u>A203851 003</u>	Nov 30, 2017
<u>AP</u>		<u>20,000 UNITS/ML</u>	<u>A203852 001</u>	Nov 30, 2017
<u>AP</u>	NANJING KING-FRIEND	<u>1,000 UNITS/ML</u>	<u>A211005 001</u>	Dec 14, 2018
<u>AP</u>		<u>1,000 UNITS/ML</u>	<u>A211007 001</u>	May 28, 2019
<u>AP</u>		<u>5,000 UNITS/ML</u>	<u>A211007 002</u>	May 28, 2019
<u>AP</u>		<u>5,000 UNITS/ML</u>	<u>A212061 001</u>	Jul 15, 2020
<u>AP</u>		<u>10,000 UNITS/ML</u>	<u>A211007 003</u>	May 28, 2019
<u>AP</u>		<u>20,000 UNITS/ML</u>	<u>A211004 001</u>	Feb 24, 2020
<u>AP</u>	SAGENT PHARMS	<u>1,000 UNITS/ML</u>	<u>A090808 001</u>	Jun 30, 2010
<u>AP</u>		<u>5,000 UNITS/ML</u>	<u>A090808 002</u>	Jun 30, 2010
<u>AP</u>		<u>10,000 UNITS/ML</u>	<u>A090808 003</u>	Jun 30, 2010
<u>AP</u>		<u>20,000 UNITS/ML</u>	<u>A090809 001</u>	Jun 30, 2010
<u>AP</u>	SANDOZ	<u>1,000 UNITS/ML</u>	<u>A091682 001</u>	Jun 08, 2011
<u>AP</u>		<u>5,000 UNITS/ML</u>	<u>A091682 002</u>	Jun 08, 2011
<u>AP</u>		<u>10,000 UNITS/ML</u>	<u>A201002 001</u>	Jun 08, 2011
<u>AP</u>	SHENZHEN TECHDOW	<u>1,000 UNITS/ML</u>	<u>A202957 001</u>	Jun 12, 2014
<u>AP</u>		<u>5,000 UNITS/ML</u>	<u>A202733 001</u>	Jun 12, 2014
<u>AP</u>		<u>5,000 UNITS/ML</u>	<u>A202957 002</u>	Jun 12, 2014
<u>AP</u>		<u>10,000 UNITS/ML</u>	<u>A203198 001</u>	Jun 12, 2014
<u>AP</u>		<u>20,000 UNITS/ML</u>	<u>A203198 002</u>	Jun 12, 2014
<u>HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>				
<u>AP</u>	BAXTER HLTHCARE	<u>200 UNITS/100ML</u>	<u>N018609 001</u>	Apr 28, 1982
<u>HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>				
<u>AP</u>	+! B BRAUN	<u>200 UNITS/100ML</u>	<u>N019953 001</u>	Jul 20, 1992
<u>AP</u>	FRESENIUS KABI USA	<u>200 UNITS/100ML</u>	<u>A212441 001</u>	Jul 24, 2020
<u>AP</u>	+! HOSPIRA	<u>200 UNITS/100ML</u>	<u>N018916 010</u>	Jun 23, 1989
<u>HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER</u>				
<u>AP</u>	HOSPIRA	<u>10,000 UNITS/100ML</u>	<u>N019339 003</u>	Mar 27, 1985
<u>HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>				
<u>AP</u>	BAXTER HLTHCARE	<u>200 UNITS/100ML</u>	<u>N018609 002</u>	Apr 28, 1982
<u>HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>				
<u>AP</u>	FRESENIUS KABI USA	<u>200 UNITS/100ML</u>	<u>A212441 002</u>	Jul 24, 2020
<u>AP</u>	+! HOSPIRA	<u>200 UNITS/100ML</u>	<u>N018916 011</u>	Jun 23, 1989
<u>HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER</u>				
<u>AP</u>	+! B BRAUN	<u>4,000 UNITS/100ML</u>	<u>N019952 001</u>	Jul 20, 1992
<u>AP</u>	HOSPIRA	<u>4,000 UNITS/100ML</u>	<u>N019805 001</u>	Jan 25, 1989

PRESCRIPTION DRUG PRODUCT LIST

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+	B BRAUN	<u>5,000 UNITS/100ML</u>	<u>N019952 004</u>	Jul 20, 1992
<u>AP</u>	+		<u>10,000 UNITS/100ML</u>	<u>N019952 005</u>	Jul 20, 1992
<u>AP</u>		HOSPIRA	<u>5,000 UNITS/100ML</u>	<u>N019339 004</u>	Mar 27, 1985
<u>AP</u>			<u>5,000 UNITS/100ML</u>	<u>N019805 002</u>	Jan 25, 1989
<u>AP</u>			<u>10,000 UNITS/100ML</u>	<u>N019339 002</u>	Mar 27, 1985

HEPARIN SODIUM IN PLASTIC CONTAINER

<u>AP</u>	+	FRESENIUS KABI USA	<u>1,000 UNITS/ML</u>	<u>N017029 013</u>	Dec 05, 1985
<u>AP</u>	+		<u>5,000 UNITS/ML</u>	<u>N017029 014</u>	Dec 05, 1985
<u>AP</u>	+		<u>10,000 UNITS/ML</u>	<u>N017029 015</u>	Dec 05, 1985
<u>AP</u>	+		<u>20,000 UNITS/ML</u>	<u>N017029 016</u>	Dec 05, 1985

HEPARIN SODIUM PRESERVATIVE FREE

<u>AP</u>	+	FRESENIUS KABI USA	<u>1,000 UNITS/ML</u>	<u>N017029 010</u>	Apr 28, 1986
<u>AP</u>	+		<u>10,000 UNITS/ML</u>	<u>N017029 019</u>	Nov 22, 2010
<u>AP</u>		HOSPIRA	<u>10,000 UNITS/ML</u>	<u>A089522 001</u>	May 04, 1987
<u>AP</u>		NANJING KING-FRIEND	<u>10,000 UNITS/ML</u>	<u>A212060 001</u>	Apr 02, 2020
<u>AP</u>		SAGENT PHARMS	<u>1,000 UNITS/ML</u>	<u>A090810 001</u>	Jun 30, 2010
<u>AP</u>		SHENZHEN TECHDOW	<u>1,000 UNITS/ML</u>	<u>A202732 001</u>	Jun 12, 2014

HEPARIN SODIUM

		B BRAUN MEDICAL INC	5,000 UNITS/0.5ML	A208827 001	Nov 19, 2018
	+	FRESENIUS KABI USA	10,000 UNITS/ML	N017029 020	Mar 31, 2011
	!	HOSPIRA	5,000 UNITS/ML	A088100 001	Apr 28, 1983
	+	PFIZER	1,000 UNITS/ML	N201370 001	Jul 21, 2011
	+		5,000 UNITS/ML	N201370 002	Jul 21, 2011

HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA 5,000 UNITS/100ML N019339 001 Mar 27, 1985

HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

HOSPIRA 5,000 UNITS/100ML N018916 006 Jan 31, 1984

HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

BAXTER HLTHCARE 2,000 UNITS/1000ML N018609 004 Apr 23, 2020

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

HOSPIRA 5,000 UNITS/100ML N018916 007 Jan 31, 1984

HOSPIRA 10,000 UNITS/100ML N018916 008 Jan 31, 1984

HEPARIN SODIUM PRESERVATIVE FREE

+! PFIZER 1,000 UNITS/ML N201370 004 Jul 21, 2011

HEXACHLOROPHENE

SPONGE; TOPICAL

PRE-OP

<u>AT</u>	+	DAVIS AND GECK	<u>480MG</u>	<u>N017433 001</u>	
-----------	---	----------------	--------------	--------------------	--

PRE-OP II

<u>AT</u>	+	DAVIS AND GECK	<u>480MG</u>	<u>N017433 002</u>	
-----------	---	----------------	--------------	--------------------	--

HEXAMINOLEVULINATE HYDROCHLORIDE

FOR SOLUTION; INTRAVESICAL

CYSVIEW KIT

+! PHOTOCURE ASA 100MG/VIAL N022555 001 May 28, 2010

HISTRELIN ACETATE

IMPLANT; SUBCUTANEOUS

SUPPRELIN LA

+! ENDO PHARM 50MG N022058 001 May 03, 2007

VANTAS

+! ENDO PHARM 50MG N021732 001 Oct 12, 2004

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYCODAN

<u>AA</u>	+	GENUS	<u>1.5MG/5ML; 5MG/5ML</u>	<u>N005213 002</u>	Jul 26, 1988
-----------	---	-------	---------------------------	--------------------	--------------

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

<u>AA</u>		ABHAI LLC	<u>1.5MG/5ML; 5MG/5ML</u>	<u>A207487 001</u>	Feb 21, 2017
-----------	--	-----------	---------------------------	--------------------	--------------

<u>AA</u>		ACTAVIS MID	<u>1.5MG/5ML; 5MG/5ML</u>	<u>A088017 001</u>	Jul 05, 1983
-----------	--	-------------	---------------------------	--------------------	--------------

ATLANTIC

<u>AA</u>	!	AKORN	<u>1.5MG/5ML; 5MG/5ML</u>	<u>A040613 001</u>	Feb 08, 2008
-----------	---	-------	---------------------------	--------------------	--------------

<u>AA</u>		NOVEL LABS INC	<u>1.5MG/5ML; 5MG/5ML</u>	<u>A203535 001</u>	Feb 13, 2017
-----------	--	----------------	---------------------------	--------------------	--------------

<u>AA</u>		PADDOCK LABS LLC	<u>1.5MG/5ML; 5MG/5ML</u>	<u>A205731 001</u>	Feb 15, 2017
-----------	--	------------------	---------------------------	--------------------	--------------

<u>AA</u>		WOCKHARDT BIO AG	<u>1.5MG/5ML; 5MG/5ML</u>	<u>A088008 001</u>	Mar 03, 1983
-----------	--	------------------	---------------------------	--------------------	--------------

TABLET; ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

<u>AA</u>		AVANTHI INC	<u>1.5MG; 5MG</u>	<u>A207176 001</u>	Aug 07, 2017
-----------	--	-------------	-------------------	--------------------	--------------

<u>AA</u>	!	NOVEL LABS INC	<u>1.5MG; 5MG</u>	<u>A091528 001</u>	Apr 20, 2011
-----------	---	----------------	-------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HYDROCHLORIDE

<u>AP</u>	!	AKORN	<u>20MG/ML</u>	<u>A040730</u>	<u>001</u>	Apr 21, 2009
<u>AP</u>		AM REGENT	<u>20MG/ML</u>	<u>A040136</u>	<u>001</u>	Jun 30, 1997
<u>AP</u>		FRESENIUS KABI USA	<u>20MG/ML</u>	<u>A040388</u>	<u>001</u>	Mar 13, 2001
<u>AP</u>		HIKMA	<u>20MG/ML</u>	<u>A213667</u>	<u>001</u>	Dec 18, 2020
<u>AP</u>		I3 PHARMS	<u>20MG/ML</u>	<u>A203110</u>	<u>001</u>	Jun 29, 2015
<u>AP</u>		MYLAN INSTITUTIONAL	<u>20MG/ML</u>	<u>A204680</u>	<u>001</u>	Apr 28, 2016
<u>AP</u>		NAVINTA LLC	<u>20MG/ML</u>	<u>A202938</u>	<u>001</u>	Mar 28, 2013

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

<u>AA</u>		ALKEM LABS LTD	<u>10MG</u>	<u>A200737</u>	<u>001</u>	Dec 07, 2012
<u>AA</u>			<u>25MG</u>	<u>A200737</u>	<u>002</u>	Dec 07, 2012
<u>AA</u>			<u>50MG</u>	<u>A200737</u>	<u>003</u>	Dec 07, 2012
<u>AA</u>			<u>100MG</u>	<u>A200737</u>	<u>004</u>	Dec 07, 2012
<u>AA</u>		CADILA PHARMS LTD	<u>25MG</u>	<u>A203845</u>	<u>001</u>	Sep 18, 2014
<u>AA</u>			<u>50MG</u>	<u>A203845</u>	<u>002</u>	Sep 18, 2014
<u>AA</u>			<u>100MG</u>	<u>A203845</u>	<u>003</u>	Sep 18, 2014
<u>AA</u>		GLENMARK PHARMS LTD	<u>10MG</u>	<u>A090527</u>	<u>001</u>	May 27, 2009
<u>AA</u>			<u>25MG</u>	<u>A090527</u>	<u>002</u>	May 27, 2009
<u>AA</u>			<u>50MG</u>	<u>A090527</u>	<u>003</u>	May 27, 2009
<u>AA</u>			<u>100MG</u>	<u>A090527</u>	<u>004</u>	May 27, 2009
<u>AA</u>		HERITAGE PHARMS INC	<u>10MG</u>	<u>A086242</u>	<u>001</u>	Feb 04, 2010
<u>AA</u>			<u>25MG</u>	<u>A086242</u>	<u>003</u>	
<u>AA</u>			<u>50MG</u>	<u>A086242</u>	<u>002</u>	
<u>AA</u>			<u>100MG</u>	<u>A086242</u>	<u>004</u>	Feb 04, 2010
<u>AA</u>		HETERO LABS LTD III	<u>10MG</u>	<u>A040901</u>	<u>001</u>	Sep 12, 2008
<u>AA</u>			<u>25MG</u>	<u>A040901</u>	<u>002</u>	Sep 12, 2008
<u>AA</u>			<u>50MG</u>	<u>A040901</u>	<u>003</u>	Sep 12, 2008
<u>AA</u>			<u>100MG</u>	<u>A040901</u>	<u>004</u>	Sep 12, 2008
<u>AA</u>		INVAGEN PHARMS	<u>10MG</u>	<u>A090255</u>	<u>001</u>	Dec 15, 2008
<u>AA</u>			<u>25MG</u>	<u>A090255</u>	<u>002</u>	Dec 15, 2008
<u>AA</u>			<u>50MG</u>	<u>A090255</u>	<u>003</u>	Dec 15, 2008
<u>AA</u>			<u>100MG</u>	<u>A090255</u>	<u>004</u>	Dec 15, 2008
<u>AA</u>		PAR PHARM	<u>10MG</u>	<u>A087836</u>	<u>001</u>	Oct 05, 1982
<u>AA</u>			<u>25MG</u>	<u>A086961</u>	<u>002</u>	
<u>AA</u>			<u>50MG</u>	<u>A086962</u>	<u>001</u>	
<u>AA</u>			<u>100MG</u>	<u>A088391</u>	<u>001</u>	Sep 27, 1983
<u>AA</u>	!	PLIVA	<u>10MG</u>	<u>A089097</u>	<u>001</u>	Dec 18, 1985
<u>AA</u>	!		<u>25MG</u>	<u>A088467</u>	<u>001</u>	May 01, 1984
<u>AA</u>	!		<u>50MG</u>	<u>A088468</u>	<u>001</u>	May 01, 1984
<u>AA</u>	!		<u>100MG</u>	<u>A089098</u>	<u>001</u>	Dec 18, 1985
<u>AA</u>		SCIEGEN PHARMS INC	<u>10MG</u>	<u>A205236</u>	<u>001</u>	May 26, 2017
<u>AA</u>			<u>25MG</u>	<u>A205236</u>	<u>002</u>	May 26, 2017
<u>AA</u>			<u>50MG</u>	<u>A205236</u>	<u>003</u>	May 26, 2017
<u>AA</u>			<u>100MG</u>	<u>A205236</u>	<u>004</u>	May 26, 2017
<u>AA</u>		STRIDES PHARMA	<u>25MG</u>	<u>A200770</u>	<u>001</u>	May 03, 2013
<u>AA</u>			<u>50MG</u>	<u>A200770</u>	<u>002</u>	May 03, 2013
<u>AA</u>			<u>100MG</u>	<u>A200770</u>	<u>003</u>	May 03, 2013
<u>AA</u>		UPSHER SMITH LABS	<u>10MG</u>	<u>A209251</u>	<u>001</u>	Jul 09, 2018
<u>AA</u>			<u>25MG</u>	<u>A209251</u>	<u>002</u>	Jul 09, 2018
<u>AA</u>			<u>50MG</u>	<u>A209251</u>	<u>003</u>	Jul 09, 2018
<u>AA</u>			<u>100MG</u>	<u>A209251</u>	<u>004</u>	Jul 09, 2018

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDRA-ZIDE

		PAR PHARM	25MG; 25MG	A088957	001	Oct 21, 1985
	!		50MG; 50MG	A088946	001	Oct 21, 1985

HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

TABLET; ORAL

BIDIL

	+	ARBOR PHARMS LLC	37.5MG; 20MG	N020727	001	Jun 23, 2005
--	---	------------------	--------------	---------	-----	--------------

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

<u>AB</u>		AUROBINDO PHARMA	<u>12.5MG</u>	<u>A078164</u>	<u>001</u>	Sep 18, 2007
<u>AB</u>		IPCA LABS LTD	<u>12.5MG</u>	<u>A079237</u>	<u>001</u>	Apr 02, 2009
<u>AB</u>		JUBILANT CADISTA	<u>12.5MG</u>	<u>A078391</u>	<u>001</u>	Feb 11, 2008
<u>AB</u>		MYLAN	<u>12.5MG</u>	<u>A075640</u>	<u>001</u>	Jan 28, 2000
<u>AB</u>		PRINSTON INC	<u>12.5MG</u>	<u>A075907</u>	<u>001</u>	Sep 17, 2002

PRESCRIPTION DRUG PRODUCT LIST

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

<u>AB</u>	SCIEGEN PHARMS INC	<u>12.5MG</u>	<u>A203561</u>	<u>001</u>	Jan 14, 2019
<u>AB</u>	SUN PHARM INDS INC	<u>12.5MG</u>	<u>A090651</u>	<u>001</u>	Apr 07, 2014
<u>AB</u>	UNICHEM	<u>12.5MG</u>	<u>A090510</u>	<u>001</u>	Jan 19, 2010

MICROZIDE

<u>AB</u>	+! ALLERGAN	<u>12.5MG</u>	<u>N020504</u>	<u>001</u>	Dec 27, 1996
-----------	-------------	---------------	----------------	------------	--------------

TABLET; ORAL

HYDROCHLOROTHIAZIDE

<u>AB</u>	!	ACCORD HLTHCARE	<u>12.5MG</u>	<u>A202556</u>	<u>001</u>	Sep 24, 2012
<u>AB</u>			<u>25MG</u>	<u>A202556</u>	<u>002</u>	Sep 24, 2012
<u>AB</u>			<u>50MG</u>	<u>A202556</u>	<u>003</u>	Sep 24, 2012
<u>AB</u>		ACTAVIS ELIZABETH	<u>12.5MG</u>	<u>A040707</u>	<u>001</u>	Feb 27, 2007
<u>AB</u>		AUROBINDO PHARMA	<u>25MG</u>	<u>A040780</u>	<u>001</u>	Jul 20, 2007
<u>AB</u>			<u>50MG</u>	<u>A040780</u>	<u>002</u>	Jul 20, 2007
<u>AB</u>		HERITAGE PHARMS INC	<u>25MG</u>	<u>A085182</u>	<u>002</u>	
<u>AB</u>			<u>50MG</u>	<u>A085182</u>	<u>001</u>	
<u>AB</u>		IPCA LABS LTD	<u>12.5MG</u>	<u>A040807</u>	<u>001</u>	Jul 20, 2007
<u>AB</u>			<u>25MG</u>	<u>A040807</u>	<u>002</u>	Jul 20, 2007
<u>AB</u>			<u>50MG</u>	<u>A040807</u>	<u>003</u>	Jul 20, 2007
<u>AB</u>		IVAX SUB TEVA PHARMS	<u>25MG</u>	<u>A083177</u>	<u>001</u>	
<u>AB</u>	!		<u>50MG</u>	<u>A083177</u>	<u>002</u>	
<u>AB</u>		LEADING PHARMA LLC	<u>12.5MG</u>	<u>A040702</u>	<u>003</u>	May 10, 2017
<u>AB</u>			<u>25MG</u>	<u>A040702</u>	<u>001</u>	Mar 16, 2007
<u>AB</u>			<u>50MG</u>	<u>A040702</u>	<u>002</u>	Mar 16, 2007
<u>AB</u>		OXFORD PHARMS	<u>25MG</u>	<u>A087059</u>	<u>001</u>	
<u>AB</u>			<u>50MG</u>	<u>A087068</u>	<u>001</u>	
<u>AB</u>		PRINSTON INC	<u>25MG</u>	<u>A040412</u>	<u>001</u>	Mar 29, 2002
<u>AB</u>			<u>50MG</u>	<u>A040412</u>	<u>002</u>	Mar 29, 2002
<u>AB</u>		SCIEGEN PHARMS INC	<u>25MG</u>	<u>A203018</u>	<u>001</u>	Jul 23, 2014
<u>AB</u>			<u>50MG</u>	<u>A203018</u>	<u>002</u>	Jul 23, 2014
<u>AB</u>		UNICHEM	<u>25MG</u>	<u>A040907</u>	<u>001</u>	Aug 15, 2008
<u>AB</u>			<u>50MG</u>	<u>A040907</u>	<u>002</u>	Aug 15, 2008

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVALIDE

<u>AB</u>	+!	SANOFI AVENTIS US	<u>12.5MG;150MG</u>	<u>N020758</u>	<u>002</u>	Sep 30, 1997
<u>AB</u>	+!		<u>12.5MG;300MG</u>	<u>N020758</u>	<u>003</u>	Aug 31, 1998

IRBESARTAN AND HYDROCHLOROTHIAZIDE

<u>AB</u>		ALEMBIC PHARMS LTD	<u>12.5MG;150MG</u>	<u>A091370</u>	<u>001</u>	Oct 15, 2012
<u>AB</u>			<u>12.5MG;300MG</u>	<u>A091370</u>	<u>002</u>	Oct 15, 2012
<u>AB</u>			<u>25MG;300MG</u>	<u>A091370</u>	<u>003</u>	Oct 12, 2016
<u>AB</u>		AUROBINDO PHARMA LTD	<u>12.5MG;150MG</u>	<u>A203630</u>	<u>001</u>	Feb 22, 2013
<u>AB</u>			<u>12.5MG;300MG</u>	<u>A203630</u>	<u>002</u>	Feb 22, 2013
<u>AB</u>			<u>25MG;300MG</u>	<u>A203630</u>	<u>003</u>	Mar 31, 2016
<u>AB</u>		DR REDDYS LABS LTD	<u>12.5MG;150MG</u>	<u>A203500</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>			<u>12.5MG;300MG</u>	<u>A203500</u>	<u>002</u>	Sep 27, 2012
<u>AB</u>		HIKMA	<u>12.5MG;150MG</u>	<u>A090351</u>	<u>001</u>	Oct 15, 2012
<u>AB</u>			<u>12.5MG;300MG</u>	<u>A090351</u>	<u>002</u>	Oct 15, 2012
<u>AB</u>			<u>25MG;300MG</u>	<u>A090351</u>	<u>003</u>	Jun 08, 2017
<u>AB</u>		HISUN PHARM HANGZHOU	<u>12.5MG;150MG</u>	<u>A207896</u>	<u>001</u>	Oct 14, 2016
<u>AB</u>			<u>12.5MG;300MG</u>	<u>A207896</u>	<u>002</u>	Oct 14, 2016
<u>AB</u>		LUPIN LTD	<u>12.5MG;150MG</u>	<u>A201524</u>	<u>001</u>	Feb 27, 2013
<u>AB</u>			<u>12.5MG;300MG</u>	<u>A201524</u>	<u>002</u>	Feb 27, 2013
<u>AB</u>		MACLEODS PHARMS LTD	<u>12.5MG;150MG</u>	<u>A202414</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>			<u>12.5MG;300MG</u>	<u>A202414</u>	<u>002</u>	Sep 27, 2012
<u>AB</u>		PRINSTON INC	<u>12.5MG;150MG</u>	<u>A203072</u>	<u>001</u>	May 09, 2014
<u>AB</u>			<u>12.5MG;300MG</u>	<u>A203072</u>	<u>002</u>	May 09, 2014
<u>AB</u>		SANDOZ	<u>12.5MG;150MG</u>	<u>A077446</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>			<u>12.5MG;300MG</u>	<u>A077446</u>	<u>002</u>	Sep 27, 2012
<u>AB</u>		TEVA	<u>12.5MG;150MG</u>	<u>A077369</u>	<u>001</u>	Mar 30, 2012
<u>AB</u>			<u>12.5MG;300MG</u>	<u>A077369</u>	<u>002</u>	Mar 30, 2012

PRESCRIPTION DRUG PRODUCT LIST

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

<u>AB</u>	AUROBINDO	<u>12.5MG;10MG</u>	<u>A077606 001</u>	Mar 14, 2006
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A077606 002</u>	Mar 14, 2006
<u>AB</u>		<u>25MG;20MG</u>	<u>A077606 003</u>	Mar 14, 2006
<u>AB</u>	INVAGEN PHARMS	<u>12.5MG;10MG</u>	<u>A204058 001</u>	May 23, 2017
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A204058 002</u>	May 23, 2017
<u>AB</u>		<u>25MG;20MG</u>	<u>A204058 003</u>	May 23, 2017
<u>AB</u>	LUPIN	<u>12.5MG;10MG</u>	<u>A077912 001</u>	Sep 27, 2006
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A077912 002</u>	Sep 27, 2006
<u>AB</u>		<u>25MG;20MG</u>	<u>A077912 003</u>	Sep 27, 2006
<u>AB</u>	PRINSTON INC	<u>12.5MG;10MG</u>	<u>A076230 001</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076230 002</u>	Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076230 003</u>	Jul 01, 2002
<u>AB</u>	SANDOZ	<u>12.5MG;10MG</u>	<u>A076262 001</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076262 002</u>	Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076262 003</u>	Jul 01, 2002
<u>AB</u>	SUN PHARM INDS LTD	<u>12.5MG;10MG</u>	<u>A076007 001</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076007 002</u>	Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076007 003</u>	Jul 01, 2002
<u>AB</u>	WATSON LABS	<u>12.5MG;10MG</u>	<u>A076194 003</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076194 001</u>	Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076194 002</u>	Jul 01, 2002
<u>ZESTORETIC</u>				
<u>AB</u>	+ ALVOGEN	<u>12.5MG;10MG</u>	<u>N019888 003</u>	Nov 18, 1993
<u>AB</u>	+!	<u>12.5MG;20MG</u>	<u>N019888 001</u>	Sep 20, 1990
<u>AB</u>	+!	<u>25MG;20MG</u>	<u>N019888 002</u>	Jul 20, 1989

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

HYZAAR

<u>AB</u>	+ ORGANON	<u>12.5MG;100MG</u>	<u>N020387 003</u>	Oct 20, 2005
<u>LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE</u>				
<u>AB</u>	ALEMBIC PHARMS LTD	<u>12.5MG;50MG</u>	<u>A091617 001</u>	Feb 17, 2012
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A091617 002</u>	Feb 17, 2012
<u>AB</u>		<u>25MG;100MG</u>	<u>A091617 003</u>	Feb 17, 2012
<u>AB</u>	AUROBINDO PHARMA	<u>12.5MG;50MG</u>	<u>A091629 001</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A091629 002</u>	Oct 06, 2010
<u>AB</u>	!	<u>25MG;100MG</u>	<u>A091629 003</u>	Jan 06, 2010
<u>AB</u>	CADISTA PHARMS	<u>12.5MG;50MG</u>	<u>A201845 001</u>	Sep 18, 2012
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A201845 002</u>	Sep 18, 2012
<u>AB</u>		<u>25MG;100MG</u>	<u>A201845 003</u>	Sep 18, 2012
<u>AB</u>	IPCA LABS LTD	<u>12.5MG;50MG</u>	<u>A201682 001</u>	Mar 01, 2013
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A201682 002</u>	Mar 01, 2013
<u>AB</u>		<u>25MG;100MG</u>	<u>A201682 003</u>	Mar 01, 2013
<u>AB</u>	LUPIN LTD	<u>12.5MG;50MG</u>	<u>A078245 001</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A078245 002</u>	May 21, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A078245 003</u>	Oct 06, 2010
<u>AB</u>	MACLEODS PHARMS LTD	<u>12.5MG;50MG</u>	<u>A202289 001</u>	Aug 09, 2012
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A202289 002</u>	Aug 09, 2012
<u>AB</u>		<u>25MG;100MG</u>	<u>A202289 003</u>	Aug 09, 2012
<u>AB</u>	PRINSTON INC	<u>12.5MG;50MG</u>	<u>A204901 001</u>	Nov 06, 2017
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A204901 002</u>	Nov 06, 2017
<u>AB</u>		<u>25MG;100MG</u>	<u>A204901 003</u>	Nov 06, 2017
<u>AB</u>	SANDOZ	<u>12.5MG;50MG</u>	<u>A077948 001</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A077948 003</u>	Aug 19, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A077948 002</u>	Oct 06, 2010
<u>AB</u>	TEVA PHARMS	<u>12.5MG;50MG</u>	<u>A077157 001</u>	Apr 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A077157 002</u>	Apr 06, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A077157 003</u>	Apr 06, 2010
<u>AB</u>	TORRENT PHARMS	<u>12.5MG;50MG</u>	<u>A090528 001</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A090528 003</u>	Apr 06, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A090528 002</u>	Oct 06, 2010
<u>AB</u>	ZYDUS PHARMS USA INC	<u>12.5MG;50MG</u>	<u>A078385 001</u>	Oct 06, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A078385 002</u>	Oct 06, 2010

PRESCRIPTION DRUG PRODUCT LIST

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

MYLAN	15MG; 250MG	A070265	002	Jan 23, 1986
!	25MG; 250MG	A070265	001	Jan 23, 1986

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DUTOPROL

+ CONCORDIA	12.5MG; EQ 25MG TARTRATE	N021956	001	Aug 28, 2006
+	12.5MG; EQ 50MG TARTRATE	N021956	002	Aug 28, 2006
+!	12.5MG; EQ 100MG TARTRATE	N021956	003	Aug 28, 2006

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

LOPRESSOR HCT

<u>AB</u>	+	US PHARMS HOLDINGS	<u>25MG; 50MG</u>	<u>N018303</u>	<u>001</u>	Dec 31, 1984
-----------	---	--------------------	-------------------	----------------	------------	--------------

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

<u>AB</u>		ALEMBIC PHARMS LTD	<u>25MG; 50MG</u>	<u>A202870</u>	<u>001</u>	Nov 06, 2013
<u>AB</u>	!		<u>25MG; 100MG</u>	<u>A202870</u>	<u>002</u>	Nov 06, 2013
<u>AB</u>			<u>50MG; 100MG</u>	<u>A202870</u>	<u>003</u>	Nov 06, 2013
<u>AB</u>		MYLAN	<u>25MG; 50MG</u>	<u>A076792</u>	<u>001</u>	Aug 20, 2004
<u>AB</u>			<u>25MG; 100MG</u>	<u>A076792</u>	<u>002</u>	Aug 20, 2004
<u>AB</u>			<u>50MG; 100MG</u>	<u>A076792</u>	<u>003</u>	Aug 20, 2004
<u>AB</u>		SUN PHARM INDS	<u>25MG; 50MG</u>	<u>A090654</u>	<u>001</u>	Jan 19, 2012
<u>AB</u>			<u>25MG; 100MG</u>	<u>A090654</u>	<u>002</u>	Jan 19, 2012
<u>AB</u>			<u>50MG; 100MG</u>	<u>A090654</u>	<u>003</u>	Jan 19, 2012

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

<u>AB</u>		GLENMARK PHARMS	<u>12.5MG; 7.5MG</u>	<u>A090718</u>	<u>001</u>	Mar 17, 2010
<u>AB</u>			<u>12.5MG; 15MG</u>	<u>A090718</u>	<u>002</u>	Mar 17, 2010
<u>AB</u>			<u>25MG; 15MG</u>	<u>A090718</u>	<u>003</u>	Mar 17, 2010
<u>AB</u>		TEVA	<u>12.5MG; 7.5MG</u>	<u>A076980</u>	<u>001</u>	Mar 07, 2007
<u>AB</u>			<u>12.5MG; 15MG</u>	<u>A076980</u>	<u>003</u>	Mar 07, 2007
<u>AB</u>	!		<u>25MG; 15MG</u>	<u>A076980</u>	<u>002</u>	Mar 07, 2007

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

BENICAR HCT

<u>AB</u>	+	DAIICHI SANKYO	<u>12.5MG; 20MG</u>	<u>N021532</u>	<u>002</u>	Jun 05, 2003
<u>AB</u>	+		<u>12.5MG; 40MG</u>	<u>N021532</u>	<u>003</u>	Jun 05, 2003
<u>AB</u>	+!		<u>25MG; 40MG</u>	<u>N021532</u>	<u>005</u>	Jun 05, 2003

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

<u>AB</u>		ACCORD HLTHCARE	<u>12.5MG; 20MG</u>	<u>A209281</u>	<u>001</u>	Feb 07, 2019
<u>AB</u>			<u>12.5MG; 40MG</u>	<u>A209281</u>	<u>002</u>	Feb 07, 2019
<u>AB</u>			<u>25MG; 40MG</u>	<u>A209281</u>	<u>003</u>	Feb 07, 2019
<u>AB</u>		ALEMBIC PHARMS LTD	<u>12.5MG; 20MG</u>	<u>A204233</u>	<u>001</u>	Apr 24, 2017
<u>AB</u>			<u>12.5MG; 40MG</u>	<u>A204233</u>	<u>002</u>	Apr 24, 2017
<u>AB</u>			<u>25MG; 40MG</u>	<u>A204233</u>	<u>003</u>	Apr 24, 2017
<u>AB</u>		AUROBINDO PHARMA LTD	<u>12.5MG; 20MG</u>	<u>A205391</u>	<u>001</u>	Apr 24, 2017
<u>AB</u>			<u>12.5MG; 40MG</u>	<u>A205391</u>	<u>002</u>	Apr 24, 2017
<u>AB</u>			<u>25MG; 40MG</u>	<u>A205391</u>	<u>003</u>	Apr 24, 2017
<u>AB</u>		PRINSTON INC	<u>12.5MG; 20MG</u>	<u>A207804</u>	<u>001</u>	Apr 24, 2017
<u>AB</u>			<u>12.5MG; 40MG</u>	<u>A207804</u>	<u>002</u>	Apr 24, 2017
<u>AB</u>			<u>25MG; 40MG</u>	<u>A207804</u>	<u>003</u>	Apr 24, 2017
<u>AB</u>		TEVA PHARMS USA	<u>12.5MG; 40MG</u>	<u>A200532</u>	<u>002</u>	Apr 24, 2017
<u>AB</u>		TORRENT	<u>12.5MG; 20MG</u>	<u>A206515</u>	<u>001</u>	May 03, 2017
<u>AB</u>			<u>12.5MG; 40MG</u>	<u>A206515</u>	<u>002</u>	May 03, 2017
<u>AB</u>			<u>25MG; 40MG</u>	<u>A206515</u>	<u>003</u>	May 03, 2017
<u>AB</u>		UMEDICA LABS PVT LTD	<u>12.5MG; 20MG</u>	<u>A208847</u>	<u>001</u>	Sep 17, 2019
<u>AB</u>			<u>12.5MG; 40MG</u>	<u>A208847</u>	<u>003</u>	Sep 17, 2019
<u>AB</u>			<u>25MG; 40MG</u>	<u>A208847</u>	<u>002</u>	Sep 17, 2019

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	!	MYLAN	<u>25MG; 80MG</u>	<u>A070947</u>	<u>001</u>	Apr 01, 1987
	!		<u>25MG; 40MG</u>	A070947	002	Mar 04, 1987

PRESCRIPTION DRUG PRODUCT LIST

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

ACCURETIC

<u>AB</u>	+	PFIZER PHARMS	<u>12.5MG;EQ 10MG BASE</u>	<u>N020125 001</u>	Dec 28, 1999
<u>AB</u>	+		<u>12.5MG;EQ 20MG BASE</u>	<u>N020125 002</u>	Dec 28, 1999
<u>AB</u>	+	!	<u>25MG;EQ 20MG BASE</u>	<u>N020125 003</u>	Dec 28, 1999

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

<u>AB</u>		APOTEX CORP	<u>12.5MG;EQ 10MG BASE</u>	<u>A091524 001</u>	Mar 12, 2013
<u>AB</u>			<u>12.5MG;EQ 20MG BASE</u>	<u>A091524 002</u>	Mar 12, 2013
<u>AB</u>			<u>25MG;EQ 20MG BASE</u>	<u>A091524 003</u>	Mar 12, 2013
<u>AB</u>		AUROBINDO PHARMA	<u>12.5MG;EQ 10MG BASE</u>	<u>A078450 001</u>	Aug 24, 2007
<u>AB</u>			<u>12.5MG;EQ 20MG BASE</u>	<u>A078450 002</u>	Aug 24, 2007
<u>AB</u>			<u>25MG;EQ 20MG BASE</u>	<u>A078450 003</u>	Aug 24, 2007
<u>AB</u>		INVAGEN PHARMS	<u>12.5MG;EQ 10MG BASE</u>	<u>A201356 001</u>	Apr 20, 2011
<u>AB</u>			<u>12.5MG;EQ 20MG BASE</u>	<u>A201356 002</u>	Apr 20, 2011
<u>AB</u>			<u>25MG;EQ 20MG BASE</u>	<u>A201356 003</u>	Apr 20, 2011

QUINARETIC

<u>AB</u>		LUPIN	<u>12.5MG;EQ 10MG BASE</u>	<u>A076374 001</u>	Mar 31, 2004
<u>AB</u>			<u>12.5MG;EQ 20MG BASE</u>	<u>A076374 002</u>	Mar 31, 2004
<u>AB</u>			<u>25MG;EQ 20MG BASE</u>	<u>A076374 003</u>	Mar 31, 2004

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

ALDACTAZIDE

<u>AB</u>	+	PFIZER	<u>25MG;25MG</u>	<u>N012616 004</u>	Dec 30, 1982
<u>SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE</u>					
<u>AB</u>		MYLAN	<u>25MG;25MG</u>	<u>A086513 001</u>	
<u>AB</u>		SUN PHARM INDUSTRIES	<u>25MG;25MG</u>	<u>A089534 001</u>	Jul 02, 1987
<u>ALDACTAZIDE</u>					
	+	PFIZER	<u>50MG;50MG</u>	<u>N012616 005</u>	Dec 30, 1982

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL

MICARDIS HCT

<u>AB</u>	+	BOEHRINGER INGELHEIM	<u>12.5MG;40MG</u>	<u>N021162 001</u>	Nov 17, 2000
<u>AB</u>	+		<u>12.5MG;80MG</u>	<u>N021162 002</u>	Nov 17, 2000
<u>AB</u>	+	!	<u>25MG;80MG</u>	<u>N021162 003</u>	Apr 19, 2004

TELMISARTAN AND HYDROCHLOROTHIAZIDE

<u>AB</u>		ALEMBIC PHARMS LTD	<u>12.5MG;40MG</u>	<u>A203010 001</u>	Feb 25, 2014
<u>AB</u>			<u>12.5MG;80MG</u>	<u>A203010 002</u>	Feb 25, 2014
<u>AB</u>			<u>25MG;80MG</u>	<u>A203010 003</u>	Feb 25, 2014
<u>AB</u>		AUROBINDO PHARMA LTD	<u>12.5MG;40MG</u>	<u>A208727 001</u>	Dec 15, 2016
<u>AB</u>			<u>12.5MG;80MG</u>	<u>A208727 002</u>	Dec 15, 2016
<u>AB</u>			<u>25MG;80MG</u>	<u>A208727 003</u>	Dec 15, 2016
<u>AB</u>		GLENMARK PHARMS LTD	<u>12.5MG;40MG</u>	<u>A202544 001</u>	Mar 04, 2019
<u>AB</u>			<u>12.5MG;80MG</u>	<u>A202544 002</u>	Mar 04, 2019
<u>AB</u>			<u>25MG;80MG</u>	<u>A202544 003</u>	Mar 04, 2019
<u>AB</u>		LUPIN LTD	<u>12.5MG;40MG</u>	<u>A091351 001</u>	Aug 07, 2014
<u>AB</u>			<u>12.5MG;80MG</u>	<u>A091351 002</u>	Aug 07, 2014
<u>AB</u>			<u>25MG;80MG</u>	<u>A091351 003</u>	Aug 07, 2014
<u>AB</u>		PRINSTON INC	<u>12.5MG;40MG</u>	<u>A209028 001</u>	Nov 06, 2017
<u>AB</u>			<u>12.5MG;80MG</u>	<u>A209028 002</u>	Nov 06, 2017
<u>AB</u>			<u>25MG;80MG</u>	<u>A209028 003</u>	Nov 06, 2017
<u>AB</u>		TORRENT	<u>12.5MG;40MG</u>	<u>A201192 001</u>	Feb 25, 2014
<u>AB</u>			<u>12.5MG;80MG</u>	<u>A201192 002</u>	Feb 25, 2014
<u>AB</u>			<u>25MG;80MG</u>	<u>A201192 003</u>	Feb 25, 2014
<u>AB</u>		ZYDUS PHARMS	<u>12.5MG;40MG</u>	<u>A204221 001</u>	Aug 15, 2017
<u>AB</u>			<u>12.5MG;80MG</u>	<u>A204221 002</u>	Aug 15, 2017
<u>AB</u>			<u>25MG;80MG</u>	<u>A204221 003</u>	Aug 15, 2017

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

<u>AB</u>		CADILA	<u>25MG;37.5MG</u>	<u>A208358 001</u>	Feb 11, 2019
<u>AB</u>		LANNETT CO INC	<u>25MG;37.5MG</u>	<u>A201407 001</u>	Dec 09, 2011
<u>AB</u>		MYLAN	<u>25MG;37.5MG</u>	<u>A074701 001</u>	Jun 07, 1996
<u>AB</u>	!	SANDOZ	<u>25MG;37.5MG</u>	<u>A074821 001</u>	Jun 05, 1997

TABLET; ORAL

MAXZIDE

<u>AB</u>	+	MYLAN PHARMS INC	<u>50MG;75MG</u>	<u>N019129 001</u>	Oct 22, 1984
-----------	---	------------------	------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

HYDROCHLOROTHIAZIDE; TRIAMTERENE

TABLET; ORAL

MAXZIDE-25

AB	+	MYLAN PHARMS INC	<u>25MG; 37.5MG</u>	<u>N019129</u>	<u>003</u>	May 13, 1988
<u>TRIAMTERENE AND HYDROCHLOROTHIAZIDE</u>						
AB		APOTEX INC	<u>25MG; 37.5MG</u>	<u>A071251</u>	<u>002</u>	May 05, 1998
AB			<u>50MG; 75MG</u>	<u>A071251</u>	<u>001</u>	Apr 17, 1988
AB		SANDOZ	<u>25MG; 37.5MG</u>	<u>A073281</u>	<u>001</u>	Apr 30, 1992
AB			<u>50MG; 75MG</u>	<u>A072011</u>	<u>001</u>	Jun 17, 1988
AB		WATSON LABS	<u>25MG; 37.5MG</u>	<u>A073449</u>	<u>001</u>	Sep 23, 1993
AB			<u>50MG; 75MG</u>	<u>A071851</u>	<u>001</u>	Nov 30, 1988
AB		ZYDUS PHARMS	<u>25MG; 37.5MG</u>	<u>A208360</u>	<u>001</u>	Jun 29, 2018
AB			<u>50MG; 75MG</u>	<u>A208360</u>	<u>002</u>	Jun 29, 2018

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

DIOVAN HCT

AB	+	NOVARTIS	<u>12.5MG; 80MG</u>	<u>N020818</u>	<u>001</u>	Mar 06, 1998
AB	+		<u>12.5MG; 160MG</u>	<u>N020818</u>	<u>002</u>	Mar 06, 1998
AB	+		<u>12.5MG; 320MG</u>	<u>N020818</u>	<u>004</u>	Apr 28, 2006
AB	+		<u>25MG; 160MG</u>	<u>N020818</u>	<u>003</u>	Jan 17, 2002
AB	+		<u>25MG; 320MG</u>	<u>N020818</u>	<u>005</u>	Apr 28, 2006

VALSARTAN AND HYDROCHLOROTHIAZIDE

AB		ALEMBOIC PHARMS LTD	<u>12.5MG; 80MG</u>	<u>A201662</u>	<u>001</u>	Mar 21, 2013
AB			<u>12.5MG; 160MG</u>	<u>A201662</u>	<u>002</u>	Mar 21, 2013
AB			<u>12.5MG; 320MG</u>	<u>A201662</u>	<u>003</u>	Mar 21, 2013
AB			<u>25MG; 160MG</u>	<u>A201662</u>	<u>004</u>	Mar 21, 2013
AB			<u>25MG; 320MG</u>	<u>A201662</u>	<u>005</u>	Mar 21, 2013
AB		AUROBINDO PHARMA LTD	<u>12.5MG; 80MG</u>	<u>A202519</u>	<u>001</u>	Mar 21, 2013
AB			<u>12.5MG; 160MG</u>	<u>A202519</u>	<u>002</u>	Mar 21, 2013
AB			<u>12.5MG; 320MG</u>	<u>A202519</u>	<u>003</u>	Mar 21, 2013
AB			<u>25MG; 160MG</u>	<u>A202519</u>	<u>004</u>	Mar 21, 2013
AB			<u>25MG; 320MG</u>	<u>A202519</u>	<u>005</u>	Mar 21, 2013
AB		LUPIN LTD	<u>12.5MG; 80MG</u>	<u>A078946</u>	<u>003</u>	Mar 21, 2013
AB			<u>12.5MG; 160MG</u>	<u>A078946</u>	<u>004</u>	Mar 21, 2013
AB			<u>12.5MG; 320MG</u>	<u>A078946</u>	<u>001</u>	Mar 21, 2013
AB			<u>25MG; 160MG</u>	<u>A078946</u>	<u>005</u>	Mar 21, 2013
AB			<u>25MG; 320MG</u>	<u>A078946</u>	<u>002</u>	Mar 21, 2013
AB		MACLEODS PHARMS LTD	<u>12.5MG; 80MG</u>	<u>A203145</u>	<u>001</u>	Apr 19, 2013
AB			<u>12.5MG; 160MG</u>	<u>A203145</u>	<u>002</u>	Apr 19, 2013
AB			<u>12.5MG; 320MG</u>	<u>A203145</u>	<u>003</u>	Apr 19, 2013
AB			<u>25MG; 160MG</u>	<u>A203145</u>	<u>004</u>	Apr 19, 2013
AB			<u>25MG; 320MG</u>	<u>A203145</u>	<u>005</u>	Apr 19, 2013
AB		MYLAN PHARMS INC	<u>12.5MG; 80MG</u>	<u>A078020</u>	<u>001</u>	Sep 21, 2012
AB			<u>12.5MG; 160MG</u>	<u>A078020</u>	<u>002</u>	Sep 21, 2012
AB			<u>12.5MG; 320MG</u>	<u>A078020</u>	<u>004</u>	Sep 21, 2012
AB			<u>25MG; 160MG</u>	<u>A078020</u>	<u>003</u>	Sep 21, 2012
AB			<u>25MG; 320MG</u>	<u>A078020</u>	<u>005</u>	Sep 21, 2012
AB		PRINSTON INC	<u>12.5MG; 80MG</u>	<u>A206083</u>	<u>001</u>	Feb 08, 2016
AB			<u>12.5MG; 160MG</u>	<u>A206083</u>	<u>002</u>	Feb 08, 2016
AB			<u>12.5MG; 320MG</u>	<u>A206083</u>	<u>003</u>	Feb 08, 2016
AB			<u>25MG; 160MG</u>	<u>A206083</u>	<u>004</u>	Feb 08, 2016
AB			<u>25MG; 320MG</u>	<u>A206083</u>	<u>005</u>	Feb 08, 2016

HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

HYDROCODONE BITARTRATE

AB		ALVOGEN	<u>10MG</u>	<u>A206986</u>	<u>001</u>	Jan 21, 2020
AB			<u>15MG</u>	<u>A206986</u>	<u>002</u>	Jan 21, 2020
AB			<u>20MG</u>	<u>A206986</u>	<u>003</u>	Jan 21, 2020
AB			<u>30MG</u>	<u>A206986</u>	<u>004</u>	Jan 21, 2020
AB			<u>40MG</u>	<u>A206986</u>	<u>005</u>	Jan 21, 2020
AB			<u>50MG</u>	<u>A206986</u>	<u>006</u>	Jan 21, 2020

ZOHYDRO ER

AB	+	PERSION	<u>10MG</u>	<u>N202880</u>	<u>001</u>	Oct 25, 2013
AB	+		<u>15MG</u>	<u>N202880</u>	<u>002</u>	Oct 25, 2013
AB	+		<u>20MG</u>	<u>N202880</u>	<u>003</u>	Oct 25, 2013
AB	+		<u>30MG</u>	<u>N202880</u>	<u>004</u>	Oct 25, 2013
AB	+		<u>40MG</u>	<u>N202880</u>	<u>005</u>	Oct 25, 2013
AB	+		<u>50MG</u>	<u>N202880</u>	<u>006</u>	Oct 25, 2013

PRESCRIPTION DRUG PRODUCT LIST

HYDROCODONE BITARTRATE

TABLET, EXTENDED RELEASE;ORAL

HYSINGLA ER

+	!	PURDUE PHARMA LP	20MG	N206627	001	Nov 20, 2014
+			30MG	N206627	002	Nov 20, 2014
+			40MG	N206627	003	Nov 20, 2014
+			60MG	N206627	004	Nov 20, 2014
+			80MG	N206627	005	Nov 20, 2014
+			100MG	N206627	006	Nov 20, 2014
+			120MG	N206627	007	Nov 20, 2014

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET;ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

AB		ACTAVIS LABS FL INC	<u>7.5MG;200MG</u>	<u>A076604</u>	<u>001</u>	Dec 31, 2003
AB		AMNEAL PHARMS NY	<u>5MG;200MG</u>	<u>A076642</u>	<u>002</u>	Mar 18, 2004
AB	!		<u>7.5MG;200MG</u>	<u>A076642</u>	<u>001</u>	Oct 12, 2004
AB		AUROLIFE PHARMA LLC	<u>7.5MG;200MG</u>	<u>A204575</u>	<u>001</u>	Jun 02, 2016
AB		VINTAGE PHARMS	<u>5MG;200MG</u>	<u>A077727</u>	<u>001</u>	Nov 06, 2006
AB			<u>7.5MG;200MG</u>	<u>A077723</u>	<u>001</u>	Nov 06, 2006
AB			<u>10MG;200MG</u>	<u>A077723</u>	<u>002</u>	Nov 06, 2006
<u>REPREXAIN</u>						
AB		AMNEAL PHARMS NY	<u>10MG;200MG</u>	<u>A076642</u>	<u>004</u>	Oct 19, 2007
			2.5MG;200MG	A076642	003	Oct 19, 2007

HYDROCORTISONE

CREAM;TOPICAL

ALA-CORT

AT		CROWN LABS	<u>2.5%</u>	<u>A080706</u>	<u>007</u>	Jan 05, 2016
AT			<u>1%</u>	<u>A080706</u>	<u>006</u>	

ANUSOL HC

AT		SALIX PHARMS	<u>2.5%</u>	<u>A088250</u>	<u>001</u>	Jun 06, 1984
-----------	--	--------------	--------------------	-----------------------	-------------------	--------------

HYDROCORTISONE

AT		ACTAVIS MID ATLANTIC	<u>1%</u>	<u>A087795</u>	<u>001</u>	May 03, 1983
AT			<u>2.5%</u>	<u>A089682</u>	<u>001</u>	Mar 10, 1988
AT	!	FOUGERA PHARMS INC	<u>1%</u>	<u>A080693</u>	<u>003</u>	
AT	!		<u>2.5%</u>	<u>A089414</u>	<u>001</u>	Dec 16, 1986
AT		LANNETT CO INC	<u>2.5%</u>	<u>A040503</u>	<u>001</u>	Mar 12, 2004
AT		PERRIGO NEW YORK	<u>2.5%</u>	<u>A085025</u>	<u>001</u>	
AT		RISING	<u>2.5%</u>	<u>A040879</u>	<u>001</u>	Aug 20, 2010
AT		TARO PHARM INDS LTD	<u>2.5%</u>	<u>A088799</u>	<u>001</u>	Nov 09, 1984

ENEMA;RECTAL

COLOCORT

AB		CP PHARMA	<u>100MG/60ML</u>	<u>A075172</u>	<u>001</u>	Dec 03, 1999
-----------	--	-----------	--------------------------	-----------------------	-------------------	--------------

CORTENEMA

AB	+	!	ANI PHARMS	<u>100MG/60ML</u>	<u>N016199</u>	<u>001</u>
-----------	---	---	------------	--------------------------	-----------------------	-------------------

GRANULE;ORAL

ALKINDI SPRINKLE

+		ETON	0.5MG	N213876	001	Sep 29, 2020
+			1MG	N213876	002	Sep 29, 2020
+			2MG	N213876	003	Sep 29, 2020
+	!		5MG	N213876	004	Sep 29, 2020

LOTION;TOPICAL

HYDROCORTISONE

AT		LANNETT CO INC	<u>2.5%</u>	<u>A040417</u>	<u>001</u>	Jul 30, 2003
AT		TARO	<u>2.5%</u>	<u>A040247</u>	<u>001</u>	Jul 23, 1999

STIE-CORT

AT	!	PERRIGO CO	<u>2.5%</u>	<u>A089074</u>	<u>001</u>	Nov 26, 1985
-----------	---	------------	--------------------	-----------------------	-------------------	--------------

ALA-SCALP

		MARNEL PHARMS	2%	A083231	001	
--	--	---------------	----	---------	-----	--

OINTMENT;TOPICAL

HYDROCORTISONE

AT	!	FOUGERA PHARMS	<u>1%</u>	<u>A080692</u>	<u>001</u>	
AT	!	FOUGERA PHARMS INC	<u>2.5%</u>	<u>A081203</u>	<u>001</u>	May 28, 1993
AT		PERRIGO NEW YORK	<u>2.5%</u>	<u>A085027</u>	<u>001</u>	
AT		TARO	<u>1%</u>	<u>A086257</u>	<u>001</u>	

HYDROCORTISONE IN ABSORBASE

AT		CMP PHARMA INC	<u>1%</u>	<u>A088138</u>	<u>001</u>	Sep 06, 1985
-----------	--	----------------	------------------	-----------------------	-------------------	--------------

SOLUTION;TOPICAL

TEXACORT

!		MISSION PHARMA	2.5%	A081271	001	Apr 17, 1992
---	--	----------------	------	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

HYDROCORTISONE

TABLET; ORAL

CORTEF

AB	+	PHARMACIA AND UPJOHN	5MG	N008697	003	
AB	+		10MG	N008697	001	
AB	+	!	20MG	N008697	002	

HYDROCORTISONE

AB		IMPAX LABS INC	5MG	A040646	001	Mar 30, 2007
AB			10MG	A040646	002	Mar 30, 2007
AB			20MG	A040646	003	Mar 30, 2007
AB		STRIDES PHARMA	5MG	A207029	001	Apr 27, 2017
AB			10MG	A207029	002	Apr 27, 2017
AB			20MG	A207029	003	Apr 27, 2017

HYDROCORTISONE ACETATE

AEROSOL, METERED; RECTAL

CORTIFOAM

+! MYLAN SPECIALITY LP 10%

N017351 001 Feb 10, 1982

CREAM; TOPICAL

MICORT-HC

SEBELA IRELAND LTD 2.5%

A040396 001 Feb 27, 2001

U-CORT

TARO 1%

A089472 001 Jun 13, 1988

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM; TOPICAL

CORTISPORIN

+! MONARCH PHARMS 0.5%; EQ 3.5MG BASE/GM; 10,000 UNITS/GM

N050218 001 Aug 09, 1985

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED; TOPICAL

EPIFOAM

BX		MYLAN SPECIALITY LP	1%; 1%	A086457	001	
		PROCTOFOAM HC				

BX		MYLAN SPECIALITY LP	1%; 1%	A086195	001	
-----------	--	---------------------	--------	---------	-----	--

CREAM; TOPICAL

PRAMOSONE

SEBELA IRELAND LTD 0.5%; 1%

A083778 001

1%; 1%

A085368 001

LOTION; TOPICAL

PRAMOSONE

SEBELA IRELAND LTD 1%; 1%

A085980 001

2.5%; 1%

A085979 001

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL

HYDROCORTISONE BUTYRATE

AB1		TARO PHARM INDS	0.1%	A076654	001	Aug 03, 2005
------------	--	-----------------	-------------	----------------	------------	--------------

LOCOID

AB1	+	!	BAUSCH	0.1%	N018514	001	Mar 31, 1982
------------	---	---	--------	-------------	----------------	------------	--------------

HYDROCORTISONE BUTYRATE

AB2		ACTAVIS MID	0.1%	A205134	001	Dec 08, 2017
------------	--	-------------	-------------	----------------	------------	--------------

ATLANTIC

AB2		GLENMARK GENERICS	0.1%	A202145	001	Sep 27, 2013
------------	--	-------------------	-------------	----------------	------------	--------------

LOCOID LIPOCREAM

AB2	+	!	PRECISION DERMAT	0.1%	N020769	001	Sep 08, 1997
------------	---	---	------------------	-------------	----------------	------------	--------------

LOTION; TOPICAL

HYDROCORTISONE BUTYRATE

AB		LUPIN LTD	0.1%	A210209	001	Aug 17, 2018
-----------	--	-----------	-------------	----------------	------------	--------------

AB		TELGENT	0.1%	A209556	001	Nov 21, 2017
-----------	--	---------	-------------	----------------	------------	--------------

LOCOID

AB	+	!	BAUSCH	0.1%	N022076	001	May 18, 2007
-----------	---	---	--------	-------------	----------------	------------	--------------

OINTMENT; TOPICAL

HYDROCORTISONE BUTYRATE

AB		TARO	0.1%	A076842	001	Dec 27, 2004
-----------	--	------	-------------	----------------	------------	--------------

LOCOID

AB	+	!	PRECISION DERMAT	0.1%	N018652	001	Oct 29, 1982
-----------	---	---	------------------	-------------	----------------	------------	--------------

SOLUTION; TOPICAL

HYDROCORTISONE BUTYRATE

AT		TARO PHARM INDS	0.1%	A076364	001	Jan 14, 2004
-----------	--	-----------------	-------------	----------------	------------	--------------

LOCOID

AT	+	!	BAUSCH	0.1%	N019116	001	Feb 25, 1987
-----------	---	---	--------	-------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

HYDROCORTISONE PROBUTATE

CREAM; TOPICAL

PANDEL

+! FOUGERA PHARMS 0.1% N020453 001 Feb 28, 1997

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

SOLU-CORTEF

+! PHARMACIA AND EQ 100MG BASE/VIAL N009866 001
UPJOHN

+! EQ 250MG BASE/VIAL N009866 002

+! EQ 500MG BASE/VIAL N009866 003

+! EQ 1GM BASE/VIAL N009866 004

HYDROCORTISONE VALERATE

CREAM; TOPICAL

HYDROCORTISONE VALERATE**AB** GLENMARK PHARMS LTD **0.2%** **A211129 001** Oct 12, 2018**AB** LUPIN LTD **0.2%** **A210307 001** Aug 15, 2019**AB** PERRIGO ISRAEL **0.2%** **A075666 001** May 24, 2000**AB** ! TARO **0.2%** **A075042 001** Aug 25, 1998

OINTMENT; TOPICAL

HYDROCORTISONE VALERATE**AB** COSETTE **0.2%** **A211764 001** Mar 04, 2020**AB** GLENMARK PHARMS LTD **0.2%** **A211750 001** Dec 14, 2018**AB** ! TARO **0.2%** **A075043 001** Aug 25, 1998HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE**AT** ! BAUSCH AND LOMB **1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML** **A064053 001** Dec 29, 1995**AT** SANDOZ INC **1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML** **A062423 001** Aug 25, 1983

SUSPENSION/DROPS; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

! SANDOZ INC 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML A062874 001 May 11, 1988

SUSPENSION/DROPS; OTIC

CASPORYN HC**AT** +! CASPER PHARMA LLC **1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML** **N060613 001**NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE**AT** AMRING PHARMS **1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML** **A065219 001** May 01, 2006**AT** SANDOZ INC **1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML** **A062488 001** Nov 06, 1985OTICAIR**AT** BAUSCH AND LOMB **1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML** **A064065 001** Aug 28, 1996HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

DILAUDID**AP** +! FRESENIUS KABI USA **1MG/ML** **N019034 003** Apr 30, 2009**AP** +! **2MG/ML** **N019034 004** Apr 30, 2009HYDROMORPHONE HYDROCHLORIDE**AP** AKORN **10MG/ML** **A078228 001** Apr 14, 2010**AP** **10MG/ML** **A078261 001** Apr 14, 2010**AP** EUROHLTH INTL SARL **2MG/ML** **A202159 001** Apr 27, 2018**AP** HOSPIRA INC **1MG/ML** **N200403 001** Dec 01, 2011**AP** **2MG/ML** **N200403 002** Dec 01, 2011**AP** **4MG/ML** **N200403 003** Dec 01, 2011**AP** **10MG/ML** **A078591 001** Jun 17, 2008

DILAUDID

+! FRESENIUS KABI USA 0.2MG/ML N019034 006 Jan 16, 2020

SOLUTION; ORAL

DILAUDID**AA** +! RHODES PHARMS **5MG/5ML** **N019891 001** Dec 07, 1992HYDROMORPHONE HYDROCHLORIDE**AA** ASCENT PHARMS INC **5MG/5ML** **A210176 001** Oct 27, 2017**AA** HIKMA **5MG/5ML** **A074653 001** Jul 29, 1998

TABLET; ORAL

DILAUDID**AB** + RHODES PHARMS **2MG** **N019892 003** Nov 09, 2007**AB** + **4MG** **N019892 002** Nov 09, 2007**AB** +! **8MG** **N019892 001** Dec 07, 1992HYDROMORPHONE HYDROCHLORIDE**AB** ASCENT PHARMS INC **2MG** **A210506 001** Jan 17, 2018**AB** **4MG** **A210506 002** Jan 17, 2018**AB** **8MG** **A210506 003** Jan 17, 2018**AB** AUROLIFE PHARMA LLC **2MG** **A205814 001** May 13, 2016

PRESCRIPTION DRUG PRODUCT LIST

HYDROMORPHONE HYDROCHLORIDE

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

<u>AB</u>		<u>4MG</u>	<u>A205814</u>	<u>002</u>	May 13, 2016
<u>AB</u>		<u>8MG</u>	<u>A205814</u>	<u>003</u>	May 13, 2016
<u>AB</u>	HIKMA	<u>4MG</u>	<u>A074597</u>	<u>003</u>	May 29, 2009
<u>AB</u>		<u>8MG</u>	<u>A074597</u>	<u>001</u>	Jul 29, 1998
<u>AB</u>	LANNETT CO INC	<u>2MG</u>	<u>A077471</u>	<u>002</u>	Dec 09, 2009
<u>AB</u>		<u>4MG</u>	<u>A077471</u>	<u>003</u>	Dec 09, 2009
<u>AB</u>		<u>8MG</u>	<u>A077471</u>	<u>001</u>	Dec 09, 2009
<u>AB</u>	SPECGX LLC	<u>2MG</u>	<u>A076855</u>	<u>002</u>	Sep 19, 2007
<u>AB</u>		<u>4MG</u>	<u>A076855</u>	<u>003</u>	Sep 19, 2007
<u>AB</u>		<u>8MG</u>	<u>A076855</u>	<u>001</u>	Dec 23, 2004

TABLET, EXTENDED RELEASE; ORAL

HYDROMORPHONE HYDROCHLORIDE

<u>AB</u>	ASCENT PHARMS INC	<u>8MG</u>	<u>A212133</u>	<u>001</u>	Sep 23, 2020
<u>AB</u>		<u>12MG</u>	<u>A212133</u>	<u>002</u>	Sep 23, 2020
<u>AB</u>		<u>16MG</u>	<u>A212133</u>	<u>003</u>	Sep 23, 2020
<u>AB</u>		<u>32MG</u>	<u>A212133</u>	<u>004</u>	Sep 23, 2020
<u>AB</u>	OSMOTICA	<u>8MG</u>	<u>A205629</u>	<u>001</u>	Jul 07, 2016
<u>AB</u>		<u>12MG</u>	<u>A205629</u>	<u>002</u>	Jul 07, 2016
<u>AB</u>		<u>16MG</u>	<u>A205629</u>	<u>003</u>	Jul 07, 2016
<u>AB</u>	!	<u>32MG</u>	<u>A205629</u>	<u>004</u>	Jul 07, 2016
<u>AB</u>	PADDOCK LABS LLC	<u>8MG</u>	<u>A204278</u>	<u>001</u>	Apr 06, 2015
<u>AB</u>		<u>12MG</u>	<u>A204278</u>	<u>002</u>	Apr 06, 2015
<u>AB</u>		<u>16MG</u>	<u>A204278</u>	<u>003</u>	Apr 06, 2015
<u>AB</u>		<u>32MG</u>	<u>A204278</u>	<u>004</u>	Sep 20, 2017

HYDROXOCOBALAMIN

INJECTABLE; INJECTION

CYANOKIT

+! SERB SA 5GM/VIAL (5GM/KIT) N022041 001 Apr 08, 2011

HYDROXOCOBALAMIN

! ACTAVIS LLC 1MG/ML A085998 001

HYDROXYAMPHETAMINE HYDROBROMIDE; TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

PAREMYD

+! AKORN 1%; 0.25% N019261 001 Jan 30, 1992

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

<u>AB</u>	ACCORD HLTHCARE	<u>200MG</u>	<u>A213342</u>	<u>001</u>	Apr 07, 2020
<u>AB</u>	ALKALOIDA ZRT	<u>200MG</u>	<u>A201691</u>	<u>001</u>	May 08, 2018
<u>AB</u>	AMNEAL PHARMS CO	<u>200MG</u>	<u>A210577</u>	<u>001</u>	May 15, 2018
<u>AB</u>	DR REDDYS	<u>200MG</u>	<u>A210441</u>	<u>001</u>	May 01, 2018
<u>AB</u>	HAVIX	<u>200MG</u>	<u>A212902</u>	<u>001</u>	May 14, 2020
<u>AB</u>	IPCA LABS LTD	<u>200MG</u>	<u>A040766</u>	<u>001</u>	Jun 14, 2007
<u>AB</u>	LAURUS LABS LTD	<u>200MG</u>	<u>A210959</u>	<u>001</u>	Jan 15, 2019
<u>AB</u>	LUPIN LTD	<u>200MG</u>	<u>A210543</u>	<u>001</u>	Jul 06, 2018
<u>AB</u>	MYLAN	<u>200MG</u>	<u>A040274</u>	<u>001</u>	May 29, 1998
<u>AB</u>	SANDOZ	<u>200MG</u>	<u>A040104</u>	<u>001</u>	Nov 30, 1995
<u>AB</u>	TEVA PHARMS	<u>200MG</u>	<u>A040081</u>	<u>001</u>	Sep 30, 1994
<u>AB</u>	WATSON LABS	<u>200MG</u>	<u>A040133</u>	<u>001</u>	Nov 30, 1995
<u>AB</u>	ZYDUS PHARMS USA INC	<u>200MG</u>	<u>A040657</u>	<u>001</u>	Sep 21, 2007

PLAQUENILAB +! CONCORDIA 200MG N009768 001HYDROXYPROGESTERONE CAPROATE

SOLUTION; INTRAMUSCULAR

HYDROXYPROGESTERONE CAPROATE

<u>AP</u>	AM REGENT	<u>250MG/ML (250MG/ML)</u>	<u>A210723</u>	<u>001</u>	Jun 21, 2018
<u>AP</u>	ASPEN	<u>250MG/ML (250MG/ML)</u>	<u>A211777</u>	<u>001</u>	Aug 08, 2019
<u>AP</u>	EUGIA PHARMA	<u>250MG/ML (250MG/ML)</u>	<u>A211071</u>	<u>001</u>	Apr 16, 2019
<u>AP</u>	SLAYBACK PHARMA LLC	<u>250MG/ML (250MG/ML)</u>	<u>A210877</u>	<u>001</u>	Mar 22, 2019

MAKENA PRESERVATIVE FREEAP +! AMAG PHARMA USA 250MG/ML (250MG/ML) N021945 002 Feb 19, 2016HYDROXYPROGESTERONE CAPROATE

<u>AP1</u>	EUGIA PHARMA	<u>1250MG/5ML (250MG/ML)</u>	<u>A211070</u>	<u>001</u>	Apr 16, 2019
<u>AP1</u>	SLAYBACK PHARMA LLC	<u>1250MG/5ML (250MG/ML)</u>	<u>A210618</u>	<u>001</u>	Dec 28, 2018
<u>AP1</u>	SUN PHARM	<u>1250MG/5ML (250MG/ML)</u>	<u>A208381</u>	<u>001</u>	Apr 09, 2019

PRESCRIPTION DRUG PRODUCT LIST

HYDROXYPROGESTERONE CAPROATE

SOLUTION; INTRAMUSCULAR

MAKENA

AP1	+!	AMAG PHARMA USA	<u>1250MG/5ML (250MG/ML)</u>	<u>N021945 001</u>	Feb 03, 2011
		HYDROXYPROGESTERONE CAPROATE			
		! ASPEN GLOBAL INC	1250MG/5ML (250MG/ML)	A200271 001	Aug 24, 2015
		SOLUTION; SUBCUTANEOUS			
		MAKENA (AUTOINJECTOR)			
		+! AMAG PHARMA USA	275MG/1.1ML (250MG/ML)	N021945 004	Feb 14, 2018

HYDROXYPROPYL CELLULOSE

INSERT; OPHTHALMIC

LACRISERT

+! VALEANT PHARMS INTL 5MG

N018771 001

HYDROXYUREA

CAPSULE; ORAL

HYDREA

AB	+!	BRISTOL MYERS SQUIBB	<u>500MG</u>	<u>N016295 001</u>	
		<u>HYDROXYUREA</u>			
AB		BARR	<u>500MG</u>	<u>A075143 001</u>	Oct 16, 1998
AB		LEADING PHARMA LLC	<u>500MG</u>	<u>A213438 001</u>	Apr 08, 2020
AB		PAR PHARM	<u>500MG</u>	<u>A075340 001</u>	Feb 24, 1999
		DROXIA			
		+ BRISTOL MYERS SQUIBB	200MG	N016295 002	Feb 25, 1998
		+	300MG	N016295 003	Feb 25, 1998
		+	400MG	N016295 004	Feb 25, 1998
		TABLET; ORAL			
		SIKLOS			
		+ ADDMEDICA SAS	100MG	N208843 001	Dec 21, 2017
		+	1GM	N208843 002	Dec 21, 2017

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE HYDROCHLORIDE

! AM REGENT 25MG/ML

A087408 001

! 50MG/ML

A087408 002

SYRUP; ORAL

HYDROXYZINE HYDROCHLORIDE

AA	!	AKORN	<u>10MG/5ML</u>	<u>A040010 001</u>	Oct 28, 1994
AA		LANNETT CO INC	<u>10MG/5ML</u>	<u>A201674 001</u>	Aug 21, 2013
AA	!	WOCKHARDT BIO AG	<u>10MG/5ML</u>	<u>A087294 001</u>	Apr 12, 1982

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

AB		AMNEAL PHARM	<u>10MG</u>	<u>A040808 001</u>	Sep 24, 2008
AB			<u>25MG</u>	<u>A040808 002</u>	Sep 24, 2008
AB			<u>50MG</u>	<u>A040808 003</u>	Sep 24, 2008
AB		DISCOVERY THERAP	<u>10MG</u>	<u>A040804 001</u>	Jun 30, 2008
AB			<u>25MG</u>	<u>A040804 002</u>	Jun 30, 2008
AB			<u>50MG</u>	<u>A040804 003</u>	Jun 30, 2008
AB		EPIC PHARMA LLC	<u>10MG</u>	<u>A040604 002</u>	Dec 28, 2004
AB			<u>25MG</u>	<u>A040604 003</u>	Dec 28, 2004
AB			<u>50MG</u>	<u>A040604 001</u>	Dec 28, 2004
AB		HERITAGE PHARMA	<u>10MG</u>	<u>A204279 001</u>	Aug 20, 2014
AB			<u>25MG</u>	<u>A204279 002</u>	Aug 20, 2014
AB			<u>50MG</u>	<u>A204279 003</u>	Aug 20, 2014
AB		HETERO LABS LTD III	<u>10MG</u>	<u>A040805 001</u>	May 29, 2008
AB			<u>25MG</u>	<u>A040805 002</u>	May 29, 2008
AB			<u>50MG</u>	<u>A040805 003</u>	May 29, 2008
AB		INVAGEN PHARMS	<u>10MG</u>	<u>A040812 001</u>	Mar 12, 2008
AB			<u>25MG</u>	<u>A040812 002</u>	Mar 12, 2008
AB			<u>50MG</u>	<u>A040812 003</u>	Mar 12, 2008
AB		KVK TECH	<u>10MG</u>	<u>A040786 001</u>	Mar 20, 2007
AB			<u>25MG</u>	<u>A040786 002</u>	Mar 20, 2007
AB			<u>50MG</u>	<u>A040786 003</u>	Mar 20, 2007
AB		NORTHSTAR HLTHCARE	<u>10MG</u>	<u>A040840 002</u>	Mar 31, 2008
AB			<u>25MG</u>	<u>A040840 003</u>	Mar 31, 2008
AB			<u>50MG</u>	<u>A040840 001</u>	Mar 31, 2008
AB		NUVO PHARMS INC	<u>10MG</u>	<u>A207121 002</u>	Mar 29, 2017
AB			<u>25MG</u>	<u>A207121 001</u>	Mar 29, 2017
AB			<u>50MG</u>	<u>A207121 003</u>	Mar 29, 2017
AB	!	PLIVA	<u>10MG</u>	<u>A088617 001</u>	Jan 10, 1986

PRESCRIPTION DRUG PRODUCT LIST

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

AB	!		25MG	A088618	001	Jan 10, 1986
AB	!		50MG	A088619	001	Jan 10, 1986
AB		PRINSTON INC	10MG	A040579	001	May 27, 2005
AB			25MG	A040574	001	May 27, 2005
AB			50MG	A040580	001	May 27, 2005

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

AB		BARR	EQ 25MG HYDROCHLORIDE	A088496	001	Jun 15, 1984
AB			EQ 50MG HYDROCHLORIDE	A088487	001	Jun 15, 1984
AB		HERITAGE PHARMA	EQ 25MG HYDROCHLORIDE	A201507	001	Jun 03, 2013
AB			EQ 50MG HYDROCHLORIDE	A201507	002	Jun 03, 2013
AB		IMPAX LABS INC	EQ 25MG HYDROCHLORIDE	A040156	001	Jul 15, 1996
AB			EQ 50MG HYDROCHLORIDE	A040156	002	Jul 15, 1996
AB		SANDOZ	EQ 25MG HYDROCHLORIDE	A087479	001	
AB	!		EQ 50MG HYDROCHLORIDE	A086183	001	

VISTARIL

AB	+	PFIZER	EQ 25MG HYDROCHLORIDE	N011459	002	
AB	+		EQ 50MG HYDROCHLORIDE	N011459	004	
		HYDROXYZINE PAMOATE				
		BARR	EQ 100MG HYDROCHLORIDE	A088488	001	Jun 15, 1984

IBANDRONATE SODIUM

INJECTABLE; INTRAVENOUS

IBANDRONATE SODIUM

AP		ACCORD HLTHCARE	EQ 3MG BASE/3ML	A206058	001	Feb 05, 2016
AP	!	APOTEX	EQ 3MG BASE/3ML	A204222	001	Oct 16, 2015
AP		AUROBINDO PHARMA LTD	EQ 3MG BASE/3ML	A205332	001	Aug 19, 2015
AP		MYLAN LABS LTD	EQ 3MG BASE/3ML	A202671	001	Sep 02, 2014
AP		SAGENT PHARMS INC	EQ 3MG BASE/3ML	A202235	001	Sep 02, 2014
AP		SUN PHARM	EQ 3MG BASE/3ML	A090853	001	Feb 14, 2014

TABLET; ORAL

BONIVA

AB	+	HOFFMANN LA ROCHE	EQ 150MG BASE	N021455	002	Mar 24, 2005
-----------	---	-------------------	----------------------	----------------	------------	--------------

IBANDRONATE SODIUM

AB		APOTEX INC	EQ 150MG BASE	A078948	001	Mar 19, 2012
AB		AUROBINDO PHARMA LTD	EQ 150MG BASE	A204502	001	Mar 11, 2016
AB		DR REDDYS LABS LTD	EQ 150MG BASE	A078997	001	Apr 30, 2012
AB		MACLEODS PHARMS LTD	EQ 150MG BASE	A206887	001	Oct 31, 2017
AB		ORCHID HLTHCARE	EQ 150MG BASE	A078998	001	Mar 19, 2012
AB		WATSON LABS TEVA	EQ 150MG BASE	A079003	001	Mar 20, 2012

IBRUTINIB

CAPSULE; ORAL

IMBRUVICA

	+	PHARMACYCLICS INC	70MG	N205552	002	Dec 20, 2017
	+	!	140MG	N205552	001	Nov 13, 2013

TABLET; ORAL

IMBRUVICA

	+	PHARMACYCLICS INC	140MG	N210563	001	Feb 16, 2018
	+		280MG	N210563	002	Feb 16, 2018
	+		420MG	N210563	003	Feb 16, 2018
	+	!	560MG	N210563	004	Feb 16, 2018

IBUPROFEN

SOLUTION; INTRAVENOUS

CALDOLOR

	+	CUMBERLAND PHARMS	800MG/8ML (100MG/ML)	N022348	002	Jun 11, 2009
	+	!	800MG/200ML (4MG/ML)	N022348	003	Jan 25, 2019

SUSPENSION; ORAL

IBUPROFEN

AB	!	ACTAVIS MID ATLANTIC	100MG/5ML	A074978	001	Mar 25, 1998
AB		AKORN	100MG/5ML	A205647	001	Nov 03, 2016
AB		L PERRIGO CO	100MG/5ML	A076925	001	Sep 23, 2004
AB		TARO	100MG/5ML	A209204	001	Jun 23, 2017
		AUROBINDO PHARMA LTD	100MG/5ML	A209178	001	Feb 16, 2018

PRESCRIPTION DRUG PRODUCT LIST

IBUPROFEN

TABLET; ORAL

IBU-TAB

<u>AB</u>	ALRA	<u>400MG</u>	<u>A071058 001</u>	Aug 11, 1988
<u>AB</u>		<u>600MG</u>	<u>A071059 001</u>	Aug 11, 1988

IBUPROFEN

<u>AB</u>	AMNEAL PHARMS NY	<u>400MG</u>	<u>A071334 001</u>	Nov 25, 1986
<u>AB</u>		<u>400MG</u>	<u>A078558 001</u>	Jun 18, 2007
<u>AB</u>		<u>600MG</u>	<u>A071335 001</u>	Nov 25, 1986
<u>AB</u>		<u>600MG</u>	<u>A078558 002</u>	Jun 18, 2007
<u>AB</u>		<u>800MG</u>	<u>A071935 001</u>	Oct 13, 1987
<u>AB</u>		<u>800MG</u>	<u>A078558 003</u>	Jun 18, 2007
<u>AB</u>	AUROBINDO PHARMA LTD	<u>400MG</u>	<u>A213794 001</u>	May 08, 2020
<u>AB</u>		<u>600MG</u>	<u>A213794 002</u>	May 08, 2020
<u>AB</u>		<u>800MG</u>	<u>A213794 003</u>	May 08, 2020
<u>AB</u>	CONTRACT PHARMACAL	<u>400MG</u>	<u>A071268 002</u>	Oct 15, 1986
<u>AB</u>		<u>600MG</u>	<u>A071268 001</u>	Oct 15, 1986
<u>AB</u>		<u>800MG</u>	<u>A071268 003</u>	Jul 01, 1988
<u>AB</u>	DR REDDYS LA	<u>400MG</u>	<u>A075682 001</u>	Nov 14, 2001
<u>AB</u>		<u>600MG</u>	<u>A075682 002</u>	Nov 14, 2001
<u>AB</u>	!	<u>800MG</u>	<u>A075682 003</u>	Nov 14, 2001
<u>AB</u>	DR REDDYS LABS INC	<u>400MG</u>	<u>A076112 001</u>	Oct 31, 2001
<u>AB</u>		<u>600MG</u>	<u>A076112 002</u>	Oct 31, 2001
<u>AB</u>		<u>800MG</u>	<u>A076112 003</u>	Oct 31, 2001
<u>AB</u>	GRANULES	<u>400MG</u>	<u>A091625 001</u>	Sep 15, 2015
<u>AB</u>		<u>600MG</u>	<u>A091625 002</u>	Sep 15, 2015
<u>AB</u>		<u>800MG</u>	<u>A091625 003</u>	Sep 15, 2015
<u>AB</u>	MARKSANS PHARMA	<u>400MG</u>	<u>A090796 001</u>	Dec 21, 2010
<u>AB</u>		<u>600MG</u>	<u>A090796 002</u>	Dec 21, 2010
<u>AB</u>		<u>800MG</u>	<u>A090796 003</u>	Dec 21, 2010
<u>AB</u>	PERRIGO PHARMS CO	<u>400MG</u>	<u>A077114 001</u>	Jul 18, 2005
<u>AB</u>		<u>600MG</u>	<u>A077114 002</u>	Jul 18, 2005
<u>AB</u>		<u>800MG</u>	<u>A077114 003</u>	Jul 18, 2005
<u>AB</u>	SHANDONG XINHUA	<u>400MG</u>	<u>A202413 001</u>	Nov 23, 2016
<u>AB</u>		<u>600MG</u>	<u>A202413 002</u>	Nov 23, 2016
<u>AB</u>		<u>800MG</u>	<u>A202413 003</u>	Nov 23, 2016
<u>AB</u>	STRIDES PHARMA	<u>400MG</u>	<u>A078329 001</u>	Feb 05, 2009
<u>AB</u>		<u>600MG</u>	<u>A078329 002</u>	Feb 05, 2009
<u>AB</u>		<u>800MG</u>	<u>A078329 003</u>	Feb 05, 2009
<u>AB</u>	VINTAGE PHARMS	<u>400MG</u>	<u>A071644 001</u>	Feb 01, 1988

IBUPROFEN LYISINE

INJECTABLE; INTRAVENOUS

IBUPROFEN LYISINE

<u>AP</u>	XGEN PHARMS	<u>EQ 20MG BASE/2ML (EQ 10MG BASE/ML)</u>	<u>A202402 001</u>	Mar 30, 2016
-----------	-------------	---	--------------------	--------------

NEOPROFEN

<u>AP</u>	+!	RECORDATI RARE	<u>EQ 20MG BASE/2ML (EQ 10MG BASE/ML)</u>	<u>N021903 001</u>	Apr 13, 2006
-----------	----	----------------	---	--------------------	--------------

IBUTILIDE FUMARATE

INJECTABLE; INJECTION

CORVERT

<u>AP</u>	+!	PHARMACIA AND UPJOHN	<u>0.1MG/ML</u>	<u>N020491 001</u>	Dec 28, 1995
-----------	----	----------------------	-----------------	--------------------	--------------

IBUTILIDE FUMARATE

<u>AP</u>		MYLAN INSTITUTIONAL	<u>0.1MG/ML</u>	<u>A090643 001</u>	Jan 11, 2010
-----------	--	---------------------	-----------------	--------------------	--------------

ICATIBANT ACETATE

INJECTABLE; SUBCUTANEOUS

FIRAZYR

<u>AP</u>	+!	SHIRE ORPHAN THERAP	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>N022150 001</u>	Aug 25, 2011
-----------	----	---------------------	---	--------------------	--------------

ICATIBANT ACETATE

<u>AP</u>		CIPLA	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A212446 001</u>	Jul 13, 2020
<u>AP</u>		DR REDDYS	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A213054 001</u>	Oct 05, 2020
<u>AP</u>		FRESENIUS KABI USA	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A208317 001</u>	Jun 18, 2020
<u>AP</u>		JIANGSU HANSONH PHARM	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A211021 001</u>	Mar 09, 2020
<u>AP</u>		NANG KUANG PHARM CO	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A212081 001</u>	Dec 16, 2020
<u>AP</u>		SLAYBACK PHARMA LLC	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A211501 001</u>	Sep 01, 2020
<u>AP</u>		TEVA PHARMS USA	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A210118 001</u>	Jul 15, 2019

PRESCRIPTION DRUG PRODUCT LIST

ICODEXTRINSOLUTION; INTRAPERITONEAL
EXTRANEAL

+! BAXTER HLTHCARE 7.5GM/100ML N021321 001 Dec 20, 2002

ICOSAPENT ETHYL

CAPSULE; ORAL

ICOSAPENT ETHYLAB DR REDDYS 1GM A209499 001 Aug 07, 2020AB HIKMA 1GM A209457 001 May 21, 2020AB TEVA PHARMS USA 500MG A209525 001 Sep 11, 2020AB 1GM A209525 002 Sep 11, 2020VASCEPAAB + AMARIN PHARMS 500MG N202057 002 Feb 16, 2017AB +! 1GM N202057 001 Jul 26, 2012IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDAMYCIN PFSAP +! PFIZER 1MG/ML N050734 001 Feb 17, 1997IDARUBICIN HYDROCHLORIDEAP FRESENIUS KABI USA 1MG/ML A065440 001 Aug 04, 2009AP WEST-WARD PHARMS 1MG/ML A065275 001 Dec 14, 2006

INT

AP 1MG/ML A065288 001 May 15, 2007IDARUBICIN HYDROCHLORIDE PFSAP TEVA PHARMS USA 1MG/ML A065036 001 May 01, 2002IDELALISIB

TABLET; ORAL

ZYDELIG

+ GILEAD SCIENCES INC 100MG N205858 001 Jul 23, 2014

+! 150MG N205858 002 Jul 23, 2014

IFOSFAMIDE

INJECTABLE; INJECTION

IFEXAP + BAXTER HLTHCARE 1GM/VIAL N019763 001 Dec 30, 1988AP + 3GM/VIAL N019763 002 Dec 30, 1988IFOSFAMIDEAP ! FRESENIUS KABI USA 1GM/VIAL A076078 001 May 28, 2002AP ! 3GM/VIAL A076078 002 May 28, 2002AP ! TEVA PHARMS USA 1GM/20ML (50MG/ML) A076657 001 Apr 04, 2007AP ! 3GM/60ML (50MG/ML) A076657 002 Apr 04, 2007AP WEST-WARD PHARMS 1GM/20ML (50MG/ML) A076619 001 Jun 29, 2011

INT

AP 3GM/60ML (50MG/ML) A076619 002 Jun 29, 2011ILOPERIDONE

TABLET; ORAL

FANAPT

+! VANDA PHARMS INC 1MG N022192 001 May 06, 2009

+ 2MG N022192 002 May 06, 2009

+ 4MG N022192 003 May 06, 2009

+ 6MG N022192 004 May 06, 2009

+ 8MG N022192 005 May 06, 2009

+ 10MG N022192 006 May 06, 2009

+ 12MG N022192 007 May 06, 2009

ILOPROST

SOLUTION; INHALATION

VENTAVIS

+! ACTELION PHARMS LTD 10MCG/ML (10MCG/ML) N021779 002 Dec 08, 2005

+! 20MCG/ML (20MCG/ML) N021779 003 Aug 07, 2009

IMATINIB MESYLATE

TABLET; ORAL

GLEEVECAB + NOVARTIS EQ 100MG BASE N021588 001 Apr 18, 2003AB +! EQ 400MG BASE N021588 002 Apr 18, 2003IMATINIB MESYLATEAB APOTEX EQ 100MG BASE A079179 001 Aug 05, 2016AB EQ 400MG BASE A079179 002 Aug 05, 2016AB BRECKENRIDGE EQ 100MG BASE A205990 001 Feb 08, 2019AB EQ 400MG BASE A205990 002 Feb 08, 2019AB DR REDDYS EQ 100MG BASE A206547 001 Aug 13, 2018

PRESCRIPTION DRUG PRODUCT LIST

IMATINIB MESYLATE

TABLET; ORAL

IMATINIB MESYLATE

<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A206547 002</u>	Aug 13, 2018
<u>AB</u>	EUGIA PHARMA	<u>EQ 100MG BASE</u>	<u>A212773 001</u>	Jul 23, 2020
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A212773 002</u>	Jul 23, 2020
<u>AB</u>	HIKMA	<u>EQ 100MG BASE</u>	<u>A207586 001</u>	Jul 13, 2018
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A207586 002</u>	Jul 13, 2018
<u>AB</u>	MYLAN	<u>EQ 100MG BASE</u>	<u>A204644 001</u>	Jun 21, 2017
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A204644 002</u>	Jun 21, 2017
<u>AB</u>	NATCO PHARMA LTD	<u>EQ 100MG BASE</u>	<u>A207818 001</u>	Mar 01, 2019
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A207818 002</u>	Mar 01, 2019
<u>AB</u>	SHILPA MEDICARE LTD	<u>EQ 100MG BASE</u>	<u>A208302 001</u>	Jan 17, 2019
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A208302 002</u>	Jan 17, 2019
<u>AB</u>	SUN PHARM	<u>EQ 100MG BASE</u>	<u>A078340 001</u>	Dec 03, 2015
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A078340 002</u>	Dec 03, 2015
<u>AB</u>	TEVA PHARMS USA	<u>EQ 100MG BASE</u>	<u>A204285 001</u>	Aug 04, 2016
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A204285 002</u>	Aug 04, 2016
<u>AB</u>	WOCKHARDT BIO AG	<u>EQ 100MG BASE</u>	<u>A208429 001</u>	Jan 17, 2019
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A208429 002</u>	Jan 17, 2019
<u>AB</u>	ZYDUS PHARMS	<u>EQ 100MG BASE</u>	<u>A210658 001</u>	Apr 08, 2020
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A210658 002</u>	Apr 08, 2020

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

<u>AB</u>	LEADING PHARMA LLC	<u>10MG</u>	<u>A040903 001</u>	Oct 24, 2012
<u>AB</u>		<u>25MG</u>	<u>A040903 002</u>	Oct 24, 2012
<u>AB</u>		<u>50MG</u>	<u>A040903 003</u>	Oct 24, 2012
<u>AB</u>	OXFORD PHARMS	<u>10MG</u>	<u>A040751 003</u>	Feb 28, 2008
<u>AB</u>		<u>25MG</u>	<u>A040751 002</u>	Feb 28, 2008
<u>AB</u>		<u>50MG</u>	<u>A040751 001</u>	Feb 28, 2008
<u>AB</u>	PAR PHARM	<u>10MG</u>	<u>A088292 001</u>	Oct 21, 1983
<u>AB</u>		<u>25MG</u>	<u>A088262 001</u>	Oct 21, 1983
<u>AB</u>		<u>50MG</u>	<u>A088276 001</u>	Oct 21, 1983
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A084936 002</u>	
<u>AB</u>		<u>25MG</u>	<u>A083745 001</u>	
<u>AB</u>		<u>50MG</u>	<u>A084937 001</u>	
<u>AB</u>	SPECGX LLC	<u>10MG</u>	<u>A087846 002</u>	May 22, 1984
<u>AB</u>		<u>25MG</u>	<u>A087846 003</u>	May 22, 1984
<u>AB</u>	SUN PHARM INDUSTRIES	<u>10MG</u>	<u>A081048 001</u>	Jun 05, 1990
<u>AB</u>		<u>25MG</u>	<u>A081049 001</u>	Jun 05, 1990
<u>AB</u>		<u>50MG</u>	<u>A081050 001</u>	Jun 05, 1990
	<u>TOFRANIL</u>			
<u>AB</u>	! SPECGX LLC	<u>50MG</u>	<u>A087846 001</u>	May 22, 1984

IMIPRAMINE PAMOATE

CAPSULE; ORAL

IMIPRAMINE PAMOATE

<u>AB</u>	! HIKMA	<u>EQ 75MG HYDROCHLORIDE</u>	<u>A091099 001</u>	Apr 16, 2010
<u>AB</u>		<u>EQ 100MG HYDROCHLORIDE</u>	<u>A091099 002</u>	Apr 16, 2010
<u>AB</u>		<u>EQ 125MG HYDROCHLORIDE</u>	<u>A091099 003</u>	Apr 16, 2010
<u>AB</u>		<u>EQ 150MG HYDROCHLORIDE</u>	<u>A091099 004</u>	Apr 16, 2010
<u>AB</u>	LUPIN LTD	<u>EQ 75MG HYDROCHLORIDE</u>	<u>A090444 001</u>	Apr 16, 2010
<u>AB</u>		<u>EQ 100MG HYDROCHLORIDE</u>	<u>A090444 002</u>	Apr 16, 2010
<u>AB</u>		<u>EQ 125MG HYDROCHLORIDE</u>	<u>A090444 003</u>	Apr 16, 2010
<u>AB</u>		<u>EQ 150MG HYDROCHLORIDE</u>	<u>A090444 004</u>	Apr 16, 2010

IMIQUIMOD

CREAM; TOPICAL

ALDARA

<u>AB</u>	+! BAUSCH	<u>5%</u>	<u>N020723 001</u>	Feb 27, 1997
-----------	-----------	-----------	--------------------	--------------

IMIQUIMOD

<u>AB</u>	APOTEX INC	<u>5%</u>	<u>A091308 001</u>	Apr 06, 2012
<u>AB</u>	FOUGERA PHARMS	<u>5%</u>	<u>A078548 001</u>	Feb 25, 2010
<u>AB</u>	GLENMARK GENERICS	<u>5%</u>	<u>A201994 001</u>	Mar 06, 2012
<u>AB</u>	PERRIGO ISRAEL	<u>5%</u>	<u>A078837 001</u>	Sep 07, 2010
<u>AB</u>	TARO	<u>5%</u>	<u>A200173 001</u>	Apr 15, 2011

ZYCLARA

+!	BAUSCH	<u>2.5%</u>	<u>N022483 002</u>	Jul 15, 2011
+!		<u>3.75%</u>	<u>N022483 001</u>	Mar 25, 2010

PRESCRIPTION DRUG PRODUCT LIST

INAMRINONE LACTATE

INJECTABLE; INJECTION

AMRINONE LACTATE

! WEST-WARD PHARMS
INT

EQ 5MG BASE/ML

A075513 001 May 09, 2000

INDAPAMIDE

TABLET; ORAL

INDAPAMIDE**AB** ACTAVIS ELIZABETH**1.25MG****A074722 001** Jun 17, 1996**AB** **2.5MG****A074722 002** Jun 17, 1996**AB** ANI PHARMS INC**1.25MG****A074299 002** Apr 29, 1996**AB** **2.5MG****A074299 001** Jul 27, 1995**AB** MYLAN**1.25MG****A074461 002** Mar 26, 1997**AB** ! **2.5MG****A074461 001** Mar 27, 1996INDIUM IN-111 CHLORIDE

INJECTABLE; INJECTION

INDIUM IN 111 CHLORIDE

+! CURIUM

5mCi/0.5ML

N019841 001 Sep 27, 1994

INDIUM IN-111 OXYQUINOLINE

INJECTABLE; INJECTION

INDIUM IN 111 OXYQUINOLINE**AP** BWXT ITG**1mCi/ML****A202586 001** Jul 25, 2018**AP** +! GE HEALTHCARE**1mCi/ML****N019044 001** Dec 24, 1985INDIUM IN-111 PENTETATE DISODIUM

INJECTABLE; INTRATHECAL

MPI INDIUM DTPA IN 111

+! GE HEALTHCARE

1mCi/ML

N017707 001 Feb 18, 1982

INDIUM IN-111 PENTETREOTIDE KIT

INJECTABLE; INJECTION

OCTREOSCAN

+! CURIUM

3mCi/ML

N020314 001 Jun 02, 1994

INDOCYANINE GREEN

INJECTABLE; INJECTION

IC-GREEN**AP** +! AKORN**25MG/VIAL****N011525 001**INDOCYANINE GREEN**AP** DIAGNOSTIC GREEN**25MG/VIAL****A040811 001** Nov 21, 2007

POWDER; INTRAVENOUS, INTERSTITIAL

SPY AGENT GREEN KIT

+! NOVADAQ TECH

25MG/VIAL

N211580 001 Nov 21, 2018

INDOMETHACIN

CAPSULE; ORAL

INDOMETHACIN**AB** CADILA**25MG****A090403 001** Nov 15, 2010**AB** **50MG****A090403 002** Nov 15, 2010**AB** GLENMARK GENERICS**25MG****A091276 001** Dec 22, 2010**AB** ! **50MG****A091276 002** Dec 22, 2010**AB** HETERO LABS LTD III**25MG****A091240 001** Apr 12, 2011**AB** **50MG****A091240 002** Apr 12, 2011**AB** JUBILANT GENERICS**25MG****A205215 001** Aug 25, 2017**AB** **50MG****A205215 002** Aug 25, 2017**AB** SANDOZ**25MG****A070673 001** Apr 29, 1987**AB** **50MG****A070674 001** Apr 29, 1987

TIVORBEX

+ GENUS

20MG

N204768 001 Feb 24, 2014

+! **40MG**

N204768 002 Feb 24, 2014

CAPSULE, EXTENDED RELEASE; ORAL

INDOMETHACIN**AB** AMNEAL PHARMS**75MG****A091549 001** Dec 01, 2010**AB** AUROBINDO PHARMA
LTD**75MG****A204243 001** Dec 27, 2016**AB** AVANTHI INC**75MG****A079175 001** Mar 06, 2009**AB** CHARTWELL RX**75MG****A200529 001** Nov 30, 2010**AB** GLENMARK PHARMS LTD**75MG****A203501 001** Jun 22, 2017**AB** HETERO LABS LTD III**75MG****A201807 001** Sep 28, 2012**AB** JUBILANT GENERICS**75MG****A202706 001** Oct 05, 2015**AB** NOVAST LABS**75MG****A204853 001** May 08, 2017**AB** ! SANDOZ**75MG****A074464 001** May 28, 1998**AB** ZYDUS PHARMS**75MG****A202711 001** Sep 25, 2017

PRESCRIPTION DRUG PRODUCT LIST

INDOMETHACIN

INJECTABLE; INJECTION

INDOMETHACIN

+! FRESENIUS KABI USA EQ 1MG BASE/VIAL N022536 001 Mar 17, 2010

SUPPOSITORY; RECTAL

INDOMETHACIN

! COSETTE 50MG A073314 001 Aug 31, 1992

SUSPENSION; ORAL

INDOCIN

+! EGALET 25MG/5ML N018332 001 Oct 10, 1985

INDOMETHACIN SODIUM

INJECTABLE; INJECTION

INDOMETHACIN SODIUMAP HOSPIRA INC EQ 1MG BASE/VIAL A204118 001 Apr 19, 2016AP ! NAVINTA LLC EQ 1MG BASE/VIAL A206561 001 Jul 19, 2017AP WEST-WARD PHARMS EQ 1MG BASE/VIAL A078713 001 Jul 16, 2008
INTINOTERSEN SODIUM

SOLUTION; SUBCUTANEOUS

TEGSEDI

+! AKCEA THERAPS EQ 284MG BASE/1.5ML (EQ 189.3MG
BASE/ML) N211172 001 Oct 05, 2018IOBENGUANE I-131

SOLUTION; INTRAVENOUS

AZEDRA

+! PROGENICS PHARMS 15mCi/ML N209607 001 Jul 30, 2018
INCIOBENGUANE SULFATE I-123

SOLUTION; INTRAVENOUS

ADREVIEW

+! GE HEALTHCARE 10mCi/5ML (2mCi/ML) N022290 001 Sep 19, 2008

IODIXANOL

INJECTABLE; INJECTION

VISIPAQUE 270

+! GE HEALTHCARE 55% N020351 001 Mar 22, 1996

VISIPAQUE 320

+! GE HEALTHCARE 65.2% N020351 002 Mar 22, 1996

65.2% N020808 002 Aug 29, 1997

IOFLUPANE I-123

SOLUTION; INTRAVENOUS

DATSCAN

+! GE HLTHCARE INC 5mCi/2.5ML (2mCi/ML) N022454 001 Jan 14, 2011

IOHEXOL

FOR SOLUTION; ORAL

ORALTAG

INTERPHARMA PRAHA 9.7GM/BOT N205383 001 Mar 26, 2015
AS

INJECTABLE; INJECTION

OMNIPAQUE 140

+! GE HEALTHCARE 30.2% N018956 005 Nov 30, 1988

SOLUTION; INJECTION, ORAL

OMNIPAQUE 350

+! GE HEALTHCARE 75.5% N018956 004 Dec 26, 1985

75.5% N020608 003 Oct 24, 1995

SOLUTION; INJECTION, ORAL, RECTAL

OMNIPAQUE 180

+! GE HEALTHCARE 38.8% N018956 001 Dec 26, 1985

OMNIPAQUE 240

+! GE HEALTHCARE 51.8% N018956 002 Dec 26, 1985

OMNIPAQUE 300

+! GE HEALTHCARE 64.7% N018956 003 Dec 26, 1985

64.7% N020608 002 Oct 24, 1995

SOLUTION; ORAL

OMNIPAQUE 12

+! GE HEALTHCARE 2.6% N018956 009 Apr 17, 2018

OMNIPAQUE 9

+! GE HEALTHCARE 1.9% N018956 008 Apr 17, 2018

PRESCRIPTION DRUG PRODUCT LIST

IOPAMIDOL

INJECTABLE; INJECTION

ISOVUE-300

AP	+ !	BRACCO	61%	N018735 002	Dec 31, 1985
-----------	------------	--------	------------	--------------------	--------------

ISOVUE-370

AP	+ !	BRACCO	76%	N018735 003	Dec 31, 1985
-----------	------------	--------	------------	--------------------	--------------

SCANLUX-300

AP		SANOCHEMIA CORP USA	61%	A090394 001	Jun 18, 2010
-----------	--	---------------------	------------	--------------------	--------------

SCANLUX-370

AP		SANOCHEMIA CORP USA	76%	A090394 002	Jun 18, 2010
-----------	--	---------------------	------------	--------------------	--------------

ISOVUE-200

	+ !	BRACCO	41%	N018735 006	Jul 07, 1987
--	------------	--------	-----	-------------	--------------

ISOVUE-250

	+ !	BRACCO	51%	N018735 007	Jul 06, 1992
--	------------	--------	-----	-------------	--------------

	+ !		51%	N020327 002	Oct 12, 1994
--	------------	--	-----	-------------	--------------

ISOVUE-300

	+ !	BRACCO	61%	N020327 003	Oct 12, 1994
--	------------	--------	-----	-------------	--------------

ISOVUE-370

	+ !	BRACCO	76%	N020327 004	Oct 12, 1994
--	------------	--------	-----	-------------	--------------

ISOVUE-M 200

	+ !	BRACCO	41%	N018735 001	Dec 31, 1985
--	------------	--------	-----	-------------	--------------

ISOVUE-M 300

	+ !	BRACCO	61%	N018735 004	Dec 31, 1985
--	------------	--------	-----	-------------	--------------

IOPROMIDE

INJECTABLE; INJECTION

ULTRAVIST (PHARMACY BULK)

	+ !	BAYER HLTHCARE	62.3%	N021425 001	Sep 20, 2002
--	------------	----------------	-------	-------------	--------------

	+ !		76.9%	N021425 002	Sep 20, 2002
--	------------	--	-------	-------------	--------------

ULTRAVIST 300

	+ !	BAYER HLTHCARE	62.3%	N020220 002	May 10, 1995
--	------------	----------------	-------	-------------	--------------

ULTRAVIST 370

	+ !	BAYER HLTHCARE	76.9%	N020220 001	May 10, 1995
--	------------	----------------	-------	-------------	--------------

IOTHALAMATE MEGLUMINE

INJECTABLE; INJECTION

CONRAY

	+ !	LIEBEL-FLARSHEIM	60%	N013295 001	
--	------------	------------------	-----	-------------	--

SOLUTION; INTRAVESICAL

CYSTO-CONRAY II

		LIEBEL-FLARSHEIM	17.2%	N017057 002	
--	--	------------------	-------	-------------	--

IOTHALAMATE SODIUM I-125

INJECTABLE; INJECTION

GLOFIL-125

		ISOTEX	250-300uCi/ML	N017279 001	
--	--	--------	---------------	-------------	--

IOVERSOL

INJECTABLE; INJECTION

OPTIRAY 240

	+ !	LIEBEL-FLARSHEIM	51%	N019710 002	Dec 30, 1988
--	------------	------------------	-----	-------------	--------------

OPTIRAY 300

	+ !	LIEBEL-FLARSHEIM	64%	N019710 004	Jan 22, 1992
--	------------	------------------	-----	-------------	--------------

	+ !		64%	N020923 004	May 13, 1999
--	------------	--	-----	-------------	--------------

OPTIRAY 320

	+ !	LIEBEL-FLARSHEIM	68%	N019710 001	Dec 30, 1988
--	------------	------------------	-----	-------------	--------------

	+ !		68%	N020923 002	May 29, 1998
--	------------	--	-----	-------------	--------------

OPTIRAY 350

	+ !	LIEBEL-FLARSHEIM	74%	N019710 005	Jan 22, 1992
--	------------	------------------	-----	-------------	--------------

	+ !		74%	N020923 003	May 28, 1998
--	------------	--	-----	-------------	--------------

IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION

ATROVENT HFA

	+ !	BOEHRINGER	0.021MG/INH	N021527 001	Nov 27, 2004
--	------------	------------	-------------	-------------	--------------

		INGELHEIM			
--	--	-----------	--	--	--

SOLUTION; INHALATION

IPRATROPIUM BROMIDE

AN		AUROBINDO PHARMA	0.02%	A206543 001	Oct 27, 2016
-----------	--	------------------	--------------	--------------------	--------------

		LTD			
--	--	-----	--	--	--

AN		LANDELA PHARM	0.02%	A077072 001	Jul 19, 2005
-----------	--	---------------	--------------	--------------------	--------------

AN		NEPHRON	0.02%	A075562 001	Sep 27, 2001
-----------	--	---------	--------------	--------------------	--------------

AN	!	RITEDOSE CORP	0.02%	A075693 001	Jan 26, 2001
-----------	----------	---------------	--------------	--------------------	--------------

AN		SUN PHARM	0.02%	A207903 001	Jan 03, 2017
-----------	--	-----------	--------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

IPRATROPIUM BROMIDE

SPRAY, METERED;NASAL

IPRATROPIUM BROMIDE

<u>AB</u>	APOTEX INC	<u>0.021MG/SPRAY</u>	<u>A076156 001</u>	Apr 18, 2003
<u>AB</u>		<u>0.042MG/SPRAY</u>	<u>A076155 001</u>	Apr 18, 2003
<u>AB</u>	BAUSCH AND LOMB	<u>0.021MG/SPRAY</u>	<u>A076025 001</u>	Mar 31, 2003
<u>AB</u>		<u>0.042MG/SPRAY</u>	<u>A076103 001</u>	Mar 31, 2003
<u>AB</u>	! HIKMA	<u>0.021MG/SPRAY</u>	<u>A076664 001</u>	Nov 05, 2003
<u>AB</u>	!	<u>0.042MG/SPRAY</u>	<u>A076598 001</u>	Nov 05, 2003

IRBESARTAN

TABLET;ORAL

AVAPRO

<u>AB</u>	+ SANOFI AVENTIS US	<u>75MG</u>	<u>N020757 001</u>	Sep 30, 1997
<u>AB</u>	+	<u>150MG</u>	<u>N020757 002</u>	Sep 30, 1997
<u>AB</u>	+	<u>300MG</u>	<u>N020757 003</u>	Sep 30, 1997

IRBESARTAN

<u>AB</u>	ALEMBIC PHARMS LTD	<u>75MG</u>	<u>A091236 001</u>	Oct 15, 2012
<u>AB</u>		<u>150MG</u>	<u>A091236 002</u>	Oct 15, 2012
<u>AB</u>		<u>300MG</u>	<u>A091236 003</u>	Oct 15, 2012
<u>AB</u>	AMNEAL PHARMS	<u>75MG</u>	<u>A204740 001</u>	Apr 17, 2018
<u>AB</u>		<u>150MG</u>	<u>A204740 002</u>	Apr 17, 2018
<u>AB</u>		<u>300MG</u>	<u>A204740 003</u>	Apr 17, 2018
<u>AB</u>	AUROBINDO PHARMA LTD	<u>75MG</u>	<u>A203081 001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A203081 002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A203081 003</u>	Sep 27, 2012
<u>AB</u>	CHARTWELL MOLECULAR	<u>75MG</u>	<u>A077205 001</u>	Nov 14, 2012
<u>AB</u>		<u>150MG</u>	<u>A077205 002</u>	Nov 14, 2012
<u>AB</u>		<u>300MG</u>	<u>A077205 003</u>	Nov 14, 2012
<u>AB</u>	HETERO LABS LTD V	<u>75MG</u>	<u>A202910 001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A202910 002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A202910 003</u>	Sep 27, 2012
<u>AB</u>	HISUN PHARM HANGZHOU	<u>75MG</u>	<u>A206194 001</u>	Jun 14, 2016
<u>AB</u>		<u>150MG</u>	<u>A206194 002</u>	Jun 14, 2016
<u>AB</u>		<u>300MG</u>	<u>A206194 003</u>	Jun 14, 2016
<u>AB</u>	JUBILANT GENERICS	<u>75MG</u>	<u>A203534 001</u>	Feb 23, 2015
<u>AB</u>		<u>150MG</u>	<u>A203534 002</u>	Feb 23, 2015
<u>AB</u>		<u>300MG</u>	<u>A203534 003</u>	Feb 23, 2015
<u>AB</u>	LUPIN LTD	<u>75MG</u>	<u>A201531 001</u>	Oct 15, 2012
<u>AB</u>		<u>150MG</u>	<u>A201531 002</u>	Oct 15, 2012
<u>AB</u>		<u>300MG</u>	<u>A201531 003</u>	Oct 15, 2012
<u>AB</u>	MACLEODS PHARMS LTD	<u>75MG</u>	<u>A202254 001</u>	Oct 03, 2012
<u>AB</u>		<u>150MG</u>	<u>A202254 002</u>	Oct 03, 2012
<u>AB</u>		<u>300MG</u>	<u>A202254 003</u>	Oct 03, 2012
<u>AB</u>	PRINSTON INC	<u>75MG</u>	<u>A203071 001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A203071 002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A203071 003</u>	Sep 27, 2012
<u>AB</u>	SANDOZ	<u>75MG</u>	<u>A077466 001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A077466 002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A077466 003</u>	Sep 27, 2012
<u>AB</u>	SCIEGEN PHARMS INC	<u>75MG</u>	<u>A204774 001</u>	Dec 07, 2015
<u>AB</u>		<u>150MG</u>	<u>A204774 002</u>	Dec 07, 2015
<u>AB</u>		<u>300MG</u>	<u>A204774 003</u>	Dec 07, 2015
<u>AB</u>	TEVA PHARMS	<u>75MG</u>	<u>A077159 001</u>	Mar 30, 2012
<u>AB</u>		<u>150MG</u>	<u>A077159 002</u>	Mar 30, 2012
<u>AB</u>		<u>300MG</u>	<u>A077159 003</u>	Mar 30, 2012
<u>AB</u>	ZYDUS PHARMS USA INC	<u>75MG</u>	<u>A079213 001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A079213 002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A079213 003</u>	Sep 27, 2012

IRINOTECAN HYDROCHLORIDE

INJECTABLE;INJECTION

CAMPTOSAR

<u>AP</u>	+! PFIZER INC	<u>40MG/2ML (20MG/ML)</u>	<u>N020571 001</u>	Jun 14, 1996
<u>AP</u>	+!	<u>100MG/5ML (20MG/ML)</u>	<u>N020571 002</u>	Jun 14, 1996
<u>AP</u>	+!	<u>300MG/15ML (20MG/ML)</u>	<u>N020571 003</u>	Aug 05, 2010

IRINOTECAN HYDROCHLORIDE

<u>AP</u>	ACCORD HLTHCARE	<u>40MG/2ML (20MG/ML)</u>	<u>A079068 001</u>	Nov 21, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A079068 002</u>	Nov 21, 2008
<u>AP</u>	ACTAVIS TOTOWA	<u>40MG/2ML (20MG/ML)</u>	<u>A078589 001</u>	Feb 27, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A078589 002</u>	Feb 27, 2008

PRESCRIPTION DRUG PRODUCT LIST

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

AP		<u>500MG/25ML (20MG/ML)</u>	<u>A078589 003</u>	Nov 18, 2015
AP	AKORN	<u>40MG/2ML (20MG/ML)</u>	<u>A090726 001</u>	Sep 16, 2009
AP		<u>100MG/5ML (20MG/ML)</u>	<u>A090726 002</u>	Sep 16, 2009
AP	EMCURE PHARMS LTD	<u>40MG/2ML (20MG/ML)</u>	<u>A200771 001</u>	Feb 14, 2012
AP		<u>100MG/5ML (20MG/ML)</u>	<u>A200771 002</u>	Feb 14, 2012
AP	EUGIA PHARMA	<u>40MG/2ML (20MG/ML)</u>	<u>A213278 001</u>	Nov 02, 2020
AP		<u>100MG/5ML (20MG/ML)</u>	<u>A213278 002</u>	Nov 02, 2020
AP		<u>300MG/15ML (20MG/ML)</u>	<u>A213278 003</u>	Nov 02, 2020
AP	FRESENIUS KABI USA	<u>40MG/2ML (20MG/ML)</u>	<u>A077776 001</u>	Feb 27, 2008
AP		<u>100MG/5ML (20MG/ML)</u>	<u>A077776 002</u>	Feb 27, 2008
AP	GLAND PHARMA LTD	<u>40MG/2ML (20MG/ML)</u>	<u>A212993 001</u>	Nov 18, 2019
AP		<u>100MG/5ML (20MG/ML)</u>	<u>A212993 002</u>	Nov 18, 2019
AP	HIKMA FARMACEUTICA	<u>40MG/2ML (20MG/ML)</u>	<u>A091032 001</u>	Dec 20, 2010
AP		<u>100MG/5ML (20MG/ML)</u>	<u>A091032 002</u>	Dec 20, 2010
AP	HISUN PHARM HANGZHOU	<u>40MG/2ML (20MG/ML)</u>	<u>A090016 001</u>	Jan 28, 2009
AP		<u>100MG/5ML (20MG/ML)</u>	<u>A090016 002</u>	Jan 28, 2009
AP	HOSPIRA	<u>40MG/2ML (20MG/ML)</u>	<u>A077915 001</u>	Feb 27, 2008
AP		<u>100MG/5ML (20MG/ML)</u>	<u>A077915 002</u>	Feb 27, 2008
AP	!	<u>500MG/25ML (20MG/ML)</u>	<u>A078796 001</u>	Feb 27, 2008
AP	INTAS PHARMS USA	<u>40MG/2ML (20MG/ML)</u>	<u>A203054 001</u>	Aug 31, 2017
AP		<u>100MG/5ML (20MG/ML)</u>	<u>A203054 002</u>	Aug 31, 2017
AP	JIANGSU HENGRUI MED	<u>40MG/2ML (20MG/ML)</u>	<u>A090675 002</u>	Dec 16, 2011
AP		<u>100MG/5ML (20MG/ML)</u>	<u>A090675 001</u>	Dec 16, 2011
AP	NOVAST LABS	<u>40MG/2ML (20MG/ML)</u>	<u>A206935 001</u>	May 26, 2017
AP		<u>100MG/5ML (20MG/ML)</u>	<u>A206935 002</u>	May 26, 2017
AP	QILU	<u>40MG/2ML (20MG/ML)</u>	<u>A203380 001</u>	May 03, 2016
AP		<u>100MG/5ML (20MG/ML)</u>	<u>A203380 002</u>	May 03, 2016
AP		<u>300MG/15ML (20MG/ML)</u>	<u>A203380 003</u>	May 03, 2016
AP	SHILPA MEDICARE LTD	<u>40MG/2ML (20MG/ML)</u>	<u>A208718 001</u>	Dec 28, 2018
AP		<u>100MG/5ML (20MG/ML)</u>	<u>A208718 002</u>	Dec 28, 2018
AP		<u>300MG/15ML (20MG/ML)</u>	<u>A208718 003</u>	Aug 16, 2019
AP	TEVA PHARMS USA	<u>40MG/2ML (20MG/ML)</u>	<u>A090101 002</u>	Feb 27, 2008
AP		<u>100MG/5ML (20MG/ML)</u>	<u>A090101 003</u>	Feb 27, 2008
AP		<u>500MG/25ML (20MG/ML)</u>	<u>A090101 001</u>	Nov 26, 2008
AP	WEST-WARD PHARMS INT	<u>40MG/2ML (20MG/ML)</u>	<u>A078753 001</u>	Dec 24, 2008
AP		<u>100MG/5ML (20MG/ML)</u>	<u>A078753 002</u>	Dec 24, 2008
AP	ZENNOVA	<u>40MG/2ML (20MG/ML)</u>	<u>A090393 002</u>	May 13, 2011
AP		<u>100MG/5ML (20MG/ML)</u>	<u>A090393 003</u>	May 13, 2011

INJECTABLE, LIPOSOMAL; INTRAVENOUS

ONIVYDE

+! IPSEN INC EQ 43MG BASE/10ML (EQ 4.3MG BASE/ML) N207793 001 Oct 22, 2015

IRON DEXTRAN

INJECTABLE; INJECTION

INFED

BP +! ALLERGAN EQ 50MG IRON/ML N017441 001

IRON SUCROSE

INJECTABLE; INTRAVENOUS

VENOFER

+ AM REGENT EQ 50MG BASE/2.5ML (EQ 20MG BASE/ML) N021135 002 Mar 20, 2005

+! EQ 100MG BASE/5ML (EQ 20MG BASE/ML) N021135 001 Nov 06, 2000

+ EQ 200MG BASE/10ML (EQ 20MG BASE/ML) N021135 004 Feb 09, 2007

ISAVUCONAZONIUM SULFATE

CAPSULE; ORAL

CRESEMBA

+! ASTELLAS 186MG N207500 001 Mar 06, 2015

POWDER; INTRAVENOUS

CRESEMBA

+! ASTELLAS 372MG N207501 001 Mar 06, 2015

ISOCARBOXAZID

TABLET; ORAL

MARPLAN

+! VALIDUS PHARMS INC 10MG N011961 001

PRESCRIPTION DRUG PRODUCT LIST

ISOFLURANE

LIQUID; INHALATION

FORANE

AN	+ !	BAXTER HLTHCARE	99.9%	N017624	001	
-----------	------------	-----------------	--------------	----------------	------------	--

ISOFLURANE

AN		HALOCARBON PRODS	99.9%	A075225	001	Oct 20, 1999
AN		PIRAMAL CRITICAL	99.9%	A074416	001	Sep 30, 1994
AN		PIRAMAL ENT	99.9%	A074502	001	Jun 27, 1995

ISONIAZID

INJECTABLE; INJECTION

ISONIAZID

!		SANDOZ INC	100MG/ML	A040648	001	Jul 05, 2005
---	--	------------	----------	---------	-----	--------------

SYRUP; ORAL

ISONIAZID

!		CMP PHARMA INC	50MG/5ML	A088235	001	Nov 10, 1983
---	--	----------------	----------	---------	-----	--------------

TABLET; ORAL

ISONIAZID

AA		ANDA REPOSITORY	100MG	A040090	001	Jun 26, 1997
AA			300MG	A040090	002	Jun 26, 1997
AA	!	BARR	100MG	A080936	001	
AA	!		300MG	A080937	002	
AA		THEPHARMANETWORK LLC	100MG	A202610	001	Oct 29, 2014
AA			300MG	A202610	002	Oct 29, 2014

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION

ISOPROTERENOL HYDROCHLORIDE

AP		AMNEAL	0.2MG/ML	A210576	001	Oct 17, 2018
AP		AMPHASTAR PHARMS INC	0.2MG/ML	A210106	001	Jun 18, 2018
AP		CIPLA	0.2MG/ML	A210322	001	Jun 12, 2018
AP			0.2MG/ML	A211738	001	Jun 28, 2019
AP		NEXUS PHARMS	0.2MG/ML	A206961	001	Aug 02, 2017

ISUPREL

AP	+ !	BAUSCH	0.2MG/ML	N010515	001	
-----------	------------	--------	-----------------	----------------	------------	--

ISOSORBIDE DINITRATE

TABLET; ORAL

ISORDIL

AB	+	BAUSCH	5MG	N012093	007	Jul 29, 1988
AB	+ !		40MG	N012093	001	Jul 29, 1988

ISOSORBIDE DINITRATE

AB		HIKMA INTL PHARMS	5MG	A086067	001	Oct 29, 1987
AB			10MG	A086066	001	Oct 29, 1987
AB			20MG	A088088	001	Nov 02, 1987
AB		PAR PHARM	5MG	A086923	001	Mar 12, 1987
AB			10MG	A086925	001	Mar 12, 1987
AB			20MG	A087537	001	Oct 02, 1987
AB	!		30MG	A087946	001	Jan 12, 1988
AB		SANDOZ	5MG	A086221	001	Jan 07, 1988
AB			10MG	A086223	001	Jan 07, 1988
AB			20MG	A089367	001	Apr 07, 1988
AB		ZYDUS	5MG	A213057	001	Nov 20, 2019
AB			10MG	A213057	002	Nov 20, 2019
AB			20MG	A213057	003	Nov 20, 2019
AB			30MG	A213057	004	Nov 20, 2019
AB			40MG	A213057	005	Nov 20, 2019

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE DINITRATE

!		SUN PHARM INDS INC	40MG	A040009	001	Dec 30, 1998
---	--	--------------------	------	---------	-----	--------------

ISOSORBIDE MONONITRATE

TABLET; ORAL

ISOSORBIDE MONONITRATE

AB		ACTAVIS ELIZABETH	10MG	A075037	002	Oct 30, 1998
AB			20MG	A075037	001	Oct 30, 1998

MONOKET

AB	+	LANNETT CO INC	10MG	N020215	002	Jun 30, 1993
AB	+ !		20MG	N020215	001	Jun 30, 1993

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE MONONITRATE

AB		DEXCEL LTD	30MG	A075522	002	Sep 20, 2016
AB			60MG	A075522	001	Apr 17, 2000

PRESCRIPTION DRUG PRODUCT LIST

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE;ORAL

ISOSORBIDE MONONITRATE

<u>AB</u>		<u>120MG</u>	<u>A210822 001</u>	Aug 29, 2018
<u>AB</u>	LANNETT CO INC	<u>30MG</u>	<u>A075155 002</u>	Jan 13, 2000
<u>AB</u>		<u>60MG</u>	<u>A075155 001</u>	Oct 30, 1998
<u>AB</u>	!	<u>120MG</u>	<u>A075155 003</u>	Aug 04, 2000
<u>AB</u>	NESHER PHARMS	<u>30MG</u>	<u>A075395 001</u>	Mar 16, 2000
<u>AB</u>		<u>60MG</u>	<u>A075395 002</u>	Mar 16, 2000
<u>AB</u>		<u>120MG</u>	<u>A075395 003</u>	Mar 16, 2000
<u>AB</u>	RICONPHARMA LLC	<u>30MG</u>	<u>A210918 001</u>	Nov 05, 2018
<u>AB</u>		<u>60MG</u>	<u>A210918 002</u>	Nov 05, 2018
<u>AB</u>		<u>120MG</u>	<u>A210918 003</u>	Nov 05, 2018
<u>AB</u>	TORRENT PHARMS	<u>30MG</u>	<u>A200270 001</u>	Jun 03, 2011
<u>AB</u>		<u>60MG</u>	<u>A200495 001</u>	Jun 03, 2011
<u>AB</u>		<u>120MG</u>	<u>A200495 002</u>	Jun 03, 2011

ISOSULFAN BLUE

INJECTABLE; INJECTION

ISOSULFAN BLUE

<u>AP</u>	AUROBINDO PHARMA LTD	<u>1%</u>	<u>A206831 001</u>	Feb 02, 2016
<u>AP</u>	! MYLAN INSTITUTIONAL	<u>1%</u>	<u>A090874 001</u>	Jul 20, 2010

ISOTRETINOIN

CAPSULE; ORAL

AMNESTEEM

<u>AB</u>	MYLAN PHARMS INC	<u>10MG</u>	<u>A075945 001</u>	Nov 08, 2002
<u>AB</u>		<u>20MG</u>	<u>A075945 002</u>	Nov 08, 2002
<u>AB</u>		<u>40MG</u>	<u>A075945 003</u>	Nov 08, 2002

CLARAVIS

<u>AB</u>	TEVA PHARMS USA	<u>10MG</u>	<u>A076356 001</u>	Apr 11, 2003
<u>AB</u>		<u>20MG</u>	<u>A076135 002</u>	Apr 11, 2003
<u>AB</u>		<u>30MG</u>	<u>A076135 003</u>	May 11, 2006
<u>AB</u>	!	<u>40MG</u>	<u>A076135 001</u>	Apr 11, 2003

ISOTRETINOIN

<u>AB</u>	AMNEAL PHARMS NY	<u>10MG</u>	<u>A207792 001</u>	Sep 29, 2017
<u>AB</u>		<u>20MG</u>	<u>A207792 002</u>	Sep 29, 2017
<u>AB</u>		<u>30MG</u>	<u>A207792 003</u>	Sep 29, 2017
<u>AB</u>		<u>40MG</u>	<u>A207792 004</u>	Sep 29, 2017

MYORISAN

<u>AB</u>	DOUGLAS PHARMS	<u>10MG</u>	<u>A076485 001</u>	Jan 19, 2012
<u>AB</u>		<u>20MG</u>	<u>A076485 002</u>	Jan 19, 2012
<u>AB</u>		<u>30MG</u>	<u>A076485 004</u>	Aug 25, 2015
<u>AB</u>		<u>40MG</u>	<u>A076485 003</u>	Jan 19, 2012

ZENATANE

<u>AB</u>	DR REDDYS LABS LTD	<u>10MG</u>	<u>A202099 001</u>	Mar 25, 2013
<u>AB</u>		<u>20MG</u>	<u>A202099 002</u>	Mar 25, 2013
<u>AB</u>		<u>30MG</u>	<u>A202099 004</u>	Feb 23, 2015
<u>AB</u>		<u>40MG</u>	<u>A202099 003</u>	Mar 25, 2013

ABSORICA

BX	+	SUN PHARM INDS INC	10MG	N021951 001	May 25, 2012
BX	+		20MG	N021951 002	May 25, 2012
BX	+		30MG	N021951 003	May 25, 2012
BX	+	!	40MG	N021951 004	May 25, 2012
	+		25MG	N021951 005	Aug 15, 2014
	+		35MG	N021951 006	Aug 15, 2014

ABSORICA LD

	+	SUN PHARM	8MG	N211913 001	Nov 05, 2019
	+		16MG	N211913 002	Nov 05, 2019
	+		24MG	N211913 004	Nov 05, 2019
	+	!	32MG	N211913 006	Nov 05, 2019

ISRADIPINE

CAPSULE; ORAL

ISRADIPINE

<u>AB</u>	ELITE LABS INC	<u>2.5MG</u>	<u>A077169 001</u>	Apr 24, 2006
<u>AB</u>		<u>5MG</u>	<u>A077169 002</u>	Apr 24, 2006
<u>AB</u>	WATSON LABS TEVA	<u>2.5MG</u>	<u>A077317 001</u>	Jan 05, 2006
<u>AB</u>	!	<u>5MG</u>	<u>A077317 002</u>	Jan 05, 2006

PRESCRIPTION DRUG PRODUCT LIST

ISTRADÉFYLLINE

TABLET; ORAL

NOURIANZ

+ KYOWA KIRIN

20MG

N022075 001 Aug 27, 2019

+!

40MG

N022075 002 Aug 27, 2019

ITRACONAZOLE

CAPSULE; ORAL

ITRACONAZOLE**AB** ACCORD HLTHCARE**100MG****A205991 001** May 26, 2016**AB** ALEMBIC PHARMS LTD**100MG****A206741 001** Dec 13, 2016**AB** ALKEM LABS LTD**100MG****A208591 001** Jun 12, 2017**AB** AMNEAL PHARMS**100MG****A205080 001** Sep 26, 2016**AB** JUBILANT GENERICS**100MG****A203445 001** Feb 23, 2017**AB** MYLAN PHARMS INC**100MG****A200463 001** Jul 20, 2012**AB** PAR PHARM INC**100MG****A205724 001** Dec 13, 2016**AB** SANDOZ**100MG****A076104 001** May 28, 2004**AB** STRIDES PHARMA**100MG****A206410 001** Jul 02, 2019**AB** TORRENT**100MG****A209460 001** Aug 24, 2018**AB** ZYDUS PHARMS**100MG****A204672 001** Sep 19, 2017SPORANOX**AB** +! JANSSEN PHARMS**100MG****N020083 001** Sep 11, 1992

TOLSURA

+! MAYNE PHARMA INTL

65MG

N208901 001 Dec 11, 2018

SOLUTION; ORAL

ITRACONAZOLE**AA** AMNEAL PHARMS**10MG/ML****A205573 001** Oct 30, 2015**AA** ANNORA PHARMA**10MG/ML****A212239 001** Sep 01, 2020SPORANOX**AA** +! JANSSEN PHARMS**10MG/ML****N020657 001** Feb 21, 1997

TABLET; ORAL

ONMEL

+! SEBELA IRELAND LTD

200MG

N022484 001 Apr 29, 2010

IVABRADINE

SOLUTION; ORAL

CORLANOR

+! AMGEN INC

5MG/5ML (1MG/ML)

N209964 001 Apr 22, 2019

IVABRADINE HYDROCHLORIDE

TABLET; ORAL

CORLANOR

+ AMGEN INC

EQ 5MG BASE

N206143 001 Apr 15, 2015

+!

EQ 7.5MG BASE

N206143 002 Apr 15, 2015

IVACAFTOR

GRANULE; ORAL

KALYDECO

+ VERTEX PHARMS INC

25MG/PACKET

N207925 003 Apr 29, 2019

+

50MG/PACKET

N207925 001 Mar 17, 2015

+!

75MG/PACKET

N207925 002 Mar 17, 2015

TABLET; ORAL

KALYDECO

+! VERTEX PHARMS

150MG

N203188 001 Jan 31, 2012

IVACAFTOR; IVACAFTOR, TEZACAFTOR

TABLET, TABLET; ORAL

SYMDEKO (COPACKAGED)

+ VERTEX PHARMS INC

75MG, N/A; 75MG, 50MG

N210491 002 Jun 21, 2019

+!

150MG, N/A; 150MG, 100MG

N210491 001 Feb 12, 2018

IVACAFTOR; LUMACAFTOR

GRANULE; ORAL

ORKAMBI

+ VERTEX PHARMS INC

125MG/PACKET; 100MG/PACKET

N211358 001 Aug 07, 2018

+!

188MG/PACKET; 150MG/PACKET

N211358 002 Aug 07, 2018

TABLET; ORAL

ORKAMBI

+ VERTEX PHARMS INC

125MG; 100MG

N206038 002 Sep 28, 2016

+!

125MG; 200MG

N206038 001 Jul 02, 2015

PRESCRIPTION DRUG PRODUCT LIST

IVERMECTIN

CREAM; TOPICAL

IVERMECTIN**AB** TEVA PHARMS USA **1%** **A210019 001** Sep 13, 2019SOOLANTRA**AB** +! GALDERMA LABS LP **1%** **N206255 001** Dec 19, 2014

LOTION; TOPICAL

IVERMECTIN

TARO

0.5%

A210720 001 May 06, 2020

TABLET; ORAL

IVERMECTIN**AB** EDENBRIDGE PHARMS **3MG** **A204154 001** Oct 24, 2014STROMEKTOL**AB** +! MERCK SHARP DOHME **3MG** **N050742 002** Oct 08, 1998IVOSIDENIB

TABLET; ORAL

TIBSOVO

+! AGIOS PHARMS INC

250MG

N211192 001 Jul 20, 2018

IXABEPILONE

INJECTABLE; INTRAVENOUS

IXEMPRA KIT

+! R-PHARM US LLC

15MG/VIAL

N022065 001 Oct 16, 2007

+!

45MG/VIAL

N022065 002 Oct 16, 2007

IXAZOMIB CITRATE

CAPSULE; ORAL

NINLARO

+ MILLENNIUM PHARMS

EQ 2.3MG BASE

N208462 001 Nov 20, 2015

+

EQ 3MG BASE

N208462 002 Nov 20, 2015

+!

EQ 4MG BASE

N208462 003 Nov 20, 2015

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

KETALAR**AP** +! PAR STERILE **EQ 10MG BASE/ML** **N016812 001**

PRODUCTS

AP +! **EQ 50MG BASE/ML** **N016812 002****AP** +! **EQ 100MG BASE/ML** **N016812 003**KETAMINE HYDROCHLORIDE**AP** HOSPIRA **EQ 50MG BASE/ML** **A074549 001** Jun 27, 1996**AP** **EQ 100MG BASE/ML** **A074549 002** Jun 27, 1996**AP** MYLAN INSTITUTIONAL **EQ 10MG BASE/ML** **A076092 001** Sep 30, 2008**AP** **EQ 50MG BASE/ML** **A076092 002** Dec 28, 2001**AP** **EQ 100MG BASE/ML** **A076092 003** Oct 25, 2002**AP** WEST-WARD PHARMS **EQ 50MG BASE/ML** **A074524 001** Mar 22, 1996

INT

AP **EQ 100MG BASE/ML** **A074524 002** Mar 22, 1996KETOCONAZOLE

AEROSOL, FOAM; TOPICAL

EXTINA**AT** +! MYLAN **2%** **N021738 001** Jun 12, 2007KETOCONAZOLE**AT** PERRIGO ISRAEL **2%** **A091550 001** Aug 25, 2011

CREAM; TOPICAL

KETOCONAZOLE**AB** FOUGERA PHARMS **2%** **A076294 001** Apr 28, 2004**AB** ! TEVA **2%** **A075581 001** Apr 25, 2000KETOZOLE**AB** TARO **2%** **A075638 001** Dec 18, 2002

GEL; TOPICAL

XOLEGEL

+! ALMIRALL

2%

N021946 001 Jul 28, 2006

SHAMPOO; TOPICAL

KETOCONAZOLE**AB** ! PERRIGO ISRAEL **2%** **A076419 001** Jan 07, 2004**AB** TOLMAR **2%** **A076942 001** Apr 11, 2005

TABLET; ORAL

KETOCONAZOLE**AB** HAVIX **200MG** **A075912 001** Jan 10, 2002**AB** MYLAN **200MG** **A075597 001** Dec 23, 1999**AB** STRIDES PHARMA **200MG** **A210457 001** Jun 18, 2018**AB** ! TARO **200MG** **A075319 001** Jun 15, 1999

PRESCRIPTION DRUG PRODUCT LIST

KETOPROFEN

CAPSULE;ORAL

KETOPROFEN

<u>AB</u>	HERITAGE PHARMS INC	<u>50MG</u>	<u>A074014</u>	<u>002</u>	Jan 29, 1993
<u>AB</u>		<u>75MG</u>	<u>A074014</u>	<u>003</u>	Jan 29, 1993
<u>AB</u>	TEVA	<u>50MG</u>	<u>A073516</u>	<u>001</u>	Dec 22, 1992
<u>AB</u>	!	<u>75MG</u>	<u>A073517</u>	<u>001</u>	Dec 22, 1992
	HERITAGE PHARMS INC	25MG	A074014	001	Jan 29, 1993

CAPSULE, EXTENDED RELEASE;ORAL

KETOPROFEN!

MYLAN

200MG

A075679 001 Feb 20, 2002

KETOROLAC TROMETHAMINE

INJECTABLE;INJECTION

KETOROLAC TROMETHAMINE

<u>AP</u>	AUROBINDO PHARMA LTD	<u>15MG/ML</u>	<u>A212939</u>	<u>001</u>	Oct 20, 2020
<u>AP</u>		<u>30MG/ML</u>	<u>A212939</u>	<u>002</u>	Oct 20, 2020
<u>AP</u>	BAXTER HLTHCARE CORP	<u>15MG/ML</u>	<u>A209900</u>	<u>002</u>	Jul 25, 2018
<u>AP</u>		<u>30MG/ML</u>	<u>A209900</u>	<u>001</u>	Sep 15, 2017
<u>AP</u>	FRESENIUS KABI USA	<u>15MG/ML</u>	<u>A075784</u>	<u>001</u>	Jan 11, 2002
<u>AP</u>		<u>15MG/ML</u>	<u>A203242</u>	<u>001</u>	Oct 07, 2015
<u>AP</u>		<u>30MG/ML</u>	<u>A075784</u>	<u>002</u>	Jan 11, 2002
<u>AP</u>		<u>30MG/ML</u>	<u>A203242</u>	<u>002</u>	Oct 07, 2015
<u>AP</u>	GLAND PHARMA LTD	<u>15MG/ML</u>	<u>A204216</u>	<u>001</u>	Nov 01, 2016
<u>AP</u>		<u>30MG/ML</u>	<u>A204216</u>	<u>002</u>	Nov 01, 2016
<u>AP</u>	!	<u>15MG/ML</u>	<u>A074802</u>	<u>001</u>	Jun 05, 1997
<u>AP</u>		<u>15MG/ML</u>	<u>A074993</u>	<u>001</u>	Jan 27, 1999
<u>AP</u>	!	<u>30MG/ML</u>	<u>A074802</u>	<u>002</u>	Jun 05, 1997
<u>AP</u>		<u>30MG/ML</u>	<u>A074993</u>	<u>002</u>	Jan 27, 1999
<u>AP</u>	NEPHRON	<u>30MG/ML</u>	<u>A211445</u>	<u>001</u>	Aug 20, 2020
<u>AP</u>	SAGENT PHARMS INC	<u>15MG/ML</u>	<u>A091065</u>	<u>001</u>	Nov 27, 2013
<u>AP</u>		<u>30MG/ML</u>	<u>A091065</u>	<u>002</u>	Nov 27, 2013
<u>AP</u>	SANDOZ INC	<u>30MG/ML</u>	<u>A076271</u>	<u>002</u>	Oct 06, 2004
<u>AP</u>	WEST-WARD PHARMS INT	<u>15MG/ML</u>	<u>A075772</u>	<u>001</u>	Jul 21, 2004
<u>AP</u>		<u>30MG/ML</u>	<u>A075772</u>	<u>002</u>	Jul 21, 2004
<u>AP</u>	WOCKHARDT	<u>15MG/ML</u>	<u>A077942</u>	<u>001</u>	Mar 27, 2007
<u>AP</u>		<u>30MG/ML</u>	<u>A077942</u>	<u>002</u>	Mar 27, 2007

SOLUTION/DROPS;OPHTHALMIC

ACULAR

<u>AT</u>	+	ALLERGAN	<u>0.5%</u>	<u>N019700</u>	<u>001</u>	Nov 09, 1992
-----------	---	----------	-------------	----------------	------------	--------------

ACULAR LS

<u>AT</u>	+	ALLERGAN	<u>0.4%</u>	<u>N021528</u>	<u>001</u>	May 30, 2003
-----------	---	----------	-------------	----------------	------------	--------------

KETOROLAC TROMETHAMINE

<u>AT</u>		AKORN	<u>0.4%</u>	<u>A078399</u>	<u>001</u>	Nov 05, 2009
<u>AT</u>			<u>0.5%</u>	<u>A078434</u>	<u>001</u>	Nov 05, 2009
<u>AT</u>		APOTEX INC	<u>0.4%</u>	<u>A077308</u>	<u>001</u>	Nov 05, 2009
<u>AT</u>			<u>0.5%</u>	<u>A076109</u>	<u>001</u>	Nov 05, 2009
<u>AT</u>		AUROBINDO PHARMA LTD	<u>0.5%</u>	<u>A205190</u>	<u>001</u>	Dec 03, 2020
<u>AT</u>		MICRO LABS LTD INDIA	<u>0.5%</u>	<u>A203410</u>	<u>001</u>	Apr 05, 2019
<u>AT</u>		SANDOZ INC	<u>0.5%</u>	<u>A076583</u>	<u>001</u>	Nov 05, 2009
<u>AT</u>		SUN PHARM	<u>0.5%</u>	<u>A090017</u>	<u>001</u>	Nov 05, 2009

ACUVAIL

+

ALLERGAN

0.45%

N022427 001 Jul 22, 2009

SPRAY, METERED;NASAL

SPRIX

+

ZYLA

15.75MG/SPRAY

N022382 001 May 14, 2010

TABLET;ORAL

KETOROLAC TROMETHAMINE

<u>AB</u>	CYCLE PHARMS LTD	<u>10MG</u>	<u>A210616</u>	<u>001</u>	Aug 16, 2018	
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A074761</u>	<u>001</u>	May 16, 1997	
<u>AB</u>	!	TEVA	<u>10MG</u>	<u>A074754</u>	<u>001</u>	May 16, 1997

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;IRRIGATION

KETOROLAC TROMETHAMINE AND PHENYLEPHRINE HYDROCHLORIDE

<u>AT</u>	LUPIN LTD	<u>EQ 0.3% BASE;EQ 1% BASE</u>	<u>A210183</u>	<u>001</u>	Jul 01, 2019
-----------	-----------	--------------------------------	----------------	------------	--------------

OMIDRIA

<u>AT</u>	+	OMEROS	<u>EQ 0.3% BASE;EQ 1% BASE</u>	<u>N205388</u>	<u>001</u>	May 30, 2014
-----------	---	--------	--------------------------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

L-GLUTAMINE

FOR SOLUTION;ORAL

ENDARI

+ EMMAUS MEDCL 5GM/PACKET N208587 001 Jul 07, 2017

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HYDROCHLORIDEAP AKORN INC 5MG/ML A075431 001 Nov 29, 1999AP GLAND PHARMA LTD 5MG/ML A090699 001 Apr 03, 2012AP ! HOSPIRA 5MG/ML A075239 001 Nov 29, 1999AP ! 5MG/ML A075240 001 Nov 29, 1999AP WEST-WARD PHARMS 5MG/ML A075303 001 May 28, 1999

INT

SOLUTION; INTRAVENOUS

LABETALOL HYDROCHLORIDE IN DEXTROSE

+! HIKMA 200MG/200ML (1MG/ML) N213330 001 Nov 09, 2020

LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE

+! HIKMA 100MG/100ML (1MG/ML) N213330 002 Nov 09, 2020

+! 200MG/200ML (1MG/ML) N213330 003 Nov 09, 2020

+! 300MG/300ML (1MG/ML) N213330 004 Nov 09, 2020

TABLET; ORAL

LABETALOL HYDROCHLORIDEAB APPCO 100MG A209603 001 Jun 20, 2018AB 200MG A209603 002 Jun 20, 2018AB 300MG A209603 003 Jun 20, 2018AB CADILA PHARMS LTD 100MG A211325 001 May 13, 2019AB 200MG A211325 002 May 13, 2019AB 300MG A211325 003 May 13, 2019AB EPIC PHARMA LLC 100MG A212990 001 Sep 30, 2020AB 200MG A212990 002 Sep 30, 2020AB 300MG A212990 003 Sep 30, 2020AB EYWA 100MG A207863 001 Feb 04, 2019AB 200MG A207863 002 Feb 04, 2019AB 300MG A207863 003 Feb 04, 2019AB HERITAGE PHARMA 100MG A074787 001 Aug 03, 1998AB 200MG A074787 002 Aug 03, 1998AB 300MG A074787 003 Aug 03, 1998AB INNOGENIX 100MG A075215 001 Jul 29, 1999AB 200MG A075215 002 Jul 29, 1999AB 300MG A075215 003 Jul 29, 1999AB PAR FORM 100MG A200908 001 Jul 10, 2012AB 200MG A200908 002 Jul 10, 2012AB 300MG A200908 003 Jul 10, 2012AB SANDOZ 100MG A075113 001 Aug 04, 1998AB ! 200MG A075113 002 Aug 04, 1998AB 300MG A075113 003 Aug 04, 1998AB WATSON LABS 100MG A075133 001 Aug 03, 1998AB 200MG A075133 002 Aug 03, 1998AB 300MG A075133 003 Aug 03, 1998AB ZYDUS PHARMS 100MG A207743 001 Sep 19, 2017AB 200MG A207743 002 Sep 19, 2017AB 300MG A207743 003 Sep 19, 2017TRANDATEAB + CNTY LINE PHARMS 100MG N018716 001 May 24, 1985AB + 200MG N018716 002 Aug 01, 1984AB + 300MG N018716 003 Aug 01, 1984LACOSAMIDE

SOLUTION; INTRAVENOUS

VIMPAT

+! UCB INC 200MG/20ML (10MG/ML) N022254 001 Oct 28, 2008

SOLUTION; ORAL

VIMPAT

+! UCB INC 10MG/ML N022255 001 Apr 20, 2010

TABLET; ORAL

VIMPAT

+ UCB INC 50MG N022253 001 Oct 28, 2008

+ 100MG N022253 002 Oct 28, 2008

+ 150MG N022253 003 Oct 28, 2008

+! 200MG N022253 004 Oct 28, 2008

PRESCRIPTION DRUG PRODUCT LIST

LACTULOSE

FOR SOLUTION;ORAL

LACTULOSE

! CUMBERLAND PHARMS 10GM/PACKET A074712 001 Dec 10, 1997
! 20GM/PACKET A074712 002 Dec 10, 1997

SOLUTION;ORAL

CONSTILAC

AA ALRA 10GM/15ML A071054 001 Jul 26, 1988

LACTULOSE

AA ! AKORN 10GM/15ML A074076 001 Jul 03, 1995
AA CHARTWELL RX 10GM/15ML A209517 001 Nov 23, 2018
AA FRESENIUS KABI 10GM/15ML A090503 001 Jan 25, 2012
AA LANNETT CO INC 10GM/15ML A075993 001 Jul 26, 2001
AA PHARM ASSOC 10GM/15ML A074623 001 Jul 30, 1996
AA VISTAPHARM 10GM/15ML A074138 001 Sep 30, 1992
AA WOCHKHARDT BIO AG 10GM/15ML A074602 001 Nov 14, 1996
AA XTTRIUM LABS INC 10GM/15ML A075911 001 Feb 21, 2002

SOLUTION;ORAL, RECTAL

CHOLAC

AA ALRA 10GM/15ML A071331 001 Jul 26, 1988

GENERLAC

AA WOCHKHARDT BIO AG 10GM/15ML A074603 001 Oct 31, 1996

LACTULOSE

AA AKORN 10GM/15ML A074077 001 Jul 03, 1995
AA ! FRESENIUS KABI 10GM/15ML A090502 001 Jan 25, 2012

LAMIVUDINE

SOLUTION;ORAL

EPIVIR

AA +! VIIV HLTHCARE 10MG/ML N020596 001 Nov 17, 1995

LAMIVUDINE

AA AUROBINDO PHARMA 10MG/ML A077695 001 Nov 21, 2016
LTD
AA LANNETT CO INC 10MG/ML A203564 001 Oct 31, 2014

EPIVIR-HBV

+! GLAXOSMITHKLINE 5MG/ML N021004 001 Dec 08, 1998

TABLET;ORAL

EPIVIR

AB + VIIV HLTHCARE 150MG N020564 001 Nov 17, 1995
AB +! 300MG N020564 003 Jun 24, 2002

EPIVIR-HBV

AB +! GLAXOSMITHKLINE 100MG N021003 001 Dec 08, 1998

LAMIVUDINE

AB ANNORA 100MG A211306 001 Mar 21, 2019
AB APOTEX 100MG A202941 001 Jan 02, 2014
AB 150MG A091606 001 Dec 02, 2011
AB 300MG A091606 002 Dec 02, 2011
AB ARISE 150MG A206974 001 Nov 21, 2016
AB 300MG A206974 002 Nov 21, 2016
AB AUROBINDO PHARMA 150MG A077464 001 Nov 21, 2016
LTD
AB 150MG A202032 001 Nov 17, 2011
AB 300MG A077464 002 Nov 21, 2016
AB 300MG A202032 002 Nov 17, 2011
AB CIPLA 150MG A077221 001 Mar 03, 2017
AB 300MG A077221 002 Mar 03, 2017
AB HETERO LABS LTD V 100MG A203260 001 Jan 02, 2014
AB 150MG A203277 001 Jan 06, 2014
AB 300MG A203277 002 Jan 06, 2014
AB LUPIN LTD 150MG A205217 001 Dec 18, 2014
AB 300MG A205217 002 Dec 18, 2014
AB MACLEODS PHARMS LTD 150MG A090198 001 May 01, 2019
AB 300MG A090198 002 May 01, 2019
AB MYLAN LABS LTD 150MG A078545 001 Mar 05, 2019
AB 300MG A078545 002 Mar 05, 2019
AB PHARMA LIFE 150MG A203586 001 Nov 21, 2016
AB STRIDES PHARMA 150MG A090457 001 Apr 19, 2018
AB 300MG A090457 002 Apr 19, 2018

PRESCRIPTION DRUG PRODUCT LIST

LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

CIMDUO

+! MYLAN LABS LTD 300MG;300MG N022141 001 Feb 28, 2018

LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

+! AUROBINDO PHARMA LTD 300MG;300MG N022344 001 May 15, 2018

TEMIXYS

+! CELLTRION 300MG;300MG N211284 001 Nov 16, 2018

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

COMBIVIRAB +! VIIV HLTHCARE 150MG;300MG N020857 001 Sep 26, 1997LAMIVUDINE AND ZIDOVUDINEAB ANDA REPOSITORY 150MG;300MG A206375 001 Apr 10, 2018AB AUROBINDO PHARMA LTD 150MG;300MG A077558 001 May 05, 2017AB 150MG;300MG A202418 001 May 15, 2012AB CIPLA 150MG;300MG A077411 001 Sep 07, 2018AB HETERO LABS LTD III 150MG;300MG A079124 001 Sep 17, 2015AB HETERO LABS LTD V 150MG;300MG A203259 001 Feb 03, 2014AB LUPIN LTD 150MG;300MG A090246 001 May 15, 2012AB MACLEODS PHARMS LTD 150MG;300MG A090679 001 Aug 29, 2018AB STRIDES PHARMA 150MG;300MG A079128 001 May 13, 2015LAMOTRIGINE

TABLET; ORAL

LAMICTALAB +! GLAXOSMITHKLINE LLC 25MG N020241 005 Dec 27, 1994AB + 100MG N020241 001 Dec 27, 1994AB + 150MG N020241 002 Dec 27, 1994AB + 200MG N020241 003 Dec 27, 1994LAMOTRIGINEAB ALEMBIC PHARMS LTD 25MG A090607 001 Jan 13, 2011AB 100MG A090607 002 Jan 13, 2011AB 150MG A090607 003 Jan 13, 2011AB 200MG A090607 004 Jan 13, 2011AB ALKEM LABS LTD 25MG A200694 001 Jun 14, 2013AB 100MG A200694 002 Jun 14, 2013AB 150MG A200694 003 Jun 14, 2013AB 200MG A200694 004 Jun 14, 2013AB AUROBINDO PHARMA 25MG A078956 001 Jan 27, 2009AB 100MG A078956 002 Jan 27, 2009AB 150MG A078956 003 Jan 27, 2009AB 200MG A078956 004 Jan 27, 2009AB DR REDDYS LABS LTD 25MG A076708 001 Jan 27, 2009AB 100MG A076708 002 Jan 27, 2009AB 150MG A076708 003 Jan 27, 2009AB 200MG A076708 004 Jan 27, 2009AB GLENMARK GENERICS 25MG A090169 001 May 12, 2012AB 100MG A090169 002 May 12, 2012AB 150MG A090169 003 May 12, 2012AB 200MG A090169 004 May 12, 2012AB JUBILANT CADISTA 25MG A079132 001 Jan 27, 2009AB 100MG A079132 002 Jan 27, 2009AB 150MG A079132 003 Jan 27, 2009AB 200MG A079132 004 Jan 27, 2009AB LUPIN LTD 25MG A078691 001 Jun 01, 2010AB 100MG A078691 002 Jun 01, 2010AB 150MG A078691 003 Jun 01, 2010AB 200MG A078691 004 Jun 01, 2010AB RUBICON 25MG A078625 001 Jan 27, 2009AB 100MG A078625 002 Jan 27, 2009AB 150MG A078625 003 Jan 27, 2009AB 200MG A078625 004 Jan 27, 2009AB TARO PHARM INDS 25MG A078525 001 Jan 27, 2009AB 100MG A078525 002 Jan 27, 2009AB 150MG A078525 003 Jan 27, 2009AB 200MG A078525 004 Jan 27, 2009AB TORRENT PHARMS 25MG A078947 001 Jan 27, 2009AB 100MG A078947 002 Jan 27, 2009AB 150MG A078947 003 Jan 27, 2009AB 200MG A078947 004 Jan 27, 2009

PRESCRIPTION DRUG PRODUCT LIST

LAMOTRIGINE

TABLET;ORAL

LAMOTRIGINE

<u>AB</u>	UNICHEM LABS LTD	<u>25MG</u>	<u>A090170 001</u>	Oct 06, 2011
<u>AB</u>		<u>100MG</u>	<u>A090170 002</u>	Oct 06, 2011
<u>AB</u>		<u>150MG</u>	<u>A090170 003</u>	Oct 06, 2011
<u>AB</u>		<u>200MG</u>	<u>A090170 004</u>	Oct 06, 2011
<u>AB</u>	ZYDUS PHARMS USA	<u>25MG</u>	<u>A077633 001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A077633 003</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A077633 004</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A077633 005</u>	Jan 27, 2009
		50MG	A077633 002	Jan 27, 2009
		250MG	A077633 006	Jan 27, 2009

TABLET, CHEWABLE;ORAL

LAMICTAL CD

<u>AB</u>	+	GLAXOSMITHKLINE LLC	<u>2MG</u>	<u>N020764 004</u>	Sep 08, 2000
<u>AB</u>	+		<u>5MG</u>	<u>N020764 001</u>	Aug 24, 1998
<u>AB</u>	+	!	<u>25MG</u>	<u>N020764 002</u>	Aug 24, 1998

LAMOTRIGINE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>5MG</u>	<u>A201168 001</u>	Jun 12, 2014
<u>AB</u>		<u>25MG</u>	<u>A201168 002</u>	Jun 12, 2014
<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A090401 002</u>	Nov 04, 2009
<u>AB</u>		<u>25MG</u>	<u>A090401 003</u>	Nov 04, 2009
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A076701 001</u>	Jan 22, 2009
<u>AB</u>		<u>25MG</u>	<u>A076701 002</u>	Jan 22, 2009
<u>AB</u>	GLENMARK PHARMS LTD	<u>5MG</u>	<u>A079099 001</u>	Feb 19, 2009
<u>AB</u>		<u>25MG</u>	<u>A079099 002</u>	Feb 19, 2009
<u>AB</u>	JUBILANT GENERICS	<u>5MG</u>	<u>A200220 001</u>	Feb 28, 2011
<u>AB</u>		<u>25MG</u>	<u>A200220 002</u>	Feb 28, 2011
<u>AB</u>	TARO	<u>5MG</u>	<u>A079204 001</u>	Feb 04, 2009
<u>AB</u>		<u>25MG</u>	<u>A079204 002</u>	Feb 04, 2009
<u>AB</u>	WATSON LABS	<u>2MG</u>	<u>A076928 001</u>	Jan 22, 2009
<u>AB</u>		<u>5MG</u>	<u>A076928 002</u>	Jan 22, 2009
<u>AB</u>		<u>25MG</u>	<u>A076928 003</u>	Jan 22, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>5MG</u>	<u>A078009 002</u>	Jan 22, 2009
<u>AB</u>		<u>25MG</u>	<u>A078009 003</u>	Jan 22, 2009

TABLET, EXTENDED RELEASE;ORAL

LAMICTAL XR

<u>AB</u>	+	GLAXOSMITHKLINE LLC	<u>25MG</u>	<u>N022115 001</u>	May 29, 2009
<u>AB</u>	+	!	<u>50MG</u>	<u>N022115 002</u>	May 29, 2009
<u>AB</u>	+		<u>100MG</u>	<u>N022115 003</u>	May 29, 2009
<u>AB</u>	+	!	<u>200MG</u>	<u>N022115 004</u>	May 29, 2009
<u>AB</u>	+		<u>250MG</u>	<u>N022115 006</u>	Jun 21, 2011
<u>AB</u>	+		<u>300MG</u>	<u>N022115 005</u>	Apr 14, 2010

LAMOTRIGINE

<u>AB</u>	ACTAVIS ELIZABETH	<u>100MG</u>	<u>A200672 003</u>	Oct 17, 2013
<u>AB</u>		<u>200MG</u>	<u>A200672 004</u>	Oct 17, 2013
<u>AB</u>		<u>25MG</u>	<u>A200672 001</u>	Oct 17, 2013
<u>AB</u>		<u>50MG</u>	<u>A200672 002</u>	Oct 17, 2013
<u>AB</u>		<u>250MG</u>	<u>A203733 001</u>	Nov 13, 2013
<u>AB</u>		<u>300MG</u>	<u>A200672 005</u>	Oct 17, 2013
<u>AB</u>	AMNEAL PHARMS	<u>25MG</u>	<u>A207497 001</u>	Nov 30, 2018
<u>AB</u>		<u>50MG</u>	<u>A207497 002</u>	Nov 30, 2018
<u>AB</u>		<u>100MG</u>	<u>A207497 003</u>	Nov 30, 2018
<u>AB</u>		<u>200MG</u>	<u>A207497 004</u>	Nov 30, 2018
<u>AB</u>		<u>250MG</u>	<u>A207497 005</u>	Nov 30, 2018
<u>AB</u>		<u>300MG</u>	<u>A207497 006</u>	Nov 30, 2018
<u>AB</u>	ANCHEN PHARMS	<u>25MG</u>	<u>A201374 001</u>	Dec 26, 2012
<u>AB</u>		<u>50MG</u>	<u>A201374 002</u>	Dec 26, 2012
<u>AB</u>		<u>100MG</u>	<u>A201374 003</u>	Dec 26, 2012
<u>AB</u>		<u>200MG</u>	<u>A201374 004</u>	Dec 26, 2012
<u>AB</u>		<u>250MG</u>	<u>A201374 005</u>	Dec 26, 2012
<u>AB</u>		<u>300MG</u>	<u>A201374 006</u>	Dec 26, 2012
<u>AB</u>	ATLANTIDE	<u>25MG</u>	<u>A202498 001</u>	Jan 04, 2013
<u>AB</u>		<u>50MG</u>	<u>A202498 002</u>	Jan 04, 2013
<u>AB</u>		<u>100MG</u>	<u>A202498 003</u>	Jan 04, 2013
<u>AB</u>		<u>200MG</u>	<u>A202498 004</u>	Jan 04, 2013
<u>AB</u>		<u>300MG</u>	<u>A202498 005</u>	Jan 04, 2013
<u>AB</u>	DR REDDYS LABS LTD	<u>25MG</u>	<u>A202383 001</u>	Jun 19, 2013
<u>AB</u>		<u>50MG</u>	<u>A202383 002</u>	Jun 19, 2013
<u>AB</u>		<u>100MG</u>	<u>A202383 003</u>	Jun 19, 2013
<u>AB</u>		<u>200MG</u>	<u>A202383 004</u>	Jun 19, 2013

PRESCRIPTION DRUG PRODUCT LIST

LAMOTRIGINE

TABLET, EXTENDED RELEASE;ORAL

LAMOTRIGINE

<u>AB</u>		<u>250MG</u>	<u>A202383</u>	<u>006</u>	Sep 06, 2018
<u>AB</u>		<u>300MG</u>	<u>A202383</u>	<u>005</u>	Jun 19, 2013
<u>AB</u>	PAR PHARM	<u>25MG</u>	<u>A201791</u>	<u>001</u>	Jan 18, 2013
<u>AB</u>		<u>50MG</u>	<u>A201791</u>	<u>002</u>	Jan 18, 2013
<u>AB</u>		<u>100MG</u>	<u>A201791</u>	<u>003</u>	Jan 18, 2013
<u>AB</u>		<u>200MG</u>	<u>A201791</u>	<u>004</u>	Jan 18, 2013
<u>AB</u>		<u>250MG</u>	<u>A201791</u>	<u>005</u>	Jan 18, 2013
<u>AB</u>		<u>300MG</u>	<u>A201791</u>	<u>006</u>	Jan 18, 2013
<u>AB</u>	RUBICON	<u>100MG</u>	<u>A202887</u>	<u>003</u>	Jun 17, 2013
<u>AB</u>		<u>200MG</u>	<u>A202887</u>	<u>004</u>	Jun 17, 2013
<u>AB</u>	TORRENT	<u>25MG</u>	<u>A203370</u>	<u>001</u>	Dec 23, 2013
<u>AB</u>		<u>50MG</u>	<u>A203370</u>	<u>002</u>	Dec 23, 2013
<u>AB</u>		<u>100MG</u>	<u>A203370</u>	<u>003</u>	Dec 23, 2013
<u>AB</u>		<u>200MG</u>	<u>A203370</u>	<u>004</u>	Dec 23, 2013
<u>AB</u>	ZYDUS PHARMS	<u>25MG</u>	<u>A207763</u>	<u>001</u>	Apr 01, 2020
<u>AB</u>		<u>50MG</u>	<u>A207763</u>	<u>002</u>	Apr 01, 2020
<u>AB</u>		<u>100MG</u>	<u>A207763</u>	<u>003</u>	Apr 01, 2020
<u>AB</u>		<u>200MG</u>	<u>A207763</u>	<u>004</u>	Apr 01, 2020
<u>AB</u>		<u>250MG</u>	<u>A207763</u>	<u>005</u>	Apr 01, 2020
<u>AB</u>		<u>300MG</u>	<u>A207763</u>	<u>006</u>	Apr 01, 2020

TABLET, ORALLY DISINTEGRATING;ORAL

LAMICTAL ODT

<u>AB</u>	+	GLAXOSMITHKLINE LLC	<u>25MG</u>	<u>N022251</u>	<u>001</u>	May 08, 2009
<u>AB</u>	+	!	<u>50MG</u>	<u>N022251</u>	<u>002</u>	May 08, 2009
<u>AB</u>	+		<u>100MG</u>	<u>N022251</u>	<u>003</u>	May 08, 2009
<u>AB</u>	+		<u>200MG</u>	<u>N022251</u>	<u>004</u>	May 08, 2009

LAMOTRIGINE

<u>AB</u>	IMPAX LABS INC	<u>25MG</u>	<u>A200828</u>	<u>001</u>	Jul 15, 2013
<u>AB</u>		<u>50MG</u>	<u>A200828</u>	<u>002</u>	Jul 15, 2013
<u>AB</u>		<u>100MG</u>	<u>A200828</u>	<u>003</u>	Jul 15, 2013
<u>AB</u>		<u>200MG</u>	<u>A200828</u>	<u>004</u>	Jul 15, 2013
<u>AB</u>	PAR PHARM	<u>25MG</u>	<u>A204158</u>	<u>001</u>	Oct 27, 2015
<u>AB</u>		<u>50MG</u>	<u>A204158</u>	<u>002</u>	Oct 27, 2015
<u>AB</u>		<u>100MG</u>	<u>A204158</u>	<u>003</u>	Oct 27, 2015
<u>AB</u>		<u>200MG</u>	<u>A204158</u>	<u>004</u>	Oct 27, 2015
<u>AB</u>	SCIEGEN PHARMS INC	<u>25MG</u>	<u>A206382</u>	<u>001</u>	Jun 17, 2016
<u>AB</u>		<u>50MG</u>	<u>A206382</u>	<u>002</u>	Jun 17, 2016
<u>AB</u>		<u>100MG</u>	<u>A206382</u>	<u>003</u>	Jun 17, 2016
<u>AB</u>		<u>200MG</u>	<u>A206382</u>	<u>004</u>	Jun 17, 2016

LANREOTIDE ACETATE

SOLUTION;SUBCUTANEOUS

SOMATULINE DEPOT

+	!	IPSEN PHARMA	EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML)	N022074	001	Aug 30, 2007
+	!		EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML)	N022074	002	Aug 30, 2007
+	!		EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML)	N022074	003	Aug 30, 2007

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE

<u>AB</u>	ALKEM LABS LTD	<u>15MG</u>	<u>A207394</u>	<u>001</u>	Jan 18, 2019
<u>AB</u>		<u>30MG</u>	<u>A207394</u>	<u>002</u>	Jan 18, 2019
<u>AB</u>	DR REDDYS LABS LTD	<u>15MG</u>	<u>A091269</u>	<u>001</u>	Oct 15, 2010
<u>AB</u>		<u>30MG</u>	<u>A091269</u>	<u>002</u>	Oct 15, 2010
<u>AB</u>	HETERO LABS LTD III	<u>15MG</u>	<u>A203083</u>	<u>001</u>	May 18, 2020
<u>AB</u>		<u>30MG</u>	<u>A203083</u>	<u>002</u>	May 18, 2020
<u>AB</u>	INVENTIA	<u>15MG</u>	<u>A205868</u>	<u>001</u>	Aug 30, 2017
<u>AB</u>		<u>30MG</u>	<u>A205868</u>	<u>002</u>	Aug 30, 2017
<u>AB</u>	LANNETT CO INC	<u>15MG</u>	<u>A207156</u>	<u>001</u>	Sep 28, 2017
<u>AB</u>		<u>30MG</u>	<u>A207156</u>	<u>002</u>	Sep 28, 2017
<u>AB</u>	MYLAN PHARMS INC	<u>15MG</u>	<u>A090763</u>	<u>001</u>	Nov 10, 2009
<u>AB</u>		<u>30MG</u>	<u>A090763</u>	<u>002</u>	Nov 10, 2009
<u>AB</u>	NATCO PHARMA LTD	<u>15MG</u>	<u>A201921</u>	<u>001</u>	Dec 18, 2012
<u>AB</u>		<u>30MG</u>	<u>A201921</u>	<u>002</u>	Dec 18, 2012
<u>AB</u>	SANDOZ	<u>15MG</u>	<u>A090331</u>	<u>001</u>	Apr 23, 2010
<u>AB</u>		<u>30MG</u>	<u>A090331</u>	<u>002</u>	Apr 23, 2010
<u>AB</u>	SUN PHARM	<u>15MG</u>	<u>A202637</u>	<u>001</u>	Sep 13, 2013
<u>AB</u>		<u>30MG</u>	<u>A091509</u>	<u>001</u>	Sep 13, 2013
<u>AB</u>	TEVA PHARMS	<u>15MG</u>	<u>A077255</u>	<u>001</u>	Nov 10, 2009
<u>AB</u>		<u>30MG</u>	<u>A077255</u>	<u>002</u>	Nov 10, 2009

PRESCRIPTION DRUG PRODUCT LIST

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE

<u>AB</u>	WOCKHARDT USA	<u>15MG</u>	<u>A202176 001</u>	Sep 14, 2012
<u>AB</u>		<u>30MG</u>	<u>A202176 002</u>	Sep 14, 2012
<u>AB</u>	XIROMED	<u>15MG</u>	<u>A203203 001</u>	Jul 25, 2016
<u>AB</u>		<u>30MG</u>	<u>A203203 002</u>	Jul 25, 2016
<u>AB</u>	ZYDUS HLTHCARE	<u>15MG</u>	<u>A202366 001</u>	Aug 19, 2013
<u>AB</u>		<u>30MG</u>	<u>A202366 002</u>	Aug 19, 2013

PREVACID

<u>AB</u>	+	TAKEDA PHARMS USA	<u>15MG</u>	<u>N020406 001</u>	May 10, 1995
<u>AB</u>	+	!	<u>30MG</u>	<u>N020406 002</u>	May 10, 1995

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

LANSOPRAZOLE

<u>AB</u>	MYLAN	<u>15MG</u>	<u>A202396 001</u>	Nov 28, 2018
<u>AB</u>		<u>30MG</u>	<u>A202396 002</u>	Nov 28, 2018
<u>AB</u>	TEVA PHARMS USA	<u>15MG</u>	<u>A208784 001</u>	Sep 21, 2017
<u>AB</u>		<u>30MG</u>	<u>A208784 002</u>	Sep 21, 2017
<u>AB</u>	ZYDUS PHARMS	<u>15MG</u>	<u>A200816 001</u>	Nov 27, 2018
<u>AB</u>		<u>30MG</u>	<u>A200816 002</u>	Nov 27, 2018

PREVACID

<u>AB</u>	+	TAKEDA PHARMS USA	<u>15MG</u>	<u>N021428 001</u>	Aug 30, 2002
<u>AB</u>	+	!	<u>30MG</u>	<u>N021428 002</u>	Aug 30, 2002

LANTHANUM CARBONATE

POWDER;ORAL

FOSRENOL

+	TAKEDA PHARMS USA	EQ 750MG BASE	N204734 001	Sep 24, 2014
+	!	EQ 1GM BASE	N204734 002	Sep 24, 2014

TABLET, CHEWABLE;ORAL

FOSRENOL

<u>AB</u>	+	TAKEDA PHARMS USA	<u>EQ 500MG BASE</u>	<u>N021468 002</u>	Oct 26, 2004
<u>AB</u>	+		<u>EQ 750MG BASE</u>	<u>N021468 003</u>	Nov 23, 2005
<u>AB</u>	+	!	<u>EQ 1GM BASE</u>	<u>N021468 004</u>	Nov 23, 2005

LANTHANUM CARBONATE

<u>AB</u>	NATCO PHARMA LTD	<u>EQ 500MG BASE</u>	<u>A090978 001</u>	Aug 11, 2017
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A090978 002</u>	Aug 11, 2017
<u>AB</u>		<u>EQ 1GM BASE</u>	<u>A090978 003</u>	Aug 11, 2017

LAPATINIB DITOSYLATE

TABLET;ORAL

LAPATINIB DITOSYLATE

<u>AB</u>	NATCO PHARMA LTD	<u>EQ 250MG BASE</u>	<u>A203007 001</u>	Sep 29, 2020	
<u>AB</u>	+	!	<u>EQ 250MG BASE</u>	<u>N022059 001</u>	Mar 13, 2007

TYKERBLAROTRECTINIB SULFATE

CAPSULE;ORAL

VITRAKVI

+	BAYER HLTHCARE	EQ 25MG BASE	N210861 001	Nov 26, 2018
+	!	EQ 100MG BASE	N210861 002	Nov 26, 2018

SOLUTION;ORAL

VITRAKVI

+	BAYER HEALTHCARE	EQ 20MG BASE/ML	N211710 001	Nov 26, 2018
---	------------------	-----------------	-------------	--------------

LASMIDITAN SUCCINATE

TABLET;ORAL

REYVOW

+	ELI LILLY AND CO	50MG	N211280 001	Jan 31, 2020
+	!	100MG	N211280 002	Jan 31, 2020
+		200MG	N211280 003	Dec 18, 2020

LATANOPROST

EMULSION;OPHTHALMIC

XELPROS

+	SUN PHARMA GLOBAL	0.005%	N206185 001	Sep 12, 2018
---	-------------------	--------	-------------	--------------

SOLUTION/DROPS;OPHTHALMIC

LATANOPROST

<u>AT</u>	AKORN	<u>0.005%</u>	<u>A090887 001</u>	Jul 19, 2011
<u>AT</u>	AMRING PHARMS	<u>0.005%</u>	<u>A200925 001</u>	Mar 22, 2011
<u>AT</u>	BAUSCH AND LOMB	<u>0.005%</u>	<u>A201006 001</u>	Mar 22, 2011
<u>AT</u>	DR REDDYS LABS LTD	<u>0.005%</u>	<u>A202077 001</u>	Feb 11, 2013
<u>AT</u>	FDC LTD	<u>0.005%</u>	<u>A202442 001</u>	Apr 22, 2016
<u>AT</u>	SANDOZ INC	<u>0.005%</u>	<u>A091449 001</u>	Mar 22, 2011
<u>AT</u>	SOMERSET	<u>0.005%</u>	<u>A201786 001</u>	Mar 22, 2011

PRESCRIPTION DRUG PRODUCT LIST

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC

XALATAN

AT	+ !	UPJOHN	0.005%	N020597 001	Jun 05, 1996
-----------	------------	--------	---------------	--------------------	--------------

LATANOPROST; NETARSUDIL DIMESYLATE

SOLUTION/DROPS;OPHTHALMIC

ROCKLATAN

+ !	AERIE PHARMS INC	0.005%;EQ 0.02% BASE	N208259 001	Mar 12, 2019
------------	------------------	----------------------	--------------------	--------------

LATANOPROSTENE BUNOD

SOLUTION/DROPS;OPHTHALMIC

VYZULTA

+ !	BAUSCH AND LOMB	0.024%	N207795 001	Nov 02, 2017
------------	-----------------	--------	--------------------	--------------

LEDIPASVIR; SOFOSBUVIR

PELLETS;ORAL

HARVONI

+	GILEAD SCIENCES INC	33.75MG;150MG/PACKET	N212477 001	Aug 28, 2019
----------	---------------------	----------------------	--------------------	--------------

+ !		45MG;200MG/PACKET	N212477 002	Aug 28, 2019
------------	--	-------------------	--------------------	--------------

TABLET;ORAL

HARVONI

+	GILEAD SCIENCES INC	45MG;200MG	N205834 002	Aug 28, 2019
----------	---------------------	------------	--------------------	--------------

+ !		90MG;400MG	N205834 001	Oct 10, 2014
------------	--	------------	--------------------	--------------

LEFAMULIN ACETATE

SOLUTION;INTRAVENOUS

XENLETA

+ !	NABRIVA	EQ 150MG BASE/15ML (EQ 10MG BASE/ML)	N211673 001	Aug 19, 2019
------------	---------	--------------------------------------	--------------------	--------------

TABLET;ORAL

XENLETA

+ !	NABRIVA	EQ 600MG BASE	N211672 001	Aug 19, 2019
------------	---------	---------------	--------------------	--------------

LEFLUNOMIDE

TABLET;ORAL

ARAVA

AB	+	SANOFI AVENTIS US	10MG	N020905 001	Sep 10, 1998
-----------	----------	-------------------	-------------	--------------------	--------------

AB	+ !		20MG	N020905 002	Sep 10, 1998
-----------	------------	--	-------------	--------------------	--------------

LEFLUNOMIDE

AB		ABHAI LLC	10MG	A212453 001	Jun 03, 2019
-----------	--	-----------	-------------	--------------------	--------------

AB			20MG	A212453 002	Jun 03, 2019
-----------	--	--	-------------	--------------------	--------------

AB		ALEMBIC PHARMS LTD	10MG	A091369 001	Nov 21, 2011
-----------	--	--------------------	-------------	--------------------	--------------

AB			20MG	A091369 002	Nov 21, 2011
-----------	--	--	-------------	--------------------	--------------

AB		APOTEX INC	10MG	A077090 001	Sep 13, 2005
-----------	--	------------	-------------	--------------------	--------------

AB			20MG	A077090 002	Sep 13, 2005
-----------	--	--	-------------	--------------------	--------------

AB		FOSUN PHARMA	10MG	A077087 001	Sep 13, 2005
-----------	--	--------------	-------------	--------------------	--------------

AB			20MG	A077087 002	Sep 13, 2005
-----------	--	--	-------------	--------------------	--------------

AB		HERITAGE PHARMS INC	10MG	A077086 001	Sep 13, 2005
-----------	--	---------------------	-------------	--------------------	--------------

AB			20MG	A077086 002	Sep 13, 2005
-----------	--	--	-------------	--------------------	--------------

AB		LUPIN LTD	10MG	A211863 001	Feb 04, 2020
-----------	--	-----------	-------------	--------------------	--------------

AB			20MG	A211863 002	Feb 04, 2020
-----------	--	--	-------------	--------------------	--------------

AB		ZYDUS	10MG	A212308 001	Apr 24, 2019
-----------	--	-------	-------------	--------------------	--------------

AB			20MG	A212308 002	Apr 24, 2019
-----------	--	--	-------------	--------------------	--------------

ARAVA

+ !	SANOFI AVENTIS US	100MG	N020905 003	Sep 10, 1998
------------	-------------------	-------	--------------------	--------------

LEMBOREXANT

TABLET;ORAL

DAYVIGO

+	EISAI INC	5MG	N212028 001	Apr 07, 2020
----------	-----------	-----	--------------------	--------------

+ !		10MG	N212028 002	Apr 07, 2020
------------	--	------	--------------------	--------------

LENALIDOMIDE

CAPSULE;ORAL

REVLIMID

+	CELGENE	2.5MG	N021880 005	Dec 21, 2011
----------	---------	-------	--------------------	--------------

+		5MG	N021880 001	Dec 27, 2005
----------	--	-----	--------------------	--------------

+		10MG	N021880 002	Dec 27, 2005
----------	--	------	--------------------	--------------

+		15MG	N021880 003	Jun 29, 2006
----------	--	------	--------------------	--------------

+		20MG	N021880 006	Jun 05, 2013
----------	--	------	--------------------	--------------

+ !		25MG	N021880 004	Jun 29, 2006
------------	--	------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

LEUCOVORIN CALCIUM

TABLET; ORAL

LEUCOVORIN CALCIUM

<u>AB</u>	NOVAST LABS	<u>EQ 5MG BASE</u>	<u>A211132 001</u>	Jul 30, 2020
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A211132 002</u>	Jul 30, 2020
<u>AB</u>		<u>EQ 15MG BASE</u>	<u>A211132 003</u>	Jul 30, 2020
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A211132 004</u>	Jul 30, 2020

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LEUPROLIDE ACETATE

<u>AP</u>	! SANDOZ	<u>1MG/0.2ML</u>	<u>A074728 001</u>	Aug 04, 1998
<u>AP</u>	SUN PHARM	<u>1MG/0.2ML</u>	<u>A078885 001</u>	Mar 09, 2009
<u>AP</u>	TEVA PHARMS USA	<u>1MG/0.2ML</u>	<u>A075471 001</u>	Oct 25, 2000
	LUPRON DEPOT			
	+! ABBVIE ENDOCRINE INC	3.75MG	N020011 002	Oct 26, 1995
	+!	7.5MG/VIAL	N019732 001	Jan 26, 1989
	+!	11.25MG/VIAL	N020708 001	Mar 07, 1997
	+	22.5MG/VIAL	N020517 001	Dec 22, 1995
	+!	30MG/VIAL	N020517 002	May 30, 1997
	+!	45MG/VIAL	N020517 003	Jun 17, 2011
	POWDER; INTRAMUSCULAR			
	LUPRON DEPOT-PED KIT			
	+! ABBVIE ENDOCRINE INC	7.5MG	N020263 002	Apr 16, 1993
	+!	11.25MG	N020263 005	Jan 21, 1994
	+!	11.25MG	N020263 007	Aug 15, 2011
	+!	15MG	N020263 006	Jan 21, 1994
	+!	30MG	N020263 008	Aug 15, 2011
	POWDER; SUBCUTANEOUS			
	ELIGARD KIT			
	+! TOLMAR THERAP	7.5MG	N021343 001	Jan 23, 2002
	+!	22.5MG	N021379 001	Jul 24, 2002
	+!	30MG	N021488 001	Feb 13, 2003
	+!	45MG	N021731 001	Dec 14, 2004
	FENSOLVI KIT			
	+! TOLMAR	45MG	N213150 001	May 01, 2020

LEUPROLIDE ACETATE; NORETHINDRONE ACETATE

INJECTABLE, TABLET; INTRAMUSCULAR, ORAL

LUPANETA PACK

	+ ABBVIE ENDOCRINE	3.75MG/VIAL, N/A; N/A, 5MG	N203696 001	Dec 14, 2012
	+!	11.25MG/VIAL, N/A; N/A, 5MG	N203696 002	Dec 14, 2012

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

LEVALBUTEROL HYDROCHLORIDE

<u>AN</u>	AUROBINDO PHARMA LTD	<u>EQ 0.25% BASE</u>	<u>A207628 001</u>	Jan 31, 2017
<u>AN</u>		<u>EQ 0.0103% BASE</u>	<u>A207625 001</u>	Dec 30, 2016
<u>AN</u>		<u>EQ 0.021% BASE</u>	<u>A207625 002</u>	Dec 30, 2016
<u>AN</u>		<u>EQ 0.042% BASE</u>	<u>A207625 003</u>	Dec 30, 2016
<u>AN</u>	CIPLA	<u>EQ 0.021% BASE</u>	<u>A078171 002</u>	Dec 13, 2013
<u>AN</u>		<u>EQ 0.042% BASE</u>	<u>A078171 003</u>	Dec 13, 2013
<u>AN</u>		<u>EQ 0.0103% BASE</u>	<u>A078171 001</u>	Dec 13, 2013
<u>AN</u>	IMPAX LABS INC	<u>EQ 0.0103% BASE</u>	<u>A077756 003</u>	Apr 09, 2008
<u>AN</u>		<u>EQ 0.021% BASE</u>	<u>A077756 001</u>	Apr 09, 2008
<u>AN</u>		<u>EQ 0.042% BASE</u>	<u>A077756 002</u>	Apr 09, 2008
<u>AN</u>	MYLAN SPECIALITY LP	<u>EQ 0.25% BASE</u>	<u>A078309 001</u>	Mar 20, 2009
<u>AN</u>	RITEDOSE CORP	<u>EQ 0.0103% BASE</u>	<u>A203653 001</u>	Mar 22, 2016
<u>AN</u>		<u>EQ 0.021% BASE</u>	<u>A203653 002</u>	Mar 22, 2016
<u>AN</u>		<u>EQ 0.042% BASE</u>	<u>A203653 003</u>	Mar 22, 2016
<u>AN</u>	SUN PHARM	<u>EQ 0.0103% BASE</u>	<u>A207820 001</u>	Nov 05, 2018
<u>AN</u>		<u>EQ 0.021% BASE</u>	<u>A207820 002</u>	Nov 05, 2018
<u>AN</u>		<u>EQ 0.042% BASE</u>	<u>A207820 003</u>	Nov 05, 2018
<u>AN</u>	TEVA PARENTERAL	<u>EQ 0.25% BASE</u>	<u>A200875 001</u>	Sep 11, 2014
<u>AN</u>	TEVA PHARMS USA	<u>EQ 0.0103% BASE</u>	<u>A090297 001</u>	Apr 26, 2013
<u>AN</u>		<u>EQ 0.021% BASE</u>	<u>A090297 002</u>	Apr 26, 2013
<u>AN</u>		<u>EQ 0.042% BASE</u>	<u>A090297 003</u>	Apr 26, 2013
	<u>XOPENEX</u>			
<u>AN</u>	+! AKORN	<u>EQ 0.0103% BASE</u>	<u>N020837 003</u>	Jan 30, 2002
<u>AN</u>	+!	<u>EQ 0.021% BASE</u>	<u>N020837 001</u>	Mar 25, 1999
<u>AN</u>	+!	<u>EQ 0.042% BASE</u>	<u>N020837 002</u>	Mar 25, 1999

PRESCRIPTION DRUG PRODUCT LIST

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

XOPENEX

AN +! **EQ 0.25% BASE** **N020837 004** Jul 18, 2003

LEVALBUTEROL TARTRATE

AEROSOL, METERED; INHALATION

XOPENEX HFA

+! SUNOVION

EQ 0.045MG BASE/INH

N021730 001 Mar 11, 2005

LEVAMLODIPINE MALEATE

TABLET; ORAL

CONJUPRI

+ CSPC OUYI

EQ 2.5MG BASE

N212895 002 Dec 19, 2019

+!

EQ 5MG BASE

N212895 003 Dec 19, 2019

LEVETIRACETAM

INJECTABLE; INTRAVENOUS

KEPPRA

AP +! UCB INC **500MG/5ML (100MG/ML)** **N021872 001** Jul 31, 2006

LEVETIRACETAM

AP AUROBINDO PHARMA LTD **500MG/5ML (100MG/ML)** **A204312 001** Feb 01, 2016

AP FRESENIUS KABI USA **500MG/5ML (100MG/ML)** **A090876 001** Aug 13, 2015

AP HAINAN POLY PHARM **500MG/5ML (100MG/ML)** **A209781 001** Mar 20, 2018

AP HIKMA FARMACEUTICA **500MG/5ML (100MG/ML)** **A090981 001** Oct 13, 2011

AP HOSPIRA INC **500MG/5ML (100MG/ML)** **A202869 001** Apr 06, 2012

AP JUBILANT GENERICS **500MG/5ML (100MG/ML)** **A206838 001** Jun 02, 2016

AP MICRO LABS **500MG/5ML (100MG/ML)** **A211954 001** Aug 09, 2019

AP MYLAN LABS LTD **500MG/5ML (100MG/ML)** **A203308 001** Sep 16, 2016

AP SAGENT PHARMS **500MG/5ML (100MG/ML)** **A091627 001** Jun 26, 2013

AP SUN PHARM INDS LTD **500MG/5ML (100MG/ML)** **A090754 001** Jun 16, 2010

AP XGEN PHARMS **500MG/5ML (100MG/ML)** **A091485 001** Aug 05, 2011

LEVETIRACETAM IN SODIUM CHLORIDE

AP AUROBINDO PHARMA LTD **500MG/100ML (5MG/ML)** **A207160 001** Jan 04, 2017

AP **1000MG/100ML (10MG/ML)** **A207160 002** Jan 04, 2017

AP **1500MG/100ML (15MG/ML)** **A207160 003** Jan 04, 2017

AP GLAND PHARMA LTD **500MG/100ML (5MG/ML)** **A206880 001** Oct 25, 2017

AP **1000MG/100ML (10MG/ML)** **A206880 002** Oct 25, 2017

AP **1500MG/100ML (15MG/ML)** **A206880 003** Oct 25, 2017

AP +! HQ SPECIALITY PHARMA **500MG/100ML (5MG/ML)** **N202543 001** Nov 09, 2011

AP +! **1000MG/100ML (10MG/ML)** **N202543 002** Nov 09, 2011

AP +! **1500MG/100ML (15MG/ML)** **N202543 003** Nov 09, 2011

AP NEXUS PHARMS **500MG/100ML (5MG/ML)** **A213532 001** Jul 06, 2020

AP **1000MG/100ML (10MG/ML)** **A213532 002** Jul 06, 2020

AP **1500MG/100ML (15MG/ML)** **A213532 003** Jul 06, 2020

+! HQ SPECIALITY PHARMA

250MG/50ML (5MG/ML)

N202543 004 Dec 14, 2020

SOLUTION; ORAL

KEPPRA

AA +! UCB INC **100MG/ML** **N021505 001** Jul 15, 2003

LEVETIRACETAM

AA ACI HEALTHCARE LTD **100MG/ML** **A078582 001** Jan 15, 2009

AA ACTAVIS MID ATLANTIC **100MG/ML** **A078976 001** Jan 15, 2009

AA ALEMBIC LABS **100MG/ML** **A203067 001** May 09, 2013

AA AMNEAL PHARMS **100MG/ML** **A090992 001** Oct 27, 2009

AA AUROBINDO PHARMA LTD **100MG/ML** **A079063 001** Jan 15, 2009

AA BRECKENRIDGE **100MG/ML** **A079120 001** Jan 16, 2009

AA HETERO LABS LTD III **100MG/ML** **A203052 001** Feb 28, 2013

AA HI-TECH PHARMACAL **100MG/ML** **A090601 001** Feb 28, 2012

AA LANNETT CO INC **100MG/ML** **A090079 001** Apr 11, 2012

AA **100MG/ML** **A090263 001** Apr 03, 2009

AA LUPIN LTD **100MG/ML** **A090893 001** Oct 17, 2011

AA PHARM ASSOC **100MG/ML** **A201157 001** Jun 04, 2015

AA TARO **100MG/ML** **A078774 001** Feb 10, 2009

AA TRIS PHARMA INC **100MG/ML** **A090461 001** Sep 30, 2010

AA WOCKHARDT BIO AG **100MG/ML** **A090028 001** Mar 03, 2010

TABLET; ORAL

KEPPRA

AB + UCB INC **250MG** **N021035 001** Nov 30, 1999

AB + **500MG** **N021035 002** Nov 30, 1999

PRESCRIPTION DRUG PRODUCT LIST

LEVETIRACETAM

TABLET; ORAL

KEPPRA

<u>AB</u>	<u>+</u>	<u>750MG</u>	<u>N021035</u>	<u>003</u>	Nov 30, 1999
<u>AB</u>	<u>+!</u>	<u>1GM</u>	<u>N021035</u>	<u>004</u>	Jan 06, 2006

LEVETIRACETAM

<u>AB</u>	ACCORD HLTHCARE	<u>250MG</u>	<u>A090843</u>	<u>001</u>	Feb 14, 2011
<u>AB</u>		<u>500MG</u>	<u>A090843</u>	<u>002</u>	Feb 14, 2011
<u>AB</u>		<u>750MG</u>	<u>A090843</u>	<u>003</u>	Feb 14, 2011
<u>AB</u>		<u>1GM</u>	<u>A090843</u>	<u>004</u>	Feb 14, 2011
<u>AB</u>	ACI HEALTHCARE LTD	<u>250MG</u>	<u>A078042</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078042</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078042</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A078042</u>	<u>004</u>	Jan 15, 2009
<u>AB</u>	AUROBINDO PHARMA	<u>250MG</u>	<u>A078993</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078993</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078993</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A078993</u>	<u>004</u>	Jan 15, 2009
<u>AB</u>	BRECKENRIDGE PHARM	<u>250MG</u>	<u>A090511</u>	<u>001</u>	Aug 18, 2011
<u>AB</u>		<u>500MG</u>	<u>A090511</u>	<u>002</u>	Aug 18, 2011
<u>AB</u>		<u>750MG</u>	<u>A090511</u>	<u>003</u>	Aug 18, 2011
<u>AB</u>		<u>1GM</u>	<u>A090511</u>	<u>004</u>	Aug 18, 2011
<u>AB</u>	CHARTWELL RX	<u>250MG</u>	<u>A201293</u>	<u>001</u>	Jun 14, 2011
<u>AB</u>		<u>500MG</u>	<u>A201293</u>	<u>002</u>	Jun 14, 2011
<u>AB</u>		<u>750MG</u>	<u>A201293</u>	<u>003</u>	Jun 14, 2011
<u>AB</u>		<u>1GM</u>	<u>A201293</u>	<u>004</u>	Jun 14, 2011
<u>AB</u>	DR REDDYS LABS LTD	<u>250MG</u>	<u>A076920</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A076920</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A076920</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A078904</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>	HETERO LABS LTD III	<u>250MG</u>	<u>A090515</u>	<u>001</u>	Oct 08, 2010
<u>AB</u>		<u>500MG</u>	<u>A090515</u>	<u>002</u>	Oct 08, 2010
<u>AB</u>		<u>750MG</u>	<u>A090515</u>	<u>003</u>	Oct 08, 2010
<u>AB</u>		<u>1GM</u>	<u>A090515</u>	<u>004</u>	Oct 08, 2010
<u>AB</u>	INVAGEN PHARMS	<u>250MG</u>	<u>A078234</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078234</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078234</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>	LOTUS PHARM CO LTD	<u>250MG</u>	<u>A090906</u>	<u>002</u>	Oct 31, 2016
<u>AB</u>		<u>500MG</u>	<u>A090906</u>	<u>001</u>	Nov 05, 2010
<u>AB</u>		<u>750MG</u>	<u>A090906</u>	<u>003</u>	Oct 31, 2016
<u>AB</u>		<u>1GM</u>	<u>A090906</u>	<u>004</u>	Oct 31, 2016
<u>AB</u>	LUPIN	<u>250MG</u>	<u>A078154</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078154</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078154</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A090025</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>	MYLAN	<u>250MG</u>	<u>A076919</u>	<u>001</u>	Nov 04, 2008
<u>AB</u>		<u>500MG</u>	<u>A076919</u>	<u>002</u>	Nov 04, 2008
<u>AB</u>		<u>750MG</u>	<u>A076919</u>	<u>003</u>	Nov 04, 2008
<u>AB</u>		<u>1GM</u>	<u>A090261</u>	<u>001</u>	Dec 08, 2009
<u>AB</u>	ORCHID HLTHCARE	<u>250MG</u>	<u>A078526</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078526</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078526</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A090484</u>	<u>001</u>	Aug 05, 2010
<u>AB</u>	OXFORD PHARMS	<u>250MG</u>	<u>A077319</u>	<u>001</u>	Mar 20, 2009
<u>AB</u>		<u>500MG</u>	<u>A077319</u>	<u>002</u>	Mar 20, 2009
<u>AB</u>		<u>750MG</u>	<u>A077319</u>	<u>003</u>	Mar 20, 2009
<u>AB</u>	PRINSTON INC	<u>250MG</u>	<u>A078106</u>	<u>001</u>	Feb 10, 2009
<u>AB</u>		<u>500MG</u>	<u>A078106</u>	<u>002</u>	Feb 10, 2009
<u>AB</u>		<u>750MG</u>	<u>A078106</u>	<u>003</u>	Feb 10, 2009
<u>AB</u>		<u>1GM</u>	<u>A078106</u>	<u>004</u>	Feb 10, 2009
<u>AB</u>	SECAN PHARMS	<u>500MG</u>	<u>A205102</u>	<u>004</u>	Dec 16, 2015
<u>AB</u>		<u>1GM</u>	<u>A205102</u>	<u>003</u>	Dec 16, 2015
<u>AB</u>	TARO	<u>250MG</u>	<u>A078960</u>	<u>004</u>	Feb 01, 2010
<u>AB</u>		<u>500MG</u>	<u>A078960</u>	<u>003</u>	Feb 01, 2010
<u>AB</u>		<u>750MG</u>	<u>A078960</u>	<u>002</u>	Feb 01, 2010
<u>AB</u>		<u>1GM</u>	<u>A078960</u>	<u>001</u>	Feb 01, 2010
<u>AB</u>	TORRENT PHARMS	<u>250MG</u>	<u>A078858</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078858</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078858</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A078858</u>	<u>004</u>	Jan 15, 2009
<u>AB</u>	VIWIT PHARM	<u>250MG</u>	<u>A078869</u>	<u>001</u>	Mar 13, 2009
<u>AB</u>		<u>500MG</u>	<u>A078869</u>	<u>002</u>	Mar 13, 2009

PRESCRIPTION DRUG PRODUCT LIST

LEVETIRACETAM

TABLET; ORAL

LEVETIRACETAM

<u>AB</u>		<u>750MG</u>	<u>A078869 003</u>	Mar 13, 2009
<u>AB</u>		<u>1GM</u>	<u>A078869 004</u>	Mar 13, 2009
<u>AB</u>	VKT PHARMA	<u>250MG</u>	<u>A090767 001</u>	Jul 28, 2010
<u>AB</u>		<u>500MG</u>	<u>A090767 002</u>	Jul 28, 2010
<u>AB</u>		<u>750MG</u>	<u>A090767 003</u>	Jul 28, 2010
<u>AB</u>		<u>1GM</u>	<u>A090767 004</u>	Jul 28, 2010
<u>AB</u>	WOCKHARDT	<u>250MG</u>	<u>A079042 001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A079042 002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A079042 003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A079042 004</u>	Jan 15, 2009
<u>AB</u>	ZHEJIANG JINGXIN	<u>250MG</u>	<u>A091491 001</u>	Dec 14, 2010
<u>AB</u>		<u>500MG</u>	<u>A091491 002</u>	Dec 14, 2010
<u>AB</u>		<u>750MG</u>	<u>A091491 003</u>	Dec 14, 2010
<u>AB</u>		<u>1GM</u>	<u>A091491 004</u>	Dec 14, 2010
<u>AB</u>	ZYDUS PHARMS USA INC	<u>250MG</u>	<u>A078918 001</u>	Apr 29, 2009
<u>AB</u>		<u>1GM</u>	<u>A078918 002</u>	Apr 29, 2009

TABLET, EXTENDED RELEASE; ORAL

KEPPRA XR

<u>AB</u>	+ UCB INC	<u>500MG</u>	<u>N022285 001</u>	Sep 12, 2008
<u>AB</u>	+!	<u>750MG</u>	<u>N022285 002</u>	Feb 12, 2009

LEVETIRACETAM

<u>AB</u>	ACTAVIS LABS FL INC	<u>500MG</u>	<u>A091093 001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091093 002</u>	Sep 12, 2011
<u>AB</u>	ANCHEN PHARMS	<u>500MG</u>	<u>A091360 001</u>	Oct 04, 2011
<u>AB</u>		<u>750MG</u>	<u>A091360 002</u>	Oct 04, 2011
<u>AB</u>	ANDA REPOSITORY	<u>500MG</u>	<u>A204511 001</u>	Feb 23, 2016
<u>AB</u>		<u>750MG</u>	<u>A204511 002</u>	Feb 23, 2016
<u>AB</u>	APOTEX INC	<u>500MG</u>	<u>A091261 001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091261 002</u>	Sep 12, 2011
<u>AB</u>	FLORIDA	<u>500MG</u>	<u>A202167 001</u>	Sep 04, 2015
<u>AB</u>		<u>750MG</u>	<u>A202167 002</u>	Sep 04, 2015
<u>AB</u>	HISUN PHARM HANGZHOU	<u>500MG</u>	<u>A207175 001</u>	Sep 28, 2017
<u>AB</u>		<u>750MG</u>	<u>A207175 002</u>	Sep 28, 2017
<u>AB</u>	LOTUS PHARM CO LTD	<u>500MG</u>	<u>A202095 002</u>	Jun 06, 2016
<u>AB</u>		<u>750MG</u>	<u>A202095 001</u>	Jun 06, 2016
<u>AB</u>	LUPIN LTD	<u>500MG</u>	<u>A091399 001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091399 002</u>	Sep 12, 2011
<u>AB</u>	PHARMA LIFE	<u>500MG</u>	<u>A204754 001</u>	Aug 26, 2016
<u>AB</u>		<u>750MG</u>	<u>A204754 002</u>	Aug 26, 2016
<u>AB</u>	PHARMADAX INC	<u>500MG</u>	<u>A201464 001</u>	May 25, 2012
<u>AB</u>		<u>750MG</u>	<u>A201464 002</u>	May 25, 2012
<u>AB</u>	PRINSTON INC	<u>500MG</u>	<u>A202533 001</u>	Jul 20, 2012
<u>AB</u>		<u>500MG</u>	<u>A203468 001</u>	May 21, 2015
<u>AB</u>		<u>750MG</u>	<u>A202533 002</u>	Jul 20, 2012
<u>AB</u>		<u>750MG</u>	<u>A203468 002</u>	May 21, 2015
<u>AB</u>	ROUSES POINT PHARMS	<u>500MG</u>	<u>A202524 001</u>	Aug 27, 2012
<u>AB</u>		<u>750MG</u>	<u>A202524 002</u>	Aug 27, 2012
<u>AB</u>	SCIEGEN PHARMS INC	<u>500MG</u>	<u>A205130 001</u>	Nov 27, 2020
<u>AB</u>		<u>750MG</u>	<u>A205130 002</u>	Nov 27, 2020
<u>AB</u>	SUN PHARM	<u>500MG</u>	<u>A203059 001</u>	Sep 09, 2013
<u>AB</u>		<u>750MG</u>	<u>A203059 002</u>	Sep 09, 2013
	ELEPSIA XR			
	+ SPARC	1GM	N204417 001	Dec 20, 2018
	+!	1.5GM	N204417 002	Dec 20, 2018
	LEVETIRACETAM			
	APOTEX	1GM	A202958 001	Feb 25, 2015
	TABLET, FOR SUSPENSION; ORAL			
	SPRITAM			
	+ APRECIA PHARMS	250MG	N207958 001	Jul 31, 2015
		500MG	N207958 002	Jul 31, 2015
		750MG	N207958 003	Jul 31, 2015
		1GM	N207958 004	Jul 31, 2015

PRESCRIPTION DRUG PRODUCT LIST

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

AKBETA

<u>AT</u>	AKORN	<u>0.25%</u>	<u>A074779</u>	<u>001</u>	Oct 29, 1996
<u>AT</u>		<u>0.5%</u>	<u>A074780</u>	<u>001</u>	Oct 29, 1996

BETAGAN

<u>AT</u>	+! ALLERGAN	<u>0.25%</u>	<u>N019814</u>	<u>001</u>	Jun 28, 1989
<u>AT</u>	+!	<u>0.5%</u>	<u>N019219</u>	<u>002</u>	Dec 19, 1985

LEVOBUNOLOL HYDROCHLORIDE

<u>AT</u>	BAUSCH AND LOMB	<u>0.5%</u>	<u>A074326</u>	<u>001</u>	Mar 04, 1994
-----------	-----------------	-------------	----------------	------------	--------------

LEVOCARNITINE

INJECTABLE; INJECTION

CARNITOR

<u>AP</u>	+! LEADIANT BIOSCI INC	<u>200MG/ML</u>	<u>N020182</u>	<u>001</u>	Dec 16, 1992
-----------	------------------------	-----------------	----------------	------------	--------------

LEVOCARNITINE

<u>AP</u>	AM REGENT	<u>200MG/ML</u>	<u>A075861</u>	<u>001</u>	Jun 22, 2001
<u>AP</u>	WEST-WARD PHARMS INT	<u>200MG/ML</u>	<u>A075567</u>	<u>001</u>	Mar 29, 2001

SOLUTION; ORAL

CARNITOR

<u>AA</u>	+! LEADIANT BIOSCI INC	<u>1GM/10ML</u>	<u>N019257</u>	<u>001</u>	Apr 10, 1986
-----------	------------------------	-----------------	----------------	------------	--------------

CARNITOR SF

<u>AA</u>	+ LEADIANT BIOSCI INC	<u>1GM/10ML</u>	<u>N019257</u>	<u>002</u>	Mar 28, 2007
-----------	-----------------------	-----------------	----------------	------------	--------------

LEVOCARNITINE

<u>AA</u>	AKORN	<u>1GM/10ML</u>	<u>A077399</u>	<u>001</u>	Oct 25, 2007
<u>AA</u>	LYNE	<u>1GM/10ML</u>	<u>A076851</u>	<u>001</u>	Aug 10, 2004
<u>AA</u>	NOVITIUM PHARMA	<u>1GM/10ML</u>	<u>A211676</u>	<u>001</u>	Aug 14, 2019

LEVOCARNITINE SF

<u>AA</u>	NOVITIUM PHARMA	<u>1GM/10ML</u>	<u>A211676</u>	<u>002</u>	Aug 14, 2019
-----------	-----------------	-----------------	----------------	------------	--------------

TABLET; ORAL

CARNITOR

<u>AB</u>	+! LEADIANT BIOSCI INC	<u>330MG</u>	<u>N018948</u>	<u>001</u>	Dec 27, 1985
-----------	------------------------	--------------	----------------	------------	--------------

LEVOCARNITINE

<u>AB</u>	RISING	<u>330MG</u>	<u>A076858</u>	<u>001</u>	Sep 20, 2004
-----------	--------	--------------	----------------	------------	--------------

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

<u>AA</u>	! L PERRIGO CO	<u>2.5MG/5ML</u>	<u>A091263</u>	<u>001</u>	Nov 07, 2011
<u>AA</u>	LANNETT CO INC	<u>2.5MG/5ML</u>	<u>A204599</u>	<u>001</u>	May 15, 2017
<u>AA</u>	TARO PHARM INDS LTD	<u>2.5MG/5ML</u>	<u>A202673</u>	<u>001</u>	Jul 26, 2013

LEVOCETIRIZINE HYDROCHLORIDE

<u>AA</u>	HETERO LABS LTD III	<u>2.5MG/5ML</u>	<u>A210914</u>	<u>001</u>	Apr 01, 2019
-----------	---------------------	------------------	----------------	------------	--------------

XYZAL

<u>AA</u>	+ SANOFI AVENTIS US	<u>2.5MG/5ML</u>	<u>N022157</u>	<u>001</u>	Jan 28, 2008
-----------	---------------------	------------------	----------------	------------	--------------

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A090392</u>	<u>001</u>	Feb 24, 2011
<u>AB</u>	GLENMARK GENERICS	<u>5MG</u>	<u>A090385</u>	<u>001</u>	Feb 24, 2011
<u>AB</u>	HETERO LABS LTD III	<u>5MG</u>	<u>A091264</u>	<u>001</u>	Jun 29, 2012
<u>AB</u>	MACLEODS PHARMS LTD	<u>5MG</u>	<u>A205564</u>	<u>001</u>	Jan 11, 2016
<u>AB</u>	MICRO LABS LTD INDIA	<u>5MG</u>	<u>A202046</u>	<u>001</u>	Sep 17, 2013
<u>AB</u>	NEOPHARMA	<u>5MG</u>	<u>A204323</u>	<u>001</u>	Dec 20, 2016
<u>AB</u>	SCIEGEN PHARMS INC	<u>5MG</u>	<u>A203646</u>	<u>001</u>	Sep 09, 2014
<u>AB</u>	SUN PHARM	<u>5MG</u>	<u>A090362</u>	<u>001</u>	Jan 31, 2013
<u>AB</u>	SUN PHARM INDS LTD	<u>5MG</u>	<u>A201653</u>	<u>001</u>	Jun 26, 2015
<u>AB</u>	SYNTHON PHARMS	<u>5MG</u>	<u>A090229</u>	<u>001</u>	Nov 26, 2010
<u>AB</u>	TEVA PHARMS	<u>5MG</u>	<u>A090199</u>	<u>001</u>	Aug 22, 2011

XYZAL

<u>AB</u>	+! SANOFI AVENTIS US	<u>5MG</u>	<u>N022064</u>	<u>001</u>	May 25, 2007
-----------	----------------------	------------	----------------	------------	--------------

LEVODOPA

POWDER; INHALATION

INBRIJA

+!	ACORDA	42MG	N209184	001	Dec 21, 2018
----	--------	------	---------	-----	--------------

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVOFLOXACIN

<u>AP</u>	AKORN	<u>EQ 500MG/20ML (EQ 25MG/ML)</u>	<u>A091644</u>	<u>001</u>	Jun 20, 2011
<u>AP</u>		<u>EQ 750MG/30ML (EQ 25MG/ML)</u>	<u>A091644</u>	<u>002</u>	Jun 20, 2011
<u>AP</u>	! AUROBINDO PHARMA LTD	<u>EQ 500MG/20ML (EQ 25MG/ML)</u>	<u>A202328</u>	<u>001</u>	Jan 24, 2013

PRESCRIPTION DRUG PRODUCT LIST

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVOFLOXACIN

<u>AP</u>	!		<u>EQ 750MG/30ML (EQ 25MG/ML)</u>	<u>A202328 002</u>	Jan 24, 2013
<u>AP</u>		BAXTER HLTHCARE CORP	<u>EQ 500MG/20ML (EQ 25MG/ML)</u>	<u>A091436 001</u>	Jun 05, 2013
<u>AP</u>		GLAND PHARMA LTD	<u>EQ 500MG/20ML (EQ 25MG/ML)</u>	<u>A205540 001</u>	Apr 22, 2020
<u>AP</u>			<u>EQ 750MG/30ML (EQ 25MG/ML)</u>	<u>A205540 002</u>	Apr 22, 2020
<u>LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER</u>					
<u>AP</u>		AUROBINDO PHARMA LTD	<u>EQ 250MG/50ML (EQ 5MG/ML)</u>	<u>A206919 001</u>	Feb 10, 2016
<u>AP</u>			<u>EQ 500MG/100ML (EQ 5MG/ML)</u>	<u>A206919 002</u>	Feb 10, 2016
<u>AP</u>			<u>EQ 750MG/150ML (EQ 5MG/ML)</u>	<u>A206919 003</u>	Feb 10, 2016
<u>AP</u>		BAXTER HLTHCARE CORP	<u>EQ 250MG/50ML (EQ 5MG/ML)</u>	<u>A091397 001</u>	Aug 08, 2013
<u>AP</u>			<u>EQ 500MG/100ML (EQ 5MG/ML)</u>	<u>A091397 002</u>	Aug 08, 2013
<u>AP</u>			<u>EQ 750MG/150ML (EQ 5MG/ML)</u>	<u>A091397 003</u>	Aug 08, 2013
<u>AP</u>		FRESENIUS KABI USA	<u>EQ 250MG/50ML (EQ 5MG/ML)</u>	<u>A200674 001</u>	Jun 19, 2013
<u>AP</u>			<u>EQ 500MG/100ML (EQ 5MG/ML)</u>	<u>A200674 002</u>	Jun 19, 2013
<u>AP</u>			<u>EQ 750MG/150ML (EQ 5MG/ML)</u>	<u>A200674 003</u>	Jun 19, 2013
<u>AP</u>		GLAND PHARMA LTD	<u>EQ 250MG/50ML (EQ 5MG/ML)</u>	<u>A206908 001</u>	Dec 30, 2020
<u>AP</u>			<u>EQ 500MG/100ML (EQ 5MG/ML)</u>	<u>A206908 002</u>	Dec 30, 2020
<u>AP</u>			<u>EQ 750MG/150ML (EQ 5MG/ML)</u>	<u>A206908 003</u>	Dec 30, 2020
<u>AP</u>		HIKMA FARMACEUTICA	<u>EQ 250MG/50ML (EQ 5MG/ML)</u>	<u>A091375 001</u>	Sep 16, 2011
<u>AP</u>			<u>EQ 500MG/100ML (EQ 5MG/ML)</u>	<u>A091375 002</u>	Sep 16, 2011
<u>AP</u>			<u>EQ 750MG/150ML (EQ 5MG/ML)</u>	<u>A091375 003</u>	Sep 16, 2011
<u>AP</u>		HOSPIRA INC	<u>EQ 250MG/50ML (EQ 5MG/ML)</u>	<u>A078579 001</u>	Sep 03, 2015
<u>AP</u>			<u>EQ 500MG/100ML (EQ 5MG/ML)</u>	<u>A078579 002</u>	Sep 03, 2015
<u>AP</u>			<u>EQ 750MG/150ML (EQ 5MG/ML)</u>	<u>A078579 003</u>	Sep 03, 2015
<u>AP</u>	!	INFORLIFE	<u>EQ 250MG/50ML (EQ 5MG/ML)</u>	<u>A090343 001</u>	Jul 07, 2011
<u>AP</u>	!		<u>EQ 500MG/100ML (EQ 5MG/ML)</u>	<u>A090343 002</u>	Jul 07, 2011
<u>AP</u>	!		<u>EQ 750MG/150ML (EQ 5MG/ML)</u>	<u>A090343 003</u>	Jul 07, 2011

SOLUTION; ORAL

LEVOFLOXACIN

<u>AA</u>	!	AKORN	<u>250MG/10ML</u>	<u>A091678 001</u>	Jun 20, 2011
<u>AA</u>		LANNETT CO INC	<u>250MG/10ML</u>	<u>A205222 001</u>	May 25, 2018

SOLUTION/DROPS; OPHTHALMIC

LEVOFLOXACIN

<u>AT</u>		AKORN	<u>0.5%</u>	<u>A090268 001</u>	Dec 20, 2010
<u>AT</u>	!	RISING	<u>0.5%</u>	<u>A077700 001</u>	Dec 20, 2010
		MICRO LABS LTD INDIA	<u>1.5%</u>	<u>A205600 001</u>	Feb 27, 2019

TABLET; ORAL

LEVOFLOXACIN

<u>AB</u>		APOTEX INC	<u>250MG</u>	<u>A090787 001</u>	Sep 29, 2011
<u>AB</u>			<u>500MG</u>	<u>A090787 002</u>	Sep 29, 2011
<u>AB</u>			<u>750MG</u>	<u>A090787 003</u>	Sep 29, 2011
<u>AB</u>		AUROBINDO PHARMA LTD	<u>250MG</u>	<u>A201043 001</u>	Jun 20, 2011
<u>AB</u>			<u>500MG</u>	<u>A201043 002</u>	Jun 20, 2011
<u>AB</u>	!		<u>750MG</u>	<u>A201043 003</u>	Jun 20, 2011
<u>AB</u>		CELLTRION	<u>250MG</u>	<u>A090367 001</u>	Jun 20, 2011
<u>AB</u>			<u>500MG</u>	<u>A090367 002</u>	Jun 20, 2011
<u>AB</u>			<u>750MG</u>	<u>A090367 003</u>	Jun 20, 2011
<u>AB</u>		CIPLA LTD	<u>250MG</u>	<u>A076890 001</u>	Mar 30, 2012
<u>AB</u>			<u>500MG</u>	<u>A076890 002</u>	Mar 30, 2012
<u>AB</u>			<u>750MG</u>	<u>A076890 003</u>	Mar 30, 2012
<u>AB</u>		DR REDDYS LABS INC	<u>250MG</u>	<u>A076710 001</u>	Jun 20, 2011
<u>AB</u>			<u>500MG</u>	<u>A076710 002</u>	Jun 20, 2011
<u>AB</u>			<u>750MG</u>	<u>A076710 003</u>	Jun 20, 2011
<u>AB</u>		GLENMARK GENERICS	<u>250MG</u>	<u>A200250 001</u>	Jun 20, 2011
<u>AB</u>			<u>500MG</u>	<u>A200250 002</u>	Jun 20, 2011
<u>AB</u>			<u>750MG</u>	<u>A200250 003</u>	Jun 20, 2011
<u>AB</u>		HEC PHARM	<u>250MG</u>	<u>A204968 001</u>	Feb 05, 2019
<u>AB</u>			<u>500MG</u>	<u>A204968 002</u>	Feb 05, 2019
<u>AB</u>			<u>750MG</u>	<u>A204968 003</u>	Feb 05, 2019
<u>AB</u>		HETERO LABS LTD V	<u>250MG</u>	<u>A202801 001</u>	Jan 08, 2015
<u>AB</u>			<u>500MG</u>	<u>A202801 002</u>	Jan 08, 2015
<u>AB</u>			<u>750MG</u>	<u>A202801 003</u>	Jan 08, 2015
<u>AB</u>		JUBILANT GENERICS	<u>250MG</u>	<u>A203613 001</u>	Jun 19, 2015
<u>AB</u>			<u>500MG</u>	<u>A203613 002</u>	Jun 19, 2015
<u>AB</u>		LUPIN	<u>250MG</u>	<u>A078424 001</u>	Jun 20, 2011
<u>AB</u>			<u>500MG</u>	<u>A078424 002</u>	Jun 20, 2011

PRESCRIPTION DRUG PRODUCT LIST

LEVOFLOXACIN

TABLET; ORAL

LEVOFLOXACIN

<u>AB</u>		<u>750MG</u>	<u>A078424 003</u>	Jun 20, 2011
<u>AB</u>	MACLEODS PHARMS LTD	<u>250MG</u>	<u>A200839 001</u>	Mar 22, 2012
<u>AB</u>		<u>500MG</u>	<u>A200839 002</u>	Mar 22, 2012
<u>AB</u>		<u>750MG</u>	<u>A200839 003</u>	Mar 22, 2012
<u>AB</u>	ORCHID HLTHCARE	<u>250MG</u>	<u>A202200 001</u>	Jan 30, 2012
<u>AB</u>		<u>500MG</u>	<u>A202200 002</u>	Jan 30, 2012
<u>AB</u>		<u>750MG</u>	<u>A202200 003</u>	Jan 30, 2012
<u>AB</u>	SANDOZ	<u>250MG</u>	<u>A077438 001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A077438 002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A077438 003</u>	Jun 20, 2011
<u>AB</u>	TEVA	<u>250MG</u>	<u>A076361 001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A076361 002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A076361 003</u>	Jun 20, 2011
<u>AB</u>	ZYDUS PHARMS USA INC	<u>250MG</u>	<u>A077652 001</u>	Sep 07, 2012
<u>AB</u>		<u>500MG</u>	<u>A077652 002</u>	Sep 07, 2012
<u>AB</u>		<u>750MG</u>	<u>A077652 003</u>	Sep 07, 2012

LEVOLEUCOVORIN

POWDER; INTRAVENOUS

KHAPZORY

+! ACROTECH

175MG/VIAL

N211226 001 Oct 19, 2018

+!

300MG/VIAL

N211226 002 Oct 19, 2018

LEVOLEUCOVORIN CALCIUM

POWDER; INTRAVENOUS

FUSILEVAP +! ACROTECHEQ 50MG BASE/VIALN020140 001 Mar 07, 2008LEVOLEUCOVORIN CALCIUMAP MEITHEALEQ 50MG BASE/VIALA211003 001 Aug 22, 2019AP WEST-WARD PHARMSEQ 50MG BASE/VIALA206263 001 Jun 16, 2016

INT

SOLUTION; INTRAVENOUS

LEVOLEUCOVORIN CALCIUMAP AMNEALEQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)A207548 001 Sep 08, 2017AP GLAND PHARMA LTDEQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)A210892 001 Sep 14, 2018APEQ 250MG BASE/25ML (EQ 10MG BASE/ML)A210892 002 Sep 14, 2018AP MEITHEALEQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)A211002 001 Aug 16, 2019APEQ 250MG BASE/25ML (EQ 10MG BASE/ML)A211002 002 Aug 16, 2019AP ! NOVAST LABSEQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)A210623 001 May 03, 2018AP !EQ 250MG BASE/25ML (EQ 10MG BASE/ML)A210623 002 May 03, 2018AP SANDOZ INCEQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)A203563 001 Mar 09, 2015LEVOMILNACIPRAN HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

FETZIMAAB + ALLERGANEQ 20MG BASEN204168 001 Jul 25, 2013AB +EQ 40MG BASEN204168 002 Jul 25, 2013AB +EQ 80MG BASEN204168 003 Jul 25, 2013AB +!EQ 120MG BASEN204168 004 Jul 25, 2013LEVOMILNACIPRAN HYDROCHLORIDEAB HIKMAEQ 20MG BASEA210732 001 Nov 05, 2020ABEQ 40MG BASEA210732 002 Nov 05, 2020ABEQ 80MG BASEA210732 003 Nov 05, 2020ABEQ 120MG BASEA210732 004 Nov 05, 2020LEVONORDEFIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

SCANDONEST L

! DEPROCO

0.05MG/ML; 2%

A088388 001 Oct 10, 1984

LEVONORGESTREL

INTRAUTERINE DEVICE; INTRAUTERINE

KYLEENA

+! BAYER HLTHCARE

19.5MG

N208224 001 Sep 16, 2016

LILETTA

MEDICINES360

52MG

N206229 001 Feb 26, 2015

MIRENA

+! BAYER HLTHCARE

52MG

N021225 001 Dec 06, 2000

SKYLA

+! BAYER HLTHCARE

13.5MG

N203159 001 Jan 09, 2013

PRESCRIPTION DRUG PRODUCT LIST

LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL

! L FERRIGO CO

0.75MG

A090740 001 Dec 30, 2010

LEVORPHANOL TARTRATE

TABLET; ORAL

LEVORPHANOL TARTRATEAB NOVITIUM PHARMA2MGA213479 001 Jul 01, 2020AB ! SENTYNL THERAPS INC2MGA074278 001 Mar 31, 2000AB SPECGX LLC2MGA212024 001 Dec 13, 2019AB VIRTUS PHARMS2MGA211484 001 Dec 13, 2018

! SENTYNL THERAPS INC

3MG

A074278 003 Jun 18, 2018

LEVOTHYROXINE SODIUM

CAPSULE; ORAL

LEVOTHYROXINE SODIUMAB TEVA PHARMS USA INC0.075MGA211369 001 Oct 28, 2020AB 0.088MGA213256 001 Jan 06, 2021AB 0.1MGA213256 002 Jan 06, 2021AB 0.125MGA213256 003 Jan 06, 2021AB 0.15MGA211369 002 Oct 28, 2020TIROSINTAB + INSTITUT0.075MGN021924 004 Oct 13, 2006

BIOCHIMIQUE

AB + 0.088MGN021924 010 Oct 02, 2009AB + 0.1MGN021924 005 Oct 13, 2006AB + 0.125MGN021924 006 Oct 13, 2006AB + 0.15MGN021924 007 Oct 13, 2006

+ 0.013MG

N021924 013 Aug 01, 2007

+ 0.025MG

N021924 002 Oct 13, 2006

+ 0.05MG

N021924 003 Oct 13, 2006

+ 0.112MG

N021924 008 Oct 02, 2009

+ 0.137MG

N021924 009 Oct 02, 2009

+ 0.175MG

N021924 011 Apr 25, 2017

+! 0.200MG

N021924 012 Apr 25, 2017

POWDER; INTRAVENOUS

LEVOTHYROXINE SODIUMAP DR REDDYS100MCG/VIALA208837 001 Mar 27, 2020AP +! FRESENIUS KABI USA100MCG/VIALN202231 001 Jun 24, 2011AP +! 200MCG/VIALN202231 002 Jun 24, 2011AP +! 500MCG/VIALN202231 003 Jun 24, 2011AP MAIA PHARMS INC100MCG/VIALA208749 001 Dec 21, 2018AP 200MCG/VIALA208749 002 Dec 21, 2018AP 500MCG/VIALA208749 003 Dec 21, 2018AP PIRAMAL CRITICAL100MCG/VIALA206163 001 Jun 29, 2016AP 500MCG/VIALA206163 002 Jun 29, 2016

SOLUTION; INTRAVENOUS

LEVOTHYROXINE SODIUM

+! FRESENIUS KABI USA 100MCG/5ML (20MCG/ML)

N210632 001 Apr 11, 2019

+! 200MCG/5ML (40MCG/ML)

N210632 002 Apr 11, 2019

+! 500MCG/5ML (100MCG/ML)

N210632 003 Apr 11, 2019

SOLUTION; ORAL

THYQUIDITY

+! EMP 100MCG/5ML

N214047 001 Nov 30, 2020

TIROSINT-SOL

+ INSTITUT

13MCG/ML

N206977 001 Dec 15, 2016

+ 25MCG/ML

N206977 002 Dec 15, 2016

+ 50MCG/ML

N206977 003 Dec 15, 2016

+ 75MCG/ML

N206977 004 Dec 15, 2016

+ 88MCG/ML

N206977 005 Dec 15, 2016

+ 100MCG/ML

N206977 006 Dec 15, 2016

+ 112MCG/ML

N206977 007 Dec 15, 2016

+ 125MCG/ML

N206977 008 Dec 15, 2016

+ 137MCG/ML

N206977 009 Dec 15, 2016

+ 150MCG/ML

N206977 010 Dec 15, 2016

+ 175MCG/ML

N206977 011 Dec 15, 2016

+! 200MCG/ML

N206977 012 Dec 15, 2016

PRESCRIPTION DRUG PRODUCT LIST

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

SYNTHROID

--> +	ABBVIE	--> <u>AB1,AB2</u>	<u>0.025MG</u>	N021402 001	Jul 24, 2002
--> +		--> <u>AB1,AB2</u>	<u>0.05MG</u>	N021402 002	Jul 24, 2002
--> +		--> <u>AB1,AB2</u>	<u>0.075MG</u>	N021402 003	Jul 24, 2002
--> +		--> <u>AB1,AB2</u>	<u>0.088MG</u>	N021402 004	Jul 24, 2002
--> +		--> <u>AB1,AB2</u>	<u>0.1MG</u>	N021402 005	Jul 24, 2002
--> +		--> <u>AB1,AB2</u>	<u>0.112MG</u>	N021402 006	Jul 24, 2002
--> +		--> <u>AB1,AB2</u>	<u>0.125MG</u>	N021402 007	Jul 24, 2002
--> +		--> <u>AB1,AB2</u>	<u>0.137MG</u>	N021402 008	Jul 24, 2002
--> +		--> <u>AB1,AB2</u>	<u>0.15MG</u>	N021402 009	Jul 24, 2002
--> +		--> <u>AB1,AB2</u>	<u>0.175MG</u>	N021402 010	Jul 24, 2002
--> +		--> <u>AB1,AB2</u>	<u>0.2MG</u>	N021402 012	Jul 24, 2002
--> +!		--> <u>AB1,AB2</u>	<u>0.3MG</u>	N021402 011	Jul 24, 2002

LEVO-T

-->	CEDIPROF INC	--> <u>AB1,AB2,AB3</u>	<u>0.025MG</u>	N021342 001	Mar 01, 2002
-->		--> <u>AB1,AB2,AB3</u>	<u>0.05MG</u>	N021342 002	Mar 01, 2002
-->		--> <u>AB1,AB2,AB3</u>	<u>0.075MG</u>	N021342 003	Mar 01, 2002
-->		--> <u>AB1,AB2,AB3</u>	<u>0.088MG</u>	N021342 004	Mar 01, 2002
-->		--> <u>AB1,AB2,AB3</u>	<u>0.1MG</u>	N021342 005	Mar 01, 2002
-->		--> <u>AB1,AB2,AB3</u>	<u>0.112MG</u>	N021342 006	Mar 01, 2002
-->		--> <u>AB1,AB2,AB3</u>	<u>0.125MG</u>	N021342 007	Mar 01, 2002
-->		--> <u>AB1,AB2,AB3</u>	<u>0.137MG</u>	N021342 012	Dec 08, 2003
-->		--> <u>AB1,AB2,AB3</u>	<u>0.15MG</u>	N021342 008	Mar 01, 2002
-->		--> <u>AB1,AB2,AB3</u>	<u>0.175MG</u>	N021342 009	Mar 01, 2002
-->		--> <u>AB1,AB2,AB3</u>	<u>0.2MG</u>	N021342 010	Mar 01, 2002
-->		--> <u>AB1,AB2,AB3</u>	<u>0.3MG</u>	N021342 011	Mar 01, 2002

LEVOTHYROXINE SODIUM

-->	LUPIN	--> <u>AB1,AB2,AB3</u>	<u>0.025MG</u>	A209713 001	Jan 18, 2019
-->		--> <u>AB1,AB2,AB3</u>	<u>0.05MG</u>	A209713 002	Jan 18, 2019
-->		--> <u>AB1,AB2,AB3</u>	<u>0.075MG</u>	A209713 003	Jan 18, 2019
-->		--> <u>AB1,AB2,AB3</u>	<u>0.088MG</u>	A209713 004	Jan 18, 2019
-->		--> <u>AB1,AB2,AB3</u>	<u>0.1MG</u>	A209713 005	Jan 18, 2019
-->		--> <u>AB1,AB2,AB3</u>	<u>0.112MG</u>	A209713 006	Jan 18, 2019
-->		--> <u>AB1,AB2,AB3</u>	<u>0.125MG</u>	A209713 007	Jan 18, 2019
-->		--> <u>AB1,AB2,AB3</u>	<u>0.137MG</u>	A209713 008	Jan 18, 2019
-->		--> <u>AB1,AB2,AB3</u>	<u>0.15MG</u>	A209713 009	Jan 18, 2019
-->		--> <u>AB1,AB2,AB3</u>	<u>0.175MG</u>	A209713 010	Jan 18, 2019
-->		--> <u>AB1,AB2,AB3</u>	<u>0.2MG</u>	A209713 011	Jan 18, 2019
-->		--> <u>AB1,AB2,AB3</u>	<u>0.3MG</u>	A209713 012	Jan 18, 2019

UNITHROID

--> +	STEVENS J	--> <u>AB1,AB2,AB3</u>	<u>0.025MG</u>	N021210 001	Aug 21, 2000
--> +		--> <u>AB1,AB2,AB3</u>	<u>0.05MG</u>	N021210 002	Aug 21, 2000
--> +		--> <u>AB1,AB2,AB3</u>	<u>0.075MG</u>	N021210 003	Aug 21, 2000
--> +		--> <u>AB1,AB2,AB3</u>	<u>0.088MG</u>	N021210 004	Aug 21, 2000
--> +		--> <u>AB1,AB2,AB3</u>	<u>0.1MG</u>	N021210 005	Aug 21, 2000
--> +		--> <u>AB1,AB2,</u>	<u>0.112MG</u>	N021210 006	Aug 21, 2000

PRESCRIPTION DRUG PRODUCT LIST

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

UNITHROID

		<u>AB3</u>	<u>0.112MG</u>				
-->	+	--> <u>AB1,AB2,AB3</u>	<u>0.125MG</u>		N021210	007	Aug 21, 2000
-->	+	--> <u>AB1,AB2,AB3</u>	<u>0.137MG</u>		N021210	012	Feb 08, 2008
-->	+	--> <u>AB1,AB2,AB3</u>	<u>0.15MG</u>		N021210	008	Aug 21, 2000
-->	+	--> <u>AB1,AB2,AB3</u>	<u>0.175MG</u>		N021210	009	Aug 21, 2000
-->	+	--> <u>AB1,AB2,AB3</u>	<u>0.2MG</u>		N021210	010	Aug 21, 2000
-->	+!	--> <u>AB1,AB2,AB3</u>	<u>0.3MG</u>		N021210	011	Aug 21, 2000

LEVOTHYROXINE SODIUM

-->	MYLAN	-->	<u>0.025MG</u>		A076187	001	Jun 05, 2002
-->		--> <u>AB1,AB2,AB3,AB4</u>	<u>0.05MG</u>		A076187	002	Jun 05, 2002
-->		--> <u>AB1,AB2,AB3,AB4</u>	<u>0.075MG</u>		A076187	003	Jun 05, 2002
-->		--> <u>AB1,AB2,AB3,AB4</u>	<u>0.088MG</u>		A076187	004	Jun 05, 2002
-->		--> <u>AB1,AB2,AB3,AB4</u>	<u>0.1MG</u>		A076187	005	Jun 05, 2002
-->		--> <u>AB1,AB2,AB3,AB4</u>	<u>0.112MG</u>		A076187	006	Jun 05, 2002
-->		--> <u>AB1,AB2,AB3,AB4</u>	<u>0.125MG</u>		A076187	007	Jun 05, 2002
-->		--> <u>AB1,AB2,AB3,AB4</u>	<u>0.137MG</u>		A076187	012	Dec 13, 2006
-->		--> <u>AB1,AB2,AB3,AB4</u>	<u>0.15MG</u>		A076187	008	Jun 05, 2002
-->		--> <u>AB1,AB2,AB3,AB4</u>	<u>0.175MG</u>		A076187	009	Jun 05, 2002
-->		--> <u>AB1,AB2,AB3,AB4</u>	<u>0.2MG</u>		A076187	010	Jun 05, 2002
-->	!	--> <u>AB1,AB2,AB3,AB4</u>	<u>0.3MG</u>		A076187	011	Jun 05, 2002

LEVOXYL

-->	+	KING PHARMS	--> <u>AB1,AB3</u>	<u>0.025MG</u>	N021301	001	May 25, 2001
-->	+		--> <u>AB1,AB3</u>	<u>0.05MG</u>	N021301	002	May 25, 2001
-->	+		--> <u>AB1,AB3</u>	<u>0.075MG</u>	N021301	003	May 25, 2001
-->	+		--> <u>AB1,AB3</u>	<u>0.088MG</u>	N021301	004	May 25, 2001
-->	+		--> <u>AB1,AB3</u>	<u>0.1MG</u>	N021301	005	May 25, 2001
-->	+		--> <u>AB1,AB3</u>	<u>0.112MG</u>	N021301	006	May 25, 2001
-->	+		--> <u>AB1,AB3</u>	<u>0.125MG</u>	N021301	007	May 25, 2001
-->	+		--> <u>AB1,AB3</u>	<u>0.137MG</u>	N021301	008	May 25, 2001
-->	+		--> <u>AB1,AB3</u>	<u>0.15MG</u>	N021301	009	May 25, 2001
-->	+		--> <u>AB1,AB3</u>	<u>0.175MG</u>	N021301	010	May 25, 2001
-->	+!		--> <u>AB1,AB3</u>	<u>0.2MG</u>	N021301	011	May 25, 2001

EUTHYROX

<u>AB2</u>	PROVELL	<u>0.025MG</u>	<u>N021292</u>	<u>001</u>	May 31, 2002
<u>AB2</u>		<u>0.05MG</u>	<u>N021292</u>	<u>002</u>	May 31, 2002
<u>AB2</u>		<u>0.075MG</u>	<u>N021292</u>	<u>003</u>	May 31, 2002
<u>AB2</u>		<u>0.088MG</u>	<u>N021292</u>	<u>004</u>	May 31, 2002
<u>AB2</u>		<u>0.1MG</u>	<u>N021292</u>	<u>005</u>	May 31, 2002
<u>AB2</u>		<u>0.112MG</u>	<u>N021292</u>	<u>006</u>	May 31, 2002
<u>AB2</u>		<u>0.125MG</u>	<u>N021292</u>	<u>007</u>	May 31, 2002
<u>AB2</u>		<u>0.137MG</u>	<u>N021292</u>	<u>008</u>	May 31, 2002
<u>AB2</u>		<u>0.15MG</u>	<u>N021292</u>	<u>009</u>	May 31, 2002
<u>AB2</u>		<u>0.175MG</u>	<u>N021292</u>	<u>010</u>	May 31, 2002
<u>AB2</u>		<u>0.2MG</u>	<u>N021292</u>	<u>011</u>	May 31, 2002

LEVOTHYROXINE SODIUM

<u>AB2</u>	ACCORD HLTHCARE	<u>0.025MG</u>	<u>A212399</u>	<u>001</u>	Oct 19, 2020
<u>AB2</u>		<u>0.05MG</u>	<u>A212399</u>	<u>002</u>	Oct 19, 2020
<u>AB2</u>		<u>0.075MG</u>	<u>A212399</u>	<u>003</u>	Oct 19, 2020
<u>AB2</u>		<u>0.088MG</u>	<u>A212399</u>	<u>004</u>	Oct 19, 2020
<u>AB2</u>		<u>0.1MG</u>	<u>A212399</u>	<u>005</u>	Oct 19, 2020
<u>AB2</u>		<u>0.112MG</u>	<u>A212399</u>	<u>006</u>	Oct 19, 2020
<u>AB2</u>		<u>0.125MG</u>	<u>A212399</u>	<u>007</u>	Oct 19, 2020
<u>AB2</u>		<u>0.137MG</u>	<u>A212399</u>	<u>008</u>	Oct 19, 2020
<u>AB2</u>		<u>0.15MG</u>	<u>A212399</u>	<u>009</u>	Oct 19, 2020

PRESCRIPTION DRUG PRODUCT LIST

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

LEVOTHYROXINE SODIUM

<u>AB2</u>		<u>0.175MG</u>	<u>A212399</u>	<u>010</u>	Oct 19, 2020
<u>AB2</u>		<u>0.2MG</u>	<u>A212399</u>	<u>011</u>	Oct 19, 2020
<u>AB2</u>		<u>0.3MG</u>	<u>A212399</u>	<u>012</u>	Oct 19, 2020
<u>THYRO-TABS</u>					
-->	+	ALVOGEN	--> <u>AB2, AB4</u>	<u>0.025MG</u>	N021116 001 Oct 24, 2002
-->	+		--> <u>AB2, AB4</u>	<u>0.05MG</u>	N021116 002 Oct 24, 2002
-->	+		--> <u>AB2, AB4</u>	<u>0.075MG</u>	N021116 003 Oct 24, 2002
-->	+		--> <u>AB2, AB4</u>	<u>0.088MG</u>	N021116 010 Oct 24, 2002
-->	+		--> <u>AB2, AB4</u>	<u>0.1MG</u>	N021116 004 Oct 24, 2002
-->	+		--> <u>AB2, AB4</u>	<u>0.112MG</u>	N021116 011 Oct 24, 2002
-->	+		--> <u>AB2, AB4</u>	<u>0.125MG</u>	N021116 005 Oct 24, 2002
-->	+		--> <u>AB2, AB4</u>	<u>0.137MG</u>	N021116 012 Dec 07, 2004
-->	+		--> <u>AB2, AB4</u>	<u>0.15MG</u>	N021116 006 Oct 24, 2002
-->	+		--> <u>AB2, AB4</u>	<u>0.175MG</u>	N021116 007 Oct 24, 2002
-->	+		--> <u>AB2, AB4</u>	<u>0.2MG</u>	N021116 008 Oct 24, 2002
-->	+		--> <u>AB2, AB4</u>	<u>0.3MG</u>	N021116 009 Oct 24, 2002

LIDOCAINE

OINTMENT;TOPICAL

LIDOCAINE

<u>AT</u>		ALEOR	<u>5%</u>	<u>A211469</u>	<u>001</u>	Nov 23, 2018
		DERMACEUTICALS				
<u>AT</u>		ALKEM LABS LTD	<u>5%</u>	<u>A207810</u>	<u>001</u>	Mar 10, 2017
<u>AT</u>		AMNEAL PHARMS	<u>5%</u>	<u>A206297</u>	<u>001</u>	Aug 07, 2015
<u>AT</u>		COSETTE	<u>5%</u>	<u>A211019</u>	<u>001</u>	Dec 12, 2018
<u>AT</u>		DR REDDYS	<u>5%</u>	<u>A208660</u>	<u>001</u>	Jan 05, 2021
<u>AT</u>	!	FOUGERA PHARMS INC	<u>5%</u>	<u>A080198</u>	<u>001</u>	
<u>AT</u>		GLENMARK PHARMS LTD	<u>5%</u>	<u>A206498</u>	<u>001</u>	Sep 09, 2016
<u>AT</u>		MACLEODS PHARMS LTD	<u>5%</u>	<u>A211697</u>	<u>001</u>	Mar 16, 2020
<u>AT</u>		SEPTODONT INC	<u>5%</u>	<u>A040911</u>	<u>001</u>	May 23, 2011
<u>AT</u>		STRIDES PHARMA	<u>5%</u>	<u>A210958</u>	<u>001</u>	Dec 11, 2018
<u>AT</u>		TARO	<u>5%</u>	<u>A086724</u>	<u>001</u>	
<u>AT</u>		TELLIGENT	<u>5%</u>	<u>A205318</u>	<u>001</u>	Feb 01, 2016
<u>AT</u>		VITRUVIAS THERAP	<u>5%</u>	<u>A208822</u>	<u>001</u>	Sep 25, 2017

PATCH;TOPICAL

LIDOCAINE

<u>AB</u>		ACTAVIS LABS UT INC	<u>5%</u>	<u>A200675</u>	<u>001</u>	Aug 23, 2012
<u>AB</u>		AMNEAL	<u>5%</u>	<u>A206463</u>	<u>001</u>	Aug 24, 2020
<u>AB</u>		MYLAN TECHNOLOGIES	<u>5%</u>	<u>A202346</u>	<u>001</u>	Aug 07, 2015
<u>AB</u>		NOVEN PHARMS INC	<u>5%</u>	<u>A203265</u>	<u>001</u>	Dec 01, 2020
<u>AB</u>		RHODES PHARMS	<u>5%</u>	<u>A209190</u>	<u>001</u>	Apr 30, 2020

LIDODERM

<u>AB</u>	+	TEIKOKU PHARMA USA	<u>5%</u>	<u>N020612</u>	<u>001</u>	Mar 19, 1999
		ZTLIDO				
	+	SCILEX PHARMS INC	1.8%	N207962	001	Feb 28, 2018

LIDOCAINE HYDROCHLORIDE

GEL;OPHTHALMIC

AKTEN

+	!	AKORN	3.5%	N022221	001	Oct 07, 2008
---	---	-------	------	---------	-----	--------------

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE

<u>AP</u>		AUROBINDO PHARMA LTD	<u>1%</u>	<u>A207182</u>	<u>001</u>	Oct 30, 2017
<u>AP</u>			<u>2%</u>	<u>A207182</u>	<u>002</u>	Oct 30, 2017
<u>AP</u>		B BRAUN MEDICAL INC	<u>1%</u>	<u>A208474</u>	<u>001</u>	Aug 03, 2018
<u>AP</u>		FRESENIUS KABI USA	<u>1%</u>	<u>A080404</u>	<u>002</u>	
<u>AP</u>			<u>2%</u>	<u>A080404</u>	<u>003</u>	
<u>AP</u>		HOSPIRA	<u>0.5%</u>	<u>A088328</u>	<u>001</u>	May 17, 1984
<u>AP</u>	!		<u>1%</u>	<u>A083158</u>	<u>001</u>	
<u>AP</u>			<u>1%</u>	<u>A088329</u>	<u>001</u>	May 17, 1984
<u>AP</u>			<u>2%</u>	<u>A040078</u>	<u>001</u>	Jun 23, 1995
<u>AP</u>	!		<u>2%</u>	<u>A083158</u>	<u>002</u>	
<u>AP</u>			<u>2%</u>	<u>A088294</u>	<u>001</u>	May 17, 1984
<u>AP</u>		HUONS	<u>1%</u>	<u>A212821</u>	<u>001</u>	May 07, 2020
<u>AP</u>		INTL MEDICATION	<u>1%</u>	<u>A083173</u>	<u>001</u>	
<u>AP</u>			<u>2%</u>	<u>A083173</u>	<u>002</u>	
<u>AP</u>		SPECTRA MDCL DEVICES	<u>1%</u>	<u>A208017</u>	<u>001</u>	Apr 18, 2018
<u>AP</u>		WEST-WARD PHARMS	<u>1%</u>	<u>A080407</u>	<u>001</u>	

PRESCRIPTION DRUG PRODUCT LIST

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE

INT

<u>AP</u>		<u>2%</u>	<u>A080407 002</u>	
	<u>LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER</u>			
<u>AP</u>	B BRAUN	<u>200MG/100ML</u>	<u>N019830 002</u>	Apr 08, 1992
<u>AP</u>	BAXTER HLTHCARE	<u>200MG/100ML</u>	<u>N018461 002</u>	
	<u>LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER</u>			
<u>AP</u>	B BRAUN	<u>400MG/100ML</u>	<u>N019830 003</u>	Apr 08, 1992
<u>AP</u>	BAXTER HLTHCARE	<u>400MG/100ML</u>	<u>N018461 003</u>	
	<u>LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER</u>			
<u>AP</u>	B BRAUN	<u>800MG/100ML</u>	<u>N019830 004</u>	Apr 08, 1992
<u>AP</u>	BAXTER HLTHCARE	<u>800MG/100ML</u>	<u>N018461 004</u>	Feb 22, 1982
	<u>LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER</u>			
<u>AP</u>	FRESENIUS KABI USA	<u>1%</u>	<u>A088586 001</u>	Jul 24, 1985
<u>AP</u>	HOSPIRA	<u>0.5%</u>	<u>A088325 001</u>	Jul 31, 1984
<u>AP</u>		<u>1%</u>	<u>A088299 001</u>	Jul 31, 1984
<u>AP</u>		<u>2%</u>	<u>A088327 001</u>	Jul 31, 1984
	<u>LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE</u>			
<u>AP</u>	AUROBINDO PHARMA LTD	<u>1%</u>	<u>A203040 001</u>	Mar 14, 2013
<u>AP</u>		<u>1%</u>	<u>A203082 001</u>	Mar 14, 2013
<u>AP</u>		<u>2%</u>	<u>A203040 002</u>	Mar 14, 2013
<u>AP</u>		<u>2%</u>	<u>A203082 002</u>	Mar 14, 2013
<u>AP</u>	FRESENIUS KABI USA	<u>2%</u>	<u>N017584 001</u>	
<u>AP</u>		<u>4%</u>	<u>N017584 002</u>	
<u>AP</u>	HOSPIRA	<u>1%</u>	<u>A080408 001</u>	
<u>AP</u>		<u>1.5%</u>	<u>A080408 002</u>	
<u>AP</u>	WEST-WARD PHARMS	<u>1%</u>	<u>A084625 001</u>	
	<u>INT</u>			
<u>AP</u>		<u>2%</u>	<u>A084625 002</u>	
	<u>LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER</u>			
<u>AP</u>	HOSPIRA	<u>1%</u>	<u>A040302 001</u>	Sep 28, 1998
<u>AP</u>		<u>2%</u>	<u>A040302 002</u>	Sep 28, 1998
	<u>XYLOCAINE</u>			
<u>AP</u>	+! FRESENIUS KABI USA	<u>0.5%</u>	<u>N006488 008</u>	
<u>AP</u>	+!	<u>1%</u>	<u>N006488 007</u>	
<u>AP</u>	+!	<u>1.5%</u>	<u>N006488 010</u>	
<u>AP</u>	+!	<u>2%</u>	<u>N006488 002</u>	
	<u>LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE</u>			
	! HOSPIRA	<u>4%</u>	<u>A088295 001</u>	May 17, 1984
	<u>INJECTABLE; SPINAL</u>			
	LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%			
	! HOSPIRA	<u>5%</u>	<u>A083914 001</u>	
	<u>JELLY; TOPICAL</u>			
	<u>GLYDO</u>			
<u>AT</u>	SAGENT PHARMS INC	<u>2%</u>	<u>A201094 001</u>	Apr 28, 2014
	<u>LIDOCAINE HYDROCHLORIDE</u>			
<u>AT</u>	AKORN	<u>2%</u>	<u>A040433 001</u>	Feb 12, 2003
<u>AT</u>	INTL MEDICATION	<u>2%</u>	<u>A086283 001</u>	
	<u>XYLOCAINE</u>			
<u>AT</u>	+! AKORN	<u>2%</u>	<u>N008816 001</u>	
	<u>SOLUTION; ORAL</u>			
	<u>LIDOCAINE HYDROCHLORIDE</u>			
<u>AT</u>	! AKORN	<u>2%</u>	<u>A040014 001</u>	Jul 10, 1995
<u>AT</u>	WOCKHARDT BIO AG	<u>2%</u>	<u>A087872 001</u>	Nov 18, 1982
	<u>LIDOCAINE VISCOUS</u>			
<u>AT</u>	HIKMA	<u>2%</u>	<u>A088802 001</u>	Apr 26, 1985
	<u>SOLUTION; TOPICAL</u>			
	<u>LARYNG-O-JET KIT</u>			
<u>AT</u>	INTL MEDICATION	<u>4%</u>	<u>A086364 001</u>	
	<u>LIDOCAINE HYDROCHLORIDE</u>			
<u>AT</u>	! HIKMA	<u>4%</u>	<u>A088803 001</u>	Apr 03, 1985
<u>AT</u>	LANNETT CO INC	<u>4%</u>	<u>A040710 001</u>	Feb 27, 2007
<u>AT</u>	TELIGENT	<u>4%</u>	<u>A204494 001</u>	Mar 12, 2014
<u>AT</u>	WOCKHARDT BIO AG	<u>4%</u>	<u>A087881 001</u>	Nov 18, 1982
	<u>SYSTEM; INTRADERMAL</u>			
	<u>ZINGO</u>			
	POWDER PHARMS	<u>0.5MG</u>	<u>N022114 001</u>	Aug 16, 2007

PRESCRIPTION DRUG PRODUCT LIST

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

EMLA

AB	+!	TEVA BRANDED PHARM	2.5%;2.5%	N019941 001	Dec 30, 1992
-----------	-----------	--------------------	------------------	--------------------	--------------

LIDOCAINE AND PRILOCAINE

AB		AKORN	2.5%;2.5%	A076290 001	Sep 25, 2003
-----------	--	-------	------------------	--------------------	--------------

AB		FOUGERA PHARMS	2.5%;2.5%	A076453 001	Aug 18, 2003
-----------	--	----------------	------------------	--------------------	--------------

AB		TELOGENT	2.5%;2.5%	A205887 001	Jun 29, 2018
-----------	--	----------	------------------	--------------------	--------------

AB		TOLMAR	2.5%;2.5%	A076320 001	Aug 27, 2003
-----------	--	--------	------------------	--------------------	--------------

GEL; PERIODONTAL

ORAQIX

+!	DENTSPLY PHARM	2.5%;2.5%	N021451 001	Dec 19, 2003
-----------	----------------	-----------	-------------	--------------

LIDOCAINE; TETRACAINE

CREAM; TOPICAL

PLIAGLIS

+!	TARO PHARMS	7%;7%	N021717 001	Jun 29, 2006
-----------	-------------	-------	-------------	--------------

PATCH; TOPICAL

SYNERA

+!	GALEN SPECIALTY	70MG;70MG	N021623 001	Jun 23, 2005
-----------	-----------------	-----------	-------------	--------------

LIFITEGRAST

SOLUTION/DROPS; OPHTHALMIC

XIIDRA

+!	NOVARTIS	5%	N208073 001	Jul 11, 2016
-----------	----------	----	-------------	--------------

LINACLOTIDE

CAPSULE; ORAL

LINZESS

+!	ALLERGAN	72MCG	N202811 003	Jan 25, 2017
-----------	----------	-------	-------------	--------------

+!		145MCG	N202811 001	Aug 30, 2012
-----------	--	--------	-------------	--------------

+		290MCG	N202811 002	Aug 30, 2012
----------	--	--------	-------------	--------------

LINAGLIPTIN

TABLET; ORAL

TRADJENTA

+!	BOEHRINGER INGELHEIM	5MG	N201280 001	May 02, 2011
-----------	-------------------------	-----	-------------	--------------

LINAGLIPTIN; METFORMIN HYDROCHLORIDE

TABLET; ORAL

JENTADUETO

+	BOEHRINGER INGELHEIM	2.5MG;500MG	N201281 001	Jan 30, 2012
----------	-------------------------	-------------	-------------	--------------

+		2.5MG;850MG	N201281 002	Jan 30, 2012
----------	--	-------------	-------------	--------------

+!		2.5MG;1GM	N201281 003	Jan 30, 2012
-----------	--	-----------	-------------	--------------

TABLET, EXTENDED RELEASE; ORAL

JENTADUETO XR

+	BOEHRINGER INGELHEIM	2.5MG;1GM	N208026 001	May 27, 2016
----------	-------------------------	-----------	-------------	--------------

+!		5MG;1GM	N208026 002	May 27, 2016
-----------	--	---------	-------------	--------------

LINCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

LINCOCIN

AP	+!	PHARMACIA AND UPJOHN	EQ 300MG BASE/ML	N050317 001	
-----------	-----------	-------------------------	-------------------------	--------------------	--

LINCOMYCIN

AP		XGEN PHARMS	EQ 300MG BASE/ML	A201746 001	Jun 04, 2015
-----------	--	-------------	-------------------------	--------------------	--------------

LINDANE

SHAMPOO; TOPICAL

LINDANE

!	WOCKHARDT BIO AG	1%	A088191 001	Sep 18, 1984
----------	------------------	----	-------------	--------------

LINEZOLID

FOR SUSPENSION; ORAL

LINEZOLID

AB		HIKMA	100MG/5ML	A200068 001	Jun 03, 2015
-----------	--	-------	------------------	--------------------	--------------

ZYVOX

AB	+!	PFIZER	100MG/5ML	N021132 001	Apr 18, 2000
-----------	-----------	--------	------------------	--------------------	--------------

SOLUTION; INTRAVENOUS

LINEZOLID

AP		AUROBINDO PHARMA LTD	600MG/300ML (2MG/ML)	A206917 001	Aug 04, 2016
-----------	--	-------------------------	-----------------------------	--------------------	--------------

AP		FRESENIUS KABI USA	600MG/300ML (2MG/ML)	A204764 001	Mar 15, 2016
-----------	--	--------------------	-----------------------------	--------------------	--------------

AP		HOSPIRA INC	600MG/300ML (2MG/ML)	A205442 001	Jul 07, 2015
-----------	--	-------------	-----------------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

LINEZOLID

SOLUTION; INTRAVENOUS

LINEZOLID

<u>AP</u>	HQ SPCLT PHARMA	<u>200MG/100ML (2MG/ML)</u>	<u>A207001 001</u>	Jul 07, 2017
<u>AP</u>		<u>600MG/300ML (2MG/ML)</u>	<u>A207001 002</u>	Jul 07, 2017
<u>AP</u>	MYLAN LABS LTD	<u>200MG/100ML (2MG/ML)</u>	<u>A205154 001</u>	Dec 06, 2017
<u>AP</u>		<u>600MG/300ML (2MG/ML)</u>	<u>A205154 002</u>	Dec 06, 2017
<u>AP</u>	NANG KUANG PHARM CO	<u>200MG/100ML (2MG/ML)</u>	<u>A207354 001</u>	Dec 20, 2016
<u>AP</u>		<u>600MG/300ML (2MG/ML)</u>	<u>A207354 002</u>	Dec 20, 2016
<u>AP</u>	SAGENT PHARMS INC	<u>200MG/100ML (2MG/ML)</u>	<u>A204696 001</u>	Mar 02, 2017
<u>AP</u>		<u>600MG/300ML (2MG/ML)</u>	<u>A204696 002</u>	Mar 02, 2017
<u>AP</u>	SANDOZ INC	<u>200MG/100ML (2MG/ML)</u>	<u>A200904 001</u>	Jul 16, 2015
<u>AP</u>		<u>600MG/300ML (2MG/ML)</u>	<u>A200904 002</u>	Jul 16, 2015
<u>AP</u>	TEVA PHARMS	<u>600MG/300ML (2MG/ML)</u>	<u>A200222 001</u>	Jun 27, 2012

ZYVOX

<u>AP</u>	+	PFIZER	<u>200MG/100ML (2MG/ML)</u>	<u>N021131 001</u>	Apr 18, 2000	
<u>AP</u>	+	!	<u>600MG/300ML (2MG/ML)</u>	<u>N021131 003</u>	Apr 18, 2000	
		LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	+	!	HOSPIRA INC	<u>600MG/300ML (2MG/ML)</u>	<u>N206473 001</u>	Jun 18, 2015

TABLET; ORAL

LINEZOLID

<u>AB</u>	ALEMBIC PHARMS LTD	<u>600MG</u>	<u>A205233 001</u>	Dec 21, 2015
<u>AB</u>	ALKEM LABS LTD	<u>600MG</u>	<u>A205517 001</u>	Dec 21, 2015
<u>AB</u>	AMNEAL PHARMS	<u>600MG</u>	<u>A204536 001</u>	Dec 21, 2015
<u>AB</u>	CELLTRION	<u>600MG</u>	<u>A210702 001</u>	Apr 25, 2019
<u>AB</u>	GLENMARK PHARMS	<u>600MG</u>	<u>A078987 001</u>	Dec 21, 2015
<u>AB</u>	HETERO LABS LTD V	<u>600MG</u>	<u>A204239 001</u>	Dec 21, 2015
<u>AB</u>	NOVEL LABS INC	<u>600MG</u>	<u>A207526 001</u>	Aug 22, 2016
<u>AB</u>	ZYDUS PHARMS	<u>600MG</u>	<u>A206097 001</u>	Feb 22, 2017

ZYVOX

<u>AB</u>	+	!	PFIZER	<u>600MG</u>	<u>N021130 002</u>	Apr 18, 2000
-----------	---	---	--------	--------------	--------------------	--------------

LIOTHYRONINE SODIUM

INJECTABLE; INJECTION

LIOTHYRONINE SODIUM

<u>AP</u>	XGEN PHARMS	<u>EQ 0.01MG BASE/ML</u>	<u>A076923 001</u>	Aug 17, 2005		
<u>AP</u>	+	!	PAR STERILE PRODUCTS	<u>EQ 0.01MG BASE/ML</u>	<u>N020105 001</u>	Dec 31, 1991

TABLET; ORAL

CYTOMEL

<u>AB</u>	+	KING PHARMS	<u>EQ 0.005MG BASE</u>	<u>N010379 001</u>
<u>AB</u>	+		<u>EQ 0.025MG BASE</u>	<u>N010379 002</u>
<u>AB</u>	+		<u>EQ 0.05MG BASE</u>	<u>N010379 003</u>

LIOTHYRONINE SODIUM

<u>AB</u>	MAYNE PHARMA INC	<u>EQ 0.005MG BASE</u>	<u>A090097 001</u>	Mar 20, 2009
<u>AB</u>		<u>EQ 0.025MG BASE</u>	<u>A090097 002</u>	Mar 20, 2009
<u>AB</u>		<u>EQ 0.05MG BASE</u>	<u>A090097 003</u>	Mar 20, 2009
<u>AB</u>	SIGMAPHARM LABS LLC	<u>EQ 0.005MG BASE</u>	<u>A200295 001</u>	Nov 29, 2012
<u>AB</u>		<u>EQ 0.025MG BASE</u>	<u>A200295 002</u>	Nov 29, 2012
<u>AB</u>	!		<u>A200295 003</u>	Nov 29, 2012
<u>AB</u>	SUN PHARM	<u>EQ 0.005MG BASE</u>	<u>A091382 001</u>	Apr 20, 2016
<u>AB</u>		<u>EQ 0.025MG BASE</u>	<u>A091382 002</u>	Apr 20, 2016
<u>AB</u>		<u>EQ 0.05MG BASE</u>	<u>A091382 003</u>	Apr 20, 2016
<u>AB</u>	TEVA PHARMS USA	<u>EQ 0.005MG BASE</u>	<u>A211510 001</u>	Oct 26, 2018
<u>AB</u>		<u>EQ 0.025MG BASE</u>	<u>A211510 002</u>	Oct 26, 2018
<u>AB</u>		<u>EQ 0.05MG BASE</u>	<u>A211510 003</u>	Oct 26, 2018

LIRAGLUTIDE RECOMBINANT

SOLUTION; SUBCUTANEOUS

SAXENDA

+	!	NOVO	<u>18MG/3ML (6MG/ML)</u>	<u>N206321 001</u>	Dec 23, 2014
		VICTOZA			
+	!	NOVO NORDISK INC	<u>18MG/3ML (6MG/ML)</u>	<u>N022341 001</u>	Jan 25, 2010

LISDEXAMFETAMINE DIMESYLATE

CAPSULE; ORAL

VYVANSE

+	TAKEDA PHARMS USA	<u>10MG</u>	<u>N021977 007</u>	Oct 30, 2014
+		<u>20MG</u>	<u>N021977 004</u>	Dec 10, 2007
+		<u>30MG</u>	<u>N021977 001</u>	Feb 23, 2007
+		<u>40MG</u>	<u>N021977 005</u>	Dec 10, 2007
+		<u>50MG</u>	<u>N021977 002</u>	Feb 23, 2007
+		<u>60MG</u>	<u>N021977 006</u>	Dec 10, 2007

PRESCRIPTION DRUG PRODUCT LIST

LISDEXAMFETAMINE DIMESYLATE

CAPSULE; ORAL

VYVANSE

+!

70MG

N021977 003 Feb 23, 2007

TABLET, CHEWABLE; ORAL

VYVANSE

+

TAKEDA PHARMS USA

10MG

N208510 001 Jan 28, 2017

+

20MG

N208510 002 Jan 28, 2017

+

30MG

N208510 003 Jan 28, 2017

+

40MG

N208510 004 Jan 28, 2017

+

50MG

N208510 005 Jan 28, 2017

+!

60MG

N208510 006 Jan 28, 2017

LISINAPRIL

SOLUTION; ORAL

QBRELIS

+!

AZURITY

1MG/ML

N208401 001 Jul 29, 2016

TABLET; ORAL

LISINAPRIL

<u>AB</u>	ACCORD HLTHCARE	<u>2.5MG</u>	<u>A202554 001</u>	Jul 30, 2013
<u>AB</u>		<u>5MG</u>	<u>A202554 002</u>	Jul 30, 2013
<u>AB</u>		<u>10MG</u>	<u>A202554 003</u>	Jul 30, 2013
<u>AB</u>		<u>20MG</u>	<u>A202554 004</u>	Jul 30, 2013
<u>AB</u>		<u>30MG</u>	<u>A202554 005</u>	Jul 30, 2013
<u>AB</u>		<u>40MG</u>	<u>A202554 006</u>	Jul 30, 2013
<u>AB</u>	ATLANTIDE	<u>2.5MG</u>	<u>A078402 001</u>	Apr 19, 2007
<u>AB</u>		<u>5MG</u>	<u>A078402 002</u>	Apr 19, 2007
<u>AB</u>		<u>10MG</u>	<u>A078402 003</u>	Apr 19, 2007
<u>AB</u>		<u>20MG</u>	<u>A078402 004</u>	Apr 19, 2007
<u>AB</u>		<u>30MG</u>	<u>A078402 005</u>	Apr 19, 2007
<u>AB</u>		<u>40MG</u>	<u>A078402 006</u>	Apr 19, 2007
<u>AB</u>	AUROBINDO	<u>2.5MG</u>	<u>A077622 001</u>	Feb 22, 2006
<u>AB</u>		<u>5MG</u>	<u>A077622 002</u>	Feb 22, 2006
<u>AB</u>		<u>10MG</u>	<u>A077622 003</u>	Feb 22, 2006
<u>AB</u>		<u>20MG</u>	<u>A077622 004</u>	Feb 22, 2006
<u>AB</u>		<u>30MG</u>	<u>A077622 005</u>	Feb 22, 2006
<u>AB</u>		<u>40MG</u>	<u>A077622 006</u>	Feb 22, 2006
<u>AB</u>	CHARTWELL RX	<u>2.5MG</u>	<u>A075994 001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A075994 002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A075994 003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A075994 004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A075994 005</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A075994 006</u>	Jul 01, 2002
<u>AB</u>	COREPHARMA	<u>2.5MG</u>	<u>A076102 001</u>	Sep 30, 2002
<u>AB</u>		<u>5MG</u>	<u>A076102 002</u>	Sep 30, 2002
<u>AB</u>		<u>10MG</u>	<u>A076102 003</u>	Sep 30, 2002
<u>AB</u>		<u>20MG</u>	<u>A076102 004</u>	Sep 30, 2002
<u>AB</u>		<u>30MG</u>	<u>A076102 005</u>	Sep 30, 2002
<u>AB</u>		<u>40MG</u>	<u>A076102 006</u>	Sep 30, 2002
<u>AB</u>	INVAGEN PHARMS	<u>2.5MG</u>	<u>A203508 001</u>	Oct 29, 2013
<u>AB</u>		<u>5MG</u>	<u>A203508 002</u>	Oct 29, 2013
<u>AB</u>		<u>10MG</u>	<u>A203508 003</u>	Oct 29, 2013
<u>AB</u>		<u>20MG</u>	<u>A203508 004</u>	Oct 29, 2013
<u>AB</u>		<u>30MG</u>	<u>A203508 005</u>	Oct 29, 2013
<u>AB</u>		<u>40MG</u>	<u>A203508 006</u>	Oct 29, 2013
<u>AB</u>	LUPIN	<u>2.5MG</u>	<u>A077321 001</u>	Sep 09, 2005
<u>AB</u>		<u>5MG</u>	<u>A077321 002</u>	Sep 09, 2005
<u>AB</u>		<u>10MG</u>	<u>A077321 003</u>	Sep 09, 2005
<u>AB</u>		<u>20MG</u>	<u>A077321 004</u>	Sep 09, 2005
<u>AB</u>		<u>30MG</u>	<u>A077321 005</u>	Sep 09, 2005
<u>AB</u>		<u>40MG</u>	<u>A077321 006</u>	Sep 09, 2005
<u>AB</u>	PRINSTON INC	<u>2.5MG</u>	<u>A075743 001</u>	Jul 01, 2002
<u>AB</u>		<u>2.5MG</u>	<u>A076164 004</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A075743 002</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A076164 005</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A075743 003</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A076164 006</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A075743 004</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A076164 001</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A075743 005</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A076164 002</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A075743 006</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A076164 003</u>	Jul 01, 2002

PRESCRIPTION DRUG PRODUCT LIST

LISINAPRIL

TABLET; ORAL

LISINAPRIL

<u>AB</u>	SUN PHARM INDS LTD	<u>2.5MG</u>	<u>A075944 001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A075944 002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A075944 003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A075944 004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A075944 006</u>	Feb 11, 2003
<u>AB</u>		<u>40MG</u>	<u>A075944 005</u>	Jul 01, 2002
<u>AB</u>	WATSON LABS	<u>2.5MG</u>	<u>A076059 001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A076059 002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A076059 003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A076059 004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A076059 005</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A076059 006</u>	Jul 01, 2002
<u>AB</u>	YILING	<u>2.5MG</u>	<u>A212041 001</u>	Sep 15, 2020
<u>AB</u>		<u>5MG</u>	<u>A212041 002</u>	Sep 15, 2020
<u>AB</u>		<u>10MG</u>	<u>A212041 003</u>	Sep 15, 2020

PRINIVIL

<u>AB</u>	MERCK	<u>5MG</u>	<u>N019558 001</u>	Dec 29, 1987
<u>AB</u>		<u>40MG</u>	<u>N019558 004</u>	Oct 25, 1988

ZESTRIL

<u>AB</u>	+ ALMATICA	<u>2.5MG</u>	<u>N019777 005</u>	Apr 29, 1993
<u>AB</u>	+	<u>5MG</u>	<u>N019777 001</u>	May 19, 1988
<u>AB</u>	+	<u>10MG</u>	<u>N019777 002</u>	May 19, 1988
<u>AB</u>	+	<u>20MG</u>	<u>N019777 003</u>	May 19, 1988
<u>AB</u>	+	<u>30MG</u>	<u>N019777 006</u>	Jan 20, 1999
<u>AB</u>	+	<u>40MG</u>	<u>N019777 004</u>	May 19, 1988

LITHIUM CARBONATE

CAPSULE; ORAL

LITHIUM CARBONATE

<u>AB</u>	ALEMBIC LTD	<u>150MG</u>	<u>A079159 001</u>	Jan 12, 2009
<u>AB</u>		<u>300MG</u>	<u>A079159 002</u>	Jan 12, 2009
<u>AB</u>		<u>600MG</u>	<u>A079159 003</u>	Jan 12, 2009
<u>AB</u>	GLENMARK GENERICS	<u>150MG</u>	<u>A079139 001</u>	Feb 03, 2009
<u>AB</u>		<u>300MG</u>	<u>A079139 002</u>	Feb 03, 2009
<u>AB</u>		<u>600MG</u>	<u>A079139 003</u>	Feb 03, 2009
<u>AB</u>	HETERO LABS LTD III	<u>150MG</u>	<u>A090702 001</u>	Sep 25, 2009
<u>AB</u>		<u>300MG</u>	<u>A090702 002</u>	Sep 25, 2009
<u>AB</u>		<u>600MG</u>	<u>A090702 003</u>	Sep 25, 2009
<u>AB</u>	+ HIKMA	<u>150MG</u>	<u>N017812 002</u>	Jan 28, 1987
<u>AB</u>	+	<u>300MG</u>	<u>N017812 001</u>	
<u>AB</u>	+	<u>600MG</u>	<u>N017812 003</u>	Jan 28, 1987

TABLET; ORAL

LITHIUM CARBONATE

<u>AB</u>	+	HIKMA	<u>300MG</u>	<u>N018558 001</u>	Jan 29, 1982
<u>AB</u>		SUN PHARM INDS INC	<u>300MG</u>	<u>A091027 001</u>	Jun 24, 2010

TABLET, EXTENDED RELEASE; ORAL

LITHIUM CARBONATE

<u>AB</u>	GLENMARK GENERICS	<u>450MG</u>	<u>A091616 001</u>	Feb 14, 2011
<u>AB</u>	GLENMARK PHARMS INC	<u>300MG</u>	<u>A091544 001</u>	Dec 27, 2010
<u>AB</u>	HERITAGE PHARMA	<u>300MG</u>	<u>A205532 001</u>	Sep 29, 2016
<u>AB</u>	HIKMA	<u>300MG</u>	<u>A076832 001</u>	Oct 28, 2004
<u>AB</u>	!	<u>450MG</u>	<u>A076691 001</u>	Jan 05, 2004
<u>AB</u>	MYLAN PHARMS INC	<u>300MG</u>	<u>A202288 001</u>	Jun 29, 2012
<u>AB</u>		<u>450MG</u>	<u>A202219 001</u>	Aug 08, 2012
<u>AB</u>	UNIQUE PHARM LABS	<u>300MG</u>	<u>A204779 001</u>	Jul 27, 2015
<u>AB</u>		<u>450MG</u>	<u>A205663 001</u>	Jun 05, 2017

LITHOBID

<u>AB</u>	+	ANI PHARMS INC	<u>300MG</u>	<u>N018027 001</u>	
-----------	---	----------------	--------------	--------------------	--

LITHIUM CITRATE

SYRUP; ORAL

LITHIUM CITRATE

<u>AA</u>	+	HIKMA	<u>EQ 300MG CARBONATE/5ML</u>	<u>N018421 001</u>	
<u>AA</u>		WOCKHARDT BIO AG	<u>EQ 300MG CARBONATE/5ML</u>	<u>A070755 001</u>	May 21, 1986

PRESCRIPTION DRUG PRODUCT LIST

LODOXAMIDE TROMETHAMINE

SOLUTION/DROPS;OPHTHALMIC

ALOMIDE

+! NOVARTIS

EQ 0.1% BASE

N020191 001 Sep 23, 1993

LOFEXIDINE HYDROCHLORIDE

TABLET;ORAL

LUCEMYRA

+! USWM

EQ 0.18MG BASE

N209229 001 May 16, 2018

LOMITAPIDE MESYLATE

CAPSULE;ORAL

JUXTAPID

+ AMRYT

EQ 5MG BASE

N203858 001 Dec 21, 2012

+

EQ 10MG BASE

N203858 002 Dec 21, 2012

+

EQ 20MG BASE

N203858 003 Dec 21, 2012

+

EQ 30MG BASE

N203858 004 Apr 23, 2015

LOMUSTINE

CAPSULE;ORAL

GLEOSTINE

+ CORDEN PHARMA

10MG

N017588 001

+

40MG

N017588 002

+!

100MG

N017588 003

LONAFARNIB

CAPSULE;ORAL

ZOKINVY

+ EIGER BIOPHARMS

50MG

N213969 001 Nov 20, 2020

+!

75MG

N213969 002 Nov 20, 2020

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

LOPERAMIDE HYDROCHLORIDEAB ! MYLAN2MGA072741 001 Sep 18, 1991AB TEVA2MGA073192 001 Apr 30, 1992LOPINAVIR; RITONAVIR

SOLUTION;ORAL

KALETRAAA +! ABBVIE80MG/ML; 20MG/MLN021251 001 Sep 15, 2000LOPINAVIR AND RITONAVIRAA LANNETT CO INC80MG/ML; 20MG/MLA207407 001 Dec 27, 2016

TABLET;ORAL

KALETRA

+ ABBVIE

100MG;25MG

N021906 002 Nov 09, 2007

+!

200MG;50MG

N021906 001 Oct 28, 2005

LORAZEPAM

CONCENTRATE;ORAL

LORAZEPAMAA AMNEAL PHARMS2MG/MLA091383 001 Dec 23, 2009AA HL-TECH PHARMA CO2MG/MLA200169 001 Jan 30, 2012AA LANNETT CO INC2MG/MLA079244 001 Apr 28, 2009AA LUPIN LTD2MG/MLA091407 001 Feb 19, 2013AA PHARM ASSOC2MG/MLA090260 001 Jun 15, 2010LORAZEPAM INTENSOLAA ! HIKMA2MG/MLA072755 001 Jun 28, 1991

INJECTABLE; INJECTION

ATIVANAP +! HIKMA2MG/MLN018140 001AP +!4MG/MLN018140 002LORAZEPAMAP AKORN2MG/MLA075025 001 Jul 23, 1998AP HOSPIRA2MG/MLA074243 001 Apr 12, 1994AP2MG/MLA074282 001 May 27, 1994AP4MG/MLA074243 002 Apr 12, 1994AP4MG/MLA074282 002 May 27, 1994AP INTL MEDICATION SYS2MG/MLA076150 001 Nov 15, 2004

TABLET;ORAL

ATIVANAB + BAUSCH0.5MGN017794 001AB +1MGN017794 002AB +!2MGN017794 003

PRESCRIPTION DRUG PRODUCT LIST

LORAZEPAM

TABLET; ORAL

LORAZEPAM

<u>AB</u>	AMNEAL PHARMS	<u>0.5MG</u>	<u>A078826 001</u>	Jun 23, 2010
<u>AB</u>		<u>1MG</u>	<u>A078826 002</u>	Jun 23, 2010
<u>AB</u>		<u>2MG</u>	<u>A078826 003</u>	Jun 23, 2010
<u>AB</u>	AUROLIFE PHARMA LLC	<u>0.5MG</u>	<u>A203572 001</u>	Dec 22, 2017
<u>AB</u>		<u>1MG</u>	<u>A203572 002</u>	Dec 22, 2017
<u>AB</u>		<u>2MG</u>	<u>A203572 003</u>	Dec 22, 2017
<u>AB</u>	LEADING PHARMA LLC	<u>0.5MG</u>	<u>A078203 001</u>	Jul 30, 2007
<u>AB</u>		<u>1MG</u>	<u>A078203 002</u>	Jul 30, 2007
<u>AB</u>		<u>2MG</u>	<u>A078203 003</u>	Jul 30, 2007
<u>AB</u>	OXFORD PHARMS	<u>0.5MG</u>	<u>A077754 001</u>	May 10, 2006
<u>AB</u>		<u>1MG</u>	<u>A077754 002</u>	May 10, 2006
<u>AB</u>		<u>2MG</u>	<u>A077754 003</u>	May 10, 2006
<u>AB</u>	SANDOZ	<u>0.5MG</u>	<u>A071141 002</u>	Apr 21, 1987
<u>AB</u>		<u>1MG</u>	<u>A071141 003</u>	Apr 21, 1987
<u>AB</u>		<u>2MG</u>	<u>A071141 001</u>	Apr 21, 1987
<u>AB</u>	WATSON LABS	<u>0.5MG</u>	<u>A072926 001</u>	Oct 31, 1991
<u>AB</u>		<u>1MG</u>	<u>A072927 001</u>	Oct 31, 1991
<u>AB</u>		<u>2MG</u>	<u>A072928 001</u>	Oct 31, 1991

LORLATINIB

TABLET; ORAL

LORBRENA

+	PFIZER	25MG	N210868 001	Nov 02, 2018
+	!	100MG	N210868 002	Nov 02, 2018

LOSARTAN POTASSIUM

TABLET; ORAL

COZAAR

<u>AB</u>	+	ORGANON	<u>100MG</u>	<u>N020386 003</u>	Oct 13, 1998
-----------	---	---------	--------------	--------------------	--------------

LOSARTAN POTASSIUM

<u>AB</u>	ALEMbic PHARMS LTD	<u>25MG</u>	<u>A090428 001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A090428 002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090428 003</u>	Oct 06, 2010
<u>AB</u>	AUROBINDO PHARMA	<u>25MG</u>	<u>A090083 001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A090083 002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090083 003</u>	Oct 06, 2010
<u>AB</u>	CADISTA PHARMS	<u>25MG</u>	<u>A201170 001</u>	Sep 18, 2012
<u>AB</u>		<u>50MG</u>	<u>A201170 002</u>	Sep 18, 2012
<u>AB</u>		<u>100MG</u>	<u>A201170 003</u>	Sep 18, 2012
<u>AB</u>	HETERO LABS LTD V	<u>25MG</u>	<u>A203835 001</u>	Aug 12, 2015
<u>AB</u>		<u>50MG</u>	<u>A203835 002</u>	Aug 12, 2015
<u>AB</u>		<u>100MG</u>	<u>A203835 003</u>	Aug 12, 2015
<u>AB</u>	IPCA LABS LTD	<u>25MG</u>	<u>A200290 001</u>	Aug 30, 2013
<u>AB</u>		<u>50MG</u>	<u>A200290 002</u>	Aug 30, 2013
<u>AB</u>		<u>100MG</u>	<u>A200290 003</u>	Aug 30, 2013
<u>AB</u>	LUPIN LTD	<u>25MG</u>	<u>A078232 001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A078232 002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A078232 003</u>	Oct 06, 2010
<u>AB</u>	MACLEODS PHARMS LTD	<u>25MG</u>	<u>A202230 001</u>	May 30, 2012
<u>AB</u>		<u>50MG</u>	<u>A202230 002</u>	May 30, 2012
<u>AB</u>		<u>100MG</u>	<u>A202230 003</u>	May 30, 2012
<u>AB</u>	MICRO LABS	<u>25MG</u>	<u>A091541 001</u>	Sep 24, 2012
<u>AB</u>		<u>50MG</u>	<u>A091541 002</u>	Sep 24, 2012
<u>AB</u>		<u>100MG</u>	<u>A091541 003</u>	Sep 24, 2012
<u>AB</u>	PRINSTON INC	<u>25MG</u>	<u>A091497 001</u>	Jun 06, 2011
<u>AB</u>		<u>50MG</u>	<u>A091497 002</u>	Jun 06, 2011
<u>AB</u>		<u>100MG</u>	<u>A091497 003</u>	Jun 06, 2011
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A077424 001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A077424 002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A077424 003</u>	Oct 06, 2010
<u>AB</u>	STRIDES PHARMA	<u>25MG</u>	<u>A090382 001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A090382 002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090382 003</u>	Oct 06, 2010
<u>AB</u>	UPSHER SMITH LABS	<u>25MG</u>	<u>A090544 001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A090544 002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090544 003</u>	Oct 06, 2010
<u>AB</u>	WATSON LABS	<u>25MG</u>	<u>A091129 001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A091129 002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A091129 003</u>	Oct 06, 2010
<u>AB</u>	ZYDUS PHARMS USA	<u>25MG</u>	<u>A078243 001</u>	Oct 06, 2010

PRESCRIPTION DRUG PRODUCT LIST

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

INC

AB		50MG	A078243 002	Oct 06, 2010
AB		100MG	A078243 003	Oct 06, 2010

LOTEPREDNOL ETABONATE

GEL; OPHTHALMIC

LOTEMAX

+	!	BAUSCH AND LOMB INC	0.5%	N202872 001	Sep 28, 2012
---	---	---------------------	------	-------------	--------------

LOTEMAX SM

+	!	BAUSCH AND LOMB INC	0.38%	N208219 001	Feb 22, 2019
---	---	---------------------	-------	-------------	--------------

OINTMENT; OPHTHALMIC

LOTEMAX

+	!	BAUSCH AND LOMB	0.5%	N200738 001	Apr 15, 2011
---	---	-----------------	------	-------------	--------------

SUSPENSION/DROPS; OPHTHALMIC

LOTEMAX

AB	+	!	BAUSCH AND LOMB	0.5%	N020583 001	Mar 09, 1998
-----------	---	---	-----------------	-------------	--------------------	--------------

LOTEPREDNOL ETABONATE

AB		AKORN	0.5%	A207609 001	Apr 17, 2019
-----------	--	-------	-------------	--------------------	--------------

ALREX

+	!	BAUSCH AND LOMB	0.2%	N020803 001	Mar 09, 1998
---	---	-----------------	------	-------------	--------------

EYSUVIS

+	!	KALA PHARMS INC	0.25%	N210933 001	Oct 26, 2020
---	---	-----------------	-------	-------------	--------------

INVELTYS

+	!	KALA PHARMS INC	1%	N210565 001	Aug 22, 2018
---	---	-----------------	----	-------------	--------------

LOTEPREDNOL ETABONATE; TOBRAMYCIN

SUSPENSION/DROPS; OPHTHALMIC

ZYLET

+	!	BAUSCH AND LOMB	0.5%; 0.3%	N050804 001	Dec 14, 2004
---	---	-----------------	------------	-------------	--------------

LOVASTATIN

TABLET; ORAL

LOVASTATIN

AB		ACTAVIS ELIZABETH	10MG	A075828 001	Dec 17, 2001
-----------	--	-------------------	-------------	--------------------	--------------

AB			20MG	A075828 002	Dec 17, 2001
-----------	--	--	-------------	--------------------	--------------

AB			40MG	A075828 003	Dec 17, 2001
-----------	--	--	-------------	--------------------	--------------

AB		BEXIMCO PHARMS USA	10MG	A075300 001	Dec 17, 2001
-----------	--	--------------------	-------------	--------------------	--------------

AB			20MG	A075300 002	Dec 17, 2001
-----------	--	--	-------------	--------------------	--------------

AB			40MG	A075300 003	Dec 17, 2001
-----------	--	--	-------------	--------------------	--------------

AB		CARLSBAD	10MG	A075991 001	Jun 05, 2002
-----------	--	----------	-------------	--------------------	--------------

AB			20MG	A075991 002	Jun 05, 2002
-----------	--	--	-------------	--------------------	--------------

AB	!		40MG	A075991 003	Jun 05, 2002
-----------	---	--	-------------	--------------------	--------------

AB		COREPHARMA	10MG	A077748 001	Feb 28, 2007
-----------	--	------------	-------------	--------------------	--------------

AB			20MG	A077748 002	Feb 28, 2007
-----------	--	--	-------------	--------------------	--------------

AB			40MG	A077748 003	Feb 28, 2007
-----------	--	--	-------------	--------------------	--------------

AB		LUPIN	10MG	A078296 001	Mar 14, 2008
-----------	--	-------	-------------	--------------------	--------------

AB			20MG	A078296 002	Nov 01, 2007
-----------	--	--	-------------	--------------------	--------------

AB			40MG	A078296 003	Nov 01, 2007
-----------	--	--	-------------	--------------------	--------------

AB		SANDOZ	10MG	A075636 001	Dec 17, 2001
-----------	--	--------	-------------	--------------------	--------------

AB			20MG	A075636 002	Dec 17, 2001
-----------	--	--	-------------	--------------------	--------------

AB			40MG	A075636 003	Dec 17, 2001
-----------	--	--	-------------	--------------------	--------------

AB		TEVA	10MG	A075551 003	Dec 17, 2001
-----------	--	------	-------------	--------------------	--------------

AB			20MG	A075551 002	Dec 17, 2001
-----------	--	--	-------------	--------------------	--------------

AB			40MG	A075551 001	Dec 17, 2001
-----------	--	--	-------------	--------------------	--------------

TABLET, EXTENDED RELEASE; ORAL

ALTOPREV

+		COVIS	20MG	N021316 002	Jun 26, 2002
---	--	-------	------	-------------	--------------

+			40MG	N021316 003	Jun 26, 2002
---	--	--	------	-------------	--------------

+	!		60MG	N021316 004	Jun 26, 2002
---	---	--	------	-------------	--------------

LOXAPINE

POWDER; INHALATION

ADASUVE

+	!	ALEXZA PHARMS	10MG	N022549 001	Dec 21, 2012
---	---	---------------	------	-------------	--------------

LOXAPINE SUCCINATE

CAPSULE; ORAL

LOXAPINE SUCCINATE

AB		ELITE LABS INC	EQ 5MG BASE	A076868 001	Aug 04, 2005
-----------	--	----------------	--------------------	--------------------	--------------

AB			EQ 10MG BASE	A076868 002	Aug 04, 2005
-----------	--	--	---------------------	--------------------	--------------

AB			EQ 25MG BASE	A076868 003	Aug 04, 2005
-----------	--	--	---------------------	--------------------	--------------

AB			EQ 50MG BASE	A076868 004	Aug 04, 2005
-----------	--	--	---------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

LOXAPINE SUCCINATE

CAPSULE; ORAL

LOXAPINE SUCCINATE

<u>AB</u>	LANNETT CO INC	<u>EQ 5MG BASE</u>	<u>A090695 001</u>	Sep 26, 2011
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090695 002</u>	Sep 26, 2011
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A090695 003</u>	Sep 26, 2011
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A090695 004</u>	Sep 26, 2011
<u>AB</u>	MYLAN	<u>EQ 5MG BASE</u>	<u>A076762 001</u>	Nov 01, 2004
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076762 002</u>	Nov 01, 2004
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A076762 003</u>	Nov 01, 2004
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076762 004</u>	Nov 01, 2004
<u>AB</u>	WATSON LABS	<u>EQ 5MG BASE</u>	<u>A072204 001</u>	Jun 15, 1988
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A072205 001</u>	Jun 15, 1988
<u>AB</u>	!	<u>EQ 25MG BASE</u>	<u>A072206 001</u>	Jun 15, 1988
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A072062 001</u>	Jun 15, 1988

LUBIPROSTONE

CAPSULE; ORAL

AMITIZA

+	SUCAMPO PHARMA LLC	8MCG	N021908 002	Apr 29, 2008
+	!	24MCG	N021908 001	Jan 31, 2006

LULICONAZOLE

CREAM; TOPICAL

LUZU

+	MEDICIS	1%	N204153 001	Nov 14, 2013
---	---------	----	-------------	--------------

LUMASIRAN SODIUM

SOLUTION; SUBCUTANEOUS

OXLUMO

+	ALNYLAM PHARMS INC	EQ 94.5MG/0.5ML BASE (EQ 94.5MG/0.5ML BASE)	N214103 001	Nov 23, 2020
---	--------------------	---	-------------	--------------

LUMATEPERONE TOSYLATE

CAPSULE; ORAL

CAPLYTA

+	INTRA-CELLULAR	EQ 42MG BASE	N209500 001	Dec 20, 2019
---	----------------	--------------	-------------	--------------

LURASIDONE HYDROCHLORIDE

TABLET; ORAL

LATUDA

<u>AB</u>	+	SUNOVION PHARMS INC	<u>20MG</u>	<u>N200603 003</u>	Dec 07, 2011
<u>AB</u>	+	!	<u>40MG</u>	<u>N200603 001</u>	Oct 28, 2010
<u>AB</u>	+		<u>60MG</u>	<u>N200603 005</u>	Jul 12, 2013
<u>AB</u>	+		<u>80MG</u>	<u>N200603 002</u>	Oct 28, 2010
<u>AB</u>	+		<u>120MG</u>	<u>N200603 004</u>	Apr 26, 2012

LURASIDONE HYDROCHLORIDE

<u>AB</u>	ACCORD HLTHCARE	<u>20MG</u>	<u>A208049 001</u>	Jan 03, 2019
<u>AB</u>		<u>40MG</u>	<u>A208049 002</u>	Jan 03, 2019
<u>AB</u>		<u>60MG</u>	<u>A208049 003</u>	Jan 03, 2019
<u>AB</u>		<u>80MG</u>	<u>A208049 004</u>	Jan 03, 2019
<u>AB</u>		<u>120MG</u>	<u>A208049 005</u>	Jan 03, 2019
<u>AB</u>	PIRAMAL HLTHCARE UK	<u>20MG</u>	<u>A212091 001</u>	Dec 28, 2020
<u>AB</u>		<u>40MG</u>	<u>A212091 002</u>	Dec 28, 2020
<u>AB</u>		<u>60MG</u>	<u>A212091 003</u>	Dec 28, 2020
<u>AB</u>		<u>80MG</u>	<u>A212091 004</u>	Dec 28, 2020
<u>AB</u>		<u>120MG</u>	<u>A212091 005</u>	Dec 28, 2020
<u>AB</u>	SUN PHARM	<u>20MG</u>	<u>A208066 001</u>	Jan 04, 2019
<u>AB</u>		<u>40MG</u>	<u>A208066 002</u>	Jan 04, 2019
<u>AB</u>		<u>60MG</u>	<u>A208066 003</u>	Jan 04, 2019
<u>AB</u>		<u>80MG</u>	<u>A208066 004</u>	Jan 04, 2019
<u>AB</u>		<u>120MG</u>	<u>A208066 005</u>	Jan 04, 2019

LURBINECTEDIN

POWDER; INTRAVENOUS

ZEPZELCA

+	JAZZ	4MG/VIAL	N213702 001	Jun 15, 2020
---	------	----------	-------------	--------------

LUSUTROMBOPAG

TABLET; ORAL

MULPLETA

+	SHIONOGI INC	3MG	N210923 001	Jul 31, 2018
---	--------------	-----	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

LUTETIUM DOTATATE LU-177

SOLUTION;INTRAVENOUS

LUTATHERA

+! AAA USA INC 10mCi/ML N208700 001 Jan 26, 2018

MACIMORELIN ACETATE

FOR SOLUTION;ORAL

MACRILEN

+! NOVO EQ 60MG BASE/POUCH N205598 001 Dec 20, 2017

MACITENTAN

TABLET;ORAL

OPSUMIT

+! ACTELION PHARMS LTD 10MG N204410 001 Oct 18, 2013

MAFENIDE ACETATE

CREAM;TOPICAL

SULFAMYLN

+! RISING EQ 85MG BASE/GM N016763 001

FOR SOLUTION;TOPICAL

MAFENIDE ACETATE**AT** NOVAST LABS **5%** **A206716 001** Jul 31, 2017**AT** PAR FORM **5%** **A201511 001** Feb 12, 2013SULFAMYLN**AT** +! MYLAN INSTITUTIONAL **5%** **N019832 003** Jun 05, 1998MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE;INJECTION

ISOLYTE S PH 7.4 IN PLASTIC CONTAINER

+! B BRAUN 30MG/100ML;37MG/100ML;0.82MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML;12MG/100ML N019696 001 Sep 29, 1989

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION

ISOLYTE S IN PLASTIC CONTAINER

B BRAUN 30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML N019711 001 Sep 29, 1989

NORMOSOL-R IN PLASTIC CONTAINER

ICU MEDICAL INC 30MG/100ML;37MG/100ML;222MG/100ML;526MG/100ML;502MG/100ML N017586 001

PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER

+! BAXTER HLTHCARE 30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML N017378 001

PLASMA-LYTE A IN PLASTIC CONTAINER

+! BAXTER HLTHCARE 30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML N017378 002 Nov 22, 1982

SOLUTION;IRRIGATION

PHYSIOLYTE IN PLASTIC CONTAINER

B BRAUN 30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML N019024 001 Jun 08, 1984

PHYSIOSOL IN PLASTIC CONTAINER

ICU MEDICAL INC 30MG/100ML;37MG/100ML;222MG/100ML;526MG/100ML;502MG/100ML N017637 002 Jul 08, 1982

MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

SOLUTION;INJECTION

NORMOCARB HF 25

+! DIALYSIS SUPS 0.21GM/100ML;2.8GM/100ML;9.07GM/100ML N021910 001 Jul 26, 2006

NORMOCARB HF 35

+! DIALYSIS SUPS 0.21GM/100ML;3.97GM/100ML;8.3GM/100ML N021910 002 Jul 26, 2006

MAGNESIUM SULFATE

INJECTABLE;INJECTION

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER**AP** B BRAUN MEDICAL INC **1GM/100ML** **A207966 001** Oct 27, 2020**AP** FRESENIUS KABI USA **1GM/100ML** **A206486 001** Mar 07, 2016**AP** +! HOSPIRA **1GM/100ML** **N020488 001** Jul 11, 1995**AP** HQ SPCLT PHARMA **1GM/100ML** **A207349 001** Mar 02, 2016**AP** MYLAN LABS LTD **1GM/100ML** **A209932 001** Sep 10, 2018MAGNESIUM SULFATE IN PLASTIC CONTAINER**AP** FRESENIUS KABI USA **4GM/100ML (40MG/ML)** **A206485 001** Mar 15, 2016**AP** **4GM/50ML (80MG/ML)** **A206485 002** Mar 15, 2016**AP** **2GM/50ML (40MG/ML)** **A206485 003** Mar 15, 2016**AP** **20GM/500ML (40MG/ML)** **A206485 004** Mar 15, 2016**AP** **40GM/1000ML (40MG/ML)** **A206485 005** Mar 15, 2016**AP** GLAND PHARMA LTD **2GM/50ML (40MG/ML)** **A213917 001** Jul 10, 2020

PRESCRIPTION DRUG PRODUCT LIST

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE IN PLASTIC CONTAINER

<u>AP</u>		<u>4GM/100ML (40MG/ML)</u>	<u>A213917 002</u>	Jul 10, 2020
<u>AP</u>	+	HOSPIRA <u>2GM/50ML (40MG/ML)</u>	<u>N020309 003</u>	Jan 26, 2007
<u>AP</u>	+	! <u>4GM/100ML (40MG/ML)</u>	<u>N020309 001</u>	Jun 24, 1994
<u>AP</u>	+	! <u>4GM/50ML (80MG/ML)</u>	<u>N020309 002</u>	Jun 24, 1994
<u>AP</u>	+	<u>20GM/500ML (40MG/ML)</u>	<u>N020309 004</u>	Jan 18, 1995
<u>AP</u>	+	<u>40GM/1000ML (40MG/ML)</u>	<u>N020309 005</u>	Jan 18, 1995
<u>AP</u>		HQ SPCLT PHARMA <u>2GM/50ML (40MG/ML)</u>	<u>A207350 001</u>	Dec 06, 2017
<u>AP</u>		<u>4GM/100ML (40MG/ML)</u>	<u>A207350 002</u>	Dec 06, 2017
<u>AP</u>		<u>4GM/50ML (80MG/ML)</u>	<u>A207350 003</u>	Dec 06, 2017
<u>AP</u>		<u>20GM/500ML (40MG/ML)</u>	<u>A207350 004</u>	Dec 06, 2017
<u>AP</u>		<u>40GM/1000ML (40MG/ML)</u>	<u>A207350 005</u>	Dec 06, 2017
<u>AP</u>		MYLAN LABS LTD <u>2GM/50ML (40MG/ML)</u>	<u>A209911 001</u>	Sep 14, 2018
<u>AP</u>		<u>4GM/100ML (40MG/ML)</u>	<u>A209911 002</u>	Sep 14, 2018

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

+	!	HOSPIRA	2GM/100ML	N020488 002	Jul 11, 1995
---	---	---------	-----------	-------------	--------------

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

<u>AP</u>		EXELA PHARMA <u>5GM/10ML (500MG/ML)</u>	<u>A206039 001</u>	Dec 18, 2014	
<u>AP</u>	+	!	FRESENIUS KABI USA <u>5GM/10ML (500MG/ML)</u>	<u>N019316 001</u>	Sep 08, 1986
<u>AP</u>	+	!	<u>10GM/20ML (500MG/ML)</u>	<u>N019316 003</u>	Jan 29, 2016
<u>AP</u>	!	HOSPIRA <u>5GM/10ML (500MG/ML)</u>	<u>A075151 001</u>	Apr 25, 2000	
<u>AP</u>		HOSPIRA INC <u>10GM/20ML (500MG/ML)</u>	<u>A202411 001</u>	May 14, 2015	
	+	!	FRESENIUS KABI USA 1GM/2ML (500MG/ML)	N019316 002	Sep 08, 1986
	+	!	25GM/50ML (500MG/ML)	N019316 004	Jan 29, 2016

MAGNESIUM SULFATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION

TIS-U-SOL

<u>AT</u>		BAXTER HLTHCARE <u>20MG/100ML; 40MG/100ML; 6.25MG/100ML; 800MG/100ML; 8.75MG/100ML</u>	<u>N018508 001</u>	Feb 19, 1982
-----------	--	---	--------------------	--------------

TIS-U-SOL IN PLASTIC CONTAINER

<u>AT</u>		BAXTER HLTHCARE <u>20MG/100ML; 40MG/100ML; 6.25MG/100ML; 800MG/100ML; 8.75MG/100ML</u>	<u>N018336 001</u>	
-----------	--	---	--------------------	--

MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE

TABLET; ORAL

SUTAB (COPACKAGED)

+	!	BRAINTREE LABS	0.225GM; 0.188GM; 1.479GM	N213135 001	Nov 10, 2020
---	---	----------------	---------------------------	-------------	--------------

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

SOLUTION; ORAL

SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE

<u>AA</u>		NOVEL LABS INC <u>1.6GM/BOT; 3.13GM/BOT; 17.5GM/BOT</u>	<u>A202511 001</u>	Feb 23, 2017	
<u>AA</u>	+	!	BRAINTREE LABS <u>1.6GM/BOT; 3.13GM/BOT; 17.5GM/BOT</u>	<u>N022372 001</u>	Aug 05, 2010

MALATHION

LOTION; TOPICAL

MALATHION

!		SUVEN PHARMS	0.5%	A091559 001	May 23, 2012
---	--	--------------	------	-------------	--------------

MANGANESE CHLORIDE

INJECTABLE; INJECTION

MANGANESE CHLORIDE IN PLASTIC CONTAINER

+	!	HOSPIRA	EQ 0.1MG MANGANESE/ML	N018962 001	Jun 26, 1986
---	---	---------	-----------------------	-------------	--------------

MANNITOL

INJECTABLE; INJECTION

MANNITOL 10% IN PLASTIC CONTAINER

<u>AP</u>		B BRAUN <u>10GM/100ML</u>	<u>N020006 002</u>	Jul 26, 1993
-----------	--	------------------------------	--------------------	--------------

MANNITOL 15% IN PLASTIC CONTAINER

<u>AP</u>		B BRAUN <u>15GM/100ML</u>	<u>N020006 003</u>	Jul 26, 1993
-----------	--	------------------------------	--------------------	--------------

MANNITOL 20% IN PLASTIC CONTAINER

<u>AP</u>		B BRAUN <u>20GM/100ML</u>	<u>N020006 004</u>	Jul 26, 1993
-----------	--	------------------------------	--------------------	--------------

<u>AP</u>		ICU MEDICAL INC <u>20GM/100ML</u>	<u>N019603 004</u>	Jan 08, 1990
-----------	--	--------------------------------------	--------------------	--------------

MANNITOL 25%

<u>AP</u>		FRESENIUS KABI USA <u>12.5GM/50ML</u>	<u>A080677 001</u>	
-----------	--	--	--------------------	--

<u>AP</u>		HOSPIRA <u>12.5GM/50ML</u>	<u>N016269 006</u>	Aug 25, 1994
-----------	--	-------------------------------	--------------------	--------------

MANNITOL 5% IN PLASTIC CONTAINER

<u>AP</u>		B BRAUN <u>5GM/100ML</u>	<u>N020006 001</u>	Jul 26, 1993
-----------	--	-----------------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

MANNITOL

INJECTABLE; INJECTION

OSMITROL 10% IN WATER

AP	BAXTER HLTHCARE	<u>10GM/100ML</u>	<u>N013684</u>	<u>002</u>
-----------	-----------------	-------------------	-----------------------	-------------------

OSMITROL 10% IN WATER IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	<u>10GM/100ML</u>	<u>N013684</u>	<u>006</u>
-----------	-----------------	-------------------	-----------------------	-------------------

OSMITROL 15% IN WATER

AP	BAXTER HLTHCARE	<u>15GM/100ML</u>	<u>N013684</u>	<u>004</u>
-----------	-----------------	-------------------	-----------------------	-------------------

OSMITROL 15% IN WATER IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	<u>15GM/100ML</u>	<u>N013684</u>	<u>008</u>
-----------	-----------------	-------------------	-----------------------	-------------------

OSMITROL 20% IN WATER

AP	BAXTER HLTHCARE	<u>20GM/100ML</u>	<u>N013684</u>	<u>003</u>
-----------	-----------------	-------------------	-----------------------	-------------------

OSMITROL 20% IN WATER IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	<u>20GM/100ML</u>	<u>N013684</u>	<u>007</u>
-----------	-----------------	-------------------	-----------------------	-------------------

OSMITROL 5% IN WATER

AP	BAXTER HLTHCARE	<u>5GM/100ML</u>	<u>N013684</u>	<u>001</u>
-----------	-----------------	------------------	-----------------------	-------------------

OSMITROL 5% IN WATER IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	<u>5GM/100ML</u>	<u>N013684</u>	<u>005</u>
-----------	-----------------	------------------	-----------------------	-------------------

POWDER; INHALATION

ARIDOL KIT

+	!	PHARMAXIS LTD	N/A, 5MG, 10MG, 20MG, 40MG	N022368	001	Oct 05, 2010
---	---	---------------	----------------------------	---------	-----	--------------

BRONCHITOL

+	!	CHIESI	40MG	N202049	001	Oct 30, 2020
---	---	--------	------	---------	-----	--------------

SOLUTION; IRRIGATION

RESECTISOL IN PLASTIC CONTAINER

		B BRAUN	5GM/100ML	N016772	002	
--	--	---------	-----------	---------	-----	--

MANNITOL; SORBITOL

SOLUTION; IRRIGATION

SORBITOL-MANNITOL IN PLASTIC CONTAINER

+	!	ICU MEDICAL INC	540MG/100ML; 2.7GM/100ML	N018316	001	
---	---	-----------------	--------------------------	---------	-----	--

MAPROTILINE HYDROCHLORIDE

TABLET; ORAL

MAPROTILINE HYDROCHLORIDE

		MYLAN	25MG	A072285	002	Oct 03, 1988
--	--	-------	------	---------	-----	--------------

!			50MG	A072285	001	Oct 03, 1988
---	--	--	------	---------	-----	--------------

			75MG	A072285	003	Oct 03, 1988
--	--	--	------	---------	-----	--------------

MARAVIROC

SOLUTION; ORAL

SELZENTRY

+	!	VIIV HLTHCARE	20MG/ML	N208984	001	Nov 04, 2016
---	---	---------------	---------	---------	-----	--------------

TABLET; ORAL

SELZENTRY

+		VIIV HLTHCARE	25MG	N022128	003	Nov 04, 2016
---	--	---------------	------	---------	-----	--------------

+			75MG	N022128	004	Nov 04, 2016
---	--	--	------	---------	-----	--------------

+			150MG	N022128	001	Aug 06, 2007
---	--	--	-------	---------	-----	--------------

+	!		300MG	N022128	002	Aug 06, 2007
---	---	--	-------	---------	-----	--------------

MEBENDAZOLE

TABLET, CHEWABLE; ORAL

EMVERM

!		IMPAX LABS INC	100MG	A073580	001	Jan 04, 1995
---	--	----------------	-------	---------	-----	--------------

MECAMYLAMINE HYDROCHLORIDE

TABLET; ORAL

MECAMYLAMINE HYDROCHLORIDE

!		LGM PHARMA	2.5MG	A204054	001	Mar 19, 2013
---	--	------------	-------	---------	-----	--------------

MECHLORETHAMINE HYDROCHLORIDE

GEL; TOPICAL

VALCHLOR

+	!	HELSINN	EQ 0.016% BASE	N202317	001	Aug 23, 2013
---	---	---------	----------------	---------	-----	--------------

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

ANTIVERT

AA	+	CASPER PHARMA LLC	<u>12.5MG</u>	<u>N010721</u>	<u>006</u>	
-----------	---	-------------------	---------------	-----------------------	-------------------	--

AA	+		<u>25MG</u>	<u>N010721</u>	<u>004</u>	
-----------	---	--	-------------	-----------------------	-------------------	--

AA	+		<u>50MG</u>	<u>N010721</u>	<u>001</u>	Jan 20, 1982
-----------	---	--	-------------	-----------------------	-------------------	--------------

MECLIZINE HYDROCHLORIDE

AA	!	AMNEAL PHARMS	<u>12.5MG</u>	<u>A201451</u>	<u>001</u>	Feb 23, 2011
-----------	---	---------------	---------------	-----------------------	-------------------	--------------

AA	!		<u>25MG</u>	<u>A201451</u>	<u>002</u>	Feb 23, 2011
-----------	---	--	-------------	-----------------------	-------------------	--------------

AA		ANNORA PHARMA	<u>12.5MG</u>	<u>A087128</u>	<u>002</u>	
-----------	--	---------------	---------------	-----------------------	-------------------	--

AA			<u>25MG</u>	<u>A087128</u>	<u>001</u>	
-----------	--	--	-------------	-----------------------	-------------------	--

PRESCRIPTION DRUG PRODUCT LIST

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

AA	EPIC PHARMA LLC	<u>12.5MG</u>	<u>A200294</u>	<u>001</u>	Apr 13, 2012
AA		<u>25MG</u>	<u>A200294</u>	<u>002</u>	Apr 13, 2012
AA	INDICUS PHARMA	<u>12.5MG</u>	<u>A205136</u>	<u>001</u>	Feb 22, 2019
AA		<u>25MG</u>	<u>A205136</u>	<u>002</u>	Feb 22, 2019
AA		<u>50MG</u>	<u>A205136</u>	<u>003</u>	Feb 22, 2019
AA	INVATECH	<u>25MG</u>	<u>A084092</u>	<u>003</u>	May 22, 1989
AA	JUBILANT CADISTA	<u>12.5MG</u>	<u>A040659</u>	<u>001</u>	Jun 04, 2010
AA		<u>25MG</u>	<u>A040659</u>	<u>002</u>	Jun 04, 2010
AA	SANDOZ	<u>12.5MG</u>	<u>A084843</u>	<u>002</u>	May 22, 1989
AA	ZYDUS	<u>12.5MG</u>	<u>A213957</u>	<u>001</u>	Jun 23, 2020
AA		<u>25MG</u>	<u>A213957</u>	<u>002</u>	Jun 23, 2020

TABLET, CHEWABLE; ORAL

ANTIVERT

AA	+ CASPER PHARMA LLC	<u>25MG</u>	<u>N010721</u>	<u>005</u>	
-----------	---------------------	-------------	----------------	------------	--

MECLOFENAMATE SODIUM

CAPSULE; ORAL

MECLOFENAMATE SODIUM

MYLAN

EQ 50MG BASE

A071081 002 Sep 03, 1986

!

EQ 100MG BASE

A071081 001 Sep 03, 1986

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

DEPO-PROVERA

AB	+! PHARMACIA AND UPJOHN	<u>150MG/ML</u>	<u>N020246</u>	<u>001</u>	Oct 29, 1992
-----------	-------------------------	-----------------	----------------	------------	--------------

MEDROXYPROGESTERONE ACETATE

AB	AMPHASTAR PHARMS INC	<u>150MG/ML</u>	<u>A077235</u>	<u>001</u>	Nov 28, 2017
AB		<u>150MG/ML</u>	<u>A077334</u>	<u>001</u>	Nov 28, 2017
AB	MYLAN LABS LTD	<u>150MG/ML</u>	<u>A210227</u>	<u>001</u>	Oct 12, 2018
AB	SUN PHARM	<u>150MG/ML</u>	<u>A210760</u>	<u>001</u>	May 01, 2019
AB		<u>150MG/ML</u>	<u>A210761</u>	<u>001</u>	Apr 24, 2019
AB	TEVA PHARMS USA	<u>150MG/ML</u>	<u>A076553</u>	<u>001</u>	Jul 28, 2004

DEPO-PROVERA

+! PHARMACIA AND UPJOHN

400MG/ML

N012541 003

INJECTABLE; SUBCUTANEOUS

DEPO-SUBQ PROVERA 104

+! PHARMACIA AND UPJOHN

104MG/0.65ML

N021583 001 Dec 17, 2004

TABLET; ORAL

MEDROXYPROGESTERONE ACETATE

AB	BARR	<u>2.5MG</u>	<u>A040159</u>	<u>001</u>	Aug 09, 1996
AB		<u>5MG</u>	<u>A040159</u>	<u>002</u>	Aug 09, 1996
AB		<u>10MG</u>	<u>A040159</u>	<u>003</u>	Aug 09, 1996

PROVERA

AB	+ PHARMACIA AND UPJOHN	<u>2.5MG</u>	<u>N011839</u>	<u>001</u>	
-----------	------------------------	--------------	----------------	------------	--

AB	+	<u>5MG</u>	<u>N011839</u>	<u>003</u>	
-----------	---	------------	----------------	------------	--

AB	+!	<u>10MG</u>	<u>N011839</u>	<u>004</u>	
-----------	----	-------------	----------------	------------	--

MEFENAMIC ACID

CAPSULE; ORAL

MEFENAMIC ACID

AB	BELCHER	<u>250MG</u>	<u>A091608</u>	<u>001</u>	Jun 02, 2014
AB	LUPIN LTD	<u>250MG</u>	<u>A091322</u>	<u>001</u>	Jul 22, 2011
AB	MICRO LABS	<u>250MG</u>	<u>A090562</u>	<u>001</u>	Nov 19, 2010
AB	STRIDES PHARMA	<u>250MG</u>	<u>A209209</u>	<u>001</u>	Sep 18, 2020

PONSTEL

AB	+! AVION PHARMS	<u>250MG</u>	<u>N015034</u>	<u>003</u>	
-----------	-----------------	--------------	----------------	------------	--

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

MEFLOQUINE HYDROCHLORIDE

! BARR

250MG

A076392 001 Dec 29, 2003

PRESCRIPTION DRUG PRODUCT LIST

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGACE ES

<u>AB</u>	<u>+!</u>	ENDO PHARMS INC	<u>125MG/ML</u>	<u>N021778</u>	<u>001</u>	Jul 05, 2005
<u>MEGESTROL ACETATE</u>						
<u>AB</u>		AKORN	<u>40MG/ML</u>	<u>A203960</u>	<u>001</u>	Jun 09, 2017
<u>AB</u>		BRECKENRIDGE	<u>125MG/ML</u>	<u>A204688</u>	<u>001</u>	Dec 01, 2017
<u>AB</u>	<u>!</u>	PAR PHARM	<u>40MG/ML</u>	<u>A075671</u>	<u>001</u>	Jul 25, 2001
<u>AB</u>		TWI PHARMS	<u>125MG/ML</u>	<u>A203139</u>	<u>001</u>	Aug 27, 2014
<u>AB</u>		WOCKHARDT BIO AG	<u>40MG/ML</u>	<u>A076721</u>	<u>001</u>	Nov 01, 2004

TABLET; ORAL

MEGESTROL ACETATE

<u>AB</u>		BARR	<u>20MG</u>	<u>A074621</u>	<u>002</u>	Aug 16, 1996
<u>AB</u>			<u>40MG</u>	<u>A074621</u>	<u>001</u>	Nov 30, 1995
<u>AB</u>		PAR PHARM	<u>20MG</u>	<u>A072422</u>	<u>001</u>	Aug 08, 1988
<u>AB</u>	<u>!</u>		<u>40MG</u>	<u>A072423</u>	<u>001</u>	Aug 08, 1988

MELOXICAM

CAPSULE; ORAL

MELOXICAM

		LUPIN LTD	5MG	A209487	001	Jun 01, 2020
	<u>!</u>		10MG	A209487	002	Jun 01, 2020

SOLUTION; INTRAVENOUS

ANJESO

<u>+!</u>	BAUDAX	30MG/ML (30MG/ML)	N210583	001	Feb 20, 2020
-----------	--------	-------------------	---------	-----	--------------

TABLET; ORAL

MELOXICAM

<u>AB</u>		APOTEX INC	<u>7.5MG</u>	<u>A077882</u>	<u>001</u>	Jul 20, 2006
<u>AB</u>			<u>15MG</u>	<u>A077882</u>	<u>002</u>	Jul 20, 2006
<u>AB</u>		AUROBINDO PHARMA	<u>7.5MG</u>	<u>A078008</u>	<u>001</u>	Oct 02, 2006
<u>AB</u>			<u>15MG</u>	<u>A078008</u>	<u>002</u>	Oct 02, 2006
<u>AB</u>		CIPLA	<u>7.5MG</u>	<u>A077929</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>			<u>15MG</u>	<u>A077929</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>		DR REDDYS LABS INC	<u>7.5MG</u>	<u>A077931</u>	<u>001</u>	Jul 25, 2006
<u>AB</u>			<u>15MG</u>	<u>A077931</u>	<u>002</u>	Jul 25, 2006
<u>AB</u>		GLENMARK GENERICS	<u>7.5MG</u>	<u>A077932</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>			<u>15MG</u>	<u>A077932</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>		LUPIN PHARMS	<u>7.5MG</u>	<u>A077944</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>			<u>15MG</u>	<u>A077944</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>		PURACAP PHARM	<u>7.5MG</u>	<u>A077938</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>			<u>15MG</u>	<u>A077938</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>		STRIDES PHARMA	<u>7.5MG</u>	<u>A077928</u>	<u>001</u>	May 13, 2009
<u>AB</u>			<u>15MG</u>	<u>A077928</u>	<u>002</u>	May 13, 2009
<u>AB</u>		TARO	<u>7.5MG</u>	<u>A078102</u>	<u>001</u>	Nov 07, 2006
<u>AB</u>			<u>15MG</u>	<u>A078102</u>	<u>002</u>	Nov 07, 2006
<u>AB</u>		UNICHEM	<u>7.5MG</u>	<u>A077927</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>			<u>15MG</u>	<u>A077927</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>		YUNG SHIN PHARM	<u>7.5MG</u>	<u>A077918</u>	<u>001</u>	Dec 07, 2006
<u>AB</u>			<u>15MG</u>	<u>A077918</u>	<u>002</u>	Dec 07, 2006
<u>AB</u>		ZYDUS PHARMS USA	<u>7.5MG</u>	<u>A077921</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>			<u>15MG</u>	<u>A077921</u>	<u>002</u>	Jul 19, 2006

MOBIC

<u>AB</u>	<u>+</u>	BOEHRINGER INGELHEIM	<u>7.5MG</u>	<u>N020938</u>	<u>001</u>	Apr 13, 2000
<u>AB</u>	<u>+!</u>		<u>15MG</u>	<u>N020938</u>	<u>002</u>	Aug 23, 2000

MELPHALAN

TABLET; ORAL

MELPHALAN

<u>!</u>	ALVOGEN	2MG	A207809	001	Mar 22, 2017
----------	---------	-----	---------	-----	--------------

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

ALKERAN

<u>AP</u>	<u>+</u>	APOTEX	<u>EQ 50MG BASE/VIAL</u>	<u>N020207</u>	<u>001</u>	Nov 18, 1992
-----------	----------	--------	--------------------------	----------------	------------	--------------

MELPHALAN HYDROCHLORIDE

<u>AP</u>		ACTAVIS LLC	<u>EQ 50MG BASE/VIAL</u>	<u>A206018</u>	<u>001</u>	Dec 19, 2016
<u>AP</u>		ALVOGEN	<u>EQ 50MG BASE/VIAL</u>	<u>A204817</u>	<u>001</u>	May 17, 2019
<u>AP</u>		BPI LABS LLC	<u>EQ 50MG BASE/VIAL</u>	<u>A209197</u>	<u>001</u>	May 08, 2020
<u>AP</u>		DR REDDYS LABS LTD	<u>EQ 50MG BASE/VIAL</u>	<u>A203655</u>	<u>001</u>	Dec 08, 2017
<u>AP</u>		FRESENIUS KABI USA	<u>EQ 50MG BASE/VIAL</u>	<u>A203393</u>	<u>001</u>	Dec 22, 2017
<u>AP</u>		GLAND PHARMA LTD	<u>EQ 50MG BASE/VIAL</u>	<u>A209826</u>	<u>001</u>	May 28, 2019
<u>AP</u>		INGENUS PHARMS LLC	<u>EQ 50MG BASE/VIAL</u>	<u>A210947</u>	<u>001</u>	Feb 18, 2020
<u>AP</u>	<u>!</u>	MYLAN INSTITUTIONAL	<u>EQ 50MG BASE/VIAL</u>	<u>A090270</u>	<u>001</u>	Jun 09, 2009

PRESCRIPTION DRUG PRODUCT LIST

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

MELPHALAN HYDROCHLORIDE

<u>AP</u>	SAGENT PHARMS INC	<u>EQ 50MG BASE/VIAL</u>	<u>A201379 001</u>	Feb 28, 2017
<u>AP</u>	WEST-WARD PHARMS INT	<u>EQ 50MG BASE/VIAL</u>	<u>A090303 001</u>	Oct 28, 2010
	POWDER; INTRAVENOUS EVOMELA			
	+! ACROTECH	EQ 50MG BASE/VIAL	N207155 001	Mar 10, 2016

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MEMANTINE HYDROCHLORIDE

<u>AB</u>	AMNEAL PHARMS	<u>7MG</u>	<u>A205825 001</u>	Oct 12, 2016
<u>AB</u>		<u>14MG</u>	<u>A205825 002</u>	Oct 12, 2016
<u>AB</u>		<u>21MG</u>	<u>A205825 003</u>	Oct 12, 2016
<u>AB</u>		<u>28MG</u>	<u>A205825 004</u>	Oct 12, 2016
<u>AB</u>	ANCHEN PHARMS	<u>7MG</u>	<u>A205784 001</u>	Jun 09, 2017
<u>AB</u>		<u>14MG</u>	<u>A205784 002</u>	Jun 09, 2017
<u>AB</u>		<u>21MG</u>	<u>A205784 003</u>	Jun 09, 2017
<u>AB</u>		<u>28MG</u>	<u>A205784 004</u>	Jun 09, 2017
<u>AB</u>	ANI PHARMS INC	<u>7MG</u>	<u>A205365 001</u>	Feb 28, 2020
<u>AB</u>		<u>14MG</u>	<u>A205365 002</u>	Feb 28, 2020
<u>AB</u>		<u>21MG</u>	<u>A205365 003</u>	Feb 28, 2020
<u>AB</u>		<u>28MG</u>	<u>A205365 004</u>	Feb 28, 2020
<u>AB</u>	APOTEX	<u>7MG</u>	<u>A206135 001</u>	Nov 22, 2016
<u>AB</u>		<u>14MG</u>	<u>A206135 002</u>	Nov 22, 2016
<u>AB</u>		<u>21MG</u>	<u>A206135 003</u>	Nov 22, 2016
<u>AB</u>		<u>28MG</u>	<u>A206135 004</u>	Nov 22, 2016
<u>AB</u>	LUPIN LTD	<u>7MG</u>	<u>A206028 001</u>	Sep 28, 2016
<u>AB</u>		<u>14MG</u>	<u>A206028 002</u>	Sep 28, 2016
<u>AB</u>		<u>21MG</u>	<u>A206028 003</u>	Sep 28, 2016
<u>AB</u>		<u>28MG</u>	<u>A206028 004</u>	Sep 28, 2016
<u>AB</u>	MYLAN	<u>7MG</u>	<u>A206032 001</u>	Sep 28, 2016
<u>AB</u>		<u>14MG</u>	<u>A206032 002</u>	Sep 28, 2016
<u>AB</u>		<u>21MG</u>	<u>A206032 003</u>	Sep 28, 2016
<u>AB</u>		<u>28MG</u>	<u>A206032 004</u>	Sep 28, 2016
<u>AB</u>	ZYDUS PHARMS	<u>7MG</u>	<u>A203293 001</u>	Aug 03, 2017
<u>AB</u>		<u>14MG</u>	<u>A203293 002</u>	Aug 03, 2017
<u>AB</u>		<u>21MG</u>	<u>A203293 003</u>	Aug 03, 2017
<u>AB</u>		<u>28MG</u>	<u>A203293 004</u>	Aug 03, 2017
	<u>NAMENDA XR</u>			
<u>AB</u>	+ FOREST LABS LLC	<u>7MG</u>	<u>N022525 001</u>	Jun 21, 2010
<u>AB</u>	+	<u>14MG</u>	<u>N022525 002</u>	Jun 21, 2010
<u>AB</u>	+	<u>21MG</u>	<u>N022525 003</u>	Jun 21, 2010
<u>AB</u>	+!	<u>28MG</u>	<u>N022525 004</u>	Jun 21, 2010

SOLUTION; ORAL

MEMANTINE HYDROCHLORIDE

<u>AA</u>	APOTEX	<u>2MG/ML</u>	<u>A209955 001</u>	Feb 09, 2018
<u>AA</u>	! LANNETT CO INC	<u>2MG/ML</u>	<u>A204033 001</u>	Oct 13, 2015
<u>AA</u>	MACLEODS PHARMS LTD	<u>2MG/ML</u>	<u>A202790 001</u>	Oct 13, 2015
<u>AA</u>	SAPTALIS PHARMS	<u>2MG/ML</u>	<u>A210319 001</u>	Aug 31, 2020

TABLET; ORAL

MEMANTINE HYDROCHLORIDE

<u>AB</u>	AJANTA PHARMA LTD	<u>5MG</u>	<u>A206528 001</u>	Nov 30, 2015
<u>AB</u>		<u>10MG</u>	<u>A206528 002</u>	Nov 30, 2015
<u>AB</u>	ALEMBIC PHARMS LTD	<u>5MG</u>	<u>A200891 001</u>	Oct 13, 2015
<u>AB</u>		<u>10MG</u>	<u>A200891 002</u>	Oct 13, 2015
<u>AB</u>	AMNEAL PHARMS	<u>5MG</u>	<u>A090041 001</u>	Apr 10, 2015
<u>AB</u>		<u>10MG</u>	<u>A090041 002</u>	Apr 10, 2015
<u>AB</u>	AUROBINDO PHARMA LTD	<u>5MG</u>	<u>A203175 001</u>	Oct 13, 2015
<u>AB</u>		<u>10MG</u>	<u>A203175 002</u>	Oct 13, 2015
<u>AB</u>	CADILA	<u>5MG</u>	<u>A090961 001</u>	Jul 10, 2017
<u>AB</u>		<u>10MG</u>	<u>A090961 002</u>	Jul 10, 2017
<u>AB</u>	CELLTRION	<u>5MG</u>	<u>A090073 001</u>	Sep 04, 2015
<u>AB</u>		<u>10MG</u>	<u>A090073 002</u>	Sep 04, 2015
<u>AB</u>	CSPC OUYI	<u>5MG</u>	<u>A209527 001</u>	May 07, 2018
<u>AB</u>		<u>10MG</u>	<u>A209527 002</u>	May 07, 2018
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A090048 001</u>	Apr 14, 2010
<u>AB</u>		<u>10MG</u>	<u>A090048 002</u>	Apr 14, 2010
<u>AB</u>	HIKMA	<u>5MG</u>	<u>A208173 001</u>	Feb 28, 2020
<u>AB</u>		<u>10MG</u>	<u>A208173 002</u>	Feb 28, 2020

PRESCRIPTION DRUG PRODUCT LIST

MEMANTINE HYDROCHLORIDE

TABLET; ORAL

MEMANTINE HYDROCHLORIDE

<u>AB</u>	JUBILANT GENERICS	<u>5MG</u>	<u>A091585 001</u>	Oct 13, 2015
<u>AB</u>		<u>10MG</u>	<u>A091585 002</u>	Oct 13, 2015
<u>AB</u>	LANNETT CO INC	<u>5MG</u>	<u>A207236 001</u>	Nov 10, 2016
<u>AB</u>		<u>10MG</u>	<u>A207236 002</u>	Nov 10, 2016
<u>AB</u>	LUPIN LTD	<u>5MG</u>	<u>A090051 001</u>	Apr 10, 2015
<u>AB</u>		<u>10MG</u>	<u>A090051 002</u>	Apr 10, 2015
<u>AB</u>	MACLEODS PHARMS LTD	<u>5MG</u>	<u>A202840 001</u>	Oct 13, 2015
<u>AB</u>		<u>10MG</u>	<u>A202840 002</u>	Oct 13, 2015
<u>AB</u>	POLYGEN PHARMS	<u>5MG</u>	<u>A210587 001</u>	Dec 11, 2020
<u>AB</u>		<u>10MG</u>	<u>A210587 002</u>	Dec 11, 2020
<u>AB</u>	PURACAP PHARM LLC	<u>5MG</u>	<u>A206855 001</u>	Nov 17, 2015
<u>AB</u>		<u>10MG</u>	<u>A206855 002</u>	Nov 17, 2015
<u>AB</u>	STRIDES PHARMA	<u>5MG</u>	<u>A202350 001</u>	May 23, 2017
<u>AB</u>		<u>10MG</u>	<u>A202350 002</u>	May 23, 2017
<u>AB</u>	SUN PHARM	<u>5MG</u>	<u>A090058 001</u>	May 05, 2010
<u>AB</u>		<u>10MG</u>	<u>A090058 002</u>	May 05, 2010
<u>AB</u>	UNICHEM	<u>5MG</u>	<u>A200022 001</u>	Oct 13, 2015
<u>AB</u>		<u>10MG</u>	<u>A200022 002</u>	Oct 13, 2015
<u>AB</u>	UPSHER SMITH LABS	<u>5MG</u>	<u>A090043 001</u>	Jul 31, 2015
<u>AB</u>		<u>10MG</u>	<u>A090043 002</u>	Jul 31, 2015

NAMENDA

<u>AB</u>	+ ALLERGAN	<u>5MG</u>	<u>N021487 001</u>	Oct 16, 2003
<u>AB</u>	+!	<u>10MG</u>	<u>N021487 002</u>	Oct 16, 2003

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEMEROL

<u>AP</u>	+! HOSPIRA	<u>25MG/ML</u>	<u>N021171 001</u>	
<u>AP</u>	+!	<u>50MG/ML</u>	<u>N021171 002</u>	
<u>AP</u>	+!	<u>75MG/ML</u>	<u>N021171 003</u>	
<u>AP</u>	+!	<u>100MG/ML</u>	<u>N021171 004</u>	

MEPERIDINE HYDROCHLORIDE

<u>AP</u>	WEST-WARD PHARMS INT	<u>25MG/ML</u>	<u>A080445 001</u>	
<u>AP</u>		<u>25MG/ML</u>	<u>A080455 007</u>	
<u>AP</u>		<u>50MG/ML</u>	<u>A080445 002</u>	
<u>AP</u>		<u>50MG/ML</u>	<u>A080455 008</u>	
<u>AP</u>		<u>75MG/ML</u>	<u>A080445 003</u>	
<u>AP</u>		<u>75MG/ML</u>	<u>A080455 009</u>	
<u>AP</u>		<u>100MG/ML</u>	<u>A080445 004</u>	
<u>AP</u>		<u>100MG/ML</u>	<u>A080455 010</u>	

MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

!	WEST-WARD PHARMS INT	10MG/ML	A081002 001	Jul 30, 1993
---	-------------------------	---------	-------------	--------------

SYRUP; ORAL

MEPERIDINE HYDROCHLORIDE

!	HIKMA	50MG/5ML	A088744 001	Jan 30, 1985
---	-------	----------	-------------	--------------

TABLET; ORAL

MEPERIDINE HYDROCHLORIDE

	EPIC PHARMA	50MG	A040331 001	May 28, 1999
		100MG	A040331 002	May 28, 1999

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CARBOCAINE

<u>AP</u>	+! HOSPIRA	<u>1%</u>	<u>N012250 001</u>	
<u>AP</u>	+!	<u>1.5%</u>	<u>N012250 005</u>	
<u>AP</u>	+!	<u>2%</u>	<u>N012250 002</u>	

POLOCAINE

<u>AP</u>	FRESENIUS KABI USA	<u>1%</u>	<u>A089407 001</u>	Dec 01, 1986
<u>AP</u>		<u>2%</u>	<u>A089410 001</u>	Dec 01, 1986

POLOCAINE-MPF

<u>AP</u>	FRESENIUS KABI USA	<u>1%</u>	<u>A089406 001</u>	Dec 01, 1986
<u>AP</u>		<u>1.5%</u>	<u>A089408 001</u>	Dec 01, 1986
<u>AP</u>		<u>2%</u>	<u>A089409 001</u>	Dec 01, 1986

SCANDONEST PLAIN

<u>AP</u>	! DEPROCO	<u>3%</u>	<u>A088387 001</u>	Oct 10, 1984
-----------	-----------	-----------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

<u>AA</u>	ALEMBIC PHARMS LTD	<u>200MG</u>	<u>A090122</u>	<u>001</u>	Feb 18, 2009
<u>AA</u>		<u>400MG</u>	<u>A090122</u>	<u>002</u>	Feb 18, 2009
<u>AA</u>	INVAGEN PHARMS	<u>200MG</u>	<u>A040797</u>	<u>001</u>	Feb 27, 2008
<u>AA</u>		<u>400MG</u>	<u>A040797</u>	<u>002</u>	Feb 27, 2008
<u>AA</u>	! WATSON LABS	<u>200MG</u>	<u>A083304</u>	<u>001</u>	
<u>AA</u>	!	<u>400MG</u>	<u>A083308</u>	<u>001</u>	

MERCAPTOPYRINE

SUSPENSION; ORAL

PURIKAN

+! NOVA LABS LTD 20MG/ML N205919 001 Apr 28, 2014

TABLET; ORAL

MERCAPTOPYRINE

<u>AB</u>	DR REDDYS LABS SA	<u>50MG</u>	<u>A040461</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>	! HIKMA	<u>50MG</u>	<u>A040528</u>	<u>001</u>	Feb 13, 2004
<u>AB</u>	MYLAN	<u>50MG</u>	<u>A040594</u>	<u>001</u>	Jul 01, 2005

PURINETHOL

<u>AB</u>	+ STASON PHARMS	<u>50MG</u>	<u>N009053</u>	<u>002</u>	
-----------	-----------------	-------------	----------------	------------	--

MEROPENEM

INJECTABLE; INJECTION

MEROPENEM

<u>AP</u>	ACS DOBFAR	<u>500MG/VIAL</u>	<u>A091404</u>	<u>001</u>	Oct 26, 2011
<u>AP</u>		<u>1GM/VIAL</u>	<u>A091404</u>	<u>002</u>	Oct 26, 2011
<u>AP</u>	ACS DOBFAR SPA	<u>500MG/VIAL</u>	<u>A204139</u>	<u>001</u>	Jun 09, 2016
<u>AP</u>		<u>1GM/VIAL</u>	<u>A204139</u>	<u>002</u>	Jun 09, 2016
<u>AP</u>	AMNEAL PHARMS	<u>500MG/VIAL</u>	<u>A205883</u>	<u>001</u>	Apr 12, 2016
<u>AP</u>		<u>1GM/VIAL</u>	<u>A205883</u>	<u>002</u>	Apr 12, 2016
<u>AP</u>	AUROBINDO PHARMA LTD	<u>500MG/VIAL</u>	<u>A205835</u>	<u>001</u>	Mar 27, 2017
<u>AP</u>		<u>1GM/VIAL</u>	<u>A205835</u>	<u>002</u>	Mar 27, 2017
<u>AP</u>	DAEWOONG PHARM CO	<u>500MG/VIAL</u>	<u>A204854</u>	<u>001</u>	Dec 18, 2015
<u>AP</u>		<u>1GM/VIAL</u>	<u>A204854</u>	<u>002</u>	Dec 18, 2015
<u>AP</u>	GLAND PHARMA LTD	<u>500MG/VIAL</u>	<u>A206141</u>	<u>001</u>	Jun 08, 2016
<u>AP</u>		<u>1GM/VIAL</u>	<u>A206141</u>	<u>002</u>	Jun 08, 2016
<u>AP</u>	HQ SPCLT PHARMA	<u>500MG/VIAL</u>	<u>A210773</u>	<u>001</u>	Aug 16, 2019
<u>AP</u>		<u>1GM/VIAL</u>	<u>A210773</u>	<u>002</u>	Aug 16, 2019
<u>AP</u>	SAVIOR LIFETEC CORP	<u>500MG/VIAL</u>	<u>A206086</u>	<u>001</u>	Apr 19, 2016
<u>AP</u>		<u>1GM/VIAL</u>	<u>A206086</u>	<u>002</u>	Apr 19, 2016
	<u>MERREM</u>				
<u>AP</u>	+! PFIZER	<u>500MG/VIAL</u>	<u>N050706</u>	<u>003</u>	Jun 21, 1996
<u>AP</u>	+!	<u>1GM/VIAL</u>	<u>N050706</u>	<u>001</u>	Jun 21, 1996

POWDER; INTRAVENOUS

MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER

B BRAUN MEDICAL INC 500MG/VIAL N202106 001 Apr 30, 2015
1GM/VIAL N202106 002 Apr 30, 2015MEROPENEM; VABORBACTAM

POWDER; INTRAVENOUS

VABOMERE

+! REMPEX PHARMS 1GM/VIAL; 1GM/VIAL N209776 001 Aug 29, 2017

MESALAMINE

CAPSULE, DELAYED RELEASE; ORAL

DELZICOL

<u>AB</u>	+! APIL	<u>400MG</u>	<u>N204412</u>	<u>001</u>	Feb 01, 2013
-----------	---------	--------------	----------------	------------	--------------

MESALAMINE

<u>AB</u>	TEVA PHARMS USA	<u>400MG</u>	<u>A207873</u>	<u>001</u>	May 09, 2019
-----------	-----------------	--------------	----------------	------------	--------------

CAPSULE, EXTENDED RELEASE; ORAL

APRISO

<u>AB</u>	+! VALEANT PHARMS INTL	<u>375MG</u>	<u>N022301</u>	<u>001</u>	Oct 31, 2008
-----------	------------------------	--------------	----------------	------------	--------------

MESALAMINE

<u>AB</u>	MYLAN	<u>375MG</u>	<u>A207271</u>	<u>001</u>	Nov 20, 2019
-----------	-------	--------------	----------------	------------	--------------

PENTASA

+ TAKEDA PHARMS USA 250MG N020049 001 May 10, 1993

+! 500MG N020049 002 Jul 08, 2004

ENEMA; RECTAL

MESALAMINE

<u>AB</u>	PERRIGO ISRAEL	<u>4GM/60ML</u>	<u>A076751</u>	<u>001</u>	Sep 17, 2004
-----------	----------------	-----------------	----------------	------------	--------------

ROWASA

<u>AB</u>	+! MYLAN SPECIALITY LP	<u>4GM/60ML</u>	<u>N019618</u>	<u>001</u>	Dec 24, 1987
-----------	------------------------	-----------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

MESALAMINE

ENEMA; RECTAL

SFROWASA

AB + MYLAN SPECIALITY LP **4GM/60ML** **N019618 002** Jun 20, 2008
SUPPOSITORY; RECTAL

CANASA

AB +! ALLERGAN **1GM** **N021252 002** Nov 05, 2004

MESALAMINE

AB ACTAVIS MID **1GM** **A205654 001** Aug 14, 2020
ATLANTIC
AB AMNEAL **1GM** **A210509 001** Jan 02, 2020
AB AMRING PHARMS **1GM** **A208362 001** Jun 21, 2019
AB ANNORA PHARMA **1GM** **A213377 001** Mar 19, 2020
AB MYLAN **1GM** **A204354 001** Nov 24, 2015
AB PHARM SOURCING **1GM** **A207448 001** Apr 19, 2019
AB SANDOZ INC **1GM** **A202065 001** Jun 12, 2019
AB ZYDUS PHARMS **1GM** **A208953 001** Feb 12, 2020

TABLET, DELAYED RELEASE; ORAL

ASACOL HD

AB +! APIL **800MG** **N021830 001** May 29, 2008

LIALDA

AB +! TAKEDA PHARMS USA **1.2GM** **N022000 001** Jan 16, 2007

MESALAMINE

AB ACTAVIS LABS FL **1.2GM** **A203817 001** Mar 23, 2018
AB MYLAN **1.2GM** **A203574 001** Nov 20, 2018
AB SUN PHARM **1.2GM** **A211858 001** Jan 25, 2019
AB ZYDUS PHARMS **800MG** **A203286 001** Jul 21, 2017
AB **1.2GM** **A091640 001** Jun 05, 2017

MESNA

INJECTABLE; INTRAVENOUS

MESNA

AP FRESENIUS KABI USA **100MG/ML** **A075811 001** Apr 26, 2001
AP GLAND PHARMA LTD **100MG/ML** **A206992 001** Dec 18, 2017
AP SAGENT PHARMS INC **100MG/ML** **A090913 001** Apr 13, 2010
AP WEST-WARD PHARMS **100MG/ML** **A075739 001** Jan 09, 2004
INT

MESNEX

AP +! BAXTER HLTHCARE **100MG/ML** **N019884 001** Dec 30, 1988
TABLET; ORAL

MESNEX

+! BAXTER HLTHCARE 400MG N020855 001 Mar 21, 2002

METAPROTERENOL SULFATE

SYRUP; ORAL

METAPROTERENOL SULFATE

! LANNETT CO INC 10MG/5ML A073632 001 Jul 22, 1992

METAXALONE

TABLET; ORAL

METAXALONE

AB ACTAVIS LABS FL INC **800MG** **A203695 001** Jun 15, 2017
AB AMNEAL PHARMS **800MG** **A203399 001** Jun 21, 2013
AB LANNETT CO INC **800MG** **A204770 001** Nov 22, 2016
AB MOUNTAIN **400MG** **A040486 001** Feb 27, 2015
AB RISING **800MG** **A208774 001** Sep 24, 2018
AB SANDOZ **800MG** **A040445 001** Mar 31, 2010
AB SCIEGEN PHARMS INC **400MG** **A207466 002** Mar 13, 2020
AB **800MG** **A207466 001** Aug 31, 2017

SKELAXIN

AB +! KING PHARMS **800MG** **N013217 003** Aug 30, 2002

METFORMIN HYDROCHLORIDE

SOLUTION; ORAL

METFORMIN HYDROCHLORIDE

AB SAPTALIS PHARMS **500MG/5ML** **A211309 001** Mar 03, 2020

RIOMET

AB +! RANBAXY **500MG/5ML** **N021591 001** Sep 11, 2003

TABLET; ORAL

METFORMIN HYDROCHLORIDE

AB ALKEM **500MG** **A091184 001** Nov 01, 2010
AB **850MG** **A091184 002** Nov 01, 2010
AB **1GM** **A091184 003** Nov 01, 2010
AB AMNEAL PHARMS NY **500MG** **A077880 001** Jun 05, 2006
AB **850MG** **A077880 002** Jun 05, 2006

PRESCRIPTION DRUG PRODUCT LISTMETFORMIN HYDROCHLORIDE

TABLET;ORAL

METFORMIN HYDROCHLORIDE

<u>AB</u>		<u>1GM</u>	<u>A077880</u>	<u>003</u>	Jun 05, 2006
<u>AB</u>	APOTEX	<u>500MG</u>	<u>A075984</u>	<u>001</u>	Apr 23, 2002
<u>AB</u>		<u>500MG</u>	<u>A090666</u>	<u>001</u>	Dec 07, 2011
<u>AB</u>		<u>850MG</u>	<u>A075984</u>	<u>002</u>	Apr 23, 2002
<u>AB</u>		<u>850MG</u>	<u>A090666</u>	<u>002</u>	Dec 07, 2011
<u>AB</u>		<u>1GM</u>	<u>A075984</u>	<u>003</u>	Apr 23, 2002
<u>AB</u>		<u>1GM</u>	<u>A090666</u>	<u>003</u>	Dec 07, 2011
<u>AB</u>	ATLAS PHARMS LLC	<u>500MG</u>	<u>A076033</u>	<u>001</u>	Jan 24, 2002
<u>AB</u>		<u>850MG</u>	<u>A076033</u>	<u>002</u>	Jan 24, 2002
<u>AB</u>		<u>1GM</u>	<u>A076033</u>	<u>003</u>	Jan 24, 2002
<u>AB</u>	AUROBINDO	<u>500MG</u>	<u>A077095</u>	<u>001</u>	Jan 14, 2005
<u>AB</u>		<u>850MG</u>	<u>A077095</u>	<u>002</u>	Jan 14, 2005
<u>AB</u>		<u>1GM</u>	<u>A077095</u>	<u>003</u>	Jan 14, 2005
<u>AB</u>	CHARTWELL LIFE SCI	<u>500MG</u>	<u>A075972</u>	<u>001</u>	Jan 24, 2002
<u>AB</u>		<u>850MG</u>	<u>A075972</u>	<u>002</u>	Jan 24, 2002
<u>AB</u>		<u>1GM</u>	<u>A075972</u>	<u>003</u>	Jan 24, 2002
<u>AB</u>	CSPC OUYI	<u>500MG</u>	<u>A205096</u>	<u>001</u>	Jul 11, 2016
<u>AB</u>		<u>850MG</u>	<u>A205096</u>	<u>002</u>	Jul 11, 2016
<u>AB</u>		<u>1GM</u>	<u>A205096</u>	<u>003</u>	Jul 11, 2016
<u>AB</u>	DR REDDYS LABS INC	<u>500MG</u>	<u>A077787</u>	<u>001</u>	Aug 23, 2006
<u>AB</u>		<u>850MG</u>	<u>A077787</u>	<u>002</u>	Aug 23, 2006
<u>AB</u>		<u>1GM</u>	<u>A077787</u>	<u>003</u>	Aug 23, 2006
<u>AB</u>	GLENMARK GENERICS	<u>500MG</u>	<u>A078170</u>	<u>001</u>	May 23, 2008
<u>AB</u>		<u>850MG</u>	<u>A078170</u>	<u>002</u>	May 23, 2008
<u>AB</u>		<u>1GM</u>	<u>A078170</u>	<u>003</u>	May 23, 2008
<u>AB</u>	GRANULES INDIA	<u>500MG</u>	<u>A090564</u>	<u>001</u>	Apr 22, 2010
<u>AB</u>		<u>850MG</u>	<u>A090564</u>	<u>002</u>	Apr 22, 2010
<u>AB</u>	!	<u>1GM</u>	<u>A090564</u>	<u>003</u>	Apr 22, 2010
<u>AB</u>	INDICUS PHARMA	<u>500MG</u>	<u>A079148</u>	<u>001</u>	Nov 25, 2008
<u>AB</u>		<u>850MG</u>	<u>A079148</u>	<u>002</u>	Nov 25, 2008
<u>AB</u>		<u>1GM</u>	<u>A079148</u>	<u>003</u>	Nov 25, 2008
<u>AB</u>	LAURUS LABS LTD	<u>500MG</u>	<u>A209882</u>	<u>001</u>	Aug 27, 2018
<u>AB</u>		<u>850MG</u>	<u>A209882</u>	<u>002</u>	Aug 27, 2018
<u>AB</u>		<u>1GM</u>	<u>A209882</u>	<u>003</u>	Aug 27, 2018
<u>AB</u>	MARKSANS PHARMA	<u>500MG</u>	<u>A090888</u>	<u>001</u>	Mar 12, 2012
<u>AB</u>		<u>850MG</u>	<u>A090888</u>	<u>002</u>	Mar 12, 2012
<u>AB</u>		<u>1GM</u>	<u>A090888</u>	<u>003</u>	Mar 12, 2012
<u>AB</u>	MYLAN	<u>500MG</u>	<u>A075973</u>	<u>001</u>	Jan 25, 2002
<u>AB</u>		<u>850MG</u>	<u>A075973</u>	<u>002</u>	Jan 25, 2002
<u>AB</u>		<u>1GM</u>	<u>A075973</u>	<u>003</u>	Jan 25, 2002
<u>AB</u>	SANDOZ	<u>500MG</u>	<u>A075965</u>	<u>001</u>	Jan 25, 2002
<u>AB</u>		<u>850MG</u>	<u>A075965</u>	<u>002</u>	Jan 25, 2002
<u>AB</u>		<u>1GM</u>	<u>A075965</u>	<u>003</u>	Jan 25, 2002
<u>AB</u>	SCIEGEN PHARMS INC	<u>500MG</u>	<u>A203769</u>	<u>001</u>	Sep 11, 2013
<u>AB</u>		<u>850MG</u>	<u>A203769</u>	<u>002</u>	Sep 11, 2013
<u>AB</u>		<u>1GM</u>	<u>A203769</u>	<u>003</u>	Sep 11, 2013
<u>AB</u>	SUN PHARM INDS INC	<u>500MG</u>	<u>A075967</u>	<u>001</u>	Jan 29, 2002
<u>AB</u>		<u>850MG</u>	<u>A075967</u>	<u>002</u>	Jan 29, 2002
<u>AB</u>		<u>1GM</u>	<u>A075967</u>	<u>003</u>	Jan 29, 2002
<u>AB</u>	ZYDUS HLTHCARE	<u>500MG</u>	<u>A203686</u>	<u>001</u>	Aug 28, 2014
<u>AB</u>		<u>850MG</u>	<u>A203686</u>	<u>002</u>	Aug 28, 2014
<u>AB</u>		<u>1GM</u>	<u>A203686</u>	<u>003</u>	Aug 28, 2014
<u>AB</u>	ZYDUS PHARMS USA	<u>500MG</u>	<u>A077064</u>	<u>001</u>	Apr 18, 2005
<u>AB</u>		<u>850MG</u>	<u>A077064</u>	<u>002</u>	Apr 18, 2005
<u>AB</u>		<u>1GM</u>	<u>A077064</u>	<u>003</u>	Apr 18, 2005
	CHARTWELL LIFE SCI	625MG	A075972	005	Jan 24, 2002
		750MG	A075972	004	Jan 24, 2002

TABLET, EXTENDED RELEASE;ORAL

METFORMIN HYDROCHLORIDE

<u>AB</u>	ACTAVIS LABS FL INC	<u>750MG</u>	<u>A076869</u>	<u>001</u>	Apr 12, 2005
<u>AB</u>	ALKEM LABS LTD	<u>750MG</u>	<u>A206145</u>	<u>002</u>	Oct 22, 2018
<u>AB</u>	!	<u>750MG</u>	<u>A078596</u>	<u>002</u>	Jan 03, 2008
<u>AB</u>	AUROBINDO PHARMA LTD	<u>750MG</u>	<u>A079118</u>	<u>002</u>	Jul 20, 2012
<u>AB</u>	BEXIMCO PHARMS USA	<u>750MG</u>	<u>A207427</u>	<u>002</u>	Dec 13, 2016
<u>AB</u>	CADILA	<u>750MG</u>	<u>A077078</u>	<u>001</u>	Apr 21, 2005
<u>AB</u>	CSPC OUYI	<u>750MG</u>	<u>A078321</u>	<u>002</u>	Apr 17, 2008
<u>AB</u>	GRANULES	<u>750MG</u>	<u>A209313</u>	<u>002</u>	Mar 16, 2018
<u>AB</u>	INTELLIPHARMACEUTIC S	<u>750MG</u>	<u>A202306</u>	<u>002</u>	Feb 23, 2017

PRESCRIPTION DRUG PRODUCT LISTMETFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

METFORMIN HYDROCHLORIDE

<u>AB</u>	MACLEODS PHARMS LTD	<u>750MG</u>	<u>A206955</u>	<u>002</u>	Dec 07, 2016
<u>AB</u>	MARKSANS PHARMA	<u>750MG</u>	<u>A090295</u>	<u>002</u>	Apr 29, 2016
<u>AB</u>	NOSTRUM PHARMS LLC	<u>750MG</u>	<u>A076756</u>	<u>002</u>	Dec 12, 2011
<u>AB</u>	PRINSTON INC	<u>750MG</u>	<u>A208880</u>	<u>002</u>	Sep 10, 2018
<u>AB</u>	SUN PHARM INDS (IN)	<u>750MG</u>	<u>A077336</u>	<u>002</u>	Feb 09, 2006
<u>AB</u>	TEVA	<u>750MG</u>	<u>A076864</u>	<u>001</u>	Apr 12, 2005
<u>AB</u>	YICHANG HUMANWELL	<u>750MG</u>	<u>A211052</u>	<u>002</u>	Sep 24, 2018
<u>AB1</u>	ALIGNSCIENCE PHARMA	<u>500MG</u>	<u>A209303</u>	<u>001</u>	Mar 19, 2018
<u>AB1</u>	ALKEM LABS LTD	<u>500MG</u>	<u>A206145</u>	<u>001</u>	Oct 22, 2018
<u>AB1</u>	AMNEAL PHARMS NY	<u>500MG</u>	<u>A078596</u>	<u>001</u>	Jan 03, 2008
<u>AB1</u>	APOTEX	<u>500MG</u>	<u>A076706</u>	<u>001</u>	Dec 14, 2004
<u>AB1</u>	AUROBINDO PHARMA LTD	<u>500MG</u>	<u>A079118</u>	<u>001</u>	Jul 20, 2012
<u>AB1</u>	BEXIMCO PHARMS USA	<u>500MG</u>	<u>A207427</u>	<u>001</u>	Dec 13, 2016
<u>AB1</u>	CADILA	<u>500MG</u>	<u>A077060</u>	<u>001</u>	Apr 20, 2005
<u>AB1</u>	CSEC OUYI	<u>500MG</u>	<u>A078321</u>	<u>001</u>	Apr 17, 2008
<u>AB1</u>	GRANULES	<u>500MG</u>	<u>A209313</u>	<u>001</u>	Mar 16, 2018
<u>AB1</u>	INTELLIPHARMACEUTIC S	<u>500MG</u>	<u>A202306</u>	<u>001</u>	Feb 23, 2017
<u>AB1</u>	INVENTIA	<u>500MG</u>	<u>A201991</u>	<u>001</u>	Jan 18, 2012
<u>AB1</u>	MACLEODS PHARMS LTD	<u>500MG</u>	<u>A206955</u>	<u>001</u>	Dec 07, 2016
<u>AB1</u>	MARKSANS PHARMA	<u>500MG</u>	<u>A090295</u>	<u>001</u>	Apr 29, 2016
<u>AB1</u>	NOSTRUM PHARMS LLC	<u>500MG</u>	<u>A076756</u>	<u>001</u>	Jul 26, 2006
<u>AB1</u>	PRINSTON INC	<u>500MG</u>	<u>A208880</u>	<u>001</u>	Sep 10, 2018
<u>AB1</u>	SANDOZ	<u>500MG</u>	<u>A076873</u>	<u>001</u>	Dec 14, 2004
<u>AB1</u>	SUN PHARM INDS (IN)	<u>500MG</u>	<u>A077336</u>	<u>001</u>	Feb 09, 2006
<u>AB1</u>	TEVA	<u>500MG</u>	<u>A076269</u>	<u>001</u>	Jun 18, 2004
<u>AB1</u>	YICHANG HUMANWELL	<u>500MG</u>	<u>A211052</u>	<u>001</u>	Sep 24, 2018

FORTAMET

<u>AB2</u>	+ ANDRX LABS LLC	<u>1GM</u>	<u>N021574</u>	<u>002</u>	Apr 27, 2004
------------	------------------	------------	----------------	------------	--------------

METFORMIN HYDROCHLORIDE

<u>AB2</u>	AJANTA PHARMA LTD	<u>500MG</u>	<u>A213651</u>	<u>001</u>	Apr 09, 2020
<u>AB2</u>		<u>1GM</u>	<u>A213651</u>	<u>002</u>	Apr 09, 2020
<u>AB2</u>	LUPIN LTD	<u>500MG</u>	<u>A090692</u>	<u>001</u>	Jun 29, 2011
<u>AB2</u>	!	<u>1GM</u>	<u>A090692</u>	<u>002</u>	Jun 29, 2011
<u>AB2</u>	MYLAN PHARMS INC	<u>500MG</u>	<u>A200690</u>	<u>001</u>	Aug 01, 2012
<u>AB2</u>		<u>1GM</u>	<u>A200690</u>	<u>002</u>	Aug 01, 2012
<u>AB2</u>	NOSTRUM LABS INC	<u>500MG</u>	<u>A203832</u>	<u>001</u>	Dec 26, 2017
<u>AB2</u>		<u>1GM</u>	<u>A203832</u>	<u>002</u>	Dec 26, 2017
<u>AB2</u>	NOVAST LABS	<u>500MG</u>	<u>A209674</u>	<u>001</u>	Nov 02, 2018
<u>AB2</u>		<u>1GM</u>	<u>A209674</u>	<u>002</u>	Nov 02, 2018
<u>AB2</u>	QINGDAO BAHEAL PHARM	<u>500MG</u>	<u>A209993</u>	<u>001</u>	Dec 27, 2018
<u>AB2</u>		<u>1GM</u>	<u>A209993</u>	<u>002</u>	Dec 27, 2018

GLUMETZA

<u>AB3</u>	+ SANTARUS INC	<u>500MG</u>	<u>N021748</u>	<u>001</u>	Jun 03, 2005
<u>AB3</u>	+	<u>1GM</u>	<u>N021748</u>	<u>002</u>	Jun 03, 2005

METFORMIN HYDROCHLORIDE

<u>AB3</u>	ACTAVIS LABS FL INC	<u>500MG</u>	<u>A203755</u>	<u>001</u>	Aug 01, 2016
<u>AB3</u>		<u>1GM</u>	<u>A203755</u>	<u>002</u>	Aug 01, 2016
<u>AB3</u>	GLENMARK PHARMS LTD	<u>500MG</u>	<u>A212969</u>	<u>001</u>	Nov 25, 2019
<u>AB3</u>		<u>1GM</u>	<u>A212969</u>	<u>002</u>	Nov 25, 2019
<u>AB3</u>	LUPIN LTD	<u>500MG</u>	<u>A091664</u>	<u>001</u>	Jul 19, 2013
<u>AB3</u>		<u>1GM</u>	<u>A091664</u>	<u>002</u>	Jul 19, 2013
<u>AB3</u>	SUN PHARM	<u>500MG</u>	<u>A202917</u>	<u>001</u>	Aug 01, 2016
<u>AB3</u>		<u>1GM</u>	<u>A202917</u>	<u>002</u>	Aug 01, 2016

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

ACTOPLUS MET

<u>AB</u>	+ TAKEDA PHARMS USA	<u>500MG;EQ 15MG BASE</u>	<u>N021842</u>	<u>001</u>	Aug 29, 2005
<u>AB</u>	+	<u>850MG;EQ 15MG BASE</u>	<u>N021842</u>	<u>002</u>	Aug 29, 2005

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

<u>AB</u>	AUROBINDO PHARMA LTD	<u>500MG;EQ 15MG BASE</u>	<u>A200823</u>	<u>001</u>	Feb 13, 2013
<u>AB</u>		<u>850MG;EQ 15MG BASE</u>	<u>A200823</u>	<u>002</u>	Feb 13, 2013
<u>AB</u>	MACLEODS PHARMS LTD	<u>500MG;EQ 15MG BASE</u>	<u>A204802</u>	<u>001</u>	Nov 05, 2015
<u>AB</u>		<u>850MG;EQ 15MG BASE</u>	<u>A204802</u>	<u>002</u>	Nov 05, 2015
<u>AB</u>	SANDOZ	<u>500MG;EQ 15MG BASE</u>	<u>A091273</u>	<u>001</u>	Apr 16, 2013
<u>AB</u>		<u>850MG;EQ 15MG BASE</u>	<u>A091273</u>	<u>002</u>	Apr 16, 2013
<u>AB</u>	TEVA PHARMS USA	<u>500MG;EQ 15MG BASE</u>	<u>A091155</u>	<u>001</u>	Mar 10, 2014

PRESCRIPTION DRUG PRODUCT LIST

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

<u>AB</u>		<u>850MG;EQ 15MG BASE</u>	<u>A091155 002</u>	Mar 10, 2014
<u>AB</u>	TORRENT PHARMS LTD	<u>500MG;EQ 15MG BASE</u>	<u>A202001 001</u>	Feb 13, 2013
<u>AB</u>		<u>850MG;EQ 15MG BASE</u>	<u>A202001 002</u>	Feb 13, 2013

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

KOMBIGLYZE XR

+	ASTRAZENECA AB	500MG;EQ 5MG BASE	N200678 001	Nov 05, 2010
+		1GM;EQ 2.5MG BASE	N200678 003	Nov 05, 2010
+	!	1GM;EQ 5MG BASE	N200678 002	Nov 05, 2010

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET;ORAL

JANUMET

+	MERCK SHARP DOHME	500MG;EQ 50MG BASE	N022044 001	Mar 30, 2007
+	!	1GM;EQ 50MG BASE	N022044 002	Mar 30, 2007

TABLET, EXTENDED RELEASE;ORAL

JANUMET XR

+	MERCK SHARP DOHME	500MG;EQ 50MG BASE	N202270 001	Feb 02, 2012
+		1GM;EQ 50MG BASE	N202270 002	Feb 02, 2012
+	!	1GM;EQ 100MG BASE	N202270 003	Feb 02, 2012

METHACHOLINE CHLORIDE

FOR SOLUTION;INHALATION

PROVOCHOLINE

+	METHAPHARM	100MG/VIAL	N019193 001	Oct 31, 1986
---	------------	------------	-------------	--------------

METHADONE HYDROCHLORIDE

CONCENTRATE;ORAL

METHADONE HYDROCHLORIDE

<u>AA</u>	HIKMA	<u>10MG/ML</u>	<u>A040180 001</u>	Apr 30, 1998
<u>AA</u>	LANNETT CO INC	<u>10MG/ML</u>	<u>A212093 001</u>	Nov 02, 2020
<u>AA</u>	SPECGX LLC	<u>10MG/ML</u>	<u>A207368 001</u>	Aug 22, 2019
<u>AA</u>	VISTAPHARM	<u>10MG/ML</u>	<u>A040088 001</u>	Nov 30, 1994

METHADONE HYDROCHLORIDE INTENSOL

<u>AA</u>	HIKMA	<u>10MG/ML</u>	<u>A089897 001</u>	Sep 06, 1988
-----------	-------	----------------	--------------------	--------------

METHADOSE

<u>AA</u>	+	SPECGX LLC	<u>10MG/ML</u>	<u>N017116 002</u>
-----------	---	------------	----------------	--------------------

INJECTABLE;INJECTION

METHADONE HYDROCHLORIDE

<u>AP</u>	AKORN	<u>10MG/ML</u>	<u>A208306 001</u>	Oct 27, 2017
<u>AP</u>	+	MYLAN INSTITUTIONAL	<u>10MG/ML</u>	<u>N021624 001</u>

SOLUTION;ORAL

METHADONE HYDROCHLORIDE

<u>AA</u>	!	HIKMA	<u>5MG/5ML</u>	<u>A087393 001</u>
<u>AA</u>	!		<u>10MG/5ML</u>	<u>A087997 001</u>
<u>AA</u>		SPECGX LLC	<u>5MG/5ML</u>	<u>A207537 001</u>
<u>AA</u>			<u>10MG/5ML</u>	<u>A207537 002</u>
<u>AA</u>		VISTAPHARM	<u>5MG/5ML</u>	<u>A090707 001</u>
<u>AA</u>			<u>10MG/5ML</u>	<u>A090707 002</u>

TABLET;ORAL

METHADONE HYDROCHLORIDE

<u>AA</u>	ASCENT PHARMS INC	<u>5MG</u>	<u>A211228 001</u>	Jan 03, 2019
<u>AA</u>		<u>10MG</u>	<u>A211228 002</u>	Jan 03, 2019
<u>AA</u>	AUROLIFE PHARMA LLC	<u>5MG</u>	<u>A203502 001</u>	Aug 31, 2015
<u>AA</u>		<u>10MG</u>	<u>A203502 002</u>	Aug 31, 2015
<u>AA</u>	EPIC PHARMA LLC	<u>5MG</u>	<u>A090065 001</u>	Aug 18, 2015
<u>AA</u>		<u>10MG</u>	<u>A090065 002</u>	Aug 18, 2015
<u>AA</u>	NOSTRUM LABS INC	<u>5MG</u>	<u>A210484 001</u>	Aug 02, 2018
<u>AA</u>		<u>10MG</u>	<u>A210484 002</u>	Aug 02, 2018
<u>AA</u>	ROXANE	<u>5MG</u>	<u>A088108 001</u>	Mar 08, 1983
<u>AA</u>		<u>10MG</u>	<u>A088109 001</u>	Mar 08, 1983
<u>AA</u>	!	SPECGX LLC	<u>5MG</u>	<u>A040517 001</u>
<u>AA</u>	!		<u>10MG</u>	<u>A040517 002</u>
<u>AA</u>	SUN PHARM INDUSTRIES	<u>5MG</u>	<u>A208305 001</u>	Mar 30, 2018
<u>AA</u>		<u>10MG</u>	<u>A208305 002</u>	Mar 30, 2018
<u>AA</u>	THEPHARMANETWORK LLC	<u>5MG</u>	<u>A090635 002</u>	Sep 22, 2020
<u>AA</u>		<u>10MG</u>	<u>A090635 001</u>	Nov 25, 2009
<u>AA</u>	VISTAPHARM	<u>10MG</u>	<u>A040241 002</u>	May 29, 1998
<u>AA</u>		<u>10MG</u>	<u>A204166 001</u>	Mar 16, 2020

PRESCRIPTION DRUG PRODUCT LISTMETHADONE HYDROCHLORIDE

TABLET, FOR SUSPENSION;ORAL

METHADONE HYDROCHLORIDE

<u>AA</u>	+	HIKMA	<u>40MG</u>	<u>N017058</u>	<u>001</u>	
<u>AA</u>		SPECGX LLC	<u>40MG</u>	<u>A077142</u>	<u>001</u>	Jul 12, 2005
<u>AA</u>		VISTAPHARM	<u>40MG</u>	<u>A075082</u>	<u>001</u>	Mar 25, 1998

METHADOSE

<u>AA</u>		SPECGX LLC	<u>40MG</u>	<u>A074184</u>	<u>001</u>	Apr 29, 1993
-----------	--	------------	-------------	----------------	------------	--------------

METHAMPHETAMINE HYDROCHLORIDE

TABLET;ORAL

DESOXYN

<u>AA</u>	+	RECORDATI RARE	<u>5MG</u>	<u>N005378</u>	<u>002</u>	
-----------	---	----------------	------------	----------------	------------	--

METHAMPHETAMINE HYDROCHLORIDE

<u>AA</u>		HIKMA	<u>5MG</u>	<u>A203846</u>	<u>001</u>	Nov 17, 2015
<u>AA</u>		MAYNE PHARMA INC	<u>5MG</u>	<u>A091189</u>	<u>001</u>	Apr 21, 2010

METHAZOLAMIDE

TABLET;ORAL

METHAZOLAMIDE

<u>AB</u>		ANI PHARMS INC	<u>25MG</u>	<u>A040001</u>	<u>001</u>	Jun 30, 1993
<u>AB</u>			<u>50MG</u>	<u>A040001</u>	<u>002</u>	Jun 30, 1993
<u>AB</u>		BAUSCH	<u>25MG</u>	<u>A207438</u>	<u>001</u>	Oct 05, 2018
<u>AB</u>			<u>50MG</u>	<u>A207438</u>	<u>002</u>	Oct 05, 2018
<u>AB</u>		MIKART	<u>25MG</u>	<u>A040062</u>	<u>001</u>	Jan 27, 1994
<u>AB</u>	!		<u>50MG</u>	<u>A040062</u>	<u>002</u>	Jan 27, 1994
<u>AB</u>		SANDOZ	<u>25MG</u>	<u>A040036</u>	<u>001</u>	Jun 30, 1993
<u>AB</u>			<u>50MG</u>	<u>A040036</u>	<u>002</u>	Jun 30, 1993

METHENAMINE HIPPURATE

TABLET;ORAL

HIPREX

<u>AB</u>	+	US PHARM HOLDINGS	<u>1GM</u>	<u>N017681</u>	<u>001</u>	
-----------	---	-------------------	------------	----------------	------------	--

METHENAMINE HIPPURATE

<u>AB</u>		AUROBINDO PHARMA LTD	<u>1GM</u>	<u>A205661</u>	<u>001</u>	Jul 05, 2016
<u>AB</u>		MICRO LABS	<u>1GM</u>	<u>A212172</u>	<u>001</u>	Aug 01, 2019
<u>AB</u>		RICONPHARMA LLC	<u>1GM</u>	<u>A210068</u>	<u>001</u>	Nov 27, 2020

UREX

<u>AB</u>		CNTY LINE PHARMS	<u>1GM</u>	<u>N016151</u>	<u>001</u>	
-----------	--	------------------	------------	----------------	------------	--

METHIMAZOLE

TABLET;ORAL

METHIMAZOLE

<u>AB</u>		CHARTWELL RX	<u>5MG</u>	<u>A040411</u>	<u>001</u>	Mar 27, 2001
<u>AB</u>			<u>10MG</u>	<u>A040411</u>	<u>002</u>	Mar 27, 2001
<u>AB</u>		DISCOVERY THERAP	<u>5MG</u>	<u>A040547</u>	<u>001</u>	Feb 18, 2005
<u>AB</u>			<u>10MG</u>	<u>A040547</u>	<u>002</u>	Feb 18, 2005
<u>AB</u>		HERITAGE PHARMA	<u>5MG</u>	<u>A040734</u>	<u>001</u>	Dec 14, 2007
<u>AB</u>			<u>10MG</u>	<u>A040734</u>	<u>002</u>	Dec 14, 2007
<u>AB</u>		MYLAN	<u>5MG</u>	<u>A040350</u>	<u>001</u>	Mar 29, 2000
<u>AB</u>	!		<u>10MG</u>	<u>A040350</u>	<u>002</u>	Mar 29, 2000
<u>AB</u>		RISING	<u>5MG</u>	<u>A202068</u>	<u>001</u>	Mar 07, 2012
<u>AB</u>			<u>10MG</u>	<u>A202068</u>	<u>002</u>	Mar 07, 2012

TAPAZOLE

<u>AB</u>		KING PHARMS LLC	<u>5MG</u>	<u>A040320</u>	<u>001</u>	Mar 31, 2000
<u>AB</u>			<u>10MG</u>	<u>A040320</u>	<u>002</u>	Mar 31, 2000

METHOCARBAMOL

SOLUTION;IM-IV

METHOCARBAMOL

<u>AP</u>		AM REGENT	<u>1GM/10ML (100MG/ML)</u>	<u>A207496</u>	<u>001</u>	Jun 22, 2017
<u>AP</u>		AUROBINDO PHARMA LTD	<u>1GM/10ML (100MG/ML)</u>	<u>A206128</u>	<u>001</u>	May 27, 2016
<u>AP</u>		FRESENIUS KABI USA	<u>1GM/10ML (100MG/ML)</u>	<u>A209331</u>	<u>001</u>	Apr 17, 2018
<u>AP</u>		GLAND PHARMA LTD	<u>1GM/10ML (100MG/ML)</u>	<u>A211504</u>	<u>001</u>	Oct 26, 2018
<u>AP</u>		MONTEREY PHARMS LLC	<u>1GM/10ML (100MG/ML)</u>	<u>A205354</u>	<u>001</u>	Oct 27, 2016
<u>AP</u>		MYLAN INSTITUTIONAL	<u>1GM/10ML (100MG/ML)</u>	<u>A204404</u>	<u>001</u>	Dec 05, 2014
<u>AP</u>		NAVINTA LLC	<u>1GM/10ML (100MG/ML)</u>	<u>A206071</u>	<u>001</u>	Nov 24, 2017
<u>AP</u>		SAGENT PHARMS INC	<u>1GM/10ML (100MG/ML)</u>	<u>A205404</u>	<u>001</u>	Jul 18, 2017
<u>AP</u>		SLATE	<u>1GM/10ML (100MG/ML)</u>	<u>A208116</u>	<u>001</u>	Jan 19, 2017
<u>AP</u>		SOMERSET THERAPS LLC	<u>1GM/10ML (100MG/ML)</u>	<u>A207522</u>	<u>001</u>	Jul 31, 2017

ROBAXIN

<u>AP</u>	+	HIKMA	<u>1GM/10ML (100MG/ML)</u>	<u>N011790</u>	<u>001</u>	
-----------	---	-------	----------------------------	----------------	------------	--

PRESCRIPTION DRUG PRODUCT LIST

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

<u>AA</u>	AUROBINDO PHARMA LTD	<u>750MG</u>	<u>A213967</u>	<u>001</u>	Aug 12, 2020
<u>AA</u>	AUSTARPHARMA LLC	<u>500MG</u>	<u>A200958</u>	<u>001</u>	Oct 21, 2011
<u>AA</u>		<u>750MG</u>	<u>A200958</u>	<u>002</u>	Oct 21, 2011
<u>AA</u>	BEXIMCO PHARMS USA	<u>500MG</u>	<u>A208507</u>	<u>001</u>	Jul 21, 2017
<u>AA</u>		<u>750MG</u>	<u>A208507</u>	<u>002</u>	Jul 21, 2017
<u>AA</u>	DBL PHARMS	<u>500MG</u>	<u>A203550</u>	<u>001</u>	Feb 08, 2017
<u>AA</u>		<u>750MG</u>	<u>A203550</u>	<u>002</u>	Feb 08, 2017
<u>AA</u>	! GRANULES	<u>500MG</u>	<u>A209312</u>	<u>001</u>	May 07, 2018
<u>AA</u>	!	<u>750MG</u>	<u>A209312</u>	<u>002</u>	May 07, 2018
<u>AA</u>	HETERO LABS LTD III	<u>500MG</u>	<u>A090200</u>	<u>001</u>	Nov 06, 2009
<u>AA</u>		<u>750MG</u>	<u>A090200</u>	<u>002</u>	Nov 06, 2009
<u>AA</u>	OXFORD PHARMS	<u>500MG</u>	<u>A040489</u>	<u>001</u>	Jan 29, 2003
<u>AA</u>		<u>750MG</u>	<u>A040489</u>	<u>002</u>	Jan 29, 2003
<u>AA</u>	PRINSTON INC	<u>500MG</u>	<u>A086989</u>	<u>001</u>	
<u>AA</u>		<u>750MG</u>	<u>A086989</u>	<u>001</u>	

METHOHEXITAL SODIUM

INJECTABLE; INJECTION

BREVITAL SODIUM

+	!	PAR STERILE PRODUCTS	500MG/VIAL	N011559	001	
---	---	----------------------	------------	---------	-----	--

METHOTREXATE

SOLUTION; SUBCUTANEOUS

OTREXUP

+	!	ANTARES PHARMA INC	10MG/0.4ML (10MG/0.4ML)	N204824	001	Oct 11, 2013
+	!		12.5MG/0.4ML (12.5MG/0.4ML)	N204824	006	Mar 24, 2016
+	!		15MG/0.4ML (15MG/0.4ML)	N204824	002	Oct 11, 2013
+	!		17.5MG/0.4ML (17.5MG/0.4ML)	N204824	007	Mar 24, 2016
+	!		20MG/0.4ML (20MG/0.4ML)	N204824	003	Oct 11, 2013
+	!		22.5MG/0.4ML (22.5MG/0.4ML)	N204824	008	Mar 24, 2016
+	!		25MG/0.4ML (25MG/0.4ML)	N204824	004	Oct 11, 2013

RASUVO

+	!	MEDEXUS	7.5MG/0.15ML (7.5MG/0.15ML)	N205776	001	Jul 10, 2014
+	!		10MG/0.20ML (10MG/0.20ML)	N205776	002	Jul 10, 2014
+	!		12.5MG/0.25ML (12.5MG/0.25ML)	N205776	003	Jul 10, 2014
+	!		15MG/0.30ML (15MG/0.30ML)	N205776	004	Jul 10, 2014
+	!		17.5MG/0.35ML (17.5MG/0.35ML)	N205776	005	Jul 10, 2014
+	!		20MG/0.4ML (20MG/0.4ML)	N205776	006	Jul 10, 2014
+	!		22.5MG/0.45ML (22.5MG/0.45ML)	N205776	007	Jul 10, 2014
+	!		25MG/0.5ML (25MG/0.5ML)	N205776	008	Jul 10, 2014
+	!		30MG/0.6ML (30MG/0.6ML)	N205776	010	Jul 10, 2014

REDITREX

+	!	CUMBERLAND PHARMS	7.5MG/0.3ML (7.5MG/0.3ML)	N210737	001	Nov 27, 2019
+	!		10MG/0.4ML (10MG/0.4ML)	N210737	002	Nov 27, 2019
+	!		12.5MG/0.5ML (12.5MG/0.5ML)	N210737	003	Nov 27, 2019
+	!		15MG/0.6ML (15MG/0.6ML)	N210737	004	Nov 27, 2019
+	!		17.5MG/0.7ML (17.5MG/0.7ML)	N210737	005	Nov 27, 2019
+	!		20MG/0.8ML (20MG/0.8ML)	N210737	006	Nov 27, 2019
+	!		22.5MG/ML (22.5MG/ML)	N210737	007	Nov 27, 2019
+	!		25MG/1ML (25MG/1ML)	N210737	008	Nov 27, 2019

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE PRESERVATIVE FREE

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 25MG BASE/ML</u>	<u>A040265</u>	<u>001</u>	Feb 26, 1999
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A040266</u>	<u>001</u>	Feb 26, 1999

METHOTREXATE SODIUM

<u>AP</u>	! FRESENIUS KABI USA	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A040263</u>	<u>001</u>	Feb 26, 1999
<u>AP</u>	+! HOSPIRA	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>N011719</u>	<u>010</u>	Dec 15, 2004
<u>AP</u>	! WEST-WARD PHARMS INT	<u>EQ 100MG BASE/4ML (EQ 25MG BASE/ML)</u>	<u>A089341</u>	<u>001</u>	Sep 16, 1986

METHOTREXATE SODIUM PRESERVATIVE FREE

<u>AP</u>	! ACCORD HLTHCARE	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A040767</u>	<u>001</u>	Apr 30, 2007
<u>AP</u>	!	<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A040768</u>	<u>001</u>	Apr 30, 2007
<u>AP</u>	!	<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>A040716</u>	<u>001</u>	Apr 30, 2007
<u>AP</u>	+! HOSPIRA	<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>N011719</u>	<u>012</u>	Apr 13, 2005
<u>AP</u>	MYLAN LABS LTD	<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A201529</u>	<u>004</u>	Mar 29, 2012
<u>AP</u>		<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>A201530</u>	<u>001</u>	Mar 29, 2012
<u>AP</u>	PHARMACHEMIE BV	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A040843</u>	<u>002</u>	Jan 11, 2010

PRESCRIPTION DRUG PRODUCT LIST

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE SODIUM PRESERVATIVE FREE

<u>AP</u>		<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A040843 004</u>	Jan 11, 2010
<u>AP</u>		<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>A040843 001</u>	Jan 11, 2010
<u>AP</u>	SAGENT PHARMS INC	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A203407 001</u>	Aug 09, 2018
<u>AP</u>		<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A203407 002</u>	Aug 09, 2018
<u>AP</u>		<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>A203407 003</u>	Aug 09, 2018
<u>AP</u>	SANDOZ INC	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A090039 001</u>	Mar 31, 2009
<u>AP</u>		<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A090039 002</u>	Mar 31, 2009
<u>AP</u>		<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>A090029 001</u>	Mar 31, 2009
<u>AP</u>	! WEST-WARD PHARMS INT	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A089340 001</u>	Sep 16, 1986
<u>AP</u>	! WEST-WARD PHARMS INT	<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A089343 001</u>	Sep 16, 1986
	METHOTREXATE SODIUM ! WEST-WARD PHARMS INT	EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A089342 001	Sep 16, 1986
	METHOTREXATE SODIUM PRESERVATIVE FREE PHARMACHEMIE BV	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A040843 003	Feb 27, 2012
	! WEST-WARD PHARMS INT	EQ 1GM BASE/VIAL	A040632 001	Aug 12, 2005

SOLUTION; ORAL

XATMEP

+! AZURITY

EQ 2.5MG BASE/ML

N208400 001 Apr 25, 2017

TABLET; ORAL

METHOTREXATE SODIUM

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 2.5MG BASE</u>	<u>A213343 001</u>	Jan 24, 2020
<u>AB</u>	AMNEAL PHARMS	<u>EQ 2.5MG BASE</u>	<u>A210040 001</u>	Dec 22, 2017
<u>AB</u>	BARR	<u>EQ 2.5MG BASE</u>	<u>A081099 001</u>	Oct 15, 1990
<u>AB</u>	EUGIA PHARMA	<u>EQ 2.5MG BASE</u>	<u>A210454 001</u>	Jan 30, 2020
<u>AB</u>	! HIKMA	<u>EQ 2.5MG BASE</u>	<u>A040054 001</u>	Aug 01, 1994
<u>AB</u>	MYLAN	<u>EQ 2.5MG BASE</u>	<u>A081235 001</u>	May 15, 1992
<u>AB</u>	SUN PHARM	<u>EQ 2.5MG BASE</u>	<u>A201749 001</u>	May 21, 2015
<u>AB</u>	ZYDUS PHARMS	<u>EQ 2.5MG BASE</u>	<u>A207812 001</u>	Jan 13, 2017
	TREXALL BARR	EQ 5MG BASE	A040385 001	Mar 21, 2001
		EQ 7.5MG BASE	A040385 002	Mar 21, 2001
		EQ 10MG BASE	A040385 003	Mar 21, 2001
	!	EQ 15MG BASE	A040385 004	Mar 21, 2001

METHOXSALLEN

CAPSULE; ORAL

METHOXSALLEN

<u>AB</u>	ACTAVIS INC	<u>10MG</u>	<u>A202603 001</u>	Jun 09, 2015
<u>AB</u>	STRIDES PHARMA	<u>10MG</u>	<u>A202687 001</u>	Jun 05, 2014
	<u>OXSORALEN-ULTRA</u>			
<u>AB</u>	+! BAUSCH	<u>10MG</u>	<u>N019600 001</u>	Oct 30, 1986
	INJECTABLE; INJECTION UVADEX			
	+! MALLINCKRODT HOSP	0.02MG/ML	N020969 001	Feb 25, 1999

METHSCOPOLAMINE BROMIDE

TABLET; ORAL

METHSCOPOLAMINE BROMIDE

<u>AA</u>	BAYSHORE PHARMS LLC	<u>2.5MG</u>	<u>A200602 001</u>	Sep 24, 2012
<u>AA</u>	!	<u>5MG</u>	<u>A200602 002</u>	Sep 24, 2012
<u>AA</u>	BRECKENRIDGE PHARM	<u>2.5MG</u>	<u>A040642 001</u>	Dec 06, 2011
<u>AA</u>		<u>5MG</u>	<u>A040642 002</u>	Dec 06, 2011

METHSUXIMIDE

CAPSULE; ORAL

CELONTIN

+! PARKE DAVIS

300MG

N010596 008

METHYLDOPA

TABLET; ORAL

METHYLDOPA

<u>AB</u>	ACCORD HLTHCARE	<u>250MG</u>	<u>A070084 001</u>	Oct 15, 1985
<u>AB</u>		<u>500MG</u>	<u>A070085 001</u>	Oct 15, 1985
<u>AB</u>	MYLAN	<u>250MG</u>	<u>A070076 002</u>	Apr 18, 1985
<u>AB</u>	!	<u>500MG</u>	<u>A070076 001</u>	Apr 18, 1985

PRESCRIPTION DRUG PRODUCT LIST

METHYLENE BLUESOLUTION; INTRAVENOUS
PROVAYBLUE

+	!	PROVEPHARM SAS	10MG/2ML (5MG/ML)	N204630 002	Jul 18, 2019
+	!		50MG/10ML (5MG/ML)	N204630 001	Apr 08, 2016

METHYLERGONOVINE MALEATE

INJECTABLE; INJECTION

METHERGINE

AP	+	!	EDISON THERAPS LLC	0.2MG/ML	N006035 004	
-----------	---	---	--------------------	-----------------	--------------------	--

METHYLERGONOVINE MALEATE

AP			AM REGENT	0.2MG/ML	A090193 001	Nov 24, 2008
AP			BRECKENRIDGE	0.2MG/ML	A040889 001	Sep 13, 2010

TABLET; ORAL

METHYLERGONOVINE MALEATE

AB			AMNEAL PHARMS	0.2MG	A211483 001	Sep 10, 2018
AB			GRANULES PHARMS	0.2MG	A210424 001	May 15, 2018
AB		!	NOVEL LABS INC	0.2MG	A091577 001	May 02, 2011
AB			TEVA PHARMS USA	0.2MG	A211455 001	Mar 20, 2019
AB			TULEX PHARMS INC	0.2MG	A212233 001	May 01, 2020

METHYLNALTREXONE BROMIDE

SOLUTION; SUBCUTANEOUS

RELISTOR

+	!	SALIX PHARMS	8MG/0.4ML (8MG/0.4ML)	N021964 002	Sep 27, 2010
+	!		12MG/0.6ML (12MG/0.6ML)	N021964 001	Apr 24, 2008
+	!		12MG/0.6ML (12MG/0.6ML)	N021964 003	Sep 27, 2010

TABLET; ORAL

RELISTOR

+	!	SALIX	150MG	N208271 001	Jul 19, 2016
---	---	-------	-------	-------------	--------------

METHYLPHENIDATE

FILM, EXTENDED RELEASE; TRANSDERMAL

DAYTRANA

+		NOVEN PHARMS INC	10MG/9HR (1.1MG/HR)	N021514 001	Apr 06, 2006
+			15MG/9HR (1.6MG/HR)	N021514 002	Apr 06, 2006
+			20MG/9HR (2.2MG/HR)	N021514 003	Apr 06, 2006
+	!		30MG/9HR (3.3MG/HR)	N021514 004	Apr 06, 2006

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE; ORAL

COTEMPLA XR-ODT

+		NEOS THERAPS INC	8.6MG	N205489 001	Jun 19, 2017
+			17.3MG	N205489 002	Jun 19, 2017
+	!		25.9MG	N205489 003	Jun 19, 2017

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB1			GRANULES PHARMS	10MG	A211796 001	May 23, 2019
AB1				20MG	A211796 002	May 23, 2019
AB1				30MG	A211796 003	May 23, 2019
AB1				40MG	A211796 004	May 23, 2019
AB1				60MG	A211796 005	May 23, 2019
AB1			MAYNE PHARMA	10MG	A200886 001	Feb 26, 2018
AB1				20MG	A078458 001	Dec 01, 2011
AB1				30MG	A078458 002	Dec 01, 2011
AB1				40MG	A078458 003	Dec 01, 2011
AB1		!		60MG	A078458 004	Jun 23, 2016

RITALIN LA

AB1	+		NOVARTIS	10MG	N021284 004	Apr 10, 2004
AB1	+			20MG	N021284 001	Jun 05, 2002
AB1	+			30MG	N021284 002	Jun 05, 2002
AB1	+			40MG	N021284 003	Jun 05, 2002

METADATE CD

AB2	+		LANNETT CO INC	10MG	N021259 003	May 27, 2003
AB2	+			20MG	N021259 001	Apr 03, 2001
AB2	+			30MG	N021259 002	Jun 19, 2003
AB2	+			40MG	N021259 004	Feb 19, 2006
AB2	+			50MG	N021259 005	Feb 19, 2006
AB2	+	!		60MG	N021259 006	Feb 19, 2006

METHYLPHENIDATE HYDROCHLORIDE

AB2			IMPAX LABS INC	10MG	A205105 001	Jul 28, 2016
AB2				20MG	A205105 002	Jul 28, 2016
AB2				30MG	A205105 003	Jul 28, 2016
AB2				40MG	A205105 004	Jul 28, 2016

PRESCRIPTION DRUG PRODUCT LIST

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

<u>AB2</u>		<u>50MG</u>	<u>A205105 005</u>	Jul 28, 2016
<u>AB2</u>		<u>60MG</u>	<u>A205105 006</u>	Jul 28, 2016
<u>AB2</u>	SPECGX LLC	<u>10MG</u>	<u>A203583 001</u>	Sep 29, 2015
<u>AB2</u>		<u>20MG</u>	<u>A203583 002</u>	Sep 29, 2015
<u>AB2</u>		<u>30MG</u>	<u>A203583 003</u>	Sep 29, 2015
<u>AB2</u>		<u>40MG</u>	<u>A203583 004</u>	Sep 29, 2015
<u>AB2</u>		<u>50MG</u>	<u>A203583 005</u>	Sep 29, 2015
<u>AB2</u>		<u>60MG</u>	<u>A203583 006</u>	Sep 29, 2015
<u>AB2</u>	TEVA PHARMS	<u>10MG</u>	<u>A077707 001</u>	Jul 19, 2012
<u>AB2</u>		<u>20MG</u>	<u>A077707 002</u>	Jul 19, 2012
<u>AB2</u>		<u>30MG</u>	<u>A077707 003</u>	Jul 19, 2012
<u>AB2</u>		<u>40MG</u>	<u>A078873 001</u>	Jul 19, 2012
<u>AB2</u>		<u>50MG</u>	<u>A078873 002</u>	Jul 19, 2012
<u>AB2</u>		<u>60MG</u>	<u>A078873 003</u>	Jul 19, 2012

APTENSIO XR

<u>AB3</u>	+	RHODES PHARMS	<u>10MG</u>	<u>N205831 001</u>	Apr 17, 2015
<u>AB3</u>	+		<u>15MG</u>	<u>N205831 002</u>	Apr 17, 2015
<u>AB3</u>	+		<u>20MG</u>	<u>N205831 003</u>	Apr 17, 2015
<u>AB3</u>	+		<u>30MG</u>	<u>N205831 004</u>	Apr 17, 2015
<u>AB3</u>	+		<u>40MG</u>	<u>N205831 005</u>	Apr 17, 2015
<u>AB3</u>	+		<u>50MG</u>	<u>N205831 006</u>	Apr 17, 2015
<u>AB3</u>	+		<u>60MG</u>	<u>N205831 007</u>	Apr 17, 2015

METHYLPHENIDATE HYDROCHLORIDE

<u>AB3</u>		ACTAVIS ELIZABETH	<u>10MG</u>	<u>A208861 001</u>	Dec 13, 2018
<u>AB3</u>			<u>15MG</u>	<u>A208861 002</u>	Dec 13, 2018
<u>AB3</u>			<u>20MG</u>	<u>A208861 003</u>	Dec 13, 2018
<u>AB3</u>			<u>30MG</u>	<u>A208861 004</u>	Dec 13, 2018
<u>AB3</u>			<u>40MG</u>	<u>A208861 005</u>	Dec 13, 2018
<u>AB3</u>			<u>50MG</u>	<u>A208861 006</u>	Dec 13, 2018
<u>AB3</u>			<u>60MG</u>	<u>A208861 007</u>	Dec 13, 2018

ADHANSIA XR

	+	PURDUE PHARMA LP	25MG	N212038 001	Feb 27, 2019
	+		35MG	N212038 002	Feb 27, 2019
	+		45MG	N212038 003	Feb 27, 2019
	+		55MG	N212038 004	Feb 27, 2019
	+		70MG	N212038 005	Feb 27, 2019
	+		85MG	N212038 006	Feb 27, 2019

JORNAY PM

	+	IRONSHORE PHARMS	20MG	N209311 001	Aug 08, 2018
	+		40MG	N209311 002	Aug 08, 2018
	+		60MG	N209311 003	Aug 08, 2018
	+		80MG	N209311 004	Aug 08, 2018
	+		100MG	N209311 005	Aug 08, 2018

FOR SUSPENSION, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>		ACTAVIS LABS FL INC	<u>5MG/ML</u>	<u>A206049 001</u>	May 17, 2018
-----------	--	---------------------	---------------	--------------------	--------------

QUILLIVANT XR

<u>AB</u>	+	NEXTWAVE	<u>5MG/ML</u>	<u>N202100 001</u>	Sep 27, 2012
-----------	---	----------	---------------	--------------------	--------------

SOLUTION;ORAL

METHYLIN

<u>AA</u>	+	SPECGX LLC	<u>5MG/5ML</u>	<u>N021419 001</u>	Dec 19, 2002
<u>AA</u>	+		<u>10MG/5ML</u>	<u>N021419 002</u>	Dec 19, 2002

METHYLPHENIDATE HYDROCHLORIDE

<u>AA</u>		ABHAI LLC	<u>5MG/5ML</u>	<u>A207485 001</u>	Nov 18, 2016
<u>AA</u>			<u>10MG/5ML</u>	<u>A207485 002</u>	Nov 18, 2016
<u>AA</u>		ALKEM LABS LTD	<u>5MG/5ML</u>	<u>A211647 001</u>	Mar 30, 2020
<u>AA</u>			<u>10MG/5ML</u>	<u>A211647 002</u>	Mar 30, 2020
<u>AA</u>		ANDA REPOSITORY	<u>5MG/5ML</u>	<u>A210764 001</u>	Apr 10, 2020
<u>AA</u>			<u>10MG/5ML</u>	<u>A210764 002</u>	Apr 10, 2020
<u>AA</u>		BRECKENRIDGE	<u>5MG/5ML</u>	<u>A201466 001</u>	Nov 12, 2013
<u>AA</u>			<u>10MG/5ML</u>	<u>A201466 002</u>	Nov 12, 2013
<u>AA</u>		EYWA	<u>5MG/5ML</u>	<u>A210139 001</u>	Oct 03, 2018
<u>AA</u>			<u>10MG/5ML</u>	<u>A210139 002</u>	Oct 03, 2018
<u>AA</u>		LANNETT CO INC	<u>5MG/5ML</u>	<u>A207414 001</u>	Dec 16, 2020
<u>AA</u>			<u>10MG/5ML</u>	<u>A207414 002</u>	Dec 16, 2020
<u>AA</u>		NOVEL LABS INC	<u>5MG/5ML</u>	<u>A204602 001</u>	Aug 14, 2015
<u>AA</u>			<u>10MG/5ML</u>	<u>A204602 002</u>	Aug 14, 2015
<u>AA</u>		QUAGEN	<u>5MG/5ML</u>	<u>A213567 001</u>	Jun 04, 2020
<u>AA</u>			<u>10MG/5ML</u>	<u>A213567 002</u>	Jun 04, 2020

PRESCRIPTION DRUG PRODUCT LIST

METHYLPHENIDATE HYDROCHLORIDE

SOLUTION;ORAL

METHYLPHENIDATE HYDROCHLORIDE

<u>AA</u>	TRIS PHARMA INC	<u>5MG/5ML</u>	<u>A091601 001</u>	Jul 23, 2010
<u>AA</u>		<u>10MG/5ML</u>	<u>A091601 002</u>	Jul 23, 2010

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>	ABHAI INC	<u>5MG</u>	<u>A206932 001</u>	May 11, 2017
<u>AB</u>		<u>10MG</u>	<u>A206932 002</u>	May 11, 2017
<u>AB</u>		<u>20MG</u>	<u>A206932 003</u>	May 11, 2017
<u>AB</u>	ACCORD HLTHCARE	<u>5MG</u>	<u>A213936 001</u>	Oct 28, 2020
<u>AB</u>		<u>10MG</u>	<u>A213936 002</u>	Oct 28, 2020
<u>AB</u>		<u>20MG</u>	<u>A213936 003</u>	Oct 28, 2020
<u>AB</u>	ALKEM LABS LTD	<u>5MG</u>	<u>A211779 001</u>	Oct 04, 2019
<u>AB</u>		<u>10MG</u>	<u>A211779 002</u>	Oct 04, 2019
<u>AB</u>		<u>20MG</u>	<u>A211779 003</u>	Oct 04, 2019
<u>AB</u>	ASCENT PHARMS INC	<u>5MG</u>	<u>A207416 001</u>	Sep 22, 2015
<u>AB</u>		<u>10MG</u>	<u>A207416 002</u>	Sep 22, 2015
<u>AB</u>		<u>20MG</u>	<u>A207416 003</u>	Sep 22, 2015
<u>AB</u>	MOUNTAIN	<u>5MG</u>	<u>A091159 001</u>	Mar 12, 2014
<u>AB</u>		<u>10MG</u>	<u>A091159 002</u>	Mar 12, 2014
<u>AB</u>		<u>20MG</u>	<u>A091159 003</u>	Mar 12, 2014
<u>AB</u>	NOVEL LABS INC	<u>5MG</u>	<u>A207884 001</u>	Nov 13, 2015
<u>AB</u>		<u>10MG</u>	<u>A207884 002</u>	Nov 13, 2015
<u>AB</u>		<u>20MG</u>	<u>A207884 003</u>	Nov 13, 2015
<u>AB</u>	OXFORD PHARMS	<u>5MG</u>	<u>A202892 001</u>	Sep 23, 2014
<u>AB</u>		<u>10MG</u>	<u>A202892 002</u>	Sep 23, 2014
<u>AB</u>		<u>20MG</u>	<u>A202892 003</u>	Sep 23, 2014
<u>AB</u>	PRINSTON INC	<u>5MG</u>	<u>A212697 001</u>	Jul 23, 2020
<u>AB</u>		<u>10MG</u>	<u>A212697 002</u>	Jul 23, 2020
<u>AB</u>		<u>20MG</u>	<u>A212697 003</u>	Jul 23, 2020
<u>AB</u>	SPECGX LLC	<u>5MG</u>	<u>A040300 001</u>	Nov 27, 1998
<u>AB</u>		<u>10MG</u>	<u>A040300 002</u>	Nov 27, 1998
<u>AB</u>		<u>20MG</u>	<u>A040300 003</u>	Nov 27, 1998
<u>AB</u>	SUN PHARM INDS INC	<u>5MG</u>	<u>A090710 001</u>	Mar 15, 2012
<u>AB</u>		<u>10MG</u>	<u>A090710 002</u>	Mar 15, 2012
<u>AB</u>		<u>20MG</u>	<u>A090710 003</u>	Mar 15, 2012
<u>AB</u>	USPHARMA	<u>5MG</u>	<u>A209753 001</u>	Mar 02, 2018
<u>AB</u>		<u>10MG</u>	<u>A209753 002</u>	Mar 02, 2018
<u>AB</u>		<u>20MG</u>	<u>A209753 003</u>	Mar 02, 2018

RITALIN

<u>AB</u>	+	NOVARTIS	<u>5MG</u>	<u>N010187 003</u>
<u>AB</u>	+		<u>10MG</u>	<u>N010187 006</u>
<u>AB</u>	+	!	<u>20MG</u>	<u>N010187 010</u>

TABLET, CHEWABLE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>	ASCENT PHARMS INC	<u>2.5MG</u>	<u>A210354 001</u>	Dec 29, 2017
<u>AB</u>		<u>5MG</u>	<u>A210354 002</u>	Dec 29, 2017
<u>AB</u>		<u>10MG</u>	<u>A210354 003</u>	Dec 29, 2017
<u>AB</u>	NOVEL LABS INC	<u>2.5MG</u>	<u>A204115 001</u>	Feb 25, 2015
<u>AB</u>		<u>5MG</u>	<u>A204115 002</u>	Feb 25, 2015
<u>AB</u>	!	<u>10MG</u>	<u>A204115 003</u>	Feb 25, 2015
<u>AB</u>	RISING	<u>2.5MG</u>	<u>A205756 001</u>	Nov 07, 2016
<u>AB</u>		<u>5MG</u>	<u>A205756 002</u>	Nov 07, 2016
<u>AB</u>		<u>10MG</u>	<u>A205756 003</u>	Nov 07, 2016

TABLET, EXTENDED RELEASE;ORAL

CONCERTA

<u>AB</u>	+	JANSSEN PHARMS	<u>18MG</u>	<u>N021121 001</u>	Aug 01, 2000
<u>AB</u>	+		<u>27MG</u>	<u>N021121 004</u>	Apr 01, 2002
<u>AB</u>	+		<u>36MG</u>	<u>N021121 002</u>	Aug 01, 2000
<u>AB</u>	+	!	<u>54MG</u>	<u>N021121 003</u>	Dec 08, 2000

METHYLIN ER

<u>AB</u>	SPECGX LLC	<u>10MG</u>	<u>A075629 001</u>	May 09, 2000
<u>AB</u>		<u>20MG</u>	<u>A075629 002</u>	May 09, 2000

METHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>	ABHAI LLC	<u>10MG</u>	<u>A207488 001</u>	Jun 09, 2015
<u>AB</u>	!	<u>20MG</u>	<u>A207488 002</u>	Jun 09, 2015
<u>AB</u>	ACTAVIS LABS FL	<u>18MG</u>	<u>A076772 001</u>	Mar 22, 2018
<u>AB</u>		<u>27MG</u>	<u>A076772 002</u>	Mar 22, 2018
<u>AB</u>		<u>36MG</u>	<u>A076772 003</u>	Mar 22, 2018
<u>AB</u>		<u>54MG</u>	<u>A076655 001</u>	Mar 21, 2018
<u>AB</u>	ALKEM LABS LTD	<u>20MG</u>	<u>A212288 001</u>	Oct 06, 2020

PRESCRIPTION DRUG PRODUCT LIST

METHYLPHENIDATE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>	ALVOGEN PINE BROOK	<u>18MG</u>	<u>A210818 001</u>	Nov 30, 2018
<u>AB</u>		<u>27MG</u>	<u>A210818 002</u>	Nov 30, 2018
<u>AB</u>		<u>36MG</u>	<u>A210818 003</u>	Nov 30, 2018
<u>AB</u>		<u>54MG</u>	<u>A210818 004</u>	Nov 30, 2018
<u>AB</u>	AMNEAL PHARMS	<u>18MG</u>	<u>A207515 001</u>	Feb 01, 2018
<u>AB</u>		<u>27MG</u>	<u>A207515 002</u>	Feb 01, 2018
<u>AB</u>		<u>36MG</u>	<u>A207515 003</u>	Feb 01, 2018
<u>AB</u>		<u>54MG</u>	<u>A207515 004</u>	Feb 01, 2018
<u>AB</u>	ANDOR PHARMS	<u>18MG</u>	<u>A211918 001</u>	Apr 24, 2019
<u>AB</u>		<u>27MG</u>	<u>A211918 002</u>	Apr 24, 2019
<u>AB</u>		<u>36MG</u>	<u>A211918 003</u>	Apr 24, 2019
<u>AB</u>		<u>54MG</u>	<u>A211918 004</u>	Apr 24, 2019
<u>AB</u>	ASCENT PHARMS INC	<u>18MG</u>	<u>A211009 001</u>	Sep 03, 2019
<u>AB</u>		<u>27MG</u>	<u>A211009 002</u>	Sep 03, 2019
<u>AB</u>		<u>36MG</u>	<u>A211009 003</u>	Sep 03, 2019
<u>AB</u>		<u>54MG</u>	<u>A211009 004</u>	Sep 03, 2019
<u>AB</u>	CNTY LINE PHARMS	<u>10MG</u>	<u>A204772 001</u>	Feb 29, 2016
<u>AB</u>		<u>20MG</u>	<u>A204772 002</u>	Feb 29, 2016
<u>AB</u>	DR REDDYS	<u>18MG</u>	<u>A213473 001</u>	Jul 29, 2020
<u>AB</u>		<u>27MG</u>	<u>A213473 002</u>	Jul 29, 2020
<u>AB</u>		<u>36MG</u>	<u>A213473 003</u>	Jul 29, 2020
<u>AB</u>		<u>54MG</u>	<u>A213473 004</u>	Jul 29, 2020
<u>AB</u>	GRANULES PHARMS	<u>10MG</u>	<u>A210992 001</u>	Nov 21, 2018
<u>AB</u>		<u>20MG</u>	<u>A210992 002</u>	Nov 21, 2018
<u>AB</u>	MYLAN	<u>18MG</u>	<u>A206726 001</u>	Oct 21, 2016
<u>AB</u>		<u>27MG</u>	<u>A206726 002</u>	Oct 21, 2016
<u>AB</u>		<u>36MG</u>	<u>A206726 003</u>	Oct 21, 2016
<u>AB</u>		<u>54MG</u>	<u>A206726 004</u>	Oct 21, 2016
<u>AB</u>	OSMOTICA	<u>18MG</u>	<u>A205327 001</u>	Jul 28, 2017
<u>AB</u>		<u>27MG</u>	<u>A205327 002</u>	Jul 28, 2017
<u>AB</u>		<u>36MG</u>	<u>A205327 003</u>	Jul 28, 2017
<u>AB</u>		<u>54MG</u>	<u>A205327 004</u>	Jul 28, 2017
<u>AB</u>	SUN PHARM INDS INC	<u>18MG</u>	<u>A205135 001</u>	Aug 19, 2020
<u>AB</u>		<u>27MG</u>	<u>A205135 002</u>	Aug 19, 2020
<u>AB</u>		<u>36MG</u>	<u>A205135 003</u>	Aug 19, 2020
<u>AB</u>		<u>54MG</u>	<u>A205135 004</u>	Aug 19, 2020
BX	LANNETT CO INC	18MG	A091695 001	Jul 09, 2013
BX		27MG	A091695 002	Jul 09, 2013
BX		36MG	A091695 003	Sep 23, 2013
BX		54MG	A091695 004	Sep 23, 2013
BX	SPECGX LLC	27MG	A202608 001	Dec 28, 2012
BX		36MG	A202608 002	Dec 28, 2012
BX		54MG	A202608 003	Dec 28, 2012
!	OSMOTICA	72MG	A205327 005	Jul 28, 2017
TABLET, EXTENDED RELEASE, CHEWABLE;ORAL				
QUILLICHEW ER				
+	NEXTWAVE PHARMS	20MG	N207960 001	Dec 04, 2015
+		30MG	N207960 002	Dec 04, 2015
+		40MG	N207960 003	Dec 04, 2015

METHYLPREDNISOLONE

TABLET;ORAL

MEDROL

<u>AB</u>	+	PFIZER	<u>2MG</u>	<u>N011153 002</u>
<u>AB</u>	+		<u>4MG</u>	<u>N011153 001</u>
<u>AB</u>	+		<u>8MG</u>	<u>N011153 004</u>
<u>AB</u>	+		<u>16MG</u>	<u>N011153 003</u>
<u>AB</u>	+		<u>32MG</u>	<u>N011153 006</u>

METHYLPREDNISOLONE

<u>AB</u>	JUBILANT CADISTA	<u>4MG</u>	<u>A040189 001</u>	Oct 31, 1997
<u>AB</u>		<u>8MG</u>	<u>A040189 002</u>	Oct 31, 1997
<u>AB</u>		<u>16MG</u>	<u>A040189 003</u>	Jul 20, 2007
<u>AB</u>		<u>32MG</u>	<u>A040189 004</u>	Jul 20, 2007
<u>AB</u>	SANDOZ	<u>4MG</u>	<u>A040194 001</u>	Oct 31, 1997
<u>AB</u>	SUNGEN PHARMA	<u>4MG</u>	<u>A212262 001</u>	Jun 27, 2019
<u>AB</u>	TIANJIN TIANYAO	<u>4MG</u>	<u>A204072 001</u>	May 14, 2018
<u>AB</u>	VINTAGE PHARMS	<u>4MG</u>	<u>A040183 001</u>	Dec 22, 1998
<u>AB</u>	WATSON LABS	<u>4MG</u>	<u>A040232 001</u>	Oct 16, 1997
<u>AB</u>	ZYDUS PHARMS	<u>4MG</u>	<u>A206751 001</u>	Apr 23, 2018
<u>AB</u>		<u>8MG</u>	<u>A206751 002</u>	Apr 23, 2018

PRESCRIPTION DRUG PRODUCT LIST

METHYLPREDNISOLONE

TABLET; ORAL

METHYLPREDNISOLONE

<u>AB</u>		<u>16MG</u>	<u>A206751</u>	<u>003</u>	Apr 23, 2018
<u>AB</u>		<u>32MG</u>	<u>A206751</u>	<u>004</u>	Apr 23, 2018

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION

DEPO-MEDROL

<u>AB</u>	<u>+</u> !	PFIZER	<u>20MG/ML</u>	<u>N011757</u>	<u>002</u>
<u>AB</u>	<u>+</u> !		<u>40MG/ML</u>	<u>N011757</u>	<u>001</u>
<u>AB</u>	<u>+</u> !		<u>80MG/ML</u>	<u>N011757</u>	<u>004</u>

METHYLPREDNISOLONE ACETATE

<u>AB</u>		AMNEAL	<u>40MG/ML</u>	<u>A210043</u>	<u>001</u>	May 20, 2019
<u>AB</u>			<u>80MG/ML</u>	<u>A210043</u>	<u>002</u>	May 20, 2019
<u>AB</u>		SAGENT PHARMS INC	<u>20MG/ML</u>	<u>A201835</u>	<u>001</u>	Jun 27, 2018
<u>AB</u>			<u>40MG/ML</u>	<u>A201835</u>	<u>002</u>	Jun 27, 2018
<u>AB</u>			<u>80MG/ML</u>	<u>A201835</u>	<u>003</u>	Jun 27, 2018
<u>AB</u>		SANDOZ INC	<u>40MG/ML</u>	<u>A040719</u>	<u>001</u>	Jan 29, 2009
<u>AB</u>			<u>40MG/ML</u>	<u>A040794</u>	<u>001</u>	Mar 05, 2009
<u>AB</u>			<u>80MG/ML</u>	<u>A040719</u>	<u>002</u>	Jan 29, 2009
<u>AB</u>			<u>80MG/ML</u>	<u>A040794</u>	<u>002</u>	Mar 05, 2009
<u>AB</u>		TEVA PHARMS USA	<u>40MG/ML</u>	<u>A040557</u>	<u>001</u>	Feb 23, 2005
<u>AB</u>			<u>40MG/ML</u>	<u>A040620</u>	<u>001</u>	Oct 27, 2006
<u>AB</u>			<u>80MG/ML</u>	<u>A040557</u>	<u>002</u>	Feb 23, 2005
<u>AB</u>			<u>80MG/ML</u>	<u>A040620</u>	<u>002</u>	Oct 27, 2006

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE

<u>AP</u>		AMNEAL	<u>EQ 40MG BASE/VIAL</u>	<u>A207549</u>	<u>001</u>	Nov 09, 2016
<u>AP</u>			<u>EQ 125MG BASE/VIAL</u>	<u>A207549</u>	<u>002</u>	Nov 09, 2016
<u>AP</u>		AUROBINDO PHARMA LTD	<u>EQ 40MG BASE/VIAL</u>	<u>A207667</u>	<u>001</u>	Dec 15, 2015
<u>AP</u>			<u>EQ 125MG BASE/VIAL</u>	<u>A207667</u>	<u>002</u>	Dec 15, 2015
<u>AP</u>			<u>EQ 500MG BASE/VIAL</u>	<u>A207667</u>	<u>003</u>	Dec 15, 2015
<u>AP</u>			<u>EQ 2GM BASE/VIAL</u>	<u>A207667</u>	<u>004</u>	Dec 15, 2015
<u>AP</u>		FRESENIUS KABI USA	<u>EQ 40MG BASE/VIAL</u>	<u>A040583</u>	<u>001</u>	Jul 30, 2004
<u>AP</u>			<u>EQ 125MG BASE/VIAL</u>	<u>A040583</u>	<u>002</u>	Jul 30, 2004
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A040612</u>	<u>001</u>	Aug 12, 2004
<u>AP</u>		HIKMA	<u>EQ 500MG BASE/VIAL</u>	<u>A202691</u>	<u>001</u>	Feb 16, 2016
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A202691</u>	<u>002</u>	Feb 16, 2016
<u>AP</u>		SAGENT PHARMS INC	<u>EQ 40MG BASE/VIAL</u>	<u>A040888</u>	<u>001</u>	Jul 18, 2011
<u>AP</u>			<u>EQ 125MG BASE/VIAL</u>	<u>A040888</u>	<u>002</u>	Jul 18, 2011
<u>AP</u>			<u>EQ 500MG BASE/VIAL</u>	<u>A040888</u>	<u>003</u>	Jul 18, 2011
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A040888</u>	<u>004</u>	Jul 18, 2011
<u>AP</u>			<u>EQ 2GM BASE/VIAL</u>	<u>A040888</u>	<u>005</u>	Jul 18, 2011

SOLU-MEDROL

<u>AP</u>	<u>+</u> !	PHARMACIA AND UPJOHN	<u>EQ 40MG BASE/VIAL</u>	<u>N011856</u>	<u>003</u>	
<u>AP</u>	<u>+</u> !		<u>EQ 125MG BASE/VIAL</u>	<u>N011856</u>	<u>004</u>	
<u>AP</u>	<u>+</u> !		<u>EQ 500MG BASE/VIAL</u>	<u>N011856</u>	<u>005</u>	
<u>AP</u>	<u>+</u> !		<u>EQ 1GM BASE/VIAL</u>	<u>N011856</u>	<u>006</u>	
<u>AP</u>	<u>+</u> !		<u>EQ 2GM BASE/VIAL</u>	<u>N011856</u>	<u>007</u>	Feb 27, 1985

METHYLTESTOSTERONE

CAPSULE; ORAL

METHYLTESTOSTERONE

	!	IMPAX LABS INC	10MG	A204851	001	Sep 21, 2015
--	---	----------------	------	---------	-----	--------------

TABLET; ORAL

		ANDROID 25				
BP		VALEANT PHARM INTL	25MG	A087147	001	

METHYLTESTOSTERONE

BP		IMPAX LABS	10MG	A080767	002	
----	--	------------	------	---------	-----	--

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

METOCLOPRAMIDE

<u>AP</u>		EMCURE PHARMS LTD	<u>EQ 5MG BASE/ML</u>	<u>A204756</u>	<u>001</u>	Dec 20, 2013
-----------	--	-------------------	-----------------------	----------------	------------	--------------

METOCLOPRAMIDE HYDROCHLORIDE

<u>AP</u>		FRESENIUS KABI USA	<u>EQ 5MG BASE/ML</u>	<u>A091392</u>	<u>001</u>	Apr 19, 2013
<u>AP</u>	!	HOSPIRA	<u>EQ 5MG BASE/ML</u>	<u>A073118</u>	<u>001</u>	Jan 17, 1991
<u>AP</u>		TEVA PHARMS USA	<u>EQ 5MG BASE/ML</u>	<u>A073135</u>	<u>001</u>	Nov 27, 1991

PRESCRIPTION DRUG PRODUCT LIST

METOCLOPRAMIDE HYDROCHLORIDE

SOLUTION;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AA	ANI PHARMS	EQ 5MG BASE/5ML	A071402 001	Jun 25, 1993
AA	PHARM ASSOC	EQ 5MG BASE/5ML	A072744 001	May 28, 1991
AA	VISTAPHARM	EQ 5MG BASE/5ML	A075051 001	Jan 26, 2001
AA	! WOCHKHARDT BIO AG	EQ 5MG BASE/5ML	A074703 001	Oct 31, 1997

SPRAY, METERED;NASAL

GIMOTI

+	!	EVOKE PHARMA INC	EQ 15MG BASE/SPRAY	N209388 001	Jun 19, 2020
---	---	------------------	--------------------	-------------	--------------

TABLET;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AB	IMPAX LABS INC	EQ 5MG BASE	A071250 002	Dec 28, 1995
AB		EQ 10MG BASE	A071250 001	Feb 03, 1988
AB	IPCA LABS LTD	EQ 5MG BASE	A078807 001	Jun 12, 2008
AB		EQ 10MG BASE	A078807 002	Jun 12, 2008
AB	PAR PHARM INC	EQ 10MG BASE	A070581 001	Oct 17, 1985
AB	TEVA	EQ 5MG BASE	A072801 001	Jun 15, 1993
AB		EQ 10MG BASE	A070184 001	Jul 29, 1985
AB	VINTAGE PHARMS	EQ 5MG BASE	A077878 001	Aug 28, 2006
AB		EQ 10MG BASE	A077878 002	Aug 28, 2006

REGLAN

AB	+	ANI PHARMS	EQ 5MG BASE	N017854 002	May 05, 1987
AB	+	!	EQ 10MG BASE	N017854 001	

TABLET, ORALLY DISINTEGRATING;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

		NOVEL LABS INC	EQ 5MG BASE	A202191 001	Aug 15, 2014
		!	EQ 10MG BASE	A202191 002	Aug 15, 2014

METOLAZONE

TABLET;ORAL

METOLAZONE

AB	ALEMbic PHARMS LTD	2.5MG	A213251 001	Dec 02, 2020
AB		5MG	A213251 002	Dec 02, 2020
AB		10MG	A213251 003	Dec 02, 2020
AB	MYLAN	2.5MG	A076698 001	Dec 23, 2003
AB		5MG	A076698 002	Oct 19, 2004
AB		10MG	A076698 003	Oct 19, 2004
AB	SANDOZ	2.5MG	A076732 001	Dec 19, 2003
AB		5MG	A076466 001	Dec 19, 2003
AB		10MG	A076466 002	Dec 19, 2003

ZAROXOLYN

AB	+	LANNETT CO INC	2.5MG	N017386 001	
AB	+	!	5MG	N017386 002	
AB	+	!	10MG	N017386 003	

METOPROLOL SUCCINATE

CAPSULE, EXTENDED RELEASE;ORAL

KAPSPARGO SPRINKLE

+		SPIL	EQ 25MG TARTRATE	N210428 001	Jan 26, 2018
+			EQ 50MG TARTRATE	N210428 002	Jan 26, 2018
+			EQ 100MG TARTRATE	N210428 003	Jan 26, 2018
+		!	EQ 200MG TARTRATE	N210428 004	Jan 26, 2018

TABLET, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

AB	ACTAVIS LABS FL INC	EQ 50MG TARTRATE	A076862 001	Aug 03, 2009
AB	ALKEM LABS LTD	EQ 25MG TARTRATE	A211143 001	Nov 25, 2020
AB		EQ 50MG TARTRATE	A211143 002	Nov 25, 2020
AB		EQ 100MG TARTRATE	A211143 003	Nov 25, 2020
AB		EQ 200MG TARTRATE	A211143 004	Nov 25, 2020
AB	CIPLA	EQ 50MG TARTRATE	A207465 001	Oct 26, 2018
AB		EQ 100MG TARTRATE	A207465 002	Oct 26, 2018
AB		EQ 200MG TARTRATE	A207465 003	Oct 26, 2018
AB	DR REDDYS LABS LTD	EQ 25MG TARTRATE	A090617 001	Aug 01, 2012
AB		EQ 50MG TARTRATE	A090617 002	Aug 01, 2012
AB	HETERO LABS LTD III	EQ 25MG TARTRATE	A205541 001	Nov 06, 2020
AB		EQ 50MG TARTRATE	A205541 002	Nov 06, 2020
AB		EQ 100MG TARTRATE	A205541 003	Nov 06, 2020
AB		EQ 200MG TARTRATE	A205541 004	Nov 06, 2020
AB	MYLAN PHARMS INC	EQ 25MG TARTRATE	A202033 001	Dec 15, 2011
AB		EQ 50MG TARTRATE	A202033 002	Dec 15, 2011
AB		EQ 100MG TARTRATE	A202033 003	Dec 15, 2011
AB		EQ 200MG TARTRATE	A202033 004	Dec 15, 2011

PRESCRIPTION DRUG PRODUCT LIST

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

<u>AB</u>	NOVAST LABS	<u>EQ 25MG TARTRATE</u>	<u>A204106 001</u>	Feb 06, 2018
<u>AB</u>		<u>EQ 50MG TARTRATE</u>	<u>A204106 002</u>	Feb 06, 2018
<u>AB</u>		<u>EQ 100MG TARTRATE</u>	<u>A204106 003</u>	Feb 06, 2018
<u>AB</u>		<u>EQ 200MG TARTRATE</u>	<u>A204106 004</u>	Feb 06, 2018
<u>AB</u>	PHARMADAX INC	<u>EQ 25MG TARTRATE</u>	<u>A203028 001</u>	Mar 31, 2020
<u>AB</u>		<u>EQ 50MG TARTRATE</u>	<u>A203028 002</u>	Mar 31, 2020
<u>AB</u>		<u>EQ 100MG TARTRATE</u>	<u>A203699 001</u>	Mar 30, 2020
<u>AB</u>		<u>EQ 200MG TARTRATE</u>	<u>A203699 002</u>	Mar 30, 2020
<u>AB</u>	REDDYS	<u>EQ 100MG TARTRATE</u>	<u>A078889 001</u>	Aug 15, 2012
<u>AB</u>		<u>EQ 200MG TARTRATE</u>	<u>A078889 002</u>	Aug 15, 2012
<u>AB</u>	TWI PHARMS	<u>EQ 25MG TARTRATE</u>	<u>A207206 001</u>	Dec 19, 2018
<u>AB</u>		<u>EQ 50MG TARTRATE</u>	<u>A207206 002</u>	Dec 19, 2018
<u>AB</u>		<u>EQ 100MG TARTRATE</u>	<u>A207206 003</u>	Dec 19, 2018
<u>AB</u>		<u>EQ 200MG TARTRATE</u>	<u>A207206 004</u>	Dec 19, 2018
<u>AB</u>	WOCKHARDT	<u>EQ 25MG TARTRATE</u>	<u>A090615 001</u>	Jul 22, 2010
<u>AB</u>		<u>EQ 50MG TARTRATE</u>	<u>A090615 002</u>	Jul 22, 2010
<u>AB</u>		<u>EQ 100MG TARTRATE</u>	<u>A090615 003</u>	Jul 22, 2010
<u>AB</u>		<u>EQ 200MG TARTRATE</u>	<u>A090615 004</u>	Jul 22, 2010
<u>AB</u>	ZYDUS PHARMS	<u>EQ 25MG TARTRATE</u>	<u>A203894 001</u>	Mar 23, 2018
<u>AB</u>		<u>EQ 50MG TARTRATE</u>	<u>A203894 002</u>	Mar 23, 2018
<u>AB</u>		<u>EQ 100MG TARTRATE</u>	<u>A203894 003</u>	Mar 23, 2018
<u>AB</u>		<u>EQ 200MG TARTRATE</u>	<u>A203894 004</u>	Mar 23, 2018

TOPROL-XL

<u>AB</u>	+	TOPROL	<u>EQ 25MG TARTRATE</u>	<u>N019962 004</u>	Feb 05, 2001
<u>AB</u>	+	!	<u>EQ 50MG TARTRATE</u>	<u>N019962 001</u>	Jan 10, 1992
<u>AB</u>	+		<u>EQ 100MG TARTRATE</u>	<u>N019962 002</u>	Jan 10, 1992
<u>AB</u>	+	!	<u>EQ 200MG TARTRATE</u>	<u>N019962 003</u>	Jan 10, 1992

METOPROLOL TARTRATE

INJECTABLE;INJECTION

METOPROLOL TARTRATE

<u>AP</u>	BAXTER HLTHCARE CORP	<u>1MG/ML</u>	<u>A078950 001</u>	Apr 29, 2013
<u>AP</u>	FRESENIUS KABI USA	<u>1MG/ML</u>	<u>A091045 001</u>	Oct 25, 2010
<u>AP</u>	GLAND PHARMA LTD	<u>1MG/ML</u>	<u>A204205 001</u>	Aug 27, 2014
<u>AP</u>	HIKMA FARMACEUTICA	<u>1MG/ML</u>	<u>A077761 001</u>	May 30, 2007
<u>AP</u>	HOSPIRA	<u>1MG/ML</u>	<u>A074133 001</u>	Dec 21, 1993
<u>AP</u>		<u>1MG/ML</u>	<u>A075160 001</u>	Jul 06, 1998
<u>AP</u>	!	<u>1MG/ML</u>	<u>A078085 001</u>	Apr 29, 2008
<u>AP</u>	SANDOZ INC	<u>1MG/ML</u>	<u>A077360 001</u>	Oct 02, 2007
<u>AP</u>	WEST-WARD PHARMS INT	<u>1MG/ML</u>	<u>A076495 001</u>	Jul 07, 2003

TABLET;ORAL

LOPRESSOR

<u>AB</u>	+	US PHARMS HOLDINGS I	<u>50MG</u>	<u>N017963 001</u>	
<u>AB</u>	+		<u>100MG</u>	<u>N017963 002</u>	
<u>METOPROLOL TARTRATE</u>					
<u>AB</u>		ALEMBIC PHARMS LTD	<u>25MG</u>	<u>A202871 001</u>	May 28, 2013
<u>AB</u>			<u>50MG</u>	<u>A202871 002</u>	May 28, 2013
<u>AB</u>			<u>100MG</u>	<u>A202871 003</u>	May 28, 2013
<u>AB</u>		AUROBINDO PHARMA	<u>25MG</u>	<u>A077739 001</u>	Sep 11, 2007
<u>AB</u>			<u>50MG</u>	<u>A077739 002</u>	Sep 11, 2007
<u>AB</u>			<u>100MG</u>	<u>A077739 003</u>	Sep 11, 2007
<u>AB</u>		IPCA LABS LTD	<u>25MG</u>	<u>A078459 001</u>	Jun 17, 2008
<u>AB</u>			<u>50MG</u>	<u>A078459 002</u>	Jun 17, 2008
<u>AB</u>			<u>100MG</u>	<u>A078459 003</u>	Jun 17, 2008
<u>AB</u>		MYLAN	<u>25MG</u>	<u>A076704 001</u>	Jan 16, 2004
<u>AB</u>			<u>37.5MG</u>	<u>A076704 004</u>	Mar 18, 2015
<u>AB</u>			<u>50MG</u>	<u>A076704 002</u>	Jan 16, 2004
<u>AB</u>			<u>75MG</u>	<u>A076704 005</u>	Mar 18, 2015
<u>AB</u>	!		<u>100MG</u>	<u>A076704 003</u>	Jan 16, 2004
<u>AB</u>		RUBICON	<u>25MG</u>	<u>A200981 001</u>	Oct 28, 2014
<u>AB</u>			<u>37.5MG</u>	<u>A200981 004</u>	Aug 21, 2019
<u>AB</u>			<u>50MG</u>	<u>A200981 002</u>	Oct 28, 2014
<u>AB</u>			<u>75MG</u>	<u>A200981 005</u>	Aug 21, 2019
<u>AB</u>			<u>100MG</u>	<u>A200981 003</u>	Oct 28, 2014
<u>AB</u>		SUN PHARM INDS INC	<u>25MG</u>	<u>A076670 001</u>	Jan 15, 2004
<u>AB</u>			<u>50MG</u>	<u>A074644 001</u>	Dec 10, 1996
<u>AB</u>			<u>100MG</u>	<u>A074644 002</u>	Dec 10, 1996

PRESCRIPTION DRUG PRODUCT LIST

METOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE

AB	YOUNGTECH PHARMS INC	25MG	A208955 001	Feb 05, 2020
AB		50MG	A208955 002	Feb 05, 2020
AB		100MG	A208955 003	Feb 05, 2020

METRONIDAZOLE

CAPSULE; ORAL

FLAGYL

AB	+ ! PFIZER	375MG	N020334 001	May 03, 1995
<u>METRONIDAZOLE</u>				
AB	ALEMBIC PHARMS LTD	375MG	A079065 001	Jun 23, 2009
AB	PAR PHARM	375MG	A076522 001	Jan 29, 2004

CREAM; TOPICAL

METROCREAM

AB	+ ! GALDERMA LABS LP	0.75%	N020531 001	Sep 20, 1995
<u>METRONIDAZOLE</u>				
AB	COSETTE	0.75%	A077549 001	Dec 19, 2007
AB	FOUGERA PHARMS	0.75%	A076408 001	May 28, 2004
NORITATE				
	+ ! VALEANT PHARMS NORTH	1%	N020743 001	Sep 26, 1997

GEL; TOPICAL

METROGEL

AB	+ ! GALDERMA LABS LP	0.75%	N019737 001	Nov 22, 1988
AB	+ !	1%	N021789 001	Jun 30, 2005
<u>METRONIDAZOLE</u>				
AB	COSETTE	0.75%	A078178 001	Jan 19, 2011
AB	FOUGERA PHARMS	0.75%	A077018 001	Jun 06, 2006
AB	TARO	0.75%	A077819 001	Jul 18, 2006
AB		1%	A204651 001	Mar 14, 2017
AB	TOLMAR	0.75%	A077547 001	Jul 13, 2006
AB		1%	A090903 001	Jul 22, 2011

GEL; VAGINAL

METROGEL-VAGINAL

AB	+ ! BAUSCH	0.75%	N020208 001	Aug 17, 1992
<u>METRONIDAZOLE</u>				
AB	PERRIGO UK FINCO	0.75%	A211786 001	Jul 02, 2019
AB	TOLMAR	0.75%	A077264 001	Oct 31, 2006
VANDAZOLE				
EX	! TEVA PHARMS	0.75%	N021806 001	May 20, 2005
NUVESSA				
	+ ! CHEMO RESEARCH SL	1.3%	N205223 001	Mar 24, 2014

INJECTABLE; INJECTION

FLAGYL I.V. RTU IN PLASTIC CONTAINER

AP	+ ! BAXTER HLTHCARE	500MG/100ML	N018657 001	
<u>METRO I.V. IN PLASTIC CONTAINER</u>				
AP	+ ! B BRAUN	500MG/100ML	N018900 001	Sep 29, 1983
<u>METRONIDAZOLE IN PLASTIC CONTAINER</u>				
AP	BAXTER HLTHCARE CORP	500MG/100ML	A078084 001	Mar 31, 2008
AP	GLAND PHARMA LTD	500MG/100ML	A212435 001	Aug 03, 2020
AP	+ ! HOSPIRA	500MG/100ML	N018890 002	Nov 18, 1983
AP	INFORLIFE	500MG/100ML	A206191 001	Feb 25, 2019

LOTION; TOPICAL

METROLOTION

AB	+ ! GALDERMA LABS LP	0.75%	N020901 001	Nov 24, 1998
<u>METRONIDAZOLE</u>				
AB	FOUGERA PHARMS	0.75%	A077197 001	May 24, 2006

TABLET; ORAL

FLAGYL

AB	+ PFIZER	250MG	N012623 001	
AB	+ !	500MG	N012623 003	

METRONIDAZOLE

AB	ALEMBIC LABS	250MG	A208681 001	Jun 20, 2017
AB		500MG	A208681 002	Jun 20, 2017
AB	ALEMBIC PHARMS LTD	250MG	A079067 001	Mar 13, 2009
AB		500MG	A079067 002	Mar 13, 2009
AB	AUROBINDO PHARMA LTD	250MG	A203974 001	May 29, 2015
AB		500MG	A203974 002	May 29, 2015
AB	CADILA	250MG	A206560 001	Nov 16, 2016

PRESCRIPTION DRUG PRODUCT LIST

METRONIDAZOLE

TABLET; ORAL

METRONIDAZOLE

<u>AB</u>		<u>500MG</u>	<u>A206560</u>	<u>002</u>	Nov 16, 2016
<u>AB</u>	CADILA PHARMS LTD	<u>250MG</u>	<u>A209794</u>	<u>001</u>	Dec 12, 2017
<u>AB</u>		<u>500MG</u>	<u>A209794</u>	<u>002</u>	Dec 12, 2017
<u>AB</u>	FLAMINGO PHARMS	<u>250MG</u>	<u>A207309</u>	<u>001</u>	May 16, 2016
<u>AB</u>		<u>500MG</u>	<u>A207309</u>	<u>002</u>	May 16, 2016
<u>AB</u>	HERITAGE PHARMS INC	<u>250MG</u>	<u>A205245</u>	<u>001</u>	Sep 23, 2015
<u>AB</u>		<u>500MG</u>	<u>A205245</u>	<u>002</u>	Sep 23, 2015
<u>AB</u>	INNOGENIX	<u>250MG</u>	<u>A070772</u>	<u>001</u>	Jul 16, 1986
<u>AB</u>		<u>500MG</u>	<u>A070772</u>	<u>002</u>	Jul 16, 1986
<u>AB</u>	LUPIN LTD	<u>250MG</u>	<u>A209096</u>	<u>001</u>	Sep 12, 2017
<u>AB</u>		<u>500MG</u>	<u>A209096</u>	<u>002</u>	Sep 12, 2017
<u>AB</u>	PLIVA	<u>500MG</u>	<u>A070033</u>	<u>001</u>	Dec 06, 1984
<u>AB</u>	STRIDES PHARMA	<u>250MG</u>	<u>A070040</u>	<u>001</u>	Jan 29, 1985
<u>AB</u>		<u>250MG</u>	<u>A208162</u>	<u>001</u>	May 25, 2016
<u>AB</u>		<u>500MG</u>	<u>A070039</u>	<u>001</u>	Jan 29, 1985
<u>AB</u>		<u>500MG</u>	<u>A208162</u>	<u>002</u>	May 25, 2016
<u>AB</u>	TEVA PHARMS USA	<u>250MG</u>	<u>A070027</u>	<u>001</u>	Nov 06, 1984
<u>AB</u>	UNICHEM	<u>250MG</u>	<u>A203458</u>	<u>001</u>	Jan 22, 2014
<u>AB</u>		<u>500MG</u>	<u>A203458</u>	<u>002</u>	Jan 22, 2014
<u>AB</u>	WATSON LABS	<u>250MG</u>	<u>A070035</u>	<u>001</u>	Dec 20, 1984
<u>AB</u>	WATSON LABS INC	<u>500MG</u>	<u>A070044</u>	<u>001</u>	Feb 08, 1985

METYRAPONE

CAPSULE; ORAL

METOPIRONE

+! HRA PHARMA

250MG

N012911 002 Aug 09, 1996

METYROSINE

CAPSULE; ORAL

DEMSE

<u>AB</u>	+! BAUSCH	<u>250MG</u>	<u>N017871</u>	<u>001</u>	
<u>AB</u>	<u>METYROSINE</u>				
<u>AB</u>	AMNEAL	<u>250MG</u>	<u>A213734</u>	<u>001</u>	Jul 24, 2020

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HYDROCHLORIDE

<u>AB</u>	ANI PHARMS INC	<u>150MG</u>	<u>A074450</u>	<u>001</u>	May 16, 1996
<u>AB</u>		<u>200MG</u>	<u>A074450</u>	<u>002</u>	May 16, 1996
<u>AB</u>		<u>250MG</u>	<u>A074450</u>	<u>003</u>	May 16, 1996
<u>AB</u>	CROSSMEDIKA SA	<u>150MG</u>	<u>A213500</u>	<u>001</u>	Jul 22, 2020
<u>AB</u>		<u>200MG</u>	<u>A213500</u>	<u>002</u>	Jul 22, 2020
<u>AB</u>		<u>250MG</u>	<u>A213500</u>	<u>003</u>	Jul 22, 2020
<u>AB</u>	TEVA	<u>150MG</u>	<u>A074377</u>	<u>001</u>	May 16, 1995
<u>AB</u>		<u>200MG</u>	<u>A074377</u>	<u>002</u>	May 16, 1995
<u>AB</u>	!	<u>250MG</u>	<u>A074377</u>	<u>003</u>	May 16, 1995

MICAFUNGIN SODIUM

INJECTABLE; INTRAVENOUS

MICAFUNGIN SODIUM

<u>AP</u>	APOTEX	<u>EQ 50MG BASE/VIAL</u>	<u>A208366</u>	<u>001</u>	Nov 05, 2020
<u>AP</u>		<u>EQ 100MG BASE/VIAL</u>	<u>A208366</u>	<u>002</u>	Nov 05, 2020
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 50MG BASE/VIAL</u>	<u>A207344</u>	<u>001</u>	May 17, 2019
<u>AP</u>		<u>EQ 100MG BASE/VIAL</u>	<u>A207344</u>	<u>002</u>	May 17, 2019
<u>AP</u>	+! ASTELLAS	<u>EQ 50MG BASE/VIAL</u>	<u>N021506</u>	<u>002</u>	Mar 16, 2005
<u>AP</u>	+!	<u>EQ 100MG BASE/VIAL</u>	<u>N021506</u>	<u>003</u>	Jun 27, 2006

MICONAZOLE

TABLET; BUCCAL

ORAVIG

+! GALT PHARMS

50MG

N022404 001 Apr 16, 2010

MICONAZOLE NITRATE

SUPPOSITORY; VAGINAL

MICONAZOLE NITRATE

<u>AB</u>	ACTAVIS PHARMA	<u>200MG</u>	<u>A073508</u>	<u>001</u>	Nov 19, 1993
<u>AB</u>	<u>MONISTAT 3</u>				
<u>AB</u>	+! MEDTECH PRODUCTS	<u>200MG</u>	<u>N018888</u>	<u>001</u>	Aug 15, 1984

PRESCRIPTION DRUG PRODUCT LIST

MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE

OINTMENT; TOPICAL

VUSION

+! MYLAN

0.25%; 81.35%; 15%

N021026 001 Feb 16, 2006

MIDAZOLAM

SPRAY; NASAL

NAYZILAM

+! UCB INC

5MG/SPRAY

N211321 001 May 17, 2019

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

<u>AP</u>	AKORN INC	<u>EQ 1MG BASE/ML</u>	<u>A075494 001</u>	Jun 30, 2000
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A075494 002</u>	Jun 30, 2000
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 1MG BASE/ML</u>	<u>A075154 002</u>	Jun 20, 2000
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A075154 001</u>	Jun 20, 2000
<u>AP</u>	GLAND PHARMA LTD	<u>EQ 1MG BASE/ML</u>	<u>A090696 001</u>	Feb 29, 2012
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A090850 001</u>	Jan 25, 2012
<u>AP</u>	HIKMA	<u>EQ 1MG BASE/ML</u>	<u>A212847 001</u>	Dec 11, 2020
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A212847 002</u>	Dec 11, 2020
<u>AP</u>	! HOSPIRA	<u>EQ 1MG BASE/ML</u>	<u>A075293 001</u>	Jun 20, 2000
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A075856 001</u>	Jun 13, 2002
<u>AP</u>	!	<u>EQ 5MG BASE/ML</u>	<u>A075293 002</u>	Jun 20, 2000
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A075856 002</u>	Jun 13, 2002
<u>AP</u>	WEST-WARD PHARMS INT	<u>EQ 1MG BASE/ML</u>	<u>A075243 001</u>	Jun 20, 2000
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A075247 002</u>	Jun 23, 2000
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A075324 001</u>	Jun 20, 2000
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A075421 002</u>	Jun 20, 2000
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A075243 002</u>	Jun 20, 2000
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A075247 001</u>	Jun 23, 2000
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A075324 002</u>	Jun 20, 2000
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A075421 001</u>	Jun 20, 2000

MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 1MG BASE/ML</u>	<u>A203460 001</u>	Aug 22, 2014
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A203460 002</u>	Aug 22, 2014
<u>AP</u>	! HOSPIRA	<u>EQ 1MG BASE/ML</u>	<u>A075857 001</u>	Jul 22, 2002
<u>AP</u>	!	<u>EQ 5MG BASE/ML</u>	<u>A075857 002</u>	Jul 22, 2002
	MIDAZOLAM HYDROCHLORIDE FRESENIUS KABI USA	EQ 5MG BASE/ML	A208878 001	Mar 28, 2017
	SOLUTION; INTRAMUSCULAR SEIZALAM			
	+! MERIDIAN MEDCL TECHN	EQ 50MG BASE/10ML (EQ 5MG BASE/ML)	N209566 001	Sep 14, 2018

SYRUP; ORAL

MIDAZOLAM HYDROCHLORIDE

<u>AA</u>	AKORN	<u>EQ 2MG BASE/ML</u>	<u>A075958 001</u>	Sep 04, 2003
<u>AA</u>	! HIKMA	<u>EQ 2MG BASE/ML</u>	<u>A075873 001</u>	Apr 30, 2002
<u>AA</u>	PADDOCK LLC	<u>EQ 2MG BASE/ML</u>	<u>A076379 001</u>	May 02, 2005

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

MIDODRINE HYDROCHLORIDE

<u>AB</u>	APOTEX	<u>2.5MG</u>	<u>A077746 001</u>	Sep 12, 2006
<u>AB</u>		<u>5MG</u>	<u>A077746 002</u>	Sep 12, 2006
<u>AB</u>		<u>10MG</u>	<u>A077746 003</u>	Sep 12, 2006
<u>AB</u>	AUROBINDO PHARMA LTD	<u>2.5MG</u>	<u>A212774 001</u>	Aug 10, 2020
<u>AB</u>		<u>5MG</u>	<u>A212774 002</u>	Aug 10, 2020
<u>AB</u>		<u>10MG</u>	<u>A212774 003</u>	Aug 10, 2020
<u>AB</u>	IMPAX PHARMS	<u>2.5MG</u>	<u>A076449 001</u>	May 27, 2004
<u>AB</u>		<u>5MG</u>	<u>A076449 002</u>	May 27, 2004
<u>AB</u>		<u>10MG</u>	<u>A076449 003</u>	Dec 16, 2005
<u>AB</u>	MYLAN PHARMS INC	<u>2.5MG</u>	<u>A076577 001</u>	Sep 10, 2003
<u>AB</u>		<u>5MG</u>	<u>A076577 002</u>	Sep 10, 2003
<u>AB</u>		<u>10MG</u>	<u>A076577 003</u>	Sep 10, 2003
<u>AB</u>	PAR PHARM INC	<u>2.5MG</u>	<u>A207169 001</u>	Oct 29, 2018
<u>AB</u>		<u>5MG</u>	<u>A207169 002</u>	Oct 29, 2018
<u>AB</u>		<u>10MG</u>	<u>A207169 003</u>	Oct 29, 2018
<u>AB</u>	RUBICON	<u>2.5MG</u>	<u>A212543 001</u>	Aug 19, 2019
<u>AB</u>		<u>5MG</u>	<u>A212543 002</u>	Aug 19, 2019
<u>AB</u>		<u>10MG</u>	<u>A212543 003</u>	Aug 19, 2019
<u>AB</u>	UNIQUE PHARM LABS	<u>2.5MG</u>	<u>A207613 001</u>	Nov 02, 2018

PRESCRIPTION DRUG PRODUCT LIST

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

MIDODRINE HYDROCHLORIDE

<u>AB</u>		<u>5MG</u>	<u>A207613 002</u>	Nov 02, 2018
<u>AB</u>		<u>10MG</u>	<u>A207613 003</u>	Nov 02, 2018
<u>AB</u>	XIROMED	<u>2.5MG</u>	<u>A207849 001</u>	Oct 01, 2020
<u>AB</u>		<u>5MG</u>	<u>A207849 002</u>	Oct 01, 2020
<u>AB</u>		<u>10MG</u>	<u>A207849 003</u>	Oct 01, 2020
<u>AB</u>	ZYDUS	<u>2.5MG</u>	<u>A213055 001</u>	Sep 01, 2020
<u>AB</u>		<u>5MG</u>	<u>A213055 002</u>	Sep 01, 2020
<u>AB</u>		<u>10MG</u>	<u>A213055 003</u>	Sep 01, 2020

ORVATEN

<u>AB</u>	UPSHER SMITH LABS	<u>2.5MG</u>	<u>A076725 001</u>	Nov 03, 2004
<u>AB</u>	!	<u>5MG</u>	<u>A076725 002</u>	Nov 03, 2004
<u>AB</u>		<u>10MG</u>	<u>A076725 003</u>	Nov 03, 2004

MIDOSTAURIN

CAPSULE; ORAL

RYDAPT

+	NOVARTIS	25MG	N207997 001	Apr 28, 2017
---	----------	------	-------------	--------------

MIFEPRISTONE

TABLET; ORAL

KORLYM

<u>AB</u>	+	CORCEPT THERAP	<u>300MG</u>	<u>N202107 001</u>	Feb 17, 2012
-----------	---	----------------	--------------	--------------------	--------------

MIFEPREX

<u>AB</u>	+	DANCO LABS LLC	<u>200MG</u>	<u>N020687 001</u>	Sep 28, 2000
-----------	---	----------------	--------------	--------------------	--------------

MIFEPRISTONE

<u>AB</u>		GENBIOPRO	<u>200MG</u>	<u>A091178 001</u>	Apr 11, 2019
<u>AB</u>		TEVA PHARMS USA INC	<u>300MG</u>	<u>A211436 001</u>	Aug 03, 2020

MIGALASTAT HYDROCHLORIDE

CAPSULE; ORAL

GALAFOLD

+	AMICUS THERAPS US	EQ 123MG BASE	N208623 001	Aug 10, 2018
---	-------------------	---------------	-------------	--------------

MIGLITOL

TABLET; ORAL

GLYSET

<u>AB</u>	+	PHARMACIA AND UPJOHN	<u>25MG</u>	<u>N020682 001</u>	Dec 18, 1996
-----------	---	----------------------	-------------	--------------------	--------------

<u>AB</u>	+		<u>50MG</u>	<u>N020682 002</u>	Dec 18, 1996
-----------	---	--	-------------	--------------------	--------------

<u>AB</u>	+		<u>100MG</u>	<u>N020682 003</u>	Dec 18, 1996
-----------	---	--	--------------	--------------------	--------------

MIGLITOL

<u>AB</u>		ORIENT PHARMA CO LTD	<u>25MG</u>	<u>A203965 001</u>	Feb 24, 2015
-----------	--	----------------------	-------------	--------------------	--------------

<u>AB</u>			<u>50MG</u>	<u>A203965 002</u>	Feb 24, 2015
-----------	--	--	-------------	--------------------	--------------

<u>AB</u>			<u>100MG</u>	<u>A203965 003</u>	Feb 24, 2015
-----------	--	--	--------------	--------------------	--------------

MIGLUSTAT

CAPSULE; ORAL

MIGLUSTAT

<u>AB</u>		ANI PHARMS INC	<u>100MG</u>	<u>A208342 001</u>	Apr 17, 2018
-----------	--	----------------	--------------	--------------------	--------------

<u>AB</u>		EDENBRIDGE PHARMS	<u>100MG</u>	<u>A209821 001</u>	Aug 06, 2020
-----------	--	-------------------	--------------	--------------------	--------------

ZAVESCA

<u>AB</u>	+	ACTELION	<u>100MG</u>	<u>N021348 001</u>	Jul 31, 2003
-----------	---	----------	--------------	--------------------	--------------

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL

SAVELLA

+	ALLERGAN	12.5MG	N022256 001	Jan 14, 2009
---	----------	--------	-------------	--------------

+		25MG	N022256 002	Jan 14, 2009
---	--	------	-------------	--------------

+	!	50MG	N022256 003	Jan 14, 2009
---	---	------	-------------	--------------

+		100MG	N022256 004	Jan 14, 2009
---	--	-------	-------------	--------------

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

<u>AP</u>		FRESENIUS KABI USA	<u>EQ 1MG BASE/ML</u>	<u>A075936 001</u>	May 28, 2002
-----------	--	--------------------	-----------------------	--------------------	--------------

<u>AP</u>	!	HIKMA FARMACEUTICA	<u>EQ 1MG BASE/ML</u>	<u>A077966 001</u>	Dec 03, 2010
-----------	---	--------------------	-----------------------	--------------------	--------------

<u>AP</u>		HOSPIRA INC	<u>EQ 1MG BASE/ML</u>	<u>A203280 001</u>	Sep 03, 2014
-----------	--	-------------	-----------------------	--------------------	--------------

<u>AP</u>		MEITHEAL	<u>EQ 1MG BASE/ML</u>	<u>A211671 001</u>	Mar 24, 2020
-----------	--	----------	-----------------------	--------------------	--------------

<u>AP</u>		WEST-WARD PHARMS INT	<u>EQ 1MG BASE/ML</u>	<u>A075530 001</u>	May 28, 2002
-----------	--	----------------------	-----------------------	--------------------	--------------

<u>AP</u>			<u>EQ 1MG BASE/ML</u>	<u>A075660 001</u>	May 28, 2002
-----------	--	--	-----------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE IN DEXTROSE 5%

<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)</u>	<u>A209666 001</u>	Sep 03, 2020
<u>AP</u>		<u>EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)</u>	<u>A209666 002</u>	Sep 03, 2020
<u>AP</u>	WOODWARD	<u>EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)</u>	<u>A077151 002</u>	Jul 20, 2005
<u>MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER</u>				
<u>AP</u>	! BAXTER HLTHCARE	<u>EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)</u>	<u>A075834 001</u>	May 28, 2002
<u>AP</u>	!	<u>EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)</u>	<u>A075834 002</u>	May 28, 2002
<u>AP</u>	GLAND PHARMA LTD	<u>EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)</u>	<u>A213585 001</u>	Jul 16, 2020
<u>AP</u>		<u>EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)</u>	<u>A213585 002</u>	Jul 16, 2020
<u>AP</u>	HOSPIRA	<u>EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)</u>	<u>A075885 001</u>	May 28, 2002
<u>AP</u>		<u>EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)</u>	<u>A075885 002</u>	May 28, 2002
<u>AP</u>	WEST-WARD PHARMS INT	<u>EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)</u>	<u>A078113 001</u>	May 21, 2008
<u>AP</u>		<u>EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)</u>	<u>A078113 002</u>	May 21, 2008
<u>MILRINONE LACTATE IN PLASTIC CONTAINER</u>				
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)</u>	<u>A090038 001</u>	Jan 21, 2010
<u>AP</u>		<u>EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)</u>	<u>A090038 002</u>	Jan 21, 2010

MILTEFOSINE

CAPSULE; ORAL

IMPAVIDO

+! KNIGHT THERAPS

50MG

N204684 001 Mar 19, 2014

MINOCYCLINE HYDROCHLORIDE

AEROSOL, FOAM; TOPICAL

AMZEEQ

+! FOAMIX

EQ 4% BASE

N212379 001 Oct 18, 2019

ZILXI

+! FOAMIX

EQ 1.5% BASE

N213690 001 May 28, 2020

CAPSULE; ORAL

DYNACIN

<u>AB</u>	CNTY LINE PHARMS	<u>EQ 50MG BASE</u>	<u>A063067 003</u>	Aug 14, 1990
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A063067 002</u>	Sep 15, 1999
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A063067 001</u>	Jul 31, 1990

MINOCIN

<u>AB</u>	+ BAUSCH	<u>EQ 50MG BASE</u>	<u>N050649 001</u>	May 31, 1990
<u>AB</u>	+	<u>EQ 100MG BASE</u>	<u>N050649 002</u>	May 31, 1990

MINOCYCLINE HYDROCHLORIDE

<u>AB</u>	AUROBINDO PHARMA	<u>EQ 50MG BASE</u>	<u>A065470 001</u>	Mar 11, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065470 002</u>	Mar 11, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065470 003</u>	Mar 11, 2008
<u>AB</u>	IMPAX LABS	<u>EQ 50MG BASE</u>	<u>A065005 001</u>	Mar 23, 1999
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065005 003</u>	Apr 18, 2001
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065005 002</u>	Mar 23, 1999
<u>AB</u>	SUN PHARM INDS INC	<u>EQ 50MG BASE</u>	<u>A090867 001</u>	May 13, 2013
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A090867 002</u>	May 13, 2013
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A090867 003</u>	May 13, 2013
<u>AB</u>	TORRENT	<u>EQ 50MG BASE</u>	<u>A065062 001</u>	Nov 30, 2000
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065062 002</u>	Nov 30, 2000
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065062 003</u>	Nov 30, 2000
<u>AB</u>	WATSON LABS	<u>EQ 75MG BASE</u>	<u>A063065 002</u>	Jun 10, 1999
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A063065 001</u>	Dec 30, 1991
<u>AB</u>	WATSON LABS TEVA	<u>EQ 50MG BASE</u>	<u>A063181 001</u>	Dec 30, 1991
<u>AB</u>	ZYDUS	<u>EQ 50MG BASE</u>	<u>A063011 001</u>	Mar 02, 1992
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A063009 002</u>	Aug 12, 2003
<u>AB</u>	!	<u>EQ 100MG BASE</u>	<u>A063009 001</u>	Mar 02, 1992
CAPSULE, EXTENDED RELEASE; ORAL				
XIMINO				
	JOURNEY	EQ 45MG BASE	N201922 001	Jul 11, 2012
		EQ 90MG BASE	N201922 003	Jul 11, 2012
		EQ 135MG BASE	N201922 005	Jul 11, 2012

INJECTABLE; INJECTION

MINOCIN

+! REMPEX PHARMS

EQ 100MG BASE/VIAL

N050444 001

POWDER, EXTENDED RELEASE; DENTAL

ARESTIN

+! ORAPHARMA

EQ 1MG BASE

N050781 001 Feb 16, 2001

TABLET; ORAL

MINOCYCLINE HYDROCHLORIDE

<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 50MG BASE</u>	<u>A213662 001</u>	May 01, 2020
-----------	----------------------	---------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

MINOCYCLINE HYDROCHLORIDE

TABLET; ORAL

MINOCYCLINE HYDROCHLORIDE

<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A213662 002</u>	May 01, 2020
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A213662 003</u>	May 01, 2020
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 50MG BASE</u>	<u>A065436 001</u>	Dec 26, 2007
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065436 002</u>	Dec 26, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065436 003</u>	Dec 26, 2007
<u>AB</u>	PAR PHARM	<u>EQ 50MG BASE</u>	<u>A065131 001</u>	Apr 16, 2003
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065131 002</u>	Apr 16, 2003
<u>AB</u>	!	<u>EQ 100MG BASE</u>	<u>A065131 003</u>	Apr 16, 2003
<u>AB</u>	SUN PHARM INDUSTRIES	<u>EQ 50MG BASE</u>	<u>A090217 001</u>	Jan 29, 2016
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A090217 002</u>	Jan 29, 2016
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A090217 003</u>	Jan 29, 2016
<u>AB</u>	TORRENT	<u>EQ 50MG BASE</u>	<u>A065156 001</u>	Jan 06, 2004
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065156 002</u>	Jan 06, 2004
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065156 003</u>	Jan 06, 2004

TABLET, EXTENDED RELEASE; ORAL

MINOCYCLINE HYDROCHLORIDE

<u>AB</u>	ALKEM LABS LTD	<u>EQ 45MG BASE</u>	<u>A204453 001</u>	Sep 28, 2016
<u>AB</u>		<u>EQ 55MG BASE</u>	<u>A204453 008</u>	Dec 19, 2019
<u>AB</u>		<u>EQ 65MG BASE</u>	<u>A204453 006</u>	Mar 16, 2018
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A204453 002</u>	Sep 28, 2016
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A204453 003</u>	Sep 28, 2016
<u>AB</u>		<u>EQ 105MG BASE</u>	<u>A204453 004</u>	Sep 28, 2016
<u>AB</u>		<u>EQ 115MG BASE</u>	<u>A204453 007</u>	Mar 16, 2018
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A204453 005</u>	Sep 28, 2016
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 45MG BASE</u>	<u>A202261 001</u>	Nov 19, 2012
<u>AB</u>		<u>EQ 55MG BASE</u>	<u>A202261 008</u>	Aug 21, 2019
<u>AB</u>		<u>EQ 65MG BASE</u>	<u>A202261 002</u>	Sep 28, 2018
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A202261 006</u>	Jun 13, 2016
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A202261 003</u>	Nov 19, 2012
<u>AB</u>		<u>EQ 105MG BASE</u>	<u>A202261 007</u>	Jun 13, 2016
<u>AB</u>		<u>EQ 115MG BASE</u>	<u>A202261 004</u>	Sep 28, 2018
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A202261 005</u>	Nov 19, 2012
<u>AB</u>	BARR LABS INC	<u>EQ 65MG BASE</u>	<u>A065485 004</u>	May 18, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A065485 007</u>	Apr 26, 2017
<u>AB</u>		<u>EQ 105MG BASE</u>	<u>A065485 008</u>	Apr 26, 2017
<u>AB</u>		<u>EQ 115MG BASE</u>	<u>A065485 005</u>	May 18, 2012
<u>AB</u>	LUPIN LTD	<u>EQ 45MG BASE</u>	<u>A091424 001</u>	Nov 30, 2011
<u>AB</u>		<u>EQ 55MG BASE</u>	<u>A091424 002</u>	Nov 30, 2011
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A091424 003</u>	Nov 30, 2011
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A091424 004</u>	Nov 30, 2011
<u>AB</u>	MYLAN	<u>EQ 80MG BASE</u>	<u>A203443 002</u>	Aug 22, 2014
<u>AB</u>		<u>EQ 105MG BASE</u>	<u>A203443 003</u>	Aug 22, 2014
<u>AB</u>	SANDOZ	<u>EQ 45MG BASE</u>	<u>A090422 001</u>	Aug 13, 2009
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A090422 002</u>	Aug 13, 2009
<u>AB</u>	!	<u>EQ 135MG BASE</u>	<u>A090422 003</u>	Aug 13, 2009
<u>AB</u>	SIDMAK LABS INDIA	<u>EQ 45MG BASE</u>	<u>A204394 001</u>	Dec 30, 2015
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A204394 004</u>	Dec 30, 2015
<u>AB</u>		<u>EQ 105MG BASE</u>	<u>A204394 005</u>	Dec 30, 2015
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A204394 007</u>	Dec 30, 2015
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 45MG BASE</u>	<u>A091118 001</u>	Sep 25, 2014
<u>AB</u>		<u>EQ 65MG BASE</u>	<u>A091118 003</u>	Dec 03, 2019
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A091118 004</u>	Sep 25, 2014
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A091118 005</u>	Sep 25, 2014
<u>AB</u>		<u>EQ 105MG BASE</u>	<u>A091118 006</u>	Sep 25, 2014
<u>AB</u>		<u>EQ 115MG BASE</u>	<u>A091118 007</u>	Dec 03, 2019
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A091118 008</u>	Sep 25, 2014
<u>AB</u>	ZYDUS PHARMS	<u>EQ 45MG BASE</u>	<u>A203553 001</u>	Nov 16, 2017
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A203553 004</u>	Nov 16, 2017
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A203553 005</u>	Nov 16, 2017
<u>AB</u>		<u>EQ 105MG BASE</u>	<u>A203553 006</u>	Nov 16, 2017
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A203553 008</u>	Nov 16, 2017

SOLODYN

<u>AB</u>	+	MEDICIS	<u>EQ 55MG BASE</u>	<u>N050808 008</u>	Aug 27, 2010
<u>AB</u>	+		<u>EQ 65MG BASE</u>	<u>N050808 004</u>	Jul 23, 2009
<u>AB</u>	+		<u>EQ 80MG BASE</u>	<u>N050808 007</u>	Aug 27, 2010
<u>AB</u>	+		<u>EQ 105MG BASE</u>	<u>N050808 006</u>	Aug 27, 2010
<u>AB</u>	+	!	<u>EQ 115MG BASE</u>	<u>N050808 005</u>	Jul 23, 2009

PRESCRIPTION DRUG PRODUCT LIST

MINOCYCLINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

MINOLIRA

EPI HLTH	EQ 105MG BASE	N209269 001	May 08, 2017
	EQ 135MG BASE	N209269 002	May 08, 2017

MINOXIDIL

TABLET;ORAL

MINOXIDIL

AB	PAR PHARM	2.5MG	A071826 001	Nov 14, 1988
AB		10MG	A071839 001	Nov 14, 1988
AB	SUN PHARM	2.5MG	A072709 002	Dec 14, 1995
	INDUSTRIES			
AB		10MG	A072709 001	Dec 14, 1995
AB	WATSON LABS	2.5MG	A071344 001	Mar 03, 1987
AB	!	10MG	A071345 001	Mar 03, 1987

MIRABEGRON

TABLET, EXTENDED RELEASE;ORAL

MYRBETRIQ

+!	APGDI	25MG	N202611 001	Jun 28, 2012
+!		50MG	N202611 002	Jun 28, 2012

MIRTAZAPINE

TABLET;ORAL

MIRTAZAPINE

AB	APOTEX INC	15MG	A077666 001	Aug 22, 2007
AB		30MG	A077666 002	Aug 22, 2007
AB		45MG	A077666 003	Aug 22, 2007
AB	AUROBINDO	7.5MG	A076921 001	Oct 22, 2004
AB		15MG	A076921 002	Oct 22, 2004
AB		30MG	A076921 003	Oct 22, 2004
AB		45MG	A076921 004	Oct 22, 2004
AB	MYLAN	15MG	A076122 001	Jun 19, 2003
AB		30MG	A076122 002	Jun 19, 2003
AB		45MG	A076122 003	Jun 19, 2003
AB	SUN PHARM INDS INC	7.5MG	A076541 004	Apr 22, 2004
AB		15MG	A076541 001	Apr 22, 2004
AB		30MG	A076541 002	Apr 22, 2004
AB		45MG	A076541 003	Apr 22, 2004
AB	TEVA	15MG	A076119 001	Jan 24, 2003
AB		30MG	A076119 002	Jan 24, 2003
AB		45MG	A076119 003	Jun 19, 2003
AB	UPSHER SMITH LABS	15MG	A076219 001	Jun 19, 2003
AB		30MG	A076219 002	Jun 19, 2003
AB		45MG	A076219 003	Jun 19, 2003
REMERON				
AB	+!	ORGANON USA INC	15MG	N020415 001
AB	+		30MG	N020415 002
TABLET, ORALLY DISINTEGRATING;ORAL				
MIRTAZAPINE				
AB	AUROBINDO PHARMA	15MG	A077376 002	Dec 08, 2005
	LTD			
AB		30MG	A077376 003	Dec 08, 2005
AB		45MG	A077376 004	Feb 28, 2006
AB	ZYDUS PHARMS	15MG	A205798 001	Jun 01, 2017
AB		30MG	A205798 002	Jun 01, 2017
AB		45MG	A205798 003	Jun 01, 2017
REMERON SOLTAB				
AB	+!	ORGANON USA INC	15MG	N021208 001
AB	+		30MG	N021208 002
AB	+		45MG	N021208 003

MIRTAZAPINE

AB	AUROBINDO PHARMA	15MG	A077376 002	Dec 08, 2005
	LTD			
AB		30MG	A077376 003	Dec 08, 2005
AB		45MG	A077376 004	Feb 28, 2006
AB	ZYDUS PHARMS	15MG	A205798 001	Jun 01, 2017
AB		30MG	A205798 002	Jun 01, 2017
AB		45MG	A205798 003	Jun 01, 2017

REMERON SOLTAB

AB	+!	ORGANON USA INC	15MG	N021208 001	Jan 12, 2001
AB	+		30MG	N021208 002	Jan 12, 2001
AB	+		45MG	N021208 003	Jan 12, 2001

MISOPROSTOL

TABLET;ORAL

CYTOTEC

AB	+	PFIZER	0.1MG	N019268 003	Sep 21, 1990
AB	+!		0.2MG	N019268 001	Dec 27, 1988

MISOPROSTOL

AB		NOVEL LABS INC	0.1MG	A091667 001	Jul 25, 2012
AB			0.2MG	A091667 002	Jul 25, 2012

PRESCRIPTION DRUG PRODUCT LIST

MITOMYCIN

FOR SOLUTION; TOPICAL

MITOSOL

+! MOBIUS THERAP

0.2MG/VIAL

N022572 001 Feb 07, 2012

INJECTABLE; INJECTION

MITOMYCIN

<u>AP</u>	!	ACCORD HLTHCARE	<u>5MG/VIAL</u>	<u>A064144</u>	<u>001</u>	Apr 30, 1998
<u>AP</u>	!		<u>20MG/VIAL</u>	<u>A064144</u>	<u>002</u>	Apr 30, 1998
<u>AP</u>	!		<u>40MG/VIAL</u>	<u>A064144</u>	<u>003</u>	Aug 11, 2009
<u>AP</u>		RK PHARMA	<u>5MG/VIAL</u>	<u>A202670</u>	<u>001</u>	Oct 13, 2017
<u>AP</u>			<u>20MG/VIAL</u>	<u>A202670</u>	<u>002</u>	Oct 13, 2017
<u>AP</u>			<u>40MG/VIAL</u>	<u>A203386</u>	<u>001</u>	Oct 13, 2017
<u>AP</u>		WEST-WARD PHARMS INT	<u>5MG/VIAL</u>	<u>A064180</u>	<u>001</u>	Dec 23, 1999
<u>AP</u>			<u>20MG/VIAL</u>	<u>A064117</u>	<u>002</u>	Apr 19, 1995
<u>AP</u>			<u>20MG/VIAL</u>	<u>A064180</u>	<u>002</u>	Dec 23, 1999
<u>AP</u>			<u>40MG/VIAL</u>	<u>A064117</u>	<u>003</u>	Jun 02, 1999

POWDER; PYELOCALYCEAL

JELMYTO

+! UROGEN PHARMA

40MG/VIAL

N211728 001 Apr 15, 2020

MITOTANE

TABLET; ORAL

LYSODREN

+! HRA PHARMA

500MG

N016885 001

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

<u>AP</u>		FRESENIUS KABI USA	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>A077496</u>	<u>001</u>	Apr 11, 2006
<u>AP</u>			<u>EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)</u>	<u>A077496</u>	<u>002</u>	Apr 11, 2006
<u>AP</u>			<u>EQ 30MG BASE/15ML (EQ 2MG BASE/ML)</u>	<u>A077496</u>	<u>003</u>	Apr 11, 2006
<u>AP</u>	!	HOSPIRA	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>A076871</u>	<u>001</u>	Apr 11, 2006
<u>AP</u>	!		<u>EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)</u>	<u>A076871</u>	<u>002</u>	Apr 11, 2006
<u>AP</u>	!		<u>EQ 30MG BASE/15ML (EQ 2MG BASE/ML)</u>	<u>A076871</u>	<u>003</u>	Apr 11, 2006
<u>AP</u>		TEVA PHARMS USA	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>A077356</u>	<u>001</u>	Apr 11, 2006
<u>AP</u>			<u>EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)</u>	<u>A077356</u>	<u>002</u>	Apr 11, 2006
<u>AP</u>			<u>EQ 30MG BASE/15ML (EQ 2MG BASE/ML)</u>	<u>A077356</u>	<u>003</u>	Apr 11, 2006
<u>AP</u>		WEST-WARD PHARMS INT	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>A076611</u>	<u>001</u>	Apr 11, 2006
<u>AP</u>			<u>EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)</u>	<u>A076611</u>	<u>002</u>	Apr 11, 2006
<u>AP</u>			<u>EQ 30MG BASE/15ML (EQ 2MG BASE/ML)</u>	<u>A076611</u>	<u>003</u>	Apr 11, 2006

MODAFINIL

TABLET; ORAL

MODAFINIL

<u>AB</u>		ALEMBIC PHARMS LTD	<u>100MG</u>	<u>A202700</u>	<u>001</u>	Oct 18, 2012
<u>AB</u>			<u>200MG</u>	<u>A202700</u>	<u>002</u>	Oct 18, 2012
<u>AB</u>		APOTEX INC	<u>100MG</u>	<u>A077667</u>	<u>001</u>	Feb 03, 2014
<u>AB</u>			<u>200MG</u>	<u>A077667</u>	<u>002</u>	Feb 03, 2014
<u>AB</u>		APPCO	<u>100MG</u>	<u>A207196</u>	<u>001</u>	Aug 16, 2017
<u>AB</u>			<u>200MG</u>	<u>A207196</u>	<u>002</u>	Aug 16, 2017
<u>AB</u>		AUROBINDO PHARMA LTD	<u>100MG</u>	<u>A202566</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>			<u>200MG</u>	<u>A202566</u>	<u>002</u>	Sep 27, 2012
<u>AB</u>		CADILA	<u>100MG</u>	<u>A209966</u>	<u>001</u>	Sep 14, 2017
<u>AB</u>			<u>200MG</u>	<u>A209966</u>	<u>002</u>	Sep 14, 2017
<u>AB</u>		MYLAN PHARMS INC	<u>100MG</u>	<u>A076594</u>	<u>001</u>	Jul 16, 2012
<u>AB</u>			<u>200MG</u>	<u>A076594</u>	<u>002</u>	Jul 16, 2012
<u>AB</u>		ORCHID HLTHCARE	<u>100MG</u>	<u>A078963</u>	<u>001</u>	Sep 26, 2012
<u>AB</u>			<u>200MG</u>	<u>A078963</u>	<u>002</u>	Sep 26, 2012
<u>AB</u>		WATSON LABS INC	<u>100MG</u>	<u>A076715</u>	<u>001</u>	Nov 01, 2012
<u>AB</u>			<u>200MG</u>	<u>A076715</u>	<u>002</u>	Nov 01, 2012
		<u>PROVIGIL</u>				
<u>AB</u>	+	CEPHALON	<u>100MG</u>	<u>N020717</u>	<u>001</u>	Dec 24, 1998
<u>AB</u>	+!		<u>200MG</u>	<u>N020717</u>	<u>002</u>	Dec 24, 1998

MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE

<u>AB</u>		APOTEX INC	<u>7.5MG</u>	<u>A078454</u>	<u>001</u>	Jun 02, 2008
<u>AB</u>			<u>15MG</u>	<u>A078454</u>	<u>002</u>	Jun 02, 2008
<u>AB</u>		CHARTWELL RX	<u>7.5MG</u>	<u>A077536</u>	<u>001</u>	Nov 30, 2006
<u>AB</u>			<u>15MG</u>	<u>A077536</u>	<u>002</u>	Nov 30, 2006
<u>AB</u>		GLENMARK GENERICS	<u>7.5MG</u>	<u>A090416</u>	<u>001</u>	Mar 30, 2010

PRESCRIPTION DRUG PRODUCT LIST

MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE

<u>AB</u>		<u>15MG</u>	<u>A090416</u>	<u>002</u>	Mar 30, 2010
<u>AB</u>	TEVA	<u>7.5MG</u>	<u>A076204</u>	<u>001</u>	May 08, 2003
<u>AB</u>	!	<u>15MG</u>	<u>A076204</u>	<u>002</u>	May 08, 2003

MOLINDONE HYDROCHLORIDE

TABLET; ORAL

MOLINDONE HYDROCHLORIDE

EPIC PHARMA LLC

5MG

A090453 001 Mar 20, 2015

10MG

A090453 002 Mar 20, 2015

!

25MG

A090453 003 Mar 20, 2015

MOMETASONE FUROATE

AEROSOL, METERED; INHALATION

ASMANEX HFA

+ MERCK SHARP DOHME

0.05MG/INH

N205641 003 Aug 12, 2019

+

0.10MG/INH

N205641 001 Apr 25, 2014

+!

0.20MG/INH

N205641 002 Apr 25, 2014

CREAM; TOPICAL

MOMETASONE FUROATE

<u>AB</u>	COSETTE	<u>0.1%</u>	<u>A077447</u>	<u>001</u>	May 22, 2006
<u>AB</u>	!	<u>0.1%</u>	<u>A078541</u>	<u>001</u>	May 28, 2008
<u>AB</u>	TARO	<u>0.1%</u>	<u>A076679</u>	<u>001</u>	Dec 21, 2004

IMPLANT; IMPLANTATION

SINUVA

+ INTERSECT ENT INC

1.35MG

N209310 001 Dec 08, 2017

LOTION; TOPICAL

ELOCON

<u>AB</u>	+!	MERCK SHARP DOHME	<u>0.1%</u>	<u>N019796</u>	<u>001</u>	Mar 30, 1989
-----------	----	-------------------	-------------	----------------	------------	--------------

MOMETASONE FUROATE

<u>AB</u>	COSETTE	<u>0.1%</u>	<u>A077678</u>	<u>001</u>	Nov 21, 2007
<u>AB</u>	FOUGERA PHARMS	<u>0.1%</u>	<u>A075919</u>	<u>001</u>	Nov 29, 2007
<u>AB</u>	GLENMARK GENERICS	<u>0.1%</u>	<u>A090506</u>	<u>001</u>	Aug 09, 2010
<u>AB</u>	PERRIGO ISRAEL	<u>0.1%</u>	<u>A077180</u>	<u>001</u>	Apr 06, 2005
<u>AB</u>	TARO	<u>0.1%</u>	<u>A076788</u>	<u>001</u>	Mar 15, 2006

OINTMENT; TOPICAL

MOMETASONE FUROATE

<u>AB</u>	COSETTE	<u>0.1%</u>	<u>A077401</u>	<u>001</u>	Jun 20, 2006
<u>AB</u>	FOUGERA PHARMS	<u>0.1%</u>	<u>A077061</u>	<u>001</u>	Mar 28, 2005
<u>AB</u>	!	<u>0.1%</u>	<u>A078571</u>	<u>001</u>	May 28, 2008
<u>AB</u>	PERRIGO NEW YORK	<u>0.1%</u>	<u>A076067</u>	<u>001</u>	Mar 18, 2002
<u>AB</u>	TORRENT	<u>0.1%</u>	<u>A207899</u>	<u>001</u>	Jul 13, 2018

POWDER; INHALATION

ASMANEX TWISTHALER

+ MERCK SHARP DOHME

0.11MG/INH

N021067 002 Feb 01, 2008

+!

0.22MG/INH

N021067 001 Mar 30, 2005

SPRAY, METERED; NASAL

MOMETASONE FUROATE

<u>AB</u>	AMNEAL PHARMS	<u>0.05MG/SPRAY</u>	<u>A207989</u>	<u>001</u>	Apr 03, 2017
<u>AB</u>	APOTEX INC	<u>0.05MG/SPRAY</u>	<u>A091161</u>	<u>001</u>	Mar 22, 2016

NASONEX

<u>AB</u>	+!	MERCK SHARP DOHME	<u>0.05MG/SPRAY</u>	<u>N020762</u>	<u>001</u>	Oct 01, 1997
-----------	----	-------------------	---------------------	----------------	------------	--------------

MONOMETHYL FUMARATE

CAPSULE, DELAYED RELEASE; ORAL

BAFIERTAM

+! BANNER LIFE

95MG

N210296 001 Apr 28, 2020

SCIENCES

MONTELUKAST SODIUM

GRANULE; ORAL

MONTELUKAST SODIUM

<u>AB</u>	AJANTA PHARMA LTD	<u>EQ 4MG BASE/PACKET</u>	<u>A203438</u>	<u>001</u>	Jul 31, 2015
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 4MG BASE/PACKET</u>	<u>A213471</u>	<u>001</u>	Feb 18, 2020
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 4MG BASE/PACKET</u>	<u>A202906</u>	<u>001</u>	Sep 17, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 4MG BASE/PACKET</u>	<u>A090955</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>	TORRENT	<u>EQ 4MG BASE/PACKET</u>	<u>A210431</u>	<u>001</u>	Jul 31, 2018

SINGULAIR

<u>AB</u>	+!	MERCK	<u>EQ 4MG BASE/PACKET</u>	<u>N021409</u>	<u>001</u>	Jul 26, 2002
-----------	----	-------	---------------------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

MONTELUKAST SODIUM

TABLET; ORAL

MONTELUKAST SODIUM

AB	ACCORD HLTHCARE	EQ 10MG BASE	A202717 001	Sep 21, 2012
AB	ADAPTIS	EQ 10MG BASE	A209012 001	Apr 24, 2017
AB	AJANTA PHARMA LTD	EQ 10MG BASE	A203432 001	Jul 31, 2015
AB	AMNEAL PHARMS	EQ 10MG BASE	A204604 001	Sep 04, 2015
AB	ANBISON LAB	EQ 10MG BASE	A205683 001	Jan 12, 2016
AB	AUROBINDO PHARMA LTD	EQ 10MG BASE	A202468 001	Aug 03, 2012
AB	CIPLA	EQ 10MG BASE	A207463 001	Oct 28, 2016
AB	DR REDDYS LABS LTD	EQ 10MG BASE	A201582 001	Aug 06, 2012
AB	GLENMARK GENERICS	EQ 10MG BASE	A090926 001	Aug 03, 2012
AB	HETERO LABS LTD V	EQ 10MG BASE	A202843 001	Sep 10, 2014
AB	L FERRIGO CO	EQ 10MG BASE	A206112 001	Apr 26, 2017
AB	LANNETT CO INC	EQ 10MG BASE	A201522 001	Aug 03, 2012
AB	MACLEODS PHARMS LTD	EQ 10MG BASE	A203366 001	Sep 11, 2014
AB	SANDOZ INC	EQ 10MG BASE	A200889 001	Aug 03, 2012
AB	TEVA PHARMS	EQ 10MG BASE	A078605 001	Aug 03, 2012
AB	TORRENT PHARMS LTD	EQ 10MG BASE	A201515 001	Aug 03, 2012
AB	UNICHEM	EQ 10MG BASE	A204290 001	Oct 08, 2015
AB	UNIMARK REMEDIES LTD	EQ 10MG BASE	A202859 001	Oct 30, 2014

SINGULAIR

AB	+ ! MSD MERCK CO	EQ 10MG BASE	N020829 002	Feb 20, 1998
-----------	-------------------------	---------------------	--------------------	--------------

TABLET, CHEWABLE; ORAL

MONTELUKAST SODIUM

AB	ADAPTIS	EQ 4MG BASE	A209011 001	Apr 18, 2017
AB		EQ 5MG BASE	A209011 002	Apr 18, 2017
AB	AJANTA PHARMA LTD	EQ 4MG BASE	A203328 001	Jul 31, 2015
AB		EQ 5MG BASE	A203328 002	Jul 31, 2015
AB	AMNEAL PHARMS	EQ 4MG BASE	A205107 001	Sep 04, 2020
AB		EQ 5MG BASE	A205107 002	Sep 04, 2020
AB	ANBISON LAB	EQ 4MG BASE	A205695 001	Nov 05, 2015
AB		EQ 5MG BASE	A205695 002	Nov 05, 2015
AB	AUROBINDO PHARMA LTD	EQ 4MG BASE	A202096 001	Aug 03, 2012
AB		EQ 5MG BASE	A202096 002	Aug 03, 2012
AB	CIPLA	EQ 4MG BASE	A207464 001	Dec 06, 2018
AB		EQ 5MG BASE	A207464 002	Dec 06, 2018
AB	DR REDDYS LABS LTD	EQ 4MG BASE	A201581 001	Aug 06, 2012
AB		EQ 5MG BASE	A201581 002	Aug 06, 2012
AB	HETERO LABS LTD V	EQ 4MG BASE	A204093 001	May 22, 2015
AB		EQ 5MG BASE	A204093 002	May 22, 2015
AB	HIKMA	EQ 4MG BASE	A091128 001	Aug 03, 2012
AB		EQ 5MG BASE	A091128 002	Aug 03, 2012
AB	LANNETT CO INC	EQ 4MG BASE	A200405 001	Aug 03, 2012
AB		EQ 5MG BASE	A200405 002	Aug 03, 2012
AB	MACLEODS PHARMS LTD	EQ 4MG BASE	A203582 001	Mar 12, 2015
AB		EQ 5MG BASE	A203582 002	Mar 12, 2015
AB	SANDOZ INC	EQ 4MG BASE	A091414 001	Aug 03, 2012
AB		EQ 5MG BASE	A091414 002	Aug 03, 2012
AB	TEVA PHARMS	EQ 4MG BASE	A078723 001	Aug 03, 2012
AB		EQ 5MG BASE	A078723 002	Aug 03, 2012
AB	TORRENT PHARMS LTD	EQ 4MG BASE	A090984 001	Aug 03, 2012
AB		EQ 5MG BASE	A090984 002	Aug 03, 2012
AB	UNIMARK REMEDIES LTD	EQ 4MG BASE	A203037 001	Oct 30, 2014
AB		EQ 5MG BASE	A203037 002	Oct 30, 2014

SINGULAIR

AB	+ MSD MERCK CO	EQ 4MG BASE	N020830 002	Mar 03, 2000
AB	+ !	EQ 5MG BASE	N020830 001	Feb 20, 1998

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

KADIAN

AB	+ ! ALLERGAN	10MG	N020616 008	Apr 20, 2007
AB	+	20MG	N020616 001	Jul 03, 1996
AB	+	30MG	N020616 004	Mar 09, 2001
AB	+	40MG	N020616 009	Jul 09, 2012
AB	+	50MG	N020616 002	Jul 03, 1996
AB	+	60MG	N020616 005	Mar 09, 2001
AB	+	80MG	N020616 006	Oct 27, 2006
AB	+ !	100MG	N020616 003	Jul 03, 1996

PRESCRIPTION DRUG PRODUCT LIST

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

<u>AB</u>	IMPAX LABS INC	<u>20MG</u>	<u>A200411 001</u>	Apr 12, 2016
<u>AB</u>		<u>30MG</u>	<u>A200411 002</u>	Apr 12, 2016
<u>AB</u>		<u>40MG</u>	<u>A200411 007</u>	Jul 25, 2018
<u>AB</u>		<u>50MG</u>	<u>A200411 003</u>	Apr 12, 2016
<u>AB</u>		<u>60MG</u>	<u>A200411 004</u>	Apr 12, 2016
<u>AB</u>		<u>80MG</u>	<u>A200411 005</u>	Apr 12, 2016
<u>AB</u>		<u>100MG</u>	<u>A200411 006</u>	Apr 12, 2016
<u>AB</u>	UPSHER SMITH LABS	<u>10MG</u>	<u>A202104 001</u>	Jun 03, 2013
<u>AB</u>		<u>20MG</u>	<u>A202104 002</u>	Jun 03, 2013
<u>AB</u>		<u>30MG</u>	<u>A202104 003</u>	Jun 03, 2013
<u>AB</u>		<u>50MG</u>	<u>A202104 004</u>	Jun 03, 2013
<u>AB</u>		<u>60MG</u>	<u>A202104 005</u>	Jun 03, 2013
<u>AB</u>		<u>80MG</u>	<u>A202104 006</u>	Jun 03, 2013
<u>AB</u>		<u>100MG</u>	<u>A202104 007</u>	Jun 03, 2013
	KADIAN			
	+ ALLERGAN	70MG	N020616 010	Jul 09, 2012
	+	130MG	N020616 011	Jul 09, 2012
	+	150MG	N020616 012	Jul 09, 2012
	+!	200MG	N020616 007	Feb 27, 2007
	MORPHINE SULFATE			
	ACTAVIS ELIZABETH	30MG	A079040 001	Jan 16, 2013
		45MG	A079040 002	Jan 16, 2013
		60MG	A079040 003	Jan 16, 2013
		75MG	A079040 004	Jan 16, 2013
		90MG	A079040 005	Jan 16, 2013
	!	120MG	A079040 006	Jan 16, 2013

INJECTABLE; INJECTION

DURAMORPH PF

<u>AP</u>	+! HIKMA	<u>0.5MG/ML</u>	<u>N018565 001</u>	Sep 18, 1984
<u>AP</u>	+!	<u>1MG/ML</u>	<u>N018565 002</u>	Sep 18, 1984

INFUMORPH

<u>AP</u>	+! HIKMA	<u>10MG/ML</u>	<u>N018565 003</u>	Jul 19, 1991
<u>AP</u>	+!	<u>25MG/ML</u>	<u>N018565 004</u>	Jul 19, 1991

MITIGO

<u>AP</u>	PIRAMAL CRITICAL	<u>10MG/ML</u>	<u>A204393 001</u>	Jul 16, 2018
<u>AP</u>		<u>25MG/ML</u>	<u>A204393 002</u>	Jul 16, 2018

MORPHINE SULFATE

<u>AP</u>	! HIKMA	<u>4MG/ML</u>	<u>A205758 001</u>	May 21, 2015
<u>AP</u>	!	<u>8MG/ML</u>	<u>A205758 002</u>	May 21, 2015
<u>AP</u>		<u>10MG/ML</u>	<u>A205758 003</u>	May 21, 2015
<u>AP</u>	HOSPIRA	<u>0.5MG/ML</u>	<u>A071849 001</u>	May 11, 1988
<u>AP</u>		<u>0.5MG/ML</u>	<u>A073509 001</u>	Sep 30, 1992
<u>AP</u>		<u>1MG/ML</u>	<u>A073510 001</u>	Sep 30, 1992
<u>AP</u>	+ HOSPIRA INC	<u>4MG/ML</u>	<u>N202515 002</u>	Nov 14, 2011
<u>AP</u>	+	<u>8MG/ML</u>	<u>N202515 003</u>	Nov 14, 2011
<u>AP</u>	+	<u>10MG/ML</u>	<u>N202515 004</u>	Nov 14, 2011
	+!	2MG/ML	N202515 001	Nov 14, 2011

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

MORPHINE SULFATE

	+! FRESENIUS KABI USA	2MG/ML (2MG/ML)	N204223 001	Oct 30, 2013
	+	4MG/ML (4MG/ML)	N204223 002	Oct 30, 2013
	+	5MG/ML (5MG/ML)	N204223 003	Oct 30, 2013
	+	8MG/ML (8MG/ML)	N204223 004	Oct 30, 2013
	+	10MG/ML (10MG/ML)	N204223 005	Oct 30, 2013

SOLUTION; ORAL

MORPHINE SULFATE

<u>AA</u>	AKORN	<u>100MG/5ML</u>	<u>A208809 001</u>	Jul 06, 2017
<u>AA</u>	ANI PHARMS INC	<u>10MG/5ML</u>	<u>A205509 001</u>	Apr 17, 2018
<u>AA</u>		<u>20MG/5ML</u>	<u>A205509 002</u>	Apr 17, 2018
<u>AA</u>		<u>100MG/5ML</u>	<u>A205509 003</u>	Apr 17, 2018
<u>AA</u>	+ HIKMA	<u>10MG/5ML</u>	<u>N022195 001</u>	Mar 17, 2008
<u>AA</u>	+	<u>20MG/5ML</u>	<u>N022195 002</u>	Mar 17, 2008
<u>AA</u>	+!	<u>100MG/5ML</u>	<u>N022195 003</u>	Jan 25, 2010
<u>AA</u>	PADDOCK LLC	<u>100MG/5ML</u>	<u>A201574 001</u>	Aug 06, 2012
<u>AA</u>	PHARM ASSOC	<u>100MG/5ML</u>	<u>A206573 001</u>	Nov 14, 2016
<u>AA</u>	RHODES PHARMS	<u>10MG/5ML</u>	<u>A206308 001</u>	Jun 22, 2017
<u>AA</u>		<u>20MG/5ML</u>	<u>A206420 001</u>	Jul 12, 2016
<u>AA</u>		<u>100MG/5ML</u>	<u>A206308 002</u>	Jun 22, 2017
<u>AA</u>	SPECGX LLC	<u>100MG/5ML</u>	<u>A202348 001</u>	Jul 15, 2011

PRESCRIPTION DRUG PRODUCT LIST

MORPHINE SULFATE

SOLUTION;ORAL

MORPHINE SULFATE

<u>AA</u>	TRIS PHARMA INC	<u>10MG/5ML</u>	<u>A203518</u>	<u>001</u>	May 12, 2015
<u>AA</u>		<u>20MG/5ML</u>	<u>A203519</u>	<u>001</u>	May 18, 2016
<u>AA</u>		<u>100MG/5ML</u>	<u>A203518</u>	<u>002</u>	May 12, 2015

TABLET;ORAL

MORPHINE SULFATE

<u>AB</u>	ALKEM LABS LTD	<u>15MG</u>	<u>A212451</u>	<u>001</u>	Dec 03, 2020
<u>AB</u>		<u>30MG</u>	<u>A212451</u>	<u>002</u>	Dec 03, 2020
<u>AB</u>	+	<u>15MG</u>	<u>N022207</u>	<u>001</u>	Mar 17, 2008
<u>AB</u>	+	<u>30MG</u>	<u>N022207</u>	<u>002</u>	Mar 17, 2008
<u>AB</u>	UPSHER SMITH LABS	<u>15MG</u>	<u>A210610</u>	<u>001</u>	Jul 22, 2019
<u>AB</u>		<u>30MG</u>	<u>A210610</u>	<u>002</u>	Jul 22, 2019

TABLET, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

<u>AB</u>	ACTAVIS ELIZABETH	<u>15MG</u>	<u>A203849</u>	<u>001</u>	Apr 06, 2015
<u>AB</u>		<u>30MG</u>	<u>A203849</u>	<u>002</u>	Apr 06, 2015
<u>AB</u>		<u>60MG</u>	<u>A203849</u>	<u>003</u>	Apr 06, 2015
<u>AB</u>		<u>100MG</u>	<u>A203849</u>	<u>004</u>	Apr 06, 2015
<u>AB</u>		<u>200MG</u>	<u>A203849</u>	<u>005</u>	Apr 06, 2015
<u>AB</u>	DAVA PHARMS INC	<u>15MG</u>	<u>A075407</u>	<u>001</u>	Jan 28, 2000
<u>AB</u>	MAYNE PHARMA INC	<u>15MG</u>	<u>A205386</u>	<u>001</u>	Oct 28, 2016
<u>AB</u>		<u>30MG</u>	<u>A205386</u>	<u>002</u>	Oct 28, 2016
<u>AB</u>		<u>60MG</u>	<u>A205386</u>	<u>003</u>	Oct 28, 2016
<u>AB</u>		<u>100MG</u>	<u>A205386</u>	<u>004</u>	Oct 28, 2016
<u>AB</u>	NESHER PHARMS	<u>30MG</u>	<u>A076720</u>	<u>002</u>	Dec 23, 2005
<u>AB</u>		<u>60MG</u>	<u>A076720</u>	<u>001</u>	May 19, 2004
<u>AB</u>	NOVEL LABS INC	<u>15MG</u>	<u>A203602</u>	<u>001</u>	Dec 16, 2015
<u>AB</u>		<u>30MG</u>	<u>A203602</u>	<u>002</u>	Dec 16, 2015
<u>AB</u>		<u>60MG</u>	<u>A203602</u>	<u>003</u>	Dec 16, 2015
<u>AB</u>		<u>100MG</u>	<u>A203602</u>	<u>004</u>	Dec 16, 2015
<u>AB</u>		<u>200MG</u>	<u>A203602</u>	<u>005</u>	Dec 16, 2015
<u>AB</u>	RHODES PHARMS	<u>15MG</u>	<u>A074862</u>	<u>001</u>	Jul 07, 1998
<u>AB</u>		<u>30MG</u>	<u>A074862</u>	<u>002</u>	Jul 07, 1998
<u>AB</u>		<u>60MG</u>	<u>A074862</u>	<u>003</u>	Jul 07, 1998
<u>AB</u>		<u>100MG</u>	<u>A074769</u>	<u>001</u>	Jul 02, 1998
<u>AB</u>		<u>200MG</u>	<u>A074769</u>	<u>002</u>	Jul 02, 1998
<u>AB</u>	SPECGX LLC	<u>15MG</u>	<u>A076412</u>	<u>001</u>	Jul 31, 2003
<u>AB</u>		<u>30MG</u>	<u>A076412</u>	<u>002</u>	Jul 31, 2003
<u>AB</u>		<u>60MG</u>	<u>A076412</u>	<u>003</u>	Jul 31, 2003
<u>AB</u>		<u>100MG</u>	<u>A076438</u>	<u>001</u>	Jul 03, 2003
<u>AB</u>		<u>200MG</u>	<u>A076438</u>	<u>002</u>	Jul 03, 2003
<u>AB</u>	SUN PHARM INDS LTD	<u>15MG</u>	<u>A078761</u>	<u>001</u>	May 11, 2012
<u>AB</u>		<u>30MG</u>	<u>A078761</u>	<u>002</u>	May 11, 2012
<u>AB</u>		<u>60MG</u>	<u>A078761</u>	<u>003</u>	May 11, 2012
<u>AB</u>		<u>100MG</u>	<u>A078761</u>	<u>004</u>	May 11, 2012
<u>AB</u>		<u>200MG</u>	<u>A078761</u>	<u>005</u>	May 11, 2012
<u>AB</u>	VINTAGE PHARMS LLC	<u>15MG</u>	<u>A075295</u>	<u>001</u>	Oct 28, 1998
<u>AB</u>		<u>30MG</u>	<u>A075295</u>	<u>002</u>	Oct 28, 1998
<u>AB</u>		<u>60MG</u>	<u>A075295</u>	<u>003</u>	Oct 28, 1998
<u>AB</u>		<u>100MG</u>	<u>A075295</u>	<u>004</u>	Sep 15, 2000
<u>AB</u>		<u>200MG</u>	<u>A075295</u>	<u>005</u>	Sep 15, 2000

MS CONTIN

<u>AB</u>	+	PURDUE PHARMA LP	<u>15MG</u>	<u>N019516</u>	<u>003</u>	Sep 12, 1989
<u>AB</u>	+		<u>30MG</u>	<u>N019516</u>	<u>001</u>	May 29, 1987
<u>AB</u>	+		<u>60MG</u>	<u>N019516</u>	<u>002</u>	Apr 08, 1988
<u>AB</u>	+		<u>100MG</u>	<u>N019516</u>	<u>004</u>	Jan 16, 1990
<u>AB</u>	+		<u>200MG</u>	<u>N019516</u>	<u>005</u>	Nov 08, 1993

MOXIDECTIN

TABLET;ORAL

MOXIDECTIN

+	MDGH	2MG	N210867	001	Jun 13, 2018
---	------	-----	---------	-----	--------------

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION;INTRAVENOUS

MOXIFLOXACIN HYDROCHLORIDE

+	FRESENIUS KABI USA	EQ 400MG BASE/250ML (EQ 1.6MG BASE/ML)	N205572	001	Apr 03, 2015
---	--------------------	--	---------	-----	--------------

MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER

!	MYLAN LABS LTD	400MG/250ML (1.6MG/ML)	A205833	001	May 05, 2017
---	----------------	------------------------	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

MOXIFLOXACIN HYDROCHLORIDE

<u>AT1</u>	AKORN	<u>EQ 0.5% BASE</u>	<u>A202916</u>	<u>001</u>	Nov 09, 2017
<u>AT1</u>	ALEMBIC PHARMS LTD	<u>EQ 0.5% BASE</u>	<u>A209469</u>	<u>001</u>	Feb 13, 2019
<u>AT1</u>	APOTEX	<u>EQ 0.5% BASE</u>	<u>A090080</u>	<u>001</u>	Jun 30, 2017
<u>AT1</u>	AUROBINDO PHARMA LTD	<u>EQ 0.5% BASE</u>	<u>A206242</u>	<u>001</u>	Oct 04, 2017
<u>AT1</u>	GLAND PHARMA LTD	<u>EQ 0.5% BASE</u>	<u>A208778</u>	<u>001</u>	Mar 30, 2020
<u>AT1</u>	LUPIN LTD	<u>EQ 0.5% BASE</u>	<u>A202867</u>	<u>001</u>	Sep 04, 2014
<u>AT1</u>	MYLAN	<u>EQ 0.5% BASE</u>	<u>A206447</u>	<u>001</u>	Mar 30, 2020
<u>AT1</u>	WATSON LABS INC	<u>EQ 0.5% BASE</u>	<u>A202525</u>	<u>001</u>	Mar 06, 2015

VIGAMOX

<u>AT1</u>	<u>+</u> ! NOVARTIS	<u>EQ 0.5% BASE</u>	<u>N021598</u>	<u>001</u>	Apr 15, 2003
<u>AT2</u>	<u>+</u> ! NOVARTIS	<u>EQ 0.5% BASE</u>	<u>N022428</u>	<u>001</u>	Nov 19, 2010

MOXIFLOXACIN HYDROCHLORIDE

<u>AT2</u>	LUPIN LTD	<u>EQ 0.5% BASE</u>	<u>A204079</u>	<u>001</u>	May 28, 2015
------------	-----------	---------------------	----------------	------------	--------------

TABLET;ORAL

MOXIFLOXACIN HYDROCHLORIDE

<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 400MG BASE</u>	<u>A202632</u>	<u>001</u>	Mar 04, 2014
<u>AB</u>	CROSSMEDIKA SA	<u>EQ 400MG BASE</u>	<u>A205348</u>	<u>001</u>	Jan 14, 2016
<u>AB</u>	<u>!</u> DR REDDYS LABS LTD	<u>EQ 400MG BASE</u>	<u>A076938</u>	<u>001</u>	Mar 04, 2014
<u>AB</u>	MSN	<u>EQ 400MG BASE</u>	<u>A208682</u>	<u>001</u>	Sep 22, 2017
<u>AB</u>	NOVEL LABS INC	<u>EQ 400MG BASE</u>	<u>A207285</u>	<u>001</u>	Feb 13, 2017
<u>AB</u>	TEVA PHARMS USA	<u>EQ 400MG BASE</u>	<u>A077437</u>	<u>001</u>	Feb 18, 2014
<u>AB</u>	TORRENT	<u>EQ 400MG BASE</u>	<u>A200160</u>	<u>001</u>	Apr 03, 2014

MUPIROCIN

OINTMENT;TOPICAL

MUPIROCIN

<u>AB</u>	FOUGERA PHARMS	<u>2%</u>	<u>A065192</u>	<u>001</u>	Nov 30, 2005
<u>AB</u>	GLENMARK PHARMS	<u>2%</u>	<u>A090480</u>	<u>001</u>	Jun 08, 2011
<u>AB</u>	<u>!</u> PERRIGO ISRAEL	<u>2%</u>	<u>A065123</u>	<u>001</u>	Nov 07, 2003
<u>AB</u>	TARO	<u>2%</u>	<u>A065170</u>	<u>001</u>	Sep 23, 2005
<u>AB</u>	TEVA	<u>2%</u>	<u>A065085</u>	<u>001</u>	Nov 07, 2003
	CENTANY				
<u>BX</u>	PERRIGO NEW YORK	<u>2%</u>	<u>N050788</u>	<u>001</u>	Dec 04, 2002

MUPIROCIN CALCIUM

CREAM;TOPICAL

MUPIROCIN

<u>AB</u>	<u>!</u> GLENMARK PHARMS INC	<u>EQ 2% BASE</u>	<u>A201587</u>	<u>001</u>	Jan 24, 2013
<u>AB</u>	TARO	<u>EQ 2% BASE</u>	<u>A207116</u>	<u>001</u>	Apr 27, 2020

MYCOPHENOLATE MOFETIL

CAPSULE;ORAL

CELLCEPT

<u>AB</u>	<u>+</u> ! ROCHE PALO	<u>250MG</u>	<u>N050722</u>	<u>001</u>	May 03, 1995
-----------	-----------------------	--------------	----------------	------------	--------------

MYCOPHENOLATE MOFETIL

<u>AB</u>	ACCORD HLTHCARE	<u>250MG</u>	<u>A090253</u>	<u>001</u>	May 04, 2009
<u>AB</u>	ALKEM LABS LTD	<u>250MG</u>	<u>A200197</u>	<u>001</u>	Jun 13, 2013
<u>AB</u>	CONCORD BIOTECH LTD	<u>250MG</u>	<u>A210181</u>	<u>001</u>	Jan 08, 2019
<u>AB</u>	HIKMA	<u>250MG</u>	<u>A065410</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>	MYLAN	<u>250MG</u>	<u>A065520</u>	<u>001</u>	May 04, 2009
<u>AB</u>	SANDOZ	<u>250MG</u>	<u>A065379</u>	<u>001</u>	Oct 15, 2008
<u>AB</u>	STRIDES PHARMA	<u>250MG</u>	<u>A090055</u>	<u>001</u>	Jun 10, 2010
<u>AB</u>	TEVA PHARMS	<u>250MG</u>	<u>A065491</u>	<u>001</u>	May 06, 2009
<u>AB</u>	ZHEJIANG HISUN PHARM	<u>250MG</u>	<u>A204077</u>	<u>001</u>	Nov 13, 2017

SUSPENSION;ORAL

CELLCEPT

<u>AB</u>	<u>+</u> ! ROCHE PALO	<u>200MG/ML</u>	<u>N050759</u>	<u>001</u>	Oct 01, 1998
-----------	-----------------------	-----------------	----------------	------------	--------------

MYCOPHENOLATE MOFETIL

<u>AB</u>	ALKEM LABS LTD	<u>200MG/ML</u>	<u>A203005</u>	<u>001</u>	Nov 14, 2014
<u>AB</u>	VISTAPHARM	<u>200MG/ML</u>	<u>A210370</u>	<u>001</u>	Feb 12, 2019

TABLET;ORAL

CELLCEPT

<u>AB</u>	<u>+</u> ! ROCHE PALO	<u>500MG</u>	<u>N050723</u>	<u>001</u>	Jun 19, 1997
-----------	-----------------------	--------------	----------------	------------	--------------

MYCOPHENOLATE MOFETIL

<u>AB</u>	ACCORD HLTHCARE	<u>500MG</u>	<u>A065416</u>	<u>001</u>	May 04, 2009
<u>AB</u>	ALKEM LABS LTD	<u>500MG</u>	<u>A091249</u>	<u>001</u>	Nov 04, 2011
<u>AB</u>	CONCORD BIOTECH LTD	<u>500MG</u>	<u>A212087</u>	<u>001</u>	Jul 31, 2020

PRESCRIPTION DRUG PRODUCT LIST

MYCOPHENOLATE MOFETIL

TABLET; ORAL

MYCOPHENOLATE MOFETIL

<u>AB</u>	HIKMA	<u>500MG</u>	<u>A065413</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>	MYLAN	<u>500MG</u>	<u>A065521</u>	<u>001</u>	May 04, 2009
<u>AB</u>	SANDOZ	<u>500MG</u>	<u>A065451</u>	<u>001</u>	Oct 15, 2008
<u>AB</u>	STRIDES PHARMA	<u>500MG</u>	<u>A090456</u>	<u>001</u>	Jun 10, 2010
<u>AB</u>	ZHEJIANG HISUN PHARM	<u>500MG</u>	<u>A204076</u>	<u>001</u>	Nov 16, 2017

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE; INJECTION

CELLCEPT

<u>AP</u>	+!	ROCHE PALO	<u>500MG/VIAL</u>	<u>N050758</u>	<u>001</u>	Aug 12, 1998
-----------	----	------------	-------------------	----------------	------------	--------------

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

<u>AP</u>		AKORN INC	<u>500MG/VIAL</u>	<u>A204043</u>	<u>001</u>	Feb 28, 2017
<u>AP</u>		MYLAN LABS LTD	<u>500MG/VIAL</u>	<u>A203859</u>	<u>001</u>	Mar 31, 2017
<u>AP</u>		PAR STERILE PRODUCTS	<u>500MG/VIAL</u>	<u>A203575</u>	<u>001</u>	Oct 28, 2016
<u>AP</u>		ZYDUS PHARMS	<u>500MG/VIAL</u>	<u>A204473</u>	<u>001</u>	Aug 31, 2017

MYCOPHENOLIC ACID

TABLET, DELAYED RELEASE; ORAL

MYCOPHENOLIC ACID

<u>AB</u>		ACCORD HLTHCARE	<u>180MG</u>	<u>A202555</u>	<u>001</u>	Aug 23, 2017
<u>AB</u>			<u>360MG</u>	<u>A202555</u>	<u>002</u>	Aug 23, 2017
<u>AB</u>		APOTEX INC	<u>180MG</u>	<u>A091558</u>	<u>001</u>	Aug 21, 2012
<u>AB</u>			<u>360MG</u>	<u>A091558</u>	<u>002</u>	Aug 19, 2014
<u>AB</u>		CONCORD BIOTECH LTD	<u>180MG</u>	<u>A211173</u>	<u>001</u>	Dec 13, 2019
<u>AB</u>			<u>360MG</u>	<u>A211173</u>	<u>002</u>	Dec 13, 2019
<u>AB</u>		RK PHARMA	<u>180MG</u>	<u>A091248</u>	<u>002</u>	Jan 08, 2014
<u>AB</u>			<u>360MG</u>	<u>A091248</u>	<u>001</u>	Jan 08, 2014
		<u>MYFORTIC</u>				
<u>AB</u>	+	NOVARTIS	<u>180MG</u>	<u>N050791</u>	<u>001</u>	Feb 27, 2004
<u>AB</u>	+!		<u>360MG</u>	<u>N050791</u>	<u>002</u>	Feb 27, 2004

NABILONE

CAPSULE; ORAL

CESAMET

	+!	BAUSCH	1MG	N018677	001	Dec 26, 1985
--	----	--------	-----	---------	-----	--------------

NABUMETONE

TABLET; ORAL

NABUMETONE

<u>AB</u>		CHARTWELL MOLECULES	<u>500MG</u>	<u>A076009</u>	<u>001</u>	Jan 24, 2003
<u>AB</u>			<u>750MG</u>	<u>A076009</u>	<u>002</u>	Jan 24, 2003
<u>AB</u>		CHARTWELL RX	<u>500MG</u>	<u>A075280</u>	<u>001</u>	Feb 25, 2002
<u>AB</u>			<u>750MG</u>	<u>A075280</u>	<u>002</u>	Feb 25, 2002
<u>AB</u>		INVAGEN PHARMS	<u>500MG</u>	<u>A078671</u>	<u>001</u>	Mar 07, 2008
<u>AB</u>	!		<u>750MG</u>	<u>A078671</u>	<u>002</u>	Mar 07, 2008
<u>AB</u>		LGM PHARMA	<u>500MG</u>	<u>A203166</u>	<u>001</u>	Aug 30, 2019
<u>AB</u>			<u>750MG</u>	<u>A203166</u>	<u>002</u>	Aug 30, 2019
<u>AB</u>		LUPIN LTD	<u>500MG</u>	<u>A090445</u>	<u>001</u>	Jan 12, 2011
<u>AB</u>			<u>750MG</u>	<u>A090445</u>	<u>002</u>	Jan 12, 2011
<u>AB</u>		SCIEGEN PHARMS INC	<u>500MG</u>	<u>A078420</u>	<u>001</u>	Sep 24, 2008
<u>AB</u>			<u>750MG</u>	<u>A078420</u>	<u>002</u>	Sep 24, 2008
<u>AB</u>		WATSON LABS	<u>500MG</u>	<u>A091083</u>	<u>001</u>	Jun 13, 2011
<u>AB</u>			<u>750MG</u>	<u>A091083</u>	<u>002</u>	Jun 13, 2011
		LGM PHARMA	1GM	A203166	003	Aug 30, 2019

NADOLOL

TABLET; ORAL

CORGARD

<u>AB</u>	+	USWM	<u>20MG</u>	<u>N018063</u>	<u>005</u>	Oct 28, 1986
<u>AB</u>	+		<u>40MG</u>	<u>N018063</u>	<u>001</u>	
<u>AB</u>	+!		<u>80MG</u>	<u>N018063</u>	<u>002</u>	

NADOLOL

<u>AB</u>		AMNEAL PHARMS CO	<u>20MG</u>	<u>A208832</u>	<u>001</u>	Jun 02, 2017
<u>AB</u>			<u>40MG</u>	<u>A208832</u>	<u>002</u>	Jun 02, 2017
<u>AB</u>			<u>80MG</u>	<u>A208832</u>	<u>003</u>	Jun 02, 2017
<u>AB</u>		AUROBINDO PHARMA LTD	<u>40MG</u>	<u>A201893</u>	<u>001</u>	Sep 16, 2015
<u>AB</u>			<u>80MG</u>	<u>A201893</u>	<u>002</u>	Sep 16, 2015
<u>AB</u>		BEXIMCO PHARMS USA	<u>20MG</u>	<u>A210955</u>	<u>001</u>	Jul 23, 2018
<u>AB</u>			<u>40MG</u>	<u>A210955</u>	<u>002</u>	Jul 23, 2018

PRESCRIPTION DRUG PRODUCT LIST

NADOLOL

TABLET; ORAL

NADOLOL

<u>AB</u>		<u>80MG</u>	<u>A210955 003</u>	Jul 23, 2018
<u>AB</u>	HERITAGE PHARMA	<u>20MG</u>	<u>A074229 001</u>	Aug 30, 1996
<u>AB</u>		<u>40MG</u>	<u>A074229 002</u>	Aug 30, 1996
<u>AB</u>		<u>80MG</u>	<u>A074255 001</u>	Jan 24, 1996
<u>AB</u>	INVAGEN PHARMS	<u>20MG</u>	<u>A203455 001</u>	Dec 18, 2015
<u>AB</u>		<u>40MG</u>	<u>A203455 002</u>	Dec 18, 2015
<u>AB</u>		<u>80MG</u>	<u>A203455 003</u>	Dec 18, 2015
<u>AB</u>	LUPIN LTD	<u>20MG</u>	<u>A209309 001</u>	Oct 05, 2017
<u>AB</u>		<u>40MG</u>	<u>A209309 002</u>	Oct 05, 2017
<u>AB</u>		<u>80MG</u>	<u>A209309 003</u>	Oct 05, 2017
<u>AB</u>	MYLAN	<u>20MG</u>	<u>A074172 001</u>	Oct 31, 1993
<u>AB</u>		<u>40MG</u>	<u>A074172 002</u>	Oct 31, 1993
<u>AB</u>		<u>80MG</u>	<u>A074172 003</u>	Oct 31, 1993
<u>AB</u>	NOVAST LABS	<u>20MG</u>	<u>A210786 001</u>	Jun 01, 2018
<u>AB</u>		<u>40MG</u>	<u>A210786 002</u>	Jun 01, 2018
<u>AB</u>		<u>80MG</u>	<u>A210786 003</u>	Jun 01, 2018
<u>AB</u>	SANDOZ	<u>20MG</u>	<u>A074501 001</u>	Nov 09, 1995
<u>AB</u>		<u>40MG</u>	<u>A074501 002</u>	Nov 09, 1995
<u>AB</u>		<u>80MG</u>	<u>A074501 003</u>	Nov 09, 1995
<u>AB</u>	ZYDUS PHARMS	<u>20MG</u>	<u>A207761 001</u>	Jul 28, 2017
<u>AB</u>		<u>40MG</u>	<u>A207761 002</u>	Jul 28, 2017
<u>AB</u>		<u>80MG</u>	<u>A207761 003</u>	Jul 28, 2017

NAFARELIN ACETATE

SPRAY, METERED; NASAL

SYNAREL

+! PFIZER

EQ 0.2MG BASE/SPRAY

N019886 001 Feb 13, 1990

NAFCILLIN SODIUM

INJECTABLE; INJECTION

NAFCILLIN SODIUM

<u>AP</u>	ANTIBIOTICE	<u>EQ 1GM BASE/VIAL</u>	<u>A090560 001</u>	Oct 03, 2011
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A090560 002</u>	Oct 03, 2011
<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 1GM BASE/VIAL</u>	<u>A091613 001</u>	Dec 26, 2012
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A091613 002</u>	Dec 26, 2012
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A091614 001</u>	Dec 26, 2012
<u>AP</u>	FRESENIUS	<u>EQ 10GM BASE/VIAL</u>	<u>A206761 001</u>	Jun 02, 2020
<u>AP</u>	ISTITUTO BIO ITA SPA	<u>EQ 1GM BASE/VIAL</u>	<u>A090002 001</u>	Jun 30, 2011
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A090002 002</u>	Jun 30, 2011
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A090005 001</u>	Apr 20, 2011
<u>AP</u>	SAGENT PHARMS	<u>EQ 1GM BASE/VIAL</u>	<u>A090582 001</u>	Aug 24, 2012
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A090582 002</u>	Aug 24, 2012
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A090580 001</u>	Aug 24, 2012
<u>AP</u>	! SANDOZ	<u>EQ 1GM BASE/VIAL</u>	<u>A062527 002</u>	Aug 02, 1984
<u>AP</u>	!	<u>EQ 1GM BASE/VIAL</u>	<u>A062732 001</u>	Dec 23, 1986
<u>AP</u>	!	<u>EQ 2GM BASE/VIAL</u>	<u>A062527 003</u>	Aug 02, 1984
<u>AP</u>	!	<u>EQ 2GM BASE/VIAL</u>	<u>A062732 002</u>	Dec 23, 1986
<u>AP</u>	!	<u>EQ 10GM BASE/VIAL</u>	<u>A062527 004</u>	Aug 02, 1984
	NALLPEN IN PLASTIC CONTAINER			
	+! BAXTER HLTHCARE	EQ 20MG BASE/ML	N050655 001	Oct 31, 1989
	+!	EQ 2GM BASE/100ML	N050655 002	Oct 31, 1989

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL

NAFTIFINE HYDROCHLORIDE

<u>AB</u>	TARO PHARMS	<u>2%</u>	<u>A206901 001</u>	Jan 06, 2016
<u>AB</u>	TOLMAR	<u>2%</u>	<u>A206960 001</u>	Apr 10, 2017
<u>AB</u>	XIROMED	<u>2.0%</u>	<u>A210038 001</u>	Sep 22, 2020
	<u>NAFTIN</u>			
<u>AB</u>	+! SEBELA IRELAND LTD	<u>2%</u>	<u>N019599 002</u>	Jan 13, 2012
	NAFTIFINE HYDROCHLORIDE			
	! TARO PHARMS	1%	A205975 001	Sep 08, 2016
	GEL; TOPICAL			
	<u>NAFTIFINE HYDROCHLORIDE</u>			
<u>AB</u>	TOLMAR	<u>1%</u>	<u>A206165 001</u>	Mar 20, 2019
	<u>NAFTIN</u>			
<u>AB</u>	+! SEBELA IRELAND LTD	<u>1%</u>	<u>N019356 001</u>	Jun 18, 1990
<u>AB</u>	+!	<u>2%</u>	<u>N204286 001</u>	Jun 27, 2013

PRESCRIPTION DRUG PRODUCT LIST

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

NALBUPHINE HYDROCHLORIDE

AP	!	HOSPIRA	<u>10MG/ML</u>	<u>A070914</u>	<u>001</u>	Feb 03, 1989
AP	!		<u>10MG/ML</u>	<u>A070915</u>	<u>001</u>	Feb 03, 1989
AP	!		<u>20MG/ML</u>	<u>A070916</u>	<u>001</u>	Feb 03, 1989
AP	!		<u>20MG/ML</u>	<u>A070918</u>	<u>001</u>	Feb 03, 1989

NALDEMEDINE TOSYLATE

TABLET; ORAL

SYMPROIC

+	!	BDSI	EQ 0.2MG BASE	N208854	001	Mar 23, 2017
---	---	------	---------------	---------	-----	--------------

NALOXEGOL OXALATE

TABLET; ORAL

MOVANTIK

+		REDHILL	EQ 12.5MG BASE	N204760	001	Sep 16, 2014
---	--	---------	----------------	---------	-----	--------------

+	!		EQ 25MG BASE	N204760	002	Sep 16, 2014
---	---	--	--------------	---------	-----	--------------

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE

AP		WEST-WARD PHARMS INT	<u>0.4MG/ML</u>	<u>A070299</u>	<u>001</u>	Sep 24, 1986
-----------	--	-------------------------	-----------------	----------------	------------	--------------

NALOXONE HYDROCHLORIDE

AP		AKORN	<u>0.4MG/ML</u>	<u>A208871</u>	<u>001</u>	Feb 28, 2017
AP			<u>0.4MG/ML</u>	<u>A208872</u>	<u>001</u>	Mar 14, 2017
AP		AUROBINDO PHARMA LTD	<u>0.4MG/ML</u>	<u>A212455</u>	<u>001</u>	Oct 15, 2019
AP			<u>0.4MG/ML</u>	<u>A212456</u>	<u>001</u>	Nov 04, 2019
AP		DR REDDYS	<u>1MG/ML</u>	<u>A213209</u>	<u>001</u>	Mar 16, 2020
AP	!	HOSPIRA	<u>0.4MG/ML</u>	<u>A070172</u>	<u>001</u>	Sep 24, 1986
AP	!		<u>0.4MG/ML</u>	<u>A070254</u>	<u>001</u>	Jan 07, 1987
AP	!		<u>0.4MG/ML</u>	<u>A070256</u>	<u>001</u>	Jan 07, 1987
AP	!		<u>0.4MG/ML</u>	<u>A070257</u>	<u>001</u>	Jan 07, 1987
AP	!	INTL MEDICATION	<u>1MG/ML</u>	<u>A072076</u>	<u>001</u>	Mar 24, 1988
AP		MYLAN INSTITUTIONAL	<u>0.4MG/ML</u>	<u>A204997</u>	<u>001</u>	Mar 06, 2014
AP			<u>0.4MG/ML</u>	<u>A205014</u>	<u>001</u>	Jun 29, 2016
AP		SOMERSET THERAPS LLC	<u>0.4MG/ML</u>	<u>A207633</u>	<u>001</u>	Aug 08, 2017
AP			<u>0.4MG/ML</u>	<u>A207634</u>	<u>001</u>	Jul 26, 2017

SPRAY, METERED; NASAL

NARCAN

+	!	EMERGENT	4MG/SPRAY	N208411	001	Nov 18, 2015
---	---	----------	-----------	---------	-----	--------------

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE

AB		LUPIN	<u>EQ 0.5MG BASE; EQ 50MG BASE</u>	<u>A075735</u>	<u>001</u>	Jul 11, 2001
AB		SUN PHARM INDS LTD	<u>EQ 0.5MG BASE; EQ 50MG BASE</u>	<u>A075523</u>	<u>001</u>	Mar 17, 2000
AB	!	WATSON LABS	<u>EQ 0.5MG BASE; EQ 50MG BASE</u>	<u>A074736</u>	<u>001</u>	Jan 21, 1997

NALTREXONE

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

VIVITROL

+	!	ALKERMES	380MG/VIAL	N021897	001	Apr 13, 2006
---	---	----------	------------	---------	-----	--------------

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

AB		ACCORD HLTHCARE	<u>50MG</u>	<u>A091205</u>	<u>001</u>	Aug 17, 2011
AB		BARR	<u>50MG</u>	<u>A074918</u>	<u>001</u>	May 08, 1998
AB		CHARTWELL	<u>50MG</u>	<u>A207905</u>	<u>001</u>	Jul 21, 2017
AB		ELITE LABS	<u>50MG</u>	<u>A075274</u>	<u>001</u>	May 26, 1999
AB	!	SPECGX LLC	<u>50MG</u>	<u>A076264</u>	<u>002</u>	Mar 22, 2002
AB		SUN PHARM	<u>50MG</u>	<u>A090356</u>	<u>001</u>	Feb 24, 2012
		SPECGX LLC	25MG	A076264	001	Mar 22, 2002
			100MG	A076264	003	Mar 22, 2002

NAPROXEN

SUSPENSION; ORAL

NAPROSYN

AB	+	ATNAHS PHARMA US	<u>25MG/ML</u>	<u>N018965</u>	<u>001</u>	Mar 23, 1987
-----------	---	------------------	----------------	----------------	------------	--------------

NAPROXEN

AB		AMNEAL	<u>25MG/ML</u>	<u>A212705</u>	<u>001</u>	Jul 31, 2020
AB	!	HIKMA	<u>25MG/ML</u>	<u>A074190</u>	<u>001</u>	Mar 30, 1994

PRESCRIPTION DRUG PRODUCT LIST

NAPROXEN

TABLET; ORAL

NAPROSYN

<u>AB</u>	<u>+</u> !	ATNAHS PHARMA US	<u>500MG</u>	<u>N017581</u>	<u>004</u>	Apr 15, 1982
-----------	------------	------------------	--------------	----------------	------------	--------------

NAPROXEN

<u>AB</u>		AMNEAL PHARMS NY	<u>250MG</u>	<u>A075927</u>	<u>001</u>	Dec 18, 2001
<u>AB</u>			<u>375MG</u>	<u>A075927</u>	<u>002</u>	Dec 18, 2001
<u>AB</u>			<u>500MG</u>	<u>A075927</u>	<u>003</u>	Dec 18, 2001
<u>AB</u>		AUROBINDO PHARMA LTD	<u>250MG</u>	<u>A200429</u>	<u>001</u>	Nov 08, 2011
<u>AB</u>			<u>375MG</u>	<u>A200429</u>	<u>002</u>	Nov 08, 2011
<u>AB</u>			<u>500MG</u>	<u>A200429</u>	<u>003</u>	Nov 08, 2011
<u>AB</u>		GLENMARK GENERICS	<u>250MG</u>	<u>A078250</u>	<u>001</u>	Mar 28, 2007
<u>AB</u>			<u>375MG</u>	<u>A078250</u>	<u>002</u>	Mar 28, 2007
<u>AB</u>			<u>500MG</u>	<u>A078250</u>	<u>003</u>	Mar 28, 2007
<u>AB</u>		INVAGEN PHARMS	<u>250MG</u>	<u>A091305</u>	<u>001</u>	Aug 24, 2011
<u>AB</u>			<u>375MG</u>	<u>A091305</u>	<u>002</u>	Aug 24, 2011
<u>AB</u>			<u>500MG</u>	<u>A091305</u>	<u>003</u>	Aug 24, 2011
<u>AB</u>		MARKSANS PHARMA	<u>250MG</u>	<u>A091416</u>	<u>001</u>	Feb 14, 2011
<u>AB</u>			<u>375MG</u>	<u>A091416</u>	<u>002</u>	Feb 14, 2011
<u>AB</u>			<u>500MG</u>	<u>A091416</u>	<u>003</u>	Feb 14, 2011
<u>AB</u>		PERRIGO PHARMS CO	<u>250MG</u>	<u>A077339</u>	<u>001</u>	Apr 27, 2005
<u>AB</u>			<u>375MG</u>	<u>A077339</u>	<u>002</u>	Apr 27, 2005
<u>AB</u>			<u>500MG</u>	<u>A077339</u>	<u>003</u>	Apr 27, 2005
<u>AB</u>		SCIEGEN PHARMS INC	<u>250MG</u>	<u>A212517</u>	<u>001</u>	Feb 21, 2020
<u>AB</u>			<u>375MG</u>	<u>A212517</u>	<u>002</u>	Feb 21, 2020
<u>AB</u>			<u>500MG</u>	<u>A212517</u>	<u>003</u>	Feb 21, 2020
<u>AB</u>		TEVA	<u>250MG</u>	<u>A074201</u>	<u>001</u>	Dec 21, 1993
<u>AB</u>			<u>375MG</u>	<u>A074201</u>	<u>002</u>	Dec 21, 1993
<u>AB</u>			<u>500MG</u>	<u>A074201</u>	<u>003</u>	Dec 21, 1993
<u>AB</u>		ZYDUS PHARMS USA	<u>250MG</u>	<u>A078620</u>	<u>001</u>	Jun 07, 2007
<u>AB</u>			<u>375MG</u>	<u>A078620</u>	<u>002</u>	Jun 07, 2007
<u>AB</u>			<u>500MG</u>	<u>A078620</u>	<u>003</u>	Jun 07, 2007

TABLET, DELAYED RELEASE; ORAL

EC-NAPROSYN

<u>AB</u>	<u>+</u> !	ATNAHS PHARMA US	<u>375MG</u>	<u>N020067</u>	<u>002</u>	Oct 14, 1994
<u>AB</u>	<u>+</u> !		<u>500MG</u>	<u>N020067</u>	<u>003</u>	Oct 14, 1994

NAPROXEN

<u>AB</u>		NUVO PHARMS INC	<u>375MG</u>	<u>A091432</u>	<u>001</u>	Sep 19, 2011
<u>AB</u>			<u>500MG</u>	<u>A091432</u>	<u>002</u>	Sep 19, 2011
<u>AB</u>		TEVA	<u>375MG</u>	<u>A075227</u>	<u>001</u>	Jun 30, 1998
<u>AB</u>			<u>500MG</u>	<u>A075227</u>	<u>002</u>	Jun 30, 1998

NAPROXEN SODIUM

TABLET; ORAL

ANAPROX DS

<u>AB</u>	<u>+</u> !	ATNAHS PHARMA US	<u>EQ 500MG BASE</u>	<u>N018164</u>	<u>003</u>	Sep 30, 1987
-----------	------------	------------------	----------------------	----------------	------------	--------------

NAPROXEN SODIUM

<u>AB</u>		AMNEAL PHARMS NY	<u>EQ 250MG BASE</u>	<u>A078432</u>	<u>001</u>	Apr 25, 2007
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A078432</u>	<u>002</u>	Apr 25, 2007
<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 250MG BASE</u>	<u>A200629</u>	<u>001</u>	Oct 31, 2011
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A200629</u>	<u>002</u>	Oct 31, 2011
<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 250MG BASE</u>	<u>A078486</u>	<u>001</u>	Jul 26, 2007
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A078486</u>	<u>002</u>	Jul 26, 2007
<u>AB</u>		GLENMARK PHARMS LTD	<u>EQ 250MG BASE</u>	<u>A078314</u>	<u>001</u>	Apr 27, 2007
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A078314</u>	<u>002</u>	Apr 27, 2007
<u>AB</u>		SCIEGEN PHARMS INC	<u>EQ 250MG BASE</u>	<u>A212199</u>	<u>001</u>	Oct 30, 2019
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A212199</u>	<u>002</u>	Oct 30, 2019

TABLET, EXTENDED RELEASE; ORAL

NAPRELAN

<u>AB</u>	<u>+</u>	ALMATICA	<u>EQ 375MG BASE</u>	<u>N020353</u>	<u>001</u>	Jan 05, 1996
<u>AB</u>	<u>+</u>		<u>EQ 500MG BASE</u>	<u>N020353</u>	<u>002</u>	Jan 05, 1996
<u>AB</u>	<u>+</u> !		<u>EQ 750MG BASE</u>	<u>N020353</u>	<u>003</u>	Jan 05, 1996

NAPROXEN SODIUM

<u>AB</u>		ACTAVIS LABS FL INC	<u>EQ 375MG BASE</u>	<u>A075416</u>	<u>002</u>	Apr 23, 2003
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A075416</u>	<u>001</u>	Aug 27, 2002
<u>AB</u>			<u>EQ 750MG BASE</u>	<u>A075416</u>	<u>003</u>	Aug 11, 2016

PRESCRIPTION DRUG PRODUCT LIST

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET; ORAL

SUMATRIPTAN AND NAPROXEN SODIUM

<u>AB</u>	AUROBINDO PHARMA LTD	<u>500MG;EQ 85MG BASE</u>	<u>A207457 001</u>	Feb 15, 2018
<u>AB</u>	MYLAN	<u>500MG;EQ 85MG BASE</u>	<u>A090872 001</u>	Sep 04, 2018
<u>AB</u>	SUN PHARM	<u>500MG;EQ 85MG BASE</u>	<u>A202803 001</u>	Jul 20, 2018
<u>TREXIMET</u>				
<u>AB</u>	+! CURRAX	<u>500MG;EQ 85MG BASE</u>	<u>N021926 001</u>	Apr 15, 2008

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

AMERGE

<u>AB</u>	+ GLAXOSMITHKLINE LLC	<u>EQ 1MG BASE</u>	<u>N020763 002</u>	Feb 10, 1998
<u>AB</u>	+!	<u>EQ 2.5MG BASE</u>	<u>N020763 001</u>	Feb 10, 1998

NARATRIPTAN

<u>AB</u>	HERITAGE PHARMS INC	<u>EQ 1MG BASE</u>	<u>A200502 001</u>	Feb 28, 2011
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A200502 002</u>	Feb 28, 2011
<u>AB</u>	HIKMA	<u>EQ 1MG BASE</u>	<u>A090381 001</u>	Jul 07, 2010
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A090381 002</u>	Jul 07, 2010
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 1MG BASE</u>	<u>A091441 001</u>	Apr 30, 2012
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A091441 002</u>	Apr 30, 2012
<u>AB</u>	PADDOCK LLC	<u>EQ 1MG BASE</u>	<u>A091326 001</u>	Jul 08, 2010
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A091326 002</u>	Jul 08, 2010
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 2.5MG BASE</u>	<u>A091552 001</u>	Feb 14, 2011

NATAMYCIN

SUSPENSION; OPHTHALMIC

NATACYN

+!	EYEVANCE	5%	N050514 001
----	----------	----	-------------

NATEGLINIDE

TABLET; ORAL

NATEGLINIDE

<u>AB</u>	CADILA PHARMS LTD	<u>60MG</u>	<u>A206432 001</u>	Apr 19, 2019
<u>AB</u>		<u>120MG</u>	<u>A206432 002</u>	Apr 19, 2019
<u>AB</u>	DR REDDYS LABS LTD	<u>60MG</u>	<u>A077461 001</u>	Sep 09, 2009
<u>AB</u>		<u>120MG</u>	<u>A077461 002</u>	Sep 09, 2009
<u>AB</u>	PAR PHARM	<u>60MG</u>	<u>A077463 001</u>	Sep 09, 2009
<u>AB</u>		<u>120MG</u>	<u>A077463 002</u>	Sep 09, 2009
<u>AB</u>	RISING	<u>60MG</u>	<u>A205544 001</u>	Jun 18, 2018
<u>AB</u>		<u>120MG</u>	<u>A205544 002</u>	Jun 18, 2018
<u>AB</u>	WATSON LABS	<u>60MG</u>	<u>A077462 001</u>	Mar 30, 2011
<u>AB</u>		<u>120MG</u>	<u>A077462 002</u>	Mar 30, 2011
<u>AB</u>	ZYDUS PHARMS	<u>60MG</u>	<u>A205248 001</u>	Jul 06, 2016
<u>AB</u>	!	<u>120MG</u>	<u>A205248 002</u>	Jul 06, 2016

NEBIVOLOL HYDROCHLORIDE

TABLET; ORAL

BYSTOLIC

<u>AB</u>	+ ALLERGAN	<u>EQ 2.5MG BASE</u>	<u>N021742 002</u>	Dec 17, 2007
<u>AB</u>	+!	<u>EQ 5MG BASE</u>	<u>N021742 003</u>	Dec 17, 2007
<u>AB</u>	+!	<u>EQ 10MG BASE</u>	<u>N021742 004</u>	Dec 17, 2007
<u>AB</u>	+!	<u>EQ 20MG BASE</u>	<u>N021742 005</u>	Oct 08, 2008

NEBIVOLOL HYDROCHLORIDE

<u>AB</u>	HETERO LABS LTD III	<u>EQ 2.5MG BASE</u>	<u>A203825 001</u>	Nov 03, 2020
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A203825 002</u>	Nov 03, 2020
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A203825 003</u>	Nov 03, 2020
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A203825 004</u>	Nov 03, 2020

NEDOCROMIL SODIUM

SOLUTION/DROPS; OPHTHALMIC

ALOCRIIL

<u>AT</u>	+! ALLERGAN	<u>2%</u>	<u>N021009 001</u>	Dec 08, 1999
-----------	-------------	-----------	--------------------	--------------

NEDOCROMIL SODIUM

<u>AT</u>	AKORN	<u>2%</u>	<u>A090638 001</u>	Aug 22, 2012
-----------	-------	-----------	--------------------	--------------

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HYDROCHLORIDE

	TEVA	50MG	A076037 001	Sep 16, 2003
		100MG	A076037 002	Sep 16, 2003
		150MG	A076037 003	Sep 16, 2003
		200MG	A076037 004	Sep 16, 2003
	!	250MG	A076037 005	Sep 16, 2003

PRESCRIPTION DRUG PRODUCT LIST

NELARABINE

INJECTABLE; INTRAVENOUS

ARRANON

+! NOVARTIS 250MG/50ML (5MG/ML) N021877 001 Oct 28, 2005

NELFINAVIR MESYLATE

TABLET; ORAL

VIRACEPT

+! AGOURON PHARMS EQ 250MG BASE N020779 001 Mar 14, 1997

+! EQ 625MG BASE N021503 001 Apr 30, 2003

NEOMYCIN SULFATE

TABLET; ORAL

NEOMYCIN SULFATE

AA	!	TEVA	500MG	A060304	001	
AA		XGEN PHARMS	500MG	A065220	001	Jul 28, 2006

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION; IRRIGATION

NEOMYCIN AND POLYMYXIN B SULFATE

AT		WATSON LABS	EQ 40MG BASE/ML; 200,000 UNITS/ML	A062664	001	Apr 08, 1986
AT		XGEN PHARMS	EQ 40MG BASE/ML; 200,000 UNITS/ML	A065106	001	Jan 31, 2006
AT			EQ 40MG BASE/ML; 200,000 UNITS/ML	A065108	001	Jan 31, 2006

NEOSPORIN G.U. IRRIGANT

AT	!	MONARCH PHARMS	EQ 40MG BASE/ML; 200,000 UNITS/ML	A060707	001	
-----------	----------	----------------	--	----------------	------------	--

NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS

BLOXIVERZ

AP	+	EXELA PHARMA	5MG/10ML (0.5MG/ML)	N204078	001	May 31, 2013
AP	+		10MG/10ML (1MG/ML)	N204078	002	May 31, 2013

NEOSTIGMINE METHYLSULFATE

AP		AM REGENT	5MG/10ML (0.5MG/ML)	A209182	001	May 04, 2018
AP			10MG/10ML (1MG/ML)	A209182	002	May 04, 2018
AP		AMNEAL	5MG/10ML (0.5MG/ML)	A210051	001	Jun 15, 2018
AP			10MG/10ML (1MG/ML)	A210051	002	Jun 15, 2018
AP		AMPHASTAR PHARMS INC	5MG/10ML (0.5MG/ML)	A209933	001	Sep 25, 2017
AP			10MG/10ML (1MG/ML)	A209933	002	Sep 25, 2017
AP		AMRING PHARMS	5MG/10ML (0.5MG/ML)	A210989	001	Aug 22, 2018
AP			10MG/10ML (1MG/ML)	A210989	002	Aug 22, 2018
AP		BE PHARMS	5MG/10ML (0.5MG/ML)	A212512	001	May 13, 2019
AP			10MG/10ML (1MG/ML)	A212512	002	May 13, 2019
AP		DR REDDYS	5MG/10ML (0.5MG/ML)	A209135	001	Jul 10, 2018
AP			10MG/10ML (1MG/ML)	A209135	002	Jul 10, 2018
AP		EUROHLTH INTL SARL	5MG/10ML (0.5MG/ML)	A207042	001	Dec 28, 2015
AP			10MG/10ML (1MG/ML)	A207042	002	Dec 28, 2015
AP		GLAND PHARMA LTD	5MG/10ML (0.5MG/ML)	A212968	001	Oct 16, 2019
AP			10MG/10ML (1MG/ML)	A212968	002	Oct 16, 2019
AP		PAR STERILE PRODUCTS	5MG/10ML (0.5MG/ML)	A208405	001	Apr 26, 2017
AP			10MG/10ML (1MG/ML)	A208405	002	Apr 26, 2017
	+	FRESENIUS KABI USA	3MG/3ML (1MG/ML)	N203629	003	Sep 18, 2018
	+		5MG/10ML (0.5MG/ML)	N203629	001	Jan 08, 2015
	+		10MG/10ML (1MG/ML)	N203629	002	Jan 08, 2015

NEPAFENAC

SUSPENSION/DROPS; OPHTHALMIC

ILEVRO

+! NOVARTIS 0.3% N203491 001 Oct 16, 2012

NEVANAC

+! NOVARTIS 0.1% N021862 001 Aug 19, 2005

NERATINIB MALEATE

TABLET; ORAL

NERLYNX

+! PUMA BIOTECH EQ 40MG BASE N208051 001 Jul 17, 2017

NETARSUDIL MESYLATE

SOLUTION/DROPS; OPHTHALMIC

RHOPRESSA

+! AERIE PHARMS INC EQ 0.02% BASE N208254 001 Dec 18, 2017

PRESCRIPTION DRUG PRODUCT LIST

NETUPITANT; PALONOSETRON HYDROCHLORIDE

CAPSULE; ORAL

AKYNZEO

+! HELSINN HLTHCARE 300MG;EQ 0.5MG BASE N205718 001 Oct 10, 2014

NEVIRAPINE

SUSPENSION; ORAL

NEVIRAPINEAA AUROBINDO 50MG/5ML A077702 001 May 22, 2012AA CIPLA 50MG/5ML A207684 001 Aug 03, 2017VIRAMUNEAA +! BOEHRINGER 50MG/5ML N020933 001 Sep 11, 1998
INGELHEIM

TABLET; ORAL

NEVIRAPINEAB AUROBINDO 200MG A077521 001 May 22, 2012AB CIPLA 200MG A077956 001 May 22, 2012AB HETERO LABS LTD III 200MG A078584 001 May 22, 2012AB MACLEODS PHARMS LTD 200MG A090688 001 Jan 14, 2019AB MICRO LABS LTD 200MG A203080 001 May 22, 2012AB MYLAN PHARMS INC 200MG A202523 001 May 22, 2012AB PRINSTON INC 200MG A078644 001 May 22, 2012AB STRIDES PHARMA 200MG A078195 001 May 22, 2012VIRAMUNEAB +! BOEHRINGER 200MG N020636 001 Jun 21, 1996
INGELHEIM

TABLET, EXTENDED RELEASE; ORAL

NEVIRAPINEAB ALVOGEN 100MG A204621 002 Nov 09, 2015AB 400MG A204621 001 Jul 10, 2015AB AUROBINDO PHARMA 100MG A208616 001 Nov 23, 2016
LTDAB 400MG A207698 001 Feb 28, 2017AB MACLEODS PHARMS LTD 400MG A206879 001 Oct 06, 2017AB MYLAN 400MG A205651 001 Oct 27, 2014AB SANDOZ INC 400MG A203411 001 Apr 03, 2014VIRAMUNE XRAB + BOEHRINGER 100MG N201152 002 Nov 08, 2012
INGELHEIMAB +! 400MG N201152 001 Mar 25, 2011NIACIN

TABLET; ORAL

NIACOR

! AVONDALE PHARMS 500MG A040378 001 May 03, 2000

TABLET, EXTENDED RELEASE; ORAL

NIACINAB AMNEAL PHARMS 500MG A203578 001 Jul 24, 2015AB 750MG A204178 001 Dec 11, 2015AB 1GM A203578 002 Jul 24, 2015AB AUROBINDO PHARMA 500MG A209236 001 Feb 01, 2018
LTDAB 750MG A209236 002 Feb 01, 2018AB 1GM A209236 003 Feb 01, 2018AB BARR 500MG A076378 001 Apr 26, 2005AB 750MG A076378 002 Apr 26, 2005AB 1GM A076250 001 Apr 14, 2005AB JUBILANT GENERICS 500MG A209156 001 May 14, 2018AB 750MG A209156 002 May 14, 2018AB 1GM A209156 003 May 14, 2018AB LANNETT CO INC 500MG A203899 001 Jun 16, 2017AB 1GM A203899 002 Jun 16, 2017AB LUPIN LTD 500MG A090860 001 Mar 20, 2014AB 750MG A090892 001 Mar 20, 2014AB 1GM A090446 001 Mar 20, 2014AB SUN PHARM 500MG A200484 001 Apr 23, 2014AB 750MG A201273 001 Apr 23, 2014AB 1GM A200484 002 Apr 23, 2014NIASPANAB + ABBVIE 500MG N020381 002 Jul 28, 1997AB +! 750MG N020381 003 Jul 28, 1997AB +! 1GM N020381 004 Jul 28, 1997

PRESCRIPTION DRUG PRODUCT LIST

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL

NICARDIPINE HYDROCHLORIDE

EPIC PHARMA	20MG	A074928	001	Mar 19, 1998
!	30MG	A074928	002	Mar 19, 1998

INJECTABLE;INJECTION

NICARDIPINE HYDROCHLORIDE

AM REGENT	25MG/10ML (2.5MG/ML)	A090534	001	Nov 17, 2009
+! EXELA PHARMA	25MG/10ML (2.5MG/ML)	N022276	001	Jul 24, 2008
SCIENCE				

INJECTABLE;INTRAVENOUS

CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER

+! CHIESI	40MG/200ML (0.2MG/ML)	N019734	004	Nov 07, 2008
-----------	-----------------------	---------	-----	--------------

CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER

+! CHIESI	20MG/200ML (0.1MG/ML)	N019734	003	Jul 31, 2008
-----------	-----------------------	---------	-----	--------------

CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER

+! CHIESI	20MG/200ML (0.1MG/ML)	N019734	002	Jul 31, 2008
-----------	-----------------------	---------	-----	--------------

NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

+! EXELA PHARMA	20MG/200ML (0.1MG/ML)	N022276	002	Apr 07, 2016
SCIENCE				

+!	40MG/200ML (0.2MG/ML)	N022276	003	Apr 07, 2016
----	-----------------------	---------	-----	--------------

NICOTINE

INHALANT;ORAL

NICOTROL

+! PFIZER	4MG/CARTRIDGE	N020714	001	May 02, 1997
-----------	---------------	---------	-----	--------------

SPRAY, METERED;NASAL

NICOTROL

+! PFIZER INC	0.5MG/SPRAY	N020385	001	Mar 22, 1996
---------------	-------------	---------	-----	--------------

NIFEDIPINE

CAPSULE;ORAL

NIFEDIPINE

<u>AB</u>	ACELLA	<u>10MG</u>	<u>A072781</u>	<u>001</u>	Jul 30, 1993
<u>AB</u>	ACTAVIS ELIZABETH	<u>10MG</u>	<u>A072579</u>	<u>001</u>	Jan 08, 1991
<u>AB</u>		<u>20MG</u>	<u>A072556</u>	<u>001</u>	Sep 20, 1990
<u>AB</u>	HERITAGE PHARMA	<u>10MG</u>	<u>A202644</u>	<u>001</u>	Apr 25, 2013
<u>AB</u>		<u>20MG</u>	<u>A202644</u>	<u>002</u>	Apr 25, 2013
<u>AB</u>	LEADING PHARMA LLC	<u>10MG</u>	<u>A073250</u>	<u>001</u>	Oct 08, 1991
<u>AB</u>		<u>20MG</u>	<u>A074045</u>	<u>001</u>	Apr 30, 1992

PROCARDIA

<u>AB</u>	+! PFIZER	<u>10MG</u>	<u>N018482</u>	<u>001</u>	
-----------	-----------	-------------	----------------	------------	--

TABLET, EXTENDED RELEASE;ORAL

NIFEDIPINE

<u>AB1</u>	MYLAN	<u>30MG</u>	<u>A201071</u>	<u>001</u>	Dec 03, 2010
<u>AB1</u>		<u>60MG</u>	<u>A201071</u>	<u>002</u>	Dec 03, 2010
<u>AB1</u>		<u>90MG</u>	<u>A201071</u>	<u>003</u>	Dec 03, 2010
<u>AB1</u>	NOVAST LABS	<u>30MG</u>	<u>A202987</u>	<u>001</u>	Aug 25, 2016
<u>AB1</u>	!	<u>60MG</u>	<u>A202987</u>	<u>002</u>	Aug 25, 2016
<u>AB1</u>	!	<u>90MG</u>	<u>A202987</u>	<u>003</u>	Aug 25, 2016
<u>AB1</u>	PAR PHARM	<u>30MG</u>	<u>A077899</u>	<u>001</u>	Dec 13, 2006
<u>AB1</u>		<u>60MG</u>	<u>A077899</u>	<u>002</u>	Dec 13, 2006
<u>AB1</u>		<u>90MG</u>	<u>A077899</u>	<u>003</u>	May 25, 2012
<u>AB1</u>	VALEANT PHARMS	<u>30MG</u>	<u>A075269</u>	<u>001</u>	Dec 04, 2000
	NORTH				
<u>AB1</u>		<u>60MG</u>	<u>A075269</u>	<u>002</u>	Dec 04, 2000
<u>AB1</u>		<u>90MG</u>	<u>A076070</u>	<u>001</u>	Aug 16, 2002
<u>AB1</u>	ZYDUS PHARMS	<u>30MG</u>	<u>A210184</u>	<u>001</u>	Jun 29, 2018
<u>AB1</u>		<u>60MG</u>	<u>A210184</u>	<u>002</u>	Jun 29, 2018
<u>AB1</u>		<u>90MG</u>	<u>A210184</u>	<u>003</u>	Jun 29, 2018
<u>AB2</u>	ELITE	<u>90MG</u>	<u>A212016</u>	<u>001</u>	Nov 18, 2020
<u>AB2</u>	NOVAST LABS	<u>30MG</u>	<u>A210614</u>	<u>001</u>	Mar 12, 2019
<u>AB2</u>		<u>60MG</u>	<u>A210614</u>	<u>002</u>	Mar 12, 2019
<u>AB2</u>		<u>90MG</u>	<u>A210614</u>	<u>003</u>	Mar 12, 2019
<u>AB2</u>	OSMOTICA PHARM US	<u>30MG</u>	<u>A077127</u>	<u>001</u>	Nov 21, 2005
<u>AB2</u>		<u>60MG</u>	<u>A077127</u>	<u>002</u>	Nov 21, 2005
<u>AB2</u>		<u>90MG</u>	<u>A077127</u>	<u>003</u>	Oct 03, 2007
<u>AB2</u>	SPIL	<u>30MG</u>	<u>A210838</u>	<u>001</u>	Apr 16, 2019
<u>AB2</u>		<u>60MG</u>	<u>A210838</u>	<u>002</u>	Apr 16, 2019
<u>AB2</u>		<u>90MG</u>	<u>A210838</u>	<u>003</u>	Apr 16, 2019
<u>AB2</u>	TWI PHARMS	<u>30MG</u>	<u>A203126</u>	<u>001</u>	Apr 03, 2014
<u>AB2</u>		<u>60MG</u>	<u>A203126</u>	<u>002</u>	Apr 03, 2014
<u>AB2</u>		<u>90MG</u>	<u>A203126</u>	<u>003</u>	Apr 03, 2014
<u>AB2</u>	VALEANT PHARMS	<u>30MG</u>	<u>A075289</u>	<u>002</u>	Feb 06, 2001

PRESCRIPTION DRUG PRODUCT LIST

NIFEDIPINE

TABLET, EXTENDED RELEASE;ORAL

NIFEDIPINE

NORTH

AB2		60MG	A075289 001	Sep 27, 2000
AB2	ZYDUS PHARMS	30MG	A210012 001	Dec 19, 2017
AB2		60MG	A210012 002	Dec 19, 2017
AB2		90MG	A210012 003	Dec 19, 2017
PROCARDIA XL				
AB2	+	PFIZER	N019684 001	Sep 06, 1989
AB2	+		N019684 002	Sep 06, 1989
AB2	+	!	N019684 003	Sep 06, 1989

NIFURTIMOX

TABLET;ORAL

LAMPIT

+	BAYER HEALTHCARE	30MG	N213464 001	Aug 06, 2020
+	!	120MG	N213464 002	Aug 06, 2020

NILOTINIB HYDROCHLORIDE

CAPSULE;ORAL

TASIGNA

+	NOVARTIS	EQ 50MG BASE	N022068 003	Mar 22, 2018
+		EQ 150MG BASE	N022068 002	Jun 17, 2010
+	!	EQ 200MG BASE	N022068 001	Oct 29, 2007

NILUTAMIDE

TABLET;ORAL

NILANDRON

AB	+	CONCORDIA	150MG	N020169 002	Apr 30, 1999
-----------	---	-----------	--------------	--------------------	--------------

NILUTAMIDE

AB		ANI PHARMS INC	150MG	A207631 001	Jul 15, 2016
-----------	--	----------------	--------------	--------------------	--------------

NIMODIPINE

CAPSULE;ORAL

NIMODIPINE

AB	!	BIONPHARMA INC	30MG	A076740 001	Jan 17, 2008
AB		HERITAGE PHARMS INC	30MG	A077811 001	May 02, 2007
AB		SOFGEN PHARMS	30MG	A201832 001	Jul 24, 2015
AB		THEPHARMANETWORK LLC	30MG	A090103 001	Apr 07, 2014

SOLUTION;ORAL

NYMALIZE

+	ARBOR PHARMS LLC	6MG/ML	N203340 002	Apr 08, 2020
---	------------------	--------	-------------	--------------

NINTEDANIB ESYLATE

CAPSULE;ORAL

OFEV

+	BOEHRINGER INGELHEIM	EQ 100MG BASE	N205832 001	Oct 15, 2014
+	!	EQ 150MG BASE	N205832 002	Oct 15, 2014

NIRAPARIB TOSYLATE

CAPSULE;ORAL

ZEJULA

+	GLAXOSMITHKLINE	EQ 100MG BASE	N208447 001	Mar 27, 2017
---	-----------------	---------------	-------------	--------------

NISOLDIPINE

TABLET, EXTENDED RELEASE;ORAL

NISOLDIPINE

AB		MYLAN	8.5MG	A091001 001	Jan 26, 2011
AB			17MG	A091001 002	Jan 26, 2011
AB			34MG	A091001 004	Jan 26, 2011

SULAR

AB	+	COVIS	8.5MG	N020356 008	Jan 02, 2008
AB	+	!	17MG	N020356 007	Jan 02, 2008
AB	+	!	34MG	N020356 005	Jan 02, 2008

NISOLDIPINE

		MYLAN	20MG	A079051 001	Jul 25, 2008
			25.5MG	A091001 003	Jan 26, 2011
	!		30MG	A079051 002	Jul 25, 2008
	!		40MG	A079051 003	Jul 25, 2008

PRESCRIPTION DRUG PRODUCT LIST

NITAZOXANIDE

FOR SUSPENSION;ORAL

ALINIA

+! ROMARK

100MG/5ML

N021498 001 Nov 22, 2002

TABLET;ORAL

ALINIA**AB** +! ROMARK**500MG****N021497 001** Jul 21, 2004**NITAZOXANIDE****AB** RISING**500MG****A213820 001** Nov 27, 2020NITISINONE

CAPSULE;ORAL

NITISINONE**AB** NOVITIUM PHARMA**2MG****A211041 001** Aug 26, 2019**AB****5MG****A211041 002** Aug 26, 2019**AB****10MG****A211041 003** Aug 26, 2019**ORFADIN****AB** + SWEDISH ORPHAN**2MG****N021232 001** Jan 18, 2002**AB** +**5MG****N021232 002** Jan 18, 2002**AB** +**10MG****N021232 003** Jan 18, 2002

+!

20MG

N021232 004 Jun 13, 2016

SUSPENSION;ORAL

ORFADIN

+! SWEDISH ORPHAN

4MG/ML

N206356 001 Apr 22, 2016

TABLET;ORAL

NITYR

+ CYCLE PHARMS LTD

2MG

N209449 001 Jul 26, 2017

+

5MG

N209449 002 Jul 26, 2017

+!

10MG

N209449 003 Jul 26, 2017

NITRIC OXIDE

GAS;INHALATION

INOMAX**AA** +! MALLINCKRODT HOSP**800PPM****N020845 003** Dec 23, 1999**NOXIVENT****AA** PRAXAIR
DISTRIBUTION**800PPM****A207141 002** Oct 02, 2018

GENOSYL

+! VERO BIOTECH

800PPM

N202860 001 Dec 20, 2019

NOXIVENT

PRAXAIR
DISTRIBUTION

100PPM

A207141 001 Oct 02, 2018

NITROFURANTOIN

SUSPENSION;ORAL

FURADANTIN**AB** +! CASPER PHARMA LLC**25MG/5ML****N009175 001****NITROFURANTOIN****AB** ACTAVIS MID
ATLANTIC**25MG/5ML****A205180 001** May 03, 2016**AB** AMNEAL PHARMS**25MG/5ML****A201679 001** May 11, 2011**AB** NOSTRUM LABS INC**25MG/5ML****A201355 001** Aug 14, 2013**AB** NOVEL LABS INC**25MG/5ML****A201693 001** Sep 08, 2014NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

MACRODANTIN**AB** + ALMATICA**25MG****N016620 003****AB** +**50MG****N016620 001****AB** +!**100MG****N016620 002****NITROFURANTOIN****AB** ACTAVIS LABS FL INC**25MG****A091095 001** Jun 18, 2015**AB****50MG****A091095 002** Jun 18, 2015**AB****100MG****A091095 003** Jun 18, 2015**AB** IMPAX LABS INC**50MG****A073671 001** Jan 28, 1993**AB****100MG****A073652 001** Jan 28, 1993**AB** NOVEL LABS INC**50MG****A203233 001** Jul 09, 2018**AB****100MG****A203233 002** Jul 09, 2018**AB** SUN PHARM
INDUSTRIES**25MG****A201722 001** Feb 16, 2016**AB****50MG****A201722 002** Feb 16, 2016**AB****100MG****A201722 003** Feb 16, 2016**AB** ZYDUS PHARMS**50MG****A205005 001** Dec 12, 2017**AB****100MG****A205005 002** Dec 12, 2017

PRESCRIPTION DRUG PRODUCT LIST

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

MACROBID

AB	+ !	ALMATICA	75MG;25MG	N020064 001	Dec 24, 1991
<u>NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)</u>					
AB		AMNEAL PHARMS	75MG;25MG	A207372 001	May 15, 2017
AB		MYLAN	75MG;25MG	A076648 001	Mar 22, 2004
AB		SANDOZ	75MG;25MG	A077066 001	Apr 05, 2005
AB		SUNNY PHARMTECH INC	75MG;25MG	A208516 001	May 24, 2018
AB		WATSON LABS INC	75MG;25MG	A202250 001	Jul 08, 2015

NITROGLYCERIN

AEROSOL, METERED; SUBLINGUAL

NITROMIST

+! EVUS 0.4MG/SPRAY

N021780 001 Nov 02, 2006

FILM, EXTENDED RELEASE; TRANSDERMAL

NITROGLYCERIN

AB2		HERCON PHARM	0.1MG/HR	A089885 002	Oct 30, 2017
AB2			0.2MG/HR	A089884 001	Oct 30, 1998
AB2			0.4MG/HR	A089885 001	Oct 30, 1998
AB2			0.6MG/HR	A089886 001	Oct 30, 1998
AB2	!	MYLAN TECHNOLOGIES	0.1MG/HR	A074559 004	Feb 06, 1998
AB2	!		0.2MG/HR	A074559 003	Aug 30, 1996
AB2	!		0.4MG/HR	A074559 002	Aug 30, 1996
AB2	!		0.6MG/HR	A074559 001	Aug 30, 1996
NITRO-DUR					
BX	+ !	USPHARMA	0.1MG/HR	N020145 001	Apr 04, 1995
BX	+ !		0.2MG/HR	N020145 002	Apr 04, 1995
BX	+ !		0.4MG/HR	N020145 004	Apr 04, 1995
BX	+ !		0.6MG/HR	N020145 005	Apr 04, 1995
	+ !		0.3MG/HR	N020145 003	Apr 04, 1995
	+ !		0.8MG/HR	N020145 006	Apr 04, 1995

INJECTABLE; INJECTION

NITROGLYCERIN IN DEXTROSE 5%

AP	+ !	BAXTER HLTHCARE	10MG/100ML	N019970 001	Dec 29, 1989
AP	+ !		20MG/100ML	N019970 002	Dec 29, 1989
AP	+ !		40MG/100ML	N019970 003	Dec 29, 1989
NITROGLYCERIN					
	!	AM REGENT	5MG/ML	A072034 001	May 24, 1988
OINTMENT; INTRA-ANAL					
RECTIV					
	+ !	ALLERGAN	0.4%	N021359 001	Jun 21, 2011
OINTMENT; TRANSDERMAL					
NITROGLYCERIN					
	!	FOUGERA PHARMS INC	2%	A087355 001	Jul 08, 1988
POWDER; SUBLINGUAL					
GONITRO					
	+ !	POHL BOSKAMP	0.4MG/PACKET	N208424 001	Jun 08, 2016
SPRAY, METERED; SUBLINGUAL					
<u>NITROGLYCERIN</u>					
AB		PERRIGO ISRAEL	0.4MG/SPRAY	A091496 001	Sep 20, 2013
<u>NITROLINGUAL PUMPSPRAY</u>					
AB	+ !	POHL BOSKAMP	0.4MG/SPRAY	N018705 002	Jan 10, 1997
TABLET; SUBLINGUAL					
<u>NITROGLYCERIN</u>					
AB		ALVOGEN	0.3MG	A211604 001	Apr 30, 2019
AB			0.4MG	A211604 002	Apr 30, 2019
AB			0.6MG	A211604 003	Apr 30, 2019
AB		DR REDDYS	0.3MG	A208191 001	Aug 26, 2016
AB			0.4MG	A208191 002	Aug 26, 2016
AB			0.6MG	A208191 003	Aug 26, 2016
AB		GLENMARK PHARMS SA	0.3MG	A206391 001	Sep 19, 2017
AB			0.4MG	A206391 002	Sep 19, 2017
AB			0.6MG	A206391 003	Sep 19, 2017
AB		SIGMAPHARM LABS LLC	0.3MG	A207745 001	May 07, 2018
AB			0.4MG	A207745 002	May 07, 2018
AB			0.6MG	A207745 003	May 07, 2018
<u>NITROSTAT</u>					
AB	+	UPJOHN	0.3MG	N021134 001	May 01, 2000
AB	+		0.4MG	N021134 002	May 01, 2000
AB	+ !		0.6MG	N021134 003	May 01, 2000

PRESCRIPTION DRUG PRODUCT LIST

NIZATIDINE

CAPSULE; ORAL

NIZATIDINE

AB	DR REDDYS LABS LTD	150MG	A077314 001	Sep 15, 2005
AB		300MG	A077314 002	Sep 15, 2005
AB	GLENMARK GENERICS	150MG	A090618 001	Jul 15, 2011
AB		300MG	A090618 002	Jul 15, 2011
AB	SANDOZ	150MG	A076178 001	Jul 05, 2002
AB		300MG	A076178 002	Jul 05, 2002
AB	WATSON LABS	150MG	A075616 001	Jul 09, 2002
AB	!	300MG	A075616 002	Jul 09, 2002

SOLUTION; ORAL

NIZATIDINE

!	AMNEAL PHARMS	15MG/ML	A090576 001	Nov 18, 2009
---	---------------	---------	-------------	--------------

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

LEVOPHED

AP	+!	HOSPIRA	EQ 1MG BASE/ML	N007513 001	
<u>NOREPINEPHRINE BITARTRATE</u>					
AP		AMNEAL	EQ 1MG BASE/ML	A210839 001	Dec 17, 2018
AP		BAXTER HLTHCARE CORP	EQ 1MG BASE/ML	A040859 001	Mar 27, 2012
AP		FRESENIUS KABI USA	EQ 1MG BASE/ML	A211382 001	Nov 03, 2020
AP		HIKMA	EQ 1MG BASE/ML	A203662 001	Nov 07, 2018
AP		MYLAN LABS LTD	EQ 1MG BASE/ML	A211242 001	Oct 04, 2018
AP		SANDOZ INC	EQ 1MG BASE/ML	A211359 001	Oct 18, 2018
AP		TEVA PHARMS USA	EQ 1MG BASE/ML	A040455 001	Mar 03, 2003
AP		WEST-WARD PHARMS INT	EQ 1MG BASE/ML	A040462 001	Oct 31, 2003

NORETHINDRONE

TABLET; ORAL-28

CAMILA

AB1		MAYNE PHARMA	0.35MG	A076177 001	Oct 21, 2002
------------	--	--------------	---------------	--------------------	--------------

HEATHER

AB1		GLENMARK GENERICS	0.35MG	A090454 001	Apr 23, 2010
------------	--	-------------------	---------------	--------------------	--------------

INCASSIA

AB1		AUROBINDO PHARMA LTD	0.35MG	A207304 001	Sep 23, 2016
------------	--	----------------------	---------------	--------------------	--------------

NOR-QD

AB1	+!	TEVA BRANDED PHARM	0.35MG	N017060 001	
------------	----	--------------------	---------------	--------------------	--

NORETHINDRONE

AB1		AMNEAL PHARMS	0.35MG	A202260 001	Aug 01, 2013
AB1		LUPIN LTD	0.35MG	A091325 001	Sep 19, 2011
AB1		MYLAN LABS LTD	0.35MG	A201483 001	Jun 24, 2013
AB1		NAARI PTE LTD	0.35MG	A206807 001	Dec 13, 2016
AB1		NOVAST LABS	0.35MG	A202014 001	Sep 13, 2013

ERRIN

AB2		MAYNE PHARMA	0.35MG	A076225 001	Oct 21, 2002
------------	--	--------------	---------------	--------------------	--------------

JENCYCLA

AB2		LUPIN LTD	0.35MG	A091323 001	Mar 28, 2013
------------	--	-----------	---------------	--------------------	--------------

NORETHINDRONE

AB2		GLENMARK GENERICS	0.35MG	A091209 001	Jul 22, 2010
AB2	!	MYLAN LABS LTD	0.35MG	A200980 001	Jun 12, 2013
AB2		NOVAST LABS	0.35MG	A200961 001	Sep 13, 2013

NORETHINDRONE ACETATE

TABLET; ORAL

NORETHINDRONE ACETATE

AB		AMNEAL PHARMS	5MG	A200275 001	Jul 30, 2012
AB	!	BARR	5MG	A075951 001	May 25, 2001
AB		GLENMARK GENERICS	5MG	A091090 001	Jul 21, 2010
AB		MYLAN LABS LTD	5MG	A205278 001	Nov 10, 2016
AB		NOVAST LABS	5MG	A206490 001	Nov 05, 2018

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

NORTRIPTYLINE HYDROCHLORIDE

AB		MAYNE PHARMA	EQ 10MG BASE	A073556 002	Mar 30, 1992
AB			EQ 25MG BASE	A073556 003	Mar 30, 1992
AB			EQ 50MG BASE	A073556 004	Mar 30, 1992
AB			EQ 75MG BASE	A073556 001	Mar 30, 1992
AB		TARO	EQ 10MG BASE	A075520 004	May 08, 2000
AB			EQ 25MG BASE	A075520 003	May 08, 2000

PRESCRIPTION DRUG PRODUCT LIST

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE;ORAL

NORTRIPTYLINE HYDROCHLORIDE

<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A075520 001</u>	May 08, 2000
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A075520 002</u>	May 08, 2000
<u>AB</u>	TEVA	<u>EQ 10MG BASE</u>	<u>A074132 001</u>	Mar 27, 1995
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A074132 002</u>	Mar 27, 1995
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A074132 003</u>	Mar 27, 1995
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A074132 004</u>	Mar 27, 1995

PAMELOR

<u>AB</u>	+	SPECGX LLC	<u>EQ 10MG BASE</u>	<u>N018013 001</u>
<u>AB</u>	+		<u>EQ 25MG BASE</u>	<u>N018013 002</u>
<u>AB</u>	+		<u>EQ 50MG BASE</u>	<u>N018013 004</u>
<u>AB</u>	+	!	<u>EQ 75MG BASE</u>	<u>N018013 003</u>

SOLUTION;ORAL

NORTRIPTYLINE HYDROCHLORIDE

<u>AA</u>	!	PHARM ASSOC	<u>EQ 10MG BASE/5ML</u>	<u>A075606 001</u>	Aug 28, 2000
<u>AA</u>		TARO	<u>EQ 10MG BASE/5ML</u>	<u>A077965 001</u>	Jun 20, 2006

NUSINERSEN SODIUM

SOLUTION;INTRATHECAL

SPINRAZA

+	!	BIOGEN IDEC	EQ 12MG BASE/5ML (EQ 2.4MG BASE/ML)	N209531 001	Dec 23, 2016
---	---	-------------	-------------------------------------	-------------	--------------

NYSTATIN

CREAM;TOPICAL

NYSTATIN

<u>AT</u>		ACTAVIS MID ATLANTIC	<u>100,000 UNITS/GM</u>	<u>A062949 001</u>	Jun 13, 1988
<u>AT</u>		COSETTE	<u>100,000 UNITS/GM</u>	<u>A061966 001</u>	
<u>AT</u>		CROWN LABS INC	<u>100,000 UNITS/GM</u>	<u>A207733 001</u>	Sep 26, 2017
<u>AT</u>		FOUGERA PHARMS	<u>100,000 UNITS/GM</u>	<u>A062129 001</u>	
<u>AT</u>		PERRIGO NEW YORK	<u>100,000 UNITS/GM</u>	<u>A062225 001</u>	
<u>AT</u>	!	TARO	<u>100,000 UNITS/GM</u>	<u>A064022 001</u>	Jan 29, 1993
<u>AT</u>		TORRENT	<u>100,000 UNITS/GM</u>	<u>A212557 001</u>	Jul 24, 2019

OINTMENT;TOPICAL

NYSTATIN

<u>AT</u>		ACTAVIS MID ATLANTIC	<u>100,000 UNITS/GM</u>	<u>A062840 001</u>	Nov 13, 1987
<u>AT</u>		CADILA	<u>100,000 UNITS/GM</u>	<u>A207767 001</u>	May 25, 2018
<u>AT</u>		COSETTE	<u>100,000 UNITS/GM</u>	<u>A209114 001</u>	Oct 06, 2017
<u>AT</u>	!	FOUGERA PHARMS	<u>100,000 UNITS/GM</u>	<u>A062124 002</u>	Sep 23, 1982
<u>AT</u>		LYNE	<u>100,000 UNITS/GM</u>	<u>A209082 001</u>	May 21, 2018
<u>AT</u>		PERRIGO NEW YORK	<u>100,000 UNITS/GM</u>	<u>A062472 001</u>	Feb 13, 1984
<u>AT</u>		TORRENT	<u>100,000 UNITS/GM</u>	<u>A211838 001</u>	Jan 28, 2019

POWDER;TOPICAL

NYSTATIN

<u>AT</u>		EPIC PHARMA LLC	<u>100,000 UNITS/GM</u>	<u>A210532 001</u>	Apr 30, 2018
<u>AT</u>		LUPIN	<u>100,000 UNITS/GM</u>	<u>A065138 001</u>	Jul 23, 2004
<u>AT</u>		LYNE	<u>100,000 UNITS/GM</u>	<u>A208838 001</u>	May 30, 2017
<u>AT</u>	!	MAYNE PHARMA INC	<u>100,000 UNITS/GM</u>	<u>A065203 001</u>	Jul 15, 2004
<u>AT</u>		NESHER PHARMS	<u>100,000 UNITS/GM</u>	<u>A208581 001</u>	Jun 08, 2017
<u>AT</u>		UPSHER SMITH LABS	<u>100,000 UNITS/GM</u>	<u>A065183 001</u>	May 03, 2005
<u>AT</u>		XGEN PHARMS	<u>100,000 UNITS/GM</u>	<u>A065175 001</u>	Dec 17, 2004

NYSTOP

<u>AT</u>		PADDOCK LLC	<u>100,000 UNITS/GM</u>	<u>A064118 001</u>	Aug 16, 1996
-----------	--	-------------	-------------------------	--------------------	--------------

SUSPENSION;ORAL

NYSTATIN

<u>AA</u>		AKORN	<u>100,000 UNITS/ML</u>	<u>A064042 001</u>	Feb 28, 1994
<u>AA</u>		FOUGERA PHARMS INC	<u>100,000 UNITS/ML</u>	<u>A062517 001</u>	Jun 07, 1984
<u>AA</u>		LANNETT CO INC	<u>100,000 UNITS/ML</u>	<u>A065148 001</u>	Jun 28, 2005
<u>AA</u>		PHARM ASSOC	<u>100,000 UNITS/ML</u>	<u>A203621 001</u>	Jan 07, 2016
<u>AA</u>		SOCORRO	<u>100,000 UNITS/ML</u>	<u>A062832 001</u>	Dec 27, 1991
<u>AA</u>		TARO	<u>100,000 UNITS/ML</u>	<u>A062876 001</u>	Feb 29, 1988
<u>AA</u>		VISTAPHARM	<u>100,000 UNITS/ML</u>	<u>A064142 001</u>	Jun 25, 1998
<u>AA</u>			<u>100,000 UNITS/ML</u>	<u>A065422 001</u>	Mar 07, 2011
<u>AA</u>	!	WOCKHARDT BIO AG	<u>100,000 UNITS/ML</u>	<u>A062512 001</u>	Oct 29, 1984

TABLET;ORAL

NYSTATIN

<u>AA</u>		HERITAGE PHARMS INC	<u>500,000 UNITS</u>	<u>A062474 001</u>	Dec 22, 1983
<u>AA</u>		SUN PHARM INDUSTRIES	<u>500,000 UNITS</u>	<u>A062838 001</u>	Dec 22, 1988
<u>AA</u>	!	TEVA	<u>500,000 UNITS</u>	<u>A062506 001</u>	Jan 16, 1984

PRESCRIPTION DRUG PRODUCT LIST

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

MYKACET

<u>AT</u>	COSETTE	<u>100,000 UNITS/GM;0.1%</u>	<u>A062367</u>	<u>001</u>	May 28, 1985
<u>NYSTATIN AND TRIAMCINOLONE ACETONIDE</u>					
<u>AT</u>	AMNEAL	<u>100,000 UNITS/GM;0.1%</u>	<u>A209990</u>	<u>001</u>	Feb 15, 2018
<u>AT</u>	CROWN LABS INC	<u>100,000 UNITS/GM;0.1%</u>	<u>A207730</u>	<u>001</u>	Dec 26, 2017
<u>AT</u>	DR REDDYS	<u>100,000 UNITS/GM;0.1%</u>	<u>A208326</u>	<u>001</u>	Oct 26, 2016
<u>AT</u>	FOUGERA PHARMS INC	<u>100,000 UNITS/GM;0.1%</u>	<u>A062599</u>	<u>001</u>	Oct 08, 1985
<u>AT</u>	GLENMARK PHARMS LTD	<u>100,000 UNITS/GM;0.1%</u>	<u>A208136</u>	<u>001</u>	Oct 24, 2016
<u>AT</u>	LUPIN LTD	<u>100,000 UNITS/GM;0.1%</u>	<u>A208205</u>	<u>001</u>	May 31, 2018
<u>AT</u>	PERRIGO UK FINCO	<u>100,000 UNITS/GM;0.1%</u>	<u>A208479</u>	<u>001</u>	Aug 14, 2017
<u>AT</u>	! TARO	<u>100,000 UNITS/GM;0.1%</u>	<u>A062364</u>	<u>001</u>	Dec 22, 1987
<u>AT</u>	TORRENT	<u>100,000 UNITS/GM;0.1%</u>	<u>A213142</u>	<u>001</u>	Jul 14, 2020

OINTMENT; TOPICAL

MYKACET

<u>AT</u>	COSETTE	<u>100,000 UNITS/GM;0.1%</u>	<u>A062733</u>	<u>001</u>	Mar 06, 1987
<u>NYSTATIN AND TRIAMCINOLONE ACETONIDE</u>					
<u>AT</u>	AKORN	<u>100,000 UNITS/GM;0.1%</u>	<u>A207217</u>	<u>001</u>	Aug 04, 2017
<u>AT</u>	CADILA	<u>100,000 UNITS/GM;0.1%</u>	<u>A207764</u>	<u>001</u>	Nov 08, 2018
<u>AT</u>	DR REDDYS	<u>100,000 UNITS/GM;0.1%</u>	<u>A207741</u>	<u>001</u>	Jan 31, 2017
<u>AT</u>	FOUGERA PHARMS INC	<u>100,000 UNITS/GM;0.1%</u>	<u>A062602</u>	<u>001</u>	Oct 09, 1985
<u>AT</u>	GLENMARK PHARMS LTD	<u>100,000 UNITS/GM;0.1%</u>	<u>A208300</u>	<u>001</u>	Jun 23, 2016
<u>AT</u>	PERRIGO UK FINCO	<u>100,000 UNITS/GM;0.1%</u>	<u>A207380</u>	<u>001</u>	Dec 20, 2016
<u>AT</u>	RISING	<u>100,000 UNITS/GM;0.1%</u>	<u>A206785</u>	<u>001</u>	Dec 29, 2016
<u>AT</u>	STRIDES PHARMA	<u>100,000 UNITS/GM;0.1%</u>	<u>A210077</u>	<u>001</u>	Jan 29, 2018
<u>AT</u>	! TARO	<u>100,000 UNITS/GM;0.1%</u>	<u>A063305</u>	<u>001</u>	Mar 29, 1993
<u>AT</u>	TELIGENT	<u>100,000 UNITS/GM;0.1%</u>	<u>A208287</u>	<u>001</u>	Dec 30, 2016

OBETICHOLIC ACID

TABLET; ORAL

OCALIVA

+	INTERCEPT PHARMS INC	5MG	N207999	001	May 27, 2016
+	!	10MG	N207999	002	May 27, 2016

OCTREOTIDE ACETATE

CAPSULE, DELAYED RELEASE; ORAL

MYCAPSSA

+	! CHIASMA	EQ 20MG BASE	N208232	001	Jun 26, 2020
---	-----------	--------------	---------	-----	--------------

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 0.2MG BASE/ML</u>	<u>A077450</u>	<u>001</u>	Feb 10, 2006
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A077450</u>	<u>002</u>	Feb 10, 2006
<u>AP</u>	SAGENT PHARMS INC	<u>EQ 0.2MG BASE/ML</u>	<u>A091041</u>	<u>001</u>	Nov 12, 2013
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A091041</u>	<u>002</u>	Nov 12, 2013
<u>AP</u>	TEVA PHARMS USA	<u>EQ 0.05MG BASE/ML</u>	<u>A075957</u>	<u>001</u>	Oct 03, 2005
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A075957</u>	<u>002</u>	Oct 03, 2005
<u>AP</u>		<u>EQ 0.2MG BASE/ML</u>	<u>A075959</u>	<u>001</u>	Nov 21, 2005
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A075957</u>	<u>003</u>	Oct 03, 2005
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A075959</u>	<u>002</u>	Nov 21, 2005
<u>AP</u>	! WEST-WARD PHARMS INT	<u>EQ 0.2MG BASE/ML</u>	<u>A076330</u>	<u>001</u>	Apr 08, 2005
<u>AP</u>	!	<u>EQ 1MG BASE/ML</u>	<u>A076330</u>	<u>002</u>	Apr 08, 2005

OCTREOTIDE ACETATE (PRESERVATIVE FREE)

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 0.05MG BASE/ML</u>	<u>A077457</u>	<u>001</u>	Feb 10, 2006
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A077457</u>	<u>002</u>	Feb 10, 2006
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A077457</u>	<u>003</u>	Feb 10, 2006
<u>AP</u>	MYLAN INSTITUTIONAL	<u>EQ 0.05MG BASE/ML</u>	<u>A079198</u>	<u>001</u>	Feb 10, 2011
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A079198</u>	<u>002</u>	Feb 10, 2011
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A079198</u>	<u>003</u>	Feb 10, 2011
<u>AP</u>	SAGENT PHARMS INC	<u>EQ 0.05MG BASE/ML</u>	<u>A090834</u>	<u>001</u>	Nov 12, 2013
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A090834</u>	<u>002</u>	Nov 12, 2013
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A090834</u>	<u>003</u>	Nov 12, 2013
<u>AP</u>	! WEST-WARD PHARMS INT	<u>EQ 0.05MG BASE/ML</u>	<u>A076313</u>	<u>001</u>	Mar 28, 2005
<u>AP</u>	!	<u>EQ 0.1MG BASE/ML</u>	<u>A076313</u>	<u>003</u>	Mar 28, 2005
<u>AP</u>	!	<u>EQ 0.5MG BASE/ML</u>	<u>A076313</u>	<u>002</u>	Mar 28, 2005

SANDOSTATIN

<u>AP</u>	! NOVARTIS	<u>EQ 0.05MG BASE/ML</u>	<u>N019667</u>	<u>001</u>	Oct 21, 1988
<u>AP</u>	+	<u>EQ 0.1MG BASE/ML</u>	<u>N019667</u>	<u>002</u>	Oct 21, 1988
<u>AP</u>	+	<u>EQ 0.5MG BASE/ML</u>	<u>N019667</u>	<u>003</u>	Oct 21, 1988

PRESCRIPTION DRUG PRODUCT LIST

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

SANDOSTATIN LAR

+ NOVARTIS

EQ 10MG BASE/VIAL

N021008 001 Nov 25, 1998

+

EQ 20MG BASE/VIAL

N021008 002 Nov 25, 1998

+!

EQ 30MG BASE/VIAL

N021008 003 Nov 25, 1998

SOLUTION; SUBCUTANEOUS

BYNFEZIA PEN

+! SUN PHARM

EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)

N213224 001 Jan 28, 2020

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

OCUFLOX**AT** +! ALLERGAN**0.3%****N019921 001** Jul 30, 1993OFLOXACIN**AT** AKORN**0.3%****A076407 001** Apr 15, 2008**AT****0.3%****A076615 001** May 14, 2004**AT** ALTAIRE PHARMS INC**0.3%****A202692 001** Apr 29, 2013**AT** ALVOGEN**0.3%****A076830 001** Aug 31, 2004**AT** APOTEX INC**0.3%****A076513 001** May 14, 2004**AT** BAUSCH AND LOMB**0.3%****A076622 001** May 14, 2004**AT** FDC LTD**0.3%****A078559 001** Feb 25, 2009

SOLUTION/DROPS; OTIC

OFLOXACIN**AT** AKORN**0.3%****A076616 001** Mar 17, 2008**AT** AMNEAL**0.3%****A211525 001** Aug 30, 2019**AT** APOTEX INC**0.3%****A076527 001** Sep 28, 2007**AT** ! BAUSCH AND LOMB**0.3%****A076128 001** Mar 17, 2008

TABLET; ORAL

OFLOXACIN**AB** CADILA PHARMS LTD**200MG****A091656 001** Sep 18, 2014**AB****300MG****A091656 002** Sep 18, 2014**AB****400MG****A091656 003** Sep 18, 2014**AB** DR REDDYS LABS LTD**200MG****A077098 001** Feb 10, 2006**AB****300MG****A077098 002** Feb 10, 2006**AB****400MG****A077098 003** Feb 10, 2006**AB** TEVA**200MG****A076182 001** Sep 02, 2003**AB****300MG****A076182 002** Sep 02, 2003**AB** !**400MG****A076182 003** Sep 02, 2003OLANZAPINE

INJECTABLE; INTRAMUSCULAR

OLANZAPINE**AP** AM REGENT**10MG/VIAL****A201741 001** Mar 20, 2012**AP** AUROBINDO PHARMA LTD**10MG/VIAL****A210968 001** Oct 22, 2020**AP** SANDOZ INC**10MG/VIAL****A201588 001** Oct 24, 2011ZYPREXA**AP** +! LILLY**10MG/VIAL****N021253 001** Mar 29, 2004

TABLET; ORAL

OLANZAPINE**AB** ALKEM LABS LTD**2.5MG****A202295 001** Oct 20, 2015**AB****5MG****A202295 002** Oct 20, 2015**AB****7.5MG****A202295 003** Oct 20, 2015**AB****10MG****A202295 004** Oct 20, 2015**AB****15MG****A202295 005** Oct 20, 2015**AB****20MG****A202295 006** Oct 20, 2015**AB** APOTEX INC**2.5MG****A090798 001** Apr 23, 2012**AB****5MG****A090798 002** Apr 23, 2012**AB****7.5MG****A090798 003** Apr 23, 2012**AB****10MG****A090798 004** Apr 23, 2012**AB****15MG****A090798 005** Apr 23, 2012**AB****20MG****A090798 006** Apr 23, 2012**AB** AUROBINDO PHARMA LTD**2.5MG****A202050 001** Apr 23, 2012**AB****5MG****A202050 002** Apr 23, 2012**AB****7.5MG****A202050 003** Apr 23, 2012**AB****10MG****A202050 004** Apr 23, 2012**AB****15MG****A202050 005** Apr 23, 2012**AB****20MG****A202050 006** Apr 23, 2012**AB** DR REDDYS LABS LTD**2.5MG****A076255 001** Apr 23, 2012**AB****5MG****A076255 002** Apr 23, 2012**AB****7.5MG****A076255 003** Apr 23, 2012**AB****10MG****A076255 004** Apr 23, 2012

PRESCRIPTION DRUG PRODUCT LIST

OLANZAPINE

TABLET; ORAL

OLANZAPINE

<u>AB</u>		<u>15MG</u>	<u>A076133 001</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A076133 002</u>	Oct 24, 2011
<u>AB</u>	INDOCO	<u>2.5MG</u>	<u>A206155 001</u>	Jul 31, 2020
<u>AB</u>		<u>5MG</u>	<u>A206155 002</u>	Jul 31, 2020
<u>AB</u>		<u>7.5MG</u>	<u>A206155 003</u>	Jul 31, 2020
<u>AB</u>		<u>10MG</u>	<u>A206155 004</u>	Jul 31, 2020
<u>AB</u>		<u>15MG</u>	<u>A206155 005</u>	Jul 31, 2020
<u>AB</u>		<u>20MG</u>	<u>A206155 006</u>	Jul 31, 2020
<u>AB</u>	INVAGEN PHARMS	<u>2.5MG</u>	<u>A203333 001</u>	Mar 15, 2016
<u>AB</u>		<u>5MG</u>	<u>A203333 002</u>	Mar 15, 2016
<u>AB</u>		<u>7.5MG</u>	<u>A203333 003</u>	Mar 15, 2016
<u>AB</u>		<u>10MG</u>	<u>A203333 004</u>	Mar 15, 2016
<u>AB</u>		<u>15MG</u>	<u>A203333 005</u>	Mar 15, 2016
<u>AB</u>		<u>20MG</u>	<u>A203333 006</u>	Mar 15, 2016
<u>AB</u>	MACLEODS PHARMS LTD	<u>2.5MG</u>	<u>A202862 001</u>	Aug 15, 2014
<u>AB</u>		<u>5MG</u>	<u>A202862 002</u>	Aug 15, 2014
<u>AB</u>		<u>7.5MG</u>	<u>A202862 003</u>	Aug 15, 2014
<u>AB</u>		<u>10MG</u>	<u>A202862 004</u>	Aug 15, 2014
<u>AB</u>		<u>15MG</u>	<u>A202862 005</u>	Aug 15, 2014
<u>AB</u>		<u>20MG</u>	<u>A202862 006</u>	Aug 15, 2014
<u>AB</u>	ORCHID HLTHCARE	<u>2.5MG</u>	<u>A202287 001</u>	Apr 23, 2012
<u>AB</u>		<u>5MG</u>	<u>A202287 002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A202287 003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A202287 004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A202287 005</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A202287 006</u>	Apr 23, 2012
<u>AB</u>	PHARMTAK INC	<u>2.5MG</u>	<u>A206924 001</u>	Dec 31, 2020
<u>AB</u>		<u>5MG</u>	<u>A206924 002</u>	Dec 31, 2020
<u>AB</u>		<u>7.5MG</u>	<u>A206924 003</u>	Dec 31, 2020
<u>AB</u>		<u>10MG</u>	<u>A206924 004</u>	Dec 31, 2020
<u>AB</u>		<u>15MG</u>	<u>A206924 005</u>	Dec 31, 2020
<u>AB</u>		<u>20MG</u>	<u>A206924 006</u>	Dec 31, 2020
<u>AB</u>	QILU	<u>2.5MG</u>	<u>A204319 001</u>	Jan 27, 2016
<u>AB</u>		<u>5MG</u>	<u>A204319 002</u>	Jan 27, 2016
<u>AB</u>		<u>7.5MG</u>	<u>A204319 003</u>	Jan 27, 2016
<u>AB</u>		<u>10MG</u>	<u>A204319 004</u>	Jan 27, 2016
<u>AB</u>		<u>15MG</u>	<u>A204319 005</u>	Jan 27, 2016
<u>AB</u>		<u>20MG</u>	<u>A204319 006</u>	Jan 27, 2016
<u>AB</u>	SUN PHARM INDS	<u>2.5MG</u>	<u>A091038 001</u>	Apr 23, 2012
<u>AB</u>		<u>5MG</u>	<u>A091038 002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A091038 003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A091038 004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A091038 005</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A091038 006</u>	Apr 23, 2012
<u>AB</u>	ZYDUS PHARMS	<u>2.5MG</u>	<u>A090459 001</u>	Jul 16, 2018
<u>AB</u>		<u>5MG</u>	<u>A090459 002</u>	Jul 16, 2018
<u>AB</u>		<u>7.5MG</u>	<u>A090459 003</u>	Jul 16, 2018
<u>AB</u>		<u>10MG</u>	<u>A090459 004</u>	Jul 16, 2018
<u>AB</u>		<u>15MG</u>	<u>A090459 005</u>	Jul 16, 2018
<u>AB</u>		<u>20MG</u>	<u>A090459 006</u>	Jul 16, 2018

ZYPREXA

<u>AB</u>	+	LILLY	<u>2.5MG</u>	<u>N020592 001</u>	Sep 30, 1996
<u>AB</u>	+	!	<u>5MG</u>	<u>N020592 002</u>	Sep 30, 1996
<u>AB</u>	+		<u>7.5MG</u>	<u>N020592 003</u>	Sep 30, 1996
<u>AB</u>	+		<u>10MG</u>	<u>N020592 004</u>	Sep 30, 1996
<u>AB</u>	+		<u>15MG</u>	<u>N020592 005</u>	Sep 09, 1997
<u>AB</u>	+		<u>20MG</u>	<u>N020592 006</u>	Sep 09, 1997

TABLET, ORALLY DISINTEGRATING; ORAL

OLANZAPINE

<u>AB</u>	APOTEX INC	<u>5MG</u>	<u>A091265 001</u>	Oct 24, 2011
<u>AB</u>		<u>10MG</u>	<u>A091265 002</u>	Oct 24, 2011
<u>AB</u>		<u>15MG</u>	<u>A091265 003</u>	Oct 24, 2011
<u>AB</u>		<u>20MG</u>	<u>A091265 004</u>	Oct 24, 2011
<u>AB</u>	AUROBINDO PHARMA LTD	<u>5MG</u>	<u>A203708 001</u>	May 15, 2014
<u>AB</u>		<u>10MG</u>	<u>A203708 002</u>	May 15, 2014
<u>AB</u>		<u>15MG</u>	<u>A203708 003</u>	May 15, 2014
<u>AB</u>		<u>20MG</u>	<u>A203708 004</u>	May 15, 2014
<u>AB</u>	BARR LABS INC	<u>5MG</u>	<u>A077243 001</u>	Jan 30, 2012
<u>AB</u>		<u>10MG</u>	<u>A077243 002</u>	Jan 30, 2012

PRESCRIPTION DRUG PRODUCT LIST

OLANZAPINE

TABLET, ORALLY DISINTEGRATING;ORAL

OLANZAPINE

<u>AB</u>		<u>15MG</u>	<u>A077243</u>	<u>003</u>	Jan 30, 2012
<u>AB</u>		<u>20MG</u>	<u>A077243</u>	<u>004</u>	Jan 30, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A076534</u>	<u>001</u>	Oct 24, 2011
<u>AB</u>		<u>10MG</u>	<u>A076534</u>	<u>002</u>	Oct 24, 2011
<u>AB</u>		<u>15MG</u>	<u>A076534</u>	<u>003</u>	Oct 24, 2011
<u>AB</u>		<u>20MG</u>	<u>A076534</u>	<u>004</u>	Oct 24, 2011
<u>AB</u>	INVAGEN PHARMS	<u>5MG</u>	<u>A203456</u>	<u>001</u>	Mar 16, 2016
<u>AB</u>		<u>10MG</u>	<u>A203456</u>	<u>002</u>	Mar 16, 2016
<u>AB</u>		<u>15MG</u>	<u>A203456</u>	<u>003</u>	Mar 16, 2016
<u>AB</u>		<u>20MG</u>	<u>A203456</u>	<u>004</u>	Mar 16, 2016
<u>AB</u>	JUBILANT GENERICS	<u>5MG</u>	<u>A200221</u>	<u>001</u>	Sep 12, 2012
<u>AB</u>		<u>10MG</u>	<u>A200221</u>	<u>002</u>	Sep 12, 2012
<u>AB</u>		<u>15MG</u>	<u>A200221</u>	<u>003</u>	Sep 12, 2012
<u>AB</u>		<u>20MG</u>	<u>A200221</u>	<u>004</u>	Sep 12, 2012
<u>AB</u>	MACLEODS PHARMS LTD	<u>5MG</u>	<u>A203044</u>	<u>001</u>	Feb 20, 2015
<u>AB</u>		<u>10MG</u>	<u>A203044</u>	<u>002</u>	Feb 20, 2015
<u>AB</u>		<u>15MG</u>	<u>A203044</u>	<u>003</u>	Feb 20, 2015
<u>AB</u>		<u>20MG</u>	<u>A203044</u>	<u>004</u>	Feb 20, 2015
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A202285</u>	<u>001</u>	May 12, 2014
<u>AB</u>		<u>10MG</u>	<u>A202285</u>	<u>002</u>	May 12, 2014
<u>AB</u>		<u>15MG</u>	<u>A202285</u>	<u>003</u>	May 12, 2014
<u>AB</u>		<u>20MG</u>	<u>A202285</u>	<u>004</u>	May 12, 2014
<u>AB</u>	ORCHID HLTHCARE	<u>5MG</u>	<u>A202937</u>	<u>001</u>	Mar 02, 2015
<u>AB</u>		<u>10MG</u>	<u>A202937</u>	<u>002</u>	Mar 02, 2015
<u>AB</u>		<u>15MG</u>	<u>A202937</u>	<u>003</u>	Mar 02, 2015
<u>AB</u>		<u>20MG</u>	<u>A202937</u>	<u>004</u>	Mar 02, 2015
<u>AB</u>	PAR PHARM	<u>5MG</u>	<u>A078109</u>	<u>001</u>	Oct 24, 2011
<u>AB</u>		<u>10MG</u>	<u>A078109</u>	<u>002</u>	Oct 24, 2011
<u>AB</u>		<u>15MG</u>	<u>A078109</u>	<u>003</u>	Oct 24, 2011
<u>AB</u>		<u>20MG</u>	<u>A078109</u>	<u>004</u>	Oct 24, 2011
<u>AB</u>	PHARMTAK INC	<u>5MG</u>	<u>A206892</u>	<u>001</u>	Dec 31, 2020
<u>AB</u>		<u>10MG</u>	<u>A206892</u>	<u>002</u>	Dec 31, 2020
<u>AB</u>		<u>15MG</u>	<u>A206892</u>	<u>003</u>	Dec 31, 2020
<u>AB</u>		<u>20MG</u>	<u>A206892</u>	<u>004</u>	Dec 31, 2020
<u>AB</u>	SUN PHARM INDS	<u>5MG</u>	<u>A090881</u>	<u>001</u>	Feb 28, 2012
<u>AB</u>		<u>10MG</u>	<u>A090881</u>	<u>002</u>	Feb 28, 2012
<u>AB</u>		<u>15MG</u>	<u>A090881</u>	<u>003</u>	Feb 28, 2012
<u>AB</u>		<u>20MG</u>	<u>A090881</u>	<u>004</u>	Feb 28, 2012
<u>AB</u>	TORRENT PHARMS LLC	<u>5MG</u>	<u>A091415</u>	<u>001</u>	Oct 25, 2011
<u>AB</u>		<u>10MG</u>	<u>A091415</u>	<u>002</u>	Oct 25, 2011
<u>AB</u>		<u>15MG</u>	<u>A091415</u>	<u>003</u>	Oct 25, 2011
<u>AB</u>		<u>20MG</u>	<u>A091415</u>	<u>004</u>	Oct 25, 2011
<u>ZYPREXA ZYDIS</u>					
<u>AB</u>	+!	LILLY	<u>5MG</u>	<u>N021086</u>	<u>001</u> Apr 06, 2000
<u>AB</u>	+		<u>10MG</u>	<u>N021086</u>	<u>002</u> Apr 06, 2000
<u>AB</u>	+		<u>15MG</u>	<u>N021086</u>	<u>003</u> Apr 06, 2000
<u>AB</u>	+		<u>20MG</u>	<u>N021086</u>	<u>004</u> Apr 06, 2000

OLANZAPINE PAMOATE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

ZYPREXA RELPREVV

+	ELI LILLY CO	EQ 210MG BASE/VIAL	N022173	001	Dec 11, 2009
+		EQ 300MG BASE/VIAL	N022173	002	Dec 11, 2009
+		EQ 405MG BASE/VIAL	N022173	003	Dec 11, 2009

OLAPARIB

TABLET;ORAL

LYNPARZA

+	ASTRAZENECA PHARMS	100MG	N208558	001	Aug 17, 2017
+		150MG	N208558	002	Aug 17, 2017

OLICERIDINE

SOLUTION;INTRAVENOUS

OLINVYK

+	TREVENA	1MG/ML (1MG/ML)	N210730	001	Oct 30, 2020
+		2MG/2ML (1MG/ML)	N210730	002	Oct 30, 2020
+		30MG/30ML (1MG/ML)	N210730	003	Oct 30, 2020

PRESCRIPTION DRUG PRODUCT LIST

OLIVE OIL; SOYBEAN OIL

EMULSION; INTRAVENOUS

CLINOLIPID 20%

+! BAXTER HLTHCARE 16% (160GM/1000ML); 4% (40GM/1000ML) N204508 001 Oct 03, 2013
CORPOLMESARTAN MEDOXOMIL

TABLET; ORAL

BENICAR

<u>AB</u>	+	DAIICHI SANKYO	<u>5MG</u>	<u>N021286</u>	<u>001</u>	Apr 25, 2002
<u>AB</u>	+		<u>20MG</u>	<u>N021286</u>	<u>003</u>	Apr 25, 2002
<u>AB</u>	+		<u>40MG</u>	<u>N021286</u>	<u>004</u>	Apr 25, 2002

OLMESARTAN MEDOXOMIL

<u>AB</u>		ACCORD HLTHCARE	<u>5MG</u>	<u>A207662</u>	<u>001</u>	Apr 24, 2017
<u>AB</u>			<u>20MG</u>	<u>A207662</u>	<u>002</u>	Apr 24, 2017
<u>AB</u>			<u>40MG</u>	<u>A207662</u>	<u>003</u>	Apr 24, 2017
<u>AB</u>		ALEMBIC PHARMS LTD	<u>5MG</u>	<u>A203012</u>	<u>001</u>	Apr 24, 2017
<u>AB</u>			<u>20MG</u>	<u>A203012</u>	<u>002</u>	Apr 24, 2017
<u>AB</u>			<u>40MG</u>	<u>A203012</u>	<u>003</u>	Apr 24, 2017
<u>AB</u>		ALKEM LABS LTD	<u>5MG</u>	<u>A206763</u>	<u>001</u>	Apr 24, 2017
<u>AB</u>			<u>20MG</u>	<u>A206763</u>	<u>002</u>	Apr 24, 2017
<u>AB</u>			<u>40MG</u>	<u>A206763</u>	<u>003</u>	Apr 24, 2017
<u>AB</u>		AUROBINDO PHARMA LTD	<u>5MG</u>	<u>A204798</u>	<u>001</u>	Apr 24, 2017
<u>AB</u>			<u>20MG</u>	<u>A204798</u>	<u>002</u>	Apr 24, 2017
<u>AB</u>			<u>40MG</u>	<u>A204798</u>	<u>003</u>	Apr 24, 2017
<u>AB</u>		GLENMARK PHARMS LTD	<u>5MG</u>	<u>A203281</u>	<u>001</u>	May 25, 2017
<u>AB</u>			<u>20MG</u>	<u>A203281</u>	<u>002</u>	May 25, 2017
<u>AB</u>			<u>40MG</u>	<u>A203281</u>	<u>003</u>	May 25, 2017
<u>AB</u>		LUPIN LTD	<u>5MG</u>	<u>A206631</u>	<u>001</u>	Apr 27, 2017
<u>AB</u>			<u>20MG</u>	<u>A206631</u>	<u>002</u>	Apr 27, 2017
<u>AB</u>			<u>40MG</u>	<u>A206631</u>	<u>003</u>	Apr 27, 2017
<u>AB</u>		MACLEODS PHARMS LTD	<u>5MG</u>	<u>A204814</u>	<u>001</u>	Apr 24, 2017
<u>AB</u>			<u>20MG</u>	<u>A204814</u>	<u>002</u>	Apr 24, 2017
<u>AB</u>			<u>40MG</u>	<u>A204814</u>	<u>003</u>	Apr 24, 2017
<u>AB</u>		MICRO LABS	<u>5MG</u>	<u>A206372</u>	<u>001</u>	Sep 17, 2019
<u>AB</u>			<u>20MG</u>	<u>A206372</u>	<u>002</u>	Sep 17, 2019
<u>AB</u>			<u>40MG</u>	<u>A206372</u>	<u>003</u>	Sep 17, 2019
<u>AB</u>		MYLAN	<u>5MG</u>	<u>A078276</u>	<u>001</u>	Oct 26, 2016
<u>AB</u>			<u>20MG</u>	<u>A078276</u>	<u>002</u>	Oct 26, 2016
<u>AB</u>			<u>40MG</u>	<u>A078276</u>	<u>003</u>	Oct 26, 2016
<u>AB</u>		QILU	<u>5MG</u>	<u>A210552</u>	<u>001</u>	Jan 10, 2019
<u>AB</u>			<u>20MG</u>	<u>A210552</u>	<u>002</u>	Jan 10, 2019
<u>AB</u>			<u>40MG</u>	<u>A210552</u>	<u>003</u>	Jan 10, 2019
<u>AB</u>		SANDOZ INC	<u>5MG</u>	<u>A090237</u>	<u>001</u>	Apr 13, 2020
<u>AB</u>			<u>20MG</u>	<u>A090237</u>	<u>002</u>	Apr 13, 2020
<u>AB</u>			<u>40MG</u>	<u>A090237</u>	<u>003</u>	Apr 13, 2020
<u>AB</u>		SCIEGEN PHARMS INC	<u>5MG</u>	<u>A208130</u>	<u>001</u>	Jun 29, 2018
<u>AB</u>			<u>20MG</u>	<u>A208130</u>	<u>002</u>	Jun 29, 2018
<u>AB</u>			<u>40MG</u>	<u>A208130</u>	<u>003</u>	Jun 29, 2018
<u>AB</u>		SUNSHINE	<u>5MG</u>	<u>A211049</u>	<u>001</u>	Feb 22, 2019
<u>AB</u>			<u>20MG</u>	<u>A211049</u>	<u>002</u>	Feb 22, 2019
<u>AB</u>			<u>40MG</u>	<u>A211049</u>	<u>003</u>	Feb 22, 2019
<u>AB</u>		TORRENT	<u>5MG</u>	<u>A202375</u>	<u>001</u>	Apr 24, 2017
<u>AB</u>			<u>20MG</u>	<u>A202375</u>	<u>002</u>	Apr 24, 2017
<u>AB</u>			<u>40MG</u>	<u>A202375</u>	<u>003</u>	Apr 24, 2017
<u>AB</u>		UMEDICA LABS PVT LTD	<u>5MG</u>	<u>A207135</u>	<u>001</u>	Jul 18, 2019
<u>AB</u>			<u>20MG</u>	<u>A207135</u>	<u>002</u>	Jul 18, 2019
<u>AB</u>			<u>40MG</u>	<u>A207135</u>	<u>003</u>	Jul 18, 2019
<u>AB</u>		ZYDUS PHARMS	<u>5MG</u>	<u>A205192</u>	<u>001</u>	Apr 24, 2017
<u>AB</u>			<u>20MG</u>	<u>A205192</u>	<u>002</u>	Apr 24, 2017
<u>AB</u>			<u>40MG</u>	<u>A205192</u>	<u>003</u>	Apr 24, 2017

OLODATEROL HYDROCHLORIDE

SPRAY, METERED; INHALATION

STRIVERDI RESPIMAT

+! BOEHRINGER EQ 0.0025MG BASE/INH N203108 001 Jul 31, 2014
INGELHEIM

PRESCRIPTION DRUG PRODUCT LISTOLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE

SPRAY, METERED; INHALATION

STIOLTO RESPIMAT

+! BOEHRINGER EQ 0.0025MG BASE/INH; EQ 0.0025MG
INGELHEIM BASE/INH

N206756 001 May 21, 2015

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

AT	AKORN	<u>EQ 0.2% BASE</u>	<u>A204723 001</u>	Dec 05, 2017
AT	AKORN INC	<u>EQ 0.1% BASE</u>	<u>A204532 001</u>	Jan 10, 2017
AT	ALEMBIC PHARMS LTD	<u>EQ 0.1% BASE</u>	<u>A209919 001</u>	Dec 07, 2018
AT		<u>EQ 0.2% BASE</u>	<u>A209420 001</u>	Apr 29, 2019
AT	APOTEX INC	<u>EQ 0.2% BASE</u>	<u>A090918 001</u>	Dec 05, 2017
AT	BARR LABS INC	<u>EQ 0.2% BASE</u>	<u>A090848 001</u>	Jul 13, 2015
AT	FDC LTD	<u>EQ 0.1% BASE</u>	<u>A209282 001</u>	Sep 26, 2019
AT	MYLAN	<u>EQ 0.1% BASE</u>	<u>A204392 001</u>	Mar 21, 2018
AT	SOMERSET THERAPS LLC	<u>EQ 0.1% BASE</u>	<u>A206306 001</u>	Dec 07, 2015
AT	USV	<u>EQ 0.1% BASE</u>	<u>A203152 001</u>	Dec 07, 2015
AT	WOCKHARDT LTD	<u>EQ 0.1% BASE</u>	<u>A200810 001</u>	Jun 28, 2017

SPRAY, METERED; NASAL

OLOPATADINE HYDROCHLORIDE

AB	AKORN	<u>0.665MG/SPRAY</u>	<u>A213757 001</u>	Aug 19, 2020
AB	AMNEAL	<u>0.665MG/SPRAY</u>	<u>A210901 001</u>	Jan 28, 2020
AB	APOTEX INC	<u>0.665MG/SPRAY</u>	<u>A091572 001</u>	Oct 08, 2014
AB	PERRIGO ISRAEL	<u>0.665MG/SPRAY</u>	<u>A202853 001</u>	Jan 31, 2017

PATANASE

AB	+! NOVARTIS	<u>0.665MG/SPRAY</u>	<u>N021861 001</u>	Apr 15, 2008
-----------	-------------	-----------------------------	---------------------------	--------------

OLSALAZINE SODIUM

CAPSULE; ORAL

DIPENTUM

+! MYLAN SPECIALITY LP 250MG N019715 001 Jul 31, 1990

OMACETAXINE MEPESUCCINATE

POWDER; SUBCUTANEOUS

SYNRIBO

+! TEVA PHARMS INTL 3.5MG/VIAL N203585 001 Oct 26, 2012

OMADACYCLINE TOSYLATE

POWDER; INTRAVENOUS

NUZYRA

+! PARATEK PHARMS INC EQ 100MG BASE/VIAL N209817 001 Oct 02, 2018

TABLET; ORAL

NUZYRA

+! PARATEK PHARMS INC EQ 150MG BASE N209816 001 Oct 02, 2018

OMEGA-3-ACID ETHYL ESTERS

CAPSULE; ORAL

LOVAZA

AB	+! SMITHKLINE BEECHAM	<u>1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS</u>	<u>N021654 001</u>	Nov 10, 2004
-----------	-----------------------	--	---------------------------	--------------

OMEGA-3-ACID ETHYL ESTERS

AB	AMNEAL PHARMS	<u>1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS</u>	<u>A204940 001</u>	Nov 27, 2015
AB	APOTEX	<u>1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS</u>	<u>A090973 001</u>	Sep 30, 2014
AB	ASCENT PHARMS INC	<u>1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS</u>	<u>A207420 001</u>	Feb 25, 2019
AB	BIONPHARMA INC	<u>1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS</u>	<u>A206455 001</u>	Aug 07, 2019
AB	CSFC-NBP PHARM	<u>1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS</u>	<u>A211979 001</u>	May 12, 2020
AB	GLW	<u>1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS</u>	<u>A212504 001</u>	Aug 19, 2020
AB	PURACAP PHARM LLC	<u>1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS</u>	<u>A210093 001</u>	Jun 15, 2020
AB	SOFGEN PHARMS	<u>1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS</u>	<u>A211355 001</u>	Jul 10, 2019
AB	STRIDES PHARMA	<u>1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS</u>	<u>A203893 001</u>	Sep 19, 2017
AB	SUN PHARM	<u>1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS</u>	<u>A210834 001</u>	Jan 09, 2020
AB	TEVA PHARMS USA	<u>1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS</u>	<u>A091028 001</u>	Apr 07, 2014

PRESCRIPTION DRUG PRODUCT LIST

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

OMEPRAZOLE

<u>AB</u>	ACTAVIS LABS FL INC	<u>10MG</u>	<u>A075347</u>	<u>001</u>	May 30, 2008
<u>AB</u>		<u>20MG</u>	<u>A075347</u>	<u>002</u>	May 30, 2008
<u>AB</u>		<u>40MG</u>	<u>A075347</u>	<u>003</u>	May 30, 2008
<u>AB</u>	APOTEX	<u>10MG</u>	<u>A076048</u>	<u>001</u>	Oct 22, 2007
<u>AB</u>		<u>20MG</u>	<u>A076048</u>	<u>002</u>	Oct 22, 2007
<u>AB</u>		<u>40MG</u>	<u>A076048</u>	<u>003</u>	Jan 21, 2009
<u>AB</u>	AUROBINDO PHARMA LTD	<u>10MG</u>	<u>A203270</u>	<u>001</u>	Aug 19, 2015
<u>AB</u>		<u>20MG</u>	<u>A203270</u>	<u>002</u>	Aug 19, 2015
<u>AB</u>		<u>40MG</u>	<u>A203270</u>	<u>003</u>	Aug 19, 2015
<u>AB</u>	BRECKENRIDGE	<u>10MG</u>	<u>A203481</u>	<u>001</u>	Jul 03, 2017
<u>AB</u>		<u>20MG</u>	<u>A203481</u>	<u>002</u>	Jul 03, 2017
<u>AB</u>		<u>40MG</u>	<u>A203481</u>	<u>003</u>	Jul 03, 2017
<u>AB</u>	DR REDDYS LABS LTD	<u>10MG</u>	<u>A075576</u>	<u>003</u>	Oct 22, 2007
<u>AB</u>		<u>10MG</u>	<u>A078490</u>	<u>002</u>	Mar 16, 2009
<u>AB</u>		<u>20MG</u>	<u>A075576</u>	<u>002</u>	Oct 22, 2007
<u>AB</u>		<u>20MG</u>	<u>A078490</u>	<u>003</u>	Mar 16, 2009
<u>AB</u>		<u>40MG</u>	<u>A075576</u>	<u>001</u>	Jan 21, 2009
<u>AB</u>		<u>40MG</u>	<u>A078490</u>	<u>001</u>	Apr 17, 2009
<u>AB</u>	GLENMARK GENERICS	<u>10MG</u>	<u>A091672</u>	<u>001</u>	Oct 31, 2014
<u>AB</u>		<u>20MG</u>	<u>A091672</u>	<u>002</u>	Oct 31, 2014
<u>AB</u>		<u>40MG</u>	<u>A091672</u>	<u>003</u>	Oct 31, 2014
<u>AB</u>	HETERO LABS LTD III	<u>10MG</u>	<u>A204012</u>	<u>001</u>	Sep 26, 2019
<u>AB</u>		<u>20MG</u>	<u>A204012</u>	<u>002</u>	Sep 26, 2019
<u>AB</u>	IMPAX LABS	<u>10MG</u>	<u>A075785</u>	<u>001</u>	Oct 22, 2007
<u>AB</u>		<u>20MG</u>	<u>A075785</u>	<u>002</u>	Oct 22, 2007
<u>AB</u>		<u>40MG</u>	<u>A075785</u>	<u>003</u>	Jan 21, 2009
<u>AB</u>	LANNETT CO INC	<u>10MG</u>	<u>A075410</u>	<u>001</u>	Nov 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A075410</u>	<u>002</u>	Nov 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A075410</u>	<u>003</u>	Jan 23, 2009
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A075757</u>	<u>001</u>	Jan 28, 2003
<u>AB</u>	!	<u>20MG</u>	<u>A075757</u>	<u>002</u>	Jan 28, 2003
<u>AB</u>	!	<u>40MG</u>	<u>A076515</u>	<u>001</u>	Jan 21, 2009
<u>AB</u>	TEVA PHARMS USA	<u>20MG</u>	<u>A204661</u>	<u>001</u>	Jun 13, 2017
<u>AB</u>	XIROMED	<u>10MG</u>	<u>A212977</u>	<u>001</u>	Dec 10, 2020
<u>AB</u>		<u>20MG</u>	<u>A212977</u>	<u>002</u>	Dec 10, 2020
<u>AB</u>	ZYDUS PHARMS USA INC	<u>10MG</u>	<u>A091352</u>	<u>001</u>	Nov 19, 2012
<u>AB</u>		<u>20MG</u>	<u>A091352</u>	<u>002</u>	Nov 19, 2012
<u>AB</u>		<u>40MG</u>	<u>A091352</u>	<u>003</u>	Nov 19, 2012

OMEPRAZOLE MAGNESIUM

FOR SUSPENSION, DELAYED RELEASE;ORAL

PRILOSEC

+ COVIS

EQ 2.5MG BASE/PACKET

N022056 001 Mar 20, 2008

+!

EQ 10MG BASE/PACKET

N022056 002 Mar 20, 2008

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

<u>AB</u>	AJANTA PHARMA LTD	<u>20MG;1.1GM</u>	<u>A204228</u>	<u>001</u>	Jul 15, 2016
<u>AB</u>		<u>40MG;1.1GM</u>	<u>A204228</u>	<u>002</u>	Jul 15, 2016
<u>AB</u>	AUROLIFE PHARMA LLC	<u>20MG;1.1GM</u>	<u>A204922</u>	<u>001</u>	Aug 19, 2016
<u>AB</u>		<u>40MG;1.1GM</u>	<u>A204922</u>	<u>002</u>	Aug 19, 2016
<u>AB</u>	DR REDDYS LABS LTD	<u>20MG;1.1GM</u>	<u>A204068</u>	<u>001</u>	Jul 15, 2016
<u>AB</u>		<u>40MG;1.1GM</u>	<u>A204068</u>	<u>002</u>	Jul 15, 2016
<u>AB</u>	GUARDIAN DRUG	<u>20MG;1.1GM</u>	<u>A212587</u>	<u>001</u>	Apr 30, 2020
<u>AB</u>		<u>40MG;1.1GM</u>	<u>A212587</u>	<u>002</u>	Apr 30, 2020
<u>AB</u>	SCIEGEN PHARMS INC	<u>20MG;1.1GM</u>	<u>A207476</u>	<u>001</u>	Dec 06, 2016
<u>AB</u>		<u>40MG;1.1GM</u>	<u>A207476</u>	<u>002</u>	Dec 06, 2016
<u>AB</u>	ZYDUS PHARMS	<u>20MG;1.1GM</u>	<u>A203290</u>	<u>001</u>	May 25, 2018
<u>AB</u>		<u>40MG;1.1GM</u>	<u>A203290</u>	<u>002</u>	May 25, 2018
<u>AB</u>	<u>ZEGERID</u>				
<u>AB</u>	+ SALIX	<u>20MG;1.1GM</u>	<u>N021849</u>	<u>001</u>	Feb 27, 2006
<u>AB</u>	+!	<u>40MG;1.1GM</u>	<u>N021849</u>	<u>002</u>	Feb 27, 2006

FOR SUSPENSION;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

<u>AB</u>	AJANTA PHARMA LTD	<u>20MG/PACKET;1.68GM/PACKET</u>	<u>A205545</u>	<u>001</u>	Jul 27, 2016
<u>AB</u>		<u>40MG/PACKET;1.68GM/PACKET</u>	<u>A205545</u>	<u>002</u>	Jul 27, 2016
<u>AB</u>	PAR PHARM	<u>20MG/PACKET;1.68GM/PACKET</u>	<u>A079182</u>	<u>001</u>	Apr 19, 2013
<u>AB</u>		<u>40MG/PACKET;1.68GM/PACKET</u>	<u>A079182</u>	<u>002</u>	Apr 19, 2013

PRESCRIPTION DRUG PRODUCT LIST

OMEPRAZOLE; SODIUM BICARBONATE

FOR SUSPENSION; ORAL

ZEGERID

<u>AB</u>	+	SALIX	<u>20MG/PACKET; 1.68GM/PACKET</u>	<u>N021636</u>	<u>001</u>	Jun 15, 2004
<u>AB</u>	+	!	<u>40MG/PACKET; 1.68GM/PACKET</u>	<u>N021636</u>	<u>002</u>	Dec 21, 2004

ONDANSETRON

TABLET, ORALLY DISINTEGRATING; ORAL

ONDANSETRON

<u>AB</u>		AUROBINDO PHARMA	<u>4MG</u>	<u>A090469</u>	<u>001</u>	Apr 12, 2010
<u>AB</u>			<u>8MG</u>	<u>A090469</u>	<u>002</u>	Apr 12, 2010
<u>AB</u>		GLENMARK GENERICS	<u>4MG</u>	<u>A078152</u>	<u>001</u>	Jun 27, 2007
<u>AB</u>			<u>8MG</u>	<u>A078152</u>	<u>002</u>	Jun 27, 2007
<u>AB</u>		MYLAN	<u>4MG</u>	<u>A078139</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>			<u>8MG</u>	<u>A078139</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>		SANDOZ	<u>4MG</u>	<u>A078050</u>	<u>001</u>	Aug 13, 2007
<u>AB</u>			<u>8MG</u>	<u>A078050</u>	<u>002</u>	Aug 13, 2007
<u>AB</u>		SUN PHARM INDS	<u>4MG</u>	<u>A077557</u>	<u>001</u>	Aug 02, 2007
<u>AB</u>			<u>8MG</u>	<u>A077557</u>	<u>002</u>	Aug 02, 2007
<u>AB</u>		SUN PHARM INDS LTD	<u>4MG</u>	<u>A078602</u>	<u>001</u>	Feb 24, 2011
<u>AB</u>			<u>8MG</u>	<u>A078602</u>	<u>002</u>	Feb 24, 2011

ZOFRAN ODT

<u>AB</u>	+	NOVARTIS	<u>4MG</u>	<u>N020781</u>	<u>001</u>	Jan 27, 1999
<u>AB</u>	+	!	<u>8MG</u>	<u>N020781</u>	<u>002</u>	Jan 27, 1999

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

<u>AP</u>		ACCORD HLTHCARE	<u>EQ 2MG BASE/ML</u>	<u>A206846</u>	<u>001</u>	Jul 13, 2015
<u>AP</u>		AUROBINDO PHARMA LTD	<u>EQ 2MG BASE/ML</u>	<u>A202599</u>	<u>001</u>	Dec 21, 2012
<u>AP</u>		FRESENIUS KABI USA	<u>EQ 2MG BASE/ML</u>	<u>A076974</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>		GLAND PHARMA LTD	<u>EQ 2MG BASE/ML</u>	<u>A079224</u>	<u>001</u>	Sep 25, 2009
<u>AP</u>	!		<u>EQ 2MG BASE/ML</u>	<u>A090648</u>	<u>001</u>	Jun 15, 2012
<u>AP</u>		HIKMA FARMACEUTICA	<u>EQ 2MG BASE/ML</u>	<u>A076781</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>		HOSPIRA	<u>EQ 2MG BASE/ML</u>	<u>A077473</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>			<u>EQ 2MG BASE/ML</u>	<u>A077840</u>	<u>001</u>	Jan 19, 2007
<u>AP</u>	!	QILU	<u>EQ 2MG BASE/ML</u>	<u>A203711</u>	<u>001</u>	Sep 08, 2014
<u>AP</u>		SANDOZ INC	<u>EQ 2MG BASE/ML</u>	<u>A077430</u>	<u>001</u>	Jun 27, 2007
<u>AP</u>		TEVA	<u>EQ 2MG BASE/ML</u>	<u>A076876</u>	<u>001</u>	Nov 22, 2006
<u>AP</u>		WEST-WARD PHARMS INT	<u>EQ 2MG BASE/ML</u>	<u>A076967</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>			<u>EQ 2MG BASE/ML</u>	<u>A077365</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>		WOCKHARDT	<u>EQ 2MG BASE/ML</u>	<u>A077577</u>	<u>001</u>	Dec 26, 2006

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>		ACCORD HLTHCARE	<u>EQ 2MG BASE/ML</u>	<u>A206845</u>	<u>001</u>	Mar 10, 2016
<u>AP</u>		AUROBINDO PHARMA LTD	<u>EQ 2MG BASE/ML</u>	<u>A202600</u>	<u>001</u>	Dec 21, 2012
<u>AP</u>	!	BAXTER HLTHCARE CORP	<u>EQ 2MG BASE/ML</u>	<u>A078287</u>	<u>001</u>	Feb 22, 2013
<u>AP</u>		EMCURE PHARMS LTD	<u>EQ 2MG BASE/ML</u>	<u>A078945</u>	<u>001</u>	Jan 03, 2013
<u>AP</u>		FRESENIUS KABI USA	<u>EQ 2MG BASE/ML</u>	<u>A076972</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>			<u>EQ 2MG BASE/ML</u>	<u>A202253</u>	<u>001</u>	Jul 19, 2013
<u>AP</u>		HOSPIRA	<u>EQ 2MG BASE/ML</u>	<u>A077548</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>		SANDOZ INC	<u>EQ 2MG BASE/ML</u>	<u>A077551</u>	<u>001</u>	Jun 27, 2007
<u>AP</u>		WEST-WARD PHARMS INT	<u>EQ 2MG BASE/ML</u>	<u>A077011</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>			<u>EQ 2MG BASE/ML</u>	<u>A077541</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>		WOCKHARDT	<u>EQ 2MG BASE/ML</u>	<u>A077716</u>	<u>001</u>	Dec 26, 2006

SOLUTION; ORAL

ONDANSETRON HYDROCHLORIDE

<u>AA</u>		AMNEAL PHARMS	<u>EQ 4MG BASE/5ML</u>	<u>A091483</u>	<u>001</u>	Jan 31, 2011
<u>AA</u>		AUROBINDO PHARMA	<u>EQ 4MG BASE/5ML</u>	<u>A078776</u>	<u>001</u>	Nov 28, 2007
<u>AA</u>		HIKMA	<u>EQ 4MG BASE/5ML</u>	<u>A076960</u>	<u>001</u>	Dec 26, 2006
<u>AA</u>		LANNETT CO INC	<u>EQ 4MG BASE/5ML</u>	<u>A091342</u>	<u>001</u>	Jan 27, 2011
<u>AA</u>		PHARM ASSOC	<u>EQ 4MG BASE/5ML</u>	<u>A078127</u>	<u>001</u>	Jun 25, 2007
<u>AA</u>		TARO	<u>EQ 4MG BASE/5ML</u>	<u>A077009</u>	<u>001</u>	Nov 30, 2007

ZOFRAN

<u>AA</u>	+	NOVARTIS	<u>EQ 4MG BASE/5ML</u>	<u>N020605</u>	<u>001</u>	Jan 24, 1997
-----------	---	----------	------------------------	----------------	------------	--------------

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

<u>AB</u>		APOTEX	<u>EQ 4MG BASE</u>	<u>A077306</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A077306</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>		AUROBINDO PHARMA	<u>EQ 4MG BASE</u>	<u>A078539</u>	<u>001</u>	Jul 31, 2007

PRESCRIPTION DRUG PRODUCT LIST

ONDANSETRON HYDROCHLORIDE

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A078539 002</u>	Jul 31, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A078539 003</u>	Jul 31, 2007
<u>AB</u>	CASI PHARMS INC	<u>EQ 4MG BASE</u>	<u>A077517 001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077517 002</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A077517 003</u>	Jun 25, 2007
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 4MG BASE</u>	<u>A076183 003</u>	Dec 26, 2006
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A076183 002</u>	Dec 26, 2006
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A076183 001</u>	Dec 26, 2006
<u>AB</u>	GLENMARK GENERICS	<u>EQ 4MG BASE</u>	<u>A077535 001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077535 002</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A077535 003</u>	Jun 25, 2007
<u>AB</u>	IPCA LABS LTD	<u>EQ 4MG BASE</u>	<u>A203761 001</u>	Jan 23, 2014
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A203761 002</u>	Jan 23, 2014
<u>AB</u>	NATCO PHARMA LTD	<u>EQ 4MG BASE</u>	<u>A077851 001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077851 002</u>	Jun 25, 2007
<u>AB</u>	SUN PHARM INDS (IN)	<u>EQ 4MG BASE</u>	<u>A077050 001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077050 002</u>	Jun 25, 2007
<u>AB</u>	TEVA	<u>EQ 4MG BASE</u>	<u>A076252 001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A076252 002</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A076252 003</u>	Jun 25, 2007

ZOFRAN

<u>AB</u>	+ NOVARTIS	<u>EQ 4MG BASE</u>	<u>N020103 001</u>	Dec 31, 1992
<u>AB</u>	+	<u>EQ 8MG BASE</u>	<u>N020103 002</u>	Dec 31, 1992
<u>AB</u>	+!	<u>EQ 24MG BASE</u>	<u>N020103 003</u>	Aug 27, 1999
	ONDANSETRON HYDROCHLORIDE			
	DR REDDYS LABS LTD	EQ 16MG BASE	A076183 004	Dec 26, 2006

OPICAPONE

CAPSULE; ORAL

ONGENTYS

+	NEUROCRINE	25MG	N212489 001	Apr 24, 2020
+	!	50MG	N212489 002	Apr 24, 2020

ORITAVANCIN DIPHOSPHATE

POWDER; INTRAVENOUS

ORBACTIV

+	MELINTA THERAP	EQ 400MG BASE/VIAL	N206334 001	Aug 06, 2014
---	----------------	--------------------	-------------	--------------

ORLISTAT

CAPSULE; ORAL

XENICAL

+	CHEPLAPHARM	120MG	N020766 001	Apr 23, 1999
---	-------------	-------	-------------	--------------

ORPHENADRINE CITRATE

INJECTABLE; INJECTION

ORPHENADRINE CITRATE

<u>AP</u>	!	AKORN	<u>30MG/ML</u>	<u>A040484 001</u>	May 24, 2006
<u>AP</u>		SAGENT PHARMS	<u>30MG/ML</u>	<u>A090585 001</u>	Aug 30, 2011
<u>AP</u>		WATSON LABS	<u>30MG/ML</u>	<u>A084779 001</u>	Mar 15, 1982
<u>AP</u>		WEST-WARD PHARMS INT	<u>30MG/ML</u>	<u>A040463 001</u>	Mar 04, 2003

TABLET, EXTENDED RELEASE; ORAL

ORPHENADRINE CITRATE

<u>AB</u>		ANDA REPOSITORY	<u>100MG</u>	<u>A040249 001</u>	Jan 29, 1999
<u>AB</u>		IMPAX PHARMS	<u>100MG</u>	<u>A040368 001</u>	Jun 23, 2000
<u>AB</u>		INVAGEN PHARMS	<u>100MG</u>	<u>A091158 001</u>	Jul 27, 2012
<u>AB</u>		LUPIN	<u>100MG</u>	<u>A040284 001</u>	Jun 19, 1998
<u>AB</u>	!	SANDOZ	<u>100MG</u>	<u>A040327 001</u>	Feb 15, 2000

OSELTAMIVIR PHOSPHATE

CAPSULE; ORAL

OSELTAMIVIR PHOSPHATE

<u>AB</u>		ALEMIC PHARMS LTD	<u>EQ 30MG BASE</u>	<u>A211823 001</u>	Jun 24, 2019
<u>AB</u>			<u>EQ 45MG BASE</u>	<u>A211823 002</u>	Jun 24, 2019
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A211823 003</u>	Jun 24, 2019
<u>AB</u>		AMNEAL PHARMS	<u>EQ 30MG BASE</u>	<u>A209093 001</u>	May 17, 2017
<u>AB</u>			<u>EQ 45MG BASE</u>	<u>A209093 002</u>	May 17, 2017
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A209093 003</u>	May 17, 2017
<u>AB</u>		HETERO LABS LTD III	<u>EQ 30MG BASE</u>	<u>A209438 001</u>	Feb 23, 2018
<u>AB</u>			<u>EQ 45MG BASE</u>	<u>A209438 002</u>	Feb 23, 2018
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A209438 003</u>	Feb 23, 2018
<u>AB</u>		LUPIN	<u>EQ 30MG BASE</u>	<u>A208348 001</u>	Jan 09, 2018

PRESCRIPTION DRUG PRODUCT LISTOSELTAMIVIR PHOSPHATE

CAPSULE;ORAL

OSELTAMIVIR PHOSPHATE

<u>AB</u>		<u>EQ 45MG BASE</u>	<u>A208348 002</u>	Jan 09, 2018
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A208348 003</u>	Jan 09, 2018
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 30MG BASE</u>	<u>A207211 001</u>	Sep 14, 2017
<u>AB</u>		<u>EQ 45MG BASE</u>	<u>A207211 002</u>	Sep 14, 2017
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A207211 003</u>	Sep 14, 2017
<u>AB</u>	MSN	<u>EQ 30MG BASE</u>	<u>A212544 001</u>	May 20, 2020
<u>AB</u>		<u>EQ 45MG BASE</u>	<u>A212544 002</u>	May 20, 2020
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A212544 003</u>	May 20, 2020
<u>AB</u>	NATCO PHARMA LTD	<u>EQ 30MG BASE</u>	<u>A202595 001</u>	Aug 03, 2016
<u>AB</u>		<u>EQ 45MG BASE</u>	<u>A202595 002</u>	Aug 03, 2016
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A202595 003</u>	Aug 03, 2016
<u>AB</u>	NESHER PHARMS	<u>EQ 30MG BASE</u>	<u>A208578 001</u>	Feb 24, 2017
<u>AB</u>		<u>EQ 45MG BASE</u>	<u>A208578 002</u>	Feb 24, 2017
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A208578 003</u>	Feb 24, 2017
<u>AB</u>	STRIDES PHARMA	<u>EQ 30MG BASE</u>	<u>A209421 001</u>	Jun 08, 2018
<u>AB</u>		<u>EQ 45MG BASE</u>	<u>A209421 002</u>	Jun 08, 2018
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A209421 003</u>	Jun 08, 2018

TAMIFLU

<u>AB</u>	+ ROCHE	<u>EQ 30MG BASE</u>	<u>N021087 003</u>	Jul 02, 2007
<u>AB</u>	+	<u>EQ 45MG BASE</u>	<u>N021087 002</u>	Jul 02, 2007
<u>AB</u>	+!	<u>EQ 75MG BASE</u>	<u>N021087 001</u>	Oct 27, 1999

FOR SUSPENSION;ORAL

OSELTAMIVIR PHOSPHATE

<u>AB</u>	AJANTA PHARMA LTD	<u>EQ 6MG BASE/ML</u>	<u>A212784 001</u>	May 27, 2020
<u>AB</u>	ALVOGEN PINE BROOK	<u>EQ 6MG BASE/ML</u>	<u>A208823 001</u>	Oct 31, 2017
<u>AB</u>	AMNEAL PHARMS NY	<u>EQ 6MG BASE/ML</u>	<u>A210186 001</u>	Feb 27, 2018
<u>AB</u>	LUPIN	<u>EQ 6MG BASE/ML</u>	<u>A208347 001</u>	Feb 20, 2018
<u>AB</u>	NESHER PHARMS	<u>EQ 6MG BASE/ML</u>	<u>A209113 001</u>	Sep 14, 2017
<u>AB</u>	TEVA PHARMS USA	<u>EQ 6MG BASE/ML</u>	<u>A211125 001</u>	Feb 27, 2019

TAMIFLU

<u>AB</u>	+! ROCHE	<u>EQ 6MG BASE/ML</u>	<u>N021246 002</u>	Mar 21, 2011
-----------	----------	-----------------------	--------------------	--------------

OSILODROSTAT PHOSPHATE

TABLET;ORAL

ISTURISA

+	RECORDATI RARE	EQ 1MG BASE	N212801 001	Mar 06, 2020
+		EQ 5MG BASE	N212801 002	Mar 06, 2020
+	!	EQ 10MG BASE	N212801 003	Mar 06, 2020

OSIMERTINIB MESYLATE

TABLET;ORAL

TAGRISSO

+	ASTRAZENECA PHARMS	EQ 40MG BASE	N208065 001	Nov 13, 2015
+	!	EQ 80MG BASE	N208065 002	Nov 13, 2015

OSPEMIFENE

TABLET;ORAL

OSPHENA

+	DUCHESNAY	60MG	N203505 001	Feb 26, 2013
---	-----------	------	-------------	--------------

OXACILLIN SODIUM

INJECTABLE;INJECTION

OXACILLIN SODIUM

<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 1GM BASE/VIAL</u>	<u>A201539 001</u>	Jan 18, 2013
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A201539 002</u>	Jan 18, 2013
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A201538 001</u>	Jan 18, 2013
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 1GM BASE/VIAL</u>	<u>A206198 001</u>	Jul 20, 2020
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A206198 002</u>	Jul 20, 2020
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A206199 001</u>	Jul 27, 2020
<u>AP</u>	PIRAMAL CRITICAL	<u>EQ 1GM BASE/VIAL</u>	<u>A206681 001</u>	Sep 11, 2017
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A206681 002</u>	Sep 11, 2017
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A206760 001</u>	Oct 26, 2017
<u>AP</u>	!	<u>EQ 1GM BASE/VIAL</u>	<u>A091246 001</u>	Mar 30, 2012
<u>AP</u>	!	<u>EQ 2GM BASE/VIAL</u>	<u>A091246 002</u>	Mar 30, 2012
<u>AP</u>	!	<u>EQ 10GM BASE/VIAL</u>	<u>A091245 001</u>	Mar 30, 2012
<u>AP</u>	WOCKHARDT BIO AG	<u>EQ 1GM BASE/VIAL</u>	<u>A207147 001</u>	Jul 31, 2017
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A207147 002</u>	Jul 31, 2017
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A207148 001</u>	Nov 24, 2017

BACTOCILL IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	EQ 20MG BASE/ML	N050640 001	Oct 26, 1989
+	!	EQ 40MG BASE/ML	N050640 002	Oct 26, 1989

PRESCRIPTION DRUG PRODUCT LIST

OXALIPLATIN

INJECTABLE; INTRAVENOUS

ELOXATIN

<u>AP</u>	+	SANOFI AVENTIS US	<u>50MG/10ML (5MG/ML)</u>	<u>N021759 001</u>	Jan 31, 2005
<u>AP</u>	+		<u>100MG/20ML (5MG/ML)</u>	<u>N021759 002</u>	Jan 31, 2005

OXALIPLATIN

<u>AP</u>		ACCORD HLTHCARE	<u>50MG/10ML (5MG/ML)</u>	<u>A207474 001</u>	Mar 21, 2017
<u>AP</u>			<u>100MG/20ML (5MG/ML)</u>	<u>A207474 002</u>	Mar 21, 2017
<u>AP</u>		ACTAVIS LLC	<u>50MG/10ML (5MG/ML)</u>	<u>A204880 001</u>	Mar 05, 2018
<u>AP</u>			<u>100MG/20ML (5MG/ML)</u>	<u>A204880 002</u>	Mar 05, 2018
<u>AP</u>	!	ACTAVIS TOTOWA	<u>50MG/VIAL</u>	<u>A078803 001</u>	Aug 08, 2012
<u>AP</u>	!		<u>100MG/VIAL</u>	<u>A078803 002</u>	Aug 08, 2012
<u>AP</u>		CIPLA	<u>50MG/10ML (5MG/ML)</u>	<u>A208523 001</u>	Feb 10, 2017
<u>AP</u>			<u>100MG/20ML (5MG/ML)</u>	<u>A208523 002</u>	Feb 10, 2017
<u>AP</u>		EUGIA PHARMA	<u>50MG/10ML (5MG/ML)</u>	<u>A205529 001</u>	Sep 06, 2017
<u>AP</u>			<u>100MG/20ML (5MG/ML)</u>	<u>A205529 002</u>	Sep 06, 2017
<u>AP</u>		FRESENIUS KABI USA	<u>50MG/10ML (5MG/ML)</u>	<u>A078811 001</u>	Jun 10, 2010
<u>AP</u>			<u>100MG/20ML (5MG/ML)</u>	<u>A078811 002</u>	Jun 10, 2010
<u>AP</u>			<u>50MG/VIAL</u>	<u>A078819 001</u>	Jun 02, 2010
<u>AP</u>			<u>50MG/10ML (5MG/ML)</u>	<u>A090030 001</u>	Jan 31, 2017
<u>AP</u>			<u>100MG/VIAL</u>	<u>A078819 002</u>	Jun 02, 2010
<u>AP</u>			<u>100MG/20ML (5MG/ML)</u>	<u>A090030 002</u>	Jan 31, 2017
<u>AP</u>		GLAND PHARMA LTD	<u>50MG/10ML (5MG/ML)</u>	<u>A207325 001</u>	Feb 10, 2017
<u>AP</u>			<u>50MG/VIAL</u>	<u>A207385 001</u>	May 23, 2017
<u>AP</u>			<u>100MG/20ML (5MG/ML)</u>	<u>A207325 002</u>	Feb 10, 2017
<u>AP</u>			<u>100MG/VIAL</u>	<u>A207385 002</u>	May 23, 2017
<u>AP</u>		HOSPIRA WORLDWIDE	<u>50MG/10ML (5MG/ML)</u>	<u>A078813 001</u>	Aug 07, 2009
<u>AP</u>			<u>100MG/20ML (5MG/ML)</u>	<u>A078813 002</u>	Aug 07, 2009
<u>AP</u>		INGENUS PHARMS LLC	<u>50MG/10ML (5MG/ML)</u>	<u>A207562 001</u>	Oct 16, 2018
<u>AP</u>			<u>100MG/20ML (5MG/ML)</u>	<u>A207562 002</u>	Oct 16, 2018
<u>AP</u>		JIANGSU HENGRUI MED	<u>50MG/10ML (5MG/ML)</u>	<u>A203869 001</u>	Jun 18, 2014
<u>AP</u>			<u>100MG/20ML (5MG/ML)</u>	<u>A203869 002</u>	Jun 18, 2014
<u>AP</u>		MYLAN LABS LTD	<u>50MG/10ML (5MG/ML)</u>	<u>A091358 001</u>	Aug 07, 2012
<u>AP</u>			<u>100MG/20ML (5MG/ML)</u>	<u>A091358 002</u>	Aug 07, 2012
<u>AP</u>		QILU	<u>50MG/10ML (5MG/ML)</u>	<u>A204368 001</u>	Jun 07, 2016
<u>AP</u>			<u>50MG/VIAL</u>	<u>A204616 001</u>	May 11, 2016
<u>AP</u>			<u>100MG/20ML (5MG/ML)</u>	<u>A204368 002</u>	Jun 07, 2016
<u>AP</u>			<u>100MG/VIAL</u>	<u>A204616 002</u>	May 11, 2016
<u>AP</u>		SANDOZ	<u>50MG/10ML (5MG/ML)</u>	<u>A078817 001</u>	Jan 24, 2011
<u>AP</u>			<u>100MG/20ML (5MG/ML)</u>	<u>A078817 002</u>	Jan 24, 2011
<u>AP</u>	+	TEVA PHARMS	<u>50MG/10ML (5MG/ML)</u>	<u>N022160 001</u>	Aug 07, 2009
<u>AP</u>	+		<u>100MG/20ML (5MG/ML)</u>	<u>N022160 002</u>	Aug 07, 2009
	!	QILU	<u>200MG/40ML (5MG/ML)</u>	<u>A204368 003</u>	Jun 07, 2016

OXANDROLONE

TABLET; ORAL

OXANDROLONE

<u>AB</u>		PAR PHARM	<u>2.5MG</u>	<u>A077827 001</u>	Jun 22, 2007
<u>AB</u>	!		<u>10MG</u>	<u>A077827 002</u>	Jun 22, 2007
<u>AB</u>		UPSHER SMITH LABS	<u>2.5MG</u>	<u>A076761 001</u>	Dec 01, 2006
<u>AB</u>			<u>10MG</u>	<u>A078033 001</u>	Mar 22, 2007

OXAPROZIN

TABLET; ORAL

DAYPRO

<u>AB</u>	+	PFIZER	<u>600MG</u>	<u>N018841 004</u>	Oct 29, 1992
-----------	---	--------	--------------	--------------------	--------------

OXAPROZIN

<u>AB</u>		AMNEAL PHARMS CO	<u>600MG</u>	<u>A208633 001</u>	May 04, 2017
<u>AB</u>		CHARTWELL	<u>600MG</u>	<u>A075987 001</u>	Sep 02, 2004
<u>AB</u>		DR REDDYS LABS LTD	<u>600MG</u>	<u>A075855 001</u>	Jan 31, 2001
<u>AB</u>		SANDOZ	<u>600MG</u>	<u>A075845 001</u>	Jan 31, 2001
<u>AB</u>		TEVA	<u>600MG</u>	<u>A075849 001</u>	Jul 03, 2002

OXAZEPAM

CAPSULE; ORAL

OXAZEPAM

<u>AB</u>		ACTAVIS ELIZABETH	<u>10MG</u>	<u>A072253 002</u>	Apr 14, 1988
<u>AB</u>			<u>15MG</u>	<u>A072253 003</u>	Apr 14, 1988
<u>AB</u>	!		<u>30MG</u>	<u>A072253 001</u>	Apr 14, 1988
<u>AB</u>		FRONTIDA BIOPHARM	<u>10MG</u>	<u>A071026 002</u>	Aug 10, 1987
<u>AB</u>			<u>15MG</u>	<u>A071026 003</u>	Aug 10, 1987
<u>AB</u>			<u>30MG</u>	<u>A071026 001</u>	Aug 10, 1987
<u>AB</u>		SANDOZ	<u>10MG</u>	<u>A071813 001</u>	Apr 19, 1988
<u>AB</u>			<u>15MG</u>	<u>A071756 001</u>	Apr 19, 1988

PRESCRIPTION DRUG PRODUCT LIST

OXAZEPAM

CAPSULE; ORAL

OXAZEPAM

AB		30MG	A071814	001	Apr 19, 1988
-----------	--	-------------	----------------	------------	--------------

OXCARBAZEPINE

SUSPENSION; ORAL

OXCARBAZEPINE

AB	AMNEAL PHARMS	300MG/5ML	A202961	001	Sep 17, 2012
AB	HIKMA	300MG/5ML	A201193	001	Oct 03, 2012
AB	SUN PHARM INDS LTD	300MG/5ML	A078734	001	Jun 26, 2009

TRILEPTAL

AB	+!	NOVARTIS	300MG/5ML	N021285	001	May 25, 2001
-----------	----	----------	------------------	----------------	------------	--------------

TABLET; ORAL

OXCARBAZEPINE

AB	BRECKENRIDGE PHARM	150MG	A078069	001	Jan 11, 2008
AB		300MG	A078069	002	Jan 11, 2008
AB		600MG	A078069	003	Jan 11, 2008
AB	GLENMARK PHARMS LTD	150MG	A077802	001	Oct 09, 2007
AB		300MG	A077802	002	Oct 09, 2007
AB		600MG	A077802	003	Oct 09, 2007
AB	RUBICON	150MG	A077747	001	Apr 09, 2008
AB		300MG	A077747	002	Apr 09, 2008
AB		600MG	A077747	003	Apr 09, 2008
AB	SUN PHARM INDS	150MG	A077794	001	Oct 09, 2007
AB		300MG	A077794	002	Oct 09, 2007
AB		600MG	A077794	003	Oct 09, 2007
AB	TARO	150MG	A077801	001	Nov 15, 2007
AB		300MG	A077801	002	Nov 15, 2007
AB		600MG	A077801	003	Nov 15, 2007

TRILEPTAL

AB	+	NOVARTIS	150MG	N021014	001	Jan 14, 2000
AB	+		300MG	N021014	002	Jan 14, 2000
AB	+!		600MG	N021014	003	Jan 14, 2000

TABLET, EXTENDED RELEASE; ORAL

OXTELLAR XR

+	SUPERMUS PHARMS	150MG	N202810	001	Oct 19, 2012
+		300MG	N202810	002	Oct 19, 2012
+		600MG	N202810	003	Oct 19, 2012

OXICONAZOLE NITRATE

CREAM; TOPICAL

OXICONAZOLE NITRATE

AB	TARO PHARMS	EQ 1% BASE	A205076	001	Mar 07, 2016
-----------	-------------	-------------------	----------------	------------	--------------

OXISTAT

AB	+!	FOUGERA PHARMS	EQ 1% BASE	N019828	001	Dec 30, 1988
-----------	----	----------------	-------------------	----------------	------------	--------------

LOTION; TOPICAL

OXISTAT

+	FOUGERA PHARMS	EQ 1% BASE	N020209	001	Sep 30, 1992
---	----------------	------------	---------	-----	--------------

OXYBUTYNIN

FILM, EXTENDED RELEASE; TRANSDERMAL

OXYTROL

+	ALLERGAN	3.9MG/24HR	N021351	002	Feb 26, 2003
---	----------	------------	---------	-----	--------------

OXYBUTYNIN CHLORIDE

GEL; TRANSDERMAL

GELNIQUE

+	ALLERGAN	10% (100MG/PACKET)	N022204	001	Jan 27, 2009
---	----------	--------------------	---------	-----	--------------

SYRUP; ORAL

OXYBUTYNIN CHLORIDE

AA	LANNETT CO INC	5MG/5ML	A074520	001	Mar 29, 1996	
AA	PHARM ASSOC	5MG/5ML	A075137	001	Dec 18, 1998	
AA	!	WOCKHARDT BIO AG	5MG/5ML	A074868	001	Feb 12, 1997

TABLET; ORAL

OXYBUTYNIN CHLORIDE

AB	ABHAI LLC	5MG	A209335	001	Dec 22, 2017
AB	EMCURE PHARMS LTD	5MG	A211682	001	May 10, 2019
AB	EYWA	5MG	A211062	001	Feb 06, 2019
AB	LEADING PHARMA LLC	5MG	A212798	001	Apr 06, 2020
AB	NOVAST LABS	5MG	A210611	001	Oct 30, 2019
AB	NOVITIUM PHARMA	5MG	A209823	001	Oct 23, 2017
AB	RISING	5MG	A209025	001	Dec 21, 2017
AB	STRIDES PHARMA	5MG	A208165	001	Dec 17, 2020

PRESCRIPTION DRUG PRODUCT LIST

OXYBUTYRNIN CHLORIDE

TABLET; ORAL

OXYBUTYRNIN CHLORIDE

<u>AB</u>	TEVA PHARMS USA	<u>5MG</u>	<u>A071655</u>	<u>001</u>	Nov 14, 1988
<u>AB</u>	TULEX PHARMS INC	<u>5MG</u>	<u>A210125</u>	<u>001</u>	Sep 06, 2018
<u>AB</u>	UPSHER SMITH LABS	<u>5MG</u>	<u>A074625</u>	<u>001</u>	Jul 31, 1996
<u>AB</u>	! VINTAGE PHARMS	<u>5MG</u>	<u>A075079</u>	<u>001</u>	Oct 31, 1997

TABLET, EXTENDED RELEASE; ORAL

DITROPAN XL

<u>AB</u>	+ JANSSEN PHARMS	<u>5MG</u>	<u>N020897</u>	<u>001</u>	Dec 16, 1998
<u>AB</u>	+	<u>10MG</u>	<u>N020897</u>	<u>002</u>	Dec 16, 1998

OXYBUTYRNIN CHLORIDE

<u>AB</u>	ACCORD HLTHCARE	<u>5MG</u>	<u>A207138</u>	<u>001</u>	Feb 29, 2016
<u>AB</u>		<u>10MG</u>	<u>A207138</u>	<u>002</u>	Feb 29, 2016
<u>AB</u>	!	<u>15MG</u>	<u>A207138</u>	<u>003</u>	Feb 29, 2016
<u>AB</u>	AJANTA PHARMA LTD	<u>5MG</u>	<u>A211655</u>	<u>001</u>	Feb 28, 2019
<u>AB</u>		<u>10MG</u>	<u>A211655</u>	<u>002</u>	Feb 28, 2019
<u>AB</u>		<u>15MG</u>	<u>A211655</u>	<u>003</u>	Feb 28, 2019
<u>AB</u>	AMNEAL PHARMS	<u>5MG</u>	<u>A204010</u>	<u>001</u>	Nov 23, 2015
<u>AB</u>		<u>10MG</u>	<u>A204010</u>	<u>002</u>	Nov 23, 2015
<u>AB</u>		<u>15MG</u>	<u>A204010</u>	<u>003</u>	Nov 23, 2015
<u>AB</u>	BIONPHARMA INC	<u>5MG</u>	<u>A210717</u>	<u>001</u>	Dec 17, 2019
<u>AB</u>		<u>10MG</u>	<u>A210717</u>	<u>002</u>	Dec 17, 2019
<u>AB</u>		<u>15MG</u>	<u>A210717</u>	<u>003</u>	Dec 17, 2019
<u>AB</u>	OSMOTICA PHARM US	<u>5MG</u>	<u>A078503</u>	<u>001</u>	Feb 04, 2009
<u>AB</u>		<u>10MG</u>	<u>A078503</u>	<u>002</u>	Feb 04, 2009
<u>AB</u>		<u>15MG</u>	<u>A078503</u>	<u>003</u>	Feb 04, 2009
<u>AB</u>	RUBICON	<u>5MG</u>	<u>A214415</u>	<u>001</u>	Oct 27, 2020
<u>AB</u>		<u>10MG</u>	<u>A214415</u>	<u>002</u>	Oct 27, 2020
<u>AB</u>		<u>15MG</u>	<u>A214415</u>	<u>003</u>	Oct 27, 2020
<u>AB</u>	UNIQUE PHARM LABS	<u>5MG</u>	<u>A206121</u>	<u>001</u>	May 27, 2016
<u>AB</u>		<u>10MG</u>	<u>A206121</u>	<u>002</u>	May 27, 2016
<u>AB</u>		<u>15MG</u>	<u>A206121</u>	<u>003</u>	May 27, 2016
<u>AB</u>	ZYDUS PHARMS	<u>5MG</u>	<u>A202332</u>	<u>001</u>	Jun 26, 2017
<u>AB</u>		<u>10MG</u>	<u>A202332</u>	<u>002</u>	Jun 26, 2017
<u>AB</u>		<u>15MG</u>	<u>A202332</u>	<u>003</u>	Jun 26, 2017

OXYCODONE

CAPSULE, EXTENDED RELEASE; ORAL

XTAMPZA ER

	+ COLLEGIUM PHARM INC	9MG	N208090	001	Apr 26, 2016
		13.5MG	N208090	002	Apr 26, 2016
		18MG	N208090	003	Apr 26, 2016
		27MG	N208090	004	Apr 26, 2016
	+	36MG	N208090	005	Apr 26, 2016

OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE HYDROCHLORIDE

<u>AB</u>	ANI PHARMS INC	<u>5MG</u>	<u>A205177</u>	<u>001</u>	Mar 31, 2016
<u>AB</u>	AVANTHI INC	<u>5MG</u>	<u>A202773</u>	<u>001</u>	Aug 17, 2015
<u>AB</u>	+! GENUS LIFESCIENCES	<u>5MG</u>	<u>N200534</u>	<u>001</u>	Oct 20, 2010
<u>AB</u>	LANNETT CO INC	<u>5MG</u>	<u>A203823</u>	<u>001</u>	Aug 01, 2014
<u>AB</u>	MAYNE PHARMA INC	<u>5MG</u>	<u>A203107</u>	<u>001</u>	Jul 26, 2012
<u>AB</u>	NOVEL LABS INC	<u>5MG</u>	<u>A204752</u>	<u>001</u>	Aug 24, 2015

SOLUTION; ORAL

OXYCODONE HYDROCHLORIDE

<u>AA</u>	ABHAI LLC	<u>5MG/5ML</u>	<u>A208593</u>	<u>001</u>	Jul 21, 2017
<u>AA</u>		<u>100MG/5ML</u>	<u>A208593</u>	<u>002</u>	Jul 21, 2017
<u>AA</u>	AKORN	<u>5MG/5ML</u>	<u>A208817</u>	<u>001</u>	Aug 10, 2017
<u>AA</u>		<u>100MG/5ML</u>	<u>A208795</u>	<u>001</u>	Aug 07, 2017
<u>AA</u>	ALKEM LABS LTD	<u>5MG/5ML</u>	<u>A211748</u>	<u>001</u>	Feb 07, 2019
<u>AA</u>		<u>100MG/5ML</u>	<u>A211749</u>	<u>001</u>	Feb 04, 2019
<u>AA</u>	ANI PHARMS INC	<u>5MG/5ML</u>	<u>A204979</u>	<u>001</u>	Jun 01, 2015
<u>AA</u>	ASCENT PHARMS INC	<u>5MG/5ML</u>	<u>A209021</u>	<u>001</u>	Nov 09, 2017
<u>AA</u>		<u>100MG/5ML</u>	<u>A209021</u>	<u>002</u>	Nov 09, 2017
<u>AA</u>	EYWA	<u>5MG/5ML</u>	<u>A207511</u>	<u>001</u>	Nov 23, 2016
<u>AA</u>		<u>100MG/5ML</u>	<u>A209897</u>	<u>001</u>	Sep 06, 2017
<u>AA</u>	+ GENUS LIFESCIENCES	<u>5MG/5ML</u>	<u>N200535</u>	<u>002</u>	Aug 22, 2013
<u>AA</u>	+	<u>100MG/5ML</u>	<u>N200535</u>	<u>001</u>	Oct 20, 2010
<u>AA</u>	HIKMA	<u>5MG/5ML</u>	<u>A204037</u>	<u>001</u>	Jul 15, 2013
<u>AA</u>	MAYNE PHARMA INC	<u>100MG/5ML</u>	<u>A204092</u>	<u>001</u>	Jun 05, 2014
<u>AA</u>	NOVEL LABS INC	<u>100MG/5ML</u>	<u>A204603</u>	<u>001</u>	Apr 29, 2015

PRESCRIPTION DRUG PRODUCT LIST

OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

<u>AA</u>	PHARM ASSOC	<u>5MG/5ML</u>	<u>A206914</u>	<u>001</u>	Feb 01, 2019
<u>AA</u>		<u>100MG/5ML</u>	<u>A206822</u>	<u>001</u>	Aug 15, 2017
<u>AA</u>	SPECGX LLC	<u>5MG/5ML</u>	<u>A210758</u>	<u>001</u>	Apr 30, 2018
<u>AA</u>		<u>100MG/5ML</u>	<u>A210758</u>	<u>002</u>	Apr 30, 2018
<u>AA</u>	+! VISTAPHARM	<u>5MG/5ML</u>	<u>N201194</u>	<u>001</u>	Jan 12, 2012
<u>AA</u>		<u>100MG/5ML</u>	<u>A202537</u>	<u>001</u>	Jul 30, 2012
<u>AA</u>	WOCKHARDT BIO AG	<u>5MG/5ML</u>	<u>A206456</u>	<u>001</u>	Jun 16, 2015

TABLET;ORAL

OXYCODONE HYDROCHLORIDE

<u>AB</u>	ALVOGEN	<u>5MG</u>	<u>A202116</u>	<u>001</u>	Dec 30, 2011
<u>AB</u>		<u>15MG</u>	<u>A202116</u>	<u>002</u>	Dec 30, 2011
<u>AB</u>		<u>30MG</u>	<u>A202116</u>	<u>003</u>	Dec 30, 2011
<u>AB</u>	AMNEAL PHARMS	<u>5MG</u>	<u>A203638</u>	<u>001</u>	Jun 03, 2014
<u>AB</u>		<u>10MG</u>	<u>A203638</u>	<u>002</u>	Jun 03, 2014
<u>AB</u>		<u>15MG</u>	<u>A203638</u>	<u>003</u>	Jun 03, 2014
<u>AB</u>		<u>20MG</u>	<u>A203638</u>	<u>004</u>	Jun 03, 2014
<u>AB</u>		<u>30MG</u>	<u>A203638</u>	<u>005</u>	Jun 03, 2014
<u>AB</u>	ASCENT PHARMS INC	<u>15MG</u>	<u>A207418</u>	<u>001</u>	Aug 07, 2017
<u>AB</u>		<u>30MG</u>	<u>A207418</u>	<u>002</u>	Aug 07, 2017
<u>AB</u>	AUROLIFE PHARMA LLC	<u>5MG</u>	<u>A202160</u>	<u>001</u>	Nov 19, 2012
<u>AB</u>		<u>15MG</u>	<u>A202160</u>	<u>002</u>	Nov 19, 2012
<u>AB</u>		<u>30MG</u>	<u>A202160</u>	<u>003</u>	Nov 19, 2012
<u>AB</u>	AVANTHI INC	<u>5MG</u>	<u>A091393</u>	<u>001</u>	Aug 31, 2009
<u>AB</u>	!	<u>10MG</u>	<u>A091393</u>	<u>002</u>	Aug 31, 2009
<u>AB</u>		<u>15MG</u>	<u>A091393</u>	<u>003</u>	Aug 31, 2009
<u>AB</u>		<u>20MG</u>	<u>A091393</u>	<u>004</u>	Aug 31, 2009
<u>AB</u>		<u>30MG</u>	<u>A091393</u>	<u>005</u>	Aug 31, 2009
<u>AB</u>	EPIC PHARMA LLC	<u>5MG</u>	<u>A090895</u>	<u>001</u>	Aug 24, 2009
<u>AB</u>		<u>5MG</u>	<u>A202662</u>	<u>001</u>	Sep 22, 2015
<u>AB</u>		<u>10MG</u>	<u>A202662</u>	<u>002</u>	Sep 22, 2015
<u>AB</u>		<u>15MG</u>	<u>A090895</u>	<u>002</u>	Aug 24, 2009
<u>AB</u>		<u>15MG</u>	<u>A202662</u>	<u>003</u>	Sep 22, 2015
<u>AB</u>		<u>20MG</u>	<u>A202662</u>	<u>005</u>	Apr 27, 2017
<u>AB</u>		<u>30MG</u>	<u>A090895</u>	<u>003</u>	Aug 24, 2009
<u>AB</u>		<u>30MG</u>	<u>A202662</u>	<u>004</u>	Sep 22, 2015
<u>AB</u>	MAYNE PHARMA INC	<u>5MG</u>	<u>A091313</u>	<u>001</u>	Feb 18, 2011
<u>AB</u>		<u>10MG</u>	<u>A091313</u>	<u>004</u>	Apr 29, 2016
<u>AB</u>		<u>15MG</u>	<u>A091313</u>	<u>002</u>	Feb 18, 2011
<u>AB</u>		<u>20MG</u>	<u>A091313</u>	<u>005</u>	Apr 29, 2016
<u>AB</u>		<u>30MG</u>	<u>A091313</u>	<u>003</u>	Feb 18, 2011
<u>AB</u>	NOVEL LABS INC	<u>5MG</u>	<u>A204021</u>	<u>001</u>	Jun 12, 2017
<u>AB</u>		<u>10MG</u>	<u>A204021</u>	<u>002</u>	Jun 12, 2017
<u>AB</u>		<u>15MG</u>	<u>A204021</u>	<u>003</u>	Jun 12, 2017
<u>AB</u>		<u>20MG</u>	<u>A204021</u>	<u>004</u>	Jun 12, 2017
<u>AB</u>		<u>30MG</u>	<u>A204021</u>	<u>005</u>	Jun 12, 2017
<u>AB</u>	NUVO PHARM	<u>5MG</u>	<u>A207119</u>	<u>001</u>	Apr 12, 2016
<u>AB</u>		<u>10MG</u>	<u>A207119</u>	<u>002</u>	Apr 12, 2016
<u>AB</u>		<u>15MG</u>	<u>A207119</u>	<u>003</u>	Apr 12, 2016
<u>AB</u>		<u>20MG</u>	<u>A207119</u>	<u>004</u>	Apr 12, 2016
<u>AB</u>		<u>30MG</u>	<u>A207119</u>	<u>005</u>	Apr 12, 2016
<u>AB</u>	RHODES PHARMS	<u>5MG</u>	<u>A091490</u>	<u>001</u>	Mar 09, 2011
<u>AB</u>		<u>10MG</u>	<u>A091490</u>	<u>002</u>	Mar 09, 2011
<u>AB</u>		<u>15MG</u>	<u>A091490</u>	<u>003</u>	Mar 09, 2011
<u>AB</u>		<u>20MG</u>	<u>A091490</u>	<u>004</u>	Mar 09, 2011
<u>AB</u>		<u>30MG</u>	<u>A091490</u>	<u>005</u>	Mar 09, 2011
<u>AB</u>	SPECGX LLC	<u>5MG</u>	<u>A076758</u>	<u>003</u>	Mar 19, 2007
<u>AB</u>		<u>15MG</u>	<u>A076758</u>	<u>001</u>	Jun 30, 2004
<u>AB</u>		<u>30MG</u>	<u>A076758</u>	<u>002</u>	Jun 30, 2004
<u>AB</u>	SUN PHARM INDS INC	<u>5MG</u>	<u>A090659</u>	<u>001</u>	Apr 10, 2009
<u>AB</u>		<u>10MG</u>	<u>A090659</u>	<u>005</u>	Nov 06, 2012
<u>AB</u>		<u>15MG</u>	<u>A090659</u>	<u>002</u>	Apr 10, 2009
<u>AB</u>		<u>20MG</u>	<u>A090659</u>	<u>004</u>	Nov 06, 2012
<u>AB</u>		<u>30MG</u>	<u>A090659</u>	<u>003</u>	Apr 10, 2009
<u>ROXICODONE</u>					
<u>AB</u>	+ SPECGX LLC	<u>5MG</u>	<u>N021011</u>	<u>003</u>	May 15, 2009
<u>AB</u>	+!	<u>15MG</u>	<u>N021011</u>	<u>001</u>	Aug 31, 2000
<u>AB</u>	+	<u>30MG</u>	<u>N021011</u>	<u>002</u>	Aug 31, 2000
OXAYDO					
	ZYLA	5MG	N202080	001	Jun 17, 2011

PRESCRIPTION DRUG PRODUCT LIST

OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXAYDO

7.5MG

N202080 002 Jun 17, 2011

TABLET, EXTENDED RELEASE;ORAL

OXYCONTIN

+ PURDUE PHARMA LP 10MG

N022272 001 Apr 05, 2010

+ 15MG

N022272 002 Apr 05, 2010

+ 20MG

N022272 003 Apr 05, 2010

+ 30MG

N022272 004 Apr 05, 2010

+! 40MG

N022272 005 Apr 05, 2010

+ 60MG

N022272 006 Apr 05, 2010

+ 80MG

N022272 007 Apr 05, 2010

OXYMETAZOLINE HYDROCHLORIDE

CREAM;TOPICAL

RHOFADE

+! EPI HLTH 1%

N208552 001 Jan 18, 2017

SOLUTION/DROPS;OPHTHALMIC

UPNEEQ

+! RVL PHARMS 0.1%

N212520 001 Jul 08, 2020

OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE

SPRAY, METERED;NASAL

KOVANAZE

+! ST RENATUS 0.1MG/SPRAY;6MG/SPRAY

N208032 001 Jun 29, 2016

OXYMETHOLONE

TABLET;ORAL

ANADROL-50

+! MYLAN SPECIALITY LP 50MG

N016848 001

OXYMORPHONE HYDROCHLORIDE

TABLET;ORAL

OXYMORPHONE HYDROCHLORIDE

AB	ASCENT PHARMS INC	5MG	A210175 001	Feb 02, 2018
AB		10MG	A210175 002	Feb 02, 2018
AB	AUROLIFE PHARMA LLC	5MG	A204459 001	Apr 26, 2016
AB		10MG	A204459 002	Apr 26, 2016
AB	AVANTHI INC	5MG	A203601 001	Jan 30, 2013
AB	!	10MG	A203601 002	Jan 30, 2013
AB	EPIC PHARMA LLC	5MG	A201187 001	Dec 15, 2014
AB		10MG	A201187 002	Dec 15, 2014
AB	HIKMA	5MG	A090964 001	Sep 27, 2010
AB		10MG	A090964 002	Sep 27, 2010
AB	SPECGX LLC	5MG	A202321 001	Apr 25, 2013
AB		10MG	A202321 002	Apr 25, 2013
AB	TEVA	5MG	A091443 002	Feb 15, 2011
AB		10MG	A091443 001	Feb 15, 2011

TABLET, EXTENDED RELEASE;ORAL

OXYMORPHONE HYDROCHLORIDE

IMPAX LABS

5MG

A079087 001 Jun 14, 2010

7.5MG

A079087 002 Dec 21, 2010

10MG

A079087 003 Jun 14, 2010

15MG

A079087 004 Dec 21, 2010

20MG

A079087 005 Jun 14, 2010

30MG

A079087 006 Jul 22, 2010

!

40MG

A079087 007 Jun 14, 2010

OXYTOCIN

INJECTABLE; INJECTION

OXYTOCIN

AP	+!	FRESENIUS KABI USA	10USP UNITS/ML (10USP UNITS/ML)	N018248 001	
AP	+!		100USP UNITS/10ML (10USP UNITS/ML)	N018248 002	
AP		HIKMA FARMACEUTICA	10USP UNITS/ML (10USP UNITS/ML)	A200219 001	Feb 13, 2013
AP		SAGENT PHARMS INC	10USP UNITS/ML (10USP UNITS/ML)	A091676 001	Jul 13, 2018
AP			100USP UNITS/10ML (10USP UNITS/ML)	A091676 002	Jul 13, 2018
AP	+!	WEST-WARD PHARMS	10USP UNITS/ML (10USP UNITS/ML)	N018243 001	
		INT			
AP	+!		100USP UNITS/10ML (10USP UNITS/ML)	N018243 002	Jan 10, 2007
AP	+!	PAR STERILE	10USP UNITS/ML (10USP UNITS/ML)	N018261 001	
		PRODUCTS			
AP	+		100USP UNITS/10ML (10USP UNITS/ML)	N018261 002	Jul 27, 2007

PRESCRIPTION DRUG PRODUCT LIST

OXYTOCIN

INJECTABLE; INJECTION

OXYTOCIN

+! FRESENIUS KABI USA 300USP UNITS/30ML (10USP UNITS/ML) N018248 003 Jul 27, 2007

PITOCIN

+ PAR STERILE PRODUCTS 500USP UNITS/50ML (10USP UNITS/ML) N018261 003 Sep 05, 2012

OZANIMOD HYDROCHLORIDE

CAPSULE; ORAL

ZEPOSIA

+ CELGENE INTL 0.23MG N209899 001 Mar 25, 2020

+ 0.46MG N209899 002 Mar 25, 2020

+! 0.92MG N209899 003 Mar 25, 2020

OZENOXACIN

CREAM; TOPICAL

XEPI

+! FERRER INTERNACIONAL 1% N208945 001 Dec 11, 2017

PACLITAXEL

FOR SUSPENSION; IV (INFUSION)

ABRAXANE

+! ABRAXIS BIOSCIENCE 100MG/VIAL N021660 001 Jan 07, 2005

INJECTABLE; INJECTION

PACITAXEL**AP** GLAND PHARMA LTD **6MG/ML** **A207326 001** Aug 23, 2016PACLITAXEL**AP** ACTAVIS TOTOWA **6MG/ML** **A090130 001** Dec 09, 2009**AP** FRESENIUS KABI USA **6MG/ML** **A077574 001** Nov 27, 2006**AP** ! HOSPIRA **6MG/ML** **A076131 001** May 08, 2002**AP** MSN **6MG/ML** **A213434 001** Aug 24, 2020**AP** MYLAN LABS LTD **6MG/ML** **A091540 001** Sep 29, 2011**AP** TEVA PHARMS **6MG/ML** **A075184 001** Jan 25, 2002**AP** WEST-WARD PHARMS INT **6MG/ML** **A075190 001** Jan 28, 2002PALBOCICLIB

CAPSULE; ORAL

IBRANCE

+ PFIZER 75MG N207103 001 Feb 03, 2015

+ 100MG N207103 002 Feb 03, 2015

+! 125MG N207103 003 Feb 03, 2015

TABLET; ORAL

IBRANCE

+ PFIZER 75MG N212436 001 Nov 01, 2019

+ 100MG N212436 002 Nov 01, 2019

+! 125MG N212436 003 Nov 01, 2019

PALIPERIDONE

TABLET, EXTENDED RELEASE; ORAL

INVEGA**AB** + JANSSEN PHARMS **1.5MG** **N021999 006** Aug 26, 2008**AB** + **3MG** **N021999 001** Dec 19, 2006**AB** +! **6MG** **N021999 002** Dec 19, 2006**AB** + **9MG** **N021999 003** Dec 19, 2006PALIPERIDONE**AB** ACTAVIS LABS FL INC **1.5MG** **A202645 001** Aug 03, 2015**AB** **3MG** **A202645 002** Aug 03, 2015**AB** **6MG** **A202645 003** Aug 03, 2015**AB** **9MG** **A202645 004** Aug 03, 2015**AB** AMNEAL PHARMS **1.5MG** **A204707 001** Sep 23, 2019**AB** **3MG** **A204707 002** Sep 23, 2019**AB** **6MG** **A204707 003** Sep 23, 2019**AB** **9MG** **A204707 004** Sep 23, 2019**AB** CSEC OUYI **1.5MG** **A212807 001** Oct 29, 2020**AB** **3MG** **A212807 002** Oct 29, 2020**AB** **6MG** **A212807 003** Oct 29, 2020**AB** **9MG** **A212807 004** Oct 29, 2020**AB** INVENTIA **1.5MG** **A204452 001** Jun 12, 2019**AB** **3MG** **A204452 002** Jun 12, 2019**AB** **6MG** **A204452 003** Jun 12, 2019**AB** **9MG** **A204452 004** Jun 12, 2019**AB** RK PHARMA **1.5MG** **A203802 001** Sep 24, 2015

PRESCRIPTION DRUG PRODUCT LIST

PALIPERIDONE

TABLET, EXTENDED RELEASE;ORAL

PALIPERIDONE

<u>AB</u>		<u>3MG</u>	<u>A203802 002</u>	Sep 24, 2015
<u>AB</u>		<u>6MG</u>	<u>A203802 003</u>	Sep 24, 2015
<u>AB</u>		<u>9MG</u>	<u>A203802 004</u>	Sep 24, 2015
<u>AB</u>	SUN PHARM	<u>1.5mg</u>	<u>A205618 001</u>	Apr 06, 2018
<u>AB</u>		<u>3MG</u>	<u>A205618 002</u>	Apr 06, 2018
<u>AB</u>		<u>6MG</u>	<u>A205618 003</u>	Apr 06, 2018
<u>AB</u>		<u>9MG</u>	<u>A205618 004</u>	Apr 06, 2018

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

INVEGA SUSTENNA

+	JANSSEN PHARMS	39MG/0.25ML (39MG/0.25ML)	N022264 001	Jul 31, 2009
+		78MG/0.5ML (78MG/0.5ML)	N022264 002	Jul 31, 2009
+		117MG/0.75ML (117MG/0.75ML)	N022264 003	Jul 31, 2009
+	!	156MG/ML (156MG/ML)	N022264 004	Jul 31, 2009
+		234MG/1.5ML (156MG/ML)	N022264 005	Jul 31, 2009

INVEGA TRINZA

+	JANSSEN PHARMS	273MG/0.875ML (273MG/0.875ML)	N207946 001	May 18, 2015
+		410MG/1.315ML (311.79MG/ML)	N207946 002	May 18, 2015
+		546MG/1.75ML (312MG/ML)	N207946 003	May 18, 2015
+	!	819MG/2.625ML (312MG/ML)	N207946 004	May 18, 2015

PALONOSETRON HYDROCHLORIDE

INJECTABLE; INTRAVENOUS

ALOXI

<u>AP</u>	+	!	HEL SINN HLTHCARE	<u>EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)</u>	<u>N021372 002</u>	Feb 29, 2008
<u>AP</u>	+	!		<u>EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)</u>	<u>N021372 001</u>	Jul 25, 2003

PALONOSETRON HYDROCHLORIDE

<u>AP</u>		AUROBINDO PHARMA LTD	<u>EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)</u>	<u>A204702 001</u>	Nov 06, 2018
<u>AP</u>		CIPLA	<u>EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)</u>	<u>A206396 001</u>	Sep 19, 2018
<u>AP</u>		DR REDDYS LABS LTD	<u>EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)</u>	<u>A201533 002</u>	Apr 21, 2016
<u>AP</u>		FRESENIUS KABI USA	<u>EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)</u>	<u>A206801 001</u>	Sep 19, 2018
<u>AP</u>			<u>EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)</u>	<u>A206802 001</u>	Sep 19, 2018
<u>AP</u>		HOSPIRA INC	<u>EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)</u>	<u>A207005 001</u>	Sep 19, 2018
<u>AP</u>			<u>EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)</u>	<u>A207005 002</u>	Sep 19, 2018
<u>AP</u>		INGENUS PHARMS LLC	<u>EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)</u>	<u>A208789 001</u>	May 22, 2020
<u>AP</u>		MYLAN INSTITUTIONAL	<u>EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)</u>	<u>A206416 001</u>	Sep 19, 2018
<u>AP</u>		QILU	<u>EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)</u>	<u>A205648 002</u>	Sep 19, 2018
<u>AP</u>			<u>EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)</u>	<u>A205648 001</u>	Sep 19, 2018
<u>AP</u>		SAGENT PHARMS INC	<u>EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)</u>	<u>A204289 001</u>	Sep 19, 2018
<u>AP</u>			<u>EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)</u>	<u>A205870 001</u>	Sep 19, 2018
<u>AP</u>		SANDOZ INC	<u>EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)</u>	<u>A202521 001</u>	Oct 13, 2015
<u>AP</u>		TEVA PHARMS USA	<u>EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)</u>	<u>A090713 002</u>	Mar 23, 2018
<u>AP</u>			<u>EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)</u>	<u>A090713 001</u>	Mar 23, 2018
<u>AP</u>		VIRTUS PHARM	<u>EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)</u>	<u>A209287 001</u>	Sep 19, 2018

SOLUTION;INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

+	FRESENIUS KABI USA	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N208109 001	Nov 21, 2017
	HIKMA	EQ 0.25MG BASE/2ML (EQ 0.125MG BASE/ML)	N207963 001	Aug 22, 2016

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

PAMIDRONATE DISODIUM

<u>AP</u>		AREVA PHARMS	<u>30MG/VIAL</u>	<u>A077433 001</u>	Nov 26, 2008
<u>AP</u>			<u>90MG/VIAL</u>	<u>A077433 003</u>	Nov 26, 2008
<u>AP</u>		DR REDDYS	<u>30MG/10ML (3MG/ML)</u>	<u>A078156 001</u>	Aug 19, 2008
<u>AP</u>			<u>60MG/10ML (6MG/ML)</u>	<u>A078156 002</u>	Aug 19, 2008
<u>AP</u>			<u>90MG/10ML (9MG/ML)</u>	<u>A078156 003</u>	Aug 19, 2008
<u>AP</u>	!	HOSPIRA	<u>30MG/10ML (3MG/ML)</u>	<u>A075841 001</u>	Jun 27, 2002
<u>AP</u>	!		<u>60MG/10ML (6MG/ML)</u>	<u>A075841 002</u>	Jun 27, 2002
<u>AP</u>	!		<u>90MG/10ML (9MG/ML)</u>	<u>A075841 003</u>	Jun 27, 2002
<u>AP</u>		MYLAN LABS LTD	<u>30MG/10ML (3MG/ML)</u>	<u>A078520 001</u>	Oct 31, 2008
<u>AP</u>			<u>90MG/10ML (9MG/ML)</u>	<u>A078520 002</u>	Oct 31, 2008
<u>AP</u>		SAGENT PHARMS INC	<u>30MG/10ML (3MG/ML)</u>	<u>A078373 001</u>	Dec 23, 2008
<u>AP</u>			<u>90MG/10ML (9MG/ML)</u>	<u>A078373 002</u>	Dec 23, 2008
<u>AP</u>		WEST-WARD PHARMS INT	<u>30MG/VIAL</u>	<u>A075290 001</u>	Apr 30, 2001

PRESCRIPTION DRUG PRODUCT LIST

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

PAMIDRONATE DISODIUM

<u>AP</u>	+		<u>30MG/10ML (3MG/ML)</u>	<u>N021113 001</u>	Mar 04, 2002
<u>AP</u>			<u>90MG/VIAL</u>	<u>A075290 003</u>	Apr 30, 2001
<u>AP</u>	+		<u>90MG/10ML (9MG/ML)</u>	<u>N021113 002</u>	Mar 04, 2002
		AREVA PHARMS	60MG/VIAL	A077433 002	Nov 26, 2008

PANCURONIUM BROMIDE

INJECTABLE; INJECTION

PANCURONIUM BROMIDE

<u>AP</u>	!	DR REDDYS	<u>1MG/ML</u>	<u>A072759 001</u>	Jul 31, 1990
<u>AP</u>		HOSPIRA	<u>1MG/ML</u>	<u>A072320 001</u>	Jan 19, 1989
	!	DR REDDYS	2MG/ML	A072760 001	Jul 31, 1990

PANOBINOSTAT LACTATE

CAPSULE; ORAL

FARYDAK

+	SECURA	EQ 10MG BASE	N205353 001	Feb 23, 2015
+		EQ 15MG BASE	N205353 002	Feb 23, 2015
+		EQ 20MG BASE	N205353 003	Feb 23, 2015

PANTOPRAZOLE SODIUM

FOR SUSPENSION, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

<u>AB</u>		SUN PHARM	<u>EQ 40MG BASE</u>	<u>A213725 001</u>	Jun 30, 2020
-----------	--	-----------	---------------------	--------------------	--------------

PROTONIX

<u>AB</u>	+	WYETH PHARMS	<u>EQ 40MG BASE</u>	<u>N022020 001</u>	Nov 14, 2007
-----------	---	--------------	---------------------	--------------------	--------------

INJECTABLE; IV (INFUSION)

PANTOPRAZOLE SODIUM

<u>AP</u>		AKORN INC	<u>EQ 40MG BASE/VIAL</u>	<u>A079197 001</u>	Nov 08, 2012
<u>AP</u>		AUROBINDO PHARMA LTD	<u>EQ 40MG BASE/VIAL</u>	<u>A205675 001</u>	Mar 30, 2016
<u>AP</u>		SANDOZ INC	<u>EQ 40MG BASE/VIAL</u>	<u>A090296 001</u>	Jul 14, 2015
<u>AP</u>		SUN PHARM	<u>EQ 40MG BASE/VIAL</u>	<u>A077674 001</u>	Aug 19, 2019

PROTONIX IV

<u>AP</u>	+	WYETH PHARMS	<u>EQ 40MG BASE/VIAL</u>	<u>N020988 001</u>	Mar 22, 2001
-----------	---	--------------	--------------------------	--------------------	--------------

POWDER; IV (INFUSION)

PANTOPRAZOLE SODIUM

+	HIKMA	EQ 40MG BASE/VIAL	N209463 001	Jun 30, 2017
---	-------	-------------------	-------------	--------------

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

<u>AB</u>		ACTAVIS TOTOWA	<u>EQ 20MG BASE</u>	<u>A090797 001</u>	Feb 07, 2011
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A090797 002</u>	Feb 07, 2011
<u>AB</u>		AMNEAL PHARMS	<u>EQ 20MG BASE</u>	<u>A205119 001</u>	Jan 26, 2016
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A205119 002</u>	Jan 26, 2016
<u>AB</u>		ATLANTIDE	<u>EQ 20MG BASE</u>	<u>A091231 001</u>	Jan 19, 2011
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A091231 002</u>	Jan 19, 2011
<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 20MG BASE</u>	<u>A202038 001</u>	Sep 28, 2012
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A202038 002</u>	Sep 28, 2012
<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 20MG BASE</u>	<u>A077619 001</u>	Jan 19, 2011
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A077619 002</u>	Jan 19, 2011
<u>AB</u>		HETERO LABS LTD V	<u>EQ 20MG BASE</u>	<u>A202882 001</u>	Sep 10, 2014
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A202882 002</u>	Sep 10, 2014
<u>AB</u>		INGENUS PHARMS LLC	<u>EQ 40MG BASE</u>	<u>A211368 001</u>	Mar 01, 2019
<u>AB</u>		JUBILANT GENERICS	<u>EQ 20MG BASE</u>	<u>A090901 001</u>	Aug 30, 2011
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A090901 002</u>	Aug 30, 2011
<u>AB</u>		L PERRIGO CO	<u>EQ 20MG BASE</u>	<u>A203024 001</u>	May 07, 2014
<u>AB</u>		LANNETT CO INC	<u>EQ 20MG BASE</u>	<u>A078281 001</u>	Jan 20, 2011
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A078281 002</u>	Jan 20, 2011
<u>AB</u>		MYLAN PHARMS INC	<u>EQ 20MG BASE</u>	<u>A090970 001</u>	Jan 19, 2011
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A090970 002</u>	Jan 19, 2011
<u>AB</u>		ORCHID HLTHCARE	<u>EQ 20MG BASE</u>	<u>A202052 001</u>	Dec 02, 2014
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A202052 002</u>	Dec 02, 2014
<u>AB</u>		RUBICON	<u>EQ 20MG BASE</u>	<u>A090807 001</u>	May 02, 2012
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A090807 002</u>	May 02, 2012
<u>AB</u>		TORRENT PHARMS	<u>EQ 20MG BASE</u>	<u>A090074 001</u>	Jan 19, 2011
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A090074 002</u>	Jan 19, 2011

PROTONIX

<u>AB</u>	+	WYETH PHARMS	<u>EQ 20MG BASE</u>	<u>N020987 002</u>	Jun 12, 2001
<u>AB</u>	+		<u>EQ 40MG BASE</u>	<u>N020987 001</u>	Feb 02, 2000

PRESCRIPTION DRUG PRODUCT LIST

PARICALCITOL

CAPSULE; ORAL

PARICALCITOL

<u>AB</u>	AMNEAL PHARMS	<u>1MCG</u>	<u>A204327 001</u>	Jan 13, 2016
<u>AB</u>		<u>2MCG</u>	<u>A204327 002</u>	Jan 13, 2016
<u>AB</u>		<u>4MCG</u>	<u>A204327 003</u>	Jan 13, 2016
<u>AB</u>	AUROBINDO PHARMA LTD	<u>1MCG</u>	<u>A207672 001</u>	Jan 14, 2016
<u>AB</u>		<u>2MCG</u>	<u>A207672 002</u>	Jan 14, 2016
<u>AB</u>		<u>4MCG</u>	<u>A207672 003</u>	Jan 14, 2016
<u>AB</u>	BIONPHARMA INC	<u>1MCG</u>	<u>A202539 001</u>	Mar 27, 2014
<u>AB</u>		<u>2MCG</u>	<u>A202539 002</u>	Mar 27, 2014
<u>AB</u>		<u>4MCG</u>	<u>A202539 003</u>	Mar 27, 2014
<u>AB</u>	DR REDDYS LABS LTD	<u>1MCG</u>	<u>A091412 001</u>	Jun 24, 2014
<u>AB</u>		<u>2MCG</u>	<u>A091412 002</u>	Jun 24, 2014
<u>AB</u>		<u>4MCG</u>	<u>A091412 003</u>	Jun 24, 2014
<u>AB</u>	MARKSANS PHARMA	<u>1MCG</u>	<u>A204948 001</u>	Oct 07, 2016
<u>AB</u>		<u>2MCG</u>	<u>A204948 002</u>	Oct 07, 2016
<u>AB</u>		<u>4MCG</u>	<u>A204948 003</u>	Oct 07, 2016
<u>AB</u>	RISING	<u>1MCG</u>	<u>A202124 001</u>	Jun 24, 2014
<u>AB</u>		<u>2MCG</u>	<u>A202124 002</u>	Jun 24, 2014
<u>AB</u>		<u>4MCG</u>	<u>A202124 003</u>	Jun 24, 2014
<u>AB</u>	TEVA PHARMS USA	<u>1MCG</u>	<u>A090829 001</u>	Sep 27, 2013
<u>AB</u>		<u>2MCG</u>	<u>A090829 002</u>	Sep 27, 2013
<u>AB</u>	!	<u>4MCG</u>	<u>A090829 003</u>	Sep 27, 2013
<u>ZEMPLAR</u>				
<u>AB</u>	+ ABBVIE	<u>1MCG</u>	<u>N021606 001</u>	May 26, 2005
<u>AB</u>	+	<u>2MCG</u>	<u>N021606 002</u>	May 26, 2005

SOLUTION; INTRAVENOUS

PARICALCITOL

<u>AP</u>	ACCORD HLTHCARE	<u>0.002MG/ML (0.002MG/ML)</u>	<u>N207174 001</u>	Feb 04, 2016
<u>AP</u>		<u>0.005MG/ML (0.005MG/ML)</u>	<u>N207174 002</u>	Feb 04, 2016
<u>AP</u>		<u>0.01MG/2ML (0.005MG/ML)</u>	<u>N207174 003</u>	Feb 04, 2016
<u>AP</u>	AKORN	<u>0.005MG/ML (0.005MG/ML)</u>	<u>A207692 001</u>	Oct 16, 2017
<u>AP</u>	AMNEAL PHARMS CO	<u>0.002MG/ML (0.002MG/ML)</u>	<u>A206699 001</u>	Mar 09, 2017
<u>AP</u>		<u>0.005MG/ML (0.005MG/ML)</u>	<u>A206699 002</u>	Mar 09, 2017
<u>AP</u>		<u>0.01MG/2ML (0.005MG/ML)</u>	<u>A206699 003</u>	Mar 09, 2017
<u>AP</u>	AUROBINDO PHARMA LTD	<u>0.002MG/ML (0.002MG/ML)</u>	<u>A205982 001</u>	Oct 09, 2018
<u>AP</u>		<u>0.005MG/ML (0.005MG/ML)</u>	<u>A205982 002</u>	Oct 09, 2018
<u>AP</u>		<u>0.01MG/2ML (0.005MG/ML)</u>	<u>A205982 003</u>	Oct 09, 2018
<u>AP</u>	DR REDDYS	<u>0.002MG/ML (0.002MG/ML)</u>	<u>A204910 001</u>	Aug 17, 2016
<u>AP</u>		<u>0.005MG/ML (0.005MG/ML)</u>	<u>A204910 002</u>	Aug 17, 2016
<u>AP</u>		<u>0.01MG/2ML (0.005MG/ML)</u>	<u>A204910 003</u>	Aug 17, 2016
<u>AP</u>	HIKMA PHARMS	<u>0.002MG/ML (0.002MG/ML)</u>	<u>N205917 001</u>	Nov 18, 2014
<u>AP</u>		<u>0.005MG/ML (0.005MG/ML)</u>	<u>N205917 002</u>	Nov 18, 2014
<u>AP</u>		<u>0.01MG/2ML (0.005MG/ML)</u>	<u>N205917 003</u>	Nov 18, 2014
<u>AP</u>	HOSPIRA INC	<u>0.002MG/ML (0.002MG/ML)</u>	<u>N201657 001</u>	Oct 21, 2014
<u>AP</u>		<u>0.005MG/ML (0.005MG/ML)</u>	<u>N201657 002</u>	Oct 21, 2014
<u>AP</u>		<u>0.01MG/2ML (0.005MG/ML)</u>	<u>N201657 003</u>	Oct 21, 2014
<u>AP</u>	MYLAN LABS LTD	<u>0.002MG/ML (0.002MG/ML)</u>	<u>A203897 001</u>	Nov 02, 2017
<u>AP</u>		<u>0.005MG/ML (0.005MG/ML)</u>	<u>A203897 002</u>	Nov 02, 2017
<u>AP</u>		<u>0.01MG/2ML (0.005MG/ML)</u>	<u>A203897 003</u>	Nov 02, 2017
<u>AP</u>	SANDOZ INC	<u>0.002MG/ML (0.002MG/ML)</u>	<u>A091108 001</u>	Jul 27, 2011
<u>AP</u>		<u>0.005MG/ML (0.005MG/ML)</u>	<u>A091108 002</u>	Jul 27, 2011
<u>AP</u>		<u>0.01MG/2ML (0.005MG/ML)</u>	<u>A091108 003</u>	Jul 27, 2011
<u>ZEMPLAR</u>				
<u>AP</u>	+! ABBVIE	<u>0.002MG/ML (0.002MG/ML)</u>	<u>N020819 002</u>	Feb 01, 2000
<u>AP</u>	+!	<u>0.005MG/ML (0.005MG/ML)</u>	<u>N020819 001</u>	Apr 17, 1998
<u>AP</u>	+!	<u>0.01MG/2ML (0.005MG/ML)</u>	<u>N020819 003</u>	Feb 01, 2000

PAROMOMYCIN SULFATE

CAPSULE; ORAL

PAROMOMYCIN SULFATE

<u>AA</u>	HERITAGE PHARMS INC	<u>EQ 250MG BASE</u>	<u>A065173 001</u>	Dec 14, 2007
<u>AA</u>	!	<u>EQ 250MG BASE</u>	<u>A064171 001</u>	Jun 30, 1997

PAROXETINE HYDROCHLORIDE

SUSPENSION; ORAL

PAXIL

+	!	APOTEX TECHNOLOGIES	<u>EQ 10MG BASE/5ML</u>	<u>N020710 001</u>	Jun 25, 1997
---	---	---------------------	-------------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

PAROXETINE HYDROCHLORIDE

TABLET; ORAL

PAROXETINE

<u>AB</u>	PRINSTON INC	<u>EQ 10MG BASE</u>	<u>A203854 001</u>	Oct 31, 2014
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A203854 002</u>	Oct 31, 2014
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A203854 003</u>	Oct 31, 2014
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A203854 004</u>	Oct 31, 2014

PAROXETINE HYDROCHLORIDE

<u>AB</u>	APOTEX	<u>EQ 10MG BASE</u>	<u>A075356 001</u>	Jul 30, 2003
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A075356 002</u>	Jul 30, 2003
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A075356 003</u>	Jul 30, 2003
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A075356 004</u>	Jul 30, 2003
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 10MG BASE</u>	<u>A078406 001</u>	Jul 25, 2007
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A078406 002</u>	Jul 25, 2007
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A078406 003</u>	Jul 25, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078406 004</u>	Jul 25, 2007
<u>AB</u>	MYLAN	<u>EQ 10MG BASE</u>	<u>A078902 001</u>	Mar 13, 2008
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A078902 002</u>	Mar 13, 2008
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A078902 003</u>	Mar 13, 2008
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078902 004</u>	Mar 13, 2008
<u>AB</u>	OXFORD PHARMS	<u>EQ 10MG BASE</u>	<u>A076968 001</u>	Jun 21, 2010
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076968 002</u>	Jun 21, 2010
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A076968 003</u>	Jun 21, 2010
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076968 004</u>	Jun 21, 2010
<u>AB</u>	TEVA	<u>EQ 10MG BASE</u>	<u>A076618 001</u>	Aug 15, 2005
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076618 002</u>	Aug 15, 2005
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A076618 003</u>	Aug 15, 2005
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076618 004</u>	Aug 15, 2005
<u>AB</u>	ZYDUS PHARMS USA	<u>EQ 10MG BASE</u>	<u>A077584 001</u>	Mar 07, 2007
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077584 002</u>	Mar 07, 2007
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A077584 003</u>	Mar 07, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077584 004</u>	Mar 07, 2007

PAXIL

<u>AB</u>	+	APOTEX TECHNOLOGIES	<u>EQ 10MG BASE</u>	<u>N020031 001</u>	Dec 29, 1992
<u>AB</u>	+		<u>EQ 20MG BASE</u>	<u>N020031 002</u>	Dec 29, 1992
<u>AB</u>	+		<u>EQ 30MG BASE</u>	<u>N020031 003</u>	Dec 29, 1992
<u>AB</u>	+		<u>EQ 40MG BASE</u>	<u>N020031 005</u>	Dec 29, 1992

TABLET, EXTENDED RELEASE; ORAL

PAROXETINE HYDROCHLORIDE

<u>AB</u>	LANNETT CO INC	<u>EQ 12.5MG BASE</u>	<u>A204744 001</u>	Jun 10, 2016
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A204744 002</u>	Jun 10, 2016
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A204744 003</u>	Jun 10, 2016
<u>AB</u>	LUPIN LTD	<u>EQ 12.5MG BASE</u>	<u>A204134 001</u>	Jan 20, 2017
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A204134 002</u>	Jan 20, 2017
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A204134 003</u>	Jan 20, 2017
<u>AB</u>	MYLAN	<u>EQ 12.5MG BASE</u>	<u>A077873 001</u>	Jun 29, 2007
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A077873 002</u>	Jun 29, 2007
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A091427 001</u>	Apr 14, 2011
<u>AB</u>	SCIECURE PHARMA INC	<u>EQ 12.5MG BASE</u>	<u>A209293 001</u>	Jun 12, 2018
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A209293 002</u>	Jun 12, 2018
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A209293 003</u>	Jun 12, 2018

PAXIL CR

<u>AB</u>	+	APOTEX TECHNOLOGIES	<u>EQ 12.5MG BASE</u>	<u>N020936 001</u>	Feb 16, 1999
<u>AB</u>	+		<u>EQ 25MG BASE</u>	<u>N020936 002</u>	Feb 16, 1999
<u>AB</u>	+		<u>EQ 37.5MG BASE</u>	<u>N020936 003</u>	Dec 06, 2000

PAROXETINE MESYLATE

CAPSULE; ORAL

BRISDELLE

<u>AB</u>	+	SEBELA IRELAND LTD	<u>EQ 7.5MG BASE</u>	<u>N204516 001</u>	Jun 28, 2013
-----------	---	--------------------	----------------------	--------------------	--------------

PAROXETINE MESYLATE

<u>AB</u>	ACTAVIS LABS FL INC	<u>EQ 7.5MG BASE</u>	<u>A207139 001</u>	Jun 20, 2017
<u>AB</u>	PRINSTON INC	<u>EQ 7.5MG BASE</u>	<u>A207188 001</u>	Aug 18, 2017

TABLET; ORAL

PEXEVA

+	SEBELA IRELAND LTD	EQ 10MG BASE	N021299 001	Jul 03, 2003
+		EQ 20MG BASE	N021299 002	Jul 03, 2003
+		EQ 30MG BASE	N021299 003	Jul 03, 2003
+		EQ 40MG BASE	N021299 004	Jul 03, 2003

PRESCRIPTION DRUG PRODUCT LIST

PASIREOTIDE DIASPARTATE

SOLUTION; SUBCUTANEOUS

SIGNIFOR

+	RECORDATI RARE	EQ 0.3MG BASE/ML (EQ 0.3MG BASE/ML)	N200677 001	Dec 14, 2012
+		EQ 0.6MG BASE/ML (EQ 0.6MG BASE/ML)	N200677 002	Dec 14, 2012
+	!	EQ 0.9MG BASE/ML (EQ 0.9MG BASE/ML)	N200677 003	Dec 14, 2012

PASIREOTIDE PAMOATE

FOR SUSPENSION; INTRAMUSCULAR

SIGNIFOR LAR KIT

+	RECORDATI RARE	EQ 10MG BASE/VIAL	N203255 004	Jun 29, 2018
+		EQ 20MG BASE/VIAL	N203255 001	Dec 15, 2014
+		EQ 30MG BASE/VIAL	N203255 005	Jun 29, 2018
+		EQ 40MG BASE/VIAL	N203255 002	Dec 15, 2014
+	!	EQ 60MG BASE/VIAL	N203255 003	Dec 15, 2014

PATIROMER SORBITE X CALCIUM

POWDER; ORAL

VELTASSA

+	RELYPSA INC	EQ 8.4GM BASE/PACKET	N205739 001	Oct 21, 2015
+		EQ 16.8GM BASE/PACKET	N205739 002	Oct 21, 2015
+	!	EQ 25.2GM BASE/PACKET	N205739 003	Oct 21, 2015

PATISIRAN SODIUM

SOLUTION; INTRAVENOUS

ONPATTRO

+	!	ALNYLAM PHARMS INC	EQ 10MG BASE/5ML (EQ 2MG BASE/ML)	N210922 001	Aug 10, 2018
---	---	--------------------	-----------------------------------	-------------	--------------

PAZOPANIB HYDROCHLORIDE

TABLET; ORAL

VOTRIENT

+	!	NOVARTIS	EQ 200MG BASE	N022465 001	Oct 19, 2009
---	---	----------	---------------	-------------	--------------

PEMETREXED

SOLUTION; INTRAVENOUS

PEMETREXED

+	!	ACTAVIS LLC	100MG/4ML (25MG/ML)	N208419 001	Aug 21, 2020
+	!		500MG/20ML (25MG/ML)	N208419 002	Aug 21, 2020
+	!		1GM/40ML (25MG/ML)	N208419 003	Aug 21, 2020
+	!	EAGLE PHARMS	500MG/20ML (25MG/ML)	N209472 001	Feb 08, 2020

PEMETREXED DISODIUM

POWDER; INTRAVENOUS

ALIMTA

+	!	LILLY	EQ 100MG BASE/VIAL	N021462 002	Sep 07, 2007
+	!		EQ 500MG BASE/VIAL	N021462 001	Feb 04, 2004

PEMIGATINIB

TABLET; ORAL

PEMAZYRE

+		INCYTE CORP	4.5MG	N213736 001	Apr 17, 2020
+			9MG	N213736 002	Apr 17, 2020
+	!		13.5MG	N213736 003	Apr 17, 2020

PENCICLOVIR

CREAM; TOPICAL

DENA VIR

+	!	MYLAN	1%	N020629 001	Sep 24, 1996
---	---	-------	----	-------------	--------------

PENICILLAMINE

CAPSULE; ORAL

CUPRIMINE**AB** +! VALEANT PHARMS INTL **250MG** **N019853 001**PENICILLAMINE

AB		ANI PHARMS INC	250MG	A209921 001	May 07, 2019
AB		APOTEX	250MG	A213310 001	Apr 28, 2020
AB		DR REDDYS	250MG	A211867 001	Aug 04, 2020
AB		GRANULES PHARMS	250MG	A211735 001	Dec 02, 2020
AB		PAR PHARM INC	250MG	A211231 001	Dec 23, 2019
AB		WATSON LABS INC	250MG	A210976 001	Jun 24, 2019

TABLET; ORAL

DEPEN**AB** +! MYLAN SPECIALITY LP **250MG** **N019854 001**PENICILLAMINE

AB		LUPIN LTD	250MG	A212933 001	Nov 30, 2020
AB		PAR PHARM INC	250MG	A211196 001	Dec 23, 2019

PRESCRIPTION DRUG PRODUCT LIST

PENICILLIN G BENZATHINE

INJECTABLE; INJECTION

BICILLIN L-A

BC +! KING PHARMS LLC 600,000 UNITS/ML N050141 001

PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE

INJECTABLE; INJECTION

BICILLIN C-R

+! KING PHARMS LLC 300,000 UNITS/ML; 300,000 UNITS/ML N050138 001

BICILLIN C-R 900/300

+! KING PHARMS LLC 900,000 UNITS/2ML; 300,000 UNITS/2ML N050138 003

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION

PENICILLIN G POTASSIUM**AP** ACS DOBFAR SPA 20,000,000 UNITS/VIAL **A205043 002** Oct 26, 2018**AP** 5,000,000 UNITS/VIAL **A205043 001** Oct 26, 2018**AP** HANFORD GC 5,000,000 UNITS/VIAL **A065149 002** Jul 23, 2009**AP** 20,000,000 UNITS/VIAL **A065149 003** Jul 23, 2009**AP** ISTITUTO BIO ITA 5,000,000 UNITS/VIAL **A065448 001** Aug 18, 2009

SPA

AP 20,000,000 UNITS/VIAL **A065448 002** Aug 18, 2009**AP** SANDOZ 5,000,000 UNITS/VIAL **A065079 002** Aug 30, 2002**AP** 20,000,000 UNITS/VIAL **A065079 003** Aug 30, 2002PFIZERPEN**AP** ! PFIZER 5,000,000 UNITS/VIAL **A060657 002****AP** ! 20,000,000 UNITS/VIAL **A060657 003**

PENICILLIN G POTASSIUM

HANFORD GC

1,000,000 UNITS/VIAL

A065149 001 Jul 23, 2009

PENICILLIN G POTASSIUM IN PLASTIC CONTAINER

+! BAXTER HLTHCARE

20,000 UNITS/ML

N050638 001 Jun 25, 1990

+!

40,000 UNITS/ML

N050638 002 Jun 25, 1990

+!

60,000 UNITS/ML

N050638 003 Jun 25, 1990

PENICILLIN G PROCAINE

INJECTABLE; INJECTION

PENICILLIN G PROCAINE

!

KING PHARMS LLC

300,000 UNITS/ML

A060101 002

!

600,000 UNITS/ML

A060101 001

PENICILLIN G SODIUM

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

PENICILLIN G SODIUM

! SANDOZ

5,000,000 UNITS/VIAL

A065068 001 Feb 26, 2001

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL

PENICILLIN V POTASSIUM**AA** DAVA PHARMS INC EQ 125MG BASE/5ML **A062981 001** Feb 10, 1989**AA** EQ 250MG BASE/5ML **A062981 002** Feb 10, 1989PENICILLIN-VK**AA** TEVA EQ 125MG BASE/5ML **A060456 001****AA** ! EQ 250MG BASE/5ML **A060456 002**

TABLET; ORAL

PENICILLIN V POTASSIUM**AB** AUROBINDO PHARMA EQ 250MG BASE **A065435 001** Apr 29, 2008**AB** EQ 500MG BASE **A065435 002** Apr 29, 2008**AB** DAVA PHARMS INC EQ 250MG BASE **A062936 001** Nov 25, 1988**AB** EQ 500MG BASE **A062935 001** Nov 23, 1988**AB** HIKMA PHARMS EQ 250MG BASE **A090549 001** Oct 11, 2013**AB** EQ 500MG BASE **A090549 002** Oct 11, 2013**AB** SANDOZ EQ 250MG BASE **A064071 001** Nov 30, 1995**AB** ! EQ 500MG BASE **A064071 002** Nov 30, 1995PENICILLIN-VK**AB** TEVA EQ 250MG BASE **A060711 002****AB** EQ 500MG BASE **A060711 003**PENTAMIDINE ISETHIONATE

FOR SOLUTION; INHALATION

NEBUPENT**AN** +! FRESENIUS KABI USA 300MG/VIAL **N019887 001** Jun 15, 1989PENTAMIDINE ISETHIONATE**AN** SETON PHARMS 300MG/VIAL **A206667 001** Apr 24, 2019

PRESCRIPTION DRUG PRODUCT LIST

PENTAMIDINE ISETHIONATE

INJECTABLE; INJECTION

PENTAM

AP	+ !	FRESENIUS KABI USA	300MG/VIAL	N019264 001	Oct 16, 1984
-----------	------------	--------------------	-------------------	--------------------	--------------

PENTAMIDINE ISETHIONATE

AP		SETON PHARMS	300MG/VIAL	A206666 001	Sep 28, 2017
-----------	--	--------------	-------------------	--------------------	--------------

PENTOBARBITAL SODIUM

INJECTABLE; INJECTION

NEMBUTAL SODIUM

AP	!	AKORN	50MG/ML	A083246 001	
-----------	----------	-------	----------------	--------------------	--

PENTOBARBITAL SODIUM

AP		ATHENEX	50MG/ML	A206677 001	Nov 27, 2017
-----------	--	---------	----------------	--------------------	--------------

AP		CUSTOPHARM INC	50MG/ML	A203619 001	Nov 13, 2017
-----------	--	----------------	----------------	--------------------	--------------

AP		SAGENT PHARMS INC	50MG/ML	A206404 001	May 23, 2016
-----------	--	-------------------	----------------	--------------------	--------------

PENTOSAN POLYSULFATE SODIUM

CAPSULE; ORAL

ELMIRON

+ !	JANSSEN PHARMS	100MG	N020193 001	Sep 26, 1996
------------	----------------	-------	-------------	--------------

PENTOSTATIN

INJECTABLE; INJECTION

NIPENT

AP	+ !	HOSPIRA INC	10MG/VIAL	N020122 001	Oct 11, 1991
-----------	------------	-------------	------------------	--------------------	--------------

PENTOSTATIN

AP		WEST-WARD PHARMS INT	10MG/VIAL	A077841 001	Aug 07, 2007
-----------	--	-------------------------	------------------	--------------------	--------------

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

PENTOXIFYLLINE

AB	!	APOTEX	400MG	A075191 001	Jun 09, 1999
-----------	----------	--------	--------------	--------------------	--------------

AB		VALEANT PHARMS	400MG	A075028 001	Jul 20, 1998
-----------	--	----------------	--------------	--------------------	--------------

PENTOXIL

AB		UPSHER SMITH LABS	400MG	A074962 001	Mar 31, 1999
-----------	--	-------------------	--------------	--------------------	--------------

PERAMIVIR

SOLUTION; INTRAVENOUS

RAPIVAB

+ !	BIOCRYS	200MG/20ML (10MG/ML)	N206426 001	Dec 19, 2014
------------	---------	----------------------	-------------	--------------

PERAMPANEL

SUSPENSION; ORAL

FYCOMPA

+ !	EISAI INC	0.5MG/ML	N208277 001	Apr 29, 2016
------------	-----------	----------	-------------	--------------

TABLET; ORAL

FYCOMPA

+	EISAI INC	2MG	N202834 001	Oct 22, 2012
----------	-----------	-----	-------------	--------------

+		4MG	N202834 002	Oct 22, 2012
----------	--	-----	-------------	--------------

+		6MG	N202834 003	Oct 22, 2012
----------	--	-----	-------------	--------------

+		8MG	N202834 004	Oct 22, 2012
----------	--	-----	-------------	--------------

+		10MG	N202834 005	Oct 22, 2012
----------	--	------	-------------	--------------

+ !		12MG	N202834 006	Oct 22, 2012
------------	--	------	-------------	--------------

PERFLUTREN

INJECTABLE; INTRAVENOUS

DEFINITY

+ !	LANTHEUS MEDCL	6.52MG/ML	N021064 001	Jul 31, 2001
------------	----------------	-----------	-------------	--------------

DEFINITY RT

+ !	LANTHEUS MEDCL	6.52MG/ML	N021064 002	Nov 17, 2020
------------	----------------	-----------	-------------	--------------

PERINDOPRIL ERBUMINE

TABLET; ORAL

PERINDOPRIL ERBUMINE

AB		AUROBINDO PHARMA	2MG	A079070 001	Nov 10, 2009
-----------	--	------------------	------------	--------------------	--------------

AB			4MG	A079070 002	Nov 10, 2009
-----------	--	--	------------	--------------------	--------------

AB	!		8MG	A079070 003	Nov 10, 2009
-----------	----------	--	------------	--------------------	--------------

AB		HIKMA	2MG	A090072 001	Nov 10, 2009
-----------	--	-------	------------	--------------------	--------------

AB			4MG	A090072 002	Nov 10, 2009
-----------	--	--	------------	--------------------	--------------

AB			8MG	A090072 003	Nov 10, 2009
-----------	--	--	------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

PERMETHRIN

CREAM; TOPICAL

PERMETHRIN

<u>AB</u>	ACTAVIS LABS	<u>5%</u>	<u>A074806</u>	<u>001</u>	Jan 23, 1998
<u>AB</u>	ENCUBE ETHICALS	<u>5%</u>	<u>A211303</u>	<u>001</u>	Apr 03, 2019
<u>AB</u>	! PERRIGO ISRAEL	<u>5%</u>	<u>A076369</u>	<u>001</u>	Apr 21, 2003

PERPHENAZINE

TABLET; ORAL

PERPHENAZINE

<u>AB</u>	MYLAN	<u>2MG</u>	<u>A206691</u>	<u>001</u>	Apr 14, 2017
<u>AB</u>		<u>4MG</u>	<u>A206691</u>	<u>002</u>	Apr 14, 2017
<u>AB</u>		<u>8MG</u>	<u>A206691</u>	<u>003</u>	Apr 14, 2017
<u>AB</u>		<u>16MG</u>	<u>A206691</u>	<u>004</u>	Apr 14, 2017
<u>AB</u>	RISING	<u>2MG</u>	<u>A205056</u>	<u>001</u>	Mar 01, 2019
<u>AB</u>		<u>4MG</u>	<u>A205056</u>	<u>002</u>	Mar 01, 2019
<u>AB</u>		<u>8MG</u>	<u>A205056</u>	<u>003</u>	Mar 01, 2019
<u>AB</u>		<u>16MG</u>	<u>A205056</u>	<u>004</u>	Mar 01, 2019
<u>AB</u>	SANDOZ	<u>2MG</u>	<u>A089685</u>	<u>002</u>	Dec 08, 1988
<u>AB</u>		<u>4MG</u>	<u>A089685</u>	<u>003</u>	Dec 08, 1988
<u>AB</u>		<u>8MG</u>	<u>A089685</u>	<u>001</u>	Dec 08, 1988
<u>AB</u>	!	<u>16MG</u>	<u>A089685</u>	<u>004</u>	Dec 08, 1988
<u>AB</u>	VINTAGE PHARMS	<u>2MG</u>	<u>A040226</u>	<u>001</u>	Dec 31, 1998
<u>AB</u>		<u>4MG</u>	<u>A040226</u>	<u>002</u>	Dec 31, 1998
<u>AB</u>		<u>8MG</u>	<u>A040226</u>	<u>003</u>	Dec 31, 1998
<u>AB</u>		<u>16MG</u>	<u>A040226</u>	<u>004</u>	Dec 31, 1998
<u>AB</u>	WATSON LABS INC	<u>2MG</u>	<u>A207582</u>	<u>001</u>	Oct 17, 2016
<u>AB</u>		<u>4MG</u>	<u>A207582</u>	<u>002</u>	Oct 17, 2016
<u>AB</u>		<u>8MG</u>	<u>A207582</u>	<u>003</u>	Oct 17, 2016
<u>AB</u>		<u>16MG</u>	<u>A207582</u>	<u>004</u>	Oct 17, 2016
<u>AB</u>	WILSHIRE PHARMS INC	<u>2MG</u>	<u>A205973</u>	<u>001</u>	Dec 17, 2015
<u>AB</u>		<u>4MG</u>	<u>A205973</u>	<u>002</u>	Dec 17, 2015
<u>AB</u>		<u>8MG</u>	<u>A205973</u>	<u>003</u>	Dec 17, 2015
<u>AB</u>		<u>16MG</u>	<u>A205973</u>	<u>004</u>	Dec 17, 2015
<u>AB</u>	ZYDUS PHARMS	<u>2MG</u>	<u>A205232</u>	<u>001</u>	Apr 06, 2020
<u>AB</u>		<u>4MG</u>	<u>A205232</u>	<u>002</u>	Apr 06, 2020
<u>AB</u>		<u>8MG</u>	<u>A205232</u>	<u>003</u>	Apr 06, 2020
<u>AB</u>		<u>16MG</u>	<u>A205232</u>	<u>004</u>	Apr 06, 2020

PEXIDARTINIB HYDROCHLORIDE

CAPSULE; ORAL

TURALIO

+	!	DAIICHI SANKYO INC	EQ 200MG BASE	N211810	001	Aug 02, 2019
---	---	--------------------	---------------	---------	-----	--------------

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

PHENDIMETRAZINE TARTRATE

+	!	VIRTUS PHARMS	105MG	N018074	001	
---	---	---------------	-------	---------	-----	--

TABLET; ORAL

BONTRIL PDM

<u>AA</u>	!	VALEANT	<u>35MG</u>	<u>A085272</u>	<u>001</u>	
-----------	---	---------	-------------	----------------	------------	--

PHENDIMETRAZINE TARTRATE

<u>AA</u>		ELITE LABS INC	<u>35MG</u>	<u>A040762</u>	<u>001</u>	Jan 28, 2008
<u>AA</u>		KVK TECH	<u>35MG</u>	<u>A091042</u>	<u>001</u>	Aug 31, 2010
<u>AA</u>		MIKART	<u>35MG</u>	<u>A089452</u>	<u>001</u>	Oct 30, 1991
<u>AA</u>		VIRTUS PHARMS	<u>35MG</u>	<u>A085588</u>	<u>001</u>	

PHENELZINE SULFATE

TABLET; ORAL

NARDIL

<u>AB</u>	+	!	PARKE DAVIS	<u>EQ 15MG BASE</u>	<u>N011909</u>	<u>002</u>
-----------	---	---	-------------	---------------------	----------------	------------

PHENELZINE SULFATE

<u>AB</u>		NOVEL LABS INC	<u>EQ 15MG BASE</u>	<u>A200181</u>	<u>001</u>	Dec 08, 2010
-----------	--	----------------	---------------------	----------------	------------	--------------

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIBENZYLINE

<u>AB</u>	+	CONCORDIA	<u>10MG</u>	<u>N008708</u>	<u>001</u>	
-----------	---	-----------	-------------	----------------	------------	--

PHENOXYBENZAMINE HYDROCHLORIDE

<u>AB</u>		AMNEAL	<u>10MG</u>	<u>A212568</u>	<u>001</u>	Oct 27, 2020
<u>AB</u>		HIKMA	<u>10MG</u>	<u>A201050</u>	<u>001</u>	Jul 16, 2012
<u>AB</u>	!	PAR PHARM INC	<u>10MG</u>	<u>A204522</u>	<u>001</u>	Jan 24, 2017

PRESCRIPTION DRUG PRODUCT LIST

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

ADIPEX-P

<u>AA</u>	!	TEVA	<u>37.5MG</u>	<u>A088023</u>	<u>001</u>	Aug 02, 1983
<u>PHENTERMINE HYDROCHLORIDE</u>						
<u>AA</u>		AUROLIFE PHARMA LLC	<u>15MG</u>	<u>A204318</u>	<u>001</u>	Nov 09, 2016
<u>AA</u>			<u>30MG</u>	<u>A204318</u>	<u>002</u>	Nov 09, 2016
<u>AA</u>		ELITE LABS	<u>15MG</u>	<u>A202248</u>	<u>001</u>	Sep 28, 2012
<u>AA</u>			<u>30MG</u>	<u>A202248</u>	<u>002</u>	Sep 28, 2012
<u>AA</u>		ELITE LABS INC	<u>37.5MG</u>	<u>A040228</u>	<u>001</u>	Jun 19, 1997
<u>AA</u>		INVAGEN PHARMS	<u>15MG</u>	<u>A202858</u>	<u>001</u>	Feb 14, 2014
<u>AA</u>			<u>30MG</u>	<u>A202858</u>	<u>002</u>	Feb 14, 2014
<u>AA</u>			<u>30MG</u>	<u>A204414</u>	<u>001</u>	May 05, 2014
<u>AA</u>			<u>37.5MG</u>	<u>A202846</u>	<u>001</u>	Feb 05, 2014
<u>AA</u>		KVK TECH	<u>15MG</u>	<u>A040886</u>	<u>002</u>	Mar 31, 2008
<u>AA</u>			<u>30MG</u>	<u>A040875</u>	<u>001</u>	Mar 21, 2008
<u>AA</u>			<u>30MG</u>	<u>A040886</u>	<u>001</u>	Mar 31, 2008
<u>AA</u>			<u>37.5MG</u>	<u>A040887</u>	<u>001</u>	Apr 24, 2008
<u>AA</u>		LANNETT	<u>15MG</u>	<u>A087022</u>	<u>002</u>	Jan 20, 2012
<u>AA</u>			<u>30MG</u>	<u>A087022</u>	<u>001</u>	Feb 03, 1983
<u>AA</u>		LANNETT CO INC	<u>37.5MG</u>	<u>A201961</u>	<u>001</u>	Jul 20, 2011
<u>AA</u>		NUVO PHARM	<u>15MG</u>	<u>A205019</u>	<u>001</u>	Dec 05, 2014
<u>AA</u>			<u>30MG</u>	<u>A205019</u>	<u>002</u>	Dec 05, 2014
<u>AA</u>			<u>37.5MG</u>	<u>A205017</u>	<u>001</u>	Sep 25, 2014
<u>AA</u>	!	SANDOZ	<u>15MG</u>	<u>A087190</u>	<u>002</u>	
<u>AA</u>	!		<u>30MG</u>	<u>A086945</u>	<u>001</u>	Jul 20, 1983
<u>AA</u>	!		<u>30MG</u>	<u>A087190</u>	<u>001</u>	
<u>AA</u>		SUN PHARM INDUSTRIES	<u>30MG</u>	<u>A040525</u>	<u>001</u>	Oct 23, 2003

TABLET; ORAL

ADIPEX-P

<u>AA</u>	!	TEVA	<u>37.5MG</u>	<u>A085128</u>	<u>001</u>	
<u>LOMAIRA</u>						
<u>AA</u>	!	AVANTHI INC	<u>8MG</u>	<u>A203495</u>	<u>001</u>	Sep 12, 2016
<u>PHENTERMINE HYDROCHLORIDE</u>						
<u>AA</u>		AUROLIFE PHARMA LLC	<u>37.5MG</u>	<u>A203068</u>	<u>001</u>	Aug 06, 2014
<u>AA</u>		ELITE LABS	<u>37.5MG</u>	<u>A200272</u>	<u>001</u>	Jan 31, 2011
<u>AA</u>		ELITE LABS INC	<u>37.5MG</u>	<u>A040190</u>	<u>001</u>	May 30, 1997
<u>AA</u>		INVAGEN PHARMS	<u>37.5MG</u>	<u>A202942</u>	<u>001</u>	Feb 05, 2014
<u>AA</u>		KVK TECH	<u>37.5MG</u>	<u>A040876</u>	<u>001</u>	Mar 31, 2008
<u>AA</u>		KVK TECH INC	<u>8MG</u>	<u>A203436</u>	<u>001</u>	Mar 17, 2017
<u>AA</u>		LANNETT	<u>37.5MG</u>	<u>A040555</u>	<u>001</u>	Apr 15, 2005
<u>AA</u>		NUVO PHARM	<u>37.5MG</u>	<u>A205008</u>	<u>001</u>	Sep 25, 2014
<u>AA</u>		POLYGEN PHARMS	<u>37.5MG</u>	<u>A206342</u>	<u>001</u>	Nov 18, 2016
<u>AA</u>		PRINSTON INC	<u>37.5MG</u>	<u>A040377</u>	<u>001</u>	Jan 04, 2002
<u>AA</u>		SUN PHARM INDUSTRIES	<u>37.5MG</u>	<u>A040526</u>	<u>001</u>	Oct 23, 2003

TABLET, ORALLY DISINTEGRATING; ORAL

PHENTERMINE HYDROCHLORIDE

ZYDUS PHARMS	15MG	A204663	001	Jun 28, 2017
	30MG	A204663	002	Jun 28, 2017
	37.5MG	A204663	003	Jun 28, 2017

PHENTERMINE HYDROCHLORIDE; TOPIRAMATE

CAPSULE, EXTENDED RELEASE; ORAL

QSYMIA

+	VIVUS	EQ 3.75MG BASE; 23MG	N022580	001	Jul 17, 2012
+		EQ 7.5MG BASE; 46MG	N022580	002	Jul 17, 2012
+		EQ 11.25MG BASE; 69MG	N022580	003	Jul 17, 2012
+	!	EQ 15MG BASE; 92MG	N022580	004	Jul 17, 2012

PHENTOLAMINE MESYLATE

INJECTABLE; INJECTION

PHENTOLAMINE MESYLATE

<u>AP</u>		PRECISION DOSE INC	<u>5MG/VIAL</u>	<u>A207686</u>	<u>001</u>	Jul 14, 2017
<u>AP</u>	!	WEST-WARD PHARMS INT	<u>5MG/VIAL</u>	<u>A040235</u>	<u>001</u>	Mar 11, 1998
ORAVERSE						
	+	SEPTODONT HOLDING	0.4MG/1.7ML	N022159	001	May 09, 2008

PRESCRIPTION DRUG PRODUCT LIST

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS

PHENYLEPHRINE HYDROCHLORIDE

<u>AP1</u>	AMNEAL	<u>10MG/ML (10MG/ML)</u>	<u>A211079 001</u>	Jul 05, 2018
<u>AP1</u>		<u>50MG/5ML (10MG/ML)</u>	<u>A211078 001</u>	Jul 19, 2018
<u>AP1</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A211078 002</u>	Jul 19, 2018
<u>AP1</u>	APOLLO	<u>10MG/ML (10MG/ML)</u>	<u>A211081 001</u>	Jul 17, 2020
<u>AP1</u>		<u>50MG/5ML (10MG/ML)</u>	<u>A211081 002</u>	Jul 17, 2020
<u>AP1</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A211081 003</u>	Jul 17, 2020
<u>AP1</u>	AUROBINDO PHARMA LTD	<u>50MG/5ML (10MG/ML)</u>	<u>A210697 001</u>	Nov 13, 2020
<u>AP1</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A210697 002</u>	Nov 13, 2020
<u>AP1</u>	FRESENIUS KABI USA	<u>50MG/5ML (10MG/ML)</u>	<u>A210666 001</u>	Jan 30, 2019
<u>AP1</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A210666 002</u>	Jan 30, 2019
<u>AP1</u>	GLAND PHARMA LTD	<u>50MG/5ML (10MG/ML)</u>	<u>A211920 001</u>	Jun 05, 2020
<u>AP1</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A211920 002</u>	Jun 05, 2020
<u>AP1</u>	MEITHEAL	<u>50MG/5ML (10MG/ML)</u>	<u>A210333 001</u>	Apr 27, 2018
<u>AP1</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A210333 002</u>	Apr 27, 2018
<u>AP1</u>	PAR STERILE PRODUCTS	<u>10MG/ML (10MG/ML)</u>	<u>A210025 001</u>	Dec 21, 2018
<u>AP1</u>		<u>50MG/5ML (10MG/ML)</u>	<u>A210025 002</u>	Dec 21, 2018
<u>AP1</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A210025 003</u>	Dec 21, 2018
<u>AP1</u>	SAGENT PHARMS INC	<u>10MG/ML (10MG/ML)</u>	<u>A209967 001</u>	Jan 16, 2020
<u>AP1</u>		<u>50MG/5ML (10MG/ML)</u>	<u>A209967 002</u>	Jan 16, 2020
<u>AP1</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A209967 003</u>	Jan 16, 2020
<u>AP1</u>	SANDOZ INC	<u>10MG/ML (10MG/ML)</u>	<u>A208905 001</u>	Jan 31, 2019
<u>AP1</u>		<u>50MG/5ML (10MG/ML)</u>	<u>A208905 002</u>	Jan 31, 2019
<u>AP1</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A208905 003</u>	Jan 31, 2019

VAZCULEP

<u>AP1</u>	+	EXELA PHARMA	<u>10MG/ML (10MG/ML)</u>	<u>N204300 001</u>	Jun 27, 2014
<u>AP1</u>	+		<u>50MG/5ML (10MG/ML)</u>	<u>N204300 002</u>	Jun 27, 2014
<u>AP1</u>	+		<u>100MG/10ML (10MG/ML)</u>	<u>N204300 003</u>	Jun 27, 2014

PHENYLEPHRINE HYDROCHLORIDE

<u>AP2</u>		FRESENIUS KABI USA	<u>10MG/ML (10MG/ML)</u>	<u>A210665 001</u>	Jan 29, 2019
<u>AP2</u>		MEITHEAL	<u>10MG/ML (10MG/ML)</u>	<u>A210334 001</u>	Apr 27, 2018
<u>AP2</u>	+	WEST WARD PHARM CORP	<u>10MG/ML (10MG/ML)</u>	<u>N203826 001</u>	Dec 20, 2012
<u>AP2</u>	+		<u>50MG/5ML (10MG/ML)</u>	<u>N203826 002</u>	Jun 19, 2019
<u>AP2</u>	+		<u>100MG/10ML (10MG/ML)</u>	<u>N203826 003</u>	Jun 19, 2019
		BIORPHEN			
	+	ETON PHARMS	<u>0.1MG/ML (0.1MG/ML)</u>	<u>N212909 001</u>	Oct 21, 2019

SOLUTION/DROPS; OPHTHALMIC

PHENYLEPHRINE HYDROCHLORIDE

<u>AT</u>	+	AKORN	<u>2.5%</u>	<u>N207926 001</u>	Jan 15, 2015
<u>AT</u>	+		<u>10%</u>	<u>N207926 002</u>	Jan 15, 2015
<u>AT</u>	+	PARAGON BIOTECK	<u>2.5%</u>	<u>N203510 001</u>	Mar 21, 2013
<u>AT</u>	+		<u>10%</u>	<u>N203510 002</u>	Mar 21, 2013

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE

<u>AA</u>		HI TECH	<u>5MG/5ML; 6.25MG/5ML</u>	<u>A040675 001</u>	Dec 23, 2014
<u>AA</u>	!	PHARM ASSOC	<u>5MG/5ML; 6.25MG/5ML</u>	<u>A040654 001</u>	Dec 07, 2006
<u>AA</u>		AMNEAL PHARMS	<u>5MG/5ML; 6.25MG/5ML</u>	<u>A040902 001</u>	Aug 25, 2009

PHENYTOIN

SUSPENSION; ORAL

DILANTIN-125

<u>AB</u>	+	UPJOHN	<u>125MG/5ML</u>	<u>N008762 001</u>	
-----------	---	--------	------------------	--------------------	--

PHENYTOIN

<u>AB</u>		TARO	<u>125MG/5ML</u>	<u>A040521 001</u>	Mar 08, 2004
<u>AB</u>		VISTAPHARM	<u>125MG/5ML</u>	<u>A040342 001</u>	Jan 31, 2001
<u>AB</u>			<u>125MG/5ML</u>	<u>A040610 001</u>	Aug 18, 2005
<u>AB</u>		WOCKHARDT BIO AG	<u>125MG/5ML</u>	<u>A040420 001</u>	Apr 19, 2002

TABLET, CHEWABLE; ORAL

DILANTIN

<u>AB</u>	!	PHARMACIA	<u>50MG</u>	<u>A084427 001</u>	
-----------	---	-----------	-------------	--------------------	--

PHENYTOIN

<u>AB</u>		EPIC PHARMA LLC	<u>50MG</u>	<u>A040884 001</u>	Nov 28, 2014
<u>AB</u>		MYLAN PHARMS INC	<u>50MG</u>	<u>A200691 001</u>	Dec 26, 2012
<u>AB</u>		TARO	<u>50MG</u>	<u>A200565 001</u>	Apr 17, 2014

PRESCRIPTION DRUG PRODUCT LIST

PHENYTOIN SODIUM

CAPSULE; ORAL

DILANTIN

<u>AB</u>	!	UPJOHN	<u>100MG EXTENDED</u>	<u>A084349 002</u>	
<u>EXTENDED PHENYTOIN SODIUM</u>					
<u>AB</u>		AMNEAL PHARMS NY	<u>100MG EXTENDED</u>	<u>A040765 001</u>	Nov 12, 2008
<u>AB</u>		MYLAN	<u>100MG EXTENDED</u>	<u>A040298 001</u>	Dec 28, 1998
<u>AB</u>		SUN PHARM INDS	<u>200MG EXTENDED</u>	<u>A040731 001</u>	Jun 30, 2008
<u>AB</u>			<u>300MG EXTENDED</u>	<u>A040731 002</u>	Jun 30, 2008
<u>AB</u>		TARO	<u>100MG EXTENDED</u>	<u>A040684 001</u>	Sep 05, 2006

PHENYTEK

<u>AB</u>		MYLAN	<u>200MG EXTENDED</u>	<u>A040298 002</u>	Dec 06, 2001
<u>AB</u>	!		<u>300MG EXTENDED</u>	<u>A040298 003</u>	Dec 06, 2001

PHENYTOIN SODIUM

<u>AB</u>		AUROBINDO PHARMA LTD	<u>100MG EXTENDED</u>	<u>A204309 001</u>	Jun 10, 2015
<u>DILANTIN</u>					
	!	UPJOHN	30MG EXTENDED	A084349 001	

INJECTABLE; INJECTION

PHENYTOIN SODIUM

<u>AP</u>		ACELLA	<u>50MG/ML</u>	<u>A040573 001</u>	Sep 13, 2006
<u>AP</u>	!	WEST-WARD PHARMS INT	<u>50MG/ML</u>	<u>A084307 001</u>	

PHYTONADIONE

INJECTABLE; INJECTION

PHYTONADIONE

<u>AB</u>		DR REDDYS LABS LTD	<u>10MG/ML</u>	<u>A207719 001</u>	May 22, 2019
<u>VITAMIN K1</u>					
<u>AB</u>	!	HOSPIRA	<u>10MG/ML</u>	<u>A087955 001</u>	Jul 25, 1983
<u>PHYTONADIONE</u>					
BP	!	INTL MEDICATION	1MG/0.5ML	A083722 001	
<u>VITAMIN K1</u>					
BP	!	HOSPIRA	1MG/0.5ML	A087954 001	Jul 25, 1983

TABLET; ORAL

MEPHYTON

<u>AB</u>	+	BAUSCH	<u>5MG</u>	<u>N010104 003</u>	
-----------	---	--------	------------	--------------------	--

PHYTONADIONE

<u>AB</u>		AMNEAL PHARMS CO	<u>5MG</u>	<u>A209373 001</u>	May 11, 2018
<u>AB</u>		ZYDUS	<u>5MG</u>	<u>A210189 001</u>	Feb 20, 2019

PILOCARPINE HYDROCHLORIDE

SOLUTION; OPHTHALMIC

ISOPTO CARPINE

<u>AT</u>	+	NOVARTIS	<u>1%</u>	<u>N200890 001</u>	Jun 22, 2010
<u>AT</u>	+		<u>2%</u>	<u>N200890 002</u>	Jun 22, 2010
<u>AT</u>	+		<u>4%</u>	<u>N200890 003</u>	Jun 22, 2010

PILOCARPINE HYDROCHLORIDE

<u>AT</u>		AKORN INC	<u>1%</u>	<u>A204398 001</u>	Sep 27, 2017
<u>AT</u>			<u>2%</u>	<u>A204398 002</u>	Sep 27, 2017
<u>AT</u>			<u>4%</u>	<u>A204398 003</u>	Sep 27, 2017
<u>AT</u>		AMNEAL	<u>1%</u>	<u>A214193 001</u>	Sep 21, 2020
<u>AT</u>			<u>2%</u>	<u>A214193 002</u>	Sep 21, 2020
<u>AT</u>			<u>4%</u>	<u>A214193 003</u>	Sep 21, 2020
<u>AT</u>		SOMERSET THERAPS LLC	<u>1%</u>	<u>A210384 001</u>	Nov 25, 2019
<u>AT</u>			<u>2%</u>	<u>A210384 002</u>	Nov 25, 2019
<u>AT</u>			<u>4%</u>	<u>A210384 003</u>	Nov 25, 2019

TABLET; ORAL

PILOCARPINE HYDROCHLORIDE

<u>AB</u>		AUROBINDO PHARMA LTD	<u>5MG</u>	<u>A212377 001</u>	Aug 13, 2019
<u>AB</u>			<u>7.5MG</u>	<u>A212377 002</u>	Aug 13, 2019
<u>AB</u>		IMPAX LABS	<u>5MG</u>	<u>A077248 001</u>	Mar 31, 2006
<u>AB</u>			<u>7.5MG</u>	<u>A077248 002</u>	Mar 31, 2006
<u>AB</u>		LANNETT CO INC	<u>5MG</u>	<u>A077220 001</u>	Oct 14, 2005
<u>AB</u>			<u>7.5MG</u>	<u>A077220 002</u>	May 06, 2009
<u>AB</u>		MLV	<u>5MG</u>	<u>A076963 001</u>	Dec 22, 2004
<u>AB</u>			<u>7.5MG</u>	<u>A076963 002</u>	Feb 27, 2007
<u>AB</u>		PERRIGO PHARMA INTL	<u>5MG</u>	<u>A076746 001</u>	Nov 16, 2004

SALAGEN

<u>AB</u>	+	CONCORDIA	<u>5MG</u>	<u>N020237 001</u>	Mar 22, 1994
<u>AB</u>	+		<u>7.5MG</u>	<u>N020237 002</u>	Apr 18, 2003

PRESCRIPTION DRUG PRODUCT LIST

PIMAVANSERIN TARTRATE

CAPSULE; ORAL

NUPLAZID

+! ACADIA PHARMS INC EQ 34MG BASE

N210793 001 Jun 28, 2018

TABLET; ORAL

NUPLAZID

+! ACADIA PHARMS INC EQ 10MG BASE

N207318 002 Jun 28, 2018

PIMECROLIMUS

CREAM; TOPICAL

ELIDELAB +! BAUSCH1%N021302 001 Dec 13, 2001PIMECROLIMUSAB ACTAVIS LABS UT INC1%A209345 001 Dec 27, 2018AB GLENMARK PHARMS LTD1%A211769 001 Aug 29, 2019PIMOZIDE

TABLET; ORAL

PIMOZIDE

PAR PHARM 1MG

A204521 001 Sep 28, 2015

! 2MG

A204521 002 Sep 28, 2015

PINDOLOL

TABLET; ORAL

PINDOLOLAB ANI PHARMS INC5MGA073609 002 Mar 29, 1993AB 10MGA073609 001 Mar 29, 1993AB BAYSHORE PHARMS LLC5MGA211712 001 Aug 01, 2019AB 10MGA211712 002 Aug 01, 2019AB MYLAN PHARMS INC5MGA074019 001 Sep 03, 1992AB ! 10MGA074019 002 Sep 03, 1992AB NOSTRUM LABS INC5MGA205415 001 Jan 13, 2016AB 10MGA205415 002 Jan 13, 2016AB SUN PHARM5MGA074063 001 Jan 27, 1994

INDUSTRIES

AB 10MGA074063 002 Jan 27, 1994PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

ACTOSAB + TAKEDA PHARMS USAEQ 15MG BASEN021073 001 Jul 15, 1999AB +EQ 30MG BASEN021073 002 Jul 15, 1999AB +!EQ 45MG BASEN021073 003 Jul 15, 1999PIOGLITAZONE HYDROCHLORIDEAB ACCORD HLTHCAREEQ 15MG BASEA200044 001 Feb 13, 2013AB 30MG BASEA200044 002 Feb 13, 2013AB 45MG BASEA200044 003 Feb 13, 2013AB AUROBINDO PHARMAEQ 15MG BASEA200268 001 Feb 13, 2013

LTD

AB 30MG BASEA200268 002 Feb 13, 2013AB 45MG BASEA200268 003 Feb 13, 2013AB CELLTRIONEQ 15MG BASEA076798 001 Oct 26, 2012AB 30MG BASEA076798 002 Oct 26, 2012AB 45MG BASEA076798 003 Oct 26, 2012AB LUPIN LTDEQ 15MG BASEA204133 001 Apr 07, 2014AB 30MG BASEA204133 002 Apr 07, 2014AB 45MG BASEA204133 003 Apr 07, 2014AB MACLEODS PHARMS LTDEQ 15MG BASEA202467 001 Feb 06, 2013AB 30MG BASEA202467 002 Feb 06, 2013AB 45MG BASEA202467 003 Feb 06, 2013AB PRINSTON INCEQ 15MG BASEA207806 001 Apr 17, 2018AB 30MG BASEA207806 002 Apr 17, 2018AB 45MG BASEA207806 003 Apr 17, 2018AB PURACAP PHARM LLCEQ 15MG BASEA206738 001 Oct 06, 2017AB 30MG BASEA206738 002 Oct 06, 2017AB 45MG BASEA206738 003 Oct 06, 2017AB SANDOZEQ 15MG BASEA078670 001 Feb 13, 2013AB 30MG BASEA078670 002 Feb 13, 2013AB 45MG BASEA078670 003 Feb 13, 2013AB TEVA PHARMS USAEQ 15MG BASEA077210 001 Jan 10, 2014AB 30MG BASEA077210 002 Jan 10, 2014AB 45MG BASEA077210 003 Jan 10, 2014AB ZYDUS PHARMS USAEQ 15MG BASEA202456 001 Feb 13, 2013

INC

AB 30MG BASEA202456 002 Feb 13, 2013

PRESCRIPTION DRUG PRODUCT LIST

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE

<u>AB</u>		<u>EQ 45MG BASE</u>	<u>A202456 003</u>	Feb 13, 2013
-----------	--	---------------------	--------------------	--------------

PIPERACILLIN SODIUM

INJECTABLE; INJECTION

PIPERACILLIN

!	ISTITUTO BIO ITA SPA	EQ 2GM BASE/VIAL	A065114 001	Nov 14, 2003
!		EQ 3GM BASE/VIAL	A065114 002	Nov 14, 2003
!		EQ 4GM BASE/VIAL	A065114 003	Nov 14, 2003
!		EQ 40GM BASE/VIAL	A065157 001	Jul 12, 2004

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

PIPERACILLIN AND TAZOBACTAM

<u>AP</u>	APOLLO	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A207847 001</u>	Jan 13, 2017
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A207847 002</u>	Jan 13, 2017
<u>AP</u>		<u>EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL</u>	<u>A207848 002</u>	Jan 13, 2017
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A207847 003</u>	Jan 13, 2017
<u>AP</u>		<u>EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL</u>	<u>A207848 001</u>	May 11, 2018
<u>AP</u>	ASTRAL	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A212287 001</u>	Jul 29, 2019
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A212287 002</u>	Jul 29, 2019
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A212287 003</u>	Jul 29, 2019
<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A065498 001</u>	May 23, 2011
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A065498 002</u>	May 23, 2011
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065498 003</u>	May 23, 2011
<u>AP</u>	FRESENIUS KABI	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A203719 001</u>	May 18, 2018
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A203719 002</u>	May 18, 2018
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A203719 003</u>	May 18, 2018
<u>AP</u>		<u>EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL</u>	<u>A203720 001</u>	May 11, 2018
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL</u>	<u>A206204 001</u>	May 11, 2018
<u>AP</u>	ISTITUTO BIO ITA SPA	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A065523 001</u>	May 31, 2011
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A065523 002</u>	May 31, 2011
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065523 003</u>	May 31, 2011
<u>AP</u>		<u>EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL</u>	<u>A090498 001</u>	May 31, 2011
<u>AP</u>	MYLAN LABS LTD	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A065458 001</u>	Aug 15, 2014
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A065458 002</u>	Aug 15, 2014
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065458 003</u>	Aug 15, 2014
<u>AP</u>	QILU	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A204959 001</u>	Aug 10, 2018
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A204959 002</u>	Aug 10, 2018
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A204959 003</u>	Aug 10, 2018
<u>AP</u>	SANDOZ	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A065362 001</u>	Oct 21, 2010
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A065363 001</u>	Oct 21, 2010
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A065362 002</u>	Oct 21, 2010
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A065363 002</u>	Oct 21, 2010
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065362 003</u>	Oct 21, 2010
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065363 003</u>	Oct 21, 2010
<u>AP</u>	SANDOZ INC	<u>EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL</u>	<u>A203557 001</u>	Oct 29, 2014
<u>AP</u>	WOCKHARDT BIO AG	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A206996 001</u>	Mar 22, 2017
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A206996 002</u>	Mar 22, 2017
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A206996 003</u>	Mar 22, 2017
<u>AP</u>		<u>EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL</u>	<u>A207146 001</u>	Mar 17, 2017

ZOSYN

<u>AP</u>	+!	WYETH PHARMS	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>N050684 001</u>	Oct 22, 1993
<u>AP</u>	+!		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>N050684 002</u>	Oct 22, 1993
<u>AP</u>	+!		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>N050684 003</u>	Oct 22, 1993
<u>AP</u>	+!		<u>EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL</u>	<u>N050684 004</u>	Oct 22, 1993
		ZOSYN IN PLASTIC CONTAINER			
	+!	WYETH PHARMS	EQ 40MG BASE/ML;EQ 5MG BASE/ML	N050750 001	Feb 24, 1998
	+!		EQ 60MG BASE/ML;EQ 7.5MG BASE/ML	N050750 002	Feb 24, 1998
	+!		EQ 4GM BASE/100ML;EQ 500MG BASE/100ML	N050750 003	Feb 24, 1998

PIRFENIDONE

CAPSULE; ORAL

ESBRIET

+	GENENTECH INC	267MG	N022535 001	Oct 15, 2014
---	---------------	-------	-------------	--------------

TABLET; ORAL

ESBRIET

+	GENENTECH INC	267MG	N208780 001	Jan 11, 2017
+		801MG	N208780 003	Jan 11, 2017

PRESCRIPTION DRUG PRODUCT LIST

PIROXICAM

CAPSULE;ORAL

FELDENE

<u>AB</u>	+	PFIZER	<u>10MG</u>	<u>N018147</u>	<u>002</u>	Apr 06, 1982
<u>AB</u>	+	!	<u>20MG</u>	<u>N018147</u>	<u>003</u>	Apr 06, 1982

PIROXICAM

<u>AB</u>		CADILA	<u>10MG</u>	<u>A205585</u>	<u>001</u>	Jul 17, 2018
<u>AB</u>			<u>20MG</u>	<u>A205585</u>	<u>002</u>	Jul 17, 2018
<u>AB</u>		FLAMINGO PHARMS	<u>10MG</u>	<u>A207938</u>	<u>001</u>	Sep 09, 2016
<u>AB</u>			<u>20MG</u>	<u>A207938</u>	<u>002</u>	Sep 09, 2016
<u>AB</u>		HIKMA	<u>10MG</u>	<u>A209256</u>	<u>001</u>	Aug 11, 2017
<u>AB</u>			<u>20MG</u>	<u>A209256</u>	<u>002</u>	Aug 11, 2017
<u>AB</u>		MICRO LABS	<u>10MG</u>	<u>A206152</u>	<u>001</u>	Dec 29, 2017
<u>AB</u>			<u>20MG</u>	<u>A206152</u>	<u>002</u>	Dec 29, 2017
<u>AB</u>		NOSTRUM LABS INC	<u>10MG</u>	<u>A074116</u>	<u>001</u>	Jun 15, 1993
<u>AB</u>			<u>20MG</u>	<u>A074116</u>	<u>001</u>	Jun 15, 1993
<u>AB</u>		STRIDES PHARMA	<u>10MG</u>	<u>A206136</u>	<u>001</u>	Jun 20, 2017
<u>AB</u>			<u>10MG</u>	<u>A210347</u>	<u>001</u>	Jan 26, 2018
<u>AB</u>			<u>20MG</u>	<u>A206136</u>	<u>002</u>	Jun 20, 2017
<u>AB</u>			<u>20MG</u>	<u>A210347</u>	<u>002</u>	Jan 26, 2018
<u>AB</u>		TEVA	<u>10MG</u>	<u>A074131</u>	<u>001</u>	Dec 11, 1992
<u>AB</u>			<u>20MG</u>	<u>A074131</u>	<u>002</u>	Dec 11, 1992
<u>AB</u>		UNICHEM	<u>10MG</u>	<u>A208340</u>	<u>001</u>	Apr 13, 2017
<u>AB</u>			<u>20MG</u>	<u>A208340</u>	<u>002</u>	Apr 13, 2017

PITAVASTATIN CALCIUM

TABLET;ORAL

LIVALO

<u>AB</u>	+	KOWA CO	<u>EQ 1MG BASE</u>	<u>N022363</u>	<u>001</u>	Aug 03, 2009
<u>AB</u>	+		<u>EQ 2MG BASE</u>	<u>N022363</u>	<u>002</u>	Aug 03, 2009
<u>AB</u>	+	!	<u>EQ 4MG BASE</u>	<u>N022363</u>	<u>003</u>	Aug 03, 2009

PITAVASTATIN CALCIUM

<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 1MG BASE</u>	<u>A206015</u>	<u>001</u>	Dec 20, 2016
<u>AB</u>			<u>EQ 2MG BASE</u>	<u>A206015</u>	<u>002</u>	Dec 20, 2016
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A206015</u>	<u>003</u>	Dec 20, 2016
<u>AB</u>		ORIENT PHARMA CO LTD	<u>EQ 1MG BASE</u>	<u>A205932</u>	<u>001</u>	Feb 03, 2017
<u>AB</u>			<u>EQ 2MG BASE</u>	<u>A205932</u>	<u>002</u>	Feb 03, 2017
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A205932</u>	<u>003</u>	Feb 03, 2017
<u>AB</u>		SAWAI USA	<u>EQ 1MG BASE</u>	<u>A205955</u>	<u>001</u>	Feb 03, 2017
<u>AB</u>			<u>EQ 2MG BASE</u>	<u>A205955</u>	<u>002</u>	Feb 03, 2017
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A205955</u>	<u>003</u>	Feb 03, 2017

PITAVASTATIN MAGNESIUM

TABLET;ORAL

ZYPITAMAG

	+	MEDICURE	EQ 2MG BASE	N208379	002	Jul 14, 2017
	+	!	EQ 4MG BASE	N208379	003	Jul 14, 2017

PITOLISANT HYDROCHLORIDE

TABLET;ORAL

WAKIX

	+	HARMONY	EQ 4.45MG BASE	N211150	001	Aug 14, 2019
	+	!	EQ 17.8MG BASE	N211150	002	Aug 14, 2019

PLAZOMICIN SULFATE

SOLUTION;INTRAVENOUS

ZEMDRI

	+	CIPLA USA	EQ 500MG BASE/10ML (EQ 50MG BASE/ML)	N210303	001	Jun 25, 2018
--	---	-----------	--------------------------------------	---------	-----	--------------

PLECANATIDE

TABLET;ORAL

TRULANCE

	+	SALIX	3MG	N208745	001	Jan 19, 2017
--	---	-------	-----	---------	-----	--------------

PLERIXAFOR

SOLUTION;SUBCUTANEOUS

MOZOBIL

	+	GENZYME	24MG/1.2ML (20MG/ML)	N022311	001	Dec 15, 2008
--	---	---------	----------------------	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

PODOFILOX

GEL; TOPICAL

CONDYLOX

+! ALLERGAN

0.5%

N020529 001 Mar 13, 1997

SOLUTION; TOPICAL

CONDYLOX**AT** +! TEVA BRANDED PHARM**0.5%****N019795 001** Dec 13, 1990PODOFILOX**AT** PADDOCK LLC**0.5%****A075600 001** Jan 29, 2002POLIDOCANOL

SOLUTION; INTRAVENOUS

ASCLERA

+ CHEMISCH FBRK

10MG/2ML (5MG/ML)

N021201 001 Mar 30, 2010

KRSSLR

+!

20MG/2ML (10MG/ML)

N021201 002 Mar 30, 2010

VARITHENA

+! PROVENISIS

77.5MG/7.75ML (10MG/ML)

N205098 002 Dec 21, 2017

+!

180MG/18ML (10MG/ML)

N205098 001 Nov 25, 2013

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; ORAL

LAX-LYTE WITH FLAVOR PACKS**AA** PADDOCK LLC**420GM/BOT; 1.48GM/BOT; 5.72GM/BOT; 11.2GM/BOT****A079232 001** Feb 25, 2010NULYTELY**AA** +! BRAINTREE**420GM/BOT; 1.48GM/BOT; 5.72GM/BOT; 11.2GM/BOT****N019797 001** Apr 22, 1991NULYTELY-FLAVORED**AA** +! BRAINTREE**420GM/BOT; 1.48GM/BOT; 5.72GM/BOT; 11.2GM/BOT****N019797 002** Nov 18, 1994PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE**AA** NOVEL LABS INC**420GM/BOT; 1.48GM/BOT; 5.72GM/BOT; 11.2GM/BOT****A090019 001** May 27, 2009**AA** STRIDES PHARMA**420GM/BOT; 1.48GM/BOT; 5.72GM/BOT; 11.2GM/BOT****A204559 001** Apr 13, 2015TRILYTE**AA** MYLAN**420GM/BOT; 1.48GM/BOT; 5.72GM/BOT; 11.2GM/BOT****A076491 001** Feb 05, 2004POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL

COLYTE WITH FLAVOR PACKS**AA** MYLAN SPECIALITY LP**240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT****N018983 012** Oct 08, 1998GOLYTELY**AA** +! BRAINTREE**236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT****N019011 001** Jul 13, 1984PEG 3350 AND ELECTROLYTES**AA** NOVEL LABS INC**236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT****A090231 001** Jun 01, 2009**AA****240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT****A090186 001** Jun 01, 2009POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES**AA** STRIDES PHARMA**236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT****A204558 001** Dec 21, 2018POLYMYXIN B SULFATE

INJECTABLE; INJECTION

POLYMYXIN B SULFATE**AP** AUROBINDO PHARMA LTD**EQ 500,000 UNITS BASE/VIAL****A206589 001** Apr 04, 2016**AP** FRESENIUS KABI USA**EQ 500,000 UNITS BASE/VIAL****A065372 001** Jan 10, 2008**AP** ! GLAND PHARMA LTD**EQ 500,000 UNITS BASE/VIAL****A207322 001** Apr 14, 2016**AP** XELLIA PHARMS APS**EQ 500,000 UNITS BASE/VIAL****A202766 001** Jan 15, 2014**AP** XGEN PHARMS**EQ 500,000 UNITS BASE/VIAL****A063000 001** Sep 30, 1994POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC

POLYTRIM**AT** +! ALLERGAN**10,000 UNITS/ML; EQ 1MG BASE/ML****N050567 001** Oct 20, 1988TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE**AT** AKORN INC**10,000 UNITS/ML; EQ 1MG BASE/ML****A065006 001** Dec 17, 1998**AT** BAUSCH AND LOMB**10,000 UNITS/ML; EQ 1MG BASE/ML****A064120 001** Feb 14, 1997**AT** SANDOZ INC**10,000 UNITS/ML; EQ 1MG BASE/ML****A064211 001** Apr 13, 1998

PRESCRIPTION DRUG PRODUCT LIST

POMALIDOMIDE

CAPSULE; ORAL

POMALIDOMIDE

<u>AB</u>	BRECKENRIDGE	<u>1MG</u>	<u>A210111</u>	<u>001</u>	Oct 30, 2020
<u>AB</u>		<u>2MG</u>	<u>A210111</u>	<u>002</u>	Oct 30, 2020
<u>AB</u>		<u>3MG</u>	<u>A210111</u>	<u>003</u>	Oct 30, 2020
<u>AB</u>		<u>4MG</u>	<u>A210111</u>	<u>004</u>	Oct 30, 2020
<u>AB</u>	EUGIA PHARMA	<u>1MG</u>	<u>A210249</u>	<u>001</u>	Oct 30, 2020
<u>AB</u>		<u>2MG</u>	<u>A210249</u>	<u>002</u>	Oct 30, 2020
<u>AB</u>		<u>3MG</u>	<u>A210249</u>	<u>003</u>	Oct 30, 2020
<u>AB</u>		<u>4MG</u>	<u>A210249</u>	<u>004</u>	Oct 30, 2020

POMALYST

<u>AB</u>	+ CELGENE	<u>1MG</u>	<u>N204026</u>	<u>001</u>	Feb 08, 2013
<u>AB</u>	+	<u>2MG</u>	<u>N204026</u>	<u>002</u>	Feb 08, 2013
<u>AB</u>	+	<u>3MG</u>	<u>N204026</u>	<u>003</u>	Feb 08, 2013
<u>AB</u>	+!	<u>4MG</u>	<u>N204026</u>	<u>004</u>	Feb 08, 2013

PONATINIB HYDROCHLORIDE

TABLET; ORAL

ICLUSIG

+	ARIAD	EQ 10MG BASE	N203469	004	Dec 18, 2020
+		EQ 15MG BASE	N203469	001	Dec 14, 2012
+		EQ 30MG BASE	N203469	003	Apr 23, 2015
+	!	EQ 45MG BASE	N203469	002	Dec 14, 2012

PORFIMER SODIUM

INJECTABLE; INJECTION

PHOTOFRIN

	PINNACLE BIOLGS	75MG/VIAL	N020451	001	Dec 27, 1995
--	-----------------	-----------	---------	-----	--------------

POSACONAZOLE

SOLUTION; INTRAVENOUS

NOXAFIL

+	MERCK SHARP DOHME	300MG/16.7ML (18MG/ML)	N205596	001	Mar 13, 2014
---	-------------------	------------------------	---------	-----	--------------

SUSPENSION; ORAL

NOXAFIL

+	SCHERING	40MG/ML	N022003	001	Sep 15, 2006
---	----------	---------	---------	-----	--------------

TABLET, DELAYED RELEASE; ORAL

NOXAFIL

<u>AB</u>	+	MERCK SHARP DOHME	<u>100MG</u>	<u>N205053</u>	<u>001</u>	Nov 25, 2013
-----------	---	-------------------	--------------	----------------	------------	--------------

POSACONAZOLE

<u>AB</u>	SINOTHEAPEUTICS INC	<u>100MG</u>	<u>A212411</u>	<u>001</u>	Aug 21, 2019
-----------	---------------------	--------------	----------------	------------	--------------

POTASSIUM ACETATE

INJECTABLE; INJECTION

POTASSIUM ACETATE

<u>AP</u>	EXELA PHARMA	<u>2MEQ/ML</u>	<u>A206203</u>	<u>001</u>	Dec 29, 2015	
<u>AP</u>	+	HOSPIRA	<u>2MEQ/ML</u>	<u>N018896</u>	<u>001</u>	Jul 20, 1984

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

KLOR-CON

<u>AB</u>	UPSHER SMITH LABS	<u>8MEQ</u>	<u>A203106</u>	<u>001</u>	Jul 10, 2015
<u>AB</u>		<u>10MEQ</u>	<u>A203106</u>	<u>002</u>	Jul 10, 2015

POTASSIUM CHLORIDE

<u>AB</u>	ACTAVIS LABS FL INC	<u>8MEQ</u>	<u>A077419</u>	<u>001</u>	Jun 02, 2008
<u>AB</u>	!	<u>10MEQ</u>	<u>A077419</u>	<u>002</u>	Jun 02, 2008
<u>AB</u>	ADARE PHARMS INC	<u>8MEQ</u>	<u>A208864</u>	<u>001</u>	Mar 17, 2017
<u>AB</u>		<u>10MEQ</u>	<u>A208864</u>	<u>002</u>	Mar 17, 2017
<u>AB</u>	AMNEAL PHARMS	<u>10MEQ</u>	<u>A202128</u>	<u>001</u>	Feb 22, 2013
<u>AB</u>	ANCHEN PHARMS	<u>8MEQ</u>	<u>A202886</u>	<u>001</u>	Dec 26, 2013
<u>AB</u>		<u>10MEQ</u>	<u>A202886</u>	<u>002</u>	Dec 26, 2013
<u>AB</u>	GLENMARK PHARMS LTD	<u>10MEQ</u>	<u>A202868</u>	<u>001</u>	Jan 19, 2016
<u>AB</u>	LANNETT CO INC	<u>8MEQ</u>	<u>A204210</u>	<u>001</u>	Mar 28, 2016
<u>AB</u>		<u>10MEQ</u>	<u>A204210</u>	<u>002</u>	Mar 28, 2016
<u>AB</u>	LUPIN LTD	<u>8MEQ</u>	<u>A203002</u>	<u>001</u>	Dec 18, 2015
<u>AB</u>		<u>10MEQ</u>	<u>A203002</u>	<u>002</u>	Dec 18, 2015
<u>AB</u>	NOVEL LABS INC	<u>8MEQ</u>	<u>A204828</u>	<u>001</u>	Aug 16, 2016
<u>AB</u>		<u>10MEQ</u>	<u>A204828</u>	<u>002</u>	Aug 16, 2016
<u>AB</u>	PADDOCK LLC	<u>8MEQ</u>	<u>A200185</u>	<u>001</u>	May 18, 2011
<u>AB</u>		<u>10MEQ</u>	<u>A200185</u>	<u>002</u>	May 18, 2011
<u>AB</u>	PRINSTON INC	<u>8MEQ</u>	<u>A209026</u>	<u>001</u>	Jun 11, 2019
<u>AB</u>		<u>10MEQ</u>	<u>A209026</u>	<u>002</u>	Jun 11, 2019
<u>AB</u>	STRIDES PHARMA	<u>8MEQ</u>	<u>A205549</u>	<u>001</u>	Dec 08, 2015

PRESCRIPTION DRUG PRODUCT LIST

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

<u>AB</u>		<u>10MEQ</u>	<u>A205549 002</u>	Dec 08, 2015
<u>AB</u>	TRIS PHARMA INC	<u>8MEQ</u>	<u>A201944 001</u>	Mar 04, 2016
<u>AB</u>		<u>10MEQ</u>	<u>A201944 002</u>	Mar 04, 2016
<u>AB</u>	ZYDUS PHARMS	<u>8MEQ</u>	<u>A208445 001</u>	Mar 11, 2019
<u>AB</u>		<u>10MEQ</u>	<u>A208445 002</u>	Mar 11, 2019

FOR SOLUTION;ORAL

KLOR-CON

<u>AA</u>	UPSHER SMITH LABS	<u>20MEQ</u>	<u>A209662 001</u>	Oct 23, 2017
-----------	-------------------	--------------	--------------------	--------------

POTASSIUM CHLORIDE

<u>AA</u>	AMNEAL	<u>20MEQ</u>	<u>A210902 001</u>	May 23, 2019
<u>AA</u>	BELCHER	<u>20MEQ</u>	<u>A212183 001</u>	May 06, 2019
<u>AA</u>	EPIC PHARMA LLC	<u>20MEQ</u>	<u>A210200 001</u>	Nov 23, 2018
<u>AA</u>	NOVEL LABS INC	<u>20MEQ</u>	<u>A210241 001</u>	Nov 21, 2018
<u>AA</u>	+! PHARMA RES SOFTWARE	<u>20MEQ</u>	<u>N208019 001</u>	Aug 19, 2015

INJECTABLE;INJECTION

POTASSIUM CHLORIDE

<u>AP</u>	B BRAUN	<u>2MEQ/ML</u>	<u>A085870 001</u>	
<u>AP</u>	FRESENIUS KABI USA	<u>2MEQ/ML</u>	<u>A080225 001</u>	
<u>AP</u>	! HOSPIRA	<u>2MEQ/ML</u>	<u>A080205 001</u>	

POTASSIUM CHLORIDE 10MEQ

<u>AP</u>	FRESENIUS KABI USA	<u>14.9MG/ML</u>	<u>A211087 001</u>	Sep 09, 2020
<u>AP</u>		<u>746MG/100ML</u>	<u>A211087 002</u>	Sep 09, 2020

POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

<u>AP</u>	+! BAXTER HLTHCARE	<u>14.9MG/ML</u>	<u>N019904 001</u>	Dec 26, 1989
<u>AP</u>	+!	<u>746MG/100ML</u>	<u>N019904 005</u>	Dec 17, 1990
<u>AP</u>	+! ICU MEDICAL INC	<u>14.9MG/ML</u>	<u>N020161 005</u>	Nov 30, 1992
<u>AP</u>	+!	<u>745MG/100ML</u>	<u>N020161 001</u>	Nov 30, 1992

POTASSIUM CHLORIDE 20MEQ

<u>AP</u>	FRESENIUS KABI USA	<u>29.8MG/ML</u>	<u>A211087 003</u>	Sep 09, 2020
-----------	--------------------	------------------	--------------------	--------------

POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER

<u>AP</u>	+! BAXTER HLTHCARE	<u>29.8MG/ML</u>	<u>N019904 002</u>	Dec 26, 1989
<u>AP</u>	+!	<u>1.49GM/100ML</u>	<u>N019904 006</u>	Dec 17, 1990
<u>AP</u>	+! ICU MEDICAL INC	<u>29.8MG/ML</u>	<u>N020161 006</u>	Aug 11, 1998
<u>AP</u>	+!	<u>1.49GM/100ML</u>	<u>N020161 002</u>	Nov 30, 1992

POTASSIUM CHLORIDE 40MEQ

<u>AP</u>	FRESENIUS KABI USA	<u>2.98GM/100ML</u>	<u>A211087 004</u>	Sep 09, 2020
-----------	--------------------	---------------------	--------------------	--------------

POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER

<u>AP</u>	+! BAXTER HLTHCARE	<u>2.98GM/100ML</u>	<u>N019904 004</u>	Dec 26, 1989
<u>AP</u>	+! ICU MEDICAL INC	<u>2.98GM/100ML</u>	<u>N020161 004</u>	Aug 11, 1998

POTASSIUM CHLORIDE IN PLASTIC CONTAINER

<u>AP</u>	FRESENIUS KABI USA	<u>2MEQ/ML</u>	<u>A088901 001</u>	Jan 25, 1985
<u>AP</u>		<u>2MEQ/ML</u>	<u>A088908 001</u>	Jan 25, 1985

POTASSIUM CHLORIDE

! FRESENIUS KABI USA 3MEQ/ML A080225 003

POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER

+! BAXTER HLTHCARE 2.24GM/100ML N019904 003 Dec 26, 1989

SOLUTION;ORAL

POTASSIUM CHLORIDE

<u>AA</u>	AMNEAL	<u>20MEQ/15ML</u>	<u>A210041 001</u>	Jul 19, 2018
<u>AA</u>		<u>40MEQ/15ML</u>	<u>A210041 002</u>	Jul 19, 2018
<u>AA</u>	APOTEX	<u>20MEQ/15ML</u>	<u>A211067 001</u>	Aug 08, 2018
<u>AA</u>		<u>40MEQ/15ML</u>	<u>A211067 002</u>	Aug 08, 2018
<u>AA</u>	+ GENUS LIFESCIENCES	<u>20MEQ/15ML</u>	<u>N206814 001</u>	Dec 22, 2014
<u>AA</u>	+!	<u>40MEQ/15ML</u>	<u>N206814 002</u>	Dec 22, 2014
<u>AA</u>	NOVEL LABS INC	<u>20MEQ/15ML</u>	<u>A209786 001</u>	Aug 29, 2018
<u>AA</u>		<u>40MEQ/15ML</u>	<u>A209786 002</u>	Aug 29, 2018
<u>AA</u>	PHARM ASSOC	<u>20MEQ/15ML</u>	<u>A210766 001</u>	Mar 29, 2019
<u>AA</u>		<u>40MEQ/15ML</u>	<u>A210766 002</u>	Mar 29, 2019

TABLET, EXTENDED RELEASE;ORAL

KLOR-CON M10

<u>AB1</u>	UPSHER SMITH LABS	<u>10MEQ</u>	<u>A074726 002</u>	Aug 09, 2000
------------	-------------------	--------------	--------------------	--------------

KLOR-CON M15

<u>AB1</u>	UPSHER SMITH LABS	<u>15MEQ</u>	<u>A074726 003</u>	Jun 06, 2003
------------	-------------------	--------------	--------------------	--------------

KLOR-CON M20

<u>AB1</u>	! UPSHER SMITH LABS	<u>20MEQ</u>	<u>A074726 001</u>	Nov 20, 1998
------------	---------------------	--------------	--------------------	--------------

POTASSIUM CHLORIDE

<u>AB1</u>	ACTAVIS LABS FL INC	<u>10MEQ</u>	<u>A075604 001</u>	Apr 10, 2002
<u>AB1</u>		<u>20MEQ</u>	<u>A075604 002</u>	Apr 10, 2002
<u>AB1</u>	ADARE PHARMS INC	<u>10MEQ</u>	<u>A076368 002</u>	Jun 05, 2019

PRESCRIPTION DRUG PRODUCT LIST

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

<u>AB1</u>		<u>20MEQ</u>	<u>A076368 001</u>	Aug 18, 2004
<u>AB1</u>	AMNEAL	<u>10MEQ</u>	<u>A212861 001</u>	May 08, 2020
<u>AB1</u>		<u>20MEQ</u>	<u>A212861 003</u>	May 08, 2020
<u>AB1</u>	ASCENT PHARMS INC	<u>10MEQ</u>	<u>A214422 001</u>	Dec 29, 2020
<u>AB1</u>		<u>15MEQ</u>	<u>A214422 002</u>	Dec 29, 2020
<u>AB1</u>		<u>20MEQ</u>	<u>A214422 003</u>	Dec 29, 2020
<u>AB1</u>	CENTAUR PHARMS PVT	<u>10MEQ</u>	<u>A213588 001</u>	Aug 21, 2020
<u>AB1</u>		<u>20MEQ</u>	<u>A213588 002</u>	Aug 21, 2020
<u>AB1</u>	GLENMARK PHARMS LTD	<u>10MEQ</u>	<u>A203562 001</u>	Jul 26, 2016
<u>AB1</u>		<u>20MEQ</u>	<u>A203562 002</u>	Jul 26, 2016
<u>AB1</u>	GRANULES	<u>10MEQ</u>	<u>A214452 001</u>	Oct 21, 2020
<u>AB1</u>		<u>20MEQ</u>	<u>A214452 002</u>	Oct 21, 2020
<u>AB1</u>	NOVEL LABS INC	<u>10MEQ</u>	<u>A206347 001</u>	Jan 21, 2016
<u>AB1</u>		<u>20MEQ</u>	<u>A206347 002</u>	Jan 21, 2016
<u>AB1</u>	PRINSTON INC	<u>10MEQ</u>	<u>A209922 001</u>	Apr 30, 2019
<u>AB1</u>		<u>15MEQ</u>	<u>A209922 002</u>	Apr 30, 2019
<u>AB1</u>		<u>20MEQ</u>	<u>A209922 003</u>	Apr 30, 2019
<u>AB1</u>	ZYDUS PHARMS	<u>10MEQ</u>	<u>A210395 001</u>	Sep 17, 2020
<u>AB1</u>		<u>20MEQ</u>	<u>A210395 002</u>	Sep 17, 2020

KLOR-CON

<u>AB2</u>	+ UPSHER SMITH LABS	<u>8MEQ</u>	<u>N019123 001</u>	Apr 17, 1986
<u>AB2</u>	+!	<u>10MEQ</u>	<u>N019123 002</u>	Apr 17, 1986

POTASSIUM CHLORIDE

<u>AB2</u>	AUROBINDO PHARMA LTD	<u>8MEQ</u>	<u>A210921 001</u>	Dec 19, 2018
<u>AB2</u>		<u>10MEQ</u>	<u>A210921 002</u>	Dec 19, 2018
<u>AB2</u>	GRANULES PHARMS	<u>8MEQ</u>	<u>A211797 001</u>	Mar 04, 2020
<u>AB2</u>		<u>10MEQ</u>	<u>A211797 002</u>	Mar 04, 2020
<u>AB2</u>	MYLAN	<u>8MEQ</u>	<u>A204662 001</u>	Aug 21, 2014
<u>AB2</u>		<u>10MEQ</u>	<u>A204662 002</u>	Aug 21, 2014
<u>AB2</u>	NOVEL LABS INC	<u>8MEQ</u>	<u>A206759 001</u>	Aug 09, 2016
<u>AB2</u>		<u>10MEQ</u>	<u>A206759 002</u>	Aug 09, 2016
<u>AB2</u>	PADDOCK LABS LLC	<u>8MEQ</u>	<u>A205993 001</u>	Nov 05, 2015
<u>AB2</u>		<u>10MEQ</u>	<u>A205993 002</u>	Nov 05, 2015
<u>AB2</u>	SIGMAPHARM LABS LLC	<u>8MEQ</u>	<u>A207528 001</u>	Aug 19, 2016
<u>AB2</u>		<u>10MEQ</u>	<u>A207528 002</u>	Aug 19, 2016
<u>AB2</u>	STRIDES PHARMA	<u>8MEQ</u>	<u>A210733 001</u>	Aug 31, 2018
<u>AB2</u>		<u>10MEQ</u>	<u>A210733 002</u>	Aug 31, 2018
<u>AB2</u>	YICHANG HUMANWELL	<u>8MEQ</u>	<u>A209314 001</u>	Jun 22, 2018
<u>AB2</u>		<u>10MEQ</u>	<u>A209314 002</u>	Jun 22, 2018

K-TAB

<u>AB3</u>	+ ABBVIE	<u>10MEQ</u>	<u>N018279 001</u>	
<u>AB3</u>	+!	<u>20MEQ</u>	<u>N018279 003</u>	Nov 25, 2013

POTASSIUM CHLORIDE

<u>AB3</u>	VITRUVIAS THERAP	<u>10MEQ</u>	<u>A209688 001</u>	Jan 12, 2018
<u>AB3</u>		<u>20MEQ</u>	<u>A209688 002</u>	Jan 12, 2018
<u>AB3</u>	YICHANG HUMANWELL	<u>10MEQ</u>	<u>A212561 001</u>	Sep 30, 2019
<u>AB3</u>		<u>20MEQ</u>	<u>A212561 002</u>	Sep 30, 2019

K-TAB

BC	+ ABBVIE	8MEQ	N018279 002	Aug 01, 1988
----	----------	------	-------------	--------------

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

<u>AP</u>	ICU MEDICAL INC	<u>149MG/100ML; 450MG/100ML</u>	<u>A078446 001</u>	Sep 10, 2008
-----------	-----------------	---------------------------------	--------------------	--------------

POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%

<u>AP</u>	FRESENIUS KABI USA	<u>150MG/100ML; 450MG/100ML</u>	<u>A212347 001</u>	Sep 17, 2020
-----------	--------------------	---------------------------------	--------------------	--------------

POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

<u>AP</u>	+! BAXTER HLTHCARE	<u>150MG/100ML; 450MG/100ML</u>	<u>N017648 005</u>	Nov 26, 2002
-----------	--------------------	---------------------------------	--------------------	--------------

POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>150MG/100ML; 900MG/100ML</u>	<u>N019708 004</u>	Sep 29, 1989
-----------	---------	---------------------------------	--------------------	--------------

<u>AP</u>	+ BAXTER HLTHCARE	<u>150MG/100ML; 900MG/100ML</u>	<u>N017648 001</u>	
-----------	-------------------	---------------------------------	--------------------	--

POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%

<u>AP</u>	FRESENIUS KABI USA	<u>300MG/100ML; 900MG/100ML</u>	<u>A212347 002</u>	Sep 17, 2020
-----------	--------------------	---------------------------------	--------------------	--------------

POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	+ BAXTER HLTHCARE	<u>300MG/100ML; 900MG/100ML</u>	<u>N017648 002</u>	
-----------	-------------------	---------------------------------	--------------------	--

POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	ICU MEDICAL INC	<u>149MG/100ML; 900MG/100ML</u>	<u>N019686 001</u>	Oct 17, 1988
-----------	-----------------	---------------------------------	--------------------	--------------

POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	ICU MEDICAL INC	<u>298MG/100ML; 900MG/100ML</u>	<u>N019686 002</u>	Oct 17, 1988
-----------	-----------------	---------------------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CITRATE

<u>AB</u>		ANI PHARMS INC	<u>10MEQ</u>	<u>A212779 001</u>	Jan 14, 2020
<u>AB</u>			<u>15MEQ</u>	<u>A212779 002</u>	Jan 14, 2020
<u>AB</u>		BIONPHARMA INC	<u>10MEQ</u>	<u>A212799 001</u>	Jun 29, 2020
<u>AB</u>			<u>15MEQ</u>	<u>A212799 002</u>	Jun 29, 2020
<u>AB</u>		RISING	<u>5MEQ</u>	<u>A077440 001</u>	Jun 09, 2006
<u>AB</u>			<u>10MEQ</u>	<u>A077440 002</u>	Jun 09, 2006
<u>AB</u>		STRIDES PHARMA	<u>5MEQ</u>	<u>A206813 001</u>	Sep 11, 2017
<u>AB</u>			<u>10MEQ</u>	<u>A206813 002</u>	Sep 11, 2017
<u>AB</u>			<u>15MEQ</u>	<u>A206813 003</u>	Sep 11, 2017
<u>AB</u>		TEVA PHARMS USA INC	<u>5MEQ</u>	<u>A209758 001</u>	Mar 05, 2018
<u>AB</u>			<u>10MEQ</u>	<u>A209758 002</u>	Mar 05, 2018
<u>AB</u>			<u>15MEQ</u>	<u>A209758 003</u>	Mar 05, 2018
<u>AB</u>		ZYDUS PHARMS	<u>5MEQ</u>	<u>A203546 001</u>	Aug 06, 2014
<u>AB</u>			<u>10MEQ</u>	<u>A203546 002</u>	Aug 06, 2014
<u>AB</u>			<u>15MEQ</u>	<u>A203546 003</u>	Aug 06, 2014

UROCIIT-K

<u>AB</u>	+	MISSION PHARMA	<u>5MEQ</u>	<u>N019071 001</u>	Aug 30, 1985
<u>AB</u>	+		<u>10MEQ</u>	<u>N019071 002</u>	Aug 31, 1992
<u>AB</u>	+		<u>15MEQ</u>	<u>N019071 003</u>	Dec 30, 2009

POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC

SOLUTION;INTRAVENOUS

POTASSIUM PHOSPHATES

+	!	CMP DEV LLC	4.5GM/15ML (300MG/ML);2.65GM/15ML (175MG/ML)	N212121 001	Sep 19, 2019
+	!	FRESENIUS KABI USA	1.18GM/5ML (236MG/ML);1.12GM/5ML (224MG/ML)	N212832 001	Nov 26, 2019
+	!		3.54GM/15ML (236MG/ML);3.36GM/15ML (224MG/ML)	N212832 002	Nov 26, 2019
+	!		11.8GM/50ML (236MG/ML);11.2GM/50ML (224MG/ML)	N212832 003	Nov 26, 2019

POVIDONE-IODINE

SOLUTION/DROPS;OPHTHALMIC

BETADINE

+	!	ALCON PHARMS LTD	5%	N018634 001	Dec 17, 1986
---	---	------------------	----	-------------	--------------

PRALATREXATE

SOLUTION;INTRAVENOUS

FOLOTYN

+		ACROTECH	20MG/ML (20MG/ML)	N022468 001	Sep 24, 2009
+	!		40MG/2ML (20MG/ML)	N022468 002	Sep 24, 2009

PRALIDOXIME CHLORIDE

INJECTABLE;INJECTION

PROTOPAM CHLORIDE

+	!	BAXTER HLTHCARE CORP	1GM/VIAL	N014134 001	
---	---	----------------------	----------	-------------	--

PRALSETINIB

CAPSULE;ORAL

GAVRETO

+	!	BLUEPRINT MEDICINES	100MG	N213721 001	Sep 04, 2020
---	---	---------------------	-------	-------------	--------------

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

MIRAPEX

<u>AB</u>	+	BOEHRINGER INGELHEIM	<u>0.125MG</u>	<u>N020667 001</u>	Jul 01, 1997
<u>AB</u>	+		<u>0.25MG</u>	<u>N020667 002</u>	Jul 01, 1997
<u>AB</u>	+		<u>0.5MG</u>	<u>N020667 006</u>	Feb 12, 1998
<u>AB</u>	+		<u>0.75MG</u>	<u>N020667 007</u>	Jul 30, 2007
<u>AB</u>	+		<u>1MG</u>	<u>N020667 003</u>	Jul 01, 1997
<u>AB</u>	+		<u>1.5MG</u>	<u>N020667 005</u>	Jul 01, 1997

PRAMIPEXOLE DIHYDROCHLORIDE

<u>AB</u>		AUROBINDO PHARMA LTD	<u>0.125MG</u>	<u>A202633 001</u>	Oct 26, 2012
<u>AB</u>			<u>0.25MG</u>	<u>A202633 002</u>	Oct 26, 2012
<u>AB</u>			<u>0.5MG</u>	<u>A202633 003</u>	Oct 26, 2012
<u>AB</u>			<u>0.75MG</u>	<u>A202633 004</u>	Oct 26, 2012
<u>AB</u>			<u>1MG</u>	<u>A202633 005</u>	Oct 26, 2012
<u>AB</u>			<u>1.5MG</u>	<u>A202633 006</u>	Oct 26, 2012
<u>AB</u>		BRECKENRIDGE PHARM	<u>0.125MG</u>	<u>A091450 001</u>	Oct 08, 2010
<u>AB</u>			<u>0.25MG</u>	<u>A091450 002</u>	Oct 08, 2010

PRESCRIPTION DRUG PRODUCT LIST

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

<u>AB</u>		<u>0.5MG</u>	<u>A091450 003</u>	Oct 08, 2010
<u>AB</u>		<u>1MG</u>	<u>A091450 004</u>	Oct 08, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A091450 005</u>	Oct 08, 2010
<u>AB</u>	GLENMARK GENERICS	<u>0.125MG</u>	<u>A090781 001</u>	Oct 08, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A090781 002</u>	Oct 08, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A090781 003</u>	Oct 08, 2010
<u>AB</u>		<u>0.75MG</u>	<u>A090781 006</u>	Sep 11, 2015
<u>AB</u>		<u>1MG</u>	<u>A090781 004</u>	Oct 08, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A090781 005</u>	Oct 08, 2010
<u>AB</u>	RISING	<u>0.25MG</u>	<u>A211088 001</u>	Oct 03, 2018
<u>AB</u>		<u>0.5MG</u>	<u>A211088 002</u>	Oct 03, 2018
<u>AB</u>		<u>0.75MG</u>	<u>A211088 003</u>	Oct 03, 2018
<u>AB</u>		<u>1MG</u>	<u>A211088 004</u>	Oct 03, 2018
<u>AB</u>		<u>1.5MG</u>	<u>A211088 005</u>	Oct 03, 2018
<u>AB</u>	SCIEGEN PHARMS INC	<u>0.125MG</u>	<u>A203855 001</u>	Oct 28, 2014
<u>AB</u>		<u>0.25MG</u>	<u>A203855 002</u>	Oct 28, 2014
<u>AB</u>		<u>0.5MG</u>	<u>A203855 003</u>	Oct 28, 2014
<u>AB</u>		<u>0.75MG</u>	<u>A203855 004</u>	Oct 28, 2014
<u>AB</u>		<u>1MG</u>	<u>A203855 005</u>	Oct 28, 2014
<u>AB</u>		<u>1.5MG</u>	<u>A203855 006</u>	Oct 28, 2014
<u>AB</u>	STRIDES PHARMA	<u>0.125MG</u>	<u>A202702 001</u>	Jun 03, 2014
<u>AB</u>		<u>0.25MG</u>	<u>A202702 002</u>	Jun 03, 2014
<u>AB</u>		<u>0.5MG</u>	<u>A202702 003</u>	Jun 03, 2014
<u>AB</u>		<u>0.75MG</u>	<u>A202702 004</u>	Jun 03, 2014
<u>AB</u>		<u>1MG</u>	<u>A202702 005</u>	Jun 03, 2014
<u>AB</u>		<u>1.5MG</u>	<u>A202702 006</u>	Jun 03, 2014
<u>AB</u>	TORRENT PHARMS	<u>0.125MG</u>	<u>A090865 001</u>	Oct 08, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A090865 002</u>	Oct 08, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A090865 003</u>	Oct 08, 2010
<u>AB</u>		<u>0.75MG</u>	<u>A090865 004</u>	Oct 08, 2010
<u>AB</u>		<u>1MG</u>	<u>A090865 005</u>	Oct 08, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A090865 006</u>	Oct 08, 2010
<u>AB</u>	ZENNOVA	<u>0.125MG</u>	<u>A090151 001</u>	Apr 30, 2012
<u>AB</u>		<u>0.25MG</u>	<u>A090151 002</u>	Apr 30, 2012
<u>AB</u>		<u>0.5MG</u>	<u>A090151 003</u>	Apr 30, 2012
<u>AB</u>		<u>0.75MG</u>	<u>A090151 006</u>	Apr 30, 2012
<u>AB</u>		<u>1MG</u>	<u>A090151 004</u>	Apr 30, 2012
<u>AB</u>		<u>1.5MG</u>	<u>A090151 005</u>	Apr 30, 2012
<u>AB</u>	ZYDUS PHARMS USA INC	<u>0.125MG</u>	<u>A078920 001</u>	Jul 06, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A078920 002</u>	Jul 06, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A078920 003</u>	Jul 06, 2010
<u>AB</u>		<u>1MG</u>	<u>A078920 004</u>	Jul 06, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A078920 005</u>	Jul 06, 2010

TABLET, EXTENDED RELEASE; ORAL

MIRAPEX ER

<u>AB</u>	+	BOEHRINGER INGELHEIM	<u>0.375MG</u>	<u>N022421 001</u>	Feb 19, 2010
<u>AB</u>	+		<u>0.75MG</u>	<u>N022421 002</u>	Feb 19, 2010
<u>AB</u>	+		<u>1.5MG</u>	<u>N022421 003</u>	Feb 19, 2010
<u>AB</u>	+		<u>2.25MG</u>	<u>N022421 006</u>	Jun 17, 2011
<u>AB</u>	+		<u>3MG</u>	<u>N022421 004</u>	Feb 19, 2010
<u>AB</u>	+		<u>3.75MG</u>	<u>N022421 007</u>	Jun 17, 2011
<u>AB</u>	+		<u>4.5MG</u>	<u>N022421 005</u>	Feb 19, 2010

PRAMIPEXOLE DIHYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>0.375MG</u>	<u>A201963 001</u>	Apr 21, 2016
<u>AB</u>		<u>0.75MG</u>	<u>A201963 002</u>	Apr 21, 2016
<u>AB</u>		<u>1.5MG</u>	<u>A201963 003</u>	Apr 21, 2016
<u>AB</u>		<u>2.25MG</u>	<u>A203615 001</u>	Oct 14, 2016
<u>AB</u>		<u>3MG</u>	<u>A201963 004</u>	Apr 21, 2016
<u>AB</u>		<u>3.75MG</u>	<u>A203615 002</u>	Jan 03, 2017
<u>AB</u>		<u>4.5MG</u>	<u>A201963 005</u>	Apr 21, 2016
<u>AB</u>	ANCHEN PHARMS	<u>0.375MG</u>	<u>A202206 001</u>	Feb 06, 2014
<u>AB</u>		<u>0.75MG</u>	<u>A202206 002</u>	Feb 06, 2014
<u>AB</u>		<u>1.5MG</u>	<u>A202206 003</u>	Feb 06, 2014
<u>AB</u>		<u>2.25MG</u>	<u>A202206 004</u>	Feb 06, 2014
<u>AB</u>		<u>3MG</u>	<u>A202206 005</u>	Feb 06, 2014
<u>AB</u>		<u>3.75MG</u>	<u>A202206 006</u>	Feb 06, 2014
<u>AB</u>		<u>4.5MG</u>	<u>A202206 007</u>	Feb 06, 2014
<u>AB</u>	DR REDDYS	<u>0.375MG</u>	<u>A203354 001</u>	Aug 07, 2015

PRESCRIPTION DRUG PRODUCT LIST

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

<u>AB</u>		<u>0.75MG</u>	<u>A203354 002</u>	Aug 07, 2015
<u>AB</u>		<u>1.5MG</u>	<u>A203354 003</u>	Aug 07, 2015
<u>AB</u>		<u>3MG</u>	<u>A203354 004</u>	Aug 07, 2015
<u>AB</u>		<u>4.5MG</u>	<u>A203354 005</u>	Aug 07, 2015
<u>AB</u>	MACLEODS PHARMS LTD	<u>0.375MG</u>	<u>A206156 001</u>	Jun 24, 2016
<u>AB</u>		<u>0.75MG</u>	<u>A206156 002</u>	Jun 24, 2016
<u>AB</u>		<u>1.5MG</u>	<u>A206156 003</u>	Jun 24, 2016
<u>AB</u>		<u>2.25MG</u>	<u>A206156 004</u>	Jun 24, 2016
<u>AB</u>		<u>3MG</u>	<u>A206156 005</u>	Jun 24, 2016
<u>AB</u>		<u>3.75MG</u>	<u>A206156 007</u>	Jan 23, 2017
<u>AB</u>		<u>4.5MG</u>	<u>A206156 006</u>	Jun 24, 2016
<u>AB</u>	SANDOZ INC	<u>0.375MG</u>	<u>A202353 001</u>	Dec 04, 2014
<u>AB</u>		<u>0.75MG</u>	<u>A202353 002</u>	Dec 04, 2014
<u>AB</u>		<u>1.5MG</u>	<u>A202353 003</u>	Dec 04, 2014
<u>AB</u>		<u>3MG</u>	<u>A202353 004</u>	Dec 04, 2014
<u>AB</u>		<u>4.5MG</u>	<u>A202353 005</u>	Dec 04, 2014
<u>AB</u>	ZYDUS PHARMS	<u>0.375MG</u>	<u>A202891 001</u>	Dec 12, 2017
<u>AB</u>		<u>0.75MG</u>	<u>A202891 002</u>	Dec 12, 2017
<u>AB</u>		<u>1.5MG</u>	<u>A202891 003</u>	Dec 12, 2017
<u>AB</u>		<u>2.25MG</u>	<u>A202891 004</u>	Dec 12, 2017
<u>AB</u>		<u>3MG</u>	<u>A202891 005</u>	Dec 12, 2017
<u>AB</u>		<u>3.75MG</u>	<u>A202891 006</u>	Dec 12, 2017
<u>AB</u>		<u>4.5MG</u>	<u>A202891 007</u>	Dec 12, 2017

PRAMLINTIDE ACETATE

INJECTABLE;SUBCUTANEOUS

SYMLIN

+	ASTRAZENECA AB	EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML)	N021332 002	Sep 25, 2007
+	!	EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)	N021332 003	Sep 25, 2007

PRASTERONE

INSERT;VAGINAL

INTRAROSA

+	!	MILLICENT	6.5MG	N208470 001	Nov 16, 2016
---	---	-----------	-------	-------------	--------------

PRASUGREL HYDROCHLORIDE

TABLET;ORAL

EFFIENT

<u>AB</u>	+	DAIICHI SANKYO INC	<u>EQ 5MG BASE</u>	<u>N022307 001</u>	Jul 10, 2009
<u>AB</u>	+	!	<u>EQ 10MG BASE</u>	<u>N022307 002</u>	Jul 10, 2009

PRASUGREL

<u>AB</u>		ACCORD HLTHCARE	<u>EQ 5MG BASE</u>	<u>A205987 001</u>	Feb 02, 2018
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A205987 002</u>	Feb 02, 2018
<u>AB</u>		AMNEAL PHARMS	<u>EQ 5MG BASE</u>	<u>A205913 001</u>	Jun 19, 2018
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A205913 002</u>	Jun 19, 2018
<u>AB</u>		ANDA REPOSITORY	<u>EQ 5MG BASE</u>	<u>A205790 001</u>	Oct 16, 2017
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A205790 002</u>	Oct 16, 2017
<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 5MG BASE</u>	<u>A205888 001</u>	Oct 16, 2017
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A205888 002</u>	Oct 16, 2017
<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 5MG BASE</u>	<u>A205926 001</u>	Jul 07, 2020
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A205926 002</u>	Jul 07, 2020
<u>AB</u>		HEC PHARM	<u>EQ 5MG BASE</u>	<u>A206021 001</u>	Jan 16, 2019
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A206021 002</u>	Jan 16, 2019
<u>AB</u>		MYLAN	<u>EQ 5MG BASE</u>	<u>A205927 001</u>	Jul 12, 2017
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A205927 002</u>	Jul 12, 2017
<u>AB</u>		PANACEA BIOTEC LTD	<u>EQ 5MG BASE</u>	<u>A205897 001</u>	Oct 16, 2017
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A205897 002</u>	Oct 16, 2017

PRAVASTATIN SODIUM

TABLET;ORAL

PRAVACHOL

<u>AB</u>	+	BRISTOL MYERS SQUIBB	<u>20MG</u>	<u>N019898 003</u>	Oct 31, 1991
<u>AB</u>	+		<u>40MG</u>	<u>N019898 004</u>	Mar 22, 1993
<u>AB</u>	+	!	<u>80MG</u>	<u>N019898 008</u>	Dec 18, 2001

PRAVASTATIN SODIUM

<u>AB</u>		ACCORD HLTHCARE	<u>10MG</u>	<u>A207068 001</u>	Nov 17, 2016
<u>AB</u>			<u>20MG</u>	<u>A207068 002</u>	Nov 17, 2016
<u>AB</u>			<u>40MG</u>	<u>A207068 003</u>	Nov 17, 2016
<u>AB</u>			<u>80MG</u>	<u>A207068 004</u>	Nov 17, 2016
<u>AB</u>		APNAR PHARMA LP	<u>10MG</u>	<u>A077491 002</u>	Oct 23, 2006

PRESCRIPTION DRUG PRODUCT LIST

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVASTATIN SODIUM

<u>AB</u>		<u>20MG</u>	<u>A077491 003</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A077491 004</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A077491 001</u>	Feb 11, 2008
<u>AB</u>	APOTEX	<u>10MG</u>	<u>A076341 001</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A076341 002</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A076341 003</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A076341 004</u>	Dec 28, 2007
<u>AB</u>	AUROBINDO PHARMA LTD	<u>10MG</u>	<u>A203367 001</u>	Feb 02, 2017
<u>AB</u>		<u>20MG</u>	<u>A203367 002</u>	Feb 02, 2017
<u>AB</u>		<u>40MG</u>	<u>A203367 003</u>	Feb 02, 2017
<u>AB</u>		<u>80MG</u>	<u>A203367 004</u>	Feb 02, 2017
<u>AB</u>	BIOCON PHARMA	<u>10MG</u>	<u>A209869 001</u>	Apr 13, 2018
<u>AB</u>		<u>20MG</u>	<u>A209869 002</u>	Apr 13, 2018
<u>AB</u>		<u>40MG</u>	<u>A209869 003</u>	Apr 13, 2018
<u>AB</u>		<u>80MG</u>	<u>A209869 004</u>	Apr 13, 2018
<u>AB</u>	CIPLA	<u>10MG</u>	<u>A077904 001</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A077904 002</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A077904 003</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A077904 004</u>	Mar 22, 2016
<u>AB</u>	DR REDDYS LABS INC	<u>10MG</u>	<u>A076714 001</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A076714 002</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A076714 003</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A076714 004</u>	Dec 28, 2007
<u>AB</u>	GLENMARK GENERICS	<u>10MG</u>	<u>A077987 001</u>	May 11, 2007
<u>AB</u>		<u>20MG</u>	<u>A077987 002</u>	May 11, 2007
<u>AB</u>		<u>40MG</u>	<u>A077987 003</u>	May 11, 2007
<u>AB</u>		<u>80MG</u>	<u>A077987 004</u>	Dec 28, 2007
<u>AB</u>	HISUN PHARM HANGZHOU	<u>20MG</u>	<u>A206061 001</u>	Nov 23, 2018
<u>AB</u>		<u>40MG</u>	<u>A206061 002</u>	Nov 23, 2018
<u>AB</u>		<u>80MG</u>	<u>A206061 003</u>	Nov 23, 2018
<u>AB</u>	LUPIN PHARMS	<u>10MG</u>	<u>A077917 001</u>	Jan 08, 2008
<u>AB</u>		<u>20MG</u>	<u>A077917 002</u>	Jan 08, 2008
<u>AB</u>		<u>40MG</u>	<u>A077917 003</u>	Jan 08, 2008
<u>AB</u>		<u>80MG</u>	<u>A077917 004</u>	Jan 08, 2008
<u>AB</u>	TEVA	<u>10MG</u>	<u>A076056 001</u>	Apr 24, 2006
<u>AB</u>		<u>20MG</u>	<u>A076056 002</u>	Apr 24, 2006
<u>AB</u>		<u>40MG</u>	<u>A076056 003</u>	Apr 24, 2006
<u>AB</u>	TEVA PHARMS	<u>80MG</u>	<u>A077793 001</u>	Jan 15, 2008
<u>AB</u>	WATSON LABS	<u>10MG</u>	<u>A076939 004</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A076939 003</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A076939 002</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A076939 001</u>	Dec 28, 2007
<u>AB</u>	ZYDUS PHARMS USA	<u>20MG</u>	<u>A077751 002</u>	Apr 30, 2008
<u>AB</u>		<u>40MG</u>	<u>A077751 003</u>	Apr 30, 2008
<u>AB</u>		<u>80MG</u>	<u>A077751 004</u>	Apr 30, 2008

PRAZIOUANTEL

TABLET; ORAL

BILTRICIDE

<u>AB</u>	+	BAYER HLTHCARE	<u>600MG</u>	<u>N018714 001</u>	Dec 29, 1982
<u>AB</u>		PAR PHARM INC	<u>600MG</u>	<u>A208820 001</u>	Nov 27, 2017

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

MINIPRESS

<u>AB</u>	+	PFIZER	<u>EQ 1MG BASE</u>	<u>N017442 002</u>	
<u>AB</u>	+		<u>EQ 2MG BASE</u>	<u>N017442 003</u>	
<u>AB</u>	+		<u>EQ 5MG BASE</u>	<u>N017442 001</u>	

PRAZOSIN HYDROCHLORIDE

<u>AB</u>		MYLAN	<u>EQ 1MG BASE</u>	<u>A072575 003</u>	May 16, 1989
<u>AB</u>			<u>EQ 2MG BASE</u>	<u>A072575 002</u>	May 16, 1989
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>A072575 001</u>	May 16, 1989
<u>AB</u>		NOVITIUM PHARMA	<u>EQ 1MG BASE</u>	<u>A210971 001</u>	Oct 03, 2018
<u>AB</u>			<u>EQ 2MG BASE</u>	<u>A210971 002</u>	Oct 03, 2018
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>A210971 003</u>	Oct 03, 2018
<u>AB</u>		TEVA PHARMS	<u>EQ 1MG BASE</u>	<u>A071745 002</u>	Sep 12, 1988
<u>AB</u>			<u>EQ 2MG BASE</u>	<u>A071745 003</u>	Sep 12, 1988
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>A071745 001</u>	Sep 12, 1988

PRESCRIPTION DRUG PRODUCT LIST

PREDNICARBATE

OINTMENT; TOPICAL

PREDNICARBATE

! FOUGERA PHARMS

0.1%

A077236 001 Mar 09, 2007

PREDNISOLONE

SYRUP; ORAL

PREDNISOLONEAA ! AKORN15MG/5MLA040401 001 Feb 27, 2003AA LANNETT CO INC15MG/5MLA040775 001 Sep 21, 2007AA PHARM ASSOC15MG/5MLA040399 001 Mar 05, 2003AA WOCKHARDT BIO AG15MG/5MLA040313 001 Sep 10, 2003PRELONEAA TEVA15MG/5MLA089081 001 Feb 04, 1986

TABLET; ORAL

PREDNISOLONE

! WATSON LABS

5MG

A080354 001

PREDNISOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC

OMNIPREDAB +! NOVARTIS1%N017469 001PRED FORTEAB +! ALLERGAN1%N017011 001

PRED MILD

+! ALLERGAN

0.12%

N017100 001

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC

BLEPHAMIDE S.O.P.

! ALLERGAN

0.2%;10%

A087748 001 Dec 03, 1986

SUSPENSION; OPHTHALMIC

BLEPHAMIDE

+! ALLERGAN

0.2%;10%

N012813 002

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PEDIAPREDAA +! SETON PHARMEQ 5MG BASE/5MLN019157 001 May 28, 1986PREDNISOLONE SODIUM PHOSPHATEAA AKORNEQ 5MG BASE/5MLA075183 001 Mar 26, 2003AA CHARTWELL RXEQ 5MG BASE/5MLA075988 001 May 25, 2004AA EDENBRIDGE PHARMSEQ 10MG BASE/5MLA203559 001 Dec 20, 2016AA PHARM ASSOCEQ 20MG BASE/5MLA203559 002 Dec 20, 2016AA ! PHARM ASSOCEQ 10MG BASE/5MLA078465 001 Mar 07, 2008AA PHARM ASSOCEQ 15MG BASE/5MLA076913 001 Apr 25, 2005AA ! PHARM ASSOCEQ 20MG BASE/5MLA078988 001 Jun 09, 2008AA WOCKHARDT BIO AGEQ 5MG BASE/5MLA075099 001 Jun 28, 2002AA ! PHARM ASSOCEQ 15MG BASE/5MLA076895 001 Oct 04, 2004

! MISSION PHARMA

EQ 25MG BASE/5ML

A091396 001 Sep 13, 2010

PHARM ASSOC

EQ 30MG BASE/5ML

A204962 001 Mar 11, 2020

SOLUTION/DROPS; OPHTHALMIC

PREDNISOLONE SODIUM PHOSPHATE

! BAUSCH AND LOMB

EQ 0.9% PHOSPHATE

A040070 001 Jul 29, 1994

TABLET, ORALLY DISINTEGRATING; ORAL

ORAPRED ODTAB + CONCORDIA PHARMSEQ 10MG BASEN021959 001 Jun 01, 2006

INC

AB + CONCORDIA PHARMSEQ 15MG BASEN021959 002 Jun 01, 2006AB +! CONCORDIA PHARMSEQ 30MG BASEN021959 003 Jun 01, 2006PREDNISOLONE SODIUM PHOSPHATEAB MYLAN PHARMS INCEQ 10MG BASEA202179 001 Apr 10, 2013AB MYLAN PHARMS INCEQ 15MG BASEA202179 002 Apr 10, 2013AB MYLAN PHARMS INCEQ 30MG BASEA202179 003 Apr 10, 2013PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

! BAUSCH AND LOMB

EQ 0.23% PHOSPHATE;10%

A074449 001 Dec 29, 1995

PRESCRIPTION DRUG PRODUCT LIST

PREDNISONE

SOLUTION;ORAL

PREDNISONE

! HIKMA

5MG/5ML

A088703 001 Nov 08, 1984

PREDNISONE INTENSOL

! HIKMA

5MG/ML

A088810 001 Feb 20, 1985

TABLET;ORAL

PREDNISONE

<u>AB</u>		GENEYORK PHARMS	<u>1MG</u>	<u>A211496 001</u>	Dec 28, 2018
<u>AB</u>			<u>2.5MG</u>	<u>A211495 001</u>	Dec 07, 2018
<u>AB</u>			<u>5MG</u>	<u>A211495 002</u>	Dec 07, 2018
<u>AB</u>			<u>10MG</u>	<u>A210525 001</u>	Dec 04, 2018
<u>AB</u>			<u>20MG</u>	<u>A210525 002</u>	Dec 04, 2018
<u>AB</u>			<u>50MG</u>	<u>A210525 003</u>	Dec 04, 2018
<u>AB</u>	!	HIKMA	<u>1MG</u>	<u>A087800 001</u>	Apr 22, 1982
<u>AB</u>	!		<u>2.5MG</u>	<u>A087801 001</u>	Apr 22, 1982
<u>AB</u>	!		<u>5MG</u>	<u>A080352 001</u>	
<u>AB</u>	!		<u>10MG</u>	<u>A084122 001</u>	
<u>AB</u>	!		<u>20MG</u>	<u>A087342 001</u>	
<u>AB</u>	!		<u>50MG</u>	<u>A084283 001</u>	
<u>AB</u>		JUBILANT CADISTA	<u>1MG</u>	<u>A040611 001</u>	Jun 06, 2005
<u>AB</u>			<u>5MG</u>	<u>A040362 002</u>	Aug 29, 2001
<u>AB</u>			<u>10MG</u>	<u>A040362 001</u>	Aug 29, 2001
<u>AB</u>			<u>20MG</u>	<u>A040362 003</u>	Jun 29, 2005
<u>AB</u>		MYLAN	<u>5MG</u>	<u>A080292 001</u>	
<u>AB</u>			<u>10MG</u>	<u>A088832 001</u>	Dec 04, 1985
<u>AB</u>			<u>20MG</u>	<u>A083677 001</u>	
<u>AB</u>		NOVITIUM PHARMA	<u>2.5MG</u>	<u>A211575 001</u>	Nov 15, 2019
<u>AB</u>			<u>5MG</u>	<u>A211575 002</u>	Nov 15, 2019
<u>AB</u>			<u>10MG</u>	<u>A211575 003</u>	Nov 15, 2019
<u>AB</u>			<u>20MG</u>	<u>A211575 004</u>	Nov 15, 2019
<u>AB</u>			<u>50MG</u>	<u>A211575 005</u>	Nov 15, 2019
<u>AB</u>		STRIDES PHARMA	<u>1MG</u>	<u>A210785 001</u>	Sep 02, 2020
<u>AB</u>			<u>2.5MG</u>	<u>A209727 001</u>	Nov 20, 2020
<u>AB</u>			<u>5MG</u>	<u>A209727 002</u>	Nov 20, 2020
<u>AB</u>		SUN PHARM INDUSTRIES	<u>5MG</u>	<u>A089247 002</u>	Dec 04, 1985
<u>AB</u>			<u>10MG</u>	<u>A089247 003</u>	Dec 04, 1985
<u>AB</u>			<u>20MG</u>	<u>A089247 001</u>	Dec 04, 1985
<u>AB</u>		VINTAGE PHARMS	<u>1MG</u>	<u>A040584 001</u>	Dec 21, 2004
<u>AB</u>			<u>2.5MG</u>	<u>A040581 001</u>	Dec 21, 2004
<u>AB</u>			<u>5MG</u>	<u>A040256 001</u>	Jul 12, 2002
<u>AB</u>			<u>10MG</u>	<u>A040256 002</u>	Jul 12, 2002
<u>AB</u>			<u>20MG</u>	<u>A040392 001</u>	Feb 12, 2003
<u>AB</u>		WATSON LABS	<u>5MG</u>	<u>A080356 001</u>	
<u>AB</u>			<u>10MG</u>	<u>A085162 001</u>	
<u>AB</u>			<u>20MG</u>	<u>A085161 001</u>	

TABLET, DELAYED RELEASE;ORAL

RAYOS

+ HORIZON PHARMA USA

1MG

N202020 001 Jul 26, 2012

+

2MG

N202020 002 Jul 26, 2012

+!

5MG

N202020 003 Jul 26, 2012

PREGABALIN

CAPSULE;ORAL

LYRICA

<u>AB</u>	+	PFIZER	<u>25MG</u>	<u>N021446 001</u>	Dec 30, 2004
<u>AB</u>	+		<u>50MG</u>	<u>N021446 002</u>	Dec 30, 2004
<u>AB</u>	+		<u>75MG</u>	<u>N021446 003</u>	Dec 30, 2004
<u>AB</u>	+		<u>100MG</u>	<u>N021446 004</u>	Dec 30, 2004
<u>AB</u>	+		<u>150MG</u>	<u>N021446 005</u>	Dec 30, 2004
<u>AB</u>	+		<u>200MG</u>	<u>N021446 006</u>	Dec 30, 2004
<u>AB</u>	+		<u>225MG</u>	<u>N021446 007</u>	Dec 30, 2004
<u>AB</u>	+	!	<u>300MG</u>	<u>N021446 008</u>	Dec 30, 2004

PREGABALIN

<u>AB</u>		ACTAVIS ELIZABETH	<u>25MG</u>	<u>A091025 001</u>	Jul 09, 2020
<u>AB</u>			<u>50MG</u>	<u>A091025 002</u>	Jul 09, 2020
<u>AB</u>			<u>75MG</u>	<u>A091025 003</u>	Jul 09, 2020
<u>AB</u>			<u>100MG</u>	<u>A091025 004</u>	Jul 09, 2020
<u>AB</u>			<u>150MG</u>	<u>A091025 005</u>	Jul 09, 2020
<u>AB</u>			<u>200MG</u>	<u>A091025 006</u>	Jul 09, 2020
<u>AB</u>			<u>225MG</u>	<u>A091025 007</u>	Jul 09, 2020
<u>AB</u>			<u>300MG</u>	<u>A091025 008</u>	Jul 09, 2020

PRESCRIPTION DRUG PRODUCT LIST

PREGABALIN

CAPSULE; ORAL

PREGABALIN

<u>AB</u>	ALEMbic PHARMS LTD	<u>25MG</u>	<u>A203459 001</u>	Jul 19, 2019
<u>AB</u>		<u>50MG</u>	<u>A203459 002</u>	Jul 19, 2019
<u>AB</u>		<u>75MG</u>	<u>A203459 003</u>	Jul 19, 2019
<u>AB</u>		<u>100MG</u>	<u>A203459 004</u>	Jul 19, 2019
<u>AB</u>		<u>150MG</u>	<u>A203459 005</u>	Jul 19, 2019
<u>AB</u>		<u>200MG</u>	<u>A203459 006</u>	Jul 19, 2019
<u>AB</u>		<u>225MG</u>	<u>A203459 007</u>	Jul 19, 2019
<u>AB</u>		<u>300MG</u>	<u>A203459 008</u>	Jul 19, 2019
<u>AB</u>	ALKEM LABS LTD	<u>25MG</u>	<u>A211177 001</u>	Sep 30, 2019
<u>AB</u>		<u>50MG</u>	<u>A211177 002</u>	Sep 30, 2019
<u>AB</u>		<u>75MG</u>	<u>A207799 001</u>	Jul 19, 2019
<u>AB</u>		<u>100MG</u>	<u>A207799 002</u>	Jul 19, 2019
<u>AB</u>		<u>150MG</u>	<u>A207799 003</u>	Jul 19, 2019
<u>AB</u>		<u>200MG</u>	<u>A207799 004</u>	Jul 19, 2019
<u>AB</u>		<u>225MG</u>	<u>A207799 005</u>	Jul 19, 2019
<u>AB</u>		<u>300MG</u>	<u>A207799 006</u>	Jul 19, 2019
<u>AB</u>	AMNEAL PHARMS CO	<u>25MG</u>	<u>A209743 001</u>	Jul 19, 2019
<u>AB</u>		<u>50MG</u>	<u>A209743 002</u>	Jul 19, 2019
<u>AB</u>		<u>75MG</u>	<u>A209743 003</u>	Jul 19, 2019
<u>AB</u>		<u>100MG</u>	<u>A209743 004</u>	Jul 19, 2019
<u>AB</u>		<u>150MG</u>	<u>A209743 005</u>	Jul 19, 2019
<u>AB</u>		<u>200MG</u>	<u>A209743 006</u>	Jul 19, 2019
<u>AB</u>		<u>225MG</u>	<u>A209743 007</u>	Jul 19, 2019
<u>AB</u>		<u>300MG</u>	<u>A209743 008</u>	Jul 19, 2019
<u>AB</u>	CELLTRION	<u>50MG</u>	<u>A212865 001</u>	Mar 20, 2020
<u>AB</u>		<u>75MG</u>	<u>A212865 002</u>	Mar 20, 2020
<u>AB</u>		<u>100MG</u>	<u>A212865 003</u>	Mar 20, 2020
<u>AB</u>		<u>150MG</u>	<u>A212865 004</u>	Mar 20, 2020
<u>AB</u>	CIPLA	<u>25MG</u>	<u>A212280 001</u>	Jan 10, 2020
<u>AB</u>		<u>50MG</u>	<u>A212280 002</u>	Jan 10, 2020
<u>AB</u>		<u>75MG</u>	<u>A212280 003</u>	Jan 10, 2020
<u>AB</u>		<u>100MG</u>	<u>A212280 004</u>	Jan 10, 2020
<u>AB</u>		<u>150MG</u>	<u>A212280 005</u>	Jan 10, 2020
<u>AB</u>		<u>200MG</u>	<u>A212280 006</u>	Jan 10, 2020
<u>AB</u>		<u>225MG</u>	<u>A212280 007</u>	Jan 10, 2020
<u>AB</u>		<u>300MG</u>	<u>A212280 008</u>	Jan 10, 2020
<u>AB</u>	CSPC OUYI	<u>50MG</u>	<u>A210585 001</u>	Dec 26, 2019
<u>AB</u>		<u>75MG</u>	<u>A210585 002</u>	Dec 26, 2019
<u>AB</u>		<u>100MG</u>	<u>A210585 003</u>	Dec 26, 2019
<u>AB</u>		<u>150MG</u>	<u>A210585 004</u>	Dec 26, 2019
<u>AB</u>		<u>200MG</u>	<u>A210585 005</u>	Dec 26, 2019
<u>AB</u>		<u>300MG</u>	<u>A210585 006</u>	Dec 26, 2019
<u>AB</u>	DR REDDYS	<u>25MG</u>	<u>A209664 001</u>	Jul 19, 2019
<u>AB</u>		<u>50MG</u>	<u>A209664 002</u>	Jul 19, 2019
<u>AB</u>		<u>75MG</u>	<u>A209664 003</u>	Jul 19, 2019
<u>AB</u>		<u>100MG</u>	<u>A209664 004</u>	Jul 19, 2019
<u>AB</u>		<u>150MG</u>	<u>A209664 005</u>	Jul 19, 2019
<u>AB</u>		<u>200MG</u>	<u>A209664 006</u>	Jul 19, 2019
<u>AB</u>		<u>225MG</u>	<u>A209664 007</u>	Jul 19, 2019
<u>AB</u>		<u>300MG</u>	<u>A209664 008</u>	Jul 19, 2019
<u>AB</u>	HETERO LABS LTD III	<u>25MG</u>	<u>A206912 001</u>	Oct 08, 2019
<u>AB</u>		<u>50MG</u>	<u>A206912 002</u>	Oct 08, 2019
<u>AB</u>		<u>75MG</u>	<u>A206912 003</u>	Oct 08, 2019
<u>AB</u>		<u>100MG</u>	<u>A206912 004</u>	Oct 08, 2019
<u>AB</u>		<u>150MG</u>	<u>A206912 005</u>	Oct 08, 2019
<u>AB</u>		<u>200MG</u>	<u>A206912 006</u>	Oct 08, 2019
<u>AB</u>		<u>225MG</u>	<u>A206912 007</u>	Oct 08, 2019
<u>AB</u>		<u>300MG</u>	<u>A206912 008</u>	Oct 08, 2019
<u>AB</u>	HIKAL	<u>25MG</u>	<u>A213423 001</u>	Mar 23, 2020
<u>AB</u>		<u>50MG</u>	<u>A213423 002</u>	Mar 23, 2020
<u>AB</u>		<u>75MG</u>	<u>A213423 003</u>	Mar 23, 2020
<u>AB</u>		<u>100MG</u>	<u>A213423 004</u>	Mar 23, 2020
<u>AB</u>		<u>150MG</u>	<u>A213423 005</u>	Mar 23, 2020
<u>AB</u>		<u>200MG</u>	<u>A213423 006</u>	Mar 23, 2020
<u>AB</u>		<u>225MG</u>	<u>A213423 007</u>	Mar 23, 2020
<u>AB</u>		<u>300MG</u>	<u>A213423 008</u>	Mar 23, 2020
<u>AB</u>	INVAGEN PHARMS	<u>25MG</u>	<u>A211384 001</u>	Jul 19, 2019
<u>AB</u>		<u>50MG</u>	<u>A211384 002</u>	Jul 19, 2019
<u>AB</u>		<u>75MG</u>	<u>A211384 003</u>	Jul 19, 2019

PRESCRIPTION DRUG PRODUCT LIST

PREGABALIN

CAPSULE; ORAL

PREGABALIN

<u>AB</u>		<u>100MG</u>	<u>A211384 004</u>	Jul 19, 2019
<u>AB</u>		<u>150MG</u>	<u>A211384 005</u>	Jul 19, 2019
<u>AB</u>		<u>200MG</u>	<u>A211384 006</u>	Jul 19, 2019
<u>AB</u>		<u>225MG</u>	<u>A211384 007</u>	Jul 19, 2019
<u>AB</u>		<u>300MG</u>	<u>A211384 008</u>	Jul 19, 2019
<u>AB</u>	MSN	<u>25MG</u>	<u>A209357 001</u>	Jul 19, 2019
<u>AB</u>		<u>50MG</u>	<u>A209357 002</u>	Jul 19, 2019
<u>AB</u>		<u>75MG</u>	<u>A209357 003</u>	Jul 19, 2019
<u>AB</u>		<u>100MG</u>	<u>A209357 004</u>	Jul 19, 2019
<u>AB</u>		<u>150MG</u>	<u>A209357 005</u>	Jul 19, 2019
<u>AB</u>		<u>200MG</u>	<u>A209357 006</u>	Jul 19, 2019
<u>AB</u>		<u>225MG</u>	<u>A209357 007</u>	Jul 19, 2019
<u>AB</u>		<u>300MG</u>	<u>A209357 008</u>	Jul 19, 2019
<u>AB</u>	RISING	<u>25MG</u>	<u>A210432 001</u>	Jul 19, 2019
<u>AB</u>		<u>50MG</u>	<u>A210432 002</u>	Jul 19, 2019
<u>AB</u>		<u>75MG</u>	<u>A210432 003</u>	Jul 19, 2019
<u>AB</u>		<u>100MG</u>	<u>A210432 004</u>	Jul 19, 2019
<u>AB</u>		<u>150MG</u>	<u>A210432 005</u>	Jul 19, 2019
<u>AB</u>		<u>200MG</u>	<u>A210432 006</u>	Jul 19, 2019
<u>AB</u>		<u>225MG</u>	<u>A210432 007</u>	Jul 19, 2019
<u>AB</u>		<u>300MG</u>	<u>A210432 008</u>	Jul 19, 2019
<u>AB</u>	SCIEGEN PHARMS INC	<u>25MG</u>	<u>A208677 001</u>	Jul 19, 2019
<u>AB</u>		<u>50MG</u>	<u>A208677 002</u>	Jul 19, 2019
<u>AB</u>		<u>75MG</u>	<u>A208677 003</u>	Jul 19, 2019
<u>AB</u>		<u>100MG</u>	<u>A208677 004</u>	Jul 19, 2019
<u>AB</u>		<u>150MG</u>	<u>A208677 005</u>	Jul 19, 2019
<u>AB</u>		<u>200MG</u>	<u>A208677 006</u>	Jul 19, 2019
<u>AB</u>		<u>225MG</u>	<u>A208677 007</u>	Jul 19, 2019
<u>AB</u>		<u>300MG</u>	<u>A208677 008</u>	Jul 19, 2019
<u>AB</u>	SHUANGCHENG	<u>75MG</u>	<u>A210891 001</u>	Sep 30, 2019
<u>AB</u>		<u>300MG</u>	<u>A210891 002</u>	Sep 30, 2019
<u>AB</u>	SUN PHARM	<u>25MG</u>	<u>A091157 001</u>	Nov 29, 2019
<u>AB</u>		<u>50MG</u>	<u>A091157 002</u>	Nov 29, 2019
<u>AB</u>		<u>75MG</u>	<u>A091157 003</u>	Nov 29, 2019
<u>AB</u>		<u>100MG</u>	<u>A091157 004</u>	Nov 29, 2019
<u>AB</u>		<u>150MG</u>	<u>A091157 005</u>	Nov 29, 2019
<u>AB</u>		<u>200MG</u>	<u>A091157 006</u>	Nov 29, 2019
<u>AB</u>		<u>225MG</u>	<u>A091157 007</u>	Nov 29, 2019
<u>AB</u>		<u>300MG</u>	<u>A091157 008</u>	Nov 29, 2019
<u>AB</u>	TEVA PHARMS	<u>25MG</u>	<u>A091219 001</u>	Jul 19, 2019
<u>AB</u>		<u>50MG</u>	<u>A091219 002</u>	Jul 19, 2019
<u>AB</u>		<u>75MG</u>	<u>A091224 001</u>	Jul 19, 2019
<u>AB</u>		<u>100MG</u>	<u>A091224 002</u>	Jul 19, 2019
<u>AB</u>		<u>150MG</u>	<u>A091224 003</u>	Jul 19, 2019
<u>AB</u>		<u>200MG</u>	<u>A091224 004</u>	Jul 19, 2019
<u>AB</u>		<u>225MG</u>	<u>A091224 005</u>	Jul 19, 2019
<u>AB</u>		<u>300MG</u>	<u>A091224 006</u>	Jul 19, 2019

SOLUTION; ORAL

LYRICA

<u>AA</u>	+!	PFIZER	<u>20MG/ML</u>	<u>N022488 001</u>	Jan 04, 2010
-----------	----	--------	----------------	--------------------	--------------

PREGABALIN

<u>AA</u>		ALKEM LABS LTD	<u>20MG/ML</u>	<u>A207623 001</u>	Jul 19, 2019
-----------	--	----------------	----------------	--------------------	--------------

TABLET, EXTENDED RELEASE; ORAL

LYRICA CR

	+	PFIZER	82.5MG	N209501 001	Oct 11, 2017
	+		165MG	N209501 002	Oct 11, 2017
	+	!	330MG	N209501 003	Oct 11, 2017

PRETOMANID

TABLET; ORAL

PRETOMANID

	+	!	MYLAN IRELAND LTD	200MG	N212862 001	Aug 14, 2019
--	---	---	-------------------	-------	-------------	--------------

PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

PRILOCAINE HYDROCHLORIDE

	!	SEPTODONT INC	4%	A079235 001	Sep 29, 2010
--	---	---------------	----	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

PRIMAQUINE PHOSPHATE

TABLET; ORAL

PRIMAQUINE

AB	+	SANOFI AVENTIS US	EQ 15MG BASE	N008316 001	
-----------	----------	-------------------	---------------------	--------------------	--

PRIMAQUINE PHOSPHATE

AB		BAYSHORE PHARMS LLC	EQ 15MG BASE	A204476 001	Feb 25, 2014
AB		NOVAST LABS	EQ 15MG BASE	A206043 001	Jun 23, 2016

PRIMIDONE

TABLET; ORAL

MYSOLINE

AB	+	VALEANT	50MG	N009170 003	
-----------	----------	---------	-------------	--------------------	--

AB	+		250MG	N009170 002	
-----------	----------	--	--------------	--------------------	--

PRIMIDONE

AB		AMNEAL PHARM	50MG	A040866 001	Apr 23, 2008
AB			250MG	A040866 002	Apr 23, 2008
AB		ANDA REPOSITORY	50MG	A040626 001	Sep 29, 2005
AB			250MG	A040626 002	Sep 29, 2005
AB		LANNETT	50MG	A084903 002	May 24, 2001
AB			250MG	A084903 001	
AB		OXFORD PHARMS	50MG	A040586 001	Feb 24, 2005
AB			250MG	A040586 002	Feb 24, 2005
AB		WATSON LABS	250MG	A083551 001	

PROBENECID

TABLET; ORAL

PROBALAN

AB		LANNETT	500MG	A080966 001	
-----------	--	---------	--------------	--------------------	--

PROBENECID

AB		MYLAN	500MG	A084211 002	
	!	WATSON LABS TEVA	500MG	A084442 004	Mar 29, 1983

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINAMIDE HYDROCHLORIDE

AP	!	HOSPIRA	100MG/ML	A089069 001	Feb 12, 1986
AP		INTL MEDICATION	100MG/ML	A088636 001	Jul 31, 1984
AP		NEXUS PHARMS	100MG/ML	A206332 001	Oct 13, 2017
AP			500MG/ML	A206332 002	Oct 13, 2017
	!	HOSPIRA	500MG/ML	A089070 001	Feb 12, 1986

PROCARBAZINE HYDROCHLORIDE

CAPSULE; ORAL

MATULANE

+	!	LEADIANT BIOSCI INC	EQ 50MG BASE	N016785 001	
----------	----------	---------------------	--------------	-------------	--

PROCHLORPERAZINE

SUPPOSITORY; RECTAL

COMPRO

AB		PADDOCK LLC	25MG	A040246 001	Jun 28, 2000
-----------	--	-------------	-------------	--------------------	--------------

PROCHLORPERAZINE

AB	!	COSETTE	25MG	A040058 001	Nov 24, 1993
-----------	----------	---------	-------------	--------------------	--------------

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATE

AP		ATHENEX INC	EQ 5MG BASE/ML	A040540 001	May 28, 2004
AP	!	EMCURE PHARMS LTD	EQ 5MG BASE/ML	A204147 001	Oct 15, 2013
AP		MYLAN LABS LTD	EQ 5MG BASE/ML	A210710 001	Oct 25, 2018
AP		NEXUS PHARMS	EQ 5MG BASE/ML	A204860 001	Feb 15, 2019
AP		WEST-WARD PHARMS INT	EQ 5MG BASE/ML	A089903 001	Aug 29, 1989

PROCHLORPERAZINE MALEATE

TABLET; ORAL

PROCHLORPERAZINE MALEATE

AB		MYLAN	EQ 5MG BASE	A040185 002	Oct 28, 1996
-----------	--	-------	--------------------	--------------------	--------------

AB			EQ 10MG BASE	A040185 001	Oct 28, 1996
-----------	--	--	---------------------	--------------------	--------------

PROCOMP

AB		JUBILANT CADISTA	EQ 5MG BASE	A040268 001	Feb 27, 1998
-----------	--	------------------	--------------------	--------------------	--------------

AB	!		EQ 10MG BASE	A040268 002	Feb 27, 1998
-----------	----------	--	---------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LISTPROGESTERONE

CAPSULE; ORAL

PROGESTERONE

<u>AB</u>	AMNEAL PHARMS NY	<u>100MG</u>	<u>A207724</u>	<u>001</u>	Sep 07, 2017
<u>AB</u>		<u>200MG</u>	<u>A207724</u>	<u>002</u>	Sep 07, 2017
<u>AB</u>	BIONPHARMA INC	<u>100MG</u>	<u>A200900</u>	<u>001</u>	Aug 16, 2013
<u>AB</u>		<u>200MG</u>	<u>A200900</u>	<u>002</u>	Aug 16, 2013
<u>AB</u>	DR REDDYS	<u>100MG</u>	<u>A208801</u>	<u>001</u>	Feb 28, 2017
<u>AB</u>		<u>200MG</u>	<u>A208801</u>	<u>002</u>	Feb 28, 2017
<u>AB</u>	EUGIA PHARMA	<u>100MG</u>	<u>A211285</u>	<u>001</u>	Oct 26, 2018
<u>AB</u>		<u>200MG</u>	<u>A211285</u>	<u>002</u>	Oct 26, 2018
<u>AB</u>	SOFGEN PHARMS	<u>100MG</u>	<u>A200456</u>	<u>001</u>	Sep 28, 2012
<u>AB</u>		<u>200MG</u>	<u>A200456</u>	<u>002</u>	Sep 28, 2012
<u>AB</u>	XIROMED	<u>100MG</u>	<u>A205229</u>	<u>001</u>	Oct 20, 2017
<u>AB</u>		<u>200MG</u>	<u>A205229</u>	<u>002</u>	Oct 20, 2017

PROMETRIUM

<u>AB</u>	+ VIRTUS PHARMS	<u>100MG</u>	<u>N019781</u>	<u>001</u>	May 14, 1998
<u>AB</u>	+!	<u>200MG</u>	<u>N019781</u>	<u>002</u>	Oct 15, 1999

GEL; VAGINAL

CRINONE

+!	ALLERGAN	4%	N020701	001	Jul 31, 1997
+!		8%	N020701	002	Jul 31, 1997

INJECTABLE; INJECTION

PROGESTERONE

<u>AO</u>	+! ACTAVIS LABS UT INC	<u>50MG/ML</u>	<u>N017362</u>	<u>002</u>	
<u>AO</u>	EUGIA PHARMA	<u>50MG/ML</u>	<u>A210965</u>	<u>001</u>	Dec 06, 2018
<u>AO</u>	FRESENIUS KABI USA	<u>50MG/ML</u>	<u>A075906</u>	<u>001</u>	Apr 25, 2001
<u>AO</u>	HIKMA FARMACEUTICA	<u>50MG/ML</u>	<u>A091033</u>	<u>001</u>	Oct 28, 2010

INSERT; VAGINAL

ENDOMETRIN

+!	FERRING	100MG	N022057	001	Jun 21, 2007
----	---------	-------	---------	-----	--------------

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROMETHAZINE HYDROCHLORIDE

<u>AP</u>	! WEST-WARD PHARMS	<u>25MG/ML</u>	<u>A083312</u>	<u>001</u>	
	INT				
<u>AP</u>	!	<u>50MG/ML</u>	<u>A083312</u>	<u>002</u>	
<u>AP</u>	XGEN PHARMS	<u>25MG/ML</u>	<u>A040737</u>	<u>001</u>	Apr 24, 2008
<u>AP</u>		<u>50MG/ML</u>	<u>A040737</u>	<u>002</u>	Apr 24, 2008

SUPPOSITORY; RECTAL

PROMETHAZINE HYDROCHLORIDE

<u>AB</u>	COSETTE	<u>12.5MG</u>	<u>A040428</u>	<u>002</u>	Mar 31, 2003
<u>AB</u>	!	<u>25MG</u>	<u>A040428</u>	<u>001</u>	Feb 05, 2002
<u>AB</u>	PERRIGO ISRAEL	<u>12.5MG</u>	<u>A040500</u>	<u>001</u>	Jun 30, 2003
<u>AB</u>		<u>25MG</u>	<u>A040500</u>	<u>002</u>	Jun 30, 2003
<u>AB</u>	TARO	<u>12.5MG</u>	<u>A040603</u>	<u>001</u>	Oct 26, 2006
<u>AB</u>		<u>25MG</u>	<u>A040603</u>	<u>002</u>	Oct 26, 2006

PROMETHEGAN

!	COSETTE	50MG	A087165	001	Aug 14, 1987
---	---------	------	---------	-----	--------------

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE

<u>AA</u>	AKORN	<u>6.25MG/5ML</u>	<u>A040026</u>	<u>001</u>	Sep 25, 1998
<u>AA</u>	AMNEAL PHARMS	<u>6.25MG/5ML</u>	<u>A040882</u>	<u>001</u>	Dec 30, 2009
<u>AA</u>	NOSTRUM LABS INC	<u>6.25MG/5ML</u>	<u>A040891</u>	<u>001</u>	Mar 13, 2009
<u>AA</u>	PHARM ASSOC	<u>6.25MG/5ML</u>	<u>A040643</u>	<u>001</u>	Apr 26, 2006
<u>AA</u>	TARO	<u>6.25MG/5ML</u>	<u>A040718</u>	<u>001</u>	Apr 04, 2007
<u>AA</u>	TRIS PHARMA INC	<u>6.25MG/5ML</u>	<u>A091675</u>	<u>001</u>	Jun 28, 2012

PROMETHAZINE PLAIN

<u>AA</u>	! WOCHKHARDT BIO AG	<u>6.25MG/5ML</u>	<u>A087953</u>	<u>001</u>	Nov 15, 1982
-----------	---------------------	-------------------	----------------	------------	--------------

TABLET; ORAL

PROMETHAZINE HYDROCHLORIDE

<u>AB</u>	AMNEAL PHARMS NY	<u>12.5MG</u>	<u>A091179</u>	<u>001</u>	Dec 13, 2010
<u>AB</u>		<u>25MG</u>	<u>A091179</u>	<u>002</u>	Dec 13, 2010
<u>AB</u>		<u>50MG</u>	<u>A091179</u>	<u>003</u>	Dec 13, 2010
<u>AB</u>	KVK TECH	<u>12.5MG</u>	<u>A040712</u>	<u>002</u>	May 04, 2007
<u>AB</u>		<u>25MG</u>	<u>A040712</u>	<u>001</u>	Jul 31, 2006
<u>AB</u>		<u>50MG</u>	<u>A040712</u>	<u>003</u>	Jul 31, 2006
<u>AB</u>	PRINSTON INC	<u>12.5MG</u>	<u>A040622</u>	<u>001</u>	Jul 18, 2006
<u>AB</u>		<u>25MG</u>	<u>A040622</u>	<u>002</u>	Jul 18, 2006
<u>AB</u>		<u>50MG</u>	<u>A040622</u>	<u>003</u>	Jul 18, 2006
<u>AB</u>	QUAGEN	<u>12.5MG</u>	<u>A040673</u>	<u>001</u>	Mar 05, 2008
<u>AB</u>		<u>25MG</u>	<u>A040673</u>	<u>002</u>	Mar 05, 2008

PRESCRIPTION DRUG PRODUCT LIST

PROMETHAZINE HYDROCHLORIDE

TABLET; ORAL

PROMETHAZINE HYDROCHLORIDE

<u>AB</u>		<u>50MG</u>	<u>A040673</u>	<u>003</u>	Mar 05, 2008
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A084176</u>	<u>003</u>	
<u>AB</u>	!	<u>50MG</u>	<u>A084176</u>	<u>001</u>	
<u>AB</u>	STRIDES PHARMA	<u>12.5MG</u>	<u>A209177</u>	<u>001</u>	Jun 30, 2017
<u>AB</u>		<u>25MG</u>	<u>A209177</u>	<u>002</u>	Jun 30, 2017
<u>AB</u>		<u>50MG</u>	<u>A209177</u>	<u>003</u>	Jun 30, 2017
<u>AB</u>	SUN PHARM INDS INC	<u>12.5MG</u>	<u>A040863</u>	<u>001</u>	Dec 30, 2008
<u>AB</u>		<u>25MG</u>	<u>A040863</u>	<u>002</u>	Dec 30, 2008
<u>AB</u>		<u>50MG</u>	<u>A040863</u>	<u>003</u>	Dec 30, 2008
<u>AB</u>	WATSON LABS	<u>25MG</u>	<u>A083426</u>	<u>001</u>	
<u>AB</u>		<u>50MG</u>	<u>A083711</u>	<u>001</u>	
<u>AB</u>	ZYDUS PHARMS USA	<u>12.5MG</u>	<u>A040596</u>	<u>001</u>	Nov 18, 2005
<u>AB</u>		<u>25MG</u>	<u>A040596</u>	<u>002</u>	Nov 18, 2005
<u>AB</u>		<u>50MG</u>	<u>A040596</u>	<u>003</u>	Nov 18, 2005

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPAFENONE HYDROCHLORIDE

<u>AB</u>	GLENMARK PHARMS LTD	<u>225MG</u>	<u>A205268</u>	<u>001</u>	Sep 08, 2017
<u>AB</u>		<u>325MG</u>	<u>A205268</u>	<u>002</u>	Sep 08, 2017
<u>AB</u>		<u>425MG</u>	<u>A205268</u>	<u>003</u>	Sep 08, 2017
<u>AB</u>	MYLAN	<u>225MG</u>	<u>A203803</u>	<u>001</u>	Apr 29, 2016
<u>AB</u>		<u>325MG</u>	<u>A203803</u>	<u>002</u>	Apr 29, 2016
<u>AB</u>		<u>425MG</u>	<u>A203803</u>	<u>003</u>	Apr 29, 2016
<u>AB</u>	PAR PHARM	<u>225MG</u>	<u>A078540</u>	<u>001</u>	Oct 18, 2010
<u>AB</u>		<u>325MG</u>	<u>A078540</u>	<u>002</u>	Oct 18, 2010
<u>AB</u>		<u>425MG</u>	<u>A078540</u>	<u>003</u>	Oct 18, 2010
<u>AB</u>	RISING	<u>225MG</u>	<u>A205956</u>	<u>001</u>	Jul 02, 2018
<u>AB</u>		<u>325MG</u>	<u>A205956</u>	<u>002</u>	Jul 02, 2018
<u>AB</u>		<u>425MG</u>	<u>A205956</u>	<u>003</u>	Jul 02, 2018
<u>AB</u>	SINOTHERAPEUTICS INC	<u>225MG</u>	<u>A210339</u>	<u>001</u>	Jan 04, 2019
<u>AB</u>		<u>325MG</u>	<u>A210339</u>	<u>002</u>	Jan 04, 2019
<u>AB</u>		<u>425MG</u>	<u>A210339</u>	<u>003</u>	Jan 04, 2019
<u>AB</u>	TWI PHARMS	<u>225MG</u>	<u>A212928</u>	<u>001</u>	Jun 18, 2020
<u>AB</u>		<u>325MG</u>	<u>A212928</u>	<u>002</u>	Jun 18, 2020
<u>AB</u>		<u>425MG</u>	<u>A212928</u>	<u>003</u>	Jun 18, 2020
<u>AB</u>	UPSHER SMITH LABS	<u>225MG</u>	<u>A212744</u>	<u>001</u>	Jun 25, 2020
<u>AB</u>		<u>325MG</u>	<u>A212744</u>	<u>002</u>	Jun 25, 2020
<u>AB</u>		<u>425MG</u>	<u>A212744</u>	<u>003</u>	Jun 25, 2020
<u>AB</u>	WATSON LABS INC	<u>225MG</u>	<u>A202688</u>	<u>001</u>	Aug 24, 2015
<u>AB</u>		<u>325MG</u>	<u>A202688</u>	<u>002</u>	Aug 24, 2015
<u>AB</u>		<u>425MG</u>	<u>A202688</u>	<u>003</u>	Aug 24, 2015
<u>RYTHMOL SR</u>					
<u>AB</u>	+ GLAXOSMITHKLINE LLC	<u>225MG</u>	<u>N021416</u>	<u>001</u>	Sep 04, 2003
<u>AB</u>	+	<u>325MG</u>	<u>N021416</u>	<u>002</u>	Sep 04, 2003
<u>AB</u>	+!	<u>425MG</u>	<u>N021416</u>	<u>003</u>	Sep 04, 2003

TABLET; ORAL

PROPAFENONE HYDROCHLORIDE

<u>AB</u>	ANI PHARMS INC	<u>150MG</u>	<u>A076550</u>	<u>001</u>	Apr 23, 2004
<u>AB</u>		<u>225MG</u>	<u>A076550</u>	<u>002</u>	Apr 23, 2004
<u>AB</u>		<u>300MG</u>	<u>A076550</u>	<u>003</u>	Apr 23, 2004
<u>AB</u>	AUROBINDO PHARMA LTD	<u>150MG</u>	<u>A202445</u>	<u>001</u>	May 11, 2016
<u>AB</u>		<u>225MG</u>	<u>A202445</u>	<u>002</u>	May 11, 2016
<u>AB</u>		<u>300MG</u>	<u>A202445</u>	<u>003</u>	May 11, 2016
<u>AB</u>	SUN PHARM INDUSTRIES	<u>150MG</u>	<u>A075998</u>	<u>001</u>	Nov 29, 2001
<u>AB</u>		<u>225MG</u>	<u>A075998</u>	<u>002</u>	Nov 29, 2001
<u>AB</u>		<u>300MG</u>	<u>A075998</u>	<u>003</u>	Nov 29, 2001
<u>AB</u>	VINTAGE PHARMS	<u>150MG</u>	<u>A075938</u>	<u>001</u>	Oct 17, 2002
<u>AB</u>		<u>225MG</u>	<u>A075938</u>	<u>002</u>	Oct 17, 2002
<u>AB</u>	!	<u>300MG</u>	<u>A075938</u>	<u>003</u>	Oct 17, 2002
<u>AB</u>	WATSON LABS	<u>150MG</u>	<u>A075203</u>	<u>001</u>	Oct 24, 2000
<u>AB</u>		<u>225MG</u>	<u>A075203</u>	<u>002</u>	Oct 24, 2000

PRESCRIPTION DRUG PRODUCT LIST

PROPANTHELINE BROMIDE

TABLET; ORAL

PROPANTHELINE BROMIDE

! HIKMA 15MG

A080927 002

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

ALCAINEAT ALCON LABS INC 0.5%A080027 001PROPARACAINE HYDROCHLORIDEAT ! AKORN INC 0.5%A040277 001 Mar 16, 2000AT BAUSCH AND LOMB 0.5%A040074 001 Sep 29, 1995PROPOFOL

INJECTABLE; INJECTION

DIPRIVANAB +! FRESENIUS KABI USA 10MG/MLN019627 002 Jun 11, 1996PROPOFOLAB DR REDDYS 10MG/MLA205067 001 Nov 15, 2018AB HOSPIRA 10MG/MLA077908 001 Mar 17, 2006AB INNOPHARMA 10MG/MLA205576 001 Sep 16, 2020AB SAGENT PHARMS INC 10MG/MLA075102 001 Jan 04, 1999AB WATSON LABS INC 10MG/MLA205307 001 Dec 22, 2015AB WEST-WARD PHARMS 10MG/MLA074848 001 Apr 19, 2005

INT

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

INDERAL LAAB + ANI PHARMS INC 60MGN018553 004 Mar 18, 1987AB + 80MGN018553 002 Apr 19, 1983AB + 120MGN018553 003 Apr 19, 1983AB +! 160MGN018553 001 Apr 19, 1983PROPRANOLOL HYDROCHLORIDEAB ACTAVIS ELIZABETH 60MGA078494 001 Aug 10, 2007AB 80MGA078494 002 Aug 10, 2007AB 120MGA078494 003 Aug 10, 2007AB 160MGA078494 004 Aug 10, 2007AB ADARE PHARMS INC 60MGA078703 001 Jul 15, 2011AB 80MGA078703 002 Jul 15, 2011AB 120MGA078703 003 Jul 15, 2011AB 160MGA078703 004 Jul 15, 2011AB AMTA 60MGA212026 001 Jan 06, 2020AB 80MGA212026 002 Jan 06, 2020AB 120MGA212026 003 Jan 06, 2020AB 160MGA212026 004 Jan 06, 2020AB NORTEC DEV ASSOC 60MGA078065 001 Jan 26, 2007AB 80MGA078065 002 Jan 26, 2007AB 120MGA078065 003 Jan 26, 2007AB 160MGA078065 004 Jan 26, 2007AB ZYDUS PHARMS USA 60MGA090321 001 Mar 25, 2011

INC

AB 80MGA090321 002 Mar 25, 2011AB 120MGA090321 003 Mar 25, 2011AB 160MGA090321 004 Mar 25, 2011

INNOPRAN XL

BX + ANI PHARMS INC 80MG

N021438 001 Mar 12, 2003

BX +! 120MG

N021438 002 Mar 12, 2003

INJECTABLE; INJECTION

PROPRANOLOL HYDROCHLORIDEAP ATHENEX INC 1MG/MLA075792 001 Aug 29, 2000AP FRESENIUS KABI USA 1MG/MLA075826 001 Aug 31, 2001

! HIKMA FARMACEUTICA 1MG/ML

A077760 001 Jan 31, 2008

SOLUTION; ORAL

HEMANGEOL

+! PIERRE FABRE DERMA 4.28MG/ML

N205410 001 Mar 14, 2014

PROPRANOLOL HYDROCHLORIDE

! HIKMA 20MG/5ML

A070979 001 May 15, 1987

! 40MG/5ML

A070690 001 May 15, 1987

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDEAB IMPAX LABS INC 60MGA071976 002 May 13, 1986AB INNOGENIX 10MGA070322 002 Oct 22, 1985AB 20MGA070322 003 Oct 22, 1985

PRESCRIPTION DRUG PRODUCT LIST

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

AB		40MG	A070322 004	Oct 22, 1985
AB		60MG	A070322 005	Sep 24, 1986
AB		80MG	A070322 001	Aug 04, 1986
AB	IPCA LABS LTD	10MG	A078955 001	Jun 02, 2008
AB		20MG	A078955 002	Jun 02, 2008
AB		40MG	A078955 003	Jun 02, 2008
AB		60MG	A078955 004	Jun 02, 2008
AB		80MG	A078955 005	Jun 02, 2008
AB	MYLAN	10MG	A070213 002	Nov 19, 1985
AB		20MG	A070213 003	Nov 19, 1985
AB		40MG	A070213 001	Nov 19, 1985
AB		60MG	A070213 005	Apr 08, 2011
AB		80MG	A070213 004	Nov 19, 1985
AB	NORTHSTAR HLTHCARE	10MG	A078213 001	Jan 10, 2008
AB		20MG	A078213 002	Jan 10, 2008
AB		40MG	A078213 003	Jan 10, 2008
AB		60MG	A078213 004	Jan 10, 2008
AB		80MG	A078213 005	Jan 10, 2008
AB	VINTAGE PHARMS	10MG	A070221 002	Aug 01, 1986
AB		20MG	A070221 003	Aug 01, 1986
AB		40MG	A070219 001	Aug 01, 1986
AB		40MG	A070221 004	Aug 01, 1986
AB		60MG	A070221 005	Sep 24, 1986
AB		80MG	A070221 001	Apr 14, 1986
AB	WATSON LABS	10MG	A070175 001	May 13, 1986
AB		20MG	A070176 001	May 13, 1986
AB		40MG	A070177 001	May 13, 1986
AB		60MG	A070178 002	Apr 23, 2018
AB	!	80MG	A070178 001	May 13, 1986

PROPYLTHIOURACIL

TABLET; ORAL

PROPYLTHIOURACIL

BD	ACTAVIS ELIZABETH	50MG	A080172 001	
BD	+! DAVA PHARMS INC	50MG	N006188 001	

PROTAMINE SULFATE

INJECTABLE; INJECTION

PROTAMINE SULFATE

!	FRESENIUS KABI USA	10MG/ML	A089454 001	Apr 07, 1987
---	--------------------	---------	-------------	--------------

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

PROTRIPTYLINE HYDROCHLORIDE

AB	EPIC PHARMA LLC	5MG	A202220 001	Nov 19, 2012
AB		10MG	A202220 002	Nov 19, 2012
AB	HIKMA	5MG	A078913 001	Sep 16, 2008
AB	!	10MG	A078913 002	Sep 16, 2008
AB	SIGMAPHARM LABS LLC	5MG	A090462 001	May 03, 2010
AB		10MG	A090462 002	May 03, 2010

PRUCALOPRIDE SUCCINATE

TABLET; ORAL

MOTEGRITY

+	TAKEDA PHARMS USA	EQ 1MG BASE	N210166 001	Dec 14, 2018
+	!	EQ 2MG BASE	N210166 002	Dec 14, 2018

PYRAZINAMIDE

TABLET; ORAL

PYRAZINAMIDE

AB	!	AKORN	500MG	A081319 001	Jun 30, 1992
AB		MACLEODS PHARMS LTD	500MG	A212541 001	Jul 27, 2020

PYRIDOSTIGMINE BROMIDE

INJECTABLE; INJECTION

MESTINON

AP	+	BAUSCH	5MG/ML	N009830 001	
-----------	---	--------	---------------	--------------------	--

REGONOL

AP		SANDOZ INC	5MG/ML	N017398 001	
-----------	--	------------	---------------	--------------------	--

SYRUP; ORAL

MESTINON

AA	+	BAUSCH	60MG/5ML	N015193 001	
-----------	---	--------	-----------------	--------------------	--

PRESCRIPTION DRUG PRODUCT LIST

PYRIDOSTIGMINE BROMIDE

SYRUP; ORAL

PYRIDOSTIGMINE BROMIDE

<u>AA</u>	AMNEAL	<u>60MG/5ML</u>	<u>A212702</u>	<u>001</u>	Jan 10, 2020
<u>AA</u>	ELYSIUM	<u>60MG/5ML</u>	<u>A208797</u>	<u>001</u>	Jan 09, 2020
<u>AA</u>	NOVITIUM PHARMA	<u>60MG/5ML</u>	<u>A211694</u>	<u>001</u>	Mar 08, 2019

TABLET; ORAL

MESTINON

<u>AB</u>	+!	BAUSCH	<u>60MG</u>	<u>N009829</u>	<u>002</u>
-----------	----	--------	-------------	----------------	------------

PYRIDOSTIGMINE BROMIDE

<u>AB</u>	EYWA	<u>60MG</u>	<u>A211181</u>	<u>001</u>	Jul 20, 2018
<u>AB</u>	IMPAX LABS	<u>60MG</u>	<u>A040502</u>	<u>001</u>	Apr 24, 2003
<u>AB</u>	ZYDUS PHARMS	<u>60MG</u>	<u>A205650</u>	<u>001</u>	Jun 22, 2015
	EYWA	30MG	A211181	002	May 14, 2019

TABLET, EXTENDED RELEASE; ORAL

MESTINON

<u>AB</u>	+!	BAUSCH	<u>180MG</u>	<u>N011665</u>	<u>001</u>
-----------	----	--------	--------------	----------------	------------

PYRIDOSTIGMINE BROMIDE

<u>AB</u>	ALVOGEN	<u>180MG</u>	<u>A204737</u>	<u>001</u>	Jun 26, 2015
<u>AB</u>	IMPAX LABS INC	<u>180MG</u>	<u>A203184</u>	<u>001</u>	Sep 15, 2015
<u>AB</u>	RISING	<u>180MG</u>	<u>A205464</u>	<u>001</u>	Aug 15, 2017

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION

	PYRIDOXINE HYDROCHLORIDE				
!	FRESENIUS KABI USA	100MG/ML	A080618	001	

PYRIMETHAMINE

TABLET; ORAL

DARAPRIM

<u>AB</u>	+!	VYERA PHARMS LLC	<u>25MG</u>	<u>N008578</u>	<u>001</u>
-----------	----	------------------	-------------	----------------	------------

PYRIMETHAMINE

<u>AB</u>	CEROVENE INC	<u>25MG</u>	<u>A207127</u>	<u>001</u>	Feb 28, 2020
-----------	--------------	-------------	----------------	------------	--------------

QUAZEPAM

TABLET; ORAL

DORAL

+	!	GALT PHARMS	15MG	N018708	001	Dec 27, 1985
---	---	-------------	------	---------	-----	--------------

QUETIAPINE FUMARATE

TABLET; ORAL

QUETIAPINE FUMARATE

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 25MG BASE</u>	<u>A202152</u>	<u>001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A202152</u>	<u>002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A202152</u>	<u>003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A202152</u>	<u>004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A202152</u>	<u>005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A202152</u>	<u>006</u>	Mar 27, 2012
<u>AB</u>	ALKEM LABS LTD	<u>EQ 25MG BASE</u>	<u>A201504</u>	<u>001</u>	Feb 12, 2013
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A201504</u>	<u>002</u>	Feb 12, 2013
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A201504</u>	<u>003</u>	Feb 12, 2013
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A201504</u>	<u>004</u>	Feb 12, 2013
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A201504</u>	<u>005</u>	Feb 12, 2013
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A201504</u>	<u>006</u>	Feb 12, 2013
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A201504</u>	<u>007</u>	Feb 12, 2013
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 25MG BASE</u>	<u>A091388</u>	<u>001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A091388</u>	<u>002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A091388</u>	<u>003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A091388</u>	<u>004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A091388</u>	<u>005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A091388</u>	<u>006</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A091388</u>	<u>007</u>	Mar 27, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 25MG BASE</u>	<u>A077380</u>	<u>001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077380</u>	<u>002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077380</u>	<u>003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A077380</u>	<u>004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A077380</u>	<u>005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A077380</u>	<u>006</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A077380</u>	<u>007</u>	Mar 27, 2012
<u>AB</u>	HIKMA	<u>EQ 25MG BASE</u>	<u>A090120</u>	<u>001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A090749</u>	<u>001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A090749</u>	<u>002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A090749</u>	<u>003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A090749</u>	<u>004</u>	Mar 27, 2012

PRESCRIPTION DRUG PRODUCT LIST

QUETIAPINE FUMARATE

TABLET; ORAL

QUETIAPINE FUMARATE

<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A090749 005</u>	Mar 27, 2012
<u>AB</u>	JUBILANT GENERICS	<u>EQ 25MG BASE</u>	<u>A203150 001</u>	Nov 26, 2013
<u>AB</u>	LUPIN LTD	<u>EQ 25MG BASE</u>	<u>A201109 001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A201109 002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A201109 003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A201109 004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A201109 005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A201109 006</u>	Mar 27, 2012
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 25MG BASE</u>	<u>A203359 001</u>	May 17, 2016
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A203359 002</u>	May 17, 2016
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A203359 003</u>	May 17, 2016
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A203359 004</u>	May 17, 2016
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A203359 005</u>	May 17, 2016
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A203359 006</u>	May 17, 2016
<u>AB</u>	SANDOZ	<u>EQ 25MG BASE</u>	<u>A078679 001</u>	Dec 14, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078679 002</u>	Dec 14, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078679 003</u>	Dec 14, 2012
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A078679 004</u>	Dec 14, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A078679 005</u>	Dec 14, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A078679 006</u>	Dec 14, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A078679 007</u>	Dec 14, 2012
<u>AB</u>	SUN PHARM	<u>EQ 25MG BASE</u>	<u>A201190 001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A201190 002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A201190 003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A201190 004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A201190 005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A201190 006</u>	Mar 27, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 25MG BASE</u>	<u>A077745 001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077745 002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077745 003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A077745 004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A077745 005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A077745 006</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A077745 007</u>	Mar 27, 2012
<u>AB</u>	UNICHEM	<u>EQ 25MG BASE</u>	<u>A202674 001</u>	Mar 08, 2016
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A202674 002</u>	Mar 08, 2016
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A202674 003</u>	Mar 08, 2016
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A202674 004</u>	Mar 08, 2016
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A202674 005</u>	Mar 08, 2016
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A202674 006</u>	Mar 08, 2016
<u>AB</u>	ZENNOVA	<u>EQ 25MG BASE</u>	<u>A090960 001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A090960 002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A090960 003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A090960 004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A090960 005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A090960 006</u>	Mar 27, 2012

SEROQUEL

<u>AB</u>	+!	ASTRAZENECA PHARMS	<u>EQ 25MG BASE</u>	<u>N020639 001</u>	Sep 26, 1997
<u>AB</u>	+		<u>EQ 50MG BASE</u>	<u>N020639 007</u>	Oct 04, 2005
<u>AB</u>	+		<u>EQ 100MG BASE</u>	<u>N020639 002</u>	Sep 26, 1997
<u>AB</u>	+		<u>EQ 200MG BASE</u>	<u>N020639 003</u>	Sep 26, 1997
<u>AB</u>	+!		<u>EQ 300MG BASE</u>	<u>N020639 005</u>	Jul 26, 2000
<u>AB</u>	+		<u>EQ 400MG BASE</u>	<u>N020639 006</u>	Oct 04, 2005

TABLET, EXTENDED RELEASE; ORAL

QUETIAPINE FUMARATE

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 50MG BASE</u>	<u>A206252 001</u>	Nov 29, 2017
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A090681 001</u>	May 09, 2017
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A090681 002</u>	May 09, 2017
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A090681 003</u>	May 09, 2017
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A090681 004</u>	Nov 01, 2016
<u>AB</u>	ALIGNSCIENCE PHARMA	<u>EQ 150MG BASE</u>	<u>A209497 001</u>	Sep 28, 2018
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A209497 002</u>	Sep 28, 2018
<u>AB</u>	ANCHEN PHARMS	<u>EQ 150MG BASE</u>	<u>A090757 001</u>	Dec 01, 2017
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A090757 002</u>	Dec 01, 2017
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A090757 003</u>	Dec 01, 2017
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A090757 004</u>	Dec 01, 2017
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 50MG BASE</u>	<u>A207655 001</u>	Nov 29, 2017
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A207655 002</u>	Nov 29, 2017
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A207655 003</u>	Nov 29, 2017

PRESCRIPTION DRUG PRODUCT LIST

QUETIAPINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL

QUETIAPINE FUMARATE

<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A207655</u>	<u>004</u>	Nov 29, 2017
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A207655</u>	<u>005</u>	Nov 29, 2017
<u>AB</u>	INTELLIPHARMACEUTICS	<u>EQ 50MG BASE</u>	<u>A202939</u>	<u>001</u>	May 09, 2017
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A202939</u>	<u>002</u>	May 09, 2017
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A202939</u>	<u>003</u>	May 09, 2017
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A202939</u>	<u>004</u>	May 09, 2017
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A202939</u>	<u>005</u>	May 09, 2017
<u>AB</u>	LUPIN LTD	<u>EQ 50MG BASE</u>	<u>A204203</u>	<u>001</u>	May 17, 2017
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A204203</u>	<u>002</u>	May 17, 2017
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A204203</u>	<u>003</u>	May 17, 2017
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A204203</u>	<u>004</u>	May 17, 2017
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A204203</u>	<u>005</u>	May 17, 2017
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 150MG BASE</u>	<u>A204253</u>	<u>001</u>	Nov 29, 2017
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A204253</u>	<u>002</u>	Nov 29, 2017
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A204253</u>	<u>003</u>	Nov 29, 2017
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A204253</u>	<u>004</u>	Nov 29, 2017
<u>AB</u>	NOVAST LABS	<u>EQ 50MG BASE</u>	<u>A208947</u>	<u>001</u>	Nov 29, 2017
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A208947</u>	<u>002</u>	Nov 29, 2017
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A208947</u>	<u>003</u>	Nov 29, 2017
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A208947</u>	<u>004</u>	Nov 29, 2017
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A208947</u>	<u>005</u>	Nov 29, 2017
<u>AB</u>	PAR PHARM	<u>EQ 50MG BASE</u>	<u>A090482</u>	<u>001</u>	May 09, 2017
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A090482</u>	<u>002</u>	May 09, 2017
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A090482</u>	<u>003</u>	May 09, 2017
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A090482</u>	<u>004</u>	May 09, 2017
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A090482</u>	<u>005</u>	May 09, 2017
<u>AB</u>	PHARMADAX INC	<u>EQ 50MG BASE</u>	<u>A206260</u>	<u>001</u>	May 09, 2017
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A206260</u>	<u>002</u>	May 09, 2017
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A206260</u>	<u>003</u>	May 09, 2017
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A206260</u>	<u>004</u>	May 09, 2017
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A206260</u>	<u>005</u>	May 09, 2017
<u>AB</u>	SCIEGEN PHARMS INC	<u>EQ 50MG BASE</u>	<u>A209635</u>	<u>005</u>	Nov 16, 2018
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A209635</u>	<u>001</u>	Nov 29, 2017
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A209635</u>	<u>002</u>	Nov 29, 2017
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A209635</u>	<u>003</u>	Nov 29, 2017
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A209635</u>	<u>004</u>	Nov 29, 2017
<u>SEROQUEL XR</u>					
<u>AB</u>	+ ASTRAZENECA	<u>EQ 50MG BASE</u>	<u>N022047</u>	<u>001</u>	May 17, 2007
<u>AB</u>	+	<u>EQ 150MG BASE</u>	<u>N022047</u>	<u>005</u>	Aug 11, 2008
<u>AB</u>	+!	<u>EQ 200MG BASE</u>	<u>N022047</u>	<u>002</u>	May 17, 2007
<u>AB</u>	+	<u>EQ 300MG BASE</u>	<u>N022047</u>	<u>003</u>	May 17, 2007
<u>AB</u>	+	<u>EQ 400MG BASE</u>	<u>N022047</u>	<u>004</u>	May 17, 2007

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

ACCUPRIL

<u>AB</u>	+ PFIZER PHARMS	<u>EQ 5MG BASE</u>	<u>N019885</u>	<u>001</u>	Nov 19, 1991
<u>AB</u>	+	<u>EQ 10MG BASE</u>	<u>N019885</u>	<u>002</u>	Nov 19, 1991
<u>AB</u>	+	<u>EQ 20MG BASE</u>	<u>N019885</u>	<u>003</u>	Nov 19, 1991
<u>AB</u>	+!	<u>EQ 40MG BASE</u>	<u>N019885</u>	<u>004</u>	Nov 19, 1991
<u>QUINAPRIL HYDROCHLORIDE</u>					
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 5MG BASE</u>	<u>A202725</u>	<u>001</u>	Apr 29, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A202725</u>	<u>002</u>	Apr 29, 2013
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A202725</u>	<u>003</u>	Apr 29, 2013
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A202725</u>	<u>004</u>	Apr 29, 2013
<u>AB</u>	INVAGEN PHARMS	<u>EQ 5MG BASE</u>	<u>A078457</u>	<u>001</u>	Aug 24, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078457</u>	<u>002</u>	Aug 24, 2007
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A078457</u>	<u>003</u>	Aug 24, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078457</u>	<u>004</u>	Aug 24, 2007
<u>AB</u>	LUPIN	<u>EQ 5MG BASE</u>	<u>A077690</u>	<u>001</u>	Jun 20, 2006
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077690</u>	<u>002</u>	Jun 20, 2006
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077690</u>	<u>003</u>	Jun 20, 2006
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077690</u>	<u>004</u>	Jun 20, 2006
<u>AB</u>	PRINSTON INC	<u>EQ 5MG BASE</u>	<u>A205823</u>	<u>001</u>	Sep 15, 2016
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A205823</u>	<u>002</u>	Sep 15, 2016
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A205823</u>	<u>003</u>	Sep 15, 2016
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A205823</u>	<u>004</u>	Sep 15, 2016

PRESCRIPTION DRUG PRODUCT LISTQUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE;ORAL

QUINIDINE GLUCONATE

!	SUN PHARM	324MG	A089338	001	Feb 11, 1987
	INDUSTRIES				

QUINIDINE SULFATE

TABLET;ORAL

QUINIDINE SULFATE

!	SANDOZ	200MG	A088072	002	
!		300MG	A088072	001	Sep 26, 1983

QUININE SULFATE

CAPSULE;ORAL

QUALAQVIN

AB	+ !	SUN PHARM	324MG	N021799	001	Aug 12, 2005
		INDUSTRIES				

QUININE SULFATE

AB		AMNEAL PHARMS	324MG	A203729	001	Jul 15, 2015
AB		LUPIN LTD	324MG	A203112	001	Apr 24, 2015
AB		NOVAST LABS	324MG	A204372	001	Jul 22, 2015
AB		TEVA PHARMS	324MG	A091661	001	Sep 28, 2012

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL

ACIPHEX

AB	+ !	EISAI INC	20MG	N020973	002	Aug 19, 1999
-----------	------------	-----------	-------------	----------------	------------	--------------

RABEPRAZOLE SODIUM

AB		ALKEM LABS LTD	20MG	A208644	001	Apr 24, 2018
AB		AMNEAL PHARMS	20MG	A204179	001	Jul 31, 2015
AB		AUROBINDO PHARMA	20MG	A205761	001	Feb 17, 2017
		LTD				
AB		DR REDDYS	20MG	A076824	001	Nov 08, 2013
AB		LANNETT CO INC	20MG	A090678	001	Nov 08, 2013
AB		LUPIN LTD	20MG	A078964	001	Nov 08, 2013
AB		RUBICON	20MG	A204237	001	Nov 18, 2015
AB		TEVA PHARMS USA	20MG	A076822	001	Nov 08, 2013
AB		TORRENT	20MG	A202376	001	Nov 08, 2013

RADIUM RA-223 DICHLORIDE

SOLUTION;INTRAVENOUS

XOFIGO

+	BAYER HLTHCARE	162mCi/6ML (27mCi/ML)	N203971	001	May 15, 2013
---	----------------	-----------------------	---------	-----	--------------

RALOXIFENE HYDROCHLORIDE

TABLET;ORAL

EVISTA

AB	+ !	LILLY	60MG	N020815	001	Dec 09, 1997
-----------	------------	-------	-------------	----------------	------------	--------------

RALOXIFENE HYDROCHLORIDE

AB		AMNEAL PHARMS	60MG	A208206	001	Apr 08, 2016
AB		AUROBINDO PHARMA	60MG	A204310	001	Aug 28, 2015
		LTD				
AB		CADILA PHARMS LTD	60MG	A211324	001	Aug 18, 2020
AB		GLENMARK PHARMS LTD	60MG	A204491	001	Mar 22, 2016
AB		INVAGEN PHARMS	60MG	A090842	001	Sep 24, 2014
AB		SCIEGEN PHARMS INC	60MG	A206384	001	Oct 12, 2016
AB		TEVA PHARMS USA	60MG	A078193	001	Mar 04, 2014
AB		WATSON LABS INC	60MG	A200825	001	Jan 21, 2015

RALTEGRAVIR POTASSIUM

POWDER;ORAL

ISENTRESS

+	MERCK SHARP DOHME	EQ 100MG BASE/PACKET	N205786	001	Dec 20, 2013
---	-------------------	----------------------	---------	-----	--------------

TABLET;ORAL

ISENTRESS

+	MERCK SHARP DOHME	EQ 400MG BASE	N022145	001	Oct 12, 2007
---	-------------------	---------------	---------	-----	--------------

ISENTRESS HD

+	MERCK SHARP DOHME	EQ 600MG BASE	N022145	002	May 26, 2017
---	-------------------	---------------	---------	-----	--------------

TABLET, CHEWABLE;ORAL

ISENTRESS

+	MERCK SHARP DOHME	EQ 25MG BASE	N203045	001	Dec 21, 2011
---	-------------------	--------------	---------	-----	--------------

+		EQ 100MG BASE	N203045	002	Dec 21, 2011
---	--	---------------	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

RAMELTEON

TABLET; ORAL

RAMELTEON

<u>AB</u>	ACTAVIS LABS FL INC	<u>8MG</u>	<u>A091610</u>	<u>001</u>	Aug 19, 2015
<u>AB</u>	APPCO	<u>8MG</u>	<u>A213815</u>	<u>001</u>	Oct 26, 2020
<u>AB</u>	DR REDDYS LABS SA	<u>8MG</u>	<u>A091693</u>	<u>001</u>	Jul 26, 2013
<u>AB</u>	GRANULES PHARMS	<u>8MG</u>	<u>A213186</u>	<u>001</u>	Aug 21, 2020
<u>AB</u>	I3 PHARMS	<u>8MG</u>	<u>A212650</u>	<u>001</u>	Apr 10, 2020
<u>AB</u>	ZYDUS PHARMS	<u>8MG</u>	<u>A211567</u>	<u>001</u>	Jul 22, 2019

ROZEREM

<u>AB</u>	+!	TAKEDA PHARMS USA	<u>8MG</u>	<u>N021782</u>	<u>001</u>	Jul 22, 2005
-----------	----	-------------------	------------	----------------	------------	--------------

RAMIPRIL

CAPSULE; ORAL

ALTACE

<u>AB</u>	+	KING PHARMS LLC	<u>1.25MG</u>	<u>N019901</u>	<u>001</u>	Jan 28, 1991
<u>AB</u>	+		<u>2.5MG</u>	<u>N019901</u>	<u>002</u>	Jan 28, 1991
<u>AB</u>	+		<u>5MG</u>	<u>N019901</u>	<u>003</u>	Jan 28, 1991
<u>AB</u>	+!		<u>10MG</u>	<u>N019901</u>	<u>004</u>	Jan 28, 1991

RAMIPRIL

<u>AB</u>		ACCORD HLTHCARE	<u>1.25MG</u>	<u>A202392</u>	<u>001</u>	Apr 15, 2014
<u>AB</u>			<u>2.5MG</u>	<u>A202392</u>	<u>002</u>	Apr 15, 2014
<u>AB</u>			<u>5MG</u>	<u>A202392</u>	<u>003</u>	Apr 15, 2014
<u>AB</u>			<u>10MG</u>	<u>A202392</u>	<u>004</u>	Apr 15, 2014
<u>AB</u>		APOTEX	<u>1.25MG</u>	<u>A079116</u>	<u>001</u>	Jun 20, 2008
<u>AB</u>			<u>2.5MG</u>	<u>A079116</u>	<u>002</u>	Jun 20, 2008
<u>AB</u>			<u>5MG</u>	<u>A079116</u>	<u>003</u>	Jun 20, 2008
<u>AB</u>			<u>10MG</u>	<u>A079116</u>	<u>004</u>	Jun 20, 2008
<u>AB</u>		AUROBINDO PHARMA LTD	<u>1.25MG</u>	<u>A091604</u>	<u>001</u>	Jun 08, 2011
<u>AB</u>			<u>2.5MG</u>	<u>A091604</u>	<u>002</u>	Jun 08, 2011
<u>AB</u>			<u>5MG</u>	<u>A091604</u>	<u>003</u>	Jun 08, 2011
<u>AB</u>			<u>10MG</u>	<u>A091604</u>	<u>004</u>	Jun 08, 2011
<u>AB</u>		CHARTWELL MOLECULAR	<u>1.25MG</u>	<u>A078745</u>	<u>001</u>	Jun 18, 2008
<u>AB</u>			<u>2.5MG</u>	<u>A078745</u>	<u>002</u>	Jun 18, 2008
<u>AB</u>			<u>5MG</u>	<u>A078745</u>	<u>003</u>	Jun 18, 2008
<u>AB</u>			<u>10MG</u>	<u>A078745</u>	<u>004</u>	Jun 18, 2008
<u>AB</u>		DR REDDYS LABS LTD	<u>1.25MG</u>	<u>A078191</u>	<u>001</u>	Jun 18, 2008
<u>AB</u>			<u>2.5MG</u>	<u>A078191</u>	<u>002</u>	Jun 18, 2008
<u>AB</u>			<u>5MG</u>	<u>A078191</u>	<u>003</u>	Jun 18, 2008
<u>AB</u>			<u>10MG</u>	<u>A078191</u>	<u>004</u>	Jun 18, 2008
<u>AB</u>		HIKMA	<u>1.25MG</u>	<u>A077900</u>	<u>001</u>	Jun 18, 2008
<u>AB</u>			<u>2.5MG</u>	<u>A077900</u>	<u>002</u>	Jun 18, 2008
<u>AB</u>			<u>5MG</u>	<u>A077900</u>	<u>003</u>	Jun 18, 2008
<u>AB</u>			<u>10MG</u>	<u>A077900</u>	<u>004</u>	Jun 18, 2008
<u>AB</u>		LUPIN	<u>1.25MG</u>	<u>A077626</u>	<u>001</u>	Jun 09, 2008
<u>AB</u>			<u>2.5MG</u>	<u>A077626</u>	<u>002</u>	Jun 09, 2008
<u>AB</u>			<u>5MG</u>	<u>A077626</u>	<u>003</u>	Jun 09, 2008
<u>AB</u>			<u>10MG</u>	<u>A077626</u>	<u>004</u>	Jun 09, 2008
<u>AB</u>		WATSON LABS	<u>1.25MG</u>	<u>A076549</u>	<u>001</u>	Oct 24, 2005
<u>AB</u>			<u>2.5MG</u>	<u>A076549</u>	<u>002</u>	Oct 24, 2005
<u>AB</u>			<u>10MG</u>	<u>A076549</u>	<u>004</u>	Oct 24, 2005
<u>AB</u>		ZYDUS PHARMS USA	<u>1.25MG</u>	<u>A078832</u>	<u>001</u>	Sep 02, 2008
<u>AB</u>			<u>2.5MG</u>	<u>A078832</u>	<u>002</u>	Sep 02, 2008
<u>AB</u>			<u>5MG</u>	<u>A078832</u>	<u>003</u>	Sep 02, 2008
<u>AB</u>			<u>10MG</u>	<u>A078832</u>	<u>004</u>	Sep 02, 2008

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL

RANITIDINE HYDROCHLORIDE

<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 150MG BASE</u>	<u>A211058</u>	<u>001</u>	Jul 16, 2018
<u>AB</u>			<u>EQ 300MG BASE</u>	<u>A211058</u>	<u>002</u>	Jul 16, 2018
<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 150MG BASE</u>	<u>A075742</u>	<u>001</u>	Nov 29, 2000
<u>AB</u>			<u>EQ 300MG BASE</u>	<u>A075742</u>	<u>002</u>	Nov 29, 2000
<u>AB</u>		SANDOZ	<u>EQ 150MG BASE</u>	<u>A074655</u>	<u>001</u>	Oct 22, 1997
<u>AB</u>	!		<u>EQ 300MG BASE</u>	<u>A074655</u>	<u>002</u>	Oct 22, 1997

INJECTABLE; INJECTION

RANITIDINE HYDROCHLORIDE

<u>AP</u>		MYLAN LABS LTD	<u>EQ 25MG BASE/ML</u>	<u>A079076</u>	<u>001</u>	Jun 09, 2016
<u>AP</u>		WEST-WARD PHARMS INT	<u>EQ 25MG BASE/ML</u>	<u>A074777</u>	<u>001</u>	Mar 02, 2005
<u>AP</u>			<u>EQ 25MG BASE/ML</u>	<u>A077458</u>	<u>001</u>	Feb 16, 2006
<u>AP</u>		ZYDUS PHARMS USA	<u>EQ 25MG BASE/ML</u>	<u>A091534</u>	<u>001</u>	Feb 22, 2013

PRESCRIPTION DRUG PRODUCT LIST

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

RANITIDINE HYDROCHLORIDE

INC

ZANTAC

<u>AP</u>	+!	TELIGENT	<u>EQ 25MG BASE/ML</u>	<u>N019090 001</u>	Oct 19, 1984
		SYRUP; ORAL			

RANITIDINE HYDROCHLORIDE

<u>AA</u>		AUROBINDO PHARMA LTD	<u>EQ 15MG BASE/ML</u>	<u>A090623 001</u>	Jul 28, 2010
<u>AA</u>		LANNETT CO INC	<u>EQ 15MG BASE/ML</u>	<u>A078890 001</u>	Jul 01, 2010
<u>AA</u>			<u>EQ 15MG BASE/ML</u>	<u>A091288 001</u>	Dec 09, 2010
<u>AA</u>	!	PHARM ASSOC	<u>EQ 15MG BASE/ML</u>	<u>A077405 001</u>	Sep 21, 2007
		TABLET; ORAL			

RANITIDINE HYDROCHLORIDE

<u>AB</u>		APOTEX	<u>EQ 150MG BASE</u>	<u>A074680 001</u>	Sep 12, 1997
<u>AB</u>			<u>EQ 300MG BASE</u>	<u>A074680 002</u>	Sep 12, 1997
<u>AB</u>		DR REDDYS LABS INC	<u>EQ 150MG BASE</u>	<u>A076705 001</u>	Jul 27, 2005
<u>AB</u>			<u>EQ 300MG BASE</u>	<u>A076705 002</u>	Jul 27, 2005
<u>AB</u>		GLENMARK PHARMS INC	<u>EQ 150MG BASE</u>	<u>A078542 001</u>	Nov 19, 2008
<u>AB</u>			<u>EQ 300MG BASE</u>	<u>A078542 002</u>	Nov 19, 2008
<u>AB</u>		PAR PHARM	<u>EQ 150MG BASE</u>	<u>A075180 001</u>	Jan 28, 1999
<u>AB</u>			<u>EQ 300MG BASE</u>	<u>A075180 002</u>	Jan 28, 1999
<u>AB</u>		SANDOZ	<u>EQ 150MG BASE</u>	<u>A074467 001</u>	Aug 29, 1997
<u>AB</u>			<u>EQ 300MG BASE</u>	<u>A074467 002</u>	Aug 29, 1997
<u>AB</u>		VKT PHARMA	<u>EQ 150MG BASE</u>	<u>A211289 001</u>	Jan 31, 2019
<u>AB</u>			<u>EQ 300MG BASE</u>	<u>A211289 002</u>	Jan 31, 2019
<u>AB</u>		WOCKHARDT LTD	<u>EQ 150MG BASE</u>	<u>A075208 001</u>	Dec 17, 1998
<u>AB</u>			<u>EQ 300MG BASE</u>	<u>A075208 002</u>	Dec 17, 1998

RANOLAZINE

TABLET, EXTENDED RELEASE; ORAL

RANEXA

<u>AB</u>	+	GILEAD	<u>500MG</u>	<u>N021526 002</u>	Jan 27, 2006
<u>AB</u>	+!		<u>1GM</u>	<u>N021526 001</u>	Feb 12, 2007

RANOLAZINE

<u>AB</u>		ACTAVIS ELIZABETH	<u>500MG</u>	<u>A208862 001</u>	May 28, 2019
<u>AB</u>			<u>1GM</u>	<u>A208862 002</u>	May 28, 2019
<u>AB</u>		AJANTA PHARMA LTD	<u>500MG</u>	<u>A210054 001</u>	May 28, 2019
<u>AB</u>			<u>1GM</u>	<u>A210054 002</u>	May 28, 2019
<u>AB</u>		ALKEM LABS LTD	<u>500MG</u>	<u>A209953 001</u>	Nov 30, 2020
<u>AB</u>			<u>1GM</u>	<u>A209953 002</u>	Nov 30, 2020
<u>AB</u>		CADILA	<u>500MG</u>	<u>A210188 001</u>	Aug 19, 2019
<u>AB</u>			<u>1GM</u>	<u>A210188 002</u>	Aug 19, 2019
<u>AB</u>		GLENMARK PHARMS LTD	<u>500MG</u>	<u>A211082 001</u>	Jul 05, 2019
<u>AB</u>			<u>1GM</u>	<u>A211082 002</u>	Jul 05, 2019
<u>AB</u>		LUPIN LTD	<u>500MG</u>	<u>A201046 001</u>	Jul 29, 2013
<u>AB</u>			<u>1GM</u>	<u>A201046 002</u>	Jul 29, 2013
<u>AB</u>		MANKIND PHARMA	<u>500MG</u>	<u>A212284 001</u>	Feb 12, 2020
<u>AB</u>			<u>1GM</u>	<u>A212284 002</u>	Feb 12, 2020
<u>AB</u>		MICRO LABS	<u>500MG</u>	<u>A211745 001</u>	Feb 27, 2020
<u>AB</u>			<u>1GM</u>	<u>A211745 002</u>	Feb 27, 2020
<u>AB</u>		SCIEGEN PHARMS INC	<u>500MG</u>	<u>A211829 001</u>	Jun 04, 2019
<u>AB</u>			<u>1GM</u>	<u>A211829 002</u>	Jun 04, 2019
<u>AB</u>		SUN PHARM	<u>500MG</u>	<u>A211707 001</u>	May 28, 2019
<u>AB</u>			<u>1GM</u>	<u>A211707 002</u>	May 28, 2019
<u>AB</u>		SUNGEN PHARMA	<u>500MG</u>	<u>A212781 001</u>	Mar 23, 2020
<u>AB</u>			<u>1GM</u>	<u>A212781 002</u>	Mar 23, 2020
<u>AB</u>		SUNSHINE	<u>500MG</u>	<u>A211865 001</u>	Mar 23, 2020
<u>AB</u>			<u>1GM</u>	<u>A211865 002</u>	Mar 23, 2020

RASAGILINE MESYLATE

TABLET; ORAL

AZILECT

<u>AB</u>	+	TEVA	<u>EQ 0.5MG BASE</u>	<u>N021641 001</u>	May 16, 2006
<u>AB</u>	+!		<u>EQ 1MG BASE</u>	<u>N021641 002</u>	May 16, 2006

RASAGILINE MESYLATE

<u>AB</u>		ALKEM LABS LTD	<u>EQ 0.5MG BASE</u>	<u>A201889 001</u>	Oct 30, 2017
<u>AB</u>			<u>EQ 1MG BASE</u>	<u>A201889 002</u>	Oct 30, 2017
<u>AB</u>		INDOCO	<u>EQ 0.5MG BASE</u>	<u>A206153 001</u>	Oct 04, 2019
<u>AB</u>			<u>EQ 1MG BASE</u>	<u>A206153 002</u>	Oct 04, 2019
<u>AB</u>		MICRO LABS	<u>EQ 0.5MG BASE</u>	<u>A207004 001</u>	Mar 29, 2019
<u>AB</u>			<u>EQ 1MG BASE</u>	<u>A207004 002</u>	Mar 29, 2019
<u>AB</u>		MYLAN	<u>EQ 0.5MG BASE</u>	<u>A201971 001</u>	May 15, 2017

PRESCRIPTION DRUG PRODUCT LIST

RASAGILINE MESYLATE

TABLET; ORAL

RASAGILINE MESYLATE

<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A201971 002</u>	May 15, 2017
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 0.5MG BASE</u>	<u>A201970 001</u>	Mar 15, 2016
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A201970 002</u>	Mar 15, 2016
<u>AB</u>	SANDOZ INC	<u>EQ 0.5MG BASE</u>	<u>A201892 001</u>	Jul 27, 2018
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A201892 002</u>	Jul 27, 2018

REGADENOSON

SOLUTION; INTRAVENOUS

LEXISCAN

+	!	ASTELLAS	0.4MG/5ML (0.08MG/ML)	N022161 001	Apr 10, 2008
---	---	----------	-----------------------	-------------	--------------

REGORAFENIB

TABLET; ORAL

STIVARGA

+	!	BAYER HLTHCARE	40MG	N203085 001	Sep 27, 2012
---	---	----------------	------	-------------	--------------

RELUGOLIX

TABLET; ORAL

ORGOVYX

+	!	MYOVANT SCIENCES	120MG	N214621 001	Dec 18, 2020
---	---	------------------	-------	-------------	--------------

REMDESIVIR

POWDER; INTRAVENOUS

VEKLURY

+	!	GILEAD SCIENCES INC	100MG/VIAL	N214787 001	Oct 22, 2020
---	---	---------------------	------------	-------------	--------------

SOLUTION; INTRAVENOUS

VEKLURY

+	!	GILEAD SCIENCES INC	100MG/20ML (5MG/ML)	N214787 002	Oct 22, 2020
---	---	---------------------	---------------------	-------------	--------------

REMIFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION

REMIFENTANIL HYDROCHLORIDE

<u>AP</u>		FRESENIUS KABI USA	<u>EQ 1MG BASE/VIAL</u>	<u>A206223 001</u>	Jan 16, 2018
<u>AP</u>			<u>EQ 2MG BASE/VIAL</u>	<u>A206223 002</u>	Jan 16, 2018
<u>AP</u>			<u>EQ 5MG BASE/VIAL</u>	<u>A206223 003</u>	Jan 16, 2018
<u>AP</u>		NAVINTA LLC	<u>EQ 1MG BASE/VIAL</u>	<u>A210594 001</u>	Oct 13, 2020
<u>AP</u>			<u>EQ 2MG BASE/VIAL</u>	<u>A210594 002</u>	Oct 13, 2020
<u>AP</u>			<u>EQ 5MG BASE/VIAL</u>	<u>A210594 003</u>	Oct 13, 2020
		<u>ULTIVA</u>			
<u>AP</u>	+	MYLAN INSTITUTIONAL	<u>EQ 1MG BASE/VIAL</u>	<u>N020630 001</u>	Jul 12, 1996
<u>AP</u>	+		<u>EQ 2MG BASE/VIAL</u>	<u>N020630 002</u>	Jul 12, 1996
<u>AP</u>	+	!	<u>EQ 5MG BASE/VIAL</u>	<u>N020630 003</u>	Jul 12, 1996

REMIMAZOLAM BESYLATE

POWDER; INTRAVENOUS

BYFAVO

+	!	ACACIA	EQ 20MG BASE/VIAL	N212295 001	Oct 06, 2020
---	---	--------	-------------------	-------------	--------------

REPAGLINIDE

TABLET; ORAL

REPAGLINIDE

<u>AB</u>		AUROBINDO PHARMA LTD	<u>0.5MG</u>	<u>A203820 001</u>	Jan 22, 2014
<u>AB</u>			<u>1MG</u>	<u>A203820 002</u>	Jan 22, 2014
<u>AB</u>	!		<u>2MG</u>	<u>A203820 003</u>	Jan 22, 2014
<u>AB</u>		BOSCOGEN	<u>0.5MG</u>	<u>A091517 001</u>	Apr 24, 2015
<u>AB</u>			<u>1MG</u>	<u>A091517 002</u>	Apr 24, 2015
<u>AB</u>			<u>2MG</u>	<u>A091517 003</u>	Apr 24, 2015
<u>AB</u>		CHARTWELL RX	<u>0.5MG</u>	<u>A078555 001</u>	Nov 22, 2013
<u>AB</u>			<u>1MG</u>	<u>A078555 002</u>	Jan 22, 2014
<u>AB</u>			<u>2MG</u>	<u>A078555 003</u>	Jan 22, 2014
<u>AB</u>		PADDOCK LABS LLC	<u>0.5MG</u>	<u>A201189 001</u>	Jul 17, 2013
<u>AB</u>			<u>1MG</u>	<u>A201189 002</u>	Jan 22, 2014
<u>AB</u>			<u>2MG</u>	<u>A201189 003</u>	Jan 22, 2014
<u>AB</u>		SUN PHARM INDS INC	<u>1MG</u>	<u>A077571 002</u>	Jul 11, 2013
<u>AB</u>			<u>2MG</u>	<u>A077571 003</u>	Jul 11, 2013

RETAPAMULIN

OINTMENT; TOPICAL

ALTABAX

+	!	ALMIRALL	1%	N022055 001	Apr 12, 2007
---	---	----------	----	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

REVEFENACIN

SOLUTION; INHALATION

YUPELRI

+! MYLAN IRELAND LTD 175MCG/3ML N210598 001 Nov 09, 2018

RIBAVIRIN

CAPSULE; ORAL

REBETOL**AB** +! MERCK SHARP DOHME **200MG** **N020903 002** Jul 25, 2001RIBAVIRIN**AB** AUROBINDO PHARMA **200MG** **A079117 001** Sep 17, 2009**AB** ZYDUS PHARMS USA **200MG** **A077224 001** Oct 28, 2005

FOR SOLUTION; INHALATION

RIBAVIRIN**AN** NAVINTA LLC **6GM/VIAL** **A207366 001** Oct 06, 2016VIRAZOLE**AN** +! BAUSCH **6GM/VIAL** **N018859 001** Dec 31, 1985

TABLET; ORAL

RIBAVIRIN**AB** AUROBINDO PHARMA **200MG** **A079111 001** Sep 17, 2009**AB** SANDOZ **200MG** **A077743 001** Oct 03, 2006**AB** ZYDUS PHARMS USA **200MG** **A077094 001** Dec 05, 2005RIBOCICLIB SUCCINATE

TABLET; ORAL

KISQALI

+! NOVARTIS EQ 200MG BASE N209092 001 Mar 13, 2017

RIBOFLAVIN 5'-PHOSPHATE SODIUM

SOLUTION/DROPS; OPHTHALMIC

PHOTREXA

+! GLAUKOS 0.146% N203324 001 Apr 15, 2016

PHOTREXA VISCOUS IN DEXTRAN 20%

+! GLAUKOS 0.146% N203324 002 Apr 15, 2016

RIFABUTIN

CAPSULE; ORAL

MYCOBUTIN**AB** +! PFIZER **150MG** **N050689 001** Dec 23, 1992RIFABUTIN**AB** LUPIN LTD **150MG** **A090033 001** Feb 24, 2014RIFAMPIN

CAPSULE; ORAL

RIFAMPIN**AB** AKORN **150MG** **A065028 001** Mar 14, 2001**AB** **300MG** **A065028 002** Mar 14, 2001**AB** LANNETT CO INC **150MG** **A065390 001** Mar 28, 2008**AB** **300MG** **A065390 002** Mar 28, 2008**AB** LUPIN PHARMS **150MG** **A090034 001** Aug 21, 2013**AB** ! **300MG** **A090034 002** Aug 21, 2013**AB** SANDOZ **150MG** **A064150 002** Jan 02, 1998**AB** **300MG** **A064150 001** May 28, 1997RIMACTANE**AB** OXFORD PHARMS **300MG** **N050429 001**

INJECTABLE; INJECTION

RIFADIN**AP** +! SANOFI AVENTIS US **600MG/VIAL** **N050627 001** May 25, 1989RIFAMPIN**AP** AKORN **600MG/VIAL** **A065502 001** Sep 21, 2010**AP** FRESENIUS KABI USA **600MG/VIAL** **A091181 001** Aug 21, 2014**AP** HIKMA PHARMS **600MG/VIAL** **A205039 001** Mar 03, 2016**AP** MYLAN LABS LTD **600MG/VIAL** **A065421 001** May 22, 2008**AP** WATSON PHARMS TEVA **600MG/VIAL** **A206736 001** Jan 19, 2016**AP** WEST-WARD PHARMS **600MG/VIAL** **A064217 001** Oct 29, 1999

INT

RIFAMYCIN SODIUM

TABLET, DELAYED RELEASE; ORAL

AEMCOLO

+! REDHILL EQ 194MG BASE N210910 001 Nov 16, 2018

PRESCRIPTION DRUG PRODUCT LIST

RIFAPENTINE

TABLET;ORAL

PRIFITIN

+! SANOFI AVENTIS US 150MG N021024 001 Jun 22, 1998

RIFAXIMIN

TABLET;ORAL

XIFAXAN

+! SALIX PHARMS 200MG N021361 001 May 25, 2004

+! 550MG N022554 001 Mar 24, 2010

RILPIVIRINE HYDROCHLORIDE

TABLET;ORAL

EDURANT

+! JANSSEN PRODS EQ 25MG BASE N202022 001 May 20, 2011

RILUZOLE

FILM;ORAL

EXSERVAN

+! AQUESTIVE THERAP 50MG N212640 001 Nov 22, 2019

SUSPENSION;ORAL

TIGLUTIK KIT

+! ITALFARMACO SPA 50MG/10ML N209080 001 Sep 05, 2018

TABLET;ORAL

RILUTEK**AB** +! COVIS **50MG** **N020599 001** Dec 12, 1995RILUZOLE**AB** ALKEM LABS LTD **50MG** **A204048 001** Mar 30, 2016**AB** GLENMARK PHARMS LTD **50MG** **A091394 001** Jun 18, 2013**AB** IMPAX LABS **50MG** **A076173 001** Jan 29, 2003**AB** KENTON **50MG** **A206045 001** Dec 09, 2019**AB** MYLAN PHARMS INC **50MG** **A203042 001** Jul 01, 2013**AB** SUN PHARM INDS LTD **50MG** **A091417 001** Jun 18, 2013RIMANTADINE HYDROCHLORIDE

TABLET;ORAL

FLUMADINE**AB** +! SUN PHARM INDS INC **100MG** **N019649 001** Sep 17, 1993RIMANTADINE HYDROCHLORIDE**AB** IMPAX LABS **100MG** **A076132 001** Aug 30, 2002RIMEGEPANT SULFATE

TABLET, ORALLY DISINTEGRATING;ORAL

NURTEC ODT

+! BIOHAVEN PHARM EQ 75MG BASE N212728 001 Feb 27, 2020

RIOCIGUAT

TABLET;ORAL

ADEMPAS

+ BAYER HLTHCARE 0.5MG N204819 001 Oct 08, 2013

+ 1MG N204819 002 Oct 08, 2013

+ 1.5MG N204819 003 Oct 08, 2013

+ 2MG N204819 004 Oct 08, 2013

+! 2.5MG N204819 005 Oct 08, 2013

RIPRETINIB

TABLET;ORAL

QINLOCK

+! DECIPHERA PHARMS 50MG N213973 001 May 15, 2020

RISDIPLAM

FOR SOLUTION;ORAL

EVRYSDI

+! GENENTECH INC 0.75MG/ML N213535 001 Aug 07, 2020

RISEDRONATE SODIUM

TABLET;ORAL

ACTONEL**AB** + APIL **5MG** **N020835 002** Apr 14, 2000**AB** + **30MG** **N020835 001** Mar 27, 1998**AB** +! **35MG** **N020835 003** May 25, 2002**AB** +! **150MG** **N020835 005** Apr 22, 2008RISEDRONATE SODIUM**AB** APOTEX INC **35MG** **A090877 001** Nov 30, 2015**AB** **75MG** **A090877 002** Jun 10, 2014**AB** **150MG** **A090877 003** Jun 10, 2014**AB** AUROBINDO PHARMA **5MG** **A200296 001** Nov 30, 2015

PRESCRIPTION DRUG PRODUCT LIST

RISEDRONATE SODIUM

TABLET; ORAL

RISEDRONATE SODIUM

LTD

<u>AB</u>		<u>30MG</u>	<u>A200296</u>	<u>002</u>	Nov 30, 2015
<u>AB</u>		<u>35MG</u>	<u>A200296</u>	<u>003</u>	Nov 30, 2015
<u>AB</u>		<u>150MG</u>	<u>A206768</u>	<u>001</u>	Oct 21, 2016
<u>AB</u>	MACLEODS PHARMS LTD	<u>5MG</u>	<u>A203533</u>	<u>001</u>	Dec 09, 2015
<u>AB</u>		<u>30MG</u>	<u>A203533</u>	<u>002</u>	Dec 09, 2015
<u>AB</u>		<u>35MG</u>	<u>A203533</u>	<u>003</u>	Nov 29, 2016
<u>AB</u>	ORCHID HLTHCARE	<u>30MG</u>	<u>A205280</u>	<u>001</u>	May 13, 2019
<u>AB</u>		<u>35MG</u>	<u>A205280</u>	<u>002</u>	May 13, 2019
<u>AB</u>	SUN PHARM	<u>5MG</u>	<u>A090886</u>	<u>001</u>	Nov 30, 2015
<u>AB</u>		<u>30MG</u>	<u>A090886</u>	<u>002</u>	Nov 30, 2015
<u>AB</u>		<u>35MG</u>	<u>A090886</u>	<u>003</u>	Nov 30, 2015
<u>AB</u>		<u>75MG</u>	<u>A090886</u>	<u>004</u>	Jun 10, 2014
<u>AB</u>		<u>150MG</u>	<u>A090886</u>	<u>005</u>	Jun 10, 2014
<u>AB</u>	TEVA PHARMS USA	<u>5MG</u>	<u>A077132</u>	<u>001</u>	Oct 05, 2007
<u>AB</u>		<u>30MG</u>	<u>A077132</u>	<u>002</u>	Oct 05, 2007
<u>AB</u>		<u>35MG</u>	<u>A077132</u>	<u>003</u>	Oct 05, 2007
<u>AB</u>		<u>150MG</u>	<u>A079215</u>	<u>001</u>	Jun 13, 2014

TABLET, DELAYED RELEASE; ORAL

ATELVIA

<u>AB</u>	<u>+</u> !	APIL	<u>35MG</u>	<u>N022560</u>	<u>001</u>	Oct 08, 2010
-----------	------------	------	-------------	----------------	------------	--------------

RISEDRONATE SODIUM

<u>AB</u>		SUN PHARM	<u>35MG</u>	<u>A203925</u>	<u>001</u>	Jul 09, 2019
<u>AB</u>		TEVA PHARMS USA	<u>35MG</u>	<u>A203217</u>	<u>001</u>	May 18, 2015

RISPERIDONE

FOR SUSPENSION, EXTENDED RELEASE; SUBCUTANEOUS

PERSERIS KIT

<u>+</u>	INDIVIOR INC	90MG	N210655	001	Jul 27, 2018
<u>+</u> !		120MG	N210655	002	Jul 27, 2018

INJECTABLE; INTRAMUSCULAR

RISPERDAL CONSTA

<u>+</u>	JANSSEN PHARMS	12.5MG/VIAL	N021346	004	Apr 12, 2007
<u>+</u> !		25MG/VIAL	N021346	001	Oct 29, 2003
<u>+</u>		37.5MG/VIAL	N021346	002	Oct 29, 2003
<u>+</u>		50MG/VIAL	N021346	003	Oct 29, 2003

SOLUTION; ORAL

RISPERDAL

<u>AA</u>	<u>+</u> !	JANSSEN PHARMS	<u>1MG/ML</u>	<u>N020588</u>	<u>001</u>	Jun 10, 1996
-----------	------------	----------------	---------------	----------------	------------	--------------

RISPERIDONE

<u>AA</u>		AMNEAL PHARMS	<u>1MG/ML</u>	<u>A091384</u>	<u>001</u>	May 25, 2011
<u>AA</u>		AUROBINDO PHARMA LTD	<u>1MG/ML</u>	<u>A078452</u>	<u>001</u>	Sep 04, 2009
<u>AA</u>		HIKMA	<u>1MG/ML</u>	<u>A076904</u>	<u>001</u>	Jul 29, 2009
<u>AA</u>		LANNETT CO INC	<u>1MG/ML</u>	<u>A079158</u>	<u>001</u>	Dec 03, 2010
<u>AA</u>		PHARM ASSOC	<u>1MG/ML</u>	<u>A077719</u>	<u>001</u>	Jul 29, 2009
<u>AA</u>		TARO	<u>1MG/ML</u>	<u>A090347</u>	<u>001</u>	Feb 07, 2011
<u>AA</u>		TRIS PHARMA INC	<u>1MG/ML</u>	<u>A079059</u>	<u>001</u>	Dec 12, 2012

TABLET; ORAL

RISPERDAL

<u>AB</u>	<u>+</u>	JANSSEN PHARMS	<u>0.25MG</u>	<u>N020272</u>	<u>008</u>	May 10, 1999
<u>AB</u>	<u>+</u>		<u>0.5MG</u>	<u>N020272</u>	<u>007</u>	Jan 27, 1999
<u>AB</u>	<u>+</u> !		<u>1MG</u>	<u>N020272</u>	<u>001</u>	Dec 29, 1993
<u>AB</u>	<u>+</u>		<u>2MG</u>	<u>N020272</u>	<u>002</u>	Dec 29, 1993
<u>AB</u>	<u>+</u>		<u>3MG</u>	<u>N020272</u>	<u>003</u>	Dec 29, 1993
<u>AB</u>	<u>+</u>		<u>4MG</u>	<u>N020272</u>	<u>004</u>	Dec 29, 1993

RISPERIDONE

<u>AB</u>		AJANTA PHARMA LTD	<u>0.25MG</u>	<u>A201003</u>	<u>001</u>	Aug 24, 2011
<u>AB</u>			<u>0.5MG</u>	<u>A201003</u>	<u>002</u>	Aug 24, 2011
<u>AB</u>			<u>1MG</u>	<u>A201003</u>	<u>003</u>	Aug 24, 2011
<u>AB</u>			<u>2MG</u>	<u>A201003</u>	<u>004</u>	Aug 24, 2011
<u>AB</u>			<u>3MG</u>	<u>A201003</u>	<u>005</u>	Aug 24, 2011
<u>AB</u>			<u>4MG</u>	<u>A201003</u>	<u>006</u>	Aug 24, 2011
<u>AB</u>		AMNEAL	<u>0.25MG</u>	<u>A078071</u>	<u>001</u>	Jun 17, 2009
<u>AB</u>			<u>0.5MG</u>	<u>A078071</u>	<u>002</u>	Jun 17, 2009
<u>AB</u>			<u>1MG</u>	<u>A078071</u>	<u>003</u>	Jun 17, 2009
<u>AB</u>			<u>2MG</u>	<u>A078071</u>	<u>004</u>	Jun 17, 2009
<u>AB</u>			<u>3MG</u>	<u>A078071</u>	<u>005</u>	Jun 17, 2009
<u>AB</u>			<u>4MG</u>	<u>A078071</u>	<u>006</u>	Jun 17, 2009
<u>AB</u>		APOTEX INC	<u>0.25MG</u>	<u>A077953</u>	<u>001</u>	Sep 15, 2008

PRESCRIPTION DRUG PRODUCT LISTRISPERIDONE

TABLET; ORAL

RISPERIDONE

<u>AB</u>		<u>0.5MG</u>	<u>A077953</u>	<u>002</u>	Sep 15, 2008
<u>AB</u>		<u>1MG</u>	<u>A077953</u>	<u>003</u>	Sep 15, 2008
<u>AB</u>		<u>2MG</u>	<u>A077953</u>	<u>004</u>	Sep 15, 2008
<u>AB</u>		<u>3MG</u>	<u>A077953</u>	<u>005</u>	Sep 15, 2008
<u>AB</u>		<u>4MG</u>	<u>A077953</u>	<u>006</u>	Sep 15, 2008
<u>AB</u>	CELLTRION	<u>0.25MG</u>	<u>A078871</u>	<u>001</u>	Oct 09, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A078871</u>	<u>002</u>	Oct 09, 2008
<u>AB</u>		<u>1MG</u>	<u>A078871</u>	<u>003</u>	Oct 09, 2008
<u>AB</u>		<u>2MG</u>	<u>A078871</u>	<u>004</u>	Oct 09, 2008
<u>AB</u>		<u>3MG</u>	<u>A078871</u>	<u>005</u>	Oct 09, 2008
<u>AB</u>		<u>4MG</u>	<u>A078871</u>	<u>006</u>	Oct 09, 2008
<u>AB</u>	CHARTWELL MOLECULAR	<u>0.25MG</u>	<u>A077543</u>	<u>001</u>	May 18, 2011
<u>AB</u>		<u>0.5MG</u>	<u>A077543</u>	<u>002</u>	May 18, 2011
<u>AB</u>		<u>1MG</u>	<u>A077543</u>	<u>003</u>	May 18, 2011
<u>AB</u>		<u>2MG</u>	<u>A077543</u>	<u>004</u>	May 18, 2011
<u>AB</u>		<u>3MG</u>	<u>A077543</u>	<u>005</u>	May 18, 2011
<u>AB</u>		<u>4MG</u>	<u>A077543</u>	<u>006</u>	May 18, 2011
<u>AB</u>	DR REDDYS LABS LTD	<u>0.25MG</u>	<u>A076879</u>	<u>001</u>	Oct 24, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A076879</u>	<u>002</u>	Oct 24, 2008
<u>AB</u>		<u>1MG</u>	<u>A076879</u>	<u>003</u>	Oct 24, 2008
<u>AB</u>		<u>2MG</u>	<u>A076879</u>	<u>004</u>	Oct 24, 2008
<u>AB</u>		<u>3MG</u>	<u>A076879</u>	<u>005</u>	Oct 24, 2008
<u>AB</u>		<u>4MG</u>	<u>A076879</u>	<u>006</u>	Oct 24, 2008
<u>AB</u>	PRINSTON INC	<u>0.25MG</u>	<u>A077493</u>	<u>001</u>	Nov 29, 2011
<u>AB</u>		<u>0.5MG</u>	<u>A077493</u>	<u>002</u>	Nov 29, 2011
<u>AB</u>		<u>1MG</u>	<u>A077493</u>	<u>003</u>	Nov 29, 2011
<u>AB</u>		<u>2MG</u>	<u>A077493</u>	<u>004</u>	Nov 29, 2011
<u>AB</u>		<u>3MG</u>	<u>A077493</u>	<u>005</u>	Nov 29, 2011
<u>AB</u>		<u>4MG</u>	<u>A077493</u>	<u>006</u>	Nov 29, 2011
<u>AB</u>	RENATA	<u>0.25MG</u>	<u>A078707</u>	<u>001</u>	Dec 29, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A078707</u>	<u>002</u>	Dec 29, 2008
<u>AB</u>		<u>1MG</u>	<u>A078707</u>	<u>003</u>	Dec 29, 2008
<u>AB</u>		<u>2MG</u>	<u>A078707</u>	<u>004</u>	Dec 29, 2008
<u>AB</u>		<u>3MG</u>	<u>A078707</u>	<u>005</u>	Dec 29, 2008
<u>AB</u>		<u>4MG</u>	<u>A078707</u>	<u>006</u>	Dec 29, 2008
<u>AB</u>	RISING	<u>0.25MG</u>	<u>A078269</u>	<u>001</u>	Oct 08, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A078269</u>	<u>002</u>	Oct 08, 2008
<u>AB</u>		<u>1MG</u>	<u>A078269</u>	<u>003</u>	Oct 08, 2008
<u>AB</u>		<u>2MG</u>	<u>A078269</u>	<u>004</u>	Oct 08, 2008
<u>AB</u>		<u>3MG</u>	<u>A078269</u>	<u>005</u>	Oct 08, 2008
<u>AB</u>		<u>4MG</u>	<u>A078269</u>	<u>006</u>	Oct 08, 2008
<u>AB</u>	SANDOZ	<u>0.25MG</u>	<u>A078528</u>	<u>001</u>	Oct 16, 2009
<u>AB</u>		<u>0.5MG</u>	<u>A078528</u>	<u>002</u>	Oct 16, 2009
<u>AB</u>		<u>1MG</u>	<u>A078528</u>	<u>003</u>	Oct 16, 2009
<u>AB</u>		<u>2MG</u>	<u>A078528</u>	<u>004</u>	Oct 16, 2009
<u>AB</u>		<u>3MG</u>	<u>A078528</u>	<u>005</u>	Oct 16, 2009
<u>AB</u>		<u>4MG</u>	<u>A078528</u>	<u>006</u>	Oct 16, 2009
<u>AB</u>	TORRENT PHARMS	<u>0.25MG</u>	<u>A079088</u>	<u>001</u>	Oct 30, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A079088</u>	<u>002</u>	Oct 30, 2008
<u>AB</u>		<u>1MG</u>	<u>A079088</u>	<u>003</u>	Oct 30, 2008
<u>AB</u>		<u>2MG</u>	<u>A079088</u>	<u>004</u>	Oct 30, 2008
<u>AB</u>		<u>3MG</u>	<u>A079088</u>	<u>005</u>	Oct 30, 2008
<u>AB</u>		<u>4MG</u>	<u>A079088</u>	<u>006</u>	Oct 30, 2008
<u>AB</u>	ZYDUS PHARMS USA INC	<u>0.25MG</u>	<u>A078040</u>	<u>001</u>	Oct 16, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A078040</u>	<u>002</u>	Oct 16, 2008
<u>AB</u>		<u>1MG</u>	<u>A078040</u>	<u>003</u>	Oct 16, 2008
<u>AB</u>		<u>2MG</u>	<u>A078040</u>	<u>004</u>	Oct 16, 2008
<u>AB</u>		<u>3MG</u>	<u>A078040</u>	<u>005</u>	Oct 16, 2008
<u>AB</u>		<u>4MG</u>	<u>A078040</u>	<u>006</u>	Oct 16, 2008

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERDAL

<u>AB</u>	+	JANSSEN PHARMS	<u>0.5MG</u>	<u>N021444</u>	<u>001</u>	Apr 02, 2003
<u>AB</u>	+	!	<u>1MG</u>	<u>N021444</u>	<u>002</u>	Apr 02, 2003
<u>AB</u>	+		<u>2MG</u>	<u>N021444</u>	<u>003</u>	Apr 02, 2003
<u>AB</u>	+		<u>3MG</u>	<u>N021444</u>	<u>004</u>	Dec 23, 2004
<u>AB</u>	+		<u>4MG</u>	<u>N021444</u>	<u>005</u>	Dec 23, 2004

RISPERIDONE

<u>AB</u>	DR REDDYS LABS LTD	<u>0.5MG</u>	<u>A077328</u>	<u>001</u>	Feb 24, 2009
<u>AB</u>		<u>1MG</u>	<u>A077328</u>	<u>002</u>	Oct 05, 2009

PRESCRIPTION DRUG PRODUCT LIST

RISPERIDONE

TABLET, ORALLY DISINTEGRATING;ORAL

RISPERIDONE

<u>AB</u>		<u>2MG</u>	<u>A077328</u>	<u>003</u>	Feb 24, 2009
<u>AB</u>		<u>3MG</u>	<u>A077328</u>	<u>004</u>	Nov 30, 2009
<u>AB</u>		<u>4MG</u>	<u>A077328</u>	<u>005</u>	Nov 30, 2009
<u>AB</u>	JUBILANT GENERICS	<u>0.5MG</u>	<u>A090839</u>	<u>001</u>	Nov 04, 2011
<u>AB</u>		<u>1MG</u>	<u>A090839</u>	<u>002</u>	Nov 04, 2011
<u>AB</u>		<u>2MG</u>	<u>A090839</u>	<u>003</u>	Nov 04, 2011
<u>AB</u>		<u>3MG</u>	<u>A090839</u>	<u>004</u>	Nov 04, 2011
<u>AB</u>		<u>4MG</u>	<u>A090839</u>	<u>005</u>	Nov 04, 2011
<u>AB</u>	PAR PHARM	<u>0.5MG</u>	<u>A077494</u>	<u>002</u>	Apr 30, 2009
<u>AB</u>		<u>1MG</u>	<u>A077494</u>	<u>003</u>	Oct 26, 2009
<u>AB</u>		<u>2MG</u>	<u>A077494</u>	<u>004</u>	Apr 30, 2009
<u>AB</u>		<u>3MG</u>	<u>A077494</u>	<u>005</u>	Apr 30, 2009
<u>AB</u>		<u>4MG</u>	<u>A077494</u>	<u>006</u>	Apr 30, 2009
<u>AB</u>	SANDOZ	<u>0.5MG</u>	<u>A078116</u>	<u>001</u>	Dec 22, 2009
<u>AB</u>		<u>1MG</u>	<u>A078116</u>	<u>002</u>	Dec 22, 2009
<u>AB</u>		<u>2MG</u>	<u>A078116</u>	<u>003</u>	Dec 22, 2009
<u>AB</u>		<u>3MG</u>	<u>A078116</u>	<u>004</u>	Dec 22, 2009
<u>AB</u>		<u>4MG</u>	<u>A078116</u>	<u>005</u>	Dec 22, 2009
<u>AB</u>	SUN PHARM INDS LTD	<u>0.5MG</u>	<u>A077542</u>	<u>001</u>	Aug 06, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A078464</u>	<u>001</u>	Apr 08, 2013
<u>AB</u>		<u>1MG</u>	<u>A077542</u>	<u>002</u>	Aug 06, 2010
<u>AB</u>		<u>1MG</u>	<u>A078464</u>	<u>002</u>	Apr 08, 2013
<u>AB</u>		<u>2MG</u>	<u>A077542</u>	<u>003</u>	Aug 06, 2010
<u>AB</u>		<u>2MG</u>	<u>A078464</u>	<u>003</u>	Apr 08, 2013
<u>AB</u>		<u>3MG</u>	<u>A078464</u>	<u>004</u>	Apr 08, 2013
<u>AB</u>		<u>3MG</u>	<u>A078474</u>	<u>001</u>	Aug 06, 2010
<u>AB</u>		<u>4MG</u>	<u>A078464</u>	<u>005</u>	Apr 08, 2013
<u>AB</u>		<u>4MG</u>	<u>A078474</u>	<u>002</u>	Aug 06, 2010
<u>AB</u>	ZYDUS PHARMS USA	<u>0.5MG</u>	<u>A078516</u>	<u>001</u>	May 01, 2009
<u>AB</u>		<u>2MG</u>	<u>A078516</u>	<u>003</u>	May 01, 2009
<u>AB</u>	PAR PHARM	0.25MG	A077494	001	Apr 30, 2009

RITONAVIR

CAPSULE;ORAL

RITONAVIR

! HIKMA

100MG

A205801 001 Dec 03, 2020

POWDER;ORAL

NORVIR

+! ABBVIE INC

100MG/PACKET

N209512 001 Jun 07, 2017

SOLUTION;ORAL

NORVIR

+! ABBVIE

80MG/ML

N020659 001 Mar 01, 1996

TABLET;ORAL

NORVIRAB +! ABBVIE100MGN022417 001 Feb 10, 2010RITONAVIRAB AMNEAL100MGA208890 001 Sep 17, 2018AB AUROBINDO PHARMA100MGA206614 001 Sep 17, 2018

LTD

AB HETERO LABS LTD III100MGA204587 001 Sep 17, 2018AB HIKMA100MGA202573 001 Jan 15, 2015RIVAROXABAN

TABLET;ORAL

XARELTO

+ JANSSEN PHARMS

2.5MG

N022406 004 Oct 11, 2018

+

10MG

N022406 001 Jul 01, 2011

+

15MG

N022406 002 Nov 04, 2011

+!

20MG

N022406 003 Nov 04, 2011

RIVASTIGMINE

FILM, EXTENDED RELEASE;TRANSDERMAL

EXELONAB + NOVARTIS4.6MG/24HRN022083 001 Jul 06, 2007AB +!9.5MG/24HRN022083 002 Jul 06, 2007AB +13.3MG/24HRN022083 005 Aug 31, 2012RIVASTIGMINEAB ALVOGEN4.6MG/24HRA204403 001 Sep 03, 2015AB9.5MG/24HRA204403 002 Sep 03, 2015AB13.3MG/24HRA204403 003 Aug 31, 2015AB AMNEAL PHARMS4.6MG/24HRA207308 001 Jan 08, 2019

PRESCRIPTION DRUG PRODUCT LIST

RIVASTIGMINE

FILM, EXTENDED RELEASE;TRANSDERMAL

RIVASTIGMINE

<u>AB</u>		<u>9.5MG/24HR</u>	<u>A207308 002</u>	Jan 08, 2019
<u>AB</u>		<u>13.3MG/24HR</u>	<u>A207308 003</u>	Jan 08, 2019
<u>AB</u>	BRECKENRIDGE	<u>4.6MG/24HR</u>	<u>A209063 001</u>	Nov 26, 2019
<u>AB</u>		<u>9.5MG/24HR</u>	<u>A209063 002</u>	Nov 26, 2019
<u>AB</u>		<u>13.3MG/24HR</u>	<u>A209063 003</u>	Nov 26, 2019
<u>AB</u>	MYLAN TECHNOLOGIES	<u>4.6MG/24HR</u>	<u>A205622 001</u>	Jun 20, 2018
<u>AB</u>		<u>9.5MG/24HR</u>	<u>A205622 002</u>	Jun 20, 2018
<u>AB</u>		<u>13.3MG/24HR</u>	<u>A205622 003</u>	Jun 20, 2018
<u>AB</u>	ZYDUS NOVELTECH INC	<u>4.6MG/24HR</u>	<u>A206318 001</u>	Mar 04, 2019
<u>AB</u>		<u>9.5MG/24HR</u>	<u>A206318 002</u>	Mar 04, 2019
<u>AB</u>		<u>13.3MG/24HR</u>	<u>A206318 003</u>	Mar 04, 2019

RIVASTIGMINE TARTRATE

CAPSULE;ORAL

RIVASTIGMINE TARTRATE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>EQ 1.5MG BASE</u>	<u>A091689 001</u>	Jun 12, 2012
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A091689 002</u>	Jun 12, 2012
<u>AB</u>		<u>EQ 4.5MG BASE</u>	<u>A091689 003</u>	Jun 12, 2012
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A091689 004</u>	Jun 12, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 1.5MG BASE</u>	<u>A204572 001</u>	Mar 25, 2016
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A204572 002</u>	Mar 25, 2016
<u>AB</u>		<u>EQ 4.5MG BASE</u>	<u>A204572 003</u>	Mar 25, 2016
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A204572 004</u>	Mar 25, 2016
<u>AB</u>	CADILA PHARMS LTD	<u>EQ 1.5MG BASE</u>	<u>A203844 001</u>	Feb 13, 2017
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A203844 002</u>	Feb 13, 2017
<u>AB</u>		<u>EQ 4.5MG BASE</u>	<u>A203844 003</u>	Feb 13, 2017
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A203844 004</u>	Feb 13, 2017
<u>AB</u>	CHARTWELL RX	<u>EQ 1.5MG BASE</u>	<u>A207797 001</u>	Sep 28, 2017
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A207797 002</u>	Sep 28, 2017
<u>AB</u>		<u>EQ 4.5MG BASE</u>	<u>A207797 003</u>	Sep 28, 2017
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A207797 004</u>	Sep 28, 2017
<u>AB</u>	! DR REDDYS LABS INC	<u>EQ 1.5MG BASE</u>	<u>A077130 001</u>	Oct 31, 2007
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A077130 002</u>	Oct 31, 2007
<u>AB</u>		<u>EQ 4.5MG BASE</u>	<u>A077130 003</u>	Oct 31, 2007
<u>AB</u>	!	<u>EQ 6MG BASE</u>	<u>A077130 004</u>	Oct 31, 2007
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 1.5MG BASE</u>	<u>A203148 001</u>	Aug 22, 2014
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A203148 002</u>	Aug 22, 2014
<u>AB</u>		<u>EQ 4.5MG BASE</u>	<u>A203148 003</u>	Aug 22, 2014
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A203148 004</u>	Aug 22, 2014
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 1.5MG BASE</u>	<u>A090879 001</u>	Jun 10, 2015
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A090879 002</u>	Jun 10, 2015
<u>AB</u>		<u>EQ 4.5MG BASE</u>	<u>A090879 003</u>	Jun 10, 2015
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A090879 004</u>	Jun 10, 2015
<u>AB</u>	SUN PHARM	<u>EQ 1.5MG BASE</u>	<u>A077131 001</u>	Oct 22, 2007
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A077131 002</u>	Oct 22, 2007
<u>AB</u>		<u>EQ 4.5MG BASE</u>	<u>A077131 003</u>	Oct 22, 2007
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A077131 004</u>	Oct 22, 2007
<u>AB</u>	WATSON LABS	<u>EQ 1.5MG BASE</u>	<u>A077129 001</u>	Jan 08, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A077129 002</u>	Jan 08, 2008
<u>AB</u>		<u>EQ 4.5MG BASE</u>	<u>A077129 003</u>	Jan 08, 2008
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A077129 004</u>	Jan 08, 2008

RIZATRIPTAN BENZOATE

TABLET;ORAL

MAXALT

<u>AB</u>	+! MERCK	<u>EQ 10MG BASE</u>	<u>N020864 002</u>	Jun 29, 1998
-----------	----------	---------------------	--------------------	--------------

RIZATRIPTAN BENZOATE

<u>AB</u>	ALKEM LABS LTD	<u>EQ 5MG BASE</u>	<u>A203269 001</u>	Feb 18, 2016
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A203269 002</u>	Feb 18, 2016
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 5MG BASE</u>	<u>A202490 001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A202490 002</u>	Dec 31, 2012
<u>AB</u>	CELLTRION	<u>EQ 5MG BASE</u>	<u>A077526 001</u>	Mar 26, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077526 002</u>	Mar 26, 2013
<u>AB</u>	GLENMARK GENERICS	<u>EQ 5MG BASE</u>	<u>A201967 001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A201967 002</u>	Dec 31, 2012
<u>AB</u>	INVAGEN PHARMS	<u>EQ 5MG BASE</u>	<u>A204339 001</u>	Jul 01, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A204339 002</u>	Jul 01, 2013
<u>AB</u>	JUBILANT GENERICS	<u>EQ 5MG BASE</u>	<u>A203252 001</u>	Dec 31, 2014
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A203252 002</u>	Dec 31, 2014

PRESCRIPTION DRUG PRODUCT LIST

RIZATRIPTAN BENZOATE

TABLET; ORAL

RIZATRIPTAN BENZOATE

<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 5MG BASE</u>	<u>A203147 001</u>	Feb 11, 2014
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A203147 002</u>	Feb 11, 2014
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 5MG BASE</u>	<u>A201993 001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A201993 002</u>	Dec 31, 2012
<u>AB</u>	NATCO PHARMA LTD	<u>EQ 5MG BASE</u>	<u>A200482 001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A200482 002</u>	Dec 31, 2012
<u>AB</u>	PHARMA LIFE	<u>EQ 5MG BASE</u>	<u>A202047 001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A202047 002</u>	Dec 31, 2012
<u>AB</u>	SANDOZ	<u>EQ 5MG BASE</u>	<u>A079230 001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A079230 002</u>	Dec 31, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 5MG BASE</u>	<u>A077263 001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077263 002</u>	Dec 31, 2012

TABLET, ORALLY DISINTEGRATING; ORAL

MAXALT-MLT

<u>AB</u>	+! MERCK	<u>EQ 10MG BASE</u>	<u>N020865 002</u>	Jun 29, 1998
-----------	----------	---------------------	--------------------	--------------

RIZATRIPTAN BENZOATE

<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 5MG BASE</u>	<u>A203062 001</u>	Jul 01, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A203062 002</u>	Jul 01, 2013
<u>AB</u>	GLENMARK PHARMS LTD	<u>EQ 5MG BASE</u>	<u>A201914 001</u>	Jul 01, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A201914 002</u>	Jul 01, 2013
<u>AB</u>	JUBILANT GENERICS	<u>EQ 5MG BASE</u>	<u>A203334 001</u>	Oct 16, 2015
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A203334 002</u>	Oct 16, 2015
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 5MG BASE</u>	<u>A203146 001</u>	Sep 19, 2014
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A203146 002</u>	Sep 19, 2014
<u>AB</u>	NATCO PHARMA LTD	<u>EQ 5MG BASE</u>	<u>A203478 001</u>	Jul 01, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A203478 002</u>	Jul 01, 2013
<u>AB</u>	PANACEA BIOTEC LTD	<u>EQ 5MG BASE</u>	<u>A204722 001</u>	Jan 11, 2017
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A204722 002</u>	Jan 11, 2017
<u>AB</u>	SANDOZ	<u>EQ 5MG BASE</u>	<u>A078739 001</u>	Jul 01, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078739 002</u>	Jul 01, 2013
<u>AB</u>	UNICHEM	<u>EQ 5MG BASE</u>	<u>A207835 001</u>	Mar 07, 2017
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A207835 002</u>	Mar 07, 2017

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ROCURONIUM BROMIDE

<u>AP</u>	AUROBINDO PHARMA LTD	<u>50MG/5ML (10MG/ML)</u>	<u>A206206 001</u>	Apr 12, 2017
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A206206 002</u>	Apr 12, 2017
<u>AP</u>	FRESENIUS KABI USA	<u>50MG/5ML (10MG/ML)</u>	<u>A078651 001</u>	Dec 29, 2008
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A078651 002</u>	Dec 29, 2008
<u>AP</u>	GLAND PHARMA LTD	<u>50MG/5ML (10MG/ML)</u>	<u>A205656 001</u>	Apr 04, 2018
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A205656 002</u>	Apr 04, 2018
<u>AP</u>	HOSPIRA	<u>50MG/5ML (10MG/ML)</u>	<u>A078519 001</u>	Nov 26, 2008
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A078519 002</u>	Nov 26, 2008
<u>AP</u>	MYLAN INSTITUTIONAL	<u>50MG/5ML (10MG/ML)</u>	<u>A079199 001</u>	Nov 26, 2008
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A079199 002</u>	Nov 26, 2008
<u>AP</u>	PIRAMAL CRITICAL	<u>50MG/5ML (10MG/ML)</u>	<u>A210437 001</u>	Aug 13, 2019
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A210437 002</u>	Aug 13, 2019
<u>AP</u>	SAGENT PHARMS INC	<u>50MG/5ML (10MG/ML)</u>	<u>A091458 001</u>	Jul 28, 2010
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A091458 002</u>	Jul 28, 2010
<u>AP</u>	! SANDOZ INC	<u>50MG/5ML (10MG/ML)</u>	<u>A079195 001</u>	Dec 05, 2008
<u>AP</u>	!	<u>100MG/10ML (10MG/ML)</u>	<u>A079195 002</u>	Dec 05, 2008
<u>AP</u>	TAMARANG	<u>50MG/5ML (10MG/ML)</u>	<u>A091115 001</u>	Aug 27, 2012
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A091115 002</u>	Aug 27, 2012
<u>AP</u>	WEST WARD PHARM CORP	<u>50MG/5ML (10MG/ML)</u>	<u>A204679 001</u>	Feb 28, 2017
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A204679 002</u>	Feb 28, 2017

ROFLUMILAST

TABLET; ORAL

DALIRESP

<u>AB</u>	+! ASTRAZENECA PHARMS	<u>500MCG</u>	<u>N022522 001</u>	Feb 28, 2011
-----------	-----------------------	---------------	--------------------	--------------

ROFLUMILAST

<u>AB</u>	BRECKENRIDGE	<u>500MCG</u>	<u>A208236 001</u>	Oct 03, 2018
<u>AB</u>	HETERO LABS LTD III	<u>500MCG</u>	<u>A208213 001</u>	Nov 23, 2018
<u>AB</u>	STRIDES PHARMA	<u>500MCG</u>	<u>A208247 001</u>	Mar 30, 2020
<u>AB</u>	TORRENT	<u>500MCG</u>	<u>A208272 001</u>	Aug 06, 2018

PRESCRIPTION DRUG PRODUCT LIST

ROFLUMILAST

TABLET; ORAL

DALIRESP

+ ASTRAZENECA PHARMS 250MCG

N022522 002 Jan 23, 2018

ROLAPITANT HYDROCHLORIDE

TABLET; ORAL

VARUBI

+! TERSERA EQ 90MG BASE

N206500 001 Sep 01, 2015

ROMIDEPSIN

POWDER; INTRAVENOUS

ISTODAX

+! CELGENE 10MG/VIAL

N022393 001 Nov 05, 2009

SOLUTION; INTRAVENOUS

ROMIDEPSIN

+! TEVA PHARMS USA INC 27.5MG/5.5ML (5MG/ML)

N208574 002 Mar 13, 2020

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

REQUIP

<u>AB</u>	<u>+!</u>	<u>GLAXOSMITHKLINE LLC</u>	<u>EQ 0.25MG BASE</u>	<u>N020658 001</u>	Sep 19, 1997
<u>AB</u>	<u>+</u>		<u>EQ 0.5MG BASE</u>	<u>N020658 002</u>	Sep 19, 1997
<u>AB</u>	<u>+</u>		<u>EQ 1MG BASE</u>	<u>N020658 003</u>	Sep 19, 1997
<u>AB</u>	<u>+</u>		<u>EQ 2MG BASE</u>	<u>N020658 004</u>	Sep 19, 1997
<u>AB</u>	<u>+</u>		<u>EQ 3MG BASE</u>	<u>N020658 006</u>	Jan 27, 1999
<u>AB</u>	<u>+</u>		<u>EQ 4MG BASE</u>	<u>N020658 007</u>	Jan 27, 1999
<u>AB</u>	<u>+</u>		<u>EQ 5MG BASE</u>	<u>N020658 005</u>	Sep 19, 1997

ROPINIROLE HYDROCHLORIDE

<u>AB</u>		<u>ACCORD HLTHCARE</u>	<u>EQ 0.25MG BASE</u>	<u>A204022 001</u>	Feb 28, 2017
<u>AB</u>			<u>EQ 0.5MG BASE</u>	<u>A204022 002</u>	Feb 28, 2017
<u>AB</u>			<u>EQ 1MG BASE</u>	<u>A204022 003</u>	Feb 28, 2017
<u>AB</u>			<u>EQ 2MG BASE</u>	<u>A204022 004</u>	Feb 28, 2017
<u>AB</u>			<u>EQ 3MG BASE</u>	<u>A204022 005</u>	Feb 28, 2017
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A204022 006</u>	Feb 28, 2017
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>A204022 007</u>	Feb 28, 2017
<u>AB</u>		<u>ALEMBIC LTD</u>	<u>EQ 0.25MG BASE</u>	<u>A090429 001</u>	Mar 24, 2010
<u>AB</u>			<u>EQ 0.5MG BASE</u>	<u>A090429 002</u>	Mar 24, 2010
<u>AB</u>			<u>EQ 1MG BASE</u>	<u>A090429 003</u>	Mar 24, 2010
<u>AB</u>			<u>EQ 2MG BASE</u>	<u>A090429 004</u>	Mar 24, 2010
<u>AB</u>			<u>EQ 3MG BASE</u>	<u>A090429 005</u>	Mar 24, 2010
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A090429 006</u>	Mar 24, 2010
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>A090429 007</u>	Mar 24, 2010
<u>AB</u>		<u>CADILA</u>	<u>EQ 0.25MG BASE</u>	<u>A090411 001</u>	Jun 01, 2009
<u>AB</u>			<u>EQ 0.5MG BASE</u>	<u>A090411 002</u>	Jun 01, 2009
<u>AB</u>			<u>EQ 1MG BASE</u>	<u>A090411 003</u>	Jun 01, 2009
<u>AB</u>			<u>EQ 2MG BASE</u>	<u>A090411 004</u>	Jun 01, 2009
<u>AB</u>			<u>EQ 3MG BASE</u>	<u>A090411 005</u>	Jun 01, 2009
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A090411 006</u>	Jun 01, 2009
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>A090411 007</u>	Jun 01, 2009
<u>AB</u>		<u>CELLTRION</u>	<u>EQ 0.25MG BASE</u>	<u>A079050 001</u>	May 29, 2008
<u>AB</u>			<u>EQ 0.5MG BASE</u>	<u>A079050 002</u>	May 29, 2008
<u>AB</u>			<u>EQ 1MG BASE</u>	<u>A079050 003</u>	May 29, 2008
<u>AB</u>			<u>EQ 2MG BASE</u>	<u>A079050 004</u>	May 29, 2008
<u>AB</u>			<u>EQ 3MG BASE</u>	<u>A079050 005</u>	May 29, 2008
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A079050 006</u>	May 29, 2008
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>A079050 007</u>	May 29, 2008
<u>AB</u>		<u>GLENMARK GENERICS</u>	<u>EQ 0.25MG BASE</u>	<u>A090135 001</u>	Feb 25, 2010
<u>AB</u>			<u>EQ 0.5MG BASE</u>	<u>A090135 002</u>	Feb 25, 2010
<u>AB</u>			<u>EQ 1MG BASE</u>	<u>A090135 003</u>	Feb 25, 2010
<u>AB</u>			<u>EQ 2MG BASE</u>	<u>A090135 004</u>	Feb 25, 2010
<u>AB</u>			<u>EQ 3MG BASE</u>	<u>A090135 005</u>	Feb 25, 2010
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A090135 006</u>	Feb 25, 2010
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>A090135 007</u>	Feb 25, 2010
<u>AB</u>		<u>MLV</u>	<u>EQ 0.25MG BASE</u>	<u>A079165 001</u>	Feb 07, 2012
<u>AB</u>			<u>EQ 0.5MG BASE</u>	<u>A079165 002</u>	Feb 07, 2012
<u>AB</u>			<u>EQ 1MG BASE</u>	<u>A079165 003</u>	Feb 07, 2012
<u>AB</u>			<u>EQ 2MG BASE</u>	<u>A079165 004</u>	Feb 07, 2012
<u>AB</u>			<u>EQ 3MG BASE</u>	<u>A079165 005</u>	Feb 07, 2012
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A079165 006</u>	Feb 07, 2012
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>A079165 007</u>	Feb 07, 2012
<u>AB</u>		<u>MYLAN</u>	<u>EQ 0.25MG BASE</u>	<u>A078881 001</u>	May 05, 2008
<u>AB</u>			<u>EQ 0.5MG BASE</u>	<u>A078881 002</u>	May 05, 2008
<u>AB</u>			<u>EQ 1MG BASE</u>	<u>A078881 003</u>	May 05, 2008

PRESCRIPTION DRUG PRODUCT LIST

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A078881 004</u>	May 05, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A078881 005</u>	May 05, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A078881 006</u>	May 05, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078881 007</u>	May 19, 2008
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 0.25MG BASE</u>	<u>A079229 001</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A079229 002</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A079229 003</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A079229 004</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A079229 005</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A079229 006</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A079229 007</u>	Nov 28, 2012
<u>AB</u>	PRINSTON INC	<u>EQ 0.25MG BASE</u>	<u>A078110 001</u>	May 05, 2008
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A078110 002</u>	May 05, 2008
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A078110 003</u>	May 05, 2008
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A078110 004</u>	May 05, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A078110 005</u>	May 05, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A078110 006</u>	May 05, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078110 007</u>	Jul 11, 2008

TABLET, EXTENDED RELEASE; ORAL

REQUIP XL

<u>AB</u>	<u>+</u>	GLAXOSMITHKLINE LLC	<u>EQ 2MG BASE</u>	<u>N022008 001</u>	Jun 13, 2008
<u>AB</u>	<u>+</u>		<u>EQ 6MG BASE</u>	<u>N022008 006</u>	Apr 10, 2009
<u>AB</u>	<u>+</u>		<u>EQ 12MG BASE</u>	<u>N022008 005</u>	Oct 31, 2008

ROPINIROLE HYDROCHLORIDE

<u>AB</u>		ACTAVIS ELIZABETH	<u>EQ 2MG BASE</u>	<u>A090869 001</u>	May 17, 2012
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A090869 002</u>	May 17, 2012
<u>AB</u>			<u>EQ 6MG BASE</u>	<u>A090869 003</u>	May 17, 2012
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A090869 004</u>	May 17, 2012
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A090869 005</u>	May 17, 2012
<u>AB</u>		ALEMBIC PHARMS LTD	<u>EQ 2MG BASE</u>	<u>A202786 001</u>	Apr 22, 2013
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A202786 002</u>	Apr 22, 2013
<u>AB</u>			<u>EQ 6MG BASE</u>	<u>A202786 003</u>	Apr 22, 2013
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A202786 004</u>	Apr 22, 2013
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A202786 005</u>	Apr 22, 2013
<u>AB</u>		CELLTRION	<u>EQ 2MG BASE</u>	<u>A091395 001</u>	Aug 27, 2012
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A091395 002</u>	Aug 27, 2012
<u>AB</u>			<u>EQ 6MG BASE</u>	<u>A091395 003</u>	Aug 27, 2012
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A091395 004</u>	Aug 27, 2012
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A091395 005</u>	Aug 27, 2012
<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 2MG BASE</u>	<u>A201576 001</u>	Jun 06, 2012
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A201576 002</u>	Jun 06, 2012
<u>AB</u>			<u>EQ 6MG BASE</u>	<u>A201576 003</u>	Jun 06, 2012
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A201576 004</u>	Jun 06, 2012
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A201576 005</u>	Jun 06, 2012
<u>AB</u>		SANDOZ INC	<u>EQ 2MG BASE</u>	<u>A201047 001</u>	Jun 06, 2012
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A201047 003</u>	Jun 06, 2012
<u>AB</u>			<u>EQ 6MG BASE</u>	<u>A201047 004</u>	Jun 06, 2012
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A201047 005</u>	Jun 06, 2012
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A201047 006</u>	Jun 06, 2012

ROPIVACAINE HYDROCHLORIDE

SOLUTION; INJECTION

NAROPIN

<u>AP</u>	<u>+</u>	FRESENIUS KABI USA	<u>20MG/10ML (2MG/ML)</u>	<u>N020533 001</u>	May 01, 1998
<u>AP</u>	<u>+</u>		<u>40MG/20ML (2MG/ML)</u>	<u>N020533 002</u>	Sep 24, 1996
<u>AP</u>	<u>+</u>		<u>100MG/20ML (5MG/ML)</u>	<u>N020533 003</u>	May 01, 1998
<u>AP</u>	<u>+</u>		<u>100MG/10ML (10MG/ML)</u>	<u>N020533 005</u>	Sep 24, 1996
<u>AP</u>	<u>+</u>		<u>150MG/20ML (7.5MG/ML)</u>	<u>N020533 004</u>	Sep 24, 1996
<u>AP</u>	<u>+</u>		<u>150MG/30ML (5MG/ML)</u>	<u>N020533 008</u>	Sep 24, 1996
<u>AP</u>	<u>+</u>		<u>200MG/100ML (2MG/ML)</u>	<u>N020533 006</u>	Sep 24, 1996
<u>AP</u>	<u>+</u>		<u>200MG/20ML (10MG/ML)</u>	<u>N020533 011</u>	Sep 24, 1996
<u>AP</u>	<u>+</u>		<u>400MG/200ML (2MG/ML)</u>	<u>N020533 007</u>	Sep 24, 1996
<u>AP</u>	<u>+</u>		<u>500MG/100ML (5MG/ML)</u>	<u>N020533 009</u>	Jan 04, 2011
<u>AP</u>	<u>+</u>		<u>1GM/200ML (5MG/ML)</u>	<u>N020533 010</u>	Jan 04, 2011

ROPIVACAINE HYDROCHLORIDE

<u>AP</u>		AKORN	<u>200MG/100ML (2MG/ML)</u>	<u>A204636 001</u>	Mar 16, 2018
<u>AP</u>			<u>400MG/200ML (2MG/ML)</u>	<u>A204636 002</u>	Mar 16, 2018
<u>AP</u>		AKORN INC	<u>150MG/30ML (5MG/ML)</u>	<u>A203955 001</u>	Apr 11, 2016
<u>AP</u>		AUROBINDO PHARMA LTD	<u>40MG/20ML (2MG/ML)</u>	<u>A205612 001</u>	Jul 13, 2016

PRESCRIPTION DRUG PRODUCT LIST

ROPIVACAINE HYDROCHLORIDE

SOLUTION; INJECTION

ROPIVACAINE HYDROCHLORIDE

<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A205612 003</u>	Jul 13, 2016
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A205612 006</u>	Jul 13, 2016
<u>AP</u>		<u>150MG/30ML (5MG/ML)</u>	<u>A205612 004</u>	Jul 13, 2016
<u>AP</u>		<u>150MG/20ML (7.5MG/ML)</u>	<u>A205612 005</u>	Jul 13, 2016
<u>AP</u>		<u>200MG/100ML (2MG/ML)</u>	<u>A205612 002</u>	Jul 13, 2016
<u>AP</u>		<u>200MG/20ML (10MG/ML)</u>	<u>A205612 007</u>	Jul 13, 2016
<u>AP</u>	CAPLIN	<u>40MG/20ML (2MG/ML)</u>	<u>A212808 001</u>	Apr 09, 2020
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A212808 002</u>	Apr 09, 2020
<u>AP</u>		<u>150MG/30ML (5MG/ML)</u>	<u>A212808 003</u>	Apr 09, 2020
<u>AP</u>		<u>200MG/20ML (10MG/ML)</u>	<u>A212808 004</u>	Apr 09, 2020
<u>AP</u>	HIKMA	<u>40MG/20ML (2MG/ML)</u>	<u>A214074 001</u>	Jul 20, 2020
<u>AP</u>		<u>150MG/30ML (5MG/ML)</u>	<u>A214074 002</u>	Jul 20, 2020
<u>AP</u>		<u>150MG/20ML (7.5MG/ML)</u>	<u>A214074 003</u>	Jul 20, 2020
<u>AP</u>		<u>200MG/20ML (10MG/ML)</u>	<u>A214074 004</u>	Jul 20, 2020
<u>AP</u>	HOSPIRA	<u>20MG/10ML (2MG/ML)</u>	<u>A090194 001</u>	Sep 23, 2014
<u>AP</u>		<u>40MG/20ML (2MG/ML)</u>	<u>A090194 005</u>	Sep 23, 2014
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A090194 004</u>	Sep 23, 2014
<u>AP</u>		<u>150MG/30ML (5MG/ML)</u>	<u>A090194 002</u>	Sep 23, 2014
<u>AP</u>		<u>150MG/20ML (7.5MG/ML)</u>	<u>A090194 003</u>	Sep 23, 2014
<u>AP</u>		<u>200MG/20ML (10MG/ML)</u>	<u>A090194 006</u>	Sep 23, 2014
<u>AP</u>	INFORLIFE	<u>200MG/100ML (2MG/ML)</u>	<u>A206166 001</u>	Jun 11, 2018
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A206166 002</u>	Jun 11, 2018
<u>AP</u>		<u>500MG/100ML (5MG/ML)</u>	<u>A206166 003</u>	Jun 11, 2018
<u>AP</u>		<u>1GM/200ML (5MG/ML)</u>	<u>A206166 004</u>	Jun 11, 2018
<u>AP</u>	MYLAN ASI	<u>150MG/30ML (5MG/ML)</u>	<u>A090318 002</u>	Sep 23, 2014
<u>AP</u>		<u>200MG/20ML (10MG/ML)</u>	<u>A090318 004</u>	Sep 23, 2014
<u>AP</u>	NAVINTA LLC	<u>150MG/30ML (5MG/ML)</u>	<u>A078601 002</u>	Jul 17, 2014
<u>AP</u>		<u>200MG/20ML (10MG/ML)</u>	<u>A078601 003</u>	Jul 17, 2014
<u>AP</u>	SOMERSET THERAPS LLC	<u>20MG/10ML (2MG/ML)</u>	<u>A207636 001</u>	Jun 15, 2018
<u>AP</u>		<u>40MG/20ML (2MG/ML)</u>	<u>A207636 002</u>	Jun 15, 2018
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A207636 003</u>	Jun 15, 2018
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A207636 006</u>	Jun 15, 2018
<u>AP</u>		<u>150MG/30ML (5MG/ML)</u>	<u>A207636 004</u>	Jun 15, 2018
<u>AP</u>		<u>150MG/20ML (7.5MG/ML)</u>	<u>A207636 005</u>	Jun 15, 2018
<u>AP</u>		<u>200MG/20ML (10MG/ML)</u>	<u>A207636 007</u>	Jun 15, 2018

ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDIA

+	SB PHARMCO	EQ 2MG BASE	N021071 002	May 25, 1999
+		EQ 4MG BASE	N021071 003	May 25, 1999

ROSUVASTATIN CALCIUM

CAPSULE; ORAL

EZALLOR SPRINKLE

+	SUN PHARMA GLOBAL	EQ 5MG BASE	N208647 001	Dec 18, 2018
+		EQ 10MG BASE	N208647 002	Dec 18, 2018
+		EQ 20MG BASE	N208647 003	Dec 18, 2018
+	!	EQ 40MG BASE	N208647 004	Dec 18, 2018

TABLET; ORAL

CRESTOR

<u>AB</u>	+	IPR	<u>5MG</u>	<u>N021366 002</u>	Aug 12, 2003
<u>AB</u>	+		<u>10MG</u>	<u>N021366 003</u>	Aug 12, 2003
<u>AB</u>	+		<u>20MG</u>	<u>N021366 004</u>	Aug 12, 2003
<u>AB</u>	+	!	<u>40MG</u>	<u>N021366 005</u>	Aug 12, 2003

ROSUVASTATIN CALCIUM

<u>AB</u>	ACCORD HLTHCARE	<u>5MG</u>	<u>A206434 001</u>	Oct 31, 2016
<u>AB</u>		<u>10MG</u>	<u>A206434 002</u>	Oct 31, 2016
<u>AB</u>		<u>20MG</u>	<u>A206434 003</u>	Oct 31, 2016
<u>AB</u>		<u>40MG</u>	<u>A206434 004</u>	Oct 31, 2016
<u>AB</u>	ALKEM LABS LTD	<u>5MG</u>	<u>A206465 001</u>	Mar 21, 2017
<u>AB</u>		<u>10MG</u>	<u>A206465 002</u>	Mar 21, 2017
<u>AB</u>		<u>20MG</u>	<u>A206465 003</u>	Mar 21, 2017
<u>AB</u>		<u>40MG</u>	<u>A206465 004</u>	Mar 21, 2017
<u>AB</u>	ALLIED	<u>5MG</u>	<u>A079168 001</u>	Jul 19, 2016
<u>AB</u>		<u>10MG</u>	<u>A079168 002</u>	Jul 19, 2016
<u>AB</u>		<u>20MG</u>	<u>A079168 003</u>	Jul 19, 2016
<u>AB</u>		<u>40MG</u>	<u>A079168 004</u>	Jul 19, 2016
<u>AB</u>	AUROBINDO PHARMA LTD	<u>5MG</u>	<u>A079170 001</u>	Jul 19, 2016

PRESCRIPTION DRUG PRODUCT LIST

ROSUVASTATIN CALCIUM

TABLET; ORAL

ROSUVASTATIN CALCIUM

<u>AB</u>		<u>10MG</u>	<u>A079170 002</u>	Jul 19, 2016
<u>AB</u>		<u>20MG</u>	<u>A079170 003</u>	Jul 19, 2016
<u>AB</u>		<u>40MG</u>	<u>A079170 004</u>	Jul 19, 2016
<u>AB</u>	BIOCON LTD	<u>5MG</u>	<u>A207752 001</u>	Oct 31, 2016
<u>AB</u>		<u>10MG</u>	<u>A207752 002</u>	Oct 31, 2016
<u>AB</u>		<u>20MG</u>	<u>A207752 003</u>	Oct 31, 2016
<u>AB</u>		<u>40MG</u>	<u>A207752 004</u>	Oct 31, 2016
<u>AB</u>	CADILA PHARMS LTD	<u>5MG</u>	<u>A207453 001</u>	Nov 23, 2016
<u>AB</u>		<u>10MG</u>	<u>A207453 002</u>	Nov 23, 2016
<u>AB</u>		<u>20MG</u>	<u>A207453 003</u>	Nov 23, 2016
<u>AB</u>		<u>40MG</u>	<u>A207453 004</u>	Nov 23, 2016
<u>AB</u>	CHANGZHOU PHARM	<u>5MG</u>	<u>A207408 001</u>	Oct 31, 2016
<u>AB</u>		<u>10MG</u>	<u>A207408 002</u>	Oct 31, 2016
<u>AB</u>		<u>20MG</u>	<u>A207408 003</u>	Oct 31, 2016
<u>AB</u>		<u>40MG</u>	<u>A207408 004</u>	Oct 31, 2016
<u>AB</u>	GLENMARK PHARMS	<u>5MG</u>	<u>A079172 001</u>	Jul 19, 2016
<u>AB</u>		<u>10MG</u>	<u>A079172 002</u>	Jul 19, 2016
<u>AB</u>		<u>20MG</u>	<u>A079172 003</u>	Jul 19, 2016
<u>AB</u>		<u>40MG</u>	<u>A079172 004</u>	Jul 19, 2016
<u>AB</u>	HETERO LABS LTD V	<u>5MG</u>	<u>A207616 001</u>	Oct 31, 2016
<u>AB</u>		<u>10MG</u>	<u>A207616 002</u>	Oct 31, 2016
<u>AB</u>		<u>20MG</u>	<u>A207616 003</u>	Oct 31, 2016
<u>AB</u>		<u>40MG</u>	<u>A207616 004</u>	Oct 31, 2016
<u>AB</u>	LUPIN	<u>5MG</u>	<u>A205587 001</u>	Jul 31, 2017
<u>AB</u>		<u>10MG</u>	<u>A205587 002</u>	Jul 31, 2017
<u>AB</u>		<u>20MG</u>	<u>A205587 003</u>	Jul 31, 2017
<u>AB</u>		<u>40MG</u>	<u>A205587 004</u>	Jul 31, 2017
<u>AB</u>	MSN	<u>5MG</u>	<u>A208898 001</u>	Nov 22, 2017
<u>AB</u>		<u>10MG</u>	<u>A208898 002</u>	Nov 22, 2017
<u>AB</u>		<u>20MG</u>	<u>A208898 003</u>	Nov 22, 2017
<u>AB</u>		<u>40MG</u>	<u>A208898 004</u>	Nov 22, 2017
<u>AB</u>	RENATA	<u>5MG</u>	<u>A207062 001</u>	Oct 31, 2016
<u>AB</u>		<u>10MG</u>	<u>A207062 002</u>	Oct 31, 2016
<u>AB</u>		<u>20MG</u>	<u>A207062 003</u>	Oct 31, 2016
<u>AB</u>		<u>40MG</u>	<u>A207062 004</u>	Oct 31, 2016
<u>AB</u>	SANDOZ INC	<u>5MG</u>	<u>A079171 001</u>	Jul 19, 2016
<u>AB</u>		<u>10MG</u>	<u>A079171 002</u>	Jul 19, 2016
<u>AB</u>		<u>20MG</u>	<u>A079171 003</u>	Jul 19, 2016
<u>AB</u>		<u>40MG</u>	<u>A079171 004</u>	Jul 19, 2016
<u>AB</u>	SHANDONG	<u>5MG</u>	<u>A207375 001</u>	May 07, 2019
<u>AB</u>		<u>10MG</u>	<u>A207375 002</u>	May 07, 2019
<u>AB</u>		<u>20MG</u>	<u>A207375 003</u>	May 07, 2019
<u>AB</u>		<u>40MG</u>	<u>A207375 004</u>	May 07, 2019
<u>AB</u>	SUN PHARM	<u>5MG</u>	<u>A079169 001</u>	Jul 19, 2016
<u>AB</u>		<u>10MG</u>	<u>A079169 002</u>	Jul 19, 2016
<u>AB</u>		<u>20MG</u>	<u>A079169 003</u>	Jul 19, 2016
<u>AB</u>		<u>40MG</u>	<u>A079169 004</u>	Jul 19, 2016
<u>AB</u>	TORRENT	<u>5MG</u>	<u>A201619 001</u>	Oct 31, 2016
<u>AB</u>		<u>10MG</u>	<u>A201619 002</u>	Oct 31, 2016
<u>AB</u>		<u>20MG</u>	<u>A201619 003</u>	Oct 31, 2016
<u>AB</u>		<u>40MG</u>	<u>A201619 004</u>	Oct 31, 2016
<u>AB</u>	WATSON LABS INC	<u>5MG</u>	<u>A079167 001</u>	Apr 29, 2016
<u>AB</u>		<u>10MG</u>	<u>A079167 002</u>	Apr 29, 2016
<u>AB</u>		<u>20MG</u>	<u>A079167 003</u>	Apr 29, 2016
<u>AB</u>		<u>40MG</u>	<u>A079167 004</u>	Apr 29, 2016

ROTIGOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

NEUPRO

+	UCB INC	1MG/24HR	N021829 004	Apr 02, 2012
+	!	2MG/24HR	N021829 001	May 09, 2007
+		3MG/24HR	N021829 005	Apr 02, 2012
+		4MG/24HR	N021829 002	May 09, 2007
+		6MG/24HR	N021829 003	May 09, 2007
+		8MG/24HR	N021829 006	Apr 02, 2012

PRESCRIPTION DRUG PRODUCT LIST

RUBIDIUM CHLORIDE RB-82

INJECTABLE; INJECTION

CARDIOGEN-82

BRACCO

N/A

N019414 001 Dec 29, 1989

SOLUTION; INTRAVENOUS

RUBY-FILL

JUBILANT

N/A

N202153 001 Sep 30, 2016

RUCAPARIB CAMSYLATE

TABLET; ORAL

RUBRACA

+ CLOVIS ONCOLOGY INC EQ 200MG BASE

N209115 001 Dec 19, 2016

+ EQ 250MG BASE

N209115 003 May 01, 2017

+! EQ 300MG BASE

N209115 002 Dec 19, 2016

RUFINAMIDE

SUSPENSION; ORAL

BANZEL**AB** +! EISAI INC **40MG/ML** **N201367 001** Mar 03, 2011RUFINAMIDE**AB** BIONPHARMA INC **40MG/ML** **A211388 001** Apr 23, 2019**AB** HIKMA **40MG/ML** **A207363 001** Apr 23, 2019**AB** LUPIN LTD **40MG/ML** **A213457 001** Dec 18, 2020

TABLET; ORAL

BANZEL**AB** + EISAI INC **200MG** **N021911 002** Nov 14, 2008**AB** +! **400MG** **N021911 003** Nov 14, 2008RUFINAMIDE**AB** GLENMARK PHARMS LTD **200MG** **A205075 001** May 16, 2016**AB** **400MG** **A205075 002** May 16, 2016**AB** HIKMA **200MG** **A204988 001** May 16, 2016**AB** **400MG** **A204988 002** May 16, 2016RUXOLITINIB PHOSPHATE

TABLET; ORAL

JAKAFI

+ INCYTE CORP EQ 5MG BASE N202192 001 Nov 16, 2011

+ EQ 10MG BASE N202192 002 Nov 16, 2011

+ EQ 15MG BASE N202192 003 Nov 16, 2011

+ EQ 20MG BASE N202192 004 Nov 16, 2011

+! EQ 25MG BASE N202192 005 Nov 16, 2011

SACUBITRIL; VALSARTAN

TABLET; ORAL

ENTRESTO

+ NOVARTIS PHARMS 24MG; 26MG N207620 001 Jul 07, 2015

CORP 49MG; 51MG N207620 002 Jul 07, 2015

+! 97MG; 103MG N207620 003 Jul 07, 2015

SAFINAMIDE MESYLATE

TABLET; ORAL

XADAGO

+ MDD US 50MG N207145 001 Mar 21, 2017

+! 100MG N207145 002 Mar 21, 2017

SALMETEROL XINAFOATE

POWDER; INHALATION

SEREVENT

+! GLAXOSMITHKLINE EQ 0.05MG BASE/INH N020692 001 Sep 19, 1997

SAMARIUM SM-153 LEXIDRONAM PENTASODIUM

INJECTABLE; INJECTION

QUADRAMET

+! LANTHEUS MEDICAL 50mCi/ML N020570 001 Mar 28, 1997

SAPROPTERIN DIHYDROCHLORIDE

POWDER; ORAL

KUVAN**AB** +! BIOMARIN PHARM **100MG/PACKET** **N205065 001** Dec 19, 2013**AB** + **500MG/PACKET** **N205065 002** Oct 27, 2015SAPROPTERIN DIHYDROCHLORIDE**AB** PAR PHARM INC **100MG/PACKET** **A207207 001** Aug 20, 2019**AB** **500MG/PACKET** **A210027 001** Aug 20, 2019

PRESCRIPTION DRUG PRODUCT LISTSAPROPTERIN DIHYDROCHLORIDE

TABLET; ORAL

KUVAN

AB	+ !	BIOMARIN PHARM	100MG	N022181	001	Dec 13, 2007
-----------	------------	----------------	--------------	----------------	------------	--------------

SAPROPTERIN DIHYDROCHLORIDE

AB		PAR PHARM INC	100MG	A207200	001	May 10, 2019
-----------	--	---------------	--------------	----------------	------------	--------------

SAQUINAVIR MESYLATE

TABLET; ORAL

INVIRASE

+ !	HOFFMANN-LA ROCHE	EQ 500MG BASE	N021785	001	Dec 17, 2004
------------	-------------------	---------------	---------	-----	--------------

SARECYCLINE HYDROCHLORIDE

TABLET; ORAL

SEYSARA

+	ALMIRALL	EQ 60MG BASE	N209521	001	Oct 01, 2018
----------	----------	--------------	---------	-----	--------------

+		EQ 100MG BASE	N209521	002	Oct 01, 2018
----------	--	---------------	---------	-----	--------------

+ !		EQ 150MG BASE	N209521	003	Oct 01, 2018
------------	--	---------------	---------	-----	--------------

SAXAGLIPTIN HYDROCHLORIDE

TABLET; ORAL

ONGLYZA

+	ASTRAZENECA AB	EQ 2.5MG BASE	N022350	001	Jul 31, 2009
----------	----------------	---------------	---------	-----	--------------

+ !		EQ 5MG BASE	N022350	002	Jul 31, 2009
------------	--	-------------	---------	-----	--------------

SCOPOLAMINE

SYSTEM; TRANSDERMAL

SCOPOLAMINE

AB		MYLAN TECHNOLOGIES	1MG/72HR	A203753	001	Jun 19, 2019
-----------	--	--------------------	-----------------	----------------	------------	--------------

AB		PERRIGO PHARMS CO	1MG/72HR	A078830	001	Jan 30, 2015
-----------	--	-------------------	-----------------	----------------	------------	--------------

AB		RICONPHARMA LLC	1MG/72HR	A212342	001	Nov 24, 2020
-----------	--	-----------------	-----------------	----------------	------------	--------------

TRANSDERM SCOP

AB	+ !	GLAXOSMITHKLINE CON	1MG/72HR	N017874	001	
-----------	------------	---------------------	-----------------	----------------	------------	--

SECNIDAZOLE

GRANULE; ORAL

SOLOSEC

+ !	LUPIN	2GM/PACKET	N209363	001	Sep 15, 2017
------------	-------	------------	---------	-----	--------------

SECRETIN SYNTHETIC HUMAN

FOR SOLUTION; INTRAVENOUS

CHIRHOSTIM

+ !	CHIRHOCLIN	16MCG/VIAL	N021256	001	Apr 09, 2004
------------	------------	------------	---------	-----	--------------

+		40MCG/VIAL	N021256	002	Jun 21, 2007
----------	--	------------	---------	-----	--------------

SELEGILINE

FILM, EXTENDED RELEASE; TRANSDERMAL

EMSAM

+ !	SOMERSET	6MG/24HR	N021336	001	Feb 27, 2006
------------	----------	----------	---------	-----	--------------

+		9MG/24HR	N021336	002	Feb 27, 2006
----------	--	----------	---------	-----	--------------

+		12MG/24HR	N021336	003	Feb 27, 2006
----------	--	-----------	---------	-----	--------------

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL

SELEGILINE HYDROCHLORIDE

AB	!	APOTEX	5MG	A075321	001	Dec 04, 1998
-----------	----------	--------	------------	----------------	------------	--------------

AB		RISING	5MG	A206803	001	Apr 02, 2019
-----------	--	--------	------------	----------------	------------	--------------

TABLET; ORAL

SELEGILINE HYDROCHLORIDE

AB	!	APOTEX INC	5MG	A074871	001	Jun 06, 1997
-----------	----------	------------	------------	----------------	------------	--------------

AB		BOSCOGEN	5MG	A074912	001	Apr 30, 1998
-----------	--	----------	------------	----------------	------------	--------------

TABLET, ORALLY DISINTEGRATING; ORAL

ZELAPAR

+ !	BAUSCH	1.25MG	N021479	001	Jun 14, 2006
------------	--------	--------	---------	-----	--------------

SELENIOS ACID

SOLUTION; INTRAVENOUS

SELENIOS ACID

+ !	AM REGENT	EQ 600MCG BASE/10ML (EQ 60MCG BASE/ML)	N209379	001	Apr 30, 2019
------------	-----------	--	---------	-----	--------------

SELENIUM SULFIDE

LOTION; SHAMPOO; TOPICAL

SELENIUM SULFIDE

AT	!	PERRIGO NEW YORK	2.5%	A089996	001	Jan 10, 1991
-----------	----------	------------------	-------------	----------------	------------	--------------

AT		WOCKHARDT BIO AG	2.5%	A088228	001	Sep 01, 1983
-----------	--	------------------	-------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

SELEXIPAG

TABLET; ORAL

UPTRAVI

+	ACTELION PHARMS LTD	0.2MG	N207947 001	Dec 21, 2015
+	!	0.4MG	N207947 002	Dec 21, 2015
+		0.6MG	N207947 003	Dec 21, 2015
+		0.8MG	N207947 004	Dec 21, 2015
+		1MG	N207947 005	Dec 21, 2015
+		1.2MG	N207947 006	Dec 21, 2015
+		1.4MG	N207947 007	Dec 21, 2015
+		1.6MG	N207947 008	Dec 21, 2015

SELINEXOR

TABLET; ORAL

XPOVIO

+	!	KARYOPHARM THERAPS	20MG	N212306 001	Jul 03, 2019
---	---	--------------------	------	-------------	--------------

SELPERCATINIB

CAPSULE; ORAL

RETEVMO

+		LOXO ONCOLOGY INC	40MG	N213246 001	May 08, 2020
+	!		80MG	N213246 002	May 08, 2020

SELUMETINIB SULFATE

CAPSULE; ORAL

KOSELUGO

+		ASTRAZENECA PHARMS	EQ 10MG BASE	N213756 001	Apr 10, 2020
+	!		EQ 25MG BASE	N213756 002	Apr 10, 2020

SEMAGLUTIDE

SOLUTION; SUBCUTANEOUS

OZEMPIC

+	!	NOVO	2MG/1.5ML (1.34MG/ML)	N209637 001	Dec 05, 2017
+	!		4MG/3ML (1.34MG/ML)	N209637 002	Apr 09, 2019

TABLET; ORAL

RYBELSUS

+		NOVO	3MG	N213051 001	Sep 20, 2019
+			7MG	N213051 002	Sep 20, 2019
+	!		14MG	N213051 003	Sep 20, 2019

SERTACONAZOLE NITRATE

CREAM; TOPICAL

ERTACZO

+	!	BAUSCH	2%	N021385 001	Dec 10, 2003
---	---	--------	----	-------------	--------------

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL

SERTRALINE HYDROCHLORIDE

AA		ACI HEALTHCARE LTD	EQ 20MG BASE/ML	A076934 001	Jun 30, 2006
AA		AUROBINDO PHARMA	EQ 20MG BASE/ML	A078861 001	Oct 31, 2008

ZOLOFT

AA	+	!	UPJOHN	EQ 20MG BASE/ML	N020990 001	Dec 07, 1999
-----------	---	---	--------	------------------------	--------------------	--------------

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

AB		ACCORD HLTHCARE	EQ 25MG BASE	A202825 001	Nov 07, 2014
AB			EQ 50MG BASE	A202825 002	Nov 07, 2014
AB			EQ 100MG BASE	A202825 003	Nov 07, 2014
AB		AUROBINDO PHARMA	EQ 25MG BASE	A077206 001	Feb 06, 2007
AB			EQ 50MG BASE	A077206 002	Feb 06, 2007
AB			EQ 100MG BASE	A077206 003	Feb 06, 2007
AB		AUSTARPHARMA LLC	EQ 25MG BASE	A078677 001	Mar 04, 2009
AB			EQ 50MG BASE	A078677 002	Mar 04, 2009
AB			EQ 100MG BASE	A078677 003	Mar 04, 2009
AB		INVAGEN PHARMS	EQ 25MG BASE	A077397 001	Feb 06, 2007
AB			EQ 50MG BASE	A077397 002	Feb 06, 2007
AB			EQ 100MG BASE	A077397 003	Feb 06, 2007
AB		LUPIN	EQ 25MG BASE	A077670 001	Feb 06, 2007
AB			EQ 50MG BASE	A077670 002	Feb 06, 2007
AB			EQ 100MG BASE	A077670 003	Feb 06, 2007
AB		OXFORD PHARMS	EQ 25MG BASE	A078175 001	Jul 21, 2010
AB			EQ 50MG BASE	A078175 002	Jul 21, 2010
AB			EQ 100MG BASE	A078175 003	Jul 21, 2010
AB		VIWIT PHARM	EQ 25MG BASE	A076882 001	Feb 06, 2007
AB			EQ 50MG BASE	A076882 002	Feb 06, 2007
AB			EQ 100MG BASE	A076882 003	Feb 06, 2007

PRESCRIPTION DRUG PRODUCT LIST

SERTRALINE HYDROCHLORIDE

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

<u>AB</u>	WOCKHARDT	<u>EQ 25MG BASE</u>	<u>A078403 001</u>	Jan 08, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078403 002</u>	Jan 08, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078403 003</u>	Jan 08, 2008
<u>ZOLOFT</u>				
<u>AB</u>	+ UPJOHN	<u>EQ 25MG BASE</u>	<u>N019839 005</u>	Mar 06, 1996
<u>AB</u>	+	<u>EQ 50MG BASE</u>	<u>N019839 001</u>	Dec 30, 1991
<u>AB</u>	+	<u>EQ 100MG BASE</u>	<u>N019839 002</u>	Dec 30, 1991

SETMELANOTIDE ACETATE

SOLUTION; SUBCUTANEOUS

IMCIVREE

+! RHYTHM

EQ 10MG/ML BASE (EQ 10MG/ML BASE)

N213793 001 Nov 25, 2020

SEVELAMER CARBONATE

FOR SUSPENSION; ORAL

RENVELA

<u>AB</u>	+ GENZYME	<u>800MG/PACKET</u>	<u>N022318 001</u>	Aug 12, 2009
<u>AB</u>	+	<u>2.4GM/PACKET</u>	<u>N022318 002</u>	Feb 18, 2009
<u>SEVELAMER CARBONATE</u>				
<u>AB</u>	AUROBINDO PHARMA LTD	<u>800MG/PACKET</u>	<u>A207624 001</u>	Jun 13, 2017
<u>AB</u>		<u>2.4GM/PACKET</u>	<u>A207624 002</u>	Jun 13, 2017
<u>AB</u>	DR REDDYS LABS LTD	<u>800MG/PACKET</u>	<u>A210464 001</u>	Oct 25, 2018
<u>AB</u>		<u>2.4GM/PACKET</u>	<u>A210464 002</u>	Oct 25, 2018
<u>AB</u>	IMPAX	<u>800MG/PACKET</u>	<u>A211316 001</u>	Nov 20, 2020
<u>AB</u>		<u>2.4GM/PACKET</u>	<u>A211316 002</u>	Nov 20, 2020

TABLET; ORAL

RENVELA

<u>AB</u>	+	SANOFI	<u>800MG</u>	<u>N022127 001</u>	Oct 19, 2007
<u>SEVELAMER CARBONATE</u>					
<u>AB</u>		AMNEAL PHARMS CO	<u>800MG</u>	<u>A207288 001</u>	Nov 28, 2017
<u>AB</u>		AUROBINDO PHARMA LTD	<u>800MG</u>	<u>A207179 001</u>	Jul 17, 2017
<u>AB</u>		DR REDDYS LABS LTD	<u>800MG</u>	<u>A206094 001</u>	Sep 29, 2017
<u>AB</u>		INVAGEN PHARMS	<u>800MG</u>	<u>A203860 001</u>	Oct 26, 2017
<u>AB</u>		RISING	<u>800MG</u>	<u>A204451 001</u>	Nov 29, 2018
<u>AB</u>		TWI PHARMS	<u>800MG</u>	<u>A200959 001</u>	Mar 20, 2018
<u>AB</u>		ZYDUS PHARMS	<u>800MG</u>	<u>A207759 001</u>	Aug 11, 2020

SEVELAMER HYDROCHLORIDE

TABLET; ORAL

RENAGEL

<u>AB</u>	+ GENZYME	<u>400MG</u>	<u>N021179 001</u>	Jul 12, 2000	
<u>AB</u>	+	<u>800MG</u>	<u>N021179 002</u>	Jul 12, 2000	
<u>SEVELAMER HYDROCHLORIDE</u>					
<u>AB</u>	GLENMARK PHARMS LTD	<u>400MG</u>	<u>A204724 001</u>	Feb 08, 2019	
<u>AB</u>		<u>800MG</u>	<u>A204724 002</u>	Feb 08, 2019	

SEVOFLURANE

LIQUID; INHALATION

SEVOFLURANE

<u>AN</u>	BAXTER HLTHCARE	<u>100%</u>	<u>A075895 001</u>	Jul 02, 2002	
<u>AN</u>	HALOCARBON PRODS	<u>100%</u>	<u>A078650 001</u>	Nov 19, 2007	
<u>AN</u>	SHANGHAI HENGRUI	<u>100%</u>	<u>A203793 001</u>	Nov 03, 2015	
<u>SOJOURN</u>					
<u>AN</u>	PIRAMAL CRITICAL	<u>100%</u>	<u>A077867 001</u>	May 02, 2007	
<u>ULTANE</u>					
<u>AN</u>	+	ABBVIE	<u>100%</u>	<u>N020478 001</u>	Jun 07, 1995

SILDENAFIL CITRATE

FOR SUSPENSION; ORAL

REVATIO

<u>AB</u>	+	UPJOHN	<u>EQ 10MG BASE/ML</u>	<u>N203109 001</u>	Aug 30, 2012
<u>SILDENAFIL CITRATE</u>					
<u>AB</u>		AJANTA PHARMA LTD	<u>EQ 10MG BASE/ML</u>	<u>A212883 001</u>	Nov 27, 2019
<u>AB</u>		ALKEM LABS LTD	<u>EQ 10MG BASE/ML</u>	<u>A212440 001</u>	Nov 27, 2019
<u>AB</u>		AMNEAL PHARMS	<u>EQ 10MG BASE/ML</u>	<u>A211092 001</u>	Nov 27, 2019
<u>AB</u>		APTAPHARMA INC	<u>EQ 10MG BASE/ML</u>	<u>A213041 001</u>	Aug 06, 2020
<u>AB</u>		NOVITIUM PHARMA	<u>EQ 10MG BASE/ML</u>	<u>A212260 001</u>	May 31, 2019
<u>AB</u>		TEVA PHARMS USA	<u>EQ 10MG BASE/ML</u>	<u>A211534 001</u>	May 29, 2020

PRESCRIPTION DRUG PRODUCT LIST

SILDENAFIL CITRATE

SOLUTION; INTRAVENOUS

REVATIO

<u>AP</u>	<u>+!</u>	UPJOHN	<u>EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)</u>	<u>N022473</u>	<u>001</u>	Nov 18, 2009
-----------	-----------	--------	---	----------------	------------	--------------

SILDENAFIL CITRATE

<u>AP</u>		AUROBINDO PHARMA LTD	<u>EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)</u>	<u>A203988</u>	<u>001</u>	Apr 01, 2015
-----------	--	----------------------	---	----------------	------------	--------------

TABLET; ORAL

REVATIO

<u>AB</u>	<u>+!</u>	UPJOHN	<u>EQ 20MG BASE</u>	<u>N021845</u>	<u>001</u>	Jun 03, 2005
-----------	-----------	--------	---------------------	----------------	------------	--------------

SILDENAFIL CITRATE

<u>AB</u>		AJANTA PHARMA LTD	<u>EQ 20MG BASE</u>	<u>A210394</u>	<u>001</u>	May 04, 2018
-----------	--	-------------------	---------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 25MG BASE</u>	<u>A206401</u>	<u>001</u>	Oct 12, 2018
-----------	--	--	---------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A206401</u>	<u>002</u>	Oct 12, 2018
-----------	--	--	---------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A206401</u>	<u>003</u>	Oct 12, 2018
-----------	--	--	----------------------	----------------	------------	--------------

<u>AB</u>		AMNEAL PHARMS	<u>EQ 20MG BASE</u>	<u>A202025</u>	<u>001</u>	Feb 28, 2013
-----------	--	---------------	---------------------	----------------	------------	--------------

<u>AB</u>		AMNEAL PHARMS NY	<u>EQ 25MG BASE</u>	<u>A202023</u>	<u>001</u>	Jun 27, 2018
-----------	--	------------------	---------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A202023</u>	<u>002</u>	Jun 27, 2018
-----------	--	--	---------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A202023</u>	<u>003</u>	Jun 27, 2018
-----------	--	--	----------------------	----------------	------------	--------------

<u>AB</u>		APPCO	<u>EQ 25MG BASE</u>	<u>A207178</u>	<u>001</u>	Mar 02, 2020
-----------	--	-------	---------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A207178</u>	<u>002</u>	Mar 02, 2020
-----------	--	--	---------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A207178</u>	<u>003</u>	Mar 02, 2020
-----------	--	--	----------------------	----------------	------------	--------------

<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 20MG BASE</u>	<u>A203963</u>	<u>001</u>	Nov 18, 2015
-----------	--	----------------------	---------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 25MG BASE</u>	<u>A203962</u>	<u>001</u>	Jun 11, 2018
-----------	--	--	---------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A203962</u>	<u>002</u>	Jun 11, 2018
-----------	--	--	---------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A203962</u>	<u>003</u>	Jun 11, 2018
-----------	--	--	----------------------	----------------	------------	--------------

<u>AB</u>		HETERO LABS LTD V	<u>EQ 20MG BASE</u>	<u>A203623</u>	<u>001</u>	Nov 26, 2014
-----------	--	-------------------	---------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 25MG BASE</u>	<u>A202659</u>	<u>001</u>	Jun 11, 2018
-----------	--	--	---------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A202659</u>	<u>002</u>	Jun 11, 2018
-----------	--	--	---------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A202659</u>	<u>003</u>	Jun 11, 2018
-----------	--	--	----------------------	----------------	------------	--------------

<u>AB</u>		LUPIN LTD	<u>EQ 25MG BASE</u>	<u>A212051</u>	<u>001</u>	Mar 22, 2019
-----------	--	-----------	---------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A212051</u>	<u>002</u>	Mar 22, 2019
-----------	--	--	---------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A212051</u>	<u>003</u>	Mar 22, 2019
-----------	--	--	----------------------	----------------	------------	--------------

<u>AB</u>		MACLEODS PHARMS LTD	<u>EQ 20MG BASE</u>	<u>A203814</u>	<u>001</u>	Dec 17, 2013
-----------	--	---------------------	---------------------	----------------	------------	--------------

<u>AB</u>		MYLAN	<u>EQ 25MG BASE</u>	<u>A201171</u>	<u>001</u>	Mar 25, 2019
-----------	--	-------	---------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A201171</u>	<u>002</u>	Mar 25, 2019
-----------	--	--	---------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A201171</u>	<u>003</u>	Mar 25, 2019
-----------	--	--	----------------------	----------------	------------	--------------

<u>AB</u>		MYLAN PHARMS INC	<u>EQ 20MG BASE</u>	<u>A201150</u>	<u>001</u>	Nov 09, 2012
-----------	--	------------------	---------------------	----------------	------------	--------------

<u>AB</u>		REYOUNG	<u>EQ 25MG BASE</u>	<u>A208494</u>	<u>001</u>	Jun 12, 2020
-----------	--	---------	---------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A208494</u>	<u>002</u>	Jun 12, 2020
-----------	--	--	---------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A208494</u>	<u>003</u>	Jun 12, 2020
-----------	--	--	----------------------	----------------	------------	--------------

<u>AB</u>		RUBICON	<u>EQ 20MG BASE</u>	<u>A204883</u>	<u>001</u>	Jun 20, 2016
-----------	--	---------	---------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 25MG BASE</u>	<u>A204882</u>	<u>001</u>	Jun 11, 2018
-----------	--	--	---------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A204882</u>	<u>002</u>	Jun 11, 2018
-----------	--	--	---------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A204882</u>	<u>003</u>	Jun 11, 2018
-----------	--	--	----------------------	----------------	------------	--------------

<u>AB</u>		SUNSHINE	<u>EQ 25MG BASE</u>	<u>A213032</u>	<u>001</u>	Jun 11, 2020
-----------	--	----------	---------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A213032</u>	<u>002</u>	Jun 11, 2020
-----------	--	--	---------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A213032</u>	<u>003</u>	Jun 11, 2020
-----------	--	--	----------------------	----------------	------------	--------------

<u>AB</u>		TEVA	<u>EQ 25MG BASE</u>	<u>A077342</u>	<u>001</u>	Mar 09, 2016
-----------	--	------	---------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A077342</u>	<u>002</u>	Mar 09, 2016
-----------	--	--	---------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A077342</u>	<u>003</u>	Mar 09, 2016
-----------	--	--	----------------------	----------------	------------	--------------

<u>AB</u>		TEVA PHARMS	<u>EQ 20MG BASE</u>	<u>A078380</u>	<u>001</u>	Jan 07, 2013
-----------	--	-------------	---------------------	----------------	------------	--------------

<u>AB</u>		TORRENT	<u>EQ 25MG BASE</u>	<u>A091448</u>	<u>001</u>	Jun 11, 2018
-----------	--	---------	---------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A091448</u>	<u>002</u>	Jun 11, 2018
-----------	--	--	---------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A091448</u>	<u>003</u>	Jun 11, 2018
-----------	--	--	----------------------	----------------	------------	--------------

<u>AB</u>		TORRENT PHARMS LTD	<u>EQ 20MG BASE</u>	<u>A091479</u>	<u>001</u>	Nov 06, 2012
-----------	--	--------------------	---------------------	----------------	------------	--------------

<u>AB</u>		UMEDICA LABS PVT LTD	<u>EQ 50MG BASE</u>	<u>A209302</u>	<u>001</u>	Aug 25, 2020
-----------	--	----------------------	---------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A209302</u>	<u>002</u>	Aug 25, 2020
-----------	--	--	----------------------	----------------	------------	--------------

<u>AB</u>		WATSON LABS INC	<u>EQ 20MG BASE</u>	<u>A202503</u>	<u>001</u>	Nov 06, 2012
-----------	--	-----------------	---------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 25MG BASE</u>	<u>A202506</u>	<u>001</u>	Nov 25, 2020
-----------	--	--	---------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A202506</u>	<u>002</u>	Nov 25, 2020
-----------	--	--	---------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A202506</u>	<u>003</u>	Nov 25, 2020
-----------	--	--	----------------------	----------------	------------	--------------

<u>AB</u>		YILING	<u>EQ 20MG BASE</u>	<u>A202598</u>	<u>001</u>	Nov 06, 2012
-----------	--	--------	---------------------	----------------	------------	--------------

VIAGRA

<u>AB</u>	<u>+</u>	UPJOHN	<u>EQ 25MG BASE</u>	<u>N020895</u>	<u>001</u>	Mar 27, 1998
-----------	----------	--------	---------------------	----------------	------------	--------------

<u>AB</u>	<u>+</u>		<u>EQ 50MG BASE</u>	<u>N020895</u>	<u>002</u>	Mar 27, 1998
-----------	----------	--	---------------------	----------------	------------	--------------

<u>AB</u>	<u>+!</u>		<u>EQ 100MG BASE</u>	<u>N020895</u>	<u>003</u>	Mar 27, 1998
-----------	-----------	--	----------------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

SILODOSIN

CAPSULE;ORAL

RAPAFLO

AB	+ !	ALLERGAN	4MG	N022206	001	Oct 08, 2008
AB	+		8MG	N022206	002	Oct 08, 2008

SILODOSIN

AB		AJANTA PHARMA LTD	4MG	A211060	001	Dec 03, 2018
AB			8MG	A211060	002	Dec 03, 2018
AB		AMNEAL PHARMS CO	4MG	A209745	001	Dec 03, 2018
AB			8MG	A209745	002	Dec 03, 2018
AB		AUROBINDO PHARMA LTD	4MG	A210626	001	Dec 10, 2018
AB			8MG	A210626	002	Dec 10, 2018
AB		HETERO LABS LTD V	4MG	A204793	001	Feb 14, 2020
AB			8MG	A204793	002	Feb 14, 2020
AB		LUPIN LTD	4MG	A206541	001	Dec 03, 2018
AB			8MG	A206541	002	Dec 03, 2018
AB		MACLEODS PHARMS LTD	4MG	A211166	001	Dec 03, 2018
AB			8MG	A211166	002	Dec 03, 2018
AB		MSN	4MG	A210687	001	Dec 03, 2018
AB			8MG	A210687	002	Dec 03, 2018
AB		SANDOZ INC	4MG	A204726	001	Mar 31, 2017
AB			8MG	A204726	002	Mar 31, 2017

SILVER SULFADIAZINE

CREAM;TOPICAL

SILVADENE

AB	+ !	KING PHARMS LLC	1%	N017381	001	
-----------	------------	-----------------	-----------	----------------	------------	--

SSD

AB		DR REDDYS LA	1%	N018578	001	Feb 25, 1982
-----------	--	--------------	-----------	----------------	------------	--------------

THERMAZENE

AB		THEPHARMANETWORK LLC	1%	N018810	001	Dec 23, 1985
-----------	--	----------------------	-----------	----------------	------------	--------------

SIMVASTATIN

SUSPENSION;ORAL

FLOLIPID

+	TCG FLUENT PHARMA	20MG/5ML	N206679	001	Apr 21, 2016
+ !		40MG/5ML	N206679	002	Apr 21, 2016

TABLET;ORAL

SIMVASTATIN

AB		ACCORD HLTHCARE	5MG	A078155	005	Apr 05, 2013
AB			10MG	A078155	002	Feb 26, 2008
AB			20MG	A078155	003	Feb 26, 2008
AB			40MG	A078155	004	Feb 26, 2008
AB			80MG	A078155	001	Feb 26, 2008
AB		AUROBINDO PHARMA	5MG	A077691	001	Dec 20, 2006
AB			10MG	A077691	002	Dec 20, 2006
AB			20MG	A077691	003	Dec 20, 2006
AB			40MG	A077691	004	Dec 20, 2006
AB			80MG	A077691	005	Dec 20, 2006
AB		BIOCON LIMITED	5MG	A078034	001	Dec 20, 2006
AB			10MG	A078034	002	Dec 20, 2006
AB			20MG	A078034	003	Dec 20, 2006
AB			40MG	A078034	004	Dec 20, 2006
AB			80MG	A078034	005	Dec 20, 2006
AB		DR REDDYS LABS INC	5MG	A077752	005	Jan 23, 2008
AB			10MG	A077752	001	Dec 20, 2006
AB			20MG	A077752	002	Dec 20, 2006
AB			40MG	A077752	003	Dec 20, 2006
AB			80MG	A077752	004	Dec 20, 2006
AB		HETERO LABS LTD III	5MG	A200895	001	Nov 25, 2014
AB			10MG	A200895	002	Nov 25, 2014
AB			20MG	A200895	003	Nov 25, 2014
AB			40MG	A200895	004	Nov 25, 2014
AB			80MG	A200895	005	Nov 25, 2014
AB		LUPIN	5MG	A078103	005	Apr 14, 2009
AB			10MG	A078103	001	May 11, 2007
AB			20MG	A078103	002	May 11, 2007
AB			40MG	A078103	003	May 11, 2007
AB			80MG	A078103	004	May 11, 2007
AB		MICRO LABS	5MG	A090383	001	Sep 16, 2011
AB			10MG	A090383	002	Sep 16, 2011
AB			20MG	A090383	003	Sep 16, 2011

PRESCRIPTION DRUG PRODUCT LIST

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

<u>AB</u>		<u>40MG</u>	<u>A090383</u>	<u>004</u>	Sep 16, 2011
<u>AB</u>		<u>80MG</u>	<u>A090383</u>	<u>005</u>	Sep 16, 2011
<u>AB</u>	OXFORD PHARMS	<u>5MG</u>	<u>A078735</u>	<u>001</u>	Aug 30, 2010
<u>AB</u>		<u>10MG</u>	<u>A078735</u>	<u>002</u>	Aug 30, 2010
<u>AB</u>		<u>20MG</u>	<u>A078735</u>	<u>003</u>	Aug 30, 2010
<u>AB</u>		<u>40MG</u>	<u>A078735</u>	<u>004</u>	Aug 30, 2010
<u>AB</u>		<u>80MG</u>	<u>A078735</u>	<u>005</u>	Aug 30, 2010
<u>AB</u>	WATSON LABS TEVA	<u>5MG</u>	<u>A076685</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>10MG</u>	<u>A076685</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>		<u>20MG</u>	<u>A076685</u>	<u>003</u>	Dec 20, 2006
<u>AB</u>		<u>40MG</u>	<u>A076685</u>	<u>004</u>	Dec 20, 2006
<u>AB</u>		<u>80MG</u>	<u>A076685</u>	<u>005</u>	Dec 20, 2006
<u>AB</u>	ZYDUS PHARMS USA	<u>5MG</u>	<u>A077837</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>10MG</u>	<u>A077837</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>		<u>20MG</u>	<u>A077837</u>	<u>003</u>	Dec 20, 2006
<u>AB</u>		<u>40MG</u>	<u>A077837</u>	<u>004</u>	Dec 20, 2006
<u>AB</u>		<u>80MG</u>	<u>A077837</u>	<u>005</u>	Dec 20, 2006

ZOCOR

<u>AB</u>	+	MSD MERCK CO	<u>5MG</u>	<u>N019766</u>	<u>001</u>	Dec 23, 1991
<u>AB</u>	+		<u>10MG</u>	<u>N019766</u>	<u>002</u>	Dec 23, 1991
<u>AB</u>	+		<u>20MG</u>	<u>N019766</u>	<u>003</u>	Dec 23, 1991
<u>AB</u>	+		<u>40MG</u>	<u>N019766</u>	<u>004</u>	Dec 23, 1991
<u>AB</u>	+	!	<u>80MG</u>	<u>N019766</u>	<u>005</u>	Jul 10, 1998

SINCALIDE

INJECTABLE; INJECTION

KINEVAC

+! BRACCO 0.005MG/VIAL N017697 001

SINECATECHINS

OINTMENT; TOPICAL

VEREGEN

+! FOUGERA PHARMS INC 15% N021902 001 Oct 31, 2006

SIPONIMOD FUMARIC ACID

TABLET; ORAL

MAYZENT

+ NOVARTIS EQ 0.25MG BASE N209884 001 Mar 26, 2019

+! EQ 2MG BASE N209884 002 Mar 26, 2019

SIROLIMUS

SOLUTION; ORAL

RAPAMUNEAA +! PF PRISM CV 1MG/ML N021083 001 Sep 15, 1999SIROLIMUSAA AMNEAL 1MG/ML A211212 001 Oct 18, 2019AA APOTEX 1MG/ML A211406 001 Oct 22, 2019AA NOVITIUM PHARMA 1MG/ML A211040 001 Jan 28, 2019

TABLET; ORAL

RAPAMUNEAB + PF PRISM CV 0.5MG N021110 004 Jan 25, 2010AB + 1MG N021110 001 Aug 25, 2000AB +! 2MG N021110 002 Aug 22, 2002SIROLIMUSAB DR REDDYS LABS LTD 1MG A201578 001 Oct 27, 2014AB 2MG A201578 002 Oct 27, 2014AB GLENMARK PHARMS LTD 0.5MG A208691 001 Oct 16, 2020AB 1MG A208691 002 Oct 16, 2020AB 2MG A208691 003 Oct 16, 2020AB ZYDUS PHARMS 0.5MG A201676 003 Jan 08, 2014SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JANUVIA

+ MERCK SHARP DOHME EQ 25MG BASE N021995 001 Oct 16, 2006

+ EQ 50MG BASE N021995 002 Oct 16, 2006

+! EQ 100MG BASE N021995 003 Oct 16, 2006

PRESCRIPTION DRUG PRODUCT LIST

SODIUM ACETATE

INJECTABLE; INJECTION

SODIUM ACETATE

FRESENIUS KABI USA 4MEQ/ML
 +! HOSPIRA 2MEQ/ML

A206687 001 Oct 30, 2017
 N018893 001 May 04, 1983

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION; INTRAVENOUS

AMMONUL

AP +! BAUSCH 10%;10% (5GM/50ML;5GM/50ML)

N020645 001 Feb 17, 2005

SODIUM PHENYLACETATE AND SODIUM BENZOATE

AP AILEX PHARMS LLC 10%;10% (5GM/50ML;5GM/50ML)

A207096 001 Feb 24, 2016

AP MAIA PHARMS INC 10%;10% (5GM/50ML;5GM/50ML)

A208521 001 May 08, 2017

AP NAVINTA LLC 10%;10% (5GM/50ML;5GM/50ML)

A205880 001 Aug 04, 2016

SODIUM BICARBONATE

INJECTABLE; INJECTION

SODIUM BICARBONATE

AP ! EXELA PHARMA 0.5MEQ/ML

A211091 001 Jun 20, 2019

AP ! 0.9MEQ/ML

A211091 002 Jun 20, 2019

AP ! 1MEQ/ML

A211091 003 Jun 20, 2019

AP HOSPIRA INC 0.5MEQ/ML

A202679 001 Mar 07, 2017

AP 0.5MEQ/ML

A202981 001 Mar 04, 2016

AP 0.9MEQ/ML

A202494 001 Mar 06, 2017

AP 1MEQ/ML

A202432 001 Sep 26, 2017

AP 1MEQ/ML

A202494 002 Mar 06, 2017

AP INTL MEDICATION SYS 1MEQ/ML

A203449 001 Sep 19, 2017

HOSPIRA INC 1MEQ/ML

A202495 001 Mar 06, 2017

SODIUM CHLORIDE

INJECTABLE; INJECTION

BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP FRESENIUS KABI USA 9MG/ML

A088911 001 Feb 07, 1985

AP +! HOSPIRA 9MG/ML

N018800 001 Oct 29, 1982

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP + B BRAUN 450MG/100ML

N019635 001 Mar 09, 1988

AP +! BAXTER HLTHCARE 450MG/100ML

N018016 001

AP FRESENIUS KABI USA 450MG/100ML

A208122 001 Jul 23, 2018

AP HOSPIRA 450MG/100ML

N019759 001 Jun 08, 1988

AP +! ICU MEDICAL INC 450MG/100ML

N018090 001

SODIUM CHLORIDE 0.9%

AP SPECTRA MDCL 9MG/ML

A206171 001 Jul 21, 2017

DEVICES

AP WEST-WARD PHARMS 9MG/ML

A201850 001 Jan 20, 2012

INT

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP +! B BRAUN 900MG/100ML

N017464 001

AP +! 900MG/100ML

N019635 002 Mar 09, 1988

AP +! BAXTER HLTHCARE 9MG/ML

N016677 004 Oct 30, 1985

AP + 9MG/ML

N020178 002 Dec 07, 1992

AP +! 900MG/100ML

N016677 001

AP +! 900MG/100ML

N020178 001 Dec 07, 1992

AP ! FRESENIUS KABI USA 9MG/ML

A088912 001 Jan 10, 1985

AP 900MG/100ML

A207310 001 Sep 19, 2017

AP FRESENIUS MEDCL 900MG/100ML

A078177 001 Apr 12, 2007

AP HAEMONETICS 900MG/100ML

A076316 001 Oct 27, 2004

AP +! HOSPIRA 9MG/ML

N018803 001 Oct 29, 1982

AP + 9MG/ML

N019465 002 Jul 15, 1985

AP +! 900MG/100ML

N019465 001 Jul 15, 1985

AP +! 900MG/100ML

N019480 001 Sep 17, 1985

AP +! ICU MEDICAL INC 900MG/100ML

N016366 001

AP JUBILANT CADISTA 9MG/ML

A203352 001 May 18, 2016

AP LABORATORIOS 900MG/100ML

A207956 001 May 25, 2017

GRIFOLS

AP NEPHRON 9MG/ML

A211968 001 Apr 23, 2020

AP ! TARO 9MG/ML

A077407 001 Aug 11, 2006

SODIUM CHLORIDE 3% IN PLASTIC CONTAINER

AP B BRAUN 3GM/100ML

N019635 003 Mar 09, 1988

AP +! BAXTER HLTHCARE 3GM/100ML

N019022 001 Nov 01, 1983

AP FRESENIUS KABI USA 3GM/100ML

A209476 001 Mar 13, 2019

SODIUM CHLORIDE 5% IN PLASTIC CONTAINER

AP B BRAUN 5GM/100ML

N019635 004 Mar 09, 1988

AP + BAXTER HLTHCARE 5GM/100ML

N019022 002 Nov 01, 1983

PRESCRIPTION DRUG PRODUCT LISTSODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9%

+	B BRAUN	9MG/10ML	N019635	005	Aug 11, 2016
+	MEDEFIL INC	9MG/ML (9MG/ML)	N202832	001	Jan 06, 2012
+		18MG/2ML (9MG/ML)	N202832	002	Jan 06, 2012
+		22.5MG/2.5ML (9MG/ML)	N202832	003	Jan 06, 2012
+		27MG/3ML (9MG/ML)	N202832	004	Jan 06, 2012
+		45MG/5ML (9MG/ML)	N202832	005	Jan 06, 2012
+		90MG/10ML (9MG/ML)	N202832	006	Jan 06, 2012
	WEST-WARD PHARMS INT	9MG/ML	A201833	001	Sep 24, 2013

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+	LIEBEL-FLARSHEIM	1012.5MG/125ML (9MG/ML)	N021569	002	Jul 27, 2006
---	------------------	-------------------------	---------	-----	--------------

SOLUTION; INTRAVENOUS

SODIUM CHLORIDE 14.6%

+	HOSPIRA	100MEQ/40ML (2.5MEQ/ML)	N018897	002	Jul 20, 1984
---	---------	-------------------------	---------	-----	--------------

SODIUM CHLORIDE 23.4%

+	HOSPIRA	400MEQ/100ML (4MEQ/ML)	N018897	003	Jun 18, 2020
---	---------	------------------------	---------	-----	--------------

SOLUTION; IRRIGATION

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AT	+	B BRAUN	900MG/100ML	N016733	001
AT		BAXTER HLTHCARE	900MG/100ML	N017427	001
AT			900MG/100ML	N017867	001
AT		ICU MEDICAL INC	900MG/100ML	N017514	001
AT			900MG/100ML	N018314	001

SOLUTION FOR SLUSH; IRRIGATION

SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER

	BAXTER HLTHCARE	900MG/100ML	N019319	002	May 17, 1985
--	-----------------	-------------	---------	-----	--------------

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE; INJECTION

FERRLECIT

AB	+	SANOFI AVENTIS US	62.5MG/5ML	N020955	001	Feb 18, 1999
-----------	---	-------------------	-------------------	----------------	------------	--------------

SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE

AB		WEST-WARD PHARMS INT	62.5MG/5ML	A078215	001	Mar 31, 2011
-----------	--	-------------------------	-------------------	----------------	------------	--------------

SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS

SODIUM FLUORIDE F-18

AP		3D IMAGING DRUG	10-200mCi/ML	A203777	001	Oct 19, 2015
AP		BIOMEDCL RES FDN	10-200mCi/ML	A204351	001	Jan 09, 2015
AP		CARDINAL HEALTH 414	10-200mCi/ML	A203780	001	Jul 30, 2015
AP		DECATUR	10-200mCi/ML	A204464	001	Oct 21, 2014
AP		ESSENTIAL ISOTOPES	10-200mCi/ML	A204541	001	Oct 29, 2014
AP		HOT SHOTS NM LLC	10-200mCi/ML	A204530	001	Jul 29, 2015
AP		JUBILANT DRAXIMAGE	10-200mCi/ML	A203968	001	Oct 23, 2015
AP		KREITCHMAN PET CTR	10-200mCi/ML	A203936	001	May 19, 2016
AP		MIDWEST MEDCL	10-200mCi/ML	A204440	001	Nov 17, 2015
AP		MIPS CRF	10-200mCi/ML	A204517	001	Jul 21, 2015
AP		NCM USA BRONX LLC	10-200mCi/ML	A204513	001	Nov 28, 2014
AP		PETNET	10-200mCi/ML	A203890	001	Sep 28, 2015
AP		PRECISION NUCLEAR	10-200mCi/ML	A204542	001	Feb 27, 2015
AP		SHERTECH LABS LLC	10-200mCi/ML	A204315	001	Sep 22, 2014
AP		SOFIE	10-200mCi/ML	A203592	001	Aug 18, 2015
AP	!		10-200mCi/ML	A203544	001	Dec 26, 2012
AP		SPECTRON MRC LLC	10-200mCi/ML	A203912	001	Apr 22, 2015
AP		UCSF RODIOPHARM	10-200mCi/ML	A204437	001	Mar 13, 2014
AP		UNIV UTAH CYCLOTRON	10-200mCi/ML	A204497	001	Apr 20, 2015
	!	MCPRF	10-91.5mCi/ML	A203605	001	Jun 28, 2013
		THE FEINSTEIN INST	20-600mCi/ML	A204328	001	Nov 19, 2014

SODIUM IODIDE I-123

CAPSULE; ORAL

SODIUM IODIDE I 123

AA	+	CARDINAL HEALTH 418	100uCi	N018671	001	May 27, 1982
AA	+		200uCi	N018671	002	May 27, 1982
AA		CURIUM	100uCi	A071909	001	Feb 28, 1989
AA			200uCi	A071910	001	Feb 28, 1989

PRESCRIPTION DRUG PRODUCT LIST

SODIUM IODIDE I-131

CAPSULE;ORAL

SODIUM IODIDE I 131

+ JUBILANT

0.009-0.1mCi

N021305 006 May 19, 2005

SOLUTION;ORAL

HICON**AA** +! JUBILANT**250-1000mCi****N021305 007** Dec 05, 2011SODIUM IODIDE I 131**AA** INTL ISOTOPES**250-1000mCi****A209166 001** Feb 05, 2020SODIUM NITRITE

SOLUTION;INTRAVENOUS

SODIUM NITRITE

+! HOPE PHARMS

300MG/10ML (30MG/ML)

N203922 001 Feb 14, 2012

SODIUM NITRITE; SODIUM THIOSULFATE

SOLUTION, SOLUTION;INTRAVENOUS, INTRAVENOUS

NITHIODOTE

+! HOPE PHARMS

300MG/10ML (30MG/ML), N/A;N/A, 12.5GM/50ML
(250MG/ML)

N201444 001 Jan 14, 2011

SODIUM NITROPRUSSIDE

INJECTABLE;INJECTION

NITROPRESS**AP** ! HOSPIRA**25MG/ML****A071961 001** Aug 01, 1988SODIUM NITROPRUSSIDE**AP** AKORN**25MG/ML****A208635 001** May 04, 2017**AP** AMNEAL**25MG/ML****A209493 001** Nov 07, 2017**AP** AUROBINDO PHARMA
LTD**25MG/ML****A211934 001** Dec 10, 2020**AP** CIPLA**25MG/ML****A210855 001** Jul 16, 2018**AP** DR REDDYS LABS LTD**25MG/ML****A210114 001** Apr 10, 2019**AP** HAINAN POLY PHARM**25MG/ML****A214199 001** Aug 25, 2020**AP** HONG KONG**25MG/ML****A211016 001** Nov 29, 2019**AP** MEDICURE**25MG/ML****A209584 001** Aug 10, 2018**AP** MICRO LABS**25MG/ML****A209352 001** Dec 08, 2017**AP** MYLAN LABS LTD**25MG/ML****A210763 001** Apr 17, 2018**AP** NEXUS PHARMS**25MG/ML****A207499 001** May 25, 2017**AP** SAGENT PHARMS INC**25MG/ML****A207426 001** Dec 08, 2016**AP** SOMERSET THERAPS
LLC**25MG/ML****A210882 001** Aug 17, 2018**AP** XIROMED**25MG/ML****A211277 001** Oct 29, 2020

SOLUTION;INTRAVENOUS

NIPRIDE RTU IN SODIUM CHLORIDE 0.9%

+! EXELA PHARMA

20MG/100ML (0.2MG/ML)

N209387 003 Jul 13, 2018

+!

50MG/100ML (0.5MG/ML)

N209387 001 Mar 08, 2017

SODIUM OXYBATE

SOLUTION;ORAL

XYREM

+! JAZZ PHARMS

0.5GM/ML

N021196 001 Jul 17, 2002

SODIUM PHENYL BUTYRATE

POWDER;ORAL

BUPHENYL**AB** +! HORIZON THERAP**3GM/TEASPOONFUL****N020573 001** Apr 30, 1996SODIUM PHENYL BUTYRATE**AB** PAR PHARM**3GM/TEASPOONFUL****A203918 001** Jun 15, 2016**AB** SIGMAPHARM LABS LLC**3GM/TEASPOONFUL****A202819 001** Mar 22, 2013

TABLET;ORAL

BUPHENYL**AB** +! HORIZON THERAP**500MG****N020572 001** May 13, 1996SODIUM PHENYL BUTYRATE**AB** PAR PHARM**500MG****A204395 001** Apr 15, 2016SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET;ORAL

OSMOPREP

+! SALIX PHARMS

0.398GM;1.102GM

N021892 001 Mar 16, 2006

PRESCRIPTION DRUG PRODUCT LIST

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION

SODIUM PHOSPHATES IN PLASTIC CONTAINER

+! HOSPIRA 142MG/ML; 276MG/ML N018892 001 May 10, 1983

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

KALEXATE**AA** ! KVK TECH **454GM/BOT** **A040905 001** Mar 30, 2009KIONEX**AA** PADDOCK LLC **454GM/BOT** **A040029 001** Feb 06, 1998SODIUM POLYSTYRENE SULFONATE**AA** BELCHER **454GM/BOT** **A205727 001** Feb 23, 2016**AA** CMP PHARMA INC **454GM/BOT** **A089910 001** Jan 19, 1989**AA** DISCOVERY THERAP **453.6GM/BOT** **A090313 001** Dec 21, 2011**AA** EPIC PHARMA LLC **453.6GM/BOT** **A202333 001** Mar 19, 2014**AA** NOVELGENIX THERAPS **454GM/BOT** **A206815 001** Feb 18, 2016**AA** NUVO PHARMS INC **454GM/BOT** **A204071 001** Nov 28, 2014

KALEXATE

KVK TECH 15GM/BOT A040905 002 Apr 03, 2015

SODIUM POLYSTYRENE SULFONATE

NUVO PHARMS INC 15GM/BOT A204071 002 Nov 28, 2014

SUSPENSION; ORAL, RECTAL

SPS

! CMP PHARMA INC 15GM/60ML A087859 001 Dec 08, 1982

SODIUM TETRADECYL SULFATE

INJECTABLE; INJECTION

SODIUM TETRADECYL SULFATE**AP** CUSTOPHARM INC **60MG/2ML (30MG/ML)** **A209937 001** Dec 09, 2019SOTRADECOL**AP** ! MYLAN INSTITUTIONAL **60MG/2ML (30MG/ML)** **A040541 002** Nov 12, 2004

! 20MG/2ML (10MG/ML) A040541 001 Nov 12, 2004

SODIUM THIOSULFATE

SOLUTION; INTRAVENOUS

SODIUM THIOSULFATE

+! HOPE PHARMS 12.5GM/50ML (250MG/ML) N203923 001 Feb 14, 2012

SODIUM ZIRCONIUM CYCLOSILICATE

FOR SUSPENSION; ORAL

LOKELMA

+ ASTRAZENECA PHARMS 5GM/PACKET N207078 001 May 18, 2018

+! 10GM/PACKET N207078 002 May 18, 2018

SOFOBUVIR

PELLETS; ORAL

SOVALDI

+ GILEAD SCIENCES INC 150MG/PACKET N212480 001 Aug 28, 2019

+! 200MG/PACKET N212480 002 Aug 28, 2019

TABLET; ORAL

SOVALDI

+ GILEAD SCIENCES INC 200MG N204671 002 Aug 28, 2019

+! 400MG N204671 001 Dec 06, 2013

SOFOBUVIR; VELPATASVIR

TABLET; ORAL

EPCLUSA

+ GILEAD SCIENCES INC 200MG; 50MG N208341 002 Mar 19, 2020

+! 400MG; 100MG N208341 001 Jun 28, 2016

SOFOBUVIR; VELPATASVIR; VOXILAPREVIR

TABLET; ORAL

VOSEVI

+! GILEAD SCIENCES INC 400MG; 100MG; 100MG N209195 001 Jul 18, 2017

SOLIFENACIN SUCCINATE

SUSPENSION; ORAL

VESICARE LS

+! ASTELLAS 1MG/ML N209529 001 May 26, 2020

TABLET; ORAL

SOLIFENACIN SUCCINATE**AB** AJANTA PHARMA LTD **5MG** **A205483 001** May 20, 2019**AB** **10MG** **A205483 002** May 20, 2019**AB** ALEMBIC PHARMS LTD **5MG** **A205575 001** May 20, 2019**AB** **10MG** **A205575 002** May 20, 2019

PRESCRIPTION DRUG PRODUCT LIST

SOLIFENACIN SUCCINATE

TABLET;ORAL

SOLIFENACIN SUCCINATE

<u>AB</u>	ALKEM LABS LTD	<u>5MG</u>	<u>A210224</u>	<u>001</u>	May 20, 2019
<u>AB</u>		<u>10MG</u>	<u>A210224</u>	<u>002</u>	May 20, 2019
<u>AB</u>	AMNEAL PHARMS CO	<u>5MG</u>	<u>A209719</u>	<u>001</u>	May 20, 2019
<u>AB</u>		<u>10MG</u>	<u>A209719</u>	<u>002</u>	May 20, 2019
<u>AB</u>	BRECKENRIDGE	<u>5MG</u>	<u>A209818</u>	<u>001</u>	May 20, 2019
<u>AB</u>		<u>10MG</u>	<u>A209818</u>	<u>002</u>	May 20, 2019
<u>AB</u>	CELLTRION	<u>5MG</u>	<u>A210582</u>	<u>001</u>	May 20, 2019
<u>AB</u>		<u>10MG</u>	<u>A210582</u>	<u>002</u>	May 20, 2019
<u>AB</u>	CIPLA	<u>5MG</u>	<u>A209839</u>	<u>001</u>	May 20, 2019
<u>AB</u>		<u>10MG</u>	<u>A209839</u>	<u>002</u>	May 20, 2019
<u>AB</u>	GLENMARK PHARMS INC	<u>5MG</u>	<u>A209239</u>	<u>001</u>	May 20, 2019
<u>AB</u>		<u>10MG</u>	<u>A209239</u>	<u>002</u>	May 20, 2019
<u>AB</u>	JIANGXI BOYA SEEHOT	<u>5MG</u>	<u>A210281</u>	<u>001</u>	May 20, 2019
<u>AB</u>		<u>10MG</u>	<u>A210281</u>	<u>002</u>	May 20, 2019
<u>AB</u>	MSN	<u>5MG</u>	<u>A210688</u>	<u>001</u>	May 20, 2019
<u>AB</u>		<u>10MG</u>	<u>A210688</u>	<u>002</u>	May 20, 2019
<u>AB</u>	QILU	<u>5MG</u>	<u>A209333</u>	<u>001</u>	May 20, 2019
<u>AB</u>		<u>10MG</u>	<u>A209333</u>	<u>002</u>	May 20, 2019
<u>AB</u>	RISING	<u>5MG</u>	<u>A211423</u>	<u>001</u>	Dec 11, 2019
<u>AB</u>		<u>10MG</u>	<u>A211423</u>	<u>002</u>	Dec 11, 2019
<u>AB</u>	SCIEGEN PHARMS INC	<u>5MG</u>	<u>A211657</u>	<u>001</u>	May 20, 2019
<u>AB</u>		<u>10MG</u>	<u>A211657</u>	<u>002</u>	May 20, 2019
<u>AB</u>	STRIDES PHARMA	<u>5MG</u>	<u>A212214</u>	<u>001</u>	Sep 26, 2019
<u>AB</u>		<u>10MG</u>	<u>A212214</u>	<u>002</u>	Sep 26, 2019
<u>AB</u>	TEVA PHARMS USA	<u>5MG</u>	<u>A091464</u>	<u>001</u>	Apr 02, 2014
<u>AB</u>		<u>10MG</u>	<u>A091464</u>	<u>002</u>	Apr 02, 2014
<u>AB</u>	UNICHEM	<u>5MG</u>	<u>A211701</u>	<u>001</u>	Aug 27, 2019
<u>AB</u>		<u>10MG</u>	<u>A211701</u>	<u>002</u>	Aug 27, 2019
<u>AB</u>	WATSON LABS INC	<u>5MG</u>	<u>A202551</u>	<u>001</u>	May 20, 2019
<u>AB</u>		<u>10MG</u>	<u>A202551</u>	<u>002</u>	May 20, 2019
<u>AB</u>	ZYDUS PHARMS	<u>5MG</u>	<u>A207721</u>	<u>001</u>	Oct 19, 2020
<u>AB</u>		<u>10MG</u>	<u>A207721</u>	<u>002</u>	Oct 19, 2020
<u>VESICARE</u>					
<u>AB</u>	+ ASTELLAS	<u>5MG</u>	<u>N021518</u>	<u>001</u>	Nov 19, 2004
<u>AB</u>	+!	<u>10MG</u>	<u>N021518</u>	<u>002</u>	Nov 19, 2004

SOLRIAMFETOL HYDROCHLORIDE

TABLET;ORAL

SUNOSI

+ JAZZ

EQ 75MG BASE

N211230 001 Jun 17, 2019

+!

EQ 150MG BASE

N211230 002 Jun 17, 2019

SONIDEGIB PHOSPHATE

CAPSULE;ORAL

ODOMZO

+! SUN PHARMA GLOBAL

EQ 200MG BASE

N205266 001 Jul 24, 2015

SORAFENIB TOSYLATE

TABLET;ORAL

NEXAVARAB +! BAYER HLTHCARE EQ 200MG BASEN021923 001 Dec 20, 2005SORAFENIB TOSYLATEAB TEVA PHARMS USA INC EQ 200MG BASEA209567 001 Nov 12, 2020SORBITOL

SOLUTION;IRRIGATION

SORBITOL 3% IN PLASTIC CONTAINER

BAXTER HLTHCARE 3GM/100ML

N017863 001

SORBITOL 3.3% IN PLASTIC CONTAINER

B BRAUN 3.3GM/100ML

N016741 001

SOTALOL HYDROCHLORIDE

SOLUTION;INTRAVENOUS

SOTALOL HYDROCHLORIDE

+! ALTATHERA PHARMS 150MG/10ML (15MG/ML)

N022306 001 Jul 02, 2009

LLC

SOLUTION;ORAL

SOTYLIZE

+! ARBOR PHARMS LLC 5MG/ML (5MG/ML)

N205108 001 Oct 22, 2014

TABLET;ORAL

BETAPACEAB + COVIS 80MGN019865 001 Oct 30, 1992

PRESCRIPTION DRUG PRODUCT LIST

SOTALOL HYDROCHLORIDE

TABLET; ORAL

BETAPACE

<u>AB</u>	+		<u>120MG</u>	<u>N019865</u>	<u>005</u>	Apr 20, 1994
<u>AB</u>	+	!	<u>160MG</u>	<u>N019865</u>	<u>002</u>	Oct 30, 1992
<u>AB</u>	+		<u>240MG</u>	<u>N019865</u>	<u>003</u>	Oct 30, 1992

BETAPACE AF

<u>AB</u>	+	COVIS	<u>80MG</u>	<u>N021151</u>	<u>001</u>	Feb 22, 2000
<u>AB</u>	+		<u>120MG</u>	<u>N021151</u>	<u>002</u>	Feb 22, 2000
<u>AB</u>	+	!	<u>160MG</u>	<u>N021151</u>	<u>003</u>	Feb 22, 2000

SORINE

<u>AB</u>		UPSHER SMITH LABS	<u>80MG</u>	<u>A075500</u>	<u>001</u>	Apr 27, 2001
<u>AB</u>			<u>120MG</u>	<u>A075500</u>	<u>004</u>	Apr 27, 2001
<u>AB</u>			<u>160MG</u>	<u>A075500</u>	<u>002</u>	Apr 27, 2001
<u>AB</u>			<u>240MG</u>	<u>A075500</u>	<u>003</u>	Apr 27, 2001

SOTALOL HYDROCHLORIDE

<u>AB</u>		APOTEX	<u>80MG</u>	<u>A076140</u>	<u>001</u>	Sep 26, 2002
<u>AB</u>			<u>80MG</u>	<u>A076214</u>	<u>001</u>	Aug 27, 2003
<u>AB</u>			<u>120MG</u>	<u>A076140</u>	<u>002</u>	Sep 26, 2002
<u>AB</u>			<u>120MG</u>	<u>A076214</u>	<u>002</u>	Aug 27, 2003
<u>AB</u>			<u>160MG</u>	<u>A076140</u>	<u>003</u>	Sep 26, 2002
<u>AB</u>			<u>160MG</u>	<u>A076214</u>	<u>003</u>	Aug 27, 2003
<u>AB</u>			<u>240MG</u>	<u>A076140</u>	<u>004</u>	Sep 26, 2002
<u>AB</u>		BEXIMCO PHARMS USA	<u>80MG</u>	<u>A207428</u>	<u>001</u>	Oct 21, 2016
<u>AB</u>			<u>80MG</u>	<u>A207429</u>	<u>001</u>	Nov 02, 2018
<u>AB</u>			<u>120MG</u>	<u>A207428</u>	<u>002</u>	Oct 21, 2016
<u>AB</u>			<u>120MG</u>	<u>A207429</u>	<u>002</u>	Nov 02, 2018
<u>AB</u>			<u>160MG</u>	<u>A207428</u>	<u>003</u>	Oct 21, 2016
<u>AB</u>			<u>160MG</u>	<u>A207429</u>	<u>003</u>	Nov 02, 2018
<u>AB</u>		EPIC PHARMA INC	<u>80MG</u>	<u>A077070</u>	<u>001</u>	Nov 04, 2005
<u>AB</u>			<u>120MG</u>	<u>A077070</u>	<u>002</u>	Nov 04, 2005
<u>AB</u>			<u>160MG</u>	<u>A077070</u>	<u>003</u>	Nov 04, 2005
<u>AB</u>		MYLAN	<u>80MG</u>	<u>A077616</u>	<u>001</u>	Feb 07, 2007
<u>AB</u>			<u>120MG</u>	<u>A077616</u>	<u>002</u>	Feb 07, 2007
<u>AB</u>			<u>160MG</u>	<u>A077616</u>	<u>003</u>	Feb 07, 2007
<u>AB</u>		OXFORD PHARMS	<u>80MG</u>	<u>A075563</u>	<u>001</u>	Nov 07, 2003
<u>AB</u>			<u>120MG</u>	<u>A075563</u>	<u>002</u>	Nov 07, 2003
<u>AB</u>			<u>160MG</u>	<u>A075563</u>	<u>003</u>	Nov 07, 2003
<u>AB</u>			<u>240MG</u>	<u>A075563</u>	<u>004</u>	Nov 07, 2003
<u>AB</u>		TEVA	<u>80MG</u>	<u>A075429</u>	<u>001</u>	May 01, 2000
<u>AB</u>			<u>120MG</u>	<u>A075429</u>	<u>002</u>	May 01, 2000
<u>AB</u>			<u>160MG</u>	<u>A075429</u>	<u>003</u>	May 01, 2000
<u>AB</u>			<u>240MG</u>	<u>A075429</u>	<u>004</u>	May 01, 2000

SOYBEAN OIL

INJECTABLE; INJECTION

INTRALIPID 10%

<u>AP</u>	+	FRESENIUS	<u>10%</u>	<u>N017643</u>	<u>001</u>	
-----------	---	-----------	------------	----------------	------------	--

INTRALIPID 20%

<u>AP</u>	+	FRESENIUS	<u>20%</u>	<u>N018449</u>	<u>001</u>	
<u>AP</u>	+	!	<u>20%</u>	<u>N020248</u>	<u>001</u>	Aug 07, 1996

NUTRILIPID 10%

<u>AP</u>	+	B BRAUN	<u>10%</u>	<u>N019531</u>	<u>001</u>	May 28, 1993
-----------	---	---------	------------	----------------	------------	--------------

NUTRILIPID 20%

<u>AP</u>	+	B BRAUN	<u>20%</u>	<u>N019531</u>	<u>002</u>	May 28, 1993
-----------	---	---------	------------	----------------	------------	--------------

INTRALIPID 30%

	+	FRESENIUS	<u>30%</u>	<u>N019942</u>	<u>001</u>	Dec 30, 1993
--	---	-----------	------------	----------------	------------	--------------

SPINOSAD

SUSPENSION; TOPICAL

NATROBA

	+	PARAPRO LLC	<u>0.9%</u>	<u>N022408</u>	<u>001</u>	Jan 18, 2011
--	---	-------------	-------------	----------------	------------	--------------

SPIRONOLACTONE

SUSPENSION; ORAL

CAROSPIR

	+	CMP DEV LLC	<u>25MG/5ML</u>	<u>N209478</u>	<u>001</u>	Aug 04, 2017
--	---	-------------	-----------------	----------------	------------	--------------

TABLET; ORAL

ALDACTONE

<u>AB</u>	+	PFIZER	<u>25MG</u>	<u>N012151</u>	<u>009</u>	Dec 30, 1983
<u>AB</u>	+		<u>50MG</u>	<u>N012151</u>	<u>008</u>	Dec 30, 1982
<u>AB</u>	+	!	<u>100MG</u>	<u>N012151</u>	<u>010</u>	Dec 30, 1983

PRESCRIPTION DRUG PRODUCT LIST

SPIRONOLACTONE

TABLET;ORAL

SPIRONOLACTONE

<u>AB</u>	ACCORD HLTHCARE	<u>25MG</u>	<u>A203512 001</u>	Sep 19, 2016
<u>AB</u>		<u>50MG</u>	<u>A203512 002</u>	Sep 19, 2016
<u>AB</u>		<u>100MG</u>	<u>A203512 003</u>	Sep 19, 2016
<u>AB</u>	AMNEAL PHARMS	<u>25MG</u>	<u>A091426 001</u>	Jul 02, 2010
<u>AB</u>		<u>50MG</u>	<u>A091426 002</u>	Jul 02, 2010
<u>AB</u>		<u>100MG</u>	<u>A091426 003</u>	Jul 02, 2010
<u>AB</u>	AUROBINDO PHARMA LTD	<u>25MG</u>	<u>A202187 001</u>	Mar 06, 2014
<u>AB</u>		<u>50MG</u>	<u>A202187 002</u>	Mar 06, 2014
<u>AB</u>		<u>100MG</u>	<u>A202187 003</u>	Mar 06, 2014
<u>AB</u>	JUBILANT GENERICS	<u>25MG</u>	<u>A203253 001</u>	Apr 23, 2014
<u>AB</u>		<u>50MG</u>	<u>A203253 002</u>	Apr 23, 2014
<u>AB</u>		<u>100MG</u>	<u>A203253 003</u>	Apr 23, 2014
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A040424 001</u>	Aug 20, 2001
<u>AB</u>		<u>50MG</u>	<u>A040424 002</u>	Aug 20, 2001
<u>AB</u>		<u>100MG</u>	<u>A040424 003</u>	Aug 20, 2001
<u>AB</u>	OXFORD PHARMS	<u>25MG</u>	<u>A040750 001</u>	Aug 29, 2006
<u>AB</u>		<u>50MG</u>	<u>A040750 002</u>	Aug 29, 2006
<u>AB</u>		<u>100MG</u>	<u>A040750 003</u>	Aug 29, 2006
<u>AB</u>	SUN PHARM INDUSTRIES	<u>25MG</u>	<u>A089424 001</u>	Jul 23, 1986
<u>AB</u>		<u>50MG</u>	<u>A089424 002</u>	Aug 11, 1999
<u>AB</u>		<u>100MG</u>	<u>A089424 003</u>	Aug 11, 1999
<u>AB</u>	ZYDUS PHARMS	<u>25MG</u>	<u>A205936 001</u>	Jul 18, 2018
<u>AB</u>		<u>50MG</u>	<u>A205936 002</u>	Jul 18, 2018
<u>AB</u>		<u>100MG</u>	<u>A205936 003</u>	Jul 18, 2018

STERILE WATER FOR INJECTION

LIQUID;N/A

BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER

<u>AP</u>	+! HOSPIRA	<u>100%</u>	<u>N018802 001</u>	Oct 27, 1982
-----------	------------	-------------	--------------------	--------------

STERILE WATER FOR INJECTION

<u>AP</u>	FRESENIUS KABI USA	<u>100%</u>	<u>A209689 001</u>	Nov 24, 2017
<u>AP</u>	+! HOSPIRA	<u>100% (10ML)</u>	<u>N018801 002</u>	Oct 27, 1982
<u>AP</u>	MEDEFIL INC	<u>100% (10ML)</u>	<u>A211188 005</u>	Dec 02, 2019
<u>AP</u>	WEST-WARD PHARMS INT	<u>100% (10ML)</u>	<u>A206369 001</u>	Sep 02, 2015

STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

<u>AP</u>	+! B BRAUN	<u>100%</u>	<u>N019633 001</u>	Feb 29, 1988
<u>AP</u>	+! BAXTER HLTHCARE	<u>100%</u>	<u>N018632 001</u>	Jun 30, 1982
<u>AP</u>	+!	<u>100%</u>	<u>N018632 002</u>	Apr 19, 1988
<u>AP</u>	FRESENIUS KABI USA	<u>100%</u>	<u>A088400 001</u>	Jan 16, 1984
<u>AP</u>	+! ICU MEDICAL INC	<u>100%</u>	<u>N018233 001</u>	
<u>AP</u>	+!	<u>100%</u>	<u>N019869 001</u>	Dec 26, 1989
<u>AP</u>	TARO	<u>100%</u>	<u>A077393 001</u>	Aug 11, 2006

STERILE WATER FOR INJECTION

+!	HOSPIRA	100% (20ML)	N018801 003	Oct 27, 1982
+!		100% (50ML)	N018801 004	Oct 27, 1982
+!		100% (100ML)	N018801 005	Oct 27, 1982
	MEDEFIL INC	100% (1ML)	A211188 001	Dec 02, 2019
!		100% (2.5ML)	A211188 002	Dec 02, 2019
!		100% (3ML)	A211188 003	Dec 02, 2019
!		100% (5ML)	A211188 004	Dec 02, 2019

STERILE WATER FOR IRRIGATION

LIQUID;IRRIGATION

STERILE WATER

<u>AT</u>	+ BAXTER HLTHCARE	<u>100%</u>	<u>N017428 001</u>	
<u>STERILE WATER IN PLASTIC CONTAINER</u>				
<u>AT</u>	+ B BRAUN	<u>100%</u>	<u>N016734 001</u>	
<u>AT</u>	BAXTER HLTHCARE	<u>100%</u>	<u>N017866 001</u>	
<u>AT</u>	ICU MEDICAL INC	<u>100%</u>	<u>N017513 001</u>	
<u>AT</u>		<u>100%</u>	<u>N018313 001</u>	

STIRIPENTOL

CAPSULE;ORAL

DIACOMIT

+	BIOCODEX SA	250MG	N206709 001	Aug 20, 2018
+!		500MG	N206709 002	Aug 20, 2018

PRESCRIPTION DRUG PRODUCT LIST

STIRIPENTOL

FOR SUSPENSION; ORAL

DIACOMIT

+ BIOCODEX SA

250MG/PACKET

N207223 001 Aug 20, 2018

+!

500MG/PACKET

N207223 002 Aug 20, 2018

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION

STREPTOMYCIN SULFATE

! XGEN PHARMS

EQ 1GM BASE/VIAL

A064210 001 Jun 30, 1998

STREPTOZOCIN

INJECTABLE; INJECTION

ZANOSAR

+! TEVA PHARMS USA

1GM/VIAL

N050577 001 May 07, 1982

STRONTIUM CHLORIDE SR-89

INJECTABLE; INJECTION

METASTRON**AP** +! Q BIOMED1mCi/ML**N020134 001** Jun 18, 1993STRONTIUM CHLORIDE SR-89**AP** Q BIOMED1mCi/ML**A075941 001** Jan 06, 2003SUCCIMER

CAPSULE; ORAL

CHEMET

+! RECORDATI RARE

100MG

N019998 002 Jan 30, 1991

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

ANECTINE**AP** +! SANDOZ INC20MG/ML**N008453 002**QUELICIN**AP** +! HOSPIRA20MG/ML**N008845 006**SUCCINYLCHOLINE CHLORIDE**AP** AMNEAL20MG/ML**A211432 001** Nov 16, 2018**AP** AMRING PHARMS20MG/ML**A210231 001** Jun 04, 2018**AP** ASPIRO20MG/ML**A213810 001** May 04, 2020**AP** BRECKENRIDGE20MG/ML**A212638 001** Oct 09, 2019**AP** DEVA HOLDING AS20MG/ML**A214491 001** Dec 21, 2020**AP** DR REDDYS20MG/ML**A210698 001** Aug 02, 2019**AP** FRESENIUS KABI USA20MG/ML**A211346 001** Nov 20, 2020**AP** GLAND PHARMA LTD20MG/ML**A214246 001** Jun 16, 2020**AP** HIKMA20MG/ML**A213229 001** Jun 12, 2020**AP** INDOCO20MG/ML**A214308 001** May 22, 2020**AP** MICRO LABS20MG/ML**A214879 001** Nov 24, 2020**AP** NEXUS PHARMS20MG/ML**A213552 001** Oct 27, 2020**AP** NIVAGEN PHARMS INC20MG/ML**A211625 001** May 19, 2020**AP** SOMERSET THERAPS20MG/ML**A211589 001** Jan 15, 2020

LLC

AP ! ZYDUS PHARMS20MG/ML**A209467 001** May 04, 2018SUCRALFATE

SUSPENSION; ORAL

CARAFATE**AB** +! ALLERGAN1GM/10ML**N019183 001** Dec 16, 1993SUCRALFATE**AB** AMNEAL1GM/10ML**A209356 001** Dec 02, 2019

TABLET; ORAL

CARAFATE**AB** +! ALLERGAN1GM**N018333 001**SUCRALFATE**AB** NOSTRUM LABS INC1GM**A074415 001** Jun 08, 1998**AB** TEVA1GM**A070848 001** Mar 29, 1996SUCROFERRIC OXYHYDROXIDE

TABLET, CHEWABLE; ORAL

VELPHORO

+! VIFOR FRESENIUS

500MG

N205109 001 Nov 27, 2013

SUFENTANIL CITRATE

INJECTABLE; INJECTION

SUFENTA PRESERVATIVE FREE**AP** +! AKORNEQ 0.05MG BASE/ML**N019050 001** May 04, 1984SUFENTANIL CITRATE**AP** HOSPIRAEQ 0.05MG BASE/ML**A074534 001** Dec 11, 1996**AP** WEST-WARD PHARMSEQ 0.05MG BASE/ML**A074413 001** Dec 15, 1995

PRESCRIPTION DRUG PRODUCT LIST

SUFENTANIL CITRATE

INJECTABLE; INJECTION

SUFENTANIL CITRATE

INT

TABLET; SUBLINGUAL

DSUVIA

+! ACELRX PHARMS EQ 0.03MG BASE N209128 001 Nov 02, 2018

SUGAMMADEX SODIUM

SOLUTION; INTRAVENOUS

BRIDION

+ ORGANON SUB MERCK EQ 200MG BASE/2ML (EQ 100MG BASE/ML) N022225 002 Dec 15, 2015

+! EQ 500MG BASE/5ML (EQ 100MG BASE/ML) N022225 001 Dec 15, 2015

SULCONAZOLE NITRATE

CREAM; TOPICAL

EXELDERM

+! JOURNEY 1% N018737 001 Feb 28, 1989

SOLUTION; TOPICAL

EXELDERM

+! JOURNEY 1% N018738 001 Aug 30, 1985

SULFACETAMIDE SODIUM

LOTION; TOPICAL

KLARON**AB** +! BAUSCH 10% **N019931 001** Dec 23, 1996SULFACETAMIDE SODIUM**AB** FOUGERA PHARMS 10% **A077015 001** Nov 17, 2006**AB** PERRIGO CO 10% **A078649 001** Mar 23, 2009

TENNESSEE

AB TARO 10% **A078668 001** May 20, 2009

OINTMENT; OPHTHALMIC

SULFACETAMIDE SODIUM

! PERRIGO CO 10% A080029 001

TENNESSEE

SOLUTION/DROPS; OPHTHALMIC

BLEPH-10**AT** ! ALLERGAN 10% **A080028 001**SULFACETAMIDE SODIUM**AT** AKORN 10% **A040215 001** May 25, 1999**AT** BAUSCH AND LOMB 10% **A040066 001** Dec 28, 1994**AT** SANDOZ INC 10% **A089560 001** Oct 18, 1988SULFADIAZINE

TABLET; ORAL

SULFADIAZINE

! SANDOZ 500MG A040091 001 Jul 29, 1994

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

SULFAMETHOXAZOLE AND TRIMETHOPRIM**AP** ! MYLAN LABS LTD **80MG/ML; 16MG/ML** **A206607 001** Aug 30, 2017**AP** SOMERSET **80MG/ML; 16MG/ML** **A212231 001** Jun 26, 2019**AP** TEVA PHARMS USA **80MG/ML; 16MG/ML** **A073303 001** Oct 31, 1991

SUSPENSION; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM**AB** ! AKORN **200MG/5ML; 40MG/5ML** **A074650 001** Dec 29, 1997**AB** ANI PHARMS INC **200MG/5ML; 40MG/5ML** **A077612 001** Nov 13, 2006**AB** AUROBINDO PHARMA **200MG/5ML; 40MG/5ML** **A091348 001** Jun 08, 2010**AB** LANNETT CO INC **200MG/5ML; 40MG/5ML** **A077785 001** Jan 24, 2007**AB** LUPIN LTD **200MG/5ML; 40MG/5ML** **A212699 001** Jan 05, 2021SULFATRIM PEDIATRIC**AB** PHARM ASSOC **200MG/5ML; 40MG/5ML** **N018615 001** Jan 07, 1983

TABLET; ORAL

BACTRIM**AB** + SUN PHARM **400MG; 80MG** **N017377 001**

INDUSTRIES

BACTRIM DS**AB** +! SUN PHARM **800MG; 160MG** **N017377 002**

INDUSTRIES

SEPTRA**AB** MONARCH PHARMS **400MG; 80MG** **N017376 001**SEPTRA DS**AB** MONARCH PHARMS **800MG; 160MG** **N017376 002**

PRESCRIPTION DRUG PRODUCT LISTSULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET;ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB	AMNEAL PHARMS NY	400MG;80MG	A076899 001	Jan 27, 2005
AB		800MG;160MG	A076899 002	Jan 27, 2005
AB	AUROBINDO PHARMA	400MG;80MG	A090624 001	Feb 16, 2010
AB		800MG;160MG	A090624 002	Feb 16, 2010
AB	CHARTWELL MOLECULES	400MG;80MG	A078060 002	Jan 25, 2007
AB		800MG;160MG	A078060 001	Jan 25, 2007
AB	GLENMARK GENERICS	400MG;80MG	A090828 002	Dec 22, 2010
AB		800MG;160MG	A090828 001	Dec 22, 2010
AB	SUN PHARM INDUSTRIES	400MG;80MG	A071017 002	Aug 25, 1986
AB		800MG;160MG	A071017 001	Aug 25, 1986
AB	VISTA PHARMS	400MG;80MG	A076817 001	Oct 07, 2005
AB		800MG;160MG	A076817 002	Oct 07, 2005

SULFASALAZINE

TABLET;ORAL

AZULFIDINE

AB	+ !	PHARMACIA AND UPJOHN	500MG	N007073 001
-----------	------------	-------------------------	--------------	--------------------

SULFASALAZINE

AB		NUVO PHARMS INC	500MG	A040349 001	Jan 11, 2002
AB		WATSON LABS	500MG	A085828 001	

TABLET, DELAYED RELEASE;ORAL

AZULFIDINE EN-TABS

AB	+ !	PHARMACIA AND UPJOHN	500MG	N007073 002	Apr 06, 1983
-----------	------------	-------------------------	--------------	--------------------	--------------

SULFASALAZINE

AB		NUVO PHARMS INC	500MG	A075339 001	Jan 11, 2002
-----------	--	-----------------	--------------	--------------------	--------------

SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES

FOR SUSPENSION;INTRAVENOUS

LUMASON

+ !	BRACCO	60.7MG/25MG	N203684 001	Oct 15, 2014
------------	--------	-------------	-------------	--------------

SULINDAC

TABLET;ORAL

SULINDAC

AB		EPIC PHARMA	150MG	A072710 001	Mar 25, 1991
AB			200MG	A072711 001	Mar 25, 1991
AB		MYLAN	150MG	A073039 002	Jun 22, 1993
AB			200MG	A073039 001	Jun 22, 1993
AB		SUN PHARM INDUSTRIES	150MG	A072050 001	Apr 17, 1991
AB			200MG	A072051 001	Apr 17, 1991
AB		WATSON LABS	150MG	A071891 001	Apr 03, 1990
AB	!		200MG	A071795 001	Apr 03, 1990

SUMATRIPTAN

SPRAY;NASAL

IMITREX

AB	+ !	GLAXOSMITHKLINE	5MG/SPRAY	N020626 001	Aug 26, 1997
AB	+ !		20MG/SPRAY	N020626 003	Aug 26, 1997

SUMATRIPTAN

AB		LANNETT CO INC	5MG/SPRAY	A204841 001	Feb 19, 2016
AB			20MG/SPRAY	A204841 002	Feb 19, 2016
AB		PERRIGO UK FINCO	5MG/SPRAY	A213650 001	Sep 21, 2020
AB			20MG/SPRAY	A213465 001	Sep 21, 2020
		TOSYMRA			
+ !		UPSHER SMITH LABS	10MG/SPRAY	N210884 001	Jan 25, 2019

SUMATRIPTAN SUCCINATE

INJECTABLE;SUBCUTANEOUS

IMITREX STATDOSE

AB	+ !	GLAXOSMITHKLINE	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	N020080 002	Feb 01, 2006
AB	+ !		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N020080 003	Dec 23, 1996

SUMATRIPTAN SUCCINATE

AB		ANTARES PHARMA INC	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	A078319 001	Dec 10, 2015
AB			EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A078319 002	Dec 10, 2015
AB		DR REDDYS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090495 001	Jan 29, 2014
AB		SUN PHARM	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090358 001	Jun 21, 2011
		<u>IMITREX</u>			
AP	+ !	GLAXOSMITHKLINE	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N020080 001	Dec 28, 1992

PRESCRIPTION DRUG PRODUCT LIST

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

SUMATRIPTAN SUCCINATE

<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A202758 001</u>	Apr 23, 2013
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A079242 001</u>	Mar 02, 2009
<u>AP</u>	HIKMA	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A200183 001</u>	Sep 16, 2013
<u>AP</u>	MYLAN ASI	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A090314 001</u>	Jun 10, 2010
<u>AP</u>		<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A090641 001</u>	Jul 28, 2010
<u>AP</u>	PAR PHARM	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A077332 001</u>	Oct 09, 2009
<u>AP</u>	WEST-WARD PHARMS INT	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A079123 001</u>	Feb 06, 2009
<u>AP</u>	WOCKHARDT	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A078593 001</u>	Feb 06, 2009
	POWDER; NASAL			
	ONZETRA XSAIL			
	+! CURRAX	EQ 11MG BASE	N206099 001	Jan 27, 2016
	SOLUTION; SUBCUTANEOUS			
	ZEMBRACE SYMTOUCH			
	+ UPSHER SMITH LABS	EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N208223 001	Jan 28, 2016
	TABLET; ORAL			

IMITREX

<u>AB</u>	+ GLAXOSMITHKLINE	<u>EQ 25MG BASE</u>	<u>N020132 002</u>	Jun 01, 1995
<u>AB</u>	+	<u>EQ 50MG BASE</u>	<u>N020132 003</u>	Jun 01, 1995
<u>AB</u>	+!	<u>EQ 100MG BASE</u>	<u>N020132 001</u>	Jun 01, 1995

SUMATRIPTAN SUCCINATE

<u>AB</u>	AUROBINDO PHARMA	<u>EQ 25MG BASE</u>	<u>A078327 001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078327 002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078327 003</u>	Aug 10, 2009
<u>AB</u>	COREPHARMA	<u>EQ 25MG BASE</u>	<u>A200263 001</u>	Jun 19, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A200263 002</u>	Jun 19, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A200263 003</u>	Jun 19, 2012
<u>AB</u>	DR REDDYS LABS INC	<u>EQ 25MG BASE</u>	<u>A076847 001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076847 002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076847 003</u>	Aug 10, 2009
<u>AB</u>	MYLAN	<u>EQ 25MG BASE</u>	<u>A077744 001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077744 002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077744 003</u>	Aug 10, 2009
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 25MG BASE</u>	<u>A078284 001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078284 002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078284 003</u>	Aug 10, 2009
<u>AB</u>	SUN PHARM INDS	<u>EQ 25MG BASE</u>	<u>A078295 001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078295 002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078295 003</u>	Aug 10, 2009
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 25MG BASE</u>	<u>A076554 001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076554 002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076572 001</u>	Feb 09, 2009
<u>AB</u>	WATSON LABS	<u>EQ 25MG BASE</u>	<u>A076933 001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076933 002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076933 003</u>	Aug 10, 2009

SUNITINIB MALATE

CAPSULE; ORAL

SUTENT

	+ CPPI CV	EQ 12.5MG BASE	N021938 001	Jan 26, 2006
	+	EQ 25MG BASE	N021938 002	Jan 26, 2006
	+	EQ 37.5MG BASE	N021938 004	Mar 31, 2009
	+!	EQ 50MG BASE	N021938 003	Jan 26, 2006

SUVOREXANT

TABLET; ORAL

BELSOMRA

	+ MERCK SHARP DOHME	5MG	N204569 001	Aug 13, 2014
	+	10MG	N204569 002	Aug 13, 2014
	+	15MG	N204569 003	Aug 13, 2014
	+!	20MG	N204569 004	Aug 13, 2014

TACROLIMUS

CAPSULE; ORAL

PROGRAF

<u>AB</u>	+ ASTELLAS	<u>EQ 0.5MG BASE</u>	<u>N050708 003</u>	Aug 24, 1998
<u>AB</u>	+	<u>EQ 1MG BASE</u>	<u>N050708 001</u>	Apr 08, 1994
<u>AB</u>	+!	<u>EQ 5MG BASE</u>	<u>N050708 002</u>	Apr 08, 1994

TACROLIMUS

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 0.5MG BASE</u>	<u>A091195 001</u>	Aug 31, 2011
-----------	-----------------	----------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

TACROLIMUS

CAPSULE;ORAL

TACROLIMUS

<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A091195 002</u>	Aug 31, 2011
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A091195 003</u>	Aug 31, 2011
<u>AB</u>	ALKEM LABS LTD	<u>EQ 0.5MG BASE</u>	<u>A203740 001</u>	Nov 12, 2020
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A203740 002</u>	Nov 12, 2020
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A203740 003</u>	Nov 12, 2020
<u>AB</u>	BELCHER	<u>EQ 0.5MG BASE</u>	<u>A206651 001</u>	Nov 30, 2017
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A206651 002</u>	Nov 30, 2017
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A206651 003</u>	Nov 30, 2017
<u>AB</u>	BIOCON PHARMA	<u>EQ 0.5MG BASE</u>	<u>A212297 001</u>	Nov 10, 2020
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A212297 002</u>	Nov 10, 2020
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A212297 003</u>	Nov 10, 2020
<u>AB</u>	CONCORD BIOTECH LTD	<u>EQ 0.5MG BASE</u>	<u>A213112 001</u>	Nov 10, 2020
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A213112 002</u>	Nov 10, 2020
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A213112 003</u>	Nov 10, 2020
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 0.5MG BASE</u>	<u>A090509 001</u>	May 12, 2010
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090509 002</u>	May 12, 2010
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090509 003</u>	May 12, 2010
<u>AB</u>	GLENMARK PHARMS LTD	<u>EQ 0.5MG BASE</u>	<u>A206662 001</u>	Nov 10, 2020
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A206662 002</u>	Nov 10, 2020
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A206662 003</u>	Nov 10, 2020
<u>AB</u>	MYLAN	<u>EQ 0.5MG BASE</u>	<u>A090596 001</u>	Sep 17, 2010
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090596 002</u>	Sep 17, 2010
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090596 003</u>	Sep 17, 2010
<u>AB</u>	PANACEA BIOTEC LTD	<u>EQ 0.5MG BASE</u>	<u>A090802 001</u>	Sep 28, 2012
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090802 002</u>	Sep 28, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090802 003</u>	Sep 28, 2012
<u>AB</u>	SANDOZ	<u>EQ 0.5MG BASE</u>	<u>A065461 001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A065461 002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A065461 003</u>	Aug 10, 2009
<u>AB</u>	STRIDES PHARMA	<u>EQ 0.5MG BASE</u>	<u>A090687 001</u>	Jul 22, 2014
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090687 002</u>	Jul 22, 2014
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090687 003</u>	Jul 22, 2014

CAPSULE, EXTENDED RELEASE;ORAL

ASTAGRAF XL

+	ASTELLAS	EQ 0.5MG BASE	N204096 001	Jul 19, 2013
+		EQ 1MG BASE	N204096 002	Jul 19, 2013
+	!	EQ 5MG BASE	N204096 003	Jul 19, 2013

FOR SUSPENSION;ORAL

PROGRAF

+	ASTELLAS	EQ 0.2MG BASE/PACKET	N210115 001	May 24, 2018
+	!	EQ 1MG BASE/PACKET	N210115 002	May 24, 2018

INJECTABLE;INJECTION

PROGRAF

<u>AP</u>	+	!	ASTELLAS	<u>EQ 5MG BASE/ML</u>	<u>N050709 001</u>	Apr 08, 1994
-----------	---	---	----------	-----------------------	--------------------	--------------

TACROLIMUS

<u>AP</u>			HOSPIRA INC	<u>EQ 5MG BASE/ML</u>	<u>A203900 001</u>	Aug 25, 2017
-----------	--	--	-------------	-----------------------	--------------------	--------------

OINTMENT;TOPICAL

PROTOPIC

<u>AB</u>	+	!	LEO PHARMA AS	<u>0.03%</u>	<u>N050777 001</u>	Dec 08, 2000
<u>AB</u>	+	!		<u>0.1%</u>	<u>N050777 002</u>	Dec 08, 2000

TACROLIMUS

<u>AB</u>			ACCORD HLTHCARE	<u>0.03%</u>	<u>A211688 001</u>	Jan 31, 2019
<u>AB</u>				<u>0.1%</u>	<u>A211688 002</u>	Jan 31, 2019
<u>AB</u>			FOUGERA PHARMS INC	<u>0.03%</u>	<u>A200744 001</u>	Sep 09, 2014
<u>AB</u>				<u>0.1%</u>	<u>A200744 002</u>	Sep 09, 2014
<u>AB</u>			GLENMARK PHARMS LTD	<u>0.1%</u>	<u>A210393 001</u>	Apr 16, 2018

TABLET, EXTENDED RELEASE;ORAL

ENVARUS XR

+	VELOXIS PHARMS INC	EQ 0.75MG BASE	N206406 001	Jul 10, 2015
+		EQ 1MG BASE	N206406 002	Jul 10, 2015
+	!	EQ 4MG BASE	N206406 003	Jul 10, 2015

TADALAFIL

TABLET;ORAL

CIALIS

<u>AB</u>	+		LILLY	<u>2.5MG</u>	<u>N021368 004</u>	Jan 07, 2008
<u>AB</u>	+			<u>5MG</u>	<u>N021368 001</u>	Nov 21, 2003
<u>AB</u>	+			<u>10MG</u>	<u>N021368 002</u>	Nov 21, 2003

PRESCRIPTION DRUG PRODUCT LIST

TADALAFIL

TABLET; ORAL

TADALAFIL

<u>AB</u>	ACCORD HLTHCARE	<u>2.5MG</u>	<u>A209167 001</u>	Mar 26, 2019
<u>AB</u>		<u>5MG</u>	<u>A209167 002</u>	Mar 26, 2019
<u>AB</u>		<u>10MG</u>	<u>A209167 003</u>	Oct 23, 2019
<u>AB</u>	AJANTA PHARMA LTD	<u>2.5MG</u>	<u>A209654 001</u>	Mar 26, 2019
<u>AB</u>		<u>5MG</u>	<u>A209654 002</u>	Mar 26, 2019
<u>AB</u>		<u>10MG</u>	<u>A209654 003</u>	Mar 26, 2019
<u>AB</u>	ALEMBIC PHARMS LTD	<u>2.5MG</u>	<u>A204809 001</u>	Mar 26, 2019
<u>AB</u>		<u>5MG</u>	<u>A204809 002</u>	Mar 26, 2019
<u>AB</u>		<u>10MG</u>	<u>A204809 003</u>	Mar 26, 2019
<u>AB</u>	AMNEAL PHARMS CO	<u>2.5MG</u>	<u>A209744 001</u>	Mar 26, 2019
<u>AB</u>		<u>5MG</u>	<u>A209744 002</u>	Mar 26, 2019
<u>AB</u>		<u>10MG</u>	<u>A209744 003</u>	Mar 26, 2019
<u>AB</u>	AUROBINDO PHARMA LTD	<u>2.5MG</u>	<u>A206285 001</u>	Mar 26, 2019
<u>AB</u>		<u>5MG</u>	<u>A206285 002</u>	Mar 26, 2019
<u>AB</u>		<u>10MG</u>	<u>A206285 003</u>	Mar 26, 2019
<u>AB</u>	CIPLA	<u>2.5MG</u>	<u>A209539 001</u>	Mar 26, 2019
<u>AB</u>		<u>5MG</u>	<u>A209539 002</u>	Mar 26, 2019
<u>AB</u>		<u>10MG</u>	<u>A209539 003</u>	Mar 26, 2019
<u>AB</u>	DR REDDYS LABS LTD	<u>2.5MG</u>	<u>A210069 001</u>	Mar 26, 2019
<u>AB</u>		<u>5MG</u>	<u>A210069 002</u>	Mar 26, 2019
<u>AB</u>		<u>10MG</u>	<u>A210069 003</u>	Mar 26, 2019
<u>AB</u>	GLENMARK PHARMS LTD	<u>2.5MG</u>	<u>A210716 001</u>	Dec 29, 2020
<u>AB</u>		<u>5MG</u>	<u>A210716 002</u>	Dec 29, 2020
<u>AB</u>		<u>10MG</u>	<u>A210716 003</u>	Dec 29, 2020
<u>AB</u>	HETERO LABS LTD III	<u>2.5MG</u>	<u>A209908 001</u>	Mar 26, 2019
<u>AB</u>		<u>5MG</u>	<u>A209908 002</u>	Mar 26, 2019
<u>AB</u>		<u>10MG</u>	<u>A209908 003</u>	Mar 26, 2019
<u>AB</u>	LUPIN LTD	<u>2.5MG</u>	<u>A210567 001</u>	Mar 26, 2019
<u>AB</u>		<u>5MG</u>	<u>A210567 002</u>	Mar 26, 2019
<u>AB</u>		<u>10MG</u>	<u>A210567 003</u>	Mar 26, 2019
<u>AB</u>	MACLEODS PHARMS LTD	<u>2.5MG</u>	<u>A207244 001</u>	Oct 07, 2019
<u>AB</u>		<u>5MG</u>	<u>A207244 002</u>	Oct 07, 2019
<u>AB</u>		<u>10MG</u>	<u>A207244 003</u>	Oct 07, 2019
<u>AB</u>	MYLAN	<u>2.5MG</u>	<u>A206956 001</u>	Apr 29, 2019
<u>AB</u>		<u>5MG</u>	<u>A206957 001</u>	Apr 29, 2019
<u>AB</u>		<u>10MG</u>	<u>A206956 002</u>	Apr 29, 2019
<u>AB</u>	QILU	<u>2.5MG</u>	<u>A210420 001</u>	Mar 26, 2019
<u>AB</u>		<u>5MG</u>	<u>A210420 002</u>	Mar 26, 2019
<u>AB</u>		<u>10MG</u>	<u>A210420 003</u>	Mar 26, 2019
<u>AB</u>	SUN PHARM	<u>2.5MG</u>	<u>A208934 001</u>	Mar 26, 2019
<u>AB</u>		<u>5MG</u>	<u>A208934 002</u>	Mar 26, 2019
<u>AB</u>		<u>10MG</u>	<u>A208934 003</u>	Mar 26, 2019
<u>AB</u>	SUNSHINE	<u>2.5MG</u>	<u>A211335 001</u>	Mar 26, 2019
<u>AB</u>		<u>5MG</u>	<u>A211335 002</u>	Mar 26, 2019
<u>AB</u>		<u>10MG</u>	<u>A211335 003</u>	Mar 26, 2019
<u>AB</u>	TEVA PHARMS USA	<u>2.5MG</u>	<u>A090141 001</u>	May 22, 2018
<u>AB</u>		<u>5MG</u>	<u>A090141 002</u>	May 22, 2018
<u>AB</u>		<u>10MG</u>	<u>A090141 003</u>	May 22, 2018
<u>AB</u>	TORRENT	<u>2.5MG</u>	<u>A211839 001</u>	Mar 26, 2019
<u>AB</u>		<u>5MG</u>	<u>A211839 002</u>	Mar 26, 2019
<u>AB</u>		<u>10MG</u>	<u>A211839 003</u>	Mar 26, 2019
<u>AB</u>	UMEDICA LABS PVT LTD	<u>2.5MG</u>	<u>A211298 001</u>	Oct 23, 2020
<u>AB</u>		<u>5MG</u>	<u>A211298 002</u>	Oct 23, 2020
<u>AB</u>		<u>10MG</u>	<u>A211298 003</u>	Oct 23, 2020
<u>AB</u>	UNICHEM	<u>2.5MG</u>	<u>A209250 001</u>	Mar 26, 2019
<u>AB</u>		<u>5MG</u>	<u>A209250 002</u>	Mar 26, 2019
<u>AB</u>		<u>10MG</u>	<u>A209250 003</u>	Mar 26, 2019
<u>AB</u>	YANGLING BUCHANG	<u>2.5MG</u>	<u>A208824 001</u>	Oct 27, 2020
<u>AB</u>		<u>5MG</u>	<u>A208824 002</u>	Oct 27, 2020
<u>AB</u>		<u>10MG</u>	<u>A208824 003</u>	Oct 27, 2020
<u>AB</u>	ZYDUS PHARMS	<u>2.5MG</u>	<u>A206693 001</u>	Mar 26, 2019
<u>AB</u>		<u>5MG</u>	<u>A206693 002</u>	Mar 26, 2019
<u>AB</u>		<u>10MG</u>	<u>A206693 003</u>	Mar 26, 2019

CIALIS

<u>AB1</u>	+! LILLY	<u>20MG</u>	<u>N021368 003</u>	Nov 21, 2003
------------	----------	-------------	--------------------	--------------

TADALAFIL

<u>AB1</u>	ACCORD HLTHCARE	<u>20MG</u>	<u>A209167 004</u>	Mar 26, 2019
<u>AB1</u>	AJANTA PHARMA LTD	<u>20MG</u>	<u>A209654 004</u>	Mar 26, 2019

PRESCRIPTION DRUG PRODUCT LIST

TADALAFIL

TABLET; ORAL

TADALAFIL

<u>AB1</u>	ALEMBIC PHARMS LTD	<u>20MG</u>	<u>A204809</u>	<u>004</u>	Mar 26, 2019
<u>AB1</u>	AMNEAL PHARMS CO	<u>20MG</u>	<u>A209744</u>	<u>004</u>	Mar 26, 2019
<u>AB1</u>	AUROBINDO PHARMA LTD	<u>20MG</u>	<u>A206285</u>	<u>004</u>	Mar 26, 2019
<u>AB1</u>	CIPLA	<u>20MG</u>	<u>A209539</u>	<u>004</u>	Mar 26, 2019
<u>AB1</u>	DR REDDYS LABS LTD	<u>20MG</u>	<u>A210069</u>	<u>004</u>	Mar 26, 2019
<u>AB1</u>	GLENMARK PHARMS LTD	<u>20MG</u>	<u>A210716</u>	<u>004</u>	Dec 29, 2020
<u>AB1</u>	HETERO LABS LTD III	<u>20MG</u>	<u>A209908</u>	<u>004</u>	Mar 26, 2019
<u>AB1</u>	LUPIN LTD	<u>20MG</u>	<u>A210567</u>	<u>004</u>	Mar 26, 2019
<u>AB1</u>	MACLEODS PHARMS LTD	<u>20MG</u>	<u>A207244</u>	<u>004</u>	Oct 07, 2019
<u>AB1</u>	MYLAN	<u>20MG</u>	<u>A206956</u>	<u>003</u>	Apr 29, 2019
<u>AB1</u>	QILU	<u>20MG</u>	<u>A210420</u>	<u>004</u>	Mar 26, 2019
<u>AB1</u>	SUN PHARM	<u>20MG</u>	<u>A208934</u>	<u>004</u>	Mar 26, 2019
<u>AB1</u>	SUNSHINE	<u>20MG</u>	<u>A211335</u>	<u>004</u>	Mar 26, 2019
<u>AB1</u>	TEVA PHARMS USA	<u>20MG</u>	<u>A090141</u>	<u>004</u>	May 22, 2018
<u>AB1</u>	TORRENT	<u>20MG</u>	<u>A211839</u>	<u>004</u>	Mar 26, 2019
<u>AB1</u>	UMEDICA LABS PVT LTD	<u>20MG</u>	<u>A211298</u>	<u>004</u>	Oct 23, 2020
<u>AB1</u>	UNICHEM	<u>20MG</u>	<u>A209250</u>	<u>004</u>	Mar 26, 2019
<u>AB1</u>	YANGLING BUCHANG	<u>20MG</u>	<u>A208824</u>	<u>004</u>	Oct 27, 2020
<u>AB1</u>	ZYDUS PHARMS	<u>20MG</u>	<u>A206693</u>	<u>004</u>	Mar 26, 2019

ADCIRCA

<u>AB2</u>	<u>+</u> ! ELI LILLY CO	<u>20MG</u>	<u>N022332</u>	<u>001</u>	May 22, 2009
------------	-------------------------	-------------	----------------	------------	--------------

ALYO

<u>AB2</u>	TEVA PHARMS USA	<u>20MG</u>	<u>A209942</u>	<u>001</u>	Feb 05, 2019
------------	-----------------	-------------	----------------	------------	--------------

TADALAFIL

<u>AB2</u>	AJANTA PHARMA LTD	<u>20MG</u>	<u>A210392</u>	<u>001</u>	Feb 05, 2019
<u>AB2</u>	AUROBINDO PHARMA LTD	<u>20MG</u>	<u>A206286</u>	<u>001</u>	Feb 05, 2019
<u>AB2</u>	CIPLA	<u>20MG</u>	<u>A210255</u>	<u>001</u>	Feb 05, 2019
<u>AB2</u>	DR REDDYS LABS LTD	<u>20MG</u>	<u>A210145</u>	<u>001</u>	Feb 05, 2019
<u>AB2</u>	HETERO LABS LTD III	<u>20MG</u>	<u>A209907</u>	<u>001</u>	Feb 05, 2019
<u>AB2</u>	LUPIN LTD	<u>20MG</u>	<u>A210572</u>	<u>001</u>	Feb 05, 2019
<u>AB2</u>	MACLEODS PHARMS LTD	<u>20MG</u>	<u>A207290</u>	<u>001</u>	Oct 16, 2019
<u>AB2</u>	MYLAN	<u>20MG</u>	<u>A200630</u>	<u>001</u>	Aug 03, 2018
<u>AB2</u>	SUNSHINE	<u>20MG</u>	<u>A213496</u>	<u>001</u>	Nov 23, 2020
<u>AB2</u>	TORRENT	<u>20MG</u>	<u>A212062</u>	<u>001</u>	Mar 26, 2019

TAFAMIDIS

CAPSULE; ORAL

VYNDAMAX

<u>+</u> !	FOLDRX PHARMS	61MG	N212161	001	May 03, 2019
------------	---------------	------	---------	-----	--------------

TAFAMIDIS MEGLUMINE

CAPSULE; ORAL

VYNDAQEL

<u>+</u> !	FOLDRX PHARMS	20MG	N211996	001	May 03, 2019
------------	---------------	------	---------	-----	--------------

TAFENOQUINE SUCCINATE

TABLET; ORAL

ARAKODA

<u>+</u> !	60 DEGREES PHARMS	EQ 100MG BASE	N210607	001	Aug 08, 2018
------------	-------------------	---------------	---------	-----	--------------

KRINTAFEL

<u>+</u> !	GLAXOSMITHKLINE	EQ 150MG BASE	N210795	001	Jul 20, 2018
------------	-----------------	---------------	---------	-----	--------------

TAFLUPROST

SOLUTION/DROPS; OPHTHALMIC

TAFLUPROST

<u>AT</u>	MICRO LABS	<u>0.0015%</u>	<u>A209051</u>	<u>001</u>	Aug 19, 2019
-----------	------------	----------------	----------------	------------	--------------

ZIOPTAN

<u>AT</u>	<u>+</u> ! AKORN	<u>0.0015%</u>	<u>N202514</u>	<u>001</u>	Feb 10, 2012
-----------	------------------	----------------	----------------	------------	--------------

TALAZOPARIB TOSYLATE

CAPSULE; ORAL

TALZENNA

<u>+</u>	PFIZER	EQ 0.25MG BASE	N211651	001	Oct 16, 2018
----------	--------	----------------	---------	-----	--------------

<u>+</u> !		EQ 1MG BASE	N211651	002	Oct 16, 2018
------------	--	-------------	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

TALC

AEROSOL; INTRAPLEURAL

SCLEROSOL

+! LYMOL MEDCL 4GM/SPRAY N020587 001 Dec 24, 1997

POWDER; INTRAPLEURAL

STERITALC

+ NOVATECH SA 2GM/VIAL N205555 001 May 01, 2017

+ 3GM/VIAL N205555 002 May 01, 2017

+! 4GM/VIAL N205555 003 May 01, 2017

TALC

+! LYMOL MEDCL 5GM/BOT N021388 001 Dec 15, 2003

TAMOXIFEN CITRATE

SOLUTION; ORAL

SOLTAMOX

+! MAYNE PHARMA INC EQ 20MG BASE/10ML N021807 001 Oct 29, 2005

TABLET; ORAL

TAMOXIFEN CITRATEAB ACTAVIS LABS FL INC EQ 10MG BASE A070929 001 Feb 20, 2003AB EQ 20MG BASE A070929 002 Feb 20, 2003AB APOTEX EQ 10MG BASE A090878 001 Sep 23, 2011AB EQ 20MG BASE A090878 002 Sep 23, 2011AB EUGIA PHARMA EQ 10MG BASE A213358 001 Aug 14, 2020AB EQ 20MG BASE A213358 002 Aug 14, 2020AB MAYNE PHARMA EQ 10MG BASE A075797 001 Feb 20, 2003AB ! EQ 20MG BASE A075797 002 Feb 20, 2003AB MYLAN EQ 10MG BASE A074732 002 Feb 20, 2003AB EQ 20MG BASE A074732 001 Feb 20, 2003AB ZYDUS PHARMS EQ 10MG BASE A206694 001 Oct 27, 2017AB EQ 20MG BASE A206694 002 Oct 27, 2017TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL

FLOMAXAB +! SANOFI AVENTIS US 0.4MG N020579 001 Apr 15, 1997TAMSULOSIN HYDROCHLORIDEAB ALKEM LABS LTD 0.4MG A207405 001 Aug 11, 2017AB ANCHEN PHARMS 0.4MG A202010 001 Jan 04, 2013AB AUROBINDO PHARMA LTD 0.4MG A202433 001 Apr 30, 2013AB IMPAX LABS 0.4MG A090377 001 Mar 02, 2010AB MACLEODS PHARMS LTD 0.4MG A204645 001 Jan 20, 2017AB SANDOZ 0.4MG A078015 001 Apr 27, 2010AB SUN PHARM INDS LTD 0.4MG A090931 001 Jul 15, 2010AB SYNTHON PHARMS 0.4MG A078801 001 Apr 27, 2010AB TEVA PHARMS 0.4MG A077630 001 Apr 27, 2010AB WOCKHARDT 0.4MG A078938 001 Apr 27, 2010AB ZYDUS PHARMS USA 0.4MG A078225 001 Apr 27, 2010

INC

TAPENTADOL HYDROCHLORIDE

TABLET; ORAL

NUCYNTA

+ COLLEGIUM PHARM INC EQ 50MG BASE N022304 001 Nov 20, 2008

+ EQ 75MG BASE N022304 002 Nov 20, 2008

+! EQ 100MG BASE N022304 003 Nov 20, 2008

TABLET, EXTENDED RELEASE; ORAL

NUCYNTA ER

+ COLLEGIUM PHARM INC EQ 50MG BASE N200533 001 Aug 25, 2011

+ EQ 100MG BASE N200533 002 Aug 25, 2011

+ EQ 150MG BASE N200533 003 Aug 25, 2011

+ EQ 200MG BASE N200533 004 Aug 25, 2011

+! EQ 250MG BASE N200533 005 Aug 25, 2011

TASIMELTEON

CAPSULE; ORAL

HETLIOZ

+! VANDA PHARMS INC 20MG N205677 001 Jan 31, 2014

SUSPENSION; ORAL

HETLIOZ LQ

+! VANDA PHARMS INC 4MG/ML N214517 001 Dec 01, 2020

PRESCRIPTION DRUG PRODUCT LIST

TAVABOROLE

SOLUTION; TOPICAL

KERYDIN

AB	+	ANACOR PHARMS INC	5%	N204427	001	Jul 07, 2014
-----------	----------	-------------------	-----------	----------------	------------	--------------

TAVABOROLE

AB		ALEOR	5%	A212188	001	Oct 21, 2020
-----------	--	-------	-----------	----------------	------------	--------------

DERMACEUTICALS

AB		AMNEAL	5%	A212256	001	Nov 25, 2020
-----------	--	--------	-----------	----------------	------------	--------------

AB		ENCUBE	5%	A211297	001	Oct 13, 2020
-----------	--	--------	-----------	----------------	------------	--------------

AB		PERRIGO PHARMA INTL	5%	A211848	001	Oct 13, 2020
-----------	--	---------------------	-----------	----------------	------------	--------------

TAZAROTENE

AEROSOL, FOAM; TOPICAL

FABIOR

+	MAYNE PHARMA	0.1%	N202428	001	May 11, 2012
----------	--------------	------	---------	-----	--------------

CREAM; TOPICAL

AVAGE

AB	+	ALLERGAN	0.1%	N021184	003	Sep 30, 2002
-----------	----------	----------	-------------	----------------	------------	--------------

TAZAROTENE

AB		COSETTE	0.1%	A208662	001	Dec 22, 2017
-----------	--	---------	-------------	----------------	------------	--------------

AB		TARO PHARMS	0.1%	A208258	001	Apr 03, 2017
-----------	--	-------------	-------------	----------------	------------	--------------

TAZORAC

AB	+	ALLERGAN	0.1%	N021184	002	Sep 29, 2000
-----------	----------	----------	-------------	----------------	------------	--------------

+			0.05%	N021184	001	Sep 29, 2000
----------	--	--	-------	---------	-----	--------------

GEL; TOPICAL

TAZORAC

+	ALLERGAN	0.05%	N020600	001	Jun 13, 1997
----------	----------	-------	---------	-----	--------------

+			0.1%	N020600	002	Jun 13, 1997
----------	--	--	------	---------	-----	--------------

LOTION; TOPICAL

ARAZLO

+	BAUSCH	0.045%	N211882	001	Dec 18, 2019
----------	--------	--------	---------	-----	--------------

TAZEMETOSTAT HYDROBROMIDE

TABLET; ORAL

TAZVERIK

+	EPIZYME INC	EQ 200MG BASE	N211723	001	Jan 23, 2020
----------	-------------	---------------	---------	-----	--------------

TECHNETIUM TC-99M BICISATE KIT

INJECTABLE; INJECTION

NEUROLITE

+	LANTHEUS MEDCL	N/A	N020256	001	Nov 23, 1994
----------	----------------	-----	---------	-----	--------------

TECHNETIUM TC-99M EXAMETAZIME KIT

INJECTABLE; INJECTION

CERETEC

+	GE HEALTHCARE	N/A	N019829	001	Dec 30, 1988
----------	---------------	-----	---------	-----	--------------

POWDER; INTRAVENOUS

DRAX EXAMETAZIME

	JUBILANT	N/A	N208870	001	Aug 17, 2017
--	----------	-----	---------	-----	--------------

TECHNETIUM TC-99M MEBROFENIN KIT

INJECTABLE; INJECTION

CHOLETEC

AP	+	BRACCO	N/A	N018963	001	Jan 21, 1987
-----------	----------	--------	------------	----------------	------------	--------------

TECHNETIUM TC-99M MEBROFENIN

AP		SUN PHARM INDS INC	N/A	A078242	001	Jan 29, 2008
-----------	--	--------------------	------------	----------------	------------	--------------

TECHNETIUM TC-99M MEDRONATE

INJECTABLE; INJECTION

DRAXIMAGE MDP-25

+	JUBILANT	N/A	N018035	002	Feb 27, 2004
----------	----------	-----	---------	-----	--------------

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION

CIS-MDP

	SUN PHARM INDS INC	N/A	N018124	001	
--	--------------------	-----	---------	-----	--

TECHNETIUM TC-99M MERTIATIDE KIT

INJECTABLE; INJECTION

TECHNESCAN MAG3

AP	+	CURIUM	N/A	N019882	001	Jun 15, 1990
-----------	----------	--------	------------	----------------	------------	--------------

TECHNETIUM TC99M MERTIATIDE KIT

AP		SOMMER PHARMS II	N/A	A206489	001	Feb 06, 2020
-----------	--	------------------	------------	----------------	------------	--------------

LLC

AP		SUN PHARM INDS INC	N/A	A208994	001	Jul 12, 2019
-----------	--	--------------------	------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

TECHNETIUM TC-99M OXIDRONATE KIT

INJECTABLE; INJECTION

TECHNISCAN

+! CURIUM N/A

N018321 001

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE; INJECTION

DRAXIMAGE DTPA

+! JUBILANT N/A

N018511 001 Dec 29, 1989

TECHNETIUM TC-99M PYROPHOSPHATE KIT

INJECTABLE; INJECTION

CIS-PYRO**AP** SUN PHARM INDS INC **N/A****N019039 001** Jun 30, 1987**TECHNISCAN PYP KIT****AP** CURIUM **N/A****N017538 001**TECHNETIUM TC-99M RED BLOOD CELL KIT

INJECTABLE; INJECTION

ULTRATAG

+! CURIUM N/A

N019981 001 Jun 10, 1991

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION

CARDIOLITE**AP** +! LANTHEUS MEDCL **N/A****N019785 001** Dec 21, 1990**TECHNETIUM TC 99M SESTAMIBI****AP** CARDINAL HEALTH 414 **N/A****A078809 001** Apr 28, 2009**AP** CURIUM **N/A****A078098 001** Sep 22, 2008**AP** JUBILANT DRAXIMAGE **N/A****A078806 001** Apr 29, 2009**AP** SUN PHARM INDS INC **10-30mCi****A079157 001** Jul 10, 2009TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INTRAVENOUS

TECHNELITE

+! LANTHEUS MEDCL 1-20 CI/GENERATOR

N017771 002 Feb 12, 2014

ULTRA-TECHNEKOW FM

+! CURIUM 1-19 CI/GENERATOR

N017243 003 Feb 18, 2014

SOLUTION; INTRAVENOUS, INTRAVESICULAR, OPHTHALMIC

RADIOGENIX SYSTEM

+ NORTHSTAR MEDICAL 30-1153mCi/GENERATOR

N202158 001 Feb 08, 2018

TECHNETIUM TC-99M SULFUR COLLOID KIT

SOLUTION; INJECTION, ORAL

AN-SULFUR COLLOID

+! SUN PHARM INDS INC N/A

N017858 001

TECHNETIUM TC-99M TETROFOSMIN KIT

INJECTABLE; INJECTION

MYOVIEW 30ML

+! GE HEALTHCARE N/A

N020372 002 Jul 07, 2005

TECHNETIUM TC-99M TILMANOCEPT

INJECTABLE; INJECTION

LYMPHOSEEK KIT

+! CARDINAL HEALTH 414 N/A

N202207 001 Mar 13, 2013

TECOVIRIMAT

CAPSULE; ORAL

TPOXX

+! SIGA TECHNOLOGIES 200MG

N208627 001 Jul 13, 2018

TEDIZOLID PHOSPHATE

POWDER; INTRAVENOUS

SIVEXTRO

+! CUBIST PHARMS LLC 200MG/VIAL

N205436 001 Jun 20, 2014

TABLET; ORAL

SIVEXTRO

+! CUBIST PHARMS LLC 200MG

N205435 001 Jun 20, 2014

TEDUGLUTIDE RECOMBINANT

POWDER; SUBCUTANEOUS

GATTEX KIT

+! NPS PHARMS INC 5MG/VIAL

N203441 001 Dec 21, 2012

PRESCRIPTION DRUG PRODUCT LIST

TEGASEROD MALEATE

TABLET; ORAL

ZELNORM

+! ALFASIGMA

EQ 6MG BASE

N021200 002 Jul 24, 2002

TELAVANCIN HYDROCHLORIDE

POWDER; INTRAVENOUS

VIBATIV

+! CUMBERLAND PHARMS

EQ 750MG BASE/VIAL

N022110 002 Sep 11, 2009

TELMISARTAN

TABLET; ORAL

MICARDIS**AB** + BOEHRINGER
INGELHEIM**20MG****N020850 003** Apr 04, 2000**AB** +
AB +!**40MG****N020850 001** Nov 10, 1998**80MG****N020850 002** Nov 10, 1998**TELMISARTAN****AB** ALEMBIC PHARMS LTD**20MG****A202130 001** Jul 07, 2014**AB** **40MG****A202130 002** Jul 07, 2014**AB** **80MG****A202130 003** Jul 07, 2014**AB** AMNEAL PHARMS**20MG****A204415 001** Sep 08, 2015**AB** **40MG****A204415 002** Sep 08, 2015**AB** **80MG****A204415 003** Sep 08, 2015**AB** AUROBINDO PHARMA
LTD**20MG****A206511 001** Sep 03, 2015**AB** **40MG****A206511 002** Sep 03, 2015**AB** **80MG****A206511 003** Sep 03, 2015**AB** CADILA PHARMS LTD**20MG****A208605 001** Jul 25, 2017**AB** **40MG****A208605 002** Jul 25, 2017**AB** **80MG****A208605 003** Jul 25, 2017**AB** GLENMARK PHARMS LTD**20MG****A090032 001** Jul 07, 2014**AB** **40MG****A090032 002** Jul 07, 2014**AB** **80MG****A090032 003** Jul 07, 2014**AB** HETERO LABS LTD V**20MG****A205901 001** Apr 22, 2016**AB** **40MG****A205901 002** Apr 22, 2016**AB** **80MG****A205901 003** Apr 22, 2016**AB** INVENTIA**20MG****A205150 001** Oct 30, 2015**AB** **40MG****A205150 002** Oct 30, 2015**AB** **80MG****A205150 003** Oct 30, 2015**AB** MICRO LABS**20MG****A207016 001** Oct 03, 2017**AB** **40MG****A207016 002** Oct 03, 2017**AB** **80MG****A207016 003** Oct 03, 2017**AB** MYLAN**20MG****A202397 001** Jul 07, 2014**AB** **40MG****A202397 002** Jul 07, 2014**AB** **80MG****A202397 003** Jul 07, 2014**AB** PRINSTON INC**20MG****A207882 001** May 03, 2017**AB** **40MG****A207882 002** May 03, 2017**AB** **80MG****A207882 003** May 03, 2017**AB** SANDOZ INC**20MG****A203867 001** Nov 03, 2014**AB** **40MG****A203867 002** Nov 03, 2014**AB** **80MG****A203867 003** Nov 03, 2014**AB** TORRENT**20MG****A203171 001** Jul 07, 2014**AB** **40MG****A203171 002** Jul 07, 2014**AB** **80MG****A203171 003** Jul 07, 2014**AB** ZYDUS PHARMS**20MG****A203325 001** Aug 26, 2014**AB** **40MG****A203325 002** Aug 26, 2014**AB** **80MG****A203325 003** Aug 26, 2014TELOTRISTAT ETIPRATE

TABLET; ORAL

KERMELO

+! TERSERA

EQ 250MG BASE

N208794 001 Feb 28, 2017

TEMAZEPAM

CAPSULE; ORAL

RESTORIL**AB** + SPECGX LLC**7.5MG****N018163 003** Oct 25, 1991**AB** +**15MG****N018163 001****AB** +**22.5MG****N018163 004** Nov 02, 2004**AB** +!**30MG****N018163 002****TEMAZEPAM****AB** ACTAVIS ELIZABETH**15MG****A071620 002** Aug 07, 1987**AB** **30MG****A071620 001** Aug 07, 1987**AB** ALEMBIC PHARMS LTD**7.5MG****A211542 001** Nov 23, 2018

PRESCRIPTION DRUG PRODUCT LIST

TEMAZEPAM

CAPSULE; ORAL

TEMAZEPAM

<u>AB</u>		<u>15MG</u>	<u>A211542 002</u>	Nov 23, 2018
<u>AB</u>		<u>22.5MG</u>	<u>A211542 003</u>	Nov 23, 2018
<u>AB</u>		<u>30MG</u>	<u>A211542 004</u>	Nov 23, 2018
<u>AB</u>	AMNEAL PHARMS	<u>7.5MG</u>	<u>A203482 001</u>	May 23, 2016
<u>AB</u>		<u>15MG</u>	<u>A203482 002</u>	May 23, 2016
<u>AB</u>		<u>22.5MG</u>	<u>A203482 003</u>	May 23, 2016
<u>AB</u>		<u>30MG</u>	<u>A203482 004</u>	May 23, 2016
<u>AB</u>	MYLAN	<u>7.5MG</u>	<u>A070920 002</u>	May 21, 2010
<u>AB</u>		<u>15MG</u>	<u>A070920 004</u>	Jul 07, 1986
<u>AB</u>		<u>22.5MG</u>	<u>A070920 003</u>	Jun 12, 2009
<u>AB</u>		<u>30MG</u>	<u>A070920 001</u>	Jul 10, 1986
<u>AB</u>	NOVEL LABS INC	<u>7.5MG</u>	<u>A071457 002</u>	Jun 22, 2012
<u>AB</u>		<u>15MG</u>	<u>A071456 001</u>	Apr 21, 1987
<u>AB</u>		<u>22.5MG</u>	<u>A071457 003</u>	Jun 22, 2012
<u>AB</u>		<u>30MG</u>	<u>A071457 001</u>	Apr 21, 1987
<u>AB</u>	PRINSTON INC	<u>7.5MG</u>	<u>A201781 001</u>	Jun 04, 2015
<u>AB</u>		<u>15MG</u>	<u>A201781 002</u>	Jun 04, 2015
<u>AB</u>		<u>22.5MG</u>	<u>A201781 003</u>	Jun 04, 2015
<u>AB</u>		<u>30MG</u>	<u>A201781 004</u>	Jun 04, 2015
<u>AB</u>	SANDOZ	<u>15MG</u>	<u>A071427 001</u>	Jan 12, 1988
<u>AB</u>		<u>30MG</u>	<u>A071428 001</u>	Jan 12, 1988
<u>AB</u>	SUN PHARM INDUSTRIES	<u>7.5MG</u>	<u>A078581 001</u>	Sep 08, 2009
<u>AB</u>		<u>22.5MG</u>	<u>A071175 002</u>	Sep 14, 2009

TEMOZOLOMIDE

CAPSULE; ORAL

TEMODAR

<u>AB</u>	+	MERCK SHARP DOHME	<u>5MG</u>	<u>N021029 001</u>	Aug 11, 1999
<u>AB</u>	+		<u>20MG</u>	<u>N021029 002</u>	Aug 11, 1999
<u>AB</u>	+		<u>100MG</u>	<u>N021029 003</u>	Aug 11, 1999
<u>AB</u>	+		<u>140MG</u>	<u>N021029 005</u>	Oct 19, 2006
<u>AB</u>	+		<u>180MG</u>	<u>N021029 006</u>	Oct 19, 2006
<u>AB</u>	+		<u>250MG</u>	<u>N021029 004</u>	Aug 11, 1999

TEMOZOLOMIDE

<u>AB</u>		ACCORD HLTHCARE	<u>5MG</u>	<u>A201528 001</u>	Feb 27, 2017
<u>AB</u>			<u>20MG</u>	<u>A201528 002</u>	Feb 27, 2017
<u>AB</u>			<u>100MG</u>	<u>A201528 003</u>	Feb 27, 2017
<u>AB</u>			<u>140MG</u>	<u>A201528 004</u>	Feb 27, 2017
<u>AB</u>			<u>180MG</u>	<u>A201528 005</u>	Feb 27, 2017
<u>AB</u>			<u>250MG</u>	<u>A201528 006</u>	Feb 27, 2017
<u>AB</u>		AMNEAL PHARMS	<u>5MG</u>	<u>A203691 001</u>	May 08, 2015
<u>AB</u>			<u>20MG</u>	<u>A203691 002</u>	May 08, 2015
<u>AB</u>			<u>100MG</u>	<u>A203691 003</u>	May 08, 2015
<u>AB</u>			<u>140MG</u>	<u>A203691 004</u>	May 08, 2015
<u>AB</u>			<u>180MG</u>	<u>A203691 005</u>	May 08, 2015
<u>AB</u>			<u>250MG</u>	<u>A203691 006</u>	May 08, 2015
<u>AB</u>		ANI PHARMS INC	<u>5MG</u>	<u>A203490 001</u>	Jul 13, 2016
<u>AB</u>			<u>20MG</u>	<u>A203490 002</u>	Jul 13, 2016
<u>AB</u>			<u>100MG</u>	<u>A203490 003</u>	Jul 13, 2016
<u>AB</u>			<u>140MG</u>	<u>A203490 004</u>	Jul 13, 2016
<u>AB</u>			<u>180MG</u>	<u>A203490 005</u>	Jul 13, 2016
<u>AB</u>			<u>250MG</u>	<u>A203490 006</u>	Jul 13, 2016
<u>AB</u>		CHARTWELL	<u>5MG</u>	<u>A206413 001</u>	Apr 12, 2016
<u>AB</u>			<u>20MG</u>	<u>A206413 002</u>	Apr 12, 2016
<u>AB</u>			<u>100MG</u>	<u>A206413 003</u>	Apr 12, 2016
<u>AB</u>			<u>140MG</u>	<u>A206413 004</u>	Apr 12, 2016
<u>AB</u>			<u>180MG</u>	<u>A206413 005</u>	Apr 12, 2016
<u>AB</u>			<u>250MG</u>	<u>A206413 006</u>	Apr 12, 2016
<u>AB</u>		CHEMI SPA	<u>5MG</u>	<u>A204639 001</u>	Nov 23, 2016
<u>AB</u>			<u>20MG</u>	<u>A204639 002</u>	Nov 23, 2016
<u>AB</u>			<u>100MG</u>	<u>A204639 003</u>	Nov 23, 2016
<u>AB</u>			<u>140MG</u>	<u>A204639 004</u>	Nov 23, 2016
<u>AB</u>			<u>180MG</u>	<u>A204639 005</u>	Nov 23, 2016
<u>AB</u>			<u>250MG</u>	<u>A204639 006</u>	Nov 23, 2016
<u>AB</u>		DEVA HOLDING AS	<u>5MG</u>	<u>A207658 001</u>	Apr 26, 2017
<u>AB</u>			<u>20MG</u>	<u>A207658 002</u>	Apr 26, 2017
<u>AB</u>			<u>100MG</u>	<u>A207658 003</u>	Apr 26, 2017
<u>AB</u>			<u>140MG</u>	<u>A207658 004</u>	Apr 26, 2017
<u>AB</u>			<u>180MG</u>	<u>A207658 005</u>	Apr 26, 2017

PRESCRIPTION DRUG PRODUCT LIST

TEMOZOLOMIDE

CAPSULE; ORAL

TEMOZOLOMIDE

<u>AB</u>		<u>250MG</u>	<u>A207658</u>	<u>006</u>	Apr 26, 2017
<u>AB</u>	RISING	<u>5MG</u>	<u>A206309</u>	<u>001</u>	Apr 27, 2016
<u>AB</u>		<u>20MG</u>	<u>A206309</u>	<u>002</u>	Apr 27, 2016
<u>AB</u>		<u>100MG</u>	<u>A206309</u>	<u>003</u>	Apr 27, 2016
<u>AB</u>		<u>140MG</u>	<u>A206309</u>	<u>004</u>	Apr 27, 2016
<u>AB</u>		<u>180MG</u>	<u>A206309</u>	<u>005</u>	Apr 27, 2016
<u>AB</u>		<u>250MG</u>	<u>A206309</u>	<u>006</u>	Apr 27, 2016
<u>AB</u>	SUN PHARM	<u>5MG</u>	<u>A201742</u>	<u>001</u>	Feb 12, 2014
<u>AB</u>		<u>20MG</u>	<u>A201742</u>	<u>002</u>	Feb 12, 2014
<u>AB</u>		<u>100MG</u>	<u>A201742</u>	<u>003</u>	Feb 12, 2014
<u>AB</u>		<u>140MG</u>	<u>A201742</u>	<u>004</u>	Feb 12, 2014
<u>AB</u>		<u>180MG</u>	<u>A201742</u>	<u>005</u>	Feb 12, 2014
<u>AB</u>		<u>250MG</u>	<u>A201742</u>	<u>006</u>	Feb 12, 2014
<u>AB</u>	WATSON LABS TEVA	<u>5MG</u>	<u>A203959</u>	<u>001</u>	Apr 18, 2017
<u>AB</u>		<u>20MG</u>	<u>A203959</u>	<u>002</u>	Apr 18, 2017
<u>AB</u>		<u>100MG</u>	<u>A203959</u>	<u>003</u>	Apr 18, 2017
<u>AB</u>		<u>140MG</u>	<u>A203959</u>	<u>004</u>	Apr 18, 2017
<u>AB</u>		<u>250MG</u>	<u>A203959</u>	<u>005</u>	Apr 18, 2017
<u>AB</u>	ZYDUS PHARMS	<u>5MG</u>	<u>A206750</u>	<u>001</u>	Jul 31, 2017
<u>AB</u>		<u>20MG</u>	<u>A206750</u>	<u>002</u>	Jul 31, 2017
<u>AB</u>		<u>100MG</u>	<u>A206750</u>	<u>003</u>	Jul 31, 2017
<u>AB</u>		<u>140MG</u>	<u>A206750</u>	<u>004</u>	Jul 31, 2017
<u>AB</u>		<u>180MG</u>	<u>A206750</u>	<u>005</u>	Jul 31, 2017
<u>AB</u>		<u>250MG</u>	<u>A206750</u>	<u>006</u>	Jul 31, 2017

POWDER; INTRAVENOUS

TEMODAR

+! MERCK SHARP DOHME 100MG/VIAL N022277 001 Feb 27, 2009

TEMSIROLIMUS

SOLUTION; INTRAVENOUS

TEMSIROLIMUS

<u>AP</u>	ACCORD HLTHCARE	<u>25MG/ML (25MG/ML)</u>	<u>A203153</u>	<u>001</u>	Jul 30, 2018
<u>AP</u>	GLAND PHARMA LTD	<u>25MG/ML (25MG/ML)</u>	<u>A207383</u>	<u>001</u>	Aug 16, 2019
<u>AP</u>	+! PF PRISM CV	<u>25MG/ML (25MG/ML)</u>	<u>N022088</u>	<u>001</u>	May 30, 2007

TENOFOVIR ALAFENAMIDE FUMARATE

TABLET; ORAL

VEMLIDY

+! GILEAD SCIENCES INC EQ 25MG BASE N208464 001 Nov 10, 2016

TENOFOVIR DISOPROXIL FUMARATE

POWDER; ORAL

VIREAD

+! GILEAD SCIENCES INC 40MG/SCOOPFUL N022577 001 Jan 18, 2012

TABLET; ORAL

TENOFOVIR DISOPROXIL FUMARATE

<u>AB</u>	AUROBINDO PHARMA LTD	<u>150MG</u>	<u>A090647</u>	<u>001</u>	Jan 26, 2018
<u>AB</u>		<u>200MG</u>	<u>A090647</u>	<u>002</u>	Jan 26, 2018
<u>AB</u>		<u>250MG</u>	<u>A090647</u>	<u>003</u>	Jan 26, 2018
<u>AB</u>		<u>300MG</u>	<u>A090647</u>	<u>004</u>	Jan 26, 2018
<u>AB</u>	CASI PHARMS INC	<u>300MG</u>	<u>A209550</u>	<u>001</u>	Feb 26, 2018
<u>AB</u>	CIPLA	<u>300MG</u>	<u>A078800</u>	<u>001</u>	Jan 26, 2018
<u>AB</u>	HETERO LABS LTD III	<u>300MG</u>	<u>A090636</u>	<u>001</u>	Jan 26, 2018
<u>AB</u>	MACLEODS PHARMS LTD	<u>300MG</u>	<u>A203232</u>	<u>001</u>	Jan 26, 2018
<u>AB</u>	QILU	<u>200MG</u>	<u>A209498</u>	<u>001</u>	Mar 02, 2018
<u>AB</u>		<u>250MG</u>	<u>A209498</u>	<u>002</u>	Mar 02, 2018
<u>AB</u>		<u>300MG</u>	<u>A209498</u>	<u>003</u>	Mar 02, 2018
<u>AB</u>	STRIDES PHARMA	<u>300MG</u>	<u>A090742</u>	<u>001</u>	Jan 26, 2018
<u>AB</u>	TEVA PHARMS USA	<u>150MG</u>	<u>A091612</u>	<u>002</u>	Jan 26, 2018
<u>AB</u>		<u>200MG</u>	<u>A091612</u>	<u>003</u>	Jan 26, 2018
<u>AB</u>		<u>250MG</u>	<u>A091612</u>	<u>004</u>	Jan 26, 2018
<u>AB</u>		<u>300MG</u>	<u>A091612</u>	<u>001</u>	Mar 18, 2015
	<u>VIREAD</u>				
<u>AB</u>	+ GILEAD SCIENCES INC	<u>150MG</u>	<u>N021356</u>	<u>002</u>	Jan 18, 2012
<u>AB</u>	+	<u>200MG</u>	<u>N021356</u>	<u>003</u>	Jan 18, 2012
<u>AB</u>	+	<u>250MG</u>	<u>N021356</u>	<u>004</u>	Jan 18, 2012
<u>AB</u>	+!	<u>300MG</u>	<u>N021356</u>	<u>001</u>	Oct 26, 2001

PRESCRIPTION DRUG PRODUCT LIST

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

AB		APNAR PHARMA LP	<u>EQ 1MG BASE</u>	<u>A074823 001</u>	Mar 30, 1998
AB			<u>EQ 2MG BASE</u>	<u>A074823 002</u>	Mar 30, 1998
AB			<u>EQ 5MG BASE</u>	<u>A074823 003</u>	Mar 30, 1998
AB			<u>EQ 10MG BASE</u>	<u>A074823 004</u>	Mar 30, 1998
AB	!	JUBILANT CADISTA	<u>EQ 1MG BASE</u>	<u>A075317 001</u>	Dec 20, 2004
AB			<u>EQ 2MG BASE</u>	<u>A075317 002</u>	Dec 20, 2004
AB			<u>EQ 5MG BASE</u>	<u>A075317 003</u>	Dec 20, 2004
AB			<u>EQ 10MG BASE</u>	<u>A075317 004</u>	Dec 20, 2004
AB		MYLAN	<u>EQ 1MG BASE</u>	<u>A075140 002</u>	Feb 11, 2000
AB			<u>EQ 2MG BASE</u>	<u>A075140 003</u>	Feb 11, 2000
AB			<u>EQ 5MG BASE</u>	<u>A075140 001</u>	Feb 11, 2000
AB			<u>EQ 10MG BASE</u>	<u>A075140 004</u>	Feb 11, 2000

TERBINAFFINE HYDROCHLORIDE

TABLET; ORAL

LAMISIL

AB	+	NOVARTIS	<u>EQ 250MG BASE</u>	<u>N020539 001</u>	May 10, 1996
-----------	---	----------	----------------------	--------------------	--------------

TERBINAFFINE HYDROCHLORIDE

AB		AUROBINDO PHARMA	<u>EQ 250MG BASE</u>	<u>A078297 001</u>	Jul 02, 2007
AB		BRECKENRIDGE PHARM	<u>EQ 250MG BASE</u>	<u>A077714 001</u>	Jun 04, 2010
AB		CIPLA	<u>EQ 250MG BASE</u>	<u>A077137 001</u>	Jul 02, 2007
AB		DR REDDYS LABS INC	<u>EQ 250MG BASE</u>	<u>A076390 001</u>	Jul 02, 2007
AB		GLENMARK GENERICS	<u>EQ 250MG BASE</u>	<u>A078157 001</u>	Jul 02, 2007
AB		HARRIS PHARM	<u>EQ 250MG BASE</u>	<u>A077919 001</u>	Jul 02, 2007
AB		HERITAGE PHARMA	<u>EQ 250MG BASE</u>	<u>A076377 001</u>	Jul 02, 2007
AB		INVAGEN PHARMS	<u>EQ 250MG BASE</u>	<u>A077533 001</u>	Jul 02, 2007
AB		ORCHID HLTHCARE	<u>EQ 250MG BASE</u>	<u>A078163 001</u>	Jul 02, 2007

TERBUTALINE SULFATE

INJECTABLE; INJECTION

TERBUTALINE SULFATE

AP		AKORN	<u>1MG/ML</u>	<u>A078151 001</u>	Jan 07, 2008
AP	!	ATHENEX INC	<u>1MG/ML</u>	<u>A076770 001</u>	Apr 23, 2004
AP		FRESENIUS KABI USA	<u>1MG/ML</u>	<u>A076887 001</u>	May 26, 2004
AP		HIKMA FARMACEUTICA	<u>1MG/ML</u>	<u>A078630 001</u>	May 20, 2009
AP		UNITED BIOMEDCL	<u>1MG/ML</u>	<u>A200122 001</u>	Nov 08, 2013

TABLET; ORAL

BRETHINE

AB	+	ANI PHARMS INC	<u>2.5MG</u>	<u>N017849 001</u>	
AB	+		<u>5MG</u>	<u>N017849 002</u>	

TERBUTALINE SULFATE

AB		IMPAX LABS	<u>2.5MG</u>	<u>A075877 001</u>	Jun 26, 2001
AB			<u>5MG</u>	<u>A075877 002</u>	Jun 26, 2001
AB		LANNETT CO INC	<u>2.5MG</u>	<u>A077152 001</u>	Mar 25, 2005
AB	!		<u>5MG</u>	<u>A077152 002</u>	Mar 25, 2005
AB		TWI PHARMS	<u>2.5MG</u>	<u>A211832 001</u>	Jun 19, 2020
AB			<u>5MG</u>	<u>A211832 002</u>	Jun 19, 2020

TERCONAZOLE

CREAM; VAGINAL

TERCONAZOLE

AB		FOUGERA PHARMS	<u>0.4%</u>	<u>A076712 001</u>	Feb 18, 2005
AB	!	TARO	<u>0.4%</u>	<u>A076043 001</u>	Jan 19, 2005
EX	+	FOUGERA PHARMS INC	0.8%	N021735 001	Oct 01, 2004
EX	!	TARO	0.8%	A075953 001	Apr 06, 2004

SUPPOSITORY; VAGINAL

TERCONAZOLE

AB	!	PERRIGO ISRAEL	<u>80MG</u>	<u>A077149 001</u>	Mar 17, 2006
AB		TARO	<u>80MG</u>	<u>A077553 001</u>	Mar 09, 2007

TERIFLUNOMIDE

TABLET; ORAL

AUBAGIO

AB	+	SANOFI AVENTIS US	<u>7MG</u>	<u>N202992 001</u>	Sep 12, 2012
AB	+		<u>14MG</u>	<u>N202992 002</u>	Sep 12, 2012

TERIFLUNOMIDE

AB		ACCORD HLTHCARE	<u>7MG</u>	<u>A209690 001</u>	Jan 07, 2019
AB			<u>14MG</u>	<u>A209690 002</u>	Jan 07, 2019
AB		ALEMBIC PHARMS LTD	<u>7MG</u>	<u>A209572 001</u>	Apr 19, 2019
AB			<u>14MG</u>	<u>A209572 002</u>	Apr 19, 2019
AB		GLENMARK PHARMS	<u>7MG</u>	<u>A209663 001</u>	Nov 15, 2018

PRESCRIPTION DRUG PRODUCT LIST

TERIFLUNOMIDE

TABLET; ORAL

TERIFLUNOMIDE

<u>AB</u>		<u>14MG</u>	<u>A209663 002</u>	Nov 15, 2018
<u>AB</u>	IMPAX	<u>14MG</u>	<u>A209677 001</u>	Jun 17, 2020
<u>AB</u>	SANDOZ INC	<u>7MG</u>	<u>A209710 001</u>	Jan 03, 2019
<u>AB</u>		<u>14MG</u>	<u>A209710 002</u>	Jan 03, 2019

TERIPARATIDE

SOLUTION; SUBCUTANEOUS

BONSITY

	ALVOGEN	0.62MG/2.48ML (0.25MG/ML)	N211939 001	Oct 04, 2019
	FORTEO			
+	LILLY	0.6MG/2.4ML (0.25MG/ML)	N021318 002	Jun 25, 2008

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL

ANDRODERM

+	ALLERGAN	2MG/24HR	N020489 003	Oct 20, 2011
+		4MG/24HR	N020489 004	Oct 20, 2011

GEL; TRANSDERMAL

ANDROGEL

<u>AB1</u>	+	ABBVIE	<u>25MG/2.5GM PACKET</u>	<u>N021015 001</u>	Feb 28, 2000
<u>AB1</u>	+	!	<u>50MG/5GM PACKET</u>	<u>N021015 002</u>	Feb 28, 2000

TESTOSTERONE

<u>AB1</u>		ACTAVIS LABS UT INC	<u>25MG/2.5GM PACKET</u>	<u>A076737 001</u>	Jan 27, 2006
<u>AB1</u>			<u>50MG/5GM PACKET</u>	<u>A076737 002</u>	Jan 27, 2006
<u>AB1</u>		PAR PHARM	<u>25MG/2.5GM PACKET</u>	<u>A076744 001</u>	May 23, 2007
<u>AB1</u>			<u>50MG/5GM PACKET</u>	<u>A076744 002</u>	May 23, 2007

ANDROGEL

<u>AB2</u>	+	ABBVIE	<u>1.62% (20.25MG/1.25GM PACKET)</u>	<u>N022309 002</u>	Sep 07, 2012
<u>AB2</u>	+	!	<u>1.62% (40.5MG/2.5GM PACKET)</u>	<u>N022309 003</u>	Sep 07, 2012

TESTIM

<u>AB2</u>	+	AUXILIUM PHARMS LLC	<u>50MG/5GM PACKET</u>	<u>N021454 001</u>	Oct 31, 2002
------------	---	---------------------	------------------------	--------------------	--------------

TESTOSTERONE

<u>AB2</u>		ACTAVIS LABS UT INC	<u>50MG/5GM PACKET</u>	<u>A091073 001</u>	Sep 18, 2017
<u>AB2</u>		PERRIGO UK FINCO	<u>1.62% (20.25MG/1.25GM PACKET)</u>	<u>A205781 001</u>	Jul 12, 2017
<u>AB2</u>			<u>1.62% (40.5MG/2.5GM PACKET)</u>	<u>A205781 002</u>	Jul 12, 2017

VOGELXO

<u>AB2</u>		UPSHER SMITH LABS	<u>50MG/5GM PACKET</u>	<u>N204399 002</u>	Jun 04, 2014
		GEL, METERED; NASAL			
		NATESTO			
		ACERUS	5.5MG/0.122GM ACTUATION	N205488 001	May 28, 2014

GEL, METERED; TRANSDERMAL

ANDROGEL

<u>AB</u>	+	ABBVIE	<u>1.62% (20.25MG/1.25GM ACTUATION)</u>	<u>N022309 001</u>	Apr 29, 2011
-----------	---	--------	---	--------------------	--------------

FORTESTA

<u>AB</u>	+	ENDO PHARMS	<u>10MG/0.5GM ACTUATION</u>	<u>N021463 001</u>	Dec 29, 2010
-----------	---	-------------	-----------------------------	--------------------	--------------

TESTOSTERONE

<u>AB</u>		ACTAVIS LABS UT INC	<u>1.62% (20.25MG/1.25GM ACTUATION)</u>	<u>A204570 001</u>	Apr 10, 2019
<u>AB</u>			<u>10MG/0.5GM ACTUATION</u>	<u>A204571 001</u>	Aug 05, 2015
<u>AB</u>		AMNEAL	<u>1.62% (20.25MG/1.25GM ACTUATION)</u>	<u>A207373 001</u>	Apr 10, 2019
<u>AB</u>		DR REDDYS	<u>1.62% (20.25MG/1.25GM ACTUATION)</u>	<u>A208620 001</u>	Apr 10, 2019
<u>AB</u>		LUPIN	<u>1.62% (20.25MG/1.25GM ACTUATION)</u>	<u>A208560 001</u>	Apr 10, 2019
<u>AB</u>		PERRIGO ISRAEL	<u>1.62% (20.25MG/1.25GM ACTUATION)</u>	<u>A204268 001</u>	Aug 04, 2015
<u>AB</u>		TWI PHARMS	<u>1.62% (20.25MG/1.25GM ACTUATION)</u>	<u>A209390 001</u>	Sep 23, 2019
<u>AB</u>		XIROMED	<u>1.62% (20.25MG/1.25GM ACTUATION)</u>	<u>A210835 001</u>	Apr 16, 2020
BX	!	ACTAVIS LABS UT INC	12.5MG/1.25GM ACTUATION	A076737 003	Mar 09, 2015

VOGELXO

BX		UPSHER SMITH LABS	12.5MG/1.25GM ACTUATION	N204399 003	Jun 04, 2014
----	--	-------------------	-------------------------	-------------	--------------

PELLET; IMPLANTATION

TESTOPEL

!	AUXILIUM PHARMS INC	75MG	A080911 001		
---	---------------------	------	-------------	--	--

SOLUTION, METERED; TRANSDERMAL

TESTOSTERONE

<u>AT</u>		ACTAVIS LABS UT INC	<u>30MG/1.5ML ACTUATION</u>	<u>A205328 001</u>	Aug 07, 2017
<u>AT</u>		APOTEX	<u>30MG/1.5ML ACTUATION</u>	<u>A209181 001</u>	Nov 25, 2020
<u>AT</u>		CIPLA	<u>30MG/1.5ML ACTUATION</u>	<u>A209533 001</u>	Jan 29, 2018
<u>AT</u>		LUPIN LTD	<u>30MG/1.5ML ACTUATION</u>	<u>A208061 001</u>	Oct 23, 2017
<u>AT</u>	!	PERRIGO ISRAEL	<u>30MG/1.5ML ACTUATION</u>	<u>A204255 001</u>	Feb 28, 2017

PRESCRIPTION DRUG PRODUCT LIST

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION

DEPO-TESTOSTERONE

<u>AO</u>	!	PHARMACIA AND UPJOHN	<u>100MG/ML</u>	<u>A085635</u>	<u>002</u>	
<u>AO</u>	!		<u>200MG/ML</u>	<u>A085635</u>	<u>003</u>	
<u>TESTOSTERONE CYPIONATE</u>						
<u>AO</u>		AM REGENT	<u>200MG/ML</u>	<u>A207742</u>	<u>001</u>	Jun 16, 2017
<u>AO</u>		CIPLA	<u>100MG/ML</u>	<u>A210362</u>	<u>001</u>	Jun 19, 2018
<u>AO</u>			<u>200MG/ML</u>	<u>A210362</u>	<u>002</u>	Jun 19, 2018
<u>AO</u>		HIKMA FARMACEUTICA	<u>200MG/ML</u>	<u>A091244</u>	<u>001</u>	May 01, 2012
<u>AO</u>		PADDOCK LLC	<u>200MG/ML</u>	<u>A040530</u>	<u>001</u>	Jan 31, 2005
<u>AO</u>		SANDOZ INC	<u>100MG/ML</u>	<u>A040615</u>	<u>001</u>	Aug 10, 2006
<u>AO</u>			<u>200MG/ML</u>	<u>A040615</u>	<u>002</u>	Aug 10, 2006
<u>AO</u>		SUN PHARM INDS LTD	<u>100MG/ML</u>	<u>A201720</u>	<u>001</u>	Jun 03, 2013
<u>AO</u>			<u>200MG/ML</u>	<u>A201720</u>	<u>002</u>	Jun 03, 2013
<u>AO</u>		WATSON PHARMS INC	<u>200MG/ML</u>	<u>A086030</u>	<u>001</u>	
<u>AO</u>		WEST-WARD PHARMS INT	<u>100MG/ML</u>	<u>A090387</u>	<u>001</u>	Jul 15, 2010
<u>AO</u>			<u>200MG/ML</u>	<u>A090387</u>	<u>002</u>	Jul 15, 2010
<u>AO</u>		WILSHIRE PHARMS INC	<u>200MG/ML</u>	<u>A206368</u>	<u>001</u>	Apr 24, 2019

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

TESTOSTERONE ENANTHATE

<u>AO</u>		HIKMA FARMACEUTICA	<u>200MG/ML</u>	<u>A091120</u>	<u>001</u>	Sep 18, 2012
<u>AO</u>		NEXUS PHARMS	<u>200MG/ML</u>	<u>A040575</u>	<u>001</u>	Jun 14, 2006
<u>AO</u>	!	WATSON PHARMS INC	<u>200MG/ML</u>	<u>A085598</u>	<u>001</u>	
SOLUTION; SUBCUTANEOUS						
XYOSTED (AUTOINJECTOR)						
	+	ANTARES PHARMA INC	50MG/0.5ML (50MG/0.5ML)	N209863	001	Sep 28, 2018
	+		75MG/0.5ML (75MG/0.5ML)	N209863	002	Sep 28, 2018
	+		100MG/0.5ML (100MG/0.5ML)	N209863	003	Sep 28, 2018

TESTOSTERONE UNDECANOATE

CAPSULE; ORAL

JATENZO

	+	CLARUS	158MG	N206089	001	Mar 27, 2019
	+		198MG	N206089	002	Mar 27, 2019
	+		237MG	N206089	003	Mar 27, 2019

INJECTABLE; INTRAMUSCULAR

AVEED

	+	ENDO PHARMS INC	750MG/3ML (250MG/ML)	N022219	001	Mar 05, 2014
--	---	-----------------	----------------------	---------	-----	--------------

TETRABENAZINE

TABLET; ORAL

TETRABENAZINE

<u>AB</u>		ACTAVIS LABS FL INC	<u>25MG</u>	<u>A206686</u>	<u>001</u>	Jul 07, 2017
<u>AB</u>		AJANTA PHARMA LTD	<u>12.5MG</u>	<u>A213621</u>	<u>001</u>	Dec 04, 2020
<u>AB</u>			<u>25MG</u>	<u>A213621</u>	<u>002</u>	Dec 04, 2020
<u>AB</u>		APOTEX	<u>12.5MG</u>	<u>A206093</u>	<u>001</u>	Mar 17, 2020
<u>AB</u>			<u>25MG</u>	<u>A206093</u>	<u>002</u>	Mar 17, 2020
<u>AB</u>		BIONPHARMA INC	<u>12.5MG</u>	<u>A208826</u>	<u>001</u>	Dec 18, 2017
<u>AB</u>			<u>25MG</u>	<u>A208826</u>	<u>002</u>	Dec 18, 2017
<u>AB</u>		DR REDDYS	<u>12.5MG</u>	<u>A209284</u>	<u>001</u>	Jan 08, 2018
<u>AB</u>			<u>25MG</u>	<u>A209284</u>	<u>002</u>	Jan 08, 2018
<u>AB</u>		HETERO LABS LTD V	<u>12.5MG</u>	<u>A204574</u>	<u>001</u>	Feb 03, 2016
<u>AB</u>			<u>25MG</u>	<u>A204574</u>	<u>002</u>	Feb 03, 2016
<u>AB</u>		HIKMA	<u>12.5MG</u>	<u>A209739</u>	<u>001</u>	Apr 08, 2019
<u>AB</u>			<u>25MG</u>	<u>A209739</u>	<u>002</u>	Apr 08, 2019
<u>AB</u>		LUPIN LTD	<u>12.5MG</u>	<u>A210544</u>	<u>001</u>	Apr 20, 2018
<u>AB</u>			<u>25MG</u>	<u>A210544</u>	<u>002</u>	Apr 20, 2018
<u>AB</u>		MYLAN	<u>12.5MG</u>	<u>A207682</u>	<u>001</u>	Jan 31, 2017
<u>AB</u>			<u>25MG</u>	<u>A207682</u>	<u>002</u>	Jan 31, 2017
<u>AB</u>		PIRAMAL HLTHCARE UK	<u>12.5MG</u>	<u>A213316</u>	<u>001</u>	Jan 22, 2020
<u>AB</u>			<u>25MG</u>	<u>A213316</u>	<u>002</u>	Jan 22, 2020
<u>AB</u>		SUN PHARM	<u>12.5MG</u>	<u>A206129</u>	<u>001</u>	Aug 17, 2015
<u>AB</u>			<u>25MG</u>	<u>A206129</u>	<u>002</u>	Aug 17, 2015
<u>XENAZINE</u>						
<u>AB</u>	+	BAUSCH	<u>12.5MG</u>	<u>N021894</u>	<u>001</u>	Aug 15, 2008
<u>AB</u>	+		<u>25MG</u>	<u>N021894</u>	<u>002</u>	Aug 15, 2008

PRESCRIPTION DRUG PRODUCT LIST

TETRACAINE HYDROCHLORIDE

SOLUTION;OPHTHALMIC

TETRACAINE HYDROCHLORIDE

+	ALCON LABS	0.5%
+	BAUSCH	0.5%

N208135	001	Feb 29, 2016
N210821	001	Mar 12, 2019

TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

ACHROMYCIN V

AB	+	AVET	250MG
AB	+	!	500MG

N050278	003
N050278	001

TETRACYCLINE HYDROCHLORIDE

AB		AMNEAL PHARMS NY	250MG	A210674	001	Sep 18, 2018
AB			500MG	A210674	002	Sep 18, 2018
AB		BRECKENRIDGE	250MG	A210662	001	Nov 07, 2018
AB			500MG	A210662	002	Nov 07, 2018
AB		CHARTWELL TETRA	250MG	A062752	001	Aug 12, 1988
AB			500MG	A062752	002	Aug 12, 1988
AB		STRIDES PHARMA	250MG	A212635	001	Mar 03, 2020
AB			500MG	A212635	002	Mar 03, 2020
AB		WATSON LABS	250MG	A061837	001	
AB			500MG	A061837	002	

TETRAHYDROZOLINE HYDROCHLORIDE

SOLUTION;NASAL

TYZINE

!	FOUGERA PHARMS	0.05%
		0.1%

A086576	002
A086576	001

SPRAY;NASAL

TYZINE

!	FOUGERA PHARMS	0.1%
---	----------------	------

A086576	003
---------	-----

THALIDOMIDE

CAPSULE;ORAL

THALOMID

+	CELGENE	50MG
+		100MG
+		150MG
+	!	200MG

N020785	001	Jul 16, 1998
N020785	002	Jan 17, 2003
N020785	004	Jan 10, 2007
N020785	003	Jan 17, 2003

THALLOUS CHLORIDE TL-201

INJECTABLE;INJECTION

THALLOUS CHLORIDE TL 201

AP	+	CURIUM	1mCi/ML
AP	+	GE HEALTHCARE	1mCi/ML
AP	+	LANTHEUS MEDCL	1mCi/ML

N018150	001	
N018110	002	Feb 27, 1996
N017806	001	

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE;ORAL

THEO-24

	ACTIENT PHARMS	100MG
!	AUXILIUM PHARMS INC	400MG
	AUXILIUM PHARMS LLC	200MG
		300MG

A087942	001	Aug 22, 1983
A081034	001	Feb 28, 1992
A087943	001	Aug 22, 1983
A087944	001	Aug 22, 1983

INJECTABLE;INJECTION

THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER

+	B BRAUN	40MG/100ML
---	---------	------------

N019826	001	Aug 14, 1992
---------	-----	--------------

THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER

+	B BRAUN	80MG/100ML
---	---------	------------

N019826	002	Aug 14, 1992
---------	-----	--------------

THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER

+	B BRAUN	160MG/100ML
---	---------	-------------

N019826	003	Aug 14, 1992
---------	-----	--------------

THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER

+	B BRAUN	320MG/100ML
---	---------	-------------

N019826	006	Aug 14, 1992
---------	-----	--------------

SOLUTION;ORAL

THEOPHYLLINE

AA	!	LANNETT CO INC	80MG/15ML
AA		TRIS PHARMA INC	80MG/15ML

A091156	001	Apr 13, 2011
A091586	001	Jun 15, 2012

SOLUTION, ELIXIR;ORAL

ELIXOPHYLLIN

AA	!	NOSTRUM LABS INC	80MG/15ML
-----------	---	------------------	------------------

A085186	001
----------------	------------

THEOPHYLLINE

AA		PHARM ASSOC	80MG/15ML
-----------	--	-------------	------------------

A206344	001	Dec 16, 2016
----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

THEOPHYLLINE

TABLET, EXTENDED RELEASE;ORAL

THEOCHRON

<u>AB</u>	NOSTRUM PHARMS LLC	<u>100MG</u>	<u>A087400</u>	<u>003</u>	Feb 21, 1985
<u>AB</u>		<u>200MG</u>	<u>A087400</u>	<u>004</u>	Feb 21, 1985

THEOPHYLLINE

<u>AB</u>	GLENMARK GENERICS	<u>400MG</u>	<u>A090355</u>	<u>001</u>	Jul 13, 2010
<u>AB</u>		<u>600MG</u>	<u>A090355</u>	<u>002</u>	Jul 13, 2010
<u>AB</u>	! HERITAGE PHARMA	<u>100MG</u>	<u>A089807</u>	<u>001</u>	Apr 30, 1990
<u>AB</u>	! HERITAGE PHARMA	<u>200MG</u>	<u>A089808</u>	<u>001</u>	Apr 30, 1990
<u>AB</u>	NOSTRUM LABS INC	<u>400MG</u>	<u>A040560</u>	<u>003</u>	Apr 21, 2006
<u>AB</u>	! NOSTRUM LABS INC	<u>600MG</u>	<u>A040560</u>	<u>002</u>	Apr 21, 2006
<u>AB</u>	RHODES PHARMS	<u>400MG</u>	<u>A040086</u>	<u>002</u>	Sep 01, 1982
<u>AB</u>		<u>600MG</u>	<u>A040086</u>	<u>001</u>	Apr 15, 1996
	ALEMBIC PHARMS LTD	300MG	A090430	001	Oct 27, 2010
	! ALEMBIC PHARMS LTD	450MG	A090430	002	Oct 27, 2010

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

THIAMINE HYDROCHLORIDE

<u>AP</u>	! FRESENIUS KABI USA	<u>100MG/ML</u>	<u>A080556</u>	<u>001</u>	
<u>AP</u>	MYLAN INSTITUTIONAL	<u>100MG/ML</u>	<u>A091623</u>	<u>001</u>	Jun 25, 2012
<u>AP</u>	SAGENT PHARMS INC	<u>100MG/ML</u>	<u>A206106</u>	<u>001</u>	Dec 01, 2017

THIOGUANINE

TABLET; ORAL

THIOGUANINE

+	! ASPEN GLOBAL INC	40MG	N012429	001	
---	--------------------	------	---------	-----	--

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HYDROCHLORIDE

<u>AB</u>	MYLAN	<u>10MG</u>	<u>A088004</u>	<u>002</u>	Mar 15, 1983
<u>AB</u>		<u>25MG</u>	<u>A088004</u>	<u>003</u>	Mar 15, 1983
<u>AB</u>		<u>50MG</u>	<u>A088004</u>	<u>004</u>	Mar 15, 1983
<u>AB</u>	! SUN PHARM	<u>100MG</u>	<u>A088004</u>	<u>001</u>	Nov 18, 1983
<u>AB</u>	INDUSTRIES	<u>10MG</u>	<u>A089953</u>	<u>004</u>	Aug 01, 1986
<u>AB</u>		<u>25MG</u>	<u>A089953</u>	<u>003</u>	Aug 01, 1986
<u>AB</u>		<u>50MG</u>	<u>A089953</u>	<u>002</u>	Aug 01, 1986
<u>AB</u>		<u>100MG</u>	<u>A089953</u>	<u>001</u>	Oct 07, 1988

THIOTEPA

INJECTABLE; INJECTION

THIOTEPA

<u>AP</u>	DR REDDYS	<u>15MG/VIAL</u>	<u>A210337</u>	<u>001</u>	May 04, 2018
<u>AP</u>	JIANGSU HENGRUI MED	<u>15MG/VIAL</u>	<u>A209150</u>	<u>001</u>	May 04, 2018
<u>AP</u>	STI PHARMA LLC	<u>15MG/VIAL</u>	<u>A208242</u>	<u>001</u>	Jan 10, 2020
<u>AP</u>	! WEST-WARD PHARMS	<u>15MG/VIAL</u>	<u>A075547</u>	<u>001</u>	Apr 02, 2001
	INT				

POWDER; INTRACAVITARY, INTRAVENOUS, INTRAVESICAL

TEPADINA

<u>AP</u>	! ADIENNE SA	<u>15MG/VIAL</u>	<u>N208264</u>	<u>001</u>	Jan 26, 2017
<u>AP</u>	! ADIENNE SA	<u>100MG/VIAL</u>	<u>N208264</u>	<u>002</u>	Jan 26, 2017

THIOTEPA

<u>AP</u>	MSN	<u>15MG/VIAL</u>	<u>A213049</u>	<u>001</u>	Mar 04, 2020
<u>AP</u>		<u>100MG/VIAL</u>	<u>A213049</u>	<u>002</u>	Mar 04, 2020

THIOTHIXENE

CAPSULE; ORAL

THIOTHIXENE

<u>AB</u>	MYLAN	<u>1MG</u>	<u>A071093</u>	<u>002</u>	Jun 23, 1987
<u>AB</u>		<u>2MG</u>	<u>A071093</u>	<u>003</u>	Jun 23, 1987
<u>AB</u>		<u>5MG</u>	<u>A071093</u>	<u>004</u>	Jun 23, 1987
<u>AB</u>		<u>10MG</u>	<u>A071093</u>	<u>001</u>	Jun 23, 1987
<u>AB</u>	NOVITIUM PHARMA	<u>1MG</u>	<u>A211642</u>	<u>001</u>	Apr 05, 2019
<u>AB</u>		<u>2MG</u>	<u>A211642</u>	<u>002</u>	Apr 05, 2019
<u>AB</u>	! NOVITIUM PHARMA	<u>5MG</u>	<u>A211642</u>	<u>003</u>	Apr 05, 2019
<u>AB</u>		<u>10MG</u>	<u>A211642</u>	<u>004</u>	Apr 05, 2019

PRESCRIPTION DRUG PRODUCT LIST

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

GABITRIL

<u>AB</u>	+	CEPHALON	<u>2MG</u>	<u>N020646</u>	<u>005</u>	Apr 16, 1999
<u>AB</u>	+	!	<u>4MG</u>	<u>N020646</u>	<u>001</u>	Sep 30, 1997
<u>AB</u>	+		<u>12MG</u>	<u>N020646</u>	<u>002</u>	Sep 30, 1997
<u>AB</u>	+		<u>16MG</u>	<u>N020646</u>	<u>003</u>	Sep 30, 1997

TIAGABINE HYDROCHLORIDE

<u>AB</u>		AMNEAL PHARMS CO	<u>2MG</u>	<u>A208181</u>	<u>001</u>	Dec 08, 2017
<u>AB</u>			<u>4MG</u>	<u>A208181</u>	<u>002</u>	Dec 08, 2017
<u>AB</u>			<u>12MG</u>	<u>A208181</u>	<u>003</u>	Dec 08, 2017
<u>AB</u>			<u>16MG</u>	<u>A208181</u>	<u>004</u>	Dec 08, 2017
<u>AB</u>		SUN PHARM INDS	<u>2MG</u>	<u>A077555</u>	<u>001</u>	Nov 04, 2011
<u>AB</u>			<u>4MG</u>	<u>A077555</u>	<u>002</u>	Nov 04, 2011
<u>AB</u>		WILSHIRE PHARMS INC	<u>2MG</u>	<u>A206857</u>	<u>001</u>	Oct 13, 2017
<u>AB</u>			<u>4MG</u>	<u>A206857</u>	<u>002</u>	Oct 13, 2017
<u>AB</u>			<u>12MG</u>	<u>A206857</u>	<u>003</u>	Oct 13, 2017
<u>AB</u>			<u>16MG</u>	<u>A206857</u>	<u>004</u>	Oct 13, 2017

TICAGRELOR

TABLET; ORAL

BRILINTA

<u>AB</u>	+	!	ASTRAZENECA PHARMS	<u>90MG</u>	<u>N022433</u>	<u>001</u>	Jul 20, 2011
-----------	---	---	--------------------	-------------	----------------	------------	--------------

TICAGRELOR

<u>AB</u>		HISUN PHARM HANGZHOU	<u>90MG</u>	<u>A208575</u>	<u>001</u>	Jan 23, 2019
<u>AB</u>		SIGMAPHARM LABS LLC	<u>90MG</u>	<u>A208596</u>	<u>001</u>	Apr 07, 2020
		BRILINTA + ASTRAZENECA PHARMS	60MG	N022433	002	Sep 03, 2015

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLOPIDINE HYDROCHLORIDE

<u>AB</u>		APOTEX	<u>250MG</u>	<u>A075089</u>	<u>001</u>	Jul 01, 1999
<u>AB</u>	!	TEVA	<u>250MG</u>	<u>A075149</u>	<u>001</u>	Aug 20, 1999

TIGECYCLINE

POWDER; INTRAVENOUS

TIGECYCLINE

<u>AP</u>		AMNEAL	<u>50MG/VIAL</u>	<u>N211158</u>	<u>001</u>	Aug 02, 2018	
<u>AP</u>		APOTEX	<u>50MG/VIAL</u>	<u>A204439</u>	<u>001</u>	Dec 21, 2018	
<u>AP</u>		AUROBINDO PHARMA LTD	<u>50MG/VIAL</u>	<u>A206335</u>	<u>001</u>	Jun 11, 2019	
<u>AP</u>	+	!	FRESENIUS KABI USA	<u>50MG/VIAL</u>	<u>N205645</u>	<u>001</u>	Dec 01, 2016
<u>AP</u>		SANDOZ INC	<u>50MG/VIAL</u>	<u>A091620</u>	<u>001</u>	May 27, 2015	
<u>AP</u>		XELLIA PHARMS APS	<u>50MG/VIAL</u>	<u>A205722</u>	<u>001</u>	Oct 18, 2019	

TYGACIL

<u>AP</u>	+	!	PF PRISM CV	<u>50MG/VIAL</u>	<u>N021821</u>	<u>001</u>	Jun 15, 2005
			TIGECYCLINE ACCORD HLTHCARE INC	50MG/VIAL	N208744	001	Jan 18, 2018

TIMOLOL

SOLUTION/DROPS; OPHTHALMIC

BETIMOL

<u>AT</u>	+	!	AKORN	<u>EQ 0.25% BASE</u>	<u>N020439</u>	<u>001</u>	Mar 31, 1995
<u>AT</u>	+	!		<u>EQ 0.5% BASE</u>	<u>N020439</u>	<u>002</u>	Mar 31, 1995

TIMOLOL

<u>AT</u>		AKORN	<u>EQ 0.25% BASE</u>	<u>A205309</u>	<u>001</u>	Sep 30, 2016
<u>AT</u>			<u>EQ 0.5% BASE</u>	<u>A205309</u>	<u>002</u>	Sep 30, 2016

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC

TIMOLOL MALEATE

<u>AB</u>		ALEMBIC PHARMS LTD	<u>EQ 0.25% BASE</u>	<u>A212942</u>	<u>001</u>	Oct 22, 2020	
<u>AB</u>			<u>EQ 0.5% BASE</u>	<u>A212942</u>	<u>002</u>	Oct 22, 2020	
<u>AB</u>	+	!	SANDOZ INC	<u>EQ 0.25% BASE</u>	<u>N020963</u>	<u>001</u>	Oct 21, 1998
<u>AB</u>	+	!		<u>EQ 0.5% BASE</u>	<u>N020963</u>	<u>002</u>	Oct 21, 1998

TIMOPTIC-XE

<u>AB</u>	+	!	VALEANT PHARMS LLC	<u>EQ 0.25% BASE</u>	<u>N020330</u>	<u>001</u>	Nov 04, 1993
<u>AB</u>	+	!		<u>EQ 0.5% BASE</u>	<u>N020330</u>	<u>002</u>	Nov 04, 1993

SOLUTION/DROPS; OPHTHALMIC

TIMOLOL MALEATE

<u>AT</u>		BAUSCH AND LOMB	<u>EQ 0.25% BASE</u>	<u>A074778</u>	<u>001</u>	Mar 25, 1997
<u>AT</u>		FDC LTD	<u>EQ 0.25% BASE</u>	<u>A077259</u>	<u>001</u>	Apr 30, 2008
<u>AT</u>		PACIFIC PHARMA	<u>EQ 0.25% BASE</u>	<u>A074746</u>	<u>001</u>	Mar 25, 1997

PRESCRIPTION DRUG PRODUCT LIST

TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

TIMOLOL MALEATE

AT	!	SANDOZ INC	EQ 0.25% BASE	A074261 001	Apr 28, 1995
AT		WOCKHARDT	EQ 0.25% BASE	A078771 001	Sep 28, 2009

TIMOPTIC

AT	+	VALEANT PHARMS INTL	EQ 0.25% BASE	N018086 001	
-----------	----------	---------------------	----------------------	--------------------	--

TIMOLOL MALEATE

AT1		AKORN	EQ 0.5% BASE	A074466 001	Mar 25, 1997
AT1			EQ 0.5% BASE	A074516 001	Mar 25, 1997
AT1			EQ 0.5% BASE	A075163 001	Sep 10, 2002
AT1		BAUSCH AND LOMB	EQ 0.5% BASE	A074776 001	Mar 25, 1997
AT1		FDC LTD	EQ 0.5% BASE	A077259 002	Apr 30, 2008
AT1		PACIFIC PHARMA	EQ 0.5% BASE	A074747 001	Mar 25, 1997
AT1	!	SANDOZ INC	EQ 0.5% BASE	A074262 001	Apr 28, 1995
AT1		WOCKHARDT	EQ 0.5% BASE	A078771 002	Sep 28, 2009

TIMOPTIC

AT1	+	VALEANT PHARMS INTL	EQ 0.5% BASE	N018086 002	
------------	----------	---------------------	---------------------	--------------------	--

ISTALOL

AT2	+	BAUSCH AND LOMB	EQ 0.5% BASE	N021516 001	Jun 04, 2004
------------	----------	-----------------	---------------------	--------------------	--------------

TIMOLOL MALEATE

AT2		APOTEX	EQ 0.5% BASE	A204936 001	Apr 17, 2015
AT3		AKORN INC	EQ 0.5% BASE	A212291 001	Sep 11, 2020

TIMOPTIC IN OCUDOSE

AT3	+	VALEANT PHARMS INTL	EQ 0.5% BASE	N019463 002	Nov 05, 1986
	+		EQ 0.25% BASE	N019463 001	Nov 05, 1986

TABLET;ORAL

TIMOLOL MALEATE

AB		ELYSIUM	5MG	A207556 001	May 02, 2019
AB			10MG	A207556 002	May 02, 2019
AB			20MG	A207556 003	May 02, 2019
AB		MYLAN	5MG	A072668 002	Jun 08, 1990
AB			10MG	A072668 003	Jun 08, 1990
AB	!		20MG	A072668 001	Jun 08, 1990

TINIDAZOLE

TABLET;ORAL

TINDAMAX

AB	+	MISSION PHARMA	250MG	N021618 001	May 17, 2004
AB	+		500MG	N021618 002	May 17, 2004

TINIDAZOLE

AB		EDENBRIDGE PHARMS	250MG	A203808 001	Aug 04, 2015
AB			500MG	A203808 002	Aug 04, 2015
AB		HIKMA	250MG	A201172 001	Apr 30, 2012
AB			500MG	A201172 002	Apr 30, 2012
AB		NOVEL LABS INC	250MG	A202044 001	Apr 30, 2012
AB			500MG	A202044 002	Apr 30, 2012
AB		UNIQUE PHARM LABS	250MG	A202489 001	Oct 09, 2013
AB			500MG	A202489 002	Oct 09, 2013

TIOPRONIN

TABLET;ORAL

THIOLA

+	!	MISSION PHARMA	100MG	N019569 001	Aug 11, 1988
----------	----------	----------------	--------------	--------------------	--------------

TABLET, DELAYED RELEASE;ORAL

THIOLA EC

+		MISSION PHARMACAL	100MG	N211843 001	Jun 28, 2019
----------	--	-------------------	--------------	--------------------	--------------

CO

+	!		300MG	N211843 002	Jun 28, 2019
----------	----------	--	--------------	--------------------	--------------

TIOTROPIUM BROMIDE

POWDER; INHALATION

SPIRIVA

+	!	BOEHRINGER	EQ 0.018MG BASE/INH	N021395 001	Jan 30, 2004
----------	----------	------------	----------------------------	--------------------	--------------

INGELHEIM

SPRAY, METERED; INHALATION

SPIRIVA RESPIMAT

+		BOEHRINGER	EQ 0.00125MG BASE/INH	N021936 002	Sep 15, 2015
----------	--	------------	------------------------------	--------------------	--------------

INGELHEIM

+	!		EQ 0.0025MG BASE/INH	N021936 001	Sep 24, 2014
----------	----------	--	-----------------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE

TABLET; ORAL

LONSURF

+	TAIHO ONCOLOGY	EQ 6.14MG BASE;15MG	N207981	001	Sep 22, 2015
+	!	EQ 8.19MG BASE;20MG	N207981	002	Sep 22, 2015

TIPRANAVIR

CAPSULE; ORAL

APTIVUS

+	BOEHRINGER INGELHEIM	250MG	N021814	001	Jun 22, 2005
---	-------------------------	-------	---------	-----	--------------

SOLUTION; ORAL

APTIVUS

+	BOEHRINGER INGELHEIM	100MG/ML	N022292	001	Jun 23, 2008
---	-------------------------	----------	---------	-----	--------------

TIRBANIBULIN

OINTMENT; TOPICAL

KLISYRI

+	ALMIRALL	1%	N213189	001	Dec 14, 2020
---	----------	----	---------	-----	--------------

TIROFIBAN HYDROCHLORIDE

INJECTABLE; INJECTION

AGGRASTAT

+	MEDICURE	EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)	N020913	002	May 17, 2002
+	!	EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML)	N020913	003	Apr 20, 2000

SOLUTION; INJECTION

AGGRASTAT

+	MEDICURE	EQ 3.75MG BASE/15ML (EQ 0.25MG BASE/ML)	N020912	002	Aug 31, 2016
---	----------	---	---------	-----	--------------

TIZANIDINE HYDROCHLORIDE

CAPSULE; ORAL

TIZANIDINE HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	EQ 2MG BASE	A213223	001	Jan 13, 2020
AB		EQ 4MG BASE	A213223	002	Jan 13, 2020
AB		EQ 6MG BASE	A213223	003	Jan 13, 2020
AB	ALKEM LABS LTD	EQ 2MG BASE	A212196	001	Mar 27, 2019
AB		EQ 4MG BASE	A212196	002	Mar 27, 2019
AB		EQ 6MG BASE	A212196	003	Mar 27, 2019
AB	APOTEX INC	EQ 2MG BASE	A078868	001	Feb 03, 2012
AB		EQ 4MG BASE	A078868	002	Feb 03, 2012
AB		EQ 6MG BASE	A078868	003	Feb 03, 2012
AB	AUROBINDO PHARMA LTD	EQ 2MG BASE	A213544	001	Mar 24, 2020
AB		EQ 4MG BASE	A213544	002	Mar 24, 2020
AB		EQ 6MG BASE	A213544	003	Mar 24, 2020
AB	CADILA PHARMS LTD	EQ 2MG BASE	A210021	001	Mar 26, 2019
AB		EQ 4MG BASE	A210021	002	Mar 26, 2019
AB		EQ 6MG BASE	A210021	003	Mar 26, 2019
AB	JUBILANT GENERICS	EQ 2MG BASE	A209605	001	Aug 04, 2017
AB		EQ 4MG BASE	A209605	002	Aug 04, 2017
AB		EQ 6MG BASE	A209605	003	Aug 04, 2017
AB	NOVAST LABS	EQ 2MG BASE	A210267	001	Mar 12, 2019
AB		EQ 4MG BASE	A210267	002	Mar 12, 2019
AB		EQ 6MG BASE	A210267	003	Mar 12, 2019
AB	PAR PHARM INC	EQ 2MG BASE	A207199	001	Mar 14, 2017
AB		EQ 4MG BASE	A207199	002	Mar 14, 2017
AB		EQ 6MG BASE	A207199	003	Mar 14, 2017
AB	RUBICON	EQ 2MG BASE	A213798	001	May 27, 2020
AB		EQ 4MG BASE	A213798	002	May 27, 2020
AB		EQ 6MG BASE	A213798	003	May 27, 2020
AB	ZYDUS PHARMS	EQ 2MG BASE	A208622	001	Mar 03, 2017
AB		EQ 4MG BASE	A208622	002	Mar 03, 2017
AB		EQ 6MG BASE	A208622	003	Mar 03, 2017
<u>ZANAFLEX</u>					
AB	+	COVIS	EQ 2MG BASE	N021447	001 Aug 29, 2002
AB	+		EQ 4MG BASE	N021447	002 Aug 29, 2002
AB	+	!	EQ 6MG BASE	N021447	003 Aug 29, 2002

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

AB	ALKEM LABS LTD	EQ 2MG BASE	A211798	001	Jan 25, 2019
AB		EQ 4MG BASE	A211798	002	Jan 25, 2019
AB	APOTEX	EQ 2MG BASE	A076533	001	Jan 16, 2004
AB		EQ 4MG BASE	A076533	002	Jan 16, 2004

PRESCRIPTION DRUG PRODUCT LIST

TIZANIDINE HYDROCHLORIDE

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

<u>AB</u>	CASI PHARMS INC	<u>EQ 2MG BASE</u>	<u>A076280 001</u>	Nov 26, 2002
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076280 002</u>	Jun 27, 2002
<u>AB</u>	DR REDDYS LABS INC	<u>EQ 2MG BASE</u>	<u>A076286 001</u>	Jul 03, 2002
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076286 002</u>	Jul 03, 2002
<u>AB</u>	EPIC PHARMA LLC	<u>EQ 2MG BASE</u>	<u>A076347 001</u>	Oct 11, 2002
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076347 002</u>	Oct 11, 2002
<u>AB</u>	MYLAN	<u>EQ 2MG BASE</u>	<u>A076354 001</u>	Mar 28, 2003
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076354 002</u>	Mar 28, 2003
<u>AB</u>	OXFORD PHARMS	<u>EQ 2MG BASE</u>	<u>A076281 001</u>	Oct 20, 2003
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076281 002</u>	Oct 20, 2003
<u>AB</u>	SUN PHARM INDS INC	<u>EQ 2MG BASE</u>	<u>A076416 001</u>	Sep 29, 2003
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076416 002</u>	Sep 29, 2003
<u>AB</u>	UNICHEM LABS LTD	<u>EQ 2MG BASE</u>	<u>A091283 001</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A091283 002</u>	Nov 28, 2012
<u>AB</u>	ZYDUS PHARMS	<u>EQ 2MG BASE</u>	<u>A208187 001</u>	Mar 09, 2018
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A208187 002</u>	Mar 09, 2018

ZANAFLEX

<u>AB</u>	+! COVIS	<u>EQ 4MG BASE</u>	<u>N020397 001</u>	Nov 27, 1996
-----------	----------	--------------------	--------------------	--------------

TOBRAMYCIN

OINTMENT; OPHTHALMIC

TOBREX

+! NOVARTIS

0.3%

N050555 001

POWDER; INHALATION

TOBI PODHALER

+! MYLAN SPECIALITY LP

28MG

N201688 001 Mar 22, 2013

SOLUTION; INHALATION

BETHKIS

<u>AN</u>	+! CHIESI	<u>300MG/4ML</u>	<u>N201820 001</u>	Oct 12, 2012
-----------	-----------	------------------	--------------------	--------------

KITABIS PAK

<u>AN</u>	PULMOFLOW INC	<u>300MG/5ML</u>	<u>N205433 001</u>	Dec 02, 2014
-----------	---------------	------------------	--------------------	--------------

TOBI

<u>AN</u>	+! MYLAN SPECIALITY LP	<u>300MG/5ML</u>	<u>N050753 001</u>	Dec 22, 1997
-----------	------------------------	------------------	--------------------	--------------

TOBRAMYCIN

<u>AN</u>	AKORN INC	<u>300MG/5ML</u>	<u>A201422 001</u>	May 28, 2014
<u>AN</u>	AMNEAL PHARMS	<u>300MG/5ML</u>	<u>A205501 001</u>	Jul 13, 2015
<u>AN</u>	DR REDDYS LABS SA	<u>300MG/5ML</u>	<u>A207080 001</u>	Jul 09, 2018
<u>AN</u>	LUPIN	<u>300MG/5ML</u>	<u>A208964 001</u>	Mar 22, 2017
<u>AN</u>	SUN PHARM	<u>300MG/5ML</u>	<u>A207136 001</u>	Dec 26, 2019
<u>AN</u>	TEVA PHARMS USA	<u>300MG/5ML</u>	<u>A091589 001</u>	Oct 10, 2013
<u>AN</u>		<u>300MG/4ML</u>	<u>A210915 001</u>	Jun 26, 2019

SOLUTION/DROPS; OPHTHALMIC

AKTOB

<u>AT</u>	AKORN	<u>0.3%</u>	<u>A064096 001</u>	Jan 31, 1996
-----------	-------	-------------	--------------------	--------------

TOBRAMYCIN

<u>AT</u>	ALEMBIC PHARMS LTD	<u>0.3%</u>	<u>A211847 001</u>	Apr 19, 2019
<u>AT</u>	BAUSCH AND LOMB	<u>0.3%</u>	<u>A064052 001</u>	Nov 29, 1993
<u>AT</u>	FERA PHARMS	<u>0.3%</u>	<u>A065026 001</u>	Sep 11, 2001
<u>AT</u>	SOMERSET THERAPS LLC	<u>0.3%</u>	<u>A207444 001</u>	Jun 28, 2017

TOBREX

<u>AT</u>	+! NOVARTIS	<u>0.3%</u>	<u>N050541 001</u>	
<u>AT</u>	SANDOZ INC	<u>0.3%</u>	<u>A062535 001</u>	Dec 13, 1984

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

TOBRAMYCIN SULFATE

<u>AP</u>	AKORN	<u>EQ 40MG BASE/ML</u>	<u>A205179 001</u>	Sep 16, 2014
<u>AP</u>	BAXTER HLTHCARE CORP	<u>EQ 40MG BASE/ML</u>	<u>A206965 001</u>	Jul 01, 2016
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 10MG BASE/ML</u>	<u>A065122 001</u>	Nov 29, 2002
<u>AP</u>	!	<u>EQ 40MG BASE/ML</u>	<u>A065122 002</u>	Nov 29, 2002
<u>AP</u>		<u>EQ 1.2GM BASE/VIAL</u>	<u>N050789 001</u>	Jul 13, 2004
<u>AP</u>	! HOSPIRA	<u>EQ 10MG BASE/ML</u>	<u>A063112 001</u>	Apr 30, 1991
<u>AP</u>		<u>EQ 40MG BASE/ML</u>	<u>A063111 001</u>	Apr 30, 1991
<u>AP</u>	MYLAN LABS LTD	<u>EQ 40MG BASE/ML</u>	<u>A065407 001</u>	Mar 11, 2008
<u>AP</u>	TEVA PHARMS USA	<u>EQ 40MG BASE/ML</u>	<u>A063100 001</u>	Jan 30, 1992
<u>AP</u>	WEST-WARD PHARMS INT	<u>EQ 40MG BASE/ML</u>	<u>A063117 001</u>	Apr 26, 1991
<u>AP</u>	XELLIA PHARMS APS	<u>EQ 1.2GM BASE/VIAL</u>	<u>A205685 001</u>	Sep 16, 2014
<u>AP</u>	! XGEN PHARMS	<u>EQ 1.2GM BASE/VIAL</u>	<u>A065013 001</u>	Aug 17, 2001

PRESCRIPTION DRUG PRODUCT LIST

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

TOBRAMYCIN SULFATE (PHARMACY BULK)

! FRESenius KABI USA EQ 40MG BASE/ML A065120 001 Nov 29, 2002

TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

! HOSPIRA EQ 1.2MG BASE/ML A063081 003 Jul 31, 1990

! EQ 1.6MG BASE/ML A063081 006 Jun 02, 1993

! EQ 80MG BASE/100ML A063081 001 Jul 31, 1990

TOFACITINIB CITRATE

SOLUTION; ORAL

Xeljanz

+! PFIZER EQ 1MG/ML BASE N213082 001 Sep 25, 2020

TABLET; ORAL

XELJANZ

+ PF PRISM CV EQ 5MG BASE N203214 001 Nov 06, 2012

+! EQ 10MG BASE N203214 002 May 30, 2018

TABLET, EXTENDED RELEASE; ORAL

XELJANZ XR

+ PFIZER EQ 11MG BASE N208246 001 Feb 23, 2016

+! EQ 22MG BASE N208246 002 Dec 12, 2019

TOLBUTAMIDE

TABLET; ORAL

TOLBUTAMIDE

! MYLAN PHARMS INC 500MG A086445 001

TOLCAPONE

TABLET; ORAL

TASMARAB +! BAUSCH 100MG N020697 001 Jan 29, 1998TOLCAPONEAB ALVOGEN 100MG A207729 001 Jul 29, 2020AB MAYNE PHARMA 100MG A210095 001 Aug 01, 2019AB NOVAST LABS 100MG A208937 001 Aug 07, 2018AB PAR PHARM INC 100MG A204584 001 Mar 26, 2015TOLMETIN SODIUM

CAPSULE; ORAL

TOLMETIN SODIUMAB MYLAN EQ 400MG BASE A073393 001 May 27, 1993AB ! TEVA EQ 400MG BASE A073290 001 Nov 27, 1991

TABLET; ORAL

TOLMETIN SODIUM

! MYLAN EQ 600MG BASE A074473 001 Aug 30, 1994

TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

DETROL LAAB + UPJOHN 2MG N021228 001 Dec 22, 2000AB +! 4MG N021228 002 Dec 22, 2000TOLTERODINE TARTRATEAB HETERO LABS LTD III 2MG A206419 001 Dec 12, 2017AB 4MG A206419 002 Dec 12, 2017AB INVENTIA HLTHCARE 2MG A204562 001 Aug 19, 2019AB 4MG A204562 002 Aug 19, 2019AB MYLAN 2MG A201486 001 Oct 31, 2013AB 4MG A201486 002 Oct 31, 2013AB TEVA PHARMS USA 2MG A079141 001 Nov 22, 2016AB 4MG A079141 002 Nov 22, 2016AB TORRENT 2MG A203016 001 Aug 11, 2015AB 4MG A203016 002 Aug 11, 2015

TABLET; ORAL

DETROLAB + UPJOHN 1MG N020771 001 Mar 25, 1998AB +! 2MG N020771 002 Mar 25, 1998TOLTERODINE TARTRATEAB ATHEM 1MG A210775 001 Dec 30, 2019AB 2MG A210775 002 Dec 30, 2019AB IVAX SUB TEVA 1MG A077006 001 Feb 23, 2015AB PHARMS 2MG A077006 002 Feb 23, 2015AB MACLEODS PHARMS LTD 1MG A203409 001 Aug 31, 2015AB 2MG A203409 002 Aug 31, 2015AB UNICHEM 1MG A205399 001 Aug 05, 2020

PRESCRIPTION DRUG PRODUCT LIST

TOLTERODINE TARTRATE

TABLET; ORAL

TOLTERODINE TARTRATE

AB		2MG	A205399 002	Aug 05, 2020
AB	UNIQUE PHARM LABS	1MG	A204721 001	Jan 24, 2020
AB		2MG	A204721 002	Jan 24, 2020

TOLVAPTAN

TABLET; ORAL

SAMSCA

AB	+ !	OTSUKA AMERICA PHARM	30MG	N022275 002	May 19, 2009
-----------	------------	----------------------	-------------	--------------------	--------------

TOLVAPTAN

AB		ALKEM LABS LTD	30MG	A211891 001	May 19, 2020
AB			60MG	A211891 002	May 19, 2020

JYNARQUE

	+	OTSUKA PHARM CO LTD	15MG	N204441 001	Apr 23, 2018
	+		30MG	N204441 002	Apr 23, 2018
	+ !		45MG	N204441 003	Apr 23, 2018
	+		60MG	N204441 004	Apr 23, 2018
	+		90MG	N204441 005	Apr 23, 2018

SAMSCA

	+	OTSUKA AMERICA PHARM	15MG	N022275 001	May 19, 2009
--	----------	----------------------	------	-------------	--------------

TOPIRAMATE

CAPSULE; ORAL

TOPAMAX

AB	+	JANSSEN PHARMS	15MG	N020844 001	Oct 26, 1998
AB	+ !		25MG	N020844 002	Oct 26, 1998

TOPIRAMATE

AB		TEVA	15MG	A076575 001	Apr 17, 2009
AB			25MG	A076575 002	Apr 17, 2009
AB		WATSON LABS	15MG	A077868 001	Apr 15, 2009
AB			25MG	A077868 002	Apr 15, 2009
AB		ZYDUS PHARMS USA INC	15MG	A078877 001	Oct 14, 2009
AB			25MG	A078877 002	Oct 14, 2009

CAPSULE, EXTENDED RELEASE; ORAL

TOPIRAMATE

AB		ZYDUS PHARMS	25MG	A207382 001	Nov 24, 2017
AB			50MG	A207382 002	Nov 24, 2017
AB			100MG	A207382 003	Nov 24, 2017

TROKENDI XR

AB	+	SUPERNUS PHARMS	25MG	N201635 001	Aug 16, 2013
AB	+		50MG	N201635 002	Aug 16, 2013
AB	+		100MG	N201635 003	Aug 16, 2013

QUDEXY XR

BC	+	UPSHER SMITH LABS	25MG	N205122 001	Mar 11, 2014
BC	+		50MG	N205122 002	Mar 11, 2014
BC	+		100MG	N205122 003	Mar 11, 2014
BC	+ !		200MG	N205122 005	Mar 11, 2014

TROKENDI XR

BC	+ !	SUPERNUS PHARMS	200MG	N201635 004	Aug 16, 2013
----	------------	-----------------	-------	-------------	--------------

QUDEXY XR

	+	UPSHER SMITH LABS	150MG	N205122 004	Mar 11, 2014
--	----------	-------------------	-------	-------------	--------------

TABLET; ORAL

TOPAMAX

AB	+	JANSSEN PHARMS	25MG	N020505 004	Dec 24, 1996
AB	+		50MG	N020505 005	Dec 24, 1996
AB	+ !		100MG	N020505 001	Dec 24, 1996
AB	+		200MG	N020505 002	Dec 24, 1996

TOPIRAMATE

AB		ACCORD HLTHCARE	25MG	A076311 001	Mar 27, 2009
AB			50MG	A076311 002	Mar 27, 2009
AB			100MG	A076311 003	Mar 27, 2009
AB			200MG	A076311 004	Mar 27, 2009
AB		AUROBINDO PHARMA	25MG	A078462 001	Mar 27, 2009
AB			50MG	A078462 002	Mar 27, 2009
AB			100MG	A078462 003	Mar 27, 2009
AB			200MG	A078462 004	Mar 27, 2009
AB		CIPLA LTD	25MG	A076343 001	Mar 27, 2009
AB			50MG	A076343 002	Mar 27, 2009
AB			100MG	A076343 003	Mar 27, 2009

PRESCRIPTION DRUG PRODUCT LIST

TOPIRAMATE

TABLET; ORAL

TOPIRAMATE

<u>AB</u>		<u>200MG</u>	<u>A076343</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	GLENMARK GENERICS	<u>25MG</u>	<u>A077627</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A077627</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A077627</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A077627</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	INVAGEN PHARMS	<u>25MG</u>	<u>A079162</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A079162</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A079162</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A079162</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	SUN PHARM	<u>25MG</u>	<u>A090278</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A090278</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A090278</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A090278</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	SUN PHARM INDS LTD	<u>25MG</u>	<u>A076327</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A076327</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A076327</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>	TEVA	<u>25MG</u>	<u>A076317</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A076317</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A076317</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A076317</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	UNICHEM LABS LTD	<u>25MG</u>	<u>A090162</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A090162</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A090162</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A090162</u>	<u>004</u>	Feb 19, 2013
<u>AB</u>	UPSHER SMITH LABS	<u>25MG</u>	<u>A078499</u>	<u>001</u>	Jan 07, 2010
<u>AB</u>		<u>50MG</u>	<u>A078499</u>	<u>002</u>	Jan 07, 2010
<u>AB</u>		<u>100MG</u>	<u>A078499</u>	<u>003</u>	Jan 07, 2010
<u>AB</u>		<u>200MG</u>	<u>A078499</u>	<u>004</u>	Jan 07, 2010
<u>AB</u>	VIWIT PHARM	<u>25MG</u>	<u>A077733</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A077733</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A077733</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A077733</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>25MG</u>	<u>A078235</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A078235</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078235</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078235</u>	<u>004</u>	Mar 27, 2009

TOPOTECAN HYDROCHLORIDE

CAPSULE; ORAL

HYCANTIN

+ NOVARTIS

EQ 0.25MG BASE

N020981 001 Oct 11, 2007

+!

EQ 1MG BASE

N020981 002 Oct 11, 2007

INJECTABLE; INJECTION

HYCANTIN

<u>AP</u>	<u>+!</u>	NOVARTIS	<u>EQ 4MG BASE/VIAL</u>	<u>N020671</u>	<u>001</u>	May 28, 1996
-----------	-----------	----------	-------------------------	----------------	------------	--------------

TOPOTECAN HYDROCHLORIDE

<u>AP</u>		ACCORD HLTHCARE	<u>EQ 4MG BASE/VIAL</u>	<u>A202351</u>	<u>001</u>	Jun 26, 2013
<u>AP</u>		ACTAVIS TOTOWA	<u>EQ 4MG BASE/VIAL</u>	<u>A090620</u>	<u>001</u>	Dec 02, 2010
<u>AP</u>		CIPLA	<u>EQ 4MG BASE/VIAL</u>	<u>A091199</u>	<u>001</u>	Dec 01, 2010
<u>AP</u>		DR REDDYS LABS LTD	<u>EQ 4MG BASE/VIAL</u>	<u>A201191</u>	<u>001</u>	Mar 09, 2011
<u>AP</u>		FRESENIUS KABI USA	<u>EQ 4MG BASE/VIAL</u>	<u>A091089</u>	<u>001</u>	Nov 29, 2010
<u>AP</u>		MEITHEAL	<u>EQ 4MG BASE/VIAL</u>	<u>A201166</u>	<u>001</u>	Aug 08, 2012
<u>AP</u>		NOVAST LABS	<u>EQ 4MG BASE/VIAL</u>	<u>A206962</u>	<u>001</u>	Nov 30, 2016
<u>AP</u>		SAGENT PHARMS	<u>EQ 4MG BASE/VIAL</u>	<u>A091284</u>	<u>001</u>	Jan 26, 2011

SOLUTION; INTRAVENOUS

TOPOTECAN HYDROCHLORIDE

<u>AP</u>		ACCORD HLTHCARE	<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A204406</u>	<u>002</u>	Jul 06, 2017
<u>AP</u>	<u>+!</u>	HOSPIRA INC	<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>N200582</u>	<u>001</u>	Feb 02, 2011
<u>AP</u>		MYLAN LABS LTD	<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A206074</u>	<u>001</u>	Nov 24, 2017
<u>AP</u>		TEVA PHARMS USA	<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>N022453</u>	<u>001</u>	Dec 20, 2012
		ACCORD HLTHCARE	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A204406	001	Jul 06, 2017

TOREMIFENE CITRATE

TABLET; ORAL

FARESTON

<u>AB</u>	<u>+!</u>	KYOWA KIRIN	<u>EQ 60MG BASE</u>	<u>N020497</u>	<u>001</u>	May 29, 1997
-----------	-----------	-------------	---------------------	----------------	------------	--------------

TOREMIFENE CITRATE

<u>AB</u>		MSN	<u>EQ 60MG BASE</u>	<u>A212818</u>	<u>001</u>	Aug 18, 2020
<u>AB</u>		RISING	<u>EQ 60MG BASE</u>	<u>A208813</u>	<u>001</u>	Dec 04, 2018

PRESCRIPTION DRUG PRODUCT LIST

TORSEMIDE

TABLET; ORAL

TORSEMIDE

<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A078249</u>	<u>001</u>	Oct 17, 2007
<u>AB</u>		<u>10MG</u>	<u>A078249</u>	<u>002</u>	Oct 17, 2007
<u>AB</u>		<u>20MG</u>	<u>A078249</u>	<u>003</u>	Oct 17, 2007
<u>AB</u>		<u>100MG</u>	<u>A078249</u>	<u>004</u>	Oct 17, 2007
<u>AB</u>	COREPHARMA	<u>5MG</u>	<u>A076894</u>	<u>001</u>	May 31, 2005
<u>AB</u>		<u>10MG</u>	<u>A076894</u>	<u>002</u>	May 31, 2005
<u>AB</u>		<u>20MG</u>	<u>A076894</u>	<u>003</u>	May 31, 2005
<u>AB</u>		<u>100MG</u>	<u>A076894</u>	<u>004</u>	May 31, 2005
<u>AB</u>	HETERO LABS LTD III	<u>5MG</u>	<u>A079234</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>10MG</u>	<u>A079234</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>20MG</u>	<u>A079234</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A079234</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	HIKMA	<u>5MG</u>	<u>A076943</u>	<u>001</u>	Mar 01, 2005
<u>AB</u>		<u>10MG</u>	<u>A076943</u>	<u>002</u>	Mar 01, 2005
<u>AB</u>		<u>20MG</u>	<u>A076943</u>	<u>003</u>	Mar 01, 2005
<u>AB</u>	PAR PHARM	<u>5MG</u>	<u>A076226</u>	<u>001</u>	May 27, 2003
<u>AB</u>		<u>10MG</u>	<u>A076226</u>	<u>002</u>	May 27, 2003
<u>AB</u>		<u>20MG</u>	<u>A076226</u>	<u>003</u>	May 27, 2003
<u>AB</u>		<u>100MG</u>	<u>A076226</u>	<u>004</u>	May 27, 2003
<u>AB</u>	PLIVA PHARM IND	<u>5MG</u>	<u>A076346</u>	<u>001</u>	May 30, 2003
<u>AB</u>		<u>10MG</u>	<u>A076346</u>	<u>002</u>	May 30, 2003
<u>AB</u>	!	<u>20MG</u>	<u>A076346</u>	<u>003</u>	May 30, 2003
<u>AB</u>		<u>100MG</u>	<u>A076346</u>	<u>004</u>	Oct 19, 2004
<u>AB</u>	TEVA	<u>5MG</u>	<u>A076110</u>	<u>001</u>	May 14, 2002
<u>AB</u>		<u>10MG</u>	<u>A076110</u>	<u>002</u>	May 14, 2002
<u>AB</u>		<u>20MG</u>	<u>A076110</u>	<u>003</u>	May 14, 2002
<u>AB</u>		<u>100MG</u>	<u>A076110</u>	<u>004</u>	May 14, 2002
<u>AB</u>	VINTAGE PHARMS	<u>5MG</u>	<u>A090613</u>	<u>001</u>	Mar 22, 2011
<u>AB</u>		<u>10MG</u>	<u>A090613</u>	<u>002</u>	Mar 22, 2011
<u>AB</u>		<u>20MG</u>	<u>A090613</u>	<u>003</u>	Mar 22, 2011
<u>AB</u>		<u>100MG</u>	<u>A090613</u>	<u>004</u>	Mar 22, 2011

TRABECTEDIN

POWDER; INTRAVENOUS

YONDELIS

+! JANSSEN PRODS 1MG/VIAL N207953 001 Oct 23, 2015

TRAMADOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CONZIP

+! CIPHER PHARMS INC 100MG N022370 001 May 07, 2010

+ 200MG N022370 002 May 07, 2010

+ 300MG N022370 003 May 07, 2010

SOLUTION; ORAL

QDOLO

+! ATHENA 5MG/ML N214044 001 Sep 01, 2020

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

<u>AB</u>	ACI HEALTHCARE LTD	<u>50MG</u>	<u>A202075</u>	<u>001</u>	Nov 28, 2011
<u>AB</u>	AMNEAL PHARMS	<u>50MG</u>	<u>A076003</u>	<u>001</u>	Jun 20, 2002
<u>AB</u>	APOTEX	<u>50MG</u>	<u>A075981</u>	<u>001</u>	Jul 10, 2002
<u>AB</u>	AUROBINDO PHARMA LTD	<u>50MG</u>	<u>A203494</u>	<u>001</u>	Mar 31, 2014
<u>AB</u>	CSPC OUYI PHARM CO	<u>50MG</u>	<u>A091498</u>	<u>001</u>	Mar 29, 2013
<u>AB</u>	IPCA LABS LTD	<u>50MG</u>	<u>A201973</u>	<u>001</u>	Nov 16, 2012
<u>AB</u>	MYLAN	<u>50MG</u>	<u>A075986</u>	<u>001</u>	Jun 21, 2002
<u>AB</u>	PLIVA	<u>50MG</u>	<u>A075982</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>	RUBICON	<u>50MG</u>	<u>A208708</u>	<u>001</u>	Jun 28, 2019
<u>AB</u>		<u>100MG</u>	<u>A208708</u>	<u>002</u>	Jun 28, 2019
<u>AB</u>	SUN PHARM INDS INC	<u>50MG</u>	<u>A075964</u>	<u>001</u>	Jun 19, 2002
<u>AB</u>	TEVA	<u>50MG</u>	<u>A075977</u>	<u>001</u>	Jun 19, 2002
<u>AB</u>	UNICHEM	<u>50MG</u>	<u>A211825</u>	<u>001</u>	Aug 09, 2019
<u>AB</u>	ZYDUS PHARMS USA INC	<u>50MG</u>	<u>A090404</u>	<u>001</u>	Jan 31, 2011

ULTRAMAB +! JANSSEN PHARMS 50MG N020281 002 Mar 03, 1995

TABLET, EXTENDED RELEASE; ORAL

TRAMADOL HYDROCHLORIDE

<u>AB1</u>	!	LUPIN LTD	<u>100MG</u>	<u>A200503</u>	<u>001</u>	Aug 29, 2011
<u>AB1</u>			<u>200MG</u>	<u>A200503</u>	<u>002</u>	Aug 29, 2011
<u>AB1</u>			<u>300MG</u>	<u>A200503</u>	<u>003</u>	Aug 29, 2011

PRESCRIPTION DRUG PRODUCT LIST

TRAMADOL HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

TRAMADOL HYDROCHLORIDE

<u>AB1</u>	MYLAN	<u>100MG</u>	<u>A205257 001</u>	Dec 22, 2015
<u>AB1</u>		<u>200MG</u>	<u>A205257 002</u>	Dec 22, 2015
<u>AB1</u>		<u>300MG</u>	<u>A205257 003</u>	Dec 22, 2015
<u>AB1</u>	SUN PHARM	<u>100MG</u>	<u>A201384 001</u>	Dec 07, 2011
<u>AB1</u>		<u>200MG</u>	<u>A201384 002</u>	Dec 07, 2011
<u>AB1</u>		<u>300MG</u>	<u>A201384 003</u>	Dec 07, 2011
<u>AB2</u>	ACTAVIS ELIZABETH	<u>100MG</u>	<u>A091609 001</u>	Jun 27, 2012
<u>AB2</u>		<u>200MG</u>	<u>A091609 002</u>	Jun 27, 2012
<u>AB2</u>		<u>300MG</u>	<u>A091609 003</u>	Jun 27, 2012
<u>AB2</u>	ANCHEN PHARMS	<u>100MG</u>	<u>A200491 001</u>	Jun 27, 2012
<u>AB2</u>		<u>200MG</u>	<u>A200491 002</u>	Jun 27, 2012
<u>AB2</u>		<u>300MG</u>	<u>A200491 003</u>	Jun 27, 2012
<u>AB2</u>	! SUN PHARM	<u>100MG</u>	<u>A091607 001</u>	Dec 30, 2011
<u>AB2</u>		<u>200MG</u>	<u>A091607 002</u>	Dec 30, 2011
<u>AB2</u>		<u>300MG</u>	<u>A091607 003</u>	Dec 30, 2011

TRAMETINIB DIMETHYL SULFOXIDE

TABLET;ORAL

MEKINIST

+	NOVARTIS	EQ 0.5MG	N204114 001	May 29, 2013
+	!	EQ 2MG	N204114 003	May 29, 2013

TRANDOLAPRIL

TABLET;ORAL

TRANDOLAPRIL

<u>AB</u>	AUROBINDO PHARMA	<u>1MG</u>	<u>A078438 001</u>	Jun 12, 2007
<u>AB</u>		<u>2MG</u>	<u>A078438 002</u>	Jun 12, 2007
<u>AB</u>		<u>4MG</u>	<u>A078438 003</u>	Jun 12, 2007
<u>AB</u>	EPIC PHARMA	<u>1MG</u>	<u>A078508 003</u>	Jun 18, 2008
<u>AB</u>		<u>2MG</u>	<u>A078508 001</u>	Jun 18, 2008
<u>AB</u>		<u>4MG</u>	<u>A078508 002</u>	Jun 18, 2008
<u>AB</u>	LUPIN	<u>1MG</u>	<u>A077522 001</u>	Jun 12, 2007
<u>AB</u>		<u>2MG</u>	<u>A077522 002</u>	Jun 12, 2007
<u>AB</u>	!	<u>4MG</u>	<u>A077522 003</u>	Jun 12, 2007
<u>AB</u>	TEVA PHARMS	<u>1MG</u>	<u>A077489 001</u>	Dec 12, 2006
<u>AB</u>		<u>2MG</u>	<u>A077489 002</u>	Dec 12, 2006
<u>AB</u>		<u>4MG</u>	<u>A077489 003</u>	Dec 12, 2006

TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

TARKA

<u>AB</u>	+	ABBVIE	<u>2MG;180MG</u>	<u>N020591 001</u>	Oct 22, 1996
<u>AB</u>	+		<u>2MG;240MG</u>	<u>N020591 004</u>	Oct 22, 1996
<u>AB</u>	+	!	<u>4MG;240MG</u>	<u>N020591 002</u>	Oct 22, 1996

TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE

<u>AB</u>	GLENMARK GENERICS	<u>2MG;180MG</u>	<u>A079135 001</u>	May 26, 2010
<u>AB</u>		<u>2MG;240MG</u>	<u>A079135 002</u>	May 26, 2010
<u>AB</u>		<u>4MG;240MG</u>	<u>A079135 003</u>	May 05, 2010
		1MG;240MG	A079135 004	Aug 30, 2010

TRANEXAMIC ACID

INJECTABLE; INJECTION

CYKLOKAPRON

<u>AP</u>	+	PHARMACIA AND UPJOHN	<u>100MG/ML</u>	<u>N019281 001</u>	Dec 30, 1986
-----------	---	----------------------	-----------------	--------------------	--------------

TRANEXAMIC ACID

<u>AP</u>	ACIC PHARMS	<u>100MG/ML</u>	<u>A202436 001</u>	Feb 11, 2014
<u>AP</u>	AKORN	<u>100MG/ML</u>	<u>A202373 001</u>	Nov 17, 2011
<u>AP</u>		<u>100MG/ML</u>	<u>A206594 001</u>	Sep 28, 2017
<u>AP</u>		<u>100MG/ML</u>	<u>A206634 001</u>	Jun 09, 2016
<u>AP</u>	AM REGENT	<u>100MG/ML</u>	<u>A201885 001</u>	Aug 10, 2011
<u>AP</u>	AMNEAL PHARMS CO	<u>100MG/ML</u>	<u>A208840 001</u>	Feb 28, 2017
<u>AP</u>	APOLLO	<u>100MG/ML</u>	<u>A212676 001</u>	Jul 17, 2019
<u>AP</u>	APOTEX	<u>100MG/ML</u>	<u>A209860 001</u>	Jan 14, 2020
<u>AP</u>	AUROBINDO PHARMA LTD	<u>100MG/ML</u>	<u>A205035 001</u>	Jan 14, 2016
<u>AP</u>	EMCURE PHARMS LTD	<u>100MG/ML</u>	<u>A203521 001</u>	Aug 12, 2014
<u>AP</u>	FRESENIUS KABI USA	<u>100MG/ML</u>	<u>A091596 001</u>	Mar 02, 2012
<u>AP</u>	GLAND PHARMA LTD	<u>100MG/ML</u>	<u>A207239 001</u>	Feb 13, 2017
<u>AP</u>	MICRO LABS	<u>100MG/ML</u>	<u>A206713 001</u>	Jun 27, 2017
<u>AP</u>	MYLAN INSTITUTIONAL	<u>100MG/ML</u>	<u>A091657 001</u>	Nov 03, 2011
<u>AP</u>	XGEN PHARMS	<u>100MG/ML</u>	<u>A201580 001</u>	Jun 14, 2013

PRESCRIPTION DRUG PRODUCT LIST

TRANEXAMIC ACID

INJECTABLE; INJECTION

TRANEXAMIC ACID

AP	+	ZYDUS PHARMS	100MG/ML	A205228 001	Jul 17, 2017
		SOLUTION; INTRAVENOUS			
		TRANEXAMIC ACID			
	+	EXELA PHARMA	1GM/100ML (10MG/ML)	N212020 001	Apr 15, 2019

TABLET; ORAL

LYSTEDA

AB	+	AMRING PHARMS	650MG	N022430 001	Nov 13, 2009
		<u>TRANEXAMIC ACID</u>			
AB		ACTAVIS LABS FL INC	650MG	A202093 001	Dec 27, 2012
AB		APOTEX INC	650MG	A202286 001	Jan 27, 2014

TRANLYCYPROMINE SULFATE

TABLET; ORAL

PARNATE

AB	+	CONCORDIA	EQ 10MG BASE	N012342 003	Aug 16, 1985
		<u>TRANLYCYPROMINE SULFATE</u>			
AB		KINEDEXE	EQ 10MG BASE	A206856 001	Apr 17, 2018
AB		PAR PHARM	EQ 10MG BASE	A040640 001	Jun 29, 2006

TRAVOPROST

SOLUTION/DROPS; OPHTHALMIC

TRAVATAN Z

AT	+	NOVARTIS	0.004%	N021994 001	Sep 21, 2006
		<u>TRAVOPROST</u>			
AT		APOTEX	0.004%	A203431 001	Jul 10, 2015
AT		MYLAN	0.004%	A205050 001	Jul 07, 2017
AT1		ALEMBIC PHARMS LTD	0.004%	A210458 001	Dec 20, 2019
AT1	!	PAR PHARM	0.004%	A091340 001	Mar 01, 2013

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HYDROCHLORIDE

AB		ACCORD HLTHCARE	50MG	A206923 001	Sep 08, 2017
AB			100MG	A206923 002	Sep 08, 2017
AB			150MG	A206923 003	Sep 08, 2017
AB			300MG	A206923 004	Sep 08, 2017
AB		ALVOGEN	50MG	A071636 001	Apr 18, 1988
AB			100MG	A071514 001	Apr 18, 1988
AB		APOTEX	50MG	A071258 001	Mar 25, 1987
AB	!	APOTEX INC	100MG	A071196 001	Mar 25, 1987
AB			150MG	A071196 002	Apr 26, 1999
AB			300MG	A071196 003	Apr 26, 1999
AB		OXFORD PHARMS	50MG	A072192 001	Feb 02, 1989
AB			100MG	A072193 001	Feb 02, 1989
AB		PLIVA	150MG	A071525 001	Mar 09, 1988
AB		SUN PHARM	50MG	A073137 002	Mar 24, 1993
		INDUSTRIES			
AB			100MG	A073137 001	Mar 24, 1993
AB			150MG	A073137 003	Dec 22, 1995
AB		TEVA PHARMS USA	50MG	A071523 001	Dec 11, 1987
AB			100MG	A071524 001	Dec 11, 1987
AB		TORRENT	50MG	A202180 001	Nov 27, 2013
AB			100MG	A202180 002	Nov 27, 2013
AB			150MG	A202180 003	Nov 27, 2013
AB			300MG	A202180 004	Nov 27, 2013
AB		ZYDUS PHARMS	50MG	A205253 001	Oct 10, 2017
AB			100MG	A205253 002	Oct 10, 2017
AB			150MG	A205253 003	Oct 10, 2017
AB			300MG	A205253 004	Oct 10, 2017

TREPROSTINIL

INJECTABLE; IV (INFUSION), SUBCUTANEOUS

REMODULIN

AP	+	UNITED THERAP	1MG/ML	N021272 001	May 21, 2002
AP	+		2.5MG/ML	N021272 002	May 21, 2002
AP	+		5MG/ML	N021272 003	May 21, 2002
AP	+		10MG/ML	N021272 004	May 21, 2002

TREPROSTINIL

AP		PAR STERILE	1MG/ML	A209382 001	Sep 24, 2019
		PRODUCTS			
AP			2.5MG/ML	A209382 002	Sep 24, 2019
AP			5MG/ML	A209382 003	Sep 24, 2019

PRESCRIPTION DRUG PRODUCT LIST

TREPROSTINIL

INJECTABLE;IV (INFUSION), SUBCUTANEOUS

TREPROSTINIL

<u>AP</u>		<u>10MG/ML</u>	<u>A209382</u>	<u>004</u>	Sep 24, 2019
<u>AP</u>	SANDOZ INC	<u>1MG/ML</u>	<u>A203649</u>	<u>001</u>	Nov 30, 2017
<u>AP</u>		<u>2.5MG/ML</u>	<u>A203649</u>	<u>002</u>	Nov 30, 2017
<u>AP</u>		<u>5MG/ML</u>	<u>A203649</u>	<u>003</u>	Nov 30, 2017
<u>AP</u>		<u>10MG/ML</u>	<u>A203649</u>	<u>004</u>	Nov 30, 2017
<u>AP</u>	TEVA PHARMS USA	<u>1MG/ML</u>	<u>A206648</u>	<u>001</u>	Sep 26, 2019
<u>AP</u>		<u>2.5MG/ML</u>	<u>A206648</u>	<u>002</u>	Sep 26, 2019
<u>AP</u>		<u>5MG/ML</u>	<u>A206648</u>	<u>003</u>	Sep 26, 2019
<u>AP</u>		<u>10MG/ML</u>	<u>A206648</u>	<u>004</u>	Sep 26, 2019

SOLUTION;INHALATION

TYVASO

+! UNITED THERAP 0.6MG/ML N022387 001 Jul 30, 2009

SOLUTION;INTRAVENOUS, SUBCUTANEOUS

REMODULIN

	UNITED THERAP	20MG/20ML (1MG/ML)	N208276	001	Jul 30, 2018
		50MG/20ML (2.5MG/ML)	N208276	002	Jul 30, 2018
		100MG/20ML (5MG/ML)	N208276	003	Jul 30, 2018
		200MG/20ML (10MG/ML)	N208276	004	Jul 30, 2018

TREPROSTINIL DIOLAMINE

TABLET, EXTENDED RELEASE;ORAL

ORENITRAM

+	UNITED THERAP	EQ 0.125MG BASE	N203496	001	Dec 20, 2013
+		EQ 0.25MG BASE	N203496	002	Dec 20, 2013
+!		EQ 1MG BASE	N203496	003	Dec 20, 2013
+		EQ 2.5MG BASE	N203496	004	Dec 20, 2013
+		EQ 5MG BASE	N203496	005	Oct 07, 2016

TRETINOIN

CAPSULE;ORAL

TRETINOIN

<u>AB</u>	ANCHEN PHARMS	<u>10MG</u>	<u>A201687</u>	<u>001</u>	Oct 24, 2012
<u>AB</u>	! BARR LABS INC	<u>10MG</u>	<u>A077684</u>	<u>001</u>	Jun 22, 2007
<u>AB</u>	GLENMARK PHARMS LTD	<u>10MG</u>	<u>A208279</u>	<u>001</u>	Dec 23, 2016

CREAM;TOPICAL

AVITA

<u>AB</u>	MYLAN PHARMS INC	<u>0.025%</u>	<u>N020404</u>	<u>003</u>	Jan 14, 1997
-----------	------------------	---------------	----------------	------------	--------------

RETIN-A

<u>AB</u>	+! VALEANT BERMUDA	<u>0.025%</u>	<u>N019049</u>	<u>001</u>	Sep 16, 1988
<u>AB</u>	+! VALEANT PHARMS NORTH	<u>0.1%</u>	<u>N017340</u>	<u>001</u>	

TRETINOIN

<u>AB</u>	PERRIGO PHARMA INTL	<u>0.025%</u>	<u>A075264</u>	<u>001</u>	Dec 24, 1998
<u>AB</u>		<u>0.1%</u>	<u>A075213</u>	<u>001</u>	Dec 24, 1998
<u>AB</u>	TARO PHARMS	<u>0.1%</u>	<u>A211645</u>	<u>001</u>	Jan 22, 2019

RETIN-A

<u>AB1</u>	+! VALEANT BERMUDA	<u>0.05%</u>	<u>N017522</u>	<u>001</u>	
------------	--------------------	--------------	----------------	------------	--

TRETINOIN

<u>AB1</u>	PERRIGO PHARMA INTL	<u>0.05%</u>	<u>A075265</u>	<u>001</u>	Dec 24, 1998
<u>AB1</u>	TARO PHARMS	<u>0.05%</u>	<u>A211644</u>	<u>001</u>	Jan 25, 2019

RENOVA

<u>AB2</u>	+! VALEANT PHARMS NORTH	<u>0.05%</u>	<u>N019963</u>	<u>001</u>	Dec 29, 1995
------------	-------------------------	--------------	----------------	------------	--------------

TRETINOIN

<u>AB2</u>	ZO SKIN HEALTH	<u>0.05%</u>	<u>A076498</u>	<u>001</u>	Sep 15, 2005
	RENOVA				
	+! VALEANT PHARMS NORTH	0.02%	N021108	001	Aug 31, 2000

GEL;TOPICAL

ATRALIN

<u>AB</u>	+! DOW PHARM	<u>0.05%</u>	<u>N022070</u>	<u>001</u>	Jul 26, 2007
-----------	--------------	--------------	----------------	------------	--------------

RETIN-A

<u>AB</u>	+! VALEANT INTL	<u>0.01%</u>	<u>N017955</u>	<u>001</u>	
<u>AB</u>	+!	<u>0.025%</u>	<u>N017579</u>	<u>002</u>	

TRETINOIN

<u>AB</u>	MYLAN	<u>0.05%</u>	<u>A207955</u>	<u>001</u>	Aug 13, 2015
<u>AB</u>	PERRIGO PHARMA INTL	<u>0.01%</u>	<u>A075589</u>	<u>001</u>	Jun 11, 2002
<u>AB</u>		<u>0.025%</u>	<u>A075529</u>	<u>001</u>	Feb 22, 2000

AVITA

BT	MYLAN	0.025%	N020400	001	Jan 29, 1998
----	-------	--------	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

TRETINOIN

GEL; TOPICAL

RETIN-A MICRO

+	!	VALEANT INTL	0.04%	N020475	002	May 10, 2002
+	!		0.1%	N020475	001	Feb 07, 1997

RETIN-A-MICRO

+	!	VALEANT INTL	0.06%	N020475	004	Oct 23, 2017
+	!		0.08%	N020475	003	Jan 28, 2014

LOTION; TOPICAL

ALTRENO

+	!	DOW PHARM	0.05%	N209353	001	Aug 23, 2018
---	---	-----------	-------	---------	-----	--------------

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

TRIAMCINOLONE ACETONIDE

AT		ALKEM LABS LTD	0.025%	A207651	001	Dec 26, 2017
AT			0.1%	A207651	002	Dec 26, 2017
AT			0.5%	A207651	003	Dec 26, 2017
AT		COSETTE	0.025%	A089797	001	May 31, 1991
AT			0.1%	A089798	001	May 31, 1991
AT	!	FOUGERA PHARMS	0.025%	A085692	001	
AT	!		0.1%	A085692	003	
AT	!		0.5%	A085692	002	
AT		GLENMARK PHARMS LTD	0.1%	A207117	001	Aug 05, 2016
AT		LUPIN	0.025%	A208763	001	Feb 01, 2017
AT			0.1%	A208763	002	Feb 01, 2017
AT			0.5%	A208763	003	Feb 01, 2017
AT		MACLEODS PHARMS LTD	0.025%	A209535	001	May 18, 2018
AT			0.1%	A209535	002	May 18, 2018
AT			0.5%	A209535	003	May 18, 2018
AT		MLV	0.025%	A040671	001	Jun 09, 2006
AT			0.1%	A040671	002	Jun 09, 2006
AT		PERRIGO NEW YORK	0.025%	A086413	002	
AT			0.1%	A086413	003	
AT			0.5%	A086413	001	
AT		STRIDES PHARMA	0.025%	A210346	001	Feb 11, 2019
AT			0.1%	A210346	002	Feb 11, 2019
AT			0.5%	A210346	003	Feb 11, 2019
AT		TARO PHARM INDS LTD	0.1%	A040039	001	Nov 26, 1997
AT		TELIGENT	0.1%	A208848	001	Sep 18, 2017
TRIDERM						
AT		CROWN LABS	0.025%	A088042	002	Mar 25, 2015
AT			0.1%	A088042	001	Mar 19, 1984
AT			0.5%	A088042	003	Mar 25, 2015

FOR SUSPENSION, EXTENDED RELEASE; INTRA-ARTICULAR

ZILRETTA

+	!	FLEXION THERAPS INC	32MG/VIAL	N208845	001	Oct 06, 2017
---	---	---------------------	-----------	---------	-----	--------------

INJECTABLE; INJECTION

KENALOG-40

AB	+	!	APOTHECON	40MG/ML	N014901	001
TRIAMCINOLONE ACETONIDE						
AB			AMNEAL	40MG/ML	A207550	001
AB			TEVA PHARMS USA	40MG/ML	A209852	001

KENALOG-10

+		APOTHECON	10MG/ML	N012041	001	
---	--	-----------	---------	---------	-----	--

KENALOG-80

+	!	APOTHECON	80MG/ML	N014901	002	Apr 12, 2019
---	---	-----------	---------	---------	-----	--------------

INJECTABLE; INTRAVITREAL

TRIESENCE

+	!	NOVARTIS	40MG/ML (40MG/ML)	N022048	001	Nov 29, 2007
---	---	----------	-------------------	---------	-----	--------------

LOTION; TOPICAL

TRIAMCINOLONE ACETONIDE

AT		AKORN	0.025%	A202374	001	May 08, 2013
AT			0.1%	A202374	002	May 08, 2013
AT		COSETTE	0.1%	A089129	001	Aug 14, 1986
AT		FOUGERA PHARMS	0.025%	A040467	001	Apr 21, 2003
AT			0.1%	A040467	002	Apr 21, 2003
AT		QUAGEN	0.025%	A213559	001	Jul 01, 2020
AT			0.1%	A213559	002	Jul 01, 2020
AT		SAPTALIS PHARMS	0.1%	A040672	002	Dec 13, 2006
AT		TELIGENT	0.025%	A204608	001	Jul 07, 2016
AT			0.1%	A204606	001	Jul 07, 2016
AT	!	WOCKHARDT BIO AG	0.025%	A088450	001	Apr 01, 1985

PRESCRIPTION DRUG PRODUCT LIST

TRIAMCINOLONE ACETONIDE

LOTION; TOPICAL

TRIAMCINOLONE ACETONIDE**AT** ! 0.1% **A088451 001** Apr 03, 1985

OINTMENT; TOPICAL

TRIAMCINOLONE ACETONIDE**AT** CINTEX SVCS 0.05% **A213619 001** Nov 10, 2020**AT** COSETTE 0.025% **A089795 001** Dec 23, 1988**AT** 0.1% **A089796 001** Dec 23, 1988**AT** 0.5% **A208925 001** Oct 06, 2017**AT** ENCUBE 0.05% **A212384 001** Nov 29, 2019**AT** FOUGERA PHARMS 0.025% **A085691 001****AT** 0.1% **A085691 003****AT** 0.5% **A085691 002****AT** GLENMARK PHARMS 0.1% **A208320 001** Aug 22, 2017**AT** GLENMARK PHARMS LTD 0.5% **A206379 001** Jul 22, 2016**AT** MACLEODS PHARMS LTD 0.025% **A209828 001** Nov 23, 2018**AT** 0.1% **A209828 002** Nov 23, 2018**AT** 0.5% **A209828 003** Nov 23, 2018**AT** NOVEL LABS INC 0.1% **A207365 001** Oct 12, 2018**AT** ! PERRIGO NEW YORK 0.025% **A087385 002****AT** ! 0.1% **A087385 003****AT** ! 0.5% **A087385 001****AT** STRIDES PHARMA 0.05% **A212356 001** Jun 01, 2020**AT** TARO PHARM INDS LTD 0.1% **A040037 001** Sep 30, 1994**AT** TELIGENT 0.1% **A205373 001** May 13, 2016**AT** 0.5% **A208590 001** Mar 03, 2017TRIAMCINOLONE ACETONIDE IN ABSORBASE**AT** ! CMP PHARMA INC 0.05% **A089595 001** Mar 23, 1995

PASTE; DENTAL

TRIAMCINOLONE ACETONIDE**AT** AKORN 0.1% **A206312 001** Aug 11, 2016**AT** COSETTE 0.1% **A205592 001** Jan 12, 2017**AT** LYNE 0.1% **A040771 001** Jul 01, 2010**AT** ! TARO 0.1% **A070730 001** Oct 01, 1986

SPRAY; TOPICAL

KENALOG**AT** +! SUN PHARM INDS INC 0.147MG/GM **N012104 001**TRIAMCINOLONE ACETONIDE**AT** AKORN 0.147MG/GM **A207094 001** Dec 07, 2016**AT** PERRIGO UK FINCO 0.147MG/GM **A205782 001** Apr 13, 2015**AT** RISING 0.147MG/GM **A206786 001** Sep 08, 2017TRIAMCINOLONE HEXACETONIDE

INJECTABLE; INJECTION

ARISTOSPAN

+! SANDOZ INC 5MG/ML N016466 001

+! 20MG/ML N016466 002

TRIAMTERENE

CAPSULE; ORAL

DYRENIUM**AB** + CONCORDIA 50MG **N013174 001****AB** +! 100MG **N013174 002**TRIAMTERENE**AB** AGNITIO 50MG **A211581 001** Aug 19, 2019**AB** 100MG **A211581 002** Aug 19, 2019TRIAZOLAM

TABLET; ORAL

HALCION**AB** + PHARMACIA AND 0.125MG **N017892 003** Apr 26, 1985**AB** +! UPJOHN 0.25MG **N017892 001** Nov 15, 1982TRIAZOLAM**AB** HIKMA 0.125MG **A074224 001** Jun 01, 1994**AB** 0.25MG **A074224 002** Jun 01, 1994**AB** RICONPHARMA LLC 0.125MG **A214219 001** Oct 20, 2020**AB** 0.25MG **A214219 002** Oct 20, 2020

PRESCRIPTION DRUG PRODUCT LIST

TRICLABENDAZOLE

TABLET; ORAL

EGATEN

+! NOVARTIS

250MG

N208711 001 Feb 13, 2019

TRIENTINE HYDROCHLORIDE

CAPSULE; ORAL

CLOVIQUE**AB** KADMON PHARMS LLC250MGA209731 001 Oct 21, 2019SYPRINE**AB** +! BAUSCH250MGN019194 001 Nov 08, 1985TRIENTINE HYDROCHLORIDE**AB** AMNEAL250MGA210619 001 Feb 08, 2019**AB** DR REDDYS LABS LTD250MGA211076 001 Jul 03, 2019**AB** KADMON PHARMS LLC250MGA209415 001 Sep 16, 2019**AB** LUPIN LTD250MGA211637 001 May 21, 2020**AB** MSN250MGA211134 001 May 22, 2019**AB** NAVINTA LLC250MGA211251 001 Jan 16, 2019**AB** PAR PHARM INC250MGA210096 001 Sep 25, 2019**AB** RISING250MGA212238 001 Feb 20, 2020**AB** WATSON LABS TEVA250MGA207567 001 Feb 07, 2018**AB** ZYDUS PHARMS250MGA211554 001 Apr 26, 2019TRIFAROTENE

CREAM; TOPICAL

AKLIEF

+! GALDERMA LABS LP

0.005%

N211527 001 Oct 04, 2019

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL

TRIFLUOPERAZINE HYDROCHLORIDE**AB** MYLANEQ 1MG BASEA040209 001 Jul 07, 1997**AB**EQ 2MG BASEA040209 002 Jul 07, 1997**AB**EQ 5MG BASEA040209 003 Jul 07, 1997**AB** !EQ 10MG BASEA040209 004 Jul 07, 1997**AB** SANDOZEQ 1MG BASEA085785 001**AB**EQ 2MG BASEA085786 001**AB**EQ 5MG BASEA085789 001**AB**EQ 10MG BASEA085788 001TRIFLURIDINE

SOLUTION/DROPS; OPHTHALMIC

TRIFLURIDINE**AT** AKORN1%A205438 001 Jul 28, 2017**AT** SANDOZ INC1%A074311 001 Oct 06, 1995VIROPTIC**AT** +! MONARCH PHARMS1%N018299 001TRIHHEPTANOIN

LIQUID; ORAL

DOJOLVI

+! ULTRAGENYX PHARM
INC

100% w/w

N213687 001 Jun 30, 2020

TRIHXYPHENIDYL HYDROCHLORIDE

ELIXIR; ORAL

TRIHXYPHENIDYL HYDROCHLORIDE**AA** MIKART2MG/5MLA040251 001 Sep 27, 1999**AA** ! PHARM ASSOC2MG/5MLA040177 001 Apr 17, 1997

TABLET; ORAL

TRIHXYPHENIDYL HYDROCHLORIDE**AA** NATCO PHARMA LTD2MGA091630 001 Nov 17, 2010**AA**5MGA091630 002 Nov 17, 2010**AA** NOVITIUM PHARMA2MGA040254 001 Dec 24, 1998**AA**5MGA040254 002 Dec 24, 1998**AA** ! WATSON LABS2MGA084363 001**AA** !5MGA084364 001TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE; ORAL

TIGAN**AB** +! KING PHARMS LLC300MGN017531 006 Dec 13, 2001TRIMETHOBENZAMIDE HYDROCHLORIDE**AB** LUPIN300MGA076546 001 Aug 20, 2003**AB** SUN PHARM300MGA076570 001 Aug 28, 2003

INDUSTRIES

PRESCRIPTION DRUG PRODUCT LIST

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

TIGAN

+	!	PAR STERILE PRODUCTS	100MG/ML	N017530	001	
---	---	----------------------	----------	---------	-----	--

TRIMETHOPRIM

TABLET; ORAL

TRIMETHOPRIM

AB	+	!	MAYNE PHARMA	100MG	N018679	001	Jul 30, 1982
AB			NOVEL LABS INC	100MG	A091437	001	Jun 15, 2011
AB			WATSON LABS	100MG	A070049	001	Jun 06, 1985

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

TRIMIPRAMINE MALEATE

AB			CROSSMEDIKA SA	EQ 25MG BASE	A208127	001	Apr 15, 2016
AB		!		EQ 50MG BASE	A208127	002	Apr 15, 2016
AB				EQ 100MG BASE	A208127	003	Apr 15, 2016
AB			ELITE LABS INC	EQ 25MG BASE	A077361	001	Aug 02, 2006
AB				EQ 50MG BASE	A077361	002	Aug 02, 2006
AB				EQ 100MG BASE	A077361	003	Aug 02, 2006

TRIPTORELIN PAMOATE

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

TRIPTODUR KIT

+	!	ARBOR PHARMS LLC	EQ 22.5MG BASE/VIAL	N208956	001	Jun 29, 2017
---	---	------------------	---------------------	---------	-----	--------------

INJECTABLE; INTRAMUSCULAR

TRELSTAR

+	!	VERITY	EQ 3.75MG BASE/VIAL	N020715	001	Jun 15, 2000
+	!		EQ 11.25MG BASE/VIAL	N021288	001	Jun 29, 2001
+	!		EQ 22.5MG BASE/VIAL	N022437	001	Mar 10, 2010

TROMETHAMINE

SOLUTION; INJECTION

THAM

+	!	HOSPIRA	18GM/500ML (3.6GM/100ML)	N013025	002	
---	---	---------	--------------------------	---------	-----	--

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

MYDRIACYL

AT	!	ALCON LABS INC	1%	A084306	001	
AT	!	SANDOZ INC	0.5%	A084305	001	

TROPICACYL

AT			0.5%	A040314	001	Sep 29, 2000
AT			1%	A040315	001	Sep 29, 2000

TROPICAMIDE

AT		BAUSCH AND LOMB	0.5%	A040067	001	Jul 27, 1994
AT			1%	A040064	001	Jul 27, 1994
AT		SOMERSET THERAPS LLC	1%	A207524	001	Dec 12, 2019

TROSPIMUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

TROSPIMUM CHLORIDE

AB	!	ACTAVIS LABS FL INC	60MG	A091289	001	Oct 12, 2012
AB		GRANULES PHARMS	60MG	A213185	001	Apr 23, 2020
AB		PADDOCK LLC	60MG	A201291	001	May 24, 2013

TABLET; ORAL

TROSPIMUM CHLORIDE

AB		APOTEX	20MG	A091513	001	Dec 06, 2011
AB	!	GLENMARK GENERICS	20MG	A091575	001	Aug 13, 2010
AB		HERITAGE PHARMS INC	20MG	A204945	001	Aug 30, 2016
AB		INVAGEN PHARMS	20MG	A091688	001	Aug 23, 2016
AB		PADDOCK LLC	20MG	A091573	001	Nov 17, 2010

TRYPAN BLUE

SOLUTION; OPHTHALMIC

MEMBRANEBLUE

+	!	DORC	0.15%	N022278	001	Feb 20, 2009
---	---	------	-------	---------	-----	--------------

VISIONBLUE

+	!	DORC	0.06%	N021670	001	Dec 16, 2004
---	---	------	-------	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

TUCATINIB

TABLET; ORAL

TUKYSA

+ SEAGEN

50MG

N213411 001 Apr 17, 2020

+!

150MG

N213411 002 Apr 17, 2020

UBROGEPANT

TABLET; ORAL

UBRELVY

+ ALLERGAN

50MG

N211765 001 Dec 23, 2019

+!

100MG

N211765 002 Dec 23, 2019

ULIPRISTAL ACETATE

TABLET; ORAL

ELLA**AB** +! LAB HRA PHARMA**30MG****N022474 001** Aug 13, 2010LOGILIA**AB** TEVA PHARMS USA**30MG****A207952 001** Feb 13, 2017UMECLIDINIUM BROMIDE

POWDER; INHALATION

INCRUSE ELLIPTA

+! GLAXO GRP ENGLAND

EQ 62.5MCG BASE/INH

N205382 001 Apr 30, 2014

UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE

POWDER; INHALATION

ANORO ELLIPTA

+! GLAXOSMITHKLINE

EQ 0.0625MG BASE/INH; EQ 0.025MG
BASE/INH

N203975 001 Dec 18, 2013

UPADACITINIB

TABLET, EXTENDED RELEASE; ORAL

RINVOQ

+! ABBVIE INC

15MG

N211675 001 Aug 16, 2019

UREA, C-14

CAPSULE; ORAL

PYTEST

+! AVENT

1uCi

N020617 001 May 09, 1997

PYTEST KIT

+! AVENT

1uCi

N020617 002 May 09, 1997

URIDINE TRIACETATE

GRANULE; ORAL

VISTOGARD

+! WELLSTAT THERAP

10GM/PACKET

N208159 001 Dec 11, 2015

XURIDEN

+! WELLSTAT THERAP

2GM/PACKET

N208169 001 Sep 04, 2015

URSODIOL

CAPSULE; ORAL

ACTIGALL**AB** +! ALLERGAN**300MG****N019594 002** Dec 31, 1987URSODIOL**AB** ABHAI LLC**300MG****A210707 001** May 17, 2018**AB** AMNEAL PHARMS CO**300MG****A211301 001** Oct 16, 2018**AB** EPIC PHARMA**300MG****A075517 001** Mar 14, 2000**AB** EYWA PHARMA**300MG****A212452 001** Oct 30, 2019**AB** LANNETT CO INC**300MG****A079082 001** Dec 15, 2008**AB** MYLAN**300MG****A090530 001** Feb 17, 2010**AB** RISING**300MG****A213200 001** Feb 12, 2020**AB** TEVA PHARMS**300MG****A075592 001** May 25, 2000**AB** UPSHER SMITH LABS**300MG****A213555 001** Aug 17, 2020**AB** ZYDUS**300MG****A214295 001** Oct 16, 2020

LGM PHARMA

200MG

A205789 001 May 08, 2020

!

400MG

A205789 002 May 08, 2020

TABLET; ORAL

URSO 250**AB** + ALLERGAN**250MG****N020675 001** Dec 10, 1997URSO FORTE**AB** +! ALLERGAN**500MG****N020675 002** Jul 21, 2004URSODIOL**AB** GLENMARK GENERICS**250MG****A090801 001** Jul 12, 2011**AB****500MG****A090801 002** Jul 12, 2011**AB** PAR PHARM**250MG****A202540 001** Feb 14, 2013**AB****500MG****A202540 002** Feb 14, 2013**AB** STRIDES PHARMA**250MG****A213504 001** Aug 20, 2020

PRESCRIPTION DRUG PRODUCT LIST

URSODIOL

TABLET; ORAL

URSODIOL

<u>AB</u>		<u>500MG</u>	<u>A213504</u>	<u>002</u>	Aug 20, 2020
<u>AB</u>	ZYDUS	<u>250MG</u>	<u>A211145</u>	<u>001</u>	Oct 30, 2018
<u>AB</u>		<u>500MG</u>	<u>A211145</u>	<u>002</u>	Oct 30, 2018

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

<u>AB</u>	APOTEX	<u>EQ 500MG BASE</u>	<u>A090500</u>	<u>001</u>	Apr 04, 2014
<u>AB</u>		<u>EQ 1GM BASE</u>	<u>A090500</u>	<u>002</u>	Apr 04, 2014
<u>AB</u>	ATLANTIDE	<u>EQ 500MG BASE</u>	<u>A090216</u>	<u>001</u>	May 24, 2010
<u>AB</u>		<u>EQ 1GM BASE</u>	<u>A090216</u>	<u>002</u>	May 24, 2010
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 500MG BASE</u>	<u>A090682</u>	<u>001</u>	May 24, 2010
<u>AB</u>		<u>EQ 1GM BASE</u>	<u>A090682</u>	<u>002</u>	May 24, 2010
<u>AB</u>	CIPLA	<u>EQ 500MG BASE</u>	<u>A077135</u>	<u>001</u>	May 24, 2010
<u>AB</u>		<u>EQ 1GM BASE</u>	<u>A077135</u>	<u>002</u>	May 24, 2010
<u>AB</u>	HETERO LABS LTD V	<u>EQ 500MG BASE</u>	<u>A203047</u>	<u>001</u>	Apr 08, 2015
<u>AB</u>		<u>EQ 1GM BASE</u>	<u>A203047</u>	<u>002</u>	Apr 08, 2015
<u>AB</u>	JUBILANT GENERICS	<u>EQ 500MG BASE</u>	<u>A201506</u>	<u>001</u>	Apr 03, 2012
<u>AB</u>		<u>EQ 1GM BASE</u>	<u>A201506</u>	<u>002</u>	Apr 03, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 500MG BASE</u>	<u>A078518</u>	<u>001</u>	May 24, 2010
<u>AB</u>		<u>EQ 1GM BASE</u>	<u>A078518</u>	<u>002</u>	May 24, 2010
<u>AB</u>	SANDOZ	<u>EQ 500MG BASE</u>	<u>A077478</u>	<u>001</u>	May 24, 2010
<u>AB</u>		<u>EQ 1GM BASE</u>	<u>A077478</u>	<u>002</u>	May 24, 2010
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 500MG BASE</u>	<u>A076588</u>	<u>001</u>	Jan 31, 2007
<u>AB</u>		<u>EQ 1GM BASE</u>	<u>A076588</u>	<u>002</u>	Jan 31, 2007
<u>AB</u>	TIME-CAP LABS INC	<u>EQ 500MG BASE</u>	<u>A079012</u>	<u>001</u>	May 24, 2010
<u>AB</u>		<u>EQ 1GM BASE</u>	<u>A079012</u>	<u>002</u>	May 24, 2010
<u>AB</u>	YILING	<u>EQ 500MG BASE</u>	<u>A209553</u>	<u>001</u>	Mar 18, 2020
<u>AB</u>		<u>EQ 1GM BASE</u>	<u>A209553</u>	<u>002</u>	Mar 18, 2020
<u>AB</u>	ZYDUS PHARMS	<u>EQ 500MG BASE</u>	<u>A079137</u>	<u>001</u>	Dec 29, 2017
<u>AB</u>		<u>EQ 1GM BASE</u>	<u>A079137</u>	<u>002</u>	Dec 29, 2017

VALTREX

<u>AB</u>	+	GLAXOSMITHKLINE	<u>EQ 500MG BASE</u>	<u>N020487</u>	<u>001</u>	Jun 23, 1995
<u>AB</u>	+	!	<u>EQ 1GM BASE</u>	<u>N020487</u>	<u>002</u>	Jun 23, 1995

VALBENZAZINE TOSYLATE

CAPSULE; ORAL

INGREZZA

+ NEUROCRINE
+!

EQ 40MG BASE
EQ 80MG BASE

N209241 001 Apr 11, 2017
N209241 002 Oct 04, 2017

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION; ORAL

VALCYTE

<u>AB</u>	+	HOFFMANN LA ROCHE	<u>50MG/ML</u>	<u>N022257</u>	<u>001</u>	Aug 28, 2009
<u>AB</u>		ACTAVIS LABS FL INC	<u>50MG/ML</u>	<u>A205220</u>	<u>001</u>	Jul 18, 2016
<u>AB</u>		AJANTA PHARMA LTD	<u>50MG/ML</u>	<u>A212890</u>	<u>001</u>	Jan 13, 2020

TABLET; ORAL

VALCYTE

<u>AB</u>	+	HOFFMANN LA ROCHE	<u>EQ 450MG BASE</u>	<u>N021304</u>	<u>001</u>	Mar 29, 2001
-----------	---	-------------------	----------------------	----------------	------------	--------------

VALGANCICLOVIR HYDROCHLORIDE

<u>AB</u>		AJANTA PHARMA LTD	<u>EQ 450MG BASE</u>	<u>A212234</u>	<u>001</u>	Dec 26, 2019
<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 450MG BASE</u>	<u>A204750</u>	<u>001</u>	Mar 31, 2016
<u>AB</u>		CIPLA	<u>EQ 450MG BASE</u>	<u>A209672</u>	<u>001</u>	Nov 09, 2018
<u>AB</u>		DR REDDYS	<u>EQ 450MG BASE</u>	<u>A206876</u>	<u>001</u>	Dec 12, 2017
<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 450MG BASE</u>	<u>A203511</u>	<u>001</u>	Nov 04, 2014
<u>AB</u>		ENDO PHARMS INC	<u>EQ 450MG BASE</u>	<u>A200790</u>	<u>001</u>	Nov 04, 2014
<u>AB</u>		HETERO LABS LTD V	<u>EQ 450MG BASE</u>	<u>A205166</u>	<u>001</u>	Mar 18, 2016

VALPROATE SODIUM

INJECTABLE; INJECTION

VALPROATE SODIUM

<u>AP</u>		ATHENEX INC	<u>EQ 100MG BASE/ML</u>	<u>A076295</u>	<u>001</u>	Nov 14, 2002
<u>AP</u>		FRESENIUS KABI USA	<u>EQ 100MG BASE/ML</u>	<u>A076539</u>	<u>001</u>	Jun 26, 2003
<u>AP</u>	!	HIKMA FARMACEUTICA	<u>EQ 100MG BASE/ML</u>	<u>A078523</u>	<u>001</u>	Feb 17, 2010

PRESCRIPTION DRUG PRODUCT LIST

VALPROIC ACID

CAPSULE; ORAL

VALPROIC ACID

<u>AB</u>	!	BIONPHARMA INC	<u>250MG</u>	<u>A073484</u>	<u>001</u>	Jun 29, 1993
<u>AB</u>		CATALENT	<u>250MG</u>	<u>A073229</u>	<u>001</u>	Oct 29, 1991
<u>AB</u>		EYWA	<u>250MG</u>	<u>A207611</u>	<u>001</u>	Aug 05, 2019
<u>AB</u>		SUN PHARM INDS LTD	<u>250MG</u>	<u>A091037</u>	<u>001</u>	Feb 22, 2013

SYRUP; ORAL

VALPROIC ACID

<u>AA</u>		HIGH TECH PHARMA	<u>250MG/5ML</u>	<u>A074060</u>	<u>001</u>	Jan 13, 1995
<u>AA</u>		LANNETT CO INC	<u>250MG/5ML</u>	<u>A077960</u>	<u>001</u>	Oct 13, 2006
<u>AA</u>	!	PHARM ASSOC	<u>250MG/5ML</u>	<u>A075379</u>	<u>001</u>	Dec 15, 2000
<u>AA</u>		PHARMA LIFE	<u>250MG/5ML</u>	<u>A090517</u>	<u>001</u>	May 28, 2010
<u>AA</u>		WOCKHARDT BIO AG	<u>250MG/5ML</u>	<u>A070868</u>	<u>001</u>	Jul 01, 1986

VALRUBICIN

SOLUTION; INTRAVESICAL

VALRUBICIN

<u>AO</u>		CUSTOPHARM INC	<u>40MG/ML</u>	<u>A206430</u>	<u>001</u>	Apr 19, 2019
<u>AO</u>	+	ENDO PHARM	<u>40MG/ML</u>	<u>N020892</u>	<u>001</u>	Sep 25, 1998

VALSARTAN

TABLET; ORAL

DIOVAN

<u>AB</u>	+	NOVARTIS	<u>40MG</u>	<u>N021283</u>	<u>004</u>	Aug 14, 2002
<u>AB</u>	+		<u>80MG</u>	<u>N021283</u>	<u>001</u>	Jul 18, 2001
<u>AB</u>	+		<u>160MG</u>	<u>N021283</u>	<u>002</u>	Jul 18, 2001
<u>AB</u>	+		<u>320MG</u>	<u>N021283</u>	<u>003</u>	Jul 18, 2001

VALSARTAN

<u>AB</u>		ALEMBIC PHARMS LTD	<u>40MG</u>	<u>A091367</u>	<u>001</u>	Jan 05, 2015
<u>AB</u>			<u>80MG</u>	<u>A091367</u>	<u>002</u>	Jan 05, 2015
<u>AB</u>			<u>160MG</u>	<u>A091367</u>	<u>003</u>	Jan 05, 2015
<u>AB</u>			<u>320MG</u>	<u>A091367</u>	<u>004</u>	Jan 05, 2015
<u>AB</u>		ALKEM LABS LTD	<u>40MG</u>	<u>A205536</u>	<u>001</u>	Mar 12, 2019
<u>AB</u>			<u>80MG</u>	<u>A205536</u>	<u>002</u>	Mar 12, 2019
<u>AB</u>			<u>160MG</u>	<u>A205536</u>	<u>003</u>	Mar 12, 2019
<u>AB</u>			<u>320MG</u>	<u>A205536</u>	<u>004</u>	Mar 12, 2019
<u>AB</u>		AMNEAL PHARMS	<u>40MG</u>	<u>A204011</u>	<u>001</u>	Jan 11, 2016
<u>AB</u>			<u>80MG</u>	<u>A204011</u>	<u>002</u>	Jan 11, 2016
<u>AB</u>			<u>160MG</u>	<u>A204011</u>	<u>003</u>	Jan 11, 2016
<u>AB</u>			<u>320MG</u>	<u>A204011</u>	<u>004</u>	Jan 11, 2016
<u>AB</u>		AUROBINDO PHARMA LTD	<u>40MG</u>	<u>A202223</u>	<u>001</u>	Jan 05, 2015
<u>AB</u>			<u>80MG</u>	<u>A202223</u>	<u>002</u>	Jan 05, 2015
<u>AB</u>			<u>160MG</u>	<u>A202223</u>	<u>003</u>	Jan 05, 2015
<u>AB</u>			<u>320MG</u>	<u>A202223</u>	<u>004</u>	Jan 05, 2015
<u>AB</u>		HETERO LABS LTD V	<u>40MG</u>	<u>A203311</u>	<u>001</u>	Jan 05, 2015
<u>AB</u>			<u>80MG</u>	<u>A203311</u>	<u>002</u>	Jan 05, 2015
<u>AB</u>			<u>160MG</u>	<u>A203311</u>	<u>003</u>	Jan 05, 2015
<u>AB</u>			<u>320MG</u>	<u>A203311</u>	<u>004</u>	Jan 05, 2015
<u>AB</u>		IVAX PHARMS	<u>40MG</u>	<u>A077530</u>	<u>001</u>	Jan 04, 2016
<u>AB</u>			<u>80MG</u>	<u>A077530</u>	<u>002</u>	Jan 04, 2016
<u>AB</u>			<u>160MG</u>	<u>A077530</u>	<u>003</u>	Jan 04, 2016
<u>AB</u>			<u>320MG</u>	<u>A077530</u>	<u>004</u>	Jan 04, 2016
<u>AB</u>		JUBILANT GENERICS	<u>40MG</u>	<u>A203536</u>	<u>001</u>	Jan 05, 2015
<u>AB</u>			<u>80MG</u>	<u>A203536</u>	<u>002</u>	Jan 05, 2015
<u>AB</u>			<u>160MG</u>	<u>A203536</u>	<u>003</u>	Jan 05, 2015
<u>AB</u>			<u>320MG</u>	<u>A203536</u>	<u>004</u>	Jan 05, 2015
<u>AB</u>		LUPIN LTD	<u>40MG</u>	<u>A201677</u>	<u>001</u>	Jan 05, 2015
<u>AB</u>			<u>80MG</u>	<u>A201677</u>	<u>002</u>	Jan 05, 2015
<u>AB</u>			<u>160MG</u>	<u>A201677</u>	<u>003</u>	Jan 05, 2015
<u>AB</u>			<u>320MG</u>	<u>A201677</u>	<u>004</u>	Jan 05, 2015
<u>AB</u>		MACLEODS PHARMS LTD	<u>40MG</u>	<u>A202696</u>	<u>001</u>	Sep 16, 2016
<u>AB</u>			<u>80MG</u>	<u>A202696</u>	<u>002</u>	Sep 16, 2016
<u>AB</u>			<u>160MG</u>	<u>A202696</u>	<u>003</u>	Sep 16, 2016
<u>AB</u>			<u>320MG</u>	<u>A202696</u>	<u>004</u>	Sep 16, 2016
<u>AB</u>		MYLAN	<u>40MG</u>	<u>A090866</u>	<u>001</u>	Jan 05, 2015
<u>AB</u>			<u>80MG</u>	<u>A090866</u>	<u>002</u>	Jan 05, 2015
<u>AB</u>			<u>160MG</u>	<u>A090866</u>	<u>003</u>	Jan 05, 2015
<u>AB</u>			<u>320MG</u>	<u>A090866</u>	<u>004</u>	Jan 05, 2015
<u>AB</u>		OHM LABS INC	<u>40MG</u>	<u>A077492</u>	<u>001</u>	Jun 26, 2014
<u>AB</u>			<u>80MG</u>	<u>A077492</u>	<u>002</u>	Jun 26, 2014
<u>AB</u>			<u>160MG</u>	<u>A077492</u>	<u>003</u>	Jun 26, 2014

PRESCRIPTION DRUG PRODUCT LIST

VALSARTAN

TABLET; ORAL

VALSARTAN

<u>AB</u>		<u>320MG</u>	<u>A077492</u>	<u>004</u>	Jun 26, 2014
<u>AB</u>	PRINSTON INC	<u>40MG</u>	<u>A204821</u>	<u>001</u>	Jun 09, 2015
<u>AB</u>		<u>80MG</u>	<u>A204821</u>	<u>002</u>	Jun 09, 2015
<u>AB</u>		<u>160MG</u>	<u>A204821</u>	<u>003</u>	Jun 09, 2015
<u>AB</u>		<u>320MG</u>	<u>A204821</u>	<u>004</u>	Jun 09, 2015
<u>AB</u>	SQUARE PHARMS LTD	<u>40MG</u>	<u>A205347</u>	<u>001</u>	Apr 09, 2018
<u>AB</u>		<u>80MG</u>	<u>A205347</u>	<u>002</u>	Apr 09, 2018
<u>AB</u>		<u>160MG</u>	<u>A205347</u>	<u>003</u>	Apr 09, 2018
<u>AB</u>		<u>320MG</u>	<u>A205347</u>	<u>004</u>	Apr 09, 2018

VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

VANCOCIN HYDROCHLORIDE

<u>AB</u>	+	ANI PHARMS INC	<u>EQ 125MG BASE</u>	<u>N050606</u>	<u>001</u>	Apr 15, 1986
<u>AB</u>	+	!	<u>EQ 250MG BASE</u>	<u>N050606</u>	<u>002</u>	Apr 15, 1986
<u>VANCOMYCIN HYDROCHLORIDE</u>						
<u>AB</u>		AKORN	<u>EQ 125MG BASE</u>	<u>A065478</u>	<u>001</u>	Apr 09, 2012
<u>AB</u>			<u>EQ 250MG BASE</u>	<u>A065478</u>	<u>002</u>	Apr 09, 2012
<u>AB</u>		LUPIN LTD	<u>EQ 125MG BASE</u>	<u>A090439</u>	<u>001</u>	Jan 28, 2015
<u>AB</u>			<u>EQ 250MG BASE</u>	<u>A090439</u>	<u>002</u>	Jan 28, 2015
<u>AB</u>		ORIENT PHARMA CO LTD	<u>EQ 125MG BASE</u>	<u>A210729</u>	<u>001</u>	Apr 29, 2019
<u>AB</u>			<u>EQ 250MG BASE</u>	<u>A210729</u>	<u>002</u>	Apr 29, 2019
<u>AB</u>		STRIDES PHARMA	<u>EQ 125MG BASE</u>	<u>A065490</u>	<u>001</u>	Apr 09, 2012
<u>AB</u>			<u>EQ 250MG BASE</u>	<u>A065490</u>	<u>002</u>	Apr 09, 2012
<u>AB</u>		WATSON LABS	<u>EQ 125MG BASE</u>	<u>A065510</u>	<u>001</u>	Apr 09, 2012
<u>AB</u>			<u>EQ 250MG BASE</u>	<u>A065510</u>	<u>002</u>	Apr 09, 2012

FOR SOLUTION; ORAL

FIRVANQ KIT

+! AZURITY

+!

VANCOCIN HYDROCHLORIDE

! ANI PHARMS INC

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

<u>AP</u>		AUROBINDO PHARMA LTD	<u>EQ 500MG BASE/VIAL</u>	<u>A205780</u>	<u>001</u>	Mar 31, 2016
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A205780</u>	<u>002</u>	Mar 31, 2016
<u>AP</u>			<u>EQ 5GM BASE/VIAL</u>	<u>A205779</u>	<u>001</u>	Mar 29, 2016
<u>AP</u>			<u>EQ 10GM BASE/VIAL</u>	<u>A205779</u>	<u>002</u>	Mar 29, 2016
<u>AP</u>	!	FRESENIUS KABI USA	<u>EQ 500MG BASE/VIAL</u>	<u>A062663</u>	<u>001</u>	Mar 17, 1987
<u>AP</u>			<u>EQ 750MG BASE/VIAL</u>	<u>A062663</u>	<u>005</u>	Aug 17, 2016
<u>AP</u>	!		<u>EQ 1GM BASE/VIAL</u>	<u>A062663</u>	<u>002</u>	Jul 31, 1987
<u>AP</u>	!		<u>EQ 5GM BASE/VIAL</u>	<u>A062663</u>	<u>003</u>	Jun 03, 1988
<u>AP</u>	!		<u>EQ 10GM BASE/VIAL</u>	<u>A062663</u>	<u>004</u>	Nov 28, 1997
<u>AP</u>		GLAND PHARMA LTD	<u>EQ 500MG BASE/VIAL</u>	<u>A205694</u>	<u>001</u>	Jan 21, 2016
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A205694</u>	<u>002</u>	Jan 21, 2016
<u>AP</u>		HAINAN POLY PHARM	<u>EQ 500MG BASE/VIAL</u>	<u>A212332</u>	<u>001</u>	Jun 12, 2019
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A212332</u>	<u>002</u>	Jun 12, 2019
<u>AP</u>		HIKMA	<u>EQ 500MG BASE/VIAL</u>	<u>A203300</u>	<u>001</u>	Aug 11, 2020
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A203300</u>	<u>002</u>	Aug 11, 2020
<u>AP</u>			<u>EQ 5GM BASE/VIAL</u>	<u>A204360</u>	<u>001</u>	Oct 15, 2018
<u>AP</u>			<u>EQ 10GM BASE/VIAL</u>	<u>A204360</u>	<u>002</u>	Oct 15, 2018
<u>AP</u>		HIKMA PHARMS	<u>EQ 750MG BASE/VIAL</u>	<u>A206616</u>	<u>001</u>	Oct 03, 2018
<u>AP</u>	!	HOSPIRA	<u>EQ 500MG BASE/VIAL</u>	<u>A062911</u>	<u>001</u>	Aug 04, 1988
<u>AP</u>	!		<u>EQ 500MG BASE/VIAL</u>	<u>A062931</u>	<u>001</u>	Oct 29, 1992
<u>AP</u>	!		<u>EQ 750MG BASE/VIAL</u>	<u>A062912</u>	<u>002</u>	Jan 07, 2009
<u>AP</u>	!		<u>EQ 750MG BASE/VIAL</u>	<u>A062933</u>	<u>002</u>	May 27, 2009
<u>AP</u>	!		<u>EQ 1GM BASE/VIAL</u>	<u>A062912</u>	<u>001</u>	Aug 04, 1988
<u>AP</u>	!		<u>EQ 1GM BASE/VIAL</u>	<u>A062933</u>	<u>001</u>	Oct 29, 1992
<u>AP</u>	!		<u>EQ 5GM BASE/VIAL</u>	<u>A063076</u>	<u>001</u>	Dec 21, 1990
<u>AP</u>			<u>EQ 10GM BASE/VIAL</u>	<u>A063076</u>	<u>002</u>	Sep 14, 2020
<u>AP</u>		HOSPIRA INC	<u>EQ 10GM BASE/VIAL</u>	<u>A065455</u>	<u>001</u>	Apr 29, 2009
<u>AP</u>		MYLAN LABS LTD	<u>EQ 500MG BASE/VIAL</u>	<u>A065397</u>	<u>001</u>	Dec 30, 2008
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A065397</u>	<u>002</u>	Dec 30, 2008
<u>AP</u>			<u>EQ 5GM BASE/VIAL</u>	<u>A065432</u>	<u>001</u>	Dec 30, 2008
<u>AP</u>	!		<u>EQ 10GM BASE/VIAL</u>	<u>A091554</u>	<u>001</u>	Sep 19, 2011
<u>AP</u>		PHARM ASSOC	<u>EQ 500MG BASE/VIAL</u>	<u>A065401</u>	<u>001</u>	Jun 30, 2008
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A065401</u>	<u>002</u>	Jun 30, 2008
<u>AP</u>		SAGENT PHARMS	<u>EQ 5GM BASE/VIAL</u>	<u>A200837</u>	<u>001</u>	Aug 10, 2012

PRESCRIPTION DRUG PRODUCT LIST

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A200837 002</u>	Sep 02, 2014
<u>AP</u>	SANDOZ	<u>EQ 500MG BASE/VIAL</u>	<u>A090250 001</u>	Apr 27, 2010
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A090250 002</u>	Apr 27, 2010
<u>AP</u>	SANDOZ INC	<u>EQ 5GM BASE/VIAL</u>	<u>A201048 001</u>	Aug 10, 2012
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A201048 002</u>	Aug 10, 2012
<u>AP</u>	XELLIA PHARMS APS	<u>EQ 5GM BASE/VIAL</u>	<u>A204125 001</u>	Dec 28, 2015
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A204125 002</u>	Dec 28, 2015
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A204107 001</u>	Dec 28, 2015
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A204107 002</u>	Dec 28, 2015
VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER				
+	BAXTER HLTHCARE	EQ 500MG BASE/100ML	N050671 001	Apr 29, 1993
+		EQ 750MG BASE/150ML	N050671 002	Dec 20, 2010
+		EQ 1GM BASE/200ML	N050671 003	Mar 01, 1999

POWDER; INTRAVENOUS

VANCOMYCIN HYDROCHLORIDE

+	MYLAN LABS LTD	EQ 250MG BASE/VIAL	N209481 001	Jul 10, 2018
+		EQ 750MG BASE/VIAL	N209481 002	Jul 10, 2018
+		EQ 1.25GM BASE/VIAL	N209481 003	Jul 10, 2018
+		EQ 1.5GM BASE/VIAL	N209481 004	Jul 10, 2018

VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER

	SAMSON MEDCL	EQ 100GM BASE	A091532 001	Jan 06, 2016
--	--------------	---------------	-------------	--------------

SOLUTION; INTRAVENOUS

VANCOMYCIN HYDROCHLORIDE

+	XELLIA PHARMS APS	EQ 500MG BASE/100ML (EQ 5MG BASE/ML)	N211962 001	Feb 15, 2019
+		EQ 750MG BASE/150ML (EQ 5MG BASE/ML)	N211962 005	May 13, 2020
+		EQ 1GM BASE/200ML (EQ 5MG BASE/ML)	N211962 002	Feb 15, 2019
+		EQ 1.25GM BASE/250ML (EQ 5MG BASE/ML)	N211962 006	May 13, 2020
+		EQ 1.5GM BASE/300ML (EQ 5MG BASE/ML)	N211962 003	Feb 15, 2019
+		EQ 1.75GM BASE/350ML (EQ 5MG BASE/ML)	N211962 007	May 13, 2020
+		EQ 2GM BASE/400ML (EQ 5MG BASE/ML)	N211962 004	Feb 15, 2019

VANDETANIB

TABLET; ORAL

CAPRELSA

+	GENZYME CORP	100MG	N022405 001	Apr 06, 2011
+		300MG	N022405 002	Apr 06, 2011

VARDENAFIL HYDROCHLORIDE

TABLET; ORAL

LEVITRA

<u>AB</u>	+	BAYER HLTHCARE	<u>EQ 5MG BASE</u>	<u>N021400 001</u>	Aug 19, 2003
<u>AB</u>	+		<u>EQ 10MG BASE</u>	<u>N021400 002</u>	Aug 19, 2003
<u>AB</u>	+		<u>EQ 20MG BASE</u>	<u>N021400 004</u>	Aug 19, 2003

VARDENAFIL HYDROCHLORIDE

<u>AB</u>		ALEMBIC PHARMS LTD	<u>EQ 2.5MG BASE</u>	<u>A214031 001</u>	Aug 04, 2020
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>A214031 002</u>	Aug 04, 2020
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A214031 003</u>	Aug 04, 2020
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A214031 004</u>	Aug 04, 2020
<u>AB</u>		CROSSMEDIKA SA	<u>EQ 2.5MG BASE</u>	<u>A209057 001</u>	Oct 31, 2018
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>A209057 002</u>	Oct 31, 2018
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A209057 003</u>	Oct 31, 2018
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A209057 004</u>	Oct 31, 2018
<u>AB</u>		MACLEODS PHARMS LTD	<u>EQ 2.5MG BASE</u>	<u>A204632 001</u>	Oct 22, 2019
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>A204632 002</u>	Oct 22, 2019
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A204632 003</u>	Oct 22, 2019
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A204632 004</u>	Oct 22, 2019
<u>AB</u>		TEVA PHARMS	<u>EQ 2.5MG BASE</u>	<u>A091347 001</u>	May 03, 2012
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>A091347 002</u>	May 03, 2012
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A091347 003</u>	May 03, 2012
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A091347 004</u>	May 03, 2012
<u>AB</u>		ZYDUS PHARMS	<u>EQ 2.5MG BASE</u>	<u>A208960 001</u>	Oct 31, 2018
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>A208960 002</u>	Oct 31, 2018
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A208960 003</u>	Oct 31, 2018
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A208960 004</u>	Oct 31, 2018

TABLET, ORALLY DISINTEGRATING; ORAL

STAXYN

<u>AB</u>	+	BAYER HLTHCARE	<u>10MG</u>	<u>N200179 001</u>	Jun 17, 2010
-----------	---	----------------	-------------	--------------------	--------------

VARDENAFIL HYDROCHLORIDE

<u>AB</u>		ALEMBIC PHARMS LTD	<u>10MG</u>	<u>A208324 001</u>	Nov 16, 2018
<u>AB</u>		MACLEODS PHARMS LTD	<u>10MG</u>	<u>A205988 001</u>	Mar 10, 2020

PRESCRIPTION DRUG PRODUCT LIST

VARENICLINE TARTRATE

TABLET; ORAL

CHANTIX

+	PF PRISM CV	EQ 0.5MG BASE	N021928	001	May 10, 2006
+	!	EQ 1MG BASE	N021928	002	May 10, 2006

VASOPRESSIN

SOLUTION; INTRAVENOUS

VASOPRESSIN

+	!	AM REGENT	20UNITS/ML (20UNITS/ML)	N212593	001	Aug 03, 2020
---	---	-----------	-------------------------	---------	-----	--------------

VASOSTRICT

+	!	PAR STERILE PRODUCTS	20UNITS/ML (20UNITS/ML)	N204485	001	Apr 17, 2014
+	!		40UNITS/100ML (0.4UNITS/ML)	N204485	003	Apr 15, 2020
+	!		60UNITS/100ML (0.6UNITS/ML)	N204485	004	Apr 15, 2020
+	!		200UNITS/10ML (20UNITS/ML)	N204485	002	Dec 17, 2016

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

AP		AUROBINDO PHARMA LTD	10MG/VIAL	A206670	001	Dec 20, 2018
AP			20MG/VIAL	A206670	002	Dec 20, 2018
AP		GLAND PHARMA LTD	10MG/VIAL	A205390	001	May 26, 2016
AP			20MG/VIAL	A205390	002	May 26, 2016
AP		HIKMA	10MG/VIAL	A203725	001	Jul 30, 2019
AP			20MG/VIAL	A203725	002	Jul 30, 2019
AP		HOSPIRA	10MG/VIAL	A075164	001	Oct 21, 1999
AP			20MG/VIAL	A075164	002	Oct 21, 1999
AP		MYLAN LABS LTD	10MG/VIAL	A090243	001	May 11, 2010
AP			20MG/VIAL	A090243	002	May 11, 2010
AP		SAGENT PHARMS INC	10MG/VIAL	A078274	001	Dec 29, 2008
AP			20MG/VIAL	A078274	002	Dec 29, 2008
AP	!	SUN PHARM	10MG/VIAL	A079001	001	Jun 17, 2009
AP	!		20MG/VIAL	A079001	002	Jun 17, 2009
AP		TEVA PHARMS USA	10MG/VIAL	A074688	001	Aug 25, 1999
AP			20MG/VIAL	A074688	002	Aug 25, 1999
AP		WEST-WARD PHARMS INT	10MG/VIAL	A075549	001	Jun 13, 2000
AP			20MG/VIAL	A075549	002	Jun 13, 2000

VEMURAFENIB

TABLET; ORAL

ZELBORAF

+	!	HOFFMANN LA ROCHE	240MG	N202429	001	Aug 17, 2011
---	---	-------------------	-------	---------	-----	--------------

VENETOCLAX

TABLET; ORAL

VENCLEXTA

+		ABBVIE INC	10MG	N208573	001	Apr 11, 2016
+			50MG	N208573	002	Apr 11, 2016
+	!		100MG	N208573	003	Apr 11, 2016

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

EFFEXOR XR

AB	+	UPJOHN	EQ 37.5MG BASE	N020699	001	Oct 20, 1997
AB	+		EQ 75MG BASE	N020699	002	Oct 20, 1997
AB	+	!	EQ 150MG BASE	N020699	004	Oct 20, 1997

VENLAFAXINE HYDROCHLORIDE

AB		ANNORA PHARMA	EQ 37.5MG BASE	A212277	001	Jul 08, 2019
AB			EQ 75MG BASE	A212277	002	Jul 08, 2019
AB			EQ 150MG BASE	A212277	003	Jul 08, 2019
AB		ATLANTIDE	EQ 37.5MG BASE	A078865	001	Apr 14, 2011
AB			EQ 75MG BASE	A078865	002	Apr 14, 2011
AB			EQ 150MG BASE	A078865	003	Apr 14, 2011
AB		AUROBINDO PHARMA LTD	EQ 37.5MG BASE	A200834	001	Apr 14, 2011
AB			EQ 75MG BASE	A200834	002	Apr 14, 2011
AB			EQ 150MG BASE	A200834	003	Apr 14, 2011
AB		DR REDDYS LABS LTD	EQ 37.5MG BASE	A078421	001	May 06, 2011
AB			EQ 75MG BASE	A078421	002	May 06, 2011
AB			EQ 150MG BASE	A078421	003	May 06, 2011
AB		INTELLIPHARMACEUTIC S	EQ 37.5MG BASE	A201272	001	Nov 23, 2018
AB			EQ 75MG BASE	A201272	002	Nov 23, 2018

PRESCRIPTION DRUG PRODUCT LIST

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A201272 003</u>	Nov 23, 2018
<u>AB</u>	INVENTIA HLTHCARE	<u>EQ 37.5MG BASE</u>	<u>A203332 001</u>	Mar 12, 2020
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A203332 002</u>	Mar 12, 2020
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A203332 003</u>	Mar 12, 2020
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 37.5MG BASE</u>	<u>A204889 001</u>	Oct 05, 2017
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A204889 002</u>	Oct 05, 2017
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A204889 003</u>	Oct 05, 2017
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 37.5MG BASE</u>	<u>A091123 001</u>	Jul 11, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A091123 002</u>	Jul 11, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A091123 003</u>	Jul 11, 2011
<u>AB</u>	TEVA	<u>EQ 37.5MG BASE</u>	<u>A076565 001</u>	Jun 28, 2010
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A076565 002</u>	Jun 28, 2010
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A076565 003</u>	Jun 28, 2010
<u>AB</u>	TORRENT PHARMS LLC	<u>EQ 37.5MG BASE</u>	<u>A090899 001</u>	Jun 01, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A090899 002</u>	Jun 01, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A090899 003</u>	Jun 01, 2011
<u>AB</u>	VALEANT PHARMS NORTH	<u>EQ 37.5MG BASE</u>	<u>A090071 001</u>	Apr 15, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A090071 002</u>	Apr 15, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A090071 003</u>	Apr 15, 2011
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 37.5MG BASE</u>	<u>A090174 001</u>	Apr 14, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A090174 002</u>	Apr 14, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A090174 003</u>	Apr 14, 2011

TABLET;ORAL

VENLAFAXINE HYDROCHLORIDE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>EQ 25MG BASE</u>	<u>A078932 001</u>	Dec 14, 2010
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A078932 002</u>	Dec 14, 2010
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078932 003</u>	Dec 14, 2010
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078932 004</u>	Dec 14, 2010
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078932 005</u>	Dec 14, 2010
<u>AB</u>	AMNEAL PHARMS	<u>EQ 25MG BASE</u>	<u>A079098 001</u>	May 11, 2010
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A079098 002</u>	May 11, 2010
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A079098 003</u>	May 11, 2010
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A079098 004</u>	May 11, 2010
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A079098 005</u>	May 11, 2010
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 25MG BASE</u>	<u>A090555 001</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A090555 002</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A090555 003</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A090555 004</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A090555 005</u>	Apr 07, 2010
<u>AB</u>	CADILA PHARMS LTD	<u>EQ 25MG BASE</u>	<u>A206250 001</u>	Nov 21, 2018
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A206250 002</u>	Nov 21, 2018
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A206250 003</u>	Nov 21, 2018
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A206250 004</u>	Nov 21, 2018
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A206250 005</u>	Nov 21, 2018
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 25MG BASE</u>	<u>A078301 001</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A078301 002</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078301 003</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078301 004</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078301 005</u>	Jun 13, 2008
<u>AB</u>	HERITAGE PHARMS INC	<u>EQ 25MG BASE</u>	<u>A078554 001</u>	Jan 09, 2009
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A078554 002</u>	Jan 09, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078554 003</u>	Jan 09, 2009
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078554 004</u>	Jan 09, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078554 005</u>	Jan 09, 2009
<u>AB</u>	MYLAN	<u>EQ 25MG BASE</u>	<u>A077166 001</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A077166 002</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077166 003</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A077166 004</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077166 005</u>	Jun 13, 2008
<u>AB</u>	SUN PHARM INDS INC	<u>EQ 25MG BASE</u>	<u>A078627 001</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A078627 002</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078627 003</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078627 004</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078627 005</u>	Jun 13, 2008
<u>AB</u>	TEVA	<u>EQ 25MG BASE</u>	<u>A076690 001</u>	Aug 03, 2006
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A076690 002</u>	Aug 03, 2006
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076690 003</u>	Aug 03, 2006
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A076690 004</u>	Aug 03, 2006

PRESCRIPTION DRUG PRODUCT LIST

VENLAFAXINE HYDROCHLORIDE

TABLET; ORAL

VENLAFAXINE HYDROCHLORIDE

<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076690 005</u>	Aug 03, 2006
<u>AB</u>	YAOPHARMA CO LTD	<u>EQ 25MG BASE</u>	<u>A202036 001</u>	May 28, 2015
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A202036 002</u>	May 28, 2015
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A202036 003</u>	May 28, 2015
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A202036 004</u>	May 28, 2015
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A202036 005</u>	May 28, 2015
<u>AB</u>	ZYDUS PHARMS USA	<u>EQ 25MG BASE</u>	<u>A077653 001</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A077653 002</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077653 003</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A077653 004</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077653 005</u>	Jun 13, 2008

TABLET, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

<u>AB</u>	ASCENT PHARMS INC	<u>EQ 37.5MG BASE</u>	<u>A214419 001</u>	Oct 21, 2020
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A214419 002</u>	Oct 21, 2020
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A214419 003</u>	Oct 21, 2020
<u>AB</u>		<u>EQ 225MG BASE</u>	<u>A214419 004</u>	Oct 21, 2020
<u>AB</u>	CADILA PHARMS LTD	<u>EQ 75MG BASE</u>	<u>A211323 001</u>	Aug 29, 2019
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A211323 002</u>	Aug 29, 2019
<u>AB</u>		<u>EQ 225MG BASE</u>	<u>A211323 003</u>	Aug 29, 2019
<u>AB</u>	DEXCEL PHARMA	<u>EQ 150MG BASE</u>	<u>A209193 001</u>	Oct 31, 2019
<u>AB</u>		<u>EQ 225MG BASE</u>	<u>A209193 002</u>	Oct 31, 2019
<u>AB</u>	NOSTRUM LABS INC	<u>EQ 150MG BASE</u>	<u>A205468 002</u>	Mar 24, 2017
<u>AB</u>		<u>EQ 225MG BASE</u>	<u>A205468 003</u>	Mar 24, 2017
<u>AB</u>	+ OSMOTICA PHARM	<u>EQ 37.5MG BASE</u>	<u>N022104 001</u>	May 20, 2008
<u>AB</u>	+	<u>EQ 75MG BASE</u>	<u>N022104 002</u>	May 20, 2008
<u>AB</u>	+!	<u>EQ 150MG BASE</u>	<u>N022104 003</u>	May 20, 2008
<u>AB</u>	+	<u>EQ 225MG BASE</u>	<u>N022104 004</u>	May 20, 2008
<u>AB</u>	SUN PHARM	<u>EQ 37.5MG BASE</u>	<u>A091272 001</u>	Aug 18, 2010
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A091272 002</u>	Aug 18, 2010
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A091272 003</u>	Aug 18, 2010
<u>AB</u>		<u>EQ 225MG BASE</u>	<u>A091272 004</u>	Jan 08, 2019

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VERAPAMIL HYDROCHLORIDE

<u>AB</u>	MYLAN	<u>120MG</u>	<u>A075138 001</u>	Apr 20, 1999
<u>AB</u>		<u>180MG</u>	<u>A075138 002</u>	Apr 20, 1999
<u>AB</u>		<u>240MG</u>	<u>A075138 003</u>	Apr 20, 1999
<u>VERELAN</u>				
<u>AB</u>	+ RECRO GAINESVILLE	<u>120MG</u>	<u>N019614 001</u>	May 29, 1990
<u>AB</u>	+	<u>180MG</u>	<u>N019614 003</u>	Jan 09, 1992
<u>AB</u>	+	<u>240MG</u>	<u>N019614 002</u>	May 29, 1990
	+!	360MG	N019614 004	May 10, 1996
VERELAN PM				
	+ RECRO GAINESVILLE	100MG	N020943 001	Nov 25, 1998
	+	200MG	N020943 002	Nov 25, 1998
	+!	300MG	N020943 003	Nov 25, 1998

INJECTABLE; INJECTION

VERAPAMIL HYDROCHLORIDE

<u>AP</u>	! AUROBINDO PHARMA LTD	<u>2.5MG/ML</u>	<u>A212965 001</u>	Jul 06, 2020
<u>AP</u>	GLAND PHARMA LTD	<u>2.5MG/ML</u>	<u>A214361 001</u>	Oct 15, 2020
<u>AP</u>	ZYDUS PHARMS	<u>2.5MG/ML</u>	<u>A214215 001</u>	Oct 15, 2020

SOLUTION; INTRAVENOUS

VERAPAMIL HYDROCHLORIDE

<u>AP</u>	AMNEAL	<u>5MG/2ML (2.5MG/ML)</u>	<u>A210994 001</u>	Jul 13, 2018
<u>AP</u>		<u>10MG/4ML (2.5MG/ML)</u>	<u>A210994 002</u>	Jul 13, 2018
<u>AP</u>	AREVA PHARMS	<u>5MG/2ML (2.5MG/ML)</u>	<u>A213352 002</u>	Sep 16, 2020
<u>AP</u>		<u>10MG/4ML (2.5MG/ML)</u>	<u>A213352 001</u>	Mar 17, 2020
<u>AP</u>	CAPLIN	<u>5MG/2ML (2.5MG/ML)</u>	<u>A213232 001</u>	Mar 25, 2020
<u>AP</u>		<u>10MG/4ML (2.5MG/ML)</u>	<u>A213232 002</u>	Mar 25, 2020
<u>AP</u>	EXELA PHARMA	<u>5MG/2ML (2.5MG/ML)</u>	<u>N018925 001</u>	Mar 30, 1984
<u>AP</u>	! HOSPIRA	<u>5MG/2ML (2.5MG/ML)</u>	<u>A070738 001</u>	May 06, 1987
<u>AP</u>	!	<u>5MG/2ML (2.5MG/ML)</u>	<u>A075136 001</u>	Oct 20, 1998
<u>AP</u>	!	<u>5MG/2ML (2.5MG/ML)</u>	<u>A070737 001</u>	May 06, 1987
<u>AP</u>	!	<u>10MG/4ML (2.5MG/ML)</u>	<u>A070737 002</u>	May 06, 1987
<u>AP</u>	MICRO LABS	<u>5MG/2ML (2.5MG/ML)</u>	<u>A211370 001</u>	Dec 28, 2018
<u>AP</u>		<u>10MG/4ML (2.5MG/ML)</u>	<u>A211370 002</u>	Dec 28, 2018
<u>AP</u>	SOMERSET	<u>5MG/2ML (2.5MG/ML)</u>	<u>A211035 001</u>	Jun 18, 2018

PRESCRIPTION DRUG PRODUCT LIST

VERAPAMIL HYDROCHLORIDE

SOLUTION;INTRAVENOUS

VERAPAMIL HYDROCHLORIDE

<u>AP</u>		<u>10MG/4ML (2.5MG/ML)</u>	<u>A211035 002</u>	Jun 18, 2018
<u>AP</u>	SOMERSET THERAPS LLC	<u>5MG/2ML (2.5MG/ML)</u>	<u>A211015 001</u>	Jun 18, 2018
<u>AP</u>		<u>10MG/4ML (2.5MG/ML)</u>	<u>A211015 002</u>	Jun 18, 2018

TABLET;ORAL

VERAPAMIL HYDROCHLORIDE

<u>AB</u>	HERITAGE PHARMS INC	<u>40MG</u>	<u>A071881 002</u>	Oct 14, 2015
<u>AB</u>		<u>80MG</u>	<u>A071881 003</u>	Apr 05, 1988
<u>AB</u>	!	<u>120MG</u>	<u>A071881 001</u>	Apr 05, 1988
<u>AB</u>	WATSON LABS	<u>40MG</u>	<u>A072924 001</u>	Jun 29, 1993
<u>AB</u>		<u>80MG</u>	<u>A070995 001</u>	Oct 01, 1986
<u>AB</u>		<u>120MG</u>	<u>A070994 001</u>	Oct 01, 1986

TABLET, EXTENDED RELEASE;ORAL

CALAN SR

<u>AB</u>	+! PFIZER	<u>120MG</u>	<u>N019152 003</u>	Mar 06, 1991
<u>AB</u>	+!	<u>240MG</u>	<u>N019152 001</u>	Dec 16, 1986

VERAPAMIL HYDROCHLORIDE

<u>AB</u>	CADILA PHARMS LTD	<u>180MG</u>	<u>A206173 001</u>	May 05, 2017
<u>AB</u>		<u>240MG</u>	<u>A206173 002</u>	May 05, 2017
<u>AB</u>	GLENMARK GENERICS	<u>120MG</u>	<u>A090700 001</u>	Aug 03, 2011
<u>AB</u>	!	<u>180MG</u>	<u>A090700 002</u>	Aug 03, 2011
<u>AB</u>		<u>240MG</u>	<u>A078906 001</u>	Sep 17, 2009
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>120MG</u>	<u>A073568 002</u>	Oct 10, 1997
<u>AB</u>		<u>180MG</u>	<u>A074330 001</u>	Jan 31, 1994
<u>AB</u>		<u>240MG</u>	<u>A073568 001</u>	Jul 31, 1992
<u>AB</u>	MYLAN	<u>120MG</u>	<u>A074587 002</u>	Feb 21, 1997
<u>AB</u>		<u>180MG</u>	<u>A074587 003</u>	Sep 09, 1997
<u>AB</u>		<u>240MG</u>	<u>A074587 001</u>	Mar 23, 1996
<u>AB</u>	PAR PHARM	<u>120MG</u>	<u>A075072 001</u>	May 25, 1999
<u>AB</u>		<u>240MG</u>	<u>A075072 003</u>	May 25, 1999
<u>AB</u>	SUN PHARM INDS INC	<u>120MG</u>	<u>A090529 001</u>	Dec 30, 2011
<u>AB</u>		<u>180MG</u>	<u>A090529 002</u>	Dec 30, 2011
<u>AB</u>		<u>240MG</u>	<u>A090529 003</u>	Dec 30, 2011

VERTEPORFIN

INJECTABLE;INJECTION

VISUDYNE

+!	VALEANT LUXEMBOURG	15MG/VIAL	N021119 001	Apr 12, 2000
----	--------------------	-----------	-------------	--------------

VIBEGRON

TABLET;ORAL

GEMTESA

+!	UROVANT	75MG	N213006 001	Dec 23, 2020
----	---------	------	-------------	--------------

VIGABATRIN

FOR SOLUTION;ORAL

SABRIL

<u>AA</u>	+! LUNDBECK PHARMS LLC	<u>500MG/PACKET</u>	<u>N022006 001</u>	Aug 21, 2009
-----------	------------------------	---------------------	--------------------	--------------

VIGABATRIN

<u>AA</u>	ACCORD HLTHCARE	<u>500MG/PACKET</u>	<u>A214425 001</u>	Nov 13, 2020
<u>AA</u>	ALKEM LABS LTD	<u>500MG/PACKET</u>	<u>A213375 001</u>	Dec 02, 2020
<u>AA</u>	AMNEAL PHARMS	<u>500MG/PACKET</u>	<u>A210155 001</u>	Mar 13, 2018
<u>AA</u>	DR REDDYS LABS LTD	<u>500MG/PACKET</u>	<u>A211481 001</u>	Nov 20, 2018
<u>AA</u>	GRANULES PHARMS	<u>500MG/PACKET</u>	<u>A213469 001</u>	Apr 24, 2020
<u>AA</u>	INVAGEN PHARMS	<u>500MG/PACKET</u>	<u>A211592 001</u>	Dec 03, 2019
<u>AA</u>	PAR PHARM INC	<u>500MG/PACKET</u>	<u>A208218 001</u>	Apr 27, 2017
<u>AA</u>	TEVA PHARMS USA	<u>500MG/PACKET</u>	<u>A209824 001</u>	Apr 23, 2018

VIGADRONE

<u>AA</u>	AUCTA	<u>500MG/PACKET</u>	<u>A210196 001</u>	Jun 21, 2018
-----------	-------	---------------------	--------------------	--------------

TABLET;ORAL

SABRIL

<u>AB</u>	+! LUNDBECK PHARMS LLC	<u>500MG</u>	<u>N020427 001</u>	Aug 21, 2009
-----------	------------------------	--------------	--------------------	--------------

VIGABATRIN

<u>AB</u>	TEVA PHARMS USA	<u>500MG</u>	<u>A209822 001</u>	Jan 14, 2019
-----------	-----------------	--------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

VILAZODONE HYDROCHLORIDE

TABLET; ORAL

VIIBRYD

AB	+ !	ALLERGAN	10MG	N022567 001	Jan 21, 2011
AB	+		20MG	N022567 002	Jan 21, 2011
AB	+		40MG	N022567 003	Jan 21, 2011

VILAZODONE HYDROCHLORIDE

AB		ALEMBIC PHARMS LTD	10MG	A208202 001	Jan 10, 2020
AB			20MG	A208202 002	Jan 10, 2020
AB			40MG	A208202 003	Jan 10, 2020

VILTOLARSEN

SOLUTION; INTRAVENOUS

VILTEPSO

+ !	NIPPON SHINYAKU	250MG/5ML (50MG/ML)	N212154 001	Aug 12, 2020
------------	-----------------	---------------------	-------------	--------------

VINBLASTINE SULFATE

INJECTABLE; INJECTION

VINBLASTINE SULFATE

!	FRESENIUS KABI USA	1MG/ML	A089515 001	Apr 29, 1987
!	WEST-WARD PHARMS	10MG/VIAL	A089395 001	Apr 09, 1987

INT

VINCRIStINE SULFATE

INJECTABLE; INJECTION

VINCRIStINE SULFATE PFS

AP	!	HOSPIRA	1MG/ML	A071484 001	Apr 19, 1988
AP		TEVA PHARMS USA	1MG/ML	A075493 001	Sep 01, 1999

INJECTABLE, LIPOSOMAL; INTRAVENOUS

+ !	ACROTECH	5MG/5ML (1MG/ML)	N202497 001	Aug 09, 2012
------------	----------	------------------	-------------	--------------

MARQIBO KIT

VINORELBINE TARTRATE

INJECTABLE; INJECTION

VINORELBINE TARTRATE

AP		ACTAVIS TOTOWA	EQ 10MG BASE/ML	A078011 001	Jul 22, 2009
AP		DR REDDYS	EQ 10MG BASE/ML	A202017 001	Sep 12, 2013
AP		FRESENIUS KABI USA	EQ 10MG BASE/ML	A076849 001	Apr 18, 2005
AP		JIANGSU HANSON PHARM	EQ 10MG BASE/ML	A091106 001	Sep 26, 2012
AP		TEVA PHARMS USA	EQ 10MG BASE/ML	A076028 001	Feb 03, 2003
AP		WEST-WARD PHARMS	EQ 10MG BASE/ML	A075992 001	Jun 10, 2003
AP		INT	EQ 10MG BASE/ML	A076461 001	Dec 11, 2003

VISMODEGIB

CAPSULE; ORAL

ERIVEDGE

+ !	GENENTECH	150MG	N203388 001	Jan 30, 2012
------------	-----------	-------	-------------	--------------

VITAMIN A PALMITATE

INJECTABLE; INJECTION

AQUASOL A

+ !	CASPER PHARMA LLC	EQ 50,000 UNITS BASE/ML	N006823 001	
------------	-------------------	-------------------------	-------------	--

VORAPAXAR SULFATE

TABLET; ORAL

ZONTIVITY

+ !	XSPIRE PHARMA	EQ 2.08MG BASE	N204886 001	May 08, 2014
------------	---------------	----------------	-------------	--------------

VORICONAZOLE

FOR SUSPENSION; ORAL

VFEND

AB	+ !	PF PRISM CV	200MG/5ML	N021630 001	Dec 19, 2003
-----------	------------	-------------	------------------	--------------------	--------------

VORICONAZOLE

AB		AMNEAL PHARMS	200MG/5ML	A205034 001	Apr 13, 2016
AB		NOVEL LABS INC	200MG/5ML	A206799 001	May 31, 2016

INJECTABLE; INTRAVENOUS

VFEND

AP	+ !	PF PRISM CV	200MG/VIAL	N021267 001	May 24, 2002
-----------	------------	-------------	-------------------	--------------------	--------------

VORICONAZOLE

AP		ALVOGEN	200MG/VIAL	A206398 001	Mar 23, 2016
AP		GLAND PHARMA LTD	200MG/VIAL	A211099 001	Mar 31, 2020
AP		HAINAN POLY PHARM	200MG/VIAL	A211661 001	Nov 30, 2018
AP		SANDOZ INC	200MG/VIAL	A090862 001	May 30, 2012
AP		ZYDUS PHARMS	200MG/VIAL	A208983 001	Jul 16, 2018

PRESCRIPTION DRUG PRODUCT LIST

VORICONAZOLE

POWDER; INTRAVENOUS

VORICONAZOLE

AP	XELLIA PHARMS APS	200MG/VIAL	N208562 001	Mar 09, 2017
-----------	-------------------	-------------------	--------------------	--------------

TABLET; ORAL

VFEND

AB	+	PF PRISM CV	50MG	N021266 001	May 24, 2002
AB	+	!	200MG	N021266 002	May 24, 2002

VORICONAZOLE

AB		AJANTA PHARMA LTD	50MG	A206181 001	May 24, 2016
AB			200MG	A206181 002	May 24, 2016
AB		AKORN	50MG	A207049 001	Sep 07, 2016
AB			200MG	A207049 002	Sep 07, 2016
AB		AUROBINDO PHARMA LTD	50MG	A206837 001	Jan 22, 2016
AB			200MG	A206837 002	Jan 22, 2016
AB		CADILA	50MG	A206747 001	May 24, 2016
AB			200MG	A206747 002	May 24, 2016
AB		GLENMARK PHARMS LTD	50MG	A203503 001	Sep 02, 2015
AB			200MG	A203503 002	Sep 02, 2015
AB		MYLAN PHARMS INC	50MG	A090547 001	Apr 22, 2010
AB			200MG	A090547 002	Apr 22, 2010
AB		NOVEL LABS INC	50MG	A207371 001	May 24, 2016
AB			200MG	A207371 002	May 24, 2016
AB		PRINSTON INC	50MG	A206654 001	Aug 08, 2016
AB			200MG	A206654 002	Aug 08, 2016
AB		RISING	50MG	A206762 001	May 24, 2016
AB			200MG	A206762 002	May 24, 2016
AB		SANDOZ INC	50MG	A200265 001	Dec 12, 2011
AB			200MG	A200265 002	Dec 12, 2011

VORINOSTAT

CAPSULE; ORAL

ZOLINZA

+	!	MERCK	100MG	N021991 001	Oct 06, 2006
---	---	-------	-------	-------------	--------------

VORTIOXETINE HYDROBROMIDE

TABLET; ORAL

TRINTELLIX

+		TAKEDA PHARMS USA	EQ 5MG BASE	N204447 001	Sep 30, 2013
+			EQ 10MG BASE	N204447 002	Sep 30, 2013
+	!		EQ 20MG BASE	N204447 004	Sep 30, 2013

VOXELOTOR

TABLET; ORAL

OXBRYTA

+	!	GLOBAL BLOOD THERAPS	500MG	N213137 001	Nov 25, 2019
---	---	----------------------	-------	-------------	--------------

WARFARIN SODIUM

TABLET; ORAL

JANTOVEN

AB		UPSHER SMITH LABS	1MG	A040416 001	Oct 02, 2003
AB			2MG	A040416 002	Oct 02, 2003
AB			2.5MG	A040416 003	Oct 02, 2003
AB			3MG	A040416 004	Oct 02, 2003
AB			4MG	A040416 005	Oct 02, 2003
AB			5MG	A040416 006	Oct 02, 2003
AB			6MG	A040416 007	Oct 02, 2003
AB			7.5MG	A040416 008	Oct 02, 2003
AB			10MG	A040416 009	Oct 02, 2003

WARFARIN SODIUM

AB		AMNEAL PHARMS	1MG	A202202 001	Mar 04, 2013
AB			2MG	A202202 002	Mar 04, 2013
AB			2.5MG	A202202 003	Mar 04, 2013
AB			3MG	A202202 004	Mar 04, 2013
AB			4MG	A202202 005	Mar 04, 2013
AB			5MG	A202202 006	Mar 04, 2013
AB			6MG	A202202 007	Mar 04, 2013
AB			7.5MG	A202202 008	Mar 04, 2013
AB			10MG	A202202 009	Mar 04, 2013
AB		BARR	1MG	A040145 001	Mar 26, 1997
AB			2MG	A040145 002	Mar 26, 1997
AB			2.5MG	A040145 003	Mar 26, 1997
AB			3MG	A040145 008	Nov 05, 1998

PRESCRIPTION DRUG PRODUCT LIST

WARFARIN SODIUM

TABLET; ORAL

WARFARIN SODIUM

<u>AB</u>		<u>4MG</u>	<u>A040145</u>	<u>004</u>	Mar 26, 1997
<u>AB</u>		<u>5MG</u>	<u>A040145</u>	<u>005</u>	Mar 26, 1997
<u>AB</u>		<u>6MG</u>	<u>A040145</u>	<u>009</u>	Nov 05, 1998
<u>AB</u>		<u>7.5MG</u>	<u>A040145</u>	<u>006</u>	Mar 26, 1997
<u>AB</u>		<u>10MG</u>	<u>A040145</u>	<u>007</u>	Mar 26, 1997
<u>AB</u>	INVAGEN PHARMS	<u>1MG</u>	<u>A090935</u>	<u>001</u>	May 25, 2011
<u>AB</u>		<u>2MG</u>	<u>A090935</u>	<u>002</u>	May 25, 2011
<u>AB</u>		<u>2.5MG</u>	<u>A090935</u>	<u>003</u>	May 25, 2011
<u>AB</u>		<u>3MG</u>	<u>A090935</u>	<u>004</u>	May 25, 2011
<u>AB</u>		<u>4MG</u>	<u>A090935</u>	<u>005</u>	May 25, 2011
<u>AB</u>		<u>5MG</u>	<u>A090935</u>	<u>006</u>	May 25, 2011
<u>AB</u>		<u>6MG</u>	<u>A090935</u>	<u>007</u>	May 25, 2011
<u>AB</u>		<u>7.5MG</u>	<u>A090935</u>	<u>008</u>	May 25, 2011
<u>AB</u>		<u>10MG</u>	<u>A090935</u>	<u>009</u>	May 25, 2011
<u>AB</u>	IPCA LABS LTD	<u>1MG</u>	<u>A200104</u>	<u>001</u>	Jun 27, 2013
<u>AB</u>		<u>2MG</u>	<u>A200104</u>	<u>002</u>	Jun 27, 2013
<u>AB</u>		<u>2.5MG</u>	<u>A200104</u>	<u>003</u>	Jun 27, 2013
<u>AB</u>		<u>3MG</u>	<u>A200104</u>	<u>004</u>	Jun 27, 2013
<u>AB</u>		<u>4MG</u>	<u>A200104</u>	<u>005</u>	Jun 27, 2013
<u>AB</u>		<u>5MG</u>	<u>A200104</u>	<u>006</u>	Jun 27, 2013
<u>AB</u>		<u>6MG</u>	<u>A200104</u>	<u>007</u>	Jun 27, 2013
<u>AB</u>		<u>7.5MG</u>	<u>A200104</u>	<u>008</u>	Jun 27, 2013
<u>AB</u>		<u>10MG</u>	<u>A200104</u>	<u>009</u>	Jun 27, 2013
<u>AB</u>	PLIVA	<u>1MG</u>	<u>A040616</u>	<u>009</u>	Jul 05, 2006
<u>AB</u>		<u>2MG</u>	<u>A040616</u>	<u>001</u>	Jul 05, 2006
<u>AB</u>		<u>2.5MG</u>	<u>A040616</u>	<u>002</u>	Jul 05, 2006
<u>AB</u>		<u>3MG</u>	<u>A040616</u>	<u>003</u>	Jul 05, 2006
<u>AB</u>		<u>4MG</u>	<u>A040616</u>	<u>004</u>	Jul 05, 2006
<u>AB</u>		<u>5MG</u>	<u>A040616</u>	<u>005</u>	Jul 05, 2006
<u>AB</u>		<u>6MG</u>	<u>A040616</u>	<u>006</u>	Jul 05, 2006
<u>AB</u>		<u>7.5MG</u>	<u>A040616</u>	<u>007</u>	Jul 05, 2006
<u>AB</u>	!	<u>10MG</u>	<u>A040616</u>	<u>008</u>	Jul 05, 2006
<u>AB</u>	TARO	<u>1MG</u>	<u>A040301</u>	<u>002</u>	Jul 15, 1999
<u>AB</u>		<u>2MG</u>	<u>A040301</u>	<u>003</u>	Jul 15, 1999
<u>AB</u>		<u>2.5MG</u>	<u>A040301</u>	<u>004</u>	Jul 15, 1999
<u>AB</u>		<u>3MG</u>	<u>A040301</u>	<u>005</u>	Jul 15, 1999
<u>AB</u>		<u>4MG</u>	<u>A040301</u>	<u>006</u>	Jul 15, 1999
<u>AB</u>		<u>5MG</u>	<u>A040301</u>	<u>007</u>	Jul 15, 1999
<u>AB</u>		<u>6MG</u>	<u>A040301</u>	<u>008</u>	Jul 15, 1999
<u>AB</u>		<u>7.5MG</u>	<u>A040301</u>	<u>009</u>	Jul 15, 1999
<u>AB</u>		<u>10MG</u>	<u>A040301</u>	<u>001</u>	Jul 15, 1999
<u>AB</u>	ZYDUS PHARMS USA	<u>1MG</u>	<u>A040663</u>	<u>001</u>	May 30, 2006
<u>AB</u>		<u>2MG</u>	<u>A040663</u>	<u>002</u>	May 30, 2006
<u>AB</u>		<u>2.5MG</u>	<u>A040663</u>	<u>003</u>	May 30, 2006
<u>AB</u>		<u>3MG</u>	<u>A040663</u>	<u>004</u>	May 30, 2006
<u>AB</u>		<u>4MG</u>	<u>A040663</u>	<u>005</u>	May 30, 2006
<u>AB</u>		<u>5MG</u>	<u>A040663</u>	<u>006</u>	May 30, 2006
<u>AB</u>		<u>6MG</u>	<u>A040663</u>	<u>007</u>	May 30, 2006
<u>AB</u>		<u>7.5MG</u>	<u>A040663</u>	<u>008</u>	May 30, 2006
<u>AB</u>		<u>10MG</u>	<u>A040663</u>	<u>009</u>	May 30, 2006

XENON XE-133

GAS; INHALATION

XENON XE 133

CURIUM

10mCi/VIAL

N018327 001 Mar 09, 1982

20mCi/VIAL

N018327 002 Mar 09, 1982

LANTHEUS MEDCL

10mCi/VIAL

N017284 001

20mCi/VIAL

N017284 002

ZAFIRLUKAST

TABLET; ORAL

ACCOLATE

<u>AB</u>	+	PAR PHARM INC	<u>10MG</u>	<u>N020547</u>	<u>003</u>	Sep 17, 1999
<u>AB</u>	+	!	<u>20MG</u>	<u>N020547</u>	<u>001</u>	Sep 26, 1996
<u>AB</u>		<u>ZAFIRLUKAST</u>				
<u>AB</u>		ANNORA PHARMA	<u>10MG</u>	<u>A212475</u>	<u>001</u>	Sep 10, 2020
<u>AB</u>			<u>20MG</u>	<u>A212475</u>	<u>002</u>	Sep 10, 2020
<u>AB</u>		DR REDDYS LABS LTD	<u>10MG</u>	<u>A090372</u>	<u>001</u>	Nov 18, 2010
<u>AB</u>			<u>20MG</u>	<u>A090372</u>	<u>002</u>	Nov 18, 2010

PRESCRIPTION DRUG PRODUCT LIST

ZALEPLON

CAPSULE; ORAL

SONATA

AB	+	PFIZER	5MG	N020859 001	Aug 13, 1999
AB	+	!	10MG	N020859 002	Aug 13, 1999

ZALEPLON

AB		AUROBINDO PHARMA	5MG	A078829 001	Jun 06, 2008
AB			10MG	A078829 002	Jun 06, 2008
AB		CIPLA LTD	5MG	A077505 001	Jun 20, 2008
AB			10MG	A077505 002	Jun 20, 2008
AB		HIKMA	5MG	A077237 001	Jun 06, 2008
AB			10MG	A077237 002	Jun 06, 2008
AB		ORCHID HLTHCARE	5MG	A090374 001	Sep 17, 2009
AB			10MG	A090374 002	Sep 17, 2009
AB		UNICHEM	5MG	A078989 001	Jun 06, 2008
AB			10MG	A078989 002	Jun 06, 2008

ZANAMIVIR

POWDER; INHALATION

RELENZA

+	!	GLAXOSMITHKLINE	5MG	N021036 001	Jul 26, 1999
----------	---	-----------------	-----	-------------	--------------

ZANUBRUTINIB

CAPSULE; ORAL

BRUKINSA

+	!	BEIGENE	80MG	N213217 001	Nov 14, 2019
----------	---	---------	------	-------------	--------------

ZICONOTIDE ACETATE

INJECTABLE; INTRATHECAL

PRIALT

+	!	TERSERA	100MCG/1ML (100MCG/ML)	N021060 002	Dec 28, 2004
+	!		500MCG/20ML (25MCG/ML)	N021060 001	Dec 28, 2004
+	!		500MCG/5ML (100MCG/ML)	N021060 004	Dec 28, 2004

ZIDOVDINE

CAPSULE; ORAL

RETROVIR

AB	+	!	VIIV HLTHCARE	100MG	N019655 001	Mar 19, 1987
-----------	----------	---	---------------	--------------	--------------------	--------------

ZIDOVDINE

AB		AUROBINDO PHARMA LTD	100MG	A078128 001	Mar 27, 2006
AB		CIPLA LTD	100MG	A078349 001	May 23, 2007

INJECTABLE; INJECTION

RETROVIR

AP	+	!	VIIV HLTHCARE	10MG/ML	N019951 001	Feb 02, 1990
-----------	----------	---	---------------	----------------	--------------------	--------------

SOLUTION; ORAL

RETROVIR

AA	+	!	VIIV HLTHCARE	50MG/5ML	N019910 001	Sep 28, 1989
-----------	----------	---	---------------	-----------------	--------------------	--------------

ZIDOVDINE

AA		AUROBINDO	50MG/5ML	A077268 001	Sep 19, 2005
AA		CIPLA LTD	50MG/5ML	A077981 001	Jun 26, 2008

TABLET; ORAL

ZIDOVDINE

AB		AUROBINDO	300MG	A077267 001	Sep 19, 2005
AB		CIPLA	300MG	A090561 001	Oct 27, 2010
AB	!	HETERO LABS LTD III	300MG	A090092 001	Apr 25, 2008
AB		MYLAN PHARMS INC	300MG	A078922 001	Feb 14, 2008

ZILEUTON

TABLET; ORAL

ZYFLO

+	!	CHIESI	600MG	N020471 003	Dec 09, 1996
----------	---	--------	-------	-------------	--------------

TABLET, EXTENDED RELEASE; ORAL

ZILEUTON

AB		AIZANT	600MG	A211390 001	Oct 23, 2020
AB		LUPIN LTD	600MG	A211972 001	Nov 05, 2019
AB		PAR PHARM INC	600MG	A212670 001	Dec 16, 2019
AB		RISING	600MG	A204929 001	Mar 17, 2017

ZYFLO CR

AB	+	!	CHIESI	600MG	N022052 001	May 30, 2007
-----------	----------	---	--------	--------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LISTZINC ACETATE

CAPSULE; ORAL

GALZIN

+ TEVA

EQ 25MG ZINC

N020458 001 Jan 28, 1997

+!

EQ 50MG ZINC

N020458 002 Jan 28, 1997

ZINC CHLORIDE

INJECTABLE; INJECTION

ZINC CHLORIDE IN PLASTIC CONTAINER

+! HOSPIRA

EQ 1MG ZINC/ML

N018959 001 Jun 26, 1986

ZINC SULFATE

SOLUTION; INTRAVENOUS

ZINC SULFATE

+! AM REGENT

EQ 10MG BASE/10ML (EQ 1MG BASE/ML)

N209377 003 Apr 15, 2020

+!

EQ 25MG BASE/5ML (EQ 5MG BASE/ML)

N209377 002 Jul 18, 2019

+!

EQ 30MG BASE/10ML (EQ 3MG BASE/ML)

N209377 001 Jul 18, 2019

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL

GEODONAB +! UPJOHNEQ 20MG BASEN020825 001 Feb 05, 2001AB +EQ 40MG BASEN020825 002 Feb 05, 2001AB +EQ 60MG BASEN020825 003 Feb 05, 2001AB +EQ 80MG BASEN020825 004 Feb 05, 2001ZIPRASIDONE HYDROCHLORIDEAB APOTEXEQ 20MG BASEA077561 001 Mar 02, 2012ABEQ 40MG BASEA077561 002 Mar 02, 2012ABEQ 60MG BASEA077561 003 Mar 02, 2012ABEQ 80MG BASEA077561 004 Mar 02, 2012AB AUROBINDO PHARMA LTDEQ 20MG BASEA204117 001 Dec 27, 2016ABEQ 40MG BASEA204117 002 Dec 27, 2016ABEQ 60MG BASEA204117 003 Dec 27, 2016ABEQ 80MG BASEA204117 004 Dec 27, 2016AB CADILAEQ 20MG BASEA208988 001 Aug 22, 2017ABEQ 40MG BASEA208988 002 Aug 22, 2017ABEQ 60MG BASEA208988 003 Aug 22, 2017ABEQ 80MG BASEA208988 004 Aug 22, 2017AB DR REDDYS LABS INCEQ 20MG BASEA077565 001 Mar 02, 2012ABEQ 40MG BASEA077565 002 Mar 02, 2012ABEQ 60MG BASEA077565 003 Mar 02, 2012ABEQ 80MG BASEA077565 004 Mar 02, 2012AB LUPIN PHARMSEQ 20MG BASEA077560 001 Mar 02, 2012ABEQ 40MG BASEA077560 002 Mar 02, 2012ABEQ 60MG BASEA077560 003 Mar 02, 2012ABEQ 80MG BASEA077560 004 Mar 02, 2012AB MACLEODS PHARMS LTDEQ 20MG BASEA204375 001 Feb 17, 2017ABEQ 40MG BASEA204375 002 Feb 17, 2017ABEQ 60MG BASEA204375 003 Feb 17, 2017ABEQ 80MG BASEA204375 004 Feb 17, 2017AB SANDOZ INCEQ 20MG BASEA077562 001 Jun 01, 2012ABEQ 40MG BASEA077562 002 Jun 01, 2012ABEQ 60MG BASEA077562 003 Jun 01, 2012ABEQ 80MG BASEA077562 004 Jun 01, 2012AB WOCKHARDT LTDEQ 20MG BASEA090348 001 Sep 05, 2012ABEQ 40MG BASEA090348 002 Sep 05, 2012ABEQ 60MG BASEA090348 003 Sep 05, 2012ABEQ 80MG BASEA090348 004 Sep 05, 2012ZIPRASIDONE MESYLATE

INJECTABLE; INTRAMUSCULAR

GEODONAP +! UPJOHNEQ 20MG BASE/MLN020919 001 Jun 21, 2002ZIPRASIDONE MESYLATEAP GLAND PHARMA LTDEQ 20MG BASE/MLA211908 001 Dec 26, 2019ZOLEDRONIC ACID

INJECTABLE; INTRAVENOUS

RECLASTAP +! NOVARTISEQ 5MG BASE/100MLN021817 001 Apr 16, 2007ZOLEDRONICAP GLAND PHARMA LTDEQ 4MG BASE/100MLA205749 001 Jun 29, 2018ZOLEDRONIC ACIDAP ACCORD HLTHCAREEQ 4MG BASE/5MLA205279 001 Nov 28, 2016

PRESCRIPTION DRUG PRODUCT LIST

ZOLEDRONIC ACID

INJECTABLE; INTRAVENOUS

ZOLEDRONIC ACID

<u>AP</u>	AKORN	<u>EQ 5MG BASE/100ML</u>	<u>A200918</u>	<u>001</u>	Aug 21, 2014
<u>AP</u>	AKORN INC	<u>EQ 4MG BASE/5ML</u>	<u>A202548</u>	<u>001</u>	May 22, 2014
<u>AP</u>	APOTEX	<u>EQ 5MG BASE/100ML</u>	<u>A204367</u>	<u>001</u>	Dec 24, 2015
<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 4MG BASE/5ML</u>	<u>A207751</u>	<u>001</u>	Sep 26, 2016
<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A209125</u>	<u>001</u>	Dec 08, 2017
<u>AP</u>	BPI LABS LLC	<u>EQ 4MG BASE/5ML</u>	<u>A207341</u>	<u>001</u>	Dec 29, 2017
<u>AP</u>	BRECKENRIDGE	<u>EQ 4MG BASE/5ML</u>	<u>A091170</u>	<u>001</u>	Mar 04, 2013
<u>AP</u>		<u>EQ 4MG BASE/5ML</u>	<u>A202571</u>	<u>001</u>	May 07, 2013
<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A202163</u>	<u>001</u>	Aug 05, 2013
<u>AP</u>	DR REDDYS LABS LTD	<u>EQ 4MG BASE/5ML</u>	<u>A091186</u>	<u>001</u>	Mar 04, 2013
<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A091363</u>	<u>001</u>	Mar 29, 2013
<u>AP</u>	EMCURE PHARMS LTD	<u>EQ 4MG BASE/5ML</u>	<u>A201783</u>	<u>001</u>	Mar 12, 2013
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 4MG BASE/5ML</u>	<u>A091516</u>	<u>001</u>	Apr 23, 2015
<u>AP</u>	GLAND PHARMA LTD	<u>EQ 4MG BASE/5ML</u>	<u>A202930</u>	<u>001</u>	Aug 05, 2013
<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A204217</u>	<u>001</u>	Aug 18, 2016
<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A209578</u>	<u>001</u>	Aug 08, 2019
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 4MG BASE/5ML</u>	<u>A202182</u>	<u>001</u>	Jun 03, 2013
<u>AP</u>	HOSPIRA INC	<u>EQ 4MG BASE/5ML</u>	<u>A090621</u>	<u>001</u>	Mar 19, 2015
<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A202837</u>	<u>001</u>	Apr 05, 2013
<u>AP</u>	INFORLIFE	<u>EQ 4MG BASE/100ML</u>	<u>N203231</u>	<u>001</u>	Aug 02, 2013
<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A202828</u>	<u>001</u>	Sep 23, 2013
<u>AP</u>	INGENUS PHARMS LLC	<u>EQ 4MG BASE/5ML</u>	<u>A208968</u>	<u>001</u>	Feb 19, 2020
<u>AP</u>	MYLAN LABS LTD	<u>EQ 4MG BASE/5ML</u>	<u>A202650</u>	<u>001</u>	Mar 04, 2013
<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A203841</u>	<u>001</u>	Feb 14, 2017
<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A205254</u>	<u>001</u>	Oct 27, 2017
<u>AP</u>	PUNISKA	<u>EQ 4MG BASE/100ML</u>	<u>A210174</u>	<u>001</u>	Oct 27, 2017
<u>AP</u>	SAGENT PHARMS INC	<u>EQ 4MG BASE/5ML</u>	<u>A091493</u>	<u>001</u>	Nov 24, 2014
<u>AP</u>	USV	<u>EQ 4MG BASE/5ML</u>	<u>A202923</u>	<u>001</u>	Sep 04, 2014

ZOMETA

<u>AP</u>	+!	NOVARTIS	<u>EQ 4MG BASE/5ML</u>	<u>N021223</u>	<u>002</u>	Mar 07, 2003
<u>AP</u>	+!		<u>EQ 4MG BASE/100ML</u>	<u>N021223</u>	<u>003</u>	Jun 17, 2011

SOLUTION; INTRAVENOUS

ZOLEDRONIC ACID

	HOSPIRA INC	EQ 4MG BASE/100ML (EQ 0.04MG BASE/ML)	N204016	001	Dec 28, 2015
--	-------------	---------------------------------------	---------	-----	--------------

ZOLMITRIPTAN

SPRAY; NASAL

ZOMIG

	+	ASTRAZENECA	2.5MG/SPRAY	N021450	003	Sep 16, 2013
	+!		5MG/SPRAY	N021450	004	Sep 30, 2003

TABLET; ORAL

ZOLMITRIPTAN

<u>AB</u>	AJANTA PHARMA LTD	<u>2.5MG</u>	<u>A204041</u>	<u>001</u>	May 20, 2016
<u>AB</u>		<u>5MG</u>	<u>A204041</u>	<u>002</u>	May 20, 2016
<u>AB</u>	ALEMBIC PHARMS LTD	<u>2.5MG</u>	<u>A204232</u>	<u>001</u>	Sep 30, 2015
<u>AB</u>		<u>5MG</u>	<u>A204232</u>	<u>002</u>	Sep 30, 2015
<u>AB</u>	APPCO	<u>2.5MG</u>	<u>A206973</u>	<u>001</u>	Jun 30, 2017
<u>AB</u>		<u>5MG</u>	<u>A206973</u>	<u>002</u>	Jun 30, 2017
<u>AB</u>	AUROBINDO PHARMA LTD	<u>2.5MG</u>	<u>A207021</u>	<u>001</u>	May 11, 2016
<u>AB</u>		<u>5MG</u>	<u>A207021</u>	<u>002</u>	May 11, 2016
<u>AB</u>	GLENMARK GENERICS	<u>2.5MG</u>	<u>A201779</u>	<u>001</u>	May 14, 2013
<u>AB</u>		<u>5MG</u>	<u>A201779</u>	<u>002</u>	May 14, 2013
<u>AB</u>	INVAGEN PHARMS	<u>2.5MG</u>	<u>A204284</u>	<u>001</u>	Apr 09, 2014
<u>AB</u>		<u>5MG</u>	<u>A204284</u>	<u>002</u>	Apr 09, 2014
<u>AB</u>	JUBILANT GENERICS	<u>2.5MG</u>	<u>A202279</u>	<u>001</u>	Nov 20, 2014
<u>AB</u>		<u>5MG</u>	<u>A202279</u>	<u>002</u>	Nov 20, 2014
<u>AB</u>	ORCHID HLTHCARE	<u>2.5MG</u>	<u>A203726</u>	<u>001</u>	Oct 21, 2019
<u>AB</u>		<u>5MG</u>	<u>A203726</u>	<u>002</u>	Oct 21, 2019
<u>AB</u>	PLD ACQUISITIONS LLC	<u>2.5MG</u>	<u>A207867</u>	<u>001</u>	Feb 27, 2017
<u>AB</u>		<u>5MG</u>	<u>A207867</u>	<u>002</u>	Feb 27, 2017
<u>AB</u>	ZYDUS PHARMS	<u>2.5MG</u>	<u>A203019</u>	<u>001</u>	Jul 11, 2018
<u>AB</u>		<u>5MG</u>	<u>A203019</u>	<u>002</u>	Jul 11, 2018

ZOMIG

<u>AB</u>	+	IPR	<u>2.5MG</u>	<u>N020768</u>	<u>001</u>	Nov 25, 1997
<u>AB</u>	+!		<u>5MG</u>	<u>N020768</u>	<u>002</u>	Nov 25, 1997

PRESCRIPTION DRUG PRODUCT LIST

ZOLMITRIPTAN

TABLET, ORALLY DISINTEGRATING;ORAL

ZOLMITRIPTAN

<u>AB</u>	ALEMBIC PHARMS LTD	<u>2.5MG</u>	<u>A205074 001</u>	Dec 01, 2016
<u>AB</u>		<u>5MG</u>	<u>A205074 002</u>	Dec 01, 2016
<u>AB</u>	GLENMARK GENERICS	<u>2.5MG</u>	<u>A202560 001</u>	May 14, 2013
<u>AB</u>		<u>5MG</u>	<u>A202560 002</u>	May 14, 2013
<u>AB</u>	JUBILANT GENERICS	<u>2.5MG</u>	<u>A202956 001</u>	Sep 17, 2015
<u>AB</u>		<u>5MG</u>	<u>A202956 002</u>	Sep 17, 2015
<u>AB</u>	ZYDUS PHARMS USA INC	<u>2.5MG</u>	<u>A202890 001</u>	May 15, 2013
<u>AB</u>		<u>5MG</u>	<u>A202890 002</u>	May 15, 2013
<u>ZOMIG-ZMT</u>				
<u>AB</u>	+ ASTRAZENECA	<u>2.5MG</u>	<u>N021231 001</u>	Feb 13, 2001
<u>AB</u>	+!	<u>5MG</u>	<u>N021231 002</u>	Sep 17, 2001

ZOLPIDEM TARTRATE

SPRAY, METERED;ORAL

ZOLPIMIST

+! AYTU

5MG/SPRAY

N022196 001 Dec 19, 2008

TABLET;ORAL

AMBIEN

<u>AB</u>	+ SANOFI AVENTIS US	<u>5MG</u>	<u>N019908 001</u>	Dec 16, 1992
<u>AB</u>	+!	<u>10MG</u>	<u>N019908 002</u>	Dec 16, 1992

ZOLPIDEM TARTRATE

<u>AB</u>	ACME LABS	<u>5MG</u>	<u>A077214 001</u>	Apr 23, 2007
<u>AB</u>		<u>10MG</u>	<u>A077214 002</u>	Apr 23, 2007
<u>AB</u>	APOTEX INC	<u>5MG</u>	<u>A077884 001</u>	Apr 23, 2007
<u>AB</u>		<u>10MG</u>	<u>A077884 002</u>	Apr 23, 2007
<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A078413 001</u>	May 04, 2007
<u>AB</u>		<u>10MG</u>	<u>A078413 002</u>	May 04, 2007
<u>AB</u>	CIPLA LTD	<u>5MG</u>	<u>A077388 001</u>	Jul 30, 2012
<u>AB</u>		<u>10MG</u>	<u>A077388 002</u>	Jul 30, 2012
<u>AB</u>	INVAGEN PHARMS	<u>5MG</u>	<u>A078184 001</u>	Sep 07, 2007
<u>AB</u>		<u>10MG</u>	<u>A078184 002</u>	Sep 07, 2007
<u>AB</u>	SANDOZ INC	<u>5MG</u>	<u>A077322 001</u>	Apr 23, 2007
<u>AB</u>		<u>10MG</u>	<u>A077322 002</u>	Apr 23, 2007
<u>AB</u>	TEVA	<u>5MG</u>	<u>A076410 001</u>	Apr 23, 2007
<u>AB</u>		<u>10MG</u>	<u>A076410 002</u>	Apr 23, 2007
<u>AB</u>	TORRENT PHARMS	<u>5MG</u>	<u>A077903 001</u>	Aug 17, 2007
<u>AB</u>		<u>10MG</u>	<u>A077903 002</u>	Aug 17, 2007

TABLET;SUBLINGUAL

EDLUAR

<u>AB</u>	+ MYLAN SPECIALITY LP	<u>5MG</u>	<u>N021997 001</u>	Mar 13, 2009
<u>AB</u>	+!	<u>10MG</u>	<u>N021997 002</u>	Mar 13, 2009

ZOLPIDEM TARTRATE

<u>AB</u>	DR REDDYS	<u>1.75MG</u>	<u>A204503 001</u>	Nov 18, 2016
<u>AB</u>		<u>3.5MG</u>	<u>A204503 002</u>	Nov 18, 2016
<u>AB</u>	NOVEL LABS INC	<u>1.75MG</u>	<u>A204299 001</u>	Jun 03, 2015
<u>AB</u>	!	<u>3.5MG</u>	<u>A204299 002</u>	Jun 03, 2015
<u>AB</u>	PAR FORM	<u>5MG</u>	<u>A201509 001</u>	Aug 01, 2016
<u>AB</u>		<u>10MG</u>	<u>A201509 002</u>	Aug 01, 2016
<u>AB</u>	PAR PHARM INC	<u>1.75MG</u>	<u>A204229 001</u>	Sep 11, 2017
<u>AB</u>		<u>3.5MG</u>	<u>A204229 002</u>	Sep 11, 2017

TABLET, EXTENDED RELEASE;ORAL

AMBIEN CR

<u>AB</u>	+ SANOFI AVENTIS US	<u>6.25MG</u>	<u>N021774 002</u>	Sep 02, 2005
<u>AB</u>	+!	<u>12.5MG</u>	<u>N021774 001</u>	Sep 02, 2005

ZOLPIDEM TARTRATE

<u>AB</u>	ACTAVIS ELIZABETH	<u>6.25MG</u>	<u>A078179 002</u>	Oct 13, 2010
<u>AB</u>		<u>12.5MG</u>	<u>A078179 001</u>	Jun 06, 2011
<u>AB</u>	ACTAVIS LABS FL INC	<u>6.25MG</u>	<u>A090153 001</u>	Mar 25, 2013
<u>AB</u>		<u>12.5MG</u>	<u>A090153 002</u>	Mar 25, 2013
<u>AB</u>	ANCHEN PHARMS	<u>6.25MG</u>	<u>A078148 002</u>	Apr 14, 2011
<u>AB</u>		<u>12.5MG</u>	<u>A078148 001</u>	Dec 03, 2010
<u>AB</u>	APOTEX INC	<u>6.25MG</u>	<u>A200266 001</u>	Sep 10, 2013
<u>AB</u>		<u>12.5MG</u>	<u>A200266 002</u>	Sep 10, 2013
<u>AB</u>	BRECKENRIDGE	<u>6.25MG</u>	<u>A213592 001</u>	Jun 04, 2020
<u>AB</u>		<u>12.5MG</u>	<u>A213592 002</u>	Jun 04, 2020
<u>AB</u>	LUPIN LTD	<u>6.25MG</u>	<u>A078970 001</u>	Sep 11, 2013
<u>AB</u>		<u>12.5MG</u>	<u>A078970 002</u>	Sep 11, 2013
<u>AB</u>	SANDOZ	<u>6.25MG</u>	<u>A090107 001</u>	Jul 01, 2011
<u>AB</u>		<u>12.5MG</u>	<u>A090107 002</u>	Jul 01, 2011

PRESCRIPTION DRUG PRODUCT LIST

ZOLPIDEM TARTRATE

TABLET, EXTENDED RELEASE;ORAL

ZOLPIDEM TARTRATE

<u>AB</u>	SUN PHARM	<u>6.25MG</u>	<u>A204170 001</u>	Jan 24, 2017
<u>AB</u>		<u>12.5MG</u>	<u>A204170 002</u>	Jan 24, 2017

ZONISAMIDE

CAPSULE;ORAL

ZONEGRAN

<u>AB</u>	+ SUNOVION PHARMS INC	<u>25MG</u>	<u>N020789 003</u>	Aug 22, 2003
<u>AB</u>	+!	<u>100MG</u>	<u>N020789 001</u>	Mar 27, 2000

ZONISAMIDE

<u>AB</u>	APOTEX INC	<u>25MG</u>	<u>A077642 001</u>	Dec 22, 2005
<u>AB</u>		<u>50MG</u>	<u>A077642 002</u>	Dec 22, 2005
<u>AB</u>		<u>100MG</u>	<u>A077642 003</u>	Dec 22, 2005
<u>AB</u>	AUROBINDO PHARMA LTD	<u>25MG</u>	<u>A077645 002</u>	Sep 29, 2006
<u>AB</u>		<u>50MG</u>	<u>A077645 003</u>	Sep 29, 2006
<u>AB</u>		<u>100MG</u>	<u>A077645 001</u>	Dec 22, 2005
<u>AB</u>	BIONPHARMA INC	<u>25MG</u>	<u>A077813 001</u>	Aug 16, 2006
<u>AB</u>		<u>50MG</u>	<u>A077813 002</u>	Aug 16, 2006
<u>AB</u>		<u>100MG</u>	<u>A077813 003</u>	Aug 16, 2006
<u>AB</u>	CELLTRION	<u>25MG</u>	<u>A077636 003</u>	Jul 27, 2006
<u>AB</u>		<u>50MG</u>	<u>A077636 002</u>	Jul 27, 2006
<u>AB</u>		<u>100MG</u>	<u>A077636 001</u>	Dec 22, 2005
<u>AB</u>	GLENMARK GENERICS	<u>25MG</u>	<u>A077651 001</u>	Jan 30, 2006
<u>AB</u>		<u>50MG</u>	<u>A077651 002</u>	Jan 30, 2006
<u>AB</u>		<u>100MG</u>	<u>A077651 003</u>	Jan 30, 2006
<u>AB</u>	INVAGEN PHARMS	<u>25MG</u>	<u>A077869 001</u>	May 31, 2006
<u>AB</u>		<u>50MG</u>	<u>A077869 002</u>	May 31, 2006
<u>AB</u>		<u>100MG</u>	<u>A077869 003</u>	May 31, 2006
<u>AB</u>	SUN PHARM INDS (IN)	<u>25MG</u>	<u>A077634 001</u>	Mar 17, 2006
<u>AB</u>		<u>50MG</u>	<u>A077634 002</u>	Mar 17, 2006
<u>AB</u>		<u>100MG</u>	<u>A077634 003</u>	Mar 17, 2006
<u>AB</u>	ZYDUS PHARMS USA	<u>25MG</u>	<u>A077625 001</u>	Oct 16, 2006
<u>AB</u>		<u>50MG</u>	<u>A077625 002</u>	Oct 16, 2006
<u>AB</u>		<u>100MG</u>	<u>A077625 003</u>	Oct 16, 2006

OTC DRUG PRODUCT LIST

ACETAMINOPHEN

SUPPOSITORY; RECTAL

ACEPHEN

COSETTE	120MG	N018060 001
	325MG	A072344 001 Mar 27, 1992
	650MG	A072237 001 Mar 27, 1992

ACETAMINOPHEN

PERRIGO NEW YORK	120MG	A070607 001 Apr 06, 1987
	650MG	A070608 001 Dec 01, 1986
+ TARO PHARM INDS LTD	120MG	N018337 003 Sep 12, 1983
+	325MG	N018337 002
+!	650MG	N018337 001

INFANTS' FEVERALL

+ TARO PHARM INDS LTD	80MG	N018337 004 Aug 26, 1992
-----------------------	------	--------------------------

NEOPAP

POLYMEDICA	120MG	N016401 001
------------	-------	-------------

TABLET, EXTENDED RELEASE; ORAL

ACETAMINOPHEN

AUROBINDO PHARMA LTD	650MG	A207229 001 Nov 09, 2016
GRANULES	650MG	A211544 001 Apr 16, 2019
HERITAGE PHARMA	650MG	A207035 001 May 31, 2018
OHM LABS	650MG	A076200 001 Mar 19, 2002
PERRIGO	650MG	A075077 001 Feb 25, 2000
SUN PHARM INDS LTD	650MG	A078569 001 Dec 14, 2011

TYLENOL

+! J AND J CONSUMER INC	650MG	N019872 001 Jun 08, 1994
+!	650MG	N019872 002 Jan 11, 2001

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET; ORAL

ACETAMINOPHEN, ASPIRIN AND CAFFEINE

PERRIGO	250MG; 250MG; 65MG	A075794 001 Nov 26, 2001
---------	--------------------	--------------------------

EXCEDRIN (MIGRAINE)

+! GLAXOSMITHKLINE CONS	250MG; 250MG; 65MG	N020802 001 Jan 14, 1998
-------------------------	--------------------	--------------------------

ACETAMINOPHEN; IBUPROFEN

TABLET; ORAL

ADVIL DUAL ACTION WITH ACETAMINOPHEN

+! GLAXOSMITHKLINE	250MG; 125MG	N211733 001 Feb 28, 2020
--------------------	--------------	--------------------------

ADAPALENE

GEL; TOPICAL

ADAPALENE

GLENMARK GENERICS	0.1%	A091314 001 Jul 01, 2010
P AND L	0.1%	A090962 001 Jun 02, 2010

DIFFERIN

+! GALDERMA LABS LP	0.1%	N020380 002 Jul 08, 2016
---------------------	------	--------------------------

ALCOHOL; CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL

AVAGARD

+! 3M	61%; 1%	N021074 001 Jun 07, 2001
-------	---------	--------------------------

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE; ORAL

GAVISCON

+ SANOFI AVENTIS US	80MG; 20MG	N018685 001 Dec 09, 1983
---------------------	------------	--------------------------

ASPIRIN

CAPSULE; ORAL

VAZALORE

+! PLX PHARMA	325MG	N203697 001 Jan 14, 2013
---------------	-------	--------------------------

AVOBENZONE; ECAMSULE; OCTOCRYLENE

CREAM; TOPICAL

ANTHELIOS SX

+! LOREAL USA	2%; 2%; 10%	N021502 001 Jul 21, 2006
---------------	-------------	--------------------------

CAPITAL SOLEIL 15

+! LOREAL USA	2%; 3%; 10%	N021501 001 Oct 02, 2006
---------------	-------------	--------------------------

OTC DRUG PRODUCT LIST

AVOBENZONE; ECAMSULE; OCTOCRYLENE; TITANIUM DIOXIDE

CREAM; TOPICAL

ANTHELIOS 20

+! LOREAL USA 2%;2%;10%;2% N021471 001 Oct 05, 2006

ANTHELIOS 40

+! LOREAL USA 2%;3%;10%;5% N022009 001 Mar 31, 2008

+! 2%;3%;10%;5% N022009 002 Oct 29, 2009

BENTOQUATAM

LOTION; TOPICAL

IVY BLOCK

+! STAND HOMEOPATH 5% N020532 001 Aug 26, 1996

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

LUMIFY

+! BAUSCH AND LOMB INC 0.025% N208144 001 Dec 22, 2017

BUDESONIDE

SPRAY, METERED; NASAL

BUDESONIDE

APOTEX INC 0.032MG/SPRAY A078949 002 Nov 20, 2015

RHINOCORT ALLERGY

+! ASTRAZENECA PHARMS 0.032MG/SPRAY N020746 003 Mar 23, 2015

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL

BUTENAFINE HYDROCHLORIDE

TARO PHARMS 1% A205181 001 Nov 16, 2017

LOTRIMIN ULTRA

+! BAYER HEALTHCARE 1% N021307 001 Dec 07, 2001

LLC

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE; ORAL

FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE

PERRIGO R AND D 800MG;10MG;165MG A077355 001 Feb 06, 2008

800MG;10MG;165MG A204782 001 Aug 29, 2016

PEPCID COMPLETE

+! J AND J CONSUMER 800MG;10MG;165MG N020958 001 Oct 16, 2000

INC

CETIRIZINE HYDROCHLORIDE

CAPSULE; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

APOTEX 10MG A207235 001 Aug 12, 2016

AUROBINDO PHARMA 10MG A209107 001 Jul 20, 2018

LTD

+ BIONPHARMA INC 5MG N022429 001 Jul 23, 2009

+! 10MG N022429 004 Jul 23, 2009

STRIDES PHARMA 10MG A205291 001 Jul 21, 2017

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

AUROBINDO PHARMA 10MG A209107 002 Jul 20, 2018

LTD

+ BIONPHARMA INC 5MG N022429 003 Jul 23, 2009

+! 10MG N022429 002 Jul 23, 2009

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

AMNEAL PHARMS 5MG/5ML A090765 002 Oct 07, 2009

ATHEM 5MG/5ML A091327 001 Oct 17, 2011

AUROBINDO PHARMA 5MG/5ML A090750 002 Feb 02, 2010

HETERO LABS LTD III 5MG/5ML A210622 001 Mar 13, 2019

LANNETT CO INC 5MG/5ML A091130 001 Apr 22, 2011

PERRIGO R AND D 5MG/5ML A204226 001 Sep 09, 2013

5MG/5ML A090254 002 Apr 09, 2008

QUAGEN 5MG/5ML A212266 001 May 16, 2019

TARO 5MG/5ML A090182 002 Apr 22, 2008

5MG/5ML A201546 001 May 20, 2011

TRIS PHARMA INC 5MG/5ML A090572 001 Nov 16, 2012

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

AMNEAL PHARMS 5MG/5ML A090765 001 Oct 07, 2009

ATHEM 5MG/5ML A091327 002 Oct 17, 2011

AUROBINDO PHARMA 5MG/5ML A090750 001 Feb 02, 2010

LANNETT CO INC 5MG/5ML A091130 002 Apr 22, 2011

PERRIGO R AND D 5MG/5ML A090254 001 Apr 09, 2008

TARO 5MG/5ML A090182 001 Apr 22, 2008

OTC DRUG PRODUCT LIST

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

	5MG/5ML	A201546	002	May 20, 2011
TRIS PHARMA INC	5MG/5ML	A090572	002	Nov 16, 2012
CHILDREN'S ZYRTEC ALLERGY				
+! J AND J CONSUMER	5MG/5ML	N022155	002	Nov 16, 2007
INC				
CHILDREN'S ZYRTEC HIVES RELIEF				
+! J AND J CONSUMER	5MG/5ML	N022155	001	Nov 16, 2007
INC				

TABLET; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

AMNEAL PHARMS NY	5MG	A078780	001	Jan 21, 2010
	10MG	A078780	004	Jan 21, 2010
APOTEX INC	5MG	A078317	001	Dec 27, 2007
	10MG	A078317	002	Dec 27, 2007
AUROBINDO PHARMA LTD	5MG	A090760	001	Aug 05, 2015
	10MG	A090760	003	Aug 05, 2015
CIPLA LTD	5MG	A077318	001	Jul 25, 2013
	10MG	A077318	002	Jul 25, 2013
CONTRACT PHARMACAL	5MG	A076047	001	Dec 27, 2007
	10MG	A076047	002	Dec 27, 2007
DR REDDYS LABS LTD	5MG	A078343	004	Jan 15, 2008
	10MG	A078343	003	Jan 15, 2008
GRANULES	10MG	A209274	001	Dec 22, 2017
IPCA LABS LTD	5MG	A202277	002	Mar 11, 2014
	10MG	A202277	004	Mar 11, 2014
MARKSANS PHARMA	5MG	A078933	001	Jun 15, 2010
	10MG	A078933	002	Jun 15, 2010
MYLAN	5MG	A076677	001	Dec 27, 2007
	10MG	A076677	002	Dec 27, 2007
ORCHID HLTHCARE	5MG	A078862	001	Feb 19, 2009
	10MG	A078862	002	Feb 19, 2009
PERRIGO R AND D	5MG	A078336	001	Dec 27, 2007
	10MG	A078336	002	Dec 27, 2007
PLD ACQUISITIONS	5MG	A077946	001	Dec 27, 2007
	10MG	A077946	002	Dec 27, 2007
SUN PHARM INDS LTD	5MG	A077498	001	Dec 27, 2007
	10MG	A077498	002	Dec 27, 2007
TARO	5MG	A078072	001	Jul 22, 2009
	5MG	A078072	003	Jul 22, 2009
UNIQUE PHARM LABS	5MG	A077829	001	Aug 26, 2009
	10MG	A077829	004	Aug 26, 2009
WOCKHARDT	5MG	A078427	003	Dec 28, 2007
	10MG	A078427	004	Dec 28, 2007

CETIRIZINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD	5MG	A078343	001	Jan 15, 2008
	10MG	A078343	002	Jan 15, 2008
IPCA LABS LTD	5MG	A202277	001	Mar 11, 2014
	10MG	A202277	003	Mar 11, 2014
MARKSANS PHARMA	5MG	A078933	003	Jun 15, 2010
	10MG	A078933	004	Jun 15, 2010
MYLAN	5MG	A076677	004	Dec 27, 2007
	10MG	A076677	003	Dec 27, 2007
ORCHID HLTHCARE	5MG	A078862	003	Feb 19, 2009
	10MG	A078862	004	Feb 19, 2009
PERRIGO R AND D	5MG	A078336	003	Dec 27, 2007
	10MG	A078336	004	Dec 27, 2007
SUN PHARM INDS LTD	5MG	A077498	003	Dec 27, 2007
	10MG	A077498	004	Dec 27, 2007
UNIQUE PHARM LABS	5MG	A077829	003	Aug 26, 2009
!	10MG	A077829	002	Aug 26, 2009

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

AMNEAL PHARMS NY	5MG	A078780	003	Jan 21, 2010
	10MG	A078780	002	Jan 21, 2010
AUROBINDO PHARMA LTD	5MG	A090760	002	Aug 05, 2015
	10MG	A090760	004	Aug 05, 2015
TARO	10MG	A078072	002	Jul 22, 2009
	10MG	A078072	004	Jul 22, 2009

OTC DRUG PRODUCT LIST

CETIRIZINE HYDROCHLORIDE

TABLET;ORAL

ZYRTEC ALLERGY

+	!	J AND J CONSUMER INC	10MG	N019835 004	Nov 16, 2007
---	---	-------------------------	------	-------------	--------------

TABLET, CHEWABLE;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

		JUBILANT GENERICS	5MG	A091116 001	Feb 19, 2015
			10MG	A091116 002	Feb 19, 2015
		NOVEL LABS INC	5MG	A206793 001	Mar 08, 2016
			10MG	A206793 002	Mar 08, 2016
		SANDOZ	5MG	A078692 001	Feb 14, 2008
	!		10MG	A078692 002	Feb 14, 2008
		SUN PHARM	5MG	A090142 001	Aug 30, 2011
			10MG	A090142 002	Aug 30, 2011

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

		JUBILANT GENERICS	5MG	A091116 003	Feb 19, 2015
			10MG	A091116 004	Feb 19, 2015
		SUN PHARM	5MG	A090142 003	Aug 30, 2011
			10MG	A090142 004	Aug 30, 2011

CHILDREN'S ZYRTEC ALLERGY

+		J AND J CONSUMER INC	2.5MG	N021621 007	Nov 30, 2020
---	--	-------------------------	-------	-------------	--------------

TABLET, ORALLY DISINTEGRATING;ORAL

CETIRIZINE HYDROCHLORIDE

		AUROBINDO PHARMA LTD	10MG	A213557 001	Sep 11, 2020
--	--	-------------------------	------	-------------	--------------

CETIRIZINE HYDROCHLORIDE ALLERGY

		PERRIGO R AND D	10MG	A205490 001	Sep 02, 2015
--	--	-----------------	------	-------------	--------------

ZYRTEC ALLERGY

+	!	J AND J CONSUMER INC	10MG	N022578 001	Sep 03, 2010
---	---	-------------------------	------	-------------	--------------

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

		IVAX SUB TEVA PHARMS	5MG;120MG	A077170 001	Feb 25, 2008
		PERRIGO R AND D	5MG;120MG	A210719 001	Nov 16, 2018
		PLD ACQUISITIONS	5MG;120MG	A077991 001	Mar 05, 2008
		SUN PHARM INDS LTD	5MG;120MG	A090922 001	Sep 28, 2012

ZYRTEC-D 12 HOUR

+	!	J AND J CONSUMER INC	5MG;120MG	N021150 002	Nov 09, 2007
---	---	-------------------------	-----------	-------------	--------------

CHLORHEXIDINE GLUCONATE

AEROSOL, METERED;TOPICAL

EXIDINE

+	!	XTTRIUM	4%	N019127 001	Dec 24, 1984
---	---	---------	----	-------------	--------------

CLOTH;TOPICAL

CHLORHEXIDINE GLUCONATE

+	!	SAGE PRODS	2%	N021669 001	Apr 25, 2005
---	---	------------	----	-------------	--------------

READYPREP CHG

		MEDLINE INDUSTRIES	2%	N207964 001	Nov 20, 2018
--	--	--------------------	----	-------------	--------------

SOLUTION;TOPICAL

BRIAN CARE

		SOAPCO	4%	A071419 001	Dec 17, 1987
--	--	--------	----	-------------	--------------

CHG SCRUB

		ECOLAB	4%	N019258 002	Jul 22, 1986
--	--	--------	----	-------------	--------------

CHLORHEXIDINE GLUCONATE

		BAJAJ	0.75%	N020111 001	Sep 11, 1997
--	--	-------	-------	-------------	--------------

CIDA-STAT

		ECOLAB	2%	N019258 001	Jul 22, 1986
--	--	--------	----	-------------	--------------

EXIDINE

+	!	XTTRIUM	2%	N019422 001	Dec 17, 1985
			4%	N019125 001	Dec 24, 1984

HIBICLENS

+	!	MOLNLYCKE HLTH	4%	N017768 001	
---	---	----------------	----	-------------	--

HIBISTAT

+	!	MOLNLYCKE HLTH	0.5%	N018300 001	
---	---	----------------	------	-------------	--

SPONGE;TOPICAL

BIOSCRUB

		GRIFFEN	4%	N019822 001	Mar 31, 1989
--	--	---------	----	-------------	--------------

OTC DRUG PRODUCT LIST

CHLORHEXIDINE GLUCONATE

SPONGE; TOPICAL

CHLORHEXIDINE GLUCONATE

!	BECTON DICKINSON	4%	A072525	001	Oct 24, 1989
---	------------------	----	---------	-----	--------------

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SOLUTION; TOPICAL

SOLUPREP

+	!	3M HEALTH CARE	2%;70%	N208288	001	Aug 08, 2018
---	---	----------------	--------	---------	-----	--------------

SPONGE; TOPICAL

CHLORAPREP ONE-STEP

+	!	BECTON DICKINSON CO	2%;70% (3ML)	N020832	001	Jul 14, 2000
---	---	---------------------	--------------	---------	-----	--------------

+	!		2%;70% (10.5ML)	N020832	004	Aug 20, 2003
---	---	--	-----------------	---------	-----	--------------

+	!		2%;70% (26ML)	N020832	006	Nov 21, 2006
---	---	--	---------------	---------	-----	--------------

+	!		2%;70% (1ML)	N020832	008	Oct 23, 2008
---	---	--	--------------	---------	-----	--------------

CHLORAPREP ONE-STEP FREPP

+	!	BECTON DICKINSON CO	2%;70% (1.5ML)	N020832	003	Apr 26, 2002
---	---	---------------------	----------------	---------	-----	--------------

CHLORAPREP WITH TINT

+	!	BECTON DICKINSON CO	2%;70% (26ML)	N020832	002	May 03, 2005
---	---	---------------------	---------------	---------	-----	--------------

+	!		2%;70% (10.5ML)	N020832	005	Apr 03, 2006
---	---	--	-----------------	---------	-----	--------------

+	!		2%;70% (3ML)	N020832	007	Oct 10, 2006
---	---	--	--------------	---------	-----	--------------

SWAB; TOPICAL

CHLORAPREP ONE-STEP SEPP

+	!	BECTON DICKINSON CO	2%;70% (0.67ML)	N021555	001	Oct 07, 2002
---	---	---------------------	-----------------	---------	-----	--------------

CHLORAPREP SINGLE SWABSTICK

+	!	BECTON DICKINSON CO	2%;70% (1.75ML)	N021555	002	May 10, 2005
---	---	---------------------	-----------------	---------	-----	--------------

CHLORAPREP TRIPLE SWABSTICK

+	!	BECTON DICKINSON CO	2%;70% (5.25ML)	N021555	003	Jun 10, 2009
---	---	---------------------	-----------------	---------	-----	--------------

PREVANTICS MAXI SWABSTICK

+	!	PROF DSPLS	3.15%;70% (5.1ML)	N021524	003	Jun 03, 2005
---	---	------------	-------------------	---------	-----	--------------

PREVANTICS SWAB

+	!	PROF DSPLS	3.15%;70% (1ML)	N021524	001	Jun 03, 2005
---	---	------------	-----------------	---------	-----	--------------

PREVANTICS SWABSTICK

+	!	PROF DSPLS	3.15%;70% (1.6ML)	N021524	002	Jun 03, 2005
---	---	------------	-------------------	---------	-----	--------------

CHLORPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE; ORAL

CHLORPHENIRAMINE MALEATE

!	AVANTHI INC	12MG	A040829	001	May 13, 2009
---	-------------	------	---------	-----	--------------

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE

TABLET; ORAL

ADVIL ALLERGY AND CONGESTION RELIEF

+	!	GLAXOSMITHKLINE	4MG;200MG;10MG	N022113	001	Dec 21, 2011
---	---	-----------------	----------------	---------	-----	--------------

ADVIL MULTI-SYMPTOM COLD & FLU

+	!	GLAXOSMITHKLINE	4MG;200MG;10MG	N022113	002	Apr 28, 2017
---	---	-----------------	----------------	---------	-----	--------------

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

SUSPENSION; ORAL

CHILDREN'S ADVIL ALLERGY SINUS

+	!	GLAXOSMITHKLINE	1MG/5ML;100MG/5ML;15MG/5ML	N021587	001	Feb 24, 2004
---	---	-----------------	----------------------------	---------	-----	--------------

TABLET; ORAL

ADVIL ALLERGY SINUS

+	!	GLAXOSMITHKLINE	2MG;200MG;30MG	N021441	001	Dec 19, 2002
---	---	-----------------	----------------	---------	-----	--------------

CIMETIDINE

TABLET; ORAL

CIMETIDINE

	APOTEX	100MG	A074948	001	Jun 19, 1998
--	--------	-------	---------	-----	--------------

		200MG	A074948	002	Jul 26, 2002
--	--	-------	---------	-----	--------------

	IVAX SUB TEVA	200MG	A075345	001	Jun 16, 1999
--	---------------	-------	---------	-----	--------------

	PHARMS				
--	--------	--	--	--	--

	L PERRIGO CO	200MG	A075285	001	Oct 29, 1998
--	--------------	-------	---------	-----	--------------

TAGAMET HB

+	!	MEDTECH PRODUCTS	200MG	N020238	002	Aug 21, 1996
---	---	------------------	-------	---------	-----	--------------

CLEMASTINE FUMARATE

TABLET; ORAL

CLEMASTINE FUMARATE

!	L PERRIGO CO	1.34MG	A074512	001	Nov 22, 1995
---	--------------	--------	---------	-----	--------------

OTC DRUG PRODUCT LIST

CLOTRIMAZOLE

CREAM; VAGINAL

CLOTRIMAZOLE

! P AND L

1%

A074165 001 Jul 16, 1993

TARO

1%

A072641 001 Dec 04, 1995

TRIVAGIZOLE 3

TARO

2%

N021143 001 Apr 12, 2000

CROMOLYN SODIUM

SPRAY, METERED; NASAL

CROMOLYN SODIUM

! BAUSCH AND LOMB

5.2MG/SPRAY

A075702 001 Jul 03, 2001

PERRIGO

5.2MG/SPRAY

A075427 001 Dec 12, 2001

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL

GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE

ACTAVIS LABS FL

30MG; 600MG

A091070 001 Aug 31, 2015

60MG; 1.2GM

A091070 002 Aug 31, 2015

AMNEAL PHARMS

30MG; 600MG

A209692 001 Nov 01, 2018

60MG; 1.2GM

A209692 002 Nov 01, 2018

AUROBINDO PHARMA

30MG; 600MG

A206941 001 Mar 17, 2017

LTD

60MG; 1.2GM

A206941 002 Mar 17, 2017

PERRIGO R AND D

30MG; 600MG

A207602 002 Mar 05, 2018

60MG; 1.2GM

A207602 001 Mar 05, 2018

MUCINEX DM

+ RB HLTH

30MG; 600MG

N021620 002 Apr 29, 2004

+!

60MG; 1.2GM

N021620 001 Apr 29, 2004

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

DELSYM

+! RB HLTH

EQ 30MG HYDROBROMIDE/5ML

N018658 001 Oct 08, 1982

DEXTROMETHORPHAN POLISTIREX

AMNEAL

EQ 30MG HYDROBROMIDE/5ML

A203133 001 Jul 28, 2017

TRIS PHARMA INC

EQ 30MG HYDROBROMIDE/5ML

A091135 001 May 25, 2012

DICLOFENAC SODIUM

GEL; TOPICAL

DICLOFENAC SODIUM

AMNEAL PHARMS

1%

A208077 001 Mar 18, 2016

ENCUBE

1%

A210986 001 Jan 27, 2020

MYLAN

1%

A204306 001 May 06, 2019

PERRIGO UK FINCO

1%

A211253 001 May 16, 2019

VOLTAREN ARTHRITIS PAIN

+! GLAXOSMITHKLINE

1%

N022122 001 Oct 17, 2007

CONS

DIPHENHYDRAMINE CITRATE; IBUPROFEN

TABLET; ORAL

ADVIL PM

+! GLAXOSMITHKLINE

38MG; 200MG

N021394 001 Dec 21, 2005

IBUPROFEN AND DIPHENHYDRAMINE CITRATE

DR REDDYS LABS LTD

38MG; 200MG

A090619 001 Jul 08, 2009

PERRIGO R AND D

38MG; 200MG

A079113 001 Dec 22, 2008

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE; ORAL

ADVIL PM

+! GLAXOSMITHKLINE

25MG; EQ 200MG FREE ACID AND POTASSIUM SALT

N021393 001 Dec 21, 2005

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

AUROBINDO PHARMA

25MG; EQ 200MG FREE ACID AND POTASSIUM SALT

A210676 001 Feb 14, 2019

LTD

BIONPHARMA INC

25MG; EQ 200MG FREE ACID AND POTASSIUM SALT

A090397 001 Nov 22, 2010

STRIDES PHARMA

25MG; EQ 200MG FREE ACID AND POTASSIUM SALT

A200888 001 Mar 05, 2012

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET; ORAL

ALEVE PM

+! BAYER HLTHCARE

25MG; 220MG

N205352 001 Jan 17, 2014

NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE

AMNEAL PHARMS CO

25MG; 220MG

A209726 001 Oct 23, 2018

APOTEX

25MG; 220MG

A211830 001 Aug 22, 2019

OTC DRUG PRODUCT LIST

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE

GRANULES 25MG; 220MG

A213663 001 Sep 24, 2020

PERRIGO R AND D 25MG; 220MG

A208499 001 May 10, 2019

DOCOSANOL

CREAM; TOPICAL

ABREVA

+! GLAXOSMITHKLINE 10%

N020941 001 Jul 25, 2000

DOCOSANOL

P AND L 10%

A208754 001 Nov 19, 2018

DOXYLAMINE SUCCINATE

TABLET; ORAL

DOXYLAMINE SUCCINATE

LNK 25MG

A040564 001 Aug 27, 2004

PERRIGO 25MG

A040167 001 Sep 18, 1996

UNISOM

+! CHATTEM 25MG

N018066 001

EPINEPHRINE

AEROSOL, METERED; INHALATION

PRIMATENE MIST

+! ARMSTRONG PHARMS 0.125MG/INH

N205920 001 Nov 07, 2018

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE; ORAL

ESOMEPRAZOLE MAGNESIUM

AMNEAL PHARMS NY EQ 20MG BASE

A209716 001 Jun 05, 2019

AUROBINDO PHARMA EQ 20MG BASE

A209339 001 Oct 16, 2017

LTD

DR REDDYS LABS LTD EQ 20MG BASE

A207673 001 May 15, 2018

HETERO LABS LTD III EQ 20MG BASE

A208939 001 May 28, 2020

EQ 20MG BASE

A212507 001 Jun 02, 2020

PERRIGO R AND D EQ 20MG BASE

A207193 001 Aug 18, 2017

SUN PHARM EQ 20MG BASE

A212866 001 May 04, 2020

NEXIUM 24HR

+! ASTRAZENECA LP EQ 20MG BASE

N204655 001 Mar 28, 2014

TABLET, DELAYED RELEASE; ORAL

ESOMEPRAZOLE MAGNESIUM

DR REDDYS LABS LTD EQ 20MG BASE

A211571 001 May 14, 2020

MYLAN EQ 20MG BASE

A212088 001 Jun 25, 2020

NEXIUM 24HR

+! ASTRAZENECA LP EQ 20MG BASE

N207920 001 Nov 23, 2015

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE; ORAL

ESOMEPRAZOLE MAGNESIUM

+! DEXCEL PHARMA EQ 20MG BASE

N214278 001 Oct 20, 2020

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

AUROBINDO PHARMA 10MG

A206531 001 Apr 26, 2016

LTD

20MG

A206531 002 Apr 26, 2016

DR REDDYS LABS LTD 10MG

A077367 002 Aug 17, 2001

20MG

A077367 001 Sep 25, 2006

P AND L 10MG

A075512 001 Jul 26, 2001

PERRIGO 10MG

A075400 001 Mar 18, 2005

PERRIGO R AND D 20MG

A077351 001 Sep 25, 2006

SUN PHARM INDS LTD 10MG

A090283 001 Nov 17, 2009

20MG

A090283 002 Nov 17, 2009

WOCKHARDT 10MG

A077146 001 Mar 07, 2005

20MG

A090837 001 Aug 04, 2010

PEPCID AC

+ J AND J CONSUMER 10MG

N020325 001 Apr 28, 1995

INC

10MG

N020902 001 Aug 05, 1999

+! 20MG

N020325 002 Sep 23, 2003

TABLET, CHEWABLE; ORAL

FAMOTIDINE

PERRIGO 10MG

A075715 001 Aug 22, 2003

PEPCID AC

+! J AND J CONSUMER 20MG

N020801 002 Dec 17, 2007

INC

OTC DRUG PRODUCT LIST

FEXOFENADINE HYDROCHLORIDE

SUSPENSION; ORAL

CHILDREN'S ALLEGRA ALLERGY

+	!	SANOFI AVENTIS US	30MG/5ML	N201373	001	Jan 24, 2011
---	---	-------------------	----------	---------	-----	--------------

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

P	AND	L	30MG/5ML	A203330	001	Nov 18, 2014
---	-----	---	----------	---------	-----	--------------

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

!	P	AND	L	30MG/5ML	A203330	002	Nov 18, 2014
---	---	-----	---	----------	---------	-----	--------------

TABLET; ORAL

ALLEGRA ALLERGY

+	SANOFI AVENTIS US	60MG	N020872	007	Jan 24, 2011
---	-------------------	------	---------	-----	--------------

+	!	180MG	N020872	010	Jan 24, 2011
---	---	-------	---------	-----	--------------

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

AUROLIFE PHARMA LLC	30MG	A202039	001	Nov 19, 2014
---------------------	------	---------	-----	--------------

DR REDDYS LABS LTD	30MG	A076502	004	Apr 12, 2011
--------------------	------	---------	-----	--------------

HETERO LABS LTD V	30MG	A204097	001	Aug 19, 2016
-------------------	------	---------	-----	--------------

SUN PHARM INDS	30MG	A091567	002	Feb 06, 2012
----------------	------	---------	-----	--------------

TEVA	30MG	A076447	004	Apr 13, 2011
------	------	---------	-----	--------------

WOCKHARDT LTD	30MG	A079112	002	Feb 08, 2012
---------------	------	---------	-----	--------------

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD	30MG	A076502	005	Apr 12, 2011
--------------------	------	---------	-----	--------------

SUN PHARM INDS	30MG	A091567	001	Feb 06, 2012
----------------	------	---------	-----	--------------

TEVA	30MG	A076447	005	Apr 13, 2011
------	------	---------	-----	--------------

WOCKHARDT LTD	30MG	A079112	001	Feb 08, 2012
---------------	------	---------	-----	--------------

FEXOFENADINE HYDROCHLORIDE ALLERGY

AUROLIFE PHARMA LLC	60MG	A202039	002	Nov 19, 2014
---------------------	------	---------	-----	--------------

	180MG	A202039	003	Nov 19, 2014
--	-------	---------	-----	--------------

DR REDDYS LABS LTD	60MG	A076502	006	Apr 12, 2011
--------------------	------	---------	-----	--------------

	180MG	A076502	008	Apr 12, 2011
--	-------	---------	-----	--------------

GRANULES	60MG	A211075	001	Oct 18, 2019
----------	------	---------	-----	--------------

	180MG	A211075	002	Oct 18, 2019
--	-------	---------	-----	--------------

HETERO LABS LTD V	60MG	A204097	002	Aug 19, 2016
-------------------	------	---------	-----	--------------

	180MG	A204097	003	Aug 19, 2016
--	-------	---------	-----	--------------

MYLAN	60MG	A077081	006	Jul 21, 2011
-------	------	---------	-----	--------------

	180MG	A077081	008	Jul 21, 2011
--	-------	---------	-----	--------------

SCIEGEN PHARMS INC	60MG	A204507	002	Sep 16, 2015
--------------------	------	---------	-----	--------------

	180MG	A204507	003	Sep 16, 2015
--	-------	---------	-----	--------------

SUN PHARM INDS	60MG	A091567	004	Feb 06, 2012
----------------	------	---------	-----	--------------

	180MG	A091567	006	Feb 06, 2012
--	-------	---------	-----	--------------

TEVA	60MG	A076447	006	Apr 13, 2011
------	------	---------	-----	--------------

	180MG	A076447	008	Apr 13, 2011
--	-------	---------	-----	--------------

UNIQUE PHARM LABS	180MG	A210137	001	Aug 13, 2018
-------------------	-------	---------	-----	--------------

WOCKHARDT LTD	60MG	A079112	004	Feb 08, 2012
---------------	------	---------	-----	--------------

	180MG	A079112	006	Feb 08, 2012
--	-------	---------	-----	--------------

FEXOFENADINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD	60MG	A076502	007	Apr 12, 2011
--------------------	------	---------	-----	--------------

	180MG	A076502	009	Apr 12, 2011
--	-------	---------	-----	--------------

MYLAN	60MG	A077081	007	Jul 21, 2011
-------	------	---------	-----	--------------

	180MG	A077081	009	Jul 21, 2011
--	-------	---------	-----	--------------

SCIEGEN PHARMS INC	60MG	A204507	004	Sep 16, 2015
--------------------	------	---------	-----	--------------

	180MG	A204507	005	Sep 16, 2015
--	-------	---------	-----	--------------

SUN PHARM INDS	60MG	A091567	003	Feb 06, 2012
----------------	------	---------	-----	--------------

	180MG	A091567	005	Feb 06, 2012
--	-------	---------	-----	--------------

TEVA	60MG	A076447	007	Apr 13, 2011
------	------	---------	-----	--------------

WOCKHARDT LTD	60MG	A079112	003	Feb 08, 2012
---------------	------	---------	-----	--------------

	180MG	A079112	005	Feb 08, 2012
--	-------	---------	-----	--------------

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION

+	!	SANOFI AVENTIS US	60MG;120MG	N020786	002	Jan 24, 2011
---	---	-------------------	------------	---------	-----	--------------

ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION

+	!	SANOFI AVENTIS US	180MG;240MG	N021704	002	Jan 24, 2011
---	---	-------------------	-------------	---------	-----	--------------

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AUROBINDO PHARMA	60MG;120MG	A209116	001	Oct 30, 2017
------------------	------------	---------	-----	--------------

LTD				
-----	--	--	--	--

DR REDDYS LABS LTD	60MG;120MG	A076667	001	Nov 18, 2014
--------------------	------------	---------	-----	--------------

	180MG;240MG	A079043	002	Jun 22, 2011
--	-------------	---------	-----	--------------

SUN PHARM	60MG;120MG	A090818	001	Jan 29, 2015
-----------	------------	---------	-----	--------------

OTC DRUG PRODUCT LIST

FLUTICASONE FUROATE

SPRAY, METERED;NASAL

FLONASE SENSIMIST ALLERGY RELIEF

+	GLAXOSMITHKLINE	0.0275MG/SPRAY	N022051	002	Aug 02, 2016
	CONS				

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

FLONASE ALLERGY RELIEF

+	GLAXOSMITHKLINE	0.05MG/SPRAY	N205434	001	Jul 23, 2014
	CONS				

FLUTICASONE PROPIONATE

	AKORN	0.05MG/SPRAY	A208024	001	Apr 17, 2019
	APOTEX	0.05MG/SPRAY	A208150	001	Feb 29, 2016
	HIKMA	0.05MG/SPRAY	A207957	001	May 26, 2016

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN

	ACTAVIS LABS FL	1.2GM	A091009	002	Sep 03, 2015
	AMNEAL PHARMS	600MG	A207342	001	Jul 11, 2018
		1.2GM	A207342	002	Jul 11, 2018
	AUROBINDO PHARMA LTD	600MG	A210453	001	Oct 21, 2019
		1.2GM	A210453	002	Oct 21, 2019
	GRANULES	600MG	A213420	001	May 08, 2020
		1.2GM	A213420	002	May 08, 2020
	GUARDIAN DRUG	600MG	A209215	001	Sep 06, 2017
		1.2GM	A209215	002	Sep 06, 2017
	PERRIGO R AND D	600MG	A078912	001	Nov 23, 2011
		1.2GM	A078912	002	Nov 05, 2020

MUCINEX

+	RB HLTH	600MG	N021282	001	Jul 12, 2002
+		1.2GM	N021282	002	Dec 18, 2002

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

	ACTAVIS LABS FL	600MG;60MG	A091071	001	May 27, 2015
		1.2GM;120MG	A091071	002	May 27, 2015
	AUROBINDO PHARMA LTD	600MG;60MG	A213203	001	Mar 25, 2020
		1.2GM;120MG	A213203	002	Mar 25, 2020
	DR REDDYS LABS LTD	600MG;60MG	A208369	001	Dec 29, 2017
		1.2GM;120MG	A208369	002	Dec 29, 2017
	SUN PHARM INDS INC	600MG;60MG	A212542	001	Apr 28, 2020
		1.2GM;120MG	A212542	002	Apr 28, 2020

MUCINEX D

+	RB HLTH	600MG;60MG	N021585	001	Jun 22, 2004
+		1.2GM;120MG	N021585	002	Jun 22, 2004

IBUPROFEN

CAPSULE;ORAL

ADVIL LIQUI-GELS

+	GLAXOSMITHKLINE	EQ 200MG FREE ACID AND POTASSIUM SALT	N020402	001	Apr 20, 1995
---	-----------------	---------------------------------------	---------	-----	--------------

ADVIL MIGRAINE LIQUI-GELS

+	GLAXOSMITHKLINE	EQ 200MG FREE ACID AND POTASSIUM SALT	N020402	002	Mar 16, 2000
---	-----------------	---------------------------------------	---------	-----	--------------

IBUPROFEN

	AMNEAL PHARMS	EQ 200MG FREE ACID AND POTASSIUM SALT	A202300	001	Dec 23, 2011
	ASCENT PHARMS INC	EQ 200MG FREE ACID AND POTASSIUM SALT	A206999	001	Dec 21, 2017
	AUROBINDO PHARMA LTD	EQ 200MG FREE ACID AND POTASSIUM SALT	A207753	001	Jun 29, 2018
	BIONPHARMA INC	EQ 200MG FREE ACID AND POTASSIUM SALT	A078682	001	Mar 24, 2009
	HUMANWELL PURACAP	EQ 200MG FREE ACID AND POTASSIUM SALT	A206568	001	Jun 21, 2016
	MARKSANS PHARMA	EQ 200MG FREE ACID AND POTASSIUM SALT	A079205	001	Jun 26, 2009
	P AND L DEV LLC	EQ 200MG FREE ACID AND POTASSIUM SALT	A077338	001	Jul 10, 2009
	SOFGEN PHARMS	EQ 200MG FREE ACID AND POTASSIUM SALT	A203599	001	Sep 07, 2016

MIDOL LIQUID GELS

+	BIONPHARMA INC	200MG	N021472	001	Oct 18, 2002
---	----------------	-------	---------	-----	--------------

SUSPENSION;ORAL

CHILDREN'S ADVIL

	GLAXOSMITHKLINE	100MG/5ML	N020589	001	Jun 27, 1996
--	-----------------	-----------	---------	-----	--------------

CHILDREN'S ADVIL-FLAVORED

	GLAXOSMITHKLINE	100MG/5ML	N020589	002	Nov 07, 1997
--	-----------------	-----------	---------	-----	--------------

OTC DRUG PRODUCT LIST

IBUPROFEN

SUSPENSION; ORAL

CHILDREN'S IBUPROFEN
PERRIGO 100MG/5ML A074937 001 Dec 22, 1998

CHILDREN'S MOTRIN
+! J AND J CONSUMER 100MG/5ML N020516 001 Jun 16, 1995
INC

IBUPROFEN

APTAPHARMA INC 100MG/5ML A210602 001 Nov 23, 2018
ARISE 100MG/5ML A200457 001 Aug 18, 2011
AUROBINDO PHARMA 100MG/5ML A209179 001 Apr 17, 2018
LTD
P AND L 100MG/5ML A074916 001 Apr 30, 1999
TARO 100MG/5ML A209207 001 Jun 27, 2017

SUSPENSION/DROPS; ORAL

CHILDREN'S MOTRIN
+! J AND J CONSUMER 40MG/ML N020603 001 Jun 10, 1996
INC

IBUPROFEN

GUARDIAN DRUG 40MG/ML A210755 001 Sep 26, 2018
L PERRIGO CO 40MG/ML A075217 001 Dec 16, 1998
TRIS PHARMA INC 40MG/ML A079058 001 Aug 31, 2009

INFANT'S ADVIL

+! GLAXOSMITHKLINE 50MG/1.25ML N020812 002 Jan 12, 2000

TABLET; ORAL

ADVIL

+! GLAXOSMITHKLINE 200MG N018989 001 May 18, 1984

IBU-TAB 200

ALRA 200MG A071057 001 Aug 11, 1988

IBUPROFEN

AMNEAL PHARMS 200MG A079233 001 Mar 18, 2014
AMNEAL PHARMS NY 200MG A071333 001 Feb 17, 1987
200MG A072199 001 May 23, 1988
AUROBINDO PHARMA 200MG A208865 001 Nov 08, 2017
LTD
AVEMA PHARMA 200MG A076460 001 Nov 26, 2003
CONTRACT PHARMACAL 200MG A072299 001 Jul 01, 1988
DR REDDYS LA 200MG A075661 001 Dec 12, 2001
DR REDDYS LABS INC 200MG A076117 001 Nov 20, 2001
GRANULES 200MG A202312 001 Oct 07, 2016
GRANULES INDIA 200MG A079174 001 Dec 10, 2010
LNK 200MG A075010 001 Mar 01, 1999
200MG A075139 001 Mar 01, 1999
MARKSANS PHARMA 200MG A091237 001 Feb 08, 2011
200MG A091239 001 Feb 01, 2011
MCNEIL 200MG A073019 001 Mar 30, 1994
MERRO PHARM 200MG A070985 001 Oct 02, 1987
OHM 200MG A071163 001 Jul 15, 1986
PAR PHARM 200MG A070481 001 Sep 24, 1986
PERRIGO 200MG A072096 001 Dec 08, 1987
200MG A075995 001 Mar 14, 2002
! PERRIGO R AND D 200MG A077349 001 Jun 21, 2005
SHANDONG XINHUA 200MG A207095 001 May 05, 2017
200MG A207095 002 Aug 21, 2018
200MG A079129 001 Mar 28, 2011
STRIDES PHARMA 200MG A091355 001 Apr 04, 2011
200MG A206989 001 Jun 29, 2018
200MG A207052 001 May 30, 2017
VINTAGE PHARMS 200MG A071229 001 Apr 01, 1987
YICHANG HUMANWELL 200MG A214003 001 Oct 19, 2020

JUNIOR STRENGTH ADVIL

GLAXOSMITHKLINE 100MG N020267 002 Dec 13, 1996

JUNIOR STRENGTH IBUPROFEN

L PERRIGO CO 100MG A075367 001 Apr 22, 1999

JUNIOR STRENGTH MOTRIN

J AND J CONSUMER 100MG N020602 001 Jun 10, 1996
INC

MOTRIN IB

+ J AND J CONSUMER 200MG N019012 003 Dec 17, 1990
INC

TAB-PROFEN

PERRIGO 200MG A072095 001 Dec 08, 1987

OTC DRUG PRODUCT LIST

IBUPROFEN

TABLET, CHEWABLE;ORAL

CHILDREN'S ADVIL

GLAXOSMITHKLINE

50MG

N020944 001 Dec 18, 1998

IBUPROFEN

! PERRIGO

100MG

A076359 002 Jan 16, 2004

JUNIOR STRENGTH ADVIL

GLAXOSMITHKLINE

100MG

N020944 002 Dec 18, 1998

IBUPROFEN SODIUM

TABLET;ORAL

ADVIL

+!

GLAXOSMITHKLINE

EQ 200MG BASE

N201803 001 Jun 12, 2012

IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE

TABLET;ORAL

ADVIL CONGESTION RELIEF

+!

GLAXOSMITHKLINE

200MG;10MG

N022565 001 May 27, 2010

IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE

PERRIGO R AND D

200MG;10MG

A203200 001 Jul 03, 2014

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE;ORAL

ADVIL COLD AND SINUS

+!

GLAXOSMITHKLINE

EQ 200MG FREE ACID AND POTASSIUM
SALT;30MG

N021374 001 May 30, 2002

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

AUROBINDO PHARMA
LTDEQ 200MG FREE ACID AND POTASSIUM
SALT;30MG

A209235 001 Dec 01, 2017

SUSPENSION;ORAL

CHILDREN'S ADVIL COLD

GLAXOSMITHKLINE

100MG/5ML;15MG/5ML

N021373 001 Apr 18, 2002

CHILDREN'S MOTRIN COLD

+!

J AND J CONSUMER
INC

100MG/5ML;15MG/5ML

N021128 001 Aug 01, 2000

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

PERRIGO

100MG/5ML;15MG/5ML

A076478 001 Nov 05, 2003

TABLET;ORAL

ADVIL COLD AND SINUS

+!

GLAXOSMITHKLINE

200MG;30MG

N019771 001 Sep 19, 1989

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

DR REDDYS LABS LTD

200MG;30MG

A077628 001 Aug 14, 2006

IBUPROHM COLD AND SINUS

OHM LABS

200MG;30MG

A074567 001 Apr 17, 2001

SINE-AID IB

+!

J AND J CONSUMER
INC

200MG;30MG

N019899 001 Dec 31, 1992

IODINE POVACRYLEX; ISOPROPYL ALCOHOL

SPONGE;TOPICAL

DURAPREP

+!

3M

EQ 0.7% IODINE;74% (6ML)

N021586 001 Sep 29, 2006

+!

EQ 0.7% IODINE;74% (26ML)

N021586 002 Sep 29, 2006

IVERMECTIN

LOTION;TOPICAL

SKLICE

+!

ARBOR PHARMS LLC

0.5%

N202736 001 Feb 07, 2012

KETOCONAZOLE

SHAMPOO;TOPICAL

NIZORAL A-D

+!

KRAMER

1%

N020310 001 Oct 10, 1997

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC

ALAWAY

BAUSCH

EQ 0.035% BASE

A208158 001 Sep 24, 2020

+!

BAUSCH AND LOMB

EQ 0.025% BASE

N021996 001 Dec 01, 2006

+

EQ 0.035% BASE

N021996 002 Feb 11, 2015

KETOTIFEN FUMARATE

AKORN

EQ 0.025% BASE

A077958 001 Jul 26, 2007

APOTEX INC

EQ 0.025% BASE

A077354 001 May 09, 2006

BAYSHORE PHARMS LLC

EQ 0.025% BASE

A204059 001 Jun 01, 2020

ZADITOR

!

ALCON PHARMS LTD

EQ 0.025% BASE

A077200 001 Sep 02, 2008

OTC DRUG PRODUCT LIST

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE

DR REDDYS LABS LTD	15MG	A202194	001	May 18, 2012
LANNETT CO INC	15MG	A207157	001	Sep 29, 2017
MYLAN	15MG	A203187	001	Jun 01, 2016
NATCO PHARMA LTD	15MG	A203306	001	Jan 13, 2016
PERRIGO R AND D	15MG	A202319	001	May 18, 2012
WOCKHARDT LTD	15MG	A202727	001	May 18, 2012

PREVACID 24 HR

+! PERRIGO PHARMA INTL	15MG	N022327	001	May 18, 2009
------------------------	------	---------	-----	--------------

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

LANSOPRAZOLE

DEXCEL PHARMA	15MG	N208025	001	Jun 07, 2016
---------------	------	---------	-----	--------------

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL

XYZAL ALLERGY 24HR

+! SANOFI AVENTIS US	2.5MG/5ML	N209090	001	Jan 31, 2017
----------------------	-----------	---------	-----	--------------

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

DR REDDYS LABS LTD	5MG	A210375	001	Jan 19, 2018
HETERO LABS LTD III	5MG	A213513	001	Apr 29, 2020
MICRO LABS	5MG	A211551	001	Nov 20, 2018
PERRIGO R AND D	5MG	A211983	001	Mar 28, 2019

XYZAL ALLERGY 24HR

+! SANOFI AVENTIS US	5MG	N209089	001	Jan 31, 2017
----------------------	-----	---------	-----	--------------

LEVONORGESTREL

TABLET;ORAL

ATHENTIA NEXT

AUROBINDO PHARMA LTD	1.5MG	A206867	001	Dec 08, 2015
----------------------	-------	---------	-----	--------------

FALLBACK SOLO

LUPIN LTD	1.5MG	A201446	001	Jun 19, 2014
-----------	-------	---------	-----	--------------

HER STYLE

NOVAST LABS	1.5MG	A207976	001	Mar 11, 2016
-------------	-------	---------	-----	--------------

LEVONORGESTREL

GLENMARK PHARMS LTD	1.5MG	A207044	001	Mar 25, 2016
! L PERRIGO CO	0.75MG	A090740	001	Dec 30, 2010
LABORATOIRE HRA	1.5MG	A204044	001	Jul 03, 2018
MYLAN LABS LTD	1.5MG	A202739	001	Oct 31, 2014
NAARI PTE LTD	1.5MG	A202380	001	May 29, 2015
NOVEL LABS INC	1.5MG	A202508	001	Feb 22, 2013
PERRIGO R AND D	1.5MG	A202334	001	Aug 20, 2014
XIROMED	1.5MG	A205329	001	Sep 18, 2018

OPCICON ONE-STEP

SUN PHARM	1.5MG	A202635	001	Sep 11, 2014
-----------	-------	---------	-----	--------------

PLAN B ONE-STEP

+! FDN CONSUMER	1.5MG	N021998	001	Jul 10, 2009
-----------------	-------	---------	-----	--------------

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

LOPERAMIDE HYDROCHLORIDE

+ BIONPHARMA INC	1MG	N021855	001	Aug 04, 2005
+!	2MG	N021855	002	Aug 04, 2005

SOLUTION;ORAL

IMODIUM A-D

+! J AND J CONSUMER INC	1MG/5ML	N019487	001	Mar 01, 1988
-------------------------	---------	---------	-----	--------------

LOPERAMIDE HYDROCHLORIDE

AKORN	1MG/5ML	A074352	001	Nov 17, 1995
PERRIGO	1MG/5ML	A073243	001	Jan 21, 1992
WOCKHARDT BIO AG	1MG/5ML	A074730	001	Aug 28, 1997

SUSPENSION;ORAL

IMODIUM A-D

+! J AND J CONSUMER INC	1MG/7.5ML	N019487	002	Jul 08, 2004
-------------------------	-----------	---------	-----	--------------

LOPERAMIDE HYDROCHLORIDE

PERRIGO R AND D	1MG/7.5ML	A091292	001	May 20, 2011
-----------------	-----------	---------	-----	--------------

TABLET;ORAL

IMODIUM A-D

+! J AND J CONSUMER INC	2MG	N019860	001	Nov 22, 1989
-------------------------	-----	---------	-----	--------------

OTC DRUG PRODUCT LIST

LOPERAMIDE HYDROCHLORIDE

TABLET;ORAL

LOPERAMIDE HYDROCHLORIDE

AUROBINDO PHARMA LTD	2MG	A206548	001	Dec 15, 2015
L PERRIGO CO	2MG	A075232	001	Jan 06, 2000
LNK	2MG	A076497	001	Jun 10, 2003
OHM LABS	2MG	A074091	001	Dec 10, 1992

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET;ORAL

IMODIUM MULTI-SYMPOM RELIEF

+! J AND J CONSUMER INC	2MG;125MG	N021140	001	Nov 30, 2000
-------------------------	-----------	---------	-----	--------------

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

AUROBINDO PHARMA LTD	2MG;125MG	A211059	001	Dec 14, 2020
PERRIGO R AND D	2MG;125MG	A209837	001	Sep 05, 2018
SUN PHARM INDS LTD	2MG;125MG	A077500	001	Sep 06, 2006

TABLET, CHEWABLE;ORAL

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

! PERRIGO	2MG;125MG	A076029	001	Aug 30, 2002
-----------	-----------	---------	-----	--------------

LORATADINE

CAPSULE;ORAL

CLARITIN

+! BAYER HEALTHCARE LLC	10MG	N021952	001	Jun 16, 2008
-------------------------	------	---------	-----	--------------

LORATADINE

BIONPHARMA INC	10MG	A202538	001	Dec 21, 2018
MARKSANS PHARMA	10MG	A206214	001	Sep 23, 2016

SUSPENSION;ORAL

LORATADINE

+! TARO	1MG/ML	N021734	001	Oct 04, 2005
---------	--------	---------	-----	--------------

SYRUP;ORAL

CLARITIN

+! BAYER HEALTHCARE LLC	1MG/ML	N020641	002	Nov 27, 2002
-------------------------	--------	---------	-----	--------------

LORATADINE

AUROBINDO PHARMA LTD	1MG/ML	A208931	001	Jun 29, 2018
LANNETT CO INC	1MG/ML	A077421	001	Jun 29, 2006
PERRIGO	1MG/ML	A075728	001	Aug 20, 2004
TARO	1MG/ML	A076805	001	Aug 20, 2004
	1MG/ML	A201865	001	Jul 31, 2015
WOCKHARDT BIO AG	1MG/ML	A075815	001	Aug 20, 2004

TABLET;ORAL

CLARITIN

+! BAYER HEALTHCARE LLC	10MG	N019658	002	Nov 27, 2002
-------------------------	------	---------	-----	--------------

CLARITIN HIVES RELIEF

+! BAYER HEALTHCARE LLC	10MG	N019658	003	Nov 19, 2003
-------------------------	------	---------	-----	--------------

LORATADINE

APOTEX INC	10MG	A076471	001	Feb 14, 2006
AUROBINDO PHARMA LTD	10MG	A208314	001	Apr 16, 2018
GRANULES	10MG	A210722	001	Dec 23, 2019
GUARDIAN DRUG	10MG	A207569	001	Mar 12, 2019
MYLAN	10MG	A076154	001	Aug 20, 2003
PERRIGO	10MG	A076301	001	Jun 25, 2004
PLD ACQUISITIONS LLC	10MG	A075209	001	Jan 21, 2003
SUN PHARM INDS LTD	10MG	A076134	001	Aug 18, 2003

TABLET, CHEWABLE;ORAL

CHILDREN'S CLARITIN

+! BAYER HEALTHCARE LLC	5MG	N021891	001	Aug 23, 2006
-------------------------	-----	---------	-----	--------------

CLARITIN

+ BAYER HEALTHCARE LLC	10MG	N021891	002	Nov 21, 2018
------------------------	------	---------	-----	--------------

LORATADINE

PERRIGO PHARMA INTL	5MG	A210033	001	Jun 12, 2019
SUN PHARM	5MG	A210088	001	Apr 16, 2018

OTC DRUG PRODUCT LIST

LORATADINE

TABLET, ORALLY DISINTEGRATING;ORAL
ALAVERT

FDN CONSUMER	10MG	N021375	001	Dec 19, 2002
CLARITIN HIVES RELIEF REDITAB				
+! BAYER HEALTHCARE	10MG	N020704	003	Nov 19, 2003
LLC				
CLARITIN REDITABS				
+! BAYER HEALTHCARE	5MG	N021993	001	Dec 12, 2006
LLC				
+!	10MG	N020704	002	Nov 27, 2002
LORATADINE				
AUROBINDO PHARMA	10MG	A208477	001	Apr 11, 2018
LTD				
GLAXOSMITHKLINE	10MG	A075822	001	Feb 10, 2003
PERRIGO PHARMA INTL	10MG	A076011	001	Sep 29, 2003
RUBICON	10MG	A214280	001	Sep 10, 2020
TENSHI	5MG	A212795	001	Sep 18, 2020
	10MG	A213294	001	Oct 30, 2020
LORATADINE REDIDOSE				
SUN PHARM INDS LTD	10MG	A077153	001	Apr 11, 2007

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

CLARITIN-D				
+! BAYER HEALTHCARE	5MG;120MG	N019670	002	Nov 27, 2002
LLC				
CLARITIN-D 24 HOUR				
+! BAYER HEALTHCARE	10MG;240MG	N020470	002	Nov 27, 2002
LLC				
LORATADINE AND PSEUDOEPHEDRINE SULFATE				
P AND L	10MG;240MG	A075706	001	Feb 21, 2003
PERRIGO PHARMA INTL	5MG;120MG	A076050	001	Jan 30, 2003
	10MG;240MG	A075989	001	Mar 04, 2004
SUN PHARM INDS LTD	10MG;240MG	A076557	001	Sep 22, 2004

MENTHOL; METHYL SALICYLATE

PATCH;TOPICAL

SALONPAS				
+! HISAMITSU PHARM CO	3%;10%	N022029	001	Feb 20, 2008
+	3%;10%	N022029	002	Nov 05, 2012

MICONAZOLE NITRATE

CREAM;TOPICAL, VAGINAL

MICONAZOLE 3 COMBINATION PACK				
PERRIGO	2%,4%	A076357	001	Mar 30, 2004
MONISTAT 3 COMBINATION PACK				
+ MEDTECH PRODUCTS	2%,4%	N021261	003	Jun 17, 2003
MONISTAT 3 COMBINATION PACK (PREFILLED)				
+! MEDTECH PRODUCTS	2%,4%	N021261	001	Feb 02, 2001
CREAM;VAGINAL				
MICONAZOLE 3				
TARO	4%	A076773	001	Mar 02, 2005
MICONAZOLE 7				
P AND L	2%	A074164	001	Mar 29, 1996
MICONAZOLE NITRATE				
COSETTE	2%	A074366	001	Feb 22, 1996
PERRIGO	2%	A074760	001	May 15, 1997
PERRIGO R AND D	4%	A091366	001	Jan 15, 2010
TARO PHARMS	2%	A074444	001	Jan 13, 1997
MONISTAT 3				
+! MEDTECH PRODUCTS	4%	N020827	001	Mar 30, 1998
MONISTAT 7				
+! MEDTECH PRODUCTS	2%	N017450	002	Feb 15, 1991
CREAM, SUPPOSITORY;TOPICAL, VAGINAL				
M-ZOLE 3 COMBINATION PACK				
P AND L	2%,200MG	A074926	001	Apr 16, 1999
MICONAZOLE NITRATE				
PERRIGO R AND D	2%,1.2GM	A079114	001	Jun 02, 2010
MICONAZOLE NITRATE COMBINATION PACK				
PERRIGO	2%,200MG	A075329	001	Apr 20, 1999
MONISTAT 1 COMBINATION PACK				
+! MEDTECH PRODUCTS	2%,1.2GM	N021308	001	Jun 29, 2001

OTC DRUG PRODUCT LIST

MICONAZOLE NITRATE

CREAM, SUPPOSITORY;TOPICAL, VAGINAL

MONISTAT 3 COMBINATION PACK

+! MEDTECH PRODUCTS 2%,200MG

N020670 002 Apr 16, 1996

MONISTAT 7 COMBINATION PACK

+! MEDTECH PRODUCTS 2%,100MG

N020288 002 Apr 26, 1993

SUPPOSITORY;VAGINAL

MICONAZOLE NITRATE

COSETTE 100MG

A074414 001 Apr 30, 1997

P AND L 100MG

A073507 001 Nov 19, 1993

! PERRIGO 100MG

A074395 001 Mar 20, 1997

MONISTAT 7

+! MEDTECH PRODUCTS 100MG

N018520 002 Feb 15, 1991

MINOXIDIL

AEROSOL, FOAM;TOPICAL

MEN'S ROGAINE

+! JOHNSON AND JOHNSON 5%

N021812 001 Jan 20, 2006

MINOXIDIL

PERRIGO ISRAEL 5%

A091344 001 Apr 28, 2011

MINOXIDIL (FOR MEN)

P AND L 5%

A208092 001 Feb 17, 2017

TARO 5%

A209074 001 Dec 31, 2018

MINOXIDIL (FOR WOMEN)

P AND L 5%

A208092 002 Jul 27, 2017

TARO 5%

A209074 002 Apr 22, 2019

WOMEN'S ROGAINE

+! JOHNSON AND JOHNSON 5%

N021812 002 Feb 28, 2014

SOLUTION;TOPICAL

MINOXIDIL (FOR MEN)

AKORN 2%

A074731 001 Dec 24, 1996

L PERRIGO CO 2%

A075357 001 Jul 30, 1999

P AND L 2%

A074588 001 Apr 05, 1996

WOCKHARDT BIO AG 2%

A074767 001 Feb 28, 1997

MINOXIDIL (FOR WOMEN)

AKORN 2%

A074731 002 May 11, 2005

L PERRIGO CO 2%

A075357 002 Jul 30, 1999

MINOXIDIL EXTRA STRENGTH (FOR MEN)

AVACOR PRODS 5%

A075619 001 Nov 17, 2000

P AND L 5%

A075518 001 Nov 17, 2000

PERRIGO 5%

A075598 001 Jun 13, 2001

PERRIGO NEW YORK 5%

A075737 001 Mar 15, 2002

WOCKHARDT BIO AG 5%

A075438 001 Feb 27, 2003

ROGAINE (FOR MEN)

+! JOHNSON AND JOHNSON 2%

N019501 002 Feb 09, 1996

ROGAINE (FOR WOMEN)

+! JOHNSON AND JOHNSON 2%

N019501 003 Feb 09, 1996

ROGAINE EXTRA STRENGTH (FOR MEN)

+! JOHNSON AND JOHNSON 5%

N020834 001 Nov 14, 1997

THEROXIDIL

EI INC 2%

A078176 001 Nov 09, 2007

5%

A076239 001 Aug 24, 2004

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

SOLUTION/DROPS;OPHTHALMIC

NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE

AKORN INC 0.025%;0.3%

A202795 001 Jan 24, 2013

ALTAIRE PHARMS INC 0.02675%;0.315%

A078208 001 Sep 27, 2010

NAPHCN-A

+! ALCON 0.025%;0.3%

N020226 001 Jun 08, 1994

OPCON-A

+! BAUSCH AND LOMB 0.02675%;0.315%

N020065 001 Jun 08, 1994

VISINE

+! JOHNSON AND JOHNSON 0.025%;0.3%

N020485 001 Jan 31, 1996

NAPROXEN SODIUM

CAPSULE;ORAL

NAPROXEN SODIUM

+! BIONPHARMA INC EQ 200MG BASE

N021920 001 Feb 17, 2006

CATALENT EQ 200MG BASE

A202807 001 Jan 04, 2019

PURACAP PHARM LLC EQ 200MG BASE

A208363 001 Mar 15, 2018

OTC DRUG PRODUCT LIST

NAPROXEN SODIUM

TABLET; ORAL

ALEVE

+	!	BAYER	220MG	N020204	002	Jan 11, 1994
NAPROXEN SODIUM						
		AMNEAL PHARMS NY	220MG	A079096	001	Dec 16, 2008
		AUROBINDO PHARMA LTD	220MG	A205497	001	Mar 18, 2016
		CONTRACT PHARMACAL	220MG	A074635	001	Jan 13, 1997
		DR REDDYS LABS INC	220MG	A075168	001	Jul 28, 1998
		GRANULES INDIA	220MG	A091353	001	Sep 20, 2011
		LNK INTL INC	220MG	A204872	001	Jan 23, 2017
		MARKSANS PHARMA	220MG	A090545	001	Mar 16, 2011
		NOVELGENIX THERAPS	220MG	A207612	001	Nov 16, 2018
		PERRIGO	220MG	A074661	001	Jan 13, 1997
		SUN PHARM INDS LTD	220MG	A091183	001	May 20, 2011

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALEVE-D SINUS & COLD

+	!	BAYER	220MG;120MG	N021076	001	Nov 29, 1999
NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE						
		DR REDDYS LABS INC	220MG;120MG	A077381	001	Sep 27, 2006
		PERRIGO	220MG;120MG	A076518	001	Mar 17, 2004

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

HABITROL

+		DR REDDYS LABS SA	7MG/24HR	N020076	004	Nov 12, 1999
+			14MG/24HR	N020076	005	Nov 12, 1999
+	!		21MG/24HR	N020076	006	Nov 12, 1999

NICODERM CQ

+		SANOFI AVENTIS US	7MG/24HR	N020165	006	Aug 02, 1996
+			14MG/24HR	N020165	005	Aug 02, 1996
+	!		21MG/24HR	N020165	004	Aug 02, 1996

NICOTINE

		AVEVA	7MG/24HR	A074612	002	Jul 28, 2003
			14MG/24HR	A074612	003	Oct 20, 1997
			21MG/24HR	A074612	001	Oct 20, 1997

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

NICORETTE

+		GLAXOSMITHKLINE	EQ 2MG BASE	N018612	002	Feb 09, 1996
+			EQ 2MG BASE	N018612	004	Sep 25, 2000
+	!		EQ 4MG BASE	N020066	002	Feb 09, 1996
+			EQ 4MG BASE	N020066	004	Sep 25, 2000

NICORETTE (MINT)

+		GLAXOSMITHKLINE	EQ 2MG BASE	N018612	003	Dec 23, 1998
+			EQ 4MG BASE	N020066	003	Dec 23, 1998

NICOTINE POLACRILEX

		L PERRIGO CO	EQ 2MG BASE	A076775	001	Sep 16, 2004
			EQ 2MG BASE	A076776	001	Sep 16, 2004
			EQ 2MG BASE	A076777	001	Sep 16, 2004
			EQ 4MG BASE	A076778	001	Sep 16, 2004
			EQ 4MG BASE	A076779	001	Sep 16, 2004
			EQ 4MG BASE	A076789	001	Sep 16, 2004
		P AND L	EQ 2MG BASE	A074507	001	Mar 15, 1999
			EQ 2MG BASE	A076569	001	Jul 29, 2004
			EQ 2MG BASE	A078699	001	Dec 29, 2008
			EQ 2MG BASE	A079044	001	Jul 08, 2009
			EQ 2MG BASE	A079216	001	Jul 08, 2009
			EQ 2MG BASE	A204794	001	May 10, 2016
			EQ 4MG BASE	A074707	001	Mar 19, 1999
			EQ 4MG BASE	A076568	002	Jul 29, 2004
			EQ 4MG BASE	A078697	001	Dec 29, 2008
			EQ 4MG BASE	A079038	001	Jul 08, 2009
			EQ 4MG BASE	A079219	001	Jul 08, 2009
			EQ 4MG BASE	A204833	001	Feb 26, 2016
		PERRIGO R AND D	EQ 2MG BASE	A078325	001	Oct 30, 2006
			EQ 2MG BASE	A078547	001	May 24, 2007
			EQ 2MG BASE	A078967	001	Apr 23, 2008
			EQ 2MG BASE	A091349	001	Jul 20, 2011
			EQ 2MG BASE	A206394	001	Dec 15, 2016

OTC DRUG PRODUCT LIST

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICOTINE POLACRILEX

EQ 4MG BASE	A078326 001	Oct 30, 2006
EQ 4MG BASE	A078546 001	May 24, 2007
EQ 4MG BASE	A078968 001	Apr 23, 2008
EQ 4MG BASE	A091354 001	Jul 20, 2011
EQ 4MG BASE	A206393 001	Dec 15, 2016

TROCHE/LOZENGE;ORAL

NICORETTE

+ GLAXOSMITHKLINE CONS	EQ 2MG BASE	N021330 001	Oct 31, 2002
+	EQ 2MG BASE	N022360 001	May 18, 2009
+	EQ 4MG BASE	N021330 002	Oct 31, 2002
+	EQ 4MG BASE	N022360 002	May 18, 2009

NICOTINE POLACRILEX

DR REDDYS LABS SA

EQ 2MG BASE	A212796 001	Jan 08, 2020	
EQ 2MG BASE	A212983 001	Feb 21, 2020	
EQ 2MG BASE	A213233 001	Aug 04, 2020	
EQ 4MG BASE	A212796 002	Jan 08, 2020	
EQ 4MG BASE	A212983 002	Feb 21, 2020	
EQ 4MG BASE	A213233 002	Aug 04, 2020	
P AND L	EQ 2MG BASE	A208875 001	Oct 31, 2019
EQ 2MG BASE	A209206 001	Jun 26, 2018	
EQ 2MG BASE	A209519 001	Jul 02, 2018	
EQ 2MG BASE	A209520 001	Oct 31, 2019	
EQ 2MG BASE	A210711 001	Oct 31, 2019	
EQ 2MG BASE	A210712 001	Sep 06, 2019	
EQ 2MG BASE	A212056 001	Jul 26, 2019	
EQ 2MG BASE	A212057 001	May 14, 2020	
EQ 4MG BASE	A208875 002	Oct 31, 2019	
EQ 4MG BASE	A209206 002	Jun 26, 2018	
EQ 4MG BASE	A209519 002	Jul 02, 2018	
EQ 4MG BASE	A209520 002	Oct 31, 2019	
EQ 4MG BASE	A210711 002	Oct 31, 2019	
EQ 4MG BASE	A210712 002	Sep 06, 2019	
EQ 4MG BASE	A212056 002	Jul 26, 2019	
EQ 4MG BASE	A212057 002	May 14, 2020	
PERRIGO R AND D	EQ 2MG BASE	A077007 001	Jan 31, 2006
EQ 2MG BASE	A090711 001	Jul 10, 2009	
EQ 2MG BASE	A090821 001	Jul 10, 2009	
EQ 2MG BASE	A203690 001	Oct 09, 2012	
EQ 4MG BASE	A077007 002	Jan 31, 2006	
EQ 4MG BASE	A090711 002	Jul 10, 2009	
EQ 4MG BASE	A090821 002	Jul 10, 2009	
EQ 4MG BASE	A203690 002	Oct 09, 2012	
PLD ACQUISITIONS	EQ 2MG BASE	A207868 001	Feb 07, 2019
EQ 4MG BASE	A207868 002	Feb 07, 2019	

NIZATIDINE

TABLET;ORAL

AXID AR

+	GLAXOSMITHKLINE	75MG	N020555 001	May 09, 1996
---	-----------------	------	-------------	--------------

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

APOTEX	EQ 0.1% BASE	A078350 001	Dec 07, 2015	
AUROBINDO PHARMA LTD	EQ 0.1% BASE	A204812 001	Dec 18, 2015	
	EQ 0.2% BASE	A209995 001	Apr 04, 2019	
GLAND PHARMA LTD	EQ 0.1% BASE	A209619 001	Aug 02, 2019	
	EQ 0.2% BASE	A209752 001	May 20, 2020	
MICRO LABS LTD INDIA	EQ 0.2% BASE	A204620 001	Jun 16, 2020	
PATADAY ONCE DAILY RELIEF				
+	ALCON LABS INC	EQ 0.2% BASE	N021545 001	Dec 22, 2004
+		EQ 0.7% BASE	N206276 001	Jan 30, 2015
PATADAY TWICE DAILY RELIEF				
+	ALCON LABS INC	EQ 0.1% BASE	N020688 001	Dec 18, 1996

OTC DRUG PRODUCT LIST

OMEPRAZOLE

TABLET, DELAYED RELEASE;ORAL

OMEPRAZOLE

+!	DEXCEL PHARMA	20MG	N022032	001	Dec 04, 2007
	DR REDDYS	20MG	A207740	001	Nov 05, 2018
	SUN PHARM	20MG	A207891	001	Oct 12, 2018

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

OMEPRAZOLE

+	DEXCEL PHARMA	20MG	N209400	001	Jul 05, 2017
---	---------------	------	---------	-----	--------------

OMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

OMEPRAZOLE MAGNESIUM

!	DR REDDYS LABS LTD	EQ 20MG BASE	A078878	001	Jun 05, 2009
	SPIL	EQ 20MG BASE	A210593	001	Jul 20, 2018

TABLET, DELAYED RELEASE;ORAL

OMEPRAZOLE MAGNESIUM

	AUROBINDO PHARMA LTD	EQ 20MG BASE	A206877	001	Jun 06, 2018
	HETERO LABS LTD III	EQ 20MG BASE	A211732	001	Mar 25, 2020
	P AND L	EQ 20MG BASE	A206582	001	Jun 01, 2020
	PERRIGO R AND D	EQ 20MG BASE	A204152	001	Jul 30, 2015
	PRILOSEC OTC				
+!	ASTRAZENECA PHARMS	EQ 20MG BASE	N021229	001	Jun 20, 2003

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

	AUROLIFE PHARMA LLC	20MG;1.1GM	A204923	001	Nov 07, 2016
	PERRIGO R AND D	20MG;1.1GM	A201361	001	Jul 15, 2016
	ZYDUS PHARMS	20MG;1.1GM	A203345	001	Mar 16, 2018

ZEGERID OTC

+!	BAYER HEALTHCARE LLC	20MG;1.1GM	N022281	001	Dec 01, 2009
----	----------------------	------------	---------	-----	--------------

FOR SUSPENSION;ORAL

ZEGERID OTC

+!	BAYER HEALTHCARE LLC	20MG/PACKET;1.68GM/PACKET	N022283	001	Jun 17, 2013
----	----------------------	---------------------------	---------	-----	--------------

ORLISTAT

CAPSULE;ORAL

ALLI

+!	GLAXOSMITHKLINE CONS	60MG	N021887	001	Feb 07, 2007
----	----------------------	------	---------	-----	--------------

OXYBUTYNYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL

OXYTROL FOR WOMEN

+!	ALLERGAN	3.9MG/24HR	N202211	001	Jan 25, 2013
----	----------	------------	---------	-----	--------------

OXYMETAZOLINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

VISINE L.R.

+!	JOHNSON AND JOHNSON	0.025%	N019407	001	Mar 31, 1989
----	---------------------	--------	---------	-----	--------------

PERMETHRIN

LOTION;TOPICAL

NIX

+!	MEDTECH PRODUCTS	1%	N019918	001	May 02, 1990
----	------------------	----	---------	-----	--------------

PERMETHRIN

	ACTAVIS MID ATLANTIC	1%	A075014	001	Mar 28, 2000
	PERRIGO NEW YORK	1%	A076090	001	Dec 20, 2001

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

GLYCOLAX

	LANNETT CO INC	17GM/PACKET	A090600	001	Oct 06, 2009
		17GM/SCOOPFUL	A090600	002	Oct 06, 2009

MIRALAX

+!	BAYER HEALTHCARE LLC	17GM/SCOOPFUL	N022015	001	Oct 06, 2006
----	----------------------	---------------	---------	-----	--------------

POLYETHYLENE GLYCOL 3350

	ANI PHARMS INC	17GM/SCOOPFUL	A202850	001	Dec 15, 2015
	AUROBINDO PHARMA LTD	17GM/SCOOPFUL	A209017	001	Apr 09, 2018
	LGM PHARMA	17GM/SCOOPFUL	A090812	001	Oct 07, 2009

OTC DRUG PRODUCT LIST

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

POLYETHYLENE GLYCOL 3350

MYLAN	17GM/PACKET	A078915 001	Oct 06, 2009
	17GM/SCOOPFUL	A078915 002	Oct 06, 2009
NOVEL LABS INC	17GM/SCOOPFUL	A091077 001	Oct 06, 2009
NOVELGENIX THERAPS	17GM/SCOOPFUL	A202071 001	Dec 28, 2012
NUVO PHARMS INC	17GM/SCOOPFUL	A206105 001	Oct 28, 2016
PAR PHARM	17GM/SCOOPFUL	A079214 001	Jan 31, 2013
PERRIGO R AND D	17GM/PACKET	A090685 001	Oct 06, 2009
	17GM/SCOOPFUL	A090685 002	Oct 06, 2009
STRIDES PHARMA	17GM/SCOOPFUL	A203928 001	Aug 24, 2016
	17GM/PACKET	A203928 002	Aug 24, 2016

POTASSIUM IODIDE

SOLUTION;ORAL

POTASSIUM IODIDE

MISSION PHARMACAL CO	65MG/ML	A206211 001	Mar 24, 2016
THYROSHIELD !	ARCO PHARMS LLC	65MG/ML	A077218 001
			Jan 12, 2005

TABLET;ORAL

IOSAT

+	ANBEX	65MG	N018664 002	May 12, 2011
+	!	130MG	N018664 001	Oct 14, 1982
THYROSAFE !	RECIP	65MG	A076350 001	Sep 10, 2002

POVIDONE-IODINE

SOLUTION;TOPICAL

POVIDONE IODINE

+	!	ALLEGIANCE HLTHCARE	1%	N019522 001	Mar 31, 1989
---	---	---------------------	----	-------------	--------------

SPONGE;TOPICAL

E-Z SCRUB 201

+	!	BECTON DICKINSON	20%	N019240 001	Nov 29, 1985
---	---	------------------	-----	-------------	--------------

E-Z SCRUB 241

+	!	BECTON DICKINSON	10%	N019476 001	Jan 07, 1987
---	---	------------------	-----	-------------	--------------

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

PSEUDOEPHEDRINE HYDROCHLORIDE

AUROBINDO PHARMA LTD	120MG	A209008 001	Jun 09, 2017		
L PERRIGO CO	120MG	A075153 001	Feb 26, 1999		
SUN PHARM INDS LTD	120MG	A077442 001	Sep 28, 2005		
SUDAFED 12 HOUR !	MCNEIL CONS	120MG	A073585 001	Oct 31, 1991	
SUDAFED 24 HOUR +	!	J AND J CONSUMER INC	240MG	N020021 002	Dec 15, 1992

PURIFIED WATER

SOLUTION;OPHTHALMIC

PUR-WASH

+	!	NIAGARA PHARMS	98.3%	N022305 001	Sep 01, 2011
---	---	----------------	-------	-------------	--------------

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

AUROBINDO PHARMA LTD	EQ 75MG BASE	A207579 001	Nov 13, 2017	
	EQ 150MG BASE	A207578 001	Nov 13, 2017	
DR REDDYS LABS LTD	EQ 75MG BASE	A075294 001	Mar 28, 2000	
	EQ 150MG BASE	A078192 001	Aug 31, 2007	
PERRIGO	EQ 75MG BASE	A076195 001	Aug 30, 2002	
PERRIGO R AND D	EQ 150MG BASE	A091429 001	May 11, 2011	
	EQ 150MG BASE	A091429 002	May 11, 2011	
UNIQUE PHARM LABS	EQ 75MG BASE	A210250 001	Aug 30, 2019	
	EQ 150MG BASE	A210228 001	Aug 30, 2019	
WOCKHARDT	EQ 75MG BASE	A076760 001	Feb 24, 2006	
ZANTAC 150 +	SANOFI US	EQ 150MG BASE	N021698 001	Aug 31, 2004
+		EQ 150MG BASE	N021698 002	Mar 13, 2007
ZANTAC 75 +	SANOFI US	EQ 75MG BASE	N020520 001	Dec 19, 1995

OTC DRUG PRODUCT LISTSODIUM CHLORIDE

AEROSOL, METERED; INHALATION

BRONCHO SALINE

+! BLAIREX 0.9% N019912 001 Sep 03, 1992

TERBINAFINE

GEL; TOPICAL

LAMISIL AT

+! GLAXOSMITHKLINE 1% N021958 001 Jul 24, 2006
CONSTERBINAFINE HYDROCHLORIDE

CREAM; TOPICAL

LAMISIL

+! GLAXOSMITHKLINE 1% N020980 001 Mar 09, 1999

TERBINAFINE HYDROCHLORIDE

TARO

1% A077511 001 Jul 02, 2007

SOLUTION; TOPICAL

LAMISIL AT

+! GLAXOSMITHKLINE 1% N021124 001 Mar 17, 2000

CONS

SPRAY; TOPICAL

LAMISIL AT

+! GLAXOSMITHKLINE 1% N021124 002 Mar 17, 2000

CONS

TIOCONAZOLE

OINTMENT; VAGINAL

TIOCONAZOLE

PERRIGO

6.5% A075915 001 Nov 21, 2001

VAGISTAT-1

+! COMBE 6.5% N020676 001 Feb 11, 1997

TRIAMCINOLONE ACETONIDE

SPRAY, METERED; NASAL

NASACORT ALLERGY 24 HOUR

+! SANOFI AVENTIS US 0.055MG/SPRAY N020468 002 Oct 11, 2013

TRIAMCINOLONE ACETONIDE

PERRIGO ISRAEL

0.055MG/SPRAY A078104 002 Nov 14, 2014

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

0.9% SODIUM CHLORIDE INJECTION USP SOLUTION

INJECTABLE; INJECTION

NONE

FRESENIUS KABI AG

N125695

Sep 05, 2019

ANTICOAGULANT 4% SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION

NONE

HAEMONETICS
MANUFACTURING INC

N760305

Jun 30, 1978

ANTICOAGULANT CITRATE DEXTROSE SOLUTION (ACD)

INJECTABLE; INJECTION

CITRA LABS LLC

N020037

Aug 26, 2003

ACD-A SOLUTION

TERUMO BCT INC

A010228

Feb 25, 2002

ADSOL WITH ACD-A

FENWAL INC

N000922

Aug 29, 2002

ANTICOAGULANT CITRATE DEXTROSE SOLUTION FORMULA A

HAEMONETICS CORP

A980728

Feb 06, 2002

AS3 SOLUTION/ACD-A

TERUMO BCT INC

N001214

May 29, 2002

NONE

HAEMONETICS
MANUFACTURING INC

A710497

Nov 06, 1987

ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION

NONE

FENWAL INC

N160918

Mar 17, 1978

ANTICOAGULANT CITRATE PHOSPHATE 2X DEXTROSE SOLUTION (CP2D)

INJECTABLE; INJECTION

CITRATE PHOSPHATE DOUBLE DEXTROSE/ADDITIVE SOLUTION 3

HAEMONETICS CORP

N000127

Jan 18, 2002

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION

INJECTABLE; INJECTION

NONE

TERUMO MEDICAL CORP

N820528

Nov 03, 1982

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION (CPDA)

INJECTABLE; INJECTION

CPDA-1 BLOOD-PACK UNIT (PL 146 PLASTIC) 250, 450, 500 ML BLOOD PACK UNITS

FENWAL INC

N770420

May 12, 1978

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION USP

INJECTABLE; INJECTION

BLOOD PACK UNIT CPDA-1 IN PLASTIC CONTAINER

FENWAL INC

N940404

Jul 28, 1994

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE-1 SOLUTION

INJECTABLE; INJECTION

NONE

N800077

Nov 06, 1980

HAEMONETICS

MANUFACTURING INC

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION

INJECTABLE; INJECTION

ADSOL IN PLASTIC CONTAINER

FENWAL INC

N900223

Dec 27, 1991

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION (CPD)

INJECTABLE; INJECTION

CPD ANTICOAGULANT IN PL 2209 PLASTIC CONTAINER

FENWAL INC

N900224

Dec 27, 1991

MACOPRODUCTIONS SAS CPD/AS-1: MACOPHARMA LEUCOFLEX MTL1 LEUKOREDUCTION SYSTEM FOR BLOOD COMPONENTS KNOWN AS MTL1-WB

MACOPHARMA

N040083

Nov 21, 2005

NONE

TERUMO BCT INC

A070025

Jan 06, 2009

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION

NONE

FENWAL INC

N170401

Dec 06, 1977

N811012

Jun 28, 1983

PALL CORP

N800222

Aug 23, 1982

TERUMO MEDICAL CORP

N781211

Jun 10, 1981

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP WITH: AS-1:
DEXTROSE USP; SODIUM CHLORIDE USP; MANNITOL USP; ADENINE

INJECTABLE; INJECTION

ADSOL RED BLOOD CELL PRESERVATIVE SOLUTION

FENWAL INC

N811104

May 16, 1983

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP WITH: AS-5:
DEXTROSE USP; SODIUM CHLORIDE USP; MANNITOL USP; ADENINE

INJECTABLE; INJECTION

OPTISOL RED BLOOD CELL PRESERVATIVE SOLUTION

TERUMO MEDICAL CORP

N880217

Oct 07, 1988

ANTICOAGULANT CITRATE PHOSPHATE DOUBLE DEXTROSE SOLUTION WITH:
AS-3: CITRIC ACID USP; MONOBASIC SODIUM PHOSPHATE USP; SODIUM CHLORIDE USP; ADENINE;
DEXTROSE USP; SODIUM CITRATE USP

INJECTABLE; INJECTION

AS-3 NUTRICEL ADDITIVE SYSTEM

HAEMONETICS

0.042GM/100ML;0.276GM/100ML;

N820915

Oct 19, 1984

MANUFACTURING INC

0.410GM/100ML;0.30GM/100ML;

1.10GM/100ML;0.588GM/100ML

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

ANTICOAGULANT CITRATE PHOSPHATE DOUBLE DEXTROSE SOLUTION WITH:

AS-2: CITRIC ACID USP; DIBASIC SODIUM PHOSPHATE USP; SODIUM CHLORIDE USP; ADENINE;
DEXTROSE USP; SODIUM CITRATE USP

INJECTABLE; INJECTION

AS-2 NUTRICEL ADDITIVE SYSTEM

MEDSEP CORP	0.042GM/100ML;0.285GM/100ML; 0.718GM/100ML;0.017GM/100ML; 0.396GM/100ML;0.588GM/100ML	N820915	Sep 22, 1983
-------------	---	---------	--------------

ANTICOAGULANT SODIUM CITRATE 4% SOLUTION

INJECTABLE; INJECTION

NONE

N980123 Mar 03, 2000

HAEMONETICS
CORPORATION
LABORATORIES
GRIFOIS, S.A.

A125697 Oct 25, 2019

TERUMO BCT

A125608 Jun 26, 2018

ANTICOAGULANT SODIUM CITRATE SOLUTION

INJECTABLE; INJECTION

TRICITRASOL

CITRA LABS, LLC

N010409 Jul 10, 2003

ANTICOAGULANT SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION

NONE

FENWAL INC

N770923 Jan 20, 1978

TERUMO MEDICAL CORP

N781214 Feb 08, 1980

CORD BLOOD STERILE COLLECTION BAG, ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION (CPD)

STERILE CORD BLOOD COLLECTION UNIT

NONE

MACOPHARMA

N125552 Dec 21, 2016

DEXTRAN 1 IN SODIUM CHLORIDE 0.6%

INJECTABLE; INJECTION

PROMIT

MEDA AB

N830715 Oct 30, 1984

DEXTRAN 40, 10% IN DEXTROSE 5%

INJECTABLE; INJECTION

LMD IN GLASS BOTTLE

HOSPIRA INC

10GM/100ML;5GM/100ML

A720563 Oct 30, 1992

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

LMD IN PLASTIC CONTAINER

HOSPIRA INC

10GM/100ML;0.9GM/100ML

A720562 Oct 30, 1992

HETASTARCH 6% IN LACTATED ELECTROLYTE INJECTION

INJECTABLE; INJECTION

HEXTEND

BIOTIME INC

6GM/100ML

N200952 Mar 31, 1999

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

HETASTARCH 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

6% HETASTARCH IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
HOSPIRA INC	6GM/100ML;0.9GM/100ML	A740193	Jan 30, 1995
HESPAN IN PLASTIC CONTAINER			
B BRAUN MEDICAL INC	6GM/100ML;0.9GM/100ML	N890105	Apr 04, 1991
NONE			
TEVA PHARMACEUTICALS USA INC	6GM/100ML;0.9GM/100ML	A740592	Nov 12, 1998

HYDROXYETHYL STARCH 130/0.4 IN 6% SODIUM CHLORIDE 0.9%STORAGE/PROCESSING SOLUTION ONLY; SHOULD NEVER BE
INFUSED DIRECTLY TO THE PATIENT.

NONE

B. BRAUN MEDICAL		A110013	Jan 09, 2015
VOLUVEN			
FRESENIUS KABI DEUTSCHLAND GMBH	6GM/100ML;0.9GM/100ML	N070012	Dec 27, 2007

ISOPLATE SOLUTION IN THE 500 ML EXCEL CONTAINERSTORAGE/PROCESSING SOLUTION ONLY; SHOULD NEVER BE
INFUSED DIRECTLY TO THE PATIENT.

ISOPLATE SOLUTION

TERUMO BCT		N90067	Mar 05, 2013
------------	--	--------	--------------

LEUKOCYTE REDUCTION FILTRATION SYSTEM FOR WHOLE BLOOD WITH CPD ANTICOAGULANT AND
SOLX ADDITIVE

INJECTABLE; INJECTION

LEUKOSEP HWB-600-XL			
HEMERUS MEDICAL, LLC		N110059	Apr 25, 2013

RED BLOOD CELL PROCESSING SOLUTIONSTORAGE/PROCESSING SOLUTION ONLY; SHOULD NEVER BE
INFUSED DIRECTLY TO THE PATIENT.

REJUVESOL

CITRA LABS LLC		N950522	Feb 26, 1997
----------------	--	---------	--------------

SODIUM CHLORIDE; SODIUM ACETATE; SODIUM CITRATE DIHYDRATE; SODIUM PHOSPHATE,
DIABASIC ANHYDROUS; SODIUM PHOSPHATE MONOBASIC, MONOHYDRATESTORAGE/PROCESSING SOLUTION ONLY; SHOULD NEVER BE
INFUSED DIRECTLY TO THE PATIENT.

INTERSOL SOLUTION

FRESENIUS KABI USA, LLC	2.26GM/500ML;2.21GM/500ML;1.59GM/ 500ML;1.53GM/500ML;0.465GM/500ML	N080041	Dec 09, 2009
-------------------------	---	---------	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ABACAIVIR SULFATE

TABLET;ORAL

ABACAIVIR SULFATE

APOTEX INC

EQ 300MG BASE

A201570 001 Dec 17, 2012

ABACAIVIR SULFATE; LAMIVUDINE

TABLET;ORAL

ABACAIVIR SULFATE AND LAMIVUDINE

ZYDUS PHARMS

EQ 600MG BASE;300MG

A208990 001 Nov 15, 2018

ABAMETAPIR

LOTION;TOPICAL

XEGLYZE

+ DR REDDYS LABS SA

0.74%

N206966 001 Jul 24, 2020

ABARELIX

INJECTABLE;INTRAMUSCULAR

PLENAXIS

SPECIALITY EUROPEAN

100MG/VIAL

N021320 001 Nov 25, 2003

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE;ORAL

ACAMPROSATE CALCIUM

BARR LABS DIV TEVA

333MG

A200143 001 Nov 18, 2013

CAMPRAL

+ FOREST LABS

333MG **

N021431 001 Jul 29, 2004

ACARBOSE

TABLET;ORAL

ACARBOSE

EMCURE PHARMS LTD

25MG

A202271 001 Feb 07, 2012

50MG

A202271 002 Feb 07, 2012

100MG

A202271 003 Feb 07, 2012

MYLAN

25MG

A091053 001 Jan 06, 2011

50MG

A091053 002 Jan 06, 2011

100MG

A091053 003 Jan 06, 2011

PRECOSE

+ BAYER HLTHCARE

25MG

N020482 004 May 29, 1997

+

50MG

N020482 001 Sep 06, 1995

+

100MG

N020482 002 Sep 06, 1995

ACEBUTOLOL HYDROCHLORIDE

CAPSULE;ORAL

ACEBUTOLOL HYDROCHLORIDE

ANI PHARMS INC

EQ 200MG BASE

A074007 001 Oct 18, 1995

EQ 400MG BASE

A074007 002 Oct 18, 1995

SECTRAL

+ PROMIUS PHARMA

EQ 200MG BASE

N018917 001 Dec 28, 1984

+

EQ 400MG BASE

N018917 003 Dec 28, 1984

ACETAMINOPHEN

INJECTABLE;INJECTION

INJECTAPAP

ORTHO MCNEIL PHARM

100MG/ML

N017785 001 Mar 07, 1986

SUPPOSITORY;RECTAL

ACEPHEN

COSETTE

120MG

A072218 001 Mar 27, 1992

325MG

N018060 003 Dec 18, 1986

650MG

N018060 002

ACETAMINOPHEN

ABLE

120MG

A073106 001 Feb 27, 1995

325MG

A073107 001 Feb 27, 1995

650MG

A073108 001 Feb 27, 1995

ACINO PRODS

120MG

A071010 001 May 12, 1987

650MG

A071011 001 May 12, 1987

TYLENOL

J AND J CONSUMER INC

120MG

N017756 002

650MG

N017756 001

TABLET, EXTENDED RELEASE;ORAL

ACETAMINOPHEN

SUN PHARM INDS LTD

650MG

A090205 001 Nov 18, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE

CAPSULE; ORAL

ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE

MIKART	150MG;180MG;15MG	A081095	001	Oct 26, 1990
	150MG;180MG;30MG	A081096	001	Oct 26, 1990
	150MG;180MG;60MG	A081097	001	Oct 26, 1990
CODEINE, ASPIRIN, APAP FORMULA NO. 2				
SCHERER LABS	150MG;180MG;15MG	A085640	001	
CODEINE, ASPIRIN, APAP FORMULA NO. 3				
SCHERER LABS	150MG;180MG;30MG	A085639	001	
CODEINE, ASPIRIN, APAP FORMULA NO. 4				
SCHERER LABS	150MG;180MG;60MG	A085638	001	

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL

BANCAP

FOREST PHARMS	325MG;50MG	A088889	001	Jan 16, 1986
BUCET				
MALLINCKRODT	650MG;50MG	A088991	001	Jun 28, 1985
PHRENILIN FORTE				
VALEANT	650MG;50MG	A088831	001	Jun 19, 1985
TENCON				
MALLINCKRODT	650MG;50MG	A089405	001	May 15, 1990
TRIAPRIN				
DUNHALL	325MG;50MG	A089268	001	Jul 02, 1987

TABLET; ORAL

BUTALBITAL AND ACETAMINOPHEN

HALSEY	325MG;50MG	A089568	001	Oct 05, 1988
WATSON LABS	325MG;50MG	A087550	001	Oct 19, 1984
BUTAPAP				
MIKART	650MG;50MG	A089988	001	Oct 26, 1992
PHRENILIN				
VALEANT	325MG;50MG **	A087811	001	Jun 19, 1985
SEDAPAP				
MAYRAND	650MG;50MG	A088944	001	Oct 17, 1985

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

ANOQUAN

SHIRE	325MG;50MG;40MG	A087628	001	Oct 01, 1986
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE				
GILBERT LABS	325MG;50MG;40MG **	A088825	001	Dec 05, 1984
GRAHAM DM	325MG;50MG;40MG	A088743	001	Jul 18, 1985
	325MG;50MG;40MG	A088765	001	Mar 27, 1985
	325MG;50MG;40MG	A089067	001	Apr 19, 1985
HIKMA	500MG;50MG;40MG	A040261	001	Oct 28, 1998
MALLINCKRODT	325MG;50MG;40MG	A088758	001	Mar 27, 1985
ESGIC-PLUS				
MIKART	500MG;50MG;40MG	A040085	001	Mar 28, 1996
FEMCET				
MALLINCKRODT	325MG;50MG;40MG	A089102	001	Jun 19, 1985
MEDIGESIC PLUS				
US CHEM	325MG;50MG;40MG	A089115	001	Jan 14, 1986
TRIAD				
MALLINCKRODT	325MG;50MG;40MG	A089023	001	Jun 19, 1985

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

ABLE	325MG;50MG;40MG	A040390	001	Jul 23, 2001
	500MG;50MG;40MG	A040394	001	Jul 23, 2001
GILBERT LABS	325MG;50MG;40MG	A087629	001	Nov 13, 1984
HIKMA	500MG;50MG;40MG	A040336	001	Aug 18, 1999
HIKMA PHARMS	325MG;50MG;40MG	A089718	001	Jun 12, 1995
MIKART	750MG;50MG;40MG	A040496	001	Dec 23, 2003
MIRROR PHARMS LLC	500MG;50MG;40MG	A040883	001	Dec 23, 2008
NOVAST LABS	325MG;50MG;40MG	A040864	001	Dec 01, 2008
SPECGX LLC	325MG;50MG;40MG	A087804	001	Jan 24, 1985
SUN PHARM INDUSTRIES	325MG;50MG;40MG	A040601	001	Jul 29, 2005
VINTAGE PHARMS	500MG;50MG;40MG	A040513	001	Aug 25, 2003
WATSON LABS	325MG;50MG;40MG	A089536	001	Feb 16, 1988
	500MG;50MG;40MG	A040267	001	Jul 30, 1998

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL

ESGIC

FOREST PHARMS 325MG; 50MG; 40MG A089660 001 Dec 23, 1988

ESGIC-PLUS

MIKART 500MG; 50MG; 40MG A089451 001 May 23, 1988

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

ABLE 325MG; 50MG; 40MG; 30MG A076528 001 Aug 21, 2003

HIKMA INTL PHARMS 325MG; 50MG; 40MG; 30MG A075618 001 Mar 23, 2001

PHRENILIN WITH CAFFEINE AND CODEINE

VALEANT 325MG; 50MG; 40MG; 30MG A074911 001 Aug 22, 2001

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

MIKART 356.4MG; 30MG; 16MG A040109 001 Aug 26, 1997

WRASER PHARMS LLC 356.4MG; 30MG; 16MG A040688 001 Apr 03, 2007

DHC PLUS

PHARM RES ASSOC 356.4MG; 30MG; 16MG A088584 001 Mar 04, 1986

SYNALGOS-DC-A

LEITNER PHARMS 356.4MG; 30MG; 16MG A089166 001 May 14, 1986

TABLET; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

BOCA PHARMA LLC 712.8MG; 60MG; 32MG A040701 001 Apr 03, 2007

MIKART 712.8MG; 60MG; 32MG A040316 001 Apr 28, 1999

WEST-WARD PHARM CORP 712.8MG; 60MG; 32MG A040637 001 Sep 22, 2006

ACETAMINOPHEN; CLEMASTINE FUMARATE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET; ORAL

TAVIST ALLERGY/SINUS/HEADACHE

NOVARTIS 500MG; EQ 0.25MG BASE; 30MG N021082 001 Mar 01, 2001

ACETAMINOPHEN; CODEINE PHOSPHATE

CAPSULE; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

TEVA 300MG; 15MG A088537 001 Jun 04, 1984

300MG; 30MG A088324 001 Dec 29, 1983

300MG; 60MG A088599 001 Jun 01, 1984

PHENAPHEN W/ CODEINE NO. 2

ROBINS AH 325MG; 15MG A084444 001

PHENAPHEN W/ CODEINE NO. 3

ROBINS AH 325MG; 30MG A084445 001

PHENAPHEN W/ CODEINE NO. 4

ROBINS AH 325MG; 60MG A084446 001

PROVAL #3

SOLVAY 325MG; 30MG A085685 001

TYLENOL W/ CODEINE NO. 3

ORTHO MCNEIL PHARM 300MG; 30MG A087422 001

TYLENOL W/ CODEINE NO. 4

ORTHO MCNEIL PHARM 300MG; 60MG A087421 001

SOLUTION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

ACI HEALTHCARE LTD 120MG/5ML; 12MG/5ML A086366 001

ACTAVIS MID ATLANTIC 120MG/5ML; 12MG/5ML A085861 001

DAVA PHARMS INC 120MG/5ML; 12MG/5ML A040098 001 Sep 20, 1996

LANNETT CO INC 120MG/5ML; 12MG/5ML A091238 001 Nov 10, 2011

WOCKHARDT BIO AG 120MG/5ML; 12MG/5ML A087006 001

TYLENOL W/ CODEINE

ORTHO MCNEIL PHARM 120MG/5ML; 12MG/5ML A085057 001

SUSPENSION; ORAL

CAPITAL AND CODEINE

ACTAVIS MID ATLANTIC 120MG/5ML; 12MG/5ML A085883 001

VALEANT PHARMS LLC 120MG/5ML; 12MG/5ML A086024 001

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

ABLE 300MG; 30MG A040452 001 Aug 01, 2002

300MG; 60MG A040459 001 Aug 01, 2002

AM THERAP 300MG; 15MG A089478 001 Mar 03, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

	300MG;15MG	A089481	001	Mar 03, 1987
	300MG;30MG	A089479	001	Mar 03, 1987
	300MG;30MG	A089482	001	Mar 03, 1987
	300MG;60MG	A089480	001	Mar 03, 1987
	300MG;60MG	A089483	001	Mar 03, 1987
DURAMED PHARMS BARR	300MG;15MG	A040223	001	Nov 18, 1997
	300MG;15MG	A088353	001	Feb 06, 1984
	300MG;30MG	A040223	002	Nov 18, 1997
	300MG;30MG	A088354	001	Feb 06, 1984
	300MG;60MG	A040223	003	Nov 18, 1997
	300MG;60MG	A088355	001	Feb 06, 1984
EVERYLIFE	325MG;30MG	A085217	001	
FOSUN PHARMA	300MG;30MG	A081250	001	Jul 16, 1992
	300MG;60MG	A081249	001	Jul 16, 1992
HALSEY	300MG;15MG	A083871	001	
	300MG;30MG	A083872	001	
	300MG;60MG	A086549	001	
KV PHARM	300MG;30MG	A085288	001	
	300MG;60MG	A085365	001	
	325MG;15MG	A085364	001	
	325MG;45MG **	A085363	001	
LEDERLE	300MG;30MG	A087141	001	
MIKART	300MG;30MG	A089238	001	Feb 25, 1986
	300MG;60MG	A089244	001	Feb 25, 1986
	650MG;30MG	A089231	001	Mar 03, 1986
	650MG;60MG	A089363	001	Sep 09, 1991
MUTUAL PHARM	300MG;15MG	A085795	001	
	300MG;30MG	A085794	001	
	300MG;60MG	A087653	001	Apr 13, 1982
PURACAP PHARM	300MG;30MG	A087762	001	Dec 10, 1982
PUREPAC PHARM	300MG;30MG	A086681	001	
	300MG;30MG	A089080	001	Jul 17, 1986
	300MG;60MG	A086683	001	
RHODES PHARMS	300MG;15MG	A089673	002	Feb 10, 1988
	300MG;30MG	A089673	003	Feb 10, 1988
	300MG;60MG	A089673	001	Feb 10, 1988
ROXANE	300MG;15MG	A084659	001	
	300MG;30MG	A084656	001	
	300MG;60MG	A084667	001	
	500MG;15MG	A089511	001	Apr 25, 1989
	500MG;30MG	A089512	001	Apr 25, 1989
	500MG;60MG	A089513	001	Apr 25, 1989
SANDOZ	300MG;15MG	A087433	001	
	300MG;30MG	A085291	002	
	300MG;30MG	A085917	001	
	300MG;60MG	A085964	001	
	300MG;60MG	A087423	001	
SUPERPHARM	300MG;15MG	A089183	001	Oct 18, 1985
	300MG;30MG	A089184	001	Oct 18, 1985
	300MG;30MG	A089253	001	May 19, 1986
	300MG;60MG	A089185	001	Oct 18, 1985
	300MG;60MG	A089254	001	May 19, 1986
USL PHARMA	300MG;30MG	A087919	001	Jun 22, 1982
	300MG;60MG	A087920	001	Jun 22, 1982
VALEANT PHARM INTL	300MG;30MG	A085896	001	
VITARINE	300MG;30MG	A085676	001	
WARNER CHILCOTT	300MG;15MG	A085992	001	
	300MG;30MG	A085218	002	
	300MG;60MG	A087306	001	
WATSON LABS	300MG;15MG	A087277	001	May 26, 1982
	300MG;15MG	A089997	001	Dec 28, 1994
	300MG;30MG	A087276	001	May 26, 1982
	300MG;30MG	A089998	001	Dec 28, 1994
	300MG;60MG	A087275	001	May 26, 1982
	300MG;60MG	A089999	001	Dec 28, 1994
WATSON LABS FLORIDA	300MG;15MG	A040443	001	Jan 22, 2003

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

	300MG;30MG	A040443 002	Jan 22, 2003
	300MG;60MG	A040443 003	Jan 22, 2003
WHITEWORTH TOWN PLSN	300MG;30MG	A084360 001	
	300MG;60MG	A085607 001	
CAPITAL AND CODEINE			
CARNRICK	325MG;30MG	A083643 001	
CODRIX			
WATSON LABS FLORIDA	500MG;15MG	A040447 001	Feb 26, 2003
	500MG;30MG	A040441 001	Mar 27, 2003
	500MG;60MG	A040488 001	Mar 28, 2003
EMPRACET W/ CODEINE PHOSPHATE #3			
GLAXOSMITHKLINE	300MG;30MG	A083951 001	
EMPRACET W/ CODEINE PHOSPHATE #4			
GLAXOSMITHKLINE	300MG;60MG	A083951 002	
PAPA-DEINE #3			
VANGARD	300MG;30MG	A088037 001	Mar 20, 1984
PAPA-DEINE #4			
VANGARD	300MG;60MG	A088715 001	Mar 20, 1984
PHENAPHEN-650 W/ CODEINE			
ROBINS AH	650MG;30MG	A085856 001	
TYLENOL W/ CODEINE			
ORTHO MCNEIL PHARM	325MG;7.5MG **	A085056 001	
	325MG;15MG **	A085056 002	
	325MG;30MG **	A085056 003	
	325MG;60MG **	A085056 004	
TYLENOL W/ CODEINE NO. 1			
JANSSEN PHARMS	300MG;7.5MG	A085055 001	
TYLENOL W/ CODEINE NO. 2			
JANSSEN PHARMS	300MG;15MG	A085055 002	
TYLENOL W/ CODEINE NO. 3			
JANSSEN PHARMS	300MG;30MG	A085055 003	
TYLENOL W/ CODEINE NO. 4			
JANSSEN PHARMS	300MG;60MG	A085055 004	

ACETAMINOPHEN; DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

DRIXORAL PLUS

SCHERING PLOUGH	500MG;3MG;60MG	N019453 001	May 22, 1987
-----------------	----------------	-------------	--------------

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

ACETAMINOPHEN AND HYDROCODONE BITARTRATE

CENT PHARMS	500MG;5MG	A088898 001	Mar 27, 1985
ALLAY			
IVAX PHARMS	500MG;5MG	A089907 001	Jan 13, 1989
BANCAP HC			
FOREST PHARMS	500MG;5MG	A087961 001	Mar 17, 1983
CO-GESIC			
CENT PHARMS	500MG;5MG	A089360 001	Mar 02, 1988
HYDROCODONE BITARTRATE AND ACETAMINOPHEN			
MALLINCKRODT	500MG;5MG	A088956 001	Jul 19, 1985
	500MG;5MG	A089006 001	Aug 09, 1985
MIKART	500MG;5MG	A081067 001	Nov 30, 1989
	500MG;5MG	A081068 001	Nov 30, 1989
	500MG;5MG	A081069 001	Nov 30, 1989
	500MG;5MG	A081070 001	Nov 30, 1989
	500MG;5MG	A089008 001	Feb 21, 1986
LORCET-HD			
MALLINCKRODT	500MG;5MG	A087336 001	Jul 08, 1982
SOLUTION; ORAL			
HYDROCODONE BITARTRATE AND ACETAMINOPHEN			
MALLINCKRODT	500MG/15ML;7.5MG/15ML	A040418 001	Jun 27, 2001
MALLINCKRODT INC	500MG/15ML;10MG/15ML	A040508 001	Aug 29, 2003
MIKART	500MG/15ML;5MG/15ML	A081226 001	Oct 27, 1992
	500MG/15ML;5MG/15ML	A089557 001	Apr 29, 1992
	500MG/15ML;7.5MG/15ML	A081051 001	Aug 28, 1992
NESHER PHARMS	500MG/15ML;7.5MG/15ML	A040366 001	Jan 23, 2002

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

PHARM ASSOC	500MG/15ML;7.5MG/15ML	A040182	001	Mar 13, 1998
VINTAGE PHARMS	500MG/15ML;7.5MG/15ML	A040520	001	Oct 30, 2003
ZYFREL				
CYPRESS PHARM INC	325MG/15ML;7.5MG/15ML	A090468	001	Apr 14, 2016

TABLET; ORAL

ANEXSIA

MALLINCKRODT	500MG;5MG	A089160	001	Apr 23, 1987
	750MG;10MG	A040468	001	Oct 31, 2002

ANEXSIA 7.5/650

MALLINCKRODT	650MG;7.5MG	A089725	001	Sep 30, 1987
--------------	-------------	---------	-----	--------------

CO-GESIC

UCB INC	500MG;5MG	A087757	001	May 03, 1982
---------	-----------	---------	-----	--------------

DURADYNE DHC

FOREST PHARMS	500MG;5MG	A087809	001	Mar 17, 1983
---------------	-----------	---------	-----	--------------

HY-PHEN

ASCHER	500MG;5MG	A087677	001	May 03, 1982
--------	-----------	---------	-----	--------------

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

ABLE	325MG;5MG	A040478	001	Nov 08, 2002
	325MG;7.5MG	A040464	001	Oct 23, 2002
	325MG;10MG	A040464	002	Oct 23, 2002
	500MG;5MG	A040477	001	Nov 06, 2002
	500MG;7.5MG	A040490	001	May 21, 2003
	500MG;10MG	A040473	001	Nov 06, 2002
	650MG;7.5MG	A040474	001	Jan 02, 2003
	650MG;10MG	A040476	001	Oct 23, 2002
	750MG;7.5MG	A040469	001	Oct 25, 2002
ACTAVIS LABS FL INC	300MG;5MG	A206470	001	Jun 02, 2016
	300MG;7.5MG	A206470	002	Jun 02, 2016
	300MG;10MG	A206470	003	Jun 02, 2016
ALVOGEN PINE BROOK	300MG;5MG	A208540	001	Nov 08, 2018
	300MG;7.5MG	A208540	002	Nov 08, 2018
	300MG;10MG	A208540	003	Nov 08, 2018
	325MG;2.5MG	A209958	001	Oct 24, 2018
	325MG;5MG	A209958	002	Oct 24, 2018
	325MG;7.5MG	A209958	003	Oct 24, 2018
	325MG;10MG	A209958	004	Oct 24, 2018
AMNEAL PHARMS NY	500MG;5MG	A040729	001	Aug 25, 2006
	500MG;7.5MG	A040748	001	Aug 25, 2006
	500MG;10MG	A040813	001	Feb 23, 2007
	650MG;7.5MG	A040754	001	Aug 25, 2006
	650MG;10MG	A040757	001	Aug 25, 2006
	750MG;7.5MG	A040769	001	Aug 28, 2006
APIL	500MG;10MG	A040148	002	Feb 14, 1997
BARR	500MG;2.5MG	A040307	001	Jul 26, 2000
	500MG;5MG	A040308	001	Jul 26, 2000
	500MG;5MG	A088577	001	Dec 21, 1984
	500MG;7.5MG	A040307	002	Jul 26, 2000
	500MG;10MG	A040309	001	Jul 26, 2000
	650MG;7.5MG	A040307	003	Jul 26, 2000
	650MG;10MG	A040307	004	Jul 26, 2000
	750MG;7.5MG	A040308	002	Jul 26, 2000
CARACO	500MG;5MG	A090265	001	Dec 23, 2008
	500MG;7.5MG	A090265	002	Dec 23, 2008
	500MG;10MG	A090265	003	Dec 23, 2008
	650MG;7.5MG	A090380	001	Dec 23, 2008
	650MG;10MG	A090380	002	Dec 23, 2008
	660MG;10MG	A090380	003	Dec 23, 2008
	750MG;7.5MG	A090380	004	Dec 23, 2008
CEROVENE INC	325MG;5MG	A211690	001	Feb 07, 2020
	325MG;7.5MG	A211690	002	Feb 07, 2020
	325MG;10MG	A211690	003	Feb 07, 2020
GRANULES PHARMS	325MG;5MG	A211729	001	Jan 03, 2020
	325MG;7.5MG	A211729	002	Jan 03, 2020
	325MG;10MG	A211729	003	Jan 03, 2020
HALSEY	500MG;5MG	A089554	001	Jun 12, 1987
IVAX PHARMS	500MG;5MG	A089696	001	Apr 21, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

LANNETT CO INC	300MG;5MG	A207171	001	Jun 20, 2017
	300MG;7.5MG	A207171	002	Jun 20, 2017
	300MG;10MG	A207171	003	Jun 20, 2017
	325MG;5MG	A207172	001	Jun 22, 2017
	325MG;7.5MG	A207172	002	Jun 22, 2017
	325MG;10MG	A207172	003	Jun 22, 2017
MALLINCKRODT	500MG;5MG	A040084	002	Jun 01, 1995
	500MG;7.5MG	A040201	001	Feb 27, 1998
	500MG;10MG	A040201	002	Feb 27, 1998
	650MG;10MG	A040084	004	Oct 16, 1996
	660MG;10MG	A040084	003	Jul 29, 1996
	750MG;7.5MG	A040084	001	Jun 01, 1995
MIKART	500MG;2.5MG	A089698	001	Aug 25, 1989
	500MG;5MG	A089271	001	Jul 16, 1986
	500MG;5MG	A089697	001	Jan 28, 1992
	500MG;7.5MG	A089699	001	Aug 25, 1989
	650MG;5MG	A040849	001	Jun 09, 2010
	650MG;7.5MG	A089689	001	Jun 29, 1988
	650MG;10MG	A081223	001	May 29, 1992
MUTUAL PHARM	500MG;5MG	A040236	001	Sep 25, 1997
	650MG;7.5MG	A040240	002	Nov 26, 1997
	650MG;10MG	A040240	001	Nov 26, 1997
	750MG;7.5MG	A040236	002	Sep 25, 1997
NOSTRUM LABS INC	325MG;2.5MG	A209924	001	Nov 16, 2018
	325MG;5MG	A209924	002	Nov 16, 2018
	325MG;7.5MG	A209924	003	Nov 16, 2018
	325MG;10MG	A209924	004	Nov 16, 2018
PAR PHARM	300MG;5MG	A205001	001	Jul 05, 2016
	300MG;7.5MG	A205001	002	Jul 05, 2016
	300MG;10MG	A205001	003	Jul 05, 2016
RANBAXY	500MG;5MG	A040825	001	Aug 16, 2007
	500MG;10MG	A040824	001	Aug 16, 2007
RANBAXY LABS LTD	750MG;7.5MG	A040822	001	Aug 16, 2007
SANDOZ	500MG;5MG	A040149	001	Jan 27, 1997
	750MG;7.5MG	A040149	002	Jan 27, 1997
SUN PHARM INDS LTD	325MG;10MG	A040826	001	Aug 16, 2007
UCB INC	500MG;10MG	A040210	001	Aug 13, 1997
	650MG;7.5MG	A040134	001	Nov 21, 1996
UPSHER SMITH LABS	325MG;5MG	A206484	001	Mar 24, 2017
	325MG;7.5MG	A206484	002	Mar 24, 2017
	325MG;10MG	A206484	003	Mar 24, 2017
USL PHARMA	500MG;5MG	A089290	001	May 29, 1987
	500MG;5MG	A089291	001	May 29, 1987
VINTAGE PHARMS	300MG;5MG	A090415	001	Jan 24, 2011
	300MG;7.5MG	A090415	002	Jan 24, 2011
	300MG;10MG	A090415	003	Jan 24, 2011
	500MG;2.5MG	A040144	002	Apr 25, 1997
	500MG;5MG	A089831	001	Sep 07, 1988
	500MG;5MG	A089971	001	Dec 02, 1988
	500MG;7.5MG	A040144	001	Feb 22, 1996
	500MG;10MG	A040356	001	May 31, 2000
	650MG;7.5MG	A040155	001	Apr 14, 1997
	650MG;10MG	A040143	001	Feb 22, 1996
	660MG;10MG	A040358	001	May 31, 2000
	750MG;7.5MG	A040157	001	Apr 12, 1996
VINTAGE PHARMS LLC	500MG;5MG	A040281	001	Sep 30, 1998
	500MG;7.5MG	A040280	001	Sep 30, 1998
	650MG;7.5MG	A040280	002	Sep 30, 1998
	650MG;10MG	A040280	003	Sep 30, 1998
	750MG;7.5MG	A040281	002	Sep 30, 1998
WATSON LABS	325MG;7.5MG	A040248	001	Apr 28, 2000
	325MG;10MG	A040248	002	Apr 28, 2000
	500MG;2.5MG	A040123	003	Mar 04, 1996
	500MG;2.5MG	A081079	001	Aug 30, 1991
	500MG;5MG	A040122	001	Mar 04, 1996
	500MG;5MG	A089883	001	Dec 01, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

500MG; 7.5MG	A040123	004	Mar 04, 1996
500MG; 7.5MG	A081080	001	Aug 30, 1991
650MG; 7.5MG	A040094	001	Sep 29, 1995
650MG; 7.5MG	A040123	001	Mar 04, 1996
650MG; 10MG	A040094	002	Sep 29, 1995
650MG; 10MG	A040123	002	Mar 04, 1996
660MG; 10MG	A040094	003	Aug 08, 2000
750MG; 7.5MG	A040122	002	Mar 04, 1996
750MG; 7.5MG	A081083	001	Aug 30, 1991
750MG; 10MG	A040094	004	Mar 22, 1999
WATSON LABS FLORIDA 500MG; 5MG	A040493	001	May 28, 2003
660MG; 10MG	A040495	001	May 28, 2003
750MG; 7.5MG	A040494	001	May 28, 2003
LORTAB			
UCB INC 500MG; 5MG	A087722	001	Jul 09, 1982
500MG; 10MG	A040100	001	Jan 26, 1996
NORCET			
ABANA 500MG; 5MG	A088871	001	May 15, 1986
TYCOLET			
ORTHO MCNEIL PHARM 500MG; 5MG	A089385	001	Aug 27, 1986
VICODIN			
ABBOTT 500MG; 5MG	A085667	001	
ABBVIE 500MG; 5MG	A088058	001	Jan 07, 1983
VICODIN ES			
ABBVIE 750MG; 7.5MG	A089736	001	Dec 09, 1988
VICODIN HP			
ABBVIE 660MG; 10MG	A040117	001	Sep 23, 1996
ZYDONE			
VINTAGE PHARMS LLC 400MG; 5MG	A040288	001	Nov 27, 1998
400MG; 7.5MG	A040288	002	Nov 27, 1998
400MG; 10MG	A040288	003	Nov 27, 1998

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE AND ACETAMINOPHEN

ACTAVIS ELIZABETH 500MG; 5MG	A040199	001	Dec 30, 1998
BARR 500MG; 5MG	A040304	001	Oct 02, 2000
DURAMED PHARMS BARR 500MG; 5MG	A040289	001	Mar 16, 1999
HALSEY 500MG; 5MG	A089994	001	May 04, 1989
MALLINCKRODT 500MG; 5MG	A040257	001	Aug 04, 1998
MUTUAL PHARM 500MG; 5MG	A040219	001	Jan 22, 1998
VINTAGE PHARMS 500MG; 5MG	A040106	001	Jul 30, 1996
VINTAGE PHARMS LLC 500MG; 5MG	A040303	001	Dec 30, 1999
WATSON LABS 500MG; 5MG	A040234	001	Oct 30, 1997
ROXILOX			
ROXANE 500MG; 5MG	A040061	001	Jul 03, 1995
TYLOX			
JANSSEN PHARMS 500MG; 5MG	A088790	001	Dec 12, 1984
TYLOX-325			
ORTHO MCNEIL PHARM 325MG; 5MG	A088246	001	Nov 08, 1984

SOLUTION; ORAL

OXYCODONE AND ACETAMINOPHEN

SPECGX LLC 325MG/5ML; 5MG/5ML	A040680	001	Sep 29, 2006
OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN			
VINTAGE PHARMS 325MG/5ML; 5MG/5ML	A203573	001	Dec 18, 2014
ROXICET			
HIKMA 325MG/5ML; 5MG/5ML	A089351	001	Dec 03, 1986

TABLET; ORAL

OXYCODONE 2.5/APAP 500

BRISTOL MYERS SQUIBB 500MG; 2.5MG	A085910	001	
OXYCODONE 5/APAP 500			
BRISTOL MYERS SQUIBB 500MG; 5MG	A085911	001	
OXYCODONE AND ACETAMINOPHEN			
ACTAVIS ELIZABETH 325MG; 5MG	A040203	001	Mar 15, 1999
325MG; 7.5MG	A040800	001	Apr 03, 2012
325MG; 10MG	A040800	002	Apr 03, 2012
AMNEAL PHARMS NY 500MG; 7.5MG	A040789	001	Nov 27, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

	650MG;10MG	A040789 002	Nov 27, 2007
BARR	325MG;5MG	A087406 001	
CEROVENE INC	325MG;5MG	A207574 001	Dec 13, 2016
DURAMED PHARMS BARR	325MG;5MG	A040272 001	Jun 30, 1998
GRANULES PHARMS	325MG;2.5MG	A211708 001	Oct 31, 2019
	325MG;5MG	A211708 002	Oct 31, 2019
	325MG;7.5MG	A211708 003	Oct 31, 2019
	325MG;10MG	A211708 004	Oct 31, 2019
LANNETT CO INC	325MG;5MG	A207333 001	Sep 25, 2017
	325MG;10MG	A207333 002	Sep 25, 2017
MALLINCKRODT	500MG;7.5MG	A040550 001	Jun 30, 2004
	650MG;10MG	A040550 002	Jun 30, 2004
MAYNE PHARMA INC	500MG;7.5MG	A090177 005	Oct 20, 2008
	650MG;10MG	A090177 006	Oct 20, 2008
MIKART	400MG;2.5MG	A040679 001	May 16, 2006
	400MG;5MG	A040687 001	Apr 27, 2006
	400MG;7.5MG	A040698 001	Apr 27, 2006
	400MG;10MG	A040692 001	Apr 27, 2006
	500MG;10MG	A040676 001	Apr 19, 2006
NOSTRUM LABS INC	325MG;5MG	A209385 001	Jul 02, 2018
	325MG;7.5MG	A209385 002	Jul 02, 2018
	325MG;10MG	A209385 003	Jul 02, 2018
WATSON LABS	325MG;5MG	A040171 001	Oct 30, 1997
	325MG;7.5MG	A040535 001	Sep 05, 2003
	325MG;10MG	A040535 002	Sep 05, 2003
	500MG;7.5MG	A040371 001	Dec 29, 2000
	650MG;10MG	A040371 002	Dec 29, 2000
PERCOCET			
VINTAGE PHARMS LLC	325MG;5MG	A085106 002	
	500MG;7.5MG	A040341 001	Jul 26, 1999
	650MG;10MG	A040341 002	Jul 26, 1999
ROXICET 5/500			
ROXANE	500MG;5MG	A089775 001	Jan 12, 1989
TABLET, EXTENDED RELEASE; ORAL			
XARTEMIS XR			
+ MALLINCKRODT INC	325MG;7.5MG	N204031 001	Mar 11, 2014

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

CAPSULE; ORAL

TYLOX

ORTHO MCNEIL PHARM	500MG;4.5MG;0.38MG	A085375 001	
--------------------	--------------------	-------------	--

ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE

GAVIS PHARMS	650MG;EQ 25MG BASE	A076202 001	Aug 02, 2002
WATSON LABS	650MG;EQ 25MG BASE	A074699 001	Mar 24, 2000

TALACEN

SANOFI AVENTIS US	650MG;EQ 25MG BASE	N018458 001	Sep 23, 1982
-------------------	--------------------	-------------	--------------

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL

DARVOCET

AAIPHARMA LLC	325MG;32.5MG	N016844 001	
---------------	--------------	-------------	--

DOLENE AP-65

LEDERLE	650MG;65MG	A085100 001	
---------	------------	-------------	--

PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN

MYLAN	325MG;32MG	A083689 001	
	650MG;65MG	A083978 001	
SANDOZ	650MG;65MG	A089959 001	Jul 18, 1989
VINTAGE PHARMS	650MG;65MG	A040507 001	Jul 30, 2003
WATSON LABS	650MG;65MG	A040139 001	Dec 16, 1996

WYGESIC

CARACO	650MG;65MG	A084999 001	
--------	------------	-------------	--

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

DARVOCET A500				
XANODYNE PHARM	500MG;100MG	A076429	001	Sep 10, 2003
DARVOCET-N 100				
XANODYNE PHARM	650MG;100MG	N017122	002	
DARVOCET-N 50				
XANODYNE PHARM	325MG;50MG	N017122	001	
PROPACET 100				
TEVA	650MG;100MG	A070107	001	Jun 12, 1985
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN				
ABLE	650MG;100MG	A075838	001	Jul 11, 2001
ACTAVIS ELIZABETH	650MG;100MG	A070910	001	Jan 02, 1987
CORNERSTONE	325MG;100MG	A076743	001	May 07, 2004
	500MG;100MG	A076750	001	Jun 28, 2004
HALSEY	325MG;50MG	A072105	001	May 13, 1988
	650MG;100MG	A072106	001	May 13, 1988
IVAX SUB TEVA PHARMS	650MG;100MG	A070146	001	Aug 02, 1985
MALLINCKRODT	650MG;100MG	A075738	001	Feb 02, 2001
MIRROR PHARMS	650MG;100MG	A077821	001	Feb 11, 2008
MUTUAL PHARM	325MG;50MG	A070115	001	Jun 12, 1985
	650MG;100MG	A070116	001	Jun 12, 1985
	650MG;100MG	A070615	001	Mar 21, 1986
	650MG;100MG	A070771	001	Mar 21, 1986
	650MG;100MG	A070775	001	Mar 21, 1986
MYLAN	650MG;100MG	A072195	001	Feb 16, 1988
MYLAN PHARMS INC	650MG;100MG	A070145	001	Jun 12, 1985
SANDOZ	650MG;100MG	A070443	001	Jan 23, 1986
SUPERPHARM	650MG;100MG	A071319	001	Jan 06, 1987
TEVA	650MG;100MG	A070732	001	Jan 03, 1986
	650MG;100MG	A074119	001	Dec 19, 1994
VINTAGE PHARMS	325MG;50MG	A074843	002	Feb 15, 2001
	650MG;100MG	A074843	001	Feb 12, 1997
WATSON LABS	325MG;50MG	A070398	001	Dec 18, 1986
	650MG;100MG	A070399	001	Dec 18, 1986
WATSON LABS FLORIDA	500MG;100MG	A077196	001	Jun 28, 2005
	650MG;100MG	A076609	001	Nov 16, 2004
WOCKHARDT LTD	325MG;50MG	A077677	001	Mar 16, 2007
	650MG;100MG	A077677	002	Mar 16, 2007

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN				
MACLEODS PHARMS LTD	325MG;37.5MG	A206885	001	May 02, 2017
NOSTRUM LABS INC	325MG;37.5MG	A078778	001	Apr 07, 2014
PAR PHARM	325MG;37.5MG	A076475	001	Apr 21, 2005
RISING	325MG;37.5MG	A076914	001	Jul 26, 2006

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL

ACETAZOLAMIDE				
ACCORD HLTHCARE	500MG	A207659	001	Oct 18, 2018
MYLAN	500MG	A203917	001	Jun 18, 2019

DIAMOX

+ TEVA BRANDED PHARM	500MG	N012945	001	
----------------------	-------	---------	-----	--

TABLET; ORAL

ACETAZOLAMIDE				
ALRA	250MG	A083320	001	
ASCOT	250MG	A087686	001	Oct 20, 1982
HERITAGE PHARMA	250MG	A088882	001	Oct 22, 1985
SUN PHARM INDUSTRIES	125MG	A089753	002	Jun 22, 1988
	250MG	A089753	001	Jun 22, 1988
VANGARD	250MG	A087654	001	Feb 05, 1982
WATSON LABS	250MG	A084498	002	
DIAMOX				
+ TEVA BRANDED PHARM	125MG **	N008943	001	
+	250MG **	N008943	002	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

EMCURE PHARMS LTD	EQ 500MG BASE/VIAL	A202693	001	Dec 19, 2014
HOSPIRA	EQ 500MG BASE/VIAL	A040108	001	Oct 30, 1995
PAR STERILE PRODUCTS	EQ 500MG BASE/VIAL	A205358	001	Jun 20, 2017
DIAMOX				
+ TEVA WOMENS	EQ 500MG BASE/VIAL **	N009388	001	

ACETIC ACID, GLACIAL

SOLUTION/DROPS; OTIC

ACETASOL

ACTAVIS MID ATLANTIC	2%	A087146	001	
----------------------	----	---------	-----	--

ACETIC ACID

KV PHARM	2%	A085493	001	
----------	----	---------	-----	--

ORLEX

WARNER CHILCOTT	2%	A086845	001	
-----------------	----	---------	-----	--

ACETIC ACID, GLACIAL; ALUMINUM ACETATE

SOLUTION/DROPS; OTIC

ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE

BAUSCH AND LOMB	2%;0.79%	A040063	001	Feb 25, 1994
-----------------	----------	---------	-----	--------------

BOROFAIR

PHARMAFAIR	2%;0.79%	A088606	001	Aug 21, 1985
------------	----------	---------	-----	--------------

DOMEBORO

BAYER PHARMS	2%;0.79%	A084476	001	
--------------	----------	---------	-----	--

ACETIC ACID, GLACIAL; DESONIDE

SOLUTION/DROPS; OTIC

TRIDESILON

BAYER PHARMS	2%;0.05%	N017914	001	
--------------	----------	---------	-----	--

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC

ACETASOL HC

ACTAVIS MID ATLANTIC	2%;1%	A087143	001	Jan 13, 1982
----------------------	-------	---------	-----	--------------

ACETIC ACID W/ HYDROCORTISONE

KV PHARM	2%;1%	A085492	001	
----------	-------	---------	-----	--

HYDROCORTISONE AND ACETIC ACID

BAUSCH AND LOMB	2%;1%	A040097	001	Oct 31, 1994
-----------------	-------	---------	-----	--------------

WOCKHARDT	2%;1%	A040168	001	Aug 30, 1996
-----------	-------	---------	-----	--------------

ORLEX HC

WARNER CHILCOTT	2%;1%	A086844	001	
-----------------	-------	---------	-----	--

ACETIC ACID, GLACIAL; HYDROCORTISONE; NEOMYCIN SULFATE

SUSPENSION/DROPS; OTIC

NEO-CORT-DOME

BAYER PHARMS	2%;1%;EQ 0.35% BASE	N050238	001	
--------------	---------------------	---------	-----	--

ACETOHEXAMIDE

TABLET; ORAL

ACETOHEXAMIDE

ANI PHARMS INC	250MG	A070870	002	Feb 09, 1987
----------------	-------	---------	-----	--------------

	500MG	A070870	001	Feb 09, 1987
--	-------	---------	-----	--------------

USL PHARMA	250MG	A070753	001	Nov 03, 1986
------------	-------	---------	-----	--------------

	500MG	A070754	001	Nov 03, 1986
--	-------	---------	-----	--------------

WATSON LABS TEVA	250MG	A071893	001	Nov 25, 1987
------------------	-------	---------	-----	--------------

	500MG	A071894	001	Nov 25, 1987
--	-------	---------	-----	--------------

DYMELOR

LILLY	250MG	N013378	002	
-------	-------	---------	-----	--

	500MG	N013378	001	
--	-------	---------	-----	--

ACETOPHENAZINE MALEATE

TABLET; ORAL

TINDAL

SCHERING	20MG	N012254	002	
----------	------	---------	-----	--

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ACETRIZOATE SODIUMSOLUTION; INTRAUTERINE
SALPIX

ORTHO MCNEIL PHARM 53% N009008 001

ACETYLCHOLINE CHLORIDEFOR SOLUTION; OPHTHALMIC
MIOCHOL

+ NOVARTIS 20MG/VIAL ** N016211 001

ACETYLCYSTEINE

INJECTABLE; INTRAVENOUS

ACETYLCYSTEINE

MYLAN INSTITUTIONAL 6GM/30ML (200MG/ML) A203624 001 Jun 19, 2015

SOLUTION; INHALATION, ORAL

ACETYLCYSTEINE

HOSPIRA 10% A071364 001 May 01, 1989

20% A071365 001 May 01, 1989

ROXANE 10% A072323 001 Apr 30, 1992

10% A072621 001 Sep 30, 1992

20% A072324 001 Apr 30, 1992

20% A072622 001 Sep 30, 1992

MUCOMYST

+ APOTHECON 10% ** N013601 002

+ 20% ** N013601 001

MUCOSIL-10

DEY 10% A070575 001 Oct 14, 1986

MUCOSIL-20

DEY 20% A070576 001 Oct 14, 1986

TABLET, EFFERVESCENT; ORAL

CETYLEV

+ ARBOR PHARMS LLC 500MG N207916 001 Jan 29, 2016

+ 2.5GM N207916 002 Jan 29, 2016

ACETYLCYSTEINE; ISOPROTERENOL HYDROCHLORIDE

SOLUTION; INHALATION

MUCOMYST W/ ISOPROTERENOL

MEAD JOHNSON 10%; 0.05% N017366 001

ACETYLDIGITOXIN

TABLET; ORAL

ACYLANID

NOVARTIS 0.1MG N009436 001

ACITRETIN

CAPSULE; ORAL

ACITRETIN

MYLAN 17.5MG A203707 001 Sep 10, 2015

22.5MG A203707 002 Sep 10, 2015

SORIATANE

+ STIEFEL LABS INC 17.5MG N019821 003 Aug 06, 2009

+ 22.5MG N019821 004 Aug 06, 2009

ACRISORCIN

CREAM; TOPICAL

AKRINOL

SCHERING 2MG/GM N012470 001

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL

SEMPREX-D

+ AUXILIUM PHARMS LLC 8MG; 60MG N019806 001 Mar 25, 1994

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

ACTAVIS ELIZABETH 200MG A074906 001 Aug 26, 1997

CHARTWELL MOLECULES 200MG A074872 001 Apr 22, 1997

DAVA PHARMS INC 200MG A074833 001 Apr 22, 1997

IVAX SUB TEVA PHARMS 200MG A074674 001 Apr 22, 1997

LEK PHARM 200MG A074750 001 Apr 22, 1997

MYLAN 200MG A074727 001 Apr 22, 1997

200MG A074977 001 Apr 13, 1998

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

RANBAXY	200MG	A074975	001	Sep 30, 1998
ROXANE	200MG	A074570	002	Apr 22, 1997
TEVA	200MG	A074828	001	Apr 22, 1997
TEVA PHARMS	200MG	A074914	001	Nov 26, 1997
WATSON LABS	200MG	A075101	001	Apr 15, 1998

ZOVIRAX

+ MYLAN	200MG **	N018828	001	Jan 25, 1985
---------	----------	---------	-----	--------------

OINTMENT; OPHTHALMIC

AVACLYR

+ FERA PHARMS LLC	3%	N202408	001	Mar 29, 2019
-------------------	----	---------	-----	--------------

OINTMENT; TOPICAL

ACYCLOVIR

PERRIGO UK FINCO	5%	A205659	001	Feb 20, 2019
------------------	----	---------	-----	--------------

TABLET; ORAL

ACYCLOVIR

ACTAVIS ELIZABETH	400MG	A074870	001	Jun 05, 1997
	800MG	A074870	002	Jun 05, 1997
CHARTWELL MOLECULES	400MG	A074834	001	Apr 24, 1997
	800MG	A074834	002	Apr 24, 1997
IVAX SUB TEVA PHARMS	400MG	A074836	001	Apr 22, 1997
	800MG	A074836	002	Apr 22, 1997
LEK PHARM	400MG	A074658	001	Apr 22, 1997
	800MG	A074658	002	Apr 22, 1997
MYLAN	400MG	A074976	001	Apr 13, 1998
	400MG	A075211	001	Sep 28, 1998
	800MG	A074976	002	Apr 13, 1998
	800MG	A075211	002	Sep 28, 1998
SUN PHARM INDS LTD	400MG	A074980	001	Sep 30, 1998
	800MG	A074980	002	Sep 30, 1998
TEVA	200MG **	A074556	001	Apr 22, 1997
TEVA PHARMS	400MG	A075021	001	Mar 18, 1998
	800MG	A075021	002	Mar 18, 1998

ZOVIRAX

+ MYLAN	400MG	N020089	001	Apr 30, 1991
---------	-------	---------	-----	--------------

+	800MG	N020089	002	Apr 30, 1991
---	-------	---------	-----	--------------

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR

ABBVIE	EQ 50MG BASE/ML	A075114	001	Jul 26, 1999
--------	-----------------	---------	-----	--------------

ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE

EUROHLTH INTL SARL	EQ 500MG BASE/VIAL	A074885	001	Dec 19, 1997
--------------------	--------------------	---------	-----	--------------

	EQ 1GM BASE/VIAL	A074885	002	Dec 19, 1997
--	------------------	---------	-----	--------------

ACYCLOVIR SODIUM

APOTHECON	EQ 500MG BASE/VIAL	A074897	001	Feb 27, 1998
-----------	--------------------	---------	-----	--------------

	EQ 1GM BASE/VIAL	A074897	002	Feb 27, 1998
--	------------------	---------	-----	--------------

ATHENEX INC	EQ 500MG BASE/VIAL	A074596	002	Apr 22, 1997
-------------	--------------------	---------	-----	--------------

	EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997
--	------------------	---------	-----	--------------

EUROHLTH INTL SARL	EQ 500MG BASE/VIAL	A074913	001	Oct 15, 1997
--------------------	--------------------	---------	-----	--------------

	EQ 1GM BASE/VIAL	A074913	002	Oct 15, 1997
--	------------------	---------	-----	--------------

FRESENIUS KABI USA	EQ 500MG BASE/VIAL	A075015	001	Apr 30, 1998
--------------------	--------------------	---------	-----	--------------

HIKMA	EQ 500MG BASE/VIAL	A205771	001	Feb 29, 2016
-------	--------------------	---------	-----	--------------

	EQ 1GM BASE/VIAL	A205771	002	Feb 29, 2016
--	------------------	---------	-----	--------------

HOSPIRA	EQ 25MG BASE/ML	A074720	001	Apr 22, 1997
---------	-----------------	---------	-----	--------------

	EQ 50MG BASE/ML	A075065	001	Feb 25, 1999
--	-----------------	---------	-----	--------------

	EQ 500MG BASE/VIAL	A074663	001	Apr 22, 1997
--	--------------------	---------	-----	--------------

	EQ 500MG BASE/VIAL	A074758	001	Apr 22, 1997
--	--------------------	---------	-----	--------------

	EQ 1GM BASE/VIAL	A074663	002	Apr 22, 1997
--	------------------	---------	-----	--------------

	EQ 1GM BASE/VIAL	A074758	002	Apr 22, 1997
--	------------------	---------	-----	--------------

MYLAN LABS LTD	EQ 500MG BASE/VIAL	A203927	001	Mar 29, 2017
----------------	--------------------	---------	-----	--------------

	EQ 1GM BASE/VIAL	A203927	002	Mar 29, 2017
--	------------------	---------	-----	--------------

TEVA PARENTERAL	EQ 50MG BASE/ML	A075627	001	Mar 28, 2001
-----------------	-----------------	---------	-----	--------------

	EQ 500MG BASE/VIAL	A074969	001	Aug 26, 1997
--	--------------------	---------	-----	--------------

	EQ 1GM BASE/VIAL	A074969	002	Aug 26, 1997
--	------------------	---------	-----	--------------

ZYDUS PHARMS	EQ 500MG BASE/VIAL	A206606	001	Jun 13, 2017
--------------	--------------------	---------	-----	--------------

	EQ 1GM BASE/VIAL	A206606	002	Jun 13, 2017
--	------------------	---------	-----	--------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ZOVIRAX

+	GLAXOSMITHKLINE	EQ 250MG BASE/VIAL **	N018603 003	Aug 30, 1983
+		EQ 500MG BASE/VIAL **	N018603 001	Oct 22, 1982
+		EQ 1GM BASE/VIAL **	N018603 002	Jun 29, 1989

ADAPALENE

SOLUTION; TOPICAL

DIFFERIN

+	GALDERMA LABS LP	0.1% **	N020338 001	May 31, 1996
---	------------------	---------	-------------	--------------

ADAPALENE; BENZOYL PEROXIDE

GEL; TOPICAL

ADAPALENE AND BENZOYL PEROXIDE

	TARO	0.3%; 2.5%	A209148 001	Oct 17, 2018
--	------	------------	-------------	--------------

ADENOSINE

INJECTABLE; INJECTION

ADENOCARD

+	ASTELLAS	3MG/ML **	N019937 002	Oct 30, 1989
---	----------	-----------	-------------	--------------

ADENOSINE

	AM REGENT	3MG/ML	A090010 001	Apr 28, 2009
	MYLAN LABS LTD	3MG/ML	A078640 001	Mar 21, 2014
	TEVA PHARMS USA	3MG/ML	A076564 001	Jun 16, 2004
		3MG/ML	A078676 001	Jul 31, 2008
	WEST-WARD PHARMS INT	3MG/ML	A076501 001	Jun 16, 2004
	WOCKHARDT	3MG/ML	A090220 001	Jul 20, 2009

SOLUTION; INTRAVENOUS

ADENOSCAN

+	ASTELLAS	60MG/20ML (3MG/ML) **	N020059 001	May 18, 1995
+		90MG/30ML (3MG/ML) **	N020059 002	May 18, 1995

ADENOSINE

	EMCURE PHARMS LTD	60MG/20ML (3MG/ML)	A202313 001	Sep 15, 2014
		90MG/30ML (3MG/ML)	A202313 002	Sep 15, 2014

ALATROFLOXACIN MESYLATE

INJECTABLE; INJECTION

TROVAN PRESERVATIVE FREE

	PFIZER	EQ 200MG BASE/VIAL	N020760 001	Dec 18, 1997
		EQ 300MG BASE/VIAL	N020760 002	Dec 18, 1997

ALBUTEROL

AEROSOL, METERED; INHALATION

ALBUTEROL

	ARMSTRONG PHARMS	0.09MG/INH	A072273 001	Aug 14, 1996
	GENPHARM	0.09MG/INH	A073045 001	Aug 19, 1997
	IVAX SUB TEVA PHARMS	0.09MG/INH	A073272 001	Dec 28, 1995
	PLIVA	0.09MG/INH	A074072 001	Aug 01, 1996

PROVENTIL

	SCHERING	0.09MG/INH	N017559 001	
--	----------	------------	-------------	--

VENTOLIN

	GLAXOSMITHKLINE	0.09MG/INH	N018473 001	
--	-----------------	------------	-------------	--

ALBUTEROL SULFATE

AEROSOL, METERED; INHALATION

ALBUTEROL SULFATE

	PERRIGO PHARMS CO	EQ 0.09MG BASE/INH	A203760 001	Feb 24, 2020
--	-------------------	--------------------	-------------	--------------

CAPSULE; INHALATION

VENTOLIN ROTACAPS

	GLAXOSMITHKLINE	EQ 0.2MG BASE	N019489 001	May 04, 1988
--	-----------------	---------------	-------------	--------------

SOLUTION; INHALATION

ALBUTEROL SULFATE

	ACTAVIS MID ATLANTIC	EQ 0.083% BASE	A073533 001	Sep 26, 1995
	AKORN	EQ 0.083% BASE	A075063 001	Feb 09, 1999
	APOTEX INC	EQ 0.021% BASE	A078623 001	Apr 05, 2010
		EQ 0.042% BASE	A078623 002	Apr 05, 2010
		EQ 0.083% BASE	A075717 001	Feb 02, 2007
		EQ 0.5% BASE	A076391 001	Apr 01, 2003
	AUROBINDO PHARMA LTD	EQ 0.021% BASE	A211888 001	Apr 20, 2020
		EQ 0.042% BASE	A211888 002	Apr 20, 2020
	BAUSCH AND LOMB	EQ 0.083% BASE	A075358 001	Mar 29, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ALBUTEROL SULFATE

SOLUTION; INHALATION

ALBUTEROL SULFATE

	EQ 0.5% BASE	A075050 001	Jun 18, 1998
COPLEY PHARM	EQ 0.083% BASE	A073495 001	May 28, 1993
	EQ 0.5% BASE	A073307 001	Nov 27, 1991
LANDELA PHARM	EQ 0.083% BASE	A077569 001	Apr 04, 2006
MYLAN SPECILT	EQ 0.083% BASE **	A072652 001	Feb 21, 1992
ROXANE	EQ 0.083% BASE	A075129 001	Feb 13, 2001
TEVA PHARMS	EQ 0.083% BASE	A075343 001	Nov 09, 1999
WATSON LABS INC	EQ 0.083% BASE	A076370 001	Nov 24, 2003
WOCKHARDT EU OPERATN	EQ 0.083% BASE	A075394 001	Nov 22, 1999
PROVENTIL			
+ SCHERING	EQ 0.083% BASE **	N019243 002	Jan 14, 1987
+	EQ 0.5% BASE **	N019243 001	Jan 14, 1987
VENTOLIN			
+ GLAXOSMITHKLINE	EQ 0.083% BASE **	N019773 001	Apr 23, 1992
	EQ 0.5% BASE **	N019269 002	Jan 16, 1987

SYRUP; ORAL

ALBUTEROL SULFATE

ACTAVIS MID ATLANTIC	EQ 2MG BASE/5ML	A075262 001	Mar 30, 1999
CHARTWELL RX	EQ 2MG BASE/5ML	A077788 001	Jun 26, 2007
MOVA	EQ 2MG BASE/5ML	A074302 001	Sep 30, 1994
WATSON LABS	EQ 2MG BASE/5ML	A073165 001	Apr 29, 1993
PROVENTIL			
+ SCHERING	EQ 2MG BASE/5ML **	N018062 001	Jan 19, 1983
VENTOLIN			
GLAXOSMITHKLINE	EQ 2MG BASE/5ML **	N019621 001	Jun 10, 1987

TABLET; ORAL

ALBUTEROL SULFATE

AIZANT	EQ 2MG BASE	A210948 001	Mar 15, 2019
	EQ 4MG BASE	A210948 002	Mar 15, 2019
AM THERAP	EQ 2MG BASE	A072449 001	Dec 05, 1989
	EQ 4MG BASE	A072450 001	Dec 05, 1989
AUROBINDO PHARMA LTD	EQ 2MG BASE	A213657 001	May 14, 2020
	EQ 4MG BASE	A213657 002	May 14, 2020
COPLEY PHARM	EQ 2MG BASE	A072966 001	Nov 22, 1991
	EQ 4MG BASE	A072967 001	Nov 22, 1991
DAVA PHARMS INC	EQ 2MG BASE	A072860 002	Dec 20, 1989
	EQ 4MG BASE	A072860 001	Dec 20, 1989
PLIVA	EQ 2MG BASE	A072316 001	Dec 05, 1989
	EQ 4MG BASE	A072317 001	Dec 05, 1989
TEVA	EQ 2MG BASE	A072619 001	Dec 05, 1989
	EQ 2MG BASE	A072779 001	Jun 25, 1993
	EQ 2MG BASE	A072938 001	Mar 30, 1990
	EQ 4MG BASE	A072620 001	Dec 05, 1989
	EQ 4MG BASE	A072780 001	Jun 25, 1993
	EQ 4MG BASE	A072939 001	Mar 30, 1990
UCB INC	EQ 2MG BASE	A073120 001	Sep 29, 1992
	EQ 4MG BASE	A073121 001	Sep 29, 1992
WARNER CHILCOTT	EQ 2MG BASE	A072817 001	Jan 09, 1990
	EQ 4MG BASE	A072818 001	Jan 09, 1990
WATSON LABS	EQ 2MG BASE	A072629 001	Jan 31, 1991
	EQ 2MG BASE	A072764 001	Aug 28, 1991
	EQ 4MG BASE	A072630 001	Jan 31, 1991
	EQ 4MG BASE	A072765 001	Aug 28, 1991
YAOPHARMA CO LTD	EQ 2MG BASE	A072151 001	Dec 05, 1989
	EQ 4MG BASE	A072152 001	Dec 05, 1989
PROVENTIL			
+ SCHERING	EQ 2MG BASE **	N017853 001	May 07, 1982
+	EQ 4MG BASE **	N017853 002	May 07, 1982
VENTOLIN			
GLAXOSMITHKLINE	EQ 2MG BASE	N019112 001	Jul 10, 1986
	EQ 4MG BASE	N019112 002	Jul 10, 1986
TABLET, EXTENDED RELEASE; ORAL			
PROVENTIL			
SCHERING	EQ 4MG BASE	N019383 001	Jul 13, 1987
VOLMAX			
+ MURO	EQ 4MG BASE	N019604 002	Dec 23, 1992

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ALBUTEROL SULFATE

TABLET, EXTENDED RELEASE;ORAL

VOLMAX

+

EQ 8MG BASE

N019604 001 Dec 23, 1992

VOSPIRE ER

DAVA PHARMS INC

EQ 8MG BASE

A076130 003 Sep 26, 2002

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION

COMBIVENT

BOEHRINGER INGELHEIM EQ 0.09MG BASE/INH;0.018MG/INH

N020291 001 Oct 24, 1996

SOLUTION; INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

APOTEX INC

EQ 0.083% BASE;0.017%

A077117 001 Dec 31, 2007

FOSUN PHARMA

EQ 0.083% BASE;0.017%

A076867 001 Dec 21, 2006

TEVA PHARMS

EQ 0.083% BASE;0.017%

A076724 001 Dec 31, 2007

WATSON LABS TEVA

EQ 0.083% BASE;0.017%

A077063 001 Dec 31, 2007

DUONEB

+

MYLAN SPECIALITY LP

EQ 0.083% BASE;0.017% **

N020950 001 Mar 21, 2001

ALCLOMETASONE DIPROPIONATE

CREAM; TOPICAL

ACLOVATE

+

FOUGERA PHARMS

0.05% **

N018707 001 Dec 14, 1982

OINTMENT; TOPICAL

ACLOVATE

+

FOUGERA PHARMS

0.05% **

N018702 001 Dec 14, 1982

ALCOHOL

INJECTABLE; INJECTION

ALCOHOL 5% IN DEXTROSE 5%

MILES

5ML/100ML

A083483 001

ALCOHOL; DEXTROSE

INJECTABLE; INJECTION

ALCOHOL 10% AND DEXTROSE 5%

B BRAUN

10ML/100ML;5GM/100ML

N004589 006

ALCOHOL 5% AND DEXTROSE 5%

B BRAUN

5ML/100ML;5GM/100ML

N004589 004

ALCOHOL 5% IN D5-W

HOSPIRA

5ML/100ML;5GM/100ML

A083263 001

ALCOHOL 5% IN DEXTROSE 5% IN WATER

BAXTER HLTHCARE

5ML/100ML;5GM/100ML

A083256 001

ALENDRONATE SODIUM

SOLUTION; ORAL

FOSAMAX

+

MERCK

EQ 70MG BASE/75ML **

N021575 001 Sep 17, 2003

TABLET; ORAL

ALENDRONATE SODIUM

MYLAN

EQ 5MG BASE

A076584 001 Aug 04, 2008

EQ 10MG BASE

A076584 002 Aug 04, 2008

EQ 35MG BASE

A076584 003 Aug 04, 2008

EQ 35MG BASE

A078638 001 Aug 04, 2008

EQ 70MG BASE

A076584 004 Aug 04, 2008

EQ 70MG BASE

A078638 002 Aug 04, 2008

NEOPHARMA

EQ 5MG BASE

A079049 003 Aug 04, 2008

EQ 10MG BASE

A079049 004 Aug 04, 2008

EQ 35MG BASE

A079049 001 Aug 04, 2008

EQ 70MG BASE

A079049 002 Aug 04, 2008

TEVA PHARMS

EQ 35MG BASE

A076184 002 Aug 04, 2008

EQ 70MG BASE

A076184 001 Feb 06, 2008

UPSHER SMITH LABS

EQ 5MG BASE

A075871 001 Apr 22, 2009

EQ 10MG BASE

A075871 002 Apr 22, 2009

EQ 35MG BASE

A075871 004 Apr 22, 2009

EQ 40MG BASE

A075871 003 Apr 22, 2009

EQ 70MG BASE

A075871 005 Apr 22, 2009

FOSAMAX

+

MERCK AND CO INC

EQ 5MG BASE **

N020560 003 Apr 25, 1997

+

EQ 10MG BASE **

N020560 001 Sep 29, 1995

+

EQ 35MG BASE **

N020560 004 Oct 20, 2000

+

EQ 40MG BASE **

N020560 002 Sep 29, 1995

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALFUZOSIN HYDROCHLORIDE

HERITAGE PHARMA	10MG	A079056	001	Jul 18, 2011
MYLAN	10MG	A079014	001	Jul 18, 2011
TORRENT PHARMS	10MG	A079054	001	Jul 18, 2011
WOCKHARDT LTD	10MG	A090221	001	Aug 10, 2012

ALISKIREN HEMIFUMARATE

CAPSULE, PELLET;ORAL

TEKTURNA

+ NODEN PHARMA	EQ 37.5MG BASE	N210709	001	Nov 14, 2017
----------------	----------------	---------	-----	--------------

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE

TABLET;ORAL

TEKAMLO

NOVARTIS	EQ 150MG BASE;EQ 5MG BASE	N022545	001	Aug 26, 2010
	EQ 150MG BASE;EQ 10MG BASE	N022545	002	Aug 26, 2010
	EQ 300MG BASE;EQ 5MG BASE	N022545	003	Aug 26, 2010
	EQ 300MG BASE;EQ 10MG BASE	N022545	004	Aug 26, 2010

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

AMTURNIDE

NOVARTIS	EQ 150MG BASE;EQ 5MG BASE;12.5MG	N200045	001	Dec 21, 2010
	EQ 300MG BASE;EQ 5MG BASE;12.5MG	N200045	002	Dec 21, 2010
	EQ 300MG BASE;EQ 5MG BASE;25MG	N200045	003	Dec 21, 2010
	EQ 300MG BASE;EQ 10MG BASE;12.5MG	N200045	004	Dec 21, 2010
	EQ 300MG BASE;EQ 10MG BASE;25MG	N200045	005	Dec 21, 2010

ALISKIREN HEMIFUMARATE; VALSARTAN

TABLET;ORAL

VALTURNA

NOVARTIS	EQ 150MG BASE;160MG	N022217	001	Sep 16, 2009
	EQ 300MG BASE;320MG	N022217	002	Sep 16, 2009

ALKAVERVIR

TABLET;ORAL

VERILOID

3M	2MG	N007336	002	
	3MG	N007336	003	

ALLOPURINOL

TABLET;ORAL

ALLOPURINOL

FOSUN PHARMA	100MG	A070268	001	Dec 31, 1985
MUTUAL PHARM	100MG	A070466	001	Dec 24, 1985
	300MG	A070467	001	Dec 24, 1985
PURACAP PHARM	100MG	A070150	001	Dec 10, 1985
	300MG	A070147	001	Dec 10, 1985
PUREPAC PHARM	100MG	A070579	001	Apr 14, 1986
	300MG	A070580	001	Apr 14, 1986
SANDOZ	300MG	A070269	001	Dec 31, 1985
SUN PHARM INDS INC	100MG	A078390	001	Aug 30, 2007
	300MG	A078390	002	Aug 30, 2007
SUPERPHARM	100MG	A070950	001	Nov 30, 1988
	300MG	A070951	001	Nov 30, 1988
WATSON LABS	100MG	N018241	001	Nov 16, 1984
	100MG	N018785	001	Sep 28, 1984
	300MG	N018241	002	Nov 16, 1984
	300MG	N018785	002	Sep 28, 1984
LOPURIN				
ABBOTT	100MG	N018297	001	
	300MG	N018297	002	

ALLOPURINOL; LESINURAD

TABLET;ORAL

DUZALLO

+ IRONWOOD PHARMS INC	200MG;200MG	N209203	001	Aug 18, 2017
+	300MG;200MG	N209203	002	Aug 18, 2017

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ALMOTRIPTAN MALATE

TABLET; ORAL

AXERT

+	JANSSEN PHARMS	EQ 6.25MG BASE	N021001 001	May 07, 2001
+		EQ 12.5MG BASE	N021001 002	May 07, 2001

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

ALOSETRON HYDROCHLORIDE

	EYWA PHARMA	EQ 0.5MG BASE	A211621 001	Sep 16, 2019
		EQ 1MG BASE	A211621 002	Sep 16, 2019

ALPRAZOLAM

SOLUTION; ORAL

ALPRAZOLAM

	ROXANE	0.5MG/5ML	A074314 001	Oct 31, 1993
--	--------	-----------	-------------	--------------

TABLET; ORAL

ALPRAZOLAM

	ANI PHARMS INC	0.25MG	A074085 001	Feb 16, 1994
		0.5MG	A074085 002	Feb 16, 1994
		1MG	A074085 003	Feb 16, 1994
		2MG	A074085 004	Feb 26, 1996
	IVAX SUB TEVA PHARMS	0.25MG	A074294 001	Jul 29, 1994
		0.5MG	A074294 002	Jul 29, 1994
		1MG	A074294 003	Jul 29, 1994
		2MG	A074294 004	Jul 29, 1994
	MYLAN PHARMS INC	0.25MG	A074046 001	Oct 19, 1993
		0.5MG	A074046 002	Oct 19, 1993
		1MG	A074046 003	Oct 19, 1993
		2MG	A074046 004	May 07, 1997
	NOVITIUM PHARMA	0.25MG	A074174 001	Oct 19, 1993
		0.5MG	A074174 002	Oct 19, 1993
		1MG	A074174 003	Oct 19, 1993
		2MG	A074174 004	Oct 19, 1993
	OXFORD PHARMS	0.25MG	A078491 001	Sep 25, 2008
		0.5MG	A078491 002	Sep 25, 2008
		1MG	A078491 003	Sep 25, 2008
		2MG	A078491 004	Dec 12, 2008
	ROXANE	0.25MG	A074199 001	Oct 19, 1993
		0.5MG	A074199 002	Oct 19, 1993
		1MG	A074199 003	Oct 19, 1993
	WATSON LABS	0.25MG	A074456 001	Aug 31, 1995
		0.25MG	A074479 001	Jan 21, 1997
		0.5MG	A074456 002	Aug 31, 1995
		0.5MG	A074479 002	Jan 21, 1997
		1MG	A074456 003	Aug 31, 1995
		1MG	A074479 003	Jan 21, 1997

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

	ACTAVIS LABS FL INC	0.5MG	A077198 001	May 13, 2010
		1MG	A077198 002	May 13, 2010
		2MG	A077198 003	May 13, 2010
		3MG	A077198 004	May 13, 2010
	ANI PHARMS INC	0.5MG	A077725 001	Jul 31, 2006
		0.5MG	A077979 001	Feb 28, 2007
		1MG	A077725 002	Jul 31, 2006
		1MG	A077979 002	Feb 28, 2007
		2MG	A077725 004	Jul 31, 2006
		2MG	A077979 003	Feb 28, 2007
		3MG	A077725 003	Jul 31, 2006
		3MG	A077979 004	Feb 28, 2007
	HERITAGE PHARMS INC	0.5MG	A078489 001	Oct 17, 2008
		1MG	A078489 002	Oct 17, 2008
		2MG	A078489 003	Oct 17, 2008
		3MG	A078489 004	Oct 17, 2008
	IMPAX LABS	0.5MG	A077968 004	May 24, 2007
		1MG	A077968 003	May 24, 2007
		2MG	A077968 002	May 24, 2007
		3MG	A077968 001	May 24, 2007
	IMPAX LABS INC	0.5MG	A077996 001	Jan 31, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ALPRAZOLAMTABLET, EXTENDED RELEASE;ORAL
ALPRAZOLAM

	1MG	A077996 002	Jan 31, 2007
	2MG	A077996 003	Jan 31, 2007
	3MG	A077996 004	Jan 31, 2007
MYLAN	0.5MG	A077391 002	Jan 26, 2006
	1MG	A077391 003	Jan 26, 2006
	2MG	A077391 004	Jan 26, 2006
	3MG	A077391 001	Jan 26, 2006
SANDOZ INC	0.5MG	A077777 001	Jun 30, 2006
	1MG	A077777 002	Jun 30, 2006
	2MG	A077777 003	Jun 30, 2006
	3MG	A077777 004	Jun 30, 2006
VINTAGE PHARMS	0.5MG	A078442 001	Oct 15, 2007
	1MG	A078442 002	Oct 15, 2007
	2MG	A078442 003	Oct 15, 2007
	3MG	A078442 004	Oct 15, 2007

TABLET, ORALLY DISINTEGRATING;ORAL

NIRAVAM

+ UCB INC	0.25MG **	N021726 001	Jan 19, 2005
+	0.5MG **	N021726 002	Jan 19, 2005
+	1MG **	N021726 003	Jan 19, 2005
+	2MG **	N021726 004	Jan 19, 2005

ALPROSTADIL

INJECTABLE;INJECTION

CAVERJECT

PFIZER	0.005MG/ML	N020755 001	Oct 31, 1997
	0.01MG/ML	N020755 002	Oct 01, 1997
	0.02MG/ML	N020755 003	Oct 01, 1997
+ PHARMACIA AND UPJOHN	0.005MG/VIAL	N020379 003	Jun 27, 1996
EDEX			
AUXILIUM PHARMS LLC	0.005MG/VIAL	N020649 001	Jun 12, 1997

ALSEROXYLON

TABLET;ORAL

RAUTENSIN

NOVARTIS	2MG	N009215 001	
RAUWILOID			
3M	2MG	N008867 001	

ALTRETAMINE

CAPSULE;ORAL

HEXALEN

+ EISAI INC	50MG	N019926 001	Dec 26, 1990
-------------	------	-------------	--------------

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE;ORAL

ALUMINUM HYDROXIDE AND MAGNESIUM TRISILICATE

PENNEX	80MG;20MG	A089449 001	Nov 27, 1987
FOAMCOAT			
GUARDIAN DRUG	80MG;20MG	A071793 001	Sep 04, 1987
FOAMICON			
NOVARTIS	80MG;20MG	A072687 001	Jun 28, 1989
GAVISCON			
+ SANOFI AVENTIS US	160MG;40MG	N018685 002	Dec 09, 1983

AMANTADINE HYDROCHLORIDE

CAPSULE;ORAL

AMANTADINE HYDROCHLORIDE

ACTAVIS ELIZABETH	100MG	A077659 001	Feb 23, 2006
INVAGEN PHARMS	100MG	A207570 001	Sep 30, 2016
LANNETT CO INC	100MG	A209221 001	Jun 15, 2017
WATSON LABS	100MG	A071382 001	Jan 21, 1987
SYMADINE			
SOLVAY	100MG	A071000 001	Sep 04, 1986
SYMMETREL			
+ ENDO PHARMS	100MG **	N016020 001	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMANTADINE HYDROCHLORIDE

SYRUP; ORAL

AMANTADINE HYDROCHLORIDE

G AND W LABS INC	50MG/5ML	A072655	001	Oct 30, 1990
LANNETT CO INC	50MG/5ML	A076352	001	Sep 10, 2004
TEVA PHARMS	50MG/5ML	A073115	001	Aug 23, 1991
VINTAGE	50MG/5ML	A077992	001	Dec 12, 2006

SYMMETREL

+ ENDO PHARMS	50MG/5ML **	N016023	002	
---------------	-------------	---------	-----	--

TABLET; ORAL

SYMMETREL

+ ENDO PHARMS	100MG **	N018101	001	
---------------	----------	---------	-----	--

TABLET, EXTENDED RELEASE; ORAL

OSMOLEX ER

+ OSMOTICA PHARM	EQ 161MG BASE	N209410	004	Apr 22, 2020
------------------	---------------	---------	-----	--------------

AMBENONIUM CHLORIDE

TABLET; ORAL

MYTELASE

SANOFI AVENTIS US	10MG	N010155	002	
-------------------	------	---------	-----	--

AMCINONIDE

CREAM; TOPICAL

CYCLOCORT

+ ASTELLAS	0.025%	N018116	001	
------------	--------	---------	-----	--

+	0.1%	N018116	002	
---	------	---------	-----	--

LOTION; TOPICAL

CYCLOCORT

+ ASTELLAS	0.1%	N019729	001	Jun 13, 1988
------------	------	---------	-----	--------------

OINTMENT; TOPICAL

CYCLOCORT

+ ASTELLAS	0.1%	N018498	001	
------------	------	---------	-----	--

AMDINOCILLIN

INJECTABLE; INJECTION

COACTIN

ROCHE	250MG/VIAL	N050565	001	Dec 21, 1984
	500MG/VIAL	N050565	002	Dec 21, 1984
	1GM/VIAL	N050565	003	Dec 21, 1984

AMIFOSTINE

INJECTABLE; INJECTION

AMIFOSTINE

MYLAN LABS LTD	500MG/VIAL	A204363	001	Jul 17, 2017
----------------	------------	---------	-----	--------------

ETHYOL

CLINIGEN	375MG/VIAL	N020221	002	Sep 10, 1999
----------	------------	---------	-----	--------------

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

ABBOTT	EQ 250MG BASE/ML	A063265	001	Nov 30, 1994
	EQ 250MG BASE/ML	A063266	001	Oct 31, 1994
HOSPIRA	EQ 50MG BASE/ML	A063263	001	Nov 30, 1994
	EQ 50MG BASE/ML	A063350	001	Jul 30, 1993
	EQ 62.5MG BASE/ML	A063283	001	Oct 31, 1994
	EQ 250MG BASE/ML	A063264	001	Nov 30, 1994
	EQ 250MG BASE/ML	A063350	002	Jul 30, 1993
	EQ 250MG BASE/ML	A064098	001	Jun 26, 1995
	EQ 250MG BASE/ML	A064099	001	Jun 20, 1995
IGI LABS INC	EQ 50MG BASE/ML	A063167	001	Dec 14, 1995
	EQ 250MG BASE/ML	A063169	001	Dec 14, 1995
TEVA PHARMS USA	EQ 50MG BASE/ML	A064045	001	Sep 28, 1993
WEST-WARD PHARMS INT	EQ 50MG BASE/ML	A063274	001	May 18, 1992
	EQ 250MG BASE/ML	A063275	001	May 18, 1992

AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

HOSPIRA	EQ 500MG BASE/100ML	A064146	001	Apr 02, 1997
---------	---------------------	---------	-----	--------------

AMIKIN

APOTHECON	EQ 50MG BASE/ML	A062311	001	
	EQ 50MG BASE/ML	A062562	001	Sep 20, 1984
+	EQ 50MG BASE/ML **	N050495	001	
	EQ 250MG BASE/ML	A062311	002	
	EQ 250MG BASE/ML	A062562	002	Sep 20, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKIN

+

EQ 250MG BASE/ML **

N050495 002

AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

APOTHECON

EQ 5MG BASE/ML

N050618 002 Nov 30, 1987

EQ 10MG BASE/ML

N050618 001 Nov 30, 1987

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

TEVA

EQ 5MG ANHYDROUS; 50MG

A070795 001 Apr 17, 1988

WATSON LABS

EQ 5MG ANHYDROUS; 50MG

A073334 001 Jul 19, 1991

YAOPHARMA CO LTD

EQ 5MG ANHYDROUS; 50MG

A073357 001 Nov 27, 1991

HYDRO-RIDE

PAR PHARM

EQ 5MG ANHYDROUS; 50MG

A070347 001 Dec 25, 1990

MODURETIC 5-50

+

MERCK

EQ 5MG ANHYDROUS; 50MG **

N018201 001

AMINO ACIDS

INJECTABLE; INJECTION

AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE

HOSPIRA

5.2% (5.2GM/100ML)

N018901 001 Apr 06, 1984

AMINOSYN 10%

ICU MEDICAL INC

10% (10GM/100ML)

N017673 003

AMINOSYN 10% (PH6)

ICU MEDICAL INC

10% (10GM/100ML)

N017673 008 Nov 18, 1985

AMINOSYN 3.5%

ICU MEDICAL INC

3.5% (3.5GM/100ML)

N017789 004

AMINOSYN 3.5% IN PLASTIC CONTAINER

ABBOTT

3.5% (3.5GM/100ML)

N018804 001 May 15, 1984

3.5% (3.5GM/100ML)

N018875 001 Aug 08, 1984

AMINOSYN 5%

ICU MEDICAL INC

5% (5GM/100ML)

N017673 001

AMINOSYN 7%

ICU MEDICAL INC

7% (7GM/100ML)

N017673 002

AMINOSYN 7% (PH6)

ICU MEDICAL INC

7% (7GM/100ML)

N017673 006 Nov 18, 1985

AMINOSYN 8.5%

ICU MEDICAL INC

8.5% (8.5GM/100ML)

N017673 004

AMINOSYN 8.5% (PH6)

ICU MEDICAL INC

8.5% (8.5GM/100ML)

N017673 007 Nov 18, 1985

AMINOSYN II 10%

ICU MEDICAL INC

10% (10GM/100ML)

N019438 005 Apr 03, 1986

AMINOSYN II 3.5%

ICU MEDICAL INC

3.5% (3.5GM/100ML)

N019438 001 Apr 03, 1986

AMINOSYN II 3.5% IN PLASTIC CONTAINER

ABBOTT

3.5% (3.5GM/100ML)

N019491 001 Oct 10, 1986

AMINOSYN II 5%

ICU MEDICAL INC

5% (5GM/100ML)

N019438 002 Apr 03, 1986

AMINOSYN II 7%

ICU MEDICAL INC

7% (7GM/100ML)

N019438 003 Apr 03, 1986

AMINOSYN II 8.5%

ICU MEDICAL INC

8.5% (8.5GM/100ML)

N019438 004 Apr 03, 1986

AMINOSYN-HBC 7%

ICU MEDICAL INC

7% (7GM/100ML)

N019374 001 Jul 12, 1985

AMINOSYN-HBC 7% IN PLASTIC CONTAINER

ABBOTT

7% (7GM/100ML)

N019400 001 Jul 23, 1986

AMINOSYN-HF 8%

ICU MEDICAL INC

8% (8GM/100ML)

A020345 001 Apr 04, 1996

AMINOSYN-RF 5.2%

ICU MEDICAL INC

5.2% (5.2GM/100ML)

N018429 001

BRANCHAMIN 4%

BAXTER HLTHCARE

4% (4GM/100ML)

N018678 001 Sep 28, 1984

BRANCHAMIN 4% IN PLASTIC CONTAINER

BAXTER HLTHCARE

4% (4GM/100ML)

N018684 001 Sep 28, 1984

FREAMINE 8.5%

B BRAUN

8.5% (8.5GM/100ML)

N016822 001

FREAMINE II 8.5%

B BRAUN

8.5% (8.5GM/100ML)

N016822 002

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMINO ACIDS

INJECTABLE; INJECTION

HEPATASOL 8%				
BAXTER HLTHCARE	8% (8GM/100ML)	A020360	001	Apr 04, 1996
NEOPHAM 6.4%				
HOSPIRA	6.4% (6.4GM/100ML)	N018792	001	Jan 17, 1984
NOVAMINE 11.4%				
HOSPIRA INC	11.4% (11.4GM/100ML)	N017957	003	Aug 09, 1982
NOVAMINE 15%				
HOSPIRA INC	15% (75GM/500ML)	N017957	004	Nov 28, 1986
NOVAMINE 15% SULFITE FREE IN PLASTIC CONTAINER				
BAXTER HLTHCARE	15% (15GM/100ML) **	N020107	001	Feb 05, 1993
NOVAMINE 8.5%				
HOSPIRA INC	8.5% (8.5GM/100ML)	N017957	002	Aug 09, 1982
RENAMIN W/O ELECTROLYTES				
BAXTER HLTHCARE	6.5% (6.5GM/100ML)	N017493	007	Oct 15, 1982
TRAVASOL 10% W/O ELECTROLYTES				
BAXTER HLTHCARE	10% (10GM/100ML)	N017493	006	
TRAVASOL 5.5% W/O ELECTROLYTES				
BAXTER HLTHCARE	5.5% (5.5GM/100ML)	N017493	004	
TRAVASOL 8.5% W/O ELECTROLYTES				
BAXTER HLTHCARE	8.5% (8.5GM/100ML)	N017493	005	

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
ABBOTT	3.5%; 36.8MG/100ML; 25GM/100ML; 51MG/100ML; 22.4MG/100ML; 261MG/100ML; 205MG/100ML	N019714	001	Sep 12, 1988
HOSPIRA INC	3.5%; 36.8MG/100ML; 25GM/100ML; 51MG/100ML; 22.4MG/100ML; 261MG/100ML; 205MG/100ML	N019683	001	Nov 07, 1988
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER				
ABBOTT	4.25%; 36.8MG/100ML; 20GM/100ML; 51MG/100ML; 22.4MG/100ML; 261MG/100ML; 205MG/100ML	N019714	002	Sep 12, 1988
HOSPIRA INC	4.25%; 36.8MG/100ML; 20GM/100ML; 51MG/100ML; 22.4MG/100ML; 261MG/100ML; 205MG/100ML	N019683	002	Nov 07, 1988
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
ABBOTT	4.25%; 36.8MG/100ML; 25GM/100ML; 51MG/100ML; 22.4MG/100ML; 261MG/100ML; 205MG/100ML	N019714	004	Sep 12, 1988
HOSPIRA INC	4.25%; 36.8MG/100ML; 25GM/100ML; 51MG/100ML; 22.4MG/100ML; 261MG/100ML; 205MG/100ML	N019683	003	Nov 07, 1988
AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
ABBOTT	5%; 36.8MG/100ML; 25GM/100ML; 51MG/100ML; 22.4MG/100ML; 261MG/100ML; 205MG/100ML	N019714	003	Sep 12, 1988
HOSPIRA INC	5%; 36.8MG/100ML; 25GM/100ML; 51MG/100ML; 22.4MG/100ML; 261MG/100ML; 205MG/100ML	N019683	004	Nov 07, 1988

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT	3.5%; 25GM/100ML	N019118	001	Oct 11, 1984
AMINOSYN 3.5% W/ DEXTROSE 5% IN PLASTIC CONTAINER				
ABBOTT	3.5%; 5GM/100ML	N019120	001	Oct 11, 1984
AMINOSYN 4.25% W/ DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT	4.25%; 25GM/100ML	N019119	001	Oct 11, 1984
AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT	3.5%; 25GM/100ML	N019505	002	Nov 07, 1986
	3.5%; 25GM/100ML	N019713	006	Sep 09, 1988
HOSPIRA	3.5%; 25GM/100ML	N019681	001	Nov 01, 1988
AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER				
ABBOTT	3.5%; 5GM/100ML	N019506	001	Nov 07, 1986
	3.5%; 5GM/100ML	N019713	002	Sep 09, 1988
HOSPIRA	3.5%; 5GM/100ML	N019681	002	Nov 01, 1988
AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER				
ABBOTT	4.25%; 10GM/100ML	N019713	001	Sep 09, 1988
HOSPIRA	4.25%; 10GM/100ML	N019681	004	Nov 01, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER			
ABBOTT	4.25%;20GM/100ML	N019713 004	Sep 09, 1988
HOSPIRA	4.25%;20GM/100ML	N019681 005	Nov 01, 1988
AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER			
ABBOTT	4.25%;25GM/100ML	N019504 002	Nov 07, 1986
	4.25%;25GM/100ML	N019713 005	Sep 09, 1988
HOSPIRA	4.25%;25GM/100ML	N019681 003	Nov 01, 1988
AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER			
ABBOTT	5%;25GM/100ML	N019565 001	Dec 17, 1986
	5%;25GM/100ML	N019713 003	Sep 09, 1988
HOSPIRA	5%;25GM/100ML	N019681 006	Nov 01, 1988
TRAVASOL 2.75% IN DEXTROSE 10% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	2.75%;10GM/100ML	N019520 002	Sep 23, 1988
TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	2.75%;15GM/100ML	N019520 003	Sep 23, 1988
TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	2.75%;20GM/100ML	N019520 004	Sep 23, 1988
TRAVASOL 2.75% IN DEXTROSE 25% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	2.75%;25GM/100ML	N019520 005	Sep 23, 1988
TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	2.75%;5GM/100ML	N019520 001	Sep 23, 1988
TRAVASOL 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4.25%;10GM/100ML	N019520 007	Sep 23, 1988
TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4.25%;15GM/100ML	N019520 008	Sep 23, 1988
TRAVASOL 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4.25%;20GM/100ML	N019520 009	Sep 23, 1988
TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4.25%;25GM/100ML	N019520 010	Sep 23, 1988
TRAVASOL 4.25% IN DEXTROSE 5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4.25%;5GM/100ML	N019520 006	Sep 23, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER			
ABBOTT	4.25%;10GM/100ML;51MG/100ML;176.5MG/100ML;22.4MG/100ML;104.5MG/100ML;205MG/100ML	N019712 002	Sep 08, 1988
HOSPIRA INC	4.25%;10GM/100ML;51MG/100ML;176.5MG/100ML;22.4MG/100ML;104.5MG/100ML;205MG/100ML	N019682 003	Nov 01, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER			
ABBOTT	3.5%;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019564 002	Dec 16, 1986
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER			
ABBOTT	4.25%;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019564 004	Dec 16, 1986

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER			
ABBOTT	3.5%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019564 001	Dec 16, 1986
	3.5%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019712 001	Sep 08, 1988
HOSPIRA INC	3.5%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019682 001	Nov 01, 1988
AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER			
ABBOTT	4.25%;10GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019564 003	Dec 16, 1986
HOSPIRA INC	4.25%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019682 002	Nov 01, 1988

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TRAVASOL 2.75% SULFITE FREE	W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	2.75%;10GM/100ML;51MG/100ML;261MG/100ML	N020147 002	Oct 23, 1995	
	;216MG/100ML;112MG/100ML			
TRAVASOL 2.75% SULFITE FREE	W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	2.75%;15GM/100ML;51MG/100ML;261MG/100ML	N020147 003	Oct 23, 1995	
	;216MG/100ML;112MG/100ML			
TRAVASOL 2.75% SULFITE FREE	W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	2.75%;20GM/100ML;51MG/100ML;261MG/100ML	N020147 004	Oct 23, 1995	
	;216MG/100ML;112MG/100ML			
TRAVASOL 2.75% SULFITE FREE	W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	2.75%;25GM/100ML;51MG/100ML;261MG/100ML	N020147 005	Oct 23, 1995	
	;216MG/100ML;112MG/100ML			
TRAVASOL 2.75% SULFITE FREE	W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	2.75%;5GM/100ML;51MG/100ML;261MG/100ML;	N020147 001	Oct 23, 1995	
	216MG/100ML;112MG/100ML			
TRAVASOL 4.25% SULFITE FREE	W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4.25%;10GM/100ML;51MG/100ML;261MG/100ML	N020147 007	Oct 23, 1995	
	;297MG/100ML;77MG/100ML			
TRAVASOL 4.25% SULFITE FREE	W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4.25%;15GM/100ML;51MG/100ML;261MG/100ML	N020147 008	Oct 23, 1995	
	;297MG/100ML;77MG/100ML			
TRAVASOL 4.25% SULFITE FREE	W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4.25%;20GM/100ML;51MG/100ML;261MG/100ML	N020147 009	Oct 23, 1995	
	;297MG/100ML;77MG/100ML			
TRAVASOL 4.25% SULFITE FREE	W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4.25%;25GM/100ML;51MG/100ML;261MG/100ML	N020147 010	Oct 23, 1995	
	;297MG/100ML;77MG/100ML			
TRAVASOL 4.25% SULFITE FREE	W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4.25%;5GM/100ML;51MG/100ML;261MG/100ML;	N020147 006	Oct 23, 1995	
	297MG/100ML;77MG/100ML			

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M				
ICU MEDICAL INC	3.5%;21MG/100ML;40MG/100ML;128MG/100ML;	N017789 003		
	234MG/100ML			
AMINOSYN 3.5% M IN PLASTIC CONTAINER				
ABBOTT	3.5%;21MG/100ML;40MG/100ML;128MG/100ML;	N018804 002	May 15, 1984	
	234MG/100ML			
	3.5%;21MG/100ML;40MG/100ML;128MG/100ML;	N018875 002	Aug 08, 1984	
	234MG/100ML			

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M				
ICU MEDICAL INC	3.5%;21MG/100ML;128MG/100ML;234MG/100ML	N017789 005		

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M IN PLASTIC CONTAINER				
ABBOTT	3.5%;32MG/100ML;128MG/100ML;222MG/100ML	N019493 001	Oct 16, 1986	
	;49MG/100ML			

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE; INJECTION

VEINAMINE 8%				
HOSPIRA INC	8%;61MG/100ML;211MG/100ML;56MG/100ML;38	N017957 001		
	8MG/100ML			

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 10% W/ ELECTROLYTES				
ICU MEDICAL INC	10%;102MG/100ML;45MG/100ML;522MG/100ML;	N019437 004	Apr 03, 1986	
	410MG/100ML			
AMINOSYN II 7% W/ ELECTROLYTES				
ICU MEDICAL INC	7%;102MG/100ML;45MG/100ML;522MG/100ML;4	N019437 006	Apr 03, 1986	
	10MG/100ML			
AMINOSYN II 8.5% W/ ELECTROLYTES				
ICU MEDICAL INC	8.5%;102MG/100ML;45MG/100ML;522MG/100ML	N019437 005	Apr 03, 1986	
	;410MG/100ML			

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE; INJECTION

AMINOSYN 8.5% W/ELECTROLYTES

ICU MEDICAL INC	8.5%;102MG/100ML;487MG/100ML;28MG/100ML ;425MG/100ML	N017673 009	Oct 25, 2002
-----------------	---	-------------	--------------

AMINOSYN II 8.5% W/ELECTROLYTES

ICU MEDICAL INC	8.5%;102MG/100ML;492MG/100ML;60MG/100ML ;425MG/100ML	N019437 008	Oct 25, 2002
-----------------	---	-------------	--------------

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M

ICU MEDICAL INC	3.5%;30MG/100ML;97MG/100ML;120MG/100ML; 49MG/100ML	N019437 007	Apr 03, 1986
-----------------	---	-------------	--------------

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER

BAXTER HLTHCARE	3.5%;51MG/100ML;131MG/100ML;218MG/100ML ;35MG/100ML	N020177 001	Oct 23, 1995
-----------------	--	-------------	--------------

TRAVASOL 3.5% W/ ELECTROLYTES

BAXTER HLTHCARE	3.5%;51MG/100ML;131MG/100ML;218MG/100ML ;35MG/100ML	N017493 003	
-----------------	--	-------------	--

TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER

BAXTER HLTHCARE	5.5%;102MG/100ML;522MG/100ML;431MG/100M L;224MG/100ML	N020173 001	Oct 27, 1995
-----------------	--	-------------	--------------

TRAVASOL 5.5% W/ ELECTROLYTES

BAXTER HLTHCARE	5.5%;102MG/100ML;522MG/100ML;431MG/100M L;224MG/100ML	N017493 001	
-----------------	--	-------------	--

TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER

BAXTER HLTHCARE	8.5%;102MG/100ML;522MG/100ML;594MG/100M L;154MG/100ML	N020173 002	Oct 27, 1995
-----------------	--	-------------	--------------

TRAVASOL 8.5% W/ ELECTROLYTES

BAXTER HLTHCARE	8.5%;102MG/100ML;522MG/100ML;594MG/100M L;154MG/100ML	N017493 002	
-----------------	--	-------------	--

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 7% W/ ELECTROLYTES

ICU MEDICAL INC	7%;102MG/100ML;522MG/100ML;410MG/100ML	N017789 002	
-----------------	--	-------------	--

AMINOSYN 8.5% W/ ELECTROLYTES

ICU MEDICAL INC	8.5%;102MG/100ML;522MG/100ML;410MG/100M L	N017673 005	
-----------------	--	-------------	--

AMINOCAPROIC ACID

INJECTABLE; INJECTION

AMICAR

+ AKORN	250MG/ML **	N015229 002	
---------	-------------	-------------	--

AMINOCAPROIC ACID

ABRAXIS PHARM	250MG/ML	A070522 001	Jun 17, 1986
---------------	----------	-------------	--------------

BAXTER HLTHCARE	250MG/ML	N018590 001	Oct 29, 1982
-----------------	----------	-------------	--------------

HOSPIRA	250MG/ML	A070888 001	Jun 16, 1988
---------	----------	-------------	--------------

SYRUP; ORAL

AMINOCAPROIC ACID

AKORN	1.25GM/5ML	A074759 001	Sep 02, 1998
-------	------------	-------------	--------------

TABLET; ORAL

AMINOCAPROIC

AKORN	500MG	A075602 001	May 24, 2001
-------	-------	-------------	--------------

AMINOGLUTETHIMIDE

TABLET; ORAL

CYTADREN

NOVARTIS	250MG	N018202 001	
----------	-------	-------------	--

AMINOHIPPURATE SODIUM

INJECTABLE; INJECTION

AMINOHIPPURATE SODIUM

MERCK	20%	N005619 001	
-------	-----	-------------	--

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMINOPHYLLINE

ENEMA;RECTAL

SOMOPHYLLIN

FISONS	300MG/5ML	N018232	001	Apr 02, 1982
--------	-----------	---------	-----	--------------

INJECTABLE; INJECTION

AMINOPHYLLIN

GD SEARLE LLC	25MG/ML	A087243	001	May 24, 1982
	25MG/ML	A087621	001	May 24, 1982

AMINOPHYLLINE

ABRAXIS PHARM	25MG/ML	A084568	001	
	25MG/ML	A087200	001	
	25MG/ML	A087250	001	Jan 06, 1982
	25MG/ML	A087886	001	Aug 30, 1983
	25MG/ML	A088407	001	Jan 25, 1984
AM REGENT	25MG/ML	A087600	001	
ELKINS SINN	25MG/ML	A087239	001	
HOSPIRA	25MG/ML	A087601	001	Jul 23, 1982
INTL MEDICATION	25MG/ML	A087209	001	Feb 01, 1982
	25MG/ML	A087867	001	Nov 10, 1983
	25MG/ML	A087868	001	Nov 10, 1983
KING PHARMS	25MG/ML	A086606	001	
LUITPOLD	25MG/ML	A087240	001	
LYPHOMED	25MG/ML	A087431	001	
PHARMA SERVE NY	25MG/ML	A087387	001	Jun 03, 1983
	25MG/ML	A087392	001	Dec 15, 1983
SMITH AND NEPHEW	25MG/ML	A088429	001	May 30, 1985
	25MG/ML	A088749	001	May 30, 1985
TEVA PARENTERAL	25MG/ML	A081142	001	Sep 25, 1991

AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%

HOSPIRA	100MG/100ML	A088147	002	May 03, 1983
	200MG/100ML	A088147	003	May 03, 1983

AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

HOSPIRA	100MG/100ML	N018924	001	Dec 12, 1984
	200MG/100ML	N018924	002	Dec 12, 1984
	400MG/100ML	N018924	003	Dec 12, 1984
	500MG/100ML	N018924	004	Dec 12, 1984

SOLUTION; ORAL

AMINOPHYLLINE

MORTON GROVE	105MG/5ML	A088156	001	Dec 05, 1983
ROXANE	105MG/5ML	A088126	001	Aug 19, 1983

AMINOPHYLLINE DYE FREE

ACTAVIS MID ATLANTIC	105MG/5ML	A087727	001	Apr 16, 1982
----------------------	-----------	---------	-----	--------------

SOMOPHYLLIN

FISONS	105MG/5ML	A086466	001	
--------	-----------	---------	-----	--

SOMOPHYLLIN-DF

FISONS	105MG/5ML	A087045	001	
--------	-----------	---------	-----	--

SUPPOSITORY; RECTAL

TRUPHYLLINE

COSETTE	250MG	A085498	001	Mar 23, 1983
	500MG	A085498	002	Jan 03, 1983

TABLET; ORAL

AMINOPHYLLIN

GD SEARLE LLC	100MG	N002386	002	
	200MG	N002386	003	

AMINOPHYLLINE

ANI PHARMS INC	100MG	A085261	004	
	200MG	A085261	002	
ASCOT	100MG	A087522	001	Feb 12, 1982
	200MG	A087523	001	Feb 12, 1982
BARR	100MG	A088297	001	Aug 19, 1983
	200MG	A088298	001	Aug 19, 1983
DURAMED PHARMS BARR	100MG	A088182	001	Mar 31, 1983
	200MG	A088183	001	Mar 31, 1983
HALSEY	100MG	A084674	001	
HIKMA INTL PHARMS	100MG	A084540	001	
	200MG	A085003	001	
IMPAX LABS	100MG	A084574	001	
	200MG	A084576	001	
KV PHARM	100MG	A085284	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMINOPHYLLINE

TABLET; ORAL

AMINOPHYLLINE

	200MG	A085289	001	
LANNETT	100MG	A084588	001	
	200MG	A084588	002	
PAL PAK	100MG	A084533	001	
PANRAY	100MG	A084552	001	
	200MG	A084552	002	
PUREPAC PHARM	100MG	A084699	001	
	200MG	A085333	001	
ROXANE	100MG	A087500	001	Feb 09, 1982
	200MG	A087501	001	Feb 09, 1982
VALEANT PHARM INTL	200MG	A084563	001	
VANGARD	100MG	A088314	001	Oct 03, 1983
	200MG	A088319	001	Oct 03, 1983
VINTAGE PHARMS	100MG	A085409	001	
	200MG	A085410	001	
WATSON LABS	100MG	A085567	001	
	200MG	A085564	001	

TABLET, DELAYED RELEASE; ORAL

AMINOPHYLLINE

IMPAX LABS	100MG	A084577	001	
	200MG	A084575	001	
TABLICAPS	100MG	A084632	002	
VALE	100MG	A084531	001	
	200MG	A084530	001	

TABLET, EXTENDED RELEASE; ORAL

PHYLLOCONTIN

PHARM RES ASSOC	225MG	A086760	001	
-----------------	-------	---------	-----	--

AMINOSALICYLATE SODIUM

POWDER; ORAL

P.A.S. SODIUM

CENTURY PHARMS	4GM/PACKET	A080947	001	
----------------	------------	---------	-----	--

SODIUM AMINOSALICYLATE

HEXCEL	100%	A080097	001	
--------	------	---------	-----	--

TABLET; ORAL

PARASAL SODIUM

PANRAY	500MG	N006811	006	
	1GM	N006811	011	

SODIUM P.A.S.

LANNETT	500MG	A080138	002	
---------	-------	---------	-----	--

TEEBACIN

CONSOLIDATED MIDLAND	500MG	N007320	002	
----------------------	-------	---------	-----	--

AMINOSALICYLATE SODIUM; AMINOSALICYLIC ACID

TABLET; ORAL

NEOPASALATE

MEDPOINTE PHARM HLC	846MG; 112MG	A080059	002	
---------------------	--------------	---------	-----	--

AMINOSALICYLIC ACID

TABLET; ORAL

PARASAL

PANRAY	500MG	N006811	001	
	1GM	N006811	002	

AMINOSALICYLIC ACID RESIN COMPLEX

POWDER; ORAL

REZIPAS

BRISTOL MYERS SQUIBB	EQ 500MG BASE/GM	N009052	001	
----------------------	------------------	---------	-----	--

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

AKORN	50MG/ML	A076232	001	Jul 05, 2006
BEDFORD	50MG/ML	A076018	001	Oct 15, 2002
BEDFORD LABS	50MG/ML	A076299	001	Oct 24, 2002
BEN VENUE	50MG/ML	A076088	001	Oct 15, 2002
DR REDDYS	50MG/ML	A076163	001	Sep 05, 2003
HOSPIRA	50MG/ML	A075955	001	Oct 18, 2002
	50MG/ML	A076108	001	Oct 15, 2002

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

INTL MEDICATION SYS 50MG/ML

N021594 001 Feb 04, 2004

PAR STERILE PRODUCTS 50MG/ML

A076394 001 Apr 25, 2003

CORDARONE

+ WYETH PHARMS INC 50MG/ML **

N020377 001 Aug 03, 1995

NEXTERONE

+ BAXTER HLTHCARE 50MG/ML **

N022325 001 Dec 24, 2008

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

MYLAN 200MG

A075188 001 Feb 24, 1999

TEVA 200MG

A074895 001 Apr 16, 1999

CORDARONE

+ WYETH PHARMS 200MG **

N018972 001 Dec 24, 1985

AMITRIPTYLINE HYDROCHLORIDE

CONCENTRATE; ORAL

ENDEP

ROCHE 40MG/ML

A085749 001

INJECTABLE; INJECTION

AMITRIPTYLINE HYDROCHLORIDE

WATSON LABS 10MG/ML

A085594 001

ELAVIL

ASTRAZENECA 10MG/ML

N012704 001

TABLET; ORAL

AMITID

BRISTOL MYERS SQUIBB 10MG

A086454 001

25MG

A086454 002

50MG

A086454 003

75MG

A086454 004

100MG

A086454 005

AMITRIL

WARNER CHILCOTT 10MG

A083939 001

25MG

A083937 001

50MG

A083938 002

75MG

A084957 001

100MG

A085093 001

150MG

A086295 001

AMITRIPTYLINE HYDROCHLORIDE

AM THERAP 25MG

A088672 001 Nov 20, 1984

50MG

A088673 001 Nov 20, 1984

75MG

A088674 001 Nov 20, 1984

100MG

A088675 001 Nov 20, 1984

ANI PHARMS INC 10MG

A085031 002

25MG

A085031 001

50MG

A085031 003

75MG

A085031 004

COPLEY PHARM 10MG

A088421 001 Apr 30, 1984

25MG

A088422 001 Apr 30, 1984

50MG

A088423 001 Apr 30, 1984

75MG

A088424 001 Apr 30, 1984

100MG

A088425 001 Apr 30, 1984

150MG

A088426 001 Apr 30, 1984

HALSEY 10MG

A085923 001

25MG

A085922 001

50MG

A085925 001

75MG

A087557 001 Mar 05, 1982

100MG

A085926 001 May 20, 1983

LEDERLE 10MG

A085927 001 May 20, 1983

10MG

A086744 001

10MG

A087366 001 Jan 04, 1982

25MG

A086746 001

25MG

A087367 001 May 03, 1982

50MG

A086743 001

50MG

A087181 001 Jan 04, 1982

75MG

A086745 001

75MG

A087369 001 Jan 04, 1982

100MG

A086747 001

100MG

A087368 001 May 03, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

	150MG	A087370 001	Jan 04, 1982
MUTUAL PHARM	10MG	A085744 001	
	25MG	A085627 001	
	50MG	A085745 001	
	75MG	A085743 001	
	100MG	A085742 002	May 11, 1982
	150MG	A089423 001	Feb 17, 1987
PAR PHARM	10MG	A088697 001	Sep 25, 1984
	25MG	A088698 001	Sep 25, 1984
	50MG	A088699 001	Sep 25, 1984
	75MG	A088700 001	Sep 25, 1984
	100MG	A088701 001	Sep 25, 1984
	150MG	A088702 001	Sep 25, 1984
PLIVA	10MG	A088883 001	Sep 26, 1984
	25MG	A088884 001	Sep 26, 1984
	50MG	A088885 001	Sep 26, 1984
	75MG	A088886 001	Sep 26, 1984
	100MG	A088887 001	Sep 26, 1984
	150MG	A088888 001	Sep 26, 1984
PUREPAC PHARM	10MG	A088075 001	Sep 16, 1983
	10MG	A088084 001	Jul 18, 1983
	25MG	A088076 001	May 20, 1983
	25MG	A088085 001	Jul 18, 1983
	50MG	A088077 001	Sep 16, 1983
	50MG	A088105 001	Jul 18, 1983
	75MG	A088078 001	Sep 16, 1983
	75MG	A088106 001	Jul 18, 1983
	100MG	A088079 001	Sep 16, 1983
	100MG	A088107 001	Jul 18, 1983
ROXANE	10MG	A086002 001	
	10MG	A086144 001	
	25MG	A085944 001	
	25MG	A086145 001	
	50MG	A085945 001	
	50MG	A086143 001	
	75MG	A086004 001	
	75MG	A086147 001	
	100MG	A086003 001	
	100MG	A086146 001	
	150MG	A086090 001	
	150MG	A086148 001	
SUN PHARM INDS INC	10MG	A040816 002	Jun 27, 2008
	25MG	A040816 001	Jun 27, 2008
	50MG	A040816 003	Jun 27, 2008
	75MG	A040816 004	Jun 27, 2008
	100MG	A040816 005	Jun 27, 2008
	150MG	A040816 006	Jun 27, 2008
SUPERPHARM	10MG	A088853 001	Nov 13, 1984
	25MG	A088854 001	Nov 13, 1984
	50MG	A088855 001	Nov 13, 1984
	75MG	A088856 001	Nov 13, 1984
	100MG	A088857 001	Nov 13, 1984
TEVA	10MG	A086610 001	
	25MG	A086859 001	
	50MG	A086857 001	
	75MG	A086860 001	
	100MG	A085836 001	
	100MG	A086854 001	
	150MG	A086853 001	
UCB INC	10MG	A085864 001	
	25MG	A085935 001	
	50MG	A085936 001	
	75MG	A086337 001	
	100MG	A086336 001	
	150MG	A086335 001	
UPSHER SMITH LABS	25MG	A212654 001	Apr 07, 2020

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

USL PHARMA	25MG	A087775	001	Feb 10, 1982
VANGARD	10MG	A087632	001	Feb 01, 1982
	50MG	A087616	001	Feb 08, 1982
	75MG	A087617	001	Feb 05, 1982
	100MG	A087639	001	Feb 08, 1982
WATSON LABS	10MG	A085816	001	
	10MG	A088620	001	Mar 02, 1984
	25MG	A085817	001	
	25MG	A088621	001	Mar 02, 1984
	50MG	A085815	001	
	50MG	A088622	001	Mar 02, 1984
	75MG	A085819	001	
	75MG	A088633	001	Mar 02, 1984
	100MG	A085820	001	
	100MG	A088634	001	Mar 02, 1984
	150MG	A085821	001	
	150MG	A088635	001	Mar 02, 1984
WEST WARD	10MG	A087647	001	Mar 05, 1982
	25MG	A087278	001	
ELAVIL				
+ ASTRAZENECA	10MG **	N012703	001	
+	25MG **	N012703	003	
+	50MG **	N012703	004	
+	75MG **	N012703	005	
+	100MG **	N012703	006	
+	150MG **	N012703	007	
ENDEP				
ROCHE	10MG	A083639	001	
	25MG	A083639	002	
	50MG	A083639	003	
	75MG	A083639	004	
	100MG	A083639	005	
	150MG	A085303	001	

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

FRONTIDA BIOPHARM	EQ 12.5MG BASE;5MG	A070765	001	Dec 10, 1986
	EQ 25MG BASE;10MG	A070766	001	Dec 10, 1986
HERITAGE PHARMA	EQ 12.5MG BASE;5MG	A072052	001	Dec 16, 1988
	EQ 25MG BASE;10MG	A072053	001	Dec 16, 1988
PAR PHARM	EQ 12.5MG BASE;5MG	A072277	001	May 09, 1988
	EQ 25MG BASE;10MG	A072278	001	May 09, 1988
USL PHARMA	EQ 12.5MG BASE;5MG	A070477	001	Jan 12, 1988
	EQ 25MG BASE;10MG	A070478	001	Jan 12, 1988
LIMBITROL				
+ HERITAGE PHARMS INC	EQ 12.5MG BASE;5MG **	N016949	001	
LIMBITROL DS				
+ HERITAGE PHARMS INC	EQ 25MG BASE;10MG **	N016949	002	

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET;ORAL

ETRAFON 2-10

SCHERING	10MG;2MG **	N014713	007	
ETRAFON 2-25				
SCHERING	25MG;2MG **	N014713	004	
ETRAFON-A				
SCHERING	10MG;4MG **	N014713	002	
ETRAFON-FORTE				
SCHERING	25MG;4MG **	N014713	006	
PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE				
FOSUN PHARMA	10MG;2MG	A071062	001	Nov 27, 1987
	10MG;4MG	A071862	001	Dec 21, 1987
	25MG;2MG	A071063	001	Nov 27, 1987
	25MG;4MG	A071064	001	Nov 27, 1987
	50MG;4MG	A071863	001	Dec 21, 1987
HERITAGE PHARMA	10MG;2MG	A073007	001	Oct 17, 1991

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

	10MG; 4MG	A073009	001	Oct 17, 1991
	25MG; 2MG	A073008	001	Oct 17, 1991
	25MG; 4MG	A073010	001	Oct 17, 1991
IVAX SUB TEVA PHARMS	10MG; 2MG	A070935	001	Sep 11, 1986
	10MG; 4MG	A070937	001	Sep 11, 1986
	25MG; 2MG	A070936	001	Sep 11, 1986
	25MG; 4MG	A070938	001	Sep 11, 1986
	50MG; 4MG	A070939	001	Sep 12, 1986
PAR PHARM	10MG; 2MG	A070565	001	Sep 11, 1986
	10MG; 4MG	A070620	001	Sep 11, 1986
	25MG; 2MG	A070621	001	Sep 11, 1986
	25MG; 4MG	A070595	001	Sep 11, 1986
	50MG; 4MG	A070574	001	Sep 11, 1986
SUN PHARM INDUSTRIES	10MG; 2MG	A071077	001	Nov 12, 1986
	10MG; 4MG	A071078	001	Nov 12, 1986
	25MG; 2MG	A070297	001	Nov 12, 1986
	25MG; 4MG	A071079	001	Nov 12, 1986
WATSON LABS	10MG; 2MG	A070373	001	Aug 25, 1986
	10MG; 2MG	A072539	001	Feb 15, 1989
	10MG; 4MG	A070375	001	Aug 25, 1986
	10MG; 4MG	A072540	001	Feb 15, 1989
	25MG; 2MG	A070374	001	Aug 25, 1986
	25MG; 2MG	A072541	001	Feb 15, 1989
	25MG; 4MG	A070376	001	Aug 25, 1986
	25MG; 4MG	A072134	001	Feb 15, 1989
	50MG; 4MG	A070377	001	Nov 04, 1986
	50MG; 4MG	A071558	001	Mar 02, 1987
	50MG; 4MG	A072135	001	Feb 15, 1989
TRIAVIL 2-10				
NEW RIVER	10MG; 2MG **	N014715	004	
TRIAVIL 2-25				
NEW RIVER	25MG; 2MG **	N014715	002	
TRIAVIL 4-10				
NEW RIVER	10MG; 4MG **	N014715	003	
TRIAVIL 4-25				
NEW RIVER	25MG; 4MG **	N014715	005	
TRIAVIL 4-50				
NEW RIVER	50MG; 4MG **	N014715	006	

AMLEXANOX

PASTE; DENTAL

APHTHASOL

ULURU 5% N020511 001 Dec 17, 1996

PATCH; TOPICAL

AMLEXANOX

ULURU 2MG N021727 001 Sep 29, 2004

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

AMNEAL PHARMS NY	EQ 2.5MG BASE	A078477	001	Jan 16, 2008
	EQ 5MG BASE	A078477	002	Jan 16, 2008
	EQ 10MG BASE	A078477	003	Jan 16, 2008
GEDEON RICHTER USA	EQ 2.5MG BASE	A077333	001	Jul 17, 2007
	EQ 5MG BASE	A077333	002	Jul 17, 2007
	EQ 10MG BASE	A077333	003	Jul 17, 2007
GENPHARM	EQ 2.5MG BASE	A077362	001	Jul 09, 2007
	EQ 5MG BASE	A077362	002	Jul 09, 2007
	EQ 10MG BASE	A077362	003	Jul 09, 2007
HIKMA	EQ 2.5MG BASE	A077262	001	Jul 09, 2007
	EQ 5MG BASE	A077262	002	Jul 09, 2007
	EQ 10MG BASE	A077262	003	Jul 09, 2007
HIKMA PHARMS	EQ 2.5MG BASE	A077771	001	Apr 12, 2011
	EQ 5MG BASE	A077771	002	Apr 12, 2011
	EQ 10MG BASE	A077771	003	Apr 12, 2011
MACLEODS PHARMS LTD	EQ 5MG BASE	A201380	001	Apr 13, 2012
	EQ 10MG BASE	A201380	002	Apr 13, 2012

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

MYLAN	EQ 2.5MG BASE	A076418	001	Oct 03, 2005
	EQ 2.5MG BASE	A078224	001	Feb 27, 2008
	EQ 5MG BASE	A076418	002	Oct 03, 2005
	EQ 5MG BASE	A078224	002	Feb 27, 2008
	EQ 10MG BASE	A076418	003	Oct 03, 2005
	EQ 10MG BASE	A078224	003	Feb 27, 2008
PURACAP PHARM	EQ 2.5MG BASE	A078131	001	Sep 04, 2007
	EQ 5MG BASE	A078131	002	Sep 04, 2007
	EQ 10MG BASE	A078131	003	Sep 04, 2007
SOVEREIGN PHARMS	EQ 2.5MG BASE	A204900	001	Jul 23, 2015
	EQ 5MG BASE	A204900	002	Jul 23, 2015
	EQ 10MG BASE	A204900	003	Jul 23, 2015
SUN PHARM INDS INC	EQ 2.5MG BASE	A078231	001	Nov 30, 2007
	EQ 5MG BASE	A078231	002	Nov 30, 2007
	EQ 10MG BASE	A078231	003	Nov 30, 2007
SUN PHARM INDUSTRIES	EQ 2.5MG BASE	A078081	001	Jan 31, 2008
	EQ 5MG BASE	A078081	002	Jan 31, 2008
	EQ 10MG BASE	A078081	003	Jan 31, 2008
SUNSHINE	EQ 2.5MG BASE	A206524	001	May 04, 2018
	EQ 5MG BASE	A206524	002	May 04, 2018
	EQ 10MG BASE	A206524	003	May 04, 2018
SYNTHON PHARMS	EQ 2.5MG BASE	A077080	001	Jun 27, 2007
	EQ 5MG BASE	A077080	002	Jun 27, 2007
	EQ 10MG BASE	A077080	003	Jun 27, 2007
TEVA	EQ 2.5MG BASE	A076846	001	Jun 28, 2007
	EQ 5MG BASE	A076846	002	Jun 28, 2007
	EQ 10MG BASE	A076846	003	Jun 28, 2007
TORRENT PHARMS	EQ 2.5MG BASE	A078573	001	Sep 22, 2008
	EQ 5MG BASE	A078573	002	Sep 22, 2008
	EQ 10MG BASE	A078573	003	Sep 22, 2008
WATSON LABS	EQ 2.5MG BASE	A077671	001	Jul 19, 2007
	EQ 5MG BASE	A077671	002	Jul 19, 2007
	EQ 10MG BASE	A077671	003	Jul 19, 2007
YAOPHARMA CO LTD	EQ 2.5MG BASE	A076859	001	Sep 10, 2007
	EQ 5MG BASE	A076859	002	Sep 10, 2007
	EQ 10MG BASE	A076859	003	Sep 10, 2007

TABLET, ORALLY DISINTEGRATING;ORAL

AMLODIPINE BESYLATE

SYNTHON PHARMS	EQ 2.5MG BASE	N022026	001	Sep 27, 2007
	EQ 5MG BASE	N022026	002	Sep 27, 2007
	EQ 10MG BASE	N022026	003	Sep 27, 2007

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE;ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

CIPLA	EQ 2.5MG BASE;10MG	A077215	001	Dec 07, 2018
	EQ 5MG BASE;10MG	A077215	002	Dec 07, 2018
	EQ 5MG BASE;20MG	A077215	003	Dec 07, 2018
	EQ 10MG BASE;20MG	A077215	004	Dec 07, 2018
MYLAN	EQ 2.5MG BASE;10MG	A077375	001	May 21, 2010
	EQ 5MG BASE;10MG	A077375	002	May 21, 2010
	EQ 5MG BASE;20MG	A077375	003	May 21, 2010
	EQ 5MG BASE;40MG	A079047	001	Jul 05, 2011
	EQ 10MG BASE;20MG	A077375	004	May 21, 2010
	EQ 10MG BASE;40MG	A079047	002	Jul 05, 2011
PAR PHARM	EQ 2.5MG BASE;10MG	A078381	001	Jul 29, 2010
	EQ 5MG BASE;10MG	A078381	002	Jul 29, 2010
	EQ 5MG BASE;20MG	A078381	003	Jul 29, 2010
	EQ 5MG BASE;40MG	A078381	005	Jul 29, 2010
	EQ 10MG BASE;20MG	A078381	004	Jul 29, 2010
	EQ 10MG BASE;40MG	A078381	006	Jul 29, 2010
TEVA PHARMS	EQ 2.5MG BASE;10MG	A077179	001	May 18, 2007
	EQ 5MG BASE;10MG	A077179	002	May 18, 2007
	EQ 5MG BASE;20MG	A077179	003	May 18, 2007
	EQ 5MG BASE;40MG	A077179	005	Jul 05, 2011
	EQ 10MG BASE;20MG	A077179	004	May 18, 2007
	EQ 10MG BASE;40MG	A077179	006	Jul 05, 2011

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

PAR PHARM	EQ 5MG BASE;12.5MG;160MG	A201087 001	Jun 01, 2015
	EQ 5MG BASE;25MG;160MG	A201087 002	Jun 01, 2015
	EQ 10MG BASE;12.5MG;160MG	A201087 003	Jun 01, 2015
	EQ 10MG BASE;25MG;160MG	A201087 004	Jun 01, 2015
	EQ 10MG BASE;25MG;320MG	A201087 005	Jun 01, 2015
TEVA PHARMS	EQ 5MG BASE;12.5MG;160MG	A200435 001	Sep 25, 2012
	EQ 5MG BASE;25MG;160MG	A200435 002	Sep 25, 2012
	EQ 10MG BASE;12.5MG;160MG	A200435 005	Sep 25, 2012
	EQ 10MG BASE;25MG;160MG	A200435 003	Sep 25, 2012
	EQ 10MG BASE;25MG;320MG	A200435 004	Sep 25, 2012
TORRENT	EQ 5MG BASE;12.5MG;160MG	A201593 001	Jun 03, 2015
	EQ 5MG BASE;25MG;160MG	A201593 002	Jun 03, 2015
	EQ 10MG BASE;12.5MG;160MG	A201593 003	Jun 03, 2015
	EQ 10MG BASE;25MG;160MG	A201593 004	Jun 03, 2015
	EQ 10MG BASE;25MG;320MG	A201593 005	Jun 03, 2015

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

ACCORD HLTHCARE INC	EQ 5MG BASE;20MG	A209600 001	Aug 30, 2018
	EQ 5MG BASE;40MG	A209600 003	Aug 30, 2018
	EQ 10MG BASE;20MG	A209600 002	Aug 30, 2018
	EQ 10MG BASE;40MG	A209600 004	Aug 30, 2018
TEVA PHARMS USA	EQ 5MG BASE;20MG	A091154 001	Oct 26, 2016
	EQ 5MG BASE;40MG	A091154 002	Oct 26, 2016
	EQ 10MG BASE;20MG	A091154 003	Oct 26, 2016
	EQ 10MG BASE;40MG	A091154 004	Oct 26, 2016

AMLODIPINE BESYLATE; TELMISARTAN

TABLET; ORAL

TELMISARTAN AND AMLODIPINE

ALEMBIC PHARMS LTD	EQ 5MG BASE;40MG	A205234 001	Nov 17, 2016
	EQ 5MG BASE;80MG	A205234 003	Nov 17, 2016
	EQ 10MG BASE;40MG	A205234 002	Nov 17, 2016
	EQ 10MG BASE;80MG	A205234 004	Nov 17, 2016

AMLODIPINE BESYLATE; VALSARTAN

TABLET; ORAL

AMLODIPINE BESYLATE AND VALSARTAN

PAR PHARM INC	EQ 5MG BASE;160MG	A090011 001	Mar 28, 2013
	EQ 5MG BASE;320MG	A090011 003	Mar 28, 2013
	EQ 10MG BASE;160MG	A090011 002	Mar 28, 2013
	EQ 10MG BASE;320MG	A090011 004	Mar 28, 2013
TEVA PHARMS USA	EQ 5MG BASE;160MG	A091235 001	Mar 30, 2015
	EQ 5MG BASE;320MG	A091235 003	Mar 30, 2015
	EQ 10MG BASE;160MG	A091235 002	Mar 30, 2015
	EQ 10MG BASE;320MG	A091235 004	Mar 30, 2015
TORRENT	EQ 5MG BASE;160MG	A202377 001	Mar 30, 2015
	EQ 5MG BASE;320MG	A202377 002	Mar 30, 2015
	EQ 10MG BASE;160MG	A202377 003	Mar 30, 2015
	EQ 10MG BASE;320MG	A202377 004	Mar 30, 2015

AMLODIPINE MALEATE

TABLET; ORAL

AMVAZ

DR REDDYS LABS INC	2.5MG	N021435 001	Oct 31, 2003
	5MG	N021435 002	Oct 31, 2003
	10MG	N021435 003	Oct 31, 2003

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

CENTRAL RADIOPHARM	3.75-260mCi/ML	A204539 001	Jun 23, 2015
UNIV TX MD ANDERSON	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A203933 001	Jun 27, 2014

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMMONIUM CHLORIDE

INJECTABLE; INJECTION

AMMONIUM CHLORIDE

ABBOTT	5MEQ/ML	A083130	001
GD SEARLE LLC	3MEQ/ML	A086205	001
AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE			
MCGAW	900MG/100ML	N006580	001
AMMONIUM CHLORIDE 2.14%			
B BRAUN	40MEQ/100ML	A085734	001

AMMONIUM LACTATE

CREAM; TOPICAL

AMMONIUM LACTATE

WATSON LABS INC	EQ 12% BASE	A076829	001	Feb 07, 2006
LAC-HYDRIN				
SUN PHARM INDS INC	EQ 12% BASE **	N020508	001	Aug 29, 1996

LOTION; TOPICAL

AMMONIUM LACTATE

WATSON LABS INC	EQ 12% BASE	A075575	001	Jun 11, 2002
LAC-HYDRIN				
+ SUN PHARM INDS INC	EQ 12% BASE **	N019155	001	Apr 24, 1985

AMODIAQUINE HYDROCHLORIDE

TABLET; ORAL

CAMOQUIN HYDROCHLORIDE

PARKE DAVIS	EQ 200MG BASE	N006441	001
-------------	---------------	---------	-----

AMOXAPINE

TABLET; ORAL

AMOXAPINE

UPSHER SMITH LABS	25MG	A072943	001	Jun 28, 1991
	50MG	A072944	001	Jun 28, 1991
	100MG	A072878	001	Jun 28, 1991
	150MG	A072879	001	Jun 28, 1991
WATSON PHARMS TEVA	25MG	A072418	001	Aug 01, 1989
	50MG	A072419	001	Aug 01, 1989
	100MG	A072420	001	May 11, 1989
	150MG	A072421	001	May 11, 1989
ASENDIN				
LEDERLE	25MG	N018021	001	
	50MG	N018021	002	
	100MG	N018021	003	
	150MG	N018021	004	

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

DAVA PHARMS INC	250MG	A062884	001	Feb 25, 1988
	500MG	A062881	001	Feb 25, 1988
LABS ATRAL	250MG	A062528	001	Aug 07, 1985
	500MG	A062528	002	Aug 07, 1985
MYLAN	250MG	A062067	001	
	500MG	A062067	002	
SUN PHARM INDS LTD	250MG	A065016	001	Apr 08, 1999
	500MG	A065016	002	Apr 08, 1999
TEVA	250MG	A062853	001	Dec 22, 1987
	250MG	A063030	001	Feb 28, 1989
	500MG	A062854	001	Dec 22, 1987
	500MG	A063031	001	Feb 28, 1989

AMOXIL

+ GLAXOSMITHKLINE	250MG **	N050459	001
+	500MG **	N050459	002

TRIMOX

APOTHECON	250MG	A061885	001	
	250MG	A062098	001	
	250MG	A062152	001	
	250MG	A063099	001	Mar 20, 1992
	500MG	A061885	002	
	500MG	A062098	002	
	500MG	A062152	002	
	500MG	A063099	002	Mar 20, 1992

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMOXICILLIN

CAPSULE; ORAL

UTIMOX

PARKE DAVIS	250MG	A062107 001
	500MG	A062107 002

WYMOX

WYETH AYERST	250MG	A062120 001
	500MG	A062120 002

FOR SUSPENSION; ORAL

AMOXICILLIN

BELCHER PHARMS	125MG/5ML	A062059 001	
	250MG/5ML	A062059 002	
MYLAN	125MG/5ML	A062090 001	
	250MG/5ML	A062090 002	
SUN PHARM INDS LTD	200MG/5ML	A065113 001	Nov 29, 2002
	400MG/5ML	A065113 002	Nov 29, 2002
TEVA	125MG/5ML	A061931 001	
	125MG/5ML	A062946 001	Nov 01, 1988
	250MG/5ML	A063001 001	Jan 06, 1989

AMOXIL

+ GLAXOSMITHKLINE	50MG/ML **	N050460 005	
+	125MG/5ML **	N050460 001	
+	250MG/5ML **	N050460 002	
+ NEOPHARMA	200MG/5ML **	N050760 001	Apr 15, 1999
+	400MG/5ML **	N050760 002	Apr 15, 1999

LAROTID

+ GLAXOSMITHKLINE	50MG/ML **	N050460 006	
-------------------	------------	-------------	--

POLYMOX

APOTHECON	125MG/5ML	A061851 001	
	125MG/5ML	A062323 001	
	250MG/5ML	A061851 002	
	250MG/5ML	A062323 002	

TRIMOX

APOTHECON	50MG/ML	A061886 001	
	125MG/5ML	A061886 002	
	125MG/5ML	A062099 001	
	125MG/5ML	A062154 001	
	125MG/5ML	A062885 001	Mar 08, 1988
	250MG/5ML	A061886 003	
	250MG/5ML	A062099 002	
	250MG/5ML	A062154 002	
	250MG/5ML	A062885 002	Mar 08, 1988

UTIMOX

PARKE DAVIS	125MG/5ML	A062127 001	
	250MG/5ML	A062127 002	

WYMOX

WYETH AYERST	125MG/5ML	A062131 001	
	250MG/5ML	A062131 002	

TABLET; ORAL

AMOXICILLIN

DAVA PHARMS INC	875MG	A065344 001	Jan 15, 2009
SUN PHARM INDS LTD	500MG	A065059 001	Nov 24, 2000
	875MG	A065059 002	Nov 24, 2000

AMOXIL

+ NEOPHARMA	500MG **	N050754 002	Jul 10, 1998
+	875MG **	N050754 001	Jul 10, 1998

TABLET, CHEWABLE; ORAL

AMOXICILLIN

APOTHECON	125MG	A064131 001	May 06, 1996
	250MG	A064131 002	May 06, 1996
DAVA PHARMS INC	125MG	A064139 001	Jan 29, 1996
	250MG	A064139 002	Jan 29, 1996
SUN PHARM INDS LTD	125MG	A065021 001	Dec 23, 1999
	200MG	A065060 001	Nov 29, 2000
	250MG	A065021 002	Dec 23, 1999
	400MG	A065060 002	Nov 29, 2000
TEVA	125MG	A064031 001	Dec 19, 1996
	250MG	A064031 002	Dec 19, 1996

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMOXICILLIN

TABLET, CHEWABLE;ORAL

AMOXIL

+	NEOPHARMA	125MG **	N050542 002	
		200MG	N050761 001	Apr 15, 1999
+		250MG **	N050542 001	
		400MG	N050761 002	Apr 15, 1999

TABLET, EXTENDED RELEASE;ORAL

MOXATAG

+	PRAGMA	775MG	N050813 001	Jan 23, 2008
---	--------	-------	-------------	--------------

TABLET, FOR SUSPENSION;ORAL

AMOXICILLIN

	AUROBINDO PHARMA LTD	200MG	A065324 001	Jan 17, 2007
		400MG	A065324 002	Jan 17, 2007

DISPERMOX

	RANBAXY LABS LTD	200MG	A065080 002	Aug 11, 2003
		400MG	A065080 001	Aug 11, 2003
		600MG	A065159 001	Dec 04, 2003

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET;ORAL

LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN

	ANI PHARMS INC	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30M G	A200218 001	Aug 30, 2013
--	----------------	--	-------------	--------------

PREVPAC

+	TAKEDA PHARMS USA	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30M G	N050757 001	Dec 02, 1997
---	-------------------	--	-------------	--------------

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

	SUN PHARM INDS LTD	200MG/5ML;EQ 28.5MG BASE/5ML	A065132 001	Mar 19, 2003
		400MG/5ML;EQ 57MG BASE/5ML	A065132 002	Mar 19, 2003
		600MG/5ML;EQ 42.9MG BASE/5ML	A065207 002	Jan 30, 2007

AUGMENTIN '200'

+	NEOPHARMA	200MG/5ML;EQ 28.5MG BASE/5ML	N050725 001	May 31, 1996
---	-----------	------------------------------	-------------	--------------

AUGMENTIN '400'

+	NEOPHARMA	400MG/5ML;EQ 57MG BASE/5ML	N050725 002	May 31, 1996
---	-----------	----------------------------	-------------	--------------

TABLET;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

	APOTEX INC	250MG;EQ 125MG BASE	A065333 001	Feb 24, 2009
		500MG;EQ 125MG BASE	A065333 002	Feb 24, 2009
		875MG;EQ 125MG BASE	A065317 003	Oct 20, 2008
	SUN PHARM INDS LTD	500MG;EQ 125MG BASE	A065109 001	Nov 04, 2002
		875MG;EQ 125MG BASE	A065102 001	Sep 17, 2002

AUGMENTIN '250'

+	NEOPHARMA	250MG;EQ 125MG BASE **	N050564 001	Aug 06, 1984
---	-----------	------------------------	-------------	--------------

AUGMENTIN '500'

+	NEOPHARMA	500MG;EQ 125MG BASE **	N050564 002	Aug 06, 1984
---	-----------	------------------------	-------------	--------------

TABLET, CHEWABLE;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

	SANDOZ	200MG;EQ 28.5MG BASE	A065065 001	Apr 18, 2002
		400MG;EQ 57MG BASE	A065065 002	Apr 18, 2002
	SUN PHARM INDS LTD	200MG;EQ 28.5MG BASE	A065161 001	Dec 03, 2003
		400MG;EQ 57MG BASE	A065161 002	Dec 03, 2003

AUGMENTIN '125'

+	NEOPHARMA	125MG;EQ 31.25MG BASE **	N050597 001	Jul 22, 1985
---	-----------	--------------------------	-------------	--------------

AUGMENTIN '200'

+	NEOPHARMA	200MG;EQ 28.5MG BASE	N050726 001	May 31, 1996
---	-----------	----------------------	-------------	--------------

AUGMENTIN '250'

+	NEOPHARMA	250MG;EQ 62.5MG BASE **	N050597 002	Jul 22, 1985
---	-----------	-------------------------	-------------	--------------

AUGMENTIN '400'

+	NEOPHARMA	400MG;EQ 57MG BASE	N050726 002	May 31, 1996
---	-----------	--------------------	-------------	--------------

TABLET, EXTENDED RELEASE;ORAL

AUGMENTIN XR

+	NEOPHARMA	1GM;EQ 62.5MG BASE	N050785 001	Sep 25, 2002
---	-----------	--------------------	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMPHETAMINE ADIPATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE ADIPATE; DEXTROAMPHETAMINE SULFATE

CAPSULE; ORAL

DELCOBESE

TEVA	1.25MG; 1.25MG; 1.25MG; 1.25MG **	A083564	001
	2.5MG; 2.5MG; 2.5MG; 2.5MG **	A083564	002
	3.75MG; 3.75MG; 3.75MG; 3.75MG **	A083564	003
	5MG; 5MG; 5MG; 5MG **	A083564	004

TABLET; ORAL

DELCOBESE

TEVA	1.25MG; 1.25MG; 1.25MG; 1.25MG	A083563	004
	2.5MG; 2.5MG; 2.5MG; 2.5MG	A083563	003
	3.75MG; 3.75MG; 3.75MG; 3.75MG	A083563	002
	5MG; 5MG; 5MG; 5MG	A083563	001

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

MYLAN	1.25MG; 1.25MG; 1.25MG; 1.25MG	A211876	001	Jun 24, 2020
	2.5MG; 2.5MG; 2.5MG; 2.5MG	A211876	002	Jun 24, 2020
	3.75MG; 3.75MG; 3.75MG; 3.75MG	A211876	003	Jun 24, 2020
	5MG; 5MG; 5MG; 5MG	A211876	004	Jun 24, 2020
	6.25MG; 6.25MG; 6.25MG; 6.25MG	A211876	005	Jun 24, 2020
	7.5MG; 7.5MG; 7.5MG; 7.5MG	A211876	006	Jun 24, 2020
NESHER PHARMS	1.25MG; 1.25MG; 1.25MG; 1.25MG	A210080	001	Jul 17, 2019
	2.5MG; 2.5MG; 2.5MG; 2.5MG	A210080	002	Jul 17, 2019
	3.75MG; 3.75MG; 3.75MG; 3.75MG	A210080	003	Jul 17, 2019
	5MG; 5MG; 5MG; 5MG	A210080	004	Jul 17, 2019
	6.25MG; 6.25MG; 6.25MG; 6.25MG	A210080	005	Jul 17, 2019
	7.5MG; 7.5MG; 7.5MG; 7.5MG	A210080	006	Jul 17, 2019
TEVA	1.25MG; 1.25MG; 1.25MG; 1.25MG	A077488	001	Apr 29, 2013
	2.5MG; 2.5MG; 2.5MG; 2.5MG	A077488	002	Apr 29, 2013
	3.75MG; 3.75MG; 3.75MG; 3.75MG	A077488	003	Apr 29, 2013
	5MG; 5MG; 5MG; 5MG	A077488	004	Apr 29, 2013
	6.25MG; 6.25MG; 6.25MG; 6.25MG	A077488	005	Apr 29, 2013
	7.5MG; 7.5MG; 7.5MG; 7.5MG	A077488	006	Apr 29, 2013
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE				
BARR LABS INC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A076536	001	Feb 12, 2013
	2.5MG; 2.5MG; 2.5MG; 2.5MG	A076536	002	Feb 12, 2013
	3.75MG; 3.75MG; 3.75MG; 3.75MG	A076536	003	Feb 12, 2013
	5MG; 5MG; 5MG; 5MG	A076536	004	Feb 12, 2013
	6.25MG; 6.25MG; 6.25MG; 6.25MG	A076536	005	Feb 12, 2013
	7.5MG; 7.5MG; 7.5MG; 7.5MG	A076536	006	Feb 12, 2013

TABLET; ORAL

ADDERALL 10

+ TEVA WOMENS	2.5MG; 2.5MG; 2.5MG; 2.5MG **	N011522	007	Feb 13, 1996
---------------	-------------------------------	---------	-----	--------------

ADDERALL 12.5

+ TEVA WOMENS	3.125MG; 3.125MG; 3.125MG; 3.125MG **	N011522	012	Aug 31, 2000
---------------	---------------------------------------	---------	-----	--------------

ADDERALL 15

+ TEVA WOMENS	3.75MG; 3.75MG; 3.75MG; 3.75MG **	N011522	013	Aug 31, 2000
---------------	-----------------------------------	---------	-----	--------------

ADDERALL 20

+ TEVA WOMENS	5MG; 5MG; 5MG; 5MG **	N011522	008	Feb 13, 1996
---------------	-----------------------	---------	-----	--------------

ADDERALL 30

+ TEVA WOMENS	7.5MG; 7.5MG; 7.5MG; 7.5MG **	N011522	010	May 12, 1997
---------------	-------------------------------	---------	-----	--------------

ADDERALL 5

+ TEVA WOMENS	1.25MG; 1.25MG; 1.25MG; 1.25MG **	N011522	009	May 12, 1997
---------------	-----------------------------------	---------	-----	--------------

ADDERALL 7.5

+ TEVA WOMENS	1.875MG; 1.875MG; 1.875MG; 1.875MG **	N011522	011	Aug 31, 2000
---------------	---------------------------------------	---------	-----	--------------

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

ACTAVIS ELIZABETH

	1.25MG; 1.25MG; 1.25MG; 1.25MG	A040456	001	May 06, 2003
	2.5MG; 2.5MG; 2.5MG; 2.5MG	A040456	002	May 06, 2003
	5MG; 5MG; 5MG; 5MG	A040456	003	May 06, 2003
	7.5MG; 7.5MG; 7.5MG; 7.5MG	A040456	004	May 06, 2003
TEVA PHARMS	1.25MG; 1.25MG; 1.25MG; 1.25MG	A040472	001	Sep 30, 2003
	2.5MG; 2.5MG; 2.5MG; 2.5MG	A040472	002	Sep 30, 2003
	5MG; 5MG; 5MG; 5MG	A040472	003	Sep 30, 2003
	7.5MG; 7.5MG; 7.5MG; 7.5MG	A040472	004	Sep 30, 2003

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMPHETAMINE RESIN COMPLEX; DEXTROAMPHETAMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE;ORAL

BIPHETAMINE 12.5

UCB INC

EQ 6.25MG BASE;EQ 6.25MG BASE

N010093 007

BIPHETAMINE 20

UCB INC

EQ 10MG BASE;EQ 10MG BASE

N010093 003

BIPHETAMINE 7.5

UCB INC

EQ 3.75MG BASE;EQ 3.75MG BASE

N010093 009

AMPHETAMINE SULFATE

TABLET;ORAL

AMPHETAMINE SULFATE

LANNETT

5MG

A083901 001 Aug 31, 1984

10MG

A083901 002 Aug 31, 1984

AMPHOTERICIN B

CREAM;TOPICAL

FUNGIZONE

APOTHECON

3%

N050314 001

INJECTABLE; INJECTION

AMPHOTERICIN B

ABBOTT

50MG/VIAL

A064141 001 Dec 23, 1996

ABRAXIS PHARM

50MG/VIAL

A062728 001 Apr 13, 1987

TEVA PARENTERAL

50MG/VIAL

A064062 001 Mar 31, 1995

FUNGIZONE

APOTHECON

50MG/VIAL

A060517 001

INJECTABLE, LIPID COMPLEX;INJECTION

AMPHOTEC

ALKOPHARMA USA

50MG/VIAL

N050729 001 Nov 22, 1996

100MG/VIAL

N050729 002 Nov 22, 1996

LOTION;TOPICAL

FUNGIZONE

APOTHECON

3%

A060570 001

OINTMENT;TOPICAL

FUNGIZONE

APOTHECON

3%

N050313 001

SUSPENSION;ORAL

FUNGIZONE

BRISTOL MYERS SQUIBB

100MG/ML

N050341 003

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

ACS DOBFAR SPA

EQ 500MG BASE/VIAL

A090884 001 Apr 03, 2013

EQ 1GM BASE/VIAL

A090884 002 Apr 03, 2013

EQ 2GM BASE/VIAL

A090884 003 Apr 03, 2013

APOTHECON

EQ 125MG BASE/VIAL

A062860 001 Feb 05, 1988

EQ 250MG BASE/VIAL

A062860 002 Feb 05, 1988

EQ 500MG BASE/VIAL

A062860 003 Feb 05, 1988

EQ 1GM BASE/VIAL

A062860 004 Feb 05, 1988

EQ 2GM BASE/VIAL

A062860 005 Feb 05, 1988

AUROBINDO PHARMA

EQ 125MG BASE/VIAL

A065499 001 Aug 17, 2010

CONSOLIDATED PHARM

EQ 125MG BASE/VIAL

A061936 005

EQ 250MG BASE/VIAL

A061936 001

EQ 500MG BASE/VIAL

A061936 002

EQ 1GM BASE/VIAL

A061936 003

EQ 2GM BASE/VIAL

A061936 004

HANFORD GC

EQ 125MG BASE/VIAL

A062772 005 Apr 15, 1993

EQ 500MG BASE/VIAL

A062772 008 Apr 15, 1993

EQ 1GM BASE/VIAL

A062772 002 Apr 15, 1993

EQ 2GM BASE/VIAL

A062772 004 Apr 15, 1993

HOSPIRA INC

EQ 250MG BASE/VIAL

A202864 001 Sep 04, 2015

EQ 500MG BASE/VIAL

A202864 002 Sep 04, 2015

EQ 1GM BASE/VIAL

A202864 003 Sep 04, 2015

EQ 2GM BASE/VIAL

A202864 004 Sep 04, 2015

EQ 10GM BASE/VIAL

A202865 001 Sep 04, 2015

INTL MEDICATION

EQ 1GM BASE/VIAL

A062634 002 Jan 09, 1987

EQ 2GM BASE/VIAL

A062634 003 Jan 09, 1987

ISTITUTO BIO ITA SPA

EQ 125MG BASE/VIAL

A062797 001 Jul 12, 1993

LILLY

EQ 500MG BASE/VIAL

A062565 001 Apr 04, 1985

EQ 1GM BASE/VIAL

A062565 002 Apr 04, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

	EQ 2GM BASE/VIAL	A062565 003	Jun 24, 1986
WATSON LABS INC	EQ 125MG BASE/VIAL	A062816 001	Oct 24, 1988
	EQ 250MG BASE/VIAL	A062816 002	Oct 24, 1988
	EQ 500MG BASE/VIAL	A062816 003	Oct 24, 1988
	EQ 1GM BASE/VIAL	A062816 004	Oct 24, 1988
	EQ 2GM BASE/VIAL	A062816 005	Oct 24, 1988
	EQ 10GM BASE/VIAL	A062994 001	Sep 15, 1988
WEST-WARD PHARMS INT	EQ 125MG BASE/VIAL	A062692 001	Jun 24, 1986
	EQ 250MG BASE/VIAL	A062692 002	Jun 24, 1986
	EQ 500MG BASE/VIAL	A062692 003	Jun 24, 1986
	EQ 1GM BASE/VIAL	A062692 004	Jun 24, 1986
	EQ 2GM BASE/VIAL	A062692 005	Jun 24, 1986
	EQ 10GM BASE/VIAL	A062692 006	Jun 24, 1986
OMNIPEN-N			
WYETH AYERST	EQ 125MG BASE/VIAL	A060626 001	
	EQ 125MG BASE/VIAL	A062718 001	Dec 16, 1986
	EQ 250MG BASE/VIAL	A060626 002	
	EQ 250MG BASE/VIAL	A062718 002	Dec 16, 1986
	EQ 500MG BASE/VIAL	A060626 003	
	EQ 500MG BASE/VIAL	A062718 003	Dec 16, 1986
	EQ 1GM BASE/VIAL	A060626 004	
	EQ 1GM BASE/VIAL	A062718 004	Dec 16, 1986
	EQ 2GM BASE/VIAL	A060626 005	
	EQ 2GM BASE/VIAL	A062718 005	Dec 16, 1986
PENBRITIN-S			
+ WYETH AYERST	EQ 125MG BASE/VIAL **	N050072 001	
+	EQ 250MG BASE/VIAL **	N050072 002	
+	EQ 500MG BASE/VIAL **	N050072 003	
+	EQ 1GM BASE/VIAL **	N050072 004	
+	EQ 2GM BASE/VIAL **	N050072 005	
+	EQ 4GM BASE/VIAL **	N050072 006	
POLYCILLIN-N			
BRISTOL	EQ 125MG BASE/VIAL **	N050309 001	
	EQ 250MG BASE/VIAL **	N050309 002	
	EQ 500MG BASE/VIAL **	N050309 003	
	EQ 1GM BASE/VIAL **	N050309 004	
	EQ 2GM BASE/VIAL **	N050309 005	
TOTACILLIN-N			
GLAXOSMITHKLINE	EQ 125MG BASE/VIAL	A060677 001	
	EQ 250MG BASE/VIAL	A060677 002	
	EQ 500MG BASE/VIAL	A060677 003	
	EQ 1GM BASE/VIAL	A060677 004	
	EQ 1GM BASE/VIAL	A062727 001	Dec 19, 1986
	EQ 2GM BASE/VIAL	A060677 005	
	EQ 2GM BASE/VIAL	A062727 002	Dec 19, 1986
	EQ 10GM BASE/VIAL	A060677 006	

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

HOSPIRA INC	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090375 001	Dec 21, 2011
	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090653 001	Dec 21, 2011
	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090375 002	Dec 21, 2011
	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090653 002	Dec 21, 2011
	EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A090646 001	Dec 21, 2011
PHARM ASSOC	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065316 001	Jun 29, 2007
	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065316 002	Jun 29, 2007
UNASYN			
PFIZER	EQ 500MG BASE/VIAL;EQ 250MG BASE/VIAL	N050608 003	Dec 31, 1986

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

AMCILL

PARKE DAVIS	EQ 250MG BASE	A062041 001	
	EQ 500MG BASE	A062041 002	
AMPICILLIN TRIHYDRATE			
BELCHER PHARMS	EQ 250MG BASE	A061602 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE;ORAL

AMPICILLIN TRIHYDRATE

	EQ 500MG BASE	A061602 002	
DAVA PHARMS INC	EQ 250MG BASE	A062883 001	Feb 25, 1988
	EQ 500MG BASE	A062882 001	Feb 25, 1988
HERITAGE PHARMA	EQ 250MG BASE	A061502 001	
	EQ 500MG BASE	A061502 002	
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A060765 001	
	EQ 500MG BASE	A060765 002	
LEDERLE	EQ 250MG BASE	A062208 001	
	EQ 500MG BASE	A062208 002	
MYLAN	EQ 250MG BASE	A061755 001	
	EQ 500MG BASE	A061755 002	
PUREPAC PHARM	EQ 250MG BASE	A061853 001	
	EQ 500MG BASE	A061853 002	
SANDOZ	EQ 250MG BASE	A064082 001	Aug 29, 1995
VITARINE	EQ 250MG BASE	A061387 001	
	EQ 500MG BASE	A061387 003	
OMNIPEN (AMPICILLIN)			
WYETH AYERST	250MG	A060624 001	
	500MG	A060624 002	
PENBRITIN			
WYETH AYERST	EQ 250MG BASE	A060908 001	
	EQ 500MG BASE	A060908 002	
PFIZERPEN-A			
PFIZER	EQ 250MG BASE	A062050 001	
	EQ 500MG BASE	A062050 002	
POLYCILLIN			
BRISTOL	EQ 250MG BASE	N050310 001	
	EQ 500MG BASE	N050310 002	
PRINCIPEN			
APOTHECON	EQ 250MG BASE	A062888 001	Mar 04, 1988
	EQ 500MG BASE	A062888 002	Mar 04, 1988
BRISTOL MYERS SQUIBB	EQ 250MG BASE	A061392 001	
	EQ 500MG BASE	A061392 002	
PRINCIPEN '250'			
APOTHECON	EQ 250MG BASE	A062157 002	
	EQ 250MG BASE	N050056 001	
PRINCIPEN '500'			
APOTHECON	EQ 500MG BASE	A062157 001	
	EQ 500MG BASE	N050056 002	
TOTACILLIN			
GLAXOSMITHKLINE	EQ 250MG BASE	A060060 001	
	EQ 250MG BASE	A062212 001	
	EQ 500MG BASE	A060060 002	
	EQ 500MG BASE	A062212 002	
FOR SUSPENSION;ORAL			
AMCILL			
PARKE DAVIS	EQ 125MG BASE/5ML	A062030 001	
	EQ 250MG BASE/5ML	A062030 002	
AMPICILLIN TRIHYDRATE			
BELCHER PHARMS	EQ 125MG BASE/5ML	A061601 001	
	EQ 250MG BASE/5ML	A061601 002	
DAVA PHARMS INC	EQ 125MG BASE/5ML	A062982 001	Feb 10, 1989
	EQ 250MG BASE/5ML	A062982 002	Feb 10, 1989
MYLAN	EQ 125MG BASE/5ML	A061829 002	
	EQ 250MG BASE/5ML	A061829 001	
PUREPAC PHARM	EQ 125MG BASE/5ML	A061980 001	
	EQ 250MG BASE/5ML	A061980 002	
TEVA	EQ 125MG BASE/5ML	A061370 001	
	EQ 250MG BASE/5ML	A061370 002	
OMNIPEN (AMPICILLIN)			
WYETH AYERST	100MG/ML	A060625 001	
	125MG/5ML	A060625 002	
	250MG/5ML	A060625 003	
	500MG/5ML	A060625 004	
PENBRITIN			
WYETH AYERST	EQ 100MG BASE/ML	N050019 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMPICILLIN/AMPICILLIN TRIHYDRATE

FOR SUSPENSION;ORAL

PENBRITIN

EQ 125MG BASE/5ML N050019 002
EQ 250MG BASE/5ML N050019 003

PFIZERPEN-A

PFIZER

EQ 125MG BASE/5ML A062049 001
EQ 250MG BASE/5ML A062049 002

POLYCILLIN

APOTHECON

EQ 125MG BASE/5ML A062297 001
EQ 250MG BASE/5ML A062297 002

BRISTOL

EQ 100MG BASE/ML N050308 004
EQ 125MG BASE/5ML N050308 001
EQ 250MG BASE/5ML N050308 002
EQ 500MG BASE/5ML N050308 003

PRINCIPEN

APOTHECON

EQ 100MG BASE/ML A061394 001
EQ 125MG BASE/5ML A061394 002
EQ 250MG BASE/5ML A061394 003

PRINCIPEN '125'

APOTHECON

EQ 125MG BASE/5ML A060127 002
EQ 125MG BASE/5ML A062151 001

PRINCIPEN '250'

APOTHECON

EQ 250MG BASE/5ML A060127 001
EQ 250MG BASE/5ML A062151 002

TOTACILLIN

GLAXOSMITHKLINE

EQ 125MG BASE/5ML A060666 001
EQ 125MG BASE/5ML A062223 001
EQ 250MG BASE/5ML A060666 002
EQ 250MG BASE/5ML A062223 002

TABLET, CHEWABLE;ORAL

POLYCILLIN

BRISTOL

EQ 125MG BASE N050093 001

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

CAPSULE;ORAL

PRINCIPEN W/ PROBENECID

APOTHECON

EQ 389MG BASE;111MG A062150 001
EQ 389MG BASE;111MG N050488 001

FOR SUSPENSION;ORAL

POLYCILLIN-PRB

APOTHECON

EQ 3.5GM BASE/BOT;1GM/BOT A061898 001

BRISTOL

EQ 3.5GM BASE/BOT;1GM/BOT N050457 001

PROBAMPACIN

COSETTE

EQ 3.5GM BASE/BOT;1GM/BOT A061741 001

AMPRENAVIR

CAPSULE;ORAL

AGENERASE

GLAXOSMITHKLINE

50MG N021007 001 Apr 15, 1999
150MG N021007 002 Apr 15, 1999

SOLUTION;ORAL

AGENERASE

+ GLAXOSMITHKLINE

15MG/ML ** N021039 001 Apr 15, 1999

ANAGRELIDE HYDROCHLORIDE

CAPSULE;ORAL

AGRYLIN

+ TAKEDA PHARMS USA

EQ 1MG BASE ** N020333 002 Mar 14, 1997

ANAGRELIDE HYDROCHLORIDE

BARR

EQ 0.5MG BASE A076530 001 Apr 18, 2005
EQ 1MG BASE A076530 002 Apr 18, 2005

MYLAN

EQ 0.5MG BASE A076811 001 Apr 18, 2005

EQ 1MG BASE A076811 002 Apr 18, 2005

MYLAN PHARMS INC

EQ 0.5MG BASE A077613 001 Jun 27, 2006

EQ 1MG BASE A077613 002 Jun 27, 2006

ROXANE

EQ 0.5MG BASE A076489 001 Apr 18, 2005

EQ 1MG BASE A076489 002 Apr 18, 2005

UPSHER SMITH LABS

EQ 0.5MG BASE A076683 001 Apr 18, 2005

EQ 1MG BASE A076683 002 Apr 18, 2005

WATSON LABS

EQ 0.5MG BASE A076417 001 Apr 18, 2005

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

ANAGRELIDE HYDROCHLORIDE

EQ 1MG BASE

A076417 002 Apr 18, 2005

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

APOTEX INC

1MG

A200654 001 May 11, 2012

HIKMA

1MG

A078485 001 Jun 28, 2010

IMPAX LABS INC

1MG

A091242 001 May 31, 2012

LANNETT CO INC

1MG

A091331 001 Jan 05, 2011

MYLAN

1MG

A091051 001 Jun 28, 2010

NEOPHARMA

1MG

A090732 001 Jun 28, 2010

SANDOZ

1MG

A079007 001 Jun 28, 2010

SUN PHARM INDS LTD

1MG

A091177 001 Jul 15, 2011

SYNTHON PHARMS

1MG

A078322 001 Jun 28, 2010

WATSON LABS TEVA

1MG

A078984 001 Jun 28, 2010

ANGIOTENSIN II ACETATE

SOLUTION; INTRAVENOUS

GIAPREZA

+ LA JOLLA PHARMA

EQ 5MG BASE/2ML (EQ 2.5MG BASE/ML)

N209360 002 Dec 21, 2017

ANILERIDINE HYDROCHLORIDE

TABLET; ORAL

LERITINE

MERCK

EQ 25MG BASE

N010585 002

ANILERIDINE PHOSPHATE

INJECTABLE; INJECTION

LERITINE

MERCK

25MG/ML

N010520 003

ANISINDIONE

TABLET; ORAL

MIRADON

SCHERING

50MG

N010909 003

ANISOTROPINE METHYLBROMIDE

TABLET; ORAL

ANISOTROPINE METHYLBROMIDE

WATSON LABS

50MG

A086046 001

VALPIN 50

ENDO PHARMS

50MG

N013428 001

ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

VASOCON-A

NOVARTIS

0.5%; 0.05%

N018746 002 Jul 11, 1994

APIXABAN

TABLET; ORAL

APIXABAN

BIONPHARMA INC

2.5MG

A210152 001 Apr 08, 2020

5MG

A210152 002 Apr 08, 2020

MICRO LABS

2.5MG

A210013 001 Dec 23, 2019

5MG

A210013 002 Dec 23, 2019

MYLAN

2.5MG

A210128 001 Dec 23, 2019

5MG

A210128 002 Dec 23, 2019

APOMORPHINE HYDROCHLORIDE

INJECTABLE; SUBCUTANEOUS

APOKYN

MDD US

20MG/2ML (10MG/ML)

N021264 001 Apr 20, 2004

APREPITANT

CAPSULE; ORAL

EMEND

+ MERCK

40MG

N021549 003 Jun 30, 2006

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ARBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

GENESA

GENSIA AUTOMEDICS 0.05MG/ML N020420 001 Sep 12, 1997

ARDEPARIN SODIUM

INJECTABLE; INJECTION

NORMIFLO

+ PHARMACIA AND UPJOHN 5,000 UNITS/0.5ML ** N020227 002 May 23, 1997

+ 10,000 UNITS/0.5ML ** N020227 001 May 23, 1997

ARGATROBAN

INJECTABLE; INTRAVENOUS

ARGATROBAN IN 0.9% SODIUM CHLORIDE

TEVA PHARMS USA 250MG/250ML (1MG/ML) N206769 001 Dec 15, 2014

SOLUTION; INTRAVENOUS

ARGATROBAN IN DEXTROSE

SANDOZ 125MG/125ML (1MG/ML) N201743 001 May 09, 2011

ARIPIPIRAZOLE

INJECTABLE; INTRAMUSCULAR

ABILIFY

OTSUKA 9.75MG/1.3ML (7.5MG/ML) N021866 001 Sep 20, 2006

SOLUTION; ORAL

ABILIFY

+ OTSUKA 1MG/ML ** N021713 001 Dec 10, 2004

TABLET; ORAL

ARIPIPIRAZOLE

MYLAN

2MG A206240 001 Sep 19, 2018

5MG A206240 002 Sep 19, 2018

10MG A206240 003 Sep 19, 2018

15MG A206240 004 Sep 19, 2018

20MG A206240 005 Sep 19, 2018

30MG A206240 006 Sep 19, 2018

TEVA PHARMS USA 2MG A078607 001 Apr 28, 2015

5MG A078607 002 Apr 28, 2015

10MG A078608 001 Apr 28, 2015

15MG A078708 001 Apr 28, 2015

20MG A078708 002 Apr 28, 2015

30MG A078708 003 Apr 28, 2015

ZYDUS PHARMS 2MG A090472 001 Jan 07, 2019

5MG A090472 002 Jan 07, 2019

10MG A090472 003 Jan 07, 2019

15MG A090472 004 Jan 07, 2019

20MG A090472 005 Jan 07, 2019

30MG A090472 006 Jan 07, 2019

TABLET, ORALLY DISINTEGRATING; ORAL

ABILIFY

+ OTSUKA 10MG ** N021729 002 Jun 07, 2006

+ 15MG ** N021729 003 Jun 07, 2006

+ 20MG ** N021729 004 Jun 07, 2006

+ 30MG ** N021729 005 Jun 07, 2006

ARMODAFINIL

TABLET; ORAL

ARMODAFINIL

APOTEX INC

50MG A201514 001 Mar 25, 2019

150MG A201514 002 Mar 25, 2019

250MG A201514 003 Mar 25, 2019

WATSON LABS INC 100MG A200156 002 Aug 29, 2012

200MG A200156 004 Aug 29, 2012

NUVIGIL

+ CEPHALON 100MG ** N021875 002 Mar 26, 2009

ARSENIC TRIOXIDE

INJECTABLE; INJECTION

TRISENOX

+ CEPHALON 1MG/ML ** N021248 001 Sep 25, 2000

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ARTICAINA HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

ARTICAINA HYDROCHLORIDE AND EPINEPHRINE BITARTRATE

HOSPIRA	4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML)	A079138 001	Jun 18, 2010
ULTACAN			
HANSAMED INC	4%;EQ 0.0085MG BASE/1.7ML (4%; EQ 0.005MG BASE/ML)	A201751 001	Jul 11, 2017
ULTACAN FORTE			
HANSAMED INC	4%;EQ 0.017MG BASE/1.7ML (4%; EQ 0.01MG BASE/ML)	A201750 001	Jul 11, 2017

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE; INJECTION

BEROCCA PN

ROCHE	50MG/ML;0.03MG/ML;0.0025MG/ML;7.5MG/ML; 100 IU/ML;0.2MG/ML;20MG/ML;2MG/ML;1.8MG/ML;	N006071 003	Oct 10, 1985
-------	---	-------------	--------------

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.C. 9+3

ABRAXIS PHARM	10MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;2 0 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/	N018440 002	Aug 08, 1985
M.V.I.-12 ADULT			
HOSPIRA	10MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;2 0 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/	N008809 004	Aug 08, 1985
+			
	20MG/ML;0.006MG/ML;0.05MCG/ML;1.5MG/ML; 0.0005MG/ML;0.06MG/ML;4MG/ML;0.6MG/ML;0 .36MG/ML;0.6MG/ML;0.1MG/ML;1MG/ML	N008809 006	Sep 09, 2004
MVC PLUS			
WATSON LABS	10MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;2 0 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/	N018439 002	Aug 08, 1985

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12 ADULT

HOSPIRA	20MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;2 0 IU/ML;0.6MG/ML;4MG/ML;0.4MG/ML;0.36MG/M	N008809 005	Apr 22, 2004
---------	---	-------------	--------------

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12 LYOPHILIZED

TELIGENT	100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15M G/VIAL;5MCG/VIAL;0.4MG/VIAL;40MG/VIAL;4 MG/VIAL;3.6MG/VIAL;3MG/VIAL;1MG/VIAL;10 MG/VIAL	N018933 002	Aug 08, 1985
----------	--	-------------	--------------

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE; INJECTION

VITAPED

HOSPIRA	N/A, 80MG/VIAL;N/A, 0.02MG/VIAL;N/A, 0.001 MG/VIAL; 400 IU/10ML, N/A; N/A, 0.14MG/VIAL; N/A, 17MG/VI AL; N/A, 5MG/VIAL; 0.2MG/10ML, N/A; N/A, 1MG/ VIAL; N/A, 1.4MG/VIAL; N/A, 1.2MG/VIAL; EQ 2, 300 UNITS BASE/10ML, N/A; 7 IU/10ML, N/A	N020176 001	Dec 29, 1993
---------	--	-------------	--------------

ASPIRIN

TABLET; ORAL

BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN

BAYER	500MG	N021317 001	Oct 18, 2001
-------	-------	-------------	--------------

TABLET, EXTENDED RELEASE; ORAL

8-HOUR BAYER

BAYER	650MG	N016030 001	
-------	-------	-------------	--

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ASPIRIN

TABLET, EXTENDED RELEASE;ORAL

MEASURIN

BAYER

650MG

N016030 002

ASPIRIN; BUTALBITAL

TABLET;ORAL

AXOTAL

SAVAGE LABS

650MG;50MG

A088305 001 Oct 13, 1983

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

NOSTRUM LABS INC

325MG;50MG;40MG

A078149 001 Jun 13, 2007

WATSON LABS

325MG;50MG;40MG

A086231 002 Feb 12, 1985

TABLET;ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

ACTAVIS ELIZABETH

325MG;50MG;40MG

A086710 002 Aug 23, 1983

FOSUN PHARMA

325MG;50MG;40MG

A086398 002 Apr 06, 1984

HALSEY

325MG;50MG;40MG

A089448 001 Dec 01, 1986

HIKMA INTL PHARMS

325MG;50MG;40MG

A086162 002 Feb 16, 1984

IVAX PHARMS

325MG;50MG;40MG

A085441 002 Oct 31, 1984

PURACAP PHARM

325MG;50MG;40MG

A087048 002 Dec 09, 1983

QUANTUM PHARMICS

325MG;50MG;40MG

A088972 001 Jun 18, 1985

WATSON LABS

325MG;50MG;40MG

A086237 002 Mar 23, 1984

FIORINAL

+ ALLERGAN

325MG;50MG;40MG **

N017534 003 Apr 16, 1986

LANORINAL

LANNETT

325MG;50MG;40MG

A086986 002 Oct 18, 1985

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

VINTAGE PHARMS LLC

325MG;50MG;40MG;30MG

A075351 001 Mar 05, 1999

WATSON LABS

325MG;50MG;40MG;30MG

A074359 001 Aug 31, 1995

ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE;ORAL

SYNALGOS-DC

+ SUN PHARM INDUSTRIES

356.4MG;30MG;16MG

N011483 004 Sep 06, 1983

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET;ORAL

INVAGESIC

SANDOZ

385MG;30MG;25MG

A074817 001 Nov 27, 1996

INVAGESIC FORTE

SANDOZ

770MG;60MG;50MG

A074817 002 Nov 27, 1996

NORGESIC

+ MEDICIS

385MG;30MG;25MG **

N013416 003 Oct 27, 1982

NORGESIC FORTE

+ MEDICIS

770MG;60MG;50MG **

N013416 004 Oct 27, 1982

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

SANDOZ

385MG;30MG;25MG

A074654 001 Dec 31, 1996

770MG;60MG;50MG

A074654 002 Dec 31, 1996

STEVENS J

385MG;30MG;25MG

A074988 001 Apr 30, 1999

770MG;60MG;50MG

A074988 002 Apr 30, 1999

ORPHENGESIC

GALT PHARMS

385MG;30MG;25MG

A075141 001 May 29, 1998

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE;ORAL

COMPOUND 65

ALRA

389MG;32.4MG;65MG

A084553 002 Aug 17, 1983

DARVON COMPOUND

XANODYNE PHARM

389MG;32.4MG;32MG

N010996 006 Mar 08, 1983

DARVON COMPOUND-65

XANODYNE PHARM

389MG;32.4MG;65MG

N010996 007 Mar 08, 1983

PROPOXYPHENE COMPOUND 65

IVAX SUB TEVA PHARMS

389MG;32.4MG;65MG

A083077 002 Dec 07, 1984

SANDOZ

389MG;32.4MG;65MG

A080044 002 Sep 16, 1983

TEVA

389MG;32.4MG;65MG

A089025 001 Mar 29, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

PROPOXYPHENE COMPOUND-65

SANDOZ 389MG; 32.4MG; 65MG A083101 002 Jun 24, 1985

PROPOXYPHENE HYDROCHLORIDE W/ ASPIRIN AND CAFFEINE

WATSON LABS 389MG; 32.4MG; 65MG A085732 002 Sep 03, 1984

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL AND ASPIRIN

HERITAGE PHARMS INC 325MG; 200MG A089594 001 Mar 31, 1989

NOVAST LABS 325MG; 200MG A040832 001 Jan 07, 2010

OXFORD PHARMS 325MG; 200MG A040252 001 Dec 10, 1997

SANDOZ 325MG; 200MG A040116 001 Apr 25, 1996

CARISOPRODOL COMPOUND

WATSON LABS 325MG; 200MG A088809 001 Oct 03, 1985

SOMA COMPOUND

MEDA PHARMS 325MG; 200MG ** N012365 005 Jul 11, 1983

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

OXFORD PHARMS 325MG; 200MG; 16MG A040283 001 Dec 29, 1998

SOMA COMPOUND W/ CODEINE

MEDA PHARMS 325MG; 200MG; 16MG ** N012366 002 Jul 11, 1983

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE; ORAL

ASPIRIN AND DIPYRIDAMOLE

ANI PHARMS INC 25MG; 200MG A206964 001 Jan 18, 2017

ASPIRIN; HYDROCODONE BITARTRATE

TABLET; ORAL

AZDONE

SCHWARZ PHARMA 500MG; 5MG ** A089420 001 Jan 25, 1988

VICOPRIN

ABBOTT 500MG; 5MG A086333 001 Sep 14, 1983

ASPIRIN; MEPROBAMATE

TABLET; ORAL

EQUAGESIC

SUN PHARM INDUSTRIES 325MG; 200MG N011702 003 Dec 29, 1983

MEPRO-ASPIRIN

SANDOZ 325MG; 200MG A089127 001 Mar 02, 1987

MEPROBAMATE AND ASPIRIN

PAR PHARM 325MG; 200MG A089126 001 Aug 19, 1986

MICRAININ

MEDPOINTE PHARM HLC 325MG; 200MG A084978 001

Q-GESIC

QUANTUM PHARMICS 325MG; 200MG A088740 001 Jun 01, 1984

ASPIRIN; METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL AND ASPIRIN

IVAX SUB TEVA PHARMS 325MG; 400MG A087211 001 Dec 22, 1982

MCNEIL 325MG; 400MG A089193 001 Feb 12, 1986

PAR PHARM 325MG; 400MG A089657 001 Nov 04, 1988

STEVENS J 325MG; 400MG A081145 001 Jan 31, 1995

ROBAXISAL

ROBINS AH 325MG; 400MG N012281 001

ASPIRIN; OMEPRAZOLE

TABLET, DELAYED RELEASE; ORAL

YOSPRALA

+ GENUS LIFESCIENCES 81MG; 40MG N205103 001 Sep 14, 2016

+ 325MG; 40MG N205103 002 Sep 14, 2016

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ASPIRIN

ACTAVIS LABS FL INC 325MG;4.8355MG

A090084 001 Mar 22, 2011

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

CODOXY

HALSEY 325MG;4.5MG;0.38MG

A087464 001 Jul 01, 1982

OXYCODONE AND ASPIRIN

ANI PHARMS INC 325MG;4.5MG;0.38MG

A040255 001 Feb 27, 1998

SUN PHARM INDUSTRIES 325MG;4.5MG;0.38MG

A040260 001 Jul 17, 1998

325MG;4.5MG;0.38MG

A087794 001 May 26, 1982

OXYCODONE AND ASPIRIN (HALF-STRENGTH)

ROXANE 325MG;2.25MG;0.19MG

A087742 001 Jun 04, 1982

PERCODAN

ENDO PHARMS 325MG;4.5MG;0.38MG **

N007337 006

PERCODAN-DEMI

ENDO PHARMS 325MG;2.25MG;0.19MG **

N007337 005

ROXIPRIN

ROXANE 325MG;4.5MG;0.38MG

A087743 001 Jun 04, 1982

ASPIRIN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

TALWIN COMPOUND

+ SANOFI AVENTIS US 325MG;EQ 12.5MG BASE **

N016891 001

ASPIRIN; PRAVASTATIN SODIUM

TABLET; ORAL

PRAVIGARD PAC (COPACKAGED)

BRISTOL MYERS SQUIBB 81MG;20MG

N021387 001 Jun 24, 2003

81MG;40MG

N021387 002 Jun 24, 2003

81MG;80MG

N021387 003 Jun 24, 2003

325MG;20MG

N021387 004 Jun 24, 2003

325MG;40MG

N021387 005 Jun 24, 2003

325MG;80MG

N021387 006 Jun 24, 2003

ASPIRIN; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVON W/ ASA

XANODYNE PHARM 325MG;65MG

N010996 005

ASPIRIN; PROPOXYPHENE NAPSYLATE

CAPSULE; ORAL

DARVON-N W/ ASA

AAIPHARMA LLC 325MG;100MG

N016829 001

TABLET; ORAL

DARVON-N W/ ASA

AAIPHARMA LLC 325MG;100MG

N016863 001

ATAZANAVIR SULFATE

CAPSULE; ORAL

ATAZANAVIR SULFATE

AMNEAL EQ 100MG BASE

A209717 001 Jun 01, 2020

MYLAN EQ 150MG BASE

A208177 001 Sep 24, 2018

EQ 200MG BASE

A208177 002 Sep 24, 2018

EQ 300MG BASE

A208177 003 Sep 24, 2018

ZYDUS PHARMS EQ 150MG BASE

A210575 001 Jun 04, 2020

EQ 200MG BASE

A210575 002 Jun 04, 2020

EQ 300MG BASE

A210575 003 Jun 04, 2020

REYATAZ

+ BRISTOL MYERS SQUIBB EQ 100MG BASE **

N021567 001 Jun 20, 2003

ATENOLOL

INJECTABLE; INJECTION

TENORMIN

+ ASTRAZENECA 0.5MG/ML **

N019058 001 Sep 13, 1989

TABLET; ORAL

ATENOLOL

ABLE 25MG

A076907 001 Jul 30, 2004

50MG

A076907 002 Jul 30, 2004

100MG

A076907 003 Jul 30, 2004

APOTHECON 50MG

A073317 001 Mar 20, 1992

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ATENOLOL

TABLET; ORAL

ATENOLOL

	100MG	A073318	001	Mar 20, 1992
DAVA PHARMS INC	25MG	A074099	001	Apr 28, 1992
	50MG	A073542	001	Dec 19, 1991
	100MG	A073543	001	Dec 19, 1991
INVATECH	25MG	A074265	001	Feb 28, 1994
	50MG	A074265	002	Feb 28, 1994
	100MG	A074265	003	Feb 28, 1994
MYLAN	25MG	A074126	003	Aug 26, 1998
	50MG	A074126	001	Mar 23, 1994
	100MG	A074126	002	Mar 23, 1994
NORTHSTAR HLTHCARE	25MG	A078254	001	Sep 25, 2009
	50MG	A078254	002	Sep 25, 2009
	100MG	A078254	003	Sep 25, 2009
NOSTRUM LABS	50MG	A074127	001	Feb 21, 1995
	100MG	A074127	002	Feb 21, 1995
PLIVA	25MG	A074101	001	Jul 17, 1997
	50MG	A074101	002	Jul 17, 1997
	100MG	A074101	003	Jul 17, 1997
SCS	50MG	A073676	001	Oct 30, 1992
	100MG	A073676	002	Oct 30, 1992
SUN PHARM INDS INC	25MG	A078210	001	Jul 10, 2007
	50MG	A078210	002	Jul 10, 2007
	100MG	A078210	003	Jul 10, 2007
SUN PHARM INDUSTRIES	25MG	A074499	001	Jul 30, 1997
	50MG	A073475	001	Mar 30, 1993
	100MG	A073476	001	Mar 30, 1993
TEVA	50MG	A073315	001	May 28, 1993
	100MG	A073316	001	May 28, 1993
TEVA PHARMS	50MG	A074120	001	Feb 24, 1995
	100MG	A074120	002	Feb 24, 1995
WATSON LABS	50MG	A073352	001	Dec 27, 1991
WATSON LABS TEVA	100MG	A073353	001	Dec 27, 1991

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

ATENOLOL AND CHLORTHALIDONE

MYLAN	50MG; 25MG	A074203	001	Oct 31, 1993
	100MG; 25MG	A074203	002	Oct 31, 1993
NOSTRUM LABS	50MG; 25MG	A074404	001	May 14, 1998
	100MG; 25MG	A074404	002	May 14, 1998
PLIVA	50MG; 25MG	A074107	001	Sep 24, 1997
	100MG; 25MG	A074107	002	Sep 24, 1997
SUN PHARM INDUSTRIES	50MG; 25MG	A073582	002	Apr 29, 1993
	100MG; 25MG	A073582	001	Apr 29, 1993

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

STRATTERA

LILLY	5MG	N021411	001	Nov 26, 2002
-------	-----	---------	-----	--------------

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

PERRIGO R AND D	EQ 10MG BASE	A208478	001	Jun 23, 2020
	EQ 20MG BASE	A208478	002	Jun 23, 2020
TEVA PHARMS	EQ 10MG BASE	A078773	001	May 29, 2012
	EQ 20MG BASE	A078773	002	May 29, 2012
	EQ 40MG BASE	A078773	003	May 29, 2012
	EQ 80MG BASE	A078773	004	May 29, 2012

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET; ORAL

EZETIMIBE AND ATORVASTATIN CALCIUM

SCOV3	EQ 10MG BASE; 10MG	A206084	001	Apr 26, 2017
	EQ 20MG BASE; 10MG	A206084	002	Apr 26, 2017
	EQ 40MG BASE; 10MG	A206084	003	Apr 26, 2017
	EQ 80MG BASE; 10MG	A206084	004	Apr 26, 2017

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET; ORAL

LIPTRUZET

+	MERCK SHARP DOHME	EQ 10MG BASE;10MG **	N200153 001	May 03, 2013
+		EQ 20MG BASE;10MG **	N200153 002	May 03, 2013
+		EQ 40MG BASE;10MG **	N200153 003	May 03, 2013
+		EQ 80MG BASE;10MG **	N200153 004	May 03, 2013

ATOVAQUONE

TABLET; ORAL

MEPRON

+	GLAXOSMITHKLINE LLC	250MG **	N020259 001	Nov 25, 1992
---	---------------------	----------	-------------	--------------

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

	BAXTER HLTHCARE	10MG/ML	A074824 001	Sep 30, 1997
	BAXTER HLTHCARE CORP	10MG/ML	A074753 001	Jan 23, 1997
	HOSPIRA	10MG/ML	A074632 001	Dec 23, 1996
		10MG/ML	A074740 001	Mar 28, 1997
	MYLAN LABS LTD	10MG/ML	A206096 001	Jun 22, 2017
	TEVA PARENTERAL	10MG/ML	A074784 001	Jun 11, 1997
	WATSON PHARMS TEVA	10MG/ML	A074945 001	Jul 28, 1998

ATRACURIUM BESYLATE PRESERVATIVE FREE

	BAXTER HLTHCARE	10MG/ML	A074825 001	Sep 30, 1997
	BAXTER HLTHCARE CORP	10MG/ML	A074768 001	Jan 23, 1997
	HOSPIRA	10MG/ML	A074633 001	Dec 23, 1996
		10MG/ML	A074639 001	Mar 25, 1997
		10MG/ML	A074741 001	Mar 28, 1997
	MYLAN LABS LTD	10MG/ML	A206001 001	Apr 07, 2017
	WATSON LABS INC	10MG/ML	A074944 001	Jul 28, 1998

TRACRIUM

+	HOSPIRA	10MG/ML **	N018831 002	Jun 20, 1985
---	---------	------------	-------------	--------------

TRACRIUM PRESERVATIVE FREE

+	HOSPIRA	10MG/ML **	N018831 001	Nov 23, 1983
---	---------	------------	-------------	--------------

ATROPINE

SOLUTION; INTRAMUSCULAR

ATROPINE

	ABBVIE	EQ 2MG SULFATE/0.7ML	A071295 001	Jan 30, 1987
--	--------	----------------------	-------------	--------------

ATROPINE (AUTOINJECTOR)

	RAFA LABS LTD	EQ 2MG SULFATE/0.7ML (EQ 2MG SULFATE/0.7ML)	N212319 001	Jul 09, 2018
--	---------------	---	-------------	--------------

ATROPINE SULFATE

AEROSOL, METERED; INHALATION

ATROPINE SULFATE

	US ARMY	EQ 0.36MG BASE/INH	N020056 001	Sep 19, 1990
--	---------	--------------------	-------------	--------------

SOLUTION; INTRAVENOUS

ATROPINE SULFATE

+	HOSPIRA	0.5MG/5ML (0.1MG/ML) **	N021146 001	Jul 09, 2001
---	---------	-------------------------	-------------	--------------

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL

MOTOFEN HALF-STRENGTH

	SEBELA IRELAND LTD	0.025MG;0.5MG	N017744 001	
--	--------------------	---------------	-------------	--

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENOXYLATE HYDROCHLORIDE W/ ATROPINE SULFATE

	SCHERER RP	0.025MG;2.5MG	A086440 001	
--	------------	---------------	-------------	--

SOLUTION; ORAL

COLONAIID

	MEDPOINTE PHARM HLC	0.025MG/5ML;2.5MG/5ML	A085735 001	
--	---------------------	-----------------------	-------------	--

LOMANATE

	ALPHARMA US PHARMS	0.025MG/5ML;2.5MG/5ML	A085746 001	
--	--------------------	-----------------------	-------------	--

LOMOTIL

	GD SEARLE LLC	0.025MG/5ML;2.5MG/5ML	N012699 001	
--	---------------	-----------------------	-------------	--

TABLET; ORAL

COLONAIID

	MEDPOINTE PHARM HLC	0.025MG;2.5MG	A085737 001	
--	---------------------	---------------	-------------	--

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

DI-ATRO

MD PHARM	0.025MG;2.5MG	A085266	001	
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE				
ABLE	0.025MG;2.5MG	A040395	001	Nov 27, 2000
ASCOT	0.025MG;2.5MG	A087934	001	Jul 19, 1983
FOSUN PHARMA	0.025MG;2.5MG	A086173	001	
HEATHER	0.025MG;2.5MG	A086798	001	
HIKMA	0.025MG;2.5MG	A087765	001	Mar 15, 1982
INWOOD LABS	0.025MG;2.5MG	A085509	001	
KV PHARM	0.025MG;2.5MG	A085659	001	
LEDERLE	0.025MG;2.5MG	A086950	001	
PAR PHARM	0.025MG;2.5MG	A040357	001	May 02, 2000
PARKE DAVIS	0.025MG;2.5MG	A087131	001	
PVT FORM	0.025MG;2.5MG	A085766	001	
R AND S PHARMA	0.025MG;2.5MG	A085035	001	
ROXANE	0.025MG;2.5MG	A086057	001	
SUN PHARM INDUSTRIES	0.025MG;2.5MG	A085506	001	
USL PHARMA	0.025MG;2.5MG	A087842	001	Mar 29, 1982
VALEANT PHARM INTL	0.025MG;2.5MG	A087195	001	Feb 16, 1982
WATSON LABS	0.025MG;2.5MG	A085876	001	
LO-TROL				
VANGARD	0.025MG;2.5MG	A088009	001	Mar 25, 1983
LOGEN				
SUPERPHARM	0.025MG;2.5MG	A088962	001	May 10, 1985
LONOX				
FOSUN PHARMA	0.025MG;2.5MG	A085311	002	
LOW-QUEL				
HALSEY	0.025MG;2.5MG	A085211	001	

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

ENLON-PLUS

MYLAN INSTITUTIONAL	0.14MG/ML;10MG/ML	N019677	001	Nov 06, 1991
+	0.14MG/ML;10MG/ML	N019678	001	Nov 06, 1991

ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

ATROPINE AND DEMEROL

ABBVIE	0.4MG/ML;50MG/ML	A087853	001	Nov 26, 1982
	0.4MG/ML;75MG/ML	A087847	001	Nov 26, 1982
	0.4MG/ML;100MG/ML	A087848	001	Nov 26, 1982
MEPERIDINE AND ATROPINE SULFATE				
WYETH AYERST	0.4MG/ML;50MG/ML	A085121	001	
	0.4MG/ML;75MG/ML	A085121	002	
	0.4MG/ML;100MG/ML	A085121	003	

ATROPINE; PRALIDOXIME CHLORIDE

INJECTABLE; INTRAMUSCULAR

ATNAA

US ARMY	2.1MG/0.7ML;600MG/2ML	N021175	001	Jan 17, 2002
---------	-----------------------	---------	-----	--------------

AVOBENZONE; OCTINOXATE; OXYBENZONE

LOTION; TOPICAL

SHADE UVAGUARD

+	BAYER HEALTHCARE LLC	3%;7.5%;3%	N020045	001	Dec 07, 1992
---	----------------------	------------	---------	-----	--------------

AZACITIDINE

POWDER; INTRAVENOUS, SUBCUTANEOUS

AZACITIDINE

LUPIN LTD	100MG/VIAL	A210748	001	Feb 27, 2019
-----------	------------	---------	-----	--------------

AZATADINE MALEATE

TABLET; ORAL

OPTIMINE

SCHERING	1MG	N017601	001	
----------	-----	---------	-----	--

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AZATADINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

TRINALIN

SCHERING

1MG;120MG

N018506 001 Mar 23, 1982

AZATHIOPRINE

TABLET;ORAL

IMURAN

+ SEBELA IRELAND LTD

25MG **

N016324 002

AZATHIOPRINE SODIUM

INJECTABLE;INJECTION

IMURAN

+ CASPER PHARMA LLC

EQ 100MG BASE/VIAL **

N017391 001

AZELAIC ACID

AEROSOL, FOAM;TOPICAL

AZELAIC ACID

TEVA PHARMS USA

15%

A210928 001 Oct 07, 2020

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OPTIVAR

+ MYLAN SPECIALITY LP

0.05% **

N021127 001 May 22, 2000

SPRAY, METEDED;NASAL

ASTEPRO

MYLAN SPECIALITY LP

EQ 0.125MG BASE/SPRAY

N022203 001 Oct 15, 2008

AZITHROMYCIN

CAPSULE;ORAL

ZITHROMAX

+ PFIZER

EQ 250MG BASE **

N050670 001 Nov 01, 1991

FOR SUSPENSION;ORAL

AZITHROMYCIN

LUPIN LTD

EQ 100MG BASE/5ML

A065488 001 May 15, 2015

EQ 200MG BASE/5ML

A065488 002 May 15, 2015

SANDOZ

EQ 100MG BASE/5ML

A065297 001 Sep 18, 2006

EQ 200MG BASE/5ML

A065297 002 Sep 18, 2006

TARO

EQ 200MG BASE/5ML

A211521 001 Dec 11, 2019

TEVA PHARMS

EQ 100MG BASE/5ML

A065419 001 Jun 24, 2008

EQ 200MG BASE/5ML

A065419 002 Jun 24, 2008

FOR SUSPENSION, EXTENDED RELEASE;ORAL

ZMAX

+ PF PRISM CV

EQ 2GM BASE/BOT

N050797 001 Jun 10, 2005

INJECTABLE;INJECTION

AZITHROMYCIN

HIKMA

EQ 500MG BASE/VIAL

A065265 001 Jan 18, 2007

MYLAN LABS LTD

EQ 500MG BASE/VIAL

A204732 001 Jan 26, 2017

TEVA PARENTERAL

EQ 500MG BASE/VIAL

N050809 001 Dec 19, 2006

EQ 2.5GM BASE/VIAL

N050809 002 Dec 19, 2006

TABLET;ORAL

AZITHROMYCIN

ALEMBIC PHARMS LTD

EQ 600MG BASE

A211793 001 Jan 27, 2020

APOTEX CORP

EQ 250MG BASE

A065507 001 Jul 13, 2011

EQ 500MG BASE

A065509 001 Jul 13, 2011

EQ 600MG BASE

A065508 001 Jul 13, 2011

MYLAN

EQ 250MG BASE

A065365 001 May 30, 2007

EQ 500MG BASE

A065366 001 May 30, 2007

EQ 600MG BASE

A065360 001 Jan 08, 2007

TEVA

EQ 250MG BASE

A065153 001 Nov 14, 2005

EQ 600MG BASE

A065150 001 Nov 14, 2005

YUNG SHIN PHARM

EQ 600MG BASE

A211068 001 May 08, 2020

ZITHROMAX

+ PFIZER

EQ 600MG BASE **

N050730 001 Jun 12, 1996

AZITHROMYCIN DIHYDRATE; TROVAFLOXACIN MESYLATE

FOR SUSPENSION, TABLET;ORAL

TROVAN/ZITHROMAX COMPLIANCE PAK

PFIZER

EQ 1GM BASE,N/A;N/A,EQ 100MG BASE

N050762 001 Dec 18, 1998

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AZLOCILLIN SODIUM

INJECTABLE; INJECTION

AZLIN

BAYER PHARMS	EQ 2GM BASE/VIAL	A062388 001	Sep 08, 1982
	EQ 2GM BASE/VIAL	A062417 001	Oct 12, 1982
	EQ 2GM BASE/VIAL	N050562 001	Sep 03, 1982
	EQ 3GM BASE/VIAL	A062388 002	Sep 08, 1982
	EQ 3GM BASE/VIAL	A062417 002	Oct 12, 1982
	EQ 3GM BASE/VIAL	N050562 002	Sep 03, 1982
	EQ 4GM BASE/VIAL	A062388 003	Sep 08, 1982
	EQ 4GM BASE/VIAL	A062417 003	Oct 12, 1982
	EQ 4GM BASE/VIAL	N050562 003	Sep 03, 1982

AZTREONAM

INJECTABLE; INJECTION

AZACTAM

BRISTOL MYERS SQUIBB	500MG/VIAL	N050580 001	Dec 31, 1986
AZACTAM IN PLASTIC CONTAINER			
BRISTOL MYERS SQUIBB	10MG/ML	N050632 003	May 24, 1989
+	20MG/ML	N050632 002	May 24, 1989
+	40MG/ML	N050632 001	May 24, 1989
AZTREONAM			
WEST-WARD PHARMS INT	1GM/VIAL	A065286 001	Mar 23, 2011
	2GM/VIAL	A065286 002	Mar 23, 2011

BACAMPICILLIN HYDROCHLORIDE

FOR SUSPENSION; ORAL

SPECTROBID

PFIZER	125MG/5ML	N050556 001	Mar 23, 1982
--------	-----------	-------------	--------------

TABLET; ORAL

SPECTROBID

PFIZER	400MG	N050520 001	
	800MG	N050520 002	Sep 12, 1983

BACITRACIN

INJECTABLE; INJECTION

BACIIM

X GEN PHARMS	50,000 UNITS/VIAL	A064153 001	May 09, 1997
--------------	-------------------	-------------	--------------

BACITRACIN

AKORN	50,000 UNITS/VIAL	A206719 001	Oct 20, 2017
FRESENIUS KABI USA	50,000 UNITS/VIAL	A065116 001	Dec 03, 2002
MYLAN ASI	50,000 UNITS/VIAL	A090211 001	May 11, 2010
PFIZER	50,000 UNITS/VIAL	A060282 001	
PHARMACIA AND UPJOHN	10,000 UNITS/VIAL	A060733 001	
	50,000 UNITS/VIAL	A060733 002	

OINTMENT; OPHTHALMIC

BACIGUENT

PHARMACIA AND UPJOHN	500 UNITS/GM	A060734 001	
----------------------	--------------	-------------	--

BACITRACIN

LILLY	500 UNITS/GM	A060687 001	
PHARMADERM	500 UNITS/GM	A062158 001	
PHARMAFAIR	500 UNITS/GM	A062453 001	Mar 28, 1984

OINTMENT; TOPICAL

BACITRACIN

COMBE	500 UNITS/GM	A062799 001	May 14, 1987
NASKA	500 UNITS/GM	A062857 001	Nov 13, 1987

POWDER; FOR RX COMPOUNDING

BACI-RX

X GEN PHARMS	5,000,000 UNITS/BOT	A061580 001	
--------------	---------------------	-------------	--

BACITRACIN

APOTHEKERNES	5,000,000 UNITS/BOT	A061699 001	
PADDOCK LLC	5,000,000 UNITS/BOT	A062456 001	Jul 27, 1983

BACITRACIN ZINC

POWDER; FOR RX COMPOUNDING

ZIBA-RX

X GEN PHARMS	500,000 UNITS/BOT	A061737 001	
--------------	-------------------	-------------	--

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

CORTISPORIN

+	CASPER PHARMA LLC	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM **	N050416 002	
---	-------------------	---	-------------	--

ZINC BACITRACIN,NEOMYCIN SULFATE,POLYMYXIN B SULFATE & HYDROCORTISONE

PHARMAFAIR	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062389 001	Jul 02, 1982
------------	--	-------------	--------------

OINTMENT;TOPICAL

NEOMYCIN & POLYMYXIN B SULFATES & BACITRACIN ZINC & HYDROCORTISONE

PHARMAFAIR	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM	A062381 001	Sep 06, 1985
------------	---	-------------	--------------

BACITRACIN ZINC; LIDOCAINE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;TOPICAL

LANABIOTIC

COMBE	400 UNITS/GM;40MG/GM;EQ 5MG BASE/GM;5,000 UNITS/GM	A062499 001	Jun 03, 1985
-------	--	-------------	--------------

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE

PHARMAFAIR	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062386 001	Sep 09, 1982
------------	---	-------------	--------------

BACITRACIN-NEOMYCIN-POLYMYXIN

PHARMADERM	400 UNITS/GM;EQ 3.5MG BASE/GM;5,000 UNITS/GM	A062167 001	
------------	--	-------------	--

NEO-POLYCIN

DOW PHARM	500 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060647 001	
-----------	---	-------------	--

OINTMENT;TOPICAL

BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE

NASKA	400 UNITS/GM;EQ 3.5MG BASE/GM;5,000 UNITS/GM	A062833 001	Nov 09, 1987
-------	--	-------------	--------------

BACITRACIN ZINC; POLYMYXIN B SULFATE

AEROSOL;TOPICAL

POLYSPORIN

GLAXOSMITHKLINE	10,000 UNITS/GM;2,000,000 UNITS/GM	N050167 002	Mar 01, 1985
-----------------	------------------------------------	-------------	--------------

OINTMENT;OPHTHALMIC

OCUMYCIN

PHARMAFAIR	500 UNITS/GM;10,000 UNITS/GM	A062430 001	Apr 08, 1983
------------	------------------------------	-------------	--------------

POLYSPORIN

MONARCH PHARMS	500 UNITS/GM;10,000 UNITS/GM **	A061229 001	
----------------	---------------------------------	-------------	--

OINTMENT;TOPICAL

BACITRACIN ZINC-POLYMYXIN B SULFATE

NASKA	500 UNITS/GM;10,000 UNITS/GM	A062849 001	Nov 13, 1987
-------	------------------------------	-------------	--------------

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

ALTANA	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060731 002	
--------	--	-------------	--

BACITRACIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

MYCITRACIN

PHARMACIA AND UPJOHN	500 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A061048 001	
----------------------	---	-------------	--

BACITRACIN; POLYMYXIN B SULFATE

DISC;TOPICAL

LANABIOTIC

COMBE	500 UNITS/GM;5,000 UNITS/GM	N050598 001	Sep 22, 1986
-------	-----------------------------	-------------	--------------

BACLOFEN

INJECTABLE;INTRATHECAL

BACLOFEN

MAIA PHARMS INC	0.5MG/ML	A210048 001	Sep 11, 2019
	2MG/ML	A210048 002	Sep 11, 2019

TABLET;ORAL

BACLOFEN

MYLAN	10MG	A077181 001	Jul 29, 2005
	20MG	A077121 002	Jul 29, 2005
MYLAN PHARMS INC	10MG	A090334 001	Feb 18, 2010

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BACLOFEN

TABLET; ORAL

BACLOFEN

	20MG	A090334 002	Feb 18, 2010
SUN PHARM INDS INC	10MG	A077862 001	Aug 14, 2006
	20MG	A077862 002	Aug 14, 2006
TEVA	10MG	A073043 001	Feb 27, 1992
	20MG	A073044 001	Feb 27, 1992
USL PHARMA	10MG	A071260 001	May 06, 1988
	20MG	A071261 001	May 06, 1988
WATSON LABS	10MG	A072824 001	Sep 18, 1991
	10MG	A073092 001	Jan 28, 1994
	10MG	A074698 001	Aug 20, 1996
	20MG	A072825 001	Sep 18, 1991
	20MG	A073093 001	Jan 28, 1994
	20MG	A074698 002	Aug 20, 1996

Lioresal

+ NOVARTIS

10MG **

N017851 001

+

20MG **

N017851 003 Jan 20, 1982

TABLET, ORALLY DISINTEGRATING; ORAL

KEMSTRO

UCB INC

10MG

N021589 001 Oct 30, 2003

20MG

N021589 002 Oct 30, 2003

BALSALAZIDE DISODIUM

CAPSULE; ORAL

BALSALAZIDE DISODIUM

MYLAN

750MG

A077807 001 Dec 28, 2007

TABLET; ORAL

BALSALAZIDE DISODIUM

PAR PHARM INC

1.1GM

A206336 001 Sep 08, 2015

GIAZO

+ VALEANT PHARMS INTL

1.1GM

N022205 001 Feb 03, 2012

BARIUM SULFATE

FOR SUSPENSION; ORAL

E-Z-CAT DRY

+ BRACCO

40% (9GM/POUCH)

N208036 003 Jan 03, 2017

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION

BECLOVENT

GLAXOSMITHKLINE

0.042MG/INH

N018153 001

QVAR 40

+ TEVA BRANDED PHARM

0.04MG/INH **

N020911 002 Sep 15, 2000

QVAR 80

+ TEVA BRANDED PHARM

0.08MG/INH **

N020911 001 Sep 15, 2000

VANCERIL

SCHERING

0.042MG/INH

N017573 001

VANCERIL DOUBLE STRENGTH

SCHERING

0.084MG/INH

N020486 001 Dec 24, 1996

AEROSOL, METERED; NASAL

BECONASE

GLAXOSMITHKLINE

0.042MG/INH

N018584 001

VANCENASE

SCHERING

0.042MG/INH

N018521 001

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED; NASAL

VANCENASE AQ

SCHERING

EQ 0.042MG DIPROP/SPRAY

N019589 001 Dec 23, 1987

EQ 0.084MG DIPROP/SPRAY

N020469 001 Jun 26, 1996

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

ANI PHARMS INC

5MG

A076333 001 Feb 11, 2004

10MG

A076333 002 Feb 11, 2004

20MG

A076333 003 Feb 11, 2004

40MG

A076333 004 Feb 11, 2004

GENPHARM

5MG

A076476 001 Feb 11, 2004

10MG

A076476 002 Feb 11, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

	20MG	A076476 003	Feb 11, 2004
	40MG	A076476 004	Feb 11, 2004
HERITAGE PHARMA	5MG	A076267 001	Feb 11, 2004
	10MG	A076267 002	Feb 11, 2004
	20MG	A076267 003	Feb 11, 2004
	40MG	A076267 004	Feb 11, 2004
MYLAN	5MG	A076430 001	Feb 11, 2004
	10MG	A076430 002	Feb 11, 2004
	20MG	A076430 003	Feb 11, 2004
	40MG	A076430 004	Feb 11, 2004

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

ANI PHARMS INC	5MG; 6.25MG	A076342 001	Feb 11, 2004
	5MG; 6.25MG	A076348 001	Feb 11, 2004
	10MG; 12.5MG	A076342 002	Feb 11, 2004
	10MG; 12.5MG	A076348 002	Feb 11, 2004
	20MG; 12.5MG	A076342 003	Feb 11, 2004
	20MG; 12.5MG	A076348 003	Feb 11, 2004
	20MG; 25MG	A076342 004	Feb 11, 2004
	20MG; 25MG	A076348 004	Feb 11, 2004
APOTEX	5MG; 6.25MG	A078794 001	Aug 21, 2014
	10MG; 12.5MG	A078794 002	Aug 21, 2014
	20MG; 12.5MG	A078794 003	Aug 21, 2014
	20MG; 25MG	A078794 004	Aug 21, 2014
MYLAN PHARMS INC	5MG; 6.25MG	A076612 001	Feb 11, 2004
	10MG; 12.5MG	A076612 002	Feb 11, 2004
	20MG; 12.5MG	A076612 003	Feb 11, 2004
	20MG; 25MG	A076612 004	Feb 11, 2004
SUN PHARM INDS LTD	5MG; 6.25MG	A077483 001	Sep 08, 2005
	10MG; 12.5MG	A077483 002	Sep 08, 2005
	20MG; 12.5MG	A077483 003	Sep 08, 2005
	20MG; 25MG	A077483 004	Sep 08, 2005
LOTENSIN HCT			
+ US PHARMS HOLDINGS I	5MG; 6.25MG **	N020033 001	May 19, 1992

BENDAMUSTINE HYDROCHLORIDE

SOLUTION; IV (INFUSION)

TREANDA

+ CEPHALON	45MG/0.5ML (90MG/ML)	N022249 003	Sep 13, 2013
+	180MG/2ML (90MG/ML)	N022249 004	Sep 13, 2013

BENDROFLUMETHIAZIDE

TABLET; ORAL

NATURETIN-10

APOTHECON	10MG	N012164 003	
NATURETIN-2.5			
APOTHECON	2.5MG	N012164 001	
NATURETIN-5			
APOTHECON	5MG	N012164 002	

BENDROFLUMETHIAZIDE; NADOLOL

TABLET; ORAL

NADOLOL AND BENDROFLUMETHIAZIDE

MYLAN	5MG; 40MG	A078688 001	Feb 15, 2008
	5MG; 80MG	A078688 002	Feb 15, 2008

BENOXINATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BENOXINATE HYDROCHLORIDE

SOLA BARNES HIND	0.4%	A084149 001	
------------------	------	-------------	--

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BENTIROMIDESOLUTION; ORAL
CHYMEX

SAVAGE LABS 500MG/7.5ML N018366 001 Dec 29, 1983

BENZONATATE

CAPSULE; ORAL

BENZONATATE

NESHER PHARMS 100MG A040795 001 Oct 31, 2007

200MG A040795 002 Oct 31, 2007

SUN PHARM INDS INC 100MG A040587 001 Mar 19, 2008

200MG A040587 002 Mar 19, 2008

TESSALON

+ PFIZER 200MG ** N011210 003 Jun 25, 1999

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

BENZAACLIN

BAUSCH 5%;EQ 1% BASE N050756 002 Apr 20, 2007

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

ANDA REPOSITORY 2.5%;EQ 1.2% BASE A207194 001 Aug 19, 2019

TARO 3.75%;EQ 1.2% BASE A208683 001 Jun 05, 2018

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

AKTIPAK

+ BIOFRONTERA 5%;3% N050769 001 Nov 27, 2000

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

EMCURE PHARMS LTD 50MG A202061 001 Jan 27, 2012

EPIC PHARMA LLC 50MG A040714 001 Oct 29, 2007

IMPAX LABS 50MG A040845 001 Nov 18, 2008

SPECGX LLC 50MG A040773 001 Apr 25, 2007

TEDOR PHARM 25MG A040747 002 Nov 20, 2015

50MG A040747 001 Mar 30, 2007

50MG A040578 001 Apr 17, 2006

DIDREX

+ PFIZER 25MG ** N012427 003

+ 50MG ** N012427 002

BENZQUINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

EMETE-CON

PFIZER EQ 50MG BASE/VIAL N016820 001

SUPPOSITORY; RECTAL

EMETE-CON

ROERIG EQ 100MG BASE N016818 006

BENZTHIAZIDE

TABLET; ORAL

AQUATAG

SOLVAY 25MG N016001 001

50MG N016001 002

BENZTHIAZIDE

PVT FORM 50MG A083206 001

EXNA

AH ROBINS INC 50MG N012489 001

FOVANE

PFIZER 50MG N012128 002

URESE

PFIZER 25MG N012128 003

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

BENZTROPINE MESYLATE

LUITPOLD 1MG/ML A091152 001 Mar 29, 2010

TABLET; ORAL

BENZTROPINE MESYLATE

CHARTWELL RX 1MG A081265 002 Jan 23, 1992

2MG A081265 001 Jan 23, 1992

LANNETT CO INC 0.5MG ** A088877 001 Apr 11, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BENZTROPINE MESYLATE

TABLET;ORAL

BENZTROPINE MESYLATE

	1MG **	A088894 001	Apr 11, 1985
	2MG **	A088895 001	Apr 11, 1985
OXFORD PHARMS	0.5MG	A040706 002	Feb 14, 2008
	1MG	A040706 003	Feb 14, 2008
	2MG	A040706 001	Feb 14, 2008
QUANTUM PHARMICS	0.5MG	A088514 001	Jan 31, 1984
	1MG	A088510 001	Jan 31, 1984
	2MG	A088511 001	Jan 31, 1984
UPSHER SMITH LABS	0.5MG	A040103 001	Dec 12, 1996
	1MG	A040103 002	Dec 12, 1996
	2MG	A040103 003	Dec 12, 1996
USL PHARMA	0.5MG	A089211 001	Jun 14, 1988
	1MG	A089212 001	Jun 14, 1988
	2MG	A089213 001	Jun 14, 1988
COGENTIN			
+ MERCK	0.5MG **	N009193 004	
+	1MG **	N009193 003	
+	2MG **	N009193 002	

BENZYL ALCOHOL

LOTION;TOPICAL

ULESFIA

+ SHIONOGI INC	5%	N022129 001	Apr 09, 2009
----------------	----	-------------	--------------

BENZYL BENZOATE

EMULSION;TOPICAL

BENZYL BENZOATE

LANNETT	50%	A084535 001	
---------	-----	-------------	--

BEPOTASTINE BESILATE

SOLUTION/DROPS;OPHTHALMIC

BEPOTASTINE BESILATE

APOTEX	1.5%	A206066 001	Mar 05, 2019
MYLAN	1.5%	A206220 001	Mar 18, 2019

BEPRIDIL HYDROCHLORIDE

TABLET;ORAL

BEPADIN

MEDPOINTE PHARM HLC	200MG	N019001 001	Dec 28, 1990
	300MG	N019001 002	Dec 28, 1990
	400MG	N019001 003	Dec 28, 1990

VASCOR

JOHNSON AND JOHNSON	200MG	N019002 001	Dec 28, 1990
	300MG	N019002 002	Dec 28, 1990
	400MG	N019002 003	Dec 28, 1990

BETA CAROTENE

CAPSULE;ORAL

SOLATENE

ROCHE	30MG	N017589 001	
-------	------	-------------	--

BETAMETHASONE

CREAM;TOPICAL

CELESTONE

SCHERING	0.2%	N014762 001	
----------	------	-------------	--

SYRUP;ORAL

CELESTONE

MERCK SHARP DOHME	0.6MG/5ML	N014215 002	
-------------------	-----------	-------------	--

TABLET;ORAL

CELESTONE

SCHERING	0.6MG	N012657 003	
----------	-------	-------------	--

BETAMETHASONE BENZOATE

CREAM;TOPICAL

UTICORT

PARKE DAVIS	0.025%	N016998 002	
-------------	--------	-------------	--

GEL;TOPICAL

UTICORT

PARKE DAVIS	0.025%	N017244 001	
-------------	--------	-------------	--

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BETAMETHASONE BENZOATE

LOTION; TOPICAL

UTICORT

PARKE DAVIS 0.025% N017528 001

OINTMENT; TOPICAL

UTICORT

PARKE DAVIS 0.025% N018089 001

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL

ALPHATREX

SAVAGE LABS EQ 0.05% BASE N019138 001 Jun 26, 1984

BETAMETHASONE DIPROPIONATE

PERRIGO NEW YORK EQ 0.05% BASE A072536 001 Jan 31, 1990

EQ 0.05% BASE A074579 001 Nov 26, 1997

PHARMADERM EQ 0.05% BASE N019136 001 Jun 26, 1984

TARO EQ 0.05% BASE A071143 001 Jun 17, 1987

TEVA EQ 0.05% BASE A071476 001 Aug 10, 1987

DIPROSONE

SCHERING EQ 0.05% BASE N017536 001

CREAM, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

ANDA REPOSITORY EQ 0.05% BASE A076603 001 Jan 23, 2004

DIPROLENE

SCHERING EQ 0.05% BASE N019408 001 Jan 31, 1986

DIPROLENE AF

+ MERCK SHARP DOHME EQ 0.05% BASE N019555 001 Apr 27, 1987

DISC; TOPICAL

DIPROSONE

SCHERING EQ 0.1% BASE N017829 001

GEL, AUGMENTED; TOPICAL

DIPROLENE

SCHERING EQ 0.05% BASE N019408 002 Nov 22, 1991

LOTION; TOPICAL

ALPHATREX

SAVAGE LABS EQ 0.05% BASE A070273 001 Aug 12, 1985

BETAMETHASONE DIPROPIONATE

ACTAVIS MID ATLANTIC EQ 0.05% BASE A070281 001 Jul 31, 1985

ALPHARMA US PHARMS EQ 0.05% BASE A071085 001 Feb 03, 1987

COSETTE EQ 0.05% BASE A071882 001 Jun 06, 1988

INVATECH EQ 0.05% BASE A070274 001 Aug 12, 1985

TARO EQ 0.05% BASE A072276 001 Aug 24, 1988

EQ 0.05% BASE A074272 001 Sep 30, 1994

DIPROSONE

+ SCHERING EQ 0.05% BASE ** N017781 001

LOTION, AUGMENTED; TOPICAL

DIPROLENE

+ MERCK SHARP DOHME EQ 0.05% BASE ** N019716 001 Aug 01, 1988

OINTMENT; TOPICAL

ALPHATREX

SAVAGE LABS EQ 0.05% BASE N019143 001 Sep 04, 1984

BETAMETHASONE DIPROPIONATE

PERRIGO NEW YORK EQ 0.05% BASE A072526 001 Jan 31, 1990

PHARMADERM EQ 0.05% BASE N019140 001 Sep 04, 1984

TEVA EQ 0.05% BASE A071477 001 Aug 10, 1987

DIPROSONE

SCHERING EQ 0.05% BASE N017691 001

SPRAY; TOPICAL

BETAMETHASONE DIPROPIONATE

TARO PHARMS EQ 0.05% BASE/SPRAY A211722 001 Jun 17, 2020

BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

BETAMETHASONE SODIUM PHOSPHATE

WATSON LABS EQ 3MG BASE/ML A085738 001

CELESTONE

+ SCHERING EQ 3MG BASE/ML ** N017561 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BETAMETHASONE VALERATE

CREAM; TOPICAL

BETADERM

ROACO EQ 0.1% BASE N018839 001 Jun 30, 1983

BETAMETHASONE VALERATE

PERRIGO NEW YORK EQ 0.1% BASE A070053 001 Jun 10, 1986

PHARMADERM EQ 0.1% BASE N018860 002 Aug 31, 1983

PHARMAFAIR EQ 0.1% BASE A070485 001 May 29, 1987

TARO EQ 0.1% BASE A070062 001 May 14, 1985

BETATREX

SAVAGE LABS EQ 0.1% BASE N018862 001 Aug 31, 1983

VALISONE

SCHERING EQ 0.01% BASE N016322 002

EQ 0.1% BASE N016322 001

LOTION; TOPICAL

BETA-VAL

COSETTE EQ 0.1% BASE A070072 001 Jun 27, 1985

BETAMETHASONE VALERATE

PHARMADERM EQ 0.1% BASE N018870 001 Aug 31, 1983

PHARMAFAIR EQ 0.1% BASE A070484 001 May 29, 1987

TEVA PHARMS EQ 0.1% BASE A071883 001 Apr 22, 1988

BETATREX

SAVAGE LABS EQ 0.1% BASE N018867 001 Aug 31, 1983

VALISONE

SCHERING EQ 0.1% BASE N016932 001

OINTMENT; TOPICAL

BETAMETHASONE VALERATE

PERRIGO NEW YORK EQ 0.1% BASE A071478 001 Dec 23, 1987

PHARMADERM EQ 0.1% BASE N018864 001 Aug 31, 1983

PHARMAFAIR EQ 0.1% BASE A070486 001 May 29, 1987

BETATREX

SAVAGE LABS EQ 0.1% BASE N018863 001 Aug 31, 1983

VALISONE

SCHERING EQ 0.1% BASE N016740 001

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

APOTEX INC EQ 0.5% BASE A075446 001 Sep 28, 2000

TABLET; ORAL

KERLONE

SANOFI AVENTIS US 10MG ** N019507 001 Oct 27, 1989

20MG ** N019507 002 Oct 27, 1989

BETAXOLOL HYDROCHLORIDE; CHLORTHALIDONE

TABLET; ORAL

KERLEDEX

SANOFI AVENTIS US 5MG;12.5MG N019807 001 Oct 30, 1992

10MG;12.5MG N019807 002 Oct 30, 1992

BETAXOLOL HYDROCHLORIDE; PILOCARPINE HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

BETOPTIC PILO

ALCON EQ 0.25% BASE;1.75% N020619 001 Apr 17, 1997

BETAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION

HISTALOG

LILLY 50MG/ML N009344 001

BETHANECHOL CHLORIDE

INJECTABLE; INJECTION

URECHOLINE

+ ODYSSEY PHARMS 5MG/ML ** N006536 001

TABLET; ORAL

BETHANECHOL CHLORIDE

ABLE 5MG A040492 001 Jul 27, 2004

10MG A040483 001 Jul 27, 2004

25MG A040485 001 Jul 27, 2004

50MG A040509 001 Jul 27, 2004

ACTAVIS ELIZABETH 5MG A040552 001 Oct 28, 2004

10MG A040553 001 Oct 28, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

	25MG	A040554 001	Oct 28, 2004
	50MG	A040551 001	Oct 28, 2004
ASCOT	10MG	A088288 001	Jun 08, 1983
	25MG	A088289 001	Jun 08, 1983
HERITAGE PHARMA	5MG	A091256 001	May 04, 2010
	10MG	A091256 002	May 04, 2010
	25MG	A091256 003	May 04, 2010
	50MG	A091256 004	May 04, 2010
IMPAX LABS	5MG	A040721 001	Nov 01, 2006
	10MG	A040721 002	Nov 01, 2006
	25MG	A040721 003	Nov 01, 2006
	50MG	A040721 004	Nov 01, 2006
IVAX SUB TEVA PHARMS	25MG	A084689 001	
LANNETT	5MG	A084702 001	
	10MG	A084712 001	
	25MG	A084074 001	
SANDOZ	5MG	A084353 001	
	10MG	A084378 001	
	10MG	A084379 001	
	25MG	A084383 001	
	25MG	A084384 001	
SUN PHARM INDS INC	5MG	A040897 001	Apr 22, 2009
	10MG	A040897 002	Apr 22, 2009
	25MG	A040897 003	Apr 22, 2009
	50MG	A040897 004	Apr 22, 2009
WATSON LABS	5MG	A084402 001	
	5MG	A085230 002	
	5MG	A085841 001	
	10MG	A084408 001	
	10MG	A085228 001	
	10MG	A085842 001	
	25MG	A084441 001	
	25MG	A085229 001	
	25MG	A085839 001	
	50MG	A087397 001	
	50MG	A087444 001	
WOCKHARDT	10MG	A040533 001	Sep 29, 2003
	25MG	A040534 001	Sep 29, 2003
MYOTONACHOL			
GLENWOOD	5MG	A084188 001	
	10MG	A084188 003	
	25MG	A084188 004	
URECHOLINE			
ODYSSEY PHARMS	5MG	A089095 001	Dec 19, 1985
+	5MG **	N006536 003	
	10MG	A088440 001	May 29, 1984
+	10MG **	N006536 002	
	25MG	A088441 001	May 29, 1984
+	25MG **	N006536 004	
	50MG	A089096 001	Dec 19, 1985
+	50MG **	N006536 005	

BETHANIDINE SULFATE

TABLET; ORAL

TENATHAN

ROBINS AH

10MG	N017675 001	
25MG	N017675 002	

BETRIXABAN

CAPSULE; ORAL

BEVYXXA

+ PORTOLA PHARMS INC

40MG	N208383 001	Jun 23, 2017
80MG	N208383 002	Jun 23, 2017

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BICALUTAMIDE

TABLET; ORAL

BICALUTAMIDE

FRESENIUS KABI USA	50MG	A079045 001	May 13, 2010
KUDCO IRELAND	50MG	A077995 001	Jul 06, 2009
MYLAN	50MG	A079185 001	Jul 06, 2009
ROXANE	50MG	A078285 001	Mar 24, 2011
SYNTHON PHARMS	50MG	A077973 001	Jul 06, 2009
TEVA	50MG	A076932 001	Jul 06, 2009

BIMATOPROST

SOLUTION/DROPS; OPHTHALMIC

BIMATOPROST

HI-TECH PHARMA CO	0.03%	A203299 001	Nov 08, 2018
LUMIGAN			
+ ALLERGAN	0.03% **	N021275 001	Mar 16, 2001

BIPERIDEN HYDROCHLORIDE

TABLET; ORAL

AKINETON

ABBVIE	2MG	N012003 001	
--------	-----	-------------	--

BIPERIDEN LACTATE

INJECTABLE; INJECTION

AKINETON

ABBVIE	5MG/ML	N012418 002	
--------	--------	-------------	--

BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION, TABLET, DELAYED RELEASE; ORAL

HALFLYTELY

+ BRAINTREE	5MG, N/A; N/A, 210GM; N/A, 0.74GM; N/A, 2.86GM	N021551 003	Jul 16, 2010
	; N/A, 5.6GM **		

PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND NOVEL LABS INC	5MG, N/A; N/A, 210GM; N/A, 0.74GM; N/A, 2.86GM	BISACODYL A202217 001	Aug 20, 2014
	; N/A, 5.6GM		

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE; ORAL

HELIDAC

+ CASPER PHARMA LLC	262.4MG, N/A, N/A; N/A, 250MG, N/A; N/A, N/A, 500MG **	N050719 001	Aug 15, 1996
---------------------	--	-------------	--------------

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

MYLAN	5MG	A075831 001	Dec 14, 2005
	10MG	A075831 002	Dec 14, 2005
TEVA PHARMS	5MG	A075644 001	Jun 26, 2001
	10MG	A075644 002	Jun 26, 2001

ZEBETA

+ TEVA WOMENS	5MG **	N019982 002	Jul 31, 1992
+	10MG **	N019982 001	Jul 31, 1992

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

ACTAVIS ELIZABETH	2.5MG; 6.25MG	A075672 001	Sep 25, 2000
	5MG; 6.25MG	A075672 002	Sep 25, 2000
	10MG; 6.25MG	A075672 003	Sep 25, 2000
APOTHECON	2.5MG; 6.25MG	A075642 002	Dec 27, 2000
	5MG; 6.25MG	A075642 001	Dec 27, 2000
	10MG; 6.25MG	A075642 003	Dec 27, 2000
IVAX SUB TEVA PHARMS	2.5MG; 6.25MG	A075632 001	Sep 27, 2000
	5MG; 6.25MG	A075632 002	Sep 27, 2000
	10MG; 6.25MG	A075632 003	Sep 27, 2000
SANDOZ	2.5MG; 6.25MG	A075527 001	Sep 25, 2000
	5MG; 6.25MG	A075527 003	Sep 25, 2000
	10MG; 6.25MG	A075527 002	Sep 25, 2000
TEVA	2.5MG; 6.25MG	A075686 001	Jan 19, 2001
	5MG; 6.25MG	A075686 002	Jan 19, 2001
	10MG; 6.25MG	A075686 003	Jan 19, 2001
WATSON LABS TEVA	2.5MG; 6.25MG	A075469 001	Sep 25, 2000
	5MG; 6.25MG	A075469 002	Sep 25, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

10MG; 6.25MG

A075469 003 Sep 25, 2000

BITOLTEROL MESYLATE

AEROSOL, METERED; INHALATION

TORNALATE

SANOFI AVENTIS US 0.37MG/INH

N018770 001 Dec 28, 1984

SOLUTION; INHALATION

TORNALATE

SANOFI AVENTIS US 0.2%

N019548 001 Feb 19, 1992

BIVALIRUDIN

INJECTABLE; INTRAVENOUS

BIVALIRUDIN

APOTEX 250MG/VIAL

A204876 001 Jul 06, 2017

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

BLENOXANE

+ BRISTOL MYERS SQUIBB EQ 15 UNITS BASE/VIAL **

N050443 001

+ EQ 30 UNITS BASE/VIAL **

N050443 002 Sep 07, 1995

BLEOMYCIN SULFATE

PHARMACHEMIE BV EQ 15 UNITS BASE/VIAL

A065201 001 Dec 13, 2007

TEVA PARENTERAL EQ 15 UNITS BASE/VIAL

A064084 001 Jun 01, 1996

EQ 30 UNITS BASE/VIAL

A064084 002 Jun 01, 1996

BOCEPREVIR

CAPSULE; ORAL

VICTRELIS

MERCK SHARP DOHME 200MG

N202258 001 May 13, 2011

BORTEZOMIB

POWDER; INTRAVENOUS, SUBCUTANEOUS

BORTEZOMIB

+ HOSPIRA INC 1MG/VIAL

N209191 002 Dec 28, 2018

+ 2.5MG/VIAL

N209191 001 Jul 12, 2018

BOSENTAN

TABLET; ORAL

BOSENTAN

ALEMBIC PHARMS LTD 62.5MG

A211461 001 Jan 23, 2020

125MG

A211461 002 Jan 23, 2020

ALVOGEN PINE BROOK 62.5MG

A206002 001 Apr 26, 2019

125MG

A206002 002 Apr 26, 2019

CIPLA 62.5MG

A210342 001 Jan 03, 2020

125MG

A210342 002 Jan 03, 2020

MYLAN 62.5MG

A205173 001 Jan 15, 2020

125MG

A205173 002 Jan 15, 2020

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE

ABRAXIS PHARM 50MG/ML

A070134 001 Apr 29, 1986

100MG/ML

A071298 001 Feb 13, 1987

ASTRAZENECA 50MG/ML

A071151 001 Aug 10, 1987

50MG/ML

A071152 001 Aug 10, 1987

50MG/ML

A071153 001 Aug 10, 1987

EUROHLTH INTL SARL 50MG/ML

A070546 001 May 14, 1986

+ HOSPIRA 50MG/ML **

N019030 001 Apr 29, 1986

50MG/ML

N019033 001 Apr 29, 1986

INTL MEDICATION 50MG/ML

A070119 001 Apr 29, 1986

LUITPOLD 50MG/ML

A070891 001 Jul 26, 1988

WEST-WARD PHARMS INT 50MG/ML

A070545 001 May 14, 1986

BRETYLIUM TOSYLATE IN DEXTROSE 5%

ABBOTT 200MG/100ML

N019005 002 Apr 29, 1986

400MG/100ML

N019005 003 Apr 29, 1986

800MG/100ML

N019005 001 Apr 29, 1986

BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 100MG/100ML

N019121 001 Apr 29, 1986

200MG/100ML

N019121 002 Apr 29, 1986

400MG/100ML

N019121 003 Apr 29, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	200MG/100ML	N019837 002	Apr 12, 1989
	400MG/100ML	N019837 001	Apr 12, 1989
HOSPIRA INC	200MG/100ML	N019008 002	Apr 29, 1986
	400MG/100ML	N019008 003	Apr 29, 1986
	800MG/100ML	N019008 001	Apr 29, 1986

BRETYLOL

HOSPIRA	50MG/ML	N017954 001	
---------	---------	-------------	--

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

ALPHAGAN

+ ALLERGAN	0.2% **	N020613 001	Sep 06, 1996
	0.5%	N020490 001	Mar 13, 1997

BRIMONIDINE TARTRATE

TEVA PARENTERAL	0.2%	A076372 001	Sep 10, 2004
-----------------	------	-------------	--------------

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

BROMDAY

+ BAUSCH AND LOMB INC	EQ 0.09% ACID **	N021664 002	Oct 16, 2010
-----------------------	------------------	-------------	--------------

BROMFENAC SODIUM

AMRING PHARMS	EQ 0.09% ACID	A202030 001	Jan 09, 2013
APOTEX	EQ 0.09% ACID	A202435 001	Jun 19, 2014
	EQ 0.09% ACID	A202620 001	Jun 23, 2014
COASTAL PHARMS	EQ 0.09% ACID	A201211 001	May 11, 2011
MYLAN	EQ 0.09% ACID	A203368 001	Jun 03, 2019
VISTAPHARM	EQ 0.09% ACID	A201941 001	Feb 10, 2015

XIBROM

+ BAUSCH AND LOMB INC	EQ 0.09% ACID **	N021664 001	Mar 24, 2005
-----------------------	------------------	-------------	--------------

BROMOCRIPTINE MESYLATE

CAPSULE; ORAL

BROMOCRIPTINE MESYLATE

LEK PHARM	EQ 5MG BASE	A075100 001	Dec 10, 1998
-----------	-------------	-------------	--------------

TABLET; ORAL

BROMOCRIPTINE MESYLATE

MYLAN	EQ 2.5MG BASE	A076962 001	Sep 24, 2004
-------	---------------	-------------	--------------

BROMODIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

AMBODRYL

PARKE DAVIS	25MG	N007984 001	
-------------	------	-------------	--

BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE

SYRUP; ORAL

AMBENYL

FOREST LABS	12.5MG/5ML; 10MG/5ML	N009319 006	Jan 10, 1984
-------------	----------------------	-------------	--------------

BROMANYL

ALPHARMA US PHARMS	12.5MG/5ML; 10MG/5ML	A088343 001	Aug 15, 1984
--------------------	----------------------	-------------	--------------

BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE

WOCKHARDT	12.5MG/5ML; 10MG/5ML	A088626 001	Oct 12, 1984
-----------	----------------------	-------------	--------------

BROMPHENIRAMINE MALEATE

ELIXIR; ORAL

BROMPHENIRAMINE MALEATE

ALPHARMA US PHARMS	2MG/5ML	A086936 001	
KV PHARM	2MG/5ML	A085466 001	
PHARM ASSOC	2MG/5ML	A087517 001	
USL PHARMA	2MG/5ML	A087964 001	Jan 25, 1983

INJECTABLE; INJECTION

BROMPHENIRAMINE MALEATE

WATSON LABS	10MG/ML	A083821 001	
	100MG/ML	A083820 001	

DIMETANE-TEN

WYETH AYERST	10MG/ML	N011418 002	
--------------	---------	-------------	--

TABLET; ORAL

BROMPHENIRAMINE MALEATE

BARR	4MG	A084468 001	
IVAX SUB TEVA PHARMS	4MG	A084351 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BROMPHENIRAMINE MALEATE

TABLET; ORAL

BROMPHENIRAMINE MALEATE

NEWTRON PHARMS	4MG	A086987	001	
NEXGEN PHARMA INC	4MG	A086187	001	
PAR PHARM	4MG	A087009	001	
PIONEER PHARMS	4MG	A088604	001	Jul 13, 1984
UPSHER SMITH LABS	4MG	A083215	001	
VITARINE	4MG	A085850	001	
WATSON LABS	4MG	A083123	001	
	4MG	A085769	001	

DIMETANE

WYETH CONS	4MG	N010799	003	
------------	-----	---------	-----	--

TABLET, EXTENDED RELEASE; ORAL

DIMETANE

WYETH CONS	8MG	N010799	010	Jun 10, 1983
	12MG	N010799	011	Jun 10, 1983

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

BROMANATE DM

ALPHARMA US PHARMS	2MG/5ML; 10MG/5ML; 30MG/5ML	A088722	001	Mar 07, 1985
--------------------	-----------------------------	---------	-----	--------------

BROMFED-DM

WOCKHARDT	2MG/5ML; 10MG/5ML; 30MG/5ML	A089681	001	Dec 22, 1988
-----------	-----------------------------	---------	-----	--------------

BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

PHARM ASSOC	2MG/5ML; 10MG/5ML; 30MG/5ML	A202940	001	Jul 21, 2014
-------------	-----------------------------	---------	-----	--------------

DIMETANE-DX

+ ROBINS AH	2MG/5ML; 10MG/5ML; 30MG/5ML **	N019279	001	Aug 24, 1984
-------------	--------------------------------	---------	-----	--------------

BROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE

ALZA	16MG; 240MG	N019672	001	Mar 29, 1996
------	-------------	---------	-----	--------------

BUCLIZINE HYDROCHLORIDE

TABLET; ORAL

BUCLADIN-S

STUART PHARMS	50MG	N010911	006	
---------------	------	---------	-----	--

BUDESONIDE

AEROSOL, METERED; NASAL

RHINOCORT

ASTRAZENECA	0.032MG/INH	N020233	001	Feb 14, 1994
-------------	-------------	---------	-----	--------------

CAPSULE; ORAL

BUDESONIDE

ALVOGEN	3MG	A206724	001	Nov 23, 2016
---------	-----	---------	-----	--------------

POWDER, METERED; INHALATION

PULMICORT

ASTRAZENECA	0.16MG/INH	N020441	002	Jun 24, 1997
	0.32MG/INH	N020441	003	Jun 24, 1997

BUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE

ATHENEX INC	0.25MG/ML	A074441	001	Jan 27, 1995
HOSPIRA	0.25MG/ML	A074160	001	Oct 30, 1997
TEVA PARENTERAL	0.25MG/ML	A074613	001	Nov 18, 1997

BUMEX

+ VALIDUS PHARMS	0.25MG/ML **	N018226	001	Feb 28, 1983
------------------	--------------	---------	-----	--------------

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE

HOSPIRA	0.75%	A070587	001	Mar 03, 1987
MYLAN ASI	0.25%	A091503	001	Oct 18, 2011
	0.5%	A091503	002	Oct 18, 2011
NOVOCOL HEALTHCARE	0.5%	A211096	001	Feb 19, 2019

BUPIVACAINE HYDROCHLORIDE KIT

HOSPIRA	0.075%	N019978	001	Sep 03, 1992
	0.114%	N019978	002	Sep 03, 1992
	0.23%	N019978	003	Sep 03, 1992

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE

INTL MEDICATED	0.25%	A076012 001	Jan 09, 2002
	0.5%	A076012 002	Jan 09, 2002
	0.75%	A076012 003	Jan 09, 2002
MYLAN ASI	0.25%	A091487 002	Oct 18, 2011
	0.5%	A091487 001	Oct 18, 2011
	0.75%	A091487 003	Oct 18, 2011

INJECTABLE; SPINAL

SENSORCAINE

FRESENIUS KABI USA	0.75%	A071202 001	Apr 15, 1987
--------------------	-------	-------------	--------------

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

HOSPIRA	0.25%; 0.005MG/ML	A071166 001	Jun 16, 1988
	0.5%; 0.005MG/ML	A071169 001	Jun 16, 1988
	0.75%; 0.005MG/ML	A071171 001	Jun 16, 1988

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

+ HOSPIRA	0.5%; 0.0091MG/ML	N022046 001	Jul 13, 1983
-----------	-------------------	-------------	--------------

BUPIVACAINE HYDROCHLORIDE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DUOCAINE

AMPHASTAR PHARMS INC	EQ 0.375% (37.5MG/10ML); EQ 1% (100MG/10ML)	N021496 001	May 23, 2003
----------------------	---	-------------	--------------

BUPRENORPHINE HYDROCHLORIDE

IMPLANT; IMPLANTATION

PROBUPHINE

+ TITAN PHARMS	EQ 80MG BASE/IMPLANT	N204442 001	May 26, 2016
----------------	----------------------	-------------	--------------

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

BARR	EQ 2MG BASE	A090360 001	May 07, 2010
	EQ 8MG BASE	A090360 002	May 07, 2010
MYLAN	EQ 2MG BASE	A201066 001	Mar 06, 2015
	EQ 8MG BASE	A201066 002	Mar 06, 2015

SUBUTEX

+ INDIVIOR INC	EQ 2MG BASE **	N020732 002	Oct 08, 2002
+	EQ 8MG BASE **	N020732 003	Oct 08, 2002

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM; BUCCAL

BUNAVAIL

+ BDSI	EQ 2.1MG BASE; EQ 0.3MG BASE	N205637 001	Jun 06, 2014
+	EQ 4.2MG BASE; EQ 0.7MG BASE	N205637 002	Jun 06, 2014
+	EQ 6.3MG BASE; EQ 1MG BASE	N205637 003	Jun 06, 2014

FILM; SUBLINGUAL

CASSIPA

+ TEVA PHARMS USA	EQ 16MG BASE; EQ 4MG BASE	N208042 001	Sep 07, 2018
-------------------	---------------------------	-------------	--------------

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

RHODES PHARMS	EQ 2MG BASE; EQ 0.5MG BASE	A205601 001	Mar 30, 2020
	EQ 8MG BASE; EQ 2MG BASE	A205601 002	Mar 30, 2020
TEVA PHARMS USA	EQ 2MG BASE; EQ 0.5MG BASE	A091149 001	Sep 08, 2014
	EQ 8MG BASE; EQ 2MG BASE	A091149 002	Sep 08, 2014

SUBOXONE

+ INDIVIOR INC	EQ 2MG BASE; EQ 0.5MG BASE **	N020733 001	Oct 08, 2002
+	EQ 8MG BASE; EQ 2MG BASE	N020733 002	Oct 08, 2002

BUPROPION HYDROCHLORIDE

TABLET; ORAL

BUPROPION HYDROCHLORIDE

HERITAGE PHARMA	75MG	A075310 001	Nov 29, 1999
	100MG	A075310 002	Nov 29, 1999
INVATECH	75MG	A075613 002	Oct 10, 2000
	100MG	A075613 001	Oct 10, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BUPROPION HYDROCHLORIDE

TABLET; ORAL

WELLBUTRIN

+	GLAXOSMITHKLINE	50MG **	N018644 001	Dec 30, 1985
+		75MG **	N018644 002	Dec 30, 1985
+		100MG **	N018644 003	Dec 30, 1985

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

	ACTAVIS LABS FL INC	300MG	A077715 002	Jun 13, 2007
	IMPAX LABS	300MG	A077415 002	Dec 15, 2006
	JUBILANT GENERICS	100MG	A202774 001	Oct 11, 2013
		150MG	A202774 002	Oct 11, 2013
		150MG	A202775 001	Oct 11, 2013
		150MG	A207459 001	Jun 30, 2017
		200MG	A202774 003	Oct 11, 2013
		300MG	A207459 002	Jun 30, 2017
	MYLAN	100MG	A090325 001	Apr 08, 2010
		150MG	A090325 002	Apr 08, 2010
		150MG	A090941 001	May 03, 2010
		150MG	A090942 001	Jul 14, 2010
		200MG	A090325 003	Apr 08, 2010
		300MG	A090942 002	Jul 14, 2010
	SANDOZ	100MG	A076845 001	Jul 14, 2005
		150MG	A076834 001	Jul 14, 2005
		150MG	A076845 002	Jul 14, 2005
	SUN PHARM	150MG	A200695 001	Dec 18, 2014
	WATSON LABS INC	100MG	A077455 001	Jul 19, 2010
		150MG	A077455 002	Mar 12, 2008
		200MG	A077455 003	Jul 19, 2010
	WOCKHARDT LTD	100MG	A201331 001	Aug 30, 2012
		150MG	A201331 002	Aug 30, 2012
		200MG	A201331 003	Aug 30, 2012

WELLBUTRIN SR

	GLAXOSMITHKLINE	50MG	N020358 001	Oct 04, 1996
--	-----------------	------	-------------	--------------

ZYBAN

	GLAXOSMITHKLINE	100MG	N020711 002	May 14, 1997
+		150MG	N020711 003	May 14, 1997

BUSPIRONE HYDROCHLORIDE

CAPSULE; ORAL

BUSPAR

	BRISTOL MYERS SQUIBB	5MG	N021190 001	Dec 20, 2000
		7.5MG	N021190 002	Dec 20, 2000
		10MG	N021190 003	Dec 20, 2000
		15MG	N021190 004	Dec 20, 2000

TABLET; ORAL

BUSPAR

+	BRISTOL MYERS SQUIBB	5MG **	N018731 001	Sep 29, 1986
+		10MG **	N018731 002	Sep 29, 1986
+		15MG **	N018731 003	Apr 22, 1996
+		30MG **	N018731 004	Apr 22, 1996

BUSPIRONE HYDROCHLORIDE

EGIS

		5MG	A075119 001	Mar 14, 2002
		10MG	A075119 002	Mar 14, 2002
		15MG	A075119 003	Jan 23, 2003

FOSUN PHARMA

		5MG	A075413 001	Mar 19, 2002
		10MG	A075413 002	Mar 19, 2002
		15MG	A075413 003	Mar 19, 2002

IVAX SUB TEVA PHARMS

		5MG **	A075385 001	Mar 01, 2002
		10MG **	A075385 002	Mar 01, 2002
		15MG **	A075385 003	Mar 01, 2002

MYLAN

		5MG	A075467 001	Feb 28, 2002
		10MG	A075467 003	Feb 28, 2002
		15MG	A075467 004	Feb 28, 2002

NESHER PHARMS

		5MG	A075572 001	Feb 27, 2002
		10MG	A075572 002	Feb 27, 2002
		15MG	A075572 003	Feb 27, 2002

RUBICON

		5MG	A075521 001	Apr 05, 2002
		10MG	A075521 002	Apr 05, 2002
		15MG	A075521 003	Apr 05, 2002

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BUSULFAN

INJECTABLE; INJECTION

BUSULFAN

ACTAVIS LLC	6MG/ML	A205139 001	Dec 08, 2017
MYLAN LABS LTD	6MG/ML	A205184 001	Jul 13, 2018

BUTABARBITAL SODIUM

CAPSULE; ORAL

BUTICAPS

MEDPOINTE PHARM HLC	15MG	A085381 001	
	30MG	A085381 002	
	50MG	A085381 003	
	100MG	A085381 004	

ELIXIR; ORAL

BUTABARB

ALPHARMA US PHARMS	30MG/5ML	A085873 001	
--------------------	----------	-------------	--

BUTABARBITAL SODIUM

WOCKHARDT	30MG/5ML	A085383 001	
-----------	----------	-------------	--

BUTALAN

LANNETT	33.3MG/5ML	A085880 001	
---------	------------	-------------	--

BUTISOL SODIUM

MEDA PHARMS	30MG/5ML	A085380 001	
-------------	----------	-------------	--

SARISOL

HALSEY	30MG/5ML	A084723 001	
--------	----------	-------------	--

TABLET; ORAL

BUTABARBITAL

BUNDY	30MG	A085550 001	
-------	------	-------------	--

BUTABARBITAL SODIUM

SANDOZ	15MG	A084292 003	Feb 09, 1982
--------	------	-------------	--------------

	15MG	A085938 001	
--	------	-------------	--

	30MG	A084272 002	
--	------	-------------	--

	30MG	A085934 001	
--	------	-------------	--

SOLVAY	16.2MG	A083606 001	
--------	--------	-------------	--

	32.4MG	A083898 001	
--	--------	-------------	--

	48.6MG	A083897 001	
--	--------	-------------	--

	97.2MG	A083896 001	
--	--------	-------------	--

TEVA	15MG	A088632 001	May 18, 1985
------	------	-------------	--------------

	30MG	A088631 001	May 01, 1985
--	------	-------------	--------------

WATSON LABS	15MG	A085764 001	
-------------	------	-------------	--

	30MG	A085772 001	
--	------	-------------	--

WHITEWORTH TOWN PLSN	15MG	A083325 002	
----------------------	------	-------------	--

	30MG	A083337 001	
--	------	-------------	--

BUTISOL SODIUM

MYLAN SPECIALITY LP	15MG **	N000793 002	
---------------------	---------	-------------	--

+	30MG	N000793 004	
---	------	-------------	--

	50MG **	N000793 003	
--	---------	-------------	--

	100MG **	N000793 005	
--	----------	-------------	--

SARISOL NO. 1

HALSEY	15MG	A084719 001	
--------	------	-------------	--

SARISOL NO. 2

HALSEY	30MG	A084719 002	
--------	------	-------------	--

SODIUM BUTABARBITAL

HIKMA	15MG	A085418 001	
-------	------	-------------	--

	30MG	A085432 001	
--	------	-------------	--

IVAX SUB TEVA PHARMS	15MG	A083484 001	
----------------------	------	-------------	--

	30MG	A084040 001	
--	------	-------------	--

LANNETT	15MG	A085849 001	
---------	------	-------------	--

	30MG	A085866 001	
--	------	-------------	--

	100MG	A085881 001	
--	-------	-------------	--

MARSHALL PHARMA	16.2MG	A083524 001	
-----------------	--------	-------------	--

	32.4MG	A083858 001	
--	--------	-------------	--

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL

MENTAX-TC

MYLAN	1%	N021408 001	Oct 17, 2002
-------	----	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BUTOCONAZOLE NITRATE

CREAM;VAGINAL

BUTOCONAZOLE NITRATE

PERRIGO PHARMA INTL 2%

N019881 001 Feb 07, 1997

FEMSTAT

ROCHE PALO 2%

N019215 001 Nov 25, 1985

FEMSTAT 3

+ BAYER 2%

N020421 001 Dec 21, 1995

SUPPOSITORY;VAGINAL

FEMSTAT

ROCHE PALO 100MG

N019359 001 Nov 25, 1985

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE

BAXTER HLTHCARE CORP 2MG/ML

A075697 001 Oct 23, 2001

HIKMA FARMACEUTICA 2MG/ML

A078247 001 Apr 29, 2009

HOSPIRA 1MG/ML

A075342 001 Nov 04, 1999

1MG/ML

A075559 001 Mar 20, 2000

2MG/ML

A075342 002 Nov 04, 1999

2MG/ML

A075559 002 Mar 20, 2000

BUTORPHANOL TARTRATE PRESERVATIVE FREE

BAXTER HLTHCARE CORP 1MG/ML

A075695 001 Oct 23, 2001

2MG/ML

A075695 002 Oct 23, 2001

HOSPIRA 1MG/ML

A074620 001 Jan 22, 1997

1MG/ML

A075170 001 Sep 28, 1998

2MG/ML

A074620 002 Jan 22, 1997

2MG/ML

A075170 002 Sep 28, 1998

STADOL

+ APOTHECON 2MG/ML **

N017857 004

STADOL PRESERVATIVE FREE

+ APOTHECON 1MG/ML **

N017857 001

+ 2MG/ML **

N017857 002

SPRAY, METERED;NASAL

STADOL

BRISTOL MYERS SQUIBB 1MG/SPRAY **

N019890 001 Dec 12, 1991

CABERGOLINE

TABLET;ORAL

CABERGOLINE

ACTAVIS LABS FL INC 0.5MG

A078035 001 Apr 21, 2008

APOTEX CORP 0.5MG

A201503 001 Mar 08, 2013

IMPAX LABS INC 0.5MG

A077843 001 Jul 03, 2007

MYLAN 0.5MG

A202947 001 Dec 02, 2013

PAR PHARM 0.5MG

A076310 001 Dec 29, 2005

DOSTINEX

+ PHARMACIA AND UPJOHN 0.5MG **

N020664 001 Dec 23, 1996

CAFFEINE CITRATE

SOLUTION;INTRAVENOUS

CAFFEINE CITRATE

SUN PHARM EQ 30MG BASE/3ML (EQ 10MG BASE/ML)

A090077 001 Sep 30, 2009

SOLUTION;ORAL

CAFFEINE CITRATE

AM REGENT EQ 30MG BASE/3ML (EQ 10MG BASE/ML)

A090064 001 Nov 20, 2009

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY;RECTAL

CAFERGOT

+ NOVARTIS 100MG;2MG **

N009000 002

TABLET;ORAL

CAFERGOT

NOVARTIS 100MG;1MG

N006620 001

ERGOTAMINE TARTRATE AND CAFFEINE

HIKMA INTL PHARMS 100MG;1MG

A040510 001 Sep 17, 2004

WIGRAINE

ORGANON USA INC 100MG;1MG

A086562 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CALCIFEDIOL

CAPSULE;ORAL

CALDEROL

ORGANON USA INC

0.02MG

N018312 001

0.05MG

N018312 002

CALCIPOTRIENE

OINTMENT;TOPICAL

DOVONEX

+ LEO PHARMA AS

0.005% **

N020273 001 Dec 29, 1993

SOLUTION;TOPICAL

DOVONEX

+ LEO PHARM

0.005% **

N020611 001 Mar 03, 1997

CALCITONIN HUMAN

INJECTABLE;INJECTION

CIBACALCIN

NOVARTIS

0.5MG/VIAL

N018470 001 Oct 31, 1986

CALCITONIN SALMON

INJECTABLE;INJECTION

CALCIMAR

+ SANOFI AVENTIS US

200 IU/ML **

N017769 001

400 IU/VIAL

N017497 001

CALCITONIN-SALMON

IGI LABS INC

200 IU/ML

A073690 001 Apr 14, 1995

MIACALCIN

+ MYLAN IRELAND LTD

100 IU/ML

N017808 001 Jul 03, 1986

SPRAY, METERED;NASAL

MIACALCIN

+ MYLAN IRELAND LTD

200 IU/SPRAY **

N020313 002 Aug 17, 1995

CALCITONIN SALMON RECOMBINANT

SPRAY, METERED;NASAL

FORTICAL

UPSHER SMITH LABS

200 IU/SPRAY **

N021406 001 Aug 12, 2005

CALCITRIOL

INJECTABLE;INJECTION

CALCIJEX

+ ABBVIE

0.001MG/ML **

N018874 001 Sep 25, 1986

+

0.002MG/ML **

N018874 002 Sep 25, 1986

CALCITRIOL

AKORN

0.002MG/ML

A078066 002 Jan 29, 2008

AM REGENT

0.001MG/ML

A075746 001 Sep 26, 2003

0.002MG/ML

A075746 002 Sep 26, 2003

FRESENIUS KABI USA

0.001MG/ML

A075836 001 Dec 31, 2002

FRESENIUS MEDCL

0.002MG/ML

A075836 002 Dec 31, 2002

FRESENIUS MEDCL

0.001MG/ML

A075766 001 Feb 20, 2003

FRESENIUS MEDCL

0.002MG/ML

A075766 002 Feb 20, 2003

HOSPIRA

0.001MG/ML

A075816 001 Jan 16, 2004

HOSPIRA

0.002MG/ML

A075816 002 Jan 16, 2004

ROCKWELL MEDCL

0.001MG/ML

A076206 001 Sep 17, 2003

SAGENT PHARMS

0.001MG/ML

A077102 001 Feb 08, 2006

TEVA PARENTERAL

0.001MG/ML

A075823 001 Mar 31, 2003

TEVA PARENTERAL

0.002MG/ML

A075823 002 Mar 31, 2003

CALCIUM ACETATE

CAPSULE;ORAL

CALCIUM ACETATE

LOTUS PHARM CO LTD

667MG

A203298 001 Jul 26, 2016

PHOSLO

FRESENIUS MEDCL

333.5MG

N021160 001 Apr 02, 2001

667MG

N021160 002 Apr 02, 2001

TABLET;ORAL

CALCIUM ACETATE

HIKMA

667MG

A077693 001 Jan 30, 2008

ELIPHOS

CYPRESS PHARM

667MG

A078502 001 Nov 25, 2008

PHOSLO

+ FRESENIUS MEDCL

667MG **

N019976 001 Dec 10, 1990

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CALCIUM CARBONATE; RISEDRONATE SODIUM

TABLET, TABLET;ORAL

ACTONEL WITH CALCIUM (COPACKAGED)

+ WARNER CHILCOTT EQ 500MG BASE,N/A;N/A,35MG ** N021823 001 Aug 12, 2005

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION;IRRIGATION

METHOTREXATE SODIUM

AKORN 0.154MG/ML;0.92MG/ML;0.184MG/ML;0.2MG/M N020079 001 Feb 26, 1999
L;0.38MG/ML;2.1MG/ML;7.14MG/ML;0.42MG/M
LCALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER

+ BAXTER HLTHCARE CORP N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.0 N021703 010 Oct 10, 2008
5GM/1000ML;0.157GM/1000ML;2.21GM/1000ML
;7.07GM/1000ML (5000ML)

PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER

BAXTER HLTHCARE CORP 3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML; N021703 012 Oct 10, 2008
3.05GM/1000ML;0.157GM/1000ML;2.21GM/100
0ML;7.07GM/1000ML (5000ML)

PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER

+ BAXTER HLTHCARE CORP 3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML; N021703 013 Oct 10, 2008
3.05GM/1000ML;0.314GM/1000ML;2.21GM/100
0ML;7.07GM/1000ML (5000ML)

PRISMASOL BGK 4/0 IN PLASTIC CONTAINER

BAXTER HLTHCARE CORP N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.0 N021703 005 Oct 25, 2006
5GM/1000ML;0.314GM/1000ML;3.09GM/1000ML
;6.46GM/1000ML (5000ML)

PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER

BAXTER HLTHCARE CORP 5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML; N021703 008 Oct 25, 2006
2.03GM/1000ML;0.314GM/1000ML;3.09GM/100
0ML;6.46GM/1000ML (5000ML)

PRISMASOL BK 0/0 IN PLASTIC CONTAINER

BAXTER HLTHCARE CORP N/A/1000ML;N/A/1000ML;5.4GM/1000ML;3.05 N021703 007 Oct 25, 2006
GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46
GM/1000ML (5000ML)

PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER

+ BAXTER HLTHCARE CORP 5.15GM/1000ML;N/A/1000ML;5.4GM/1000ML;2 N021703 001 Oct 25, 2006
.03GM/1000ML;N/A/1000ML;3.09GM/1000ML;6
.46GM/1000ML (5000ML)

PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER

BAXTER HLTHCARE CORP 3.68GM/1000ML;N/A/1000ML;5.4GM/1000ML;3 N021703 009 Oct 25, 2006
.05GM/1000ML;0.314GM/1000ML;3.09GM/1000
ML;6.46GM/1000ML (5000ML)CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; OXIGLUTATIONE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION;IRRIGATION

NAVSTEL

ALCON PHARMS LTD 0.154MG/ML;0.92MG/ML;0.2MG/ML;0.184MG/M N022193 001 Jul 24, 2008
L;0.38MG/ML;2.1MG/ML;7.14MG/ML;0.42MG/M
LCALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 37MG/100ML;5GM/100ML;31MG/100ML;120MG/1 N019864 001 Jun 10, 1993
00ML;330MG/100ML;88MG/100ML

ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 37MG/100ML;5GM/100ML;31MG/100ML;120MG/1 N018271 001
00ML;330MG/100ML;88MG/100MLCALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE;INJECTION

ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 35MG/100ML;5GM/100ML;30MG/100ML;74MG/10 N019867 001 Dec 20, 1993
0ML;640MG/100ML;500MG/100ML;74MG/100ML

ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 35MG/100ML;5GM/100ML;30MG/100ML; N018269 002 Jan 17, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER
 74MG/100ML; 640MG/100ML; 500MG/100ML; 74MG
 /100ML

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER
 + BAXTER HLTHCARE 37MG/100ML; 5GM/100ML; 30MG/100ML; 119MG/100ML N017390 001
 00ML; 161MG/100ML; 94MG/100ML; 138MG/100ML
 **

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SOLUTION; INTRAPERITONEAL

DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER
 B BRAUN 510MG/100ML; 30GM/100ML; 200MG/100ML; 9.2GM/100ML; 9.6GM/100ML N018807 001 Aug 26, 1983
 510MG/100ML; 30GM/100ML; 200MG/100ML; 9.4GM/100ML; 11GM/100ML N018807 003 Aug 26, 1983
 DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER
 B BRAUN 510MG/100ML; 50GM/100ML; 200MG/100ML; 9.2GM/100ML; 9.6GM/100ML N018807 002 Aug 26, 1983
 510MG/100ML; 50GM/100ML; 200MG/100ML; 9.4GM/100ML; 11GM/100ML N018807 004 Aug 26, 1983
 DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER
 B BRAUN 29MG/100ML; 2.5GM/100ML; 15MG/100ML; 610MG/100ML; 560MG/100ML N018460 006 Jan 29, 1986
 DIALYTE W/ DEXTROSE 1.5% IN PLASTIC CONTAINER
 B BRAUN 29MG/100ML; 1.5GM/100ML; 15MG/100ML; 610MG/100ML; 560MG/100ML N018460 001
 DIALYTE W/ DEXTROSE 4.25% IN PLASTIC CONTAINER
 B BRAUN 29MG/100ML; 4.25GM/100ML; 15MG/100ML; 610MG/100ML; 560MG/100ML N018460 003

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DELFLX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER
 FRESENIUS MEDCL 25.7MG/100ML; 1.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML N018379 002
 DELFLX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER
 FRESENIUS MEDCL 25.7MG/100ML; 2.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML N018379 003
 DELFLX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER
 FRESENIUS MEDCL 25.7MG/100ML; 3.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML N018379 007 Jun 24, 1988
 DELFLX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER
 FRESENIUS MEDCL 25.7MG/100ML; 4.25GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML N018379 001
 DELFLX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER
 FRESENIUS MEDCL 25.7MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML N018379 004 Jul 07, 1982
 DELFLX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER
 FRESENIUS MEDCL 25.7MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML N018379 005 Jul 07, 1982
 DELFLX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER
 FRESENIUS MEDCL 25.7MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML N018379 008 Jun 24, 1988
 DELFLX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER
 FRESENIUS MEDCL 25.7MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML N018379 006 Jul 07, 1982
 DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER
 B BRAUN 26MG/100ML; 1.5GM/100ML; 5MG/100ML; 530MG/100ML; 450MG/100ML N018460 007 Jan 29, 1986
 26MG/100ML; 1.5GM/100ML; 15MG/100ML; 560MG/100ML; 390MG/100ML N018460 002
 DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER
 B BRAUN 26MG/100ML; 2.5GM/100ML; 5MG/100ML; 530MG/100ML; 450MG/100ML N018460 005 Nov 02, 1983
 26MG/100ML; 5GM/100ML; 5MG/100ML; 530MG/100ML; 450MG/100ML N018460 008 Jan 29, 1986
 DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER
 B BRAUN 26MG/100ML; 4.25GM/100ML; 5MG/100ML; N018460 009 Jan 29, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER	530MG/100ML; 450MG/100ML		
	26MG/100ML; 4.25GM/100ML; 15MG/100ML; 560M	N018460	004
	G/100ML; 390MG/100ML		
DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	25.7MG/100ML; 1.5GM/100ML; 15.2MG/100ML; 5	N017512	001
	67MG/100ML; 392MG/100ML		
DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	25.7MG/100ML; 2.5GM/100ML; 15.2MG/100ML; 5	N017512	003
	67MG/100ML; 392MG/100ML		
DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	25.7MG/100ML; 4.25GM/100ML; 15.2MG/100ML; 5	N017512	002
	567MG/100ML; 392MG/100ML		
DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER			
+ BAXTER HLTHCARE	18.3MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 5	N020183	003 Dec 04, 1992
	38MG/100ML; 448MG/100ML		
DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	25.7MG/100ML; 1.5GM/100ML; 15.2MG/100ML; 5	N017512	007 Jul 09, 1984
	67MG/100ML; 392MG/100ML		
DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	25.7MG/100ML; 2.5GM/100ML; 15.2MG/100ML; 5	N017512	008 Jul 09, 1984
	67MG/100ML; 392MG/100ML		
DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	25.7MG/100ML; 3.5GM/100ML; 15.2MG/100ML; 5	N017512	010 Nov 18, 1985
	67MG/100ML; 392MG/100ML		
DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	25.7MG/100ML; 4.25GM/100ML; 15.2MG/100ML; 5	N017512	009 Jul 09, 1984
	567MG/100ML; 392MG/100ML		
DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER			
+ BAXTER HLTHCARE	25.7MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 5	N017512	011 Nov 18, 1985
	38MG/100ML; 448MG/100ML		
INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER			
FRESENIUS	18.4MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 5	A020374	001 Jun 13, 1994
	38MG/100ML; 448MG/100ML		
INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER			
FRESENIUS	18.4MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 5	A020374	002 Jun 13, 1994
	38MG/100ML; 448MG/100ML		
INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER			
FRESENIUS	18.4MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 5	A020374	003 Jun 13, 1994
	38MG/100ML; 448MG/100ML		
INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER			
FRESENIUS	18.4MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 5	A020374	004 Jun 13, 1994
	538MG/100ML; 448MG/100ML		

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% IN ACETATED RINGER'S IN PLASTIC CONTAINER			
B BRAUN	20MG/100ML; 5GM/100ML; 30MG/100ML; 380MG/1	N018258	001
	00ML; 600MG/100ML		

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER			
HOSPIRA	33MG/100ML; 5GM/100ML; 30MG/100ML; 860MG/1	N018254	001
	00ML		
DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER			
B BRAUN	33MG/100ML; 5GM/100ML; 30MG/100ML; 860MG/1	N018256	001
	00ML		
	33MG/100ML; 5GM/100ML; 30MG/100ML; 860MG/1	N020000	001 Apr 17, 1992
	00ML		
BAXTER HLTHCARE	33MG/100ML; 5GM/100ML; 30MG/100ML; 860MG/1	N016695	001
	00ML		

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 4% IN MODIFIED LACTATED RINGER'S IN PLASTIC CONTAINER			
B BRAUN	4MG/100ML; 4GM/100ML; 6MG/100ML; 120MG/100	N019634	002 Feb 24, 1988
	ML; 62MG/100ML		
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER			
B BRAUN	20MG/100ML; 5GM/100ML; 30MG/100ML; 600MG/1	N017510	001
	00ML; 310MG/100ML		
MILES	20MG/100ML; 5GM/100ML; 30MG/100ML; 600MG/1	N018499	001
	00ML; 310MG/100ML		

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER			
+ ICU MEDICAL INC	20MG/100ML;5GM/100ML;104MG/100ML;600MG/100ML;310MG/100ML	N019685 005	Oct 17, 1988
+ ICU MEDICAL INC	20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML	N019685 006	Oct 17, 1988
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER			
+ ICU MEDICAL INC	20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML	N019685 007	Oct 17, 1988
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER			
+ ICU MEDICAL INC	20MG/100ML;5GM/100ML;328MG/100ML;600MG/100ML;310MG/100ML	N019685 008	Oct 17, 1988
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER			
+ ICU MEDICAL INC	20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML	N019685 003	Oct 17, 1988
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER			
+ ICU MEDICAL INC	20MG/100ML;5GM/100ML;328MG/100ML;600MG/100ML;310MG/100ML	N019685 004	Oct 17, 1988
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER			
+ ICU MEDICAL INC	20MG/100ML;5GM/100ML;104MG/100ML;600MG/100ML;310MG/100ML	N019685 001	Oct 17, 1988

CALCIUM CHLORIDE; DEXTROSE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

INPERSOL-ZM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER			
FRESENIUS MEDCL	25.7MG/100ML;1.5GM/100ML;538MG/100ML;448MG/100ML	N019395 001	Mar 26, 1986
INPERSOL-ZM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER			
FRESENIUS MEDCL	25.7MG/100ML;2.5GM/100ML;538MG/100ML;448MG/100ML	N019395 002	Mar 26, 1986
INPERSOL-ZM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER			
FRESENIUS MEDCL	25.7MG/100ML;4.25GM/100ML;538MG/100ML;448MG/100ML	N019395 003	Mar 26, 1986

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TPN ELECTROLYTES IN PLASTIC CONTAINER			
ABBOTT	16.5MG/ML;25.4MG/ML;74.6MG/ML;121MG/ML;16.1MG/ML	N019399 001	Jun 16, 1986

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

ISOLYTE E IN PLASTIC CONTAINER			
B BRAUN	35MG/100ML;30MG/100ML;74MG/100ML;640MG/100ML;500MG/100ML;74MG/100ML	N018899 001	Oct 31, 1983
B BRAUN	35MG/100ML;30MG/100ML;74MG/100ML;640MG/100ML;500MG/100ML;74MG/100ML	N019718 001	Sep 29, 1989

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

PLASMA-LYTE R IN PLASTIC CONTAINER			
BAXTER HLTHCARE	36.8MG/100ML;30.5MG/100ML;74.6MG/100ML;640MG/100ML;496MG/100ML;89.6MG/100ML	N017438 001	

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ACETATED RINGER'S IN PLASTIC CONTAINER			
B BRAUN	20MG/100ML;30MG/100ML;380MG/100ML;600MG/100ML	N018725 001	Nov 29, 1982

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

RINGER'S IN PLASTIC CONTAINER			
B BRAUN	33MG/100ML;30MG/100ML;860MG/100ML	N018721 001	Nov 09, 1982
SOLUTION; IRRIGATION			
RINGER'S IN PLASTIC CONTAINER			
ABBOTT	33MG/100ML;30MG/100ML;860MG/100ML	N018462 001	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

ABBOTT	20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG /100ML	N019485 001	Oct 24, 1985
B BRAUN	20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG /100ML	N018023 001	
MILES	20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG /100ML	N018417 001	

SOLUTION; IRRIGATION

LACTATED RINGER'S IN PLASTIC CONTAINER

BAXTER HLTHCARE	20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG /100ML	N019933 001	Aug 29, 1989
-----------------	--	-------------	--------------

CALCIUM GLUCEPTATE

INJECTABLE; INJECTION

CALCIUM GLUCEPTATE

ABBOTT	EQ 90MG CALCIUM/5ML	A080001 001	
	EQ 90MG CALCIUM/5ML	A083159 001	
ABRAXIS PHARM	EQ 90MG CALCIUM/5ML	A089373 001	Apr 30, 1987
LILLY	EQ 90MG CALCIUM/5ML	N006470 001	

CALCIUM METRIZOATE; MEGLUMINE METRIZOATE; METRIZOATE MAGNESIUM; METRIZOATE SODIUM

INJECTABLE; INJECTION

ISOPAQUE 440

GE HEALTHCARE	0.78MG/ML; 75.9MG/ML; 0.15MG/ML; 16.6MG/ML	N016847 001	
---------------	--	-------------	--

CALCIUM; MEGLUMINE; METRIZOIC ACID

INJECTABLE; INJECTION

ISOPAQUE 280

GE HEALTHCARE	0.35MG/ML; 140.1MG/ML; 461.8MG/ML	N017506 001	
---------------	-----------------------------------	-------------	--

CANDESARTAN CILEXETIL

TABLET; ORAL

CANDESARTAN CILEXETIL

APOTEX INC	4MG	A202079 001	Jan 10, 2014
	8MG	A202079 002	Jan 10, 2014
	16MG	A202079 003	Jan 10, 2014
	32MG	A202079 004	Jan 10, 2014

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

APOTEX INC	16MG; 12.5MG	A202884 001	Dec 04, 2012
	32MG; 12.5MG	A202884 002	Dec 04, 2012
	32MG; 25MG	A202884 003	Jun 03, 2013

CANDICIDIN

OINTMENT; VAGINAL

VANOVID

SANOFI AVENTIS US	0.6MG/GM	A061596 001	
-------------------	----------	-------------	--

TABLET; VAGINAL

VANOVID

SANOFI AVENTIS US	3MG	A061613 001	
-------------------	-----	-------------	--

CAPREOMYCIN SULFATE

INJECTABLE; INJECTION

CAPREOMYCIN SULFATE

HISUN PHARM HANGZHOU	EQ 1GM BASE/VIAL	A204796 001	Oct 18, 2018
MYLAN LABS LTD	EQ 1GM BASE/VIAL	A202634 001	Nov 27, 2017

CAPTOPRIL

TABLET; ORAL

CAPOTEN

+	PAR PHARM	12.5MG **	N018343 005	Jan 17, 1985
+		25MG **	N018343 002	
+		37.5MG **	N018343 006	Sep 17, 1986
+		50MG **	N018343 001	
+		75MG **	N018343 007	Jun 13, 1995
+		100MG **	N018343 003	
+		150MG **	N018343 004	Jun 13, 1995

CAPTOPRIL

ANNORA PHARMA	12.5MG	A074737 001	Oct 28, 1998
	25MG	A074737 002	Oct 28, 1998

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

	50MG	A074737 003	Oct 28, 1998
	100MG	A074737 004	Oct 28, 1998
APOTHECON	12.5MG	A074472 001	Mar 31, 1995
	25MG	A074472 002	Mar 31, 1995
	50MG	A074472 003	Mar 31, 1995
	100MG	A074472 004	Mar 31, 1995
COSETTE	12.5MG	A074433 001	Feb 13, 1996
	12.5MG	A074462 001	Feb 13, 1996
	12.5MG	A074483 001	Feb 13, 1996
	25MG	A074433 002	Feb 13, 1996
	25MG	A074462 002	Feb 13, 1996
	25MG	A074483 002	Feb 13, 1996
	50MG	A074433 003	Feb 13, 1996
	50MG	A074462 003	Feb 13, 1996
	50MG	A074483 003	Feb 13, 1996
	100MG	A074433 004	Feb 13, 1996
	100MG	A074462 004	Feb 13, 1996
	100MG	A074483 004	Feb 13, 1996
DAVA PHARMS INC	12.5MG	A074423 001	Feb 13, 1996
	25MG	A074423 002	Feb 13, 1996
	50MG	A074423 003	Feb 13, 1996
	100MG	A074423 004	Feb 13, 1996
EGIS PHARMS	12.5MG	A074748 004	May 29, 1997
	25MG	A074748 002	May 29, 1997
	50MG	A074748 001	May 29, 1997
	100MG	A074748 003	May 29, 1997
G AND W LABS INC	12.5MG	A074590 004	Aug 30, 1996
	25MG	A074590 002	Aug 30, 1996
	50MG	A074590 001	Aug 30, 1996
	100MG	A074590 003	Aug 30, 1996
OXFORD PHARMS	12.5MG	A074418 001	Feb 13, 1996
	25MG	A074418 002	Feb 13, 1996
	50MG	A074418 003	Feb 13, 1996
	100MG	A074418 004	Feb 13, 1996
PAR PHARM	12.5MG	A074493 001	Feb 13, 1996
	25MG	A074493 002	Feb 13, 1996
	50MG	A074493 003	Feb 13, 1996
	100MG	A074493 004	Feb 13, 1996
PUREPAC PHARM	12.5MG	A074640 001	Mar 31, 1997
	25MG	A074640 002	Mar 31, 1997
	50MG	A074640 003	Mar 31, 1997
	100MG	A074640 004	Mar 31, 1997
SANDOZ	12.5MG	A074481 001	Feb 13, 1996
	25MG	A074481 002	Feb 13, 1996
	50MG	A074481 003	Feb 13, 1996
	100MG	A074481 004	Feb 13, 1996
SETON PHARMS	12.5MG	A212223 001	Oct 30, 2019
	25MG	A212223 002	Oct 30, 2019
	50MG	A212223 003	Oct 30, 2019
	100MG	A212223 004	Oct 30, 2019
TEVA	12.5MG	A074322 001	Feb 13, 1996
	25MG	A074322 002	Feb 13, 1996
	50MG	A074322 003	Feb 13, 1996
	100MG	A074322 004	Feb 13, 1996
WATSON LABS	12.5MG	A074386 001	May 23, 1996
	12.5MG	A074451 001	Feb 13, 1996
	12.5MG	A074576 001	Apr 23, 1996
	25MG	A074386 002	May 23, 1996
	25MG	A074451 002	Feb 13, 1996
	25MG	A074576 002	Apr 23, 1996
	50MG	A074386 003	May 23, 1996
	50MG	A074451 003	Feb 13, 1996
	50MG	A074576 003	Apr 23, 1996
	100MG	A074386 004	May 23, 1996
	100MG	A074451 004	Feb 13, 1996
	100MG	A074576 004	Apr 23, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

YAOPHARMA CO LTD	12.5MG	A074363 001	Nov 09, 1995
	12.5MG	A074519 001	Feb 13, 1996
	25MG	A074363 002	Nov 09, 1995
	25MG	A074519 002	Feb 13, 1996
	50MG	A074363 003	Nov 09, 1995
	50MG	A074519 003	Feb 13, 1996
	100MG	A074363 004	Nov 09, 1995
	100MG	A074519 004	Feb 13, 1996

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPOZIDE 25/15

+ APOTHECON	25MG;15MG **	N018709 001	Oct 12, 1984
-------------	--------------	-------------	--------------

CAPOZIDE 25/25

+ APOTHECON	25MG;25MG **	N018709 002	Oct 12, 1984
-------------	--------------	-------------	--------------

CAPOZIDE 50/15

+ APOTHECON	50MG;15MG **	N018709 004	Oct 12, 1984
-------------	--------------	-------------	--------------

CAPOZIDE 50/25

+ APOTHECON	50MG;25MG **	N018709 003	Oct 12, 1984
-------------	--------------	-------------	--------------

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

COSETTE

25MG;15MG	A074827 001	Dec 29, 1997
-----------	-------------	--------------

25MG;25MG	A074827 002	Dec 29, 1997
-----------	-------------	--------------

50MG;15MG	A074827 004	Dec 29, 1997
-----------	-------------	--------------

50MG;25MG	A074827 003	Dec 29, 1997
-----------	-------------	--------------

IVAX SUB TEVA PHARMS

25MG;15MG	A075055 001	Jun 18, 1998
-----------	-------------	--------------

25MG;25MG	A075055 002	Jun 18, 1998
-----------	-------------	--------------

50MG;15MG	A075055 004	Jun 18, 1998
-----------	-------------	--------------

50MG;25MG	A075055 003	Jun 18, 1998
-----------	-------------	--------------

VINTAGE PHARMS LLC

25MG;15MG	A074788 001	Dec 29, 1997
-----------	-------------	--------------

25MG;25MG	A074788 002	Dec 29, 1997
-----------	-------------	--------------

50MG;15MG	A074788 004	Dec 29, 1997
-----------	-------------	--------------

50MG;25MG	A074788 003	Dec 29, 1997
-----------	-------------	--------------

WATSON LABS

50MG;25MG	A074832 001	Dec 29, 1997
-----------	-------------	--------------

CARBACHOL

SOLUTION; INTRAOCULAR

CARBACHOL

PHARMAFAIR	0.01%	A070292 001	May 21, 1986
------------	-------	-------------	--------------

CARBASTAT

NOVARTIS	0.01%	A073677 001	Apr 28, 1995
----------	-------	-------------	--------------

CARBAMAZEPINE

SOLUTION; INTRAVENOUS

CARNEXIV

+ LUNDBECK PHARMS LLC	200MG/20ML (10MG/ML)	N206030 001	Oct 07, 2016
-----------------------	----------------------	-------------	--------------

SUSPENSION; ORAL

CARBAMAZEPINE

TARO	100MG/5ML	A075875 001	Dec 21, 2000
------	-----------	-------------	--------------

TABLET; ORAL

CARBAMAZEPINE

ACTAVIS ELIZABETH	200MG	A071696 001	Nov 09, 1987
-------------------	-------	-------------	--------------

INWOOD LABS	200MG	A070231 001	Aug 14, 1986
-------------	-------	-------------	--------------

PLIVA	200MG	A071479 001	Jul 24, 1987
-------	-------	-------------	--------------

USL PHARMA	200MG	A070300 001	May 15, 1986
------------	-------	-------------	--------------

WARNER CHILCOTT	200MG	A070429 001	Jan 02, 1987
-----------------	-------	-------------	--------------

TERIL

TARO	200MG	A076525 001	Sep 26, 2003
------	-------	-------------	--------------

TABLET, CHEWABLE; ORAL

CARBAMAZEPINE

JUBILANT CADISTA	100MG	A071940 001	Feb 01, 1988
------------------	-------	-------------	--------------

TEGRETOL

+ NOVARTIS	100MG	N018281 001	
------------	-------	-------------	--

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CARBENICILLIN DISODIUM

INJECTABLE; INJECTION

GEOPEN

ROERIG	EQ 1GM BASE/VIAL	N050306	001
	EQ 2GM BASE/VIAL	N050306	004
	EQ 5GM BASE/VIAL	N050306	002
	EQ 10GM BASE/VIAL	N050306	006
	EQ 30GM BASE/VIAL	N050306	007

PYOPEN

GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	N050298	001
	EQ 2GM BASE/VIAL	N050298	002
	EQ 5GM BASE/VIAL	N050298	003
	EQ 10GM BASE/VIAL	N050298	006
	EQ 20GM BASE/VIAL	N050298	007

CARBENICILLIN INDANYL SODIUM

TABLET; ORAL

GEOCILLIN

PFIZER	EQ 382MG BASE	N050435	001
--------	---------------	---------	-----

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

MYLAN	12.5MG; 200MG; 50MG	A203424	001	Aug 13, 2020
	18.75MG; 200MG; 75MG	A203424	002	Aug 13, 2020
	25MG; 200MG; 100MG	A203424	003	Aug 13, 2020
	31.25MG; 200MG; 125MG	A203424	004	Aug 13, 2020
	37.5MG; 200MG; 150MG	A203424	005	Aug 13, 2020
	50MG; 200MG; 200MG	A203424	006	Aug 13, 2020
WOCKHARDT LTD	12.5MG; 200MG; 50MG	A090786	001	Nov 20, 2012
	18.75MG; 200MG; 75MG	A090833	001	Nov 20, 2012
	25MG; 200MG; 100MG	A090833	002	Nov 20, 2012
	31.25MG; 200MG; 125MG	A090833	003	Nov 20, 2012
	37.5MG; 200MG; 150MG	A090833	004	Nov 20, 2012
50MG; 200MG; 200MG	A090833	005	Nov 20, 2012	

CARBIDOPA; LEVODOPA

TABLET; ORAL

CARBIDOPA AND LEVODOPA

ANI PHARMS INC	10MG; 100MG	A073587	002	Jun 29, 1995
	25MG; 100MG	A073587	001	Jun 29, 1995
	25MG; 250MG	A073587	003	Jun 29, 1995
SCS	10MG; 100MG	A074080	001	Mar 25, 1994
	25MG; 100MG	A074080	002	Mar 25, 1994
	25MG; 250MG	A074080	003	Mar 25, 1994
WATSON LABS	10MG; 100MG	A073381	001	Sep 28, 1993
	25MG; 100MG	A073382	001	Sep 28, 1993
	25MG; 250MG	A073383	001	Sep 28, 1993

TABLET, EXTENDED RELEASE; ORAL

CARBIDOPA AND LEVODOPA

KV PHARM	50MG; 200MG	A076663	001	Jun 24, 2004	
SINEMET CR					
	+ MERCK SHARP DOHME	25MG; 100MG	N019856	002	Dec 24, 1992
	+	50MG; 200MG	N019856	001	May 30, 1991

TABLET, FOR SUSPENSION; ORAL

CARBILEV

RANBAXY	10MG; 100MG	A076643	001	Jun 10, 2005
	25MG; 100MG	A076643	002	Jun 10, 2005
	25MG; 250MG	A076643	003	Jun 10, 2005

TABLET, ORALLY DISINTEGRATING; ORAL

CARBIDOPA AND LEVODOPA

IMPAX LABS	10MG; 100MG	A090631	001	Jun 08, 2010
	25MG; 100MG	A090631	002	Jun 08, 2010
	25MG; 250MG	A090631	003	Jun 08, 2010

PARCOPA

UCB INC	10MG; 100MG **	A076699	001	Aug 27, 2004
	25MG; 100MG **	A076699	002	Aug 27, 2004
	25MG; 250MG **	A076699	003	Aug 27, 2004

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CARBINOXAMINE MALEATE

ELIXIR; ORAL

CLISTIN

+ MCNEIL

4MG/5ML **

N008955 001

SOLUTION; ORAL

CARBINOXAMINE MALEATE

CYPRESS PHARM

4MG/5ML

A090418 001 May 04, 2010

VINTAGE PHARMS

4MG/5ML

A040814 001 Feb 26, 2008

TABLET; ORAL

CARBINOXAMINE MALEATE

CYPRESS PHARM

4MG

A090417 001 Aug 23, 2010

VINTAGE PHARMS

4MG

A040639 002 May 30, 2008

CLISTIN

+ ORTHO MCNEIL PHARM

4MG **

N008915 001

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

CIPLA LTD

50MG/VIAL

A077383 001 Jan 27, 2006

150MG/VIAL

A077383 002 Jan 27, 2006

450MG/VIAL

A077383 003 Jan 27, 2006

FRESENIUS KABI USA

50MG/VIAL

A076235 001 Oct 14, 2004

150MG/VIAL

A076235 002 Oct 14, 2004

450MG/VIAL

A076235 003 Oct 14, 2004

HOSPIRA

50MG/VIAL

A076473 001 Oct 27, 2004

150MG/VIAL

A076473 002 Oct 27, 2004

450MG/VIAL

A076473 003 Oct 27, 2004

MYLAN LABS LTD

50MG/VIAL

A091510 001 May 29, 2012

150MG/VIAL

A091510 002 May 29, 2012

450MG/VIAL

A091510 003 May 29, 2012

PLIVA

50MG/VIAL

A076602 001 Nov 16, 2004

150MG/VIAL

A076602 002 Nov 16, 2004

450MG/VIAL

A076602 003 Nov 16, 2004

SANDOZ

50MG/VIAL

A076959 001 Mar 18, 2005

150MG/VIAL

A076959 002 Mar 18, 2005

450MG/VIAL

A076959 003 Mar 18, 2005

WATSON LABS TEVA

50MG/VIAL

A076162 001 Oct 14, 2004

150MG/VIAL

A076162 002 Oct 14, 2004

450MG/VIAL

A076162 003 Oct 14, 2004

WEST-WARD PHARMS INT

50MG/VIAL

A076099 001 Oct 14, 2004

150MG/VIAL

A076099 002 Oct 14, 2004

450MG/VIAL

A076099 003 Oct 14, 2004

PARAPLATIN

+ CORDEN PHARMA

50MG/VIAL **

N019880 001 Mar 03, 1989

+

150MG/VIAL **

N019880 002 Mar 03, 1989

+

450MG/VIAL **

N019880 003 Mar 03, 1989

INJECTABLE; INTRAVENOUS

CARBOPLATIN

ACTAVIS TOTOWA

50MG/5ML (10MG/ML)

A078732 001 Feb 06, 2012

150MG/15ML (10MG/ML)

A078732 002 Feb 06, 2012

450MG/45ML (10MG/ML)

A078732 003 Feb 06, 2012

600MG/60ML (10MG/ML)

A078732 004 Feb 06, 2012

FRESENIUS KABI USA

50MG/5ML (10MG/ML)

A077432 001 Sep 29, 2006

150MG/15ML (10MG/ML)

A077432 002 Sep 29, 2006

450MG/45ML (10MG/ML)

A077432 003 Sep 29, 2006

50MG/5ML (10MG/ML)

A077247 001 Oct 21, 2004

50MG/5ML (10MG/ML)

A077266 001 Feb 15, 2006

150MG/15ML (10MG/ML)

A077247 002 Oct 21, 2004

150MG/15ML (10MG/ML)

A077266 002 Feb 15, 2006

MYLAN INSTITUTIONAL

50MG/5ML (10MG/ML)

A077998 001 Apr 24, 2007

150MG/15ML (10MG/ML)

A077998 002 Apr 24, 2007

450MG/45ML (10MG/ML)

A077998 003 Apr 24, 2007

MYLAN LABS LTD

50MG/5ML (10MG/ML)

A091063 001 Nov 09, 2011

150MG/15ML (10MG/ML)

A091063 002 Nov 09, 2011

450MG/45ML (10MG/ML)

A091063 003 Nov 09, 2011

600MG/60ML (10MG/ML)

A091063 004 Nov 09, 2011

1GM/100ML (10MG/ML)

A091478 001 Nov 23, 2011

PHARMACHEMIE BV

50MG/5ML (10MG/ML)

A077679 001 Feb 25, 2009

150MG/15ML (10MG/ML)

A077679 002 Feb 25, 2009

450MG/45ML (10MG/ML)

A077679 003 Feb 25, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CARBOPLATIN

INJECTABLE; INTRAVENOUS

CARBOPLATIN

PLIVA LACHEMA	50MG/5ML (10MG/ML)	A078631 001	Dec 02, 2008
	150MG/15ML (10MG/ML)	A078631 002	Dec 02, 2008
	450MG/45ML (10MG/ML)	A078631 003	Dec 02, 2008
	600MG/60ML (10MG/ML)	A078631 004	Dec 02, 2008
TEVA PARENTERAL	50MG/5ML (10MG/ML)	A077389 001	Mar 30, 2007
	150MG/15ML (10MG/ML)	A077389 002	Mar 30, 2007
	450MG/45ML (10MG/ML)	A077389 003	Mar 30, 2007
TEVA PHARMS USA	50MG/5ML (10MG/ML)	A077139 001	Sep 21, 2005
	150MG/15ML (10MG/ML)	A077139 002	Sep 21, 2005
	450MG/45ML (10MG/ML)	A077139 003	Sep 21, 2005
	600MG/60ML (10MG/ML)	A077139 004	Sep 21, 2005
PARAPLATIN			
+ CORDENPHARMA	50MG/5ML (10MG/ML) **	N020452 001	Jul 14, 2003
+	150MG/15ML (10MG/ML) **	N020452 002	Jul 14, 2003
+	450MG/45ML (10MG/ML) **	N020452 003	Jul 14, 2003
+	600MG/60ML (10MG/ML) **	N020452 004	Jan 15, 2004

CARFILZOMIB

POWDER; INTRAVENOUS

CARFILZOMIB

APOTEX	30MG/VIAL	A211185 001	Mar 20, 2020
	60MG/VIAL	A209425 001	Mar 16, 2020

CARISOPRODOL

CAPSULE; ORAL

SOMA

+ MYLAN SPECIALITY LP 250MG N011792 003

TABLET; ORAL

CARISOPRODOL

ABLE	350MG	A040421 001	Jun 21, 2001
EPIC PHARMA LLC	350MG	A040397 001	Sep 21, 2000
HIKMA INTL PHARMS	350MG	A040124 001	Jan 24, 1996
PIONEER PHARMS	350MG	A089390 001	Oct 13, 1988
SANDOZ	350MG	A089566 001	Aug 30, 1988
SUN PHARM INDS LTD	350MG	A040755 001	Feb 27, 2007
SUN PHARM INDUSTRIES	350MG	A089346 001	Oct 17, 1991
WATSON LABS	350MG	A040152 001	Dec 03, 1996
	350MG	A085433 001	
WATSON LABS TEVA	350MG	A086179 001	
RELA			
SCHERING	350MG	N012155 001	

CARPENAZINE MALEATE

CONCENTRATE; ORAL

PROKETAZINE

WYETH AYERST 50MG/ML N014173 001

TABLET; ORAL

PROKETAZINE

WYETH AYERST	12.5MG	N012768 001	
	25MG	N012768 002	
	50MG	N012768 004	

CARPROFEN

TABLET; ORAL

RIMADYL

ROCHE	100MG	N018550 002	Dec 31, 1987
	150MG	N018550 003	Dec 31, 1987

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CARTEOLOL HYDROCHLORIDE

APOTEX INC	1%	A076097 001	Feb 06, 2002
BAUSCH AND LOMB	1%	A075546 001	Jan 20, 2000

OCUPRESS

+ NOVARTIS 1% ** N019972 001 May 23, 1990

TABLET; ORAL

CARTROL

ABBVIE	2.5MG	N019204 001	Dec 28, 1988
	5MG	N019204 002	Dec 28, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CARTEOLOL HYDROCHLORIDE

TABLET; ORAL

CARTROL

10MG

N019204 003 Dec 28, 1988

CARVEDILOL

TABLET; ORAL

CARVEDILOL

HIKMA

3.125MG

A077887 001 Sep 07, 2007

6.25MG

A077887 002 Sep 07, 2007

12.5MG

A077887 003 Sep 07, 2007

25MG

A077887 004 Sep 07, 2007

PLIVA HRVATSKA DOO

3.125MG

A078240 001 Oct 30, 2007

6.25MG

A078240 002 Oct 30, 2007

12.5MG

A078240 003 Oct 30, 2007

25MG

A078240 004 Oct 30, 2007

SUN PHARM INDS INC

3.125MG

A077346 004 Sep 05, 2007

6.25MG

A077346 001 Sep 05, 2007

12.5MG

A077346 002 Sep 05, 2007

25MG

A077346 003 Sep 05, 2007

WOCKHARDT LTD

3.125MG

A078786 001 Dec 22, 2009

6.25MG

A078786 002 Dec 22, 2009

12.5MG

A078786 003 Dec 22, 2009

25MG

A078786 004 Dec 22, 2009

CASPOFUNGIN ACETATE

POWDER; INTRAVENOUS

CASPOFUNGIN ACETATE

CIPLA

50MG/VIAL

A209489 001 Jul 12, 2018

70MG/VIAL

A209489 002 Jul 12, 2018

MYLAN LABS LTD

70MG/VIAL

A207650 002 Sep 29, 2017

CEFACLOR

CAPSULE; ORAL

CECLOR

+ LILLY

EQ 250MG BASE **

N050521 001

+

EQ 500MG BASE **

N050521 002

CEFACLOR

CEPH INTL

EQ 250MG BASE

A062205 001

EQ 500MG BASE

A062205 002

DAVA PHARMS INC

EQ 250MG BASE

A064107 001 Apr 27, 1995

EQ 500MG BASE

A064107 002 Apr 27, 1995

HERITAGE PHARMA

EQ 250MG BASE

A064148 001 May 23, 1996

EQ 500MG BASE

A064148 002 May 23, 1996

IVAX SUB TEVA PHARMS

EQ 250MG BASE

A064061 001 Apr 27, 1995

EQ 500MG BASE

A064061 002 Apr 27, 1995

RANBAXY

EQ 250MG BASE

A064156 001 Aug 28, 1997

EQ 500MG BASE

A064156 002 Aug 28, 1997

TEVA

EQ 250MG BASE

A064081 001 Sep 16, 1996

EQ 250MG BASE

A064145 001 Jun 24, 1996

EQ 500MG BASE

A064081 002 Sep 16, 1996

EQ 500MG BASE

A064145 002 Jun 24, 1996

FOR SUSPENSION; ORAL

CECLOR

+ LILLY

EQ 125MG BASE/5ML **

N050522 001

+

EQ 250MG BASE/5ML **

N050522 002

CEFACLOR

DAVA PHARMS INC

EQ 125MG BASE/5ML

A064114 001 Apr 28, 1995

EQ 187MG BASE/5ML

A064115 001 Apr 28, 1995

EQ 250MG BASE/5ML

A064116 001 Apr 28, 1995

EQ 375MG BASE/5ML

A064110 001 Apr 28, 1995

FACTA FARMA

EQ 125MG BASE/5ML

A062206 001

EQ 187MG BASE/5ML

A062206 003 Apr 20, 1988

EQ 250MG BASE/5ML

A062206 002

EQ 375MG BASE/5ML

A062206 004 Apr 20, 1988

IVAX SUB TEVA PHARMS

EQ 125MG BASE/5ML

A064087 001 Apr 28, 1995

EQ 187MG BASE/5ML

A064086 001 Apr 28, 1995

EQ 250MG BASE/5ML

A064085 001 Apr 28, 1995

EQ 375MG BASE/5ML

A064070 001 Apr 28, 1995

RANBAXY

EQ 125MG BASE/5ML

A064166 001 Oct 02, 1997

EQ 187MG BASE/5ML

A064165 001 Oct 02, 1997

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CEFACTOR

FOR SUSPENSION;ORAL

CEFACTOR

EQ 250MG BASE/5ML	A064164	001	Oct 02, 1997	
EQ 375MG BASE/5ML	A064155	001	Oct 02, 1997	
WATSON LABS INC	EQ 125MG BASE/5ML	A064204	001	Feb 18, 1998
EQ 187MG BASE/5ML	A064205	001	Feb 18, 1998	
EQ 250MG BASE/5ML	A064206	001	Feb 18, 1998	
EQ 375MG BASE/5ML	A064207	001	Feb 18, 1998	

TABLET, CHEWABLE;ORAL

RANICLOR

RANBAXY LABS LTD

EQ 125MG BASE	A065092	001	Dec 22, 2003
EQ 187MG BASE	A065092	002	Dec 22, 2003
EQ 250MG BASE	A065092	003	Dec 22, 2003
EQ 375MG BASE	A065092	004	Dec 22, 2003

TABLET, EXTENDED RELEASE;ORAL

CECLOR CD

LILLY

EQ 375MG BASE	N050673	001	Jun 28, 1996
EQ 500MG BASE	N050673	002	Jun 28, 1996

CEFACTOR

WORLD GEN

EQ 500MG BASE	A065057	001	Jan 05, 2001
---------------	---------	-----	--------------

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE;ORAL

CEFADROXIL

CSPC OUYI

EQ 500MG BASE	A205072	001	Jul 28, 2017
---------------	---------	-----	--------------

IVAX SUB TEVA PHARMS

EQ 500MG BASE	A062766	001	Mar 03, 1987
---------------	---------	-----	--------------

PUREPAC PHARM

EQ 500MG BASE	A063017	001	Jan 05, 1989
---------------	---------	-----	--------------

RANBAXY LABS LTD

EQ 500MG BASE	A065015	001	Jun 22, 1999
---------------	---------	-----	--------------

SANDOZ

EQ 500MG BASE	A062291	001	
---------------	---------	-----	--

TEVA

EQ 500MG BASE	A062695	001	Feb 10, 1989
---------------	---------	-----	--------------

DURICEF

WARNER CHILCOTT

EQ 250MG BASE	N050512	002	
---------------	---------	-----	--

+

EQ 500MG BASE **	N050512	001	
------------------	---------	-----	--

ULTRACEF

BRISTOL

EQ 500MG BASE	A062378	001	Mar 16, 1982
---------------	---------	-----	--------------

FOR SUSPENSION;ORAL

CEFADROXIL

ANI PHARMS INC

EQ 125MG BASE/5ML	A062698	001	Mar 01, 1989
-------------------	---------	-----	--------------

EQ 250MG BASE/5ML	A062698	002	Mar 01, 1989
-------------------	---------	-----	--------------

EQ 250MG BASE/5ML	A065278	001	Jan 20, 2006
-------------------	---------	-----	--------------

EQ 500MG BASE/5ML	A062698	003	Mar 01, 1989
-------------------	---------	-----	--------------

EQ 500MG BASE/5ML	A065278	002	Jan 20, 2006
-------------------	---------	-----	--------------

APOTHECON

EQ 125MG BASE/5ML	A062334	001	
-------------------	---------	-----	--

EQ 250MG BASE/5ML	A062334	002	
-------------------	---------	-----	--

EQ 500MG BASE/5ML	A062334	003	
-------------------	---------	-----	--

SUN PHARM INDS LTD

EQ 125MG BASE/5ML	A065115	001	Mar 26, 2003
-------------------	---------	-----	--------------

EQ 250MG BASE/5ML	A065115	002	Mar 26, 2003
-------------------	---------	-----	--------------

EQ 500MG BASE/5ML	A065115	003	Mar 26, 2003
-------------------	---------	-----	--------------

DURICEF

+

WARNER CHILCOTT

EQ 125MG BASE/5ML **	N050527	002	
----------------------	---------	-----	--

+

EQ 250MG BASE/5ML **	N050527	003	
----------------------	---------	-----	--

+

EQ 500MG BASE/5ML **	N050527	001	
----------------------	---------	-----	--

ULTRACEF

BRISTOL

EQ 125MG BASE/5ML	A062376	001	Mar 16, 1982
-------------------	---------	-----	--------------

EQ 250MG BASE/5ML	A062376	002	Mar 16, 1982
-------------------	---------	-----	--------------

EQ 500MG BASE/5ML	A062376	003	Mar 16, 1982
-------------------	---------	-----	--------------

TABLET;ORAL

CEFADROXIL

RANBAXY

EQ 1GM BASE	A065018	001	Apr 23, 1999
-------------	---------	-----	--------------

DURICEF

+

WARNER CHILCOTT

EQ 1GM BASE **	N050528	001	
----------------	---------	-----	--

ULTRACEF

APOTHECON

EQ 1GM BASE	A062390	001	Jun 10, 1982
-------------	---------	-----	--------------

BRISTOL

EQ 1GM BASE	A062408	001	Aug 31, 1982
-------------	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CEFAMANDOLE NAFATEINJECTABLE; INJECTION
MANDOL

LILLY	EQ 500MG BASE/VIAL	N050504 001	
	EQ 1GM BASE/VIAL	A062560 001	Sep 10, 1985
	EQ 1GM BASE/VIAL	N050504 002	
	EQ 2GM BASE/VIAL	A062560 002	Sep 10, 1985
	EQ 2GM BASE/VIAL	N050504 003	
	EQ 10GM BASE/VIAL	N050504 004	

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

ANCEF

+	GLAXOSMITHKLINE	EQ 250MG BASE/VIAL **	N050461 001	
+		EQ 500MG BASE/VIAL	N050461 002	
+		EQ 1GM BASE/VIAL **	N050461 003	
+		EQ 5GM BASE/VIAL **	N050461 004	
+		EQ 10GM BASE/VIAL **	N050461 005	
ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER				
+	BAXTER HLTHCARE	EQ 10MG BASE/ML	N050566 003	Jun 08, 1983
+		EQ 20MG BASE/ML	N050566 004	Jun 08, 1983
ANCEF IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	EQ 10MG BASE/ML	A063002 001	Mar 28, 1991
ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
+	BAXTER HLTHCARE	EQ 10MG BASE/ML	N050566 001	Jun 08, 1983
+		EQ 20MG BASE/ML	N050566 002	Jun 08, 1983

CEFAZOLIN AND DEXTROSE

B BRAUN	EQ 500MG BASE/VIAL	N050779 001	Jul 27, 2000
---------	--------------------	-------------	--------------

CEFAZOLIN SODIUM

ABRAXIS PHARM	EQ 500MG BASE/VIAL	A062688 002	Nov 17, 1986
	EQ 1GM BASE/VIAL	A062688 003	Nov 17, 1986
	EQ 10GM BASE/VIAL	A062688 004	Nov 17, 1986
	EQ 20GM BASE/VIAL	A062688 005	Aug 03, 1987
AUROBINDO PHARMA	EQ 500MG BASE/VIAL	A065395 001	Aug 08, 2008
	EQ 1GM BASE/VIAL	A065395 002	Aug 08, 2008
BEDFORD	EQ 250MG BASE/VIAL	A062894 001	Jul 21, 1988
	EQ 500MG BASE/VIAL	A062894 002	Jul 21, 1988
	EQ 1GM BASE/VIAL	A062894 003	Jul 21, 1988
	EQ 5GM BASE/VIAL	A062894 004	Jul 21, 1988
	EQ 10GM BASE/VIAL	A062894 005	Jul 21, 1988
CEPHAZONE PHARMA	EQ 500MG BASE/VIAL	A065280 001	Mar 18, 2009
	EQ 1GM BASE/VIAL	A065280 002	Mar 18, 2009
	EQ 10GM BASE/VIAL	A065295 001	Mar 18, 2009
	EQ 20GM BASE/VIAL	A065296 001	Mar 18, 2009
DR REDDYS	EQ 250MG BASE/VIAL	A062988 001	Dec 29, 1989
	EQ 500MG BASE/VIAL	A062988 002	Dec 29, 1989
	EQ 1GM BASE/VIAL	A062988 003	Dec 29, 1989
	EQ 5GM BASE/VIAL	A062989 001	Dec 29, 1989
	EQ 10GM BASE/VIAL	A062989 002	Dec 29, 1989
	EQ 20GM BASE/VIAL	A062989 003	Dec 29, 1989
FACTA FARMA	EQ 500MG BASE/VIAL	A063214 001	Dec 27, 1991
	EQ 1GM BASE/VIAL	A063207 001	Dec 27, 1991
	EQ 10GM BASE/VIAL	A063209 001	Dec 27, 1991
	EQ 20GM BASE/VIAL	A063209 002	Apr 30, 1999
FRESENIUS KABI USA	EQ 500MG BASE/VIAL **	A064169 001	Aug 14, 1998
	EQ 1GM BASE/VIAL **	A064169 002	Aug 14, 1998
	EQ 10GM BASE/VIAL	A064170 001	Mar 18, 1998
	EQ 20GM BASE/VIAL	A064170 002	Mar 18, 1998
GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	A064033 001	Oct 31, 1993
HOSPIRA INC	EQ 500MG BASE/VIAL	A065226 001	Apr 21, 2005
	EQ 1GM BASE/VIAL	A065226 002	Apr 21, 2005
	EQ 1GM BASE/VIAL	A065244 001	Aug 12, 2005
	EQ 1GM BASE/VIAL	A201654 001	Feb 03, 2016
	EQ 10GM BASE/VIAL	A065247 001	Aug 12, 2005
STERI PHARMA	EQ 500MG BASE/VIAL	A063216 001	Dec 27, 1991
	EQ 1GM BASE/VIAL	A063208 001	Dec 27, 1991
TEVA PHARMS	EQ 250MG BASE/VIAL	A063016 001	Mar 14, 1989
	EQ 500MG BASE/VIAL	A063016 002	Mar 14, 1989
	EQ 1GM BASE/VIAL	A063016 003	Mar 14, 1989
	EQ 5GM BASE/VIAL	A063018 001	Mar 05, 1990

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

	EQ 10GM BASE/VIAL	A063018 002	Mar 05, 1990
WEST-WARD PHARMS INT	EQ 250MG BASE/VIAL	A062807 001	Jan 12, 1988
	EQ 500MG BASE/VIAL	A062807 002	Jan 12, 1988
	EQ 1GM BASE/VIAL	A062807 003	Jan 12, 1988
	EQ 5GM BASE/VIAL	A062807 004	Jan 12, 1988
	EQ 10GM BASE/VIAL	A062807 005	Jan 12, 1988
	EQ 20GM BASE/VIAL	A062807 006	Jan 12, 1988

KEFZOL

ACS DOBFAR

	EQ 250MG BASE/VIAL	A061773 001	
	EQ 500MG BASE/VIAL	A061773 002	
	EQ 1GM BASE/VIAL	A061773 003	
	EQ 10GM BASE/VIAL	A061773 004	
	EQ 20GM BASE/VIAL	A061773 005	Sep 08, 1987

LILLY

	EQ 500MG BASE/VIAL	A062557 001	Sep 10, 1985
	EQ 1GM BASE/VIAL	A062557 002	Sep 10, 1985

CEFDINIR

CAPSULE; ORAL

OMNICEF

+ ABBVIE

300MG ** N050739 001 Dec 04, 1997

FOR SUSPENSION; ORAL

OMNICEF

+ ABBVIE

125MG/5ML ** N050749 001 Dec 04, 1997

+

250MG/5ML ** N050749 002 Jul 29, 2004

CEFDITOREN PIVOXIL

TABLET; ORAL

SPECTRACEF

VANSEN PHARMA

200MG N021222 001 Aug 29, 2001

400MG N021222 002 Jul 21, 2008

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

FOSUN PHARMA

EQ 500MG BASE/VIAL A090291 001 Dec 21, 2010

EQ 1GM BASE/VIAL A090291 002 Dec 21, 2010

EQ 2GM BASE/VIAL A090291 003 Dec 21, 2010

HOSPIRA INC

EQ 500MG BASE/VIAL A065369 001 Jun 18, 2007

EQ 1GM BASE/VIAL A065369 002 Jun 18, 2007

EQ 1GM BASE/VIAL A202268 001 Jul 30, 2012

EQ 2GM BASE/VIAL A065369 003 Jun 18, 2007

EQ 2GM BASE/VIAL A202268 002 Jul 30, 2012

CEFIXIME

CAPSULE; ORAL

SUPRAX

+ LUPIN LTD

400MG N203195 001 Jun 01, 2012

FOR SUSPENSION; ORAL

CEFIXIME

SANDOZ INC

100MG/5ML A206144 001 Nov 17, 2017

200MG/5ML A206144 002 Nov 17, 2017

SUPRAX

+ LEDERLE

100MG/5ML ** N050622 001 Apr 28, 1989

LUPIN PHARMS

100MG/5ML A065129 001 Feb 23, 2004

TABLET; ORAL

SUPRAX

+ LEDERLE

200MG ** N050621 001 Apr 28, 1989

+

400MG ** N050621 002 Apr 28, 1989

LUPIN PHARMS

400MG A065130 001 Feb 12, 2004

CEFMENOXIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFMAX

TAP PHARM

EQ 500MG BASE/VIAL N050571 001 Dec 30, 1987

EQ 1GM BASE/VIAL N050571 002 Dec 30, 1987

EQ 2GM BASE/VIAL N050571 003 Dec 30, 1987

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CEFMETAZOLE SODIUM

INJECTABLE; INJECTION

ZEFAZONE

+	PHARMACIA AND UPJOHN	EQ 1GM BASE/VIAL **	N050637	001	Dec 11, 1989
+		EQ 2GM BASE/VIAL **	N050637	002	Dec 11, 1989
ZEFAZONE IN PLASTIC CONTAINER					
+	PHARMACIA AND UPJOHN	EQ 20MG BASE/ML **	N050683	001	Dec 29, 1992
+		EQ 40MG BASE/ML **	N050683	002	Dec 29, 1992

CEFONICID SODIUM

INJECTABLE; INJECTION

MONOCID

GLAXOSMITHKLINE	EQ 500MG BASE/VIAL	N050579	001	May 23, 1984
	EQ 1GM BASE/VIAL	A063295	001	Jul 26, 1993
	EQ 1GM BASE/VIAL	N050579	002	May 23, 1984
	EQ 2GM BASE/VIAL	N050579	003	May 23, 1984
	EQ 10GM BASE/VIAL	N050579	004	May 23, 1984

CEFOPERAZONE SODIUM

INJECTABLE; INJECTION

CEFOBID

PFIZER	EQ 1GM BASE/VIAL	A063333	001	Mar 31, 1995
	EQ 1GM BASE/VIAL	N050551	001	Nov 18, 1982
	EQ 2GM BASE/VIAL	A063333	002	Mar 31, 1995
	EQ 2GM BASE/VIAL	N050551	002	Nov 18, 1982
	EQ 10GM BASE/VIAL	N050551	003	Mar 05, 1990

CEFOBID IN PLASTIC CONTAINER

PFIZER	EQ 20MG BASE/ML	N050613	002	Jul 31, 1987
	EQ 40MG BASE/ML	N050613	001	Jul 23, 1986

CEFORANIDE

INJECTABLE; INJECTION

PRECEF

APOTHECON	500MG/VIAL	A062579	001	Nov 26, 1984
	1GM/VIAL	A062579	002	Nov 26, 1984
	2GM/VIAL	A062579	003	Nov 26, 1984
	10GM/VIAL	A062579	004	Nov 26, 1984
	20GM/VIAL	A062579	005	Nov 26, 1984
BRISTOL	500MG/VIAL	N050554	001	May 24, 1984
	1GM/VIAL	N050554	002	May 24, 1984
	2GM/VIAL	N050554	003	May 24, 1984
	10GM/VIAL	N050554	004	May 24, 1984
	20GM/VIAL	N050554	005	May 24, 1984

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME

FRESENIUS KABI USA	EQ 500MG BASE/VIAL	A064200	001	Mar 24, 2000
	EQ 1GM BASE/VIAL	A064200	002	Mar 24, 2000
	EQ 2GM BASE/VIAL	A064200	003	Mar 24, 2000
	EQ 10GM BASE/VIAL	A064201	001	Mar 24, 2000
	EQ 20GM BASE/VIAL	A064201	002	Mar 24, 2000
WOCKHARDT	EQ 1GM BASE/VIAL	A065197	001	Aug 29, 2006

CEFOTAXIME AND DEXTROSE 2.4% IN PLASTIC CONTAINER

B BRAUN	EQ 2GM BASE	N050792	001	Jul 29, 2004
---------	-------------	---------	-----	--------------

CEFOTAXIME AND DEXTROSE 3.9% IN PLASTIC CONTAINER

B BRAUN	EQ 1GM BASE	N050792	002	Jul 29, 2004
---------	-------------	---------	-----	--------------

CEFOTAXIME SODIUM

AUROBINDO PHARMA	EQ 500MG BASE/VIAL	A065517	001	Nov 06, 2009
	EQ 1GM BASE/VIAL	A065517	002	Nov 06, 2009
	EQ 2GM BASE/VIAL	A065517	003	Nov 06, 2009
AUROBINDO PHARMA LTD	EQ 10GM BASE/VIAL	A065516	001	Nov 06, 2009
CEPHAZONE PHARMA	EQ 10GM BASE/VIAL	A065348	001	Jan 25, 2010
HOSPIRA INC	EQ 500MG BASE/VIAL	A065290	001	Aug 11, 2006
	EQ 1GM BASE/VIAL	A065290	002	Aug 11, 2006
	EQ 1GM BASE/VIAL	A065293	001	Aug 10, 2006
	EQ 1GM BASE/VIAL	A203132	001	Feb 19, 2016
	EQ 2GM BASE/VIAL	A065290	003	Aug 11, 2006
	EQ 2GM BASE/VIAL	A065293	002	Aug 10, 2006
	EQ 2GM BASE/VIAL	A203132	002	Feb 19, 2016
	EQ 10GM BASE/VIAL	A065292	001	Aug 10, 2006

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME SODIUM

LUPIN	EQ 500MG BASE/VIAL	A065124 001	Sep 24, 2003
	EQ 1GM BASE/VIAL	A065124 002	Sep 24, 2003
	EQ 2GM BASE/VIAL	A065124 003	Sep 24, 2003
WOCKHARDT	EQ 500MG BASE/VIAL	A065197 002	Jun 20, 2008
	EQ 2GM BASE/VIAL	A065197 003	Jun 20, 2008
CLAFORAN			
SANOFI AVENTIS US	EQ 1GM BASE/VIAL	A062659 001	Jan 13, 1987
	EQ 2GM BASE/VIAL	A062659 002	Jan 13, 1987
+ US PHARM HOLDINGS	EQ 500MG BASE/VIAL **	N050547 001	
+	EQ 1GM BASE/VIAL **	N050547 002	
+	EQ 2GM BASE/VIAL **	N050547 003	
+	EQ 10GM BASE/VIAL **	N050547 004	Dec 29, 1983
CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER			
US PHARM HOLDINGS	EQ 20MG BASE/ML	N050596 002	May 20, 1985
	EQ 40MG BASE/ML	N050596 004	May 20, 1985
CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
US PHARM HOLDINGS	EQ 20MG BASE/ML	N050596 001	May 20, 1985
	EQ 40MG BASE/ML	N050596 003	May 20, 1985

CEFOTETAN DISODIUM

INJECTABLE; INJECTION

CEFOTAN

TELIGENT	EQ 1GM BASE/VIAL	A063293 001	Apr 29, 1993
	EQ 2GM BASE/VIAL	A063293 002	Apr 29, 1993
	EQ 10GM BASE/VIAL	N050588 003	Apr 25, 1988
CEFOTAN IN PLASTIC CONTAINER			
TELIGENT	EQ 20MG BASE/ML	N050694 002	Jul 30, 1993
	EQ 40MG BASE/ML	N050694 001	Jul 30, 1993
CEFOTETAN			
FRESENIUS KABI USA	EQ 10GM BASE/VIAL	A065375 001	Aug 09, 2007
WEST-WARD PHARM CORP	EQ 10GM BASE/VIAL	A091030 001	Oct 26, 2011

CEFOTIAM HYDROCHLORIDE

INJECTABLE; INJECTION

CERADON

TAKEDA	EQ 1GM BASE/VIAL	N050601 001	Dec 30, 1988
--------	------------------	-------------	--------------

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN

ACS DOBFAR SPA	EQ 1GM BASE/VIAL	A065467 001	Aug 31, 2011
	EQ 2GM BASE/VIAL	A065467 002	Aug 31, 2011
	EQ 10GM BASE/VIAL	A065464 001	Aug 31, 2011
FRESENIUS KABI USA	EQ 1GM BASE/VIAL **	A065012 001	Jul 03, 2000
	EQ 2GM BASE/VIAL **	A065012 002	Jul 03, 2000
	EQ 10GM BASE/VIAL	A065011 001	Jul 03, 2000
HOSPIRA INC	EQ 1GM BASE/VIAL	A065313 001	Jan 23, 2006
	EQ 2GM BASE/VIAL	A065313 002	Jan 23, 2006
	EQ 10GM BASE/VIAL	A065312 001	Feb 13, 2006
MEFOXIN			
MYLAN INSTITUTIONAL	EQ 1GM BASE/VIAL	A062757 001	Jan 08, 1987
+	EQ 1GM BASE/VIAL **	N050517 001	
	EQ 2GM BASE/VIAL	A062757 002	Jan 08, 1987
+	EQ 2GM BASE/VIAL **	N050517 002	
+	EQ 10GM BASE/VIAL **	N050517 003	
MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER			
+ MERCK	EQ 20MG BASE/ML **	N050581 003	Sep 20, 1984
+	EQ 40MG BASE/ML **	N050581 004	Sep 20, 1984
MEFOXIN IN PLASTIC CONTAINER			
MYLAN INSTITUTIONAL	EQ 20MG BASE/ML	A063182 001	Jan 25, 1993
	EQ 40MG BASE/ML	A063182 002	Jan 25, 1993
MEFOXIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
+ MERCK	EQ 20MG BASE/ML **	N050581 002	Sep 20, 1984
+	EQ 40MG BASE/ML **	N050581 001	Sep 20, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CEFPARAMIDE SODIUM

INJECTABLE; INJECTION

CEFPARAMIDE SODIUM

WYETH AYERST

EQ 1GM BASE/VIAL

N050633 002 Jan 31, 1989

EQ 2GM BASE/VIAL

N050633 003 Jan 31, 1989

EQ 10GM BASE/VIAL

N050633 005 Jan 31, 1989

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL

BANAN

SANKYO

EQ 50MG BASE/5ML

N050688 002 Aug 07, 1992

EQ 100MG BASE/5ML

N050688 001 Aug 07, 1992

CEFPODOXIME PROXETIL

SANDOZ

EQ 50MG BASE/5ML

A090031 001 Jan 14, 2009

EQ 100MG BASE/5ML

A090031 002 Jan 14, 2009

SUN PHARM INDS LTD

EQ 50MG BASE/5ML

A065082 001 May 31, 2002

EQ 100MG BASE/5ML

A065082 002 May 31, 2002

VANTIN

+ PHARMACIA AND UPJOHN

EQ 50MG BASE/5ML **

N050675 001 Aug 07, 1992

+

EQ 100MG BASE/5ML **

N050675 002 Aug 07, 1992

TABLET; ORAL

BANAN

SANKYO

EQ 100MG BASE

N050687 001 Aug 07, 1992

EQ 200MG BASE

N050687 002 Aug 07, 1992

CEFPODOXIME PROXETIL

SUN PHARM INDS LTD

EQ 100MG BASE

A065083 001 Aug 20, 2003

EQ 200MG BASE

A065083 002 Aug 20, 2003

VANTIN

+ PHARMACIA AND UPJOHN

EQ 100MG BASE **

N050674 001 Aug 07, 1992

+

EQ 200MG BASE **

N050674 002 Aug 07, 1992

CEFPROZIL

FOR SUSPENSION; ORAL

CEFPROZIL

RANBAXY LABS LTD

125MG/5ML

A065202 001 Jun 30, 2006

250MG/5ML

A065202 002 Jun 30, 2006

TEVA PHARMS

125MG/5ML

A065236 001 Dec 08, 2005

250MG/5ML

A065236 002 Dec 08, 2005

CEFZIL

+ CORDEN PHARMA

125MG/5ML **

N050665 001 Dec 23, 1991

+

250MG/5ML **

N050665 002 Dec 23, 1991

TABLET; ORAL

CEFPROZIL

RANBAXY LABS LTD

250MG

A065198 001 Dec 13, 2006

500MG

A065198 002 Dec 13, 2006

WOCKHARDT

250MG

A065428 001 Jun 14, 2007

500MG

A065428 002 Jun 14, 2007

CEFZIL

+ CORDEN PHARMA

250MG **

N050664 001 Dec 23, 1991

+

500MG **

N050664 002 Dec 23, 1991

CEFTAZIDIME

INJECTABLE; INJECTION

CEFTAZIDIME

ACS DOBFAR

500MG/VIAL

A062640 001 Nov 20, 1985

AUROBINDO PHARMA LTD

500MG/VIAL

A065481 001 May 28, 2010

1GM/VIAL

A065481 002 May 28, 2010

2GM/VIAL

A065481 003 May 28, 2010

6GM/VIAL

A065482 001 May 28, 2010

WOCKHARDT

1GM/VIAL

A065196 001 Oct 15, 2008

CEPTAZ

GLAXOSMITHKLINE

500MG/VIAL

N050646 001 Sep 27, 1990

1GM/VIAL

N050646 002 Sep 27, 1990

2GM/VIAL

N050646 003 Sep 27, 1990

10GM/VIAL

N050646 004 Sep 27, 1990

PENTACEF

GLAXOSMITHKLINE

1GM/VIAL

A063322 001 Nov 07, 1995

1GM/VIAL

A064006 001 Mar 31, 1992

2GM/VIAL

A063322 002 Nov 07, 1995

2GM/VIAL

A064006 002 Mar 31, 1992

6GM/VIAL

A064008 001 Mar 31, 1992

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CEFTAZIDIME

INJECTABLE; INJECTION

PENTACEF

10GM/VIAL

A064008 002 Mar 31, 1992

TAZIDIME

LILLY

1GM/VIAL

A062655 001 Nov 20, 1985

2GM/VIAL

A062655 002 Nov 20, 1985

TAZIDIME IN PLASTIC CONTAINER

LILLY

1GM/VIAL

A062739 001 Jul 10, 1986

2GM/VIAL

A062739 002 Jul 10, 1986

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION

CEFTAZIDIME SODIUM IN PLASTIC CONTAINER

BAXTER HLTHCARE

EQ 10MG BASE/ML

A063221 001 Apr 29, 1993

EQ 20MG BASE/ML

A063221 002 Apr 29, 1993

EQ 40MG BASE/ML

A063221 003 Apr 29, 1993

FORTAZ IN PLASTIC CONTAINER

TELIGENT

EQ 10MG BASE/ML

N050634 001 Apr 28, 1989

+

EQ 20MG BASE/ML

N050634 002 Apr 28, 1989

+

EQ 40MG BASE/ML

N050634 003 Apr 28, 1989

CEFTIBUTEN DIHYDRATE

CAPSULE; ORAL

CEDAX

SI PHARMS

EQ 400MG BASE

N050685 002 Dec 20, 1995

FOR SUSPENSION; ORAL

CEDAX

+

SI PHARMS

EQ 90MG BASE/5ML **

N050686 001 Dec 20, 1995

+

EQ 180MG BASE/5ML **

N050686 002 Dec 20, 1995

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION

CEFIZOX

ASTELLAS

EQ 500MG BASE/VIAL

N050560 001 Sep 15, 1983

EQ 1GM BASE/VIAL

A063294 002 Mar 31, 1994

EQ 1GM BASE/VIAL

N050560 002 Sep 15, 1983

EQ 2GM BASE/VIAL

A063294 003 Mar 31, 1994

EQ 2GM BASE/VIAL

N050560 003 Sep 15, 1983

EQ 10GM BASE/VIAL

N050560 005 Mar 19, 1993

CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER

ASTELLAS

EQ 20MG BASE/ML

N050589 001 Oct 03, 1984

EQ 40MG BASE/ML

N050589 002 Oct 03, 1984

CEFIZOX IN PLASTIC CONTAINER

ASTELLAS

EQ 20MG BASE/ML

N050589 003 Apr 13, 1995

EQ 40MG BASE/ML

N050589 004 Apr 13, 1995

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION

CEFTRIAXONE

AGILA SPECLTS

EQ 10GM BASE/VIAL

A091068 001 Jan 07, 2013

AUROBINDO PHARMA LTD

EQ 10GM BASE/VIAL

A065504 001 Jul 31, 2008

BEDFORD

EQ 10GM BASE/VIAL

A065475 001 Aug 18, 2008

FACTA FARMA

EQ 10GM BASE/VIAL

A065269 001 Feb 28, 2007

FRESENIUS KABI USA

EQ 10GM BASE/VIAL

A065252 001 Feb 15, 2006

HOSPIRA INC

EQ 1GM BASE/VIAL

A065231 001 Aug 02, 2005

EQ 1GM BASE/VIAL

A202563 001 Aug 20, 2012

EQ 2GM BASE/VIAL

A065231 002 Aug 02, 2005

EQ 2GM BASE/VIAL

A202563 002 Aug 20, 2012

EQ 10GM BASE/VIAL

A065232 001 Aug 02, 2005

LUPIN

EQ 10GM BASE/VIAL

A065263 001 Sep 12, 2006

TEVA

EQ 10GM BASE/VIAL

A065274 001 May 01, 2006

ROCEPHIN

HOFFMANN LA ROCHE

EQ 250MG BASE/VIAL

A063239 001 Aug 13, 1993

EQ 500MG BASE/VIAL

A062654 001 Apr 30, 1987

EQ 500MG BASE/VIAL

A063239 002 Aug 13, 1993

EQ 1GM BASE/VIAL

A062654 002 Apr 30, 1987

EQ 1GM BASE/VIAL

A063239 003 Aug 13, 1993

EQ 2GM BASE/VIAL

A062654 003 Apr 30, 1987

+

EQ 10GM BASE/VIAL **

N050585 005 Dec 21, 1984

ROCHE

EQ 250MG BASE/VIAL

A062510 001 Mar 12, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CEFTRIAOXONE SODIUM

INJECTABLE; INJECTION

ROCEPHIN

	EQ 500MG BASE/VIAL	A062510 002	Mar 12, 1985
	EQ 1GM BASE/VIAL	A062510 003	Mar 12, 1985
ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER			
+	HOFFMANN LA ROCHE EQ 10MG BASE/ML **	N050624 001	Feb 11, 1987
+	EQ 20MG BASE/ML **	N050624 002	Feb 11, 1987
+	EQ 40MG BASE/ML **	N050624 003	Feb 11, 1987

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

CEFTRIAOXONE

AUROBINDO PHARMA LTD	EQ 250MG BASE/VIAL	A065505 001	Jul 31, 2008
	EQ 500MG BASE/VIAL	A065505 002	Jul 31, 2008
	EQ 1GM BASE/VIAL	A065505 003	Jul 31, 2008
	EQ 2GM BASE/VIAL	A065505 004	Jul 31, 2008
BEDFORD	EQ 250MG BASE/VIAL	A065465 001	Aug 18, 2008
	EQ 500MG BASE/VIAL	A065465 002	Aug 18, 2008
	EQ 1GM BASE/VIAL	A065465 003	Aug 18, 2008
	EQ 2GM BASE/VIAL	A065465 004	Aug 18, 2008
CEPHAZONE PHARMA	EQ 250MG BASE/VIAL	A065294 001	Mar 26, 2007
	EQ 500MG BASE/VIAL	A065294 002	Mar 26, 2007
	EQ 1GM BASE/VIAL	A065294 003	Mar 26, 2007
	EQ 2GM BASE/VIAL	A065294 004	Mar 26, 2007
FACTA FARMA	EQ 1GM BASE/VIAL	A065268 001	Feb 28, 2007
	EQ 2GM BASE/VIAL	A065268 002	Feb 28, 2007
FRESENIUS KABI USA	EQ 250MG BASE/VIAL	A065245 001	Feb 15, 2006
	EQ 500MG BASE/VIAL	A065245 002	Feb 15, 2006
	EQ 1GM BASE/VIAL	A065245 003	Feb 15, 2006
	EQ 2GM BASE/VIAL	A065245 004	Feb 15, 2006
HOSPIRA INC	EQ 250MG BASE/VIAL	A065230 001	Aug 02, 2005
	EQ 500MG BASE/VIAL	A065230 002	Aug 02, 2005
	EQ 1GM BASE/VIAL	A065230 003	Aug 02, 2005
	EQ 2GM BASE/VIAL	A065230 004	Aug 02, 2005
TEVA	EQ 1GM BASE/VIAL	A065262 001	Jun 29, 2006
	EQ 2GM BASE/VIAL	A065262 002	Jun 29, 2006
TEVA PHARMS USA	EQ 250MG BASE/VIAL	A065227 001	Mar 15, 2007
	EQ 500MG BASE/VIAL	A065227 002	Mar 15, 2007
	EQ 1GM BASE/VIAL	A065227 003	Mar 15, 2007
	EQ 2GM BASE/VIAL	A065227 004	Mar 15, 2007
ROCEPHIN			
+	HOFFMANN LA ROCHE EQ 250MG BASE/VIAL **	N050585 001	Dec 21, 1984
+	EQ 500MG BASE/VIAL **	N050585 002	Dec 21, 1984
+	EQ 1GM BASE/VIAL **	N050585 003	Dec 21, 1984
+	EQ 2GM BASE/VIAL **	N050585 004	Dec 21, 1984

CEFTRIAOXONE SODIUM; LIDOCAINE

INJECTABLE; INJECTION

ROCEPHIN KIT

HOFFMANN LA ROCHE	EQ 500MG BASE/VIAL, N/A; N/A, 1%	N050585 007	May 08, 1996
	EQ 1GM BASE/VIAL, N/A; N/A, 1%	N050585 006	May 08, 1996

CEFUROXIME AXETIL

FOR SUSPENSION; ORAL

CEFTIN

+	GLAXOSMITHKLINE EQ 125MG BASE/5ML	N050672 001	Jun 30, 1994
+	EQ 250MG BASE/5ML	N050672 002	Apr 29, 1997

CEFUROXIME AXETIL

SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065323 001	Feb 05, 2008
	EQ 250MG BASE/5ML	A065323 002	Feb 05, 2008

TABLET; ORAL

CEFTIN

+	GLAXOSMITHKLINE EQ 125MG BASE **	N050605 001	Dec 28, 1987
+	EQ 250MG BASE **	N050605 002	Dec 28, 1987
+	EQ 500MG BASE **	N050605 003	Dec 28, 1987

CEFUROXIME AXETIL

ANI PHARMS INC	EQ 250MG BASE	A065190 001	Oct 18, 2004
	EQ 500MG BASE	A065190 002	Oct 18, 2004
FOSUN PHARMA	EQ 250MG BASE	A065126 001	Oct 28, 2003
	EQ 500MG BASE	A065126 002	Oct 28, 2003
RANBAXY LABS LTD	EQ 125MG BASE	A065043 003	Feb 15, 2002

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

	EQ 250MG BASE	A065043 002	Feb 15, 2002
	EQ 500MG BASE	A065043 001	Feb 15, 2002
SUN PHARM INDS LTD	EQ 125MG BASE	A065118 001	Apr 25, 2003
	EQ 250MG BASE	A065118 002	Apr 25, 2003
	EQ 500MG BASE	A065118 003	Apr 25, 2003

CEFUROXIME SODIUM

INJECTABLE; INJECTION

CEFUROXIME SODIUM

FRESENIUS KABI USA	EQ 1.5GM BASE/VIAL	A065001 002	May 30, 2001
	EQ 7.5GM BASE/VIAL	A065002 001	Sep 28, 1998
HOSPIRA INC	EQ 1.5GM BASE/VIAL	A065483 002	Oct 15, 2008
	EQ 1.5GM BASE/VIAL	A065503 001	Oct 15, 2008
	EQ 7.5GM BASE/VIAL	A065484 001	Oct 15, 2008
TEVA PHARMS	EQ 7.5GM BASE/VIAL	A064191 001	Apr 16, 1998
WATSON LABS INC	EQ 1.5GM BASE/VIAL	A064035 002	Feb 26, 1993
	EQ 7.5GM BASE/VIAL	A064036 001	Feb 26, 1993

CEFUROXIME SODIUM IN PLASTIC CONTAINER

SAMSON MEDCL	EQ 75GM BASE/VIAL	A065251 001	Dec 30, 2009
	EQ 225GM BASE/VIAL	A065251 002	Dec 30, 2009

KEFUROX

ACS DOBFAR	EQ 1.5GM BASE/VIAL	A062591 002	Jan 10, 1986
	EQ 7.5GM BASE/VIAL	A062591 003	Dec 17, 1987
LILLY	EQ 1.5GM BASE/VIAL	A062592 002	Jan 10, 1986

KEFUROX IN PLASTIC CONTAINER

LILLY	EQ 1.5GM BASE/VIAL	A062590 002	Jan 10, 1986
-------	--------------------	-------------	--------------

ZINACEF IN PLASTIC CONTAINER

TELIGENT	EQ 15MG BASE/ML	N050643 001	Apr 28, 1989
+	EQ 30MG BASE/ML	N050643 002	Apr 28, 1989

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

CEFUROXIME SODIUM

FRESENIUS KABI USA	EQ 750MG BASE/VIAL	A065001 001	May 30, 2001
HOSPIRA INC	EQ 750MG BASE/VIAL	A065483 001	Oct 15, 2008
TEVA PHARMS	EQ 750MG BASE/VIAL	A064192 002	Apr 16, 1998
	EQ 1.5GM BASE/VIAL	A064192 001	Apr 16, 1998
WATSON LABS INC	EQ 750MG BASE/VIAL	A064035 001	Feb 26, 1993

KEFUROX

ACS DOBFAR	EQ 750MG BASE/VIAL	A062591 001	Jan 10, 1986
------------	--------------------	-------------	--------------

INJECTABLE; INTRAVENOUS

KEFUROX

LILLY	EQ 750MG BASE/VIAL	A062592 001	Jan 10, 1986
-------	--------------------	-------------	--------------

KEFUROX IN PLASTIC CONTAINER

LILLY	EQ 750MG BASE/VIAL	A062590 001	Jan 10, 1986
-------	--------------------	-------------	--------------

CELECOXIB

CAPSULE; ORAL

CELECOXIB

YILING	50MG	A211412 001	Mar 06, 2020
	100MG	A211412 002	Mar 06, 2020
	200MG	A211412 003	Mar 06, 2020
	400MG	A211412 004	Mar 06, 2020

SOLUTION; ORAL

ELYXYB

+	DR REDDYS	25MG/ML	N212157 001	May 05, 2020
---	-----------	---------	-------------	--------------

CELLULOSE SODIUM PHOSPHATE

POWDER; ORAL

CALCIBIND

MISSION PHARMA	2.5GM/PACKET	N018757 002	Dec 28, 1982
	300GM/BOT	N018757 003	Oct 16, 1984

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

APOTHECON	EQ 250MG BASE	A062973 001	Nov 08, 1988
	EQ 250MG BASE	A063063 001	Sep 29, 1989
	EQ 250MG BASE	A063186 001	Dec 30, 1994
	EQ 500MG BASE	A062974 001	Nov 23, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CEPHALEXIN

CAPSULE;ORAL

CEPHALEXIN

	EQ 500MG BASE	A063063	002	Sep 29, 1989
	EQ 500MG BASE	A063186	002	Dec 30, 1994
BARR	EQ 250MG BASE	A062773	001	Jun 26, 1987
	EQ 500MG BASE	A062775	001	Apr 22, 1987
FACTA FARMA	EQ 250MG BASE	A062118	001	
	EQ 500MG BASE	A062118	002	
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A061969	001	
	EQ 500MG BASE	A061969	002	
PUREPAC PHARM	EQ 250MG BASE	A062809	001	Apr 22, 1987
	EQ 500MG BASE	A062809	002	Apr 22, 1987
STEVENS J	EQ 250MG BASE	A062870	001	Mar 17, 1988
	EQ 500MG BASE	A062869	001	Mar 17, 1988
SUN PHARM INDS (IN)	EQ 250MG BASE	A062791	001	Jun 11, 1987
	EQ 500MG BASE	A062791	002	Jun 11, 1987
SUN PHARM INDS LTD	EQ 250MG BASE	A065007	001	Sep 16, 1999
	EQ 500MG BASE	A065007	002	Sep 16, 1999
TEVA	EQ 250MG BASE	A062760	001	Apr 24, 1987
	EQ 250MG BASE	A062821	001	Feb 05, 1988
	EQ 500MG BASE	A062761	001	Apr 24, 1987
	EQ 500MG BASE	A062823	001	Feb 05, 1988
YOSHITOMI	EQ 250MG BASE	A062872	001	Jun 20, 1988
	EQ 500MG BASE	A062871	001	Jul 05, 1988
KEFLEX				
+ PRAGMA	EQ 333MG BASE **	N050405	004	May 12, 2006
FOR SUSPENSION;ORAL				
CEPHALEXIN				
APOTHECON	EQ 125MG BASE/5ML	A062986	001	Apr 18, 1991
	EQ 250MG BASE/5ML	A062987	001	Jul 25, 1989
BARR	EQ 125MG BASE/5ML	A062778	001	Aug 06, 1987
	EQ 250MG BASE/5ML	A062777	001	Aug 06, 1987
FACTA FARMA	EQ 100MG BASE/ML **	A062117	001	
	EQ 125MG BASE/5ML **	A062117	002	
	EQ 250MG BASE/5ML **	A062117	003	
HIKMA PHARMS	EQ 125MG BASE/5ML	A065444	001	Aug 28, 2009
	EQ 250MG BASE/5ML	A065444	002	Aug 28, 2009
SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065081	001	Jul 27, 2001
	EQ 250MG BASE/5ML	A065081	002	Jul 27, 2001
TEVA	EQ 125MG BASE/5ML	A062767	001	Jun 16, 1987
	EQ 125MG BASE/5ML	A062873	001	May 23, 1988
	EQ 250MG BASE/5ML	A062768	001	Jun 16, 1987
	EQ 250MG BASE/5ML	A062867	001	Apr 15, 1988
VITARINE	EQ 125MG BASE/5ML	A062779	001	Dec 22, 1987
	EQ 250MG BASE/5ML	A062781	001	Dec 22, 1987
KEFLEX				
+ PRAGMA	EQ 100MG BASE/ML **	N050406	003	
+	EQ 125MG BASE/5ML **	N050406	001	
+	EQ 250MG BASE/5ML **	N050406	002	
TABLET;ORAL				
CEPHALEXIN				
BARR	EQ 250MG BASE	A062826	001	Aug 17, 1987
	EQ 500MG BASE	A062827	001	Aug 17, 1987
VITARINE	EQ 250MG BASE	A062863	001	Aug 11, 1988
	EQ 500MG BASE	A062863	002	Aug 11, 1988
	EQ 1GM BASE	A062863	003	Aug 11, 1988
KEFLET				
LILLY	EQ 250MG BASE	A062745	001	Dec 01, 1986
	EQ 250MG BASE	N050440	003	Feb 26, 1987
	EQ 500MG BASE	A062745	002	Dec 01, 1986
	EQ 500MG BASE	N050440	001	
	EQ 1GM BASE	N050440	002	
TABLET, FOR SUSPENSION;ORAL				
PANIXINE DISPERDOSE				
RANBAXY LABS LTD	EQ 125MG BASE	A065100	002	Sep 11, 2003
	EQ 250MG BASE	A065100	001	Sep 11, 2003

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CEPHALEXIN HYDROCHLORIDE

TABLET; ORAL

KEFTAB

LILLY	EQ 250MG BASE	N050614 001	Oct 29, 1987
	EQ 333MG BASE	N050614 003	May 16, 1988
	EQ 500MG BASE	N050614 002	Oct 29, 1987

CEPHALOGLYCIN

CAPSULE; ORAL

KAFOCIN

LILLY	250MG	N050219 001	
-------	-------	-------------	--

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION

CEPHALOTHIN

INTL MEDICATION	EQ 500MG BASE/VIAL	A062426 001	May 03, 1985
	EQ 1GM BASE/VIAL	A062426 002	May 03, 1985
	EQ 2GM BASE/VIAL	A062426 003	May 03, 1985
	EQ 4GM BASE/VIAL	A062426 004	May 03, 1985

CEPHALOTHIN SODIUM

ABBOTT	EQ 1GM BASE/VIAL	A062547 001	Sep 11, 1985
	EQ 1GM BASE/VIAL	A062548 001	Sep 11, 1985
	EQ 2GM BASE/VIAL	A062547 002	Sep 11, 1985
	EQ 2GM BASE/VIAL	A062548 002	Sep 11, 1985
ABRAXIS PHARM	EQ 1GM BASE/VIAL	A062666 002	Jun 10, 1987
	EQ 2GM BASE/VIAL	A062666 001	Jun 10, 1987
BRISTOL	EQ 1GM BASE/VIAL	A062464 001	May 07, 1984
	EQ 2GM BASE/VIAL	A062464 002	May 07, 1984
	EQ 4GM BASE/VIAL	A062464 003	May 07, 1984

CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER

BAXTER HLTHCARE	EQ 20MG BASE/ML	A062422 003	Jan 31, 1984
	EQ 20MG BASE/ML	A062422 005	Jul 16, 1991
	EQ 20MG BASE/ML	A062730 001	Mar 05, 1987
	EQ 40MG BASE/ML	A062422 004	Jan 31, 1984
	EQ 40MG BASE/ML	A062422 006	Jul 16, 1991
	EQ 40MG BASE/ML	A062730 002	Mar 05, 1987

CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER

BAXTER HLTHCARE	EQ 20MG BASE/ML	A062422 001	Jan 31, 1984
	EQ 40MG BASE/ML	A062422 002	Jan 31, 1984

KEFLIN

LILLY	EQ 1GM BASE/VIAL	N050482 001	
	EQ 2GM BASE/VIAL	N050482 002	
	EQ 4GM BASE/VIAL	N050482 003	
	EQ 20GM BASE/VIAL	N050482 007	

KEFLIN IN PLASTIC CONTAINER

LILLY	EQ 1GM BASE/VIAL	A062549 001	Sep 10, 1985
	EQ 2GM BASE/VIAL	A062549 002	Sep 10, 1985

SEFFIN

GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	A062435 001	Nov 15, 1983
	EQ 2GM BASE/VIAL	A062435 002	Nov 15, 1983
	EQ 10GM BASE/VIAL	A062435 003	Nov 15, 1983

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION

CEFADYL

APOTHECON	EQ 500MG BASE/VIAL	A062961 001	Sep 20, 1988
	EQ 500MG BASE/VIAL	N050446 005	
	EQ 1GM BASE/VIAL	A061769 001	
	EQ 1GM BASE/VIAL	A062724 001	Dec 23, 1986
	EQ 1GM BASE/VIAL	A062961 002	Sep 20, 1988
	EQ 1GM BASE/VIAL	N050446 001	
	EQ 2GM BASE/VIAL	A061769 002	
	EQ 2GM BASE/VIAL	A062724 002	Dec 23, 1986
	EQ 2GM BASE/VIAL	A062961 003	Sep 20, 1988
	EQ 2GM BASE/VIAL	N050446 002	
	EQ 4GM BASE/VIAL	A061769 003	
	EQ 4GM BASE/VIAL	A062961 004	Sep 20, 1988
	EQ 4GM BASE/VIAL	N050446 003	
	EQ 20GM BASE/VIAL	N050446 004	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION

CEPHAPIRIN SODIUM

ABRAXIS PHARM

EQ 500MG BASE/VIAL

A062723 001 Nov 17, 1986

EQ 1GM BASE/VIAL

A062723 002 Nov 17, 1986

EQ 2GM BASE/VIAL

A062723 003 Nov 17, 1986

EQ 4GM BASE/VIAL

A062723 004 Nov 17, 1986

EQ 20GM BASE/VIAL

A062723 005 Nov 17, 1986

WEST-WARD PHARMS INT

EQ 500MG BASE/VIAL

A062720 001 Jul 02, 1987

EQ 1GM BASE/VIAL

A062720 002 Jul 02, 1987

EQ 2GM BASE/VIAL

A062720 003 Jul 02, 1987

EQ 20GM BASE/VIAL

A062720 004 Jul 02, 1987

CEPHRADINE

CAPSULE; ORAL

ANSPOR

GLAXOSMITHKLINE

250MG

A061859 001

500MG

A061859 002

CEPHRADINE

BARR

250MG

A062850 001 Apr 22, 1988

500MG

A062851 001 Apr 22, 1988

IVAX SUB TEVA PHARMS

250MG

A062762 001 Mar 06, 1987

500MG

A062762 002 Mar 06, 1987

TEVA

250MG

A062683 001 Jan 09, 1987

500MG

A062683 002 Jan 09, 1987

VITARINE

250MG

A062813 001 Feb 25, 1988

500MG

A062813 002 Feb 25, 1988

VELOSEF

APOTHECON

250MG

A061764 001

500MG

A061764 002

VELOSEF '250'

ERSANA

250MG

N050548 001

VELOSEF '500'

ERSANA

500MG

N050548 002

FOR SUSPENSION; ORAL

ANSPOR

GLAXOSMITHKLINE

125MG/5ML

A061866 001

250MG/5ML

A061866 002

CEPHRADINE

BARR

125MG/5ML

A062858 001 May 19, 1988

250MG/5ML

A062859 001 May 19, 1988

TEVA

125MG/5ML

A062693 001 Jan 09, 1987

250MG/5ML

A062693 002 Jan 09, 1987

VELOSEF '125'

APOTHECON

125MG/5ML

A061763 001

VELOSEF '250'

APOTHECON

250MG/5ML

A061763 002

INJECTABLE; INJECTION

VELOSEF

APOTHECON

250MG/VIAL

A061976 001

500MG/VIAL

A061976 002

1GM/VIAL

A061976 004

2GM/VIAL

A061976 003

4GM/VIAL

A061976 005

TABLET; ORAL

VELOSEF

BRISTOL MYERS SQUIBB

1GM

N050530 001

CERITINIB

CAPSULE; ORAL

ZYKADIA

+ NOVARTIS

150MG

N205755 001 Apr 29, 2014

CERIVASTATIN SODIUM

TABLET; ORAL

BAYCOL

BAYER PHARMS

0.05MG

N020740 001 Jun 26, 1997

0.1MG

N020740 002 Jun 26, 1997

0.2MG

N020740 003 Jun 26, 1997

0.3MG

N020740 004 Jun 26, 1997

0.4MG

N020740 005 May 24, 1999

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CERIVASTATIN SODIUM

TABLET; ORAL

BAYCOL

0.8MG

N020740 006 Jul 24, 2000

CERULETIDE DIETHYLAMINE

INJECTABLE; INJECTION

TYMTRAN

PHARMACIA AND UPJOHN 0.02MG/ML

N018296 001

CETIRIZINE HYDROCHLORIDE

CAPSULE; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

CATALENT 10MG

A213105 001 Sep 21, 2020

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC 5MG/5ML

A078617 001 Feb 02, 2010

AUROBINDO PHARMA LTD 5MG/5ML

A090751 001 Dec 16, 2009

LANNETT CO INC 5MG/5ML

A078496 001 Sep 25, 2009

PHARM ASSOC 5MG/5ML

A078412 001 Jun 18, 2008

RANBAXY LABS LTD 5MG/5ML

A077472 001 Jun 18, 2008

TORRENT 5MG/5ML

A078870 001 Apr 27, 2009

WOCKHARDT 5MG/5ML

A078757 001 Aug 28, 2009

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

ACTAVIS MID ATLANTIC 5MG/5ML

A090378 002 May 09, 2008

CYPRESS PHARM 5MG/5ML

A090300 001 Oct 10, 2008

PHARM ASSOC 5MG/5ML

A090188 002 Apr 22, 2008

RANBAXY LABS LTD 5MG/5ML

A090183 002 Apr 24, 2008

TORRENT 5MG/5ML

A090474 002 Mar 30, 2009

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

ACTAVIS MID ATLANTIC 5MG/5ML

A090378 001 May 09, 2008

CYPRESS PHARM 5MG/5ML

A090300 002 Oct 10, 2008

PHARM ASSOC 5MG/5ML

A090188 001 Apr 22, 2008

RANBAXY LABS LTD 5MG/5ML

A090183 001 Apr 24, 2008

TORRENT 5MG/5ML

A090474 001 Mar 30, 2009

ZYRTEC

J AND J CONSUMER INC 5MG/5ML **

N020346 001 Sep 27, 1996

TABLET; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

HERITAGE PHARMA 5MG

A078615 003 Dec 28, 2007

10MG

A078615 004 Dec 28, 2007

SUN PHARM INDS INC 5MG

A077499 001 Dec 27, 2007

10MG

A077499 002 Dec 27, 2007

TORRENT PHARMS LLC 5MG

A079191 001 Apr 15, 2010

10MG

A079191 004 Apr 15, 2010

UNICHEM 5MG

A078680 003 Jun 26, 2009

10MG

A078680 004 Jun 26, 2009

CETIRIZINE HYDROCHLORIDE HIVES

SUN PHARM INDS INC 5MG

A077499 003 Dec 27, 2007

10MG

A077499 004 Dec 27, 2007

UNICHEM 5MG

A078680 001 Jun 26, 2009

10MG

A078680 002 Jun 26, 2009

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

TORRENT PHARMS LLC 5MG

A079191 003 Apr 15, 2010

10MG

A079191 002 Apr 15, 2010

ZYRTEC ALLERGY

+ J AND J CONSUMER INC 5MG

N019835 003 Nov 16, 2007

ZYRTEC HIVES RELIEF

+ J AND J CONSUMER INC 5MG

N019835 005 Nov 16, 2007

+ 10MG

N019835 006 Nov 16, 2007

TABLET, CHEWABLE; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

SUN PHARM INDS INC 5MG

A077631 004 Jan 11, 2008

10MG

A077631 003 Jan 11, 2008

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

SUN PHARM INDS INC 5MG

A077631 001 Jan 11, 2008

10MG

A077631 002 Jan 11, 2008

CHILDREN'S ZYRTEC ALLERGY

+ J AND J CONSUMER INC 5MG **

N021621 003 Nov 16, 2007

+ 10MG **

N021621 004 Nov 16, 2007

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CETIRIZINE HYDROCHLORIDE

TABLET, CHEWABLE;ORAL

CHILDREN'S ZYRTEC HIVES RELIEF

+ J AND J CONSUMER INC 5MG **

N021621 005 Nov 16, 2007

+ 10MG **

N021621 006 Nov 16, 2007

CETRORELIX

INJECTABLE;INJECTION

CETROTIDE

EMD SERONO INC EQ 3MG BASE/ML

N021197 002 Aug 11, 2000

CETYL ALCOHOL; COLFOSCERIL PALMITATE; TYLOXAPOL

FOR SUSPENSION;INTRATRACHEAL

EXOSURF NEONATAL

GLAXOSMITHKLINE 12MG/VIAL;108MG/VIAL;8MG/VIAL

N020044 001 Aug 02, 1990

CEVIMELINE HYDROCHLORIDE

CAPSULE;ORAL

CEVIMELINE HYDROCHLORIDE

APOTEX INC 30MG

A091260 001 Aug 25, 2011

CHENODIOL

TABLET;ORAL

CHENIX

+ LEADIANT BIOSCI INC 250MG **

N018513 002 Jul 28, 1983

CHLOPHEDIANOL HYDROCHLORIDE

SYRUP;ORAL

ULO

3M 25MG/5ML

N012126 001

CHLORAMPHENICOL

CREAM;TOPICAL

CHLOROMYCETIN

PARKE DAVIS 1%

N050183 001

FOR SOLUTION;OPHTHALMIC

CHLOROMYCETIN

PARKEDALE 25MG/VIAL

N050143 001

INJECTABLE;INJECTION

CHLOROMYCETIN

PARKE DAVIS 250MG/ML

N050153 001

OINTMENT;OPHTHALMIC

CHLORAMPHENICOL

ALTANA 1%

A060133 001

CHLOROFAIR

PHARMAFAIR 1%

A062439 001 Apr 21, 1983

CHLOROMYCETIN

PARKEDALE 1%

N050156 001

CHLOROPTIC S.O.P.

ALLERGAN 1%

A061187 001

ECONOCHLOR

ALCON 1%

A061648 001

SOLUTION/DROPS;OPHTHALMIC

CHLORAMPHENICOL

AKORN 0.5%

A062042 001

ALCON 0.5%

A062628 001 Sep 25, 1985

CHLOROFAIR

PHARMAFAIR 0.5%

A062437 001 Apr 14, 1983

CHLOROPTIC

ALLERGAN 0.5%

N050091 001

ECONOCHLOR

ALCON 0.5%

A061645 001

OPHTHOCHLOR

PARKEDALE 0.5%

A061220 001

OPTOMYCIN

OPTOPICS 0.5%

A062171 001 Mar 31, 1982

SOLUTION/DROPS;OTIC

CHLOROMYCETIN

PARKEDALE 0.5%

N050205 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION

CHLORAMPHENICOL

ELKINS SINN EQ 1GM BASE/VIAL

A062406 001 Nov 09, 1982

CHLORAMPHENICOL SODIUM SUCCINATE

GRUPPO LEPETIT EQ 1GM BASE/VIAL

A062278 001

CHLOROMYCETIN

+ PARKE DALE EQ 1GM BASE/VIAL

N050155 001

MYCHEL-S

ANGUS EQ 1GM BASE/VIAL

A060132 001

CHLORAMPHENICOL; HYDROCORTISONE ACETATE

FOR SUSPENSION; OPHTHALMIC

CHLOROMYCETIN HYDROCORTISONE

PARKE DALE 12.5MG/VIAL; 25MG/VIAL

N050202 001

CHLORAMPHENICOL; HYDROCORTISONE ACETATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

OPHTHOCORT

PARKE DALE 10MG/GM; 5MG/GM; 10,000 UNITS/GM

N050201 002

CHLORAMPHENICOL; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

CHLOROMYCIN

PARKE DAVIS 1%; 10,000 UNITS/GM

N050203 002

CHLORAMPHENICOL; PREDNISOLONE

OINTMENT; OPHTHALMIC

CHLOROPTIC-P S.O.P.

ALLERGAN 1%; 0.5%

A061188 001

CHLORDIAZEPOXIDE

CAPSULE, EXTENDED RELEASE; ORAL

LIBRELEAS

VALEANT PHARM INTL 30MG

N017813 001 Sep 12, 1983

TABLET; ORAL

LIBRITABS

VALEANT PHARM INTL 5MG

A085482 001

10MG A085481 001

25MG A085488 001

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

A-POXIDE

ABBOTT 5MG

A085447 001

5MG A085517 001

10MG A085447 002

10MG A085518 001

25MG A085447 003

25MG A085513 001

CHLORDIAZACHEL

RACHELLE 5MG

A085086 001

10MG A084639 001

25MG A085087 001

CHLORDIAZEPOXIDE HYDROCHLORIDE

ASCOT 5MG

A087525 001 Jan 07, 1982

10MG A087524 001 Jan 07, 1982

25MG A087512 001 Jan 07, 1982

FERRANTE 5MG A085118 001

10MG A085119 001

25MG A085120 001

HALSEY 5MG A085340 001

10MG A085339 001

25MG A084685 001

IMPAX LABS 5MG A086213 001

10MG A085113 001

25MG A086212 001

IVAX SUB TEVA PHARMS 5MG A083741 001

10MG A083742 001

25MG A083570 001

LEDERLE 5MG A086892 001

5MG A087234 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE

	10MG	A086876	001	
	10MG	A087037	001	
	25MG	A086893	001	
	25MG	A087231	001	
MAST MM	10MG	A086217	001	
MYLAN	5MG	A084886	001	
	10MG	A084601	001	
	25MG	A084887	001	
PARKE DAVIS	5MG	A085163	001	
	10MG	A084598	001	
	25MG	A085164	001	
PIONEER PHARMS	10MG	A089533	001	Jul 15, 1988
	25MG	A089558	001	Jul 15, 1988
PUREPAC PHARM	5MG	A085155	001	
	10MG	A084939	002	
	25MG	A085144	001	
ROXANE	5MG	A084706	001	
	10MG	A084700	001	
	25MG	A084705	001	
SUPERPHARM	5MG	A088987	001	Apr 25, 1985
	10MG	A088986	001	Apr 25, 1985
	25MG	A088988	001	Apr 25, 1985
TEVA	5MG	A088705	001	Jan 18, 1985
	10MG	A088706	001	Jan 18, 1985
	25MG	A086494	001	
	25MG	A088707	001	Jan 18, 1985
UPSHER SMITH LABS	5MG	A084678	001	
	5MG	A084919	001	
	10MG	A084041	001	
	10MG	A084920	001	
	25MG	A084679	002	
	25MG	A084823	001	
USL PHARMA	5MG	A084644	001	
	10MG	A084623	001	
	25MG	A084645	001	
VANGARD	5MG	A088129	001	Mar 28, 1983
	10MG	A088010	001	Mar 28, 1983
	25MG	A088130	001	Mar 28, 1983
WATSON LABS	5MG	A086383	001	
	10MG	A086294	001	
	25MG	A086382	001	
WEST WARD	5MG	A085014	001	
	10MG	A085000	001	
	25MG	A085294	001	
LIBRIUM				
+ VALEANT PHARM INTL	5MG **	N012249	002	
+	10MG **	N012249	001	
+	25MG **	N012249	003	
LYGEN				
ALRA	5MG	A085107	001	
	10MG	A085009	001	
	25MG	A085108	001	

INJECTABLE; INJECTION

LIBRIUM

BAUSCH 100MG/AMP N012301 001

CHLORDIAZEPOXIDE; ESTROGENS, ESTERIFIED

TABLET; ORAL

MENRIUM 10-4				
ROCHE	10MG; 0.4MG	N014740	006	
MENRIUM 5-2				
ROCHE	5MG; 0.2MG	N014740	002	
MENRIUM 5-4				
ROCHE	5MG; 0.4MG	N014740	004	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

CHLORHEXIDINE GLUCONATE

BAJAJ

0.12%

A075561 001 Nov 14, 2000

SOLUTION; TOPICAL

EXIDINE

XTTRIUM

2.5%

N019421 001 Dec 17, 1985

MICRODERM

J AND J

4%

A072255 001 Apr 15, 1991

PREVACARE R

J AND J

0.5%

A072292 001 Jan 28, 1992

STERI-STAT

MATRIX MEDCL

4%

A070104 001 Jul 24, 1986

SPONGE; TOPICAL

CHLORHEXIDINE GLUCONATE

KENDALL IL

4%

N019490 001 Mar 27, 1987

E-Z SCRUB

BECTON DICKINSON

4%

A073416 001 Mar 14, 2000

HIBICLENS

+ MOLNLYCKE HLTH

4% **

N018423 001

MICRODERM

J AND J

4%

A072295 001 Feb 28, 1991

PHARMASEAL SCRUB CARE

CAREFUSION 2200

4%

N019793 001 Dec 02, 1988

CHLORMERODRIN HG-197

INJECTABLE; INJECTION

CHLORMERODRIN HG 197

BRACCO

0.6-1.4mCi/ML

N017269 001

CHLORMEZANONE

TABLET; ORAL

TRANCOPAL

SANOFI AVENTIS US

100MG

N011467 003

200MG

N011467 005

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

NESACAINE-MPF

FRESENIUS KABI USA

2%

N009435 003

3%

N009435 004

CHLOROQUINE HYDROCHLORIDE

INJECTABLE; INJECTION

ARALEN HYDROCHLORIDE

SANOFI AVENTIS US

EQ 40MG BASE/ML

N006002 002

CHLOROQUINE PHOSPHATE

TABLET; ORAL

ARALEN

+ SANOFI AVENTIS US

500MG

N006002 001

CHLOROQUINE PHOSPHATE

HIKMA PHARMS

250MG

A083082 001

500MG

A083082 002 Sep 17, 1999

IMPAX LABS

250MG

A080880 001

500MG

A040516 001 Aug 29, 2003

MD PHARM

250MG

A087228 001

PUREPAC PHARM

250MG

A080886 001

TEVA

250MG

A087504 001 Jan 13, 1982

WATSON LABS

250MG

A087979 001 Dec 21, 1982

500MG

A088030 001 Dec 21, 1982

CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE

TABLET; ORAL

ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE

SANOFI AVENTIS US

EQ 300MG BASE; EQ 45MG BASE

N014860 002

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CHLOROTHIAZIDE

TABLET; ORAL

CHLOROTHIAZIDE

ABC HOLDING	250MG	A085569	001	
HIKMA INTL PHARMS	250MG	A086028	001	Jul 14, 1982
	500MG	A087736	001	Jul 14, 1982
LEDERLE	250MG	A086940	001	
	500MG	A086938	001	
MYLAN	250MG	A084217	002	
	500MG	A084217	001	
SANDOZ	250MG	A085485	001	
WATSON LABS	250MG	A085165	001	
	250MG	A085173	001	
	250MG	A086795	001	Aug 15, 1983
	500MG	A084026	001	Sep 01, 1982
	500MG	A086796	001	Aug 15, 1983
DIURIL				
+ AKORN	250MG **	N011145	004	
+	500MG **	N011145	002	

CHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

ALDOCLOR-150

MERCK	150MG;250MG	N016016	001	
-------	-------------	---------	-----	--

ALDOCLOR-250

MERCK	250MG;250MG	N016016	002	
-------	-------------	---------	-----	--

METHYLDOPA AND CHLOROTHIAZIDE

PAR PHARM	150MG;250MG	A070783	001	Nov 06, 1987
	250MG;250MG	A070654	001	Nov 06, 1987

CHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

CHLOROTHIAZIDE AND RESERPINE

HIKMA	250MG;0.125MG	A088557	001	Dec 22, 1983
	500MG;0.125MG	A088365	001	Dec 22, 1983

CHLOROTHIAZIDE W/ RESERPINE

WATSON LABS	250MG;0.125MG	A084853	001	
	500MG;0.125MG	A088151	001	Jun 09, 1983

CHLOROTHIAZIDE-RESERPINE

MYLAN	250MG;0.125MG	A087744	001	May 06, 1982
	500MG;0.125MG	A087745	001	May 06, 1982

DIUPRES-250

MERCK	250MG;0.125MG	N011635	003	Aug 26, 1987
-------	---------------	---------	-----	--------------

DIUPRES-500

MERCK	500MG;0.125MG	N011635	006	Aug 26, 1987
-------	---------------	---------	-----	--------------

CHLOROTRIANISENE

CAPSULE; ORAL

CHLOROTRIANISENE

BANNER PHARMACAPS	12MG	A084652	001	
-------------------	------	---------	-----	--

TACE

SANOFI AVENTIS US	12MG	N008102	004	
	25MG	N011444	001	
	72MG	N016235	001	

CHLOROXYLINE

SHAMPOO; TOPICAL

CAPITROL

WESTWOOD SQUIBB	2%	N017594	001	
-----------------	----	---------	-----	--

CHLORPHENESIN CARBAMATE

TABLET; ORAL

MAOLATE

PAMLAB LLC	400MG	N014217	002	
------------	-------	---------	-----	--

CHLORPHENIRAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

CHLORPHENIRAMINE MALEATE

AUROLIFE PHARMA LLC	12MG	A070797	001	Aug 12, 1988
---------------------	------	---------	-----	--------------

TELDRIN

GLAXOSMITHKLINE	8MG	N017369	001	
	12MG	N017369	002	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CHLORPHENIRAMINE MALEATE

INJECTABLE; INJECTION

CHLOR-TRIMETON

SCHERING PLOUGH	10MG/ML	N008826	001
	100MG/ML	N008794	001

CHLORPHENIRAMINE MALEATE

BEL MAR	10MG/ML	A080821	001
ELKINS SINN	10MG/ML	A080797	001
WATSON LABS	10MG/ML	A083593	001
	10MG/ML	A086096	001
	100MG/ML	A086095	001

PYRIDAMAL 100

BEL MAR	100MG/ML	A083733	001
---------	----------	---------	-----

SYRUP; ORAL

CHLOR-TRIMETON

SCHERING	2MG/5ML	N006921	006
----------	---------	---------	-----

CHLORPHENIRAMINE MALEATE

PHARM ASSOC	2MG/5ML	A087520	001 Feb 10, 1982
-------------	---------	---------	------------------

TABLET; ORAL

ANTAGONATE

BAYER PHARMS	4MG	A083381	001
--------------	-----	---------	-----

CHLOR-TRIMETON

SCHERING	4MG	N006921	002
----------	-----	---------	-----

CHLORPHENIRAMINE MALEATE

ANABOLIC	4MG	A083078	001
AUROLIFE PHARMA LLC	4MG	A080961	001
BELL PHARMA	4MG	A083062	001
ELKINS SINN	4MG	A080938	001
IMPAX LABS	4MG	A080809	001
IVAX SUB TEVA PHARMS	4MG	A080779	001
KV PHARM	4MG	A087164	001
LEDERLE	4MG	A086941	001
NEWTRON PHARMS	4MG	A086519	001
PANRAY	4MG	A083243	001
PHARMAVITE	4MG	A085104	001
PHARMERAL	4MG	A083753	001
PIONEER PHARMS	4MG	A088556	001 Jul 13, 1984
PUREPAC PHARM	4MG	A086306	001
PVT FORM	4MG	A080786	001
ROXANE	4MG	A080626	001
SUN PHARM INDUSTRIES	4MG	A080700	001
VITARINE	4MG	A085837	001
WATSON LABS	4MG	A080696	001
	4MG	A080791	001
	4MG	A085139	001
WEST WARD	4MG	A083787	001

KLOROMIN

HALSEY	4MG	A083629	001
--------	-----	---------	-----

PHENETRON

LANNETT	4MG	A080846	001
---------	-----	---------	-----

TABLET, EXTENDED RELEASE; ORAL

CHLOR-TRIMETON

+ BAYER HEALTHCARE LLC	8MG **	N007638	001
+	12MG **	N007638	002

EFIDAC 24 CHLORPHENIRAMINE MALEATE

ALZA	16MG	N019746	002 Nov 18, 1994
------	------	---------	------------------

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE

ACELLA	4MG/5ML; 5MG/5ML	A206891	001 Jun 09, 2017
TRIS PHARMA INC	4MG/5ML; 5MG/5ML	A206438	001 Jan 27, 2015

VITUZ

+ PERSION	4MG/5ML; 5MG/5ML	N204307	001 Feb 20, 2013
-----------	------------------	---------	------------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

MAYNE PHARMA INC	4MG/5ML;5MG/5ML;60MG/5ML	A205657 001	Aug 03, 2015
TORRENT	4MG/5ML;5MG/5ML;60MG/5ML	A206660 001	May 15, 2017
TRIS PHARMA INC	4MG/5ML;5MG/5ML;60MG/5ML	A203838 001	Nov 26, 2014

ZUTRIPRO

+ PERSION	4MG/5ML;5MG/5ML;60MG/5ML	N022439 001	Jun 08, 2011
-----------	--------------------------	-------------	--------------

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

COLD CAPSULE IV

GRAHAM DM	12MG;75MG	N018793 001	Apr 25, 1985
-----------	-----------	-------------	--------------

COLD CAPSULE V

GRAHAM DM	8MG;75MG	N018794 001	Apr 23, 1985
-----------	----------	-------------	--------------

TABLET, EXTENDED RELEASE;ORAL

TRIAMINIC-12

NOVARTIS	12MG;75MG	N018115 001	
----------	-----------	-------------	--

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

CODIMAL-L.A. 12

SCHWARZ PHARMA	12MG;120MG	N018935 001	Apr 15, 1985
----------------	------------	-------------	--------------

ISOCOLOR

FISONS	8MG;120MG	N018747 001	Mar 06, 1986
--------	-----------	-------------	--------------

PSEUDOEPHEDRINE HYDROCHLORIDE AND CHLORPHENIRAMINE MALEATE

CENT PHARMS	8MG;120MG	N019428 001	Aug 02, 1988
-------------	-----------	-------------	--------------

GRAHAM DM	8MG;120MG	N018844 001	Mar 20, 1985
-----------	-----------	-------------	--------------

	12MG;120MG	N018843 001	Mar 18, 1985
--	------------	-------------	--------------

KV PHARM	12MG;120MG	A071455 001	Mar 01, 1989
----------	------------	-------------	--------------

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

CHLOR-TRIMETON

+ BAYER HEALTHCARE LLC	8MG;120MG	N018397 001	
------------------------	-----------	-------------	--

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL

CODEPREX

LANNETT CO INC	EQ 4MG MALEATE/5ML;EQ 20MG BASE/5ML	N021369 001	Jun 21, 2004
----------------	-------------------------------------	-------------	--------------

PENNTUSS

FISONS	EQ 4MG MALEATE/5ML;EQ 10MG BASE/5ML	N018928 001	Aug 14, 1985
--------	-------------------------------------	-------------	--------------

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL

TUSSIONEX PENNKINETIC

+ UCB INC	EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML **	N019111 001	Dec 31, 1987
-----------	--	-------------	--------------

CHLORPHERMINE HYDROCHLORIDE

TABLET;ORAL

PRE-SATE

PARKE DAVIS	EQ 65MG BASE	N014696 001	
-------------	--------------	-------------	--

CHLORPROMAZINE

SUPPOSITORY;RECTAL

THORAZINE

+ GLAXOSMITHKLINE	25MG **	N009149 024	
-------------------	---------	-------------	--

+ GLAXOSMITHKLINE	100MG **	N009149 033	
-------------------	----------	-------------	--

CHLORPROMAZINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

THORAZINE

GLAXOSMITHKLINE	30MG	N011120 016	
-----------------	------	-------------	--

	75MG	N011120 017	
--	------	-------------	--

	150MG	N011120 018	
--	-------	-------------	--

	200MG	N011120 019	
--	-------	-------------	--

	300MG	N011120 020	
--	-------	-------------	--

CONCENTRATE;ORAL

CHLORPROMAZINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC	100MG/ML	A086863 001	
----------------------	----------	-------------	--

PHARM ASSOC	30MG/ML	A040231 001	Dec 30, 1999
-------------	---------	-------------	--------------

	100MG/ML	A040224 001	Jan 26, 1999
--	----------	-------------	--------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

CHLORPROMAZINE HYDROCHLORIDE

WOCKHARDT	30MG/ML	A087032	001	Jul 08, 1982
	100MG/ML	A087053	001	

CHLORPROMAZINE HYDROCHLORIDE INTENSOL

HIKMA	30MG/ML	A088157	001	Apr 27, 1983
	100MG/ML	A088158	001	Apr 27, 1983

SONAZINE

FOSUN PHARMA	30MG/ML	A080983	004	
	100MG/ML	A080983	005	

THORAZINE

+	GLAXOSMITHKLINE	30MG/ML **	N009149	032
+		100MG/ML **	N009149	043

INJECTABLE; INJECTION

CHLORPROMAZINE HYDROCHLORIDE

ABRAXIS PHARM	25MG/ML	A084911	001	
DR REDDYS	25MG/ML	A080365	001	
MARSAM PHARMS LLC	25MG/ML	A089563	001	Apr 15, 1988
WATSON LABS	25MG/ML	A085591	001	
WYETH AYERST	25MG/ML	A080370	001	

THORAZINE

+	GLAXOSMITHKLINE	25MG/ML **	N009149	011
---	-----------------	------------	---------	-----

SYRUP; ORAL

CHLORPROMAZINE HYDROCHLORIDE

ALPHARMA US PHARMS	10MG/5ML	A086712	001	
--------------------	----------	---------	-----	--

SONAZINE

FOSUN PHARMA	10MG/5ML	A083040	001	
--------------	----------	---------	-----	--

THORAZINE

+	GLAXOSMITHKLINE	10MG/5ML **	N009149	022
---	-----------------	-------------	---------	-----

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

ABBOTT	10MG	A084414	001	
	25MG	A084415	001	
	50MG	A084411	001	
	100MG	A084412	001	
	200MG	A084413	001	
CYCLE PHARMS LTD	10MG	A085331	001	
	25MG	A085331	002	
	50MG	A085331	003	
	100MG	A085331	004	
	200MG	A085331	005	
IVAX SUB TEVA PHARMS	10MG	A083549	001	
	25MG	A083549	002	
	50MG	A083549	003	
	100MG	A083574	001	
	200MG	A083575	001	
KV PHARM	10MG	A085750	002	Jan 04, 1982
	25MG	A085751	001	
	50MG	A085484	001	
	100MG	A085752	001	
	200MG	A085748	002	Jan 04, 1982
LEDERLE	10MG	A084803	001	
	25MG	A084801	001	
	50MG	A084800	001	
	100MG	A084789	001	
	200MG	A084802	001	
PUREPAC PHARM	10MG	A080403	004	
	25MG	A080403	001	
	50MG	A080403	002	
	100MG	A080403	003	
	200MG	A080403	005	
PVT FORM	25MG	A080340	001	
	50MG	A080340	002	
	200MG	A080340	003	
SANDOZ	10MG **	A080439	001	
	25MG **	A080439	002	
	50MG **	A080439	003	
	100MG **	A080439	004	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CHLORPROMAZINE HYDROCHLORIDE

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

	200MG **	A080439 005	
VANGARD	10MG	A088038 001	Aug 16, 1982
	25MG	A087645 001	
	50MG	A087646 001	
WATSON LABS	10MG	A085959 001	
	25MG	A085956 001	
	50MG	A085960 001	
	100MG	A085957 001	
	200MG	A085958 001	
WEST WARD	10MG	A087783 001	Sep 16, 1982
	25MG	A087865 001	Sep 16, 1982
	50MG	A087878 001	Sep 15, 1982
	100MG	A087884 001	Sep 15, 1982
	200MG	A087880 001	Sep 16, 1982
PROMAPAR			
PARKE DAVIS	10MG	A086886 001	
	25MG	A084423 001	
	50MG	A086887 001	
	100MG	A086888 001	
	200MG	A086885 001	
THORAZINE			
GLAXOSMITHKLINE	10MG **	N009149 002	
	25MG **	N009149 007	
	50MG **	N009149 013	
	100MG **	N009149 018	
	200MG **	N009149 020	

CHLORPROPAMIDE

TABLET;ORAL

CHLORPROPAMIDE

ANI PHARMS INC	100MG	A088768 001	Oct 11, 1984
	100MG	A088812 001	Oct 19, 1984
	100MG	A088840 001	Oct 25, 1984
	100MG	A088918 001	Oct 16, 1984
	100MG	A088921 001	Apr 12, 1985
	100MG	A089446 001	Nov 17, 1986
	250MG	A087353 001	
	250MG	A088813 001	Oct 19, 1984
	250MG	A088826 001	Sep 26, 1984
	250MG	A088919 001	Oct 16, 1984
	250MG	A088922 001	Apr 12, 1985
	250MG	A089447 001	Nov 17, 1986
AUROLIFE PHARMA LLC	100MG	A088725 001	Aug 31, 1984
	250MG	A088726 001	Aug 31, 1984
DAVA PHARMS INC	100MG	A089561 001	Sep 04, 1987
	250MG	A089562 001	Sep 04, 1987
HALSEY	100MG	A089321 001	Jan 16, 1986
	250MG	A088662 001	Jan 09, 1986
MYLAN	100MG	A088549 002	Jun 01, 1984
	250MG	A088549 001	Jun 01, 1984
PAR PHARM	100MG	A088175 001	Feb 27, 1984
	250MG	A088176 001	Feb 27, 1984
SANDOZ	250MG	A084669 001	
SUPERPHARM	100MG	A088694 001	Sep 17, 1984
	250MG	A088695 001	Sep 17, 1984
USL PHARMA	100MG	A088708 001	Aug 30, 1984
	250MG	A088709 001	Aug 30, 1984
WATSON LABS	100MG	A086865 001	Sep 24, 1984
	100MG	A088608 001	Apr 12, 1984
	250MG	A086866 001	
	250MG	A088568 001	Apr 12, 1984
WATSON LABS TEVA	100MG	A088852 001	Sep 26, 1984
DIABINESE			
+ PFIZER	100MG	N011641 003	
+	250MG	N011641 006	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CHLORPROPAMIDE

TABLET; ORAL

GLUCAMIDE

ANI PHARMS INC 250MG A088641 001 Oct 11, 1984

CHLORPROTHIXENE

CONCENTRATE; ORAL

TARACTAN

ROCHE 100MG/5ML N016149 002

INJECTABLE; INJECTION

TARACTAN

ROCHE 12.5MG/ML N012487 001

TABLET; ORAL

TARACTAN

ROCHE 10MG N012486 005

25MG N012486 004

50MG N012486 003

100MG N012486 001

CHLORTETRACYCLINE HYDROCHLORIDE

OINTMENT; OPHTHALMIC

AUREOMYCIN

LEDERLE 1% N050404 001

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

ABBOTT 25MG A087364 001

50MG A087384 001

ANI PHARMS INC 25MG A087296 001

25MG A087706 001

25MG A088164 001 Jan 09, 1984

50MG A087689 001

ASCOT 25MG A087698 001 Oct 20, 1982

50MG A087699 001 Oct 20, 1982

BARR LABS INC 25MG A088902 001 Sep 19, 1985

50MG A088903 001 Sep 19, 1985

COSETTE 50MG A088651 001 May 30, 1985

DAVA PHARMS INC 25MG A087451 001

50MG A087450 001

IVAX PHARMS 25MG A087555 001

50MG A087176 001

50MG A087947 001 Feb 27, 1984

KV PHARM 25MG A087311 001

50MG A087312 001

MUTUAL PHARM 25MG A087292 001

25MG A089738 001 Sep 19, 1988

50MG A087293 001

50MG A089739 001 Sep 19, 1988

PIONEER PHARMS 50MG A089591 001 Jul 21, 1988

PUREPAC PHARM 25MG A088139 001 Jul 16, 1986

50MG A088140 001 Aug 11, 1983

SANDOZ 25MG A087380 001

50MG A087118 001

50MG A087381 001

SUPERPHARM 25MG A087473 001 Feb 09, 1983

50MG A087247 001 Feb 09, 1983

USL PHARMA 25MG A089051 001 Jun 01, 1987

50MG A089052 001 Jun 01, 1987

VANGARD 25MG A088012 001 Jul 14, 1982

50MG A088073 001 Mar 25, 1983

WARNER CHILCOTT 25MG A087515 001 Jan 24, 1983

50MG A087516 001 Feb 09, 1983

WATSON LABS 25MG A087050 001

25MG A087100 001

50MG A087029 001

50MG A087082 001

50MG A087521 001

HYGROTON

+ SANOFI AVENTIS US 25MG ** N012283 004

+ 50MG ** N012283 003

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CHLORTHALIDONE

TABLET; ORAL

THALITONE

+	CASPER PHARMA LLC	15MG **	N019574 001	Dec 20, 1988
		25MG	N019574 002	Feb 12, 1992
	MONARCH PHARMS	25MG	A088051 001	Nov 12, 1982

CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLONIDINE HYDROCHLORIDE AND CHLORTHALIDONE

	PAR PHARM	15MG; 0.1MG	A071179 001	Dec 16, 1987
		15MG; 0.2MG	A071178 001	Dec 16, 1987
		15MG; 0.3MG	A071142 001	Dec 16, 1987

CLORPRES

	MYLAN	15MG; 0.1MG	A071325 003	Feb 09, 1987
		15MG; 0.2MG	A071325 002	Feb 09, 1987
		15MG; 0.3MG	A071325 001	Feb 09, 1987

COMBIPRES

+	BOEHRINGER INGELHEIM	15MG; 0.1MG **	N017503 001	
+		15MG; 0.2MG **	N017503 002	
+		15MG; 0.3MG **	N017503 003	Apr 10, 1984

CHLORTHALIDONE; METOPROLOL TARTRATE

CAPSULE; ORAL

LOPRESSIDONE

	NOVARTIS	25MG; 100MG	N019451 001	Dec 31, 1987
		25MG; 200MG	N019451 002	Dec 31, 1987

CHLORTHALIDONE; RESERPINE

TABLET; ORAL

DEMI-REGROTON

	SANOFI AVENTIS US	25MG; 0.125MG	N015103 002	
--	-------------------	---------------	-------------	--

REGROTON

	SANOFI AVENTIS US	50MG; 0.25MG	N015103 001	
--	-------------------	--------------	-------------	--

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

	ACTAVIS ELIZABETH	250MG	A088928 001	May 08, 1987
		500MG	A040113 001	Sep 29, 1995
	BARR	500MG	A089895 001	May 04, 1988
	OHM LABS	250MG	A081298 001	Dec 29, 1993
		500MG	A081299 001	Dec 29, 1993
	PAR PHARM	250MG	A087981 001	Sep 20, 1983
	PIONEER PHARMS	250MG	A089592 001	Jan 06, 1989
		500MG	A089948 001	Jan 06, 1989
	RISING	250MG	A089852 001	May 04, 1988
	SUN PHARM INDUSTRIES	500MG	A089970 001	Sep 27, 1990
	WATSON LABS	250MG	A086901 001	
		250MG	A086948 001	Aug 09, 1982
		500MG	A040137 001	Aug 09, 1996
		500MG	A081019 001	Jul 29, 1991
		500MG	A081040 001	Aug 22, 1989

PARAFLEX

+	ORTHO MCNEIL PHARM	250MG **	N011300 003	
---	--------------------	----------	-------------	--

PARAFON FORTE DSC

+	JANSSEN R AND D	500MG **	N011529 002	Jun 15, 1987
---	-----------------	----------	-------------	--------------

STRIFON FORTE DSC

	FERNDAL LABS	500MG	A081008 001	Dec 23, 1988
--	--------------	-------	-------------	--------------

CHOLESTYRAMINE

BAR, CHEWABLE; ORAL

CHOLYBAR

	PARKE DAVIS	EQ 4GM RESIN/BAR	A071621 001	May 26, 1988
		EQ 4GM RESIN/BAR	A071739 001	May 26, 1988

POWDER; ORAL

CHOLESTYRAMINE

	IVAX SUB TEVA PHARMS	EQ 4GM RESIN/PACKET	A074771 001	Jul 09, 1997
		EQ 4GM RESIN/SCOOPFUL	A074771 002	Jul 09, 1997
	TEVA	EQ 4GM RESIN/PACKET	A074347 001	May 28, 1998
		EQ 4GM RESIN/SCOOPFUL	A074347 002	May 28, 1998

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE LIGHT

TEVA

EQ 4GM RESIN/PACKET

A074348 001 May 28, 1998

EQ 4GM RESIN/SCOOPFUL

A074348 002 May 28, 1998

TEVA PHARMS

EQ 4GM RESIN/PACKET

A074555 001 Sep 30, 1998

EQ 4GM RESIN/SCOOPFUL

A074555 002 Sep 30, 1998

LOCHOLEST

CHARTWELL RX

EQ 4GM RESIN/PACKET

A074561 001 Aug 15, 1996

EQ 4GM RESIN/SCOOPFUL

A074561 002 Aug 15, 1996

LOCHOLEST LIGHT

ALLIED

EQ 4GM RESIN/PACKET

A074562 001 Aug 15, 1996

EQ 4GM RESIN/SCOOPFUL

A074562 002 Aug 15, 1996

QUESTRAN

+ BRISTOL MYERS

EQ 4GM RESIN/PACKET **

N016640 001

+

EQ 4GM RESIN/SCOOPFUL **

N016640 003

QUESTRAN LIGHT

+ BRISTOL MYERS

EQ 4GM RESIN/PACKET **

N019669 001 Dec 05, 1988

+

EQ 4GM RESIN/SCOOPFUL **

N019669 003 Dec 05, 1988

TABLET; ORAL

QUESTRAN

APOTHECON

EQ 800MG RESIN

A073403 002 Dec 27, 1999

EQ 1GM RESIN

A073403 001 Apr 28, 1994

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL

FENOFIBRIC ACID

MYLAN PHARMS INC

EQ 45MG FENOFIBRIC ACID

A200913 001 Mar 25, 2013

EQ 135MG FENOFIBRIC ACID

A200913 002 Mar 25, 2013

CHROMIC CHLORIDE

INJECTABLE; INJECTION

CHROMIC CHLORIDE

ABRAXIS PHARM

EQ 0.004MG CHROMIUM/ML

N019271 001 May 05, 1987

CHROMIC PHOSPHATE P-32

INJECTABLE; INJECTION

PHOSPHOCOL P32

CURIUM

5mCi/ML

N017084 001

CICLOPIROX

SOLUTION; TOPICAL

CICLOPIROX

ANDA REPOSITORY

8%

A077687 001 Sep 18, 2007

MYLAN PHARMS INC

8%

A078567 001 Sep 18, 2007

TEVA PHARMS

8%

A078079 001 Sep 18, 2007

CIDOFOVIR

INJECTABLE; INJECTION

VISTIDE

+ GILEAD SCIENCES INC

EQ 75MG BASE/ML **

N020638 001 Jun 26, 1996

CILASTATIN SODIUM; IMIPENEM

INJECTABLE; INJECTION

PRIMAXIN

MERCK

EQ 250MG BASE/VIAL; 250MG/VIAL

A062756 001 Jan 08, 1987

EQ 500MG BASE/VIAL; 500MG/VIAL

A062756 002 Jan 08, 1987

POWDER; INTRAMUSCULAR

PRIMAXIN

MERCK

EQ 500MG BASE/VIAL; 500MG/VIAL

N050630 001 Dec 14, 1990

EQ 750MG BASE/VIAL; 750MG/VIAL

N050630 002 Dec 14, 1990

POWDER; INTRAVENOUS

IMIPENEM AND CILASTATIN

HOSPIRA INC

EQ 250MG BASE/VIAL; 250MG/VIAL

A090825 001 Nov 16, 2011

EQ 500MG BASE/VIAL; 500MG/VIAL

A090825 002 Nov 16, 2011

EQ 500MG BASE/VIAL; 500MG/VIAL

A091007 001 Nov 16, 2011

PRIMAXIN

+ MERCK

EQ 250MG BASE/VIAL; 250MG/VIAL **

N050587 001 Nov 26, 1985

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CILOSTAZOL

TABLET;ORAL

CILOSTAZOL

ACTAVIS ELIZABETH	100MG	A077028	002	Nov 26, 2004
EPIC PHARMA LLC	50MG	A077150	001	Mar 11, 2005
	100MG	A077022	001	Nov 23, 2004
IVAX SUB TEVA PHARMS	100MG	A077020	002	Mar 01, 2005
MYLAN	50MG	A077323	002	Apr 20, 2006
	100MG	A077323	001	Apr 20, 2006
MYLAN PHARMS INC	50MG	A077019	001	Nov 23, 2004
	100MG	A077019	002	Nov 23, 2004
PLIVA HRVATSKA DOO	50MG	A077898	001	Oct 29, 2007
	100MG	A077898	002	Oct 29, 2007

PLETAL

+ OTSUKA	50MG **	N020863	001	Jan 15, 1999
+	100MG **	N020863	002	Jan 15, 1999

CIMETIDINE

SUSPENSION;ORAL

TAGAMET HB 200

GLAXOSMITHKLINE	200MG/20ML	N020951	001	Jul 09, 1999
-----------------	------------	---------	-----	--------------

TABLET;ORAL

CIMETIDINE

CHARTWELL MOLECULES	200MG	A074329	002	May 17, 1994
	300MG	A074329	003	May 17, 1994
	400MG	A074329	004	May 17, 1994
	800MG	A074329	001	May 17, 1994
CONTRACT PHARMACAL	200MG	A074961	001	Jun 19, 1998
	200MG	A074963	001	Jun 19, 1998
CYCLE PHARMS LTD	300MG	A074361	001	Dec 23, 1994
	400MG	A074361	002	Dec 23, 1994
	800MG	A074371	001	Dec 23, 1994
DAVA PHARMS INC	300MG	A074340	001	Jun 23, 1995
	400MG	A074340	002	Jun 23, 1995
	800MG	A074339	001	Jun 23, 1995
HIKMA	200MG	A074890	001	Dec 18, 1998
	300MG	A074890	002	Dec 18, 1998
	400MG	A074890	003	Dec 18, 1998
	800MG	A074890	004	Dec 18, 1998
IVAX SUB TEVA PHARMS	200MG	A074401	001	May 30, 1995
	200MG	A074424	001	Jul 28, 1995
	300MG	A074401	002	May 30, 1995
	300MG	A074424	002	Jul 28, 1995
	400MG	A074401	003	May 30, 1995
	400MG	A074424	003	Jul 28, 1995
	800MG	A074402	001	May 30, 1995
	800MG	A074424	004	Jul 28, 1995
PERRIGO	100MG	A074972	001	Jun 19, 1998
PLIVA	200MG	A074568	001	Feb 27, 1997
	300MG	A074568	002	Feb 27, 1997
	400MG	A074568	003	Feb 27, 1997
SANDOZ INC	100MG	A075122	001	Jun 19, 1998
	200MG	A074250	001	Jun 29, 1995
	200MG	A075122	002	Jun 19, 1998
	300MG	A074250	002	Jun 29, 1995
	400MG	A074250	003	Jun 29, 1995
	800MG	A074250	004	Jun 29, 1995
TEVA	200MG	A074365	001	Feb 28, 1995
	300MG	A074365	002	Feb 28, 1995
	400MG	A074365	003	Feb 28, 1995
	800MG	A074365	004	Feb 28, 1995
UPSHER SMITH LABS	200MG	A074506	001	Jan 24, 1996
	300MG	A074506	002	Jan 24, 1996
	400MG	A074506	003	Jan 24, 1996
	800MG	A074506	004	Jan 24, 1996
WATSON LABS INC	200MG	A074349	001	Aug 30, 1996
	300MG	A074349	002	Aug 30, 1996
	400MG	A074349	003	Aug 30, 1996
	800MG	A074316	001	Feb 28, 1996
WATSON LABS TEVA	200MG	A075425	001	Jul 29, 1999

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CIMETIDINE

TABLET; ORAL

CIMETIDINE

YAOPHARMA CO LTD	200MG	A074100 001	Jan 31, 1995
	300MG	A074100 002	Jan 31, 1995
	400MG	A074100 003	Jan 31, 1995
	800MG	A074100 004	Jan 31, 1995

TAGAMET

GLAXOSMITHKLINE	200MG **	N017920 002	
	300MG **	N017920 003	
	400MG **	N017920 004	Dec 14, 1983
	800MG **	N017920 005	Apr 30, 1986

TAGAMET HB

+ MEDTECH PRODUCTS	100MG **	N020238 001	Jun 19, 1995
--------------------	----------	-------------	--------------

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HYDROCHLORIDE

DAVA PHARMS INC	EQ 300MG BASE/2ML	A074428 001	Apr 25, 1996
HOSPIRA	EQ 300MG BASE/2ML	A074296 001	Mar 28, 1997
	EQ 300MG BASE/2ML	A074344 001	Jan 31, 1995
	EQ 300MG BASE/2ML	A074345 001	Jan 31, 1995
	EQ 300MG BASE/2ML	A074412 001	Mar 28, 1997
	EQ 300MG BASE/2ML	A074422 001	Jan 31, 1995
LUITPOLD	EQ 300MG BASE/2ML	A074353 001	Dec 20, 1994
TEVA PARENTERAL	EQ 300MG BASE/2ML	A074252 001	Nov 26, 1997
VINTAGE PHARMS LLC	EQ 300MG BASE/2ML	A074005 001	Aug 31, 1994

CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

HOSPIRA	EQ 6MG BASE/ML	A074269 001	Dec 27, 1994
	EQ 90MG BASE/100ML	A074468 005	Dec 29, 1994
	EQ 120MG BASE/100ML	A074468 006	Dec 29, 1994
	EQ 180MG BASE/100ML	A074468 003	Dec 29, 1994
	EQ 240MG BASE/100ML	A074468 004	Dec 29, 1994
	EQ 360MG BASE/100ML	A074468 001	Dec 29, 1994
	EQ 480MG BASE/100ML	A074468 002	Dec 29, 1994

TAGAMET

GLAXOSMITHKLINE	EQ 300MG BASE/2ML **	N017939 002	
TAGAMET HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
+ GLAXOSMITHKLINE	EQ 6MG BASE/ML **	N019434 001	Oct 31, 1985

SOLUTION; ORAL

CIMETIDINE HYDROCHLORIDE

ANI PHARMS INC	EQ 300MG BASE/5ML	A074610 001	Sep 26, 1996
	EQ 300MG BASE/5ML	A074859 001	Jul 09, 1998
	EQ 300MG BASE/5ML	A075110 001	Jun 18, 1998
CYCLE PHARMS LTD	EQ 300MG BASE/5ML	A074541 001	Aug 05, 1997
G AND W LABS INC	EQ 300MG BASE/5ML	A074176 001	Jun 01, 1994
LANNETT CO INC	EQ 300MG BASE/5ML	A074251 001	Dec 22, 1994
PHARM ASSOC	EQ 300MG BASE/5ML	A075560 001	Mar 15, 2000

TAGAMET

GLAXOSMITHKLINE	EQ 300MG BASE/5ML **	N017924 001	
-----------------	----------------------	-------------	--

CINACALCET HYDROCHLORIDE

TABLET; ORAL

CINACALCET HYDROCHLORIDE

LUPIN LTD	EQ 30MG BASE	A210548 001	Jun 28, 2019
	EQ 60MG BASE	A210548 002	Jun 28, 2019
	EQ 90MG BASE	A210548 003	Jun 28, 2019

CINOXACIN

CAPSULE; ORAL

CINOXACIN

LILLY	250MG	N018067 001	
	500MG	N018067 002	

CINOXACIN

TEVA	250MG	A073005 001	Feb 28, 1992
	500MG	A073006 001	Feb 28, 1992

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CIPROFLOXACIN

FOR SUSPENSION;ORAL

CIPROFLOXACIN

CHARTWELL

250MG/5ML

A200563 001 Mar 05, 2014

500MG/5ML

A200563 002 Mar 05, 2014

INJECTABLE;INJECTION

CIPRO

+ BAYER HLTHCARE

400MG/40ML (10MG/ML) **

N019847 001 Dec 26, 1990

+ BAYER HLTHCARE

200MG/20ML (10MG/ML) **

N019847 002 Dec 26, 1990

1200MG/120ML (10MG/ML) **

N019847 003 Dec 26, 1990

CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER

+ BAYER HLTHCARE

200MG/100ML **

N019857 001 Dec 26, 1990

+ BAYER HLTHCARE

400MG/200ML **

N019857 002 Dec 26, 1990

CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

BAYER PHARMS

200MG/100ML

N019858 001 Dec 26, 1990

CIPROFLOXACIN

BEDFORD LABS

200MG/20ML (10MG/ML)

A076992 001 Aug 28, 2006

400MG/40ML (10MG/ML)

A076992 002 Aug 28, 2006

1200MG/120ML (10MG/ML)

A076993 001 Aug 28, 2006

DR REDDYS

200MG/20ML (10MG/ML)

A077782 001 Aug 28, 2006

400MG/40ML (10MG/ML)

A077782 002 Aug 28, 2006

FRESENIUS KABI USA

200MG/20ML (10MG/ML)

A076484 001 Aug 28, 2006

400MG/40ML (10MG/ML)

A076484 002 Aug 28, 2006

CIPROFLOXACIN IN DEXTROSE 5%

HIKMA FARMACEUTICA

200MG/100ML

A076757 001 Apr 21, 2008

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE

200MG/100ML

A077888 001 Mar 18, 2008

400MG/200ML

A077888 002 Mar 18, 2008

BEDFORD

200MG/100ML

A078114 001 Mar 18, 2008

400MG/200ML

A078114 002 Mar 18, 2008

TEVA PHARMS

200MG/100ML

A077138 001 Mar 18, 2008

400MG/200ML

A077138 002 Mar 18, 2008

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CIPROFLOXACIN HYDROCHLORIDE

AMRING PHARMS

EQ 0.3% BASE

A078598 001 Jan 16, 2008

RUBICON

EQ 0.3% BASE

A075928 001 Jun 09, 2004

TABLET;ORAL

CIPRO

+ BAYER HLTHCARE

EQ 100MG BASE **

N019537 001 Apr 08, 1996

+ BAYER HLTHCARE

EQ 750MG BASE **

N019537 004 Oct 22, 1987

CIPROFLOXACIN HYDROCHLORIDE

ANI PHARMS INC

EQ 100MG BASE

A075939 001 Mar 03, 2005

EQ 250MG BASE

A075939 002 Jun 09, 2004

EQ 500MG BASE

A075939 003 Jun 09, 2004

EQ 750MG BASE

A075939 004 Jun 09, 2004

BARR

EQ 250MG BASE

A074124 001 Jun 09, 2004

EQ 500MG BASE

A074124 002 Jun 09, 2004

EQ 750MG BASE

A074124 003 Jun 09, 2004

FOSUN PHARMA

EQ 250MG BASE

A076593 002 Jun 09, 2004

EQ 500MG BASE

A076593 003 Jun 09, 2004

EQ 750MG BASE

A076593 004 Jun 09, 2004

MYLAN

EQ 100MG BASE

A075817 001 Jun 25, 2007

EQ 250MG BASE

A075685 002 Jun 09, 2004

EQ 250MG BASE

A075817 002 Jun 09, 2004

EQ 500MG BASE

A075685 003 Jun 09, 2004

EQ 750MG BASE

A075685 001 Jun 09, 2004

EQ 750MG BASE

A075817 004 Jun 09, 2004

NOSTRUM LABS

EQ 250MG BASE

A076138 001 Jun 09, 2004

EQ 500MG BASE

A076138 002 Jun 09, 2004

EQ 750MG BASE

A076138 003 Jun 09, 2004

PLIVA

EQ 100MG BASE

A076426 001 Jun 15, 2005

EQ 250MG BASE

A076426 002 Jun 15, 2005

EQ 500MG BASE

A076426 003 Jun 15, 2005

EQ 750MG BASE

A076426 004 Jun 15, 2005

SUN PHARM INDS LTD

EQ 250MG BASE

A075747 001 Jun 09, 2004

EQ 500MG BASE

A075747 002 Jun 09, 2004

EQ 750MG BASE

A075747 003 Jun 09, 2004

TEVA

EQ 250MG BASE

A076136 001 Jun 09, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

EQ 500MG BASE

A076136 002 Jun 09, 2004

EQ 750MG BASE

A076136 003 Jun 09, 2004

TABLET, EXTENDED RELEASE; ORAL

PROQUIN XR

DEPOMED INC

EQ 500MG BASE

N021744 001 May 19, 2005

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPRO XR

BAYER HLTHCARE

212.6MG;EQ 287.5MG BASE **

N021473 001 Dec 13, 2002

425.2MG;EQ 574.9MG BASE **

N021473 002 Aug 28, 2003

CIPROFLOXACIN EXTENDED RELEASE

ANI PHARMS INC

212.6MG;EQ 287.5MG BASE

A077809 002 Nov 30, 2010

425.2MG;EQ 574.9MG BASE

A077809 001 Nov 30, 2010

DR REDDYS LABS LTD

212.6MG;EQ 287.5MG BASE

A077701 002 Oct 31, 2007

FOSUN PHARMA

212.6MG;EQ 287.5MG BASE

A078712 001 Dec 11, 2007

MYLAN PHARMS INC

212.6MG;EQ 287.5MG BASE

A078183 001 Mar 22, 2007

425.2MG;EQ 574.9MG BASE

A078183 002 Mar 22, 2007

CISAPRIDE MONOHYDRATE

SUSPENSION; ORAL

PROPULSID

JANSSEN PHARMS

EQ 1MG BASE/ML

N020398 001 Sep 15, 1995

TABLET; ORAL

PROPULSID

JANSSEN PHARMS

EQ 10MG BASE

N020210 001 Jul 29, 1993

EQ 20MG BASE

N020210 002 Dec 23, 1993

TABLET, ORALLY DISINTEGRATING; ORAL

PROPULSID QUICKSOLV

JANSSEN PHARMA

EQ 20MG BASE

N020767 001 Nov 07, 1997

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION

CISATRACURIUM BESYLATE

ACCORD HLTHCARE

EQ 2MG BASE/ML

A205873 001 Jun 16, 2017

PIRAMAL HLTHCARE UK

EQ 2MG BASE/ML

A212190 001 May 04, 2020

CISATRACURIUM BESYLATE PRESERVATIVE FREE

ACCORD HLTHCARE

EQ 2MG BASE/ML

A205872 001 Jun 16, 2017

EQ 10MG BASE/ML

A205872 002 Jun 16, 2017

CISPLATIN

INJECTABLE; INJECTION

CISPLATIN

BEDFORD

10MG/VIAL

A074713 001 Nov 14, 2000

50MG/VIAL

A074713 002 Nov 14, 2000

MYLAN LABS LTD

1MG/ML

A091062 001 Apr 18, 2012

TEVA PHARMS USA

1MG/ML

A074814 001 May 16, 2000

PLATINOL

+ HQ SPCLT PHARMA

10MG/VIAL

N018057 001

+

50MG/VIAL

N018057 002

PLATINOL-AQ

+ HQ SPCLT PHARMA

0.5MG/ML

N018057 003 Jul 18, 1984

CITALOPRAM HYDROBROMIDE

CAPSULE; ORAL

CITALOPRAM HYDROBROMIDE

MYLAN PHARMS INC

EQ 10MG BASE

A077668 001 Feb 28, 2007

EQ 20MG BASE

A077668 002 Feb 28, 2007

EQ 40MG BASE

A077668 003 Feb 28, 2007

SOLUTION; ORAL

CELEXA

+ FOREST LABS

EQ 10MG BASE/5ML **

N021046 001 Dec 22, 1999

CITALOPRAM HYDROBROMIDE

PHARM ASSOC

EQ 10MG BASE/5ML

A077601 001 Nov 15, 2005

TABLET; ORAL

CELEXA

ALLERGAN

EQ 60MG BASE

N020822 004 Jul 17, 1998

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CITALOPRAM HYDROBROMIDE

TABLET;ORAL

CITALOPRAM HYDROBROMIDE

EPIC PHARMA LLC	EQ 10MG BASE	A077036 001	Oct 28, 2004
	EQ 20MG BASE	A077036 002	Oct 28, 2004
	EQ 40MG BASE	A077036 003	Oct 28, 2004
FOSUN PHARMA	EQ 10MG BASE	A077035 001	Oct 28, 2004
	EQ 10MG BASE	A077040 001	Aug 17, 2005
	EQ 20MG BASE	A077035 002	Oct 28, 2004
	EQ 20MG BASE	A077040 002	Aug 17, 2005
	EQ 40MG BASE	A077035 003	Oct 28, 2004
	EQ 40MG BASE	A077040 003	Aug 17, 2005
HERITAGE PHARMA	EQ 10MG BASE	A077033 001	Oct 28, 2004
	EQ 10MG BASE	A077034 001	Jun 30, 2005
	EQ 10MG BASE	A077213 001	Mar 31, 2006
	EQ 10MG BASE	A077232 001	Oct 31, 2005
	EQ 20MG BASE	A077033 002	Oct 28, 2004
	EQ 20MG BASE	A077034 002	Jun 30, 2005
	EQ 20MG BASE	A077213 002	Mar 31, 2006
	EQ 20MG BASE	A077232 002	Oct 31, 2005
	EQ 40MG BASE	A077033 003	Oct 28, 2004
	EQ 40MG BASE	A077034 003	Jun 30, 2005
	EQ 40MG BASE	A077213 003	Mar 31, 2006
	EQ 40MG BASE	A077232 003	Oct 31, 2005
JUBILANT GENERICS	EQ 10MG BASE	A205407 001	Dec 23, 2015
	EQ 20MG BASE	A205407 002	Dec 23, 2015
	EQ 40MG BASE	A205407 003	Dec 23, 2015
MYLAN	EQ 10MG BASE	A077039 001	Feb 03, 2005
	EQ 20MG BASE	A077039 002	Feb 03, 2005
	EQ 40MG BASE	A077039 003	Feb 03, 2005
MYLAN PHARMS INC	EQ 10MG BASE	A077037 001	Nov 05, 2004
	EQ 20MG BASE	A077037 002	Nov 05, 2004
	EQ 40MG BASE	A077037 003	Nov 05, 2004
NATCO PHARMA LTD	EQ 20MG BASE	A077141 002	Apr 10, 2008
	EQ 40MG BASE	A077141 001	Apr 10, 2008
ROXANE	EQ 10MG BASE	A077041 001	Nov 23, 2004
	EQ 20MG BASE	A077041 002	Nov 23, 2004
	EQ 40MG BASE	A077041 003	Nov 23, 2004
SUN PHARM INDS INC	EQ 10MG BASE	A077032 001	Nov 12, 2004
	EQ 20MG BASE	A077032 002	Nov 12, 2004
	EQ 40MG BASE	A077032 003	Nov 12, 2004
SUN PHARM INDUSTRIES	EQ 10MG BASE	A077052 001	Jul 03, 2006
	EQ 20MG BASE	A077052 002	Jul 03, 2006
	EQ 40MG BASE	A077052 003	Jul 03, 2006
TARO	EQ 10MG BASE	A077278 001	Mar 22, 2006
	EQ 20MG BASE	A077278 002	Mar 22, 2006
	EQ 40MG BASE	A077278 003	Mar 22, 2006

TABLET, ORALLY DISINTEGRATING;ORAL

CITALOPRAM HYDROBROMIDE

+ BIOVAIL LABS INTL	EQ 10MG BASE	N021763 001	Dec 20, 2005
+	EQ 20MG BASE	N021763 002	Dec 20, 2005
+	EQ 40MG BASE	N021763 003	Dec 20, 2005

CITRIC ACID; MAGNESIUM OXIDE; SODIUM CARBONATE

SOLUTION;IRRIGATION

IRRIGATING SOLUTION G IN PLASTIC CONTAINER

BAXTER HLTHCARE	3.24GM/100ML;380MG/100ML;430MG/100ML	N018519 001	Jun 22, 1982
UROLOGIC G IN PLASTIC CONTAINER			
HOSPIRA	3.24GM/100ML;380MG/100ML;430MG/100ML	N018904 001	May 27, 1983

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

FOR SOLUTION;ORAL

PREPOPIK

+ FERRING PHARMS INC	12GM/PACKET;3.5GM/PACKET;10MG/PACKET	N202535 001	Jul 16, 2012
----------------------	--------------------------------------	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CLADRIBINE

INJECTABLE; INJECTION

LEUSTATIN

+ JANSSEN PHARMS 1MG/ML ** N020229 001 Feb 26, 1993

CLARITHROMYCIN

FOR SUSPENSION; ORAL

BIAXIN

+ ABBVIE 125MG/5ML N050698 001 Dec 23, 1993

187MG/5ML N050698 003 Sep 30, 1998

+ 250MG/5ML N050698 002 Dec 23, 1993

CLARITHROMYCIN

SUN PHARM INDS LTD 125MG/5ML A065382 001 Aug 30, 2007

250MG/5ML A065382 002 Aug 30, 2007

TABLET; ORAL

BIAXIN

+ ABBVIE 250MG ** N050662 001 Oct 31, 1991

+ 500MG ** N050662 002 Oct 31, 1991

CLARITHROMYCIN

AJANTA PHARMA LTD 250MG A206714 001 Apr 25, 2019

500MG A206714 002 Apr 25, 2019

HIKMA 250MG A065178 002 May 25, 2004

500MG A065178 001 May 25, 2004

IVAX SUB TEVA PHARMS 250MG A065137 001 May 31, 2005

500MG A065137 002 May 31, 2005

MYLAN 250MG A065195 001 Mar 11, 2005

500MG A065195 002 Mar 11, 2005

SUN PHARM INDS LTD 250MG A065174 001 Sep 24, 2004

500MG A065174 002 Sep 24, 2004

TABLET, EXTENDED RELEASE; ORAL

BIAXIN XL

+ ABBVIE 500MG ** N050775 001 Mar 03, 2000

CLARITHROMYCIN

ANI PHARMS INC 500MG A065250 001 Aug 25, 2005

LUPIN LTD 500MG A202532 001 Sep 15, 2015

NOSTRUM LABS INC 500MG A203243 001 Feb 29, 2016

RANBAXY 1GM A065210 001 Jan 26, 2005

CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM

INJECTABLE; INJECTION

TIMENTIN

GLAXOSMITHKLINE EQ 100MG BASE/VIAL;EQ 3GM BASE/VIAL A062691 001 Dec 19, 1986

EQ 100MG BASE/VIAL;EQ 3GM BASE/VIAL N050590 001 Apr 01, 1985

EQ 200MG BASE/VIAL;EQ 3GM BASE/VIAL N050590 002 Apr 01, 1985

EQ 1GM BASE/VIAL;EQ 30GM BASE/VIAL N050590 003 Aug 18, 1987

TIMENTIN IN PLASTIC CONTAINER

GLAXOSMITHKLINE EQ 100MG BASE/100ML;EQ 3GM BASE/100ML N050658 001 Dec 15, 1989

CLEMASTINE FUMARATE

SYRUP; ORAL

CLEMASTINE FUMARATE

ACTAVIS MID ATLANTIC EQ 0.5MG BASE/5ML A074075 001 Oct 31, 1993

APOTEX INC EQ 0.5MG BASE/5ML A075703 001 Nov 27, 2000

LANNETT CO INC EQ 0.5MG BASE/5ML A074884 001 Dec 17, 1997

TEVA PHARMS EQ 0.5MG BASE/5ML A073095 001 Apr 21, 1992

WOCKHARDT BIO AG EQ 0.5MG BASE/5ML A074863 001 Mar 13, 1998

TAVIST

+ NOVARTIS EQ 0.5MG BASE/5ML ** N018675 001 Jun 28, 1985

TABLET; ORAL

CLEMASTINE FUMARATE

ANI PHARMS INC 1.34MG A073282 001 Jan 31, 1992

1.34MG A073282 002 Dec 03, 1992

PLD ACQUISITIONS LLC 1.34MG A073458 001 Oct 31, 1993

SANDOZ 2.68MG A073459 001 Oct 31, 1993

TAVIST

+ NOVARTIS 2.68MG N017661 001

TAVIST-1

+ GLAXOSMITHKLINE CONS 1.34MG N020925 001 Aug 21, 1992

NOVARTIS 1.34MG N017661 002

1.34MG N017661 003 Aug 21, 1992

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CLEVIDIPINE

EMULSION; INTRAVENOUS

CLEVIPREX

+ CHIESI

125MG/250ML (0.5MG/ML)

N022156 003 Nov 08, 2013

CLIDINIUM BROMIDE

CAPSULE; ORAL

QUARZAN

ROCHE

2.5MG

N010355 001

5MG

N010355 002

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLEOCIN

PHARMACIA AND UPJOHN

EQ 75MG BASE

A061809 001

EQ 150MG BASE

A061809 002

CLINDAMYCIN HYDROCHLORIDE

LANNETT CO INC

EQ 150MG BASE

A065243 003 Aug 12, 2005

EQ 300MG BASE

A065243 001 Aug 12, 2005

MYLAN PHARMS INC

EQ 75MG BASE

A091225 001 May 31, 2011

EQ 150MG BASE

A091225 002 May 31, 2011

EQ 300MG BASE

A091225 003 May 31, 2011

TEVA

EQ 75MG BASE

A063027 001 Sep 20, 1989

WATSON LABS

EQ 75MG BASE

A063082 001 Jul 31, 1991

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL

CLEOCIN

PHARMACIA AND UPJOHN EQ 75MG BASE/5ML **

A061827 001

CLINDAMYCIN PALMITATE HYDROCHLORIDE

MYLAN

EQ 75MG BASE/5ML

A203063 001 May 25, 2016

CLINDAMYCIN PHOSPHATE

AEROSOL, FOAM; TOPICAL

CLINDAMYCIN PHOSPHATE

TARO PHARM INDS LTD 1%

A210004 001 Mar 11, 2020

CREAM; VAGINAL

CLEOCIN

PHARMACIA AND UPJOHN EQ 2% BASE

N050680 001 Aug 11, 1992

INJECTABLE; INJECTION

CLEOCIN PHOSPHATE

PHARMACIA AND UPJOHN EQ 150MG BASE/ML

A061839 001

CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

+ PHARMACIA AND UPJOHN EQ 6MG BASE/ML

N050639 001 Aug 30, 1989

+ EQ 12MG BASE/ML

N050639 002 Aug 30, 1989

+ EQ 18MG BASE/ML

N050639 003 Apr 10, 1991

CLINDAMYCIN PHOSPHATE

ABRAXIS PHARM

EQ 150MG BASE/ML

A062747 001 Jun 03, 1988

ALVOGEN

EQ 150MG BASE/ML

A062801 001 Jul 24, 1987

BEDFORD

EQ 150MG BASE/ML

A063163 001 Jun 30, 1994

BRISTOL MYERS SQUIBB

EQ 150MG BASE/ML

A062908 001 Feb 01, 1989

IGI LABS INC

EQ 150MG BASE/ML

A062928 001 Feb 13, 1989

LOCH

EQ 150MG BASE/ML

A062905 001 May 09, 1988

MARSAM PHARMS LLC

EQ 150MG BASE/ML

A062913 001 Oct 20, 1988

MYLAN LABS LTD

EQ 150MG BASE/ML

A204749 001 Oct 10, 2017

SOLOPAK

EQ 150MG BASE/ML

A062819 001 Mar 15, 1988

EQ 150MG BASE/ML

A062852 001 Mar 17, 1988

TEVA PARENTERAL

EQ 150MG BASE/ML

A063041 001 Dec 29, 1989

EQ 150MG BASE/ML

A063282 001 May 29, 1992

WATSON LABS

EQ 150MG BASE/ML

A062900 001 Jun 08, 1988

EQ 150MG BASE/ML

A063079 001 Mar 05, 1990

WEST-WARD PHARMS INT

EQ 150MG BASE/ML

A062806 001 Oct 15, 1987

EQ 150MG BASE/ML

A062953 001 Apr 21, 1988

EQ 150MG BASE/ML

A063068 001 Aug 28, 1989

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%

ABRAXIS PHARM

EQ 12MG BASE/ML

N050636 001 Dec 22, 1989

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT LABS

EQ 6MG BASE/ML

A065027 001 Jun 29, 2001

EQ 12MG BASE/ML

A065027 002 Jun 29, 2001

EQ 18MG BASE/ML

A065027 003 Jun 29, 2001

BAXTER HLTHCARE

EQ 6MG BASE/ML

N050648 001 Dec 29, 1989

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

EQ 12MG BASE/ML

N050648 002 Dec 29, 1989

EQ 900MG BASE/100ML

N050648 003 Dec 29, 1989

SOLUTION; TOPICAL

CLEOCIN T

PHARMACIA AND UPJOHN EQ 1% BASE

A062363 001 Feb 08, 1982

CLINDAMYCIN PHOSPHATE

BOCA PHARMA LLC EQ 1% BASE

A062944 001 Jan 11, 1989

FOUGERA PHARMS EQ 1% BASE

A065254 001 Feb 14, 2006

G AND W LABS INC EQ 1% BASE

A062811 001 Sep 01, 1988

NOVAST LABS EQ 1% BASE

A064108 001 Sep 27, 1996

VINTAGE PHARMS EQ 1% BASE

A062930 001 Jun 28, 1989

EQ 1% BASE

A203343 001 May 29, 2015

WOCKHARDT BIO AG EQ 1% BASE

A063304 001 Jul 15, 1997

CLIOQUINOL; NYSTATIN

OINTMENT; TOPICAL

NYSTAFORM

BAYER PHARMS 10MG/GM; 100,000 UNITS/GM

N050235 001

CLOBAZAM

SUSPENSION; ORAL

CLOBAZAM

TARO 2.5MG/ML

A210978 001 Apr 15, 2019

TEVA PHARMS USA 2.5MG/ML

A211032 001 Jan 31, 2020

TABLET; ORAL

CLOBAZAM

ACCORD HLTHCARE 10MG

A212398 001 May 23, 2019

20MG

A212398 002 May 23, 2019

APOTEX 10MG

A209853 001 Jun 09, 2020

20MG

A209853 002 Jun 09, 2020

TARO 10MG

A209440 001 Oct 22, 2018

20MG

A209440 002 Oct 22, 2018

ONFI

+ LUNDBECK PHARMS LLC 5MG **

N202067 001 Oct 21, 2011

CLOBETASOL PROPIONATE

CREAM; TOPICAL

CLOBETASOL PROPIONATE

TEVA PHARMS USA 0.05%

A074087 001 Feb 16, 1994

TEMOVATE

+ FOUGERA PHARMS 0.05% **

N019322 001 Dec 27, 1985

TEMOVATE E

+ FOUGERA PHARMS 0.05% **

N020340 001 Jun 17, 1994

GEL; TOPICAL

TEMOVATE

+ FOUGERA PHARMS 0.05% **

N020337 001 Apr 29, 1994

LOTION; TOPICAL

CLOBETASOL PROPIONATE

AKORN 0.05%

A211348 001 Oct 26, 2018

OINTMENT; TOPICAL

CLOBETASOL PROPIONATE

ACTAVIS MID ATLANTIC 0.05%

A074128 001 Aug 03, 1994

AMNEAL 0.05%

A210551 001 Aug 21, 2018

TEMOVATE

+ FOUGERA PHARMS 0.05% **

N019323 001 Dec 27, 1985

SOLUTION; TOPICAL

TEMOVATE

+ FOUGERA PHARMS 0.05% **

N019966 001 Feb 22, 1990

SPRAY; TOPICAL

CLOBETASOL PROPIONATE

APOTEX 0.05%

A210446 001 Apr 17, 2018

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CLOCORTOLONE PIVALATE

CREAM;TOPICAL

CLOCORTOLONE PIVALATE

TARO

0.1%

A206370 001 Apr 21, 2020

CLOFARABINE

SOLUTION;INTRAVENOUS

CLOFARABINE

HOSPIRA INC

20MG/20ML (1MG/ML)

A210283 001 Dec 27, 2018

CLOFAZIMINE

CAPSULE;ORAL

LAMPRENE

+ NOVARTIS

50MG

N019500 002 Dec 15, 1986

100MG

N019500 001 Dec 15, 1986

CLOFIBRATE

CAPSULE;ORAL

ATROMID-S

WYETH AYERST

500MG

N016099 002

CLOFIBRATE

BANNER PHARMACAPS

500MG

A073396 001 Mar 20, 1992

SANDOZ

500MG

A072191 001 May 02, 1988

TEVA

500MG

A072600 001 Jul 25, 1991

USL PHARMA

500MG

A070531 001 Jun 16, 1986

WATSON LABS

500MG

A071603 001 Sep 18, 1987

CLOMIPHENE CITRATE

TABLET;ORAL

CLOMID

+ SANOFI AVENTIS US

50MG

N016131 002

MILOPHENE

GRANATA BIO

50MG

A072196 001 Dec 20, 1988

SEROPHENE

EMD SERONO

50MG

N018361 001 Mar 22, 1982

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL

CLOMIPRAMINE HYDROCHLORIDE

TEVA

25MG

A074849 001 Apr 04, 1997

25MG

A074958 001 Aug 26, 1997

50MG

A074849 002 Apr 04, 1997

50MG

A074958 002 Aug 26, 1997

75MG

A074849 003 Apr 04, 1997

75MG

A074958 003 Aug 26, 1997

VGYAAN

25MG

A213221 001 Jun 22, 2020

50MG

A213221 002 Jun 22, 2020

75MG

A213221 003 Jun 22, 2020

WATSON LABS

25MG

A074600 001 Nov 27, 1996

25MG

A074751 001 Sep 30, 1998

50MG

A074600 002 Nov 27, 1996

50MG

A074751 002 Sep 30, 1998

75MG

A074600 003 Nov 27, 1996

75MG

A074751 003 Sep 30, 1998

CLONAZEPAM

TABLET;ORAL

CLONAZEPAM

MYLAN

0.5MG

A075150 001 Oct 05, 1998

1MG

A075150 002 Oct 05, 1998

2MG

A075150 003 Oct 05, 1998

MYLAN PHARMS INC

0.5MG

A074940 001 Oct 30, 1997

1MG

A074940 002 Oct 30, 1997

2MG

A074940 003 Oct 30, 1997

RUBICON

0.5MG

A075468 001 Oct 06, 2000

1MG

A075468 002 Oct 06, 2000

2MG

A075468 003 Oct 06, 2000

SANDOZ

0.5MG

A074925 001 Sep 30, 1997

1MG

A074925 002 Sep 30, 1997

2MG

A074925 003 Sep 30, 1997

SUN PHARM INDS INC

0.5MG

A075423 001 Apr 27, 2001

1MG

A075423 002 Apr 27, 2001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CLONAZEPAMTABLET; ORAL
CLONAZEPAM

	2MG	A075423 003	Apr 27, 2001
TEVA	0.5MG	A074920 001	Aug 04, 1998
	1MG	A074920 002	Aug 04, 1998
	2MG	A074920 003	Aug 04, 1998
KLONOPIN			
ROCHE	0.125MG	N017533 005	Apr 09, 1997
	0.25MG	N017533 006	Apr 09, 1997

TABLET, ORALLY DISINTEGRATING; ORAL

KLONOPIN RAPIDLY DISINTEGRATING

+	ROCHE	0.125MG **	N020813 001	Dec 23, 1997
+		0.25MG **	N020813 002	Dec 23, 1997
+		0.5MG **	N020813 003	Dec 23, 1997
+		1MG **	N020813 004	Dec 23, 1997
+		2MG **	N020813 005	Dec 23, 1997

CLONIDINE

SUSPENSION, EXTENDED RELEASE; ORAL

CLONIDINE

TRIS PHARMA INC	EQ 0.09MG BASE/ML	N022499 001	Dec 03, 2009
-----------------	-------------------	-------------	--------------

TABLET, EXTENDED RELEASE; ORAL

NEXICLON XR

TRIS PHARMA INC	EQ 0.17MG BASE	N022500 001	Dec 03, 2009
	EQ 0.26MG BASE	N022500 002	Dec 03, 2009

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CLONIDINE HYDROCHLORIDE

AM REGENT	1MG/10ML (0.1MG/ML)	A091104 001	Oct 08, 2009
	5MG/10ML (0.5MG/ML)	A091104 002	Oct 08, 2009

TABLET; ORAL

CLONIDINE HYDROCHLORIDE

AM THERAP	0.1MG	A070881 001	Jul 08, 1986
	0.2MG	A070882 001	Jul 08, 1986
	0.3MG	A070883 001	Jul 08, 1986
AUROBINDO PHARMA LTD	0.1MG	A070886 002	Aug 31, 1988
	0.2MG	A070886 001	Aug 31, 1988
	0.3MG	A070886 003	Aug 31, 1988
CHARTWELL MOLECULES	0.1MG	A071785 002	Apr 05, 1988
	0.2MG	A071785 003	Apr 05, 1988
	0.3MG	A071785 001	Apr 05, 1988
DURAMED PHARMS BARR	0.1MG	A071103 001	Aug 14, 1986
	0.2MG	A071102 001	Aug 14, 1986
	0.3MG	A071101 001	Aug 14, 1986
INTERPHARM	0.1MG	A071252 001	Oct 01, 1986
	0.2MG	A071253 001	Oct 01, 1986
	0.3MG	A071254 001	Oct 01, 1986
MYLAN	0.1MG	A070317 002	Jul 09, 1987
	0.2MG	A070317 003	Jun 09, 1987
	0.3MG	A070317 001	Jun 09, 1987
PAR PHARM	0.1MG	A070461 001	Jul 08, 1986
	0.2MG	A070460 001	Jul 08, 1986
	0.3MG	A070459 001	Jul 08, 1986
SUN PHARM INDS INC	0.1MG	A090329 001	Jul 03, 2014
	0.2MG	A090329 002	Jul 03, 2014
	0.3MG	A090329 003	Jul 03, 2014
TEVA	0.1MG	A070747 001	Jul 08, 1986
	0.2MG	A070702 001	Jul 08, 1986
	0.3MG	A070659 001	Jul 08, 1986
WARNER CHILCOTT	0.1MG	A072138 001	Jun 13, 1988
	0.2MG	A072139 001	Jun 13, 1988
	0.3MG	A072140 001	Jun 13, 1988
WATSON LABS	0.1MG	A070395 001	Mar 23, 1987
	0.1MG	A070965 001	Jul 08, 1986
	0.2MG	A070396 001	Mar 23, 1987
	0.2MG	A070964 001	Jul 08, 1986
	0.3MG	A070397 001	Mar 23, 1987
	0.3MG	A070963 001	Jul 08, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CLONIDINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

ACTAVIS ELIZABETH	0.2MG	A202792 002	May 15, 2015
	0.2MG	A203320 002	May 15, 2015
ANCHEN PHARMS	0.1MG	A202983 001	Apr 02, 2014
	0.2MG	A202983 002	Apr 02, 2014
	0.2MG	A202984 002	Sep 30, 2013
JENLOGA			
+ CONCORDIA PHARMS INC	0.1MG **	N022331 001	Sep 30, 2009
+	0.2MG **	N022331 002	May 25, 2010
KAPVAY			
+ CONCORDIA PHARMS INC	0.2MG **	N022331 004	Sep 28, 2010

CLOPIDOGREL BISULFATE

TABLET;ORAL

CLOPIDOGREL BISULFATE

ACTAVIS TOTOWA	EQ 75MG BASE	A090307 001	May 28, 2013
ANI PHARMS INC	EQ 300MG BASE	A090625 001	May 17, 2012
	EQ 300MG BASE	A091216 001	May 17, 2012
CADILA	EQ 75MG BASE	A201686 001	Oct 10, 2012
CELLTRION	EQ 75MG BASE	A202266 001	Aug 14, 2012
	EQ 300MG BASE	A202266 002	Nov 20, 2012
MYLAN PHARMS INC	EQ 75MG BASE	A077665 001	May 17, 2012
	EQ 300MG BASE	A077665 002	May 17, 2012
POLYGEN PHARMS	EQ 75MG BASE	A213351 001	Jul 17, 2020
	EQ 300MG BASE	A213351 002	Jul 17, 2020
SUN PHARM INDUSTRIES	EQ 75MG BASE	A078133 001	Jun 10, 2013

CLORAZEPATE DIPOTASSIUM

CAPSULE;ORAL

CLORAZEPATE DIPOTASSIUM

ABLE	3.75MG	A071777 001	Jul 14, 1987
	7.5MG	A071778 001	Jul 14, 1987
	15MG	A071779 001	Jul 14, 1987
AM THERAP	3.75MG	A071429 001	Jun 23, 1987
	7.5MG	A071430 001	Jun 23, 1987
	15MG	A071431 001	Jun 23, 1987
DAVA PHARMS INC	3.75MG	A071742 001	Dec 14, 1987
	7.5MG	A071743 001	Dec 14, 1987
	15MG	A071744 001	Dec 14, 1987
GD SEARLE LLC	3.75MG	A071727 001	Dec 18, 1987
	7.5MG	A071728 001	Dec 18, 1987
	15MG	A071729 001	Dec 18, 1987
MYLAN	3.75MG	A071509 001	Oct 19, 1987
	7.5MG	A071510 001	Oct 19, 1987
	15MG	A071511 001	Oct 19, 1987
PUREPAC PHARM	3.75MG	A071924 001	Apr 25, 1988
	7.5MG	A071925 001	Apr 25, 1988
	15MG	A071926 001	Apr 25, 1988
QUANTUM PHARMICS	3.75MG	A071549 001	Sep 12, 1988
	7.5MG	A071550 001	Sep 12, 1988
	15MG	A071522 001	Sep 12, 1988
RISING	3.75MG	A072112 002	Aug 26, 1988
	7.5MG	A072112 003	Aug 26, 1988
	15MG	A072112 001	Aug 26, 1988
USL PHARMA	3.75MG	A071242 001	Jun 23, 1987
	7.5MG	A071243 001	Jun 23, 1987
	15MG	A071244 001	Jun 23, 1987
WARNER CHILCOTT	3.75MG	A071774 001	Mar 01, 1988
	7.5MG	A071775 001	Mar 01, 1988
	15MG	A071776 001	Mar 01, 1988
WATSON LABS	3.75MG	A071878 001	Mar 15, 1988
	7.5MG	A071879 001	Mar 15, 1988
	15MG	A071860 001	Mar 15, 1988
TRANXENE			
RECORDATI RARE	3.75MG **	N017105 001	
	7.5MG **	N017105 002	
	15MG **	N017105 003	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CLORAZEPATE DIPOTASSIUM

TABLET;ORAL

CLORAZEPATE DIPOTASSIUM

ABLE	3.75MG	A071780 001	Jun 26, 1987
	7.5MG	A071781 001	Jun 26, 1987
	15MG	A071782 001	Jun 26, 1987
AM THERAP	3.75MG	A071747 001	Jun 23, 1987
	7.5MG	A071748 001	Jun 23, 1987
	15MG	A071749 001	Jun 23, 1987
AUROLIFE PHARMA LLC	3.75MG	A072514 002	May 11, 1990
	7.5MG	A072514 003	May 11, 1990
	15MG	A072514 001	May 11, 1990
LEDERLE	3.75MG	A072013 001	Dec 15, 1987
	7.5MG	A072014 001	Dec 15, 1987
	15MG	A072015 001	Dec 15, 1987
PUREPAC PHARM	3.75MG	A072330 001	Aug 08, 1988
	7.5MG	A072331 001	Aug 08, 1988
	15MG	A072332 001	Aug 08, 1988
QUANTUM PHARMICS	3.75MG	A071730 001	Oct 26, 1987
	7.5MG	A071731 001	Oct 26, 1987
	15MG	A071702 001	Oct 26, 1987
SUN PHARM INDS LTD	3.75MG	A076911 001	Sep 29, 2004
	7.5MG	A076911 002	Sep 29, 2004
	15MG	A076911 003	Sep 29, 2004
WARNER CHILCOTT	3.75MG	A071828 001	Mar 03, 1988
	7.5MG	A071829 001	Mar 03, 1988
	15MG	A071830 001	Mar 03, 1988
WATSON LABS	3.75MG	A071852 001	Feb 09, 1988
	7.5MG	A071853 001	Feb 09, 1988
	15MG	A071854 001	Feb 09, 1988
TRANXENE			
RECORDATI RARE	3.75MG **	N017105 006	
+	15MG **	N017105 008	
TRANXENE SD			
RECORDATI RARE	11.25MG **	N017105 005	
	22.5MG **	N017105 004	

CLOTRIMAZOLE

CREAM;TOPICAL

LOTRIMIN

SCHERING PLOUGH	1% **	N017619 001	
MYCELEX			
BAYER HEALTHCARE LLC	1%	N018183 001	
CREAM;VAGINAL			
GYNE-LOTRIMIN			
+	BAYER HEALTHCARE LLC 1% **	N018052 002	Nov 30, 1990
GYNE-LOTRIMIN 3			
+	BAYER HEALTHCARE LLC 2%	N020574 001	Nov 24, 1998
MYCELEX-7			
BAYER HEALTHCARE LLC	1%	N018230 002	Dec 26, 1991
CREAM, TABLET;TOPICAL, VAGINAL			
GYNE-LOTRIMIN 3 COMBINATION PACK			
+	BAYER HEALTHCARE LLC 1%,200MG	N020526 002	Jul 29, 1996
GYNE-LOTRIMIN COMBINATION PACK			
+	BAYER HEALTHCARE LLC 1%,100MG	N020289 002	Apr 26, 1993
MYCELEX-7 COMBINATION PACK			
BAYER HEALTHCARE LLC	1%,100MG	N020389 002	Jun 23, 1994
LOTION;TOPICAL			
LOTRIMIN			
SCHERING	1%	N018813 001	Feb 17, 1984
SOLUTION;TOPICAL			
LOTRIMIN			
+	SCHERING PLOUGH 1% **	N017613 001	
MYCELEX			
+	BAYER HLTHCARE 1% **	N018181 001	
TABLET;VAGINAL			
GYNE-LOTRIMIN			
+	BAYER HEALTHCARE LLC 100MG	N017717 002	Nov 30, 1990

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CLOTRIMAZOLE

TABLET; VAGINAL

GYNE-LOTRIMIN 3

+ BAYER HEALTHCARE LLC 200MG N020525 001 Jul 29, 1996

GYNIX

TEVA PHARMS 100MG A073249 001 Feb 13, 1998

MYCELEX-7

BAYER HEALTHCARE LLC 100MG N018182 002 Dec 26, 1991

MYCELEX-G

BAYER PHARMS 500MG N019069 001 Apr 19, 1985

TROCHE/LOZENGE; ORAL

MYCELEX

+ BAYER HLTHCARE 10MG ** N018713 001 Jun 17, 1983

CLOXACILLIN SODIUM

CAPSULE; ORAL

CLOXACILLIN SODIUM

APOTHECON EQ 250MG BASE A061452 001

EQ 500MG BASE A061452 002

TEVA EQ 250MG BASE A062240 001

EQ 500MG BASE A062240 002

CLOXAPEN

GLAXOSMITHKLINE EQ 250MG BASE A061806 001

EQ 250MG BASE A062233 001

EQ 500MG BASE A061806 002

EQ 500MG BASE A062233 002

FOR SOLUTION; ORAL

CLOXACILLIN SODIUM

TEVA EQ 125MG BASE/5ML A062268 001

EQ 125MG BASE/5ML A062978 001 Apr 06, 1989

TEGOPEN

APOTHECON EQ 125MG BASE/5ML A061453 001

EQ 125MG BASE/5ML N050192 001

CLOZAPINE

TABLET; ORAL

CLOZAPINE

MYLAN 12.5MG A075417 003 Apr 15, 2010

PAR PHARM 25MG A075162 001 Apr 26, 2005

100MG A075162 002 Apr 26, 2005

SANDOZ 25MG A074546 001 Aug 30, 1996

100MG A074546 002 Aug 30, 1996

ZYDUS PHARMS 25MG A209480 001 Dec 06, 2017

50MG A209480 002 Dec 06, 2017

100MG A209480 003 Dec 06, 2017

200MG A209480 004 Dec 06, 2017

TABLET, ORALLY DISINTEGRATING; ORAL

FAZACLO ODT

+ JAZZ 12.5MG N021590 004 May 30, 2007

+ 25MG N021590 001 Feb 10, 2004

50MG N021590 003 Jun 03, 2005

+ 100MG N021590 002 Feb 10, 2004

+ 150MG N021590 005 Jul 09, 2010

+ 200MG N021590 006 Jul 09, 2010

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHENERGAN VC W/ CODEINE

+ ANI PHARMS 10MG/5ML; 5MG/5ML; 6.25MG/5ML ** N008306 005 Apr 02, 1984

PHERAZINE VC W/ CODEINE

HALSEY 10MG/5ML; 5MG/5ML; 6.25MG/5ML A088870 001 Mar 02, 1987

PROMETHAZINE VC W/ CODEINE

CENCI 10MG/5ML; 5MG/5ML; 6.25MG/5ML A088816 001 Nov 22, 1985

WOCKHARDT 10MG/5ML; 5MG/5ML; 6.25MG/5ML A088896 001 Jan 04, 1985

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PHENERGAN W/ CODEINE

+ ANI PHARMS 10MG/5ML;6.25MG/5ML ** N008306 004 Apr 02, 1984

PHERAZINE W/ CODEINE

HALSEY 10MG/5ML;6.25MG/5ML A088739 001 Dec 23, 1988

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

PHARM ASSOC 10MG/5ML;6.25MG/5ML A089647 001 Dec 22, 1988

PROMETHAZINE W/ CODEINE

CENCI 10MG/5ML;6.25MG/5ML A088814 001 Nov 22, 1985

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP;ORAL

ACTIFED W/ CODEINE

GLAXOSMITHKLINE 10MG/5ML;30MG/5ML;1.25MG/5ML N012575 003 Apr 04, 1984

TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES W/ CODEINE

CENCI 10MG/5ML;30MG/5ML;1.25MG/5ML A089018 001 Jul 23, 1986

TRIPROLIDINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE AND CODEINE PHOSPHATE

WOCKHARDT 10MG/5ML;30MG/5ML;1.25MG/5ML A088833 001 Nov 16, 1984

CODEINE SULFATE

SOLUTION;ORAL

CODEINE SULFATE

HIKMA 30MG/5ML N202245 001 Jun 30, 2011

COLCHICINE

CAPSULE;ORAL

COLCHICINE

PAR PHARM INC 0.6MG A208678 001 Nov 29, 2018

COLCHICINE; PROBENECID

TABLET;ORAL

COLBENEMID

+ MERCK 0.5MG;500MG ** N012383 001

PROBEN-C

WATSON LABS 0.5MG;500MG A085552 001

PROBENECID AND COLCHICINE

ANI PHARMS INC 0.5MG;500MG A083734 001

BEECHAM 0.5MG;500MG A084321 001

IMPAX LABS 0.5MG;500MG A083720 002

SANDOZ 0.5MG;500MG A086130 001

PROBENECID W/ COLCHICINE

LEDERLE 0.5MG;500MG A086954 001

WATSON LABS 0.5MG;500MG A083221 001

COLESEVELAM HYDROCHLORIDE

BAR, CHEWABLE;ORAL

WELCHOL

+ DAIICHI SANKYO INC 3.75GM N210895 001 Apr 03, 2019

CAPSULE;ORAL

WELCHOL

DAIICHI SANKYO 375MG N021141 001 May 26, 2000

FOR SUSPENSION;ORAL

WELCHOL

+ DAIICHI SANKYO 1.875GM/PACKET ** N022362 001 Oct 02, 2009

TABLET;ORAL

COLESEVELAM HYDROCHLORIDE

INVAGEN PHARMS 625MG A212602 001 Apr 20, 2020

COLISTIMETHATE SODIUM

INJECTABLE;INJECTION

COLISTIMETHATE SODIUM

EMCURE PHARMS LTD EQ 150MG BASE/VIAL A202359 001 Sep 28, 2012

COLISTIN SULFATE

SUSPENSION;ORAL

COLY-MYCIN S

PARKE DAVIS EQ 25MG BASE/5ML N050355 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CONIVAPTAN HYDROCHLORIDEINJECTABLE; INTRAVENOUS
VAPRISOL

CUMBERLAND PHARMS 20MG/4ML (5MG/ML) N021697 001 Dec 29, 2005

COPPERINTRAUTERINE DEVICE; INTRAUTERINE
CU-7

GD SEARLE LLC 89MG N017408 001

TATUM-T

GD SEARLE LLC 120MG N018205 001

CORTICOTROPIN

INJECTABLE; INJECTION

ACTH

PARKEDALE 25 UNITS/VIAL N008317 002

40 UNITS/VIAL N008317 004

ACTHAR

SANOFI AVENTIS US 25 UNITS/VIAL N007504 002

40 UNITS/VIAL N007504 003

CORTICOTROPIN

ORGANICS LAGRANGE 40 UNITS/ML N010831 001

80 UNITS/ML N010831 002

WATSON LABS

40 UNITS/VIAL A088772 001 Nov 21, 1984

H.P. ACTHAR GEL

MALLINCKRODT ARD 40 UNITS/ML N008372 006

PURIFIED CORTROPHIN GEL

ANI PHARMS INC 40 UNITS/ML N008975 001

80 UNITS/ML N008975 002

CORTICOTROPIN-ZINC HYDROXIDE

INJECTABLE; INJECTION

CORTROPHIN-ZINC

ANI PHARMS INC 40 UNITS/ML N009854 001

CORTISONE ACETATE

INJECTABLE; INJECTION

CORTISONE ACETATE

PHARMACIA AND UPJOHN 25MG/ML N008126 002

WATSON LABS 25MG/ML A083147 003

25MG/ML A085677 001

50MG/ML A083147 004

50MG/ML A085677 002

CORTONE

MERCK 25MG/ML N007110 002

50MG/ML N007110 003

TABLET; ORAL

CORTISONE ACETATE

BARR 25MG A083471 001

ELKINS SINN 25MG A080836 001

EVERYLIFE 25MG A084246 001

HEATHER 25MG A085736 001

IMPAX LABS 25MG N009458 001

INWOOD LABS 25MG A080731 001

IVAX SUB TEVA PHARMS 25MG A080630 001

25MG A083536 001

LANNETT 25MG A080694 001

PANRAY 5MG N008284 002

25MG N008284 001

PHARMACIA AND UPJOHN 5MG N008126 003

10MG N008126 004

25MG N008126 001

PUREPAC PHARM 25MG A080493 001

VITARINE 25MG A080333 001

WATSON LABS 25MG A085884 001

WHITEWORTH TOWN PLSN 25MG A080341 001

CORTONE

+ MERCK 25MG ** N007750 003

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

COSYNTROPIN

SOLUTION; INTRAVENOUS

COSYNTROPIN

SANDOZ INC

0.25MG/ML (0.25MG/ML)

N022028 001 Feb 21, 2008

CROMOLYN SODIUM

AEROSOL, METERED; INHALATION

INTAL

KING PHARMS LLC

0.8MG/INH

N018887 001 Dec 05, 1985

CAPSULE; INHALATION

INTAL

+ SANOFI AVENTIS US

20MG **

N016990 001

CAPSULE; ORAL

GASTROCROM

UCB INC

100MG

N019188 001 Dec 22, 1989

CONCENTRATE; ORAL

CROMOLYN SODIUM

GENERA PHARMS

100MG/5ML

A090954 001 Dec 18, 2009

SOLUTION; INHALATION

CROMOLYN SODIUM

ACTAVIS MID ATLANTIC

10MG/ML

A075067 001 Jul 19, 1999

BAUSCH AND LOMB

10MG/ML

A075585 001 Dec 21, 2000

FERA PHARMS LLC

10MG/ML

A075437 001 Apr 21, 2000

HIKMA

10MG/ML

A075333 001 Apr 30, 2002

MYLAN SPECIALITY LP

10MG/ML

A074209 001 Apr 26, 1994

ROXANE

10MG/ML

A075175 001 Sep 30, 1999

WATSON LABS

10MG/ML

A076469 001 Jun 17, 2005

INTAL

+ KING PHARMS LLC

10MG/ML **

N018596 001 May 28, 1982

SOLUTION/DROPS; OPHTHALMIC

CROLOM

BAUSCH AND LOMB

4%

A074443 001 Jan 30, 1995

CROMOLYN SODIUM

APOTEX INC

4%

A075615 001 Jan 26, 2001

CROMOPTIC

KING PHARMS

4%

A075088 001 Apr 27, 1999

OPTICROM

+ ALLERGAN

4% **

N018155 001 Oct 03, 1984

SPRAY, METERED; NASAL

CROMOLYN SODIUM

ACTAVIS MID ATLANTIC

5.2MG/SPRAY

A074800 001 Jul 26, 2001

HH AND P

5.2MG/SPRAY

A077976 001 Sep 07, 2007

NASALCROM

+ BLACKSMITH BRANDS

5.2MG/SPRAY **

N020463 001 Jan 03, 1997

CROTAMITON

CREAM; TOPICAL

EURAX

+ SUN PHARM INDS INC

10%

N006927 001

CRYPTENAMINE ACETATES

INJECTABLE; INJECTION

UNITENSEN

MEDPOINTE PHARM HLC

260CSR UNIT/ML

N008814 001

CRYPTENAMINE TANNATES

TABLET; ORAL

UNITENSEN

MEDPOINTE PHARM HLC

260CSR UNIT

N009217 001

CUPRIC SULFATE

INJECTABLE; INJECTION

CUPRIC SULFATE

+ ABRAXIS PHARM

EQ 0.4MG COPPER/ML

N019350 001 May 05, 1987

CYANOCOBALAMIN

GEL, METERED; NASAL

NASCOBAL

PAR PHARM

0.5MG/INH

N019722 001 Nov 05, 1996

INJECTABLE; INJECTION

BERUBIGEN

PHARMACIA AND UPJOHN

1MG/ML

N006798 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CYANOCOBALAMIN

INJECTABLE; INJECTION

BETALIN 12			
LILLY	0.1MG/ML	A080855	001
	1MG/ML	A080855	002
COBAVITE			
WATSON LABS	0.1MG/ML	A083013	001
	1MG/ML	A083064	001
CYANOCOBALAMIN			
ABRAXIS PHARM	0.03MG/ML	A080510	003
	0.1MG/ML	A080510	001
	1MG/ML	A080510	002
AKORN	1MG/ML	A087969	001 Nov 10, 1983
DELL LABS	0.03MG/ML	A080689	001
	0.1MG/ML	A080689	002
	1MG/ML	A080689	003
DR REDDYS	0.1MG/ML	A080573	002
	1MG/ML	A080573	001
FRESENIUS KABI USA	0.1MG/ML	A080557	002
LUITPOLD	0.03MG/ML	A080668	001
LYPHOMED	1MG/ML	A083075	001
MYLAN INSTITUTIONAL	1MG/ML	A040451	001 Sep 23, 2003
SANOFI AVENTIS US	1MG/ML	A080564	001
SOLOPAK	1MG/ML	A087551	001 Feb 29, 1984
WARNER CHILCOTT	1MG/ML	N007085	002
WATSON LABS	0.1MG/ML	A083120	001
	1MG/ML	A083120	002
WYETH AYERST	0.1MG/ML	A080554	001
	1MG/ML	A080554	002
DODEX			
ACCORD HLTHCARE	1MG/ML	A083022	001
REDISOL			
MERCK	1MG/ML	N006668	010
RUBIVITE			
BEL MAR	0.03MG/ML	N010791	004
	0.05MG/ML	N010791	001
	0.1MG/ML	N010791	002
	0.12MG/ML	N010791	005
	1MG/ML	N010791	003
RUBRAMIN PC			
BRISTOL MYERS SQUIBB	0.1MG/ML	N006799	002
+	1MG/ML **	N006799	004
+	1MG/ML **	N006799	010 Apr 28, 1988
RUVITE			
SAVAGE LABS	1MG/ML	A080570	002
VI-TWEL			
BAYER HLTHCARE	1MG/ML	N007012	002
SPRAY, METERED; NASAL			
CALOMIST			
PAR PHARM	25MCG/SPRAY	N022102	001 Jul 27, 2007
CYANOCOBALAMIN			
PERRIGO UK FINCO	0.5MG/SPRAY	A212458	001 Sep 09, 2020
TABLET; ORAL			
CYANOCOBALAMIN			
WEST WARD	1MG	A084264	001
<u>CYANOCOBALAMIN; CYANOCOBALAMIN CO-57; CYANOCOBALAMIN CO-58</u>			
N/A; N/A			
DICOPAC KIT			
GE HEALTHCARE	N/A; N/A; N/A	N017406	001
<u>CYANOCOBALAMIN; TANNIC ACID; ZINC ACETATE</u>			
INJECTABLE; INJECTION			
DEPINAR			
ARMOUR PHARM	0.5MG/ML; 2.3MG/ML; 1MG/ML	N011208	001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CYCLACILLIN

FOR SUSPENSION; ORAL

CYCLAPEN-W

WYETH AYERST	125MG/5ML	N050508	001	
	250MG/5ML	N050508	002	
	500MG/5ML	N050508	003	

TABLET; ORAL

CYCLACILLIN

TEVA	250MG	A062895	001	Aug 04, 1988
	500MG	A062895	002	Aug 04, 1988

CYCLAPEN-W

WYETH AYERST	250MG	N050509	001	
	500MG	N050509	002	

CYCLIZINE LACTATE

INJECTABLE; INJECTION

MAREZINE

GLAXOSMITHKLINE	50MG/ML	N009495	001	
-----------------	---------	---------	-----	--

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

SANDOZ	10MG	A073683	001	Feb 26, 1993
UPSHER SMITH LABS	5MG	A072854	002	Feb 03, 2006
	10MG	A072854	001	Nov 19, 1991
WATSON LABS	10MG	A073143	001	Nov 27, 1991
	10MG	A074436	001	Nov 30, 1994

FLEXERIL

+ JANSSEN RES AND DEV	5MG **	N017821	001	
+	10MG **	N017821	002	

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AK-PENTOLATE

AKORN	1%	A085555	001	
-------	----	---------	-----	--

AKPENTOLATE

AKORN	2%	A040165	001	Jan 13, 1997
-------	----	---------	-----	--------------

CYCLOPENTOLATE HYDROCHLORIDE

ALCON PHARMS LTD	1%	A089162	001	Jan 24, 1991
SOLA BARNES HIND	1%	A084150	001	
	1%	A084863	001	

PENTOLAIR

PHARMAFAIR	0.5%	A088643	001	Feb 09, 1987
	1%	A088150	001	Feb 25, 1983

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYCLOPHOSPHAMIDE

BAXTER HLTHCARE	100MG/VIAL	A088371	001	Jul 03, 1986
	200MG/VIAL	A088372	001	Jul 03, 1986
	500MG/VIAL	A088373	001	Jul 03, 1986
	1GM/VIAL	A088374	001	Sep 24, 1986

CYTOXAN

+ BAXTER HLTHCARE	100MG/VIAL **	N012142	001	
+	200MG/VIAL **	N012142	002	

CYTOXAN (LYOPHILIZED)

+ BAXTER HLTHCARE	500MG/VIAL	N012142	003	
+	500MG/VIAL **	N012142	008	Jan 04, 1984
+	1GM/VIAL	N012142	004	Aug 30, 1982
+	1GM/VIAL **	N012142	010	Sep 24, 1985
+	2GM/VIAL	N012142	005	Aug 30, 1982
+	2GM/VIAL **	N012142	009	Dec 10, 1985

LYOPHILIZED CYTOXAN

+ BAXTER HLTHCARE	100MG/VIAL **	N012142	006	Dec 05, 1985
+	200MG/VIAL **	N012142	007	Dec 10, 1985

NEOSAR

BEDFORD	100MG/VIAL	A087442	001	Feb 16, 1982
	200MG/VIAL	A087442	002	Feb 16, 1982
	500MG/VIAL	A087442	003	Feb 16, 1982
	1GM/VIAL	A087442	004	Jul 08, 1983
	2GM/VIAL	A087442	005	Mar 30, 1989

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

NEOSAR

TEVA PARENTERAL	100MG/VIAL	A040015 001	Apr 29, 1993
	200MG/VIAL	A040015 002	Apr 29, 1993
	500MG/VIAL	A040015 003	Apr 29, 1993
	1GM/VIAL	A040015 004	Apr 29, 1993
	2GM/VIAL	A040015 005	Apr 29, 1993

TABLET; ORAL

CYCLOPHOSPHAMIDE

ROXANE	25MG	A040032 001	Aug 17, 1999
	50MG	A040032 002	Aug 17, 1999

CYCLOSPORINE

CAPSULE; ORAL

GENGRAF

ABBVIE	50MG	A065003 002	May 12, 2000
--------	------	-------------	--------------

NEORAL

+ NOVARTIS

50MG **	N050715 003	Jul 14, 1995
---------	-------------	--------------

SOLUTION; ORAL

CYCLOSPORINE

PHARM ASSOC	100MG/ML	A065167 001	Jan 05, 2005
-------------	----------	-------------	--------------

CYCLOTHIAZIDE

TABLET; ORAL

ANHYDRON

LILLY	2MG	N013157 002
-------	-----	-------------

FLUIDIL

PHARMACIA AND UPJOHN	2MG	N018173 001
----------------------	-----	-------------

CYCRIMINE HYDROCHLORIDE

TABLET; ORAL

PAGITANE

LILLY	1.25MG	N008951 001
	2.5MG	N008951 002

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

CYPROHEPTADINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC	2MG/5ML **	A086833 001	
HALSEY	2MG/5ML	A089199 001	Jul 03, 1986
MORTON GROVE	2MG/5ML	A087001 001	Nov 04, 1982
NASKA	2MG/5ML	A089021 001	Dec 21, 1987

PERIACTIN

+ MERCK

2MG/5ML **	N013220 002
------------	-------------

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

AM THERAP	4MG	A088798 001	Feb 15, 1985
ASCOT	4MG	A087685 001	Oct 25, 1982
CHARTWELL RX	4MG	A088212 001	May 26, 1983
DURAMED PHARMS BARR	4MG	A088232 001	Oct 25, 1983
FOSUN PHARMA	4MG	A086808 001	
HALSEY	4MG	A089057 001	Jul 03, 1986
KV PHARM	4MG	A086737 001	
MD PHARM	4MG	A087566 001	Nov 10, 1982
MYLAN	4MG	A086678 001	
PAR PHARM	4MG	A087129 001	
PIONEER PHARMS	4MG	A087839 001	Feb 08, 1984
PLIVA	4MG	A088205 001	Jul 26, 1983
SUPERPHARM	4MG	A087405 001	
VITARINE	4MG	A087284 001	
WATSON LABS	4MG	A085245 001	
	4MG	A086165 001	
	4MG	A086580 001	

PERIACTIN

+ MERCK

4MG **	N012649 001
--------	-------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CYSTEINE HYDROCHLORIDE

INJECTABLE; INJECTION

CYSTEINE HYDROCHLORIDE

+ HOSPIRA 7.25% ** N019523 001 Oct 22, 1986

SOLUTION; INTRAVENOUS

NOURESS

+ BAXTER HLTHCARE CORP 500MG/10ML (50MG/ML) N212535 001 Dec 13, 2019

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

MYLAN LABS LTD 20MG/ML A200916 001 Dec 13, 2011

+ TEVA PARENTERAL 100MG/VIAL ** N016793 001

+ 500MG/VIAL ** N016793 002

+ 1GM/VIAL ** N016793 003 Dec 21, 1987

+ 2GM/VIAL ** N016793 004 Dec 21, 1987

CYTOSAR-U

TEVA PHARMS USA 100MG/VIAL A075206 001 Dec 30, 1998

500MG/VIAL A075206 002 Dec 30, 1998

1GM/VIAL A075206 004 Dec 30, 1998

2GM/VIAL A075206 003 Dec 30, 1998

INJECTABLE, LIPOSOMAL; INJECTION

DEPOCYT

+ PACIRA PHARMS INC 10MG/ML N021041 001 Apr 01, 1999

DACARBAZINE

INJECTABLE; INJECTION

DACARBAZINE

ABRAXIS PHARM 100MG/VIAL A070962 001 Aug 28, 1986

200MG/VIAL A070990 001 Aug 28, 1986

DTIC-DOME

+ BAYER HLTHCARE 100MG/VIAL ** N017575 001

+ 200MG/VIAL ** N017575 002

DACLATASVIR DIHYDROCHLORIDE

TABLET; ORAL

DAKLINZA

+ BRISTOL-MYERS SQUIBB EQ 30MG BASE N206843 001 Jul 24, 2015

+ EQ 60MG BASE N206843 002 Jul 24, 2015

+ EQ 90MG BASE N206843 003 Apr 13, 2016

DACTINOMYCIN

INJECTABLE; INJECTION

DACTINOMYCIN

AM REGENT 0.5MG/VIAL A202562 001 Aug 23, 2013

WEST-WARD PHARMS INT 0.5MG/VIAL A090304 001 Mar 16, 2010

DALFAMPRIDINE

TABLET, EXTENDED RELEASE; ORAL

DALFAMPRIDINE

MYLAN 10MG A206858 001 Jul 06, 2020

DALFOPRISTIN; QUINUPRISTIN

INJECTABLE; INTRAVENOUS

SYNERCID

KING PHARMS 420MG/VIAL; 180MG/VIAL N050748 002 Aug 24, 2000

DALTEPARIN SODIUM

INJECTABLE; INJECTION

FRAGMIN

PFIZER 7,500 IU/0.75ML N020287 008 Apr 04, 2002

INJECTABLE; SUBCUTANEOUS

FRAGMIN

PFIZER 10,000IU/0.4ML (25,000IU/ML) N020287 002 May 01, 2007

95,000IU/9.5ML (10,000IU/ML) N020287 007 Apr 04, 2002

DANAPAROID SODIUM

INJECTABLE; INJECTION

ORGARAN

ASPEN GLOBAL INC 750 UNITS/0.6ML N020430 001 Dec 24, 1996

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DANAZOL

CAPSULE; ORAL

DANAZOL

AM THERAP 200MG A071569 001 Dec 30, 1987

DANOCRINE

SANOFI AVENTIS US 50MG ** N017557 003

100MG ** N017557 004

200MG ** N017557 002

DANTROLENE SODIUM

INJECTABLE; INJECTION

DANTROLENE SODIUM

MYLAN INSTITUTIONAL 20MG/VIAL A205239 001 Feb 18, 2016

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

QTERNMET XR

+ ASTRAZENECA AB 2.5MG;1GM;EQ 2.5MG BASE N210874 001 May 02, 2019

+ 5MG;1GM;EQ 2.5MG BASE N210874 002 May 02, 2019

+ 5MG;1GM;EQ 5MG BASE N210874 003 May 02, 2019

+ 10MG;1GM;EQ 5MG BASE N210874 004 May 02, 2019

DAPIPRAZOLE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DAPIPRAZOLE HYDROCHLORIDE

+ FERA PHARMS 0.5% ** N019849 001 Dec 31, 1990

WOODWARD 0.5% A204902 001 May 30, 2019

DAPSONE

TABLET; ORAL

DAPSONE

TARO 25MG A209430 001 Mar 01, 2019

100MG A209430 002 Mar 01, 2019

DAPTOMYCIN

POWDER; INTRAVENOUS

CUBICIN

CUBIST PHARMS LLC 250MG/VIAL N021572 001 Sep 12, 2003

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL

DARIFENACIN HYDROBROMIDE

ANCHEN PHARMS EQ 7.5MG BASE A091190 001 Mar 13, 2015

EQ 15MG BASE A091190 002 Mar 13, 2015

DARUNAVIR

TABLET; ORAL

PREZISTA

+ JANSSEN PRODS 300MG ** N021976 001 Jun 23, 2006

+ 400MG ** N021976 003 Oct 21, 2008

DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR

TABLET, EXTENDED RELEASE; ORAL

VIEKIRA XR

+ ABBVIE INC EQ 200MG BASE;8.33MG;50MG;33.33MG N208624 001 Jul 22, 2016

DASATINIB

TABLET; ORAL

DASATINIB

APOTEX INC 20MG A202103 001 Jun 10, 2016

50MG A202103 002 Jun 10, 2016

70MG A202103 003 Jun 10, 2016

100MG A202103 004 Jun 10, 2016

DAUNORUBICIN CITRATE

INJECTABLE, LIPOSOMAL; INJECTION

DAUNOXOME

GALEN (UK) EQ 2MG BASE/ML N050704 002 Apr 08, 1996

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

CERUBIDINE

SANOFI AVENTIS US	EQ 20MG BASE/VIAL	A061876 001	
WYETH AYERST	EQ 20MG BASE/VIAL **	N050484 001	

DAUNORUBICIN HYDROCHLORIDE

HISUN PHARM HANGZHOU	EQ 20MG BASE/VIAL	A206195 001	Apr 25, 2019
TEVA PARENTERAL	EQ 20MG BASE/VIAL	A064212 001	Jun 23, 1998
	EQ 50MG BASE/VIAL	A064212 002	May 03, 1999

DECAMETHONIUM BROMIDE

INJECTABLE; INJECTION

SYNCURINE

GLAXOSMITHKLINE	1MG/ML	N006931 002	
-----------------	--------	-------------	--

DEFERASIROX

TABLET, FOR SUSPENSION; ORAL

DEFERASIROX

ZYDUS PHARMS	125MG	A208882 001	May 05, 2020
	250MG	A208882 002	May 05, 2020
	500MG	A208882 003	May 05, 2020

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION

DEFEROXAMINE MESYLATE

DR REDDYS	500MG/VIAL	A076806 001	Mar 31, 2006
	2GM/VIAL	A076806 002	Mar 31, 2006

DESFERAL

+ NOVARTIS	2GM/VIAL	N016267 002	May 25, 2000
------------	----------	-------------	--------------

DELAVIRDINE MESYLATE

TABLET; ORAL

RESCRIPTOR

+ VIIV HLTHCARE	100MG	N020705 001	Apr 04, 1997
+	200MG	N020705 002	Jul 14, 1999

DEMECARIUM BROMIDE

SOLUTION/DROPS; OPHTHALMIC

HUMORSOL

MERCK	0.125%	N011860 002	
	0.25%	N011860 001	

DEMECLOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

DECLOMYCIN

LEDERLE	150MG	N050262 001	
---------	-------	-------------	--

SYRUP; ORAL

DECLOMYCIN

LEDERLE	75MG/5ML	N050257 001	
---------	----------	-------------	--

TABLET; ORAL

DECLOMYCIN

COREPHARMA	75MG	N050261 001	
	150MG	N050261 002	
	300MG	N050261 003	

DEMECLOCYCLINE HYDROCHLORIDE

BARR	150MG	A065171 001	Dec 13, 2004
	300MG	A065171 002	Dec 13, 2004
IMPAX LABS	150MG	A065094 001	Mar 22, 2004
	300MG	A065094 002	Mar 22, 2004

DESERPIDINE

TABLET; ORAL

HARMONYL

ABBVIE	0.1MG	N010796 001	
	0.25MG	N010796 002	

DESERPIDINE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ORETICYL 25

ABBVIE	0.125MG; 25MG	N012148 001	
--------	---------------	-------------	--

ORETICYL 50

ABBVIE	0.125MG; 50MG	N012148 003	
--------	---------------	-------------	--

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DESERPIDINE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ORETICYL FORTE

ABBVIE

0.25MG; 25MG

N012148 002

DESERPIDINE; METHYLCLOTHIAZIDE

TABLET; ORAL

ENDURONYL

ABBOTT

0.25MG; 5MG

N012775 001

ENDURONYL FORTE

ABBOTT

0.5MG; 5MG

N012775 002

METHYLCLOTHIAZIDE AND DESERPIDINE

WATSON LABS

0.25MG; 5MG

A088486 001 Aug 10, 1984

0.5MG; 5MG

A088452 001 Aug 10, 1984

DESIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

PERTOFRANE

SANOFI AVENTIS US

25MG

N013621 001

50MG

N013621 002

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

ANI PHARMS INC

10MG

A205153 001 Oct 28, 2016

25MG

A071803 002 Dec 08, 1987

25MG

A205153 002 Oct 28, 2016

50MG

A071803 003 Dec 08, 1987

50MG

A205153 003 Oct 28, 2016

75MG

A071803 004 Dec 08, 1987

75MG

A205153 004 Oct 28, 2016

100MG

A071803 001 May 29, 1997

100MG

A205153 005 Oct 28, 2016

150MG

A071803 005 May 29, 1997

150MG

A205153 006 Oct 28, 2016

USL PHARMA

25MG

A071864 001 Sep 09, 1987

50MG

A071865 001 Sep 09, 1987

75MG

A071866 001 Sep 09, 1987

100MG

A071867 001 Sep 09, 1987

DESLANOSIDE

INJECTABLE; INJECTION

CEDILANID-D

NOVARTIS

0.2MG/ML

N009282 002

DESLORATADINE

SOLUTION; ORAL

CLARINEX

+ MERCK SHARP DOHME

0.5MG/ML

N021300 001 Sep 01, 2004

DESLORATADINE

TARO

0.5MG/ML

A202936 001 May 26, 2016

TARO PHARM INDS LTD

0.5MG/ML

A202592 001 Jun 30, 2015

TABLET; ORAL

DESLORATADINE

MYLAN PHARMS INC

5MG

A078351 001 Feb 10, 2012

TABLET, ORALLY DISINTEGRATING; ORAL

CLARINEX

+ MERCK SHARP DOHME

2.5MG

N021312 002 Jul 14, 2005

+

5MG

N021312 001 Jun 26, 2002

DESLORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CLARINEX D 24 HOUR

+ MERCK SHARP DOHME

5MG; 240MG

N021605 001 Mar 03, 2005

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION

DDAVP

FERRING PHARMS INC

0.015MG/ML

N018938 002 Apr 25, 1995

DESMOPRESSIN ACETATE

BEDFORD

0.004MG/ML

A074575 001 Feb 18, 2000

HOSPIRA

0.004MG/ML

A075220 001 Aug 28, 2000

DESMOPRESSIN ACETATE PRESERVATIVE FREE

BEDFORD

0.004MG/ML

A074574 001 Feb 18, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DESMOPRESSIN ACETATE

SOLUTION;NASAL

CONCENTRAID

FERRING 0.01% N019776 001 Dec 26, 1990

DDAVP

+ FERRING PHARMS INC 0.01% N017922 001

DESMOPRESSIN ACETATE

SUN PHARM INDS 0.01% A077212 001 Apr 12, 2012

SPRAY, METERED;NASAL

DDAVP

+ FERRING PHARMS INC 0.01MG/SPRAY ** N017922 002 Feb 06, 1989

DDAVP (NEEDS NO REFRIGERATION)

+ FERRING PHARMS INC 0.01MG/SPRAY N017922 003 Aug 07, 1996

MINIRIN

+ FERRING 0.01MG/SPRAY N021333 001 Sep 16, 2002

NOCTIVA

+ ALYVANT 0.00083MG/SPRAY N201656 001 Mar 03, 2017

+ 0.00166MG/SPRAY N201656 002 Mar 03, 2017

STIMATE

FERRING PHARMS INC 0.15MG/SPRAY N020355 001 Mar 07, 1994

STIMATE (NEEDS NO REFRIGERATION)

+ FERRING PHARMS INC 0.15MG/SPRAY N020355 002 Oct 24, 2007

TABLET;ORAL

DESMOPRESSIN ACETATE

FERRING 0.1MG N021795 001 May 08, 2008

0.2MG N021795 002 May 08, 2008

IMPAX LABS INC 0.1MG A077122 001 Jan 25, 2006

0.2MG A077122 002 Jan 25, 2006

MYLAN 0.1MG A200653 001 Jun 27, 2014

0.2MG A200653 002 Jun 27, 2014

DESOGESTREL; ETHINYL ESTRADIOL

TABLET;ORAL-21

DESOGEN

ORGANON USA INC 0.15MG;0.03MG N020071 001 Dec 10, 1992

DESOGESTREL AND ETHINYL ESTRADIOL

DURAMED PHARMS BARR 0.15MG;0.03MG A075256 001 Aug 12, 1999

ORTHO-CEPT

JANSSEN PHARMS 0.15MG;0.03MG N020301 001 Dec 14, 1992

TABLET;ORAL-28

DESOGEN

ORGANON USA INC 0.15MG;0.03MG N020071 002 Dec 10, 1992

DESOGESTREL AND ETHINYL ESTRADIOL

MYLAN LABS LTD 0.15MG;0.03MG A202085 001 May 20, 2015

NAARI PTE LTD 0.15MG;0.03MG A207067 001 Sep 13, 2018

EMOQUETTE

VINTAGE PHARMS LLC 0.15MG;0.03MG A076675 001 Feb 25, 2011

MIRCETTE

+ TEVA BRANDED PHARM 0.15MG,N/A;0.02MG,0.01MG ** N020713 001 Apr 22, 1998

ORTHO-CEPT

JANSSEN PHARMS 0.15MG;0.03MG N020301 002 Dec 14, 1992

DESOXIMETASONE

CREAM;TOPICAL

TOPICORT

+ TARO PHARM INDS LTD 0.25% ** N017856 001

TOPICORT LP

+ TARO PHARM INDS LTD 0.05% ** N018309 001

GEL;TOPICAL

TOPICORT

+ TARO PHARM INDS LTD 0.05% ** N018586 001 Mar 29, 1982

OINTMENT;TOPICAL

DESOXIMETASONE

ALTANA 0.25% A073440 001 Apr 01, 1998

TOPICORT

+ TARO PHARM INDS LTD 0.25% ** N018763 001 Sep 30, 1983

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DESOXYCORTICOSTERONE ACETATE

INJECTABLE; INJECTION

DOCA

ORGANON USA INC 5MG/ML N001104 001

PELLET; IMPLANTATION

PERCORTEN

NOVARTIS 125MG N005151 001

DESOXYCORTICOSTERONE PIVALATE

INJECTABLE; INJECTION

PERCORTEN

NOVARTIS 25MG/ML N008822 001

DESVENLAFAXINE

TABLET, EXTENDED RELEASE; ORAL

KHEDEZLA

OSMOTICA PHARM CORP 50MG N204683 001 Jul 10, 2013

100MG N204683 002 Jul 10, 2013

DESVENLAFAXINE FUMARATE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE

+ SUN PHARMA GLOBAL EQ 50MG BASE N205583 001 Jan 28, 2014

+ EQ 100MG BASE N205583 002 Jan 28, 2014

TEVA PHARMS USA EQ 50MG BASE N205208 001 Oct 11, 2013

EQ 100MG BASE N205208 002 Oct 11, 2013

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE SUCCINATE

MYLAN EQ 50MG BASE A204095 001 Jun 29, 2015

EQ 100MG BASE A204095 002 Jun 29, 2015

DEXAMETHASONE

AEROSOL; TOPICAL

AEROSEB-DEX

ALLERGAN HERBERT 0.01% ** A083296 002

DECASPRAY

+ MERCK 0.04% ** N012731 002

ELIXIR; ORAL

DECADRON

MERCK 0.5MG/5ML N012376 002

DEXAMETHASONE

ALPHARMA US PHARMS 0.5MG/5ML A088997 001 Oct 10, 1986

HEXADROL

ASPEN GLOBAL INC 0.5MG/5ML N012674 001

GEL; TOPICAL

DECADERM

MERCK 0.1% N013538 001

SUSPENSION/DROPS; OPHTHALMIC

DEXAMETHASONE

WATSON LABS 0.1% A089170 001 May 09, 1989

TABLET; ORAL

DECADRON

+ MERCK 0.25MG ** N011664 004

+ 0.5MG ** N011664 001

+ 0.75MG ** N011664 002

+ 1.5MG ** N011664 003

+ 4MG ** N011664 005

+ 6MG ** N011664 006 Jul 30, 1982

DEXAMETHASONE

ANI PHARMS INC 0.75MG A080399 001

HERITAGE PHARMA 1.5MG A085456 001

IMPAX LABS 0.75MG A085376 001

PAR PHARM 0.25MG A088149 001 Apr 28, 1983

PHOENIX LABS NY 0.75MG A083806 001

PVT FORM 0.75MG A083420 001

ROXANE 0.25MG A084614 001

SUN PHARM INDUSTRIES 0.25MG A084013 001

0.25MG A084764 001

0.5MG A084084 001

0.5MG A084766 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DEXAMETHASONE

TABLET; ORAL

DEXAMETHASONE

	0.75MG	A084081	001
	0.75MG	A084765	001
	1.5MG	A084086	001
	1.5MG	A084763	001
UPSHER SMITH	0.75MG	A087534	001
	1.5MG	A087533	001
WATSON LABS	0.25MG	A085455	001
	0.5MG	A085458	001
	0.75MG	A080968	001
	0.75MG	A084457	001
	0.75MG	A085818	001
	1.5MG	A085840	001
WHITEWORTH TOWN PLSN	0.75MG	A084327	001
DEXONE 0.5			
SOLVAY	0.5MG	A084991	001
DEXONE 0.75			
SOLVAY	0.75MG	A084993	001
DEXONE 1.5			
SOLVAY	1.5MG	A084990	001
DEXONE 4			
SOLVAY	4MG	A084992	001
HEXADROL			
ASPEN GLOBAL INC	0.5MG	N012675	004
	0.75MG	N012675	007
	1.5MG	N012675	009
	4MG	N012675	010

DEXAMETHASONE ACETATE

INJECTABLE; INJECTION

DECADRON-LA

+ MERCK

EQ 8MG BASE/ML **

N016675 001

DEXAMETHASONE ACETATE

WATSON LABS

EQ 8MG BASE/ML

A084315 001

WATSON LABS TEVA

EQ 16MG BASE/ML

A087711 001 May 24, 1982

DEXAMETHASONE SODIUM PHOSPHATE

AEROSOL; NASAL

DEXACORT

UCB INC

EQ 0.1MG PHOSPHATE/INH

N014242 001

AEROSOL, METERED; INHALATION

DEXACORT

UCB INC

EQ 0.1MG PHOSPHATE/INH

N013413 001

CREAM; TOPICAL

DECADRON

MERCK

EQ 0.1% PHOSPHATE

N011983 002

INJECTABLE; INJECTION

DECADRON

+ MERCK

EQ 4MG PHOSPHATE/ML **

N012071 002

+

EQ 24MG PHOSPHATE/ML **

N012071 004

DEXACEN-4

CENT PHARMS

EQ 4MG PHOSPHATE/ML

A084342 001

DEXAMETHASONE

ABRAXIS PHARM

EQ 4MG PHOSPHATE/ML

A088448 001 Jan 25, 1984

FRESENIUS KABI USA

EQ 10MG PHOSPHATE/ML

A088469 001 Jan 25, 1984

DEXAMETHASONE SODIUM PHOSPHATE

AKORN

EQ 4MG PHOSPHATE/ML

A084493 001

BEL MAR

EQ 4MG PHOSPHATE/ML

A084752 001

DELL LABS

EQ 4MG PHOSPHATE/ML

A083161 001

DR REDDYS

EQ 4MG PHOSPHATE/ML

A089169 001 Apr 09, 1986

INTL MEDICATION

EQ 20MG PHOSPHATE/ML

A088522 001 Feb 17, 1984

LUITPOLD

EQ 4MG PHOSPHATE/ML

A087440 001 Jul 21, 1982

LYPHOMED

EQ 4MG PHOSPHATE/ML

A087065 001

TEVA PARENTERAL

EQ 4MG PHOSPHATE/ML

A081125 001 Aug 31, 1990

EQ 10MG PHOSPHATE/ML

A081126 001 Aug 31, 1990

WATSON LABS

EQ 4MG PHOSPHATE/ML

A083702 001

EQ 4MG PHOSPHATE/ML

A084355 001

EQ 10MG PHOSPHATE/ML

A087668 001 Jul 01, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

	EQ 24MG PHOSPHATE/ML	A085606 001
WYETH AYERST	EQ 4MG PHOSPHATE/ML	A085641 001
HEXADROL		
+ ASPEN GLOBAL INC	EQ 4MG PHOSPHATE/ML **	N014694 002
+	EQ 10MG PHOSPHATE/ML **	N014694 003
	EQ 20MG PHOSPHATE/ML	N014694 004

OINTMENT; OPHTHALMIC

DECADRON

MERCK	EQ 0.05% PHOSPHATE	N011977 001
-------	--------------------	-------------

DEXAIR

PHARMAFAIR	EQ 0.05% PHOSPHATE	A088071 001 Dec 28, 1982
------------	--------------------	--------------------------

MAXIDEX

ALCON	EQ 0.05% PHOSPHATE	A083342 001
-------	--------------------	-------------

SOLUTION/DROPS; OPHTHALMIC

DEXAIR

PHARMAFAIR	EQ 0.1% PHOSPHATE	A088433 001 Dec 15, 1983
------------	-------------------	--------------------------

DEXAMETHASONE SODIUM PHOSPHATE

SOLA BARNES HIND	EQ 0.1% PHOSPHATE	A084170 001
	EQ 0.1% PHOSPHATE	A084173 001

SOLUTION/DROPS; OPHTHALMIC, OTIC

DECADRON

+ MERCK	EQ 0.1% PHOSPHATE	N011984 001
---------	-------------------	-------------

DEXAMETHASONE SODIUM PHOSPHATE

SANDOZ INC	EQ 0.1% PHOSPHATE	A088771 001 Jan 16, 1985
------------	-------------------	--------------------------

SOLUTION/DROPS; OTIC

DEXAMETHASONE SODIUM PHOSPHATE

AKORN	EQ 0.1% PHOSPHATE	A084855 001
-------	-------------------	-------------

DEXAMETHASONE SODIUM PHOSPHATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DECADRON W/ XYLOCAINE

MERCK	EQ 4MG PHOSPHATE/ML; 10MG/ML	N013334 002
-------	------------------------------	-------------

DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE

OINTMENT; OPHTHALMIC

NEODECADRON

MERCK	EQ 0.05% PHOSPHATE; EQ 3.5MG BASE/GM	N050324 001
-------	--------------------------------------	-------------

SOLUTION/DROPS; OPHTHALMIC

NEODECADRON

MERCK	EQ 0.1% PHOSPHATE; EQ 3.5MG BASE/ML	N050322 001
-------	-------------------------------------	-------------

NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE

BAUSCH AND LOMB	EQ 0.1% PHOSPHATE; EQ 3.5MG BASE/ML	A064055 001 Oct 30, 1995
-----------------	-------------------------------------	--------------------------

NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE

ALCON PHARMS LTD	EQ 0.1% PHOSPHATE; EQ 3.5MG BASE/ML	A062714 001 Jul 21, 1986
PHARMAFAIR	EQ 0.1% PHOSPHATE; EQ 3.5MG BASE/ML	A062539 001 Jan 10, 1985

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

DEXACIDIN

NOVARTIS	0.1%; EQ 3.5MG BASE/GM; 10,000 UNITS/GM	A062566 001 Feb 22, 1985
----------	---	--------------------------

DEXASPORIN

PHARMAFAIR	0.1%; EQ 3.5MG BASE/GM; 10,000 UNITS/GM	A062411 001 May 16, 1983
------------	---	--------------------------

SUSPENSION/DROPS; OPHTHALMIC

DEXACIDIN

NOVARTIS	0.1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML	A062544 001 Oct 29, 1984
----------	---	--------------------------

DEXASPORIN

PHARMAFAIR	0.1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML	A062428 001 May 18, 1983
------------	---	--------------------------

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

ALCON PHARMS LTD	0.1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML	A062721 001 Nov 17, 1986
------------------	---	--------------------------

DEXBROMPHENIRAMINE MALEATE

SYRUP; ORAL

DISOMER

SCHERING	2MG/5ML	N011814 002
----------	---------	-------------

TABLET; ORAL

DISOMER

SCHERING	2MG	N011814 001
----------	-----	-------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET; ORAL

DISOPHROL

SCHERING 2MG; 60MG N012394 002

TABLET, EXTENDED RELEASE; ORAL

BROMPHERIL

COPLY PHARM 6MG; 120MG A089116 001 Jan 22, 1987

DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE

AVANTHI INC 6MG; 120MG A078648 001 Feb 27, 2013

DISOBROM

SANDOZ 6MG; 120MG A070770 001 Sep 30, 1991

DISOPHROL

SCHERING PLOUGH 6MG; 120MG N013483 004 Sep 13, 1982

DRIXORAL

+ SCHERING PLOUGH 6MG; 120MG ** N013483 003 Sep 13, 1982

RESPORAL

PIONEER PHARMS 6MG; 120MG A089139 001 Jun 16, 1988

DEXCHLORPHENIRAMINE MALEATE

SYRUP; ORAL

POLARAMINE

SCHERING 2MG/5ML A086837 001 Jul 19, 1982

TABLET; ORAL

DEXCHLORPHENIRAMINE MALEATE

ANI PHARMS INC 2MG A088682 001 Jan 17, 1986

POLARAMINE

SCHERING 2MG A086835 001

DEXLANSOPRAZOLE

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE; ORAL

DEXILANT SOLUTAB

+ TAKEDA PHARMS USA 30MG N208056 001 Jan 26, 2016

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AM REGENT EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) A203773 001 May 12, 2017

HONG KONG EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) A204843 001 Jan 18, 2019

SLAYBACK PHARMA LLC EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML) A212791 003 May 08, 2020

DEXMETHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

LANNETT CO INC 2.5MG A209468 001 Sep 25, 2017

5MG A209468 002 Sep 25, 2017

10MG A209468 003 Sep 25, 2017

TEVA PHARMS 2.5MG A077107 003 Jan 29, 2007

5MG A077107 001 Jan 29, 2007

10MG A077107 002 Jan 29, 2007

USPHARMA 5MG A209754 001 Mar 24, 2020

10MG A209754 002 Mar 24, 2020

DEXTROAMPHETAMINE SULFATE

CAPSULE; ORAL

DEXAMPEX

TEVA 15MG A085355 001

CAPSULE, EXTENDED RELEASE; ORAL

DEXTROAMPHETAMINE SULFATE

ABLE 5MG A076814 001 Aug 25, 2004

10MG A076814 002 Aug 25, 2004

15MG A076814 003 Aug 25, 2004

MYLAN 5MG A206735 001 Jan 27, 2016

10MG A206735 002 Jan 27, 2016

15MG A206735 003 Jan 27, 2016

STRIDES PHARMA 5MG A205077 001 Jun 21, 2019

10MG A205077 002 Jun 21, 2019

15MG A205077 003 Jun 21, 2019

ELIXIR; ORAL

DEXEDRINE

GLAXOSMITHKLINE 5MG/5ML ** A083902 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXAMPEX

TEVA	5MG	A083735	001
	10MG	A083735	002

DEXEDRINE

GLAXOSMITHKLINE	5MG **	A084935	001
-----------------	--------	---------	-----

DEXTROAMPHETAMINE SULFATE

ANI PHARMS INC	5MG	A085370	001
----------------	-----	---------	-----

EPIC PHARMA LLC	5MG	A090652	001 Mar 07, 2014
-----------------	-----	---------	------------------

	10MG	A090652	002 Mar 07, 2014
--	------	---------	------------------

HALSEY	10MG	A083930	001
--------	------	---------	-----

LANNETT	5MG	A083903	001
---------	-----	---------	-----

	10MG	A083903	003
--	------	---------	-----

	15MG	A085652	001
--	------	---------	-----

MAST MM	5MG	A086521	001
---------	-----	---------	-----

NESHER PHARMS	5MG	A040365	001 Oct 31, 2002
---------------	-----	---------	------------------

	10MG	A040367	001 Oct 31, 2002
--	------	---------	------------------

PUREPAC PHARM	5MG	A084125	001
---------------	-----	---------	-----

SANDOZ	10MG	A085371	001
--------	------	---------	-----

VINTAGE PHARMS LLC	5MG	A040299	001 May 13, 1999
--------------------	-----	---------	------------------

VITARINE	5MG	A084986	001
----------	-----	---------	-----

	10MG	A085892	001
--	------	---------	-----

DEXTROSTAT

SHIRE	5MG **	A084051	001
-------	--------	---------	-----

	10MG **	A084051	002
--	---------	---------	-----

FERNDEX

FERNDALE LABS	5MG	A084001	001
---------------	-----	---------	-----

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHERAZINE DM

HALSEY	15MG/5ML; 6.25MG/5ML	A088913	001 Mar 02, 1987
--------	----------------------	---------	------------------

PROMETH W/ DEXTROMETHORPHAN

G AND W LABS INC	15MG/5ML; 6.25MG/5ML **	A088762	001 Oct 31, 1984
------------------	-------------------------	---------	------------------

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AKORN	15MG/5ML; 6.25MG/5ML	A040027	001 Jul 31, 1996
-------	----------------------	---------	------------------

+ ANI PHARMS	15MG/5ML; 6.25MG/5ML **	N011265	002 Apr 02, 1984
--------------	-------------------------	---------	------------------

TRIS PHARMA INC	15MG/5ML; 6.25MG/5ML	A091687	001 Jun 28, 2012
-----------------	----------------------	---------	------------------

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 10% IN PLASTIC CONTAINER

B BRAUN	10GM/100ML	N018046	001
---------	------------	---------	-----

MILES	10GM/100ML	N018504	001
-------	------------	---------	-----

DEXTROSE 2.5% IN PLASTIC CONTAINER

B BRAUN	2.5GM/100ML	N018358	001
---------	-------------	---------	-----

	2.5GM/100ML	N019626	001 Feb 02, 1988
--	-------------	---------	------------------

DEXTROSE 20% IN PLASTIC CONTAINER

+ BAXTER HLTHCARE	20GM/100ML **	N017521	004
-------------------	---------------	---------	-----

DEXTROSE 30% IN PLASTIC CONTAINER

+ BAXTER HLTHCARE	30GM/100ML **	N017521	003
-------------------	---------------	---------	-----

DEXTROSE 38.5% IN PLASTIC CONTAINER

ABBOTT	38.5GM/100ML	N018923	001 Sep 19, 1984
--------	--------------	---------	------------------

DEXTROSE 40% IN PLASTIC CONTAINER

+ BAXTER HLTHCARE	40GM/100ML **	N017521	002
-------------------	---------------	---------	-----

DEXTROSE 5% IN PLASTIC CONTAINER

DHL	5GM/100ML	N019971	001 Sep 28, 1995
-----	-----------	---------	------------------

+ ICU MEDICAL INC	50GM/ML	N019222	001 Jul 13, 1984
-------------------	---------	---------	------------------

DEXTROSE 50% IN PLASTIC CONTAINER

+ BAXTER HLTHCARE	50GM/100ML **	N017521	001
-------------------	---------------	---------	-----

ICU MEDICAL INC	50GM/100ML	N019894	001 Dec 26, 1989
-----------------	------------	---------	------------------

DEXTROSE 60%

B BRAUN	60GM/100ML	N017995	002 Sep 22, 1982
---------	------------	---------	------------------

DEXTROSE 60% IN PLASTIC CONTAINER

B BRAUN	60GM/100ML	N017995	001
---------	------------	---------	-----

+ BAXTER HLTHCARE	60GM/100ML **	N017521	005 Mar 26, 1982
-------------------	---------------	---------	------------------

	60GM/100ML	N020047	002 Jul 02, 1991
--	------------	---------	------------------

HOSPIRA	60GM/100ML	N019346	001 Jan 25, 1985
---------	------------	---------	------------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 7.7% IN PLASTIC CONTAINER

B BRAUN 7.7GM/100ML

N019626 003 Feb 02, 1988

DEXTROSE 70% IN PLASTIC CONTAINER

+ BAXTER HLTHCARE 70GM/100ML **

N017521 006 Mar 26, 1982

DEXTROSE; MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE 5GM/100ML; 32MG/100ML; 128MG/100ML; 234MG/
100ML

N017385 001

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE; INJECTION

ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML; 31MG/100ML; 130MG/100ML; 26MG/1
00ML; 320MG/100ML

N019025 001 Dec 27, 1984

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE; INJECTION

IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA 5GM/100ML; 53MG/100ML; 100MG/100ML; 100MG/
100ML; 180MG/100ML; 280MG/100ML; 16MG/100M
L

N019515 001 May 08, 1986

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML; 30MG/100ML; 97MG/100ML; 220MG/1
00ML; 140MG/100ML

N019844 001 Jun 10, 1993

ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML; 30MG/100ML; 97MG/100ML; 220MG/1
00ML; 140MG/100ML

N018273 001

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML; 30MG/100ML; 37MG/100ML; 370MG/1
00ML; 530MG/100ML; 500MG/100ML

N019843 001 Aug 09, 1993

ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML; 30MG/100ML; 37MG/100ML; 370MG/1
00ML; 530MG/100ML; 500MG/100ML

N018274 001

PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER

+ BAXTER HLTHCARE 5GM/100ML; 30MG/100ML; 37MG/100ML; 368MG/1
00ML; 526MG/100ML; 502MG/100ML

N017451 001

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML; 37MG/100ML

N019699 001 Sep 29, 1989

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML; 75MG/100ML

N018744 001 Nov 09, 1982

5GM/100ML; 75MG/100ML

N019699 002 Sep 29, 1989

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML; 110MG/100ML

N019699 003 Sep 29, 1989

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML; 150MG/100ML

N018744 002 Nov 09, 1982

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML; 220MG/100ML

N018744 003 Nov 09, 1982

5GM/100ML; 220MG/100ML

N019699 005 Sep 29, 1989

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML; 300MG/100ML

N018744 004 Nov 09, 1982

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

ICU MEDICAL INC 5GM/100ML; 224MG/100ML

N018371 003

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

ICU MEDICAL INC 5GM/100ML; 298MG/100ML

N018371 002

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE; INJECTION

IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML;111MG/100ML;256MG/100ML;146MG	N019514	001	May 08, 1986
	/100ML;207MG/100ML			

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;150MG/100ML;130MG/100ML;280MG	N019870	001	Jun 10, 1993
	/100ML;91MG/100ML			

ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;150MG/100ML;130MG/100ML;280MG	N018270	001	
	/100ML;91MG/100ML			

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% AND ELECTROLYTE NO. 75 IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML;205MG/100ML;100MG/100ML;120MG	N018840	001	Jun 29, 1983
	/100ML;220MG/100ML			

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.075%

B BRAUN	5GM/100ML;75MG/100ML;200MG/100ML	N018268	009	
---------	----------------------------------	---------	-----	--

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;150MG/100ML;200MG/100ML	N018268	004	
---------	-----------------------------------	---------	-----	--

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;220MG/100ML;200MG/100ML	N018268	005	
---------	-----------------------------------	---------	-----	--

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;300MG/100ML;200MG/100ML	N018268	006	
---------	-----------------------------------	---------	-----	--

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;75MG/100ML;330MG/100ML	N018268	011	Jan 18, 1986
---------	----------------------------------	---------	-----	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;150MG/100ML;330MG/100ML	N018268	012	Jan 18, 1986
---------	-----------------------------------	---------	-----	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;220MG/100ML;330MG/100ML	N018268	013	Jan 18, 1986
---------	-----------------------------------	---------	-----	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.30% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;300MG/100ML;330MG/100ML	N018268	014	Jan 18, 1986
---------	-----------------------------------	---------	-----	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.075%

B BRAUN	5GM/100ML;75MG/100ML;450MG/100ML	N018268	010	
---------	----------------------------------	---------	-----	--

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;150MG/100ML;450MG/100ML	N018268	001	
---------	-----------------------------------	---------	-----	--

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;220MG/100ML;450MG/100ML	N018268	002	
---------	-----------------------------------	---------	-----	--

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;300MG/100ML;450MG/100ML	N018268	003	
---------	-----------------------------------	---------	-----	--

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML;224MG/100ML;450MG/100ML	N018008	003	
-----------------	-----------------------------------	---------	-----	--

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML;300MG/100ML;450MG/100ML	N018008	001	
-----------------	-----------------------------------	---------	-----	--

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML;75MG/100ML;450MG/100ML	N018008	002	
-----------------	----------------------------------	---------	-----	--

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

+ ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;225MG/100ML **	N018365	002	Jul 05, 1983
-------------------	---------------------------------------	---------	-----	--------------

+ ICU MEDICAL INC	5GM/100ML;149MG/100ML;225MG/100ML **	N018365	006	Mar 28, 1988
-------------------	--------------------------------------	---------	-----	--------------

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;300MG/100ML	N018876	001	Jan 17, 1986
-----------------	------------------------------------	---------	-----	--------------

ICU MEDICAL INC	5GM/100ML;149MG/100ML;300MG/100ML	N018876	006	Mar 28, 1988
-----------------	-----------------------------------	---------	-----	--------------

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+ ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;900MG/100ML	N019691	002	Mar 24, 1988
-------------------	------------------------------------	---------	-----	--------------

+ ICU MEDICAL INC	5GM/100ML;149MG/100ML;900MG/100ML	N019691	004	Mar 24, 1988
-------------------	-----------------------------------	---------	-----	--------------

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

ICU MEDICAL INC	5GM/100ML;224MG/100ML;225MG/100ML **	N018365	008	Mar 28, 1988
-----------------	--------------------------------------	---------	-----	--------------

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

ICU MEDICAL INC	5GM/100ML;224MG/100ML;300MG/100ML	N018876	007	Mar 28, 1988
-----------------	-----------------------------------	---------	-----	--------------

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

+ ICU MEDICAL INC	5GM/100ML;224MG/100ML;450MG/100ML	N018362	006	Mar 28, 1988
-------------------	-----------------------------------	---------	-----	--------------

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+ ICU MEDICAL INC	5GM/100ML;224MG/100ML;900MG/100ML	N019691	006	Mar 24, 1988
-------------------	-----------------------------------	---------	-----	--------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 20MEQ	IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.225%	IN	PLASTIC CONTAINER	
+ ICU MEDICAL INC		5GM/100ML;298MG/100ML;225MG/100ML	**	N018365 009	Mar 28, 1988
POTASSIUM CHLORIDE 20MEQ	IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.3%	IN	PLASTIC CONTAINER	
ICU MEDICAL INC		5GM/100ML;298MG/100ML;300MG/100ML		N018876 008	Mar 28, 1988
POTASSIUM CHLORIDE 20MEQ	IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.45%	IN	PLASTIC CONTAINER	
+ ICU MEDICAL INC		5GM/100ML;298MG/100ML;450MG/100ML		N018362 007	Mar 28, 1988
POTASSIUM CHLORIDE 20MEQ	IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.9%	IN	PLASTIC CONTAINER	
+ ICU MEDICAL INC		5GM/100ML;298MG/100ML;900MG/100ML		N019691 008	Mar 24, 1988
POTASSIUM CHLORIDE 20MEQ	IN	DEXTROSE 5% IN SODIUM CHLORIDE 0.3%	IN	PLASTIC CONTAINER	
ICU MEDICAL INC		5GM/100ML;149MG/100ML;300MG/100ML		N018876 002	Jan 17, 1986
POTASSIUM CHLORIDE 30MEQ	IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.225%	IN	PLASTIC CONTAINER	
ICU MEDICAL INC		5GM/100ML;224MG/100ML;225MG/100ML	**	N018365 003	Jul 05, 1983
POTASSIUM CHLORIDE 30MEQ	IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.3%	IN	PLASTIC CONTAINER	
ICU MEDICAL INC		5GM/100ML;224MG/100ML;300MG/100ML		N018876 003	Jan 17, 1986
POTASSIUM CHLORIDE 30MEQ	IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.9%	IN	PLASTIC CONTAINER	
+ ICU MEDICAL INC		5GM/100ML;224MG/100ML;900MG/100ML		N019691 007	Mar 24, 1988
POTASSIUM CHLORIDE 40MEQ	IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.225%	IN	PLASTIC CONTAINER	
ICU MEDICAL INC		5GM/100ML;298MG/100ML;225MG/100ML	**	N018365 004	Jul 05, 1983
POTASSIUM CHLORIDE 40MEQ	IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.3%	IN	PLASTIC CONTAINER	
ICU MEDICAL INC		5GM/100ML;298MG/100ML;300MG/100ML		N018876 004	Mar 28, 1988
POTASSIUM CHLORIDE 5MEQ	IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.225%	IN	PLASTIC CONTAINER	
ICU MEDICAL INC		5GM/100ML;74.5MG/100ML;225MG/100ML	**	N018365 005	Mar 28, 1988
		5GM/100ML;149MG/100ML;225MG/100ML	**	N018365 007	Mar 28, 1988
POTASSIUM CHLORIDE 5MEQ	IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.3%	IN	PLASTIC CONTAINER	
ICU MEDICAL INC		5GM/100ML;74.5MG/100ML;300MG/100ML		N018876 005	Mar 28, 1988
		5GM/100ML;149MG/100ML;300MG/100ML		N018876 009	Mar 28, 1988
POTASSIUM CHLORIDE 5MEQ	IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.45%	IN	PLASTIC CONTAINER	
+ ICU MEDICAL INC		5GM/100ML;74.5MG/100ML;450MG/100ML		N018362 008	Mar 28, 1988
+ ICU MEDICAL INC		5GM/100ML;149MG/100ML;450MG/100ML		N018362 004	Mar 28, 1988
POTASSIUM CHLORIDE 5MEQ	IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.9%	IN	PLASTIC CONTAINER	
+ ICU MEDICAL INC		5GM/100ML;74.5MG/100ML;900MG/100ML		N019691 001	Mar 24, 1988
+ ICU MEDICAL INC		5GM/100ML;149MG/100ML;900MG/100ML		N019691 003	Mar 24, 1988

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 10% AND SODIUM CHLORIDE 0.2%	IN	PLASTIC CONTAINER			
B BRAUN		10GM/100ML;200MG/100ML		N018386 001	
DEXTROSE 10% AND SODIUM CHLORIDE 0.45%	IN	PLASTIC CONTAINER			
B BRAUN		10GM/100ML;450MG/100ML		N018229 001	
DEXTROSE 10% AND SODIUM CHLORIDE 0.9%	IN	PLASTIC CONTAINER			
B BRAUN		10GM/100ML;900MG/100ML		N018047 001	
BAXTER HLTHCARE		10GM/100ML;900MG/100ML		N016696 001	
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45%	IN	PLASTIC CONTAINER			
B BRAUN		2.5GM/100ML;450MG/100ML		N018030 001	
FRESENIUS KABI USA		2.5GM/100ML;450MG/100ML		A211190 001	Dec 20, 2019
HOSPIRA		2.5GM/100ML;450MG/100ML		N018096 001	
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9%	IN	PLASTIC CONTAINER			
B BRAUN		2.5GM/100ML;900MG/100ML		N018376 001	
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3%	IN	PLASTIC CONTAINER			
ABBOTT		3.3GM/100ML;300MG/100ML		N018055 001	
DEXTROSE 5% AND SODIUM CHLORIDE 0.11%	IN	PLASTIC CONTAINER			
B BRAUN		5GM/100ML;110MG/100ML		N018030 005	
DEXTROSE 5% AND SODIUM CHLORIDE 0.2%	IN	PLASTIC CONTAINER			
B BRAUN		5GM/100ML;200MG/100ML		N018030 004	
MILES		5GM/100ML;200MG/100ML		N018399 001	
DEXTROSE 5% AND SODIUM CHLORIDE 0.225%	IN	PLASTIC CONTAINER			
ABBOTT		5GM/100ML;225MG/100ML		N019482 001	Oct 04, 1985
DEXTROSE 5% AND SODIUM CHLORIDE 0.3%	IN	PLASTIC CONTAINER			
ABBOTT		5GM/100ML;300MG/100ML		N019486 001	Oct 04, 1985
MILES		5GM/100ML;300MG/100ML		N018501 001	
DEXTROSE 5% AND SODIUM CHLORIDE 0.33%	IN	PLASTIC CONTAINER			
B BRAUN		5GM/100ML;330MG/100ML		N018030 003	
DEXTROSE 5% AND SODIUM CHLORIDE 0.45%	IN	PLASTIC CONTAINER			
ABBOTT		5GM/100ML;450MG/100ML		N019484 001	Oct 04, 1985
B BRAUN		5GM/100ML;450MG/100ML		N018030 002	
MILES		5GM/100ML;450MG/100ML		N018400 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

ABBOTT	5GM/100ML; 900MG/100ML	N019483 001	Oct 04, 1985
B BRAUN	5GM/100ML; 900MG/100ML	N018026 001	
MILES	5GM/100ML; 900MG/100ML	N018500 001	

DEXTROTHYROXINE SODIUM

TABLET; ORAL

CHOLOXIN

ABBVIE	1MG	N012302 005	
	2MG	N012302 002	
	4MG	N012302 004	
	6MG	N012302 006	

DEZOCINE

INJECTABLE; INJECTION

DALGAN

ASTRAZENECA	5MG/ML	N019082 001	Dec 29, 1989
	10MG/ML	N019082 002	Dec 29, 1989
	15MG/ML	N019082 003	Dec 29, 1989

DIATRIZOATE MEGLUMINE

INJECTABLE; INJECTION

ANGIOVIST 282

BAYER HLTHCARE	60%	A087726 001	Sep 23, 1982
----------------	-----	-------------	--------------

CARDIOGRAFIN

BRACCO	85%	N011620 002	
--------	-----	-------------	--

DIATRIZOATE MEGLUMINE

BRACCO	76%	N010040 017	
--------	-----	-------------	--

HYPAQUE

GE HEALTHCARE	30%	N016403 002	
	60%	N016403 001	

RENO-60

BRACCO	60%	N010040 016	
--------	-----	-------------	--

RENO-DIP

BRACCO	30%	N010040 012	
--------	-----	-------------	--

UROVIST MEGLUMINE DIU/CT

BAYER HLTHCARE	30%	A087739 001	Sep 23, 1982
----------------	-----	-------------	--------------

SOLUTION; URETERAL

RENO-30

BRACCO	30%	N010040 021	
--------	-----	-------------	--

UROVIST CYSTO

BAYER HLTHCARE	30%	A087729 001	Sep 23, 1982
----------------	-----	-------------	--------------

UROVIST CYSTO PEDIATRIC

BAYER HLTHCARE	30%	A087731 001	Sep 23, 1982
----------------	-----	-------------	--------------

SOLUTION; URETHRAL

HYPAQUE-CYSTO

GE HEALTHCARE	30%	N016403 003	
---------------	-----	-------------	--

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

ANGIOVIST 292

BAYER HLTHCARE	52%; 8%	A087724 001	Sep 23, 1982
----------------	---------	-------------	--------------

ANGIOVIST 370

BAYER HLTHCARE	66%; 10%	A087723 001	Sep 23, 1982
----------------	----------	-------------	--------------

DIATRIZOATE-60

INTL MEDICATION	52%; 8%	A088166 001	Jun 17, 1983
-----------------	---------	-------------	--------------

HYPAQUE-76

GE HEALTHCARE	66%; 10%	A086505 001	
---------------	----------	-------------	--

HYPAQUE-M, 75%

GE HEALTHCARE	50%; 25%	N010220 003	
---------------	----------	-------------	--

HYPAQUE-M, 90%

GE HEALTHCARE	60%; 30%	N010220 002	
---------------	----------	-------------	--

MD-60

MALLINCKRODT	52%; 8%	A087074 001	
--------------	---------	-------------	--

MD-76

MALLINCKRODT	66%; 10%	A087073 001	
--------------	----------	-------------	--

MD-76R

+ LIEBEL-FLARSHEIM	66%; 10%	N019292 001	Sep 29, 1989
--------------------	----------	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

RENOCAL-76

BRACCO 66%;10%

A089347 001 Jun 01, 1988

RENOGRAFIN-60

BRACCO 52%;8%

N010040 006

RENOGRAFIN-76

+ BRACCO 66%;10%

N010040 001

RENOVIST

BRACCO 34.3%;35%

N010040 020

RENOVIST II

BRACCO 28.5%;29.1%

N010040 019

SOLUTION; ORAL, RECTAL

GASTROVIST

BAYER HLTHCARE 66%;10%

A087728 001 Sep 23, 1982

DIATRIZOATE MEGLUMINE; IODIPAMIDE MEGLUMINE

SOLUTION; INTRAUTERINE

SINOGRAFIN

+ BRACCO 52.7%;26.8%

N011324 002

DIATRIZOATE SODIUM

FOR SOLUTION; ORAL, RECTAL

HYPAQUE

GE HEALTHCARE 100%

N011386 001

INJECTABLE; INJECTION

HYPAQUE

GE HEALTHCARE 25%

N009561 003

50%

N009561 001

MD-50

MALLINCKRODT 50%

A087075 001

UROVIST SODIUM 300

BAYER HLTHCARE 50%

A087725 001 Sep 23, 1982

SOLUTION; ORAL, RECTAL

HYPAQUE

GE HEALTHCARE 40%

N011386 003

SOLUTION; URETERAL

HYPAQUE SODIUM 20%

GE HEALTHCARE 20%

N009561 002

DIAZEPAM

CAPSULE, EXTENDED RELEASE; ORAL

VALRELEASE

ROCHE 15MG

N018179 001

GEL; RECTAL

DIASTAT

+ BAUSCH 5MG/ML (5MG/ML) **

N020648 002 Jul 29, 1997

+ 10MG/2ML (5MG/ML) **

N020648 003 Jul 29, 1997

+ 15MG/3ML (5MG/ML) **

N020648 004 Jul 29, 1997

+ 20MG/4ML (5MG/ML) **

N020648 005 Jul 29, 1997

INJECTABLE; INJECTION

DIAZEPAM

ABRAXIS PHARM 5MG/ML

A070662 001 Jun 25, 1986

HOSPIRA 5MG/ML

A071584 001 Oct 13, 1987

MARSAM PHARMS LLC 5MG/ML

A072371 001 Jan 29, 1993

PARENTA PHARMS 5MG/ML

A076815 001 Apr 15, 2004

US ARMY 5MG/ML **

N020124 001 Dec 05, 1990

WARNER CHILCOTT 5MG/ML

A071613 001 Oct 22, 1987

5MG/ML

A071614 001 Oct 22, 1987

WATSON LABS 5MG/ML

A070296 001 Feb 12, 1986

5MG/ML

A070911 001 Aug 28, 1986

5MG/ML

A070912 001 Aug 28, 1986

5MG/ML

A070930 001 Dec 01, 1986

WATSON LABS INC 5MG/ML

A072370 001 Jan 29, 1993

5MG/ML

A072397 001 Jan 29, 1993

WEST-WARD PHARMS INT 5MG/ML

A070311 001 Dec 16, 1985

5MG/ML

A070312 001 Dec 16, 1985

5MG/ML

A070313 001 Dec 16, 1985

5MG/ML

A071308 001 Jul 17, 1987

5MG/ML

A071309 001 Jul 17, 1987

5MG/ML

A071310 001 Jul 17, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DIAZEPAM

INJECTABLE; INJECTION

DIZAC

PHARMACIA AND UPJOHN 5MG/ML **

N019287 001 Jun 18, 1993

VALIUM

+ ROCHE 5MG/ML **

N016087 001

TABLET; ORAL

DIAZEPAM

ACTAVIS ELIZABETH

2MG

A070781 001 Mar 19, 1986

5MG

A070706 001 Mar 19, 1986

10MG

A070707 001 Mar 19, 1986

DAVA PHARMS INC

2MG

A070228 002 Sep 26, 1985

5MG

A070228 003 Sep 26, 1985

10MG

A070228 001 Sep 26, 1985

DURAMED PHARMS BARR

2MG

A070894 001 Aug 27, 1986

5MG

A070895 001 Aug 27, 1986

10MG

A070896 001 Aug 27, 1986

FERNDALE LABS

2MG

A070903 001 Apr 01, 1987

5MG

A070904 001 Apr 01, 1987

10MG

A070905 001 Apr 01, 1987

HALSEY

2MG

A070987 001 Aug 15, 1986

5MG

A070996 001 Aug 15, 1986

10MG

A070956 001 Aug 15, 1986

IVAX SUB TEVA PHARMS

2MG

A070360 001 Sep 04, 1985

5MG

A070361 001 Sep 04, 1985

10MG

A070362 001 Sep 04, 1985

MARTEC USA LLC

10MG

A072402 001 Apr 25, 1989

NUVO PHARM

10MG

A070464 001 Feb 25, 1986

PIONEER PHARMS

2MG

A070787 001 Aug 02, 1988

5MG

A070788 001 Aug 02, 1988

10MG

A070776 001 Aug 02, 1988

ROXANE

2MG

A070356 001 Jun 17, 1986

5MG

A070357 001 Jun 17, 1986

10MG

A070358 001 Jun 17, 1986

TEVA PHARMS

5MG

A070153 001 Nov 01, 1985

UPSHER SMITH LABS

2MG

A070302 001 Dec 20, 1985

5MG

A070303 001 Dec 20, 1985

10MG

A070304 001 Dec 20, 1985

VIRTUS PHARMS

2MG

A070462 001 Feb 25, 1986

5MG

A070463 001 Feb 25, 1986

WARNER CHILCOTT

2MG

A070209 001 Sep 04, 1985

5MG

A070210 001 Sep 04, 1985

10MG

A070222 001 Sep 04, 1985

WATSON LABS

2MG

A070456 001 Nov 01, 1985

5MG

A070457 001 Nov 01, 1985

10MG

A070458 001 Nov 01, 1985

Q-PAM

QUANTUM PHARMICS

2MG

A070423 001 Dec 12, 1985

2MG

A072431 001 Apr 29, 1988

5MG

A070424 001 Dec 12, 1985

5MG

A072432 001 Apr 29, 1988

10MG

A070425 001 Dec 12, 1985

10MG

A072433 001 Apr 29, 1988

DIAZOXIDE

CAPSULE; ORAL

PROGLYCEM

TEVA BRANDED PHARM

50MG

N017425 001

100MG

N017425 002

INJECTABLE; INJECTION

DIAZOXIDE

ABRAXIS PHARM

15MG/ML

A071519 001 Aug 26, 1987

HYPERSTAT

SCHERING

15MG/ML

N016996 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DIBUCAINE HYDROCHLORIDE

INJECTABLE; INJECTION				
HEAVY SOLUTION NUPERCAINE				
NOVARTIS	2.5MG/ML		N006203	001

DICHLORPHENAMIDE

TABLET; ORAL				
DARANIDE				
+ STRONGBRIDGE US	50MG **		N011366	001

DICLOFENAC

CAPSULE; ORAL				
ZORVOLEX				
+ ZYLA	18MG		N204592	001 Oct 18, 2013

DICLOFENAC POTASSIUM

CAPSULE; ORAL				
DICLOFENAC POTASSIUM				
STRIDES PHARMA	25MG		A210078	001 Dec 03, 2019
TABLET; ORAL				
CATAFLAM				
+ NOVARTIS	25MG **		N020142	001 Nov 24, 1993
+ NOVARTIS	50MG **		N020142	002 Nov 24, 1993
DICLOFENAC POTASSIUM				
SANDOZ	50MG		A075582	001 Feb 23, 2001
SUN PHARM INDUSTRIES	50MG		A075470	001 Feb 21, 2002
WATSON LABS TEVA	50MG		A075152	001 Nov 27, 1998

DICLOFENAC SODIUM

SOLUTION; INTRAVENOUS				
DICLOFENAC SODIUM				
MYLAN LABS LTD	37.5MG/ML (37.5MG/ML)		A208786	001 Jun 18, 2019
DYLOJECT				
+ JAVELIN PHARMS INC	37.5MG/ML (37.5MG/ML) **		N022396	001 Dec 23, 2014
SOLUTION; TOPICAL				
DICLOFENAC SODIUM				
APOTEX INC	1.5%		A202027	001 May 27, 2014
NOVAST LABS	1.5%		A206715	001 Aug 07, 2017
PENNSAID				
+ NUVO PHARMS INC	1.5% **		N020947	001 Nov 04, 2009
SOLUTION/DROPS; OPHTHALMIC				
DICLOFENAC SODIUM				
FALCON PHARMS	0.1%		N020809	001 May 04, 1998
RUBICON	0.1%		A077600	001 Nov 13, 2008
TABLET, DELAYED RELEASE; ORAL				
DICLOFENAC SODIUM				
CHARTWELL RX	25MG		A074376	001 Sep 28, 1995
	50MG		A074376	002 Sep 28, 1995
	75MG		A074394	001 Nov 30, 1995
MICRO LABS USA	50MG		A074986	001 Feb 26, 1999
	75MG		A074986	002 Feb 26, 1999
MYLAN PHARMS INC	50MG		A075281	002 Feb 12, 2002
	75MG		A075281	003 Feb 12, 2002
PLIVA	50MG		A074432	002 Jul 29, 1999
	75MG		A074432	003 Jul 29, 1999
ROXANE	25MG		A074391	001 Jun 29, 1995
	50MG		A074391	002 Jun 29, 1995
	75MG		A074391	003 Jun 29, 1995
TEVA	50MG		A074723	001 Mar 30, 1999
	75MG		A074390	001 Aug 15, 1996
TEVA PHARMS	25MG		A074459	001 Jun 25, 1997
	50MG		A074459	002 Jun 25, 1997
	75MG		A074459	003 Jun 25, 1997
VOLTAREN				
+ NOVARTIS	25MG **		N019201	001 Jul 28, 1988
+ NOVARTIS	50MG **		N019201	002 Jul 28, 1988
+ NOVARTIS	75MG **		N019201	003 Jul 28, 1988
TABLET, EXTENDED RELEASE; ORAL				
DICLOFENAC SODIUM				
ACTAVIS ELIZABETH	100MG		A075910	001 Jan 07, 2002
MYLAN	100MG		A076152	001 Dec 13, 2001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DICLOFENAC SODIUM

TABLET, EXTENDED RELEASE;ORAL

VOLTAREN-XR

+ NOVARTIS

100MG **

N020254 001 Mar 08, 1996

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE;ORAL

DICLOFENAC SODIUM AND MISOPROSTOL

EXELA HOLDINGS 50MG;0.2MG

A200540 001 Mar 14, 2014

75MG;0.2MG

A200540 002 Mar 14, 2014

DICLOXACILLIN SODIUM

CAPSULE;ORAL

DYCILL

GLAXOSMITHKLINE

EQ 250MG BASE

A060254 002

EQ 250MG BASE

A062238 001

EQ 500MG BASE

A060254 003

EQ 500MG BASE

A062238 002

PATHOCIL

+ WYETH AYERST

EQ 250MG BASE

N050011 002

+

EQ 500MG BASE

N050011 003 Mar 28, 1983

FOR SUSPENSION;ORAL

DICLOXACILLIN SODIUM

APOTHECON

EQ 62.5MG BASE/5ML

A061455 001

DYNAPEN

APOTHECON

EQ 62.5MG BASE/5ML

N050337 002

PATHOCIL

WYETH AYERST

EQ 62.5MG BASE/5ML

N050092 001

DICUMAROL

CAPSULE;ORAL

DICUMAROL

LILLY

25MG

N005509 003

50MG

N005509 001

TABLET;ORAL

DICUMAROL

ABBVIE

25MG

N005545 003

50MG

N005545 004

100MG

N005545 005

DICYCLOMINE HYDROCHLORIDE

CAPSULE;ORAL

BENTYL

+ ALLERGAN

10MG

N007409 003 Oct 15, 1984

DICYCLOMINE HYDROCHLORIDE

PIONEER PHARMS

10MG

A089361 001 Jan 10, 1989

SUN PHARM INDUSTRIES

10MG

A084505 001 Oct 21, 1986

WATSON LABS

10MG

A083179 001 Feb 12, 1986

INJECTABLE; INJECTION

DICYCLOMINE HYDROCHLORIDE

DR REDDYS

10MG/ML

A080614 001 Feb 11, 1986

SYRUP;ORAL

BENTYL

+ APTALIS PHARMA US

10MG/5ML **

N007961 002 Oct 15, 1984

DICYCLOMINE HYDROCHLORIDE

ALPHARMA US PHARMS

10MG/5ML

A084479 001

TABLET;ORAL

BENTYL

+ ALLERGAN

20MG

N007409 001 Oct 15, 1984

DICYCLOMINE HYDROCHLORIDE

PIONEER PHARMS

20MG

A088585 001 Aug 20, 1986

SUN PHARM INDUSTRIES

20MG

A084600 001 Jul 29, 1985

WATSON LABS

20MG

A084361 001 Feb 06, 1986

DIDANOSINE

CAPSULE, DELAYED REL PELLETS;ORAL

DIDANOSINE

BARR

200MG

A077167 001 Dec 03, 2004

250MG

A077167 002 Dec 03, 2004

400MG

A077167 003 Dec 03, 2004

MYLAN PHARMS INC

125MG

A090788 001 Apr 08, 2010

200MG

A090788 002 Apr 08, 2010

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DIRIDANOSINE

CAPSULE, DELAYED REL PELLETS;ORAL

DIRIDANOSINE

250MG

A090788 003 Apr 08, 2010

400MG

A090788 004 Apr 08, 2010

VIDEX EC

+ BRISTOL MYERS SQUIBB 125MG

N021183 001 Oct 31, 2000

+ 200MG

N021183 002 Oct 31, 2000

+ 250MG

N021183 003 Oct 31, 2000

+ 400MG

N021183 004 Oct 31, 2000

FOR SOLUTION;ORAL

DIRIDANOSINE

AUROBINDO PHARMA 10MG/ML

A078112 001 Mar 08, 2007

VIDEX

BRISTOL MYERS SQUIBB 100MG/PACKET

N020155 003 Oct 09, 1991

167MG/PACKET

N020155 004 Oct 09, 1991

250MG/PACKET

N020155 005 Oct 09, 1991

375MG/PACKET

N020155 006 Oct 09, 1991

+ BRISTOL-MYERS SQUIBB 10MG/ML

N020156 001 Oct 09, 1991

TABLET, CHEWABLE;ORAL

VIDEX

+ BRISTOL MYERS SQUIBB 25MG **

N020154 002 Oct 09, 1991

+ 50MG **

N020154 003 Oct 09, 1991

+ 100MG **

N020154 004 Oct 09, 1991

+ 150MG **

N020154 005 Oct 09, 1991

+ 200MG **

N020154 006 Oct 28, 1999

TABLET, FOR SUSPENSION;ORAL

DIRIDANOSINE

AUROBINDO 100MG

A077275 001 Aug 14, 2012

150MG

A077275 002 Aug 14, 2012

200MG

A077275 003 Aug 14, 2012

DIENESTROL

CREAM;VAGINAL

DIENESTROL

ORTHO MCNEIL PHARM 0.01%

N006110 005

DV

SANOFI AVENTIS US 0.01%

A083518 001

ESTRAGUARD

SOLVAY 0.01%

A084436 001

SUPPOSITORY;VAGINAL

DV

SANOFI AVENTIS US 0.7MG

A083517 001

DIETHYLCARBAMAZINE CITRATE

TABLET;ORAL

HETRAZAN

LEDERLE 50MG

N006459 001

DIETHYLPROPION HYDROCHLORIDE

TABLET;ORAL

DIETHYLPROPION HYDROCHLORIDE

CHARTWELL RX 25MG

A088267 001 Aug 25, 1983

25MG

A088268 001 Aug 25, 1983

EPIC PHARMA LLC 25MG

A040828 001 Nov 05, 2008

SANDOZ 25MG

A085916 001

TEVA 25MG

A088642 001 Sep 20, 1984

UCB INC 25MG

A085544 001

WATSON LABS 25MG

A085741 001

TENUATE

+ NOSTRUM LABS INC 25MG

N011722 002

SANOFI AVENTIS US 25MG

N017668 001

TEPANIL

3M 25MG

N011673 001

TABLET, EXTENDED RELEASE;ORAL

TENUATE

SANOFI AVENTIS US 75MG

N017669 001

TENUATE DOSPAN

+ NOSTRUM LABS INC 75MG

N012546 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DIETHYLPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

TEPANIL TEN-TAB

3M

75MG

N017956 001

DIETHYLSTILBESTROL

INJECTABLE; INJECTION

STILBESTROL

BRISTOL MYERS SQUIBB 0.2MG/ML

N004056 003

0.5MG/ML

N004056 004

1MG/ML

N004056 005

5MG/ML

N004056 006

SUPPOSITORY; VAGINAL

DIETHYLSTILBESTROL

LILLY

0.1MG

N004040 001

0.5MG

N004040 002

STILBESTROL

BRISTOL MYERS SQUIBB 0.1MG

N004056 001

0.5MG

N004056 002

TABLET; ORAL

DIETHYLSTILBESTROL

LILLY

0.1MG

N004041 002

0.5MG

N004041 003

1MG

N004041 004

5MG

N004041 005

STILBESTROL

TABLICAPS 0.5MG

A083004 001

1MG

A083002 001

5MG

A083006 001

STILBETIN

BRISTOL MYERS SQUIBB 0.1MG

N004056 007

0.25MG

N004056 017

0.5MG

N004056 008

1MG

N004056 009

5MG

N004056 010

TABLET, DELAYED RELEASE;ORAL

DIETHYLSTILBESTROL

LILLY

0.1MG

N004039 002

0.25MG

N004039 005

0.5MG

N004039 003

1MG

N004039 004

5MG

N004039 006

STILBESTROL

TABLICAPS 0.5MG

A083003 001

1MG

A083005 001

5MG

A083007 001

STILBETIN

BRISTOL MYERS SQUIBB 0.1MG

N004056 011

0.5MG

N004056 012

1MG

N004056 013

5MG

N004056 014

DIETHYLSTILBESTROL DIPHOSPHATE

INJECTABLE; INJECTION

STILPHOSTROL

BAYER PHARMS

250MG/5ML

N010010 001

TABLET; ORAL

STILPHOSTROL

BAYER PHARMS

50MG

N010010 002

DIFLORASONE DIACETATE

CREAM; TOPICAL

DIFLORASONE DIACETATE

FOUGERA PHARMS

0.05%

A075187 001 Mar 30, 1998

FLORONE

PFIZER

0.05% **

N017741 001

FLORONE E

PFIZER

0.05%

N019259 001 Aug 28, 1985

PSORCON

+ TARO PHARMS NORTH

0.05% **

N020205 001 Nov 20, 1992

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DIFLORASONE DIACETATE

OINTMENT; TOPICAL

PSORCON

+ PFIZER

0.05%

N019260 001 Aug 28, 1985

PSORCON E

PFIZER

0.05%

N017994 001

DIFLUNISAL

TABLET; ORAL

DIFLUNISAL

ANI PHARMS INC

500MG

A074604 001 Jun 10, 1996

PUREPAC PHARM

250MG

A074285 001 May 07, 1996

500MG

A074285 002 May 07, 1996

SOCORRO

250MG

A073562 001 Nov 27, 1992

500MG

A073563 001 Nov 27, 1992

TEVA

250MG

A073679 001 Jul 31, 1992

WATSON LABS

250MG

A074400 001 Jul 17, 1997

500MG

A074400 002 Jul 17, 1997

DOLOBID

+ MERCK

250MG **

N018445 001 Apr 19, 1982

+

500MG **

N018445 002 Apr 19, 1982

DIGITOXIN

INJECTABLE; INJECTION

CRYSTODIGIN

LILLY

0.2MG/ML

A084100 005

DIGOXIN

CAPSULE; ORAL

LANOXICAPS

GLAXOSMITHKLINE LLC

0.05MG

N018118 002 Jul 26, 1982

0.1MG

N018118 003 Jul 26, 1982

0.15MG

N018118 004 Sep 24, 1984

0.2MG

N018118 001 Jul 26, 1982

INJECTABLE; INJECTION

DIGOXIN

ABRAXIS PHARM

0.25MG/ML

A083217 001

HOSPIRA

0.25MG/ML

A040093 001 May 16, 1996

0.25MG/ML

A040206 001 Aug 28, 1998

WYETH AYERST

0.25MG/ML

A084386 001

DIGOXIN PEDIATRIC

HOSPIRA

0.1MG/ML

A040092 001 Apr 25, 1996

TABLET; ORAL

LANOXIN

+ CONCORDIA

0.1875MG

N020405 003 Sep 30, 1997

0.375MG

N020405 005 Sep 30, 1997

0.5MG

N020405 006 Sep 30, 1997

DIHYDROERGOTAMINE MESYLATE; HEPARIN SODIUM; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

EMBOLEX

NOVARTIS

0.5MG/0.5ML; 2,500
UNITS/0.5ML; 5.33MG/0.5ML

N018885 001 Nov 30, 1984

0.5MG/0.7ML; 5,000

N018885 002 Nov 30, 1984

UNITS/0.7ML; 7.46MG/0.7ML

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CARDIZEM SR

+ BIOVAIL

60MG **

N019471 001 Jan 23, 1989

+

90MG **

N019471 002 Jan 23, 1989

+

120MG **

N019471 003 Jan 23, 1989

+

180MG **

N019471 004 Jan 23, 1989

DILACOR XR

+ ALLERGAN

120MG **

N020092 001 May 29, 1992

+

180MG **

N020092 002 May 29, 1992

+

240MG **

N020092 003 May 29, 1992

DILT-CD

APOTEX

120MG

A076151 001 May 20, 2004

180MG

A076151 002 May 20, 2004

240MG

A076151 003 May 20, 2004

300MG

A076151 004 May 20, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DILTIAZEM HYDROCHLORIDE

ACTAVIS LABS FL INC	120MG	A074852 001	Oct 10, 1997
	180MG	A074852 002	Oct 10, 1997
	240MG	A074852 003	Oct 10, 1997
BIOVAIL	60MG	A074845 001	Sep 15, 1999
	90MG	A074845 002	Sep 15, 1999
	120MG	A074845 003	Sep 15, 1999
	120MG	N020939 001	Jan 28, 2000
	180MG	N020939 002	Jan 28, 2000
	240MG	N020939 003	Jan 28, 2000
	300MG	N020939 004	Jan 28, 2000
	360MG	N020939 005	Sep 14, 2001
	420MG	N020939 006	Sep 14, 2001
MYLAN	120MG	A075124 002	Mar 18, 1998
	180MG	A075124 003	Mar 18, 1998
	240MG	A075124 001	Mar 18, 1998
NESHER PHARMS	120MG	A076563 002	Sep 12, 2006
	180MG	A076563 003	Sep 12, 2006
	240MG	A076563 004	Sep 12, 2006
	300MG	A076563 005	Sep 12, 2006
	360MG	A076563 006	Sep 12, 2006
	420MG	A076563 001	Sep 12, 2006
PAR PHARM	360MG	A209766 001	May 30, 2018
TEVA	60MG	A074079 001	Nov 30, 1993
	90MG	A074079 002	Nov 30, 1993
	120MG	A074079 003	Nov 30, 1993
DILTZAC			
APOTEX	120MG	A076395 001	Feb 01, 2006
	180MG	A076395 002	Feb 01, 2006
	240MG	A076395 003	Feb 01, 2006
	300MG	A076395 004	Feb 01, 2006
	360MG	A076395 005	Feb 01, 2006
INJECTABLE; INJECTION			
CARDIZEM			
BIOVAIL	100MG/VIAL **	N020792 001	Sep 05, 1997
+ BIOVAIL LABS INTL	5MG/ML **	N020027 001	Oct 24, 1991
+	25MG/VIAL **	N020027 003	Aug 18, 1995
DILTIAZEM HYDROCHLORIDE			
DR REDDYS	5MG/ML	A074894 001	Aug 26, 1997
HOSPIRA	5MG/ML	A075004 001	Feb 16, 2000
	5MG/ML	A075106 001	Apr 29, 1999
MYLAN LABS LTD	5MG/ML	A075375 001	Sep 30, 1999
TABLET; ORAL			
DILTIAZEM HYDROCHLORIDE			
APOTHECON	30MG	A074051 001	Mar 31, 1993
	60MG	A074051 002	Mar 31, 1993
	90MG	A074051 003	Mar 31, 1993
	120MG	A074051 004	Mar 31, 1993
CHARTWELL MOLECULES	30MG	A074093 001	Nov 05, 1992
	60MG	A074093 002	Nov 05, 1992
	90MG	A074093 003	Nov 05, 1992
	120MG	A074093 004	Nov 05, 1992
IVAX SUB TEVA PHARMS	30MG	A074168 001	Mar 03, 1995
	60MG	A074168 002	Mar 03, 1995
	90MG	A074168 003	Mar 03, 1995
	120MG	A074168 004	Mar 03, 1995
TEVA	30MG	A074084 001	Feb 25, 1994
	60MG	A074084 002	Feb 25, 1994
TEVA PHARMS	30MG	A074067 001	Nov 05, 1992
	60MG	A074067 002	Nov 05, 1992
	90MG	A074067 003	Nov 05, 1992
	120MG	A074067 004	Nov 05, 1992

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DILTIAZEM MALATETABLET, EXTENDED RELEASE;ORAL
TIAMATE

MERCK	EQ 120MG HYDROCHLORIDE	N020506 001	Oct 04, 1996
	EQ 180MG HYDROCHLORIDE	N020506 002	Oct 04, 1996
	EQ 240MG HYDROCHLORIDE	N020506 003	Oct 04, 1996

DILTIAZEM MALATE; ENALAPRIL MALEATETABLET, EXTENDED RELEASE;ORAL
TECZEM

BIOVAIL	EQ 180MG HYDROCHLORIDE;5MG	N020507 001	Oct 04, 1996
---------	----------------------------	-------------	--------------

DIMENHYDRINATE

INJECTABLE; INJECTION

DIMENHYDRINATE

BAXTER HLTHCARE	50MG/ML	A084767 001	
WATSON LABS	50MG/ML	A083531 001	
WATSON LABS TEVA	50MG/ML	A080615 001	
WYETH AYERST	50MG/ML	A084316 001	

LIQUID; ORAL

DIMENHYDRINATE

ALRA	12.5MG/4ML	A080715 001	
------	------------	-------------	--

TABLET; ORAL

DIMENHYDRINATE

HEATHER	50MG	A080841 001	
NEXGEN PHARMA INC	50MG	A085985 001	
WATSON LABS	50MG	A085166 001	

DIMETHYL SULFOXIDE

SOLUTION; INTRAVESICAL

DIMETHYL SULFOXIDE

MYLAN INSTITUTIONAL	50%	A076185 001	Nov 29, 2002
---------------------	-----	-------------	--------------

DIMYRISTOYL LECITHIN; PERFLEXANE

INJECTABLE; INTRAVENOUS

IMAGENT

VESSELON SPV LLC	0.92MG/VIAL;0.092MG/VIAL	N021191 001	May 31, 2002
------------------	--------------------------	-------------	--------------

DINOPROST TROMETHAMINE

INJECTABLE; INJECTION

PROSTIN F2 ALPHA

PHARMACIA AND UPJOHN	EQ 5MG BASE/ML	N017434 001	
----------------------	----------------	-------------	--

DIPHEMANIL METHYLSULFATE

TABLET; ORAL

PRANTAL

SCHERING	100MG	N008114 004	
----------	-------	-------------	--

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

BENADRYL

MCNEIL CONS	25MG	N005845 007	
	50MG	N005845 001	

DIPHENHYDRAMINE HYDROCHLORIDE

ALRA	25MG	A080519 004	
	50MG	A080519 003	
ANABOLIC	50MG	A083275 001	
ELKINS SINN	25MG	A085701 001	
	50MG	A085701 002	
FOSUN PHARMA	25MG	A080832 001	
	25MG	A080845 002	
	50MG	A080832 002	
	50MG	A080845 001	
HALSEY	50MG	A087914 001	Jun 04, 1984
HEATHER	25MG	A084524 001	
	50MG	A083953 001	
HERITAGE PHARMA	50MG	A080727 001	
	50MG	A080738 001	
HIKMA INTL PHARMS	50MG	A083567 001	
IMPAX LABS	25MG	A080807 001	
	50MG	A080807 002	
IVAX SUB TEVA PHARMS	25MG	A080762 001	
	50MG	A080762 002	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

LANNETT	25MG	A080868	001	
	50MG	A080868	002	
LEDERLE	25MG	A086874	001	
	50MG	A086875	001	
LNK	25MG	A087977	001	Jan 27, 1983
	50MG	A087978	001	Jan 27, 1983
MK LABS	25MG	A083087	001	
	50MG	A083087	002	
MUTUAL PHARM	25MG	A084506	001	
NEWTRON PHARMS	25MG	A086543	001	
	50MG	A086544	001	
NEXGEN PHARMA INC	25MG	A083634	001	
PERRIGO	25MG	A083061	001	
	50MG	A083061	002	
PIONEER PHARMS	25MG	A089101	001	Dec 20, 1985
	50MG	A088880	001	Dec 20, 1985
PUREPAC PHARM	25MG	A085156	001	
	50MG	A085150	001	
PVT FORM	25MG	A083027	001	
	50MG	A083027	002	
ROXANE	50MG	A080635	001	
SUN PHARM INDUSTRIES	25MG	A089488	001	Jan 02, 1987
	50MG	A089489	001	Jan 02, 1987
SUPERPHARM	25MG	A089040	001	May 15, 1985
	50MG	A089041	001	May 15, 1985
TEVA	25MG	A085874	001	
	50MG	A085874	002	
VALEANT PHARM INTL	25MG	A080596	001	
	50MG	A080592	001	
VANGARD	25MG	A088034	001	Oct 27, 1982
	50MG	A087630	001	
WATSON LABS	25MG	A080728	001	
	25MG	A083797	001	
	25MG	A085138	001	
	50MG	A083797	002	
	50MG	A085083	001	
WHITEWORTH TOWN PLSN	25MG	A083441	001	
	50MG	A080800	001	

ELIXIR; ORAL

BELIX

HALSEY	12.5MG/5ML	A086586	001	Oct 03, 1983
--------	------------	---------	-----	--------------

BENADRYL

MCNEIL CONS	12.5MG/5ML	N005845	004	
-------------	------------	---------	-----	--

DIBENIL

CENCI	12.5MG/5ML	A088304	001	Dec 16, 1983
-------	------------	---------	-----	--------------

DIPHEN

USL PHARMA	12.5MG/5ML	A084640	001	
------------	------------	---------	-----	--

DIPHENHYDRAMINE HYDROCHLORIDE

BUNDY	12.5MG/5ML	A083674	001	
CENCI	12.5MG/5ML	A087941	001	Dec 17, 1982
KV PHARM	12.5MG/5ML	A085621	001	
LANNETT	12.5MG/5ML	A080939	002	
LEDERLE	12.5MG/5ML	A086937	001	
MK LABS	12.5MG/5ML	A083088	002	
NASKA	12.5MG/5ML	A088680	001	May 31, 1985
PERRIGO	12.5MG/5ML	A083063	001	
PUREPAC PHARM	12.5MG/5ML	A083237	001	Jan 25, 1982
PVT FORM	12.5MG/5ML	A085287	001	
ROXANE	12.5MG/5ML	A080643	001	

HYDRAMINE

ALPHARMA US PHARMS	12.5MG/5ML	A080763	002	
--------------------	------------	---------	-----	--

INJECTABLE; INJECTION

BENADRYL

MCNEIL CONS	10MG/ML	N006146	001	
-------------	---------	---------	-----	--

+	50MG/ML **	N006146	002	
---	------------	---------	-----	--

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

BENADRYL PRESERVATIVE FREE

+ MCNEIL CONS 50MG/ML ** N009486 001

DIPHENHYDRAMINE HYDROCHLORIDE

BEL MAR 10MG/ML A080822 001

DR REDDYS 10MG/ML A080873 001

50MG/ML A080873 002

EUROHLTH INTL SARL 50MG/ML A083183 001

LYPHOMED 10MG/ML A087066 001

WATSON LABS 10MG/ML A083533 001

WYETH AYERST 50MG/ML A080577 001

DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

ABRAXIS PHARM 50MG/ML A080586 002

DR REDDYS 50MG/ML A080873 003

INTL MEDICATION 50MG/ML A084094 001

SYRUP; ORAL

ANTITUSSIVE

PERRIGO 12.5MG/5ML A071292 001 Apr 10, 1987

BELDIN

HALSEY 12.5MG/5ML A089179 001 Jun 05, 1986

BENYLIN

PARKE DAVIS 12.5MG/5ML N006514 004

DIPHEN

MORTON GROVE 12.5MG/5ML A070118 001 Oct 01, 1985

DIPHENHYDRAMINE HYDROCHLORIDE

AKORN 12.5MG/5ML A072416 001 Sep 28, 1990

ALPHARMA US PHARMS 12.5MG/5ML A070497 001 Apr 25, 1989

CUMBERLAND SWAN 12.5MG/5ML A073611 001 Aug 20, 1992

HYDRAMINE

ALPHARMA US PHARMS 12.5MG/5ML A070205 001 Jan 28, 1986

SILPHEN

LANNETT CO INC 12.5MG/5ML A072646 001 Feb 27, 1992

VICKS FORMULA 44

WARNER CHILCOTT 12.5MG/5ML A070524 001 Jan 14, 1987

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE

P AND L 25MG; 220MG A207597 001 Jan 25, 2019

DIPHENHYDRAMINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

BENYLIN

PARKE DAVIS 12.5MG/5ML; 30MG/5ML N019014 001 Jun 11, 1985

DIPHENIDOL HYDROCHLORIDE

TABLET; ORAL

VONTROL

GLAXOSMITHKLINE EQ 25MG BASE N016033 001

DIPHENYLPYRALINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

HISPRIL

GLAXOSMITHKLINE 5MG N011945 001

DIPIVEFRIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AKPRO

AKORN 0.1% A074382 001 Sep 29, 1995

DIPIVEFRIN HYDROCHLORIDE

BAUSCH AND LOMB 0.1% A074188 001 May 19, 1995

FALCON PHARMS 0.1% A073636 001 Jun 30, 1994

PROPINE

ALLERGAN 0.1% N018239 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

DR REDDYS	5MG/ML	A074952	001	Nov 26, 1997
HOSPIRA	5MG/ML	A074601	001	Dec 19, 1997
MYLAN LABS LTD	5MG/ML	A075769	001	Nov 27, 2002

IV PERSANTINE

+ BOEHRINGER INGELHEIM	5MG/ML **	N019817	001	Dec 13, 1990
------------------------	-----------	---------	-----	--------------

TABLET; ORAL

DIPYRIDAMOLE

ANI PHARMS INC	25MG	A086944	002	Apr 16, 1991
	50MG	A086944	001	Feb 25, 1992
	75MG	A086944	003	Feb 25, 1992
GLENMARK GENERICS	25MG	A088999	001	Feb 05, 1991
	50MG	A089000	001	Feb 05, 1991
	75MG	A089001	001	Feb 05, 1991
LANNETT CO INC	25MG	A040898	001	Apr 23, 2008
	50MG	A040898	002	Apr 23, 2008
	75MG	A040898	003	Apr 23, 2008
OXFORD PHARMS	25MG	A040542	001	Apr 21, 2006
	50MG	A040542	002	Apr 21, 2006
	75MG	A040542	003	Apr 21, 2006
PUREPAC PHARM	25MG	A089425	001	Jul 12, 1990
	50MG	A089426	001	Jul 12, 1990
	75MG	A089427	001	Jul 12, 1990
WATSON LABS	50MG	A087160	001	Jun 07, 1996

DIRITHROMYCIN

TABLET, DELAYED RELEASE; ORAL

DYNABAC

LILLY RES LABS	250MG	N050678	001	Jun 19, 1995
----------------	-------	---------	-----	--------------

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

DISOPYRAMIDE PHOSPHATE

INTERPHARM	EQ 100MG BASE	A071190	001	Jan 15, 1987
	EQ 150MG BASE	A071191	001	Jan 15, 1987
IVAX SUB TEVA PHARMS	EQ 100MG BASE	A070186	001	Nov 18, 1985
	EQ 150MG BASE	A070187	001	Nov 18, 1985
MYLAN	EQ 100MG BASE	A070138	001	Jun 14, 1985
	EQ 150MG BASE	A070139	001	Jun 14, 1985
RISING	EQ 100MG BASE	A070470	001	Dec 10, 1985
	EQ 150MG BASE	A070471	001	Dec 10, 1985
SUN PHARM INDUSTRIES	EQ 100MG BASE	A070351	001	Dec 17, 1985
	EQ 150MG BASE	A070352	001	Dec 17, 1985
SUPERPHARM	EQ 100MG BASE	A070940	001	Feb 09, 1987
	EQ 150MG BASE	A070941	001	Feb 09, 1987
WATSON LABS	EQ 100MG BASE	A070240	001	Feb 02, 1986
	EQ 150MG BASE	A070241	001	Feb 02, 1986

CAPSULE, EXTENDED RELEASE; ORAL

DISOPYRAMIDE PHOSPHATE

NESHER PHARMS	EQ 150MG BASE	A071200	001	Dec 15, 1987
---------------	---------------	---------	-----	--------------

DISULFIRAM

TABLET; ORAL

ANTABUSE

+ TEVA WOMENS	250MG **	N007883	003	
+	500MG **	N007883	002	

DISULFIRAM

MYLAN	250MG	A203916	001	Mar 04, 2015
	500MG	A203916	002	Mar 04, 2015
PAR PHARM	250MG	A088792	001	Aug 14, 1984
	500MG	A088793	001	Aug 14, 1984
WATSON LABS	250MG	A086889	001	
	250MG	A087973	001	Aug 05, 1983
	500MG	A087974	001	Aug 05, 1983
WATSON LABS TEVA	500MG	A086890	001	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS;ORAL

DIVALPROEX SODIUM

MYLAN

EQ 125MG VALPROIC ACID

A090407 001 Mar 28, 2011

TABLET, DELAYED RELEASE;ORAL

DEPAKOTE CP

ABBOTT

EQ 250MG BASE

N019794 001 Jul 11, 1990

EQ 500MG BASE

N019794 002 Jul 11, 1990

DIVALPROEX SODIUM

MYLAN

EQ 125MG VALPROIC ACID

A077254 001 Jul 29, 2008

EQ 125MG VALPROIC ACID

A090062 001 Mar 17, 2009

EQ 250MG VALPROIC ACID

A077254 002 Jul 29, 2008

EQ 250MG VALPROIC ACID

A090062 002 Mar 17, 2009

EQ 500MG VALPROIC ACID

A077254 003 Jul 29, 2008

EQ 500MG VALPROIC ACID

A090062 003 Mar 17, 2009

TEVA

EQ 125MG VALPROIC ACID

A076941 001 Jul 29, 2008

EQ 250MG VALPROIC ACID

A076941 002 Jul 29, 2008

EQ 500MG VALPROIC ACID

A076941 003 Jul 29, 2008

TABLET, EXTENDED RELEASE;ORAL

DIVALPROEX SODIUM

ANCHEN PHARMS

EQ 250MG VALPROIC ACID

A078445 001 Feb 26, 2009

EQ 500MG VALPROIC ACID

A078445 002 Aug 04, 2009

COSETTE

EQ 500MG VALPROIC ACID

A078700 001 Aug 03, 2009

IMPAX LABS

EQ 250MG VALPROIC ACID

A078791 001 May 06, 2009

EQ 500MG VALPROIC ACID

A078791 002 Aug 04, 2009

DOBUTAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DOBUTAMINE HYDROCHLORIDE

BAXTER HLTHCARE

EQ 12.5MG BASE/ML

A074381 001 Sep 26, 1996

DR REDDYS

EQ 12.5MG BASE/ML

A074995 001 Mar 31, 1998

HOSPIRA

EQ 12.5MG BASE/ML

A074292 001 Feb 16, 1995

EQ 1.25GM BASE/100ML

A074634 001 Sep 27, 1996

LUITPOLD

EQ 12.5MG BASE/ML

A074545 001 Jun 25, 1998

TELISTENT

EQ 12.5MG BASE/ML

A074098 001 Feb 21, 1995

TEVA PARENTERAL

EQ 12.5MG BASE/ML

A074206 001 Oct 19, 1993

WATSON LABS

EQ 12.5MG BASE/ML

A074114 001 Nov 30, 1993

WATSON LABS INC

EQ 12.5MG BASE/ML

A074279 001 Feb 18, 1998

DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5%

HOSPIRA

EQ 50MG BASE/100ML

N020269 001 Oct 19, 1993

EQ 100MG BASE/100ML

N020269 002 Oct 19, 1993

EQ 200MG BASE/100ML

N020269 003 Oct 19, 1993

DOBUTREX

+ LILLY

EQ 12.5MG BASE/ML **

N017820 002

DOCETAXEL

INJECTABLE;INJECTION

DOCEFREZ

+ SUN PHARMA GLOBAL

20MG/VIAL

N022534 001 May 03, 2011

+

80MG/VIAL

N022534 002 May 03, 2011

DOCETAXEL

+ ACCORD HLTHCARE

20MG/0.5ML (40MG/ML)

N201195 001 Jun 08, 2011

+

80MG/2ML (40MG/ML)

N201195 002 Jun 08, 2011

APOTEX INC

20MG/0.5ML (40MG/ML)

N022312 001 Jan 11, 2012

80MG/2ML (40MG/ML)

N022312 002 Jan 11, 2012

HONG KONG

20MG/2ML (10MG/ML)

A209634 001 Aug 24, 2018

80MG/8ML (10MG/ML)

A209634 002 Aug 24, 2018

160MG/16ML (10MG/ML)

A209634 003 Aug 24, 2018

+ HOSPIRA INC

120MG/6ML (20MG/ML)

N022234 006 Jun 23, 2016

PFIZER LABS

20MG/2ML (10MG/ML)

N202356 001 Mar 13, 2014

80MG/8ML (10MG/ML)

N202356 002 Mar 13, 2014

130MG/13ML (10MG/ML)

N202356 003 Mar 13, 2014

200MG/20ML (10MG/ML)

N202356 004 Mar 13, 2014

TEVA PHARMS USA

20MG/ML (20MG/ML)

A203877 001 Sep 16, 2015

80MG/4ML (20MG/ML)

A203877 002 Sep 16, 2015

TAXOTERE

+ SANOFI AVENTIS US

40MG/ML **

N020449 001 May 14, 1996

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DOFETILIDE

CAPSULE; ORAL

DOFETILIDE

PRINSTON INC	0.125MG	A211223 001	Dec 17, 2019
	0.25MG	A211223 002	Dec 17, 2019
	0.5MG	A211223 003	Dec 17, 2019

DOLASETRON MESYLATE

INJECTABLE; INJECTION

ANZEMET

+ US PHARM HOLDINGS	12.5MG/0.625ML (20MG/ML)	N020624 002	Sep 11, 1997
+	100MG/5ML (20MG/ML)	N020624 001	Sep 11, 1997
	500MG/25ML (20MG/ML)	N020624 003	Dec 11, 2001

TABLET; ORAL

ANZEMET

+ US PHARM HOLDINGS	50MG	N020623 001	Sep 11, 1997
+	100MG	N020623 002	Sep 11, 1997

DONEPEZIL HYDROCHLORIDE

SOLUTION; ORAL

ARICEPT

EISAI INC	5MG/5ML	N021719 001	Oct 18, 2004
-----------	---------	-------------	--------------

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

ACCORD HLTHCARE	5MG	A201335 001	Aug 29, 2011
	10MG	A201335 002	Aug 29, 2011
ACTAVIS ELIZABETH	23MG	A202415 001	Dec 17, 2015
APOTEX	5MG	A078841 001	Jun 02, 2011
	10MG	A078841 002	Jun 02, 2011
HERITAGE PHARMA	5MG	A077344 001	May 31, 2011
	10MG	A077344 002	May 31, 2011
HIKMA PHARMS	5MG	A090247 001	May 31, 2011
	10MG	A090247 002	May 31, 2011
HISUN PHARM HANGZHOU	23MG	A202410 001	Mar 24, 2017
MYLAN PHARMS INC	5MG	A090521 001	May 31, 2011
	10MG	A090521 002	May 31, 2011
OSMOTICA PHARM US	23MG	A203114 001	Jan 26, 2016
PAR PHARM	23MG	A202542 001	Jul 24, 2013
SUN PHARM	23MG	A204293 001	Jun 05, 2015
SUN PHARM INDS LTD	5MG	A076786 001	Nov 26, 2010
	10MG	A076786 002	Nov 26, 2010
UNICHEM	5MG	A203656 001	Jun 23, 2016
	10MG	A203656 002	Jun 23, 2016
WOCKHARDT	5MG	A091267 001	May 31, 2011
	10MG	A091267 002	May 31, 2011

TABLET, ORALLY DISINTEGRATING; ORAL

ARICEPT ODT

+ EISAI INC	5MG	N021720 001	Oct 18, 2004
+	10MG	N021720 002	Oct 18, 2004

DONEPEZIL HYDROCHLORIDE

HERITAGE PHARMA	5MG	A078388 002	Nov 26, 2010
	10MG	A078388 001	Nov 26, 2010
SUN PHARM INDUSTRIES	5MG	A077975 002	Dec 11, 2009
	10MG	A077975 001	Dec 11, 2009
UNICHEM	5MG	A204831 001	Nov 10, 2016
	10MG	A204831 002	Nov 10, 2016
ZYDUS PHARMS USA INC	5MG	A090175 001	May 10, 2011
	10MG	A090175 002	May 10, 2011

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE

AMNEAL PHARMS	10MG;14MG	A208328 001	Jan 27, 2017
	10MG;28MG	A208328 002	Jan 27, 2017

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HYDROCHLORIDE

ABBOTT	40MG/ML	A070656	001	Jan 24, 1989
	80MG/ML	A070657	001	Jan 24, 1989
ABRAXIS PHARM	40MG/ML	A070012	001	Jun 12, 1985
	40MG/ML	A070058	001	Mar 20, 1985
	80MG/ML	A070013	001	Jun 12, 1985
	80MG/ML	A070059	001	Mar 20, 1985
	160MG/ML	A070364	001	Dec 04, 1985
AM REGENT	40MG/ML	A070799	001	Feb 11, 1987
	80MG/ML	A070820	001	Feb 11, 1987
	160MG/ML	A070826	001	Feb 11, 1987
BAXTER HLTHCARE	40MG/ML	N018398	001	
	80MG/ML	N018398	002	Mar 22, 1982
HOSPIRA	40MG/ML	A074403	001	May 23, 1996
IGI LABS INC	40MG/ML	A070087	001	Oct 23, 1985
	80MG/ML	A070089	001	Oct 23, 1985
	80MG/ML	A070090	001	Oct 23, 1985
	80MG/ML	A070091	001	Oct 23, 1985
	160MG/ML	A070092	001	Oct 23, 1985
	160MG/ML	A070093	001	Oct 23, 1985
	160MG/ML	A070094	001	Oct 23, 1985
INTL MEDICATION	40MG/ML	N018014	001	
LYPHOMED	40MG/ML	N018549	001	Mar 11, 1983
SMITH AND NEPHEW	40MG/ML	A070011	001	Aug 29, 1985
	40MG/ML	A070046	001	Aug 29, 1985
	80MG/ML	A070047	001	Aug 29, 1985
TELIGENT	40MG/ML	N018656	001	Jun 28, 1983
TEVA PARENTERAL	40MG/ML	A072999	001	Oct 23, 1991
	80MG/ML	A073000	001	Oct 23, 1991
WARNER CHILCOTT	40MG/ML	A070558	001	Sep 20, 1985
	40MG/ML	N018138	001	
	80MG/ML	A070559	001	Sep 20, 1985
DOPAMINE HYDROCHLORIDE IN DEXTROSE 5%				
HOSPIRA	1.6MG/ML	N020542	001	Aug 30, 1995
INTROPIN				
HOSPIRA	40MG/ML	N017395	001	
	80MG/ML	N017395	002	
	160MG/ML	N017395	003	

DORIPENEM

INJECTABLE; INTRAVENOUS

DORIBAX

+	SHIONOGI INC	250MG/VIAL	N022106	002	Oct 05, 2010
+		500MG/VIAL	N022106	001	Oct 12, 2007

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

AM REGENT	EQ 2% BASE	A079186	001	Nov 18, 2009
INDOCO	EQ 2% BASE	A202053	001	Sep 11, 2014
RUBICON	EQ 2% BASE	A078395	001	Oct 28, 2008
TEVA PHARMS	EQ 2% BASE	A078756	001	Dec 04, 2008
ZAMBON SPA	EQ 2% BASE	A091034	001	Dec 04, 2013

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

FDC LTD	EQ 2% BASE;EQ 0.5% BASE	A205295	001	Jun 13, 2019
INDOCO	EQ 2% BASE;EQ 0.5% BASE	A202054	001	Sep 03, 2014
LANNETT CO INC	EQ 2% BASE;EQ 0.5% BASE	A201998	001	Dec 17, 2014
RUBICON	EQ 2% BASE;EQ 0.5% BASE	A078201	001	Oct 28, 2008
ZAMBON SPA	EQ 2% BASE;EQ 0.5% BASE	A091180	001	Dec 04, 2013

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DOXACURIUM CHLORIDEINJECTABLE; INJECTION
NUROMAX

ABBVIE	EQ 1MG BASE/ML	N019946 001	Mar 07, 1991
--------	----------------	-------------	--------------

DOXAPRAM HYDROCHLORIDEINJECTABLE; INJECTION
DOXAPRAM HYDROCHLORIDE
WATSON LABS

20MG/ML	A073529 001	Jan 30, 1992
---------	-------------	--------------

DOXAZOSIN MESYLATETABLET; ORAL
DOXAZOSIN MESYLATE

ACTAVIS ELIZABETH	EQ 1MG BASE	A075574 001	Oct 18, 2000
	EQ 2MG BASE	A075574 002	Oct 18, 2000
	EQ 4MG BASE	A075574 003	Oct 18, 2000
	EQ 8MG BASE	A075574 004	Oct 18, 2000
ANI PHARMS INC	EQ 1MG BASE	A075432 001	Oct 18, 2000
	EQ 2MG BASE	A075432 002	Oct 18, 2000
	EQ 4MG BASE	A075432 003	Oct 18, 2000
	EQ 8MG BASE	A075432 004	Oct 18, 2000
DAVA PHARMS INC	EQ 1MG BASE	A076161 001	Jun 10, 2004
	EQ 2MG BASE	A076161 002	Jun 10, 2004
	EQ 4MG BASE	A076161 003	Jun 10, 2004
	EQ 8MG BASE	A076161 004	Jun 10, 2004
GENPHARM	EQ 1MG BASE	A075466 001	Oct 18, 2000
	EQ 2MG BASE	A075466 002	Oct 18, 2000
	EQ 4MG BASE	A075466 003	Oct 18, 2000
	EQ 8MG BASE	A075466 004	Oct 18, 2000
IVAX SUB TEVA PHARMS	EQ 1MG BASE	A075453 001	Oct 18, 2000
	EQ 2MG BASE	A075453 002	Oct 18, 2000
	EQ 4MG BASE	A075453 003	Oct 18, 2000
	EQ 8MG BASE	A075453 004	Oct 18, 2000
NESHER PHARMS	EQ 1MG BASE	A075609 001	Oct 18, 2000
	EQ 2MG BASE	A075609 002	Oct 18, 2000
	EQ 4MG BASE	A075609 003	Oct 18, 2000
	EQ 8MG BASE	A075609 004	Oct 18, 2000
TEVA	EQ 1MG BASE	A075353 001	Jan 12, 2001
	EQ 2MG BASE	A075353 002	Jan 12, 2001
	EQ 4MG BASE	A075353 003	Jan 12, 2001
	EQ 8MG BASE	A075353 004	Jan 12, 2001
WATSON LABS INC	EQ 1MG BASE	A075426 001	Oct 18, 2000
	EQ 2MG BASE	A075426 002	Oct 18, 2000
	EQ 4MG BASE	A075426 003	Oct 18, 2000
	EQ 8MG BASE	A075426 004	Oct 18, 2000
YAOPHARMA CO LTD	EQ 1MG BASE	A075646 001	Oct 18, 2000
	EQ 2MG BASE	A075646 002	Oct 18, 2000
	EQ 4MG BASE	A075646 003	Oct 18, 2000
	EQ 8MG BASE	A075646 004	Oct 18, 2000

DOXEPIN HYDROCHLORIDECAPSULE; ORAL
DOXEPIN HYDROCHLORIDE

DAVA PHARMS INC	EQ 10MG BASE	A071685 001	Jan 05, 1988
	EQ 25MG BASE	A071686 001	Jan 05, 1988
	EQ 50MG BASE	A071673 001	Jan 05, 1988
	EQ 75MG BASE	A071674 001	Jan 05, 1988
	EQ 100MG BASE	A071675 001	Jan 05, 1988
	EQ 150MG BASE	A071676 001	Jan 05, 1988
LANNETT CO INC	EQ 10MG BASE	A212997 001	Jul 24, 2020
	EQ 25MG BASE	A212997 002	Jul 24, 2020
	EQ 50MG BASE	A212997 003	Jul 24, 2020
	EQ 75MG BASE	A212997 004	Jul 24, 2020
	EQ 100MG BASE	A212997 005	Jul 24, 2020
NEW RIVER	EQ 10MG BASE	N016987 001	
	EQ 25MG BASE	N016987 002	
	EQ 50MG BASE	N016987 003	
	EQ 75MG BASE	N016987 006	
	EQ 100MG BASE	N016987 004	
	EQ 150MG BASE	N016987 007	Apr 13, 1987
PUREPAC PHARM	EQ 10MG BASE	A073054 001	Dec 28, 1990

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE

	EQ 25MG BASE	A072109 001	Dec 28, 1990
	EQ 50MG BASE	A073055 001	Dec 28, 1990
	EQ 75MG BASE	A072386 001	Sep 08, 1988
	EQ 100MG BASE	A072110 001	Sep 08, 1988
	EQ 150MG BASE	A072387 001	Sep 08, 1988
QUANTUM PHARMICS	EQ 10MG BASE	A070972 001	Sep 29, 1987
	EQ 25MG BASE	A070973 001	Sep 29, 1987
	EQ 50MG BASE	A070931 001	Sep 29, 1987
	EQ 75MG BASE	A070932 001	Sep 29, 1987
	EQ 100MG BASE	A072375 001	Mar 15, 1989
	EQ 150MG BASE	A072376 001	Mar 15, 1989
SANDOZ	EQ 10MG BASE	A071487 001	Mar 02, 1987
	EQ 25MG BASE	A070827 001	May 15, 1986
	EQ 50MG BASE	A070828 001	May 15, 1986
	EQ 75MG BASE	A070825 001	May 15, 1986
	EQ 100MG BASE	A071562 001	Mar 02, 1987
SUN PHARM INDUSTRIES	EQ 25MG BASE	A071502 001	Feb 18, 1988
	EQ 50MG BASE	A071653 001	Feb 18, 1988
	EQ 75MG BASE	A071654 001	Feb 18, 1988
	EQ 100MG BASE	A071521 001	Feb 18, 1988
WATSON LABS	EQ 10MG BASE	A070952 001	Mar 04, 1987
	EQ 10MG BASE	A071485 001	Apr 30, 1987
	EQ 10MG BASE	A072985 001	Mar 29, 1991
	EQ 25MG BASE	A070953 001	May 15, 1986
	EQ 25MG BASE	A071486 001	Apr 30, 1987
	EQ 25MG BASE	A072986 001	Mar 29, 1991
	EQ 50MG BASE	A070954 001	May 15, 1986
	EQ 50MG BASE	A071238 001	Apr 30, 1987
	EQ 75MG BASE	A071326 001	Apr 30, 1987
	EQ 75MG BASE	A071763 001	Feb 09, 1988
	EQ 100MG BASE	A070955 001	May 15, 1986
	EQ 100MG BASE	A071239 001	Apr 30, 1987
	EQ 150MG BASE	A071764 001	Feb 09, 1988
WATSON LABS TEVA	EQ 50MG BASE	A072987 001	Mar 29, 1991
SINEQUAN			
+ PFIZER	EQ 10MG BASE **	N016798 003	
+	EQ 25MG BASE **	N016798 001	
+	EQ 50MG BASE **	N016798 002	
+	EQ 75MG BASE **	N016798 006	
+	EQ 100MG BASE **	N016798 005	
+	EQ 150MG BASE **	N016798 007	
CONCENTRATE; ORAL			
DOXEPIN HYDROCHLORIDE			
PHARM ASSOC	EQ 10MG BASE/ML	A075924 001	Jan 15, 2004
TEVA PHARMS	EQ 10MG BASE/ML	A071609 001	Nov 09, 1987
SINEQUAN			
+ PFIZER	EQ 10MG BASE/ML **	N017516 001	

DOXERCALCIFEROL

CAPSULE; ORAL

DOXERCALCIFEROL

HIKMA

0.5MCG

A091433 001 Sep 23, 2011

1MCG

A091433 002 Jan 14, 2014

2.5MCG

A091433 003 Jan 14, 2014

INJECTABLE; INJECTION

DOXERCALCIFEROL

AMNEAL

4MCG/2ML (2MCG/ML)

A208975 001 May 24, 2017

+ HOSPIRA INC

10MCG/5ML (2MCG/ML)

N208614 002 Jul 24, 2018

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

ADRIAMYCIN PFS

PFIZER

2MG/ML

A063165 001 Jan 30, 1991

200MG/100ML

A063165 002 Jan 30, 1991

DOXORUBICIN HYDROCHLORIDE

ALVOGEN INC

2MG/ML

A065515 001 Nov 08, 2012

HISUN PHARM HANGZHOU

20MG/VIAL

A206062 001 May 13, 2019

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

HLTHCARE	2MG/ML	A200146 001	Jul 18, 2012
MYLAN LABS LTD	2MG/ML	A200901 001	Feb 14, 2012
	10MG/VIAL	A200170 001	Oct 28, 2011
PFIZER	10MG/VIAL	N050467 001	
	20MG/VIAL	N050467 003	May 20, 1985
	50MG/VIAL	N050467 002	
	150MG/VIAL	N050467 004	Jul 22, 1987
RUBEX			
BRISTOL MYERS SQUIBB	10MG/VIAL	A062926 001	Apr 13, 1989
	50MG/VIAL	A062926 002	Apr 13, 1989
	100MG/VIAL	A062926 003	Apr 13, 1989

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

MYLAN PHARMS INC	EQ 150MG BASE	A202778 001	Jun 08, 2012
PAR PHARM	EQ 75MG BASE	A065055 004	Apr 18, 2005
SANDOZ INC	EQ 50MG BASE	A065032 001	Jun 30, 2000
	EQ 100MG BASE	A065032 002	Jun 30, 2000
WATSON LABS	EQ 50MG BASE	A065041 001	Apr 28, 2000
	EQ 100MG BASE	A065041 002	Apr 28, 2000
MONODOX			
+ CHARTWELL RX	EQ 50MG BASE	N050641 002	Feb 10, 1992
+	EQ 75MG BASE	N050641 003	Oct 18, 2006
+	EQ 100MG BASE	N050641 001	Dec 29, 1989

FOR SUSPENSION; ORAL

DOXYCHEL

RACHELLE	EQ 25MG BASE/5ML	A061720 001	
----------	------------------	-------------	--

TABLET; ORAL

DOXYCYCLINE

MYLAN	EQ 50MG BASE	A065377 001	Nov 07, 2006
	EQ 75MG BASE	A065377 002	Nov 07, 2006
	EQ 100MG BASE	A065377 003	Nov 07, 2006
	EQ 150MG BASE	A065427 001	Jun 07, 2007
PAR PHARM	EQ 50MG BASE	A065070 001	Dec 15, 2000
	EQ 75MG BASE	A065070 003	Dec 30, 2002
	EQ 100MG BASE	A065070 002	Dec 15, 2000
	EQ 150MG BASE	A065070 004	Jul 14, 2005
SANDOZ INC	EQ 50MG BASE	A065353 001	Nov 27, 2006
	EQ 75MG BASE	A065353 002	Nov 27, 2006
	EQ 100MG BASE	A065353 003	Nov 27, 2006
SUN PHARM INDUSTRIES	EQ 50MG BASE	A065471 001	Apr 17, 2009
	EQ 75MG BASE	A065471 002	Apr 17, 2009
	EQ 100MG BASE	A065471 003	Apr 17, 2009

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

ACTICLATE CAP

+ ALMIRALL	EQ 75MG BASE	N208253 001	Apr 26, 2016
DOXY-LEMMON			
TEVA	EQ 50MG BASE	A062497 001	Aug 23, 1984
	EQ 100MG BASE	A062497 002	Jun 15, 1984

DOXYCYCLINE HYCLATE

AJANTA PHARMA LTD	EQ 50MG BASE	A211012 001	Sep 24, 2018
	EQ 100MG BASE	A211012 002	Sep 24, 2018
HALSEY	EQ 50MG BASE	A062119 002	May 24, 1985
	EQ 100MG BASE	A062119 001	May 24, 1985
HEATHER	EQ 50MG BASE	A062463 001	Dec 07, 1983
	EQ 100MG BASE	A062463 002	Dec 07, 1983
HIKMA INTL PHARMS	EQ 20MG BASE	A065103 001	May 13, 2005
INTERPHARM	EQ 50MG BASE	A062763 001	Sep 02, 1988
	EQ 100MG BASE	A062763 002	Sep 02, 1988
MUTUAL PHARM	EQ 50MG BASE	A062418 001	Jan 28, 1983
	EQ 100MG BASE	A062418 002	Jan 28, 1983
MYLAN	EQ 50MG BASE	A062337 001	Mar 29, 1982
	EQ 100MG BASE	A062337 002	Mar 29, 1982
PAR PHARM	EQ 50MG BASE	A062434 001	Oct 19, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DOXYCYCLINE HYCLATE

CAPSULE;ORAL

DOXYCYCLINE HYCLATE

	EQ 100MG BASE	A062442 001	Dec 22, 1983
PVT FORM	EQ 50MG BASE	A062631 001	Jul 24, 1986
	EQ 100MG BASE	A062631 002	Jul 24, 1986
RANBAXY	EQ 50MG BASE	A062479 001	Dec 23, 1983
	EQ 100MG BASE	A062479 002	Dec 23, 1983
SUPERPHARM	EQ 50MG BASE	A062469 001	Oct 31, 1984
	EQ 100MG BASE	A062469 002	Oct 31, 1984
WARNER CHILCOTT	EQ 50MG BASE	A062594 001	Dec 05, 1985
	EQ 100MG BASE	A062594 002	Dec 05, 1985
WATSON LABS	EQ 50MG BASE	A061717 001	
	EQ 50MG BASE	A062142 001	
	EQ 100MG BASE	A061717 002	
	EQ 100MG BASE	A062142 002	
ZHEJIANG YONGTAI	EQ 50MG BASE	A212610 001	Mar 31, 2020
	EQ 100MG BASE	A212610 002	Mar 31, 2020
PERIOSTAT			
+ COLLAGENEX	EQ 20MG BASE **	N050744 001	Sep 30, 1998
VIBRAMYCIN			
+ PFIZER	EQ 50MG BASE **	N050007 001	
CAPSULE, COATED PELLETS;ORAL			
DOXYCYCLINE HYCLATE			
PLIVA	EQ 100MG BASE	A063187 001	Jun 30, 1992
CAPSULE, DELAYED RELEASE;ORAL			
DORYX			
+ MAYNE PHARMA INTL	EQ 75MG BASE	N050582 002	Aug 13, 2001
+ WARNER CHILCOTT	EQ 100MG BASE	N050582 001	Jul 22, 1985
	EQ 100MG BASE	A062653 001	Oct 30, 1985
DOXYCYCLINE HYCLATE			
MEDICIS	EQ 75MG BASE	A065281 001	Dec 21, 2005
	EQ 100MG BASE	A065281 002	Dec 21, 2005
INJECTABLE; INJECTION			
DOXYCHEL HYCLATE			
RACHELLE	EQ 100MG BASE/VIAL	A061953 001	
DOXYCYCLINE			
WEST-WARD PHARMS INT	EQ 100MG BASE/VIAL	A062450 001	Oct 27, 1983
	EQ 200MG BASE/VIAL	A062450 002	Oct 27, 1983
	EQ 200MG BASE/VIAL	A062569 002	Mar 09, 1988
DOXYCYCLINE HYCLATE			
WEST-WARD PHARMS INT	EQ 100MG BASE/VIAL	A062992 001	Feb 16, 1989
	EQ 200MG BASE/VIAL	A062992 002	Feb 16, 1989
VIBRAMYCIN			
+ PFIZER	EQ 100MG BASE/VIAL **	N050442 002	
+ PFIZER	EQ 200MG BASE/VIAL **	N050442 001	
TABLET;ORAL			
DOXY-LEMMON			
TEVA	EQ 100MG BASE	A062581 001	Mar 15, 1985
DOXYCYCLINE HYCLATE			
ALEMBIC PHARMS LTD	EQ 100MG BASE	A210536 001	May 14, 2020
HEATHER	EQ 100MG BASE	A062462 001	May 11, 1983
HERITAGE PHARMA	EQ 20MG BASE	A065163 001	May 13, 2005
INTERPHARM	EQ 100MG BASE	A062764 001	Sep 02, 1988
MUTUAL PHARM	EQ 100MG BASE	A062391 001	Sep 30, 1982
MYLAN	EQ 75MG BASE	A209987 001	Oct 05, 2020
	EQ 150MG BASE	A209987 002	Oct 05, 2020
SUPERPHARM	EQ 100MG BASE	A062494 001	Feb 20, 1985
VINTAGE PHARMS	EQ 100MG BASE	A062538 001	Apr 07, 1986
WARNER CHILCOTT	EQ 100MG BASE	A062593 001	Aug 28, 1985
WATSON LABS	EQ 50MG BASE	A062392 001	Mar 31, 1983
	EQ 100MG BASE	A062392 002	Mar 31, 1983
LYMEPAK			
+ CHARTWELL PHARMA	EQ 100MG BASE	N209844 001	Jun 15, 2018
PERIOSTAT			
+ GALDERMA LABS LP	EQ 20MG BASE **	N050783 001	Feb 02, 2001
VIBRA-TABS			
+ PFIZER	EQ 100MG BASE **	N050533 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DOXYCYCLINE HYCLATE

TABLET, DELAYED RELEASE;ORAL

DORYX MPC

+ MAYNE PHARMA EQ 60MG BASE ** N050795 007 May 20, 2016

DOXYCYCLINE HYCLATE

IMPAX LABS INC EQ 75MG BASE A090505 001 Dec 28, 2010

EQ 100MG BASE A090505 002 Dec 28, 2010

MYLAN EQ 75MG BASE A090431 001 Dec 28, 2010

EQ 80MG BASE A090431 004 Apr 29, 2016

EQ 100MG BASE A090431 002 Dec 28, 2010

EQ 200MG BASE A090431 005 May 19, 2016

MYLAN PHARMS INC EQ 150MG BASE A091052 001 Feb 08, 2012

ZYDUS PHARMS EQ 75MG BASE A206772 001 Dec 21, 2018

EQ 100MG BASE A206772 002 Dec 21, 2018

EQ 150MG BASE A206772 003 Dec 21, 2018

DOXYLAMINE SUCCINATE

CAPSULE;ORAL

UNISOM

PFIZER 25MG N019440 001 Feb 05, 1986

TABLET;ORAL

DECAPRYN

SANOFI AVENTIS US 12.5MG N006412 015

25MG N006412 014

DOXY-SLEEP-AID

PAR PHARM 25MG A070156 001 Jul 02, 1987

DOXYLAMINE SUCCINATE

COPLBY PHARM 25MG A088900 002 Feb 12, 1988

QUANTUM PHARMICS 25MG A088603 001 Aug 07, 1984

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BENDECTIN

SANOFI AVENTIS US 10MG;10MG ** N010598 002

DROMOSTANOLONE PROPIONATE

INJECTABLE;INJECTION

DROLBAN

LILLY 50MG/ML N012936 001

DRONABINOL

CAPSULE;ORAL

DRONABINOL

INSYS THERAP 2.5MG A078501 001 Aug 19, 2011

5MG A078501 002 Aug 19, 2011

10MG A078501 003 Aug 19, 2011

DROPERIDOL

INJECTABLE;INJECTION

DROPERIDOL

ABRAXIS PHARM 2.5MG/ML A070992 001 Nov 17, 1986

2.5MG/ML A070993 001 Nov 17, 1986

ASTRAZENECA 2.5MG/ML A072018 001 Oct 20, 1988

HOSPIRA 2.5MG/ML A071645 001 Apr 07, 1988

2.5MG/ML A072272 001 Aug 31, 1995

IGI LABS INC 2.5MG/ML A072019 001 Oct 19, 1988

2.5MG/ML A072020 001 Oct 19, 1988

2.5MG/ML A072021 001 Oct 19, 1988

LUITPOLD 2.5MG/ML A072335 001 Oct 24, 1988

SMITH AND NEPHEW 2.5MG/ML A071750 001 Sep 06, 1988

SOLOPAK 2.5MG/ML A071754 001 Sep 06, 1988

2.5MG/ML A071755 001 Sep 06, 1988

WATSON LABS 2.5MG/ML A073520 001 Nov 27, 1991

2.5MG/ML A073521 001 Nov 27, 1991

2.5MG/ML A073523 001 Nov 27, 1991

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DROPERIDOL; FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE AND DROPERIDOL

ASTRAZENECA	2.5MG/ML;EQ 0.05MG BASE/ML	A072026 001	Apr 13, 1989
	2.5MG/ML;EQ 0.05MG BASE/ML	A072027 001	Apr 13, 1989
	2.5MG/ML;EQ 0.05MG BASE/ML	A072028 001	Apr 13, 1989
HOSPIRA	2.5MG/ML;EQ 0.05MG BASE/ML	A071982 001	May 04, 1988
INNOVAR			
AKORN MFG	2.5MG/ML;EQ 0.05MG BASE/ML	N016049 001	

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL-28

DROSPIRENONE AND ETHINYL ESTRADIOL

APOTEX	3MG;0.03MG	A205876 001	Sep 21, 2016
--------	------------	-------------	--------------

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS; ORAL

DULOXETINE HYDROCHLORIDE

TEVA PHARMS USA	EQ 20MG BASE	A090783 001	Dec 11, 2013
	EQ 30MG BASE	A090783 002	Dec 11, 2013
	EQ 60MG BASE	A090783 003	Dec 11, 2013
YAOPHARMA CO LTD	EQ 20MG BASE	A207219 001	Aug 16, 2019
	EQ 30MG BASE	A207219 002	Aug 16, 2019
	EQ 60MG BASE	A207219 003	Aug 16, 2019

DUTASTERIDE

CAPSULE; ORAL

DUTASTERIDE

ACTAVIS LABS FL INC	0.5MG	A202808 001	Nov 20, 2015
APOTEX INC	0.5MG	A204292 001	Nov 24, 2015
BRECKENRIDGE	0.5MG	A204705 001	Nov 20, 2015
HERITAGE PHARMS INC	0.5MG	A207935 001	Oct 13, 2017
HIKMA	0.5MG	A202204 001	Nov 23, 2015
MYLAN	0.5MG	A203241 001	Jun 14, 2016
RISING	0.5MG	A202530 001	Nov 20, 2015
STRIDES PHARMA	0.5MG	A208227 001	Jun 22, 2018

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL

DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE

ACTAVIS LABS FL INC	0.5MG;0.4MG	A202975 001	Nov 20, 2015
---------------------	-------------	-------------	--------------

DYCLONINE HYDROCHLORIDE

SOLUTION; TOPICAL

DYCLONE

+ ASTRAZENECA	0.5% **	N009925 002	
+	1% **	N009925 001	

DYDROGESTERONE

TABLET; ORAL

GYNOREST

SOLVAY	5MG **	N017388 001	
	10MG **	N017388 002	

DYPHYLLINE

ELIXIR; ORAL

NEOTHYLLINE

TEVA	160MG/15ML	N007794 003	
------	------------	-------------	--

INJECTABLE; INJECTION

NEOTHYLLINE

TEVA	250MG/ML	N009088 001	
------	----------	-------------	--

TABLET; ORAL

DILOR

SAVAGE LABS	200MG	A084514 001	
-------------	-------	-------------	--

DILOR-400

SAVAGE LABS	400MG	A084751 001	
-------------	-------	-------------	--

LUFYLLIN

MYLAN SPECIALITY LP	200MG	A084566 001	
	400MG	A084566 002	

NEOTHYLLINE

TEVA	200MG	N007794 001	
	400MG	N007794 002	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ECHOTHIOPHATE IODIDE

FOR SOLUTION;OPHTHALMIC

PHOSPHOLINE IODIDE

WYETH PHARMS

0.03%

N011963 002

0.06%

N011963 004

0.25%

N011963 003

ECONAZOLE NITRATE

CREAM;TOPICAL

ECONAZOLE NITRATE

CHARTWELL RX

1%

A076075 001 Nov 26, 2002

MYLAN

1%

A210364 001 Apr 18, 2018

EDETATE CALCIUM DISODIUM

TABLET;ORAL

CALCIUM DISODIUM VERSENATE

MEDICIS

500MG

N008922 002

EDROPHONIUM CHLORIDE

INJECTABLE;INJECTION

EDROPHONIUM CHLORIDE

HOSPIRA

10MG/ML

A040131 001 Feb 24, 1998

WATSON LABS

10MG/ML

A040044 001 Mar 20, 1996

EDROPHONIUM CHLORIDE PRESERVATIVE FREE

WATSON LABS

10MG/ML

A040043 001 Mar 20, 1996

ENLON

MYLAN INSTITUTIONAL

10MG/ML

A088873 001 Aug 06, 1985

REVERSOL

ORGANON USA INC

10MG/ML

A089624 001 May 13, 1988

TENSILON

+ TELIGENT

10MG/ML **

N007959 001

TENSILON PRESERVATIVE FREE

+ TELIGENT

10MG/ML **

N007959 002

EFAVIRENZ

CAPSULE;ORAL

SUSTIVA

+ BRISTOL MYERS SQUIBB

100MG **

N020972 002 Sep 17, 1998

TABLET;ORAL

SUSTIVA

+ BRISTOL MYERS SQUIBB

300MG **

N021360 001 Feb 01, 2002

EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

MACLEODS PHARMS LTD 400MG;300MG;300MG

N210649 001 Mar 15, 2019

EFLORNITHINE HYDROCHLORIDE

INJECTABLE;INJECTION

ORNIDYL

SANOFI AVENTIS US

200MG/ML

N019879 002 Nov 28, 1990

ELETRIPTAN HYDROBROMIDE

TABLET;ORAL

ELETRIPTAN HYDROBROMIDE

AMNEAL PHARMS CO

EQ 20MG BASE

A206787 001 May 25, 2018

EQ 40MG BASE

A206787 002 May 25, 2018

YUNG SHIN PHARM

EQ 20MG BASE

A209680 001 Jul 13, 2020

EQ 40MG BASE

A209680 002 Jul 13, 2020

ELTROMBOPAG OLAMINE

TABLET;ORAL

PROMACTA

+ NOVARTIS

EQ 100MG ACID **

N022291 005 Nov 16, 2012

ELVITEGRAVIR

TABLET;ORAL

VITEKTA

+ GILEAD SCIENCES INC

85MG

N203093 001 Sep 24, 2014

+

150MG

N203093 002 Sep 24, 2014

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

EMEDASTINE DIFUMARATE

SOLUTION/DROPS;OPHTHALMIC

EMADINE

+ NOVARTIS

0.05%

N020706 001 Dec 29, 1997

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

LAURUS LABS LTD 200MG;300MG

A212114 001 Jul 26, 2019

MACLEODS PHARMS LTD 200MG;300MG

A203442 001 May 15, 2020

MYLAN 200MG;300MG

A206436 001 Apr 09, 2018

ENALAPRIL MALEATE

FOR SOLUTION;ORAL

EPANED KIT

+ SILVERGATE PHARMS

1MG/ML

N204308 001 Aug 13, 2013

TABLET;ORAL

ENALAPRIL MALEATE

APOTHECON 2.5MG

A075583 001 Aug 22, 2000

5MG

A075583 002 Aug 22, 2000

10MG

A075583 003 Aug 22, 2000

20MG

A075583 004 Aug 22, 2000

BEXIMCO PHARMS USA 2.5MG

A075621 001 Aug 22, 2000

5MG

A075621 002 Aug 22, 2000

10MG

A075621 003 Aug 22, 2000

20MG

A075621 004 Aug 22, 2000

IVAX SUB TEVA PHARMS 2.5MG

A075482 001 Aug 22, 2000

5MG

A075482 002 Aug 22, 2000

10MG

A075482 003 Aug 22, 2000

20MG

A075482 004 Aug 22, 2000

KRKA DD NOVO MESTO 2.5MG

A075370 001 Aug 22, 2000

5MG

A075370 002 Aug 22, 2000

10MG

A075369 001 Aug 22, 2000

20MG

A075369 002 Aug 22, 2000

MYLAN 2.5MG

A075472 001 Aug 22, 2000

2.5MG

A075480 001 Aug 22, 2000

5MG

A075472 002 Aug 22, 2000

5MG

A075480 002 Aug 22, 2000

10MG

A075472 003 Aug 22, 2000

10MG

A075480 003 Aug 22, 2000

20MG

A075472 004 Aug 22, 2000

20MG

A075480 004 Aug 22, 2000

NOSTRUM LABS INC 2.5MG

A075178 002 Mar 23, 2001

5MG

A075178 001 Mar 23, 2001

10MG

A075178 003 Mar 23, 2001

20MG

A075178 004 Mar 23, 2001

SANDOZ 2.5MG

A075048 001 Aug 22, 2000

5MG

A075048 002 Aug 22, 2000

10MG

A075048 003 Aug 22, 2000

20MG

A075048 004 Aug 22, 2000

SUN PHARM INDS LTD 2.5MG

A075556 001 Aug 22, 2000

5MG

A075556 002 Aug 22, 2000

10MG

A075556 003 Aug 22, 2000

20MG

A075556 004 Aug 22, 2000

WATSON LABS 2.5MG

A075501 001 Aug 22, 2000

5MG

A075501 002 Aug 22, 2000

10MG

A075501 003 Aug 22, 2000

20MG

A075501 004 Aug 22, 2000

ENALAPRIL MALEATE; FELODIPINE

TABLET, EXTENDED RELEASE;ORAL

LEXXEL

ASTRAZENECA 5MG;2.5MG

N020668 002 Oct 28, 1998

5MG;5MG

N020668 001 Dec 27, 1996

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

IVAX SUB TEVA PHARMS	5MG;12.5MG	A075736 001	Mar 25, 2003
	10MG;25MG	A075736 002	Mar 25, 2003
NOSTRUM LABS INC	5MG;12.5MG	A076486 001	Oct 27, 2004
	10MG;25MG	A076486 002	Oct 27, 2004
UPSHER SMITH LABS	5MG;12.5MG	A076116 001	Sep 19, 2001
	10MG;25MG	A076116 002	Sep 19, 2001

ENALAPRILAT

INJECTABLE; INJECTION

ENALAPRILAT

HOSPIRA	1.25MG/ML	A075456 001	Aug 22, 2000
	1.25MG/ML	A075571 001	Aug 22, 2000

VASOTEC

+ BIOVAIL LABS INTL	1.25MG/ML **	N019309 001	Feb 09, 1988
---------------------	--------------	-------------	--------------

ENCORAFENIB

CAPSULE; ORAL

BRAFTOVI

+ ARRAY BIOPHARMA INC	50MG	N210496 001	Jun 27, 2018
-----------------------	------	-------------	--------------

ENFLURANE

LIQUID; INHALATION

ENFLURANE

ABBOTT	99.9%	A070803 001	Sep 08, 1987
PIRAMAL CRITICAL	99.9%	A074396 001	Jul 29, 1994

ETHRANE

BAXTER HLTHCARE	99.9%	N017087 001	
-----------------	-------	-------------	--

ENOXACIN

TABLET; ORAL

PENETREX

SANOFI AVENTIS US	200MG	N019616 004	Dec 31, 1991
	400MG	N019616 005	Dec 31, 1991

ENOXAPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

LOVENOX (PRESERVATIVE FREE)

+ SANOFI AVENTIS US	90MG/0.6ML (150MG/ML) **	N020164 006	Jun 02, 2000
---------------------	--------------------------	-------------	--------------

ENTACAPONE

TABLET; ORAL

ENTACAPONE

MYLAN PHARMS INC	200MG	A202394 001	May 13, 2013
------------------	-------	-------------	--------------

ENTECAVIR

TABLET; ORAL

ENTECAVIR

MYLAN	0.5MG	A206226 001	Mar 26, 2019
	1MG	A206226 002	Mar 26, 2019
PAR PHARM INC	0.5MG	A206294 001	Nov 23, 2016
	1MG	A206294 002	Nov 23, 2016
SUNSHINE	0.5MG	A211978 001	May 20, 2020
	1MG	A211978 002	May 20, 2020
TEVA PHARMS USA	0.5MG	A202122 001	Aug 26, 2014
	1MG	A202122 002	Aug 26, 2014
YAOPHARMA CO LTD	0.5MG	A212201 001	Nov 04, 2019
	1MG	A212201 002	Nov 04, 2019

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

EPINASTINE HYDROCHLORIDE

CHARTWELL RX	0.05%	A203384 001	Dec 07, 2016
SUN PHARM INDS	0.05%	A091626 001	Oct 31, 2011

EPINEPHRINE

AEROSOL, METERED; INHALATION

BRONKAID MIST

STERLING	0.25MG/INH	N016803 001	
----------	------------	-------------	--

EPINEPHRINE

ARMSTRONG PHARMS	0.2MG/INH	A087907 001	May 23, 1984
------------------	-----------	-------------	--------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

EPINEPHRINE

AEROSOL, METERED; INHALATION

PRIMATENE MIST

WYETH CONS 0.2MG/INH N016126 001

INJECTABLE; INJECTION

SUS-PHRINE SULFITE FREE

FOREST LABS 1.5MG/AMP N007942 003 Feb 05, 1999
5MG/ML N007942 001

INJECTABLE; INTRAMUSCULAR

EPI E Z PEN JR

MYLAN SPECIALITY LP 0.15MG/DELIVERY N019430 004 Aug 03, 1995

EPIPEN E Z PEN

MYLAN SPECIALITY LP 0.3MG/DELIVERY N019430 003 Aug 03, 1995

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

TWINJECT 0.15

IMPAX EQ 0.15MG/DELIVERY N020800 002 May 28, 2004

TWINJECT 0.3

IMPAX EQ 0.3MG/DELIVERY N020800 001 May 30, 2003

SOLUTION; INTRAMUSCULAR, SUBCUTANEOUS

EPINEPHRINE

AM REGENT EQ 1MG BASE/ML (EQ 1MG BASE/ML) A207568 001 Jul 06, 2018

EPINEPHRINE BITARTRATE

AEROSOL, METERED; INHALATION

BRONITIN MIST

WYETH CONS 0.3MG/INH N016126 002

MEDIHALER-EPI

3M 0.3MG/INH N010374 003

EPINEPHRINE BITARTRATE; ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURANEST

+ ASTRAZENECA 0.005MG/ML; 1% ** N017751 006

+ 0.005MG/ML; 1.5% ** N017751 007

+ DENTSPLY PHARM 0.005MG/ML; 1.5% ** N021384 001

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST FORTE

ASTRAZENECA 0.005MG/ML; 4% N014763 008

EPINEPHRINE; ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURANEST

+ ASTRAZENECA 0.005MG/ML; 0.5% ** N017751 004

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ALPHACAINE HYDROCHLORIDE W/ EPINEPHRINE

CARLISLE 0.01MG/ML; 2% A084720 001

0.02MG/ML; 2% A084732 001

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

BELMORA LLC 0.01MG/ML; 2% A080504 004 Oct 19, 1983

0.02MG/ML; 2% A080504 005 Oct 19, 1983

EASTMAN KODAK 0.01MG/ML; 2% A040057 002 Feb 26, 1993

0.02MG/ML; 2% A040057 001 Feb 26, 1993

HOSPIRA 0.005MG/ML; 1% A089649 001 Jun 21, 1988

0.005MG/ML; 1.5% A089650 001 Jun 21, 1988

0.01MG/ML; 2% A078772 001 May 12, 2008

0.02MG/ML; 2% A078772 002 May 12, 2008

WEST-WARD PHARMS INT 0.01MG/ML; 1% A080406 001

0.01MG/ML; 2% A080406 002

LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE

ABBOTT 0.01MG/ML; 1% A083154 001

BEL MAR 0.01MG/ML; 1% A080820 001

0.01MG/ML; 2% A080757 001

DELL LABS 0.01MG/ML; 1% A083389 001

0.01MG/ML; 2% A083390 001

INTL MEDICATION 0.01MG/ML; 1% A086402 001

WATSON LABS 0.01MG/ML; 1% A080377 003

0.01MG/ML; 1% A085463 001

0.01MG/ML; 2% A080377 004

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCATON			
PHARMATON	0.01MG/ML;2%	A084729 001	Aug 17, 1983
	0.02MG/ML;2%	A084728 001	Aug 17, 1983
OCTOCAINE			
SEPTODONT	0.01MG/ML;2%	A084048 001	
	0.02MG/ML;2%	A084048 002	
XYLOCAINE DENTAL WITH EPINEPHRINE			
DENTSPLY PHARM	0.01MG/ML;2% **	N021381 001	
	0.02MG/ML;2% **	N021381 002	
XYLOCAINE W/ EPINEPHRINE			
ASTRAZENECA	0.005MG/ML;1%	N010418 006	
	0.005MG/ML;1.5%	N010418 010	
	0.005MG/ML;2%	N010418 008	
FRESENIUS KABI USA	0.01MG/ML;2%	N006488 003	
PATCH; IONTOPHORESIS, TOPICAL			
LIDOSITE TOPICAL SYSTEM KIT			
VYTERIS	1.05MG/PATCH;100MG/PATCH	N021504 001	May 06, 2004
SOLUTION; IONTOPHORESIS			
IONTOCAINE			
IOMED	0.01MG/ML;2%	N020530 001	Dec 21, 1995
SOLUTION; IONTOPHORESIS, TOPICAL			
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE			
EMPI	0.01MG/ML;2%	N021486 001	Oct 26, 2004

EPINEPHRINE; PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINE HYDROCHLORIDE W/ EPINEPHRINE			
BEL MAR	0.02MG/ML;1%	A080758 001	
	0.02MG/ML;2%	A080759 001	

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE			
ACTAVIS TOTOWA	10MG/5ML (2MG/ML)	A065445 001	Sep 18, 2008
EBEWE PHARMA	50MG/25ML (2MG/ML)	A065339 001	Dec 22, 2009
	200MG/100ML (2MG/ML)	A065339 002	Dec 22, 2009
FRESENIUS KABI USA	200MG/100ML (2MG/ML)	A065411 001	Aug 20, 2007
	50MG/25ML (2MG/ML)	A065411 002	Aug 20, 2007
HOSPIRA	10MG/5ML (2MG/ML)	A065343 001	Apr 19, 2007
	50MG/25ML (2MG/ML)	A065343 002	Apr 19, 2007
	150MG/75ML (2MG/ML)	A065343 003	Apr 19, 2007
	200MG/100ML (2MG/ML)	A065343 004	Apr 19, 2007
MYLAN INSTITUTIONAL	50MG/25ML (2MG/ML)	A065371 001	Nov 28, 2007
	200MG/100ML (2MG/ML)	A065371 002	Nov 28, 2007
MYLAN LABS LTD	50MG/25ML (2MG/ML)	A091599 001	Mar 12, 2012
	200MG/100ML (2MG/ML)	A091599 002	Mar 12, 2012
ZENNOVA	50MG/25ML (2MG/ML)	A090266 001	Apr 15, 2011
	200MG/100ML (2MG/ML)	A090266 002	Apr 15, 2011
POWDER; INTRAVENOUS			
EPIRUBICIN HYDROCHLORIDE			
HOSPIRA	50MG/VIAL	N050807 001	Sep 15, 2006
	200MG/VIAL	N050807 002	Sep 15, 2006

EPLERENONE

TABLET; ORAL

INSPRA			
GD SEARLE LLC	100MG	N021437 003	Sep 27, 2002

EPROSARTAN MESYLATE

TABLET; ORAL

EPROSARTAN MESYLATE			
MYLAN PHARMS INC	EQ 400MG BASE	A202012 001	Nov 16, 2011
	EQ 600MG BASE	A202012 002	Nov 16, 2011
TEVETEN			
ABBVIE	EQ 300MG BASE	N020738 004	Dec 22, 1997
+	EQ 400MG BASE	N020738 005	Dec 22, 1997
+	EQ 600MG BASE	N020738 006	May 27, 1999

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

TEVETEN HCT

ABBVIE

600MG;12.5MG

N021268 001 Nov 01, 2001

600MG;25MG

N021268 002 Nov 01, 2001

EPTIFIBATIDE

INJECTABLE; INJECTION

EPTIFIBATIDE

AMNEAL PHARMS

2MG/ML

A205581 001 Dec 08, 2016

75MG/100ML

A205581 002 Dec 08, 2016

HYBIO

2MG/ML

A207864 001 Mar 20, 2020

75MG/100ML

A207864 002 Mar 20, 2020

TEVA PHARMS USA

75MG/100ML

A091555 001 Jun 05, 2015

USV

2MG/ML

A204361 001 Mar 14, 2019

2MG/ML

A204362 001 Mar 11, 2019

75MG/100ML

A204361 002 Mar 14, 2019

ERGOCALCIFEROL

CAPSULE; ORAL

DELTALIN

LILLY

50,000 IU

A080884 001

VITAMIN D

CHASE CHEM

50,000 IU

A080747 001

EVERYLIFE

50,000 IU

A080956 001

IMPAX LABS

50,000 IU

A080951 001

LANNETT

50,000 IU

A080825 001

VITARINE

50,000 IU

A084053 001

WEST WARD

50,000 IU

A083102 001

ERGOLOID MESYLATES

CAPSULE; ORAL

HYDERGINE LC

NOVARTIS

1MG

N018706 001 Jan 18, 1983

SOLUTION; ORAL

HYDERGINE

NOVARTIS

1MG/ML

N018418 001

TABLET; ORAL

ERGOLOID MESYLATES

MUTUAL PHARM

1MG

A088891 001 Nov 01, 1985

WATSON LABS

1MG

A086433 001 May 27, 1982

1MG

A087244 001 Aug 16, 1982

GERIMAL

WATSON LABS

1MG

A088207 001 Mar 22, 1984

HYDERGINE

NOVARTIS

0.5MG

N017993 003

+

1MG

N017993 001

TABLET; SUBLINGUAL

ALKERGOT

SANDOZ

0.5MG

A085153 001

1MG

A087417 001

CIRCANOL

3M

0.5MG

A084868 001

1MG

A085809 001

DEAPRIL-ST

BRISTOL MYERS SQUIBB

1MG

A085020 002

ERGOLOID MESYLATES

KV PHARM

0.5MG

A085899 001

0.5MG

A086265 001

1MG

A085900 001

1MG

A086264 001

LEDERLE

0.5MG

A086984 001

1MG

A086985 001

SUN PHARM INDUSTRIES

0.5MG

A087407 001

1MG

A087552 001

SUPERPHARM

0.5MG

A089233 001 Sep 23, 1986

1MG

A089234 001 Sep 23, 1986

VANGARD

0.5MG

A088013 001 Sep 20, 1982

1MG

A088014 001 Sep 20, 1982

WATSON LABS

0.5MG

A084930 001

0.5MG

A087233 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ERGOLOID MESYLATES

TABLET;SUBLINGUAL

ERGOLOID MESYLATES

1MG	A085177	001
1MG	A087183	001

GERIMAL

WATSON LABS

0.5MG	A086189	001
1MG	A086188	001

HYDERGINE

NOVARTIS

0.5MG	N009087	002
1MG	N009087	001

HYDROGENATED ERGOT ALKALOIDS

IVAX PHARMS

0.5MG	A087186	001
1MG	A087185	001

ERGOTAMINE TARTRATE

AEROSOL, METERED;INHALATION

MEDIHALER ERGOTAMINE

3M

0.36MG/INH	N012102	001
------------	---------	-----

TABLET;SUBLINGUAL

ERGOSTAT

WATSON LABS INC

2MG	A088337	001	Jun 08, 1984
-----	---------	-----	--------------

WIGRETTES

ORGANON USA INC

2MG	A086750	001	Jul 29, 1982
-----	---------	-----	--------------

ERLOTINIB HYDROCHLORIDE

TABLET;ORAL

ERLOTINIB HYDROCHLORIDE

ACCORD HLTHCARE

EQ 25MG BASE	A211083	001	Jul 02, 2020
EQ 100MG BASE	A211083	002	Jul 02, 2020
EQ 150MG BASE	A211083	003	Jul 02, 2020

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS;ORAL

ERYC

PARKE DAVIS

250MG	A062546	001	Jul 25, 1985
250MG	A062618	001	Sep 25, 1985
250MG	A062338	001	

WARNER CHILCOTT LLC

ERYC 125

PARKE DAVIS

125MG	A062648	001	Oct 24, 1985
-------	---------	-----	--------------

ERYC SPRINKLES

HOSPIRA

125MG	N050593	001	Jul 22, 1985
-------	---------	-----	--------------

ERYTHROMYCIN

BARR

250MG	A063098	001	May 04, 1989
-------	---------	-----	--------------

GEL;TOPICAL

E-GLADES

MYLAN

2%	A065009	001	Mar 18, 2002
----	---------	-----	--------------

EMGEL

ALTANA

2%	A063107	001	Aug 23, 1991
----	---------	-----	--------------

LOTION;TOPICAL

E-SOLVE 2

SYOSSET

2%	A062467	001	Jul 03, 1985
----	---------	-----	--------------

OINTMENT;OPHTHALMIC

ERYTHROMYCIN

PHARMADERM

5MG/GM	A062446	001	Sep 26, 1983
--------	---------	-----	--------------

PHARMAFAIR

5MG/GM	A062481	001	Apr 05, 1984
--------	---------	-----	--------------

ILOTYCIN

DISTA

0.5% **	N050368	001	
---------	---------	-----	--

OINTMENT;TOPICAL

AKNE-MYCIN

+ BAUSCH

2%	N050584	001	Jan 10, 1985
----	---------	-----	--------------

POWDER;FOR RX COMPOUNDING

ERYTHROMYCIN

PADDOCK LLC

100%	N050610	001	Nov 07, 1986
------	---------	-----	--------------

SOLUTION;TOPICAL

A/T/S

TARO

2%	A062405	001	Nov 18, 1982
----	---------	-----	--------------

C-SOLVE-2

FOUGERA PHARMS

2%	A062468	001	Jul 03, 1985
----	---------	-----	--------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ERYTHROMYCIN

SOLUTION; TOPICAL

ERYDERM					
ARBOR PHARMS INC	2%		A062290	001	
ERYMAX					
MERZ PHARMS	2%		A062508	002	Jul 11, 1985
ERYTHRA-DERM					
SAPTALIS PHARMS	2%		A062687	001	Feb 05, 1988
ERYTHRO-STATIN					
AKORN	2%		A064101	001	Oct 22, 1996
ERYTHROMYCIN					
ALPHARMA US PHARMS	1.5%		A062328	001	Apr 19, 1982
	2%		A062326	001	Apr 19, 1982
	2%		A062327	001	Apr 19, 1982
	2%		A062342	001	Feb 25, 1982
	2%		A062957	001	Jul 21, 1988
BAUSCH AND LOMB	2%		A064039	001	Jan 27, 1994
FOUGERA PHARMS	2%		A064187	001	Sep 30, 1997
LILLY	2%		N050532	001	
PHARMAFAIR	1.5%		A062485	001	Jul 11, 1984
	2%		A062616	001	Jul 25, 1985
RENAISSANCE PHARMA	2%		A064127	001	Feb 14, 1997
SANSAC					
DOW PHARM	2%		A062522	001	Jan 24, 1985
STATICIN					
+ WESTWOOD SQUIBB	1.5% **		N050526	001	
T-STAT					
WESTWOOD SQUIBB	2% **		A062436	001	Mar 09, 1983
SWAB; TOPICAL					
C-SOLVE-2					
IVAX SUB TEVA PHARMS	2%		A062751	001	Jul 30, 1993
ERYCETTE					
+ JOHNSON AND JOHNSON	2% **		N050594	001	Feb 15, 1985
ERYTHROMYCIN					
FOUGERA PHARMS	2%		A065320	001	Jul 25, 2006
MYLAN	2%		A064128	001	Jul 03, 1996
T-STAT					
WESTWOOD SQUIBB	2%		A062748	001	Jul 23, 1987
TABLET, COATED PARTICLES; ORAL					
PCE					
+ ARBOR PHARMS LLC	333MG		N050611	001	Sep 09, 1986
+ 500MG			N050611	002	Aug 22, 1990
TABLET, DELAYED RELEASE; ORAL					
E-BASE					
BARR	333MG		A063028	001	May 15, 1990
	333MG		A063086	001	May 15, 1990
	500MG		A062999	001	Nov 25, 1988
E-MYCIN					
ARBOR PHARMS INC	250MG		A060272	001	
	333MG		A060272	002	
ILOTYCIN					
DISTA	250MG		A061910	001	
R-P MYCIN					
SOLVAY	250MG		A061659	001	
ROBIMYCIN					
ROBINS AH	250MG		A061633	001	

ERYTHROMYCIN ESTOLATE

CAPSULE; ORAL

ERYTHROMYCIN ESTOLATE					
BARR	EQ 125MG BASE		A062162	001	
	EQ 250MG BASE		A062162	002	
IVAX SUB TEVA PHARMS	EQ 250MG BASE		A062237	001	
WATSON LABS	EQ 250MG BASE		A062087	001	
ILOSONE					
LILLY	EQ 125MG BASE		A061897	001	
	EQ 250MG BASE		A061897	002	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ERYTHROMYCIN ESTOLATE

FOR SUSPENSION;ORAL

ILOSONE

DISTA EQ 125MG BASE/5ML A061893 001

SUSPENSION;ORAL

ERYTHROMYCIN ESTOLATE

ALPHARMA US PHARMS EQ 125MG BASE/5ML A062353 001 Nov 18, 1982

EQ 250MG BASE/5ML A062409 001 Dec 16, 1982

COSETTE EQ 125MG BASE/5ML A062169 001 Oct 17, 1990

EQ 250MG BASE/5ML A062169 002 Oct 17, 1990

LIFE LABS EQ 250MG BASE/5ML A062362 001 Dec 17, 1982

ILOSONE

LILLY EQ 125MG BASE/5ML A061894 001

EQ 125MG BASE/5ML N050010 001

EQ 250MG BASE/5ML A061894 002

EQ 250MG BASE/5ML N050010 002

SUSPENSION/DROPS;ORAL

ILOSONE

LILLY EQ 100MG BASE/ML A061894 003

TABLET;ORAL

ILOSONE

LILLY EQ 500MG BASE A061896 001

TABLET, CHEWABLE;ORAL

ILOSONE

DISTA EQ 125MG BASE A061895 001

EQ 250MG BASE A061895 002

ERYTHROMYCIN ESTOLATE; SULFISOXAZOLE ACETYL

SUSPENSION;ORAL

ILOSONE SULFA

LILLY EQ 125MG BASE/5ML;EQ 600MG BASE/5ML N050599 001 Sep 29, 1989

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE;ORAL

PEDIAMYCIN

ROSS LABS EQ 200MG BASE/5ML A062305 001

SUSPENSION;ORAL

E-MYCIN E

PHARMACIA AND UPJOHN EQ 200MG BASE/5ML A062198 001

EQ 400MG BASE/5ML A062198 002

E.E.S. 200

ARBOR PHARMS LLC EQ 200MG BASE/5ML ** A061639 001

E.E.S. 400

ARBOR PHARMS LLC EQ 400MG BASE/5ML ** A061639 002

ERYTHROMYCIN ETHYLSUCCINATE

ALPHARMA US PHARMS EQ 200MG BASE/5ML A062200 001

EQ 400MG BASE/5ML A062200 002

DISTA EQ 200MG BASE/5ML A062177 001

EQ 400MG BASE/5ML A062177 002

NASKA EQ 400MG BASE/5ML A062674 001 Mar 10, 1987

PARKE DAVIS EQ 200MG BASE/5ML A062231 001

EQ 400MG BASE/5ML A062231 002

PHARMAFAIR EQ 200MG BASE/5ML A062559 001 Mar 15, 1985

EQ 400MG BASE/5ML A062558 001 Mar 15, 1985

PEDIAMYCIN

ARBOR PHARMS LLC EQ 200MG BASE/5ML A062304 001

PEDIAMYCIN 400

ARBOR PHARMS LLC EQ 400MG BASE/5ML A062304 002

WYAMYCIN E

WYETH AYERST EQ 200MG BASE/5ML A062123 002

EQ 400MG BASE/5ML A062123 001

SUSPENSION/DROPS;ORAL

PEDIAMYCIN

ROSS LABS EQ 100MG BASE/2.5ML A062305 002

TABLET;ORAL

E.E.S. 400

ARBOR PHARMS LLC EQ 400MG BASE A061905 001

ERYTHROMYCIN ETHYLSUCCINATE

BARR EQ 400MG BASE A062256 001

MYLAN EQ 400MG BASE A062847 001 Sep 14, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ERYTHROMYCIN ETHYLSUCCINATE

TABLET, CHEWABLE;ORAL

E.E.S.

ARBOR PHARMS INC EQ 200MG BASE

N050297 002

ERYPED

ARBOR PHARMS INC EQ 200MG BASE

N050297 003 Jul 05, 1988

PEDIAMYCIN

ROSS LABS EQ 200MG BASE

A062306 001

ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

GRANULE;ORAL

ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL

BARR EQ 200MG BASE/5ML;EQ 600MG BASE/5ML

A062759 001 May 20, 1988

ERYZOLE

ALRA EQ 200MG BASE/5ML;EQ 600MG BASE/5ML

A062758 001 Jun 15, 1988

PEDIAZOLE

ROSS LABS EQ 200MG BASE/5ML;EQ 600MG BASE/5ML

N050529 001

ERYTHROMYCIN GLUCEPTATE

INJECTABLE;INJECTION

ILOTYCIN GLUCEPTATE

DISTA EQ 250MG BASE/VIAL

N050370 001

EQ 500MG BASE/VIAL

N050370 002

EQ 1GM BASE/VIAL

N050370 003

ERYTHROMYCIN LACTOBIONATE

INJECTABLE;INJECTION

ERYTHROCIN

ABBOTT EQ 500MG BASE/VIAL

A062586 001 Jan 04, 1988

EQ 1GM BASE/VIAL

A062586 002 Jan 04, 1988

HOSPIRA EQ 500MG BASE/VIAL

N050182 002

EQ 1GM BASE/VIAL

A062638 002 Oct 31, 1986

EQ 1GM BASE/VIAL

N050182 003

+

EQ 1GM BASE/VIAL

N050609 002 Sep 24, 1986

ERYTHROMYCIN

ELKINS SINN EQ 500MG BASE/VIAL

A062563 001 Mar 28, 1985

EQ 1GM BASE/VIAL

A062563 002 Mar 28, 1985

ERYTHROMYCIN LACTOBIONATE

ABRAXIS PHARM EQ 500MG BASE/VIAL

A062604 001 Nov 24, 1986

EQ 1GM BASE/VIAL

A062604 002 Nov 24, 1986

BAXTER HLTHCARE EQ 500MG BASE/VIAL

A062993 001 May 09, 1989

EQ 1GM BASE/VIAL

A062993 002 May 09, 1989

TEVA PARENTERAL EQ 500MG BASE/VIAL

A063253 001 Jul 30, 1993

EQ 1GM BASE/VIAL

A063253 002 Jul 30, 1993

ERYTHROMYCIN STEARATE

TABLET;ORAL

BRISTAMYCIN

BRISTOL EQ 250MG BASE

A061304 001

EQ 250MG BASE

A061887 001

ERYPAR

PARKE DAVIS EQ 250MG BASE

A062032 001

EQ 500MG BASE

A062032 002

WARNER CHILCOTT EQ 250MG BASE

A062322 001

ERYTHROCIN STEARATE

ARBOR PHARMS LLC EQ 125MG BASE

A060359 002

EQ 500MG BASE

A060359 003

ERYTHROMYCIN STEARATE

ANI PHARMS INC EQ 250MG BASE

A061461 001

EQ 250MG BASE

A061591 001

EQ 500MG BASE

A061461 002

EQ 500MG BASE

A063179 001 May 15, 1990

LEDERLE EQ 250MG BASE

A062089 001

EQ 500MG BASE

A062089 002

MYLAN EQ 250MG BASE

A061505 001

EQ 500MG BASE

A061505 002

PUREPAC PHARM EQ 250MG BASE

A061743 001

WATSON LABS EQ 250MG BASE

A062121 002

EQ 500MG BASE

A062121 001

ETHRIL 250

BRISTOL MYERS SQUIBB EQ 250MG BASE

A061605 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ERYTHROMYCIN STEARATE

TABLET; ORAL

ETHRIL 500

BRISTOL MYERS SQUIBB EQ 500MG BASE A061605 002

PFIZER-E

PFIZER EQ 250MG BASE A061791 001

EQ 500MG BASE A061791 002

WYAMYCIN S

WYETH AYERST EQ 250MG BASE A061675 001

EQ 500MG BASE A061675 002

ESCITALOPRAM OXALATE

CAPSULE; ORAL

ESCITALOPRAM OXALATE

MYLAN PHARMS INC EQ 5MG BASE A077660 001 Jul 31, 2007

EQ 10MG BASE A077660 002 Jul 31, 2007

EQ 20MG BASE A077660 003 Jul 31, 2007

SOLUTION; ORAL

LEXAPRO

+ ALLERGAN

EQ 5MG BASE/5ML N021365 001 Nov 27, 2002

TABLET; ORAL

ESCITALOPRAM OXALATE

HIKMA PHARMS EQ 5MG BASE A078766 001 Sep 11, 2012

EQ 10MG BASE A078766 002 Sep 11, 2012

EQ 20MG BASE A078766 003 Sep 11, 2012

MACLEODS PHARMS LTD EQ 5MG BASE A202210 001 Sep 11, 2012

EQ 10MG BASE A202210 002 Sep 11, 2012

EQ 20MG BASE A202210 003 Sep 11, 2012

MYLAN EQ 5MG BASE A077550 001 May 14, 2015

EQ 10MG BASE A077550 002 May 14, 2015

EQ 20MG BASE A077550 003 May 14, 2015

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

BREVIBLOC

BAXTER HLTHCARE 10MG/ML N019386 003 Aug 15, 1988

20MG/ML N019386 007 May 28, 2003

ESMOLOL HYDROCHLORIDE

AM REGENT 10MG/ML A201126 001 Feb 20, 2015

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL

ESOMEPRAZOLE MAGNESIUM

AMNEAL PHARMS NY EQ 20MG BASE A209647 001 Apr 10, 2019

EQ 40MG BASE A209647 002 Apr 10, 2019

HEC PHARM EQ 20MG BASE A207265 002 May 18, 2018

EQ 40MG BASE A207265 001 May 18, 2018

CAPSULE, DELAYED RELEASE; ORAL

ESOMEPRAZOLE MAGNESIUM

MYLAN EQ 20MG BASE A212376 001 Oct 16, 2019

TABLET, DELAYED RELEASE; ORAL

ESOMEPRAZOLE MAGNESIUM

P AND L EQ 20MG BASE A209202 001 Mar 05, 2019

ESOMEPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS

ESOMEPRAZOLE SODIUM

AUROBINDO PHARMA LTD EQ 20MG BASE/VIAL A204657 001 Aug 10, 2016

MYLAN LABS LTD EQ 20MG BASE/VIAL A202686 001 May 17, 2017

SUN PHARMA GLOBAL EQ 20MG BASE/VIAL A200882 001 Mar 18, 2013

NEXIUM IV

+ ASTRAZENECA PHARMS EQ 20MG BASE/VIAL ** N021689 001 Mar 31, 2005

ESOMEPRAZOLE STRONTIUM

CAPSULE, DELAYED RELEASE; ORAL

ESOMEPRAZOLE STRONTIUM

+ BELCHER 24.65MG N202342 001 Aug 06, 2013

+ 49.3MG N202342 002 Aug 06, 2013

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ESTAZOLAM

TABLET;ORAL

PROSOM

+ ABBOTT

1MG **

N019080 001 Dec 26, 1990

+

2MG **

N019080 002 Dec 26, 1990

ESTRADIOL

FILM, EXTENDED RELEASE;TRANSDERMAL

FEMPATCH

PARKE DAVIS

0.025MG/24HR

N020417 001 Dec 03, 1996

GEL;TOPICAL

ESTROGEL

ASCEND THERAPS US

0.06%

N021166 001 Feb 09, 2004

SYSTEM;TRANSDERMAL

ESCLIM

WOMEN FIRST HLTHCARE

0.025MG/24HR

N020847 001 Aug 04, 1998

0.0375MG/24HR

N020847 002 Aug 04, 1998

0.05MG/24HR

N020847 003 Aug 04, 1998

0.075MG/24HR

N020847 004 Aug 04, 1998

0.1MG/24HR

N020847 005 Aug 04, 1998

ESTRADERM

+ NOVARTIS

0.05MG/24HR

N019081 002 Sep 10, 1986

+

0.1MG/24HR

N019081 003 Sep 10, 1986

ESTRADIOL

ORTHO MCNEIL PHARM

0.05MG/24HR

N021048 001 Sep 20, 1999

0.075MG/24HR

N021048 002 Sep 20, 1999

0.1MG/24HR

N021048 003 Sep 20, 1999

VIVELLE

NOVARTIS

0.025MG/24HR

N020323 005 Aug 16, 2000

0.0375MG/24HR

N020323 001 Oct 28, 1994

0.05MG/24HR

N020323 002 Oct 28, 1994

0.075MG/24HR

N020323 003 Oct 28, 1994

0.1MG/24HR

N020323 004 Oct 28, 1994

TABLET;ORAL

ESTRACE

BRISTOL MYERS SQUIBB

0.5MG

A081295 001 Jun 30, 1993

1MG

A084499 001

2MG

A084500 001

ESTRADIOL

LANNETT HOLDINGS INC

0.5MG

A040138 001 Jan 30, 1998

1MG

A040138 002 Jan 30, 1998

2MG

A040138 003 Jan 30, 1998

USL PHARMA

0.5MG

A040297 001 Apr 17, 2002

1MG

A040297 002 Apr 17, 2002

2MG

A040297 003 Apr 17, 2002

GYNODIOL

DURAMED PHARMS BARR

0.5MG

A040212 001 Dec 29, 1997

1MG

A040212 002 Dec 29, 1997

1.5MG

A040212 003 Dec 29, 1997

2MG

A040212 004 Dec 29, 1997

INNOFEM

NOVO NORDISK INC

0.5MG

A040312 001 Nov 19, 1999

1MG

A040312 002 Nov 19, 1999

2MG

A040312 003 Nov 19, 1999

TABLET;VAGINAL

VAGIFEM

+ NOVO NORDISK INC

25MCG **

N020908 001 Mar 26, 1999

ESTRADIOL ACETATE

TABLET;ORAL

FEMTRACE

+ APIL

0.45MG

N021633 001 Aug 20, 2004

+

0.9MG

N021633 002 Aug 20, 2004

+

1.8MG

N021633 003 Aug 20, 2004

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ESTRADIOL CYPIONATE

INJECTABLE; INJECTION

DEPO-ESTRADIOL

PHARMACIA AND UPJOHN	1MG/ML	A085470	001
	3MG/ML	A085470	002

ESTRADIOL CYPIONATE

DR REDDYS	5MG/ML	A085620	001
-----------	--------	---------	-----

ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE

INJECTABLE; INTRAMUSCULAR

LUNELLE

PHARMACIA AND UPJOHN	5MG/0.5ML; 25MG/0.5ML	N020874	001	Oct 05, 2000
----------------------	-----------------------	---------	-----	--------------

ESTRADIOL CYPIONATE; TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION

DEPO-TESTADIOL

PHARMACIA AND UPJOHN	2MG/ML; 50MG/ML	N017968	001
----------------------	-----------------	---------	-----

TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE

WATSON LABS	2MG/ML; 50MG/ML	A085603	001	Mar 13, 1986
-------------	-----------------	---------	-----	--------------

ESTRADIOL HEMIHYDRATE

EMULSION; TOPICAL

ESTRASORB

+ EXELTIS USA INC	0.25%	N021371	001	Oct 09, 2003
-------------------	-------	---------	-----	--------------

ESTRADIOL VALERATE

INJECTABLE; INJECTION

ESTRADIOL VALERATE

DR REDDYS	20MG/ML	A083547	001
-----------	---------	---------	-----

	40MG/ML	A083714	001
--	---------	---------	-----

FOSUN PHARMA	10MG/ML	A040628	001	Oct 04, 2007
--------------	---------	---------	-----	--------------

	20MG/ML	A040628	002	Oct 04, 2007
--	---------	---------	-----	--------------

	40MG/ML	A040628	003	Oct 04, 2007
--	---------	---------	-----	--------------

WATSON LABS	10MG/ML	A083546	001
-------------	---------	---------	-----

ESTRADIOL VALERATE; TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

DITATE-DS

SAVAGE LABS	8MG/ML; 180MG/ML	A086423	001
-------------	------------------	---------	-----

TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE

WATSON LABS	4MG/ML; 90MG/ML	A085865	001
-------------	-----------------	---------	-----

	8MG/ML; 180MG/ML	A085860	001
--	------------------	---------	-----

ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

ESTRADIOL AND NORETHINDRONE ACETATE

NAARI PTE LTD	1MG; 0.5MG	A210233	001	Feb 28, 2018
---------------	------------	---------	-----	--------------

TEVA PHARMS USA	0.5MG; 0.1MG	A200747	001	Mar 08, 2012
-----------------	--------------	---------	-----	--------------

ESTRADIOL; NORGESTIMATE

TABLET; ORAL

PREFEST

+ TEVA WOMENS	1MG, 1MG; N/A, 0.09MG **	N021040	001	Oct 22, 1999
---------------	--------------------------	---------	-----	--------------

ESTROGENS, CONJUGATED

TABLET; ORAL

PREMARIN

WYETH PHARMS	2.5MG	N004782	002
--------------	-------	---------	-----

ESTROGENS, CONJUGATED SYNTHETIC A

CREAM; VAGINAL

SYNTHETIC CONJUGATED ESTROGENS A

TEVA WOMENS	0.625MG/GM	N021788	001	Nov 28, 2008
-------------	------------	---------	-----	--------------

TABLET; ORAL

CENESTIN

+ ASPEN	0.3MG **	N020992	001	Jun 21, 2002
---------	----------	---------	-----	--------------

	0.45MG **	N020992	005	Feb 05, 2004
--	-----------	---------	-----	--------------

	0.625MG **	N020992	002	Mar 24, 1999
--	------------	---------	-----	--------------

	0.9MG **	N020992	003	Mar 24, 1999
--	----------	---------	-----	--------------

	1.25MG **	N020992	004	Mar 13, 2000
--	-----------	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET;ORAL

ENJUVIA

ASPEN	0.3MG	N021443 001	Dec 20, 2004
	0.45MG	N021443 002	Dec 20, 2004
	0.625MG **	N021443 003	May 10, 2004
	0.9MG	N021443 005	Apr 27, 2007
	1.25MG **	N021443 004	May 10, 2004

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET;ORAL-28

PREMPHASE (PREMARIN;CYCRIN 14/14)

WYETH PHARMS INC	0.625MG,0.625MG;N/A,5MG	N020303 002	Dec 30, 1994
------------------	-------------------------	-------------	--------------

PREMPRO (PREMARIN;CYCRIN)

WYETH PHARMS INC	0.625MG,0.625MG;2.5MG,2.5MG	N020303 001	Dec 30, 1994
------------------	-----------------------------	-------------	--------------

ESTROGENS, CONJUGATED; MEPROBAMATE

TABLET;ORAL

MILPREM-200

MEDPOINTE PHARM HLC	0.45MG;200MG	N011045 002	
---------------------	--------------	-------------	--

MILPREM-400

MEDPOINTE PHARM HLC	0.45MG;400MG	N011045 001	
---------------------	--------------	-------------	--

PMB 200

WYETH AYERST	0.45MG;200MG	N010971 005	
--------------	--------------	-------------	--

PMB 400

WYETH AYERST	0.45MG;400MG	N010971 003	
--------------	--------------	-------------	--

ESTROGENS, ESTERIFIED

TABLET;ORAL

AMNESTROGEN

BRISTOL MYERS SQUIBB	0.3MG	A083266 001	
	0.625MG	A083266 002	
	1.25MG	A083266 003	
	2.5MG	A083266 004	

ESTERIFIED ESTROGENS

PVT FORM	0.625MG	A083414 001	
	1.25MG	A083765 001	
	2.5MG	A085907 001	
SANDOZ	1.25MG	A085302 001	

ESTRATAB

SOLVAY	0.3MG	A086715 001	
	0.625MG	A083209 001	
	1.25MG	A083856 001	
	2.5MG	A083857 001	

EVEX

ROCHE PALO	0.625MG	A084215 001	
	1.25MG	A083376 002	

FEMOGEN

PVT FORM	0.625MG	A085076 001	
	1.25MG	A085008 001	
	2.5MG	A085007 001	

ESTRONE

INJECTABLE;INJECTION

ESTROGENIC SUBSTANCE

WYETH AYERST	2MG/ML	A083488 001	
--------------	--------	-------------	--

ESTRONE

DR REDDYS	5MG/ML	A085239 001	
WATSON LABS	2MG/ML	A083397 001	

NATURAL ESTROGENIC SUBSTANCE-ESTRONE

WATSON LABS	2MG/ML	A085237 001	Nov 23, 1982
-------------	--------	-------------	--------------

THEELIN

PARKEDEALE	1MG/ML	N003977 001	
	2MG/ML	N003977 002	
	5MG/ML	N003977 003	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ESTROPIPATECREAM;VAGINAL
OGEN

PHARMACIA AND UPJOHN 1.5MG/GM A084710 001

TABLET;ORAL

ESTROPIPATE

BARR 0.75MG A040135 001 Nov 27, 1996

1.5MG A040135 002 Nov 27, 1996

3MG A040135 003 Nov 27, 1996

DURAMED PHARMS BARR 0.75MG A040296 001 Nov 01, 1999

1.5MG A040296 002 Nov 01, 1999

3MG A040296 003 Nov 01, 1999

MYLAN 0.75MG A040359 001 Aug 26, 1999

1.5MG A040359 002 Aug 26, 1999

3MG A040359 003 Aug 26, 1999

WATSON LABS 0.75MG A081213 001 Sep 23, 1993

1.5MG A081214 001 Sep 23, 1993

6MG A081216 001 Sep 23, 1993

WATSON LABS TEVA 3MG A081215 001 Sep 23, 1993

OGEN .625

PHARMACIA AND UPJOHN 0.75MG A083220 001

OGEN 1.25

PHARMACIA AND UPJOHN 1.5MG A083220 002

OGEN 2.5

PHARMACIA AND UPJOHN 3MG A083220 003

ORTHO-EST

SUN PHARM INDS INC 0.75MG A089567 001 Feb 27, 1991

1.5MG A089582 001 Jul 17, 1991

ESZOPICLONE

TABLET;ORAL

ESZOPICLONE

BRECKENRIDGE 1MG A203087 001 May 08, 2019

2MG A203087 002 May 08, 2019

3MG A203087 003 May 08, 2019

HIKMA 1MG A091153 001 Apr 15, 2014

2MG A091153 002 Apr 15, 2014

3MG A091153 003 Apr 15, 2014

WOCKHARDT LTD 1MG A091165 001 Jul 14, 2011

2MG A091165 002 Jul 14, 2011

3MG A091165 003 Jul 14, 2011

ETHACRYNIC ACID

TABLET;ORAL

EDECIN

BAUSCH 50MG N016092 002

ETHAMBUTOL HYDROCHLORIDE

TABLET;ORAL

MYAMBUTOL

STI PHARMA LLC 200MG N016320 002

500MG N016320 004

ETHCHLORVYNOL

CAPSULE;ORAL

ETHCHLORVYNOL

BANNER PHARMACAPS 100MG A084463 001

200MG A084463 002

500MG A084463 003

750MG A084463 004

PLACIDYL

ABBVIE 100MG N010021 004

200MG N010021 007

500MG N010021 002

750MG N010021 010

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ETHINAMATE

CAPSULE;ORAL

VALMID

DISTA 500MG N009750 001

ETHINYL ESTRADIOL

TABLET;ORAL

ESTINYL

SCHERING 0.02MG N005292 001
0.05MG N005292 002
0.5MG N005292 003

FEMINONE

PHARMACIA AND UPJOHN 0.05MG N016649 001

LYNORAL

ORGANON USA INC 0.01MG N005490 003
0.05MG N005490 002ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET;ORAL-21

DEMULEN 1/35-21

GD SEARLE LLC 0.035MG;1MG ** N018168 001

DEMULEN 1/50-21

GD SEARLE LLC 0.05MG;1MG N016927 001

ZOVIA 1/35E-21

WATSON PHARMS TEVA 0.035MG;1MG A072720 001 Dec 30, 1991

ZOVIA 1/50E-21

WATSON LABS 0.05MG;1MG A072722 001 Dec 30, 1991

TABLET;ORAL-28

DEMULEN 1/35-28

GD SEARLE LLC 0.035MG;1MG ** N018160 001

DEMULEN 1/50-28

GD SEARLE LLC 0.05MG;1MG ** N016936 001

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE

TABLET;ORAL-28

NORQUEST FE

PFIZER 0.035MG;75MG;1MG N018926 001 Jul 18, 1986

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE ACETATE

TABLET;ORAL-28

NORLESTRIN FE 1/50

PARKE DAVIS 0.05MG;75MG;1MG N016766 001

NORLESTRIN FE 2.5/50

PARKE DAVIS 0.05MG;75MG;2.5MG N016854 001

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL

FAYOSIM

LUPIN LTD 0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A A205943 001 Mar 29, 2016

LYBREL

+ WYETH PHARMS INC 0.02MG;0.09MG ** N021864 001 May 22, 2007

PREVEN EMERGENCY CONTRACEPTIVE KIT

TEVA BRANDED PHARM 0.05MG;0.25MG N020946 001 Sep 01, 1998

TABLET;ORAL-21

ALESSE

+ CADENCE HEALTH 0.02MG;0.1MG ** N020683 001 Mar 27, 1997

AVIANE-21

DURAMED PHARMS BARR 0.02MG;0.1MG A075796 002 Apr 30, 2001

ENPRESSE-21

DURAMED PHARMS BARR 0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG A075809 001 Jul 16, 2001

LESSINA-21

BARR 0.02MG;0.1MG A075803 001 Mar 20, 2002

LEVLITE

+ BAYER HLTHCARE 0.02MG;0.1MG ** N020860 001 Jul 13, 1998

LEVONORGESTREL AND ETHINYL ESTRADIOL

BARR 0.02MG;0.1MG A075862 001 Apr 29, 2003

LEVORA 0.15/30-21

WATSON LABS 0.03MG;0.15MG A073592 001 Dec 13, 1993

NORDETTE-21

TEVA BRANDED PHARM 0.03MG;0.15MG N018668 001 May 10, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21

PORTIA-21

BARR 0.03MG;0.15MG A075866 001 May 23, 2002

TRIPHASIL-21

+ WYETH PHARMS 0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG ** N019192 001 Nov 01, 1984

TRIVORA-21

MAYNE PHARMA 0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG A074538 001 Dec 18, 1997

TABLET; ORAL-28

ALESSE

+ CADENCE HEALTH 0.02MG;0.1MG ** N020683 002 Mar 27, 1997

ELIFEMME

XIROMED 0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG A202507 001 Dec 04, 2015

LEVLITE

+ BAYER HLTHCARE 0.02MG;0.1MG ** N020860 002 Jul 13, 1998

LEVONORGESTREL AND ETHINYL ESTRADIOL

BARR 0.02MG;0.1MG A075862 002 Apr 29, 2003

MYLAN LABS LTD 0.02MG;0.1MG A202247 001 Dec 08, 2014

0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG A202970 001 Mar 23, 2018

NORDETTE-28

+ TEVA BRANDED PHARM 0.03MG;0.15MG ** N018782 001 Jul 21, 1982

ORSYTHIA

VINTAGE PHARMS LLC 0.02MG;0.1MG A077099 001 May 11, 2011

TRIPHASIL-28

+ WYETH PHARMS INC 0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG ** N019190 001 Nov 01, 1984

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE; TRANSDERMAL

ORTHO EVRA

+ JANSSEN PHARMS 0.035MG/24HR;0.15MG/24HR ** N021180 001 Nov 20, 2001

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

BALZIVA-21

BARR 0.035MG;0.4MG A076198 001 Apr 22, 2004

BREVICON 21-DAY

ALLERGAN 0.035MG;0.5MG N017566 001

GENCEPT 10/11-21

BARR 0.035MG,0.035MG;0.5MG,1MG A072694 001 Feb 28, 1992

MODICON 21

ORTHO MCNEIL PHARM 0.035MG;0.5MG ** N017488 001

N.E.E. 1/35 21

LPI 0.035MG;1MG A071541 001 Dec 14, 1987

NORCEPT-E 1/35 21

ORTHO MCNEIL PHARM 0.035MG;1MG A071545 001 Feb 09, 1989

NORETHIN 1/35E-21

WATSON PHARMS TEVA 0.035MG;1MG A071480 001 Apr 12, 1988

NORETHINDRONE AND ETHINYL ESTRADIOL

WATSON LABS 0.035MG;0.4MG A078379 001 Feb 23, 2010

0.035MG;0.5MG A070684 001 Jan 29, 1987

WATSON PHARMS TEVA 0.035MG;1MG A070685 001 Jan 29, 1987

NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)

WATSON LABS 0.035MG,0.035MG;0.5MG,1MG A071043 001 Apr 01, 1988

NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

WATSON LABS TEVA 0.035MG,0.035MG;0.5MG,1MG A071041 001 Sep 24, 1991

NORTREL 0.5/35-21

BARR 0.035MG;0.5MG A072692 001 Feb 28, 1992

ORTHO-NOVUM 1/35-21

ORTHO MCNEIL PHARM 0.035MG;1MG ** N017489 002

ORTHO-NOVUM 10/11-21

+ ORTHO MCNEIL JANSSEN 0.035MG,0.035MG;0.5MG,1MG ** N018354 001 Jan 11, 1982

ORTHO-NOVUM 7/14-21

ORTHO MCNEIL PHARM 0.035MG,0.035MG;0.5MG,1MG ** N019004 001 Apr 04, 1984

ORTHO-NOVUM 7/7/7-21

JANSSEN PHARMS 0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG N018985 001 Apr 04, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

OVCON-35

+ WARNER CHILCOTT 0.035MG;0.4MG ** N018127 001

OVCON-50

WARNER CHILCOTT 0.05MG;1MG N018128 001

TRI-NORINYL 21-DAY

MAYNE PHARMA 0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG N018977 001 Apr 13, 1984

TABLET; ORAL-28

BREVICON 28-DAY

ALLERGAN 0.035MG;0.5MG N017743 001

CYCLAFEM 0.5/35

VINTAGE PHARMS 0.035MG;0.5MG A203413 001 Dec 16, 2015

GENCEPT 10/11-28

BARR 0.035MG,0.035MG;0.5MG,1MG A072697 001 Feb 28, 1992

MODICON 28

+ JANSSEN PHARMS 0.035MG;0.5MG N017735 001

N.E.E. 1/35 28

LPI 0.035MG;1MG A071542 001 Dec 14, 1987

NORCEPT-E 1/35 28

ORTHO MCNEIL PHARM 0.035MG;1MG A071546 001 Feb 09, 1989

NORETHIN 1/35E-28

WATSON LABS 0.035MG;1MG A071481 001 Apr 12, 1988

NORETHINDRONE AND ETHINYL ESTRADIOL

MYLAN LABS LTD 0.035MG;0.4MG A200897 001 May 11, 2015

0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG A200486 001 Dec 28, 2015

0.035MG;0.5MG A200488 001 Oct 21, 2015

0.035MG;1MG A200489 001 Oct 21, 2015

0.05MG;1MG A203006 001 Aug 05, 2013

WATSON LABS 0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG A076393 001 Feb 04, 2010

NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

WATSON LABS 0.035MG,0.035MG;0.5MG,1MG A071042 001 Sep 24, 1991

ORTHO-NOVUM 1/35-28

+ JANSSEN PHARMS 0.035MG;1MG ** N017919 002

ORTHO-NOVUM 10/11-28

+ ORTHO MCNEIL JANSSEN 0.035MG,0.035MG;0.5MG,1MG N018354 002 Jan 11, 1982

ORTHO-NOVUM 7/14-28

ORTHO MCNEIL PHARM 0.035MG,0.035MG;0.5MG,1MG ** N019004 002 Apr 04, 1984

ORTHO-NOVUM 7/7/7-28

+ JANSSEN PHARMS 0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG N018985 002 Apr 04, 1984

OVCON-35

+ WARNER CHILCOTT LLC 0.035MG;0.4MG ** N017716 001

OVCON-50

WARNER CHILCOTT LLC 0.05MG;1MG ** N017576 001

TABLET, CHEWABLE; ORAL

FEMCON FE

+ APIL 0.035MG;0.4MG N021490 001 Nov 14, 2003

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

FEMHRT

+ APIL 0.005MG;1MG ** N021065 002 Oct 15, 1999

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

MYLAN LABS LTD 0.0025MG;0.5MG A207260 001 Feb 02, 2017

0.005MG;1MG A207259 001 Dec 27, 2016

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

MYLAN LABS LTD 0.01MG,0.01MG;1MG,N/A A205049 001 May 31, 2016

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

APOTEX 0.02MG;1MG A208639 001 Mar 21, 2018

MYLAN LABS LTD 0.02MG;1MG A202742 001 Oct 30, 2014

TABLET; ORAL-21

ESTROSTEP 21

+ APIL 0.02MG,0.03MG,0.035MG;1MG,1MG,1MG ** N020130 001 Oct 09, 1996

GILDESS 1.5/30

VINTAGE PHARMS LLC 0.03MG;1.5MG A077075 002 Jul 24, 2012

NORLESTRIN 21 1/50

PARKE DAVIS 0.05MG;1MG N016749 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL-21			
NORLESTRIN 21 2.5/50			
PARKE DAVIS	0.05MG;2.5MG		N016852 001
TABLET;ORAL-28			
GILDESS FE 1.5/30			
VINTAGE PHARMS LLC	0.03MG;1.5MG		A077075 001 Apr 28, 2005
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL			
MYLAN LABS LTD	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG		A205069 001 Jun 22, 2018
NORLESTRIN 28 1/50			
PARKE DAVIS	0.05MG;1MG		N016723 001
TABLET, CHEWABLE;ORAL			
FINZALA			
TEVA PHARMS USA INC	0.02MG;1MG		A210087 001 Apr 07, 2020
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE			
MYLAN LABS LTD	0.02MG;1MG		A206120 001 Sep 12, 2017
TABLET, CHEWABLE, TABLET;ORAL			
LO MINASTRIN FE			
+ APIL	0.01MG,0.01MG,N/A;1MG,N/A,N/A		N204654 001 Jul 24, 2013

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-21			
ORTHO CYCLEN-21			
JANSSEN PHARMS	0.035MG;0.25MG **		N019653 001 Dec 29, 1989
ORTHO TRI-CYCLEN			
JANSSEN PHARMS	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG		N019697 002 Jul 03, 1992
TABLET;ORAL-28			
NORGESTIMATE AND ETHINYL ESTRADIOL			
MYLAN LABS LTD	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG		A202132 001 Sep 09, 2015
WATSON LABS	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG		A090479 001 Mar 09, 2011
	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG		A076626 001 Aug 17, 2006
	0.035MG;0.25MG		A076627 001 Aug 17, 2006
ORTHO CYCLEN-28			
+ JANSSEN PHARMS	0.035MG;0.25MG **		N019653 002 Dec 29, 1989
ORTHO TRI-CYCLEN			
+ JANSSEN PHARMS	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG		N019697 001 Jul 03, 1992
ORTHO TRI-CYCLEN LO			
+ JANSSEN PHARMS	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG		N021241 001 Aug 22, 2002
TRI-PREVIFEM			
VINTAGE PHARMS LLC	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG		A076335 001 Mar 26, 2004

ETHINYL ESTRADIOL; NORGESTREL

TABLET;ORAL-21			
LO/OVRAL			
CADENCE HEALTH	0.03MG;0.3MG		N017612 001
LOW-OGESTREL-21			
MAYNE PHARMA	0.03MG;0.3MG		A075288 001 Jul 28, 1999
OGESTREL 0.5/50-21			
WATSON LABS	0.05MG;0.5MG		A075406 001 Dec 15, 1999
OVRAL			
WYETH PHARMS	0.05MG;0.5MG		N016672 001
TABLET;ORAL-28			
LO/OVRAL-28			
WYETH PHARMS	0.03MG;0.3MG **		N017802 001
NORGESTREL AND ETHINYL ESTRADIOL			
MYLAN LABS LTD	0.03MG;0.3MG		A201828 001 Jun 21, 2016
	0.05MG;0.5MG		A202875 001 May 08, 2017
OGESTREL 0.5/50-28			
WATSON LABS	0.05MG;0.5MG		A075406 002 Dec 15, 1999
OVRAL-28			
WYETH PHARMS	0.05MG;0.5MG		N016806 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ETHOPROPAZINE HYDROCHLORIDE

TABLET; ORAL

PARSIDOL

PARKE DAVIS	10MG	N009078 003
	50MG	N009078 006
	100MG	N009078 008

ETHOSUXIMIDE

SYRUP; ORAL

ETHOSUXIMIDE

TEVA PHARMS	250MG/5ML	A081306 001 Jul 30, 1993
-------------	-----------	--------------------------

ETHOTOIN

TABLET; ORAL

PEGANONE

+ RECORDATI RARE	250MG	N010841 001
	500MG	N010841 003

ETHOXZOLAMIDE

TABLET; ORAL

CARDRASE

PHARMACIA AND UPJOHN	62.5MG	N011047 002
	125MG	N011047 001

ETHAMIDE

ALLERGAN	125MG	N016144 001
----------	-------	-------------

ETHYLESTRENOL

ELIXIR; ORAL

MAXIBOLIN

ORGANON USA INC	2MG/5ML	N014006 002
-----------------	---------	-------------

TABLET; ORAL

MAXIBOLIN

ORGANON USA INC	2MG	N014005 002
-----------------	-----	-------------

ETHYNODIOL DIACETATE; MESTRANOL

TABLET; ORAL-20

OVULEN

GD SEARLE LLC	1MG;0.1MG	N016029 002
---------------	-----------	-------------

TABLET; ORAL-21

OVULEN-21

GD SEARLE LLC	1MG;0.1MG	N016029 003
---------------	-----------	-------------

TABLET; ORAL-28

OVULEN-28

GD SEARLE LLC	1MG;0.1MG	N016705 001
---------------	-----------	-------------

ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURANEST

+ ASTRAZENECA	0.5% **	N017751 003
---------------	---------	-------------

+	1% **	N017751 005
---	-------	-------------

ETIDRONATE DISODIUM

INJECTABLE; INJECTION

DIDRONEL

MGI PHARMA INC	50MG/ML	N019545 001 Apr 20, 1987
----------------	---------	--------------------------

TABLET; ORAL

DIDRONEL

+ APIL	200MG **	N017831 001
--------	----------	-------------

+	400MG **	N017831 002
---	----------	-------------

ETIDRONATE DISODIUM

MYLAN	200MG	A075800 001 Jan 24, 2003
-------	-------	--------------------------

	400MG	A075800 002 Jan 24, 2003
--	-------	--------------------------

ETODOLAC

CAPSULE; ORAL

ETODOLAC

ANI PHARMS INC	200MG	A074840 001 Aug 29, 1997
----------------	-------	--------------------------

	200MG	A074844 001 Dec 23, 1997
--	-------	--------------------------

	200MG	A074899 001 Jul 08, 1997
--	-------	--------------------------

	300MG	A074840 002 Aug 29, 1997
--	-------	--------------------------

	300MG	A074844 002 Dec 23, 1997
--	-------	--------------------------

	300MG	A074899 002 Jul 08, 1997
--	-------	--------------------------

BIOPHARM	300MG	A074929 001 Jan 30, 1998
----------	-------	--------------------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ETODOLAC

CAPSULE; ORAL

ETODOLAC

CHARTWELL MOLECULES	200MG	A074842 001	Jul 17, 1997
	300MG	A074842 002	Jul 17, 1997
MYLAN	200MG	A074932 001	May 16, 1997
	200MG	A075071 001	Sep 30, 1998
	300MG	A074932 002	May 16, 1997
	300MG	A075071 002	Sep 30, 1998
SANDOZ	200MG	A074942 001	Sep 30, 1997
	300MG	A074942 002	Sep 30, 1997

LODINE

+ WYETH PHARMS INC	200MG **	N018922 002	Jan 31, 1991
+	300MG	N018922 003	Jan 31, 1991

TABLET; ORAL

ETODOLAC

BIOPHARM	400MG	A074927 001	Oct 30, 1997
CHARTWELL MOLECULES	400MG	A074841 001	Jun 27, 1997
IVAX SUB TEVA PHARMS	400MG	A074883 001	Feb 28, 1997
	500MG	A074883 002	Nov 20, 1998
MYLAN	400MG	A075012 001	Sep 30, 1998
	400MG	A075104 001	Feb 06, 1998
	500MG	A075012 002	Sep 30, 1998
	500MG	A075104 002	Nov 20, 1998
OXFORD PHARMS	400MG	A074819 001	Feb 28, 1997
	500MG	A074819 002	Apr 28, 1998
PHARMGEN	400MG	A074839 001	Jul 11, 1997
	400MG	A074846 001	Feb 28, 1997
RANBAXY LABS LTD	400MG	A075226 001	Nov 24, 1998
	500MG	A075226 002	Nov 24, 1998
TEVA	400MG	A074847 001	Apr 23, 1999
	400MG	A075009 001	Nov 26, 1997
	500MG	A074847 002	Apr 23, 1999
	500MG	A075009 002	Dec 28, 1999
WATSON LABS	400MG	A074892 001	Apr 16, 1997
	400MG	A075069 001	Apr 16, 1998
	500MG	A074892 002	Oct 29, 1998

LODINE

+ WYETH PHARMS INC	400MG **	N018922 004	Jul 29, 1993
+	500MG **	N018922 005	Jun 28, 1996

TABLET, EXTENDED RELEASE; ORAL

ETODOLAC

ACTAVIS ELIZABETH	400MG	A075696 001	Jul 31, 2000
ANI PHARMS INC	400MG	A075943 001	Jul 26, 2002
	500MG	A075943 002	Jul 26, 2002
	600MG	A075943 003	Jul 26, 2002
WATSON LABS FLORIDA	400MG	A075829 001	Nov 30, 2001
	500MG	A075829 002	Nov 30, 2001

LODINE XL

WYETH PHARMS INC	400MG **	N020584 001	Oct 25, 1996
	500MG **	N020584 003	Jan 20, 1998
+	600MG **	N020584 002	Oct 25, 1996

ETOMIDATE

INJECTABLE; INJECTION

ETOMIDATE

LUITPOLD	2MG/ML	A078867 001	Dec 22, 2009
MYLAN LABS LTD	2MG/ML	A078289 001	Jan 02, 2009
PAR STERILE PRODUCTS	2MG/ML	A091297 001	Jun 20, 2012

ETONOGESTREL

IMPLANT; IMPLANTATION

IMPLANON

ORGANON USA INC	68MG/IMPLANT	N021529 001	Jul 17, 2006
-----------------	--------------	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ETOPOSID

CAPSULE; ORAL

VEPESID

+ DAVA PHARMS INC

50MG

N019557 001 Dec 30, 1986

+

100MG

N019557 002 Dec 30, 1986

INJECTABLE; INJECTION

ETOPOSID

HOSPIRA

20MG/ML

A074320 001 Aug 30, 1995

20MG/ML

A074351 001 Aug 30, 1995

MYLAN LABS LTD

20MG/ML

A203507 001 Nov 20, 2017

20MG/ML

A204927 001 Oct 31, 2017

PHARMACHEMIE BV

20MG/ML

A074227 001 Feb 22, 1996

PIERRE FABRE

20MG/ML

A074813 001 Jul 09, 1997

TEVA PARENTERAL

20MG/ML

A074510 001 Jun 29, 1995

TEVA PHARMS USA

20MG/ML

A074284 001 Feb 10, 1994

WATSON LABS

20MG/ML

A074228 001 Oct 15, 1996

WATSON LABS INC

20MG/ML

A074968 001 Jan 09, 1998

TOPOSAR

TEVA PARENTERAL

20MG/ML

A074166 001 Feb 27, 1995

VEPESID

+ CORDEN PHARMA

20MG/ML **

N018768 001 Nov 10, 1983

ETOPOSID PHOSPHATE

INJECTABLE; INJECTION

ETOPOPHOS PRESERVATIVE FREE

BRISTOL MYERS SQUIBB EQ 500MG BASE/VIAL

N020906 001 Feb 27, 1998

EQ 1GM BASE/VIAL

N020906 002 Feb 27, 1998

ETRETINATE

CAPSULE; ORAL

TEGISON

ROCHE

10MG

N019369 001 Sep 30, 1986

25MG

N019369 002 Sep 30, 1986

EVANS BLUE

INJECTABLE; INJECTION

EVANS BLUE

PARKE DAVIS

0.5% **

N008041 001

EVEROLIMUS

TABLET; ORAL

EVEROLIMUS

MYLAN

10MG

A212936 004 Jun 08, 2020

TEVA PHARMS USA

10MG

A210050 004 Dec 09, 2019

TABLET, FOR SUSPENSION; ORAL

EVEROLIMUS

MYLAN

2MG

A210130 001 Apr 19, 2019

3MG

A210130 002 Apr 19, 2019

5MG

A210130 003 Apr 19, 2019

EXEMESTANE

TABLET; ORAL

EXEMESTANE

AMNEAL PHARMS

25MG

A206421 001 Dec 28, 2018

MAYNE PHARMA INC

25MG

A208764 001 Aug 08, 2019

EZETIMIBE

TABLET; ORAL

EZETIMIBE

MYLAN

10MG

A201790 001 Apr 26, 2019

TEVA PHARMS USA

10MG

A078724 001 Jun 12, 2017

EZOGABINE

TABLET; ORAL

POTIGA

+ GLAXOSMITHKLINE

50MG

N022345 001 Jun 10, 2011

+

200MG

N022345 002 Jun 10, 2011

+

300MG

N022345 003 Jun 10, 2011

+

400MG

N022345 004 Jun 10, 2011

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FAMCICLOVIR

TABLET; ORAL

FAMCICLOVIR

HIKMA

125MG

A090128 001 Mar 21, 2011

250MG

A090128 002 Mar 21, 2011

500MG

A090128 003 Mar 21, 2011

MYLAN

125MG

A201333 001 Mar 24, 2011

250MG

A201333 002 Mar 24, 2011

500MG

A201333 003 Mar 24, 2011

FAMVIR

+ NOVARTIS

125MG **

N020363 003 Dec 11, 1995

+

250MG **

N020363 001 Apr 26, 1996

+

500MG **

N020363 002 Jun 29, 1994

FAMOTIDINE

FOR SUSPENSION; ORAL

PEPCID

+ SALIX PHARMS

40MG/5ML

N019527 001 Feb 02, 1987

INJECTABLE; INJECTION

FAMOTIDINE

APOTEX INC

10MG/ML

A075942 001 Aug 02, 2002

APOTHECON

10MG/ML

A075707 001 Apr 16, 2001

HOSPIRA

10MG/ML

A075705 001 Apr 16, 2001

10MG/ML

A075870 001 Nov 23, 2001

10MG/ML

A075905 001 Nov 23, 2001

WEST-WARD PHARMS INT

10MG/ML

A075799 001 Apr 30, 2002

FAMOTIDINE PRESERVATIVE FREE

APOTEX INC

10MG/ML

A076324 001 Nov 27, 2002

APOTHECON

10MG/ML

A075708 001 Apr 16, 2001

HOSPIRA

10MG/ML

A075669 001 Apr 16, 2001

WEST-WARD PHARMS INT

10MG/ML

A075789 001 Apr 30, 2002

FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK)

APOTEX INC

10MG/ML

A076322 001 Nov 27, 2002

FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER

ABBVIE

0.4MG/ML

A075729 001 Dec 17, 2001

PEPCID

+ MERCK

10MG/ML **

N019510 001 Nov 04, 1986

PEPCID PRESERVATIVE FREE

+ MERCK

10MG/ML **

N019510 004 Nov 04, 1986

PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER

+ MERCK SHARP DOHME

0.4MG/ML **

N020249 001 Feb 18, 1994

TABLET; ORAL

FAMOTIDINE

ACTAVIS ELIZABETH

20MG

A075650 001 Sep 14, 2001

40MG

A075650 002 Sep 14, 2001

APOTEX

10MG

A075610 001 Mar 12, 2002

MYLAN

10MG

A075674 001 Dec 21, 2001

20MG

A075704 001 Apr 16, 2001

40MG

A075704 002 Apr 16, 2001

MYLAN PHARMS INC

20MG

A075457 001 Apr 18, 2001

40MG

A075457 002 Apr 18, 2001

PLD ACQUISITIONS

20MG

A075302 001 Apr 16, 2001

40MG

A075302 002 Apr 16, 2001

SANDOZ

10MG

A076101 001 Oct 21, 2002

20MG

A075607 001 May 10, 2001

20MG

A075793 001 Apr 16, 2001

40MG

A075607 002 May 10, 2001

40MG

A075793 002 Apr 16, 2001

SUN PHARM INDUSTRIES

20MG

A075639 002 Dec 12, 2001

40MG

A075639 001 Dec 12, 2001

TEVA

10MG

A075312 001 May 31, 2001

20MG

A075311 001 Apr 16, 2001

40MG

A075311 002 Apr 16, 2001

WATSON LABS

10MG

A075404 001 Nov 28, 2001

20MG

A075062 002 Apr 16, 2001

40MG

A075062 001 Apr 16, 2001

PEPCID

+ VALEANT PHARMS NORTH

20MG

N019462 001 Oct 15, 1986

+

40MG

N019462 002 Oct 15, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FAMOTIDINE

TABLET, CHEWABLE;ORAL

PEPCID AC

+ J AND J CONSUMER INC 10MG **

N020801 001 Sep 24, 1998

TABLET, ORALLY DISINTEGRATING;ORAL

FLUXID

UCB INC

20MG

N021712 001 Sep 24, 2004

40MG

N021712 002 Sep 24, 2004

PEPCID RPD

MERCK

20MG

N020752 001 May 28, 1998

40MG

N020752 002 May 28, 1998

FELODIPINE

TABLET, EXTENDED RELEASE;ORAL

FELODIPINE

MYLAN

2.5MG

A078855 001 Apr 17, 2008

5MG

A078855 002 Apr 17, 2008

10MG

A078855 003 Apr 17, 2008

WOCKHARDT LTD

2.5MG

A091484 001 Aug 15, 2012

5MG

A091484 002 Aug 15, 2012

10MG

A091484 003 Aug 15, 2012

PLENDIL

+ ASTRAZENECA

2.5MG **

N019834 004 Sep 22, 1994

+

5MG **

N019834 001 Jul 25, 1991

+

10MG **

N019834 002 Jul 25, 1991

FENOFIBRATE

CAPSULE;ORAL

ANTARA (MICRONIZED)

LUPIN

87MG

N021695 002 Nov 30, 2004

FENOFIBRATE (MICRONIZED)

MYLAN PHARMS INC

43MG

A202579 001 Jan 10, 2013

130MG

A202579 002 Jan 10, 2013

NOVAST LABS

67MG

A207564 001 Apr 19, 2019

134MG

A207564 002 Apr 19, 2019

200MG

A207564 003 Apr 19, 2019

LIPIDIL

ABBVIE

100MG

N019304 001 Dec 31, 1993

LIPOFEN

CIPHER PHARMS INC

100MG

N021612 002 Jan 11, 2006

TRICOR (MICRONIZED)

+ ABBVIE

67MG **

N019304 002 Feb 09, 1998

+

134MG **

N019304 003 Jun 30, 1999

+

200MG **

N019304 004 Jun 30, 1999

TABLET;ORAL

FENOFIBRATE

ALEMBIC PHARMS LTD

54MG

A213252 001 Jan 17, 2020

160MG

A213252 002 Jan 17, 2020

MYLAN

107MG

A076520 002 Dec 29, 2005

TRICOR

+ ABBVIE INC

54MG **

N021203 001 Sep 04, 2001

+

160MG **

N021203 003 Sep 04, 2001

TRIGLIDE

SKYEPHARMA AG

50MG

N021350 001 May 07, 2005

FENOFIBRIC ACID

TABLET;ORAL

FIBRICOR

+ ATHENA

35MG

N022418 001 Aug 14, 2009

FENOLDOPAM MESYLATE

INJECTABLE;INJECTION

FENOLDOPAM MESYLATE

LUITPOLD

EQ 10MG BASE/ML

A076656 001 Dec 01, 2003

TEVA PARENTERAL

EQ 10MG BASE/ML

A077826 001 Mar 07, 2007

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FENOPROFEN CALCIUM

CAPSULE;ORAL

FENOPROFEN CALCIUM

AM THERAP	EQ 200MG BASE	A072307	001	Aug 22, 1988
	EQ 300MG BASE	A072308	001	Aug 22, 1988
AUROLIFE PHARMA LLC	EQ 200MG BASE	A072394	001	Oct 17, 1988
	EQ 300MG BASE	A072395	001	Oct 17, 1988
HALSEY	EQ 200MG BASE	A072355	001	Aug 17, 1988
	EQ 300MG BASE	A072356	001	Aug 17, 1988
PAR PHARM	EQ 200MG BASE	A072437	001	Aug 22, 1988
	EQ 300MG BASE	A072438	001	Aug 22, 1988
QUANTUM PHARMICS	EQ 200MG BASE	A072214	001	Aug 17, 1988
	EQ 300MG BASE	A071738	001	Aug 17, 1988
WARNER CHILCOTT	EQ 200MG BASE	A072946	001	Apr 30, 1991
	EQ 300MG BASE	A072472	001	Apr 30, 1991
WATSON LABS	EQ 200MG BASE	A072294	001	Aug 17, 1988
	EQ 200MG BASE	A072981	001	Aug 19, 1991
	EQ 300MG BASE	A072293	001	Aug 17, 1988
	EQ 300MG BASE	A072982	001	Aug 19, 1991

NALFON

XSPIRE PHARMA	EQ 300MG BASE	N017604	002	
---------------	---------------	---------	-----	--

TABLET;ORAL

FENOPROFEN CALCIUM

AM THERAP	EQ 600MG BASE	A072309	001	Aug 17, 1988
ANI PHARMS INC	EQ 600MG BASE	A072274	001	May 02, 1988
DAVA PHARMS INC	EQ 600MG BASE	A072326	001	Aug 17, 1988
HALSEY	EQ 600MG BASE	A072357	001	Aug 17, 1988
IVAX SUB TEVA PHARMS	EQ 600MG BASE	A072557	001	Aug 29, 1988
PAR PHARM	EQ 600MG BASE	A072429	001	Aug 17, 1988
QUANTUM PHARMICS	EQ 600MG BASE	A072194	001	Aug 17, 1988
RISING	EQ 600MG BASE	A072396	001	Oct 17, 1988
SUN PHARM INDUSTRIES	EQ 600MG BASE	A072902	001	Dec 21, 1990
USL PHARMA	EQ 600MG BASE	A072362	001	Aug 17, 1988
WATSON LABS	EQ 600MG BASE	A072165	001	Aug 17, 1988
	EQ 600MG BASE	A072602	001	Oct 11, 1988
WATSON LABS TEVA	EQ 600MG BASE	A072407	001	Aug 17, 1988

NALFON

DISTA	EQ 600MG BASE	N017710	001	
-------	---------------	---------	-----	--

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL

FENTANYL-100

ACTAVIS LABS UT INC	100MCG/HR	A076709	004	Aug 20, 2007
LAVIPHARM LABS	100MCG/HR	A077051	004	Aug 04, 2006
MAYNE PHARMA	100MCG/HR	A077062	004	Aug 20, 2007
NOVEN	100MCG/HR	A077775	004	Oct 16, 2009

FENTANYL-25

ACTAVIS LABS UT INC	25MCG/HR	A076709	001	Aug 20, 2007
LAVIPHARM LABS	25MCG/HR	A077051	001	Aug 04, 2006
MAYNE PHARMA	25MCG/HR	A077062	001	Aug 20, 2007
NOVEN	25MCG/HR	A077775	001	Oct 16, 2009

FENTANYL-50

ACTAVIS LABS UT INC	50MCG/HR	A076709	002	Aug 20, 2007
LAVIPHARM LABS	50MCG/HR	A077051	002	Aug 04, 2006
MAYNE PHARMA	50MCG/HR	A077062	002	Aug 20, 2007
NOVEN	50MCG/HR	A077775	002	Oct 16, 2009

FENTANYL-75

ACTAVIS LABS UT INC	75MCG/HR	A076709	003	Aug 20, 2007
LAVIPHARM LABS	75MCG/HR	A077051	003	Aug 04, 2006
MAYNE PHARMA	75MCG/HR	A077062	003	Aug 20, 2007
NOVEN	75MCG/HR	A077775	003	Oct 16, 2009

FENTANYL CITRATE

FILM;BUCCAL

ONSOLIS

BDSI	EQ 0.2MG BASE	N022266	001	Jul 16, 2009
	EQ 0.4MG BASE	N022266	002	Jul 16, 2009
	EQ 0.6MG BASE	N022266	003	Jul 16, 2009
	EQ 0.8MG BASE	N022266	004	Jul 16, 2009
	EQ 1.2MG BASE	N022266	005	Jul 16, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE

ABBOTT

EQ 0.05MG BASE/ML

A070636 001 Apr 30, 1990

EQ 0.05MG BASE/ML

A070637 001 Apr 30, 1990

WATSON LABS

EQ 0.05MG BASE/ML

A073488 001 Jun 30, 1992

FENTANYL CITRATE PRESERVATIVE FREE

DR REDDYS

EQ 0.05MG BASE/ML

A074917 001 Feb 03, 1998

SPRAY, METERED; NASAL

LAZANDA

+ BTCP PHARMA

EQ 0.3MG BASE

N022569 003 Dec 21, 2015

TABLET; BUCCAL, SUBLINGUAL

FENTANYL CITRATE

WATSON LABS

EQ 0.1MG BASE

A079075 001 Jan 07, 2011

EQ 0.2MG BASE

A079075 002 Jan 07, 2011

EQ 0.4MG BASE

A079075 003 Jan 07, 2011

EQ 0.6MG BASE

A079075 004 Jan 07, 2011

EQ 0.8MG BASE

A079075 005 Jan 07, 2011

FENTORA

+ CEPHALON

EQ 0.3MG BASE **

N021947 006 Mar 02, 2007

TABLET; SUBLINGUAL

ABSTRAL

+ SENTYNL THERAPS INC

EQ 0.1MG BASE

N022510 001 Jan 07, 2011

+

EQ 0.2MG BASE

N022510 002 Jan 07, 2011

+

EQ 0.3MG BASE

N022510 003 Jan 07, 2011

+

EQ 0.4MG BASE

N022510 004 Jan 07, 2011

+

EQ 0.6MG BASE

N022510 005 Jan 07, 2011

+

EQ 0.8MG BASE

N022510 006 Jan 07, 2011

FENTANYL CITRATE

ACTAVIS LABS FL INC

EQ 0.1MG BASE

A207338 001 Nov 17, 2017

EQ 0.2MG BASE

A207338 002 Nov 17, 2017

EQ 0.3MG BASE

A207338 003 Nov 17, 2017

EQ 0.4MG BASE

A207338 004 Nov 17, 2017

EQ 0.6MG BASE

A207338 005 Nov 17, 2017

EQ 0.8MG BASE

A207338 006 Nov 17, 2017

TROCHE/LOZENGE; ORAL

FENTANYL

CEPHALON

EQ 0.1MG BASE

N020195 007 Oct 30, 1995

EQ 0.2MG BASE

N020195 001 Oct 04, 1993

EQ 0.3MG BASE

N020195 002 Oct 04, 1993

EQ 0.4MG BASE

N020195 003 Oct 04, 1993

TROCHE/LOZENGE; TRANSMUCOSAL

FENTANYL CITRATE

PAR PHARM

EQ 0.2MG BASE

A077312 001 Oct 30, 2009

EQ 0.4MG BASE

A077312 002 Oct 30, 2009

EQ 0.6MG BASE

A077312 003 Oct 30, 2009

EQ 0.8MG BASE

A077312 004 Oct 30, 2009

EQ 1.2MG BASE

A077312 005 Oct 30, 2009

EQ 1.6MG BASE

A077312 006 Oct 30, 2009

FENTANYL HYDROCHLORIDE

SYSTEM; IONTOPHORESIS, TRANSDERMAL

IONSYS

+ THE MEDICINES CO

EQ 40MCG BASE/ACTIVATION

N021338 001 May 22, 2006

FERRIC AMMONIUM CITRATE

FOR SOLUTION; ORAL

FERRISELTZ

OTSUKA

600MG/PACKET

N020292 001 Oct 14, 1997

FERRIC DERISOMALTOSE

SOLUTION; INTRAVENOUS

MONOFERRIC

+ PHARMACOSMOS AS

100MG/ML (100MG/ML)

N208171 001 Jan 16, 2020

+

500MG/5ML (100MG/ML)

N208171 002 Jan 16, 2020

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FERRIC MALTOI

CAPSULE;ORAL

ACCRUFER

+ SHIELD TX

30MG IRON

N212320 001 Jul 25, 2019

FERRIC PYROPHOSPHATE CITRATE

SOLUTION;INTRAVENOUS

TRIFERIC

+ ROCKWELL MEDICAL INC 272MG IRON/50ML (5.44MG IRON/ML)

N206317 002 Sep 04, 2015

FERROUS CITRATE, FE-59

INJECTABLE;INJECTION

FERROUS CITRATE FE 59

MALLINCKRODT

25uCi/ML

N016729 001

FERROUS SULFATE; FOLIC ACID

CAPSULE;ORAL

FOLVRON

LEDERLE

182MG;0.33MG

N006012 003

FERUMOXIDES

INJECTABLE;INJECTION

FERIDEX I.V.

AMAG PHARMS INC

EQ 11.2MG IRON/ML

N020416 001 Aug 30, 1996

FERUMOXSIIL

SUSPENSION;ORAL

GASTROMARK

AMAG PHARMS INC

EQ 0.175MG IRON/ML

N020410 001 Dec 06, 1996

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL

FESOTERODINE FUMARATE

ALKEM LABS LTD

4MG

A204827 001 Dec 10, 2015

8MG

A204827 002 Dec 10, 2015

DR REDDYS LABS LTD

4MG

A204975 001 Aug 13, 2019

8MG

A204975 002 Aug 13, 2019

FEXOFENADINE HYDROCHLORIDE

CAPSULE;ORAL

ALLEGRA

SANOFI AVENTIS US

60MG **

N020625 001 Jul 25, 1996

FEXOFENADINE HYDROCHLORIDE

BARR

60MG

A076169 001 Jul 13, 2005

SUSPENSION;ORAL

ALLEGRA

+ SANOFI AVENTIS US

30MG/5ML

N021963 001 Oct 16, 2006

CHILDREN'S ALLEGRA HIVES

+ SANOFI AVENTIS US

30MG/5ML **

N201373 002 Jan 24, 2011

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

TARO

30MG/5ML

A208123 001 Nov 09, 2017

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

TARO

30MG/5ML

A208123 002 Nov 09, 2017

FEXOFENADINE HYDROCHLORIDE

P AND L

30MG/5ML

A201311 001 Jul 25, 2012

TABLET;ORAL

ALLEGRA HIVES

+ SANOFI AVENTIS US

60MG

N020872 008 Jan 24, 2011

+ 180MG

N020872 009 Jan 24, 2011

CHILDREN'S ALLEGRA ALLERGY

+ SANOFI AVENTIS US

30MG **

N020872 005 Jan 24, 2011

CHILDREN'S ALLEGRA HIVES

+ SANOFI AVENTIS US

30MG

N020872 006 Jan 24, 2011

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

MYLAN

30MG

A077081 004 Jul 21, 2011

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

MYLAN

30MG

A077081 005 Jul 21, 2011

FEXOFENADINE HYDROCHLORIDE

BARR

30MG

A076191 001 Aug 31, 2005

60MG

A076191 002 Aug 31, 2005

180MG

A076191 003 Aug 31, 2005

L PERRIGO CO

60MG

A212971 001 Feb 24, 2020

180MG

A212971 002 Feb 24, 2020

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL

FEXOFENADINE HYDROCHLORIDE				
MYLAN	30MG	A077081	002	Apr 11, 2008
TABLET, ORALLY DISINTEGRATING;ORAL				
CHILDREN'S ALLEGRA ALLERGY				
+ SANOFI AVENTIS US	30MG	N021909	002	Jan 24, 2011
CHILDREN'S ALLEGRA HIVES				
+ SANOFI AVENTIS US	30MG **	N021909	003	Jan 24, 2011
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY				
DR REDDYS LABS LTD	30MG	A202978	001	Jan 18, 2013
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES				
DR REDDYS LABS LTD	30MG	A202978	002	Jan 18, 2013

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE				
BARR	60MG;120MG	A076236	001	Apr 14, 2005
IMPAX PHARMS	60MG;120MG	A076298	001	Nov 12, 2010

FINAFLOXACIN

SUSPENSION/DROPS;OTIC

XTORO				
+ MERLION PHARMS GMBH	0.3%	N206307	001	Dec 17, 2014

FINASTERIDE

TABLET;ORAL

FINASTERIDE				
ACTAVIS TOTOWA	1MG	A078371	001	Nov 05, 2013
GEDEON RICHTER USA	5MG	A077251	001	Dec 22, 2006
IVAX SUB TEVA PHARMS	5MG	A076340	001	Jun 19, 2006
MYLAN	1MG	A078161	001	Nov 05, 2013
	5MG	A077578	001	Dec 18, 2006
TEVA	1MG	A076905	001	Nov 05, 2013

FINGOLIMOD HYDROCHLORIDE

CAPSULE;ORAL

FINGOLIMOD HYDROCHLORIDE				
BIOCON LTD	EQ 0.5MG BASE	A207979	001	Dec 04, 2019
TEVA PHARMS USA	EQ 0.5MG BASE	A208008	001	Jul 02, 2020

FLAVOXATE HYDROCHLORIDE

TABLET;ORAL

FLAVOXATE HYDROCHLORIDE				
IMPAX PHARMS	100MG	A076234	001	Aug 28, 2003
URISPAS				
ORTHO MCNEIL JANSSEN	100MG	N016769	001	

FLECAINIDE ACETATE

TABLET;ORAL

FLECAINIDE ACETATE				
ANI PHARMS INC	50MG	A076030	001	Oct 28, 2002
	100MG	A076030	002	Oct 28, 2002
	150MG	A076030	003	Oct 28, 2002
APOTEX INC	50MG	A079164	001	Jul 09, 2009
	100MG	A079164	002	Jul 09, 2009
	150MG	A079164	003	Jul 09, 2009
TAMBOCOR				
CNTY LINE PHARMS	200MG	N018830	002	Oct 31, 1985

FLORBETAPIR F-18

SOLUTION;INTRAVENOUS

AMYVID				
AVID RADIOPHARMS INC	10ML (13.5-51mCi/ML)	N202008	001	Apr 06, 2012

FLOXURIDINE

INJECTABLE;INJECTION

FLOXURIDINE				
AM REGENT	500MG/VIAL	A203008	001	Nov 22, 2017
FUDR				
+ HOSPIRA	500MG/VIAL **	N016929	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FLUCONAZOLE

FOR SUSPENSION; ORAL

FLUCONAZOLE

HIKMA	50MG/5ML	A076246 001	Jul 29, 2004
	200MG/5ML	A076246 002	Jul 29, 2004
IVAX SUB TEVA PHARMS	50MG/5ML	A077523 001	Sep 12, 2007
	200MG/5ML	A077523 002	Sep 12, 2007
SUN PHARM INDS LTD	50MG/5ML	A076332 001	Jul 29, 2004
	200MG/5ML	A076332 002	Jul 29, 2004
TARO PHARM INDS	50MG/5ML	A076918 001	Dec 18, 2006
	200MG/5ML	A076918 002	Dec 18, 2006

INJECTABLE; INJECTION

DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER

+ PFIZER	200MG/100ML (2MG/ML)	N019950 003	Sep 29, 1992
+ PFIZER	400MG/200ML (2MG/ML)	N019950 005	Jul 08, 1994

DIFLUCAN IN SODIUM CHLORIDE 0.9%

+ PFIZER	200MG/100ML (2MG/ML)	N019950 001	Jan 29, 1990
+ PFIZER	400MG/200ML (2MG/ML)	N019950 006	Jan 29, 1990

DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+ PFIZER	200MG/100ML (2MG/ML)	N019950 002	Jan 29, 1990
+ PFIZER	400MG/200ML (2MG/ML)	N019950 004	Jan 29, 1990

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

HIKMA FARMACEUTICA	200MG/100ML (2MG/ML)	A078764 001	Jan 30, 2012
	400MG/200ML (2MG/ML)	A078764 002	Jan 30, 2012
HOSPIRA	200MG/100ML (2MG/ML)	A076304 001	Jul 29, 2004
	400MG/200ML (2MG/ML)	A076304 002	Jul 29, 2004
MYLAN LABS LTD	200MG/100ML (2MG/ML)	A076888 001	Mar 25, 2005
	400MG/200ML (2MG/ML)	A076888 002	Mar 25, 2005
WOODWARD	200MG/100ML (2MG/ML)	A077988 001	May 26, 2010
	400MG/200ML (2MG/ML)	A077988 002	May 26, 2010

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

DR REDDYS	200MG/100ML (2MG/ML)	A076653 001	Jul 29, 2004
	400MG/200ML (2MG/ML)	A076653 002	Jul 29, 2004

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

DR REDDYS	200MG/100ML (2MG/ML)	A076837 001	Jan 13, 2005
	400MG/200ML (2MG/ML)	A076837 002	Jan 13, 2005
HOSPIRA	200MG/100ML (2MG/ML)	A076617 001	Jul 29, 2004
	400MG/200ML (2MG/ML)	A076617 002	Jul 29, 2004
MYLAN LABS LTD	200MG/100ML (2MG/ML)	A076889 001	Mar 25, 2005
	400MG/200ML (2MG/ML)	A076889 002	Mar 25, 2005

TABLET; ORAL

FLUCONAZOLE

ANI PHARMS INC	50MG	A076086 001	Jul 29, 2004
	100MG	A076086 002	Jul 29, 2004
	150MG	A076086 003	Jul 29, 2004
	200MG	A076086 004	Jul 29, 2004
GEDEON RICHTER USA	50MG	A076432 001	Jul 29, 2004
	100MG	A076432 002	Jul 29, 2004
	150MG	A076432 003	Jul 29, 2004
	200MG	A076432 004	Jul 29, 2004
MYLAN	50MG	A076351 001	Jul 29, 2004
	100MG	A076351 002	Jul 29, 2004
	150MG	A076351 003	Jul 29, 2004
	200MG	A076351 004	Jul 29, 2004
MYLAN PHARMS INC	50MG	A076042 001	Jul 29, 2004
	100MG	A076042 002	Jul 29, 2004
	150MG	A076042 003	Jul 29, 2004
	200MG	A076042 004	Jul 29, 2004
PLIVA	50MG	A076424 001	Jul 29, 2004
	100MG	A076424 002	Jul 29, 2004
	150MG	A076424 003	Jul 29, 2004
	200MG	A076424 004	Jul 29, 2004
RANBAXY LABS LTD	50MG	A076386 001	Jul 29, 2004
	100MG	A076386 002	Jul 29, 2004
	150MG	A076386 003	Jul 29, 2004
	200MG	A076386 004	Jul 29, 2004
ROXANE	50MG	A076213 001	Jul 29, 2004
	100MG	A076213 002	Jul 29, 2004
	150MG	A076213 003	Jul 29, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FLUCONAZOLE

TABLET; ORAL

FLUCONAZOLE

	200MG	A076213 004	Jul 29, 2004
TEVA	50MG	A074681 001	Jul 29, 2004
	100MG	A074681 002	Jul 29, 2004
	150MG	A074681 003	Jul 29, 2004
	200MG	A074681 004	Jul 29, 2004

FLUCYDOSINE

CAPSULE; ORAL

FLUCYDOSINE

STRIDES PHARMA	250MG	A207536 001	Jun 18, 2018
	250MG	A212632 001	Apr 17, 2020
	500MG	A207536 002	Jun 18, 2018
	500MG	A212632 002	Apr 17, 2020

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARA

+ GENZYME CORP	50MG/VIAL **	N020038 001	Apr 18, 1991
FLUDARABINE PHOSPHATE			
MYLAN LABS LTD	50MG/2ML (25MG/ML)	A200647 001	Dec 21, 2011
	50MG/VIAL	A200648 001	Oct 16, 2012

TABLET; ORAL

OFORTA

SANOFI AVENTIS US	10MG	N022273 001	Dec 18, 2008
-------------------	------	-------------	--------------

FLUDEOXYGLUCOSE F-18

INJECTABLE; INJECTION

FLUDEOXYGLUCOSE F18

+ DOWNSTATE CLINCL	4-40mCi/ML **	N020306 001	Aug 19, 1994
	4-90mCi/ML **	N020306 002	Sep 25, 2001

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

+ FEINSTEIN	20-200mCi/ML	N021870 001	Aug 19, 2005
MIDWEST MEDCL	20-200mCi/ML	A203736 001	Nov 19, 2015
UNIV TX SW MEDCTR	20-200mCi/ML	A210265 001	Feb 06, 2020
WEILL MEDCL COLL	10-100mCi/ML **	N021768 001	Aug 05, 2004

FLUDROCORTISONE ACETATE

TABLET; ORAL

FLORINEF

+ CASPER PHARMA LLC	0.1MG **	N010060 001	
FLUDROCORTISONE ACETATE			
HIKMA PHARMS	0.1MG	A091302 001	Jul 22, 2011

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

BAXTER HLTHCARE CORP	0.5MG/5ML (0.1MG/ML)	A076755 002	Oct 12, 2004
	1MG/10ML (0.1MG/ML)	A076755 001	Oct 12, 2004
DR REDDYS	0.5MG/5ML (0.1MG/ML)	A076589 002	Oct 12, 2004
	1MG/10ML (0.1MG/ML)	A076589 001	Oct 12, 2004
MYLAN LABS LTD	1MG/10ML (0.1MG/ML)	A078595 002	May 13, 2008
ROMAZICON			
+ HOFFMANN LA ROCHE	1MG/10ML (0.1MG/ML) **	N020073 001	Dec 20, 1991
	0.5MG/5ML (0.1MG/ML) **	N020073 002	Dec 20, 1991

FLUMETHASONE PIVALATE

CREAM; TOPICAL

LOCORTEN

NOVARTIS	0.03%	N016379 001	
----------	-------	-------------	--

FLUNISOLIDE

AEROSOL, METERED; INHALATION

AEROBID

ROCHE PALO	0.25MG/INH	N018340 001	Aug 17, 1984
AEROSPAN HFA			
+ MYLAN SPECIALITY LP	0.078MG/INH	N021247 001	Jan 27, 2006

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FLUNISOLIDE

SPRAY, METERED;NASAL

NASALIDE

+ IVAX RES

0.025MG/SPRAY **

N018148 001

NASAREL

TEVA BRANDED PHARM

0.029MG/SPRAY

N020409 001 Mar 08, 1995

FLUOCINOLONE ACETONIDE

CREAM;TOPICAL

FLUOCET

ALPHARMA US PHARMS

0.025%

A088360 001 Jan 16, 1984

FLUOCINOLONE ACETONIDE

ALPHARMA US PHARMS

0.01%

A088361 001 Jan 16, 1984

COSETTE

0.025%

A089525 001 Jul 26, 1988

INVATECH

0.01%

A088047 001 Dec 16, 1982

0.025%

A088045 001 Dec 16, 1982

PERRIGO NEW YORK

0.01%

A086810 001 Mar 04, 1982

0.025%

A086811 001 Mar 04, 1982

PHARMAFAIR

0.01%

A088499 001 Aug 02, 1984

0.025%

A088506 001 Aug 02, 1984

TARO

0.01%

A040035 001 Oct 31, 1994

0.01%

A087102 001 Apr 27, 1982

0.025%

A040042 001 Oct 31, 1994

USL PHARMA

0.01%

A088757 001 Feb 11, 1985

0.025%

A088756 001 Mar 28, 1985

FLUONID

ALLERGAN HERBERT

0.025%

A087156 002 Sep 06, 1984

FLUOTREX

SAVAGE LABS

0.01%

A088174 001 May 06, 1983

0.025%

A088173 001 Mar 09, 1983

SYNALAR-HP

MEDIMETRIKS PHARMS

0.2%

N016161 002

GEL;TOPICAL

FLUONID

ALLERGAN HERBERT

0.025%

A087300 001 May 27, 1982

OINTMENT;TOPICAL

FLUOCINOLONE ACETONIDE

PHARMADERM

0.025%

A088046 001 Dec 16, 1982

PHARMAFAIR

0.025%

A088507 001 Feb 27, 1984

USL PHARMA

0.025%

A088742 001 Feb 08, 1985

FLUONID

ALLERGAN HERBERT

0.025%

A087157 001 Sep 06, 1984

FLUOTREX

SAVAGE LABS

0.025%

A088172 001 Mar 09, 1983

SOLUTION;TOPICAL

FLUOCINOLONE ACETONIDE

ACTAVIS LABS UT INC

0.01%

A208386 001 Oct 21, 2016

ALPHARMA US PHARMS

0.01%

A087159 001 Jun 16, 1982

BAUSCH AND LOMB

0.01%

A040059 001 Dec 20, 1993

COSETTE

0.01%

A207441 001 Sep 28, 2016

INVATECH

0.01%

A088048 001 Dec 16, 1982

MORTON GROVE

0.01%

A088312 001 Jan 27, 1984

PHARMAFAIR

0.01%

A088449 001 Feb 08, 1984

FLUONID

ALLERGAN HERBERT

0.01%

A087158 001 Mar 17, 1983

FLUOTREX

SAVAGE LABS

0.01%

A088171 001 Mar 09, 1983

FLUOCINONIDE

CREAM;TOPICAL

FLUOCINONIDE

PERRIGO NEW YORK

0.05%

A071790 001 Jul 13, 1988

TELIGENT

0.05%

A211410 001 Oct 16, 2018

LIDEX

+ CNTY LINE PHARMS

0.05%

N016908 002

SOLUTION;TOPICAL

FLUOCINONIDE

TARO

0.05%

A072857 001 Aug 02, 1989

TEVA

0.05%

A072511 001 Feb 07, 1989

TEVA PHARMS

0.05%

A072522 001 Sep 28, 1990

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FLUORESCHEIN SODIUM

INJECTABLE; INJECTION

FUNDUSCEIN-25

+ NOVARTIS

25% **

N017869 001

FLUORODOPA F-18

SOLUTION; INTRAVENOUS

FLUORODOPA F18

+ FEINSTEIN

0.42-8.33mCi/ML

N200655 001 Oct 10, 2019

FLUOROMETHOLONE

CREAM; TOPICAL

OXYLONE

PHARMACIA AND UPJOHN 0.025%

N011748 001

SUSPENSION/DROPS; OPHTHALMIC

FLUOR-OP

NOVARTIS

0.1%

A070185 001 Feb 27, 1986

FLUOROMETHOLONE ACETATE; TOBRAMYCIN

SUSPENSION/DROPS; OPHTHALMIC

TOBRASONE

EYEVANCE

0.1%; 0.3%

N050628 001 Jul 21, 1989

FLUOROMETHOLONE; SULFACETAMIDE SODIUM

SUSPENSION/DROPS; OPHTHALMIC

FML-S

ALLERGAN

0.1%; 10%

N019525 001 Sep 29, 1989

FLUOROURACIL

CREAM; TOPICAL

FLUOROURACIL

MYLAN

0.5%

A203122 001 Apr 20, 2015

INJECTABLE; INJECTION

ADRUCIL

PHARMACIA AND UPJOHN

50MG/ML

A081222 001 Jun 28, 1991

+

TEVA PARENTERAL

50MG/ML

N017959 001

TEVA PARENTERAL

50MG/ML

A040023 001 Oct 18, 1991

TEVA PARENTERAL

50MG/ML

A081225 001 Aug 28, 1991

FLUOROURACIL

ABIC

50MG/ML

A088929 001 Mar 04, 1986

ABRAXIS PHARM

50MG/ML

A089152 001 Mar 21, 1986

50MG/ML

50MG/ML

A089428 001 Jan 12, 1987

50MG/ML

50MG/ML

A089519 001 Mar 12, 1987

BEDFORD

50MG/ML

A089508 001 Jan 26, 1988

EBEWE PHARMA

500MG/10ML (50MG/ML)

A040772 001 Aug 11, 2008

FRESENIUS KABI USA

50MG/ML

A040291 001 Mar 24, 1999

50MG/ML

50MG/ML

A040379 001 Nov 15, 2000

MARCHAR

50MG/ML

A087791 001 Jan 18, 1983

MYLAN LABS LTD

500MG/10ML (50MG/ML)

A202668 001 Jul 17, 2012

1GM/20ML (50MG/ML)

A202668 002 Jul 17, 2012

2.5GM/50ML (50MG/ML)

A202669 001 Jul 17, 2012

5GM/100ML (50MG/ML)

A202669 002 Jul 17, 2012

NOVAST LABS

500MG/10ML (50MG/ML)

A209219 001 Dec 12, 2019

500MG/10ML (50MG/ML)

A209271 001 Dec 11, 2019

1GM/20ML (50MG/ML)

A209219 002 Dec 12, 2019

2.5GM/50ML (50MG/ML)

A209271 002 Dec 11, 2019

SANDOZ

2.5GM/50ML (50MG/ML)

A091299 001 May 02, 2011

5GM/100ML (50MG/ML)

A091299 002 May 02, 2011

SMITH AND NEPHEW

50MG/ML

A088766 001 Dec 28, 1984

50MG/ML

A088767 001 Dec 28, 1984

50MG/ML

A089434 001 Mar 26, 1987

50MG/ML

A087792 001 Oct 13, 1982

+

500MG/10ML (50MG/ML) **

N012209 001

+

2.5GM/50ML (50MG/ML)

N012209 002 Jul 29, 2016

TEVA PHARMS USA

2.5GM/50ML (50MG/ML)

A040334 001 Feb 25, 2000

5GM/100ML (50MG/ML)

A040334 002 Feb 25, 2000

SOLUTION; TOPICAL

EFUDEX

+ BAUSCH

5%

N016831 002

FLUOROPLEX

ELORAC

1%

N016765 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

FLUOXETINE

SUN PHARM INDUSTRIES	EQ 10MG BASE	A075787 001	Jan 29, 2002
	EQ 20MG BASE	A075787 002	Jan 29, 2002
WATSON LABS	EQ 10MG BASE	A075662 001	Jan 29, 2002
	EQ 20MG BASE	A075662 002	Jan 29, 2002

FLUOXETINE HYDROCHLORIDE

ANI PHARMS INC	EQ 10MG BASE	A076287 001	May 20, 2008
	EQ 20MG BASE	A076287 002	May 20, 2008
BARR	EQ 10MG BASE	A074803 002	Jan 30, 2002
	EQ 20MG BASE	A074803 001	Aug 02, 2001
	EQ 40MG BASE	A076251 001	May 18, 2005
BEXIMCO PHARMS USA	EQ 10MG BASE	A075807 001	Jan 29, 2002
	EQ 20MG BASE	A075807 002	Jan 29, 2002
CARLSBAD	EQ 10MG BASE	A076022 001	Jan 30, 2002
	EQ 20MG BASE	A076022 002	Jan 30, 2002
CELLTRION	EQ 10MG BASE	A078143 001	Jan 16, 2008
	EQ 20MG BASE	A078143 002	Jan 16, 2008
	EQ 40MG BASE	A078143 003	Jan 16, 2008
CR DOUBLE CRANE	EQ 10MG BASE	A076165 001	Feb 01, 2002
	EQ 20MG BASE	A076165 002	Feb 01, 2002
HERITAGE PHARMS INC	EQ 10MG BASE	A201336 001	Oct 01, 2012
	EQ 20MG BASE	A201336 002	Oct 01, 2012
	EQ 40MG BASE	A201336 003	Oct 01, 2012
MYLAN	EQ 10MG BASE	A075207 001	Jan 30, 2002
	EQ 10MG BASE	A078045 001	Nov 17, 2008
	EQ 20MG BASE	A075207 002	Jan 30, 2002
	EQ 20MG BASE	A078045 002	Nov 17, 2008
	EQ 40MG BASE	A075207 003	May 25, 2007
MYLAN PHARMS INC	EQ 10MG BASE	A075577 001	Jan 29, 2002
	EQ 20MG BASE	A075577 002	Jan 29, 2002
PAR PHARM	EQ 10MG BASE	A076922 001	Dec 16, 2004
	EQ 20MG BASE	A076922 002	Dec 16, 2004
	EQ 40MG BASE	A076922 003	Dec 16, 2004
SANDOZ	EQ 10MG BASE	A077469 001	Nov 17, 2008
	EQ 20MG BASE	A077469 002	Nov 17, 2008
SPECGX LLC	EQ 10MG BASE	A075658 001	Jan 29, 2002
	EQ 20MG BASE	A075658 002	Jan 29, 2002

PROZAC

ELI LILLY AND CO	EQ 60MG BASE	N018936 004	Jun 15, 1999
------------------	--------------	-------------	--------------

SARAFEM

+ ELI LILLY AND CO	EQ 10MG BASE **	N018936 007	Jul 06, 2000
+	EQ 20MG BASE **	N018936 008	Jul 06, 2000

CAPSULE, DELAYED REL PELLETS;ORAL

FLUOXETINE HYDROCHLORIDE

BARR	EQ 90MG BASE	A076237 001	Mar 24, 2010
PROZAC WEEKLY			
+ LILLY	EQ 90MG BASE **	N021235 001	Feb 26, 2001

SOLUTION;ORAL

FLUOXETINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC	EQ 20MG BASE/5ML	A075690 001	Jan 31, 2002
AKORN	EQ 20MG BASE/5ML	A075525 001	Jun 27, 2002
LANNETT CO INC	EQ 20MG BASE/5ML	A076458 001	May 14, 2004
NOSTRUM LABS INC	EQ 20MG BASE/5ML	A075292 001	Feb 07, 2002
SPECGX LLC	EQ 20MG BASE/5ML	A075920 001	Jan 29, 2002

PROZAC

+ LILLY	EQ 20MG BASE/5ML **	N020101 001	Apr 24, 1991
---------	---------------------	-------------	--------------

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE

BARR	EQ 10MG BASE	A075810 001	Feb 01, 2002
FOSUN PHARMA	EQ 10MG BASE	A076024 001	Jan 29, 2002
G AND W LABS INC	EQ 60MG BASE	A212191 001	Jul 05, 2019
IVAX SUB TEVA PHARMS	EQ 10MG BASE	A075865 001	Feb 28, 2002
	EQ 40MG BASE	A075865 003	Aug 30, 2004

PROZAC

+ LILLY	EQ 10MG BASE **	N020974 001	Mar 09, 1999
+	EQ 20MG BASE **	N020974 002	Mar 09, 1999

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FLUOXETINE HYDROCHLORIDE

TABLET; ORAL

SARAFEM

+ APIL

EQ 15MG BASE

N021860 002 May 19, 2006

SELFEMRA

TEVA PHARMS USA

EQ 10MG BASE

A200151 001 Feb 03, 2014

EQ 15MG BASE

A200151 002 Feb 03, 2014

EQ 20MG BASE

A200151 003 Feb 03, 2014

FLUOXYMESTERONE

TABLET; ORAL

ANDROID-F

VALEANT PHARM INTL

10MG

A087196 001

FLUOXYMESTERONE

VALEANT PHARM INTL

10MG

A088221 001 May 05, 1983

WATSON LABS

2MG

A088260 001 Dec 06, 1983

5MG

A088265 001 Dec 06, 1983

10MG

A088309 001 Dec 06, 1983

HALOTESTIN

PHARMACIA AND UPJOHN

2MG

N010611 002

5MG

N010611 006

10MG

N010611 010

ORA-TESTRYL

BRISTOL MYERS SQUIBB

2MG

N011359 001

5MG

N011359 002

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

HOSPIRA

25MG/ML

A074966 001 Apr 16, 1998

TEVA PARENTERAL

25MG/ML

A074795 001 Sep 10, 1996

PROLIXIN DECANOATE

+ BRISTOL MYERS SQUIBB

25MG/ML **

N016727 001

FLUPHENAZINE ENANTHATE

INJECTABLE; INJECTION

PROLIXIN ENANTHATE

APOTHECON

25MG/ML **

N016110 001

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

FLUPHENAZINE HYDROCHLORIDE

ANI PHARMS INC

5MG/ML

A073058 001 Aug 30, 1991

PERMITIL

SCHERING

5MG/ML **

N016008 001

PROLIXIN

APOTHECON

5MG/ML

A070533 001 Nov 07, 1985

ELIXIR; ORAL

FLUPHENAZINE HYDROCHLORIDE

ANI PHARMS INC

2.5MG/5ML

A081310 001 Apr 29, 1993

PROLIXIN

+ APOTHECON

2.5MG/5ML **

N012145 003

INJECTABLE; INJECTION

PROLIXIN

APOTHECON

2.5MG/ML **

N011751 005

TABLET; ORAL

FLUPHENAZINE HYDROCHLORIDE

MYLAN

1MG

A089804 002 Aug 12, 1988

2.5MG

A089804 003 Aug 12, 1988

5MG

A089804 004 Aug 12, 1988

10MG

A089804 001 Aug 12, 1988

SANDOZ

1MG

A089586 002 Oct 16, 1987

2.5MG

A089586 003 Oct 16, 1987

5MG

A089586 004 Oct 16, 1987

10MG

A089586 001 Oct 16, 1987

WATSON LABS

1MG

A088555 001 Dec 18, 1987

2.5MG

A088544 001 Dec 18, 1987

5MG

A088527 001 Dec 18, 1987

10MG

A088550 001 Dec 18, 1987

PERMITIL

SCHERING

0.25MG

N012034 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FLUPHENAZINE HYDROCHLORIDE

TABLET; ORAL

PERMITIL

2.5MG	N012034	004
5MG	N012034	005
10MG	N012034	006

PROLIXIN

+ APOTHECON	1MG **	N011751	004
+	2.5MG **	N011751	001
+	5MG **	N011751	003
+	10MG **	N011751	002

TABLET, EXTENDED RELEASE; ORAL

PERMITIL

SCHERING

1MG	N012419	004
-----	---------	-----

FLUPREDNISOLONE

TABLET; ORAL

ALPHADROL

PHARMACIA AND UPJOHN	1.5MG	N012259	002
----------------------	-------	---------	-----

FLURANDRENOLIDE

CREAM; TOPICAL

CORDRAN SP

+ ALMIRALL	0.025%	N012806	003
------------	--------	---------	-----

LOTION; TOPICAL

FLURANDRENOLIDE

ALPHARMA US PHARMS	0.05%	A087203	001	Apr 29, 1982
--------------------	-------	---------	-----	--------------

OINTMENT; TOPICAL

CORDRAN

+ ALMIRALL	0.025% **	N012806	004
------------	-----------	---------	-----

FLURANDRENOLIDE; NEOMYCIN SULFATE

CREAM; TOPICAL

CORDRAN N

LILLY	0.05%;EQ 3.5MG BASE/GM	N050346	001
-------	------------------------	---------	-----

OINTMENT; TOPICAL

CORDRAN N

LILLY	0.05%;EQ 3.5MG BASE/GM	N050345	001
-------	------------------------	---------	-----

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

DALMANE

VALEANT PHARM INTL	15MG **	N016721	001
+	30MG **	N016721	002

FLURAZEPAM HYDROCHLORIDE

HALSEY

15MG	A071808	001	Jan 07, 1988
------	---------	-----	--------------

30MG	A071809	001	Jan 07, 1988
------	---------	-----	--------------

HERITAGE PHARMA

15MG	A071205	001	Nov 25, 1986
------	---------	-----	--------------

15MG	A072368	001	Mar 30, 1989
------	---------	-----	--------------

30MG	A071068	001	Nov 25, 1986
------	---------	-----	--------------

30MG	A072369	001	Mar 30, 1989
------	---------	-----	--------------

HIKMA

30MG	A071108	001	Dec 08, 1986
------	---------	-----	--------------

HIKMA INTL PHARMS

15MG	A071107	001	Dec 08, 1986
------	---------	-----	--------------

PAR PHARM

15MG	A070444	001	Mar 20, 1986
------	---------	-----	--------------

30MG	A070445	001	Mar 20, 1986
------	---------	-----	--------------

PUREPAC PHARM

15MG	A071927	001	Sep 09, 1987
------	---------	-----	--------------

30MG	A071551	001	Sep 09, 1987
------	---------	-----	--------------

RISING

15MG	A071717	002	Jul 31, 1991
------	---------	-----	--------------

30MG	A071717	001	Jul 31, 1991
------	---------	-----	--------------

SUN PHARM INDUSTRIES

15MG	A070454	001	Aug 04, 1986
------	---------	-----	--------------

30MG	A070455	001	Aug 04, 1986
------	---------	-----	--------------

SUPERPHARM

15MG	A071659	001	Aug 04, 1988
------	---------	-----	--------------

30MG	A071660	001	Aug 04, 1988
------	---------	-----	--------------

USL PHARMA

15MG	A070562	001	Jul 09, 1987
------	---------	-----	--------------

30MG	A070563	001	Jul 09, 1987
------	---------	-----	--------------

WARNER CHILCOTT

15MG	A071767	001	Dec 04, 1987
------	---------	-----	--------------

30MG	A071768	001	Dec 04, 1987
------	---------	-----	--------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FLURBIPROFEN

TABLET; ORAL

ANSAID

PHARMACIA AND UPJOHN	50MG	N018766 002	Oct 31, 1988
	100MG	N018766 003	Oct 31, 1988

FLURBIPROFEN

IVAX SUB TEVA PHARMS	50MG	A074411 001	May 31, 1995
	100MG	A074411 002	May 31, 1995
MYLAN	50MG	A074358 001	Jun 20, 1994
	100MG	A074358 002	Jun 20, 1994
PLIVA	50MG	A074647 001	Apr 01, 1997
	100MG	A074647 002	Apr 01, 1997
RISING	50MG	A074448 001	Jul 28, 1995
	100MG	A074448 002	Jul 28, 1995
SUN PHARM INDS INC	50MG	A075058 001	Apr 27, 2001
	100MG	A075058 002	Apr 27, 2001
TEVA	50MG	A074405 002	May 24, 1995
	100MG	A074405 001	May 24, 1995
THERAGEN	100MG	A074560 002	May 16, 1997

FLUTAMIDE

CAPSULE; ORAL

EULEXIN

+ SCHERING	125MG **	N018554 001	Jan 27, 1989
------------	----------	-------------	--------------

FLUTAMIDE

ACTAVIS LABS FL INC	125MG	A075820 001	Sep 18, 2001
MYLAN	125MG	A076224 001	May 09, 2003
YAOPHARMA CO LTD	125MG	A075818 001	Sep 18, 2001

FLUTEMETAMOL F-18

INJECTABLE; INTRAVENOUS

VIZAMYL

+ GE HEALTHCARE	40.5mCi/10ML (4.05mCi/ML)	N203137 001	Oct 25, 2013
-----------------	---------------------------	-------------	--------------

FLUTICASONE PROPIONATE

AEROSOL, METERED; INHALATION

FLOVENT

GLAXOSMITHKLINE	0.044MG/INH	N020548 001	Mar 27, 1996
	0.11MG/INH	N020548 002	Mar 27, 1996
	0.22MG/INH	N020548 003	Mar 27, 1996

CREAM; TOPICAL

CUTIVATE

+ FOUGERA PHARMS	0.05% **	N019958 001	Dec 18, 1990
------------------	----------	-------------	--------------

FLUTICASONE PROPIONATE

ANDA REPOSITORY	0.05%	A076633 001	May 14, 2004
NESHER PHARMS	0.05%	A076865 001	Sep 10, 2004

OINTMENT; TOPICAL

CUTIVATE

+ FOUGERA PHARMS	0.005%	N019957 001	Dec 14, 1990
------------------	--------	-------------	--------------

FLUTICASONE PROPIONATE

FOUGERA PHARMS	0.005%	A076300 001	May 14, 2004
TARO PHARM INDS	0.005%	A077145 001	Jun 14, 2005

POWDER; INHALATION

ARMONAIR RESPICLICK

+ TEVA PHARM	0.055MG/INH	N208798 001	Jan 27, 2017
	0.113MG/INH	N208798 002	Jan 27, 2017
	0.232MG/INH	N208798 003	Jan 27, 2017

FLOVENT

GLAXOSMITHKLINE	0.044MG/INH	N020549 001	Nov 07, 1997
	0.088MG/INH	N020549 002	Nov 07, 1997
	0.22MG/INH	N020549 003	Nov 07, 1997

SPRAY, METERED; NASAL

FLONASE

+ GLAXOSMITHKLINE	0.05MG/SPRAY **	N020121 001	Oct 19, 1994
-------------------	-----------------	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FLUVASTATIN SODIUM

CAPSULE;ORAL

LESCOL

+ NOVARTIS

EQ 20MG BASE **

N020261 001 Dec 31, 1993

+

EQ 40MG BASE **

N020261 002 Dec 31, 1993

TABLET, EXTENDED RELEASE;ORAL

FLUVASTATIN SODIUM

MYLAN

EQ 80MG BASE

A202458 001 Sep 11, 2015

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL

FLUVOXAMINE MALEATE

TORRENT

100MG

A203240 001 Oct 31, 2014

150MG

A203240 002 Oct 31, 2014

LUVOX CR

+ JAZZ PHARMS

100MG **

N022033 001 Feb 28, 2008

+

150MG **

N022033 002 Feb 28, 2008

TABLET;ORAL

FLUVOXAMINE MALEATE

ACTAVIS ELIZABETH

25MG

A075901 001 Dec 28, 2000

50MG

A075901 002 Dec 28, 2000

100MG

A075901 003 Dec 28, 2000

ANI PHARMS INC

25MG

A075897 001 Jan 25, 2001

25MG

A075898 001 Mar 12, 2001

50MG

A075897 002 Jan 25, 2001

50MG

A075898 002 Mar 12, 2001

100MG

A075897 003 Jan 25, 2001

100MG

A075898 003 Mar 12, 2001

HERITAGE PHARMA

25MG

A075894 001 Apr 18, 2001

50MG

A075894 002 Apr 18, 2001

100MG

A075894 003 Apr 18, 2001

MYLAN

25MG

A075889 001 Nov 29, 2000

50MG

A075889 002 Nov 29, 2000

50MG

A075950 001 Oct 15, 2001

100MG

A075889 003 Nov 29, 2000

100MG

A075950 002 Oct 15, 2001

PHARMA LIFE

25MG

A075900 001 Feb 23, 2006

50MG

A075900 002 Feb 23, 2006

100MG

A075900 003 Feb 23, 2006

SUN PHARM INDUSTRIES

25MG

A076125 001 Apr 29, 2002

50MG

A076125 002 Apr 29, 2002

100MG

A076125 003 Apr 29, 2002

SYNTHON PHARMS

25MG

A075899 001 Jan 17, 2001

50MG

A075899 002 Jan 17, 2001

100MG

A075899 003 Jan 17, 2001

TEVA

25MG

A075893 001 Sep 10, 2002

50MG

A075893 002 Sep 10, 2002

100MG

A075893 003 Sep 10, 2002

UPSHER SMITH LABS

25MG

A075887 001 Jan 05, 2001

50MG

A075887 002 Jan 05, 2001

100MG

A075887 003 Jan 05, 2001

LUVOX

+ SOLVAY

25MG **

N020243 001 Dec 05, 1994

+

50MG **

N020243 002 Dec 05, 1994

+

100MG **

N020243 003 Dec 05, 1994

+

150MG **

N020243 004 Dec 05, 1994

FOLIC ACID

INJECTABLE;INJECTION

FOLIC ACID

BEN VENUE

5MG/ML

A081066 001 Dec 29, 1993

FOLVITE

+ WYETH PHARMS INC

5MG/ML

N005897 008

TABLET;ORAL

FOLIC ACID

BARR

1MG

A089177 001 Jan 08, 1986

CONTRACT PHARMACAL

1MG

A085061 001

EVERYLIFE

1MG

A080755 001

HALSEY

1MG

A083598 001

HIKMA PHARMS

1MG

A080600 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FOLIC ACID

TABLET; ORAL

FOLIC ACID

IMPAX LABS	1MG	A080686	001	
IVAX SUB TEVA PHARMS	1MG	A083000	001	
JUBILANT CADISTA	1MG	A040514	001	Jun 14, 2005
LANNETT	1MG	A080816	001	
LILLY	1MG	N006135	003	
MK LABS	1MG	A083526	001	
NEXGEN PHARMA INC	1MG	A084915	001	
PHARMERAL	1MG	A084158	001	
PIONEER PHARMS	1MG	A088949	001	Sep 13, 1985
PUREPAC PHARM	1MG	A080784	001	
SANDOZ	1MG	A084472	001	
SUN PHARM INDUSTRIES	1MG	A040582	001	Jul 18, 2005
TABLICAPS	1MG	A083133	002	
UDL	1MG	A088199	001	Mar 29, 1983
USL PHARMA	1MG	A087828	001	May 13, 1982
VALEANT PHARM INTL	1MG	A080903	001	
VANGARD	1MG	A088730	001	Mar 23, 1984
VINTAGE	1MG	A040756	001	Jun 04, 2010
VINTAGE PHARMS	1MG	A086296	001	
WATSON LABS	1MG	A083141	001	
	1MG	A085141	002	
WHITEWORTH TOWN PLSN	1MG	A080691	002	
FOLICET				
MISSION PHARMA	1MG	A087438	001	
FOLVITE				
WYETH PHARMS INC	1MG	N005897	004	

FOMEPIZOLE

INJECTABLE; INJECTION

ANTIZOL

+ PAR PHARM INC	1.5GM/1.5ML (1GM/ML)	N020696	001	Dec 04, 1997
FOMEPIZOLE				
MYLAN INSTITUTIONAL	1.5GM/1.5ML (1GM/ML)	A079033	001	Apr 07, 2009

FOMIVIRSEN SODIUM

INJECTABLE; INJECTION

VITRAVENE PRESERVATIVE FREE

NOVARTIS	6.6MG/ML	N020961	001	Aug 26, 1998
----------	----------	---------	-----	--------------

FORMOTEROL FUMARATE

POWDER; INHALATION

FORADIL

+ NOVARTIS	0.012MG/INH	N020831	001	Feb 16, 2001
FORADIL CERTIHALER				
NOVARTIS	0.0085MG/INH	N021592	001	Dec 15, 2006

FOSAPREPITANT DIMEGLUMINE

POWDER; INTRAVENOUS

EMEND

+ MERCK AND CO INC	EQ 115MG BASE/VIAL **	N022023	001	Jan 25, 2008
--------------------	-----------------------	---------	-----	--------------

FOSCARNET SODIUM

INJECTABLE; INJECTION

FOSCARNET SODIUM

HOSPIRA	2.4GM/100ML	A077174	001	May 31, 2005
---------	-------------	---------	-----	--------------

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

ACTAVIS LABS FL INC	10MG	A076620	001	Oct 15, 2004
	20MG	A076620	002	Oct 15, 2004
	40MG	A076620	003	Oct 15, 2004
RANBAXY LABS LTD	10MG	A076580	001	Apr 23, 2004
	20MG	A076580	002	Apr 23, 2004
	40MG	A076580	003	Apr 23, 2004
UPSHER SMITH LABS	10MG	A076188	001	Oct 08, 2004
	20MG	A076188	002	Oct 08, 2004
	40MG	A076188	003	Oct 08, 2004
WATSON LABS	10MG	A076987	001	Dec 23, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

10MG	A077531	001	Aug 31, 2006
20MG	A076987	002	Dec 23, 2004
20MG	A077531	002	Aug 31, 2006
40MG	A076987	003	Dec 23, 2004
40MG	A077531	003	Aug 31, 2006

MONOPRIL

+ BRISTOL MYERS SQUIBB	10MG **	N019915	002	May 16, 1991
+	20MG **	N019915	003	May 16, 1991
+	40MG **	N019915	004	Mar 28, 1995

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

ANI PHARMS INC	10MG;12.5MG	A076608	001	Dec 03, 2004
	10MG;12.5MG	A077144	001	Aug 16, 2005
	20MG;12.5MG	A076608	002	Dec 03, 2004
	20MG;12.5MG	A077144	002	Aug 16, 2005
EMCURE PHARMS LTD	10MG;12.5MG	A079025	001	Sep 17, 2010
	20MG;12.5MG	A079025	002	Sep 17, 2010
MYLAN	10MG;12.5MG	A077705	001	Aug 14, 2006
	20MG;12.5MG	A077705	002	Aug 14, 2006
SUN PHARM INDS LTD	10MG;12.5MG	A076739	001	Dec 17, 2004
	20MG;12.5MG	A076739	002	Dec 17, 2004
TEVA	10MG;12.5MG	A076945	001	Jul 05, 2006
	20MG;12.5MG	A076945	002	Jul 05, 2006

MONOPRIL-HCT

+ BRISTOL MYERS SQUIBB	10MG;12.5MG **	N020286	002	Nov 30, 1994
+	20MG;12.5MG **	N020286	001	Nov 30, 1994

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

AM REGENT	EQ 50MG PHENYTOIN NA/ML	A078277	001	Aug 06, 2007
	EQ 50MG PHENYTOIN NA/ML	A090099	001	May 13, 2010
AMNEAL	EQ 50MG PHENYTOIN NA/ML	A078476	001	Mar 18, 2008
APOTEX INC	EQ 50MG PHENYTOIN NA/ML	A078126	001	Aug 06, 2007
DR REDDYS	EQ 50MG PHENYTOIN NA/ML	A076886	001	Aug 06, 2007
HOSPIRA	EQ 50MG PHENYTOIN NA/ML	A078158	001	Aug 06, 2007

FOSPROPOFOL DISODIUM

SOLUTION; INTRAVENOUS

LUSEDRA

EISAI INC	1050MG/30ML (35MG/ML)	N022244	001	Dec 12, 2008
-----------	-----------------------	---------	-----	--------------

FURAZOLIDONE

SUSPENSION; ORAL

FUROXONE

SHIRE	50MG/15ML	N011323	002	
-------	-----------	---------	-----	--

TABLET; ORAL

FUROXONE

SHIRE	100MG	N011270	002	
-------	-------	---------	-----	--

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

ABRAXIS PHARM	10MG/ML	N018507	001	Jul 30, 1982
	10MG/ML	N019036	001	Aug 13, 1984
ACCORD HLTHCARE	10MG/ML	A070017	001	Dec 15, 1986
+ AM REGENT	10MG/ML **	N018579	001	Nov 30, 1983
AMNEAL PHARMS CO	10MG/ML	A207552	001	Jul 20, 2016
ASTRAZENECA	10MG/ML	A070014	001	Sep 09, 1985
HOSPIRA	10MG/ML	A070578	001	Jul 08, 1987
	10MG/ML	A072080	001	Aug 13, 1991
	10MG/ML	A074337	001	Oct 31, 1994
IGI LABS INC	10MG/ML	A070095	001	Sep 09, 1985
	10MG/ML	A070096	001	Sep 09, 1985
INTL MEDICATION	10MG/ML	N018025	001	
MARSAM PHARMS LLC	10MG/ML	A074017	001	Jun 30, 1994
SMITH AND NEPHEW	10MG/ML	A070023	001	Feb 05, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

	10MG/ML	A070078 001	Feb 05, 1986
WARNER CHILCOTT	10MG/ML	N018420 001	Feb 26, 1982
WATSON LABS	10MG/ML	A070019 001	Sep 22, 1986
	10MG/ML	A070604 001	Jan 02, 1987
WEST-WARD PHARMS INT	10MG/ML	A071439 001	Sep 14, 1990
	10MG/ML	N018267 001	
WYETH AYERST	10MG/ML	N018670 001	Jul 20, 1982

LASIX

+ SANOFI AVENTIS US	10MG/ML **	N016363 001	
---------------------	------------	-------------	--

SOLUTION; ORAL

LASIX

SANOFI AVENTIS US	10MG/ML	N017688 001	
-------------------	---------	-------------	--

TABLET; ORAL

FUROSEMIDE

ANI PHARMS INC	20MG	A071379 001	Jan 02, 1987
	40MG	A070413 001	Feb 26, 1986
	80MG	A071594 001	Feb 09, 1988
AVET	20MG	N018413 001	Nov 30, 1983
	40MG	N018413 002	Nov 30, 1983
DAVA PHARMS INC	20MG	N018415 001	Jul 27, 1982
	40MG	N018415 002	Jul 27, 1982
	80MG	N018415 003	Nov 26, 1984
INTL MEDICATION	20MG	N018753 001	Feb 28, 1984
	40MG	N018753 002	Feb 28, 1984
KALAPHARM	20MG	N018868 001	Jun 28, 1983
	40MG	N018868 002	Jun 28, 1983
SANDOZ	40MG	N018750 002	Jul 30, 1984
SUN PHARM INDS INC	20MG	A091258 001	Apr 01, 2014
	40MG	A091258 002	Apr 01, 2014
	40MG	N018790 001	Nov 29, 1983
	80MG	A091258 003	Apr 01, 2014
SUN PHARM INDUSTRIES	20MG	A070043 001	Sep 26, 1985
	80MG	A070100 001	Jan 26, 1988
SUPERPHARM	20MG	N018370 002	Jun 26, 1984
	40MG	N018370 001	Feb 10, 1983
WARNER CHILCOTT	20MG	N018419 001	Jan 31, 1983
	40MG	N018419 002	Jan 31, 1983
	80MG	N018419 003	Nov 13, 1984
WATSON LABS	20MG	A070412 001	Feb 26, 1986
	20MG	N018369 001	May 14, 1982
	40MG	A070450 001	Nov 22, 1985
	40MG	N018369 002	May 14, 1982
WATSON LABS TEVA	20MG	A070449 001	Nov 22, 1985
	80MG	A070528 001	Jan 07, 1986

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

HIKMA	100MG	A078150 001	Sep 25, 2007
	300MG	A078150 002	Sep 25, 2007
	400MG	A078150 003	Sep 25, 2007
JIANGSU HENGRUI MED	100MG	A091008 001	Oct 26, 2017
	300MG	A091008 002	Oct 26, 2017
	400MG	A091008 003	Oct 26, 2017
MYLAN	100MG	A090158 001	Feb 14, 2011
	300MG	A090158 002	Feb 14, 2011
	400MG	A090158 003	Feb 14, 2011
SANDOZ	100MG	A075428 001	Jan 24, 2006
	100MG	A075539 001	Apr 06, 2005
	300MG	A075428 002	Jan 24, 2006
	300MG	A075539 002	Apr 06, 2005
	400MG	A075428 003	Jan 24, 2006
	400MG	A075539 003	Apr 06, 2005
SUN PHARM INDS LTD	100MG	A076606 001	Oct 07, 2005
	300MG	A076606 002	Oct 07, 2005
	400MG	A076606 003	Oct 07, 2005
SUN PHARM INDUSTRIES	100MG	A076537 001	Jun 30, 2005

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

	300MG	A076537 002	Jun 30, 2005
	400MG	A076537 003	Jun 30, 2005
TEVA PHARMS	100MG	A075435 001	Oct 08, 2004
	300MG	A075435 002	Oct 08, 2004
	400MG	A075435 003	Oct 08, 2004
WATSON LABS	100MG	A075485 003	May 11, 2007
	300MG	A075485 002	May 11, 2007
	400MG	A075485 001	May 11, 2007

SOLUTION; ORAL

GABAPENTIN

VISTAPHARM	250MG/5ML	A211330 001	Dec 03, 2019
------------	-----------	-------------	--------------

TABLET; ORAL

GABAPENTIN

HIKMA PHARMS	600MG	A078782 001	Jul 21, 2011
	800MG	A078782 002	Jul 21, 2011
INVATECH	600MG	A076877 001	Jul 06, 2006
	800MG	A076877 002	Jul 06, 2006
IVAX SUB TEVA PHARMS	600MG	A076017 004	Apr 29, 2005
	800MG	A076017 005	Apr 29, 2005
LUPIN LTD	600MG	A209306 001	Aug 24, 2018
	800MG	A209306 002	Aug 24, 2018
MYLAN PHARMS INC	600MG	A090335 001	Jun 01, 2010
	800MG	A090335 002	Jun 01, 2010
RANBAXY	600MG	A076605 001	Sep 14, 2005
	800MG	A076605 002	Sep 14, 2005
SANDOZ	600MG	A076120 001	Jan 27, 2006
	800MG	A076120 002	Jan 27, 2006
TEVA	600MG	A075827 001	Dec 15, 2004
	800MG	A075827 002	Dec 15, 2004
TEVA PHARMS USA	600MG	A205807 001	Mar 10, 2017
	800MG	A205807 002	Mar 10, 2017

GADODIAMIDE

INJECTABLE; INJECTION

OMNISCAN

GE HEALTHCARE	14.35GM/50ML (287MG/ML)	N022066 001	Sep 05, 2007
---------------	-------------------------	-------------	--------------

GADOFOSVESET TRISODIUM

SOLUTION; INTRAVENOUS

ABLAVAR

LANTHEUS MEDCL	2440MG/10ML (244MG/ML)	N021711 001	Dec 22, 2008
	3660MG/15ML (244MG/ML)	N021711 002	Dec 22, 2008

GADOPENTETATE DIMEGLUMINE

INJECTABLE; INJECTION

MAGNEVIST

+ BAYER HLTHCARE	469.01MG/ML	N019596 001	Jun 02, 1988
+	469.01MG/ML	N021037 001	Mar 10, 2000

GADOVERSETAMIDE

INJECTABLE; INJECTION

OPTIMARK

+ LIEBEL-FLARSHEIM	1654.5MG/5ML (330.9MG/ML)	N020937 001	Dec 08, 1999
+	3309MG/10ML (330.9MG/ML)	N020937 002	Dec 08, 1999
+	4963.5MG/15ML (330.9MG/ML)	N020937 003	Dec 08, 1999
+	6618MG/20ML (330.9MG/ML)	N020937 004	Dec 08, 1999
+	16.545GM/50ML (330.9MG/ML)	N020975 001	Dec 08, 1999
OPTIMARK IN PLASTIC CONTAINER			
+ LIEBEL-FLARSHEIM	3309MG/10ML (330.9MG/ML)	N020976 002	Dec 08, 1999
+	4963.5MG/15ML (330.9MG/ML)	N020976 003	Dec 08, 1999
+	6618MG/20ML (330.9MG/ML)	N020976 004	Dec 08, 1999
+	9927MG/30ML (330.9MG/ML)	N020976 001	Dec 08, 1999

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE;ORAL

GALANTAMINE HYDROBROMIDE

IMPAX LABS

EQ 8MG BASE

A078484 001 May 27, 2009

EQ 16MG BASE

A078484 002 May 27, 2009

EQ 24MG BASE

A078484 003 May 27, 2009

MYLAN

EQ 8MG BASE

A090900 001 Jan 24, 2011

EQ 16MG BASE

A090900 002 Jan 24, 2011

EQ 24MG BASE

A090900 003 Jan 24, 2011

SOLUTION;ORAL

RAZADYNE

JANSSEN PHARMS

4MG/ML **

N021224 001 Jun 22, 2001

TABLET;ORAL

GALANTAMINE HYDROBROMIDE

APOTEX INC

EQ 4MG BASE

A077781 001 Sep 27, 2011

EQ 8MG BASE

A077781 002 Sep 27, 2011

EQ 12MG BASE

A077781 003 Sep 27, 2011

HERITAGE PHARMA

EQ 4MG BASE

A077585 001 Sep 15, 2009

EQ 4MG BASE

A077587 001 Jul 09, 2009

EQ 8MG BASE

A077585 002 Sep 15, 2009

EQ 8MG BASE

A077587 002 Jul 09, 2009

EQ 12MG BASE

A077585 003 Sep 15, 2009

EQ 12MG BASE

A077587 003 Jul 09, 2009

HIKMA

EQ 4MG BASE

A077608 001 Feb 11, 2009

EQ 8MG BASE

A077608 002 Feb 11, 2009

EQ 12MG BASE

A077608 003 Feb 11, 2009

MYLAN

EQ 4MG BASE

A077590 001 May 29, 2009

EQ 4MG BASE

A077603 001 Aug 28, 2008

EQ 8MG BASE

A077590 002 May 29, 2009

EQ 8MG BASE

A077603 002 Aug 28, 2008

EQ 12MG BASE

A077590 003 May 29, 2009

EQ 12MG BASE

A077603 003 Aug 28, 2008

GALLAMINE TRIETHIODIDE

INJECTABLE;INJECTION

FLAXEDIL

DAVIS AND GECK

20MG/ML

N007842 001

100MG/ML

N007842 002

GALLIUM CITRATE GA-67

INJECTABLE;INJECTION

GALLIUM CITRATE GA 67

GE HEALTHCARE

1mCi/ML

N017700 001

NEOSCAN

GE HEALTHCARE

2mCi/ML

N017655 001

GALLIUM NITRATE

INJECTABLE;INJECTION

GANITE

CHAPTER 7 TRUSTEE

25MG/ML **

N019961 002 Jan 17, 1991

GANCICLOVIR

CAPSULE;ORAL

CYTOVENE

+ ROCHE PALO

250MG **

N020460 001 Dec 22, 1994

+

500MG **

N020460 002 Dec 12, 1997

GANCICLOVIR

RANBAXY LABS LTD

250MG

A076457 001 Jun 27, 2003

500MG

A076457 002 Jun 27, 2003

IMPLANT;IMPLANTATION

VITRASERT

BAUSCH AND LOMB

4.5MG

N020569 001 Mar 04, 1996

GANCICLOVIR SODIUM

INJECTABLE;INJECTION

GANCICLOVIR SODIUM

AM REGENT

EQ 500MG BASE/VIAL

A202624 001 Sep 18, 2013

CUSTOPHARM INC

EQ 500MG BASE/VIAL

A212001 001 Jun 20, 2019

MYLAN LABS LTD

EQ 500MG BASE/VIAL

A204560 001 Nov 17, 2017

WEST-WARD PHARMS INT

EQ 500MG BASE/VIAL

A076222 001 Jul 16, 2003

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

GATIFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

GATIFLOXACIN

APOTEX INC

0.3%

A079084 001 Aug 19, 2011

GEFITINIB

TABLET;ORAL

IRESSA

ASTRAZENECA

250MG

N021399 001 May 05, 2003

GEMCITABINE HYDROCHLORIDE

INJECTABLE;INJECTION

GEMCITABINE HYDROCHLORIDE

ACTAVIS INC

200MG/5.26ML (38MG/ML)

A204549 001 Apr 11, 2016

1GM/26.3ML (38MG/ML)

A204549 002 Apr 11, 2016

2GM/52.6ML (38MG/ML)

A204549 003 Apr 11, 2016

ACTAVIS TOTOWA

EQ 200MG BASE/VIAL

A079160 001 Jul 25, 2011

EQ 1GM BASE/VIAL

A079160 002 Jul 25, 2011

EQ 2GM BASE/VIAL

A079160 003 Jul 28, 2016

AM REGENT

EQ 200MG BASE/VIAL

A202031 001 May 07, 2013

EQ 1GM BASE/VIAL

A202031 002 May 07, 2013

APOTEX

200MG/5.26ML (38MG/ML)

A206776 001 May 23, 2017

1GM/26.3ML (38MG/ML)

A206776 002 May 23, 2017

2GM/52.6ML (38MG/ML)

A206776 003 May 23, 2017

EMCURE PHARMS LTD

EQ 200MG BASE/VIAL

A202063 001 Sep 11, 2012

EQ 1GM BASE/VIAL

A202063 002 Sep 11, 2012

HAMELN RDS GMBH

EQ 200MG BASE/VIAL

A090663 001 Sep 10, 2012

EQ 1GM BASE/VIAL

A090663 002 Sep 10, 2012

MYLAN LABS LTD

EQ 200MG BASE/VIAL

A200145 001 Jul 25, 2011

EQ 1GM BASE/VIAL

A200145 002 Jul 25, 2011

EQ 2GM BASE/VIAL

A200145 003 Jul 25, 2011

NOVAST LABS

200MG/5.26ML (38MG/ML)

A210383 001 Feb 14, 2019

1GM/26.3ML (38MG/ML)

A210383 002 Feb 14, 2019

2GM/52.6ML (38MG/ML)

A210383 003 Feb 14, 2019

SAGENT PHARMS

EQ 200MG BASE/VIAL

A091597 001 May 07, 2013

EQ 1GM BASE/VIAL

A091597 002 May 07, 2013

TEVA PHARMS

EQ 200MG BASE/VIAL

A077983 002 Jan 25, 2011

EQ 1GM BASE/VIAL

A077983 001 Jan 25, 2011

GEMFIBROZIL

CAPSULE;ORAL

GEMFIBROZIL

MYLAN

300MG

A073466 001 Jan 25, 1993

PUREPAC PHARM

300MG

A072929 001 Jan 29, 1993

LOPID

PFIZER PHARMS

200MG

N018422 001

300MG

N018422 002

TABLET;ORAL

GEMFIBROZIL

HIKMA PHARMS

600MG

A078599 001 Aug 16, 2010

MYLAN

600MG

A074452 001 Feb 16, 1995

PUREPAC PHARM

600MG

A074360 001 Aug 31, 1994

SUN PHARM INDS INC

600MG

A079239 001 Dec 29, 2008

TEVA

600MG

A074256 001 Oct 31, 1993

WATSON LABS

600MG

A074156 001 Oct 24, 1994

600MG

A074442 001 Apr 28, 1995

YAOPHARMA CO LTD

600MG

A074615 001 Sep 29, 1995

GENTAMICIN SULFATE

CREAM;TOPICAL

GARAMYCIN

SCHERING

EQ 0.1% BASE **

A060462 001

GENTAFAIR

PHARMAFAIR

EQ 0.1% BASE

A062458 001 Sep 01, 1983

GENTAMICIN SULFATE

ALPHARMA US PHARMS

EQ 0.1% BASE

A062471 001 Sep 27, 1983

FOUGERA PHARMS INC

EQ 0.1% BASE

A062531 001 Jul 05, 1984

PHARMADERM

EQ 1MG BASE/GM

A062530 001 Jul 05, 1984

TARO

EQ 0.1% BASE

A062427 001 May 26, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

GENTAMICIN SULFATE

INJECTABLE; INJECTION

APOGEN

KING PHARMS	EQ 10MG BASE/ML	A062289	001	
	EQ 40MG BASE/ML	A062289	002	

BRISTAGEN

BRISTOL	EQ 40MG BASE/ML	A062288	001	
---------	-----------------	---------	-----	--

GARAMYCIN

SCHERING	EQ 1MG BASE/ML **	A061716	002	
	EQ 10MG BASE/ML **	A061739	001	
	EQ 40MG BASE/ML **	A061716	001	

GENTAFAIR

PHARMAFAIR	EQ 40MG BASE/ML	A062493	001	Aug 28, 1985
------------	-----------------	---------	-----	--------------

GENTAMICIN

INTL MEDICATION	EQ 1MG BASE/ML	A062325	003	Jun 23, 1982
	EQ 40MG BASE/ML	A062325	001	
	EQ 100MG BASE/100ML	A062325	004	Jun 23, 1982

GENTAMICIN SULFATE

ABBOTT	EQ 1.2MG BASE/ML	A062413	001	Aug 11, 1983
	EQ 1.4MG BASE/ML	A062413	002	Aug 11, 1983
	EQ 1.6MG BASE/ML	A062413	003	Aug 11, 1983
	EQ 1.8MG BASE/ML	A062413	004	Aug 11, 1983
	EQ 2MG BASE/ML	A062413	005	Aug 11, 1983
	EQ 60MG BASE/100ML	A062413	006	Aug 11, 1983
	EQ 70MG BASE/100ML	A062413	007	Aug 11, 1983
	EQ 80MG BASE/100ML	A062413	008	Aug 11, 1983
	EQ 90MG BASE/100ML	A062413	009	Aug 11, 1983
	EQ 100MG BASE/100ML	A062413	010	Aug 11, 1983
FRESENIUS KABI USA	EQ 10MG BASE/ML	A062356	001	Mar 04, 1982
	EQ 40MG BASE/ML	A062356	002	Mar 04, 1982
HOSPIRA	EQ 10MG BASE/ML	A062612	004	Feb 20, 1986
KALAPHARM	EQ 40MG BASE/ML	A062354	001	Apr 05, 1982
PHARM SPEC	EQ 40MG BASE/ML	A062340	001	Mar 28, 1983
SOLOPAK	EQ 10MG BASE/ML	A062507	001	Jun 06, 1985
	EQ 40MG BASE/ML	A062507	002	Jun 06, 1985
TEVA PARENTERAL	EQ 10MG BASE/ML	A063149	001	Nov 21, 1991
	EQ 40MG BASE/ML	A063106	002	Nov 21, 1991
WATSON LABS	EQ 10MG BASE/ML	A062318	002	
	EQ 40MG BASE/ML	A062318	001	
WEST-WARD PHARMS INT	EQ 10MG BASE/ML	A062251	002	
	EQ 40MG BASE/ML	A062251	001	
WYETH AYERST	EQ 10MG BASE/ML	A062264	001	
	EQ 40MG BASE/ML	A062264	002	

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN	EQ 0.8MG BASE/ML	A062814	001	Aug 28, 1987
	EQ 1.2MG BASE/ML	A062814	002	Aug 28, 1987
	EQ 1.4MG BASE/ML	A062814	003	Aug 28, 1987
	EQ 1.6MG BASE/ML	A062814	004	Aug 28, 1987
	EQ 1.8MG BASE/ML	A062814	005	Aug 28, 1987
	EQ 2MG BASE/ML	A062814	006	Aug 28, 1987
	EQ 2.4MG BASE/ML	A062814	007	Aug 28, 1987
	EQ 40MG BASE/100ML	A062814	008	Aug 28, 1987
	EQ 60MG BASE/100ML	A062814	009	Aug 28, 1987
	EQ 70MG BASE/100ML	A062814	010	Aug 28, 1987
	EQ 80MG BASE/100ML	A062814	011	Aug 28, 1987
	EQ 90MG BASE/100ML	A062814	012	Aug 28, 1987
	EQ 100MG BASE/100ML	A062814	013	Aug 28, 1987
	EQ 120MG BASE/100ML	A062814	014	Aug 28, 1987
BAXTER HLTHCARE	EQ 0.8MG BASE/ML	A062373	001	Sep 07, 1982
	EQ 2.4MG BASE/ML	A062373	010	Sep 07, 1982
	EQ 40MG BASE/100ML	A062373	003	Sep 07, 1982
	EQ 60MG BASE/100ML	A062373	004	Sep 07, 1982
HOSPIRA	EQ 1.2MG BASE/ML	A062588	001	Jan 06, 1986
	EQ 1.4MG BASE/ML	A062414	002	Aug 15, 1983
	EQ 1.4MG BASE/ML	A062588	002	Jan 06, 1986
	EQ 1.6MG BASE/ML	A062588	003	Jan 06, 1986
	EQ 1.8MG BASE/ML	A062414	004	Aug 15, 1983
	EQ 1.8MG BASE/ML	A062588	004	Jan 06, 1986
	EQ 2MG BASE/ML	A062414	005	Aug 15, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

GENTAMICIN SULFATE

INJECTABLE; INJECTION

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

EQ 2MG BASE/ML	A062588	005	Jan 06, 1986
EQ 60MG BASE/100ML	A062414	006	Aug 15, 1983
EQ 60MG BASE/100ML	A062588	006	Jan 06, 1986
EQ 70MG BASE/100ML	A062414	007	Aug 15, 1983
EQ 70MG BASE/100ML	A062588	007	Jan 06, 1986
EQ 80MG BASE/100ML	A062588	008	Jan 06, 1986
EQ 90MG BASE/100ML	A062414	009	Aug 15, 1983
EQ 90MG BASE/100ML	A062588	009	Jan 06, 1986
EQ 100MG BASE/100ML	A062588	010	Jan 06, 1986

U-GENCIN

PHARMACIA AND UPJOHN EQ 10MG BASE/ML	A062248	001	
EQ 40MG BASE/ML	A062248	002	

INJECTABLE; INTRATHECAL

GARAMYCIN

+ SCHERING EQ 2MG BASE/ML **	N050505	001	
------------------------------	---------	-----	--

OINTMENT; OPHTHALMIC

GARAMYCIN

SCHERING EQ 0.3% BASE	N050425	001	
-----------------------	---------	-----	--

GENTACIDIN

NOVARTIS EQ 0.3% BASE	A062501	001	Jul 26, 1984
-----------------------	---------	-----	--------------

GENTAFAIR

PHARMAFAIR EQ 3MG BASE/GM	A062443	001	May 26, 1983
---------------------------	---------	-----	--------------

OINTMENT; TOPICAL

GARAMYCIN

SCHERING EQ 0.1% BASE **	A060463	001	
--------------------------	---------	-----	--

GENTAFAIR

PHARMAFAIR EQ 0.1% BASE	A062444	001	May 26, 1983
-------------------------	---------	-----	--------------

GENTAMICIN SULFATE

ALPHARMA US PHARMS EQ 0.1% BASE	A062496	001	Mar 14, 1984
---------------------------------	---------	-----	--------------

PHARMADERM EQ 0.1% BASE	A062534	001	Oct 10, 1984
-------------------------	---------	-----	--------------

SOLUTION/DROPS; OPHTHALMIC

GARAMYCIN

+ SCHERING EQ 0.3% BASE **	N050039	002	
----------------------------	---------	-----	--

GENTACIDIN

NOVARTIS EQ 0.3% BASE	A062480	001	Mar 30, 1984
-----------------------	---------	-----	--------------

GENTAFAIR

PHARMAFAIR EQ 0.3% BASE	A062440	001	May 03, 1983
-------------------------	---------	-----	--------------

GENTAMICIN SULFATE

ALCON PHARMS LTD EQ 0.3% BASE	A062523	001	Nov 25, 1985
-------------------------------	---------	-----	--------------

PACO EQ 3MG BASE/ML	A062932	001	Nov 07, 1988
---------------------	---------	-----	--------------

GENTIAN VIOLET

SUPPOSITORY; VAGINAL

GVS

SAVAGE LABS 0.4%	A083513	001	
------------------	---------	-----	--

TAMPON; VAGINAL

GENAPAX

KEY PHARMS 5MG	A085017	001	
----------------	---------	-----	--

GLATIRAMER ACETATE

FOR SOLUTION; SUBCUTANEOUS

COPAXONE

TEVA PHARMS USA 20MG/VIAL	N020622	001	Dec 20, 1996
---------------------------	---------	-----	--------------

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

ACTAVIS LABS FL INC 1MG	A076995	001	Apr 27, 2010
2MG	A076995	002	Apr 27, 2010
4MG	A076995	003	Apr 27, 2010
EPIC PHARMA LLC 1MG	A077274	001	Oct 06, 2005
2MG	A077274	002	Oct 06, 2005
4MG	A077274	003	Oct 06, 2005
HIKMA PHARMS 1MG	A078952	001	Aug 01, 2013
2MG	A078952	002	Aug 01, 2013
4MG	A078952	003	Aug 01, 2013
MYLAN 1MG	A077486	001	Feb 10, 2006
1MG	A077624	001	Nov 28, 2005

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

	2MG	A077486 002	Feb 10, 2006
	2MG	A077624 002	Nov 28, 2005
	4MG	A077486 003	Feb 10, 2006
	4MG	A077624 003	Nov 28, 2005
RANBAXY	3MG	A077366 001	Oct 06, 2005
	6MG	A077366 002	Oct 06, 2005
RANBAXY LABS LTD	1MG	A076875 001	Oct 06, 2005
	2MG	A076875 002	Oct 06, 2005
	4MG	A076875 003	Oct 06, 2005
	8MG	A076875 004	Oct 06, 2005
TEVA	1MG	A076802 001	Oct 06, 2005
	2MG	A076802 002	Oct 06, 2005
	4MG	A076802 003	Oct 06, 2005
WATSON LABS	1MG	A077280 001	Feb 03, 2006
	2MG	A077280 002	Feb 03, 2006
	4MG	A077280 003	Feb 03, 2006

GLIMEPIRIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDARYL

+	SB PHARMCO	1MG; 4MG **	N021700 001	Nov 23, 2005
+		2MG; 4MG **	N021700 002	Nov 23, 2005
+		2MG; 8MG **	N021700 004	Mar 30, 2007
+		4MG; 4MG **	N021700 003	Nov 23, 2005
+		4MG; 8MG **	N021700 005	Mar 30, 2007

ROSIGLITAZONE MALEATE AND GLIMEPIRIDE

TEVA PHARMS USA	1MG; 4MG	A078709 001	Apr 01, 2016
	2MG; 4MG	A078709 002	Apr 01, 2016
	2MG; 8MG	A078709 004	Apr 01, 2016
	4MG; 4MG	A078709 003	Apr 01, 2016
	4MG; 8MG	A078709 005	Apr 01, 2016

GLIPIZIDE

TABLET; ORAL

GLIPIZIDE

ANI PHARMS INC	5MG	A074387 001	Mar 04, 1996
	5MG	A074497 001	Aug 31, 1995
	10MG	A074387 002	Mar 04, 1996
	10MG	A074497 002	Aug 31, 1995
BARR LABS INC	5MG	A074619 001	Apr 04, 1997
	10MG	A074619 002	Apr 04, 1997
BEXIMCO PHARMS USA	5MG	A074542 001	Jun 20, 1995
	10MG	A074542 002	Jun 20, 1995
MYLAN	5MG	A074438 001	Jun 20, 1995
	10MG	A074438 002	Jun 20, 1995
OXFORD PHARMS	5MG	A074378 001	Nov 28, 1994
	10MG	A074378 002	Nov 28, 1994
WATSON LABS	5MG	A074370 001	Nov 22, 1994
	10MG	A074370 002	Nov 22, 1994

GLUCOTROL

PFIZER	2.5MG	N017783 003	May 11, 1993
--------	-------	-------------	--------------

TABLET, EXTENDED RELEASE; ORAL

GLIPIZIDE

MYLAN	2.5MG	A202298 001	May 19, 2015
	5MG	A202298 002	May 19, 2015
	10MG	A202298 003	May 19, 2015

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

MYLAN	2.5MG; 250MG	A078083 001	Apr 12, 2007
	2.5MG; 500MG	A078083 002	Apr 12, 2007
	5MG; 500MG	A078083 003	Apr 12, 2007
SUN PHARM INDS INC	2.5MG; 250MG	A077620 001	Jan 11, 2008
	2.5MG; 500MG	A077620 002	Jan 11, 2008
	5MG; 500MG	A077620 003	Jan 11, 2008

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

METAGLIP

+	BRISTOL MYERS SQUIBB	2.5MG;250MG **	N021460	001	Oct 21, 2002
+		2.5MG;500MG **	N021460	002	Oct 21, 2002
+		5MG;500MG **	N021460	003	Oct 21, 2002

GLUCAGON HYDROCHLORIDE

INJECTABLE; INJECTION

GLUCAGON

+	LILLY	EQ 1MG BASE/VIAL **	N012122	001	
+		EQ 10MG BASE/VIAL **	N012122	002	

GLUTETHIMIDE

CAPSULE; ORAL

DORIDEN

	SANOFI AVENTIS US	500MG	N009519	008	
--	-------------------	-------	---------	-----	--

TABLET; ORAL

DORIDEN

	SANOFI AVENTIS US	250MG	N009519	002	
		500MG	N009519	005	

GLUTETHIMIDE

	HALSEY	250MG	A089458	001	Oct 10, 1986
		500MG	A089459	001	Oct 10, 1986
	LANNETT	250MG	A083475	001	
		500MG	A085571	001	
	UCB INC	500MG	A085171	001	
	UPSHER SMITH LABS	500MG	A083234	002	
	VITARINE	500MG	A087297	001	
	WATSON LABS	500MG	A084362	001	
		500MG	A085763	001	

GLYBURIDE

TABLET; ORAL

GLYBURIDE

	ACTAVIS ELIZABETH	1.5MG	A075947	001	Nov 14, 2002
		3MG	A075947	002	Nov 14, 2002
		6MG	A075947	003	Nov 14, 2002
	AUROBINDO PHARMA	1.25MG	A077537	001	Oct 18, 2007
		2.5MG	A077537	002	Oct 18, 2007
		5MG	A077537	003	Oct 18, 2007

GLYBURIDE (MICRONIZED)

	DAVA PHARMS INC	1.5MG	A074591	001	Dec 22, 1997
		3MG	A074591	002	Dec 22, 1997
		4.5MG	A074591	003	Dec 22, 1997
		6MG	A074591	004	Dec 22, 1997
	MYLAN	1.5MG	A074792	001	Jun 26, 1998
		3MG	A074792	002	Jun 26, 1998
		6MG	A074792	003	Aug 17, 1999
	SANOFI AVENTIS US	1.5MG	N020055	001	Apr 17, 1992
		3MG	N020055	002	Apr 17, 1992
		6MG	N020055	003	Mar 08, 2000
	YAOPHARMA CO LTD	1.5MG	A075174	001	Jun 22, 1998
		3MG	A075174	002	Jun 22, 1998

GLYNASE

+	PHARMACIA AND UPJOHN	4.5MG **	N020051	003	Sep 24, 1993
---	----------------------	----------	---------	-----	--------------

MICRONASE

+	PHARMACIA AND UPJOHN	1.25MG **	N017498	001	May 01, 1984
		2.5MG	N017498	002	May 01, 1984
+		5MG **	N017498	003	May 01, 1984

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLUCOVANCE

+	BRISTOL MYERS SQUIBB	1.25MG;250MG **	N021178	001	Jul 31, 2000
+		2.5MG;500MG **	N021178	002	Jul 31, 2000
+		5MG;500MG **	N021178	003	Jul 31, 2000

GLYBURIDE AND METFORMIN HYDROCHLORIDE

	HERITAGE PHARMS INC	1.25MG;250MG	A079009	001	Jun 03, 2009
		2.5MG;500MG	A079009	002	Jun 03, 2009
		5MG;500MG	A079009	003	Jun 03, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

IMPAX LABS INC	1.25MG;250MG	A076731 001	Nov 19, 2004
	2.5MG;500MG	A076731 002	Nov 19, 2004
	5MG;500MG	A076731 003	Nov 19, 2004
TEVA	1.25MG;250MG	A076821 001	Jan 27, 2005
	2.5MG;500MG	A076821 002	Jan 27, 2005
	5MG;500MG	A076821 003	Jan 27, 2005

GLYCINE

SOLUTION; IRRIGATION

GLYCINE 1.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	1.5GM/100ML	N018522 001	Feb 19, 1982
HOSPIRA	1.5GM/100ML	N017633 001	

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

ABRAXIS PHARM	0.2MG/ML	A088475 001	Jun 12, 1984
HOSPIRA	0.2MG/ML	A089393 001	Jun 15, 1988
TEVA PARENTERAL	0.2MG/ML	A081169 001	Sep 10, 1991
WATSON LABS	0.2MG/ML	A086947 001	Jun 24, 1983

ROBINUL

+ HIKMA	0.2MG/ML **	N017558 001	
ROBINS AH	0.2MG/ML	N014764 001	

POWDER; INHALATION

SEEBRI

+ NOVARTIS	15.6MCG/INH	N207923 001	Oct 29, 2015
------------	-------------	-------------	--------------

TABLET; ORAL

GLYCOPYRROLATE

HIKMA INTL PHARMS	1MG	A040836 001	Mar 05, 2009
	2MG	A040836 002	Mar 05, 2009
RENATA	1MG	A040568 001	Dec 22, 2004
	2MG	A040568 002	Dec 22, 2004
WATSON LABS	1MG	A085562 001	
	1MG	A086902 001	
	2MG	A085563 001	
	2MG	A086178 001	
	2MG	A086900 001	

ROBINUL

+ CASPER PHARMA LLC	1MG **	N012827 001	
---------------------	--------	-------------	--

ROBINUL FORTE

+ CASPER PHARMA LLC	2MG **	N012827 002	
---------------------	--------	-------------	--

GLYCOPYRROLATE; INDACATEROL MALEATE

POWDER; INHALATION

UTIBRON

+ NOVARTIS	15.6MCG/INH;27.5MCG/INH	N207930 001	Oct 29, 2015
------------	-------------------------	-------------	--------------

GONADORELIN ACETATE

INJECTABLE; INJECTION

LUTREPULSE KIT

FERRING	0.8MG/VIAL	N019687 001	Oct 10, 1989
	3.2MG/VIAL	N019687 002	Oct 10, 1989

GONADORELIN HYDROCHLORIDE

INJECTABLE; INJECTION

FACTREL

WEST-WARD PHARMS INT	EQ 0.1MG BASE/VIAL	N018123 001	Sep 30, 1982
	EQ 0.2MG BASE/VIAL	N018123 002	Sep 30, 1982
	EQ 0.5MG BASE/VIAL	N018123 003	Sep 30, 1982

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC

NEO-POLYCIN

DOW PHARM	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A060427 001	
-----------	--	-------------	--

NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

IPHARM	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A062818 001	Oct 11, 1988
WATSON LABS	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A062788 001	Jun 11, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OPHTHALMIC

NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN

PHARMAFAIR	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A062383 001	Aug 31, 1982
------------	--	-------------	--------------

GRANISETRON HYDROCHLORIDE

INJECTABLE;INJECTION

GRANISETRON HYDROCHLORIDE

AM REGENT	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A091274 001	Sep 22, 2010
BAXTER HLTHCARE CORP	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078197 001	Dec 31, 2007
	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078198 001	Jun 30, 2008
	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078198 002	Jun 30, 2008
MYLAN LABS LTD	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A203454 001	Apr 04, 2017
	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A203454 002	Apr 04, 2017
	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A203453 001	Jan 31, 2017
SANDOZ INC	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078808 001	Apr 29, 2008
TEVA PHARMS USA	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077963 001	Jan 03, 2008
YUNG SHIN PHARM	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A202647 001	Mar 06, 2020
	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A202648 001	Jun 29, 2020
	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A202648 002	Jun 29, 2020

GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE

DR REDDYS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077165 001	Dec 31, 2007
-----------	---------------------------------	-------------	--------------

KYTRIL

+	ROCHE	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML) **	N020239 003	Sep 17, 2004
+		EQ 1MG BASE/ML (EQ 1MG BASE/ML) **	N020239 004	Mar 11, 1994
+		EQ 3MG BASE/ML **	N020239 001	Dec 29, 1993
+		EQ 4MG BASE/4ML (EQ 1MG BASE/ML) **	N020239 002	Mar 11, 1994

SOLUTION;ORAL

GRANISOL

PEDIATRX	EQ 2MG BASE/10ML	A078334 001	Feb 28, 2008
----------	------------------	-------------	--------------

KYTRIL

+	ROCHE	EQ 2MG BASE/10ML **	N021238 001	Jun 27, 2001
---	-------	---------------------	-------------	--------------

TABLET;ORAL

GRANISETRON HYDROCHLORIDE

BARR	EQ 1MG BASE	A078221 001	Dec 31, 2007
EPIC PHARMA LLC	EQ 1MG BASE	A078260 001	Dec 31, 2007
MYLAN	EQ 1MG BASE	A078725 001	Jan 30, 2008
TEVA PHARMS	EQ 1MG BASE	A078080 001	Dec 31, 2007

KYTRIL

+	ROCHE	EQ 1MG BASE **	N020305 001	Mar 16, 1995
+		EQ 2MG BASE **	N020305 002	Jun 15, 1998

GREPAFLOXACIN HYDROCHLORIDE

TABLET;ORAL

RAXAR

OTSUKA	EQ 200MG BASE	N020695 001	Nov 06, 1997
	EQ 400MG BASE	N020695 002	May 14, 1998
	EQ 600MG BASE	N020695 003	May 14, 1998

GRISEOFULVIN, MICROCRYSTALLINE

CAPSULE;ORAL

GRISACTIN

WYETH AYERST	125MG	N050051 002
	250MG	N050051 001

SUSPENSION;ORAL

GRIFULVIN V

+	JOHNSON AND JOHNSON	125MG/5ML **	N050448 001
---	---------------------	--------------	-------------

TABLET;ORAL

FULVICIN-U/F

CHARTWELL RX	250MG	A060569 002
	500MG	A060569 001

GRIFULVIN V

J AND J	125MG	A060618 001
	250MG	A060618 002
	500MG	A060618 003
VALEANT LUXEMBOURG	125MG	A062279 001
	250MG **	A062279 002

GRISACTIN

WYETH AYERST	500MG	A060212 001
--------------	-------	-------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

GRISEOFULVIN, MICROSIZE

SUSPENSION;ORAL

GRIFULVIN V

VALEANT LUXEMBOURG 125MG/5ML ** A062483 001 Jan 26, 1984

TABLET;ORAL

GRIFULVIN V

VALEANT LUXEMBOURG 500MG A062279 003

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET;ORAL

FULVICIN P/G

CHARTWELL RX 125MG A061996 001

250MG A061996 002

FULVICIN P/G 165

CHARTWELL RX 165MG A061996 003 Apr 06, 1982

FULVICIN P/G 330

CHARTWELL RX 330MG A061996 004 Apr 06, 1982

GRISACTIN ULTRA

WYETH AYERST 125MG A062178 001

165MG A062438 001 Nov 17, 1983

250MG A062178 002

330MG A062438 002 Nov 17, 1983

ULTRAGRIS-165

PLIVA 165MG A062645 001 Jun 30, 1992

ULTRAGRIS-330

PLIVA 330MG A062646 001 Jun 30, 1992

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN

OHM LABS INC 600MG A209254 001 Jul 16, 2018

1.2GM A209254 002 Jul 16, 2018

GUAIFENESIN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

FLOWTUSS

BKK PHARMS 200MG/5ML;2.5MG/5ML N022424 001 May 14, 2015

OBREDON

+ SOVEREIGN PHARMS 200MG/5ML;2.5MG/5ML N205474 001 Nov 14, 2014

TABLET;ORAL

XTRELUS

+ ECI PHARMS LLC 400MG;5MG N208085 001 Apr 25, 2018

GUAIFENESIN; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYCOFENIX

+ BKK PHARMS 200MG/5ML;2.5MG/5ML;30MG/5ML N022279 001 May 14, 2015

GUANABENZ ACETATE

TABLET;ORAL

GUANABENZ ACETATE

ANI PHARMS INC EQ 4MG BASE A074149 001 Apr 07, 1995

EQ 4MG BASE A074267 001 Jun 01, 1994

EQ 8MG BASE A074149 002 Apr 07, 1995

EQ 8MG BASE A074267 002 Jun 01, 1994

WATSON LABS EQ 4MG BASE A074025 001 Feb 28, 1994

EQ 8MG BASE A074025 002 Feb 28, 1994

YAOPHARMA CO LTD EQ 4MG BASE A074517 001 Sep 30, 1998

EQ 8MG BASE A074517 002 Sep 30, 1998

WYTENSIN

WYETH AYERST EQ 4MG BASE N018587 001 Sep 07, 1982

EQ 8MG BASE N018587 002 Sep 07, 1982

EQ 16MG BASE N018587 003 Sep 07, 1982

GUANADREL SULFATE

TABLET;ORAL

HYLOREL

PHARMACIA AND UPJOHN 10MG N018104 001 Dec 29, 1982

25MG N018104 002 Dec 29, 1982

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

GUANETHIDINE MONOSULFATE

TABLET; ORAL

GUANETHIDINE MONOSULFATE

WATSON LABS

EQ 10MG SULFATE

A086113 001 Mar 26, 1985

EQ 25MG SULFATE

A086114 001 Mar 26, 1985

ISMELIN

NOVARTIS

EQ 10MG SULFATE

N012329 001

EQ 25MG SULFATE

N012329 002

GUANETHIDINE MONOSULFATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ESIMIL

NOVARTIS

10MG; 25MG

N013553 001

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HYDROCHLORIDE

WATSON LABS

EQ 1MG BASE

A074762 001 Jun 25, 1997

EQ 2MG BASE

A074762 002 Jun 25, 1997

TENEX

+

PROMIUS PHARMA

EQ 1MG BASE **

N019032 001 Oct 27, 1986

+

EQ 2MG BASE **

N019032 002 Nov 07, 1988

EQ 3MG BASE **

N019032 003 Nov 07, 1988

TABLET, EXTENDED RELEASE; ORAL

GUANFACINE HYDROCHLORIDE

IMPAX LABS INC

EQ 1MG BASE

A202238 001 Oct 20, 2015

EQ 2MG BASE

A202238 002 Oct 20, 2015

EQ 3MG BASE

A202238 003 Oct 20, 2015

EQ 4MG BASE

A202238 004 Oct 20, 2015

MYLAN

EQ 1MG BASE

A202578 001 Jun 02, 2015

EQ 2MG BASE

A202578 002 Jun 02, 2015

EQ 3MG BASE

A202578 003 Jun 02, 2015

EQ 4MG BASE

A202578 004 Jun 02, 2015

GUANIDINE HYDROCHLORIDE

TABLET; ORAL

GUANIDINE HYDROCHLORIDE

MERCK SHARP DOHME

125MG

N001546 001

HALAZEPAM

TABLET; ORAL

PAXIPAM

SCHERING

20MG

N017736 003

40MG

N017736 004

HALCINONIDE

CREAM; TOPICAL

HALOG

WESTWOOD SQUIBB

0.025%

N017818 001

HALOG-E

SUN PHARM INDS INC

0.1%

N018234 001

OINTMENT; TOPICAL

HALOG

BRISTOL MYERS SQUIBB

0.025%

N018125 001

HALOBETASOL PROPIONATE

CREAM; TOPICAL

ULTRAVATE

+

SUN PHARM INDS INC

0.05%

N019967 001 Dec 27, 1990

LOTION; TOPICAL

HALOBETASOL PROPIONATE

PERRIGO ISRAEL

0.05%

A211464 001 Jun 03, 2020

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE

FOUGERA PHARMS

0.05%

A076903 001 Dec 16, 2004

HALOFANTRINE HYDROCHLORIDE

TABLET; ORAL

HALFAN

GLAXOSMITHKLINE

250MG

N020250 001 Jul 24, 1992

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HALOPERIDOL

TABLET; ORAL

HALDOL

+	ORTHO MCNEIL	0.5MG **	N015921 001	
+		1MG **	N015921 002	
+		2MG **	N015921 003	
+		5MG **	N015921 004	
+		10MG **	N015921 005	
+		20MG **	N015921 006	Feb 02, 1982

HALDOL SOLUTAB

	ORTHO MCNEIL PHARM	1MG	N017079 001	
--	--------------------	-----	-------------	--

HALOPERIDOL

	CYCLE PHARMS LTD	0.5MG	A071128 001	Feb 17, 1987
		1MG	A071129 001	Feb 17, 1987
		2MG	A071130 001	Feb 17, 1987
		5MG	A071131 001	Feb 17, 1987
		10MG	A071132 001	May 12, 1987
		20MG	A071133 001	May 12, 1987
	DURAMED PHARMS BARR	0.5MG	A071216 001	Dec 04, 1986
		1MG	A071217 001	Dec 04, 1986
		2MG	A071218 001	Dec 04, 1986
		5MG	A071219 001	Dec 04, 1986
		10MG	A071220 001	Jul 07, 1987
		20MG	A071221 001	Jul 07, 1987
	LEDERLE	0.5MG	A072727 001	Sep 19, 1989
		1MG	A072728 001	Sep 19, 1989
		2MG	A072729 001	Sep 19, 1989
		5MG	A072730 001	Sep 19, 1989
		10MG	A072731 001	Sep 19, 1989
		20MG	A072732 001	Sep 19, 1989
	PAR PHARM	20MG	A071328 001	Jul 20, 1987
	PUREPAC PHARM	0.5MG	A071071 001	Nov 03, 1986
		1MG	A071072 001	Nov 03, 1986
		2MG	A071073 001	Nov 03, 1986
		5MG	A071074 001	Nov 03, 1986
		10MG	A071075 001	Aug 04, 1987
		20MG	A071076 001	Aug 04, 1987
	QUANTUM PHARMICS	0.5MG	A071255 001	Feb 17, 1987
		1MG	A071269 001	Feb 17, 1987
		2MG	A071256 001	Feb 17, 1987
		5MG	A071257 001	Feb 17, 1987
	ROYCE LABS	0.5MG	A071722 001	Dec 24, 1987
		1MG	A071723 001	Dec 24, 1987
		2MG	A071724 001	Dec 24, 1987
		5MG	A071725 001	Dec 24, 1987
		10MG	A072121 001	Dec 24, 1987
		20MG	A072122 001	Dec 24, 1987
	SANDOZ	2MG	A071208 001	Nov 17, 1986
	SCS	0.5MG	A070720 001	Jun 10, 1986
		1MG	A070721 001	Jun 10, 1986
		2MG	A070722 001	Jun 10, 1986
		5MG	A070723 001	Jun 10, 1986
		10MG	A070724 001	Jun 10, 1986
		20MG	A070725 001	Sep 24, 1986
	VINTAGE	0.5MG	A071235 002	Nov 03, 1986
		1MG	A071235 003	Nov 03, 1986
		2MG	A071235 001	Nov 03, 1986
		5MG	A071235 004	Nov 03, 1986
		10MG	A071235 005	Jul 20, 1987
	WATSON LABS	0.5MG	A070981 001	Mar 06, 1987
		0.5MG	A071571 001	Jun 03, 1988
		1MG	A070982 001	Mar 06, 1987
		1MG	A071572 001	Jun 03, 1988
		2MG	A070983 001	Mar 06, 1987
		2MG	A071573 001	Jun 03, 1988
		5MG	A070984 001	Mar 06, 1987
		5MG	A071374 001	Jun 03, 1988
		10MG	A071375 001	Jun 03, 1988
		10MG	A072113 001	Aug 27, 1991

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

20MG

A071376 001 Jun 03, 1988

20MG

A072353 001 Aug 27, 1991

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE

HOSPIRA

EQ 50MG BASE/ML

A075176 001 Feb 09, 2000

EQ 100MG BASE/ML

A075176 002 Feb 09, 2000

SANDOZ INC

EQ 50MG BASE/ML

A076463 001 Jun 24, 2005

EQ 100MG BASE/ML

A076463 002 Jun 24, 2005

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALDOL

ORTHO MCNEIL

EQ 2MG BASE/ML **

N015922 001

HALOPERIDOL

ALPHARMA

EQ 2MG BASE/ML

A070318 001 Apr 11, 1986

MORTON GROVE

EQ 2MG BASE/ML

A070710 001 Mar 07, 1986

SCS

EQ 2MG BASE/ML

A070726 001 Jun 10, 1986

TEVA

EQ 2MG BASE/ML

A071015 001 Aug 25, 1987

TEVA PHARMS

EQ 2MG BASE/ML

A071617 001 Dec 01, 1988

HALOPERIDOL INTENSOL

HIKMA

EQ 2MG BASE/ML

A072045 001 Apr 12, 1988

INJECTABLE; INJECTION

HALDOL

+ JANSSEN PHARMS

EQ 5MG BASE/ML

N015923 001

HALOPERIDOL

ABRAXIS PHARM

EQ 5MG BASE/ML

A071187 001 Jan 20, 1987

BAXTER HLTHCARE CORP

EQ 5MG BASE/ML

A076791 001 Aug 25, 2004

EQ 5MG BASE/ML

A076828 001 Aug 25, 2004

FOSUN PHARMA

EQ 5MG BASE/ML

A076464 001 Sep 29, 2004

MARSAM PHARMS LLC

EQ 5MG BASE/ML

A072516 001 Feb 25, 1993

EQ 5MG BASE/ML

A072517 001 Feb 25, 1993

SMITH AND NEPHEW

EQ 5MG BASE/ML

A070802 001 Dec 14, 1987

SOLOPAK

EQ 5MG BASE/ML

A070800 001 Dec 14, 1987

EQ 5MG BASE/ML

A070801 001 Dec 14, 1987

EQ 5MG BASE/ML

A070864 001 Dec 14, 1987

TEVA PHARMS USA

EQ 5MG BASE/ML

A076035 001 Aug 29, 2001

WATSON LABS

EQ 5MG BASE/ML

A070713 001 May 17, 1988

EQ 5MG BASE/ML

A070714 001 May 17, 1988

EQ 5MG BASE/ML

A070744 001 May 17, 1988

SOLUTION; ORAL

HALOPERIDOL LACTATE

ACTAVIS MID ATLANTIC

EQ 1MG BASE/ML

A074536 001 Nov 02, 1995

HALOPROGIN

CREAM; TOPICAL

HALOTEX

WESTWOOD SQUIBB

1%

N016942 001

SOLUTION; TOPICAL

HALOTEX

WESTWOOD SQUIBB

1%

N016943 001

HALOTHANE

LIQUID; INHALATION

FLUOTHANE

WYETH AYERST

99.99%

N011338 001

HALOTHANE

BH

99.99%

A084977 001

HALOCARBON

99.99%

A080810 001

HOSPIRA

99.99%

A083254 001

HEPARIN CALCIUM

INJECTABLE; INJECTION

CALCIPARINE

SANOFI AVENTIS US

25,000 UNITS/ML

N018237 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN LOCK FLUSH

HOSPIRA	100 UNITS/ML	N005264	010	
INTL MEDICATION	10 UNITS/ML	A086357	001	
	500 UNITS/ML	A086357	002	
LUITPOLD	10 UNITS/ML	A089063	001	Oct 09, 1985
	100 UNITS/ML	A089064	001	Oct 09, 1985
PARKE DAVIS	10 UNITS/ML	N017346	006	
SMITH AND NEPHEW	10 UNITS/ML	A087904	001	Apr 20, 1983
	10 UNITS/ML	A087958	001	Apr 20, 1983
	10 UNITS/ML	A088458	001	Jul 26, 1984
	10 UNITS/ML	A088580	001	Oct 25, 1984
	100 UNITS/ML	A087906	001	Apr 20, 1983
	100 UNITS/ML	A087959	001	Apr 20, 1983
	100 UNITS/ML	A088460	001	Jul 26, 1984
	100 UNITS/ML	A088581	001	Oct 25, 1984
SOLOPAK	10 UNITS/ML	A087903	001	Apr 20, 1983
	10 UNITS/ML	A088457	001	Oct 25, 1984
	100 UNITS/ML	A087905	001	Apr 20, 1983
	100 UNITS/ML	A088459	001	Jul 26, 1984

HEPARIN SODIUM

ABRAXIS PHARM	1,000 UNITS/ML	N017033	001	
	1,000 UNITS/ML	N017979	001	
	5,000 UNITS/ML	N017979	003	
	10,000 UNITS/ML	N017979	002	
AKORN	1,000 UNITS/ML	N017486	001	
	5,000 UNITS/ML	N017486	002	
	10,000 UNITS/ML	N017486	003	
	20,000 UNITS/ML	N017486	004	
	40,000 UNITS/ML	N017486	005	
CASI PHARMS INC	5,000 UNITS/ML	A091659	001	Jun 08, 2011
CHAMBERLIN PARENTERL	1,000 UNITS/ML	N017130	001	
	5,000 UNITS/ML	N017130	002	
	10,000 UNITS/ML	N017130	003	
	20,000 UNITS/ML	N017130	004	
DELL LABS	1,000 UNITS/ML	N017540	001	
	5,000 UNITS/ML	N017540	002	
	10,000 UNITS/ML	N017540	003	
	20,000 UNITS/ML	N017540	004	
	40,000 UNITS/ML	N017540	005	
DR REDDYS	1,000 UNITS/ML	A040007	001	Jun 07, 1996
	1,000 UNITS/ML	N017064	002	
	2,500 UNITS/ML	N017064	015	
	3,000 UNITS/ML	N017064	016	
	4,000 UNITS/ML	N017064	017	
	5,000 UNITS/ML	N017064	003	
	6,000 UNITS/ML	N017064	018	
	7,500 UNITS/ML	N017064	019	
	10,000 UNITS/ML	N017064	004	
	20,000 UNITS/ML	N017064	005	
	40,000 UNITS/ML	N017064	006	
FRESENIUS KABI USA	1,000 UNITS/ML	N017651	005	
	5,000 UNITS/ML	N017029	002	
	10,000 UNITS/ML	N017651	003	
	20,000 UNITS/ML	N017651	008	
HIKMA	5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986
HOSPIRA	2,500 UNITS/ML	A088099	001	Apr 28, 1983
	10,000 UNITS/ML	A040095	001	Jul 26, 1996
LILLY	1,000 UNITS/ML	N005521	001	
	10,000 UNITS/ML	N005521	002	
	20,000 UNITS/ML	N005521	004	
LUITPOLD	1,000 UNITS/ML	A087452	001	Oct 31, 1983
ORGANON USA INC	1,000 UNITS/ML	N000552	008	
	5,000 UNITS/ML	N000552	009	
	10,000 UNITS/ML	N000552	010	
PARKE DAVIS	1,000 UNITS/ML	N017346	001	
	5,000 UNITS/ML	N017346	002	
	7,500 UNITS/ML	N017346	003	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

		10,000 UNITS/ML	N017346 004	
		20,000 UNITS/ML	N017346 005	
+	PFIZER	10,000 UNITS/ML	N201370 003	Jul 21, 2011
	PHARM SPEC	1,000 UNITS/ML	N017780 001	
		5,000 UNITS/ML	N017780 002	
		10,000 UNITS/ML	N017780 003	
		20,000 UNITS/ML	N017780 004	
		40,000 UNITS/ML	N017780 005	
	PHARMACIA AND UPJOHN	1,000 UNITS/ML	N004570 001	
		5,000 UNITS/ML	N004570 002	
		10,000 UNITS/ML	N004570 003	
	SMITH AND NEPHEW	1,000 UNITS/ML	A088239 001	Jul 26, 1984
	SOLOPAK	1,000 UNITS/ML	A087043 001	
		5,000 UNITS/ML	A087077 001	
		5,000 UNITS/0.5ML	A087395 001	
		10,000 UNITS/ML	A087107 001	
		10,000 UNITS/0.5ML	A087363 001	
	WATSON LABS INC	1,000 UNITS/ML	A040008 001	Oct 10, 1995
+	WEST-WARD PHARMS INT	1,000 UNITS/ML **	N017007 001	
+		2,500 UNITS/ML **	N017007 007	
+		5,000 UNITS/ML **	N017007 002	
+		5,000 UNITS/0.5ML **	N017007 010	
+		7,500 UNITS/ML **	N017007 003	
+		10,000 UNITS/ML **	N017007 004	
+		15,000 UNITS/ML **	N017007 005	
+		20,000 UNITS/ML **	N017007 006	
HEPARIN SODIUM	1,000 UNITS	IN DEXTROSE 5% IN PLASTIC CONTAINER		
	MCGAW	200 UNITS/100ML	N019130 001	Dec 31, 1984
HEPARIN SODIUM	1,000 UNITS	IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER		
	B BRAUN	200 UNITS/100ML	N019042 001	Mar 29, 1985
HEPARIN SODIUM	10,000 UNITS	AND DEXTROSE 5% IN PLASTIC CONTAINER		
	BAXTER HLTHCARE	2,000 UNITS/100ML	N018814 002	Jul 09, 1985
HEPARIN SODIUM	10,000 UNITS	IN DEXTROSE 5%		
	HOSPIRA	10,000 UNITS/100ML	N018911 006	Jan 30, 1985
HEPARIN SODIUM	10,000 UNITS	IN SODIUM CHLORIDE 0.45%		
	HOSPIRA	10,000 UNITS/100ML	N018911 001	Jan 30, 1985
		10,000 UNITS/100ML	N018916 005	Jan 31, 1984
HEPARIN SODIUM	10,000 UNITS	IN SODIUM CHLORIDE 0.9%		
	HOSPIRA	10,000 UNITS/100ML	N018911 003	Jan 30, 1985
		10,000 UNITS/100ML	N018916 002	Jan 31, 1984
HEPARIN SODIUM	12,500 UNITS	IN DEXTROSE 5%		
	HOSPIRA	5,000 UNITS/100ML	N018911 007	Jan 30, 1985
HEPARIN SODIUM	12,500 UNITS	IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER		
	B BRAUN	5,000 UNITS/100ML	N019802 001	Jul 20, 1992
HEPARIN SODIUM	12,500 UNITS	IN SODIUM CHLORIDE 0.9%		
	HOSPIRA	5,000 UNITS/100ML	N018911 005	Jan 30, 1985
		5,000 UNITS/100ML	N018916 003	Jan 31, 1984
HEPARIN SODIUM	2,000 UNITS	IN DEXTROSE 5% IN PLASTIC CONTAINER		
	MCGAW	200 UNITS/100ML	N019130 003	Dec 31, 1984
HEPARIN SODIUM	2,000 UNITS	IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER		
	B BRAUN	200 UNITS/100ML	N019042 002	Mar 29, 1985
HEPARIN SODIUM	20,000 UNITS	AND DEXTROSE 5% IN PLASTIC CONTAINER		
	BAXTER HLTHCARE	4,000 UNITS/100ML	N018814 001	Oct 31, 1983
HEPARIN SODIUM	25,000 UNITS	AND DEXTROSE 5% IN PLASTIC CONTAINER		
	BAXTER HLTHCARE	5,000 UNITS/100ML	N018814 003	Jul 09, 1985
		10,000 UNITS/100ML	N018814 004	Jul 02, 1987
HEPARIN SODIUM	25,000 UNITS	IN DEXTROSE 5%		
	HOSPIRA	5,000 UNITS/100ML	N018911 009	Jan 30, 1985
		10,000 UNITS/100ML	N018911 008	Jan 30, 1985
HEPARIN SODIUM	25,000 UNITS	IN DEXTROSE 5% IN PLASTIC CONTAINER		
	B BRAUN	5,000 UNITS/100ML	N019134 001	Mar 29, 1985
HEPARIN SODIUM	25,000 UNITS	IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER		
	B BRAUN	5,000 UNITS/100ML	N019802 005	Jul 20, 1992
		10,000 UNITS/100ML	N019802 002	Jul 20, 1992
HEPARIN SODIUM	25,000 UNITS	IN SODIUM CHLORIDE 0.9%		
	HOSPIRA	5,000 UNITS/100ML	N018911 004	Jan 30, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN	5,000 UNITS/100ML	N019135 001	Mar 29, 1985
	5,000 UNITS/100ML	N019802 003	Jul 20, 1992
HOSPIRA	5,000 UNITS/100ML	N018916 009	Jan 31, 1984

HEPARIN SODIUM 5,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

BAXTER HLTHCARE	500 UNITS/100ML	N018609 003	Apr 28, 1982
-----------------	-----------------	-------------	--------------

HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

MCGAW	1,000 UNITS/100ML	N019130 002	Dec 31, 1984
-------	-------------------	-------------	--------------

HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.45%

HOSPIRA	100 UNITS/ML	N018911 002	Jan 30, 1985
	100 UNITS/ML	N018916 004	Jan 31, 1984

HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9%

HOSPIRA	1,000 UNITS/100ML	N018916 001	Jan 31, 1984
---------	-------------------	-------------	--------------

HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN	1,000 UNITS/100ML	N019042 004	Mar 29, 1985
---------	-------------------	-------------	--------------

HEPARIN SODIUM PRESERVATIVE FREE

DR REDDYS	1,000 UNITS/ML	A089464 001	Jun 03, 1986
HOSPIRA	2,000 UNITS/ML	N005264 013	Apr 07, 1986
	2,500 UNITS/ML	N005264 014	Apr 07, 1986
PHARMA SERVE NY	1,000 UNITS/ML	A086129 001	

LIPO-HEPIN

3M	1,000 UNITS/0.5ML	N017027 001	
	1,000 UNITS/ML	N017027 006	
	5,000 UNITS/0.5ML	N017027 002	
	5,000 UNITS/ML	N017027 008	
	7,500 UNITS/0.5ML	N017027 010	
	10,000 UNITS/0.5ML	N017027 003	
	10,000 UNITS/ML	N017027 009	
	15,000 UNITS/0.5ML	N017027 011	
	20,000 UNITS/0.5ML	N017027 004	
	20,000 UNITS/ML	N017027 007	
	40,000 UNITS/ML	N017027 005	

LIQUAEMIN LOCK FLUSH

ORGANON USA INC	100 UNITS/ML	N000552 007	
-----------------	--------------	-------------	--

LIQUAEMIN SODIUM

ORGANON USA INC	1,000 UNITS/ML	N000552 004	
	5,000 UNITS/ML	N000552 003	
	10,000 UNITS/ML	N000552 005	
	20,000 UNITS/ML	N000552 001	
	40,000 UNITS/ML	N000552 002	

LIQUAEMIN SODIUM PRESERVATIVE FREE

ORGANON USA INC	1,000 UNITS/ML	N000552 011	Apr 11, 1986
	5,000 UNITS/ML	N000552 012	Apr 11, 1986
	10,000 UNITS/ML	N000552 013	Apr 11, 1986

PANHEPRIN

HOSPIRA	1,000 UNITS/ML	N005264 004	
	5,000 UNITS/ML	N005264 006	
	10,000 UNITS/ML	N005264 007	
	20,000 UNITS/ML	N005264 008	
	40,000 UNITS/ML	N005264 009	

SODIUM HEPARIN

ABRAXIS PHARM	5,000 UNITS/ML	N017033 002	
	10,000 UNITS/ML	N017033 003	
	20,000 UNITS/ML	N017033 004	
BAXTER HLTHCARE	1,000 UNITS/ML	N017036 001	Mar 04, 1988

HETACILLIN

FOR SUSPENSION; ORAL

VERSAPEN

BRISTOL	EQ 112.5MG AMPICIL/ML	A061398 001	
	EQ 112.5MG AMPICIL/5ML	N050060 001	
	EQ 112.5MG AMPICIL/ML	N050060 003	
	EQ 225MG AMPICIL/5ML	A061398 002	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HETACILLIN POTASSIUM

CAPSULE; ORAL

VERSAPEN-K

BRISTOL

EQ 225MG AMPICIL

A061396 001

EQ 450MG AMPICIL

A061396 002

HEXACHLOROPHENE

AEROSOL; TOPICAL

SEPTISOL

VESTAL LABS

0.23%

N017424 001

TURGEX

XTTRIUM

3%

N018375 001

EMULSION; TOPICAL

HEXA-GERM

HUNTINGTON LABS

3%

N017411 001

PHISOHEX

SANOFI AVENTIS US

3%

N006882 001

3%

N008402 001

SOY-DOME

BAYER PHARMS

3%

N017405 001

TURGEX

XTTRIUM

3%

N019055 001 Nov 30, 1984

SOAP; TOPICAL

GAMOPHEN

ARBROOK

2%

N006270 003

SOLUTION; TOPICAL

DIAL

DIAL

0.25%

N017421 002

GERMA-MEDICA

HUNTINGTON LABS

1%

N017412 001

GERMA-MEDICA "MG"

HUNTINGTON LABS

0.25%

N017412 002

SEPTI-SOFT

CALGON

0.25%

N017460 001

SEPTISOL

VESTAL LABS

0.25%

N017423 001

SPONGE; TOPICAL

E-Z SCRUB

BECTON DICKINSON

450MG

N017452 001

HEXASCRUB

PROF DSPLS

3%

N018363 001

PHISO-SCRUB

SANOFI AVENTIS US

3%

N017446 001

SCRUBTEAM SURGICAL SPONGEBRUSH

3M

330MG

N017413 001

HEXAFLUORENIUM BROMIDE

INJECTABLE; INJECTION

MYLAXEN

MEDPOINTE PHARM HLC 20MG/ML

N009789 003

HEXOCYCLIUM METHYLSULFATE

TABLET; ORAL

TRAL

ABBVIE

25MG

N010599 001

HEXYLCAINE HYDROCHLORIDE

SOLUTION; TOPICAL

CYCLAINE

MERCK

5%

N008472 001

HISTAMINE PHOSPHATE

INJECTABLE; INJECTION

HISTAMINE PHOSPHATE

LILLY

EQ 0.1MG BASE/ML

N000734 003

EQ 0.2MG BASE/ML

N000734 002

EQ 1MG BASE/ML

N000734 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HISTRELIN ACETATE

INJECTABLE; INJECTION

SUPPRELIN

SHIRE

EQ 0.2MG BASE/ML

N019836 001 Dec 24, 1991

EQ 0.5MG BASE/ML

N019836 002 Dec 24, 1991

EQ 1MG BASE/ML

N019836 003 Dec 24, 1991

HOMATROPINE METHYLBROMIDE

TABLET; ORAL

HOMAPIN-10

MISSION PHARMA

10MG

A086308 001

HOMAPIN-5

MISSION PHARMA

5MG

A086309 001

TABLET, CHEWABLE; ORAL

EQUIPIN

MISSION PHARMA

3MG

A086310 001

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

IVAX SUB TEVA PHARMS 1.5MG/5ML; 5MG/5ML

A040285 001 Jul 19, 1999

NOSTRUM LABS INC 1.5MG/5ML; 5MG/5ML

A210663 001 Jun 11, 2019

TORRENT 1.5MG/5ML; 5MG/5ML

A204765 001 Mar 06, 2017

HYDROPANE

HALSEY 1.5MG/5ML; 5MG/5ML

A088066 001 Jun 28, 1985

TABLET; ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

ACTAVIS ELIZABETH 1.5MG; 5MG

A040295 001 Dec 01, 2000

HYCODAN

+ GENUS

1.5MG; 5MG **

N005213 001 Jul 26, 1988

TUSSIGON

KING PHARMS

1.5MG; 5MG

A088508 001 Jul 30, 1985

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

APRESOLINE

+ NOVARTIS

20MG/ML **

N008303 003

HYDRALAZINE HYDROCHLORIDE

ABRAXIS PHARM 20MG/ML

A089532 001 Aug 11, 1987

SMITH AND NEPHEW 20MG/ML

A088518 001 Apr 20, 1984

SOLOPAK 20MG/ML

A088517 001 Aug 22, 1985

TEVA PARENTERAL 20MG/ML

A040373 001 Feb 23, 2000

TABLET; ORAL

APRESOLINE

+ NOVARTIS

10MG **

N008303 004

+ 25MG **

N008303 001

+ 50MG **

N008303 002

+ 100MG **

N008303 005

DRALZINE

TEVA

25MG

A084301 001

HYDRALAZINE HYDROCHLORIDE

ACTAVIS ELIZABETH 25MG

A088560 001 Oct 04, 1984

50MG

A088649 001 Oct 18, 1984

ACTAVIS GRP PTC 10MG

A091679 001 Mar 04, 2013

25MG

A091679 002 Mar 04, 2013

50MG

A091679 003 Mar 04, 2013

100MG

A091679 004 Mar 04, 2013

ANDA REPOSITORY 10MG

A089359 001 Jul 25, 1986

25MG

A089258 001 May 05, 1986

50MG

A089259 001 May 05, 1986

100MG

A088729 001 Apr 11, 1985

ASCOT 25MG

A088310 001 Dec 19, 1984

50MG

A088311 001 Dec 19, 1984

CHARTWELL RX 10MG

A088846 001 Feb 26, 1985

25MG

A088847 001 Feb 26, 1985

50MG

A088848 001 Feb 26, 1985

100MG

A088849 001 Feb 26, 1985

HALSEY 10MG

A089218 001 Jan 22, 1986

25MG

A089130 001 Jan 15, 1986

50MG

A089222 001 Jan 22, 1986

100MG

A089178 001 Jan 15, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

HERITAGE PHARMS INC	10MG	A040858 001	Feb 26, 2010
	25MG	A040858 002	Feb 26, 2010
	50MG	A040858 003	Feb 26, 2010
	100MG	A040858 004	Feb 26, 2010
IMPAX LABS	25MG	A084922 001	
	50MG	A084923 001	
IVAX SUB TEVA PHARMS	10MG	A084443 001	
	25MG	A084437 001	
	50MG	A084469 002	
	100MG	A084581 001	
MUTUAL PHARM	10MG	A088728 001	Apr 11, 1985
	25MG	A084106 002	
	50MG	A084107 002	
MYLAN	10MG	A090413 001	Dec 08, 2010
	25MG	A090413 002	Dec 08, 2010
	50MG	A090413 003	Dec 08, 2010
	100MG	A090413 004	Dec 08, 2010
PUREPAC PHARM	25MG	A088177 001	Jul 29, 1983
	50MG	A088178 001	Aug 15, 1983
QUANTUM PHARMICS	10MG	A088671 001	May 01, 1984
	25MG	A088657 001	Jun 15, 1984
	50MG	A088652 001	May 08, 1984
	100MG	A088686 001	May 01, 1984
STRIDES PHARMA	10MG	A200770 004	Jun 25, 2019
SUPERPHARM	10MG	A088787 001	Aug 28, 1984
	25MG	A088788 001	Aug 28, 1984
	50MG	A088789 001	Aug 28, 1984
UPSHER SMITH LABS	10MG	A083241 001	
	25MG	A083560 001	
	50MG	A083561 001	
	50MG	A085088 001	
USL PHARMA	25MG	A087780 001	Mar 29, 1982
	50MG	A087751 001	Mar 29, 1982
VANGARD	25MG	A087712 001	
	50MG	A087908 001	May 07, 1982
VITARINE	25MG	A086088 001	
WATSON LABS	25MG	A084504 001	
	25MG	A085532 002	May 24, 1982
	50MG	A084503 001	
	50MG	A085533 002	May 25, 1982
WEST WARD	25MG	A088240 001	May 27, 1983
	50MG	A088241 001	May 27, 1983

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

APRESAZIDE

NOVARTIS	25MG; 25MG	A084735 001	
	50MG; 50MG	A084810 001	
	100MG; 50MG	A084811 001	
HYDRA-ZIDE			
PAR PHARM	100MG; 50MG	A088961 001	Oct 21, 1985
HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE			
SOLVAY	25MG; 25MG	A087608 001	Feb 08, 1982
	50MG; 50MG	A087213 001	Feb 08, 1982
	100MG; 50MG	A087609 001	Feb 08, 1982
SUPERPHARM	25MG; 25MG	A089200 001	Feb 09, 1987
	50MG; 50MG	A089201 001	Feb 09, 1987
WATSON LABS	25MG; 25MG	A085457 001	Mar 04, 1982
	50MG; 50MG	A085446 001	Mar 04, 1982
	100MG; 50MG	A085440 001	Mar 04, 1982
HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 100/50			
IVAX PHARMS	100MG; 50MG	A088358 001	Apr 10, 1984
HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 25/25			
IVAX PHARMS	25MG; 25MG	A088356 001	Apr 10, 1984
HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 50/50			
IVAX PHARMS	50MG; 50MG	A088357 001	Apr 10, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

APRESOLINE-ESIDRIX			
NOVARTIS	25MG;15MG	N012026	002
HYDRALAZINE AND HYDROCHLOROTHIAZIDE			
WATSON LABS	25MG;15MG	A085827	001
HYDROCHLOROTHIAZIDE W/ HYDRALAZINE			
WATSON LABS	25MG;15MG	A085373	001

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

CAM-AP-ES			
CHARTWELL RX	25MG;15MG;0.1MG	A084897	001
HYDRALAZINE HYDROCHLORIDE, HYDROCHLOROTHIAZIDE AND RESERPINE			
IVAX SUB TEVA PHARMS	25MG;15MG;0.1MG	A084291	001
HYDRALAZINE HYDROCHLORIDE-HYDROCHLOROTHIAZIDE-RESERPINE			
MYLAN	25MG;15MG;0.1MG	A087085	001
HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE			
WATSON LABS	25MG;15MG;0.1MG	A085771	001
HYDRAP-ES			
SANDOZ	25MG;15MG;0.1MG	A084876	001
HYDROCHLOROTHIAZIDE W/ RESERPINE AND HYDRALAZINE			
WATSON LABS	25MG;15MG;0.1MG	A083770	001
HYDROSERPINE PLUS (R-H-H)			
IVAX SUB TEVA PHARMS	25MG;15MG;0.1MG	A083877	001
RESERPINE, HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE			
SOLVAY	25MG;15MG;0.1MG	A088376	001 Oct 28, 1983
SUN PHARM INDUSTRIES	25MG;15MG;0.1MG	A088570	001 Apr 10, 1984
WATSON LABS	25MG;15MG;0.1MG	A085549	001
	25MG;15MG;0.1MG	A087556	001
RESERPINE, HYDROCHLOROTHIAZIDE, AND HYDRALAZINE HYDROCHLORIDE			
LEDERLE	25MG;15MG;0.1MG	A087709	001 May 13, 1982
SER-A-GEN			
SOLVAY	25MG;15MG;0.1MG	A087210	001
SER-AP-ES			
NOVARTIS	25MG;15MG;0.1MG	N012193	005
UNIPRES			
SOLVAY	25MG;15MG;0.1MG	A085893	001
	25MG;15MG;0.1MG	A086298	001

HYDRALAZINE HYDROCHLORIDE; RESERPINE

TABLET; ORAL

DRALSERP			
SANDOZ	25MG;0.1MG	A084617	001
SERPASIL-APRESOLINE			
NOVARTIS	25MG;0.1MG	N009296	004
	50MG;0.2MG	N009296	002

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE			
ALEMBIC PHARMS LTD	12.5MG	A200645	001 Nov 30, 2010
APOTEX	12.5MG	A078389	001 May 16, 2008
HIKMA INTL PHARMS	12.5MG	A077885	001 Nov 26, 2007
IVAX SUB TEVA PHARMS	12.5MG	A077005	001 Jul 13, 2005
LANNETT CO INC	12.5MG	A091662	001 Jan 27, 2012

SOLUTION; ORAL

HYDROCHLOROTHIAZIDE			
MORTON GROVE	50MG/5ML	A089661	001 Jun 20, 1988
ROXANE	50MG/5ML	A088587	001 Jul 02, 1984
HYDROCHLOROTHIAZIDE INTENSOL			
ROXANE	100MG/ML	A088588	001 Jul 02, 1984

TABLET; ORAL

ESIDRIX			
NOVARTIS	25MG	N011793	005
	50MG	N011793	008
	100MG	N011793	009
HYDRO-D			
HALSEY	25MG	A086504	001
	50MG	A083891	002

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROCHLOROTHIAZIDE

TABLET;ORAL

HYDROCHLOROTHIAZIDE

ABC HOLDING	50MG	A085672	001	
ACTAVIS ELIZABETH	25MG	A085054	002	
	50MG	A085208	001	
ALRA	25MG	A086369	001	
	50MG	A083554	001	
APOTEX	25MG	A040774	001	Oct 03, 2007
	50MG	A040774	002	Oct 03, 2007
ASCOT	25MG	A087539	001	Feb 03, 1982
	50MG	A087540	001	Feb 03, 1982
AUROLIFE PHARMA LLC	25MG	A083899	001	
	50MG	A085219	001	
BARR	50MG	A084771	001	
CHARTWELL RX	25MG	A085683	001	
	50MG	A083965	001	
DAVA PHARMS INC	100MG	A087060	001	
ELKINS SINN	50MG	A085152	002	
HEATHER	50MG	A084135	001	
HIKMA INTL PHARMS	25MG	A084878	002	Jul 12, 2006
	50MG	A084878	001	
IMPAX LABS	25MG	A084029	001	
	50MG	A083607	002	
	100MG	A085098	001	
INWOOD LABS	25MG	A084776	001	
	25MG	A085067	001	
	50MG	A084776	002	
IVAX SUB TEVA PHARMS	50MG	A084658	001	
	100MG	A085022	001	
JUBILANT CADISTA	25MG	A040809	001	Sep 04, 2007
	50MG	A040809	002	Sep 04, 2007
LANNETT CO INC	25MG	A084325	001	
	50MG	A084324	001	
MAST MM	25MG	A086192	001	
	50MG	A086192	002	
MYLAN	25MG	A084880	001	
	50MG	A085112	001	
MYLAN PHARMS INC	12.5MG	A040770	001	Jan 23, 2007
	25MG	A040735	002	Jan 23, 2007
	50MG	A040735	003	Jan 23, 2007
PVT FORM	50MG	A086597	001	
ROXANE	25MG	A085004	001	
	50MG	A084536	002	
	50MG	A085005	001	
SOLVAY	25MG	A085323	001	
SUN PHARM INDS INC	12.5MG	A040857	001	May 30, 2008
	25MG	A040810	001	Mar 27, 2007
	50MG	A040810	002	Mar 27, 2007
SUN PHARM INDUSTRIES	25MG	A083972	001	
	50MG	A083972	002	
	100MG	A083972	003	
SUPERPHARM	25MG	A088827	001	Dec 28, 1984
	50MG	A088828	001	Dec 28, 1984
	100MG	A088829	001	Dec 28, 1984
TEVA	25MG	A088924	001	Feb 07, 1985
	50MG	A088923	001	Feb 07, 1985
USL PHARMA	25MG	A087827	001	Apr 19, 1982
	50MG	A087752	001	Apr 19, 1982
VANGARD	25MG	A087638	001	
	50MG	A087610	001	
WARNER CHILCOTT	25MG	A087586	001	May 03, 1982
	50MG	A087587	001	May 03, 1982
WATSON LABS	25MG	A081189	001	Jan 24, 1992
	25MG	A083458	001	
	25MG	A085232	002	
	50MG	A083456	001	
	50MG	A085233	001	
	50MG	A086087	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

	50MG	A086594	001	
	100MG	A081190	001	Jan 24, 1992
	100MG	A085099	001	
	100MG	A087002	001	
WATSON LABS TEVA	50MG	A083232	001	
WEST WARD	25MG	A084899	001	
WHITEWORTH TOWN PLSN	25MG	A083809	002	
	50MG	A083809	001	
	100MG	A085347	001	
YAOPHARMA CO LTD	25MG	A087565	001	Mar 09, 1982
	50MG	A084912	001	
HYDRODIURIL				
+ MERCK	25MG **	N011835	003	
+	50MG **	N011835	006	
+	100MG **	N011835	007	
ORETIC				
ABBVIE	25MG	N011971	001	
	50MG	N011971	002	
ZIDE				
SOLVAY	50MG	A083925	001	

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVALIDE

+ SANOFI AVENTIS US	12.5MG; 75MG **	N020758	001	Sep 30, 1997
+	25MG; 300MG **	N020758	004	Mar 15, 2005

IRBESARTAN AND HYDROCHLOROTHIAZIDE

APOTEX INC	12.5MG; 150MG	A201505	001	Oct 15, 2012
	12.5MG; 300MG	A201505	002	Oct 15, 2012
ATLAS PHARMS LLC	12.5MG; 150MG	A203036	001	Jan 15, 2016
	12.5MG; 300MG	A203036	002	Jan 15, 2016
	25MG; 300MG	A203036	003	Jan 15, 2016
MYLAN PHARMS INC	12.5MG; 150MG	A077969	001	Sep 27, 2012
	12.5MG; 300MG	A077969	002	Sep 27, 2012
	25MG; 300MG	A077969	003	Jul 20, 2016
TEVA	25MG; 300MG	A077369	003	Mar 30, 2012
UNICHEM	12.5MG; 150MG	A207018	001	Sep 19, 2017
	12.5MG; 300MG	A207018	002	Sep 19, 2017
WATSON LABS INC	12.5MG; 150MG	A091539	001	Oct 22, 2012
	12.5MG; 300MG	A091539	002	Oct 22, 2012

HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE

TABLET; ORAL

NORMOZIDE

SCHERING	25MG; 100MG	N019046	001	Apr 06, 1987
	25MG; 200MG	N019046	002	Apr 06, 1987
	25MG; 300MG	N019046	003	Apr 06, 1987
	25MG; 400MG	N019046	004	Apr 06, 1987
TRANDATE HCT				
GLAXOSMITHKLINE	25MG; 100MG	N019174	001	Apr 10, 1987
	25MG; 200MG	N019174	002	Apr 10, 1987
	25MG; 300MG	N019174	003	Apr 10, 1987
	25MG; 400MG	N019174	004	Apr 10, 1987

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

COREPHARMA	12.5MG; 10MG	A076674	001	Oct 05, 2004
	12.5MG; 20MG	A076674	002	Oct 05, 2004
	25MG; 20MG	A076674	003	Oct 05, 2004
HERITAGE PHARMA	12.5MG; 10MG	A075776	001	Jul 01, 2002
	12.5MG; 20MG	A075776	002	Jul 01, 2002
	25MG; 20MG	A075776	003	Jul 01, 2002
HIKMA INTL PHARMS	12.5MG; 10MG	A076265	001	Jul 08, 2002
	12.5MG; 20MG	A076265	002	Jul 08, 2002
	25MG; 20MG	A076265	003	Jul 08, 2002
MYLAN	12.5MG; 10MG	A076113	001	Jul 01, 2002
	12.5MG; 20MG	A076113	002	Jul 01, 2002

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

		25MG; 20MG	A076113	003	Jul 01, 2002
SANDOZ		12.5MG; 10MG	A075926	001	Jul 01, 2002
		12.5MG; 20MG	A075926	002	Jul 01, 2002
		25MG; 20MG	A075926	003	Jul 01, 2002
TEVA		12.5MG; 10MG	A075869	001	Jul 01, 2002
		12.5MG; 20MG	A075869	002	Jul 01, 2002
		25MG; 20MG	A075869	003	Jul 01, 2002
PRINZIDE					
+	MERCK	12.5MG; 10MG **	N019778	003	Nov 18, 1993
+		12.5MG; 20MG **	N019778	001	Feb 16, 1989
+		25MG; 20MG **	N019778	002	Feb 16, 1989

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

HYZAAR

+	ORGANON	12.5MG; 50MG	N020387	001	Apr 28, 1995
+		25MG; 100MG	N020387	002	Nov 10, 1998

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

APOTEX		12.5MG; 50MG	A090150	001	Oct 06, 2010
		12.5MG; 100MG	A090150	002	Aug 11, 2010
		25MG; 100MG	A090150	003	Oct 06, 2010
HIKMA		12.5MG; 50MG	A077732	002	Oct 06, 2010
		12.5MG; 100MG	A077732	001	Apr 06, 2010
		25MG; 100MG	A077732	003	Oct 06, 2010
MYLAN		12.5MG; 50MG	A091652	001	Oct 06, 2010
		12.5MG; 100MG	A091652	002	Apr 06, 2010
		25MG; 100MG	A091652	003	Oct 06, 2010
UNICHEM		12.5MG; 50MG	A204832	001	Jul 21, 2017
		12.5MG; 100MG	A204832	002	Jul 21, 2017
		25MG; 100MG	A204832	003	Jul 21, 2017
WATSON LABS		12.5MG; 50MG	A200180	001	Jan 12, 2011
		12.5MG; 100MG	A200180	002	Jan 12, 2011
		25MG; 100MG	A200180	003	Jan 12, 2011

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

ALDORIL 15

	MERCK	15MG; 250MG	N013402	001	
--	-------	-------------	---------	-----	--

ALDORIL 25

	MERCK	25MG; 250MG	N013402	002	
--	-------	-------------	---------	-----	--

ALDORIL D30

	MERCK	30MG; 500MG	N013402	003	
--	-------	-------------	---------	-----	--

ALDORIL D50

	MERCK	50MG; 500MG	N013402	004	
--	-------	-------------	---------	-----	--

METHYLDOPA AND HYDROCHLOROTHIAZIDE

DAVA PHARMS INC		15MG; 250MG	A072507	001	Jun 02, 1989
		25MG; 250MG	A072508	001	Jun 02, 1989
		30MG; 500MG	A072509	001	Jun 02, 1989
		50MG; 500MG	A072510	001	Jun 02, 1989
IVAX SUB TEVA PHARMS		15MG; 250MG	A071458	001	Mar 08, 1988
		25MG; 250MG	A071459	001	Mar 08, 1988
		30MG; 500MG	A071460	001	Mar 08, 1988
		50MG; 500MG	A071461	001	Mar 08, 1988
PAR PHARM		15MG; 250MG	A070616	001	Feb 02, 1987
		25MG; 250MG	A070612	001	Feb 02, 1987
		30MG; 500MG	A070613	001	Feb 02, 1987
		50MG; 500MG	A070614	001	Feb 02, 1987
PARKE DAVIS		15MG; 250MG	A071897	001	Nov 23, 1987
		25MG; 250MG	A071898	001	Nov 23, 1987
		30MG; 500MG	A071899	001	Nov 23, 1987
		50MG; 500MG	A071900	001	Nov 23, 1987
PUREPAC PHARM		15MG; 250MG	A070853	001	Oct 08, 1986
		25MG; 250MG	A070688	001	Apr 24, 1986
		30MG; 500MG	A070854	001	Oct 08, 1986
		50MG; 500MG	A070689	001	Apr 24, 1986
SANDOZ		15MG; 250MG	A070829	001	Mar 09, 1987
		25MG; 250MG	A070830	001	Mar 09, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

TEVA	15MG; 250MG	A071819	001	Apr 08, 1988	
	25MG; 250MG	A071820	001	Apr 08, 1988	
	30MG; 500MG	A071821	001	Apr 08, 1988	
	50MG; 500MG	A071822	001	Apr 08, 1988	
	15MG; 250MG	A070365	001	Mar 19, 1986	
WATSON LABS	15MG; 250MG	A070958	001	Feb 06, 1989	
	15MG; 250MG	A071920	001	Aug 29, 1988	
	25MG; 250MG	A070366	001	Apr 16, 1986	
	25MG; 250MG	A070959	001	Jan 19, 1989	
	25MG; 250MG	A071921	001	Aug 29, 1988	
	30MG; 500MG	A070367	001	Mar 19, 1986	
	30MG; 500MG	A071069	001	Jan 19, 1989	
	30MG; 500MG	A071922	001	Aug 29, 1988	
	50MG; 500MG	A070368	001	Apr 16, 1986	
	50MG; 500MG	A070960	001	Feb 06, 1989	
	50MG; 500MG	A071923	001	Aug 29, 1988	
	YAOPHARMA CO LTD	15MG; 250MG	A070182	001	Jan 15, 1986
		25MG; 250MG	A070183	001	Jan 15, 1986
		30MG; 500MG	A070543	001	Jan 15, 1986
		50MG; 500MG	A070544	001	Jan 15, 1986

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

LOPRESSOR HCT

+	US PHARMS HOLDINGS I	25MG; 100MG	N018303	002	Dec 31, 1984
+		50MG; 100MG **	N018303	003	Dec 31, 1984

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

CHARTWELL RX	12.5MG; 7.5MG	A090096	001	Sep 25, 2008
	12.5MG; 15MG	A090096	002	Sep 25, 2008
	25MG; 15MG	A090096	003	Sep 25, 2008
HERITAGE PHARMS INC	12.5MG; 7.5MG	A202150	001	Mar 07, 2014
	12.5MG; 15MG	A202150	002	Mar 07, 2014
	25MG; 15MG	A202150	003	Mar 07, 2014
UNIRETIC UCB INC	12.5MG; 7.5MG **	N020729	001	Jun 27, 1997
	12.5MG; 15MG **	N020729	003	Feb 14, 2002
	25MG; 15MG **	N020729	002	Jun 27, 1997

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

MYLAN	12.5MG; 20MG	A078827	001	Oct 26, 2016
	12.5MG; 40MG	A078827	002	Oct 26, 2016
	25MG; 40MG	A078827	003	Oct 26, 2016
TEVA PHARMS USA	12.5MG; 20MG	A200532	001	Apr 24, 2017
	25MG; 40MG	A200532	003	Apr 24, 2017

HYDROCHLOROTHIAZIDE; PINDOLOL

TABLET; ORAL

VISKAZIDE

NOVARTIS	25MG; 5MG	N018872	001	Jul 22, 1987
	25MG; 10MG	N018872	002	Jul 22, 1987

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

INDERIDE LA 120/50

WYETH AYERST	50MG; 120MG	N019059	002	Jul 03, 1985
INDERIDE LA 160/50 WYETH AYERST	50MG; 160MG	N019059	003	Jul 03, 1985
	50MG; 80MG	N019059	001	Jul 03, 1985

TABLET; ORAL

INDERIDE-40/25

+	WYETH PHARMS INC	25MG; 40MG **	N018031	001
---	------------------	---------------	---------	-----

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

INDERIDE-80/25

+	WYETH PHARMS INC	25MG;80MG **	N018031	002	
PROPRANOLOL HYDROCHLORIDE & HYDROCHLOROTHIAZIDE					
	DURAMED PHARMS BARR	25MG;40MG	A071126	001	Mar 02, 1987
		25MG;80MG	A071127	001	Mar 02, 1987
PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE					
	ACTAVIS ELIZABETH	25MG;40MG	A070851	001	May 15, 1986
		25MG;80MG	A070852	001	May 15, 1986
	ANI PHARMS INC	25MG;40MG	A070704	001	Oct 01, 1986
		25MG;40MG	A072043	002	Mar 14, 1988
		25MG;80MG	A070705	001	Oct 01, 1986
		25MG;80MG	A072043	001	Mar 14, 1988
	IVAX SUB TEVA PHARMS	25MG;40MG	A071552	001	Dec 01, 1988
		25MG;80MG	A071553	001	Dec 01, 1988
	WARNER CHILCOTT	25MG;40MG	A071771	001	Jan 26, 1988
		25MG;80MG	A071772	001	Jan 26, 1988
	WATSON LABS	25MG;40MG	A070301	001	Apr 18, 1986
		25MG;40MG	A071498	001	Dec 18, 1991
		25MG;80MG	A070305	001	Apr 18, 1986
		25MG;80MG	A071501	001	Dec 18, 1991
	YAOPHARMA CO LTD	25MG;40MG	A071060	001	Aug 26, 1987
		25MG;80MG	A071061	001	Aug 26, 1987

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

	MYLAN	12.5MG;EQ 10MG BASE	A077093	001	Mar 28, 2005
		12.5MG;EQ 20MG BASE	A077093	002	Mar 28, 2005
		25MG;EQ 20MG BASE	A077093	003	Mar 28, 2005
	SUN PHARM INDS LTD	12.5MG;EQ 10MG BASE	A078211	001	Mar 04, 2009
		12.5MG;EQ 20MG BASE	A078211	002	Mar 04, 2009
		25MG;EQ 20MG BASE	A078211	003	Mar 04, 2009

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

H.R.-50

	WHITEWORTH TOWN PLSN	50MG;0.125MG	A085338	001	
HYDRO-RESERP					
	ABC HOLDING	50MG;0.125MG	A084714	002	Jun 29, 1982
HYDRO-SERP "25"					
	SANDOZ	25MG;0.125MG	A084827	001	
HYDRO-SERP "50"					
	SANDOZ	50MG;0.125MG	A085213	001	
HYDROCHLOROTHIAZIDE W/ RESERPINE					
	IVAX SUB TEVA PHARMS	25MG;0.1MG	A083572	001	
		25MG;0.125MG	A083571	001	
		50MG;0.1MG	A083568	001	
		50MG;0.125MG	A083573	001	
	PHARMERAL	25MG;0.125MG	A085421	001	
		50MG;0.125MG	A085420	001	
	ROXANE	50MG;0.125MG	A084603	001	
	WATSON LABS	25MG;0.125MG	A084466	001	
		25MG;0.125MG	A085317	001	
		25MG;0.125MG	A086330	002	
		50MG;0.125MG	A083666	001	
		50MG;0.125MG	A084467	001	
		50MG;0.125MG	A086331	001	
HYDROPRES 25					
	MERCK	25MG;0.125MG	N011958	002	
HYDROPRES 50					
	MERCK	50MG;0.125MG	N011958	003	
RESERPINE AND HYDROCHLOROTHIAZIDE					
	BARR	25MG;0.125MG	A084580	001	
		50MG;0.125MG	A084579	001	
	SANDOZ	50MG;0.125MG	A088200	001	Jan 31, 1984
RESERPINE AND HYDROCHLOROTHIAZIDE-50					
	WEST WARD	50MG;0.125MG	A088189	001	May 10, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

SERPASIL-ESIDRIX #1				
NOVARTIS	25MG; 0.1MG		N011878	003
SERPASIL-ESIDRIX #2				
NOVARTIS	50MG; 0.1MG		N011878	005

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

ASCOT	25MG; 25MG		A088025	001	Nov 23, 1984
MUTUAL PHARM	25MG; 25MG		A087267	001	
PUREPAC PHARM	25MG; 25MG		A087999	001	Nov 06, 1985
SUPERPHARM	25MG; 25MG		A089137	001	Aug 26, 1985
WATSON LABS	25MG; 25MG		A087398	001	
YAOPHARMA CO LTD	25MG; 25MG		A086881	001	

SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE

IVAX PHARMS	25MG; 25MG		A087004	002	May 24, 1982
LEDERLE	25MG; 25MG		A087511	001	
PARKE DAVIS	25MG; 25MG		A087948	001	Feb 22, 1983
PUREPAC PHARM	25MG; 25MG		A088054	001	Aug 18, 1983
UPSHER SMITH	25MG; 25MG		A087553	001	
USL PHARMA	25MG; 25MG		A087651	001	
VANGARD	25MG; 25MG		A087655	001	
WATSON LABS	25MG; 25MG		A085974	001	
	25MG; 25MG		A086026	001	

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL

TELMISARTAN AND HYDROCHLOROTHIAZIDE

MACLEODS PHARMS LTD	12.5MG; 40MG		A204169	001	Nov 02, 2015
	12.5MG; 80MG		A204169	002	Nov 02, 2015
	25MG; 80MG		A204169	003	Nov 02, 2015
MYLAN	12.5MG; 40MG		A091648	001	Feb 25, 2014
	12.5MG; 80MG		A091648	002	Feb 25, 2014
	25MG; 80MG		A091648	003	Feb 25, 2014

HYDROCHLOROTHIAZIDE; TIMOLOL MALEATE

TABLET; ORAL

TIMOLIDE 10-25

MERCK	25MG; 10MG		N018061	001	
-------	------------	--	---------	-----	--

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

DYAZIDE

+ GLAXOSMITHKLINE LLC	25MG; 37.5MG		N016042	003	Mar 03, 1994
	25MG; 50MG		N016042	002	

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

ANI PHARMS INC	25MG; 37.5MG		A074970	001	Jan 06, 1998
	25MG; 50MG		A074259	001	Mar 30, 1995
CHARTWELL RX	25MG; 50MG		A073191	001	Jul 31, 1991
DURAMED PHARMS BARR	25MG; 37.5MG		A075052	001	Jun 18, 1999
NOVARTIS	25MG; 37.5MG		A074857	001	Sep 09, 1997
VITARINE	25MG; 50MG		A071737	001	Feb 12, 1988

TABLET; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AM THERAP	50MG; 75MG		A072022	001	Apr 17, 1988
ANI PHARMS INC	50MG; 75MG		A073467	001	Jan 31, 1996
PLIVA	25MG; 37.5MG		A074026	001	Apr 26, 1996
QUANTUM PHARMICS	50MG; 75MG		A071980	001	Apr 17, 1988
WATSON LABS	50MG; 75MG		A071969	001	Apr 17, 1988

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

APOTEX INC	12.5MG; 80MG		A203026	001	Mar 21, 2013
	12.5MG; 160MG		A203026	002	Mar 21, 2013
	12.5MG; 320MG		A203026	003	Mar 21, 2013
	25MG; 160MG		A203026	004	Mar 21, 2013
	25MG; 320MG		A203026	005	Mar 21, 2013
WATSON LABS TEVA	12.5MG; 80MG		A091519	001	Mar 21, 2013
	12.5MG; 160MG		A091519	002	Mar 21, 2013

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

	12.5MG; 320MG	A091519 003	Mar 21, 2013
	25MG; 160MG	A091519 004	Mar 21, 2013
	25MG; 320MG	A091519 005	Mar 21, 2013
ZYDUS PHARMS	12.5MG; 80MG	A203000 001	Mar 15, 2019
	12.5MG; 160MG	A203000 002	Mar 15, 2019
	12.5MG; 320MG	A203000 003	Mar 15, 2019
	25MG; 160MG	A203000 004	Mar 15, 2019
	25MG; 320MG	A203000 005	Mar 15, 2019

HYDROCODONE BITARTRATE

TABLET, EXTENDED RELEASE; ORAL

VANTRELA ER

+	TEVA BRANDED PHARM	15MG	N207975 001	Jan 17, 2017
+		30MG	N207975 002	Jan 17, 2017
+		45MG	N207975 003	Jan 17, 2017
+		60MG	N207975 004	Jan 17, 2017
+		90MG	N207975 005	Jan 17, 2017

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

	ANI PHARMS INC	5MG; 200MG	A077454 001	Jun 23, 2010
	SUN PHARM INDS INC	2.5MG; 200MG	A091633 001	May 28, 2013
		5MG; 200MG	A091633 002	May 28, 2013
		7.5MG; 200MG	A091633 003	May 28, 2013
		10MG; 200MG	A091633 004	May 28, 2013
	TEVA	7.5MG; 200MG	A076023 001	Apr 11, 2003
	VICOPROFEN			
+	ABBVIE	7.5MG; 200MG	N020716 001	Sep 23, 1997

HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP; ORAL

CODAMINE

	ALPHARMA US PHARMS	5MG/5ML; 25MG/5ML	A075103 001	Sep 29, 2000
--	--------------------	-------------------	-------------	--------------

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

	MAYNE PHARMA INC	5MG/5ML; 60MG/5ML	A205658 001	Nov 17, 2015
	PADDOCK LABS LLC	5MG/5ML; 60MG/5ML	A204658 001	Apr 29, 2014
	TORRENT	5MG/5ML; 60MG/5ML	A206661 001	Jan 23, 2019
	TRIS PHARMA INC	5MG/5ML; 60MG/5ML	A203839 001	Oct 28, 2014
	REZIRA			
+	PERSION	5MG/5ML; 60MG/5ML	N022442 001	Jun 08, 2011

HYDROCORTAMATE HYDROCHLORIDE

OINTMENT; TOPICAL

MAGNACORT

	PFIZER	0.5%	N010554 001	
--	--------	------	-------------	--

HYDROCORTISONE

AEROSOL; TOPICAL

AEROSEB-HC

	ALLERGAN HERBERT	0.5%	A085805 001	
--	------------------	------	-------------	--

CREAM; TOPICAL

CORT-DOME

	BAYER PHARMS	0.5%	N009585 003	
		1%	N009585 001	

DERMACORT

	MONARCH PHARMS	1%	A083011 002	
--	----------------	----	-------------	--

ELDECORT

	VALEANT PHARM INTL	1%	A080459 001	
		2.5%	A084055 001	

FLEXICORT

	WESTWOOD SQUIBB	0.5%	A087136 003	Apr 08, 1982
		1%	A087136 002	Apr 08, 1982
		2.5%	A087136 001	Apr 08, 1982

H-CORT

	PHARM ASSOC	0.5%	A086823 001	
--	-------------	------	-------------	--

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROCORTISONE

CREAM;TOPICAL

HC #1				
	BAYER PHARMS	0.5%	A080438 001	
HC #4				
	BAYER PHARMS	1%	A080438 002	
HC (HYDROCORTISONE)				
	C AND M PHARMA	0.5%	A080482 003	
		1%	A080482 004	
HI-COR				
	C AND M PHARMA	2.5%	A080483 001	
HYDROCORTISONE				
	ALPHARMA US PHARMS	2.5%	A089754 001	Feb 01, 1989
	ALTANA	0.5%	A080848 002	
		1%	A080848 003	
	AMBIX	1%	A086080 001	
		2.5%	A086271 001	
	EVERYLIFE	0.5%	A080452 001	
		1%	A080452 002	
	G AND W LABS	1%	A084059 001	
	INGRAM PHARM	0.5%	A080456 002	
		1%	A080456 003	
	IVAX PHARMS	1%	A085733 001	
	NASKA	1%	A089706 001	Mar 10, 1988
	PERRIGO NEW YORK	0.5%	A084970 002	
		1%	A085026 001	
	PHARMADERM	1%	A088845 001	Feb 27, 1986
		2.5%	A089413 001	Dec 16, 1986
	PHARMAFAIR	1%	A087838 001	Jul 28, 1982
	STIEFEL	1%	A086170 001	
	SYOSSET	0.5%	A085527 001	
	TARO	0.5%	A086154 001	
	TARO PHARM INDS LTD	1%	A086155 001	
	TELAGENT	2.5%	A203810 001	Jul 23, 2018
	TEVA	0.5%	A080400 002	
		1%	A080400 003	
		1%	A085191 001	
		2.5%	A080400 004	
	TOPIDERM	1%	A089273 001	Feb 17, 1989
	USL PHARMA	1%	A088027 001	Sep 27, 1983
		2.5%	A088029 001	Sep 27, 1983
	WHITEWORTH TOWN PLSN	1%	A080496 002	
HYTONE				
	VALEANT INTL	1% **	A080472 003	
		2.5% **	A080472 004	
NOGENIC HC				
	IVAX PHARMS	1%	A087427 001	Apr 04, 1988
NUTRACORT				
	BAUSCH	0.5%	A080442 002	
		1%	A080442 003	
PENECORT				
	ALLERGAN HERBERT	1%	A088216 001	Jun 06, 1984
PROTOCORT				
	MONARCH PHARMS	1%	A083011 001	
SYNACORT				
	MEDICIS	0.5%	A087459 001	
		1%	A087458 001	
		2.5%	A087457 001	
ENEMA;RECTAL				
HYDROCORTISONE				
	TEVA PHARMS	100MG/60ML	A074171 001	May 27, 1994
GEL;TOPICAL				
NUTRACORT				
	HEALTHPOINT	1%	A084698 001	
PENECORT				
	ALLERGAN HERBERT	1%	A088215 001	Jun 06, 1984
INJECTABLE;INJECTION				
CORTEF				
	PHARMACIA AND UPJOHN	50MG/ML	N009864 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROCORTISONE

LOTION; TOPICAL

ACTICORT

BAKER NORTON 1% A086535 001

ALA-CORT

CROWN LABS 1% A083201 001

BALNEOL-HC

SOLVAY 1% A088041 001 Dec 03, 1982

BETA-HC

BETA DERMAC 1% A089495 001 Jan 25, 1988

CETACORT

BAUSCH 0.5% A080426 002

1% A080426 001

CORT-DOME

BAYER PHARMS 0.5% N009895 003

1% N009895 001

DERMACORT

SOLVAY 0.5% A084573 002

1% A086462 001

EPICORT

BLULINE 0.5% A083219 002

GLYCORT

HERAN 1% A087489 001 Oct 03, 1983

H-CORT

PHARM ASSOC 0.5% A086824 001

HYDROCORTISONE

ALPHARMA US PHARMS 0.5% A087317 001 Jun 07, 1982

1% A087315 001 Jun 07, 1982

FOUGERA PHARMS 2.5% A040351 001 Jul 25, 2000

MERICON 0.5% A085282 001

1% A085282 002 Feb 26, 1987

NASKA 1% A089705 001 Apr 25, 1988

PERRIGO NEW YORK 0.5% A085662 001

1% A085663 001

TARO 1% A089024 001 Feb 12, 1986

TELIGENT 2.5% A203804 001 Jul 27, 2018

HYTONE

VALEANT INTL 1% ** A080473 003

2.5% ** A080473 004 Nov 30, 1982

NUTRACORT

DOW PHARM 0.5% A080443 002

1% A080443 003

2.5% A087644 001 Aug 24, 1982

STIE-CORT

PERRIGO CO 1% A089066 001 Nov 25, 1985

OINTMENT; TOPICAL

CORTRIL

PFIZER GLOBAL 1% N009176 001

2.5% N009176 002

HC (HYDROCORTISONE)

C AND M PHARMA 0.5% A080481 001

1% A080481 002

HYDROCORTISONE

ACTAVIS MID ATLANTIC 1% A087796 001 Oct 13, 1982

ALTANA 0.5% A080489 002

1% A080489 003

AMBIX 1% A086079 001

2.5% A086272 001

NASKA 1% A089704 001 Mar 10, 1988

PERRIGO NEW YORK 0.5% A084969 003

1% A085028 001

PHARMADERM 1% A088842 001 Feb 09, 1987

TARO 0.5% A086256 001

2.5% A040310 001 Dec 29, 2000

USL PHARMA 1% A088061 001 Sep 27, 1983

2.5% A088039 001 Sep 27, 1983

HYTONE

DERMIK LABS 1% ** A080474 003

2.5% ** A080474 004

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROCORTISONE

OINTMENT; TOPICAL

PENECORT

ALLERGAN HERBERT 2.5% A088217 001 Jun 06, 1984

POWDER; FOR RX COMPOUNDING

H-CORT

TORCH 100% A087834 001 Mar 29, 1982

HYDRO-RX

X GEN PHARMS 100% A085982 001

HYDROCORTISONE

PADDOCK LLC 100% A088082 001 Apr 08, 1983

SOLUTION; TOPICAL

PENECORT

ALLERGAN HERBERT 1% A088214 001 Jun 06, 1984

TEXACORT

MISSION PHARMA 1% A080425 001

TABLET; ORAL

CORTRIL

PFIZER 10MG N009127 005

20MG N009127 003

HYDROCORTISONE

BARR 20MG A083999 001

ELKINS SINN 20MG A080624 001

FERRANTE 10MG A080568 001

20MG A080568 002

HIKMA INTL PHARMS 5MG A083365 002 Feb 23, 2015

10MG A083365 003 Feb 23, 2015

20MG A083365 001

IMPAX LABS 20MG A080781 001

INWOOD LABS 20MG A080732 001

LANNETT 20MG A085070 001

NEXGEN PHARMA INC 20MG A083140 001

PANRAY 10MG N009659 001

20MG N009659 002

PARKE DAVIS 20MG A084243 001

PUREPAC PHARM 10MG A084247 003 Aug 31, 1982

20MG A080395 001

20MG A084247 002

ROXANE 10MG A088539 001 Mar 21, 1984

SANDOZ 20MG A080642 002

VINTAGE 5MG A040761 001 Jul 16, 2007

10MG A040761 002 Jul 16, 2007

20MG A040761 003 Jul 16, 2007

WATSON LABS 20MG A080355 001

WHITEWORTH TOWN PLSN 10MG A080344 001

20MG A080344 002

HYDROCORTONE

MERCK 10MG N008506 007

20MG N008506 011

TABLET; VAGINAL

CORTRIL

PFIPHARMECS 10MG N009796 001

HYDROCORTISONE ACETATE

CREAM; TOPICAL

CARMOL HC

FOUGERA PHARMS 1% A080505 001

HEMSOL-HC

ABLE 1% A081274 001 Jun 19, 1992

HYDROCORTISONE ACETATE

CENCI 1% A080419 001 Jan 25, 1982

IMPERIUM 2.5% A040259 001 Jul 29, 1999

PARKE DAVIS 1% A089914 001 Jan 03, 1989

PUREPAC PHARM 0.5% A086050 001

1% A086052 001

MICORT-HC

SEBELA IRELAND LTD 2% A040398 001 Mar 29, 2002

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROCORTISONE ACETATE

INJECTABLE; INJECTION

CORTEF ACETATE

PHARMACIA AND UPJOHN 50MG/ML N009378 002

CORTRIL

PFIZER 25MG/ML N009164 001

HYDROCORTISONE ACETATE

AKORN 25MG/ML N009637 001

50MG/ML N009637 002

BEL MAR 25MG/ML A083739 001

50MG/ML A083739 002

WATSON LABS 25MG/ML A083128 001

25MG/ML A083759 001

50MG/ML A083759 002

50MG/ML A085214 001

HYDROCORTONE

MERCK 25MG/ML N008228 001

50MG/ML N008228 004

LOTION; TOPICAL

DRICORT

INGRAM PHARM 0.5% A086207 001

OINTMENT; OPHTHALMIC

HYDROCORTISONE ACETATE

FERA PHARMS 0.5% A080828 001

OINTMENT; OPHTHALMIC, OTIC

HYDROCORTONE

MERCK 1.5% N009018 003

OINTMENT; TOPICAL

CORTEF ACETATE

PHARMACIA AND UPJOHN 1% N008917 002

+ 2.5% ** N008917 001

PASTE; TOPICAL

ORABASE HCA

COLGATE 0.5% A083205 001

POWDER; FOR RX COMPOUNDING

HYDROCORTISONE ACETATE

X GEN PHARMS 100% A085981 001

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE

CREAM; TOPICAL

NEO-CORTEF

PHARMACIA AND UPJOHN 1%;EQ 3.5MG BASE/GM A061049 001

2.5%;EQ 3.5MG BASE/GM A061049 002

OINTMENT; OPHTHALMIC

NEO-CORTEF

PHARMACIA AND UPJOHN 0.5%;EQ 3.5MG BASE/GM A060610 001

1.5%;EQ 3.5MG BASE/GM A060610 002

OINTMENT; TOPICAL

NEO-CORTEF

PHARMACIA AND UPJOHN 0.5%;EQ 3.5MG BASE/GM A060751 001

1%;EQ 3.5MG BASE/GM A060751 002

2.5%;EQ 3.5MG BASE/GM A060751 003

SUSPENSION/DROPS; OPHTHALMIC

COR-OTICIN

AKORN 1.5%;EQ 3.5MG BASE/ML A060188 001

NEO-CORTEF

PHARMACIA AND UPJOHN 0.5%;EQ 3.5MG BASE/ML A060612 002

1.5%;EQ 3.5MG BASE/ML A060612 001

HYDROCORTISONE ACETATE; OXYTETRACYCLINE HYDROCHLORIDE

SUSPENSION; OPHTHALMIC

TERRA-CORTRIL

PFIZER 1.5%;EQ 5MG BASE/ML A061016 001

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED; TOPICAL

HYDROCORTISONE ACETATE 1% AND PRAMOXINE HYDROCHLORIDE 1%

GENUS 1%;1% A089440 001 May 17, 1988

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

LOTION; TOPICAL

PRAMOSONE

FERNDALE LABS

0.5%;1%

A083213 002

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL

LOCOID

YAMANOUCHI

0.1%

N018795 001 Jan 07, 1983

OINTMENT; TOPICAL

LOCOID

YAMANOUCHI

0.1%

N019106 001 Jul 03, 1984

SOLUTION; TOPICAL

LOCOID

YAMANOUCHI

0.1%

N019819 001 Sep 15, 1988

HYDROCORTISONE CYPIONATE

SUSPENSION; ORAL

CORTEF

PHARMACIA AND UPJOHN EQ 10MG BASE/5ML

N009900 001

HYDROCORTISONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

HYDROCORTONE

MERCK

EQ 50MG BASE/ML

N012052 001

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-HYDROCORT

ABBOTT

EQ 100MG BASE/VIAL

A085928 001

EQ 100MG BASE/VIAL

A089577 001 Apr 11, 1989

EQ 250MG BASE/VIAL

A089578 001 Apr 11, 1989

EQ 500MG BASE/VIAL

A089579 001 Apr 11, 1989

EQ 1GM BASE/VIAL

A089580 001 Apr 11, 1989

HOSPIRA

EQ 100MG BASE/VIAL

A040666 001 Apr 06, 2006

EQ 100MG BASE/VIAL

A085929 001

EQ 250MG BASE/VIAL

A085930 001

EQ 500MG BASE/VIAL

A085931 001

EQ 1GM BASE/VIAL

A085932 001

HYDROCORTISONE SODIUM SUCCINATE

ABRAXIS PHARM

EQ 100MG BASE/VIAL

A088667 001 Jun 08, 1984

EQ 100MG BASE/VIAL

A088712 001 Jun 08, 1984

EQ 250MG BASE/VIAL

A088668 001 Jun 08, 1984

EQ 500MG BASE/VIAL

A088669 001 Jun 08, 1984

EQ 1GM BASE/VIAL

A088670 001 Jun 08, 1984

BAXTER HLTHCARE

EQ 100MG BASE/VIAL

A086619 001

EQ 250MG BASE/VIAL

A087567 001

EQ 500MG BASE/VIAL

A087568 001

EQ 1GM BASE/VIAL

A087569 001

INTL MEDICATION

EQ 100MG BASE/VIAL

A087532 001 Mar 19, 1982

WATSON LABS

EQ 100MG BASE/VIAL

A084737 002

EQ 100MG BASE/VIAL

A084738 001

EQ 250MG BASE/VIAL

A084737 001

EQ 500MG BASE/VIAL

A084747 001

EQ 1GM BASE/VIAL

A084748 001

HYDROCORTISONE VALERATE

CREAM; TOPICAL

HYDROCORTISONE VALERATE

COSETTE

0.2%

A074489 001 Aug 12, 1998

WESTCORT

+ SUN PHARM INDS INC

0.2% **

N017950 001

OINTMENT; TOPICAL

HYDROCORTISONE VALERATE

FOUGERA PHARMS

0.2%

A075085 001 Jul 31, 2001

WESTCORT

+ SUN PHARM INDS INC

0.2% **

N018726 001 Aug 08, 1983

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROCORTISONE; NEOMYCIN SULFATE

CREAM;TOPICAL

NEO-CORT-DOME

BAYER PHARMS	0.5%;EQ 3.5MG BASE/GM	N050237	006	Jun 05, 1984
	1%;EQ 3.5MG BASE/GM	N050237	005	Jun 05, 1984

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OTIC

CORTISPORIN

+ MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML **	N050479	001	
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE				
AMRING PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A065216	001	Oct 31, 2005
NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE				
PHARMAFAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062394	001	Sep 29, 1982
OTOCORT				
WATSON LABS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A060730	002	

SUSPENSION/DROPS;OPHTHALMIC

CORTISPORIN

MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050169	001	
NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE				
PHARMAFAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062623	001	Sep 24, 1985

SUSPENSION/DROPS;OTIC

NEOMYCIN SULFATE, POLYMYXIN B SULFATE & HYDROCORTISONE

PHARMAFAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062617	001	Sep 18, 1985
OTICAIR				
PHARMAFAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062399	001	Nov 18, 1982
OTOBIONE				
SCHERING	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A061816	001	
OTOCORT				
ACTAVIS LABS FL INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062521	001	Jul 11, 1985
PEDIOTIC				
MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062822	001	Sep 29, 1987

HYDROCORTISONE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OTIC

OTOBiotic

SCHERING	5MG/ML;EQ 10,000 UNITS BASE/ML	A062302	001	
PYOCIDIN				
FOREST LABS	5MG/ML;EQ 10,000 UNITS BASE/ML	A061606	001	

HYDROCORTISONE; TETRACYCLINE HYDROCHLORIDE

OINTMENT;OPHTHALMIC

ACHROMYCIN

LEDERLE	1.5%;1%	N050272	001	
---------	---------	---------	-----	--

HYDROCORTISONE; UREA

CREAM;TOPICAL

ALPHADERM

BIOGLAN	1%;10%	A086008	001	
CALMURID HC				
PHARMACIA AND UPJOHN	1%;10%	A083947	001	

HYDROFLUMETHIAZIDE

TABLET;ORAL

DIUCARDIN

WYETH AYERST	50MG	A083383	001	
HYDROFLUMETHIAZIDE				
PAR PHARM	50MG	A088850	001	May 31, 1985
WATSON LABS	50MG	A088031	001	Apr 06, 1983
	50MG	A088528	001	Aug 15, 1984

SALURON

+ SHIRE LLC	50MG	N011949	001	
-------------	------	---------	-----	--

HYDROFLUMETHIAZIDE; RESERPINE

TABLET;ORAL

HYDROFLUMETHIAZIDE AND RESERPINE

USL PHARMA	50MG;0.125MG	A088195	001	Oct 26, 1983
WATSON LABS	25MG;0.125MG	A088127	001	Mar 22, 1983
	50MG;0.125MG	A088110	001	Mar 22, 1983
RESERPINE AND HYDROFLUMETHIAZIDE				
IVAX PHARMS	50MG;0.125MG	A088932	001	Jan 11, 1985
PAR PHARM	50MG;0.125MG	A088907	001	Sep 20, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROFLUMETHIAZIDE; RESERPINE

TABLET; ORAL

SALUTENSIN

SHIRE

50MG; 0.125MG

N012359 003

SALUTENSIN-DEMI

SHIRE

25MG; 0.125MG

N012359 004

HYDROGEN PEROXIDE

SOLUTION; TOPICAL

ESKATA

+ ACLARIS

40%

N209305 001 Dec 14, 2017

HYDROMORPHONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PALLADONE

PURDUE PHARMA LP

12MG

N021044 001 Sep 24, 2004

16MG

N021044 002 Sep 24, 2004

24MG

N021044 003 Sep 24, 2004

32MG

N021044 004 Sep 24, 2004

INJECTABLE; INJECTION

DILAUDID

+ FRESENIUS KABI USA

4MG/ML

N019034 005 Apr 30, 2009

DILAUDID-HP

+ FRESENIUS KABI USA

10MG/ML

N019034 001 Jan 11, 1984

250MG/VIAL

N019034 002 Aug 04, 1994

HYDROMORPHONE HYDROCHLORIDE

BARR

10MG/ML

A076444 001 Apr 25, 2003

HOSPIRA

10MG/ML

A074598 001 Jun 19, 1997

WATSON LABS

10MG/ML

A074317 001 Aug 23, 1995

SOLUTION; ORAL

HYDROMORPHONE HYDROCHLORIDE

LANNETT CO INC

5MG/5ML

A207108 001 Apr 22, 2020

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

NESHER PHARMS

2MG

A077311 001 Nov 09, 2005

4MG

A077311 002 Nov 09, 2005

8MG

A077311 003 Nov 09, 2005

NOSTRUM LABS INC

8MG

A076723 001 Oct 18, 2005

TABLET, EXTENDED RELEASE; ORAL

EXALGO

+ SPECGX LLC

8MG

N021217 001 Mar 01, 2010

+

12MG

N021217 002 Mar 01, 2010

+

16MG

N021217 003 Mar 01, 2010

+

32MG

N021217 004 Aug 24, 2012

HYDROMORPHONE HYDROCHLORIDE

ACTAVIS LABS FL INC

8MG

A202144 001 May 12, 2014

12MG

A202144 002 May 12, 2014

16MG

A202144 003 May 12, 2014

32MG

A202144 004 Jun 30, 2016

HYDROXOCOBALAMIN

INJECTABLE; INJECTION

ALPHAREDISOL

MERCK

1MG/ML

A080778 001

CYANOKIT

SERB SA

2.5GM/VIAL (5GM/KIT)

N022041 002 Dec 15, 2006

HYDROXOCOBALAMIN

ABRAXIS PHARM

1MG/ML

A084921 001

WATSON LABS

1MG/ML

A085528 001

HYDROXOMIN

BEL MAR

1MG/ML

A084629 001

HYDROXYAMPHETAMINE HYDROBROMIDE

SOLUTION/DROPS; OPHTHALMIC

PAREDRINE

PHARMICS

1%

N000004 004

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

HIKMA PHARMS	200MG	A040760	001	Aug 15, 2007
INVATECH	200MG	A040150	001	Jan 27, 1996

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION

HYDROXYPROGESTERONE CAPROATE

AKORN	125MG/ML	N018004	001	
ALLERGAN	125MG/ML	N017439	001	
	250MG/ML	N017439	002	

SOLUTION; INTRAMUSCULAR

DELALUTIN

+	BRISTOL MYERS SQUIBB	125MG/ML (125MG/ML)	**	N010347	004
+		125MG/ML (125MG/ML)	**	N016911	001
+		250MG/ML (250MG/ML)	**	N010347	002
+		250MG/ML (250MG/ML)	**	N016911	002

HYDROXYPROGESTERONE CAPROATE

AM REGENT	1250MG/5ML (250MG/ML)	A210724	001	Aug 09, 2019
EUGIA PHARMA	1250MG/5ML (250MG/ML)	A211142	001	May 09, 2019

HYDROXYSTILBAMIDINE ISETHIONATE

INJECTABLE; INJECTION

HYDROXYSTILBAMIDINE ISETHIONATE

SANOFI AVENTIS US	225MG/AMP	N009166	001	
-------------------	-----------	---------	-----	--

HYDROXYUREA

CAPSULE; ORAL

HYDROXYUREA

BARR	250MG	A075143	002	Sep 21, 2000
BARR LABS INC	250MG	A075020	002	Jun 26, 2000
	500MG	A075020	001	Jul 30, 1998
ROXANE	500MG	A074476	001	Aug 18, 1995

TABLET; ORAL

HYDROXYUREA

BARR	1GM	A075734	001	Aug 29, 2000
------	-----	---------	-----	--------------

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE

BAXTER HLTHCARE	50MG/ML	A085551	002	
-----------------	---------	---------	-----	--

HYDROXYZINE HYDROCHLORIDE

ALTANA	25MG/ML	A087273	001	Apr 20, 1982
	50MG/ML	A087273	002	Apr 20, 1982
BAXTER HLTHCARE	25MG/ML	A085551	001	
DR REDDYS	50MG/ML	A085779	001	
FRESENIUS KABI USA	25MG/ML	A087329	001	
	25MG/ML	A088184	001	Mar 31, 1983
	50MG/ML	A087329	002	
	50MG/ML	A088185	001	Mar 31, 1983
HOSPIRA	25MG/ML	A087416	001	
	50MG/ML	A086821	001	
	50MG/ML	A087546	001	
PHARMAFAIR	25MG/ML	A088862	001	Feb 14, 1986
	25MG/ML	A089106	001	Feb 14, 1986
	50MG/ML	A088881	001	Feb 14, 1986
	50MG/ML	A089107	001	Feb 14, 1986
SMITH AND NEPHEW	25MG/ML	A087592	001	
SOLOPAK	25MG/ML	A086822	001	
	25MG/ML	A087591	001	
	50MG/ML	A087310	001	
	50MG/ML	A087593	001	
	50MG/ML	A087595	001	
	50MG/ML	A087596	001	
WATSON LABS	25MG/ML	A085778	001	
	25MG/ML	A087274	001	
	50MG/ML	A087274	002	
WYETH AYERST	25MG/ML	A086258	001	
	50MG/ML	A086258	002	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

ORGATRA

ORGANON USA INC	25MG/ML	A087014	001	
	50MG/ML	A087014	002	

VISTARIL

+ PFIZER	25MG/ML **	N011111	001	
+	50MG/ML **	N011111	002	

SYRUP; ORAL

ATARAX

ROERIG	10MG/5ML **	N010485	001	
--------	-------------	---------	-----	--

HYDROXYZINE HYDROCHLORIDE

ALPHARMA US PHARMS	10MG/5ML	A088785	001	Feb 03, 1988
ANIMA	10MG/5ML	A086880	001	
KV PHARM	10MG/5ML	A087730	001	Jul 01, 1982
TORRENT	10MG/5ML	A210634	001	Feb 26, 2019
VINTAGE PHARMS	10MG/5ML	A040391	001	Apr 10, 2002

TABLET; ORAL

ATARAX

+ PFIZER	10MG **	N010392	001	
+	25MG **	N010392	004	
+	50MG **	N010392	006	
+	100MG **	N010392	005	

HYDROXYZINE HYDROCHLORIDE

ABLE	10MG	A040559	001	Jul 22, 2004
	25MG	A040562	001	Jul 22, 2004
	50MG	A040563	001	Jul 22, 2004
ACTAVIS ELIZABETH	10MG	A089071	001	Jul 22, 1986
	25MG	A089072	001	Jul 22, 1986
	50MG	A089073	001	Jul 22, 1986
AUROBINDO PHARMA LTD	10MG	A087871	002	Dec 20, 1982
	25MG	A087871	003	Dec 20, 1982
	50MG	A087871	001	Dec 20, 1982
HALSEY	10MG	A089366	001	May 02, 1988
	25MG	A089117	001	May 02, 1988
	50MG	A089396	001	May 02, 1988
IVAX PHARMS	10MG	A087216	001	
	25MG	A087410	001	
	50MG	A087411	001	
KV PHARM	10MG	A087819	001	Jun 23, 1982
	25MG	A087820	001	Jun 23, 1982
	50MG	A087821	001	Jun 23, 1982
	100MG	A087822	001	Jun 23, 1982
MUTUAL PHARM	10MG	A088409	001	Nov 15, 1983
	25MG	A087857	001	Apr 18, 1983
	50MG	A087860	001	Apr 18, 1983
MYLAN	10MG	A091176	001	Jun 07, 2010
	25MG	A091176	002	Jun 07, 2010
	50MG	A091176	003	Jun 07, 2010
PLIVA	100MG	A081054	001	Sep 25, 1995
PUREPAC PHARM	10MG	A088120	001	Sep 25, 1984
	25MG	A088121	001	Sep 25, 1984
	50MG	A088122	001	Sep 25, 1984
QUANTUM PHARMICS	10MG	A088540	001	Oct 22, 1985
	25MG	A088551	001	Oct 22, 1985
	50MG	A088529	001	Oct 22, 1985
SANDOZ	10MG	A087246	002	
	25MG	A085247	001	
	50MG	A087245	001	
SUN PHARM INDS INC	10MG	A040899	001	Jun 10, 2008
	25MG	A040899	002	Jun 10, 2008
	50MG	A040899	003	Jun 10, 2008
SUN PHARM INDUSTRIES	10MG	A089381	001	May 19, 1986
	25MG	A089382	001	May 19, 1986
	50MG	A089383	001	May 19, 1986
	100MG	A087862	001	Apr 18, 1983
SUPERPHARM	10MG	A088794	001	Dec 05, 1984
	25MG	A088795	001	Dec 05, 1984
	50MG	A088796	001	Dec 05, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROXYZINE HYDROCHLORIDE

TABLET;ORAL

HYDROXYZINE HYDROCHLORIDE

USL PHARMA	10MG	A089121	001	Mar 20, 1986
	25MG	A089122	001	Mar 20, 1986
	50MG	A089123	001	Mar 20, 1986
VINTAGE	10MG	A087602	001	Jan 22, 1982
	25MG	A087603	001	Jan 22, 1982
	50MG	A087604	001	Jan 22, 1982
WATSON LABS	10MG	A081149	001	Mar 18, 1994
	10MG	A086827	001	
	10MG	A088348	001	Sep 15, 1983
	25MG	A081150	001	Mar 18, 1994
	25MG	A086829	001	
	25MG	A088349	001	Sep 15, 1983
	50MG	A081151	001	Mar 18, 1994
	50MG	A086836	001	
	50MG	A088350	001	Sep 15, 1983

HYDROXYZINE PAMOATE

CAPSULE;ORAL

HY-PAM "25"

TEVA	EQ 25MG HYDROCHLORIDE	A088713	001	Mar 04, 1985
------	-----------------------	---------	-----	--------------

HYDROXYZINE PAMOATE

BEXIMCO PHARMS USA	EQ 25MG HYDROCHLORIDE	A081127	001	Jun 28, 1991
DURAMED PHARMS BARR	EQ 25MG HYDROCHLORIDE	A088593	001	Feb 29, 1984
	EQ 50MG HYDROCHLORIDE	A088594	001	Feb 29, 1984
	EQ 100MG HYDROCHLORIDE	A088595	001	Feb 29, 1984
IVAX SUB TEVA PHARMS	EQ 25MG HYDROCHLORIDE	A087761	001	Mar 05, 1982
	EQ 50MG HYDROCHLORIDE	A087760	001	Mar 05, 1982
PAR PHARM	EQ 25MG HYDROCHLORIDE	A087656	001	Jun 11, 1982
	EQ 25MG HYDROCHLORIDE	A089145	001	Mar 17, 1986
	EQ 50MG HYDROCHLORIDE	A087657	001	Jun 11, 1982
	EQ 50MG HYDROCHLORIDE	A089146	001	Mar 17, 1986
	EQ 100MG HYDROCHLORIDE	A087658	001	Jun 11, 1982
SANDOZ	EQ 50MG HYDROCHLORIDE	A081128	001	Jun 28, 1991
	EQ 100MG HYDROCHLORIDE	A081129	001	Jun 28, 1991
SUPERPHARM	EQ 25MG HYDROCHLORIDE	A089031	001	Jan 02, 1987
	EQ 50MG HYDROCHLORIDE	A089032	001	Jan 02, 1987
	EQ 100MG HYDROCHLORIDE	A089033	001	Jan 02, 1987
VANGARD	EQ 25MG HYDROCHLORIDE	A088392	001	Sep 19, 1983
	EQ 50MG HYDROCHLORIDE	A088393	001	Sep 19, 1983
WATSON LABS	EQ 25MG HYDROCHLORIDE	A081165	001	Jul 31, 1991
	EQ 25MG HYDROCHLORIDE	A086698	001	
	EQ 25MG HYDROCHLORIDE	A086840	001	Jul 01, 1982
	EQ 50MG HYDROCHLORIDE	A086695	001	
	EQ 50MG HYDROCHLORIDE	A086705	001	Jul 01, 1982
	EQ 50MG HYDROCHLORIDE	A087767	001	Aug 16, 1982
	EQ 100MG HYDROCHLORIDE	A086697	001	
	EQ 100MG HYDROCHLORIDE	A086728	001	Oct 05, 1982
	EQ 100MG HYDROCHLORIDE	A087790	001	Aug 16, 1982

VISTARIL

PFIZER	EQ 100MG HYDROCHLORIDE **	N011459	006	
--------	---------------------------	---------	-----	--

SUSPENSION;ORAL

VISTARIL

PFIZER	EQ 25MG HYDROCHLORIDE/5ML	N011795	001	
--------	---------------------------	---------	-----	--

IBANDRONATE SODIUM

INJECTABLE;INTRAVENOUS

BONIVA

+ ROCHE	EQ 3MG BASE/3ML	N021858	001	Jan 06, 2006
---------	-----------------	---------	-----	--------------

IBANDRONATE SODIUM

EMCURE PHARMS LTD	EQ 3MG BASE/3ML	A203987	001	Sep 02, 2014
-------------------	-----------------	---------	-----	--------------

TABLET;ORAL

BONIVA

+ HOFFMANN LA ROCHE	EQ 2.5MG BASE **	N021455	001	May 16, 2003
---------------------	------------------	---------	-----	--------------

IBANDRONATE SODIUM

MYLAN PHARMS INC	EQ 150MG BASE	A078995	001	Mar 19, 2012
------------------	---------------	---------	-----	--------------

SUN PHARM INDUSTRIES	EQ 150MG BASE	A078996	001	Aug 15, 2012
----------------------	---------------	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

IBUPROFEN

CAPSULE; ORAL

IBUPROFEN

CONTRACT PHARMACAL	200MG	A074782 001	Jul 06, 1998
STRIDES PHARMA	EQ 200MG FREE ACID AND POTASSIUM SALT	A204469 001	Mar 28, 2018

MIDOL

BAYER	200MG **	A070626 001	Sep 02, 1987
	200MG **	A071002 001	Sep 02, 1987

SOLUTION; INTRAVENOUS

CALDOLOR

CUMBERLAND PHARMS	400MG/4ML (100MG/ML)	N022348 001	Jun 11, 2009
-------------------	----------------------	-------------	--------------

SUSPENSION; ORAL

CHILDREN'S ADVIL

GLAXOSMITHKLINE	100MG/5ML	N019833 002	Sep 19, 1989
-----------------	-----------	-------------	--------------

CHILDREN'S ELIXSURE

MOBERG PHARMA NORTH	100MG/5ML	N021604 001	Jan 07, 2004
---------------------	-----------	-------------	--------------

IBU

ABBOTT	100MG/5ML	N019784 001	Dec 18, 1989
--------	-----------	-------------	--------------

IBUPROFEN

GUARDIAN DRUG	100MG/5ML	A210149 001	Aug 17, 2018
---------------	-----------	-------------	--------------

MOTRIN

+ MCNEIL CONSUMER	100MG/5ML **	N019842 001	Sep 19, 1989
-------------------	--------------	-------------	--------------

SUSPENSION/DROPS; ORAL

MOTRIN

MCNEIL	40MG/ML	N020476 001	May 25, 1995
--------	---------	-------------	--------------

PEDIATRIC ADVIL

+ GLAXOSMITHKLINE	100MG/2.5ML	N020812 001	Jan 30, 1998
-------------------	-------------	-------------	--------------

TABLET; ORAL

ACHES-N-PAIN

LEDERLE	200MG	A071065 001	May 28, 1987
---------	-------	-------------	--------------

CAP-PROFEN

PERRIGO	200MG	A072097 001	Dec 08, 1987
---------	-------	-------------	--------------

IBU

BASF	400MG	A070083 001	Feb 22, 1985
	400MG	N018197 001	
	600MG	A070088 001	Feb 08, 1985
	600MG	A070099 001	Mar 29, 1985
	800MG	A070745 001	Jul 23, 1986

IBU-TAB

ALRA	800MG	A071965 001	Aug 11, 1988
------	-------	-------------	--------------

IBUPRIN

PLIVA	200MG	A071773 001	Jul 16, 1987
-------	-------	-------------	--------------

IBUPROFEN

ABBOTT	600MG	A070556 001	Jun 14, 1985
--------	-------	-------------	--------------

	800MG	A071264 001	Jul 25, 1986
--	-------	-------------	--------------

ANI PHARMS INC	200MG	A071144 001	Jan 20, 1987
----------------	-------	-------------	--------------

	200MG	A072901 001	Dec 19, 1991
--	-------	-------------	--------------

	200MG	A072903 001	Dec 19, 1991
--	-------	-------------	--------------

CONTRACT PHARMACAL	200MG	A071265 001	Oct 15, 1986
--------------------	-------	-------------	--------------

	200MG	A071265 002	Sep 10, 1987
--	-------	-------------	--------------

	200MG	A071735 001	Sep 10, 1987
--	-------	-------------	--------------

	200MG	A073691 001	Feb 25, 1994
--	-------	-------------	--------------

	200MG	A074931 001	Jul 20, 1998
--	-------	-------------	--------------

HALSEY	200MG	A071027 001	Sep 29, 1987
--------	-------	-------------	--------------

	300MG	A071028 001	Mar 23, 1987
--	-------	-------------	--------------

	400MG	A071029 001	Mar 23, 1987
--	-------	-------------	--------------

	600MG	A071030 001	Mar 23, 1987
--	-------	-------------	--------------

	800MG	A072137 001	Feb 05, 1988
--	-------	-------------	--------------

HEC PHARM	400MG	A204062 001	Sep 10, 2018
-----------	-------	-------------	--------------

	600MG	A204062 002	Sep 10, 2018
--	-------	-------------	--------------

	800MG	A204062 003	Sep 10, 2018
--	-------	-------------	--------------

IVAX SUB TEVA PHARMS	200MG	A071154 001	Oct 27, 1987
----------------------	-------	-------------	--------------

	200MG	A072040 001	Apr 29, 1988
--	-------	-------------	--------------

	400MG	A071145 001	Sep 23, 1986
--	-------	-------------	--------------

	600MG	A071146 001	Sep 23, 1986
--	-------	-------------	--------------

	800MG	A071769 001	May 08, 1987
--	-------	-------------	--------------

J AND J CONSUMER INC	400MG	A070081 001	Jun 16, 1986
----------------------	-------	-------------	--------------

LEDERLE	400MG	A070629 001	Sep 19, 1986
---------	-------	-------------	--------------

	600MG	A070630 001	Sep 19, 1986
--	-------	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

IBUPROFEN

TABLET; ORAL

IBUPROFEN

LEINER	300MG	A071266	001	Oct 15, 1986
LNK	100MG	A076741	001	Jun 17, 2004
MCNEIL	600MG	A070476	001	Jun 16, 1986
MYLAN	200MG	A071870	001	May 05, 1988
	400MG	A070045	001	Sep 24, 1985
	600MG	A070057	001	Sep 24, 1985
	800MG	A071999	001	Dec 03, 1987
NORTHSTAR HLTHCARE	400MG	A078132	001	Sep 10, 2007
	600MG	A078132	002	Sep 10, 2007
	800MG	A078132	003	Sep 10, 2007
OHM LABS	400MG	A070818	001	Dec 26, 1985
P AND L DEV LLC	200MG	A070733	001	Sep 19, 1986
PAR PHARM	200MG	A071575	001	May 08, 1987
	300MG	A070328	001	Aug 06, 1985
	400MG	A070329	001	Aug 06, 1985
	600MG	A070330	001	Aug 06, 1985
	800MG	A070986	001	Jul 25, 1986
PERRIGO	200MG	A072098	001	Dec 08, 1987
PLIVA	400MG	A071666	001	Jun 18, 1987
	600MG	A071667	001	Jun 18, 1987
	800MG	A071668	001	Jun 18, 1987
PUREPAC PHARM	200MG	A071122	001	Oct 03, 1986
	200MG	A071664	001	Feb 03, 1987
	300MG	A071123	001	Sep 19, 1986
	400MG	A071124	001	Sep 19, 1986
	600MG	A071125	001	Sep 19, 1986
	800MG	A071964	001	Feb 01, 1988
RISING	300MG	A070736	002	Jun 12, 1986
	400MG	A070736	003	Jun 12, 1986
	600MG	A070736	001	Jun 12, 1986
	800MG	A071938	001	Jan 14, 1988
SANDOZ	200MG	A071807	001	Feb 25, 1988
	200MG	A074525	001	Dec 15, 1995
	200MG	A074533	001	Dec 15, 1995
	400MG	A072064	001	Jan 14, 1988
	600MG	A072065	001	Jan 14, 1988
	800MG	A072169	001	Dec 11, 1987
SUN PHARM INDUSTRIES	200MG	A070493	001	Dec 24, 1985
	200MG	A070908	001	Sep 26, 1986
	200MG	A071462	001	Oct 02, 1986
	400MG	A070079	001	Jul 24, 1985
	600MG	A070080	001	Jul 24, 1985
	800MG	A071448	001	Feb 18, 1987
SUPERPHARM	600MG	A070709	001	Apr 25, 1986
TEVA	200MG	A073141	001	May 29, 1992
	400MG	A073343	001	Jun 30, 1992
	600MG	A073344	001	Jun 30, 1992
	800MG	A073345	001	Jun 30, 1992
ULTRATAB LABS INC	200MG	A209076	001	Jan 06, 2020
VINTAGE PHARMS	200MG	A071639	001	Feb 02, 1988
	200MG	A072249	001	Jan 10, 1989
	300MG	A071230	001	Oct 22, 1986
	400MG	A071231	001	Oct 22, 1986
	600MG	A071232	001	Oct 22, 1986
	800MG	A072004	001	Nov 18, 1987
WATSON LABS	200MG	A070435	001	Mar 05, 1986
	200MG	A071765	001	Sep 04, 1987
	200MG	A071905	001	Mar 08, 1988
	300MG	A071338	001	Dec 01, 1986
	400MG	A070038	001	Sep 06, 1985
	400MG	A070436	001	Aug 21, 1985
	600MG	A070041	001	Sep 06, 1985
	600MG	A070437	001	Aug 21, 1985
	800MG	A071547	001	Jul 02, 1987
	800MG	A071911	001	Oct 13, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

IBUPROFEN

TABLET; ORAL

IBUPROHM					
	OHM LABS	200MG		A071214	001 Dec 01, 1986
		400MG		A070469	001 Aug 29, 1985
MEDIPREN					
	MCNEIL	200MG		A070475	001 Feb 06, 1986
		200MG		A071215	001 Jun 26, 1986
MIDOL					
	BAYER	200MG		A070591	001 Sep 02, 1987
		200MG		A071001	001 Sep 02, 1987
MOTRIN					
+	MCNEIL CONSUMER	300MG **		N017463	003
+		400MG **		N017463	002
+		600MG **		N017463	004
+		800MG **		N017463	005 May 22, 1985
	MCNEIL PED	100MG		N020418	001 Nov 16, 1994
MOTRIN MIGRAINE PAIN					
	J AND J CONSUMER INC	200MG		N019012	004 Feb 25, 2000
NUPRIN					
	BRISTOL MYERS	200MG		A072035	001 Feb 16, 1988
		200MG		A072036	001 Feb 16, 1988
	J AND J CONSUMER INC	200MG		N019012	001 May 18, 1984
		200MG		N019012	002 Jul 29, 1987
RUFEN					
	BASF	600MG		N018197	002 Mar 05, 1984
TABLET, CHEWABLE; ORAL					
CHILDREN'S MOTRIN					
+	J AND J CONSUMER INC	50MG		N020601	001 Nov 15, 1996
IBUPROFEN					
	FERRIGO	50MG		A076359	001 Jan 16, 2004
JUNIOR STRENGTH MOTRIN					
+	J AND J CONSUMER INC	100MG		N020601	003 Nov 15, 1996
MOTRIN					
	MCNEIL PED	50MG		N020135	001 Nov 16, 1994
		100MG		N020135	002 Nov 16, 1994

IBUPROFEN SODIUM

TABLET; ORAL

IBUPROFEN SODIUM					
	FERRIGO R AND D	EQ 200MG BASE		A206581	001 Aug 03, 2015

IBUPROFEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

COMBUNOX					
+	FOREST LABS	400MG; 5MG **		N021378	001 Nov 26, 2004
OXYCODONE HYDROCHLORIDE AND IBUPROFEN					
	ACTAVIS ELIZABETH	400MG; 5MG		A078769	001 Jan 04, 2008
	BARR LABS INC	400MG; 5MG		A078316	001 Nov 29, 2007
	WATSON LABS	400MG; 5MG		A078394	001 Nov 26, 2007

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET; ORAL

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE					
	CONTRACT PHARMACAL	200MG; 30MG		A075588	001 Apr 08, 2002

IBUTILIDE FUMARATE

INJECTABLE; INJECTION

IBUTILIDE FUMARATE					
	LUITPOLD	0.1MG/ML		A090240	001 Jan 11, 2010
	MYLAN INSTITUTIONAL	0.1MG/ML		A090924	001 Jan 11, 2010

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDAMYCIN					
	PFIZER	5MG/VIAL		N050661	002 Sep 27, 1990
		10MG/VIAL		N050661	001 Sep 27, 1990
		20MG/VIAL		N050661	003 Apr 25, 1995
IDARUBICIN HYDROCHLORIDE					
	MYLAN LABS LTD	1MG/ML		A200144	001 Oct 11, 2012
	SANDOZ	1MG/ML		A091293	001 Mar 29, 2011
	TEVA PARENTERAL	5MG/VIAL		A065037	003 May 01, 2002

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDARUBICIN HYDROCHLORIDE

10MG/VIAL

A065037 002 May 01, 2002

20MG/VIAL

A065037 001 May 01, 2002

IDOXURIDINE

OINTMENT; OPHTHALMIC

STOXIL

GLAXOSMITHKLINE

0.5%

N015868 001

SOLUTION/DROPS; OPHTHALMIC

DENDRID

+ ALCON

0.1%

N014169 001

HERPLEX

ALLERGAN

0.1%

N013935 002

STOXIL

GLAXOSMITHKLINE

0.1%

N013934 001

IFOSFAMIDE

INJECTABLE; INJECTION

IFOSFAMIDE

FRESENIUS KABI USA

1GM/20ML (50MG/ML)

A090181 001 Sep 22, 2009

3GM/60ML (50MG/ML)

A090181 002 Sep 22, 2009

MYLAN LABS LTD

1GM/20ML (50MG/ML)

A201689 001 Nov 26, 2012

3GM/60ML (50MG/ML)

A201689 002 Nov 26, 2012

IFOSFAMIDE; MESNA

INJECTABLE; INJECTION

IFEX/MESNEX KIT

BAXTER HLTHCARE

1GM/VIAL; 100MG/ML

N019763 003 Oct 10, 1992

3GM/VIAL; 100MG/ML

N019763 004 Oct 10, 1992

INJECTABLE; INTRAVENOUS

IFOSFAMIDE/MESNA KIT

TEVA PHARMS USA

1GM/20ML; 1GM/10ML (50MG/ML; 100MG/ML)

A075874 001 Feb 26, 2002

3GM/60ML; 1GM/10ML (50MG/ML; 100MG/ML)

A075874 002 Feb 26, 2002

ILOPERIDONE

TABLET; ORAL

ILOPERIDONE

INVENTIA

1MG

A207231 001 Nov 28, 2016

2MG

A207231 002 Nov 28, 2016

4MG

A207231 003 Nov 28, 2016

6MG

A207231 004 Nov 28, 2016

8MG

A207231 005 Nov 28, 2016

10MG

A207231 006 Nov 28, 2016

12MG

A207231 007 Nov 28, 2016

TARO PHARM INDS LTD

1MG

A207098 001 Jul 22, 2019

2MG

A207098 002 Jul 22, 2019

4MG

A207098 003 Jul 22, 2019

6MG

A207098 004 Jul 22, 2019

8MG

A207098 005 Jul 22, 2019

10MG

A207098 006 Jul 22, 2019

12MG

A207098 007 Jul 22, 2019

ILOPROST

SOLUTION; INHALATION

VENTAVIS

ACTELION PHARMS LTD

20MCG/2ML (10MCG/ML)

N021779 001 Dec 29, 2004

IMATINIB MESYLATE

CAPSULE; ORAL

GLEEVEC

+ NOVARTIS

EQ 50MG BASE **

N021335 001 May 10, 2001

+

EQ 100MG BASE **

N021335 002 May 10, 2001

TABLET; ORAL

IMATINIB MESYLATE

AMNEAL PHARMS

EQ 100MG BASE

A207495 001 Feb 08, 2019

EQ 400MG BASE

A207495 002 Feb 08, 2019

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

IMIPRAMINE HYDROCHLORIDE

CONCENTRATE; ORAL

IMIPRAMINE HYDROCHLORIDE

NOVARTIS

25MG/ML

A086765 001

INJECTABLE; INJECTION

TOFRANIL

NOVARTIS

12.5MG/ML

N011838 002

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

CHARTWELL

10MG

A090441 002 Mar 11, 2010

25MG

A090441 003 Mar 11, 2010

50MG

A090441 001 Mar 11, 2010

LEDERLE

10MG

A086269 001

25MG

A086267 001

50MG

A086268 001

PAR PHARM

10MG

A089422 001 Jul 14, 1987

25MG

A089497 001 Jul 14, 1987

ROXANE

10MG

A083799 001

25MG

A083799 002

50MG

A083799 003

SANDOZ

10MG

A085200 001

25MG

A084869 002

50MG

A085133 001

TEVA

10MG

A083729 001

25MG

A083729 004

50MG

A083729 003

USL PHARMA

25MG

A087776 001 Feb 10, 1982

VANGARD

10MG

A088036 001 Nov 03, 1982

25MG

A087619 001 Feb 09, 1982

50MG

A087631 001 Jan 04, 1982

WATSON LABS

10MG

A085220 001

10MG

A085875 001

25MG

A084252 002

25MG

A085878 001

50MG

A085221 001

50MG

A085877 001

WEST WARD

25MG

A088222 001 May 26, 1983

50MG

A088223 001 May 26, 1983

JANIMINE

ABBOTT

10MG

N017895 001

25MG

N017895 002

50MG

N017895 003

PRAMINE

ALRA

10MG

A083827 001

25MG

A083827 002

50MG

A083827 003

PRESAMINE

SANOFI AVENTIS US

10MG

N011836 006

25MG

N011836 003

50MG

N011836 007

IMIPRAMINE PAMOATE

CAPSULE; ORAL

IMIPRAMINE PAMOATE

MYLAN PHARMS INC

EQ 75MG HYDROCHLORIDE

A202338 001 Jun 28, 2013

EQ 100MG HYDROCHLORIDE

A202338 002 Jun 28, 2013

EQ 125MG HYDROCHLORIDE

A202338 003 Jun 28, 2013

EQ 150MG HYDROCHLORIDE

A202338 004 Jun 28, 2013

TOFRANIL-PM

+ SPECGX LLC

EQ 75MG HYDROCHLORIDE **

N017090 001

+

EQ 100MG HYDROCHLORIDE **

N017090 004

+

EQ 125MG HYDROCHLORIDE **

N017090 003

+

EQ 150MG HYDROCHLORIDE **

N017090 002

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

IMIQUIMOD

CREAM; TOPICAL

IMIQUIMOD

ANDA REPOSITORY	5%	A091044	001	Feb 28, 2011
COSETTE	5%	A200481	001	Apr 18, 2011
STRIDES PHARMA	5%	A202002	001	Jun 24, 2014

INAMRINONE LACTATE

INJECTABLE; INJECTION

AMRINONE LACTATE

BAXTER HLTHCARE CORP	EQ 5MG BASE/ML	A075542	001	May 10, 2000
HOSPIRA	EQ 5MG BASE/ML	A074616	001	Aug 03, 1998
INOCOR				
SANOFI AVENTIS US	EQ 5MG BASE/ML	N018700	001	Jul 31, 1984

INDACATEROL MALEATE

POWDER; INHALATION

ARCAPTA NEOHALER

+ NOVARTIS	EQ 75MCG BASE	N022383	001	Jul 01, 2011
------------	---------------	---------	-----	--------------

INDAPAMIDE

TABLET; ORAL

INDAPAMIDE

ANI PHARMS INC	1.25MG	A074498	002	Feb 12, 1998
	1.25MG	A075201	001	Dec 04, 1998
	2.5MG	A074498	001	Oct 31, 1996
	2.5MG	A075201	002	Dec 04, 1998
MYLAN PHARMS INC	1.25MG	A075105	001	Jul 23, 1998
	2.5MG	A075105	002	Jul 23, 1998
TEVA	1.25MG	A074665	001	Apr 04, 1997
	2.5MG	A074665	002	Apr 04, 1997
WATSON LABS	1.25MG	A074585	001	Sep 26, 1996
	2.5MG	A074585	002	Sep 26, 1996
YAOPHARMA CO LTD	1.25MG	A074594	001	May 23, 1996
	2.5MG	A074594	002	May 23, 1996
LOZOL				
+ SANOFI AVENTIS US	1.25MG **	N018538	002	Apr 29, 1993
+	2.5MG **	N018538	001	Jul 06, 1983

INDECAINIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

DECABID

LILLY	EQ 50MG BASE	N019693	001	Dec 29, 1989
	EQ 75MG BASE	N019693	002	Dec 29, 1989
	EQ 100MG BASE	N019693	003	Dec 29, 1989

INDINAVIR SULFATE

CAPSULE; ORAL

CRIXIVAN

MERCK SHARP DOHME	EQ 100MG BASE	N020685	006	Apr 19, 2000
+	EQ 200MG BASE	N020685	003	Mar 13, 1996
	EQ 333MG BASE	N020685	005	Dec 17, 1998
+	EQ 400MG BASE	N020685	001	Mar 13, 1996

INDIUM IN-111 CHLORIDE

INJECTABLE; INJECTION

INDICLOR

+ GE HEALTHCARE	2mCi/0.2ML	N019862	001	Dec 29, 1992
-----------------	------------	---------	-----	--------------

INDOCYANINE GREEN

INJECTABLE; INJECTION

IC-GREEN

AKORN	10MG/VIAL **	N011525	003	
	40MG/VIAL **	N011525	004	
	50MG/VIAL **	N011525	002	

INDOMETHACIN

CAPSULE; ORAL

INDO-LEMMON

TEVA	25MG	A070266	001	Nov 07, 1985
	50MG	A070267	001	Nov 07, 1985

INDOCIN

+ EGALET	25MG **	N016059	001	
----------	---------	---------	-----	--

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

INDOMETHACIN

CAPSULE; ORAL

INDOCIN

+

50MG **

N016059 002

INDOMETHACIN

ABLE

25MG

A076666 001 Dec 17, 2003

50MG

A076666 002 Dec 17, 2003

ANI PHARMS INC

25MG

A071148 001 Mar 18, 1987

50MG

A071149 001 Mar 18, 1987

CHARTWELL MOLECULES

25MG

N018829 002 Aug 06, 1984

50MG

A070651 001 Mar 05, 1986

50MG

N018829 001 Aug 06, 1984

CYCLE PHARMS LTD

25MG

A070353 001 Jun 18, 1985

50MG

A070354 001 Jun 18, 1985

DURAMED PHARMS BARR

25MG

A070326 001 Oct 18, 1985

50MG

A070327 001 Oct 18, 1985

HALSEY

25MG

A070782 001 Jun 03, 1987

50MG

A070635 001 Jun 03, 1987

HERITAGE

25MG

N018851 001 May 18, 1984

50MG

N018851 002 May 18, 1984

HERITAGE PHARMA

25MG

A070719 001 Feb 12, 1986

50MG

A070756 001 Feb 12, 1986

IVAX SUB TEVA PHARMS

25MG

N018730 001 May 04, 1984

50MG

N018730 002 May 04, 1984

MUTUAL PHARM

25MG

A070067 001 Oct 03, 1986

50MG

A070068 001 Oct 03, 1986

MYLAN

25MG

N018858 001 Apr 20, 1984

50MG

A070624 001 Sep 04, 1985

50MG

N018858 002 Apr 20, 1984

PARKE DAVIS

25MG

N018806 001 Nov 23, 1984

50MG

N018806 002 Nov 23, 1984

PIONEER PHARMS

25MG

A070813 001 Aug 11, 1986

50MG

A070592 001 Aug 11, 1986

SUN PHARM INDS INC

25MG

A091401 001 Mar 28, 2013

50MG

A091401 002 Mar 28, 2013

SUN PHARM INDUSTRIES

25MG

A070900 002 Feb 09, 1987

50MG

A070900 001 Feb 09, 1987

SUPERPHARM

25MG

A070487 001 Oct 10, 1986

50MG

A070488 001 Oct 10, 1986

TEVA

25MG

A071342 001 Apr 18, 1988

50MG

A071343 001 Apr 18, 1988

WATSON LABS

25MG

A070529 001 Oct 18, 1985

25MG

A070784 001 Aug 20, 1986

25MG

A072996 001 Jul 31, 1991

25MG

N018690 001 Jul 31, 1984

50MG

A070530 001 Oct 18, 1985

50MG

A070785 001 Aug 20, 1986

50MG

A071635 001 May 18, 1987

50MG

A072997 001 Jul 31, 1991

50MG

N018690 002 Jul 31, 1984

CAPSULE, EXTENDED RELEASE; ORAL

INDOCIN SR

+ EGALET

75MG **

N018185 001 Feb 23, 1982

INDOMETHACIN

ABLE

75MG

A076114 001 Feb 06, 2002

INWOOD LABS

75MG

A072410 001 Mar 15, 1989

MYLAN

75MG

A202139 001 Mar 20, 2014

WATSON LABS INC

75MG

A202572 001 Dec 09, 2013

SUPPOSITORY; RECTAL

INDOCIN

+ EGALET

50MG **

N017814 001 Aug 13, 1984

SUSPENSION; ORAL

INDOMETHACIN

HIKMA

25MG/5ML

A071412 001 Mar 18, 1987

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

INDOMETHACIN SODIUM

INJECTABLE; INJECTION

INDOCIN

+ RECORDATI RARE EQ 1MG BASE/VIAL N018878 001 Jan 30, 1985

INGENOL MEBUTATE

GEL; TOPICAL

INGENOL MEBUTATE

PERRIGO UK FINCO 0.015% A209018 001 Jan 07, 2019

0.05% A209019 001 Jan 09, 2019

PICATO

+ LEO LABS 0.015% N202833 001 Jan 23, 2012

+ 0.05% N202833 002 Jan 23, 2012

INULIN

INJECTABLE; INJECTION

INULIN AND SODIUM CHLORIDE

ISO TEX 100MG/ML N002282 001

INVERT SUGAR

INJECTABLE; INJECTION

TRAVERT 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE 10GM/100ML N016717 001

IOBENGUANE SULFATE I-131

INJECTABLE; INJECTION

IOBENGUANE SULFATE I 131

PHARMALUCENCE 2.3mCi/ML N020084 001 Mar 25, 1994

IO CETAMIC ACID

TABLET; ORAL

CHOLEBRINE

MALLINCKRODT 750MG N017129 001

IODAMIDE MEGLUMINE

INJECTABLE; INJECTION

RENOVUE-65

BRACCO 65% N017902 001

RENOVUE-DIP

BRACCO 24% N017903 001

IODIPAMIDE MEGLUMINE

INJECTABLE; INJECTION

CHOLOGRAFIN MEGLUMINE

BRACCO 10.3% N009321 007

+ 52% N009321 003

IODIPAMIDE SODIUM

INJECTABLE; INJECTION

CHOLOGRAFIN SODIUM

BRACCO 20% N009321 001

IODIXANOL

INJECTABLE; INJECTION

VISIPAQUE 270

GE HEALTHCARE 55% N020808 001 Aug 29, 1997

IODOHIPPURATE SODIUM I-123

INJECTABLE; INJECTION

NEPHROFLOW

GE HEALTHCARE 1mCi/ML N018289 001 Dec 28, 1984

IODOHIPPURATE SODIUM I-131

INJECTABLE; INJECTION

HIPURAN I 131

MALLINCKRODT 0.25mCi/ML N016666 001

HIPPUTOPE

BRACCO 1-2mCi/VIAL N015419 002

IODOHIPPURATE SODIUM I 131

PHARMALUCENCE 0.2mCi/ML N017313 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

IODOXAMATE MEGLUMINEINJECTABLE; INJECTION
CHOLOVUE

BRACCO	9.9%	N018077 001
	40.3%	N018076 001

IOFETAMINE HYDROCHLORIDE I-123INJECTABLE; INJECTION
SPECTAMINE

IMP	1mCi/ML	N019432 001	Dec 24, 1987
-----	---------	-------------	--------------

IOHEXOLINJECTABLE; INJECTION
OMNIPAQUE 210

GE HEALTHCARE	45.3%	N018956 006	Jun 30, 1989
---------------	-------	-------------	--------------

SOLUTION; INJECTION, ORAL, RECTAL

OMNIPAQUE 240

GE HEALTHCARE	51.8%	N020608 001	Oct 24, 1995
---------------	-------	-------------	--------------

SOLUTION; URETHRAL

OMNIPAQUE 70

GE HEALTHCARE	15.1%	N018956 007	Jun 01, 1994
---------------	-------	-------------	--------------

IOPAMIDOLINJECTABLE; INJECTION
IOPAMIDOL

BAXTER HLTHCARE	41%	A074629 001	Nov 06, 1996
	51%	A074629 004	Mar 31, 1998
	61%	A074629 002	Nov 06, 1996
	76%	A074629 003	Nov 06, 1996
HOSPIRA	61%	A074734 001	Dec 10, 1996
	76%	A074734 002	Dec 10, 1996

IOPAMIDOL-200

COOK IMAGING	41%	A074881 001	Jul 28, 2000
HOSPIRA	41%	A074898 001	Dec 30, 1997

IOPAMIDOL-200 IN PLASTIC CONTAINER

HOSPIRA	41%	A074636 001	Dec 30, 1997
---------	-----	-------------	--------------

IOPAMIDOL-250

COOK IMAGING	51%	A074881 002	Jul 28, 2000
FRESENIUS KABI USA	51%	A074679 001	Apr 02, 1997
HOSPIRA	51%	A074898 002	Dec 30, 1997
	51%	A075005 001	Feb 24, 1998

IOPAMIDOL-250 IN PLASTIC CONTAINER

HOSPIRA	51%	A074636 002	Dec 30, 1997
---------	-----	-------------	--------------

IOPAMIDOL-300

ABBVIE	61%	A074638 001	Apr 30, 1997
COOK IMAGING	61%	A074881 003	Jul 28, 2000
FRESENIUS KABI USA	61%	A074679 002	Apr 02, 1997
HOSPIRA	61%	A074898 003	Dec 30, 1997
	61%	A075005 002	Feb 24, 1998

IOPAMIDOL-300 IN PLASTIC CONTAINER

HOSPIRA	61%	A074636 003	Dec 30, 1997
	61%	A074637 001	Apr 03, 1997

IOPAMIDOL-370

COOK IMAGING	76%	A074881 004	Jul 28, 2000
FRESENIUS KABI USA	76%	A074679 003	Apr 02, 1997
HOSPIRA	76%	A074898 004	Dec 30, 1997
	76%	A075005 003	Feb 24, 1998

IOPAMIDOL-370 IN PLASTIC CONTAINER

HOSPIRA	76%	A074636 004	Dec 30, 1997
---------	-----	-------------	--------------

ISOVUE-128

BRACCO	26%	N018735 005	Oct 21, 1986
--------	-----	-------------	--------------

ISOVUE-200

BRACCO	41%	N020327 001	Oct 12, 1994
--------	-----	-------------	--------------

IOPANOIC ACIDTABLET; ORAL
TELEPAQUE

GE HEALTHCARE	500MG	N008032 001
---------------	-------	-------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

IOPHENDYLATE

INJECTABLE; INJECTION			
PANTOPAQUE			
ALCON	100%		N005319 001

IOPROMIDE

INJECTABLE; INJECTION			
ULTRAVIST (PHARMACY BULK)			
+ BAYER HLTHCARE	49.9%		N021425 003 Mar 12, 2004
ULTRAVIST 150			
+ BAYER HLTHCARE	31.2%		N020220 004 May 10, 1995
ULTRAVIST 240			
+ BAYER HLTHCARE	49.9%		N020220 003 May 10, 1995
ULTRAVIST 300 IN PLASTIC CONTAINER			
+ BAYER HLTHCARE	62.3%		N020220 005 Nov 18, 2008

IOTHALAMATE MEGLUMINE

INJECTABLE; INJECTION			
CONRAY 30			
+ LIEBEL-FLARSHEIM	30%		N016983 001
CONRAY 43			
+ LIEBEL-FLARSHEIM	43%		N013295 002

IOTHALAMATE MEGLUMINE; IOTHALAMATE SODIUM

INJECTABLE; INJECTION			
VASCORAY			
MALLINCKRODT	52%;26%		N016783 001

IOTHALAMATE SODIUM

INJECTABLE; INJECTION			
ANGIO-CONRAY			
MALLINCKRODT	80%		N013319 001
CONRAY 325			
MALLINCKRODT	54.3%		N017685 001
CONRAY 400			
MALLINCKRODT	66.8%		N014295 001

IOTROLAN

INJECTABLE; INTRATHECAL			
OSMOVIST 190			
BAYER HLTHCARE	40.6%		N019580 001 Dec 07, 1989
OSMOVIST 240			
BAYER HLTHCARE	51.3%		N019580 002 Dec 07, 1989

IOVERSOL

INJECTABLE; INJECTION			
OPTIRAY 160			
LIEBEL-FLARSHEIM	34%		N019710 003 Dec 30, 1988
OPTIRAY 240			
LIEBEL-FLARSHEIM	51%		N020923 001 May 28, 1998

IOXAGLATE MEGLUMINE; IOXAGLATE SODIUM

INJECTABLE; INJECTION			
HEXABRIX			
GUERBET	39.3%;19.6%		N018905 002 Jul 26, 1985

IOXILAN

INJECTABLE; INJECTION			
OXILAN-300			
GUERBET	62%		N020316 001 Dec 21, 1995
OXILAN-350			
GUERBET	73%		N020316 002 Dec 21, 1995

IPODATE CALCIUM

GRANULE; ORAL			
ORAGRAFIN CALCIUM			
BRACCO	3GM/PACKET		N012968 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

IPODATE SODIUM

CAPSULE; ORAL

BILIVIST

BAYER HLTHCARE 500MG A087768 001 Aug 11, 1982

ORAGRAFIN SODIUM

BRACCO 500MG N012967 001

IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION

ATROVENT

BOEHRINGER INGELHEIM 0.018MG/INH N019085 001 Dec 29, 1986

SOLUTION; INHALATION

ATROVENT

+ BOEHRINGER INGELHEIM 0.02% ** N020228 001 Sep 29, 1993

IPRATROPIUM BROMIDE

ACTAVIS MID ATLANTIC 0.02% A075111 001 Apr 22, 1999

APOTEX INC 0.02% A075441 001 Mar 28, 2001

BAUSCH AND LOMB INC 0.02% A075835 001 Oct 15, 2001

MYLAN SPECIALITY LP 0.02% A074755 001 Jan 10, 1997

PHARMASCIENCE INC 0.02% A075507 001 Jan 19, 2001

ROXANE 0.02% A075867 001 Jul 22, 2002

TEVA PHARMS USA 0.02% A075313 001 Feb 07, 2000

WATSON LABS 0.02% A076291 001 May 09, 2005

SPRAY, METERED; NASAL

ATROVENT

+ BOEHRINGER INGELHEIM 0.021MG/SPRAY N020393 001 Oct 20, 1995

+ 0.042MG/SPRAY N020394 001 Oct 20, 1995

IPRATROPIUM BROMIDE

MYLAN SPECIALITY LP 0.021MG/SPRAY A075552 001 Mar 31, 2003

0.042MG/SPRAY A075553 001 Mar 31, 2003

IRBESARTAN

TABLET; ORAL

IRBESARTAN

AJANTA PHARMA LTD 75MG A203685 001 Dec 10, 2015

150MG A203685 002 Dec 10, 2015

300MG A203685 003 Dec 10, 2015

APOTEX INC 75MG A200832 001 Oct 15, 2012

150MG A200832 002 Oct 15, 2012

300MG A200832 003 Oct 15, 2012

HIKMA 75MG A090201 001 Oct 15, 2012

150MG A090201 002 Oct 15, 2012

300MG A090201 003 Oct 15, 2012

MYLAN PHARMS INC 75MG A200461 001 Sep 27, 2012

150MG A200461 002 Sep 27, 2012

300MG A200461 003 Sep 27, 2012

NEOPHARMA 75MG A203161 001 Sep 27, 2012

150MG A203161 002 Sep 27, 2012

300MG A203161 003 Sep 27, 2012

UNICHEM 75MG A203020 001 Dec 07, 2015

150MG A203020 002 Dec 07, 2015

300MG A203020 003 Dec 07, 2015

WATSON LABS INC 75MG A090720 001 Oct 12, 2012

150MG A090720 002 Oct 12, 2012

300MG A090720 003 Oct 12, 2012

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

CIPLA LTD 40MG/2ML (20MG/ML) A077219 001 Feb 20, 2008

100MG/5ML (20MG/ML) A077219 002 Feb 20, 2008

FRESENIUS KABI USA 40MG/2ML (20MG/ML) A078188 001 Feb 27, 2008

100MG/5ML (20MG/ML) A078188 002 Feb 27, 2008

NEOPHARMA 40MG/2ML (20MG/ML) A078953 001 Apr 15, 2010

100MG/5ML (20MG/ML) A078953 002 Apr 15, 2010

PLIVA LACHEMA 40MG/2ML (20MG/ML) A078122 001 Oct 31, 2008

100MG/5ML (20MG/ML) A078122 002 Oct 31, 2008

SANDOZ 40MG/2ML (20MG/ML) A077994 001 Feb 27, 2008

100MG/5ML (20MG/ML) A077994 002 Feb 27, 2008

SANDOZ INC 40MG/2ML (20MG/ML) A090137 001 Nov 12, 2009

100MG/5ML (20MG/ML) A090137 002 Nov 12, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

SUN PHARMA GLOBAL

40MG/2ML (20MG/ML)

A078805 001 Apr 21, 2008

100MG/5ML (20MG/ML)

A078805 002 Apr 21, 2008

IRON DEXTRAN

INJECTABLE; INJECTION

DEXFERRUM

AM REGENT

EQ 50MG IRON/ML

N040024 001 Feb 23, 1996

IRON DEXTRAN

SANOFI AVENTIS US

EQ 50MG IRON/ML

N010787 002

PROFERDEX

NEW RIVER

EQ 50MG IRON/ML

N017807 001

IRON SUCROSE

INJECTABLE; INTRAVENOUS

VENOFER

AM REGENT

EQ 65MG BASE/3.25ML (EQ 20MG BASE/ML)

N021135 005 Mar 29, 2013

EQ 75MG BASE/3.75ML (EQ 20MG BASE/ML)

N021135 003 Mar 29, 2005

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION

BETA-2

NEPHRON

1%

A086711 001

BRONKOSOL

SANOFI AVENTIS US

0.25%

N012339 009

1%

N012339 008

ISOETHARINE HYDROCHLORIDE

ALPHARMA US PHARMS

1%

A087101 001

ASTRAZENECA

0.062%

A087937 001 Nov 15, 1982

0.062%

A089614 001 Jun 13, 1991

0.125%

A087938 001 Nov 15, 1982

0.125%

A089615 001 Jun 13, 1991

0.167%

A088470 001 Mar 14, 1984

0.167%

A089616 001 Jun 13, 1991

0.2%

A088471 001 Mar 14, 1984

0.2%

A089617 001 Jun 13, 1991

0.25%

A088472 001 Mar 14, 1984

0.25%

A089618 001 Jun 13, 1991

BAXTER HLTHCARE

0.08%

A088144 001 Jul 29, 1983

0.14%

A088145 001 Mar 26, 1984

0.25%

A088146 001 Aug 01, 1983

DEY

0.08%

A088187 001 Dec 03, 1982

0.1%

A087389 001

0.17%

A087390 001

0.25%

A088188 001 Dec 03, 1982

1%

A086763 001

INTL MEDICATION

0.077%

A086651 001

0.08%

A086651 002

0.1%

A086651 003

0.143%

A086651 004

0.167%

A086651 005

0.2%

A086651 006

0.25%

A086651 007

1%

A086651 008

PARKE DAVIS

0.5%

A085997 001

1%

A085889 001

ROXANE

0.1%

A087396 001

0.125%

A087025 001

0.167%

A088226 001 Sep 16, 1983

0.2%

A087324 001

0.25%

A088275 001 Jun 03, 1983

1%

A086899 001

ISOETHARINE HYDROCHLORIDE S/F

DEY

0.08%

A089817 001 Nov 22, 1988

0.1%

A089818 001 Nov 22, 1988

0.17%

A089819 001 Nov 22, 1988

0.25%

A089820 001 Nov 22, 1988

1%

A089252 001 Sep 15, 1986

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ISOETHARINE MESYLATEAEROSOL, METERED; INHALATION
BRONKOMETER

SANOFI AVENTIS US 0.34MG/INH

N012339 007

ISOETHARINE MESYLATE

ALPHARMA US PHARMS 0.34MG/INH

A087858 001 Aug 21, 1984

ISOFLURANE

LIQUID; INHALATION

ISOFLURANE

HOSPIRA 99.9%

A074097 001 Jan 25, 1993

WATSON LABS INC 99.9%

A074393 001 May 12, 1995

ISOFLUROPHATE

OINTMENT; OPHTHALMIC

FLOROPRYL

MERCK 0.025%

N010656 001

ISONIAZID

INJECTABLE; INJECTION

NYDRAZID

SANDOZ 100MG/ML **

N008662 001

RIMIFON

ROCHE 25MG/ML

N008420 002

100MG/ML

N008420 003

SYRUP; ORAL

ISONIAZID

ANDA REPOSITORY 50MG/5ML

A081118 001 Jul 21, 1997

LANIAZID

LANNETT 50MG/5ML

A089243 001 Feb 03, 1986

RIMIFON

ROCHE 50MG/5ML

N008420 001

TABLET; ORAL

DOW-ISONIAZID

DOW PHARM 300MG

A080330 002

HYZYD

MEDPOINTE PHARM HLC 100MG

A080134 003

300MG

A080134 004

INH

NOVARTIS 300MG

A080935 001

ISONIAZID

DURAMED PHARMS BARR 100MG

A088231 001 Mar 17, 1983

300MG

A088119 001 Mar 17, 1983

HALSEY 50MG

A083632 001

HIKMA INTL PHARMS 100MG

A080212 001

300MG

A087425 001

IMPAX LABS 100MG

A080153 001

IVAX SUB TEVA PHARMS 100MG

A080270 001

300MG

A083610 001

LILLY 100MG

N008499 002

300MG

N008499 003

MK LABS 100MG

A080941 001

NEXGEN PHARMA INC 100MG

A084050 001

PANRAY 50MG

N008428 001

100MG

N008428 002

300MG

N008428 003

PERRIGO 100MG

A083060 001

PHARMAVITE 100MG

A085091 001

PHOENIX LABS NY 50MG

A080368 001

100MG

A080368 002

PUREPAC PHARM 50MG

A080132 003 Jul 14, 1982

100MG

A080132 004 Jul 14, 1982

+ SANDOZ 100MG

N008678 002

+ 300MG

N008678 003

SUN PHARM INDUSTRIES 100MG

A080136 001

300MG

A083633 001

WATSON LABS 50MG

A080522 001

100MG

A080401 001

100MG

A080523 001

100MG

A085790 001

300MG

A080521 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ISONIAZID

TABLET;ORAL

ISONIAZID

300MG

A083178 001

300MG

A085784 001

WHITEWORTH TOWN PLSN 100MG

A080120 002

LANIAZID

LANNETT

50MG

A080140 001

100MG

A080140 002

300MG

A089776 001 Jun 13, 1988

NYDRAZID

BRISTOL MYERS SQUIBB 100MG

N008392 003

STANOZIDE

EVERYLIFE 100MG

A080126 001

300MG

A080126 002

ISONIAZID; PYRAZINAMIDE; RIFAMPIN

TABLET;ORAL

RIFATER

+ SANOFI AVENTIS US 50MG;300MG;120MG

N050705 001 May 31, 1994

ISONIAZID; RIFAMPIN

CAPSULE;ORAL

RIFAMATE

SANOFI AVENTIS US 150MG;300MG

A061884 001

RIFAMPIN AND ISONIAZID

HIKMA INTL PHARMS 150MG;300MG

A065221 001 Jul 29, 2005

ISOPROPAMIDE IODIDE

TABLET;ORAL

DARBID

GLAXOSMITHKLINE EQ 5MG BASE

N010744 001

ISOPROPYL ALCOHOL

SOLUTION;TOPICAL

ZURAGARD

+ ZUREX PHARMA 70% (10.5ML)

N210872 001 Apr 26, 2019

ISOPROTERENOL HYDROCHLORIDE

AEROSOL, METERED;INHALATION

ISOPROTERENOL HYDROCHLORIDE

3M 0.12MG/INH

N010375 004

ALPHARMA US PHARMS 0.12MG/INH

A085904 001

ISUPREL

SANOFI AVENTIS US 0.103MG/INH

N011178 001

DISC;INHALATION

NORISODRINE AEROTROL

ABBOTT 0.25%

N016814 001

INJECTABLE;INJECTION

ISOPROTERENOL HYDROCHLORIDE

ABRAXIS PHARM 0.2MG/ML

A083431 001

BAXTER HLTHCARE 0.2MG/ML

A083486 001

HOSPIRA 0.02MG/ML

A083283 001

0.2MG/ML

A083346 001

INTL MEDICATION 0.2MG/ML

A083724 001

SOLUTION;INHALATION

AEROLONE

LILLY 0.25%

N007245 001

ISOPROTERENOL HYDROCHLORIDE

ARMOUR PHARM 0.031%

A087935 001 Nov 18, 1982

0.062%

A087936 001 Nov 18, 1982

DEY 0.5%

A086764 001 Jan 04, 1982

PARKE DAVIS 0.25%

A085994 001

0.5%

A085540 001

ISUPREL

SANOFI AVENTIS US 0.5%

N006327 002

1%

N006327 003

VAPO-ISO

FISONS 0.5%

N016813 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ISOPROTERENOL HYDROCHLORIDETABLET;RECTAL, SUBLINGUAL
ISUPREL

SANOFI AVENTIS US	10MG	N006328	001
	15MG	N006328	002

ISOPROTERENOL HYDROCHLORIDE; PHENYLEPHRINE BITARTRATEAEROSOL, METERED; INHALATION
DUO-MEDIHALER

3M	0.16MG/INH;0.24MG/INH	N013296	001
----	-----------------------	---------	-----

ISOPROTERENOL SULFATEAEROSOL, METERED; INHALATION
MEDIHALER-ISO

3M	0.08MG/INH	N010375	003
----	------------	---------	-----

POWDER; INHALATION
NORISODRINE

ABBVIE	10%	N006905	003
	25%	N006905	002

ISOSORBIDESOLUTION; ORAL
ISMOTIC

ALCON	100GM/220ML	N017063	001
-------	-------------	---------	-----

ISOSORBIDE DINITRATECAPSULE, EXTENDED RELEASE; ORAL
DILATRATE-SR

+ AUXILIUM PHARMS LLC	40MG	N019790	001	Sep 02, 1988
-----------------------	------	---------	-----	--------------

ISORDIL

WYETH AYERST	40MG	N012882	002	Jul 29, 1988
--------------	------	---------	-----	--------------

TABLET; ORAL

ISORDIL

+ BAUSCH	10MG **	N012093	002	Jul 29, 1988
----------	---------	---------	-----	--------------

	20MG **	N012093	006	Jul 29, 1988
--	---------	---------	-----	--------------

	30MG **	N012093	005	Jul 29, 1988
--	---------	---------	-----	--------------

ISOSORBIDE DINITRATE

ANI PHARMS INC	10MG	A086032	001	Jan 07, 1988
----------------	------	---------	-----	--------------

HIKMA INTL PHARMS	30MG	A040591	001	Jan 10, 2007
-------------------	------	---------	-----	--------------

SUN PHARM INDUSTRIES	5MG	A086166	002	Sep 19, 1986
----------------------	-----	---------	-----	--------------

	10MG	A086169	001	Sep 19, 1986
--	------	---------	-----	--------------

	20MG	A086167	001	Sep 19, 1986
--	------	---------	-----	--------------

	30MG	A087564	001	Sep 18, 1986
--	------	---------	-----	--------------

SUPERPHARM	5MG	A089190	001	Feb 17, 1987
------------	-----	---------	-----	--------------

	10MG	A089191	001	Feb 17, 1987
--	------	---------	-----	--------------

	20MG	A089192	001	Feb 17, 1987
--	------	---------	-----	--------------

WATSON LABS	5MG	A086034	001	Jan 06, 1988
-------------	-----	---------	-----	--------------

SORBITRATE

ASTRAZENECA	5MG	N016192	001	Apr 01, 1996
-------------	-----	---------	-----	--------------

	10MG	N016192	002	Apr 01, 1996
--	------	---------	-----	--------------

	20MG	A086405	002	Aug 21, 1990
--	------	---------	-----	--------------

	30MG	A088124	001	Aug 21, 1990
--	------	---------	-----	--------------

	40MG	A088125	001	Aug 21, 1990
--	------	---------	-----	--------------

TABLET; SUBLINGUAL

ISORDIL

+ BIOVAIL	2.5MG **	N012940	004	Jul 29, 1988
-----------	----------	---------	-----	--------------

	5MG **	N012940	003	Jul 29, 1988
--	--------	---------	-----	--------------

	10MG **	N012940	005	Jul 29, 1988
--	---------	---------	-----	--------------

ISOSORBIDE DINITRATE

HIKMA INTL PHARMS	2.5MG	A086054	001	Oct 29, 1987
-------------------	-------	---------	-----	--------------

	5MG	A086055	001	Nov 02, 1987
--	-----	---------	-----	--------------

SANDOZ	2.5MG	A086225	001	Feb 19, 1988
--------	-------	---------	-----	--------------

	5MG	A086222	001	Feb 19, 1988
--	-----	---------	-----	--------------

SUN PHARM INDUSTRIES	2.5MG	A084204	001	Sep 18, 1986
----------------------	-------	---------	-----	--------------

	5MG	A086168	001	Sep 18, 1986
--	-----	---------	-----	--------------

	10MG	A087545	001	Sep 18, 1986
--	------	---------	-----	--------------

WATSON LABS	2.5MG **	A086033	001	Feb 26, 1988
-------------	----------	---------	-----	--------------

WATSON LABS TEVA	5MG **	A086031	001	Sep 29, 1987
------------------	--------	---------	-----	--------------

SORBITRATE

ASTRAZENECA	2.5MG	N016191	002	Apr 01, 1996
-------------	-------	---------	-----	--------------

	5MG	N016191	001	Apr 01, 1996
--	-----	---------	-----	--------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ISOSORBIDE DINITRATETABLET, CHEWABLE;ORAL
SORBITRATE

ASTRAZENECA	5MG	N016776 002	Apr 01, 1996
	10MG	N016776 003	Apr 01, 1996

TABLET, EXTENDED RELEASE;ORAL
ISORDIL

WYETH AYERST	40MG	N012882 001	Jul 29, 1988
--------------	------	-------------	--------------

ISOSORBIDE DINITRATE

IMPAX LABS INC	40MG	A040723 001	Mar 17, 2008
----------------	------	-------------	--------------

ISOSORBIDE MONONITRATE

TABLET;ORAL

ISMO

PROMIUS PHARMA	20MG	N019091 001	Dec 30, 1991
----------------	------	-------------	--------------

ISOSORBIDE MONONITRATE

ANI PHARMS INC	20MG	A075147 001	Nov 27, 1998
----------------	------	-------------	--------------

HIKMA PHARMS	20MG	A075361 001	Oct 05, 2000
--------------	------	-------------	--------------

TABLET, EXTENDED RELEASE;ORAL

IMDUR

+ SCHERING PLOUGH	30MG **	N020225 001	Aug 12, 1993
-------------------	---------	-------------	--------------

+	60MG **	N020225 002	Aug 12, 1993
---	---------	-------------	--------------

+	120MG **	N020225 003	Mar 30, 1995
---	----------	-------------	--------------

ISOSORBIDE MONONITRATE

ACCORD HLTHCARE	30MG	A209684 001	Oct 24, 2017
-----------------	------	-------------	--------------

	60MG	A209684 002	Oct 24, 2017
--	------	-------------	--------------

	120MG	A209684 003	Oct 24, 2017
--	-------	-------------	--------------

ACTAVIS ELIZABETH	30MG	A075306 001	Dec 31, 1998
-------------------	------	-------------	--------------

	60MG	A075306 002	Dec 31, 1998
--	------	-------------	--------------

ALKERMES GAINESVILLE	60MG	A075041 001	Sep 22, 1998
----------------------	------	-------------	--------------

HIKMA INTL PHARMS	30MG	A076813 002	Mar 30, 2006
-------------------	------	-------------	--------------

	60MG	A076813 001	Jan 07, 2005
--	------	-------------	--------------

IVAX SUB TEVA PHARMS	30MG	A075448 002	Aug 07, 2001
----------------------	------	-------------	--------------

	60MG	A075448 001	Jun 19, 2000
--	------	-------------	--------------

	120MG	A075448 003	Aug 07, 2001
--	-------	-------------	--------------

SKYEPHARMA AG	60MG	A075166 001	Oct 07, 1999
---------------	------	-------------	--------------

VINTAGE PHARMS	30MG	A090598 001	Aug 11, 2010
----------------	------	-------------	--------------

	60MG	A090598 002	Aug 11, 2010
--	------	-------------	--------------

	120MG	A090598 003	Aug 11, 2010
--	-------	-------------	--------------

ISOSULFAN BLUE

INJECTABLE; INJECTION

ISOSULFAN BLUE

BELOTECA INC	1%	A210714 001	Jan 16, 2019
--------------	----	-------------	--------------

SOMERSET THERAPS LLC	1%	A210558 001	Jul 12, 2019
----------------------	----	-------------	--------------

LYMPHAZURIN

+ COVIDIEN	1% **	N018310 001	
------------	-------	-------------	--

ISOTRETINOIN

CAPSULE;ORAL

ABSORICA LD

+ SUN PHARM	20MG	N211913 003	Nov 05, 2019
-------------	------	-------------	--------------

+	28MG	N211913 005	Nov 05, 2019
---	------	-------------	--------------

AC CUTANE

+ HOFFMANN LA ROCHE	10MG **	N018662 002	May 07, 1982
---------------------	---------	-------------	--------------

+	20MG **	N018662 004	Mar 28, 1983
---	---------	-------------	--------------

+	40MG **	N018662 003	May 07, 1982
---	---------	-------------	--------------

SOTRET

SUN PHARM INDS LTD	10MG	A076041 001	Dec 24, 2002
--------------------	------	-------------	--------------

	20MG	A076041 002	Dec 24, 2002
--	------	-------------	--------------

	30MG	A076503 001	Jun 20, 2003
--	------	-------------	--------------

	40MG	A076041 003	Dec 24, 2002
--	------	-------------	--------------

ISRADIPINE

CAPSULE;ORAL

DYNACIRC

+ SMITHKLINE BEECHAM	2.5MG	N019546 001	Dec 20, 1990
----------------------	-------	-------------	--------------

+	5MG	N019546 002	Dec 20, 1990
---	-----	-------------	--------------

TABLET, EXTENDED RELEASE;ORAL

DYNACIRC CR

+ GLAXOSMITHKLINE LLC	5MG **	N020336 001	Jun 01, 1994
-----------------------	--------	-------------	--------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ISRADIPINE

TABLET, EXTENDED RELEASE;ORAL

DYNACIRC CR

+

10MG **

N020336 002 Jun 01, 1994

ISRADIPINE

MYLAN

5MG

A201067 001 Nov 27, 2015

10MG

A201067 002 Nov 27, 2015

ITRACONAZOLE

INJECTABLE; INJECTION

SPORANOX

JANSSEN PHARMS

10MG/ML

N020966 001 Mar 30, 1999

SOLUTION;ORAL

ITRACONAZOLE

APOTEX

10MG/ML

A208481 001 Aug 02, 2019

IVERMECTIN

CREAM; TOPICAL

IVERMECTIN

PERRIGO UK FINCO

1%

A210225 001 Apr 13, 2020

TABLET; ORAL

STROMEKTOL

MERCK SHARP DOHME

6MG

N050742 001 Nov 22, 1996

KANAMYCIN SULFATE

CAPSULE; ORAL

KANTREX

APOTHECON

EQ 500MG BASE

A060516 001

EQ 500MG BASE

A061911 001

EQ 500MG BASE

A062726 001 Mar 06, 1987

INJECTABLE; INJECTION

KANAMYCIN

WEST-WARD PHARMS INT

EQ 75MG BASE/2ML

A062324 001

EQ 500MG BASE/2ML

A062324 002

EQ 1GM BASE/3ML

A062324 003

KANAMYCIN SULFATE

ABRAXIS PHARM

EQ 75MG BASE/2ML

A062504 001 Apr 05, 1984

EQ 500MG BASE/2ML

A062504 002 Apr 05, 1984

EQ 1GM BASE/3ML

A062504 003 Apr 05, 1984

FRESENIUS KABI USA

EQ 500MG BASE/2ML

A065111 001 Dec 17, 2002

EQ 1GM BASE/3ML

A065111 002 Dec 17, 2002

INTL MEDICATION

EQ 500MG BASE/2ML

A062466 001 Sep 30, 1983

EQ 1GM BASE/3ML

A062466 002 Sep 30, 1983

LOCH

EQ 75MG BASE/2ML

A063021 001 Jul 31, 1992

EQ 500MG BASE/2ML

A063022 001 Jul 31, 1992

EQ 1GM BASE/3ML

A063025 001 Jul 31, 1992

PHARMAFAIR

EQ 75MG BASE/2ML

A062668 001 May 07, 1987

EQ 500MG BASE/2ML

A062672 001 May 07, 1987

EQ 1GM BASE/3ML

A062669 001 May 07, 1987

SOLOPAK

EQ 75MG BASE/2ML

A062605 003 Feb 26, 1986

EQ 500MG BASE/2ML

A062605 001 Feb 26, 1986

EQ 1GM BASE/3ML

A062605 002 Feb 26, 1986

WARNER CHILCOTT

EQ 1GM BASE/3ML

A063092 001 Oct 11, 1989

WATSON LABS

EQ 1GM BASE/3ML

A062520 003 May 09, 1985

KANTREX

APOTHECON

EQ 75MG BASE/2ML

A061655 003

EQ 75MG BASE/2ML

A061901 003

EQ 75MG BASE/2ML

A062564 001 Sep 21, 1984

EQ 500MG BASE/2ML

A061655 001

EQ 500MG BASE/2ML

A061901 001

EQ 500MG BASE/2ML

A062564 002 Sep 21, 1984

EQ 1GM BASE/3ML

A061655 002

EQ 1GM BASE/3ML

A061901 002

EQ 1GM BASE/3ML

A062564 003 Sep 21, 1984

KLEBCIL

KING PHARMS

EQ 75MG BASE/2ML

A062170 001

EQ 500MG BASE/2ML

A062170 002

EQ 1GM BASE/3ML

A062170 003

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

KETOCONAZOLE

CREAM;TOPICAL

NIZORAL

+ JANSSEN PHARMA 2% ** N019084 001 Dec 31, 1985

SHAMPOO;TOPICAL

NIZORAL

+ JANSSEN PHARMS 2% N019927 001 Aug 31, 1990

SUSPENSION;ORAL

NIZORAL

JANSSEN PHARMA 100MG/5ML A070767 001 Nov 07, 1986

TABLET;ORAL

KETOCONAZOLE

AAIPHARMA LLC 200MG A075341 001 Jul 27, 1999

HERITAGE PHARMA 200MG A074971 001 Jun 15, 1999

200MG A075362 001 Jun 15, 1999

SUN PHARM INDUSTRIES 200MG A075314 001 Jun 15, 1999

TEVA 200MG A075273 001 Jun 15, 1999

NIZORAL

+ JANSSEN PHARMS 200MG ** N018533 001

KETOPROFEN

CAPSULE;ORAL

KETOPROFEN

AUROLIFE PHARMA LLC 50MG A074024 001 Dec 29, 1995

75MG A074024 002 Dec 29, 1995

MYLAN 50MG A074035 002 Dec 31, 1996

75MG A074035 003 Dec 31, 1996

TEVA 25MG A073515 001 Dec 22, 1992

ORUDIS

+ WYETH AYERST 25MG ** N018754 001 Jul 31, 1987

+ 50MG ** N018754 002 Jan 09, 1986

+ 75MG ** N018754 003 Jan 09, 1986

CAPSULE, EXTENDED RELEASE;ORAL

KETOPROFEN

ACTAVIS LABS FL INC 100MG A075270 002 Mar 24, 1999

150MG A075270 003 Mar 24, 1999

200MG A075270 001 Mar 24, 1999

ALKERMES GAINESVILLE 200MG A074879 001 Dec 10, 1997

MYLAN 100MG A075679 003 Feb 20, 2002

150MG A075679 002 Feb 20, 2002

ORUVAIL

+ WYETH PHARMS INC 100MG ** N019816 003 Feb 08, 1995

+ 150MG ** N019816 002 Feb 08, 1995

+ 200MG ** N019816 001 Sep 24, 1993

FILM;ORAL

NEXCEDE

NOVARTIS 12.5MG N022470 001 Nov 25, 2009

TABLET;ORAL

ACTRON

BAYER 12.5MG N020499 001 Oct 06, 1995

KETOPROFEN

PERRIGO 12.5MG A075364 001 Feb 07, 2002

ORUDIS KT

+ WYETH CONS 12.5MG ** N020429 001 Oct 06, 1995

KETOROLAC TROMETHAMINE

INJECTABLE;INJECTION

KETOROLAC TROMETHAMINE

AMPHASTAR PHARM 15MG/ML A076209 001 Jul 21, 2004

30MG/ML A076209 002 Jul 21, 2004

APOTEX INC 30MG/ML A075626 001 Jul 24, 2001

30MG/ML A077201 001 Oct 14, 2005

APOTHECON 15MG/ML A075348 001 Nov 28, 2000

30MG/ML A075348 002 Nov 28, 2000

ATLANTIDE 30MG/ML A077943 001 Mar 27, 2007

BAXTER HLTHCARE CORP 15MG/ML A075631 002 Jun 29, 2001

30MG/ML A075631 001 Jun 29, 2001

BEDFORD 15MG/ML A075230 002 Oct 25, 1999

30MG/ML A075230 001 Oct 25, 1999

GLAND PHARMA LTD 15MG/ML A076722 001 Jul 27, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

	30MG/ML	A076722 002	Jul 27, 2004
HOSPIRA	15MG/ML	A074801 001	Jun 05, 1997
	30MG/ML	A074801 002	Jun 05, 1997
LUITPOLD	15MG/ML	A078145 001	Jan 14, 2008
	30MG/ML	A078145 002	Jan 14, 2008
MYLAN LABS LTD	15MG/ML	A078299 001	Jul 16, 2007
	15MG/ML	A201155 001	Aug 04, 2014
	30MG/ML	A078299 002	Jul 16, 2007
	30MG/ML	A201155 002	Aug 04, 2014
SANDOZ INC	15MG/ML	A076271 001	Oct 06, 2004
SUN PHARM	15MG/ML	A078737 001	Oct 06, 2008
	30MG/ML	A078737 002	Oct 06, 2008
WEST-WARD PHARMS INT	15MG/ML **	A075222 001	Apr 26, 1999
	15MG/ML	A075299 001	Nov 03, 1999
	30MG/ML **	A075222 002	Apr 26, 1999
	30MG/ML **	A075228 001	Apr 26, 1999
	30MG/ML	A075299 002	Nov 03, 1999
TORADOL			
+ ROCHE PALO	15MG/ML **	N019698 001	Nov 30, 1989
+	30MG/ML **	N019698 002	Nov 30, 1989
SOLUTION/DROPS; OPHTHALMIC			
ACULAR PRESERVATIVE FREE			
ALLERGAN	0.5%	N020811 001	Nov 03, 1997
KETOROLAC TROMETHAMINE			
AKORN	0.45%	A203376 001	Feb 10, 2014
AUROBINDO PHARMA LTD	0.4%	A205191 001	Nov 15, 2018
SANDOZ INC	0.4%	A078721 001	Nov 05, 2009

TABLET; ORAL

KETOROLAC TROMETHAMINE

CYCLE PHARMS LTD	10MG	A074790 001	Jun 26, 1997
PLIVA	10MG	A075284 001	Jun 23, 1999
WATSON LABS	10MG	A074955 001	Sep 19, 1997
TORADOL			
+ ROCHE PALO	10MG **	N019645 001	Dec 20, 1991

KETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC

ZADITOR

+ ALCON PHARMA	EQ 0.025% BASE **	N021066 002	Oct 19, 2006
----------------	-------------------	-------------	--------------

KRYPTON, KR-81M

GAS; INHALATION

MPI KRYPTON 81M GENERATOR

GE HEALTHCARE	N/A	N018088 001	
---------------	-----	-------------	--

L-GLUTAMINE

FOR SOLUTION; ORAL

NUTRESTORE

+ EMMAUS MEDCL	5GM/PACKET	N021667 001	Jun 10, 2004
----------------	------------	-------------	--------------

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HYDROCHLORIDE

AKORN INC	5MG/ML	A075524 001	Nov 29, 1999
APOTHECON	5MG/ML	A075355 001	Nov 29, 1999
BAXTER HLTHCARE CORP	5MG/ML	A076051 001	Jul 05, 2002
HOSPIRA	5MG/ML	A075242 001	Sep 30, 1999
MYLAN ASI	5MG/ML	A079134 001	Feb 03, 2010
NORMODYNE			
+ SCHERING	5MG/ML	N018686 001	Aug 01, 1984
TRANDATE			
+ SEBELA IRELAND LTD	5MG/ML **	N019425 001	Dec 31, 1985

TABLET; ORAL

LABETALOL HYDROCHLORIDE

APOTHECON	100MG	A075223 001	Nov 20, 1998
	200MG	A075223 002	Nov 20, 1998
	300MG	A075223 003	Nov 20, 1998
TEVA	100MG	A074989 001	Sep 30, 1998

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LABETALOL HYDROCHLORIDE

TABLET; ORAL

LABETALOL HYDROCHLORIDE

200MG	A074989 002	Sep 30, 1998
300MG	A074989 003	Sep 30, 1998

NORMODYNE

+ SCHERING	100MG **	N018687 001	Aug 31, 1987
+	200MG **	N018687 002	Aug 01, 1984
+	300MG **	N018687 003	Aug 01, 1984
+	400MG **	N018687 004	Aug 01, 1984

TRANDATE

+ CNTY LINE PHARMS	400MG **	N018716 004	Aug 01, 1984
--------------------	----------	-------------	--------------

LACTITOL

FOR SOLUTION; ORAL

PIZENSY

+ BRAINTREE LABS	10GM	N211281 001	Feb 12, 2020
------------------	------	-------------	--------------

LACTULOSE

SOLUTION; ORAL

CHRONULAC

+ SANOFI AVENTIS US	10GM/15ML **	N017884 001	
---------------------	--------------	-------------	--

CONSTULOSE

ACTAVIS MID ATLANTIC	10GM/15ML	A070288 001	Aug 15, 1988
----------------------	-----------	-------------	--------------

DUPHALAC

SOLVAY	10GM/15ML	A072372 001	Mar 22, 1989
--------	-----------	-------------	--------------

EVALOSE

TEVA PHARMS	10GM/15ML	A073497 001	May 28, 1993
-------------	-----------	-------------	--------------

LACTULOSE

ANI PHARMS	10GM/15ML	A078430 001	Nov 28, 2007
HIKMA	10GM/15ML	A073591 001	May 29, 1992
MORTON GROVE	10GM/15ML	A071841 001	Sep 22, 1988
PACO	10GM/15ML	A073160 001	Aug 25, 1992
TORRENT	10GM/15ML	A207786 001	Jun 11, 2018

LAXILOSE

NOSTRUM LABS	10GM/15ML	A073686 001	May 28, 1993
--------------	-----------	-------------	--------------

SOLUTION; ORAL, RECTAL

ACILAC

NOSTRUM LABS	10GM/15ML	A073685 001	May 28, 1993
--------------	-----------	-------------	--------------

CEPHULAC

+ SANOFI AVENTIS US	10GM/15ML **	N017657 001	
---------------------	--------------	-------------	--

ENULOSE

ACTAVIS MID ATLANTIC	10GM/15ML	A071548 001	Aug 15, 1988
----------------------	-----------	-------------	--------------

GENERLAC

MORTON GROVE	10GM/15ML	A071842 001	Sep 27, 1988
--------------	-----------	-------------	--------------

HEPTALAC

TEVA PHARMS	10GM/15ML	A073504 001	May 28, 1993
-------------	-----------	-------------	--------------

LACTULOSE

ANI PHARMS	10GM/15ML	A090426 001	Nov 21, 2008
BAJAJ	10GM/15ML	A076645 001	Jul 28, 2003
PACO	10GM/15ML	A072029 001	Aug 25, 1992
ROXANE	10GM/15ML	A073590 001	May 29, 1992
SOLVAY	10GM/15ML	N017906 001	
TORRENT	10GM/15ML	A203762 001	Mar 27, 2015

PORTALAC

SOLVAY	10GM/15ML	A072374 001	Mar 22, 1989
--------	-----------	-------------	--------------

LAMIVUDINE

TABLET; ORAL

LAMIVUDINE

MYLAN	100MG	A204002 001	Dec 31, 2014
	150MG	A204528 001	Mar 04, 2016
	300MG	A204528 002	Mar 04, 2016

LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE

TABLET; ORAL

LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE

+ MICRO LABS	150MG; 200MG; 300MG	N205626 001	Aug 13, 2018
--------------	---------------------	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LAMIVUDINE; RALTEGRAVIR POTASSIUM

TABLET; ORAL

DUTREBIS

MERCK SHARP DOHME	150MG;EQ 300MG BASE	N206510	001	Feb 06, 2015
-------------------	---------------------	---------	-----	--------------

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

LAMIVUDINE AND ZIDOVUDINE

MYLAN	150MG;300MG	A204005	001	Aug 28, 2014
MYLAN LABS LTD	150MG;300MG	A079079	001	Aug 12, 2019
PHARMACARE	150MG;300MG	N022018	001	Mar 17, 2017
TEVA PHARMS	150MG;300MG	A079081	001	May 25, 2011

LAMOTRIGINE

TABLET; ORAL

LAMICTAL

+ GLAXOSMITHKLINE LLC	50MG **	N020241	006	Dec 27, 1994
+	250MG **	N020241	004	Dec 27, 1994

LAMOTRIGINE

ACTAVIS TOTOWA	25MG	A078669	001	Apr 08, 2011
	100MG	A078669	002	Apr 08, 2011
	150MG	A078669	003	Apr 08, 2011
	200MG	A078669	004	Apr 08, 2011
CELLTRION	25MG	A078982	001	Jan 27, 2009
	100MG	A078982	002	Jan 27, 2009
	150MG	A078982	003	Jan 27, 2009
	200MG	A078982	004	Jan 27, 2009
CIPLA	25MG	A077783	001	Nov 01, 2010
	100MG	A077783	002	Nov 01, 2010
	150MG	A077783	003	Nov 01, 2010
	200MG	A077783	004	Nov 01, 2010
HIKMA PHARMS	25MG	A078134	001	Apr 19, 2011
	100MG	A078134	002	Apr 19, 2011
	150MG	A078134	003	Apr 19, 2011
	200MG	A078134	004	Apr 19, 2011
MYLAN	25MG	A077420	001	Jan 27, 2009
	25MG	A077428	001	Jan 27, 2009
	100MG	A077420	002	Jan 27, 2009
	100MG	A077428	002	Jan 27, 2009
	150MG	A077420	003	Jan 27, 2009
	150MG	A077428	003	Jan 27, 2009
	200MG	A077420	004	Jan 27, 2009
	200MG	A077428	004	Jan 27, 2009
MYLAN LABS LTD	25MG	A078443	001	Feb 11, 2009
	100MG	A078443	002	Feb 11, 2009
	150MG	A078443	003	Feb 11, 2009
	200MG	A078443	004	Feb 11, 2009
PHARMASCIENCE INC	25MG	A078310	001	Feb 04, 2009
	100MG	A078310	002	Feb 04, 2009
	150MG	A078310	003	Feb 04, 2009
	200MG	A078310	004	Feb 04, 2009
ROXANE	25MG	A077392	001	Jan 27, 2009
	100MG	A077392	002	Jan 27, 2009
	150MG	A077392	003	Jan 27, 2009
	200MG	A077392	004	Jan 27, 2009
SANDOZ	25MG	A078645	001	Jan 27, 2009
	100MG	A078645	002	Jan 27, 2009
	150MG	A078645	003	Jan 27, 2009
	200MG	A078645	004	Jan 27, 2009
TEVA	25MG	A076388	001	Aug 30, 2006
	100MG	A076388	002	Aug 30, 2006
	150MG	A076388	003	Aug 30, 2006
	200MG	A076388	004	Aug 30, 2006

TABLET, CHEWABLE; ORAL

LAMICTAL CD

GLAXOSMITHKLINE LLC	100MG	N020764	003	Aug 24, 1998
---------------------	-------	---------	-----	--------------

LAMOTRIGINE

MYLAN	5MG	A076630	001	Jan 22, 2009
	25MG	A076630	002	Jan 22, 2009
SANDOZ	5MG	A078409	002	Jan 22, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LAMOTRIGINE

TABLET, CHEWABLE;ORAL

LAMOTRIGINE

	25MG	A078409 003	Jan 22, 2009
TEVA	5MG	A076420 001	Jun 21, 2006
	25MG	A076420 002	Jun 21, 2006

TABLET, EXTENDED RELEASE;ORAL

LAMOTRIGINE

RUBICON	25MG	A202887 001	Jun 17, 2013
	50MG	A202887 002	Jun 17, 2013

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE

AJANTA PHARMA LTD	15MG	A203957 001	Oct 14, 2016
	30MG	A203957 002	Oct 14, 2016
BRECKENRIDGE	15MG	A203964 001	Oct 17, 2018
	30MG	A203964 002	Oct 17, 2018
KRKA TOVARNA ZDRAVIL	15MG	A091212 001	Sep 16, 2013
	30MG	A091212 002	Sep 16, 2013

FOR SUSPENSION, DELAYED RELEASE;ORAL

PREVACID

TAKEDA PHARMS NA	15MG/PACKET	N021281 001	May 03, 2001
	30MG/PACKET	N021281 002	May 03, 2001

INJECTABLE;INTRAVENOUS

PREVACID IV

+ TAKEDA PHARMS NA	30MG/VIAL **	N021566 001	May 27, 2004
--------------------	--------------	-------------	--------------

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

LANSOPRAZOLE

ANI PHARMS INC	15MG	A078730 001	Oct 15, 2010
	30MG	A078730 002	Oct 15, 2010

LANSOPRAZOLE; NAPROXEN

CAPSULE, DELAYED REL PELLETS, TABLET;ORAL

PREVACID NAPRAPAC 250 (COPACKAGED)

+ TAKEDA PHARMS NA	15MG,N/A;N/A,250MG **	N021507 002	Nov 14, 2003
--------------------	-----------------------	-------------	--------------

PREVACID NAPRAPAC 375 (COPACKAGED)

TAKEDA PHARMS NA	15MG,N/A;N/A,375MG	N021507 003	Nov 14, 2003
------------------	--------------------	-------------	--------------

PREVACID NAPRAPAC 500 (COPACKAGED)

TAKEDA PHARMS NA	15MG,N/A;N/A,500MG	N021507 004	Nov 14, 2003
------------------	--------------------	-------------	--------------

LANTHANUM CARBONATE

TABLET, CHEWABLE;ORAL

FOSRENOL

TAKEDA PHARMS USA	EQ 250MG BASE	N021468 001	Oct 26, 2004
-------------------	---------------	-------------	--------------

LAPYRIUM CHLORIDE; UNDECOYLIUM CHLORIDE IODINE COMPLEX

SOLUTION;TOPICAL

VIRAC REX

CHESEBROUGH PONDS	0.5%;1.8%	N011914 001	
-------------------	-----------	-------------	--

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC

LATANOPROST

APOTEX INC	0.005%	A077697 001	Mar 22, 2011
AUROBINDO PHARMA LTD	0.005%	A206519 001	Sep 03, 2019

LEFLUNOMIDE

TABLET;ORAL

LEFLUNOMIDE

BARR	10MG	A077083 001	Sep 13, 2005
	20MG	A077083 002	Sep 13, 2005
SANDOZ	10MG	A077085 001	Sep 13, 2005
	20MG	A077085 002	Sep 13, 2005
TEVA PHARMS	10MG	A077084 001	Sep 13, 2005
	20MG	A077084 002	Sep 13, 2005

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LESINURAD

TABLET; ORAL

ZURAMPIC

+ IRONWOOD PHARMS INC 200MG N207988 001 Dec 22, 2015

LETROZOLE

TABLET; ORAL

LETROZOLE

ACTAVIS TOTOWA	2.5MG	A090292	001	Jul 13, 2011
FRESENIUS KABI USA	2.5MG	A090491	001	Jun 03, 2011
HIKMA	2.5MG	A090838	001	Jun 03, 2011
HIKMA PHARMS	2.5MG	A203796	001	Jun 03, 2016
IMPAX LABS	2.5MG	A091638	001	Jun 03, 2011
JIANGSU HENGRUI MED	2.5MG	A202716	001	May 16, 2013
LANNETT CO INC	2.5MG	A091098	001	Jun 03, 2011
	2.5MG	A202048	001	Oct 29, 2014
MYLAN	2.5MG	A078190	001	Dec 24, 2008
SUN PHARM INDS LTD	2.5MG	A091466	001	Jun 03, 2011
SYNTHON PHARMS	2.5MG	A090196	001	Jun 03, 2011
VINTAGE PHARMS LLC	2.5MG	A090789	001	Jun 03, 2011

LEUCOVORIN CALCIUM

FOR SOLUTION; ORAL

LEUCOVORIN CALCIUM

HOSPIRA EQ 60MG BASE/VIAL N008107 003 Jan 30, 1987

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

ABIC EQ 3MG BASE/ML A089352 001 Jun 01, 1988

EQ 50MG BASE/VIAL A089353 001 Jun 01, 1988

ABRAXIS PHARM EQ 50MG BASE/VIAL A088939 001 Dec 01, 1986

ELKINS SINN EQ 50MG BASE/VIAL A070480 001 Jan 02, 1987

EQ 100MG BASE/VIAL A081224 001 Jun 03, 1994

+ HOSPIRA EQ 3MG BASE/ML ** N008107 001

+ EQ 50MG BASE/VIAL ** N008107 002

+ EQ 100MG BASE/VIAL ** N008107 004 May 23, 1988

+ EQ 350MG BASE/VIAL ** N008107 005 Apr 05, 1989

INGENUS PHARMS LLC EQ 10MG BASE/ML A210917 001 Nov 23, 2018

PHARMACHEMIE EQ 350MG BASE/VIAL A040262 001 Dec 15, 1999

PHARMACHEMIE USA EQ 50MG BASE/VIAL A089628 001 Apr 17, 1997

EQ 100MG BASE/VIAL A089915 001 Apr 17, 1997

TEVA PARENTERAL EQ 50MG BASE/VIAL A081278 001 Sep 28, 1993

LEUCOVORIN CALCIUM PRESERVATIVE FREE

AM REGENT EQ 50MG BASE/VIAL A040338 001 Jan 31, 2001

HOSPIRA EQ 10MG BASE/ML ** A040147 001 Jun 25, 1997

TEVA PARENTERAL EQ 10MG BASE/ML A040332 001 Jun 28, 1999

WELLCOVORIN

GLAXOSMITHKLINE EQ 5MG BASE/ML A087439 001 Oct 19, 1982

EQ 25MG BASE/VIAL A089833 001 Jan 23, 1989

EQ 50MG BASE/VIAL A089465 001 Jan 23, 1989

EQ 100MG BASE/VIAL A089834 001 Jan 23, 1989

TABLET; ORAL

LEUCOVORIN CALCIUM

ANI PHARMS INC EQ 15MG BASE A075327 001 Mar 24, 1999

PAR PHARM EQ 5MG BASE A071600 001 Oct 14, 1987

EQ 25MG BASE A071598 001 Oct 14, 1987

PHARMACHEMIE EQ 5MG BASE A073099 001 Mar 28, 1997

EQ 25MG BASE A073101 001 Mar 28, 1997

XANODYNE PHARM EQ 5MG BASE N018459 001 Jan 30, 1986

EQ 10MG BASE A071962 001 Nov 19, 1987

EQ 15MG BASE A071104 001 Mar 04, 1987

WELLCOVORIN

+ GLAXOSMITHKLINE EQ 5MG BASE ** N018342 001 Jul 08, 1983

+ EQ 25MG BASE ** N018342 002 Jul 08, 1983

LEUPROLIDE ACETATE

FOR SUSPENSION; INTRAMUSCULAR

LUTRATE DEPOT KIT

+ GP-PHARM SA 22.5MG/VIAL N205054 001 Aug 28, 2018

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LEUPROLIDE ACETATE

IMPLANT; IMPLANTATION

VIADUR

ORTHO MCNEIL JANSSEN EQ 65MG BASE

N021088 001 Mar 03, 2000

INJECTABLE; INJECTION

LEUPROLIDE ACETATE

GENZYME 1MG/0.2ML

A075721 001 Nov 29, 2001

LUPRON

+ ABBVIE ENDOCRINE INC 1MG/0.2ML **

N019010 001 Apr 09, 1985

LUPRON DEPOT

+ ABBVIE ENDOCRINE INC 3.75MG/VIAL **

N020011 001 Oct 22, 1990

POWDER; INTRAMUSCULAR

LUPRON DEPOT-PED KIT

+ ABBVIE ENDOCRINE INC 3.75MG, 7.5MG **

N020263 003 Apr 16, 1993

+ 7.5MG, 7.5MG **

N020263 004 Apr 16, 1993

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

LEVALBUTEROL HYDROCHLORIDE

MYLAN SPECIALITY LP EQ 0.0103% BASE

A077800 001 Mar 15, 2013

EQ 0.021% BASE

A077800 002 Mar 15, 2013

EQ 0.042% BASE

A077800 003 Mar 15, 2013

LEVALLORPHAN TARTRATE

INJECTABLE; INJECTION

LORFAN

ROCHE 1MG/ML

N010423 001

LEVAMISOLE HYDROCHLORIDE

TABLET; ORAL

ERGAMISOL

JANSSEN PHARMA EQ 50MG BASE

N020035 001 Jun 18, 1990

LEVAMLODIPINE MALEATE

TABLET; ORAL

CONJUPRI

+ CSPC OUYI EQ 1.25MG BASE

N212895 001 Dec 19, 2019

LEVETIRACETAM

INJECTABLE; INTRAVENOUS

LEVETIRACETAM

AKORN 500MG/5ML (100MG/ML)

A209934 001 May 04, 2018

AM REGENT 500MG/5ML (100MG/ML)

A202143 001 Jan 31, 2012

FRESENIUS KABI USA 500MG/5ML (100MG/ML)

A090813 001 May 26, 2010

SOLUTION; ORAL

LEVETIRACETAM

ANDA REPOSITORY 100MG/ML

A079107 001 Jan 15, 2009

APOTEX INC 100MG/ML

A090187 001 Aug 05, 2011

TABLET; ORAL

LEVETIRACETAM

ACTAVIS LABS FL INC 250MG

A077408 001 Mar 02, 2009

500MG

A077408 002 Mar 02, 2009

750MG

A077408 003 Mar 02, 2009

FOSUN PHARMA 250MG

A077324 001 Jan 15, 2009

500MG

A077324 002 Jan 15, 2009

750MG

A077324 003 Jan 15, 2009

1GM

A077324 004 Jan 15, 2009

MYLAN 250MG

A078731 001 Feb 10, 2009

500MG

A078731 002 Feb 10, 2009

750MG

A078731 003 Feb 10, 2009

1GM

A078731 004 Feb 10, 2009

TEVA PHARMS 250MG

A078101 001 Jan 15, 2009

500MG

A078101 002 Jan 15, 2009

750MG

A078101 003 Jan 15, 2009

1GM

A078101 004 Jan 15, 2009

WATSON LABS INC 250MG

A078797 002 Jan 15, 2009

500MG

A078797 003 Jan 15, 2009

750MG

A078797 004 Jan 15, 2009

1GM

A078797 001 Jan 15, 2009

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LEVETIRACETAM

TABLET, EXTENDED RELEASE;ORAL

LEVETIRACETAM

ACTAVIS ELIZABETH	500MG	A091557 001	Sep 12, 2011
	750MG	A091557 002	Sep 12, 2011
MYLAN PHARMS INC	500MG	A200475 001	Dec 19, 2011
	750MG	A200475 002	Dec 19, 2011
	1GM	A200475 003	Dec 07, 2015
OVERSEAS	750MG	A212688 001	Jun 11, 2020
SANDOZ	500MG	A091668 001	Nov 01, 2012
	750MG	A091668 002	Nov 01, 2012
SUN PHARM INDUSTRIES	500MG	A091285 001	Sep 12, 2011
	750MG	A091285 002	Sep 12, 2011
TEVA PHARMS	500MG	A091430 001	Sep 12, 2011
	750MG	A091430 002	Sep 12, 2011
TORRENT PHARMS LTD	500MG	A091338 001	May 29, 2012
	750MG	A091338 002	May 29, 2012
VIRTUS PHARMS	500MG	A091291 001	Sep 12, 2011
	750MG	A091291 002	Sep 12, 2011

LEVOBETAXOLOL HYDROCHLORIDE

SUSPENSION/DROPS;OPHTHALMIC

BETAXON

ALCON PHARMS LTD	EQ 0.5% BASE	N021114 001	Feb 23, 2000
------------------	--------------	-------------	--------------

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

LEVOBUNOLOL HYDROCHLORIDE

ALCON LABS INC	0.25%	A074851 001	Oct 28, 1996
APOTEX INC	0.25%	A075473 001	Aug 03, 2000
	0.5%	A075475 001	Aug 03, 2000
BAUSCH AND LOMB	0.25%	A074307 001	Mar 04, 1994
SANDOZ INC	0.5%	A074850 001	Oct 28, 1996

LEVOBUPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

CHIROCAINE

PURDUE PHARMA LP	EQ 2.5MG BASE/ML	N020997 001	Aug 05, 1999
	EQ 5MG BASE/ML	N020997 002	Aug 05, 1999
	EQ 7.5MG BASE/ML	N020997 003	Aug 05, 1999

LEVOCABASTINE HYDROCHLORIDE

SUSPENSION/DROPS;OPHTHALMIC

LIVOSTIN

NOVARTIS	EQ 0.05% BASE	N020219 001	Nov 10, 1993
----------	---------------	-------------	--------------

LEVOCARNITINE

INJECTABLE;INJECTION

LEVOCARNITINE

TEVA PHARMS USA	200MG/ML	A075881 001	Mar 29, 2001
-----------------	----------	-------------	--------------

SOLUTION;ORAL

CARNITOR

LEADIANT BIOSCI INC	1GM/10ML	N018948 002	Apr 27, 1988
---------------------	----------	-------------	--------------

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

APOTEX	2.5MG/5ML	A202915 001	Aug 21, 2014
--------	-----------	-------------	--------------

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

APOTEX	5MG	A203027 001	Feb 13, 2015
FOSUN PHARMA	5MG	A090486 001	Mar 26, 2013

LEVODOPA

CAPSULE;ORAL

BENDOPA

VALEANT PHARM INTL	100MG	N016948 003	
	250MG	N016948 001	
	500MG	N016948 002	

DOPAR

SHIRE	100MG	N016913 003	
	250MG	N016913 001	
	500MG	N016913 002	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LEVODOPA

CAPSULE; ORAL

LARODOPA

ROCHE	100MG	N016912 002
	250MG	N016912 001
	500MG	N016912 006

TABLET; ORAL

DOPAR

SHIRE	250MG	N016913 004
	500MG	N016913 005

LARODOPA

ROCHE	100MG	N016912 005
	250MG	N016912 003
	500MG	N016912 004

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVAQUIN

+ JANSSEN PHARMS	EQ 500MG/20ML (EQ 25MG/ML)	N020635 001	Dec 20, 1996
+ JANSSEN PHARMS	EQ 750MG/30ML (EQ 25MG/ML)	N020635 004	Dec 20, 1996

LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER

+ JANSSEN PHARMS	EQ 250MG/50ML (EQ 5MG/ML) **	N020635 002	Dec 20, 1996
+ JANSSEN PHARMS	EQ 500MG/100ML (EQ 5MG/ML) **	N020635 003	Dec 20, 1996
+ JANSSEN PHARMS	EQ 750MG/150ML (EQ 5MG/ML) **	N020635 005	Dec 20, 1996

LEVOFLOXACIN

EMCURE PHARMS LTD	EQ 500MG/20ML (EQ 25MG/ML)	A202590 001	Jan 24, 2013
	EQ 750MG/30ML (EQ 25MG/ML)	A202590 002	Jan 24, 2013
HOSPIRA INC	EQ 500MG/20ML (EQ 25MG/ML)	A078577 001	Aug 12, 2015
	EQ 750MG/30ML (EQ 25MG/ML)	A078577 002	Aug 12, 2015
MYLAN ASI	EQ 500MG/20ML (EQ 25MG/ML)	A200560 001	Jun 20, 2011
	EQ 750MG/30ML (EQ 25MG/ML)	A200560 002	Jun 20, 2011
ZYDUS PHARMS	EQ 500MG/20ML (EQ 25MG/ML)	A205968 001	Jun 01, 2017
	EQ 750MG/30ML (EQ 25MG/ML)	A205968 002	Jun 01, 2017

SOLUTION; ORAL

LEVAQUIN

+ JANSSEN PHARMS	250MG/10ML	N021721 001	Oct 21, 2004
------------------	------------	-------------	--------------

SOLUTION/DROPS; OPHTHALMIC

IQUIX

+ SANTEN	1.5% **	N021571 001	Mar 01, 2004
----------	---------	-------------	--------------

LEVOFLOXACIN

MYLAN LABS LTD	0.5%	A204899 001	Dec 08, 2017
RUBICON	0.5%	A078282 001	Dec 20, 2010
WATSON LABS TEVA	0.5%	A076826 001	Feb 10, 2011

QUIXIN

+ SANTEN	0.5% **	N021199 001	Aug 18, 2000
----------	---------	-------------	--------------

TABLET; ORAL

LEVAQUIN

+ JANSSEN PHARMS	250MG	N020634 001	Dec 20, 1996
+ JANSSEN PHARMS	500MG	N020634 002	Dec 20, 1996
+ JANSSEN PHARMS	750MG	N020634 003	Sep 08, 2000

LEVOFLOXACIN

MYLAN	250MG	A076276 001	Jun 20, 2011
	500MG	A076276 002	Jun 20, 2011
	750MG	A077097 001	Jun 20, 2011
TORRENT PHARMS	250MG	A090722 001	Jun 20, 2011
	500MG	A090722 002	Jun 20, 2011
	750MG	A090722 003	Jun 20, 2011
WATSON LABS INC	250MG	A201484 001	Nov 22, 2013
	500MG	A201484 002	Nov 22, 2013
	750MG	A201484 003	Nov 22, 2013

LEVOLEUCOVORIN CALCIUM

POWDER; INTRAVENOUS

LEVOLEUCOVORIN CALCIUM

ACTAVIS LLC	EQ 50MG BASE/VIAL	A206516 001	Feb 13, 2017
+ AMNEAL	EQ 175MG BASE/VIAL	N208723 001	Sep 29, 2016
+ AMNEAL	EQ 50MG BASE/VIAL	A207547 001	Feb 13, 2017

SOLUTION; INTRAVENOUS

FUSILEV

+ ACROTECH	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	N020140 002	Apr 29, 2011
------------	--	-------------	--------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LEVOLEUCOVORIN CALCIUMSOLUTION; INTRAVENOUS
FUSILEV

	**				
+	EQ 250MG BASE/25ML (EQ 10MG BASE/ML) **	N020140	003	Apr 29, 2011	
LEVOLEUCOVORIN CALCIUM					
MYLAN TEORANTA	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A203576	001	Oct 20, 2015	
	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203576	002	Oct 20, 2015	
SANDOZ INC	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203563	002	Mar 09, 2015	

LEVOMEPRMAZINE

INJECTABLE; INJECTION

LEVOPROME

IMMUNEX

20MG/ML

N015865 001

LEVOMETHADYL ACETATE HYDROCHLORIDE

CONCENTRATE; ORAL

ORLAAM

+ ROXANE

10MG/ML **

N020315 001 Jul 09, 1993

LEVOMILNACIPRAN HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

LEVOMILNACIPRAN HYDROCHLORIDE

AMNEAL PHARMS CO

EQ 20MG BASE

A210790 001 Feb 04, 2019

EQ 40MG BASE

A210790 002 Feb 04, 2019

EQ 80MG BASE

A210790 003 Feb 04, 2019

EQ 120MG BASE

A210790 004 Feb 04, 2019

LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN

SOLVAY

0.05MG/ML; 2%

A085010 001

CARBOCAINE W/ NEO-COBEFRIN

EASTMAN KODAK

0.05MG/ML; 2%

N012125 002

ISOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN

SEPTODONT INC

0.05MG/ML; 2%

A084697 001

MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN

BELMORA LLC

0.05MG/ML; 2%

A084850 002 Oct 21, 1983

POLOCAINE W/ LEVONORDEFRIN

DENTSPLY PHARM

0.05MG/ML; 2%

A089517 001 Apr 14, 1988

LEVONORDEFRIN; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

RAVOCAINE AND NOVOCAIN W/ NEO-COBEFRIN

EASTMAN KODAK

0.05MG/ML; 2%; 0.4%

N008592 007

LEVONORGESTREL

IMPLANT; IMPLANTATION

JADELLE

+ POPULATION COUNCIL

75MG/IMPLANT **

N020544 001 Nov 01, 1996

LEVONORGESTREL

WYETH PHARMS INC

75MG/IMPLANT

N020627 001 Aug 15, 1996

NORPLANT

POPULATION COUNCIL

36MG/IMPLANT

N019897 001 Dec 10, 1990

NORPLANT SYSTEM IN PLASTIC CONTAINER

WYETH PHARMS INC

36MG/IMPLANT

N020088 001 Dec 10, 1990

TABLET; ORAL

LEVONORGESTREL

ALVOGEN

1.5MG

A202246 001 Jun 05, 2015

FDN CONSUMER

0.75MG **

A078665 001 Aug 28, 2009

1.5MG

A200670 001 Jul 12, 2012

LOTUS PHARM CO LTD

0.75MG

A202684 001 Sep 02, 2016

LUPIN LTD

0.75MG

A091328 001 Jan 23, 2013

MYLAN LABS LTD

0.75MG

A202740 001 Sep 02, 2016

NAARI PTE LTD

1.5MG

A207660 001 May 02, 2019

WATSON LABS

0.75MG

A078666 001 Jun 24, 2009

PLAN B

+ FDN CONSUMER

0.75MG **

N021045 001 Jul 28, 1999

+

0.75MG **

N021045 002 Aug 24, 2006

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LEVOPROPOXYPHENE NAPSYLATE ANHYDROUS

CAPSULE; ORAL

NOVRAD

LILLY	EQ 50MG BASE	N012928	006	
	EQ 100MG BASE	N012928	004	

SUSPENSION; ORAL

NOVRAD

LILLY	EQ 50MG BASE/5ML	N012928	002	
-------	------------------	---------	-----	--

LEVORPHANOL TARTRATE

INJECTABLE; INJECTION

LEVO-DROMORAN

VALEANT PHARM INTL	2MG/ML	N008719	001	Dec 19, 1991
--------------------	--------	---------	-----	--------------

TABLET; ORAL

LEVO-DROMORAN

+ VALEANT PHARM INTL	2MG **	N008720	001	Dec 19, 1991
----------------------	--------	---------	-----	--------------

LEVORPHANOL TARTRATE

SENTYNL THERAPS INC	1MG	A074278	002	Jun 18, 2018
---------------------	-----	---------	-----	--------------

LEVOTHYROXINE SODIUM

POWDER; INTRAVENOUS

LEVOTHYROXINE SODIUM

PAR STERILE PRODUCTS	200MCG/VIAL	A205366	001	Dec 07, 2015
----------------------	-------------	---------	-----	--------------

TABLET; ORAL

EUTHYROX

PROVELL	0.3MG	N021292	012	May 31, 2002
---------	-------	---------	-----	--------------

LEVOLET

GENUS LIFESCIENCES	0.025MG	N021137	001	Jun 06, 2003
--------------------	---------	---------	-----	--------------

	0.05MG	N021137	002	Jun 06, 2003
--	--------	---------	-----	--------------

	0.075MG	N021137	003	Jun 06, 2003
--	---------	---------	-----	--------------

	0.088MG	N021137	004	Jun 06, 2003
--	---------	---------	-----	--------------

	0.1MG	N021137	005	Jun 06, 2003
--	-------	---------	-----	--------------

	0.112MG	N021137	006	Jun 06, 2003
--	---------	---------	-----	--------------

	0.125MG	N021137	007	Jun 06, 2003
--	---------	---------	-----	--------------

	0.137MG	N021137	008	Jun 06, 2003
--	---------	---------	-----	--------------

	0.15MG	N021137	009	Jun 06, 2003
--	--------	---------	-----	--------------

	0.175MG	N021137	010	Jun 06, 2003
--	---------	---------	-----	--------------

	0.2MG	N021137	011	Jun 06, 2003
--	-------	---------	-----	--------------

	0.3MG	N021137	012	Jun 06, 2003
--	-------	---------	-----	--------------

LEVOTHYROXINE SODIUM

AMNEAL

	0.025MG	A210831	001	Feb 19, 2019
--	---------	---------	-----	--------------

	0.05MG	A210831	002	Feb 19, 2019
--	--------	---------	-----	--------------

	0.075MG	A210831	003	Feb 19, 2019
--	---------	---------	-----	--------------

	0.088MG	A210831	004	Feb 19, 2019
--	---------	---------	-----	--------------

	0.1MG	A210831	005	Feb 19, 2019
--	-------	---------	-----	--------------

	0.112MG	A210831	006	Feb 19, 2019
--	---------	---------	-----	--------------

	0.125MG	A210831	007	Feb 19, 2019
--	---------	---------	-----	--------------

	0.137MG	A210831	008	Feb 19, 2019
--	---------	---------	-----	--------------

	0.15MG	A210831	009	Feb 19, 2019
--	--------	---------	-----	--------------

	0.175MG	A210831	010	Feb 19, 2019
--	---------	---------	-----	--------------

	0.2MG	A210831	011	Feb 19, 2019
--	-------	---------	-----	--------------

	0.3MG	A210831	012	Feb 19, 2019
--	-------	---------	-----	--------------

MERCK KGAA	0.025MG	A076752	001	Jun 16, 2005
------------	---------	---------	-----	--------------

	0.05MG	A076752	002	Jun 16, 2005
--	--------	---------	-----	--------------

	0.075MG	A076752	003	Jun 16, 2005
--	---------	---------	-----	--------------

	0.088MG	A076752	004	Jun 16, 2005
--	---------	---------	-----	--------------

	0.1MG	A076752	005	Jun 16, 2005
--	-------	---------	-----	--------------

	0.112MG	A076752	006	Jun 16, 2005
--	---------	---------	-----	--------------

	0.125MG	A076752	007	Jun 16, 2005
--	---------	---------	-----	--------------

	0.15MG	A076752	008	Jun 16, 2005
--	--------	---------	-----	--------------

	0.175MG	A076752	009	Jun 16, 2005
--	---------	---------	-----	--------------

	0.2MG	A076752	010	Jun 16, 2005
--	-------	---------	-----	--------------

	0.3MG	A076752	011	Jun 16, 2005
--	-------	---------	-----	--------------

LEVOXYL

+ KING PHARMS	0.3MG **	N021301	012	May 25, 2001
---------------	----------	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LIDOCAINE

AEROSOL;ORAL

XYLOCAINE

ASTRAZENECA 10% N014394 001

FILM, EXTENDED RELEASE;BUCCAL

DENTIPATCH

NOVEN 23MG/PATCH N020575 001 May 21, 1996

OINTMENT;TOPICAL

ALPHACAINE

CARLISLE 5% A084944 001

5% A084946 001

5% A084947 001

LIDOCAINE

BELMORA LLC 5% A080210 001

GENEYORK PHARMS 5% A212486 001 Oct 17, 2019

NOVAST LABS 5% A208604 001 Sep 20, 2017

TEVA PHARMS USA 5% A210256 001 Jan 16, 2018

XYLOCAINE

+ ASTRAZENECA 5% ** N008048 001

PATCH;TOPICAL

DENTIPATCH

NOVEN 46.1MG/PATCH N020575 002 May 21, 1996

SOLUTION;TOPICAL

XYLOCAINE

ASTRAZENECA 5% N014127 001

SUPPOSITORY;RECTAL

XYLOCAINE

ASTRAZENECA 100MG N013077 001

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

ALPHACAINE HYDROCHLORIDE

CARLISLE 2% A084721 001

LIDOCAINE HYDROCHLORIDE

ABBOTT 10% A087980 001 Feb 02, 1983

20% A089362 001 May 25, 1988

ABRAXIS PHARM 1% A080420 001

1% A086761 001

1.5% A080420 005

2% A080420 002

2% A080420 004

2% A086761 002

2% N017508 001

4% N017508 002

20% N017508 004

AKORN 1% A085037 001

2% A085037 002

AM REGENT 1% A080850 001

1% A091564 001 Aug 14, 2015

BEL MAR 1% A080710 001

2% A080760 001

BELMORA LLC 2% A080504 001

DELL LABS 1% A083387 001

2% A083388 001

ELKINS SINN 0.5% A085131 001

4% A084626 001

GD SEARLE LLC 1% A083135 001

2% A083135 002

HOSPIRA 1% A040013 001 Jun 23, 1995

1.5% A088330 001 May 17, 1984

2% A088331 001 May 17, 1984

20% A083158 003

INTL MEDICATION 1% N017701 002

2% N017701 001

1GM/VIAL N018543 001

2GM/VIAL N018543 002

LUITPOLD 2% A083198 001

LYPHOMED 1% A080390 001

2% A080390 002

MILES 1% A080414 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE	2%	A080414 002	
MYLAN LABS LTD	0.5%	A091056 001	Dec 08, 2010
	0.5%	A091058 001	Sep 30, 2010
	1%	A091056 002	Dec 08, 2010
	1%	A091058 002	Sep 30, 2010
	2%	A202242 001	Apr 11, 2014
WATSON LABS	1%	A080377 001	
	1%	A083627 001	
	2%	A080377 002	
	2%	A083627 002	
WYETH AYERST	1%	A083083 001	
	2%	A083083 002	
LIDOCAINE HYDROCHLORIDE 0.1% AND DEXTROSE 5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	100MG/100ML	N018461 001	
LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	200MG/100ML	N018967 001	Mar 30, 1984
LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5%			
HOSPIRA	200MG/100ML	A083158 005	
LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER			
ABBOTT	200MG/100ML	N018954 001	Jul 09, 1985
HOSPIRA	200MG/100ML	N018388 001	
LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	400MG/100ML	N018967 002	Mar 30, 1984
LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5%			
HOSPIRA	400MG/100ML	A083158 006	
LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER			
HOSPIRA	400MG/100ML	N018388 002	
LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	800MG/100ML	N018967 003	Mar 30, 1984
LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER			
HOSPIRA	800MG/100ML	N018388 003	Nov 05, 1982
LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER			
HOSPIRA	1.5%	A088326 001	Jul 31, 1984
	10%	A088367 001	Jul 31, 1984
	20%	A088368 001	Jul 31, 1984
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE			
INTL MEDICATION	4%	N017702 002	
	20%	N017702 001	
MYLAN LABS LTD	2%	A090665 001	Sep 27, 2010
LIDOCATON			
PHARMATON	2%	A084727 001	Aug 17, 1983
LIDOPEN			
MERIDIAN MEDCL TECHN	10%	N017549 001	
XYLOCAINE			
ASTRAZENECA	1%	N010418 005	
	1.5%	N010418 009	
	2%	N010418 007	
XYLOCAINE 4% PRESERVATIVE FREE			
+ FRESENIUS KABI USA	4%	N010417 001	
XYLOCAINE DENTAL			
DENTSPLY PHARM	2%	N021380 001	
XYLOCAINE PRESERVATIVE FREE			
+ FRESENIUS KABI USA	1%	N016801 005	Jan 19, 1988
	2%	N016801 001	
	4%	N016801 002	
	10%	N016801 003	
	20%	N016801 004	
INJECTABLE; SPINAL			
XYLOCAINE 1.5% W/ DEXTROSE 7.5%			
FRESENIUS KABI USA	1.5%	N016297 001	
XYLOCAINE 5% W/ GLUCOSE 7.5%			
ASTRAZENECA	5%	N010496 002	Jul 07, 1982
JELLY; TOPICAL			
ANESTACON			
BIONPHARMA INC	2%	A080429 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LIDOCAINE HYDROCHLORIDE

JELLY;TOPICAL

LIDOCAINE HYDROCHLORIDE

COSETTE	2%	A081318	001	Apr 29, 1993
WATSON LABS INC	2%	A040837	001	Mar 23, 2011

SOLUTION;ORAL

LIDOCAINE HYDROCHLORIDE VISCOUS

ACTAVIS MID ATLANTIC	2%	A086578	001	
INTL MEDICATION	2%	A086389	001	Feb 02, 1982
LANNETT CO INC	2%	A040708	001	Feb 27, 2007

XYLOCAINE VISCOUS

+ FRESenius KABI USA	2% **	N009470	001	
----------------------	-------	---------	-----	--

SOLUTION;TOPICAL

LARYNGOTRACHEAL ANESTHESIA KIT

KENDALL IL	4%	A087931	001	Jun 10, 1983
------------	----	---------	-----	--------------

LIDOCAINE HYDROCHLORIDE

PACO	4%	A089688	001	Jun 30, 1989
------	----	---------	-----	--------------

LTA II KIT

HOSPIRA	4%	A080409	001	
---------	----	---------	-----	--

	4%	A088542	001	Jul 31, 1984
--	----	---------	-----	--------------

PEDIATRIC LTA KIT

ABBOTT	2%	A088572	001	Jul 31, 1984
--------	----	---------	-----	--------------

HOSPIRA	2%	A085995	001	
---------	----	---------	-----	--

XYLOCAINE 4% PRESERVATIVE FREE

+ FRESenius KABI USA	4%	N010417	002	
----------------------	----	---------	-----	--

LIDOCAINE HYDROCHLORIDE; OXYTETRACYCLINE

INJECTABLE;INJECTION

TERRAMYCIN

PFIZER	2%;50MG/ML	A060567	001	
	2%;125MG/ML	A060567	002	

LIDOCAINE; PRILOCAINE

CREAM;TOPICAL

LIDOCAINE AND PRILOCAINE

RHODES PHARMS	2.5%;2.5%	A213253	001	Sep 21, 2020
---------------	-----------	---------	-----	--------------

DISC;TOPICAL

EMLA

ASTRAZENECA	2.5%;2.5%	N020962	001	Feb 04, 1998
-------------	-----------	---------	-----	--------------

LINCOMYCIN HYDROCHLORIDE

CAPSULE;ORAL

LINCOCIN

PHARMACIA AND UPJOHN	EQ 250MG BASE	N050316	001	
	EQ 500MG BASE	N050316	002	

INJECTABLE;INJECTION

LINCOMYCIN HYDROCHLORIDE

WATSON LABS	EQ 300MG BASE/ML	A063180	001	Apr 16, 1991
-------------	------------------	---------	-----	--------------

LINDANE

CREAM;TOPICAL

KWELL

REED AND CARNRICK	1%	A084218	001	
	1%	N006309	001	

LOTION;TOPICAL

GAMENE

SOLA BARNES HIND	1%	A084989	001	
------------------	----	---------	-----	--

KWELL

REED AND CARNRICK	1%	A084218	002	
	1%	N006309	003	

LINDANE

OLTA PHARMS	1%	A087313	001	
-------------	----	---------	-----	--

WOCKHARDT BIO AG	1%	A088190	001	Aug 16, 1984
------------------	----	---------	-----	--------------

SCABENE

STIEFEL	1%	A086769	001	
---------	----	---------	-----	--

SHAMPOO;TOPICAL

GAMENE

SOLA BARNES HIND	1%	A084988	001	
------------------	----	---------	-----	--

KWELL

REED AND CARNRICK	1%	A084219	001	
	1%	N010718	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LINDANE

SHAMPOO; TOPICAL

LINDANE

OLTA PHARMS

1%

A087266 001

SCABENE

STIEFEL

1%

A087940 001 Apr 08, 1983

LINEZOLID

SOLUTION; INTRAVENOUS

ZYVOX

+ PFIZER

400MG/200ML (2MG/ML) **

N021131 002 Apr 18, 2000

TABLET; ORAL

LINEZOLID

GATE PHARMS

600MG

A091210 001 Feb 05, 2016

MYLAN

600MG

A078845 001 Dec 21, 2015

TEVA PHARMS USA

600MG

A078061 001 May 18, 2015

ZYVOX

+ PFIZER

400MG **

N021130 001 Apr 18, 2000

LIOTHYRONINE SODIUM

TABLET; ORAL

LIOTHYRONINE SODIUM

MYLAN

EQ 0.005MG BASE

A090326 001 Jul 14, 2009

EQ 0.025MG BASE

A090326 002 Jul 14, 2009

EQ 0.05MG BASE

A090326 003 Jul 14, 2009

WATSON LABS

EQ 0.025MG BASE

A085755 001 Jan 25, 1982

EQ 0.05MG BASE

A085753 001 Feb 03, 1982

LIOTRIX (T4;T3)

TABLET; ORAL

EUTHROID-0.5

PARKE DAVIS

0.03MG;0.0075MG

N016680 001

EUTHROID-1

PARKE DAVIS

0.06MG;0.015MG

N016680 002

EUTHROID-2

PARKE DAVIS

0.12MG;0.03MG

N016680 003

EUTHROID-3

PARKE DAVIS

0.18MG;0.045MG

N016680 004

THYROLAR-0.25

+ ALLERGAN

0.0125MG;0.0031MG

N016807 001

THYROLAR-0.5

+ ALLERGAN

0.025MG;0.0063MG

N016807 005

THYROLAR-1

+ ALLERGAN

0.05MG;0.0125MG

N016807 004

THYROLAR-2

+ ALLERGAN

0.1MG;0.025MG

N016807 002

THYROLAR-3

+ ALLERGAN

0.15MG;0.0375MG

N016807 003

THYROLAR-5

ALLERGAN

0.25MG;0.0625MG

N016807 006

LISINAPRIL

TABLET; ORAL

LISINAPRIL

ASCENT PHARMS INC

2.5MG

A075903 001 Jul 01, 2002

5MG

A075903 002 Jul 01, 2002

10MG

A075903 003 Jul 01, 2002

20MG

A075903 004 Jul 01, 2002

30MG

A075903 005 Jul 01, 2002

40MG

A075903 006 Jul 01, 2002

HERITAGE PHARMA

2.5MG

A075752 001 Jul 01, 2002

5MG

A075752 002 Jul 01, 2002

10MG

A075752 003 Jul 01, 2002

20MG

A075752 004 Jul 01, 2002

30MG

A075752 005 Jul 01, 2002

40MG

A075752 006 Jul 01, 2002

HIKMA INTL PHARMS

2.5MG

A076063 001 Jul 01, 2002

5MG

A076063 002 Jul 01, 2002

10MG

A076063 003 Jul 01, 2002

20MG

A076063 004 Jul 01, 2002

30MG

A076063 006 Jun 27, 2003

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LISINAPRIL

TABLET; ORAL

LISINAPRIL

	40MG	A076063 005	Jul 01, 2002
MYLAN	2.5MG	A076071 001	Jul 01, 2002
	5MG	A076071 002	Jul 01, 2002
	10MG	A076071 003	Jul 01, 2002
	20MG	A076071 004	Jul 01, 2002
	30MG	A076071 005	Jul 01, 2002
	40MG	A076071 006	Jul 01, 2002
PHARMGEN	2.5MG	A075999 001	Jul 01, 2002
	5MG	A075999 002	Jul 01, 2002
	10MG	A075999 003	Jul 01, 2002
	20MG	A075999 004	Jul 01, 2002
	30MG	A075999 005	Jul 01, 2002
	40MG	A075999 006	Jul 01, 2002
TEVA	2.5MG	A075783 001	Jul 01, 2002
	5MG	A075783 002	Jul 01, 2002
	10MG	A075783 003	Jul 01, 2002
	20MG	A075783 004	Jul 01, 2002
	30MG	A075783 005	Jul 01, 2002
	40MG	A075783 006	Jul 01, 2002
PRINIVIL			
MERCK	2.5MG	N019558 006	Jan 28, 1994
	10MG	N019558 002	Dec 29, 1987
	20MG	N019558 003	Dec 29, 1987

LITHIUM CARBONATE

CAPSULE; ORAL

ESKALITH

NOVEN THERAP

300MG N016860 001

LITHIUM CARBONATE

ABLE

	150MG	A076823 001	Jun 29, 2004
	300MG	A076121 001	Sep 27, 2001
	300MG	A076823 002	Jun 29, 2004
	600MG	A076823 003	Jun 29, 2004
APOTEX INC	300MG	A076795 001	Nov 22, 2004
MYLAN	150MG	A076243 002	Feb 24, 2003
	300MG	A076243 001	Jun 27, 2002
	600MG	A078763 001	Apr 15, 2008
USL PHARMA	300MG	A072542 001	Feb 01, 1989
WATSON LABS	300MG	A070407 001	Mar 19, 1987

LITHONATE

SOLVAY

300MG N016782 001

TABLET; ORAL

ESKALITH

JDS PHARMS

300MG N017971 001

LITHANE

BAYER PHARMS

300MG N018833 001 Jul 18, 1985

LITHIUM CARBONATE

HIKMA INTL PHARMS

300MG A078715 001 Dec 28, 2010

PFIZER

300MG N016834 001

LITHOTABS

SOLVAY

300MG N016980 001

TABLET, EXTENDED RELEASE; ORAL

ESKALITH CR

JDS PHARMS

450MG ** N018152 001 Mar 29, 1982

LITHIUM CARBONATE

ABLE

ALEMBIC PHARMS LTD

300MG A076382 001 Apr 21, 2003

HERITAGE PHARMA

300MG A204445 001 Jun 10, 2015

450MG

A076170 001 Jun 10, 2002

HIKMA INTL PHARMS

450MG A076366 001 Aug 21, 2003

450MG A076490 001 Jun 17, 2003

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LITHIUM CITRATE

SYRUP;ORAL
LITHONATE
SOLVAY EQ 300MG CARBONATE/5ML N017672 001

LOMEFLOXACIN HYDROCHLORIDE

TABLET;ORAL
MAXAQUIN
PHARMACIA EQ 400MG BASE N020013 001 Feb 21, 1992

LOMITAPIDE MESYLATE

CAPSULE;ORAL
JUXTAPID
+ AMRYT EQ 40MG BASE N203858 005 Apr 23, 2015
+ EQ 60MG BASE N203858 006 Apr 23, 2015

LOMUSTINE

CAPSULE;ORAL
GLEOSTINE
+ CORDEN PHARMA 5MG N017588 004 Dec 19, 2014

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL
IMODIUM
J AND J CONSUMER INC 2MG ** N017690 001
+ 2MG ** N017694 001
LOPERAMIDE HYDROCHLORIDE
ROXANE 2MG A073080 001 Nov 27, 1991
TEVA 2MG A073122 001 Aug 30, 1991
YAOPHARMA CO LTD 2MG A072993 001 Aug 28, 1992

SOLUTION;ORAL

IMODIUM
JANSSEN PHARMS 1MG/5ML N019037 001 Jul 31, 1984
LOPERAMIDE HYDROCHLORIDE
ALLIED 1MG/5ML A073079 001 Apr 30, 1992
ALPHARMA US PHARMS 1MG/5ML A073187 001 Sep 15, 1992
DURAMED PHARMS BARR 1MG/5ML A074991 001 Dec 29, 1997
TEVA 1MG/5ML A073478 001 Jun 23, 1995
WATSON LABS 1MG/5ML A073062 001 May 28, 1993

TABLET;ORAL

LOPERAMIDE HYDROCHLORIDE
ABLE 2MG A073528 001 Nov 30, 1993
CONTRACT PHARMACAL 2MG A073254 001 Jul 30, 1993
PERRIGO 2MG A074194 001 Oct 30, 1992

TABLET, CHEWABLE;ORAL

IMODIUM A-D EZ CHEWS
+ J AND J CONSUMER INC 2MG N020448 001 Jul 24, 1997

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET, CHEWABLE;ORAL
IMODIUM MULTI-SYMPTOM RELIEF
+ J AND J CONSUMER INC 2MG;125MG N020606 001 Jun 26, 1996

LOPINAVIR; RITONAVIR

CAPSULE;ORAL
KALETRA
ABBVIE 133.3MG;33.3MG N021226 001 Sep 15, 2000

LORACARBEEF

CAPSULE;ORAL
LORABID
KING PHARMS 200MG N050668 001 Dec 31, 1991
400MG N050668 002 Apr 05, 1996
FOR SUSPENSION;ORAL
LORABID
KING PHARMS 100MG/5ML N050667 001 Dec 31, 1991
200MG/5ML N050667 002 Dec 31, 1991

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LORATADINE

CAPSULE; ORAL

LORATADINE

STRIDES PHARMA 10MG A211926 001 Jan 15, 2020

SYRUP; ORAL

CLARITIN HIVES RELIEF

+ BAYER HEALTHCARE LLC 1MG/ML ** N020641 003 Nov 19, 2003

LORATADINE

PHARM ASSOC 1MG/ML A075565 001 Oct 05, 2004

RANBAXY LABS LTD 1MG/ML A076529 001 Aug 20, 2004

TEVA 1MG/ML A075505 001 Nov 07, 2003

TABLET; ORAL

LORATADINE

MYLAN 10MG A075790 001 Nov 07, 2008

10MG A078447 001 Aug 12, 2011

PERRIGO 10MG N021512 001 Jun 24, 2004

TABLET, ORALLY DISINTEGRATING; ORAL

LORATADINE

ACTAVIS LABS FL INC 10MG A075990 001 Nov 03, 2003

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

LORATADINE AND PSEUDOEPHEDRINE SULFATE

HERITAGE PHARMA 5MG;120MG A076208 001 Jan 28, 2004

LORAZEPAM

INJECTABLE; INJECTION

LORAZEPAM

AKORN 2MG/ML A074974 001 Jul 23, 1998

BEDFORD 2MG/ML A077076 001 Jul 13, 2005

4MG/ML A077076 002 Jul 13, 2005

DAVA PHARMS INC 2MG/ML A074793 001 Mar 16, 2000

4MG/ML A074793 002 Mar 16, 2000

DR REDDYS 1MG/0.5ML A074551 003 Sep 12, 1996

2MG/ML A074535 001 Sep 12, 1996

2MG/ML A074551 001 Sep 12, 1996

4MG/ML A074535 002 Sep 12, 1996

4MG/ML A074551 002 Sep 12, 1996

HOSPIRA 2MG/ML A074280 001 May 27, 1994

2MG/ML A074300 001 Apr 12, 1994

4MG/ML A074280 002 May 27, 1994

4MG/ML A074300 003 Mar 19, 1997

MYLAN ASI 2MG/ML A200217 001 Apr 04, 2017

2MG/ML A200542 001 Apr 28, 2017

4MG/ML A200217 002 Apr 04, 2017

4MG/ML A200542 002 Apr 28, 2017

WATSON LABS 2MG/ML A074276 001 Apr 15, 1994

4MG/ML A074276 002 Apr 15, 1994

WEST-WARD PHARMS INT 2MG/ML A074496 001 Sep 28, 1998

4MG/ML A074496 002 Sep 28, 1998

LORAZEPAM PRESERVATIVE FREE

BEDFORD LABS 2MG/ML A077074 001 Jul 13, 2005

4MG/ML A077074 002 Jul 13, 2005

SOLUTION; ORAL

LORAZEPAM

ROXANE 0.5MG/5ML A074648 001 Mar 18, 1997

TABLET; ORAL

LORAZ

QUANTUM PHARMICS 0.5MG A070200 001 Aug 09, 1985

1MG A070201 001 Aug 09, 1985

2MG A070202 001 Aug 09, 1985

LORAZEPAM

AM THERAP 0.5MG A070727 001 Mar 07, 1986

1MG A070728 001 Mar 07, 1986

2MG A070729 001 Mar 07, 1986

ANDA REPOSITORY 0.5MG A072555 002 Mar 29, 1991

1MG A072555 003 Mar 29, 1991

2MG A072555 001 Mar 29, 1991

ANI PHARMS INC 0.5MG A077396 001 Dec 13, 2006

1MG A077396 002 Dec 13, 2006

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LORAZEPAM

TABLET;ORAL

LORAZEPAM

	2MG	A077396 003	Dec 13, 2006
HALSEY	0.5MG	A071434 001	Sep 01, 1987
	1MG	A071435 001	Sep 01, 1987
	2MG	A071436 001	Sep 01, 1987
MUTUAL PHARM	0.5MG	A070472 001	Dec 10, 1985
	1MG	A070473 001	Dec 10, 1985
	2MG	A070474 001	Dec 10, 1985
MYLAN	0.5MG	A071591 002	Oct 13, 1987
	0.5MG	A077657 001	Mar 16, 2006
	1MG	A071591 003	Oct 13, 1987
	1MG	A077657 002	Mar 16, 2006
	2MG	A071591 001	Oct 13, 1987
	2MG	A077657 003	Mar 16, 2006
PAR PHARM	0.5MG	A070675 001	Dec 01, 1986
	1MG	A070676 001	Dec 01, 1986
	2MG	A070677 001	Dec 01, 1986
SANDOZ	0.5MG	A071193 001	Apr 15, 1988
	1MG	A071194 001	Apr 15, 1988
	2MG	A071195 001	Apr 15, 1988
SUN PHARM INDS LTD	0.5MG	A076045 001	Aug 29, 2001
	1MG	A076045 002	Aug 29, 2001
	2MG	A076045 003	Aug 29, 2001
SUPERPHARM	0.5MG	A071245 001	Feb 09, 1987
	1MG	A071246 001	Feb 09, 1987
	2MG	A071247 001	Feb 09, 1987
USL PHARMA	1MG	A070539 001	Dec 22, 1986
	2MG	A070540 001	Dec 22, 1986
WARNER CHILCOTT	1MG	A071038 001	Jan 12, 1988
	2MG	A071039 001	Jan 12, 1988
WATSON LABS	0.5MG	A071086 001	Mar 23, 1987
	0.5MG	A071117 001	Jul 24, 1986
	1MG	A071087 001	Mar 23, 1987
	1MG	A071118 001	Jul 24, 1986
	2MG	A071088 001	Mar 23, 1987
	2MG	A071110 001	Jul 24, 1986

LORCASERIN HYDROCHLORIDE

TABLET;ORAL

BELVIQ

+ EISAI INC

10MG

N022529 001 Jun 27, 2012

TABLET, EXTENDED RELEASE;ORAL

BELVIQ XR

+ EISAI INC

20MG

N208524 001 Jul 15, 2016

LOSARTAN POTASSIUM

TABLET;ORAL

COZAAR

+ ORGANON

25MG

N020386 001 Apr 14, 1995

+

50MG

N020386 002 Apr 14, 1995

LOSARTAN POTASSIUM

APOTEX CORP

25MG

A090790 001 Oct 06, 2010

50MG

A090790 002 Oct 06, 2010

100MG

A090790 003 Oct 06, 2010

HIKMA

25MG

A077459 001 Oct 06, 2010

50MG

A077459 002 Oct 06, 2010

100MG

A077459 003 Oct 06, 2010

HISUN PHARM HANGZHOU

25MG

A204795 001 Apr 04, 2019

50MG

A204795 002 Apr 04, 2019

100MG

A204795 003 Apr 04, 2019

MYLAN

25MG

A091590 001 Oct 06, 2010

50MG

A091590 002 Oct 06, 2010

100MG

A091590 003 Oct 06, 2010

TEVA

25MG

A076958 001 Apr 06, 2010

50MG

A076958 002 Apr 06, 2010

100MG

A076958 003 Apr 06, 2010

TORRENT PHARMS

25MG

A090467 001 Oct 06, 2010

50MG

A090467 002 Oct 06, 2010

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

	100MG	A090467 003	Oct 06, 2010
UNICHEM	25MG	A203030 001	Oct 14, 2015
	50MG	A203030 002	Oct 14, 2015
	100MG	A203030 003	Oct 14, 2015

LOTEPREDNOL ETABONATE

SUSPENSION/DROPS; OPHTHALMIC

LOTEMAX

PHARMOS	0.5%	N020841 001	Mar 09, 1998
---------	------	-------------	--------------

LOVASTATIN

TABLET; ORAL

LOVASTATIN

MYLAN	10MG	A075451 001	Dec 17, 2001
	10MG	A075935 001	Dec 17, 2001
	20MG	A075451 002	Dec 17, 2001
	20MG	A075935 002	Dec 17, 2001
	40MG	A075451 003	Dec 17, 2001
	40MG	A075935 003	Dec 17, 2001
SUN PHARM INDUSTRIES	10MG	A077520 001	Apr 14, 2006
	20MG	A077520 002	Apr 14, 2006
	40MG	A077520 003	Apr 14, 2006

MEVACOR

+ MERCK	10MG **	N019643 002	Mar 28, 1991
+	20MG **	N019643 003	Aug 31, 1987
+	40MG **	N019643 004	Dec 14, 1988

TABLET, EXTENDED RELEASE; ORAL

ALTOPREV

COVIS	10MG	N021316 001	Jun 26, 2002
-------	------	-------------	--------------

LOXAPINE HYDROCHLORIDE

CONCENTRATE; ORAL

LOXITANE C

TEVA BRANDED PHARM	EQ 25MG BASE/ML	N017658 001	
--------------------	-----------------	-------------	--

INJECTABLE; INJECTION

LOXITANE IM

ACTAVIS LABS UT INC	EQ 50MG BASE/ML	N018039 001	
---------------------	-----------------	-------------	--

LOXAPINE SUCCINATE

CAPSULE; ORAL

LOXITANE

+ TEVA BRANDED PHARM	EQ 5MG BASE **	N017525 001	
+	EQ 10MG BASE **	N017525 002	
+	EQ 25MG BASE **	N017525 003	
+	EQ 50MG BASE **	N017525 004	

TABLET; ORAL

LOXITANE

+ TEVA BRANDED PHARM	EQ 10MG BASE **	N017525 006	
+	EQ 25MG BASE **	N017525 007	
+	EQ 50MG BASE **	N017525 008	

LUCINACTANT

SUSPENSION; INTRATRACHEAL

SURFAXIN

WINDTREE THERAP	8.5ML	N021746 001	Mar 06, 2012
-----------------	-------	-------------	--------------

LURASIDONE HYDROCHLORIDE

TABLET; ORAL

LURASIDONE HYDROCHLORIDE

AMNEAL PHARMS CO	20MG	A208002 001	Jan 03, 2019
	40MG	A208002 002	Jan 03, 2019
	60MG	A208002 003	Jan 03, 2019
	80MG	A208002 004	Jan 03, 2019
	120MG	A208002 005	Jan 03, 2019
EMCURE PHARMS LTD	20MG	A208058 001	Sep 04, 2019
	40MG	A208058 002	Sep 04, 2019
	60MG	A208058 003	Sep 04, 2019
	80MG	A208058 004	Sep 04, 2019
INVAGEN PHARMS	20MG	A208028 001	Jan 03, 2019

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LURASIDONE HYDROCHLORIDE

TABLET; ORAL

LURASIDONE HYDROCHLORIDE

	40MG	A208028 002	Jan 03, 2019
	60MG	A208028 003	Jan 03, 2019
	80MG	A208028 004	Jan 03, 2019
	120MG	A208028 005	Jan 03, 2019
LUPIN LTD	20MG	A208031 001	Jan 03, 2019
	40MG	A208031 002	Jan 03, 2019
	60MG	A208031 003	Jan 03, 2019
	80MG	A208031 004	Jan 03, 2019
	120MG	A208031 005	Jan 03, 2019
TEVA PHARMS USA	20MG	A208060 001	May 17, 2019
	40MG	A208060 002	May 17, 2019
	60MG	A208060 003	May 17, 2019
	80MG	A208060 004	May 17, 2019
	120MG	A208060 005	May 17, 2019
TORRENT	20MG	A208055 001	Jan 03, 2019
	40MG	A208055 002	Jan 03, 2019
	80MG	A208055 003	Jan 03, 2019
	120MG	A208055 004	Jan 03, 2019
ZYDUS PHARMS	20MG	A208052 001	Mar 19, 2019
	40MG	A208052 002	Mar 19, 2019
	60MG	A208052 003	Mar 19, 2019
	80MG	A208052 004	Mar 19, 2019
	120MG	A208052 005	Mar 19, 2019

LYPRESSIN

SOLUTION; NASAL

DIAPID

NOVARTIS 0.185MG/ML N016755 001

MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PLASMA-LYTE 56 IN PLASTIC CONTAINER

BAXTER HLTHCARE 32MG/100ML; 128MG/100ML; 234MG/100ML N019047 001 Jun 15, 1984

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

ISOLYTE S PH 7.4 IN PLASTIC CONTAINER

B BRAUN 30MG/100ML; 37MG/100ML; 0.82MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML; 12MG/100ML N019006 001 Apr 04, 1984

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

ISOLYTE S IN PLASTIC CONTAINER

B BRAUN 30MG/100ML; 37MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML N018252 001

SOLUTION; IRRIGATION

PHYSIOSOL IN PLASTIC CONTAINER

HOSPIRA INC 14MG/100ML; 37MG/100ML; 222MG/100ML; 526MG/100ML; 502MG/100ML N018406 001

PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER

HOSPIRA INC 30MG/100ML; 37MG/100ML; 222MG/100ML; 526MG/100ML; 502MG/100ML N018406 002 Jul 08, 1982

SYNOVALYTE IN PLASTIC CONTAINER

BAXTER HLTHCARE 30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG/100ML; 502MG/100ML N019326 001 Jan 25, 1985

MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE

TABLET; ORAL

MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE

SANTARUS 343MG; 20MG; 750MG N022456 001 Dec 04, 2009

343MG; 40MG; 750MG N022456 002 Dec 04, 2009

TABLET, CHEWABLE; ORAL

ZEGERID

SANTARUS 700MG; 20MG; 600MG N021850 001 Mar 24, 2006

700MG; 40MG; 600MG N021850 002 Mar 24, 2006

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE CORP 1GM/100ML

A211965 001 Aug 11, 2020

MAGNESIUM SULFATE IN PLASTIC CONTAINER

BAXTER HLTHCARE CORP 2GM/50ML (40MG/ML)

A211966 001 Jun 01, 2020

4GM/50ML (80MG/ML)

A211966 002 Jun 01, 2020

4GM/100ML (40MG/ML)

A211966 003 Jun 01, 2020

MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

SOLUTION; ORAL

SUCLEAR

+ BRAINTREE LABS

1.6GM/BOT, 3.13GM/BOT, 17.5GM/BOT, N/A, N/A, N/A, N/A, N/A, N/A, N/A, 210GM, 0.74GM, 2.86GM, 5.6GM **

N203595 001 Jan 18, 2013

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

POWDER; ORAL

COLPREP KIT

+ GATOR PHARMS

1.6GM/BOT; 3.13GM/BOT; 17.5GM/BOT

N204553 001 Dec 27, 2016

MALATHION

LOTION; TOPICAL

MALATHION

MYLAN PHARMS INC 0.5%

A078743 001 Mar 06, 2009

OVIDE

+ TARO PHARM INDS LTD 0.5%

N018613 001 Aug 02, 1982

MANGAFODIPIR TRISODIUM

INJECTABLE; INJECTION

TESLASCAN

IC TARGETS 37.9MG/ML

N020652 001 Nov 26, 1997

MANGANESE CHLORIDE TETRAHYDRATE

FOR SOLUTION; ORAL

LUMENHANCE

BRACCO 3.49MG/GM

N020686 001 Dec 19, 1997

MANGANESE SULFATE

INJECTABLE; INJECTION

MANGANESE SULFATE

ABRAXIS PHARM EQ 0.1MG MANGANESE/ML

N019228 001 May 05, 1987

MANNITOL

INJECTABLE; INJECTION

MANNITOL 10%

B BRAUN 10GM/100ML

N016080 002

HOSPIRA 10GM/100ML

N016269 002

MILES 10GM/100ML

N016472 002

MANNITOL 10% IN PLASTIC CONTAINER

ICU MEDICAL INC 10GM/100ML

N019603 002 Jan 08, 1987

MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER

B BRAUN 10GM/100ML

N016080 006

MANNITOL 15%

B BRAUN 15GM/100ML

N016080 003

HOSPIRA 15GM/100ML

N016269 003

MILES 15GM/100ML

N016472 005

MANNITOL 15% IN PLASTIC CONTAINER

ICU MEDICAL INC 15GM/100ML

N019603 003 Jan 08, 1990

MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%

B BRAUN 15GM/100ML

N016080 005

MANNITOL 20%

B BRAUN 20GM/100ML

N014738 001

20GM/100ML

N016080 004

HOSPIRA 20GM/100ML

N016269 004

MILES 20GM/100ML

N016472 004

MANNITOL 25%

ABRAXIS PHARM 12.5GM/50ML

A086754 001

HOSPIRA 12.5GM/50ML

N016269 005

IGI LABS INC 12.5GM/50ML

A089239 001 May 06, 1987

12.5GM/50ML

A089240 001 May 06, 1987

INTL MEDICATION 12.5GM/50ML

A083051 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MANNITOL

INJECTABLE; INJECTION

MANNITOL 25%

LUITPOLD	12.5GM/50ML	A087409 001	Jan 21, 1982
MERCK	12.5GM/50ML	N005620 001	
WATSON LABS	12.5GM/50ML	A087460 001	Jun 27, 1983

MANNITOL 5%

B BRAUN	5GM/100ML	N016080 001	
HOSPIRA	5GM/100ML	N016269 001	

MANNITOL 5% IN PLASTIC CONTAINER

ICU MEDICAL INC	5GM/100ML	N019603 001	Jan 08, 1987
-----------------	-----------	-------------	--------------

MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%

B BRAUN	5GM/100ML	N016080 007	
---------	-----------	-------------	--

SOLUTION; IRRIGATION

RESECTISOL

B BRAUN	5GM/100ML	N016704 002	
---------	-----------	-------------	--

MANNITOL; SORBITOL

SOLUTION; IRRIGATION

SORBITOL-MANNITOL

HOSPIRA	540MG/100ML; 2.7GM/100ML	A080224 001	
---------	--------------------------	-------------	--

SORBITOL-MANNITOL IN PLASTIC CONTAINER

HOSPIRA	540MG/100ML; 2.7GM/100ML	N017636 001	
---------	--------------------------	-------------	--

MAPROTILOLINE HYDROCHLORIDE

TABLET; ORAL

LUDIOMIL

NOVARTIS	25MG	N017543 001	
	50MG	N017543 002	
	75MG	N017543 003	Sep 30, 1982

MAPROTILOLINE HYDROCHLORIDE

AM THERAP	25MG	A072129 001	Jan 14, 1988
	50MG	A072130 001	Jan 14, 1988
	75MG	A072131 001	Jan 14, 1988
HERITAGE PHARMA	25MG	A072162 001	Jun 01, 1988
WATSON LABS	25MG	A071943 001	Dec 30, 1987
	50MG	A071944 001	Dec 30, 1987
	75MG	A071945 001	Dec 30, 1987
	75MG	A072164 001	Jun 01, 1988
WATSON LABS TEVA	50MG	A072163 001	Jun 01, 1988

MASOPROCOL

CREAM; TOPICAL

ACTINEX

UNIV AZ CANCER CTR	10%	N019940 001	Sep 04, 1992
--------------------	-----	-------------	--------------

MAZINDOL

TABLET; ORAL

MAZANOR

WYETH AYERST	1MG	N017980 002	
	2MG	N017980 001	

SANOREX

+ NOVARTIS	1MG **	N017247 001	
+	2MG **	N017247 002	

MEBENDAZOLE

TABLET, CHEWABLE; ORAL

VERMOX

+ JANSSEN PHARMS	100MG **	N017481 001	
+	500MG	N208398 001	Oct 19, 2016

MEBUTAMATE

TABLET; ORAL

DORMATE

MEDPOINTE PHARM HLC	600MG	N017374 001	
---------------------	-------	-------------	--

MECAMYLAMINE HYDROCHLORIDE

TABLET; ORAL

INVERSINE

+ TARGACEPT	2.5MG **	N010251 001	
-------------	----------	-------------	--

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MECHLORETHAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

MUSTARGEN

+ RECORDATI RARE 10MG/VIAL N006695 001

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

ABC HOLDING	12.5MG	A085253	001	
	25MG	A085252	001	
AMNEAL PHARMS	50MG	A201451	003	Feb 23, 2011
ANABOLIC	25MG	A085891	001	
ANI PHARMS INC	12.5MG	A084657	002	
	12.5MG	A085269	001	
	12.5MG	A088732	001	Dec 11, 1985
	25MG	A084657	001	
	25MG	A085740	001	
BUNDY	12.5MG	A084382	001	
	25MG	A084872	001	
IVAX SUB TEVA PHARMS	12.5MG	A083784	001	
KV PHARM	12.5MG	A085524	001	
	25MG	A085523	001	
MYLAN PHARMS INC	12.5MG	A202640	001	Sep 17, 2012
	25MG	A202640	002	Sep 17, 2012
	50MG	A202640	003	Sep 17, 2012
PAR PHARM	50MG	A089674	001	Mar 31, 1988
PLIVA	25MG	A088734	001	Dec 11, 1985
RISING	12.5MG	A040179	001	Jan 30, 1997
	25MG	A040179	002	Jan 30, 1997
SUPERPHARM	12.5MG	A089113	001	Aug 20, 1985
	25MG	A089114	001	Aug 20, 1985
UDL	12.5MG	A088256	001	Jun 13, 1983
	25MG	A088257	001	Jun 13, 1983
VANGARD	12.5MG	A087877	001	Apr 20, 1982
	25MG	A087620	001	Jan 04, 1982
WATSON LABS	12.5MG	A085195	001	

TABLET, CHEWABLE; ORAL

MECLIZINE HYDROCHLORIDE

IVAX SUB TEVA PHARMS	25MG	A084976	001	
NEXGEN PHARMA INC	25MG	A086392	001	
PLIVA	25MG	A088733	001	Dec 11, 1985

MECLOCYCLINE SULFOSALICYLATE

CREAM; TOPICAL

MECLAN

JOHNSON AND JOHNSON 1% N050518 001

MECLOFENAMATE SODIUM

CAPSULE; ORAL

MECLODIUM

QUANTUM PHARMICS	EQ 50MG BASE	A071380	001	Jul 14, 1987
	EQ 100MG BASE	A071381	001	Jul 14, 1987
MECLOFENAMATE SODIUM				
AM THERAP	EQ 50MG BASE	A071362	001	Feb 10, 1987
	EQ 100MG BASE	A071363	001	Feb 10, 1987
ANI PHARMS INC	EQ 50MG BASE	A071469	002	Apr 15, 1987
	EQ 100MG BASE	A071469	001	Apr 15, 1987
BARR	EQ 50MG BASE	A072848	001	Mar 20, 1989
	EQ 100MG BASE	A072809	001	Mar 20, 1989
FOSUN PHARMA	EQ 50MG BASE	A072262	001	Nov 29, 1988
	EQ 100MG BASE	A072263	001	Nov 29, 1988
PAR PHARM	EQ 50MG BASE	A072077	001	Mar 10, 1988
	EQ 100MG BASE	A072078	001	Mar 10, 1988
USL PHARMA	EQ 50MG BASE	A071007	001	Mar 25, 1988
	EQ 100MG BASE	A071008	001	Mar 25, 1988
VITARINE	EQ 50MG BASE	A071710	001	Jun 15, 1988
	EQ 100MG BASE	A071684	001	Jun 15, 1988
WATSON LABS	EQ 50MG BASE	A070400	001	Nov 25, 1986
	EQ 50MG BASE	A071640	001	Aug 11, 1987
	EQ 100MG BASE	A070401	001	Nov 25, 1986
	EQ 100MG BASE	A071641	001	Aug 11, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MECLOFENAMATE SODIUM

CAPSULE; ORAL

MECLOMEN

PARKE DAVIS

EQ 50MG BASE

N018006 001

EQ 100MG BASE

N018006 002

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

DEPO-PROVERA

+ PHARMACIA AND UPJOHN 100MG/ML **

N012541 002

MEDROXYPROGESTERONE ACETATE

CIPLA

150MG/ML

A210335 001 Jan 25, 2019

SANDOZ INC

150MG/ML

A078711 001 May 20, 2009

TEVA PHARMS USA

150MG/ML

A076552 001 Oct 27, 2004

TABLET; ORAL

AMEN

AMARIN PHARMS

10MG

A083242 001

CURRETAB

SOLVAY

10MG

A085686 001

CYCRIN

ESI

2.5MG

A081239 001 Oct 30, 1992

5MG

A081240 001 Oct 30, 1992

10MG

A089386 001 Sep 09, 1987

MEDROXYPROGESTERONE ACETATE

DURAMED PHARMS BARR

2.5MG

A040311 001 Dec 01, 1999

5MG

A040311 002 Dec 01, 1999

10MG

A040311 003 Dec 01, 1999

UPSHER SMITH LABS

10MG

A088484 001 Jul 26, 1984

MEDRYSONE

SUSPENSION; OPHTHALMIC

HMS

ALLERGAN

1%

N016624 003

MEFENAMIC ACID

CAPSULE; ORAL

MEFENAMIC ACID

NOSTRUM LABS INC

250MG

A090359 001 Feb 05, 2013

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

LARIAM

+ ROCHE 250MG **

N019591 001 May 02, 1989

MEFLOQUINE HYDROCHLORIDE

HIKMA

250MG

A076523 001 Oct 01, 2004

HIKMA INTL PHARMS

250MG

A077699 001 Apr 21, 2010

SANDOZ

250MG

A076175 001 Feb 20, 2002

US ARMY WALTER REED

250MG **

N019578 001 May 02, 1989

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGACE

+ BRISTOL MYERS SQUIBB 40MG/ML **

N020264 001 Sep 10, 1993

MEGESTROL ACETATE

HIKMA

40MG/ML

A075997 001 Feb 15, 2002

PHARM ASSOC

40MG/ML

A077404 001 Feb 16, 2006

TEVA PHARMS

40MG/ML

A075681 001 May 05, 2003

TABLET; ORAL

MEGACE

+ BRISTOL MYERS SQUIBB 20MG **

N016979 001

+ 40MG **

N016979 002

MEGESTROL ACETATE

HIKMA

20MG

A074458 001 Sep 29, 1995

40MG

A074458 002 Sep 29, 1995

TEVA

40MG

A074745 001 Feb 27, 1998

USL PHARMA

20MG

A070646 001 Oct 02, 1987

40MG

A070647 001 Oct 02, 1987

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MELOXICAM

CAPSULE; ORAL

VIVLODEX

+ ZYLA

5MG

N207233 001 Oct 22, 2015

+

10MG

N207233 002 Oct 22, 2015

SUSPENSION; ORAL

MOBIC

+ AVONDALE PHARMS

7.5MG/5ML **

N021530 001 Jun 01, 2004

TABLET; ORAL

MELOXICAM

ANDA REPOSITORY

7.5MG

A077935 001 Jul 19, 2006

15MG

A077935 002 Jul 19, 2006

CR DOUBLE CRANE

7.5MG

A078039 001 Dec 14, 2006

15MG

A078039 002 Dec 14, 2006

HERITAGE PHARMA

7.5MG

A077936 001 Jul 19, 2006

15MG

A077936 002 Jul 19, 2006

IMPAX LABS INC

7.5MG

A077930 001 Jul 19, 2006

15MG

A077930 002 Jul 19, 2006

MYLAN

7.5MG

A077923 001 Jul 19, 2006

7.5MG

A077934 001 Jul 20, 2006

15MG

A077923 002 Jul 19, 2006

15MG

A077934 002 Jul 20, 2006

NOSTRUM LABS INC

7.5MG

A077920 001 Jul 19, 2006

15MG

A077920 002 Jul 19, 2006

ROXANE

7.5MG

A077925 001 Jul 19, 2006

15MG

A077925 002 Jul 19, 2006

SUN PHARM INDS INC

7.5MG

A077937 001 Jul 19, 2006

15MG

A077937 002 Jul 19, 2006

YABAO PHARM

7.5MG

A077933 001 Jul 19, 2006

15MG

A077933 002 Jul 19, 2006

TABLET, ORALLY DISINTEGRATING; ORAL

QMIIZ ODT

+ TERSERA

7.5MG

N211210 001 Oct 19, 2018

+

15MG

N211210 002 Oct 19, 2018

MELPHALAN

TABLET; ORAL

ALKERAN

+ APOTEX

2MG

N014691 002

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

MELPHALAN HYDROCHLORIDE

MYLAN INSTITUTIONAL EQ 50MG BASE/VIAL

A090299 001 Oct 27, 2009

PAR STERILE PRODUCTS EQ 50MG BASE/VIAL

A204773 001 Aug 22, 2016

TWI PHARMS EQ 50MG BASE/VIAL

A211463 001 Sep 13, 2019

USWM EQ 50MG BASE/VIAL

A207032 001 May 03, 2019

POWDER; INTRAVENOUS

MELPHALAN HYDROCHLORIDE

ACTAVIS LLC EQ 50MG BASE/VIAL

A209323 001 Mar 06, 2020

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MEMANTINE HYDROCHLORIDE

SUN PHARM

7MG

A205905 001 Sep 28, 2016

14MG

A205905 002 Sep 28, 2016

21MG

A205905 003 Sep 28, 2016

28MG

A205905 004 Sep 28, 2016

SOLUTION; ORAL

MEMANTINE HYDROCHLORIDE

TORRENT

2MG/ML

A205446 001 Dec 07, 2015

NAMENDA

+ ALLERGAN

2MG/ML

N021627 001 Apr 18, 2005

TABLET; ORAL

MEMANTINE HYDROCHLORIDE

CHARTWELL

5MG

A090244 001 Jul 11, 2018

10MG

A090244 002 Jul 11, 2018

MYLAN

5MG

A079225 001 Jan 30, 2015

10MG

A079225 002 Jan 30, 2015

NINGBO

5MG

A212947 001 Apr 03, 2020

10MG

A212947 002 Apr 03, 2020

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MEMANTINE HYDROCHLORIDE

TABLET; ORAL

MEMANTINE HYDROCHLORIDE

ORCHID HLTHCARE	5MG	A090044 001	Mar 12, 2012
	10MG	A090044 002	Mar 12, 2012
TEVA PHARMS	5MG	A090052 001	Oct 25, 2011
	10MG	A090052 002	Oct 25, 2011
TORRENT	5MG	A200155 001	Oct 13, 2015
	10MG	A200155 002	Oct 13, 2015

MENADIOL SODIUM DIPHOSPHATE

INJECTABLE; INJECTION

KAPPADIONE

LILLY	10MG/ML	N005725 001	
SYNKAYVITE			
ROCHE	5MG/ML	N003718 004	
	10MG/ML	N003718 006	
	37.5MG/ML	N003718 008	

TABLET; ORAL

SYNKAYVITE

ROCHE	5MG	N003718 010	
-------	-----	-------------	--

MENADIONE

TABLET; ORAL

MENADIONE

LILLY	5MG	N002139 003	
-------	-----	-------------	--

MEPENZOLATE BROMIDE

SOLUTION; ORAL

CANTIL

SANOFI AVENTIS US	25MG/5ML	N010679 004	
-------------------	----------	-------------	--

TABLET; ORAL

CANTIL

+ SANOFI AVENTIS US	25MG	N010679 003	
---------------------	------	-------------	--

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEMEROL

US PHARM HOLDINGS	25MG/ML	N005010 007	
	50MG/ML	N005010 002	
	75MG/ML	N005010 009	
	100MG/ML	N005010 003	

MEPERIDINE HYDROCHLORIDE

ABBOTT

	25MG/ML	A080388 001	
	50MG/ML	A080385 001	
	50MG/ML	A080387 001	
	75MG/ML	A080389 001	
	100MG/ML	A080386 001	
BAXTER HLTHCARE	25MG/ML	A088279 001	Jun 15, 1984
	50MG/ML	A088280 001	Jun 15, 1984
	75MG/ML	A088281 001	Jun 15, 1984
	100MG/ML	A088282 001	Jun 15, 1984
IGI LABS INC	25MG/ML	A089781 001	Mar 31, 1989
	50MG/ML	A089782 001	Mar 31, 1989
	50MG/ML	A089783 001	Mar 31, 1989
	50MG/ML	A089784 001	Mar 31, 1989
	75MG/ML	A089785 001	Mar 31, 1989
	100MG/ML	A089786 001	Mar 31, 1989
	100MG/ML	A089787 001	Mar 31, 1989
	100MG/ML	A089788 001	Mar 31, 1989

INTL MEDICATION

PARKE DAVIS

	10MG/ML	A086332 001	
	50MG/ML	A080364 002	
	75MG/ML	A080364 003	
	100MG/ML	A080364 001	
WATSON LABS	50MG/ML	A073444 001	Mar 17, 1992
	100MG/ML	A073445 001	Mar 17, 1992

MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

HOSPIRA

	10MG/ML	A040305 001	Mar 10, 1999
ICU MEDICAL INC	10MG/ML	A088432 001	Aug 16, 1984
INTL MEDICATION	10MG/ML	A081309 001	Aug 30, 1993
SPECGX LLC	10MG/ML	A040163 001	May 12, 1997

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

WATSON LABS 10MG/ML

A073443 001 Mar 17, 1992

SYRUP; ORAL

DEMEROL

US PHARM HOLDINGS 50MG/5ML **

N005010 005

TABLET; ORAL

DEMEROL

+ US PHARM HOLDINGS 50MG

N005010 001

+ 100MG

N005010 004

MEPERIDINE HYDROCHLORIDE

ANDA REPOSITORY 50MG

A040893 001 Jun 24, 2009

75MG

A040893 002 Jun 24, 2009

100MG

A040893 003 Jun 24, 2009

150MG

A040893 004 Jun 24, 2009

BARR 50MG

A088639 001 Jul 02, 1984

100MG

A088640 001 Sep 19, 1984

DURAMED PHARMS BARR 50MG

A040318 001 Oct 05, 1999

100MG

A040318 002 Oct 05, 1999

HIKMA 50MG

A040110 001 Mar 12, 1997

100MG

A040110 002 Mar 12, 1997

SPECGX LLC 50MG

A040352 001 Jun 13, 2000

100MG

A040352 002 Jun 13, 2000

SUN PHARM INDS INC 50MG

A040446 001 Aug 08, 2002

100MG

A040446 002 Aug 08, 2002

SUN PHARM INDUSTRIES 50MG

A080448 001

100MG

A080448 002

VINTAGE PHARMS 50MG

A040191 001 Dec 17, 1998

100MG

A040191 002 Dec 17, 1998

WATSON LABS 50MG

A040186 001 Jun 30, 1997

100MG

A040186 002 Jun 30, 1997

WYETH AYERST 50MG

A080454 001

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERGAN

HIKMA 25MG/ML; 25MG/ML

N011730 001

MEPHENTERMINE SULFATE

INJECTABLE; INJECTION

WYAMINE SULFATE

BAXTER HLTHCARE CORP EQ 15MG BASE/ML

N008248 002

EQ 30MG BASE/ML

N008248 001

MEPHENYTOIN

TABLET; ORAL

MESANTOIN

+ NOVARTIS 100MG **

N006008 001

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ARESTOCAINE HYDROCHLORIDE

SOLVAY 3%

A084777 002 Apr 18, 1982

CARBOCAINE

+ EASTMAN KODAK 3% **

N012125 003

ISOCAINE HYDROCHLORIDE

SEPTODONT INC 3%

A080925 001

MEPIVACAINE HYDROCHLORIDE

BELMORA LLC 3%

A083559 001

HOSPIRA INC 3%

A040806 001 Apr 28, 2008

INTL MEDICATION SYS 1%

A087509 001 Oct 05, 1982

WATSON LABS 1%

A088769 001 Nov 20, 1984

2%

A088770 001 Nov 20, 1984

POLOCAINE

DENTSPLY PHARM 3%

A088653 001 Aug 21, 1984

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MEPREDNISON

TABLET; ORAL

BETAPAR

SCHERING 4MG N016053 002

MEPROBAMATE

CAPSULE; ORAL

EQUANIL

WYETH AYERST 400MG N012455 002

CAPSULE, EXTENDED RELEASE; ORAL

MEPROSPAN

MEDPOINTE PHARM HLC 200MG N011284 001

400MG N011284 002

TABLET; ORAL

AMOSENE

FERNDAL LABS 400MG A084030 001

BAMATE

ALRA 200MG A080380 001

400MG A080380 002

EQUANIL

WYETH AYERST 200MG N010028 005

400MG N010028 004

MEPRIAM

TEVA 400MG N016069 001

MEPROBAMATE

ACELLA 400MG A084153 001

BARR 600MG A084230 001

ELKINS SINN 200MG N015426 002

400MG N015426 001

HEATHER 400MG N016928 003

600MG A084329 001

IMPAX LABS 200MG N014322 002

400MG N014322 001

IVAX SUB TEVA PHARMS 200MG N015438 001

400MG N015438 002

600MG A084181 001

LANNETT 200MG N014882 002

400MG N014882 001

LEDERLE 400MG A086299 001

LEE KM 400MG A089538 001 Nov 25, 1987

MALLARD 400MG N015072 002

MK LABS 200MG N014368 004

400MG N014368 002

MYLAN 400MG A083618 001

NEXGEN PHARMA INC 200MG A084220 001

400MG A084589 001

PARKE DAVIS 200MG A084744 001

400MG A084744 002

PERRIGO 200MG A084546 001

400MG A084547 001

PHARMAVITE 400MG A084438 001

PUREPAC PHARM 200MG A084804 001

400MG A084804 002

PVT FORM 400MG N014601 001

RISING 400MG A080655 001

ROXANE 600MG A084332 001

SANDOZ 200MG N014547 002

400MG N014547 001

SCHERER LABS 400MG A083343 001

SOLVAY 200MG A084435 001

STANLABS PHARM 200MG N014474 002

400MG N014474 004

SUN PHARM INDUSTRIES 200MG A080699 001

400MG A080699 002

TABLICAPS 400MG A083494 001

TARO 200MG A200998 001 May 23, 2011

400MG A200998 002 May 23, 2011

USL PHARMA 200MG A087825 001 Mar 18, 1982

400MG A087826 001 Mar 18, 1982

VALEANT PHARM INTL 200MG N015139 006

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

	400MG		N015139 005	
VANGARD	400MG		A088011 001	Jul 14, 1982
WATSON LABS	200MG		A085720 001	
	400MG		A085721 001	
	600MG		A084274 001	
	600MG		A085719 001	
WEST WARD	200MG		N015417 003	
	400MG		N015417 002	
WHITEWORTH TOWN PLSN	200MG		A083830 001	
	400MG		A083442 001	
MILTOWN				
+ MEDPOINTE PHARM HLC	200MG **		N009698 004	
+	400MG **		N009698 002	
	600MG		A083919 001	
NEURAMATE				
HALSEY	200MG		N014359 002	
	400MG		N014359 001	
TRANMEP				
SOLVAY	400MG		A084369 001	
	400MG		N016249 001	

MEQUINOL; TRETINOIN

SOLUTION; TOPICAL

SOLAGE

ALMIRALL	2%;0.01%		N020922 001	Dec 10, 1999
----------	----------	--	-------------	--------------

MEROPENEM

INJECTABLE; INJECTION

MEROPENEM

HOSPIRA INC	500MG/VIAL		A090940 001	Jun 22, 2010
	1GM/VIAL		A090940 002	Jun 22, 2010
SANDOZ	500MG/VIAL		A091201 001	Mar 29, 2011
	1GM/VIAL		A091201 002	Mar 29, 2011

MERSALYL SODIUM; THEOPHYLLINE

INJECTABLE; INJECTION

MERSALYL-THEOPHYLLINE

WATSON LABS	100MG/ML; 50MG/ML		A084875 001	
-------------	-------------------	--	-------------	--

MESALAMINE

ENEMA; RECTAL

MESALAMINE

G AND W LABS INC	4GM/60ML		A076841 001	Sep 30, 2004
------------------	----------	--	-------------	--------------

SUPPOSITORY; RECTAL

CANASA

ALLERGAN	500MG		N021252 001	Jan 05, 2001
----------	-------	--	-------------	--------------

ROWASA

+ MEDA PHARMS

500MG **			N019919 001	Dec 18, 1990
----------	--	--	-------------	--------------

TABLET, DELAYED RELEASE; ORAL

ASACOL

APIL	400MG		N019651 001	Jan 31, 1992
------	-------	--	-------------	--------------

MESNA

INJECTABLE; INTRAVENOUS

MESNA

MYLAN INSTITUTIONAL	100MG/ML		A076488 001	Mar 08, 2012
MYLAN LABS LTD	100MG/ML		A203364 001	Jul 18, 2014
TEVA PHARMS USA	100MG/ML		A075764 001	Apr 27, 2001

MESORIDAZINE BESYLATE

CONCENTRATE; ORAL

SERENTIL

NOVARTIS	EQ 25MG BASE/ML		N016997 001	
----------	-----------------	--	-------------	--

INJECTABLE; INJECTION

SERENTIL

NOVARTIS	EQ 25MG BASE/ML		N016775 001	
----------	-----------------	--	-------------	--

TABLET; ORAL

SERENTIL

NOVARTIS	EQ 10MG BASE		N016774 001	
----------	--------------	--	-------------	--

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MESORIDAZINE BESYLATETABLET; ORAL
SERENTIL

EQ 25MG BASE	N016774 002
EQ 50MG BASE	N016774 003
EQ 100MG BASE	N016774 004

MESTRANOL; NORETHINDRONETABLET; ORAL-20
NORINYL

ACTAVIS LABS UT INC 0.1MG;2MG N013625 004

TABLET; ORAL-21

NORETHIN 1/50M-21

HERITAGE PHARMA 0.05MG;1MG A071539 001 Apr 12, 1988

NORETHINDRONE AND MESTRANOL

WATSON LABS 0.05MG;1MG A070758 001 Jul 01, 1988

NORINYL 1+50 21-DAY

ACTAVIS LABS UT INC 0.05MG;1MG N013625 002

NORINYL 1+80 21-DAY

GD SEARLE LLC 0.08MG;1MG N016724 001

ORTHO-NOVUM 1/50 21

ORTHO MCNEIL PHARM 0.05MG;1MG N012728 004

ORTHO-NOVUM 1/80 21

ORTHO MCNEIL PHARM 0.08MG;1MG N016715 001

ORTHO-NOVUM 10-21

ORTHO MCNEIL PHARM 0.06MG;10MG N012728 001

ORTHO-NOVUM 2-21

ORTHO MCNEIL PHARM 0.1MG;2MG N012728 005

TABLET; ORAL-28

NORETHIN 1/50M-28

HERITAGE PHARMA 0.05MG;1MG A071540 001 Apr 12, 1988

NORETHINDRONE AND MESTRANOL

WATSON LABS 0.05MG;1MG A070759 001 Jul 01, 1988

NORINYL 1+50 28-DAY

+ ACTAVIS LABS UT INC 0.05MG;1MG N016659 001

NORINYL 1+80 28-DAY

GD SEARLE LLC 0.08MG;1MG N016725 001

ORTHO-NOVUM 1/50 28

ORTHO MCNEIL JANSSEN 0.05MG;1MG N016709 001

ORTHO-NOVUM 1/80 28

ORTHO MCNEIL PHARM 0.08MG;1MG N016715 002

MESTRANOL; NORETHYNODRELTABLET; ORAL
ENOVIDGD SEARLE LLC 0.075MG;5MG N010976 008
0.15MG;9.85MG N010976 005

TABLET; ORAL-20

ENOVID

GD SEARLE LLC 0.075MG;5MG N010976 004

ENOVID-E

GD SEARLE LLC 0.1MG;2.5MG N010976 006

TABLET; ORAL-21

ENOVID-E 21

GD SEARLE LLC 0.1MG;2.5MG N010976 007

METAPROTERENOL SULFATEAEROSOL, METERED; INHALATION
ALUPENT

BOEHRINGER INGELHEIM 0.65MG/INH N016402 001

SOLUTION; INHALATION

ALUPENT

BOEHRINGER INGELHEIM 0.4% N018761 002 Oct 10, 1986
0.6% N018761 001 Jun 30, 1983
5% N017659 001

METAPROTERENOL SULFATE

APOTEX INC 0.4% A075402 001 Feb 28, 2001

0.6% A075403 001 Feb 28, 2001

ASTRAZENECA 0.4% A071275 001 Jul 27, 1988

0.6% A071018 001 Jul 27, 1988

DEY 0.33% A071806 001 Aug 05, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METAPROTERENOL SULFATE

SOLUTION; INHALATION

METAPROTERENOL SULFATE

	0.5%	A071805 001	Aug 05, 1988
	5%	A070805 001	Aug 17, 1987
MYLAN SPECIALITY LP	0.4%	A071786 001	Aug 05, 1988
	0.6%	A070804 001	Aug 17, 1987
NEPHRON	0.4%	A071855 001	Jul 14, 1988
	0.6%	A071726 001	Jul 14, 1988
WOCKHARDT	0.4%	A075586 001	May 30, 2002
	0.6%	A075586 002	May 30, 2002
	5%	A072190 001	Jun 07, 1988
PROMETA			
MURO	5%	A073340 001	Mar 30, 1992
SYRUP; ORAL			
ALUPENT			
BOEHRINGER INGELHEIM	10MG/5ML	N017571 001	
METAPROTERENOL SULFATE			
APOTEX INC	10MG/5ML	A075235 001	Jan 27, 2000
COSETTE	10MG/5ML	A072761 001	Feb 27, 1992
G AND W LABS INC	10MG/5ML	A073034 001	Aug 30, 1991
MORTON GROVE	10MG/5ML	A071656 001	Oct 13, 1987
WOCKHARDT	10MG/5ML	A074702 001	Mar 24, 1997
PROMETA			
MURO	10MG/5ML	A072023 001	Sep 15, 1988

TABLET; ORAL

ALUPENT

BOEHRINGER INGELHEIM	10MG	N015874 002	
	20MG	N015874 001	
METAPROTERENOL SULFATE			
AM THERAP	10MG	A072054 001	Jun 23, 1988
	20MG	A072055 001	Jun 23, 1988
HERITAGE PHARMA	10MG	A072519 001	Mar 30, 1990
	20MG	A072520 001	Mar 30, 1990
PAR PHARM	10MG	A072024 001	Jun 28, 1988
	20MG	A072025 001	Jun 28, 1988
USL PHARMA	10MG	A071013 001	Jan 25, 1988
	20MG	A071014 001	Jan 25, 1988
WATSON LABS	10MG	A073013 001	Jan 31, 1991
	20MG	A072795 001	Jan 31, 1991

METARAMINOL BITARTRATE

INJECTABLE; INJECTION

ARAMINE

+ MERCK	EQ 10MG BASE/ML **	N009509 002	Dec 22, 1987
METARAMINOL BITARTRATE			
ABRAXIS PHARM	EQ 10MG BASE/ML	A080431 001	
ELKINS SINN	EQ 10MG BASE/ML	A083363 001	
FRESENIUS KABI USA	EQ 10MG BASE/ML	A080722 001	
GD SEARLE LLC	EQ 10MG BASE/ML	A086418 001	
	EQ 20MG BASE/ML	A086418 002	

METAXALONE

TABLET; ORAL

METAXALONE

INGENUS PHARMS LLC	800MG	A213836 001	Oct 21, 2020
+ PRIMUS PHARMS	640MG **	N022503 001	Jun 01, 2015
SKELAXIN			
+ KING PHARMS	400MG **	N013217 001	

METFORMIN HYDROCHLORIDE

FOR SUSPENSION, EXTENDED RELEASE; ORAL

RIOMET ER

+ SUN PHARM	500MG/5ML	N212595 001	Aug 29, 2019
-------------	-----------	-------------	--------------

TABLET; ORAL

GLUCOPHAGE

+ EMD SERONO INC	500MG **	N020357 001	Mar 03, 1995
	625MG **	N020357 003	Nov 05, 1998
	750MG **	N020357 004	Nov 05, 1998
	850MG **	N020357 002	Mar 03, 1995
	1GM **	N020357 005	Nov 05, 1998

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METFORMIN HYDROCHLORIDE

TABLET;ORAL

METFORMIN HYDROCHLORIDE

BARR	500MG	A075971 001	Jan 25, 2002
	850MG	A075971 002	Jan 25, 2002
	1GM	A075971 003	Jan 25, 2002
HERITAGE PHARMA	500MG	A075978 001	Jan 25, 2002
	850MG	A075978 002	Jan 25, 2002
	1GM	A075978 003	Nov 05, 2002
IPCA LABS LTD	500MG	A078422 001	Aug 06, 2007
	850MG	A078422 002	Aug 06, 2007
	1GM	A078422 003	Aug 06, 2007
IVAX SUB TEVA PHARMS	500MG	A075975 001	Jan 24, 2002
	625MG	A075975 004	Jan 24, 2002
	750MG	A075975 005	Jan 24, 2002
	850MG	A075975 002	Jan 24, 2002
	1GM	A075975 003	Jan 24, 2002
MACLEODS PHARMS LTD	500MG	A205330 001	Oct 31, 2017
	850MG	A205330 002	Oct 31, 2017
	1GM	A205330 003	Oct 31, 2017
MYLAN	500MG	A075976 001	Jan 24, 2002
	850MG	A075976 002	Jan 24, 2002
	1GM	A075976 003	Jan 24, 2002
MYLAN PHARMS INC	500MG	A075969 001	Jan 29, 2002
	850MG	A075969 002	Jan 29, 2002
	1GM	A075969 003	Jan 29, 2002
PROVIDENT PHARM	500MG	A077853 001	Jul 28, 2006
	850MG	A077853 002	Jul 28, 2006
	1GM	A077853 003	Jul 28, 2006
SANDOZ	500MG	A075985 001	Jan 25, 2002
	850MG	A075985 002	Jan 25, 2002
	1GM	A075985 003	Jan 25, 2002
SUN PHARM INDUSTRIES	500MG	A076038 001	Feb 21, 2002
	850MG	A076038 002	Feb 21, 2002
	1GM	A076038 003	Feb 21, 2002
SUNSHINE	500MG	A208999 001	Oct 12, 2018
	850MG	A208999 002	Oct 12, 2018
	1GM	A208999 003	Oct 12, 2018
TEVA	500MG	A076328 001	Dec 16, 2002
	850MG	A076328 002	Dec 16, 2002
	1GM	A076328 003	Dec 16, 2002
TORRENT PHARMS	500MG	A077711 001	Jan 24, 2007
	850MG	A077711 002	Jan 24, 2007
	1GM	A077711 003	Jan 24, 2007
WATSON LABS	500MG	A075979 001	Jan 24, 2002
	850MG	A075979 002	Jan 24, 2002
	1GM	A075979 003	Jan 24, 2002
WATSON LABS FLORIDA	500MG	A075961 001	Jan 25, 2002
	850MG	A075961 002	Jan 25, 2002
	1GM	A075961 003	Jan 25, 2002

TABLET, EXTENDED RELEASE;ORAL

FORTAMET

+ ANDRX LABS LLC	500MG **	N021574 001	Apr 27, 2004
GLUCOPHAGE XR			
+ EMD SERONO INC	500MG **	N021202 001	Oct 13, 2000
+	750MG **	N021202 004	Apr 11, 2003

METFORMIN HYDROCHLORIDE

ACTAVIS ELIZABETH	500MG	A076450 001	Oct 01, 2004
	750MG	A076878 001	Apr 13, 2005
ACTAVIS LABS FL INC	500MG	A076172 001	Jun 16, 2004
APOTEX	750MG	A076706 002	Dec 29, 2005
BARR	500MG	A076496 001	Nov 25, 2005
	750MG	A076863 001	Oct 14, 2004
IMPAX LABS	500MG	A076249 001	Jul 30, 2004
	750MG	A076985 001	Sep 13, 2005
IVAX SUB TEVA PHARMS	500MG	A076545 001	Dec 01, 2003
MYLAN	500MG	A076650 001	Sep 13, 2005
	750MG	A077113 001	Sep 08, 2005
RANBAXY LABS LTD	500MG	A076413 001	Jun 18, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

METFORMIN HYDROCHLORIDE

	750MG	A077211	001	Jun 29, 2005
SANDOZ	500MG	A076223	001	Dec 14, 2004
SUN PHARM INDUSTRIES	500MG	A077124	001	Dec 21, 2005
TORRENT	500MG	A090014	001	Dec 30, 2009
TORRENT PHARMS LTD	750MG	A079226	001	Feb 18, 2010
WATSON LABS INC	500MG	A076818	001	Dec 14, 2004

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

MYLAN	500MG;EQ 15MG BASE	A090406	001	Feb 25, 2011
	850MG;EQ 15MG BASE	A090406	002	Feb 25, 2011

TABLET, EXTENDED RELEASE;ORAL

ACTOPLUS MET XR

+	TAKEDA PHARMS USA	1GM;EQ 15MG BASE	N022024	001	May 12, 2009
+		1GM;EQ 30MG BASE	N022024	002	May 12, 2009

METFORMIN HYDROCHLORIDE; REPAGLINIDE

TABLET;ORAL

PRANDIMET

+	NOVO NORDISK INC	500MG;1MG	N022386	001	Jun 23, 2008
+		500MG;2MG	N022386	002	Jun 23, 2008

REPAGLINIDE AND METFORMIN HYDROCHLORIDE

LUPIN LTD	500MG;1MG	A200624	001	Jul 15, 2015
	500MG;2MG	A200624	002	Jul 15, 2015

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET;ORAL

AVANDAMET

+	SB PHARMCO	500MG;EQ 1MG BASE **	N021410	001	Oct 10, 2002
+		500MG;EQ 2MG BASE **	N021410	002	Oct 10, 2002
+		500MG;EQ 4MG BASE **	N021410	003	Oct 10, 2002
+		1GM;EQ 2MG BASE **	N021410	004	Aug 25, 2003
+		1GM;EQ 4MG BASE **	N021410	005	Aug 25, 2003

ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE

TEVA	500MG;EQ 2MG BASE	A077337	001	May 07, 2014
	500MG;EQ 1MG BASE	A077337	005	May 19, 2017
	500MG;EQ 4MG BASE	A077337	002	May 07, 2014
	1GM;EQ 4MG BASE	A077337	004	May 07, 2014
	1GM;EQ 2MG BASE	A077337	003	May 07, 2014

METHACHOLINE CHLORIDE

FOR SOLUTION;INHALATION

PROVOCHOLINE

+	METHAPHARM	1600MG/VIAL	N019193	002	Aug 29, 2016
---	------------	-------------	---------	-----	--------------

METHACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

RONDONMYCIN

MEDPOINTE PHARM HLC	EQ 140MG BASE	A060641	001	
	EQ 280MG BASE	A060641	002	

SYRUP;ORAL

RONDONMYCIN

MEDPOINTE PHARM HLC	EQ 70MG BASE/5ML	A060641	003	
---------------------	------------------	---------	-----	--

METHADONE HYDROCHLORIDE

POWDER;FOR RX COMPOUNDING

METHADONE HYDROCHLORIDE

MALLINCKRODT INC	50GM/BOT	N006383	002	
	100GM/BOT	N006383	003	
	500GM/BOT	N006383	004	

SYRUP;ORAL

DOLOPHINE HYDROCHLORIDE

HIKMA	10MG/30ML	N006134	004	
-------	-----------	---------	-----	--

TABLET;ORAL

DOLOPHINE HYDROCHLORIDE

+	HIKMA	5MG	N006134	002
+		10MG	N006134	010

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METHADONE HYDROCHLORIDE

TABLET;ORAL

METHADONE HYDROCHLORIDE

ROXANE 40MG

A074081 001 Apr 28, 1995

VISTAPHARM 5MG

A040241 001 May 29, 1998

METHADOSE

SPECGX LLC 5MG

A040050 001 Apr 15, 1993

10MG

A040050 002 Apr 15, 1993

TABLET, DISPERSIBLE;ORAL

WESTADONE

SANDOZ 2.5MG

N017108 001

TABLET, EFFERVESCENT;ORAL

WESTADONE

SANDOZ 5MG

N017108 002

10MG

N017108 003

40MG

N017108 004

METHAMPHETAMINE HYDROCHLORIDE

TABLET;ORAL

METHAMPEX

TEVA 10MG

A083889 001

METHAMPHETAMINE HYDROCHLORIDE

ABLE 5MG

A040529 001 Feb 25, 2004

REXAR 5MG

A084931 001

10MG

A084931 002

TEVA 5MG

A086359 001

TABLET, EXTENDED RELEASE;ORAL

DESOXYN

RECORDATI RARE 5MG

N005378 004

10MG

N005378 003

15MG

N005378 005

METHANTHELINE BROMIDE

TABLET;ORAL

BANTHINE

SHIRE 50MG

N007390 001

METHARBITAL

TABLET;ORAL

GEMONIL

ABBVIE 100MG

N008322 001

METHAZOLAMIDE

TABLET;ORAL

METHAZOLAMIDE

APPLIED ANAL 25MG

A040011 001 Jul 17, 1997

50MG

A040011 002 Jul 17, 1997

ATHEM 25MG

A040102 001 Aug 28, 1996

50MG

A040102 002 Aug 28, 1996

NEPTAZANE

+ LEDERLE 25MG **

N011721 002 Nov 25, 1991

+ 50MG **

N011721 001

METHDILAZINE

TABLET, CHEWABLE;ORAL

TACARYL

WESTWOOD SQUIBB 3.6MG

N011950 009

METHDILAZINE HYDROCHLORIDE

SYRUP;ORAL

METHDILAZINE HYDROCHLORIDE

ALPHARMA US PHARMS 4MG/5ML

A087122 001

TACARYL

WESTWOOD SQUIBB 4MG/5ML

N011950 007

TABLET;ORAL

TACARYL

WESTWOOD SQUIBB 8MG

N011950 006

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METHENAMINE HIPPURATE

TABLET; ORAL

METHENAMINE HIPPURATE

IMPAX LABS INC

1GM

A076411 001 Jun 20, 2003

METHICILLIN SODIUM

INJECTABLE; INJECTION

STAPHICILLIN

APOTHECON

EQ 900MG BASE/VIAL

A061449 001

EQ 900MG BASE/VIAL

N050117 001

EQ 3.6GM BASE/VIAL

A061449 002

EQ 3.6GM BASE/VIAL

N050117 002

EQ 5.4GM BASE/VIAL

A061449 003

EQ 5.4GM BASE/VIAL

N050117 003

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

DISCOVERY THERAP

15MG

A040619 003 Jul 12, 2005

20MG

A040547 004 Feb 18, 2005

MYLAN

20MG

A040350 003 Jun 07, 2001

SUN PHARM INDS INC

5MG

A040870 001 Sep 25, 2007

10MG

A040870 002 Sep 25, 2007

TAPAZOLE

+ KING PHARMS

5MG **

N007517 002

+

10MG **

N007517 004

METHIXENE HYDROCHLORIDE

TABLET; ORAL

TREST

NOVARTIS

1MG

N013420 001

METHOCARBAMOL

INJECTABLE; INJECTION

METHOCARBAMOL

DR REDDYS

100MG/ML

A086459 001

MARSAM PHARMS LLC

100MG/ML

A089849 001 Dec 27, 1991

TABLET; ORAL

DELAXIN

FERNDALE LABS

500MG

A085454 001

FORBAXIN

FOREST LABS

750MG

A085136 001

METHOCARBAMOL

ABLE

500MG

A040413 001 Mar 17, 2003

750MG

A040413 002 Mar 17, 2003

AM THERAP

500MG

A089417 001 Feb 11, 1987

750MG

A089418 001 Feb 11, 1987

ANI PHARMS INC

500MG

A084277 001

750MG

A084276 002

ASCOT

500MG

A087660 001 Oct 27, 1982

750MG

A087661 001 Oct 27, 1982

CLONMEL HLTHCARE

500MG

A085961 001

750MG

A085963 001

FOSUN PHARMA

500MG

A084616 001

750MG

A084615 001

HEATHER

500MG

A084675 001

750MG

A084924 001

HIKMA INTL PHARMS

500MG

A085159 001

750MG

A085123 001

IMPAX LABS

500MG

A084927 001

750MG

A084928 001

INWOOD LABS

500MG

A085137 001

IVAX SUB TEVA PHARMS

500MG

A084648 001

750MG

A084649 001

KV PHARM

500MG

A085660 001

750MG

A085658 001

LANNETT CO INC

500MG

A084756 002 Mar 31, 2003

750MG

A084756 001

MYLAN

500MG

A084259 001

750MG

A084323 001

NYLOS

750MG

A085033 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

PIONEER PHARMS	500MG	A088731 001	Dec 13, 1985
	750MG	A089082 001	Dec 13, 1985
PURACAP PHARM	500MG	A084231 002	
	750MG	A084471 001	
PUREPAC PHARM	500MG	A085718 001	
	750MG	A085718 002	
ROXANE	500MG	A088646 001	Feb 29, 1984
	750MG	A088647 001	Feb 29, 1984
SANDOZ	500MG	A087283 001	
	750MG	A087282 001	
SOLVAY	500MG	A084448 001	
	750MG	A084449 001	
SUN PHARM INDUSTRIES	500MG	A084488 001	
	750MG	A084486 001	
SUPERPHARM	500MG	A087589 001	Jan 22, 1982
	750MG	A087590 001	Jan 22, 1982
TABLICAPS	500MG	A084846 001	
UPSHER SMITH	500MG	A087453 001	
	750MG	A087454 001	
WATSON LABS	500MG	A083605 001	
	500MG	A085180 001	
	750MG	A083605 002	
	750MG	A085192 001	
ROBAXIN			
+ AUXILIUM PHARMS LLC	500MG	N011011 004	
ROBAXIN-750			
+ AUXILIUM PHARMS LLC	750MG	N011011 006	

METHOHEXITAL SODIUM

INJECTABLE; INJECTION

BREVITAL SODIUM

PAR STERILE PRODUCTS	200MG/VIAL	N011559 004	Dec 21, 2012
+	2.5GM/VIAL	N011559 002	
	5GM/VIAL	N011559 003	

METHOTREXATE

SOLUTION; INTRAVENOUS

METHOTREXATE

+ ACCORD HLTHCARE	5GM/50ML (100MG/ML)	N214121 001	Aug 24, 2020
SOLUTION; SUBCUTANEOUS			
OTREXUP			
+ ANTARES PHARMA INC	7.5MG/0.4ML (7.5MG/0.4ML)	N204824 005	Nov 07, 2014
OTREXUP PFS			
+ ANTARES PHARMA INC	10MG/0.4ML (10MG/0.4ML)	N204824 009	May 31, 2017
+	15MG/0.6ML (15MG/0.6ML)	N204824 010	May 31, 2017
+	17.5MG/0.7ML (17.5MG/0.7ML)	N204824 011	May 31, 2017
+	20MG/0.8ML (20MG/0.8ML)	N204824 012	May 31, 2017
+	22.5MG/0.9ML (22.5MG/0.9ML)	N204824 013	May 31, 2017
+	25MG/ML (25MG/ML)	N204824 014	May 31, 2017
RASUVO			
+ MEDEXUS	27.5MG/0.55ML (27.5MG/0.55ML)	N205776 009	Jul 10, 2014

METHOTREXATE SODIUM

INJECTABLE; INJECTION

ABITREXATE

ABIC	EQ 25MG BASE/ML	A089161 001	Mar 10, 1987
	EQ 50MG BASE/VIAL	A089354 001	Jul 17, 1987
	EQ 100MG BASE/VIAL	A089355 001	Jul 17, 1987
	EQ 250MG BASE/VIAL	A089356 001	Jul 17, 1987
FOLEX			
PHARMACIA AND UPJOHN	EQ 25MG BASE/VIAL	A087695 001	Apr 08, 1983
	EQ 50MG BASE/VIAL	A087695 002	Apr 08, 1983
	EQ 100MG BASE/VIAL	A087695 003	Apr 08, 1983
	EQ 250MG BASE/VIAL	A088954 001	Oct 24, 1985
FOLEX PFS			
PHARMACIA AND UPJOHN	EQ 25MG BASE/ML	A081242 001	Aug 23, 1991
	EQ 25MG BASE/ML	A089180 001	Jan 03, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE LPF

HOSPIRA EQ 25MG BASE/ML N011719 007 Mar 31, 1982

METHOTREXATE PRESERVATIVE FREE

HOSPIRA EQ 20MG BASE/2ML (EQ 10MG BASE/ML) N011719 014 Apr 13, 2005

+ EQ 500MG BASE/20ML (EQ 25MG BASE/ML) ** N011719 013 Apr 13, 2005

EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML) N011719 011 Apr 13, 2005

METHOTREXATE SODIUM

ABRAXIS PHARM

EQ 2.5MG BASE/ML A089323 001 Jun 13, 1986

EQ 20MG BASE/VIAL A088935 001 Oct 11, 1985

EQ 25MG BASE/ML A089263 001 Jun 13, 1986

EQ 25MG BASE/ML A089322 001 Jun 13, 1986

EQ 50MG BASE/VIAL A088936 001 Oct 11, 1985

EQ 100MG BASE/VIAL A088937 001 Oct 11, 1985

FRESENIUS KABI USA EQ 250MG BASE/10ML (EQ 25MG BASE/ML) A040263 002 Feb 26, 1999

HOSPIRA EQ 2.5MG BASE/ML N011719 004

EQ 20MG BASE/VIAL N011719 001

EQ 25MG BASE/ML N011719 005

EQ 50MG BASE/VIAL N011719 003

EQ 100MG BASE/VIAL N011719 006

NORBROOK EQ 25MG BASE/ML A088648 001 May 09, 1986

PHARMACHEMIE USA EQ 25MG BASE/ML A089158 001 Jul 08, 1988

METHOTREXATE SODIUM PRESERVATIVE FREE

HOSPIRA EQ 1GM BASE/VIAL N011719 009 Apr 07, 1988

MYLAN LABS LTD EQ 50MG BASE/2ML (EQ 25MG BASE/ML) A201529 001 Mar 29, 2012

EQ 100MG BASE/4ML (EQ 25MG BASE/ML) A201529 002 Mar 29, 2012

EQ 200MG BASE/8ML (EQ 25MG BASE/ML) A201529 003 Mar 29, 2012

MEXATE

BRISTOL EQ 20MG BASE/VIAL A086358 001

EQ 50MG BASE/VIAL A086358 002

EQ 100MG BASE/VIAL A086358 003

EQ 250MG BASE/VIAL A086358 004

MEXATE-AQ

BRISTOL MYERS EQ 25MG BASE/ML A088760 001 Feb 14, 1985

MEXATE-AQ PRESERVED

BRISTOL MYERS SQUIBB EQ 25MG BASE/ML A089887 001 Apr 14, 1989

TABLET; ORAL

METHOTREXATE SODIUM

+ DAVA PHARMS INC EQ 2.5MG BASE N008085 002

DURAMED PHARMS BARR EQ 2.5MG BASE A040233 001 Jun 17, 1999

METHOXAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

VASOXYL

GLAXOSMITHKLINE 10MG/ML N006772 002

20MG/ML N006772 001

METHOXSALEN

CAPSULE; ORAL

8-MOP

+ VALEANT PHARM INTL 10MG N009048 001

METHOXSALEN

ANI PHARMS INC 10MG A087781 001 Jun 08, 1982

LOTION; TOPICAL

OXSORALEN

+ VALEANT PHARM INTL 1% N009048 002

METHSCOPOLAMINE BROMIDE

TABLET; ORAL

METHSCOPOLAMINE BROMIDE

PVT FORM 2.5MG A080970 001

VINTAGE PHARMS 2.5MG A040624 001 Dec 28, 2006

5MG A040624 002 Dec 28, 2006

PAMINE

FOUGERA PHARMS 2.5MG ** N008848 001

PAMINE FORTE

FOUGERA PHARMS 5MG ** N008848 002 Mar 25, 2003

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METHSUXIMIDE

CAPSULE; ORAL

CELONTIN

+ PARKE DAVIS 150MG N010596 007

METHYCLOTHIAZIDE

TABLET; ORAL

AQUATENSEN

MEDPOINTE PHARM HLC 5MG N017364 001

ENDURON

+ ABBVIE 2.5MG ** N012524 001

+ 5MG ** N012524 004

METHYCLOTHIAZIDE

IVAX PHARMS 2.5MG A087913 001 Jun 03, 1982

5MG A087786 001 May 18, 1982

MYLAN 2.5MG A087671 001 Aug 17, 1982

MYLAN PHARMS INC 5MG A087672 001 Aug 17, 1982

PAR PHARM 2.5MG A089135 001 Feb 12, 1986

5MG A089136 001 Feb 12, 1986

USL PHARMA 5MG A088745 001 Mar 21, 1985

WATSON LABS 2.5MG A085487 001 Mar 11, 1982

2.5MG A088750 001 Sep 06, 1984

5MG A085476 001 Mar 11, 1982

5MG A088724 001 Sep 06, 1984

YAOPHARMA CO LTD 2.5MG A089835 001 Aug 18, 1988

5MG A089837 001 Aug 18, 1988

METHYCLOTHIAZIDE; PARGYLINE HYDROCHLORIDE

TABLET; ORAL

EUTRON

ABBOTT 5MG; 25MG N016047 001

METHYCLOTHIAZIDE; RESERPINE

TABLET; ORAL

DIUTENSEN-R

MEDPOINTE PHARM HLC 2.5MG; 0.1MG N012708 005

METHYL AMINOLEVULINATE HYDROCHLORIDE

CREAM; TOPICAL

METVIXIA

GALDERMA LABS LP EQ 16.8% BASE N021415 001 Jul 27, 2004

METHYLDOPA

SUSPENSION; ORAL

ALDOMET

MERCK 250MG/5ML N018389 001

TABLET; ORAL

ALDOMET

+ MERCK 125MG ** N013400 003

+ 250MG ** N013400 001

+ 500MG ** N013400 002

METHYLDOPA

ACCORD HLTHCARE 125MG A070070 003 Oct 15, 1985

250MG A071006 001 Dec 16, 1986

500MG A071009 001 Dec 16, 1986

HALSEY 125MG A071751 001 Mar 28, 1988

250MG A071752 001 Mar 28, 1988

500MG A071753 001 Mar 28, 1988

HERITAGE PHARMA 250MG A070098 001 Feb 20, 1986

500MG A070343 001 Feb 20, 1986

PAR PHARM 125MG A070535 001 Jan 02, 1987

250MG A070536 001 Jan 02, 1987

500MG A070537 001 Jan 02, 1987

PARKE DAVIS 125MG A070331 001 Apr 15, 1986

250MG A070332 001 Apr 15, 1986

500MG A070333 001 Apr 15, 1986

PLIVA 125MG A072126 001 Jul 07, 1988

250MG A072127 001 Jul 07, 1988

500MG A072128 001 Jul 07, 1988

PUREPAC PHARM 125MG A070749 001 Feb 07, 1986

250MG A070750 001 Feb 07, 1986

500MG A070452 001 Feb 07, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METHYLDOPA

TABLET; ORAL

METHYLDOPA

ROXANE	125MG	A070192	001	Apr 25, 1986
	250MG	A070193	001	Apr 25, 1986
	500MG	A070194	001	Apr 25, 1986
SUN PHARM INDUSTRIES	125MG	A070073	001	Oct 09, 1986
	250MG	A070060	001	Oct 09, 1986
	500MG	A070074	001	Oct 09, 1986
SUPERPHARM	250MG	A070669	001	Jun 23, 1989
	500MG	A070670	001	Jun 23, 1989
TEVA	125MG	A071105	001	Dec 05, 1986
	250MG	A071106	001	Dec 05, 1986
	500MG	A071067	001	Dec 05, 1986
WATSON LABS	125MG	A070245	001	Feb 25, 1986
	125MG	A070260	001	Jun 24, 1985
	250MG	A070246	001	Feb 25, 1986
	250MG	A070261	001	Jun 24, 1985
	250MG	A070703	001	Jun 06, 1986
	500MG	A070247	001	Feb 25, 1986
	500MG	A070262	001	Jun 24, 1985
	500MG	A070625	001	Jun 06, 1986
YAOPHARMA CO LTD	125MG	A071700	001	Mar 02, 1988
	250MG	N018934	001	Jun 29, 1984
	500MG	N018934	002	Jun 29, 1984

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

ALDOMET

+ MERCK

50MG/ML **

N013401 001

METHYLDOPATE HYDROCHLORIDE

ABRAXIS PHARM	50MG/ML	A070652	001	Jun 03, 1986
AM REGENT	50MG/ML	A071279	001	Oct 02, 1987
BAXTER HLTHCARE	50MG/ML	A070291	001	Jul 01, 1986
HOSPIRA	50MG/ML	A070691	001	Jun 19, 1987
	50MG/ML	A070698	001	Jun 15, 1987
	50MG/ML	A070699	001	Jun 15, 1987
	50MG/ML	A070849	001	Jun 19, 1987
MARSAM PHARMS LLC	50MG/ML	A071812	001	Dec 22, 1987
SMITH AND NEPHEW	50MG/ML	A070841	001	Jan 02, 1987
TEVA PARENTERAL	50MG/ML	A072974	001	Nov 22, 1991

METHYLERGONOVINE MALEATE

TABLET; ORAL

METHERGINE

+ EDISON THERAPS LLC

0.2MG **

N006035 003

METHYLPHENIDATE

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE; ORAL

METHYLPHENIDATE

ACTAVIS ELIZABETH	8.6MG	A210924	001	Jun 19, 2020
	17.3MG	A210924	002	Jun 19, 2020
	25.9MG	A210924	003	Jun 19, 2020

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

METHYLPHENIDATE HYDROCHLORIDE

BARR LABS INC	10MG	A079031	004	Oct 15, 2014
	20MG	A079031	001	Jul 13, 2012
	30MG	A079031	002	Jul 13, 2012
	40MG	A079031	003	Jul 13, 2012

RITALIN LA

+ NOVARTIS

60MG **

N021284 005 Oct 27, 2014

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

ABLE	5MG	A040404	001	Mar 29, 2001
	10MG	A040404	002	Mar 29, 2001
	20MG	A040404	003	Mar 29, 2001
ACTAVIS ELIZABETH	5MG	A040321	001	Feb 05, 2002
	10MG	A040321	002	Feb 05, 2002
	20MG	A040321	003	Feb 05, 2002

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METHYLPHENIDATE HYDROCHLORIDE

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AUROLIFE PHARMA LLC	5MG	A209276 001	Oct 25, 2018
	10MG	A209276 002	Oct 25, 2018
	20MG	A209276 003	Oct 25, 2018
CEDIPROF INC	5MG	A208737 001	Feb 01, 2019
	10MG	A208737 002	Feb 01, 2019
	20MG	A208737 003	Feb 01, 2019
CNTY LINE PHARMS	5MG	A206840 001	Sep 15, 2016
	10MG	A206840 002	Sep 15, 2016
	20MG	A206840 003	Sep 15, 2016
LANNETT CO INC	5MG	A086429 001	
	10MG	A085799 001	
	20MG	A086428 001	
NOSTRUM LABS INC	5MG	A207587 001	Mar 03, 2017
	10MG	A207587 002	Mar 03, 2017
	20MG	A207587 003	Mar 03, 2017
WATSON LABS	5MG	A040220 001	Aug 29, 1997
	10MG	A040220 002	Aug 29, 1997
	20MG	A040220 003	Aug 29, 1997

TABLET, CHEWABLE;ORAL

METHYLIN

+ SPECGX LLC	2.5MG **	N021475 001	Apr 15, 2003
+	5MG **	N021475 002	Apr 15, 2003
+	10MG **	N021475 003	Apr 15, 2003

METHYLPHENIDATE HYDROCHLORIDE

NOSTRUM LABS INC	2.5MG	A204954 001	Jan 26, 2017
	5MG	A204954 002	Jan 26, 2017
	10MG	A204954 003	Jan 26, 2017

TABLET, EXTENDED RELEASE;ORAL

METADATE ER

LANNETT CO INC	10MG	A040306 001	Oct 20, 1999
	20MG	A089601 001	Jun 01, 1988

METHYLPHENIDATE HYDROCHLORIDE

ABLE	20MG	A076032 001	May 09, 2001
ANI PHARMS INC	18MG	A208607 001	Jul 14, 2017
	27MG	A208607 002	Jul 14, 2017
	36MG	A208607 003	Jul 14, 2017
	54MG	A208607 004	Jul 14, 2017
HERITAGE PHARMA	20MG	A075450 001	Dec 21, 2001
PAR PHARM	36MG	A204659 001	Jul 15, 2019
	54MG	A204659 002	Jul 15, 2019
WATSON LABS	20MG	A040410 001	Feb 09, 2001

RITALIN-SR

+ NOVARTIS	20MG **	N018029 001	Mar 30, 1982
------------	---------	-------------	--------------

METHYLPREDNISOLONE

TABLET;ORAL

MEDROL

PFIZER	24MG	N011153 005	
--------	------	-------------	--

METHYLPREDNISOLONE

DURAMED PHARMS BARR	4MG	A088497 001	Feb 21, 1984
HEATHER	4MG	A085650 001	
INVATECH	4MG	A087341 001	
LUPIN LTD	2MG	A209097 001	Feb 22, 2019
	4MG	A209097 002	Feb 22, 2019
	8MG	A209097 003	Feb 22, 2019
	16MG	A209097 004	Feb 22, 2019
	32MG	A209097 005	Feb 22, 2019
NOVAST LABS	4MG	A210985 001	Jan 09, 2019
PAR PHARM	16MG	A089207 001	Apr 25, 1988
	24MG	A089208 001	Apr 25, 1988
	32MG	A089209 001	Apr 25, 1988
WATSON LABS	4MG	A086161 001	Feb 09, 1982
	16MG	A086159 001	Feb 09, 1982

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METHYLPREDNISOLONE ACETATE

ENEMA;RECTAL

MEDROL

PHARMACIA AND UPJOHN 40MG/BOT N018102 001

INJECTABLE; INJECTION

M-PREDROL

BEL MAR 40MG/ML A086666 001

80MG/ML A087135 001

METHYLPREDNISOLONE ACETATE

AKORN 40MG/ML A086903 001 Oct 20, 1982

80MG/ML A086903 002 Oct 20, 1982

WATSON LABS 20MG/ML A085597 001

20MG/ML A087248 001

40MG/ML A085374 001

40MG/ML A085600 001

80MG/ML A085595 001

80MG/ML A086507 001

OINTMENT;TOPICAL

MEDROL ACETATE

PHARMACIA AND UPJOHN 0.25% N012421 001

1% N012421 002

METHYLPREDNISOLONE ACETATE; NEOMYCIN SULFATE

CREAM;TOPICAL

NEO-MEDROL ACETATE

PHARMACIA AND UPJOHN 0.25%;EQ 3.5MG BASE/GM A060611 002

1%;EQ 3.5MG BASE/GM A060611 001

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-METHAPRED

ABBOTT EQ 40MG BASE/VIAL A089573 001 Feb 22, 1991

EQ 125MG BASE/VIAL A089574 001 Feb 22, 1991

EQ 500MG BASE/VIAL A089575 001 Feb 22, 1991

EQ 1GM BASE/VIAL A089576 001 Feb 22, 1991

HOSPIRA EQ 40MG BASE/VIAL A040664 001 Dec 20, 2005

EQ 40MG BASE/VIAL A085853 001

EQ 125MG BASE/VIAL A040665 001 Dec 20, 2005

EQ 125MG BASE/VIAL A085855 001

EQ 500MG BASE/VIAL A085854 001

EQ 500MG BASE/VIAL A089173 001 Aug 18, 1987

EQ 1GM BASE/VIAL A085852 001

EQ 1GM BASE/VIAL A089174 001 Aug 18, 1987

HOSPIRA INC EQ 40MG BASE/VIAL A040793 001 Nov 25, 2008

EQ 125MG BASE/VIAL A040827 001 Nov 25, 2008

METHYLPREDNISOLONE

ELKINS SINN EQ 125MG BASE/VIAL A086906 002

EQ 500MG BASE/VIAL A086906 003

EQ 1GM BASE/VIAL A086906 004

ORGANON USA INC EQ 500MG BASE/VIAL A087535 001 Jun 25, 1982

EQ 1GM BASE/VIAL A087535 002 Jun 25, 1982

METHYLPREDNISOLONE SODIUM SUCCINATE

ABRAXIS PHARM EQ 40MG BASE/VIAL A088676 001 Jun 08, 1984

EQ 40MG BASE/VIAL A089143 001 Mar 28, 1986

EQ 125MG BASE/VIAL A088677 001 Jun 08, 1984

EQ 125MG BASE/VIAL A089144 001 Mar 28, 1986

EQ 500MG BASE/VIAL A088678 001 Jun 08, 1984

EQ 500MG BASE/VIAL A089186 001 Mar 28, 1986

EQ 500MG BASE/VIAL A089187 001 Mar 28, 1986

EQ 1GM BASE/VIAL A088679 001 Jun 08, 1984

EQ 1GM BASE/VIAL A089188 001 Mar 28, 1986

EQ 1GM BASE/VIAL A089189 001 Mar 28, 1986

BEDFORD LABS EQ 40MG BASE/VIAL A040662 001 Feb 21, 2007

EQ 125MG BASE/VIAL A040641 002 Feb 21, 2007

EQ 500MG BASE/VIAL A040641 003 Feb 21, 2007

EQ 500MG BASE/VIAL A040709 001 Feb 21, 2007

EQ 1GM BASE/VIAL A040641 004 Feb 21, 2007

EQ 1GM BASE/VIAL A040709 002 Feb 21, 2007

ELKINS SINN EQ 40MG BASE/VIAL A086906 001

INTL MEDICATION EQ 40MG BASE/VIAL A087812 001 Feb 09, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE

	EQ 125MG BASE/VIAL	A087813 001	Feb 09, 1983
	EQ 500MG BASE/VIAL	A087851 001	Feb 09, 1983
	EQ 1GM BASE/VIAL	A087852 001	Feb 09, 1983
TEVA PARENTERAL	EQ 125MG BASE/VIAL	A081266 001	Nov 30, 1992
	EQ 500MG BASE/VIAL	A081267 001	Nov 30, 1992
	EQ 1GM BASE/VIAL	A081268 001	Nov 30, 1992
WATSON LABS	EQ 40MG BASE/VIAL	A086953 001	Jul 22, 1982
	EQ 125MG BASE/VIAL	A087030 001	Jul 22, 1982
	EQ 500MG BASE/VIAL	A088523 001	Jul 24, 1984
	EQ 1GM BASE/VIAL	A088524 001	Jul 24, 1984

METHYLPREDNISOLONE; NEOMYCIN SULFATE

OINTMENT; OPHTHALMIC

NEO-MEDROL

PHARMACIA AND UPJOHN	0.1%; EQ 3.5MG BASE/GM	A060645 001	
----------------------	------------------------	-------------	--

METHYLTESTOSTERONE

CAPSULE; ORAL

METHYLTESTOSTERONE

HEATHER	10MG	A084967 001	
TESTRED			
BAUSCH	10MG	A083976 001	
VIRILON			
CHARTWELL	10MG	A087750 001	Nov 24, 1982
TABLET; BUCCAL			
ANDROID 5			
VALEANT PHARM INTL	5MG	A087222 001	
ORETON			
SCHERING	10MG	A080281 001	
TABLET; BUCCAL, SUBLINGUAL			
METANDREN			
NOVARTIS	5MG	N003240 004	
	10MG	N003240 001	
	10MG	N003240 005	
	25MG	N003240 003	
METHYLTESTOSTERONE			
IMPAX LABS	10MG	A084287 001	
LILLY	10MG	A080256 001	
	25MG	A080256 002	
PUREPAC PHARM	10MG	A080308 001	
	10MG	A080475 001	
	10MG	A080475 002	
	25MG	A080475 003	
PVT FORM	5MG	A083836 001	
TABLICAPS	10MG	A085125 001	
USL PHARMA	10MG	A080271 001	
TABLET; ORAL			
ANDROID 10			
VALEANT PHARMS NORTH	10MG	A086450 001	
METHYLTESTOSTERONE			
IMPAX LABS	25MG	A084310 001	
INWOOD LABS	10MG	A080839 001	
	25MG	A080973 001	
KV PHARM	10MG	A084312 001	
LANNETT	10MG	A087092 001	Nov 05, 1982
	25MG	A087111 001	Jan 27, 1983
PARKE DAVIS	10MG	A084244 001	
	25MG	A084241 001	
PUREPAC PHARM	10MG	A080309 001	
	25MG	A080310 001	
PVT FORM	5MG	A080214 001	
	10MG	A080214 002	
	25MG	A080214 003	
TABLICAPS	10MG	A080313 001	
	25MG	A085270 001	
WATSON LABS	10MG	A080933 001	
	25MG	A080931 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METHYLTESTOSTERONE

TABLET; ORAL

METHYLTESTOSTERONE

WEST WARD

10MG

A084331 001

25MG

A084331 002

25MG

A084642 001

ORETON METHYL

SCHERING

10MG

N003158 001

25MG

N003158 002

METHYPRYLON

CAPSULE; ORAL

NOLUDAR

ROCHE

300MG

N009660 008

ELIXIR; ORAL

NOLUDAR

ROCHE

50MG/5ML

N009660 007

TABLET; ORAL

NOLUDAR

ROCHE

50MG

N009660 002

200MG

N009660 004

METHYSERGIDE MALEATE

TABLET; ORAL

SANSERT

NOVARTIS

2MG

N012516 001

METIPRANOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

METIPRANOLOL

SANDOZ INC

0.3%

A075720 001 Aug 06, 2001

OPTIPRANOLOL

+ BAUSCH AND LOMB

0.3%

N019907 001 Dec 29, 1989

METOCLOPRAMIDE HYDROCHLORIDE

CONCENTRATE; ORAL

METOCLOPRAMIDE INTENSOL

ROXANE

EQ 10MG BASE/ML

A072995 001 Jan 30, 1992

INJECTABLE; INJECTION

METOCLOPRAMIDE HYDROCHLORIDE

BEDFORD

EQ 5MG BASE/ML

A072155 001 Mar 30, 1992

EQ 5MG BASE/ML

A072244 001 Mar 30, 1992

EQ 5MG BASE/ML

A072247 001 May 18, 1992

HOSPIRA

EQ 5MG BASE/ML

A070505 001 Jun 23, 1989

EQ 5MG BASE/ML

A070506 001 Jun 22, 1989

EQ 5MG BASE/ML

A070847 001 Nov 07, 1988

EQ 5MG BASE/ML

A071291 001 Mar 03, 1989

EQ 5MG BASE/ML

A071990 001 Jan 18, 1989

EQ 5MG BASE/ML

A073117 001 Jan 17, 1991

EQ 5MG BASE/ML

A074147 001 Aug 02, 1996

LYPHOMED

EQ 10MG BASE/2ML

A070293 001 Jan 24, 1986

NORBROOK

EQ 10MG BASE/2ML

A070892 001 Aug 26, 1988

SMITH AND NEPHEW

EQ 5MG BASE/ML

A070623 001 Mar 02, 1987

EQ 10MG BASE/2ML

A070622 001 Mar 02, 1987

REGLAN

WEST-WARD PHARMS INT

EQ 5MG BASE/ML

N017862 001

EQ 10MG BASE/ML

N017862 004 May 28, 1987

SOLUTION; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

ACTAVIS MID ATLANTIC

EQ 5MG BASE/5ML

A071340 001 Aug 18, 1988

LANNETT CO INC

EQ 5MG BASE/5ML

A073680 001 Oct 27, 1992

MORTON GROVE

EQ 5MG BASE/5ML

A070949 001 Mar 06, 1987

PACO

EQ 5MG BASE/5ML

A071665 001 Dec 05, 1988

ROXANE

EQ 5MG BASE/5ML

A072038 001 Dec 05, 1988

TEVA

EQ 5MG BASE/5ML

A070819 001 Jul 10, 1987

EQ 5MG BASE/5ML

A071315 001 Jun 30, 1993

REGLAN

+ ROBINS AH

EQ 5MG BASE/5ML **

N018821 001 Mar 25, 1983

TABLET; ORAL

CLOPRA

QUANTUM PHARMICS

EQ 5MG BASE

A072384 001 Jun 02, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METOCLOPRAMIDE HYDROCHLORIDE

TABLET; ORAL

CLOPRA

	EQ 10MG BASE	A070294 001	Jul 29, 1985
CLOPRA-"YELLOW"			
QUANTUM PHARMICS	EQ 10MG BASE	A070632 001	Oct 28, 1985
MAXOLON			
KING PHARMS	EQ 10MG BASE	A070106 001	Mar 04, 1986
METOCLOPRAMIDE HYDROCHLORIDE			
CLONMEL	EQ 10MG BASE	A072639 001	May 09, 1991
HALSEY	EQ 10MG BASE	A070906 001	Oct 28, 1986
INTERPHARM	EQ 10MG BASE	A071213 001	Sep 24, 1986
MUTUAL PHARM	EQ 10MG BASE	A070660 001	Feb 10, 1987
NORTHSTAR HLTHCARE	EQ 5MG BASE	A078374 001	Nov 30, 2007
	EQ 10MG BASE	A078374 002	Nov 30, 2007
PAR PHARM	EQ 10MG BASE	A070342 001	Mar 25, 1986
SANDOZ	EQ 5MG BASE	A072436 001	Jun 22, 1989
	EQ 10MG BASE	A070850 001	Feb 03, 1987
SCHERING	EQ 10MG BASE	A070598 001	Feb 02, 1987
SUN PHARM INDUSTRIES	EQ 5MG BASE	A071536 002	Jan 16, 1997
	EQ 10MG BASE	A071536 001	Apr 28, 1993
SUPERPHARM	EQ 10MG BASE	A070926 001	Jun 26, 1987
USL PHARMA	EQ 10MG BASE	A070339 001	Jul 29, 1985
WATSON LABS	EQ 10MG BASE	A070363 001	Mar 02, 1987
	EQ 10MG BASE	A070453 001	Jun 06, 1986
	EQ 10MG BASE	A070511 001	Jan 22, 1986
	EQ 10MG BASE	A070645 001	May 11, 1987
YAOPHARMA CO LTD	EQ 5MG BASE	A074478 001	Oct 05, 1995
	EQ 10MG BASE	A072215 001	Jan 30, 1990
	EQ 10MG BASE	A074478 002	Oct 05, 1995

TABLET, ORALLY DISINTEGRATING; ORAL

METOZOLV ODT

+	SALIX PHARMS	EQ 5MG BASE **	N022246 001	Sep 04, 2009
+		EQ 10MG BASE **	N022246 002	Sep 04, 2009
REGLAN ODT				
MEDA PHARMS	EQ 5MG BASE	N021793 001	Jun 10, 2005	
	EQ 10MG BASE	N021793 002	Jun 10, 2005	

METOCURINE IODIDE

INJECTABLE; INJECTION

METUBINE IODIDE

LILLY	2MG/ML	N006632 003
-------	--------	-------------

METOLAZONE

TABLET; ORAL

DIULO

GD SEARLE LLC	2.5MG	N018535 001	
	5MG	N018535 002	
	10MG	N018535 003	
METOLAZONE			
ANI PHARMS INC	2.5MG	A075543 001	Jan 06, 2004
	5MG	A075543 002	Mar 01, 2004
	10MG	A075543 003	Dec 24, 2003
ROXANE	10MG	A076482 002	Apr 29, 2004
WATSON LABS	10MG	A076891 001	Jul 21, 2004
MYKROX			
LANNETT CO INC	0.5MG	N019532 001	Oct 30, 1987

METOPROLOL FUMARATE

TABLET, EXTENDED RELEASE; ORAL

LOPRESSOR

NOVARTIS	EQ 100MG TARTRATE	N019786 001	Dec 27, 1989
	EQ 200MG TARTRATE	N019786 002	Dec 27, 1989
	EQ 300MG TARTRATE	N019786 003	Dec 27, 1989
	EQ 400MG TARTRATE	N019786 004	Dec 27, 1989

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

ACTAVIS ELIZABETH	EQ 25MG TARTRATE	A204161 001	Nov 25, 2016
	EQ 50MG TARTRATE	A204161 002	Nov 25, 2016
	EQ 100MG TARTRATE	A204161 003	Nov 25, 2016
	EQ 200MG TARTRATE	A204161 004	Nov 25, 2016
ACTAVIS LABS FL INC	EQ 25MG TARTRATE	A076862 002	Aug 03, 2009
	EQ 100MG TARTRATE	A077298 001	Apr 15, 2010
	EQ 200MG TARTRATE	A077298 002	Apr 15, 2010
NESHER PHARMS	EQ 25MG TARTRATE	A077779 001	Mar 20, 2008
	EQ 50MG TARTRATE	A077176 001	May 14, 2008
	EQ 100MG TARTRATE	A076640 002	May 18, 2007
	EQ 200MG TARTRATE	A076640 001	May 18, 2007
SANDOZ	EQ 25MG TARTRATE	A076969 001	Jul 31, 2006
	EQ 50MG TARTRATE	A076969 002	May 18, 2007
	EQ 100MG TARTRATE	A076969 003	Mar 20, 2008
	EQ 200MG TARTRATE	A076969 004	Mar 20, 2008

METOPROLOL TARTRATE

INJECTABLE; INJECTION

LOPRESSOR

+ NOVARTIS

1MG/ML

N018704 001 Mar 30, 1984

METOPROLOL TARTRATE

AM REGENT

1MG/ML

A090386 001 Sep 30, 2009

LUITPOLD

1MG/ML

A091307 001 Dec 29, 2010

MYLAN ASI

1MG/ML

A090317 001 Apr 19, 2010

WATSON LABS

1MG/ML

A074032 001 Dec 21, 1993

TABLET; ORAL

METOPROLOL TARTRATE

APOTHECON

50MG

A074258 001 Jan 27, 1994

100MG

A074258 002 Jan 27, 1994

HERITAGE PHARMA

50MG

A074141 001 Jan 31, 1995

100MG

A074141 002 Jan 31, 1995

MYLAN

50MG

A073666 001 Dec 21, 1993

100MG

A073666 002 Dec 21, 1993

PUREPAC PHARM

50MG

A074380 001 Jul 29, 1994

100MG

A074380 002 Jul 29, 1994

RENATA

50MG

A074453 001 Apr 27, 1995

100MG

A074453 002 Apr 27, 1995

SUN PHARM INDUSTRIES

25MG

A073654 002 Jul 15, 2009

50MG

A073654 003 Dec 21, 1993

100MG

A073654 001 Dec 21, 1993

TEVA

50MG

A074143 001 Sep 30, 1994

100MG

A074143 002 Sep 30, 1994

TEVA PHARMS

50MG

A074333 001 Jan 27, 1994

100MG

A074333 002 Jan 27, 1994

WATSON LABS

50MG

A074217 001 May 27, 1994

100MG

A074217 002 May 27, 1994

YAOPHARMA CO LTD

50MG

A073288 001 Mar 25, 1994

100MG

A073289 001 Mar 25, 1994

METRIZAMIDE

INJECTABLE; INJECTION

AMIPAQUE

GE HEALTHCARE

2.5GM/VIAL

N017982 003 Sep 12, 1983

3.75GM/VIAL

N017982 001

6.75GM/VIAL

N017982 002

13.5GM/VIAL

N017982 004 Sep 12, 1983

METRONIDAZOLE

CAPSULE; ORAL

METRONIDAZOLE

ABLE

375MG

A076505 001 Nov 13, 2003

INJECTABLE; INJECTION

FLAGYL I.V. RTU IN PLASTIC CONTAINER

PFIZER

500MG/100ML

N018353 002

METRO I.V.

B BRAUN

500MG/100ML

N018674 001 Aug 31, 1982

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METRONIDAZOLE

INJECTABLE; INJECTION

METRONIDAZOLE

ABBOT	500MG/100ML	N018889	001	Nov 18, 1983
ABRAXIS PHARM	500MG/100ML	A070071	001	Dec 03, 1984
INTL MEDICATION	500MG/100ML	A070004	001	May 08, 1985
WATSON LABS	500MG/100ML	A070042	001	Dec 20, 1984
	500MG/100ML	A070170	001	Apr 01, 1986
WEST-WARD PHARMS INT	500MG/100ML	N018907	001	Mar 30, 1984

METRONIDAZOLE IN PLASTIC CONTAINER

MYLAN LABS LTD	500MG/100ML	A205531	001	May 09, 2017
----------------	-------------	---------	-----	--------------

TABLET; ORAL

METROMIDOL

LABS AF	250MG	A074523	001	Oct 24, 1996
	500MG	A074523	002	Oct 24, 1996

METRONIDAZOLE

ABLE	250MG	A076519	001	Jun 27, 2003
	500MG	A076519	002	Jun 27, 2003
CHARTWELL MOLECULES	250MG	N018845	001	Aug 18, 1983
	500MG	N018930	001	Aug 18, 1983
FOSUN PHARMA	250MG	N018620	001	Mar 04, 1982
	250MG	N018740	001	Oct 22, 1982
	500MG	N018620	002	Jun 02, 1983
	500MG	N018740	002	Oct 22, 1982
HALSEY	250MG	A070021	001	Apr 02, 1985
	500MG	A070593	001	Feb 27, 1986
IVAX SUB TEVA PHARMS	250MG	N018517	001	
	500MG	N018517	002	May 05, 1982
LNK	250MG	N019029	001	Apr 10, 1984
MUTUAL PHARM	250MG	N018818	001	Feb 16, 1983
	500MG	N018818	002	Feb 16, 1983
SUPERPHARM	250MG	A070008	001	Dec 11, 1984
	500MG	A070009	001	Dec 11, 1984
WATSON LABS	250MG	N018599	001	Sep 17, 1982
	250MG	N018764	001	Sep 17, 1982
	500MG	N018599	002	Feb 13, 1984
	500MG	N018764	002	Dec 20, 1982

PROTOSTAT

ORTHO MCNEIL PHARM	250MG	N018871	001	Mar 02, 1983
	500MG	N018871	002	Mar 02, 1983

SATRIC

SAVAGE LABS	250MG	A070029	001	Mar 19, 1985
	500MG	A070731	001	Jun 08, 1987

TABLET, EXTENDED RELEASE; ORAL

FLAGYL ER

+ PFIZER	750MG	N020868	001	Nov 26, 1997
----------	-------	---------	-----	--------------

METRONIDAZOLE

ABLE	750MG	A076462	001	Jun 25, 2003
ALEMBIC PHARMS LTD	750MG	A090222	001	May 05, 2010

METRONIDAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION

FLAGYL I.V.

PFIZER	EQ 500MG BASE/VIAL **	N018353	001	
--------	-----------------------	---------	-----	--

METRONIDAZOLE HYDROCHLORIDE

ABRAXIS PHARM	EQ 500MG BASE/VIAL	A070295	001	Oct 15, 1985
---------------	--------------------	---------	-----	--------------

METYRAPONE

TABLET; ORAL

METOPIRONE

HRA PHARMA	250MG	N012911	001	
------------	-------	---------	-----	--

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HYDROCHLORIDE

WATSON LABS	150MG	A074711	001	Feb 26, 1997
	150MG	A074865	001	Apr 13, 1998
	200MG	A074711	002	Feb 26, 1997
	200MG	A074865	002	Apr 13, 1998
	250MG	A074711	003	Feb 26, 1997
	250MG	A074865	003	Apr 13, 1998

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXITIL

+	BOEHRINGER INGELHEIM	150MG	N018873	002	Dec 30, 1985
+		200MG	N018873	003	Dec 30, 1985
+		250MG	N018873	004	Dec 30, 1985

MEZLOCILLIN SODIUM MONOHYDRATE

INJECTABLE; INJECTION

MEZLIN

	BAYER PHARMS	EQ 1GM BASE/VIAL	A062333	001	
		EQ 1GM BASE/VIAL	A062372	005	Jan 13, 1983
		EQ 1GM BASE/VIAL	N050549	001	
		EQ 2GM BASE/VIAL	A062333	002	
		EQ 2GM BASE/VIAL	A062372	001	May 13, 1982
		EQ 2GM BASE/VIAL	N050549	002	
		EQ 3GM BASE/VIAL	A062333	003	
		EQ 3GM BASE/VIAL	A062372	002	May 13, 1982
		EQ 3GM BASE/VIAL	A062697	001	Jan 22, 1987
		EQ 3GM BASE/VIAL	N050549	003	
		EQ 4GM BASE/VIAL	A062333	004	
		EQ 4GM BASE/VIAL	A062372	003	May 13, 1982
		EQ 4GM BASE/VIAL	A062697	002	Jan 22, 1987
		EQ 4GM BASE/VIAL	N050549	004	
		EQ 20GM BASE/VIAL	A062372	004	Mar 02, 1988
		EQ 20GM BASE/VIAL	N050549	005	Mar 02, 1988

MICONAZOLE

INJECTABLE; INJECTION

MONISTAT

	JANSSEN PHARMA	10MG/ML	N018040	001	
--	----------------	---------	---------	-----	--

MICONAZOLE NITRATE

CREAM; TOPICAL

MONISTAT-DERM

	INSIGHT PHARMS	2%	N017494	001	
--	----------------	----	---------	-----	--

CREAM; VAGINAL

MICONAZOLE NITRATE

	TEVA	2%	A074136	001	Jan 04, 1995
	TEVA PHARMS	2%	A074030	001	Oct 30, 1992

CREAM, SUPPOSITORY; TOPICAL, VAGINAL

M-ZOLE 7 DUAL PACK

	ACTAVIS MID ATLANTIC	2%, 100MG	A074586	001	Jul 17, 1997
--	----------------------	-----------	---------	-----	--------------

MICONAZOLE 7 COMBINATION PACK

	COSETTE	2%, 100MG	A076585	001	Mar 26, 2004
--	---------	-----------	---------	-----	--------------

LOTION; TOPICAL

MONISTAT-DERM

	INSIGHT PHARMS	2%	N017739	001	
--	----------------	----	---------	-----	--

TAMPON; VAGINAL

MONISTAT 5

	PERSONAL PRODS	100MG	N018592	001	Oct 27, 1989
--	----------------	-------	---------	-----	--------------

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

	AKORN INC	EQ 5MG BASE/ML	A075481	001	Jun 30, 2000
	APOTHECON	EQ 1MG BASE/ML	A075620	001	Nov 01, 2000
		EQ 5MG BASE/ML	A075620	002	Nov 01, 2000
		EQ 5MG BASE/ML	A075641	001	Oct 19, 2000
	ATLANTIDE	EQ 1MG BASE/ML	A078141	001	May 30, 2008
		EQ 1MG BASE/ML	A078511	001	Nov 10, 2008
		EQ 5MG BASE/ML	A078141	002	May 30, 2008
		EQ 5MG BASE/ML	A078511	002	Nov 10, 2008
	BAXTER HLTHCARE CORP	EQ 1MG BASE/ML	A075637	001	Oct 31, 2000
		EQ 5MG BASE/ML	A075637	002	Oct 31, 2000
	BEDFORD	EQ 5MG BASE/ML	A075249	001	Jun 23, 2000
	BEN VENUE	EQ 5MG BASE/ML	A075455	001	Jun 20, 2000
	HOSPIRA	EQ 1MG BASE/ML	A075396	001	Jun 20, 2000
		EQ 5MG BASE/ML	A075396	002	Jun 20, 2000
		EQ 5MG BASE/ML	A075484	001	Jun 20, 2000
	HOSPIRA INC	EQ 1MG BASE/ML	A075409	002	Jun 20, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

	EQ 5MG BASE/ML	A075409 001	Jun 20, 2000
IGI LABS INC	EQ 5MG BASE/ML	A075263 001	Jun 26, 2000
INTL MEDICATED	EQ 1MG BASE/ML	A076144 001	Jan 26, 2005
	EQ 5MG BASE/ML	A076144 002	Jan 26, 2005
INTL MEDICATION	EQ 1MG BASE/ML	A076020 001	Jul 16, 2004
	EQ 5MG BASE/ML	A076020 002	Jul 16, 2004
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE			
MYLAN ASI	EQ 1MG BASE/ML	A090315 001	Nov 29, 2010
	EQ 5MG BASE/ML	A090315 002	Nov 29, 2010
MIDOZALAM HYDROCHLORIDE			
MYLAN ASI	EQ 1MG BASE/ML	A090316 001	May 04, 2011
	EQ 5MG BASE/ML	A090316 002	May 04, 2011
VERSED			
+ HLR	EQ 1MG BASE/ML **	N018654 002	May 26, 1987
+	EQ 5MG BASE/ML **	N018654 001	Dec 20, 1985

SYRUP; ORAL

MIDAZOLAM HYDROCHLORIDE

PHARM ASSOC	EQ 2MG BASE/ML	A077115 001	Sep 09, 2005
SUN PHARM INDS LTD	EQ 2MG BASE/ML	A076058 001	Mar 15, 2002
VERSED			
+ ROCHE	EQ 2MG BASE/ML **	N020942 001	Oct 15, 1998

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

MIDODRINE HYDROCHLORIDE

CHARTWELL RX	2.5MG	A076514 001	Sep 11, 2003
	5MG	A076514 002	Sep 11, 2003
	10MG	A076514 003	Jul 02, 2004
PROAMATINE			
+ TAKEDA PHARMS USA	2.5MG **	N019815 001	Sep 06, 1996
+	5MG **	N019815 002	Sep 06, 1996
+	10MG **	N019815 003	Mar 20, 2002

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL

MILNACIPRAN HYDROCHLORIDE

AMNEAL PHARMS	12.5MG	A205081 001	Apr 22, 2016
	25MG	A205081 002	Apr 22, 2016
	50MG	A205081 003	Apr 22, 2016
	100MG	A205081 004	Apr 22, 2016
USPHARMA	12.5MG	A205071 001	Jan 27, 2016
	25MG	A205071 002	Jan 27, 2016
	50MG	A205071 003	Jan 27, 2016
	100MG	A205071 004	Jan 27, 2016

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

BAXTER HLTHCARE CORP	EQ 1MG BASE/ML	A076427 001	Sep 21, 2004
GLAND PHARMA LTD	EQ 1MG BASE/ML	A077190 001	Oct 31, 2006
HOSPIRA	EQ 1MG BASE/ML	A075830 001	May 28, 2002
	EQ 1MG BASE/ML	A075884 001	May 28, 2002
INTL MEDICATED	EQ 1MG BASE/ML	A076013 001	Aug 02, 2002
MYLAN INSTITUTIONAL	EQ 1MG BASE/ML	A076428 001	Jun 16, 2003
WEST-WARD PHARMS INT	EQ 1MG BASE/ML	A075852 001	May 28, 2002
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A076414 001	Aug 18, 2004
BAXTER HLTHCARE	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A076259 001	Aug 08, 2002
WEST-WARD PHARMS INT	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A075510 001	May 28, 2002
WOODWARD	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A077151 001	Jul 20, 2005
PRIMACOR			
+ SANOFI AVENTIS US	EQ 1MG BASE/ML **	N019436 001	Dec 31, 1987
PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER			
+ SANOFI AVENTIS US	EQ 10MG BASE/100ML **	N020343 001	Aug 09, 1994
+	EQ 15MG BASE/100ML **	N020343 002	Aug 09, 1994
+	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	N020343 003	Aug 09, 1994
+	**		
+	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	N020343 004	Aug 09, 1994

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MILRINONE LACTATE

INJECTABLE;INJECTION
 PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER
 **

MINOCYCLINE HYDROCHLORIDE

CAPSULE;ORAL

MINOCIN

+	BAUSCH	EQ 75MG BASE **	N050649	003	Feb 12, 2001
	TRIAx PHARMS	EQ 50MG BASE	N050315	002	
		EQ 100MG BASE	N050315	001	

CAPSULE, EXTENDED RELEASE;ORAL

XIMINO

	JOURNEY	EQ 67.5MG BASE	N201922	002	Jul 11, 2012
		EQ 112.5MG BASE	N201922	004	Jul 11, 2012

INJECTABLE;INJECTION

MINOCIN

	LEDERLE	EQ 100MG BASE/VIAL	A062139	001	
--	---------	--------------------	---------	-----	--

SUSPENSION;ORAL

MINOCIN

	BAUSCH	EQ 50MG BASE/5ML	N050445	001	
--	--------	------------------	---------	-----	--

TABLET;ORAL

MINOCYCLINE HYDROCHLORIDE

+	TRIAx PHARMS	EQ 50MG BASE **	N050451	003	Aug 10, 1982
+		EQ 100MG BASE **	N050451	002	Aug 10, 1982

TABLET, EXTENDED RELEASE;ORAL

MINOCYCLINE HYDROCHLORIDE

	BARR LABS INC	EQ 45MG BASE	A065485	001	Mar 17, 2009
		EQ 90MG BASE	A065485	002	Mar 17, 2009
		EQ 135MG BASE	A065485	003	Mar 17, 2009
	IMPAX LABS INC	EQ 45MG BASE	A090024	001	Feb 03, 2009
		EQ 90MG BASE	A090024	002	Feb 03, 2009
		EQ 135MG BASE	A090024	003	Feb 03, 2009
	MYLAN	EQ 55MG BASE	A203443	001	Aug 21, 2019
	MYLAN LABS LTD	EQ 65MG BASE	A201467	001	Jul 30, 2019
		EQ 115MG BASE	A201467	002	Jul 30, 2019
	MYLAN PHARMS INC	EQ 45MG BASE	A090911	001	Jul 20, 2010
		EQ 90MG BASE	A090911	002	Jul 20, 2010
		EQ 135MG BASE	A090911	003	Jul 20, 2010

SOLODYN

+	MEDICIS	EQ 45MG BASE **	N050808	001	May 08, 2006
+		EQ 90MG BASE **	N050808	002	May 08, 2006
+		EQ 135MG BASE **	N050808	003	May 08, 2006

MINOXIDIL

SOLUTION;TOPICAL

MINOXIDIL (FOR MEN)

	APOTEX INC	2%	A074924	001	Apr 29, 1998
	BAUSCH AND LOMB	2%	A074643	001	Apr 09, 1996
	COPELY PHARM	2%	A074500	001	May 23, 1996
	SIGHT PHARMS	2%	A074743	002	Oct 18, 1996
	TEVA	2%	A074589	001	Apr 05, 1996

MINOXIDIL (FOR WOMEN)

	APOTEX INC	2%	A074924	002	Apr 29, 1998
	SIGHT PHARMS	2%	A074743	001	Oct 18, 1996

MINOXIDIL EXTRA STRENGTH (FOR MEN)

	APOTEX INC	5%	A075839	001	Oct 01, 2001
--	------------	----	---------	-----	--------------

TABLET;ORAL

LONITEN

+	PHARMACIA AND UPJOHN	2.5MG **	N018154	001	
+		10MG **	N018154	003	

MINODYL

	QUANTUM PHARMICS	2.5MG	A072153	001	Jul 13, 1988
		10MG	A071534	001	Mar 19, 1987

MINOXIDIL

	ROYCE LABS	2.5MG	A071799	001	Nov 10, 1987
		10MG	A071796	001	Nov 10, 1987
	USL PHARMA	2.5MG	A071537	001	Dec 16, 1988

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MIPOMERSEN SODIUM

SOLUTION; SUBCUTANEOUS

KYNAMRO

+ KASTLE THERAPS LLC 200MG/ML (200MG/ML) N203568 001 Jan 29, 2013

MIRABEGRON

TABLET, EXTENDED RELEASE; ORAL

MIRABEGRON

SAWAI USA 25MG A209446 001 Dec 27, 2019

MIRTAZAPINE

TABLET; ORAL

MIRTAZAPINE

ACTAVIS ELIZABETH 15MG A076241 001 Jun 25, 2003

15MG A076308 001 Jun 20, 2003

30MG A076241 002 Jun 25, 2003

30MG A076308 002 Jun 20, 2003

45MG A076241 003 Jun 25, 2003

45MG A076308 003 Jun 20, 2003

ACTAVIS LABS FL INC 15MG A076336 001 Jun 20, 2003

30MG A076336 002 Jun 20, 2003

45MG A076336 003 Jun 20, 2003

IVAX SUB TEVA PHARMS 15MG A076244 001 Dec 22, 2003

30MG A076244 002 Dec 22, 2003

45MG A076244 003 Dec 22, 2003

MYLAN PHARMS INC 15MG A076176 001 Jun 19, 2003

30MG A076176 002 Jun 19, 2003

45MG A076176 003 Jun 19, 2003

ROXANE 15MG A076270 001 Jun 19, 2003

30MG A076270 002 Jun 19, 2003

45MG A076270 003 Jun 19, 2003

UPSHER SMITH LABS 15MG A076189 001 Jun 19, 2003

30MG A076189 002 Jun 19, 2003

45MG A076189 003 Jun 19, 2003

WATSON LABS 15MG A076312 001 Jun 19, 2003

30MG A076312 002 Jun 19, 2003

45MG A076312 003 Jun 19, 2003

REMERON

+ ORGANON USA INC 45MG ** N020415 003 Mar 17, 1997

TABLET, ORALLY DISINTEGRATING; ORAL

MIRTAZAPINE

ACTAVIS ELIZABETH 15MG A076689 001 Aug 31, 2005

15MG A077959 001 Feb 14, 2011

30MG A076689 002 Aug 31, 2005

30MG A077959 002 Feb 14, 2011

45MG A076689 003 Aug 31, 2005

45MG A077959 003 Feb 14, 2011

ACTAVIS LABS FL INC 15MG A076307 001 Dec 17, 2003

30MG A076307 002 Dec 17, 2003

45MG A076307 003 Feb 28, 2006

IMPAX LABS INC 15MG A076901 001 Jun 28, 2005

30MG A076901 002 Jun 28, 2005

45MG A076901 003 Jun 28, 2005

MISOPROSTOL

TABLET; ORAL

MISOPROSTOL

ACQ PHARMA 0.1MG A210201 001 Jul 02, 2019

0.2MG A210201 002 Jul 02, 2019

ANI PHARMS INC 0.1MG A076095 001 Jul 10, 2002

0.2MG A076095 002 Jul 10, 2002

MITOMYCIN

INJECTABLE; INJECTION

MITOMYCIN

HOSPIRA 20MG/VIAL A064106 001 Nov 29, 1995

WEST-WARD PHARMS INT 5MG/VIAL A064117 001 Apr 19, 1995

MITOZYTREX

+ SUPERGEN 5MG/VIAL ** N050763 001 Nov 14, 2002

MUTAMYCIN

+ BRISTOL 5MG/VIAL ** N050450 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MITOMYCIN

INJECTABLE; INJECTION

MUTAMYCIN

+		20MG/VIAL **	N050450	002	
	BRISTOL MYERS	5MG/VIAL	A062336	001	
		20MG/VIAL	A062336	002	
		40MG/VIAL	A062336	003	Mar 10, 1988

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

	FRESENIUS KABI ONCOL	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A078606	001	May 14, 2008
		EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A078606	002	May 14, 2008
		EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A078606	003	May 14, 2008
	MYLAN INSTITUTIONAL	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A078980	001	Apr 13, 2009
		EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A078980	002	Apr 13, 2009
	MYLAN LABS LTD	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A201014	001	Dec 11, 2012
	NOVANTRONE				
+	EMD SERONO	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	N019297	001	Dec 23, 1987
+		EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML) **	N019297	002	Dec 23, 1987
+		EQ 30MG BASE/15ML (EQ 2MG BASE/ML) **	N019297	003	Dec 23, 1987

MIVACURIUM CHLORIDE

INJECTABLE; INJECTION

MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER

	ABBVIE	EQ 0.5MG BASE/ML	N020098	002	Jan 22, 1992
		EQ 50MG BASE/100ML	N020098	003	Jan 22, 1992
	MIVACURIUM CHLORIDE				
	MYLAN LABS LTD	EQ 2MG BASE/ML	A078562	001	Apr 30, 2009

SOLUTION; INTRAVENOUS

MIVACRON

+	ABBVIE	EQ 2MG BASE/ML (EQ 2MG BASE/ML) **	N020098	001	Jan 22, 1992
+		EQ 10MG BASE/5ML (EQ 2MG BASE/ML)	N020098	004	Jan 22, 1992
+		EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	N020098	005	Jan 22, 1992

MODAFINIL

TABLET; ORAL

MODAFINIL

	HIKMA PHARMS	100MG	A090543	001	Sep 26, 2012
		200MG	A090543	002	Sep 26, 2012

MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

UNIVASC

	UCB INC	7.5MG **	N020312	001	Apr 19, 1995
		15MG **	N020312	002	Apr 19, 1995

MOLINDONE HYDROCHLORIDE

CAPSULE; ORAL

MOBAN

+	ENDO PHARMS	5MG **	N017111	001	
+		10MG **	N017111	002	
+		25MG **	N017111	003	

CONCENTRATE; ORAL

MOBAN

	ENDO PHARMS	20MG/ML	N017938	001	
--	-------------	---------	---------	-----	--

TABLET; ORAL

MOBAN

+	ENDO PHARMS	5MG **	N017111	004	
+		10MG **	N017111	005	
+		25MG **	N017111	006	
+		50MG **	N017111	007	
+		100MG **	N017111	008	

MOMETASONE FUROATE

CREAM; TOPICAL

ELOCON

	MERCK SHARP DOHME	0.1%	N019625	001	May 06, 1987
+		0.1%	N019625	002	Apr 19, 2013

MOMETASONE FUROATE

	ANDA REPOSITORY	0.1%	A076591	001	Apr 18, 2007
	FOUGERA PHARMS	0.1%	A076171	001	Apr 08, 2005

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MOMETASONE FUROATE

LOTION;TOPICAL

MOMETASONE FUROATE

ANDA REPOSITORY 0.1%

A076499 001 Nov 21, 2007

OINTMENT;TOPICAL

ELOCON

+ MERCK SHARP DOHME 0.1%

N019543 001 Apr 30, 1987

MOMETASONE FUROATE

ANDA REPOSITORY 0.1%

A076481 001 Nov 14, 2003

TARO 0.1%

A076624 001 Dec 03, 2004

MONOBENZONE

CREAM;TOPICAL

BENOQUIN

VALEANT PHARM INTL 20%

N008173 003

MONOCTANOIN

LIQUID;PERFUSION, BILIARY

MOCTANIN

ETHITEK 100%

N019368 001 Oct 29, 1985

MONTELUKAST SODIUM

GRANULE;ORAL

MONTELUKAST SODIUM

MYLAN PHARMS INC EQ 4MG BASE/PACKET

A202776 001 Dec 18, 2012

TABLET;ORAL

MONTELUKAST SODIUM

APOTEX CORP EQ 10MG BASE

A201294 001 Aug 03, 2012

HIKMA EQ 10MG BASE

A090655 001 Aug 03, 2012

LABORATORIOS LIOMONT EQ 10MG BASE

A205319 001 Oct 30, 2020

MYLAN PHARMS INC EQ 10MG BASE

A079103 001 Aug 03, 2012

VINTAGE PHARMS LLC EQ 10MG BASE

A091576 001 Aug 03, 2012

TABLET, CHEWABLE;ORAL

MONTELUKAST SODIUM

APOTEX INC EQ 4MG BASE

A201508 001 Aug 03, 2012

EQ 5MG BASE

A201508 002 Aug 03, 2012

JUBILANT GENERICS EQ 4MG BASE

A203795 001 Feb 27, 2015

EQ 5MG BASE

A203795 002 Feb 27, 2015

MYLAN PHARMS INC EQ 4MG BASE

A079142 001 Aug 03, 2012

EQ 5MG BASE

A079142 002 Aug 03, 2012

UNICHEM EQ 4MG BASE

A208621 001 Jul 02, 2018

EQ 5MG BASE

A208621 002 Jul 02, 2018

VINTAGE PHARMS LLC EQ 4MG BASE

A091588 001 Aug 03, 2012

EQ 5MG BASE

A091588 002 Aug 03, 2012

MORICIZINE HYDROCHLORIDE

TABLET;ORAL

ETHMOZINE

SHIRE 200MG

N019753 001 Jun 19, 1990

250MG

N019753 002 Jun 19, 1990

300MG

N019753 003 Jun 19, 1990

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

AVINZA

KING PHARMS LLC 30MG

N021260 001 Mar 20, 2002

45MG

N021260 005 Dec 18, 2008

60MG

N021260 002 Mar 20, 2002

75MG

N021260 006 Dec 18, 2008

90MG

N021260 003 Mar 20, 2002

120MG

N021260 004 Mar 20, 2002

MORPHINE SULFATE

PAR PHARM INC 20MG

A200812 001 Nov 10, 2011

30MG

A200812 002 Nov 10, 2011

50MG

A200812 003 Nov 10, 2011

60MG

A200812 004 Nov 10, 2011

80MG

A200812 005 Nov 10, 2011

100MG

A200812 006 Nov 10, 2011

TEVA PHARMS USA 20MG

A202718 001 Dec 29, 2014

30MG

A202718 002 Dec 29, 2014

40MG

A202718 007 Jun 03, 2015

50MG

A202718 003 Dec 29, 2014

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

60MG	A202718	004	Dec 29, 2014
70MG	A202718	008	Jun 03, 2015
80MG	A202718	005	Dec 29, 2014
100MG	A202718	006	Dec 29, 2014

INJECTABLE;INJECTION

ASTRAMORPH PF

FRESENIUS KABI USA	0.5MG/ML	A071050	001	Oct 07, 1986
	0.5MG/ML	A071051	001	Oct 07, 1986
	1MG/ML	A071052	001	Oct 07, 1986
	1MG/ML	A071053	001	Oct 07, 1986

MORPHINE SULFATE

HOSPIRA	1MG/ML	A071850	001	May 11, 1988
+ HOSPIRA INC	15MG/ML	N202515	005	Nov 14, 2011
ICU MEDICAL INC	0.5MG/ML	N019917	001	Oct 30, 1992
+	1MG/ML	N019916	001	Oct 30, 1992
+	5MG/ML	N019916	002	Oct 27, 2006
SPECGX LLC	1MG/ML	N020631	001	Jul 03, 1996
	2MG/ML	N020631	002	Jul 03, 1996
WATSON LABS	0.5MG/ML	A073373	001	Sep 30, 1991
	0.5MG/ML	A073375	001	Sep 30, 1991
	1MG/ML	A073374	001	Sep 30, 1991
	1MG/ML	A073376	001	Sep 30, 1991

INJECTABLE, LIPOSOMAL;EPIDURAL

DEPODUR

PACIRA PHARMS INC	10MG/ML (10MG/ML)	N021671	001	May 18, 2004
	15MG/1.5ML (10MG/ML)	N021671	002	May 18, 2004
	20MG/2ML (10MG/ML)	N021671	003	May 18, 2004

SOLUTION;INTRAMUSCULAR

MORPHINE SULFATE (AUTOINJECTOR)

+ MERIDIAN MEDCL TECHN	10MG/0.7ML (10MG/0.7ML)	N019999	001	Jul 12, 1990
------------------------	-------------------------	---------	-----	--------------

SOLUTION;ORAL

MORPHINE SULFATE

LANNETT CO INC	10MG/5ML	A202309	001	Nov 25, 2015
	20MG/5ML	A202310	001	Oct 30, 2015
	100MG/5ML	N201517	001	Jun 23, 2011
NOSTRUM LABS INC	10MG/5ML	A201011	001	Feb 05, 2014
	20MG/5ML	A201011	002	Feb 05, 2014
	100MG/5ML	A201011	003	Oct 06, 2016
VISTAPHARM	10MG/5ML	A201947	001	Jan 05, 2012
	20MG/5ML	A201947	002	Jan 05, 2012

TABLET, EXTENDED RELEASE;ORAL

ARYMO ER

+ ZYLA	15MG	N208603	001	Jan 09, 2017
+	30MG	N208603	002	Jan 09, 2017
+	60MG	N208603	003	Jan 09, 2017

MORPHABOND ER

+ DAIICHI SANKYO INC	15MG	N206544	001	Oct 02, 2015
+	30MG	N206544	002	Oct 02, 2015
+	60MG	N206544	003	Oct 02, 2015
+	100MG	N206544	004	Oct 02, 2015

MORPHINE SULFATE

EPIC PHARMA LLC	15MG	A091357	001	Jun 23, 2016
	30MG	A091357	002	Jun 23, 2016
	60MG	A091357	003	Jun 23, 2016
	100MG	A091357	004	Jun 23, 2016
	200MG	A091357	005	Jun 23, 2016
MYLAN PHARMS INC	15MG	A200824	001	Oct 18, 2011
	30MG	A200824	002	Oct 18, 2011
	60MG	A200824	003	Oct 18, 2011
	100MG	A200824	004	Oct 18, 2011
	200MG	A200824	005	Oct 18, 2011
NESHER PHARMS	15MG	A076733	001	May 19, 2004
	100MG	A077855	001	Sep 27, 2007
	200MG	A077855	002	Sep 27, 2007
SUN PHARM INDUSTRIES	15MG	A205634	001	Aug 25, 2016
	30MG	A205634	002	Aug 25, 2016

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MORPHINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

	60MG	A205634 003	Aug 25, 2016
	100MG	A205634 004	Aug 25, 2016
	200MG	A205634 005	Aug 25, 2016
WATSON LABS	100MG	A075656 001	Jan 30, 2001
ORAMORPH SR			
XANODYNE PHARMS INC	15MG	N019977 004	Nov 23, 1994
	30MG	N019977 001	Aug 15, 1991
	60MG	N019977 002	Aug 15, 1991
	100MG	N019977 003	Aug 15, 1991

MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

EMBEDA

+	ALPHARMA PHARMS	20MG;0.8MG	N022321 001	Aug 13, 2009
+		30MG;1.2MG	N022321 002	Aug 13, 2009
+		50MG;2MG	N022321 003	Aug 13, 2009
+		60MG;2.4MG	N022321 004	Aug 13, 2009
+		80MG;3.2MG	N022321 005	Aug 13, 2009
+		100MG;4MG	N022321 006	Aug 13, 2009

MOXALACTAM DISODIUM

INJECTABLE; INJECTION

MOXAM

LILLY	EQ 250MG BASE/VIAL	N050550 001	
	EQ 500MG BASE/VIAL	N050550 002	
	EQ 1GM BASE/VIAL	N050550 003	
	EQ 2GM BASE/VIAL	N050550 004	
	EQ 10GM BASE/VIAL	N050550 008	

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION; INTRAVENOUS

AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER

+	BAYER HLTHCARE	400MG/250ML (1.6MG/ML) **	N021277 001	Nov 30, 2001
---	----------------	---------------------------	-------------	--------------

TABLET; ORAL

AVELOX

+	BAYER HLTHCARE	EQ 400MG BASE	N021085 001	Dec 10, 1999
---	----------------	---------------	-------------	--------------

MOXIFLOXACIN HYDROCHLORIDE

MYLAN	EQ 400MG BASE	A204635 001	Aug 31, 2015
SUNSHINE	EQ 400MG BASE	A206295 001	Sep 28, 2018

MUPIROICIN

OINTMENT; TOPICAL

BACTROBAN

+	GLAXOSMITHKLINE	2% **	N050591 001	Dec 31, 1987
---	-----------------	-------	-------------	--------------

MUPIROICIN CALCIUM

CREAM; TOPICAL

BACTROBAN

+	GLAXOSMITHKLINE	EQ 2% BASE **	N050746 001	Dec 11, 1997
---	-----------------	---------------	-------------	--------------

OINTMENT; NASAL

BACTROBAN

+	GLAXOSMITHKLINE	EQ 2% BASE	N050703 001	Sep 18, 1995
---	-----------------	------------	-------------	--------------

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL

MYCOPHENOLATE MOFETIL

APOTEX CORP	250MG	A090419 001	Apr 22, 2009
DR REDDYS LABS LTD	250MG	A091315 001	Oct 27, 2011
JUBILANT CADISTA	250MG	A090762 001	Dec 15, 2014
VINTAGE PHARMS LLC	250MG	A090111 001	Dec 22, 2009
ZYDUS PHARMS USA INC	250MG	A065433 001	May 04, 2009

TABLET; ORAL

MYCOPHENOLATE MOFETIL

AMNEAL	500MG	A090606 001	Jul 16, 2010
APOTEX	500MG	A090499 001	Apr 22, 2009
DR REDDYS LABS LTD	500MG	A090464 001	Sep 13, 2010
JUBILANT CADISTA	500MG	A090661 001	Dec 15, 2014
TEVA PHARMS	500MG	A065457 001	May 04, 2009
ZYDUS PHARMS USA INC	500MG	A065477 001	May 04, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MYCOPHENOLIC ACID

TABLET, DELAYED RELEASE;ORAL

MYCOPHENOLIC ACID

TEVA PHARMS USA	180MG	A202720 001	Oct 30, 2014
	360MG	A202720 002	Oct 30, 2014

NABUMETONE

TABLET;ORAL

NABUMETONE

COPLEY PHARM	750MG	A075179 001	Jun 06, 2000
IMPAX LABS INC	500MG	A075189 001	May 26, 2000
	750MG	A075189 002	Sep 24, 2001
MYLAN PHARMS INC	500MG	A090516 001	Jul 12, 2010
	750MG	A090516 002	Jul 12, 2010
NOSTRUM LABS INC	500MG	A090427 001	Dec 30, 2011
	750MG	A090427 002	Dec 30, 2011
OXFORD PHARMS	500MG	A079093 001	Feb 27, 2009
	750MG	A079093 002	Feb 27, 2009
SANDOZ	500MG	A075590 001	Feb 25, 2002
	750MG	A075590 002	Feb 25, 2002

RELAFEN

+ SMITHKLINE BEECHAM	500MG **	N019583 001	Dec 24, 1991
+	750MG **	N019583 002	Dec 24, 1991

NADOLOL

TABLET;ORAL

CORCARD

USWM	120MG	N018063 003	
	160MG	N018063 004	

NADOLOL

HERITAGE PHARMA	120MG	A074255 002	Jan 24, 1996
	160MG	A074255 003	Jan 24, 1996
TEVA PHARMS	80MG	A074368 001	Aug 31, 1994
	120MG	A074368 002	Aug 31, 1994
	160MG	A074368 003	Aug 31, 1994
VGYAAN	20MG	A212856 001	Sep 13, 2019
	40MG	A212856 002	Sep 13, 2019
	80MG	A212856 003	Sep 13, 2019

NAFCILLIN SODIUM

CAPSULE;ORAL

UNIPEN

WYETH AYERST	EQ 250MG BASE	N050111 001	
--------------	---------------	-------------	--

FOR SOLUTION;ORAL

UNIPEN

WYETH AYERST	EQ 250MG BASE/5ML	N050199 001	
--------------	-------------------	-------------	--

INJECTABLE; INJECTION

NAFCILLIN SODIUM

APOTHECON	EQ 500MG BASE/VIAL	A061984 001	
	EQ 1GM BASE/VIAL	A061984 002	
	EQ 2GM BASE/VIAL	A061984 003	
	EQ 4GM BASE/VIAL	A061984 005	
FRESENIUS	EQ 1GM BASE/VIAL	A206682 001	Dec 10, 2019
	EQ 2GM BASE/VIAL	A206682 002	Dec 10, 2019
MYLAN LABS LTD	EQ 1GM BASE/VIAL	A200002 001	Apr 07, 2014
	EQ 2GM BASE/VIAL	A200002 002	Apr 07, 2014
SANDOZ	EQ 500MG BASE/VIAL	A062527 001	Aug 02, 1984
WATSON LABS INC	EQ 500MG BASE/VIAL	A062844 001	Oct 26, 1988
	EQ 1GM BASE/VIAL	A062844 002	Oct 26, 1988
	EQ 1.5GM BASE/VIAL	A062844 003	Oct 26, 1988
	EQ 2GM BASE/VIAL	A062844 004	Oct 26, 1988
	EQ 4GM BASE/VIAL	A062844 005	Oct 26, 1988
	EQ 10GM BASE/VIAL	A063008 001	Sep 29, 1988

NALLPEN

GLAXOSMITHKLINE	EQ 500MG BASE/VIAL	A061999 001	
	EQ 1GM BASE/VIAL	A061999 002	
	EQ 1GM BASE/VIAL	A062755 001	Dec 19, 1986
	EQ 2GM BASE/VIAL	A061999 003	
	EQ 2GM BASE/VIAL	A062755 002	Dec 19, 1986
	EQ 10GM BASE/VIAL	A061999 004	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NAFCILLIN SODIUM

INJECTABLE; INJECTION

UNIPEN

WYETH AYERST	EQ 500MG BASE/VIAL **	A062717 001	Dec 16, 1986
+	EQ 500MG BASE/VIAL **	N050320 001	
	EQ 1GM BASE/VIAL **	A062717 002	Dec 16, 1986
	EQ 2GM BASE/VIAL **	A062717 004	Dec 16, 1986
+	EQ 2GM BASE/VIAL **	N050320 003	
+	EQ 4GM BASE/VIAL **	N050320 004	
+	EQ 10GM BASE/VIAL **	N050320 005	
+	EQ 20GM BASE/VIAL **	N050320 006	
UNIPEN IN PLASTIC CONTAINER			
+	WYETH AYERST	EQ 1GM BASE/VIAL **	N050320 002

TABLET; ORAL

UNIPEN

WYETH AYERST	EQ 500MG BASE	N050462 001	
--------------	---------------	-------------	--

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL

NAFTIN

+	SEBELA IRELAND LTD	1% **	N019599 001	Feb 29, 1988
---	--------------------	-------	-------------	--------------

GEL; TOPICAL

NAFTIFINE HYDROCHLORIDE

TARO	2%	A208201 001	Apr 10, 2019
------	----	-------------	--------------

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

NALBUPHINE

ABRAXIS PHARM	10MG/ML	A070751 001	Jul 02, 1986
	20MG/ML	A070752 001	Sep 24, 1986

NALBUPHINE HYDROCHLORIDE

ABBOTT	20MG/ML	A070917 001	Feb 03, 1989
ABBVIE	1.5MG/ML	N020200 001	Mar 12, 1993
DR REDDYS	10MG/ML	A074471 001	Mar 19, 1998
	20MG/ML	A074471 002	Mar 19, 1998
IGI LABS INC	10MG/ML	A072070 001	Apr 10, 1989
	10MG/ML	A072071 001	Apr 10, 1989
	10MG/ML	A072072 001	Apr 10, 1989
	20MG/ML	A072073 001	Apr 10, 1989
	20MG/ML	A072074 001	Apr 10, 1989
	20MG/ML	A072075 001	Apr 10, 1989
MYLAN LABS LTD	10MG/ML	A206506 001	Feb 06, 2019
	10MG/ML	A207595 001	Jan 11, 2019
	20MG/ML	A206506 002	Feb 06, 2019
	20MG/ML	A207595 002	Jan 11, 2019

NUBAIN

+	PAR PHARM INC	10MG/ML **	N018024 001	
+		20MG/ML **	N018024 002	May 27, 1982

NALIDIXIC ACID

SUSPENSION; ORAL

NEGGRAM

SANOFI AVENTIS US	250MG/5ML	N017430 001	
-------------------	-----------	-------------	--

TABLET; ORAL

NALIDIXIC ACID

SUN PHARM INDUSTRIES	250MG	A070270 001	Jun 29, 1988
	500MG	A070271 001	Jun 29, 1988
	1GM	A070272 001	Jun 29, 1988
WATSON LABS	250MG	A071936 001	Jun 29, 1988
	500MG	A072061 001	Jun 29, 1988
	1GM	A071919 001	Jun 29, 1988

NEGGRAM

SANOFI AVENTIS US	250MG	N014214 002	
	500MG	N014214 004	
	1GM	N014214 005	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NALMEFENE HYDROCHLORIDE

INJECTABLE; INJECTION

REVEX

+	EUROHLTH INTL SARL	EQ 0.1MG BASE/ML **	N020459 001	Apr 17, 1995
+		EQ 1MG BASE/ML **	N020459 002	Apr 17, 1995

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE

WEST-WARD PHARMS INT	0.4MG/ML	A070298 001	Sep 24, 1986
	0.4MG/ML	A070496 001	Sep 24, 1986
WYETH AYERST	0.02MG/ML	A070188 001	Sep 24, 1986
	0.02MG/ML	A070189 001	Sep 24, 1986
	0.4MG/ML	A070190 001	Sep 24, 1986
	0.4MG/ML	A070191 001	Sep 24, 1986

NALOXONE HYDROCHLORIDE

ABRAXIS PHARM

0.02MG/ML	A070648 001	Nov 17, 1986
0.02MG/ML	A070661 001	Nov 17, 1986
0.4MG/ML	A070649 001	Nov 17, 1986
1MG/ML	A071604 001	Dec 16, 1988

ASTRAZENECA

0.02MG/ML	A072081 001	Apr 11, 1989
-----------	-------------	--------------

EUROHLTH INTL SARL

0.02MG/ML	A071272 001	May 24, 1988
-----------	-------------	--------------

1MG/ML	A071273 001	May 24, 1988
--------	-------------	--------------

1MG/ML	A071274 001	May 24, 1988
--------	-------------	--------------

1MG/ML	A071287 001	May 24, 1988
--------	-------------	--------------

HOSPIRA

0.02MG/ML	A070171 001	Sep 24, 1986
-----------	-------------	--------------

0.02MG/ML	A070252 001	Jan 16, 1987
-----------	-------------	--------------

0.02MG/ML	A070253 001	Jan 16, 1987
-----------	-------------	--------------

0.4MG/ML	A070255 001	Jan 07, 1987
----------	-------------	--------------

IGI LABS INC

0.02MG/ML	A072082 001	Apr 11, 1989
-----------	-------------	--------------

0.02MG/ML	A072083 001	Apr 11, 1989
-----------	-------------	--------------

0.02MG/ML	A072084 001	Apr 11, 1989
-----------	-------------	--------------

0.02MG/ML	A072085 001	Apr 11, 1989
-----------	-------------	--------------

0.4MG/ML	A072086 001	Apr 11, 1989
----------	-------------	--------------

0.4MG/ML	A072087 001	Apr 11, 1989
----------	-------------	--------------

0.4MG/ML	A072088 001	Apr 11, 1989
----------	-------------	--------------

0.4MG/ML	A072089 001	Apr 11, 1989
----------	-------------	--------------

0.4MG/ML	A072090 001	Apr 11, 1989
----------	-------------	--------------

1MG/ML	A072091 001	Apr 11, 1989
--------	-------------	--------------

1MG/ML	A072092 001	Apr 11, 1989
--------	-------------	--------------

1MG/ML	A072093 001	Apr 11, 1989
--------	-------------	--------------

INTL MEDICATION

0.4MG/ML	A070417 001	Sep 24, 1986
----------	-------------	--------------

0.4MG/ML	A070639 001	Sep 24, 1986
----------	-------------	--------------

1MG/ML	A072115 001	Apr 27, 1988
--------	-------------	--------------

MARSAM PHARMS LLC

0.4MG/ML	A071811 001	Jul 19, 1988
----------	-------------	--------------

PAR STERILE PRODUCTS

0.4MG/ML	A211286 001	Jan 17, 2020
----------	-------------	--------------

SMITH AND NEPHEW

0.02MG/ML	A071671 001	Nov 17, 1987
-----------	-------------	--------------

0.4MG/ML	A071681 001	Nov 17, 1987
----------	-------------	--------------

0.4MG/ML	A071682 001	Nov 17, 1987
----------	-------------	--------------

SOLOPAK

0.02MG/ML	A071672 001	Nov 17, 1987
-----------	-------------	--------------

0.4MG/ML	A071683 001	Nov 17, 1987
----------	-------------	--------------

VIRTUS PHARMS

0.4MG/ML	A207846 001	Dec 17, 2018
----------	-------------	--------------

WATSON LABS

0.4MG/ML	A071339 001	Nov 18, 1987
----------	-------------	--------------

NARCAN

+	ADAPT	0.02MG/ML **	N016636 002	
---	-------	--------------	-------------	--

+		0.4MG/ML **	N016636 001	
---	--	-------------	-------------	--

+		1MG/ML **	N016636 003	Jun 14, 1982
---	--	-----------	-------------	--------------

	BRISTOL MYERS SQUIBB	0.4MG/ML	A071083 001	Jul 28, 1988
--	----------------------	----------	-------------	--------------

		1MG/ML	A071084 001	Jul 28, 1988
--	--	--------	-------------	--------------

		1MG/ML	A071311 001	Jul 28, 1988
--	--	--------	-------------	--------------

SOLUTION; INTRAMUSCULAR, SUBCUTANEOUS

EVZIO

+	KALEO INC	0.4MG/0.4ML (0.4MG/0.4ML)	N205787 001	Apr 03, 2014
---	-----------	---------------------------	-------------	--------------

EVZIO (AUTOINJECTOR)

+	KALEO INC	2MG/0.4ML (2MG/0.4ML)	N209862 001	Oct 19, 2016
---	-----------	-----------------------	-------------	--------------

SPRAY, METERED; NASAL

NALOXONE HYDROCHLORIDE

	TEVA PHARMS USA	4MG/SPRAY	A209522 001	Apr 19, 2019
--	-----------------	-----------	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NALOXONE HYDROCHLORIDE

SPRAY, METERED;NASAL

NARCAN

+ EMERGENT 2MG/SPRAY ** N208411 002 Jan 24, 2017

NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

TARGINIQ

+ PURDUE PHARMA LP 5MG;10MG N205777 001 Jul 23, 2014

+ 10MG;20MG N205777 002 Jul 23, 2014

+ 20MG;40MG N205777 003 Jul 23, 2014

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET;ORAL

TALWIN NX

SANOFI AVENTIS US EQ 0.5MG BASE;EQ 50MG BASE ** N018733 001 Dec 16, 1982

NALTREXONE HYDROCHLORIDE

TABLET;ORAL

NALTREXONE HYDROCHLORIDE

FOSUN PHARMA 50MG A075434 001 Mar 08, 2000

REVIA

TEVA WOMENS 50MG N018932 001 Nov 20, 1984

NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

TROXYCA ER

PFIZER 1.2MG;10MG N207621 001 Aug 19, 2016

2.4MG;20MG N207621 002 Aug 19, 2016

3.6MG;30MG N207621 003 Aug 19, 2016

4.8MG;40MG N207621 004 Aug 19, 2016

7.2MG;60MG N207621 005 Aug 19, 2016

9.6MG;80MG N207621 006 Aug 19, 2016

NANDROLONE DECANOATE

INJECTABLE;INJECTION

DECA-DURABOLIN

ASPEN GLOBAL INC 50MG/ML N013132 001 Jun 12, 1986

100MG/ML N013132 002 Jun 12, 1986

+ 200MG/ML ** N013132 003 Jun 12, 1986

NANDROLONE DECANOATE

ABRAXIS PHARM 100MG/ML A088290 001 Oct 03, 1983

200MG/ML A088317 001 Oct 14, 1983

AKORN 100MG/ML A087519 001 Sep 28, 1983

AM REGENT 200MG/ML A091252 001 Aug 30, 2010

WATSON LABS 50MG/ML A086385 001 Jan 13, 1984

50MG/ML A087598 001 Oct 06, 1983

50MG/ML A088554 001 Feb 10, 1986

100MG/ML A086598 001 Jan 13, 1984

100MG/ML A087599 001 Oct 06, 1983

200MG/ML A088128 001 Dec 05, 1983

NANDROLONE PHENPROPIONATE

INJECTABLE;INJECTION

DURABOLIN

ORGANON USA INC 25MG/ML N011891 001

50MG/ML N011891 002

NANDROLONE PHENPROPIONATE

WATSON LABS 25MG/ML A086386 001 Jun 17, 1983

50MG/ML A087488 001 Jun 17, 1983

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

ALBALON

ALLERGAN 0.1% ** A080248 001

NAFAZAIR

BAUSCH AND LOMB 0.1% A040073 001 May 25, 1994

PHARMAFAIR 0.1% A088101 001 Apr 15, 1983

NAPHAZOLINE HYDROCHLORIDE

AKORN INC 0.1% A083590 001

NAPHCON FORTE

ALCON 0.1% A080229 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NAPHAZOLINE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
OPCON

BAUSCH AND LOMB	0.1%	A087506	001	
VASOCON				
NOVARTIS	0.1%	A080235	002	Mar 24, 1983

NAPROXEN

TABLET;ORAL

NAPROSYN

+	ATNAHS PHARMA US	250MG	N017581	002
+		375MG	N017581	003

NAPROXEN

CHARTWELL MOLECULES	250MG	A074410	001	Apr 28, 1995
	375MG	A074410	002	Apr 28, 1995
	500MG	A074410	003	Apr 28, 1995
DAVA PHARMS INC	250MG	A074105	001	Dec 21, 1993
	375MG	A074105	002	Dec 21, 1993
	500MG	A074105	003	Dec 21, 1993
GRANULES	250MG	A074140	001	Dec 21, 1993
	375MG	A074140	002	Dec 21, 1993
	500MG	A074140	003	Dec 21, 1993
HAMILTON PHARMS	250MG	A074110	001	Oct 30, 1992
	375MG	A074110	002	Oct 30, 1992
	500MG	A074110	003	Oct 30, 1992
HIKMA INTL PHARMS	250MG	A076494	001	Jan 14, 2004
	375MG	A076494	002	Jan 14, 2004
	500MG	A076494	003	Jan 14, 2004
IVAX SUB TEVA PHARMS	250MG	A074111	001	Feb 28, 1995
	375MG	A074111	002	Feb 28, 1995
	500MG	A074111	003	Feb 28, 1995
MYLAN	250MG	A074121	001	Dec 21, 1993
	375MG	A074121	002	Dec 21, 1993
	500MG	A074121	003	Dec 21, 1993
PLIVA	250MG	A074182	001	Jun 27, 1996
	375MG	A074182	002	Jun 27, 1996
	500MG	A074182	003	Jun 27, 1996
PUREPAC PHARM	250MG	A074263	001	Dec 21, 1993
	375MG	A074263	002	Dec 21, 1993
	500MG	A074263	003	Dec 21, 1993
ROXANE	250MG	A074211	001	Feb 28, 1994
	375MG	A074211	002	Feb 28, 1994
	500MG	A074211	003	Feb 28, 1994
TEVA	250MG	A074129	001	Dec 21, 1993
	250MG	A074216	001	Apr 11, 1996
	375MG	A074129	002	Dec 21, 1993
	375MG	A074216	002	Apr 11, 1996
	500MG	A074129	003	Dec 21, 1993
	500MG	A074216	003	Apr 11, 1996
TEVA PHARMS	250MG	A074207	001	Dec 21, 1993
	375MG	A074207	002	Dec 21, 1993
	500MG	A074207	003	Dec 21, 1993
WATSON LABS	250MG	A074457	001	May 31, 1995
	375MG	A074457	002	May 31, 1995
	500MG	A074457	003	May 31, 1995
WATSON LABS TEVA	250MG	A074163	001	Feb 10, 1995
	375MG	A074163	002	Feb 10, 1995
	500MG	A074163	003	Feb 10, 1995

TABLET, DELAYED RELEASE;ORAL

NAPROXEN

ACTAVIS ELIZABETH	375MG	A074936	001	Feb 24, 1998
	500MG	A074936	002	Feb 24, 1998
FOSUN PHARMA	375MG	A075061	001	Feb 18, 1998
	500MG	A075061	002	Feb 18, 1998
MYLAN PHARMS INC	375MG	A075390	001	Apr 19, 2001
	500MG	A075390	002	Apr 19, 2001
PLIVA	375MG	A075337	001	May 26, 1999
	500MG	A075337	002	May 26, 1999

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NAPROXEN SODIUM

TABLET; ORAL

ANAPROX

+ ATNAHS PHARMA US

EQ 250MG BASE **

N018164 001

NAPROXEN SODIUM

ABLE

EQ 250MG BASE

A076544 001 Aug 22, 2003

EQ 500MG BASE

A076544 002 Aug 22, 2003

CONTRACT PHARMACAL

220MG

A074789 001 Feb 27, 1997

HAMILTON PHARMS

EQ 250MG BASE

A074106 001 Aug 31, 1993

EQ 500MG BASE

A074106 002 Aug 31, 1993

HIKMA

EQ 250MG BASE

A074480 002 Feb 18, 1998

EQ 500MG BASE

A074480 001 May 14, 1996

IVAX SUB TEVA PHARMS

EQ 250MG BASE

A074230 001 Mar 14, 1995

EQ 500MG BASE

A074230 002 Mar 14, 1995

MYLAN

EQ 250MG BASE

A074367 001 Aug 31, 1994

EQ 500MG BASE

A074367 002 Aug 31, 1994

PLD ACQUISITIONS LLC

220MG

A074646 001 Jan 13, 1997

PLIVA

EQ 250MG BASE

A074242 001 Jun 20, 1996

EQ 500MG BASE

A074242 002 Jun 20, 1996

PUREPAC PHARM

EQ 250MG BASE

A074319 001 Mar 20, 1995

EQ 500MG BASE

A074319 002 Mar 20, 1995

ROXANE

EQ 250MG BASE

A074257 001 Dec 21, 1993

EQ 500MG BASE

A074257 002 Dec 21, 1993

SANDOZ

EQ 250MG BASE

A074162 001 Dec 21, 1993

EQ 250MG BASE

A074495 001 Dec 05, 1994

EQ 500MG BASE

A074162 002 Dec 21, 1993

EQ 500MG BASE

A074495 002 Dec 05, 1994

TEVA

EQ 250MG BASE

A074142 001 Dec 21, 1993

EQ 250MG BASE

A074198 001 Dec 21, 1993

EQ 500MG BASE

A074142 002 Dec 21, 1993

EQ 500MG BASE

A074198 002 Dec 21, 1993

TEVA PHARMS

EQ 250MG BASE

A074289 001 Jan 27, 1994

EQ 500MG BASE

A074289 002 Jan 27, 1994

WATSON LABS

EQ 250MG BASE

A074195 001 Dec 21, 1993

EQ 250MG BASE

A074455 001 May 31, 1995

EQ 500MG BASE

A074195 002 Dec 21, 1993

EQ 500MG BASE

A074455 002 May 31, 1995

YICHANG HUMANWELL

220MG

A212033 001 Aug 30, 2019

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET; ORAL

TREXIMET

+ CURRAX

60MG; EQ 10MG BASE

N021926 002 May 14, 2015

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

NARATRIPTAN

ANI PHARMS INC

EQ 1MG BASE

A078751 001 Jul 07, 2010

EQ 2.5MG BASE

A078751 002 Jul 07, 2010

APOTEX CORP

EQ 1MG BASE

A091373 001 Apr 22, 2011

EQ 2.5MG BASE

A091373 002 Apr 22, 2011

CHARTWELL RX

EQ 1MG BASE

A090288 001 Jul 07, 2010

EQ 2.5MG BASE

A090288 002 Jul 07, 2010

MYLAN PHARMS INC

EQ 1MG BASE

A202431 001 May 31, 2012

EQ 2.5MG BASE

A202431 002 May 31, 2012

NATEGLINIDE

TABLET; ORAL

NATEGLINIDE

ALVOGEN

60MG

A205055 001 Dec 11, 2015

120MG

A205055 002 Dec 11, 2015

TEVA PHARMS

60MG

A077467 001 Sep 09, 2009

120MG

A077467 002 Sep 09, 2009

STARLIX

+ NOVARTIS

60MG

N021204 001 Dec 22, 2000

+

120MG

N021204 002 Dec 22, 2000

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NEBIVOLOL HYDROCHLORIDE

TABLET;ORAL

NEBIVOLOL HYDROCHLORIDE

ALKEM LABS LTD	EQ 2.5MG BASE	A203741 001	Jun 24, 2015
	EQ 5MG BASE	A203741 002	Jun 24, 2015
	EQ 10MG BASE	A203741 003	Jun 24, 2015
	EQ 20MG BASE	A203741 004	Jun 24, 2015
ANI PHARMS INC	EQ 2.5MG BASE	A203659 001	Apr 16, 2015
	EQ 5MG BASE	A203659 002	Apr 16, 2015
	EQ 10MG BASE	A203659 003	Apr 16, 2015
	EQ 20MG BASE	A203659 004	Apr 16, 2015
GLENMARK PHARMS LTD	EQ 2.5MG BASE	A203821 001	May 25, 2017
	EQ 5MG BASE	A203821 002	May 25, 2017
	EQ 10MG BASE	A203821 003	May 25, 2017
	EQ 20MG BASE	A203821 004	May 25, 2017
INDCHEMIE HEALTH	EQ 2.5MG BASE	A203828 001	Jul 29, 2015
	EQ 5MG BASE	A203828 002	Jul 29, 2015
	EQ 10MG BASE	A203828 003	Jul 29, 2015
	EQ 20MG BASE	A203828 004	Jul 29, 2015
TORRENT	EQ 2.5MG BASE	A203966 001	Mar 02, 2018
	EQ 5MG BASE	A203966 002	Mar 02, 2018
	EQ 10MG BASE	A203966 003	Mar 02, 2018
	EQ 20MG BASE	A203966 004	Mar 02, 2018
WATSON LABS INC	EQ 2.5MG BASE	A203683 001	Nov 27, 2015
	EQ 5MG BASE	A203683 002	Nov 27, 2015
	EQ 10MG BASE	A203683 003	Nov 27, 2015
	EQ 20MG BASE	A203683 004	Nov 27, 2015

NEBIVOLOL HYDROCHLORIDE; VALSARTAN

TABLET;ORAL

BYVALSON

+ ALLERGAN	EQ 5MG BASE;80MG	N206302 001	Jun 03, 2016
------------	------------------	-------------	--------------

NEDOCROMIL SODIUM

AEROSOL, METERED; INHALATION

TILADE

KING PHARMS LLC	1.75MG/INH	N019660 001	Dec 30, 1992
-----------------	------------	-------------	--------------

SOLUTION; INHALATION

TILADE

SANOFI AVENTIS US	0.5%	N020750 001	Oct 01, 1997
-------------------	------	-------------	--------------

NEFAZODONE HYDROCHLORIDE

TABLET;ORAL

NEFAZODONE HYDROCHLORIDE

ANI PHARMS INC	50MG	A076072 001	Sep 16, 2003
	100MG	A076072 002	Sep 16, 2003
	150MG	A076072 003	Sep 16, 2003
	200MG	A076072 004	Sep 16, 2003
	250MG	A076072 005	Sep 16, 2003
DR REDDYS LABS INC	50MG	A076309 001	Sep 16, 2003
	100MG	A076309 002	Sep 16, 2003
	150MG	A076309 003	Sep 16, 2003
	200MG	A076309 004	Sep 16, 2003
	250MG	A076309 005	Sep 16, 2003
FOSUN PHARMA	50MG	A076302 001	Sep 16, 2003
	100MG	A076302 002	Sep 16, 2003
	150MG	A076302 003	Sep 16, 2003
	200MG	A076302 004	Sep 16, 2003
	250MG	A076302 005	Sep 16, 2003
IVAX SUB TEVA PHARMS	50MG	A075763 001	Sep 16, 2003
	100MG	A075763 002	Sep 16, 2003
	150MG	A075763 003	Sep 16, 2003
	200MG	A075763 004	Sep 16, 2003
	250MG	A075763 005	Sep 16, 2003
MYLAN	100MG	A076129 002	Sep 16, 2003
	150MG	A076129 003	Sep 16, 2003
	200MG	A076129 004	Sep 16, 2003
	250MG	A076129 005	Sep 16, 2003
ROXANE	50MG	A076196 001	Sep 16, 2003
	100MG	A076196 002	Sep 16, 2003
	150MG	A076196 003	Sep 16, 2003

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HYDROCHLORIDE

	200MG	A076196 004	Sep 16, 2003
	250MG	A076196 005	Sep 16, 2003
SUN PHARM INDS LTD	50MG	A076409 001	Sep 16, 2003
	100MG	A076409 002	Sep 16, 2003
	150MG	A076409 003	Sep 16, 2003
	200MG	A076409 004	Sep 16, 2003
	250MG	A076409 005	Sep 16, 2003
WATSON LABS	100MG	A076073 002	Sep 16, 2003
	150MG	A076073 003	Sep 16, 2003
	200MG	A076073 004	Sep 16, 2003
	250MG	A076073 005	Sep 16, 2003
SERZONE			
+	BRISTOL MYERS SQUIBB 50MG **	N020152 001	Dec 22, 1994
+	100MG **	N020152 002	Dec 22, 1994
+	150MG **	N020152 003	Dec 22, 1994
+	200MG **	N020152 004	Dec 22, 1994
+	250MG **	N020152 005	Dec 22, 1994
+	300MG **	N020152 006	Dec 22, 1994

NELFINAVIR MESYLATE

POWDER; ORAL

VIRACEPT

AGOURON PHARMS	EQ 50MG BASE/SCOOPFUL	N020778 001	Mar 14, 1997
----------------	-----------------------	-------------	--------------

NEOMYCIN SULFATE

SOLUTION; ORAL

MYCIFRADIN

PHARMACIA AND UPJOHN	EQ 87.5MG BASE/5ML	N050285 001	
----------------------	--------------------	-------------	--

NEO-FRADIN

X GEN PHARMS	EQ 87.5MG BASE/5ML	A065010 001	May 23, 2002
--------------	--------------------	-------------	--------------

TABLET; ORAL

MYCIFRADIN

PHARMACIA AND UPJOHN	EQ 350MG BASE	A060520 001	
----------------------	---------------	-------------	--

NEOBIOTIC

PFIZER	EQ 350MG BASE	A060475 001	
--------	---------------	-------------	--

NEOMYCIN SULFATE

BRISTOL MYERS SQUIBB	500MG	A060365 001	
LANNETT	500MG	A060607 001	
LANNETT CO INC	500MG	A204435 001	Jun 10, 2016
LILLY	500MG	A060385 001	
NOSTRUM LABS INC	500MG	A065468 001	Mar 29, 2010
ROXANE	500MG	A062173 001	
SANDOZ	500MG	A061586 001	

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM; TOPICAL

NEOSPORIN

GLAXOSMITHKLINE	EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050176 002	Jan 14, 1985
-----------------	----------------------------------	-------------	--------------

OINTMENT; OPHTHALMIC

STATROL

ALCON	EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050344 002	
-------	----------------------------------	-------------	--

SOLUTION/DROPS; OPHTHALMIC

STATROL

ALCON	EQ 3.5MG BASE/ML;16,250 UNITS/ML	A062339 001	Nov 30, 1984
	EQ 3.5MG BASE/ML;16,250 UNITS/ML	N050456 001	

NEOMYCIN SULFATE; POLYMYXIN B SULFATE; PREDNISOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC

POLY-PRED

ALLERGAN	EQ 0.35% BASE;10,000 UNITS/ML;0.5%	N050081 002	
----------	------------------------------------	-------------	--

NEOMYCIN SULFATE; PREDNISOLONE ACETATE

OINTMENT; OPHTHALMIC

NEO-DELTA-CORTEF

PHARMACIA AND UPJOHN	EQ 3.5MG BASE/GM;0.25%	A061039 002	
	EQ 3.5MG BASE/GM;0.5%	A061039 001	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NEOMYCIN SULFATE; PREDNISOLONE ACETATE

SUSPENSION/DROPS;OPHTHALMIC

NEO-DELTA-CORTEF

PHARMACIA AND UPJOHN EQ 3.5MG BASE/ML;0.25%

A061037 001

NEOMYCIN SULFATE; PREDNISOLONE SODIUM PHOSPHATE

OINTMENT;OPHTHALMIC

NEO-HYDELTRASOL

MERCK EQ 3.5MG BASE/GM;EQ 0.25% PHOSPHATE

N050378 001

NEOMYCIN SULFATE; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

MYTREX A

SAVAGE LABS EQ 3.5MG BASE/GM;0.1%

A062598 001 Jul 21, 1986

NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE

FOUGERA EQ 3.5MG BASE/GM;0.1%

A062600 001 Jul 21, 1986

PHARMADERM EQ 3.5MG BASE/GM;0.1%

A062595 001 Jul 21, 1986

OINTMENT;TOPICAL

MYTREX A

SAVAGE LABS EQ 3.5MG BASE/GM;0.1%

A062609 001 May 23, 1986

NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE

FOUGERA EQ 3.5MG BASE/GM;0.1%

A062608 001 May 23, 1986

PHARMADERM EQ 3.5MG BASE/GM;0.1%

A062607 001 May 23, 1986

NESIRITIDE RECOMBINANT

FOR SOLUTION;INTRAVENOUS

NATRECOR

+ SCIOS LLC 1.5MG/VIAL

N020920 001 Aug 10, 2001

NETILMICIN SULFATE

INJECTABLE;INJECTION

NETROMYCIN

SCHERING EQ 10MG BASE/ML

N050544 001 Feb 28, 1983

EQ 25MG BASE/ML

N050544 002 Feb 28, 1983

EQ 100MG BASE/ML

N050544 003 Feb 28, 1983

NEVIRAPINE

TABLET;ORAL

NEVIRAPINE

APOTEX INC 200MG

A203021 001 May 22, 2012

MYLAN LABS 200MG

A078864 001 May 22, 2012

TECH ORGANIZED 200MG

A203176 001 May 22, 2012

TABLET, EXTENDED RELEASE;ORAL

NEVIRAPINE

APOTEX 400MG

A205258 001 Apr 03, 2014

CIPLA 400MG

A206448 001 Oct 15, 2015

MYLAN 100MG

A206271 001 Nov 09, 2015

TECH ORGANIZED 100MG

A207467 001 Jul 31, 2017

400MG

A207467 002 Jul 31, 2017

NIACIN

CAPSULE;ORAL

WAMPOCAP

MEDPOINTE PHARM HLC 500MG

N011073 003

TABLET;ORAL

NIACIN

EVERYLIFE 500MG

A083203 001

HALSEY 500MG

A083453 001

HIKMA 500MG

A083718 001

IMPAX LABS 500MG

A083115 001

IVAX SUB TEVA PHARMS 500MG

A083180 001

MK LABS 500MG

A083525 001

PUREPAC PHARM 500MG

A083271 001

SANDOZ 500MG

A083306 001

TABLICAPS 500MG

A084237 001

WATSON LABS 500MG

A083136 001

500MG

A083305 001

500MG

A085172 001

WOCKHARDT 500MG

A081134 001 Apr 28, 1992

NICOLAR

SANOFI AVENTIS US 500MG

A083823 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NIACIN

TABLET, EXTENDED RELEASE;ORAL

NIACIN

MYLAN	500MG	A203742 001	Feb 22, 2019
	750MG	A203742 002	Feb 22, 2019
	1GM	A203742 003	Feb 22, 2019
YICHANG HUMANWELL	500MG	A212017 001	Jun 10, 2019
	750MG	A212017 002	Jun 10, 2019
	1GM	A212017 003	Jun 10, 2019
NIASPAN			
ABBVIE	375MG	N020381 001	Jul 28, 1997
NIASPAN TITRATION STARTER PACK			
ABBVIE	375MG;500MG;750MG	N020381 005	Jul 28, 1997

NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; TYROSINE

SUSPENSION;ORAL

TPN

INTL MINERALS	15MG/5ML;3.75MG/5ML;600MG/5ML	N008378 003	
---------------	-------------------------------	-------------	--

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL

CARDENE

CHIESI	20MG **	N019488 001	Dec 21, 1988
	30MG **	N019488 002	Dec 21, 1988
NICARDIPINE HYDROCHLORIDE			
ANI PHARMS INC	20MG	A074439 001	Dec 10, 1996
	20MG	A074540 001	Oct 28, 1996
	20MG	A074670 001	Oct 28, 1996
	30MG	A074439 002	Dec 10, 1996
	30MG	A074540 002	Oct 28, 1996
	30MG	A074670 002	Oct 28, 1996
MYLAN	20MG	A074642 001	Jul 18, 1996
	30MG	A074642 002	Jul 18, 1996

CAPSULE, EXTENDED RELEASE;ORAL

CARDENE SR

+ CHIESI	30MG **	N020005 001	Feb 21, 1992
+ CHIESI	45MG **	N020005 002	Feb 21, 1992
+ CHIESI	60MG **	N020005 003	Feb 21, 1992

INJECTABLE;INJECTION

CARDENE

+ CHIESI	25MG/10ML (2.5MG/ML) **	N019734 001	Jan 30, 1992
NICARDIPINE HYDROCHLORIDE			
NAVINTA LLC	25MG/10ML (2.5MG/ML)	A090125 001	Nov 17, 2009
RK PHARMA	25MG/10ML (2.5MG/ML)	A090664 001	Nov 17, 2009
SUN PHARMA GLOBAL	25MG/10ML (2.5MG/ML)	N078405 001	Nov 17, 2009
WEST-WARD PHARMS INT	25MG/10ML (2.5MG/ML)	A078714 001	Dec 28, 2009
WOCKHARDT	25MG/10ML (2.5MG/ML)	A090671 001	Nov 17, 2009

INJECTABLE;INTRAVENOUS

CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER

+ CHIESI	40MG/200ML (0.2MG/ML)	N019734 005	Nov 07, 2008
----------	-----------------------	-------------	--------------

NICLOSAMIDE

TABLET, CHEWABLE;ORAL

NICLOCIDE

BAYER PHARMS	500MG	N018669 001	May 14, 1982
--------------	-------	-------------	--------------

NICOTINE

FILM, EXTENDED RELEASE;TRANSDERMAL

NICOTROL

MCNEIL CONS	15MG/16HR	N020536 001	Jul 03, 1996
PROSTEP			
AVEVA	11MG/24HR	N019983 003	Dec 23, 1998
	22MG/24HR	N019983 004	Dec 23, 1998

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICOTINE POLACRILEX

IVAX SUB TEVA PHARMS	EQ 2MG BASE	A076880 001	Feb 18, 2009
	EQ 4MG BASE	A077850 001	Feb 18, 2009
THRIVE			
GLAXOSMITHKLINE CONS	EQ 2MG BASE	A077658 001	Jun 19, 2007
	EQ 4MG BASE	A077656 001	Jun 19, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NIFEDIPINE

CAPSULE;ORAL

ADALAT

BAYER PHARMS	10MG	N019478 001	Nov 27, 1985
	20MG	N019478 002	Sep 17, 1986

NIFEDIPINE

CHASE LABS NJ	10MG	A072409 001	Jul 04, 1990
	20MG	A073421 001	Jun 19, 1991
TEVA	10MG	A072651 001	Feb 19, 1992

PROCARDIA

+ PFIZER

20MG **	N018482 002	Jul 24, 1986
---------	-------------	--------------

TABLET, EXTENDED RELEASE;ORAL

ADALAT CC

+ ALVOGEN

30MG	N020198 001	Apr 21, 1993
------	-------------	--------------

+

60MG	N020198 002	Apr 21, 1993
------	-------------	--------------

+

90MG	N020198 003	Apr 21, 1993
------	-------------	--------------

AFEDITAB CR

WATSON LABS

60MG	A075659 001	Oct 26, 2001
------	-------------	--------------

WATSON LABS TEVA

30MG	A075128 001	Mar 10, 2000
------	-------------	--------------

NIFEDIPINE

MARTEC USA LLC

90MG	A075414 003	Mar 23, 2004
------	-------------	--------------

MYLAN

30MG	A075108 001	Dec 17, 1999
------	-------------	--------------

30MG	A090649 001	Jun 21, 2010
------	-------------	--------------

60MG	A090649 002	Jun 21, 2010
------	-------------	--------------

90MG	A090649 003	Jun 21, 2010
------	-------------	--------------

MYLAN LABS LTD

30MG	A090602 001	Sep 13, 2010
------	-------------	--------------

60MG	A090602 002	Sep 13, 2010
------	-------------	--------------

90MG	A090602 003	Sep 13, 2010
------	-------------	--------------

NILUTAMIDE

TABLET;ORAL

NILANDRON

CONCORDIA	50MG	N020169 001	Sep 19, 1996
-----------	------	-------------	--------------

NIMODIPINE

CAPSULE;ORAL

NIMODIPINE

SUN PHARM INDS INC

30MG	A077067 001	Apr 17, 2007
------	-------------	--------------

NIMOTOP

+ BAYER PHARMS

30MG **	N018869 001	Dec 28, 1988
---------	-------------	--------------

SOLUTION;ORAL

NYMALIZE

+ ARBOR PHARMS LLC

3MG/ML	N203340 001	May 10, 2013
--------	-------------	--------------

NISOLDIPINE

TABLET, EXTENDED RELEASE;ORAL

SULAR

+ COVIS

10MG **	N020356 001	Feb 02, 1995
---------	-------------	--------------

+

20MG **	N020356 002	Feb 02, 1995
---------	-------------	--------------

+

25.5MG **	N020356 006	Jan 02, 2008
-----------	-------------	--------------

+

30MG **	N020356 003	Feb 02, 1995
---------	-------------	--------------

+

40MG **	N020356 004	Feb 02, 1995
---------	-------------	--------------

NITRIC OXIDE

GAS;INHALATION

INOMAX

+ MALLINCKRODT HOSP

100PPM **	N020845 002	Dec 23, 1999
-----------	-------------	--------------

NITROFURANTOIN

CAPSULE;ORAL

NITROFURANTOIN

WATSON LABS

50MG	A084326 001
------	-------------

100MG	A084326 002
-------	-------------

TABLET;ORAL

FURADANTIN

PROCTER AND GAMBLE

50MG	N008693 001
------	-------------

100MG	N008693 002
-------	-------------

FURALAN

LANNETT

50MG	A080017 001
------	-------------

100MG	A080017 002
-------	-------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NITROFURANTOIN

TABLET; ORAL

NITROFURANTOIN

ELKINS SINN	50MG	A080003	001
	100MG	A080003	002
IVAX SUB TEVA PHARMS	50MG	A080078	002
	100MG	A080078	001
SANDOZ	50MG	A080043	001
	100MG	A080043	002
WATSON LABS	50MG	A080447	001
	50MG	A085797	001
	100MG	A080447	002
	100MG	A085796	001
WHITEWORTH TOWN PLSN	100MG	A084085	002

NITROFURANTOIN SODIUM

INJECTABLE; INJECTION

IVADANTIN

PROCTER AND GAMBLE	EQ 180MG BASE/VIAL	N012402	001
--------------------	--------------------	---------	-----

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTOIN

MYLAN	50MG	A074967	001	Jul 09, 1997
	100MG	A074967	002	Jul 09, 1997
	100MG	A077025	001	Aug 18, 2004
PHARMGEN	25MG	A074336	001	Jan 25, 1995
	50MG	A074336	002	Jan 25, 1995
	100MG	A074336	003	Jan 25, 1995
WATSON LABS	25MG	A073696	001	Dec 31, 1992
	50MG	A073696	002	Dec 31, 1992
	100MG	A073696	003	Dec 31, 1992

NITROFURANTOIN MACROCRYSTALLINE

WATSON LABS	50MG	A070248	001	Jun 24, 1988
	100MG	A070249	001	Jun 24, 1988

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

RANBAXY LABS LTD	75MG; 25MG	A076951	001	Mar 30, 2005
------------------	------------	---------	-----	--------------

NITROFURAZONE

CREAM; TOPICAL

FURACIN

SHIRE	0.2%	A083789	001
-------	------	---------	-----

DRESSING; TOPICAL

ACTIN-N

SHERWOOD MEDCL	0.2%	N017343	001
----------------	------	---------	-----

OINTMENT; TOPICAL

FURACIN

SHIRE	0.2%	N005795	001
-------	------	---------	-----

NITROFURAZONE

AMBIX	0.2%	A086077	001
LANNETT	0.2%	A084393	001
PERRIGO NEW YORK	0.2%	A084968	001
TARO	0.2%	A086156	001
WENDT	0.2%	A086766	001

POWDER; TOPICAL

FURACIN

SHIRE	0.2%	A083791	001
-------	------	---------	-----

SOLUTION; TOPICAL

NITROFURAZONE

PERRIGO NEW YORK	0.2%	A085130	001
WENDT	0.2%	A087081	001

NITROGLYCERIN

AEROSOL; SUBLINGUAL

NITROLINGUAL

POHL BOSKAMP	0.4MG/SPRAY	N018705	001	Oct 31, 1985
--------------	-------------	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

MINITRAN

MEDICIS	0.4MG/HR	A089773	001	Aug 30, 1996
VALEANT PHARMS	0.1MG/HR	A089771	001	Aug 30, 1996
	0.6MG/HR	A089774	001	Aug 30, 1996
VALEANT PHARMS NORTH	0.2MG/HR	A089772	001	Aug 30, 1996

NITROGLYCERIN

LANNETT CO INC	0.2MG/HR	A075115	001	Aug 10, 2004
	0.4MG/HR	A075115	002	Aug 10, 2004
MYLAN TECHNOLOGIES	0.1MG/HR	A074992	004	Nov 12, 1999
	0.2MG/HR	A074992	003	Nov 12, 1999
	0.4MG/HR	A074992	002	Nov 12, 1999
	0.6MG/HR	A074992	001	Nov 12, 1999

TRANSDERM-NITRO

+ NOVARTIS	0.1MG/HR **	N020144	001	Feb 27, 1996
+	0.2MG/HR **	N020144	002	Feb 27, 1996
+	0.4MG/HR **	N020144	003	Feb 27, 1996
+	0.6MG/HR **	N020144	004	Feb 27, 1996
+	0.8MG/HR **	N020144	005	Feb 27, 1996

INJECTABLE; INJECTION

NITRO IV

POHL BOSKAMP	5MG/ML	N018672	002	Aug 30, 1983
--------------	--------	---------	-----	--------------

NITRO-BID

SANOFI AVENTIS US	5MG/ML	N018621	001	Jan 05, 1982
	10MG/ML	A071159	001	Feb 28, 1990

NITROGLYCERIN

ABRAXIS PHARM	5MG/ML	A070077	001	Dec 13, 1985
	5MG/ML	A071203	001	May 08, 1987
+ HOSPIRA	5MG/ML **	N018531	001	
INTL MEDICATION	5MG/ML	A070026	001	Sep 10, 1985
LUITPOLD	5MG/ML	A071492	001	May 24, 1988
SMITH AND NEPHEW	5MG/ML	A070633	001	Jun 19, 1986
	5MG/ML	A070634	001	Jun 19, 1986

NITROGLYCERIN IN DEXTROSE 5%

HOSPIRA	0.1MG/ML	A074083	001	Oct 26, 1994
	10MG/100ML	A071846	001	Aug 31, 1990
	20MG/100ML	A071847	001	Aug 31, 1990
	40MG/100ML	A071848	001	Aug 31, 1990

NITROL

RORER	0.8MG/ML	N018774	001	Jan 19, 1983
-------	----------	---------	-----	--------------

NITRONAL

POHL BOSKAMP	1MG/ML	N018672	001	Aug 30, 1983
--------------	--------	---------	-----	--------------

NITROSTAT

PARKE DAVIS	0.8MG/ML	N018588	001	
	5MG/ML	A070863	001	Jan 08, 1987
	5MG/ML	N018588	002	Dec 23, 1983
	10MG/ML	A070871	001	Jan 08, 1987
	10MG/ML	A070872	001	Jan 08, 1987

TRIDIL

HOSPIRA	0.5MG/ML	N018537	002	Jun 16, 1983
	5MG/ML	N018537	001	

TABLET; SUBLINGUAL

NITROGLYCERIN

ACTAVIS LABS FL INC	0.3MG	A203693	001	Oct 16, 2017
	0.4MG	A203693	002	Oct 16, 2017
	0.6MG	A203693	003	Oct 16, 2017

NIZATIDINE

CAPSULE; ORAL

AXID

SMITHKLINE BEECHAM	150MG	N019508	001	Apr 12, 1988
	300MG	N019508	002	Apr 12, 1988

NIZATIDINE

ANI PHARMS INC	150MG	A075461	001	Jul 08, 2002
	150MG	A075668	001	Sep 12, 2002
	300MG	A075461	002	Jul 08, 2002
	300MG	A075668	002	Sep 12, 2002
APOTEX INC	150MG	A076383	001	Jan 23, 2003
	300MG	A076383	002	Jan 23, 2003

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NIZATIDINE

CAPSULE; ORAL

NIZATIDINE

MYLAN PHARMS INC	150MG	A075806 001	Jul 05, 2002
	150MG	A075934 001	Jul 09, 2002
	300MG	A075806 002	Jul 05, 2002
	300MG	A075934 002	Jul 09, 2002

SOLUTION; ORAL

AXID

+ BRAINTREE	15MG/ML **	N021494 001	May 25, 2004
-------------	------------	-------------	--------------

NONOXYNOL-9

AEROSOL; VAGINAL

DELFIN

PERSONAL PRODS	12.5%	N014349 002	
----------------	-------	-------------	--

SPONGE; VAGINAL

TODAY

+ MAYER LABS INC	1GM	N018683 001	Apr 01, 1983
------------------	-----	-------------	--------------

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

NOREPINEPHRINE BITARTRATE

METRICS PHARM	EQ 1MG BASE/ML	A040522 001	Sep 30, 2004
---------------	----------------	-------------	--------------

NOREPINEPHRINE BITARTRATE; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

RAVOCAINE AND NOVOCAIN W/ LEVOPHED

EASTMAN KODAK	EQ 0.033MG BASE/ML; 2%; 0.4%	N008592 003	
---------------	------------------------------	-------------	--

NORETHINDRONE

TABLET; ORAL

NORLUTIN

PARKE DAVIS	5MG	N010895 002	
-------------	-----	-------------	--

TABLET; ORAL-28

MICRONOR

+ JANSSEN PHARMS	0.35MG	N016954 001	
------------------	--------	-------------	--

NORETHINDRONE ACETATE

TABLET; ORAL

AYGESTIN

+ DURAMED RES	5MG **	N018405 001	Apr 21, 1982
---------------	--------	-------------	--------------

NORETHINDRONE ACETATE

AUROBINDO PHARMA LTD	5MG	A204236 001	Jan 08, 2016
----------------------	-----	-------------	--------------

NORLUTATE

PARKE DAVIS	5MG	N012184 002	
-------------	-----	-------------	--

NORFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

CHIBROXIN

MERCK	0.3%	N019757 001	Jun 17, 1991
-------	------	-------------	--------------

TABLET; ORAL

NOROXIN

+ MERCK	400MG **	N019384 002	Oct 31, 1986
---------	----------	-------------	--------------

NORGESTREL

TABLET; ORAL

OPILL

+ LABORATOIRE HRA	0.075MG	N017031 001	
-------------------	---------	-------------	--

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

AVENTYL HYDROCHLORIDE

LILLY	EQ 10MG BASE	N014684 001	
-------	--------------	-------------	--

	EQ 25MG BASE	N014684 002	
--	--------------	-------------	--

NORTRIPTYLINE HYDROCHLORIDE

ANI PHARMS INC	EQ 10MG BASE	A074054 001	Dec 31, 1992
----------------	--------------	-------------	--------------

	EQ 25MG BASE	A074054 002	Dec 31, 1992
--	--------------	-------------	--------------

	EQ 50MG BASE	A074054 003	Dec 31, 1992
--	--------------	-------------	--------------

	EQ 75MG BASE	A074054 004	Dec 31, 1992
--	--------------	-------------	--------------

AUROLIFE PHARMA LLC	EQ 10MG BASE	A074835 001	Jun 30, 1997
---------------------	--------------	-------------	--------------

	EQ 25MG BASE	A074835 002	Jun 30, 1997
--	--------------	-------------	--------------

	EQ 50MG BASE	A074835 003	Jun 30, 1997
--	--------------	-------------	--------------

	EQ 75MG BASE	A074835 004	Jun 30, 1997
--	--------------	-------------	--------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE;ORAL

NORTRIPTYLINE HYDROCHLORIDE

MYLAN	EQ 10MG BASE	A074234 001	Jul 26, 1993
	EQ 25MG BASE	A074234 002	Jul 26, 1993
	EQ 50MG BASE	A074234 003	Jul 26, 1993
	EQ 75MG BASE	A074234 004	Jul 26, 1993
TEVA	EQ 10MG BASE	A073667 001	Apr 11, 1996
	EQ 25MG BASE	A073667 002	Apr 11, 1996
	EQ 50MG BASE	A073667 003	Apr 11, 1996
	EQ 75MG BASE	A073667 004	Apr 11, 1996

SOLUTION;ORAL

AVENTYL

+ RANBAXY

EQ 10MG BASE/5ML **

N014685 001

PAMELOR

SPECGX LLC

EQ 10MG BASE/5ML

N018012 001

NYSTATIN

CREAM;TOPICAL

CANDEX

BAYER PHARMS

100,000 UNITS/GM

A061810 001

MYCOSTATIN

DELCOR ASSET CORP

100,000 UNITS/GM **

A060575 001

MYKINAC

ALPHARMA US PHARMS

100,000 UNITS/GM

A062387 001 Jul 29, 1982

NILSTAT

LEDERLE

100,000 UNITS/GM

A061445 001

NYSTATIN

TARO

100,000 UNITS/GM

A062457 001 Jul 28, 1983

VINTAGE

100,000 UNITS/GM

A065315 001 May 31, 2006

LOTION;TOPICAL

CANDEX

BAYER PHARMS

100,000 UNITS/ML

N050233 001

OINTMENT;TOPICAL

MYCOSTATIN

DELCOR ASSET CORP

100,000 UNITS/GM **

A060571 001

MYKINAC

ALPHARMA US PHARMS

100,000 UNITS/GM

A062731 001 Sep 22, 1986

NILSTAT

LEDERLE

100,000 UNITS/GM

A061444 001

PASTILLE;ORAL

MYCOSTATIN

DELCOR ASSET CORP

200,000 UNITS

N050619 001 Apr 09, 1987

POWDER;ORAL

BARSTATIN 100

BARLAN

100%

A062489 001 Apr 27, 1988

NILSTAT

+ DAVA PHARMS INC

100% **

N050576 001 Dec 22, 1983

NYSTATIN

PADDOCK LLC

100%

A062613 001 Nov 26, 1985

POWDER;TOPICAL

MYCOSTATIN

DELCOR ASSET CORP

100,000 UNITS/GM **

A060578 001

NYSTATIN

NESHER PHARMS

100,000 UNITS/GM

A065321 001 Aug 18, 2006

SUPPOSITORY;VAGINAL

NYSERT

WARNER CHILCOTT

100,000 UNITS

N050478 001

SUSPENSION;ORAL

MYCOSTATIN

DELCOR ASSET CORP

100,000 UNITS/ML

A061533 001

NILSTAT

+ GLENMARK GENERICS

100,000 UNITS/ML **

N050299 001

NYSTATIN

ALPHARMA US PHARMS

100,000 UNITS/ML

A062571 001 Oct 29, 1985

COSETTE

100,000 UNITS/ML

A062776 001 Dec 17, 1987

G AND W LABS INC

100,000 UNITS/ML

A062349 001 Jul 14, 1982

MORTON GROVE

100,000 UNITS/ML

A062835 001 Nov 19, 1987

PHARMADERM

100,000 UNITS/ML

A062518 001 Jul 06, 1984

PHARMAFAIR

100,000 UNITS/ML

A062541 001 Jan 16, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NYSTATIN

SUSPENSION;ORAL

NYSTATIN

TEVA 100,000 UNITS/ML A062670 001 Jun 18, 1987

NYSTEX

SAVAGE LABS 100,000 UNITS/ML A062519 001 Jul 06, 1984

TABLET;ORAL

MYCOSTATIN

DELCOR ASSET CORP 500,000 UNITS A060574 001

NILSTAT

LEDERLE 500,000 UNITS A061151 001

NYSTATIN

QUANTUM PHARMICS 500,000 UNITS A062525 001 Oct 29, 1984

SANDOZ 500,000 UNITS A062065 001

UPSHER SMITH LABS 500,000 UNITS A062524 001 Nov 26, 1985

WATSON LABS 500,000 UNITS A062402 001 Dec 16, 1982

TABLET;VAGINAL

KOROSTATIN

HOLLAND RANTOS 100,000 UNITS A061718 001

MYCOSTATIN

DELCOR ASSET CORP 100,000 UNITS A060577 001

NILSTAT

LEDERLE 100,000 UNITS A061325 001

NYSTATIN

FOUGERA 100,000 UNITS A062459 001 Nov 09, 1983

ODYSSEY PHARMS 100,000 UNITS A062615 001 Oct 17, 1985

PHARMADERM 100,000 UNITS A062460 001 Nov 09, 1983

QUANTUM PHARMICS 100,000 UNITS A062509 001 Apr 03, 1984

SANDOZ 100,000 UNITS A061965 001

TEVA 100,000 UNITS A062502 001 Dec 23, 1983

WATSON LABS 100,000 UNITS A062176 001

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

MYCO-TRIACET II

TEVA 100,000 UNITS/GM;0.1% A061954 002 Sep 20, 1985

MYCOLOG-II

DELCOR ASSET CORP 100,000 UNITS/GM;0.1% ** A060576 002 May 01, 1985

MYLAN 100,000 UNITS/GM;0.1% ** A062606 001 May 15, 1985

MYTRES F

SAVAGE LABS 100,000 UNITS/GM;0.1% A062597 001 Oct 08, 1985

NYSTATIN AND TRIAMCINOLONE ACETONIDE

ALPHARMA US PHARMS 100,000 UNITS/GM;0.1% A063010 001 Dec 20, 1988

PERRIGO NEW YORK 100,000 UNITS/GM;0.1% A062186 002 Jun 06, 1985

PHARMAFAIR 100,000 UNITS/GM;0.1% A062657 001 Jul 30, 1986

TARO 100,000 UNITS/GM;0.1% A062347 001 Mar 30, 1987

NYSTATIN TRIAMCINOLONE ACETONIDE

PHARMADERM 100,000 UNITS/GM;0.1% A062596 001 Oct 08, 1985

OINTMENT;TOPICAL

MYCO-TRIACET II

TEVA 100,000 UNITS/GM;0.1% A062045 002 Nov 26, 1985

MYCOLOG-II

MYLAN 100,000 UNITS/GM;0.1% ** A060572 001 Jun 28, 1985

MYTRES F

SAVAGE LABS 100,000 UNITS/GM;0.1% A062601 001 Oct 09, 1985

NYSTATIN AND TRIAMCINOLONE ACETONIDE

CROWN LABS INC 100,000 UNITS/GM;0.1% A207731 001 Dec 26, 2017

PERRIGO NEW YORK 100,000 UNITS/GM;0.1% A062280 002 Oct 10, 1985

PHARMAFAIR 100,000 UNITS/GM;0.1% A062656 001 Jul 30, 1986

VITRUVIAS THERAP 100,000 UNITS/GM;0.1% A207316 001 Nov 18, 2019

NYSTATIN-TRIAMCINOLONE ACETONIDE

PHARMADERM 100,000 UNITS/GM;0.1% A062603 001 Oct 09, 1985

OCTREOTIDE ACETATE

INJECTABLE;INJECTION

OCTREOTIDE ACETATE

HERITAGE PHARMS INC EQ 0.05MG BASE/ML A204669 001 Dec 27, 2018

EQ 0.1MG BASE/ML A204669 002 Dec 27, 2018

EQ 0.2MG BASE/ML A203765 001 Sep 07, 2018

EQ 0.5MG BASE/ML A204669 003 Dec 27, 2018

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

	EQ 1MG BASE/ML	A203765	002	Sep 07, 2018
SUN PHARM INDS	EQ 0.05MG BASE/ML	A077329	001	Mar 04, 2008
	EQ 0.05MG BASE/ML	A077372	001	Aug 14, 2007
	EQ 0.1MG BASE/ML	A077329	002	Mar 04, 2008
	EQ 0.1MG BASE/ML	A077372	002	Aug 14, 2007
	EQ 0.2MG BASE/ML	A077330	001	Mar 04, 2008
	EQ 0.2MG BASE/ML	A077373	001	Aug 14, 2007
	EQ 0.5MG BASE/ML	A077329	003	Mar 04, 2008
	EQ 0.5MG BASE/ML	A077372	003	Aug 14, 2007
	EQ 1MG BASE/ML	A077331	001	Mar 04, 2008
	EQ 1MG BASE/ML	A077373	002	Aug 14, 2007
WOCKHARDT USA	EQ 0.2MG BASE/ML	A090986	001	May 11, 2011
	EQ 1MG BASE/ML	A090986	002	May 11, 2011
OCTREOTIDE ACETATE PRESERVATIVE FREE				
WOCKHARDT USA	EQ 0.05MG BASE/ML	A090985	001	May 11, 2011
	EQ 0.1MG BASE/ML	A090985	002	May 11, 2011
	EQ 0.5MG BASE/ML	A090985	003	May 11, 2011
SANDOSTATIN				
+ NOVARTIS	EQ 0.2MG BASE/ML	N019667	004	Jun 12, 1991
+	EQ 1MG BASE/ML	N019667	005	Jun 12, 1991

OFLOXACIN

INJECTABLE; INJECTION

FLOXIN

ORTHO MCNEIL PHARM	20MG/ML	N020087	002	Mar 31, 1992
	40MG/ML	N020087	003	Mar 31, 1992
FLOXIN IN DEXTROSE 5%				
ORTHO MCNEIL PHARM	400MG/100ML	N020087	001	Mar 31, 1992
FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER				
ORTHO MCNEIL PHARM	4MG/ML	N020087	004	Mar 31, 1992
	400MG/100ML	N020087	005	Mar 31, 1992
OFLOXACIN				
BEDFORD	40MG/ML	A075762	001	Jan 16, 2002
SOLUTION/DROPS; OPHTHALMIC				
OFLOXACIN				
SANDOZ	0.3%	A076848	001	Nov 25, 2008
SANDOZ INC	0.3%	A076231	001	May 14, 2004
SOLUTION/DROPS; OTIC				
FLOXIN OTIC				
+ DAIICHI	0.3% **	N020799	001	Dec 16, 1997
OFLOXACIN				
ALVOGEN	0.3%	A090395	001	Aug 11, 2009
SANDOZ INC	0.3%	A078222	001	Mar 17, 2008

TABLET; ORAL

FLOXIN

JANSSEN PHARMS	200MG **	N019735	001	Dec 28, 1990
	300MG **	N019735	002	Dec 28, 1990
	400MG **	N019735	003	Dec 28, 1990
OFLOXACIN				
LARKEN LABS	200MG	A076093	001	Sep 02, 2003
	300MG	A076093	002	Sep 02, 2003
	400MG	A076093	003	Sep 02, 2003
RANBAXY LABS LTD	200MG	A076220	001	Sep 02, 2003
	300MG	A076220	002	Sep 02, 2003
	400MG	A076220	003	Sep 02, 2003

OLANZAPINE

TABLET; ORAL

OLANZAPINE

AJANTA PHARMA LTD	2.5MG	A206711	001	Aug 30, 2016
	5MG	A206711	002	Aug 30, 2016
	7.5MG	A206711	003	Aug 30, 2016
	10MG	A206711	004	Aug 30, 2016
	15MG	A206711	005	Aug 30, 2016
	20MG	A206711	006	Aug 30, 2016
HIKMA	2.5MG	A204866	001	Jun 16, 2017
	5MG	A204866	002	Jun 16, 2017

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

OLANZAPINETABLET; ORAL
OLANZAPINE

	7.5MG	A204866 003	Jun 16, 2017
	10MG	A204866 004	Jun 16, 2017
	15MG	A204866 005	Jun 16, 2017
	20MG	A204866 006	Jun 16, 2017
IVAX PHARMS INC	20MG	A077301 001	Apr 29, 2015
JIANGSU HANSOH PHARM	2.5MG	A209399 001	Sep 24, 2018
	5MG	A209399 002	Sep 24, 2018
	10MG	A209399 003	Sep 24, 2018
MYLAN	2.5MG	A076866 001	Apr 23, 2012
	5MG	A076866 002	Apr 23, 2012
	7.5MG	A076866 003	Apr 23, 2012
	10MG	A076866 004	Apr 23, 2012
	15MG	A076866 005	Apr 23, 2012
	20MG	A076866 006	Apr 23, 2012
SUNSHINE	2.5MG	A206238 001	Nov 19, 2018
	5MG	A206238 002	Nov 19, 2018
	7.5MG	A206238 003	Nov 19, 2018
	10MG	A206238 004	Nov 19, 2018
	15MG	A206238 005	Nov 19, 2018
	20MG	A206238 006	Nov 19, 2018
TEVA PHARMS	2.5MG	A076000 001	Oct 24, 2011
	5MG	A076000 002	Oct 24, 2011
	7.5MG	A076000 003	Oct 24, 2011
	10MG	A076000 004	Oct 24, 2011
	15MG	A076000 005	Oct 24, 2011
TORRENT PHARMS LTD	2.5MG	A091434 001	Apr 23, 2012
	5MG	A091434 002	Apr 23, 2012
	7.5MG	A091434 003	Apr 23, 2012
	10MG	A091434 004	Apr 23, 2012
	15MG	A091434 005	Apr 23, 2012
	20MG	A091434 006	Apr 23, 2012

TABLET, ORALLY DISINTEGRATING; ORAL
OLANZAPINE

AJANTA PHARMA LTD	5MG	A204320 001	May 30, 2017
	10MG	A204320 002	May 30, 2017
	15MG	A204320 003	May 30, 2017
	20MG	A204320 004	May 30, 2017
HEC PHARM	5MG	A208146 001	Jul 02, 2018
	10MG	A208146 002	Jul 02, 2018
	15MG	A208146 003	Jul 02, 2018
	20MG	A208146 004	Jul 02, 2018

OLAPARIBCAPSULE; ORAL
LYNPARZA

+ ASTRAZENECA PHARMS 50MG N206162 001 Dec 19, 2014

OLMESARTAN MEDOXOMIL

TABLET; ORAL

OLMESARTAN MEDOXOMIL

INVENTIA	5MG	A208659 001	May 18, 2020
	20MG	A208659 002	May 18, 2020
	40MG	A208659 003	May 18, 2020
JUBILANT GENERICS	5MG	A205482 001	Apr 24, 2017
	20MG	A205482 002	Apr 24, 2017
	40MG	A205482 003	Apr 24, 2017
TEVA PHARMS USA	5MG	A091079 001	Apr 24, 2017
	20MG	A091079 002	Apr 24, 2017
	40MG	A091079 003	Apr 24, 2017

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

CIPLA	EQ 0.1% BASE	A206046 001	Jul 26, 2017
	EQ 0.2% BASE	A206087 001	Dec 05, 2017
WATSON LABS INC	EQ 0.7% BASE	A208637 001	Feb 19, 2020
ZAMBON SPA	EQ 0.1% BASE	A204706 001	Dec 07, 2015

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

OMBITASVIR; PARITAPREVIR; RITONAVIR

TABLET; ORAL

TECHNIVIE

+ ABBVIE INC

12.5MG; 75MG; 50MG

N207931 001 Jul 24, 2015

OMEGA-3-ACID ETHYL ESTERS

CAPSULE; ORAL

OMEGA-3-ACID ETHYL ESTERS

PAR PHARM INC

1GM CONTAINS AT LEAST 900MG OF THE
ETHYL ESTERS OF OMEGA-3 FATTY ACIDS

A091018 001 Jun 24, 2014

ZYDUS

1GM CONTAINS AT LEAST 900MG OF THE
ETHYL ESTERS OF OMEGA-3 FATTY ACIDS

A210107 001 Jun 14, 2019

OMEGA-3-ACID ETHYL ESTERS TYPE A

CAPSULE; ORAL

OMTRYG

+ OSMOTICA

1.2GM CONTAINS AT LEAST 900MG OF THE
ETHYL ESTERS OF OMEGA-3 FATTY ACIDS

N204977 001 Apr 23, 2014

OMEGA-3-CARBOXYLIC ACIDS

CAPSULE; ORAL

EPANOVA

+ ASTRAZENECA PHARMS

1GM CONTAINS AT LEAST 850MG OF
POLYUNSATURATED FATTY ACIDS

N205060 001 May 05, 2014

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

OMEPRAZOLE

LUPIN LTD

40MG

A202384 001 Aug 25, 2015

MYLAN

10MG

A075876 001 May 29, 2003

10MG

A205070 001 Jun 29, 2018

20MG

A075876 002 May 29, 2003

20MG

A205070 002 Jun 29, 2018

40MG

A075876 003 Jan 21, 2009

40MG

A205070 003 Jun 29, 2018

TEVA PHARMS USA

40MG

A204661 002 Jun 13, 2017

PRILOSEC

+ ASTRAZENECA PHARMS

10MG **

N019810 003 Oct 05, 1995

+

20MG **

N019810 001 Sep 14, 1989

+

40MG **

N019810 002 Jan 15, 1998

TABLET, DELAYED RELEASE; ORAL

OMEPRAZOLE

APOTEX

20MG

A210070 001 Feb 11, 2019

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE; ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

PAR PHARM

20MG; 1.1GM

A078966 001 May 25, 2010

20MG; 1.1GM

A201946 001 Jul 15, 2016

UNICORN

40MG; 1.1GM

A078966 002 May 25, 2010

UNICORN

20MG; 1.1GM

A204137 001 Jul 15, 2016

ONDANSETRON

FILM; ORAL

ZUPLENZ

+ FORTOVIA

4MG

N022524 001 Jul 02, 2010

+

8MG

N022524 002 Jul 02, 2010

TABLET, ORALLY DISINTEGRATING; ORAL

ONDANSETRON

BARR

4MG

A076693 001 Jun 25, 2007

8MG

A076693 002 Jun 25, 2007

CHARTWELL MOLECULES

4MG

A077406 003 Dec 26, 2006

8MG

A077406 004 Dec 26, 2006

16MG

A077406 001 Dec 26, 2006

24MG

A077406 002 Dec 26, 2006

NESHER PHARMS

4MG

A077717 001 Jun 25, 2007

8MG

A077717 002 Jun 25, 2007

TEVA

4MG

A076810 001 Jun 25, 2007

8MG

A076810 002 Jun 25, 2007

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

APOTEX INC	EQ 2MG BASE/ML	A077368	001	Dec 26, 2006
BAXTER HLTHCARE CORP	EQ 2MG BASE/ML	A078288	001	Feb 22, 2013
EMCURE PHARMS	EQ 2MG BASE/ML	A090424	001	Apr 16, 2010
HOSPIRA	EQ 2MG BASE/ML	A076695	001	Dec 26, 2006
LANNETT CO INC	EQ 2MG BASE/ML	A090116	001	Apr 14, 2010
	EQ 2MG BASE/ML	A090883	001	Aug 05, 2010
LUITPOLD	EQ 2MG BASE/ML	A077582	001	Dec 26, 2006
	EQ 2MG BASE/ML	A079039	001	Nov 18, 2008
MYLAN LABS LTD	EQ 2MG BASE/ML	A078257	001	Apr 23, 2008
	EQ 2MG BASE/ML	A204906	001	Jul 31, 2017
PLIVA HRVATSKA DOO	EQ 2MG BASE/ML	A077544	001	Dec 26, 2006
SAGENT PHARMS	EQ 2MG BASE/ML	A078180	001	Mar 26, 2007
SUN PHARM INDS (IN)	EQ 2MG BASE/ML	A077172	001	Dec 26, 2006

ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER

HOSPIRA	EQ 0.64MG BASE/ML	A076978	001	Feb 26, 2007
---------	-------------------	---------	-----	--------------

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

AM REGENT	EQ 2MG BASE/ML	A079032	001	Nov 18, 2008
APOTEX INC	EQ 2MG BASE/ML	A077343	001	Dec 26, 2006
HIKMA FARMACEUTICA	EQ 2MG BASE/ML	A076780	001	Dec 26, 2006
HOSPIRA	EQ 2MG BASE/ML	A076696	001	Dec 26, 2006
LUITPOLD	EQ 2MG BASE/ML	A077387	001	Dec 26, 2006
MYLAN LABS LTD	EQ 2MG BASE/ML	A078244	001	Apr 23, 2008
SUN PHARM INDS LTD	EQ 2MG BASE/ML	A077173	001	Dec 26, 2006
TARO PHARMS IRELAND	EQ 2MG BASE/ML	A078014	001	Mar 21, 2008
TEVA	EQ 2MG BASE/ML	A076759	001	Nov 22, 2006

ZOFRAN

+ NOVARTIS	EQ 2MG BASE/ML **	N020007	001	Jan 04, 1991
------------	-------------------	---------	-----	--------------

ZOFRAN AND DEXTROSE IN PLASTIC CONTAINER

+ GLAXOSMITHKLINE	EQ 0.64MG BASE/ML **	N020403	001	Jan 31, 1995
-------------------	----------------------	---------	-----	--------------

ZOFRAN PRESERVATIVE FREE

+ NOVARTIS	EQ 2MG BASE/ML **	N020007	003	Dec 10, 1993
------------	-------------------	---------	-----	--------------

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

CHARTWELL MOLECULES	EQ 4MG BASE	A077303	001	Jun 25, 2007
	EQ 8MG BASE	A077303	002	Jun 25, 2007
	EQ 24MG BASE	A077303	004	Jun 25, 2007
HIKMA INTL PHARMS	EQ 4MG BASE	A077545	001	Sep 06, 2007
	EQ 8MG BASE	A077545	002	Sep 06, 2007
	EQ 24MG BASE	A077545	003	Sep 06, 2007
MYLAN	EQ 4MG BASE	A076930	001	Jun 25, 2007
	EQ 8MG BASE	A076930	002	Jun 25, 2007
	EQ 24MG BASE	A076930	004	Jun 25, 2007
PLIVA HRVATSKA DOO	EQ 4MG BASE	A077112	001	Jun 25, 2007
	EQ 8MG BASE	A077112	002	Jun 25, 2007
	EQ 24MG BASE	A077112	003	Jun 25, 2007
TARO	EQ 4MG BASE	A077729	001	Mar 28, 2011
	EQ 8MG BASE	A077729	002	Mar 28, 2011
	EQ 24MG BASE	A077729	003	Mar 28, 2011

ORPHENADRINE CITRATE

INJECTABLE; INJECTION

NORFLEX

+ TELIGENT	30MG/ML	N013055	001	
------------	---------	---------	-----	--

ORPHENADRINE CITRATE

WATSON LABS	30MG/ML	A087062	001	
-------------	---------	---------	-----	--

TABLET, EXTENDED RELEASE; ORAL

NORFLEX

+ MEDICIS	100MG	N012157	001	
-----------	-------	---------	-----	--

ORPHENADRINE CITRATE

ASCOT	100MG	A088067	001	Apr 06, 1983
SANDOZ	100MG	A085046	001	
WATSON LABS	100MG	A084303	001	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ORPHENADRINE HYDROCHLORIDE

TABLET; ORAL

DISIPAL

3M

50MG

N010653 001

OSELTAMIVIR PHOSPHATE

CAPSULE; ORAL

OSELTAMIVIR PHOSPHATE

SUNSHINE

EQ 30MG BASE

A212739 001 Mar 04, 2020

EQ 45MG BASE

A212739 002 Mar 04, 2020

EQ 75MG BASE

A212739 003 Mar 04, 2020

FOR SUSPENSION; ORAL

TAMIFLU

ROCHE

EQ 12MG BASE/ML

N021246 001 Dec 14, 2000

OXACILLIN SODIUM

CAPSULE; ORAL

BACTOCILL

GLAXOSMITHKLINE

EQ 250MG BASE

A061336 001

EQ 250MG BASE

A062241 001

EQ 500MG BASE

A061336 002

EQ 500MG BASE

A062241 002

OXACILLIN SODIUM

ANI PHARMS INC

EQ 250MG BASE

A062222 001

EQ 500MG BASE

A062222 002

APOTHECON

EQ 250MG BASE

A061450 002

EQ 500MG BASE

A061450 001

PROSTAPHLIN

APOTHECON

EQ 500MG BASE

N050118 002

FOR SOLUTION; ORAL

BACTOCILL

GLAXOSMITHKLINE

EQ 250MG BASE/5ML

A062321 001

OXACILLIN SODIUM

APOTHECON

EQ 250MG BASE/5ML

A061457 001

TEVA

EQ 250MG BASE/5ML

A062252 001

PROSTAPHLIN

APOTHECON

EQ 250MG BASE/5ML

N050194 001

INJECTABLE; INJECTION

BACTOCILL

GLAXOSMITHKLINE

EQ 500MG BASE/VIAL **

A061334 009 Mar 26, 1982

EQ 1GM BASE/VIAL **

A061334 006 Mar 26, 1982

EQ 1GM BASE/VIAL **

A062736 001 Dec 19, 1986

EQ 2GM BASE/VIAL **

A061334 007 Mar 26, 1982

EQ 2GM BASE/VIAL **

A062736 002 Dec 19, 1986

EQ 4GM BASE/VIAL **

A061334 008 Mar 26, 1982

EQ 10GM BASE/VIAL **

A061334 010

OXACILLIN SODIUM

+ APOTHECON

EQ 250MG BASE/VIAL **

N050195 001

+ APOTHECON

EQ 500MG BASE/VIAL **

N050195 002

+ APOTHECON

EQ 1GM BASE/VIAL **

N050195 003

+ APOTHECON

EQ 2GM BASE/VIAL **

N050195 004

+ APOTHECON

EQ 4GM BASE/VIAL **

N050195 005

ELKINS SINN

EQ 250MG BASE/VIAL

A062711 001 Feb 03, 1989

EQ 500MG BASE/VIAL

A062711 002 Feb 03, 1989

EQ 1GM BASE/VIAL

A062711 003 Feb 03, 1989

EQ 2GM BASE/VIAL

A062711 004 Feb 03, 1989

EQ 4GM BASE/VIAL

A062711 005 Feb 03, 1989

EQ 10GM BASE/VIAL

A062711 006 Feb 03, 1989

HOSPIRA INC

EQ 1GM BASE/VIAL

A203950 001 Dec 11, 2015

EQ 2GM BASE/VIAL

A203950 002 Dec 11, 2015

ISTITUTO BIO ITA SPA

EQ 125MG BASE/VIAL

A062798 003 Dec 11, 1995

EQ 250MG BASE/VIAL

A062798 004 Dec 11, 1995

EQ 500MG BASE/VIAL

A062798 005 Dec 11, 1995

EQ 1GM BASE/VIAL

A062798 001 Dec 11, 1995

EQ 2GM BASE/VIAL

A062798 002 Dec 11, 1995

MYLAN LABS LTD

EQ 1GM BASE/VIAL

A091486 001 Aug 25, 2014

EQ 2GM BASE/VIAL

A091486 002 Aug 25, 2014

SANDOZ

EQ 250MG BASE/VIAL

A061490 001

EQ 500MG BASE/VIAL

A061490 002

EQ 1GM BASE/VIAL

A061490 003

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

OXACILLIN SODIUMINJECTABLE; INJECTION
OXACILLIN SODIUM

	EQ 2GM BASE/VIAL	A061490 004	
	EQ 10GM BASE/VIAL	A061490 006	May 09, 1991
WATSON LABS INC	EQ 250MG BASE/VIAL	A062856 001	Oct 26, 1988
	EQ 500MG BASE/VIAL	A062856 002	Oct 26, 1988
	EQ 1GM BASE/VIAL	A062856 003	Oct 26, 1988
	EQ 2GM BASE/VIAL	A062856 004	Oct 26, 1988
	EQ 4GM BASE/VIAL	A062856 005	Oct 26, 1988
	EQ 10GM BASE/VIAL	A062984 001	Sep 29, 1988

POWDER; INTRAVENOUS
OXACILLIN SODIUM

SANDOZ	EQ 1GM BASE/VIAL	A062737 001	Dec 23, 1986
	EQ 2GM BASE/VIAL	A062737 002	Dec 23, 1986

OXALIPLATIN

INJECTABLE; INTRAVENOUS

ELOXATIN

+	SANOFI AVENTIS US	50MG/VIAL **	N021492 001	Aug 09, 2002
+		100MG/VIAL **	N021492 002	Aug 09, 2002
+		200MG/40ML (5MG/ML) **	N021759 003	Nov 17, 2006

OXALIPLATIN

ACCORD HLTHCARE	200MG/40ML (5MG/ML)	A207474 003	Mar 21, 2017
AM REGENT	50MG/10ML (5MG/ML)	A204378 001	May 12, 2017
	100MG/20ML (5MG/ML)	A204378 002	May 12, 2017
FRESENIUS KABI ONCOL	50MG/VIAL	A078810 001	Aug 07, 2009
	100MG/VIAL	A078810 002	Aug 07, 2009
FRESENIUS KABI USA	200MG/40ML (5MG/ML)	A090030 003	Jan 31, 2017
GLAND PHARMA LTD	200MG/40ML (5MG/ML)	A207325 003	Oct 18, 2017
HOSPIRA INC	50MG/VIAL	A078815 001	Sep 30, 2009
	100MG/VIAL	A078815 002	Sep 30, 2009
MYLAN LABS LTD	50MG/VIAL	A200979 001	Aug 08, 2012
	100MG/VIAL	A200979 002	Aug 08, 2012
	200MG/40ML (5MG/ML)	A091358 003	Nov 14, 2017
SANDOZ	50MG/VIAL	A090849 001	Apr 28, 2011
	100MG/VIAL	A090849 002	Apr 28, 2011
SANDOZ INC	50MG/10ML (5MG/ML)	A078812 001	Aug 07, 2009
	100MG/20ML (5MG/ML)	A078812 002	Aug 07, 2009
SUN PHARM	50MG/VIAL	A078818 001	Aug 07, 2009
	50MG/10ML (5MG/ML)	A202922 001	Apr 08, 2014
	100MG/VIAL	A078818 002	Aug 07, 2009
	100MG/20ML (5MG/ML)	A202922 002	Apr 08, 2014
	200MG/40ML (5MG/ML)	A202922 003	Feb 15, 2019

OXAMNIQUINE

CAPSULE; ORAL

VANSIL

PFIZER	250MG	N018069 001	
--------	-------	-------------	--

OXANDROLONE

TABLET; ORAL

OXANDRIN

+	GEMINI LABS LLC	2.5MG	N013718 001	
+		10MG	N013718 002	Nov 05, 2001

OXANDROLONE

ROXANE	2.5MG	A077249 001	Jul 10, 2007
	10MG	A077249 002	Jul 10, 2007
SANDOZ	2.5MG	A076897 001	Dec 01, 2006
	10MG	A076897 002	Dec 01, 2006

OXAPROZIN

TABLET; ORAL

OXAPROZIN

ACTAVIS ELIZABETH	600MG	A075843 001	Oct 03, 2001
BEXIMCO PHARMS USA	600MG	A075842 001	Apr 12, 2001
IVAX SUB TEVA PHARMS	600MG	A075846 001	May 13, 2002
MYLAN	600MG	A075851 001	Aug 17, 2001
MYLAN PHARMS INC	600MG	A075847 001	Feb 28, 2001
SANDOZ	600MG	A075850 001	Apr 27, 2001
SUN PHARM INDS INC	600MG	A075844 001	Jan 03, 2002

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

OXAPROZIN

TABLET; ORAL

OXAPROZIN

WATSON LABS

600MG

A075848 001 Feb 09, 2001

OXAPROZIN POTASSIUM

TABLET; ORAL

DAYPRO ALTA

PFIZER

600MG

N020776 001 Oct 17, 2002

OXAZEPAM

CAPSULE; ORAL

OXAZEPAM

AM THERAP

10MG

A071955 001 Mar 03, 1988

15MG

A071956 001 Mar 03, 1988

30MG

A071957 001 Mar 03, 1988

IVAX SUB TEVA PHARMS

10MG

A070943 001 Aug 03, 1987

15MG

A070944 001 Aug 03, 1987

30MG

A070945 001 Aug 03, 1987

MYLAN

10MG

A071713 001 Oct 20, 1987

15MG

A071714 001 Oct 20, 1987

30MG

A071715 001 Oct 20, 1987

WATSON LABS

15MG

A072953 001 Sep 28, 1990

30MG

A072954 001 Sep 28, 1990

WATSON LABS TEVA

10MG

A072952 001 Sep 28, 1990

SERAX

ALPHARMA US PHARMS

10MG **

N015539 002

15MG **

N015539 004

30MG **

N015539 006

ZAXOPAM

QUANTUM PHARMICS

10MG

A070650 001 Mar 01, 1988

15MG

A070640 001 Mar 01, 1988

30MG

A070641 001 Mar 01, 1988

TABLET; ORAL

OXAZEPAM

PARKE DAVIS

15MG

A071508 001 Feb 02, 1987

SUN PHARM INDUSTRIES

15MG

A070683 001 Jan 16, 1987

WATSON LABS

15MG

A071494 001 Apr 21, 1987

SERAX

ALPHARMA US PHARMS

15MG **

N015539 008

OXCARBAZEPINE

TABLET; ORAL

OXCARBAZEPINE

ANI PHARMS INC

150MG

A078005 001 Dec 11, 2007

300MG

A078005 002 Dec 11, 2007

600MG

A078005 003 Dec 11, 2007

HIKMA

150MG

A077795 001 Oct 09, 2007

300MG

A077795 002 Oct 09, 2007

600MG

A077795 003 Oct 09, 2007

JUBILANT CADISTA

150MG

A090239 001 Jan 25, 2010

300MG

A090239 002 Jan 25, 2010

600MG

A090239 003 Jan 25, 2010

OPRENOLOL HYDROCHLORIDE

CAPSULE; ORAL

TRASICOR

NOVARTIS

20MG

N018166 001 Dec 28, 1983

40MG

N018166 002 Dec 28, 1983

80MG

N018166 003 Dec 28, 1983

160MG

N018166 004 Dec 28, 1983

OXTRIPHYLLINE

SOLUTION; ORAL

CHOLEDYL

PARKE DAVIS

100MG/5ML

N009268 012 Nov 27, 1984

OXTRIPHYLLINE

MORTON GROVE

100MG/5ML

A088243 001 Dec 05, 1983

SYRUP; ORAL

CHOLEDYL

PARKE DAVIS

50MG/5ML

N009268 011

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

OXTRIPHYLLINE

SYRUP;ORAL

OXTRIPHYLLINE PEDIATRIC

MORTON GROVE

50MG/5ML

A088242 001 Dec 05, 1983

TABLET, DELAYED RELEASE;ORAL

CHOLEDYL

PARKE DAVIS

100MG

N009268 003

200MG

N009268 007

OXTRIPHYLLINE

WATSON LABS

100MG

A087866 001 Aug 25, 1983

200MG

A087835 001 Aug 25, 1983

TABLET, EXTENDED RELEASE;ORAL

CHOLEDYL SA

WARNER CHILCOTT LLC

400MG

A087863 001 May 24, 1983

600MG

A086742 001

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL

OXYBUTYNIN

BARR LABS DIV TEVA

3.9MG/24HR

A090526 001 Mar 04, 2014

GEL, METERED;TRANSDERMAL

GELNIQUE 3%

+ ALLERGAN

3%

N202513 001 Dec 07, 2011

OXYBUTYNIN CHLORIDE

GEL;TRANSDERMAL

OXYBUTYNIN CHLORIDE

PAR PHARM INC

10% (100MG/PACKET)

A207329 001 May 31, 2018

SYRUP;ORAL

DITROPAN

+ ORTHO MCNEIL JANSSEN

5MG/5ML **

N018211 001

OXYBUTYNIN CHLORIDE

ANDA REPOSITORY

5MG/5ML

A075039 001 Jan 29, 1999

LANNETT CO INC

5MG/5ML

A076682 001 Dec 28, 2004

PHARM ASSOC

5MG/5ML

A074997 001 Oct 15, 1997

TABLET;ORAL

DITROPAN

+ JANSSEN PHARMS

5MG **

N017577 001

OXYBUTYNIN CHLORIDE

QUANTUM PHARMICS

5MG

A072296 001 Dec 08, 1988

USL PHARMA

5MG

A070746 001 Mar 10, 1988

WATSON LABS

5MG

A072485 001 Apr 19, 1989

TABLET, EXTENDED RELEASE;ORAL

DITROPAN XL

+ JANSSEN PHARMS

15MG **

N020897 003 Jun 22, 1999

OXYBUTYNIN CHLORIDE

IMPAX PHARMS

5MG

A076745 002 May 09, 2007

10MG

A076745 003 May 09, 2007

15MG

A076745 001 Nov 09, 2006

MYLAN

5MG

A076702 001 Nov 09, 2006

MYLAN PHARMS INC

10MG

A076644 001 Nov 09, 2006

15MG

A076644 002 May 10, 2007

OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

ANI PHARMS INC

100MG/5ML

A203447 001 Aug 30, 2017

AUROLIFE PHARMA LLC

5MG/5ML

A212429 001 Jan 27, 2020

100MG/5ML

A212429 002 Jan 27, 2020

HIKMA

100MG/5ML

A203208 001 Jul 12, 2013

LANNETT CO INC

100MG/5ML

A204085 001 Sep 09, 2014

RHODES PHARMS

100MG/5ML

A205853 001 Apr 29, 2020

TABLET;ORAL

OXYCODONE HYDROCHLORIDE

ACTAVIS ELIZABETH

5MG

A076636 003 Apr 07, 2015

15MG

A076636 001 Feb 06, 2004

30MG

A076636 002 Feb 06, 2004

NESHER PHARMS

5MG

A077290 001 Dec 08, 2005

10MG

A077290 002 Dec 08, 2005

15MG

A077290 003 Dec 08, 2005

20MG

A077290 004 Dec 08, 2005

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

	30MG	A077290 005	Dec 08, 2005
VINTAGE PHARMS	5MG	A077712 003	Mar 02, 2009
	10MG	A077712 004	Apr 13, 2015
	15MG	A077712 001	Jan 31, 2007
	20MG	A077712 005	Apr 13, 2015
	30MG	A077712 002	Jan 31, 2007
ROXYBOND			
OHEMO LIFE	5MG	N209777 001	Apr 20, 2017
	15MG	N209777 002	Apr 20, 2017
	30MG	N209777 003	Apr 20, 2017

TABLET, EXTENDED RELEASE; ORAL

ROXICODONE

ROXANE	10MG	N020932 001	Oct 26, 1998
	30MG	N020932 002	Oct 26, 1998

OXYMETAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

OCUCLEAR

BAYER HEALTHCARE LLC	0.025%	N018471 001	May 30, 1986
----------------------	--------	-------------	--------------

OXYMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

OPANA

+ ENDO PHARMS	1MG/ML	N011707 002	
	1.5MG/ML	N011707 001	

SUPPOSITORY; RECTAL

NUMORPHAN

ENDO PHARMS	5MG	N011738 004	
-------------	-----	-------------	--

TABLET; ORAL

OPANA

+ ENDO PHARMS	5MG	N021611 001	Jun 22, 2006
	10MG	N021611 002	Jun 22, 2006

TABLET, EXTENDED RELEASE; ORAL

OPANA ER

+ ENDO PHARMS	5MG **	N021610 001	Jun 22, 2006
	5MG	N201655 001	Dec 09, 2011
	7.5MG **	N021610 005	Feb 29, 2008
	7.5MG	N201655 002	Dec 09, 2011
	10MG **	N021610 002	Jun 22, 2006
	10MG	N201655 003	Dec 09, 2011
	15MG **	N021610 006	Feb 29, 2008
	15MG	N201655 004	Dec 09, 2011
	20MG **	N021610 003	Jun 22, 2006
	20MG	N201655 005	Dec 09, 2011
	30MG **	N021610 007	Feb 29, 2008
	30MG	N201655 006	Dec 09, 2011
	40MG **	N021610 004	Jun 22, 2006
	40MG	N201655 007	Dec 09, 2011

OXYMORPHONE HYDROCHLORIDE

ACTAVIS ELIZABETH

	5MG	A079046 003	Jul 11, 2013
	7.5MG	A079046 001	Dec 13, 2010
	10MG	A079046 004	Jul 11, 2013
	15MG	A079046 002	Dec 13, 2010
	20MG	A079046 005	Jul 11, 2013
	30MG	A079046 006	Jul 11, 2013
	40MG	A079046 007	Jul 11, 2013

HIKMA

	5MG	A200822 002	Jul 15, 2013
	7.5MG	A200822 003	Jul 15, 2013
	10MG	A200822 004	Jul 15, 2013
	15MG	A200822 005	Jul 15, 2013
	20MG	A200822 006	Jul 15, 2013
	30MG	A200822 007	Jul 15, 2013
	40MG	A200822 001	Jul 15, 2013

PAR PHARM

	5MG	A200792 001	Oct 24, 2014
	7.5MG	A200792 002	Oct 24, 2014
	10MG	A200792 003	Oct 24, 2014
	15MG	A200792 004	Oct 24, 2014

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

OXYMORPHONE HYDROCHLORIDETABLET, EXTENDED RELEASE;ORAL
OXYMORPHONE HYDROCHLORIDE

	20MG	A200792 005	Oct 24, 2014
	30MG	A200792 006	Oct 24, 2014
	40MG	A200792 007	Oct 24, 2014
SPECGX LLC	5MG	A202946 001	Jun 27, 2014
	7.5MG	A202946 002	Jun 27, 2014
	10MG	A202946 003	Jun 27, 2014
	15MG	A202946 004	Jun 27, 2014
	20MG	A202946 005	Jun 27, 2014
	30MG	A202946 006	Jun 27, 2014
	40MG	A202946 007	Jun 27, 2014
SUN PHARM INDS LTD	5MG	A203506 001	Apr 24, 2015
	7.5MG	A203506 002	Apr 24, 2015
	10MG	A203506 003	Apr 24, 2015
	15MG	A203506 004	Apr 24, 2015
	20MG	A203506 005	Apr 24, 2015
	30MG	A203506 006	Apr 24, 2015
	40MG	A203506 007	Apr 24, 2015

OXYPHENBUTAZONE

TABLET;ORAL

OXYPHENBUTAZONE

WATSON LABS

100MG

A088399 001 Sep 17, 1984

TANDEARIL

NOVARTIS

100MG

N012542 004 Sep 03, 1982

OXYPHENCYCLIMINE HYDROCHLORIDE

TABLET;ORAL

DARICON

PFIZER

10MG

N011612 001

OXYPHENONIUM BROMIDE

TABLET;ORAL

ANTRENYL

NOVARTIS

5MG

N008492 002

OXYTETRACYCLINE

TABLET;ORAL

TERRAMYCIN

PFIZER

250MG

N050287 001

OXYTETRACYCLINE CALCIUM

SYRUP;ORAL

TERRAMYCIN

PFIZER

EQ 125MG BASE/5ML

A060595 001

OXYTETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

OXY-KESSO-TETRA

FERRANTE

EQ 250MG BASE

A060179 001

OXYTETRACYCLINE HYDROCHLORIDE

HIKMA

EQ 250MG BASE

A060770 001

IMPAX LABS

EQ 250MG BASE

A060760 001

PROTER

EQ 250MG BASE

A060869 001

PUREPAC PHARM

EQ 250MG BASE

A060634 001

TERRAMYCIN

PFIZER

EQ 125MG BASE

N050286 001

EQ 250MG BASE

N050286 002

INJECTABLE;INJECTION

TERRAMYCIN

PFIZER

EQ 250MG BASE/VIAL

A060586 001

EQ 500MG BASE/VIAL

A060586 002

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

TERRAMYCIN W/ POLYMYXIN B SULFATE

CASPER PHARMA LLC

EQ 5MG BASE/GM;10,000 UNITS/GM

N061015 001

OINTMENT;OTIC

TERRAMYCIN W/ POLYMYXIN

PFIZER

EQ 5MG BASE/GM;10,000 UNITS/GM

A061841 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

TABLET; VAGINAL

TERRAMYCIN-POLYMYXIN

PFIZER

EQ 100MG BASE;100,000 UNITS

A061009 001

OXYTOCIN

INJECTABLE; INJECTION

OXYTOCIN

DR REDDYS

10USP UNITS/ML (10USP UNITS/ML)

A077453 001 Jan 24, 2008

100USP UNITS/10ML (10USP UNITS/ML)

A077453 002 Jan 24, 2008

OXYTOCIN 10 USP UNITS IN DEXTROSE 5%

+ ABBOTT

1USP UNITS/100ML **

N019185 004 Mar 29, 1985

+

2USP UNITS/100ML **

N019185 003 Mar 29, 1985

OXYTOCIN 20 USP UNITS IN DEXTROSE 5%

+ ABBOTT

2USP UNITS/100ML **

N019185 002 Mar 29, 1985

OXYTOCIN 5 USP UNITS IN DEXTROSE 5%

+ ABBOTT

1USP UNITS/100ML **

N019185 001 Mar 29, 1985

SYNTOCINON

NOVARTIS

10USP UNITS/ML

N018245 001

SOLUTION; NASAL

SYNTOCINON

RTRX

40USP UNITS/ML

N012285 001

PACLITAXEL

INJECTABLE; INJECTION

PACLITAXEL

ACCORD HLTHCARE

6MG/ML

A075436 001 Nov 12, 2004

6MG/ML

A205720 001 Aug 17, 2018

HOSPIRA

6MG/ML

A076233 001 Aug 01, 2002

MYLAN

6MG/ML

A075278 001 Jan 25, 2002

PLIVA LACHEMA

6MG/ML

A077413 001 Mar 12, 2008

SANDOZ INC

6MG/ML

A078167 001 Dec 26, 2007

TEVA PHARMS USA

6MG/ML

A075297 001 Jan 25, 2002

TAXOL

+ HQ SPCLT PHARMA

6MG/ML

N020262 001 Dec 29, 1992

PALIPERIDONE

TABLET, EXTENDED RELEASE; ORAL

INVEGA

+ JANSSEN PHARMS

12MG **

N021999 004 Dec 19, 2006

PALONOSETRON HYDROCHLORIDE

CAPSULE; ORAL

ALOXI

+ HELSINN HLTHCARE

EQ 0.5MG BASE **

N022233 001 Aug 22, 2008

INJECTABLE; INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

DR REDDYS LABS LTD

EQ 0.075MG BASE/1.5ML (EQ 0.05MG
BASE/ML)

A201533 001 Apr 21, 2016

SOLUTION; INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

DR REDDYS LABS LTD

EQ 0.075MG BASE/1.5ML (EQ 0.05MG
BASE/ML)

N203050 001 Mar 01, 2016

EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)

N203050 002 Mar 01, 2016

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

AREZIA

+ NOVARTIS

30MG/VIAL **

N020036 001 Oct 31, 1991

60MG/VIAL

N020036 003 May 06, 1993

90MG/VIAL

N020036 004 May 06, 1993

PAMIDRONATE DISODIUM

AESGEN

30MG/VIAL

A075594 001 May 06, 2002

90MG/VIAL

A075594 002 May 06, 2002

AM REGENT

30MG/10ML (3MG/ML)

A078942 001 Jul 25, 2008

90MG/10ML (9MG/ML)

A078942 002 Jul 25, 2008

FRESENIUS KABI USA

30MG/VIAL

A075773 001 May 06, 2002

30MG/10ML (3MG/ML)

A076207 001 May 17, 2002

90MG/VIAL

A075773 002 May 06, 2002

90MG/10ML (9MG/ML)

A076207 002 May 17, 2002

MN PHARMS

30MG/VIAL

A078300 001 Mar 10, 2009

90MG/VIAL

A078300 002 Mar 10, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

PAMIDRONATE DISODIUM

SUN PHARMA GLOBAL	30MG/VIAL	A077703 001	Dec 24, 2008
	90MG/VIAL	A077703 002	Dec 24, 2008
TEVA PHARMS USA	30MG/10ML (3MG/ML)	A076153 001	Mar 27, 2002
	90MG/10ML (9MG/ML)	A076153 002	Mar 27, 2002

PANCURONIUM BROMIDE

INJECTABLE; INJECTION

PANCURONIUM BROMIDE

ELKINS SINN	1MG/ML	A072058 001	Mar 23, 1988
	2MG/ML	A072059 001	Mar 23, 1988
	2MG/ML	A072060 001	Mar 23, 1988
HOSPIRA	2MG/ML	A072321 001	Jan 19, 1989
IGI LABS INC	1MG/ML	A072210 001	Mar 31, 1988
	2MG/ML	A072211 001	Mar 31, 1988
	2MG/ML	A072212 001	Mar 31, 1988
	2MG/ML	A072213 001	Mar 31, 1988
PAVULON			
+ ORGANON USA INC	1MG/ML **	N017015 002	
+	2MG/ML **	N017015 001	

PANTOPRAZOLE SODIUM

INJECTABLE; IV (INFUSION)

PANTOPRAZOLE SODIUM

MYLAN LABS LTD	EQ 40MG BASE/VIAL	A208580 001	May 04, 2018
TABLET, DELAYED RELEASE; ORAL			
PANTOPRAZOLE SODIUM			
MACLEODS PHARMS LTD	EQ 20MG BASE	A200821 001	Feb 16, 2012
	EQ 40MG BASE	A200821 002	Feb 16, 2012
SUN PHARM	EQ 20MG BASE	A077058 001	Sep 10, 2007
	EQ 40MG BASE	A077058 002	Sep 10, 2007
SUN PHARM INDS LTD	EQ 20MG BASE	A200794 001	May 02, 2012
	EQ 40MG BASE	A200794 002	May 02, 2012
TEVA	EQ 20MG BASE	A077056 001	Aug 02, 2007
	EQ 40MG BASE	A077056 002	Aug 02, 2007

PARAMETHADIONE

CAPSULE; ORAL

PARADIONE

ABBVIE	150MG	N006800 003	
	300MG	N006800 001	

SOLUTION; ORAL

PARADIONE

ABBVIE	300MG/ML	N006800 002	
--------	----------	-------------	--

PARAMETHASONE ACETATE

TABLET; ORAL

HALDRONE

LILLY	1MG	N012772 005	
	2MG	N012772 006	

PARGYLINE HYDROCHLORIDE

TABLET; ORAL

EUTONYL

ABBOTT	10MG	N013448 002	
	25MG	N013448 003	
	50MG	N013448 004	

PARICALCITOL

CAPSULE; ORAL

PARICALCITOL

LOTUS PHARM CO LTD	1MCG	A206710 001	Feb 24, 2016
	2MCG	A206710 002	Feb 24, 2016
	4MCG	A206710 003	Feb 24, 2016
ZEMPLAR			
+ ABBVIE	4MCG **	N021606 003	May 26, 2005

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PAROMOMYCIN SULFATE

CAPSULE; ORAL

HUMATIN

KING PFIZER	EQ 250MG BASE	A062310	001
PARKE DALE	EQ 250MG BASE	A060521	001

SYRUP; ORAL

HUMATIN

PARKE DAVIS	EQ 125MG BASE/5ML	A060522	001
-------------	-------------------	---------	-----

PAROXETINE HYDROCHLORIDE

CAPSULE; ORAL

PAXIL

+	APOTEX TECHNOLOGIES	EQ 10MG BASE **	N020885	001	Oct 09, 1998
+		EQ 20MG BASE **	N020885	002	Oct 09, 1998
+		EQ 30MG BASE **	N020885	003	Oct 09, 1998
+		EQ 40MG BASE **	N020885	004	Oct 09, 1998

SUSPENSION; ORAL

PAROXETINE HYDROCHLORIDE

APOTEX INC	EQ 10MG BASE/5ML	A077395	001	Dec 05, 2006
------------	------------------	---------	-----	--------------

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

JUBILANT GENERICS	EQ 10MG BASE	A205528	001	Nov 27, 2015
	EQ 20MG BASE	A205528	002	Nov 27, 2015
	EQ 30MG BASE	A205528	003	Nov 27, 2015
	EQ 40MG BASE	A205528	004	Nov 27, 2015
MYLAN PHARMS INC	EQ 10MG BASE	A075716	001	Mar 08, 2004
	EQ 20MG BASE	A075716	002	Mar 08, 2004
	EQ 30MG BASE	A075716	003	Mar 08, 2004
	EQ 40MG BASE	A075716	004	Mar 08, 2004
ROXANE	EQ 10MG BASE	A078026	001	Jun 29, 2007
	EQ 20MG BASE	A078026	002	Jun 29, 2007
	EQ 30MG BASE	A078026	003	Jun 29, 2007
	EQ 40MG BASE	A078026	004	Jun 29, 2007
SUN PHARM INDS INC	EQ 10MG BASE	A078194	001	Jun 29, 2007
	EQ 20MG BASE	A078194	002	Jun 29, 2007
	EQ 30MG BASE	A078194	003	Jun 29, 2007
	EQ 40MG BASE	A078194	004	Jun 29, 2007
TEVA PHARMS	EQ 10MG BASE	A077082	001	Jun 29, 2007
	EQ 20MG BASE	A077082	002	Jun 29, 2007
	EQ 30MG BASE	A077082	003	Jun 29, 2007
	EQ 40MG BASE	A077082	004	Jun 29, 2007
UPSHER SMITH LABS	EQ 10MG BASE	A075566	001	Mar 08, 2004
	EQ 20MG BASE	A075566	002	Mar 08, 2004
	EQ 30MG BASE	A075566	003	Mar 08, 2004
	EQ 40MG BASE	A075566	004	Mar 08, 2004
PAXIL				
APOTEX TECHNOLOGIES	EQ 50MG BASE	N020031	004	Dec 29, 1992

PAZOPANIB HYDROCHLORIDE

TABLET; ORAL

VOTRIENT

+	NOVARTIS	EQ 400MG BASE	N022465	002	Oct 19, 2009
---	----------	---------------	---------	-----	--------------

PEGAPTANIB SODIUM

INJECTABLE; INTRAVITREAL

MACUGEN

+	VALEANT PHARMS LLC	EQ 0.3MG ACID/0.09ML	N021756	001	Dec 17, 2004
---	--------------------	----------------------	---------	-----	--------------

PEGINESATIDE ACETATE

SOLUTION; INTRAVENOUS, SUBCUTANEOUS

OMONTYS

TAKEDA PHARMS USA	EQ 10MG BASE/ML (EQ 10MG BASE/ML)	N202799	007	Mar 27, 2012
	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N202799	008	Mar 27, 2012

OMONTYS PRESERVATIVE FREE

TAKEDA PHARMS USA	EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML)	N202799	001	Mar 27, 2012
	EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML)	N202799	002	Mar 27, 2012
	EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N202799	003	Mar 27, 2012
	EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML)	N202799	004	Mar 27, 2012
	EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML)	N202799	005	Mar 27, 2012
	EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML)	N202799	006	Mar 27, 2012

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PEMIROLAST POTASSIUM

SOLUTION/DROPS;OPHTHALMIC

ALAMAST

SANTEN 0.1% N021079 001 Sep 24, 1999

PEMOLINE

TABLET;ORAL

CYLERT

ABBOTT 18.75MG N016832 001

37.5MG N016832 002

75MG N016832 003

PEMOLINE

ACTAVIS ELIZABETH 18.75MG A075595 001 Feb 28, 2000

37.5MG A075595 002 Feb 28, 2000

75MG A075595 003 Feb 28, 2000

FOSUN PHARMA 18.75MG A075286 001 Dec 27, 1999

37.5MG A075286 002 Jun 30, 1999

75MG A075286 003 Jun 30, 1999

MALLINCKRODT 18.75MG A075726 003 Mar 30, 2001

37.5MG A075726 002 Mar 30, 2001

75MG A075726 001 Mar 30, 2001

TEVA PHARMS 18.75MG A075030 003 Feb 22, 2000

37.5MG A075030 001 Jan 29, 1999

75MG A075030 002 Jan 29, 1999

VINTAGE PHARMS 18.75MG A075328 001 Apr 19, 2000

37.5MG A075328 002 Apr 19, 2000

75MG A075328 003 Apr 19, 2000

WATSON LABS 18.75MG A075287 001 Jun 13, 2001

37.5MG A075287 002 Sep 18, 2000

75MG A075287 003 Sep 18, 2000

TABLET, CHEWABLE;ORAL

CYLERT

ABBOTT 37.5MG N017703 001

PEMOLINE

ACTAVIS ELIZABETH 37.5MG A075678 001 Jul 26, 2000

TEVA PHARMS 37.5MG A075555 001 Feb 18, 2000

PENBUTOLOL SULFATE

TABLET;ORAL

LEVATOL

+ AUXILIUM PHARMS LLC 10MG ** N018976 001 Dec 30, 1987

+ 20MG ** N018976 004 Jan 05, 1989

PENICILLAMINE

CAPSULE;ORAL

CUPRIMINE

VALEANT PHARMS INTL 125MG N019853 002

TABLET;ORAL

PENICILLAMINE

TEVA PHARMS USA 250MG A211497 001 Feb 13, 2020

PENICILLIN G BENZATHINE

INJECTABLE;INJECTION

BICILLIN L-A

+ KING PHARMS LLC 300,000 UNITS/ML N050141 003

WYETH AYERST 300,000 UNITS/ML N050131 001

PERMAPEN

CASPER PHARMA LLC 600,000 UNITS/ML N060014 001

SUSPENSION;ORAL

BICILLIN

WYETH AYERST 300,000 UNITS/5ML N050126 002

TABLET;ORAL

BICILLIN

WYETH AYERST 200,000 UNITS N050128 001

PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE

INJECTABLE;INJECTION

BICILLIN C-R

+ KING PHARMS LLC 150,000 UNITS/ML;150,000 UNITS/ML N050138 002

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PENICILLIN G POTASSIUM

FOR SOLUTION;ORAL

PENICILLIN

TEVA	200,000 UNITS/5ML	A060307 002
	400,000 UNITS/5ML	A060307 004

PENICILLIN G POTASSIUM

MYLAN	200,000 UNITS/5ML	A060752 003
	250,000 UNITS/5ML	A060752 002
	400,000 UNITS/5ML	A060752 001
PUREPAC PHARM	250,000 UNITS/5ML	A061740 001
	400,000 UNITS/5ML	A061740 002

PENICILLIN-2

TEVA	250,000 UNITS/5ML	A060307 003
------	-------------------	-------------

PENTIDS '200'

APOTHECON	200,000 UNITS/5ML	A062149 001
-----------	-------------------	-------------

PENTIDS '400'

APOTHECON	400,000 UNITS/5ML	A062149 002
-----------	-------------------	-------------

PFIZERPEN G

PFIZER	400,000 UNITS/5ML	A060587 001
--------	-------------------	-------------

INJECTABLE;INJECTION

PENICILLIN G POTASSIUM

APOTHECON	1,000,000 UNITS/VIAL	A060362 001
-----------	----------------------	-------------

	5,000,000 UNITS/VIAL	A060362 003
--	----------------------	-------------

	10,000,000 UNITS/VIAL	A060362 004
--	-----------------------	-------------

	20,000,000 UNITS/VIAL	A060362 002
--	-----------------------	-------------

CONSOLIDATED PHARM	500,000 UNITS/VIAL	A060806 001
--------------------	--------------------	-------------

	1,000,000 UNITS/VIAL	A060806 002
--	----------------------	-------------

	5,000,000 UNITS/VIAL	A060806 003
--	----------------------	-------------

	10,000,000 UNITS/VIAL	A060806 004
--	-----------------------	-------------

LILLY	200,000 UNITS/VIAL	A060384 004
-------	--------------------	-------------

	500,000 UNITS/VIAL	A060384 003
--	--------------------	-------------

	1,000,000 UNITS/VIAL	A060384 002
--	----------------------	-------------

	5,000,000 UNITS/VIAL	A060384 001
--	----------------------	-------------

	20,000,000 UNITS/VIAL	A060384 005
--	-----------------------	-------------

	20,000,000 UNITS/VIAL	A060601 001
--	-----------------------	-------------

PARKE DAVIS	1,000,000 UNITS/VIAL	A062003 001
-------------	----------------------	-------------

	5,000,000 UNITS/VIAL	A062003 002
--	----------------------	-------------

PFIZER	20,000,000 UNITS/VIAL	A060074 003
--------	-----------------------	-------------

SANDOZ	1,000,000 UNITS/VIAL **	A065079 001	Aug 30, 2002
--------	-------------------------	-------------	--------------

WATSON LABS INC	1,000,000 UNITS/VIAL	A062991 001	Sep 13, 1988
-----------------	----------------------	-------------	--------------

	5,000,000 UNITS/VIAL	A062991 002	Sep 13, 1988
--	----------------------	-------------	--------------

	10,000,000 UNITS/VIAL	A062991 003	Sep 13, 1988
--	-----------------------	-------------	--------------

	20,000,000 UNITS/VIAL	A062991 004	Sep 13, 1988
--	-----------------------	-------------	--------------

PFIZERPEN

PFIZER	1,000,000 UNITS/VIAL **	A060657 001
--------	-------------------------	-------------

TABLET;ORAL

PENICILLIN G POTASSIUM

APOTHECON	250,000 UNITS	A060392 003
-----------	---------------	-------------

IVAX SUB TEVA PHARMS	400,000 UNITS	A060073 004
----------------------	---------------	-------------

LILLY	250,000 UNITS	A060403 001
-------	---------------	-------------

MYLAN	200,000 UNITS	A060781 001
-------	---------------	-------------

	250,000 UNITS	A060781 002
--	---------------	-------------

	400,000 UNITS	A060781 003
--	---------------	-------------

	500,000 UNITS	A060781 005
--	---------------	-------------

	800,000 UNITS	A060781 004
--	---------------	-------------

PUREPAC PHARM	200,000 UNITS	A061588 001
---------------	---------------	-------------

	250,000 UNITS	A061588 002
--	---------------	-------------

	400,000 UNITS	A061588 003
--	---------------	-------------

TEVA	200,000 UNITS	A060306 001
------	---------------	-------------

	250,000 UNITS	A060306 002
--	---------------	-------------

	400,000 UNITS	A060306 003
--	---------------	-------------

	500,000 UNITS	A060306 004
--	---------------	-------------

WYETH AYERST	200,000 UNITS	A060413 001
--------------	---------------	-------------

	250,000 UNITS	A060413 002
--	---------------	-------------

	400,000 UNITS	A060413 003
--	---------------	-------------

PENTIDS '200'

APOTHECON	200,000 UNITS	A062155 001
-----------	---------------	-------------

PENTIDS '250'

APOTHECON	250,000 UNITS	A062155 002
-----------	---------------	-------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PENICILLIN G POTASSIUM

TABLET; ORAL

PENTIDS '400'

APOTHECON	400,000 UNITS	A060392 004
	400,000 UNITS	A062155 003

PENTIDS '800'

APOTHECON	800,000 UNITS	A060392 005
	800,000 UNITS	A062155 004

PFIZERPEN G

PFIZER	50,000 UNITS	A060075 001
	100,000 UNITS	A060075 002
	200,000 UNITS	A060075 003
	250,000 UNITS	A060075 004
	400,000 UNITS	A060075 005
	800,000 UNITS	A060075 006

PENICILLIN G PROCAINE

INJECTABLE; INJECTION

DURACILLIN A.S.

LILLY	300,000 UNITS/ML	A060093 001
-------	------------------	-------------

PENICILLIN G PROCAINE

CONSOLIDATED PHARM	300,000 UNITS/ML	A060800 001
	600,000 UNITS/1.2ML	A060800 002
PARKE DAVIS	300,000 UNITS/ML	A062029 001
PFIZER	300,000 UNITS/VIAL	A060099 001
	1,500,000 UNITS/VIAL	A060099 002

PFIZERPEN-AS

PFIZER	300,000 UNITS/ML	A060286 001
	600,000 UNITS/ML	A060286 002

PENICILLIN G SODIUM

INJECTABLE; INJECTION

PENICILLIN G SODIUM

BRISTOL MYERS SQUIBB	5,000,000 UNITS/VIAL	A061935 001
COPANOS	5,000,000 UNITS/VIAL	A061051 001
PHARMACIA AND UPJOHN	1,000,000 UNITS/VIAL	A061046 001

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

PENICILLIN G SODIUM

WATSON LABS INC	5,000,000 UNITS/VIAL	A063014 001	Sep 13, 1988
-----------------	----------------------	-------------	--------------

PENICILLIN V

FOR SUSPENSION; ORAL

V-CILLIN

LILLY	125MG/0.6ML	A060002 001
-------	-------------	-------------

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL

BEEPEN-VK

GLAXOSMITHKLINE	EQ 125MG BASE/5ML	A062270 001
	EQ 250MG BASE/5ML	A062270 002

BETAPEN-VK

APOTHECON	EQ 125MG BASE/5ML	A061149 001
	EQ 250MG BASE/5ML	A061149 002

LEDERCILLIN VK

LEDERLE	EQ 125MG BASE/5ML	A060136 001
	EQ 250MG BASE/5ML	A060136 002

PEN-VEE K

WYETH AYERST	EQ 125MG BASE/5ML	A060007 001
	EQ 250MG BASE/5ML	A060007 002

PENAPAR-VK

PARKE DAVIS	EQ 125MG BASE/5ML	A062002 001
	EQ 250MG BASE/5ML	A062002 002

PENICILLIN V POTASSIUM

BELCHER PHARMS	EQ 125MG BASE/5ML	A061529 001
	EQ 250MG BASE/5ML	A061529 002
MYLAN	EQ 125MG BASE/5ML	A061624 002
	EQ 250MG BASE/5ML	A061624 001
PUREPAC PHARM	EQ 125MG BASE/5ML	A061758 001
	EQ 250MG BASE/5ML	A061758 002

PFIZERPEN VK

PFIZER	EQ 125MG BASE/5ML	A061815 001
--------	-------------------	-------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PENICILLIN V POTASSIUM

FOR SOLUTION;ORAL

PFIZERPEN VK

EQ 250MG BASE/5ML A061815 002

V-CILLIN K

LILLY

EQ 125MG BASE/5ML A060004 001

EQ 250MG BASE/5ML A060004 002

VEETIDS

APOTHECON

EQ 125MG BASE/5ML A061410 001

EQ 250MG BASE/5ML A061410 002

VEETIDS '125'

APOTHECON

EQ 125MG BASE/5ML A061206 001

EQ 125MG BASE/5ML A062153 001

VEETIDS '250'

APOTHECON

EQ 250MG BASE/5ML A061206 002

EQ 250MG BASE/5ML A062153 002

TABLET;ORAL

BEEPEN-VK

GLAXOSMITHKLINE

EQ 250MG BASE A062273 001

EQ 500MG BASE A062273 002

BETAPEN-VK

BRISTOL

EQ 250MG BASE A061150 001

EQ 500MG BASE A061150 002

LEDERCILLIN VK

LEDERLE

EQ 250MG BASE A060134 001

EQ 500MG BASE A060134 002

PEN-VEE K

WYETH AYERST

EQ 125MG BASE A060006 001

EQ 250MG BASE A060006 002

EQ 500MG BASE A060006 003

PENAPAR-VK

PARKE DAVIS

EQ 250MG BASE A062001 001

EQ 500MG BASE A062001 002

PENICILLIN V POTASSIUM

BELCHER PHARMS

EQ 250MG BASE A061528 001

EQ 500MG BASE A061528 002

IVAX SUB TEVA PHARMS

EQ 125MG BASE A060518 001

EQ 250MG BASE A060518 002

EQ 500MG BASE A060518 003

MYLAN

EQ 250MG BASE A061530 001

EQ 500MG BASE A061530 002

PUREPAC PHARM

EQ 125MG BASE A061571 001

EQ 250MG BASE A061571 002

EQ 500MG BASE A061571 003

PFIZERPEN VK

PFIZER

EQ 250MG BASE A061836 001

EQ 500MG BASE A061836 002

UTICILLIN VK

PHARMACIA AND UPJOHN

EQ 250MG BASE A061651 001

EQ 500MG BASE A061651 002

V-CILLIN K

LILLY

EQ 125MG BASE ** A060003 001

EQ 250MG BASE ** A060003 002

EQ 500MG BASE ** A060003 003

VEETIDS

APOTHECON

EQ 250MG BASE A061411 001

EQ 500MG BASE A061411 002

VEETIDS '250'

APOTHECON

EQ 250MG BASE A061164 001

EQ 250MG BASE A062156 002

VEETIDS '500'

APOTHECON

EQ 500MG BASE A061164 002

EQ 500MG BASE A062156 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PENTAGASTRIN

INJECTABLE; INJECTION

PEPTAVLON

+ WYETH AYERST 0.25MG/ML ** N017048 001

PENTAMIDINE ISETHIONATE

FOR SOLUTION; INHALATION

NEBUPENT

FRESENIUS KABI USA 600MG/VIAL N019887 002 Mar 22, 1996

INJECTABLE; INJECTION

PENTACARINAT

ARMOUR PHARM 300MG/VIAL A073447 001 Apr 28, 1994

PENTAMIDINE ISETHIONATE

BAXTER HLTHCARE 300MG/VIAL A073617 001 Dec 18, 1995

HOSPIRA 300MG/VIAL A073479 001 Jun 30, 1992

WATSON LABS 300MG/VIAL A074303 001 Aug 17, 1995

PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

TALWIN 50

SANOFI AVENTIS US EQ 50MG BASE N016732 001

PENTAZOCINE LACTATE

INJECTABLE; INJECTION

TALWIN

+ HOSPIRA EQ 30MG BASE/ML N016194 001

PENTETATE CALCIUM TRISODIUM

SOLUTION; INHALATION, INTRAVENOUS

PENTETATE CALCIUM TRISODIUM

+ HAMELN EQ 1GM BASE/5ML (EQ 200MG BASE/ML) ** N021749 001 Aug 11, 2004

PENTETATE CALCIUM TRISODIUM YB-169

INJECTABLE; INJECTION

YTTERBIUM YB 169 DTPA

3M 2mCi/ML N017518 001

PENTETATE ZINC TRISODIUM

SOLUTION; INHALATION, INTRAVENOUS

PENTETATE ZINC TRISODIUM

+ HAMELN PHARMA PLUS EQ 1GM BASE/5ML (EQ 200MG BASE/ML) ** N021751 001 Aug 11, 2004

PENTOBARBITAL

ELIXIR; ORAL

NEMBUTAL

AKORN 18.2MG/5ML A083244 001

PENTOBARBITAL SODIUM

CAPSULE; ORAL

NEMBUTAL SODIUM

AKORN 30MG A084095 001

50MG A084093 001

100MG A083245 001

PENTOBARBITAL SODIUM

LANNETT 50MG A085937 001

100MG A085915 001

VITARINE 100MG A083284 001

WHITEWORTH TOWN PLSN 100MG A083338 001

SODIUM PENTOBARBITAL

ANABOLIC 100MG A084590 001

ELKINS SINN 100MG A083368 001

EVERYLIFE 100MG A083259 001

HALSEY 100MG A084677 001

IVAX SUB TEVA PHARMS 50MG A083461 001

100MG A083461 002

PARKE DAVIS 100MG A084156 001

PERRIGO 100MG A084560 001

PUREPAC PHARM 100MG A083301 001

VALEANT PHARM INTL 100MG A083264 001

WATSON LABS 100MG A085791 001

WYETH AYERST 100MG A083239 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PENTOBARBITAL SODIUM

INJECTABLE; INJECTION

PENTOBARBITAL SODIUM

ELKINS SINN

50MG/ML

A083270 001

SODIUM PENTOBARBITAL

WYETH AYERST

50MG/ML

A083261 001

SUPPOSITORY; RECTAL

NEMBUTAL

AKORN

30MG

A083247 001 Jan 25, 1982

60MG

A083247 002 Jan 25, 1982

120MG

A083247 003 Jan 25, 1982

200MG

A083247 004 Jan 25, 1982

TABLET; ORAL

PENTOBARBITAL SODIUM

VITARINE

100MG

A083285 001

SODIUM PENTOBARBITAL

NEXGEN PHARMA INC

100MG

A084238 001

PENTOLINIUM TARTRATE

INJECTABLE; INJECTION

ANSOLYSEN

WYETH AYERST

10MG/ML

N009372 001

PENTOSTATIN

INJECTABLE; INJECTION

PENTOSTATIN

MYLAN INSTITUTIONAL

10MG/VIAL

A203554 001 Sep 19, 2014

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

PENTOXIFYLLINE

ANI PHARMS INC

400MG

A074878 001 Jul 09, 1997

400MG

A075107 001 Sep 04, 1998

400MG

A075199 001 Sep 03, 1999

HERITAGE PHARMS INC

400MG

A074877 001 Jul 08, 1997

IMPAX LABS

400MG

A075093 001 Aug 10, 1999

MYLAN

400MG

A074425 001 Jul 08, 1997

PLIVA

400MG

A074874 001 May 25, 1999

TRENAL

+ US PHARM HOLDINGS

400MG **

N018631 001 Aug 30, 1984

PERFLUBRON

LIQUID; ORAL

IMAGENT

ALLIANCE PHARM

100%

N020091 001 Aug 13, 1993

PERFLUOROPOLYMETHYLISOPROPYL ETHER; POLYTETRAFLUOROETHYLENE

PASTE; TOPICAL

SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS

US ARMY

50%;50%

N021084 001 Feb 17, 2000

PERGOLIDE MESYLATE

TABLET; ORAL

PERGOLIDE MESYLATE

IVAX SUB TEVA PHARMS

EQ 0.05MG BASE

A076094 001 Sep 04, 2003

EQ 0.25MG BASE

A076094 002 Sep 04, 2003

EQ 1MG BASE

A076094 003 Sep 04, 2003

PAR PHARM

EQ 0.05MG BASE

A076061 001 Nov 27, 2002

EQ 0.25MG BASE

A076061 002 Nov 27, 2002

EQ 1MG BASE

A076061 003 Nov 27, 2002

PERMAX

VALEANT PHARM INTL

EQ 0.05MG BASE

N019385 001 Dec 30, 1988

EQ 0.25MG BASE

N019385 002 Dec 30, 1988

EQ 1MG BASE

N019385 003 Dec 30, 1988

PERINDOPRIL ERBUMINE

TABLET; ORAL

ACEON

+ SYMPLMED PHARMS LLC

2MG

N020184 001 Dec 30, 1993

+

4MG

N020184 002 Dec 30, 1993

+

8MG

N020184 003 Dec 30, 1993

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PERINDOPRIL ERBUMINE

TABLET; ORAL

PERINDOPRIL ERBUMINE

ANI PHARMS INC	2MG	A078138 001	Nov 10, 2009
	4MG	A078138 002	Nov 10, 2009
	8MG	A078138 003	Nov 10, 2009
APOTEX	2MG	A090463 001	Aug 30, 2010
	4MG	A090463 002	Aug 30, 2010
	8MG	A090463 003	Aug 30, 2010
LUPIN LTD	2MG	A078263 001	Jan 27, 2010
	4MG	A078263 002	Jan 27, 2010
	8MG	A078263 003	Jan 27, 2010

PERMETHRIN

CREAM; TOPICAL

ELIMITE

+ MYLAN

5%

N019855 001 Aug 25, 1989

LOTION; TOPICAL

NIX

GLAXOSMITHKLINE

1%

N019435 001 Mar 31, 1986

PERPHENAZINE

CONCENTRATE; ORAL

PERPHENAZINE

PHARM ASSOC

16MG/5ML

A040360 001 May 25, 2001

TRILAFON

SCHERING

16MG/5ML

N011557 001

INJECTABLE; INJECTION

TRILAFON

SCHERING

5MG/ML

N011213 002

SYRUP; ORAL

TRILAFON

SCHERING

2MG/5ML

N011294 002

TABLET; ORAL

PERPHENAZINE

ANI PHARMS INC

2MG

A089707 001 Sep 10, 1987

4MG

A089708 001 Sep 10, 1987

8MG

A089456 001 Sep 10, 1987

16MG

A089457 001 Sep 10, 1987

TRILAFON

+ SCHERING

2MG **

N010775 001

+

4MG **

N010775 002

+

8MG **

N010775 003

+

16MG **

N010775 004

TABLET, EXTENDED RELEASE; ORAL

TRILAFON

SCHERING

8MG

N011361 002

PHENACEMIDE

TABLET; ORAL

PHENURONE

+ ABBVIE

500MG **

N007707 001

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE

TABLET; ORAL

AZO GANTANOL

+ ROCHE

100MG; 500MG **

N013294 001 Sep 10, 1987

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PHENAZOPYRIDINE HYDROCHLORIDE

ABLE

200MG, N/A, N/A; N/A, 800MG, 160MG

N021105 001 Jun 26, 2001

PHENAZOPYRIDINE HYDROCHLORIDE; SULFISOXAZOLE

TABLET; ORAL

AZO GANTRISIN

+ ROCHE

50MG; 500MG **

N019358 001 Aug 31, 1990

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PHENDIMETRAZINE TARTRATE

CAPSULE; ORAL

PHENAZINE				
MAST MM	35MG	A086523	001	
	35MG	A086524	001	
	35MG	A086525	001	
PHENDIMETRAZINE TARTRATE				
SANDOZ	35MG	A085633	001	
	35MG	A085694	001	
	35MG	A085702	001	
VIRTUS PHARMS	35MG	A085695	001	
VITARINE	35MG	A085634	001	
	35MG	A085645	001	
	35MG	A085670	001	
	35MG	A086403	001	
	35MG	A086408	001	
	35MG	A086410	001	
	35MG	A087424	001	
SPRX-3				
SOLVAY	35MG	A085897	001	
STATOBEX				
TEVA	35MG	A085507	001	
X-TROZINE				
SHIRE RICHWOOD	35MG	A087394	001	Sep 22, 1982
CAPSULE, EXTENDED RELEASE; ORAL				
BONTRIL				
VALEANT	105MG	A088021	001	Sep 21, 1982
MELFIAT-105				
NUMARK	105MG	A087487	001	Oct 13, 1982
PHENDIMETRAZINE TARTRATE				
GRAHAM DM	105MG	A087214	001	May 26, 1982
	105MG	A088020	001	Aug 16, 1982
	105MG	A088028	001	Aug 16, 1982
	105MG	A088062	001	Sep 13, 1982
	105MG	A088063	001	Sep 10, 1982
	105MG	A088111	001	Oct 18, 1982
VIRTUS PHARMS	105MG	A087378	001	
SPRX-105				
NUMARK	105MG	A088024	001	Dec 22, 1982
X-TROZINE L.A.				
SHIRE RICHWOOD	105MG	A087371	001	Aug 24, 1982
TABLET; ORAL				
ADPHEN				
FERNDALE LABS	35MG	A083655	001	
ALPHAZINE				
SANDOZ	35MG	A085034	001	
CAM-METRAZINE				
ABC HOLDING	35MG	A085511	001	
CAMALL	35MG	A085756	001	
CHARTWELL RX	35MG	A083922	001	
	35MG	A085318	001	
	35MG	A085320	001	
	35MG	A085321	001	
DI-METREX				
PVT FORM	35MG	A085698	001	
MELFIAT				
NUMARK	35MG	A083790	002	
METRA				
FOREST PHARMS	35MG	A083754	001	
PHENAZINE				
MAST MM	35MG	A087305	001	
PHENAZINE-35				
ABC HOLDING	35MG	A085512	001	
PHENDIMETRAZINE TARTRATE				
BARR	35MG	A083644	001	
	35MG	A083684	001	
	35MG	A083686	001	
	35MG	A083687	001	
	35MG	A084831	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PHENDIMETRAZINE TARTRATE

TABLET;ORAL

PHENDIMETRAZINE TARTRATE

	35MG	A084834	001	
	35MG	A084835	001	
CHARTWELL RX	35MG	A085761	001	
	35MG	A085941	001	Jun 27, 1983
FERNDALE LABS	35MG	A086834	001	Sep 15, 1983
INWOOD LABS	35MG	A084740	001	
	35MG	A084741	001	
	35MG	A084742	001	
	35MG	A084743	001	
IVAX PHARMS	35MG	A085611	001	
	35MG	A085612	001	
IVAX SUB TEVA PHARMS	35MG	A083682	001	
KV PHARM	35MG	A084138	001	
	35MG	A084141	001	
	35MG	A085525	001	
MFG CHEMISTS	35MG	A085914	001	
NEXGEN PHARMA INC	35MG	A086020	001	
NOSTRUM LABS INC	35MG	A203600	001	Dec 27, 2017
NUMARK	35MG	A083790	001	
PVT FORM	35MG	A085199	001	
	35MG	A085697	001	
SANDOZ	35MG	A085402	001	
	35MG	A085830	001	
	35MG	A086370	001	
SOLVAY	35MG	A083993	001	
UPSHER SMITH LABS	35MG	A084399	001	
USL PHARMA	35MG	A083805	001	
	35MG	A084398	001	
VIRTUS PHARMS	35MG	A085497	001	
	35MG	A086365	001	
VITARINE	35MG	A085519	001	
	35MG	A086005	001	
	35MG	A086106	001	
WATSON LABS	35MG	A085767	001	
	35MG	A085768	001	
	35MG	A085770	001	
	35MG	A085773	001	
PLEGINE				
WYETH AYERST	35MG **	N012248	001	
STATOBEX				
TEVA	35MG	A086013	001	
STATOBEX-G				
TEVA	35MG	A085095	001	
X-TROZINE				
SHIRE RICHWOOD	35MG	A086550	001	
	35MG	A086551	001	
	35MG	A086552	001	
	35MG	A086553	001	
	35MG	A086554	001	

PHENINDIONE

TABLET;ORAL

HEDULIN

SANOFI AVENTIS US 50MG N008767 002

PHENMETRAZINE HYDROCHLORIDE

TABLET;ORAL

PRELUDIN

BOEHRINGER INGELHEIM 25MG N010460 005

TABLET, EXTENDED RELEASE;ORAL

PRELUDIN

BOEHRINGER INGELHEIM 50MG N011752 004

75MG N011752 003

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PHENPROCOUMONTABLET; ORAL
LIQUAMAR

ORGANON USA INC 3MG N011228 001

PHENSUXIMIDECAPSULE; ORAL
MILONTIN

PARKE DAVIS 500MG N008855 004

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

FASTIN

GLAXOSMITHKLINE 30MG ** N017352 001

OBESTIN-30

FERNDALE LABS 30MG A087144 001

OBY-TRIM

SHIRE RICHWOOD 30MG A087764 001 Mar 18, 1982

ONA-MAST

MAST MM 30MG A086511 001

30MG A086516 001

PHENTERMINE HYDROCHLORIDE

ABC HOLDING 30MG A085411 001

ABLE 15MG A040497 001 Mar 13, 2003

30MG A040403 001 Aug 30, 2001

30MG A040427 001 Aug 30, 2001

BARR 15MG A090591 001 Mar 18, 2010

30MG A090591 002 Mar 18, 2010

CAMALL 15MG A086735 001

30MG A087226 001

CHARTWELL RX 18.75MG A088576 001 May 23, 1984

30MG A085417 001

30MG A086732 002

30MG A087215 001

37.5MG A087915 001 Dec 22, 1983

37.5MG A087918 001 Dec 22, 1983

37.5MG A087930 001 Oct 14, 1983

37.5MG A088610 001 Jun 04, 1984

37.5MG A088611 001 Jun 04, 1984

37.5MG A088625 001 Aug 23, 1984

DURAMED PHARMS BARR 30MG A088948 001 Apr 25, 1986

ELITE LABS INC 15MG A040460 001 Jan 14, 2003

30MG A040227 001 Jun 18, 1997

30MG A040448 001 Jan 22, 2003

IVAX PHARMS 30MG A086329 001

LANNETT CO INC 30MG A091359 001 Jul 16, 2010

SANDOZ 30MG A087208 001

30MG A087223 001

37.5MG A088414 001 Oct 19, 1983

SUN PHARM INDUSTRIES 37.5MG A040527 001 Oct 23, 2003

TEVA 30MG A086911 001

30MG A087126 001

30MG A087777 001 Nov 01, 1985

30MG A088612 001 Apr 04, 1984

30MG A088613 001 Apr 09, 1984

30MG A088614 001 Apr 09, 1984

TG UNITED INC 30MG A040083 001 Mar 07, 1997

UPSHER SMITH LABS 30MG A084487 001 Apr 09, 1982

30MG A088430 001 Mar 27, 1984

USL PHARMA 30MG A088797 001 Dec 10, 1984

VITARINE 30MG A087202 001

30MG A087235 001

WATSON LABS 30MG A086740 001 Mar 21, 1985

TABLET; ORAL

ONA-MAST

MAST MM 8MG A086260 001

PHENTERMINE HYDROCHLORIDE

ABLE 37.5MG A040402 001 Aug 30, 2001

ACTAVIS ELIZABETH 37.5MG A040276 001 Nov 25, 1998

BARR 37.5MG A090470 001 Aug 31, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PHENTERMINE HYDROCHLORIDE

TABLET;ORAL

PHENTERMINE HYDROCHLORIDE			
CHARTWELL RX	8MG	A083923	001
	8MG	A085319	001
	37.5MG	A087805	001 Dec 06, 1982
	37.5MG	A088596	001 Apr 04, 1984
IVAX PHARMS	8MG	A085553	001
NOVAST LABS	37.5MG	A091451	001 Sep 21, 2012
SANDOZ	8MG	A085671	001
	8MG	A085689	001
SANDOZ INC	30MG	A088605	001 Sep 28, 1987
SUN PHARM INDS INC	37.5MG	A040790	001 Aug 21, 2007
USL PHARMA	8MG	A083804	001
	37.5MG	A088910	001 Jul 17, 1985
	37.5MG	A088917	001 Jul 17, 1985
VITARINE	8MG	A086453	001
	8MG	A086456	001
WATSON LABS	8MG	A085739	001
TORA			
SOLVAY	8MG	A084035	001
WILPO			
+ SANDOZ	8MG **	N012737	001
TABLET, ORALLY DISINTEGRATING;ORAL			
SUPRENZA			
CITIUS PHARMS	15MG **	N202088	001 Jun 13, 2011
	30MG **	N202088	002 Jun 13, 2011
	37.5MG **	N202088	003 Mar 27, 2012

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE;ORAL

IONAMIN			
UCB INC	EQ 15MG BASE **	N011613	004
	EQ 30MG BASE **	N011613	002
PHENTERMINE RESIN 30			
QUANTUM PHARMICS	EQ 30MG BASE	A089120	001 Feb 04, 1988
PHENTERMINE RESIN COMPLEX			
LANNETT CO INC	EQ 15MG BASE	A040872	001 Jul 28, 2011
	EQ 30MG BASE	A040872	002 Jul 28, 2011

PHENTOLAMINE MESYLATE

INJECTABLE;INJECTION

REGITINE			
+ NOVARTIS	5MG/VIAL **	N008278	003

PHENYL AMINOSALICYLATE

POWDER;ORAL

PHENY-PAS-TEBAMIN			
PHARM RES ASSOC	50%	N011695	002

TABLET;ORAL

PHENY-PAS-TEBAMIN			
PHARM RES ASSOC	500MG	N011695	003

PHENYLBUTAZONE

CAPSULE;ORAL

AZOLID			
SANOFI AVENTIS US	100MG	A087260	001
BUTAZOLIDIN			
NOVARTIS	100MG	N008319	009
PHENYLBUTAZONE			
FOSUN PHARMA	100MG	A087774	001 Jun 16, 1982
IVAX PHARMS	100MG	A088218	001 Jun 24, 1983
SUN PHARM INDUSTRIES	100MG	A088994	001 Dec 04, 1985
WATSON LABS	100MG	A087756	001 Dec 17, 1982
TABLET;ORAL			
AZOLID			
SANOFI AVENTIS US	100MG	A087091	001
BUTAZOLIDIN			
NOVARTIS	100MG	N008319	008
PHENYLBUTAZONE			
FOSUN PHARMA	100MG	A084339	001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PHENYLBUTAZONE

TABLET; ORAL

PHENYLBUTAZONE

SUN PHARM INDUSTRIES	100MG	A088863	001	Dec 04, 1985
WATSON LABS	100MG	A086151	001	
	100MG	A087674	001	Apr 21, 1982

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS

PHENYLEPHRINE HYDROCHLORIDE

ACCORD HLTHCARE	10MG/ML (10MG/ML)	A213237	001	Jul 01, 2020
	50MG/5ML (10MG/ML)	A213237	002	Jul 01, 2020
	100MG/10ML (10MG/ML)	A213237	003	Jul 01, 2020
CAPLIN	10MG/ML (10MG/ML)	A213318	001	Jun 11, 2020
	50MG/5ML (10MG/ML)	A213318	002	Jun 11, 2020
	100MG/10ML (10MG/ML)	A213318	003	Jun 11, 2020

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHENERGAN VC

+ ANI PHARMS	5MG/5ML; 6.25MG/5ML **	N008604	003	Apr 02, 1984
--------------	------------------------	---------	-----	--------------

PHERAZINE VC

HALSEY	5MG/5ML; 6.25MG/5ML	A088868	001	Mar 02, 1987
--------	---------------------	---------	-----	--------------

PROMETH VC PLAIN

G AND W LABS INC	5MG/5ML; 6.25MG/5ML	A088761	001	Nov 08, 1984
------------------	---------------------	---------	-----	--------------

PROMETHAZINE VC PLAIN

CENCI	5MG/5ML; 6.25MG/5ML	A088815	001	Nov 22, 1985
WOCKHARDT	5MG/5ML; 6.25MG/5ML	A088897	001	Jan 04, 1985

PHENYLEPHRINE HYDROCHLORIDE; PYRILAMINE MALEATE

SOLUTION/DROPS; OPHTHALMIC

PREFRIN-A

ALLERGAN	0.12%; 0.1%	N007953	001	
----------	-------------	---------	-----	--

PHENYTOIN

SUSPENSION; ORAL

DILANTIN-30

UPJOHN	30MG/5ML	N008762	002	
--------	----------	---------	-----	--

PHENYTOIN

ACTAVIS MID ATLANTIC	125MG/5ML	A089892	001	Sep 25, 1992
----------------------	-----------	---------	-----	--------------

PHENYTOIN SODIUM

CAPSULE; ORAL

DIPHENYLAN SODIUM

LANNETT	30MG PROMPT	A080857	001	
	100MG PROMPT	A080857	002	

EXTENDED PHENYTOIN SODIUM

ANI PHARMS INC	100MG EXTENDED	A040435	001	Jun 20, 2003
----------------	----------------	---------	-----	--------------

	100MG EXTENDED	A089441	001	Dec 18, 1986
--	----------------	---------	-----	--------------

LUPIN LTD	100MG EXTENDED	A211633	001	Sep 30, 2019
-----------	----------------	---------	-----	--------------

SUN PHARM INDS (IN)	100MG EXTENDED	A040621	001	Dec 11, 2006
---------------------	----------------	---------	-----	--------------

WOCKHARDT	30MG EXTENDED	A040759	001	Dec 18, 2007
-----------	---------------	---------	-----	--------------

WOCKHARDT USA	100MG EXTENDED	A040732	001	Jan 30, 2008
---------------	----------------	---------	-----	--------------

PHENYTEX

WATSON LABS	100MG EXTENDED	A088711	001	Dec 21, 1984
-------------	----------------	---------	-----	--------------

PHENYTOIN SODIUM

PHARMERAL	100MG PROMPT	A085435	001	
-----------	--------------	---------	-----	--

WATSON LABS	100MG PROMPT	A085894	001	
-------------	--------------	---------	-----	--

PROMPT PHENYTOIN SODIUM

ANI PHARMS INC	100MG PROMPT	A080259	001	
----------------	--------------	---------	-----	--

WATSON LABS	100MG PROMPT	A080905	001	
-------------	--------------	---------	-----	--

INJECTABLE; INJECTION

DILANTIN

PARKE DAVIS	50MG/ML	N010151	001	
-------------	---------	---------	-----	--

PHENYTOIN SODIUM

AM REGENT	50MG/ML	A040781	001	Dec 04, 2007
-----------	---------	---------	-----	--------------

FRESENIUS KABI USA	50MG/ML	A089003	001	May 31, 1985
--------------------	---------	---------	-----	--------------

HOSPIRA	50MG/ML	A089521	001	Mar 17, 1987
---------	---------	---------	-----	--------------

	50MG/ML	A089744	001	Dec 18, 1987
--	---------	---------	-----	--------------

MARSAM PHARMS LLC	50MG/ML	A089501	001	Oct 13, 1987
-------------------	---------	---------	-----	--------------

	50MG/ML	A089779	001	Nov 27, 1992
--	---------	---------	-----	--------------

SMITH AND NEPHEW	50MG/ML	A088519	001	Dec 19, 1984
------------------	---------	---------	-----	--------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PHENYTOIN SODIUM

INJECTABLE; INJECTION

PHENYTOIN SODIUM

	50MG/ML	A088521	001	Dec 18, 1984
SOLOPAK	50MG/ML	A088520	001	Dec 17, 1984
WARNER CHILCOTT	50MG/ML	A089900	001	Mar 30, 1990
WATSON LABS	50MG/ML	A085434	001	

PHYTONADIONE

INJECTABLE; INJECTION

AQUAMEPHYTON

+ TELIGENT	1MG/0.5ML **	N012223	002	
+	10MG/ML **	N012223	001	

KONAKION

ROCHE	1MG/0.5ML	N011745	001	
	10MG/ML	N011745	003	

PHYTONADIONE

GLAXOSMITHKLINE	1MG/0.5ML	A084060	001	
	10MG/ML	A084060	002	

VITAMIN K1

HOSPIRA	10MG/ML	A087956	001	Jul 25, 1983
---------	---------	---------	-----	--------------

PILOCARPINE

INSERT, EXTENDED RELEASE; OPTHALMIC

OCUSERT PILO-20

AKORN	5MG	N017431	001	
-------	-----	---------	-----	--

OCUSERT PILO-40

AKORN	11MG	N017548	001	
-------	------	---------	-----	--

PILOCARPINE HYDROCHLORIDE

GEL; OPTHALMIC

PILOPINE HS

ALCON	4%	N018796	001	Oct 01, 1984
-------	----	---------	-----	--------------

PIMAVANSERIN TARTRATE

TABLET; ORAL

NUPLAZID

+ ACADIA PHARMS INC	EQ 17MG BASE	N207318	001	Apr 29, 2016
---------------------	--------------	---------	-----	--------------

PIMOZIDE

TABLET; ORAL

ORAP

+ TEVA	1MG	N017473	003	Aug 27, 1997
+	2MG	N017473	001	Jul 31, 1984

PINACIDIL

CAPSULE, EXTENDED RELEASE; ORAL

PINDAC

LEO PHARM	12.5MG	N019456	001	Dec 28, 1989
	25MG	N019456	002	Dec 28, 1989

PINDOLOL

TABLET; ORAL

PINDOLOL

COSETTE	5MG	A073661	001	Oct 31, 1993
	5MG	A073687	001	Feb 26, 1993
	5MG	A074123	001	Apr 17, 1997
	10MG	A073661	002	Oct 31, 1993
	10MG	A073687	002	Feb 26, 1993
	10MG	A074123	002	Apr 17, 1997
MYLAN PHARMS INC	5MG	A074013	001	Sep 24, 1992
	10MG	A074018	001	Sep 24, 1992
NOSTRUM LABS	5MG	A074474	001	Oct 28, 1996
	10MG	A074474	002	Oct 28, 1996
PUREPAC PHARM	5MG	A074125	001	Apr 28, 1993
	10MG	A074125	002	Apr 28, 1993
WATSON LABS	5MG	A074437	001	Feb 27, 1995
	10MG	A074437	002	Feb 27, 1995
ZYDUS PHARMS	5MG	A209866	001	Aug 18, 2017
	10MG	A209866	002	Aug 18, 2017
VISKEN				
+ NOVARTIS	5MG **	N018285	001	Sep 03, 1982
+	10MG **	N018285	002	Sep 03, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE

MYLAN PHARMS INC	EQ 15MG BASE	A076801 001	Aug 17, 2012
	EQ 30MG BASE	A076801 002	Aug 17, 2012
	EQ 45MG BASE	A076801 003	Aug 17, 2012
NEOPHARMA	EQ 15MG BASE	A078383 001	Mar 12, 2013
	EQ 30MG BASE	A078383 002	Mar 12, 2013
	EQ 45MG BASE	A078383 003	Mar 12, 2013
NOSTRUM LABS INC	EQ 15MG BASE	A078472 001	Feb 13, 2013
	EQ 30MG BASE	A078472 002	Feb 13, 2013
	EQ 45MG BASE	A078472 003	Feb 13, 2013
TORRENT PHARMS LTD	EQ 15MG BASE	A091298 001	Feb 13, 2013
	EQ 30MG BASE	A091298 002	Feb 13, 2013
	EQ 45MG BASE	A091298 003	Feb 13, 2013

PIPECURONIUM BROMIDE

INJECTABLE; INJECTION

ARDUAN

ORGANON USA INC	10MG/VIAL	N019638 001	Jun 26, 1990
-----------------	-----------	-------------	--------------

PIPERACETAZINE

TABLET; ORAL

QUIDE

DOW PHARM	10MG	N013615 001	
	25MG	N013615 002	

PIPERACILLIN SODIUM

INJECTABLE; INJECTION

PIPRACIL

WYETH PHARMS INC	EQ 2GM BASE/VIAL	A062750 001	Oct 13, 1987
+	EQ 2GM BASE/VIAL **	N050545 002	
	EQ 3GM BASE/VIAL	A062750 002	Oct 13, 1987
+	EQ 3GM BASE/VIAL **	N050545 003	
	EQ 4GM BASE/VIAL	A062750 003	Oct 13, 1987
+	EQ 4GM BASE/VIAL **	N050545 004	
+	EQ 40GM BASE/VIAL **	N050545 006	Sep 30, 1985

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

PIPERACILLIN AND TAZOBACTAM

HOSPIRA INC	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065386 001	Sep 15, 2009
	EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065386 002	Sep 15, 2009
	EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065386 003	Sep 15, 2009
	EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A065446 001	Sep 15, 2009

PIPERAZINE CITRATE

SYRUP; ORAL

ANTEPAR

GLAXOSMITHKLINE	EQ 500MG BASE/5ML	N009102 001	
BRYREL			
SANOFI AVENTIS US	EQ 500MG BASE/5ML	N017796 001	
MULTIFUGE			
BLULINE	EQ 500MG BASE/5ML	N009452 001	
PIPERAZINE CITRATE			
ALPHARMA US PHARMS	EQ 500MG BASE/5ML	A080774 001	
LANNETT	EQ 500MG BASE/5ML	A080963 001	
LUITPOLD	EQ 500MG BASE/5ML	A080671 001	
VERMIDOL			
SOLVAY	EQ 500MG BASE/5ML	A080992 001	

TABLET; ORAL

ANTEPAR

GLAXOSMITHKLINE	EQ 500MG BASE	N009102 003	
PIPERAZINE CITRATE			
IMPAX LABS	EQ 250MG BASE	A080874 001	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PIPERONYL BUTOXIDE; PYRETHRINS

AEROSOL; TOPICAL

RID MOUSSE

BAYER HEALTHCARE LLC 4%;EQ 0.33% BASE

N021043 001 Mar 07, 2000

PIPOBROMAN

TABLET; ORAL

VERCYTE

ABBOTT 10MG

N016245 001

25MG

N016245 002

PIRBUTEROL ACETATE

AEROSOL, METERED; INHALATION

MAXAIR

BAUSCH EQ 0.2MG BASE/INH

N019009 001 Dec 30, 1986

MEDICIS EQ 0.2MG BASE/INH

N020014 001 Nov 30, 1992

PIRFENIDONE

TABLET; ORAL

ESBRIET

+ GENENTECH INC 534MG **

N208780 002 Jan 11, 2017

PIROXICAM

CAPSULE; ORAL

PIROXICAM

BRECKENRIDGE 10MG

A208991 001 Feb 21, 2018

20MG

A208991 002 Feb 21, 2018

CYCLE PHARMS LTD 10MG

A073651 001 Feb 26, 1993

20MG

A073651 002 Feb 26, 1993

EGIS 10MG

A074808 001 Jul 08, 1997

20MG

A074808 002 Jul 08, 1997

IVAX SUB TEVA PHARMS 10MG

A074148 001 Jun 03, 1996

20MG

A074148 002 Jun 03, 1996

MYLAN 10MG

A074043 001 Sep 22, 1992

10MG

A074102 001 Jul 31, 1992

20MG

A074043 002 Sep 22, 1992

20MG

A074102 002 Jul 31, 1992

SCS 10MG

A074036 001 May 29, 1992

20MG

A074036 002 May 29, 1992

SUN PHARM INDUSTRIES 10MG

A073536 002 Jan 23, 2008

20MG

A073536 001 Mar 12, 1993

TEVA 10MG

A073637 001 Jan 28, 1994

20MG

A073638 001 Jan 28, 1994

TEVA PHARMS 10MG

A074103 001 Aug 28, 1992

20MG

A074103 002 Aug 28, 1992

WATSON LABS 10MG

A074287 001 May 16, 1996

10MG

A074460 001 Sep 29, 1995

20MG

A074287 002 May 16, 1996

20MG

A074460 002 Sep 29, 1995

PITAVASTATIN CALCIUM

TABLET; ORAL

PITAVASTATIN CALCIUM

MYLAN EQ 1MG BASE

A206070 001 Apr 04, 2019

EQ 2MG BASE

A206070 002 Apr 04, 2019

EQ 4MG BASE

A206070 003 Apr 04, 2019

PITAVASTATIN MAGNESIUM

TABLET; ORAL

ZYPITAMAG

+ MEDICURE EQ 1MG BASE

N208379 001 Jul 14, 2017

PITAVASTATIN SODIUM

TABLET; ORAL

NIKITA

+ LUPIN LTD EQ 1MG BASE

N209875 001 Aug 04, 2017

+ EQ 2MG BASE

N209875 002 Aug 04, 2017

+ EQ 4MG BASE

N209875 003 Aug 04, 2017

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PLICAMYCIN

INJECTABLE; INJECTION

MITHRACIN

PFIZER

2.5MG/VIAL

N050109 001

PODOFILOX

SOLUTION; TOPICAL

PODOFILOX

BAUSCH AND LOMB INC

0.5%

A090184 001 Jul 21, 2010

POLYESTRADIOL PHOSPHATE

INJECTABLE; INJECTION

ESTRADURIN

WYETH AYERST

40MG/AMP

N010753 001

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL

GLYCOLAX

LANNETT CO INC

17GM/SCOOPFUL

A076652 001 Jul 02, 2004

POLYETHYLENE GLYCOL 3350

BRECKENRIDGE PHARM

17GM/SCOOPFUL

A077736 001 May 26, 2006

NEXGEN PHARMA INC

17GM/SCOOPFUL

A077706 001 Sep 27, 2006

PADDOCK LLC

17GM/SCOOPFUL

A077893 001 May 26, 2006

17GM/SCOOPFUL

A090567 001 Oct 15, 2009

TEVA PHARMS

17GM/SCOOPFUL

A077445 001 May 04, 2006

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; ORAL

PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE

MYLAN

420GM/BOT; 1.48GM/BOT; 5.72GM/BOT; 11.2GM/BOT

A090409 001 Apr 02, 2010

NOSTRUM LABS INC

420GM/BOT; 1.48GM/BOT; 5.72GM/BOT; 11.2GM/BOT

A202060 001 Mar 08, 2017

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

CLENZ-LYTE

PADDOCK LLC

236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT

A090769 001 Jun 07, 2010

SOLUTION; ORAL

OCL

HOSPIRA

6GM/100ML; 75MG/100ML; 168MG/100ML; 146MG/100ML; 1.29GM/100ML

N019284 001 Apr 30, 1986

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATEANHYDROUS

FOR SOLUTION; ORAL

COLYTE

MYLAN SPECIALITY LP

120GM/PACKET; 1.49GM/PACKET; 3.36GM/PACKET; 2.92GM/PACKET; 11.36GM/PACKET

N018983 005 Oct 26, 1984

227.1GM/PACKET; 2.82GM/PACKET; 6.36GM/PACKET; 5.53GM/PACKET; 21.5GM/PACKET

N018983 004 Oct 26, 1984

227.1GM/BOT; 2.82GM/BOT; 6.36GM/BOT; 5.53GM/BOT; 21.5GM/BOT

N018983 010 Jan 31, 1989

240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT

N018983 007 Jun 12, 1987

360GM/PACKET; 4.47GM/PACKET; 10.08GM/PACKET; 8.76GM/PACKET; 34.08GM/PACKET

N018983 006 Oct 26, 1984

COLYTE-FLAVORED

MYLAN SPECIALITY LP

227.1GM/BOT; 2.82GM/BOT; 6.36GM/BOT; 5.53GM/BOT; 21.5GM/BOT

N018983 008 Nov 14, 1991

240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT

N018983 009 Nov 14, 1991

GOLYTELY

+

BRAINTREE

227.1GM/PACKET; 2.82GM/PACKET; 6.36GM/PACKET; 5.53GM/PACKET; 21.5GM/PACKET

N019011 002 Jun 02, 1992

PEG 3350 AND ELECTROLYTES

MYLAN

236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT

A090928 001 Jan 28, 2010

POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES

PADDOCK LLC

240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT

A090712 001 Feb 25, 2010

FOR SUSPENSION; ORAL

CO-LAV

VINTAGE PHARMS

240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84

A073428 001 Jan 28, 1992

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SUSPENSION; ORAL

CO-LAV

GM/BOT; 22.72GM/BOT

COLOVAGE

DYNAPHARM

227.1GM/PACKET; 2.82GM/PACKET; 6.36GM/PACKET; 5.53GM/PACKET; 21.5GM/PACKET

A071320 001 Apr 20, 1988

E-Z-EM PREP LYTE

E Z EM

236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT

A071278 001 Nov 21, 1988

GLYCOPREP

GOLDLINE

236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT

A072319 001 Dec 23, 1988

GO-EVAC

VINTAGE PHARMS

236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT

A073433 001 Apr 28, 1992

PEG-LYTE

SANDOZ

236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT

A073098 001 Aug 31, 1993

POLYMYXIN B SULFATE

INJECTABLE; INJECTION

AEROSPORIN

GLAXOSMITHKLINE

EQ 500,000 UNITS BASE/VIAL

A062036 001

POLYMYXIN B SULFATE

MYLAN ASI

EQ 500,000 UNITS BASE/VIAL

A090110 001 Jun 29, 2011

WEST-WARD PHARMS INT

EQ 500,000 UNITS BASE/VIAL

A060716 001

POWDER; FOR RX COMPOUNDING

POLY-RX

X GEN PHARMS

100,000,000 UNITS/BOT

A061578 001

POLYMYXIN B SULFATE

PADDOCK LLC

100,000,000 UNITS/BOT

A062455 001 Jul 27, 1983

POLYTHIAZIDE

TABLET; ORAL

RENESE

PFIZER

1MG

N012845 001

2MG

N012845 002

4MG

N012845 003

POLYTHIAZIDE; PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

MINIZIDE

PFIZER

0.5MG; EQ 1MG BASE

N017986 001

0.5MG; EQ 2MG BASE

N017986 002

0.5MG; EQ 5MG BASE

N017986 003

POLYTHIAZIDE; RESERPINE

TABLET; ORAL

RENESE-R

PFIZER

2MG; 0.25MG

N013636 001

POSACONAZOLE

SUSPENSION; ORAL

POSACONAZOLE

HIKMA

40MG/ML

A208773 001 May 15, 2020

POTASSIUM AMINOSALICYLATE

CAPSULE; ORAL

PASKALIUM

GLENWOOD

500MG

N009395 004

POWDER; ORAL

POTASSIUM AMINOSALICYLATE

HEXCEL

100%

A080098 001

TABLET; ORAL

PASKALIUM

GLENWOOD

1GM

N009395 003

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

K-LEASE

SAVAGE LABS	8MEQ	A073398	001	Jan 28, 1992
	10MEQ	A072427	001	Mar 28, 1990
MICRO-K				
+ NESHER PHARMS	8MEQ	N018238	001	
MICRO-K 10				
+ NESHER PHARMS	10MEQ	N018238	002	May 14, 1984
POTASSIUM CHLORIDE				
NESHER PHARMS	10MEQ	A070980	001	Feb 17, 1987
TEVA	8MEQ	A073531	001	Apr 26, 1996
	10MEQ	A073532	001	Apr 26, 1996

FOR SUSPENSION, EXTENDED RELEASE;ORAL

MICRO-K LS

+ KV PHARM	20MEQ/PACKET **	N019561	003	Aug 26, 1988
------------	-----------------	---------	-----	--------------

INJECTABLE;INJECTION

POTASSIUM CHLORIDE

ABRAXIS PHARM	2MEQ/ML	A080204	001	
	2MEQ/ML	A084290	001	
	2MEQ/ML	A086713	001	
	2MEQ/ML	A086714	001	
	2MEQ/ML	A087787	001	Apr 20, 1982
	2MEQ/ML	A087885	001	Feb 03, 1983
AKORN	2MEQ/ML	A088286	001	Sep 05, 1985
BAXTER HLTHCARE	2MEQ/ML	A080203	001	
	2MEQ/ML	A085499	001	
FRESENIUS KABI USA	2MEQ/ML	A087817	001	Oct 20, 1982
GD SEARLE LLC	1MEQ/ML	A086219	001	
	2MEQ/ML	A086219	002	
	2MEQ/ML	A086220	002	
	3MEQ/ML	A086219	003	
	3MEQ/ML	A086220	001	
	4MEQ/ML	A086219	004	
HOSPIRA	1MEQ/ML	A080205	003	
	1MEQ/ML	A083345	003	
	1.5MEQ/ML	A083345	001	
	2MEQ/ML	A083345	002	
	2.4MEQ/ML	A080205	004	
	3.2MEQ/ML	A080205	005	
INTL MEDICATION	2MEQ/ML	A083163	001	
LILLY	2MEQ/ML	N007865	002	
LUITPOLD	2MEQ/ML	A080221	001	
	2MEQ/ML	A080736	001	
	2MEQ/ML	A087584	001	
	2MEQ/ML	A087585	001	
MILES	1MEQ/ML	A080195	002	
	2MEQ/ML	A080195	001	
	3MEQ/ML	A080195	003	
	4MEQ/ML	A080195	004	
PHARMA SERVE NY	2MEQ/ML	A086297	001	
	2MEQ/ML	A087362	001	Mar 08, 1983
WATSON LABS	2MEQ/ML	A086208	001	
	2MEQ/ML	A089163	001	Mar 10, 1988
	2MEQ/ML	A089421	001	Jan 02, 1987
	3MEQ/ML	A086210	001	

POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER

+ ICU MEDICAL INC	2.24GM/100ML	N020161	003	Aug 11, 1998
-------------------	--------------	---------	-----	--------------

TABLET, EXTENDED RELEASE;ORAL

K+10

FUTURE PAK	10MEQ	A070999	001	Oct 22, 1987
------------	-------	---------	-----	--------------

K+8

FUTURE PAK	8MEQ	A070998	001	Jan 25, 1993
------------	------	---------	-----	--------------

KAON CL

SAVAGE LABS	6.7MEQ	N017046	001	
-------------	--------	---------	-----	--

KAON CL-10

SAVAGE LABS	10MEQ	N017046	002	
-------------	-------	---------	-----	--

KLOTRIX

APOTHECON	10MEQ	N017850	001	
-----------	-------	---------	-----	--

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

AMNEAL	15MEQ	A212861	002	May 08, 2020
COPLY PHARM	8MEQ	A070618	001	Sep 09, 1987
NESHER PHARMS	20MEQ	A076044	001	Apr 05, 2002
+ SCHERING	10MEQ **	N019439	002	Jun 13, 1986
+ STRIDES PHARMA	20MEQ **	N019439	001	Jun 13, 1986
	8MEQ	A206881	001	Jan 22, 2019
	10MEQ	A206630	001	Mar 29, 2019
	10MEQ	A206881	002	Jan 22, 2019
	10MEQ	A210097	001	Jun 17, 2019
	15MEQ	A206630	002	Mar 29, 2019
	20MEQ	A206630	003	Mar 29, 2019
	20MEQ	A210098	001	Apr 26, 2019
SLOW-K				
NOVARTIS	8MEQ	N017476	002	
TEN-K				
NOVARTIS	10MEQ	N019381	001	Apr 16, 1986

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	37MG/100ML;900MG/100ML	N019708	001	Sep 29, 1989
POTASSIUM CHLORIDE 0.075% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	75MG/100ML;900MG/100ML	N019708	002	Sep 29, 1989
POTASSIUM CHLORIDE 0.11% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	110MG/100ML;900MG/100ML	N019708	003	Sep 29, 1989
POTASSIUM CHLORIDE 0.22% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	220MG/100ML;900MG/100ML	N019708	005	Sep 29, 1989
POTASSIUM CHLORIDE 0.224% IN SODIUM CHLORIDE 0.9%				
+ BAXTER HLTHCARE	224MG/100ML;900MG/100ML	N017648	003	
POTASSIUM CHLORIDE 0.3% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	300MG/100ML;900MG/100ML	N019708	006	Sep 29, 1989
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER				
B BRAUN	75MG/100ML;900MG/100ML	N018722	001	Nov 09, 1982
BAXTER HLTHCARE	75MG/100ML;900MG/100ML	N017648	004	
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER				
B BRAUN	150MG/100ML;900MG/100ML	N018722	002	Nov 09, 1982
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER				
B BRAUN	220MG/100ML;900MG/100ML	N018722	003	Nov 09, 1982
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
B BRAUN	300MG/100ML;900MG/100ML	N018722	004	Nov 09, 1982

POTASSIUM CHLORIDE; SODIUM CHLORIDE; TROMETHAMINE

INJECTABLE;INJECTION

THAM-E

HOSPIRA	370MG/VIAL;1.75GM/VIAL;36GM/VIAL	N013025	001	
---------	----------------------------------	---------	-----	--

POTASSIUM CITRATE

FOR SOLUTION;ORAL

POTASSIUM CITRATE

+ UT SW MEDCTR	10MEQ/PACKET **	N019647	002	Oct 13, 1988
+	20MEQ/PACKET **	N019647	001	Oct 13, 1988

POTASSIUM IODIDE

SOLUTION;ORAL

POTASSIUM IODIDE

ROXANE	1GM/ML **	N018551	001	Feb 19, 1982
--------	-----------	---------	-----	--------------

TABLET;ORAL

THYRO-BLOCK

MEDA PHARMS	130MG	N018307	001	
-------------	-------	---------	-----	--

POTASSIUM PERCHLORATE

CAPSULE;ORAL

PERCHLORACAP

MALLINCKRODT	200MG	N017551	001	
--------------	-------	---------	-----	--

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

POVIDONE-IODINE

SOLUTION; TOPICAL

E-Z PREP

CLINIPAD

10%

N019382 001 Jul 25, 1989

SPONGE; TOPICAL

E-Z PREP

CLINIPAD

5%

N019382 002 Jul 25, 1989

E-Z PREP 220

CLINIPAD

5%

N019382 003 Jul 25, 1989

PRALIDOXIME CHLORIDE

INJECTABLE; INJECTION

PRALIDOXIME CHLORIDE

BAXTER HLTHCARE CORP 300MG/ML

N018799 001 Dec 13, 1982

SOLUTION; INTRAMUSCULAR

PRALIDOXIME CHLORIDE (AUTOINJECTOR)

+ MERIDIAN MEDCL TECHN 600MG/2ML (300MG/ML)

N018986 001 Apr 26, 1983

TABLET; ORAL

PROTOPAM CHLORIDE

WYETH AYERST

500MG

N014122 002

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

MIRAPEX

BOEHRINGER INGELHEIM 1.25MG

N020667 004 Jul 01, 1997

PRAMIPEXOLE DIHYDROCHLORIDE

ALEMBIC PHARMS LTD 0.125MG

A078894 001 Oct 08, 2010

0.25MG

A078894 002 Oct 08, 2010

0.5MG

A078894 003 Oct 08, 2010

1MG

A078894 004 Oct 08, 2010

1.5MG

A078894 005 Oct 08, 2010

HERITAGE PHARMA

0.125MG

A077724 001 Feb 19, 2008

0.125MG

A078551 001 Oct 08, 2010

0.125MG

A090241 001 Oct 08, 2010

0.125MG

A091254 001 Nov 30, 2010

0.25MG

A077724 002 Feb 19, 2008

0.25MG

A078551 002 Oct 08, 2010

0.25MG

A090241 002 Oct 08, 2010

0.25MG

A091254 002 Nov 30, 2010

0.5MG

A077724 003 Feb 19, 2008

0.5MG

A078551 003 Oct 08, 2010

0.5MG

A090241 003 Oct 08, 2010

0.5MG

A091254 003 Nov 30, 2010

0.75MG

A090241 004 Oct 08, 2010

0.75MG

A091254 004 Nov 30, 2010

1MG

A077724 004 Feb 19, 2008

1MG

A078551 004 Oct 08, 2010

1MG

A090241 005 Oct 08, 2010

1MG

A091254 005 Nov 30, 2010

1.5MG

A077724 005 Feb 19, 2008

1.5MG

A078551 005 Oct 08, 2010

1.5MG

A090241 006 Oct 08, 2010

1.5MG

A091254 006 Nov 30, 2010

MACLEODS PHARMS LTD

0.125MG

A202164 001 Sep 20, 2012

0.25MG

A202164 002 Sep 20, 2012

0.5MG

A202164 003 Sep 20, 2012

1MG

A202164 004 Sep 20, 2012

1.5MG

A202164 005 Sep 20, 2012

MYLAN

0.125MG

A077854 001 Oct 08, 2010

0.25MG

A077854 002 Oct 08, 2010

0.5MG

A077854 003 Oct 08, 2010

0.75MG

A090764 001 Apr 09, 2010

1MG

A077854 004 Oct 08, 2010

1.5MG

A077854 005 Oct 08, 2010

SANDOZ

0.125MG

A090190 001 Jul 06, 2010

0.25MG

A090190 002 Jul 06, 2010

0.5MG

A090190 003 Jul 06, 2010

0.75MG

A090190 006 Oct 08, 2010

1MG

A090190 004 Jul 06, 2010

1.5MG

A090190 005 Jul 06, 2010

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

SUN PHARM INDS INC	0.125MG	A091683 001	Mar 27, 2013
	0.25MG	A091683 002	Mar 27, 2013
	0.5MG	A091683 003	Mar 27, 2013
	0.75MG	A091683 004	Mar 27, 2013
	1MG	A091683 005	Mar 27, 2013
	1.5MG	A091683 006	Mar 27, 2013
UNICHEM	0.125MG	A207011 001	Dec 19, 2018
	0.25MG	A207011 002	Dec 19, 2018
	0.5MG	A207011 003	Dec 19, 2018
	0.75MG	A207011 004	Dec 19, 2018
	1MG	A207011 005	Dec 19, 2018
	1.5MG	A207011 006	Dec 19, 2018

TABLET, EXTENDED RELEASE; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

ALEMBIC PHARMS LTD	0.375MG	A204518 001	Jan 02, 2019
	0.75MG	A204518 002	Jan 02, 2019
	1.5MG	A204518 003	Jan 02, 2019
	2.25MG	A204518 004	Jan 02, 2019
	3MG	A204518 005	Jan 02, 2019
	3.75MG	A204518 006	Jan 02, 2019
	4.5MG	A204518 007	Jan 02, 2019

PRAMLINTIDE ACETATE

INJECTABLE; SUBCUTANEOUS

SYMLIN

ASTRAZENECA AB	EQ 3MG BASE/5ML (EQ 600MCG BASE/ML)	N021332 001	Mar 16, 2005
----------------	-------------------------------------	-------------	--------------

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVACHOL

+ BRISTOL MYERS SQUIBB 10MG **

N019898 002 Oct 31, 1991

PRAVASTATIN SODIUM

MYLAN	10MG	A077013 001	Oct 23, 2006
	20MG	A077013 002	Oct 23, 2006
	40MG	A077013 003	Oct 23, 2006
	80MG	A077013 004	Dec 28, 2007
MYLAN PHARMS INC	10MG	A079187 001	May 27, 2010
	20MG	A079187 002	May 27, 2010
	40MG	A079187 003	May 27, 2010
	80MG	A079187 004	May 27, 2010
PLIVA HRVATSKA DOO	10MG	A077730 001	Nov 21, 2006
	20MG	A077730 002	Nov 21, 2006
	30MG	A077730 003	Nov 21, 2006
	40MG	A077730 005	Nov 21, 2006
RANBAXY LABS LTD	10MG	A076445 001	Apr 23, 2007
	20MG	A076445 002	Apr 23, 2007
	40MG	A076445 003	Apr 23, 2007
	80MG	A076445 004	Apr 23, 2007
ZYDUS PHARMS USA	10MG	A077751 001	Apr 30, 2008

PRAZEPAM

CAPSULE; ORAL

CENTRAX

PARKE DAVIS	5MG	N018144 001	
	10MG	N018144 002	
	20MG	N018144 003	May 10, 1982

PRAZEPAM

USL PHARMA	5MG	A070427 001	Nov 06, 1987
	10MG	A070428 001	Nov 06, 1987

TABLET; ORAL

CENTRAX

PARKE DAVIS	10MG	N017415 001	
-------------	------	-------------	--

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

PRAZOSIN HYDROCHLORIDE

AM THERAP	EQ 1MG BASE	A072782 001	May 16, 1989
	EQ 2MG BASE	A072783 001	May 16, 1989
	EQ 5MG BASE	A072784 001	May 16, 1989
ANI PHARMS INC	EQ 1MG BASE	A072577 002	May 16, 1989
	EQ 2MG BASE	A072577 001	May 16, 1989
	EQ 5MG BASE	A072577 003	May 16, 1989
DAVA PHARMS INC	EQ 1MG BASE	A072705 001	May 16, 1989
	EQ 2MG BASE	A072706 001	May 16, 1989
	EQ 5MG BASE	A072707 001	May 16, 1989
PUREPAC PHARM	EQ 1MG BASE	A072991 001	May 16, 1989
	EQ 2MG BASE	A072921 001	May 16, 1989
	EQ 5MG BASE	A072992 001	May 16, 1989
WATSON LABS	EQ 1MG BASE	A072352 001	May 16, 1989
	EQ 2MG BASE	A072333 001	May 16, 1989
	EQ 5MG BASE	A072609 001	May 16, 1989

TABLET, EXTENDED RELEASE; ORAL

MINIPRESS XL

PFIZER	2.5MG	N019775 001	Jan 29, 1992
	5MG	N019775 002	Jan 29, 1992

PREDNICARBATE

CREAM; TOPICAL

DERMATOP E EMOLLIENT

+ VALEANT BERMUDA	0.1%	N020279 001	Oct 29, 1993
-------------------	------	-------------	--------------

PREDNICARBATE

FOUGERA PHARMS	0.1%	A077287 001	Sep 19, 2006
----------------	------	-------------	--------------

OINTMENT; TOPICAL

DERMATOP

+ VALEANT PHARMS NORTH	0.1%	N019568 001	Sep 23, 1991
------------------------	------	-------------	--------------

PREDNISOLONE

CREAM; TOPICAL

METI-DERM

SCHERING	0.5%	N010209 002	
----------	------	-------------	--

SYRUP; ORAL

PREDNISOLONE

CHARTWELL RX	15MG/5ML	A040323 001	May 13, 1999
IVAX SUB TEVA PHARMS	15MG/5ML	A040287 001	May 28, 1999
NESHER PHARMS	5MG/5ML	A040423 001	Oct 22, 2001
	15MG/5ML	A040364 001	Apr 10, 2002
PHARM ASSOC	5MG/5ML	A040570 001	Aug 25, 2005
	15MG/5ML	A040571 001	Aug 25, 2005
TEVA PHARMS	15MG/5ML	A040322 001	Jan 19, 2000
WE PHARMS	15MG/5ML	A040192 001	May 28, 1998

PRELONE

MURO	5MG/5ML	A089654 001	Jan 17, 1989
------	---------	-------------	--------------

TABLET; ORAL

CORTALONE

HALSEY	1MG	A080304 003	
	2.5MG	A080304 002	
	5MG	A080304 001	

DELTA-CORTEF

PHARMACIA AND UPJOHN	5MG	N009987 004	
----------------------	-----	-------------	--

FERNISOLONE-P

FERNDALE LABS	5MG	A083941 001	
---------------	-----	-------------	--

PREDNISOLONE

AUROLIFE PHARMA LLC	5MG	A084773 001	
BARR	5MG	A084426 002	
BUNDY	5MG	A083675 001	
CHARTWELL RX	5MG	A084542 001	
ELKINS SINN	5MG	A080625 001	
EVERYLIFE	1MG	A084439 001	
	2.5MG	A084439 002	
	5MG	A084439 003	
FERRANTE	2.5MG	A080562 001	
	5MG	A080562 002	
FOSUN PHARMA	5MG	A080339 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PREDNISOLONE

TABLET; ORAL

PREDNISOLONE

HEATHER	5MG	A080326	001	
IMPAX LABS	5MG	A080780	001	
INWOOD LABS	5MG	A080748	001	
IVAX SUB TEVA PHARMS	5MG	A080378	001	
LANNETT	5MG	A080531	002	
MARSHALL PHARMA	5MG	A080307	001	
PANRAY	1MG	A080351	001	
	5MG	A080351	002	
PHOENIX LABS NY	5MG	A080322	001	
PUREPAC PHARM	5MG	A080325	001	
PVT FORM	5MG	A080211	001	
ROXANE	5MG	A080327	002	
SPERTI	1MG	A080358	001	
	2.5MG	A080358	002	
	5MG	A080358	003	
SUPERPHARM	5MG	A088892	001	Feb 26, 1985
TABLICAPS	5MG	A085170	001	
TEVA	5MG	A080398	001	
UDL	5MG	A087987	001	Jan 18, 1983
VALEANT PHARM INTL	5MG	A080236	001	
VITARINE	5MG	A080534	001	
WATSON LABS	5MG	A085085	002	
	5MG	A085415	001	
	5MG	A085416	001	
WEST WARD	5MG	A080324	001	
WHITEWORTH TOWN PLSN	5MG	A080342	001	
STERANE				
PFIZER	5MG	N009996	001	

PREDNISOLONE ACETATE

INJECTABLE; INJECTION

METICORTELONE

SCHERING	25MG/ML	N010255	002	
----------	---------	---------	-----	--

PREDNISOLONE ACETATE

AKORN	25MG/ML	A083032	001	
	50MG/ML	A084492	001	
BEL MAR	25MG/ML	A083738	001	
	50MG/ML	A083738	002	
CENT PHARMS	25MG/ML	A084717	001	
	50MG/ML	A084717	002	
WATSON LABS	25MG/ML	A083398	001	
	25MG/ML	A083654	001	
	40MG/ML	A083767	001	
	50MG/ML	A083764	001	
	50MG/ML	A085781	001	

STERANE

PFIZER	25MG/ML	N011446	001	
--------	---------	---------	-----	--

SUSPENSION; ORAL

FLO-PRED

TARO	EQ 5MG BASE/5ML	N022067	001	Jan 17, 2008
	EQ 15MG BASE/5ML	N022067	002	Jan 17, 2008

SUSPENSION/DROPS; OPHTHALMIC

ECONOPRED

EYEVANCE	0.125%	N017468	001	
----------	--------	---------	-----	--

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC

CETAPRED

ALCON	0.25%;10%	A087771	001	Aug 06, 1993
-------	-----------	---------	-----	--------------

METIMYD

SCHERING	0.5%;10%	N010210	002	Sep 09, 1984
----------	----------	---------	-----	--------------

PREDSULFAIR

PHARMAFAIR	0.5%;10%	A088032	001	Apr 15, 1983
------------	----------	---------	-----	--------------

VASOCIDIN

NOVARTIS	0.5%;10%	A088791	001	Oct 05, 1984
----------	----------	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

SUSPENSION;OPHTHALMIC

ISOPTO CETAPRED

ALCON 0.25%;10% A087547 001

SUSPENSION/DROPS;OPHTHALMIC

METIMYD

SCHERING 0.5%;10% N010210 001

PREDAMIDE

AKORN 0.5%;10% A088059 001 Jul 29, 1983

PREDSULFAIR

PHARMAFAIR 0.5%;10% A088007 001 Apr 19, 1983

PREDSULFAIR II

PHARMAFAIR 0.2%;10% A088837 001 Dec 24, 1985

SULPHRIN

BAUSCH AND LOMB 0.5%;10% A088089 001 Dec 28, 1982

PREDNISOLONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

HYDELTRASOL

MERCCK EQ 20MG PHOSPHATE/ML N011583 002

PREDNISOLONE SODIUM PHOSPHATE

WATSON LABS EQ 20MG PHOSPHATE/ML A080517 001

OINTMENT;OPHTHALMIC, OTIC

HYDELTRASOL

MERCCK EQ 0.25% PHOSPHATE N011028 001

SOLUTION;ORAL

ORAPRED

CONCORDIA PHARMS INC EQ 15MG BASE/5ML ** A075117 001 Dec 14, 2000

PREDNISOLONE SODIUM PHOSPHATE

AMNEAL PHARMS EQ 15MG BASE/5ML A078345 001 Mar 10, 2009

MEDICIS PHARMS EQ 15MG BASE/5ML A075250 001 Jul 12, 2002

NESHER PHARMS EQ 5MG BASE/5ML A076982 001 May 24, 2005

EQ 15MG BASE/5ML A076988 001 May 24, 2005

PHARM ASSOC EQ 5MG BASE/5ML A076123 001 Dec 23, 2002

VINTAGE EQ 15MG BASE/5ML A079010 001 May 26, 2009

VINTAGE PHARMS EQ 5MG BASE/5ML A078416 001 Oct 31, 2007

WE PHARMS EQ 5MG BASE/5ML A075181 001 Dec 23, 2002

SOLUTION/DROPS;OPHTHALMIC

INFLAMASE FORTE

NOVARTIS EQ 0.9% PHOSPHATE A080751 002

INFLAMASE MILD

NOVARTIS EQ 0.11% PHOSPHATE A080751 001

METRETON

SCHERING EQ 0.5% PHOSPHATE A083834 001

PREDAIR

PHARMAFAIR EQ 0.11% PHOSPHATE A088415 001 Feb 29, 1984

PREDAIR FORTE

PHARMAFAIR EQ 0.9% PHOSPHATE A088165 001 Mar 28, 1983

PREDNISOLONE SODIUM PHOSPHATE

AKORN EQ 0.11% PHOSPHATE A083358 001

EQ 0.9% PHOSPHATE A083358 002

ALCON PHARMS LTD EQ 0.11% PHOSPHATE A081043 001 Oct 24, 1991

EQ 0.9% PHOSPHATE A081044 001 Oct 24, 1991

BAUSCH AND LOMB EQ 0.11% PHOSPHATE A040065 001 Jul 29, 1994

SOLA BARNES HIND EQ 0.11% PHOSPHATE A084171 001

EQ 0.9% PHOSPHATE A084168 001

EQ 0.9% PHOSPHATE A084169 001

EQ 0.9% PHOSPHATE A084172 001

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS;OPHTHALMIC

SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

SANDOZ INC EQ 0.23% PHOSPHATE;10% A073630 001 May 27, 1993

SULSTER

AKORN EQ 0.23% PHOSPHATE;10% A074511 001 Jul 30, 1996

VASOCIDIN

+ NOVARTIS EQ 0.23% PHOSPHATE;10% ** N018988 001 Aug 26, 1988

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PREDNISOLONE TEBUTATE

INJECTABLE; INJECTION

HYDELTRA-TBA

MERCCK

20MG/ML

N010562 001

PREDNISOLONE TEBUTATE

WATSON LABS

20MG/ML

A083362 001 Feb 17, 1984

PREDNISONE

SOLUTION; ORAL

PREDNISONE

WOCKHARDT

5MG/5ML

A089726 001 Aug 02, 1988

SYRUP; ORAL

LIQUID PRED

MURO

5MG/5ML

A087611 002 Sep 07, 1982

TABLET; ORAL

CORTAN

HALSEY

20MG

A087480 001

DELTA-DOME

BAYER PHARMS

5MG

A080293 001

DELTASONE

+ PHARMACIA AND UPJOHN

2.5MG **

N009986 005

+

5MG **

N009986 002

+

10MG **

N009986 006

+

20MG **

N009986 007

+

50MG **

N009986 008

FERNISONE

FERNDALE LABS

5MG

A083364 001

METICORTEN

+ SCHERING

1MG **

N009766 002

+

5MG **

N009766 001

ORASONE

SOLVAY

1MG

A083009 001

5MG

A083009 002

10MG

A083009 003

20MG

A083009 004

50MG

A085999 001

PARACORT

PARKE DAVIS

5MG

N010962 002

PREDNICEN-M

SCHWARZ PHARMA

5MG

A084655 001

PREDNISONE

AM THERAP

5MG

A089387 001 Nov 06, 1986

10MG

A089388 001 Nov 06, 1986

20MG

A089389 001 Nov 06, 1986

AMNEAL

1MG

A213385 001 Jun 16, 2020

5MG

A213385 002 Jun 16, 2020

10MG

A213386 001 Jun 24, 2020

20MG

A213386 002 Jun 24, 2020

AMNEAL PHARMS NY

5MG

A089597 001 Oct 05, 1987

10MG

A089598 001 Oct 05, 1987

20MG

A089599 001 Oct 05, 1987

AUROLIFE PHARMA LLC

10MG

A089983 001 Jan 12, 1989

20MG

A085813 001

50MG

A089984 001 Jan 12, 1989

BUNDY

5MG

A083676 001

CHARTWELL RX

5MG

A083059 001

CONTRACT PHARMACAL

5MG

A080209 001

DURAMED PHARMS BARR

5MG

A088394 001 Oct 04, 1983

10MG

A088395 001 Oct 04, 1983

20MG

A088396 001 Oct 04, 1983

ELKINS SINN

5MG

A080491 001

20MG

A085811 001

EVERYLIFE

1MG

A084440 001

2.5MG

A084440 002

5MG

A084440 003

FERRANTE

2.5MG

A080563 001

5MG

A080563 002

HALSEY

5MG

A080300 001

HEATHER

5MG

A080320 001

10MG

A084341 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PREDNISONETABLET;ORAL
PREDNISONE

	20MG	A084417	001	
	20MG	A085543	001	
	50MG	A086946	001	
HIKMA PHARMS	1MG	A040890	001	Nov 01, 2010
	2.5MG	A040538	001	Jan 08, 2004
	50MG	A088465	001	Jun 01, 1984
IMPAX LABS	5MG	A080782	001	
INWOOD LABS	1MG	A080328	001	
	2.5MG	A080306	001	
	5MG	A080279	001	
IVAX SUB TEVA PHARMS	5MG	A080283	001	
	10MG	A084133	001	
	20MG	A084134	001	
KV PHARM	5MG	A084236	001	
LANNETT	5MG	A080514	001	
	20MG	A084275	001	
LEDERLE	5MG	A086968	001	
MARSHALL PHARMA	5MG	A080301	001	
MUTUAL PHARM	5MG	A080701	001	
	10MG	A086595	001	
	20MG	A084634	001	
NYLOS	5MG	A085115	001	
PANRAY	1MG	A080350	001	
	2.5MG	A080350	002	
	5MG	A080350	003	
PHARMAVITE	5MG	A084662	002	
PHOENIX LABS NY	5MG	A080321	001	
	20MG	A083807	001	
PUREPAC PHARM	5MG	A080353	001	
	10MG	A086062	001	
	20MG	A086061	001	
PVT FORM	20MG	A085151	001	
REXALL	5MG	A080232	001	
RISING	5MG	A084774	001	
ROXANE	20MG	N017109	001	
	25MG	A087833	001	May 04, 1982
SANDOZ	5MG	A080336	002	
SCHERER LABS	5MG	A080371	001	
SPERTI	1MG	A080359	001	
	2.5MG	A080359	002	
	5MG	A080359	003	
SUN PHARM INDUSTRIES	50MG	A086596	001	
SUPERPHARM	5MG	A088865	001	Oct 25, 1984
	10MG	A088866	001	Oct 25, 1984
	20MG	A088867	001	Oct 25, 1984
TEVA	5MG	A080397	001	
UDL	5MG	A087984	001	Jan 18, 1983
	10MG	A087985	001	Jan 18, 1983
	20MG	A087986	001	Jan 18, 1983
UPSHER SMITH	5MG	A087471	001	
	20MG	A087470	001	
VALEANT PHARM INTL	5MG	A080237	001	
VANGARD	5MG	A087682	001	Jan 15, 1982
	20MG	A087701	001	Jan 15, 1982
VITARINE	5MG	A080334	001	
	5MG	A080506	001	
WATSON LABS	5MG	A085084	002	
	10MG	A087773	001	Jul 13, 1982
	20MG	A086813	001	
	50MG	A086867	001	
	50MG	A087772	001	Jul 13, 1982
WHITEWORTH TOWN PLSN	2.5MG	A084913	001	
	5MG	A080343	001	
	10MG	A089028	001	Jul 24, 1986
	20MG	A084913	002	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PREDNISONE

TABLET;ORAL

SERVISONE

LEDERLE

5MG

A080223 001

TABLET, DELAYED RELEASE;ORAL

PREDNISONE

ACTAVIS LABS FL INC

1MG

A204867 001 Apr 25, 2017

2MG

A204867 002 Apr 25, 2017

5MG

A204867 003 Apr 25, 2017

PREGABALIN

CAPSULE;ORAL

PREGABALIN

MYLAN

25MG

A091228 001 Sep 20, 2019

50MG

A091228 002 Sep 20, 2019

75MG

A091228 003 Sep 20, 2019

100MG

A091228 004 Sep 20, 2019

150MG

A091228 005 Sep 20, 2019

200MG

A091228 006 Sep 20, 2019

225MG

A091228 007 Sep 20, 2019

300MG

A091228 008 Sep 20, 2019

PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST

+ ASTRAZENECA

1% **

N014763 004

+

2% **

N014763 005

+

3% **

N014763 003

CITANEST PLAIN

+ ASTRAZENECA

4% **

N014763 007

CITANEST PLAIN DENTAL

+ DENTSPLY PHARM

4%

N021382 001

PRIMAQUINE PHOSPHATE

TABLET;ORAL

PRIMAQUINE PHOSPHATE

ALVOGEN

EQ 15MG BASE

A203924 001 Feb 03, 2014

PRIMIDONE

SUSPENSION;ORAL

MYSOLINE

+ NURO PHARMA

250MG/5ML

N010401 001

TABLET;ORAL

PRIMIDONE

DR REDDYS LABS LTD

50MG

A040862 001 Oct 03, 2008

250MG

A040862 002 Oct 03, 2008

HIKMA INTL PHARMS

50MG

A040667 001 Jul 27, 2006

250MG

A040667 002 Jul 27, 2006

IMPAX LABS

50MG

A040717 001 Feb 12, 2008

250MG

A040717 002 Feb 12, 2008

WATSON LABS

250MG

A085052 001

PROBENECID

TABLET;ORAL

BENEMID

+ MERCK

500MG **

N007898 004

PROBENECID

IVAX SUB TEVA PHARMS

500MG

A083740 001 May 09, 1984

LEDERLE

500MG

A086917 001

WATSON LABS

500MG

A086150 002 Apr 23, 1982

PROBUCOL

TABLET;ORAL

LORELCO

SANOFI AVENTIS US

250MG

N017535 001

500MG

N017535 002 Jul 06, 1988

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PROCAINAMIDE HYDROCHLORIDE

CAPSULE; ORAL

PROCAINAMIDE HYDROCHLORIDE

ANI PHARMS INC	250MG		A089219 001	Jul 01, 1986
	375MG		A089219 002	Jul 01, 1986
	500MG		A089219 003	Jul 01, 1986
ASCOT	250MG		A087542 001	Jan 08, 1982
	375MG		A087697 001	Mar 01, 1983
	500MG		A087543 001	Jan 08, 1982
IVAX SUB TEVA PHARMS	250MG		A084604 001	
	375MG		A084595 001	
	500MG		A084606 001	
LANNETT	250MG		A083693 001	
	500MG		A084696 001	
LEDERLE	250MG		A086942 001	
	375MG		A086952 001	
	500MG		A086943 001	
ROXANE	250MG		A088989 001	Apr 26, 1985
	500MG		A088990 001	Apr 26, 1985
VANGARD	250MG		A087643 001	Jun 01, 1982
	500MG		A087875 001	Jun 01, 1982
WATSON LABS	250MG		A083287 001	
	250MG		A083795 001	
	250MG		A085167 001	
	375MG		A084403 001	
	375MG		A087020 001	
	500MG		A084280 001	
	500MG		A084357 001	
	500MG		A087021 001	
PROCAN				
PARKE DAVIS	250MG		A085804 001	
	375MG		A087502 001	
	500MG		A085079 001	
PROCAPAN				
PANRAY	250MG		A083553 002	
PRONESTYL				
+ APOTHECON	250MG **		N007335 001	
+	375MG **		N007335 004	
+	500MG **		N007335 003	

INJECTABLE; INJECTION

PROCAINAMIDE HYDROCHLORIDE

ABRAXIS PHARM	100MG/ML		A089415 001	Nov 17, 1986
	500MG/ML		A089416 001	Nov 17, 1986
HOSPIRA	500MG/ML		A089537 001	Aug 25, 1987
INTL MEDICATION	500MG/ML		A088637 001	Jul 31, 1984
PHARMAFAIR	100MG/ML		A088824 001	Nov 20, 1985
	500MG/ML		A088830 001	Nov 20, 1985
SMITH AND NEPHEW	100MG/ML		A088530 001	Mar 04, 1985
	500MG/ML		A088531 001	Mar 04, 1985
SOLOPAK	500MG/ML		A088532 001	Mar 04, 1985
WARNER CHILCOTT	100MG/ML		A089528 001	May 03, 1988
	500MG/ML		A089529 001	May 03, 1988
WATSON LABS	100MG/ML		A087079 001	
	500MG/ML		A087080 001	
WEST-WARD PHARMS INT	100MG/ML		A089029 001	Apr 17, 1986
	500MG/ML		A089030 001	Apr 17, 1986
PRONESTYL				
+ APOTHECON	100MG/ML **		N007335 002	
+	500MG/ML **		N007335 005	

TABLET; ORAL

PRONESTYL

APOTHECON	250MG		N017371 001	
	375MG		N017371 002	
	500MG		N017371 003	

TABLET, EXTENDED RELEASE; ORAL

PROCAINAMIDE HYDROCHLORIDE

ANI PHARMS INC	250MG		A088958 001	Dec 02, 1985
	250MG		A089369 001	Aug 14, 1987
	500MG		A088959 001	Dec 02, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PROCAINAMIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

PROCAINAMIDE HYDROCHLORIDE

	500MG	A088974 001	Jul 22, 1985
	500MG	A089369 002	Jan 09, 1987
	750MG	A089369 003	Aug 14, 1987
	750MG	A089438 001	Mar 23, 1987
	1GM	A040111 001	Dec 13, 1996
INWOOD LABS	500MG	A089840 001	Mar 06, 1989
SANDOZ	500MG	A089284 001	Jun 23, 1986
WATSON LABS	250MG	A088533 001	Dec 03, 1984
	250MG	A089026 001	Oct 22, 1985
	500MG	A088534 001	Dec 03, 1984
	500MG	A089027 001	Oct 22, 1985
	750MG	A088535 001	Nov 03, 1984
	750MG	A089042 001	Oct 22, 1985
	1GM	A089520 001	Jan 15, 1987
PROCAN SR			
PARKE DAVIS	250MG	A086468 001	
PARKE DALE	500MG	A086065 001	
	750MG	A087510 001	Apr 01, 1982
	1GM	A088489 001	Jan 16, 1985
PROCANBID			
KING PHARMS	500MG	N020545 001	Jan 31, 1996
	1GM	N020545 002	Jan 31, 1996
PRONESTYL-SR			
APOTHECON	500MG	A087361 001	

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

NOVOCAIN

HOSPIRA	1%	A085362 003	
	2%	A085362 004	
	10%	A086797 001	
PROCAINE HYDROCHLORIDE			
ABRAXIS PHARM	1%	A080384 002	
	1%	A080421 001	
	2%	A080384 003	
	2%	A080421 002	
BEL MAR	1%	A080711 001	
	2%	A080756 001	
ELKINS SINN	1%	A083315 001	
	2%	A083315 002	
GD SEARLE LLC	1%	A086202 001	
	2%	A086202 002	
HOSPIRA	1%	A080416 001	
	2%	A080416 002	
MILES	1%	A080415 001	
	2%	A080415 002	
WATSON LABS	1%	A080658 001	
	1%	A083535 001	
	2%	A080658 002	
	2%	A083535 002	

PROCAINE HYDROCHLORIDE; TETRACYCLINE HYDROCHLORIDE

INJECTABLE; INJECTION

ACHROMYCIN

LEDERLE	40MG/VIAL;100MG/VIAL	N050276 001	
	40MG/VIAL;250MG/VIAL	N050276 003	
TETRACYN			
PFIZER	40MG/VIAL;100MG/VIAL	A060285 002	
	40MG/VIAL;250MG/VIAL	A060285 003	

PROCAINE MERETHOXYLLINE; THEOPHYLLINE

INJECTABLE; INJECTION

DICURIN PROCAINE

LILLY	100MG/ML;50MG/ML	N008869 001	
-------	------------------	-------------	--

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PROCHLORPERAZINE

SUPPOSITORY;RECTAL

COMPAZINE

GLAXOSMITHKLINE	2.5MG **	N011127	003
	5MG **	N011127	001
	25MG **	N011127	002

PROCHLORPERAZINE

ABLE

2.5MG	A040407	001	Jul 11, 2001
5MG	A040407	002	Jul 11, 2001
25MG	A040407	003	Jul 11, 2001

PROCHLORPERAZINE EDISYLATE

CONCENTRATE;ORAL

COMPAZINE

GLAXOSMITHKLINE	EQ 10MG BASE/ML	N011276	001
-----------------	-----------------	---------	-----

PROCHLORPERAZINE

ALPHARMA US PHARMS

EQ 10MG BASE/ML	A087153	001	Jun 08, 1982
-----------------	---------	-----	--------------

PROCHLORPERAZINE EDISYLATE

MORTON GROVE

EQ 10MG BASE/ML	A088598	001	Oct 25, 1984
-----------------	---------	-----	--------------

INJECTABLE;INJECTION

COMPAZINE

+ GLAXOSMITHKLINE	EQ 5MG BASE/ML **	N010742	002
-------------------	-------------------	---------	-----

PROCHLORPERAZINE

BAXTER HLTHCARE

EQ 5MG BASE/ML	A087759	001	Oct 01, 1982
----------------	---------	-----	--------------

PROCHLORPERAZINE EDISYLATE

HOSPIRA

EQ 5MG BASE/ML	A089703	001	Apr 07, 1988
----------------	---------	-----	--------------

MARSAM PHARMS LLC

EQ 5MG BASE/ML	A089675	001	Dec 05, 1988
----------------	---------	-----	--------------

SMITH AND NEPHEW

EQ 5MG BASE/ML	A089251	001	Dec 04, 1986
----------------	---------	-----	--------------

TEVA PARENTERAL

EQ 5MG BASE/ML	A040505	001	May 30, 2003
----------------	---------	-----	--------------

WATSON LABS

EQ 5MG BASE/ML	A089530	001	Jul 08, 1987
----------------	---------	-----	--------------

EQ 5MG BASE/ML	A089605	001	Jul 08, 1987
----------------	---------	-----	--------------

EQ 5MG BASE/ML	A089606	001	Jul 08, 1987
----------------	---------	-----	--------------

WEST-WARD PHARMS INT

EQ 5MG BASE/ML	A089523	001	May 03, 1988
----------------	---------	-----	--------------

WYETH AYERST

EQ 5MG BASE/ML	A086348	001	
----------------	---------	-----	--

SYRUP;ORAL

COMPAZINE

GLAXOSMITHKLINE	EQ 5MG BASE/5ML	N011188	001
-----------------	-----------------	---------	-----

PROCHLORPERAZINE EDISYLATE

ALPHARMA US PHARMS

EQ 5MG BASE/5ML	A087154	001	Sep 01, 1982
-----------------	---------	-----	--------------

MORTON GROVE

EQ 5MG BASE/5ML	A088597	001	Oct 25, 1984
-----------------	---------	-----	--------------

PROCHLORPERAZINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL

COMPAZINE

GLAXOSMITHKLINE	EQ 10MG BASE	N011000	001
	EQ 10MG BASE	N021019	001 Oct 06, 1999
	EQ 15MG BASE	N011000	002
	EQ 15MG BASE	N021019	002 Oct 06, 1999
	EQ 30MG BASE	N011000	003
	EQ 75MG BASE	N011000	004

TABLET;ORAL

COMPAZINE

+ GLAXOSMITHKLINE	EQ 5MG BASE **	N010571	001
-------------------	----------------	---------	-----

+	EQ 10MG BASE **	N010571	002
---	-----------------	---------	-----

+	EQ 25MG BASE **	N010571	003
---	-----------------	---------	-----

PROCHLORPERAZINE

WATSON LABS

EQ 5MG BASE	A085580	001
-------------	---------	-----

EQ 10MG BASE	A085178	001
--------------	---------	-----

EQ 25MG BASE	A085579	001
--------------	---------	-----

PROCHLORPERAZINE MALEATE

DURAMED PHARMS BARR

EQ 5MG BASE	A040207	001	May 01, 1997
-------------	---------	-----	--------------

EQ 5MG BASE	A089484	001	Jan 20, 1987
-------------	---------	-----	--------------

EQ 10MG BASE	A040207	002	May 01, 1997
--------------	---------	-----	--------------

EQ 10MG BASE	A089485	001	Jan 20, 1987
--------------	---------	-----	--------------

EQ 25MG BASE	A089486	001	Jan 20, 1987
--------------	---------	-----	--------------

IVAX SUB TEVA PHARMS

EQ 5MG BASE	A040162	001	Jan 20, 1998
-------------	---------	-----	--------------

EQ 10MG BASE	A040162	002	Jan 20, 1998
--------------	---------	-----	--------------

SANDOZ

EQ 5MG BASE	A040101	001	Jul 19, 1996
-------------	---------	-----	--------------

EQ 10MG BASE	A040101	002	Jul 19, 1996
--------------	---------	-----	--------------

EQ 25MG BASE	A040101	003	Jul 19, 1996
--------------	---------	-----	--------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PROCHLORPERAZINE MALEATE

TABLET; ORAL

PROCHLORPERAZINE MALEATE

TEVA PHARMS

EQ 5MG BASE
EQ 10MG BASEA040120 001 Jul 11, 1996
A040120 002 Jul 11, 1996PROCYCLIDINE HYDROCHLORIDE

TABLET; ORAL

KEMADRIN

MONARCH PHARMS

2MG
5MGN009818 005
N009818 003PROGESTERONE

CAPSULE; ORAL

PROGESTERONE

TEVA PHARMS

100MG
200MGA202121 001 Feb 29, 2012
A202121 002 Feb 29, 2012

PROMETRIUM

VIRTUS PHARMS

300MG

N019781 003 Oct 15, 1999

INJECTABLE; INJECTION

PROGESTERONE

AM REGENT

50MG/ML

A090845 001 Jun 22, 2009

LILLY

25MG/ML

N009238 002

50MG/ML

N009238 001

INSERT, EXTENDED RELEASE; INTRAUTERINE

PROGESTASERT

ALZA

38MG

N017553 001

SYSTEM; VAGINAL

MILPROSA

+ FERRING PHARMS INC

1.78GM

N201110 001 Apr 29, 2020

PROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

SPARINE

WYETH AYERST

30MG/ML
100MG/MLN010942 001
N010942 004

INJECTABLE; INJECTION

PROMAZINE HYDROCHLORIDE

WATSON LABS

25MG/ML
50MG/MLA084510 001
A084517 001

SPARINE

BAXTER HLTHCARE CORP

25MG/ML
50MG/MLN010349 008
N010349 006

SYRUP; ORAL

SPARINE

WYETH AYERST

10MG/5ML

N010942 003

TABLET; ORAL

SPARINE

WYETH AYERST

10MG
25MG
50MG
100MG
200MGN010348 006
N010348 001
N010348 002
N010348 003
N010348 004PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PHENERGAN

WYETH AYERST

25MG/ML
50MG/MLN008857 002
N008857 003

PROMETHAZINE HYDROCHLORIDE

ABBOTT

25MG/ML
50MG/MLA084223 001
A084222 001

AKORN

25MG/ML
50MG/MLA083955 002
A083955 001

AM REGENT

25MG/ML

A040515 001 Mar 19, 2003

BEDFORD LABS

25MG/ML
50MG/MLA040524 001 Mar 17, 2004
A040524 002 Mar 17, 2004

HOSPIRA

25MG/ML
50MG/MLA040372 001 Jun 08, 2000
A040372 002 Jun 08, 2000

50MG/ML

A083838 002

MARSAM PHARMS LLC

25MG/ML

A089463 001 May 02, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROMETHAZINE HYDROCHLORIDE

	50MG/ML	A089477 001	May 02, 1988
MYLAN INSTITUTIONAL	25MG/ML	A040471 001	Nov 21, 2002
SANDOZ	25MG/ML	A040593 001	Nov 08, 2006
	50MG/ML	A040593 002	Nov 08, 2006
TEVA PHARMS USA	25MG/ML **	A040454 001	Aug 22, 2002
	50MG/ML **	A040454 002	Aug 22, 2002
WATSON LABS	25MG/ML	A083532 001	
	25MG/ML	A084591 001	
	50MG/ML	A080629 002	
	50MG/ML	A083532 002	
WOCKHARDT	25MG/ML	A040785 001	Sep 26, 2008
	50MG/ML	A040785 002	Sep 26, 2008
ZIPAN-25			
ALTANA	25MG/ML	A083997 001	
ZIPAN-50			
ALTANA	50MG/ML	A083997 002	

SUPPOSITORY; RECTAL

PHENERGAN

+	MYLAN	12.5MG **	N010926 002
+		25MG **	N010926 001
+		50MG **	N011689 001

PROMETHACON

POLYMEDICA	25MG	A084901 001	
	50MG	A084902 001	

PROMETHAZINE HYDROCHLORIDE

ABLE	12.5MG	A040504 001	Apr 11, 2003
	25MG	A040504 002	Apr 11, 2003
	50MG	A040449 001	Feb 27, 2003
WATSON LABS INC	12.5MG	A040479 001	Jun 24, 2003
	25MG	A040479 002	Jun 24, 2003

SYRUP; ORAL

MYMETHAZINE FORTIS

USL PHARMA	25MG/5ML	A087996 001	Jan 18, 1983
------------	----------	-------------	--------------

PROMETH FORTIS

ALPHARMA US PHARMS	25MG/5ML	A084772 001	
--------------------	----------	-------------	--

PROMETH PLAIN

ACTAVIS MID ATLANTIC	6.25MG/5ML	A085953 001	
----------------------	------------	-------------	--

PROMETHAZINE

CENCI	6.25MG/5ML	A089013 001	Sep 20, 1985
-------	------------	-------------	--------------

PROMETHAZINE HYDROCHLORIDE

KV PHARM	6.25MG/5ML	A085388 001	
	25MG/5ML	A085385 001	
PHARM ASSOC	6.25MG/5ML	A087518 001	
WHITEWORTH TOWN PLSN	6.25MG/5ML	A086395 001	

PROMETHAZINE HYDROCHLORIDE PLAIN

+	ANI PHARMS	6.25MG/5ML **	N008381 004	Apr 18, 1984
+		25MG/5ML **	N008381 003	

TABLET; ORAL

PHENERGAN

+	DELCOR ASSET CORP	12.5MG **	N007935 002
+		25MG **	N007935 003
+		50MG **	N007935 004

PROMETHAZINE HYDROCHLORIDE

ABBOTT	12.5MG	A084160 001	
	25MG	A084166 001	
	50MG	A084539 001	
ABLE	12.5MG	A040558 001	Jul 01, 2004
	25MG	A040558 002	Jul 01, 2004
	50MG	A040558 003	Jul 01, 2004
IMPAX LABS	12.5MG	A040791 002	Feb 12, 2008
	25MG	A040791 003	Feb 12, 2008
	25MG	A084214 002	Jul 07, 1982
	50MG	A040791 001	May 20, 2008
INVATECH	12.5MG	A084233 001	
	25MG	A085146 001	
	50MG	A085146 002	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PROMETHAZINE HYDROCHLORIDE

TABLET; ORAL

PROMETHAZINE HYDROCHLORIDE

IVAX SUB TEVA PHARMS	12.5MG	A083604	001	
	25MG	A083603	001	
	50MG	A083613	001	
LANNETT	12.5MG	A080949	001	
	25MG	A080949	002	
	50MG	A080949	003	
MYLAN	12.5MG	A091054	001	Aug 30, 2011
	25MG	A091054	002	Aug 30, 2011
	50MG	A091054	003	Aug 30, 2011
PVT FORM	12.5MG	A083214	001	
	25MG	A083658	001	
SANDOZ	12.5MG	A084176	002	May 22, 2009
SUN PHARM INDUSTRIES	12.5MG	A084555	001	
	25MG	A084554	001	
	50MG	A084557	001	
TABLICAPS	12.5MG	A084080	001	
	25MG	A084027	001	
TEVA	25MG	A089109	001	Sep 10, 1985
WATSON LABS	12.5MG	A083401	001	
	12.5MG	A083712	001	
	12.5MG	A085986	001	
	25MG	A083204	001	
	25MG	A085684	001	
	50MG	A083403	001	
	50MG	A085664	001	
REMSD				
BRISTOL MYERS SQUIBB	25MG	A083176	002	
	50MG	A083176	001	

PROPAFENONE HYDROCHLORIDE

TABLET; ORAL

PROPAFENONE HYDROCHLORIDE

NESHER PHARMS	150MG	A076193	001	Feb 07, 2002
	225MG	A076193	002	Feb 07, 2002
	300MG	A076193	003	Feb 07, 2002
RYTHMOL				
+ GLAXOSMITHKLINE LLC	150MG **	N019151	001	Nov 27, 1989
+	225MG **	N019151	003	Nov 20, 1992
+	300MG **	N019151	002	Nov 27, 1989

PROPANTHELINE BROMIDE

INJECTABLE; INJECTION

PRO-BANTHINE

GD SEARLE LLC	30MG/VIAL	N008843	001	
---------------	-----------	---------	-----	--

TABLET; ORAL

PRO-BANTHINE

+ SHIRE	7.5MG **	N008732	003	
+	15MG **	N008732	002	

PROPANTHELINE BROMIDE

ASCOT	15MG	A087663	001	Oct 25, 1982
HEATHER	15MG	A085780	001	
HIKMA	7.5MG	A080927	001	
IMPAX LABS	15MG	A084541	002	
MYLAN	15MG	A083706	001	
PAR PHARM	15MG	A088377	001	Dec 08, 1983
PVT FORM	15MG	A080977	001	
SANDOZ	15MG	A080928	001	
TABLICAPS	15MG	A084428	001	
WATSON LABS	15MG	A083029	002	
	15MG	A083151	001	

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

KAINAIR

PHARMAFAIR	0.5%	A088087	001	Jun 07, 1983
------------	------	---------	-----	--------------

OPHTHAINE

+ APOTHECON	0.5% **	N008883	001	
-------------	---------	---------	-----	--

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OPHTHETIC

+ ALLERGAN

0.5% **

N012583 001

PARACAINE

OPTOPICS

0.5%

A087681 001 Aug 05, 1982

PROPARACAINE HYDROCHLORIDE

SOLA BARNES HIND

0.5%

A084144 001

0.5%

A084151 001

PROPIOLACTONE

SOLUTION;IRRIGATION

BETAPRONE

FOREST LABS

N/A

N011657 001

PROPIOMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

LARGON

WEST-WARD PHARMS INT 20MG/ML

N012382 002

PROPOFOL

INJECTABLE; INJECTION

DIPRIVAN

FRESENIUS KABI USA

10MG/ML

N019627 001 Oct 02, 1989

PROPOFOL

TEVA PARENTERAL

10MG/ML

A075392 001 Sep 19, 2000

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVON

XANODYNE PHARM

32MG

N010997 001

65MG

N010997 003

DOLENE

HERITAGE PHARMS INC

65MG

A080530 001

KESSO-GESIC

MK LABS

65MG

A083544 001

PROPHENE 65

HALSEY

65MG

A083538 002

PROPOXYPHENE HYDROCHLORIDE

ALRA

65MG

A083184 001

IMPAX LABS

65MG

A083317 001

IVAX SUB TEVA PHARMS

32MG

A083597 001

MUTUAL PHARM

65MG

A083186 001

MYLAN

32MG

A083528 001

65MG

A040569 001 Dec 16, 2004

65MG

A083299 001

NEXGEN PHARMA INC

65MG

A083185 001

PAR PHARM

65MG

A080269 001

PUREPAC PHARM

65MG

A083278 001

PVT FORM

32MG

A083464 001

65MG

A083113 001

ROXANE

32MG

A083089 001

65MG

A083089 002

SANDOZ

32MG

A084014 001

65MG

A083125 002

65MG

A083688 001

65MG

A083870 002

65MG

A086495 001

TEVA

65MG

A088615 001 Oct 22, 1984

VALEANT PHARM INTL

65MG

A080783 001

VINTAGE PHARMS

65MG

A040908 001 Jul 17, 2009

WATSON LABS

65MG

A080908 002

65MG

A085190 001

WEST WARD

65MG

A083501 001

WHITEWORTH TOWN PLSN

65MG

A084551 001

PROPOXYPHENE HYDROCHLORIDE 65

WARNER CHILCOTT

65MG

A083786 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PROPOXYPHENE NAPSYLATE

SUSPENSION;ORAL

DARVON-N

AAIPHARMA LLC 50MG/5ML N016861 001

TABLET;ORAL

DARVON-N

XANODYNE PHARM 100MG N016862 002

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

PROPRANOLOL HYDROCHLORIDE

INWOOD LABS 60MG A072499 001 Apr 11, 1989

80MG A072500 001 Apr 11, 1989

120MG A072501 001 Apr 11, 1989

160MG A072502 001 Apr 11, 1989

MYLAN 60MG A078022 001 Feb 15, 2007

80MG A078022 002 Feb 15, 2007

120MG A078022 003 Feb 15, 2007

160MG A078022 004 Feb 15, 2007

UPSHER SMITH LABS 60MG A078311 001 Mar 06, 2009

80MG A078311 002 Mar 06, 2009

120MG A078311 003 Mar 06, 2009

160MG A078311 004 Mar 06, 2009

CONCENTRATE;ORAL

PROPRANOLOL HYDROCHLORIDE INTENSOL

ROXANE 80MG/ML A071388 001 May 15, 1987

INJECTABLE;INJECTION

PROPRANOLOL HYDROCHLORIDE

+ BAXTER HLTHCARE CORP 1MG/ML N016419 001

FOSUN PHARMA 1MG/ML A076400 001 Feb 26, 2003

SMITH AND NEPHEW 1MG/ML A070135 001 Apr 15, 1986

1MG/ML A070137 001 Apr 15, 1986

SOLOPAK 1MG/ML A070136 001 Apr 15, 1986

SOLUTION;ORAL

PROPRANOLOL HYDROCHLORIDE

MORTON GROVE 20MG/5ML A071984 001 Mar 03, 1989

40MG/5ML A071985 001 Mar 03, 1989

SUSPENSION;ORAL

INDERAL

WYETH AYERST 10MG/ML N019536 001 Dec 12, 1986

TABLET;ORAL

INDERAL

+ WYETH PHARMS 10MG ** N016418 001

+ 20MG ** N016418 003

+ 40MG ** N016418 002

+ 60MG ** N016418 009 Oct 18, 1982

+ 80MG ** N016418 004

+ 90MG ** N016418 010 Oct 18, 1982

PROPRANOLOL HYDROCHLORIDE

ANI PHARMS INC 60MG A071791 001 Jul 15, 1987

90MG A071977 001 Apr 06, 1988

DAVA PHARMS INC 10MG A070125 001 Jul 30, 1985

20MG A070126 001 Jul 30, 1985

40MG A070127 001 Jul 30, 1985

60MG A071495 001 Dec 31, 1987

80MG A070128 001 Jul 30, 1985

90MG A071496 001 Dec 31, 1987

DURAMED PHARMS BARR 10MG A070306 001 Sep 09, 1985

20MG A070307 001 Sep 09, 1985

40MG A070308 001 Sep 09, 1985

60MG A070309 001 Oct 01, 1986

80MG A070310 001 Sep 09, 1985

90MG A071327 001 Oct 01, 1986

IMPAX LABS INC 10MG A071972 001 Apr 06, 1988

20MG A071972 002 Apr 06, 1988

40MG A071972 003 Apr 06, 1988

80MG A071976 001 Apr 06, 1988

INTERPHARM 10MG A071368 001 May 05, 1987

20MG A071369 001 May 05, 1987

40MG A071370 001 May 05, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PROPRANOLOL HYDROCHLORIDE

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE

	80MG	A071371	001	May 05, 1987
IVAX SUB TEVA PHARMS	10MG	A072063	001	Jul 29, 1988
	20MG	A072066	001	Jul 29, 1988
	40MG	A072067	001	Jul 29, 1988
	60MG	A072068	001	Jul 29, 1988
	80MG	A072069	001	Jul 29, 1988
LEDERLE	10MG	A072117	001	Jun 23, 1988
	20MG	A072118	001	Jun 23, 1988
	40MG	A072119	001	Jun 23, 1988
	80MG	A072120	001	Jun 23, 1988
MYLAN	60MG	A072275	001	Jun 09, 1989
PAR PHARM	90MG	A071288	001	Oct 22, 1986
PUREPAC PHARM	10MG	A070814	001	Nov 03, 1986
	20MG	A070815	001	Nov 03, 1986
	40MG	A070816	001	Nov 03, 1986
	60MG	A070817	001	Nov 03, 1986
	80MG	A070757	001	Nov 03, 1986
ROXANE	10MG	A070516	001	Jul 07, 1986
	20MG	A070517	001	Jul 07, 1986
	40MG	A070518	001	Jul 07, 1986
	60MG	A070519	001	Sep 24, 1986
	80MG	A070520	001	Jul 07, 1986
	90MG	A070521	001	Sep 24, 1986
SANDOZ	10MG	A071658	001	Jul 05, 1988
	20MG	A071687	001	Jul 05, 1988
	40MG	A071688	001	Jul 05, 1988
	60MG	A072197	001	Jul 05, 1988
	80MG	A071689	001	Jul 05, 1988
	90MG	A072198	001	Jul 05, 1988
SCHERING	10MG	A070120	001	Aug 06, 1985
	20MG	A070121	001	Aug 06, 1985
	40MG	A070122	001	Aug 06, 1985
	60MG	A070123	001	Oct 29, 1986
	80MG	A070124	001	Aug 06, 1985
SUPERPHARM	10MG	A071515	001	Jun 08, 1988
	20MG	A071516	001	Jun 08, 1988
	40MG	A071517	001	Jun 08, 1988
	80MG	A071518	001	Jun 08, 1988
TEVA	10MG	A070232	001	Oct 07, 1987
	20MG	A070233	001	Jun 23, 1986
	40MG	A070234	001	Jun 23, 1986
WARNER CHILCOTT	10MG	A070438	001	Sep 15, 1986
	20MG	A070439	001	Sep 15, 1986
	40MG	A070440	001	Sep 15, 1986
	60MG	A070441	001	Sep 24, 1986
	80MG	A070442	001	Sep 15, 1986
WATSON LABS	10MG	A070140	001	Jul 30, 1985
	10MG	A070378	001	Mar 19, 1987
	20MG	A070141	001	Jul 30, 1985
	20MG	A070379	001	Mar 19, 1987
	40MG	A070142	001	Jul 30, 1985
	40MG	A070380	001	Mar 19, 1987
	60MG	A070143	001	Jan 15, 1987
	60MG	A070381	001	Mar 19, 1987
	60MG	A071098	001	Oct 06, 1986
	80MG	A070144	001	Jul 30, 1985
	80MG	A070382	001	Mar 19, 1987
	80MG	A070551	001	Jul 10, 1986
	90MG	A071183	001	Oct 06, 1986
	90MG	A071792	001	Jul 15, 1987
WATSON LABS TEVA	10MG	A070548	001	Jul 10, 1986
	20MG	A070549	001	Apr 11, 1986
	40MG	A070550	001	Apr 11, 1986
YAOPHARMA CO LTD	10MG	A070663	001	Jun 13, 1986
	20MG	A070664	001	Jun 13, 1986
	40MG	A070665	001	Jun 13, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

60MG	A070666 001	Oct 10, 1986
80MG	A070667 001	Jun 13, 1986

PROPYLIODONE

SUSPENSION; INTRATRACHEAL

DIONOSIL AQUEOUS

GLAXOSMITHKLINE	50%	N009309 001
-----------------	-----	-------------

DIONOSIL OILY

GLAXOSMITHKLINE	60%	N009309 002
-----------------	-----	-------------

PROPYLTHIOURACIL

TABLET; ORAL

PROPYLTHIOURACIL

ABBOTT	50MG	A084075 001
ANABOLIC	50MG	A080285 001
ANI PHARMS INC	50MG	A080215 001
CHARTWELL RX	50MG	A084543 001
HALSEY	50MG	A080015 001
IMPAX LABS	50MG	A080159 001
LANNETT	50MG	A080016 001
LILLY	50MG	N006213 001
QUAGEN	50MG	A080154 001
SUN PHARM INDUSTRIES	50MG	A083982 001
TABLICAPS	50MG	A080840 001
WATSON LABS	50MG	A080932 001
	50MG	A085201 001

PROTAMINE SULFATE

INJECTABLE; INJECTION

PROTAMINE SULFATE

+	LILLY	10MG/ML **	N006460 002
	PHARMACIA AND UPJOHN	50MG/VIAL	N007413 001
		250MG/VIAL	N007413 002
	WEST-WARD PHARMS INT	10MG/ML	A089474 001
		10MG/ML	A089475 001
			Aug 02, 1984
			Nov 05, 1986
			Nov 05, 1986

PROTEIN HYDROLYSATE

INJECTABLE; INJECTION

AMINOSOL 5%

ABBVIE	5%	N005932 012	Jan 31, 1985
--------	----	-------------	--------------

HYPROTIGEN 5%

B BRAUN	5%	N006170 003	Jan 10, 1984
---------	----	-------------	--------------

PROTIRELIN

INJECTABLE; INJECTION

THYPINONE

ABBOTT	0.5MG/ML	N017638 001
--------	----------	-------------

THYREL TRH

FERRING	0.5MG/ML	N018087 001
---------	----------	-------------

PROTOKYLLOL HYDROCHLORIDE

TABLET; ORAL

VENTAIRE

SANOFI AVENTIS US	2MG	A083459 001
-------------------	-----	-------------

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

VIVACTIL

HERITAGE PHARMA	5MG	A073644 001	Aug 24, 1995
	10MG	A073645 001	Aug 24, 1995
TEVA WOMENS	5MG **	N016012 001	
	10MG **	N016012 002	

PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

NOVAFED

SANOFI AVENTIS US	120MG	N017603 001
-------------------	-------	-------------

SUDAFED 12 HOUR

+	GLAXOSMITHKLINE	120MG **	N017941 002
---	-----------------	----------	-------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

ACTIFED

GLAXOSMITHKLINE 120MG;5MG N018996 001 Jun 17, 1985

TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES

KV PHARM 120MG;5MG A071798 001 Mar 16, 1989

SYRUP;ORAL

ACTAHIST

CENCI 30MG/5ML;1.25MG/5ML A088344 001 Feb 09, 1984

HISTAFED

CENCI 30MG/5ML;1.25MG/5ML A088283 001 Apr 20, 1984

MYFED

USL PHARMA 30MG/5ML;1.25MG/5ML A088116 001 Mar 04, 1983

TRILITRON

NEWTRON PHARMS 30MG/5ML;1.25MG/5ML A088474 001 Feb 12, 1985

TABLET;ORAL

ALLERFED

PVT FORM 60MG;2.5MG A088860 001 Jan 31, 1985

CORPHED

FOSUN PHARMA 60MG;2.5MG A088602 001 Apr 11, 1985

PSEUDOEPHEDRINE HYDROCHLORIDE AND TRIPROLIDINE HYDROCHLORIDE

SANDOZ 60MG;2.5MG A088193 001 May 17, 1983

TRILITRON

NEWTRON PHARMS 60MG;2.5MG A088515 001 Jan 09, 1985

TRIPHED

TEVA 60MG;2.5MG A088630 001 May 17, 1984

TRIPROLIDINE AND PSEUDOEPHEDRINE

WATSON LABS 60MG;2.5MG A088318 002 Jan 13, 1984

WEST WARD 60MG;2.5MG A088117 001 Apr 19, 1983

TRIPROLIDINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

IVAX SUB TEVA PHARMS 60MG;2.5MG A085273 001 Dec 12, 1984

SUPERPHARM 60MG;2.5MG A088578 001 Feb 21, 1985

TABLET, EXTENDED RELEASE;ORAL

TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES

KV PHARM 120MG;5MG A072758 001 Nov 25, 1991

PSEUDOEPHEDRINE POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL

PSEUDO-12

UCB INC EQ 60MG HYDROCHLORIDE/5ML N019401 001 Jun 19, 1987

PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

AFRINOL

+ SCHERING PLOUGH 120MG N018191 001

PYRAZINAMIDE

TABLET;ORAL

PYRAZINAMIDE

NOVITIUM PHARMA 500MG A080157 001

PYRIDOSTIGMINE BROMIDE

TABLET;ORAL

PYRIDOSTIGMINE BROMIDE

ANI PHARMS INC 30MG A040512 002 Jul 20, 2005

60MG A040512 001 Oct 08, 2003

IMPAX LABS INC 60MG A040457 001 Dec 26, 2002

SOLVAY 30MG A089572 001 Nov 27, 1990

US ARMY 30MG N020414 001 Feb 05, 2003

PYRIDOXINE HYDROCHLORIDE

INJECTABLE;INJECTION

HEXA-BETALIN

LILLY 100MG/ML A080854 001

PYRIDOXINE HYDROCHLORIDE

AKORN 100MG/ML A087967 001 Oct 01, 1982

BEL MAR 100MG/ML A080761 001

DELL LABS 50MG/ML A083771 001

100MG/ML A083772 001

DR REDDYS 100MG/ML A080572 001

ELKINS SINN 100MG/ML A080581 001

LUITPOLD 100MG/ML A080669 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION

PYRIDOXINE HYDROCHLORIDE

MYLAN INSTITUTIONAL 100MG/ML

A204879 001 Jul 14, 2016

WATSON LABS 100MG/ML

A083760 001

PYRILAMINE MALEATE

TABLET; ORAL

PYRILAMINE MALEATE

IMPAX LABS 25MG

A080808 001

WATSON LABS 25MG

A085231 001

PYRIMETHAMINE; SULFADOXINE

TABLET; ORAL

FANSIDAR

ROCHE 25MG; 500MG

N018557 001

PYRITHIONE ZINC

LOTION; TOPICAL

HEAD & SHOULDERS CONDITIONER

WARNER CHILCOTT 0.3%

N019412 002 Mar 10, 1986

PYRVINIUM PAMOATE

SUSPENSION; ORAL

POVAN

PARKE DAVIS EQ 50MG BASE/5ML

N011964 001

TABLET; ORAL

POVAN

PARKE DAVIS EQ 50MG BASE

N012485 002

QUAZEPAM

TABLET; ORAL

DORAL

GALT PHARMS 7.5MG

N018708 003 Feb 26, 1987

QUETIAPINE FUMARATE

TABLET; ORAL

QUETIAPINE FUMARATE

ACTAVIS GRP PTC EQ 25MG BASE

A201762 001 Feb 27, 2013

EQ 50MG BASE

A201762 002 Feb 27, 2013

EQ 100MG BASE

A201762 003 Feb 27, 2013

EQ 150MG BASE

A201762 004 Feb 27, 2013

EQ 200MG BASE

A201762 005 Feb 27, 2013

EQ 300MG BASE

A201762 006 Feb 27, 2013

EQ 400MG BASE

A201762 007 Feb 27, 2013

ALEMBIC PHARMS LTD EQ 25MG BASE

A203390 001 Oct 28, 2014

EQ 50MG BASE

A203390 002 Oct 28, 2014

EQ 100MG BASE

A203390 003 Oct 28, 2014

EQ 200MG BASE

A203390 004 Oct 28, 2014

EQ 300MG BASE

A203390 005 Oct 28, 2014

EQ 400MG BASE

A203390 006 Oct 28, 2014

MYLAN PHARMS INC EQ 25MG BASE

A090323 001 Mar 27, 2012

TORRENT PHARMS LTD EQ 25MG BASE

A200363 001 Mar 27, 2012

EQ 50MG BASE

A200363 002 Mar 27, 2012

EQ 100MG BASE

A200363 003 Mar 27, 2012

EQ 200MG BASE

A200363 004 Mar 27, 2012

EQ 300MG BASE

A200363 005 Mar 27, 2012

EQ 400MG BASE

A200363 006 Mar 27, 2012

SEROQUEL

+ ASTRAZENECA PHARMS EQ 150MG BASE **

N020639 004 Dec 20, 1998

TABLET, EXTENDED RELEASE; ORAL

QUETIAPINE FUMARATE

AMNEAL PHARMS EQ 400MG BASE

A211405 001 Oct 26, 2018

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

ACTAVIS ELIZABETH EQ 5MG BASE

A076459 001 Dec 22, 2004

EQ 10MG BASE

A076459 002 Dec 22, 2004

EQ 20MG BASE

A076459 003 Dec 22, 2004

EQ 40MG BASE

A076459 004 Dec 22, 2004

ACTAVIS LABS FL INC EQ 5MG BASE

A076049 001 Jan 14, 2005

EQ 10MG BASE

A076049 002 Jan 14, 2005

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

	EQ 20MG BASE	A076049 003	Jan 14, 2005
	EQ 40MG BASE	A076049 004	Jan 14, 2005
ANI PHARMS INC	EQ 5MG BASE	A075504 001	Aug 24, 2007
	EQ 10MG BASE	A075504 002	Aug 24, 2007
	EQ 20MG BASE	A075504 003	Aug 24, 2007
	EQ 40MG BASE	A075504 004	Aug 24, 2007
APOTEX INC	EQ 5MG BASE	A076240 001	Jan 26, 2006
	EQ 10MG BASE	A076240 002	Jan 26, 2006
	EQ 20MG BASE	A076240 003	Jan 26, 2006
	EQ 40MG BASE	A076240 004	Jan 26, 2006
MYLAN	EQ 5MG BASE	A076036 001	Jan 28, 2005
	EQ 5MG BASE	A076694 001	Dec 23, 2004
	EQ 10MG BASE	A076036 002	Jan 28, 2005
	EQ 10MG BASE	A076694 002	Dec 23, 2004
	EQ 20MG BASE	A076036 003	Jan 28, 2005
	EQ 20MG BASE	A076694 003	Dec 23, 2004
	EQ 40MG BASE	A076036 004	Jan 28, 2005
	EQ 40MG BASE	A076694 004	Dec 23, 2004
SUN PHARM INDS LTD	EQ 5MG BASE	A076607 001	Dec 15, 2004
	EQ 5MG BASE	A090800 001	Jun 18, 2009
	EQ 10MG BASE	A076607 002	Dec 15, 2004
	EQ 10MG BASE	A090800 002	Jun 18, 2009
	EQ 20MG BASE	A076607 003	Dec 15, 2004
	EQ 20MG BASE	A090800 003	Jun 18, 2009
	EQ 40MG BASE	A076607 004	Dec 15, 2004
	EQ 40MG BASE	A090800 004	Jun 18, 2009
YAOPHARMA CO LTD	EQ 5MG BASE	A076803 001	Mar 02, 2005
	EQ 10MG BASE	A076803 002	Mar 02, 2005
	EQ 20MG BASE	A076803 003	Mar 02, 2005
	EQ 40MG BASE	A076803 004	Mar 02, 2005

QUINESTROL

TABLET; ORAL

ESTROVIS

PARKE DAVIS	0.1MG	N016768 002	
	0.2MG	N016768 003	

QUINETHAZONE

TABLET; ORAL

HYDROMOX

LEDERLE	50MG	N013264 001	
---------	------	-------------	--

QUINETHAZONE; RESERPINE

TABLET; ORAL

HYDROMOX R

LEDERLE	50MG;0.125MG	N013927 001	
---------	--------------	-------------	--

QUINIDINE GLUCONATE

INJECTABLE; INJECTION

QUINIDINE GLUCONATE

+ LILLY

80MG/ML

N007529 002 Feb 10, 1989

TABLET; ORAL

QUINACT

BAYER HLTHCARE

266MG

A085978 001

400MG

A086099 001

TABLET, EXTENDED RELEASE; ORAL

DURAQUIN

WARNER CHILCOTT

330MG

N017917 001

QUINAGLUTE

+ BAYER HLTHCARE

324MG

N016647 001

QUINALAN

LANNETT

324MG

A088081 001 Feb 10, 1986

QUINATIME

WATSON LABS

324MG

A087448 001

QUINIDINE GLUCONATE

ANI PHARMS INC

324MG

A087810 001 Sep 29, 1982

ASCOT

324MG

A088582 001 Jun 17, 1985

AUROLIFE PHARMA LLC

324MG

A089894 001 Dec 15, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE;ORAL

QUINIDINE GLUCONATE

CYCLE PHARMS LTD	324MG	A088431	001	Jan 06, 1984
HALSEY	324MG	A089476	001	Apr 10, 1987
SUPERPHARM	324MG	A089164	001	Nov 21, 1985
WATSON LABS	324MG	A087785	001	Jan 24, 1983

QUINIDINE POLYGALACTURONATE

TABLET;ORAL

CARDIOQUIN

PHARM RES ASSOC	275MG	N011642	002	
-----------------	-------	---------	-----	--

QUINIDINE SULFATE

CAPSULE;ORAL

CIN-QUIN

SOLVAY	200MG	A085296	001	
	300MG	A085297	001	

QUINIDINE SULFATE

LILLY	200MG	A085103	001	
-------	-------	---------	-----	--

TABLET;ORAL

CIN-QUIN

SOLVAY	100MG	A085299	001	
	200MG	A084932	001	
	300MG	A085298	001	

QUINIDINE SULFATE

BARR	200MG	A084177	001	
CONTRACT PHARMACAL	200MG	A083808	001	
CYCLE PHARMS LTD	200MG	A083640	001	
	300MG	A085632	001	
DAVA PHARMS INC	200MG	A087011	001	
ELKINS SINN	200MG	A083622	001	
EVERYLIFE	200MG	A083439	001	
HALSEY	200MG	A083583	001	
HIKMA	200MG	A083862	001	
IMPAX LABS	200MG	A083347	001	
IVAX SUB TEVA PHARMS	200MG	A084549	001	
KING PHARMS	200MG	A085175	001	
KV PHARM	200MG	A085276	001	
LANNETT	200MG	A083743	001	
LEDERLE	200MG	A086176	001	
LILLY	200MG	A085038	001	
PERRIGO	200MG	A085322	001	
PHARMAVITE	200MG	A084627	001	
PUREPAC PHARM	200MG	A084003	001	
SANDOZ	200MG	A084631	001	
	200MG	A084914	001	
	300MG	A089839	001	Sep 29, 1988
SCHERER LABS	200MG	A085068	001	
SUN PHARM INDUSTRIES	100MG	A081029	001	Apr 14, 1989
	200MG	A081030	001	Apr 14, 1989
	300MG	A081031	001	Apr 14, 1989
SUPERPHARM	200MG	A088973	001	Apr 10, 1985
USL PHARMA	200MG	A087837	001	Apr 14, 1982
VALEANT PHARM INTL	200MG	A083393	001	
VANGARD	200MG	A087909	001	Jul 13, 1982
VINTAGE PHARMS	200MG	A083963	001	
WARNER CHILCOTT	200MG	A083879	001	
WATSON LABS	100MG	A085584	001	
	200MG	A083288	001	
	200MG	A085140	002	
	300MG	A085583	001	
WHITEWORTH TOWN PLSN	200MG	A085444	001	

QUINORA

KEY PHARMS	200MG	A083576	001	
SCHERING	300MG	A085222	001	

TABLET, EXTENDED RELEASE;ORAL

QUINIDEX

WYETH PHARMS INC	300MG	N012796	002	
------------------	-------	---------	-----	--

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

QUINIDINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

QUINIDINE SULFATE

COSETTE

300MG

A040045 001 Jun 30, 1994

QUININE SULFATE

CAPSULE;ORAL

QUININE SULFATE

MYLAN PHARMS INC

324MG

A202581 001 Dec 14, 2012

RABEPRAZOLE SODIUM

CAPSULE, DELAYED RELEASE;ORAL

ACIPHEX SPRINKLE

+ AYTU

5MG

N204736 001 Mar 26, 2013

+

10MG

N204736 002 Mar 26, 2013

TABLET, DELAYED RELEASE;ORAL

ACIPHEX

+ EISAI INC

10MG **

N020973 001 May 29, 2002

RABEPRAZOLE SODIUM

MYLAN

20MG

A076885 001 Nov 08, 2013

RAMIPRIL

CAPSULE;ORAL

RAMIPRIL

ACTAVIS ELIZABETH

1.25MG

A077513 001 Jun 18, 2008

2.5MG

A077513 002 Jun 18, 2008

5MG

A077513 003 Jun 18, 2008

10MG

A077513 004 Jun 18, 2008

CIPLA

1.25MG

A077004 001 Aug 07, 2008

2.5MG

A077004 002 Aug 07, 2008

5MG

A077004 003 Aug 07, 2008

10MG

A077004 004 Aug 07, 2008

RANBAXY LABS LTD

5MG

A078849 001 Mar 06, 2009

10MG

A078849 002 Mar 06, 2009

TEVA PHARMS

1.25MG

A077470 001 Jun 18, 2008

2.5MG

A077470 002 Jun 18, 2008

5MG

A077470 003 Jun 18, 2008

10MG

A077470 004 Jun 18, 2008

WATSON LABS

5MG

A076549 003 Oct 24, 2005

YAOPHARMA CO LTD

1.25MG

A077514 001 Jun 18, 2008

2.5MG

A077514 002 Jun 18, 2008

5MG

A077514 003 Jun 18, 2008

10MG

A077514 004 Jun 18, 2008

TABLET;ORAL

ALTACE

+ KING PFIZER

1.25MG **

N022021 001 Feb 27, 2007

+

2.5MG **

N022021 002 Feb 27, 2007

+

5MG **

N022021 003 Feb 27, 2007

+

10MG **

N022021 004 Feb 27, 2007

RAMIPRIL

APOTEX

1.25MG

A091069 001 Dec 02, 2015

2.5MG

A091069 002 Dec 02, 2015

5MG

A091069 003 Dec 02, 2015

10MG

A091069 004 Dec 02, 2015

MYLAN PHARMS INC

1.25MG

A090650 001 Jun 30, 2011

2.5MG

A090650 002 Jun 30, 2011

5MG

A090650 003 Jun 30, 2011

10MG

A090650 004 Jun 30, 2011

ZYDUS PHARMS USA INC

1.25MG

A090697 001 Sep 24, 2009

2.5MG

A090697 002 Sep 24, 2009

5MG

A090697 003 Sep 24, 2009

10MG

A090697 004 Sep 24, 2009

RANITIDINE BISMUTH CITRATE

TABLET;ORAL

TRITEC

GLAXOSMITHKLINE

400MG

N020559 001 Aug 08, 1996

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

RANITIDINE HYDROCHLORIDE

CAPSULE;ORAL

RANITIDINE HYDROCHLORIDE

AJANTA PHARMA LTD	EQ 150MG BASE	A209859 001	Sep 27, 2018
	EQ 300MG BASE	A209859 002	Sep 27, 2018
APPCO	EQ 150MG BASE	A211893 001	Apr 05, 2019
	EQ 300MG BASE	A211893 002	Apr 05, 2019
MYLAN	EQ 150MG BASE	A075564 001	Oct 27, 2000
	EQ 300MG BASE	A075564 002	Oct 27, 2000
NOVITIUM PHARMA	EQ 150MG BASE	A210681 001	Nov 23, 2018
	EQ 300MG BASE	A210681 002	Nov 23, 2018
TEVA	EQ 150MG BASE	A075557 001	Oct 31, 2003
	EQ 300MG BASE	A075557 002	Oct 31, 2003

ZANTAC 150

+ GLAXOSMITHKLINE	EQ 150MG BASE **	N020095 001	Mar 08, 1994
-------------------	------------------	-------------	--------------

ZANTAC 300

+ GLAXOSMITHKLINE	EQ 300MG BASE **	N020095 002	Mar 08, 1994
-------------------	------------------	-------------	--------------

GRANULE, EFFERVESCENT;ORAL

ZANTAC 150

GLAXO GRP LTD	EQ 150MG BASE/PACKET	N020251 002	Mar 31, 1994
---------------	----------------------	-------------	--------------

INJECTABLE;INJECTION

RANITIDINE HYDROCHLORIDE

BEDFORD	EQ 25MG BASE/ML	A074764 001	Nov 19, 2004
---------	-----------------	-------------	--------------

ZANTAC IN PLASTIC CONTAINER

TELIGENT	EQ 1MG BASE/ML	N019593 002	Sep 27, 1991
----------	----------------	-------------	--------------

	EQ 50MG BASE/100ML	N019593 001	Dec 17, 1986
--	--------------------	-------------	--------------

SYRUP;ORAL

RANITIDINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC	EQ 15MG BASE/ML	A076124 001	Feb 21, 2007
AKORN	EQ 15MG BASE/ML	A091078 001	Mar 22, 2011
AMNEAL PHARMS	EQ 15MG BASE/ML	A078312 001	Sep 02, 2008
ANDA REPOSITORY	EQ 15MG BASE/ML	A090054 001	Nov 15, 2010
APOTEX INC	EQ 15MG BASE/ML	A077602 001	Sep 17, 2007
NOSTRUM LABS INC	EQ 15MG BASE/ML	A078684 001	Aug 27, 2009
	EQ 15MG BASE/ML	A091091 001	Sep 20, 2011
RANBAXY	EQ 15MG BASE/ML	A078448 001	Dec 13, 2007
TARO	EQ 15MG BASE/ML	A077476 001	Jun 13, 2011
TORRENT	EQ 15MG BASE/ML	A090102 001	May 26, 2009
WOCKHARDT	EQ 15MG BASE/ML	A079211 001	May 26, 2009
	EQ 15MG BASE/ML	A079212 001	Feb 23, 2009

ZANTAC

+ GLAXO GRP LTD	EQ 15MG BASE/ML	N019675 001	Dec 30, 1988
-----------------	-----------------	-------------	--------------

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

AMNEAL PHARMS NY	EQ 150MG BASE	A077824 001	Oct 13, 2006
	EQ 300MG BASE	A077824 002	Oct 13, 2006
ANI PHARMS INC	EQ 75MG BASE	A075212 001	Jan 14, 2000
	EQ 75MG BASE	A075296 001	Jan 14, 2000
	EQ 150MG BASE	A074488 001	Jul 31, 1997
	EQ 150MG BASE	A077426 001	Dec 19, 2005
	EQ 300MG BASE	A074488 002	Jul 31, 1997
	EQ 300MG BASE	A077426 002	Dec 19, 2005
APOTEX INC	EQ 75MG BASE	A075167 001	May 04, 2000
	EQ 150MG BASE	A200172 001	May 31, 2012
BOEHRINGER INGELHEIM	EQ 150MG BASE	A074662 001	Aug 29, 1997
	EQ 300MG BASE	A074662 002	Aug 29, 1997
CONTRACT PHARMACAL	EQ 75MG BASE	A075094 001	Jun 21, 1999
GRANULES	EQ 150MG BASE	A210243 001	Aug 20, 2018
	EQ 150MG BASE	A210243 002	Aug 20, 2018
HERITAGE PHARMA	EQ 150MG BASE	A075165 001	Sep 30, 1998
	EQ 300MG BASE	A075165 002	Sep 30, 1998
MYLAN	EQ 75MG BASE	A075497 001	Jan 14, 2000
	EQ 150MG BASE	A074023 001	Aug 22, 1997
	EQ 150MG BASE	A074552 001	Jul 30, 1998
	EQ 300MG BASE	A074023 002	Aug 22, 1997
	EQ 300MG BASE	A074552 002	Jul 30, 1998
NOSTRUM LABS INC	EQ 150MG BASE	A203694 001	Nov 30, 2017
	EQ 300MG BASE	A203694 002	Nov 30, 2017
RANBAXY	EQ 75MG BASE	A075254 001	Jan 14, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

	EQ 150MG BASE	A075000 001	Jan 30, 1998
	EQ 300MG BASE	A075000 002	Jan 30, 1998
SANDOZ	EQ 75MG BASE	A075519 001	Sep 26, 2002
STRIDES PHARMA	EQ 75MG BASE	A201745 001	Feb 29, 2012
	EQ 75MG BASE	A209160 001	Mar 05, 2018
	EQ 150MG BASE	A200536 001	Jun 28, 2011
	EQ 150MG BASE	A205512 001	Aug 22, 2016
	EQ 150MG BASE	A209161 001	Feb 22, 2018
	EQ 150MG BASE	A210010 001	Aug 01, 2018
	EQ 300MG BASE	A205512 002	Aug 22, 2016
	EQ 300MG BASE	A210010 002	Aug 01, 2018
SUN PHARM INDS LTD	EQ 75MG BASE	A075132 001	Jan 14, 2000
	EQ 150MG BASE	A075439 001	Apr 19, 2000
	EQ 300MG BASE	A075439 002	Apr 19, 2000
WATSON LABS	EQ 150MG BASE	A074864 001	Oct 20, 1997
	EQ 300MG BASE	A074864 002	Oct 20, 1997
WOCKHARDT	EQ 75MG BASE	A078884 001	Jul 31, 2008
	EQ 150MG BASE	A078653 001	Nov 26, 2007
	EQ 150MG BASE	A078701 001	Nov 12, 2009
	EQ 300MG BASE	A078701 002	Dec 11, 2009
ZANTAC 150			
+ GLAXO GRP LTD	EQ 150MG BASE **	N018703 001	Jun 09, 1983
ZANTAC 300			
+ GLAXO GRP LTD	EQ 300MG BASE **	N018703 002	Dec 09, 1985
TABLET, EFFERVESCENT;ORAL			
ZANTAC 150			
GLAXO GRP LTD	EQ 150MG BASE	N020251 001	Mar 31, 1994
ZANTAC 25			
GLAXO GRP LTD	EQ 25MG BASE	N020251 003	Apr 01, 2004
ZANTAC 75			
+ SANOFI US	EQ 75MG BASE **	N020745 001	Feb 26, 1998

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL

RANOLAZINE

ANI PHARMS INC	500MG	A210482 001	Oct 29, 2019
	1GM	A210482 002	Oct 29, 2019
CIPLA	500MG	A211291 001	May 28, 2019
	1GM	A211291 002	May 28, 2019

RAPACURONIUM BROMIDE

INJECTABLE;INJECTION

RAPLON

ORGANON USA INC	100MG/VIAL	N020984 001	Aug 18, 1999
	200MG/VIAL	N020984 002	Aug 18, 1999

RASAGILINE MESYLATE

TABLET;ORAL

RASAGILINE MESYLATE

APOTEX INC	EQ 0.5MG BASE	A201950 001	Sep 12, 2013
	EQ 1MG BASE	A201950 002	Sep 12, 2013
WATSON LABS INC	EQ 0.5MG BASE	A201823 001	Jul 01, 2013
	EQ 1MG BASE	A201823 002	Jul 01, 2013

RAUWOLFIA SERPENTINA ROOT

TABLET;ORAL

HIWOLFIA

BOWMAN PHARMS	50MG	N009276 003	
	50MG	N009276 005	
	100MG	N009276 004	
HYSERPIN			
PHYS PRODS VA	50MG	N010581 001	
KOGLUCOID			
PANRAY	50MG	N009278 001	
	100MG	N009278 002	
RAUDIXIN			
APOTHECON	50MG	N008842 001	
	100MG	N008842 002	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

RAUWOLFIA SERPENTINA ROOT

TABLET; ORAL

RAUSERPIN

FERNDALE LABS	50MG	N009926 002
	100MG	N009926 004

RAUVAL

PAL PAK	50MG	N009108 002
	100MG	N009108 004

RAUWOLFIA SERPENTINA

BUNDY	50MG	N009477 001
	100MG	N009477 002

HALSEY	50MG	A080498 001
	100MG	A080498 002

IMPAX LABS	50MG	N009273 001
	100MG	N009273 002

IVAX SUB TEVA PHARMS	50MG	N011521 001
	100MG	N011521 002

PUREPAC PHARM	50MG	A080842 001
	100MG	A080842 002

PVT FORM	50MG	A080583 001
	100MG	A080583 002

SOLVAY	50MG	A080500 001
	100MG	A080500 002

TABLICAPS	50MG	A083867 001
	100MG	A083444 001

VALEANT PHARM INTL	50MG	N009668 001
	100MG	N009668 002

WATSON LABS	50MG	A080907 001
	100MG	A080914 001

WOLFINA

FOREST PHARMS	50MG	N009255 008
	100MG	N009255 006

REPAGLINIDE

TABLET; ORAL

PRANDIN

+ GEMINI LABS LLC	0.5MG **	N020741 001	Dec 22, 1997
+	1MG **	N020741 002	Dec 22, 1997
+	2MG **	N020741 003	Dec 22, 1997

REPAGLINIDE

ACTAVIS TOTOWA	0.5MG	A090008 001	Jan 22, 2014
	1MG	A090008 002	Jan 22, 2014
	2MG	A090008 003	Jan 22, 2014

MYLAN	0.5MG	A090252 001	Aug 23, 2013
	1MG	A090252 002	Jan 22, 2014
	2MG	A090252 003	Jan 22, 2014

RESCINNAMINE

CAPSULE; ORAL

CINNASIL

PANRAY	0.5MG	A084736 001
--------	-------	-------------

TABLET; ORAL

MODERIL

PFIZER	0.25MG	N010686 003
	0.5MG	N010686 006

RESERPINE

ELIXIR; ORAL

SERPASIL

NOVARTIS	0.2MG/4ML	N009115 005
----------	-----------	-------------

INJECTABLE; INJECTION

SANDRIL

LILLY	2.5MG/ML	N010012 001
-------	----------	-------------

SERPASIL

NOVARTIS	2.5MG/ML	N009434 002
----------	----------	-------------

TABLET; ORAL

HISERPIA

BOWMAN PHARMS	0.1MG	N009631 002
	0.25MG	N009631 004

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

RESERPINE

TABLET;ORAL

RAU-SED

BRISTOL MYERS SQUIBB	0.1MG	N009357	001	
	0.25MG	N009357	004	
	0.5MG	N009357	006	
	1MG	N009357	008	
RESERPINE				
BARR	0.25MG	A080721	002	
BELL PHARMA	0.1MG	A083058	001	
	0.25MG	A083058	002	
BUNDY	0.1MG	N009663	001	
	0.25MG	N009663	003	
CYCLE PHARMS LTD	0.1MG	N009859	001	
	0.25MG	N009859	002	
ELKINS SINN	0.1MG	A083145	001	
	0.25MG	A083145	002	
EVERYLIFE	0.1MG	N010441	001	
	0.25MG	N010441	002	
	0.5MG	N010441	003	
	1MG	N010441	004	
HALSEY	0.1MG	A080457	002	
	0.25MG	A080457	001	
	1MG	A080457	003	
HIKMA INTL PHARMS	0.1MG	A080975	001	
	0.25MG	A080975	002	
	1MG	A080975	003	
IMPAX LABS	0.1MG	N009627	001	
	0.25MG	N009627	002	
IVAX SUB TEVA PHARMS	0.1MG	N011185	001	
	0.25MG	N011185	002	
MARSHALL PHARMA	0.1MG	A080492	001	
	0.25MG	A080492	002	
MK LABS	0.1MG	A080525	002	
	0.25MG	A080525	001	
MYLAN	1MG	A084974	001	
PHARMAVITE	0.25MG	A084663	001	
PUREPAC PHARM	0.1MG	A080753	002	
	0.25MG	A080753	001	
PVT FORM	0.1MG	A086117	001	
	0.25MG	A080582	001	
	0.25MG	A085775	001	
	1MG	A080582	002	
REXALL	0.25MG	A080637	001	
+ SANDOZ	0.1MG	N009838	001	
+	0.25MG	N009838	002	
SOLVAY	0.25MG	A080446	001	
TABLICAPS	0.25MG	A085207	001	
TEVA	0.1MG	A089020	001	Mar 07, 1985
	0.25MG	A089019	001	Mar 07, 1985
VALEANT PHARM INTL	0.1MG	N009667	001	
	0.25MG	N009667	002	
WATSON LABS	0.1MG	A080679	001	
	0.25MG	A080393	001	
	0.25MG	A085401	001	
	1MG	A080749	001	
WHITEWORTH TOWN PLSN	0.1MG	A080723	001	
	0.25MG	A080723	002	
	1MG	A080723	003	
SANDRIL				
LILLY	0.1MG	N009376	004	
	0.25MG	N009376	001	
SERPALAN				
LANNETT	0.1MG	N010124	001	
	0.25MG	N010124	002	
SERPANRAY				
PANRAY	0.1MG	N009391	001	
	0.25MG	N009391	002	
	1MG	N009391	004	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

RESERPINE

TABLET; ORAL

SERPASIL

NOVARTIS	0.1MG	N009115 001
	0.25MG	N009115 003
	1MG	N009115 004

SERPATE

VALE	0.1MG	N009453 001
	0.25MG	N009453 002

SERPIVITE

VITARINE	0.25MG	N009645 002
----------	--------	-------------

RESERPINE; TRICHLORMETHIAZIDE

TABLET; ORAL

METATENSIN #2

SANOFI AVENTIS US	0.1MG;2MG	N012972 001
-------------------	-----------	-------------

METATENSIN #4

SANOFI AVENTIS US	0.1MG;4MG	N012972 002
-------------------	-----------	-------------

NAQUIVAL

SCHERING	0.1MG;4MG	N012265 003
----------	-----------	-------------

TRICHLORMETHIAZIDE W/ RESERPINE

WATSON LABS	0.1MG;4MG	A085248 001
-------------	-----------	-------------

RIBAVIRIN

CAPSULE; ORAL

REBETOL

MERCK SHARP DOHME	200MG**Indicated for use and comarketed with Interferon ALFA-2B, Recombinant (INTRON A), as Rebetrone Combination Therapy**	N020903 001	Jun 03, 1998
-------------------	---	-------------	--------------

RIBASPHERE

CHARTWELL RX	200MG	A076203 001	Apr 06, 2004
--------------	-------	-------------	--------------

RIBAVIRIN

CHARTWELL RX	200MG	A076192 001	Apr 06, 2004
TEVA	200MG	A076277 001	Oct 04, 2004

SOLUTION; ORAL

REBETOL

+ SCHERING	40MG/ML	N021546 001	Jul 29, 2003
------------	---------	-------------	--------------

TABLET; ORAL

COPEGUS

+ ROCHE	200MG **	N021511 001	Dec 03, 2002
---------	----------	-------------	--------------

+	400MG **	N021511 002	Jun 21, 2005
---	----------	-------------	--------------

RIBAVIRIN

BEXIMCO PHARMS USA	200MG	A202546 001	Aug 12, 2014
	400MG	A202546 002	Aug 12, 2014
	500MG	A202546 003	Aug 12, 2014
	600MG	A202546 004	Aug 12, 2014
CHARTWELL RX	200MG	A077456 001	Dec 05, 2005
	400MG	A077456 002	Dec 05, 2005
	600MG	A077456 003	Dec 05, 2005
HERITAGE PHARMA	200MG	A077053 001	Dec 05, 2005
ZYDUS PHARMS USA	400MG	A077094 002	Mar 16, 2007
	500MG	A077094 004	Apr 18, 2008
	600MG	A077094 003	Mar 16, 2007

RIFAMPIN

CAPSULE; ORAL

RIFADIN

SANOFI AVENTIS US	150MG	A062303 001
+	300MG	N050420 001

INJECTABLE; INJECTION

RIFAMPIN

EMCURE PHARMS LTD	600MG/VIAL	A204101 001	Aug 18, 2014
-------------------	------------	-------------	--------------

RILUZOLE

TABLET; ORAL

RILUZOLE

APOTEX CORP	50MG	A091300 001	Jun 18, 2013
DAITO PHARMS CO LTD	50MG	A204430 001	Oct 16, 2018

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

RIMANTADINE HYDROCHLORIDE

SYRUP;ORAL

FLUMADINE

FOREST LABS

50MG/5ML

N019650 001 Sep 17, 1993

TABLET;ORAL

RIMANTADINE HYDROCHLORIDE

HERITAGE PHARMA

100MG

A076375 001 Jan 14, 2003

IMPAX LABS INC

100MG

A075916 001 Nov 02, 2001

RIMEXOLONE

SUSPENSION/DROPS;OPHTHALMIC

VEXOL

EYEVANCE

1%

N020474 001 Dec 30, 1994

RISEDRONATE SODIUM

TABLET;ORAL

ACTONEL

+ APIL

75MG **

N020835 004 Apr 16, 2007

RISEDRONATE SODIUM

HANGZHOU BINJIANG

35MG

A207516 001 Feb 15, 2019

MYLAN

5MG

A200477 001 Nov 30, 2015

30MG

A200477 002 Nov 30, 2015

35MG

A200477 003 Nov 30, 2015

75MG

A200477 004 Jun 10, 2014

150MG

A200477 005 Jun 10, 2014

TABLET, DELAYED RELEASE;ORAL

RISEDRONATE SODIUM

IMPAX LABS INC

35MG

A205066 001 Jun 29, 2018

ZYDUS PHARMS

35MG

A203822 001 Sep 11, 2018

RISPERIDONE

SOLUTION;ORAL

RISPERIDONE

ANI PHARMS INC

1MG/ML

A076440 001 Jan 30, 2009

LANNETT CO INC

1MG/ML

A202386 001 Jan 12, 2015

PRECISION DOSE

1MG/ML

A076797 001 Jun 28, 2010

TORRENT

1MG/ML

A078909 001 Jul 29, 2009

WOCKHARDT

1MG/ML

A078744 001 Oct 08, 2009

TABLET;ORAL

RISPERDAL

JANSSEN PHARMS

5MG

N020272 005 Dec 29, 1993

RISPERIDONE

HERITAGE PHARMA

0.25MG

A076228 001 Jun 30, 2008

0.25MG

A077769 001 Oct 16, 2008

0.5MG

A076228 002 Jun 30, 2008

0.5MG

A077769 002 Oct 16, 2008

1MG

A076228 003 Jun 30, 2008

1MG

A077769 003 Oct 16, 2008

2MG

A076228 004 Jun 30, 2008

2MG

A077769 004 Oct 16, 2008

3MG

A076228 005 Jun 30, 2008

3MG

A077769 005 Oct 16, 2008

4MG

A076228 006 Jun 30, 2008

4MG

A077769 006 Oct 16, 2008

JUBILANT CADISTA

0.25MG

A078828 001 Mar 23, 2009

0.5MG

A078828 002 Mar 23, 2009

1MG

A078828 003 Mar 23, 2009

2MG

A078828 004 Mar 23, 2009

3MG

A078828 005 Mar 23, 2009

4MG

A078828 006 Mar 23, 2009

MYLAN

0.25MG

A076288 001 Sep 15, 2008

0.5MG

A076288 002 Sep 15, 2008

1MG

A076288 003 Sep 15, 2008

2MG

A076288 004 Sep 15, 2008

3MG

A076288 005 Sep 15, 2008

4MG

A076288 006 Sep 15, 2008

RATIOPHARM

0.25MG

A077784 001 Jun 08, 2010

0.5MG

A077784 002 Jun 08, 2010

1MG

A077784 003 Jun 08, 2010

2MG

A077784 004 Jun 08, 2010

3MG

A077784 005 Jun 08, 2010

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

RISPERIDONE

TABLET; ORAL

RISPERIDONE

	4MG	A077784 006	Jun 08, 2010
SUN PHARM INDS INC	0.25MG	A078036 001	Mar 10, 2014
	0.5MG	A078036 002	Mar 10, 2014
	1MG	A078036 003	Mar 10, 2014
	2MG	A078036 004	Mar 10, 2014
	3MG	A078036 005	Mar 10, 2014
	4MG	A078036 006	Mar 10, 2014
SYNTHON PHARMS	0.25MG	A078187 001	Oct 22, 2009
	0.5MG	A078187 002	Oct 22, 2009
	1MG	A078187 003	Oct 22, 2009
	2MG	A078187 004	Oct 22, 2009
	3MG	A078187 005	Oct 22, 2009
	4MG	A078187 006	Oct 22, 2009
WATSON LABS	0.25MG	A077860 001	Dec 05, 2008
	0.5MG	A077860 002	Dec 05, 2008
	1MG	A077860 003	Dec 05, 2008
	2MG	A077860 004	Dec 05, 2008
	3MG	A077860 005	Dec 05, 2008
	4MG	A077860 006	Dec 05, 2008
WEST WARD PHARMS	0.25MG	A078740 001	May 29, 2009
	0.5MG	A078740 002	May 29, 2009
	1MG	A078740 003	May 29, 2009
	2MG	A078740 004	May 29, 2009
	3MG	A078740 005	May 29, 2009
	4MG	A078740 006	May 29, 2009

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERIDONE

ACTAVIS LABS FL INC	0.5MG	A076996 001	Apr 19, 2011
	1MG	A076996 002	Apr 19, 2011
	2MG	A076996 003	Apr 19, 2011
	3MG	A076996 004	Apr 19, 2011
	4MG	A076996 005	Apr 19, 2011
HERITAGE PHARMA	0.5MG	A076908 001	Mar 12, 2012
	1MG	A076908 002	Mar 12, 2012
	2MG	A076908 003	Mar 12, 2012
MYLAN PHARMS INC	0.25MG	A091537 006	Feb 12, 2013
	0.5MG	A091537 001	Mar 30, 2011
	1MG	A091537 002	Mar 30, 2011
	2MG	A091537 003	Mar 30, 2011
	3MG	A091537 004	Mar 30, 2011
	4MG	A091537 005	Mar 30, 2011

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION

RITODRINE HYDROCHLORIDE

ABRAXIS PHARM	10MG/ML	A071188 001	Jul 23, 1987
	15MG/ML	A071189 001	Jul 23, 1987
HOSPIRA	10MG/ML	A071618 001	Feb 28, 1991
	15MG/ML	A071619 001	Feb 28, 1991
RITODRINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER			
HOSPIRA	30MG/100ML	A071438 001	Jan 22, 1991
YUTOPAR			
ASTRAZENECA	10MG/ML	N018580 001	
	15MG/ML	N018580 002	Sep 27, 1984
TABLET; ORAL			
YUTOPAR			
ASTRAZENECA	10MG	N018555 001	

RITONAVIR

CAPSULE; ORAL

NORVIR

ABBOTT	100MG	N020680 001	Mar 01, 1996
+ ABBVIE	100MG **	N020945 001	Jun 29, 1999

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

RIVASTIGMINE TARTRATE

CAPSULE; ORAL

EXELON

+	NOVARTIS	EQ 1.5MG BASE	N020823 003	Apr 21, 2000
+		EQ 3MG BASE	N020823 004	Apr 21, 2000
+		EQ 4.5MG BASE	N020823 005	Apr 21, 2000
+		EQ 6MG BASE	N020823 006	Apr 21, 2000

RIVASTIGMINE TARTRATE

APOTEX INC

		EQ 1.5MG BASE	A091072 001	May 16, 2013
		EQ 3MG BASE	A091072 002	May 16, 2013
		EQ 4.5MG BASE	A091072 003	May 16, 2013
		EQ 6MG BASE	A091072 004	May 16, 2013

SOLUTION; ORAL

EXELON

NOVARTIS

		EQ 2MG BASE/ML	N021025 001	Apr 21, 2000
--	--	----------------	-------------	--------------

RIZATRIPTAN BENZOATE

TABLET; ORAL

MAXALT

+	MERCK	EQ 5MG BASE **	N020864 001	Jun 29, 1998
---	-------	----------------	-------------	--------------

RIZATRIPTAN BENZOATE

APOTEX INC

		EQ 5MG BASE	A202244 001	Dec 31, 2012
		EQ 10MG BASE	A202244 002	Dec 31, 2012

EMCURE PHARMS LTD

		EQ 5MG BASE	A204090 001	Nov 26, 2013
		EQ 10MG BASE	A204090 002	Nov 26, 2013

UNICHEM

		EQ 5MG BASE	A207836 001	Mar 07, 2017
		EQ 10MG BASE	A207836 002	Mar 07, 2017

TABLET, ORALLY DISINTEGRATING; ORAL

MAXALT-MLT

+	MERCK	EQ 5MG BASE **	N020865 001	Jun 29, 1998
---	-------	----------------	-------------	--------------

RIZATRIPTAN BENZOATE

APOTEX INC

		EQ 5MG BASE	A202477 001	Jul 01, 2013
		EQ 10MG BASE	A202477 002	Jul 01, 2013

MYLAN PHARMS INC

		EQ 5MG BASE	A078173 001	Dec 31, 2012
		EQ 10MG BASE	A078173 002	Dec 31, 2012

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ROCURONIUM BROMIDE

TEVA PHARMS

		50MG/5ML (10MG/ML)	A078717 001	Nov 26, 2008
		100MG/10ML (10MG/ML)	A078717 002	Nov 26, 2008

ZEMURON

+	ORGANON USA INC	50MG/5ML (10MG/ML) **	N020214 001	Mar 17, 1994
+		10MG/ML (10MG/ML) **	N020214 002	Mar 17, 1994
+		100MG/10ML (10MG/ML) **	N020214 003	Mar 17, 1994

ROFECOXIB

SUSPENSION; ORAL

VIOXX

MERCK

		12.5MG/5ML	N021052 001	May 20, 1999
		25MG/5ML	N021052 002	May 20, 1999

TABLET; ORAL

VIOXX

MERCK

		12.5MG	N021042 001	May 20, 1999
		25MG	N021042 002	May 20, 1999
		50MG	N021042 003	Feb 25, 2000

ROFLUMILAST

TABLET; ORAL

ROFLUMILAST

MICRO LABS

		500MCG	A208180 001	Mar 22, 2019
--	--	--------	-------------	--------------

MYLAN

		500MCG	A208257 001	Jul 13, 2018
--	--	--------	-------------	--------------

ROLAPITANT HYDROCHLORIDE

EMULSION; INTRAVENOUS

VARUBI

+	TERSERA	EQ 166.5MG BASE/92.5ML (EQ 1.8MG BASE/ML)	N208399 001	Oct 25, 2017
---	---------	---	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ROMIDEPSIN

SOLUTION; INTRAVENOUS

ROMIDEPSIN

+ TEVA PHARMS USA INC 10MG/2ML (5MG/ML) N208574 001 Mar 13, 2020

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

COSETTE

EQ 0.25MG BASE A077460 001 May 05, 2008

EQ 0.5MG BASE A077460 002 May 05, 2008

EQ 1MG BASE A077460 003 May 05, 2008

EQ 2MG BASE A077460 004 May 05, 2008

EQ 3MG BASE A077460 005 May 05, 2008

EQ 4MG BASE A077460 006 May 05, 2008

EQ 5MG BASE A077460 007 May 19, 2008

EPIC PHARMA LLC EQ 0.25MG BASE A078230 001 May 20, 2008

EQ 0.5MG BASE A078230 002 May 20, 2008

EQ 1MG BASE A078230 003 May 20, 2008

EQ 2MG BASE A078230 004 May 20, 2008

EQ 3MG BASE A078230 005 May 20, 2008

EQ 4MG BASE A078230 006 May 20, 2008

EQ 5MG BASE A078230 007 May 20, 2008

HIKMA EQ 0.25MG BASE A077852 001 May 05, 2008

EQ 0.5MG BASE A077852 002 May 05, 2008

EQ 1MG BASE A077852 003 May 05, 2008

EQ 2MG BASE A077852 004 May 05, 2008

EQ 3MG BASE A077852 005 May 05, 2008

EQ 4MG BASE A077852 006 May 05, 2008

EQ 5MG BASE A077852 007 May 19, 2008

TABLET, EXTENDED RELEASE; ORAL

REQUIP XL

+ GLAXOSMITHKLINE LLC EQ 3MG BASE ** N022008 002 Jun 13, 2008

+ EQ 4MG BASE N022008 003 Jun 13, 2008

+ EQ 8MG BASE N022008 004 Jun 13, 2008

ROPINIROLE HYDROCHLORIDE

MYLAN PHARMS INC

EQ 2MG BASE A200462 001 Oct 15, 2012

EQ 3MG BASE A200462 002 Oct 15, 2012

EQ 4MG BASE A200462 003 Oct 15, 2012

EQ 6MG BASE A200462 004 Oct 15, 2012

EQ 8MG BASE A200462 005 Oct 15, 2012

EQ 12MG BASE A200462 006 Oct 15, 2012

WATSON LABS INC EQ 2MG BASE A200431 001 Jun 06, 2012

EQ 4MG BASE A200431 002 Jun 06, 2012

EQ 6MG BASE A200431 003 Jun 06, 2012

EQ 8MG BASE A200431 004 Jun 06, 2012

EQ 12MG BASE A200431 005 Jun 06, 2012

ROPIVACAINE HYDROCHLORIDE

SOLUTION; INJECTION

NAROPIN

FRESENIUS KABI USA 50MG/10ML (5MG/ML) N020533 013 May 01, 1998

75MG/10ML (7.5MG/ML) N020533 012 Sep 24, 1996

ROPIVACAINE HYDROCHLORIDE

MYLAN ASI

40MG/20ML (2MG/ML) A090318 001 Sep 23, 2014

150MG/20ML (7.5MG/ML) A090318 003 Sep 23, 2014

ROSE BENGAL SODIUM I-131

INJECTABLE; INJECTION

ROBENGATOPE

BRACCO

0.5mCi/VIAL N016224 001

1mCi/VIAL N016224 002

2mCi/VIAL N016224 003

SODIUM ROSE BENGAL I 131

SORIN

0.5mCi/ML N017318 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDIA

+ SB PHARMCO

EQ 8MG BASE **

N021071 004 May 25, 1999

ROSIGLITAZONE MALEATE

ANI PHARMS INC

EQ 2MG BASE

A076747 001 Jan 25, 2013

EQ 4MG BASE

A076747 002 Jan 25, 2013

EQ 8MG BASE

A076747 003 Jan 25, 2013

ROSUVASTATIN CALCIUM

TABLET; ORAL

ROSUVASTATIN CALCIUM

AMNEAL PHARMS CO

5MG

A208850 001 Oct 16, 2018

10MG

A208850 002 Oct 16, 2018

20MG

A208850 003 Oct 16, 2018

40MG

A208850 004 Oct 16, 2018

APOTEX INC

5MG

A079145 001 Jul 19, 2016

10MG

A079145 002 Jul 19, 2016

20MG

A079145 003 Jul 19, 2016

40MG

A079145 004 Jul 19, 2016

MYLAN

5MG

A079161 001 Jul 19, 2016

10MG

A079161 002 Jul 19, 2016

20MG

A079161 003 Jul 19, 2016

40MG

A079161 004 Jul 19, 2016

SCIEGEN PHARMS INC

5MG

A206381 001 Apr 24, 2019

10MG

A206381 002 Apr 24, 2019

20MG

A206381 003 Apr 24, 2019

40MG

A206381 004 Apr 24, 2019

SUNSHINE

5MG

A210667 001 Apr 01, 2020

10MG

A210667 002 Apr 01, 2020

20MG

A210667 003 Apr 01, 2020

40MG

A210667 004 Apr 01, 2020

TEVA PHARMS USA

5MG

A079166 001 Jul 19, 2016

10MG

A079166 002 Jul 19, 2016

20MG

A079166 003 Jul 19, 2016

40MG

A079166 004 Jul 19, 2016

UMEDICA LABS PVT LTD

5MG

A207626 001 Apr 09, 2019

10MG

A207626 002 Apr 09, 2019

20MG

A207626 003 Apr 09, 2019

40MG

A207626 004 Apr 09, 2019

ZHEJIANG YONGTAI

5MG

A212059 001 Nov 04, 2019

10MG

A212059 002 Nov 04, 2019

20MG

A212059 003 Nov 04, 2019

40MG

A212059 004 Nov 04, 2019

ZYDUS PHARMS

5MG

A206513 001 Mar 01, 2019

10MG

A206513 002 Mar 01, 2019

20MG

A206513 003 Mar 01, 2019

40MG

A206513 004 Mar 01, 2019

RUFINAMIDE

TABLET; ORAL

BANZEL

+ EISAI INC

100MG **

N021911 001 Nov 14, 2008

RUFINAMIDE

MYLAN

200MG

A205095 001 May 16, 2016

400MG

A205095 002 May 16, 2016

SAFFLOWER OIL

INJECTABLE; INJECTION

LIPOSYN 10%

ABBOTT

10% (10GM/100ML)

N018203 001

LIPOSYN 20%

ABBOTT

20% (20GM/100ML)

N018614 001

SAFFLOWER OIL; SOYBEAN OIL

INJECTABLE; INJECTION

LIPOSYN II 10%

HOSPIRA

5%;5% (5GM/100ML)

N018997 001 Aug 27, 1984

LIPOSYN II 20%

HOSPIRA

10%;10% (10GM/100ML)

N018991 001 Aug 27, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SALMETEROL XINAFOATEAEROSOL, METERED; INHALATION
SEREVENT

GLAXOSMITHKLINE EQ 0.021MG BASE/INH N020236 001 Feb 04, 1994

SAQUINAVIRCAPSULE; ORAL
FORTOVASE

+ HOFFMANN LA ROCHE 200MG ** N020828 001 Nov 07, 1997

SAQUINAVIR MESYLATECAPSULE; ORAL
INVIRASE

+ HOFFMANN LA ROCHE EQ 200MG BASE N020628 001 Dec 06, 1995

SARALASIN ACETATEINJECTABLE; INJECTION
SARENIN

PROCTER AND GAMBLE EQ 0.6MG BASE/ML N018009 001

SECOBARBITAL SODIUM

CAPSULE; ORAL

SECOBARBITAL SODIUM

ANABOLIC 100MG A084422 001

BARR 100MG A084225 001

EVERYLIFE 100MG A085895 001

HALSEY 100MG A084676 001

IVAX PHARMS 100MG A085869 001

KV PHARM 100MG A085285 001

LANNETT 50MG A085909 001

100MG A085903 001

PARKE DAVIS 100MG A084762 001

PERRIGO 100MG A084561 001

PUREPAC PHARM 100MG A085867 001

VALEANT PHARM INTL 100MG A085477 001

VITARINE 100MG A085898 001

100MG A086273 001

WATSON LABS 100MG A085792 001

WEST WARD 100MG A084926 001

WHITEWORTH TOWN PLSN 100MG A085798 001

WYETH AYERST 100MG A086390 001

SECONAL SODIUM

VALEANT PHARMS NORTH 50MG A086101 001 Oct 03, 1983

100MG A086101 002 Oct 03, 1983

INJECTABLE; INJECTION

SECOBARBITAL SODIUM

ELKINS SINN 100MG/VIAL A083281 001

WYETH AYERST 50MG/ML A083262 001

SECONAL SODIUM

LILLY 50MG/ML ** N007392 002

SUPPOSITORY; RECTAL

SECONAL SODIUM

LILLY 30MG A086530 001

60MG A086530 002

120MG A086530 003

200MG A086530 004

SECRETIN

INJECTABLE; INJECTION

SECRETIN-FERRING

FERRING 75CU/VIAL N018290 001

SECRETIN SYNTHETIC PORCINE

FOR SOLUTION; INTRAVENOUS

SECREFLO

CHIRHOCLIN 16MCG/VIAL N021136 001 Apr 04, 2002

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL

ELDEPRYL

+	SOMERSET	5MG	N020647	001	May 15, 1996
	SELEGILINE HYDROCHLORIDE				
	LANNETT CO INC	5MG	A075145	001	Sep 15, 2003
	NOVITIUM PHARMA	5MG	A075352	001	Nov 30, 1998

TABLET; ORAL

SELEGILINE HYDROCHLORIDE

	CHARTWELL MOLECULES	5MG	A074565	001	Aug 02, 1996
		5MG	A074641	001	Aug 02, 1996
	COSETTE	5MG	A074744	001	Jan 27, 1997
		5MG	A074756	001	Nov 25, 1998
	G AND W LABS INC	5MG	A074537	001	Aug 02, 1996
	I3 PHARMS	5MG	A074672	001	Apr 01, 1997
	MYLAN	5MG	A074866	001	Nov 26, 1997
+	SOMERSET	5MG **	N019334	001	Jun 05, 1989

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL

EXSEL

	ALLERGAN HERBERT	2.5%	A083892	001	
	SELENIUM SULFIDE				
	ACTAVIS MID ATLANTIC	2.5%	A084394	001	
	COSETTE	2.5%	A086209	001	
	IVAX PHARMS	2.5%	A085777	001	

SELSUN

+	CHATTEM	2.5%	N007936	001	
---	---------	------	---------	-----	--

SELENOMETHIONINE SE-75

INJECTABLE; INJECTION

SELENOMETHIONINE SE 75

	GE HEALTHCARE	250uCi/ML	N017257	001	
	MALLINCKRODT	100uCi/ML	N017098	001	
	PHARMALUCENCE	500uCi/ML	N017322	001	
	SETHOTOPE				
	BRACCO	85-550uCi/ML	N017047	001	

SERMORELIN ACETATE

INJECTABLE; INJECTION

GEREF

+	EMD SERONO	EQ 0.05MG BASE/AMP **	N019863	001	Dec 28, 1990
+	EMD SERONO INC	EQ 0.5MG BASE/VIAL **	N020443	001	Sep 26, 1997
+		EQ 1MG BASE/VIAL **	N020443	002	Sep 26, 1997

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL

SERTRALINE HYDROCHLORIDE

	RANBAXY LABS LTD	EQ 20MG BASE/ML	A078053	001	Feb 05, 2007
--	------------------	-----------------	---------	-----	--------------

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

	ACI HEALTHCARE LTD	EQ 25MG BASE	A076881	001	Feb 06, 2007
		EQ 50MG BASE	A076881	002	Feb 06, 2007
		EQ 100MG BASE	A076881	003	Feb 06, 2007
	ANDA REPOSITORY	EQ 25MG BASE	A077818	001	Feb 06, 2007
		EQ 50MG BASE	A077818	002	Feb 06, 2007
		EQ 100MG BASE	A077818	003	Feb 06, 2007
	CADILA	EQ 25MG BASE	A077106	001	Feb 06, 2007
		EQ 50MG BASE	A077106	002	Feb 06, 2007
		EQ 100MG BASE	A077106	003	Feb 06, 2007
	CHARTWELL MOLECULAR	EQ 25MG BASE	A077162	001	Feb 06, 2007
		EQ 50MG BASE	A077162	002	Feb 06, 2007
		EQ 100MG BASE	A077162	003	Feb 06, 2007
	FOSUN PHARMA	EQ 25MG BASE	A077713	001	Feb 06, 2007
		EQ 50MG BASE	A077713	002	Feb 06, 2007
		EQ 100MG BASE	A077713	003	Feb 06, 2007
	HERITAGE PHARMA	EQ 25MG BASE	A076465	001	Aug 11, 2006
		EQ 25MG BASE	A077299	001	Feb 06, 2007
		EQ 25MG BASE	A077345	001	Feb 06, 2007
		EQ 25MG BASE	A077663	001	Feb 06, 2007
		EQ 50MG BASE	A076465	002	Aug 11, 2006

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SERTRALINE HYDROCHLORIDE

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

	EQ 50MG BASE	A077299	002	Feb 06, 2007
	EQ 50MG BASE	A077345	002	Feb 06, 2007
	EQ 50MG BASE	A077663	002	Feb 06, 2007
	EQ 100MG BASE	A076465	003	Aug 11, 2006
	EQ 100MG BASE	A077299	003	Feb 06, 2007
	EQ 100MG BASE	A077345	003	Feb 06, 2007
	EQ 100MG BASE	A077663	003	Feb 06, 2007
HIKMA PHARMS	EQ 25MG BASE	A077864	001	Aug 10, 2009
	EQ 50MG BASE	A077864	002	Aug 10, 2009
	EQ 100MG BASE	A077864	003	Aug 10, 2009
IVAX SUB TEVA PHARMS	EQ 25MG BASE	A075719	003	Jun 30, 2006
	EQ 50MG BASE	A075719	001	Jun 30, 2006
	EQ 100MG BASE	A075719	002	Jun 30, 2006
MYLAN	EQ 25MG BASE	A076671	001	Feb 06, 2007
	EQ 50MG BASE	A076671	002	Feb 06, 2007
	EQ 100MG BASE	A076671	003	Feb 06, 2007
MYLAN PHARMS INC	EQ 25MG BASE	A076540	001	Mar 20, 2007
	EQ 25MG BASE	A078626	001	Jan 31, 2008
	EQ 50MG BASE	A076540	002	Mar 20, 2007
	EQ 50MG BASE	A078626	002	Jan 31, 2008
	EQ 100MG BASE	A076540	003	Mar 20, 2007
	EQ 100MG BASE	A078626	003	Jan 31, 2008
SCIEGEN PHARMS INC	EQ 25MG BASE	A076442	001	Apr 30, 2007
	EQ 50MG BASE	A076442	002	Apr 30, 2007
	EQ 100MG BASE	A076442	003	Apr 30, 2007
SUN PHARM INDS (IN)	EQ 25MG BASE	A078108	001	Feb 06, 2007
	EQ 50MG BASE	A078108	002	Feb 06, 2007
	EQ 100MG BASE	A078108	003	Feb 06, 2007
SUN PHARM INDS LTD	EQ 25MG BASE	A077977	001	Feb 06, 2007
	EQ 50MG BASE	A077977	002	Feb 06, 2007
	EQ 100MG BASE	A077977	003	Feb 06, 2007
	EQ 150MG BASE	A077977	004	Feb 06, 2007
	EQ 200MG BASE	A077977	005	Feb 06, 2007
TORRENT PHARMS	EQ 25MG BASE	A077765	001	Feb 06, 2007
	EQ 50MG BASE	A077765	002	Feb 06, 2007
	EQ 100MG BASE	A077765	003	Feb 06, 2007
ZOLOFT				
+	UPJOHN	EQ 150MG BASE	**	N019839 003 Dec 30, 1991
+		EQ 200MG BASE	**	N019839 004 Dec 30, 1991

SEVELAMER CARBONATE

TABLET;ORAL

SEVELAMER CARBONATE

ANXIN	800MG	A212970	001	Apr 09, 2020
IMPAX LABS INC	800MG	A090975	001	Oct 23, 2017
MYLAN	800MG	A201069	001	Aug 05, 2020

SEVELAMER HYDROCHLORIDE

CAPSULE;ORAL

RENAGEL

GENZYME	403MG	N020926	001	Oct 30, 1998
---------	-------	---------	-----	--------------

TABLET;ORAL

SEVELAMER HYDROCHLORIDE

MYLAN	400MG	A201068	001	Dec 14, 2020
	800MG	A201068	002	Dec 14, 2020

SIBUTRAMINE HYDROCHLORIDE

CAPSULE;ORAL

MERIDIA

ABBOTT	5MG	N020632	001	Nov 22, 1997
	10MG	N020632	002	Nov 22, 1997
	15MG	N020632	003	Nov 22, 1997

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SILDENAFIL CITRATE

TABLET;ORAL

SILDENAFIL CITRATE

ACTAVIS GRP PTC	EQ 20MG BASE	A200149	001	Feb 25, 2013
APOTEX CORP	EQ 20MG BASE	A091379	001	Nov 06, 2012
PERRIGO R AND D	EQ 25MG BASE	A205791	001	Apr 23, 2020
	EQ 50MG BASE	A205791	002	Apr 23, 2020

SILODOSIN

CAPSULE;ORAL

SILODOSIN

ALEMBIC PHARMS LTD	4MG	A211731	001	Nov 22, 2019
	8MG	A211731	002	Nov 22, 2019

SILVER SULFADIAZINE

CREAM;TOPICAL

SSD AF

DR REDDYS LA	1%	N018578	003	Jul 11, 1990
--------------	----	---------	-----	--------------

DRESSING;TOPICAL

SILDAFLO

FRANKLIN PHARMS	1%	N019608	001	Nov 30, 1989
-----------------	----	---------	-----	--------------

SIMEPREVIR SODIUM

CAPSULE;ORAL

OLYSIO

+ JANSSEN PRODS	EQ 150MG BASE	N205123	001	Nov 22, 2013
-----------------	---------------	---------	-----	--------------

SIMETHICONE-CELLULOSE

SUSPENSION;ORAL

SONORX

BRACCO	7.5MG/ML	N020773	001	Oct 29, 1998
--------	----------	---------	-----	--------------

SIMVASTATIN

TABLET;ORAL

SIMVASTATIN

HISUN PHARM HANGZHOU	10MG	A206557	001	Nov 13, 2017
	20MG	A206557	002	Nov 13, 2017
	40MG	A206557	003	Nov 13, 2017
	80MG	A206557	004	Nov 13, 2017
IVAX SUB TEVA PHARMS	5MG	A076052	001	Jun 23, 2006
	10MG	A076052	002	Jun 23, 2006
	20MG	A076052	003	Jun 23, 2006
	40MG	A076052	004	Jun 23, 2006
	80MG	A076052	005	Dec 20, 2006
MYLAN PHARMS INC	5MG	A090868	001	Jun 08, 2010
	10MG	A090868	002	Jun 08, 2010
	20MG	A090868	003	Jun 08, 2010
	40MG	A090868	004	Jun 08, 2010
	80MG	A090868	005	Jun 08, 2010
SUN PHARM INDS LTD	5MG	A076285	001	Dec 20, 2006
	10MG	A076285	002	Dec 20, 2006
	20MG	A076285	003	Dec 20, 2006
	40MG	A076285	004	Dec 20, 2006
	80MG	A076285	005	Jun 23, 2006
YAOPHARMA CO LTD	5MG	A077766	001	Dec 20, 2006
	10MG	A077766	002	Dec 20, 2006
	20MG	A077766	003	Dec 20, 2006
	40MG	A077766	004	Dec 20, 2006
	80MG	A077766	005	Dec 20, 2006

TABLET, ORALLY DISINTEGRATING;ORAL

SIMVASTATIN

SYNTHON PHARMS	10MG	N021961	001	Oct 09, 2007
	20MG	N021961	002	Oct 09, 2007
	40MG	N021961	003	Oct 09, 2007
	80MG	N021961	004	Oct 09, 2007

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SIMVASTATIN; SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JUVISYNC

+	MERCK SHARP DOHME	10MG;EQ 50MG BASE **	N202343 004	Sep 18, 2012
+		10MG;EQ 100MG BASE **	N202343 001	Oct 07, 2011
+		20MG;EQ 50MG BASE **	N202343 005	Sep 18, 2012
+		20MG;EQ 100MG BASE **	N202343 002	Oct 07, 2011
+		40MG;EQ 50MG BASE **	N202343 006	Sep 18, 2012
+		40MG;EQ 100MG BASE **	N202343 003	Oct 07, 2011

SIROLIMUS

TABLET; ORAL

RAPAMUNE

+	PF PRISM CV	5MG **	N021110 003	Feb 23, 2004
---	-------------	--------	-------------	--------------

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION; ORAL

UCEPHAN

	B BRAUN	100MG/ML;100MG/ML	N019530 001	Dec 23, 1987
--	---------	-------------------	-------------	--------------

SODIUM BICARBONATE

INJECTABLE; INJECTION

SODIUM BICARBONATE

	HOSPIRA	0.9MEQ/ML	A077394 001	Nov 09, 2005
		1MEQ/ML	A077394 002	Nov 09, 2005

SODIUM BICARBONATE IN PLASTIC CONTAINER

+	ABBOTT	0.9MEQ/ML **	N019443 001	Jun 03, 1986
+		1MEQ/ML **	N019443 002	Jun 03, 1986

SODIUM BICARBONATE; TARTARIC ACID

GRANULE, EFFERVESCENT; ORAL

BAROS

	MALLINCKRODT INC	460MG/GM;420MG/GM	N018509 001	Aug 07, 1985
--	------------------	-------------------	-------------	--------------

SODIUM CHLORIDE

INJECTABLE; INJECTION

BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	ABRAXIS PHARM	9MG/ML	A088909 001	Feb 07, 1985
--	---------------	--------	-------------	--------------

SODIUM CHLORIDE

	ABBOTT	20GM/100ML	N017013 001	
	B BRAUN	20GM/100ML	N017038 001	

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	B BRAUN	450MG/100ML	N018184 001	
	MILES	450MG/100ML	N018503 001	

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	ABBOTT	9MG/ML	N019218 001	Jul 13, 1984
+	ICU MEDICAL INC	9MG/ML	N019217 001	Jul 13, 1984
+	LIEBEL-FLARSHEIM	405MG/50ML (9MG/ML)	N021569 001	Jul 27, 2006
	MILES	900MG/100ML	N018502 001	

SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER

+	ABRAXIS PHARM	234MG/ML **	N019329 001	Apr 22, 1987
---	---------------	-------------	-------------	--------------

SOLUTION; INTRAVENOUS

SODIUM CHLORIDE 14.6%

+	HOSPIRA	50MEQ/20ML (2.5MEQ/ML)	N018897 001	Jul 20, 1984
---	---------	------------------------	-------------	--------------

SOLUTION; IRRIGATION

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	450MG/100ML	N017864 001	
		450MG/100ML	N018497 001	Feb 19, 1982
	HOSPIRA	450MG/100ML	N017670 001	
		450MG/100ML	N018380 001	

SODIUM CHLORIDE IN PLASTIC CONTAINER

	MILES	900MG/100ML	N018247 001	
--	-------	-------------	-------------	--

SODIUM CHROMATE CR-51

INJECTABLE; INJECTION

CHROMITOPE SODIUM

	BRACCO	2mCi/VIAL	N013993 002	
		200uCi/ML	N013993 001	

SODIUM CHROMATE CR 51

	CURIUM	100uCi/ML	N016708 001	
--	--------	-----------	-------------	--

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS

FLUORINE F-18

+ GE HEALTHCARE

2mCi/ML **

N017042 001

SODIUM FLUORIDE F 18

NIH NCI DCTD

10-200mCi/ML **

N022494 001 Jan 26, 2011

SODIUM FLUORIDE F-18

UIHC PET IMAGING

10-200mCi/ML

A204462 001 Nov 17, 2015

UNIV TX MD ANDERSON

10-200mCi/ML

A203247 001 Dec 23, 2013

SODIUM FLUORIDE; TRICLOSAN

PASTE; DENTAL

COLGATE TOTAL

+ COLGATE PALMOLIVE

0.24%; 0.3%

N020231 001 Jul 11, 1997

SODIUM IODIDE I-123

CAPSULE; ORAL

SODIUM IODIDE I 123

CARDINAL HEALTH 418

400uCi

N018671 003 May 27, 1982

GE HEALTHCARE

100uCi

N017630 001

SOLUTION; ORAL

SODIUM IODIDE I 123

GE HEALTHCARE

2mCi/ML **

N017630 002

SODIUM IODIDE I-131

CAPSULE; ORAL

IODOTOPE

BRACCO

1-130mCi

N010929 001

1-150mCi

N010929 003

SODIUM IODIDE I 131

CIS

50uCi

N017316 001

100uCi

N017316 002

CURIUM

0.8-100mCi

N016515 002

+

0.8-100mCi

N016517 001

15-100uCi

N016517 002

JUBILANT

2-200mCi

N021305 004 Nov 18, 2004

SOLUTION; ORAL

HICON

JUBILANT

1-250mCi/0.25ML

N021305 002 Jan 24, 2003

1-500mCi/0.5ML

N021305 003 Jan 24, 2003

1-1000mCi/ML

N021305 005 Apr 04, 2006

IODOTOPE

BRACCO

7-106mCi/BOT

N010929 002

SODIUM IODIDE I 131

CIS

50mCi/ML

N017315 001

+

CURIUM

3.5-150mCi/VIAL

N016515 001

SODIUM LACTATE

INJECTABLE; INJECTION

SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER

B BRAUN

1.87GM/100ML

N018186 001

BAXTER HLTHCARE

1.87GM/100ML

N016692 001

HOSPIRA

1.87GM/100ML

N018249 001

SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER

B BRAUN

1.87GM/100ML

N020004 001 Apr 21, 1992

SODIUM LACTATE IN PLASTIC CONTAINER

+

HOSPIRA

5MEQ/ML

N018947 001 Sep 05, 1984

SODIUM MONOFLUOROPHOSPHATE

GEL; DENTAL

EXTRA-STRENGTH AIM

CHESEBROUGH PONDS

1.2%

N019518 002 Aug 06, 1986

PASTE; DENTAL

EXTRA-STRENGTH AIM

CHESEBROUGH PONDS

1.2%

N019518 001 Jun 03, 1987

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION

NIPRIDE

ROCHE	50MG/VIAL	N017546	001	
NITROPRESS				
ABBOTT	50MG/VIAL	A071555	001	Nov 16, 1987
+ ABBVIE	50MG/VIAL **	N018450	001	
HOSPIRA	50MG/VIAL	A070566	001	Jun 09, 1986

SODIUM NITROPRUSSIDE

ABRAXIS PHARM	50MG/VIAL	A070031	001	Jan 17, 1985
AMPHASTAR PHARMS INC	25MG/ML	A209832	001	Dec 18, 2017
+ BAXTER HLTHCARE	50MG/VIAL **	N018581	001	Jul 28, 1982
SUN PHARM	25MG/ML	A210467	001	Nov 26, 2018
TEVA PARENTERAL	25MG/ML	A073465	001	Mar 30, 1992
VIRTUS PHARM	25MG/ML	A209834	001	Jun 26, 2018

SOLUTION; INTRAVENOUS

NIPRIDE RTU IN SODIUM CHLORIDE 0.9%				
+ EXELA PHARMA	10MG/50ML (0.2MG/ML)	N209387	002	Dec 07, 2017

SODIUM OXYBATE

SOLUTION; ORAL

SODIUM OXYBATE

HIKMA	0.5GM/ML	A202090	001	Jan 17, 2017
-------	----------	---------	-----	--------------

SODIUM PHENYL BUTYRATE

TABLET; ORAL

SODIUM PHENYL BUTYRATE

ALVOGEN	500MG	A090910	001	Nov 18, 2011
---------	-------	---------	-----	--------------

SODIUM PHOSPHATE P-32

SOLUTION; INJECTION, ORAL

PHOSPHOTOPE

BRACCO	1-8mCi/VIAL	N010927	001	
--------	-------------	---------	-----	--

SODIUM PHOSPHATE P 32

MALLINCKRODT	0.67mCi/ML	N011777	001	
--------------	------------	---------	-----	--

	1.5mCi/VIAL	N011777	002	
--	-------------	---------	-----	--

SODIUM PHOSPHATE, DIBASIC ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET; ORAL

VISICOL

SALIX PHARMS	0.398GM;1.102GM	N021097	001	Sep 21, 2000
--------------	-----------------	---------	-----	--------------

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET; ORAL

MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE

NOVEL LABS INC	0.398GM;1.102GM	A079247	001	Dec 30, 2011
----------------	-----------------	---------	-----	--------------

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

KAYEXALATE

+ CONCORDIA	453.6GM/BOT **	N011287	001	
-------------	----------------	---------	-----	--

SODIUM POLYSTYRENE SULFONATE

CITRUSPHARMA	454GM/BOT	A040909	001	Dec 03, 2008
--------------	-----------	---------	-----	--------------

WOCKHARDT	453.6GM/BOT	A088786	001	Sep 11, 1984
-----------	-------------	---------	-----	--------------

SUSPENSION; ORAL, RECTAL

KIONEX

PADDOCK LLC	15GM/60ML	A040028	001	Sep 17, 2007
-------------	-----------	---------	-----	--------------

SODIUM POLYSTYRENE SULFONATE

HIKMA	15GM/60ML	A089049	001	Nov 17, 1986
-------	-----------	---------	-----	--------------

MORTON GROVE	15GM/60ML	A088717	001	Sep 11, 1984
--------------	-----------	---------	-----	--------------

PADDOCK LLC	15GM/60ML	A090590	001	May 13, 2011
-------------	-----------	---------	-----	--------------

ROXANE	15GM/60ML	A088453	001	Nov 17, 1983
--------	-----------	---------	-----	--------------

SODIUM SUCCINATE

INJECTABLE; INJECTION

SODIUM SUCCINATE

ELKINS SINN	30%	A080516	001	
-------------	-----	---------	-----	--

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SODIUM TETRADECYL SULFATE

INJECTABLE; INJECTION

SOTRADECOL

+ ELKINS SINN

1% **

N005970 004

+

3% **

N005970 005

SODIUM THIOSULFATE

INJECTABLE; INJECTION

SODIUM THIOSULFATE

US ARMY

250MG/ML

N020166 001 Feb 14, 1992

SOLIFENACIN SUCCINATE

TABLET; ORAL

SOLIFENACIN SUCCINATE

SUNSHINE

5MG

A213346 001 Apr 13, 2020

10MG

A213346 002 Apr 13, 2020

SORAFENIB TOSYLATE

TABLET; ORAL

SORAFENIB TOSYLATE

MYLAN

EQ 200MG BASE

A207012 001 Sep 10, 2020

SORBITOL

SOLUTION; IRRIGATION

SORBITOL 3% IN PLASTIC CONTAINER

BAXTER HLTHCARE

3GM/100ML

N018512 001 May 27, 1982

SOTALOL HYDROCHLORIDE

TABLET; ORAL

BETAPACE

COVIS

320MG

N019865 004 Oct 30, 1992

BETAPACE AF

COVIS

40MG

N021151 006 Apr 02, 2003

60MG

N021151 007 Apr 02, 2003

100MG

N021151 005 Mar 14, 2003

SOTALOL HYDROCHLORIDE

IMPAX PHARMS

80MG

A075663 001 Nov 07, 2000

120MG

A075663 002 Nov 07, 2000

160MG

A075663 003 Nov 07, 2000

240MG

A075663 004 Nov 07, 2000

MYLAN

80MG

A075237 001 May 01, 2000

80MG

A075725 001 Dec 19, 2000

120MG

A075237 002 May 01, 2000

120MG

A075725 002 Dec 19, 2000

160MG

A075237 003 May 01, 2000

160MG

A075725 003 Dec 19, 2000

240MG

A075237 004 May 01, 2000

240MG

A075725 004 Dec 19, 2000

SUN PHARM INDUSTRIES

80MG

A075515 001 Oct 15, 2001

80MG

A076576 001 Apr 08, 2004

120MG

A075515 004 Oct 15, 2001

120MG

A076576 002 Apr 08, 2004

160MG

A075515 002 Oct 15, 2001

160MG

A076576 003 Apr 08, 2004

240MG

A075515 003 Oct 15, 2001

TEVA

80MG

A076883 001 Jul 26, 2004

120MG

A076883 002 Jul 26, 2004

160MG

A076883 003 Jul 26, 2004

UPSHER SMITH LABS

80MG

A075366 001 May 01, 2000

120MG

A075366 002 May 01, 2000

160MG

A075366 003 May 01, 2000

240MG

A075366 004 May 01, 2000

WATSON LABS

80MG

A075238 001 Jul 13, 2000

120MG

A075238 002 Jul 13, 2000

160MG

A075238 003 Jul 13, 2000

240MG

A075238 004 Jul 13, 2000

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SOYBEAN OIL

INJECTABLE; INJECTION

LIPOSYN III 10%				
HOSPIRA	10%	N018969	001	Sep 24, 1984
LIPOSYN III 20%				
HOSPIRA	20%	N018970	001	Sep 25, 1984
LIPOSYN III 30%				
HOSPIRA	30%	N020181	001	Jan 13, 1998
SOYACAL 10%				
ALPHA THERA	10%	N018465	001	Jun 29, 1983
SOYACAL 20%				
ALPHA THERA	20%	N018786	001	Jun 29, 1983
TRAVAMULSION 10%				
BAXTER HLTHCARE	10%	N018660	001	Feb 26, 1982
TRAVAMULSION 20%				
BAXTER HLTHCARE	20%	N018758	001	Feb 15, 1983

SPARFLOXACIN

TABLET; ORAL

ZAGAM				
MYLAN	200MG	N020677	001	Dec 19, 1996

SPECTINOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

TROBICIN				
PFIZER	EQ 2GM BASE/VIAL	N050347	001	
	EQ 4GM BASE/VIAL	N050347	002	

SPIRAPRIL HYDROCHLORIDE

TABLET; ORAL

RENORMAX				
SCHERING	3MG	N020240	001	Dec 29, 1994
	6MG	N020240	002	Dec 29, 1994
	12MG	N020240	003	Dec 29, 1994
	24MG	N020240	004	Dec 29, 1994

SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE				
ACTAVIS ELIZABETH	25MG	A040353	003	Mar 15, 2006
	50MG	A040353	001	Jul 29, 1999
	100MG	A040353	002	Jul 29, 1999
ASCOT	25MG	A087687	001	Oct 20, 1982
CHARTWELL RX	25MG	A086809	001	
IVAX PHARMS	25MG	A087108	001	
LEDERLE	25MG	A087634	001	
MUTUAL PHARM	25MG	A087265	001	
MYLAN	25MG	A087086	001	
PUREPAC PHARM	25MG	A087998	001	Oct 14, 1983
	25MG	A088053	001	Aug 25, 1983
SUPERPHARM	25MG	A089364	001	Nov 07, 1986
UPSHER SMITH	25MG	A087554	001	
VANGARD	25MG	A087648	001	Feb 01, 1982
WARNER CHILCOTT	25MG	A087952	001	Nov 18, 1982
WATSON LABS	25MG	A086898	002	Mar 02, 1982
	25MG	A087078	001	

STANOZOLOL

TABLET; ORAL

WINSTROL				
+ LUNDBECK INC	2MG	N012885	001	May 14, 1984

STAVUDINE

CAPSULE; ORAL

STAVUDINE				
AUROBINDO PHARMA	15MG	A077672	003	Dec 29, 2008
	20MG	A077672	004	Dec 29, 2008
	30MG	A077672	001	Dec 29, 2008
	40MG	A077672	002	Dec 29, 2008
HETERO LABS LTD III	15MG	A078957	001	Dec 29, 2008
	20MG	A078957	002	Dec 29, 2008
	30MG	A078957	003	Dec 29, 2008

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

STAVUDINE

CAPSULE; ORAL

STAVUDINE

	40MG	A078957	004	Dec 29, 2008
MYLAN	15MG	A079069	001	Dec 29, 2008
	20MG	A079069	002	Dec 29, 2008
	30MG	A079069	003	Dec 29, 2008
	40MG	A079069	004	Dec 29, 2008
MYLAN LABS LTD	30MG	A078775	001	Jan 05, 2009
	40MG	A078775	002	Jan 05, 2009

ZERIT

BRISTOL MYERS SQUIBB	5MG	N020412	001	Jun 24, 1994
+ BRISTOL-MYERS SQUIBB	15MG	N020412	002	Jun 24, 1994
+	20MG	N020412	003	Jun 24, 1994
+	30MG	N020412	004	Jun 24, 1994
+	40MG	N020412	005	Jun 24, 1994

CAPSULE, EXTENDED RELEASE; ORAL

ZERIT XR

BRISTOL MYERS SQUIBB	37.5MG	N021453	001	Dec 31, 2002
	50MG	N021453	002	Dec 31, 2002
	75MG	N021453	003	Dec 31, 2002
	100MG	N021453	004	Dec 31, 2002

FOR SOLUTION; ORAL

STAVUDINE

AUROBINDO PHARMA	1MG/ML	A077774	001	Dec 29, 2008
CIPLA LTD	1MG/ML	A078030	001	Mar 20, 2009

ZERIT

+ BRISTOL-MYERS SQUIBB	1MG/ML **	N020413	001	Sep 06, 1996
------------------------	-----------	---------	-----	--------------

STERILE WATER FOR INJECTION

LIQUID; N/A

BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER

ABRAXIS PHARM	100%	A089099	001	Dec 29, 1987
	100%	A089100	001	Dec 29, 1987

STERILE WATER FOR INJECTION

+ HOSPIRA	100% (1ML)	N018801	001	Oct 27, 1982
WEST-WARD PHARMS INT	100% (20ML)	A206369	002	Sep 02, 2015

STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

B BRAUN	100%	N019077	001	Mar 02, 1984
---------	------	---------	-----	--------------

STERILE WATER FOR IRRIGATION

LIQUID; IRRIGATION

STERILE WATER IN PLASTIC CONTAINER

MILES	100%	N018246	001	
-------	------	---------	-----	--

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION

STREPTOMYCIN SULFATE

COPANOS	EQ 500MG BASE/ML	A060684	001	
LILLY	EQ 1GM BASE/VIAL	A060107	001	
	EQ 1GM BASE/2ML	A060404	001	
	EQ 5GM BASE/VIAL	A060107	002	
PFIZER	EQ 1GM BASE/VIAL **	A060076	001	
	EQ 1GM BASE/2.5ML	A060111	001	
	EQ 5GM BASE/VIAL **	A060076	002	

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

ANECTINE

SANDOZ INC	50MG/ML	N008453	003	
	500MG/VIAL	N008453	001	
	1GM/VIAL	N008453	004	

QUELICIN PRESERVATIVE FREE

+ HOSPIRA	20MG/ML	N008845	001	
+	50MG/ML	N008845	002	
+	100MG/ML	N008845	004	

SUCCINYLCHOLINE CHLORIDE

ACCORD HLTHCARE	20MG/ML	A213705	001	May 20, 2020
AMPHASTAR PHARMS INC	20MG/ML	A213432	001	Jun 08, 2020
INTL MEDICATION	100MG/VIAL	A085400	001	Feb 04, 1982
ORGANON USA INC	20MG/ML	A080997	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

SUOSTRIN

+ APOTHECON

20MG/ML

N008847 001

+

100MG/ML

N008847 003

SUFENTANIL CITRATE

INJECTABLE; INJECTION

SUFENTANIL CITRATE

WATSON LABS

EQ 0.05MG BASE/ML

A074406 001 Dec 15, 1995

SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC

BLEPH-10

ALLERGAN

10%

A084015 001

CETAMIDE

ALCON

10%

A080021 001

SODIUM SULAMYD

+ SCHERING

10% **

N005963 002

SULFAIR 10

PHARMAFAIR

10%

A088000 001 Dec 22, 1982

SOLUTION/DROPS; OPHTHALMIC

BLEPH-30

ALLERGAN

30%

A080028 002

ISOPTO CETAMIDE

ALCON

15%

A080020 002

OCUSULF-10

MIZA PHARMS USA

10%

A080660 001

OCUSULF-30

MIZA PHARMS USA

30%

A080660 002

SODIUM SULAMYD

+ SCHERING

10% **

N005963 001

+

30% **

N005963 003

SODIUM SULFACETAMIDE

AKORN

10%

A083021 001

15%

A083021 002

30%

A083021 003

SOLA BARNES HIND

10%

A084143 001

10%

A084145 001

30%

A084146 001

30%

A084147 001

SULF-10

NOVARTIS

10%

A080025 001

SULF-15

NOVARTIS

15%

A089047 001 Oct 31, 1995

SULFACEL-15

OPTOPICS

15%

A080024 001

SULFACETAMIDE SODIUM

AKORN

30%

A040216 001 May 25, 1999

ALCON PHARMS LTD

30%

A089068 001 May 05, 1987

PHARMAFAIR

10%

A088947 001 May 17, 1985

SULFAIR 10

PHARMAFAIR

10%

A087949 001 Dec 13, 1982

SULFAIR FORTE

PHARMAFAIR

30%

A088385 001 Oct 13, 1983

SULFAIR-15

PHARMAFAIR

15%

A088186 001 May 25, 1983

SULTEN-10

BAUSCH AND LOMB

10%

A087818 001 Feb 03, 1983

SULFACYTINE

TABLET; ORAL

RENOQUID

GLENWOOD

250MG

N017569 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SULFADIAZINE

TABLET; ORAL

SULFADIAZINE

ABBVIE	300MG	N004125	005
EVERYLIFE	500MG	A080088	001
IMPAX LABS	500MG	A080081	001
LANNETT	500MG	A080084	001
LEDERLE	500MG	N004054	001
+ LILLY	500MG	N004122	002

SULFADIAZINE SODIUM

INJECTABLE; INJECTION

SULFADIAZINE SODIUM

LEDERLE	250MG/ML	N004054	002
---------	----------	---------	-----

SULFADIAZINE; SULFAMERAZINE

SUSPENSION; ORAL

SULFONAMIDES DUPLEX

LILLY	250MG/5ML; 250MG/5ML	N006317	007
-------	----------------------	---------	-----

SULFAMETER

TABLET; ORAL

SULLA

BAYER HLTHCARE	500MG	N016000	002
----------------	-------	---------	-----

SULFAMETHIZOLE

TABLET; ORAL

MICROSUL

FOREST PHARMS	1GM	A086012	001
---------------	-----	---------	-----

PROKLAR

FOREST PHARMS	500MG	A080273	001
---------------	-------	---------	-----

THIOSULFIL

WYETH AYERST	250MG	N008565	001
--------------	-------	---------	-----

	500MG	N008565	004
--	-------	---------	-----

SULFAMETHOXAZOLE

SUSPENSION; ORAL

GANTANOL

ROCHE	500MG/5ML	N013664	002
-------	-----------	---------	-----

TABLET; ORAL

GANTANOL

ROCHE	500MG	N012715	002
-------	-------	---------	-----

GANTANOL-DS

ROCHE	1GM	N012715	003
-------	-----	---------	-----

SULFAMETHOXAZOLE

ASCOT	500MG	A087662	001	Oct 20, 1982
-------	-------	---------	-----	--------------

AUROLIFE PHARMA LLC	500MG	A085844	001
---------------------	-------	---------	-----

BARR	500MG	A087189	001	Jul 25, 1983
------	-------	---------	-----	--------------

HEATHER	500MG	A086163	001
---------	-------	---------	-----

WATSON LABS	500MG	A085053	001
-------------	-------	---------	-----

	1GM	A086000	001
--	-----	---------	-----

UROBAK

SHIONOGI	500MG	A087307	001
----------	-------	---------	-----

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

BACTRIM

+ SUN PHARM INDS INC	80MG/ML; 16MG/ML **	N018374	001
----------------------	---------------------	---------	-----

SEPTRA

MONARCH PHARMS	80MG/ML; 16MG/ML **	N018452	001
----------------	---------------------	---------	-----

SULFAMETHOXAZOLE AND TRIMETHOPRIM

ABRAXIS PHARM	80MG/ML; 16MG/ML	A070223	001	Dec 29, 1987
---------------	------------------	---------	-----	--------------

BEDFORD	80MG/ML; 16MG/ML	A072383	001	Apr 29, 1992
---------	------------------	---------	-----	--------------

HOSPIRA	80MG/ML; 16MG/ML	A073199	001	Sep 11, 1992
---------	------------------	---------	-----	--------------

WATSON LABS	80MG/ML; 16MG/ML	A071556	001	Dec 29, 1987
-------------	------------------	---------	-----	--------------

WEST-WARD PHARMS INT	80MG/ML; 16MG/ML	A070627	001	Dec 29, 1987
----------------------	------------------	---------	-----	--------------

	80MG/ML; 16MG/ML	A070628	001	Dec 29, 1987
--	------------------	---------	-----	--------------

SUSPENSION; ORAL

BACTRIM

+ SUN PHARM INDUSTRIES	200MG/5ML; 40MG/5ML **	N017560	001
------------------------	------------------------	---------	-----

BACTRIM PEDIATRIC

SUN PHARM INDUSTRIES	200MG/5ML; 40MG/5ML **	N017560	002
----------------------	------------------------	---------	-----

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL

SEPTRA

MONARCH PHARMS 200MG/5ML; 40MG/5ML **

N017598 001

SEPTRA GRAPE

MONARCH PHARMS 200MG/5ML; 40MG/5ML **

N017598 002 Feb 12, 1986

SULFAMETHOXAZOLE AND TRIMETHOPRIM

ANI PHARMS INC 200MG/5ML; 40MG/5ML

A070028 001 Jun 02, 1987

TEVA 200MG/5ML; 40MG/5ML

N018812 001 Jan 28, 1983

200MG/5ML; 40MG/5ML

N018812 002 Jun 10, 1983

SULFATRIM

PHARM ASSOC 200MG/5ML; 40MG/5ML

N018615 002 Jan 07, 1983

SULMEPRIM

USL PHARMA 200MG/5ML; 40MG/5ML

A070063 001 Aug 01, 1986

SULMEPRIM PEDIATRIC

USL PHARMA 200MG/5ML; 40MG/5ML

A070064 001 Aug 01, 1986

TRIMETH/SULFA

ALPHARMA US PHARMS 200MG/5ML; 40MG/5ML

A072289 001 May 23, 1988

200MG/5ML; 40MG/5ML

A072398 001 May 23, 1988

200MG/5ML; 40MG/5ML

A072399 001 May 23, 1988

TABLET; ORAL

COTRIM

TEVA 400MG; 80MG

A070034 001 May 16, 1985

COTRIM D.S.

TEVA 800MG; 160MG

A070048 001 Mar 18, 1985

SULFAMETHOPRIM

NOVEL LABS INC 400MG; 80MG

A070022 001 Feb 15, 1985

SULFAMETHOPRIM-DS

NOVEL LABS INC 800MG; 160MG

A070032 001 Feb 15, 1985

SULFAMETHOXAZOLE AND TRIMETHOPRIM

FOSUN PHARMA 400MG; 80MG

A070889 001 Nov 13, 1986

400MG; 80MG

N018598 003 May 19, 1982

800MG; 160MG

A070890 001 Nov 13, 1986

HEATHER 400MG; 80MG

N018946 001 Aug 10, 1984

800MG; 160MG

N018946 002 Aug 10, 1984

INTERPHARM 400MG; 80MG

A071299 001 Oct 27, 1987

800MG; 160MG

A071300 001 Oct 27, 1987

MARTEC USA LLC 400MG; 80MG

A072408 001 Dec 07, 1988

MUTUAL PHARM 400MG; 80MG

A070006 001 Nov 14, 1984

PLIVA 400MG; 80MG

A070215 001 Sep 10, 1985

800MG; 160MG

A070216 001 Sep 10, 1985

ROXANE 400MG; 80MG

A072768 001 Aug 30, 1991

TEVA 400MG; 80MG

N018242 001

800MG; 160MG

N018242 002

USL PHARMA 400MG; 80MG

A070203 001 Nov 08, 1985

800MG; 160MG

A070204 001 Nov 08, 1985

WATSON LABS 400MG; 80MG

A070002 001 Nov 07, 1984

400MG; 80MG

N018852 001 May 09, 1983

800MG; 160MG

A070000 001 Nov 07, 1984

SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH

FOSUN PHARMA 800MG; 160MG

N018598 004 May 19, 1982

HERITAGE PHARMA 800MG; 160MG

A070037 001 Jun 02, 1987

MARTEC USA LLC 800MG; 160MG

A072417 001 Dec 07, 1988

MUTUAL PHARM 800MG; 160MG

A070007 001 Nov 14, 1984

ROXANE 800MG; 160MG

A072769 001 Aug 30, 1991

WATSON LABS 800MG; 160MG

N018854 001 May 09, 1983

SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH

HERITAGE PHARMA 400MG; 80MG

A070030 001 Jun 02, 1987

SULFATRIM-DS

SUPERPHARM 800MG; 160MG

A070066 001 Jun 24, 1985

SULFATRIM-SS

SUPERPHARM 400MG; 80MG

A070065 002 Jun 24, 1985

UROPLUS DS

SHIONOGI 800MG; 160MG

A071816 001 Sep 28, 1987

UROPLUS SS

SHIONOGI 400MG; 80MG

A071815 001 Sep 28, 1987

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SULFANILAMIDE

CREAM;VAGINAL

AVC

+ MYLAN SPECIALITY LP 15%

N006530 003 Jan 27, 1987

SULFANILAMIDE

COSETTE 15%

A088718 001 Sep 19, 1985

SUPPOSITORY;VAGINAL

AVC

MYLAN SPECIALITY LP 1.05GM

N006530 004 Jan 27, 1987

SULFAPHENAZOLE

SUSPENSION;ORAL

SULFABID

PHARM RES ASSOC 500MG/5ML

N013093 001

TABLET;ORAL

SULFABID

PURDUE FREDERICK 500MG

N013092 002

SULFAPYRIDINE

TABLET;ORAL

SULFAPYRIDINE

LILLY 500MG

N000159 001

SULFASALAZINE

SUSPENSION;ORAL

AZULFIDINE

PHARMACIA AND UPJOHN 250MG/5ML

N018605 001

TABLET;ORAL

S.A.S.-500

SOLVAY 500MG

A083450 001

SULFASALAZINE

CHARTWELL 500MG

A080197 001

SANDOZ 500MG

A086184 001

SUN PHARM INDUSTRIES 500MG

A089590 001 Oct 19, 1987

SUPERPHARM 500MG

A089339 001 Oct 26, 1987

WATSON LABS 500MG

A084964 001

500MG

A087197 001

TABLET, DELAYED RELEASE;ORAL

SULFASALAZINE

WATSON LABS 500MG

A088052 001 May 24, 1983

SULFINPYRAZONE

CAPSULE;ORAL

ANTURANE

+ NOVARTIS 200MG **

N011556 004

SULFINPYRAZONE

BARR 200MG

A087666 001 Sep 17, 1982

IVAX PHARMS 200MG

A087770 001 Nov 19, 1982

PAR PHARM 200MG

A088934 001 Sep 06, 1985

VANGARD 200MG

A088666 001 Feb 17, 1984

TABLET;ORAL

ANTURANE

NOVARTIS 100MG **

N011556 003

SULFINPYRAZONE

BARR 100MG

A087665 001 Sep 17, 1982

IVAX PHARMS 100MG

A087769 001 Jun 01, 1982

PAR PHARM 100MG

A088933 001 Sep 06, 1985

WATSON LABS 100MG

A087667 001 May 26, 1982

SULFISOXAZOLE

TABLET;ORAL

GANTRISIN

ROCHE 500MG

N006525 001

SOSOL

MK LABS 500MG

A080036 001

SOXAZOLE

ALRA 500MG

A080366 001

SULFALAR

PARKE DAVIS 500MG

A084955 001

SULFISOXAZOLE

ANI PHARMS INC 500MG

A080142 001

AUROLIFE PHARMA LLC 500MG

A085628 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SULFISOXAZOLE

TABLET; ORAL

SULFISOXAZOLE

BARR	500MG	A084031	001
HEATHER	500MG	A080189	001
IMPAX LABS	500MG	A080109	001
LANNETT	500MG	A080085	001
LEDERLE	500MG	A087649	001
PHARMERAL	500MG	A084385	001
PUREPAC PHARM	500MG	A080087	001
ROXANE	500MG	A080082	001
VALEANT PHARM INTL	500MG	A080268	002
VITARINE	500MG	A087332	001
WATSON LABS	500MG	A085534	001
WEST WARD	500MG	A080379	001

SULSOXIN

SOLVAY	500MG	A080040	001
--------	-------	---------	-----

SULFISOXAZOLE ACETYL

EMULSION; ORAL

LIPO GANTRISIN

ROCHE	EQ 1GM BASE/5ML	N009182	009
-------	-----------------	---------	-----

SUSPENSION; ORAL

GANTRISIN PEDIATRIC

ROCHE	EQ 500MG BASE/5ML	N009182	004
-------	-------------------	---------	-----

SYRUP; ORAL

GANTRISIN

ROCHE	EQ 500MG BASE/5ML	N009182	002
-------	-------------------	---------	-----

SULFISOXAZOLE DIOLAMINE

INJECTABLE; INJECTION

GANTRISIN

ROCHE	EQ 400MG BASE/ML	N006917	001
-------	------------------	---------	-----

OINTMENT; OPHTHALMIC

GANTRISIN

ROCHE	EQ 4% BASE	N008414	002
-------	------------	---------	-----

SOLUTION/DROPS; OPHTHALMIC

GANTRISIN

ROCHE	EQ 4% BASE	N007757	002
-------	------------	---------	-----

SULFISOXAZOLE DIOLAMINE

SOLA BARNES HIND	EQ 4% BASE	A084148	001
------------------	------------	---------	-----

SULFOXONE SODIUM

TABLET, DELAYED RELEASE; ORAL

DIASONE SODIUM

ABBVIE	165MG	N006044	003
--------	-------	---------	-----

SULFUR

POWDER; TOPICAL

BENSULFOID

POYTHRESS	33.32%	N002918	001
-----------	--------	---------	-----

SULINDAC

TABLET; ORAL

CLINORIL

+ MERCK	150MG **	N017911	001
---------	----------	---------	-----

+	200MG **	N017911	002
---	----------	---------	-----

SULINDAC

ANI PHARMS INC	150MG	A072972	001	Feb 28, 1992
----------------	-------	---------	-----	--------------

	200MG	A072973	001	Feb 28, 1992
--	-------	---------	-----	--------------

EPIC PHARMA LLC	150MG	A073262	002	Sep 06, 1991
-----------------	-------	---------	-----	--------------

	200MG	A073262	001	Sep 06, 1991
--	-------	---------	-----	--------------

FOSUN PHARMA	150MG	A072712	001	Aug 30, 1991
--------------	-------	---------	-----	--------------

	200MG	A072713	001	Aug 30, 1991
--	-------	---------	-----	--------------

SUMATRIPTAN

SPRAY; NASAL

IMITREX

GLAXOSMITHKLINE	10MG/SPRAY	N020626	002	Aug 26, 1997
-----------------	------------	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SUMATRIPTAN SUCCINATE

INJECTABLE;SUBCUTANEOUS

ALSUMA

MERIDIAN MEDCL EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) N022377 001 Jun 29, 2010

SUMATRIPTAN SUCCINATE

FRESENIUS KABI USA EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A079240 002 Sep 18, 2009

EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) A079240 001 Sep 18, 2009

MYLAN LABS LTD EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A203322 001 Apr 14, 2014

PAR STERILE PRODUCTS EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A077871 001 Jul 09, 2009

SANDOZ INC EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) A078067 002 Feb 06, 2009

EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A078067 001 Feb 06, 2009

TEVA PARENTERAL EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) A078318 001 Feb 06, 2009

EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A078318 002 Feb 06, 2009

TEVA PHARMS USA EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A077907 001 Feb 06, 2009

ZYDUS EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A090310 001 Aug 11, 2010

SUMAVEL DOSEPRO

+ ENDO VENTURES LTD EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) N022239 002 Nov 26, 2013

+ EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) N022239 001 Jul 15, 2009

SYSTEM; IONTOPHORESIS

ZECUITY

+ TEVA BRANDED PHARM EQ 6.5MG BASE/4HR N202278 001 Jan 17, 2013

TABLET; ORAL

SUMATRIPTAN SUCCINATE

FOSUN PHARMA EQ 25MG BASE A076976 001 Aug 10, 2009

EQ 50MG BASE A076976 002 Aug 10, 2009

EQ 100MG BASE A076976 003 Aug 10, 2009

HIKMA PHARMS EQ 25MG BASE A078298 001 May 21, 2013

EQ 50MG BASE A078298 002 May 21, 2013

EQ 100MG BASE A078298 003 May 21, 2013

MYLAN EQ 25MG BASE A077163 001 Nov 02, 2009

EQ 50MG BASE A077163 002 Nov 02, 2009

EQ 100MG BASE A077163 003 Nov 02, 2009

ROXANE EQ 25MG BASE A078241 001 Aug 10, 2009

EQ 50MG BASE A078241 002 Aug 10, 2009

EQ 100MG BASE A078241 003 Aug 10, 2009

TEVA EQ 25MG BASE A076840 001 Feb 09, 2009

EQ 50MG BASE A076840 002 Feb 09, 2009

EQ 100MG BASE A076840 003 Feb 09, 2009

SUPROFEN

SOLUTION/DROPS;OPHTHALMIC

PROFENAL

ALCON 1% N019387 001 Dec 23, 1988

TACRINE HYDROCHLORIDE

CAPSULE; ORAL

COGNEX

SHIONOGI INC EQ 10MG BASE N020070 001 Sep 09, 1993

EQ 20MG BASE N020070 002 Sep 09, 1993

EQ 30MG BASE N020070 003 Sep 09, 1993

EQ 40MG BASE N020070 004 Sep 09, 1993

TACROLIMUS

CAPSULE; ORAL

TACROLIMUS

HERITAGE PHARMA EQ 5MG BASE A090402 001 Jul 01, 2010

TADALAFIL

TABLET; ORAL

TADALAFIL

WATSON LABS INC 2.5MG A205885 001 Mar 29, 2019

5MG A205885 002 Mar 29, 2019

10MG A205885 003 Mar 29, 2019

20MG A205885 004 Mar 29, 2019

TALBUTAL

TABLET; ORAL

LOTUSATE

SANOFI AVENTIS US 120MG N009410 005

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TAMOXIFEN CITRATE

TABLET; ORAL

NOLVADEX

+ ASTRAZENECA

EQ 10MG BASE **

N017970 001

+

EQ 20MG BASE **

N017970 002 Mar 21, 1994

TAMOXIFEN CITRATE

ACTAVIS LABS FL INC EQ 10MG BASE

A076179 001 Feb 20, 2003

EQ 20MG BASE

A076179 002 Feb 20, 2003

AEGIS PHARMS EQ 10MG BASE

A076398 001 Mar 31, 2003

EQ 20MG BASE

A076398 002 Mar 31, 2003

IVAX SUB TEVA PHARMS EQ 10MG BASE

A075740 001 Feb 20, 2003

EQ 20MG BASE

A075740 002 Feb 20, 2003

PHARMACHEMIE EQ 10MG BASE

A074539 001 Mar 31, 2003

ROXANE EQ 10MG BASE

A076027 001 Feb 20, 2003

EQ 20MG BASE

A076027 002 Feb 20, 2003

TEVA EQ 10MG BASE

A074504 001 Apr 28, 2003

EQ 20MG BASE

A074504 002 Apr 28, 2003

TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL

TAMSULOSIN HYDROCHLORIDE

ANBISON LAB 0.4MG

A211885 001 Oct 17, 2019

MYLAN 0.4MG

A090408 001 Apr 27, 2010

TAPENTADOL HYDROCHLORIDE

SOLUTION; ORAL

NUCYNTA

+ COLLEGIUM PHARM INC EQ 20MG BASE/ML

N203794 001 Oct 15, 2012

TAZAROTENE

CREAM; TOPICAL

TAZAROTENE

FOUGERA PHARMS INC 0.1%

A211175 001 Jan 28, 2019

TECHNETIUM TC-99M APCITIDE

INJECTABLE; INJECTION

ACUTECT

CIS BIO INTL SA N/A

N020887 001 Sep 14, 1998

TECHNETIUM TC-99M DEPREOTIDE

INJECTABLE; INJECTION

NEO TECT KIT

CIS BIO INTL SA N/A **

N021012 001 Aug 03, 1999

TECHNETIUM TC-99M DISOFENIN KIT

INJECTABLE; INJECTION

HEPATOLITE

SUN PHARM INDS INC N/A

N018467 001 Mar 16, 1982

TECHNETIUM TC-99M ETIDRONATE KIT

INJECTABLE; INJECTION

CINTICHEM TECHNETIUM 99M HEDSPA

GE HEALTHCARE N/A

N017653 001

MPI STANNOUS DIPHOSPHONATE

GE HEALTHCARE N/A

N017667 001

OSTEOSCAN

MALLINCKRODT N/A

N017454 001

TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT

GE HEALTHCARE N/A

N017562 001

TECHNETIUM TC-99M FERRENTEATE KIT

INJECTABLE; INJECTION

RENOTEC

BRACCO N/A

N017045 001

TECHNETIUM TC-99M GLUCEPTATE KIT

INJECTABLE; INJECTION

GLUCOSCAN

BRISTOL MYERS SQUIBB N/A

N017907 001

TECHNESCAN GLUCEPTATE

DRAXIMAGE N/A

N018272 001 Jan 27, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TECHNETIUM TC-99M LIDOFENIN KIT

INJECTABLE; INJECTION

TECHNESCAN HIDA

DRAXIMAGE

N/A

N018489 001 Oct 31, 1986

TECHNETIUM TC-99M MEDRONATE

INJECTABLE; INJECTION

DRAXIMAGE MDP-10

JUBILANT

N/A

N018035 001

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION

AMERSCAN MDP KIT

GE HEALTHCARE

N/A

N018335 001 Aug 05, 1982

MDP-BRACCO

CARDINAL HEALTH 414

N/A

N018107 001

OSTEOLITE

PHARMALUCENCE

N/A

N017972 001

TECHNETIUM TC 99M MPI MDP

GE HEALTHCARE

N/A

N018141 001

N/A

N018141 002 Jun 12, 1989

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE; INJECTION

AN-DTPA

JUBILANT DRAXIMAGE

N/A

N017714 001

MPI DTPA KIT - CHELATE

GE HEALTHCARE

N/A

N017255 001

TECHNETIUM TC-99M PENTETATE KIT

GE HEALTHCARE

N/A

N017264 002

TECHNETIUM TC-99M POLYPHOSPHATE KIT

INJECTABLE; INJECTION

SODIUM POLYPHOSPHATE-TIN KIT

GE HEALTHCARE

N/A

N017664 001

TECHNETIUM TC-99M PYRO/TRIMETA PHOSPHATES KIT

INJECTABLE; INJECTION

PYROLITE

PHARMALUCENCE

N/A

N017684 001

TECHNETIUM TC-99M PYROPHOSPHATE KIT

INJECTABLE; INJECTION

PHOSPHOTEC

BRACCO

N/A

N017680 001

TECHNETIUM TC-99M RED BLOOD CELL KIT

INJECTABLE; INJECTION

RBC-SCAN

CADEMA

N/A

N020063 001 Jun 11, 1992

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION

MIRALUMA

LANTHEUS MEDCL

N/A

N019785 003 May 23, 1997

TECHNETIUM TC-99M SODIUM PERTECHNETATE

SOLUTION; INJECTION, ORAL

SODIUM PERTECHNETATE TC 99M

+ GE HEALTHCARE

2-100mCi/ML **

N017471 001

+ MALLINCKRODT

10-60mCi/ML **

N017725 001

PHARMALUCENCE

12mCi/ML

N017321 001

24mCi/ML

N017321 002

48mCi/ML

N017321 003

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INJECTION, ORAL

MINITEC

BRACCO

0.22-2.22 CI/GENERATOR

N017339 001

SOLUTION; INTRAVENOUS

TECHNELITE

LANTHEUS MEDCL

0.0083-2.7 CI/GENERATOR

N017771 001

ULTRA-TECHNEKOW FM

CURIUM

0.25-3 CI/GENERATOR

N017243 002

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION;INTRAVENOUS, ORAL

TECHNETIUM TC 99M GENERATOR

+	GE HEALTHCARE	68-2703mCi/GENERATOR	N017693	002	Dec 13, 2013
		830-16600mCi/GENERATOR	N017693	001	

TECHNETIUM TC-99M SUCCIMER KIT

INJECTABLE;INJECTION

MPI DMSA KIDNEY REAGENT

	GE HEALTHCARE	N/A	N017944	001	May 18, 1982
--	---------------	-----	---------	-----	--------------

TECHNETIUM TC-99M SULFUR COLLOID

SOLUTION;INJECTION, ORAL

TECHNETIUM TC 99M SULFUR COLLOID

	GE HEALTHCARE	4mCi/ML	N017456	001	
--	---------------	---------	---------	-----	--

SOLUTION;ORAL

TECHNETIUM TC 99M SULFUR COLLOID

	MALLINCKRODT	3mCi/ML	N017724	001	
--	--------------	---------	---------	-----	--

TECHNETIUM TC-99M SULFUR COLLOID KIT

SOLUTION;INJECTION, ORAL

TECHNECOLL

	MALLINCKRODT	N/A	N017059	001	
--	--------------	-----	---------	-----	--

TECHNETIUM TC 99M TSC

	GE HEALTHCARE	N/A	N017784	001	
--	---------------	-----	---------	-----	--

TESULOID

	BRACCO	N/A	N016923	001	
--	--------	-----	---------	-----	--

TECHNETIUM TC-99M TEBOROXIME KIT

INJECTABLE;INJECTION

CARDIOTEC

	BRACCO	N/A	N019928	001	Dec 19, 1990
--	--------	-----	---------	-----	--------------

TECHNETIUM TC-99M TETROFOSMIN KIT

INJECTABLE;INJECTION

MYOVIEW

+	GE HEALTHCARE	N/A	N020372	001	Feb 09, 1996
---	---------------	-----	---------	-----	--------------

TEGASEROD MALEATE

TABLET;ORAL

ZELNORM

+	ALFASIGMA	EQ 2MG BASE	N021200	001	Jul 24, 2002
---	-----------	-------------	---------	-----	--------------

TELAPREVIR

TABLET;ORAL

INCIVEK

	VERTEX PHARMS	375MG	N201917	001	May 23, 2011
--	---------------	-------	---------	-----	--------------

TELAVANCIN HYDROCHLORIDE

POWDER;INTRAVENOUS

VIBATIV

+	CUMBERLAND PHARMS	EQ 250MG BASE/VIAL	N022110	001	Sep 11, 2009
---	-------------------	--------------------	---------	-----	--------------

TELBIVUDINE

SOLUTION;ORAL

TYZEKA

	NOVARTIS	100MG/5ML	N022154	001	Apr 28, 2009
--	----------	-----------	---------	-----	--------------

TABLET;ORAL

TYZEKA

+	NOVARTIS	600MG	N022011	001	Oct 25, 2006
---	----------	-------	---------	-----	--------------

TELITHROMYCIN

TABLET;ORAL

KETEK

	SANOFI AVENTIS US	300MG	N021144	002	Feb 09, 2005
--	-------------------	-------	---------	-----	--------------

		400MG	N021144	001	Apr 01, 2004
--	--	-------	---------	-----	--------------

TELMISARTAN

TABLET;ORAL

TELMISARTAN

	CELLTRION	20MG	A078710	001	Jan 08, 2014
--	-----------	------	---------	-----	--------------

		40MG	A078710	002	Jan 08, 2014
--	--	------	---------	-----	--------------

		80MG	A078710	003	Jan 08, 2014
--	--	------	---------	-----	--------------

	HISUN PHARM HANGZHOU	20MG	A207843	001	Feb 19, 2019
--	----------------------	------	---------	-----	--------------

		40MG	A207843	002	Feb 19, 2019
--	--	------	---------	-----	--------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TELMISARTAN

TABLET; ORAL

TELMISARTAN

	80MG	A207843 003	Feb 19, 2019
JUBILANT GENERICS	20MG	A204164 001	Aug 22, 2016
	40MG	A204164 002	Aug 22, 2016
	80MG	A204164 003	Aug 22, 2016

TEMAZEPAM

CAPSULE; ORAL

TEMAZ

QUANTUM PHARMICS	15MG	A070564 001	Oct 15, 1985
	30MG	A070547 001	Oct 15, 1985

TEMAZEPAM

DURAMED PHARMS BARR	15MG	A071708 001	Sep 29, 1988
	30MG	A071709 001	Sep 29, 1988
SUN PHARM INDUSTRIES	15MG	A071174 001	Jul 10, 1986
	30MG	A071175 001	Jul 10, 1986
USL PHARMA	15MG	A070489 001	Jul 07, 1986
	30MG	A070490 001	Jul 07, 1986
WATSON LABS	15MG	A070383 001	Mar 23, 1987
	15MG	A071446 001	May 21, 1993
	30MG	A070384 001	Mar 23, 1987
	30MG	A071447 001	May 21, 1993

TEMOZOLOMIDE

CAPSULE; ORAL

TEMOZOLOMIDE

APOTEX INC	5MG	A204159 001	Jul 05, 2018
	20MG	A204159 002	Jul 05, 2018
	100MG	A204159 003	Jul 05, 2018
	140MG	A204159 004	Jul 05, 2018
	180MG	A204159 005	Jul 05, 2018
	250MG	A204159 006	Jul 05, 2018
BARR	5MG	A078879 001	Mar 01, 2010
	20MG	A078879 002	Mar 01, 2010
	100MG	A078879 003	Mar 01, 2010
	140MG	A078879 005	Mar 01, 2010
	180MG	A078879 006	Mar 01, 2010
	250MG	A078879 004	Mar 01, 2010
LANNETT CO INC	5MG	A203898 001	Feb 10, 2016
	20MG	A203898 002	Feb 10, 2016
	100MG	A203898 003	Feb 10, 2016
	140MG	A203898 004	Feb 10, 2016
	180MG	A203898 005	Feb 10, 2016
	250MG	A203898 006	Feb 10, 2016
MYLAN	5MG	A205227 001	Jun 29, 2016
	20MG	A205227 002	Jun 29, 2016
	100MG	A205227 003	Jun 29, 2016
	140MG	A205227 004	Jun 29, 2016
	180MG	A205227 005	Jun 29, 2016
	250MG	A205227 006	Jun 29, 2016

TENAPANOR HYDROCHLORIDE

TABLET; ORAL

IBSRELA

+ ARDELYX INC	EQ 50MG BASE	N211801 001	Sep 12, 2019
---------------	--------------	-------------	--------------

TENIPOSIDE

INJECTABLE; INJECTION

VUMON

+ HQ SPECLT PHARMA	10MG/ML	N020119 001	Jul 14, 1992
--------------------	---------	-------------	--------------

TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

TENOFVIR DISOPROXIL FUMARATE

CHARTWELL	300MG	A206481 001	Jul 26, 2018
MYLAN	150MG	A206569 001	Nov 27, 2018
	200MG	A206569 002	Nov 27, 2018
	250MG	A206569 003	Nov 27, 2018
	300MG	A206569 004	Nov 27, 2018

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TERAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

HYTRIN

+	ABBOTT	EQ 1MG BASE **	N020347 001	Dec 14, 1994
+		EQ 2MG BASE **	N020347 002	Dec 14, 1994
+		EQ 5MG BASE **	N020347 003	Dec 14, 1994
+		EQ 10MG BASE **	N020347 004	Dec 14, 1994

TERAZOSIN HYDROCHLORIDE

BEXIMCO PHARMS USA

EQ 1MG BASE	A075667 001	Jul 28, 2000
EQ 2MG BASE	A075667 002	Jul 28, 2000
EQ 5MG BASE	A075667 003	Jul 28, 2000
EQ 10MG BASE	A075667 004	Jul 28, 2000

HERITAGE PHARMA

EQ 1MG BASE	A075614 002	Jan 30, 2001
EQ 2MG BASE	A075614 001	Jan 30, 2001
EQ 5MG BASE	A075614 003	Jan 30, 2001
EQ 10MG BASE	A075614 004	Jan 30, 2001

HIKMA

EQ 1MG BASE	A075498 001	Apr 12, 2001
EQ 2MG BASE	A075498 002	Apr 12, 2001
EQ 5MG BASE	A075498 003	Apr 12, 2001
EQ 10MG BASE	A075498 004	Apr 12, 2001

MYLAN TECHNOLOGIES

EQ 1MG BASE	A075384 001	Dec 01, 2000
EQ 2MG BASE	A075384 002	Dec 01, 2000
EQ 5MG BASE	A075384 003	Dec 01, 2000
EQ 10MG BASE	A075384 004	Dec 01, 2000

RANBAXY LABS LTD

EQ 1MG BASE	A076021 001	Aug 22, 2002
EQ 2MG BASE	A076021 002	Aug 22, 2002
EQ 5MG BASE	A076021 003	Aug 22, 2002
EQ 10MG BASE	A076021 004	Aug 22, 2002

TABLET;ORAL

HYTRIN

ABBOTT

EQ 1MG BASE	N019057 001	Aug 07, 1987
EQ 2MG BASE	N019057 002	Aug 07, 1987
EQ 5MG BASE	N019057 003	Aug 07, 1987
EQ 10MG BASE	N019057 004	Aug 07, 1987

TERAZOSIN HYDROCHLORIDE

IVAX SUB TEVA PHARMS

EQ 1MG BASE	A074530 001	Apr 21, 2000
EQ 2MG BASE	A074530 002	Apr 21, 2000
EQ 5MG BASE	A074530 003	Apr 21, 2000
EQ 10MG BASE	A074530 004	Apr 21, 2000

SANDOZ

EQ 1MG BASE	A074315 001	Dec 31, 1998
EQ 1MG BASE	A074657 001	Apr 28, 2000
EQ 2MG BASE	A074315 002	Dec 31, 1998
EQ 2MG BASE	A074657 002	Apr 28, 2000
EQ 5MG BASE	A074315 003	Dec 31, 1998
EQ 5MG BASE	A074657 003	Apr 28, 2000
EQ 10MG BASE	A074315 004	Dec 31, 1998
EQ 10MG BASE	A074657 004	Apr 28, 2000

TEVA

EQ 1MG BASE	A074446 001	May 18, 2000
EQ 2MG BASE	A074446 002	May 18, 2000
EQ 5MG BASE	A074446 003	May 18, 2000
EQ 10MG BASE	A074446 004	May 18, 2000

TERBINAFINE

GEL;TOPICAL

LAMISIL

GLAXOSMITHKLINE CONS 1%

N020846 001 Apr 29, 1998

TERBINAFINE HYDROCHLORIDE

CREAM;TOPICAL

LAMISIL

NOVARTIS 1%

N020192 001 Dec 30, 1992

GRANULE;ORAL

LAMISIL

+ NOVARTIS

EQ 125MG BASE/PACKET

N022071 001 Sep 28, 2007

+

EQ 187.5MG BASE/PACKET

N022071 002 Sep 28, 2007

SOLUTION;TOPICAL

LAMISIL

GLAXOSMITHKLINE CONS 1%

N020749 001 Oct 17, 1997

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TERBINAFINE HYDROCHLORIDE

TABLET; ORAL

TERBINAFINE HYDROCHLORIDE

CHARTWELL	EQ 250MG BASE	A078199 001	Jul 02, 2007
GEDEON RICHTER USA	EQ 250MG BASE	A077065 001	Jul 02, 2007
MYLAN	EQ 250MG BASE	A077136 001	Jul 02, 2007
	EQ 250MG BASE	A077195 001	Jul 02, 2007
ROXANE	EQ 250MG BASE	A077223 001	Jul 02, 2007
WOCKHARDT	EQ 250MG BASE	A078229 001	Jul 02, 2007

TERBUTALINE SULFATE

AEROSOL, METERED; INHALATION

BRETHAIRE

NOVARTIS	0.2MG/INH	N018762 001	Aug 17, 1984
----------	-----------	-------------	--------------

BRICANYL

SANOFI AVENTIS US	0.2MG/INH	N018000 001	Mar 19, 1985
-------------------	-----------	-------------	--------------

INJECTABLE; INJECTION

BRETHINE

+ PHARMACARE 1MG/ML **

N018571 001

BRICANYL

SANOFI AVENTIS US	1MG/ML	N017466 001	
-------------------	--------	-------------	--

TERBUTALINE SULFATE

DR REDDYS	1MG/ML	A076853 001	Jul 20, 2004
-----------	--------	-------------	--------------

TABLET; ORAL

BRICANYL

SANOFI AVENTIS US	2.5MG	N017618 001	
	5MG	N017618 002	

TERCONAZOLE

CREAM; VAGINAL

TERAZOL 3

+ JANSSEN PHARMS 0.8% ** N019964 001 Feb 21, 1991

TERAZOL 7

+ JANSSEN PHARMS 0.4% ** N019579 001 Dec 31, 1987

SUPPOSITORY; VAGINAL

TERAZOL 3

+ JANSSEN PHARMS 80MG N019641 001 May 24, 1988

TERCONAZOLE

FOUGERA PHARMS	80MG	A076850 001	Jul 12, 2006
----------------	------	-------------	--------------

TERIFLUNOMIDE

TABLET; ORAL

TERIFLUNOMIDE

AMNEAL PHARMS CO	7MG	A209613 001	Sep 28, 2018
	14MG	A209613 002	Sep 28, 2018
APOTEX	7MG	A209601 001	Nov 02, 2018
	14MG	A209601 002	Nov 02, 2018
AUROBINDO PHARMA LTD	7MG	A209638 001	Oct 26, 2018
	14MG	A209638 002	Oct 26, 2018
MSN	7MG	A209623 001	Apr 24, 2019
	14MG	A209623 002	Apr 24, 2019
MYLAN	7MG	A209702 001	Feb 28, 2020
	14MG	A209702 002	Feb 28, 2020
TEVA PHARMS USA	7MG	A209700 001	Sep 04, 2018
	14MG	A209700 002	Sep 04, 2018
WATSON LABS TEVA	7MG	A209549 001	Jul 27, 2018
	14MG	A209549 002	Jul 27, 2018
ZYDUS PHARMS	7MG	A209668 001	Nov 30, 2018
	14MG	A209668 002	Nov 30, 2018

TERIPARATIDE

SOLUTION; SUBCUTANEOUS

FORTEO

LILLY	0.75MG/3ML (0.25MG/ML)	N021318 001	Nov 26, 2002
-------	------------------------	-------------	--------------

TERIPARATIDE ACETATE

INJECTABLE; INJECTION

PARATHAR

SANOFI AVENTIS US	200 UNITS/VIAL	N019498 001	Dec 23, 1987
-------------------	----------------	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TESTOLACTONE

INJECTABLE; INJECTION

TESLAC

BRISTOL MYERS SQUIBB 100MG/ML N016119 001

TABLET; ORAL

TESLAC

BRISTOL MYERS SQUIBB 50MG N016118 001
250MG N016118 002TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL

ANDRODERM

ALLERGAN 2.5MG/24HR N020489 001 Sep 29, 1995
5MG/24HR N020489 002 May 02, 1997

TESTODERM

ALZA 4MG/24HR N019762 001 Oct 12, 1993
6MG/24HR N019762 002 Oct 12, 1993

TESTODERM TTS

ALZA 5MG/24HR N020791 001 Dec 18, 1997

GEL; TRANSDERMAL

TESTOSTERONE

ANI PHARMS INC 25MG/2.5GM PACKET N202763 001 Feb 14, 2012
50MG/5GM PACKET N202763 002 Feb 14, 2012
PERRIGO ISRAEL 25MG/2.5GM PACKET N203098 002 Jan 31, 2013
50MG/5GM PACKET N203098 003 Jan 31, 2013

GEL, METERED; TRANSDERMAL

ANDROGEL

+ ABBVIE 12.5MG/1.25GM ACTUATION N021015 003 Sep 26, 2003

TESTOSTERONE

PERRIGO ISRAEL 12.5MG/1.25GM ACTUATION N203098 001 Jan 31, 2013

INJECTABLE; INJECTION

TESTOSTERONE

DR REDDYS 100MG/ML A086417 001 Jul 07, 1983
WATSON LABS 25MG/ML A086420 001 May 10, 1983
50MG/ML A086419 001 Aug 23, 1983

SOLUTION, METERED; TRANSDERMAL

AXIRON

+ ELI LILLY AND CO 30MG/1.5ML ACTUATION ** N022504 001 Nov 23, 2010

TABLET, EXTENDED RELEASE; BUCCAL

STRIANT

+ AUXILIUM PHARMS LLC 30MG N021543 001 Jun 19, 2003

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION

DEPO-TESTOSTERONE

PHARMACIA AND UPJOHN 50MG/ML A085635 001

TESTOSTERONE CYPIONATE

MYLAN INSTITUTIONAL 200MG/ML A040652 001 Dec 11, 2006
WATSON LABS 100MG/ML A084401 001
100MG/ML A086029 001
200MG/ML A084401 002TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

DELATESTRYL

ENDO PHARMS 200MG/ML N009165 001
+ 200MG/ML N009165 003

TESTOSTERONE ENANTHATE

MYLAN INSTITUTIONAL 200MG/ML A040647 001 Oct 05, 2009
WATSON LABS 100MG/ML A083667 001
100MG/ML A085599 001
200MG/ML A083667 002TESTOSTERONE PROPIONATE

INJECTABLE; INJECTION

TESTOSTERONE PROPIONATE

BEL MAR 25MG/ML A080741 001
50MG/ML A080742 001
100MG/ML A080743 001
ELKINS SINN 25MG/ML A080276 001
LILLY 50MG/ML A080254 002

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TESTOSTERONE PROPIONATE

INJECTABLE; INJECTION

TESTOSTERONE PROPIONATE

WATSON LABS

25MG/ML
25MG/ML
50MG/ML
50MG/ML
100MG/ML
100MG/MLA080188 001
A085490 001
A080188 002
A085490 002
A080188 003
A083595 003TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

BRISTACYCLINE

BRISTOL

250MG
250MG
500MG
500MGA061658 001
A061888 001
A061658 002
A061888 002

CYCLOPAR

WARNER CHILCOTT

250MG
250MG
250MG
500MG
500MGA061725 001
A062175 001
A062332 001
A061725 002
A062332 002

PANMYCIN

PHARMACIA AND UPJOHN

250MG

A060347 001

RETET

SOLVAY

250MG
500MGA061443 001
A061443 002

ROBITET

WYETH AYERST

250MG
500MGA061734 001
A061734 002

SUMYCIN

APOTHECON

100MG
125MG
250MG
500MGA060429 002
A060429 004
A060429 001
A060429 003

TETRACHEL

ANGUS

250MG
500MGA060343 001
A060343 003

TETRACYCLINE HYDROCHLORIDE

ABBOTT

250MG
500MGA061802 001
A061802 002

ANI PHARMS INC

250MG

A061471 001

ELKINS SINN

250MG

A060059 001

FERRANTE

125MG

A060173 001

250MG

250MG

A060173 002

HEATHER

250MG

A061148 001

500MG

A061148 002

HIKMA

250MG

A060768 001

500MG

A060768 002

IMPAX LABS

100MG

A060469 002

250MG

A060469 001

500MG

A060469 003

IVAX SUB TEVA PHARMS

250MG

A060704 001

500MG

A060704 002

MAST MM

250MG

A062085 001

MYLAN

250MG

A060783 001

500MG

A060783 002

PUREPAC PHARM

250MG

A060290 001

500MG

A060290 002

PVT FORM

250MG

A062686 001 Jul 24, 1986

500MG

A062686 002 Jul 24, 1986

ROXANE

500MG

A061214 002

SUN PHARM INDUSTRIES

250MG

A060736 001

500MG

A060736 002

SUPERPHARM

250MG

A062540 001 Mar 21, 1985

500MG

A062540 002 Mar 21, 1985

VALEANT PHARM INTL

250MG

A060471 001

500MG

A060471 002

WARNER CHILCOTT

250MG

A062300 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

TETRACYCLINE HYDROCHLORIDE

	500MG	A062300 002	
WATSON LABS	250MG	A062103 001	
	250MG	A062343 001	
	500MG	A062103 002	
	500MG	A062343 002	
WYETH AYERST	250MG	A061685 001	
	500MG	A061685 002	
TETRACYN			
PFIPHARMECS	250MG	A060082 003	
	500MG	A060082 004	
FIBER, EXTENDED RELEASE; PERIODONTAL			
ACTISITE			
SCHIFF AND CO	12.7MG/FIBER	N050653 001	Mar 25, 1994
FOR SOLUTION; TOPICAL			
TOPICYCLINE			
SHIRE	2.2MG/ML	N050493 001	
INJECTABLE; INJECTION			
ACHROMYCIN			
LEDERLE	250MG/VIAL	N050273 002	
	500MG/VIAL	N050273 003	
TETRACYN			
PFIZER	250MG/VIAL	A060096 001	
	500MG/VIAL	A060096 002	
OINTMENT; OPHTHALMIC			
ACHROMYCIN			
STORZ	10MG/GM	N050266 001	
SUSPENSION; ORAL			
ACHROMYCIN V			
LEDERLE	125MG/5ML	N050263 002	
SUMYCIN			
PAR PHARM	125MG/5ML	A060400 001	
TETRACYCLINE HYDROCHLORIDE			
ALPHARMA US PHARMS	125MG/5ML	A060633 001	
FERRANTE	125MG/5ML	A060174 001	
PROTER	125MG/5ML	A060446 001	
PUREPAC PHARM	125MG/5ML	A060291 001	
TETRACYN			
PFIPHARMECS	125MG/5ML	A060095 001	
TETRAMED			
IVAX SUB TEVA PHARMS	125MG/5ML	A061468 001	
SUSPENSION/DROPS; OPHTHALMIC			
ACHROMYCIN			
STORZ	1%	N050268 001	
TABLET; ORAL			
PANMYCIN			
PHARMACIA AND UPJOHN	250MG	A061705 001	
	500MG	A061705 002	
SUMYCIN			
PAR PHARM	50MG	A061147 003	
	100MG	A061147 002	
	250MG	A061147 001	
	500MG	A061147 004	

TETRACYCLINE PHOSPHATE COMPLEX

CAPSULE; ORAL

TETREX

BRISTOL	EQ 100MG HYDROCHLORIDE	A061653 001	
	EQ 250MG HYDROCHLORIDE	A061653 002	
	EQ 250MG HYDROCHLORIDE	A061889 002	
	EQ 250MG HYDROCHLORIDE	N050212 002	
	EQ 500MG HYDROCHLORIDE	A061653 003	
	EQ 500MG HYDROCHLORIDE	A061889 001	
	EQ 500MG HYDROCHLORIDE	N050212 003	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

THALLOUS CHLORIDE TL-201

INJECTABLE; INJECTION

THALLOUS CHLORIDE TL 201

BRACCO 1mCi/ML

N018548 001 Dec 30, 1982

TRACE LIFE 1mCi/ML

A075569 001 Nov 21, 2001

INJECTABLE; INTRAVENOUS

THALLOUS CHLORIDE TL 201

CURIUM 2mCi/ML

A077698 001 Nov 09, 2006

+ LANTHEUS MEDCL 2mCi/ML

N017806 002 Oct 09, 1998

THEOPHYLLINE

CAPSULE; ORAL

BRONKODYL

SANOFI AVENTIS US 100MG

A085264 001

200MG

A085264 002

ELIXOPHYLLIN

FOREST LABS 100MG

A085545 001 Jul 31, 1984

200MG

A083921 001 Jul 31, 1984

SOMOPHYLLIN-T

FISONS 100MG

A087155 001 Feb 25, 1985

200MG

A087155 002 Feb 25, 1985

250MG

A087155 003 Feb 25, 1985

THEOPHYLLINE

KV PHARM 100MG

A085263 001

200MG

A085263 002

SCHERER RP 100MG

A084731 002 Nov 07, 1986

200MG

A084731 001 Nov 07, 1986

250MG

A084731 003 Nov 07, 1986

CAPSULE, EXTENDED RELEASE; ORAL

AEROLATE III

FLEMING PHARMS 65MG

A085075 003 Nov 24, 1986

AEROLATE JR

FLEMING PHARMS 130MG

A085075 002 Nov 24, 1986

AEROLATE SR

FLEMING PHARMS 260MG

A085075 001 Nov 24, 1986

ELIXOPHYLLIN SR

FOREST LABS 125MG

A086826 001 Jan 29, 1985

250MG

A086826 002 Jan 29, 1985

SLO-BID

SANOFI AVENTIS US 50MG

A088269 001 Jan 31, 1985

75MG

A089539 001 May 10, 1989

100MG

A087892 001 Jan 31, 1985

125MG

A089540 001 May 10, 1989

200MG

A087893 001 Jan 31, 1985

300MG

A087894 001 Jan 31, 1985

SLO-PHYLLIN

SANOFI AVENTIS US 60MG

A085206 001 May 24, 1982

125MG

A085203 001 May 24, 1982

250MG

A085205 001 May 24, 1982

SOMOPHYLLIN-CRT

GRAHAM DM 50MG

A087763 001 Feb 27, 1985

100MG

A087194 001

200MG

A088382 001 Feb 27, 1985

250MG

A087193 001

300MG

A088383 001 Feb 27, 1985

THEO-DUR

SCHERING 50MG

A088022 001 Sep 10, 1985

75MG

A088015 001 Sep 10, 1985

125MG

A088016 001 Sep 10, 1985

200MG

A087995 001 Sep 10, 1985

THEOBID

WHITBY 260MG

A085983 001 Mar 20, 1985

THEOBID JR.

WHITBY 130MG

A087854 001 Mar 20, 1985

THEOCLEAR L.A.-130

SCHWARZ PHARMA 130MG

A086569 001 May 27, 1982

THEOCLEAR L.A.-260

SCHWARZ PHARMA 260MG

A086569 002 May 27, 1982

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE;ORAL

THEOPHYL-SR

ORTHO MCNEIL PHARM	125MG	A086480	001	Feb 08, 1985
	250MG	A086471	001	Feb 08, 1985

THEOPHYLLINE

CENT PHARMS	125MG	A088654	001	Feb 12, 1985
	250MG	A088689	001	Feb 12, 1985
HOSPIRA	100MG	A089976	001	Jan 04, 1995
	200MG	A089977	001	Jan 04, 1995
	300MG	A089932	001	Jan 04, 1995
INWOOD LABS	100MG	A040052	001	Feb 14, 1994
	125MG	A040052	002	Feb 14, 1994
	200MG	A040052	003	Feb 14, 1994
	300MG	A040052	004	Feb 14, 1994
SANDOZ	260MG	A087462	001	May 11, 1982

THEOPHYLLINE-SR

SCHERER RP	300MG	A088255	001	Jun 12, 1986
------------	-------	---------	-----	--------------

THEOVENT

SCHERING	125MG	A087010	001	Jan 31, 1985
	250MG	A087910	001	Jan 31, 1985

ELIXIR;ORAL

ELIXOMIN

CENCI	80MG/15ML	A088303	001	Jan 25, 1984
-------	-----------	---------	-----	--------------

LANOPHYLLIN

LANNETT	80MG/15ML	A084578	001	
---------	-----------	---------	-----	--

THEOLIXIR

PANRAY	80MG/15ML	A084559	001	
--------	-----------	---------	-----	--

THEOPHYL-225

ORTHO MCNEIL PHARM	112.5MG/15ML	A086485	001	
--------------------	--------------	---------	-----	--

THEOPHYLLINE

ALPHARMA US PHARMS	80MG/15ML	A089223	001	May 27, 1988
CENCI	80MG/15ML	A087679	001	Apr 15, 1982
CHARTWELL RX	80MG/15ML	A085952	001	
HALSEY	80MG/15ML	A085169	001	
PHARM ASSOC	80MG/15ML	A086720	001	
PRECISION DOSE	80MG/15ML	A085863	001	
ROXANE	80MG/15ML	A084739	001	
TARO	80MG/15ML	A089626	001	Oct 28, 1988
WOCKHARDT	80MG/15ML	A086748	001	

INJECTABLE;INJECTION

THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	40MG/100ML	N019083	001	Nov 07, 1984
---------	------------	---------	-----	--------------

THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	80MG/100ML	N019083	002	Nov 07, 1984
---------	------------	---------	-----	--------------

THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	160MG/100ML	N019083	003	Nov 07, 1984
---------	-------------	---------	-----	--------------

THEOPHYLLINE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	200MG/100ML	N019212	001	Nov 07, 1984
---------	-------------	---------	-----	--------------

	200MG/100ML	N019826	004	Aug 14, 1992
--	-------------	---------	-----	--------------

THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	4MG/ML	N019212	003	Nov 07, 1984
---------	--------	---------	-----	--------------

	400MG/100ML	N019212	002	Nov 07, 1984
--	-------------	---------	-----	--------------

	400MG/100ML	N019826	005	Aug 14, 1992
--	-------------	---------	-----	--------------

THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4MG/ML	N018649	007	Jul 26, 1982
-----------------	--------	---------	-----	--------------

	40MG/100ML	N018649	001	Jul 26, 1982
--	------------	---------	-----	--------------

	80MG/100ML	N018649	002	Jul 26, 1982
--	------------	---------	-----	--------------

	160MG/100ML	N018649	003	Jul 26, 1982
--	-------------	---------	-----	--------------

	200MG/100ML	N018649	004	Jul 26, 1982
--	-------------	---------	-----	--------------

	320MG/100ML	N018649	006	Nov 13, 1985
--	-------------	---------	-----	--------------

	400MG/100ML	N018649	005	Jul 26, 1982
--	-------------	---------	-----	--------------

THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER

+	HOSPIRA INC	4MG/ML	N019211	007	Dec 14, 1984
---	-------------	--------	---------	-----	--------------

+		40MG/100ML	N019211	001	Dec 14, 1984
---	--	------------	---------	-----	--------------

+		80MG/100ML	N019211	002	Dec 14, 1984
---	--	------------	---------	-----	--------------

+		160MG/100ML	N019211	003	Dec 14, 1984
---	--	-------------	---------	-----	--------------

+		200MG/100ML	N019211	004	Dec 14, 1984
---	--	-------------	---------	-----	--------------

+		320MG/100ML	N019211	006	Jan 20, 1988
---	--	-------------	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

THEOPHYLLINE

INJECTABLE; INJECTION

THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER
400MG/100ML

N019211 005 Dec 14, 1984

SOLUTION; ORAL

AEROLATE

FLEMING PHARMS 150MG/15ML

A089141 001 Dec 03, 1986

THEOLAIR

3M 80MG/15ML

A086107 001

THEOPHYLLINE

ROXANE 80MG/15ML

A087449 001 Sep 15, 1983

SUSPENSION; ORAL

ELIXICON

FOREST LABS 100MG/5ML

A085502 001

SYRUP; ORAL

ACCURBRON

SANOFI AVENTIS US 150MG/15ML

A088746 001 Nov 22, 1985

AQUAPHYLLIN

FERNDALE LABS 80MG/15ML

A087917 001 Jan 18, 1983

SLO-PHYLLIN

SANOFI AVENTIS US 80MG/15ML

A085187 001

THEOCLEAR-80

CENT PHARMS 80MG/15ML

A087095 001 Mar 01, 1982

THEOPHYLLINE

ALPHARMA US PHARMS 80MG/15ML

A086001 001

150MG/15ML

A086545 001

TABLET; ORAL

QUIBRON-T

MONARCH PHARMS 300MG

A088656 001 Aug 22, 1985

SLO-PHYLLIN

SANOFI AVENTIS US 100MG

A085202 001

200MG

A085204 001

THEOCLEAR-100

CENT PHARMS 100MG

A085353 002

THEOCLEAR-200

CENT PHARMS 200MG

A085353 001

THEOLAIR

MEDICIS 125MG

A086399 001

250MG

A086399 002

THEOPHYL-225

ORTHO MCNEIL PHARM 225MG

A084726 001

TABLET, CHEWABLE; ORAL

THEOPHYL

ORTHO MCNEIL PHARM 100MG

A086506 001 Sep 12, 1985

TABLET, EXTENDED RELEASE; ORAL

DURAPHYL

FOREST LABS 100MG

A088503 001 Apr 03, 1985

200MG

A088504 001 Apr 03, 1985

300MG

A088505 001 Apr 03, 1985

LABID

WARNER CHILCOTT 250MG

A087225 001

QUIBRON-T/SR

MONARCH PHARMS 300MG

A087563 001 Jun 21, 1983

SUSTAIRE

ROERIG 100MG

A085665 001

300MG

A085665 002

T-PHYL

PHARM RES ASSOC 200MG

A088253 001 Aug 17, 1983

THEO-DUR

SCHERING 100MG

A085328 001

200MG

A086998 001

300MG

A085328 002

450MG

A089131 001 Jun 25, 1986

THEOCHRON

NOSTRUM PHARMS LLC 300MG

A087400 002 Jan 11, 1983

THEOLAIR-SR

3M 200MG

A088369 001 Jul 16, 1987

250MG

A086363 002 Jul 16, 1987

300MG

A088364 001 Jul 16, 1987

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

THEOPHYLLINE

TABLET, EXTENDED RELEASE;ORAL

THEOLAIR-SR

500MG

A089132 001 Jul 16, 1987

THEOPHYLLINE

ABLE

300MG

A040548 001 Apr 30, 2004

400MG

A040543 001 Apr 27, 2004

450MG

A040546 001 Apr 30, 2004

600MG

A040539 001 Apr 27, 2004

HERITAGE PHARMA

300MG

A089763 001 Apr 30, 1990

450MG

A081236 001 Nov 09, 1992

450MG

A040034 001 Apr 28, 1995

UNI-DUR

SCHERING

400MG

A089822 001 Jan 04, 1995

600MG

A089823 001 Jan 04, 1995

THEOPHYLLINE SODIUM GLYCINATE

ELIXIR;ORAL

SYNOHYLATE

CENT PHARMS

EQ 165MG BASE/15ML

N006333 008

TABLET;ORAL

ASBRON

NOVARTIS

EQ 150MG BASE

A085148 001

THIABENDAZOLE

SUSPENSION;ORAL

MINTEZOL

MERCK SHARP DOHME

500MG/5ML

N016097 001

TABLET, CHEWABLE;ORAL

MINTEZOL

MERCK SHARP DOHME

500MG

N016096 001

THIAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

BETALIN S

LILLY

100MG/ML

A080853 001

THIAMINE HYDROCHLORIDE

ABRAXIS PHARM

100MG/ML

A080509 001

AKORN

100MG/ML

A087968 001 Oct 01, 1982

BEL MAR

100MG/ML

A080718 001

200MG/ML

A080712 001

DELL LABS

100MG/ML

A083775 001

DR REDDYS

100MG/ML

A080571 001

200MG/ML

A080571 002

HOSPIRA

100MG/ML

A040079 001 May 03, 1996

LUITPOLD

100MG/ML

A080667 001

PARKE DAVIS

100MG/ML

A080770 001

WATSON LABS

100MG/ML

A083534 001

200MG/ML

A083534 002

WEST-WARD PHARMS INT

100MG/ML

A080575 001

WYETH AYERST

100MG/ML

A080553 001

THIAMYLAL SODIUM

INJECTABLE;INJECTION

SURITAL

PARKEDALE

1GM/VIAL

N007600 003

5GM/VIAL

N007600 005

10GM/VIAL

N007600 009

THIETHYLPERAZINE MALATE

INJECTABLE;INJECTION

TORECAN

NOVARTIS

5MG/ML

N012754 002

THIETHYLPERAZINE MALEATE

SUPPOSITORY;RECTAL

TORECAN

NOVARTIS

10MG

N013247 001

TABLET;ORAL

TORECAN

NOVARTIS

10MG

N012753 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

THIOPENTAL SODIUM

SUSPENSION;RECTAL

PENTOTHAL

ABBOTT

400MG/GM

N011679 001

THIORIDAZINE

SUSPENSION;ORAL

MELLARIL-S

NOVARTIS

EQ 25MG HYDROCHLORIDE/5ML **

N017923 001

EQ 100MG HYDROCHLORIDE/5ML **

N017923 002

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE;ORAL

MELLARIL

NOVARTIS

30MG/ML **

N011808 012

100MG/ML **

N011808 018

THIORIDAZINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC

100MG/ML

A088229 001 Aug 23, 1983

AKORN

30MG/ML

A040125 001 Aug 16, 1996

100MG/ML

A040126 001 Aug 16, 1996

ALPHARMA US PHARMS

30MG/ML

A087766 001 Apr 26, 1983

ANI PHARMS INC

30MG/ML

A089602 001 Nov 09, 1987

100MG/ML

A089603 001 Nov 09, 1987

PHARM ASSOC

30MG/ML

A040187 001 Aug 28, 1997

100MG/ML

A040213 001 May 29, 1998

SANDOZ

30MG/ML

A088307 001 Nov 23, 1983

100MG/ML

A088308 001 Nov 23, 1983

WOCKHARDT

30MG/ML

A088258 001 Jul 25, 1983

100MG/ML

A088227 001 Jul 05, 1983

THIORIDAZINE HYDROCHLORIDE INTENSOL

ROXANE

30MG/ML

A088941 001 Dec 16, 1985

100MG/ML

A088942 001 Dec 16, 1985

TABLET;ORAL

MELLARIL

+ NOVARTIS

10MG **

N011808 003

+

15MG **

N011808 016

+

25MG **

N011808 006

+

50MG **

N011808 011

+

100MG **

N011808 009

+

150MG **

N011808 017

+

200MG **

N011808 015

THIORIDAZINE HYDROCHLORIDE

ANI PHARMS INC

10MG

A088270 001 Apr 14, 1983

10MG

A088493 001 May 17, 1985

15MG

A088271 001 Apr 14, 1983

25MG

A088272 001 Apr 14, 1983

50MG

A088194 001 Apr 14, 1983

100MG

A088273 001 Oct 03, 1983

100MG

A088456 001 May 17, 1985

FOSUN PHARMA

10MG

A088131 001 Aug 30, 1983

15MG

A088132 001 Aug 30, 1983

25MG

A088133 001 Aug 30, 1983

50MG

A088134 001 Aug 30, 1983

100MG

A088135 001 Nov 20, 1984

150MG

A088136 001 Sep 17, 1986

200MG

A088137 001 Sep 17, 1986

HERITAGE PHARMA

10MG

A088476 001 Nov 08, 1983

25MG

A088478 001 Nov 08, 1983

50MG

A088479 001 Nov 08, 1983

100MG

A088736 001 Jul 24, 1984

MUTUAL PHARM

10MG

A088375 001 Nov 18, 1983

25MG

A087264 001 Nov 18, 1983

50MG

A088370 001 Nov 18, 1983

100MG

A088379 001 Nov 16, 1983

MYLAN

10MG

A088332 001 Jun 27, 1983

25MG

A088333 001 Jun 27, 1983

50MG

A088334 001 Jun 27, 1983

100MG

A088335 001 Nov 18, 1983

PAR PHARM

10MG

A088351 001 Dec 05, 1983

15MG

A088352 001 Dec 05, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HYDROCHLORIDE

	25MG	A088336	001	Dec 05, 1983
	50MG	A088322	001	Dec 05, 1983
	100MG	A088480	001	Dec 29, 1983
	150MG	A089764	001	Feb 09, 1988
	200MG	A089765	001	Feb 09, 1988
ROXANE	10MG	A088663	001	Mar 15, 1984
	25MG	A088664	001	Mar 15, 1984
	50MG	A088665	001	Mar 15, 1984
	100MG	A089048	001	Feb 26, 1985
SUN PHARM INDUSTRIES	15MG	A088461	001	Nov 18, 1983
	150MG	A088737	001	Sep 26, 1984
	200MG	A088738	001	Oct 16, 1984
SUPERPHARM	10MG	A089103	001	Jul 02, 1985
	25MG	A089104	001	Jul 02, 1985
	50MG	A089105	001	Jul 02, 1985
WATSON LABS	10MG	A088412	001	Sep 12, 1983
	10MG	A088561	001	May 11, 1984
	15MG	A088345	001	Jul 28, 1983
	15MG	A088562	001	May 11, 1984
	25MG	A088296	001	Jul 28, 1983
	25MG	A088755	001	Jul 24, 1984
	50MG	A088323	001	Jul 28, 1983
	50MG	A088563	001	May 11, 1984
	100MG	A088284	001	Aug 25, 1983
	100MG	A088564	001	May 11, 1984
	150MG	A088410	001	Mar 05, 1984
	150MG	A088869	001	Jun 28, 1985
	200MG	A088381	001	Mar 14, 1984
WATSON LABS TEVA	15MG	A088477	001	Nov 08, 1983
	25MG	A088567	001	May 11, 1984
	200MG	A088872	001	Apr 26, 1985
WEST WARD	10MG	A088658	001	Mar 26, 1984
	15MG	A088659	001	Mar 26, 1984
	25MG	A088660	001	Mar 26, 1984
	50MG	A088661	001	Mar 26, 1984

THIOTEPA

INJECTABLE; INJECTION

THIOPLEX

+ IMMUNEX

15MG/VIAL **

N020058 001 Dec 22, 1994

THIOTEPA

FRESENIUS KABI USA

15MG/VIAL

A075698 001 Sep 20, 2001

IMMUNEX

15MG/VIAL

N011683 001

TEVA PARENTERAL

15MG/VIAL **

A075730 001 Apr 20, 2001

30MG/VIAL **

A075730 002 Apr 20, 2001

THIOTHIXENE

CAPSULE; ORAL

NAVANE

+ PFIZER

1MG **

N016584 001

+

2MG **

N016584 002

+

5MG **

N016584 003

+

10MG **

N016584 004

+

20MG **

N016584 005

THIOTHIXENE

AM THERAP

1MG

A071884 001 Aug 12, 1987

2MG

A071885 001 Aug 12, 1987

5MG

A071886 001 Aug 12, 1987

10MG

A071887 001 Aug 12, 1987

20MG

A072200 001 Dec 17, 1987

HERITAGE PHARMA

1MG

A070600 001 Jun 05, 1987

2MG

A070601 001 Jun 05, 1987

5MG

A070602 001 Jun 05, 1987

10MG

A070603 001 Jun 05, 1987

SANDOZ

1MG

A071529 002 Jun 24, 1987

2MG

A071529 003 Jun 24, 1987

5MG

A071529 001 Jun 24, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

THIOTHIXENE

CAPSULE; ORAL

THIOTHIXENE

	10MG	A071529 004	Jun 24, 1987
WATSON LABS	2MG	A071626 001	Jun 25, 1987
	5MG	A071627 001	Jun 25, 1987
	10MG	A071628 001	Jun 25, 1987

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE; ORAL

NAVANE

PFIZER	EQ 5MG BASE/ML	N016758 001	
THIOTHIXENE HYDROCHLORIDE			
ALPHARMA US PHARMS	EQ 5MG BASE/ML	A070969 001	Oct 16, 1987
PACO	EQ 1MG BASE/ML	A071917 001	Sep 20, 1989
	EQ 5MG BASE/ML	A071939 001	Dec 16, 1988
TEVA	EQ 5MG BASE/ML	A071184 001	Jun 22, 1987
TEVA PHARMS	EQ 5MG BASE/ML	A071554 001	Oct 16, 1987
THIOTHIXENE HYDROCHLORIDE INTENSOL			
HIKMA	EQ 5MG BASE/ML	A073494 001	Jun 30, 1992
INJECTABLE; INJECTION			
NAVANE			
PFIZER	EQ 2MG BASE/ML	N016904 001	
	EQ 10MG BASE/VIAL	N016904 002	

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

GABITRIL

CEPHALON	6MG	N020646 006	Nov 29, 2005
	8MG	N020646 007	Nov 29, 2005
	10MG	N020646 008	Nov 29, 2005
	20MG	N020646 004	Sep 30, 1997

TICAGRELOR

TABLET; ORAL

TICAGRELOR

AMNEAL	90MG	A208531 001	Jan 23, 2019
SUNSHINE	90MG	A208508 001	Apr 06, 2020
WATSON LABS INC	60MG	A208390 001	Sep 04, 2018
	90MG	A208390 002	Sep 04, 2018

TICARCILLIN DISODIUM

INJECTABLE; INJECTION

TICAR

GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	N050497 001	
	EQ 3GM BASE/VIAL	A062690 001	Dec 19, 1986
	EQ 3GM BASE/VIAL	N050497 002	
	EQ 6GM BASE/VIAL	N050497 003	
	EQ 20GM BASE/VIAL	N050497 004	
	EQ 30GM BASE/VIAL	N050497 005	Apr 04, 1984

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLID

ROCHE PALO	125MG	N019979 001	Mar 24, 1993
	250MG	N019979 002	Oct 31, 1991
THIOTHIXENE HYDROCHLORIDE			
ACTAVIS ELIZABETH	250MG	A075253 001	Aug 20, 1999
MYLAN	250MG	A075161 001	Sep 13, 1999
	250MG	A075316 001	Nov 02, 1999
SUN PHARM INDS INC	250MG	A075526 001	Sep 26, 2002
WATSON LABS	250MG	A075309 001	Apr 26, 2000
YAOPHARMA CO LTD	250MG	A075318 001	Aug 20, 1999
	250MG	A075326 001	Aug 20, 1999

TILUDRONATE DISODIUM

TABLET; ORAL

SKELID

+ SANOFI AVENTIS US	EQ 200MG BASE **	N020707 001	Mar 07, 1997
---------------------	------------------	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

TIMOLOL MALEATE

AKORN	EQ 0.25% BASE	A074465 001	Mar 25, 1997
	EQ 0.25% BASE	A074515 001	Mar 25, 1997
APOTEX INC	EQ 0.25% BASE	A075411 001	Sep 08, 2000
	EQ 0.5% BASE	A075412 001	Sep 08, 2000
FOUGERA	EQ 0.25% BASE	A074667 001	Mar 25, 1997
	EQ 0.5% BASE	A074668 001	Mar 25, 1997

TABLET;ORAL

BLOCADREN

+ MERCK	5MG **	N018017 001	
+	10MG **	N018017 002	
+	20MG **	N018017 004	

TIMOLOL MALEATE

ANI PHARMS INC	5MG	A072917 001	Jul 31, 1991
	10MG	A072918 001	Jul 31, 1991
	20MG	A072919 001	Jul 31, 1991
QUANTUM PHARMICS	5MG	A072466 001	May 19, 1989
	10MG	A072467 001	May 19, 1989
	20MG	A072468 001	May 19, 1989
TEVA	5MG	A072648 001	Jun 16, 1993
	10MG	A072649 001	Jun 16, 1993
	20MG	A072650 001	Jun 16, 1993
USL PHARMA	5MG	A072001 001	Apr 11, 1989
	10MG	A072002 001	Apr 11, 1989
	20MG	A072003 001	Apr 11, 1989
WATSON LABS	5MG	A072269 001	Apr 11, 1989
	10MG	A072270 001	Apr 11, 1989
	20MG	A072271 001	Apr 11, 1989
YAOPHARMA CO LTD	5MG	A072550 001	Apr 13, 1989
	10MG	A072551 001	Apr 13, 1989
	20MG	A072552 001	Apr 13, 1989

TINZAPARIN SODIUM

INJECTABLE;INJECTION

INNOHEP

LEO PHARMA AS	20,000 IU/ML	N020484 001	Jul 14, 2000
---------------	--------------	-------------	--------------

TIOCONAZOLE

CREAM;TOPICAL

TZ-3

PFIZER	1%	N018682 001	Feb 18, 1983
--------	----	-------------	--------------

TIROFIBAN HYDROCHLORIDE

INJECTABLE;INJECTION

AGGRASTAT

MEDICURE	EQ 12.5MG BASE/50ML (EQ 0.25MG BASE/ML)	N020912 001	May 14, 1998
	EQ 25MG BASE/500ML (EQ 0.05MG BASE/ML)	N020913 001	May 14, 1998

TIZANIDINE HYDROCHLORIDE

CAPSULE;ORAL

TIZANIDINE HYDROCHLORIDE

MYLAN PHARMS INC	EQ 2MG BASE	A091502 001	Nov 09, 2012
	EQ 4MG BASE	A091502 002	Nov 09, 2012
	EQ 6MG BASE	A091502 003	Nov 09, 2012

TABLET;ORAL

TIZANIDINE HYDROCHLORIDE

ANI PHARMS INC	EQ 2MG BASE	A076283 001	Jul 12, 2002
	EQ 2MG BASE	A076284 001	Jul 03, 2002
	EQ 2MG BASE	A076321 001	Sep 30, 2004
	EQ 2MG BASE	A076371 001	Apr 09, 2003
	EQ 4MG BASE	A076283 002	Jul 12, 2002
	EQ 4MG BASE	A076284 002	Jul 03, 2002
	EQ 4MG BASE	A076321 002	Sep 30, 2004
	EQ 4MG BASE	A076371 002	Apr 09, 2003
MYLAN PHARMS INC	EQ 2MG BASE	A076282 001	Dec 16, 2003
	EQ 4MG BASE	A076282 002	Dec 16, 2003
PAR PHARM INC	EQ 2MG BASE	A207170 001	Jan 26, 2017
	EQ 4MG BASE	A207170 002	Jan 26, 2017

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TIZANIDINE HYDROCHLORIDE

TABLET; ORAL

ZANAFLEX

+ COVIS

EQ 2MG BASE **

N020397 002 Feb 04, 2000

TOBRAMYCIN

SOLUTION; INHALATION

TOBRAMYCIN

MYLAN

300MG/5ML

A209554 001 Oct 13, 2017

SOLUTION/DROPS; OPHTHALMIC

TOBRAMYCIN

ALCON PHARMS LTD

0.3%

A063176 001 May 25, 1994

APOTEX INC

0.3%

A065087 001 Feb 25, 2002

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

NEBCIN

LILLY

EQ 10MG BASE/ML

A062008 004

EQ 10MG BASE/ML

A062707 001 Apr 29, 1987

+

EQ 10MG BASE/ML **

N050477 005

EQ 40MG BASE/ML

A062008 001

+

EQ 1.2GM BASE/VIAL **

N050519 001

TOBRAMYCIN SULFATE

APOTHECON

EQ 10MG BASE/ML

A064021 001 May 31, 1994

EQ 40MG BASE/ML

A064021 002 May 31, 1994

EQ 40MG BASE/ML

A064026 001 May 31, 1994

HOSPIRA

EQ 10MG BASE/ML

A063080 001 Apr 30, 1991

EQ 40MG BASE/ML

A063161 001 May 29, 1991

IGI LABS INC

EQ 10MG BASE/ML

A063119 001 Oct 31, 1994

EQ 40MG BASE/ML

A063120 001 Oct 31, 1994

EQ 40MG BASE/ML

A063121 001 Oct 31, 1994

EQ 40MG BASE/ML

A063122 001 Oct 31, 1994

WATSON LABS INC

EQ 10MG BASE/ML

A062945 001 Aug 09, 1989

EQ 40MG BASE/ML

A062945 002 Aug 09, 1989

WEST-WARD PHARMS INT

EQ 10MG BASE/ML

A063113 001 Apr 26, 1991

EQ 10MG BASE/ML

A063128 001 Nov 27, 1991

EQ 40MG BASE/ML

A063118 001 Jul 29, 1991

EQ 40MG BASE/ML

A063127 001 Nov 27, 1991

TOBRAMYCIN SULFATE (PHARMACY BULK)

HOSPIRA

EQ 40MG BASE/ML **

A063116 001 May 18, 1992

TOCAINIDE HYDROCHLORIDE

TABLET; ORAL

TONOCARD

ASTRAZENECA

400MG

N018257 001 Nov 09, 1984

600MG

N018257 002 Nov 09, 1984

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

BARR

100MG

A070162 001 Jan 14, 1986

250MG

A070163 001 Jan 14, 1986

500MG

A070164 001 Jan 14, 1986

COSETTE

100MG

N018894 001 Nov 02, 1984

250MG

N018894 002 Nov 02, 1984

500MG

N018894 003 Nov 02, 1984

DURAMED PHARMS BARR

100MG

A070165 001 Jan 10, 1986

250MG

A070166 001 Jan 10, 1986

500MG

A070167 001 Jan 10, 1986

INTERPHARM

250MG

A071270 001 Sep 23, 1986

500MG

A071271 001 Sep 23, 1986

MYLAN PHARMS INC

250MG

A070259 001 Jan 02, 1986

500MG

A070259 003 Mar 17, 1986

PAR PHARM

100MG

A070159 001 Jan 06, 1986

250MG

A070160 001 Jan 06, 1986

500MG

A070161 001 Jan 06, 1986

SUN PHARM INDUSTRIES

100MG

A071357 001 Jul 16, 1987

250MG

A071358 001 Jul 16, 1987

500MG

A071359 001 Jul 16, 1987

SUPERPHARM

250MG

A070763 001 Jun 16, 1986

500MG

A070764 001 Jun 16, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

USL PHARMA	100MG	A071355 001	Jan 11, 1988
	250MG	A070168 001	Apr 02, 1986
	500MG	A070169 001	Apr 02, 1986
WATSON LABS	100MG	A070242 001	Aug 01, 1986
	100MG	A070513 001	Jan 09, 1986
	250MG	A070243 001	Aug 01, 1986
	250MG	A070514 001	Jan 09, 1986
	500MG	A070244 001	Aug 01, 1986
	500MG	A070515 001	Jan 09, 1986
YAOPHARMA CO LTD	100MG	A071633 001	Dec 09, 1987
	250MG	A070289 001	Mar 13, 1986
	500MG	A070290 001	Mar 13, 1986

TOLINASE

+ PHARMACIA AND UPJOHN	100MG **	N015500 002	
+	250MG **	N015500 004	
+	500MG **	N015500 005	

TOLAZOLINE HYDROCHLORIDE

INJECTABLE; INJECTION

PRISCOLINE

NOVARTIS	25MG/ML	N006403 005	Feb 22, 1985
----------	---------	-------------	--------------

TOLBUTAMIDE

TABLET; ORAL

ORINASE

PHARMACIA AND UPJOHN	250MG **	N010670 002	
	500MG **	N010670 001	

TOLBUTAMIDE

ALRA	500MG	A086141 001	
ANI PHARMS INC	500MG	A087093 001	
ASCOT	500MG	A087541 001	Mar 01, 1983
BARR	500MG	A087121 001	
DAVA PHARMS INC	500MG	A086926 001	
PARKE DAVIS	500MG	A086047 001	
PUREPAC PHARM	500MG	A088950 001	Jun 17, 1985
SANDOZ	500MG	N012678 001	
SUPERPHARM	500MG	A088893 001	Nov 19, 1984
VANGARD	500MG	A087876 001	Apr 20, 1982
WATSON LABS	250MG	A089110 001	May 29, 1987
	500MG	A086109 001	
	500MG	A087318 001	
	500MG	A089111 001	May 29, 1987
YAOPHARMA CO LTD	500MG	A086574 001	

TOLBUTAMIDE SODIUM

INJECTABLE; INJECTION

ORINASE DIAGNOSTIC

PHARMACIA AND UPJOHN	EQ 1GM BASE/VIAL	N012095 001	
----------------------	------------------	-------------	--

TOLCAPONE

TABLET; ORAL

TASMAR

BAUSCH	200MG	N020697 002	Jan 29, 1998
--------	-------	-------------	--------------

TOLMETIN SODIUM

CAPSULE; ORAL

TOLECTIN DS

+ ORTHO MCNEIL JANSSEN	EQ 400MG BASE	N018084 001	
------------------------	---------------	-------------	--

TOLMETIN SODIUM

ANI PHARMS INC	EQ 400MG BASE	A073308 001	Jan 24, 1992
	EQ 400MG BASE	A073392 001	Jan 24, 1992
	EQ 400MG BASE	A073519 001	May 29, 1992
FOSUN PHARMA	EQ 400MG BASE	A073462 001	Apr 30, 1992
SUN PHARM INDUSTRIES	EQ 400MG BASE	A073311 001	Nov 27, 1991

TABLET; ORAL

TOLECTIN

+ ORTHO MCNEIL JANSSEN	EQ 200MG BASE	N017628 001	
------------------------	---------------	-------------	--

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TOLMETIN SODIUM

TABLET;ORAL

TOLECTIN 600

+ ORTHO MCNEIL JANSSEN EQ 600MG BASE N017628 002 Mar 08, 1989

TOLMETIN SODIUM

ANI PHARMS INC EQ 600MG BASE A073527 001 Jun 30, 1992

COSETTE EQ 600MG BASE A074399 001 Mar 28, 1996

EQ 600MG BASE A074729 001 Feb 27, 1997

FOSUN PHARMA EQ 200MG BASE A073588 001 Jul 31, 1992

EQ 600MG BASE A074002 001 Sep 27, 1993

SUN PHARM INDUSTRIES EQ 200MG BASE A073310 001 Nov 27, 1991

TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

TOLTERODINE TARTRATE

AJANTA PHARMA LTD 2MG A213397 001 May 19, 2020

4MG A213397 002 May 19, 2020

TABLET;ORAL

TOLTERODINE TARTRATE

APOTEX CORP 1MG A200164 001 Sep 25, 2012

2MG A200164 002 Sep 25, 2012

MYLAN PHARMS INC 1MG A202641 001 Nov 27, 2012

2MG A202641 002 Nov 27, 2012

TOLVAPTAN

TABLET;ORAL

SAMSCA

+ OTSUKA AMERICA PHARM 60MG ** N022275 003 May 19, 2009

TOLVAPTAN

APOTEX 30MG A207605 001 May 19, 2020

TOPIRAMATE

CAPSULE;ORAL

TOPAMAX SPRINKLE

JANSSEN PHARMS 50MG N020844 003 Oct 26, 1998

TOPIRAMATE

BARR 15MG A076448 001 Apr 15, 2009

25MG A076448 002 Apr 15, 2009

FOSUN PHARMA 15MG A079206 001 Oct 14, 2009

25MG A079206 002 Oct 14, 2009

MYLAN 15MG A078418 001 Oct 14, 2009

25MG A078418 002 Oct 14, 2009

TABLET;ORAL

TOPAMAX

JANSSEN PHARMS 300MG N020505 003 Dec 24, 1996

400MG N020505 006 Dec 24, 1996

TOPIRAMATE

ACTAVIS TOTOWA 25MG A078637 001 Feb 27, 2013

50MG A078637 002 Feb 27, 2013

100MG A078637 003 Feb 27, 2013

200MG A078637 004 Feb 27, 2013

BARR 25MG A076315 001 Mar 27, 2009

100MG A076315 002 Mar 27, 2009

200MG A076315 003 Mar 27, 2009

CHARTWELL 25MG A078410 001 Sep 11, 2013

50MG A078410 002 Sep 11, 2013

100MG A078410 003 Sep 11, 2013

200MG A078410 004 Sep 11, 2013

HIKMA PHARMS 25MG A091185 001 Nov 25, 2013

50MG A091185 002 Nov 25, 2013

100MG A091185 003 Nov 25, 2013

200MG A091185 004 Nov 25, 2013

MYLAN 25MG A076314 001 Mar 27, 2009

50MG A076314 002 Mar 27, 2009

100MG A076314 003 Mar 27, 2009

200MG A076314 004 Mar 27, 2009

PLIVA HRVATSKA DOO 25MG A077905 001 Mar 30, 2009

50MG A077905 002 Mar 30, 2009

100MG A077905 003 Mar 30, 2009

200MG A077905 004 Mar 30, 2009

ROXANE 25MG A076306 001 Mar 27, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TOPIRAMATETABLET; ORAL
TOPIRAMATE

	50MG	A076306 002	Mar 27, 2009
	100MG	A076306 003	Mar 27, 2009
	200MG	A076306 004	Mar 27, 2009
TORRENT PHARMS	25MG	A079153 001	Mar 27, 2009
	50MG	A079153 002	Mar 27, 2009
	100MG	A079153 003	Mar 27, 2009
	200MG	A079153 004	Mar 27, 2009
WATSON LABS	25MG	A077643 001	Mar 27, 2009
	50MG	A077643 002	Mar 27, 2009
	100MG	A077643 003	Mar 27, 2009
	200MG	A077643 004	Mar 27, 2009
WOCKHARDT USA	25MG	A090353 001	Sep 01, 2010
	50MG	A090353 002	Sep 01, 2010
	100MG	A090353 003	Sep 01, 2010
	200MG	A090353 004	Sep 01, 2010

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

TOPOTECAN HYDROCHLORIDE

FRESENIUS KABI USA	EQ 4MG BASE/VIAL	A091376 001	Nov 29, 2010
MYLAN LABS LTD	EQ 4MG BASE/VIAL	A091542 001	Aug 28, 2012
SUN PHARM INDS LTD	EQ 4MG BASE/VIAL	A202203 001	Aug 29, 2013

SOLUTION; INTRAVENOUS

TOPOTECAN

+	SANDOZ INC	EQ 1MG BASE/ML (EQ 1MG BASE/ML) **	N200199 001	Feb 25, 2011
+		EQ 3MG BASE/3ML (EQ 1MG BASE/ML) **	N200199 002	Feb 25, 2011
+		EQ 4MG BASE/4ML (EQ 1MG BASE/ML) **	N200199 003	Feb 25, 2011

TORSEMIDE

INJECTABLE; INJECTION

DEMADEX

+	ROCHE	50MG/5ML (10MG/ML) **	N020137 002	Aug 23, 1993
+		20MG/2ML (10MG/ML) **	N020137 001	Aug 23, 1993

TORSEMIDE

AM REGENT	20MG/2ML (10MG/ML)	A090656 001	Apr 21, 2010
	50MG/5ML (10MG/ML)	A090656 002	Apr 21, 2010
WEST-WARD PHARMS INT	20MG/2ML (10MG/ML)	A078007 001	Jun 11, 2008
	50MG/5ML (10MG/ML)	A078007 002	Jun 11, 2008

TABLET; ORAL

DEMADEX

+	MYLAN SPECIALITY LP	5MG	N020136 001	Aug 23, 1993
+		10MG	N020136 002	Aug 23, 1993
+		20MG	N020136 003	Aug 23, 1993
+		100MG	N020136 004	Aug 23, 1993

TORSEMIDE

SUN PHARM INDS	5MG	A078478 001	Feb 26, 2008
	10MG	A078478 002	Feb 26, 2008
	20MG	A078478 003	Feb 26, 2008
	100MG	A078478 004	Feb 26, 2008

TRAMADOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CONZIP

+	CIPHER PHARMS INC	150MG	N022370 004	Aug 01, 2011
---	-------------------	-------	-------------	--------------

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

ACCORD HLTHCARE	50MG	A202390 001	May 16, 2013
ACTAVIS ELIZABETH	50MG	A075960 001	Jun 19, 2002
ASTA	50MG	A075974 001	Jul 12, 2002
FOSUN PHARMA	50MG	A075968 001	Jun 25, 2002
IVAX SUB TEVA PHARMS	50MG	A075963 001	Jul 03, 2002
MACLEODS PHARMS LTD	50MG	A205702 001	Sep 25, 2015
MYLAN PHARMS INC	50MG	A075980 001	Nov 21, 2002
NORTHSTAR HLTHCARE	50MG	A078935 001	May 26, 2010
POLYGEN PHARMS	50MG	A206706 001	Jul 02, 2019
SPECGX LLC	50MG	A075983 001	Jun 25, 2002
SUN PHARM INDUSTRIES	50MG	A076100 001	Jun 20, 2002
WATSON LABS	50MG	A075962 001	Jun 24, 2002

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

ULTRAM

JANSSEN PHARMS 100MG N020281 001 Mar 03, 1995

TABLET, EXTENDED RELEASE; ORAL

RYZOLT

+ PURDUE PHARMA 100MG ** N021745 001 Dec 30, 2008

+ 200MG ** N021745 002 Dec 30, 2008

+ 300MG ** N021745 003 Dec 30, 2008

TRAMADOL HYDROCHLORIDE

AUROBINDO PHARMA LTD 100MG A204421 001 Oct 20, 2015

200MG A204421 002 Oct 20, 2015

300MG A204421 003 Oct 20, 2015

PAR PHARM INC 100MG A078783 001 Nov 13, 2009

200MG A078783 002 Nov 13, 2009

300MG A078783 003 Sep 20, 2011

ULTRAM ER

+ VALEANT PHARMS 100MG N021692 001 Sep 08, 2005

+ 200MG N021692 002 Sep 08, 2005

+ 300MG N021692 003 Sep 08, 2005

TABLET, ORALLY DISINTEGRATING; ORAL

RYBIX ODT

SHIONOGI INC 50MG N021693 001 May 05, 2005

TRAMETINIB DIMETHYL SULFOXIDE

TABLET; ORAL

MEKINIST

+ NOVARTIS EQ 1MG N204114 002 May 29, 2013

TRANDOLAPRIL

TABLET; ORAL

MAVIK

+ ABBVIE 1MG ** N020528 001 Apr 26, 1996

+ 2MG ** N020528 002 Apr 26, 1996

+ 4MG ** N020528 003 Apr 26, 1996

TRANDOLAPRIL

CIPLA 1MG A077307 002 Jun 12, 2007

2MG A077307 001 Jun 12, 2007

4MG A077307 003 Jun 12, 2007

DR REDDYS LABS LTD 1MG A078493 001 Aug 25, 2008

2MG A078493 002 Aug 25, 2008

4MG A078493 003 Aug 25, 2008

EPIC PHARMA LLC 1MG A077256 001 Jun 12, 2007

2MG A077256 002 Jun 12, 2007

4MG A077256 003 Jun 12, 2007

INVAGEN PHARMS 1MG A078320 001 Jun 12, 2007

2MG A078320 002 Jun 12, 2007

4MG A078320 003 Jun 12, 2007

MYLAN 1MG A078346 001 Apr 28, 2008

2MG A078346 002 Apr 28, 2008

4MG A078346 003 Apr 28, 2008

WATSON LABS 1MG A077805 001 Jun 12, 2007

2MG A077805 002 Jun 12, 2007

4MG A077805 003 Jun 12, 2007

TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

TARKA

+ ABBVIE 1MG; 240MG N020591 003 Oct 22, 1996

TRANEXAMIC ACID

INJECTABLE; INJECTION

TRANEXAMIC ACID

CAPLIN 100MG/ML A212360 001 Jul 17, 2019

VIRTUS PHARMS 100MG/ML A202755 001 Feb 25, 2016

TABLET; ORAL

CYKLOKAPRON

PHARMACIA AND UPJOHN 500MG N019280 001 Dec 30, 1986

TRANEXAMIC ACID

ANI PHARMS INC 650MG A203256 001 Jul 25, 2016

MYLAN PHARMS INC 650MG A205133 001 Sep 21, 2015

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TRAVOPROST

SOLUTION/DROPS;OPHTHALMIC

IZBA

+ NOVARTIS 0.003% ** N204822 001 May 15, 2014

TRAVATAN

+ ALCON PHARMS LTD 0.004% ** N021257 001 Mar 16, 2001

TRAZODONE HYDROCHLORIDE

TABLET;ORAL

DESYREL

+ PRAGMA 50MG ** N018207 001

+ 100MG ** N018207 002

+ 150MG ** N018207 003 Mar 25, 1985

+ 300MG ** N018207 004 Nov 07, 1988

TRAZODONE HYDROCHLORIDE

AM THERAP

50MG A071139 001 Oct 29, 1986

100MG A071140 001 Oct 29, 1986

AUROLIFE PHARMA LLC

50MG A072484 001 Apr 30, 1990

50MG A204852 001 Feb 05, 2020

100MG A204852 002 Feb 05, 2020

150MG A204852 003 Feb 05, 2020

300MG A204852 004 Feb 05, 2020

FOSUN PHARMA

100MG A072483 001 Apr 30, 1990

MYLAN

50MG A071405 001 Feb 27, 1991

100MG A071406 001 Feb 27, 1991

MYLAN PHARMS INC

50MG A090514 001 Jun 02, 2009

100MG A090514 002 Jun 02, 2009

150MG A090514 003 Jun 02, 2009

300MG A090514 004 Jun 02, 2009

QUANTUM PHARMICS

100MG A070921 001 Dec 01, 1986

TEVA

150MG A074357 001 Apr 30, 1997

USL PHARMA

50MG A070491 001 Apr 29, 1987

100MG A070492 001 Apr 29, 1987

WATSON LABS

50MG A070857 001 Oct 10, 1986

50MG A071112 001 Nov 17, 1986

100MG A070858 001 Oct 10, 1986

100MG A071113 001 Nov 17, 1986

TRIALODINE

QUANTUM PHARMICS

50MG A070942 001 Dec 01, 1986

TABLET, EXTENDED RELEASE;ORAL

OLEPTRO

+ ANGELINI PHARMA 150MG ** N022411 001 Feb 02, 2010

+ 300MG ** N022411 002 Feb 02, 2010

TREPROSTINIL

INJECTABLE;IV (INFUSION), SUBCUTANEOUS

TREPROSTINIL

DR REDDYS

1MG/ML A210214 001 May 22, 2020

2.5MG/ML A210214 002 May 22, 2020

5MG/ML A210214 003 May 22, 2020

10MG/ML A210214 004 May 22, 2020

TRETINOIN

CAPSULE;ORAL

VESANOID

+ CHEPLAPHARM 10MG ** N020438 001 Nov 22, 1995

CREAM;TOPICAL

TRETINOIN

ALLERGAN

0.0375% A090098 001 Mar 22, 2010

0.075% A202209 001 Oct 11, 2012

GEL;TOPICAL

TRETINOIN

MYLAN

0.04% A202567 001 Jul 17, 2013

0.1% A202026 001 Jul 17, 2013

SOLUTION;TOPICAL

RETIN-A

+ VALEANT INTL 0.05% N016921 001

TRETINOIN

TEVA PHARMS

0.05% A074873 001 Jun 19, 1998

WOCKHARDT

0.05% A075260 001 Jan 25, 1999

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TRETINOIN

SWAB; TOPICAL

RETIN-A

VALEANT INTL 0.05% N016921 002

TRIAMCINOLONE

TABLET; ORAL

ARISTOCORT

ASTELLAS	1MG	N011161 009
	2MG	N011161 004
	4MG	N011161 007
	8MG	N011161 011
	16MG	N011161 010

KENACORT

DELCOR ASSET CORP	1MG	N011283 003
	2MG	N011283 008
	4MG	N011283 006
	8MG	N011283 010

TRIAMCINOLONE

BARR	2MG	A084286 001
	2MG	A084318 001
	4MG	A084267 001
	4MG	A084319 001
	8MG	A084268 001
	8MG	A084320 001
IMPAX LABS	4MG	A084340 001
IVAX SUB TEVA PHARMS	4MG	A083750 001
MYLAN	2MG	A084406 001
PUREPAC PHARM	2MG	A084020 002
	4MG	A084020 003
ROXANE	2MG	A084708 001
	4MG	A084709 001
	8MG	A084707 001
SANDOZ	4MG	A085601 001
TEVA	4MG	A084775 001
WATSON LABS	4MG	A084270 001
	4MG	A085834 001

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED; INHALATION

AZMACORT

ABBVIE 0.1MG/INH N018117 001 Apr 23, 1982

AEROSOL, METERED; NASAL

NASACORT

SANOFI AVENTIS US 0.055MG/INH N019798 001 Jul 11, 1991

CREAM; TOPICAL

ARISTOCORT

ASTELLAS	0.025%	A083017 003
	0.1%	A083016 004
	0.5%	A083015 002

ARISTOCORT A

ASTELLAS	0.025%	A083017 004
	0.025%	A088818 001 Oct 16, 1984
	0.1%	A083016 005
	0.1%	A088819 001 Oct 16, 1984
	0.5%	A083015 003
	0.5%	A088820 001 Oct 16, 1984

FLUTEX

IVAX PHARMS	0.025%	A085539 001
	0.1%	A085539 002
	0.5%	A085539 003

KENALOG

DELCOR ASSET CORP 0.5% A083943 001

KENALOG-H

DELCOR ASSET CORP 0.1% A086240 001

TRIACET

TEVA	0.025%	A084908 001
	0.1%	A084908 002
	0.5%	A084908 003

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

TRIAACORT			
	SOLVAY	0.1%	A087113 001
TRIAMCINOLONE ACETONIDE			
	ACTAVIS MID ATLANTIC	0.1%	A087798 001 Jun 04, 1982
	ALPHARMA US PHARMS	0.025%	A087797 001 Jun 07, 1982
	AMBIX	0.025%	A087932 001 May 09, 1983
	MORTON GROVE	0.025%	A088094 001 Sep 01, 1983
		0.1%	A088095 001 Sep 01, 1983
		0.5%	A088096 001 Sep 01, 1983
+	MYLAN	0.025% **	N011601 003
+		0.1% **	N011601 006
	PHARMADERM	0.025%	A087990 001 Jul 07, 1983
		0.1%	A087991 001 Jul 07, 1983
		0.5%	A087992 001 Jul 07, 1983
	PHARMAFAIR	0.025%	A087921 001 Aug 10, 1982
		0.1%	A087912 001 Aug 10, 1982
		0.5%	A087922 001 Aug 10, 1982
	TARO	0.025%	A040038 001 Oct 26, 1994
		0.025%	A086277 001
		0.1%	A086276 001
		0.5%	A086275 001
	TOPIDERM	0.025%	A089274 001 Feb 21, 1989
		0.1%	A089275 001 Feb 21, 1989
		0.5%	A089276 001 Feb 21, 1989
TRIADEX			
	IVAX PHARMS	0.025%	A087430 001 Nov 01, 1988
		0.1%	A087429 001 Nov 01, 1988
		0.5%	A087428 001 Nov 01, 1988
TRYMEX			
	SAVAGE LABS	0.025%	A088196 001 Mar 25, 1983
		0.1%	A088197 001 Mar 25, 1983
		0.5%	A088198 001 Mar 25, 1983
GEL;TOPICAL			
ARISTOGEL			
	ASTELLAS	0.1%	A083380 001
INJECTABLE;INJECTION			
TRIAMCINOLONE ACETONIDE			
	PARNELL	3MG/ML	N019503 001 Oct 16, 1987
	SANDOZ INC	10MG/ML	A090166 001 May 27, 2009
		40MG/ML	A090164 001 Jun 01, 2009
	WATSON LABS	40MG/ML	A085825 001
INJECTABLE;INTRA-ARTICULAR, INTRAMUSCULAR, INTRAVITREAL			
TRIVARIS			
+	ALLERGAN	8MG/0.1ML (8MG/0.1ML) **	N022220 001 Jun 16, 2008
LOTION;TOPICAL			
KENALOG			
	DELCOR ASSET CORP	0.025% **	A084343 001
+		0.025% **	N011602 003
		0.1% **	A084343 002
+		0.1% **	N011602 001
TRIAMCINOLONE ACETONIDE			
	ALPHARMA US PHARMS	0.025%	A087191 001 Sep 08, 1982
		0.1%	A087192 001 Sep 08, 1982
OINTMENT;TOPICAL			
ARISTOCORT			
	ASTELLAS	0.1%	A080750 004
		0.5% **	A080745 002
ARISTOCORT A			
	ASTELLAS	0.1%	A080750 003
		0.1%	A088780 001 Oct 01, 1984
		0.5% **	A080745 003
		0.5%	A088781 001 Oct 05, 1984
FLUTEX			
	IVAX PHARMS	0.025%	A087375 001 Nov 01, 1988
		0.1%	A087377 001 Nov 01, 1988
		0.5%	A087376 001 Nov 01, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TRIAMCINOLONE ACETONIDE

OINTMENT; TOPICAL

KENALOG

DELCOR ASSET CORP	0.5% **	A083944	001	
TRIAMCINOLONE ACETONIDE				
ACTAVIS MID ATLANTIC	0.1%	A087799	001	Jun 07, 1982
ALPHARMA US PHARMS	0.5%	A089913	001	Dec 23, 1988
MORTON GROVE	0.025%	A088090	001	Sep 01, 1983
	0.1%	A088091	001	Sep 01, 1983
	0.5%	A088092	001	Sep 01, 1983
+ MYLAN	0.025% **	N011600	003	
+ PHARMADERM	0.025%	N011600	001	
	0.1%	A088692	001	Aug 02, 1984
	0.1%	A088690	001	Aug 02, 1984
STRIDES PHARMA	0.1%	A211315	001	Mar 18, 2020
	0.5%	A211315	002	Mar 18, 2020
TARO	0.025%	A040040	001	Sep 30, 1994
	0.025%	A040374	001	Jun 05, 2001
	0.1%	A087902	001	Dec 27, 1982
	0.5%	A040386	001	Jun 05, 2001
TRYMEX				
SAVAGE LABS	0.025%	A088693	001	Aug 02, 1984
	0.1%	A088691	001	Aug 02, 1984

PASTE; DENTAL

KENALOG IN ORABASE

+ DELCOR ASSET CORP	0.1% **	N012097	001	
ORALONE				
TARO	0.1%	A071383	001	Jul 06, 1987

SPRAY, METERED; NASAL

ALLERNAZE

LUPIN ATLANTIS	0.05MG/SPRAY	N020120	001	Feb 04, 2000
NASACORT HFA				
SANOFI AVENTIS US	0.055MG/SPRAY	N020784	001	Apr 07, 2004
TRIAMCINOLONE ACETONIDE				
PERRIGO ISRAEL	0.055MG/SPRAY	A078104	001	Jul 30, 2009

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION

ARISTOCORT

FOSUN PHARMA	25MG/ML	N011685	003	
+ WATSON LABS	40MG/ML **	N012802	001	
TRIAMCINOLONE DIACETATE				
AKORN	25MG/ML	A085122	001	
	40MG/ML	A086394	001	
WATSON LABS	40MG/ML	A084072	001	
	40MG/ML	A085529	001	

SYRUP; ORAL

ARISTOCORT

ASTELLAS	2MG/5ML	N011960	004	
KENACORT				
DELCOR ASSET CORP	EQ 4MG BASE/5ML	N012515	001	

TRIAZOLAM

TABLET; ORAL

HALCION

PHARMACIA AND UPJOHN	0.5MG	N017892	002	Nov 15, 1982
TRIAZOLAM				
MYLAN PHARMS INC	0.125MG	A074031	001	Mar 25, 1994
	0.25MG	A074031	002	Mar 25, 1994
WATSON LABS	0.125MG	A074445	001	Oct 20, 1995
	0.25MG	A074445	002	Oct 20, 1995

TRICHLORMETHIAZIDE

TABLET; ORAL

METAHYDRIN

SANOFI AVENTIS US	2MG	N012594	001	Jun 16, 1988
	4MG	N012594	002	Jun 16, 1988
NAQUA				
SCHERING	2MG	N012265	001	
	4MG	N012265	002	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TRICHLORMETHIAZIDE

TABLET; ORAL

TRICHLOREX

LANNETT	4MG	A083436	001
	4MG	A085630	001

TRICHLORMAS

MAST MM	4MG	A086259	001
---------	-----	---------	-----

TRICHLORMETHIAZIDE

CHARTWELL RX	4MG	A085568	001
IMPAX LABS	4MG	A083967	001
PAR PHARM	2MG	A087007	001
	4MG	A087005	001
SANDOZ	4MG	A086171	001
WATSON LABS	2MG	A083847	001
	2MG	A086458	001
	4MG	A083462	001
	4MG	A083855	001
	4MG	A085962	001

TRICLOFOS SODIUM

SOLUTION; ORAL

TRICLOS

SANOFI AVENTIS US	1.5GM/15ML	N016830	001
-------------------	------------	---------	-----

TABLET; ORAL

TRICLOS

SANOFI AVENTIS US	750MG	N016809	002
-------------------	-------	---------	-----

TRIDIHEXETHYL CHLORIDE

INJECTABLE; INJECTION

PATHILON

LEDERLE	10MG/ML	N009729	001
---------	---------	---------	-----

TABLET; ORAL

PATHILON

LEDERLE	25MG	N009489	005
---------	------	---------	-----

TRIFLUOPERAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

STELAZINE

+ GLAXOSMITHKLINE	EQ 10MG BASE/ML **	N011552	006
-------------------	--------------------	---------	-----

TRIFLUOPERAZINE HYDROCHLORIDE

FOSUN PHARMA	EQ 10MG BASE/ML	A085787	001	Apr 15, 1982
WOCKHARDT	EQ 10MG BASE/ML	A088143	001	Jul 26, 1983

INJECTABLE; INJECTION

STELAZINE

+ GLAXOSMITHKLINE	EQ 2MG BASE/ML **	N011552	005
-------------------	-------------------	---------	-----

TABLET; ORAL

STELAZINE

+ GLAXOSMITHKLINE	EQ 1MG BASE **	N011552	001
	EQ 2MG BASE **	N011552	002
	EQ 5MG BASE **	N011552	003
	EQ 10MG BASE **	N011552	004

TRIFLUOPERAZINE HYDROCHLORIDE

ATHEM	EQ 1MG BASE	A040153	001	Oct 25, 1996
	EQ 2MG BASE	A040153	002	Oct 25, 1996
	EQ 5MG BASE	A040153	003	Oct 25, 1996
	EQ 10MG BASE	A040153	004	Oct 25, 1996
DURAMED PHARMS BARR	EQ 1MG BASE	A088967	001	Apr 23, 1985
	EQ 2MG BASE	A088968	001	Apr 23, 1985
	EQ 5MG BASE	A088969	001	Apr 23, 1985
	EQ 10MG BASE	A088970	001	Apr 23, 1985
IVAX PHARMS	EQ 1MG BASE	A087612	001	Nov 19, 1982
	EQ 2MG BASE	A087613	001	Nov 19, 1982
	EQ 5MG BASE	A087328	001	Nov 19, 1982
	EQ 10MG BASE	A087614	001	Nov 19, 1982
WATSON LABS	EQ 1MG BASE	A085975	001	Jun 23, 1988
	EQ 2MG BASE	A085976	001	Jun 23, 1988
	EQ 5MG BASE	A085973	001	Jun 23, 1988
	EQ 10MG BASE	A088710	001	Jun 23, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TRIFLUPROMAZINE

SUSPENSION; ORAL

VESPRIN

APOTHECON

EQ 50MG HYDROCHLORIDE/5ML

N011491 004

TRIFLUPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

VESPRIN

APOTHECON

3MG/ML

N011325 005

10MG/ML

N011325 004

20MG/ML

N011325 001

TABLET; ORAL

VESPRIN

BRISTOL MYERS SQUIBB

10MG

N011123 001

25MG

N011123 002

50MG

N011123 003

TRIHExYPHENIDYL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

ARTANE

LEDERLE

5MG

N006773 010

5MG

N012947 001

ELIXIR; ORAL

ARTANE

LEDERLE

2MG/5ML

N006773 009

TRIHExYPHENIDYL HYDROCHLORIDE

PHARM VENTURES

2MG/5ML

A089514 001 Apr 07, 1989

TABLET; ORAL

ARTANE

+ LEDERLE

2MG **

N006773 005

+

LEDERLE

5MG **

N006773 003

TREMIM

SCHERING

2MG

A080381 001

5MG

A080381 003

TRIHExYPHENIDYL HYDROCHLORIDE

HIKMA

2MG

A040337 002 Feb 16, 2000

5MG

A040337 001 Feb 16, 2000

NYLOS

5MG

A085622 001

VANGARD

2MG

A088035 001 Jul 30, 1982

WATSON LABS

2MG

A040184 001 Feb 06, 1998

2MG

A085117 001

5MG

A040184 002 Feb 06, 1998

5MG

A085105 001

TRILOSTANE

CAPSULE; ORAL

MODRASTANE

BIOENVISION

30MG

N018719 002 Dec 31, 1984

60MG

N018719 001 Dec 31, 1984

TRIMEPRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

TEMARIL

ALLERGAN HERBERT

EQ 5MG BASE

N011316 004

SYRUP; ORAL

TEMARIL

ALLERGAN HERBERT

EQ 2.5MG BASE/5ML

N011316 003

TRIMEPRAZINE TARTRATE

ALPHARMA US PHARMS

EQ 2.5MG BASE/5ML

A085015 001 Feb 18, 1982

MORTON GROVE

EQ 2.5MG BASE/5ML

A088285 001 Apr 11, 1985

TABLET; ORAL

TEMARIL

ALLERGAN HERBERT

EQ 2.5MG BASE

N011316 001

TRIMETHADIONE

CAPSULE; ORAL

TRIDIONE

ABBVIE

300MG

N005856 005

SOLUTION; ORAL

TRIDIONE

ABBVIE

200MG/5ML

N005856 002

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TRIMETHADIONE

TABLET; ORAL

TRIDIONE

+ ABBVIE

150MG

N005856 009

TRIMETHAPHAN CAMSYLATE

INJECTABLE; INJECTION

ARFONAD

ROCHE

50MG/ML

N008983 001

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

TRIMETHOBENZAMIDE HYDROCHLORIDE

AM REGENT

100MG/ML

A091330 001 Mar 08, 2011

HOSPIRA

100MG/ML

A088804 001 Apr 03, 1987

SMITH AND NEPHEW

100MG/ML

A088960 001 Apr 04, 1986

100MG/ML

A089043 001 Apr 04, 1986

SOLOPAK

100MG/ML

A089094 001 Apr 04, 1986

WATSON LABS

100MG/ML

A086577 001 Oct 19, 1982

100MG/ML

A087939 001 Dec 28, 1982

TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE

AM REGENT

100MG/ML

A091329 001 Mar 08, 2011

TRIMETHOPRIM

TABLET; ORAL

PROLOPRIM

MONARCH PHARMS

100MG

N017943 001

200MG

N017943 003 Jul 14, 1982

TRIMETHOPRIM

SUN PHARM INDUSTRIES

100MG

A070494 001 Jan 22, 1986

200MG

A070495 001 Sep 24, 1986

TEVA

200MG **

A071259 001 Jun 18, 1987

TRIMPEX

ROCHE

100MG

N017952 001

TRIMPEX 200

ROCHE

200MG

N017952 002 Nov 09, 1982

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION; ORAL

PRIMSOL

ALLEGIS

EQ 25MG BASE/5ML

N074374 001 Jun 23, 1995

+

EQ 50MG BASE/5ML

N074973 001 Jan 24, 2000

TRIMETREXATE GLUCURONATE

INJECTABLE; INJECTION

NEUTREXIN

MEDIMMUNE ONCOLOGY

EQ 25MG BASE/VIAL

N020326 001 Dec 17, 1993

EQ 200MG BASE/VIAL

N020326 002 Jul 31, 1998

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

SURMONTIL

+ ODYSSEY PHARMS

EQ 25MG BASE

N016792 001

+

EQ 50MG BASE

N016792 002

+

EQ 100MG BASE

N016792 003 Sep 15, 1982

TRIMIPRAMINE MALEATE

USL PHARMA

EQ 25MG BASE

A071283 001 Dec 08, 1987

EQ 50MG BASE

A071284 001 Dec 08, 1987

EQ 100MG BASE

A071285 001 Dec 08, 1987

TRIOXSALEN

TABLET; ORAL

TRISORALEN

VALEANT PHARM INTL

5MG

N012697 001

TRIPLENNAMINE CITRATE

ELIXIR; ORAL

PBZ

NOVARTIS

EQ 25MG HYDROCHLORIDE/5ML

N005914 004

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TRIPLENNAMINE HYDROCHLORIDE

TABLET; ORAL

PBZ

NOVARTIS	25MG	A083149	001
	50MG	N005914	002

TRIPLENNAMINE HYDROCHLORIDE

ANABOLIC	50MG	A083037	001
BARR	50MG	A080744	001
HEATHER	50MG	A083989	001
IMPAX LABS	50MG	A080785	001
LANNETT	50MG	A083557	001
NYLOS	50MG	A085412	001
PARKE DAVIS	25MG	A083625	001
	50MG	A083626	001
WATSON LABS	50MG	A080713	001
	50MG	A080790	001
	50MG	A085188	001

TABLET, EXTENDED RELEASE; ORAL

PBZ-SR

NOVARTIS	50MG	N010533	002
	100MG	N010533	001

TRIPLE SULFA (SULFABENZAMIDE; SULFACETAMIDE; SULFATHIAZOLE)

CREAM; VAGINAL

GYNE-SULF

COSETTE	3.7%;2.86%;3.42%	A088607	001	Jun 09, 1986
---------	------------------	---------	-----	--------------

SULTRIN

ORTHO MCNEIL PHARM	3.7%;2.86%;3.42%	N005794	001
--------------------	------------------	---------	-----

TRIPLE SULFA

ALPHARMA US PHARMS	3.7%;2.86%;3.42%	A087864	001	Sep 01, 1982
FOUGERA	3.7%;2.86%;3.42%	A086424	001	
PERRIGO NEW YORK	3.7%;2.86%;3.42%	A087285	001	Nov 15, 1982

TRYSUL

SAVAGE LABS	3.7%;2.86%;3.42%	A087887	001	Jul 23, 1982
-------------	------------------	---------	-----	--------------

VAGILIA

COSETTE	3.7%;2.86%;3.42%	A088821	001	Nov 09, 1987
---------	------------------	---------	-----	--------------

TABLET; VAGINAL

SULTRIN

ORTHO MCNEIL PHARM	184MG;143.75MG;172.5MG	N005794	002
--------------------	------------------------	---------	-----

TRIPLE SULFA

FOUGERA	184MG;143.75MG;172.5MG	A088463	001	Jan 03, 1985
PHARMADERM	184MG;143.75MG;172.5MG	A088462	001	Jan 03, 1985

TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

ACTIDIL

GLAXOSMITHKLINE	1.25MG/5ML	N011496	002	Jul 01, 1983
-----------------	------------	---------	-----	--------------

MYIDYL

USL PHARMA	1.25MG/5ML	A087963	001	Jan 18, 1983
------------	------------	---------	-----	--------------

TRIPROLIDINE HYDROCHLORIDE

ALPHARMA US PHARMS	1.25MG/5ML	A085940	001	
HALSEY	1.25MG/5ML	A088735	001	Jan 17, 1985
PHARM ASSOC	1.25MG/5ML	A087514	001	Feb 10, 1982

TABLET; ORAL

ACTIDIL

GLAXOSMITHKLINE	2.5MG	N011110	002	Jul 01, 1983
-----------------	-------	---------	-----	--------------

TRIPROLIDINE HYDROCHLORIDE

VITARINE	2.5MG	A085610	001
WATSON LABS	2.5MG	A085094	001

TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE; SULFAMETHAZINE)

SUSPENSION; ORAL

LANTRISUL

LANNETT	167MG/5ML;167MG/5ML;167MG/5ML	A080123	002
---------	-------------------------------	---------	-----

NEOTRIZINE

LILLY	167MG/5ML;167MG/5ML;167MG/5ML	N006317	012
-------	-------------------------------	---------	-----

SULFALOID

FOREST PHARMS	167MG/5ML;167MG/5ML;167MG/5ML	A080100	001
---------------	-------------------------------	---------	-----

SULFOSE

WYETH AYERST	167MG/5ML;167MG/5ML;167MG/5ML	A080013	002
--------------	-------------------------------	---------	-----

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)

SUSPENSION;ORAL

TERFONYL

BRISTOL MYERS SQUIBB 167MG/5ML;167MG/5ML;167MG/5ML N006904 002

TRIPLE SULFA

ALPHARMA US PHARMS 167MG/5ML;167MG/5ML;167MG/5ML A080280 001

TRIPLE SULFAS

LEDERLE 167MG/5ML;167MG/5ML;167MG/5ML N006920 003

TABLET;ORAL

NEOTRIZINE

LILLY 167MG;167MG;167MG N006317 011

SULFA-TRIPLE #2

IMPAX LABS 167MG;167MG;167MG A080079 001

SULFALOID

FOREST PHARMS 167MG;167MG;167MG A080099 001

SULFOSE

WYETH AYERST 167MG;167MG;167MG A080013 001

TERFONYL

BRISTOL MYERS SQUIBB 167MG;167MG;167MG N006904 001

TRIPLE SULFA

PUREPAC PHARM 167MG;167MG;167MG A080086 001

TRIPLE SULFAS

LEDERLE 167MG;167MG;167MG N006920 002

TRIPLE SULFOID

PAL PAK 167MG;167MG;167MG A080094 001

TROGLITAZONE

TABLET;ORAL

PRELAY

SANKYO 200MG N020719 001 Jan 29, 1997
300MG N020719 003 Aug 04, 1997
400MG N020719 002 Jan 29, 1997

REZULIN

PFIZER PHARMS 200MG N020720 001 Jan 29, 1997
300MG N020720 003 Aug 04, 1997
400MG N020720 002 Jan 29, 1997TROLAMINE POLYPEPTIDE OLEATE CONDENSATE

SOLUTION/DROPS;OTIC

CERUMENEX

PHARM RES ASSOC 10% N011340 002

TROLEANDOMYCIN

CAPSULE;ORAL

TAO

PFIZER EQ 250MG BASE N050336 002

SUSPENSION;ORAL

TAO

PFIZER EQ 125MG BASE/5ML N050332 001

TROPICAMIDE

SOLUTION/DROPS;OPHTHALMIC

MYDRIACYL

ALCON 0.5% ** N012111 002
1% ** N012111 004

MYDRIAFAIR

PHARMAFAIR 0.5% A088274 001 Sep 16, 1983
1% A088230 001 Sep 16, 1983

TROPICAMIDE

AKORN 1% A088447 001 Aug 28, 1985
ALCON PHARMS LTD 1% A089172 001 Dec 28, 1990
MIZA PHARMS USA 0.5% A087636 001 Jul 30, 1982
1% A087637 001 Aug 09, 1982
WATSON LABS 0.5% A089171 001 Dec 28, 1990TROSPIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

SANCTURA XR

+ ALLERGAN 60MG ** N022103 001 Aug 03, 2007

TROSPIUM CHLORIDE

UPSHER SMITH LABS 60MG A091635 001 Apr 29, 2015

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TROSPIUM CHLORIDE

TABLET; ORAL

SANCTURA

+ ALLERGAN

20MG **

N021595 001 May 28, 2004

TROVAFLOXACIN MESYLATE

TABLET; ORAL

TROVAN

PFIZER

EQ 100MG BASE

N020759 001 Dec 18, 1997

EQ 200MG BASE

N020759 002 Dec 18, 1997

TUBOCURARINE CHLORIDE

INJECTABLE; INJECTION

TUBOCURARINE CHLORIDE

BRISTOL MYERS SQUIBB

3MG/ML

N005657 001

HOSPIRA

3MG/ML

N006095 001

LILLY

3MG/ML

N006325 001

TYROPANOATE SODIUM

CAPSULE; ORAL

BILOPAQUE

GE HEALTHCARE

750MG

N013731 001

UNOPROSTONE ISOPROPYL

SOLUTION/DROPS; OPHTHALMIC

RESCULA

+ SUCAMPO PHARMA LLC

0.15% **

N021214 001 Aug 03, 2000

URACIL MUSTARD

CAPSULE; ORAL

URACIL MUSTARD

SHIRE

1MG

N012892 001

UREA

INJECTABLE; INJECTION

STERILE UREA

HOSPIRA

40GM/VIAL

N017698 001

UREAPHIL

HOSPIRA

40GM/VIAL

N012154 001

UREA C-13

FOR SOLUTION; ORAL

BREATHTEK UBT FOR H-PYLORI

OTSUKA AMERICA

EQ 75MG/POUCH

N020586 002 May 10, 2001

HELICOSOL

METABOLIC SOLUTIONS

125MG/VIAL

N021092 001 Dec 17, 1999

MERETEK UBT KIT (W/ PRANACTIN)

OTSUKA AMERICA

125MG/VIAL

N020586 001 Sep 17, 1996

PYLORI-CHEK BREATH TEST

DXS DEVICES

100MG/VIAL

N020900 001 Feb 04, 1999

URSODIOL

CAPSULE; ORAL

ACTIGALL

ALLERGAN

150MG

N019594 001 Dec 31, 1987

URSODIOL

IMPAX LABS INC

300MG

A077895 001 Jul 27, 2006

TABLET; ORAL

URSODIOL

IMPAX LABS INC

250MG

A200826 001 Dec 23, 2011

500MG

A200826 002 Dec 23, 2011

TEVA PHARMS USA

250MG

A079184 001 May 13, 2009

500MG

A079184 002 May 13, 2009

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

HIKMA

EQ 500MG BASE

A078656 001 May 24, 2010

EQ 1GM BASE

A078656 002 May 24, 2010

MYLAN

EQ 500MG BASE

A078070 001 May 24, 2010

EQ 1GM BASE

A078070 002 May 24, 2010

TEVA PHARMS

EQ 500MG BASE

A077655 001 May 24, 2010

EQ 1GM BASE

A077655 002 May 24, 2010

WATSON LABS INC

EQ 500MG BASE

A090370 001 Mar 16, 2011

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

EQ 1GM BASE

A090370 002 Mar 16, 2011

VALDECOXIB

TABLET; ORAL

BEXTRA

GD SEARLE

10MG

N021341 002 Nov 16, 2001

20MG

N021341 003 Nov 16, 2001

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION; ORAL

VALGANCICLOVIR HYDROCHLORIDE

GRANULES PHARMS

50MG/ML

A213306 001 Jan 31, 2020

VALPROATE SODIUM

INJECTABLE; INJECTION

DEPACON

+ ABBVIE

EQ 100MG BASE/ML

N020593 001 Dec 30, 1996

VALPROIC ACID

CAPSULE; ORAL

DEPAKENE

+ ABBVIE

250MG

N018081 001

VALPROIC ACID

PAR PHARM

250MG

A070431 001 Feb 28, 1986

SCHERER RP

250MG

A070195 001 Jul 02, 1987

UPSHER SMITH LABS

250MG

A070631 001 Jun 11, 1987

CAPSULE, DELAYED RELEASE; ORAL

STAVZOR

+ BIONPHARMA INC

125MG **

N022152 001 Jul 29, 2008

+

250MG **

N022152 002 Jul 29, 2008

+

500MG **

N022152 003 Jul 29, 2008

SYRUP; ORAL

DEPAKENE

+ ABBVIE

250MG/5ML

N018082 001

VALPROIC ACID

ANI PHARMS INC

250MG/5ML

A073178 001 Aug 25, 1992

CHARTWELL RX

250MG/5ML

A075782 001 Dec 22, 2000

NOSTRUM LABS INC

250MG/5ML

A077105 001 Jul 29, 2005

VALSARTAN

CAPSULE; ORAL

DIOVAN

NOVARTIS

80MG

N020665 001 Dec 23, 1996

160MG

N020665 002 Dec 23, 1996

SOLUTION; ORAL

PREXXARTAN

+ CARMEL BIOSCIENCES

20MG/5ML

N209139 001 Dec 19, 2017

+

80MG/20ML

N209139 002 Dec 19, 2017

TABLET; ORAL

VALSARTAN

TORRENT

40MG

A202728 001 Jan 05, 2015

80MG

A202728 002 Jan 05, 2015

160MG

A202728 003 Jan 05, 2015

320MG

A202728 004 Jan 05, 2015

UNICHEM

40MG

A209261 001 May 04, 2018

80MG

A209261 002 May 04, 2018

160MG

A209261 003 May 04, 2018

320MG

A209261 004 May 04, 2018

WATSON LABS INC

40MG

A090642 001 Jan 05, 2015

80MG

A090642 002 Jan 05, 2015

160MG

A090642 003 Jan 05, 2015

320MG

A090642 004 Jan 05, 2015

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

VANCOMYCIN HYDROCHLORIDE

FRESENIUS KABI USA

EQ 125MG BASE

A065453 001 Jun 18, 2012

EQ 250MG BASE

A065453 002 Jun 18, 2012

FOR SOLUTION; ORAL

VANCOCIN HYDROCHLORIDE

ANI PHARMS INC

EQ 500MG BASE/6ML

A061667 001

VANCOLED

LEDERLE

EQ 250MG BASE/5ML

A063321 002 Oct 15, 1993

EQ 500MG BASE/6ML

A063321 003 Oct 15, 1993

INJECTABLE; INJECTION

VANCOCIN HYDROCHLORIDE

ANI PHARMS INC

EQ 500MG BASE/VIAL **

A060180 001

EQ 500MG BASE/VIAL

A062476 001 Mar 15, 1984

EQ 500MG BASE/VIAL

A062716 001 Mar 13, 1987

EQ 500MG BASE/VIAL **

A062812 001 Nov 17, 1987

EQ 1GM BASE/VIAL **

A060180 002 Mar 21, 1986

EQ 1GM BASE/VIAL

A062476 002 Mar 21, 1986

EQ 1GM BASE/VIAL

A062716 002 Mar 13, 1987

EQ 1GM BASE/VIAL **

A062812 002 Nov 17, 1987

EQ 10GM BASE/VIAL **

A062812 003 Nov 17, 1987

VANCOLED

WEST-WARD PHARMS INT

EQ 500MG BASE/VIAL **

A062682 001 Jul 22, 1986

EQ 1GM BASE/VIAL **

A062682 002 Mar 30, 1988

EQ 2GM BASE/VIAL **

A062682 003 May 11, 1988

EQ 5GM BASE/VIAL **

A062682 004 May 11, 1988

EQ 10GM BASE/VIAL **

A062682 005 May 11, 1988

VANCOMYCIN HYDROCHLORIDE

EMCURE PHARMS LTD

EQ 500MG BASE/VIAL

A202275 001 Oct 31, 2013

EQ 1GM BASE/VIAL

A202275 002 Oct 31, 2013

EQ 10GM BASE/VIAL

A202464 001 Oct 09, 2013

EQ 5GM BASE/VIAL

A202274 001 Oct 31, 2013

HOSPIRA

EQ 1.5GM BASE/VIAL

A062912 003 Jul 10, 2020

MYLAN LABS LTD

EQ 10GM BASE/VIAL

A091469 001 Jul 01, 2011

TEVA PHARMS USA

EQ 500MG BASE/VIAL

A201251 001 Dec 23, 2015

EQ 1GM BASE/VIAL

A201251 002 Dec 23, 2015

EQ 5GM BASE/VIAL

A201250 001 Dec 23, 2015

EQ 10GM BASE/VIAL

A201250 002 Dec 23, 2015

WEST-WARD PHARMS INT

EQ 500MG BASE/VIAL

A062879 001 Aug 02, 1988

EQ 1GM BASE/VIAL

A062879 002 Aug 02, 1988

XELLIA PHARMS APS

EQ 500MG BASE/VIAL

A091377 001 Sep 09, 2015

EQ 1GM BASE/VIAL

A091377 002 Sep 09, 2015

EQ 5GM BASE/VIAL

A206243 001 Dec 23, 2015

EQ 10GM BASE/VIAL

A206243 002 Dec 23, 2015

VANCOR

PHARMACIA AND UPJOHN

EQ 500MG BASE/VIAL

A062956 001 Aug 01, 1988

EQ 1GM BASE/VIAL

A062956 002 Aug 01, 1988

VARDENAFIL HYDROCHLORIDE

TABLET; ORAL

LEVITRA

+ BAYER HLTHCARE

EQ 2.5MG BASE **

N021400 003 Aug 19, 2003

VARDENAFIL HYDROCHLORIDE

AMNEAL PHARMS CO

EQ 5MG BASE

A210738 001 Oct 31, 2018

EQ 10MG BASE

A210738 002 Oct 31, 2018

EQ 20MG BASE

A210738 003 Oct 31, 2018

VASOPRESSIN TANNATE

INJECTABLE; INJECTION

PITRESSIN TANNATE

+ PARKE DAVIS

5PRESSOR UNITS/ML **

N003402 001

VECURONIUM BROMIDE

INJECTABLE; INJECTION

NORCURON

+ ORGANON USA INC

10MG/VIAL **

N018776 002 Apr 30, 1984

+

20MG/VIAL **

N018776 003 Jan 03, 1992

VECURONIUM BROMIDE

HOSPIRA

4MG/VIAL

A075558 001 Sep 11, 2001

WATSON LABS

10MG/VIAL

A074334 001 Aug 31, 1995

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

	20MG/VIAL	A074334	002	Aug 31, 1995
WEST-WARD PHARMS INT	10MG/VIAL	A075218	001	Aug 23, 1999
	20MG/VIAL	A075218	002	Aug 23, 1999

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

EFFEXOR XR

UPJOHN	EQ 100MG BASE	N020699	003	Oct 20, 1997
--------	---------------	---------	-----	--------------

VENLAFAXINE HYDROCHLORIDE

ANCHEN PHARMS	EQ 37.5MG BASE	A078087	001	Mar 16, 2012
	EQ 75MG BASE	A078087	002	Mar 16, 2012
	EQ 150MG BASE	A078087	003	Mar 16, 2012
MYLAN	EQ 37.5MG BASE	A078789	001	Jun 01, 2011
	EQ 75MG BASE	A078789	002	Jun 01, 2011
	EQ 150MG BASE	A078789	003	Jun 01, 2011

TABLET; ORAL

EFFEXOR

+	WYETH PHARMS INC	EQ 12.5MG BASE **	N020151	001	Dec 28, 1993
+		EQ 25MG BASE **	N020151	002	Dec 28, 1993
+		EQ 37.5MG BASE **	N020151	006	Dec 28, 1993
+		EQ 50MG BASE **	N020151	003	Dec 28, 1993
+		EQ 75MG BASE **	N020151	004	Dec 28, 1993
+		EQ 100MG BASE **	N020151	005	Dec 28, 1993

VENLAFAXINE HYDROCHLORIDE

FOSUN PHARMA	EQ 25MG BASE	A077515	001	Jun 13, 2008
	EQ 37.5MG BASE	A077515	002	Jun 13, 2008
	EQ 50MG BASE	A077515	003	Jun 13, 2008
	EQ 75MG BASE	A077515	004	Jun 13, 2008
	EQ 100MG BASE	A077515	005	Jun 13, 2008
PLIVA HRVATSKA DOO	EQ 25MG BASE	A078517	001	Jun 13, 2008
	EQ 37.5MG BASE	A078517	002	Jun 13, 2008
	EQ 50MG BASE	A078517	003	Jun 13, 2008
	EQ 75MG BASE	A078517	004	Jun 13, 2008
	EQ 100MG BASE	A078517	005	Jun 13, 2008
PRINSTON INC	EQ 25MG BASE	A090027	001	Aug 04, 2010
	EQ 37.5MG BASE	A090027	002	Aug 04, 2010
	EQ 50MG BASE	A090027	003	Aug 04, 2010
	EQ 75MG BASE	A090027	004	Aug 04, 2010
	EQ 100MG BASE	A090027	005	Aug 04, 2010

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VERAPAMIL HYDROCHLORIDE

MYLAN	100MG	A078306	001	Aug 09, 2007
	200MG	A078306	002	Aug 09, 2007
	300MG	A078306	003	Aug 09, 2007

INJECTABLE; INJECTION

CALAN

GD SEARLE LLC	2.5MG/ML	N019038	001	Mar 30, 1984
---------------	----------	---------	-----	--------------

ISOPTIN

+	MT ADAMS	2.5MG/ML **	N018485	001
---	----------	-------------	---------	-----

VERAPAMIL HYDROCHLORIDE

ABRAXIS PHARM	2.5MG/ML	A070348	001	May 01, 1986
BEDFORD	2.5MG/ML	A072888	001	Jul 28, 1995
HOSPIRA	2.5MG/ML	A070577	001	Feb 02, 1987
	2.5MG/ML	A070739	001	May 06, 1987
	2.5MG/ML	A070740	001	May 06, 1987
INTL MEDICATION	2.5MG/ML	A070451	001	Dec 16, 1985
LUITPOLD	2.5MG/ML	A070225	001	Nov 12, 1985
	2.5MG/ML	A070617	001	Nov 12, 1985
MARSAM PHARMS LLC	2.5MG/ML	A072233	001	Feb 26, 1993
	2.5MG/ML	A073485	001	Sep 27, 1993
SMITH AND NEPHEW	2.5MG/ML	A070696	001	Jul 31, 1987
	2.5MG/ML	A070697	001	Jul 31, 1987
SOLOPAK	2.5MG/ML	A070695	001	Jul 31, 1987

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

VERAPAMIL HYDROCHLORIDE

SOLUTION; INTRAVENOUS

VERAPAMIL HYDROCHLORIDE

EXELA PHARMA

10MG/4ML (2.5MG/ML)

N018925 002 Apr 05, 2018

TABLET; ORAL

CALAN

PFIZER

40MG

N018817 003 Feb 23, 1988

+

80MG

N018817 001 Sep 10, 1984

+

120MG

N018817 002 Sep 10, 1984

160MG

N018817 004 Feb 23, 1988

ISOPTIN

+ MT ADAMS

40MG

N018593 003 Nov 23, 1987

+

80MG

N018593 001 Mar 08, 1982

+

120MG

N018593 002 Mar 08, 1982

VERAPAMIL HYDROCHLORIDE

ACTAVIS ELIZABETH

80MG

A071019 001 Sep 24, 1986

120MG

A070468 001 Sep 24, 1986

MUTUAL PHARM

80MG

A070482 001 Sep 24, 1986

120MG

A070483 001 Sep 24, 1986

MYLAN

80MG

A071483 002 Feb 15, 1989

120MG

A071483 001 Feb 15, 1989

PLIVA

40MG

A072751 001 Feb 23, 1996

80MG

A072124 001 Jan 26, 1989

120MG

A072125 001 Jan 26, 1989

SUN PHARM INDUSTRIES

80MG

A071489 002 Jan 13, 1988

120MG

A071489 001 Jan 13, 1988

WARNER CHILCOTT

80MG

A070340 001 Sep 24, 1986

120MG

A070341 001 Sep 24, 1986

WATSON LABS

40MG

A072799 001 Apr 28, 1989

40MG

A072923 001 Jun 29, 1993

80MG

A070855 001 Sep 24, 1986

80MG

A071366 001 Oct 01, 1986

120MG

A070856 001 Sep 24, 1986

120MG

A071367 001 Oct 01, 1986

YAOPHARMA CO LTD

40MG

A073168 001 Jul 31, 1992

80MG

A071423 001 May 24, 1988

120MG

A071424 001 May 25, 1988

TABLET, EXTENDED RELEASE; ORAL

CALAN SR

+ PFIZER

180MG **

N019152 002 Dec 15, 1989

COVERA-HS

PFIZER

180MG

N020552 001 Feb 26, 1996

240MG

N020552 002 Feb 26, 1996

VERAPAMIL HYDROCHLORIDE

APOTEX CORP

120MG

A200878 001 Apr 20, 2012

180MG

A200878 002 Apr 20, 2012

240MG

A200878 003 Apr 20, 2012

PLIVA

240MG

A072922 001 Mar 01, 1996

VERATRUM VIRIDE ROOT

TABLET; ORAL

VERTAVIS

MEDPOINTE PHARM HLC

130CSR UNIT

N005691 002

VIDARABINE

INJECTABLE; INJECTION

VIRA-A

PARKEDALE

EQ 187.4MG BASE/ML

N050523 001

OINTMENT; OPHTHALMIC

VIRA-A

PARKEDALE

3%

N050486 001

VILAZODONE HYDROCHLORIDE

TABLET; ORAL

VILAZODONE HYDROCHLORIDE

TEVA PHARMS USA

10MG

A208212 001 Sep 30, 2019

20MG

A208212 002 Sep 30, 2019

40MG

A208212 003 Sep 30, 2019

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

VINBLASTINE SULFATE

INJECTABLE; INJECTION

VELBAN

+ LILLY	10MG/VIAL **	N012665 001	
VINBLASTINE SULFATE			
ABRAXIS PHARM	10MG/VIAL	A089011 001	Nov 18, 1985
HOSPIRA	10MG/VIAL	A089565 001	Aug 18, 1987

VINCRIStINE SULFATE

INJECTABLE; INJECTION

ONCOVIN

+ LILLY	1MG/VIAL	N014103 001	
+	1MG/ML	N014103 003	Mar 07, 1984
+	5MG/VIAL	N014103 002	

VINCASAR PFS

TEVA PARENTERAL	1MG/ML	A071426 001	Jul 17, 1987
-----------------	--------	-------------	--------------

VINCREX

BRISTOL MYERS SQUIBB	5MG/VIAL	A070867 001	Jul 12, 1988
----------------------	----------	-------------	--------------

VINCRIStINE SULFATE

ABIC	1MG/ML	A070873 001	Feb 19, 1987
ABRAXIS PHARM	1MG/ML	A070411 001	Sep 10, 1986
FRESENIUS KABI USA	1MG/ML	A076296 001	Dec 20, 2002
	1MG/ML	A076401 001	Oct 28, 2003
HOSPIRA	1MG/VIAL	A071559 001	Apr 11, 1988
	2MG/VIAL	A071560 001	Apr 11, 1988
	5MG/VIAL	A071561 001	Apr 11, 1988

VINORELBINE TARTRATE

INJECTABLE; INJECTION

NAVELBINE

+ PIERRE FABRE	EQ 10MG BASE/ML **	N020388 001	Dec 23, 1994
----------------	--------------------	-------------	--------------

VINORELBINE TARTRATE

EBEWE PHARMA	EQ 10MG BASE/ML	A078408 001	Feb 13, 2008
HOSPIRA	EQ 10MG BASE/ML	A076827 001	Jun 02, 2005
MYLAN LABS LTD	EQ 10MG BASE/ML	A200148 001	Aug 31, 2012
NOVAST LABS	EQ 10MG BASE/ML	A208997 001	Aug 05, 2019

VIOMYCIN SULFATE

INJECTABLE; INJECTION

VIOCIN SULFATE

PFIZER	EQ 1GM BASE/VIAL	A061086 001	
	EQ 5GM BASE/VIAL	A061086 002	

VITAMIN A

CAPSULE; ORAL

AQUASOL A

ASTRAZENECA	25,000USP UNITS	A083080 002	
	50,000USP UNITS	A083080 001	

VITAMIN A

BANNER PHARMACAPS	50,000USP UNITS	A083973 001	
CHASE CHEM	50,000 IU	A083351 001	
EVERYLIFE	50,000 IU	A083134 001	
IMPAX LABS	50,000USP UNITS	A080952 001	
WEST WARD	50,000USP UNITS	A080985 001	

VITAMIN A PALMITATE

CAPSULE; ORAL

AFAXIN

STERLING WINTHROP	EQ 50,000 UNITS BASE	A083187 001	
-------------------	----------------------	-------------	--

ALPHALIN

LILLY	EQ 50,000 UNITS BASE	A080883 001	
-------	----------------------	-------------	--

DEL-VI-A

DEL RAY LABS	EQ 50,000 UNITS BASE	A080830 001	
--------------	----------------------	-------------	--

VI-DOM-A

BAYER PHARMS	EQ 50,000 UNITS BASE	A080972 001	
--------------	----------------------	-------------	--

VITAMIN A

BANNER PHARMACAPS	EQ 50,000 UNITS BASE	A080702 001	
BRISTOL MYERS SQUIBB	EQ 50,000 UNITS BASE	A080860 001	
CHASE CHEM	EQ 50,000 UNITS BASE	A080746 001	
	EQ 50,000 UNITS BASE	A083207 001	
ELKINS SINN	EQ 50,000 UNITS BASE	A085479 001	
EVERYLIFE	EQ 50,000 UNITS BASE	A080943 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

VITAMIN A PALMITATE

CAPSULE; ORAL

VITAMIN A

	EQ 50,000 UNITS BASE	A083114 001
IMPAX LABS	EQ 50,000 UNITS BASE	A080953 001
	EQ 50,000 UNITS BASE	A080955 001
IVAX SUB TEVA PHARMS	EQ 50,000 UNITS BASE	A083035 001
	EQ 50,000 UNITS BASE	A083190 001
MK LABS	EQ 25,000 UNITS BASE	A083457 002
	EQ 50,000 UNITS BASE	A083457 001
WEST WARD	EQ 50,000 UNITS BASE	A080967 001
WHARTON LABS	EQ 50,000 UNITS BASE	A083665 001

VITAMIN A PALMITATE

ARCUM	EQ 50,000 UNITS BASE	A083311 001
	EQ 50,000 UNITS BASE	A083321 001
BANNER PHARMACAPS	EQ 50,000 UNITS BASE	A083948 001
	EQ 50,000 UNITS BASE	A083981 001

VITAMIN A SOLUBILIZED

TEVA	EQ 50,000 UNITS BASE	A080921 001
------	----------------------	-------------

INJECTABLE; INJECTION

VITAMIN A PALMITATE

BEL MAR	EQ 50,000 UNITS BASE/ML	A080819 001
---------	-------------------------	-------------

VORICONAZOLE

FOR SUSPENSION; ORAL

VORICONAZOLE

MYLAN PHARMS INC	200MG/5ML	A202361 001	May 28, 2013
------------------	-----------	-------------	--------------

TABLET; ORAL

VORICONAZOLE

TEVA PHARMS	50MG	A091658 001	Apr 06, 2012
	200MG	A091658 002	Apr 06, 2012

VORTIOXETINE HYDROBROMIDE

TABLET; ORAL

TRINTELLIX

+ TAKEDA PHARMS USA	EQ 15MG BASE **	N204447 003	Sep 30, 2013
---------------------	-----------------	-------------	--------------

WARFARIN POTASSIUM

TABLET; ORAL

ATHROMBIN-K

PHARM RES ASSOC	2MG	N011771 007
	5MG	N011771 004
	10MG	N011771 005
	25MG	N011771 006

WARFARIN SODIUM

INJECTABLE; INJECTION

COUMADIN

BRISTOL MYERS SQUIBB	5MG/VIAL	N009218 024	Feb 07, 1995
	50MG/VIAL	N009218 020	
	75MG/VIAL	N009218 012	

TABLET; ORAL

ATHROMBIN

PHARM RES ASSOC	5MG	N011771 003
	10MG	N011771 002
	25MG	N011771 001

COUMADIN

+ BRISTOL MYERS SQUIBB	1MG	N009218 022	Mar 01, 1990
	2MG	N009218 013	
	2.5MG	N009218 018	
	3MG	N009218 025	Nov 18, 1996
	4MG	N009218 023	Aug 24, 1993
	5MG	N009218 007	
	6MG	N009218 026	Nov 18, 1996
	7.5MG	N009218 016	
	10MG	N009218 005	

PANWARFIN

ABBOTT	2MG	N017020 001
	2.5MG	N017020 002
	5MG	N017020 003
	7.5MG	N017020 004

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

WARFARIN SODIUMTABLET; ORAL
PANWARFIN

	10MG	N017020 005	
WARFARIN SODIUM			
MYLAN	1MG	A040415 001	Sep 27, 2004
	2MG	A040415 002	Sep 27, 2004
	2.5MG	A040415 003	Sep 29, 2004
	3MG	A040415 004	Sep 27, 2004
	4MG	A040415 005	Sep 27, 2004
	5MG	A040415 006	Sep 27, 2004
	6MG	A040415 007	Sep 27, 2004
	7.5MG	A040415 008	Sep 27, 2004
	10MG	A040415 009	Sep 27, 2004
USL PHARMA	2MG	A088719 001	Jun 27, 1985
	2.5MG	A088720 001	Aug 06, 1985
	5MG	A088721 001	Jul 02, 1985
WATSON LABS	2MG	A086123 001	Aug 17, 1982
	2.5MG	A086120 001	Aug 17, 1982
	5MG	A086119 001	Aug 17, 1982
	7.5MG	A086118 001	Aug 17, 1982
	10MG	A086122 001	Aug 17, 1982
YAOPHARMA CO LTD	1MG	A040196 001	Sep 30, 1997
	2MG	A040196 002	Sep 30, 1997
	2.5MG	A040196 003	Sep 30, 1997
	3MG	A040196 008	Jul 26, 2000
	4MG	A040196 004	Sep 30, 1997
	5MG	A040196 005	Sep 30, 1997
	6MG	A040196 009	Jul 26, 2000
	7.5MG	A040196 006	Sep 30, 1997
	10MG	A040196 007	Sep 30, 1997

XENON XE-127GAS; INHALATION
XENON XE 127

MALLINCKRODT	5mCi/VIAL	N018536 001	Oct 01, 1982
	10mCi/VIAL	N018536 002	Oct 01, 1982

XENON XE-133GAS; INHALATION
XENON XE 133

GE HEALTHCARE	1 CI/AMP	N017256 002	
	10mCi/VIAL	N017687 002	
	20mCi/VIAL	N017687 003	
GEN ELECTRIC	5-100 CI/CYLINDER	N017550 001	
	0.25-5 CI/AMP	N017550 003	
XENON XE 133-V.S.S.			
GE HEALTHCARE	10mCi/VIAL	N017687 001	
INJECTABLE; INJECTION			
XENON XE 133			
GE HEALTHCARE	1.3-1.7 CI/AMP	N017256 001	
LANTHEUS MEDCL	6.3mCi/ML	N017283 001	
SOLUTION; INHALATION, INJECTION			
XENEISOL			
MALLINCKRODT	18-25mCi/AMP	N017262 002	

XYLOSEPOWDER; ORAL
XYLO-PFAN

SAVAGE LABS	25GM/BOT	N017605 001	
XYLOSE			
LYNE	25GM/BOT	N018856 001	Mar 26, 1987

ZALCITABINETABLET; ORAL
HIVID

ROCHE	0.375MG	N020199 001	Jun 19, 1992
	0.75MG	N020199 002	Jun 19, 1992

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ZALEPLON

CAPSULE; ORAL

ZALEPLON

HIKMA PHARMS	5MG	A078147 001	Nov 25, 2008
	10MG	A078147 002	Nov 25, 2008
MYLAN	5MG	A077238 001	Jun 06, 2008
	10MG	A077238 002	Jun 06, 2008
TEVA PHARMS	5MG	A077239 001	Jun 06, 2008
	10MG	A077239 002	Jun 06, 2008
UPSHER SMITH LABS	5MG	A078095 001	Jun 06, 2008
	5MG	A078706 001	Jun 06, 2008
	10MG	A078095 002	Jun 06, 2008
	10MG	A078706 002	Jun 06, 2008

ZICONOTIDE ACETATE

INJECTABLE; INTRATHECAL

PRIALT

TERSERA	200MCG/2ML (100MCG/ML)	N021060 003	Dec 28, 2004
---------	------------------------	-------------	--------------

ZIDOVUDINE

INJECTABLE; INJECTION

ZIDOVUDINE

AM REGENT	10MG/ML	A091457 001	May 06, 2010
LIAONING CHENGDA	10MG/ML	A204538 001	Nov 26, 2013

TABLET; ORAL

RETROVIR

VIIV HLTHCARE	200MG	N020518 001	Dec 19, 1995
+	300MG **	N020518 002	Oct 04, 1996

ZIDOVUDINE

AUROBINDO PHARMA	60MG	N022294 001	Jul 23, 2009
HEC PHARM	300MG	A202058 001	Oct 07, 2011
HIKMA	300MG	A076844 001	Sep 19, 2005
MYLAN LABS LTD	100MG	N200732 001	Feb 23, 2011
RANBAXY LABS LTD	300MG	A077327 001	Sep 19, 2005

ZILEUTON

TABLET; ORAL

ZYFLO

CHIESI	300MG	N020471 001	Dec 09, 1996
--------	-------	-------------	--------------

ZINC SULFATE

INJECTABLE; INJECTION

ZINC SULFATE

ABRAXIS PHARM	EQ 1MG ZINC/ML	N019229 002	May 05, 1987
---------------	----------------	-------------	--------------

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL

ZIPRASIDONE HYDROCHLORIDE

MYLAN	EQ 20MG BASE	A202395 001	Oct 10, 2013
	EQ 40MG BASE	A202395 002	Oct 10, 2013
	EQ 60MG BASE	A202395 003	Oct 10, 2013
	EQ 80MG BASE	A202395 004	Oct 10, 2013

SUSPENSION; ORAL

GEODON

PFIZER INC	EQ 10MG BASE/ML	N021483 001	Mar 29, 2006
------------	-----------------	-------------	--------------

ZOLEDRONIC ACID

INJECTABLE; INTRAVENOUS

ZOLEDRONIC ACID

ACTAVIS INC	EQ 4MG BASE/5ML	A202472 001	Mar 04, 2013
DR REDDYS LABS LTD	EQ 4MG BASE/100ML	A204344 001	Nov 19, 2018
EMCURE PHARMS LTD	EQ 5MG BASE/100ML	A201801 001	Mar 29, 2013
SHILPA MEDICARE LTD	EQ 4MG BASE/5ML	A208513 001	May 15, 2019
SUN PHARMA GLOBAL	EQ 4MG BASE/VIAL	A090018 001	Mar 04, 2013
	EQ 4MG BASE/5ML	A202746 001	Mar 04, 2013

ZOMETA

+	NOVARTIS	EQ 4MG BASE/VIAL **	N021223 001	Aug 20, 2001
---	----------	---------------------	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ZOLMITRIPTAN

TABLET;ORAL

ZOLMITRIPTAN

ANI PHARMS INC	2.5MG	A090861 001	Mar 04, 2014
	5MG	A090861 002	Mar 04, 2014
APOTEX INC	2.5MG	A202078 001	May 14, 2013
	5MG	A202078 002	May 14, 2013
MACLEODS PHARMS LTD	2.5MG	A203772 001	Sep 30, 2015
	5MG	A203772 002	Sep 30, 2015
MYLAN PHARMS INC	2.5MG	A203186 001	May 14, 2013
	5MG	A203186 002	May 14, 2013
SUN PHARMA GLOBAL	2.5MG	A203476 001	Nov 13, 2014
	5MG	A203476 002	Nov 13, 2014

TABLET, ORALLY DISINTEGRATING;ORAL

ZOLMITRIPTAN

APOTEX INC	2.5MG	A202476 001	May 14, 2013
	5MG	A202476 002	May 14, 2013
MACLEODS PHARMS LTD	2.5MG	A204336 001	Oct 22, 2015
	5MG	A204336 002	Oct 22, 2015
MYLAN	2.5MG	A202855 001	Sep 20, 2019
	5MG	A202855 002	Sep 20, 2019

ZOLPIDEM TARTRATE

TABLET;ORAL

ZOLPIDEM TARTRATE

DR REDDYS LABS LTD	5MG	A077985 001	Apr 23, 2007
	10MG	A077985 002	Apr 23, 2007
HIKMA	5MG	A078129 001	Apr 30, 2008
	10MG	A078129 002	Apr 30, 2008
MYLAN	5MG	A076578 001	Apr 23, 2007
	10MG	A076578 002	Apr 23, 2007
MYLAN PHARMS INC	5MG	A078016 001	Apr 23, 2007
	10MG	A078016 002	Apr 23, 2007
STRIDES PHARMA	5MG	A076062 001	Apr 23, 2007
	10MG	A076062 002	Apr 23, 2007
SUN PHARM INDS INC	5MG	A077359 001	Apr 23, 2007
	10MG	A077359 002	Apr 23, 2007
SUN PHARM INDS LTD	5MG	A078055 001	Apr 23, 2007
	10MG	A078055 002	Apr 23, 2007
SUN PHARM INDUSTRIES	5MG	A077288 001	Apr 23, 2007
	10MG	A077288 002	Apr 23, 2007
SYNTHON PHARMS	5MG	A077540 001	Apr 23, 2007
	10MG	A077540 002	Apr 23, 2007
VINTAGE	5MG	A078616 001	Nov 21, 2008
	10MG	A078616 002	Nov 21, 2008
WATSON LABS	5MG	A077773 001	Apr 23, 2007
	10MG	A077773 002	Apr 23, 2007
WOCKHARDT	5MG	A078426 001	May 15, 2007
	10MG	A078426 002	May 15, 2007
YUNG SHIN PHARM	5MG	A077990 001	Apr 23, 2007
	10MG	A077990 002	Apr 23, 2007

TABLET;SUBLINGUAL

INTERMEZZO

+ PURDUE PHARMA	1.75MG	N022328 001	Nov 23, 2011
+	3.5MG	N022328 002	Nov 23, 2011

ZOLPIDEM TARTRATE

MYLAN	5MG	A202657 001	Aug 08, 2016
	10MG	A202657 002	Aug 08, 2016

TABLET, EXTENDED RELEASE;ORAL

ZOLPIDEM TARTRATE

SYNTHON PHARMS	6.25MG	A078483 001	Apr 12, 2011
	12.5MG	A078483 002	Jun 06, 2011

TABLET, ORALLY DISINTEGRATING;ORAL

TOVALT ODT

BIOVAIL LABS INTL	5MG	N021412 001	Apr 25, 2007
	10MG	N021412 002	Apr 25, 2007

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ZONISAMIDE

CAPSULE; ORAL

ZONEGRAN

+ SUNOVION PHARMS INC 50MG **

N020789 002 Aug 22, 2003

ZONISAMIDE

ANI PHARMS INC	25MG	A077639 001	Dec 22, 2005
	25MG	A077641 003	Dec 22, 2005
	50MG	A077639 002	Dec 22, 2005
	50MG	A077641 002	Dec 22, 2005
	100MG	A077639 003	Dec 22, 2005
	100MG	A077641 001	Dec 22, 2005
EPIC PHARMA LLC	25MG	A077876 001	Feb 21, 2007
	50MG	A077876 002	Feb 21, 2007
	100MG	A077876 003	Feb 21, 2007
HERITAGE PHARMA	25MG	A077650 001	Apr 20, 2006
	50MG	A077650 002	Apr 20, 2006
	100MG	A077650 003	Apr 20, 2006
MYLAN	25MG	A077637 001	Dec 22, 2005
	50MG	A077637 002	Dec 22, 2005
	100MG	A077637 003	Dec 22, 2005
MYLAN PHARMS INC	25MG	A077647 001	Dec 22, 2005
	50MG	A077647 002	Dec 22, 2005
	100MG	A077647 003	Dec 22, 2005
ROXANE	25MG	A077648 001	Dec 22, 2005
	50MG	A077648 002	Dec 22, 2005
	100MG	A077648 003	Dec 22, 2005
SUN PHARM INDUSTRIES	25MG	A077635 001	Dec 22, 2005
	50MG	A077635 002	Dec 22, 2005
	100MG	A077635 003	Dec 22, 2005
UPSHER SMITH LABS	25MG	A077644 001	Dec 22, 2005
	50MG	A077644 002	Dec 22, 2005
	100MG	A077644 003	Dec 22, 2005

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

<http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/default.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

ACETAMINOPHEN;ASPIRIN;BUTALBITAL
CAPSULE OR TABLET; ORAL
160-165MG;160-165MG;50MG
325MG;325MG;50MG

ASPIRIN;CAFFEINE;CARISOPRODOL;
CODEINE PHOSPHATE
TABLET; ORAL
160MG;32MG;200MG;16MG

ACETAMINOPHEN;ASPIRIN;BUTALBITAL;
CAFFEINE
CAPSULE OR TABLET; ORAL
160-165MG;160-165MG;50MG;40MG
325MG;325MG;50MG;40MG

ASPIRIN;CARISOPRODOL
TABLET; ORAL
325MG;200MG

ACETAMINOPHEN;BUTALBITAL
CAPSULE OR TABLET; ORAL
325MG;50MG

ASPIRIN;CARISOPRODOL;
CODEINE PHOSPHATE
TABLET; ORAL
325MG;200MG;16MG

ACETAMINOPHEN;BUTALBITAL;CAFFEINE
CAPSULE OR TABLET; ORAL
325MG;50MG;40MG

ASPIRIN;MEPROBAMATE
TABLET; ORAL
325MG;200MG

AMINOPHYLLINE
TABLET; ORAL
100MG;200MG

ASPIRIN;METHOCARBAMOL
TABLET; ORAL
325MG;400MG

ASPIRIN;BUTALBITAL
CAPSULE OR TABLET; ORAL
325MG;50MG
650MG;50MG

CHLOROTHIAZIDE
TABLET; ORAL
250MG

ASPIRIN;BUTALBITAL;CAFFEINE
CAPSULE OR TABLET; ORAL
325MG;50MG;40MG
650MG;50MG;40MG

HYDROXYZINE HYDROCHLORIDE
TABLET; ORAL
10MG;25MG;
50MG;100MG

ASPIRIN;CAFFEINE;CARISOPRODOL
TABLET; ORAL
160MG;32MG;200MG

PREDNISONE
TABLET; ORAL
1MG;2.5MG;5MG;10MG;
20MG;25MG;50MG

APPENDIX A - PRODUCT NAME INDEX**** A ****

ABACAVIR SULFATE, ABACAVIR SULFATE
ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE, ABACAVIR SULFATE
ABELCET, AMPHOTERICIN B
ABILIFY, ARIPIPIRAZOLE
ABILIFY MAINTENA KIT, ARIPIPIRAZOLE
ABILIFY MYCITE KIT, ARIPIPIRAZOLE
ABIRATERONE ACETATE, ABIRATERONE ACETATE
ABLYSINOL, ALCOHOL
ABRAXANE, PACLITAXEL
ABREVA, DOCOSANOL (OTC)
ABSORICA, ISOTRETINOIN
ABSORICA LD, ISOTRETINOIN
ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
ACANYA, BENZOYL PEROXIDE
ACARBOSE, ACARBOSE
ACCOLATE, ZAFIRLUKAST
ACCUNEB, ALBUTEROL SULFATE
ACCUPRIL, QUINAPRIL HYDROCHLORIDE
ACCURETIC, HYDROCHLOROTHIAZIDE
ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE
ACEPHEN, ACETAMINOPHEN (OTC)
ACETADOTE, ACETYLCYSTEINE
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE, ACETAMINOPHEN
ACETAZOLAMIDE, ACETAZOLAMIDE
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ACETIC ACID, ACETIC ACID, GLACIAL
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
ACETYLCYSTEINE, ACETYLCYSTEINE
ACHROMYCIN V, TETRACYCLINE HYDROCHLORIDE
ACIPHEX, RABEPRAZOLE SODIUM
ACITRETIN, ACITRETIN
ACTICLATE, DOXYCYCLINE HYCLATE
ACTIGALL, URSODIOL
ACTIQ, FENTANYL CITRATE
ACTIVELLA, ESTRADIOL
ACTONEL, RISEDRONATE SODIUM
ACTOPLUS MET, METFORMIN HYDROCHLORIDE
ACTOS, PIOGLITAZONE HYDROCHLORIDE
ACULAR, KETOROLAC TROMETHAMINE
ACULAR LS, KETOROLAC TROMETHAMINE
ACUVAIL, KETOROLAC TROMETHAMINE
ACYCLOVIR, ACYCLOVIR
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ACZONE, DAPSONE
ADAPALENE, ADAPALENE (OTC)
ADAPALENE, ADAPALENE
ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
ADASUVE, LOXAPINE
ADCIRCA, TADALAFIL
ADDERALL XR 10, AMPHETAMINE ASPARTATE
ADDERALL XR 15, AMPHETAMINE ASPARTATE
ADDERALL XR 20, AMPHETAMINE ASPARTATE
ADDERALL XR 25, AMPHETAMINE ASPARTATE
ADDERALL XR 30, AMPHETAMINE ASPARTATE
ADDERALL XR 5, AMPHETAMINE ASPARTATE
ADDYI, FLIBANSERIN
ADEFOVIR DIPIVOXIL, ADEFOVIR DIPIVOXIL
ADEMPAS, RIOCIQUAT
ADENOSINE, ADENOSINE
ADHANSIA XR, METHYLPHENIDATE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX**** A ****

ADIPEX-P, PHENTERMINE HYDROCHLORIDE
ADRENACLICK, EPINEPHRINE
ADRENALIN, EPINEPHRINE
ADREVIEW, IOBENGUANE SULFATE I-123
ADVAIR DISKUS 100/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 250/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 500/50, FLUTICASONE PROPIONATE
ADVAIR HFA, FLUTICASONE PROPIONATE
ADVIL, IBUPROFEN (OTC)
ADVIL, IBUPROFEN SODIUM (OTC)
ADVIL ALLERGY AND CONGESTION RELIEF, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL COLD AND SINUS, IBUPROFEN (OTC)
ADVIL CONGESTION RELIEF, IBUPROFEN (OTC)
ADVIL DUAL ACTION WITH ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ADVIL LIQUI-GELS, IBUPROFEN (OTC)
ADVIL MIGRAINE LIQUI-GELS, IBUPROFEN (OTC)
ADVIL MULTI-SYMPATOM COLD & FLU, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL PM, DIPHENHYDRAMINE CITRATE (OTC)
ADVIL PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
ADZENYS ER, AMPHETAMINE
ADZENYS XR-ODT, AMPHETAMINE
AEMCOLO, RIFAMYCIN SODIUM
AFINITOR, EVEROLIMUS
AFINITOR DISPERZ, EVEROLIMUS
AFIRMELLE, ETHINYL ESTRADIOL
AGGRASTAT, TIROFIBAN HYDROCHLORIDE
AGGRENOLX, ASPIRIN
AGRYLIN, ANAGRELIDE HYDROCHLORIDE
AIRDUO DIGIHALER, FLUTICASONE PROPIONATE
AIRDUO RESPICLICK, FLUTICASONE PROPIONATE
AK-FLUOR 10%, FLUORESCEIN SODIUM
AK-FLUOR 25%, FLUORESCEIN SODIUM
AKBETA, LEVOBUNOLOL HYDROCHLORIDE
AKLIEF, TRIFAROTENE
AKOAZ, EPHEDRINE SULFATE
AKPENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE
AKTEN, LIDOCAINE HYDROCHLORIDE
AKTOB, TOBRAMYCIN
AKYNZEO, FOSNETUPITANT CHLORIDE HYDROCHLORIDE
AKYNZEO, NETUPITANT
ALA-CORT, HYDROCORTISONE
ALA-SCALP, HYDROCORTISONE
ALAVERT, LORATADINE (OTC)
ALAWAY, KETOTIFEN FUMARATE (OTC)
ALBENDAZOLE, ALBENDAZOLE
ALBENZA, ALBENDAZOLE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALCAINE, PROPARACAINE HYDROCHLORIDE
ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
ALDACTAZIDE, HYDROCHLOROTHIAZIDE
ALDACTONE, SPIRONOLACTONE
ALDARA, IMIQUIMOD
ALECENSA, ALECTINIB HYDROCHLORIDE
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALEVE, NAPROXEN SODIUM (OTC)
ALEVE PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
ALEVE-D SINUS & COLD, NAPROXEN SODIUM (OTC)
ALFENTA, ALFENTANIL HYDROCHLORIDE
ALFENTANIL, ALFENTANIL HYDROCHLORIDE
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
ALIMTA, PEMETREXED DISODIUM
ALINIA, NITAZOXANIDE
ALIQOPA, COPANLISIB DIHYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX**** A ****

ALISKIREN HEMIFUMARATE, ALISKIREN HEMIFUMARATE
 ALKERAN, MELPHALAN HYDROCHLORIDE
 ALKINDI SPRINKLE, HYDROCORTISONE
 ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
 ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
 ALLI, ORLISTAT (OTC)
 ALLOPURINOL, ALLOPURINOL
 ALLOPURINOL SODIUM, ALLOPURINOL SODIUM
 ALLZITAL, ACETAMINOPHEN
 ALMOTRIPTAN MALATE, ALMOTRIPTAN MALATE
 ALOCRIIL, NEDOCROMIL SODIUM
 ALOMIDE, LODOXAMIDE TROMETHAMINE
 ALOPRIM, ALLOPURINOL SODIUM
 ALORA, ESTRADIOL
 ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
 ALOXI, PALONOSETRON HYDROCHLORIDE
 ALPHAGAN P, BRIMONIDINE TARTRATE
 ALPRAZOLAM, ALPRAZOLAM
 ALPROSTADIL, ALPROSTADIL
 ALREX, LOTEPREDNOL ETABONATE
 ALTABAX, RETAPAMULIN
 ALTACE, RAMIPRIL
 ALTAFLUOR BENOX, BENOXINATE HYDROCHLORIDE
 ALTAVERA, ETHINYL ESTRADIOL
 ALTOPREV, LOVASTATIN
 ALTRENO, TRETINOIN
 ALUNBRIG, BRIGATINIB
 ALVESCO, CICLESONIDE
 ALVIMOPAN, ALVIMOPAN
 ALYACEN 1/35, ETHINYL ESTRADIOL
 ALYACEN 7/7/7, ETHINYL ESTRADIOL
 ALYQ, TADALAFIL
 AMABELZ, ESTRADIOL
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 AMARYL, GLIMEPIRIDE
 AMBIEN, ZOLPIDEM TARTRATE
 AMBIEN CR, ZOLPIDEM TARTRATE
 AMBISOME, AMPHOTERICIN B
 AMBRISENTAN, AMBRISENTAN
 AMCINONIDE, AMCINONIDE
 AMELUZ, AMINOLEVULINIC ACID HYDROCHLORIDE
 AMERGE, NARATRIPTAN HYDROCHLORIDE
 AMICAR, AMINOCAPROIC ACID
 AMIDATE, ETOMIDATE
 AMIFOSTINE, AMIFOSTINE
 AMIKACIN SULFATE, AMIKACIN SULFATE
 AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
 AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
 AMINO ACIDS, AMINO ACIDS
 AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER, GLYCINE
 AMINOCAPROIC ACID, AMINOCAPROIC ACID
 AMINOCAPROIC ACID IN PLASTIC CONTAINER, AMINOCAPROIC ACID
 AMINOPHYLLINE, AMINOPHYLLINE
 AMINOSYN II 10% IN PLASTIC CONTAINER, AMINO ACIDS
 AMINOSYN II 15% IN PLASTIC CONTAINER, AMINO ACIDS
 AMINOSYN-PF 10%, AMINO ACIDS
 AMINOSYN-PF 7%, AMINO ACIDS
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 AMITIZA, LUBIPROSTONE
 AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
 AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE

APPENDIX A - PRODUCT NAME INDEX**** A ****

AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
AMMONIA N 13, AMMONIA N-13
AMMONIUM CHLORIDE IN PLASTIC CONTAINER, AMMONIUM CHLORIDE
AMMONIUM LACTATE, AMMONIUM LACTATE
AMMONUL, SODIUM BENZOATE
AMNESTEEM, ISOTRETINOIN
AMOXAPINE, AMOXAPINE
AMOXICILLIN, AMOXICILLIN
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN PEDIATRIC, AMOXICILLIN
AMOXIL, AMOXICILLIN
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
AMPHOTERICIN B, AMPHOTERICIN B
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
AMPYRA, DALFAMPRIDINE
AMRINONE LACTATE, INAMRINONE LACTATE
AMRIX, CYCLOBENZAPRINE HYDROCHLORIDE
AMYVID, FLORBETAPIR F-18
AMZEEQ, MINOCYCLINE HYDROCHLORIDE
AN-SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID KIT
ANADROL-50, OXYMETHOLONE
ANAFRANIL, CLOMIPRAMINE HYDROCHLORIDE
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
ANAPROX DS, NAPROXEN SODIUM
ANASTROZOLE, ANASTROZOLE
ANCEF IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
ANCOBON, FLUCYTOSINE
ANDRODERM, TESTOSTERONE
ANDROGEL, TESTOSTERONE
ANDROID 25, METHYLTESTOSTERONE
ANECTINE, SUCCINYLCHOLINE CHLORIDE
ANEXSIA 5/325, ACETAMINOPHEN
ANEXSIA 7.5/325, ACETAMINOPHEN
ANGELIQ, DROSPIRENONE
ANGIOMAX, BIVALIRUDIN
ANGIOMAX RTU, BIVALIRUDIN
ANJESO, MELOXICAM
ANNOVERA, ETHINYL ESTRADIOL
ANORO ELLIPTA, UMECLIDINIUM BROMIDE
ANTABUSE, DISULFIRAM
ANTARA (MICRONIZED), FENOFIBRATE
ANTHELIOS 20, AVOBENZONE (OTC)
ANTHELIOS 40, AVOBENZONE (OTC)
ANTHELIOS SX, AVOBENZONE (OTC)
ANTIVERT, MECLIZINE HYDROCHLORIDE
ANUSOL HC, HYDROCORTISONE
APADAZ, ACETAMINOPHEN
APIXABAN, APIXABAN
APLENZIN, BUPROPION HYDROBROMIDE
APOKYN, APOMORPHINE HYDROCHLORIDE
APRACLONIDINE HYDROCHLORIDE, APRACLONIDINE HYDROCHLORIDE
APREPITANT, APREPITANT
APRISO, MESALAMINE
APTENSIO XR, METHYLPHENIDATE HYDROCHLORIDE
APTIOM, ESLICARBAZEPINE ACETATE
APTIVUS, TIPRANAVIR
AQUASOL A, VITAMIN A PALMITATE
ARAKODA, TAFENOQUINE SUCCINATE
ARANELLE, ETHINYL ESTRADIOL
ARAVA, LEFLUNOMIDE
ARAZLO, TAZAROTENE
ARESTIN, MINOCYCLINE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX**** A ****

ARGATROBAN, ARGATROBAN
ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
ARICEPT, DONEPEZIL HYDROCHLORIDE
ARIDOL KIT, MANNITOL
ARIKAYCE KIT, AMIKACIN SULFATE
ARIMIDEX, ANASTROZOLE
ARIPIPRAZOLE, ARIPIPRAZOLE
ARISTADA, ARIPIPRAZOLE LAUROXIL
ARISTADA INITIO KIT, ARIPIPRAZOLE LAUROXIL
ARISTOSPAN, TRIAMCINOLONE HEXACETONIDE
ARIXTRA, FONDAPARINUX SODIUM
ARMODAFINIL, ARMODAFINIL
ARMONAIR DIGIHALER, FLUTICASONE PROPIONATE
ARNUITY ELLIPTA, FLUTICASONE FUROATE
AROMASIN, EXEMESTANE
ARRANON, NELARABINE
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
ARTESUNATE, ARTESUNATE
ARTHROTEC, DICLOFENAC SODIUM
ASACOL HD, MESALAMINE
ASCLERA, POLIDOCANOL
ASCOR, ASCORBIC ACID
ASENAPINE MALEATE, ASENAPINE MALEATE
ASHLYNA, ETHINYL ESTRADIOL
ASMANEX HFA, MOMETASONE FUROATE
ASMANEX TWISTHALER, MOMETASONE FUROATE
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
ASTAGRAF XL, TACROLIMUS
ASTELIN, AZELASTINE HYDROCHLORIDE
ASTEPRO, AZELASTINE HYDROCHLORIDE
ATACAND, CANDESARTAN CILEXETIL
ATACAND HCT, CANDESARTAN CILEXETIL
ATAZANAVIR SULFATE, ATAZANAVIR SULFATE
ATELVIA, RISEDRONATE SODIUM
ATENOLOL, ATENOLOL
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATHENTIA NEXT, LEVONORGESTREL (OTC)
ATIVAN, LORAZEPAM
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
ATOVAQUONE, ATOVAQUONE
ATOVAQUONE AND PROGUANIL HYDROCHLORIDE, ATOVAQUONE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRALIN, TRETINOIN
ATRIDOX, DOXYCYCLINE HYCLATE
ATRIPLA, EFAVIRENZ
ATROPEN, ATROPINE
ATROPINE SULFATE, ATROPINE SULFATE
ATROVENT HFA, IPRATROPIUM BROMIDE
AUBAGIO, TERIFLUNOMIDE
AUGMENTIN '125', AMOXICILLIN
AUGMENTIN '250', AMOXICILLIN
AUGMENTIN '875', AMOXICILLIN
AUGMENTIN ES-600, AMOXICILLIN
AUROVELA 1.5/30, ETHINYL ESTRADIOL
AUROVELA 1/20, ETHINYL ESTRADIOL
AUROVELA 24 FE, ETHINYL ESTRADIOL
AUROVELA FE 1.5/30, ETHINYL ESTRADIOL
AUROVELA FE 1/20, ETHINYL ESTRADIOL
AURYXIA, FERRIC CITRATE
AUSTEDO, DEUTETRABENAZINE
AUVI-Q, EPINEPHRINE
AVAGARD, ALCOHOL (OTC)
AVAGE, TAZAROTENE

APPENDIX A - PRODUCT NAME INDEX**** A ****

AVALIDE, HYDROCHLOROTHIAZIDE
 AVANDIA, ROSIGLITAZONE MALEATE
 AVAPRO, IRBESARTAN
 AVEED, TESTOSTERONE UNDECANOATE
 AVIANE-28, ETHINYL ESTRADIOL
 AVITA, TRETINOIN
 AVODART, DUTASTERIDE
 AVYCAZ, AVIBACTAM SODIUM
 AXID AR, NIZATIDINE (OTC)
 AXUMIN, FLUCICLOVINE F-18
 AYUNA, ETHINYL ESTRADIOL
 AYVAKIT, AVAPRITINIB
 AZACITIDINE, AZACITIDINE
 AZACTAM, AZTREONAM
 AZASAN, AZATHIOPRINE
 AZASITE, AZITHROMYCIN
 AZATHIOPRINE, AZATHIOPRINE
 AZATHIOPRINE SODIUM, AZATHIOPRINE SODIUM
 AZEDRA, IOBENGUANE I-131
 AZELAIC ACID, AZELAIC ACID
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE, AZELASTINE HYDROCHLORIDE
 AZELEX, AZELAIC ACID
 AZILECT, RASAGILINE MESYLATE
 AZITHROMYCIN, AZITHROMYCIN
 AZOPT, BRINZOLAMIDE
 AZOR, AMLODIPINE BESYLATE
 AZTREONAM, AZTREONAM
 AZULFIDINE, SULFASALAZINE
 AZULFIDINE EN-TABS, SULFASALAZINE

**** B ****

BACITRACIN, BACITRACIN
 BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
 BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE, BACITRACIN ZINC
 BACLOFEN, BACLOFEN
 BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
 BACTOCILL IN PLASTIC CONTAINER, OXACILLIN SODIUM
 BACTRIM, SULFAMETHOXAZOLE
 BACTRIM DS, SULFAMETHOXAZOLE
 BAFIERTAM, MONOMETHYL FUMARATE
 BAL, DIMERCAPROL
 BALANCED SALT, CALCIUM CHLORIDE
 BALCOLTRA, ETHINYL ESTRADIOL
 BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
 BALVERSA, ERDAFITINIB
 BALZIVA-28, ETHINYL ESTRADIOL
 BANZEL, RUFINAMIDE
 BAQSIMI, GLUCAGON
 BARACLUDE, ENTECAVIR
 BARHEMSYS, AMISULPRIDE
 BAXDELA, DELAFLOXACIN MEGLUMINE
 BECONASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE
 BEKYREE, DESOGESTREL
 BELBUCA, BUPRENORPHINE HYDROCHLORIDE
 BELEODAQ, BELINOSTAT
 BELRAPZO, BENDAMUSTINE HYDROCHLORIDE
 BELSOMRA, SUVOREXANT
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
 BENDEKA, BENDAMUSTINE HYDROCHLORIDE
 BENICAR, OLMESARTAN MEDOXOMIL
 BENICAR HCT, HYDROCHLOROTHIAZIDE
 BENTYL, DICYCLOMINE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

** B **

BENTYL PRESERVATIVE FREE, DICYCLOMINE HYDROCHLORIDE
BENZAFLIN, BENZOYL PEROXIDE
BENZAMYCIN, BENZOYL PEROXIDE
BENZNIDAZOLE, BENZNIDAZOLE
BENZONATATE, BENZONATATE
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BEPREVE, BEPOTASTINE BESILATE
BESIVANCE, BESIFLOXACIN HYDROCHLORIDE
BETA-VAL, BETAMETHASONE VALERATE
BETADINE, POVIDONE-IODINE
BETAGAN, LEVOBUNOLOL HYDROCHLORIDE
BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE ACETATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
BETAPACE, SOTALOL HYDROCHLORIDE
BETAPACE AF, SOTALOL HYDROCHLORIDE
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BETHKIS, TOBRAMYCIN
BETIMOL, TIMOLOL
BETOPTIC, BETAXOLOL HYDROCHLORIDE
BETOPTIC S, BETAXOLOL HYDROCHLORIDE
BEVESPI AEROSPHERE, FORMOTEROL FUMARATE
BEXAROTENE, BEXAROTENE
BEYAZ, DROSPIRENONE
BICALUTAMIDE, BICALUTAMIDE
BICILLIN C-R, PENICILLIN G BENZATHINE
BICILLIN C-R 900/300, PENICILLIN G BENZATHINE
BICILLIN L-A, PENICILLIN G BENZATHINE
BICNU, CARMUSTINE
BIDIL, HYDRALAZINE HYDROCHLORIDE
BIJUVA, ESTRADIOL
BIKTARVY, BICTEGRAVIR SODIUM
BILTRICIDE, PRAZIQUANTEL
BIMATOPROST, BIMATOPROST
BINOSTO, ALENDRONATE SODIUM
BIORPHEN, PHENYLEPHRINE HYDROCHLORIDE
BIOSCRUB, CHLORHEXIDINE GLUCONATE (OTC)
BISMUTH SUBSALICYLATE, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE, BISMUTH SUBSALICYLATE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BIVALIRUDIN, BIVALIRUDIN
BIVALIRUDIN IN 0.9% SODIUM CHLORIDE, BIVALIRUDIN
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BLEPH-10, SULFACETAMIDE SODIUM
BLEPHAMIDE, PREDNISOLONE ACETATE
BLEPHAMIDE S.O.P., PREDNISOLONE ACETATE
BLISOVI 24 FE, ETHINYL ESTRADIOL
BLISOVI FE 1.5/30, ETHINYL ESTRADIOL
BLISOVI FE 1/20, ETHINYL ESTRADIOL
BLOXIVERZ, NEOSTIGMINE METHYLSULFATE
BONIVA, IBANDRONATE SODIUM
BONJESTA, DOXYLAMINE SUCCINATE
BONSITY, TERIPARATIDE
BONTRIL PDM, PHENDIMETRAZINE TARTRATE
BORTEZOMIB, BORTEZOMIB
BOSENTAN, BOSENTAN
BOSULIF, BOSUTINIB MONOHYDRATE
BRAFTOVI, ENCORAFENIB
BREO ELLIPTA, FLUTICASONE FUROATE
BRETHINE, TERBUTALINE SULFATE
BRETILIUM TOSYLATE, BRETILIUM TOSYLATE
BREVIBLOC, ESMOLOL HYDROCHLORIDE
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX**** B ****

BREVIBLOC IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
 BREVITAL SODIUM, METHOHEXITAL SODIUM
 BREZTRI AEROSPHERE, BUDESONIDE
 BRIAN CARE, CHLORHEXIDINE GLUCONATE (OTC)
 BRIDION, SUGAMMADEX SODIUM
 BRIELLYN, ETHINYL ESTRADIOL
 BRILINTA, TICAGRELOR
 BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
 BRINZOLAMIDE, BRINZOLAMIDE
 BRISDELLE, PAROXETINE MESYLATE
 BRIVIACT, BRIVARACETAM
 BROMFED-DM, BROMPHENIRAMINE MALEATE
 BROMFENAC SODIUM, BROMFENAC SODIUM
 BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
 BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE,
 BROMSITE, BROMFENAC SODIUM
 BRONCHITOL, MANNITOL
 BRONCHO SALINE, SODIUM CHLORIDE (OTC)
 BROVANA, ARFORMOTEROL TARTRATE
 BRUKINSA, ZANUBRUTINIB
 BRYHALI, HALOBETASOL PROPIONATE
 BSS, CALCIUM CHLORIDE
 BSS PLUS, CALCIUM CHLORIDE
 BUDESONIDE, BUDESONIDE (OTC)
 BUDESONIDE, BUDESONIDE
 BUMETANIDE, BUMETANIDE
 BUMEX, BUMETANIDE
 BUPHENYL, SODIUM PHENYLBUTYRATE
 BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
 BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
 BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
 BUPRENEX, BUPRENORPHINE HYDROCHLORIDE
 BUPRENORPHINE, BUPRENORPHINE
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 BUSULFAN, BUSULFAN
 BUSULFEX, BUSULFAN
 BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
 BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
 BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
 BUTAPAP, ACETAMINOPHEN
 BUTENAFINE HYDROCHLORIDE, BUTENAFINE HYDROCHLORIDE (OTC)
 BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
 BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
 BUTRANS, BUPRENORPHINE
 BYDUREON, EXENATIDE SYNTHETIC
 BYDUREON BCISE, EXENATIDE
 BYDUREON PEN, EXENATIDE SYNTHETIC
 BYETTA, EXENATIDE SYNTHETIC
 BYFAVO, REMIMAZOLAM BESYLATE
 BYNFEZIA PEN, OCTREOTIDE ACETATE
 BYSTOLIC, NEBIVOLOL HYDROCHLORIDE

**** C ****

CABERGOLINE, CABERGOLINE
 CABOMETYX, CABOZANTINIB S-MALATE
 CADUET, AMLODIPINE BESYLATE
 CAFKIT, CAFFEINE CITRATE
 CAFERGOT, CAFFEINE
 CAFFEINE CITRATE, CAFFEINE CITRATE
 CALAN SR, VERAPAMIL HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

** C **

CALCIPOTRIENE, CALCIPOTRIENE
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCITONIN-SALMON, CALCITONIN SALMON
CALCITRIOL, CALCITRIOL
CALCIUM ACETATE, CALCIUM ACETATE
CALCIUM CHLORIDE 10%, CALCIUM CHLORIDE
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CALCIUM DISODIUM VERSENATE, EDETATE CALCIUM DISODIUM
CALCIUM GLUCONATE, CALCIUM GLUCONATE
CALCIUM GLUCONATE IN SODIUM CHLORIDE, CALCIUM GLUCONATE
CALDOLOR, IBUPROFEN
CALQUENCE, ACALABRUTINIB
CAMBIA, DICLOFENAC POTASSIUM
CAMILA, NORETHINDRONE
CAMPTOSAR, IRINOTECAN HYDROCHLORIDE
CANASA, MESALAMINE
CANCIDAS, CASPOFUNGIN ACETATE
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
CAPASTAT SULFATE, CAPREOMYCIN SULFATE
CAPECITABINE, CAPECITABINE
CAPEX, FLUOCINOLONE ACETONIDE
CAPITAL SOLEIL 15, AVOBENZONE (OTC)
CAPLYTA, LUMATEPERONE TOSYLATE
CAPRELSA, VANDETANIB
CAPTOPRIL, CAPTOPRIL
CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
CARAC, FLUOROURACIL
CARAFATE, SUCRALFATE
CARBAGLU, CARGLUMIC ACID
CARBAMAZEPINE, CARBAMAZEPINE
CARBATROL, CARBAMAZEPINE
CARBIDOPA, CARBIDOPA
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARBIDOPA, LEVODOPA AND ENTACAPONE, CARBIDOPA
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
CARBOCAINE, MEPIVACAINE HYDROCHLORIDE
CARBOPLATIN, CARBOPLATIN
CARBOPROST TROMETHAMINE, CARBOPROST TROMETHAMINE
CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDIOGEN-82, RUBIDIUM CHLORIDE RB-82
CARDIOLITE, TECHNETIUM TC-99M SESTAMIBI KIT
CARDIOPLEGIC IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CARDIZEM, DILTIAZEM HYDROCHLORIDE
CARDIZEM CD, DILTIAZEM HYDROCHLORIDE
CARDIZEM LA, DILTIAZEM HYDROCHLORIDE
CARDURA, DOXAZOSIN MESYLATE
CARDURA XL, DOXAZOSIN MESYLATE
CARFILZOMIB, CARFILZOMIB
CARISOPRODOL, CARISOPRODOL
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN
CARMUSTINE, CARMUSTINE
CARNITOR, LEVOCARNITINE
CARNITOR SF, LEVOCARNITINE
CAROSPIR, SPIRONOLACTONE
CARTEOLOL HYDROCHLORIDE, CARTEOLOL HYDROCHLORIDE
CARTIA XT, DILTIAZEM HYDROCHLORIDE
CARVEDILOL, CARVEDILOL
CARVEDILOL PHOSPHATE, CARVEDILOL PHOSPHATE
CASODEX, BICALUTAMIDE
CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
CASPORYN HC, HYDROCORTISONE

APPENDIX A - PRODUCT NAME INDEX

** C **

CATAPRES, CLONIDINE HYDROCHLORIDE
CATAPRES-TTS-1, CLONIDINE
CATAPRES-TTS-2, CLONIDINE
CATAPRES-TTS-3, CLONIDINE
CAVERJECT, ALPROSTADIL
CAVERJECT IMPULSE, ALPROSTADIL
CAYSTON, AZTREONAM
CEFACLOR, CEFACLOR
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFAZOLIN AND DEXTROSE, CEFAZOLIN SODIUM
CEFAZOLIN IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFDINIR, CEFDINIR
CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER, CEFEPIME HYDROCHLORIDE
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE
CEFEPIME IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE
CEFIXIME, CEFIXIME
CEFOTAN, CEFOTETAN DISODIUM
CEFOTAXIME, CEFOTAXIME SODIUM
CEFOTETAN, CEFOTETAN DISODIUM
CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER, CEFOTETAN DISODIUM
CEFOXITIN, CEFOXITIN SODIUM
CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER, CEFOXITIN SODIUM
CEFOXITIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFPROZIL, CEFPROZIL
CEFTAZIDIME, CEFTAZIDIME
CEFTAZIDIME IN DEXTROSE CONTAINER, CEFTAZIDIME
CEFTRIAXONE, CEFTRIAXONE SODIUM
CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER, CEFTRIAXONE SODIUM
CEFTRIAXONE IN PLASTIC CONTAINER, CEFTRIAXONE SODIUM
CEFTRIAXONE SODIUM, CEFTRIAXONE SODIUM
CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER, CEFUROXIME SODIUM
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEFUROXIME SODIUM, CEFUROXIME SODIUM
CELEBREX, CELECOXIB
CELECOXIB, CELECOXIB
CELESTONE SOLUSPAN, BETAMETHASONE ACETATE
CELEXA, CITALOPRAM HYDROBROMIDE
CELLCEPT, MYCOPHENOLATE MOFETIL
CELLCEPT, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
CELONTIN, METHSUXIMIDE
CENTANY, MUPIROCIN
CEPHALEXIN, CEPHALEXIN
CEQUA, CYCLOSPORINE
CERDELGA, ELIGLUSTAT TARTRATE
CEREBYX, FOSPHENYTOIN SODIUM
CERETEC, TECHNETIUM TC-99M EXAMETAZIME KIT
CERIANNA, FLUOROESTRADIOL F-18
CERINTA, ETHINYL ESTRADIOL
CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE
CERVIDIL, DINOPROSTONE
CESAMET, NABILONE
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CETRAXAL, CIPROFLOXACIN HYDROCHLORIDE
CETROTIDE, CETRORELIX
CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
CHABELINA FE, ETHINYL ESTRADIOL
CHANTIX, VARENICLINE TARTRATE

APPENDIX A - PRODUCT NAME INDEX

** C **

CHEMET, SUCCIMER
 CHENODIOL, CHENODIOL
 CHG SCRUB, CHLORHEXIDINE GLUCONATE (OTC)
 CHILDREN'S ADVIL, IBUPROFEN (OTC)
 CHILDREN'S ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
 CHILDREN'S ADVIL COLD, IBUPROFEN (OTC)
 CHILDREN'S ADVIL-FLAVORED, IBUPROFEN (OTC)
 CHILDREN'S ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CLARITIN, LORATADINE (OTC)
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHILDREN'S IBUPROFEN, IBUPROFEN (OTC)
 CHILDREN'S MOTRIN, IBUPROFEN (OTC)
 CHILDREN'S MOTRIN COLD, IBUPROFEN (OTC)
 CHILDREN'S ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CHIRHOSTIM, SECRETIN SYNTHETIC HUMAN
 CHLORAMPHENICOL SODIUM SUCCINATE, CHLORAMPHENICOL SODIUM SUCCINATE
 CHLORAPREP ONE-STEP, CHLORHEXIDINE GLUCONATE (OTC)
 CHLORAPREP ONE-STEP FREPP, CHLORHEXIDINE GLUCONATE (OTC)
 CHLORAPREP ONE-STEP SEPP, CHLORHEXIDINE GLUCONATE (OTC)
 CHLORAPREP SINGLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
 CHLORAPREP TRIPLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
 CHLORAPREP WITH TINT, CHLORHEXIDINE GLUCONATE (OTC)
 CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
 CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
 CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)
 CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
 CHLOROPROCAINE HYDROCHLORIDE, CHLOROPROCAINE HYDROCHLORIDE
 CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
 CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
 CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
 CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
 CHLORTHALIDONE, CHLORTHALIDONE
 CHLORZOXAZONE, CHLORZOXAZONE
 CHOLAC, LACTULOSE
 CHOLBAM, CHOLIC ACID
 CHOLESTYRAMINE, CHOLESTYRAMINE
 CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
 CHOLETEC, TECHNETIUM TC-99M MEBROFENIN KIT
 CHOLINE C-11, CHOLINE C-11
 CHROMIC CHLORIDE IN PLASTIC CONTAINER, CHROMIC CHLORIDE
 CIALIS, TADALAFIL
 CICLOPIROX, CICLOPIROX
 CIDA-STAT, CHLORHEXIDINE GLUCONATE (OTC)
 CIDOFOVIR, CIDOFOVIR
 CILOSTAZOL, CILOSTAZOL
 CILOXAN, CIPROFLOXACIN HYDROCHLORIDE
 CIMDUO, LAMIVUDINE
 CIMETIDINE, CIMETIDINE (OTC)
 CIMETIDINE, CIMETIDINE
 CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
 CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
 CINVANTI, APREPITANT
 CIPRO, CIPROFLOXACIN
 CIPRO, CIPROFLOXACIN HYDROCHLORIDE
 CIPRO HC, CIPROFLOXACIN HYDROCHLORIDE
 CIPRODEX, CIPROFLOXACIN
 CIPROFLOXACIN, CIPROFLOXACIN
 CIPROFLOXACIN AND DEXAMETHASONE, CIPROFLOXACIN
 CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

** C **

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
 CIS-MDP, TECHNETIUM TC-99M MEDRONATE KIT
 CIS-PYRO, TECHNETIUM TC-99M PYROPHOSPHATE KIT
 CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
 CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
 CISPLATIN, CISPLATIN
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 CITANEST FORTE DENTAL, EPINEPHRINE BITARTRATE
 CLADRIBINE, CLADRIBINE
 CLARAVIS, ISOTRETINOIN
 CLARINEX, DESLORATADINE
 CLARINEX-D 12 HOUR, DESLORATADINE
 CLARISCAN, GADOTERATE MEGLUMINE
 CLARITHROMYCIN, CLARITHROMYCIN
 CLARITIN, LORATADINE (OTC)
 CLARITIN HIVES RELIEF, LORATADINE (OTC)
 CLARITIN HIVES RELIEF REDITAB, LORATADINE (OTC)
 CLARITIN REDITABS, LORATADINE (OTC)
 CLARITIN-D, LORATADINE (OTC)
 CLARITIN-D 24 HOUR, LORATADINE (OTC)
 CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)
 CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
 CLENPIQ, CITRIC ACID
 CLEOCIN, CLINDAMYCIN PALMITATE HYDROCHLORIDE
 CLEOCIN, CLINDAMYCIN PHOSPHATE
 CLEOCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 CLEOCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CLEOCIN T, CLINDAMYCIN PHOSPHATE
 CLEVIPREX, CLEVIDIPINE
 CLIMARA, ESTRADIOL
 CLIMARA PRO, ESTRADIOL
 CLINDA-DERM, CLINDAMYCIN PHOSPHATE
 CLINDAGEL, CLINDAMYCIN PHOSPHATE
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
 CLINDAMYCIN PHOSPHATE AND TRETINOIN, CLINDAMYCIN PHOSPHATE
 CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE, CLINDAMYCIN PHOSPHATE
 CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
 CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%, CLINDAMYCIN PHOSPHATE
 CLINDESSE, CLINDAMYCIN PHOSPHATE
 CLINDETS, CLINDAMYCIN PHOSPHATE
 CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER,

APPENDIX A - PRODUCT NAME INDEX**** C ****

CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER,
CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
CLINOLIPID 20%, OLIVE OIL
CLOBAZAM, CLOBAZAM
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
CLOBEX, CLOBETASOL PROPIONATE
CLODERM, CLOCORTOLONE PIVALATE
CLOFARABINE, CLOFARABINE
CLOLAR, CLOFARABINE
CLOMIPHENE CITRATE, CLOMIPHENE CITRATE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CLONIDINE, CLONIDINE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CLOROTEKAL, CHLOROPROCAINE HYDROCHLORIDE
CLOTTRIMAZOLE, CLOTTRIMAZOLE (OTC)
CLOTTRIMAZOLE, CLOTTRIMAZOLE
CLOTTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOVIQUE, TRIENTINE HYDROCHLORIDE
CLOZAPINE, CLOZAPINE
CLOZARIL, CLOZAPINE
COARTEM, ARTEMETHER
CODEINE SULFATE, CODEINE SULFATE
COGENTIN, BENZTROPINE MESYLATE
COL-PROBENECID, COLCHICINE
COLAZAL, BALSALAZIDE DISODIUM
COLCHICINE, COLCHICINE
COLCRYS, COLCHICINE
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
COLESTID, COLESTIPOL HYDROCHLORIDE
COLESTIPOL HYDROCHLORIDE, COLESTIPOL HYDROCHLORIDE
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
COLOCORT, HYDROCORTISONE
COLY-MYCIN M, COLISTIMETHATE SODIUM
COLY-MYCIN S, COLISTIN SULFATE
COLYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
COMBIGAN, BRIMONIDINE TARTRATE
COMBIPATCH, ESTRADIOL
COMBIVENT RESPIMAT, ALBUTEROL SULFATE
COMBIVIR, LAMIVUDINE
COMETRIQ, CABOZANTINIB S-MALATE
COMPLERA, EMTRICITABINE
COMPRO, PROCHLORPERAZINE
COMTAN, ENTACAPONE
CONCERTA, METHYLPHENIDATE HYDROCHLORIDE
CONDYLOX, PODOFILOX
CONJUPRI, LEVAMLODIPINE MALEATE
CONRAY, IOTHALAMATE MEGLUMINE
CONSENSI, AMLODIPINE BESYLATE
CONSTILAC, LACTULOSE
CONTRAVE, BUPROPION HYDROCHLORIDE
CONZIP, TRAMADOL HYDROCHLORIDE
COPAXONE, GLATIRAMER ACETATE
COPIKTRA, DUVELISIB
CORDRAN, FLURANDRENOLIDE
CORDRAN SP, FLURANDRENOLIDE
COREG, CARVEDILOL
COREG CR, CARVEDILOL PHOSPHATE
CORGARD, NADOLOL
CORLANOR, IVABRADINE
CORLANOR, IVABRADINE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

** C **

CORLOPAM, FENOLDOPAM MESYLATE
 CORMAX, CLOBETASOL PROPIONATE
 CORPHEDRA, EPHEDRINE SULFATE
 CORTEF, HYDROCORTISONE
 CORTENEMA, HYDROCORTISONE
 CORTIFOAM, HYDROCORTISONE ACETATE
 CORTISONE ACETATE, CORTISONE ACETATE
 CORTISPORIN, BACITRACIN ZINC
 CORTISPORIN, HYDROCORTISONE ACETATE
 CORTROSYN, COSYNTROPIN
 CORVERT, IBUTILIDE FUMARATE
 CORZIDE, BENDROFLUMETHIAZIDE
 COSMEGEN, DACTINOMYCIN
 COSOPT, DORZOLAMIDE HYDROCHLORIDE
 COSOPT PF, DORZOLAMIDE HYDROCHLORIDE
 COSYNTROPIN, COSYNTROPIN
 COTELLIC, COBIMETINIB FUMARATE
 COTEMPLA XR-ODT, METHYLPHENIDATE
 COZAAR, LOSARTAN POTASSIUM
 CRESEMBA, ISAVUCONAZONIUM SULFATE
 CRESTOR, ROSUVASTATIN CALCIUM
 CRINONE, PROGESTERONE
 CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
 CROMOLYN SODIUM, CROMOLYN SODIUM
 CROTAN, CROTAMITON
 CRYSELLE, ETHINYL ESTRADIOL
 CUBICIN, DAPTOMYCIN
 CUBICIN RF, DAPTOMYCIN
 CUPRIC CHLORIDE IN PLASTIC CONTAINER, CUPRIC CHLORIDE
 CUPRIMINE, PENICILLAMINE
 CUTIVATE, FLUTICASONE PROPIONATE
 CUVPOSA, GLYCOPYRROLATE
 CYANOCOBALAMIN, CYANOCOBALAMIN
 CYANOKIT, HYDROXOCOBALAMIN
 CYCLAFEM 1/35, ETHINYL ESTRADIOL
 CYCLAFEM 7/7/7, ETHINYL ESTRADIOL
 CYCLESSA, DESOGESTREL
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 CYCLOGYL, CYCLOPENTOLATE HYDROCHLORIDE
 CYCLOMYDRIL, CYCLOPENTOLATE HYDROCHLORIDE
 CYCLOPENTOLATE HYDROCHLORIDE, CYCLOPENTOLATE HYDROCHLORIDE
 CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
 CYCLOSET, BROMOCRIPTINE MESYLATE
 CYCLOSPORINE, CYCLOSPORINE
 CYKLOKAPRON, TRANEXAMIC ACID
 CYMBALTA, DULOXETINE HYDROCHLORIDE
 CYONANZ, ETHINYL ESTRADIOL
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
 CYSTADANE, BETAINE
 CYSTADROPS, CYSTEAMINE HYDROCHLORIDE
 CYSTAGON, CYSTEAMINE BITARTRATE
 CYSTARAN, CYSTEAMINE HYDROCHLORIDE
 CYSTO-CONRAY II, IOTHALAMATE MEGLUMINE
 CYSTOGRAFIN, DIATRIZOATE MEGLUMINE
 CYSTOGRAFIN DILUTE, DIATRIZOATE MEGLUMINE
 CYSVIEW KIT, HEXAMINOLEVULINATE HYDROCHLORIDE
 CYTARABINE, CYTARABINE
 CYTOMEL, LIOTHYRONINE SODIUM
 CYTOTEC, MISOPROSTOL
 CYTOVENE, GANCICLOVIR SODIUM
 CYTOXAN, CYCLOPHOSPHAMIDE

** D **

D.H.E. 45, DIHYDROERGOTAMINE MESYLATE
 DABIGATRAN ETEXILATE MESYLATE, DABIGATRAN ETEXILATE MESYLATE

APPENDIX A - PRODUCT NAME INDEX

** D **

DACARBAZINE, DACARBAZINE
 DACOGEN, DECITABINE
 DACTINOMYCIN, DACTINOMYCIN
 DALFAMPRIDINE, DALFAMPRIDINE
 DALIRESP, ROFLUMILAST
 DALVANCE, DALBAVANCIN HYDROCHLORIDE
 DANAZOL, DANAZOL
 DANTRIUM, DANTROLENE SODIUM
 DANTROLENE SODIUM, DANTROLENE SODIUM
 DAPSONE, DAPSONE
 DAPTOMYCIN, DAPTOMYCIN
 DARAPRIM, PYRIMETHAMINE
 DARIFENACIN, DARIFENACIN HYDROBROMIDE
 DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
 DARUNAVIR, DARUNAVIR
 DASETTA 1/35, ETHINYL ESTRADIOL
 DASETTA 7/7/7, ETHINYL ESTRADIOL
 DATSCAN, IOFLUPANE I-123
 DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
 DAURISMO, GLASDEGIB MALEATE
 DAYPRO, OXAPROZIN
 DAYSEE, ETHINYL ESTRADIOL
 DAYTRANA, METHYLPHENIDATE
 DAYVIGO, LEMBOREXANT
 DDAVP, DESMOPRESSIN ACETATE
 DECITABINE, DECITABINE
 DEFERASIROX, DEFERASIROX
 DEFERIPRONE, DEFERIPRONE
 DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
 DEFINITY, PERFLUTREN
 DEFINITY RT, PERFLUTREN
 DEFITELIO, DEFIBROTIDE SODIUM
 DELESTROGEN, ESTRADIOL VALERATE
 DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELSTRIGO, DORAVIRINE
 DELSYM, DEXTROMETHORPHAN POLISTIREX (OTC)
 DELZICOL, MESALAMINE
 DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
 DEMEROL, MEPERIDINE HYDROCHLORIDE
 DEMSER, METYROSINE
 DENAVIR, PENCICLOVIR
 DEPAKOTE, DIVALPROEX SODIUM
 DEPAKOTE ER, DIVALPROEX SODIUM
 DEPEN, PENICILLAMINE
 DEPO-ESTRADIOL, ESTRADIOL CYPIONATE
 DEPO-MEDROL, METHYLPREDNISOLONE ACETATE
 DEPO-PROVERA, MEDROXYPROGESTERONE ACETATE
 DEPO-SUBQ PROVERA 104, MEDROXYPROGESTERONE ACETATE
 DEPO-TESTOSTERONE, TESTOSTERONE CYPIONATE
 DERMA-SMOOTH/FS, FLUOCINOLONE ACETONIDE
 DERMABET, BETAMETHASONE VALERATE
 DERMOTIC, FLUOCINOLONE ACETONIDE
 DESCOVY, EMTRICITABINE
 DESFERAL, DEFEROXAMINE MESYLATE
 DESFLURANE, DESFLURANE
 DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
 DESLORATADINE, DESLORATADINE

APPENDIX A - PRODUCT NAME INDEX

** D **

DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR, DESLORATADINE
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
 DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
 DESONATE, DESONIDE
 DESONIDE, DESONIDE
 DESOWEN, DESONIDE
 DESOXIMETASONE, DESOXIMETASONE
 DESOXYN, METHAMPHETAMINE HYDROCHLORIDE
 DESVENLAFAXINE, DESVENLAFAXINE
 DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
 DETECTNET, COPPER DOTATATE CU-64
 DETROL, TOLTERODINE TARTRATE
 DETROL LA, TOLTERODINE TARTRATE
 DEXAMETHASONE, DEXAMETHASONE
 DEXAMETHASONE INTENSOL, DEXAMETHASONE
 DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
 DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE, DEXAMETHASONE SODIUM PHOSPHATE
 DEXASPORIN, DEXAMETHASONE
 DEXCHLORPHENIRAMINE MALEATE, DEXCHLORPHENIRAMINE MALEATE
 DEXEDRINE, DEXTROAMPHETAMINE SULFATE
 DEXILANT, DEXLANSOPRAZOLE
 DEXLANSOPRAZOLE, DEXLANSOPRAZOLE
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
 DEXTENZA, DEXAMETHASONE
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE, DEXTROMETHORPHAN HYDROBROMIDE
 DEXTROMETHORPHAN POLISTIREX, DEXTROMETHORPHAN POLISTIREX (OTC)
 DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 25%, DEXTROSE
 DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075%, DEXTROSE
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15%, DEXTROSE
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.225%, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.45%, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.9%, DEXTROSE

APPENDIX A - PRODUCT NAME INDEX

** D **

DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER,
DEXTROSE 50%, DEXTROSE
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
DEXYCU KIT, DEXAMETHASONE
DIABETA, GLYBURIDE
DIACOMIT, STIRIPENTOL
DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIASTAT, DIAZEPAM
DIASTAT ACUDIAL, DIAZEPAM
DIAZEPAM, DIAZEPAM
DIAZEPAM INTENSOL, DIAZEPAM
DIAZOXIDE, DIAZOXIDE
DIBENZYLINE, PHENOXYBENZAMINE HYDROCHLORIDE
DICLEGIS, DOXYLAMINE SUCCINATE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM (OTC)
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE), DICYCLOMINE HYDROCHLORIDE
DIDANOSINE, DIDANOSINE
DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
DIFFERIN, ADAPALENE (OTC)
DIFFERIN, ADAPALENE
DIFICID, FIDAXOMICIN
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
DIFLUCAN, FLUCONAZOLE
DIFLUNISAL, DIFLUNISAL
DIGOXIN, DIGOXIN
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
DILANTIN, PHENYTOIN
DILANTIN, PHENYTOIN SODIUM
DILANTIN-125, PHENYTOIN

APPENDIX A - PRODUCT NAME INDEX**** D ****

DILAUDID, HYDROMORPHONE HYDROCHLORIDE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIMENHYDRINATE, DIMENHYDRINATE
DIMETHYL FUMARATE, DIMETHYL FUMARATE
DIOVAN, VALSARTAN
DIOVAN HCT, HYDROCHLOROTHIAZIDE
DIPENTUM, OLSALAZINE SODIUM
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DIPRIVAN, PROPOFOL
DIPROLENE, BETAMETHASONE DIPROPIONATE
DIPYRIDAMOLE, DIPYRIDAMOLE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DISULFIRAM, DISULFIRAM
DITROPAN XL, OXYBUTYNIN CHLORIDE
DIURIL, CHLOROTHIAZIDE
DIURIL, CHLOROTHIAZIDE SODIUM
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DIVIGEL, ESTRADIOL
DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
DOCETAXEL, DOCETAXEL
DOCOSANOL, DOCOSANOL (OTC)
DOFETILDE, DOFETILIDE
DOFETILIDE, DOFETILIDE
DOJOLVI, TRIHEPTANOIN
DOLISHALE, ETHINYL ESTRADIOL
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPRAM, DOXAPRAM HYDROCHLORIDE
DOPTelet, AVATROMBOPAG MALEATE
DORAL, QUAZEPAM
DORYX, DOXYCYCLINE HYCLATE
DORYX MPC, DOXYCYCLINE HYCLATE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DOTAREM, GADOTERATE MEGLUMINE
DOVATO, DOLUTEGRAVIR SODIUM
DOVONEX, CALCIPOTRIENE
DOXAPRAM HYDROCHLORIDE, DOXAPRAM HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXERCALCIFEROL, DOXERCALCIFEROL
DOXIL (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
DOXY 100, DOXYCYCLINE HYCLATE
DOXY 200, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
DOXYCYCLINE, DOXYCYCLINE HYCLATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE, DOXYLAMINE SUCCINATE
DRAX EXAMETAZIME, TECHNETIUM TC-99M EXAMETAZIME KIT
DRAXIMAGE DTPA, TECHNETIUM TC-99M PENTETATE KIT
DRAXIMAGE MDP-25, TECHNETIUM TC-99M MEDRONATE
DRISDOL, ERGOCALCIFEROL
DRIZALMA SPRINKLE, DULOXETINE HYDROCHLORIDE
DRONABINOL, DRONABINOL
DROPERIDOL, DROPERIDOL
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE

APPENDIX A - PRODUCT NAME INDEX**** D ****

DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM, DROSPIRENONE
DROXIA, HYDROXYUREA
DSUVIA, SUFENTANIL CITRATE
DUAC, BENZOYL PEROXIDE
DUAKLIR PRESSAIR, ACLIDINIUM BROMIDE
DUAVEE, BAZEDOXIFENE ACETATE
DUETACT, GLIMEPIRIDE
DUEXIS, FAMOTIDINE
DULERA, FORMOTEROL FUMARATE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
DUOBRII, HALOBETASOL PROPIONATE
DUODOTE, ATROPINE
DUOPA, CARBIDOPA
DURACLON, CLONIDINE HYDROCHLORIDE
DURAGESIC-100, FENTANYL
DURAGESIC-12, FENTANYL
DURAGESIC-25, FENTANYL
DURAGESIC-37, FENTANYL
DURAGESIC-50, FENTANYL
DURAGESIC-75, FENTANYL
DURAMORPH PF, MORPHINE SULFATE
DURAPREP, IODINE POVACRYLEX (OTC)
DUREZOL, DIFLUPREDNATE
DURLAZA, ASPIRIN
DURYSTA, BIMATOPROST
DUTASTERIDE, DUTASTERIDE
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, DUTASTERIDE
DUTOPROL, HYDROCHLOROTHIAZIDE
DUVOID, BETHANECHOL CHLORIDE
DYANAVEL XR, AMPHETAMINE
DYCLOPRO, DYCLONINE HYDROCHLORIDE
DYMISTA, AZELASTINE HYDROCHLORIDE
DYNACIN, MINOCYCLINE HYDROCHLORIDE
DYRENIUM, TRIAMTERENE

**** E ****

E-Z SCRUB 201, POVIDONE-IODINE (OTC)
E-Z SCRUB 241, POVIDONE-IODINE (OTC)
E-Z-HD, BARIUM SULFATE
E-Z-PAQUE, BARIUM SULFATE
E.E.S., ERYTHROMYCIN ETHYLSUCCINATE
E.E.S. 400, ERYTHROMYCIN ETHYLSUCCINATE
EC-NAPROSYN, NAPROXEN
ECONAZOLE NITRATE, ECONAZOLE NITRATE
ECOZA, ECONAZOLE NITRATE
EDARBI, AZILSARTAN KAMEDOXOMIL
EDARBYCLOR, AZILSARTAN KAMEDOXOMIL
EDECRIN, ETHACRYNATE SODIUM
EDECRIN, ETHACRYNIC ACID
EDEX, ALPROSTADIL
EDLUAR, ZOLPIDEM TARTRATE
EDURANT, RILPIVIRINE HYDROCHLORIDE
EFAVIRENZ, EFAVIRENZ
EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ
EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ
EFFEXOR XR, VENLAFAXINE HYDROCHLORIDE
EFFIENT, PRASUGREL HYDROCHLORIDE
EFINACONAZOLE, EFINACONAZOLE
EFUDEX, FLUOROURACIL
EGATEN, TRICLABENDAZOLE
ELCYS, CYSTEINE HYDROCHLORIDE
ELEPSIA XR, LEVETIRACETAM
ELESTAT, EPINASTINE HYDROCHLORIDE
ELESTRIN, ESTRADIOL
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE

APPENDIX A - PRODUCT NAME INDEX

** E **

ELIDEL, PIMECROLIMUS
ELIGARD KIT, LEUPROLIDE ACETATE
ELINEST, ETHINYL ESTRADIOL
ELIQUIS, APIXABAN
ELIXOPHYLLIN, THEOPHYLLINE
ELLA, ULIPRISTAL ACETATE
ELLENCEN, EPIRUBICIN HYDROCHLORIDE
ELLIOTTS B SOLUTION, CALCIUM CHLORIDE
ELMIRON, PENTOSAN POLYSULFATE SODIUM
ELOCON, MOMETASONE FUROATE
ELOXATIN, OXALIPLATIN
ELURYNG, ETHINYL ESTRADIOL
EMBELINE, CLOBETASOL PROPIONATE
EMBELINE E, CLOBETASOL PROPIONATE
EMCYT, ESTRAMUSTINE PHOSPHATE SODIUM
EMEND, APREPITANT
EMEND, FOSAPREPITANT DIMEGLUMINE
EMERPHED, EPHEDRINE SULFATE
EMFLAZA, DEFLAZACORT
EMLA, LIDOCAINE
EMSAM, SELEGILINE
EMTRICITABINE, EMTRICITABINE
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
EMTRIVA, EMTRICITABINE
EMVERM, MEBENDAZOLE
ENABLEX, DARIFENACIN HYDROBROMIDE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ENALAPRILAT, ENALAPRILAT
ENDARI, L-GLUTAMINE
ENDOMETRIN, PROGESTERONE
ENOXAPARIN SODIUM, ENOXAPARIN SODIUM
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
ENPRESSE-28, ETHINYL ESTRADIOL
ENSKYCE, DESOGESTREL
ENSTILAR, BETAMETHASONE DIPROPIONATE
ENTACAPONE, ENTACAPONE
ENTECAVIR, ENTECAVIR
ENTEREG, ALVIMOPAN
ENTERO VU 24%, BARIUM SULFATE
ENTOCORT EC, BUDESONIDE
ENTRESTO, SACUBITRIL
ENVARUS XR, TACROLIMUS
EOVIST, GADOXETATE DISODIUM
EPANED, ENALAPRIL MALEATE
EPCLUSA, SOFOSBUVIR
EPHEDRINE SULFATE, EPHEDRINE SULFATE
EPIDIOLEX, CANNABIDIOL
EPIDUO, ADAPALENE
EPIDUO FORTE, ADAPALENE
EPIFOAM, HYDROCORTISONE ACETATE
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
EPINEPHRINE, EPINEPHRINE
EPINEPHRINE (AUTOINJECTOR), EPINEPHRINE
EPINEPHRINE (COPACKAGED), EPINEPHRINE
EPIPEN, EPINEPHRINE
EPIPEN JR., EPINEPHRINE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
EPITOL, CARBAMAZEPINE
EPIVIR, LAMIVUDINE
EPIVIR-HBV, LAMIVUDINE
EPLERENONE, EPLERENONE
EPOPROSTENOL SODIUM, EPOPROSTENOL SODIUM
EPTIFIBATIDE, EPTIFIBATIDE
EPZICOM, ABACAVIR SULFATE

APPENDIX A - PRODUCT NAME INDEX

** E **

EQUETRO, CARBAMAZEPINE
ERAXIS, ANIDULAFUNGIN
ERGOALCIFIEROL, ERGOALCIFIEROL
ERGOLOID MESYLATES, ERGOLOID MESYLATES
ERGOMAR, ERGOTAMINE TARTRATE
ERGOTAMINE TARTRATE AND CAFFEINE, CAFFEINE
ERIVEDGE, VISMODEGIB
ERLEADA, APALUTAMIDE
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
ERRIN, NORETHINDRONE
ERTACZO, SERTACONAZOLE NITRATE
ERTAPENEM SODIUM, ERTAPENEM SODIUM
ERY-TAB, ERYTHROMYCIN
ERYC, ERYTHROMYCIN
ERYGEL, ERYTHROMYCIN
ERYPED, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE
ERYTHROCIN STEARATE, ERYTHROMYCIN STEARATE
ERYTHROMYCIN, ERYTHROMYCIN
ERYTHROMYCIN AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN LACTOBIONATE, ERYTHROMYCIN LACTOBIONATE
ESBRIET, PIRFENIDONE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
ESTARYLLA, ETHINYL ESTRADIOL
ESTAZOLAM, ESTAZOLAM
ESTRACE, ESTRADIOL
ESTRADIOL, ESTRADIOL
ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
ESTRADIOL AND NORGESTIMATE, ESTRADIOL
ESTRADIOL VALERATE, ESTRADIOL VALERATE
ESTRING, ESTRADIOL
ESTROGEL, ESTRADIOL
ESTROSTEP FE, ETHINYL ESTRADIOL
ESZOPICLONE, ESZOPICLONE
ETHACRYNATE SODIUM, ETHACRYNATE SODIUM
ETHACRYNIC ACID, ETHACRYNIC ACID
ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
ETHAMOLIN, ETHANOLAMINE OLEATE
ETHOSUXIMIDE, ETHOSUXIMIDE
ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
ETHYOL, AMIFOSTINE
ETODOLAC, ETODOLAC
ETOMIDATE, ETOMIDATE
ETOPOPHOS PRESERVATIVE FREE, ETOPOSIDE PHOSPHATE
ETOPOSIDE, ETOPOSIDE
EUCRISA, CRISABOROLE
EURAX, CROTAMITON
EUTHYROX, LEVOTHYROXINE SODIUM **
EVAMIST, ESTRADIOL
EVEKEO, AMPHETAMINE SULFATE
EVEKEO ODT, AMPHETAMINE SULFATE
EVEROLIMUS, EVEROLIMUS
EVISTA, RALOXIFENE HYDROCHLORIDE
EVOCLIN, CLINDAMYCIN PHOSPHATE
EVOMELA, MELPHALAN HYDROCHLORIDE
EVOTAZ, ATAZANAVIR SULFATE
EVOXAC, CEVIMELINE HYDROCHLORIDE
EVRYSDI, RISDIPLAM

APPENDIX A - PRODUCT NAME INDEX

** E **

EXCEDRIN (MIGRAINE), ACETAMINOPHEN (OTC)
 EXELDERM, SULCONAZOLE NITRATE
 EXELON, RIVASTIGMINE
 EXEM FOAM KIT, AIR POLYMER-TYPE A
 EXEMESTANE, EXEMESTANE
 EXFORGE, AMLODIPINE BESYLATE
 EXFORGE HCT, AMLODIPINE BESYLATE
 EXIDINE, CHLORHEXIDINE GLUCONATE (OTC)
 EXJADE, DEFERASIROX
 EXONDYS 51, ETEPLIRSEN
 EXPAREL, BUPIVACAINE
 EXSERVAN, RILUZOLE
 EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
 EXTINA, KETOCONAZOLE
 EXTRANEAL, ICODEXTRIN
 EYSUVIS, LOTEPREDNOL ETABONATE
 EZALLOR SPRINKLE, ROSUVASTATIN CALCIUM
 EZETIMIBE, EZETIMIBE
 EZETIMIBE AND SIMVASTATIN, EZETIMIBE

** F **

FABIOR, TAZAROTENE
 FACTIVE, GEMIFLOXACIN MESYLATE
 FALLBACK SOLO, LEVONORGESTREL (OTC)
 FALMINA, ETHINYL ESTRADIOL
 FAMCICLOVIR, FAMCICLOVIR
 FAMOTIDINE, FAMOTIDINE (OTC)
 FAMOTIDINE, FAMOTIDINE
 FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
 FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE
 FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE, CALCIUM CARBONATE (OTC)
 FANAPT, ILOPERIDONE
 FARESTON, TOREMIFENE CITRATE
 FARXIGA, DAPAGLIFLOZIN
 FARYDAK, PANOBINOSTAT LACTATE
 FASLODEX, FULVESTRANT
 FEBUXOSTAT, FEBUXOSTAT
 FELBAMATE, FELBAMATE
 FELBATOL, FELBAMATE
 FELDENE, PIROXICAM
 FELODIPINE, FELODIPINE
 FEMARA, LETROZOLE
 FEMHRT, ETHINYL ESTRADIOL
 FEMRING, ESTRADIOL ACETATE
 FENOFIBRATE, FENOFIBRATE
 FENOFIBRATE (MICRONIZED), FENOFIBRATE
 FENOFIBRIC ACID, CHOLINE FENOFIBRATE
 FENOGLIDE, FENOFIBRATE
 FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE
 FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
 FENSOLVI KIT, LEUPROLIDE ACETATE
 FENTANYL CITRATE, FENTANYL CITRATE
 FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
 FENTANYL-100, FENTANYL
 FENTANYL-12, FENTANYL
 FENTANYL-25, FENTANYL
 FENTANYL-37, FENTANYL
 FENTANYL-50, FENTANYL
 FENTANYL-62, FENTANYL
 FENTANYL-75, FENTANYL
 FENTANYL-87, FENTANYL
 FENTORA, FENTANYL CITRATE
 FERAHEME, FERUMOXYTOL
 FERRIPROX, DEFERIPRONE
 FERRLECIT, SODIUM FERRIC GLUCONATE COMPLEX

APPENDIX A - PRODUCT NAME INDEX

** F **

FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
FETROJA, CEFIDEROCOL SULFATE TOSYLATE
FETZIMA, LEVOMILNACIPRAN HYDROCHLORIDE
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
FIBRICOR, FENOFIBRIC ACID
FINACEA, AZELAIC ACID
FINASTERIDE, FINASTERIDE
FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
FINTEPLA, FENFLURAMINE HYDROCHLORIDE
FIORICET W/ CODEINE, ACETAMINOPHEN
FIORINAL, ASPIRIN
FIORINAL W/CODEINE, ASPIRIN
FIRAZYR, ICATIBANT ACETATE
FIRDAPSE, AMIFAMPRIDINE PHOSPHATE
FIRMAGON, DEGARELIX ACETATE
FIRVANQ KIT, VANCOMYCIN HYDROCHLORIDE
FLAC, FLUOCINOLONE ACETONIDE
FLAGYL, METRONIDAZOLE
FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE
FLAREX, FLUOROMETHOLONE ACETATE
FLAVORED COLESTID, COLESTIPOL HYDROCHLORIDE
FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLECTOR, DICLOFENAC EPOLAMINE
FLOLAN, EPOPROSTENOL SODIUM
FLOLIPID, SIMVASTATIN
FLOMAX, TAMSULOSIN HYDROCHLORIDE
FLONASE ALLERGY RELIEF, FLUTICASONE PROPIONATE (OTC)
FLONASE SENSIMIST ALLERGY RELIEF, FLUTICASONE FUROATE (OTC)
FLOVENT DISKUS 100, FLUTICASONE PROPIONATE
FLOVENT DISKUS 250, FLUTICASONE PROPIONATE
FLOVENT DISKUS 50, FLUTICASONE PROPIONATE
FLOVENT HFA, FLUTICASONE PROPIONATE
FLOXURIDINE, FLOXURIDINE
FLUCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUCONAZOLE, FLUCONAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUCYTOSINE, FLUCYTOSINE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
FLUMADINE, RIMANTADINE HYDROCHLORIDE
FLUMAZENIL, FLUMAZENIL
FLUNISOLIDE, FLUNISOLIDE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUOCINONIDE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE, BENOXINATE HYDROCHLORIDE
FLUORESCITE, FLUORESCEIN SODIUM
FLUOROPLEX, FLUOROURACIL
FLUOROURACIL, FLUOROURACIL
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUOXYMESTERONE, FLUOXYMESTERONE
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
FLURANDRENOLIDE, FLURANDRENOLIDE
FLURAZEPAM HYDROCHLORIDE, FLURAZEPAM HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN
FLURBIPROFEN SODIUM, FLURBIPROFEN SODIUM
FLUTAMIDE, FLUTAMIDE

APPENDIX A - PRODUCT NAME INDEX

** F **

FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE (OTC)
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, FLUTICASONE PROPIONATE
 FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
 FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
 FML, FLUOROMETHOLONE
 FML FORTE, FLUOROMETHOLONE
 FOCALIN, DEXMETHYLPHENIDATE HYDROCHLORIDE
 FOCALIN XR, DEXMETHYLPHENIDATE HYDROCHLORIDE
 FOLIC ACID, FOLIC ACID
 FOLOTYN, PRALATREXATE
 FOMEPIZOLE, FOMEPIZOLE
 FONDAPARINUX SODIUM, FONDAPARINUX SODIUM
 FORANE, ISOFLURANE
 FORFIVO XL, BUPROPION HYDROCHLORIDE
 FORTAMET, METFORMIN HYDROCHLORIDE
 FORTAZ, CEFTAZIDIME
 FORTEO, TERIPARATIDE
 FORTESTA, TESTOSTERONE
 FOSAMAX, ALENDRONATE SODIUM
 FOSAMAX PLUS D, ALENDRONATE SODIUM
 FOSAMPRENAVIR CALCIUM, FOSAMPRENAVIR CALCIUM
 FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
 FOSCAVIR, FOSCARNET SODIUM
 FOSFOMYCIN TROMETHAMINE, FOSFOMYCIN TROMETHAMINE
 FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
 FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 FOSRENOL, LANTHANUM CARBONATE
 FRAGMIN, DALTEPARIN SODIUM
 FREAMINE HBC 6.9%, AMINO ACIDS
 FREAMINE III 10%, AMINO ACIDS
 FREAMINE III 3% W/ ELECTROLYTES, AMINO ACIDS
 FREAMINE III 8.5%, AMINO ACIDS
 FREAMINE III 8.5% W/ ELECTROLYTES, AMINO ACIDS
 FROVA, FROVATRIPTAN SUCCINATE
 FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE
 FULVESTRANT, FULVESTRANT
 FURADANTIN, NITROFURANTOIN
 FUROSEMIDE, FUROSEMIDE
 FUSILEV, LEVOLEUCOVORIN CALCIUM
 FUZEON, ENFUVRTIDE
 FYAVOLV, ETHINYL ESTRADIOL
 FYCOMPA, PERAMPANEL

** G **

GABAPENTIN, GABAPENTIN
 GABITRIL, TIAGABINE HYDROCHLORIDE
 GABLOFEN, BACLOFEN
 GADAVIST, GADOBUTROL
 GALAFOLD, MIGALASTAT HYDROCHLORIDE
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67
 GALLIUM DOTATOC GA 68, GALLIUM DOTATOC GA-68
 GALLIUM GA 68 PSMA-11, GALLIUM GA-68 PSMA-11
 GALZIN, ZINC ACETATE
 GANCICLOVIR SODIUM, GANCICLOVIR SODIUM
 GANIRELIX ACETATE, GANIRELIX ACETATE
 GANZYK-RTU, GANCICLOVIR
 GASTROCROM, CROMOLYN SODIUM
 GASTROGRAFIN, DIATRIZOATE MEGLUMINE
 GATIFLOXACIN, GATIFLOXACIN
 GATTEX KIT, TEDUGLUTIDE RECOMBINANT
 GAVISCON, ALUMINUM HYDROXIDE (OTC)
 GAVRETO, PRALSETINIB

APPENDIX A - PRODUCT NAME INDEX

** G **

GELNIQUE, OXYBUTYNIN CHLORIDE
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 GEMFIBROZIL, GEMFIBROZIL
 GEMIFLOXACIN MESYLATE, GEMIFLOXACIN MESYLATE
 GEMMILY, ETHINYL ESTRADIOL
 GEMTESA, VIBEGRON
 GEMZAR, GEMCITABINE HYDROCHLORIDE
 GEN-XENE, CLORAZEPATE DIPOTASSIUM
 GENERLAC, LACTULOSE
 GENGRAF, CYCLOSPORINE
 GENOPTIC, GENTAMICIN SULFATE
 GENOSYL, NITRIC OXIDE
 GENTAK, GENTAMICIN SULFATE
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
 GENVOYA, COBICISTAT
 GEODON, ZIPRASIDONE HYDROCHLORIDE
 GEODON, ZIPRASIDONE MESYLATE
 GIAPREZA, ANGIOTENSIN II ACETATE
 GILDAGIA, ETHINYL ESTRADIOL
 GILDESS 1/20, ETHINYL ESTRADIOL
 GILDESS 24 FE, ETHINYL ESTRADIOL
 GILDESS FE 1/20, ETHINYL ESTRADIOL
 GILENYA, FINGOLIMOD HYDROCHLORIDE
 GILOTRIF, AFATINIB DIMALEATE
 GIMOTI, METOCLOPRAMIDE HYDROCHLORIDE
 GIVLAARI, GIVOSIRAN SODIUM
 GLATIRAMER ACETATE, GLATIRAMER ACETATE
 GLATOPA, GLATIRAMER ACETATE
 GLEEVEC, IMATINIB MESYLATE
 GLEOLAN, AMINOLEVULINIC ACID HYDROCHLORIDE
 GLEOSTINE, LOMUSTINE
 GLIADEL, CARMUSTINE
 GLIMEPIRIDE, GLIMEPIRIDE
 GLIPIZIDE, GLIPIZIDE
 GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
 GLOFIL-125, IOTHALAMATE SODIUM I-125
 GLOPERBA, COLCHICINE
 GLUCAGEN, GLUCAGON HYDROCHLORIDE
 GLUCAGON, GLUCAGON
 GLUCAGON, GLUCAGON HYDROCHLORIDE
 GLUCOTROL, GLIPIZIDE
 GLUCOTROL XL, GLIPIZIDE
 GLUMETZA, METFORMIN HYDROCHLORIDE
 GLYBURIDE, GLYBURIDE
 GLYBURIDE (MICRONIZED), GLYBURIDE
 GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
 GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
 GLYCOLAX, POLYETHYLENE GLYCOL 3350 (OTC)
 GLYCOPYRROLATE, GLYCOPYRROLATE
 GLYDO, LIDOCAINE HYDROCHLORIDE
 GLYNASE, GLYBURIDE
 GLYRX-PF, GLYCOPYRROLATE
 GLYSET, MIGLITOL
 GLYXAMBI, EMPAGLIFLOZIN
 GOCOVRI, AMANTADINE HYDROCHLORIDE
 GOLYTELY, POLYETHYLENE GLYCOL 3350
 GONITRO, NITROGLYCERIN
 GOPRELTO, COCAINE HYDROCHLORIDE
 GRALISE, GABAPENTIN
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE
 GRIS-PEG, GRISEOFULVIN, ULTRAMICROSIZE
 GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
 GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE

APPENDIX A - PRODUCT NAME INDEX

** G **

GRISEOFULVIN,ULTRAMICROSIZED, GRISEOFULVIN, ULTRAMICROSIZED
 GUAIFENESIN, GUAIFENESIN (OTC)
 GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
 GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN (OTC)
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 GVOKE HYPOPEN, GLUCAGON
 GVOKE PFS, GLUCAGON
 GYNAZOLE-1, BUTOCONAZOLE NITRATE

** H **

H.P. ACTHAR GEL, CORTICOTROPIN
 HABITROL, NICOTINE (OTC)
 HAILEY 1.5/30, ETHINYL ESTRADIOL
 HAILEY FE 1.5/30, ETHINYL ESTRADIOL
 HAILEY FE 1/20, ETHINYL ESTRADIOL
 HALAVEN, ERIBULIN MESYLATE
 HALCINONIDE, HALCINONIDE
 HALCION, TRIAZOLAM
 HALDOL, HALOPERIDOL DECANOATE
 HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
 HALOG, HALCINONIDE
 HALOPERIDOL, HALOPERIDOL
 HALOPERIDOL, HALOPERIDOL LACTATE
 HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
 HARVONI, LEDIPASVIR
 HEATHER, NORETHINDRONE
 HECTOROL, DOXERCALCIFEROL
 HEMABATE, CARBOPROST TROMETHAMINE
 HEMADY, DEXAMETHASONE
 HEMANGEOL, PROPRANOLOL HYDROCHLORIDE
 HEPARIN SODIUM, HEPARIN SODIUM
 HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
 HEPATAMINE 8%, AMINO ACIDS
 HEPSERA, ADEFOVIR DIPIVOXIL
 HER STYLE, LEVONORGESTREL (OTC)
 HETLIOZ, TASIMELTEON
 HETLIOZ LQ, TASIMELTEON
 HIBICLENS, CHLORHEXIDINE GLUCONATE (OTC)
 HIBISTAT, CHLORHEXIDINE GLUCONATE (OTC)
 HICON, SODIUM IODIDE I-131
 HIPREX, METHENAMINE HIPPURATE
 HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE, HOMATROPINE METHYLBROMIDE
 HORIZANT, GABAPENTIN ENACARBIL
 HYCAMTIN, TOPOTECAN HYDROCHLORIDE
 HYCODAN, HOMATROPINE METHYLBROMIDE
 HYDRA-ZIDE, HYDRALAZINE HYDROCHLORIDE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDREA, HYDROXYUREA
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 HYDROCODONE BITARTRATE, HYDROCODONE BITARTRATE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
 HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
 HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE,

APPENDIX A - PRODUCT NAME INDEX**** H ****

HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX, CHLORPHENIRAMINE POLISTIREX
 HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX, CHLORPHENIRAMINE POLISTIREX
 HYDROCORTISONE, HYDROCORTISONE
 HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
 HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
 HYDROCORTISONE IN ABSORBASE, HYDROCORTISONE
 HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 HYDROXOCOBALAMIN, HYDROXOCOBALAMIN
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
 HYDROXYUREA, HYDROXYUREA
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
 HYSINGLA ER, HYDROCODONE BITARTRATE
 HYZAAR, HYDROCHLOROTHIAZIDE

**** I ****

IBANDRONATE SODIUM, IBANDRONATE SODIUM
 IBRANCE, PALBOCICLIB
 IBU-TAB, IBUPROFEN
 IBU-TAB 200, IBUPROFEN (OTC)
 IBUPROFEN, IBUPROFEN (OTC)
 IBUPROFEN, IBUPROFEN
 IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
 IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
 IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE, IBUPROFEN (OTC)
 IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
 IBUPROFEN LYSINE, IBUPROFEN LYSINE
 IBUPROHM COLD AND SINUS, IBUPROFEN (OTC)
 IBUTILIDE FUMARATE, IBUTILIDE FUMARATE
 IC-GREEN, INDOCYANINE GREEN
 ICATIBANT ACETATE, ICATIBANT ACETATE
 ICLEVIA, ETHINYL ESTRADIOL
 ICLUSIG, PONATINIB HYDROCHLORIDE
 ICOSAPENT ETHYL, ICOSAPENT ETHYL
 IDAMYCIN PFS, IDARUBICIN HYDROCHLORIDE
 IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
 IDARUBICIN HYDROCHLORIDE PFS, IDARUBICIN HYDROCHLORIDE
 IDHIFA, ENASIDENIB MESYLATE
 IDKIT:HP, CITRIC ACID
 IFEX, IFOSFAMIDE
 IFOSFAMIDE, IFOSFAMIDE
 ILEVRO, NEPAFENAC
 ILUVIEN, FLUOCINOLONE ACETONIDE
 IMATINIB MESYLATE, IMATINIB MESYLATE
 IMBRUVICA, IBRUTINIB
 IMCIVREE, SETMELANOTIDE ACETATE
 IMIPENEM AND CILASTATIN, CILASTATIN SODIUM
 IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
 IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
 IMIQUIMOD, IMIQUIMOD
 IMITREX, SUMATRIPTAN
 IMITREX, SUMATRIPTAN SUCCINATE
 IMITREX STATDOSE, SUMATRIPTAN SUCCINATE
 IMODIUM A-D, LOPERAMIDE HYDROCHLORIDE (OTC)
 IMODIUM MULTI-SYMPTOM RELIEF, LOPERAMIDE HYDROCHLORIDE (OTC)
 IMPAVIDO, MILTEFOSINE
 IMPEKLO, CLOBETASOL PROPIONATE
 IMPOYZ, CLOBETASOL PROPIONATE
 IMURAN, AZATHIOPRINE
 IMVEXXY, ESTRADIOL
 INAPSINE, DROPERIDOL
 INBRIJA, LEVODOPA
 INCASSIA, NORETHINDRONE

APPENDIX A - PRODUCT NAME INDEX**** I ****

INCRUSE ELLIPTA, UMECLIDINIUM BROMIDE
INDAPAMIDE, INDAPAMIDE
INDERAL LA, PROPRANOLOL HYDROCHLORIDE
INDIUM IN 111 CHLORIDE, INDIUM IN-111 CHLORIDE
INDIUM IN 111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE
INDOCIN, INDOMETHACIN
INDOCYANINE GREEN, INDOCYANINE GREEN
INDOMETHACIN, INDOMETHACIN
INDOMETHACIN SODIUM, INDOMETHACIN SODIUM
INFANT'S ADVIL, IBUPROFEN (OTC)
INFANTS' FEVERALL, ACETAMINOPHEN (OTC)
INFED, IRON DEXTRAN
INFUGEM, GEMCITABINE HYDROCHLORIDE
INFUMORPH, MORPHINE SULFATE
INFUVITE ADULT, ALPHA-TOCOPHEROL ACETATE
INFUVITE PEDIATRIC, ASCORBIC ACID
INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE), ASCORBIC ACID
INGREZZA, VALBENAZINE TOSYLATE
INJECTAFER, FERRIC CARBOXYMALTOSIDE
INLYTA, AXITINIB
INNOPRAN XL, PROPRANOLOL HYDROCHLORIDE
INOMAX, NITRIC OXIDE
INQOVI, CEDAZURIDINE
INREBIC, FEDRATINIB HYDROCHLORIDE
INSPRA, EPLERENONE
INTEGRILIN, EPTIFIBATIDE
INTELENCE, ETRAVIRINE
INTRALIPID 10%, SOYBEAN OIL
INTRALIPID 20%, SOYBEAN OIL
INTRALIPID 30%, SOYBEAN OIL
INTRAROSA, PRASTERONE
INTROVALE, ETHINYL ESTRADIOL
INTUNIV, GUANFACINE HYDROCHLORIDE
INVANZ, ERTAPENEM SODIUM
INVEGA, PALIPERIDONE
INVEGA SUSTENNA, PALIPERIDONE PALMITATE
INVEGA TRINZA, PALIPERIDONE PALMITATE
INVELTYS, LOTEPREDNOL ETABONATE
INVIRASE, SAQUINAVIR MESYLATE
INVOKAMET, CANAGLIFLOZIN
INVOKAMET XR, CANAGLIFLOZIN
INVOKANA, CANAGLIFLOZIN
IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
IOPIDINE, APRACLOnidine HYDROCHLORIDE
IOSAT, POTASSIUM IODIDE (OTC)
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
IRBESARTAN, IRBESARTAN
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRESSA, GEFITINIB
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
ISENTRESS, RALTEGRAVIR POTASSIUM
ISENTRESS HD, RALTEGRAVIR POTASSIUM
ISIBLOOM, DESOGESTREL
ISOFLURANE, ISOFLURANE
ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE S IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ISONIAZID, ISONIAZID
ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
ISOPTO ATROPINE, ATROPINE SULFATE
ISOPTO CARPINE, Pilocarpine HYDROCHLORIDE
ISORDIL, ISOSORBIDE DINITRATE
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
ISOSULFAN BLUE, ISOSULFAN BLUE

APPENDIX A - PRODUCT NAME INDEX**** I ****

ISOTRETINOIN, ISOTRETINOIN
 ISOVUE-200, IOPAMIDOL
 ISOVUE-250, IOPAMIDOL
 ISOVUE-300, IOPAMIDOL
 ISOVUE-370, IOPAMIDOL
 ISOVUE-M 200, IOPAMIDOL
 ISOVUE-M 300, IOPAMIDOL
 ISRADIPINE, ISRADIPINE
 ISTALOL, TIMOLOL MALEATE
 ISTODAX, ROMIDEPSIN
 ISTURISA, OSILODROSTAT PHOSPHATE
 ISUPREL, ISOPROTERENOL HYDROCHLORIDE
 ITRACONAZOLE, ITRACONAZOLE
 IVERMECTIN, IVERMECTIN
 IVY BLOCK, BENTOQUATAM (OTC)
 IXEMPRA KIT, IXABEPILONE

**** J ****

JADENU, DEFERASIROX
 JADENU SPRINKLE, DEFERASIROX
 JAIMIESS, ETHINYL ESTRADIOL
 JAKAFI, RUXOLITINIB PHOSPHATE
 JALYN, DUTASTERIDE
 JANTOVEN, WARFARIN SODIUM
 JANUMET, METFORMIN HYDROCHLORIDE
 JANUMET XR, METFORMIN HYDROCHLORIDE
 JANUVIA, SITAGLIPTIN PHOSPHATE
 JARDIANCE, EMPAGLIFLOZIN
 JATENZO, TESTOSTERONE UNDECANOATE
 JELMYTO, MITOMYCIN
 JENCYCLA, NORETHINDRONE
 JENTADUETO, LINAGLIPTIN
 JENTADUETO XR, LINAGLIPTIN
 JEVTANA KIT, CABAZITAXEL
 JORNAY PM, METHYLPHENIDATE HYDROCHLORIDE
 JUBLIA, EFINACONAZOLE
 JULUCA, DOLUTEGRAVIR SODIUM
 JUNEL 1.5/30, ETHINYL ESTRADIOL
 JUNEL 1/20, ETHINYL ESTRADIOL
 JUNEL FE 1.5/30, ETHINYL ESTRADIOL
 JUNEL FE 1/20, ETHINYL ESTRADIOL
 JUNIOR STRENGTH ADVIL, IBUPROFEN (OTC)
 JUNIOR STRENGTH IBUPROFEN, IBUPROFEN (OTC)
 JUNIOR STRENGTH MOTRIN, IBUPROFEN (OTC)
 JUXTAPID, LOMITAPIDE MESYLATE
 JYNARQUE, TOLVAPTAN

**** K ****

K-TAB, POTASSIUM CHLORIDE
 KABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
 KADIAN, MORPHINE SULFATE
 KAITLIB FE, ETHINYL ESTRADIOL
 KALETRA, LOPINAVIR
 KALEXATE, SODIUM POLYSTYRENE SULFONATE
 KALLIGA, DESOGESTREL
 KALYDECO, IVACAFTOR
 KAPSPARGO SPRINKLE, METOPROLOL SUCCINATE
 KAPVAY, CLONIDINE HYDROCHLORIDE
 KARBINAL ER, CARBINOXAMINE MALEATE
 KARIVA, DESOGESTREL
 KATERZIA, AMLODIPINE BENZOATE
 KAZANO, ALOGLIPTIN BENZOATE
 KEFLEX, CEPHALEXIN
 KELNOR, ETHINYL ESTRADIOL
 KEMEYA, DROSPIRENONE

APPENDIX A - PRODUCT NAME INDEX

** K **

KENALOG, TRIAMCINOLONE ACETONIDE
 KENALOG-10, TRIAMCINOLONE ACETONIDE
 KENALOG-40, TRIAMCINOLONE ACETONIDE
 KENALOG-80, TRIAMCINOLONE ACETONIDE
 KENGREAL, CANGRELOR
 KEPPRA, LEVETIRACETAM
 KEPPRA XR, LEVETIRACETAM
 KERYDIN, TAVABOROLE
 KETALAR, KETAMINE HYDROCHLORIDE
 KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
 KETOCONAZOLE, KETOCONAZOLE
 KETOPROFEN, KETOPROFEN
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 KETOROLAC TROMETHAMINE AND PHENYLEPHRINE HYDROCHLORIDE, KETOROLAC TROMETHAMINE
 KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
 KETOZOLE, KETOCONAZOLE
 KEVEYIS, DICHLORPHENAMIDE
 KHAPZORY, LEVOLEUCOVORIN
 KIMIDESS, DESOGESTREL
 KINEVAC, SINCALIDE
 KIONEX, SODIUM POLYSTYRENE SULFONATE
 KISQALI, RIBOCICLIB SUCCINATE
 KISQALI FEMARA CO-PACK (COPACKAGED), LETROZOLE
 KITABIS PAK, TOBRAMYCIN
 KLARON, SULFACETAMIDE SODIUM
 KLISYRI, TIRBANIBULIN
 KLONOPIN, CLONAZEPAM
 KLOR-CON, POTASSIUM CHLORIDE
 KLOR-CON M10, POTASSIUM CHLORIDE
 KLOR-CON M15, POTASSIUM CHLORIDE
 KLOR-CON M20, POTASSIUM CHLORIDE
 KOMBIGLYZE XR, METFORMIN HYDROCHLORIDE
 KORLYM, MIFEPRISTONE
 KOSELUGO, SELUMETINIB SULFATE
 KOVANAZE, OXYMETAZOLINE HYDROCHLORIDE
 KRINTAFEL, TAFENOQUINE SUCCINATE
 KURVELO, ETHINYL ESTRADIOL
 KUVAN, SAPROPTERIN DIHYDROCHLORIDE
 KYBELLA, DEOXYCHOLIC ACID
 KYLEENA, LEVONORGESTREL
 KYNMOBI, APOMORPHINE HYDROCHLORIDE
 KYPROLIS, CARFILZOMIB
 KYRA, DROSPIRENONE

** L **

LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 LABETALOL HYDROCHLORIDE IN DEXTROSE, LABETALOL HYDROCHLORIDE
 LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE, LABETALOL HYDROCHLORIDE
 LACRISERT, HYDROXYPROPYL CELLULOSE
 LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 LACTULOSE, LACTULOSE
 LAMICTAL, LAMOTRIGINE
 LAMICTAL CD, LAMOTRIGINE
 LAMICTAL ODT, LAMOTRIGINE
 LAMICTAL XR, LAMOTRIGINE
 LAMISIL, TERBINAFFINE HYDROCHLORIDE (OTC)
 LAMISIL, TERBINAFFINE HYDROCHLORIDE
 LAMISIL AT, TERBINAFFINE (OTC)
 LAMISIL AT, TERBINAFFINE HYDROCHLORIDE (OTC)
 LAMIVUDINE, LAMIVUDINE
 LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE, LAMIVUDINE
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
 LAMOTRIGINE, LAMOTRIGINE
 LAMPIT, NIFURTIMOX

APPENDIX A - PRODUCT NAME INDEX

** L **

LANORINAL, ASPIRIN
 LANOXIN, DIGOXIN
 LANOXIN PEDIATRIC, DIGOXIN
 LANSOPRAZOLE, LANSOPRAZOLE (OTC)
 LANSOPRAZOLE, LANSOPRAZOLE
 LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN, AMOXICILLIN
 LANTHANUM CARBONATE, LANTHANUM CARBONATE
 LAPATINIB DITOSYLATE, LAPATINIB DITOSYLATE
 LARIN 1.5/30, ETHINYL ESTRADIOL
 LARIN 1/20, ETHINYL ESTRADIOL
 LARIN 24 FE, ETHINYL ESTRADIOL
 LARIN FE 1.5/30, ETHINYL ESTRADIOL
 LARIN FE 1/20, ETHINYL ESTRADIOL
 LAROTID, AMOXICILLIN
 LARYNG-O-JET KIT, LIDOCAINE HYDROCHLORIDE
 LASIX, FUROSEMIDE
 LASTACAFT, ALCAFTADINE
 LATANOPROST, LATANOPROST
 LATISSE, BIMATOPROST
 LATUDA, LURASIDONE HYDROCHLORIDE
 LAX-LYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
 LAZANDA, FENTANYL CITRATE
 LEFLUNOMIDE, LEFLUNOMIDE
 LENVIMA, LENVATINIB MESYLATE
 LERIBANE, ETHINYL ESTRADIOL
 LESCOL XL, FLUVASTATIN SODIUM
 LESSINA-28, ETHINYL ESTRADIOL
 LETAIRIS, AMBRISENTAN
 LETROZOLE, LETROZOLE
 LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
 LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
 LEUKERAN, CHLORAMBUCIL
 LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
 LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
 LEVETIRACETAM, LEVETIRACETAM
 LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM
 LEVITRA, VARDENAFIL HYDROCHLORIDE
 LEVO-T, LEVOTHYROXINE SODIUM **
 LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE
 LEVOCARNITINE, LEVOCARNITINE
 LEVOCARNITINE SF, LEVOCARNITINE
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 LEVOCETIRIZINE HYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 LEVOFLOXACIN, LEVOFLOXACIN
 LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
 LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
 LEVOMILNACIPRAN HYDROCHLORIDE, LEVOMILNACIPRAN HYDROCHLORIDE
 LEVONEST, ETHINYL ESTRADIOL
 LEVONORGESTREL, LEVONORGESTREL (OTC)
 LEVONORGESTREL, LEVONORGESTREL
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LEVOPHED, NOREPINEPHRINE BITARTRATE
 LEVORA 0.15/30-28, ETHINYL ESTRADIOL
 LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
 LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
 LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM **
 LEVOXYL, LEVOTHYROXINE SODIUM **
 LEVULAN, AMINOLEVULINIC ACID HYDROCHLORIDE
 LEXAPRO, ESCITALOPRAM OXALATE
 LEXETTE, HALOBETASOL PROPIONATE
 LEXISCAN, REGADENOSON
 LEXIVA, FOSAMPRENAVIR CALCIUM
 LIALDA, MESALAMINE

APPENDIX A - PRODUCT NAME INDEX

** L **

LIBRAX, CHLORDIAZEPOXIDE HYDROCHLORIDE
 LIBRIUM, CHLORDIAZEPOXIDE HYDROCHLORIDE
 LICART, DICLOFENAC EPOLAMINE
 LIDEX, FLUOCINONIDE
 LIDEX-E, FLUOCINONIDE
 LIDOCAINE, LIDOCAINE
 LIDOCAINE AND PRILOCAINE, LIDOCAINE
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, EPINEPHRINE
 LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
 LIDODERM, LIDOCAINE
 LIGNOSPAN FORTE, EPINEPHRINE BITARTRATE
 LIGNOSPAN STANDARD, EPINEPHRINE BITARTRATE
 LILETTA, LEVONORGESTREL
 LINCOCIN, LINCOMYCIN HYDROCHLORIDE
 LINCOMYCIN, LINCOMYCIN HYDROCHLORIDE
 LINDANE, LINDANE
 LINEZOLID, LINEZOLID
 LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, LINEZOLID
 LINZESS, LINACLOTIDE
 LIORESAL, BACLOFEN
 LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
 LIPIODOL, ETHIODIZED OIL
 LIPITOR, ATORVASTATIN CALCIUM
 LIPOFEN, FENOFIBRATE
 LIQUID E-Z-PAQUE, BARIUM SULFATE
 LISINOPRIL, LISINOPRIL
 LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LITHIUM CARBONATE, LITHIUM CARBONATE
 LITHIUM CITRATE, LITHIUM CITRATE
 LITHOBID, LITHIUM CARBONATE
 LITHOSTAT, ACETOHYDROXAMIC ACID
 LIVALO, PITAVASTATIN CALCIUM
 LO LOESTRIN FE, ETHINYL ESTRADIOL
 LO SIMPESE, ETHINYL ESTRADIOL
 LO-MALMOREDE, ETHINYL ESTRADIOL
 LO-ZUMANDIMINE, DROSPIRENONE
 LOCID, HYDROCORTISONE BUTYRATE
 LOCID LIPOCREAM, HYDROCORTISONE BUTYRATE
 LODOSYN, CARBIDOPA
 LOESTRIN 21 1.5/30, ETHINYL ESTRADIOL
 LOESTRIN 21 1/20, ETHINYL ESTRADIOL
 LOESTRIN 24 FE, ETHINYL ESTRADIOL
 LOESTRIN FE 1.5/30, ETHINYL ESTRADIOL
 LOESTRIN FE 1/20, ETHINYL ESTRADIOL
 LOGILIA, ULIPRISTAL ACETATE
 LOKELMA, SODIUM ZIRCONIUM CYCLOSILICATE
 LOMAIRA, PHENTERMINE HYDROCHLORIDE
 LOMOTIL, ATROPINE SULFATE
 LONHALA MAGNAIR KIT, GLYCOPYRROLATE
 LONSURF, TIPIRACIL HYDROCHLORIDE
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
 LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
 LOPID, GEMFIBROZIL
 LOPINAVIR AND RITONAVIR, LOPINAVIR
 LOPRESSOR, METOPROLOL TARTRATE
 LOPRESSOR HCT, HYDROCHLOROTHIAZIDE

APPENDIX A - PRODUCT NAME INDEX

** L **

LOPROX, CICLOPIROX
 LOPURIN, ALLOPURINOL
 LORATADINE, LORATADINE (OTC)
 LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
 LORATADINE REDIDOSE, LORATADINE (OTC)
 LORAZEPAM, LORAZEPAM
 LORAZEPAM INTENSOL, LORAZEPAM
 LORBRENA, LORLATINIB
 LORYNA, DROSPIRENONE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSEASONIQUE, ETHINYL ESTRADIOL
 LOTEMAX, LOTEPIREDNOL ETABONATE
 LOTEMAX SM, LOTEPIREDNOL ETABONATE
 LOTENSIN, BENAZEPRIL HYDROCHLORIDE
 LOTENSIN HCT, BENAZEPRIL HYDROCHLORIDE
 LOTEPIREDNOL ETABONATE, LOTEPIREDNOL ETABONATE
 LOTREL, AMLODIPINE BESYLATE
 LOTRIMIN ULTRA, BUTENAFINE HYDROCHLORIDE (OTC)
 LOTRISONE, BETAMETHASONE DIPROPIONATE
 LOTRONEX, ALOSETRON HYDROCHLORIDE
 LOVASTATIN, LOVASTATIN
 LOVAZA, OMEGA-3-ACID ETHYL ESTERS
 LOVENOX, ENOXAPARIN SODIUM
 LOVENOX (PRESERVATIVE FREE), ENOXAPARIN SODIUM
 LOW-OGESTREL-28, ETHINYL ESTRADIOL
 LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
 LUCEMYRA, LOFEXIDINE HYDROCHLORIDE
 LUMASON, SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES
 LUMI-SPORYN, BACITRACIN ZINC
 LUMIFY, BRIMONIDINE TARTRATE (OTC)
 LUMIGAN, BIMATOPROST
 LUNESTA, ESZOPICLONE
 LUPANETA PACK, LEUPROLIDE ACETATE
 LUPRON DEPOT, LEUPROLIDE ACETATE
 LUPRON DEPOT-PED KIT, LEUPROLIDE ACETATE
 LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
 LUTATHERA, LUTETIUM DOTATATE LU-177
 LUVOX, FLUVOXAMINE MALEATE
 LUXIQ, BETAMETHASONE VALERATE
 LUZU, LULICONAZOLE
 LYMPHOSEEK KIT, TECHNETIUM TC-99M TILMANOCEPT
 LYNPARZA, OLAPARIB
 LYRICA, PREGABALIN
 LYRICA CR, PREGABALIN
 LYSODREN, MITOTANE
 LYSTEDA, TRANEXAMIC ACID

** M **

M-ZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
 M.V.I. ADULT, ASCORBIC ACID
 M.V.I. ADULT (PHARMACY BULK PACKAGE), ASCORBIC ACID
 M.V.I. PEDIATRIC, ASCORBIC ACID
 MACRILEN, MACIMORELIN ACETATE
 MACROBID, NITROFURANTOIN
 MACRODANTIN, NITROFURANTOIN, MACROCRYSTALLINE
 MAFENIDE ACETATE, MAFENIDE ACETATE
 MAGNESIUM SULFATE, MAGNESIUM SULFATE
 MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 MAKENA, HYDROXYPROGESTERONE CAPROATE
 MAKENA (AUTOINJECTOR), HYDROXYPROGESTERONE CAPROATE
 MAKENA PRESERVATIVE FREE, HYDROXYPROGESTERONE CAPROATE
 MALARONE, ATOVAQUONE
 MALARONE PEDIATRIC, ATOVAQUONE

APPENDIX A - PRODUCT NAME INDEX

** M **

MALATHION, MALATHION
MALMOREDE, ETHINYL ESTRADIOL
MANGANESE CHLORIDE IN PLASTIC CONTAINER, MANGANESE CHLORIDE
MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 25%, MANNITOL
MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL
MAPROTILINE HYDROCHLORIDE, MAPROTILINE HYDROCHLORIDE
MARCAINE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE W/ EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARINOL, DRONABINOL
MARLISSA, ETHINYL ESTRADIOL
MARPLAN, ISOCARBOXAZID
MARQIBO KIT, VINCRISTINE SULFATE
MATULANE, PROCARBAZINE HYDROCHLORIDE
MAVENCLAD, CLADRIBINE
MAVYRET, GLECAPREVIR
MAXALT, RIZATRIPTAN BENZOATE
MAXALT-MLT, RIZATRIPTAN BENZOATE
MAXIDEX, DEXAMETHASONE
MAXIPIME, CEFEPIME HYDROCHLORIDE
MAXITROL, DEXAMETHASONE
MAXZIDE, HYDROCHLOROTHIAZIDE
MAXZIDE-25, HYDROCHLOROTHIAZIDE
MAYZENT, SIPONIMOD FUMARIC ACID
MD-GASTROVIEW, DIATRIZOATE MEGLUMINE
MECAMYLAMINE HYDROCHLORIDE, MECAMYLAMINE HYDROCHLORIDE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MEDROL, METHYLPREDNISOLONE
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
MEFENAMIC ACID, MEFENAMIC ACID
MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
MEGACE ES, MEGESTROL ACETATE
MEGESTROL ACETATE, MEGESTROL ACETATE
MEKINIST, TRAMETINIB DIMETHYL SULFOXIDE
MEKTOVI, BINIMETINIB
MELAMISA, DROSPIRENONE
MELOXICAM, MELOXICAM
MELPHALAN, MELPHALAN
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MEMBRANEBLUE, TRYPAN BLUE
MEN'S ROGAINE, MINOXIDIL (OTC)
MENEST, ESTROGENS, ESTERIFIED
MENOSTAR, ESTRADIOL
MENTAX, BUTENAFINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
MEPHYTON, PHYTONADIONE
MEPROBAMATE, MEPROBAMATE
MEPRON, ATOVAQUONE
MERCAPTOPYRINE, MERCAPTOPYRINE
MEROPENEM, MEROPENEM
MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER, MEROPENEM
MERREM, MEROPENEM
MERZEE, ETHINYL ESTRADIOL
MESALAMINE, MESALAMINE
MESNA, MESNA
MESNEX, MESNA
MESTINON, PYRIDOSTIGMINE BROMIDE

APPENDIX A - PRODUCT NAME INDEX

** M **

METADATE CD, METHYLPHENIDATE HYDROCHLORIDE
 METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
 METASTRON, STRONTIUM CHLORIDE SR-89
 METAXALONE, METAXALONE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 METHADONE HYDROCHLORIDE INTENSOL, METHADONE HYDROCHLORIDE
 METHADOSE, METHADONE HYDROCHLORIDE
 METHAMPHETAMINE HYDROCHLORIDE, METHAMPHETAMINE HYDROCHLORIDE
 METHAZOLAMIDE, METHAZOLAMIDE
 METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
 METHERGINE, METHYLERGONOVINE MALEATE
 METHIMAZOLE, METHIMAZOLE
 METHOCARBAMOL, METHOCARBAMOL
 METHOTREXATE PRESERVATIVE FREE, METHOTREXATE SODIUM
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
 METHOXSALEN, METHOXSALEN
 METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
 METHYLDOPA, METHYLDOPA
 METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
 METHYLIN, METHYLPHENIDATE HYDROCHLORIDE
 METHYLIN ER, METHYLPHENIDATE HYDROCHLORIDE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 METHYLPREDNISOLONE, METHYLPREDNISOLONE
 METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
 METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
 METHYLTESTOSTERONE, METHYLTESTOSTERONE
 METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 METOLAZONE, METOLAZONE
 METOPIRONE, METYRAPONE
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 METRO I.V. IN PLASTIC CONTAINER, METRONIDAZOLE
 METROCREAM, METRONIDAZOLE
 METROGEL, METRONIDAZOLE
 METROGEL-VAGINAL, METRONIDAZOLE
 METROLOTION, METRONIDAZOLE
 METRONIDAZOLE, METRONIDAZOLE
 METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
 METYROSINE, METYROSINE
 MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
 MIACALCIN, CALCITONIN SALMON
 MIBELAS 24 FE, ETHINYL ESTRADIOL
 MICAFUNGIN SODIUM, MICAFUNGIN SODIUM
 MICARDIS, TELMISARTAN
 MICARDIS HCT, HYDROCHLOROTHIAZIDE
 MICONAZOLE 3, MICONAZOLE NITRATE (OTC)
 MICONAZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
 MICONAZOLE 7, MICONAZOLE NITRATE (OTC)
 MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
 MICONAZOLE NITRATE, MICONAZOLE NITRATE
 MICONAZOLE NITRATE COMBINATION PACK, MICONAZOLE NITRATE (OTC)
 MICORT-HC, HYDROCORTISONE ACETATE
 MICROGESTIN 1.5/30, ETHINYL ESTRADIOL
 MICROGESTIN 1/20, ETHINYL ESTRADIOL
 MICROGESTIN FE 1.5/30, ETHINYL ESTRADIOL
 MICROGESTIN FE 1/20, ETHINYL ESTRADIOL
 MICROZIDE, HYDROCHLOROTHIAZIDE
 MIDAMOR, AMILORIDE HYDROCHLORIDE
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

** M **

MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
MIDOL LIQUID GELS, IBUPROFEN (OTC)
MIFEPREX, MIFEPRISTONE
MIFEPRISTONE, MIFEPRISTONE
MIGERGOT, CAFFEINE
MIGLITOL, MIGLITOL
MIGLUSTAT, MIGLUSTAT
MIGRANAL, DIHYDROERGOTAMINE MESYLATE
MILI, ETHINYL ESTRADIOL
MILRINONE LACTATE, MILRINONE LACTATE
MILRINONE LACTATE IN DEXTROSE 5%, MILRINONE LACTATE
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
MILRINONE LACTATE IN PLASTIC CONTAINER, MILRINONE LACTATE
MINASTRIN 24 FE, ETHINYL ESTRADIOL
MINIPRESS, PRAZOSIN HYDROCHLORIDE
MINIVELLE, ESTRADIOL
MINOCIN, MINOCYCLINE HYDROCHLORIDE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MINOLIRA, MINOCYCLINE HYDROCHLORIDE
MINOXIDIL, MINOXIDIL (OTC)
MINOXIDIL, MINOXIDIL
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
MIOCHOL-E, ACETYLCHOLINE CHLORIDE
MIOSTAT, CARBACHOL
MIRALAX, POLYETHYLENE GLYCOL 3350 (OTC)
MIRAPEX, PRAMIPEXOLE DIHYDROCHLORIDE
MIRAPEX ER, PRAMIPEXOLE DIHYDROCHLORIDE
MIRENA, LEVONORGESTREL
MIRTAZAPINE, MIRTAZAPINE
MIRVASO, BRIMONIDINE TARTRATE
MISOPROSTOL, MISOPROSTOL
MITIGARE, COLCHICINE
MITIGO, MORPHINE SULFATE
MITOMYCIN, MITOMYCIN
MITOSOL, MITOMYCIN
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
MOBIC, MELOXICAM
MODAFINIL, MODAFINIL
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MOLINDONE HYDROCHLORIDE, MOLINDONE HYDROCHLORIDE
MOMETASONE FUROATE, MOMETASONE FUROATE
MONISTAT 1 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3, MICONAZOLE NITRATE (OTC)
MONISTAT 3, MICONAZOLE NITRATE
MONISTAT 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3 COMBINATION PACK (PREFILLED), MICONAZOLE NITRATE (OTC)
MONISTAT 7, MICONAZOLE NITRATE (OTC)
MONISTAT 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONO-LINYAH, ETHINYL ESTRADIOL
MONOFERRIC, FERRIC DERISOMALTOSE
MONOKET, ISOSORBIDE MONONITRATE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MONUROL, FOSFOMYCIN TROMETHAMINE
MORPHINE SULFATE, MORPHINE SULFATE
MOTEGRITY, PRUCALOPRIDE SUCCINATE
MOTOFEN, ATROPINE SULFATE
MOTRIN IB, IBUPROFEN (OTC)
MOVANTIK, NALOXEGOL OXALATE
MOVIPREP, ASCORBIC ACID
MOXEZA, MOXIFLOXACIN HYDROCHLORIDE
MOXIDECTIN, MOXIDECTIN
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX**** M ****

MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER, MOXIFLOXACIN
 MOZOBIL, PLERIXAFOR
 MPI INDIUM DTPA IN 111, INDIUM IN-111 PENTETATE DISODIUM
 MS CONTIN, MORPHINE SULFATE
 MUCINEX, GUAIFENESIN (OTC)
 MUCINEX D, GUAIFENESIN (OTC)
 MUCINEX DM, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
 MULPLETA, LUSUTROMBOPAG
 MULTAQ, DRONEDARONE HYDROCHLORIDE
 MULTIHANCE, GADOBENATE DIMEGLUMINE
 MULTIHANCE MULTIPACK, GADOBENATE DIMEGLUMINE
 MUPIROCIN, MUPIROCIN
 MUPIROCIN, MUPIROCIN CALCIUM
 MUSE, ALPROSTADIL
 MYAMBUTOL, ETHAMBUTOL HYDROCHLORIDE
 MYCAMINE, MICAFUNGIN SODIUM
 MYCAPSSA, OCTREOTIDE ACETATE
 MYCOBUTIN, RIFABUTIN
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
 MYCOPHENOLIC ACID, MYCOPHENOLIC ACID
 MYDAYIS, AMPHETAMINE ASPARTATE
 MYDRIACYL, TROPICAMIDE
 MYFORTIC, MYCOPHENOLIC ACID
 MYKACET, NYSTATIN
 MYLERAN, BUSULFAN
 MYORISAN, ISOTRETINOIN
 MYOVIEV 30ML, TECHNETIUM TC-99M TETROFOSMIN KIT
 MYRBETRIQ, MIRABEGRON
 MYSOLINE, PRIMIDONE
 MYTESI, CROFELEMER
 MYZILRA, ETHINYL ESTRADIOL

**** N ****

NABUMETONE, NABUMETONE
 NADOLOL, NADOLOL
 NADOLOL AND BENDROFLUMETHIAZIDE, BENDROFLUMETHIAZIDE
 NAFCILLIN SODIUM, NAFCILLIN SODIUM
 NAFTIFINE HYDROCHLORIDE, NAFTIFINE HYDROCHLORIDE
 NAFTIN, NAFTIFINE HYDROCHLORIDE
 NALBUPHINE HYDROCHLORIDE, NALBUPHINE HYDROCHLORIDE
 NALFON, FENOPROFEN CALCIUM
 NALLPEN IN PLASTIC CONTAINER, NAFCILLIN SODIUM
 NALOXONE, NALOXONE HYDROCHLORIDE
 NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
 NAMENDA, MEMANTINE HYDROCHLORIDE
 NAMENDA XR, MEMANTINE HYDROCHLORIDE
 NAMZARIC, DONEPEZIL HYDROCHLORIDE
 NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)
 NAPHCN-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
 NAPRELAN, NAPROXEN SODIUM
 NAPROSYN, NAPROXEN
 NAPROXEN, NAPROXEN
 NAPROXEN AND ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
 NAPROXEN SODIUM, NAPROXEN SODIUM
 NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
 NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)
 NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
 NARCAN, NALOXONE HYDROCHLORIDE
 NARDIL, PHENELZINE SULFATE
 NAROPIN, ROPIVACAINE HYDROCHLORIDE
 NASACORT ALLERGY 24 HOUR, TRIAMCINOLONE ACETONIDE (OTC)

APPENDIX A - PRODUCT NAME INDEX

** N **

NASCOBAL, CYANOCOBALAMIN
 NASONEX, MOMETASONE FUROATE
 NATACYN, NATAMYCIN
 NATAZIA, DIENOGEST
 NATEGLINIDE, NATEGLINIDE
 NATESTO, TESTOSTERONE
 NATROBA, SPINOSAD
 NAYZILAM, MIDAZOLAM
 NEBIVOLOL HYDROCHLORIDE, NEBIVOLOL HYDROCHLORIDE
 NEBUPENT, PENTAMIDINE ISETHIONATE
 NEDOCROMIL SODIUM, NEDOCROMIL SODIUM
 NEFAZODONE HYDROCHLORIDE, NEFAZODONE HYDROCHLORIDE
 NEMBUTAL SODIUM, PENTOBARBITAL SODIUM
 NEO-SYNALAR, FLUOCINOLONE ACETONIDE
 NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE
 NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
 NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
 NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
 NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
 NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
 NEOMYCIN SULFATE, NEOMYCIN SULFATE
 NEOPAP, ACETAMINOPHEN (OTC)
 NEOPROFEN, IBUPROFEN LYSINE
 NEORAL, CYCLOSPORINE
 NEOSPORIN, GRAMICIDIN
 NEOSPORIN G.U. IRRIGANT, NEOMYCIN SULFATE
 NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
 NEPHRAMINE 5.4%, AMINO ACIDS
 NERLYNX, NERATINIB MALEATE
 NESACAINE, CHLOROPROCAINE HYDROCHLORIDE
 NESACAINE-MPF, CHLOROPROCAINE HYDROCHLORIDE
 NESINA, ALOGLIPTIN BENZOATE
 NETSPOT, GALLIUM DOTATATE GA-68
 NEUPRO, ROTIGOTINE
 NEURACEQ, FLORBETABEN F-18
 NEUROLITE, TECHNETIUM TC-99M BICISATE KIT
 NEURONTIN, GABAPENTIN
 NEVANAC, NEPAFENAC
 NEVIRAPINE, NEVIRAPINE
 NEXAVAR, SORAFENIB TOSYLATE
 NEXESTA FE, ETHINYL ESTRADIOL
 NEXIUM, ESOMEPRAZOLE MAGNESIUM
 NEXIUM 24HR, ESOMEPRAZOLE MAGNESIUM (OTC)
 NEXIUM IV, ESOMEPRAZOLE SODIUM
 NEXLETOL, BEMPEDOIC ACID
 NEXLIZET, BEMPEDOIC ACID
 NEXPLANON, ETNOGESTREL
 NEXTERONE, AMIODARONE HYDROCHLORIDE
 NIACIN, NIACIN
 NIACOR, NIACIN
 NIASPAN, NIACIN
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
 NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE, NICARDIPINE HYDROCHLORIDE
 NICODERM CQ, NICOTINE (OTC)
 NICORETTE, NICOTINE POLACRILEX (OTC)
 NICORETTE (MINT), NICOTINE POLACRILEX (OTC)
 NICOTINE, NICOTINE (OTC)
 NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
 NICOTROL, NICOTINE
 NIFEDIPINE, NIFEDIPINE
 NIKKI, DROSPIRENONE
 NILANDRON, NILUTAMIDE
 NILUTAMIDE, NILUTAMIDE
 NIMBEX, CISATRACURIUM BESYLATE
 NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE

APPENDIX A - PRODUCT NAME INDEX

** N **

NIMODIPINE, NIMODIPINE
NINLARO, IXAZOMIB CITRATE
NIPENT, PENTOSTATIN
NIPRIDE RTU IN SODIUM CHLORIDE 0.9%, SODIUM NITROPRUSSIDE
NISOLDIPINE, NISOLDIPINE
NITAZOXANIDE, NITAZOXANIDE
NITHIODE, SODIUM NITRITE
NITISINONE, NITISINONE
NITRO-DUR, NITROGLYCERIN
NITROFURANTOIN, NITROFURANTOIN
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
NITROGLYCERIN, NITROGLYCERIN
NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
NITROLINGUAL PUMPSPRAY, NITROGLYCERIN
NITROMIST, NITROGLYCERIN
NITROPRESS, SODIUM NITROPRUSSIDE
NITROSTAT, NITROGLYCERIN
NITYR, NITISINONE
NIX, PERMETHRIN (OTC)
NIZATIDINE, NIZATIDINE
NIZORAL A-D, KETOCONAZOLE (OTC)
NOCDURNA, DESMOPRESSIN ACETATE
NOR-QD, NORETHINDRONE
NORCO, ACETAMINOPHEN
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
NORETHINDRONE, NORETHINDRONE
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL (10/11), ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORINYL 1+35 21-DAY, ETHINYL ESTRADIOL
NORINYL 1+35 28-DAY, ETHINYL ESTRADIOL
NORITATE, METRONIDAZOLE
NORMOCARB HF 25, MAGNESIUM CHLORIDE
NORMOCARB HF 35, MAGNESIUM CHLORIDE
NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
NORPACE, DISOPYRAMIDE PHOSPHATE
NORPACE CR, DISOPYRAMIDE PHOSPHATE
NORPRAMIN, DESIPRAMINE HYDROCHLORIDE
NORTHERA, DROXIDOPA
NORTREL 0.5/35-28, ETHINYL ESTRADIOL
NORTREL 1/35-21, ETHINYL ESTRADIOL
NORTREL 1/35-28, ETHINYL ESTRADIOL
NORTREL 7/7/7, ETHINYL ESTRADIOL
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
NORVASC, AMLODIPINE BESYLATE
NORVIR, RITONAVIR
NOURIANZ, ISTRADefylline
NOXAFIL, POSACONAZOLE
NOXIVENT, NITRIC OXIDE
NUBEQA, DAROLUTAMIDE
NUCYNTA, TAPENTADOL HYDROCHLORIDE
NUCYNTA ER, TAPENTADOL HYDROCHLORIDE
NUEDEXTA, DEXTROMETHORPHAN HYDROBROMIDE
NULYTELY, POLYETHYLENE GLYCOL 3350
NULYTELY-FLAVORED, POLYETHYLENE GLYCOL 3350
NUMBRINO, COCAINE HYDROCHLORIDE
NUPLAZID, PIMAVANSERIN TARTRATE
NURTEC ODT, RIMEGEPANT SULFATE

APPENDIX A - PRODUCT NAME INDEX

** N **

NUTRILIPID 10%, SOYBEAN OIL
 NUTRILIPID 20%, SOYBEAN OIL
 NUVARING, ETHINYL ESTRADIOL
 NUVESSA, METRONIDAZOLE
 NUVIGIL, ARMODAFINIL
 NUZYRA, OMADACYCLINE TOSYLATE
 NYLIA 1/35, ETHINYL ESTRADIOL
 NYLIA 7/7/7, ETHINYL ESTRADIOL
 NYMALIZE, NIMODIPINE
 NYSTATIN, NYSTATIN
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 NYSTOP, NYSTATIN

** O **

OCALIVA, OBETICHOLIC ACID
 OCTREOSCAN, INDIUM IN-111 PENTETREOTIDE KIT
 OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
 OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
 OCUFEN, FLURBIPROFEN SODIUM
 OCUFLOX, OFLOXACIN
 ODEFSEY, EMTRICITABINE
 ODOMZO, SONIDEGIB PHOSPHATE
 OFEV, NINTEDANIB ESYLATE
 OFIRMEV, ACETAMINOPHEN
 OFLOXACIN, OFLOXACIN
 OGEN 5, ESTROPIPATE
 OLANZAPINE, OLANZAPINE
 OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 OLINVYK, OLICERIDINE
 OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
 OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE (OTC)
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
 OLUMIANT, BARICITINIB
 OLUX, CLOBETASOL PROPIONATE
 OLUX E, CLOBETASOL PROPIONATE
 OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
 OMEGAVEN, FISH OIL TRIGLYCERIDES
 OMEPRAZOLE, OMEPRAZOLE (OTC)
 OMEPRAZOLE, OMEPRAZOLE
 OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN, AMOXICILLIN
 OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
 OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
 OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)
 OMIDRIA, KETOROLAC TROMETHAMINE
 OMNARIS, CICLESONIDE
 OMNIPAQUE 12, IOHEXOL
 OMNIPAQUE 140, IOHEXOL
 OMNIPAQUE 180, IOHEXOL
 OMNIPAQUE 240, IOHEXOL
 OMNIPAQUE 300, IOHEXOL
 OMNIPAQUE 350, IOHEXOL
 OMNIPAQUE 9, IOHEXOL
 OMNIPRED, PREDNISOLONE ACETATE
 OMNISCAN, GADODIAMIDE
 ONDANSETRON, ONDANSETRON
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONEXTON, BENZOYL PEROXIDE
 ONFI, CLOBAZAM
 ONGENTYS, OPICAPONE
 ONGLYZA, SAXAGLIPTIN HYDROCHLORIDE
 ONIVYDE, IRINOTECAN HYDROCHLORIDE
 ONMEL, ITRACONAZOLE

APPENDIX A - PRODUCT NAME INDEX

** O **

ONPATTRO, PATISIRAN SODIUM
ONUREG, AZACITIDINE
ONZETRA XSAIL, SUMATRIPTAN SUCCINATE
OPCICON ONE-STEP, LEVONORGESTREL (OTC)
OPCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
OPSUMIT, MACITENTAN
OPTIRAY 240, IOVERSOL
OPTIRAY 300, IOVERSOL
OPTIRAY 320, IOVERSOL
OPTIRAY 350, IOVERSOL
OPTISON, ALBUMIN HUMAN
ORABLOC, ARTICAIN HYDROCHLORIDE
ORACEA, DOXYCYCLINE
ORALTAG, IOHEXOL
ORAPRED ODT, PREDNISOLONE SODIUM PHOSPHATE
ORAQIX, LIDOCAINE
ORAVERSE, PHENTOLAMINE MESYLATE
ORAVIG, MICONAZOLE
ORBACTIV, ORITAVANCIN DIPHOSPHATE
ORENITRAM, TREPROSTINIL DIOLAMINE
ORFADIN, NITISINONE
ORGOVYX, RELUGOLIX
ORIAHNN (COPACKAGED), ELAGOLIX SODIUM, ESTRADIOL, NORETHINDRONE ACETATE
ORILISSA, ELAGOLIX SODIUM
ORKAMBI, IVACAFTOR
ORLADEYO, BEROTRALSTAT HYDROCHLORIDE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
ORPHENGESIC FORTE, ASPIRIN
ORTIKOS, BUDESONIDE
ORVATEN, MIDODRINE HYDROCHLORIDE
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
OSENI, ALOGLIPTIN BENZOATE
OSMITROL 10% IN WATER, MANNITOL
OSMITROL 10% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 15% IN WATER, MANNITOL
OSMITROL 15% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 20% IN WATER, MANNITOL
OSMITROL 20% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 5% IN WATER, MANNITOL
OSMITROL 5% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMOLEX ER, AMANTADINE HYDROCHLORIDE
OSMOPREP, SODIUM PHOSPHATE, DIBASIC, ANHYDROUS
OSPHENA, OSPEMIFENE
OTEZLA, APREMILAST
OTICAIR, HYDROCORTISONE
OTIPRIO, CIPROFLOXACIN
OTOVEL, CIPROFLOXACIN HYDROCHLORIDE
OTREXUP, METHOTREXATE
OXACILLIN SODIUM, OXACILLIN SODIUM
OXALIPLATIN, OXALIPLATIN
OXANDROLONE, OXANDROLONE
OXAPROZIN, OXAPROZIN
OXAYDO, OXYCODONE HYDROCHLORIDE
OXAZEPAM, OXAZEPAM
OXBRYTA, VOXELOTOR
OXCARBAZEPINE, OXCARBAZEPINE
OXICONAZOLE NITRATE, OXICONAZOLE NITRATE
OXISTAT, OXICONAZOLE NITRATE
OXLUMO, LUMASIRAN SODIUM
OXSORALEN-ULTRA, METHOXSALLEN
OXTELLAR XR, OXCARBAZEPINE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCET, ACETAMINOPHEN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE AND ASPIRIN, ASPIRIN

APPENDIX A - PRODUCT NAME INDEX**** O ****

OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 OXYCONTIN, OXYCODONE HYDROCHLORIDE
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
 OXYTOCIN, OXYTOCIN
 OXYTROL, OXYBUTYNIN
 OXYTROL FOR WOMEN, OXYBUTYNIN (OTC)
 OZEMPIC, SEMAGLUTIDE
 OZOBAX, BACLOFEN
 OZURDEX, DEXAMETHASONE

**** P ****

PACERONE, AMIODARONE HYDROCHLORIDE
 PACITAXEL, PACLITAXEL
 PACLITAXEL, PACLITAXEL
 PALIPERIDONE, PALIPERIDONE
 PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
 PAMELOR, NORTRIPTHYLINE HYDROCHLORIDE
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
 PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
 PANDEL, HYDROCORTISONE PROBUTATE
 PANRETIN, ALITRETINOIN
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PARAGARD T 380A, COPPER
 PAREMYD, HYDROXYAMPHETAMINE HYDROBROMIDE
 PARICALCITOL, PARICALCITOL
 PARLODEL, BROMOCRIPTINE MESYLATE
 PARNATE, TRANYLCPROMINE SULFATE
 PAROEX, CHLORHEXIDINE GLUCONATE
 PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
 PAROXETINE, PAROXETINE HYDROCHLORIDE
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PAROXETINE MESYLATE, PAROXETINE MESYLATE
 PARSABIV, ETELCALCETIDE
 PASER, AMINOSALICYLIC ACID
 PATADAY ONCE DAILY RELIEF, OLOPATADINE HYDROCHLORIDE (OTC)
 PATADAY TWICE DAILY RELIEF, OLOPATADINE HYDROCHLORIDE (OTC)
 PATANASE, OLOPATADINE HYDROCHLORIDE
 PAXIL, PAROXETINE HYDROCHLORIDE
 PAXIL CR, PAROXETINE HYDROCHLORIDE
 PEDIAPRED, PREDNISOLONE SODIUM PHOSPHATE
 PEG 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
 PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE, POLYETHYLENE GLYCOL
 PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND
 PEMAZYRE, PEMIGATINIB
 PEMETREXED, PEMETREXED
 PEMFEXY, PEMETREXED
 PENICILLAMINE, PENICILLAMINE
 PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
 PENICILLIN G POTASSIUM IN PLASTIC CONTAINER, PENICILLIN G POTASSIUM
 PENICILLIN G PROCAINE, PENICILLIN G PROCAINE
 PENICILLIN G SODIUM, PENICILLIN G SODIUM
 PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
 PENICILLIN-VK, PENICILLIN V POTASSIUM
 PENLAC, CICLOPIROX
 PENNSAID, DICLOFENAC SODIUM
 PENTAM, PENTAMIDINE ISETHIONATE
 PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE
 PENTASA, MESALAMINE
 PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
 PENTOLAIR, CYCLOPENTOLATE HYDROCHLORIDE
 PENTOSTATIN, PENTOSTATIN
 PENTOXIFYLLINE, PENTOXIFYLLINE
 PENTOXIL, PENTOXIFYLLINE
 PEPCID AC, FAMOTIDINE (OTC)
 PEPCID COMPLETE, CALCIUM CARBONATE (OTC)

APPENDIX A - PRODUCT NAME INDEX

** P **

PERCOCET, ACETAMINOPHEN
PERCODAN, ASPIRIN
PERFOROMIST, FORMOTEROL FUMARATE
PERIDEX, CHLORHEXIDINE GLUCONATE
PERIKABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
PERIOCHIP, CHLORHEXIDINE GLUCONATE
PERIOGARD, CHLORHEXIDINE GLUCONATE
PERMETHRIN, PERMETHRIN (OTC)
PERMETHRIN, PERMETHRIN
PERPHENAZINE, PERPHENAZINE
PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
PERSANTINE, DIPYRIDAMOLE
PERSERIS KIT, RISPERIDONE
PEXEVA, PAROXETINE MESYLATE
PFIZERPEN, PENICILLIN G POTASSIUM
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENELZINE SULFATE, PHENELZINE SULFATE
PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PHENYTEK, PHENYTOIN SODIUM
PHENYTOIN, PHENYTOIN
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PHEXXI, CITRIC ACID
PHILITH, ETHINYL ESTRADIOL
PHOSLO GELCAPS, CALCIUM ACETATE
PHOSLYRA, CALCIUM ACETATE
PHOSPHOLINE IODIDE, ECHOTHIOPHATE IODIDE
PHOTOFRIN, PORFIMER SODIUM
PHOTREXA, RIBOFLAVIN 5'-PHOSPHATE SODIUM
PHOTREXA VISCOUS IN DEXTRAN 20%, RIBOFLAVIN 5'-PHOSPHATE SODIUM
PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PHYSIOLYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PHYSIOSOL IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PHYTONADIONE, PHYTONADIONE
PIFELTRO, DORAVIRINE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
PIMECROLIMUS, PIMECROLIMUS
PIMOZIDE, PIMOZIDE
PIMTREA, DESOGESTREL
PINDOLOL, PINDOLOL
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE, GLIMEPIRIDE
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PIPERACILLIN, PIPERACILLIN SODIUM
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PIQRAY, ALPELISIB
PIRMELLA 1/35, ETHINYL ESTRADIOL
PIRMELLA 7/7/7, ETHINYL ESTRADIOL
PIROXICAM, PIROXICAM
PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM
PITOCIN, OXYTOCIN
PLAN B ONE-STEP, LEVONORGESTREL (OTC)
PLAQUENIL, HYDROXYCHLOROQUINE SULFATE
PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLASMA-LYTE A IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLAVIX, CLOPIDOGREL BISULFATE
PLEGISOL IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PLENVU, ASCORBIC ACID
PLIAGLIS, LIDOCAINE
PODOFILOX, PODOFILOX

APPENDIX A - PRODUCT NAME INDEX

** P **

POLMON, DEXCHLORPHENIRAMINE MALEATE
 POLOCAINE, MEPIVACAINE HYDROCHLORIDE
 POLOCAINE-MPF, MEPIVACAINE HYDROCHLORIDE
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
 POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 POLYTRIM, POLYMYXIN B SULFATE
 POMALIDOMIDE, POMALIDOMIDE
 POMALYST, POMALIDOMIDE
 PONSTEL, MEFENAMIC ACID
 PORTIA-28, ETHINYL ESTRADIOL
 POSACONAZOLE, POSACONAZOLE
 POTASSIUM ACETATE, POTASSIUM ACETATE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE

APPENDIX A - PRODUCT NAME INDEX

** P **

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 10MEQ, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 40MEQ, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CITRATE, POTASSIUM CITRATE
 POTASSIUM IODIDE, POTASSIUM IODIDE (OTC)
 POTASSIUM PHOSPHATES, POTASSIUM PHOSPHATE, DIBASIC
 POVIDONE IODINE, POVIDONE-IODINE (OTC)
 PRADAXA, DABIGATRAN ETEXILATE MESYLATE
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 PRAMOSONE, HYDROCORTISONE ACETATE
 PRASUGREL, PRASUGREL HYDROCHLORIDE
 PRAVACHOL, PRAVASTATIN SODIUM
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 PRAZIQUANTEL, PRAZIQUANTEL
 PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
 PRE-OP, HEXACHLOROPHENE
 PRE-OP II, HEXACHLOROPHENE
 PRE-PEN, BENZYL PENICILLOYL POLYLYSINE
 PRECEDEX, DEXMEDETOMIDINE HYDROCHLORIDE
 PRED FORTE, PREDNISOLONE ACETATE
 PRED MILD, PREDNISOLONE ACETATE
 PRED-G, GENTAMICIN SULFATE
 PREDNICARBATE, PREDNICARBATE
 PREDNISOLONE, PREDNISOLONE
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 PREDNISONE, PREDNISONE
 PREDNISONE INTENSOL, PREDNISONE
 PREGABALIN, PREGABALIN
 PRELONE, PREDNISOLONE
 PREMARIN, ESTROGENS, CONJUGATED

APPENDIX A - PRODUCT NAME INDEX

** P **

PREMASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
 PREMASOL 6% IN PLASTIC CONTAINER, AMINO ACIDS
 PREMPHASE 14/14, ESTROGENS, CONJUGATED
 PREMPRO, ESTROGENS, CONJUGATED
 PREPIDIL, DINOPROSTONE
 PRESTALIA, AMLODIPINE BESYLATE
 PRETOMANID, PRETOMANID
 PREVACID, LANSOPRAZOLE
 PREVACID 24 HR, LANSOPRAZOLE (OTC)
 PREVALITE, CHOLESTYRAMINE
 PREVANTICS MAXI SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
 PREVANTICS SWAB, CHLORHEXIDINE GLUCONATE (OTC)
 PREVANTICS SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
 PREVIFEM, ETHINYL ESTRADIOL
 PREVYMIS, LETERMOVIR
 PREZCOBIX, COBICISTAT
 PREZISTA, DARUNAVIR
 PRIALT, ZICONOTIDE ACETATE
 PRIFTIN, RIFAPENTINE
 PRILOCAINE HYDROCHLORIDE, PRILOCAINE HYDROCHLORIDE
 PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, EPINEPHRINE BITARTRATE
 PRILOSEC, OMEPRAZOLE MAGNESIUM
 PRILOSEC OTC, OMEPRAZOLE MAGNESIUM (OTC)
 PRIMAQUINE, PRIMAQUINE PHOSPHATE
 PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE
 PRIMATENE MIST, EPINEPHRINE (OTC)
 PRIMAXIN, CILASTATIN SODIUM
 PRIMIDONE, PRIMIDONE
 PRINIVIL, LISINAPRIL
 PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PRISMASOL BGK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PRISTIQ, DESVENLAFAXINE SUCCINATE
 PROAIR DIGIHALER, ALBUTEROL SULFATE
 PROAIR HFA, ALBUTEROL SULFATE
 PROAIR RESPICLICK, ALBUTEROL SULFATE
 PROBALAN, PROBENECID
 PROBENECID, PROBENECID
 PROBENECID AND COLCHICINE, COLCHICINE
 PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE
 PROCALAMINE, AMINO ACIDS
 PROCARDIA, NIFEDIPINE
 PROCARDIA XL, NIFEDIPINE
 PROCHLORPERAZINE, PROCHLORPERAZINE
 PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
 PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
 PROCOMP, PROCHLORPERAZINE MALEATE
 PROCTOFOAM HC, HYDROCORTISONE ACETATE
 PROCYSBI, CYSTEAMINE BITARTRATE
 PROGESTERONE, PROGESTERONE
 PROGLYCEM, DIAZOXIDE
 PROGRAF, TACROLIMUS
 PROHANCE, GADOTERIDOL
 PROHANCE MULTIPACK, GADOTERIDOL
 PROLENSA, BROMFENAC SODIUM
 PROMACTA, ELTROMBOPAG OLAMINE
 PROMACTA KIT, ELTROMBOPAG OLAMINE
 PROMETH HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE PHOSPHATE
 PROMETH VC W/ CODEINE, CODEINE PHOSPHATE
 PROMETHAZINE DM, DEXTROMETHORPHAN HYDROBROMIDE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX**** P ****

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
 PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN
 PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
 PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
 PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
 PROMETHAZINE PLAIN, PROMETHAZINE HYDROCHLORIDE
 PROMETHAZINE W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
 PROMETHAZINE WITH CODEINE, CODEINE PHOSPHATE
 PROMETHEGAN, PROMETHAZINE HYDROCHLORIDE
 PROMETRIUM, PROGESTERONE
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
 PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
 PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE
 PROPECIA, FINASTERIDE
 PROPOFOL, PROPOFOL
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 PROPYLTHIOURACIL, PROPYLTHIOURACIL
 PROSCAR, FINASTERIDE
 PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
 PROSTIN E2, DINOPROSTONE
 PROSTIN VR PEDIATRIC, ALPROSTADIL
 PROTAMINE SULFATE, PROTAMINE SULFATE
 PROTONIX, PANTOPRAZOLE SODIUM
 PROTONIX IV, PANTOPRAZOLE SODIUM
 PROTOPAM CHLORIDE, PRALIDOXIME CHLORIDE
 PROTOPIC, TACROLIMUS
 PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
 PROVAYBLUE, METHYLENE BLUE
 PROVENTIL-HFA, ALBUTEROL SULFATE
 PROVERA, MEDROXYPROGESTERONE ACETATE
 PROVIGIL, MODAFINIL
 PROVOCHOLINE, METHACHOLINE CHLORIDE
 PROZAC, FLUOXETINE HYDROCHLORIDE
 PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
 PULMICORT FLEXHALER, BUDESONIDE
 PULMICORT RESPULES, BUDESONIDE
 PUR-WASH, PURIFIED WATER (OTC)
 PURINETHOL, MERCAPTOPURINE
 PURIXAN, MERCAPTOPURINE
 PYLERA, BISMUTH SUBCITRATE POTASSIUM
 PYRAZINAMIDE, PYRAZINAMIDE
 PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
 PYRIDOXINE HYDROCHLORIDE, PYRIDOXINE HYDROCHLORIDE
 PYRIMETHAMINE, PYRIMETHAMINE
 PYTEST, UREA, C-14
 PYTEST KIT, UREA, C-14

**** Q ****

QBRELIS, LISINAPRIL
 QBREXZA, GLYCOPYRRONIUM TOSYLATE
 QDOLO, TRAMADOL HYDROCHLORIDE
 QINLOCK, RIPRETINIB
 QNASL, BECLOMETHASONE DIPROPIONATE
 QOLIANA, BRIMONIDINE TARTRATE
 QSYMIA, PHENTERMINE HYDROCHLORIDE
 QTERN, DAPAGLIFLOZIN
 QUADRAMET, SAMARIUM SM-153 LEXIDRONAM PENTASODIUM
 QUALAQUIN, QUININE SULFATE
 QUARTETTE, ETHINYL ESTRADIOL
 QUASENSE, ETHINYL ESTRADIOL
 QUDEXY XR, TOPIRAMATE
 QUELICIN, SUCCINYLCHOLINE CHLORIDE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 QUILLICHEW ER, METHYLPHENIDATE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

** Q **

QUILLIVANT XR, METHYLPHENIDATE HYDROCHLORIDE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
QUINARETIC, HYDROCHLOROTHIAZIDE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
QUININE SULFATE, QUININE SULFATE
QUTENZA, CAPSAICIN
QUZYTIR, CETIRIZINE HYDROCHLORIDE
QVAR REDIHALER, BECLOMETHASONE DIPROPIONATE

** R **

R-GENE 10, ARGININE HYDROCHLORIDE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
RADICAVA, EDARAVONE
RADIOGARDASE (PRUSSIAN BLUE), FERRIC HEXACYANOFERRATE(II)
RADIOGENIX SYSTEM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RAMELTEON, RAMELTEON
RAMIPRIL, RAMIPRIL
RANEXA, RANOLAZINE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RANOLAZINE, RANOLAZINE
RAPAFLO, SILODOSIN
RAPAMUNE, SIROLIMUS
RAPIVAB, PERAMIVIR
RASAGILINE MESYLATE, RASAGILINE MESYLATE
RASUVO, METHOTREXATE
RAVICTI, GLYCEROL PHENYL BUTYRATE
RAYALDEE, CALCIFEDIOL
RAYOS, PREDNISONE
RAZADYNE, GALANTAMINE HYDROBROMIDE
RAZADYNE ER, GALANTAMINE HYDROBROMIDE
READI-CAT 2, BARIUM SULFATE
READI-CAT 2 SMOOTHIE, BARIUM SULFATE
READYPREP CHG, CHLORHEXIDINE GLUCONATE (OTC)
REBETOL, RIBAVIRIN
RECARBRIO, CILASTATIN SODIUM
RECLAST, ZOLEDRONIC ACID
RECTIV, NITROGLYCERIN
REDITREX, METHOTREXATE
REGLAN, METOCLOPRAMIDE HYDROCHLORIDE
REGONOL, PYRIDOSTIGMINE BROMIDE
RELENZA, ZANAMIVIR
RELISTOR, METHYLNALTREXONE BROMIDE
RELPAK, ELETRIPTAN HYDROBROMIDE
REMERON, MIRTAZAPINE
REMERON SOLTAB, MIRTAZAPINE
REMIFENTANIL HYDROCHLORIDE, REMIFENTANIL HYDROCHLORIDE
REMODULIN, TREPROSTINIL
RENACIDIN, CITRIC ACID
RENAGEL, SEVELAMER HYDROCHLORIDE
RENOVA, TRETINOIN
RENVELA, SEVELAMER CARBONATE
REPAGLINIDE, REPAGLINIDE
REPREXAIN, HYDROCODONE BITARTRATE
REQUIP, ROPINIROLE HYDROCHLORIDE
REQUIP XL, ROPINIROLE HYDROCHLORIDE
RESECTISOL IN PLASTIC CONTAINER, MANNITOL
RESTASIS, CYCLOSPORINE
RESTASIS MULTIDOSE, CYCLOSPORINE
RESTORIL, TEMAZEPAM
RETEVMO, SELPERCATINIB
RETIN-A, TRETINOIN

APPENDIX A - PRODUCT NAME INDEX

** R **

RETIN-A MICRO, TRETINOIN
RETIN-A-MICRO, TRETINOIN
RETISERT, FLUOCINOLONE ACETONIDE
RETROVIR, ZIDOVUDINE
REVATIO, SILDENAFIL CITRATE
REVLIMID, LENALIDOMIDE
REVONTO, DANTROLENE SODIUM
REXULTI, BREXPIPIRAZOLE
REYATAZ, ATAZANAVIR SULFATE
REYVOW, LASMIDITAN SUCCINATE
RHINOCORT ALLERGY, BUDESONIDE (OTC)
RHOFADE, OXYMETAZOLINE HYDROCHLORIDE
RHOPRESSA, NETARSUDIL MESYLATE
RIBAVIRIN, RIBAVIRIN
RIDAURA, AURANOFIN
RIFABUTIN, RIFABUTIN
RIFADIN, RIFAMPIN
RIFAMPIN, RIFAMPIN
RILUTEK, RILUZOLE
RILUZOLE, RILUZOLE
RIMACTANE, RIFAMPIN
RIMANTADINE HYDROCHLORIDE, RIMANTADINE HYDROCHLORIDE
RIMSO-50, DIMETHYL SULFOXIDE
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
RINVOQ, UPADACITINIB
RIOMET, METFORMIN HYDROCHLORIDE
RISEDRONATE SODIUM, RISEDRONATE SODIUM
RISPERDAL, RISPERIDONE
RISPERDAL CONSTA, RISPERIDONE
RISPERIDONE, RISPERIDONE
RITALIN, METHYLPHENIDATE HYDROCHLORIDE
RITALIN LA, METHYLPHENIDATE HYDROCHLORIDE
RITONAVIR, RITONAVIR
RIVASTIGMINE, RIVASTIGMINE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROBAXIN, METHOCARBAMOL
ROCALTROL, CALCITRIOL
ROCKLATAN, LATANOPROST
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
ROFLUMILAST, ROFLUMILAST
ROGAINE (FOR MEN), MINOXIDIL (OTC)
ROGAINE (FOR WOMEN), MINOXIDIL (OTC)
ROGAINE EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
ROMIDEPSIN, ROMIDEPSIN
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
ROWASA, MESALAMINE
ROXICET, ACETAMINOPHEN
ROXICODONE, OXYCODONE HYDROCHLORIDE
ROZEREM, RAMELTEON
ROZLYTREK, ENTRECTINIB
RUBRACA, RUCAPARIB CAMSYLATE
RUBY-FILL, RUBIDIUM CHLORIDE RB-82
RUFINAMIDE, RUFINAMIDE
RUKOBIA, FOSTEMSAVIR TROMETHAMINE
RUZURGI, AMIFAMPRIDINE
RYANODEX, DANTROLENE SODIUM
RYBELSUS, SEMAGLUTIDE
RYDAPT, MIDOSTAURIN
RYTARY, CARBIDOPA
RYTHMOL SR, PROPAFENONE HYDROCHLORIDE

** S **

APPENDIX A - PRODUCT NAME INDEX

** S **

SABRIL, VIGABATRIN
SAFYRAL, DROSPIRENONE
SALAGEN, PILOCARPINE HYDROCHLORIDE
SALONPAS, MENTHOL (OTC)
SAMSCA, TOLVAPTAN
SANCUSO, GRANISETRON
SANDIMMUNE, CYCLOSPORINE
SANDOSTATIN, OCTREOTIDE ACETATE
SANDOSTATIN LAR, OCTREOTIDE ACETATE
SAPHRIS, ASENAPINE MALEATE
SAPROPTERIN DIHYDROCHLORIDE, SAPROPTERIN DIHYDROCHLORIDE
SARAFEM, FLUOXETINE HYDROCHLORIDE
SAVAYSA, EDOXABAN TOSYLATE
SAVELLA, MILNACIPRAN HYDROCHLORIDE
SAXENDA, LIRAGLUTIDE RECOMBINANT
SCANDONEST L, LEVONORDEFIN
SCANDONEST PLAIN, MEPIVACAINE HYDROCHLORIDE
SCANLUX-300, IOPAMIDOL
SCANLUX-370, IOPAMIDOL
SCENESSE, AFAMELANOTIDE
SCLEROSOL, TALC
SCOPOLAMINE, SCOPOLAMINE
SEASONALE, ETHINYL ESTRADIOL
SEASONIQUE, ETHINYL ESTRADIOL
SECUADO, ASENAPINE
SEGLUOMET, ERTUGLIFLOZIN
SEIZALAM, MIDAZOLAM HYDROCHLORIDE
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
SELENIUS ACID, SELENIUS ACID
SELENIUM SULFIDE, SELENIUM SULFIDE
SELZENTRY, MARAVIROC
SENSIPAR, CINACALCET HYDROCHLORIDE
SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
SEPTOCAINE, ARTICAINE HYDROCHLORIDE
SEPTRA, SULFAMETHOXAZOLE
SEPTRA DS, SULFAMETHOXAZOLE
SEREVENT, SALMETEROL XINAFOATE
SERNIVO, BETAMETHASONE DIPROPIONATE
SEROMYCIN, CYCLOSERINE
SEROQUEL, QUETIAPINE FUMARATE
SEROQUEL XR, QUETIAPINE FUMARATE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SESQUIENT, FOSPHENYTOIN SODIUM
SETLAKIN, ETHINYL ESTRADIOL
SEVELAMER CARBONATE, SEVELAMER CARBONATE
SEVELAMER HYDROCHLORIDE, SEVELAMER HYDROCHLORIDE
SEVOFLURANE, SEVOFLURANE
SEYSARA, SARECYCLINE HYDROCHLORIDE
SFROWASA, MESALAMINE
SIGNIFOR, PASIREOTIDE DIASPARTATE
SIGNIFOR LAR KIT, PASIREOTIDE PAMOATE
SIKLOS, HYDROXYUREA
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SILENOR, DOXEPIN HYDROCHLORIDE
SILODOSIN, SILODOSIN
SILVADENE, SILVER SULFADIAZINE
SIMBRINZA, BRIMONIDINE TARTRATE
SIMLIYA, DESOGESTREL
SIMPESE, ETHINYL ESTRADIOL
SIMVASTATIN, SIMVASTATIN
SINE-AID IB, IBUPROFEN (OTC)
SINEMET, CARBIDOPA
SINGULAIR, MONTELUKAST SODIUM
SINUVA, MOMETASONE FUROATE
SIROLIMUS, SIROLIMUS

APPENDIX A - PRODUCT NAME INDEX

** S **

SIRTURO, BEDAQUILINE FUMARATE
SITAVIG, ACYCLOVIR
SIVEXTRO, TEDIZOLID PHOSPHATE
SKELAXIN, METAXALONE
SKLICE, IVERMECTIN (OTC)
SKYLA, LEVONORGESTREL
SLYND, DROSPIRENONE
SMOFLIPID 20%, FISH OIL
SODIUM ACETATE, SODIUM ACETATE
SODIUM BICARBONATE, SODIUM BICARBONATE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 14.6%, SODIUM CHLORIDE
SODIUM CHLORIDE 23.4%, SODIUM CHLORIDE
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE, SODIUM FERRIC GLUCONATE COMPLEX
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18
SODIUM IODIDE I 123, SODIUM IODIDE I-123
SODIUM IODIDE I 131, SODIUM IODIDE I-131
SODIUM NITRITE, SODIUM NITRITE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SODIUM PHENYLACETATE AND SODIUM BENZOATE, SODIUM BENZOATE
SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE
SODIUM PHOSPHATES IN PLASTIC CONTAINER, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE, MAGNESIUM SULFATE
SODIUM TETRADECYL SULFATE, SODIUM TETRADECYL SULFATE
SODIUM THIOSULFATE, SODIUM THIOSULFATE
SOJOURN, SEVOFLURANE
SOLARAZE, DICLOFENAC SODIUM
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
SOLODYN, MINOCYCLINE HYDROCHLORIDE
SOLOSEC, SECNIDAZOLE
SOLTAMOX, TAMOXIFEN CITRATE
SOLU-CORTEF, HYDROCORTISONE SODIUM SUCCINATE
SOLU-MEDROL, METHYLPREDNISOLONE SODIUM SUCCINATE
SOLUPREP, CHLORHEXIDINE GLUCONATE (OTC)
SOMA, CARISOPRODOL
SOMATULINE DEPOT, LANREOTIDE ACETATE
SONATA, ZALEPLON
SOOLANTRA, IVERMECTIN
SORAFENIB TOSYLATE, SORAFENIB TOSYLATE
SORBITOL 3% IN PLASTIC CONTAINER, SORBITOL
SORBITOL 3.3% IN PLASTIC CONTAINER, SORBITOL
SORBITOL-MANNITOL IN PLASTIC CONTAINER, MANNITOL
SORIATANE, ACITRETIN
SORILUX, CALCIPOTRIENE
SORINE, SOTALOL HYDROCHLORIDE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
SOTRADECOL, SODIUM TETRADECYL SULFATE
SOTYLIZE, SOTALOL HYDROCHLORIDE
SOVALDI, SOFOSBUVIR
SPECTAZOLE, ECONAZOLE NITRATE
SPINRAZA, NUSINERSEN SODIUM
SPIRIVA, TIOTROPIUM BROMIDE
SPIRIVA RESPIMAT, TIOTROPIUM BROMIDE
SPIRONOLACTONE, SPIRONOLACTONE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPORANOX, ITRACONAZOLE
SPRAVATO, ESKETAMINE HYDROCHLORIDE
SPRINTEC, ETHINYL ESTRADIOL
SPRITAM, LEVETIRACETAM

APPENDIX A - PRODUCT NAME INDEX

** S **

SPRIX, KETOROLAC TROMETHAMINE
SPRYCEL, DASATINIB
SPS, SODIUM POLYSTYRENE SULFONATE
SPY AGENT GREEN KIT, INDOCYANINE GREEN
SSD, SILVER SULFADIAZINE
STALEVO 100, CARBIDOPA
STALEVO 125, CARBIDOPA
STALEVO 150, CARBIDOPA
STALEVO 200, CARBIDOPA
STALEVO 50, CARBIDOPA
STALEVO 75, CARBIDOPA
STAXYN, VARDENAFIL HYDROCHLORIDE
STEGLATRO, ERTUGLIFLOZIN
STEGLUJAN, ERTUGLIFLOZIN
STENDRA, AVANAFIL
STERILE WATER, STERILE WATER FOR IRRIGATION
STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
STERITALC, TALC
STIE-CORT, HYDROCORTISONE
STIOLTO RESPIMAT, OLODATEROL HYDROCHLORIDE
STIVARGA, REGORAFENIB
STRATTERA, ATOMOXETINE HYDROCHLORIDE
STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE
STRIBILD, COBICISTAT
STRIVERDI RESPIMAT, OLODATEROL HYDROCHLORIDE
STROMECTOL, IVERMECTIN
STRONTIUM CHLORIDE SR-89, STRONTIUM CHLORIDE SR-89
SUBLIMAZE PRESERVATIVE FREE, FENTANYL CITRATE
SUBLOCADE, BUPRENORPHINE
SUBOXONE, BUPRENORPHINE HYDROCHLORIDE
SUBSYS, FENTANYL
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
SUCRALFATE, SUCRALFATE
SUDAFED 12 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
SUDAFED 24 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
SUFENTA PRESERVATIVE FREE, SUFENTANIL CITRATE
SUFENTANIL CITRATE, SUFENTANIL CITRATE
SULAR, NISOLDIPINE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
SULFADIAZINE, SULFADIAZINE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFAMYLON, MAFENIDE ACETATE
SULFASALAZINE, SULFASALAZINE
SULFATRIM PEDIATRIC, SULFAMETHOXAZOLE
SULINDAC, SULINDAC
SUMATRIPTAN, SUMATRIPTAN
SUMATRIPTAN AND NAPROXEN SODIUM, NAPROXEN SODIUM
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
SUNOSI, SOLRIAMFETOL HYDROCHLORIDE
SUPPRELIN LA, HISTRELIN ACETATE
SUPRANE, DESFLURANE
SUPRAX, CEFIXIME
SUPREP BOWEL PREP KIT, MAGNESIUM SULFATE
SUSTIVA, EFAVIRENZ
SUSTOL, GRANISETRON
SUTAB (COPACKAGED), MAGNESIUM SULFATE
SUTENT, SUNITINIB MALATE
SYEDA, DROSPIRENONE
SYLEVIA, ETHINYL ESTRADIOL
SYMBICORT, BUDESONIDE
SYMBYAX, FLUOXETINE HYDROCHLORIDE
SYMDEKO (COPACKAGED), IVACAFTOR

APPENDIX A - PRODUCT NAME INDEX

** S **

SYMFI, EFAVIRENZ
 SYMFI LO, EFAVIRENZ
 SYMJEPI, EPINEPHRINE
 SYMLIN, PRAMLINTIDE ACETATE
 SYMPAZAN, CLOBAZAM
 SYMPROIC, NALDEMEDINE TOSYLATE
 SYMTUZA, COBICISTAT
 SYNALAR, FLUOCINOLONE ACETONIDE
 SYNAREL, NAFARELIN ACETATE
 SYNDROS, DRONABINOL
 SYNERA, LIDOCAINE
 SYNERCID, DALFOPRISTIN
 SYNJARDY, EMPAGLIFLOZIN
 SYNJARDY XR, EMPAGLIFLOZIN
 SYNRIPO, OMACETAXINE MEPESUCCINATE
 SYNTHROID, LEVOTHYROXINE SODIUM **
 SYPRINE, TRIENTINE HYDROCHLORIDE

** T **

TAB-PROFEN, IBUPROFEN (OTC)
 TABRECTA, CAPMATINIB HYDROCHLORIDE
 TACLONEX, BETAMETHASONE DIPROPIONATE
 TACROLIMUS, TACROLIMUS
 TADALAFIL, TADALAFIL
 TAFINLAR, DABRAFENIB MESYLATE
 TAFLUPROST, TAFLUPROST
 TAGAMET HB, CIMETIDINE (OTC)
 TAGITOL V, BARIUM SULFATE
 TAGRISSO, OSIMERTINIB MESYLATE
 TALC, TALC
 TALICIA, AMOXICILLIN
 TALZENNA, TALAZOPARIB TOSYLATE
 TAMBOCOR, FLECAINIDE ACETATE
 TAMIFLU, OSELTAMIVIR PHOSPHATE
 TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TAPAZOLE, METHIMAZOLE
 TARCEVA, ERLOTINIB HYDROCHLORIDE
 TARGRETIN, BEXAROTENE
 TARKA, TRANDOLAPRIL
 TASIGNA, NILOTINIB HYDROCHLORIDE
 TASMAR, TOLCAPONE
 TAUVID, FLORTAUCIPIR F-18
 TAVABOROLE, TAVABOROLE
 TAVALISSE, FOSTAMATINIB DISODIUM
 TAXOTERE, DOCETAXEL
 TAYTULLA, ETHINYL ESTRADIOL
 TAZAROTENE, TAZAROTENE
 TAZICEF, CEFTAZIDIME
 TAZORAC, TAZAROTENE
 TAZTIA XT, DILTIAZEM HYDROCHLORIDE
 TAZVERIK, TAZEMETOSTAT HYDROBROMIDE
 TECFIDERA, DIMETHYL FUMARATE
 TECHNELITE, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
 TECHNESCAN, TECHNETIUM TC-99M OXIDRONATE KIT
 TECHNESCAN MAG3, TECHNETIUM TC-99M MERTIATIDE KIT
 TECHNESCAN PYP KIT, TECHNETIUM TC-99M PYROPHOSPHATE KIT
 TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
 TECHNETIUM TC-99M MEBROFENIN, TECHNETIUM TC-99M MEBROFENIN KIT
 TECHNETIUM TC99M MERTIATIDE KIT, TECHNETIUM TC-99M MERTIATIDE KIT
 TEFLARO, CEFTAROLINE FOSAMIL
 TEGRETOL, CARBAMAZEPINE
 TEGRETOL-XR, CARBAMAZEPINE
 TEGSEDI, INOTERSEN SODIUM
 TEKTURNA, ALISKIREN HEMIFUMARATE

APPENDIX A - PRODUCT NAME INDEX

** T **

TEKTURNA HCT, ALISKIREN HEMIFUMARATE
 TELMISARTAN, TELMISARTAN
 TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
 TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TEMAZEPAM, TEMAZEPAM
 TEMIXYS, LAMIVUDINE
 TEMODAR, TEMOZOLOMIDE
 TEMOZOLOMIDE, TEMOZOLOMIDE
 TEMSIROLIMUS, TEMSIROLIMUS
 TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
 TENORETIC 100, ATENOLOL
 TENORETIC 50, ATENOLOL
 TENORMIN, ATENOLOL
 TEPADINA, THIOTEPA
 TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE (OTC)
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
 TERBUTALINE SULFATE, TERBUTALINE SULFATE
 TERCONAZOLE, TERCONAZOLE
 TERIFLUNOMIDE, TERIFLUNOMIDE
 TERIL, CARBAMAZEPINE
 TESSALON, BENZONATATE
 TESTIM, TESTOSTERONE
 TESTOPEL, TESTOSTERONE
 TESTOSTERONE, TESTOSTERONE
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
 TETRABENAZINE, TETRABENAZINE
 TETRACAINE HYDROCHLORIDE, TETRACAINE HYDROCHLORIDE
 TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE
 TEXACORT, HYDROCORTISONE
 THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
 THALOMID, THALIDOMIDE
 THAM, TROMETHAMINE
 THEO-24, THEOPHYLLINE
 THEOCHRON, THEOPHYLLINE
 THEOPHYLLINE, THEOPHYLLINE
 THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 THERMAZENE, SILVER SULFADIAZINE
 THEROXIDIL, MINOXIDIL (OTC)
 THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
 THIOGUANINE, THIOGUANINE
 THIOLA, TIOPRONIN
 THIOLA EC, TIOPRONIN
 THIORIDAZINE HYDROCHLORIDE, THIORIDAZINE HYDROCHLORIDE
 THIOTEPA, THIOTEPA
 THIOTHIXENE, THIOTHIXENE
 THYQUIDITY, LEVOTHYROXINE SODIUM
 THYRO-TABS, LEVOTHYROXINE SODIUM **
 THYROSAFE, POTASSIUM IODIDE (OTC)
 THYROSHIELD, POTASSIUM IODIDE (OTC)
 TIAGABINE HYDROCHLORIDE, TIAGABINE HYDROCHLORIDE
 TIAZAC, DILTIAZEM HYDROCHLORIDE
 TIBSOVO, IVOSIDENIB
 TICAGRELOR, TICAGRELOR
 TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
 TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE
 TIGECYCLINE, TIGECYCLINE
 TIGLUTIK KIT, RILUZOLE
 TIKOSYN, DOFETILIDE
 TIMOLOL, TIMOLOL
 TIMOLOL MALEATE, TIMOLOL MALEATE

APPENDIX A - PRODUCT NAME INDEX

** T **

TIMOPTIC, TIMOLOL MALEATE
TIMOPTIC IN OCUDOSE, TIMOLOL MALEATE
TIMOPTIC-XE, TIMOLOL MALEATE
TINDAMAX, TINIDAZOLE
TINIDAZOLE, TINIDAZOLE
TIOCONAZOLE, TIOCONAZOLE (OTC)
TIROSINT, LEVOTHYROXINE SODIUM
TIROSINT-SOL, LEVOTHYROXINE SODIUM
TIS-U-SOL, MAGNESIUM SULFATE
TIS-U-SOL IN PLASTIC CONTAINER, MAGNESIUM SULFATE
TISSUEBLUE, BRILLIANT BLUE G
TIVICAY, DOLUTEGRAVIR SODIUM
TIVICAY PD, DOLUTEGRAVIR SODIUM
TIVORBEX, INDOMETHACIN
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOBI, TOBRAMYCIN
TOBI PODHALER, TOBRAMYCIN
TOBRADEX, DEXAMETHASONE
TOBRADEX ST, DEXAMETHASONE
TOBRAMYCIN, TOBRAMYCIN
TOBRAMYCIN AND DEXAMETHASONE, DEXAMETHASONE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TOBRAMYCIN SULFATE (PHARMACY BULK), TOBRAMYCIN SULFATE
TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, TOBRAMYCIN SULFATE
TOBEX, TOBRAMYCIN
TOFRANIL, IMIPRAMINE HYDROCHLORIDE
TOLAK, FLUOROURACIL
TOLBUTAMIDE, TOLBUTAMIDE
TOLCAPONE, TOLCAPONE
TOLMETIN SODIUM, TOLMETIN SODIUM
TOLSURA, ITRACONAZOLE
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TOLVAPTAN, TOLVAPTAN
TOPAMAX, TOPIRAMATE
TOPICORT, DESOXIMETASONE
TOPIRAMATE, TOPIRAMATE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
TOPROL-XL, METOPROLOL SUCCINATE
TOREMIFENE CITRATE, TOREMIFENE CITRATE
TORISEL, TEMSIROLIMUS
TORSEMIDE, TORSEMIDE
TOSYMRA, SUMATRIPTAN
TOTECT, DEXRAZOXANE HYDROCHLORIDE
TOVIAZ, FESOTERODINE FUMARATE
TPN ELECTROLYTES IN PLASTIC CONTAINER, CALCIUM CHLORIDE
TPOXX, TECOVIRIMAT
TRACLEER, BOSENTAN
TRADJENTA, LINAGLIPTIN
TRALEMENT, CUPRIC SULFATE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRANDATE, LABETALOL HYDROCHLORIDE
TRANDOLAPRIL, TRANDOLAPRIL
TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE, TRANDOLAPRIL
TRANEXAMIC ACID, TRANEXAMIC ACID
TRANSERM SCOP, SCOPOLAMINE
TRANXENE, CLORAZEPATE DIPOTASSIUM
TRANLYCYPROMINE SULFATE, TRANLYCYPROMINE SULFATE
TRAVASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 5.5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 8.5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVATAN Z, TRAVOPROST
TRAVOPROST, TRAVOPROST
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TREANDA, BENDAMUSTINE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

** T **

TRECATOR, ETHIONAMIDE
TRELEGY ELLIPTA, FLUTICASONE FUROATE
TRELSTAR, TRIPTORELIN PAMOATE
TREPROSTINIL, TREPROSTINIL
TRETINOIN, TRETINOIN
Trexall, METHOTREXATE SODIUM
Treximet, NAPROXEN SODIUM
Trezix, ACETAMINOPHEN
TRI LO SPRINTEC, ETHINYL ESTRADIOL
TRI-ESTARYLLA, ETHINYL ESTRADIOL
TRI-LEGEST 21, ETHINYL ESTRADIOL
TRI-LEGEST FE, ETHINYL ESTRADIOL
TRI-LINYAH, ETHINYL ESTRADIOL
TRI-LO-ESTARYLLA, ETHINYL ESTRADIOL
TRI-LO-MILI, ETHINYL ESTRADIOL
TRI-LUMA, FLUOCINOLONE ACETONIDE
TRI-MILI, ETHINYL ESTRADIOL
TRI-NORINYL 28-DAY, ETHINYL ESTRADIOL
TRI-SPRINTEC, ETHINYL ESTRADIOL
TRIACIN-C, CODEINE PHOSPHATE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE (OTC)
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIAMCINOLONE ACETONIDE IN ABSORBASE, TRIAMCINOLONE ACETONIDE
TRIAMTERENE, TRIAMTERENE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIAZOLAM, TRIAZOLAM
TRIBENZOR, AMLODIPINE BESYLATE
TRICOR, FENOFIBRATE
TRIDERM, TRIAMCINOLONE ACETONIDE
TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE
TRIESENCE, TRIAMCINOLONE ACETONIDE
TRIFERIC, FERRIC PYROPHOSPHATE CITRATE
TRIFERIC AVNU, FERRIC PYROPHOSPHATE CITRATE
TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE
TRIFLURIDINE, TRIFLURIDINE
TRIGLIDE, FENOFIBRATE
TRIHXYPHENIDYL HYDROCHLORIDE, TRIHXYPHENIDYL HYDROCHLORIDE
TRIJARDY XR, EMPAGLIFLOZIN
TRIKAFTA (COPACKAGED), ELEXACAF TOR, IVACAF TOR, TEZACAF TOR
TRILEPTAL, OXCARBAZEPINE
TRILIPIX, CHOLINE FENOFIBRATE
TRILYTE, POLYETHYLENE GLYCOL 3350
TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE
TRIMETHOPRIM, TRIMETHOPRIM
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE
TRINTELLIX, VORTIOXETINE HYDROBROMIDE
TRIOSTAT, LIOTHYRONINE SODIUM
TRIPTODUR KIT, TRIPTORELIN PAMOATE
TRISENOX, ARSENIC TRIOXIDE
TRIUMEQ, ABACAVIR SULFATE
TRIVAGIZOLE 3, CLOTRIMAZOLE (OTC)
TRIVORA-28, ETHINYL ESTRADIOL
TRIZIVIR, ABACAVIR SULFATE
Trokendi XR, TOPIRAMATE
Trophamine, AMINO ACIDS
Trophamine 10%, AMINO ACIDS
TROPICACYL, TROPICAMIDE
TROPICAMIDE, TROPICAMIDE
TROSPIMUM CHLORIDE, TROSPIMUM CHLORIDE
TRULANCE, PLECANATIDE
TRUSOPT, DORZOLAMIDE HYDROCHLORIDE
TRUVADA, EMTRICITABINE
TUDORZA PRESSAIR, ACLIDINIUM BROMIDE
TUKYSA, TUCATINIB

APPENDIX A - PRODUCT NAME INDEX

** T **

TURALIO, PEXIDARTINIB HYDROCHLORIDE
 TUSSICAPS, CHLORPHENIRAMINE POLISTIREX
 TUXARIN ER, CHLORPHENIRAMINE MALEATE
 TUZISTRA XR, CHLORPHENIRAMINE POLISTIREX
 TWIRLA, ETHINYL ESTRADIOL
 TWYNSTA, AMLODIPINE BESYLATE
 TYBLUME, ETHINYL ESTRADIOL
 TYBOST, COBICISTAT
 TYDEMY, DROSPIRENONE
 TYGACIL, TIGECYCLINE
 TYKERB, LAPATINIB DITOSYLATE
 TYLENOL, ACETAMINOPHEN (OTC)
 TYMLOS, ABALOPARATIDE
 TYVASO, TREPROSTINIL
 TYZINE, TETRAHYDROZOLINE HYDROCHLORIDE

** U **

U-CORT, HYDROCORTISONE ACETATE
 UBRELVY, UBROGEPANT
 UCERIS, BUDESONIDE
 ULORIC, FEBUXOSTAT
 ULTANE, SEVOFLURANE
 ULTIVA, REMIFENTANIL HYDROCHLORIDE
 ULTRA-TECHNEKOW FM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
 ULTRACET, ACETAMINOPHEN
 ULTRAM, TRAMADOL HYDROCHLORIDE
 ULTRATAG, TECHNETIUM TC-99M RED BLOOD CELL KIT
 ULTRAVATE, HALOBETASOL PROPIONATE
 ULTRAVIST (PHARMACY BULK), IOPROMIDE
 ULTRAVIST 300, IOPROMIDE
 ULTRAVIST 370, IOPROMIDE
 UNASYN, AMPICILLIN SODIUM
 UNISOM, DOXYLAMINE SUCCINATE (OTC)
 UNITHROID, LEVOTHYROXINE SODIUM **
 UPNEEQ, OXYMETAZOLINE HYDROCHLORIDE
 UPTRAVI, SELEXIPAG
 UREX, METHENAMINE HIPPURATE
 UROCIT-K, POTASSIUM CITRATE
 UROXATRAL, ALFUZOSIN HYDROCHLORIDE
 URSO 250, URSODIOL
 URSO FORTE, URSODIOL
 URSODIOL, URSODIOL
 UVADEX, METHOXSALEN

** V **

VABOMERE, MEROPENEM
 VAGIFEM, ESTRADIOL
 VAGISTAT-1, TIOCONAZOLE (OTC)
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VALCHLOR, MECHLORETHAMINE HYDROCHLORIDE
 VALCYTE, VALGANCICLOVIR HYDROCHLORIDE
 VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
 VALIUM, DIAZEPAM
 VALNAC, BETAMETHASONE VALERATE
 VALPROATE SODIUM, VALPROATE SODIUM
 VALPROIC ACID, VALPROIC ACID
 VALRUBICIN, VALRUBICIN
 VALSARTAN, VALSARTAN
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 VALSTAR PRESERVATIVE FREE, VALRUBICIN
 VALTOCO, DIAZEPAM
 VALTRES, VALACYCLOVIR HYDROCHLORIDE
 VANCOCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

** v **

VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE
VANDAZOLE, METRONIDAZOLE
VANIQA, EFLORNITHINE HYDROCHLORIDE
VANOS, FLUOCINONIDE
VANTAS, HISTRELIN ACETATE
VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER, CONIVAPTAN HYDROCHLORIDE
VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE
VARIBAR HONEY, BARIUM SULFATE
VARIBAR NECTAR, BARIUM SULFATE
VARIBAR PUDDING, BARIUM SULFATE
VARIBAR THIN HONEY, BARIUM SULFATE
VARIBAR THIN LIQUID, BARIUM SULFATE
VARITHENA, POLIDOCANOL
VARUBI, ROLAPITANT HYDROCHLORIDE
VASCEPA, ICOSAPENT ETHYL
VASERETIC, ENALAPRIL MALEATE
VASOPRESSIN, VASOPRESSIN
VASOSTRICT, VASOPRESSIN
VASOTEC, ENALAPRIL MALEATE
VAZALORE, ASPIRIN (OTC)
VAZCULEP, PHENYLEPHRINE HYDROCHLORIDE
VECTICAL, CALCITRIOL
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VEKLURY, REMDESIVIR
VELCADE, BORTEZOMIB
VELETRI, EPOPROSTENOL SODIUM
VELIVET, DESOGESTREL
VELPHORO, SUCROFERRIC OXYHYDROXIDE
VELTASSA, PATIROMER SORBITE X CALCIUM
VELTIN, CLINDAMYCIN PHOSPHATE
VEMLIDY, TENOFOVIR ALAFENAMIDE FUMARATE
VENCLEXTA, VENETOCLAX
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VENOFER, IRON SUCROSE
VENTAVIS, ILOPROST
VENTOLIN HFA, ALBUTEROL SULFATE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
VERDESO, DESONIDE
VEREGEN, SINECATECHINS
VERELAN, VERAPAMIL HYDROCHLORIDE
VERELAN PM, VERAPAMIL HYDROCHLORIDE
VERSACLOZ, CLOZAPINE
VERZENIO, ABEMACICLIB
VESICARE, SOLIFENACIN SUCCINATE
VESICARE LS, SOLIFENACIN SUCCINATE
VFEND, VORICONAZOLE
VIAGRA, SILDENAFIL CITRATE
VIBATIV, TELAVANCIN HYDROCHLORIDE
VIBERZI, ELUXADOLINE
VIBISONE, CYANOCOBALAMIN
VIBRAMYCIN, DOXYCYCLINE
VIBRAMYCIN, DOXYCYCLINE CALCIUM
VIBRAMYCIN, DOXYCYCLINE HYCLATE
VICTOZA, LIRAGLUTIDE RECOMBINANT
VIDAZA, AZACITIDINE
VIEKIRA PAK (COPACKAGED), DASABUVIR SODIUM
VIENVA, ETHINYL ESTRADIOL
VIGABATRIN, VIGABATRIN
VIGADRONE, VIGABATRIN
VIGAMOX, MOXIFLOXACIN HYDROCHLORIDE
VIIBRYD, VILAZODONE HYDROCHLORIDE
VILAZODONE HYDROCHLORIDE, VILAZODONE HYDROCHLORIDE
VILTEPSO, VILTOLARSEN
VIMOVO, ESOMEPRAZOLE MAGNESIUM
VIMPAT, LACOSAMIDE

APPENDIX A - PRODUCT NAME INDEX**** V ****

VINBLASTINE SULFATE, VINBLASTINE SULFATE
 VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE
 VINOURELBINE TARTRATE, VINOURELBINE TARTRATE
 VIORELE, DESOGESTREL
 VIRACEPT, NELFINAVIR MESYLATE
 VIRAMUNE, NEVIRAPINE
 VIRAMUNE XR, NEVIRAPINE
 VIRAZOLE, RIBAVIRIN
 VIREAD, TENOFOVIR DISOPROXIL FUMARATE
 VIROPTIC, TRIFLURIDINE
 VISINE, NAPHAZOLINE HYDROCHLORIDE (OTC)
 VISINE L.R., OXYMETAZOLINE HYDROCHLORIDE (OTC)
 VISIONBLUE, TRYPAN BLUE
 VISIPAQUE 270, IODIXANOL
 VISIPAQUE 320, IODIXANOL
 VISTARIL, HYDROXYZINE PAMOATE
 VISTOGARD, URIDINE TRIACETATE
 VISUDYNE, VERTEPORFIN
 VITAMIN D, ERGOCALCIFEROL
 VITAMIN K1, PHYTONADIONE
 VITRAKVI, LAROTRECTINIB SULFATE
 VIVELLE-DOT, ESTRADIOL
 VIVITROL, NALTREXONE
 VIZAMYL, FLUTEMETAMOL F-18
 VIZIMPRO, DACOMITINIB
 VOGELXO, TESTOSTERONE
 VOLNEA, DESOGESTREL
 VOLTAREN, DICLOFENAC SODIUM
 VOLTAREN ARTHRITIS PAIN, DICLOFENAC SODIUM (OTC)
 VORICONAZOLE, VORICONAZOLE
 VOSEVI, SOFOSBUVIR
 VOSOL, ACETIC ACID, GLACIAL
 VOSOL HC, ACETIC ACID, GLACIAL
 VOSPIRE ER, ALBUTEROL SULFATE
 VOTRIENT, PAZOPANIB HYDROCHLORIDE
 VRAYLAR, CARIPRAZINE HYDROCHLORIDE
 VUMERITY, DIROXIMEL FUMARATE
 VUSION, MICONAZOLE NITRATE
 VYFEMLA, ETHINYL ESTRADIOL
 VYLEESI (AUTOINJECTOR), BREMELANOTIDE ACETATE
 VYNDAMAX, TAFAMIDIS
 VYNDAQEL, TAFAMIDIS MEGLUMINE
 VYONDYS 53, GOLODIRSEN
 VYTORIN, EZETIMIBE
 VYVANSE, LISDEXAMFETAMINE DIMESYLATE
 VYXEOS, CYTARABINE
 VYZULTA, LATANOPROSTENE BUNOD

**** W ****

WAKIX, PITOLISANT HYDROCHLORIDE
 WARFARIN SODIUM, WARFARIN SODIUM
 WELCHOL, COLESEVELAM HYDROCHLORIDE
 WELLBUTRIN SR, BUPROPION HYDROCHLORIDE
 WELLBUTRIN XL, BUPROPION HYDROCHLORIDE
 WERA, ETHINYL ESTRADIOL
 WINLEVI, CLASCOTERONE
 WIXELA INHUB, FLUTICASONE PROPIONATE
 WOMEN'S ROGAINE, MINOXIDIL (OTC)
 WYNZORA, BETAMETHASONE DIPROPIONATE

**** X ****

XADAGO, SAFINAMIDE MESYLATE
 XALATAN, LATANOPROST
 XALKORI, CRIZOTINIB
 XANAX, ALPRAZOLAM

APPENDIX A - PRODUCT NAME INDEX

** X **

XANAX XR, ALPRAZOLAM
 XARACOLL, BUPIVACAINE HYDROCHLORIDE
 XARELTO, RIVAROXABAN
 XATMEP, METHOTREXATE SODIUM
 XCOPRI, CENOBAMATE
 KELJANZ, TOFACITINIB CITRATE
 KELJANZ XR, TOFACITINIB CITRATE
 XELODA, CAPECITABINE
 XELPROS, LATANOPROST
 XENAZINE, TETRABENAZINE
 XENICAL, ORLISTAT
 XENLETA, LEFAMULIN ACETATE
 XENON XE 133, XENON XE-133
 XEPI, OZENOXACIN
 XERAVA, ERAVACYCLINE DIHYDROCHLORIDE
 XERESE, ACYCLOVIR
 XERMELLO, TELOTTRISTAT ETIPRATE
 XHANCE, FLUTICASONE PROPIONATE
 XIFAXAN, RIFAXIMIN
 XIGDUO XR, DAPAGLIFLOZIN
 XIIDRA, LIFITEGRAST
 XIMINO, MINOCYCLINE HYDROCHLORIDE
 XOFIGO, RADIUM RA-223 DICHLORIDE
 XOFLUZA, BALOXAVIR MARBOXIL
 XOLEGEL, KETOCONAZOLE
 XOPENEX, LEVALBUTEROL HYDROCHLORIDE
 XOPENEX HFA, LEVALBUTEROL TARTRATE
 XOSPATA, GILTERITINIB FUMARATE
 XPOVIO, SELINEXOR
 XTAMPZA ER, OXYCODONE
 XTANDI, ENZALUTAMIDE
 XULANE, ETHINYL ESTRADIOL
 XURIDEN, URIDINE TRIACETATE
 XYLOCAINE, LIDOCAINE HYDROCHLORIDE
 XYLOCAINE W/ EPINEPHRINE, EPINEPHRINE
 XYOSTED (AUTOINJECTOR), TESTOSTERONE ENANTHATE
 XYREM, SODIUM OXYBATE
 XYWAV, CALCIUM OXYBATE
 XYZAL, LEVOCETIRIZINE DIHYDROCHLORIDE
 XYZAL ALLERGY 24HR, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)
 Keljanz, TOFACITINIB CITRATE

** Y **

YAELA, DROSPIRENONE
 YASMIN, DROSPIRENONE
 YAZ, DROSPIRENONE
 YONDELIS, TRABECTEDIN
 YONSA, ABIRATERONE ACETATE
 YUPELRI, REVEFENACIN
 YUTIQ, FLUOCINOLONE ACETONIDE

** Z **

ZADITOR, KETOTIFEN FUMARATE (OTC)
 ZAFIRLUKAST, ZAFIRLUKAST
 ZALEPLON, ZALEPLON
 ZANAFLEX, TIZANIDINE HYDROCHLORIDE
 ZANOSAR, STREPTOZOCIN
 ZANTAC, RANITIDINE HYDROCHLORIDE
 ZANTAC 150, RANITIDINE HYDROCHLORIDE (OTC)
 ZANTAC 75, RANITIDINE HYDROCHLORIDE (OTC)
 ZARONTIN, ETHOSUXIMIDE
 ZAROXOLYN, METOLAZONE
 ZAVESCA, MIGLUSTAT
 ZEGERID, OMEPRAZOLE
 ZEGERID OTC, OMEPRAZOLE (OTC)

APPENDIX A - PRODUCT NAME INDEX

** Z **

ZEJULA, NIRAPARIB TOSYLATE
ZELAPAR, SELEGILINE HYDROCHLORIDE
ZELBORAF, VEMURAFENIB
ZELNORM, TEGASEROD MALEATE
ZEMBRACE SYMTOUCH, SUMATRIPTAN SUCCINATE
ZEMDRI, PLAZOMICIN SULFATE
ZEMPLAR, PARICALCITOL
ZENATANE, ISOTRETINOIN
ZEPATIER, ELBASVIR
ZEPOSIA, OZANIMOD HYDROCHLORIDE
ZEPZELCA, LURBINECTEDIN
ZERBAXA, CEFTOLOZANE SULFATE
ZERVIAE, CETIRIZINE HYDROCHLORIDE
ZESTORETIC, HYDROCHLOROTHIAZIDE
ZESTRIL, LISINOPRIL
ZETIA, EZETIMIBE
ZETONNA, CICLESONIDE
ZIAC, BISOPROLOL FUMARATE
ZIAGEN, ABACAVIR SULFATE
ZIANA, CLINDAMYCIN PHOSPHATE
ZIDOVUDINE, ZIDOVUDINE
ZILEUTON, ZILEUTON
ZILRETTA, TRIAMCINOLONE ACETONIDE
ZILXI, MINOCYCLINE HYDROCHLORIDE
ZINACEF, CEFUROXIME SODIUM
ZINC CHLORIDE IN PLASTIC CONTAINER, ZINC CHLORIDE
ZINC SULFATE, ZINC SULFATE
ZINECARD, DEXRAZOXANE HYDROCHLORIDE
ZINGO, LIDOCAINE HYDROCHLORIDE
ZIOPTAN, TAFLUPROST
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
ZIPRASIDONE MESYLATE, ZIPRASIDONE MESYLATE
ZIPSOR, DICLOFENAC POTASSIUM
ZIRGAN, GANCICLOVIR
ZITHROMAX, AZITHROMYCIN
ZOCOR, SIMVASTATIN
ZOFRAN, ONDANSETRON HYDROCHLORIDE
ZOFRAN ODT, ONDANSETRON
ZOHYDRO ER, HYDROCODONE BITARTRATE
ZOKINVY, LONAFARNIB
ZOLADEX, GOSERELIN ACETATE
ZOLEDRONIC, ZOLEDRONIC ACID
ZOLEDRONIC ACID, ZOLEDRONIC ACID
ZOLINZA, VORINOSTAT
ZOLMITRIPTAN, ZOLMITRIPTAN
ZOLOFT, SERTRALINE HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
ZOLPIMIST, ZOLPIDEM TARTRATE
ZOMETA, ZOLEDRONIC ACID
ZOMIG, ZOLMITRIPTAN
ZOMIG-ZMT, ZOLMITRIPTAN
ZONALON, DOXEPIN HYDROCHLORIDE
ZONEGRAN, ZONISAMIDE
ZONISAMIDE, ZONISAMIDE
ZONTIVITY, VORAPAXAR SULFATE
ZORTRESS, EVEROLIMUS
ZORVOLEX, DICLOFENAC
ZOSYN, PIPERACILLIN SODIUM
ZOSYN IN PLASTIC CONTAINER, PIPERACILLIN SODIUM
ZOVIA 1/35E-28, ETHINYL ESTRADIOL
ZOVIA 1/50E-28, ETHINYL ESTRADIOL
ZOVIRAX, ACYCLOVIR
ZTLIDO, LIDOCAINE
ZUBSOLV, BUPRENORPHINE HYDROCHLORIDE
ZULRESSO, BREXANOLONE

APPENDIX A - PRODUCT NAME INDEX**** Z ****

ZUMANDIMINE, DROSPIRENONE
ZYCLARA, IMIQUIMOD
ZYDELIG, IDELALISIB
ZYFLO, ZILEUTON
ZYFLO CR, ZILEUTON
ZYKADIA, CERITINIB
ZYLET, LOTE Prednol Etabonate
ZYLOPRIM, ALLOPURINOL
ZYMAR, GATIFLOXACIN
ZYMAXID, GATIFLOXACIN
ZYPITAMAG, PITAVASTATIN MAGNESIUM
ZYPREXA, OLANZAPINE
ZYPREXA RELPREVV, OLANZAPINE PAMOATE
ZYPREXA ZYDIS, OLANZAPINE
ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
ZYRTEC-D 12 HOUR, CETIRIZINE HYDROCHLORIDE (OTC)
ZYTIGA, ABIRATERONE ACETATE
ZYVOX, LINEZOLID

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** 3 ******3D IMAGING DRUG**

- * 3D IMAGING DRUG DESIGN AND DEVELOPMENT LLC
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

3M

- * 3M CO
PERIDEX, CHLORHEXIDINE GLUCONATE
- * 3M HEALTH CARE INC
AVAGARD, ALCOHOL (OTC)
DURAPREP, IODINE POVACRYLEX (OTC)

3M HEALTH CARE

- * 3M HEALTH CARE INFECTION PREVENTION DIV
SOLUPREP, CHLORHEXIDINE GLUCONATE (OTC)

**** 6 ******60 DEGREES PHARMS**

- * 60 DEGREES PHARMACEUTICALS LLC
ARAKODA, TAFENOQUINE SUCCINATE

**** A ******AAA USA INC**

- * ADVANCED ACCELERATOR APPLICATIONS USA INC
LUTATHERA, LUTETIUM DOTATATE LU-177
NETSPOT, GALLIUM DOTATATE GA-68

AAIPHARMA LLC

- * AAIPHARMA LLC
AZASAN, AZATHIOPRINE

ABBVIE

- * ABBVIE INC
ANDROGEL, TESTOSTERONE
CYCLOSPORINE, CYCLOSPORINE
DEPAKOTE ER, DIVALPROEX SODIUM
DEPAKOTE, DIVALPROEX SODIUM
GENGRAF, CYCLOSPORINE
K-TAB, POTASSIUM CHLORIDE
KALETRA, LOPINAVIR
NIASPAN, NIACIN
NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE
NIMBEX, CISATRACURIUM BESYLATE
NORVIR, RITONAVIR
SYNTHROID, LEVOTHYROXINE SODIUM **
TARKA, TRANDOLAPRIL
TRICOR, FENOFIBRATE
TRILIPIX, CHOLINE FENOFIBRATE
ULTANE, SEVOFLURANE
ZEMPLAR, PARICALCITOL

ABBVIE ENDOCRINE

- * ABBVIE ENDOCRINE INC
LUPANETA PACK, LEUPROLIDE ACETATE

ABBVIE ENDOCRINE INC

- * ABBVIE ENDOCRINE INC
LUPRON DEPOT, LEUPROLIDE ACETATE
LUPRON DEPOT-PED KIT, LEUPROLIDE ACETATE

ABBVIE INC

- * ABBVIE INC
DUOPA, CARBIDOPA
MAVYRET, GLECAPREVIR
NORVIR, RITONAVIR
ORIAHNN (COPACKAGED), ELAGOLIX SODIUM, ESTRADIOL, NORETHINDRONE ACETATE
ORILISSA, ELAGOLIX SODIUM
RINVOQ, UPADACITINIB
VENCLEXTA, VENETOCLAX
VIEKIRA PAK (COPACKAGED), DASABUVIR SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******ABHAI INC**

* ABHAI INC
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE

ABHAI LLC

* ABHAI LLC
 ATOVAQUONE, ATOVAQUONE
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
 LEFLUNOMIDE, LEFLUNOMIDE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 OXYBUTYNYN CHLORIDE, OXYBUTYNYN CHLORIDE
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 URSODIOL, URSODIOL

ABON PHARMS LLC

* ABON PHARMACEUTICALS LLC
 CLOFARABINE, CLOFARABINE

ABRAXIS BIOSCIENCE

* ABRAXIS BIOSCIENCE LLC
 ABRAXANE, PACLITAXEL

ABRAXIS PHARM

* ABRAXIS PHARMACEUTICAL PRODUCTS
 CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%, CLINDAMYCIN PHOSPHATE

ACACIA

* ACACIA PHARMA LTD
 BARHEMSYS, AMISULPRIDE
 BYFAVO, REMIMAZOLAM BESYLATE

ACADIA PHARMS INC

* ACADIA PHARMACEUTICALS INC
 NUPLAZID, PIMAVANSERIN TARTRATE

ACCELRX LABS

* ACCELRX LABS LLC
 CARISOPRODOL, CARISOPRODOL

ACCORD HLTHCARE

* ACCORD HEALTHCARE INC
 ALLOPURINOL, ALLOPURINOL
 AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 ANASTROZOLE, ANASTROZOLE
 APIXABAN, APIXABAN
 ARIPIPIRAZOLE, ARIPIPIRAZOLE
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 ATROPINE SULFATE, ATROPINE SULFATE
 AZACITIDINE, AZACITIDINE
 BICALUTAMIDE, BICALUTAMIDE
 BIVALIRUDIN, BIVALIRUDIN
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 CAPECITABINE, CAPECITABINE
 CARBIDOPA AND LEVODOPA, CARBIDOPA
 CARBOPLATIN, CARBOPLATIN
 CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
 CISPLATIN, CISPLATIN
 CLOFARABINE, CLOFARABINE
 CLONAZEPAM, CLONAZEPAM
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 CLOZAPINE, CLOZAPINE
 DALFAMPRIDINE, DALFAMPRIDINE
 DAPTOMYCIN, DAPTOMYCIN
 DECITABINE, DECITABINE
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ACCORD HEALTHCARE INC
 DIMETHYL FUMARATE, DIMETHYL FUMARATE
 DOCETAXEL, DOCETAXEL
 DOFETILIDE, DOFETILIDE
 DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
 ENTECAVIR, ENTECAVIR
 EPLERENONE, EPLERENONE
 EPTIFIBATIDE, EPTIFIBATIDE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
 ETOPOSIDE, ETOPOSIDE
 EZETIMIBE, EZETIMIBE
 FINASTERIDE, FINASTERIDE
 FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
 FLUOROURACIL, FLUOROURACIL
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
 FULVESTRANT, FULVESTRANT
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 GLIMEPIRIDE, GLIMEPIRIDE
 GLIPIZIDE, GLIPIZIDE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 ITRACONAZOLE, ITRACONAZOLE
 LETROZOLE, LETROZOLE
 LEVETIRACETAM, LEVETIRACETAM
 LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM **
 LISINAPRIL, LISINAPRIL
 LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
 METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 METHYLDOPA, METHYLDOPA
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 MITOMYCIN, MITOMYCIN
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 MYCOPHENOLIC ACID, MYCOPHENOLIC ACID
 NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
 OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 OXALIPLATIN, OXALIPLATIN
 OXYBUTYNYN CHLORIDE, OXYBUTYNYN CHLORIDE
 PARICALCITOL, PARICALCITOL
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 PRASUGREL, PRASUGREL HYDROCHLORIDE
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RAMIPRIL, RAMIPRIL
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SIMVASTATIN, SIMVASTATIN
 SPIRONOLACTONE, SPIRONOLACTONE
 TACROLIMUS, TACROLIMUS
 TADALAFIL, TADALAFIL
 TEMOZOLOMIDE, TEMOZOLOMIDE
 TEMSIROLIMUS, TEMSIROLIMUS
 TERIFLUNOMIDE, TERIFLUNOMIDE
 TOPIRAMATE, TOPIRAMATE
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ACCORD HEALTHCARE INC
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
VIGABATRIN, VIGABATRIN
ZOLEDRONIC ACID, ZOLEDRONIC ACID

ACCORD HLTHCARE INC

* ACCORD HEALTHCARE INC USA
BUSULFAN, BUSULFAN
TIGECYCLINE, TIGECYCLINE

ACELLA

* ACELLA PHARMACEUTICALS LLC
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
CICLOPIROX, CICLOPIROX
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DUTASTERIDE, DUTASTERIDE
NIFEDIPINE, NIFEDIPINE
PHENYTOIN SODIUM, PHENYTOIN SODIUM

ACELLA PHARMS LLC

* ACELLA PHARMACEUTICALS LLC
GABAPENTIN, GABAPENTIN

ACELRX PHARMS

* ACELRX PHARMACEUTICALS INC
DSUVIA, SUFENTANIL CITRATE

ACERUS

* ACERUS PHARMACEUTICALS CORP
NATESTO, TESTOSTERONE

ACI HEALTHCARE LTD

* ACI HEALTHCARE LTD
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
LEVETIRACETAM, LEVETIRACETAM
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

ACIC PHARMS

* ACIC PHARMACEUTICALS INC
CELECOXIB, CELECOXIB
TRANEXAMIC ACID, TRANEXAMIC ACID

ACORDA

* ACORDA THERAPEUTICS INC
AMPYRA, DALFAMPRIDINE
INBRIJA, LEVODOPA

ACROTECH

* ACROTECH BIOPHARMA LLC
BELEODAQ, BELINOSTAT
EVOMELA, MELPHALAN HYDROCHLORIDE
FOLOTYN, PRALATREXATE
FUSILEV, LEVOLEUCOVORIN CALCIUM
KHAPZORY, LEVOLEUCOVORIN
MARQIBO KIT, VINCRISTINE SULFATE

ACS DOBFAR

* ACS DOBFAR SPA
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
CEFOXITIN, CEFOXITIN SODIUM
CEFTAZIDIME, CEFTAZIDIME
CEFTRIAZONE, CEFTRIAZONE SODIUM
IMIPENEM AND CILASTATIN, CILASTATIN SODIUM
MEROPENEM, MEROPENEM

ACS DOBFAR SPA

* ACS DOBFAR SPA
AMPICILLIN SODIUM, AMPICILLIN SODIUM
CEFUROXIME SODIUM, CEFUROXIME SODIUM
ERTAPENEM SODIUM, ERTAPENEM SODIUM
MEROPENEM, MEROPENEM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ACS DOBFAR SPA

PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM

ACTAVIS ELIZABETH

* ACTAVIS ELIZABETH LLC

ALBENDAZOLE, ALBENDAZOLE

ALPRAZOLAM, ALPRAZOLAM

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE

BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE

CARBIDOPA AND LEVODOPA, CARBIDOPA

CLONAZEPAM, CLONAZEPAM

CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE

DEFERASIROX, DEFERASIROX

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE

DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE

DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE, DEXTROMETHORPHAN HYDROBROMIDE

DICLOFENAC SODIUM, DICLOFENAC SODIUM

DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE

DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE

DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE

DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE

FENOFIBRIC ACID, CHOLINE FENOFIBRATE

FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE

GABAPENTIN, GABAPENTIN

GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE

GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE

HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

INDAPAMIDE, INDAPAMIDE

ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE

LAMOTRIGINE, LAMOTRIGINE

LOVASTATIN, LOVASTATIN

METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE

NIFEDIPINE, NIFEDIPINE

OXAZEPAM, OXAZEPAM

OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN

PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE

PREGABALIN, PREGABALIN

PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

PROPYLTHIOURACIL, PROPYLTHIOURACIL

RANOLAZINE, RANOLAZINE

ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE

TEMAZEPAM, TEMAZEPAM

TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

* ACTAVIS ELIZABETH LLC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC

ALPRAZOLAM, ALPRAZOLAM

CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE

LAMOTRIGINE, LAMOTRIGINE

MORPHINE SULFATE, MORPHINE SULFATE

PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE

ACTAVIS INC

* ACTAVIS INC

DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE

DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE

METHOXSALLEN, METHOXSALLEN

ACTAVIS LABS

* ACTAVIS LABORATORIES INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC

PERMETHRIN, PERMETHRIN

ACTAVIS LABS FL

* ACTAVIS LABORATORIES FL INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC

DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE

GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN (OTC)

GUAIFENESIN, GUAIFENESIN (OTC)

MESALAMINE, MESALAMINE

METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******ACTAVIS LABS FL INC**

* ACTAVIS LABORATORIES FL INC
 BUDESONIDE, BUDESONIDE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CARTIA XT, DILTIAZEM HYDROCHLORIDE
 CLARITHROMYCIN, CLARITHROMYCIN
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 DALFAMPRIDINE, DALFAMPRIDINE
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE, DOXYLAMINE SUCCINATE
 HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
 LEVETIRACETAM, LEVETIRACETAM
 METAXALONE, METAXALONE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
 NAPROXEN SODIUM, NAPROXEN SODIUM
 NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
 OMEPRAZOLE, OMEPRAZOLE
 PALIPERIDONE, PALIPERIDONE
 PAROXETINE MESYLATE, PAROXETINE MESYLATE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 RAMELTEON, RAMELTEON
 TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
 TAZTIA XT, DILTIAZEM HYDROCHLORIDE
 TETRABENZAZINE, TETRABENZAZINE
 TRANEXAMIC ACID, TRANEXAMIC ACID
 TROSPIMUM CHLORIDE, TROSPIMUM CHLORIDE
 VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

ACTAVIS LABS UT INC

* ACTAVIS LABORATORIES UT INC
 AZELAIC ACID, AZELAIC ACID
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
 CLONIDINE, CLONIDINE
 FIORICET W/ CODEINE, ACETAMINOPHEN
 LIDOCAINE, LIDOCAINE
 PROGESTERONE, PROGESTERONE
 TESTOSTERONE, TESTOSTERONE

* ACTAVIS LABORATORIES UT INC INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
 PIMECROLIMUS, PIMECROLIMUS
 TESTOSTERONE, TESTOSTERONE

ACTAVIS LLC

* ACTAVIS LLC
 AZACITIDINE, AZACITIDINE
 DAPSONE, DAPSONE
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
 MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE

* ACTAVIS LLC AN INDIRECT WHOLLY-OWNED SUB OF TEVA PHARMACEUTICALS USA INC
 DOCETAXEL, DOCETAXEL
 HYDROXOCOBALAMIN, HYDROXOCOBALAMIN
 OXALIPLATIN, OXALIPLATIN
 PEMETREXED, PEMETREXED

ACTAVIS MID ATLANTIC

* ACTAVIS MID ATLANTIC LLC
 ACYCLOVIR, ACYCLOVIR
 ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
 ADAPALENE, ADAPALENE
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 BETAMETHASONE VALERATE, BETAMETHASONE VALERATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

- * ACTAVIS MID ATLANTIC LLC
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE AND TRETINOIN, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
DESOXIMETASONE, DESOXIMETASONE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
HYDROCORTISONE, HYDROCORTISONE
LEVETIRACETAM, LEVETIRACETAM
MESALAMINE, MESALAMINE
NITROFURANTOIN, NITROFURANTOIN
NYSTATIN, NYSTATIN
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
VALNAC, BETAMETHASONE VALERATE
- * ACTAVIS MID ATLANTIC LLC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
IBUPROFEN, IBUPROFEN
PERMETHRIN, PERMETHRIN (OTC)

ACTAVIS PHARMA

- * ACTAVIS PHARMA INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
MICONAZOLE NITRATE, MICONAZOLE NITRATE

ACTAVIS TOTOWA

- * ACTAVIS TOTOWA LLC
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN
PACLITAXEL, PACLITAXEL
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
VINORELBINE TARTRATE, VINORELBINE TARTRATE

ACTAVIS TOTOWA TEVA

- * ACTAVIS TOTOWA LLC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
FINASTERIDE, FINASTERIDE

ACTELION

- * ACTELION PHARMACEUTICALS US INC
ZAVESCA, MIGLUSTAT

ACTELION PHARMS

- * ACTELION PHARMACEUTICALS LTD
TRACLEER, BOSENTAN

ACTELION PHARMS LTD

- * ACTELION PHARMACEUTICALS LTD
OPSUMIT, MACITENTAN
TRACLEER, BOSENTAN
UPTRAVI, SELEXIPAG
VELETRI, EPOPROSTENOL SODIUM
VENTAVIS, ILOPROST

ACTIENT PHARMS

- * ACTIENT PHARMACEUTICALS LLC
THEO-24, THEOPHYLLINE

ADAMAS PHARMA

- * ADAMAS PHARMA LLC
GOCOVRI, AMANTADINE HYDROCHLORIDE

ADAMIS PHARMS CORP

- * ADAMIS PHARMACEUTICALS CORP
SYMJEPI, EPINEPHRINE

ADAPTIS

- * ADAPTIS PHARMA PRIVATE LTD
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
MONTELUKAST SODIUM, MONTELUKAST SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******ADARE PHARMS INC**

* ADARE PHARMACEUTICALS INC
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

ADDMEDICA SAS

* ADDMEDICA SAS
 SIKLOS, HYDROXYUREA

ADHERA

* ADHERA THERAPEUTICS INC
 PRESTALIA, AMLODIPINE BESYLATE

ADIENNE SA

* ADIENNE SA
 TEPADINA, THIOTEPA

AERIE PHARMS INC

* AERIE PHARMACEUTICALS INC
 RHOPRESSA, NETARSUDIL MESYLATE
 ROCKLATAN, LATANOPROST

AGILE

* AGILE THERAPEUTICS INC
 TWIRLA, ETHINYL ESTRADIOL

AGIOS PHARMS INC

* AGIOS PHARMACEUTICALS INC
 TIBSOVO, IVOSIDENIB

AGNITIO

* AGNITIO INC
 ETHACRYNIC ACID, ETHACRYNIC ACID
 TRIAMTERENE, TRIAMTERENE

AGOURON PHARMS

* AGOURON PHARMACEUTICALS LLC
 VIRACEPT, NELFINAVIR MESYLATE

AILEX PHARMS LLC

* AILEX PHARMACEUTICALS LLC
 BISMUTH SUBSALICYLATE, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE, BISMUTH
 CROMOLYN SODIUM, CROMOLYN SODIUM
 SODIUM PHENYLACETATE AND SODIUM BENZOATE, SODIUM BENZOATE

AIZANT

* AIZANT DRUG RESEARCH SOLUTIONS PRIVATE LTD
 ZILEUTON, ZILEUTON

AJANTA PHARMA LTD

* AJANTA PHARMA LTD
 ALMOTRIPTAN MALATE, ALMOTRIPTAN MALATE
 AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
 ARIPIPRAZOLE, ARIPIPRAZOLE
 CAPTOPRIL, CAPTOPRIL
 CHLORTHALIDONE, CHLORTHALIDONE
 CHOLESTYRAMINE, CHOLESTYRAMINE
 CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
 ENTACAPONE, ENTACAPONE
 FENOFIBRATE (MICRONIZED), FENOFIBRATE
 FENOFIBRATE, FENOFIBRATE
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
 OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 RANOLAZINE, RANOLAZINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******* AJANTA PHARMA LTD**

RISPERIDONE, RISPERIDONE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SILODOSIN, SILODOSIN
 SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
 TADALAFIL, TADALAFIL
 TETRABENAZINE, TETRABENAZINE
 VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
 VORICONAZOLE, VORICONAZOLE
 ZOLMITRIPTAN, ZOLMITRIPTAN

AKARX INC*** AKARX INC**

DOPTELET, AVATROMBOPAG MALEATE

AKCEA THERAPS*** AKCEA THERAPEUTICS INC**

TEGSEDI, INOTERSEN SODIUM

AKORN*** AKORN INC**

ADENOSINE, ADENOSINE
 AKBETA, LEVOBUNOLOL HYDROCHLORIDE
 AKPENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE
 AKTOB, TOBRAMYCIN
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
 BALANCED SALT, CALCIUM CHLORIDE
 BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
 BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
 CALCITRIOL, CALCITRIOL
 CARBOPLATIN, CARBOPLATIN
 CICLOPIROX, CICLOPIROX
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CROMOLYN SODIUM, CROMOLYN SODIUM
 DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
 DESOXIMETASONE, DESOXIMETASONE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
 EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
 EPTIFIBATIDE, EPTIFIBATIDE
 ERYTHROMYCIN, ERYTHROMYCIN
 ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
 ETHOSUXIMIDE, ETHOSUXIMIDE
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
 GENTAK, GENTAMICIN SULFATE
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 HALOPERIDOL, HALOPERIDOL LACTATE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LATANOPROST, LATANOPROST
 LEVOFLOXACIN, LEVOFLOXACIN
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 LORAZEPAM, LORAZEPAM
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 NEDOCROMIL SODIUM, NEDOCROMIL SODIUM
 NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
 NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
 PARICALCITOL, PARICALCITOL
 PYRAZINAMIDE, PYRAZINAMIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* AKORN INC
RIFAMPIN, RIFAMPIN
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TERBUTALINE SULFATE, TERBUTALINE SULFATE
TIMOLOL MALEATE, TIMOLOL MALEATE
TIMOLOL, TIMOLOL
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TRANEXAMIC ACID, TRANEXAMIC ACID
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TROPICACYL, TROPICAMIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

* AKORN OPERATING CO LLC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETYLCYSTEINE, ACETYLCYSTEINE
ACYCLOVIR, ACYCLOVIR
AK-FLUOR 10%, FLUORESCHEIN SODIUM
AK-FLUOR 25%, FLUORESCHEIN SODIUM
AKTEN, LIDOCAINE HYDROCHLORIDE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALFENTA, ALFENTANIL HYDROCHLORIDE
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMICAR, AMINOCAPROIC ACID
ATROPINE SULFATE, ATROPINE SULFATE
AZASITE, AZITHROMYCIN
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BAL, DIMERCAPROL
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETIMOL, TIMOLOL
BIMATOPROST, BIMATOPROST
BROMFENAC SODIUM, BROMFENAC SODIUM
CALCIPOTRIENE, CALCIPOTRIENE
CAPASTAT SULFATE, CAPREOMYCIN SULFATE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CICLOPIROX, CICLOPIROX
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
COGENTIN, BENZTROPINE MESYLATE
CORMAX, CLOBETASOL PROPIONATE
COSOPT PF, DORZOLAMIDE HYDROCHLORIDE
COSOPT, DORZOLAMIDE HYDROCHLORIDE
DESONIDE, DESONIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIURIL, CHLOROTHIAZIDE SODIUM
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
EMBELINE E, CLOBETASOL PROPIONATE
EMBELINE, CLOBETASOL PROPIONATE
EPHEDRINE SULFATE, EPHEDRINE SULFATE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE (OTC)
GABAPENTIN, GABAPENTIN
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
IBUPROFEN, IBUPROFEN
IC-GREEN, INDOCYANINE GREEN
INAPSINE, DROPERIDOL
KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
LACTULOSE, LACTULOSE
LEVOCARNITINE, LEVOCARNITINE
LEVOFLOXACIN, LEVOFLOXACIN
LIDOCAINE AND PRILOCAINE, LIDOCAINE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* AKORN OPERATING CO LLC
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
 LOTE Prednol Etabonate, LOTE Prednol Etabonate
 MEGESTROL ACETATE, MEGESTROL ACETATE
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
 MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
 MORPHINE SULFATE, MORPHINE SULFATE
 NEMBUTAL SODIUM, PENTOBARBITAL SODIUM
 NYSTATIN, NYSTATIN
 OFLOXACIN, OFLOXACIN
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PAREMYD, HYDROXYAMPHETAMINE HYDROBROMIDE
 PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 PREDNISOLONE, PREDNISOLONE
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 RIFAMPIN, RIFAMPIN
 SUBLIMAZE PRESERVATIVE FREE, FENTANYL CITRATE
 SUFENTA PRESERVATIVE FREE, SUFENTANIL CITRATE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 TIMOLOL MALEATE, TIMOLOL MALEATE
 TRIFLURIDINE, TRIFLURIDINE
 VORICONAZOLE, VORICONAZOLE
 VOSOL HC, ACETIC ACID, GLACIAL
 VOSOL, ACETIC ACID, GLACIAL
 XOPENEX, LEVALBUTEROL HYDROCHLORIDE
 XYLOCAINE, LIDOCAINE HYDROCHLORIDE
 ZIOPTAN, TAFLUPROST

AKORN INC

* AKORN INC
 APRACLOnidine Hydrochloride, Apraclonidine Hydrochloride
 CEFTRIAXONE, CEFTRIAXONE SODIUM
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
 CYCLOPENTOLATE HYDROCHLORIDE, CYCLOPENTOLATE HYDROCHLORIDE
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
 DOXERCALCIFEROL, DOXERCALCIFEROL
 DRONABINOL, DRONABINOL
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
 NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
 PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE
 ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
 TIMOLOL MALEATE, TIMOLOL MALEATE
 TOBRAMYCIN, TOBRAMYCIN
 TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

ALCON

* ALCON LABORATORIES INC
 BSS PLUS, CALCIUM CHLORIDE
 BSS, CALCIUM CHLORIDE
 MIOSTAT, CARBACHOL
 NAPHCN-A, NAPHAZOLINE HYDROCHLORIDE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******ALCON LABS**

* ALCON LABORATORIES LTD
TETRACAINE HYDROCHLORIDE, TETRACAINE HYDROCHLORIDE

ALCON LABS INC

* ALCON LABORATORIES INC
ALCAINE, PROPARACAINE HYDROCHLORIDE
CYCLOGYL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOMYDRIL, CYCLOPENTOLATE HYDROCHLORIDE
FLUORESCITE, FLUORESCHEIN SODIUM
ISOPTO ATROPINE, ATROPINE SULFATE
MYDRIACYL, TROPICAMIDE
PATADAY ONCE DAILY RELIEF, OLOPATADINE HYDROCHLORIDE (OTC)
PATADAY TWICE DAILY RELIEF, OLOPATADINE HYDROCHLORIDE (OTC)

ALCON PHARMS LTD

* ALCON PHARMACEUTICALS LTD
BETADINE, POVIDONE-IODINE
ZADITOR, KETOTIFEN FUMARATE (OTC)

ALEMBIC LABS

* ALEMBIC LABS LLC
BENZONATATE, BENZONATATE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
ERGOCALCIFEROL, ERGOCALCIFEROL
FENOFIBRATE, FENOFIBRATE
GLYCOPYRROLATE, GLYCOPYRROLATE
LEVETIRACETAM, LEVETIRACETAM
METRONIDAZOLE, METRONIDAZOLE

ALEMBIC LTD

* ALEMBIC LTD
LITHIUM CARBONATE, LITHIUM CARBONATE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE

ALEMBIC PHARMS LTD

* ALEMBIC PHARMACEUTICALS LTD
ACETAZOLAMIDE, ACETAZOLAMIDE
ACYCLOVIR, ACYCLOVIR
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
ARIPIPIRAZOLE, ARIPIPIRAZOLE
ASENAPINE MALEATE, ASENAPINE MALEATE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
AZITHROMYCIN, AZITHROMYCIN
BIMATOPROST, BIMATOPROST
BROMFENAC SODIUM, BROMFENAC SODIUM
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
CARBIDOPA AND LEVODOPA, CARBIDOPA
CELECOXIB, CELECOXIB
CLONAZEPAM, CLONAZEPAM
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
DEFERASIROX, DEFERASIROX
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DESVENLAFAXINE, DESVENLAFAXINE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
FAMOTIDINE, FAMOTIDINE
FEBUXOSTAT, FEBUXOSTAT
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOFIBRATE, FENOFIBRATE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ALEMBIC PHARMACEUTICALS LTD
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRBESARTAN, IRBESARTAN
 ITRACONAZOLE, ITRACONAZOLE
 LAMOTRIGINE, LAMOTRIGINE
 LEFLUNOMIDE, LEFLUNOMIDE
 LINEZOLID, LINEZOLID
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 MEPROBAMATE, MEPROBAMATE
 METOLAZONE, METOLAZONE
 METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 METRONIDAZOLE, METRONIDAZOLE
 MODAFINIL, MODAFINIL
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
 OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
 PREGABALIN, PREGABALIN
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
 TADALAFIL, TADALAFIL
 TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TELMISARTAN, TELMISARTAN
 TEMAZEPAM, TEMAZEPAM
 TERIFLUNOMIDE, TERIFLUNOMIDE
 THEOPHYLLINE, THEOPHYLLINE
 TIMOLOL MALEATE, TIMOLOL MALEATE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TOBRAMYCIN, TOBRAMYCIN
 TRAVOPROST, TRAVOPROST
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 VALSARTAN, VALSARTAN
 VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 VILAZODONE HYDROCHLORIDE, VILAZODONE HYDROCHLORIDE
 ZOLMITRIPTAN, ZOLMITRIPTAN

ALEOR DERMACEUTICALS

* ALEOR DERMACEUTICALS LTD
 ADAPALENE, ADAPALENE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 DESONIDE, DESONIDE
 LIDOCAINE, LIDOCAINE
 TAVABOROLE, TAVABOROLE

ALEXZA PHARMS

* ALEXZA PHARMACEUTICALS INC
 ADASUVE, LOXAPINE

ALFASIGMA

* ALFASIGMA USA INC
 ZELNORM, TEGASEROD MALEATE

ALIGNSCIENCE PHARMA

* ALIGNSCIENCE PHARMA INC
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE

ALIMERA SCIENCES INC

* ALIMERA SCIENCES INC
 ILUVIEN, FLUOCINOLONE ACETONIDE

ALKALOIDA ZRT

* ALKALOIDA CHEMICAL CO ZRT
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******ALKEM**

* ALKEM LABORATORIES LTD
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 GABAPENTIN, GABAPENTIN
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

ALKEM LABS LTD

* ALKEM LABORATORIES LTD
 AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
 AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
 ARIPIPIRAZOLE, ARIPIPIRAZOLE
 AZATHIOPRINE, AZATHIOPRINE
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
 CAPECITABINE, CAPECITABINE
 CEFIXIME, CEFIXIME
 CEFUROXIME AXETIL, CEFUROXIME AXETIL
 CEPHALEXIN, CEPHALEXIN
 CHLORTHALIDONE, CHLORTHALIDONE
 CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
 CLOBAZAM, CLOBAZAM
 COLCHICINE, COLCHICINE
 COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
 DABIGATRAN ETEXILATE MESYLATE, DABIGATRAN ETEXILATE MESYLATE
 DALFAMPRIDINE, DALFAMPRIDINE
 DEFERASIROX, DEFERASIROX
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 DIMETHYL FUMARATE, DIMETHYL FUMARATE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 EZETIMIBE AND SIMVASTATIN, EZETIMIBE
 EZETIMIBE, EZETIMIBE
 FINASTERIDE, FINASTERIDE
 FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
 GABAPENTIN, GABAPENTIN
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 ITRACONAZOLE, ITRACONAZOLE
 LAMOTRIGINE, LAMOTRIGINE
 LANSOPRAZOLE, LANSOPRAZOLE
 LIDOCAINE, LIDOCAINE
 LINEZOLID, LINEZOLID
 MARINOL, DRONABINOL
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 OLANZAPINE, OLANZAPINE
 OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PREGABALIN, PREGABALIN
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 RANOLAZINE, RANOLAZINE
 RASAGILINE MESYLATE, RASAGILINE MESYLATE
 RILUZOLE, RILUZOLE
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
 TACROLIMUS, TACROLIMUS
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TOLVAPTAN, TOLVAPTAN
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ALKEM LABORATORIES LTD
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 VALSARTAN, VALSARTAN
 VIGABATRIN, VIGABATRIN

ALKERMES

* ALKERMES INC
 VIVITROL, NALTREXONE

ALKERMES INC

* ALKERMES INC
 ARISTADA INITIO KIT, ARIPIPIRAZOLE LAUROXIL
 ARISTADA, ARIPIPIRAZOLE LAUROXIL

ALLEGIANCE HLTHCARE

* ALLEGIANCE HEALTHCARE CORP
 POVIDONE IODINE, POVIDONE-IODINE (OTC)

ALLERGAN

* ALLERGAN
 ACULAR LS, KETOROLAC TROMETHAMINE
 ALPHAGAN P, BRIMONIDINE TARTRATE
 BLEPH-10, SULFACETAMIDE SODIUM
 GENOPTIC, GENTAMICIN SULFATE
 ZYMAXID, GATIFLOXACIN

* ALLERGAN INC
 ACULAR, KETOROLAC TROMETHAMINE
 ACUVAIL, KETOROLAC TROMETHAMINE
 ACZONE, DAPSONE
 ALOCRIAL, NEDOCROMIL SODIUM
 ALPHAGAN P, BRIMONIDINE TARTRATE
 AVAGE, TAZAROTENE
 COMBIGAN, BRIMONIDINE TARTRATE
 ELESTAT, EPINASTINE HYDROCHLORIDE
 LASTACAFT, ALCAFTADINE
 LATISSE, BIMATOPROST
 LUMIGAN, BIMATOPROST
 OCUFLOX, OFLOXACIN
 OZURDEX, DEXAMETHASONE
 POLYTRIM, POLYMYXIN B SULFATE
 RESTASIS MULTIDOSE, CYCLOSPORINE
 RESTASIS, CYCLOSPORINE
 TAZORAC, TAZAROTENE
 ZYMAR, GATIFLOXACIN

* ALLERGAN PHARMACEUTICAL
 BETAGAN, LEVOBUNOLOL HYDROCHLORIDE
 BLEPHAMIDE S.O.P., PREDNISOLONE ACETATE
 BLEPHAMIDE, PREDNISOLONE ACETATE
 FML FORTE, FLUOROMETHOLONE
 FML, FLUOROMETHOLONE
 OCUFEN, FLURBIPROFEN SODIUM
 PRED FORTE, PREDNISOLONE ACETATE
 PRED MILD, PREDNISOLONE ACETATE
 PRED-G, GENTAMICIN SULFATE

* ALLERGAN SALES LLC
 ACTIGALL, URSODIOL
 ALORA, ESTRADIOL
 ANDRODERM, TESTOSTERONE
 AVYCAZ, AVIBACTAM SODIUM
 BENTYL PRESERVATIVE FREE, DICYCLOMINE HYDROCHLORIDE
 BENTYL, DICYCLOMINE HYDROCHLORIDE
 BYSTOLIC, NEBIVOLOL HYDROCHLORIDE
 CANASA, MESALAMINE
 CARAFATE, SUCRALFATE
 CELEXA, CITALOPRAM HYDROBROMIDE
 CONDYLOX, PODOFILOX
 CRINONE, PROGESTERONE
 DALVANCE, DALBAVANCIN HYDROCHLORIDE
 ESTRACE, ESTRADIOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ALLERGAN SALES LLC
 FETZIMA, LEVOMILNACIPRAN HYDROCHLORIDE
 FIORINAL W/CODEINE, ASPIRIN
 FIORINAL, ASPIRIN
 GELNIQUE, OXYBUTYNIN CHLORIDE
 INFED, IRON DEXTRAN
 KADIAN, MORPHINE SULFATE
 LEXAPRO, ESCITALOPRAM OXALATE
 LINZESS, LINACLOTIDE
 MICROZIDE, HYDROCHLOROTHIAZIDE
 NAMENDA, MEMANTINE HYDROCHLORIDE
 NAMZARIC, DONEPEZIL HYDROCHLORIDE
 NORINYL 1+35 21-DAY, ETHINYL ESTRADIOL
 NORINYL 1+35 28-DAY, ETHINYL ESTRADIOL
 OXYTROL FOR WOMEN, OXYBUTYNIN (OTC)
 OXYTROL, OXYBUTYNIN
 PYLERA, BISMUTH SUBCITRATE POTASSIUM
 RAPAFLO, SILODOSIN
 RECTIV, NITROGLYCERIN
 SAPHRIS, ASENAPINE MALEATE
 SAVELLA, MILNACIPRAN HYDROCHLORIDE
 TEFLARO, CEFTAROLINE FOSAMIL
 UBRELVY, UBROGEPANT
 URSO 250, URSODIOL
 URSO FORTE, URSODIOL
 VIIBRYD, VILAZODONE HYDROCHLORIDE
 VRAYLAR, CARIPRAZINE HYDROCHLORIDE

ALLERGAN HOLDINGS

* ALLERGAN HOLDINGS UNLTD CO
 VIBERZI, ELUXADOLINE

ALLERGAN INC

* ALLERGAN INC
 DURYSTA, BIMATOPROST

ALLERQUEST

* ALLERQUEST LLC
 PRE-PEN, BENZYL PENICILLOYL POLYLYSINE

ALLIED

* ALLIED PHARMA INC
 CARISOPRODOL, CARISOPRODOL
 DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM

ALMATICA

* ALMATICA PHARMA INC
 GRALISE, GABAPENTIN

* ALMATICA PHARMA LLC
 MACROBID, NITROFURANTOIN
 MACRODANTIN, NITROFURANTOIN, MACROCRYSTALLINE
 NAPRELAN, NAPROXEN SODIUM
 TENORETIC 100, ATENOLOL
 TENORETIC 50, ATENOLOL
 TENORMIN, ATENOLOL
 ZESTRIL, LISINAPRIL

ALMIRALL

* ALMIRALL LLC
 ACTICLATE, DOXYCYCLINE HYCLATE
 ACZONE, DAPSONE
 ALTABAX, RETAPAMULIN
 AZELEX, AZELAIC ACID
 CORDRAN SP, FLURANDRENOLIDE
 CORDRAN, FLURANDRENOLIDE
 FLUOROPLEX, FLUOROURACIL
 KLISYRI, TIRBANIBULIN
 SEYSARA, SARECYCLINE HYDROCHLORIDE
 VELTIN, CLINDAMYCIN PHOSPHATE
 VERDESO, DESONIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ALMIRALL LLC
XOLEGEL, KETOCONAZOLE

ALNYLAM PHARMS INC

* ALNYLAM PHARMACEUTICALS INC
GIVLAARI, GIVOSIRAN SODIUM
ONPATRO, PATISIRAN SODIUM
OXLUMO, LUMASIRAN SODIUM

ALRA

* ALRA LABORATORIES INC
CHOLAC, LACTULOSE
CONSTILAC, LACTULOSE
GEN-XENE, CLORAZEPATE DIPOTASSIUM
IBU-TAB 200, IBUPROFEN (OTC)
IBU-TAB, IBUPROFEN

ALTAIRE PHARMS INC

* ALTAIRE PHARMACEUTICALS INC
ALTAFLUOR BENOX, BENOXINATE HYDROCHLORIDE
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)
OFLOXACIN, OFLOXACIN

ALTATHERA PHARMS LLC

* ALTATHERA PHARMACEUTICALS LLC
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

ALVOGEN

* ALVOGEN GROUP HOLDINGS 2 LLC
DAPSONE, DAPSONE
ETHACRYNIC ACID, ETHACRYNIC ACID
OFLOXACIN, OFLOXACIN

* ALVOGEN GROUP HOLDINGS 3 LLC
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FORFIVO XL, BUPROPION HYDROCHLORIDE

* ALVOGEN GROUP HOLDINGS 4 LLC
THYRO-TABS, LEVOTHYROXINE SODIUM **

* ALVOGEN INC
ACETYLCYSTEINE, ACETYLCYSTEINE
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
BONSITY, TERIPARATIDE
CARBIDOPA, CARBIDOPA
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DISULFIRAM, DISULFIRAM
EXEMESTANE, EXEMESTANE
FELBAMATE, FELBAMATE
HYDROCODONE BITARTRATE, HYDROCODONE BITARTRATE
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
NEVIRAPINE, NEVIRAPINE
NITROGLYCERIN, NITROGLYCERIN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
RIVASTIGMINE, RIVASTIGMINE
SPECTAZOLE, ECONAZOLE NITRATE
TOLCAPONE, TOLCAPONE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE

* ALVOGEN MALTA OPERATIONS LTD
MELPHALAN, MELPHALAN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE
ZESTORETIC, HYDROCHLOROTHIAZIDE

ALVOGEN PINE BROOK

* ALVOGEN PINE BROOK LLC
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
ESTRADIOL, ESTRADIOL
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ALVOGEN PINE BROOK LLC
 OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE

AM REGENT

* AMERICAN REGENT INC
 ACETYLCYSTEINE, ACETYLCYSTEINE
 BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE ACETATE
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 CAFFEINE CITRATE, CAFFEINE CITRATE
 CALCIUM CHLORIDE 10%, CALCIUM CHLORIDE
 CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
 CYANOCOBALAMIN, CYANOCOBALAMIN
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
 DROPERIDOL, DROPERIDOL
 ESTRADIOL VALERATE, ESTRADIOL VALERATE
 FOMEPIZOLE, FOMEPIZOLE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 INJECTAFER, FERRIC CARBOXYMALTOSIDE
 LEVOCARNITINE, LEVOCARNITINE
 METHOCARBAMOL, METHOCARBAMOL
 METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
 NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
 NITROGLYCERIN, NITROGLYCERIN
 OLANZAPINE, OLANZAPINE
 SELENIOUS ACID, SELENIOUS ACID
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 TRALEMENT, CUPRIC SULFATE
 TRANEXAMIC ACID, TRANEXAMIC ACID
 VASOPRESSIN, VASOPRESSIN
 VENOFER, IRON SUCROSE
 ZINC SULFATE, ZINC SULFATE

AMAG PHARMA USA

* AMAG PHARMA USA INC
 MAKENA (AUTOINJECTOR), HYDROXYPROGESTERONE CAPROATE
 MAKENA PRESERVATIVE FREE, HYDROXYPROGESTERONE CAPROATE
 MAKENA, HYDROXYPROGESTERONE CAPROATE

AMAG PHARMS INC

* AMAG PHARMACEUTICALS INC
 FERAHEME, FERUMOXYTOL

AMARIN PHARMS

* AMARIN PHARMACEUTICALS IRELAND LTD
 VASCEPA, ICOSAPENT ETHYL

AMGEN

* AMGEN INC
 SENSIPAR, CINACALCET HYDROCHLORIDE

AMGEN INC

* AMGEN INC
 CORLANOR, IVABRADINE
 CORLANOR, IVABRADINE HYDROCHLORIDE
 OTEZLA, APREMILAST

AMICI

* AMICI PHARMACEUTICALS LLC
 DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM

AMICUS THERAPS US

* AMICUS THERAPEUTICS US INC
 GALAFOLD, MIGALASTAT HYDROCHLORIDE

AMIVAS

* AMIVAS LLC
 ARTESUNATE, ARTESUNATE

AMNEAL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* AMNEAL EU LTD

AMINOCAPROIC ACID, AMINOCAPROIC ACID
 ATAZANAVIR SULFATE, ATAZANAVIR SULFATE
 BUSULFAN, BUSULFAN
 CARMUSTINE, CARMUSTINE
 CLOFARABINE, CLOFARABINE
 CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
 DEFERASIROX, DEFERASIROX
 DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE, DEXAMETHASONE SODIUM PHOSPHATE
 DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
 DIMETHYL FUMARATE, DIMETHYL FUMARATE
 DOCETAXEL, DOCETAXEL
 DOXERCALCIFEROL, DOXERCALCIFEROL
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 EPHEDRINE SULFATE, EPHEDRINE SULFATE
 FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
 FULVESTRANT, FULVESTRANT
 GLYCOPYRROLATE, GLYCOPYRROLATE
 ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
 LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
 METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
 METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
 METYROSINE, METYROSINE
 NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
 NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
 OFLOXACIN, OFLOXACIN
 PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE
 PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
 PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
 SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

* AMNEAL PHARMACEUTICALS LLC

ACTIVELLA, ESTRADIOL
 ACYCLOVIR, ACYCLOVIR
 AMINOCAPROIC ACID, AMINOCAPROIC ACID
 AZATHIOPRINE, AZATHIOPRINE
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 AZITHROMYCIN, AZITHROMYCIN
 BUPRENORPHINE, BUPRENORPHINE
 CLOBAZAM, CLOBAZAM
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 DEXTROMETHORPHAN POLISTIREX, DEXTROMETHORPHAN POLISTIREX (OTC)
 ELURYNG, ETHINYL ESTRADIOL
 ESTRADIOL, ESTRADIOL
 FENOFIBRATE, FENOFIBRATE
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
 FLUOCINONIDE, FLUOCINONIDE
 LIDOCAINE, LIDOCAINE
 MESALAMINE, MESALAMINE
 NAPROXEN, NAPROXEN
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
 RISPERIDONE, RISPERIDONE
 RITONAVIR, RITONAVIR
 SIROLIMUS, SIROLIMUS
 SUCRALFATE, SUCRALFATE
 TAVABOROLE, TAVABOROLE
 TESTOSTERONE, TESTOSTERONE
 TIGECYCLINE, TIGECYCLINE
 TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******AMNEAL PHARM**

* AMNEAL PHARMACEUTICAL
 ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE
 BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
 DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
 FLECAINIDE ACETATE, FLECAINIDE ACETATE
 FOLIC ACID, FOLIC ACID
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 PRIMIDONE, PRIMIDONE

AMNEAL PHARMS

* AMNEAL PHARMACEUTICALS
 ACYCLOVIR, ACYCLOVIR
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 ARIPIPIRAZOLE, ARIPIPIRAZOLE
 ATOVAQUONE, ATOVAQUONE
 CALCITRIOL, CALCITRIOL
 CALCIUM ACETATE, CALCIUM ACETATE
 CAPECITABINE, CAPECITABINE
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 COLCHICINE, COLCHICINE
 DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DICLOFENAC SODIUM, DICLOFENAC SODIUM (OTC)
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 ENTECAVIR, ENTECAVIR
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 ESTRADIOL, ESTRADIOL
 FELBAMATE, FELBAMATE
 GABAPENTIN, GABAPENTIN
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 INDOMETHACIN, INDOMETHACIN
 ITRACONAZOLE, ITRACONAZOLE
 LEVETIRACETAM, LEVETIRACETAM
 LIDOCAINE, LIDOCAINE
 LINEZOLID, LINEZOLID
 LORAZEPAM, LORAZEPAM
 MEROPENEM, MEROPENEM
 METAXALONE, METAXALONE
 MOMETASONE FUROATE, MOMETASONE FUROATE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 NIACIN, NIACIN
 NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
 NITROFURANTOIN, NITROFURANTOIN
 NIZATIDINE, NIZATIDINE
 NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 OXCARBAZEPINE, OXCARBAZEPINE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
 PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN
 PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
 QUININE SULFATE, QUININE SULFATE
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
 RISPERIDONE, RISPERIDONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

- * AMNEAL PHARMACEUTICALS
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 TELMISARTAN, TELMISARTAN
 TEMAZEPAM, TEMAZEPAM
 TEMOZOLOMIDE, TEMOZOLOMIDE
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 VORICONAZOLE, VORICONAZOLE
 WARFARIN SODIUM, WARFARIN SODIUM
- * AMNEAL PHARMACEUTICALS HOLDINGS GMBH
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
- * AMNEAL PHARMACEUTICALS OF NEW YORK LLC
 ABIRATERONE ACETATE, ABIRATERONE ACETATE
 ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
 AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
 ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 BUDESONIDE, BUDESONIDE
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 CELECOXIB, CELECOXIB
 DUTASTERIDE, DUTASTERIDE
 ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
 GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
 GUAIFENESIN, GUAIFENESIN (OTC)
 IBUPROFEN, IBUPROFEN (OTC)
 IRBESARTAN, IRBESARTAN
 LAMOTRIGINE, LAMOTRIGINE
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 NORETHINDRONE, NORETHINDRONE
 NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
 OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 PALIPERIDONE, PALIPERIDONE
 PARICALCITOL, PARICALCITOL
 PRASUGREL, PRASUGREL HYDROCHLORIDE
 RIVASTIGMINE, RIVASTIGMINE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SPIRONOLACTONE, SPIRONOLACTONE
 TOBRAMYCIN, TOBRAMYCIN
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 VALSARTAN, VALSARTAN
 VIGABATRIN, VIGABATRIN

AMNEAL PHARMS CO

- * AMNEAL PHARMACEUTICALS CO GMBH
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 ARGATROBAN, ARGATROBAN
 BOSENTAN, BOSENTAN
 BUMETANIDE, BUMETANIDE
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
 CHLORTHALIDONE, CHLORTHALIDONE
 CLOBAZAM, CLOBAZAM
 CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
 DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* AMNEAL PHARMACEUTICALS CO GMBH
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
 ERYTHROMYCIN, ERYTHROMYCIN
 ETHACRYNIC ACID, ETHACRYNIC ACID
 ETODOLAC, ETODOLAC
 EZETIMIBE AND SIMVASTATIN, EZETIMIBE
 EZETIMIBE, EZETIMIBE
 FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 NADOLOL, NADOLOL
 NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
 OXAPROZIN, OXAPROZIN
 PARICALCITOL, PARICALCITOL
 PHYTONADIONE, PHYTONADIONE
 PREGABALIN, PREGABALIN
 SEVELAMER CARBONATE, SEVELAMER CARBONATE
 SILODOSIN, SILODOSIN
 SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
 TADALAFIL, TADALAFIL
 TIAGABINE HYDROCHLORIDE, TIAGABINE HYDROCHLORIDE
 TRANEXAMIC ACID, TRANEXAMIC ACID
 URSODIOL, URSODIOL

AMNEAL PHARMS NY

* AMNEAL PHARMACEUTICALS NY LLC
 ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 ALPRAZOLAM, ALPRAZOLAM
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
 GABAPENTIN, GABAPENTIN
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
 IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 NAPROXEN SODIUM, NAPROXEN SODIUM
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
 NAPROXEN, NAPROXEN
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 REPRESXAIN, HYDROCODONE BITARTRATE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE

* AMNEAL PHARMACEUTICALS OF NY LLC
 BEXAROTENE, BEXAROTENE
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 ISOTRETINOIN, ISOTRETINOIN
 OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
 PROGESTERONE, PROGESTERONE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE

AMPHASTAR PHARM

* AMPHASTAR PHARMACEUTICAL INC
 ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM

AMPHASTAR PHARMS INC

* AMPHASTAR PHARMACEUTICALS INC
 CORTROSYN, COSYNTROPIN
 ENOXAPARIN SODIUM, ENOXAPARIN SODIUM
 GLUCAGON, GLUCAGON
 ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
 MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
 NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******AMRING PHARMS**

- * AMRING PHARMACEUTICALS INC
 - ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
 - LATANOPROST, LATANOPROST
 - LYSTEDA, TRANEXAMIC ACID
 - MESALAMINE, MESALAMINE
 - NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
 - NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
 - NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
 - SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE

AMRYT

- * AMRYT PHARMACEUTICALS DAC
 - JUXTAPID, LOMITAPIDE MESYLATE

AMTA

- * AMTA LABS LTD
 - ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 - PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

ANACOR PHARMS INC

- * ANACOR PHARMACEUTICALS INC
 - EUCRISA, CRISABOROLE
 - KERYDIN, TAVABOROLE

ANBEX

- * ANBEX INC
 - IOSAT, POTASSIUM IODIDE (OTC)

ANBISON LAB

- * ANBISON LABORATORY CO LTD
 - BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 - MONTELUKAST SODIUM, MONTELUKAST SODIUM

ANCHEN PHARMS

- * ANCHEN PHARMACEUTICALS INC
 - ALISKIREN HEMIFUMARATE, ALISKIREN HEMIFUMARATE
 - BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 - CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 - DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 - DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, DUTASTERIDE
 - FENOFIBRIC ACID, CHOLINE FENOFIBRATE
 - FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
 - LAMOTRIGINE, LAMOTRIGINE
 - LEVETIRACETAM, LEVETIRACETAM
 - MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 - POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 - PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 - QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 - TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 - TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 - TRETINOIN, TRETINOIN
 - ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
- * ANCHEN PHARMACEUTICALS TAIWAN INC
 - DIVALPROEX SODIUM, DIVALPROEX SODIUM
- * ANCHEN PHARMACEUTICALS, INC
 - ALPRAZOLAM, ALPRAZOLAM
 - CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN

ANDA REPOSITORY

- * ANDA REPOSITORY LLC
 - ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 - ACYCLOVIR, ACYCLOVIR
 - AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 - AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
 - BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
 - CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 - CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
 - FLAC, FLUOCINOLONE ACETONIDE
 - HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 - ISONIAZID, ISONIAZID
 - LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******* ANDA REPOSITORY LLC**

LEVETIRACETAM, LEVETIRACETAM
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 PRASUGREL, PRASUGREL HYDROCHLORIDE
 PRIMIDONE, PRIMIDONE

ANDOR PHARMS*** ANDOR PHARMACEUTICALS LLC**

METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE

ANDRX LABS LLC*** ANDRX LABS LLC**

FORTAMET, METFORMIN HYDROCHLORIDE

ANI PHARMS*** ANI PHARMACEUTICALS INC**

CORTENEMA, HYDROCORTISONE
 LUVOX, FLUVOXAMINE MALEATE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 REGLAN, METOCLOPRAMIDE HYDROCHLORIDE

ANI PHARMS INC*** ANI PHARMACEUTICALS INC**

AMINOCAPROIC ACID, AMINOCAPROIC ACID
 ARIMIDEX, ANASTROZOLE
 ATACAND HCT, CANDESARTAN CILEXETIL
 ATACAND, CANDESARTAN CILEXETIL
 BEXAROTENE, BEXAROTENE
 BRETHINE, TERBUTALINE SULFATE
 CARBIDOPA, CARBIDOPA
 CASODEX, BICALUTAMIDE
 CHOLESTYRAMINE, CHOLESTYRAMINE
 CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
 CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
 ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
 ETODOLAC, ETODOLAC
 EZETIMIBE AND SIMVASTATIN, EZETIMIBE
 FELBAMATE, FELBAMATE
 FENOFIBRATE (MICRONIZED), FENOFIBRATE
 FLECAINIDE ACETATE, FLECAINIDE ACETATE
 FLUCONAZOLE, FLUCONAZOLE
 INDAPAMIDE, INDAPAMIDE
 INDERAL LA, PROPRANOLOL HYDROCHLORIDE
 INNOPRAN XL, PROPRANOLOL HYDROCHLORIDE
 LITHOBID, LITHIUM CARBONATE
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 METHAZOLAMIDE, METHAZOLAMIDE
 MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
 MIGLUSTAT, MIGLUSTAT
 MORPHINE SULFATE, MORPHINE SULFATE
 NILUTAMIDE, NILUTAMIDE
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PENICILLAMINE, PENICILLAMINE
 PINDOLOL, PINDOLOL
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 POTASSIUM CITRATE, POTASSIUM CITRATE
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 TEMOZOLOMIDE, TEMOZOLOMIDE
 VANCOCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

ANIMA*** ANIMA PHARMACEUTICALS PVT LTD**

BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
 DEXAMETHASONE, DEXAMETHASONE

ANNORA

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ANNORA PHARMA PRIVATE LTD
LAMIVUDINE, LAMIVUDINE

ANNORA PHARMA

* ANNORA PHARMA PRIVATE LTD
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
ITRACONAZOLE, ITRACONAZOLE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
MESALAMINE, MESALAMINE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZAFIRLUKAST, ZAFIRLUKAST

ANTARES PHARMA INC

* ANTARES PHARMA INC
OTREXUP, METHOTREXATE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
XYOSTED (AUTOINJECTOR), TESTOSTERONE ENANTHATE

ANTIBIOTICE

* ANTIBIOTICE SA
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
NAFCILLIN SODIUM, NAFCILLIN SODIUM

ANTRIM PHARMS LLC

* ANTRIM PHARMACEUTICALS LLC
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE

APGDI

* ASTELLAS PHARMA GLOBAL DEVELOPMENT INC
MYRBETRIQ, MIRABEGRON

APIL

* ALLERGAN PHARMACEUTICALS INTERNATIONAL LTD
ACTONEL, RISEDRONATE SODIUM
ASACOL HD, MESALAMINE
ATELVIA, RISEDRONATE SODIUM
DELZICOL, MESALAMINE
ENABLEX, DARIFENACIN HYDROBROMIDE
ESTROSTEP FE, ETHINYL ESTRADIOL
FEMHRT, ETHINYL ESTRADIOL
LO LOESTRIN FE, ETHINYL ESTRADIOL
MINASTRIN 24 FE, ETHINYL ESTRADIOL
NORCO, ACETAMINOPHEN
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
SARAFEM, FLUOXETINE HYDROCHLORIDE
TAYTULLA, ETHINYL ESTRADIOL

APNAR PHARMA LP

* APNAR PHARMA LP
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE

APOLLO

* APOLLO PHARMACEUTICALS INC
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
TRANEXAMIC ACID, TRANEXAMIC ACID

APOTEX

* APOTEX INC
ABIRATERONE ACETATE, ABIRATERONE ACETATE
ACYCLOVIR, ACYCLOVIR
ADEFOVIR DIPIVOXIL, ADEFOVIR DIPIVOXIL
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALKERAN, MELPHALAN HYDROCHLORIDE
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
ATOVAQUONE, ATOVAQUONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* APOTEX INC
 AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE, AZELASTINE HYDROCHLORIDE
 BUSULFAN, BUSULFAN
 CARBIDOPA AND LEVODOPA, CARBIDOPA
 CEFUROXIME AXETIL, CEFUROXIME AXETIL
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CIMETIDINE, CIMETIDINE (OTC)
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 CYCLOSPORINE, CYCLOSPORINE
 DECITABINE, DECITABINE
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
 ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
 ETODOLAC, ETODOLAC
 EZETIMIBE, EZETIMIBE
 FAMCICLOVIR, FAMCICLOVIR
 FAMOTIDINE, FAMOTIDINE
 FENOFIBRATE (MICRONIZED), FENOFIBRATE
 FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
 FLUNISOLIDE, FLUNISOLIDE
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE (OTC)
 FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
 FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
 GEMFIBROZIL, GEMFIBROZIL
 GLIPIZIDE, GLIPIZIDE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 IMATINIB MESYLATE, IMATINIB MESYLATE
 LAMIVUDINE, LAMIVUDINE
 LEVETIRACETAM, LEVETIRACETAM
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 MICAFUNGIN SODIUM, MICAFUNGIN SODIUM
 MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE (OTC)
 OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
 OMEPRAZOLE, OMEPRAZOLE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PENICILLAMINE, PENICILLAMINE
 PENTOXIFYLLINE, PENTOXIFYLLINE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 RAMIPRIL, RAMIPRIL
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
 SIROLIMUS, SIROLIMUS
 SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
 TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
 TESTOSTERONE, TESTOSTERONE
 TETRABENAZINE, TETRABENAZINE
 TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
 TIGECYCLINE, TIGECYCLINE
 TIMOLOL MALEATE, TIMOLOL MALEATE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 TRANEXAMIC ACID, TRANEXAMIC ACID
 TRAVOPROST, TRAVOPROST

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******* APOTEX INC**

TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
 TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

APOTEX CORP*** APOTEX CORP**

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

APOTEX INC*** APOTEX INC**

ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
 ALPRAZOLAM, ALPRAZOLAM
 ARIPIPIRAZOLE, ARIPIPIRAZOLE
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 BENZONATATE, BENZONATATE
 BICALUTAMIDE, BICALUTAMIDE
 BIMATOPROST, BIMATOPROST
 BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
 CALCITONIN-SALMON, CALCITONIN SALMON
 CARBAMAZEPINE, CARBAMAZEPINE
 CARBIDOPA AND LEVODOPA, CARBIDOPA
 CEFPROZIL, CEFPROZIL
 CELECOXIB, CELECOXIB
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 IMIQUIMOD, IMIQUIMOD
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
 KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
 LETROZOLE, LETROZOLE
 LEVETIRACETAM, LEVETIRACETAM
 LEVOFLOXACIN, LEVOFLOXACIN
 MODAFINIL, MODAFINIL
 MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
 MOMETASONE FUROATE, MOMETASONE FUROATE
 MYCOPHENOLIC ACID, MYCOPHENOLIC ACID
 OFLOXACIN, OFLOXACIN
 OLANZAPINE, OLANZAPINE
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
 RISEDRONATE SODIUM, RISEDRONATE SODIUM
 RISPERIDONE, RISPERIDONE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TRANEXAMIC ACID, TRANEXAMIC ACID
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

*** APOTEX INC ETOBICOKE SITE**

ACYCLOVIR, ACYCLOVIR
 ALLOPURINOL, ALLOPURINOL
 BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CARBAMAZEPINE, CARBAMAZEPINE
 CILOSTAZOL, CILOSTAZOL
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 ETODOLAC, ETODOLAC
 FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
 GABAPENTIN, GABAPENTIN
 LEFLUNOMIDE, LEFLUNOMIDE
 LORATADINE, LORATADINE (OTC)
 MELOXICAM, MELOXICAM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

- * APOTEX INC ETOBICOKE SITE
MIRTAZAPINE, MIRTAZAPINE
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
ZONISAMIDE, ZONISAMIDE
- * APOTEX INC RICHMOND HILL
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BUDESONIDE, BUDESONIDE (OTC)
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE

APOTEX TECHNOLOGIES

- * APOTEX TECHNOLOGIES INC
PAXIL CR, PAROXETINE HYDROCHLORIDE
PAXIL, PAROXETINE HYDROCHLORIDE

APOTHECON

- * APOTHECON INC DIV BRISTOL MYERS SQUIBB
KENALOG-10, TRIAMCINOLONE ACETONIDE
KENALOG-40, TRIAMCINOLONE ACETONIDE
KENALOG-80, TRIAMCINOLONE ACETONIDE

APP PHARMS

- * APP PHARMACEUTICALS LLC
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE

APPCO

- * APPCO PHARMA LLC
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
MODAFINIL, MODAFINIL
RAMELTEON, RAMELTEON
SILDENAFIL CITRATE, SILDENAFIL CITRATE
ZOLMITRIPTAN, ZOLMITRIPTAN

APRECIA PHARMS

- * APRECIA PHARMACEUTICALS LLC
SPRITAM, LEVETIRACETAM

APTAPHARMA INC

- * APTAPHARMA INC
IBUPROFEN, IBUPROFEN (OTC)
SILDENAFIL CITRATE, SILDENAFIL CITRATE

AQUESTIVE THERAP

- * AQUESTIVE THERAPEUTICS
EXSERVAN, RILUZOLE
SYMPAZAN, CLOBAZAM

ARBOR PHARMS LLC

- * ARBOR PHARMACEUTICALS LLC
BIDIL, HYDRALAZINE HYDROCHLORIDE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
E.E.S. 400, ERYTHROMYCIN ETHYLSUCCINATE
E.E.S., ERYTHROMYCIN ETHYLSUCCINATE
EDARBI, AZILSARTAN KAMEDOXOMIL
EDARBYCLOR, AZILSARTAN KAMEDOXOMIL
ERY-TAB, ERYTHROMYCIN
ERYPED, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROCIN STEARATE, ERYTHROMYCIN STEARATE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN, ERYTHROMYCIN
EVEKEO ODT, AMPHETAMINE SULFATE
EVEKEO, AMPHETAMINE SULFATE
GLIADEL, CARMUSTINE
HORIZANT, GABAPENTIN ENACARBIL
NYMALIZE, NIMODIPINE
SKLICE, IVERMECTIN (OTC)
SOTYLIZE, SOTALOL HYDROCHLORIDE
TRIPTODUR KIT, TRIPTORELIN PAMOATE

ARCO PHARMS LLC

- * ARCO PHARMACEUTICALS LLC
THYROSHIELD, POTASSIUM IODIDE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******AREVA PHARMS**

* AREVA PHARMACEUTICALS INC
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
 FUROSEMIDE, FUROSEMIDE
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

ARIAD

* ARIAD PHARMACEUTICALS INC
 ALUNBRIG, BRIGATINIB
 ICLUSIG, PONATINIB HYDROCHLORIDE

ARISE

* ARISE PHARMACEUTICALS LLC
 IBUPROFEN, IBUPROFEN (OTC)
 LAMIVUDINE, LAMIVUDINE

ARMSTRONG PHARMS

* ARMSTRONG PHARMACEUTICALS INC
 PRIMATENE MIST, EPINEPHRINE (OTC)

ARRAY BIOPHARMA INC

* ARRAY BIOPHARMA INC
 BRAFTOVI, ENCORAFENIB
 MEKTOVI, BINIMETINIB

ASCEND THERAPY US

* ASCEND THERAPEUTICS US LLC
 BINOSTO, ALENDRONATE SODIUM
 ESTROGEL, ESTRADIOL

ASCENT PHARMS INC

* ASCENT PHARMACEUTICALS INC
 BENZONATATE, BENZONATATE
 DRONABINOL, DRONABINOL
 DUTASTERIDE, DUTASTERIDE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 IBUPROFEN, IBUPROFEN (OTC)
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

ASPEN

* ASPEN PHARMA USA INC
 HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE

ASPEN GLOBAL

* ASPEN GLOBAL INC
 MYLERAN, BUSULFAN

ASPEN GLOBAL INC

* ASPEN GLOBAL INC
 BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
 CYCLESSA, DESOGESTREL
 HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
 LEUKERAN, CHLORAMBUCIL
 THIOGUANINE, THIOGUANINE

ASPIRO

* ASPIRO PHARMA LTD
 SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE

ASSERTIO

* ASSERTIO THERAPEUTICS INC
 CAMBIA, DICLOFENAC POTASSIUM
 ZIPSOR, DICLOFENAC POTASSIUM

ASTELLAS

* ASTELLAS PHARMA US INC
 AMBISOME, AMPHOTERICIN B

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ASTELLAS PHARMA US INC
 ASTAGRAF XL, TACROLIMUS
 CRESEMBA, ISAVUCONAZONIUM SULFATE
 LEXISCAN, REGADENOSON
 MYCAMINE, MICAFUNGIN SODIUM
 PROGRAF, TACROLIMUS
 VESICARE LS, SOLIFENACIN SUCCINATE
 VESICARE, SOLIFENACIN SUCCINATE
 XOSPATA, GILTERITINIB FUMARATE
 XTANDI, ENZALUTAMIDE

ASTRAL

* ASTRAL STERITECH PVT LTD
 AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
 CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
 CEFTRIAXONE SODIUM, CEFTRIAXONE SODIUM
 CEFTRIAXONE, CEFTRIAXONE SODIUM
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM

ASTRAZENECA

* ASTRAZENECA LP
 PULMICORT FLEXHALER, BUDESONIDE
 SYMBICORT, BUDESONIDE
 * ASTRAZENECA PHARMACEUTICALS LP
 FASLODEX, FULVESTRANT
 ZOMIG, ZOLMITRIPTAN
 ZOMIG-ZMT, ZOLMITRIPTAN
 * ASTRAZENECA UK LTD
 CALQUENCE, ACALABRUTINIB
 SEROQUEL XR, QUETIAPINE FUMARATE

ASTRAZENECA AB

* ASTRAZENECA AB
 BREZTRI AEROSPHERE, BUDESONIDE
 BYDUREON BCISE, EXENATIDE
 BYDUREON PEN, EXENATIDE SYNTHETIC
 BYDUREON, EXENATIDE SYNTHETIC
 BYETTA, EXENATIDE SYNTHETIC
 FARXIGA, DAPAGLIFLOZIN
 KOMBIGLYZE XR, METFORMIN HYDROCHLORIDE
 ONGLYZA, SAXAGLIPTIN HYDROCHLORIDE
 QTERN, DAPAGLIFLOZIN
 SYMLIN, PRAMLINTIDE ACETATE
 XIGDUO XR, DAPAGLIFLOZIN

ASTRAZENECA LP

* ASTRAZENECA LP
 NEXIUM 24HR, ESOMEPRAZOLE MAGNESIUM (OTC)

ASTRAZENECA PHARMS

* ASTRAZENECA PHARMACEUTICALS LP
 BEVESPI AEROSPHERE, FORMOTEROL FUMARATE
 BRILINTA, TICAGRELOR
 DALIRESP, ROFLUMILAST
 IRESSA, GEFITINIB
 KOSELUGO, SELUMETINIB SULFATE
 LOKELMA, SODIUM ZIRCONIUM CYCLOSILICATE
 LYNPARZA, OLAPARIB
 NEXIUM IV, ESOMEPRAZOLE SODIUM
 NEXIUM, ESOMEPRAZOLE MAGNESIUM
 PRILOSEC OTC, OMEPRAZOLE MAGNESIUM (OTC)
 PULMICORT RESPULES, BUDESONIDE
 RHINOCORT ALLERGY, BUDESONIDE (OTC)
 SEROQUEL, QUETIAPINE FUMARATE
 TAGRISSO, OSIMERTINIB MESYLATE

ATHEM

* ATHEM HOLDINGS LLC
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 FOLIC ACID, FOLIC ACID

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ATHEM HOLDINGS LLC
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE

ATHENA

* ATHENA BIOSCIENCES LLC
FIBRICOR, FENOFIBRIC ACID
QDOLO, TRAMADOL HYDROCHLORIDE

ATHENEX

* ATHENEX PHARMACEUTICAL DIV
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM

ATHENEX INC

* ATHENEX INC
BUSULFAN, BUSULFAN
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
DOXAPRAM HYDROCHLORIDE, DOXAPRAM HYDROCHLORIDE
ENALAPRILAT, ENALAPRILAT
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
TERBUTALINE SULFATE, TERBUTALINE SULFATE
VALPROATE SODIUM, VALPROATE SODIUM

ATLANTIDE

* ATLANTIDE PHARMACEUTICALS AG
ENTACAPONE, ENTACAPONE
LAMOTRIGINE, LAMOTRIGINE
LISINOPRIL, LISINOPRIL
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

ATLAS PHARMS LLC

* ATLAS PHARMACEUTICALS LLC
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

ATNAHS PHARMA US

* ATNAHS PHARMA US LTD
ANAPROX DS, NAPROXEN SODIUM
EC-NAPROSYN, NAPROXEN
NAPROSYN, NAPROXEN

ATON

* ATON PHARMA INC
LODOSYN, CARBIDOPA

AUCTA

* AUCTA PHARMACEUTICALS INC
VIGADRONE, VIGABATRIN

AUROBINDO

* AUROBINDO PHARMA LTD
AMOXICILLIN, AMOXICILLIN
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLARITHROMYCIN, CLARITHROMYCIN
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
NEVIRAPINE, NEVIRAPINE
ZIDOVUDINE, ZIDOVUDINE

AUROBINDO PHARMA

* AUROBINDO PHARMA
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
* AUROBINDO PHARMA LTD
ALENDRONATE SODIUM, ALENDRONATE SODIUM
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMPICILLIN SODIUM, AMPICILLIN SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* AUROBINDO PHARMA LTD
 ATENOLOL, ATENOLOL
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
 CARISOPRODOL, CARISOPRODOL
 CARVEDILOL, CARVEDILOL
 CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
 CEFDINIR, CEFDINIR
 CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
 CEFPROZIL, CEFPROZIL
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 DIDANOSINE, DIDANOSINE
 FINASTERIDE, FINASTERIDE
 FLUCONAZOLE, FLUCONAZOLE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
 GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LAMOTRIGINE, LAMOTRIGINE
 LEVETIRACETAM, LEVETIRACETAM
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 MELOXICAM, MELOXICAM
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON, ONDANSETRON
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
 PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
 QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 RIBAVIRIN, RIBAVIRIN
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SIMVASTATIN, SIMVASTATIN
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TERBINAFFINE HYDROCHLORIDE, TERBINAFFINE HYDROCHLORIDE
 TOPIRAMATE, TOPIRAMATE
 TORSEMIDE, TORSEMIDE
 TRANDOLAPRIL, TRANDOLAPRIL
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 ZALEPLON, ZALEPLON
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

AUROBINDO PHARMA LTD

* AUROBINDO PHARMA LIMITED
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 LEVOFLOXACIN, LEVOFLOXACIN
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

* AUROBINDO PHARMA LTD
 ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
 ABACAVIR SULFATE, ABACAVIR SULFATE
 ACETAMINOPHEN, ACETAMINOPHEN
 ACETAMINOPHEN, ACETAMINOPHEN (OTC)
 ACETYLCYSTEINE, ACETYLCYSTEINE
 ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
 ADENOSINE, ADENOSINE
 AFIRMELLE, ETHINYL ESTRADIOL
 ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* AUROBINDO PHARMA LTD
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
ALPRAZOLAM, ALPRAZOLAM
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
ARIPIPIRAZOLE, ARIPIPIRAZOLE
ARMODAFINIL, ARMODAFINIL
ATAZANAVIR SULFATE, ATAZANAVIR SULFATE
ATHENTIA NEXT, LEVONORGESTREL (OTC)
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
AUROVELA 1.5/30, ETHINYL ESTRADIOL
AUROVELA 1/20, ETHINYL ESTRADIOL
AUROVELA 24 FE, ETHINYL ESTRADIOL
AUROVELA FE 1.5/30, ETHINYL ESTRADIOL
AUROVELA FE 1/20, ETHINYL ESTRADIOL
AYUNA, ETHINYL ESTRADIOL
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
AZITHROMYCIN, AZITHROMYCIN
BIVALIRUDIN, BIVALIRUDIN
BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CAFFEINE CITRATE, CAFFEINE CITRATE
CARBIDOPA, CARBIDOPA
CEFIXIME, CEFIXIME
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFPROZIL, CEFPROZIL
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CELECOXIB, CELECOXIB
CEPHALEXIN, CEPHALEXIN
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE (OTC)
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CHLORZOXAZONE, CHLORZOXAZONE
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CLOZAPINE, CLOZAPINE
CYANOCOBALAMIN, CYANOCOBALAMIN
CYONANZ, ETHINYL ESTRADIOL
DALFAMPRIDINE, DALFAMPRIDINE
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DOFETILDE, DOFETILIDE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
DUTASTERIDE, DUTASTERIDE
EFAVIRENZ, EFAVIRENZ
EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* AUROBINDO PHARMA LTD
EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
ENTACAPONE, ENTACAPONE
ENTECAVIR, ENTECAVIR
EPTIFIBATIDE, EPTIFIBATIDE
ERTAPENEM SODIUM, ERTAPENEM SODIUM
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
ESZOPICLONE, ESZOPICLONE
ETOMIDATE, ETOMIDATE
EZETIMIBE, EZETIMIBE
FAMCICLOVIR, FAMCICLOVIR
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FELODIPINE, FELODIPINE
FENOFIBRATE, FENOFIBRATE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE
FINASTERIDE, FINASTERIDE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLUCONAZOLE, FLUCONAZOLE
FLUCYTOSINE, FLUCYTOSINE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FONDAPARINUX SODIUM, FONDAPARINUX SODIUM
FUROSEMIDE, FUROSEMIDE
GABAPENTIN, GABAPENTIN
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GEMFIBROZIL, GEMFIBROZIL
GLIMEPIRIDE, GLIMEPIRIDE
GLIPIZIDE, GLIPIZIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN (OTC)
GUAIFENESIN, GUAIFENESIN (OTC)
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
ICLEVIA, ETHINYL ESTRADIOL
INCASSIA, NORETHINDRONE
INDOMETHACIN, INDOMETHACIN
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
ISOSULFAN BLUE, ISOSULFAN BLUE
KALLIGA, DESOGESTREL
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE, LAMIVUDINE
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMIVUDINE, LAMIVUDINE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVOFLOXACIN, LEVOFLOXACIN
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* AUROBINDO PHARMA LTD
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 LINEZOLID, LINEZOLID
 LO SIMPESSE, ETHINYL ESTRADIOL
 LO-ZUMANDIMINE, DROSPIRENONE
 LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
 LORATADINE, LORATADINE (OTC)
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 MEROPENEM, MEROPENEM
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
 METHOCARBAMOL, METHOCARBAMOL
 METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
 METRONIDAZOLE, METRONIDAZOLE
 MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
 MILI, ETHINYL ESTRADIOL
 MILRINONE LACTATE IN DEXTROSE 5%, MILRINONE LACTATE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MIRTAZAPINE, MIRTAZAPINE
 MODAFINIL, MODAFINIL
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 NADOLOL, NADOLOL
 NAFCILLIN SODIUM, NAFCILLIN SODIUM
 NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 NAPROXEN SODIUM, NAPROXEN SODIUM
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
 NAPROXEN, NAPROXEN
 NEVIRAPINE, NEVIRAPINE
 NEXESTA FE, ETHINYL ESTRADIOL
 NIACIN, NIACIN
 NYLIA 1/35, ETHINYL ESTRADIOL
 NYLIA 7/7/7, ETHINYL ESTRADIOL
 OLANZAPINE, OLANZAPINE
 OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE (OTC)
 OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)
 OMEPRAZOLE, OMEPRAZOLE
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 OXACILLIN SODIUM, OXACILLIN SODIUM
 PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PARICALCITOL, PARICALCITOL
 PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
 PHENYTOIN SODIUM, PHENYTOIN SODIUM
 PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
 PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
 PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 PRASUGREL, PRASUGREL HYDROCHLORIDE
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
 PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* AUROBINDO PHARMA LTD

RAMIPRIL, RAMIPRIL
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
 REPAGLINIDE, REPAGLINIDE
 RISEDRONATE SODIUM, RISEDRONATE SODIUM
 RISPERIDONE, RISPERIDONE
 RITONAVIR, RITONAVIR
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
 ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 SEVELAMER CARBONATE, SEVELAMER CARBONATE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SILODOSIN, SILODOSIN
 SIMLIYA, DESOGESTREL
 SIMPESE, ETHINYL ESTRADIOL
 SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
 SPIRONOLACTONE, SPIRONOLACTONE
 SUMATRIPTAN AND NAPROXEN SODIUM, NAPROXEN SODIUM
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TADALAFIL, TADALAFIL
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TELMISARTAN, TELMISARTAN
 TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
 TIGECYCLINE, TIGECYCLINE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 TRANEXAMIC ACID, TRANEXAMIC ACID
 TRI-LO-MILI, ETHINYL ESTRADIOL
 TRI-MILI, ETHINYL ESTRADIOL
 VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 VALSARTAN, VALSARTAN
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VECURONIUM BROMIDE, VECURONIUM BROMIDE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
 VORICONAZOLE, VORICONAZOLE
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID
 ZOLMITRIPTAN, ZOLMITRIPTAN
 ZONISAMIDE, ZONISAMIDE
 ZUMANDIMINE, DROSPIRENONE

* AUROBINDO PHARMA LTD INC

ZIDOVUDINE, ZIDOVUDINE

AUROLIFE PHARMA LLC

* AUROLIFE PHARMA LLC

ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 GLYCOPYRROLATE, GLYCOPYRROLATE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 LORAZEPAM, LORAZEPAM
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
 OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******* AUROLIFE PHARMA LLC**

OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

AUSTARPHARMA*** AUSTARPHARMA LLC**

FENOFIBRATE (MICRONIZED), FENOFIBRATE
 FENOFIBRATE, FENOFIBRATE

AUSTARPHARMA LLC*** AUSTARPHARMA LLC**

METHOCARBAMOL, METHOCARBAMOL
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE

AUXILIUM PHARMS INC*** AUXILIUM PHARMACEUTICALS INC**

TESTOPEL, TESTOSTERONE
 THEO-24, THEOPHYLLINE

AUXILIUM PHARMS LLC*** AUXILIUM PHARMACEUTICALS LLC**

EDEX, ALPROSTADIL
 TESTIM, TESTOSTERONE
 THEO-24, THEOPHYLLINE

AVACOR PRODS*** AVACOR PRODUCTS LLC**

MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)

AVANIR PHARMS*** AVANIR PHARMACEUTICALS INC**

NUEDEXTA, DEXTROMETHORPHAN HYDROBROMIDE

AVANTHI INC*** AVANTHI INC**

CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
 HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE, HOMATROPINE METHYLBROMIDE
 INDOMETHACIN, INDOMETHACIN
 LOMAIRA, PHENTERMINE HYDROCHLORIDE
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE

AVEMA PHARMA*** AVEMA PHARMA SOLUTIONS**

IBUPROFEN, IBUPROFEN (OTC)

AVENT*** AVENT INC**

PYTEST KIT, UREA, C-14
 PYTEST, UREA, C-14

AVERITAS*** AVERITAS PHARMA INC**

QUTENZA, CAPSAICIN

AVET*** AVET PHARMACEUTICALS INC**

ACHROMYCIN V, TETRACYCLINE HYDROCHLORIDE
 DOXERCALCIFEROL, DOXERCALCIFEROL

AVEVA*** AVEVA DRUG DELIVERY SYSTEMS INC**

CLONIDINE, CLONIDINE
 FENTANYL-100, FENTANYL
 FENTANYL-12, FENTANYL
 FENTANYL-25, FENTANYL
 FENTANYL-37, FENTANYL
 FENTANYL-50, FENTANYL
 FENTANYL-62, FENTANYL
 FENTANYL-75, FENTANYL
 FENTANYL-87, FENTANYL
 NICOTINE, NICOTINE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******AVID RADIOPHARMS INC**

- * AVID RADIOPHARMACEUTICALS INC
AMYVID, FLORBETAPIR F-18
TAUVID, FLORTAUCIPIR F-18

AVION PHARMS

- * AVION PHARMACEUTICALS LLC
BALCOLTRA, ETHINYL ESTRADIOL
GLOPERBA, COLCHICINE
PONSTEL, MEFENAMIC ACID

AVONDALE PHARMS

- * AVONDALE PHARMACEUTICALS LLC
NIACOR, NIACIN

AYTU

- * AYTU BIOSCIENCE INC
KARBINAL ER, CARBINOXAMINE MALEATE
TUZISTRA XR, CHLORPHENIRAMINE POLISTIREX
ZOLPIMIST, ZOLPIDEM TARTRATE

AZURITY

- * AZURITY PHARMACEUTICALS INC
EPANED, ENALAPRIL MALEATE
FIRVANQ KIT, VANCOMYCIN HYDROCHLORIDE
KATERZIA, AMLODIPINE BENZOATE
QBRELIS, LISINOPRIL
XATMEP, METHOTREXATE SODIUM

**** B ******B BRAUN**

- * B BRAUN MEDICAL INC
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
AMINO ACIDS, AMINO ACIDS
BALANCED SALT, CALCIUM CHLORIDE
CEFAZOLIN AND DEXTROSE, CEFAZOLIN SODIUM
CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER, CEFEPIME HYDROCHLORIDE
CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER, CEFOTETAN DISODIUM
CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER, CEFOXITIN SODIUM
CEFTAZIDIME IN DEXTROSE CONTAINER, CEFTAZIDIME
CEFTRIAOXONE AND DEXTROSE IN DUPLEX CONTAINER, CEFTRIAOXONE SODIUM
CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER, CEFUROXIME SODIUM
DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%, DOPAMINE HYDROCHLORIDE
FREAMINE HBC 6.9%, AMINO ACIDS
FREAMINE III 10%, AMINO ACIDS
FREAMINE III 3% W/ ELECTROLYTES, AMINO ACIDS
FREAMINE III 8.5% W/ ELECTROLYTES, AMINO ACIDS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

* B BRAUN MEDICAL INC

FREAMINE III 8.5%, AMINO ACIDS
 GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
 HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
 HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPATAMINE 8%, AMINO ACIDS
 ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 ISOLYTE S IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 ISOLYTE S PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
 LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
 LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
 MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL
 MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL
 MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
 MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL
 METRO I.V. IN PLASTIC CONTAINER, METRONIDAZOLE
 NEPHRAMINE 5.4%, AMINO ACIDS
 NUTRILIPID 10%, SOYBEAN OIL
 NUTRILIPID 20%, SOYBEAN OIL
 PHYSIOLYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ******* B BRAUN MEDICAL INC**

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PROCALAMINE, AMINO ACIDS
 RESECTISOL IN PLASTIC CONTAINER, MANNITOL
 RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE
 SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SORBITOL 3.3% IN PLASTIC CONTAINER, SORBITOL
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
 STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
 THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 TROPHAMINE 10%, AMINO ACIDS
 TROPHAMINE, AMINO ACIDS

B BRAUN MEDICAL INC*** B BRAUN MEDICAL INC**

BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
 CLOROTEKAL, CHLOROPROCAINE HYDROCHLORIDE
 HEPARIN SODIUM, HEPARIN SODIUM
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER, MEROPENEM

BAJAJ*** BAJAJ MEDICAL LLC**

CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)

BANNER LIFE SCIENCES*** BANNER LIFE SCIENCES LLC**

BAFIERTAM, MONOMETHYL FUMARATE

BARR*** BARR LABORATORIES INC**

AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
 ARANELLE, ETHINYL ESTRADIOL
 ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
 BALZIVA-28, ETHINYL ESTRADIOL
 CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
 CLONAZEPAM, CLONAZEPAM
 DANAZOL, DANAZOL
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 DIAZEPAM, DIAZEPAM
 DIPYRIDAMOLE, DIPYRIDAMOLE
 DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
 DUTASTERIDE, DUTASTERIDE
 ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
 ESTRADIOL AND NORGESTIMATE, ESTRADIOL
 ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

- * BARR LABORATORIES INC
 FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 HYDROXYUREA, HYDROXYUREA
 HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
 ISONIAZID, ISONIAZID
 JUNEL 1.5/30, ETHINYL ESTRADIOL
 JUNEL 1/20, ETHINYL ESTRADIOL
 JUNEL FE 1.5/30, ETHINYL ESTRADIOL
 JUNEL FE 1/20, ETHINYL ESTRADIOL
 KARIVA, DESOGESTREL
 KELNOR, ETHINYL ESTRADIOL
 LESSINA-28, ETHINYL ESTRADIOL
 MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
 MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
 MEGESTROL ACETATE, MEGESTROL ACETATE
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
 NIACIN, NIACIN
 NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
 NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 NORTREL 0.5/35-28, ETHINYL ESTRADIOL
 NORTREL 1/35-21, ETHINYL ESTRADIOL
 NORTREL 1/35-28, ETHINYL ESTRADIOL
 NORTREL 7/7/7, ETHINYL ESTRADIOL
 PORTIA-28, ETHINYL ESTRADIOL
 SPRINTec, ETHINYL ESTRADIOL
 TREXALL, METHOTREXATE SODIUM
 TRI-LEGEST 21, ETHINYL ESTRADIOL
 TRI-LEGEST FE, ETHINYL ESTRADIOL
 TRI-SPRINTEC, ETHINYL ESTRADIOL
 WARFARIN SODIUM, WARFARIN SODIUM
- * BARR PHARMACEUTICALS
 LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
- BARR LABS DIV TEVA**
- * BARR LABORATORIES INC SUB TEVA PHARMACEUTICALS USA
 BUDESONIDE, BUDESONIDE
- BARR LABS INC**
- * BARR LABORATORIES INC
 ACITRETIN, ACITRETIN
 CLOZAPINE, CLOZAPINE
 ESTRADIOL, ESTRADIOL
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 OLANZAPINE, OLANZAPINE
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
 TRETINOIN, TRETINOIN
 TRI LO SPRINTec, ETHINYL ESTRADIOL
- BAUDAX**
- * BAUDAX BIO INC
 ANJESO, MELOXICAM
- BAUSCH**
- * BAUSCH HEALTH AMERICAS INC
 ACANYA, BENZOYL PEROXIDE
 ARAZLO, TAZAROTENE
 BENZACLIN, BENZOYL PEROXIDE
 BRYHALI, HALOBETASOL PROPIONATE
 DUOBRII, HALOBETASOL PROPIONATE
 EDECRIN, ETHACRYNATE SODIUM
 EDECRIN, ETHACRYNIC ACID
 EFUDEX, FLUOROURACIL
 JUBLIA, EFINACONAZOLE
 LOCID, HYDROCORTISONE BUTYRATE
 MEPHYTON, PHYTONADIONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

- * BAUSCH HEALTH AMERICAS INC
 - ONEXTON, BENZOYL PEROXIDE
 - OXSORALEN-ULTRA, METHOXSALEN
 - SYPRINE, TRIENTINE HYDROCHLORIDE
- * BAUSCH HEALTH IRELAND LTD
 - ERTACZO, SERTACONAZOLE NITRATE
 - FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE, BENOXINATE HYDROCHLORIDE
 - TARGRETIN, BEXAROTENE
 - TETRACAINE HYDROCHLORIDE, TETRACAINE HYDROCHLORIDE
- * BAUSCH HEALTH US LLC
 - ALAWAY, KETOTIFEN FUMARATE (OTC)
 - ALDARA, IMIQUIMOD
 - AMMONUL, SODIUM BENZOATE
 - ANCOBON, FLUCYTOSINE
 - ATIVAN, LORAZEPAM
 - CARDIZEM CD, DILTIAZEM HYDROCHLORIDE
 - CARDIZEM LA, DILTIAZEM HYDROCHLORIDE
 - CARDIZEM, DILTIAZEM HYDROCHLORIDE
 - CESAMET, NABILONE
 - CLINDAGEL, CLINDAMYCIN PHOSPHATE
 - D.H.E. 45, DIHYDROERGOTAMINE MESYLATE
 - DEMSEK, METYROSINE
 - DIASSTAT ACUDIAL, DIAZEPAM
 - DIASSTAT, DIAZEPAM
 - ELIDEL, PIMECROLIMUS
 - GRIS-PEG, GRISEOFULVIN, ULTRAMICROSIZE
 - ISORDIL, ISOSORBIDE DINITRATE
 - ISUPREL, ISOPROTERENOL HYDROCHLORIDE
 - KLARON, SULFACETAMIDE SODIUM
 - LIBRAX, CHLORDIAZEPOXIDE HYDROCHLORIDE
 - LOCOID, HYDROCORTISONE BUTYRATE
 - LOPROX, CICLOPIROX
 - MESTINON, PYRIDOSTIGMINE BROMIDE
 - METHAZOLAMIDE, METHAZOLAMIDE
 - METROGEL-VAGINAL, METRONIDAZOLE
 - MIGRANAL, DIHYDROERGOTAMINE MESYLATE
 - MINOCIN, MINOCYCLINE HYDROCHLORIDE
 - TASMAR, TOLCAPONE
 - TIAZAC, DILTIAZEM HYDROCHLORIDE
 - VASERETIC, ENALAPRIL MALEATE
 - VASOTEC, ENALAPRIL MALEATE
 - VIRAZOLE, RIBAVIRIN
 - XENAZINE, TETRABENAZINE
 - XERESE, ACYCLOVIR
 - ZELAPAR, SELEGILINE HYDROCHLORIDE
 - ZOVIRAX, ACYCLOVIR
 - ZYCLARA, IMIQUIMOD

BAUSCH AND LOMB

- * BAUSCH AND LOMB INC
 - ALAWAY, KETOTIFEN FUMARATE (OTC)
 - ALREX, LOTEPREDNOL ETABONATE
 - BESIVANCE, BESIFLOXACIN HYDROCHLORIDE
 - DICLOFENAC SODIUM, DICLOFENAC SODIUM
 - DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
 - DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
 - FLURBIPROFEN SODIUM, FLURBIPROFEN SODIUM
 - IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
 - ISTALOL, TIMOLOL MALEATE
 - LATANOPROST, LATANOPROST
 - LOTEMAX, LOTEPREDNOL ETABONATE
 - MIOCHOL-E, ACETYLCHOLINE CHLORIDE
 - OFLOXACIN, OFLOXACIN
 - OPCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
 - PROLENSA, BROMFENAC SODIUM
 - RETISERT, FLUOCINOLONE ACETONIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

- * BAUSCH AND LOMB INC
 SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 TIMOLOL MALEATE, TIMOLOL MALEATE
 TROPICAMIDE, TROPICAMIDE
 VYZULTA, LATANOPROSTENE BUNOD
 ZIRGAN, GANCICLOVIR
 ZYLET, LOTEPIREDNOL ETABONATE
- * BAUSCH AND LOMB PHARMACEUTICALS INC
 BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
 BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
 CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
 DEXASPORIN, DEXAMETHASONE
 ERYTHROMYCIN, ERYTHROMYCIN
 FLUNISOLIDE, FLUNISOLIDE
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
 LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE
 NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
 NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
 NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
 NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
 NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
 OFLOXACIN, OFLOXACIN
 OTICAIR, HYDROCORTISONE
 PENTOLAIR, CYCLOPENTOLATE HYDROCHLORIDE
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE
 SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
 TIMOLOL MALEATE, TIMOLOL MALEATE
 TOBRAMYCIN AND DEXAMETHASONE, DEXAMETHASONE
 TOBRAMYCIN, TOBRAMYCIN
 TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 TROPICAMIDE, TROPICAMIDE

BAUSCH AND LOMB INC

- * BAUSCH AND LOMB INC
 BEPREVE, BEPOTASTINE BESILATE
 LOTE MAX SM, LOTEPIREDNOL ETABONATE
 LOTE MAX, LOTEPIREDNOL ETABONATE
 LUMIFY, BRIMONIDINE TARTRATE (OTC)

BAXTER HLTHCARE

- * BAXTER HEALTHCARE CORP
 ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
 AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER, GLYCINE
 ANCEF IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
 BACTOCILL IN PLASTIC CONTAINER, OXACILLIN SODIUM
 BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
 BREVIBLOC IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
 BREVIBLOC, ESMOLOL HYDROCHLORIDE
 CARDIOPLEGIC IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 CEFEPIME IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE
 CEFTRIAZONE IN PLASTIC CONTAINER, CEFTRIAZONE SODIUM
 CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER, AMINO ACIDS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

* BAXTER HEALTHCARE CORP

CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC
 CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC
 CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC
 CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC
 CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC
 CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
 CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
 CYTOXAN, CYCLOPHOSPHAMIDE
 DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K), DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K), DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K), DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC
 DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
 DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
 DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
 EXTRANEAL, ICODEXTRIN
 FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE
 FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
 FORANE, ISOFLURANE
 GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
 HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
 HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

* BAXTER HEALTHCARE CORP
 IFEX, IFOSFAMIDE
 LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
 LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
 LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
 MESNEX, MESNA
 MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
 NALLPEN IN PLASTIC CONTAINER, NAFCILLIN SODIUM
 NEXTERONE, AMIODARONE HYDROCHLORIDE
 NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
 OSMITROL 10% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMITROL 10% IN WATER, MANNITOL
 OSMITROL 15% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMITROL 15% IN WATER, MANNITOL
 OSMITROL 20% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMITROL 20% IN WATER, MANNITOL
 OSMITROL 5% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMITROL 5% IN WATER, MANNITOL
 PENICILLIN G POTASSIUM IN PLASTIC CONTAINER, PENICILLIN G POTASSIUM
 PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 PLASMA-LYTE A IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM
 POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
 POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 PREMASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
 PREMASOL 6% IN PLASTIC CONTAINER, AMINO ACIDS
 RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 SEVOFLURANE, SEVOFLURANE
 SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SORBITOL 3% IN PLASTIC CONTAINER, SORBITOL
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
 STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
 STERILE WATER, STERILE WATER FOR IRRIGATION
 SUPRANE, DESFLURANE
 TIS-U-SOL IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 TIS-U-SOL, MAGNESIUM SULFATE
 TRAVASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
 TRAVASOL 5.5% IN PLASTIC CONTAINER, AMINO ACIDS
 TRAVASOL 8.5% IN PLASTIC CONTAINER, AMINO ACIDS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

- * BAXTER HEALTHCARE CORP
VANCOGIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE
- * BAXTER HEALTHCARE INTERNATIONAL SPECIALTY THERAPIES DIV
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS

BAXTER HLTHCARE CORP

- * BAXTER HEALTHCARE CORP
BIVALIRUDIN IN 0.9% SODIUM CHLORIDE, BIVALIRUDIN
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
CEFAZOLIN IN PLASTIC CONTAINER, CEFZOLIN SODIUM
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIPROFLOXACIN, CIPROFLOXACIN
CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLINOLIPID 20%, OLIVE OIL
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DOXIL (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
EPTIFIBATIDE, EPTIFIBATIDE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
FUROSEMIDE, FUROSEMIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVOFLOXACIN, LEVOFLOXACIN
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
- * BAXTER HEALTHCARE CORP ANESTHESIA AND CRITICAL CARE
PROTOPAM CHLORIDE, PRALIDOXIME CHLORIDE

BAYER

- * BAYER HEALTHCARE LLC
ALEVE, NAPROXEN SODIUM (OTC)
ALEVE-D SINUS & COLD, NAPROXEN SODIUM (OTC)

BAYER HEALTHCARE

- * BAYER HEALTHCARE PHARMACEUTICALS INC
ALIQOPA, COPANLISIB DIHYDROCHLORIDE
LAMPIT, NIFURTIMOX
NUBEQA, DAROLUTAMIDE
VITRAKVI, LAROTRECTINIB SULFATE

BAYER HEALTHCARE LLC

- * BAYER HEALTHCARE LLC
CHILDREN'S CLARITIN, LORATADINE (OTC)
CLARITIN HIVES RELIEF REDITAB, LORATADINE (OTC)
CLARITIN HIVES RELIEF, LORATADINE (OTC)
CLARITIN REDITABS, LORATADINE (OTC)
CLARITIN, LORATADINE (OTC)
CLARITIN-D 24 HOUR, LORATADINE (OTC)
CLARITIN-D, LORATADINE (OTC)
LOTRIMIN ULTRA, BUTENAFINE HYDROCHLORIDE (OTC)
MIRALAX, POLYETHYLENE GLYCOL 3350 (OTC)
ZEGERID OTC, OMEPRAZOLE (OTC)

BAYER HLTHCARE

- * BAYER HEALTHCARE CONSUMER CARE
ALEVE PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
- * BAYER HEALTHCARE PHARMACEUTICALS INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ******* BAYER HEALTHCARE PHARMACEUTICALS INC**

ADEMPAS, RIOCIQUAT
 ANGELIQ, DROSPIRENONE
 BEYAZ, DROSPIRENONE
 BILTRICIDE, PRAZIQUANTEL
 CIPRO, CIPROFLOXACIN
 CIPRO, CIPROFLOXACIN HYDROCHLORIDE
 CLIMARA PRO, ESTRADIOL
 CLIMARA, ESTRADIOL
 EOVIIST, GADOXETATE DISODIUM
 GADAVIST, GADOBUTROL
 KYLEENA, LEVONORGESTREL
 LEVITRA, VARDENAFIL HYDROCHLORIDE
 MENOSTAR, ESTRADIOL
 MIRENA, LEVONORGESTREL
 NATAZIA, DIENOGEST
 NEXAVAR, SORAFENIB TOSYLATE
 SAFYRAL, DROSPIRENONE
 SKYLA, LEVONORGESTREL
 STAXYN, VARDENAFIL HYDROCHLORIDE
 STIVARGA, REGORAFENIB
 ULTRAVIST (PHARMACY BULK), IOPROMIDE
 ULTRAVIST 300, IOPROMIDE
 ULTRAVIST 370, IOPROMIDE
 VITRAKVI, LAROTRECTINIB SULFATE
 XOFIGO, RADIUM RA-223 DICHLORIDE
 YASMIN, DROSPIRENONE
 YAZ, DROSPIRENONE

BAYSHORE PHARMS LLC

*** BAYSHORE PHARMACEUTICALS LLC**
 DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
 ETODOLAC, ETODOLAC
 KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
 METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
 PINDOLOL, PINDOLOL
 PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE

BDSI

*** BIODELIVERY SCIENCES INTERNATIONAL INC**
 BELBUCA, BUPRENORPHINE HYDROCHLORIDE
 SYMPROIC, NALDEMEDINE TOSYLATE

BE PHARMS

*** BE PHARMACEUTICALS AG**
 DAPTOMYCIN, DAPTOMYCIN
 FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
 HEPARIN SODIUM, HEPARIN SODIUM
 NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE

BECTON DICKINSON

*** BECTON DICKINSON AND CO**
 CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)
 E-Z SCRUB 201, POVIDONE-IODINE (OTC)
 E-Z SCRUB 241, POVIDONE-IODINE (OTC)

BECTON DICKINSON CO

*** BECTON DICKINSON AND CO**
 CHLORAPREP ONE-STEP FREPP, CHLORHEXIDINE GLUCONATE (OTC)
 CHLORAPREP ONE-STEP SEPP, CHLORHEXIDINE GLUCONATE (OTC)
 CHLORAPREP ONE-STEP, CHLORHEXIDINE GLUCONATE (OTC)
 CHLORAPREP SINGLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
 CHLORAPREP TRIPLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
 CHLORAPREP WITH TINT, CHLORHEXIDINE GLUCONATE (OTC)

BEIGENE

*** BEIGENE USA INC**
 BRUKINSA, ZANUBRUTINIB

BEIJING YILING

*** BEIJING YILING BIO-ENGINEERING AND TECHNOLOGY CO LTD**
 ANASTROZOLE, ANASTROZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

* BEIJING YILING BIO-ENGINEERING AND TECHNOLOGY CO LTD
LETROZOLE, LETROZOLE

BELCHER

* BELCHER PHARMACEUTICALS LLC
ABLYSINOL, ALCOHOL
CEFIXIME, CEFIXIME
EPINEPHRINE, EPINEPHRINE
MEFENAMIC ACID, MEFENAMIC ACID
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
TACROLIMUS, TACROLIMUS

BELCHER PHARMS

* BELCHER PHARMACEUTICALS INC
AMOXICILLIN, AMOXICILLIN
* BELCHER PHARMACEUTICALS LLC
CEPHALEXIN, CEPHALEXIN
DESLORATADINE, DESLORATADINE

BELOTECA INC

* BELOTECA INC
DIAZEPAM, DIAZEPAM

BENUVIA

* BENUVIA THERAPEUTICS INC
SYNDROS, DRONABINOL

BEXIMCO PHARMS USA

* BEXIMCO PHARMACEUTICALS USA INC
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
LOVASTATIN, LOVASTATIN
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL
NADOLOL, NADOLOL
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

BEXIMCO USA

* BEXIMCO PHARMACEUTICALS USA INC
CARVEDILOL, CARVEDILOL

BIOCODEX SA

* BIOCODEX SA
DIACOMIT, STIRIPENTOL

BIOCON LIMITED

* BIOCON LIMITED
SIMVASTATIN, SIMVASTATIN

BIOCON LTD

* BIOCON LTD
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM

BIOCON PHARMA

* BIOCON PHARMA LTD
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
TACROLIMUS, TACROLIMUS

BIOCRYST

* BIOCRYST PHARMACEUTICALS INC
ORLADEYO, BEROTRALSTAT HYDROCHLORIDE
RAPIVAB, PERAMIVIR

BIOFRONTERA

* BIOFRONTERA BIOSCIENCE GMBH
AMELUZ, AMINOLEVULINIC ACID HYDROCHLORIDE

BIOGEN

* BIOGEN
VUMERITY, DIROXIMEL FUMARATE

BIOGEN IDEC

* BIOGEN IDEC INC
SPINRAZA, NUSINERSEN SODIUM

BIOGEN IDEC INC

* BIOGEN IDEC INC
TECFIDERA, DIMETHYL FUMARATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ******BIOHAVEN PHARM**

* BIOHAVEN PHARMACEUTICAL HOLDING CO LTD
NURTEC ODT, RIMEGEPANT SULFATE

BIOMARIN PHARM

* BIOMARIN PHARMACEUTICAL INC
KUVAN, SAPROPTERIN DIHYDROCHLORIDE

BIOMEDCL RES FDN

* BIOMEDICAL RESEARCH FOUNDATION NORTHWEST LOUISIANA
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

BIONPHARMA INC

* BIONPHARMA INC
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
AZITHROMYCIN, AZITHROMYCIN
BENZONATATE, BENZONATATE
BEXAROTENE, BEXAROTENE
CALCITRIOL, CALCITRIOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CLOBAZAM, CLOBAZAM
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
DEFERASIROX, DEFERASIROX
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DOFETILIDE, DOFETILIDE
DUTASTERIDE, DUTASTERIDE
ETHOSUXIMIDE, ETHOSUXIMIDE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
IBUPROFEN, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
LORATADINE, LORATADINE (OTC)
MIDOL LIQUID GELS, IBUPROFEN (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NIMODIPINE, NIMODIPINE
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PARICALCITOL, PARICALCITOL
POTASSIUM CITRATE, POTASSIUM CITRATE
PROGESTERONE, PROGESTERONE
RUFINAMIDE, RUFINAMIDE
TETRABENAZINE, TETRABENAZINE
VALPROIC ACID, VALPROIC ACID
VITAMIN D, ERGOCALCIFEROL
ZONISAMIDE, ZONISAMIDE

BLAIREX

* BLAIREX LABORATORIES INC
BRONCHO SALINE, SODIUM CHLORIDE (OTC)

BLUE EARTH

* BLUE EARTH DIAGNOSTICS LTD
AXUMIN, FLUCICLOVINE F-18

BLUEPRINT MEDICINES

* BLUEPRINT MEDICINES CORP
AYVAKIT, AVAPRITINIB
GAVRETO, PRALSETINIB

BOEHRINGER INGELHEIM

* BOEHRINGER INGELHEIM
CATAPRES, CLONIDINE HYDROCHLORIDE
CATAPRES-TTS-1, CLONIDINE
CATAPRES-TTS-2, CLONIDINE
CATAPRES-TTS-3, CLONIDINE
GILOTRIF, AFATINIB DIMALEATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

* BOEHRINGER INGELHEIM
 GLYXAMBI, EMPAGLIFLOZIN
 MICARDIS HCT, HYDROCHLOROTHIAZIDE
 MICARDIS, TELMISARTAN
 MIRAPEX, PRAMIPEXOLE DIHYDROCHLORIDE

* BOEHRINGER INGELHEIM PHARMACEUTICALS INC
 AGGRENOX, ASPIRIN
 APTIVUS, TIPRANAVIR
 ATROVENT HFA, IPRATROPIUM BROMIDE
 COMBIVENT RESPIMAT, ALBUTEROL SULFATE
 JARDIANCE, EMPAGLIFLOZIN
 JENTADUETO XR, LINAGLIPTIN
 JENTADUETO, LINAGLIPTIN
 MIRAPEX ER, PRAMIPEXOLE DIHYDROCHLORIDE
 MOBIC, MELOXICAM
 OFEV, NINTEDANIB ESYLATE
 PERSANTINE, DIPYRIDAMOLE
 PRADAXA, DABIGATRAN ETEXILATE MESYLATE
 SPIRIVA RESPIMAT, TIOTROPIUM BROMIDE
 SPIRIVA, TIOTROPIUM BROMIDE
 STIOLTO RESPIMAT, OLODATEROL HYDROCHLORIDE
 STRIVERDI RESPIMAT, OLODATEROL HYDROCHLORIDE
 SYNJARDY XR, EMPAGLIFLOZIN
 SYNJARDY, EMPAGLIFLOZIN
 TRADJENTA, LINAGLIPTIN
 TRIJARDY XR, EMPAGLIFLOZIN
 TWYNSTA, AMLODIPINE BESYLATE
 VIRAMUNE XR, NEVIRAPINE
 VIRAMUNE, NEVIRAPINE

BOSCOGEN

* BOSCOGEN INC
 ARIPIPIRAZOLE, ARIPIPIRAZOLE
 CAPTOPRIL, CAPTOPRIL
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
 REPAGLINIDE, REPAGLINIDE
 SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE

BPI LABS LLC

* BPI LABS LLC
 MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

BRACCO

* BRACCO DIAGNOSTICS INC
 CARADIOGEN-82, RUBIDIUM CHLORIDE RB-82
 CHOLETEC, TECHNETIUM TC-99M MEBROFENIN KIT
 CYSTOGRAFIN DILUTE, DIATRIZOATE MEGLUMINE
 CYSTOGRAFIN, DIATRIZOATE MEGLUMINE
 E-Z-HD, BARIUM SULFATE
 E-Z-PAQUE, BARIUM SULFATE
 ENTERO VU 24%, BARIUM SULFATE
 GASTROGRAFIN, DIATRIZOATE MEGLUMINE
 ISOVUE-200, IOPAMIDOL
 ISOVUE-250, IOPAMIDOL
 ISOVUE-300, IOPAMIDOL
 ISOVUE-370, IOPAMIDOL
 ISOVUE-M 200, IOPAMIDOL
 ISOVUE-M 300, IOPAMIDOL
 KINEVAC, SINCALIDE
 LIQUID E-Z-PAQUE, BARIUM SULFATE
 LUMASON, SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES
 MULTIHANCE MULTIPACK, GADOBENATE DIMEGLUMINE
 MULTIHANCE, GADOBENATE DIMEGLUMINE
 PROHANCE MULTIPACK, GADOTERIDOL
 PROHANCE, GADOTERIDOL
 READI-CAT 2 SMOOTHIE, BARIUM SULFATE
 READI-CAT 2, BARIUM SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

* BRACCO DIAGNOSTICS INC
 TAGITOL V, BARIUM SULFATE
 VARIBAR HONEY, BARIUM SULFATE
 VARIBAR NECTAR, BARIUM SULFATE
 VARIBAR PUDDING, BARIUM SULFATE
 VARIBAR THIN HONEY, BARIUM SULFATE
 VARIBAR THIN LIQUID, BARIUM SULFATE

BRAINTREE

* BRAINTREE LABORATORIES INC
 GOLYTELY, POLYETHYLENE GLYCOL 3350
 NULYTELY, POLYETHYLENE GLYCOL 3350
 NULYTELY-FLAVORED, POLYETHYLENE GLYCOL 3350

BRAINTREE LABS

* BRAINTREE LABORATORIES INC
 SUPREP BOWEL PREP KIT, MAGNESIUM SULFATE
 SUTAB (COPACKAGED), MAGNESIUM SULFATE

BRECKENRIDGE

* BRECKENRIDGE PHARMACEUTICAL INC
 ACETAZOLAMIDE, ACETAZOLAMIDE
 ALPRAZOLAM, ALPRAZOLAM
 ASENAPINE MALEATE, ASENAPINE MALEATE
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 BRETILUM TOSYLATE, BRETILUM TOSYLATE
 BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CLOBAZAM, CLOBAZAM
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 ENTECAVIR, ENTECAVIR
 EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
 EPLERENONE, EPLERENONE
 EXEMESTANE, EXEMESTANE
 IMATINIB MESYLATE, IMATINIB MESYLATE
 LEVETIRACETAM, LEVETIRACETAM
 MEGESTROL ACETATE, MEGESTROL ACETATE
 METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 OMEPRAZOLE, OMEPRAZOLE
 POMALIDOMIDE, POMALIDOMIDE
 RIVASTIGMINE, RIVASTIGMINE
 ROFLUMILAST, ROFLUMILAST
 SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
 SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
 TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

BRECKENRIDGE PHARM

* BRECKENRIDGE PHARMACEUTICAL INC
 CILOSTAZOL, CILOSTAZOL
 ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
 LEVETIRACETAM, LEVETIRACETAM
 METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
 OXCARBAZEPINE, OXCARBAZEPINE
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE

BRIGHAM WOMENS

* BRIGHAM AND WOMENS HOSP
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

BRIGHAM WOMENS HOSP

* BRIGHAM AND WOMENS HOSP INC
 AMMONIA N 13, AMMONIA N-13

BRIGHTGENE

* BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO LTD
 ENTECAVIR, ENTECAVIR

BRISTOL MYERS SQUIBB

* BRISTOL MYERS SQUIBB

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

- * BRISTOL MYERS SQUIBB
AZACTAM, AZTREONAM
BARACLUDE, ENTECAVIR
PRAVACHOL, PRAVASTATIN SODIUM
- * BRISTOL MYERS SQUIBB CO
DROXIA, HYDROXYUREA
HYDREA, HYDROXYUREA
REYATAZ, ATAZANAVIR SULFATE
SPRYCEL, DASATINIB
SUSTIVA, EFAVIRENZ
- * BRISTOL MYERS SQUIBB CO PHARMACEUTICAL RESEARCH INSTITUTE
ELIQUIS, APIXABAN

BRISTOL-MYERS SQUIBB

- * BRISTOL-MYERS SQUIBB CO
EVOTAZ, ATAZANAVIR SULFATE

BTCP PHARMA

- * BTCP PHARMA LLC
LAZANDA, FENTANYL CITRATE
SUBSYS, FENTANYL

BWXT ITG

- * BWXT ITG CANADA INC
INDIUM IN 111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE

**** C ******CADILA**

- * CADILA HEALTHCARE LTD
ACETAZOLAMIDE, ACETAZOLAMIDE
ACYCLOVIR, ACYCLOVIR
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DESONIDE, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DUTASTERIDE, DUTASTERIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FELBAMATE, FELBAMATE
FLUOCINONIDE, FLUOCINONIDE
GEMFIBROZIL, GEMFIBROZIL
INDOMETHACIN, INDOMETHACIN
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
MODAFINIL, MODAFINIL
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN
PIROXICAM, PIROXICAM
RANOLAZINE, RANOLAZINE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VORICONAZOLE, VORICONAZOLE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

CADILA PHARMS LTD

- * CADILA PHARMACEUTICALS LTD
ACYCLOVIR, ACYCLOVIR
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CELECOXIB, CELECOXIB
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
GEMFIBROZIL, GEMFIBROZIL
GLYBURIDE, GLYBURIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ****

- * CADILA PHARMACEUTICALS LTD
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 METRONIDAZOLE, METRONIDAZOLE
 NATEGLINIDE, NATEGLINIDE
 OFLOXACIN, OFLOXACIN
 RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 TELMISARTAN, TELMISARTAN
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
- CADISTA PHARMS**
- * CADISTA PHARMACEUTICALS INC
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
- CALL INC**
- * CALL INC DBA ROCHESTER PHARMACEUTICALS
 ADAPALENE, ADAPALENE
- CAPELLON PHARMS LLC**
- * CAPELLON PHARMACEUTICALS LLC
 POLMON, DEXCHLORPHENIRAMINE MALEATE
- CAPLIN**
- * CAPLIN STERILES LTD
 ETOMIDATE, ETOMIDATE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
- CARDINAL HEALTH 414**
- * CARDINAL HEALTH 414 LLC CARDINAL HEALTH NUCLEAR PHARMACY SERVICES
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 LYMPHOSEEK KIT, TECHNETIUM TC-99M TILMANOCEPT
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18
 TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
- CARDINAL HEALTH 418**
- * CARDINAL HEALTH 418 INC
 SODIUM IODIDE I 123, SODIUM IODIDE I-123
- CARDINAL HLTH 414**
- * CARDINAL HEALTH 414 LLC
 AMMONIA N 13, AMMONIA N-13
- CARIBE HOLDINGS**
- * CARIBE HOLDINGS CAYMAN CO LTD DBA PURACAP CARIBE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 GEMFIBROZIL, GEMFIBROZIL
- CARLSBAD**
- * CARLSBAD TECHNOLOGY INC
 ACYCLOVIR, ACYCLOVIR
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 FAMOTIDINE, FAMOTIDINE
 GLIMEPIRIDE, GLIMEPIRIDE
 LOVASTATIN, LOVASTATIN
- CARLSBAD TECHNOLOGY**
- * CARLSBAD TECHNOLOGY INC
 ACYCLOVIR, ACYCLOVIR
- CASI PHARMS INC**
- * CASI PHARMACEUTICALS INC
 CILOSTAZOL, CILOSTAZOL
 ENTECAVIR, ENTECAVIR
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
- CASPER PHARMA LLC**
- * CASPER PHARMA LLC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ******* CASPER PHARMA LLC**

ANTIVERT, MECLIZINE HYDROCHLORIDE
 AQUASOL A, VITAMIN A PALMITATE
 CASPORYN HC, HYDROCORTISONE
 FURADANTIN, NITROFURANTOIN
 LUMI-SPORYN, BACITRACIN ZINC
 ZYLOPRIM, ALLOPURINOL

CASSIOPEA SPA

* CASSIOPEA SPA
 WINLEVI, CLASCOTERONE

CATALENT

* CATALENT PHARMA SOLUTIONS LLC
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
 VALPROIC ACID, VALPROIC ACID

CATALYST PHARMS

* CATALYST PHARMACEUTICALS INC
 FIRDAPSE, AMIFAMPRIDINE PHOSPHATE

CEDIPROF INC

* CEDIPROF INC
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 LEVO-T, LEVOTHYROXINE SODIUM **

CELATOR PHARMS

* CELATOR PHARMACEUTICALS INC
 VYXEOS, CYTARABINE

CELGENE

* CELGENE CORP
 ISTODAX, ROMIDEPSIN
 POMALYST, POMALIDOMIDE
 REVLIMID, LENALIDOMIDE
 THALOMID, THALIDOMIDE
 VIDAZA, AZACITIDINE

CELGENE CORP

* CELGENE CORP
 IDHIFA, ENASIDENIB MESYLATE
 ONUREG, AZACITIDINE

CELGENE INTL

* CELGENE INTERNATIONAL II SARL
 ZEPOSIA, OZANIMOD HYDROCHLORIDE

CELLTRION

* CELLTRION INC
 CLOBAZAM, CLOBAZAM
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 FAMOTIDINE, FAMOTIDINE
 LEVOFLOXACIN, LEVOFLOXACIN
 LINEZOLID, LINEZOLID
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 PREGABALIN, PREGABALIN
 RISPERIDONE, RISPERIDONE
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
 TEMIXYS, LAMIVUDINE
 ZONISAMIDE, ZONISAMIDE

CENTAUR PHARMS PVT

* CENTAUR PHARMACEUTICALS PVT LTD
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

CEPHALON

* CEPHALON INC
 ACTIQ, FENTANYL CITRATE
 FENTORA, FENTANYL CITRATE
 GABITRIL, TIAGABINE HYDROCHLORIDE
 NUVIGIL, ARMODAFINIL
 PROVIGIL, MODAFINIL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ******* CEPHALON INC**

TREANDA, BENDAMUSTINE HYDROCHLORIDE
 TRISENOX, ARSENIC TRIOXIDE

CEROVENE INC*** CEROVENE INC**

AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
 PYRIMETHAMINE, PYRIMETHAMINE

CHANGZHOU PHARM*** CHANGZHOU PHARMACEUTICAL FACTORY**

DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM

CHARTWELL*** CHARTWELL LIFE MOLECULES LLC**

CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 CLARITHROMYCIN, CLARITHROMYCIN
 FLUCONAZOLE, FLUCONAZOLE
 NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
 OXAPROZIN, OXAPROZIN
 TEMOZOLOMIDE, TEMOZOLOMIDE

CHARTWELL LIFE SCI*** CHARTWELL LIFE SCIENCE LLC**

DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DOXYCYCLINE, DOXYCYCLINE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

CHARTWELL MOLECULAR*** CHARTWELL MOLECULAR HOLDINGS LLC**

CALCIUM ACETATE, CALCIUM ACETATE
 CARVEDILOL, CARVEDILOL
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 FOLIC ACID, FOLIC ACID
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 IRBESARTAN, IRBESARTAN
 RAMIPRIL, RAMIPRIL
 RISPERIDONE, RISPERIDONE

CHARTWELL MOLECULES*** CHARTWELL MOLECULES LLC**

DISULFIRAM, DISULFIRAM
 GEMFIBROZIL, GEMFIBROZIL
 NABUMETONE, NABUMETONE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE

CHARTWELL RX*** CHARTWELL RX SCIENCES LLC**

BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 CALCIUM ACETATE, CALCIUM ACETATE
 CEFPROZIL, CEFPROZIL
 CILOSTAZOL, CILOSTAZOL
 DUVOID, BETHANECHOL CHLORIDE
 GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
 INDOMETHACIN, INDOMETHACIN
 LACTULOSE, LACTULOSE
 LEVETIRACETAM, LEVETIRACETAM
 LISINOPRIL, LISINOPRIL
 METHIMAZOLE, METHIMAZOLE
 MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
 NABUMETONE, NABUMETONE
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 REPAGLINIDE, REPAGLINIDE
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE

CHARTWELL TETRA*** CHARTWELL TETRA LLC**

TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE

CHATTEM*** CHATTEM INC**

UNISOM, DOXYLAMINE SUCCINATE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ******CHEMI SPA**

* CHEMI SPA
DECITABINE, DECITABINE
TEMOZOLOMIDE, TEMOZOLOMIDE

CHEMISCH FBRK KRSSLR

* CHEMISCHE FABRIK KREUSSLER & CO. GMBH
ASCLERA, POLIDOCANOL

CHEMO RESEARCH SL

* CHEMO RESEARCH SL
BENZNIDAZOLE, BENZNIDAZOLE
GEMMILY, ETHINYL ESTRADIOL
NUVESSA, METRONIDAZOLE

CHEPLAPHARM

* CHEPLAPHARM ARZNEIMITTEL GMBH
CYTOVENE, GANCICLOVIR SODIUM
ETOPOPHOS PRESERVATIVE FREE, ETOPOSIDE PHOSPHATE
XENICAL, ORLISTAT

CHIA TAI TIANQING

* CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD
FULVESTRANT, FULVESTRANT

CHIASMA

* CHIASMA INC
MYCAPSSA, OCTREOTIDE ACETATE

CHIESI

* CHIESI USA INC
BETHKIS, TOBRAMYCIN
BRONCHITOL, MANNITOL
CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CLEVIPREX, CLEVIDIPINE
FERRIPROX, DEFERIPRONE
KENGREAL, CANGRELOR
ZYFLO CR, ZILEUTON
ZYFLO, ZILEUTON

CHILDRENS HOSP MI

* CHILDRENS HOSP MICHIGAN
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

CHINA RESOURCES

* CHINA RESOURCES SAIKE PHARMACEUTICAL CO LTD
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE

CHIRHOCLIN

* CHIRHOCLIN INC
CHIRHOSTIM, SECRETIN SYNTHETIC HUMAN

CINTEX SVCS

* CINTEX SERVICES LLC
DESONIDE, DESONIDE
FLURANDRENOLIDE, FLURANDRENOLIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

CIPHER PHARMS INC

* CIPHER PHARMACEUTICALS INC
CONZIP, TRAMADOL HYDROCHLORIDE
LIPOFEN, FENOFIBRATE

CIPLA

* CIPLA LTD
ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
ABACAVIR SULFATE, ABACAVIR SULFATE
ACYCLOVIR, ACYCLOVIR
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALENDRONATE SODIUM, ALENDRONATE SODIUM
AMBRISANTAN, AMBRISANTAN
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ANASTROZOLE, ANASTROZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ******* CIPLA LTD**

ATAZANAVIR SULFATE, ATAZANAVIR SULFATE
 AZACITIDINE, AZACITIDINE
 BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
 BUDESONIDE, BUDESONIDE
 CELECOXIB, CELECOXIB
 CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
 CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
 DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
 DECITABINE, DECITABINE
 DEFERASIROX, DEFERASIROX
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
 DIMETHYL FUMARATE, DIMETHYL FUMARATE
 EFAVIRENZ, EFAVIRENZ
 EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ
 EMTRICITABINE, EMTRICITABINE
 ENTECAVIR, ENTECAVIR
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 EXEMESTANE, EXEMESTANE
 FAMCICLOVIR, FAMCICLOVIR
 FENOFIBRATE, FENOFIBRATE
 FINASTERIDE, FINASTERIDE
 FLUTAMIDE, FLUTAMIDE
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
 ICATIBANT ACETATE, ICATIBANT ACETATE
 ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
 LAMIVUDINE, LAMIVUDINE
 LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
 MELOXICAM, MELOXICAM
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 NEVIRAPINE, NEVIRAPINE
 OXALIPLATIN, OXALIPLATIN
 PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 PREGABALIN, PREGABALIN
 SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
 SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
 TADALAFIL, TADALAFIL
 TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 TESTOSTERONE, TESTOSTERONE
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
 ZIDOVUDINE, ZIDOVUDINE

CIPLA LTD*** CIPLA LTD**

ALBENDAZOLE, ALBENDAZOLE
 CARBOPLATIN, CARBOPLATIN
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
 LEVOFLOXACIN, LEVOFLOXACIN
 TOPIRAMATE, TOPIRAMATE
 ZALEPLON, ZALEPLON
 ZIDOVUDINE, ZIDOVUDINE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

CIPLA USA*** CIPLA USA INC**

ZEMDRI, PLAZOMICIN SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ******CIRCASSIA**

* CIRCASSIA LTD
 DUAKLIR PRESSAIR, ACLIDINIUM BROMIDE
 TUDORZA PRESSAIR, ACLIDINIUM BROMIDE

CISEN

* CISEN PHARMACEUTICAL CO LTD
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM

CLARUS

* CLARUS THERAPEUTICS INC
 JATENZO, TESTOSTERONE UNDECANOATE

CLINIGEN

* CLINIGEN INC
 ETHYOL, AMIFOSTINE
 TOTECT, DEXRAZOXANE HYDROCHLORIDE

CLINIGEN HLTHCARE

* CLINIGEN HEALTHCARE LTD
 FOCAVIR, FOSCARNET SODIUM

CLIVUNEL INC

* CLINUVEL INC
 SCENESSE, AFAMELANOTIDE

CLOVIS ONCOLOGY INC

* CLOVIS ONCOLOGY INC
 RUBRACA, RUCAPARIB CAMSYLATE

CMP DEV LLC

* CMP DEVELOPMENT LLC
 CAROSPIR, SPIRONOLACTONE
 POTASSIUM PHOSPHATES, POTASSIUM PHOSPHATE, DIBASIC

CMP PHARMA INC

* CMP PHARMA INC
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 HYDROCORTISONE IN ABSORBASE, HYDROCORTISONE
 ISONIAZID, ISONIAZID
 SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
 SPS, SODIUM POLYSTYRENE SULFONATE
 TRIAMCINOLONE ACETONIDE IN ABSORBASE, TRIAMCINOLONE ACETONIDE

CNTY LINE PHARMS

* COUNTY LINE PHARMACEUTICALS LLC
 BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 CICLOPIROX, CICLOPIROX
 DYNACIN, MINOCYCLINE HYDROCHLORIDE
 FLUOCINONIDE, FLUOCINONIDE
 LIDEX, FLUOCINONIDE
 LIDEX-E, FLUOCINONIDE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 TAMBOCOR, FLECAINIDE ACETATE
 TRANDATE, LABETALOL HYDROCHLORIDE
 UREX, METHENAMINE HIPPURATE

CODY LABS INC

* CODY LABORATORIES INC A WHOLLY OWNED SUBSIDIARY OF LANNETT CO INC
 NUMBRINO, COCAINE HYDROCHLORIDE

COEPTIS

* COEPTIS PHARMACEUTICALS INC
 CONSENSI, AMLODIPINE BESYLATE

COLGATE PALMOLIVE CO

* COLGATE PALMOLIVE CO
 PERIOGARD, CHLORHEXIDINE GLUCONATE

COLGATE-PALMOLIVE CO

* COLGATE-PALMOLIVE CO
 PERIOGARD, CHLORHEXIDINE GLUCONATE

COLLEGIUM PHARM INC

* COLLEGIUM PHARMACEUTICAL INC
 NUCYN TA ER, TAPENTADOL HYDROCHLORIDE
 NUCYN TA, TAPENTADOL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ****

* COLLEGIUM PHARMACEUTICAL INC
XTAMPZA ER, OXYCODONE

COMBE

* COMBE INC
VAGISTAT-1, TIOCONAZOLE (OTC)

CONCORD BIOTECH LTD

* CONCORD BIOTECH LTD
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
MYCOPHENOLIC ACID, MYCOPHENOLIC ACID
TACROLIMUS, TACROLIMUS

CONCORDIA

* CONCORDIA PHARMACEUTICALS INC
DIBENZYLINE, PHENOXYBENZAMINE HYDROCHLORIDE
DUTOPROL, HYDROCHLOROTHIAZIDE
DYRENIUM, TRIAMTERENE
LANOXIN, DIGOXIN
NILANDRON, NILUTAMIDE
PANRETIN, ALITRETINOIN
PARNATE, TRANYLCPROMINE SULFATE
PLAQUENIL, HYDROXYCHLOROQUINE SULFATE
SALAGEN, PILOCARPINE HYDROCHLORIDE
UROXATRAL, ALFUZOSIN HYDROCHLORIDE

CONCORDIA PHARMS INC

* CONCORDIA PHARMACEUTICALS INC
KAPVAY, CLONIDINE HYDROCHLORIDE
ORAPRED ODT, PREDNISOLONE SODIUM PHOSPHATE

CONTRACT PHARMACAL

* CONTRACT PHARMACAL CORP
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)

COOPERSURGICAL

* COOPERSURGICAL INC
PARAGARD T 380A, COPPER

CORCEPT THERAP

* CORCEPT THERAPEUTICS INC
KORLYM, MIFEPRISTONE

CORDEN PHARMA

* CORDEN PHARMA LATINA SPA
GLEOSTINE, LOMUSTINE

COREPHARMA

* COREPHARMA LLC
EPLERENONE, EPLERENONE
LISINOPRIL, LISINOPRIL
LOVASTATIN, LOVASTATIN
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TORSEMIDE, TORSEMIDE

COSETTE

* COSETTE PHARMACEUTICALS INC
ACEPHEN, ACETAMINOPHEN (OTC)
ACYCLOVIR, ACYCLOVIR
ALBUTEROL SULFATE, ALBUTEROL SULFATE
BETA-VAL, BETAMETHASONE VALERATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCIPOTRIENE, CALCIPOTRIENE
CICLOPIROX, CICLOPIROX
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DESONIDE, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
DOXYCYCLINE, DOXYCYCLINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ****

* COSETTE PHARMACEUTICALS INC
 ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
 FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
 FLUOCINONIDE, FLUOCINONIDE
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
 HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
 HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
 HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
 INDOMETHACIN, INDOMETHACIN
 LIDOCAINE, LIDOCAINE
 METRONIDAZOLE, METRONIDAZOLE
 MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
 MIGERGOT, CAFFEINE
 MOMETASONE FUROATE, MOMETASONE FUROATE
 MYKACET, NYSTATIN
 NYSTATIN, NYSTATIN
 PROCHLORPERAZINE, PROCHLORPERAZINE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 PROMETHEGAN, PROMETHAZINE HYDROCHLORIDE
 TAZAROTENE, TAZAROTENE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

COVIS

* COVIS PHARMA GMBH
 ALTOPREV, LOVASTATIN
 ALVESCO, CICLESONIDE
 BETAPACE AF, SOTALOL HYDROCHLORIDE
 BETAPACE, SOTALOL HYDROCHLORIDE
 LANOXIN PEDIATRIC, DIGOXIN
 LANOXIN, DIGOXIN
 OMNARIS, CICLESONIDE
 PRILOSEC, OMEPRAZOLE MAGNESIUM
 RILUTEK, RILUZOLE
 SULAR, NISOLDIPINE
 ZANAFLEX, TIZANIDINE HYDROCHLORIDE
 ZETONNA, CICLESONIDE

CP PHARMA

* CP PHARMA LLC
 COLOCORT, HYDROCORTISONE

CPDC

* CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

CPPI CV

* CP PHARMACEUTICALS INTERNATIONAL CV
 SUTENT, SUNITINIB MALATE

CROSSMEDIKA SA

* CROSSMEDIKA SA
 MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE
 VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE

CROWN LABS

* CROWN LABORATORIES INC
 ALA-CORT, HYDROCORTISONE
 TRIDERM, TRIAMCINOLONE ACETONIDE

CROWN LABS INC

* CROWN LABORATORIES INC
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 NYSTATIN, NYSTATIN

CSPC OUYI

* CSPC OUYI PHARMACEUTICAL CO LTD
 AZITHROMYCIN, AZITHROMYCIN
 CELECOXIB, CELECOXIB

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ******* CSPC OUYI PHARMACEUTICAL CO LTD**

CONJUPRI, LEVAMLODIPINE MALEATE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 GABAPENTIN, GABAPENTIN
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 PALIPERIDONE, PALIPERIDONE
 PREGABALIN, PREGABALIN

CSPC OUYI PHARM CO*** CSPC OUYI PHARMACEUTICAL CO LTD**

TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

CSPC-NBP PHARM*** CSPC-NBP PHARMACEUTICAL CO LTD**

BENZONATATE, BENZONATATE
 OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS

CUBIST PHARMS*** CUBIST PHARMACEUTICALS INC**

ENTEREG, ALVIMOPAN

CUBIST PHARMS LLC*** CUBIST PHARMACEUTICALS LLC**

CUBICIN RF, DAPTOMYCIN
 CUBICIN, DAPTOMYCIN
 DIFICID, FIDAXOMICIN
 SIVEXTRO, TEDIZOLID PHOSPHATE
 ZERBAXA, CEFTOLOZANE SULFATE

CUMBERLAND PHARMS*** CUMBERLAND PHARMACEUTICALS INC**

ACETADOTE, ACETYLCYSTEINE
 CALDOLOR, IBUPROFEN
 LACTULOSE, LACTULOSE
 OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN, AMOXICILLIN
 REDITREX, METHOTREXATE
 VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER, CONIVAPTAN HYDROCHLORIDE
 VIBATIV, TELAVANCIN HYDROCHLORIDE

CURIUM*** CURIUM US LLC**

GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67
 INDIUM IN 111 CHLORIDE, INDIUM IN-111 CHLORIDE
 OCTREOSCAN, INDIUM IN-111 PENTETREOTIDE KIT
 SODIUM IODIDE I 123, SODIUM IODIDE I-123
 TECHNISCAN MAG3, TECHNETIUM TC-99M MERTIATIDE KIT
 TECHNISCAN PYP KIT, TECHNETIUM TC-99M PYROPHOSPHATE KIT
 TECHNISCAN, TECHNETIUM TC-99M OXIDRONATE KIT
 TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
 THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
 ULTRA-TECHNEKOW FM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
 ULTRATAG, TECHNETIUM TC-99M RED BLOOD CELL KIT
 XENON XE 133, XENON XE-133

CURRAX*** CURRAX PHARMACEUTICALS LLC**

ONZETRA XSAIL, SUMATRIPTAN SUCCINATE
 SILENOR, DOXEPIN HYDROCHLORIDE
 TREXIMET, NAPROXEN SODIUM

CUSTOPHARM INC*** CUSTOPHARM INC**

ACETAMINOPHEN, ACETAMINOPHEN
 DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
 DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
 PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
 SODIUM TETRADECYL SULFATE, SODIUM TETRADECYL SULFATE
 VALRUBICIN, VALRUBICIN

CYCLE PHARMS LTD*** CYCLE PHARMACEUTICALS LTD**

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ****

* CYCLE PHARMACEUTICALS LTD
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 NITYR, NITISINONE

**** D ******DAEWOONG PHARM CO**

* DAEWOONG PHARMACEUTICAL CO LTD
 MEROPENEM, MEROPENEM

DAIICHI SANKYO

* DAIICHI SANKYO INC
 AZOR, AMLODIPINE BESYLATE
 BENICAR HCT, HYDROCHLOROTHIAZIDE
 BENICAR, OLMESARTAN MEDOXOMIL
 TRIBENZOR, AMLODIPINE BESYLATE
 WELCHOL, COLESEVELAM HYDROCHLORIDE

DAIICHI SANKYO INC

* DAIICHI SANKYO INC
 EFFIENT, PRASUGREL HYDROCHLORIDE
 EVOXAC, CEVIMELINE HYDROCHLORIDE
 SAVAYSA, EDOXABAN TOSYLATE
 TURALIO, PEXIDARTINIB HYDROCHLORIDE

DANCO LABS LLC

* DANCO LABORATORIES LLC
 MIFEPREX, MIFEPRISTONE

DAVA PHARMS INC

* DAVA PHARMACEUTICALS INC
 ACYCLOVIR, ACYCLOVIR
 AMOXICILLIN, AMOXICILLIN
 MORPHINE SULFATE, MORPHINE SULFATE
 PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
 PROPYLTHIOURACIL, PROPYLTHIOURACIL
 VOSPIRE ER, ALBUTEROL SULFATE

DAVIS AND GECK

* DAVIS AND GECK DIV AMERICAN CYANAMID CO
 PRE-OP II, HEXACHLOROPHENE
 PRE-OP, HEXACHLOROPHENE

DBL PHARMS

* DBL PHARMACEUTICALS INC
 METHOCARBAMOL, METHOCARBAMOL

DECATUR

* DECATUR MEMORIAL HOSP
 AMMONIA N 13, AMMONIA N-13
 CHOLINE C-11, CHOLINE C-11
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

DECIPHERA PHARMS

* DECIPHERA PHARMACEUTICALS LLC
 QINLOCK, RIPRETINIB

DEN-MAT

* DEN-MAT HOLDINGS LLC
 ATRIDOX, DOXYCYCLINE HYCLATE

DENTSPLY PHARM

* DENTSPLY PHARMACEUTICAL INC
 CITANEST FORTE DENTAL, EPINEPHRINE BITARTRATE
 ORAQIX, LIDOCAINE

DEPROCO

* DEPROCO INC
 LIGNOSPAN FORTE, EPINEPHRINE BITARTRATE
 LIGNOSPAN STANDARD, EPINEPHRINE BITARTRATE
 SCANDONEST L, LEVONORDEFIN
 SCANDONEST PLAIN, MEPIVACAINE HYDROCHLORIDE
 SEPTOCAINE, ARTICAINE HYDROCHLORIDE

DERMIRA INC

* DERMIRA INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** D ****

* DERMIRA INC
QBREXZA, GLYCOPYRRONIUM TOSYLATE

DEVA HOLDING AS

* DEVA HOLDING AS
ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
TEMOZOLOMIDE, TEMOZOLOMIDE

DEXCEL LTD

* DEXCEL LTD
DICLOFENAC SODIUM, DICLOFENAC SODIUM
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE

DEXCEL PHARMA

* DEXCEL PHARMA TECHNOLOGIES LTD
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
HEMADY, DEXAMETHASONE
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
OMEPRAZOLE, OMEPRAZOLE (OTC)
PERIOCHIP, CHLORHEXIDINE GLUCONATE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

DFB ONCOLOGY LTD

* DFB ONCOLOGY LTD
DOCETAXEL, DOCETAXEL

DIAGNOSTIC GREEN

* DIAGNOSTIC GREEN GMBH
INDOCYANINE GREEN, INDOCYANINE GREEN

DIALYSIS SUPS

* DIALYSIS SUPPLIES INC
NORMOCARB HF 25, MAGNESIUM CHLORIDE
NORMOCARB HF 35, MAGNESIUM CHLORIDE

DISCOVERY THERAP

* DISCOVERY THERAPEUTICS LLC
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
METHIMAZOLE, METHIMAZOLE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE

DORC

* DORC INTERNATIONAL BV
MEMBRANEBLUE, TRYPAN BLUE
VISIONBLUE, TRYPAN BLUE

DOUGLAS PHARMS

* DOUGLAS PHARMACEUTICALS AMERICA LTD
MYORISAN, ISOTRETINOIN

DOW PHARM

* DOW PHARMACEUTICAL SCIENCES
ALTRENO, TRETINOIN
ATRALIN, TRETINOIN

DR REDDYS

* DR REDDYS LABORATORIES INC
CHLORTHALIDONE, CHLORTHALIDONE
FENOFIBRATE, FENOFIBRATE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
ICOSAPENT ETHYL, ICOSAPENT ETHYL
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
NITROGLYCERIN, NITROGLYCERIN
PROGESTERONE, PROGESTERONE
PROPOFOL, PROPOFOL
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TESTOSTERONE, TESTOSTERONE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

* DR REDDYS LABORATORIES LTD
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
AZACITIDINE, AZACITIDINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** D ****

* DR REDDYS LABORATORIES LTD
 CARFILZOMIB, CARFILZOMIB
 CARMUSTINE, CARMUSTINE
 CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
 COLCHICINE, COLCHICINE
 COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
 DAPTOMYCIN, DAPTOMYCIN
 DECITABINE, DECITABINE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 ENALAPRILAT, ENALAPRILAT
 FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
 FULVESTRANT, FULVESTRANT
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 ICATIBANT ACETATE, ICATIBANT ACETATE
 IMATINIB MESYLATE, IMATINIB MESYLATE
 LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
 LIDOCAINE, LIDOCAINE
 NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 OMEPRAZOLE, OMEPRAZOLE (OTC)
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
 PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
 PARICALCITOL, PARICALCITOL
 PENICILLAMINE, PENICILLAMINE
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 PREGABALIN, PREGABALIN
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
 TETRABENAZINE, TETRABENAZINE
 THIOTEPA, THIOTEPA
 VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
 VINOURELBINE TARTRATE, VINOURELBINE TARTRATE

DR REDDYS LA

* DR REDDYS LABORATORIES LOUISIANA LLC
 IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)
 LOPURIN, ALLOPURINOL
 SSD, SILVER SULFADIAZINE

DR REDDYS LABS INC

* DR REDDYS LABORATORIES INC
 AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 FINASTERIDE, FINASTERIDE
 FLUCONAZOLE, FLUCONAZOLE
 IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)
 LEVOFLOXACIN, LEVOFLOXACIN
 MELOXICAM, MELOXICAM
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
 SIMVASTATIN, SIMVASTATIN
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

DR REDDYS LABS LTD

* DR REDDYS LABORATORIES LIMITED
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 * DR REDDYS LABORATORIES LTD
 ABIRATERONE ACETATE, ABIRATERONE ACETATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** D ****

* DR REDDYS LABORATORIES LTD
 ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 BIVALIRUDIN, BIVALIRUDIN
 BORTEZOMIB, BORTEZOMIB
 CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
 CAPECITABINE, CAPECITABINE
 CARBOPROST TROMETHAMINE, CARBOPROST TROMETHAMINE
 CARVEDILOL, CARVEDILOL
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 CIPROFLOXACIN AND DEXAMETHASONE, CIPROFLOXACIN
 CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 CLOFARABINE, CLOFARABINE
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR, DESLORATADINE
 DESLORATADINE, DESLORATADINE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 DOCETAXEL, DOCETAXEL
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
 ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
 EPHEDRINE SULFATE, EPHEDRINE SULFATE
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
 ESZOPICLONE, ESZOPICLONE
 FAMOTIDINE, FAMOTIDINE
 FAMOTIDINE, FAMOTIDINE (OTC)
 FEBUXOSTAT, FEBUXOSTAT
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE
 FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
 FINASTERIDE, FINASTERIDE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FONDAPARINUX SODIUM, FONDAPARINUX SODIUM
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 GLIMEPIRIDE, GLIMEPIRIDE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN (OTC)
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
 IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LAMOTRIGINE, LAMOTRIGINE
 LANSOPRAZOLE, LANSOPRAZOLE
 LANSOPRAZOLE, LANSOPRAZOLE (OTC)
 LATANOPROST, LATANOPROST
 LETROZOLE, LETROZOLE
 LEVETIRACETAM, LEVETIRACETAM
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)
 MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 NAPROXEN AND ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 NAPROXEN SODIUM, NAPROXEN SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** D ****

* DR REDDYS LABORATORIES LTD
 NATEGLINIDE, NATEGLINIDE
 NIZATIDINE, NIZATIDINE
 OFLOXACIN, OFLOXACIN
 OLANZAPINE, OLANZAPINE
 OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
 OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)
 OMEPRAZOLE, OMEPRAZOLE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 OXAPROZIN, OXAPROZIN
 PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PARICALCITOL, PARICALCITOL
 PHYTONADIONE, PHYTONADIONE
 PRASUGREL, PRASUGREL HYDROCHLORIDE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RAMIPRIL, RAMIPRIL
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
 RISPERIDONE, RISPERIDONE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 SEVELAMER CARBONATE, SEVELAMER CARBONATE
 SIROLIMUS, SIROLIMUS
 SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
 TACROLIMUS, TACROLIMUS
 TADALAFIL, TADALAFIL
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE
 VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 VIGABATRIN, VIGABATRIN
 ZAFIRLUKAST, ZAFIRLUKAST
 ZENATANE, ISOTRETINOIN
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

DR REDDYS LABS SA

* DR REDDYS LABORATORIES SA
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 EZETIMIBE AND SIMVASTATIN, EZETIMIBE
 FENOFIBRATE (MICRONIZED), FENOFIBRATE
 HABITROL, NICOTINE (OTC)
 MERCAPTOPYRINE, MERCAPTOPYRINE
 NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
 RAMELTEON, RAMELTEON
 TOBRAMYCIN, TOBRAMYCIN

DUCHESNAY

* DUCHESNAY INC
 BONJESTA, DOXYLAMINE SUCCINATE
 DICLEGIS, DOXYLAMINE SUCCINATE
 OSPHENA, OSPHEMIFENE

DURAMED PHARMS BARR

* DURAMED PHARMACEUTICALS INC SUB BARR LABORATORIES INC
 AVIANE-28, ETHINYL ESTRADIOL
 CRYSELLE, ETHINYL ESTRADIOL
 DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
 ENPRESSE-28, ETHINYL ESTRADIOL
 VELIVET, DESOGESTREL

DUSA

* DUSA PHARMACEUTICALS INC
 LEVULAN, AMINOLEVULINIC ACID HYDROCHLORIDE

DUTCH OPHTHALMIC

* DUTCH OPHTHALMIC RESEARCH CENTER INTERNATIONAL BV
 TISSUEBLUE, BRILLIANT BLUE G

REDDYS

* DOCTOR REDDYS LABORATORIES LTD
 DESLORATADINE, DESLORATADINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** D ****

* DOCTOR REDDYS LABORATORIES LTD
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE

**** E ******E5 PHARMA INC**

* E5 PHARMA INC
 DIAZOXIDE, DIAZOXIDE

EAGLE PHARMS

* EAGLE PHARMACEUTICALS INC
 ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
 BELRAPZO, BENDAMUSTINE HYDROCHLORIDE
 BENDEKA, BENDAMUSTINE HYDROCHLORIDE
 PEMFEXY, PEMETREXED
 RYANODEX, DANTROLENE SODIUM

ECI PHARMS LLC

* ECI PHARMACEUTICALS LLC
 CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
 DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE

ECOLAB

* ECOLAB INC
 CHG SCRUB, CHLORHEXIDINE GLUCONATE (OTC)
 CIDA-STAT, CHLORHEXIDINE GLUCONATE (OTC)

ECR

* ECR PHARMACEUTICALS
 DEXAMETHASONE, DEXAMETHASONE

ECR PHARMA

* ECR PHARMA
 TUSSICAPS, CHLORPHENIRAMINE POLISTIREX

EDENBRIDGE PHARMS

* EDENBRIDGE PHARMACEUTICALS LLC
 ALBENDAZOLE, ALBENDAZOLE
 BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
 CARBIDOPA, CARBIDOPA
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 ETHACRYNIC ACID, ETHACRYNIC ACID
 ETODOLAC, ETODOLAC
 IVERMECTIN, IVERMECTIN
 MIGLUSTAT, MIGLUSTAT
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 TINIDAZOLE, TINIDAZOLE

EDISON THERAPS LLC

* EDISON THERAPEUTICS LLC
 METHERGINE, METHYLERGONOVINE MALEATE

EGALET

* EGALET US INC
 INDOCIN, INDOMETHACIN

EI INC

* EI INC
 THEROXIDIL, MINOXIDIL (OTC)

EIGER BIOPHARMS

* EIGER BIOPHARMACEUTICALS INC
 ZOKINVY, LONAFARNIB

EIRGEN

* EIRGEN PHARMA LTD
 RAYALDEE, CALCIFEDIOL

EISAI INC

* EISAI INC
 ACIPHEX, RABEPRAZOLE SODIUM
 ARICEPT, DONEPEZIL HYDROCHLORIDE
 BANZEL, RUFINAMIDE
 DAYVIGO, LEMBOREXANT
 FYCOMPA, PERAMPANEL
 HALAVEN, ERIBULIN MESYLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** E ****

* EISAI INC

LENVIMA, LENVATINIB MESYLATE

ELI LILLY AND CO

* ELI LILLY AND CO

BAQSIMI, GLUCAGON

OLUMIANT, BARICITINIB

PROZAC, FLUOXETINE HYDROCHLORIDE

REYVOW, LASMIDITAN SUCCINATE

VERZENIO, ABEMACICLIB

ELI LILLY CO

* ELI LILLY CO

ADCIRCA, TADALAFIL

ZYPREXA RELPREVV, OLANZAPINE PAMOATE

ELITE

* ELITE PHARMACEUTICAL TECHNOLOGY SHANGHAI CO LTD

NIFEDIPINE, NIFEDIPINE

ELITE LABS

* ELITE LABORATORIES INC

NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE

PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

ELITE LABS INC

* ELITE LABORATORIES INC

ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN

DANTROLENE SODIUM, DANTROLENE SODIUM

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE

ISRADIPINE, ISRADIPINE

LOXAPINE SUCCINATE, LOXAPINE SUCCINATE

PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE

PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE

ELYSIUM

* ELYSIUM PHARMACEUTICALS LTD

CALCITRIOL, CALCITRIOL

CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE

PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE

TIMOLOL MALEATE, TIMOLOL MALEATE

EMCURE PHARMS LTD

* EMCURE PHARMACEUTICALS LTD

AMIKACIN SULFATE, AMIKACIN SULFATE

BICNU, CARMUSTINE

CIDOFOVIR, CIDOFOVIR

DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE

ETOMIDATE, ETOMIDATE

FUROSEMIDE, FUROSEMIDE

IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE

METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE

OXYBUTYNYN CHLORIDE, OXYBUTYNYN CHLORIDE

PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE

TRANEXAMIC ACID, TRANEXAMIC ACID

ZOLEDRONIC ACID, ZOLEDRONIC ACID

EMD SERONO INC

* EMD SERONO INC

CETROTIDE, CETRORELIX

MAVENCLAD, CLADRIBINE

EMERALD INTL LTD

* EMERALD INTERNATIONAL LTD

BACLOFEN, BACLOFEN

EMERGENT

* EMERGENT OPERATIONS IRELAND LTD

NARCAN, NALOXONE HYDROCHLORIDE

EMMAUS MEDCL

* EMMAUS MEDICAL INC

ENDARI, L-GLUTAMINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** E ******EMP**

* EMP LEVO US BV
 THYQUIDITY, LEVOTHYROXINE SODIUM

ENCORE DERMAT

* ENCORE DERMATOLOGY INC
 IMPOYZ, CLOBETASOL PROPIONATE
 SERNIVO, BETAMETHASONE DIPROPIONATE

ENCUBE

* ENCUBE ETHICALS PRIVATE LTD
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM (OTC)
 TAVABOROLE, TAVABOROLE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

ENCUBE ETHICALS

* ENCUBE ETHICALS PVT LTD
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 DESONIDE, DESONIDE
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
 FLUOCINONIDE, FLUOCINONIDE
 PERMETHRIN, PERMETHRIN

ENDO PHARM

* ENDO PHARMACEUTICAL SOLUTIONS INC
 SUPPRELIN LA, HISTRELIN ACETATE
 VALSTAR PRESERVATIVE FREE, VALRUBICIN
 VANTAS, HISTRELIN ACETATE

ENDO PHARMS

* ENDO PHARMACEUTICALS INC
 FORTESTA, TESTOSTERONE
 FROVA, FROVATRIPTAN SUCCINATE
 PERCODAN, ASPIRIN

ENDO PHARMS INC

* ENDO PHARMACEUTICALS INC
 AVEED, TESTOSTERONE UNDECANOATE
 COLY-MYCIN S, COLISTIN SULFATE
 MEGACE ES, MEGESTROL ACETATE
 NASCOBAL, CYANOCOBALAMIN
 VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE

ENDO VENTURES

* ENDO VENTURES LTD
 EPHEDRINE SULFATE, EPHEDRINE SULFATE

EPI HLTH

* EPI HEALTH LLC
 CLODERM, CLOCORTOLONE PIVALATE
 MINOLIRA, MINOCYCLINE HYDROCHLORIDE
 RHOFAD, OXYMETAZOLINE HYDROCHLORIDE
 SITAVIG, ACYCLOVIR

EPIC PHARMA

* EPIC PHARMA INC
 MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE

* EPIC PHARMA LLC
 BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
 SULINDAC, SULINDAC
 TRANDOLAPRIL, TRANDOLAPRIL
 URSODIOL, URSODIOL

EPIC PHARMA INC

* EPIC PHARMA INC
 ESTRADIOL, ESTRADIOL
 SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

EPIC PHARMA LLC

* EPIC PHARMA LLC
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** E ****

* EPIC PHARMA LLC
 AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
 AZITHROMYCIN, AZITHROMYCIN
 BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
 BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 DEMECLOXYCLINE HYDROCHLORIDE, DEMECLOXYCLINE HYDROCHLORIDE
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 GABAPENTIN, GABAPENTIN
 GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
 GLYBURIDE, GLYBURIDE
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
 MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 MOLINDONE HYDROCHLORIDE, MOLINDONE HYDROCHLORIDE
 NYSTATIN, NYSTATIN
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE AND ASPIRIN, ASPIRIN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
 PHENYTOIN, PHENYTOIN
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
 SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE

EPIZYME INC

* EPIZYME INC
 TAZVERIK, TAZEMETOSTAT HYDROBROMIDE

ESPERION THERAPS INC

* ESPERION THERAPEUTICS INC
 NEXLETOL, BEMPEDOIC ACID
 NEXLIZET, BEMPEDOIC ACID

ESPERO

* ESPERO BIOPHARMA INC
 DURLAZA, ASPIRIN

ESSENTIAL ISOTOPES

* ESSENTIAL ISOTOPES LLC
 AMMONIA N 13, AMMONIA N-13
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

ETHYPHARM

* ETHYPHARM
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE

ETHYPHARM USA CORP

* ETHYPHARM USA CORP
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE

ETON

* ETON PHARMACEUTICALS INC
 ALKINDI SPRINKLE, HYDROCORTISONE

ETON PHARMS

* ETON PHARMACEUTICALS
 BIORPHEN, PHENYLEPHRINE HYDROCHLORIDE

EUGIA PHARMA

* EUGIA PHARMA SPECIALITIES LTD
 ANASTROZOLE, ANASTROZOLE
 CAPECITABINE, CAPECITABINE
 CARBOPLATIN, CARBOPLATIN
 HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** E ******* EUGIA PHARMA SPECIALITIES LTD**

IMATINIB MESYLATE, IMATINIB MESYLATE
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 LETROZOLE, LETROZOLE
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 OXALIPLATIN, OXALIPLATIN
 POMALIDOMIDE, POMALIDOMIDE
 PROGESTERONE, PROGESTERONE
 TAMOXIFEN CITRATE, TAMOXIFEN CITRATE

EUROHLTH INTL SARL*** EUROHEALTH INTERNATIONAL SARL**

AZACITIDINE, AZACITIDINE
 DROPERIDOL, DROPERIDOL
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE

EVOFEM INC*** EVOFEM INC**

PHEXXI, CITRIC ACID

EVOKE PHARMA INC*** EVOKE PHARMA INC**

GIMOTI, METOCLOPRAMIDE HYDROCHLORIDE

EVUS*** EVUS HEALTH SOLUTIONS LLC**

NITROMIST, NITROGLYCERIN

EXALENZ BIOSCIENCE*** EXALENZ BIOSCIENCE LTD**

IDKIT:HP, CITRIC ACID

EXELA PHARMA*** EXELA PHARMA SCIENCES LLC**

ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
 AKOVAZ, EPHEDRINE SULFATE
 BLOXIVERZ, NEOSTIGMINE METHYLSULFATE
 CAFFEINE CITRATE, CAFFEINE CITRATE
 ELCYS, CYSTEINE HYDROCHLORIDE
 ERYTHROMYCIN LACTOBIONATE, ERYTHROMYCIN LACTOBIONATE
 GANZYK-RTU, GANCICLOVIR
 GLYRX-PF, GLYCOPYRROLATE
 MAGNESIUM SULFATE, MAGNESIUM SULFATE
 NIPRIDE RTU IN SODIUM CHLORIDE 0.9%, SODIUM NITROPRUSSIDE
 POTASSIUM ACETATE, POTASSIUM ACETATE
 SODIUM BICARBONATE, SODIUM BICARBONATE
 TRANEXAMIC ACID, TRANEXAMIC ACID
 VAZCULEP, PHENYLEPHRINE HYDROCHLORIDE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

EXELA PHARMA SCIENCE*** EXELA PHARMA SCIENCES**

CAFFEINE CITRATE, CAFFEINE CITRATE
 NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE, NICARDIPINE HYDROCHLORIDE
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE

EXELIXIS*** EXELIXIS INC**

COMETRIQ, CABOZANTINIB S-MALATE

EXELIXIS INC*** EXELIXIS INC**

CABOMETYX, CABOZANTINIB S-MALATE

EXELTIS USA INC*** EXELTIS USA INC**

SLYND, DROSPIRENONE
 TYBLUME, ETHINYL ESTRADIOL

EYEPOINT PHARMS*** EYEPOINT PHARMACEUTICALS INC**

DEXYCU KIT, DEXAMETHASONE
 YUTIQ, FLUOCINOLONE ACETONIDE

EYEVANCE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** E ****

* EYEVANCE PHARMACEUTICALS LLC
 FLAREX, FLUOROMETHOLONE ACETATE
 NATACYN, NATAMYCIN
 TOBRADEX ST, DEXAMETHASONE
 ZERVIATE, CETIRIZINE HYDROCHLORIDE

EYWA

* EYWA PHARMA INC
 ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 OXYBUTYNYN CHLORIDE, OXYBUTYNYN CHLORIDE
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
 VALPROIC ACID, VALPROIC ACID

EYWA PHARMA

* EYWA PHARMA PTE LTD
 ACETAZOLAMIDE, ACETAZOLAMIDE
 BACLOFEN, BACLOFEN
 URSODIOL, URSODIOL

LILLY

* ELI LILLY AND CO
 ALIMTA, PEMETREXED DISODIUM
 CIALIS, TADALAFIL
 CYMBALTA, DULOXETINE HYDROCHLORIDE
 EVISTA, RALOXIFENE HYDROCHLORIDE
 FORTEO, TERIPARATIDE
 GEMZAR, GEMCITABINE HYDROCHLORIDE
 GLUCAGON, GLUCAGON
 STRATTERA, ATOMOXETINE HYDROCHLORIDE
 SYMBYAX, FLUOXETINE HYDROCHLORIDE
 ZYPREXA ZYDIS, OLANZAPINE
 ZYPREXA, OLANZAPINE

**** F ******FDC LTD**

* FDC LTD
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
 LATANOPROST, LATANOPROST
 OFLOXACIN, OFLOXACIN
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
 TIMOLOL MALEATE, TIMOLOL MALEATE

FDN CONSUMER

* FOUNDATION CONSUMER BRANDS LLC
 ALAVERT, LORATADINE (OTC)
 * FOUNDATION CONSUMER HEALTHCARE LLC
 PLAN B ONE-STEP, LEVONORGESTREL (OTC)

FEINSTEIN

* FEINSTEIN INSTITUTE MEDICAL RESEARCH
 AMMONIA N 13, AMMONIA N-13
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

FERA PHARMS

* FERA PHARMACEUTICALS LLC
 TOBRAMYCIN, TOBRAMYCIN

FERA PHARMS LLC

* FERA PHARMACEUTICALS LLC
 DEXAMETHASONE, DEXAMETHASONE
 GENTAMICIN SULFATE, GENTAMICIN SULFATE

FERRER INTERNACIONAL

* FERRER INTERNACIONAL SA
 XEPI, OZENOXACIN

FERRING

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** F ****

* FERRING PHARMACEUTICALS INC
 ENDOMETRIN, PROGESTERONE
 FIRMAGON, DEGARELIX ACETATE

FERRING PHARMS INC

* FERRING PHARMACEUTICALS INC
 CERVIDIL, DINOPROSTONE
 CLENPIQ, CITRIC ACID
 DDAVP, DESMOPRESSIN ACETATE
 NOCDURNA, DESMOPRESSIN ACETATE

FLAMINGO PHARMS

* FLAMINGO PHARMACEUTICALS LTD
 METRONIDAZOLE, METRONIDAZOLE
 PIROXICAM, PIROXICAM

FLEXION THERAPS INC

* FLEXION THERAPEUTICS INC
 ZILRETTA, TRIAMCINOLONE ACETONIDE

FLORIDA

* FLORIDA PHARMACEUTICAL PRODUCTS LLC
 LEVETIRACETAM, LEVETIRACETAM

FOAMIX

* FOAMIX PHARMACEUTICALS INC
 AMZEEQ, MINOCYCLINE HYDROCHLORIDE
 ZILXI, MINOCYCLINE HYDROCHLORIDE

FOLDRX PHARMS

* FOLDRX PHARMACEUTICALS INC SUB PFIZER INC
 VYNDAMAX, TAFAMIDIS
 VYNDAQEL, TAFAMIDIS MEGLUMINE

FOREST LABS LLC

* FOREST LABORATORIES LLC
 NAMENDA XR, MEMANTINE HYDROCHLORIDE

FOSUN PHARMA

* FOSUN PHARMA USA INC
 CARISOPRODOL, CARISOPRODOL
 DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
 LEFLUNOMIDE, LEFLUNOMIDE

FOUGERA PHARMS

* FOUGERA PHARMACEUTICALS INC
 ADAPALENE, ADAPALENE
 ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
 AMCINONIDE, AMCINONIDE
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 CALCIPOTRIENE, CALCIPOTRIENE
 CICLOPIROX, CICLOPIROX
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 CLOTRIMAZOLE, CLOTRIMAZOLE
 CUTIVATE, FLUTICASONE PROPIONATE
 DESONIDE, DESONIDE
 DESOXIMETASONE, DESOXIMETASONE
 DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
 ERYTHROMYCIN, ERYTHROMYCIN
 FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
 FLUOCINONIDE, FLUOCINONIDE
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
 HYDROCORTISONE, HYDROCORTISONE
 IMIQUIMOD, IMIQUIMOD
 KETOCONAZOLE, KETOCONAZOLE
 LIDOCAINE AND PRILOCAINE, LIDOCAINE
 METRONIDAZOLE, METRONIDAZOLE
 MOMETASONE FUROATE, MOMETASONE FUROATE
 MUPIROCIN, MUPIROCIN
 NYSTATIN, NYSTATIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** F ****

* FOUGERA PHARMACEUTICALS INC
 OXISTAT, OXICONAZOLE NITRATE
 PANDEL, HYDROCORTISONE PROBUTATE
 PREDNICARBATE, PREDNICARBATE
 SOLARAZE, DICLOFENAC SODIUM
 SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
 TERCONAZOLE, TERCONAZOLE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 TYZINE, TETRAHYDROZOLINE HYDROCHLORIDE

FOUGERA PHARMS INC

* FOUGERA PHARMACEUTICALS INC
 ACYCLOVIR, ACYCLOVIR
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
 FLUOCINONIDE, FLUOCINONIDE
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 HYDROCORTISONE, HYDROCORTISONE
 LIDOCAINE, LIDOCAINE
 NITROGLYCERIN, NITROGLYCERIN
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 NYSTATIN, NYSTATIN
 TACROLIMUS, TACROLIMUS
 TERCONAZOLE, TERCONAZOLE
 VEREGEN, SINECATECHINS

FRESENIUS

* FRESENIUS KABI DEUTSCHLAND GMBH
 INTRALIPID 10%, SOYBEAN OIL
 INTRALIPID 20%, SOYBEAN OIL
 INTRALIPID 30%, SOYBEAN OIL
 * FRESENIUS KABI IPSUM SRL
 NAFCILLIN SODIUM, NAFCILLIN SODIUM

FRESENIUS KABI

* FRESENIUS KABI ANTI INFECTIVES SRL
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
 * FRESENIUS KABI AUSTRIA GMBH
 LACTULOSE, LACTULOSE

FRESENIUS KABI USA

* FRESENIUS KABI USA LLC
 ACETAMINOPHEN, ACETAMINOPHEN
 ACETYLCYSTEINE, ACETYLCYSTEINE
 ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
 ADENOSINE, ADENOSINE
 AMIKACIN SULFATE, AMIKACIN SULFATE
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 ANASTROZOLE, ANASTROZOLE
 ARGATROBAN, ARGATROBAN
 ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
 ATROPINE SULFATE, ATROPINE SULFATE
 AZITHROMYCIN, AZITHROMYCIN
 AZTREONAM, AZTREONAM
 BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
 BIVALIRUDIN, BIVALIRUDIN
 BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
 BORTEZOMIB, BORTEZOMIB
 CAFFEINE CITRATE, CAFFEINE CITRATE
 CALCIUM GLUCONATE, CALCIUM GLUCONATE
 CARBOPLATIN, CARBOPLATIN
 CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
 CEFOTETAN, CEFOTETAN DISODIUM
 CHLORAMPHENICOL SODIUM SUCCINATE, CHLORAMPHENICOL SODIUM SUCCINATE
 CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** F ****

* FRESENIUS KABI USA LLC
 CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
 CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
 CISPLATIN, CISPLATIN
 CLADRIBINE, CLADRIBINE
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
 CYTARABINE, CYTARABINE
 DACARBAZINE, DACARBAZINE
 DAPTOMYCIN, DAPTOMYCIN
 DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
 DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
 DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE, DEXAMETHASONE SODIUM PHOSPHATE
 DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075%, DEXTROSE
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15%, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.225%, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.45%, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.9%, DEXTROSE
 DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
 DILAUDID, HYDROMORPHONE HYDROCHLORIDE
 DIMENHYDRINATE, DIMENHYDRINATE
 DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
 DIPRIVAN, PROPOFOL
 DIPYRIDAMOLE, DIPYRIDAMOLE
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 DOXY 100, DOXYCYCLINE HYCLATE
 DOXY 200, DOXYCYCLINE HYCLATE
 EPHEDRINE SULFATE, EPHEDRINE SULFATE
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
 ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
 ETOPOSIDE, ETOPOSIDE
 FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
 FAMOTIDINE, FAMOTIDINE
 FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
 FENTANYL CITRATE, FENTANYL CITRATE
 FLOXURIDINE, FLOXURIDINE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
 FLUMAZENIL, FLUMAZENIL
 FLUOROURACIL, FLUOROURACIL
 FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
 FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
 FOLIC ACID, FOLIC ACID
 FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 FULVESTRANT, FULVESTRANT
 FUROSEMIDE, FUROSEMIDE
 GANCICLOVIR SODIUM, GANCICLOVIR SODIUM
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 GLUCAGON, GLUCAGON HYDROCHLORIDE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
 HALOPERIDOL, HALOPERIDOL LACTATE
 HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
 HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
 HEPARIN SODIUM IN PLASTIC CONTAINER, HEPARIN SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** F ****

* FRESENIUS KABI USA LLC
 HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
 HEPARIN SODIUM, HEPARIN SODIUM
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 ICATIBANT ACETATE, ICATIBANT ACETATE
 IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
 IFOSFAMIDE, IFOSFAMIDE
 INDOMETHACIN, INDOMETHACIN
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 KABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
 LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
 LEVETIRACETAM, LEVETIRACETAM
 LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
 LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
 LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 LINEZOLID, LINEZOLID
 MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 MAGNESIUM SULFATE, MAGNESIUM SULFATE
 MANNITOL 25%, MANNITOL
 MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
 MESNA, MESNA
 METHOCARBAMOL, METHOCARBAMOL
 METHOTREXATE PRESERVATIVE FREE, METHOTREXATE SODIUM
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MICAFUNGIN SODIUM, MICAFUNGIN SODIUM
 MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 MILRINONE LACTATE, MILRINONE LACTATE
 MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 NAROPIN, ROPIVACAINE HYDROCHLORIDE
 NEBUPENT, PENTAMIDINE ISETHIONATE
 NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
 NESACAINE, CHLOROPROCAINE HYDROCHLORIDE
 NESACAINE-MPF, CHLOROPROCAINE HYDROCHLORIDE
 NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
 OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
 OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
 OMEGAVEN, FISH OIL TRIGLYCERIDES
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 OXACILLIN SODIUM, OXACILLIN SODIUM
 OXALIPLATIN, OXALIPLATIN
 OXYTOCIN, OXYTOCIN
 PACLITAXEL, PACLITAXEL
 PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
 PENTAM, PENTAMIDINE ISETHIONATE
 PERIKABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
 PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
 POLOCAINE, MEPIVACAINE HYDROCHLORIDE
 POLOCAINE-MPF, MEPIVACAINE HYDROCHLORIDE
 POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%, POTASSIUM CHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** F ****

* FRESENIUS KABI USA LLC
 POTASSIUM CHLORIDE 10MEQ, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 20MEQ, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 40MEQ, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 POTASSIUM PHOSPHATES, POTASSIUM PHOSPHATE, DIBASIC
 PROGESTERONE, PROGESTERONE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 PROTAMINE SULFATE, PROTAMINE SULFATE
 PYRIDOXINE HYDROCHLORIDE, PYRIDOXINE HYDROCHLORIDE
 REMIFENTANIL HYDROCHLORIDE, REMIFENTANIL HYDROCHLORIDE
 RIFAMPIN, RIFAMPIN
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
 SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
 SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
 SMOFLIPID 20%, FISH OIL
 SODIUM ACETATE, SODIUM ACETATE
 SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
 STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION
 SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TERBUTALINE SULFATE, TERBUTALINE SULFATE
 THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
 TIGECYCLINE, TIGECYCLINE
 TOBRAMYCIN SULFATE (PHARMACY BULK), TOBRAMYCIN SULFATE
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 TRANEXAMIC ACID, TRANEXAMIC ACID
 VALPROATE SODIUM, VALPROATE SODIUM
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VIBISONE, CYANOCOBALAMIN
 VINBLASTINE SULFATE, VINBLASTINE SULFATE
 VINOELBINE TARTRATE, VINOELBINE TARTRATE
 XYLOCAINE W/ EPINEPHRINE, EPINEPHRINE
 XYLOCAINE, LIDOCAINE HYDROCHLORIDE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

FRESENIUS MEDCL

* FRESENIUS MEDICAL CARE NORTH AMERICA
 DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM
 DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM
 DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM
 PHOSLO GELCAPS, CALCIUM ACETATE
 PHOSLYRA, CALCIUM ACETATE
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

FRONTIDA BIOPHARM

* FRONTIDA BIOPHARM INC
 BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 OXAZEPAM, OXAZEPAM

**** G ******GAGE DEVELOPMENT**

* GAGE DEVELOPMENT CO LLC
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE

GALDERMA LABS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** G ****

* GALDERMA LABORATORIES INC
CLOBEX, CLOBETASOL PROPIONATE
EPIDUO FORTE, ADAPALENE

GALDERMA LABS LP

* GALDERMA LABORATORIES L P
CLOBEX, CLOBETASOL PROPIONATE

* GALDERMA LABORATORIES LP
AKLIEF, TRIFAROTENE
CAPEX, FLUOCINOLONE ACETONIDE
CLOBEX, CLOBETASOL PROPIONATE
DESOWEN, DESONIDE
DIFFERIN, ADAPALENE
DIFFERIN, ADAPALENE (OTC)
EPIDUO, ADAPALENE
METROCREAM, METRONIDAZOLE
METROGEL, METRONIDAZOLE
METROLOTION, METRONIDAZOLE
MIRVASO, BRIMONIDINE TARTRATE
ORACEA, DOXYCYCLINE
SOOLANTRA, IVERMECTIN
TRI-LUMA, FLUOCINOLONE ACETONIDE
VECTICAL, CALCITRIOL

GALEN SPECIALTY

* GALEN SPECIALTY PHARMA US LLC
SYNERA, LIDOCAINE

GALT PHARMS

* GALT PHARMACEUTICALS LLC
DORAL, QUAZEPAM
ORAVIG, MICONAZOLE
ORPHENGESIC FORTE, ASPIRIN

GD SEARLE

* GD SEARLE LLC
CELEBREX, CELECOXIB

GD SEARLE LLC

* GD SEARLE LLC
INSPIRA, EPLERENONE

GE HEALTHCARE

* GE HEALTHCARE
ADREVIEW, IOBENGUANE SULFATE I-123
CERETEC, TECHNETIUM TC-99M EXAMETAZIME KIT
CLARISCAN, GADOTERATE MEGLUMINE
INDIUM IN 111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE
MPI INDIUM DTPA IN 111, INDIUM IN-111 PENTETATE DISODIUM
MYOVUE 30ML, TECHNETIUM TC-99M TETROFOSMIN KIT
OMNIPAQUE 12, IOHEXOL
OMNIPAQUE 140, IOHEXOL
OMNIPAQUE 180, IOHEXOL
OMNIPAQUE 240, IOHEXOL
OMNIPAQUE 300, IOHEXOL
OMNIPAQUE 350, IOHEXOL
OMNIPAQUE 9, IOHEXOL
OMNISCAN, GADODIAMIDE
OPTISON, ALBUMIN HUMAN
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
VISIPAQUE 270, IODIXANOL
VISIPAQUE 320, IODIXANOL
VIZAMYL, FLUTEMETAMOL F-18

GE HLTHCARE INC

* GE HEALTHCARE INC
DATSCAN, IOFLUPANE I-123

GENBIOPRO

* GENBIOPRO INC
MIFEPRISTONE, MIFEPRISTONE

GENENTECH

* GENENTECH INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** G ****

* GENENTECH INC
ERIVEDGE, VISMODEGIB

GENENTECH INC

* GENENTECH INC
COTELLIC, COBIMETINIB FUMARATE
ESBRIET, PIRFENIDONE
EVRYSDI, RISDIPLAM
ROZLYTREK, ENTRECTINIB
XOFLUZA, BALOXAVIR MARBOXIL

GENERIC

* GENERICS INTERNATIONAL VENTURES ENTERPRISES LLC
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE

GENEYORK PHARMS

* GENEYORK PHARMACEUTICALS GROUP LLC
PREDNISONE, PREDNISONE

GENUS

* GENUS LIFESCIENCES INC
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
HYCODAN, HOMATROPINE METHYLBROMIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
TIVORBEX, INDOMETHACIN

GENUS LIFESCIENCES

* GENUS LIFE SCIENCES INC
GOPRELTO, COCAINE HYDROCHLORIDE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

GENZYME

* GENZYME CORP
CLOLAR, CLOFARABINE
MOZOBIL, PLERIXAFOR
RENAGEL, SEVELAMER HYDROCHLORIDE
RENVELA, SEVELAMER CARBONATE

GENZYME CORP

* GENZYME CORP
CAPRELSA, VANDETANIB
CERDELGA, ELIGLUSTAT TARTRATE

GILEAD

* GILEAD SCIENCES INC
CAYSTON, AZTREONAM
EMTRIVA, EMTRICITABINE
HEPSERA, ADEFOVIR DIPIVOXIL
LETAIRIS, AMBRISENTAN
RANEXA, RANOLAZINE
TRUVADA, EMTRICITABINE

GILEAD SCIENCES

* GILEAD SCIENCES LLC
ATRIPLA, EFAVIRENZ

GILEAD SCIENCES INC

* GILEAD SCIENCES INC
BIKTARVY, BICTEGRAVIR SODIUM
COMPLERA, EMTRICITABINE
DESCOVY, EMTRICITABINE
EPCLUSA, SOFOSBUVIR
GENVOYA, COBICISTAT
HARVONI, LEDIPASVIR
ODEFSEY, EMTRICITABINE
SOVALDI, SOFOSBUVIR
STRIBILD, COBICISTAT
TYBOST, COBICISTAT
VEKLURY, REMDESIVIR
VEMLIDY, TENOFOVIR ALAFENAMIDE FUMARATE
VIREAD, TENOFOVIR DISOPROXIL FUMARATE
VOSEVI, SOFOSBUVIR
ZYDELIG, IDELALISIB

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** G ******GISKIT**

* GISKIT BV
EXEM FOAM KIT, AIR POLYMER-TYPE A

GLAND PHARMA LTD

* GLAND PHARMA LTD
ADENOSINE, ADENOSINE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
AZITHROMYCIN, AZITHROMYCIN
BIMATOPROST, BIMATOPROST
BROMFENAC SODIUM, BROMFENAC SODIUM
CALCITRIOL, CALCITRIOL
CARBOPLATIN, CARBOPLATIN
CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
CISPLATIN, CISPLATIN
CLOFARABINE, CLOFARABINE
CYANOCOBALAMIN, CYANOCOBALAMIN
CYTARABINE, CYTARABINE
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
DOXERCALCIFEROL, DOXERCALCIFEROL
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
ETOMIDATE, ETOMIDATE
FLUOROURACIL, FLUOROURACIL
FUROSEMIDE, FUROSEMIDE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL, HALOPERIDOL LACTATE
HEPARIN SODIUM, HEPARIN SODIUM
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVOFLOXACIN, LEVOFLOXACIN
LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MEROPENEM, MEROPENEM
MESNA, MESNA
METHOCARBAMOL, METHOCARBAMOL
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE (OTC)
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN
PACITAXEL, PACITAXEL
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
TEMSIROLIMUS, TEMSIROLIMUS
TRANEXAMIC ACID, TRANEXAMIC ACID
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** G ******* GLAND PHARMA LTD**

VORICONAZOLE, VORICONAZOLE
 ZIPRASIDONE MESYLATE, ZIPRASIDONE MESYLATE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID
 ZOLEDRONIC, ZOLEDRONIC ACID

GLASSHOUSE PHARMS

*** GLASSHOUSE PHARMACEUTICALS LTD CANADA**
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
 FLUOCINONIDE, FLUOCINONIDE

GLAUKOS

*** GLAUKOS CORP**
 PHOTREXA VISCOUS IN DEXTRAN 20%, RIBOFLAVIN 5'-PHOSPHATE SODIUM
 PHOTREXA, RIBOFLAVIN 5'-PHOSPHATE SODIUM

GLAXO GRP ENGLAND

*** GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE**
 INCRUSE ELLIPTA, UMECLIDINIUM BROMIDE

GLAXO GRP LTD

*** GLAXO GROUP LTD DBA GLAXOSMITHKLINE**
 FLOVENT HFA, FLUTICASONE PROPIONATE

*** GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE**
 ADVAIR DISKUS 100/50, FLUTICASONE PROPIONATE
 ADVAIR DISKUS 250/50, FLUTICASONE PROPIONATE
 ADVAIR DISKUS 500/50, FLUTICASONE PROPIONATE
 ADVAIR HFA, FLUTICASONE PROPIONATE
 BREO ELLIPTA, FLUTICASONE FUROATE
 FLOVENT DISKUS 100, FLUTICASONE PROPIONATE
 FLOVENT DISKUS 250, FLUTICASONE PROPIONATE
 FLOVENT DISKUS 50, FLUTICASONE PROPIONATE

GLAXOSMITHKLINE

*** GLAXOSMITHKLINE**
 ABREVA, DOCOSANOL (OTC)
 AVODART, DUTASTERIDE
 BECONASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE
 EPIVIR-HBV, LAMIVUDINE
 IMITREX STATDOSE, SUMATRIPTAN SUCCINATE
 IMITREX, SUMATRIPTAN
 IMITREX, SUMATRIPTAN SUCCINATE
 JALYN, DUTASTERIDE
 MALARONE PEDIATRIC, ATOVAQUONE
 MALARONE, ATOVAQUONE
 NICORETTE (MINT), NICOTINE POLACRILEX (OTC)
 NICORETTE, NICOTINE POLACRILEX (OTC)
 RELENZA, ZANAMIVIR
 VALTREX, VALACYCLOVIR HYDROCHLORIDE
 WELLBUTRIN SR, BUPROPION HYDROCHLORIDE

*** GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS US LLC**
 ADVIL ALLERGY AND CONGESTION RELIEF, CHLORPHENIRAMINE MALEATE (OTC)
 ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
 ADVIL COLD AND SINUS, IBUPROFEN (OTC)
 ADVIL CONGESTION RELIEF, IBUPROFEN (OTC)
 ADVIL DUAL ACTION WITH ACETAMINOPHEN, ACETAMINOPHEN (OTC)
 ADVIL LIQUI-GELS, IBUPROFEN (OTC)
 ADVIL MIGRAINE LIQUI-GELS, IBUPROFEN (OTC)
 ADVIL MULTI-SYMPTOM COLD & FLU, CHLORPHENIRAMINE MALEATE (OTC)
 ADVIL PM, DIPHENHYDRAMINE CITRATE (OTC)
 ADVIL PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
 ADVIL, IBUPROFEN (OTC)
 ADVIL, IBUPROFEN SODIUM (OTC)
 AXID AR, NIZATIDINE (OTC)
 CHILDREN'S ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
 CHILDREN'S ADVIL COLD, IBUPROFEN (OTC)
 CHILDREN'S ADVIL, IBUPROFEN (OTC)
 CHILDREN'S ADVIL-FLAVORED, IBUPROFEN (OTC)
 INFANT'S ADVIL, IBUPROFEN (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** G ****

- * GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS US LLC
JUNIOR STRENGTH ADVIL, IBUPROFEN (OTC)
LAMISIL, TERBINAFINE HYDROCHLORIDE (OTC)
LORATADINE, LORATADINE (OTC)
- * GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND
ANORO ELLIPTA, UMECLIDINIUM BROMIDE
ARNUITY ELLIPTA, FLUTICASONE FUROATE
KRINTAFEL, TAFENOQUINE SUCCINATE
TRELEGY ELLIPTA, FLUTICASONE FUROATE
- * GLAXOSMITHKLINE INTELLECTUAL PROPERTY LTD ENGLAND
SEREVENT, SALMETEROL XINAFOATE
VENTOLIN HFA, ALBUTEROL SULFATE
- * GLAXOSMITHKLINE LLC
ZEJULA, NIRAPARIB TOSYLATE

GLAXOSMITHKLINE CON

- * GLAXOSMITHKLINE CONSUMER HEALTH
TRANSDERM SCOP, SCOPOLAMINE

GLAXOSMITHKLINE CONS

- * GLAXOSMITHKLINE CONSUMER HEALTHCARE
ALLI, ORLISTAT (OTC)
EXCEDRIN (MIGRAINE), ACETAMINOPHEN (OTC)
FLONASE ALLERGY RELIEF, FLUTICASONE PROPIONATE (OTC)
FLONASE SENSIMIST ALLERGY RELIEF, FLUTICASONE FUROATE (OTC)
LAMISIL AT, TERBINAFINE (OTC)
LAMISIL AT, TERBINAFINE HYDROCHLORIDE (OTC)
NICORETTE, NICOTINE POLACRILEX (OTC)
VOLTAREN ARTHRITIS PAIN, DICLOFENAC SODIUM (OTC)

GLAXOSMITHKLINE LLC

- * GLAXOSMITHKLINE LLC
AMERGE, NARATRIPTAN HYDROCHLORIDE
FLOLAN, EPOPROSTENOL SODIUM
LAMICTAL CD, LAMOTRIGINE
LAMICTAL ODT, LAMOTRIGINE
LAMICTAL XR, LAMOTRIGINE
LAMICTAL, LAMOTRIGINE
MEPRON, ATOVAQUONE
REQUIP XL, ROPINIROLE HYDROCHLORIDE
REQUIP, ROPINIROLE HYDROCHLORIDE
RYTHMOL SR, PROPAFENONE HYDROCHLORIDE

GLENMARK

- * GLENMARK THERAPEUTICS INC USA
ECOZA, ECONAZOLE NITRATE

GLENMARK GENERICS

- * GLENMARK GENERICS INC USA
ADAPALENE, ADAPALENE (OTC)
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
IMIQUIMOD, IMIQUIMOD
MOMETASONE FUROATE, MOMETASONE FUROATE
NIZATIDINE, NIZATIDINE
ZONISAMIDE, ZONISAMIDE
- * GLENMARK GENERICS LIMITED
BRIELLYN, ETHINYL ESTRADIOL
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
- * GLENMARK GENERICS LTD
ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
ALYACEN 1/35, ETHINYL ESTRADIOL
ALYACEN 7/7/7, ETHINYL ESTRADIOL
ASHLYNA, ETHINYL ESTRADIOL
ATOVAQUONE AND PROGUANIL HYDROCHLORIDE, ATOVAQUONE
CARVEDILOL, CARVEDILOL
CICLOPIROX, CICLOPIROX
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
DESOXIMETASONE, DESOXIMETASONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** G ****

- * GLENMARK GENERICS LTD
 ESZOPICLONE, ESZOPICLONE
 FELODIPINE, FELODIPINE
 FLUCONAZOLE, FLUCONAZOLE
 FLUOCINONIDE, FLUOCINONIDE
 HEATHER, NORETHINDRONE
 HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
 LAMOTRIGINE, LAMOTRIGINE
 LEVOFLOXACIN, LEVOFLOXACIN
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LITHIUM CARBONATE, LITHIUM CARBONATE
 MARLISSA, ETHINYL ESTRADIOL
 MELOXICAM, MELOXICAM
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
 MOMETASONE FUROATE, MOMETASONE FUROATE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 NAPROXEN, NAPROXEN
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NORETHINDRONE, NORETHINDRONE
 NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 OMEPRAZOLE, OMEPRAZOLE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON, ONDANSETRON
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
 THEOPHYLLINE, THEOPHYLLINE
 TOPIRAMATE, TOPIRAMATE
 TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE, TRANDOLAPRIL
 TROSPIMUM CHLORIDE, TROSPIMUM CHLORIDE
 URSODIOL, URSODIOL
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
 VIORELE, DESOGESTREL
 ZOLMITRIPTAN, ZOLMITRIPTAN
- * GLENMARK GENERICS LTD INDIA
 INDOMETHACIN, INDOMETHACIN
 NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
- GLENMARK PHARMS**
- * GLENMARK PHARMACEUTICALS INC
 TERIFLUNOMIDE, TERIFLUNOMIDE
- * GLENMARK PHARMACEUTICALS INC USA
 CICLOPIROX, CICLOPIROX
 CLOTRIMAZOLE, CLOTRIMAZOLE
 MUPIROCIN, MUPIROCIN
- * GLENMARK PHARMACEUTICALS LTD
 MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
- * GLENMARK PHARMACEUTICALS SA
 ABIRATERONE ACETATE, ABIRATERONE ACETATE
 ATOVAQUONE, ATOVAQUONE
 AZELAIC ACID, AZELAIC ACID
 CALCIPOTRIENE, CALCIPOTRIENE
 CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 DESONIDE, DESONIDE
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 HAILEY 1.5/30, ETHINYL ESTRADIOL
 HAILEY FE 1.5/30, ETHINYL ESTRADIOL
 LINEZOLID, LINEZOLID
 NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** G ****

* GLENMARK PHARMACEUTICALS SA
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

GLENMARK PHARMS INC

* GLENMARK PHARMACEUTICALS INC USA
 CALCIPOTRIENE, CALCIPOTRIENE
 FULVESTRANT, FULVESTRANT
 LITHIUM CARBONATE, LITHIUM CARBONATE
 MUPIROCIN, MUPIROCIN CALCIUM
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE

GLENMARK PHARMS LTD

* GLENMARK PHARMACEUTICALS LTD
 ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
 AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
 ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
 CHLORZOXAZONE, CHLORZOXAZONE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 DESONIDE, DESONIDE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DIMETHYL FUMARATE, DIMETHYL FUMARATE
 DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
 ESTRADIOL, ESTRADIOL
 EZETIMIBE AND SIMVASTATIN, EZETIMIBE
 EZETIMIBE, EZETIMIBE
 FENOFIBRATE (MICRONIZED), FENOFIBRATE
 FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
 FLUCINOLONE ACETONIDE, FLUCINOLONE ACETONIDE
 FLUCINONIDE ACETONIDE, FLUCINOLONE ACETONIDE
 FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE
 GABAPENTIN, GABAPENTIN
 HAILEY FE 1/20, ETHINYL ESTRADIOL
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
 INDOMETHACIN, INDOMETHACIN
 LAMOTRIGINE, LAMOTRIGINE
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LEVONORGESTREL, LEVONORGESTREL (OTC)
 LIDOCAINE, LIDOCAINE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 NAPROXEN SODIUM, NAPROXEN SODIUM
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
 OXCARBAZEPINE, OXCARBAZEPINE
 PIMECROLIMUS, PIMECROLIMUS
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
 RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
 RANOLAZINE, RANOLAZINE
 RILUZOLE, RILUZOLE
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 RUFINAMIDE, RUFINAMIDE
 SEVELAMER HYDROCHLORIDE, SEVELAMER HYDROCHLORIDE
 SIROLIMUS, SIROLIMUS
 TACROLIMUS, TACROLIMUS
 TADALAFIL, TADALAFIL
 TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TELMISARTAN, TELMISARTAN
 TRETINOIN, TRETINOIN
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 VORICONAZOLE, VORICONAZOLE

GLENMARK PHARMS SA

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** G ****

* GLENMARK PHARMACEUTICALS SA SWITZERLAND

ACYCLOVIR, ACYCLOVIR
 APREPITANT, APREPITANT
 ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
 NITROGLYCERIN, NITROGLYCERIN

GLOBAL BLOOD THERAPYS

* GLOBAL BLOOD THERAPEUTICS INC

OXBRYTA, VOXELOTOR

GLW

* GLW PHARMA GMBH

OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS

GRANULES

* GRANULES INDIA LTD

ACETAMINOPHEN, ACETAMINOPHEN (OTC)
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 GABAPENTIN, GABAPENTIN
 GUAIFENESIN, GUAIFENESIN (OTC)
 IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)
 LORATADINE, LORATADINE (OTC)
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHOCARBAMOL, METHOCARBAMOL
 NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

GRANULES INDIA

* GRANULES INDIA LTD

IBUPROFEN, IBUPROFEN (OTC)
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)

GRANULES PHARMS

* GRANULES PHARMACEUTICALS INC

AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
 BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 COLCHICINE, COLCHICINE
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 PENICILLAMINE, PENICILLAMINE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 RAMELTEON, RAMELTEON
 TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
 VIGABATRIN, VIGABATRIN

GRAVITI PHARMS

* GRAVITI PHARMACEUTICALS PRIVATE LTD

ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 FENOFIBRATE, FENOFIBRATE
 FENOFIBRIC ACID, CHOLINE FENOFIBRATE

GUARDIAN DRUG

* GUARDIAN DRUG CO

GUAIFENESIN, GUAIFENESIN (OTC)
 IBUPROFEN, IBUPROFEN (OTC)
 LORATADINE, LORATADINE (OTC)
 OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE

GUERBET

* GUERBET LLC

DOTAREM, GADOTERATE MEGLUMINE
 LIPIODOL, ETHIODIZED OIL

GW RES LTD

* GW RESEARCH LTD

EPIDIOLEX, CANNABIDIOL

HANFORD GC

* GC HANFORD MANUFACTURING CO

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** G ****

* GC HANFORD MANUFACTURING CO
 AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
 AMPICILLIN SODIUM, AMPICILLIN SODIUM
 PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM

POHL BOSKAMP

* G POHL BOSKAMP GMBH AND CO KG
 GONITRO, NITROGLYCERIN

**** H ******HAEMONETICS**

* HAEMONETICS CORP
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

HAINAN POLY PHARM

* HAINAN POLY PHARMACEUTICAL CO LTD
 AZITHROMYCIN, AZITHROMYCIN
 EPTIFIBATIDE, EPTIFIBATIDE
 GANCICLOVIR SODIUM, GANCICLOVIR SODIUM
 LEVETIRACETAM, LEVETIRACETAM
 SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VORICONAZOLE, VORICONAZOLE

HALOCARBON PRODS

* HALOCARBON PRODUCTS CORP
 ISOFLURANE, ISOFLURANE
 SEVOFLURANE, SEVOFLURANE

HANGZHOU BINJIANG

* HANGZHOU MINSHENG BINJIANG PHARMACEUTICAL CO LTD
 ALENDRONATE SODIUM, ALENDRONATE SODIUM

HANGZHOU ZHONGMEI

* HANGZHOU ZHONGMEI HUADONG PHARMACEUTICAL CO LTD
 ACARBOSE, ACARBOSE

HARMONY

* HARMONY BIOSCIENCES LLC
 WAKIX, PITOLISANT HYDROCHLORIDE

HARRIS PHARM

* HARRIS PHARMACEUTICAL INC
 TERBINAFAFINE HYDROCHLORIDE, TERBINAFAFINE HYDROCHLORIDE

HAVIX

* HAVIX GROUP INC DBA AAVIS PHARMACEUTICALS
 AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 KETOCONAZOLE, KETOCONAZOLE

HBT LABS INC

* HBT LABS INC
 FULVESTRANT, FULVESTRANT

HEC PHARM

* HEC PHARM USA INC
 CLARITHROMYCIN, CLARITHROMYCIN
 LEVOFLOXACIN, LEVOFLOXACIN
 PRASUGREL, PRASUGREL HYDROCHLORIDE

HEC PHARM CO LTD

* HEC PHARM CO LTD
 FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE

HELSINN

* HELSINN BIREX PHARMACEUTICALS LTD
 VALCHLOR, MECHLORETHAMINE HYDROCHLORIDE

HELSINN HLTHCARE

* HELSINN HEALTHCARE SA
 AKYNZEO, FOSNETUPITANT CHLORIDE HYDROCHLORIDE
 AKYNZEO, NETUPITANT
 ALOXI, PALONOSETRON HYDROCHLORIDE

HERCON PHARM

* HERCON PHARMACEUTICAL LLC
 NITROGLYCERIN, NITROGLYCERIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ******HERITAGE LIFE**

* HERITAGE LIFE SCIENCES BARBADOS INC
CLOZARIL, CLOZAPINE

HERITAGE PHARMA

* HERITAGE PHARMA LABS INC
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETAZOLAMIDE, ACETAZOLAMIDE
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
BUMETANIDE, BUMETANIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DIFLUNISAL, DIFLUNISAL
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LITHIUM CARBONATE, LITHIUM CARBONATE
METHIMAZOLE, METHIMAZOLE
NADOLOL, NADOLOL
NIFEDIPINE, NIFEDIPINE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE

HERITAGE PHARMS INC

* HERITAGE PHARMACEUTICALS INC
ACETAZOLAMIDE, ACETAZOLAMIDE
ACYCLOVIR, ACYCLOVIR
CALCIUM ACETATE, CALCIUM ACETATE
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
ETHOSUXIMIDE, ETHOSUXIMIDE
FELODIPINE, FELODIPINE
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GLYBURIDE, GLYBURIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
KETOPROFEN, KETOPROFEN
LEFLUNOMIDE, LEFLUNOMIDE
METRONIDAZOLE, METRONIDAZOLE
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
NIMODIPINE, NIMODIPINE
NYSTATIN, NYSTATIN
PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

HERON THERAPS INC

* HERON THERAPEUTICS INC
CINVANTI, APREPITANT
SUSTOL, GRANISETRON

HETERO LABS LTD

* HETERO LABS LTD
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE

HETERO LABS LTD III

* HETERO LABS LTD UNIT III
ABACAVIR SULFATE, ABACAVIR SULFATE
ATOVAQUONE, ATOVAQUONE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLOBAZAM, CLOBAZAM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ****

* HETERO LABS LTD UNIT III
 DABIGATRAN ETEXILATE MESYLATE, DABIGATRAN ETEXILATE MESYLATE
 DIMETHYL FUMARATE, DIMETHYL FUMARATE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 EFAVIRENZ, EFAVIRENZ
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
 FENOFIBRATE, FENOFIBRATE
 FINASTERIDE, FINASTERIDE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 INDOMETHACIN, INDOMETHACIN
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
 LANSOPRAZOLE, LANSOPRAZOLE
 LEVETIRACETAM, LEVETIRACETAM
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)
 LEVOCETIRIZINE HYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 LITHIUM CARBONATE, LITHIUM CARBONATE
 METHOCARBAMOL, METHOCARBAMOL
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
 NEBIVOLOL HYDROCHLORIDE, NEBIVOLOL HYDROCHLORIDE
 NEVIRAPINE, NEVIRAPINE
 OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)
 OMEPRAZOLE, OMEPRAZOLE
 OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
 PREGABALIN, PREGABALIN
 RITONAVIR, RITONAVIR
 ROFLUMILAST, ROFLUMILAST
 SIMVASTATIN, SIMVASTATIN
 TADALAFIL, TADALAFIL
 TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
 TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
 TORSEMIDE, TORSEMIDE
 ZIDOVUDINE, ZIDOVUDINE

HETERO LABS LTD V

* HETERO LABS LTD UNIT V
 ACYCLOVIR, ACYCLOVIR
 ARIPIPRAZOLE, ARIPIPRAZOLE
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 ENTECAVIR, ENTECAVIR
 FAMCICLOVIR, FAMCICLOVIR
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
 IRBESARTAN, IRBESARTAN
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
 LAMIVUDINE, LAMIVUDINE
 LEVOFLOXACIN, LEVOFLOXACIN
 LINEZOLID, LINEZOLID
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SILODOSIN, SILODOSIN
 TELMISARTAN, TELMISARTAN
 TETRABENAZINE, TETRABENAZINE
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
 VALSARTAN, VALSARTAN

HEYL CHEMISCH

* HEYL CHEMISCH PHARMAZEUTISCHE FABRIK

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ****

* HEYL CHEMISCH PHARMAZEUTISCHE FABRIK
RADIOGARDASE (PRUSSIAN BLUE), FERRIC HEXACYANOFERRATE (II)

HI TECH

* HI-TECH PHARMACAL CO INC
PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE

HI-TECH PHARMA CO

* HI-TECH PHARMACAL CO INC
FAMOTIDINE, FAMOTIDINE
GATIFLOXACIN, GATIFLOXACIN
LORAZEPAM, LORAZEPAM
PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE

HI-TECH PHARMACAL

* HI-TECH PHARMACAL CO INC
LEVETIRACETAM, LEVETIRACETAM

HIGH TECH PHARMA

* HIGH TECHNOLOGY PHARMACAL CO INC
VALPROIC ACID, VALPROIC ACID

HIKAL

* HIKAL LTD
PREGABALIN, PREGABALIN

HIKMA

* HIKMA FARMACEUTICA LDA
CEFOTAXIME, CEFOTAXIME SODIUM

* HIKMA FARMACEUTICA PORTUGAL SA
CEFOTETAN, CEFOTETAN DISODIUM
CEFTRIAZONE SODIUM, CEFTRIAZONE SODIUM
ESTRADIOL VALERATE, ESTRADIOL VALERATE
ETOMIDATE, ETOMIDATE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE

* HIKMA PHARMACEUTICALS
AMOXICILLIN, AMOXICILLIN
CEFACTOR, CEFACTOR
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEPHALEXIN, CEPHALEXIN
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
GLYBURIDE (MICRONIZED), GLYBURIDE

* HIKMA PHARMACEUTICALS INTERNATIONAL LTD
ATIVAN, LORAZEPAM
CAFCIT, CAFFEINE CITRATE
CODEINE SULFATE, CODEINE SULFATE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DIGOXIN, DIGOXIN
DOPRAM, DOXAPRAM HYDROCHLORIDE
FUROSEMIDE, FUROSEMIDE
HEPARIN SODIUM, HEPARIN SODIUM
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
LABETALOL HYDROCHLORIDE IN DEXTROSE, LABETALOL HYDROCHLORIDE
LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE, LABETALOL HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
ROBAXIN, METHOCARBAMOL
RUFINAMIDE, RUFINAMIDE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE

* HIKMA PHARMACEUTICALS LLC
ABIRATERONE ACETATE, ABIRATERONE ACETATE
AMOXICILLIN, AMOXICILLIN
DANTROLENE SODIUM, DANTROLENE SODIUM
DOXERCALCIFEROL, DOXERCALCIFEROL
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ****

* HIKMA PHARMACEUTICALS LLC
 PIROXICAM, PIROXICAM

* HIKMA PHARMACEUTICALS USA INC
 ACARBOSE, ACARBOSE
 ALENDRONATE SODIUM, ALENDRONATE SODIUM
 ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
 ALPRAZOLAM, ALPRAZOLAM
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
 BEXAROTENE, BEXAROTENE
 BOSENTAN, BOSENTAN
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
 CALCITRIOL, CALCITRIOL
 CALCIUM ACETATE, CALCIUM ACETATE
 CAPECITABINE, CAPECITABINE
 CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
 CILOSTAZOL, CILOSTAZOL
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 CLOBAZAM, CLOBAZAM
 CLOTRIMAZOLE, CLOTRIMAZOLE
 CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
 DALFAMPRIDINE, DALFAMPRIDINE
 DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
 DEXAMETHASONE INTENSOL, DEXAMETHASONE
 DEXAMETHASONE, DEXAMETHASONE
 DIAZEPAM INTENSOL, DIAZEPAM
 DIAZEPAM, DIAZEPAM
 DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
 DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
 DISULFIRAM, DISULFIRAM
 DURAMORPH PF, MORPHINE SULFATE
 EPHEDRINE SULFATE, EPHEDRINE SULFATE
 ETHACRYNIC ACID, ETHACRYNIC ACID
 EVEROLIMUS, EVEROLIMUS
 EXEMESTANE, EXEMESTANE
 FEBUXOSTAT, FEBUXOSTAT
 FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
 FLECAINIDE ACETATE, FLECAINIDE ACETATE
 FLUCYTOSINE, FLUCYTOSINE
 FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, FLUTICASONE PROPIONATE
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE (OTC)
 FUROSEMIDE, FUROSEMIDE
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 ICOSAPENT ETHYL, ICOSAPENT ETHYL
 IMATINIB MESYLATE, IMATINIB MESYLATE
 IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
 INFUMORPH, MORPHINE SULFATE
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
 LEVOMILNACIPRAN HYDROCHLORIDE, LEVOMILNACIPRAN HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
 LINEZOLID, LINEZOLID
 LITHIUM CARBONATE, LITHIUM CARBONATE
 LITHIUM CITRATE, LITHIUM CITRATE
 LORAZEPAM INTENSOL, LORAZEPAM
 MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
 MERCAPTOPYRINE, MERCAPTOPYRINE
 METHADONE HYDROCHLORIDE INTENSOL, METHADONE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ****

* HIKMA PHARMACEUTICALS USA INC
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 METHAMPHETAMINE HYDROCHLORIDE, METHAMPHETAMINE HYDROCHLORIDE
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 MORPHINE SULFATE, MORPHINE SULFATE
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 NAPROXEN, NAPROXEN
 NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 OXCARBAZEPINE, OXCARBAZEPINE
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
 PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
 PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE
 PREDNISONE INTENSOL, PREDNISONE
 PREDNISONE, PREDNISONE
 PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RAMIPRIL, RAMIPRIL
 RISPERIDONE, RISPERIDONE
 RITONAVIR, RITONAVIR
 ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
 ROXICET, ACETAMINOPHEN
 RUFINAMIDE, RUFINAMIDE
 TETRABENAZINE, TETRABENAZINE
 TINIDAZOLE, TINIDAZOLE
 TORSEMIDE, TORSEMIDE
 TRIAZOLAM, TRIAZOLAM
 ZALEPLON, ZALEPLON

HIKMA FARMACEUTICA

* HIKMA FARMACEUTICA (PORTUGAL) SA
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
 BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
 CEFOXITIN, CEFOXITIN SODIUM
 CEFTRIAZONE, CEFTRIAZONE SODIUM
 CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
 CIPROFLOXACIN, CIPROFLOXACIN
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 ENALAPRILAT, ENALAPRILAT
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
 FLUMAZENIL, FLUMAZENIL
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 GLYCOPYRROLATE, GLYCOPYRROLATE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 LEVETIRACETAM, LEVETIRACETAM
 LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MILRINONE LACTATE IN PLASTIC CONTAINER, MILRINONE LACTATE
 MILRINONE LACTATE, MILRINONE LACTATE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 PROGESTERONE, PROGESTERONE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 TERBUTALINE SULFATE, TERBUTALINE SULFATE
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 VALPROATE SODIUM, VALPROATE SODIUM

* HIKMA FARMACEUTICA PORTUGAL LDA
 CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
 CEFUROXIME SODIUM, CEFUROXIME SODIUM
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ****

* HIKMA FARMACEUTICA PORTUGAL SA
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 OXYTOCIN, OXYTOCIN
 TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE

* HIKMA FARMACEUTICA SA
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

HIKMA INTL PHARMS

* HIKMA INTERNATIONAL PHARMACEUTICALS LLC
 CAPTOPRIL, CAPTOPRIL
 CORTISONE ACETATE, CORTISONE ACETATE
 DIGOXIN, DIGOXIN
 DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
 MITIGARE, COLCHICINE

HIKMA PHARM CO LTD

* HIKMA PHARM CO LTD
 ARGATROBAN, ARGATROBAN

HIKMA PHARMS

* HIKMA PHARMACEUTICALS
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 AMOXICILLIN, AMOXICILLIN
 CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
 DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
 DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
 PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
 RIFAMPIN, RIFAMPIN
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

* HIKMA PHARMACEUTICALS CO LTD
 PARICALCITOL, PARICALCITOL

HILL DERMAC

* HILL DERMACEUTICALS INC
 DERMA-SMOOTH/FS, FLUOCINOLONE ACETONIDE
 DERMOTIC, FLUOCINOLONE ACETONIDE

HILL DERMACEUTICALS

* HILL DERMACEUTICALS INC
 TOLAK, FLUOROURACIL

HISAMITSU

* HISAMITSU PHARMACEUTICAL CO INC
 SECUADO, ASENAPINE

HISAMITSU PHARM CO

* HISAMITSU PHARMACEUTICAL CO INC
 SALONPAS, MENTHOL (OTC)

HISUN PHARM HANGZHOU

* HISUN PHARMACEUTICAL (HANGZHOU) CO LTD
 CLADRIBINE, CLADRIBINE
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRBESARTAN, IRBESARTAN
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 LEVETIRACETAM, LEVETIRACETAM

* HISUN PHARMACEUTICAL HANGZHOU CO LTD
 DACTINOMYCIN, DACTINOMYCIN
 DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 TICAGRELOR, TICAGRELOR

HLTHCARE

* HEALTHCARE PHARMACEUTICALS LTD
 ATENOLOL, ATENOLOL

HOFFMANN LA ROCHE

* HOFFMANN LA ROCHE INC
 BONIVA, IBANDRONATE SODIUM
 VALCYTE, VALGANCICLOVIR HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ****

* HOFFMANN LA ROCHE INC
 XELODA, CAPECITABINE
 ZELBORAF, VEMURAFENIB

HOFFMANN-LA ROCHE

* HOFFMANN-LA ROCHE INC
 ALECENSA, ALECTINIB HYDROCHLORIDE
 INVIRASE, SAQUINAVIR MESYLATE

HONG KONG

* HONG KONG KING FRIEND INDUSTRIAL CO LTD
 BIVALIRUDIN, BIVALIRUDIN
 CLOFARABINE, CLOFARABINE
 CYTARABINE, CYTARABINE
 DACTINOMYCIN, DACTINOMYCIN
 SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE

HOPE PHARMS

* HOPE PHARMACEUTICALS
 NITHIODE, SODIUM NITRITE
 SODIUM NITRITE, SODIUM NITRITE
 SODIUM THIOSULFATE, SODIUM THIOSULFATE

HORIZON

* HORIZON MEDICINES LLC
 DUEXIS, FAMOTIDINE
 VIMOVO, ESOPEPRAZOLE MAGNESIUM
 * HORIZON THERAPEUTICS IRELAND DAC
 PENNSAID, DICLOFENAC SODIUM

HORIZON PHARMA USA

* HORIZON PHARMA USA INC
 PROCYSBI, CYSTEAMINE BITARTRATE
 RAYOS, PREDNISONE

HORIZON THERAP

* HORIZON THERAPEUTICS LLC
 BUPHENYL, SODIUM PHENYL BUTYRATE
 RAVICTI, GLYCEROL PHENYL BUTYRATE

HOSPIRA

* HOSPIRA INC
 ACETYLCYSTEINE, ACETYLCYSTEINE
 ALFENTANIL, ALFENTANIL HYDROCHLORIDE
 AMIDATE, ETOMIDATE
 AMINOCAPROIC ACID IN PLASTIC CONTAINER, AMINOCAPROIC ACID
 AMINOPHYLLINE, AMINOPHYLLINE
 AMMONIUM CHLORIDE IN PLASTIC CONTAINER, AMMONIUM CHLORIDE
 ATROPINE SULFATE, ATROPINE SULFATE
 AZITHROMYCIN, AZITHROMYCIN
 BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
 BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
 BUMETANIDE, BUMETANIDE
 BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
 BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
 CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 CARBOCAINE, MEPIVACAINE HYDROCHLORIDE
 CARBOPLATIN, CARBOPLATIN
 CHLOROPROCAINE HYDROCHLORIDE, CHLOROPROCAINE HYDROCHLORIDE
 CHROMIC CHLORIDE IN PLASTIC CONTAINER, CHROMIC CHLORIDE
 CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
 CIPROFLOXACIN, CIPROFLOXACIN
 CORLOPAM, FENOLDOPAM MESYLATE
 CUPRIC CHLORIDE IN PLASTIC CONTAINER, CUPRIC CHLORIDE
 CYTARABINE, CYTARABINE
 DACARBAZINE, DACARBAZINE
 DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
 DEMEROL, MEPERIDINE HYDROCHLORIDE
 DEXTROSE 25%, DEXTROSE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ****

* HOSPIRA INC

DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 50%, DEXTROSE
 DIAZEPAM, DIAZEPAM
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
 DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
 DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
 DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
 DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE
 DROPERIDOL, DROPERIDOL
 ENALAPRILAT, ENALAPRILAT
 ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE
 FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
 FENTANYL CITRATE, FENTANYL CITRATE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
 FUROSEMIDE, FUROSEMIDE
 GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
 HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN
 HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
 HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN
 HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
 HEPARIN SODIUM, HEPARIN SODIUM
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 LEVOPHED, NOREPINEPHRINE BITARTRATE
 LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, EPINEPHRINE
 LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER, LIDOCAINE
 LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 LORAZEPAM, LORAZEPAM
 M.V.I. ADULT (PHARMACY BULK PACKAGE), ASCORBIC ACID
 M.V.I. ADULT, ASCORBIC ACID
 M.V.I. PEDIATRIC, ASCORBIC ACID
 MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 MAGNESIUM SULFATE, MAGNESIUM SULFATE
 MANGANESE CHLORIDE IN PLASTIC CONTAINER, MANGANESE CHLORIDE
 MANNITOL 25%, MANNITOL
 MARCAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
 MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
 MARCAINE HYDROCHLORIDE W/ EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
 MARCAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
 MARCAINE, BUPIVACAINE HYDROCHLORIDE
 METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
 MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
 MORPHINE SULFATE, MORPHINE SULFATE
 NALBUPHINE HYDROCHLORIDE, NALBUPHINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ****

* HOSPIRA INC

NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 PACLITAXEL, PACLITAXEL
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
 PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
 PLEGISOL IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 POTASSIUM ACETATE, POTASSIUM ACETATE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PRECEDEX, DEXMEDETOMIDINE HYDROCHLORIDE
 PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE
 PROPOFOL, PROPOFOL
 QUELICIN, SUCCINYLCHOLINE CHLORIDE
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
 ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
 SODIUM ACETATE, SODIUM ACETATE
 SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 14.6%, SODIUM CHLORIDE
 SODIUM CHLORIDE 23.4%, SODIUM CHLORIDE
 SODIUM PHOSPHATES IN PLASTIC CONTAINER, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
 STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION
 SUFENTANIL CITRATE, SUFENTANIL CITRATE
 TAZICEF, CEFTAZIDIME
 THAM, TROMETHAMINE
 TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, TOBRAMYCIN SULFATE
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 TPN ELECTROLYTES IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VECURONIUM BROMIDE, VECURONIUM BROMIDE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
 VITAMIN K1, PHYTONADIONE
 ZINC CHLORIDE IN PLASTIC CONTAINER, ZINC CHLORIDE

* HOSPIRA WORLDWIDE, INC

FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
 NITROPRESS, SODIUM NITROPRUSSIDE
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE

HOSPIRA INC

* HOSPIRA INC

ADENOSINE, ADENOSINE
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 ARGATROBAN, ARGATROBAN
 ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
 ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
 BIVALIRUDIN, BIVALIRUDIN
 BUSULFAN, BUSULFAN
 CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
 DAPTOMYCIN, DAPTOMYCIN
 DOCETAXEL, DOCETAXEL
 DOXERCALCIFEROL, DOXERCALCIFEROL
 EPINEPHRINE (COPACKAGED), EPINEPHRINE
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 HEPARIN SODIUM, HEPARIN SODIUM
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 INDOMETHACIN SODIUM, INDOMETHACIN SODIUM
 LEVETIRACETAM, LEVETIRACETAM
 LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
 LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, LINEZOLID
 LINEZOLID, LINEZOLID
 MAGNESIUM SULFATE, MAGNESIUM SULFATE
 MAXIPIME, CEFEPIME HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ****

* HOSPIRA INC
 MILRINONE LACTATE, MILRINONE LACTATE
 MORPHINE SULFATE, MORPHINE SULFATE
 NIPENT, PENTOSTATIN
 PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
 PARICALCITOL, PARICALCITOL
 SODIUM BICARBONATE, SODIUM BICARBONATE
 TACROLIMUS, TACROLIMUS
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

HOSPIRA WORLDWIDE

* HOSPIRA WORLDWIDE PTY
 OXALIPLATIN, OXALIPLATIN

HOT SHOTS NM LLC

* HOT SHOTS NUCLEAR MEDICINE LLC
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

HQ SPCLT PHARMA

* HQ SPECIALTY PHARMA CORP
 CALCIUM GLUCONATE IN SODIUM CHLORIDE, CALCIUM GLUCONATE
 CISPLATIN, CISPLATIN
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
 ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
 IMIPENEM AND CILASTATIN, CILASTATIN SODIUM
 LINEZOLID, LINEZOLID
 MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 MEROPENEM, MEROPENEM

HQ SPECIALITY PHARMA

* HQ SPECIALITY PHARMA LLC
 LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM

HRA PHARMA

* HRA PHARMA RARE DISEASES
 LYSODREN, MITOTANE
 METOPIRONE, METYRAPONE

HUMANWELL PURACAP

* HUMANWELL PURACAP PHARMACEUTICAL WUHAN CO LTD
 DUTASTERIDE, DUTASTERIDE
 IBUPROFEN, IBUPROFEN (OTC)

HUONS

* HUONS CO LTD
 BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE

ROCHE

* HOFFMANN LA ROCHE INC
 FUZEON, ENFUVIRTIDE
 KLONOPIN, CLONAZEPAM
 TAMIFLU, OSELTAMIVIR PHOSPHATE
 VALIUM, DIAZEPAM

SHUANGCHENG

* HAINAN SHUANGCHENG PHARMACEUTICALS CO LTD
 BIVALIRUDIN, BIVALIRUDIN
 PREGABALIN, PREGABALIN

**** I ******I3 PHARMS**

* I3 PHARMACEUTICALS LLC
 CHLORZOXAZONE, CHLORZOXAZONE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 RAMELTEON, RAMELTEON

IBSA INST BIO

* IBSA INSTITUT BIOCHIMIQUE SA

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** I ****

* IBSA INSTITUT BIOCHIMIQUE SA
LICART, DICLOFENAC EPOLAMINE

ICHNOS

* ICHNOS SCIENCES SA
DEFERASIROX, DEFERASIROX

ICU MEDICAL INC

* ICU MEDICAL INC
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
AMINOSYN II 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 15% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN-PF 10%, AMINO ACIDS
AMINOSYN-PF 7%, AMINO ACIDS
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PHYSIOSOL IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SORBITOL-MANNITOL IN PLASTIC CONTAINER, MANNITOL
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION

IMPACT

* IMPACT BIOMEDICINES INC A WHOLLY OWNED SUB OF CELGENE CORP
INREBIC, FEDRATINIB HYDROCHLORIDE

IMPAX

* IMPAX LABORATORIES LLC
ADRENACLICK, EPINEPHRINE
SEVELAMER CARBONATE, SEVELAMER CARBONATE
TERIFLUNOMIDE, TERIFLUNOMIDE

IMPAX LABS

* IMPAX LABORATORIES INC
ACARBOSE, ACARBOSE
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** I ****

* IMPAX LABORATORIES INC
 BACLOFEN, BACLOFEN
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CARBIDOPA AND LEVODOPA, CARBIDOPA
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 COLESTIPOL HYDROCHLORIDE, COLESTIPOL HYDROCHLORIDE
 DANTROLENE SODIUM, DANTROLENE SODIUM
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DIGOXIN, DIGOXIN
 DIPYRIDAMOLE, DIPYRIDAMOLE
 FENOFIBRATE (MICRONIZED), FENOFIBRATE
 FENOFIBRATE, FENOFIBRATE
 FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
 METHYLTESTOSTERONE, METHYLTESTOSTERONE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 NADOLOL AND BENDROFLUMETHIAZIDE, BENDROFLUMETHIAZIDE
 OMEPRAZOLE, OMEPRAZOLE
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
 PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
 PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
 RILUZOLE, RILUZOLE
 RIMANTADINE HYDROCHLORIDE, RIMANTADINE HYDROCHLORIDE
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TERBUTALINE SULFATE, TERBUTALINE SULFATE

IMPAX LABS INC

* IMPAX LABORATORIES INC
 ACITRETIN, ACITRETIN
 ALBENZA, ALBENDAZOLE
 ALENDRONATE SODIUM, ALENDRONATE SODIUM
 BUDESONIDE, BUDESONIDE
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 CARVEDILOL PHOSPHATE, CARVEDILOL PHOSPHATE
 COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
 DEXEDRINE, DEXTROAMPHETAMINE SULFATE
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 DOXYCYCLINE, DOXYCYCLINE
 EMVERM, MEBENDAZOLE
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
 FENOFIBRIC ACID, CHOLINE FENOFIBRATE
 GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
 GLYBURIDE, GLYBURIDE
 HYDROCORTISONE, HYDROCORTISONE
 HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
 LAMOTRIGINE, LAMOTRIGINE
 LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 METHYLTESTOSTERONE, METHYLTESTOSTERONE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
 RYTARY, CARBIDOPA

IMPAX PHARMS

* IMPAX PHARMACEUTICALS
 GEMFIBROZIL, GEMFIBROZIL
 MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE

INCYTE CORP

* INCYTE CORP
 JAKAFI, RUXOLITINIB PHOSPHATE
 PEMAZYRE, PEMIGATINIB

INDICUS PHARMA

* INDICUS PHARMA LLC
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** I ****

* INDICUS PHARMA LLC
 LETROZOLE, LETROZOLE
 MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

INDIVIOR INC

* INDIVIOR INC
 BUPRENEX, BUPRENORPHINE HYDROCHLORIDE
 PERSERIS KIT, RISPERIDONE
 SUBLOCADE, BUPRENORPHINE
 SUBOXONE, BUPRENORPHINE HYDROCHLORIDE

INDOCO

* INDOCO REMEDIES LTD
 ALLOPURINOL, ALLOPURINOL
 APIXABAN, APIXABAN
 BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
 FEBUXOSTAT, FEBUXOSTAT
 OLANZAPINE, OLANZAPINE
 RASAGILINE MESYLATE, RASAGILINE MESYLATE
 SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE

INDOCO REMEDIES

* INDOCO REMEDIES LTD
 GLIMEPIRIDE, GLIMEPIRIDE

INFORLIFE

* INFORLIFE SA
 CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
 LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
 METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
 ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

INGENUS PHARMS LLC

* INGENUS PHARMACEUTICALS LLC
 ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
 CABERGOLINE, CABERGOLINE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
 DECITABINE, DECITABINE
 DOCETAXEL, DOCETAXEL
 MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
 OXALIPLATIN, OXALIPLATIN
 PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

INGENUS PHARMS NJ

* INGENUS PHARMACEUTICALS NJ LLC
 CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN

INNOCOLL PHARMS

* INNOCOLL PHARMACEUTICALS
 XARACOLL, BUPIVACAINE HYDROCHLORIDE

INNOGENIX

* INNOGENIX LLC
 BACLOFEN, BACLOFEN
 HALOPERIDOL, HALOPERIDOL
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 METRONIDAZOLE, METRONIDAZOLE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

INNOPHARMA

* INNOPHARMA LICENSING LLC A SUB OF PFIZER INC
 PROPOFOL, PROPOFOL

INSMED INC

* INSMED INC
 ARIKAYCE KIT, AMIKACIN SULFATE

INST BIOCHEM

* INSTITUT BIOCHEMIQUE SA

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** I ****

* INSTITUT BIOCHEMIQUE SA
FLECTOR, DICLOFENAC EPOLAMINE

INSTITUT BIOCHIMIQUE

* INSTITUT BIOCHIMIQUE SA (IBSA)
TIROSINT, LEVOTHYROXINE SODIUM
TIROSINT-SOL, LEVOTHYROXINE SODIUM

INTAS PHARMS USA

* INTAS PHARMACEUTICALS USA
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE

INTELLIPHARMACEUTICS

* INTELLIPHARMACEUTICS CORP
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

INTERCEPT PHARMS INC

* INTERCEPT PHARMACEUTICALS INC
OCALIVA, OBETICHOLIC ACID

INTERPHARMA PRAHA AS

* INTERPHARMA PRAHA AS
ORALTAG, IOHEXOL

INTERSECT ENT INC

* INTERSECT ENT INC
SINUVA, MOMETASONE FUROATE

INTL ISOTOPES

* INTERNATIONAL ISOTOPES INC
SODIUM IODIDE I 131, SODIUM IODIDE I-131

INTL MEDICATION

* INTERNATIONAL MEDICATION SYSTEM
LARYNG-O-JET KIT, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
PHYTONADIONE, PHYTONADIONE
PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE
* INTERNATIONAL MEDICATION SYSTEMS LTD
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE

INTL MEDICATION SYS

* INTERNATIONAL MEDICATION SYSTEMS LTD
ATROPINE SULFATE, ATROPINE SULFATE
CALCIUM CHLORIDE 10%, CALCIUM CHLORIDE
EPINEPHRINE, EPINEPHRINE
LORAZEPAM, LORAZEPAM
SODIUM BICARBONATE, SODIUM BICARBONATE

INTRA-CELLULAR

* INTRA-CELLULAR THERAPIES INC
CAPLYTA, LUMATEPERONE TOSYLATE

INVAGEN PHARMS

* INVAGEN PHARMACEUTICALS INC
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CALCIUM ACETATE, CALCIUM ACETATE
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** I ****

* INVAGEN PHARMACEUTICALS INC
 GABAPENTIN, GABAPENTIN
 GEMFIBROZIL, GEMFIBROZIL
 GLIMEPIRIDE, GLIMEPIRIDE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 LEVETIRACETAM, LEVETIRACETAM
 LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LISINOPRIL, LISINOPRIL
 MEPROBAMATE, MEPROBAMATE
 NABUMETONE, NABUMETONE
 NADOLOL, NADOLOL
 NAPROXEN, NAPROXEN
 OLANZAPINE, OLANZAPINE
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 PREGABALIN, PREGABALIN
 QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
 RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SEVELAMER CARBONATE, SEVELAMER CARBONATE
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
 TOPIRAMATE, TOPIRAMATE
 TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
 VIGABATRIN, VIGABATRIN
 WARFARIN SODIUM, WARFARIN SODIUM
 ZOLMITRIPTAN, ZOLMITRIPTAN
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
 ZONISAMIDE, ZONISAMIDE

INVATECH

* INVATECH PHARMA SOLUTIONS LLC
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE

INVENTIA

* INVENTIA HEALTHCARE LTD
 COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 LANSOPRAZOLE, LANSOPRAZOLE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 PALIPERIDONE, PALIPERIDONE
 TELMISARTAN, TELMISARTAN

INVENTIA HLTHCARE

* INVENTIA HEALTHCARE PRIVATE LTD
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

IONETIX

* IONETIX CORP
 AMMONIA N 13, AMMONIA N-13

IPCA LABS LTD

* IPCA LABORATORIES LTD
 ALLOPURINOL, ALLOPURINOL
 ATENOLOL, ATENOLOL
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
 CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
 FUROSEMIDE, FUROSEMIDE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** I ****

* IPCA LABORATORIES LTD
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 WARFARIN SODIUM, WARFARIN SODIUM

IPR

* IPR PHARMACEUTICALS INC
 CRESTOR, ROSUVASTATIN CALCIUM
 ZOMIG, ZOLMITRIPTAN

IPSEN INC

* IPSEN BIOPHARMACEUTICALS INC
 ONIVYDE, IRINOTECAN HYDROCHLORIDE

IPSEN PHARMA

* IPSEN PHARMA BIOTECH SAS
 SOMATULINE DEPOT, LANREOTIDE ACETATE

IRONSHORE PHARMS

* IRONSHORE PHARMACEUTICALS AND DEVELOPMENT INC
 JORNAY PM, METHYLPHENIDATE HYDROCHLORIDE

ISOTEX

* ISOTEX DIAGNOSTICS
 GLOFIL-125, IOTHALAMATE SODIUM I-125

ISTITUTO BIO ITA SPA

* ISTITUTO BIOCHIMICO ITALIANO SPA
 AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
 AMPICILLIN SODIUM, AMPICILLIN SODIUM
 NAFCILLIN SODIUM, NAFCILLIN SODIUM
 PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
 PIPERACILLIN, PIPERACILLIN SODIUM

ITALFARMACO SPA

* ITALFARMACO SPA
 TIGLUTIK KIT, RILUZOLE

IVAX PHARMS

* IVAX PHARMACEUTICALS INC
 VALSARTAN, VALSARTAN

IVAX SUB TEVA PHARMS

* IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA
 ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
 BACLOFEN, BACLOFEN
 CABERGOLINE, CABERGOLINE
 CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CIMETIDINE, CIMETIDINE (OTC)
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 CLOZAPINE, CLOZAPINE
 CYCLOSPORINE, CYCLOSPORINE
 DIAZEPAM, DIAZEPAM
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 FAMOTIDINE, FAMOTIDINE
 FLUCONAZOLE, FLUCONAZOLE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 GABAPENTIN, GABAPENTIN
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

**** J ******J AND J CONSUMER INC**

* JOHNSON AND JOHNSON CONSUMER INC MCNEIL CONSUMER HEALTHCARE DIVISION
 CHILDREN'S MOTRIN COLD, IBUPROFEN (OTC)
 CHILDREN'S MOTRIN, IBUPROFEN (OTC)
 CHILDREN'S ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 IMODIUM A-D, LOPERAMIDE HYDROCHLORIDE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** J ****

* JOHNSON AND JOHNSON CONSUMER INC MCNEIL CONSUMER HEALTHCARE DIVISION
 IMODIUM MULTI-SYMP TOM RELIEF, LOPERAMIDE HYDROCHLORIDE (OTC)
 JUNIOR STRENGTH MOTRIN, IBUPROFEN (OTC)
 MOTRIN IB, IBUPROFEN (OTC)
 PEPCID AC, FAMOTIDINE (OTC)
 PEPCID COMPLETE, CALCIUM CARBONATE (OTC)
 SINE-AID IB, IBUPROFEN (OTC)
 SUDAFED 24 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
 TYLENOL, ACETAMINOPHEN (OTC)
 ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 ZYRTEC-D 12 HOUR, CETIRIZINE HYDROCHLORIDE (OTC)

JACOBUS

* JACOBUS PHARMACEUTICAL CO
 DAPSONE, DAPSONE
 PASER, AMINOSALICYLIC ACID

JACOBUS PHARM CO INC

* JACOBUS PHARMACEUTICAL CO INC
 RUZURGI, AMIFAMPRIDINE

JANSSEN BIOTECH

* JANSSEN BIOTECH INC
 BALVERSA, ERDAFITINIB
 ERLEADA, APALUTAMIDE
 ZYTIGA, ABIRATERONE ACETATE

JANSSEN PHARMS

* JANSSEN PHARMACEUTICALS INC
 CONCERTA, METHYLPHENIDATE HYDROCHLORIDE
 DITROPAN XL, OXYBUTYNIN CHLORIDE
 DURAGESIC-100, FENTANYL
 DURAGESIC-12, FENTANYL
 DURAGESIC-25, FENTANYL
 DURAGESIC-37, FENTANYL
 DURAGESIC-50, FENTANYL
 DURAGESIC-75, FENTANYL
 ELMIRON, PENTOSAN POLYSULFATE SODIUM
 HALDOL, HALOPERIDOL DECANOATE
 INVEGA SUSTENNA, PALIPERIDONE PALMITATE
 INVEGA TRINZA, PALIPERIDONE PALMITATE
 INVEGA, PALIPERIDONE
 INVOKAMET XR, CANAGLIFLOZIN
 INVOKAMET, CANAGLIFLOZIN
 INVOKANA, CANAGLIFLOZIN
 RAZADYNE ER, GALANTAMINE HYDROBROMIDE
 RAZADYNE, GALANTAMINE HYDROBROMIDE
 RISPERDAL CONSTA, RISPERIDONE
 RISPERDAL, RISPERIDONE
 SPORANOX, ITRACONAZOLE
 SPRAVATO, ESKETAMINE HYDROCHLORIDE
 TOPAMAX, TOPIRAMATE
 ULTRACET, ACETAMINOPHEN
 ULTRAM, TRAMADOL HYDROCHLORIDE
 XARELTO, RIVAROXABAN

JANSSEN PRODS

* JANSSEN PRODUCTS LP
 EDURANT, RILPIVIRINE HYDROCHLORIDE
 PREZCOBIX, COBICISTAT
 PREZISTA, DARUNAVIR
 SYMTUZA, COBICISTAT
 YONDELIS, TRABECTEDIN

JANSSEN R AND D

* JANSSEN RESEARCH AND DEVELOPMENT LLC
 INTELENCE, ETRAVIRINE

JANSSEN THERAP

* JANSSEN THERAPEUTICS DIV JANSSEN PRODUCTS LP
 SIRTURO, BEDAQUILINE FUMARATE

JAZZ

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** J ****

* JAZZ PHARMACEUTICALS IRELAND LTD
 SUNOSI, SOLRIAMFETOL HYDROCHLORIDE
 XYWAV, CALCIUM OXYBATE
 ZEPZELCA, LURBINECTEDIN

JAZZ PHARMS

* JAZZ PHARMACEUTICALS INC
 XYREM, SODIUM OXYBATE

JAZZ PHARMS INC

* JAZZ PHARMACEUTICALS INC
 DEFITELIO, DEFIBROTIDE SODIUM

JDP

* JDP THERAPEUTICS LLC
 QUZYTIR, CETIRIZINE HYDROCHLORIDE

JIANGSU HANSOH PHARM

* JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 ICATIBANT ACETATE, ICATIBANT ACETATE
 VINOELBINE TARTRATE, VINOELBINE TARTRATE

JIANGSU HENGRUI MED

* JIANGSU HENGRUI MEDICINE CO LTD
 CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
 CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
 CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
 CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
 DAPTOMYCIN, DAPTOMYCIN
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DOCETAXEL, DOCETAXEL
 FONDAPARINUX SODIUM, FONDAPARINUX SODIUM
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 OXALIPLATIN, OXALIPLATIN
 THIOTEPA, THIOTEPA

JIANGXI BOYA SEEHOT

* JIANGXI BOYA SEEHOT PHARMACEUTICAL CO LTD
 SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE

JOHNS HOPKINS UNIV

* JOHNS HOPKINS UNIV
 AMMONIA N 13, AMMONIA N-13

JOHNSON AND JOHNSON

* JOHNSON AND JOHNSON CONSUMER INC
 VISINE L.R., OXYMETAZOLINE HYDROCHLORIDE (OTC)
 VISINE, NAPHAZOLINE HYDROCHLORIDE (OTC)
 * JOHNSON AND JOHNSON GROUP CONSUMER COMPANIES
 MEN'S ROGAINE, MINOXIDIL (OTC)
 ROGAINE (FOR MEN), MINOXIDIL (OTC)
 ROGAINE (FOR WOMEN), MINOXIDIL (OTC)
 ROGAINE EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
 WOMEN'S ROGAINE, MINOXIDIL (OTC)

JOURNEY

* JOURNEY MEDICAL CORP
 EXELDERM, SULCONAZOLE NITRATE
 XIMINO, MINOCYCLINE HYDROCHLORIDE

JUBILANT

* JUBILANT DRAXIMAGE INC DBA JUBILANT RADIOPHARMA
 DRAX EXAMETAZIME, TECHNETIUM TC-99M EXAMETAZIME KIT
 DRAXIMAGE DTPA, TECHNETIUM TC-99M PENTETATE KIT
 DRAXIMAGE MDP-25, TECHNETIUM TC-99M MEDRONATE
 HICON, SODIUM IODIDE I-131
 RUBY-FILL, RUBIDIUM CHLORIDE RB-82
 SODIUM IODIDE I 131, SODIUM IODIDE I-131

JUBILANT CADISTA

* JUBILANT CADISTA PHARMACEUTICALS INC
 ALENDRONATE SODIUM, ALENDRONATE SODIUM
 CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** J ****

- * JUBILANT CADISTA PHARMACEUTICALS INC
 - DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
 - HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 - LAMOTRIGINE, LAMOTRIGINE
 - MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
 - METHYLPREDNISOLONE, METHYLPREDNISOLONE
 - PREDNISONE, PREDNISONE
 - PROCOMP, PROCHLORPERAZINE MALEATE
 - SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 - TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE

JUBILANT DRAXIMAGE

- * JUBILANT DRAXIMAGE RADIOPHARMACIES INC
 - FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 - SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18
- * JUBILANT DRAXIMAGE USA INC
 - TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT

JUBILANT GENERICS

- * JUBILANT GENERICS LTD
 - AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 - AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
 - CELECOXIB, CELECOXIB
 - CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 - CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 - CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 - DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
 - DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 - ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 - FELODIPINE, FELODIPINE
 - INDOMETHACIN, INDOMETHACIN
 - IRBESARTAN, IRBESARTAN
 - ITRACONAZOLE, ITRACONAZOLE
 - LAMOTRIGINE, LAMOTRIGINE
 - LEVETIRACETAM, LEVETIRACETAM
 - LEVOFLOXACIN, LEVOFLOXACIN
 - MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 - NIACIN, NIACIN
 - OLANZAPINE, OLANZAPINE
 - PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 - QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 - RISPERIDONE, RISPERIDONE
 - RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 - SPIRONOLACTONE, SPIRONOLACTONE
 - TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 - VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 - VALSARTAN, VALSARTAN
 - ZOLMITRIPTAN, ZOLMITRIPTAN

STEVENS J

- * JEROME STEVENS PHARMACEUTICALS INC
 - BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
 - DIGOXIN, DIGOXIN
 - UNITHROID, LEVOTHYROXINE SODIUM **

**** K ******GRIFFEN**

- * KW GRIFFEN CO
 - BIOSCRUB, CHLORHEXIDINE GLUCONATE (OTC)

KADMON PHARMS LLC

- * KADMON PHARMACEUTICALS LLC
 - CLOVIQUE, TRIENTINE HYDROCHLORIDE
 - TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE

KAI PHARMS INC

- * KAI PHARMACEUTICALS INC A WHOLLY OWNED SUBSIDIARY OF AMGEN INC
 - PARSABIV, ETELCALCETIDE

KALA PHARMS INC

- * KALA PHARMACEUTICALS INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** K ****

* KALA PHARMACEUTICALS INC
EYSUVIS, LOTEPREDNOL ETABONATE
INVELTYS, LOTEPREDNOL ETABONATE

KALEO INC

* KALEO INC
AUVI-Q, EPINEPHRINE

KARYOPHARM THERAPS

* KARYOPHARM THERAPEUTICS INC
XPOVIO, SELINEXOR

KENTON

* KENTON CHEMICALS AND PHARMACEUTICALS CORP
ACYCLOVIR, ACYCLOVIR
ANASTROZOLE, ANASTROZOLE
BICALUTAMIDE, BICALUTAMIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
RILUZOLE, RILUZOLE

KERYX BIOPHARMS

* KERYX BIOPHARMACEUTICALS INC
AURYXIA, FERRIC CITRATE

KETTERING MEDCTR

* KETTERING MEDCTR
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

KINDEVA

* KINDEVA DRUG DELIVERY LP
FENTANYL-100, FENTANYL
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-75, FENTANYL
PROVENTIL-HFA, ALBUTEROL SULFATE

KINEDEXE

* KINEDEXE UK LTD
TRANLYCYPROMINE SULFATE, TRANLYCYPROMINE SULFATE

KING PHARMS

* KING PHARMACEUTICALS INC
SYNERCID, DALFOPRISTIN
* KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT LLC
CYTOMEL, LIOTHYRONINE SODIUM
LEVOXYL, LEVOTHYROXINE SODIUM **
* KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT LLC A SUB OF PFIZER INC
SKELAXIN, METAXALONE

KING PHARMS LLC

* KING PHARMACEUTICALS LLC
ALTACE, RAMIPRIL
BICILLIN C-R 900/300, PENICILLIN G BENZATHINE
BICILLIN C-R, PENICILLIN G BENZATHINE
BICILLIN L-A, PENICILLIN G BENZATHINE
CORZIDE, BENDROFLUMETHIAZIDE
PENICILLIN G PROCAINE, PENICILLIN G PROCAINE
SILVADENE, SILVER SULFADIAZINE
TAPAZOLE, METHIMAZOLE
TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE

KNIGHT THERAPS

* KNIGHT THERAPEUTICS USA INC
IMPAVIDO, MILTEFOSINE

KOWA CO

* KOWA CO LTD
LIVALO, PITAVASTATIN CALCIUM

KRAMER

* KRAMER LABORATORIES INC
NIZORAL A-D, KETOCONAZOLE (OTC)

KREITCHMAN PET CTR

* KREITCHMAN PET CENTER
AMMONIA N 13, AMMONIA N-13

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** K ****

* KREITCHMAN PET CENTER
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

KVK TECH

* KVK TECH INC
 BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
 BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 KALEXATE, SODIUM POLYSTYRENE SULFONATE
 PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE

KVK TECH INC

* KVK TECH INC
 APADAZ, ACETAMINOPHEN
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

KYOWA KIRIN

* KYOWA KIRIN INC
 FARESTON, TOREMIFENE CITRATE
 NOURIANZ, ISTRADefYLLINE
 SANCUSO, GRANISETRON

KYTHERA BIOPHARMS

* KYTHERA BIOPHARMACEUTICALS INC
 KYBELLA, DEOXYCHOLIC ACID

**** L ******L PERRIGO CO**

* L PERRIGO CO
 CIMETIDINE, CIMETIDINE (OTC)
 CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)
 IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)
 JUNIOR STRENGTH IBUPROFEN, IBUPROFEN (OTC)
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 LEVONORGESTREL, LEVONORGESTREL
 LEVONORGESTREL, LEVONORGESTREL (OTC)
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
 MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
 MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)

LA JOLLA PHARMA

* LA JOLLA PHARMA LLC
 GIAPREZA, ANGIOTENSIN II ACETATE

LAB HRA PHARMA

* LABORATOIRE HRA PHARMA
 ELLA, ULIPRISTAL ACETATE

LABORATOIRE HRA

* LABORATOIRE HRA PHARMA
 LEVONORGESTREL, LEVONORGESTREL (OTC)

LABORATORIOS GRIFOLS

* LABORATORIOS GRIFOLS SA
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

LABORATORIOS SALVAT

* LABORATORIOS SALVAT SA
 OTOVEL, CIPROFLOXACIN HYDROCHLORIDE

LANDELA PHARM

* LANDELA PHARMACEUTICAL
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE

LANNETT

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** L ****

* LANNETT CO INC

ACETAZOLAMIDE, ACETAZOLAMIDE
 DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
 DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
 LANORINAL, ASPIRIN
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 PRIMIDONE, PRIMIDONE
 PROBALAN, PROBENECID

LANNETT CO INC

* LANNETT CO INC

ALBUTEROL SULFATE, ALBUTEROL SULFATE
 ARIPIPIRAZOLE, ARIPIPIRAZOLE
 ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 BACLOFEN, BACLOFEN
 BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
 BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 CLOBAZAM, CLOBAZAM
 CODEINE SULFATE, CODEINE SULFATE
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
 DANAZOL, DANAZOL
 DEXAMETHASONE, DEXAMETHASONE
 DIAZEPAM, DIAZEPAM
 DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DOXYCYCLINE, DOXYCYCLINE
 DRONABINOL, DRONABINOL
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
 GLYCOLAX, POLYETHYLENE GLYCOL 3350 (OTC)
 HALOPERIDOL, HALOPERIDOL LACTATE
 HYDROCORTISONE, HYDROCORTISONE
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
 LACTULOSE, LACTULOSE
 LAMIVUDINE, LAMIVUDINE
 LANSOPRAZOLE, LANSOPRAZOLE
 LANSOPRAZOLE, LANSOPRAZOLE (OTC)
 LEVETIRACETAM, LEVETIRACETAM
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 LEVOFLOXACIN, LEVOFLOXACIN
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 LOPINAVIR AND RITONAVIR, LOPINAVIR
 LORATADINE, LORATADINE (OTC)
 LORAZEPAM, LORAZEPAM
 LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 METADATE CD, METHYLPHENIDATE HYDROCHLORIDE
 METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
 METAXALONE, METAXALONE
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 MONOKET, ISOSORBIDE MONONITRATE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** L ****

* LANNETT CO INC
 NIACIN, NIACIN
 NYSTATIN, NYSTATIN
 OMEPRAZOLE, OMEPRAZOLE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PREDNISOLONE, PREDNISOLONE
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RIFAMPIN, RIFAMPIN
 RISPERIDONE, RISPERIDONE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 SUMATRIPTAN, SUMATRIPTAN
 TERBUTALINE SULFATE, TERBUTALINE SULFATE
 THEOPHYLLINE, THEOPHYLLINE
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 URSODIOL, URSODIOL
 VALPROIC ACID, VALPROIC ACID
 ZAROXOLYN, METOLAZONE

LANTHEUS MEDCL

* LANTHEUS MEDICAL IMAGING INC
 CARDIOLITE, TECHNETIUM TC-99M SESTAMIBI KIT
 DEFINITY RT, PERFLUTREN
 DEFINITY, PERFLUTREN
 GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67
 NEUROLITE, TECHNETIUM TC-99M BICISATE KIT
 TECHNELITE, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
 THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
 XENON XE 133, XENON XE-133

LANTHEUS MEDICAL

* LANTHEUS MEDICAL IMAGING INC
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 QUADRAMET, SAMARIUM SM-153 LEXIDRONAM PENTASODIUM

LARKEN LABS

* LARKEN LABORATORIES INC
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE

LARKEN LABS INC

* LARKEN LABORATORIES INC
 ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE, ACETAMINOPHEN
 ALLZITAL, ACETAMINOPHEN
 BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
 DEXAMETHASONE, DEXAMETHASONE

LAURUS LABS LTD

* LAURUS LABS LTD
 EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

LEADIANT BIOSCI INC

* LEADIANT BIOSCIENCES INC
 ABELCET, AMPHOTERICIN B
 CARNITOR SF, LEVOCARNITINE
 CARNITOR, LEVOCARNITINE
 CYSTARAN, CYSTEAMINE HYDROCHLORIDE
 MATULANE, PROCARBAZINE HYDROCHLORIDE

LEADING PHARMA LLC

* LEADING PHARMA LLC
 BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
 CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
 DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** L ****

* LEADING PHARMA LLC
 FOLIC ACID, FOLIC ACID
 FUROSEMIDE, FUROSEMIDE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 HYDROXYUREA, HYDROXYUREA
 IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
 LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
 LORAZEPAM, LORAZEPAM
 NIFEDIPINE, NIFEDIPINE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

LEO PHARMA AS

* LEO PHARMA AS
 DESONATE, DESONIDE
 DOVONEX, CALCIPOTRIENE
 ENSTILAR, BETAMETHASONE DIPROPIONATE
 FINACEA, AZELAIC ACID
 PROTOPIC, TACROLIMUS
 TACLONEX, BETAMETHASONE DIPROPIONATE

LG CHEM LTD

* LG CHEM LTD
 FACTIVE, GEMIFLOXACIN MESYLATE

LGM PHARMA

* LGM PHARMA SOLUTIONS LLC
 BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
 BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
 CHENODIOL, CHENODIOL
 GLYCOPYRROLATE, GLYCOPYRROLATE
 MECAMYLAMINE HYDROCHLORIDE, MECAMYLAMINE HYDROCHLORIDE
 NABUMETONE, NABUMETONE
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 URSODIOL, URSODIOL

LIEBEL-FLARSHEIM

* LIEBEL-FLARSHEIM CO LLC
 CONRAY, IOTHALAMATE MEGLUMINE
 CYSTO-CONRAY II, IOTHALAMATE MEGLUMINE
 MD-GASTROVIEW, DIATRIZOATE MEGLUMINE
 OPTIRAY 240, IOVERSOL
 OPTIRAY 300, IOVERSOL
 OPTIRAY 320, IOVERSOL
 OPTIRAY 350, IOVERSOL
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

LIFE MOLECULAR

* LIFE MOLECULAR IMAGING SA
 NEURACEQ, FLORBETABEN F-18

LNK

* LNK INTERNATIONAL INC
 DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
 IBUPROFEN, IBUPROFEN (OTC)
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)

LNK INTL INC

* LNK INTERNATIONAL INC
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)

LOREAL USA

* LOREAL USA PRODUCTS INC
 ANTHELIOS 20, AVOBENZONE (OTC)
 ANTHELIOS 40, AVOBENZONE (OTC)
 ANTHELIOS SX, AVOBENZONE (OTC)
 CAPITAL SOLEIL 15, AVOBENZONE (OTC)

LOTUS PHARM CO LTD

* LOTUS PHARMACEUTICAL CO LTD
 LEVETIRACETAM, LEVETIRACETAM
 * LOTUS PHARMACEUTICAL CO LTD NANTOU PLANT

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** L ****

* LOTUS PHARMACEUTICAL CO LTD NANTOU PLANT
LEVETIRACETAM, LEVETIRACETAM

LOXO ONCOLOGY INC

* LOXO ONCOLOGY INC
RETEVMO, SELPERCATINIB

LUITPOLD

* LUITPOLD PHARMACEUTICALS INC
AMINOCAPROIC ACID, AMINOCAPROIC ACID
BUSULFAN, BUSULFAN

LUKARE MEDICAL LLC

* LUKARE MEDICAL LLC
ELLIOTTS B SOLUTION, CALCIUM CHLORIDE

LUNDBECK NA LTD

* LUNDBECK NA LTD
NORTHERA, DROXIDOPA

LUNDBECK PHARMS LLC

* LUNDBECK PHARMACEUTICALS LLC
ONFI, CLOBAZAM
SABRIL, VIGABATRIN

LUPIN

* LUPIN INC
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ANTARA (MICRONIZED), FENOFIBRATE
BUDESONIDE, BUDESONIDE
DESOXIMETASONE, DESOXIMETASONE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM **
MIBELAS 24 FE, ETHINYL ESTRADIOL
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NYSTATIN, NYSTATIN
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
QUINARETIC, HYDROCHLOROTHIAZIDE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SOLOSEC, SECNIDAZOLE
TESTOSTERONE, TESTOSTERONE
TOBRAMYCIN, TOBRAMYCIN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE

* LUPIN LTD
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
CARVEDILOL, CARVEDILOL
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFDINIR, CEFDINIR
CEFPROZIL, CEFPROZIL
CEFTRIAZONE, CEFTRIAZONE SODIUM
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEPHALEXIN, CEPHALEXIN
DIVALPROEX SODIUM, DIVALPROEX SODIUM
ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN, LEVOFLOXACIN
LISINAPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINAPRIL, LISINAPRIL
LOVASTATIN, LOVASTATIN
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RAMIPRIL, RAMIPRIL
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN
TRANDOLAPRIL, TRANDOLAPRIL

LUPIN ATLANTIS

* LUPIN ATLANTIS HOLDINGS SA
DIMETHYL FUMARATE, DIMETHYL FUMARATE

LUPIN LTD

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** L ****

* LUPIN LIMITED
 LEVETIRACETAM, LEVETIRACETAM
 LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL

* LUPIN LTD
 ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
 ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE, ABACAVIR SULFATE
 ALBENDAZOLE, ALBENDAZOLE
 AMABELZ, ESTRADIOL
 AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
 ARMODAFINIL, ARMODAFINIL
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 ATOVAQUONE, ATOVAQUONE
 AZITHROMYCIN, AZITHROMYCIN
 BEKYREE, DESOGESTREL
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 BIMATOPROST, BIMATOPROST
 BLISOVI 24 FE, ETHINYL ESTRADIOL
 BLISOVI FE 1.5/30, ETHINYL ESTRADIOL
 BLISOVI FE 1/20, ETHINYL ESTRADIOL
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CALCIUM ACETATE, CALCIUM ACETATE
 CELECOXIB, CELECOXIB
 CLOBAZAM, CLOBAZAM
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
 DAYSEE, ETHINYL ESTRADIOL
 DECITABINE, DECITABINE
 DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DOXERCALCIFEROL, DOXERCALCIFEROL
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DOXYCYCLINE, DOXYCYCLINE
 DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
 DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM, DROSPIRENONE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 ENSKYCE, DESOGESTREL
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 ESZOPICLONE, ESZOPICLONE
 ETHACRYNIC ACID, ETHACRYNIC ACID
 FALLBACK SOLO, LEVONORGESTREL (OTC)
 FAMOTIDINE, FAMOTIDINE
 FENOFIBRATE, FENOFIBRATE
 FENOFIBRIC ACID, CHOLINE FENOFIBRATE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
 FYAVOLV, ETHINYL ESTRADIOL
 GATIFLOXACIN, GATIFLOXACIN
 HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
 HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRBESARTAN, IRBESARTAN
 JENCYCLA, NORETHINDRONE
 KAITLIB FE, ETHINYL ESTRADIOL
 KETOROLAC TROMETHAMINE AND PHENYLEPHRINE HYDROCHLORIDE, KETOROLAC TROMETHAMINE
 KURVELO, ETHINYL ESTRADIOL
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
 LAMIVUDINE, LAMIVUDINE
 LAMOTRIGINE, LAMOTRIGINE
 LEFLUNOMIDE, LEFLUNOMIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** L ******* LUPIN LTD**

LEVETIRACETAM, LEVETIRACETAM
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LORAZEPAM, LORAZEPAM
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 MEFENAMIC ACID, MEFENAMIC ACID
 MELOXICAM, MELOXICAM
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METRONIDAZOLE, METRONIDAZOLE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 NABUMETONE, NABUMETONE
 NADOLOL, NADOLOL
 NIACIN, NIACIN
 NIKKI, DROSPIRENONE
 NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 NORETHINDRONE, NORETHINDRONE
 NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PENICILLAMINE, PENICILLAMINE
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 PIRMELLA 1/35, ETHINYL ESTRADIOL
 PIRMELLA 7/7/7, ETHINYL ESTRADIOL
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 QUININE SULFATE, QUININE SULFATE
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 RANOLAZINE, RANOLAZINE
 RIFABUTIN, RIFABUTIN
 RUFINAMIDE, RUFINAMIDE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SILODOSIN, SILODOSIN
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 SUPRAX, CEFIXIME
 TADALAFIL, TADALAFIL
 TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
 TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TESTOSTERONE, TESTOSTERONE
 TETRABENAZINE, TETRABENAZINE
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE
 TYDEMY, DROSPIRENONE
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 VALSARTAN, VALSARTAN
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VYFEMLA, ETHINYL ESTRADIOL
 ZILEUTON, ZILEUTON
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

LUPIN PHARMS

*** LUPIN PHARMACEUTICALS INC**
 AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
 DESLORATADINE, DESLORATADINE
 MELOXICAM, MELOXICAM
 NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 RIFAMPIN, RIFAMPIN
 SUPRAX, CEFIXIME
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

LYMOL MEDCL

*** LYMOL MEDICAL CORP**
 SCLEROSOL, TALC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** L ****

* LYMOL MEDICAL CORP
TALC, TALC

LYNE

* LYNE LABORATORIES INC
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DEXAMETHASONE, DEXAMETHASONE
ERYTHROMYCIN AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
LEVOCARNITINE, LEVOCARNITINE
NYSTATIN, NYSTATIN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

PERRIGO

* L PERRIGO CO
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC)
CHILDREN'S IBUPROFEN, IBUPROFEN (OTC)
CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
FAMOTIDINE, FAMOTIDINE (OTC)
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
LORATADINE, LORATADINE (OTC)
MICONAZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
TAB-PROFEN, IBUPROFEN (OTC)
TIOCONAZOLE, TIOCONAZOLE (OTC)

**** M ******MA GENERAL HOSP**

* MASSACHUSETTS GENERAL HOSP
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

MACLEODS PHARMS LTD

* MACLEODS PHARMACEUTICALS LTD
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
ARIPIRAZOLE, ARIPIRAZOLE
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
CELECOXIB, CELECOXIB
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DARIFENACIN, DARIFENACIN HYDROBROMIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ENTACAPONE, ENTACAPONE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESZOPICLONE, ESZOPICLONE
FAMCICLOVIR, FAMCICLOVIR
FLUOCINONIDE, FLUOCINONIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMIVUDINE, LAMIVUDINE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LEVOFLOXACIN, LEVOFLOXACIN
LIDOCAINE, LIDOCAINE
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MACLEODS PHARMACEUTICALS LTD
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 NEVIRAPINE, NEVIRAPINE
 OLANZAPINE, OLANZAPINE
 OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
 OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
 PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 PYRAZINAMIDE, PYRAZINAMIDE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RISEDRONATE SODIUM, RISEDRONATE SODIUM
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SILODOSIN, SILODOSIN
 TADALAFIL, TADALAFIL
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
 TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 VALSARTAN, VALSARTAN
 VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

MAIA PHARMS INC

* MAIA PHARMACEUTICALS INC
 ANGIOMAX RTU, BIVALIRUDIN
 BACLOFEN, BACLOFEN
 LEVOTHYroxINE SODIUM, LEVOTHYroxINE SODIUM
 SODIUM PHENYLACETATE AND SODIUM BENZOATE, SODIUM BENZOATE

MAINPOINTE

* MAINPOINTE PHARMACEUTICALS LLC
 TUXARIN ER, CHLORPHENIRAMINE MALEATE

MALLINCKRODT ARD

* MALLINCKRODT ARD INC
 H.P. ACTHAR GEL, CORTICOTROPIN

MALLINCKRODT HOSP

* MALLINCKRODT HOSP PRODUCTS IP LTD
 INOMAX, NITRIC OXIDE
 OFIRMEV, ACETAMINOPHEN
 UVADEX, METHOXSALEN

MANKIND PHARMA

* MANKIND PHARMA LTD
 ACETAZOLAMIDE, ACETAZOLAMIDE
 ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
 CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
 FENOFIBRATE, FENOFIBRATE
 RANOLAZINE, RANOLAZINE

MARKSANS PHARMA

* MARKSANS PHARMA LTD
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
 DULOxETINE HYDROCHLORIDE, DULOxETINE HYDROCHLORIDE
 DUTASTERIDE, DUTASTERIDE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 GABAPENTIN, GABAPENTIN
 IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)
 LORATADINE, LORATADINE (OTC)
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MARKSANS PHARMA LTD
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
 NAPROXEN, NAPROXEN
 PARICALCITOL, PARICALCITOL

MARNEL PHARMS

* MARNEL PHARMACEUTICALS LLC
 ALA-SCALP, HYDROCORTISONE
 CROTAN, CROTAMITON

MAYNE PHARMA

* MAYNE PHARMA INTERNATIONAL PTY LTD
 DORYX MPC, DOXYCYCLINE HYCLATE
 DORYX, DOXYCYCLINE HYCLATE
 ERYC, ERYTHROMYCIN

* MAYNE PHARMA LLC
 AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
 BUDESONIDE, BUDESONIDE
 CAMILA, NORETHINDRONE
 CARBIDOPA AND LEVODOPA, CARBIDOPA
 CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
 CHLORZOXAZONE, CHLORZOXAZONE
 CLARITHROMYCIN, CLARITHROMYCIN
 CLONIDINE, CLONIDINE
 CLOZAPINE, CLOZAPINE
 CYCLOSPORINE, CYCLOSPORINE
 DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 DIAZEPAM, DIAZEPAM
 DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
 DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
 ERRIN, NORETHINDRONE
 ESTAZOLAM, ESTAZOLAM
 ESTRADIOL, ESTRADIOL
 FABIOR, TAZAROTENE
 FLUOROURACIL, FLUOROURACIL
 LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LEVORA 0.15/30-28, ETHINYL ESTRADIOL
 LEXETTE, HALOBETASOL PROPIONATE
 LOW-OGESTREL-28, ETHINYL ESTRADIOL
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 MICROGESTIN 1.5/30, ETHINYL ESTRADIOL
 MICROGESTIN 1/20, ETHINYL ESTRADIOL
 MICROGESTIN FE 1.5/30, ETHINYL ESTRADIOL
 MICROGESTIN FE 1/20, ETHINYL ESTRADIOL
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
 SORILUX, CALCIPOTRIENE
 TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
 TOLCAPONE, TOLCAPONE
 TRI-NORINYL 28-DAY, ETHINYL ESTRADIOL
 TRIMETHOPRIM, TRIMETHOPRIM
 TRIVORA-28, ETHINYL ESTRADIOL
 ZOVIA 1/35E-28, ETHINYL ESTRADIOL

MAYNE PHARMA INC

* MAYNE PHARMA INC
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
 DOFETILIDE, DOFETILIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MAYNE PHARMA INC
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DOXYCYCLINE, DOXYCYCLINE
 LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
 METHAMPHETAMINE HYDROCHLORIDE, METHAMPHETAMINE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 NYSTATIN, NYSTATIN
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE AND ASPIRIN, ASPIRIN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 SOLTAMOX, TAMOXIFEN CITRATE

MAYNE PHARMA INTL

* MAYNE PHARMA INTERNATIONAL PTY LTD
 TOLSURA, ITRACONAZOLE

MC2

* MC2 THERAPEUTICS LTD
 WYNZORA, BETAMETHASONE DIPROPIONATE

MCGUFF

* MCGUFF PHARMACEUTICALS INC
 ASCOR, ASCORBIC ACID

MCNEIL

* MCNEIL CONSUMER PRODUCTS CO DIV MCNEILAB INC
 IBUPROFEN, IBUPROFEN (OTC)

MCNEIL CONS

* MCNEIL CONSUMER HEALTHCARE
 SUDAFED 12 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)

MCPRF

* MAYO CLINIC PET RADIOCHEMISTRY FACILITY
 AMMONIA N 13, AMMONIA N-13
 CHOLINE C-11, CHOLINE C-11
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

MDD US

* MDD US OPERATIONS LLC
 APOKYN, APOMORPHINE HYDROCHLORIDE
 XADAGO, SAFINAMIDE MESYLATE

MDGH

* MEDICINES DEVELOPMENT FOR GLOBAL HEALTH
 MOXIDECTIN, MOXIDECTIN

MEDEFIL INC

* MEDEFIL INC
 CALCIUM CHLORIDE 10%, CALCIUM CHLORIDE
 SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE
 STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION

MEDEXUS

* MEDEXUS PHARMA INC
 RASUVO, METHOTREXATE

MEDICINES360

* MEDICINES360
 LILETTA, LEVONORGESTREL

MEDICIS

* MEDICIS PHARMACEUTICAL CORP
 CALCIUM DISODIUM VERSENATE, EDETATE CALCIUM DISODIUM
 LUZU, LULICONAZOLE
 SOLODYN, MINOCYCLINE HYDROCHLORIDE
 VANOS, FLUOCINONIDE
 ZIANA, CLINDAMYCIN PHOSPHATE

MEDICURE

* MEDICURE INTERNATIONAL INC
 AGGRASTAT, TIROFIBAN HYDROCHLORIDE
 SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
 ZYPITAMAG, PITAVASTATIN MAGNESIUM

MEDIMETRIKS PHARMS

* MEDIMETRIKS PHARMACEUTICALS INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MEDIMETRIKS PHARMACEUTICALS INC
 BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
 LOPROX, CICLOPIROX
 NEO-SYNALAR, FLUOCINOLONE ACETONIDE
 SYNALAR, FLUOCINOLONE ACETONIDE

MEDLINE INDUSTRIES

* MEDLINE INDUSTRIES INC
 READYPREP CHG, CHLORHEXIDINE GLUCONATE (OTC)

MEDTECH PRODUCTS

* MEDTECH PRODUCTS INC
 MONISTAT 1 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
 MONISTAT 3 COMBINATION PACK (PREFILLED), MICONAZOLE NITRATE (OTC)
 MONISTAT 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
 MONISTAT 3, MICONAZOLE NITRATE
 MONISTAT 3, MICONAZOLE NITRATE (OTC)
 MONISTAT 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
 MONISTAT 7, MICONAZOLE NITRATE (OTC)
 NIX, PERMETHRIN (OTC)
 TAGAMET HB, CIMETIDINE (OTC)

MEITHEAL

* MEITHEAL PHARMACEUTICALS INC
 ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
 ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
 AZACITIDINE, AZACITIDINE
 BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
 BUSULFAN, BUSULFAN
 CARBOPLATIN, CARBOPLATIN
 CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
 CYTARABINE, CYTARABINE
 DOXERCALCIFEROL, DOXERCALCIFEROL
 LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
 MILRINONE LACTATE, MILRINONE LACTATE
 PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE

MELINTA

* MELINTA SUBSIDIARY CORP
 BAXDELA, DELAFLOXACIN MEGLUMINE

MELINTA THERAP

* MELINTA THERAPEUTICS INC
 ORBACTIV, ORITAVANCIN DIPHOSPHATE

MEM SLOAN-KETTERING

* MEMORIAL SLOAN-KETTERING CANCER CENTER
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

MERCK

* MERCK AND CO INC
 CANCIDAS, CASPOFUNGIN ACETATE
 EMEND, APREPITANT
 FOSAMAX PLUS D, ALENDRONATE SODIUM
 MAXALT, RIZATRIPTAN BENZOATE
 MAXALT-MLT, RIZATRIPTAN BENZOATE
 PRIMAXIN, CILASTATIN SODIUM
 PROSCAR, FINASTERIDE
 ZOLINZA, VORINOSTAT
 * MERCK RESEARCH LABORATORIES DIV MERCK CO INC
 PRINIVIL, LISINOPRIL
 PROPECIA, FINASTERIDE
 SINGULAIR, MONTELUKAST SODIUM
 TRUSOPT, DORZOLAMIDE HYDROCHLORIDE

MERCK AND CO INC

* MERCK AND CO INC
 EMEND, FOSAPREPITANT DIMEGLUMINE
 FOSAMAX, ALENDRONATE SODIUM

MERCK SHARP DOHME

* MERCK SHARP AND DOHME CORP
 ASMANEX HFA, MOMETASONE FUROATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

- * MERCK SHARP AND DOHME CORP
 ASMANEX TWISTHALER, MOMETASONE FUROATE
 BELSOMRA, SUVOREXANT
 CELESTONE SOLUSPAN, BETAMETHASONE ACETATE
 CLARINEX, DESLORATADINE
 CLARINEX-D 12 HOUR, DESLORATADINE
 DIPROLENE, BETAMETHASONE DIPROPIONATE
 DULERA, FORMOTEROL FUMARATE
 ELOCON, MOMETASONE FUROATE
 INVANZ, ERTAPENEM SODIUM
 ISENTRESS HD, RALTEGRAVIR POTASSIUM
 ISENTRESS, RALTEGRAVIR POTASSIUM
 JANUMET XR, METFORMIN HYDROCHLORIDE
 JANUMET, METFORMIN HYDROCHLORIDE
 JANUVIA, SITAGLIPTIN PHOSPHATE
 LOTRISONE, BETAMETHASONE DIPROPIONATE
 NASONEX, MOMETASONE FUROATE
 NOXAFIL, POSACONAZOLE
 PREVYMIS, LETERMOVIR
 REBETOL, RIBAVIRIN
 SEGLUROMET, ERTUGLIFLOZIN
 SINEMET, CARBIDOPA
 STEGLATRO, ERTUGLIFLOZIN
 STEGLUJAN, ERTUGLIFLOZIN
 STROMEKTOL, IVERMECTIN
 TEMODAR, TEMOZOLOMIDE
 ZEPATIER, ELBASVIR
- MERIDIAN MEDCL**
- * MERIDIAN MEDICAL TECHNOLOGIES INC
 DUODOTE, ATROPINE
- MERIDIAN MEDCL TECHN**
- * MERIDIAN MEDICAL TECHNOLOGIES INC
 ATROPEN, ATROPINE
 SEIZALAM, MIDAZOLAM HYDROCHLORIDE
- MERRO PHARM**
- * MERRO PHARMACEUTICAL CO LTD
 IBUPROFEN, IBUPROFEN (OTC)
- MERZ PHARMS**
- * MERZ PHARMACEUTICALS LLC
 CUVPOSA, GLYCOPYRROLATE
- METACEL PHARMS LLC**
- * METACEL PHARMACEUTICALS LLC
 OZOBAX, BACLOFEN
- METHAPHARM**
- * METHAPHARM INC
 PROVOCHOLINE, METHACHOLINE CHLORIDE
- METUCHEN PHARMS**
- * METUCHEN PHARMACEUTICALS LLC
 STENDRA, AVANAFIL
- MICRO LABS**
- * MICRO LABS LTD
 AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
 BIMATOPROST, BIMATOPROST
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CAFFEINE CITRATE, CAFFEINE CITRATE
 CELECOXIB, CELECOXIB
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 CLOBAZAM, CLOBAZAM
 CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
 DALFAMPRIDINE, DALFAMPRIDINE
 DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
 DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
 FENOFIBRIC ACID, CHOLINE FENOFIBRATE
 GLIMEPIRIDE, GLIMEPIRIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MICRO LABS LTD
 LEVETIRACETAM, LEVETIRACETAM
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 MEFENAMIC ACID, MEFENAMIC ACID
 METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
 OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
 PIROXICAM, PIROXICAM
 RANOLAZINE, RANOLAZINE
 RASAGILINE MESYLATE, RASAGILINE MESYLATE
 SIMVASTATIN, SIMVASTATIN
 SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
 SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
 TAFLUPROST, TAFLUPROST
 TELMISARTAN, TELMISARTAN
 TRANEXAMIC ACID, TRANEXAMIC ACID
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

MICRO LABS LTD

* MICRO LABS LTD
 NEVIRAPINE, NEVIRAPINE

MICRO LABS LTD INDIA

* MICRO LABS LTD INDIA
 ACETAZOLAMIDE, ACETAZOLAMIDE
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 CROMOLYN SODIUM, CROMOLYN SODIUM
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 LEVOFLOXACIN, LEVOFLOXACIN
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE (OTC)
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN

MIDWEST MEDCL

* MIDWEST MEDICAL ISOTOPES LLC CYCLOTRON DIV
 AMMONIA N 13, AMMONIA N-13
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

MIKART

* MIKART LLC
 BENZONATATE, BENZONATATE
 BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 BUTAPAP, ACETAMINOPHEN
 CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
 CHLORZOAZONE, CHLORZOAZONE
 ERGOTAMINE TARTRATE AND CAFFEINE, CAFFEINE
 ETHOSUXIMIDE, ETHOSUXIMIDE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 METHAZOLAMIDE, METHAZOLAMIDE
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
 TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE

MIKART INC

* MIKART INC
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN

MILLENNIUM PHARMS

* MILLENNIUM PHARMACEUTICALS INC
 NINLARO, IXAZOMIB CITRATE
 VELCADE, BORTEZOMIB

MILLICENT

* MILLICENT HOLDINGS LTD
 FEMRING, ESTRADIOL ACETATE
 * MILLICENT PHARMA LTD
 INTRAROSA, PRASTERONE

MIPS CRF

* MIPS CYCLOTRON AND RADIOCHEMISTRY FACILITY
 AMMONIA N 13, AMMONIA N-13

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MIPS CYCLOTRON AND RADIOCHEMISTRY FACILITY
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

MISEMER

* MISEMER PHARMACEUTICALS INC
 CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE

MISSION PHARMA

* MISSION PHARMACAL CO
 LITHOSTAT, ACETOHYDROXAMIC ACID
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 TEXACORT, HYDROCORTISONE
 THIOLA, TIOPRONIN
 TINDAMAX, TINIDAZOLE
 UROCIT-K, POTASSIUM CITRATE

MISSION PHARMACAL CO

* MISSION PHARMACAL CO
 CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
 POTASSIUM IODIDE, POTASSIUM IODIDE (OTC)
 THIOLA EC, TIOPRONIN

MITSUBISHI TANABE

* MITSUBISHI TANABE PHARMA CORP
 RADICAVA, EDARAVONE

MLV

* MLV PHARMA LLC
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

MOBIUS THERAP

* MOBIUS THERAPEUTICS LLC
 MITOSOL, MITOMYCIN

MOLNLYCKE HLTH

* MOLNLYCKE HEALTH CARE
 HIBICLENS, CHLORHEXIDINE GLUCONATE (OTC)
 HIBISTAT, CHLORHEXIDINE GLUCONATE (OTC)

MONARCH PHARMS

* MONARCH PHARMACEUTICALS LLC
 CORTISPORIN, BACITRACIN ZINC
 CORTISPORIN, HYDROCORTISONE ACETATE
 MENEST, ESTROGENS, ESTERIFIED
 NEOSPORIN G.U. IRRIGANT, NEOMYCIN SULFATE
 NEOSPORIN, GRAMICIDIN
 SEPTRA DS, SULFAMETHOXAZOLE
 SEPTRA, SULFAMETHOXAZOLE
 VIROPTIC, TRIFLURIDINE

MONTEREY PHARMS LLC

* MONTEREY PHARMACEUTICALS LLC
 METHOCARBAMOL, METHOCARBAMOL

MOUNTAIN

* MOUNTAIN LLC
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
 GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
 METAXALONE, METAXALONE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE

MSD INTL

* MSD INTERNATIONAL GMBH
 VYTORIN, EZETIMIBE

MSD INTL GMBH

* MSD INTERNATIONAL GMBH
 ZETIA, EZETIMIBE

MSD MERCK CO

* MERCK SHARP AND DOHME CORP A SUB OF MERCK AND CO INC
 DELSTRIGO, DORAVIRINE
 EMEND, APREPITANT

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MERCK SHARP AND DOHME CORP A SUB OF MERCK AND CO INC
 PIFELTRO, DORAVIRINE
 RECARBRIO, CILASTATIN SODIUM
 SINGULAIR, MONTELUKAST SODIUM
 ZOCOR, SIMVASTATIN

MSN

* MSN LABORATORIES PRIVATE LTD
 ABIRATERONE ACETATE, ABIRATERONE ACETATE
 AMINOCAPROIC ACID, AMINOCAPROIC ACID
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 CAPECITABINE, CAPECITABINE
 CLOFARABINE, CLOFARABINE
 DECITABINE, DECITABINE
 DEFERASIROX, DEFERASIROX
 DIMETHYL FUMARATE, DIMETHYL FUMARATE
 DOFETILIDE, DOFETILIDE
 FEBUXOSTAT, FEBUXOSTAT
 FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
 PACLITAXEL, PACLITAXEL
 PREGABALIN, PREGABALIN
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 SILODOSIN, SILODOSIN
 SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
 THIOTEPA, THIOTEPA
 TOREMIFENE CITRATE, TOREMIFENE CITRATE
 TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE

MURTY PHARMS

* MURTY PHARMACEUTICALS INC
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 DIPYRIDAMOLE, DIPYRIDAMOLE

MYLAN

* MYLAN PHARMACEUTICALS
 METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

* MYLAN PHARMACEUTICALS INC
 ABIRATERONE ACETATE, ABIRATERONE ACETATE
 ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
 ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE
 ACETAMINOPHEN, ACETAMINOPHEN
 ACITRETIN, ACITRETIN
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 ALLOPURINOL, ALLOPURINOL
 ALMOTRIPTAN MALATE, ALMOTRIPTAN MALATE
 ALPRAZOLAM, ALPRAZOLAM
 AMBRISENTAN, AMBRISENTAN
 AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
 AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
 AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
 ATENOLOL, ATENOLOL
 ATOVAQUONE AND PROGUANIL HYDROCHLORIDE, ATOVAQUONE
 AVITA, TRETINOIN
 BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
 BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
 BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
 BUDESONIDE, BUDESONIDE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
 CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
 CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
 CAPECITABINE, CAPECITABINE
 CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
 CAPTOPRIL, CAPTOPRIL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MYLAN PHARMACEUTICALS INC
 CARBIDOPA AND LEVODOPA, CARBIDOPA
 CARVEDILOL, CARVEDILOL
 CELECOXIB, CELECOXIB
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
 CHLORTHALIDONE, CHLORTHALIDONE
 CIMETIDINE, CIMETIDINE
 CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 CLOBAZAM, CLOBAZAM
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
 CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
 CLOZAPINE, CLOZAPINE
 COLCHICINE, COLCHICINE
 CYSTAGON, CYSTEAMINE BITARTRATE
 DENAVIR, PENCICLOVIR
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DIAZEPAM, DIAZEPAM
 DICLOFENAC SODIUM, DICLOFENAC SODIUM (OTC)
 DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DIMETHYL FUMARATE, DIMETHYL FUMARATE
 DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
 DOXYCYCLINE HCLATE, DOXYCYCLINE HCLATE
 EFAVIRENZ, EFAVIRENZ
 ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
 ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
 ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
 ERYGEL, ERYTHROMYCIN
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
 ESTRADIOL, ESTRADIOL
 ETOPOSIDE, ETOPOSIDE
 EVEROLIMUS, EVEROLIMUS
 EVOCLIN, CLINDAMYCIN PHOSPHATE
 EXEMESTANE, EXEMESTANE
 EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
 EXTINA, KETOCONAZOLE
 EZETIMIBE AND SIMVASTATIN, EZETIMIBE
 FEBUXOSTAT, FEBUXOSTAT
 FENOFIBRATE, FENOFIBRATE
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FOSAMPRENAVIR CALCIUM, FOSAMPRENAVIR CALCIUM
 FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE
 FUROSEMIDE, FUROSEMIDE
 GATIFLOXACIN, GATIFLOXACIN
 GLATIRAMER ACETATE, GLATIRAMER ACETATE
 GLIPIZIDE, GLIPIZIDE
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 HALCINONIDE, HALCINONIDE
 HALOPERIDOL, HALOPERIDOL
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 IMATINIB MESYLATE, IMATINIB MESYLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MYLAN PHARMACEUTICALS INC
 IMPEKLO, CLOBETASOL PROPIONATE
 INDAPAMIDE, INDAPAMIDE
 KETOCONAZOLE, KETOCONAZOLE
 KETOPROFEN, KETOPROFEN
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LANSOPRAZOLE, LANSOPRAZOLE
 LANSOPRAZOLE, LANSOPRAZOLE (OTC)
 LEVETIRACETAM, LEVETIRACETAM
 LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM **
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
 LORATADINE, LORATADINE (OTC)
 LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
 LUXIQ, BETAMETHASONE VALERATE
 MAPROTILINE HYDROCHLORIDE, MAPROTILINE HYDROCHLORIDE
 MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 MENTAX, BUTENAFINE HYDROCHLORIDE
 MERCAPTOPYRINE, MERCAPTOPYRINE
 MESALAMINE, MESALAMINE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHIMAZOLE, METHIMAZOLE
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 METHYLDOPA, METHYLDOPA
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 METOLAZONE, METOLAZONE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MIRTAZAPINE, MIRTAZAPINE
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 NADOLOL, NADOLOL
 NEVIRAPINE, NEVIRAPINE
 NIFEDIPINE, NIFEDIPINE
 NISOLDIPINE, NISOLDIPINE
 NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
 OLANZAPINE, OLANZAPINE
 OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
 OLUX E, CLOBETASOL PROPIONATE
 OLUX, CLOBETASOL PROPIONATE
 ONDANSETRON, ONDANSETRON
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 PERPHENAZINE, PERPHENAZINE
 PHENYTEK, PHENYTOIN SODIUM
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PRASUGREL, PRASUGREL HYDROCHLORIDE
 PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
 PREDNISONE, PREDNISONE
 PROBENECID, PROBENECID
 PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
 PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 RASAGILINE MESYLATE, RASAGILINE MESYLATE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
 SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 SPIRONOLACTONE, SPIRONOLACTONE
 SULINDAC, SULINDAC
 SUMATRIPTAN AND NAPROXEN SODIUM, NAPROXEN SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MYLAN PHARMACEUTICALS INC
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 SYMFI LO, EFAVIRENZ
 TACROLIMUS, TACROLIMUS
 TADALAFIL, TADALAFIL
 TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
 TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
 TELMISARTAN, TELMISARTAN
 TEMAZEPAM, TEMAZEPAM
 TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
 TETRABENAZINE, TETRABENAZINE
 THIORIDAZINE HYDROCHLORIDE, THIORIDAZINE HYDROCHLORIDE
 THIOTHIXENE, THIOTHIXENE
 TIMOLOL MALEATE, TIMOLOL MALEATE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TOLMETIN SODIUM, TOLMETIN SODIUM
 TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 TRAVOPROST, TRAVOPROST
 TRETINOIN, TRETINOIN
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE
 TRILYTE, POLYETHYLENE GLYCOL 3350
 URSODIOL, URSODIOL
 VALSARTAN, VALSARTAN
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
 VUSION, MICONAZOLE NITRATE
 WIXELA INHUB, FLUTICASONE PROPIONATE
 ZONALON, DOXEPIN HYDROCHLORIDE
 ZOVIRAX, ACYCLOVIR

MYLAN ASI

* MYLAN ASI LLC
 ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
 ADENOSINE, ADENOSINE
 AZITHROMYCIN, AZITHROMYCIN
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE

MYLAN INSTITUTIONAL

* MYLAN INSTITUTIONAL INC
 BUSULFAN, BUSULFAN
 SULFAMYLOL, MAFENIDE ACETATE

* MYLAN INSTITUTIONAL LLC
 ALOPRIM, ALLOPURINOL SODIUM
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 ARGATROBAN, ARGATROBAN
 AZACITIDINE, AZACITIDINE
 BIVALIRUDIN, BIVALIRUDIN
 CIDOFOVIR, CIDOFOVIR
 COSYNTROPIN, COSYNTROPIN
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
 DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
 DURACLON, CLONIDINE HYDROCHLORIDE
 ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
 ETHACRYNATE SODIUM, ETHACRYNATE SODIUM
 FOMEPIZOLE, FOMEPIZOLE
 FULVESTRANT, FULVESTRANT
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 IBUTILIDE FUMARATE, IBUTILIDE FUMARATE
 ISOSULFAN BLUE, ISOSULFAN BLUE
 KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
 MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MYLAN INSTITUTIONAL LLC
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 METHOCARBAMOL, METHOCARBAMOL
 NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
 PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
 RIMSO-50, DIMETHYL SULFOXIDE
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
 SOTRADECOL, SODIUM TETRADECYL SULFATE
 THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
 TRANEXAMIC ACID, TRANEXAMIC ACID
 ULTIVA, REMIFENTANIL HYDROCHLORIDE

MYLAN IRELAND LTD

* MYLAN IRELAND LTD
 ARIXTRA, FONDAPARINUX SODIUM
 MIACALCIN, CALCITONIN SALMON
 PRETOMANID, PRETOMANID
 YUPELRI, REVEFENACIN

MYLAN LABS LTD

* MYLAN LABORATORIES LTD
 ADENOSINE, ADENOSINE
 AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
 AMPICILLIN SODIUM, AMPICILLIN SODIUM
 BACLOFEN, BACLOFEN
 CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
 CIMDUO, LAMIVUDINE
 CLADRIBINE, CLADRIBINE
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CLOFARABINE, CLOFARABINE
 CYANOCOBALAMIN, CYANOCOBALAMIN
 CYTARABINE, CYTARABINE
 DACTINOMYCIN, DACTINOMYCIN
 DAPTOMYCIN, DAPTOMYCIN
 DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
 DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DOCETAXEL, DOCETAXEL
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 DOXYCYCLINE, DOXYCYCLINE HYCLATE
 DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
 EPTIFIBATIDE, EPTIFIBATIDE
 ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
 ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
 ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
 ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 ETOMIDATE, ETOMIDATE
 FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
 FAMOTIDINE, FAMOTIDINE
 FLUMAZENIL, FLUMAZENIL
 FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
 FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
 HALOPERIDOL, HALOPERIDOL LACTATE
 HEPARIN SODIUM, HEPARIN SODIUM
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 LAMIVUDINE, LAMIVUDINE
 LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
 LEVETIRACETAM, LEVETIRACETAM
 LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LEVONORGESTREL, LEVONORGESTREL (OTC)
 LINEZOLID, LINEZOLID
 MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ******* MYLAN LABORATORIES LTD**

MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
 METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
 MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER, MOXIFLOXACIN
 MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
 NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
 NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 NORETHINDRONE, NORETHINDRONE
 NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 OXALIPLATIN, OXALIPLATIN
 PACLITAXEL, PACLITAXEL
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
 PARICALCITOL, PARICALCITOL
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
 PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RIFAMPIN, RIFAMPIN
 SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 SYMFI, EFAVIRENZ
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VECURONIUM BROMIDE, VECURONIUM BROMIDE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

MYLAN PHARMS INC*** MYLAN PHARMACEUTICALS INC**

ABACAVIR SULFATE, ABACAVIR SULFATE
 ACYCLOVIR, ACYCLOVIR
 AMNESTEEM, ISOTRETINOIN
 ARMODAFINIL, ARMODAFINIL
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 AVITA, TRETINOIN
 CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 DIGOXIN, DIGOXIN
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
 DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE, DOXYLAMINE SUCCINATE
 ESZOPICLONE, ESZOPICLONE
 FENOFIBRATE (MICRONIZED), FENOFIBRATE
 FENOFIBRATE, FENOFIBRATE
 FLURAZEPAM HYDROCHLORIDE, FLURAZEPAM HYDROCHLORIDE
 ITRACONAZOLE, ITRACONAZOLE
 LANSOPRAZOLE, LANSOPRAZOLE
 LITHIUM CARBONATE, LITHIUM CARBONATE
 MAXZIDE, HYDROCHLOROTHIAZIDE
 MAXZIDE-25, HYDROCHLOROTHIAZIDE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
 MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
 MODAFINIL, MODAFINIL
 NEVIRAPINE, NEVIRAPINE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PHENYTOIN, PHENYTOIN
 PINDOLOL, PINDOLOL
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 RILUZOLE, RILUZOLE
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 TOLBUTAMIDE, TOLBUTAMIDE
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

- * MYLAN PHARMACEUTICALS INC
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VORICONAZOLE, VORICONAZOLE
ZIDOVUDINE, ZIDOVUDINE
- * MYLAN PHARMACEUTICALS INC.
FLUVASTATIN SODIUM, FLUVASTATIN SODIUM

MYLAN SPECIALITY LP

- * MYLAN SPECIALTY LP
ACCUNEB, ALBUTEROL SULFATE
ANADROL-50, OXYMETHOLONE
ASTELIN, AZELASTINE HYDROCHLORIDE
ASTEPRO, AZELASTINE HYDROCHLORIDE
COLYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
CORTIFOAM, HYDROCORTISONE ACETATE
DEPEN, PENICILLAMINE
DIPENTUM, OLSALAZINE SODIUM
DYMISTA, AZELASTINE HYDROCHLORIDE
EDLUAR, ZOLPIDEM TARTRATE
ELESTRIN, ESTRADIOL
EPIFOAM, HYDROCORTISONE ACETATE
EPIPEN JR., EPINEPHRINE
EPIPEN, EPINEPHRINE
FELBATOL, FELBAMATE
GASTROCROM, CROMOLYN SODIUM
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
MUSE, ALPROSTADIL
PROCTOFOAM HC, HYDROCORTISONE ACETATE
ROWASA, MESALAMINE
SFROWASA, MESALAMINE
SOMA, CARISOPRODOL
TOBI PODHALER, TOBRAMYCIN
TOBI, TOBRAMYCIN

MYLAN SPECLT

- * MYLAN SPECIALTY LP
PERFOROMIST, FORMOTEROL FUMARATE

MYLAN TECHNOLOGIES

- * MYLAN TECHNOLOGIES INC
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CLONIDINE, CLONIDINE
ESTRADIOL, ESTRADIOL
FENTANYL-100, FENTANYL
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-37, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-62, FENTANYL
FENTANYL-75, FENTANYL
FENTANYL-87, FENTANYL
LIDOCAINE, LIDOCAINE
NITROGLYCERIN, NITROGLYCERIN
RIVASTIGMINE, RIVASTIGMINE
SCOPOLAMINE, SCOPOLAMINE
XULANE, ETHINYL ESTRADIOL

MYOVANT SCIENCES

- * MYOVANT SCIENCES GMBH
ORGOVYX, RELUGOLIX

**** N ******NAARI PTE LTD**

- * NAARI PTE LTD
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL, LEVONORGESTREL (OTC)
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** N ****

* NAARI PTE LTD
 NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NORETHINDRONE, NORETHINDRONE
 NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL

NABRIVA

* NABRIVA THERAPEUTICS IRELAND DAC
 XENLETA, LEFAMULIN ACETATE

NALPROPION

* NALPROPION PHARMACEUTICALS LLC
 CONTRAVE, BUPROPION HYDROCHLORIDE

NANG KUANG PHARM CO

* NANG KUANG PHARMACEUTICAL CO LTD
 ICATIBANT ACETATE, ICATIBANT ACETATE
 LINEZOLID, LINEZOLID

NANJING

* NANJING SIMCERE DONGYUAN PHARMACEUTICAL CO LTD
 CELECOXIB, CELECOXIB

NANJING KING-FRIEND

* NANJING KING-FRIEND BIOCHEMICAL PHARMACEUTICAL CO LTD
 ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
 HEPARIN SODIUM, HEPARIN SODIUM

NAPO PHARMS INC

* NAPO PHARMACEUTICALS INC
 MYTESI, CROFELEMER

NATCO PHARMA

* NATCO PHARMA LTD
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE

NATCO PHARMA LTD

* NATCO PHARMA LIMITED
 CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE

* NATCO PHARMA LTD
 ALPRAZOLAM, ALPRAZOLAM
 ANASTROZOLE, ANASTROZOLE
 ARMODAFINIL, ARMODAFINIL
 AZACITIDINE, AZACITIDINE
 BOSENTAN, BOSENTAN
 CARISOPRODOL, CARISOPRODOL
 CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
 ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 IMATINIB MESYLATE, IMATINIB MESYLATE
 LANSOPRAZOLE, LANSOPRAZOLE
 LANSOPRAZOLE, LANSOPRAZOLE (OTC)
 LANTHANUM CARBONATE, LANTHANUM CARBONATE
 LAPATINIB DITOSYLATE, LAPATINIB DITOSYLATE
 LETROZOLE, LETROZOLE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE

NAVINTA LLC

* NAVINTA LLC
 BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
 CARMUSTINE, CARMUSTINE
 FAMOTIDINE, FAMOTIDINE
 FOMEPIZOLE, FOMEPIZOLE
 FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 INDOMETHACIN SODIUM, INDOMETHACIN SODIUM
 METHOCARBAMOL, METHOCARBAMOL
 REMIFENTANIL HYDROCHLORIDE, REMIFENTANIL HYDROCHLORIDE
 RIBAVIRIN, RIBAVIRIN
 ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** N ******* NAVINTA LLC**

SODIUM PHENYLACETATE AND SODIUM BENZOATE, SODIUM BENZOATE
 TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE

NCM USA BRONX LLC*** NCM USA BRONX LLC**

AMMONIA N 13, AMMONIA N-13
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

NEOPHARMA*** NEOPHARMA INC**

AMOXIL, AMOXICILLIN
 AUGMENTIN '125', AMOXICILLIN
 AUGMENTIN '250', AMOXICILLIN
 AUGMENTIN '875', AMOXICILLIN
 AUGMENTIN ES-600, AMOXICILLIN
 LAROTID, AMOXICILLIN
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE

NEOS THERAP INC*** NEOS THERAPEUTICS INC**

HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX, CHLORPHENIRAMINE POLISTIREX

NEOS THERAPS*** NEOS THERAPEUTICS**

ADZENYS XR-ODT, AMPHETAMINE

NEOS THERAPS INC*** NEOS THERAPEUTICS INC**

ADZENYS ER, AMPHETAMINE
 COTEMPLA XR-ODT, METHYLPHENIDATE

NEPHRON*** NEPHRON CORP**

ALBUTEROL SULFATE, ALBUTEROL SULFATE
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE

*** NEPHRON PHARMACEUTICALS CORP**

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 BUDESONIDE, BUDESONIDE
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

NESHER PHARMS*** NESHER PHARMACEUTICALS USA LLC**

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
 MORPHINE SULFATE, MORPHINE SULFATE
 NYSTATIN, NYSTATIN
 OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN

NEURELIS INC*** NEURELIS INC**

VALTOCO, DIAZEPAM

NEUROCRINE*** NEUROCRINE BIOSCIENCES INC**

INGREZZA, VALBENAZINE TOSYLATE
 ONGENTYS, OPICAPONE

NEXTWAVE*** NEXTWAVE PHARMACEUTICALS INC A SUB OF TRIS PHARMA INC**

QUILLIVANT XR, METHYLPHENIDATE HYDROCHLORIDE

NEXTWAVE PHARMS*** NEXTWAVE PHARMACEUTICALS INC**

QUILLICHEW ER, METHYLPHENIDATE HYDROCHLORIDE

NEXUS PHARMS*** NEXUS PHARMACEUTICALS INC**

ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
 BUSULFAN, BUSULFAN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** N ****

* NEXUS PHARMACEUTICALS INC
 COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
 DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
 EMERPHED, EPHEDRINE SULFATE
 ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
 LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM
 PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE
 PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
 SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
 SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
 TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE

NIAGARA PHARMS

* NIAGARA PHARMACEUTICALS INC
 PUR-WASH, PURIFIED WATER (OTC)

NIPPON SHINYAKU

* NIPPON SHINYAKU CO LTD
 VILTEPSO, VILTOLARSEN

NIVAGEN PHARMS INC

* NIVAGEN PHARMACEUTICALS INC
 DECITABINE, DECITABINE
 SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE

NODEN PHARMA

* NODEN PHARMA DAC
 TEKTRNA HCT, ALISKIREN HEMIFUMARATE
 TEKTRNA, ALISKIREN HEMIFUMARATE

NORTEC DEV ASSOC

* NORTEC DEVELOPMENT ASSOC INC
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

NORTHLAND

* NORTHLAND NUCLEAR MEDICINE LLC
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

NORTHSTAR HLTHCARE

* NORTHSTAR HEALTHCARE HOLDINGS LTD
 ALLOPURINOL, ALLOPURINOL
 BACLOFEN, BACLOFEN
 GEMFIBROZIL, GEMFIBROZIL
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

NORTHSTAR MEDICAL

* NORTHSTAR MEDICAL RADIOISOTOPES LLC
 RADIOGENIX SYSTEM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

NORTON WATERFORD

* NORTON WATERFORD LTD
 QVAR REDIHALER, BECLOMETHASONE DIPROPIONATE

NOSTRUM LABS INC

* NOSTRUM LABORATORIES INC
 ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 ACETAZOLAMIDE, ACETAZOLAMIDE
 CALCIUM ACETATE, CALCIUM ACETATE
 CARBAMAZEPINE, CARBAMAZEPINE
 CARISOPRODOL, CARISOPRODOL
 DAPSONE, DAPSONE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 ELIXOPHYLLIN, THEOPHYLLINE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 NITROFURANTOIN, NITROFURANTOIN
 PINDOLOL, PINDOLOL
 PIROXICAM, PIROXICAM
 PROMETH VC W/ CODEINE, CODEINE PHOSPHATE
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 SUCRALFATE, SUCRALFATE
 THEOPHYLLINE, THEOPHYLLINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** N ****

* NOSTRUM LABORATORIES INC
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

NOSTRUM PHARMS LLC

* NOSTRUM PHARMACEUTICALS LLC
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
THEOCHRON, THEOPHYLLINE

NOVA LABS LTD

* NOVA LABORATORIES LTD
PURIXAN, MERCAPTOPYRINE

NOVADAQ TECH

* NOVADAQ TECHNOLOGIES ULC
SPY AGENT GREEN KIT, INDOCYANINE GREEN

NOVARTIS

* NOVARTIS PHARMACEUTICALS CORP
AFINITOR, EVEROLIMUS
ALOMIDE, LODOXAMIDE TROMETHAMINE
ARGATROBAN, ARGATROBAN
ARRANON, NELARABINE
AZOPT, BRINZOLAMIDE
BETOPTIC S, BETAXOLOL HYDROCHLORIDE
CILOXAN, CIPROFLOXACIN HYDROCHLORIDE
CIPRO HC, CIPROFLOXACIN HYDROCHLORIDE
CIPRODEX, CIPROFLOXACIN
COARTEM, ARTEMETHER
DEFERAL, DEFEROXAMINE MESYLATE
DIOVAN HCT, HYDROCHLOROTHIAZIDE
DIOVAN, VALSARTAN
DUREZOL, DIFLUPREDNATE
EGATEN, TRICLABENDAZOLE
EXELON, RIVASTIGMINE
EXFORGE HCT, AMLODIPINE BESYLATE
EXFORGE, AMLODIPINE BESYLATE
EXJADE, DEFERASIROX
FOCALIN XR, DEXMETHYLPHENIDATE HYDROCHLORIDE
FOCALIN, DEXMETHYLPHENIDATE HYDROCHLORIDE
GILENYA, FINGOLIMOD HYDROCHLORIDE
GLEEVEC, IMATINIB MESYLATE
HYCANTIN, TOPOTECAN HYDROCHLORIDE
ILEVRO, NEPAFENAC
IOPIDINE, APRACLONIDINE HYDROCHLORIDE
ISOPTO CARPINE, PILOCARPINE HYDROCHLORIDE
JADENU SPRINKLE, DEFERASIROX
KISQALI FEMARA CO-PACK (COPACKAGED), LETROZOLE
KISQALI, RIBOCICLIB SUCCINATE
LAMISIL, TERBINAFINE HYDROCHLORIDE
LESCOL XL, FLUVASTATIN SODIUM
LOTREL, AMLODIPINE BESYLATE
MAXIDEX, DEXAMETHASONE
MAXITROL, DEXAMETHASONE
MAYZENT, SIPONIMOD FUMARIC ACID
MEKINIST, TRAMETINIB DIMETHYL SULFOXIDE
MOXEZA, MOXIFLOXACIN HYDROCHLORIDE
MYFORTIC, MYCOPHENOLIC ACID
NEORAL, CYCLOSPORINE
NEVANAC, NEPAFENAC
OMNIPRED, PREDNISOLONE ACETATE
PATANASE, OLOPATADINE HYDROCHLORIDE
PIQRAY, ALPELISIB
PROMACTA KIT, ELTROMBOPAG OLAMINE
PROMACTA, ELTROMBOPAG OLAMINE
RECLAST, ZOLEDRONIC ACID
RITALIN LA, METHYLPHENIDATE HYDROCHLORIDE
RITALIN, METHYLPHENIDATE HYDROCHLORIDE
RYDAPT, MIDOSTAURIN
SANDIMMUNE, CYCLOSPORINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** N ****

* NOVARTIS PHARMACEUTICALS CORP
 SANDOSTATIN LAR, OCTREOTIDE ACETATE
 SANDOSTATIN, OCTREOTIDE ACETATE
 SIMBRINZA, BRIMONIDINE TARTRATE
 TAFINLAR, DABRAFENIB MESYLATE
 TASIGNA, NILOTINIB HYDROCHLORIDE
 TEGRETOL, CARBAMAZEPINE
 TEGRETOL-XR, CARBAMAZEPINE
 TOBRADEX, DEXAMETHASONE
 TOBREX, TOBRAMYCIN
 TRAVATAN Z, TRAVOPROST
 TRIESENCE, TRIAMCINOLONE ACETONIDE
 TRILEPTAL, OXCARBAZEPINE
 TYKERB, LAPATINIB DITOSYLATE
 VIGAMOX, MOXIFLOXACIN HYDROCHLORIDE
 VIVELLE-DOT, ESTRADIOL
 VOLTAREN, DICLOFENAC SODIUM
 VOTRIENT, PAZOPANIB HYDROCHLORIDE
 XIIDRA, LIFITEGRAST
 ZOFRAN ODT, ONDANSETRON
 ZOFRAN, ONDANSETRON HYDROCHLORIDE
 ZOMETA, ZOLEDRONIC ACID
 ZORTRESS, EVEROLIMUS
 ZYKADIA, CERITINIB

NOVARTIS PHARM

* NOVARTIS PHARMACEUTICAL CORP
 AFINITOR DISPERZ, EVEROLIMUS
 TABRECTA, CAPMATINIB HYDROCHLORIDE

NOVARTIS PHARMS

* NOVARTIS PHARMACEUTICALS CORP
 FEMARA, LETROZOLE

NOVARTIS PHARMS CORP

* NOVARTIS PHARMACEUTICALS CORP
 ENTRESTO, SACUBITRIL
 JADENU, DEFERASIROX

NOVAST LABS

* NOVAST LABORATORIES CHINA LTD
 NORETHINDRONE, NORETHINDRONE

* NOVAST LABORATORIES LTD
 ACETAZOLAMIDE, ACETAZOLAMIDE
 AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
 CARBOPLATIN, CARBOPLATIN
 CARISOPRODOL, CARISOPRODOL
 CHABELINA FE, ETHINYL ESTRADIOL
 CICLOPIROX, CICLOPIROX
 CLOFARABINE, CLOFARABINE
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
 DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DOLISHALE, ETHINYL ESTRADIOL
 ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
 HER STYLE, LEVONORGESTREL (OTC)
 INDOMETHACIN, INDOMETHACIN
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 LARIN 1.5/30, ETHINYL ESTRADIOL
 LARIN 1/20, ETHINYL ESTRADIOL
 LARIN 24 FE, ETHINYL ESTRADIOL
 LARIN FE 1.5/30, ETHINYL ESTRADIOL
 LARIN FE 1/20, ETHINYL ESTRADIOL
 LERIBANE, ETHINYL ESTRADIOL
 LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
 LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** N ****

* NOVAST LABORATORIES LTD
 LO-MALMOREDE, ETHINYL ESTRADIOL
 MAFENIDE ACETATE, MAFENIDE ACETATE
 MALMOREDE, ETHINYL ESTRADIOL
 MELAMISA, DROSPIRENONE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
 NADOLOL, NADOLOL
 NIFEDIPINE, NIFEDIPINE
 NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
 NORETHINDRONE, NORETHINDRONE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 PIMTREA, DESOGESTREL
 PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE
 PROBENECID AND COLCHICINE, COLCHICINE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 QUININE SULFATE, QUININE SULFATE
 SETLAKIN, ETHINYL ESTRADIOL
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TOLCAPONE, TOLCAPONE
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 YAELA, DROSPIRENONE

NOVAST LABS LTD

* NOVAST LABORATORIES LTD
 DASETTA 1/35, ETHINYL ESTRADIOL
 DASETTA 7/7/7, ETHINYL ESTRADIOL
 ELINEST, ETHINYL ESTRADIOL
 FALMINA, ETHINYL ESTRADIOL
 LEVONEST, ETHINYL ESTRADIOL
 MONO-LINYAH, ETHINYL ESTRADIOL
 PHILITH, ETHINYL ESTRADIOL
 TRI-LINYAH, ETHINYL ESTRADIOL
 WERA, ETHINYL ESTRADIOL

NOVATECH SA

* NOVATECH SA
 STERITALC, TALC

NOVEL LABS INC

* NOVEL LABORATORIES INC
 AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
 CALCIPOTRIENE, CALCIPOTRIENE
 CARBIDOPA, CARBIDOPA
 CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 DESOXIMETASONE, DESOXIMETASONE
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 FAMOTIDINE, FAMOTIDINE
 FLUCYTOSINE, FLUCYTOSINE
 FLUOCINONIDE, FLUOCINONIDE
 HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE, HOMATROPINE METHYLBROMIDE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
 LEVONORGESTREL, LEVONORGESTREL (OTC)
 LINEZOLID, LINEZOLID
 METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 MISOPROSTOL, MISOPROSTOL
 MORPHINE SULFATE, MORPHINE SULFATE
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 NITROFURANTOIN, NITROFURANTOIN
 NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** N ******* NOVEL LABORATORIES INC**

OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PEG 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
 PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE, POLYETHYLENE GLYCOL
 PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND
 PHENELZINE SULFATE, PHENELZINE SULFATE
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE, MAGNESIUM SULFATE
 TEMAZEPAM, TEMAZEPAM
 TINIDAZOLE, TINIDAZOLE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 TRIMETHOPRIM, TRIMETHOPRIM
 VORICONAZOLE, VORICONAZOLE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

NOVELGENIX THERAPIS*** NOVELGENIX THERAPEUTICS PVT LTD**

AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE

NOVEN*** NOVEN PHARMACEUTICALS INC**

MINIVELLE, ESTRADIOL

NOVEN PHARMS INC*** NOVEN PHARMACEUTICALS INC**

COMBIPATCH, ESTRADIOL
 DAYTRANA, METHYLPHENIDATE
 LIDOCAINE, LIDOCAINE

NOVITIUM PHARMA*** NOVITIUM PHARMA LLC**

ACETAZOLAMIDE, ACETAZOLAMIDE
 ACYCLOVIR, ACYCLOVIR
 CHLORZOXAZONE, CHLORZOXAZONE
 CLOTRIMAZOLE, CLOTRIMAZOLE
 DAPSONE, DAPSONE
 DIAZOXIDE, DIAZOXIDE
 ESTAZOLAM, ESTAZOLAM
 LEVOCARNITINE SF, LEVOCARNITINE
 LEVOCARNITINE, LEVOCARNITINE
 LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
 NITISINONE, NITISINONE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
 PREDNISONE, PREDNISONE
 PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SIROLIMUS, SIROLIMUS
 THIOTHIXENE, THIOTHIXENE
 TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE

NOVO*** NOVO NORDISK INC**

MACRILEN, MACIMORELIN ACETATE
 OZEMPIC, SEMAGLUTIDE
 RYBELSUS, SEMAGLUTIDE
 SAXENDA, LIRAGLUTIDE RECOMBINANT

NOVO NORDISK*** NOVO NORDISK PHARMACEUTICALS INC**

GLUCAGEN, GLUCAGON HYDROCHLORIDE

NOVO NORDISK INC*** NOVO NORDISK INC**

VAGIFEM, ESTRADIOL
 VICTOZA, LIRAGLUTIDE RECOMBINANT

NOVOCOL INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** N ****

* NOVOCOL INC
DYCLOPRO, DYCLONINE HYDROCHLORIDE

NPS PHARMS INC

* NPS PHARMACEUTICALS INC
GATEX KIT, TEDUGLUTIDE RECOMBINANT

NUVO PHARM

* NUVO PHARMACEUTICAL INC
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

NUVO PHARMS INC

* NUVO PHAMACEUTICALS INC
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
NAPROXEN, NAPROXEN
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
SULFASALAZINE, SULFASALAZINE

NXDC

* NX DEVELOPMENT CORP
GLEOLAN, AMINOLEVULINIC ACID HYDROCHLORIDE

**** O ******OCULAR THERAPEUTIX**

* OCULAR THERAPEUTIX INC
DEXTENZA, DEXAMETHASONE

ODYSSEY PHARMS

* ODYSSEY PHARMACEUTICALS INC
ANTABUSE, DISULFIRAM

OHM

* OHM CORP
IBUPROFEN, IBUPROFEN (OTC)

OHM LABS

* OHM LABORATORIES INC
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
IBUPROHM COLD AND SINUS, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)

OHM LABS INC

* OHM LABORATORIES INC
EZETIMIBE, EZETIMIBE
VALSARTAN, VALSARTAN

OMEROS

* OMEROS CORP
OMIDRIA, KETOROLAC TROMETHAMINE

ONYX THERAP

* ONYX THERAPEUTICS INC A WHOLLY OWNED SUB OF AMGEN INC
KYPROLIS, CARFILZOMIB

OPTINOSE US INC

* OPTINOSE US INC
XHANCE, FLUTICASONE PROPIONATE

ORAPHARMA

* ORAPHARMA INC
ARESTIN, MINOCYCLINE HYDROCHLORIDE

ORCHID HLTHCARE

* ORCHID HEALTHCARE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ARIPIPIRAZOLE, ARIPIPIRAZOLE
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFDINIR, CEFDINIR
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFPROZIL, CEFPROZIL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** O **

* ORCHID HEALTHCARE

CEFUROXIME AXETIL, CEFUROXIME AXETIL
 CEPHALEXIN, CEPHALEXIN
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
 DESLORATADINE, DESLORATADINE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 ESZOPICLONE, ESZOPICLONE
 FELODIPINE, FELODIPINE
 GEMIFLOXACIN MESYLATE, GEMIFLOXACIN MESYLATE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 LEVETIRACETAM, LEVETIRACETAM
 LEVOFLOXACIN, LEVOFLOXACIN
 MODAFINIL, MODAFINIL
 NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
 OLANZAPINE, OLANZAPINE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 RASAGILINE MESYLATE, RASAGILINE MESYLATE
 RISEDRONATE SODIUM, RISEDRONATE SODIUM
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 ZALEPLON, ZALEPLON
 ZOLMITRIPTAN, ZOLMITRIPTAN

OREXO US INC

* OREXO US INC
 ZUBSOLV, BUPRENORPHINE HYDROCHLORIDE

ORGANON

* ORGANON LLC A SUB OF ORGANON AND CO
 COZAAR, LOSARTAN POTASSIUM
 HYZAAR, HYDROCHLOROTHIAZIDE

ORGANON SUB MERCK

* ORGANON USA INC A SUB OF MERCK AND CO INC
 BRIDION, SUGAMMADEX SODIUM
 NUVARING, ETHINYL ESTRADIOL

ORGANON USA INC

* ORGANON USA INC
 GANIRELIX ACETATE, GANIRELIX ACETATE
 NEXPLANON, ETNOGESTREL
 REMERON SOLTAB, MIRTAZAPINE
 REMERON, MIRTAZAPINE

ORIENT PHARMA CO LTD

* ORIENT PHARMA CO LTD
 CARISOPRODOL, CARISOPRODOL
 GLYBURIDE, GLYBURIDE
 MIGLITOL, MIGLITOL
 PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

ORION PHARMA

* ORION PHARMA
 COMTAN, ENTACAPONE
 STALEVO 100, CARBIDOPA
 STALEVO 125, CARBIDOPA
 STALEVO 150, CARBIDOPA
 STALEVO 200, CARBIDOPA
 STALEVO 50, CARBIDOPA
 STALEVO 75, CARBIDOPA

ORPHAN EUROPE

* ORPHAN EUROPE SARL
 CYSTADANE, BETAINE

OSI PHARMS

* OSI PHARMACEUTICALS LLC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** O ****

* OSI PHARMACEUTICALS LLC
TARCEVA, ERLOTINIB HYDROCHLORIDE

OSMOTICA

* OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE

OSMOTICA PHARM

* OSMOTICA PHARMACEUTICAL
OSMOLEX ER, AMANTADINE HYDROCHLORIDE
* OSMOTICA PHARMACEUTICAL CORP
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

OSMOTICA PHARM US

* OSMOTICA PHARMACEUTICAL US LLC
NIFEDIPINE, NIFEDIPINE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

OTONOMY INC

* OTONOMY INC
OTIPRIO, CIPROFLOXACIN

OTSUKA

* OTSUKA PHARMACEUTICAL CO LTD
ABILIFY MYCITE KIT, ARIPIPIRAZOLE
ABILIFY, ARIPIPIRAZOLE
DACOGEN, DECITABINE
INQOVI, CEDAZURIDINE

OTSUKA AMERICA PHARM

* OTSUKA AMERICA PHARMACEUTICAL INC
SAMSCA, TOLVAPTAN

OTSUKA PHARM

* OTSUKA PHARMACEUTICAL CO LTD
BUSULFEX, BUSULFAN

OTSUKA PHARM CO LTD

* OTSUKA PHARMACEUTICAL CO LTD
ABILIFY MAINTENA KIT, ARIPIPIRAZOLE
JYNARQUE, TOLVAPTAN
REXULTI, BREXPIPIRAZOLE

OUTLOOK PHARMS

* OUTLOOK PHARMACEUTICALS INC
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE

OXFORD PHARMS

* OXFORD PHARMACEUTICALS LLC
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
BACLOFEN, BACLOFEN
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CARISOPRODOL, CARISOPRODOL
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
LORAZEPAM, LORAZEPAM
METHOCARBAMOL, METHOCARBAMOL
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PRIMIDONE, PRIMIDONE
RIMACTANE, RIFAMPIN
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
SPIRONOLACTONE, SPIRONOLACTONE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE

**** P ******P AND L**

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ******* P AND L DEVELOPMENT LLC**

ADAPALENE, ADAPALENE (OTC)
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
 DOCOSANOL, DOCOSANOL (OTC)
 FAMOTIDINE, FAMOTIDINE (OTC)
 IBUPROFEN, IBUPROFEN (OTC)
 LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
 M-ZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
 MICONAZOLE 7, MICONAZOLE NITRATE (OTC)
 MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
 MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
 MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
 MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
 NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
 OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)

P AND L DEV LLC

* P AND L DEVELOPMENT LLC DBA PLD DEVELOPMENTS LLC
 IBUPROFEN, IBUPROFEN (OTC)

PACIFIC PHARMA

* PACIFIC PHARMA
 TIMOLOL MALEATE, TIMOLOL MALEATE
 * PACIFIC PHARMA INC
 TIMOLOL MALEATE, TIMOLOL MALEATE

PACIRA PHARMS INC

* PACIRA PHARMACEUTICALS INC
 EXPAREL, BUPIVACAINE

PADDOCK LABS LLC

* PADDOCK LABORATORIES LLC
 ATOVAQUONE, ATOVAQUONE
 BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
 CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
 CYCLOSPORINE, CYCLOSPORINE
 HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
 HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE,
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 REPAGLINIDE, REPAGLINIDE

PADDOCK LLC

* PADDOCK LABORATORIES LLC
 BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
 CALCIUM ACETATE, CALCIUM ACETATE
 CICLOPIROX, CICLOPIROX
 CLINDA-DERM, CLINDAMYCIN PHOSPHATE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CLOTRIMAZOLE, CLOTRIMAZOLE
 COMPRO, PROCHLORPERAZINE
 DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
 FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
 KIONEX, SODIUM POLYSTYRENE SULFONATE
 LAX-LYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
 MIDAMOR, AMILORIDE HYDROCHLORIDE
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
 NYSTOP, NYSTATIN
 PODOFILOX, PODOFILOX
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 TROSPIMUM CHLORIDE, TROSPIMUM CHLORIDE

PALATIN TECHNOLOGIES

* PALATIN TECHNOLOGIES INC
 VYLEESI (AUTOINJECTOR), BREMELANOTIDE ACETATE

PANACEA BIOTEC LTD

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

* PANACEA BIOTEC LTD
 PRASUGREL, PRASUGREL HYDROCHLORIDE
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 TACROLIMUS, TACROLIMUS

PAR FORM

* PAR FORMULATIONS PRIVATE LTD
 DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 MAFENIDE ACETATE, MAFENIDE ACETATE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

PAR PHARM

* PAR PHARMACEUTICAL
 EVEROLIMUS, EVEROLIMUS
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
 TESTOSTERONE, TESTOSTERONE

* PAR PHARMACEUTICAL INC
 ALPRAZOLAM, ALPRAZOLAM
 AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
 CALCITONIN-SALMON, CALCITONIN SALMON
 CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
 CHOLESTYRAMINE, CHOLESTYRAMINE
 CLOMIPHENE CITRATE, CLOMIPHENE CITRATE
 CLONAZEPAM, CLONAZEPAM
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
 DOXYCYCLINE, DOXYCYCLINE
 FLUTAMIDE, FLUTAMIDE
 GLIPIZIDE, GLIPIZIDE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 HYDRA-ZIDE, HYDRALAZINE HYDROCHLORIDE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROXYUREA, HYDROXYUREA
 IBUPROFEN, IBUPROFEN (OTC)
 IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
 ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
 LAMOTRIGINE, LAMOTRIGINE
 MEGESTROL ACETATE, MEGESTROL ACETATE
 METRONIDAZOLE, METRONIDAZOLE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MINOXIDIL, MINOXIDIL
 NATEGLINIDE, NATEGLINIDE
 NIFEDIPINE, NIFEDIPINE
 OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 OLANZAPINE, OLANZAPINE
 OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
 OXANDROLONE, OXANDROLONE
 PIMOZIDE, PIMOZIDE
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RISPERIDONE, RISPERIDONE
 SODIUM PHENYL BUTYRATE, SODIUM PHENYL BUTYRATE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TORSEMIDE, TORSEMIDE
 TRANYLCPROMINE SULFATE, TRANYLCPROMINE SULFATE
 TRAVOPROST, TRAVOPROST
 URSODIOL, URSODIOL
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

PAR PHARM INC

* PAR PHARMACEUTICAL INC
 ACCOLATE, ZAFIRLUKAST
 ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
 AMBRISENTAN, AMBRISENTAN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

* PAR PHARMACEUTICAL INC
 ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
 BOSENTAN, BOSENTAN
 CHLORZOXAZONE, CHLORZOXAZONE
 DEXLANSOPRAZOLE, DEXLANSOPRAZOLE
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DOFETILIDE, DOFETILIDE
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
 DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE, DOXYLAMINE SUCCINATE
 ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
 ETHACRYNIC ACID, ETHACRYNIC ACID
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 ITRACONAZOLE, ITRACONAZOLE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
 OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
 PENICILLAMINE, PENICILLAMINE
 PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE
 PRAZIQUANTEL, PRAZIQUANTEL
 SAPROPTERIN DIHYDROCHLORIDE, SAPROPTERIN DIHYDROCHLORIDE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TOLCAPONE, TOLCAPONE
 TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE
 VIGABATRIN, VIGABATRIN
 ZILEUTON, ZILEUTON
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

PAR STERILE PRODUCTS

* PAR STERILE PRODUCTS LLC
 ADRENALIN, EPINEPHRINE
 ARGATROBAN, ARGATROBAN
 BREVITAL SODIUM, METHOHEXITAL SODIUM
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 COLY-MYCIN M, COLISTIMETHATE SODIUM
 CORPHEDRA, EPHEDRINE SULFATE
 DANTRIUM, DANTROLENE SODIUM
 DELESTROGEN, ESTRADIOL VALERATE
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 ETHACRYNATE SODIUM, ETHACRYNATE SODIUM
 FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
 GANCICLOVIR SODIUM, GANCICLOVIR SODIUM
 KETALAR, KETAMINE HYDROCHLORIDE
 MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
 NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
 PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
 PITOCIN, OXYTOCIN
 TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE
 TREPROSTINIL, TREPROSTINIL
 TRIOSTAT, LIOETHYRONINE SODIUM
 VASOSTRICT, VASOPRESSIN

PARAGON BIOTECK

* PARAGON BIOTECK INC
 PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE

PARAPRO LLC

* PARAPRO LLC
 NATROBA, SPINOSAD

PARATEK PHARMS INC

* PARATEK PHARMACEUTICALS INC
 NUZYRA, OMADACYCLINE TOSYLATE

PARKE DAVIS

* PARKE DAVIS DIV WARNER LAMBERT CO
 CELONTIN, METHSUXIMIDE
 CEREBYX, FOSPHENYTOIN SODIUM
 NARDIL, PHENELZINE SULFATE
 ZARONTIN, ETHOSUXIMIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ******PARKE-DAVIS**

* PARKE-DAVIS DIVISION OF PFIZER INC
ZARONTIN, ETHOSUXIMIDE

PERRIGO

* PERRIGO CO
MICONAZOLE NITRATE COMBINATION PACK, MICONAZOLE NITRATE (OTC)
* PERRIGO LLC
DESLORATADINE, DESLORATADINE

PERRIGO CO

* PERRIGO CO OF TENNESSEE INC
CICLOPIROX, CICLOPIROX
CLINDETS, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
ERYTHROMYCIN, ERYTHROMYCIN
STIE-CORT, HYDROCORTISONE

PERRIGO CO TENNESSEE

* PERRIGO CO TENNESSEE INC
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BACITRACIN, BACITRACIN
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE, BACITRACIN ZINC
ERYTHROMYCIN, ERYTHROMYCIN
GENTAMICIN SULFATE, GENTAMICIN SULFATE
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM

PERRIGO ISRAEL

* PERRIGO ISRAEL PHARMACEUTICALS LTD
AMMONIUM LACTATE, AMMONIUM LACTATE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DESOXIMETASONE, DESOXIMETASONE
ECONAZOLE NITRATE, ECONAZOLE NITRATE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
GYNAZOLE-1, BUTOCONAZOLE NITRATE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
IMIQUIMOD, IMIQUIMOD
KETOCONAZOLE, KETOCONAZOLE
MESALAMINE, MESALAMINE
MINOXIDIL, MINOXIDIL (OTC)
MOMETASONE FUROATE, MOMETASONE FUROATE
MUPIROCIN, MUPIROCIN
NITROGLYCERIN, NITROGLYCERIN
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
PERMETHRIN, PERMETHRIN
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
TERCONAZOLE, TERCONAZOLE
TESTOSTERONE, TESTOSTERONE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE (OTC)

PERRIGO NEW YORK

* PERRIGO NEW YORK INC
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CENTANY, MUPIROCIN
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
DESONIDE, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
ERYTHROMYCIN, ERYTHROMYCIN
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

* PERRIGO NEW YORK INC
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 HYDROCORTISONE, HYDROCORTISONE
 MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
 MOMETASONE FUROATE, MOMETASONE FUROATE
 NYSTATIN, NYSTATIN
 PERMETHRIN, PERMETHRIN (OTC)
 SELENIUM SULFIDE, SELENIUM SULFIDE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

PERRIGO PHARMA INTL

* PERRIGO PHARMA INTERNATIONAL DAC
 CLINDESSE, CLINDAMYCIN PHOSPHATE
 EFINAACONAZOLE, EFINAACONAZOLE
 ENTOCORT EC, BUDESONIDE
 EVAMIST, ESTRADIOL
 LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
 LORATADINE, LORATADINE (OTC)
 PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
 TAVABOROLE, TAVABOROLE
 TRETINOIN, TRETINOIN

* PERRIGO PHARMA INTERNATIONAL DESIGNATED ACTIVITY CO
 LORATADINE, LORATADINE (OTC)
 PREVACID 24 HR, LANSOPRAZOLE (OTC)

PERRIGO PHARMS CO

* PERRIGO PHARMACEUTICALS CO
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 IBUPROFEN, IBUPROFEN
 NAPROXEN, NAPROXEN
 SCOPOLAMINE, SCOPOLAMINE

PERRIGO R AND D

* PERRIGO R AND D CO
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
 FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE, CALCIUM CARBONATE (OTC)
 FAMOTIDINE, FAMOTIDINE
 FAMOTIDINE, FAMOTIDINE (OTC)
 GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
 GUAIFENESIN, GUAIFENESIN (OTC)
 IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
 IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE, IBUPROFEN (OTC)
 IBUPROFEN, IBUPROFEN (OTC)
 LANSOPRAZOLE, LANSOPRAZOLE (OTC)
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)
 LEVONORGESTREL, LEVONORGESTREL (OTC)
 LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
 MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
 NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
 NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
 OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
 OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)

PERRIGO UK FINCO

* PERRIGO UK FINCO LTD PARTNERSHIP
 ACYCLOVIR, ACYCLOVIR
 ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
 BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
 CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

* PERRIGO UK FINCO LTD PARTNERSHIP
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DICLOFENAC SODIUM, DICLOFENAC SODIUM (OTC)
 ESTRADIOL, ESTRADIOL
 FLURANDRENOLIDE, FLURANDRENOLIDE
 METRONIDAZOLE, METRONIDAZOLE
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 SUMATRIPTAN, SUMATRIPTAN
 TESTOSTERONE, TESTOSTERONE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

PERSION

* PERSION PHARMACEUTICALS LLC
 ZOHYDRO ER, HYDROCODONE BITARTRATE

PETNET

* PETNET SOLUTIONS INC
 AMMONIA N 13, AMMONIA N-13
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

PF PRISM CV

* PF PRISM CV
 BOSULIF, BOSUTINIB MONOHYDRATE
 CHANTIX, VARENICLINE TARTRATE
 INLYTA, AXITINIB
 PRISTIQ, DESVENLAFAXINE SUCCINATE
 RAPAMUNE, SIROLIMUS
 TORISEL, TEMSIROLIMUS
 TYGACIL, TIGECYCLINE
 VFEND, VORICONAZOLE
 XALKORI, CRIZOTINIB
 XELJANZ, TOFACITINIB CITRATE

PFIZER

* PFIZER CENTRAL RESEARCH
 DIFLUCAN, FLUCONAZOLE
 ZITHROMAX, AZITHROMYCIN

* PFIZER CHEMICALS DIV PFIZER INC
 DIFLUCAN, FLUCONAZOLE
 ZITHROMAX, AZITHROMYCIN

* PFIZER INC
 ALDACTAZIDE, HYDROCHLOROTHIAZIDE
 ALDACTONE, SPIRONOLACTONE
 ARTHROTEC, DICLOFENAC SODIUM
 CALAN SR, VERAPAMIL HYDROCHLORIDE
 CYTOTEC, MISOPROSTOL
 DAURISMO, GLASDEGIB MALEATE
 DAYPRO, OXAPROZIN
 DEPO-MEDROL, METHYLPREDNISOLONE ACETATE
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 FLAGYL, METRONIDAZOLE
 FRAGMIN, DALTEPARIN SODIUM
 GLUCOTROL XL, GLIPIZIDE
 GLUCOTROL, GLIPIZIDE
 HEMABATE, CARBOPROST TROMETHAMINE
 HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
 HEPARIN SODIUM, HEPARIN SODIUM
 IBRANCE, PALBOCICLIB
 IDAMYCIN PFS, IDARUBICIN HYDROCHLORIDE
 LOMOTIL, ATROPINE SULFATE
 LORBRENA, LORLATINIB
 MEDROL, METHYLPREDNISOLONE
 MERREM, MEROPENEM
 MYCOBUTIN, RIFABUTIN
 NICOTROL, NICOTINE
 NORPACE CR, DISOPYRAMIDE PHOSPHATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

- * PFIZER INC
 - NORPACE, DISOPYRAMIDE PHOSPHATE
 - PROCARDIA, NIFEDIPINE
 - SONATA, ZALEPLON
 - SYNAREL, NAFARELIN ACETATE
 - TALZENNA, TALAZOPARIB TOSYLATE
 - TESSALON, BENZONATATE
 - TOVIAZ, FESOTERODINE FUMARATE
 - UNASYN, AMPICILLIN SODIUM
 - VIZIMPRO, DACOMITINIB
 - XELJANZ XR, TOFACITINIB CITRATE
 - Xeljanz, TOFACITINIB CITRATE
 - ZITHROMAX, AZITHROMYCIN
 - ZYVOX, LINEZOLID
- * PFIZER LABORATORIES DIV PFIZER INC
 - FELDENE, PIROXICAM
 - MINIPRESS, PRAZOSIN HYDROCHLORIDE
 - PFIZERPEN, PENICILLIN G POTASSIUM
 - PROCARDIA XL, NIFEDIPINE
 - UNASYN, AMPICILLIN SODIUM
 - VIBRAMYCIN, DOXYCYCLINE
 - VIBRAMYCIN, DOXYCYCLINE CALCIUM
 - VIBRAMYCIN, DOXYCYCLINE HYCLATE
 - VISTARIL, HYDROXYZINE PAMOATE
- * PFIZER PFE US HOLDINGS 4 LLC
 - LYRICA CR, PREGABALIN
 - LYRICA, PREGABALIN
- * PFIZER PHARMACEUTICALS PRODUCTION CORP LTD
 - TIKOSYN, DOFETILIDE

PFIZER INC

- * PFIZER INC
 - CAMPTOSAR, IRINOTECAN HYDROCHLORIDE
 - ELLENCEN, EPIRUBICIN HYDROCHLORIDE
 - NICOTROL, NICOTINE

PFIZER PHARMS

- * PFIZER PHARMACEUTICALS LTD
 - ACCUPRIL, QUINAPRIL HYDROCHLORIDE
 - ACCURETIC, HYDROCHLOROTHIAZIDE
 - LOPID, GEMFIBROZIL

PHARM ASSOC

- * PHARMACEUTICAL ASSOC INC
 - CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
 - HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 - LORAZEPAM, LORAZEPAM
 - PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
- * PHARMACEUTICAL ASSOCIATES INC
 - ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 - AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 - CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
 - CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
 - DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
 - ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 - ETHOSUXIMIDE, ETHOSUXIMIDE
 - FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 - FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
 - HALOPERIDOL, HALOPERIDOL LACTATE
 - HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 - LACTULOSE, LACTULOSE
 - LEVETIRACETAM, LEVETIRACETAM
 - METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 - MORPHINE SULFATE, MORPHINE SULFATE
 - NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
 - NYSTATIN, NYSTATIN
 - ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 - OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

* PHARMACEUTICAL ASSOCIATES INC
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 PREDNISOLONE, PREDNISOLONE
 PROMETH HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 PROMETHAZINE WITH CODEINE, CODEINE PHOSPHATE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RISPERIDONE, RISPERIDONE
 SULFATRIM PEDIATRIC, SULFAMETHOXAZOLE
 THEOPHYLLINE, THEOPHYLLINE
 TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE
 VALPROIC ACID, VALPROIC ACID
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

PHARM SOURCING

* PHARMACEUTICAL SOURCING PARTNERS INC
 MESALAMINE, MESALAMINE

PHARMA LIFE

* PHARMA LIFE SCIENCES LLC
 LAMIVUDINE, LAMIVUDINE
 LEVETIRACETAM, LEVETIRACETAM
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 VALPROIC ACID, VALPROIC ACID

PHARMA RES SOFTWARE

* PHARMA RESEARCH SOFTWARE SOLUTION LLC
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

PHARMACHEMIE BV

* PHARMACHEMIE BV
 CARBOPLATIN, CARBOPLATIN
 CISPLATIN, CISPLATIN
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM

PHARMACIA

* PHARMACIA AND UPJOHN CO LLC
 CADUET, AMLODIPINE BESYLATE
 DILANTIN, PHENYTOIN

PHARMACIA AND UPJOHN

* PHARMACIA AND UPJOHN CO
 AROMASIN, EXEMESTANE
 AZULFIDINE EN-TABS, SULFASALAZINE
 AZULFIDINE, SULFASALAZINE
 CAVERJECT IMPULSE, ALPROSTADIL
 CAVERJECT, ALPROSTADIL
 CLEOCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 CLEOCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CLEOCIN T, CLINDAMYCIN PHOSPHATE
 CLEOCIN, CLINDAMYCIN PALMITATE HYDROCHLORIDE
 CLEOCIN, CLINDAMYCIN PHOSPHATE
 CORTEF, HYDROCORTISONE
 CORVERT, IBUTILIDE FUMARATE
 CYKLOKAPRON, TRANEXAMIC ACID
 DEPO-ESTRADIOL, ESTRADIOL CYPIONATE
 DEPO-PROVERA, MEDROXYPROGESTERONE ACETATE
 DEPO-TESTOSTERONE, TESTOSTERONE CYPIONATE
 EMCYT, ESTRAMUSTINE PHOSPHATE SODIUM
 ESTRING, ESTRADIOL
 GLYNASE, GLYBURIDE
 GLYSET, MIGLITOL
 HALCION, TRIAZOLAM
 LINCOCIN, LINCOMYCIN HYDROCHLORIDE
 OGEN 5, ESTROPIPATE
 PREPIDIL, DINOPROSTONE
 PROSTIN E2, DINOPROSTONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

- * PHARMACIA AND UPJOHN CO
PROSTIN VR PEDIATRIC, ALPROSTADIL
PROVERA, MEDROXYPROGESTERONE ACETATE
R-GENE 10, ARGININE HYDROCHLORIDE
SOLU-CORTEF, HYDROCORTISONE SODIUM SUCCINATE
SOLU-MEDROL, METHYLPREDNISOLONE SODIUM SUCCINATE
ZINECARD, DEXRAZOXANE HYDROCHLORIDE
- * PHARMACIA AND UPJOHN SUB PFIZER INC
DEPO-SUBQ PROVERA 104, MEDROXYPROGESTERONE ACETATE

PHARMACIA UPJOHN

- * PHARMACIA AND UPJOHN CO A SUB OF PFIZER INC
COLESTID, COLESTIPOL HYDROCHLORIDE
FLAVORED COLESTID, COLESTIPOL HYDROCHLORIDE

PHARMACOSMOS AS

- * PHARMACOSMOS AS
MONOFERRIC, FERRIC DERISOMALTOSE

PHARMACYCLICS INC

- * PHARMACYCLICS INC
IMBRUVICA, IBRUTINIB

PHARMADAX INC

- * PHARMADAX INC
ENTECAVIR, ENTECAVIR
LEVETIRACETAM, LEVETIRACETAM
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE

PHARMASCIENCE INC

- * PHARMASCIENCE INC
BUSULFAN, BUSULFAN
DECITABINE, DECITABINE
GANCICLOVIR SODIUM, GANCICLOVIR SODIUM

PHARMAXIS LTD

- * PHARMAXIS LTD
ARIDOL KIT, MANNITOL

PHARMTAK INC

- * PHARMTAK INC
OLANZAPINE, OLANZAPINE

PHOTOCURE ASA

- * PHOTOCURE ASA
CYSVIEW KIT, HEXAMINOLEVULINATE HYDROCHLORIDE

PIERRE FABRE DERMA

- * PIERRE FABRE DERMATOLOGIE
HEMANGEOL, PROPRANOLOL HYDROCHLORIDE

PIERREL

- * PIERREL S.P.A.
ORABLOC, ARTICAINA HYDROCHLORIDE

PINNACLE BIOLGS

- * PINNACLE BIOLOGICS INC
PHOTOFRIN, PORFIMER SODIUM

PIRAMAL CRITICAL

- * PIRAMAL CRITICAL CARE INC
GABLOFEN, BACLOFEN
GLYCOPYRROLATE, GLYCOPYRROLATE
ISOFLURANE, ISOFLURANE
MITIGO, MORPHINE SULFATE
OXACILLIN SODIUM, OXACILLIN SODIUM
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
SOJOURN, SEVOFLURANE
- * PIRAMAL CRITICAL CARE LTD
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM

PIRAMAL ENT

- * PIRAMAL ENTERPRISES LTD
ISOFLURANE, ISOFLURANE

PIRAMAL HLTHCARE UK

- * PIRAMAL HEALTHCARE UK LTD

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

* PIRAMAL HEALTHCARE UK LTD
 CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
 CLOBAZAM, CLOBAZAM
 DEFERASIROX, DEFERASIROX
 EPLERENONE, EPLERENONE
 LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
 TETRABENAZINE, TETRABENAZINE

PLD ACQUISITIONS

* PLD ACQUISITIONS LLC DBA AVEMA PHARMA SOLUTIONS
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)

PLD ACQUISITIONS LLC

* PLD ACQUISITIONS LLC
 LORATADINE, LORATADINE (OTC)
 ZOLMITRIPTAN, ZOLMITRIPTAN

PLIVA

* PLIVA INC
 AZITHROMYCIN, AZITHROMYCIN
 BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
 CIMETIDINE, CIMETIDINE
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 METRONIDAZOLE, METRONIDAZOLE
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
 WARFARIN SODIUM, WARFARIN SODIUM

PLIVA HRVATSKA DOO

* PLIVA HRVATSKA DOO
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE

PLIVA PHARM IND

* PLIVA PHARMACEUTICAL INDUSTRY INC
 TORSEMIDE, TORSEMIDE

PLX PHARMA

* PLX PHARMA INC
 VAZALORE, ASPIRIN (OTC)

POHL BOSKAMP

* POHL BOSKAMP
 NITROLINGUAL PUMPSPRAY, NITROGLYCERIN

POLYGEN PHARMS

* POLYGEN PHARMACEUTICALS INC
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

POLYMEDICA

* POLYMEDICA INDUSTRIES INC
 NEOPAP, ACETAMINOPHEN (OTC)

POWDER PHARMS

* POWDER PHARMACEUTICALS INC
 ZINGO, LIDOCAINE HYDROCHLORIDE

PRAGMA

* PRAGMA PHARMACEUTICALS LLC
 KEFLEX, CEPHALEXIN

PRASCO

* PRASCO LLC DBA PRASCO LABORATORIES
 EPLERENONE, EPLERENONE

PRAXAIR DISTRIBUTION

* PRAXAIR DISTRIBUTION INC
 NOXIVENT, NITRIC OXIDE

PRECISION DERMAT

* PRECISION DERMATOLOGY INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

* PRECISION DERMATOLOGY INC
 LOCID LIPOCREAM, HYDROCORTISONE BUTYRATE
 LOCID, HYDROCORTISONE BUTYRATE

PRECISION DOSE INC

* PRECISION DOSE INC
 PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE

PRECISION NUCLEAR

* PRECISION NUCLEAR LLC
 AMMONIA N 13, AMMONIA N-13
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

PRINSTON INC

* PRINSTON PHARMACEUTICAL INC
 AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
 ARIPIPIRAZOLE, ARIPIPIRAZOLE
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
 CAPTOPRIL, CAPTOPRIL
 CLONAZEPAM, CLONAZEPAM
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 ENTECAVIR, ENTECAVIR
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 FENOFIBRATE, FENOFIBRATE
 FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
 FUROSEMIDE, FUROSEMIDE
 GLIMEPIRIDE, GLIMEPIRIDE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRBESARTAN, IRBESARTAN
 LEVETIRACETAM, LEVETIRACETAM
 LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LISINOPRIL, LISINOPRIL
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHOCARBAMOL, METHOCARBAMOL
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 NEVIRAPINE, NEVIRAPINE
 OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 PAROXETINE MESYLATE, PAROXETINE MESYLATE
 PAROXETINE, PAROXETINE HYDROCHLORIDE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
 RISPERIDONE, RISPERIDONE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TELMISARTAN, TELMISARTAN
 TEMAZEPAM, TEMAZEPAM
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 VALSARTAN, VALSARTAN
 VORICONAZOLE, VORICONAZOLE

PROF DSPLS

* PROFESSIONAL DISPOSABLES INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

- * PROFESSIONAL DISPOSABLES INC
 - PREVANTICS MAXI SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
 - PREVANTICS SWAB, CHLORHEXIDINE GLUCONATE (OTC)
 - PREVANTICS SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)

PROGENICS PHARMS INC

- * PROGENICS PHARMACEUTICALS INC
 - AZEDRA, IOBENGUANE I-131

PROVELL

- * PROVELL PHARMACEUTICALS LLC
 - EUTHYROX, LEVOTHYROXINE SODIUM **

PROVENSIS

- * PROVENSIS LTD
 - VARITHENA, POLIDOCANOL

PROVEPHARM SAS

- * PROVEPHARM SAS
 - PROVAYBLUE, METHYLENE BLUE

PTC THERAP

- * PTC THERAPEUTICS INC
 - EMFLAZA, DEFLAZACORT

PULMOFLOW INC

- * PULMOFLOW INC
 - KITABIS PAK, TOBRAMYCIN

PUMA BIOTECH

- * PUMA BIOTECHNOLOGY INC
 - NERLYNX, NERATINIB MALEATE

PUNISKA

- * PUNISKA HEALTHCARE PRIVATE LTD
 - GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 - ZOLEDRONIC ACID, ZOLEDRONIC ACID

PURACAP PHARM

- * PURACAP PHARMACEUTICAL LLC
 - MELOXICAM, MELOXICAM

PURACAP PHARM LLC

- * PURACAP PHARMACEUTICAL LLC
 - BENZONATATE, BENZONATATE
 - ERGOCALCIFEROL, ERGOCALCIFEROL
 - ETHOSUXIMIDE, ETHOSUXIMIDE
 - MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 - NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
 - OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
 - PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE

PURDUE

- * PURDUE GMP CENTER LLC
 - SEROMYCIN, CYCLOSERINE

PURDUE PHARMA LP

- * PURDUE PHARMA LP
 - ADHANSIA XR, METHYLPHENIDATE HYDROCHLORIDE
 - BUTRANS, BUPRENORPHINE
 - HYSINGLA ER, HYDROCODONE BITARTRATE
 - MS CONTIN, MORPHINE SULFATE
 - OXYCONTIN, OXYCODONE HYDROCHLORIDE

**** Q ******Q BIOMED**

- * Q BIOMED INC
 - METASTRON, STRONTIUM CHLORIDE SR-89
 - STRONTIUM CHLORIDE SR-89, STRONTIUM CHLORIDE SR-89

QILU

- * QILU PHARMACEUTICAL CO LTD
 - ABIRATERONE ACETATE, ABIRATERONE ACETATE
 - CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
 - CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
 - CEFTRIAZONE, CEFTRIAZONE SODIUM
 - EXEMESTANE, EXEMESTANE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** Q ****

* QILU PHARMACEUTICAL CO LTD
 FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 OLANZAPINE, OLANZAPINE
 OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 OXALIPLATIN, OXALIPLATIN
 PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
 SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
 TADALAFIL, TADALAFIL
 TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE

QINGDAO BAHEAL PHARM

* QINGDAO BAHEAL PHARMACEUTICAL CO LTD
 BENZONATATE, BENZONATATE
 CELECOXIB, CELECOXIB
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 FOLIC ACID, FOLIC ACID
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

QOL MEDCL

* QOL MEDICAL LLC
 ETHAMOLIN, ETHANOLAMINE OLEATE

QUAGEN

* QUAGEN PHARMACEUTICALS LLC
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
 HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

QUEEN HAMAMATSU PET

* QUEEN HAMAMATSU PET IMAGING CENTER
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**** R ******R-PHARM US LLC**

* R-PHARM US LLC
 IXEMPRA KIT, IXABEPILONE

RADIOMEDIX

* RADIOMEDIX INC
 DETECTNET, COPPER DOTATATE CU-64

RADIUS HEALTH INC

* RADIUS HEALTH INC
 TYMLOS, ABALOPARATIDE

RANBAXY

* RANBAXY SIGNATURE LLC
 RIOMET, METFORMIN HYDROCHLORIDE

RB HLTH

* RB HEALTH US LLC
 DELSYM, DEXTROMETHORPHAN POLISTIREX (OTC)
 MUCINEX D, GUAIFENESIN (OTC)
 MUCINEX DM, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
 MUCINEX, GUAIFENESIN (OTC)

RECIP

* RECIP AB
 THYROSAFE, POTASSIUM IODIDE (OTC)

RECORDATI RARE

* RECORDATI RARE DISEASES INC
 CARBAGLU, CARGLUMIC ACID
 CHEMET, SUCCIMER
 COSMEGEN, DACTINOMYCIN
 CYSTADROPS, CYSTEAMINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** R ****

* RECORDATI RARE DISEASES INC
 DESOXYN, METHAMPHETAMINE HYDROCHLORIDE
 ISTURISA, OSILODROSTAT PHOSPHATE
 NEOPROFEN, IBUPROFEN LYSINE
 SIGNIFOR LAR KIT, PASIREOTIDE PAMOATE
 SIGNIFOR, PASIREOTIDE DIASPARTATE
 TRANXENE, CLORAZEPATE DIPOTASSIUM

RECRO GAINESVILLE

* RECRO GAINESVILLE LLC
 VERELAN PM, VERAPAMIL HYDROCHLORIDE
 VERELAN, VERAPAMIL HYDROCHLORIDE

REDHILL

* REDHILL BIOPHARMA INC
 AEMCOLO, RIFAMYCIN SODIUM
 MOVANTIK, NALOXEGOL OXALATE
 * REDHILL BIOPHARMA LTD
 TALICIA, AMOXICILLIN

RELIANCE LIFE

* RELIANCE LIFE SCIENCES PVT LTD
 CAPECITABINE, CAPECITABINE

RELYPSA INC

* RELYPSA INC
 VELTASSA, PATIROMER SORBITE CALCIUM

REMPEX PHARMS

* REMPEX PHARMACEUTICALS
 MINOCIN, MINOCYCLINE HYDROCHLORIDE
 * REMPEX PHARMACEUTICALS A WHOLLY OWNED SUB OF MELINTA THERAPEUTICS INC
 VABOMERE, MEROPENEM

RENATA

* RENATA LTD
 RISPERIDONE, RISPERIDONE
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM

REYOUNG

* REYOUNG PHARMACEUTICALS CO LTD
 SILDENAFIL CITRATE, SILDENAFIL CITRATE

RHODES PHARMS

* RHODES PHARMACEUTICALS LP
 APTENSIO XR, METHYLPHENIDATE HYDROCHLORIDE
 BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DILAUDID, HYDROMORPHONE HYDROCHLORIDE
 FENOFIBRATE (MICRONIZED), FENOFIBRATE
 FENOFIBRATE, FENOFIBRATE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 LIDOCAINE, LIDOCAINE
 MORPHINE SULFATE, MORPHINE SULFATE
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 THEOPHYLLINE, THEOPHYLLINE

RHYTHM

* RHYTHM PHARMACEUTICALS INC
 IMCIVREE, SETMELANOTIDE ACETATE

RICONPHARMA LLC

* RICONPHARMA LLC
 BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
 CHLORTHALIDONE, CHLORTHALIDONE
 DOFETILIDE, DOFETILIDE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
 METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
 SCOPOLAMINE, SCOPOLAMINE
 TRIAZOLAM, TRIAZOLAM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** R ******RIGEL PHARMS INC**

* RIGEL PHARMACEUTICALS INC
TAVALISSE, FOSTAMATINIB DISODIUM

RISING

* RISING PHARMA HOLDING INC
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FLUNISOLIDE, FLUNISOLIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE

* RISING PHARMA HOLDINGS INC
ABIRATERONE ACETATE, ABIRATERONE ACETATE
ACETIC ACID, ACETIC ACID, GLACIAL
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
AZATHIOPRINE, AZATHIOPRINE
BUDESONIDE, BUDESONIDE
BUMETANIDE, BUMETANIDE
CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CROMOLYN SODIUM, CROMOLYN SODIUM
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DAPSONE, DAPSONE
DESOXIMETASONE, DESOXIMETASONE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
DOXERCALCIFEROL, DOXERCALCIFEROL
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDROCORTISONE, HYDROCORTISONE
LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN, AMOXICILLIN
LEVOCARNITINE, LEVOCARNITINE
LEVOFLOXACIN, LEVOFLOXACIN
METAXALONE, METAXALONE
METHIMAZOLE, METHIMAZOLE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
NATEGLINIDE, NATEGLINIDE
NITAZOXANIDE, NITAZOXANIDE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
PARICALCITOL, PARICALCITOL
PERPHENAZINE, PERPHENAZINE
POTASSIUM CITRATE, POTASSIUM CITRATE
PREGABALIN, PREGABALIN
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
RISPERIDONE, RISPERIDONE
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
SEVELAMER CARBONATE, SEVELAMER CARBONATE
SULFAMYLON, MAFENIDE ACETATE
TEMOZOLOMIDE, TEMOZOLOMIDE
TOREMIFENE CITRATE, TOREMIFENE CITRATE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE
ZILEUTON, ZILEUTON

* RISING PHARMACEUTICALS
URSODIOL, URSODIOL

RK PHARMA

* RK PHARMA INC
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
MITOMYCIN, MITOMYCIN
MYCOPHENOLIC ACID, MYCOPHENOLIC ACID
PALIPERIDONE, PALIPERIDONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** R ******ROCHE PALO**

- * ROCHE PALO ALTO LLC
 - CELLCEPT, MYCOPHENOLATE MOFETIL
 - CELLCEPT, MYCOPHENOLATE MOFETIL HYDROCHLORIDE

ROCKWELL MEDICAL INC

- * ROCKWELL MEDICAL INC
 - TRIFERIC AVNU, FERRIC PYROPHOSPHATE CITRATE
 - TRIFERIC, FERRIC PYROPHOSPHATE CITRATE

ROMARK

- * ROMARK LABORATORIES
 - ALINIA, NITAZOXANIDE

ROUSES POINT PHARMS

- * ROUSES POINT PHARMACEUTICALS LLC
 - LEVETIRACETAM, LEVETIRACETAM

ROXANE

- * ROXANE LABORATORIES INC
 - METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE

RUBICON

- * RUBICON RESEARCH PRIVATE LTD
 - AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 - AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 - BACLOFEN, BACLOFEN
 - BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
 - BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 - CARVEDILOL, CARVEDILOL
 - CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 - DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
 - DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
 - GABAPENTIN, GABAPENTIN
 - LAMOTRIGINE, LAMOTRIGINE
 - LORATADINE, LORATADINE (OTC)
 - METOPROLOL TARTRATE, METOPROLOL TARTRATE
 - MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
 - OXCARBAZEPINE, OXCARBAZEPINE
 - OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 - PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 - RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 - SILDENAFIL CITRATE, SILDENAFIL CITRATE
 - TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 - TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

RVL PHARMS

- * RVL PHARMACEUTICALS INC
 - UPNEEQ, OXYMETAZOLINE HYDROCHLORIDE

**** S ******SAGE PRODS**

- * SAGE PRODUCTS INC
 - CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)

SAGE THERAP

- * SAGE THERAPEUTICS INC
 - ZULRESSO, BREXANOLONE

SAGENT PHARMS

- * SAGENT PHARMACEUTICALS INC
 - CAFFEINE CITRATE, CAFFEINE CITRATE
 - DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 - FLUMAZENIL, FLUMAZENIL
 - HALOPERIDOL, HALOPERIDOL LACTATE
 - HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
 - HEPARIN SODIUM, HEPARIN SODIUM
 - LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
 - LEVETIRACETAM, LEVETIRACETAM
 - NAFCILLIN SODIUM, NAFCILLIN SODIUM
 - ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
 - OXACILLIN SODIUM, OXACILLIN SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SAGENT PHARMACEUTICALS INC
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

SAGENT PHARMS INC

* SAGENT PHARMACEUTICALS INC
 ACETYLCYSTEINE, ACETYLCYSTEINE
 AMIKACIN SULFATE, AMIKACIN SULFATE
 AMPICILLIN SODIUM, AMPICILLIN SODIUM
 CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
 CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
 CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
 DAPTOMYCIN, DAPTOMYCIN
 DECITABINE, DECITABINE
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
 EPTIFIBATIDE, EPTIFIBATIDE
 ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
 FLUOROURACIL, FLUOROURACIL
 FULVESTRANT, FULVESTRANT
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 GLYDO, LIDOCAINE HYDROCHLORIDE
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
 LINEZOLID, LINEZOLID
 MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
 MESNA, MESNA
 METHOCARBAMOL, METHOCARBAMOL
 METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
 METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
 METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
 OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
 OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
 OXYTOCIN, OXYTOCIN
 PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
 PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
 PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
 PROPOFOL, PROPOFOL
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
 SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
 THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
 VECURONIUM BROMIDE, VECURONIUM BROMIDE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

SALIX

* SALIX PHARMACEUTICALS INC
 FENOGLIDE, FENOFIBRATE
 PLENVU, ASCORBIC ACID
 RELISTOR, METHYLNALTREXONE BROMIDE
 TRULANCE, PLECANATIDE
 UCERIS, BUDESONIDE
 ZEGERID, OMEPRAZOLE

SALIX PHARMS

* SALIX PHARMACEUTICALS INC
 ANUSOL HC, HYDROCORTISONE
 DIURIL, CHLOROTHIAZIDE
 MOVIPREP, ASCORBIC ACID
 OSMOPREP, SODIUM PHOSPHATE, DIBASIC, ANHYDROUS
 RELISTOR, METHYLNALTREXONE BROMIDE
 XIFAXAN, RIFAXIMIN

SAMSON MEDCL

* SAMSON MEDICAL TECHNOLOGIES LLC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

- * SAMSON MEDICAL TECHNOLOGIES LLC
 CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
 CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE
 CEFOXITIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
 CEFTRIAZONE, CEFTRIAZONE SODIUM
 VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE
- SANDOZ**
- * SANDOZ
 DOCETAXEL, DOCETAXEL
- * SANDOZ INC
 ALPRAZOLAM, ALPRAZOLAM
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 AMOXICILLIN, AMOXICILLIN
 AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
 AMPICILLIN SODIUM, AMPICILLIN SODIUM
 AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
 APREPITANT, APREPITANT
 ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
 AZITHROMYCIN, AZITHROMYCIN
 BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
 BICALUTAMIDE, BICALUTAMIDE
 BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
 BUMETANIDE, BUMETANIDE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CAFERGOT, CAFFEINE
 CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN
 CARVEDILOL, CARVEDILOL
 CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
 CEFDINIR, CEFDINIR
 CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
 CEFPROZIL, CEFPROZIL
 CEFTRIAZONE, CEFTRIAZONE SODIUM
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
 CHOLESTYRAMINE, CHOLESTYRAMINE
 CLARITHROMYCIN, CLARITHROMYCIN
 CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
 CLONAZEPAM, CLONAZEPAM
 COSYNTROPIN, COSYNTROPIN
 CYCLOSPORINE, CYCLOSPORINE
 DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
 DESLORATADINE, DESLORATADINE
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
 DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
 ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
 EPLERENONE, EPLERENONE
 ETODOLAC, ETODOLAC
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
 FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
 FUROSEMIDE, FUROSEMIDE
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 GLIPIZIDE, GLIPIZIDE
 HALOPERIDOL, HALOPERIDOL
 HEPARIN SODIUM, HEPARIN SODIUM
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
 IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
 INDOMETHACIN, INDOMETHACIN
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SANDOZ INC
 IRBESARTAN, IRBESARTAN
 ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
 ITRACONAZOLE, ITRACONAZOLE
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 LANSOPRAZOLE, LANSOPRAZOLE
 LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
 LEVOFLOXACIN, LEVOFLOXACIN
 LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LORAZEPAM, LORAZEPAM
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 LOVASTATIN, LOVASTATIN
 MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
 METAXALONE, METAXALONE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHAZOLAMIDE, METHAZOLAMIDE
 METHYLPREDNISOLONE, METHYLPREDNISOLONE
 METOLAZONE, METOLAZONE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 NADOLOL, NADOLOL
 NAFCILLIN SODIUM, NAFCILLIN SODIUM
 NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
 NIZATIDINE, NIZATIDINE
 OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 OMEPRAZOLE, OMEPRAZOLE
 ONDANSETRON, ONDANSETRON
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
 OXALIPLATIN, OXALIPLATIN
 OXAPROZIN, OXAPROZIN
 OXAZEPAM, OXAZEPAM
 PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
 PENICILLIN G SODIUM, PENICILLIN G SODIUM
 PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
 PERPHENAZINE, PERPHENAZINE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE, GLIMEPIRIDE
 PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 QUINIDINE SULFATE, QUINIDINE SULFATE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RIBAVIRIN, RIBAVIRIN
 RIFAMPIN, RIFAMPIN
 RISPERIDONE, RISPERIDONE
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 SULFADIAZINE, SULFADIAZINE
 TACROLIMUS, TACROLIMUS
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TEMAZEPAM, TEMAZEPAM
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

SANDOZ CANADA INC

* SANDOZ CANADA INC
 INFUVITE ADULT, ALPHA-TOCOPHEROL ACETATE
 INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE), ASCORBIC ACID
 INFUVITE PEDIATRIC, ASCORBIC ACID

SANDOZ INC

* SANDOZ INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SANDOZ INC
 ACETAMINOPHEN, ACETAMINOPHEN
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 ANECTINE, SUCCINYLCHOLINE CHLORIDE
 ANGIOMAX, BIVALIRUDIN
 ARISTOSPAN, TRIAMCINOLONE HEXACETONIDE
 ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 BETOPTIC, BETAXOLOL HYDROCHLORIDE
 BIMATOPROST, BIMATOPROST
 BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
 BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
 BUDESONIDE, BUDESONIDE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CARBOPLATIN, CARBOPLATIN
 CARTEOLOL HYDROCHLORIDE, CARTEOLOL HYDROCHLORIDE
 CEFTRIAZONE, CEFTRIAZONE SODIUM
 CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
 CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
 CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
 CROMOLYN SODIUM, CROMOLYN SODIUM
 CYANOCOBALAMIN, CYANOCOBALAMIN
 DECITABINE, DECITABINE
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DIGOXIN, DIGOXIN
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
 DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
 DOXERCALCIFEROL, DOXERCALCIFEROL
 ENALAPRIL MALEATE, ENALAPRIL MALEATE
 ENOXAPARIN SODIUM, ENOXAPARIN SODIUM
 EPHEDRINE SULFATE, EPHEDRINE SULFATE
 EZETIMIBE, EZETIMIBE
 FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE
 FLUMAZENIL, FLUMAZENIL
 FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
 FULVESTRANT, FULVESTRANT
 GATIFLOXACIN, GATIFLOXACIN
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 GLATOPA, GLATIRAMER ACETATE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
 GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 ISONIAZID, ISONIAZID
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN, AMOXICILLIN
 LATANOPROST, LATANOPROST
 LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
 LINEZOLID, LINEZOLID
 MAXITROL, DEXAMETHASONE
 MESALAMINE, MESALAMINE
 METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
 METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 MYDRIACYL, TROPICAMIDE
 NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
 NEVIRAPINE, NEVIRAPINE
 NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
 OLANZAPINE, OLANZAPINE
 OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SANDOZ INC
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PARICALCITOL, PARICALCITOL
 PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 QOLIANA, BRIMONIDINE TARTRATE
 RASAGILINE MESYLATE, RASAGILINE MESYLATE
 REGONOL, PYRIDOSTIGMINE BROMIDE
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 SILODOSIN, SILODOSIN
 SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
 TELMISARTAN, TELMISARTAN
 TERIFLUNOMIDE, TERIFLUNOMIDE
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 TIGECYCLINE, TIGECYCLINE
 TIMOLOL MALEATE, TIMOLOL MALEATE
 TOBREX, TOBRAMYCIN
 TREPROSTINIL, TREPROSTINIL
 TRIFLURIDINE, TRIFLURIDINE
 TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VORICONAZOLE, VORICONAZOLE
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

SANOCHEMIA CORP USA

* SANOCHEMIA CORP USA
 SCANLUX-300, IOPAMIDOL
 SCANLUX-370, IOPAMIDOL

SANOFI

* SANOFI GENZYME
 HECTOROL, DOXERCALCIFEROL
 RENVELA, SEVELAMER CARBONATE

SANOFI AVENTIS US

* SANOFI AVENTIS US INC
 JEVTANA KIT, CABAZITAXEL

* SANOFI AVENTIS US LLC
 ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
 ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
 AMARYL, GLIMEPIRIDE
 AMBIEN CR, ZOLPIDEM TARTRATE
 AMBIEN, ZOLPIDEM TARTRATE
 ARAVA, LEFLUNOMIDE
 AUBAGIO, TERIFLUNOMIDE
 AVALIDE, HYDROCHLOROTHIAZIDE
 AVAPRO, IRBESARTAN
 CHILDREN'S ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 DIABETA, GLYBURIDE
 ELOXATIN, OXALIPLATIN
 FERRLECIT, SODIUM FERRIC GLUCONATE COMPLEX
 FLOMAX, TAMSULOSIN HYDROCHLORIDE
 GAVISCON, ALUMINUM HYDROXIDE (OTC)
 LOVENOX (PRESERVATIVE FREE), ENOXAPARIN SODIUM
 LOVENOX, ENOXAPARIN SODIUM
 MULTAQ, DRONEDARONE HYDROCHLORIDE
 NASACORT ALLERGY 24 HOUR, TRIAMCINOLONE ACETONIDE (OTC)
 NICODERM CQ, NICOTINE (OTC)
 PLAVIX, CLOPIDOGREL BISULFATE
 PRIFTIN, RIFAPENTINE
 PRIMAQUINE, PRIMAQUINE PHOSPHATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SANOFI AVENTIS US LLC
 RIFADIN, RIFAMPIN
 TAXOTERE, DOCETAXEL
 XYZAL ALLERGY 24HR, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)
 XYZAL, LEVOCETIRIZINE DIHYDROCHLORIDE

SANOFI US

* SANOFI US
 ZANTAC 150, RANITIDINE HYDROCHLORIDE (OTC)
 ZANTAC 75, RANITIDINE HYDROCHLORIDE (OTC)

SANTARUS INC

* SANTARUS INC
 GLUMETZA, METFORMIN HYDROCHLORIDE

SAOL THERAPS RES LTD

* SAOL THERAPEUTICS RESEARCH LTD
 LIORESAL, BACLOFEN

SAPTALIS PHARMS

* SAPTALIS PHARMACEUTICALS LLC
 ACETIC ACID, ACETIC ACID, GLACIAL
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

SAREPTA THERAPS INC

* SAREPTA THERAPEUTICS INC
 EXONDYS 51, ETEPLIRSEN
 VYONDYS 53, GOLODIRSEN

SAVIOR LIFETEC CORP

* SAVIOR LIFETEC CORP
 ERTAPENEM SODIUM, ERTAPENEM SODIUM
 MEROPENEM, MEROPENEM

SAWAI USA

* SAWAI USA INC
 PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM

SB PHARMCO

* SB PHARMCO PUERTO RICO INC
 AVANDIA, ROSIGLITAZONE MALEATE

SCHERING

* SCHERING CORP
 INTEGRILIN, EPTIFIBATIDE
 NOXAFIL, POSACONAZOLE

SCIECURE PHARMA INC

* SCIECURE PHARMA INC
 BUDESONIDE, BUDESONIDE
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE

SCIEGEN PHARMS INC

* SCIEGEN PHARMACEUTICALS INC
 AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
 ARIPIPRAZOLE, ARIPIPRAZOLE
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CARISOPRODOL, CARISOPRODOL
 CELECOXIB, CELECOXIB
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 ETHACRYNIC ACID, ETHACRYNIC ACID
 EZETIMIBE, EZETIMIBE
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 GABAPENTIN, GABAPENTIN
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRBESARTAN, IRBESARTAN
 LAMOTRIGINE, LAMOTRIGINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ******* SCIEGEN PHARMACEUTICALS INC**

LEVETIRACETAM, LEVETIRACETAM
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 METAXALONE, METAXALONE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 NABUMETONE, NABUMETONE
 NAPROXEN SODIUM, NAPROXEN SODIUM
 NAPROXEN, NAPROXEN
 OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
 OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 PREGABALIN, PREGABALIN
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
 RANOLAZINE, RANOLAZINE
 SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE

SCILEX PHARMS INC

*** SCILEX PHARMACEUTICALS**
 ZTLIDO, LIDOCAINE

SCINOPHARM TAIWAN

*** SCINOPHARM TAIWAN LTD**
 FONDAPARINUX SODIUM, FONDAPARINUX SODIUM

SEAGEN

*** SEAGEN INC**
 TUKYSA, TUCATINIB

SEBELA IRELAND LTD

*** SEBELA IRELAND LTD**
 BRISDELLE, PAROXETINE MESYLATE
 IMURAN, AZATHIOPRINE
 LOTRONEX, ALOSETRON HYDROCHLORIDE
 MICORT-HC, HYDROCORTISONE ACETATE
 MOTOFEN, ATROPINE SULFATE
 NAFTIN, NAFTIFINE HYDROCHLORIDE
 ONMEL, ITRACONAZOLE
 PEXEVA, PAROXETINE MESYLATE
 PRAMOSONE, HYDROCORTISONE ACETATE
 RIDAURA, AURANOFIN

SECAN PHARMS

*** SECAN PHARMACEUTICALS INC**
 LEVETIRACETAM, LEVETIRACETAM

SECURA

*** SECURA BIO INC**
 COPIKTRA, DUVELISIB
 FARYDAK, PANOBINOSTAT LACTATE

SEDOR PHARMS LLC

*** SEDOR PHARMACEUTICALS LLC**
 SESQUIENT, FOSPHENYTOIN SODIUM

SENTYNL THERAPS INC

*** SENTYNL THERAPEUTICS INC**
 LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE

SEPTODONT

*** SEPTODONT INC**
 BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE

SEPTODONT HOLDING

*** SEPTODONT HOLDING SAS**
 ORAVERSE, PHENTOLAMINE MESYLATE

SEPTODONT INC

*** SEPTODONT INC**
 LIDOCAINE, LIDOCAINE
 PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, EPINEPHRINE BITARTRATE
 PRILOCAINE HYDROCHLORIDE, PRILOCAINE HYDROCHLORIDE

SERB SA

*** SERB SA**
 CYANOKIT, HYDROXOCOBALAMIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

SETON PHARM

* SETON PHARMACEUTICAL LLC
PEDIAPRED, PREDNISOLONE SODIUM PHOSPHATE

SETON PHARMS

* SETON PHARMACEUTICALS LLC
PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE

SHANDONG

* SHANDONG NEW TIME PHARMACEUTICAL CO LTD
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM

SHANDONG XINHUA

* SHANDONG XINHUA PHARMACEUTICAL CO LTD
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)

SHANGHAI HENGRUI

* SHANGHAI HENGRUI PHARMACEUTICAL CO LTD
DESFLURANE, DESFLURANE
SEVOFLURANE, SEVOFLURANE

SHENZHEN TECHDOW

* SHENZHEN TECHDOW PHARMACEUTICAL CO LTD
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM

SHERTECH LABS LLC

* SHERTECH LABORATORIES LLC
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

SHILPA MEDICARE

* SHILPA MEDICARE LTD
AZACITIDINE, AZACITIDINE

SHILPA MEDICARE LTD

* SHILPA MEDICARE LTD
BUSULFAN, BUSULFAN
CAPECITABINE, CAPECITABINE
DOCETAXEL, DOCETAXEL
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
IMATINIB MESYLATE, IMATINIB MESYLATE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE

SHIONOGI INC

* SHIONOGI INC
FETROJA, CEFIDEROCOL SULFATE TOSYLATE
MULPLETA, LUSUTROMBOPAG

SHIRE ORPHAN THERAP

* SHIRE ORPHAN THERAPIES LLC
FIRAZYR, ICATIBANT ACETATE

SIDMAK LABS INDIA

* SIDMAK LABORATORIES INDIA PVT LTD
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE

SIGA TECHNOLOGIES

* SIGA TECHNOLOGIES INC
TPOXX, TECOVIRIMAT

SIGMAPHARM LABS LLC

* SIGMAPHARM LABORATORIES LLC
ACITRETIN, ACITRETIN
ADEFOVIR DIPIVOXIL, ADEFOVIR DIPIVOXIL
AMBRISENTAN, AMBRISENTAN
AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
ASENAPINE MALEATE, ASENAPINE MALEATE
DISULFIRAM, DISULFIRAM
DOFETILIDE, DOFETILIDE
ERGOALCIFEROL, ERGOALCIFEROL
FLUCYTOSINE, FLUCYTOSINE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SIGMAPHARM LABORATORIES LLC
 LIOETHYRONINE SODIUM, LIOETHYRONINE SODIUM
 NITROGLYCERIN, NITROGLYCERIN
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
 SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE
 TICAGRELOR, TICAGRELOR

SINOTHERAPEUTICS INC

* SINOTHERAPEUTICS INC
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 POSACONAZOLE, POSACONAZOLE
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE

SK LIFE

* SK LIFE SCIENCE INC
 XCOPRI, CENOBAMATE

SKINMEDICA

* SKINMEDICA INC
 VANIQA, EFLORNITHINE HYDROCHLORIDE

SKYEPHARMA AG

* SKYEPHARMA AG
 TRIGLIDE, FENOFIBRATE

SLATE

* SLATE RUN PHARMACEUTICALS LLC
 CILOSTAZOL, CILOSTAZOL
 DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
 METHOCARBAMOL, METHOCARBAMOL
 PROMETHAZINE DM, DEXTROMETHORPHAN HYDROBROMIDE

SLAYBACK PHARMA LLC

* SLAYBACK PHARMA LLC
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
 ICATIBANT ACETATE, ICATIBANT ACETATE
 MERZEE, ETHINYL ESTRADIOL

SMITHKLINE BEECHAM

* SMITHKLINE BEECHAM
 LOVAZA, OMEGA-3-ACID ETHYL ESTERS
 * SMITHKLINE BEECHAM (CORK) LTD IRELAND
 COREG CR, CARVEDILOL PHOSPHATE
 COREG, CARVEDILOL

SOAPCO

* SOAPCO INC
 BRIAN CARE, CHLORHEXIDINE GLUCONATE (OTC)

SOCORRO

* SOCORRO NST-1 LLC
 NYSTATIN, NYSTATIN

SOFGEN PHARMS

* SOFGEN PHARMACEUTICALS
 NIMODIPINE, NIMODIPINE
 * SOFGEN PHARMACEUTICALS LLC
 IBUPROFEN, IBUPROFEN (OTC)
 OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
 PROGESTERONE, PROGESTERONE

SOFIE

* SOFIE CO DBA SOFIE
 AMMONIA N 13, AMMONIA N-13
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18
 * SOFIE CO DBA SOFIE (FKA ZEVACOR PHARMA INC)
 AMMONIA N 13, AMMONIA N-13
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

SOLARIS PHARMA CORP

* SOLARIS PHARMA CORP
 ACYCLOVIR, ACYCLOVIR

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SOLARIS PHARMA CORP
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE

SOMERSET

* SOMERSET PHARMACEUTICALS INC
EMSAM, SELEGILINE

* SOMERSET THERAPEUTICS LLC
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
LATANOPROST, LATANOPROST
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

SOMERSET THERAPS LLC

* SOMERSET THERAPEUTICS LLC
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BIMATOPROST, BIMATOPROST
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
CYANOCOBALAMIN, CYANOCOBALAMIN
DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
METHOCARBAMOL, METHOCARBAMOL
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
TOBRAMYCIN, TOBRAMYCIN
TROPICAMIDE, TROPICAMIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

SOMMER PHARMS II LLC

* SOMMER PHARMACEUTICALS II LLC
TECHNETIUM TC99M MERTIATIDE KIT, TECHNETIUM TC-99M MERTIATIDE KIT

SPARC

* SUN PHARMA ADVANCED RESEARCH CO LTD
ELEPSIA XR, LEVETIRACETAM

SPECGX LLC

* SPECGX LLC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ANAFRANIL, CLOMIPRAMINE HYDROCHLORIDE
ANEXSIA 5/325, ACETAMINOPHEN
ANEXSIA 7.5/325, ACETAMINOPHEN
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
FENTANYL CITRATE, FENTANYL CITRATE
FENTANYL-100, FENTANYL
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-37, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-62, FENTANYL
FENTANYL-75, FENTANYL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHADOSE, METHADONE HYDROCHLORIDE
METHYLIN ER, METHYLPHENIDATE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SPECGX LLC
 METHYLIN, METHYLPHENIDATE HYDROCHLORIDE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
 OXYCET, ACETAMINOPHEN
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
 PAMELOR, NORTRIPTYLINE HYDROCHLORIDE
 RESTORIL, TEMAZEPAM
 ROXICODONE, OXYCODONE HYDROCHLORIDE
 TOFRANIL, IMIPRAMINE HYDROCHLORIDE

SPECTRA MDCL DEVICES

* SPECTRA MEDICAL DEVICES INC
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE

SPECTRON MRC LLC

* SPECTRON MRC LLC
 AMMONIA N 13, AMMONIA N-13
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

SPIL

* SUN PHARMA INDUSTRIES LTD
 KASPARGO SPRINKLE, METOPROLOL SUCCINATE
 NIFEDIPINE, NIFEDIPINE
 OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)

SPROUT PHARMS

* SPROUT PHARMACEUTICALS INC
 ADDYI, FLIBANSERIN

SQUARE PHARMS LTD

* SQUARE PHARMACEUTICALS LTD
 ACYCLOVIR, ACYCLOVIR
 VALSARTAN, VALSARTAN

ST RENATUS

* ST RENATUS LLC
 KOVANAZE, OXYMETAZOLINE HYDROCHLORIDE

STAND HOMEOPATH

* STANDARD HOMEOPATHIC CO
 IVY BLOCK, BENTOQUATAM (OTC)

STASON PHARMS

* STASON PHARMACEUTICALS INC
 PURINETHOL, MERCAPTOPYRINE

STI PHARMA LLC

* STI PHARMA LLC
 ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
 CARMUSTINE, CARMUSTINE
 CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
 MYAMBUTOL, ETHAMBUTOL HYDROCHLORIDE
 THIOTEPA, THIOTEPA
 TRIACIN-C, CODEINE PHOSPHATE

STIEFEL

* STIEFEL LABORATORIES INC
 DUAC, BENZOYL PEROXIDE

STIEFEL LABS INC

* STIEFEL LABORATORIES INC
 SORIATANE, ACITRETIN

STRIDES PHARMA

* STRIDES PHARMA GLOBAL PTE LTD
 ABACAVIR SULFATE, ABACAVIR SULFATE
 ACARBOSE, ACARBOSE
 ACETAZOLAMIDE, ACETAZOLAMIDE
 ALBENDAZOLE, ALBENDAZOLE
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* STRIDES PHARMA GLOBAL PTE LTD
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 BENZONATATE, BENZONATATE
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
 BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
 CALCITRIOL, CALCITRIOL
 CARISOPRODOL, CARISOPRODOL
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
 CLARITHROMYCIN, CLARITHROMYCIN
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DUTASTERIDE, DUTASTERIDE
 EFAVIRENZ, EFAVIRENZ
 ERGOCALCIFEROL, ERGOCALCIFEROL
 ETHACRYNIC ACID, ETHACRYNIC ACID
 ETHOSUXIMIDE, ETHOSUXIMIDE
 FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
 GABAPENTIN, GABAPENTIN
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDROCORTISONE, HYDROCORTISONE
 IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
 IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)
 ITRACONAZOLE, ITRACONAZOLE
 KETOCONAZOLE, KETOCONAZOLE
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
 LAMIVUDINE, LAMIVUDINE
 LIDOCAINE, LIDOCAINE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 MEFENAMIC ACID, MEFENAMIC ACID
 MELOXICAM, MELOXICAM
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 METHOXSALLEN, METHOXSALLEN
 METRONIDAZOLE, METRONIDAZOLE
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 NEVIRAPINE, NEVIRAPINE
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
 OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE, POLYETHYLENE GLYCOL
 PIROXICAM, PIROXICAM
 POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 POTASSIUM CITRATE, POTASSIUM CITRATE
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 PREDNISONE, PREDNISONE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 ROFLUMILAST, ROFLUMILAST
 SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
 TACROLIMUS, TACROLIMUS
 TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
 TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 URSODIOL, URSODIOL
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

STRONGBRIDGE US

* STRONGBRIDGE US INC
 KEVEYIS, DICHLORPHENAMIDE

SUCAMPO PHARMA LLC

* SUCAMPO PHARMA AMERICAS LLC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SUCAMPO PHARMA AMERICAS LLC
AMITIZA, LUBIPROSTONE

SUN PHARM

* SUN PHARMACEUTICAL INDUSTRIES LTD
ABSORICA LD, ISOTRETINOIN
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
ALPRAZOLAM, ALPRAZOLAM
AMBRISENTAN, AMBRISENTAN
AMIFOSTINE, AMIFOSTINE
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BICALUTAMIDE, BICALUTAMIDE
BOSENTAN, BOSENTAN
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BYNFEZIA PEN, OCTREOTIDE ACETATE
CAFFEINE CITRATE, CAFFEINE CITRATE
CALCITRIOL, CALCITRIOL
CAPECITABINE, CAPECITABINE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARBIDOPA, LEVODOPA AND ENTACAPONE, CARBIDOPA
CARBOPLATIN, CARBOPLATIN
CERINTA, ETHINYL ESTRADIOL
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DALFAMPRIDINE, DALFAMPRIDINE
DEFERASIROX, DEFERASIROX
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DOFETILIDE, DOFETILIDE
DOXERCALCIFEROL, DOXERCALCIFEROL
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ENTACAPONE, ENTACAPONE
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
ESZOPICLONE, ESZOPICLONE
FEBUXOSTAT, FEBUXOSTAT
FENOFIBRATE, FENOFIBRATE
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE
FINASTERIDE, FINASTERIDE
FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
FOSAMPRENAVIR CALCIUM, FOSAMPRENAVIR CALCIUM
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GANIRELIX ACETATE, GANIRELIX ACETATE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IMATINIB MESYLATE, IMATINIB MESYLATE
INFUGEM, GEMCITABINE HYDROCHLORIDE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
KEMEYA, DROSPIRENONE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
KYRA, DROSPIRENONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SUN PHARMACEUTICAL INDUSTRIES LTD
 LANSOPRAZOLE, LANSOPRAZOLE
 LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
 LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
 LEVETIRACETAM, LEVETIRACETAM
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
 LORATADINE, LORATADINE (OTC)
 LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
 MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 MESALAMINE, MESALAMINE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
 NIACIN, NIACIN
 OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
 OMEPRAZOLE, OMEPRAZOLE (OTC)
 OPCICON ONE-STEP, LEVONORGESTREL (OTC)
 PALIPERIDONE, PALIPERIDONE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PREGABALIN, PREGABALIN
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RANOLAZINE, RANOLAZINE
 RISEDRONATE SODIUM, RISEDRONATE SODIUM
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 SUMATRIPTAN AND NAPROXEN SODIUM, NAPROXEN SODIUM
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 SYLEVIA, ETHINYL ESTRADIOL
 TADALAFIL, TADALAFIL
 TEMOZOLOMIDE, TEMOZOLOMIDE
 TETRABENAZINE, TETRABENAZINE
 TOBRAMYCIN, TOBRAMYCIN
 TOPIRAMATE, TOPIRAMATE
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 VECURONIUM BROMIDE, VECURONIUM BROMIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

SUN PHARM INDS

* SUN PHARMACEUTICAL INDUSTRIES LTD
 CARBIDOPA AND LEVODOPA, CARBIDOPA
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 DESLORATADINE, DESLORATADINE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 OLANZAPINE, OLANZAPINE
 ONDANSETRON, ONDANSETRON
 OXCARBAZEPINE, OXCARBAZEPINE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TIAGABINE HYDROCHLORIDE, TIAGABINE HYDROCHLORIDE

SUN PHARM INDS (IN)

* SUN PHARMACEUTICAL INDUSTRIES LTD
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 ZONISAMIDE, ZONISAMIDE

SUN PHARM INDS INC

* SUN PHARMACEUTICAL INDUSTRIES INC
 ABSORICA, ISOTRETINOIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SUN PHARMACEUTICAL INDUSTRIES INC
 AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 AN-SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID KIT
 CIS-MDP, TECHNETIUM TC-99M MEDRONATE KIT
 CIS-PYRO, TECHNETIUM TC-99M PYROPHOSPHATE KIT
 CLONAZEPAM, CLONAZEPAM
 CLOZAPINE, CLOZAPINE
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DIGOXIN, DIGOXIN
 ERGOCALCIFEROL, ERGOCALCIFEROL
 EURAX, CROTAMITON
 FLUMADINE, RIMANTADINE HYDROCHLORIDE
 GLIPIZIDE, GLIPIZIDE
 GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN (OTC)
 HALOG, HALCINONIDE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
 KENALOG, TRIAMCINOLONE ACETONIDE
 LITHIUM CARBONATE, LITHIUM CARBONATE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MIRTAZAPINE, MIRTAZAPINE
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 REPAGLINIDE, REPAGLINIDE
 TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
 TECHNETIUM TC-99M MEBROFENIN, TECHNETIUM TC-99M MEBROFENIN KIT
 TECHNETIUM TC99M MERTIATIDE KIT, TECHNETIUM TC-99M MERTIATIDE KIT
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 ULTRAVATE, HALOBETASOL PROPIONATE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

SUN PHARM INDS LTD

* SUN PHARMACEUTICAL INDUSTRIES LTD
 ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 ACETAMINOPHEN, ACETAMINOPHEN (OTC)
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 AZITHROMYCIN, AZITHROMYCIN
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 CARVEDILOL, CARVEDILOL
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 DOXYCYCLINE, DOXYCYCLINE
 FAMOTIDINE, FAMOTIDINE (OTC)
 FELODIPINE, FELODIPINE
 FENOFIBRATE, FENOFIBRATE
 FLECAINIDE ACETATE, FLECAINIDE ACETATE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 GABAPENTIN, GABAPENTIN
 GLYCOPYRROLATE, GLYCOPYRROLATE
 LEVETIRACETAM, LEVETIRACETAM
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 LISINAPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SUN PHARMACEUTICAL INDUSTRIES LTD
 LISINOPRIL, LISINOPRIL
 LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
 LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
 LORATADINE REDIDOSE, LORATADINE (OTC)
 LORATADINE, LORATADINE (OTC)
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
 NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
 ONDANSETRON, ONDANSETRON
 OXCARBAZEPINE, OXCARBAZEPINE
 PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
 RILUZOLE, RILUZOLE
 RISPERIDONE, RISPERIDONE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 TOPIRAMATE, TOPIRAMATE
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VALPROIC ACID, VALPROIC ACID

SUN PHARM INDUSTRIES

* SUN PHARMACEUTICAL INDUSTRIES INC
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 ALLOPURINOL, ALLOPURINOL
 BACTRIM DS, SULFAMETHOXAZOLE
 BACTRIM, SULFAMETHOXAZOLE
 CARVEDILOL PHOSPHATE, CARVEDILOL PHOSPHATE
 CHLORTHALIDONE, CHLORTHALIDONE
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 ERGOLOID MESYLATES, ERGOLOID MESYLATES
 FELODIPINE, FELODIPINE
 IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MINOXIDIL, MINOXIDIL
 NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
 NYSTATIN, NYSTATIN
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 PINDOLOL, PINDOLOL
 PREDNISONE, PREDNISONE
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
 QUALAQUIN, QUININE SULFATE
 QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
 SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 SPIRONOLACTONE, SPIRONOLACTONE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 SULINDAC, SULINDAC
 TEMAZEPAM, TEMAZEPAM
 THIORIDAZINE HYDROCHLORIDE, THIORIDAZINE HYDROCHLORIDE
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
 TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE
 ULTRAVATE, HALOBETASOL PROPIONATE

SUN PHARMA GLOBAL

* SUN PHARMA GLOBAL FZE
 BROMSITE, BROMFENAC SODIUM
 CEQUA, CYCLOSPORINE
 DECITABINE, DECITABINE
 DOCETAXEL, DOCETAXEL
 DRIZALMA SPRINKLE, DULOXETINE HYDROCHLORIDE
 ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
 EZALLOR SPRINKLE, ROSUVASTATIN CALCIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SUN PHARMA GLOBAL FZE
 ODOMZO, SONIDEGIB PHOSPHATE
 ORTIKOS, BUDESONIDE
 XELPROS, LATANOPROST
 YONSA, ABIRATERONE ACETATE

SUNGEN PHARMA

* SUNGEN PHARMA LLC
 DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
 FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
 METHYLPREDNISOLONE, METHYLPREDNISOLONE
 RANOLAZINE, RANOLAZINE

SUNNY PHARMTECH INC

* SUNNY PHARMTECH INC
 AMINOCAPROIC ACID, AMINOCAPROIC ACID
 NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN

SUNOVION

* SUNOVION PHARMACEUTICALS INC
 BROVANA, ARFORMOTEROL TARTRATE
 XOPENEX HFA, LEVALBUTEROL TARTRATE

SUNOVION PHARMS INC

* SUNOVION PHARMACEUTICALS INC
 APTIOM, ESLICARBAZEPINE ACETATE
 KYNMOBI, APOMORPHINE HYDROCHLORIDE
 LATUDA, LURASIDONE HYDROCHLORIDE
 LUNESTA, ESZOPICLONE
 ZONEGRAN, ZONISAMIDE

SUNOVION RESP

* SUNOVION RESPIRATORY DEVELOPMENT INC
 LONHALA MAGNAIR KIT, GLYCOPYRROLATE

SUNSHINE

* SUNSHINE LAKE PHARMA CO LTD
 AZITHROMYCIN, AZITHROMYCIN
 CLARITHROMYCIN, CLARITHROMYCIN
 ENTACAPONE, ENTACAPONE
 FEBUXOSTAT, FEBUXOSTAT
 OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
 RANOLAZINE, RANOLAZINE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 TADALAFIL, TADALAFIL

SUNSTAR AMERICAS

* SUNSTAR AMERICAS INC
 PAROEX, CHLORHEXIDINE GLUCONATE

SUPERNUS PHARMS

* SUPERNUS PHARMACEUTICALS INC
 OXTELLAR XR, OXCARBAZEPINE
 TROKENDI XR, TOPIRAMATE

SUVEN PHARMS

* SUVEN PHARMACEUTICALS LTD
 CALCIUM ACETATE, CALCIUM ACETATE
 MALATHION, MALATHION

SVC PHARMA

* SVC PHARMA LP
 DRONABINOL, DRONABINOL

SWEDISH ORPHAN

* SWEDISH ORPHAN BIOVITRUM AB PUBL
 ORFADIN, NITISINONE

SWISS PHARM

* SWISS PHARMACEUTICAL CO LTD
 GLYBURIDE, GLYBURIDE

SYNTHON PHARMS

* SYNTHON PHARMACEUTICALS INC
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ******ACME LABS**

* THE ACME LABORATORIES LTD
 CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

GEN HOSP

* THE GENERAL HOSPITAL CORP
 AMMONIA N 13, AMMONIA N-13

METHODIST HOSP RES

* THE METHODIST HOSP RESEARCH INSTITUTE
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

RITEDOSE CORP

* THE RITEDOSE CORP
 ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
 LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE

TAGI

* TAGI PHARMA INC
 CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE

TAIHO ONCOLOGY

* TAIHO ONCOLOGY INC
 LONSURF, TIPIRACIL HYDROCHLORIDE

TAKEDA PHARMS USA

* TAKEDA PHARMACEUTICALS USA INC
 ACTOPLUS MET, METFORMIN HYDROCHLORIDE
 ACTOS, PIOGLITAZONE HYDROCHLORIDE
 ADDERALL XR 10, AMPHETAMINE ASPARTATE
 ADDERALL XR 15, AMPHETAMINE ASPARTATE
 ADDERALL XR 20, AMPHETAMINE ASPARTATE
 ADDERALL XR 25, AMPHETAMINE ASPARTATE
 ADDERALL XR 30, AMPHETAMINE ASPARTATE
 ADDERALL XR 5, AMPHETAMINE ASPARTATE
 AGRYLIN, ANAGRELIDE HYDROCHLORIDE
 CARBATROL, CARBAMAZEPINE
 COLCRYS, COLCHICINE
 DEXILANT, DEXLANSOPRAZOLE
 DUEFACT, GLIMEPIRIDE
 FOSRENOL, LANTHANUM CARBONATE
 INTUNIV, GUANFACINE HYDROCHLORIDE
 KAZANO, ALOGLIPTIN BENZOATE
 LIALDA, MESALAMINE
 MOTTEGRITY, PRUCALOPRIDE SUCCINATE
 MYDAYIS, AMPHETAMINE ASPARTATE
 NESINA, ALOGLIPTIN BENZOATE
 OSENI, ALOGLIPTIN BENZOATE
 PENTASA, MESALAMINE
 PREVACID, LANSOPRAZOLE
 ROZEREM, RAMELTEON
 TRINTELLIX, VORTIOXETINE HYDROBROMIDE
 ULORIC, FEBUXOSTAT
 VYVANSE, LISDEXAMFETAMINE DIMESYLATE

TAMARANG

* TAMARANG SA
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE

TARO

* TARO PHARMACEUTICAL INDUSTRIES LTD
 ACETAZOLAMIDE, ACETAZOLAMIDE
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
 BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
 CARBAMAZEPINE, CARBAMAZEPINE
 CARVEDILOL, CARVEDILOL
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

- * TARO PHARMACEUTICAL INDUSTRIES LTD
 CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
 CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
 DESONIDE, DESONIDE
 ENALAPRIL MALEATE, ENALAPRIL MALEATE
 ETODOLAC, ETODOLAC
 EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
 FELBAMATE, FELBAMATE
 FLUCONAZOLE, FLUCONAZOLE
 FLUOROURACIL, FLUOROURACIL
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 GABAPENTIN, GABAPENTIN
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
 IMIQUIMOD, IMIQUIMOD
 IVERMECTIN, IVERMECTIN
 KETOCONAZOLE, KETOCONAZOLE
 LAMOTRIGINE, LAMOTRIGINE
 LEVETIRACETAM, LEVETIRACETAM
 LORATADINE, LORATADINE (OTC)
 MELOXICAM, MELOXICAM
 METRONIDAZOLE, METRONIDAZOLE
 MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
 MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
 NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
 NYSTATIN, NYSTATIN
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 OXCARBAZEPINE, OXCARBAZEPINE
 PHENYTOIN, PHENYTOIN
 TERIL, CARBAMAZEPINE
 WARFARIN SODIUM, WARFARIN SODIUM
- * TARO PHARMACEUTICALS USA INC
 ACETIC ACID, ACETIC ACID, GLACIAL
 ACYCLOVIR, ACYCLOVIR
 ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
 ADAPALENE, ADAPALENE
 ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
 AMMONIUM LACTATE, AMMONIUM LACTATE
 AZELAIC ACID, AZELAIC ACID
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 CICLOPIROX, CICLOPIROX
 CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
 CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 CLOTRIMAZOLE, CLOTRIMAZOLE
 CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
 DAPSONE, DAPSONE
 DERMABET, BETAMETHASONE VALERATE
 DESONIDE, DESONIDE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
 ECONAZOLE NITRATE, ECONAZOLE NITRATE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
 FLUOCINONIDE, FLUOCINONIDE
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
 HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

* TARO PHARMACEUTICALS USA INC
 HYDROCORTISONE, HYDROCORTISONE
 IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)
 KETOZOLE, KETOCONAZOLE
 LIDOCAINE, LIDOCAINE
 LORATADINE, LORATADINE (OTC)
 MICONAZOLE 3, MICONAZOLE NITRATE (OTC)
 MOMETASONE FUROATE, MOMETASONE FUROATE
 MUPIROCIN, MUPIROCIN
 MUPIROCIN, MUPIROCIN CALCIUM
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 NYSTATIN, NYSTATIN
 PHENYTOIN, PHENYTOIN
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 RISPERIDONE, RISPERIDONE
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
 SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE (OTC)
 TERCONAZOLE, TERCONAZOLE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 TRIVAGIZOLE 3, CLOTRIMAZOLE (OTC)
 U-CORT, HYDROCORTISONE ACETATE

TARO PHARM INDS

* TARO PHARMACEUTICAL INDUSTRIES LTD
 AMCINONIDE, AMCINONIDE
 CARBAMAZEPINE, CARBAMAZEPINE
 CICLOPIROX, CICLOPIROX
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
 ETODOLAC, ETODOLAC
 HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
 LAMOTRIGINE, LAMOTRIGINE

TARO PHARM INDS LTD

* TARO PHARMACEUTICAL INDUSTRIES LTD
 ACETAMINOPHEN, ACETAMINOPHEN (OTC)
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 DEFERIPRONE, DEFERIPRONE
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
 FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
 HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
 HYDROCORTISONE, HYDROCORTISONE
 INFANTS' FEVERALL, ACETAMINOPHEN (OTC)
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 TOPICORT, DESOXIMETASONE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

TARO PHARMS

* TARO PHARMACEUTICALS INC
 BUTENAFINE HYDROCHLORIDE, BUTENAFINE HYDROCHLORIDE (OTC)
 CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 DAPSONE, DAPSONE
 MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
 NAFTIFINE HYDROCHLORIDE, NAFTIFINE HYDROCHLORIDE
 OXICONAZOLE NITRATE, OXICONAZOLE NITRATE
 PLIAGLIS, LIDOCAINE
 TAZAROTENE, TAZAROTENE
 TOPICORT, DESOXIMETASONE
 TRETINOIN, TRETINOIN

TASMAN PHARMA

* TASMAN PHARMA INC
 CLOTRIMAZOLE, CLOTRIMAZOLE
 VERSACLOZ, CLOZAPINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ******TCG FLUENT PHARMA**

* TCG FLUENT PHARMA INVESTORS LP
FLOLIPID, SIMVASTATIN

TEIKOKU PHARMA

* TEIKOKU PHARMA USA INC
DOCETAXEL, DOCETAXEL

TEIKOKU PHARMA USA

* TEIKOKU PHARMA USA INC
LIDODERM, LIDOCAINE

TELIGENT

* TELIGENT OU
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
FORTAZ, CEFTAZIDIME
ZANTAC, RANITIDINE HYDROCHLORIDE
ZINACEF, CEFUROXIME SODIUM

* TELIGENT PHARMA INC
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CEFOTAN, CEFOTETAN DISODIUM
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DESONIDE, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
ECONAZOLE NITRATE, ECONAZOLE NITRATE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOCINONIDE, FLUOCINONIDE
FLURANDRENOLIDE, FLURANDRENOLIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
LIDOCAINE AND PRILOCAINE, LIDOCAINE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE, LIDOCAINE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

TENSHI

* TENSHI KAIZEN PVT LTD
LORATADINE, LORATADINE (OTC)

TERSERA

* TERSERA THERAPEUTICS LLC
ERGOMAR, ERGOTAMINE TARTRATE
PRIALT, ZICONOTIDE ACETATE
VARUBI, ROLAPITANT HYDROCHLORIDE
XERMELO, TELOTRISTAT ETIPRATE
ZOLADEX, GOSERELIN ACETATE

TETRAPHASE PHARMS

* TETRAPHASE PHARMACEUTICALS INC
XERAVA, ERAVACYCLINE DIHYDROCHLORIDE

TEVA

* TEVA NEUROSCIENCE INC
AZILECT, RASAGILINE MESYLATE

* TEVA PHARMACEUTICALS USA INC
ACYCLOVIR, ACYCLOVIR
ADIPEX-P, PHENTERMINE HYDROCHLORIDE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN PEDIATRIC, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
ATENOLOL, ATENOLOL
AZITHROMYCIN, AZITHROMYCIN
BENZAEPRILOL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

* TEVA PHARMACEUTICALS USA INC
 CALCITRIOL, CALCITRIOL
 CARVEDILOL, CARVEDILOL
 CEFACLOR, CEFACLOR
 CEFPROZIL, CEFPROZIL
 CELECOXIB, CELECOXIB
 CEPHALEXIN, CEPHALEXIN
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 CILOSTAZOL, CILOSTAZOL
 CIMETIDINE, CIMETIDINE
 CLARITHROMYCIN, CLARITHROMYCIN
 CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
 CLONAZEPAM, CLONAZEPAM
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 CLOTRIMAZOLE, CLOTRIMAZOLE
 DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
 DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
 DIFLUNISAL, DIFLUNISAL
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
 DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
 EPITOL, CARBAMAZEPINE
 ESZOPICLONE, ESZOPICLONE
 ETODOLAC, ETODOLAC
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
 FINASTERIDE, FINASTERIDE
 FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
 FLUOCINONIDE, FLUOCINONIDE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FLURBIPROFEN, FLURBIPROFEN
 FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
 GALZIN, ZINC ACETATE
 GLYBURIDE (MICRONIZED), GLYBURIDE
 GLYBURIDE, GLYBURIDE
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 KETOCONAZOLE, KETOCONAZOLE
 KETOPROFEN, KETOPROFEN
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LEVOFLOXACIN, LEVOFLOXACIN
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
 LOVASTATIN, LOVASTATIN
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
 MIRTAZAPINE, MIRTAZAPINE
 MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
 MUPIROCIN, MUPIROCIN
 NAPROXEN, NAPROXEN
 NEFAZODONE HYDROCHLORIDE, NEFAZODONE HYDROCHLORIDE
 NEOMYCIN SULFATE, NEOMYCIN SULFATE
 NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
 NYSTATIN, NYSTATIN
 OFLOXACIN, OFLOXACIN
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 OXAPROZIN, OXAPROZIN
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PENICILLIN-VK, PENICILLIN V POTASSIUM
 PIROXICAM, PIROXICAM
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 PRELONE, PREDNISOLONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

* TEVA PHARMACEUTICALS USA INC
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
 SUCRALFATE, SUCRALFATE
 TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
 TOLMETIN SODIUM, TOLMETIN SODIUM
 TOPIRAMATE, TOPIRAMATE
 TORSEMIDE, TORSEMIDE
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

TEVA BRANDED PHARM

* TEVA BRANDED PHARMACEUTICAL PRODUCTS R AND D INC
 AUSTEDO, DEUTETRABENAZINE
 CONDYLOX, PODOFILOX
 EMLA, LIDOCAINE
 LOESTRIN 21 1.5/30, ETHINYL ESTRADIOL
 LOESTRIN 21 1/20, ETHINYL ESTRADIOL
 LOESTRIN 24 FE, ETHINYL ESTRADIOL
 LOESTRIN FE 1.5/30, ETHINYL ESTRADIOL
 LOESTRIN FE 1/20, ETHINYL ESTRADIOL
 LOSEASONIQUE, ETHINYL ESTRADIOL
 NOR-QD, NORETHINDRONE
 PROAIR DIGIHALER, ALBUTEROL SULFATE
 PROAIR HFA, ALBUTEROL SULFATE
 PROAIR RESPICLICK, ALBUTEROL SULFATE
 PROGLYCEM, DIAZOXIDE
 QNASL, BECLOMETHASONE DIPROPIONATE
 QUARTETTE, ETHINYL ESTRADIOL
 SEASONALE, ETHINYL ESTRADIOL
 SEASONIQUE, ETHINYL ESTRADIOL
 ZIAC, BISOPROLOL FUMARATE

TEVA PARENTERAL

* TEVA PARENTERAL MEDICINES INC
 LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE

TEVA PHARM

* TEVA PHARMACEUTICAL INDUSTRIES LTD
 AIRDUO DIGIHALER, FLUTICASONE PROPIONATE
 AIRDUO RESPICLICK, FLUTICASONE PROPIONATE
 ARMONAIR DIGIHALER, FLUTICASONE PROPIONATE

TEVA PHARMS

* TEVA PHARMACEUTICALS USA
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 ANASTROZOLE, ANASTROZOLE
 BUDESONIDE, BUDESONIDE
 CARBAMAZEPINE, CARBAMAZEPINE
 CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
 CEFDINIR, CEFDINIR
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CROMOLYN SODIUM, CROMOLYN SODIUM
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
 FAMCICLOVIR, FAMCICLOVIR
 FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
 GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 IRBESARTAN, IRBESARTAN
 LANSOPRAZOLE, LANSOPRAZOLE
 LETROZOLE, LETROZOLE
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 LINEZOLID, LINEZOLID
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

* TEVA PHARMACEUTICALS USA
 OXALIPLATIN, OXALIPLATIN
 PACLITAXEL, PACLITAXEL
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
 PREGABALIN, PREGABALIN
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 QUININE SULFATE, QUININE SULFATE
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TRANDOLAPRIL, TRANDOLAPRIL
 URSODIOL, URSODIOL
 VANDAZOLE, METRONIDAZOLE
 VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE

TEVA PHARMS INTL

* TEVA PHARMACEUTICALS INTERNATIONAL GMBH
 AMRIX, CYCLOBENZAPRINE HYDROCHLORIDE
 SYNRIPO, OMACETAXINE MEPESSUCINATE

TEVA PHARMS USA

* TEVA PHARMACEUTICALS USA
 ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
 ACITRETIN, ACITRETIN
 ADENOSINE, ADENOSINE
 ALMOTRIPTAN MALATE, ALMOTRIPTAN MALATE
 ALPROSTADIL, ALPROSTADIL
 AMIKACIN SULFATE, AMIKACIN SULFATE
 ATAZANAVIR SULFATE, ATAZANAVIR SULFATE
 ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
 BUDESONIDE, BUDESONIDE
 CLARAVIS, ISOTRETINOIN
 CLOZAPINE, CLOZAPINE
 COPAXONE, GLATIRAMER ACETATE
 DACARBAZINE, DACARBAZINE
 DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ
 EPOPROSTENOL SODIUM, EPOPROSTENOL SODIUM
 EPTIFIBATIDE, EPTIFIBATIDE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 ESTRADIOL, ESTRADIOL
 ETOPOSIDE, ETOPOSIDE
 FLUOROURACIL, FLUOROURACIL
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
 FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
 ICOSAPENT ETHYL, ICOSAPENT ETHYL
 IDARUBICIN HYDROCHLORIDE PFS, IDARUBICIN HYDROCHLORIDE
 IFOSFAMIDE, IFOSFAMIDE
 IMATINIB MESYLATE, IMATINIB MESYLATE
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 LANSOPRAZOLE, LANSOPRAZOLE
 LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
 LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
 LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
 LOGILIA, ULIPRISTAL ACETATE
 METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

- * TEVA PHARMACEUTICALS USA
 MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
 OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
 OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
 OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
 OMEPRAZOLE, OMEPRAZOLE
 PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
 PARICALCITOL, PARICALCITOL
 PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
 RISEDRONATE SODIUM, RISEDRONATE SODIUM
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 TADALAFIL, TADALAFIL
 TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 TOBRAMYCIN, TOBRAMYCIN
 TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 TREPROSTINIL, TREPROSTINIL
 VECURONIUM BROMIDE, VECURONIUM BROMIDE
 VIGABATRIN, VIGABATRIN
 VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE
 VINORELBINE TARTRATE, VINORELBINE TARTRATE
 ZANOSAR, STREPTOZOCIN
- * TEVA PHARMACEUTICALS USA INC
 ABIRATERONE ACETATE, ABIRATERONE ACETATE
 ALYQ, TADALAFIL
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 CAPECITABINE, CAPECITABINE
 DAPTOMYCIN, DAPTOMYCIN
 DARUNAVIR, DARUNAVIR
 DEFERASIROX, DEFERASIROX
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 EFINACONAZOLE, EFINACONAZOLE
 ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
 EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
 EPINEPHRINE (AUTOINJECTOR), EPINEPHRINE
 ESTRADIOL, ESTRADIOL
 EVEROLIMUS, EVEROLIMUS
 ICATIBANT ACETATE, ICATIBANT ACETATE
 IVERMECTIN, IVERMECTIN
 LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
 MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
 MESALAMINE, MESALAMINE
 METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
 METRONIDAZOLE, METRONIDAZOLE
 OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 TOBRAMYCIN, TOBRAMYCIN
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
- TEVA PHARMS USA INC**
- * TEVA PHARMACEUTICALS USA INC
 CHLORZOAZONE, CHLORZOAZONE
 ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
 FULVESTRANT, FULVESTRANT
 LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
 MIFEPRISTONE, MIFEPRISTONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

* TEVA PHARMACEUTICALS USA INC
 POTASSIUM CITRATE, POTASSIUM CITRATE
 ROMIDEPSIN, ROMIDEPSIN
 SORAFENIB TOSYLATE, SORAFENIB TOSYLATE

THE FEINSTEIN INST

* THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

THEPHARMANETWORK LLC

* THEPHARMANETWORK LLC
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 BENZONATATE, BENZONATATE
 ISONIAZID, ISONIAZID
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 NIMODIPINE, NIMODIPINE
 THERMAZENE, SILVER SULFADIAZINE

THERAPEUTICSMD INC

* THERAPEUTICSMD INC
 ANNOVERA, ETHINYL ESTRADIOL
 BIJUVA, ESTRADIOL
 IMVEXXY, ESTRADIOL

TIANJIN TIANYAO

* TIANJIN TIANYAO PHARMACEUTICALS CO LTD
 CELECOXIB, CELECOXIB
 METHYLPREDNISOLONE, METHYLPREDNISOLONE

TIME-CAP LABS INC

* TIME-CAP LABORATORIES INC
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE

TOLMAR

* TOLMAR INC
 ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
 ADAPALENE, ADAPALENE
 AZELAIC ACID, AZELAIC ACID
 CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 CALCIPOTRIENE, CALCIPOTRIENE
 CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 ERYTHROMYCIN AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
 KETOCONAZOLE, KETOCONAZOLE
 LIDOCAINE AND PRILOCAINE, LIDOCAINE
 METRONIDAZOLE, METRONIDAZOLE
 NAFTIFINE HYDROCHLORIDE, NAFTIFINE HYDROCHLORIDE

* TOLMAR INTERNATIONAL LTD
 FENSOLVI KIT, LEUPROLIDE ACETATE

TOLMAR THERAP

* TOLMAR THERAPEUTICS INC
 ELIGARD KIT, LEUPROLIDE ACETATE

TOPROL

* TOPROL ACQUISITION LLC
 TOPROL-XL, METOPROLOL SUCCINATE

TORPHARM

* TORPHARM INC
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE

TORRENT

* TORRENT PHARMA INC
 APREPITANT, APREPITANT
 ERYTHROMYCIN, ERYTHROMYCIN
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE

* TORRENT PHARMACEUTICALS LTD
 ACYCLOVIR, ACYCLOVIR
 AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
 ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
 ARIPIPRAZOLE, ARIPIPRAZOLE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

* TORRENT PHARMACEUTICALS LTD
 CELECOXIB, CELECOXIB
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 FENOFIBRATE (MICRONIZED), FENOFIBRATE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 ITRACONAZOLE, ITRACONAZOLE
 LAMOTRIGINE, LAMOTRIGINE
 MOMETASONE FUROATE, MOMETASONE FUROATE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 NYSTATIN, NYSTATIN
 OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
 OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 ROFLUMILAST, ROFLUMILAST
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 TADALAFIL, TADALAFIL
 TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
 TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TELMISARTAN, TELMISARTAN
 TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE

TORRENT PHARMS

* TORRENT PHARMACEUTICALS LTD
 CARBAMAZEPINE, CARBAMAZEPINE
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
 LAMOTRIGINE, LAMOTRIGINE
 LEVETIRACETAM, LEVETIRACETAM
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 RISPERIDONE, RISPERIDONE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

TORRENT PHARMS LLC

* TORRENT PHARMACEUTICALS LLC
 OLANZAPINE, OLANZAPINE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

TORRENT PHARMS LTD

* TORRENT PHARMACEUTICALS LTD
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 FELODIPINE, FELODIPINE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE

TRAVERE

* TRAVERE THERAPEUTICS INC
 CHOLBAM, CHOLIC ACID

TREVENA

* TREVENA INC
 OLINVYK, OLICERIDINE

TRIS PHARMA INC

* TRIS PHARMA INC
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

* TRIS PHARMA INC
 DEXTROMETHORPHAN POLISTIREX, DEXTROMETHORPHAN POLISTIREX (OTC)
 DYANAVEL XR, AMPHETAMINE
 GABAPENTIN, GABAPENTIN
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX, CHLORPHENIRAMINE POLISTIREX
 IBUPROFEN, IBUPROFEN (OTC)
 LEVETIRACETAM, LEVETIRACETAM
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 RISPERIDONE, RISPERIDONE
 THEOPHYLLINE, THEOPHYLLINE

TRUSTEES UNIV PA

* TRUSTEES OF THE UNIV OF PENNSYLVANIA
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

TULEX PHARMS INC

* TULEX PHARMACEUTICALS INC
 AMINOCAPROIC ACID, AMINOCAPROIC ACID
 CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
 METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

TWI PHARMS

* TWI PHARMACEUTICALS INC
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DIMETHYL FUMARATE, DIMETHYL FUMARATE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 FENOFIBRIC ACID, CHOLINE FENOFIBRATE
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 MEGESTROL ACETATE, MEGESTROL ACETATE
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
 NIFEDIPINE, NIFEDIPINE
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
 SEVELAMER CARBONATE, SEVELAMER CARBONATE
 TERBUTALINE SULFATE, TERBUTALINE SULFATE
 TESTOSTERONE, TESTOSTERONE

TWI PHARMS INC

* TWI PHARMACEUTICALS INC
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE

**** U ******UBI**

* UBI PHARMA INC
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE

UCB INC

* UCB INC
 BRIVIACT, BRIVARACETAM
 KEPPRA XR, LEVETIRACETAM
 KEPPRA, LEVETIRACETAM
 NAYZILAM, MIDAZOLAM
 NEUPRO, ROTIGOTINE
 VIMPAT, LACOSAMIDE

UCLA BIOMEDICAL

* UCLA BIOMEDICAL CYCLOTRON
 AMMONIA N 13, AMMONIA N-13
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

UCSF RADIOPHARM

* UCSF RADIOPHARMACEUTICAL FACILITY
 AMMONIA N 13, AMMONIA N-13
 CHOLINE C-11, CHOLINE C-11
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** U ****

* UCSF RADIOPHARMACEUTICAL FACILITY
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

UIHC PET IMAGING

* UNIV IOWA HOSPS AND CLINICS PET IMAGING CENTER
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
GALLIUM DOTATOC GA 68, GALLIUM DOTATOC GA-68

ULTRAGENYX PHARM INC

* ULTRAGENYX PHARMACEUTICAL INC
DOJOLVI, TRIHEPTANOIN

UMEDICA LABS PVT LTD

* UMEDICA LABORATORIES PRIVATE LTD
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
CARBAMAZEPINE, CARBAMAZEPINE
CELECOXIB, CELECOXIB
CHLORTHALIDONE, CHLORTHALIDONE
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TADALAFIL, TADALAFIL

UNICHEM

* UNICHEM LABORATORIES LTD
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
ALLOPURINOL, ALLOPURINOL
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
BACLOFEN, BACLOFEN
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CHLORTHALIDONE, CHLORTHALIDONE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MELOXICAM, MELOXICAM
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
PIROXICAM, PIROXICAM
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
TADALAFIL, TADALAFIL
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
ZALEPLON, ZALEPLON

UNICHEM LABS LTD

* UNICHEM LABORATORIES LIMITED
DIVALPROEX SODIUM, DIVALPROEX SODIUM

* UNICHEM LABORATORIES LTD
LAMOTRIGINE, LAMOTRIGINE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE

UNICHEM PHARMS (USA)

* UNICHEM PHARMACEUTICALS (USA) INC
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE

UNIMARK REMEDIES LTD

* UNIMARK REMEDIES LTD
MONTELUKAST SODIUM, MONTELUKAST SODIUM

UNIQUE PHARM

* UNIQUE PHARMACEUTICAL LABORATORIES
CARBAMAZEPINE, CARBAMAZEPINE

UNIQUE PHARM LABS

* UNIQUE PHARMACEUTICAL LABORATORIES A DIVISION OF J.B. CHEMICALS AND PHARMACEUTICALS LTD
ATENOLOL, ATENOLOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** U ****

* UNIQUE PHARMACEUTICAL LABORATORIES A DIVISION OF J.B. CHEMICALS AND PHARMACEUTICALS LTD
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 FLUCONAZOLE, FLUCONAZOLE
 GLIPIZIDE, GLIPIZIDE
 LITHIUM CARBONATE, LITHIUM CARBONATE
 MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
 TINIDAZOLE, TINIDAZOLE
 TOLTERODINE TARTRATE, TOLTERODINE TARTRATE

UNITED BIOMEDCL

* UNITED BIOMEDICAL INC
 TERBUTALINE SULFATE, TERBUTALINE SULFATE

UNITED GUARDIAN

* UNITED GUARDIAN INC
 RENACIDIN, CITRIC ACID

UNITED THERAP

* UNITED THERAPEUTICS CORP
 ORENITRAM, TREPROSTINIL DIOLAMINE
 REMODULIN, TREPROSTINIL
 TYVASO, TREPROSTINIL

UNIV CA LOS ANGELES

* UNIV CALIFORNIA LOS ANGELES
 GALLIUM GA 68 PSMA-11, GALLIUM GA-68 PSMA-11

UNIV MICHIGAN

* UNIV MICHIGAN PET RADIOPHARMACEUTICAL PRODUCTION PROGRAM
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

UNIV OF CA SAN FRAN

* UNIV OF CALIFORNIA SAN FRANCISCO
 GALLIUM GA 68 PSMA-11, GALLIUM GA-68 PSMA-11

UNIV SOUTHERN CA

* UNIV SOUTHERN CALIFORNIA DBA USC MOLECULAR IMAGING CENTER
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

UNIV TX MD ANDERSON

* UNIV TEXAS MD ANDERSON CANCER CENTER
 CHOLINE C-11, CHOLINE C-11
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

UNIV TX SW MEDCTR

* UNIV TEXAS SOUTHWESTERN MEDCTR
 AMMONIA N 13, AMMONIA N-13

UNIV UTAH CYCLOTRON

* UNIV UTAH CYCLOTRON RADIOCHEMISTRY LAB
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

UNIV WISCONSIN

* UNIV WISCONSIN SYSTEM
 AMMONIA N 13, AMMONIA N-13

UPJOHN

* UPJOHN MANUFACTURING IRELAND UNLTD
 LIPITOR, ATORVASTATIN CALCIUM
 RELPAX, ELETRIPTAN HYDROBROMIDE
 * UPJOHN US 1 LLC
 CARDURA XL, DOXAZOSIN MESYLATE
 CARDURA, DOXAZOSIN MESYLATE
 DILANTIN, PHENYTOIN SODIUM
 DILANTIN-125, PHENYTOIN
 GEODON, ZIPRASIDONE HYDROCHLORIDE
 GEODON, ZIPRASIDONE MESYLATE
 NEURONTIN, GABAPENTIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** U ****

* UPJOHN US 1 LLC
 NITROSTAT, NITROGLYCERIN
 NORVASC, AMLODIPINE BESYLATE
 REVATIO, SILDENAFIL CITRATE
 VIAGRA, SILDENAFIL CITRATE
 ZOLOFT, SERTRALINE HYDROCHLORIDE

* UPJOHN US 2 LLC
 DETROL LA, TOLTERODINE TARTRATE
 DETROL, TOLTERODINE TARTRATE
 EFFEXOR XR, VENLAFAXINE HYDROCHLORIDE
 XALATAN, LATANOPROST
 XANAX XR, ALPRAZOLAM
 XANAX, ALPRAZOLAM

UPSHER SMITH LABS

* UPSHER SMITH LABORATORIES INC
 DOXEPIIN HYDROCHLORIDE, DOXEPIIN HYDROCHLORIDE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE

* UPSHER SMITH LABORATORIES LLC
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 BACLOFEN, BACLOFEN
 BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
 BEXAROTENE, BEXAROTENE
 BUMETANIDE, BUMETANIDE
 CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
 CLOBAZAM, CLOBAZAM
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
 ETHACRYNIC ACID, ETHACRYNIC ACID
 EXEMESTANE, EXEMESTANE
 FLUOXYMESTERONE, FLUOXYMESTERONE
 FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
 FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
 HALOPERIDOL, HALOPERIDOL
 JANTOVEN, WARFARIN SODIUM
 Klor-CON M10, POTASSIUM CHLORIDE
 Klor-CON M15, POTASSIUM CHLORIDE
 Klor-CON M20, POTASSIUM CHLORIDE
 Klor-CON, POTASSIUM CHLORIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 MIRTAZAPINE, MIRTAZAPINE
 MORPHINE SULFATE, MORPHINE SULFATE
 NYSTATIN, NYSTATIN
 ORVATEN, MIDODRINE HYDROCHLORIDE
 OXANDROLONE, OXANDROLONE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 PACERONE, AMIODARONE HYDROCHLORIDE
 PENTOXIL, PENTOXIFYLLINE
 PREVALITE, CHOLESTYRAMINE
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
 QUDEXY XR, TOPIRAMATE
 SORINE, SOTALOL HYDROCHLORIDE
 TOPIRAMATE, TOPIRAMATE
 TOSYMRA, SUMATRIPTAN
 URSODIOL, URSODIOL
 VOGELXO, TESTOSTERONE
 ZEMBRACE SYMTOUCH, SUMATRIPTAN SUCCINATE

UROGEN PHARMA

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** U ****

* UROGEN PHARMA LTD
JELMYTO, MITOMYCIN

UROVANT

* UROVANT SCIENCES GMBH
GEMTESA, VIBEGRON

US PHARM HOLDINGS

* US PHARMACEUTICAL HOLDINGS II LLC
DRISDOL, ERGOCALCIFEROL
HIPREX, METHENAMINE HIPPURATE
LASIX, FUROSEMIDE
NORPRAMIN, DESIPRAMINE HYDROCHLORIDE

US PHARMS HOLDINGS I

* US PHARMACEUTICALS HOLDINGS I LLC
LOPRESSOR HCT, HYDROCHLOROTHIAZIDE
LOPRESSOR, METOPROLOL TARTRATE
LOTENSIN HCT, BENAZEPRIL HYDROCHLORIDE
LOTENSIN, BENAZEPRIL HYDROCHLORIDE
PARLODEL, BROMOCRIPTINE MESYLATE

USPHARMA

* USPHARMA LTD
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
NITRO-DUR, NITROGLYCERIN

USV

* USV PRIVATE LTD
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

USWM

* USWM LLC
CORGARD, NADOLOL
LUCEMYRA, LOFEXIDINE HYDROCHLORIDE
REVONTO, DANTROLENE SODIUM

**** V ******VALEANT**

* VALEANT PHARMACEUTICALS INTERNATIONAL
BONTRIL PDM, PHENDIMETRAZINE TARTRATE
MYSOLINE, PRIMIDONE

VALEANT BERMUDA

* VALEANT INTERNATIONAL BERMUDA
PENLAC, CICLOPIROX
RETIN-A, TRETINOIN

VALEANT INTL

* VALEANT INTERNATIONAL BARBADOS SRL
RETIN-A MICRO, TRETINOIN
RETIN-A, TRETINOIN
RETIN-A-MICRO, TRETINOIN
WELLBUTRIN XL, BUPROPION HYDROCHLORIDE
* VALEANT INTERNATIONAL SRL
BENZAMYCIN, BENZOYL PEROXIDE

VALEANT LUXEMBOURG

* VALEANT PHARMACEUTICALS LUXEMBOURG SARL
TARGRETIN, BEXAROTENE
VISUDYNE, VERTEPORFIN

VALEANT PHARM INTL

* VALEANT PHARMACEUTICALS INTERNATIONAL
ANDROID 25, METHYLTESTOSTERONE
LIBRIUM, CHLORDIAZEPOXIDE HYDROCHLORIDE

VALEANT PHARMS

* VALEANT PHARMACEUTICALS NORTH AMERICA LLC
PENTOXIFYLLINE, PENTOXIFYLLINE

VALEANT PHARMS INTL

* VALEANT PHARMACEUTICALS INTERNATIONAL
APRISO, MESALAMINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** V ****

* VALEANT PHARMACEUTICALS INTERNATIONAL
 COLAZAL, BALSALAZIDE DISODIUM
 CUPRIMINE, PENICILLAMINE
 LACRISERT, HYDROXYPROPYL CELLULOSE
 TIMOPTIC IN OCUDOSE, TIMOLOL MALEATE
 TIMOPTIC, TIMOLOL MALEATE

VALEANT PHARMS LLC

* VALEANT PHARMACEUTICALS NORTH AMERICA LLC
 TIMOPTIC-XE, TIMOLOL MALEATE

VALEANT PHARMS NORTH

* VALEANT PHARMACEUTICALS NORTH AMERICA LLC
 APLENZIN, BUPROPION HYDROBROMIDE
 CARAC, FLUOROURACIL
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 FENOFIBRATE, FENOFIBRATE
 NIFEDIPINE, NIFEDIPINE
 NORITATE, METRONIDAZOLE
 RENOVA, TRETINOIN
 RETIN-A, TRETINOIN
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

VALIDUS PHARMS

* VALIDUS PHARMACEUTICALS LLC
 BUMEX, BUMETANIDE
 EQUETRO, CARBAMAZEPINE
 ROCALTROL, CALCITRIOL

VALIDUS PHARMS INC

* VALIDUS PHARMACEUTICALS INC
 MARPLAN, ISOCARBOXAZID

VANDA PHARMS INC

* VANDA PHARMACEUTICALS INC
 FANAPT, ILOPERIDONE
 HETLIOZ LQ, TASIMELTEON
 HETLIOZ, TASIMELTEON

VELOXIS PHARMS INC

* VELOXIS PHARMACEUTICALS INC
 ENVARBUS XR, TACROLIMUS

VERITY

* VERITY PHARMACEUTICALS INC
 TRELSTAR, TRIPTORELIN PAMOATE

VERO BIOTECH

* VERO BIOTECH
 GENOSYL, NITRIC OXIDE

VEROSCIENCE

* VEROSCIENCE LLC
 CYCLOSET, BROMOCRIPTINE MESYLATE

VERTEX PHARMS

* VERTEX PHARMACEUTICALS INC
 KALYDECO, IVACAFTOR

VERTEX PHARMS INC

* VERTEX PHARMACEUTICALS INC
 KALYDECO, IVACAFTOR
 ORKAMBI, IVACAFTOR
 SYMDEKO (COPACKAGED), IVACAFTOR
 TRIKAFTA (COPACKAGED), ELEXACAFTOR, IVACAFTOR, TEZACAFTOR

VERTICAL PHARMS LLC

* VERTICAL PHARMACEUTICALS LLC
 DIVIGEL, ESTRADIOL

VICURON

* VICURON PHARMACEUTICALS INC
 ERAXIS, ANIDULAFUNGIN

VIFOR FRESENIUS

* VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE
 VELPHORO, SUCROFERRIC OXYHYDROXIDE

VIIV HLTHCARE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** V ****

* VIIV HEALTHCARE CO
 COMBIVIR, LAMIVUDINE
 DOVATO, DOLUTEGRAVIR SODIUM
 EPIVIR, LAMIVUDINE
 EPZICOM, ABACAVIR SULFATE
 JULUCA, DOLUTEGRAVIR SODIUM
 LEXIVA, FOSAMPRENAVIR CALCIUM
 RETROVIR, ZIDOVUDINE
 RUKOBIA, FOSTEMSAVIR TROMETHAMINE
 SELZENTRY, MARAVIROC
 TIVICAY PD, DOLUTEGRAVIR SODIUM
 TIVICAY, DOLUTEGRAVIR SODIUM
 TRIUMEQ, ABACAVIR SULFATE
 TRIZIVIR, ABACAVIR SULFATE
 ZIAGEN, ABACAVIR SULFATE

VINTAGE

* VINTAGE PHARMACEUTICALS LLC
 ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 BENZTROPINE MESYLATE, BENZTROPINE MESYLATE

VINTAGE PHARMS

* VINTAGE PHARMACEUTICALS
 ALPRAZOLAM, ALPRAZOLAM
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 GILDAGIA, ETHINYL ESTRADIOL
 GILDESS 24 FE, ETHINYL ESTRADIOL
 KIMIDESS, DESOGESTREL
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

* VINTAGE PHARMACEUTICALS INC
 ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 ALLOPURINOL, ALLOPURINOL
 AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 BACLOFEN, BACLOFEN
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
 DIAZEPAM, DIAZEPAM
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
 IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)
 METHYLPREDNISOLONE, METHYLPREDNISOLONE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 PERPHENAZINE, PERPHENAZINE
 PREDNISONE, PREDNISONE
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
 TORSEMIDE, TORSEMIDE

VINTAGE PHARMS LLC

* VINTAGE PHARMACEUTICALS LLC
 CYCLAFEM 1/35, ETHINYL ESTRADIOL
 CYCLAFEM 7/7/7, ETHINYL ESTRADIOL
 DUTASTERIDE, DUTASTERIDE
 FELODIPINE, FELODIPINE
 GILDESS 1/20, ETHINYL ESTRADIOL
 GILDESS FE 1/20, ETHINYL ESTRADIOL
 MORPHINE SULFATE, MORPHINE SULFATE
 MYZILRA, ETHINYL ESTRADIOL
 PERCOCET, ACETAMINOPHEN
 PREVIFEM, ETHINYL ESTRADIOL

VIRTUS PHARM

* VIRTUS PHARMACEUTICAL INC
 ACARBOSE, ACARBOSE
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE

VIRTUS PHARMS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** V ****

* VIRTUS PHARMACEUTICALS LLC
 DAPSONE, DAPSONE
 LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
 PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
 PROMETRIUM, PROGESTERONE

VISTA PHARMS

* VISTA PHARMACEUTICALS INC
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE

VISTAPHARM

* VISTAPHARM INC
 AMINOCAPROIC ACID, AMINOCAPROIC ACID
 ARIPIPRAZOLE, ARIPIPRAZOLE
 CHLORTHALIDONE, CHLORTHALIDONE
 CLOBAZAM, CLOBAZAM
 DIGOXIN, DIGOXIN
 FELBAMATE, FELBAMATE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 LACTULOSE, LACTULOSE
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 NYSTATIN, NYSTATIN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PHENYTOIN, PHENYTOIN

VITRUVIAS THERAP

* VITRUVIAS THERAPEUTICS
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 * VITRUVIAS THERAPEUTICS LLC
 CYANOCOBALAMIN, CYANOCOBALAMIN
 LIDOCAINE, LIDOCAINE

VIVUS

* VIVUS INC
 QSYMIA, PHENTERMINE HYDROCHLORIDE

VIWIT PHARM

* VIWIT PHARMACEUTICAL CO LTD
 LEVETIRACETAM, LEVETIRACETAM
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 TOPIRAMATE, TOPIRAMATE

VKT PHARMA

* VKT PHARMA PRIVATE LTD
 LEVETIRACETAM, LEVETIRACETAM
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

VPI PHARMS INC

* VPI PHARMACEUTICALS INC
 ETHACRYNATE SODIUM, ETHACRYNATE SODIUM

VPNA

* VALEANT PHARMACEUTICALS NORTH AMERICA
 DICLOFENAC SODIUM, DICLOFENAC SODIUM

VYERA PHARMS LLC

* VYERA PHARMACEUTICALS LLC
 DARAPRIM, PYRIMETHAMINE

**** W ******WA UNIV SCH MED**

* WASHINGTON UNIV SCHOOL MEDICINE
 AMMONIA N 13, AMMONIA N-13
 CHOLINE C-11, CHOLINE C-11

WATSON LABS

* WATSON LABORATORIES
 FOLIC ACID, FOLIC ACID
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
 * WATSON LABORATORIES INC
 ACARBOSE, ACARBOSE
 ALBUTEROL SULFATE, ALBUTEROL SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** W ****

- * WATSON LABORATORIES INC
 ALENDRONATE SODIUM, ALENDRONATE SODIUM
 ALLOPURINOL, ALLOPURINOL
 AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
 AMOXAPINE, AMOXAPINE
 ATENOLOL AND CHLORTHALIDONE, ATENOLOL
 CARISOPRODOL, CARISOPRODOL
 CHLORZOXAZONE, CHLORZOXAZONE
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 CLONAZEPAM, CLONAZEPAM
 COL-PROBENECID, COLCHICINE
 DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
 DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
 DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
 ESTAZOLAM, ESTAZOLAM
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 GLIPIZIDE, GLIPIZIDE
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 LAMOTRIGINE, LAMOTRIGINE
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LISINOPRIL, LISINOPRIL
 LORAZEPAM, LORAZEPAM
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
 MEPROBAMATE, MEPROBAMATE
 METHYLPREDNISOLONE, METHYLPREDNISOLONE
 METRONIDAZOLE, METRONIDAZOLE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MINOXIDIL, MINOXIDIL
 NABUMETONE, NABUMETONE
 NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 NATEGLINIDE, NATEGLINIDE
 NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE
 NIZATIDINE, NIZATIDINE
 NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 PREDNISOLONE, PREDNISOLONE
 PREDNISON, PREDNISON
 PRIMIDONE, PRIMIDONE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 QUASENSE, ETHINYL ESTRADIOL
 RAMIPRIL, RAMIPRIL
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
 SULFASALAZINE, SULFASALAZINE
 SULINDAC, SULINDAC
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE
 TOPIRAMATE, TOPIRAMATE
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE
 TRIMETHOPRIM, TRIMETHOPRIM
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
 ZOVIA 1/50E-28, ETHINYL ESTRADIOL
- * WATSON LABS INC
 LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
- WATSON LABS INC**
- * WATSON LABORATORIES INC
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 AMBRISANTAN, AMBRISANTAN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** W ****

* WATSON LABORATORIES INC
 AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
 BOSENTAN, BOSENTAN
 BRINZOLAMIDE, BRINZOLAMIDE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CELECOXIB, CELECOXIB
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 COLCHICINE, COLCHICINE
 COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM, DROSPIRENONE
 EZETIMIBE AND SIMVASTATIN, EZETIMIBE
 EZETIMIBE, EZETIMIBE
 METRONIDAZOLE, METRONIDAZOLE
 MODAFINIL, MODAFINIL
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
 PENICILLAMINE, PENICILLAMINE
 PERPHENAZINE, PERPHENAZINE
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
 PROPOFOL, PROPOFOL
 RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE

WATSON LABS TEVA

* WATSON LABORATORIES INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
 ALVIMOPAN, ALVIMOPAN
 BICALUTAMIDE, BICALUTAMIDE
 BUPRENORPHINE, BUPRENORPHINE
 CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
 GLIPIZIDE, GLIPIZIDE
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 ISRADIPINE, ISRADIPINE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 NORETHINDRONE AND ETHINYL ESTRADIOL (10/11), ETHINYL ESTRADIOL
 NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 PROBENECID, PROBENECID
 SIMVASTATIN, SIMVASTATIN
 TEMOZOLOMIDE, TEMOZOLOMIDE
 TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE

WATSON PHARMS INC

* WATSON PHARMACEUTICALS INC
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE

WATSON PHARMS TEVA

* WATSON PHARMACEUTICALS INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
 RIFAMPIN, RIFAMPIN

WELLSTAT THERAP

* WELLSTAT THERAPEUTICS CORP
 VISTOGARD, URIDINE TRIACETATE
 XURIDEN, URIDINE TRIACETATE

WES PHARMA INC

* WES PHARMA INC
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN

WEST WARD

* WEST WARD PHARMACEUTICAL CORP
 DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE

WEST WARD PHARM CORP

* WEST WARD PHARMACEUTICAL CORP
 PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE

WEST-WARD PHARMS INT

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** W ****

* WEST-WARD PHARMACEUTICALS INTERNATIONAL LTD
 ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
 ADENOSINE, ADENOSINE
 ALLOPURINOL SODIUM, ALLOPURINOL SODIUM
 ALPROSTADIL, ALPROSTADIL
 AMIKACIN SULFATE, AMIKACIN SULFATE
 AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
 AMRINONE LACTATE, INAMRINONE LACTATE
 ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
 ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
 AZATHIOPRINE SODIUM, AZATHIOPRINE SODIUM
 BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
 BUMETANIDE, BUMETANIDE
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
 BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
 CARBOPLATIN, CARBOPLATIN
 CEFOXITIN, CEFOXITIN SODIUM
 CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE
 CHLOROPROCAINE HYDROCHLORIDE, CHLOROPROCAINE HYDROCHLORIDE
 CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
 CISPLATIN, CISPLATIN
 CLADRIBINE, CLADRIBINE
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CYANOCOBALAMIN, CYANOCOBALAMIN
 CYCLOSPORINE, CYCLOSPORINE
 CYTARABINE, CYTARABINE
 DACARBAZINE, DACARBAZINE
 DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
 DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
 DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
 DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE), DICYCLOMINE HYDROCHLORIDE
 DIGOXIN, DIGOXIN
 DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
 DIPYRIDAMOLE, DIPYRIDAMOLE
 DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 DOXYCYCLINE, DOXYCYCLINE HYCLATE
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
 ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
 ETOMIDATE, ETOMIDATE
 ETOPOSIDE, ETOPOSIDE
 FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
 FAMOTIDINE, FAMOTIDINE
 FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE
 FLOXURIDINE, FLOXURIDINE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
 FLUMAZENIL, FLUMAZENIL
 FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
 HALOPERIDOL, HALOPERIDOL LACTATE
 IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
 IFOSFAMIDE, IFOSFAMIDE
 INDOMETHACIN SODIUM, INDOMETHACIN SODIUM
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** W ****

* WEST-WARD PHARMACEUTICALS INTERNATIONAL LTD
 LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
 LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
 LEVOCARNITINE, LEVOCARNITINE
 LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
 LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
 MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
 MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
 MESNA, MESNA
 METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
 MILRINONE LACTATE, MILRINONE LACTATE
 MITOMYCIN, MITOMYCIN
 MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
 NALOXONE, NALOXONE HYDROCHLORIDE
 NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
 OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
 OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
 OXYTOCIN, OXYTOCIN
 PACLITAXEL, PACLITAXEL
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
 PENTOSTATIN, PENTOSTATIN
 PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE
 PHENYTOIN SODIUM, PHENYTOIN SODIUM
 PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 PROPOFOL, PROPOFOL
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RIFAMPIN, RIFAMPIN
 SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE
 SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE, SODIUM FERRIC GLUCONATE COMPLEX
 STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION
 SUFENTANIL CITRATE, SUFENTANIL CITRATE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 THIOTEPA, THIOTEPA
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 VECURONIUM BROMIDE, VECURONIUM BROMIDE
 VINBLASTINE SULFATE, VINBLASTINE SULFATE
 VINOELBINE TARTRATE, VINOELBINE TARTRATE

WILSHIRE PHARMS INC

* WILSHIRE PHARMACEUTICALS INC
 CARISOPRODOL, CARISOPRODOL
 PERPHENAZINE, PERPHENAZINE
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 TIAGABINE HYDROCHLORIDE, TIAGABINE HYDROCHLORIDE

WISCONSIN

* WISCONSIN MEDICAL RADIOPHARMACY LLC
 AMMONIA N 13, AMMONIA N-13
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

WOCKHARDT

* WOCKHARDT LTD
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 AZITHROMYCIN, AZITHROMYCIN
 BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
 BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** W ******* WOCKHARDT LTD**

CEFTRIAZONE, CEFTRIAZONE SODIUM
 CEFUROXIME AXETIL, CEFUROXIME AXETIL
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CLARITHROMYCIN, CLARITHROMYCIN
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 FAMOTIDINE, FAMOTIDINE (OTC)
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 FUROSEMIDE, FUROSEMIDE
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LEVETIRACETAM, LEVETIRACETAM
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TIMOLOL MALEATE, TIMOLOL MALEATE

WOCKHARDT BIO AG*** WOCKHARDT BIO AG**

ABIRATERONE ACETATE, ABIRATERONE ACETATE
 ACETIC ACID, ACETIC ACID, GLACIAL
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 AMOXICILLIN, AMOXICILLIN
 BROMFED-DM, BROMPHENIRAMINE MALEATE
 CARBAMAZEPINE, CARBAMAZEPINE
 CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
 CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CROMOLYN SODIUM, CROMOLYN SODIUM
 CYCLOSPORINE, CYCLOSPORINE
 DECITABINE, DECITABINE
 DEXAMETHASONE, DEXAMETHASONE
 DEXCHLORPHENIRAMINE MALEATE, DEXCHLORPHENIRAMINE MALEATE
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
 ERYTHROMYCIN, ERYTHROMYCIN
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 FUROSEMIDE, FUROSEMIDE
 GENERLAC, LACTULOSE
 HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 IMATINIB MESYLATE, IMATINIB MESYLATE
 LACTULOSE, LACTULOSE
 LEVETIRACETAM, LEVETIRACETAM
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 LINDANE, LINDANE
 LITHIUM CITRATE, LITHIUM CITRATE
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
 LORATADINE, LORATADINE (OTC)
 MEGESTROL ACETATE, MEGESTROL ACETATE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
 MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
 NYSTATIN, NYSTATIN
 OXACILLIN SODIUM, OXACILLIN SODIUM
 OXYBUTYNYN CHLORIDE, OXYBUTYNYN CHLORIDE
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PHENYTOIN, PHENYTOIN
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 PREDNISOLONE, PREDNISOLONE
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** W ******* WOCKHARDT BIO AG**

PROMETHAZINE PLAIN, PROMETHAZINE HYDROCHLORIDE
 PROMETHAZINE W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
 SELENIUM SULFIDE, SELENIUM SULFIDE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 VALPROIC ACID, VALPROIC ACID

WOCKHARDT LTD*** WOCKHARDT LTD**

BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CAPTOPRIL, CAPTOPRIL
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 ENALAPRIL MALEATE, ENALAPRIL MALEATE
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 LANSOPRAZOLE, LANSOPRAZOLE (OTC)
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

WOCKHARDT USA*** WOCKHARDT USA INC**

GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE

*** WOCKHARDT USA LLC**

LANSOPRAZOLE, LANSOPRAZOLE

WOODWARD*** WOODWARD PHARMA SERVICES LLC**

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
 MILRINONE LACTATE IN DEXTROSE 5%, MILRINONE LACTATE

WRASER PHARMS*** WRASER PHARMACEUTICALS LLC**

CETRAXAL, CIPROFLOXACIN HYDROCHLORIDE

WRASER PHARMS LLC*** WRASER PHARMACEUTICALS LLC**

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 TREZIX, ACETAMINOPHEN

WUSM CYCLOTRON*** WASHINGTON UNIV SCH MEDICINE CYCLOTRON FACILITY**

FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

WYETH PHARMS*** WYETH PHARMACEUTICALS LLC**

DUAVEE, BAZEDOXIFENE ACETATE
 PHOSPHOLINE IODIDE, ECHOTHIOPHATE IODIDE
 PREMARIN, ESTROGENS, CONJUGATED
 PREMPHASE 14/14, ESTROGENS, CONJUGATED
 PREMPRO, ESTROGENS, CONJUGATED
 PROTONIX IV, PANTOPRAZOLE SODIUM
 PROTONIX, PANTOPRAZOLE SODIUM
 TRECATOR, ETHIONAMIDE
 ZOSYN IN PLASTIC CONTAINER, PIPERACILLIN SODIUM
 ZOSYN, PIPERACILLIN SODIUM

**** X ******XELLIA PHARMS APS***** XELLIA PHARMACEUTICALS APS**

BACITRACIN, BACITRACIN
 CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
 COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
 DAPTOMYCIN, DAPTOMYCIN
 POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 TIGECYCLINE, TIGECYCLINE
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VORICONAZOLE, VORICONAZOLE

XERIS*** XERIS PHARMACEUTICALS INC**

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** X ****

* XERIS PHARMACEUTICALS INC
 GVOKE HYPOPEN, GLUCAGON
 GVOKE PFS, GLUCAGON

XGEN PHARMS

* XGEN PHARMACEUTICALS DJB INC
 ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
 AMPHOTERICIN B, AMPHOTERICIN B
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
 DACTINOMYCIN, DACTINOMYCIN
 FOLIC ACID, FOLIC ACID
 IBUPROFEN LYSINE, IBUPROFEN LYSINE
 LEVETIRACETAM, LEVETIRACETAM
 LINCOMYCIN, LINCOMYCIN HYDROCHLORIDE
 LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
 NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE
 NEOMYCIN SULFATE, NEOMYCIN SULFATE
 NYSTATIN, NYSTATIN
 POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 TRANEXAMIC ACID, TRANEXAMIC ACID

XIAMEN LP PHARM CO

* XIAMEN LP PHARMACEUTICAL CO LTD
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE

XIROMED

* XIROMED PHARMA ESPANA SL
 ACYCLOVIR, ACYCLOVIR
 ALTAVERA, ETHINYL ESTRADIOL
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
 ESTARYLLA, ETHINYL ESTRADIOL
 FLUOCINONIDE, FLUOCINONIDE
 FOSFOMYCIN TROMETHAMINE, FOSFOMYCIN TROMETHAMINE
 INTROVALE, ETHINYL ESTRADIOL
 ISIBLOOM, DESOGESTREL
 JAIMIESS, ETHINYL ESTRADIOL
 LANSOPRAZOLE, LANSOPRAZOLE
 LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LEVONORGESTREL, LEVONORGESTREL (OTC)
 LORYNA, DROSPIRENONE
 MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
 NAFTIFINE HYDROCHLORIDE, NAFTIFINE HYDROCHLORIDE
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 OMEPRAZOLE, OMEPRAZOLE
 PROGESTERONE, PROGESTERONE
 SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
 SYEDA, DROSPIRENONE
 TESTOSTERONE, TESTOSTERONE
 TRI-ESTARYLLA, ETHINYL ESTRADIOL
 TRI-LO-ESTARYLLA, ETHINYL ESTRADIOL
 VIENVA, ETHINYL ESTRADIOL
 VOLNEA, DESOGESTREL

XSPIRE PHARMA

* XSPIRE PHARMA
 NALFON, FENOPROFEN CALCIUM
 ZONTIVITY, VORAPAXAR SULFATE

* XSPIRE PHARMA LLC
 DEXAMETHASONE, DEXAMETHASONE
 FENOPROFEN CALCIUM, FENOPROFEN CALCIUM

XTTRIUM

* XTTRIUM LABORATORIES INC
 CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
 EXIDINE, CHLORHEXIDINE GLUCONATE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** X ******XTTRIUM LABS INC**

* XTTRIUM LABORATORIES INC
LACTULOSE, LACTULOSE

**** Y ******YABAO PHARM**

* YABAO PHARMACEUTICAL CO LTD BEIJING
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE

YANGLING BUCHANG

* YANGLING BUCHANG PHARMACEUTICAL CO LTD
TADALAFIL, TADALAFIL

YAOPHARMA CO LTD

* YAOPHARMA CO LTD
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

YICHANG HUMANWELL

* YICHANG HUMANWELL PHARMACEUTICAL CO LTD
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
IBUPROFEN, IBUPROFEN (OTC)
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

YILING

* YILING PHARMACEUTICAL LTD
ACYCLOVIR, ACYCLOVIR
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
FELODIPINE, FELODIPINE
LISINAPRIL, LISINAPRIL
SILDENAFIL CITRATE, SILDENAFIL CITRATE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE

YOUNGTECH PHARMS INC

* YOUNGTECH PHARMACEUTICALS INC
METOPROLOL TARTRATE, METOPROLOL TARTRATE

YUNG SHIN PHARM

* YUNG SHIN PHARMACEUTICAL INDUSTRIAL CO LTD
CEFACLOR, CEFACLOR
CEPHALEXIN, CEPHALEXIN
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
FELODIPINE, FELODIPINE
MELOXICAM, MELOXICAM

**** Z ******ZAMBON SPA**

* ZAMBON SPA ITALY
MONUROL, FOSFOMYCIN TROMETHAMINE

ZENNOVA

* ZENNOVA PHARMACEUTICALS CHENGDU CO LTD
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE

ZHEJIANG HISUN PHARM

* ZHEJIANG HISUN PHARMACEUTICAL CO LTD
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL

ZHEJIANG JINGXIN

* ZHEJIANG JINGXIN PHARMACEUTICAL CO LTD
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM

ZHEJIANG JUTAI PHARM

* ZHEJIANG JUTAI PHARMACEUTICAL CO LTD
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** Z ******ZHEJIANG YONGTAI**

* ZHEJIANG YONGTAI PHARMACEUTICAL CO LTD
GABAPENTIN, GABAPENTIN

ZIONEXA

* ZIONEXA US CORP
CERIANNA, FLUOROESTRADIOL F-18

ZO SKIN HEALTH

* ZO SKIN HEALTH
TRETINOIN, TRETINOIN

ZOGENIX INC

* ZOGENIX INC
FINTEPLA, FENFLURAMINE HYDROCHLORIDE

ZYDUS

* ZYDUS WORLDWIDE DMCC
AZITHROMYCIN, AZITHROMYCIN
BACLOFEN, BACLOFEN
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
LEFLUNOMIDE, LEFLUNOMIDE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
PHYTONADIONE, PHYTONADIONE
URSODIOL, URSODIOL

ZYDUS HLTHCARE

* ZYDUS HEALTHCARE USA LLC
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
LANSOPRAZOLE, LANSOPRAZOLE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

ZYDUS NOVELTECH INC

* ZYDUS NOVELTECH INC
RIVASTIGMINE, RIVASTIGMINE

ZYDUS PHARMS

* ZYDUS PHARMACEUTICALS USA INC
ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ACETYLCYSTEINE, ACETYLCYSTEINE
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ACYCLOVIR, ACYCLOVIR
ALBENDAZOLE, ALBENDAZOLE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALLOPURINOL, ALLOPURINOL
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMBRISENTAN, AMBRISENTAN
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
ARIPIPIRAZOLE, ARIPIPIRAZOLE
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BOSENTAN, BOSENTAN
BUDESONIDE, BUDESONIDE
BUMETANIDE, BUMETANIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
CARBAMAZEPINE, CARBAMAZEPINE
CARBIDOPA, CARBIDOPA
CHLORTHALIDONE, CHLORTHALIDONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** Z ****

* ZYDUS PHARMACEUTICALS USA INC
 CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
 CHOLESTYRAMINE, CHOLESTYRAMINE
 CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
 CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
 CLOBAZAM, CLOBAZAM
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 COLCHICINE, COLCHICINE
 COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
 DEFERASIROX, DEFERASIROX
 DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
 DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DIFLUNISAL, DIFLUNISAL
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DIMETHYL FUMARATE, DIMETHYL FUMARATE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DOXYCYCLINE, DOXYCYCLINE
 DOXYCYCLINE, DOXYCYCLINE HYCLATE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, DUTASTERIDE
 ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
 EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
 ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
 ENTECAVIR, ENTECAVIR
 ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 ETHACRYNATE SODIUM, ETHACRYNATE SODIUM
 ETODOLAC, ETODOLAC
 ETOMIDATE, ETOMIDATE
 EXEMESTANE, EXEMESTANE
 EZETIMIBE, EZETIMIBE
 FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
 FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
 FLUCONAZOLE, FLUCONAZOLE
 FLUOCINONIDE, FLUOCINONIDE
 GLIPIZIDE, GLIPIZIDE
 GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
 GLYBURIDE, GLYBURIDE
 HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
 IMATINIB MESYLATE, IMATINIB MESYLATE
 INDOMETHACIN, INDOMETHACIN
 ITRACONAZOLE, ITRACONAZOLE
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 LAMOTRIGINE, LAMOTRIGINE
 LANSOPRAZOLE, LANSOPRAZOLE
 LINEZOLID, LINEZOLID
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 MESALAMINE, MESALAMINE
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 METHYLPREDNISOLONE, METHYLPREDNISOLONE
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MIRTAZAPINE, MIRTAZAPINE
 MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
 NADOLOL, NADOLOL
 NATEGLINIDE, NATEGLINIDE
 NIFEDIPINE, NIFEDIPINE
 NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
 OLANZAPINE, OLANZAPINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** Z ****

* ZYDUS PHARMACEUTICALS USA INC
 OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
 OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
 OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 PERPHENAZINE, PERPHENAZINE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 POTASSIUM CITRATE, POTASSIUM CITRATE
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
 RAMELTEON, RAMELTEON
 SEVELAMER CARBONATE, SEVELAMER CARBONATE
 SIROLIMUS, SIROLIMUS
 SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
 SPIRONOLACTONE, SPIRONOLACTONE
 SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
 TADALAFIL, TADALAFIL
 TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
 TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TELMISARTAN, TELMISARTAN
 TEMOZOLOMIDE, TEMOZOLOMIDE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TOPIRAMATE, TOPIRAMATE
 TRANEXAMIC ACID, TRANEXAMIC ACID
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
 VORICONAZOLE, VORICONAZOLE
 ZOLMITRIPTAN, ZOLMITRIPTAN

ZYDUS PHARMS USA

* ZYDUS PHARMACEUTICALS USA INC
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 ATENOLOL, ATENOLOL
 AZATHIOPRINE, AZATHIOPRINE
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 BENZONATATE, BENZONATATE
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 HALOPERIDOL, HALOPERIDOL
 LAMOTRIGINE, LAMOTRIGINE
 MELOXICAM, MELOXICAM
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 NAPROXEN, NAPROXEN
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 RAMIPRIL, RAMIPRIL
 RIBAVIRIN, RIBAVIRIN
 RISPERIDONE, RISPERIDONE
 SIMVASTATIN, SIMVASTATIN
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 WARFARIN SODIUM, WARFARIN SODIUM
 ZONISAMIDE, ZONISAMIDE

ZYDUS PHARMS USA INC

* ZYDUS PHARMACEUTICALS USA INC
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 ANASTROZOLE, ANASTROZOLE
 ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
 BICALUTAMIDE, BICALUTAMIDE
 BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
 CARVEDILOL, CARVEDILOL
 DIPYRIDAMOLE, DIPYRIDAMOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** Z ****

* ZYDUS PHARMACEUTICALS USA INC
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 FINASTERIDE, FINASTERIDE
 GABAPENTIN, GABAPENTIN
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 IRBESARTAN, IRBESARTAN
 LAMOTRIGINE, LAMOTRIGINE
 LEVETIRACETAM, LEVETIRACETAM
 LEVOFLOXACIN, LEVOFLOXACIN
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 OMEPRAZOLE, OMEPRAZOLE
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RISPERIDONE, RISPERIDONE
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TOPIRAMATE, TOPIRAMATE
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 ZOLMITRIPTAN, ZOLMITRIPTAN

ZYLA

* ZYLA LIFE SCIENCES US INC
 OXAYDO, OXYCODONE HYDROCHLORIDE
 SPRIX, KETOROLAC TROMETHAMINE
 ZORVOLEX, DICLOFENAC

41ST EDITION 2021 - APPROVED DRUG PRODUCTS LIST

APPENDIX C
UNIFORM TERMS

DOSAGE FORMS

AEROSOL, FOAM	OINTMENT
AEROSOL, METERED	OINTMENT, AUGMENTED
CAPSULE	PASTE
CAPSULE, DELAYED REL PELLETS	PATCH
CAPSULE, DELAYED RELEASE	PELLET
CAPSULE, EXTENDED RELEASE	PELLETS
CLOTH	POWDER
CONCENTRATE	POWDER, EXTENDED RELEASE
CREAM	POWDER, METERED
CREAM, AUGMENTED	RING
ELIXIR	SHAMPOO
EMULSION	SOLUTION
ENEMA	SOLUTION FOR SLUSH
FILM	SOLUTION, EXTENDED RELEASE
FILM, EXTENDED RELEASE	SOLUTION, GEL FORMING/DROPS
FOAM	SOLUTION, METERED
FOR SOLUTION	SOLUTION/DROPS
FOR SUSPENSION	SPONGE
FOR SUSPENSION, DELAYED RELEASE	SPRAY
FOR SUSPENSION, EXTENDED RELEASE	SPRAY, METERED
GAS	SUPPOSITORY
GEL	SUSPENSION
GEL, AUGMENTED	SUSPENSION, EXTENDED RELEASE
GEL, METERED	SUSPENSION, LIPOSOMAL
GRANULE	SUSPENSION/DROPS
GRANULE, DELAYED RELEASE	SWAB
GUM, CHEWING	SYRUP
IMPLANT	SYSTEM
INHALANT	SYSTEM, EXTENDED RELEASE
INJECTABLE	TABLET
INJECTABLE, LIPID COMPLEX	TABLET, CHEWABLE
INJECTABLE, LIPOSOMAL	TABLET, DELAYED RELEASE
INJECTION, EXTENDED RELEASE	TABLET, EFFERVESCENT
INSERT	TABLET, EXTENDED RELEASE
INSERT, EXTENDED RELEASE	TABLET, EXTENDED RELEASE, CHEWABLE
INTRAUTERINE DEVICE	TABLET, FOR SUSPENSION
JELLY	TABLET, ORALLY DISINTEGRATING
LIQUID	TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE
LOTION	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE
LOTION, AUGMENTED	TAPE
LOTION/SHAMPOO	TROCHE/LOZENGE
OIL	
OIL/DROPS	

Note: Terms comprise currently marketed products

41ST EDITION 2021 - APPROVED DRUG PRODUCTS LIST

APPENDIX C

UNIFORM TERMS

ROUTES OF ADMINISTRATION

BUCCAL	INTRAVESICULAR
DENTAL	INTRAVITREAL
ENDOCERVICAL	IRRIGATION
ENTERAL	IV (INFUSION)
IMPLANTATION	N/A
INHALATION	NASAL
INJECTION	OPHTHALMIC
INTRA-ANAL	ORAL
INTRA-ARTERIAL	ORAL-21
INTRA-ARTICULAR	ORAL-28
INTRACAVITARY	OTIC
INTRACRANIAL	PERFUSION, CARDIAC
INTRADERMAL	PERIODONTAL
INTRAMUSCULAR	PYELOCALYCEAL
INTRAOCULAR	RECTAL
INTRAOSSEOUS	SPINAL
INTRAPERITONEAL	SUBCUTANEOUS
INTRAPLEURAL	SUBLINGUAL
INTRATHECAL	TOPICAL
INTRATRACHEAL	TRANSDERMAL
INTRAUTERINE	TRANSMUCOSAL
INTRAVENOUS	URETHRAL
INTRAVESICAL	VAGINAL

Note: Terms comprise currently marketed products

41ST EDITION 2021 - APPROVED DRUG PRODUCTS LIST

APPENDIX C
UNIFORM TERMS***ABBREVIATIONS***

AMP	AMPULE
AMPICIL	AMPICILLIN
APPROX	APPROXIMATELY
BOT	BOTTLE
CI	CURIE
CSR	CAROTID SINUS REFLEX
CU	CLINICAL UNITS
DIPROP	DIPROPIONATE
ELECT	ELECTROLYTE
EQ	EQUIVALENT TO
ER	EXTENDED RELEASE
GM	GRAM
HBR	HYDROBROMIDE
HCL	HYDROCHLORIDE
HR	HOURLY
IM	INTRAMUSCULAR
INH	INHALATION
IU	INTERNATIONAL UNITS
IV	INTRAVENOUS
KIU	KALLIKREIN INHIBITOR UNITS
MCG	MICROGRAM
mCi	MILLICURIE
MEQ	MILLIEQUIVALENT
MG	MILLIGRAM
ML	MILLILITER
N/A	NOT APPLICABLE
PPM	PARTS PER MILLION
REL	RELEASE
SQ CM	SQUARE CENTIMETER
SC	SUBCUTANEOUS
U	UNITS
uCi	MICROCURIE
UMOLAR	MICROMOLAR
USP	UNITED STATES PHARMACOPEIA

PATENT AND EXCLUSIVITY INFORMATION ADDENDUM

This *Addendum* identifies drugs that qualify under the Federal Food, Drug, and Cosmetic Act (FD&C Act) for periods of exclusivity and provides patent information that has been submitted to the Food and Drug Administration (FDA) concerning the listed drug products.

Exclusivity

This *Addendum* identifies:

- Drugs approved under section 505(c) of the FD&C Act that have qualified under the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Amendments) for five-year and three-year periods of exclusivity pursuant to Section 505(c) (3) (E) and Section 505(j) (5) (F) of the FD&C Act
- Drugs that have qualified for Orphan Drug Exclusivity pursuant to Section 527 of the FD&C Act
- Drugs that have qualified for Pediatric Exclusivity pursuant to Section 505A of the FD&C Act
- Drugs that have qualified for Generating Antibiotics Incentives Now (GAIN) exclusivity pursuant to Section 505E of the FD&C Act
- Generic drugs approved under section 505(j) of the FD&C Act that have qualified for 180-day exclusivity pursuant to Section 505(j) (5) (B) (iv) of the FD&C Act
- Generic drugs approved under section 505(j) of the FD&C Act that have qualified for Competitive Generic Therapy (CGT) exclusivity pursuant to Section 505(j) (5) (B) (v) of the FD&C Act

This section is arranged in alphabetical order by established name of the active ingredient, followed by the proprietary name (brand name or trade name) of the drug product. Active ingredient headings for multiple ingredient fixed-combination drug products are arranged alphabetically.

Individual descriptions of the protected use have been added to each Orphan Drug Exclusivity entry listed in the Orange Book. Such descriptions of Orphan Drug Exclusivity were included beginning with the 38th edition of the Orange Book.

For an explanation of the codes used in the *Addendum*, see the *Patent and Exclusivity Terms* Section. The exclusivity codes are general shorthand descriptions and do not necessarily identify, with specificity, the actual scope of exclusivity.

Patent Information

The FD&C Act requires that patent information be filed with all newly submitted Section 505(b) drug applications. In addition, patent information must be filed on Form FDA 3542 within 30 days of the date of approval of a Section 505(b) drug application.¹ FDA publishes certain information from Form FDA 3542 in the Orange Book after approval of the NDA or supplement.

The Orange Book includes the patent submission date (i.e., the date on which the FDA receives patent information from the NDA holder) for each newly listed patent to facilitate assessments of whether patent information is untimely filed with respect to a pending 505(b)(2) application or ANDA.²

The patents that FDA regards as covered by the statutory provisions for submission of patent information are:

- Patents that claim the drug substance (i.e., active ingredient(s))
- Drug product patents, which include formulation/composition patents
- Method-of-use patents that claim one or more approved methods of using the approved drug product

This information, as provided by the sponsor on Form FDA 3542, will be published as described above. An NDA holder submitting information on a patent that claims both the drug substance and the drug product (and is eligible for listing on either basis) is required only to specify that the patent claims either the drug substance or the drug product.

The Addendum lists patent and exclusivity information up to January of the Edition year. The monthly Cumulative Supplements to the Annual Edition list patent and exclusivity information changes since the Annual Edition Addendum. Since all parts of this publication are subject to changes, additions, or deletions, the [Orange Book](#), updated daily, should be consulted for the most recent patent and exclusivity information.

¹ Please note that the date of approval for an NDA for a drug for which FDA intends to recommend controls under the Controlled Substances Act is the later of the date on the approval letter for the NDA or the date of issuance of the interim final rule controlling the drug (see Section 505(x)(1) and (2) of the FD&C Act).

² See 21 CFR 314.50(i)(4) and 314.94(a)(12)(vi). The submission date for patent information is determined in accordance with 21 CFR 314.53(d)(5).

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEO</u>						
N 205551	001	8129385	Oct 05, 2027	DS DP		
		9242986	Dec 08, 2029	DS DP		
<u>ABALOPARATIDE - TYMLOS</u>						
N 208743	001	7803770	Apr 28, 2031	U-2009	NCE	Apr 28, 2022
		8148333	Nov 08, 2027	DP		
		8748382	Oct 03, 2027	U-2009		
<u>ABAMETAPIR - XEGLYZE</u>						
N 206966	001	10292389	Dec 17, 2034	DP U-2863	NCE	Jul 24, 2025
		7812163	Oct 28, 2026	DP U-2863		
		8212038	Jul 16, 2024	DP U-2863		
		9357783	Jul 16, 2024	DP		
		9839631	Jul 16, 2024	DS DP U-2863		
<u>ABEMACICLIB - VERZENIO</u>						
N 208716	001	7855211	Dec 15, 2029	DS DP U-2132	I-768	Feb 26, 2021
		7855211	Dec 15, 2029	DS DP U-2135	NCE	Sep 28, 2022
		7855211	Dec 15, 2029	DS DP U-2251		
<u>ABEMACICLIB - VERZENIO</u>						
N 208716	002	7855211	Dec 15, 2029	DS DP U-2132	I-768	Feb 26, 2021
		7855211	Dec 15, 2029	DS DP U-2135	NCE	Sep 28, 2022
		7855211	Dec 15, 2029	DS DP U-2251		
<u>ABEMACICLIB - VERZENIO</u>						
N 208716	003	7855211	Dec 15, 2029	DS DP U-2132	I-768	Feb 26, 2021
		7855211	Dec 15, 2029	DS DP U-2135	NCE	Sep 28, 2022
		7855211	Dec 15, 2029	DS DP U-2251		
<u>ABEMACICLIB - VERZENIO</u>						
N 208716	004	7855211	Dec 15, 2029	DS DP U-1981	I-768	Feb 26, 2021
		7855211	Dec 15, 2029	DS DP U-2132	NCE	Sep 28, 2022
		7855211	Dec 15, 2029	DS DP U-2135		
		7855211	Dec 15, 2029	DS DP U-2251		
<u>ABIRATERONE ACETATE - ZYTIGA</u>						
N 202379	001				I-765	Feb 07, 2021
<u>ABIRATERONE ACETATE - ZYTIGA</u>						
N 202379	002				I-765	Feb 07, 2021
<u>ABIRATERONE ACETATE - YONSA</u>						
N 210308	001	10292990	May 20, 2034	U-2535		
		9889144	Mar 17, 2034	DP		
<u>ACALABRUTINIB - CALOQUENCE</u>						
N 210259	001	10167291	Jul 01, 2036	DP U-2145	I-817	Nov 21, 2022
		10167291	Jul 01, 2036	DP U-2666	NCE	Oct 31, 2022
		10167291	Jul 01, 2036	DP U-2667	ODE-175	Oct 31, 2024
		10167291	Jul 01, 2036	DP U-2668	ODE-274	Nov 21, 2026
		10167291	Jul 01, 2036	DP U-2669		
		10167291	Jul 01, 2036	DP U-2670		
		10167291	Jul 01, 2036	DP U-2671		
		10239883	Jul 11, 2032	U-2666		
		10239883	Jul 11, 2032	U-2668		
		10272083	Jan 21, 2035	U-2519		
		10272083	Jan 21, 2035	U-2682		
		10272083	Jan 21, 2035	U-2683		
		10272083	Jan 21, 2035	U-2684		
		10272083	Jan 21, 2035	U-2685		
		10272083	Jan 21, 2035	U-2686		
		10272083	Jan 21, 2035	U-2687		
		7459554	Nov 24, 2026	DS		
		9290504	Jul 11, 2032	DS DP		
		9758524	Jul 11, 2032	U-2145		
		9796721	Jul 01, 2036	DS DP U-2145		
		9796721	Jul 01, 2036	DS DP U-2666		
		9796721	Jul 01, 2036	DS DP U-2667		
		9796721	Jul 01, 2036	DS DP U-2668		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ACALABRUTINIB - CALQUENCE</u>						
N 210259	001 9796721	Jul 01, 2036	DS DP U-2669			
	9796721	Jul 01, 2036	DS DP U-2670			
	9796721	Jul 01, 2036	DS DP U-2671			
<u>ACETAMINOPHEN - OFIRMEV</u>						
N 022450	001 10383834	Nov 13, 2028		U-2262	M-196	Jan 27, 2020
	10383834	Nov 13, 2028		U-2621	PED	Jul 27, 2020
	6992218	Jun 06, 2021	DP			
	6992218*PED	Dec 06, 2021				
	9399012	Sep 11, 2031		U-2261		
	9399012	Sep 11, 2031		U-2262		
	9399012*PED	Mar 11, 2032				
	9610265	Nov 13, 2028		U-2263		
	9610265*PED	May 13, 2029				
	9987238	Nov 13, 2028		U-2261		
	9987238*PED	May 13, 2029				
<u>ACETAMINOPHEN - ACETAMINOPHEN</u>						
N 204767	001 8741959	Apr 19, 2030	DP			
<u>ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ</u>						
N 208653	001 8461137	Feb 22, 2031	DS DP			
	8748413	Jul 01, 2030	DS DP			
	8828978	Jul 01, 2030	DP			
	9132125	Jul 01, 2030	DS DP U-2249			
	9549923	Jul 01, 2030	DS DP			
<u>ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ</u>						
N 208653	002 8461137	Feb 22, 2031	DS DP			
	8748413	Jul 10, 2030	DS DP			
	8828978	Jul 01, 2030	DP			
	9132125	Jul 01, 2030	DS DP U-2249			
	9549923	Jul 01, 2030	DS DP			
<u>ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ</u>						
N 208653	003 8461137	Feb 22, 2031	DS DP			
	8748413	Jul 10, 2030	DS DP			
	8828978	Jul 01, 2030	DP			
	9132125	Jul 01, 2030	DS DP U-2249			
	9549923	Jul 01, 2030	DS DP			
<u>ACETAMINOPHEN; BUTALBITAL - BUTALBITAL AND ACETAMINOPHEN</u>						
A 213115	001				CGT	Jul 28, 2020
<u>ACETAMINOPHEN; IBUPROFEN - ADVIL DUAL ACTION WITH ACETAMINOPHEN</u>						
N 211733	001				NP	Feb 28, 2023
<u>ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE - XARTEMIS XR</u>						
N 204031	001 6488962	Jun 20, 2020	DP			
	7976870	Jun 01, 2027		U-1498		
	8372432	Mar 11, 2029	DP U-1499			
	8377453	Nov 19, 2029	DP U-1499			
	8394408	Mar 11, 2029	DP			
	8597681	Dec 21, 2030	DP			
	8658631	May 16, 2032	DP			
	8668929	Mar 11, 2029		U-1499		
	8741885	May 16, 2032	DP U-1499			
	8980319	Dec 21, 2030	DP			
	8992975	May 16, 2032	DP			
	9050335	May 16, 2032	DP			
	9468636	May 16, 2032		U-1499		
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N 021539	001 8148356	May 21, 2026	DP			
	8399445	Aug 24, 2025		U-1373		
	8653061	Aug 24, 2025		U-1373		
	8722738	Apr 06, 2032		U-1373		
	9327028	Jul 21, 2031		U-1839		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916	001	8747894	May 08, 2032	DP U-1373		
		9427421	May 08, 2032	DP		
		9561204	May 08, 2032	U-1373		
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916	002	8747894	May 08, 2032	DP U-1373		
		9427421	May 08, 2032	DP		
		9561204	May 08, 2032	U-1373		
<u>ACCLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450	001	10034867	Jul 07, 2020	DP U-2513	M-256	Mar 29, 2022
		10034867	Jul 07, 2020	DP U-2514		
		10085974	Mar 13, 2029	DP U-2513		
		10588895	Jul 07, 2020	U-2772		
		6681768	Aug 07, 2022	DP		
		7078412	Jul 07, 2020	DS DP U-2513		
		8051851	Apr 22, 2027	DP		
		9056100	Jul 07, 2020	DP U-2513		
		9333195	Jul 07, 2020	DP U-2513		
		RE46417	Feb 10, 2025	DS DP U-2513		
<u>ACCLIDINIUM BROMIDE; FORMOTEROL FUMARATE - DUAKLIR PRESSAIR</u>						
N 210595	001	10034867	Jul 07, 2020	DP U-2513	NC	Mar 29, 2022
		10034867	Jul 07, 2020	DP U-2514		
		10085974	Mar 13, 2029	DP U-2513		
		10588895	Jul 07, 2020	U-2772		
		6681768	Aug 07, 2022	DP		
		7078412	Jul 07, 2020	DS DP U-2513		
		7750023	Jul 07, 2020	DP U-2513		
		8051851	Apr 22, 2027	DP		
		8129405	Jul 07, 2020	DP U-2513		
		9056100	Jul 07, 2020	DP U-2513		
		9333195	Jul 07, 2020	DP U-2513		
		RE46417	Feb 10, 2025	DS DP U-2513		
<u>ACYCLOVIR - AVACLIR</u>						
N 202408	001				ODE-235	Mar 29, 2026
<u>ACYCLOVIR - SITAVIG</u>						
N 203791	001	8592434	Jun 16, 2030	DP U-1460		
		8747896	Jun 03, 2027	DP U-1460		
		8791127	Mar 23, 2027	DP U-1460		
<u>ACYCLOVIR; HYDROCORTISONE - XERESE</u>						
N 022436	001	7223387	Nov 13, 2022	DP U-1006		
		7223387	Nov 13, 2022	DP U-1484		
<u>ADAPALENE - DIFFERIN</u>						
N 021753	001	7579377	Feb 23, 2025	U-818		
		7737181	Aug 29, 2024	DP		
		7834060	Mar 12, 2023	U-1078		
		7838558	Mar 12, 2023	DP		
		7868044	Mar 12, 2023	U-1078		
		8703820	Mar 12, 2023	U-1078		
<u>ADAPALENE - DIFFERIN</u>						
N 022502	001	7998467	May 31, 2028	DP U-1078		
		8435502	Sep 15, 2026	DP U-1078		
		8709392	Sep 15, 2026	DP U-1078		
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N 022320	001	7820186	Nov 23, 2025	DP		
		7964202	Sep 01, 2024	DP U-1078		
		8071644	Jul 18, 2027	DP U-1078		
		8080537	Jul 18, 2027	U-1078		
		8105618	Dec 23, 2022	U-1078		
		8129362	Jul 18, 2027	U-1078		
		8241649	Dec 23, 2022	DP		
		8445543	Jul 12, 2027	U-1078		
		8809305	Dec 23, 2022	U-1078		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N 022320	001 8936800	Dec 23, 2022	DP U-1078			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE</u>						
N 207917	001 8445543	Dec 23, 2022	U-1078			
	8703820	Mar 12, 2023	U-1078			
	8729127	Mar 12, 2023	U-1078			
	8785420	Dec 23, 2022	U-1078			
	8809305	Dec 23, 2022	U-1078			
	8936800	Dec 23, 2022	DP U-1078			
	9381179	Mar 12, 2023	U-1078			
	9387187	Mar 12, 2023	U-1078			
	9814690	Dec 23, 2022	DP U-1078			
<u>AFAMELANOTIDE - SCENESSE</u>						
N 210797	001 10076555	Feb 11, 2025	U-2638		NCE	Oct 08, 2024
	8334265	Mar 11, 2029	U-2638		ODE-270	Oct 08, 2026
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292	001 10004743	Jul 05, 2030	DP		I-763	Jan 12, 2021
	8426586	Oct 10, 2029	DS		ODE-115	Apr 15, 2023
	8545884	Dec 19, 2029	DP		ODE-230	Jan 12, 2025
	9539258	Nov 09, 2026	U-1950		ODE-50	Jul 12, 2020
	RE43431	Jan 13, 2026	DS			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292	002 10004743	Jul 05, 2030	DP		I-763	Jan 12, 2021
	8426586	Oct 10, 2029	DS		ODE-115	Apr 15, 2023
	8545884	Dec 19, 2029	DP		ODE-230	Jan 12, 2025
	9539258	Nov 09, 2026	U-1950		ODE-50	Jul 12, 2020
	RE43431	Jan 13, 2026	DS			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292	003 10004743	Jul 05, 2030	DP		I-763	Jan 12, 2021
	8426586	Oct 10, 2029	DS		ODE-115	Apr 15, 2023
	8545884	Dec 19, 2029	DP		ODE-230	Jan 12, 2025
	9539258	Nov 09, 2026	U-1950		ODE-50	Jul 12, 2020
	RE43431	Jan 13, 2026	DS			
<u>AIR POLYMER-TYPE A - EXEM FOAM KIT</u>						
N 212279	001 9034300	Oct 15, 2030	DP U-2663		NCE	Nov 07, 2024
	9259494	May 04, 2035	DP U-2663			
	9849199	Feb 11, 2036	DP			
<u>ALBUMIN HUMAN - OPTISON</u>						
N 020899	001 6723303	Apr 20, 2021	DP			
<u>ALBUTEROL SULFATE - ACCUNEE</u>						
N 020949	001 6702997	Dec 28, 2021	U-558			
<u>ALBUTEROL SULFATE - ACCUNEE</u>						
N 020949	002 6702997	Dec 28, 2021	U-558			
<u>ALBUTEROL SULFATE - VENTOLIN HFA</u>						
N 020983	001 7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
	7832351	Jun 19, 2023	DP			
	9861771	Oct 11, 2020	DP			
<u>ALBUTEROL SULFATE - PROAIR HFA</u>						
N 021457	001 10022509	May 18, 2031	DP			
	10022510	May 18, 2031	DP			
	10086156	May 18, 2031	DP			
	10561808	Jan 01, 2032	DP			
	10695512	May 18, 2031	DP			
	7105152	Sep 12, 2023	DP			
	8132712	Sep 07, 2028	DP			
	9463289	May 18, 2031	DP			
	9808587	May 18, 2031	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636 001	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	10561808	Jan 01, 2032	DP			
	10765820	May 19, 2025	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9731087	May 18, 2031	DP			
<u>ALBUTEROL SULFATE - PROAIR DIGIHALER</u>						
N 205636 002	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	10561808	Jan 01, 2032	DP			
	10569034	Aug 16, 2036	DP			
	10765820	May 19, 2025	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - DUONEB</u>						
N 020950 001	6632842	Dec 28, 2021		U-532		
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT RESPIMAT</u>						
N 021747 001	6988496	Feb 23, 2020	DP			
	7284474	Aug 26, 2024	DP			
	7396341	Oct 10, 2026	DP			
	7837235	Mar 13, 2028	DP			
	7896264	May 26, 2025	DP			
	7988001	Aug 04, 2021	DP			
	8733341	Oct 16, 2030	DP			
	9027967	Mar 31, 2027	DP			
<u>ALCAFTADINE - LASTACRAFT</u>						
N 022134 001	10617695	Mar 19, 2027	DP	U-1493		
	8664215	Dec 23, 2027		U-1493		
<u>ALCOHOL - ABLYSINOL</u>						
N 207987 001					ODE-192	Jun 21, 2025
<u>ALCOHOL - ABLYSINOL</u>						
N 207987 002					ODE-192	Jun 21, 2025
<u>ALECTINIB HYDROCHLORIDE - ALECENSA</u>						
N 208434 001	10350214	Apr 24, 2035	DP		I-756	Nov 06, 2020
	9126931	May 29, 2031	DS		NCE	Dec 11, 2020
	9365514	Mar 04, 2032	DP		ODE-105	Dec 11, 2022
	9440922	Jun 09, 2030	DP		ODE-159	Nov 06, 2024
<u>ALENDRONATE SODIUM - BINOSTO</u>						
N 202344 001	7488496	Aug 11, 2023	DS DP			
	7964212	Mar 06, 2023	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALISKIREN HEMIFUMARATE - TEKTURNA</u>						
N 021985	001	8617595	Feb 19, 2026	DP		
		8617595*PED	Aug 19, 2026			
<u>ALISKIREN HEMIFUMARATE - TEKTURNA</u>						
N 021985	002	8617595	Feb 19, 2026	DP		
		8617595*PED	Aug 19, 2026			
<u>ALISKIREN HEMIFUMARATE - TEKTURNA</u>						
N 210709	001				NP	Nov 14, 2020
					PED	May 14, 2021
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545	001	8613949	Dec 21, 2029	DP		
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545	002	8613949	Dec 21, 2029	DP		
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545	003	8613949	Dec 21, 2029	DP		
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545	004	8613949	Dec 21, 2029	DP		
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045	001	8183295	May 16, 2023	DP		
		8618174	Nov 15, 2021	DP		
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045	002	8183295	May 16, 2023	DP		
		8618174	Nov 15, 2021	DP		
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045	003	8183295	May 16, 2023	DP		
		8618174	Nov 15, 2021	DP		
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045	004	8183295	May 16, 2023	DP		
		8618174	Nov 15, 2021	DP		
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045	005	8183295	May 16, 2023	DP		
		8618174	Nov 15, 2021	DP		
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT</u>						
N 022107	001	8618172	Jul 13, 2028	DP		
		9023893	Mar 03, 2022	DP		
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT</u>						
N 022107	002	8618172	Jul 13, 2028	DP		
		9023893	Mar 03, 2022	DP		
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT</u>						
N 022107	003	8618172	Jul 13, 2028	DP		
		9023893	Mar 03, 2022	DP		
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT</u>						
N 022107	004	8618172	Jul 13, 2028	DP		
		9023893	Mar 03, 2022	DP		
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA</u>						
N 022217	001	8168616	Jul 03, 2026	DP		
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA</u>						
N 022217	002	8168616	Jul 03, 2026	DP		
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203	001	10183012	Nov 26, 2028		U-2104	
		8003681	Aug 25, 2025	DS		
		8084483	Aug 17, 2029		U-2104	
		8283369	Nov 26, 2028		U-2104	
		8357713	Nov 26, 2028	DP	U-2104	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203	001	8546436	Feb 29, 2032	DS		
		8546437	Apr 29, 2029		U-2104	
		9216179	Aug 01, 2031		U-2104	
		9956205	Dec 28, 2031		U-2104	
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203	002	10183012	Nov 26, 2028		U-2104	
		8003681	Aug 25, 2025	DS		
		8084483	Aug 17, 2029		U-2104	
		8283369	Nov 26, 2028		U-2104	
		8357713	Nov 26, 2028	DP	U-2104	
		8546436	Feb 29, 2032	DS		
		8546437	Apr 29, 2029		U-2104	
		9216179	Aug 01, 2031		U-2104	
		9956205	Dec 28, 2031		U-2104	
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271	001	7807689	Jun 27, 2028	DS DP	U-1337	
		8173663	Dec 02, 2025		U-1338	
		8288539	Mar 15, 2025	DS		
		8697125	Jun 16, 2029		DP	
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271	002	7807689	Jun 27, 2028	DS DP	U-1337	
		8173663	Dec 02, 2025		U-1338	
		8288539	Mar 15, 2025	DS		
		8697125	Jun 16, 2029		DP	
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271	003	7807689	Jun 27, 2028	DS DP	U-1337	
		8173663	Dec 02, 2025		U-1338	
		8288539	Mar 15, 2025	DS		
		8697125	Jun 16, 2029		DP	
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414	001	7807689	Jun 27, 2028	DS DP	U-1337	
		8173663	Mar 15, 2025		U-1338	
		8288539	Jun 24, 2025	DS		
		8900638	May 24, 2029		DP	
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414	002	7807689	Jun 27, 2028	DS DP	U-1337	
		8173663	Mar 15, 2025		U-1338	
		8288539	Jun 24, 2025	DS		
		8900638	May 24, 2029		DP	
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426	001	6329404	Jun 19, 2021		DP U-1334	
		7807689	Jun 27, 2028	DS DP	U-1337	
		8173663	Mar 15, 2025		U-1338	
		8288539	Mar 15, 2025	DS		
		8637079	Jun 04, 2029		DP	
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426	002	6329404	Jun 19, 2021		DP U-1334	
		7807689	Jun 27, 2028	DS DP	U-1337	
		8173663	Mar 15, 2025		U-1338	
		8288539	Mar 15, 2025	DS		
		8637079	Jun 04, 2029		DP	
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426	003	6329404	Jun 19, 2021		DP U-1334	
		7807689	Jun 27, 2028	DS DP	U-1337	
		8173663	Mar 15, 2025		U-1338	
		8288539	Mar 15, 2025	DS		
		8637079	Jun 04, 2029		DP	
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426	004	6329404	Jun 19, 2021		DP U-1334	
		7807689	Jun 27, 2028	DS DP	U-1337	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426	004	8173663	Mar 15, 2025		U-1338	
		8288539	Mar 15, 2025	DS		
		8637079	Jun 04, 2029	DP		
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426	005	6329404	Jun 19, 2021	DP	U-1334	
		7807689	Jun 27, 2028	DS DP	U-1337	
		8173663	Mar 15, 2025		U-1338	
		8288539	Mar 15, 2025	DS		
		8637079	Jun 04, 2029	DP		
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426	006	6329404	Jun 19, 2021	DP	U-1334	
		7807689	Jun 27, 2028	DS DP	U-1337	
		8173663	Mar 15, 2025		U-1338	
		8288539	Mar 15, 2025	DS		
		8637079	Jun 04, 2029	DP		
<u>ALPELISIB - PIORAY</u>						
N 212526	001	8227462	Sep 28, 2030	DS DP	U-2539	NCE May 24, 2024
		8476268	Sep 10, 2029	DS DP		
<u>ALPELISIB - PIORAY</u>						
N 212526	002	8227462	Sep 28, 2030	DS DP	U-2539	NCE May 24, 2024
		8476268	Sep 10, 2029	DS DP		
<u>ALPELISIB - PIORAY</u>						
N 212526	003	8227462	Sep 28, 2030	DS DP	U-2539	NCE May 24, 2024
		8476268	Sep 10, 2029	DS DP		
<u>ALVIMOPAN - ENTEREG</u>						
N 021775	001	6469030	Nov 29, 2020		U-879	
		8112290	Jul 31, 2030		U-1443	Y
		8645160	Jun 18, 2029		U-1485	Y
		8946262	Feb 12, 2030		U-1655	
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944	001	10154971	Dec 04, 2034		U-2459	I-769 Aug 24, 2020
		10646456	Jun 17, 2034		U-2808	ODE-153 Aug 24, 2024
		8389578	Jan 22, 2028		U-2105	
		8741343	Dec 02, 2030		U-2106	
		8796337	Nov 23, 2025		U-2106	
		8889740	Nov 23, 2025	DP		
		8895614	Nov 23, 2025	DP		
		8895615	Nov 23, 2025		U-2106	
		8895616	Nov 23, 2025		U-2106	
		8895617	Nov 23, 2025		U-2106	
		8895618	Nov 23, 2025	DP		
		9867791	Dec 02, 2030		U-2106	
		9867792	Dec 02, 2030		U-2106	
		9867793	Dec 02, 2030		U-2106	
		9877933	Dec 02, 2030		U-2224	
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944	002	10154971	Dec 04, 2034		U-2459	I-769 Aug 24, 2020
		10646456	Jun 17, 2034		U-2808	ODE-153 Aug 24, 2024
		8389578	Jan 22, 2028		U-2105	
		8741343	Dec 02, 2030		U-2106	
		8796337	Nov 23, 2025		U-2106	
		8889740	Nov 23, 2025	DP		
		8895614	Nov 23, 2025	DP		
		8895615	Nov 23, 2025		U-2106	
		8895616	Nov 23, 2025		U-2106	
		8895617	Nov 23, 2025		U-2106	
		8895618	Nov 23, 2025	DP		
		9867791	Dec 02, 2030		U-2106	
		9867792	Dec 02, 2030		U-2106	
		9867793	Dec 02, 2030		U-2106	
		9877933	Dec 02, 2030		U-2224	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410	001	10213393	Feb 15, 2038	U-20		
		10213394	Feb 15, 2038	U-2497		
		10500170	Feb 15, 2038	U-20		
		10500171	Feb 15, 2038	U-2497		
		10500172	Feb 15, 2038	U-2497		
		10512617	Feb 15, 2038	U-2497		
		8252331	Mar 13, 2030	DP		
		8574626	Nov 28, 2025	DP U-20		
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410	002	10213393	Feb 15, 2038	U-20		
		10213394	Feb 15, 2038	U-2497		
		10500170	Feb 15, 2038	U-20		
		10500171	Feb 15, 2038	U-2497		
		10500172	Feb 15, 2038	U-2497		
		10512617	Feb 15, 2038	U-2497		
		8252331	Mar 13, 2030	DP		
		8574626	Nov 28, 2025	DP U-20		
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410	003	10213393	Feb 15, 2038	U-20		
		10213394	Feb 15, 2038	U-2497		
		10500170	Feb 15, 2038	U-20		
		10500171	Feb 15, 2038	U-2497		
		10500172	Feb 15, 2038	U-2497		
		10512617	Feb 15, 2038	U-2497		
		8252331	Mar 13, 2030	DP		
		8574626	Nov 28, 2025	DP U-20		
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410	004	10213393	Feb 15, 2038	U-20		
		10213394	Feb 15, 2038	U-2497		
		10500170	Feb 15, 2038	U-20		
		10500171	Feb 15, 2038	U-2497		
		10500172	Feb 15, 2038	U-2497		
		10512617	Feb 15, 2038	U-2497		
		8252331	Mar 13, 2030	DP		
		8574626	Nov 28, 2025	DP U-20		
<u>AMBRISENTAN - LETAIRIS</u>						
N 022081	001	8377933	Dec 11, 2027	U-1754		
		9474752	Dec 11, 2027	U-1754		
		9549926	Oct 14, 2031	U-1965		
<u>AMBRISENTAN - LETAIRIS</u>						
N 022081	002	8377933	Dec 11, 2027	U-1754		
		9474752	Dec 11, 2027	U-1754		
		9549926	Oct 14, 2031	U-1965		
<u>AMIFAMPRIDINE - RUZURGI</u>						
N 209321	001				ODE-244	May 06, 2026
<u>AMIFAMPRIDINE PHOSPHATE - FIRDAPSE</u>						
N 208078	001	10793893	Apr 07, 2034	U-2956	NCE ODE-223	Nov 28, 2023 Nov 28, 2025
<u>AMIKACIN SULFATE - ARIKAYCE KIT</u>						
N 207356	001	10251900	May 15, 2035	U-2414	ODE-214	Sep 28, 2025
		10751355	May 15, 2035	U-2414	GAIN	Sep 28, 2030
		7718189	Jun 06, 2025	DP U-2415		
		8226975	Aug 15, 2028	DP		
		8632804	Dec 05, 2026	U-2416		
		8642075	Dec 05, 2026	DP		
		8679532	Dec 05, 2026	U-2415		
		8802137	Apr 08, 2024	DP U-2414		
		9566234	Jan 18, 2034	DP U-2415		
		9827317	Apr 08, 2024	DP U-2415		
		9895385	May 15, 2035	U-2417		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMINOCAPROIC ACID - AMINOCAPROIC ACID</u>						
A 212492	001				CGT	May 30, 2020
<u>AMINOCAPROIC ACID - AMINOCAPROIC ACID</u>						
A 212780	001				CGT	Feb 26, 2020
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u>						
N 020965	001	10357567	Jan 12, 2038	U-804	I-766	Mar 09, 2021
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - GLEOLAN</u>						
N 208630	001				ODE-146	Jun 06, 2024
<u>AMIODARONE HYDROCHLORIDE - NEXTERONE</u>						
N 022325	001	6869939	May 04, 2022	DP		
		7635773	Mar 13, 2029	DP		
<u>AMIODARONE HYDROCHLORIDE - NEXTERONE</u>						
N 022325	002	6869939	May 04, 2022	DP		
		7635773	Mar 13, 2029	DP		
<u>AMIODARONE HYDROCHLORIDE - NEXTERONE</u>						
N 022325	003	6869939	May 04, 2022	DP		
		7635773	Mar 13, 2029	DP		
<u>AMISULPRIDE - BARHEMSYS</u>						
N 209510	001	10525033	Mar 10, 2031	DP	NCE	Feb 26, 2025
		9084765	Mar 10, 2031	U-1744		
		9084765	Mar 10, 2031	U-2754		
		9545426	Mar 10, 2031	U-1744		
		9545426	Mar 10, 2031	U-2754		
		9889118	Mar 10, 2031	U-1744		
		9889118	Mar 10, 2031	U-2754		
<u>AMLODIPINE BENZOATE - KATERZIA</u>						
N 211340	001	10695329	Oct 16, 2037	DP		
		10799453	Apr 11, 2039	DP		
<u>AMLODIPINE BESYLATE - AMLODIPINE BESYLATE</u>						
N 022026	001	6828339	Nov 20, 2022	DS		
<u>AMLODIPINE BESYLATE - AMLODIPINE BESYLATE</u>						
N 022026	002	6828339	Nov 20, 2022	DS		
<u>AMLODIPINE BESYLATE - AMLODIPINE BESYLATE</u>						
N 022026	003	6828339	Nov 20, 2022	DS		
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045	001	10350171	Jun 14, 2038	DP	NC	May 31, 2021
		9408837	Feb 28, 2030	U-2410		
		9662315	May 22, 2029	DP U-2410		
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045	002	10350171	Jun 14, 2038	DP	NC	May 31, 2021
		9408837	Feb 28, 2030	U-2410		
		9662315	May 22, 2029	DP U-2410		
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045	003	10350171	Jun 14, 2038	DP	NC	May 31, 2021
		9408837	Feb 28, 2030	U-2410		
		9662315	May 22, 2029	DP U-2410		
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314	001	8101599	May 16, 2023	DP		
		8475839	May 16, 2023	DP		
		8475839*PED	Nov 16, 2023			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314	002	8101599	May 16, 2023	DP		
		8475839	May 16, 2023	DP		
		8475839*PED	Nov 16, 2023			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314	003	8101599	May 16, 2023	DP		
		8475839	May 16, 2023	DP		
		8475839*PED	Nov 16, 2023			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314	004	8101599	May 16, 2023	DP		
		8475839	May 16, 2023	DP		
		8475839*PED	Nov 16, 2023			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314	005	8101599	May 16, 2023	DP		
		8475839	May 16, 2023	DP		
		8475839*PED	Nov 16, 2023			
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003	001	6696481	Apr 15, 2023	DS DP U-3		
		7846961	Oct 05, 2029	DS DP U-3		
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003	002	6696481	Apr 15, 2023	DS DP U-3		
		7846961	Oct 05, 2029	DS DP U-3		
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003	003	6696481	Apr 15, 2023	DS DP U-3		
		7846961	Oct 05, 2029	DS DP U-3		
<u>AMOXICILLIN - MOXATAG</u>						
N 050813	001	6544555	Oct 13, 2020	DS DP U-897		
		6669948	Oct 13, 2020	DS DP U-897		
		6723341	Oct 13, 2020	DS DP U-897		
		8299052	May 07, 2027		U-1304	
		8357394	Dec 08, 2026	DP		
		8778924	Dec 08, 2026	DS DP U-897		
<u>AMOXICILLIN; CLAVULANATE POTASSIUM - AUGMENTIN XR</u>						
N 050785	001	6746692	Apr 04, 2020	DP		
		6783773	Apr 04, 2020	DP		
		6878386	Apr 04, 2020		U-926	
		7217430	Apr 04, 2020	DP	U-926	
		7250176	Apr 04, 2020		U-926	
<u>AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN - TALICIA</u>						
N 213004	001	10238606	Feb 12, 2034	DP		
		9050263	Feb 12, 2034	DP	U-2660	
		9498445	Feb 12, 2034	DP	U-2660	
		9603806	Feb 12, 2034	DP	U-2660	
<u>AMPHETAMINE - ADZENYS ER</u>						
N 204325	001	8709491	Jun 28, 2032	DP		
		9017731	Jun 28, 2032	DP		
		9265737	Jun 28, 2032	DP		
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326	001	8709491	Jun 28, 2032	DP		
		8840924	Apr 09, 2026	DP		
		9017731	Jun 28, 2032	DP		
		9265737	Jun 28, 2032	DP		
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326	002	8709491	Jun 28, 2032	DP		
		8840924	Apr 09, 2026	DP		
		9017731	Jun 28, 2032	DP		
		9265737	Jun 28, 2032	DP		
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326	003	8709491	Jun 28, 2032	DP		
		8840924	Apr 09, 2026	DP		
		9017731	Jun 28, 2032	DP		
		9265737	Jun 28, 2032	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 004	8709491	Jun 28, 2032	DP			
	8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 005	8709491	Jun 28, 2032	DP			
	8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 006	8709491	Jun 28, 2032	DP			
	8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - DYANA VEL XR</u>						
N 208147 001	10086087	Mar 15, 2027	DP			
	8062667	Mar 29, 2029	DP			
	8597684	Mar 15, 2027	DP			
	8747902	Mar 15, 2027	DP			
	8883217	Mar 15, 2027	DP			
	9675703	Mar 15, 2027	DP			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 10</u>						
N 011522 007	6384020	Jul 06, 2020				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 20</u>						
N 011522 008	6384020	Jul 06, 2020				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 5</u>						
N 011522 009	6384020	Jul 06, 2020				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 30</u>						
N 011522 010	6384020	Jul 06, 2020				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 7.5</u>						
N 011522 011	6384020	Jul 06, 2020				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 12.5</u>						
N 011522 012	6384020	Jul 06, 2020				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 15</u>						
N 011522 013	6384020	Jul 06, 2020				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS</u>						
N 022063 001	6913768	May 24, 2023	DP U-2025		M-248	Sep 13, 2022
	8846100	Aug 24, 2029	DP		NP	Jun 20, 2020
	9173857	May 12, 2026	U-2025		PED	Mar 13, 2023
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS</u>						
N 022063 002	6913768	May 24, 2023	DP U-2025		M-248	Sep 13, 2022
	8846100	Aug 24, 2029	DP		NP	Jun 20, 2020
	9173857	May 12, 2026	U-2025		PED	Mar 13, 2023
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS</u>						
N 022063 003	6913768	May 24, 2023	DP U-2025		M-248	Sep 13, 2022
	8846100	Aug 24, 2029	DP		NP	Jun 20, 2020
	9173857	May 12, 2026	U-2025		PED	Mar 13, 2023

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS</u>						
N 022063	004	6913768	May 24, 2023	DP U-2025	M-248	Sep 13, 2022
		8846100	Aug 24, 2029	DP	NP	Jun 20, 2020
		9173857	May 12, 2026	U-2025	PED	Mar 13, 2023
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905	001	10130580	Apr 19, 2024	DP		
		10441554	Mar 10, 2037	DP		
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905	002	10130580	Apr 19, 2024	DP		
		10441554	Mar 10, 2037	DP		
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905	003	10130580	Apr 19, 2024	DP		
		10441554	Mar 10, 2037	DP		
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905	004	10130580	Apr 19, 2024	DP		
		10441554	Mar 10, 2037	DP		
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360	001	10028995	Dec 18, 2034	U-2338	NCE	Dec 21, 2022
		10335451	Dec 16, 2029	U-2581		
		10493124	Dec 18, 2034	U-2679		
		10500247	Dec 16, 2029	U-2680		
		10500247	Dec 16, 2029	U-2681		
		10548943	Dec 16, 2029	U-2739		
		10548943	Dec 16, 2029	U-2740		
		9220745	Dec 18, 2034	U-2217		
		9220745	Dec 18, 2034	U-2218		
		9572856	Nov 20, 2030	U-2221		
		9867863	Dec 16, 2029	U-2231		
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360	002	10028995	Dec 18, 2034	U-2338	NCE	Dec 21, 2022
		10335451	Dec 16, 2029	U-2581		
		10493124	Dec 18, 2034	U-2679		
		10500247	Dec 16, 2029	U-2680		
		10500247	Dec 16, 2029	U-2681		
		10548943	Dec 16, 2029	U-2739		
		10548943	Dec 16, 2029	U-2740		
		9220745	Dec 18, 2034	U-2217		
		9220745	Dec 18, 2034	U-2218		
		9572856	Nov 20, 2030	U-2221		
		9867863	Dec 16, 2029	U-2231		
<u>ANIDULAFUNGIN - ERAXIS</u>						
N 021632	001	5965525	Feb 17, 2020	DS DP U-540	NPP	Sep 22, 2023
		6960564	Apr 12, 2021	DP U-540		
		7709444	Apr 12, 2021	DP U-540		
<u>ANIDULAFUNGIN - ERAXIS</u>						
N 021632	002	5965525	Feb 17, 2020	DS DP U-540	NPP	Sep 22, 2023
		6960564	Apr 12, 2021	DP U-540		
		7709444	Apr 12, 2021	DP U-540		
<u>APALUTAMIDE - ERLEADA</u>						
N 210951	001	10052314	Sep 23, 2033	U-2381	I-808	Sep 17, 2022
		10052314	Sep 23, 2033	U-2382	NCE	Feb 14, 2023
		10702508	Apr 30, 2038	U-3012		
		10849888	Sep 23, 2033	U-3013		
		8445507	Sep 15, 2030	DS DP U-2237		
		8445507	Sep 15, 2030	DS DP U-2624		
		8802689	Mar 27, 2027	U-2237		
		8802689	Mar 27, 2027	U-2624		
		9388159	Mar 27, 2027	DS DP		
		9481663	Jun 04, 2033	DS DP U-2237		
		9481663	Jun 04, 2033	DS DP U-2624		
		9884054	Sep 23, 2033	U-2237		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APALUTAMIDE - ERLEADA</u>						
N 210951	001	9987261	Mar 27, 2027	DP		
<u>APIXABAN - ELIQUIS</u>						
N 202155	001	6967208	Nov 21, 2026	DS DP U-1167		
		6967208	Nov 21, 2026	DS DP U-1200		
		6967208	Nov 21, 2026	DS DP U-1301		
		6967208	Nov 21, 2026	DS DP U-1302		
		6967208	Nov 21, 2026	DS DP U-1323		
		6967208	Nov 21, 2026	DS DP U-1501		
		6967208	Nov 21, 2026	DS DP U-1502		
		6967208	Nov 21, 2026	DS DP U-1729		
		6967208	Nov 21, 2026	DS DP U-1730		
		9326945	Feb 24, 2031	DP		
<u>APIXABAN - ELIQUIS</u>						
N 202155	002	6967208	Nov 21, 2026	DS DP U-1200		
		6967208	Nov 21, 2026	DS DP U-1301		
		6967208	Nov 21, 2026	DS DP U-1302		
		6967208	Nov 21, 2026	DS DP U-1323		
		9326945	Feb 24, 2031	DP		
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875	001	10420763	Jun 11, 2030	DP U-2825	NP	May 21, 2023
		10449146	Apr 19, 2036	U-2825		
		10821074	Aug 07, 2029	DP		
		8414922	Dec 16, 2031	DP U-2825		
		8603514	Apr 03, 2024	DP		
		8663687	Feb 02, 2023	DP		
		8765167	Feb 20, 2024	DP		
		8846074	Dec 16, 2031	DP U-2825		
		9044475	Jun 11, 2030	DP		
		9283219	Jun 11, 2030	DP U-2825		
		9326981	Jun 11, 2030	U-2825		
		9669019	Jun 11, 2030	DP U-2825		
		9669021	Jun 11, 2030	U-2825		
		9855221	Feb 14, 2022	DP		
		9931305	Feb 14, 2022	DP		
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875	002	10420763	Jun 11, 2030	DP U-2825	NP	May 21, 2023
		10449146	Apr 19, 2036	U-2825		
		10821074	Aug 07, 2029	DP		
		8414922	Dec 16, 2031	DP U-2825		
		8603514	Apr 03, 2024	DP		
		8663687	Feb 02, 2023	DP		
		8765167	Feb 20, 2024	DP		
		8846074	Dec 16, 2031	DP U-2825		
		9044475	Jun 11, 2030	DP		
		9283219	Jun 11, 2030	DP U-2825		
		9326981	Jun 11, 2030	U-2825		
		9669019	Jun 11, 2030	DP U-2825		
		9669021	Jun 11, 2030	U-2825		
		9855221	Feb 14, 2022	DP		
		9931305	Feb 14, 2022	DP		
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875	003	10420763	Jun 11, 2030	DP U-2825	NP	May 21, 2023
		10449146	Apr 19, 2036	U-2825		
		10821074	Aug 07, 2029	DP		
		8414922	Dec 16, 2031	DP U-2825		
		8603514	Apr 03, 2024	DP		
		8663687	Feb 02, 2023	DP		
		8765167	Feb 20, 2024	DP		
		8846074	Dec 16, 2031	DP U-2825		
		9044475	Jun 11, 2030	DP		
		9283219	Jun 11, 2030	DP U-2825		
		9326981	Jun 11, 2030	U-2825		
		9669019	Jun 11, 2030	DP U-2825		
		9669021	Jun 11, 2030	U-2825		
		9855221	Feb 14, 2022	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875	003	9931305	Feb 14, 2022	DP		
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875	004	10420763	Jun 11, 2030	DP U-2825	NP	May 21, 2023
		10449146	Apr 19, 2036	U-2825		
		10821074	Aug 07, 2029	DP		
		8414922	Dec 16, 2031	DP U-2825		
		8603514	Apr 03, 2024	DP		
		8663687	Feb 02, 2023	DP		
		8765167	Feb 20, 2024	DP		
		8846074	Dec 16, 2031	DP U-2825		
		9044475	Jun 11, 2030	DP		
		9283219	Jun 11, 2030	DP U-2825		
		9326981	Jun 11, 2030	U-2825		
		9669019	Jun 11, 2030	DP U-2825		
		9669021	Jun 11, 2030	U-2825		
		9855221	Feb 14, 2022	DP		
		9931305	Feb 14, 2022	DP		
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875	005	10420763	Jun 11, 2030	DP U-2825	NP	May 21, 2023
		10449146	Apr 19, 2036	U-2825		
		10821074	Aug 07, 2029	DP		
		8414922	Dec 16, 2031	DP U-2825		
		8603514	Apr 03, 2024	DP		
		8663687	Feb 02, 2023	DP		
		8765167	Feb 20, 2024	DP		
		8846074	Dec 16, 2031	DP U-2825		
		9044475	Jun 11, 2030	DP		
		9283219	Jun 11, 2030	DP U-2825		
		9326981	Jun 11, 2030	U-2825		
		9669019	Jun 11, 2030	DP U-2825		
		9669021	Jun 11, 2030	U-2825		
		9855221	Feb 14, 2022	DP		
		9931305	Feb 14, 2022	DP		
<u>APREMILAST - OTEZLA</u>						
N 205437	001	10092541	May 29, 2034	U-2403	I-803	Jul 19, 2022
		10092541	May 29, 2034	U-2659	M-257	Apr 10, 2023
		6962940	Mar 19, 2023	U-1504	ODE-248	Jul 19, 2026
		6962940	Mar 19, 2023	U-2656		
		6962940	Mar 19, 2023	U-2657		
		6962940	Mar 19, 2023	U-2658		
		7208516	Mar 19, 2023	U-1505		
		7427638	Feb 16, 2028	DS DP		
		7659302	Mar 19, 2023	U-1505		
		7659302	Mar 19, 2023	U-1595		
		7659302	Mar 19, 2023	U-2657		
		7659302	Mar 19, 2023	U-2658		
		7893101	Dec 09, 2023	DS DP		
		8455536	Mar 19, 2023	U-1505		
		8455536	Mar 19, 2023	U-1595		
		8455536	Mar 19, 2023	U-2657		
		8455536	Mar 19, 2023	U-2658		
		8802717	Mar 19, 2023	U-1561		
		9018243	Mar 19, 2023	U-1505		
		9018243	Mar 19, 2023	U-1595		
		9018243	Mar 19, 2023	U-2656		
		9018243	Mar 19, 2023	U-2657		
		9018243	Mar 19, 2023	U-2658		
		9724330	Mar 19, 2023	U-1561		
		9724330	Mar 19, 2023	U-1595		
		9724330	Mar 19, 2023	U-2656		
		9724330	Mar 19, 2023	U-2657		
		9724330	Mar 19, 2023	U-2658		
		9872854	May 29, 2034	U-2232		
		9872854	May 29, 2034	U-2233		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>APREMILAST - OTEZLA</u>						
N 205437 002	10092541	May 29, 2034	U-2403		I-803	Jul 19, 2022
	10092541	May 29, 2034	U-2659		M-257	Apr 10, 2023
	6962940	Mar 19, 2023	U-1504		ODE-248	Jul 19, 2026
	6962940	Mar 19, 2023	U-2656			
	6962940	Mar 19, 2023	U-2657			
	6962940	Mar 19, 2023	U-2658			
	7208516	Mar 19, 2023	U-1505			
	7427638	Feb 16, 2028	DS DP			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7659302	Mar 19, 2023	U-2657			
	7659302	Mar 19, 2023	U-2658			
	7893101	Dec 09, 2023	DS DP			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8455536	Mar 19, 2023	U-2657			
	8455536	Mar 19, 2023	U-2658			
	8802717	Mar 19, 2023	U-1561			
	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
	9018243	Mar 19, 2023	U-2656			
	9018243	Mar 19, 2023	U-2657			
	9018243	Mar 19, 2023	U-2658			
	9724330	Mar 19, 2023	U-1561			
	9724330	Mar 19, 2023	U-1595			
	9724330	Mar 19, 2023	U-2656			
	9724330	Mar 19, 2023	U-2657			
	9724330	Mar 19, 2023	U-2658			
	9872854	May 29, 2034	U-2232			
	9872854	May 29, 2034	U-2233			
<u>APREMILAST - OTEZLA</u>						
N 205437 003	10092541	May 29, 2034	U-2403		I-803	Jul 19, 2022
	10092541	May 29, 2034	U-2659		M-257	Apr 10, 2023
	6962940	Mar 19, 2023	U-1504		ODE-248	Jul 19, 2026
	6962940	Mar 19, 2023	U-2656			
	6962940	Mar 19, 2023	U-2657			
	6962940	Mar 19, 2023	U-2658			
	7208516	Mar 19, 2023	U-1505			
	7427638	Feb 16, 2028	DS DP			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7659302	Mar 19, 2023	U-2657			
	7659302	Mar 19, 2023	U-2658			
	7893101	Dec 09, 2023	DS DP			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8455536	Mar 19, 2023	U-2657			
	8455536	Mar 19, 2023	U-2658			
	8802717	Mar 19, 2023	U-1561			
	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
	9018243	Mar 19, 2023	U-2656			
	9018243	Mar 19, 2023	U-2657			
	9018243	Mar 19, 2023	U-2658			
	9724330	Mar 19, 2023	U-1561			
	9724330	Mar 19, 2023	U-1595			
	9724330	Mar 19, 2023	U-2656			
	9724330	Mar 19, 2023	U-2657			
	9724330	Mar 19, 2023	U-2658			
	9872854	May 29, 2034	U-2232			
	9872854	May 29, 2034	U-2233			
<u>APREPITANT - EMEND</u>						
N 021549 001	8258132	Sep 26, 2027	DP U-1743			
	8258132	Sep 26, 2027	DP U-901			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>APREPITANT - EMEND</u>						
N 021549	002	8258132	Sep 26, 2027	DP	U-1743	
		8258132	Sep 26, 2027	DP	U-901	
<u>APREPITANT - EMEND</u>						
N 021549	003	8258132	Sep 26, 2027	DP	U-1743	
		8258132	Sep 26, 2027	DP	U-901	
<u>APREPITANT - EMEND</u>						
N 207865	001	8258132	Sep 26, 2027	DP	U-1916	
<u>APREPITANT - CINVANTI</u>						
N 209296	001	10500208	Sep 18, 2035	DP		
		10624850	Sep 18, 2035		U-2161	
		9561229	Sep 18, 2035	DP	U-2161	
		9808465	Sep 18, 2035		U-2161	
		9974742	Sep 18, 2035	DP		
		9974793	Sep 18, 2035	DP		
		9974794	Sep 18, 2035	DP	U-2161	
<u>ARFORMOTEROL TARTRATE - BROVANA</u>						
N 021912	001	6472563	Nov 09, 2021	DS		
		6667344	Jun 22, 2021		DP	
		6720453	Nov 09, 2021	DS		
		6814953	Jun 22, 2021		U-793	
		7145036	Nov 09, 2021	DS		
		7348362	Jun 22, 2021		DP U-793	
		7462645	Jun 22, 2021		U-793	
		7465756	Jun 22, 2021	DP		
		7473710	Jun 22, 2021		U-793	
		7541385	Jun 22, 2021		U-793	
		8110706	Nov 09, 2021	DP		
<u>ARGATROBAN - ARGATROBAN IN SODIUM CHLORIDE</u>						
N 022434	001	7589106	Sep 26, 2027	DP	U-1163	
		7687516	Sep 26, 2027	DP	U-1164	
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436	001	7053092	Jan 28, 2022		U-839	ODE-80
		8017615	Jun 16, 2024	DP		Dec 12, 2021
		8017615*PED	Dec 16, 2024			
		8580796	Sep 25, 2022	DS		
		8580796*PED	Mar 25, 2023			
		8642600	Jan 28, 2022		U-1492	
		8642600*PED	Jul 28, 2022			
		8642760	Sep 25, 2022	DS		
		8642760*PED	Mar 25, 2023			
		8759350	Mar 02, 2027		U-1529	
		9089567	Jan 28, 2022		U-543	
		9125939	Jul 28, 2026		U-1749	
		9359302	Sep 25, 2022	DS DP	U-1859	
		9387182	Dec 25, 2023		U-1529	
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436	002	7053092	Jan 28, 2022		U-839	ODE-80
		8017615	Jun 16, 2024	DP		Dec 12, 2021
		8017615*PED	Dec 16, 2024			
		8580796	Sep 25, 2022	DS		
		8580796*PED	Mar 25, 2023			
		8642600	Jan 28, 2022		U-1492	
		8642600*PED	Jul 28, 2022			
		8642760	Sep 25, 2022	DS		
		8642760*PED	Mar 25, 2023			
		8759350	Mar 02, 2027		U-1529	
		9089567	Jan 28, 2022		U-543	
		9125939	Jul 28, 2026		U-1749	
		9359302	Sep 25, 2022	DS DP	U-1859	
		9387182	Dec 25, 2023		U-1529	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 003	7053092	Jan 28, 2022		U-839	ODE-80	Dec 12, 2021
	8017615	Jun 16, 2024		DP		
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022		U-1492		
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027		U-1529		
	9089567	Jan 28, 2022		U-543		
	9125939	Jul 28, 2026		U-1749		
	9359302	Sep 25, 2022	DS DP	U-1859		
	9387182	Dec 25, 2023		U-1529		
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 004	7053092	Jan 28, 2022		U-839	ODE-80	Dec 12, 2021
	8017615	Jun 16, 2024		DP		
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022		U-1492		
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027		U-1529		
	9089567	Jan 28, 2022		U-543		
	9125939	Jul 28, 2026		U-1749		
	9359302	Sep 25, 2022	DS DP	U-1859		
	9387182	Dec 25, 2023		U-1529		
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 005	7053092	Jan 28, 2022		U-839	ODE-80	Dec 12, 2021
	8017615	Jun 16, 2024		DP		
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022		U-1492		
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027		U-1529		
	9089567	Jan 28, 2022		U-543		
	9125939	Jul 28, 2026		U-1749		
	9359302	Sep 25, 2022	DS DP	U-1859		
	9387182	Dec 25, 2023		U-1529		
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 006	7053092	Jan 28, 2022		U-839	ODE-80	Dec 12, 2021
	8017615	Jun 16, 2024		DP		
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022		U-1492		
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027		U-1529		
	9089567	Jan 28, 2022		U-543		
	9125939	Jul 28, 2026		U-1749		
	9359302	Sep 25, 2022	DS DP	U-1859		
	9387182	Dec 25, 2023		U-1529		
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021713 001	6977257	Apr 24, 2022	DP		ODE-80	Dec 12, 2021
	6977257*PED	Oct 24, 2022				
	7053092	Jan 28, 2022		U-839		
	8642600	Jan 28, 2022		U-1492		
	8642600*PED	Jul 28, 2022				
	8759350	Mar 02, 2027		U-1529		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021713	001	9387182	Dec 25, 2023	U-1529		
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021729	002	7053092	Jan 28, 2022	U-839	ODE-80	Dec 12, 2021
		8017615	Jun 16, 2024	DP		
		8017615*PED	Dec 16, 2024			
		8518421	Jan 24, 2021	DP		
		8518421*PED	Jul 24, 2021			
		8580796	Sep 25, 2022	DS		
		8580796*PED	Mar 25, 2023			
		8642600	Jan 28, 2022	U-1492		
		8642600*PED	Jul 28, 2022			
		8642760	Sep 25, 2022	DS		
		8642760*PED	Mar 25, 2023			
		8759350	Mar 02, 2027	U-1529		
		9089567	Jan 28, 2022	U-543		
		9125939	Jul 28, 2026	U-1749		
		9358207	Apr 12, 2020	DP		
		9359302	Sep 25, 2022	DS DP	U-1859	
		9387182	Dec 25, 2023	U-1529		
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021729	003	7053092	Jan 28, 2022	U-839	ODE-80	Dec 12, 2021
		8017615	Jun 16, 2024	DP		
		8017615*PED	Dec 16, 2024			
		8518421	Jan 24, 2021	DP		
		8518421*PED	Jul 24, 2021			
		8580796	Sep 25, 2022	DS		
		8580796*PED	Mar 25, 2023			
		8642600	Jan 28, 2022	U-1492		
		8642600*PED	Jul 28, 2022			
		8642760	Sep 25, 2022	DS		
		8642760*PED	Mar 25, 2023			
		8759350	Mar 02, 2027	U-1529		
		9089567	Jan 28, 2022	U-543		
		9125939	Jul 28, 2026	U-1749		
		9358207	Apr 12, 2020	DP		
		9359302	Sep 25, 2022	DS DP	U-1859	
		9387182	Dec 25, 2023	U-1529		
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021729	004	7053092	Jan 28, 2022	U-839	ODE-80	Dec 12, 2021
		8017615	Jun 16, 2024	DP		
		8017615*PED	Dec 16, 2024			
		8518421	Jan 24, 2021	DP		
		8518421*PED	Jul 24, 2021			
		8580796	Sep 25, 2022	DS		
		8580796*PED	Mar 25, 2023			
		8642600	Jan 28, 2022	U-1492		
		8642600*PED	Jul 28, 2022			
		8642760	Sep 25, 2022	DS		
		8642760*PED	Mar 25, 2023			
		9358207	Apr 12, 2020	DP		
		9359302	Sep 25, 2022	DS DP	U-1859	
		9387182	Dec 25, 2023	U-1529		
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021729	005	7053092	Jan 28, 2022	U-839	ODE-80	Dec 12, 2021
		8017615	Jun 16, 2024	DP		
		8017615*PED	Dec 16, 2024			
		8518421	Jan 24, 2021	DP		
		8518421*PED	Jul 24, 2021			
		8580796	Sep 25, 2022	DS		
		8580796*PED	Mar 25, 2023			
		8642600	Jan 28, 2022	U-1492		
		8642600*PED	Jul 28, 2022			
		8642760	Sep 25, 2022	DS		
		8642760*PED	Mar 25, 2023			
		9358207	Apr 12, 2020	DP		
		9359302	Sep 25, 2022	DS DP	U-1859	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021729	005 9387182	Dec 25, 2023	U-1529			
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021866	001 7115587	Jul 21, 2024	DP U-764		ODE-80	Dec 12, 2021
	7115587*PED	Jan 21, 2025				
	7550445	Jul 21, 2024	DP			
<u>ARIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971	001 10525057	Mar 08, 2034	U-1632		I-746	Jul 27, 2020
	10525057	Mar 08, 2034	U-2723			
	10525057	Mar 08, 2034	U-543			
	7807680	Oct 19, 2024	DP			
	8030313	Oct 19, 2024	U-1632			
	8030313	Oct 19, 2024	U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338427	Mar 15, 2025	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8399469	Jun 29, 2025	DS			
	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
	9089567	Jan 28, 2022	U-543			
<u>ARIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971	002 10525057	Mar 08, 2034	U-1632		I-746	Jul 27, 2020
	10525057	Mar 08, 2034	U-2723			
	10525057	Mar 08, 2034	U-543			
	7807680	Oct 19, 2024	DP			
	8030313	Oct 19, 2024	U-1632			
	8030313	Oct 19, 2024	U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338427	Mar 15, 2025	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8399469	Jun 29, 2025	DS			
	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
	9089567	Jan 28, 2022	U-543			
<u>ARIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971	003 10525057	Mar 08, 2034	U-1632		I-746	Jul 27, 2020
	10525057	Mar 08, 2034	U-2723			
	10525057	Mar 08, 2034	U-543			
	7807680	Oct 19, 2024	DP			
	8030313	Oct 19, 2024	U-1632			
	8030313	Oct 19, 2024	U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338427	Mar 15, 2025	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8399469	Jun 29, 2025	DS			
	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
	9089567	Jan 28, 2022	U-543			
<u>ARIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971	004 10525057	Mar 08, 2034	U-1632		I-746	Jul 27, 2020
	10525057	Mar 08, 2034	U-2723			
	10525057	Mar 08, 2034	U-543			
	7807680	Oct 19, 2024	DP			
	8030313	Oct 19, 2024	U-1632			
	8030313	Oct 19, 2024	U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338427	Mar 15, 2025	DP U-543			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971	004	8338428	Aug 06, 2023	DP	U-1633	
		8338428	Aug 06, 2023	DP	U-543	
		8399469	Jun 29, 2025	DS		
		8722679	Oct 19, 2024	DP		
		8759351	Aug 06, 2023	DP	U-1530	
		8759351	Aug 06, 2023	DP	U-1633	
		8993761	Sep 25, 2022	DS		
		9089567	Jan 28, 2022		U-543	
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202	001	10441194	Jul 26, 2029	DP		I-746 Jul 27, 2020
		10517507	Jun 13, 2032	DP		
		7053092	Jan 28, 2022		U-1529	
		7978064	Sep 14, 2026	DP		
		8017615	Jun 16, 2024	DP		
		8114021	Jun 21, 2030	DP		
		8258962	Nov 25, 2030	DP		
		8545402	Apr 27, 2030	DP		
		8547248	Dec 18, 2030	DP	U-2167	
		8580796	Sep 25, 2022	DS		
		8642760	Sep 25, 2022	DS		
		8674825	Apr 09, 2029	DP	U-2170	
		8718193	Dec 05, 2029	DP		
		8759350	Mar 02, 2027		U-1529	
		8847766	Mar 29, 2030	DP	U-2167	
		8945005	Aug 19, 2029	DP	U-2167	
		8956288	Jul 06, 2029	DP	U-2167	
		8961412	Nov 17, 2030	DP		
		9060708	Mar 05, 2029	DP		
		9089567	Jan 28, 2022		U-543	
		9119554	Dec 16, 2028	DP		
		9125939	Jul 28, 2026		U-1749	
		9149577	Dec 15, 2029	DP		
		9258035	Mar 05, 2029	DP		
		9268909	Oct 15, 2033	DP	U-2168	
		9320455	Dec 15, 2031	DP		
		9359302	Sep 25, 2022	DS DP	U-1529	
		9359302	Sep 25, 2022	DS DP	U-1749	
		9359302	Sep 25, 2022	DS DP	U-543	
		9387182	Dec 25, 2023		U-1529	
		9433371	Sep 15, 2029	DP		
		9444503	Nov 19, 2027	DP	U-2169	
		9941931	Nov 04, 2030	DP		
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202	002	10441194	Jul 26, 2029	DP		I-746 Jul 27, 2020
		10517507	Jun 13, 2032	DP		
		7053092	Jan 28, 2022		U-1529	
		7978064	Sep 14, 2026	DP		
		8017615	Jun 16, 2024	DP		
		8114021	Jun 21, 2030	DP		
		8258962	Nov 25, 2030	DP		
		8545402	Apr 27, 2030	DP		
		8547248	Dec 18, 2030	DP	U-2167	
		8580796	Sep 25, 2022	DS		
		8642760	Sep 25, 2022	DS		
		8674825	Apr 09, 2029	DP	U-2170	
		8718193	Dec 05, 2029	DP		
		8759350	Mar 02, 2027		U-1529	
		8847766	Mar 29, 2030	DP	U-2167	
		8945005	Aug 19, 2029	DP	U-2167	
		8956288	Jul 06, 2029	DP	U-2167	
		8961412	Nov 17, 2030	DP		
		9060708	Mar 05, 2029	DP		
		9089567	Jan 28, 2022		U-543	
		9119554	Dec 16, 2028	DP		
		9125939	Jul 28, 2026		U-1749	
		9149577	Dec 15, 2029	DP		
		9258035	Mar 05, 2029	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 002	9268909	Oct 15, 2033	DP U-2168			
	9320455	Dec 15, 2031	DP			
	9359302	Sep 25, 2022	DS DP U-1529			
	9359302	Sep 25, 2022	DS DP U-1749			
	9359302	Sep 25, 2022	DS DP U-543			
	9387182	Dec 25, 2023	U-1529			
	9433371	Sep 15, 2029	DP			
	9444503	Nov 19, 2027	DP U-2169			
	9941931	Nov 04, 2030	DP			
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 003	10441194	Jul 26, 2029	DP		I-746	Jul 27, 2020
	10517507	Jun 13, 2032	DP			
	7053092	Jan 28, 2022	U-1529			
	7978064	Sep 14, 2026	DP			
	8017615	Jun 16, 2024	DP			
	8114021	Jun 21, 2030	DP			
	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			
	8547248	Dec 18, 2030	DP U-2167			
	8580796	Sep 25, 2022	DS			
	8642760	Sep 25, 2022	DS			
	8674825	Apr 09, 2029	DP U-2170			
	8718193	Dec 05, 2029	DP			
	8759350	Mar 02, 2027	U-1529			
	8847766	Mar 29, 2030	DP U-2167			
	8945005	Aug 19, 2029	DP U-2167			
	8956288	Jul 06, 2029	DP U-2167			
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9089567	Jan 28, 2022	U-543			
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026	U-1749			
	9149577	Dec 15, 2029	DP			
	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP U-2168			
	9320455	Dec 15, 2031	DP			
	9359302	Sep 25, 2022	DS DP U-1529			
	9359302	Sep 25, 2022	DS DP U-1749			
	9359302	Sep 25, 2022	DS DP U-543			
	9387182	Dec 25, 2023	U-1529			
	9433371	Sep 15, 2029	DP			
	9444503	Nov 19, 2027	DP U-2169			
	9941931	Nov 04, 2030	DP			
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 004	10441194	Jul 26, 2029	DP		I-746	Jul 27, 2020
	10517507	Jun 13, 2032	DP			
	7053092	Jan 28, 2022	U-1529			
	7978064	Sep 14, 2026	DP			
	8017615	Jun 16, 2024	DP			
	8114021	Jun 21, 2030	DP			
	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			
	8547248	Dec 18, 2030	DP U-2167			
	8580796	Sep 25, 2022	DS			
	8642760	Sep 25, 2022	DS			
	8674825	Apr 09, 2029	DP U-2170			
	8718193	Dec 05, 2029	DP			
	8759350	Mar 02, 2027	U-1529			
	8847766	Mar 29, 2030	DP U-2167			
	8945005	Aug 19, 2029	DP U-2167			
	8956288	Jul 06, 2029	DP U-2167			
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9089567	Jan 28, 2022	U-543			
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026	U-1749			
	9149577	Dec 15, 2029	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 004	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP U-2168			
	9320455	Dec 15, 2031	DP			
	9359302	Sep 25, 2022	DS DP U-1529			
	9359302	Sep 25, 2022	DS DP U-1749			
	9359302	Sep 25, 2022	DS DP U-543			
	9387182	Dec 25, 2023	U-1529			
	9433371	Sep 15, 2029	DP			
	9444503	Nov 19, 2027	DP U-2169			
	9941931	Nov 04, 2030	DP			
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 005	10441194	Jul 26, 2029	DP		I-746	Jul 27, 2020
	10517507	Jun 13, 2032	DP			
	7053092	Jan 28, 2022	U-1529			
	7978064	Sep 14, 2026	DP			
	8017615	Jun 16, 2024	DP			
	8114021	Jun 21, 2030	DP			
	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			
	8547248	Dec 18, 2030	DP U-2167			
	8580796	Sep 25, 2022	DS			
	8642760	Sep 25, 2022	DS			
	8674825	Apr 09, 2029	DP U-2170			
	8718193	Dec 05, 2029	DP			
	8759350	Mar 02, 2027	U-1529			
	8847766	Mar 29, 2030	DP U-2167			
	8945005	Aug 19, 2029	DP U-2167			
	8956288	Jul 06, 2029	DP U-2167			
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9089567	Jan 28, 2022	U-543			
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026	U-1749			
	9149577	Dec 15, 2029	DP			
	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP U-2168			
	9320455	Dec 15, 2031	DP			
	9359302	Sep 25, 2022	DS DP U-1529			
	9359302	Sep 25, 2022	DS DP U-1749			
	9359302	Sep 25, 2022	DS DP U-543			
	9387182	Dec 25, 2023	U-1529			
	9433371	Sep 15, 2029	DP			
	9444503	Nov 19, 2027	DP U-2169			
	9941931	Nov 04, 2030	DP			
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 006	10441194	Jul 26, 2029	DP		I-746	Jul 27, 2020
	10517507	Jun 13, 2032	DP			
	7053092	Jan 28, 2022	U-1529			
	7978064	Sep 14, 2026	DP			
	8017615	Jun 16, 2024	DP			
	8114021	Jun 21, 2030	DP			
	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			
	8547248	Dec 18, 2030	DP U-2167			
	8580796	Sep 25, 2022	DS			
	8642760	Sep 25, 2022	DS			
	8674825	Apr 09, 2029	DP U-2170			
	8718193	Dec 05, 2029	DP			
	8759350	Mar 02, 2027	U-1529			
	8847766	Mar 29, 2030	DP U-2167			
	8945005	Aug 19, 2029	DP U-2167			
	8956288	Jul 06, 2029	DP U-2167			
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9089567	Jan 28, 2022	U-543			
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026	U-1749			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202	006	9149577	Dec 15, 2029	DP		
		9258035	Mar 05, 2029	DP		
		9268909	Oct 15, 2033	DP	U-2168	
		9320455	Dec 15, 2031	DP		
		9359302	Sep 25, 2022	DS DP	U-1529	
		9359302	Sep 25, 2022	DS DP	U-1749	
		9359302	Sep 25, 2022	DS DP	U-543	
		9387182	Dec 25, 2023		U-1529	
		9433371	Sep 15, 2029	DP		
		9444503	Nov 19, 2027	DP	U-2169	
		9941931	Nov 04, 2030	DP		
<u>ARIPIRAZOLE LAUROXIL - ARISTADA</u>						
N 207533	001	10112903	Jun 24, 2030	DS	U-543	NCE Oct 05, 2020
		10226458	Mar 19, 2032		U-543	
		10238651	Mar 19, 2035		U-2402	
		10813928	Mar 19, 2035		U-2983	
		8431576	Oct 26, 2030	DS		
		8796276	Jun 24, 2030		U-543	
		9034867	Nov 07, 2032	DP	U-543	
		9193685	Oct 24, 2033	DP	U-543	
		9452131	Mar 19, 2035		U-2402	
<u>ARIPIRAZOLE LAUROXIL - ARISTADA</u>						
N 207533	002	10112903	Jun 24, 2030	DS	U-543	NCE Oct 05, 2020
		10226458	Mar 19, 2032		U-543	
		10238651	Mar 19, 2035		U-2402	
		10813928	Mar 19, 2035		U-2983	
		8431576	Oct 26, 2030	DS		
		8796276	Jun 24, 2030		U-543	
		9034867	Nov 07, 2032	DP	U-543	
		9193685	Oct 24, 2033	DP	U-543	
		9452131	Mar 19, 2035		U-2402	
		9526726	Mar 19, 2035	DP		
<u>ARIPIRAZOLE LAUROXIL - ARISTADA</u>						
N 207533	003	10112903	Jun 24, 2030	DS	U-543	NCE Oct 05, 2020
		10226458	Mar 19, 2032		U-543	
		10238651	Mar 19, 2035		U-2402	
		10813928	Mar 19, 2035		U-2402	
		8431576	Oct 26, 2030	DS		
		8796276	Jun 24, 2030		U-543	
		9034867	Nov 07, 2032	DP	U-543	
		9193685	Oct 24, 2033	DP	U-543	
		9452131	Mar 19, 2035		U-2402	
		9526726	Mar 19, 2035	DP		
<u>ARIPIRAZOLE LAUROXIL - ARISTADA</u>						
N 207533	004	10112903	Jun 24, 2030	DS	U-543	NCE Oct 05, 2020
		10226458	Mar 19, 2032		U-543	
		10238651	Mar 19, 2035		U-2402	
		10813928	Mar 19, 2035		U-2983	
		8431576	Oct 26, 2030	DS		
		8796276	Jun 24, 2030		U-543	
		9034867	Nov 07, 2032	DP	U-543	
		9193685	Oct 24, 2033	DP	U-543	
		9452131	Mar 19, 2035		U-2402	
<u>ARIPIRAZOLE LAUROXIL - ARISTADA INITIO KIT</u>						
N 209830	001	10016415	Sep 08, 2035	DP		NCE Oct 05, 2020
		10112903	Jun 24, 2030	DS	U-543	
		10688091	Aug 17, 2035	DP		
		10849894	Aug 17, 2035		U-543	
		8431576	Oct 26, 2030	DS		
		8796276	Jun 24, 2030		U-543	
<u>ARMODAFINIL - NUVIGIL</u>						
N 021875	001	7132570	Dec 18, 2023	DS DP		
		7297346	Nov 29, 2023	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARMODAFINIL - NUVIGIL</u>						
N 021875	002	7132570	Dec 18, 2023	DS DP		
		7297346	Nov 29, 2023	DP		
<u>ARMODAFINIL - NUVIGIL</u>						
N 021875	003	7132570	Dec 18, 2023	DS DP		
		7297346	Nov 29, 2023	DP		
<u>ARMODAFINIL - NUVIGIL</u>						
N 021875	004	7132570	Dec 18, 2023	DS DP		
		7297346	Nov 29, 2023	DP		
<u>ARMODAFINIL - NUVIGIL</u>						
N 021875	005	7132570	Dec 18, 2023	DS DP		
		7297346	Nov 29, 2023	DP		
<u>ARSENIC TRIOXIDE - TRISENOX</u>						
N 021248	001				ODE-167	Jan 12, 2025
<u>ARSENIC TRIOXIDE - TRISENOX</u>						
N 021248	002				ODE-167	Jan 12, 2025
<u>ARTESUNATE - ARTESUNATE</u>						
N 213036	001				NCE	May 26, 2025
					ODE-290	May 26, 2027
<u>ASCORBIC ACID - ASCOR</u>						
N 209112	001				ODE-160	Oct 02, 2024
<u>ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC ACID</u>						
A 090145	001				PC	Feb 27, 2021
<u>ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - MOVIPREP</u>						
N 021881	001	7169381	Sep 01, 2024	DS DP		
		7658914	Sep 01, 2024	DS DP		
<u>ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - PLENUV</u>						
N 209381	001	10016504	Sep 10, 2033	DP	NP	May 04, 2021
		10646512	Mar 25, 2032	DP		
		10780112	Mar 09, 2032	DP		
		10792306	Mar 09, 2032	DP U-2310		
		8999313	Sep 10, 2033	DP		
		9326969	Sep 10, 2033	U-2310		
		9592252	Aug 11, 2032	DP U-2310		
		9707297	Sep 10, 2033	DP		
<u>ASENAPINE - SECUADO</u>						
N 212268	001	10022445	Jul 25, 2033	DP	NP	Oct 11, 2022
		10583121	Jul 25, 2033	DP U-2763		
		10814002	Jul 25, 2033	DP U-2763		
		9687474	Jul 25, 2033	DP		
<u>ASENAPINE - SECUADO</u>						
N 212268	002	10022445	Jul 25, 2033	DP	NP	Oct 11, 2022
		10583121	Jul 25, 2033	DP U-2763		
		10814002	Jul 25, 2033	DP U-2763		
		9687474	Jul 25, 2033	DP		
<u>ASENAPINE - SECUADO</u>						
N 212268	003	10022445	Jul 25, 2033	DP	NP	Oct 11, 2022
		10583121	Jul 25, 2033	DP U-2763		
		10814002	Jul 25, 2033	DP U-2763		
		9687474	Jul 25, 2033	DP		
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117	001	5763476	Jun 09, 2020	DP U-1960	D-166	Jan 13, 2020
		5763476	Jun 09, 2020	DP U-1961	I-597	Jan 13, 2020
		5763476	Jun 09, 2020	DP U-1962		
		5763476	Jun 09, 2020	DP U-1963		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117	001	5763476	Jun 09, 2020	DP U-326		
		5763476*PED	Dec 09, 2020			
		7741358	Apr 06, 2026	DS DP U-1064		
		7741358	Apr 06, 2026	DS DP U-1960		
		7741358	Apr 06, 2026	DS DP U-1961		
		7741358	Apr 06, 2026	DS DP U-1962		
		7741358	Apr 06, 2026	DS DP U-1963		
		7741358*PED	Oct 06, 2026			
		8022228	Apr 06, 2026	DS DP		
		8022228*PED	Oct 06, 2026			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117	002	5763476	Jun 09, 2020	DP U-1960	D-166	Jan 13, 2020
		5763476	Jun 09, 2020	DP U-1961	I-597	Jan 13, 2020
		5763476	Jun 09, 2020	DP U-1962		
		5763476	Jun 09, 2020	DP U-1963		
		5763476	Jun 09, 2020	DP U-326		
		5763476*PED	Dec 09, 2020			
		7741358	Apr 06, 2026	DS DP U-1064		
		7741358	Apr 06, 2026	DS DP U-1960		
		7741358	Apr 06, 2026	DS DP U-1961		
		7741358	Apr 06, 2026	DS DP U-1962		
		7741358	Apr 06, 2026	DS DP U-1963		
		7741358*PED	Oct 06, 2026			
		8022228	Apr 06, 2026	DS DP		
		8022228*PED	Oct 06, 2026			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117	003	5763476	Jun 09, 2020	DP U-1893	D-166	Jan 13, 2020
		5763476	Jun 09, 2020	DP U-1966	I-597	Jan 13, 2020
		5763476*PED	Dec 09, 2020			
		7741358	Apr 06, 2026	DS DP U-1893		
		7741358	Apr 06, 2026	DS DP U-1966		
		7741358*PED	Oct 06, 2026			
		8022228	Apr 06, 2026	DS DP		
		8022228*PED	Oct 06, 2026			
<u>ASPIRIN - VAZALORE</u>						
N 203697	001	8865187	Mar 23, 2022	DP		
		9101637	Mar 23, 2022	U-1731		
		9101637	Mar 23, 2022	U-1732		
		9101637	Mar 23, 2022	U-1733		
		9216150	Sep 29, 2032	DP		
		9226892	Sep 29, 2032	U-1731		
		9226892	Sep 29, 2032	U-1732		
		9226892	Sep 29, 2032	U-1733		
		9351984	Dec 19, 2021	DP		
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103	001	6926907	Feb 28, 2023	DP U-1902		
		8206741	Feb 28, 2023	DP U-1902		
		9364439	May 31, 2022	DP U-1902		
		9539214	Mar 13, 2033	U-1902		
		9987231	Jan 02, 2033	U-2324		
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103	002	6926907	Feb 28, 2023	DP U-1902		
		8206741	Feb 28, 2023	DP U-1902		
		9364439	May 31, 2022	DP U-1902		
		9539214	Mar 13, 2033	U-1902		
		9987231	Jan 02, 2033	U-2324		
<u>ATAZANAVIR SULFATE; COBICISTAT - EVOTAZ</u>						
N 206353	001	10039718	Oct 06, 2032	DP		
		8148374	Sep 03, 2029	DS DP U-1279		
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N 020702	001				M-204	Jun 23, 2020

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N 020702	002				M-204	Jun 23, 2020
<u>AVANAFIL - STENDRA</u>						
N 202276	001	6656935	Apr 27, 2025	DS DP U-155		
		7501409	May 05, 2023	DP		
<u>AVANAFIL - STENDRA</u>						
N 202276	002	6656935	Apr 27, 2025	DS DP U-155		
		7501409	May 05, 2023	DP		
<u>AVANAFIL - STENDRA</u>						
N 202276	003	6656935	Apr 27, 2025	DS DP U-155		
		7501409	May 05, 2023	DP		
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608	001	9200002	Oct 15, 2034	DS DP U-2726	NCE	Jan 09, 2025
		9944651	Oct 15, 2034	DS DP U-2726		
		9994575	Oct 15, 2034	DS DP U-2726		
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608	002	9200002	Oct 15, 2034	DS DP U-2726	NCE	Jan 09, 2025
		9944651	Oct 15, 2034	DS DP U-2726		
		9994575	Oct 15, 2034	DS DP U-2726		
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608	003	9200002	Oct 15, 2034	DS DP U-2726	NCE	Jan 09, 2025
		9944651	Oct 15, 2034	DS DP U-2726		
		9994575	Oct 15, 2034	DS DP U-2726		
<u>AVATROMBOPAG MALEATE - DOPTELET</u>						
N 210238	001	7638536	May 05, 2025	DS DP	I-802	Jun 26, 2022
		8338429	Jun 30, 2023	U-2577	NCE	May 21, 2023
		8765764	Jan 15, 2023	U-2314	ODE-246	Jun 26, 2026
		8765764	Jan 15, 2023	U-2578		
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494	001	7112592	Jan 07, 2026	DS DP U-2244	NCE	Feb 25, 2020
		7112592	Jan 07, 2026	DS DP U-2508	GAIN	Feb 25, 2025
		7112592	Jan 07, 2026	DS DP U-282		
		7612087	Nov 12, 2026	DP		
		8178554	Jul 24, 2021	DS DP U-2245		
		8178554	Jul 24, 2021	DS DP U-2509		
		8178554	Jul 24, 2021	DS DP U-282		
		8471025	Aug 12, 2031	DS		
		8835455	Oct 08, 2030	DP		
		8969566	Jun 15, 2032	DS		
		9284314	Jun 15, 2032	DS		
		9695122	Jun 15, 2032	DS		
<u>AXITINIB - INLYTA</u>						
N 202324	001	10570202	Feb 03, 2035		U-2844	
		6534524	Apr 29, 2025	DS DP		
		7141581	Jun 30, 2020		U-1220	
		8791140	Dec 14, 2030	DS		
<u>AXITINIB - INLYTA</u>						
N 202324	002	10570202	Feb 03, 2035		U-2844	
		6534524	Apr 29, 2025	DS DP		
		7141581	Jun 30, 2020		U-1220	
		8791140	Dec 14, 2030	DS		
<u>AZACITIDINE - ONUREG</u>						
N 214120	001	8846628	Jun 03, 2030	DP U-2950	NP	Sep 01, 2023
<u>AZACITIDINE - ONUREG</u>						
N 214120	002	8846628	Jun 03, 2030	DP U-2950	NP	Sep 01, 2023
<u>AZELAIC ACID - FINACEA</u>						
N 207071	001	10117812	Oct 18, 2027	DP U-1796		
		10322085	Oct 24, 2023	DP		
		7700076	Sep 18, 2027	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AZELAIC ACID - FINACEA</u>						
N 207071	001	8435498	Mar 01, 2024		U-1727	
		8722021	Oct 24, 2023		DP	
		8900554	Oct 24, 2023		DP	
		9211259	Feb 28, 2029		U-1796	
		9265725	Dec 08, 2027		DP	
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N 022203	001	8071073	Jun 04, 2028		DP	
		8518919	Nov 22, 2025		U-1430	
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N 022203	002	8071073	Jun 04, 2028		DP	
		8518919	Nov 22, 2025		U-1430	
		9919050	Nov 22, 2025		DP	
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE</u>						
A 207712	001				PC	Aug 29, 2020
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N 202236	001	8163723	Aug 29, 2023		U-1667	
		8163723	Aug 29, 2023		U-644	
		8163723	Aug 29, 2023		U-707	
		8163723	Aug 29, 2023		U-77	
		8163723	Aug 29, 2023		U-81	
		8163723*PED	Feb 29, 2024			
		8168620	Feb 24, 2026		DP	
		9259428	Jun 13, 2023		U-644	
		9259428*PED	Dec 13, 2023			
		9901585	Jun 13, 2023		DP	
<u>AZILSARTAN KAMEDOXOMIL - EDARBI</u>						
N 200796	001	7157584	May 22, 2025		DS	
		7572920	Jan 07, 2025		DP U-3	
		9066936	Mar 26, 2028		DP	
<u>AZILSARTAN KAMEDOXOMIL - EDARBI</u>						
N 200796	002	7157584	May 22, 2025		DS	
		7572920	Jan 07, 2025		DP U-3	
		9066936	Mar 26, 2028		DP	
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331	001	7157584	May 22, 2025		DS	
		7572920	Jan 07, 2025		DP U-3	
		9066936	Mar 26, 2028		DP	
		9169238	Feb 04, 2030		DP	
		9387249	Jul 01, 2031		U-3	
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331	002	7157584	May 22, 2025		DS	
		7572920	Jan 07, 2025		DP U-3	
		9066936	Mar 26, 2028		DP	
		9169238	Feb 04, 2030		DP	
		9387249	Jul 01, 2031		U-3	
<u>AZITHROMYCIN - ZMAX</u>						
N 050797	001	6984403	Feb 14, 2024		DP U-282	
		7887844	Feb 14, 2024		DP	
<u>AZTREONAM - CAYSTON</u>						
N 050814	001	7208141	Dec 20, 2021		DP U-1031	
		7214364	Dec 20, 2021		DP	
		7427633	Dec 20, 2021		DP U-1031	
		8399496	Dec 20, 2021		DP U-1377	
<u>BACLOFEN - OZOBAX</u>						
N 208193	001	10610502	Aug 30, 2039		U-2779	
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854	001	10392406	Apr 27, 2036		DS	
		10633397	Apr 27, 2036		U-2816	
					I-811	Oct 16, 2022
					NCE	Oct 24, 2023

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854	001	10633397	Apr 27, 2036		U-3000	
		10759814	Aug 09, 2037	DS DP		
		8927710	May 05, 2031	DP		
		8987441	Sep 21, 2031	DS DP		
		9815835	Jun 14, 2030	DP		
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854	002	10392406	Apr 27, 2036	DS	I-811	Oct 16, 2022
		10633397	Apr 27, 2036		NCE	Oct 24, 2023
		10633397	Apr 27, 2036		U-2816	
		10759814	Aug 09, 2037	DS DP	U-3000	
		8927710	May 05, 2031	DP		
		8987441	Sep 21, 2031	DS DP		
		9815835	Jun 14, 2030	DP		
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410	001	10392406	Apr 27, 2036	DS		
		10633397	Apr 27, 2036		U-2816	
		10633397	Apr 27, 2036		U-3000	
		10759814	Aug 09, 2037	DS DP		
		8927710	May 05, 2031	DP		
		8987441	Sep 21, 2031	DS DP		
		9815835	Jun 14, 2030	DP		
<u>BALSALAZIDE DISODIUM - COLAZAL</u>						
N 020610	001	7452872	Aug 24, 2026		U-141	
		7625884	Aug 24, 2026		U-141	
<u>BALSALAZIDE DISODIUM - GIAZO</u>						
N 022205	001	7452872	Aug 24, 2026		U-1229	
		7625884	Aug 24, 2026		U-1229	
		8497256	Jun 23, 2031		U-1229	
		9192616	Aug 02, 2026		U-1229	
<u>BARICITINIB - OLUMIANT</u>						
N 207924	001	8158616	Jun 08, 2030	DS DP	NCE	May 31, 2023
		8420629	Mar 10, 2029		U-247	
<u>BARICITINIB - OLUMIANT</u>						
N 207924	002	8158616	Jun 08, 2030	DS DP		
		8420629	Mar 10, 2029		U-247	
<u>BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE</u>						
N 022247	001	6479535	May 06, 2024		DP U-594	
		6479535	May 06, 2024		DP U-904	
		7683051	Mar 10, 2027	DS DP	U-594	
		7683051	Mar 10, 2027	DS DP	U-904	
<u>BECLOMETHASONE DIPROPIONATE - QVAR 80</u>						
N 020911	001	10022509	May 18, 2031		DP	
		10022510	May 18, 2031		DP	
		10086156	May 18, 2031		DP	
		10561808	Jan 01, 2032		DP	
		10695512	May 18, 2031		DP	
		9463289	May 18, 2031		DP	
		9808587	May 18, 2031		DP	
<u>BECLOMETHASONE DIPROPIONATE - QVAR 40</u>						
N 020911	002	10022509	May 18, 2031		DP	
		10022510	May 18, 2031		DP	
		10086156	May 18, 2031		DP	
		10561808	Jan 01, 2032		DP	
		10695512	May 18, 2031		DP	
		9463289	May 18, 2031		DP	
		9808587	May 18, 2031		DP	
<u>BECLOMETHASONE DIPROPIONATE - QNASL</u>						
N 202813	001	10188811	Oct 21, 2031		DP	
		7780038	Jan 24, 2027		DP	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BECLOMETHASONE DIPROPIONATE - QNASL</u>						
N 202813	002	10188811	Oct 21, 2031	DP		
		7780038	Jan 24, 2027	DP		
<u>BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER</u>						
N 207921	001	10022509	May 18, 2031	DP		
		10022510	May 18, 2031	DP		
		10086156	May 18, 2031	DP		
		10561808	Jan 01, 2032	DP		
		10695512	May 18, 2031	DP		
		10792447	Jan 25, 2039	DP		
		7637260	Aug 25, 2020	DP		
		8132712	Sep 07, 2028	DP		
		8931476	Jul 17, 2031	DP		
<u>BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER</u>						
N 207921	002	10022509	May 18, 2031	DP		
		10022510	May 18, 2031	DP		
		10086156	May 18, 2031	DP		
		10561808	Jan 01, 2032	DP		
		10695512	May 18, 2031	DP		
		10792447	Jan 25, 2039	DP		
		7637260	Aug 25, 2020	DP		
		8132712	Sep 07, 2028	DP		
		8931476	Jul 17, 2031	DP		
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384	001	7498343	Dec 01, 2026	DS DP U-1321	NPP	Aug 09, 2022
		8546428	Mar 19, 2029	DS DP U-1321	ODE-251	Aug 09, 2026
					ODE-307	May 27, 2027
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384	002	7498343	Dec 01, 2026	DS DP U-1321	ODE-307	May 27, 2027
		8546428	Mar 19, 2029	DS DP U-1321		
<u>BELINOSTAT - BELEODAO</u>						
N 206256	001	6888027	Sep 27, 2021	DS DP U-1544	ODE-68	Jul 03, 2021
		8835501	Oct 27, 2027	DP		
<u>BEMPEDOIC ACID - NEXLETOI</u>						
N 211616	001	10118881	Dec 23, 2023		U-2747	NCE
		7335799	Dec 03, 2025	DS		Feb 21, 2025
		8497301	Dec 23, 2023		U-2747	
		9000041	Dec 23, 2023		U-2747	
		9624152	Dec 23, 2023		U-2748	
<u>BEMPEDOIC ACID; EZETIMIBE - NEXLIZET</u>						
N 211617	001	10118881	Dec 23, 2023		U-2746	NCE
		7335799	Dec 03, 2025	DS		NP
		8497301	Dec 23, 2023		U-2746	Feb 21, 2025
		9000041	Dec 23, 2023		U-2746	Feb 26, 2023
		9624152	Dec 23, 2023		U-2749	
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249	001	8436190	Oct 26, 2030		DP	
		8436190*PED	Apr 26, 2031			
		8445524	Mar 26, 2029	DS DP U-1402		
		8445524*PED	Sep 26, 2029			
		8609863	Jan 12, 2026		DP	
		8609863*PED	Jul 12, 2026			
		8669279	Mar 26, 2029		DP U-1402	
		8669279*PED	Sep 26, 2029			
		8791270	Jan 12, 2026		DP U-1542	
		8791270*PED	Jul 12, 2026			
		8883836	Mar 26, 2029		DP U-1402	
		8883836*PED	Sep 26, 2029			
		8895756	Jan 12, 2026		DP	
		8895756*PED	Jul 12, 2026			
		9533955	Mar 26, 2029		DP U-1949	
		9533955	Mar 26, 2029		DP U-1952	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 002	8436190	Oct 26, 2030	DP			
	8436190*PED	Apr 26, 2031				
	8445524	Mar 26, 2029	DS DP U-1402			
	8445524*PED	Sep 26, 2029				
	8609863	Jan 12, 2026	DP			
	8609863*PED	Jul 12, 2026				
	8669279	Mar 26, 2029	DP U-1402			
	8669279*PED	Sep 26, 2029				
	8791270	Jan 12, 2026	DP U-1542			
	8791270*PED	Jul 12, 2026				
	8883836	Mar 26, 2029	DP U-1402			
	8883836*PED	Sep 26, 2029				
	8895756	Jan 12, 2026	DP			
	8895756*PED	Jul 12, 2026				
	9533955	Mar 26, 2029	DP U-1949			
	9533955	Mar 26, 2029	DP U-1952			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 003	8344006	Sep 23, 2029	DP U-1402			
	8344006*PED	Mar 23, 2030				
	8445524	Mar 26, 2029	DS			
	8445524*PED	Sep 26, 2029				
	8791270	Jan 12, 2026	DP U-1542			
	8791270*PED	Jul 12, 2026				
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 004	8344006	Sep 23, 2029	DP U-1402			
	8344006*PED	Mar 23, 2030				
	8445524	Mar 26, 2029	DS			
	8445524*PED	Sep 26, 2029				
	8791270	Jan 12, 2026	DP U-1542			
	8791270*PED	Jul 12, 2026				
<u>BENDAMUSTINE HYDROCHLORIDE - BELRAPZO</u>						
N 205580 001	10010533	Jan 28, 2031	DP			
	8609707	Aug 11, 2031	DP U-1971			
	8609707	Aug 11, 2031	DP U-1972			
	8791270	Jan 12, 2026	DP U-1971			
	8791270	Jan 12, 2026	DP U-1972			
	9265831	Jan 28, 2031	DP			
	9572796	Jan 28, 2031	DP U-1971			
	9572796	Jan 28, 2031	DP U-1972			
	9572797	Jan 28, 2031	U-1971			
	9572797	Jan 28, 2031	U-1972			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	10010533	Jan 28, 2031	DP		ODE-179	Dec 07, 2022
	10052385	Mar 15, 2033	U-1971			
	10052385	Mar 15, 2033	U-1972			
	8609707	Aug 11, 2031	DP U-1542			
	8791270	Jan 12, 2026	DP U-1790			
	9000021	Mar 15, 2033	U-1542			
	9034908	Mar 15, 2033	U-1542			
	9144568	Mar 15, 2033	U-1542			
	9265831	Jan 28, 2031	DP			
	9572796	Jan 28, 2031	DP U-1971			
	9572796	Jan 28, 2031	DP U-1972			
	9572797	Jan 28, 2031	U-1971			
	9572797	Jan 28, 2031	U-1972			
	9572887	Mar 15, 2033	U-1971			
	9572887	Mar 15, 2033	U-1972			
	9579384	Mar 15, 2033	U-1971			
	9579384	Mar 15, 2033	U-1972			
	9597397	Mar 15, 2033	U-1971			
	9597397	Mar 15, 2033	U-1972			
	9597398	Mar 15, 2033	U-1971			
	9597399	Mar 15, 2033	U-1971			
	9597399	Mar 15, 2033	U-1972			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BENOXINATE HYDROCHLORIDE; FLUORESCHEIN SODIUM - FLUORESCHEIN SODIUM AND BENOXINATE HYDROCHLORIDE</u>						
N 211039	001	10293047	Nov 15, 2037	DP U-2755		
		10632197	Nov 15, 2037	DP U-2755		
		10842872	Nov 15, 2037	U-3001		
<u>BENZNIDAZOLE - BENZNIDAZOLE</u>						
N 209570	001				NCE ODE-154	Aug 29, 2022 Aug 29, 2024
<u>BENZNIDAZOLE - BENZNIDAZOLE</u>						
N 209570	002				NCE ODE-154	Aug 29, 2022 Aug 29, 2024
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
N 050819	001	10220049	Jun 03, 2029	DP U-916		
		10624918	Jun 03, 2029	U-916		
		8288434	Aug 05, 2029	DP U-124		
		8663699	Jun 03, 2029	U-124		
		8895070	Jun 03, 2029	U-124		
		9078870	Jun 03, 2029	DP		
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ONEXTON</u>						
N 050819	002	10137142	Jun 03, 2029	DP U-916		
		10220049	Jun 03, 2029	DP U-916		
		8288434	Aug 05, 2029	DP U-1033		
		8288434	Aug 05, 2029	DP U-124		
		8288434	Aug 05, 2029	DP U-134		
		8288434	Aug 05, 2029	DP U-818		
		8288434	Aug 05, 2029	DP U-916		
		8288434	Aug 05, 2029	DP U-921		
		9504704	Jun 03, 2029	DP U-124		
		9504704	Jun 03, 2029	DP U-134		
		9504704	Jun 03, 2029	DP U-818		
		9504704	Jun 03, 2029	DP U-916		
		9561208	Jun 03, 2029	DP U-916		
<u>BENZYL ALCOHOL - ULESFIA</u>						
N 022129	001	6793931	Jul 11, 2022	DP U-970		
		7294342	May 19, 2024	U-970		
<u>BEPOTASTINE BESILATE - BEPREVE</u>						
N 022288	001	8784789	Jan 13, 2025	DP		
		8877168	Jul 30, 2023	DP		
<u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u>						
N 214094	001	10125102	Mar 09, 2035	DS U-3010		
		10329260	Mar 09, 2035	DS		
		10662160	Nov 01, 2039	DS U-3010		
		10689346	Mar 09, 2035	U-3010		
<u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u>						
N 214094	002	10125102	Mar 09, 2035	DS U-3010		
		10329260	Mar 09, 2035	DS		
		10662160	Nov 01, 2039	DS U-3010		
		10689346	Mar 09, 2035	U-3010		
<u>BESIFLOXACIN HYDROCHLORIDE - BESIVANCE</u>						
N 022308	001	6685958	Jun 29, 2021	DP U-80		
		8415342	Nov 07, 2030	U-80		
		8481526	Jan 09, 2031	DS		
		8604020	Mar 12, 2030	DP		
		8937062	Nov 13, 2029	U-80		
<u>BETAMETHASONE DIPROPIONATE - SERNIVO</u>						
N 208079	001	10179137	Aug 31, 2030	DP U-1858		
		9364485	Aug 31, 2030	DP U-1858		
		9433630	Aug 31, 2030	DP U-1858		
		9439911	Aug 31, 2030	DP U-1858		
		9655907	Aug 31, 2030	DP U-1858		
		9775851	Aug 31, 2030	DP U-1858		
		9877974	Aug 31, 2030	DP U-1858		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BETAMETHASONE DIPROPIONATE - SERNIVO</u>						
N 208079	001	10179137	Aug 31, 2030	DP U-1858		
		9364485	Aug 31, 2030	DP U-1858		
		9433630	Aug 31, 2030	DP U-1858		
		9439911	Aug 31, 2030	DP U-1858		
		9655907	Aug 31, 2030	DP U-1858		
		9775851	Aug 31, 2030	DP U-1858		
		9877974	Aug 31, 2030	DP U-1858		
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - TACLONEX</u>						
N 021852	001	6753013	Jan 27, 2020	DP U-193		
		6753013	Jan 27, 2020	DP U-88		
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - TACLONEX</u>						
N 022185	001	6753013	Jan 27, 2020	DP U-1761	NPP	Jul 25, 2022
		6753013	Jan 27, 2020	DP U-193	PED	Jan 25, 2023
		6753013	Jan 27, 2020	DP U-88		
		6787529	Jan 27, 2020	DP U-1761		
		6787529	Jan 27, 2020	DP U-193		
		6787529	Jan 27, 2020	DP U-88		
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - ENSTILAR</u>						
N 207589	001	10130640	Jun 10, 2031	DP	NPP	Jul 30, 2022
		10130640*PED	Dec 10, 2031		PED	Jan 30, 2023
		10617698	Jun 10, 2031	DP		
		10660908	Jun 10, 2031	DP U-2627		
		10682364	Jun 10, 2031	DP		
		10688108	Jun 10, 2031	U-2627		
		10716799	Jun 10, 2031	DP		
		6753013	Jan 27, 2020	DP U-1761		
		6753013	Jan 27, 2020	DP U-2627		
		9119781	Jun 10, 2031	DP U-1761		
		9119781	Jun 10, 2031	DP U-2627		
		9119781*PED	Dec 10, 2031			
		9566286	Jun 10, 2031	DP		
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - WYNZORA</u>						
N 213422	001	10265265	Sep 27, 2027	DP	NDF	Jul 20, 2023
<u>BETRIXABAN - BEVYXXA</u>						
N 208383	001	6376515	Sep 15, 2020	DS DP U-1167	NCE	Jun 23, 2022
		6376515	Sep 15, 2020	DS DP U-1502		
		6376515	Sep 15, 2020	DS DP U-2029		
		6376515	Sep 15, 2020	DS DP U-2030		
		6835739	Sep 15, 2020	DS DP		
		7598276	Nov 08, 2026	DS		
		8404724	Mar 29, 2031	DP U-2034		
		8518977	Sep 15, 2020	DS		
		8557852	Sep 08, 2028	U-1167		
		8557852	Sep 08, 2028	U-2030		
		8691847	Sep 15, 2020	DS DP U-2029		
		8691847	Sep 15, 2020	DS DP U-2035		
		8987463	Dec 28, 2030	DP		
		9555023	Nov 07, 2026	U-1502		
		9629831	Sep 15, 2020	U-1167		
		9629831	Sep 15, 2020	U-1502		
		9629831	Sep 15, 2020	U-2030		
		9629831	Sep 15, 2020	U-2035		
<u>BETRIXABAN - BEVYXXA</u>						
N 208383	002	6376515	Sep 15, 2020	DS DP U-1167	NCE	Jun 23, 2022
		6376515	Sep 15, 2020	DS DP U-1502		
		6376515	Sep 15, 2020	DS DP U-2029		
		6376515	Sep 15, 2020	DS DP U-2030		
		6835739	Sep 15, 2020	DS DP		
		7598276	Nov 08, 2026	DS		
		8404724	Mar 29, 2031	DP U-2034		
		8518977	Sep 15, 2020	DS		
		8557852	Sep 08, 2028	U-1167		
		8557852	Sep 08, 2028	U-2030		
		8691847	Sep 15, 2020	DS DP U-2029		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BETRIXABAN - BEVYXXA</u>						
N 208383	002	8691847	Sep 15, 2020	DS DP	U-2035	
		8987463	Dec 28, 2030	DP		
		9555023	Nov 07, 2026		U-1502	
		9629831	Sep 15, 2020		U-1167	
		9629831	Sep 15, 2020		U-1502	
		9629831	Sep 15, 2020		U-2030	
		9629831	Sep 15, 2020		U-2035	
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251	001	10385067	Jun 19, 2035		U-257	NCE Feb 07, 2023
		10548846	Nov 08, 2036	DP		NPP Jun 18, 2022
		6642245	Nov 04, 2020		U-257	ODE-256 Jun 18, 2026
		6703396	Mar 09, 2021	DS DP		
		7390791	Apr 17, 2025	DS DP		
		7803788	Feb 02, 2022		U-257	
		8754065	Aug 15, 2032	DS DP	U-257	
		9216996	Dec 19, 2033	DS DP		
		9296769	Aug 15, 2032	DS DP	U-257	
		9708342	Jun 19, 2035	DS DP		
		9732092	Dec 19, 2033	DS DP		
<u>BIMATOPROST - LUMIGAN</u>						
N 022184	001	7851504	Jun 13, 2027	DS DP		
		8278353	Mar 16, 2025	DP		
		8299118	Mar 16, 2025		U-1295	
		8309605	Mar 16, 2025		U-1293	
		8309605	Mar 16, 2025		U-1294	
		8338479	Mar 16, 2025	DP	U-1295	
		8524777	Mar 16, 2025		U-1235	
		8586630	Mar 16, 2025		U-1458	
		8772338	Mar 16, 2025	DP	U-1528	
		8933120	Mar 16, 2025	DP		
		8933127	Mar 16, 2025	DP		
		9155716	Mar 16, 2025	DP	U-1528	
		9241918	Mar 16, 2025	DP	U-1814	
<u>BIMATOPROST - LATISSE</u>						
N 022369	001	8038988	Aug 25, 2023	DS DP	U-1208	
		8101161	May 25, 2024		U-1217	
		8101161	May 25, 2024		U-1218	
		8263054	Jan 15, 2023		U-1277	
		8541466	Jan 31, 2021		U-1217	
		8632760	Jan 15, 2023		U-1487	
		8758733	Jan 15, 2023		U-1487	
		8906962	Jan 31, 2021		U-1217	
		8986715	Jan 15, 2023		U-1217	
		9216183	Jan 15, 2023		U-1487	
		9226931	Jan 15, 2023		U-1799	
		9579270	Jan 31, 2021		U-1975	
<u>BIMATOPROST - DURYSTA</u>						
N 211911	001	10398707	Apr 30, 2024		U-2759	NP Mar 04, 2023
		10441543	Dec 19, 2026	DP		
		7033605	Oct 20, 2020	DP		
		7799336	Apr 24, 2029	DP		
		8206737	Apr 07, 2027		U-2759	
		8629185	Jul 15, 2031	DS DP		
		8673341	Feb 19, 2025		U-2759	
		9149428	Dec 19, 2026	DP		
		9492316	Oct 31, 2034	DP		
		9980974	Oct 31, 2034		U-2759	
<u>BINIMETINIB - MEKTOVI</u>						
N 210498	001	10005761	Aug 27, 2030		U-2331	NCE Jun 27, 2023
		7777050	Mar 13, 2023	DS DP		ODE-194 Jun 27, 2025
		8178693	Mar 13, 2023	DS DP		
		8193229	Mar 13, 2023		U-2330	
		8513293	Mar 13, 2023		U-2331	
		9314464	Jul 04, 2031		U-2332	
		9562016	Oct 18, 2033	DS DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BINIMETINIB - MEKTOVI</u>						
N 210498	001	9593100	Aug 27, 2030	DP		
		9598376	Oct 18, 2033	U-2330		
		9850229	Aug 27, 2030	U-2333		
		9980944	Oct 18, 2033	U-2334		
<u>BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE - HALFLYTELY</u>						
N 021551	003	7291324	Oct 22, 2022	U-837		
<u>BIVALIRUDIN - ANGIOMAX</u>						
N 020873	001	7582727	Jul 27, 2028	DP		
		7598343	Jul 27, 2028	DP		
<u>BOCEPREVIR - VICTRELIS</u>						
N 202258	001	7772178	Nov 11, 2027	DP	U-1128	
		8119602	Mar 17, 2027		U-1233	
		RE43298	Dec 22, 2024	DS DP	U-1128	
<u>BORTEZOMIB - VELCADE</u>						
N 021602	001	6713446	Jan 25, 2022	DS DP	ODE-76	Oct 08, 2021
		6713446*PED	Jul 25, 2022		PED	Apr 08, 2022
		6958319	Jan 25, 2022	DS DP		
		6958319*PED	Jul 25, 2022			
<u>BORTEZOMIB - BORTEZOMIB</u>						
N 205004	001	8962572	Nov 03, 2032	DP		
<u>BOSENTAN - TRACLEER</u>						
N 021290	001				NPP	Sep 05, 2020
<u>BOSENTAN - TRACLEER</u>						
N 021290	002				NPP	Sep 05, 2020
<u>BOSENTAN - TRACLEER</u>						
N 209279	001	7959945	Dec 28, 2027	DP	NP	Sep 05, 2020
		8309126	May 15, 2026	DP	ODE-161	Sep 05, 2024
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341	001	7417148	Dec 11, 2025		U-1283	I-759
		7767678	Nov 23, 2026	DS DP		ODE-163
		7919625	Dec 11, 2025		DP	
		RE42376	Apr 13, 2024	DS		
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341	002	7417148	Dec 11, 2025		U-1283	I-759
		7767678	Nov 23, 2026	DS DP		ODE-163
		7919625	Dec 11, 2025		DP	
		RE42376	Apr 13, 2024	DS		
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341	003	7417148	Dec 11, 2025		U-1283	I-759
		7767678	Nov 23, 2026	DS DP		ODE-163
		7919625	Dec 11, 2025		DP	
		RE42376	Apr 13, 2024	DS		
<u>BREMELANOTIDE ACETATE - VYLEESI (AUTOINJECTOR)</u>						
N 210557	001	10286034	Nov 05, 2033		U-2568	NCE
		6579968	Jun 28, 2021	DS DP		
		6794489	Jun 28, 2021	DS DP		
		9352013	Nov 05, 2033		U-2568	
		9700592	Nov 05, 2033		U-2568	
<u>BREXANOLONE - ZULRESSO</u>						
N 211371	001	10117951	Mar 13, 2029	DP		NCE
		10251894	Nov 27, 2033		U-2552	
		10322139	Jan 23, 2033	DP		
		7635773	Mar 13, 2029	DP		
		8410077	Mar 13, 2029	DP		
		9200088	Mar 13, 2029	DP		
		9750822	Mar 13, 2029	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 001	10307419	Oct 12, 2032	DP		NCE	Jul 10, 2020
	7888362	Apr 12, 2026	DS	Y		
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-543			
	RE48059	Apr 12, 2026	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 002	10307419	Oct 12, 2032	DP		NCE	Jul 10, 2020
	7888362	Apr 12, 2026	DS	Y		
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-543			
	RE48059	Apr 12, 2026	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 003	10307419	Oct 12, 2032	DP		NCE	Jul 10, 2020
	7888362	Apr 12, 2026	DS	Y		
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-543			
	RE48059	Apr 12, 2026	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 004	10307419	Oct 12, 2032	DP		NCE	Jul 10, 2020
	7888362	Apr 12, 2026	DS	Y		
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-543			
	RE48059	Apr 12, 2026	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 005	10307419	Oct 12, 2032	DP		NCE	Jul 10, 2020
	7888362	Apr 12, 2026	DS	Y		
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-543			
	RE48059	Apr 12, 2026	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 006	7888362	Apr 12, 2026	DS	Y	NCE	Jul 10, 2020
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-543			
	RE48059	Apr 12, 2026	DS			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 001	10385078	Nov 10, 2035	DS DP U-2837		I-847	May 22, 2023
	9012462	Jul 31, 2030	DS		NCE	Apr 28, 2022
	9273077	May 21, 2029	U-2837		ODE-142	Apr 28, 2024
	9611283	Apr 10, 2034	U-2837		ODE-300	May 22, 2027
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 002	10385078	Nov 10, 2035	DS DP U-2837		I-847	May 22, 2023
	9012462	Jul 31, 2030	DS		NCE	Apr 28, 2022
	9273077	May 21, 2029	U-2837		ODE-142	Apr 28, 2024
	9611283	Apr 10, 2034	U-2837		ODE-300	May 22, 2027
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 003	10385078	Nov 10, 2035	DS DP U-2837		I-847	May 22, 2023
	9012462	Jul 31, 2030	DS		NCE	Apr 28, 2022
	9273077	May 21, 2029	U-2837		ODE-142	Apr 28, 2024
	9611283	Apr 10, 2034	U-2837		ODE-300	May 22, 2027

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BRILLIANT BLUE G - TISSUEBLUE</u>						
N 209569	001				NCE ODE-282	Dec 20, 2024 Dec 20, 2026
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021262	001	6562873	Jul 10, 2021			
		6627210	Jul 18, 2021	DP		
		6641834	Jul 28, 2021	DP		
		6673337	Jul 26, 2021	DP		
		9295641	Jul 10, 2021	U-1833		
		9295641*PED	Jan 10, 2022			
<u>BRIMONIDINE TARTRATE - OOLIANA</u>						
N 021764	001	7265117	Aug 19, 2025	DP		
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021770	001	10307368	Jul 10, 2021	DP		
		6562873	Jul 10, 2021	DP		
		6627210	Jul 18, 2021	DP		
		6641834	Jul 28, 2021	DP		
		6673337	Jul 26, 2021	DP		
		8858961	Sep 02, 2023	DP		
		8858961*PED	Mar 02, 2024			
		9295641	Jul 10, 2021	U-1833		
		9295641*PED	Jan 10, 2022			
		9687443	Jul 10, 2021	DP		
		9687443*PED	Jan 10, 2022			
<u>BRIMONIDINE TARTRATE - MIRVASO</u>						
N 204708	001	10201517	Jun 13, 2031	DP		
		7439241	Aug 25, 2025	U-1428		
		8053427	Jun 13, 2031	DP U-1428		
		8163725	Jun 13, 2031	DP		
		8231885	May 24, 2025	DP		
		8410102	May 24, 2025	U-1428		
		8426410	May 24, 2025	U-1428		
		8513247	Mar 25, 2031	DP U-1428		
		8513249	Mar 25, 2031	DP U-1428		
		8859551	May 25, 2024	U-1428		
		9861631	Mar 25, 2031	U-1428		
		9861632	Mar 25, 2031	U-1428		
<u>BRIMONIDINE TARTRATE - LUMIFY</u>						
N 208144	001	8293742	Jul 14, 2030	U-2222	NP	Dec 22, 2020
<u>BRIMONIDINE TARTRATE; BRINZOLAMIDE - SIMBRINZA</u>						
N 204251	001	9044484	Oct 30, 2030	DP		
		9421265	Jun 17, 2030	DP		
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N 021398	001	7030149	Apr 19, 2022	U-849		
		7320976	Apr 19, 2022	U-849		
		7323463	Jan 19, 2023	DP	Y	
		7642258	Apr 19, 2022	DS DP U-1024		
		8133890	Apr 19, 2022	U-1235		
		8354409	Apr 19, 2022	DP U-1371		
		8748425	Apr 19, 2022	DP U-1524		
		9474751	Apr 19, 2022	DP U-1524		
		9770453	Apr 19, 2022	DP U-2131		
		9907801	Apr 19, 2022	DP U-2239		
		9907802	Apr 19, 2022	DP U-2240		
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836	001	10729653	Apr 09, 2030	DP	NCE	May 12, 2021
		6784197	Feb 21, 2021	DS DP U-2295		
		6911461	Feb 21, 2026	DS DP U-2295		
		8492416	Feb 21, 2021	U-2295		
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836	002	10729653	Apr 09, 2030	DP	NCE	May 12, 2021
		6784197	Feb 21, 2021	DS DP U-2295		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 002	6911461	Feb 21, 2026	DS DP U-2295			
	8492416	Feb 21, 2021	U-2295			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 003	10729653	Apr 09, 2030	DP		NCE	May 12, 2021
	6784197	Feb 21, 2021	DS DP U-2295			
	6911461	Feb 21, 2026	DS DP U-2295			
	8492416	Feb 21, 2021	U-2295			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 004	10729653	Apr 09, 2030	DP		NCE	May 12, 2021
	6784197	Feb 21, 2021	DS DP U-2295			
	6911461	Feb 21, 2026	DS DP U-2295			
	8492416	Feb 21, 2021	U-2295			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 005	10729653	Apr 09, 2030	DP		NCE	May 12, 2021
	6784197	Feb 21, 2021	DS DP U-2295			
	6911461	Feb 21, 2026	DS DP U-2295			
	8492416	Feb 21, 2021	U-2295			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205837 001	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6784197	Feb 21, 2021	DS DP U-2130			
	6911461	Feb 21, 2026	DS DP U-1815			
	6911461	Feb 21, 2026	DS DP U-2130			
	8492416	Feb 21, 2021	U-1815			
	8492416	Feb 21, 2021	U-2130			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205838 001	6784197	Feb 21, 2021	DS DP U-2295		NCE	May 12, 2021
	6911461	Feb 21, 2026	DS DP U-2295			
	8492416	Feb 21, 2021	U-2295			
<u>BROMFENAC SODIUM - PROLENSA</u>						
N 203168 001	10085958	Nov 19, 2032	DP			
	8129431	Sep 11, 2025	DS DP			
	8669290	Jan 16, 2024	DP			
	8754131	Jan 16, 2024	DP			
	8871813	Jan 16, 2024	DP			
	8927606	Jan 16, 2024	U-100			
	8927606	Jan 16, 2024	U-1095			
	8927606	Jan 16, 2024	U-810			
	9144609	Jan 16, 2024	DP			
	9517220	Nov 11, 2033	U-1933			
	9561277	Jan 16, 2024	U-1933			
<u>BROMFENAC SODIUM - BROMSITE</u>						
N 206911 001	8778999	Aug 07, 2029	DP U-1834			
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	10688094	Apr 30, 2032	U-2870			
	10688094	Apr 30, 2032	U-2871			
	10688094	Apr 30, 2032	U-2872			
	10688094	Apr 30, 2032	U-2873			
	10688094	Apr 30, 2032	U-2874			
	10688094	Apr 30, 2032	U-2875			
	10688094	Apr 30, 2032	U-2876			
	10688094	Apr 30, 2032	U-2877			
	10688094	Apr 30, 2032	U-2878			
	10688094	Apr 30, 2032	U-2879			
	10688094	Apr 30, 2032	U-2880			
	10688094	Apr 30, 2032	U-2881			
	10688094	Apr 30, 2032	U-2882			
	10688094	Apr 30, 2032	U-2883			
	10688094	Apr 30, 2032	U-2884			
	10688094	Apr 30, 2032	U-2885			
	10688094	Apr 30, 2032	U-2886			
	10688094	Apr 30, 2032	U-2887			
	10688094	Apr 30, 2032	U-2888			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	10688155	Jun 07, 2030	U-2281			
	10688155	Jun 07, 2030	U-2890			
	10688155	Jun 07, 2030	U-2891			
	10688155	Jun 07, 2030	U-2892			
	10688155	Jun 07, 2030	U-2893			
	10688155	Jun 07, 2030	U-2894			
	10688155	Jun 07, 2030	U-2895			
	10688155	Jun 07, 2030	U-2896			
	10688155	Jun 07, 2030	U-2897			
	10688155	Jun 07, 2030	U-2898			
	10688155	Jun 07, 2030	U-2899			
	10688155	Jun 07, 2030	U-2900			
	10688155	Jun 07, 2030	U-2901			
	10688155	Jun 07, 2030	U-2902			
	10688155	Jun 07, 2030	U-2903			
	10688155	Jun 07, 2030	U-2904			
	10688155	Jun 07, 2030	U-2905			
	10688155	Jun 07, 2030	U-2906			
	10688155	Jun 07, 2030	U-2907			
	10688155	Jun 07, 2030	U-2908			
	10688155	Jun 07, 2030	U-2909			
	10688155	Jun 07, 2030	U-2910			
	10688155	Jun 07, 2030	U-2911			
	10688155	Jun 07, 2030	U-2912			
	10688155	Jun 07, 2030	U-2913			
	10688155	Jun 07, 2030	U-2914			
	10688155	Jun 07, 2030	U-2915			
	10688155	Jun 07, 2030	U-2916			
	10688155	Jun 07, 2030	U-2917			
	10688155	Jun 07, 2030	U-2918			
	10688155	Jun 07, 2030	U-2919			
	10688155	Jun 07, 2030	U-2920			
	10688155	Jun 07, 2030	U-2921			
	10688155	Jun 07, 2030	U-2922			
	10688155	Jun 07, 2030	U-2923			
	10688155	Jun 07, 2030	U-2924			
	10688155	Jun 07, 2030	U-2925			
	10688155	Jun 07, 2030	U-2926			
	10688155	Jun 07, 2030	U-2927			
	10688155	Jun 07, 2030	U-2928			
	10688155	Jun 07, 2030	U-2929			
	10688155	Jun 07, 2030	U-2930			
	10688155	Jun 07, 2030	U-2931			
	10688155	Jun 07, 2030	U-2932			
	10688155	Jun 07, 2030	U-2933			
	10688155	Jun 07, 2030	U-2934			
	10688155	Jun 07, 2030	U-2935			
	10688155	Jun 07, 2030	U-2936			
	10688155	Jun 07, 2030	U-2937			
	7888310	Jul 25, 2023	U-1433			
	8137992	Jul 25, 2023	U-1433			
	8137993	Jul 25, 2023	U-1433			
	8137994	Jul 25, 2023	U-1433			
	8431155	Apr 30, 2032	DP U-976			
	8613947	Apr 30, 2032	DP U-976			
	8877708	Jun 07, 2030	DP U-1706			
	9192576	Apr 30, 2032	DP U-976			
	9352025	Jun 07, 2030	U-2111			
	9352025	Jun 07, 2030	U-2112			
	9352025	Jun 07, 2030	U-2113			
	9352025	Jun 07, 2030	U-2114			
	9352025	Jun 07, 2030	U-2115			
	9352025	Jun 07, 2030	U-2116			
	9352025	Jun 07, 2030	U-2117			
	9352025	Jun 07, 2030	U-2118			
	9352025	Jun 07, 2030	U-2119			
	9522117	Apr 30, 2032	DP U-1939			
	9522117	Apr 30, 2032	DP U-976			
	9700555	Apr 30, 2032	DP U-2183			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	9700555	Apr 30, 2032	DP U-2184			
	9700555	Apr 30, 2032	DP U-2185			
	9700555	Apr 30, 2032	DP U-2186			
	9700555	Apr 30, 2032	DP U-2187			
	9700555	Apr 30, 2032	DP U-2188			
	9700555	Apr 30, 2032	DP U-2189			
	9700555	Apr 30, 2032	DP U-2190			
	9700555	Apr 30, 2032	DP U-2191			
	9700555	Apr 30, 2032	DP U-2192			
	9700555	Apr 30, 2032	DP U-2193			
	9700555	Apr 30, 2032	DP U-2194			
	9700555	Apr 30, 2032	DP U-2195			
	9700555	Apr 30, 2032	DP U-2196			
	9700555	Apr 30, 2032	DP U-2197			
	9700555	Apr 30, 2032	DP U-2198			
	9895422	Jun 07, 2030	U-2114			
	9895422	Jun 07, 2030	U-2116			
	9895422	Jun 07, 2030	U-2281			
	9895422	Jun 07, 2030	U-2282			
	9895422	Jun 07, 2030	U-2283			
	9895422	Jun 07, 2030	U-2284			
	9895422	Jun 07, 2030	U-2285			
	9895422	Jun 07, 2030	U-2286			
	9895422	Jun 07, 2030	U-2287			
	9993474	Apr 30, 2032	U-2384			
	9993474	Apr 30, 2032	U-2385			
	9993474	Apr 30, 2032	U-2386			
	9993474	Apr 30, 2032	U-2387			
	9993474	Apr 30, 2032	U-2388			
	9993474	Apr 30, 2032	U-2389			
	9993474	Apr 30, 2032	U-2390			
	9993474	Apr 30, 2032	U-2391			
	9993474	Apr 30, 2032	U-2392			
	9993474	Apr 30, 2032	U-2393			
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	10064878	Jun 09, 2020	DP U-1325			
	10105374	Jun 09, 2020	DP U-1325			
	10143698	Jun 09, 2020	DP U-1325			
	10307375	Sep 07, 2031	DP			
	10660858	Sep 07, 2031	DP			
	7410651	Jun 09, 2020	DP U-1325			
	7431943	Jun 09, 2020	DP			
	8293273	Jun 09, 2020	DP			
	8784888	Jun 09, 2020	DP			
	8895064	Sep 07, 2031	DP			
	9132093	Sep 07, 2031	DP			
	9192581	Sep 07, 2031	DP U-1325			
	9320716	Jun 09, 2020	DP U-1325			
	9532954	Jun 09, 2020	DP U-1325			
	RE43799	Jun 09, 2020	DP U-1325			
<u>BUDESONIDE - ORTIKOS</u>						
N 211929 001	10172802	Sep 09, 2036		U-2554		
	9707182	Sep 09, 2036	DP U-2554			
<u>BUDESONIDE - ORTIKOS</u>						
N 211929 002	10172802	Sep 09, 2036		U-2554		
	9707182	Sep 09, 2036	DP U-2554			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	10166247	Jan 29, 2023	DP U-2001		M-210	Sep 11, 2020
	10166247	Jan 29, 2023	DP U-2002		M-214	Dec 20, 2020
	10166247	Jan 29, 2023	DP U-2122		NPP	Jan 27, 2020
	10166247*PED	Jul 29, 2023			PED	Jul 27, 2020
	7587988	Apr 10, 2026	DP			
	7587988*PED	Oct 10, 2026				
	7759328	Jan 29, 2023	DP U-2001			
	7759328	Jan 29, 2023	DP U-2002			
	7759328	Jan 29, 2023	DP U-2122			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	7759328*PED	Jul 29, 2023				
	7967011	Aug 11, 2021	DP			
	7967011*PED	Feb 11, 2022				
	8143239	Jan 29, 2023	DP U-2001			
	8143239	Jan 29, 2023	DP U-2002			
	8143239	Jan 29, 2023	DP U-2122			
	8143239*PED	Jul 29, 2023				
	8387615	Mar 26, 2027	DP			
	8387615*PED	Sep 26, 2027				
	8528545	Oct 16, 2028	DP			
	8528545*PED	Apr 16, 2029				
	8575137	Jan 29, 2023	DP U-2001			
	8575137	Jan 29, 2023	DP U-2002			
	8575137	Jan 29, 2023	DP U-2122			
	8575137*PED	Jul 29, 2023				
	8616196	Apr 07, 2029	DP			
	8616196*PED	Oct 07, 2029				
	8875699	Nov 10, 2024	DP			
	8875699*PED	May 10, 2025				
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	10166247	Jan 29, 2023	DP U-2001		M-210	Sep 11, 2020
	10166247	Jan 29, 2023	DP U-2002		M-214	Dec 20, 2020
	10166247	Jan 29, 2023	DP U-2122			
	10166247*PED	Jul 29, 2023				
	7587988	Apr 10, 2026	DP			
	7587988*PED	Oct 10, 2026				
	7759328	Jan 29, 2023	DP U-2001			
	7759328	Jan 29, 2023	DP U-2002			
	7759328	Jan 29, 2023	DP U-2122			
	7759328*PED	Jul 29, 2023				
	7967011	Aug 11, 2021	DP			
	7967011*PED	Feb 11, 2022				
	8143239	Jan 29, 2023	DP U-2001			
	8143239	Jan 29, 2023	DP U-2002			
	8143239	Jan 29, 2023	DP U-2122			
	8143239*PED	Jul 29, 2023				
	8387615	Mar 26, 2027	DP			
	8387615*PED	Sep 26, 2027				
	8528545	Oct 16, 2028	DP			
	8528545*PED	Apr 16, 2029				
	8575137	Jan 29, 2023	DP U-2001			
	8575137	Jan 29, 2023	DP U-2002			
	8575137	Jan 29, 2023	DP U-2122			
	8575137*PED	Jul 29, 2023				
	8616196	Apr 07, 2029	DP			
	8616196*PED	Oct 07, 2029				
	8875699	Nov 10, 2024	DP			
	8875699*PED	May 10, 2025				
<u>BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE - BREZTRI AEROSPHERE</u>						
N 212122 001	10716753	May 28, 2030	DP U-2889		NC	Jul 23, 2023
	8324266	May 28, 2030	U-2889			
	8703806	May 28, 2030	U-2889			
	8808713	May 28, 2030	DP U-2889			
	8815258	Mar 17, 2031	U-2889			
	9415009	May 28, 2030	U-2889			
	9463161	May 28, 2030	DP U-2889			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 001	9585838	Dec 24, 2021	DP		I-771	Apr 06, 2021
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002	9585838	Dec 24, 2021	DP		I-771	Apr 06, 2021
<u>BUPIVACAINE HYDROCHLORIDE - XARACOLL</u>						
N 209511 001	RE47826	May 20, 2029	U-2949		NP	Aug 28, 2023

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE - BUPRENORPHINE</u>						
A 211586	002				CGT	Oct 13, 2020
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306	001				M-250	Oct 13, 2020
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306	002				M-250	Oct 13, 2020
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306	003				M-250	Oct 13, 2020
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306	004				M-250	Oct 13, 2020
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306	005				M-250	Oct 13, 2020
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819	001	10198218	Jun 06, 2031	U-2489	NP	Nov 30, 2020
		10558394	Jun 25, 2031	DP		
		10592168	Jun 06, 2031	U-2489		
		8921387	Jan 06, 2032	DP U-2173		
		8921387	Jan 06, 2032	DP U-2174		
		8975270	Sep 05, 2031	DP U-2175		
		8975270	Sep 05, 2031	DP U-2206		
		9272044	Jun 06, 2031	U-2176		
		9272044	Jun 06, 2031	U-2177		
		9272044	Jun 06, 2031	U-2178		
		9272044	Jun 06, 2031	U-2209		
		9498432	Jun 06, 2031	DP U-2179		
		9782402	Jun 06, 2031	DP U-2176		
		9782402	Jun 06, 2031	DP U-2180		
		9782402	Jun 06, 2031	DP U-2207		
		9782402	Jun 06, 2031	DP U-2208		
		9827241	Jun 06, 2031	DP U-2174		
		9827241	Jun 06, 2031	DP U-2181		
		9827241	Jun 06, 2031	DP U-2206		
		9827241	Jun 06, 2031	DP U-2210		
		9827241	Jun 06, 2031	DP U-2211		
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819	002	10198218	Jun 06, 2031	U-2489	NP	Nov 30, 2020
		10558394	Jun 25, 2031	DP		
		10592168	Jun 06, 2031	U-2489		
		10646484	Jun 22, 2038	U-2489		
		8921387	Jan 06, 2032	DP U-2173		
		8921387	Jan 06, 2032	DP U-2174		
		8975270	Sep 05, 2031	DP U-2175		
		8975270	Sep 05, 2031	DP U-2206		
		9272044	Jun 06, 2031	U-2176		
		9272044	Jun 06, 2031	U-2177		
		9272044	Jun 06, 2031	U-2178		
		9272044	Jun 06, 2031	U-2209		
		9498432	Jun 06, 2031	DP U-2179		
		9782402	Jun 06, 2031	DP U-2176		
		9782402	Jun 06, 2031	DP U-2180		
		9782402	Jun 06, 2031	DP U-2207		
		9782402	Jun 06, 2031	DP U-2208		
		9827241	Jun 06, 2031	DP U-2174		
		9827241	Jun 06, 2031	DP U-2181		
		9827241	Jun 06, 2031	DP U-2206		
		9827241	Jun 06, 2031	DP U-2210		
		9827241	Jun 06, 2031	DP U-2211		
<u>BUPRENORPHINE HYDROCHLORIDE - PROBUPHINE</u>						
N 204442	001	7736665	Apr 25, 2024	U-1878		
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932	001	7579019	Jan 22, 2020	U-1769		
		8147866	Jul 23, 2027	DP U-1769		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932	001	9655843	Jul 23, 2027	DP	U-1556	
		9901539	Dec 21, 2032		U-1556	
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932	002	7579019	Jan 22, 2020		U-1769	
		8147866	Jul 23, 2027	DP	U-1769	
		9655843	Jul 23, 2027	DP	U-1556	
		9901539	Dec 21, 2032		U-1556	
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932	003	7579019	Jan 22, 2020		U-1769	
		8147866	Jul 23, 2027	DP	U-1769	
		9655843	Jul 23, 2027	DP	U-1556	
		9901539	Dec 21, 2032		U-1556	
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932	004	7579019	Jan 22, 2020		U-1769	
		8147866	Jul 23, 2027	DP	U-1769	
		9655843	Jul 23, 2027	DP	U-1556	
		9901539	Dec 21, 2032		U-1556	
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932	005	7579019	Jan 22, 2020		U-1769	
		8147866	Jul 23, 2027	DP	U-1769	
		9655843	Jul 23, 2027	DP	U-1556	
		9901539	Dec 21, 2032		U-1556	
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932	006	7579019	Jan 22, 2020		U-1769	
		8147866	Jul 23, 2027	DP	U-1769	
		9655843	Jul 23, 2027	DP	U-1556	
		9901539	Dec 21, 2032		U-1556	
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932	007	7579019	Jan 22, 2020		U-1769	
		8147866	Jul 23, 2027	DP	U-1769	
		9655843	Jul 23, 2027	DP	U-1556	
		9901539	Dec 21, 2032		U-1556	
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410	001	10285910	Oct 11, 2022	DP		
		8017150	Feb 13, 2023	DP		
		8475832	Mar 26, 2030	DP	U-1411	
		8603514	Apr 03, 2024	DP	U-1464	
		9687454	Aug 07, 2029	DP	U-1464	
		9855221	Feb 14, 2022	DP		
		9931305	Feb 14, 2022	DP		
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410	002	10285910	Oct 11, 2022	DP		
		8017150	Feb 13, 2023	DP		
		8475832	Mar 26, 2030	DP	U-1411	
		8603514	Apr 03, 2024	DP	U-1464	
		9687454	Aug 07, 2029	DP	U-1464	
		9855221	Feb 14, 2022	DP		
		9931305	Feb 14, 2022	DP		
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410	003	10285910	Oct 11, 2022	DP		
		8017150	Feb 13, 2023	DP		
		8475832	Mar 26, 2030	DP	U-1411	
		8603514	Apr 03, 2024	DP	U-1464	
		9687454	Aug 07, 2029	DP	U-1464	
		9855221	Feb 14, 2022	DP		
		9931305	Feb 14, 2022	DP		
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410	004	10285910	Oct 11, 2022	DP		
		8017150	Feb 13, 2023	DP		
		8475832	Mar 26, 2030	DP	U-1411	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410	004	8603514	Apr 03, 2024	DP	U-1464	
		9687454	Aug 07, 2029	DP	U-1464	
		9855221	Feb 14, 2022	DP		
		9931305	Feb 14, 2022	DP		
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242	001	8470361	May 22, 2030	DP	U-1425	
		8658198	Dec 03, 2027	DP	U-1494	
		8940330	Sep 18, 2032	DP		
		9259421	Sep 18, 2032	DP		
		9439900	Sep 18, 2032	DP		
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242	002	8470361	May 22, 2030	DP	U-1425	
		8658198	Dec 03, 2027	DP	U-1494	
		8940330	Sep 18, 2032	DP		
		9259421	Sep 18, 2032	DP		
		9439900	Sep 18, 2032	DP		
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242	003	8470361	May 22, 2030	DP	U-1425	
		8658198	Dec 03, 2027	DP	U-1494	
		8940330	Sep 18, 2032	DP		
		9259421	Sep 18, 2032	DP		
		9439900	Sep 18, 2032	DP		
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242	004	8470361	May 22, 2030	DP	U-1425	
		8658198	Dec 03, 2027	DP	U-1494	
		8940330	Sep 18, 2032	DP		
		9259421	Sep 18, 2032	DP		
		9439900	Sep 18, 2032	DP		
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242	005	8470361	May 22, 2030	DP	U-1425	
		8658198	Dec 03, 2027	DP	U-1494	
		8940330	Sep 18, 2032	DP		
		9259421	Sep 18, 2032	DP		
		9439900	Sep 18, 2032	DP		
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242	006	8470361	May 22, 2030	DP	U-1425	
		8658198	Dec 03, 2027	DP	U-1494	
		8940330	Sep 18, 2032	DP		
		9259421	Sep 18, 2032	DP		
		9439900	Sep 18, 2032	DP		
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637	001	7579019	Jan 22, 2020		U-1521	
		8147866	Jul 23, 2027	DP	U-1521	
		8703177	Aug 20, 2032	DP		
		9522188	Apr 24, 2035	DP		
		9655843	Jul 23, 2027	DP	U-2017	
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637	002	7579019	Jan 22, 2020		U-1521	
		8147866	Jul 23, 2027	DP	U-1521	
		8703177	Aug 20, 2032	DP		
		9522188	Apr 24, 2035	DP		
		9655843	Jul 23, 2027	DP	U-2017	
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637	003	7579019	Jan 22, 2020		U-1521	
		8147866	Jul 23, 2027	DP	U-1521	
		8703177	Aug 20, 2032	DP		
		9522188	Apr 24, 2035	DP		
		9655843	Jul 23, 2027	DP	U-2017	

Y

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPROPION HYDROBROMIDE - APLENZIN</u>						
N 022108	001	7241805	Jun 27, 2026	DP		
		7569610	Jun 27, 2026	U-997		
		7572935	Jun 27, 2026	DP		
		7585897	Jun 27, 2026	DP		
		7645802	Jun 27, 2026	DP		
		7649019	Jun 27, 2026	DP		
		7662407	Jun 27, 2026	DP		
		7671094	Jun 27, 2026	DP		
<u>BUPROPION HYDROBROMIDE - APLENZIN</u>						
N 022108	002	7241805	Jun 27, 2026	DP		
		7569610	Jun 27, 2026	U-997		
		7572935	Jun 27, 2026	DP		
		7585897	Jun 27, 2026	DP		
		7645802	Jun 27, 2026	DP		
		7649019	Jun 27, 2026	DP		
		7662407	Jun 27, 2026	DP		
		7671094	Jun 27, 2026	DP		
<u>BUPROPION HYDROBROMIDE - APLENZIN</u>						
N 022108	003	7241805	Jun 27, 2026	DP		
		7569610	Jun 27, 2026	U-997		
		7572935	Jun 27, 2026	DP		
		7585897	Jun 27, 2026	DP		
		7645802	Jun 27, 2026	DP		
		7649019	Jun 27, 2026	DP		
		7662407	Jun 27, 2026	DP		
		7671094	Jun 27, 2026	DP		
<u>BUPROPION HYDROCHLORIDE - FORFIVO XL</u>						
N 022497	001	7674479	Jun 25, 2027	DP		
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063	001	10231964	Jul 02, 2034	U-1583		
		10307376	Nov 08, 2027	U-1585		
		10828294	Jul 02, 2034	U-1583		
		10835527	Jul 02, 2034	U-1583		
		7375111	Mar 26, 2025	DP		
		7462626	Jul 20, 2024	U-1583		
		8088786	Feb 03, 2029	DP		
		8318788	Nov 08, 2027	U-1584		
		8722085	Nov 08, 2027	U-1585		
		8815889	Jul 20, 2024	U-1586		
		8916195	Feb 02, 2030	U-1639		
		9107837	Jun 04, 2027	U-1639		
		9125868	Nov 08, 2027	U-1585		
		9248123	Jan 13, 2032	U-1808		
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023	001	10583110	Oct 27, 2030	U-2753	M-201	May 17, 2020
		10716777	Oct 27, 2030	U-2856	M-209	Sep 14, 2020
		5847170	Mar 26, 2021	DS DP	PED	Nov 17, 2020
		5847170*PED	Sep 26, 2021			
		7241907	Dec 10, 2025	DS		
		7241907*PED	Jun 10, 2026			
		8927592	Oct 27, 2030	U-1630		
		8927592*PED	Apr 27, 2031			
<u>CABOZANTINIB S-MALATE - COMETRIQ</u>						
N 203756	001	7579473	Aug 14, 2026	DS DP		
		8877776	Oct 08, 2030	DS DP	U-1617	
		9717720	Feb 10, 2032	DP		
<u>CABOZANTINIB S-MALATE - COMETRIQ</u>						
N 203756	002	7579473	Aug 14, 2026	DS DP		
		8877776	Oct 08, 2030	DS DP	U-1617	
		9717720	Feb 10, 2032	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692	001	10034873	Jul 18, 2031	U-2488	I-760	Dec 19, 2020
		10039757	Jul 18, 2031	U-1480	I-792	Jan 14, 2022
		7579473	Aug 14, 2026	DS DP	ODE-227	Jan 14, 2026
		8497284	Sep 24, 2024	U-1220		
		8497284	Sep 24, 2024	U-1480		
		8497284	Sep 24, 2024	U-2488		
		8877776	Oct 08, 2030	DS DP		
		9724342	Jul 09, 2033	DP		
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692	002	10034873	Jul 18, 2031	U-2488	I-760	Dec 19, 2020
		10039757	Jul 18, 2031	U-1480	I-792	Jan 14, 2022
		7579473	Aug 14, 2026	DS DP	ODE-227	Jan 14, 2026
		8497284	Sep 24, 2024	U-1220		
		8497284	Sep 24, 2024	U-1480		
		8497284	Sep 24, 2024	U-2488		
		8877776	Oct 08, 2030	DS DP		
		9724342	Jul 09, 2033	DP		
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692	003	10034873	Jul 18, 2031	U-2488	I-760	Dec 19, 2020
		10039757	Jul 18, 2031	U-1480	I-792	Jan 14, 2022
		7579473	Aug 14, 2026	DS DP	ODE-227	Jan 14, 2026
		8497284	Sep 24, 2024	U-1220		
		8497284	Sep 24, 2024	U-1480		
		8497284	Sep 24, 2024	U-2488		
		8877776	Oct 08, 2030	DS DP		
		9724342	Jul 09, 2033	DP		
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010	001	10213442	Feb 02, 2027	DP		
		10300078	Mar 14, 2034	DP		
		10357502	Mar 14, 2034	DP		
		6582727	Aug 22, 2020	DP		
		8207149	Apr 25, 2028	U-1871		
		8361488	Jul 19, 2028	DP		
		8426391	Aug 27, 2028	U-1872		
		8778373	Apr 25, 2028	U-1873		
		8906410	Feb 02, 2027	DP		
		9408858	Apr 25, 2028	U-1888		
		9498486	Apr 25, 2028	U-1920		
		9861644	Mar 14, 2034	DP		
		9925147	Apr 25, 2028	DP U-2255		
		9925147	Apr 25, 2028	DP U-2256		
		9925147	Apr 25, 2028	DP U-2257		
		9925147	Apr 25, 2028	DP U-2258		
		9925147	Apr 25, 2028	DP U-2259		
		9943530	Feb 02, 2027	U-2274		
<u>CALCIPOTRIENE - SORILUX</u>						
N 022563	001	8263580	May 07, 2028	DP U-1280	NPP	May 06, 2022
		8263580	May 07, 2028	DP U-2662	NPP	Nov 05, 2022
		8629128	May 26, 2026	DP U-1280		
		8629128	May 26, 2026	DP U-1767		
		8629128	May 26, 2026	DP U-2662		
<u>CALCITONIN SALMON RECOMBINANT - FORTICAL</u>						
N 021406	001	6440392	Feb 02, 2021	DP U-227		
		RE40812	Feb 02, 2021	DP		
		RE43580	Feb 02, 2021	DP U-227		
<u>CALCITRIOL - VECTICAL</u>						
N 022087	001				NPP	Jul 17, 2023
<u>CALCIUM ACETATE - PHOSLO</u>						
N 021160	002	6576665	Apr 03, 2021			
<u>CALCIUM ACETATE - PHOSLO GELCAPS</u>						
N 021160	003	6576665	Apr 03, 2021			
		6875445	Jul 30, 2021	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CALCIUM ACETATE - PHOSLO GELCAPS</u>						
N 021160	003	6576665	Apr 03, 2021			
		6875445	Jul 30, 2021	DP		
<u>CALCIUM ACETATE - PHOSLYRA</u>						
N 022581	001	8591938	Feb 23, 2030	DP	U-1469	
		8592480	Jul 20, 2027		U-1469	
		9089528	Jul 20, 2027		U-1469	
<u>CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE - PEPCID COMPLETE</u>						
N 020958	001	6814978	Aug 26, 2021	DP		
<u>CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; OXIGLUTATONE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - NAVSTEL</u>						
N 022193	001	7084130	Nov 29, 2021	DP	U-891	
<u>CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER</u>						
N 207026	001				ODE-85	Jan 13, 2022
<u>CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - PHOXILLUM B2K 4/0 IN PLASTIC CONTAINER</u>						
N 207026	002				ODE-85	Jan 13, 2022
<u>CALCIUM GLUCONATE - CALCIUM GLUCONATE IN SODIUM CHLORIDE</u>						
N 210906	001	10130646	Jul 25, 2037	DP		
		10342813	Jul 25, 2037	DP		
<u>CALCIUM GLUCONATE - CALCIUM GLUCONATE IN SODIUM CHLORIDE</u>						
N 210906	002	10130646	Jul 25, 2037	DP		
		10342813	Jul 25, 2037	DP		
<u>CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV</u>						
N 212690	001	10195168	Jan 11, 2033	DP		NP Jul 21, 2023
		10213400	Mar 15, 2033		U-2499	
		10675258	Jan 11, 2033		U-2938	
		8591922	Jan 11, 2033	DP		
		8731963	Dec 17, 2022		U-1110	
		8772306	Mar 15, 2033		U-1532	
		8901173	Jan 11, 2033	DP		
		9050302	Mar 15, 2033		U-1532	
		9132107	Jan 11, 2033	DP		
		9486426	Mar 15, 2033		U-1532	
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042	001	10617668	May 11, 2031	DP	U-2441	I-788 Oct 29, 2021
		10617668	May 11, 2031	DP	U-2632	I-809 Sep 27, 2022
		10617668	May 11, 2031	DP	U-2794	M-197 Feb 01, 2020
		10617668	May 11, 2031	DP	U-2795	
		10617668	May 11, 2031	DP	U-2796	
		10617668	May 11, 2031	DP	U-2797	
		10617668	May 11, 2031	DP	U-2798	
		10617668	May 11, 2031	DP	U-2799	
		10617668	May 11, 2031	DP	U-493	
		7943582	Feb 26, 2029	DS DP	U-2441	
		7943582	Feb 26, 2029	DS DP	U-2632	
		7943582	Feb 26, 2029	DS DP	U-493	
		7943788	Jul 14, 2027	DS DP		
		8222219	Apr 11, 2025		U-2441	
		8222219	Apr 11, 2025		U-2632	
		8222219	Apr 11, 2025		U-493	
		8513202	Dec 03, 2027	DS DP	U-2441	
		8513202	Dec 03, 2027	DS DP	U-2632	
		8513202	Dec 03, 2027	DS DP	U-493	
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042	002	10617668	May 11, 2031	DP	U-2441	I-788 Oct 29, 2021
		10617668	May 11, 2031	DP	U-2632	I-809 Sep 27, 2022
		10617668	May 11, 2031	DP	U-2794	M-197 Feb 01, 2020
		10617668	May 11, 2031	DP	U-2795	
		10617668	May 11, 2031	DP	U-2796	
		10617668	May 11, 2031	DP	U-2797	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042	002	10617668	May 11, 2031	DP	U-2798	
		10617668	May 11, 2031	DP	U-2799	
		10617668	May 11, 2031	DP	U-493	
		7943582	Feb 26, 2029	DS DP	U-2441	
		7943582	Feb 26, 2029	DS DP	U-2632	
		7943582	Feb 26, 2029	DS DP	U-493	
		7943788	Jul 14, 2027	DS DP		
		8222219	Apr 11, 2025		U-2441	
		8222219	Apr 11, 2025		U-2632	
		8222219	Apr 11, 2025		U-493	
		8513202	Dec 03, 2027	DS DP	U-2441	
		8513202	Dec 03, 2027	DS DP	U-2632	
		8513202	Dec 03, 2027	DS DP	U-493	
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353	001	7943582	Feb 26, 2029	DS DP	U-2441	I-788 Oct 29, 2021
		7943582	Feb 26, 2029	DS DP	U-2632	M-197 Feb 01, 2020
		7943582	Feb 26, 2029	DS DP	U-493	
		7943788	Jul 14, 2027	DS DP		
		8222219	Apr 11, 2025		U-2441	
		8222219	Apr 11, 2025		U-2632	
		8222219	Apr 11, 2025		U-493	
		8513202	Dec 03, 2027	DS DP	U-2441	
		8513202	Dec 03, 2027	DS DP	U-2632	
		8513202	Dec 03, 2027	DS DP	U-493	
		8785403	Jul 30, 2024	DP		
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353	002	7943582	Feb 26, 2029	DS DP	U-2441	I-788 Oct 29, 2021
		7943582	Feb 26, 2029	DS DP	U-2632	M-197 Feb 01, 2020
		7943582	Feb 26, 2029	DS DP	U-493	
		7943788	Jul 14, 2027	DS DP		
		8222219	Apr 11, 2025		U-2441	
		8222219	Apr 11, 2025		U-2632	
		8222219	Apr 11, 2025		U-493	
		8513202	Dec 03, 2027	DS DP	U-2441	
		8513202	Dec 03, 2027	DS DP	U-2632	
		8513202	Dec 03, 2027	DS DP	U-493	
		8785403	Jul 30, 2024	DP		
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353	003	7943582	Feb 26, 2029	DS DP	U-2441	I-788 Oct 29, 2021
		7943582	Feb 26, 2029	DS DP	U-2632	M-197 Feb 01, 2020
		7943582	Feb 26, 2029	DS DP	U-493	
		7943788	Jul 14, 2027	DS DP		
		8222219	Apr 11, 2025		U-2441	
		8222219	Apr 11, 2025		U-2632	
		8222219	Apr 11, 2025		U-493	
		8513202	Dec 03, 2027	DS DP	U-2441	
		8513202	Dec 03, 2027	DS DP	U-2632	
		8513202	Dec 03, 2027	DS DP	U-493	
		8785403	Jul 30, 2024	DP		
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353	004	7943582	Feb 26, 2029	DS DP	U-2441	I-788 Oct 29, 2021
		7943582	Feb 26, 2029	DS DP	U-2632	M-197 Feb 01, 2020
		7943582	Feb 26, 2029	DS DP	U-493	
		7943788	Jul 14, 2027	DS DP		
		8222219	Apr 11, 2025		U-2441	
		8222219	Apr 11, 2025		U-2632	
		8222219	Apr 11, 2025		U-493	
		8513202	Dec 03, 2027	DS DP	U-2441	
		8513202	Dec 03, 2027	DS DP	U-2632	
		8513202	Dec 03, 2027	DS DP	U-493	
		8785403	Jul 30, 2024	DP		
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879	001	6723340	Oct 25, 2021	DP		I-788 Oct 29, 2021
		7943582	Feb 26, 2029	DS DP	U-2441	
		7943582	Feb 26, 2029	DS DP	U-2632	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879	001	7943582	Feb 26, 2029	DS DP	U-493	
		7943788	Jul 14, 2027	DS DP		
		8222219	Apr 11, 2025		U-2441	
		8222219	Apr 11, 2025		U-2632	
		8222219	Apr 11, 2025		U-493	
		8513202	Dec 03, 2027	DS DP	U-2441	
		8513202	Dec 03, 2027	DS DP	U-2632	
		8513202	Dec 03, 2027	DS DP	U-493	
		8785403	Jul 30, 2024	DP		
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879	002	7943582	Feb 26, 2029	DS DP	U-2441	I-788 Oct 29, 2021
		7943582	Feb 26, 2029	DS DP	U-2632	
		7943582	Feb 26, 2029	DS DP	U-493	
		7943788	Jul 14, 2027	DS DP		
		8222219	Apr 11, 2025		U-2441	
		8222219	Apr 11, 2025		U-2632	
		8222219	Apr 11, 2025		U-493	
		8513202	Dec 03, 2027	DS DP	U-2441	
		8513202	Dec 03, 2027	DS DP	U-2632	
		8513202	Dec 03, 2027	DS DP	U-493	
		8785403	Jul 30, 2024	DP		
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879	003	6723340	Oct 25, 2021	DP		I-788 Oct 29, 2021
		7943582	Feb 26, 2029	DS DP	U-2441	
		7943582	Feb 26, 2029	DS DP	U-2632	
		7943582	Feb 26, 2029	DS DP	U-493	
		7943788	Jul 14, 2027	DS DP		
		8222219	Apr 11, 2025		U-2441	
		8222219	Apr 11, 2025		U-2632	
		8222219	Apr 11, 2025		U-493	
		8513202	Dec 03, 2027	DS DP	U-2441	
		8513202	Dec 03, 2027	DS DP	U-2632	
		8513202	Dec 03, 2027	DS DP	U-493	
		8785403	Jul 30, 2024	DP		
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879	004	7943582	Feb 26, 2029	DS DP	U-2441	I-788 Oct 29, 2021
		7943582	Feb 26, 2029	DS DP	U-2632	
		7943582	Feb 26, 2029	DS DP	U-493	
		7943788	Jul 14, 2027	DS DP		
		8222219	Apr 11, 2025		U-2441	
		8222219	Apr 11, 2025		U-2632	
		8222219	Apr 11, 2025		U-493	
		8513202	Dec 03, 2027	DS DP	U-2441	
		8513202	Dec 03, 2027	DS DP	U-2632	
		8513202	Dec 03, 2027	DS DP	U-493	
		8785403	Jul 30, 2024	DP		
<u>CANGRELOR - KENGREAL</u>						
N 204958	001	10039780	Jul 10, 2035		U-2260	NCE Jun 22, 2020
		6130208	Jun 29, 2023	DP	U-1715	
		8680052	Mar 09, 2033		U-1715	
		8680052	Mar 09, 2033		U-2979	
		9295687	Jul 10, 2035	DP		
		9427448	Nov 10, 2030		U-1926	
		9439921	Jul 10, 2035	DP		
		9700575	Jul 10, 2035	DP		
		9925265	May 13, 2029		U-2260	
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365	001	10092525	Jun 17, 2035		U-2427	NCE Sep 28, 2023
		10111840	Jun 17, 2035		U-2442	NPP Jul 31, 2023
		10111840	Jun 17, 2035		U-2443	ODE-216 Sep 28, 2025
		10137095	Jun 17, 2035		U-2454	
		10137095	Jun 17, 2035		U-2455	
		10195159	May 07, 2022	DS		
		10603288	Jun 17, 2035		U-2780	
		10603288	Jun 17, 2035		U-2781	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365	001	10603288	Jun 17, 2035	U-2782		
		10603288	Jun 17, 2035	U-2783		
		10709671	Jun 17, 2035	U-2862		
		10709673	Jun 17, 2035	DP		
		10709674	Jun 17, 2035	U-2780		
		10709674	Jun 17, 2035	U-2781		
		10849860	Jun 17, 2035	U-2427		
		10849860	Jun 17, 2035	U-2454		
		9949937	Jun 17, 2035	U-2421		
		9956183	Jun 17, 2035	U-2422		
		9956183	Jun 17, 2035	U-2423		
		9956184	Jun 17, 2035	U-2424		
		9956185	Jun 17, 2035	U-2425		
		9956186	Jun 17, 2035	U-2426		
<u>CAPMATINIB HYDROCHLORIDE - TABRECTA</u>						
N 213591	001	10596178	Jul 22, 2035	DS DP	NCE	May 06, 2025
		7767675	Nov 19, 2027	DS DP	ODE-291	May 06, 2027
		8420645	Jun 05, 2031	DS DP		
		8461330	Nov 19, 2027	DS DP		
		8901123	May 20, 2029	U-2813		
<u>CAPMATINIB HYDROCHLORIDE - TABRECTA</u>						
N 213591	002	10596178	Jul 22, 2035	DS DP	NCE	May 06, 2025
		7767675	Nov 19, 2027	DS DP	ODE-291	May 06, 2027
		8420645	Jun 05, 2031	DS DP		
		8461330	Nov 19, 2027	DS DP		
		8901123	May 20, 2029	U-2813		
<u>CAPSAICIN - OUTENZA</u>						
N 022395	001	10034841	Sep 06, 2025	DP	I-838	Jul 17, 2023
		10463598	Sep 05, 2023	DP		
		6239180	Jun 04, 2021	DP		
		8263059	Sep 05, 2023	U-2705		
		8821920	Mar 26, 2030	DP		
		8889113	Sep 05, 2023	U-2705		
		9226903	Dec 15, 2028	DP		
<u>CARBAMAZEPINE - EQUETRO</u>						
N 021710	001	6977253	May 19, 2024	U-693		
<u>CARBAMAZEPINE - EQUETRO</u>						
N 021710	002	6977253	May 19, 2024	U-693		
<u>CARBAMAZEPINE - EQUETRO</u>						
N 021710	003	6977253	May 19, 2024	U-693		
<u>CARBAMAZEPINE - CARNEXIV</u>						
N 206030	001	7635773	Mar 13, 2029	DP	ODE-124	Oct 07, 2023
		8410077	Mar 13, 2029	DP		
		9493582	Feb 27, 2033	DP		
		9629797	Nov 10, 2028	U-2004		
		9629797	Nov 10, 2028	U-2005		
		9629797	Nov 10, 2028	U-2006		
		9750822	Mar 13, 2029	DP		
		9770407	Nov 10, 2028	DP		
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 50</u>						
N 021485	001	6500867	Jun 29, 2020	DP U-219		
		6797732	Jun 29, 2020	DP		
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 100</u>						
N 021485	002	6500867	Jun 29, 2020	DP U-219		
		6797732	Jun 29, 2020	DP		
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 150</u>						
N 021485	003	6500867	Jun 29, 2020	DP U-219		
		6797732	Jun 29, 2020	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 200</u>						
N 021485	004	6500867	Jun 29, 2020	DP U-219		
		6797732	Jun 29, 2020	DP		
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 75</u>						
N 021485	005	6500867	Jun 29, 2020	DP U-219		
		6797732	Jun 29, 2020	DP		
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 125</u>						
N 021485	006	6500867	Jun 29, 2020	DP U-219		
		6797732	Jun 29, 2020	DP		
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	001	7094427	May 29, 2022	DP U-1645	Y	
		8377474	Dec 26, 2028	DP U-1645		
		8377474	Dec 26, 2028	DP U-219		
		8454998	Dec 26, 2028	DP U-1645		
		8454998	Dec 26, 2028	DP U-1646		
		8454998	Dec 26, 2028	DP U-1647		
		8454998	Dec 26, 2028	DP U-1649		
		8454998	Dec 26, 2028	DP U-219		
		8557283	Dec 26, 2028	DP U-1645		
		8557283	Dec 26, 2028	DP U-219		
		9089607	Dec 26, 2028	DP U-1645		
		9089607	Dec 26, 2028	DP U-1720		
		9089608	Dec 26, 2028	DP		
		9463246	Dec 26, 2028	DP U-219		
		9533046	Dec 26, 2028	DP U-219		
		9901640	Dec 26, 2028	DP U-219		
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	002	7094427	May 29, 2022	DP U-1645	Y	
		8377474	Dec 26, 2028	DP U-1645		
		8377474	Dec 26, 2028	DP U-219		
		8454998	Dec 26, 2028	DP U-1645		
		8454998	Dec 26, 2028	DP U-1646		
		8454998	Dec 26, 2028	DP U-1647		
		8454998	Dec 26, 2028	DP U-1649		
		8454998	Dec 26, 2028	DP U-219		
		8557283	Dec 26, 2028	DP U-1645		
		8557283	Dec 26, 2028	DP U-219		
		9089607	Dec 26, 2028	DP U-1645		
		9089607	Dec 26, 2028	DP U-1720		
		9089608	Dec 26, 2028	DP		
		9463246	Dec 26, 2028	DP U-219		
		9533046	Dec 26, 2028	DP U-219		
		9901640	Dec 26, 2028	DP U-219		
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	003	7094427	May 29, 2022	DP U-1645	Y	
		8377474	Dec 26, 2028	DP U-1645		
		8377474	Dec 26, 2028	DP U-219		
		8454998	Dec 26, 2028	DP U-1645		
		8454998	Dec 26, 2028	DP U-1646		
		8454998	Dec 26, 2028	DP U-1647		
		8454998	Dec 26, 2028	DP U-1649		
		8454998	Dec 26, 2028	DP U-219		
		8557283	Dec 26, 2028	DP U-1645		
		8557283	Dec 26, 2028	DP U-219		
		9089607	Dec 26, 2028	DP U-1645		
		9089607	Dec 26, 2028	DP U-1720		
		9089608	Dec 26, 2028	DP		
		9463246	Dec 26, 2028	DP U-219		
		9533046	Dec 26, 2028	DP U-219		
		9901640	Dec 26, 2028	DP U-219		
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	004	7094427	May 29, 2022	DP U-1645	Y	
		8377474	Dec 26, 2028	DP U-1645		
		8377474	Dec 26, 2028	DP U-219		
		8454998	Dec 26, 2028	DP U-1645		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	004	8454998	Dec 26, 2028	DP U-1646		
		8454998	Dec 26, 2028	DP U-1647		
		8454998	Dec 26, 2028	DP U-1649		
		8454998	Dec 26, 2028	DP U-219		
		8557283	Dec 26, 2028	DP U-1645		
		8557283	Dec 26, 2028	DP U-219		
		9089607	Dec 26, 2028	DP U-1645		
		9089607	Dec 26, 2028	DP U-1720		
		9089608	Dec 26, 2028	DP		
		9463246	Dec 26, 2028	DP U-219		
		9533046	Dec 26, 2028	DP U-219		
		9901640	Dec 26, 2028	DP U-219		
<u>CARBIDOPA; LEVODOPA - DUOPA</u>						
N 203952	001				ODE-84	Jan 09, 2022
<u>CARBINOXAMINE MALEATE - KARBINAL ER</u>						
N 022556	001	8062667	Mar 29, 2029	DP		
		9522191	Jun 15, 2027	DP		
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714	001	7232818	Apr 14, 2025	DS DP	D-172	Sep 28, 2021
		7417042	Jul 20, 2026	DS DP	I-842	Aug 20, 2023
		7491704	Apr 14, 2025		U-1260	
		7491704	Apr 14, 2025		U-2319	
		7491704	Apr 14, 2025		U-2320	
		7491704	Apr 14, 2025		U-2947	
		7737112	Dec 07, 2027	DP		
		8129346	Apr 14, 2025		U-1260	
		8129346	Apr 14, 2025		U-2319	
		8129346	Apr 14, 2025		U-2320	
		8129346	Apr 14, 2025		U-2947	
		8207125	Apr 14, 2025	DS DP		
		8207126	Apr 14, 2025	DP		
		8207127	Apr 14, 2025		U-1260	
		8207127	Apr 14, 2025		U-2319	
		8207127	Apr 14, 2025		U-2320	
		8207127	Apr 14, 2025		U-2947	
		8207297	Apr 14, 2025	DS DP		
		9493582	Feb 27, 2033	DP		
		9511109	Oct 21, 2029		U-1924	
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714	002	7232818	Apr 14, 2025	DS DP	D-172	Sep 28, 2021
		7417042	Jul 20, 2026	DS DP	I-842	Aug 20, 2023
		7491704	Apr 14, 2025		U-1260	
		7491704	Apr 14, 2025		U-2319	
		7491704	Apr 14, 2025		U-2320	
		7491704	Apr 14, 2025		U-2947	
		7737112	Dec 07, 2027	DP		
		8129346	Apr 14, 2025		U-1260	
		8129346	Apr 14, 2025		U-2319	
		8129346	Apr 14, 2025		U-2320	
		8129346	Apr 14, 2025		U-2947	
		8207125	Apr 14, 2025	DS DP		
		8207126	Apr 14, 2025	DP		
		8207127	Apr 14, 2025		U-1260	
		8207127	Apr 14, 2025		U-2319	
		8207127	Apr 14, 2025		U-2320	
		8207127	Apr 14, 2025		U-2947	
		8207297	Apr 14, 2025	DS DP		
		9493582	Feb 27, 2033	DP		
		9511109	Oct 21, 2029		U-1924	
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714	003	7232818	Apr 14, 2025	DS DP	D-172	Sep 28, 2021
		7417042	Jul 20, 2026	DS DP	I-842	Aug 20, 2023
		7491704	Apr 14, 2025		U-2319	
		7491704	Apr 14, 2025		U-2320	
		7491704	Apr 14, 2025		U-2947	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714	003	7737112	Dec 07, 2027	DP		
		8129346	Apr 14, 2025	U-2319		
		8129346	Apr 14, 2025	U-2320		
		8129346	Apr 14, 2025	U-2947		
		8207125	Apr 14, 2025	DS DP		
		8207126	Apr 14, 2025	DP		
		8207127	Apr 14, 2025	U-2319		
		8207127	Apr 14, 2025	U-2320		
		8207127	Apr 14, 2025	U-2947		
		8207297	Apr 14, 2025	DS DP		
		9493582	Feb 27, 2033	DP		
		9511109	Oct 21, 2029	U-1924		
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370	001	7737142	Sep 17, 2029	DS DP U-1750	I-798	May 24, 2022
		7737142	Sep 17, 2029	DS DP U-2543	M-213	Nov 09, 2020
		7737142	Sep 17, 2029	DS DP U-2544	NCE	Sep 17, 2020
		7737142	Sep 17, 2029	DS DP U-2545		
		7943621	Dec 16, 2028	DS DP		
		RE47350	Jul 16, 2029	U-1750		
		RE47350	Jul 16, 2029	U-2543		
		RE47350	Jul 16, 2029	U-2544		
		RE47350	Jul 16, 2029	U-2545		
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370	002	7737142	Sep 17, 2029	DS DP U-1750	I-798	May 24, 2022
		7737142	Sep 17, 2029	DS DP U-2543	M-213	Nov 09, 2020
		7737142	Sep 17, 2029	DS DP U-2544	NCE	Sep 17, 2020
		7737142	Sep 17, 2029	DS DP U-2545		
		7943621	Dec 16, 2028	DS DP		
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370	003	7737142	Sep 17, 2029	DS DP U-1750	I-798	May 24, 2022
		7737142	Sep 17, 2029	DS DP U-2543	M-213	Nov 09, 2020
		7737142	Sep 17, 2029	DS DP U-2544	NCE	Sep 17, 2020
		7943621	Dec 16, 2028	DS DP		
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370	004	7737142	Sep 17, 2029	DS DP U-1750	I-798	May 24, 2022
		7737142	Sep 17, 2029	DS DP U-2543	M-213	Nov 09, 2020
		7737142	Sep 17, 2029	DS DP U-2544	NCE	Sep 17, 2020
		7943621	Dec 16, 2028	DS DP		
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N 022012	001	7268156	Jun 27, 2023	DS DP U-3		
		7268156	Jun 27, 2023	DS DP U-313		
		8101209	Sep 11, 2025	DP		
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N 022012	002	7268156	Jun 27, 2023	DS DP U-3		
		7268156	Jun 27, 2023	DS DP U-313		
		8101209	Sep 11, 2025	DP		
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N 022012	003	7268156	Jun 27, 2023	DS DP U-3		
		7268156	Jun 27, 2023	DS DP U-313		
		8101209	Sep 11, 2025	DP		
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N 022012	004	7268156	Jun 27, 2023	DS DP U-3		
		7268156	Jun 27, 2023	DS DP U-313		
		8101209	Sep 11, 2025	DP		
<u>CASPOFUNGIN ACETATE - CASPOFUNGIN ACETATE</u>						
N 206110	001	9636407	Dec 21, 2032	DP		
<u>CASPOFUNGIN ACETATE - CASPOFUNGIN ACETATE</u>						
N 206110	002	9636407	Dec 21, 2032	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CEDAZURIDINE; DECITABINE - INQOVI</u>						
N 212576	001	8268800	Aug 22, 2030	DS U-2864	NCE	Jul 07, 2025
		8268800	Aug 22, 2030	DS U-2865	ODE-316	Jul 07, 2027
		8268800	Aug 22, 2030	DS U-2866		
		8268800	Aug 22, 2030	DS U-2867		
		8618075	Oct 16, 2028	U-2864		
		8618075	Oct 16, 2028	U-2867		
		9567363	Oct 16, 2028	DS		
<u>CEFIDEROCOL SULFATE TOSYLATE - FETROJA</u>						
N 209445	001	10004750	Sep 03, 2035	DS DP	I-844	Sep 25, 2023
		9238657	Nov 19, 2031	DS DP U-282	NCE	Nov 14, 2024
		9949982	Sep 03, 2035	DP	GAIN	Nov 14, 2029
<u>CEFIXIME - SUPRAX</u>						
N 202091	001	9233112	Dec 14, 2028	DP U-1676		
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327	001	6417175	Apr 11, 2022	DS DP U-1676	NPP	Sep 13, 2022
		6906055	Dec 15, 2021	DS DP		
		7419973	Dec 15, 2021	DP		
		8247400	Feb 10, 2031	DP U-282		
		9629861	Sep 21, 2030	DP		
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327	002	6417175	Apr 11, 2022	DS DP U-1676	NPP	Sep 13, 2022
		6906055	Dec 15, 2021	DS DP		
		7419973	Dec 15, 2021	DP		
		8247400	Feb 10, 2031	DP U-282		
		9629861	Sep 21, 2030	DP		
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829	001	10028963	Sep 07, 2032	U-2565	NCE	Dec 19, 2019
		10028963	Sep 07, 2032	U-2566	GAIN	Dec 19, 2024
		10125149	Aug 14, 2035	DP		
		10376496	Sep 09, 2034	U-2610		
		10376496	Sep 09, 2034	U-2611		
		10420841	Mar 14, 2034	U-1672		
		10420841	Mar 14, 2034	U-2631		
		7129232	May 15, 2028	DS DP U-1676		
		7129232	May 15, 2028	DS DP U-36		
		8476425	Sep 27, 2032	DS		
		8685957	Sep 27, 2032	DS U-36		
		8906898	May 28, 2034	DS DP		
		8968753	Mar 14, 2034	U-1672		
		8968753	Mar 14, 2034	U-1673		
		9320740	Mar 14, 2034	DP		
		9724353	Sep 07, 2032	U-2565		
		9724353	Sep 07, 2032	U-2566		
		9872906	Mar 14, 2034	DP		
<u>CELECOXIB - ELYXYB</u>						
N 212157	001	10376527	May 27, 2036	DP U-2718	NP	May 05, 2023
		10722456	May 27, 2036	DP U-2718		
		10799517	May 27, 2036	DP U-2718		
		9572819	May 27, 2036	DP U-2718		
		9795620	May 27, 2036	DP U-2718		
		9949990	May 27, 2036	DP U-2718		
<u>CENOBAMATE - XCOPRI</u>						
N 212839	001	7598279	Oct 30, 2027	DS	NCE	Mar 10, 2025
<u>CENOBAMATE - XCOPRI</u>						
N 212839	002	7598279	Oct 30, 2027	DS	NCE	Mar 10, 2025
<u>CENOBAMATE - XCOPRI</u>						
N 212839	003	7598279	Oct 30, 2027	DS	NCE	Mar 10, 2025
<u>CENOBAMATE - XCOPRI</u>						
N 212839	004	7598279	Oct 30, 2027	DS	NCE	Mar 10, 2025

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CENOBAMATE - XCOPRI</u>						
N 212839	005 7598279	Oct 30, 2027	DS		NCE	Mar 10, 2025
<u>CENOBAMATE - XCOPRI</u>						
N 212839	006 7598279	Oct 30, 2027	DS		NCE	Mar 10, 2025
<u>CERITINIB - ZYKADIA</u>						
N 205755	001 7153964	Feb 26, 2021	DS DP		M-199	May 26, 2020
	7893074	Apr 25, 2026	DS DP		ODE-145	May 26, 2024
	7964592	Apr 29, 2028	DS DP		ODE-66	Apr 29, 2021
	8039479	Jun 29, 2030	DS DP			
	8188276	Jan 31, 2023	DS DP			
	8377921	Nov 20, 2027		U-1179		
	8399450	Nov 20, 2027	DS DP			
	8703787	Feb 02, 2032		U-1179		
	8835430	Jan 31, 2023	DS DP			
	9018204	Jan 31, 2023	DS DP			
	9309229	Jan 18, 2032	DS DP			
	9416112	Jan 31, 2023	DS DP			
<u>CERITINIB - ZYKADIA</u>						
N 211225	001 7153964	Feb 26, 2021	DS DP			
	7893074	Apr 25, 2026	DS DP			
	7964592	Apr 29, 2028	DS DP			
	8039479	Jun 29, 2030	DS DP			
	8188276	Jan 31, 2023	DS DP			
	8377921	Nov 20, 2027		U-1179		
	8399450	Nov 20, 2027	DS DP			
	8703787	Feb 02, 2032		U-1179		
	8835430	Jan 31, 2023	DS DP			
	9018204	Jan 31, 2023	DS DP			
	9309229	Jan 18, 2032	DS DP			
	9416112	Jan 31, 2023	DS DP			
<u>CETIRIZINE HYDROCHLORIDE - ZERVIAE</u>						
N 208694	001 8829005	Mar 15, 2030		U-1680	NDF	May 30, 2020
	8829005*PED	Sep 15, 2030			PED	Nov 30, 2020
	9254286	Jul 09, 2032	DP			
	9254286*PED	Jan 09, 2033				
	9750684	Mar 15, 2030	DP			
	9993471	Mar 15, 2030		U-1680		
<u>CETIRIZINE HYDROCHLORIDE - QUZYTIR</u>						
N 211415	001 8263581	Feb 28, 2030		U-2635	NP	Oct 04, 2022
	8314083	Feb 28, 2030		U-2634		
	8513259	Feb 11, 2030		U-2636		
	9119771	Feb 11, 2030		U-2635		
	9180090	Feb 11, 2030		U-2635		
<u>CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ZYRTEC-D 12 HOUR</u>						
N 021150	002 7014867	Jun 10, 2022	DP			
	7226614	Jun 10, 2022		U-295		
<u>CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE - CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE</u>						
A 213530	001				CGT	Apr 24, 2021
<u>CHLORHEXIDINE GLUCONATE - CHLORHEXIDINE GLUCONATE</u>						
N 021669	001 7066916	Feb 17, 2024		U-737		
	7427574	Apr 25, 2026	DP			
	7595021	May 12, 2023	DP	U-1022		
	7717889	Feb 27, 2025	DP	U-1022		
	7935093	Oct 02, 2027	DP	U-1022		
<u>CHLORHEXIDINE GLUCONATE - READYPREP CHG</u>						
N 207964	001				NP	Nov 20, 2021
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP</u>						
N 020832	001 6536975	Nov 10, 2020	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N 020832	002	6729786	Mar 14, 2023	DP		
		6991394	Jan 31, 2024	DP		
		7182536	Dec 30, 2023	DP		
		7241065	Mar 14, 2023	DP		
		7422388	Apr 25, 2027	DP U-1397		
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP</u>						
N 020832	004	6536975	Nov 10, 2020	DP		
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N 020832	005	6536975	Nov 10, 2020	DP		
		6729786	Mar 14, 2023	DP		
		7241065	Mar 14, 2023	DP		
		7422388	Apr 25, 2027	DP U-1397		
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP</u>						
N 020832	006	6991394	Jan 31, 2024	DP		
		7182536	Dec 30, 2023	DP		
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N 020832	007	6536975	Nov 10, 2020	DP		
		6729786	Mar 14, 2023	DP		
		7241065	Mar 14, 2023	DP		
		7422388	Apr 25, 2027	DP U-1397		
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - PREVANTICS SWAB</u>						
N 021524	001				M-221	Feb 14, 2021
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - PREVANTICS SWABSTICK</u>						
N 021524	002				M-221	Feb 14, 2021
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - PREVANTICS MAXI SWABSTICK</u>						
N 021524	003				M-221	Feb 14, 2021
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - SOLUPREP</u>						
N 208288	001	8623935	Jul 26, 2029	DP U-1022	NP	Aug 08, 2021
<u>CHLOROPROCAINE HYDROCHLORIDE - CLOROTEKAL</u>						
N 208791	001	8969412	Sep 05, 2026	DP U-2609	NP	Sep 26, 2020
		9504666	Dec 11, 2033	DP		
<u>CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE - TUXARIN ER</u>						
N 206323	001	9066942	Jan 03, 2032	U-1716		
		9107921	Jan 03, 2032	DP		
<u>CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - ADVIL ALLERGY SINUS</u>						
N 021441	001	7863287	Feb 28, 2027	DP		
<u>CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - CHILDREN'S ADVIL ALLERGY SINUS</u>						
N 021587	001	10238640	May 25, 2024	DP		
<u>CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX - TUZISTRA XR</u>						
N 207768	001	8062667	Mar 29, 2029	DP		
		8790700	Mar 15, 2027	DP		
<u>CHLORZOXAZONE - CHLORZOXAZONE</u>						
A 212253	001				CGT	May 25, 2020
<u>CHLORZOXAZONE - CHLORZOXAZONE</u>						
A 212253	002				CGT	May 25, 2020
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750	001				NCE ODE-91	Mar 17, 2020 Mar 17, 2022
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750	002				NCE ODE-91	Mar 17, 2020 Mar 17, 2022

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CHOLINE FENOFIBRATE - TRILIPIX</u>						
N 022224	001 7259186	Jan 07, 2025	DS			
<u>CHOLINE FENOFIBRATE - TRILIPIX</u>						
N 022224	002 7259186	Jan 07, 2025	DS			
<u>CICLESONIDE - ALVESCO</u>						
N 021658	002 8371292	Feb 01, 2028		U-1355		
<u>CICLESONIDE - ALVESCO</u>						
N 021658	003 8371292	Feb 01, 2028		U-1355		
<u>CICLESONIDE - OMNARIS</u>						
N 022004	001 6767901	Oct 21, 2020	DP			
	8371292	Feb 01, 2028		U-1356		
	8383611	Oct 20, 2020	DP			
<u>CICLESONIDE - ZETONNA</u>						
N 202129	001 8371292	Feb 01, 2028		U-1357		
<u>CILASTATIN SODIUM; IMPENEM; RELEBACTAM - RECARBRIO</u>						
N 212819	001 8487093	Nov 19, 2029	DS DP	U-2586		
	8487093	Nov 19, 2029	DS DP	U-2587		
	8487093	Nov 19, 2029	DS DP	U-2840		
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688	001 7829595	Sep 22, 2026	DP	U-1098	M-200	May 23, 2020
	9375405	Sep 22, 2026	DP		ODE-78	Nov 21, 2021
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688	002 7829595	Sep 22, 2026	DP	U-1098	M-200	May 23, 2020
	9375405	Sep 22, 2026	DP		ODE-78	Nov 21, 2021
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688	003 7829595	Sep 22, 2026	DP	U-1098	M-200	May 23, 2020
	9375405	Sep 22, 2026	DP		ODE-78	Nov 21, 2021
<u>CIPROFLOXACIN - OTIPRIO</u>						
N 207986	001 8318817	Apr 27, 2030		U-1792	I-770	Mar 02, 2021
	9205048	Apr 21, 2029		U-1793		
	9220796	Jul 01, 2035	DP			
	9233068	Dec 11, 2029	DP			
	9603796	Apr 21, 2029	DS DP	U-2252		
<u>CIPROFLOXACIN HYDROCHLORIDE - PROQUIN XR</u>						
N 021744	001 6488962	Jun 20, 2020	DP			
<u>CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE - OTOVEL</u>						
N 208251	001 8932610	Mar 24, 2030	DP	U-1578		
<u>CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR</u>						
N 021473	001 7709022	Jun 23, 2021	DP			
	8187632	Jun 23, 2021	DP			
	8187632*PED	Dec 23, 2021				
<u>CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR</u>						
N 021473	002 7709022	Jun 23, 2021	DP			
	8187632	Jun 23, 2021	DP			
	8187632*PED	Dec 23, 2021				
<u>CIPROFLOXACIN; DEXAMETHASONE - CIPRODEX</u>						
N 021537	001 6284804	Aug 10, 2020				
	6359016	Aug 10, 2020				
	8846650	Jun 04, 2025	DP	U-1578		
	9149486	Sep 13, 2022	DP	U-1578		
	9345714	Sep 13, 2022	DP	U-1578		
	9402805	Sep 13, 2022	DP	U-1578		
	9402805	Sep 13, 2022	DP	U-1679		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE - PHEXXI</u>						
N 208352	001	10568855	Mar 15, 2033	U-1	NP	May 22, 2023
		6706276	Mar 06, 2021	DP		
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - PREPOPIK</u>						
N 202535	001	8450338	Oct 10, 2028	DP	NPP	Aug 15, 2021
		8481083	Oct 10, 2028	DP		
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - CLENPIO</u>						
N 209589	001	10624879	Jun 23, 2034	DP		
		9827231	Jun 26, 2034	DP U-2162		
<u>CLADRIBINE - MAVENCLAD</u>						
N 022561	001	7713947	Oct 16, 2026	U-2520	NP	Mar 29, 2022
		7888328	Apr 11, 2024	DP U-2521		
		8377903	May 31, 2026	U-2522		
		8785415	Apr 11, 2024	DP U-2523		
<u>CLASCOTERONE - WINLEVI</u>						
N 213433	001	10159682	Aug 14, 2028	U-2942	NCE	Aug 26, 2025
		8143240	Jan 12, 2023	U-2942		
		8785427	Jul 25, 2030	DP		
		8865690	Jul 24, 2022	U-2942		
		9211295	Jul 24, 2022	DP		
		9433628	Feb 08, 2029	DP		
		9486458	Jul 24, 2028	U-2942		
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156	001	10010537	Oct 10, 2031	DP		
		5856346	Jan 05, 2021	DS DP U-893		
		8658676	Oct 10, 2031	DP		
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156	002	10010537	Oct 10, 2031	DP		
		5856346	Jan 05, 2021	DS DP U-893		
		8658676	Oct 10, 2031	DP		
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156	003	10010537	Oct 10, 2031	DP		
		5856346	Jan 05, 2021	DS DP U-893		
		8658676	Oct 10, 2031	DP		
<u>CLINDAMYCIN PHOSPHATE - CLEOCIN</u>						
N 050767	001	6495157	Jul 20, 2020	DP		
<u>CLINDAMYCIN PHOSPHATE - CLINDAGEL</u>						
N 050782	001	6387383	Aug 03, 2020	DP U-818		
<u>CLINDAMYCIN PHOSPHATE - CLINDESSE</u>						
N 050793	001	6899890	Apr 27, 2023	DP U-137		
		9789057	Dec 02, 2026	DP U-137		
<u>CLINDAMYCIN PHOSPHATE - EVOCLIN</u>						
N 050801	001	7141237	Feb 03, 2024	DP		
		7374747	Jan 23, 2024	DP U-921		
<u>CLINDAMYCIN PHOSPHATE; TRETINOIN - ZIANA</u>						
N 050802	001	6387383	Aug 03, 2020	DP U-916		
<u>CLOBAZAM - SYMPAZAN</u>						
N 210833	001	8603514	Apr 03, 2024	DP		
		8765167	Feb 20, 2024	DP		
<u>CLOBAZAM - SYMPAZAN</u>						
N 210833	002	8603514	Apr 03, 2024	DP		
		8765167	Feb 20, 2024	DP		
<u>CLOBAZAM - SYMPAZAN</u>						
N 210833	003	8603514	Apr 03, 2024	DP		
		8765167	Feb 20, 2024	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CLOBETASOL PROPIONATE - CLOBEX</u>						
N 021644	001 7700081	Jan 03, 2022	U-1044			
<u>CLOBETASOL PROPIONATE - OLUX E</u>						
N 022013	001 8460641	Nov 05, 2028	DP U-1410			
	8962000	Aug 31, 2025	DP U-1410			
<u>CLOBETASOL PROPIONATE - IMPOYZ</u>						
N 209483	001 10064875	Aug 31, 2030	DP U-1408		NP	Nov 28, 2020
	10064875	Aug 31, 2030	DP U-1858			
	10064875	Aug 31, 2030	DP U-193			
	10064875	Aug 31, 2030	DP U-742			
	10064875	Aug 31, 2030	DP U-88			
	10588914	Aug 31, 2030	DP U-2771			
	9855334	Mar 11, 2035	DP			
	9956231	Aug 31, 2030	DP U-1408			
	9956231	Aug 31, 2030	DP U-1761			
	9956231	Aug 31, 2030	DP U-1858			
	9956231	Aug 31, 2030	DP U-193			
	9956231	Aug 31, 2030	DP U-742			
	9956231	Aug 31, 2030	DP U-88			
<u>CLONIDINE - NEXICLON XR</u>						
N 022500	001 8337890	Apr 17, 2027	DP			
	8623409	Sep 08, 2031	DP			
<u>CLONIDINE - NEXICLON XR</u>						
N 022500	002 8337890	Apr 17, 2027	DP			
	8623409	Sep 08, 2031	DP			
<u>CLOZAPINE - VERSACLOZ</u>						
N 203479	001 8057811	May 01, 2028	DP			
<u>COBICISTAT - TYBOST</u>						
N 203094	001 10039718	Oct 06, 2032	DP		NPP	Aug 22, 2022
	8148374	Sep 03, 2029	DS DP U-1279		ODE-260	Aug 22, 2026
<u>COBICISTAT; DARUNAVIR - PREZCOBIX</u>						
N 205395	001 10039718	Oct 06, 2032	DP			
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	8148374	Sep 03, 2029	DS DP U-1279			
	8148374	Sep 03, 2029	DS DP U-2939			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
<u>COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - SYMTUZA</u>						
N 210455	001 10039718	Oct 06, 2032	DP		NC	Jul 17, 2021
	10786515	Jul 19, 2038	U-2978		NCE	Nov 05, 2020
	6642245	Nov 04, 2020	U-2352			
	6642245	Nov 04, 2020	U-2765			
	6703396	Mar 09, 2021	DS DP			
	7390791	Apr 17, 2025	DS DP			
	7700645	Dec 26, 2026	DS DP			
	7803788	Feb 02, 2022	U-2352			
	7803788	Feb 02, 2022	U-2765			
	8148374	Sep 03, 2029	DS DP U-2353			
	8148374	Sep 03, 2029	DS DP U-2364			
	8148374	Sep 03, 2029	DS DP U-2365			
	8148374	Sep 03, 2029	DS DP U-2766			
	8148374	Sep 03, 2029	DS DP U-2767			
	8148374	Sep 03, 2029	DS DP U-2768			
	8518987	Feb 16, 2024	DS DP			
	8754065	Aug 15, 2032	DS DP U-2352			
	8754065	Aug 15, 2032	DS DP U-2765			
	9296769	Aug 15, 2032	DS DP U-2352			
	9296769	Aug 15, 2032	DS DP U-2765			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561	001 10039718	Oct 06, 2032	DP		D-173	Dec 10, 2021
	6642245	Nov 04, 2020	U-257		NCE	Nov 05, 2020

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561	001	6642245*PED	May 04, 2021		NPP	Sep 25, 2020
		6703396	Mar 09, 2021	DS DP		
		6703396*PED	Sep 09, 2021			
		7176220	Aug 27, 2026	DS DP U-257		
		7390791	Apr 17, 2025	DS DP		
		7635704	Oct 26, 2026	DS DP U-257		
		7803788	Feb 02, 2022	U-257		
		8148374	Sep 03, 2029	DS DP U-1279		
		8633219	Apr 24, 2030	DP U-257		
		8754065	Aug 15, 2032	DS DP U-257		
		8981103	Oct 26, 2026	DS DP		
		9296769	Aug 15, 2032	DS DP U-257		
		9891239	Sep 03, 2029	DP U-257		
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100	001	10039718	Oct 06, 2032	DP	NPP	Jan 27, 2020
		6642245	Nov 04, 2020	U-257		
		6703396	Mar 09, 2021	DS DP		
		7176220	Aug 27, 2026	DS DP U-257		
		7635704	Oct 26, 2026	DS DP U-257		
		8148374	Sep 03, 2029	DS DP U-1279		
		8592397	Jan 13, 2024	DP U-257		
		8633219	Apr 24, 2030	DP U-257		
		8716264	Jan 13, 2024	DP U-257		
		8981103	Oct 26, 2026	DS DP		
		9457036	Jan 13, 2024	DP U-257		
		9744181	Jan 13, 2024	DP U-257		
		9891239	Sep 03, 2029	DP U-257		
<u>COBIMETINIB FUMARATE - COTELLIC</u>						
N 206192	001	10478400	Jun 29, 2036	DS DP U-1776	NCE	Nov 10, 2020
		10590102	Jun 30, 2036	DS DP U-1776	ODE-101	Nov 10, 2022
		7803839	Nov 10, 2029	DS DP		
		8362002	Oct 05, 2026	U-1776		
<u>COCAINE HYDROCHLORIDE - GOPRELTO</u>						
N 209963	001	10016407	Feb 07, 2037	U-2329	NCE	Dec 14, 2022
		10149843	Feb 07, 2037	U-2478		
		10149843	Feb 07, 2037	U-2479		
		10231961	Feb 07, 2037	DP		
		10413505	Feb 07, 2037	U-2479		
		10420760	Feb 07, 2037	U-2478		
		10857095	Feb 07, 2037	U-3014		
		9867815	Feb 07, 2037	U-2225		
		9867815	Feb 07, 2037	U-2226		
		9867815	Feb 07, 2037	U-2227		
<u>COLCHICINE - COLCRYS</u>						
N 022352	001	7601758	Feb 10, 2029	U-1007		
		7619004	Dec 03, 2028	U-1020		
		7820681	Feb 17, 2029	U-1020		
		7906519	Feb 17, 2029	U-1116		
		7915269	Feb 17, 2029	U-1007		
		7935731	Dec 03, 2028	U-1116		
		7964647	Oct 06, 2028	U-1007		
		7964648	Oct 06, 2028	U-1161		
		7981938	Oct 06, 2028	U-1166		
		8093296	Oct 06, 2028	U-1007		
		8093297	Oct 06, 2028	U-1161		
		8093298	Oct 06, 2028	U-1116		
		8097655	Oct 06, 2028	U-1020		
		8415395	Oct 06, 2028	U-1007		
		8415396	Oct 06, 2028	U-1007		
		8440721	Feb 17, 2029	U-1007		
		8440722	Feb 17, 2029	U-1020		
<u>COLCHICINE - MITIGARE</u>						
N 204820	001	8927607	Aug 22, 2033	U-1020		
		9399036	Aug 22, 2033	U-1020		
		9555029	Aug 22, 2033	U-1020		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>COLCHICINE - MITIGARE</u>						
N 204820	001	9675613	Aug 22, 2033	U-1020		
		9789108	Aug 22, 2033	U-1020		
<u>COLCHICINE - GLOPERBA</u>						
N 210942	001	10226423	Dec 20, 2037	DP		
		10383820	Nov 22, 2036	DP	U-2814	
		10383821	Nov 22, 2036	DP		
		9907751	Nov 22, 2036	DP		
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N 021176	001	7229613	Apr 17, 2022	U-851		
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N 022362	001	7229613	Apr 17, 2022	U-493		
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N 022362	002	7229613	Apr 17, 2022	U-493		
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N 210895	001	7229613	Apr 17, 2022	U-2516		
<u>COPANLISIB DIHYDROCHLORIDE - ALIOOPA</u>						
N 209936	001	10383876	Mar 29, 2032	DS DP	NCE	Sep 14, 2022
		7511041	May 13, 2024	DS DP	ODE-155	Sep 14, 2024
		9636344	Mar 29, 2032		U-2124	
		RE46856	Oct 22, 2029	DS DP	U-2124	
<u>COPPER DOTATATE CU-64 - DETECTNET</u>						
N 213227	001	10159759	Aug 23, 2032	U-2951	NCE	Sep 03, 2025
		10383961	Aug 23, 2032	U-2951	ODE-317	Sep 03, 2027
<u>CRISABOROLE - EUCRISA</u>						
N 207695	001	8039451	Jun 11, 2026	DS DP	NCE	Dec 14, 2021
		8039451*PED	Dec 11, 2026		NPP	Mar 23, 2023
		8168614	Jan 20, 2030		U-1932	Jun 14, 2022
		8168614*PED	Jul 20, 2030		PED	Sep 23, 2023
		8501712	Feb 16, 2027		U-1932	
		8501712*PED	Aug 16, 2027			
		9682092	Feb 16, 2027		U-1932	
		9682092*PED	Aug 16, 2027			
<u>CRIZOTINIB - XALKORI</u>						
N 202570	001	7230098	Aug 26, 2025	DS	ODE-111	Mar 11, 2023
		7825137	May 12, 2027		U-1179	
		7858643	Oct 08, 2029	DS DP		
		8217057	Nov 06, 2029	DS DP		
		8785632	Mar 01, 2025	DS		
<u>CRIZOTINIB - XALKORI</u>						
N 202570	002	7230098	Aug 26, 2025	DS	ODE-111	Mar 11, 2023
		7825137	May 12, 2027		U-1179	
		7858643	Oct 08, 2029	DS DP		
		8217057	Nov 06, 2029	DS DP		
		8785632	Mar 01, 2025	DS		
<u>CROFLEMER - MYTESI</u>						
N 202292	001	7341744	Jun 02, 2022	DP	U-1319	
		8962680	Oct 31, 2031		U-1319	
		9585868	Oct 31, 2031		U-1319	
<u>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - TRALEMENT</u>						
N 209376	001				NCE	Apr 30, 2024
<u>CYANOCOBALAMIN - NASCOBAL</u>						
N 021642	001	7229636	Aug 01, 2024	DP	U-817	
		7404489	Mar 12, 2024	DP		
		7879349	Aug 01, 2024	DP	U-1152	
		8003353	Aug 01, 2024		U-817	
		8940714	Feb 26, 2024		U-1152	
		9415007	Jul 28, 2024		U-1896	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>						
N 021777	001	7387793	Feb 26, 2025	DP		
		7544372	Nov 14, 2023	U-979		
		7790199	Nov 14, 2023	DP		
		7820203	Nov 14, 2023	DP		
		7829121	Nov 14, 2023	U-1088		
		8877245	Nov 14, 2023	U-979		
		9375410	Nov 14, 2023	U-1088		
		9399025	Nov 14, 2023	DP U-979		
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>						
N 021777	002	7387793	Feb 26, 2025	DP		
		7544372	Nov 14, 2023	U-979		
		7790199	Nov 14, 2023	DP		
		7820203	Nov 14, 2023	DP		
		7829121	Nov 14, 2023	U-1088		
		8877245	Nov 14, 2023	U-979		
		9375410	Nov 14, 2023	U-1088		
		9399025	Nov 14, 2023	DP U-979		
<u>CYCLOSPORINE - RESTASIS</u>						
N 050790	001	8629111	Aug 27, 2024	DP		
		8633162	Aug 27, 2024	U-1479		
		8642556	Aug 27, 2024	DP		
		8648048	Aug 27, 2024	U-1483		
		8685930	Aug 27, 2024	DP		
		9248191	Aug 27, 2024	U-1479		
<u>CYCLOSPORINE - RESTASIS MULTIDOSE</u>						
N 050790	002	8292129	Feb 25, 2031	DP		
		8561859	Apr 16, 2032	DP		
		8629111	Aug 27, 2024	DP		
		8633162	Aug 27, 2024	U-1479		
		8642556	Aug 27, 2024	DP		
		8648048	Aug 27, 2024	U-1483		
		8685930	Aug 27, 2024	DP		
		9248191	Aug 27, 2024	U-1479		
		9669974	May 11, 2034	DP		
		9676525	Feb 07, 2034	DP		
<u>CYCLOSPORINE - CEQUA</u>						
N 210913	001	10441630	Aug 23, 2033	DP		
		8980839	Aug 23, 2033	DP U-1483		
		9937225	Aug 23, 2033	DP U-1483		
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389	001	10143665	Aug 16, 2036	U-1399	M-216	Dec 22, 2020
		10328037	Aug 16, 2036	U-1399	ODE-162	Dec 22, 2024
		10548859	Aug 16, 2036	U-1399	ODE-45	Apr 30, 2020
		8026284	Sep 22, 2027	U-1399	ODE-97	Aug 14, 2022
		8026284*PED	Mar 22, 2028		PED	Oct 30, 2020
		9173851	Jun 17, 2034	DP	PED	Jun 22, 2021
		9173851*PED	Dec 17, 2034		PED	Feb 14, 2023
		9192590	Jan 26, 2027	U-1399		
		9192590*PED	Jul 26, 2027			
		9198882	Jan 26, 2027	U-1399		
		9198882*PED	Jul 26, 2027			
		9233077	Jun 17, 2034	DP		
		9233077*PED	Dec 17, 2034			
		9925156	Jan 26, 2027	DS DP U-1399		
		9925157	Jan 26, 2027	DS DP U-1399		
		9925158	Jan 26, 2027	DS DP U-1399		
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389	002	10143665	Aug 16, 2036	U-1399	M-216	Dec 22, 2020
		10328037	Aug 16, 2036	U-1399	ODE-162	Dec 22, 2024
		10548859	Aug 16, 2036	U-1399	ODE-45	Apr 30, 2020
		8026284	Sep 22, 2027	U-1399	ODE-97	Aug 14, 2022
		8026284*PED	Mar 22, 2028		PED	Oct 30, 2020
		9173851	Jun 17, 2034	DP	PED	Jun 22, 2021
		9173851*PED	Dec 17, 2034		PED	Feb 14, 2023

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389	002	9192590	Jan 26, 2027	U-1399		
		9192590*PED	Jul 26, 2027			
		9198882	Jan 26, 2027	U-1399		
		9198882*PED	Jul 26, 2027			
		9233077	Jun 17, 2034	DP		
		9233077*PED	Dec 17, 2034			
		9925156	Jan 26, 2027	DS DP U-1399		
		9925157	Jan 26, 2027	DS DP U-1399		
		9925158	Jan 26, 2027	DS DP U-1399		
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 213491	001	10143665	Aug 16, 2036	U-1399	M-216	Dec 22, 2020
		10328037	Aug 16, 2036	U-1399	PED	Jun 22, 2021
		10548859	Aug 16, 2036	U-1399		
		8026284	Sep 22, 2027	U-1399		
		9173851	Jun 17, 2034	DP		
		9192590	Jan 26, 2027	U-1399		
		9198882	Jan 26, 2027	U-1399		
		9233077	Jun 17, 2034	DP		
		9925156	Jan 26, 2027	DP U-1399		
		9925157	Jan 26, 2027	DP U-1399		
		9925158	Jan 26, 2027	DP U-1399		
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 213491	002	10143665	Aug 16, 2036	U-1399	M-216	Dec 22, 2020
		10328037	Aug 16, 2036	U-1399	PED	Jun 22, 2021
		10548859	Aug 16, 2036	U-1399		
		8026284	Sep 22, 2027	U-1399		
		9173851	Jun 17, 2034	DP		
		9192590	Jan 26, 2027	U-1399		
		9198882	Jan 26, 2027	U-1399		
		9233077	Jun 17, 2034	DP		
		9925156	Jan 26, 2027	DP U-1399		
		9925157	Jan 26, 2027	DP U-1399		
		9925158	Jan 26, 2027	DP U-1399		
<u>CYSTEAMINE HYDROCHLORIDE - CYSTADROPS</u>						
N 211302	001				NP	Aug 19, 2023
<u>CYSTEINE HYDROCHLORIDE - ELCYS</u>						
N 210660	001	10478453	Jan 15, 2039	DP U-2752		
		10583155	Jan 15, 2039	DP U-2752		
		10653719	Jan 15, 2039	DP		
<u>CYSTEINE HYDROCHLORIDE - NOURESS</u>						
N 212535	001	10478453	Jan 15, 2039	DP U-2752		
		10493051	Mar 15, 2039	DP		
		10543186	Mar 15, 2039	U-2722		
		10583155	Jan 15, 2039	DP U-2752		
		10653719	Jan 15, 2039	DP		
		10702490	Mar 15, 2039	DP		
<u>CYTARABINE; DAUNORUBICIN - VYXEOS</u>						
N 209401	001	10028912	Sep 29, 2034	DP U-2341	NP	Aug 03, 2020
		10028912	Sep 29, 2034	DP U-2342	ODE-287	Aug 03, 2024
		10166184	Oct 15, 2032	DP U-2341		
		10835492	Oct 15, 2032	U-2341		
		7850990	Jan 23, 2027	DP U-2090		
		8022279	Sep 14, 2027	DP U-2090		
		8092828	Apr 01, 2029	U-2090		
		8431806	Apr 22, 2025	DP U-2090		
		8518437	Jun 07, 2026	DP		
		9271931	Jan 23, 2027	DP		
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512	001	6087380	Dec 28, 2021	DS DP U-1931		
		7866474	Aug 31, 2027	DP	Y	
		7932273	Sep 07, 2025	DS DP		
		9034822	Jan 20, 2031	U-1759		
		9925174	Jun 14, 2023	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512	001	6087380	Dec 28, 2021	DS DP U-1931		
		7866474	Aug 31, 2027	DP	Y	
		7932273	Sep 07, 2025	DS DP		
		9034822	Jan 20, 2031	U-1759		
		9925174	Jun 14, 2023	DP		
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512	002	6087380	Dec 28, 2021	DS DP U-1931		
		7866474	Aug 31, 2027	DP	Y	
		7932273	Sep 07, 2025	DS DP		
		9034822	Jan 20, 2031	U-1759		
		9925174	Jun 14, 2023	DP		
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512	003	6087380	Dec 28, 2021	DS DP U-1931		
		7866474	Aug 31, 2027	DP	Y	
		7932273	Sep 07, 2025	DS DP		
		9034822	Jan 20, 2031	U-1759		
		9925174	Jun 14, 2023	DP		
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806	001	7994185	Jan 20, 2030	DS DP U-1406	I-745	Jun 22, 2020
		7994185	Jan 20, 2030	DS DP U-2031	I-778	Apr 30, 2021
		7994185	Jan 20, 2030	DS DP U-2032	I-781	May 04, 2021
		7994185	Jan 20, 2030	DS DP U-2296	M-246	Oct 06, 2022
		8415345	Jan 20, 2030	DS DP U-1406	ODE-147	Jun 22, 2024
		8415345	Jan 20, 2030	DS DP U-2031	ODE-182	Apr 30, 2025
		8415345	Jan 20, 2030	DS DP U-2032	ODE-183	May 04, 2025
		8415345	Jan 20, 2030	DS DP U-2296	ODE-47	May 29, 2020
		8703781	Oct 15, 2030	DS DP U-1713	ODE-58	Jan 09, 2021
		8703781	Oct 15, 2030	DS DP U-2032		
		8703781	Oct 15, 2030	DS DP U-2296		
		8703781	Oct 15, 2030	DS DP U-2297		
		8703781	Oct 15, 2030	DS DP U-2298		
		8835443	Jun 10, 2025	U-2026		
		8835443	Jun 10, 2025	U-2027		
		8835443	Jun 10, 2025	U-2296		
		8835443	Jun 10, 2025	U-2298		
		8952018	Oct 15, 2030	U-2027		
		9233956	May 04, 2029	U-1811		
		9233956	May 04, 2029	U-2031		
		9233956	May 04, 2029	U-2032		
		9233956	May 04, 2029	U-2296		
		9233956	May 04, 2029	U-2297		
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806	002	7994185	Jan 20, 2030	DS DP U-1406	I-745	Jun 22, 2020
		7994185	Jan 20, 2030	DS DP U-2031	I-778	Apr 30, 2021
		7994185	Jan 20, 2030	DS DP U-2032	I-781	May 04, 2021
		7994185	Jan 20, 2030	DS DP U-2296	M-246	Oct 06, 2022
		8415345	Jan 20, 2030	DS DP U-1406	ODE-147	Jun 22, 2024
		8415345	Jan 20, 2030	DS DP U-2031	ODE-182	Apr 30, 2025
		8415345	Jan 20, 2030	DS DP U-2032	ODE-183	May 04, 2025
		8415345	Jan 20, 2030	DS DP U-2296	ODE-47	May 29, 2020
		8703781	Oct 15, 2030	DS DP U-1713	ODE-58	Jan 09, 2021
		8703781	Oct 15, 2030	DS DP U-2032		
		8703781	Oct 15, 2030	DS DP U-2296		
		8703781	Oct 15, 2030	DS DP U-2297		
		8703781	Oct 15, 2030	DS DP U-2298		
		8835443	Jun 10, 2025	U-2026		
		8835443	Jun 10, 2025	U-2027		
		8835443	Jun 10, 2025	U-2296		
		8835443	Jun 10, 2025	U-2298		
		8952018	Oct 15, 2030	U-2027		
		9233956	May 04, 2029	U-1811		
		9233956	May 04, 2029	U-2031		
		9233956	May 04, 2029	U-2032		
		9233956	May 04, 2029	U-2296		
		9233956	May 04, 2029	U-2297		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843	001	8329159	Jul 24, 2029	DS	NCE	Jul 24, 2020
		8629171	Jun 13, 2031	DS DP U-1724		
		8642025	Aug 11, 2027	DS DP U-1724		
		8642025	Aug 11, 2027	DS DP U-1725		
		8900566	Aug 08, 2027	U-1724		
		8900566	Aug 08, 2027	U-1725		
		9421192	Aug 08, 2027	DS U-1724		
		9421192	Aug 08, 2027	DS U-1725		
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843	002	8329159	Jul 24, 2029	DS	NCE	Jul 24, 2020
		8629171	Jun 13, 2031	DS DP U-1724		
		8642025	Aug 11, 2027	DS DP U-1724		
		8642025	Aug 11, 2027	DS DP U-1725		
		8900566	Aug 08, 2027	U-1724		
		8900566	Aug 08, 2027	U-1725		
		9421192	Aug 08, 2027	DS U-1724		
		9421192	Aug 08, 2027	DS U-1725		
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843	003	9421192	Aug 08, 2027	DS U-1724		
		9421192	Aug 08, 2027	DS U-1725		
<u>DACOMITINIB - VIZIMPRO</u>						
N 211288	001	7772243	Aug 26, 2028	DS DP	NCE	Sep 27, 2023
		8623883	May 05, 2025	U-1403	ODE-206	Sep 27, 2025
					ODE-213	Sep 27, 2025
<u>DACOMITINIB - VIZIMPRO</u>						
N 211288	002	7772243	Aug 26, 2028	DS DP	NCE	Sep 27, 2023
		8623883	May 05, 2025	U-1403	ODE-206	Sep 27, 2025
					ODE-213	Sep 27, 2025
<u>DACOMITINIB - VIZIMPRO</u>						
N 211288	003	7772243	Aug 26, 2028	DS DP	NCE	Sep 27, 2023
		8623883	May 05, 2025	U-1403	ODE-206	Sep 27, 2025
					ODE-213	Sep 27, 2025
<u>DALBAVANCIN HYDROCHLORIDE - DALVANCE</u>						
N 021883	001	6900175	Dec 25, 2023	U-1517	NCE	May 23, 2019
		7115564	Nov 14, 2023	DP	GAIN	May 23, 2024
		7119061	Nov 14, 2023	DP		
		8143212	Nov 14, 2023	U-1517		
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	001				NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	002				NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	003				NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	004				NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	005				NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	006				NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	007				NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	008				NPP	May 16, 2022

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	009				NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	010				NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	011				NPP	May 16, 2022
<u>DANTROLENE SODIUM - RYANODEX</u>						
N 205579	001	7758890	Jul 01, 2025	DP	ODE-69	Jul 22, 2021
		8110225	Dec 24, 2022	DP		
		8604072	Dec 24, 2022	DP		
		8685460	Feb 15, 2023	U-1546		
		9884044	Jun 13, 2022	DP U-1546		
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293	001	6414126	Oct 04, 2020	DS DP U-2139	I-834	May 05, 2023
		6414126	Oct 04, 2020	DS DP U-493	I-841	Oct 18, 2022
		6515117	Oct 04, 2025	DS DP U-2139	M-212	Oct 20, 2020
		6515117	Oct 04, 2025	DS DP U-493	M-238	Feb 22, 2022
		6936590	Oct 04, 2020	U-493		
		7456254	Jun 30, 2025	DP U-2139		
		7851502	Aug 19, 2028	DP		
		7919598	Dec 16, 2029	DS		
		8221786	Mar 21, 2028	DP		
		8329648	Aug 18, 2026	U-2139		
		8329648	Aug 18, 2026	U-2212		
		8329648	Aug 18, 2026	U-2213		
		8361972	Mar 21, 2028	U-2139		
		8361972	Mar 21, 2028	U-493		
		8431685	Apr 13, 2025	DP U-2139		
		8461105	Apr 13, 2025	DP U-2139		
		8501698	Jun 20, 2027	DP U-493		
		8685934	May 26, 2030	U-1522		
		8716251	Mar 21, 2028	DP		
		8721615	Jan 18, 2030	DP	Y	
		8906851	Aug 18, 2026	U-2139		
		9198925	Oct 04, 2020	U-2139		
		9198925	Oct 04, 2020	U-493		
		9238076	Apr 15, 2024	DP U-2139		
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293	002	6414126	Oct 04, 2020	DS DP U-2139	I-834	May 05, 2023
		6414126	Oct 04, 2020	DS DP U-493	I-841	Oct 18, 2022
		6515117	Oct 04, 2025	DS DP U-2139	M-212	Oct 20, 2020
		6515117	Oct 04, 2025	DS DP U-493	M-238	Feb 22, 2022
		6936590	Oct 04, 2020	U-493		
		7456254	Jun 30, 2025	DP U-2139		
		7851502	Aug 19, 2028	DP		
		7919598	Dec 16, 2029	DS		
		8221786	Mar 21, 2028	DP		
		8329648	Aug 18, 2026	U-2139		
		8329648	Aug 18, 2026	U-2212		
		8329648	Aug 18, 2026	U-2213		
		8361972	Mar 21, 2028	U-2139		
		8361972	Mar 21, 2028	U-493		
		8431685	Apr 13, 2025	DP U-2139		
		8461105	Apr 13, 2025	DP U-2139		
		8501698	Jun 20, 2027	DP U-493		
		8685934	May 26, 2030	U-1522		
		8716251	Mar 21, 2028	DP		
		8721615	Jan 18, 2030	DP	Y	
		8906851	Aug 18, 2026	U-2139		
		9198925	Oct 04, 2020	U-2139		
		9198925	Oct 04, 2020	U-493		
		9238076	Apr 15, 2024	DP U-2139		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 001	6414126	Oct 04, 2020	DS DP U-493		I-841	Oct 18, 2022
	6515117	Oct 04, 2025	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	9198925	Oct 04, 2020	U-493			
	9616028	Nov 12, 2030	DP			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 002	6414126	Oct 04, 2020	DS DP U-493		I-841	Oct 18, 2022
	6515117	Oct 04, 2025	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	9198925	Oct 04, 2020	U-493			
	9616028	Nov 12, 2030	DP			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 003	6414126	Oct 04, 2020	DS DP U-493		I-841	Oct 18, 2022
	6515117	Oct 04, 2025	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	9198925	Oct 04, 2020	U-493			
	9616028	Nov 12, 2030	DP			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 004	6414126	Oct 04, 2020	DS DP U-493		I-841	Oct 18, 2022
	6515117	Oct 04, 2025	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	9198925	Oct 04, 2020	U-493			
	9616028	Nov 12, 2030	DP			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 005	6414126	Oct 04, 2020	DS DP U-493		I-841	Oct 18, 2022
	6515117	Oct 04, 2025	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	9198925	Oct 04, 2020	U-493			
	9616028	Nov 12, 2030	DP			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - OTERNET XR</u>						
N 210874 001	6414126	Oct 04, 2020	DS DP U-493		NP	May 02, 2022
	6515117	Oct 04, 2025	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9198925	Oct 04, 2020	U-493			
	9616028	Nov 12, 2030	DP			
	RE44186	Jul 31, 2023	DS DP U-493			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - OTERNET XR</u>						
N 210874 002	6414126	Oct 04, 2020	DS DP U-493		NP	May 02, 2022
	6515117	Oct 04, 2025	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9198925	Oct 04, 2020	U-493			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR</u>						
N 210874	002	9616028	Nov 12, 2030	DP		
		RE44186	Jul 31, 2023	DS DP U-493		
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR</u>						
N 210874	003	6414126	Oct 04, 2020	DS DP U-493	NP	May 02, 2022
		6515117	Oct 04, 2025	DS DP U-493		
		6936590	Oct 04, 2020	U-493		
		7919598	Dec 16, 2029	DS		
		8501698	Jun 20, 2027	DP U-493		
		8628799	Jul 13, 2025	DP		
		8716251	Mar 21, 2028	DP		
		9198925	Oct 04, 2020	U-493		
		9616028	Nov 12, 2030	DP		
		RE44186	Jul 31, 2023	DS DP U-493		
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR</u>						
N 210874	004	6414126	Oct 04, 2020	DS DP U-493	NP	May 02, 2022
		6515117	Oct 04, 2025	DS DP U-493		
		6936590	Oct 04, 2020	U-493		
		7919598	Dec 16, 2029	DS		
		8501698	Jun 20, 2027	DP U-493		
		8628799	Jul 13, 2025	DP		
		8716251	Mar 21, 2028	DP		
		9198925	Oct 04, 2020	U-493		
		9616028	Nov 12, 2030	DP		
		RE44186	Jul 31, 2023	DS DP U-493		
<u>DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE - QTERN</u>						
N 209091	001	6414126	Oct 04, 2020	DS DP U-493	I-804	May 02, 2022
		6515117	Oct 04, 2025	DS DP U-493	NC	Feb 27, 2020
		6936590	Oct 04, 2020	U-1976		
		6936590	Oct 04, 2020	U-1977		
		6936590	Oct 04, 2020	U-493		
		7919598	Dec 16, 2029	DS		
		8221786	Mar 21, 2028	DP		
		8361972	Mar 21, 2028	U-1976		
		8361972	Mar 21, 2028	U-1977		
		8361972	Mar 21, 2028	U-493		
		8501698	Jun 20, 2027	DP U-1976		
		8501698	Jun 20, 2027	DP U-1977		
		8501698	Jun 20, 2027	DP U-493		
		8628799	Jul 13, 2025	DP		
		8716251	Mar 21, 2028	DP		
		9198925	Oct 04, 2020	U-1976		
		9198925	Oct 04, 2020	U-1977		
		9198925	Oct 04, 2020	U-493		
		RE44186	Jul 31, 2023	DS DP U-493		
<u>DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE - QTERN</u>						
N 209091	002	6414126	Oct 04, 2020	DS DP U-493	NS	May 02, 2022
		6515117	Oct 04, 2025	DS DP U-493		
		6936590	Oct 04, 2020	U-493		
		7919598	Dec 16, 2029	DS		
		8221786	Mar 21, 2028	DP		
		8361972	Mar 21, 2028	U-493		
		8501698	Jun 20, 2027	DP U-493		
		8628799	Jul 13, 2025	DP		
		8716251	Mar 21, 2028	DP		
		9198925	Oct 04, 2020	U-493		
		RE44186	Jul 31, 2023	DS DP U-493		
<u>DAPSONE - ACZONE</u>						
N 207154	001	9161926	Nov 18, 2033	DP	NPP	Sep 10, 2022
		9517219	Nov 18, 2033	U-1033		
<u>DAPTOMYCIN - DAPTOMYCIN</u>						
A 212667	001				CGT	Jan 12, 2020

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPTOMYCIN - CUBICIN</u>						
N 021572 002	8003673	Sep 04, 2028	U-1180		M-211 NPP	Sep 01, 2020 Mar 29, 2020
<u>DAPTOMYCIN - CUBICIN RF</u>						
N 021572 003	9138456	Nov 23, 2030	DP		M-211 NPP	Sep 01, 2020 Mar 29, 2020
<u>DAROLUTAMIDE - NUBEQA</u>						
N 212099 001	10010530	Jan 28, 2036	DS		NCE	Jul 30, 2024
	10383853	Jan 28, 2036	DS			
	10711013	Oct 27, 2030	DS DP			
	10835515	Jan 28, 2036	DP U-2605			
	8975254	Oct 27, 2030	DS DP U-2605			
	9657003	Oct 27, 2030	DS DP U-2605			
<u>DARUNAVIR - PREZISTA</u>						
N 021976 001	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
<u>DARUNAVIR - PREZISTA</u>						
N 021976 002	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
<u>DARUNAVIR - PREZISTA</u>						
N 021976 003	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
<u>DARUNAVIR - PREZISTA</u>						
N 021976 004	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
<u>DARUNAVIR - PREZISTA</u>						
N 021976 005	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
<u>DARUNAVIR - PREZISTA</u>						
N 021976 006	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
<u>DARUNAVIR - PREZISTA</u>						
N 202895 001	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
<u>DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619 001	10201542	Oct 18, 2033	DP U-1753			
	7364752	Nov 10, 2020	DP			
	8188104	May 17, 2029	DS DP U-1636			
	8268349	Aug 25, 2024	DP			
	8399015	Aug 25, 2024	DP			
	8420596	Apr 10, 2031	DS DP			
	8466159	Sep 04, 2032	U-1637			
	8492386	Sep 04, 2032	U-1840			
	8501238	Sep 17, 2028	DS DP U-1636			
	8642538	Sep 10, 2029	DS DP U-1638			
	8680106	Sep 04, 2032	U-1637			
	8685984	Sep 04, 2032	U-1840			
	8686026	Jun 09, 2031	DP			
	8691938	Apr 13, 2032	DS DP			
	9006387	Jun 10, 2030	U-1687			
	9044480	Apr 10, 2031	U-1638			
	9139536	Nov 09, 2028	U-1753			
	9629841	Oct 18, 2033	DP U-1753			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA XR</u>						
N 208624 001	10105365	Jan 02, 2035	DP U-1889			
	10201541	May 17, 2032	DP			
	10201584	May 17, 2032	U-1889			
	7364752	Nov 10, 2020	DP			
	8188104	May 17, 2029	DS DP U-1636			
	8268349	Aug 25, 2024	DP			
	8399015	Aug 25, 2024	DP			
	8420596	Apr 10, 2031	DS DP			
	8466159	Sep 04, 2032	U-1637			
	8492386	Sep 04, 2032	U-1840			
	8501238	Sep 17, 2028	DS DP U-1636			
	8642538	Sep 10, 2029	DS DP U-1638			
	8680106	Sep 04, 2032	U-1637			
	8685984	Sep 04, 2032	U-1840			
	8686026	Jun 09, 2031	DP			
	8691938	Apr 13, 2032	DS DP			
	9006387	Jun 10, 2030	U-1687			
	9044480	Apr 10, 2031	U-1638			
	9139536	Nov 09, 2028	U-1753			
	9333204	Jan 02, 2035	DP U-1889			
	9744170	Jan 02, 2035	DP U-1889			
<u>DASATINIB - SPRYCEL</u>						
N 021986 001	6596746	Jun 28, 2020	DS DP U-748		I-791	Dec 21, 2021
	6596746	Jun 28, 2020	DS DP U-780		NPP	Nov 09, 2020
	6596746*PED	Dec 28, 2020			ODE-164	Nov 09, 2024
	7125875	Apr 13, 2020	U-779		ODE-225	Dec 21, 2025
	7125875	Apr 13, 2020	U-780		PED	May 09, 2021
	7125875*PED	Oct 13, 2020			PED	Jun 21, 2022
	7153856	Apr 28, 2020	U-780		PED	May 09, 2025
	7153856*PED	Oct 28, 2020			PED	Jun 21, 2026
	7491725	Mar 28, 2026	DS DP			
	7491725*PED	Sep 28, 2026				
	8680103	Feb 04, 2025	DP			
	8680103*PED	Aug 04, 2025				
<u>DASATINIB - SPRYCEL</u>						
N 021986 002	6596746	Jun 28, 2020	DS DP U-748		I-791	Dec 21, 2021
	6596746	Jun 28, 2020	DS DP U-780		NPP	Nov 09, 2020
	6596746*PED	Dec 28, 2020			ODE-164	Nov 09, 2024
	7125875	Apr 13, 2020	U-779		ODE-225	Dec 21, 2025
	7125875	Apr 13, 2020	U-780		PED	May 09, 2021
	7125875*PED	Oct 13, 2020			PED	Jun 21, 2022
	7153856	Apr 28, 2020	U-780		PED	May 09, 2025
	7153856*PED	Oct 28, 2020			PED	Jun 21, 2026
	7491725	Mar 28, 2026	DS DP			
	7491725*PED	Sep 28, 2026				
	8680103	Feb 04, 2025	DP			
	8680103*PED	Aug 04, 2025				
<u>DASATINIB - SPRYCEL</u>						
N 021986 003	6596746	Jun 28, 2020	DS DP U-748		I-791	Dec 21, 2021
	6596746	Jun 28, 2020	DS DP U-780		NPP	Nov 09, 2020
	6596746*PED	Dec 28, 2020			ODE-164	Nov 09, 2024
	7125875	Apr 13, 2020	U-779		ODE-225	Dec 21, 2025
	7125875	Apr 13, 2020	U-780		PED	May 09, 2021
	7125875*PED	Oct 13, 2020			PED	Jun 21, 2022
	7153856	Apr 28, 2020	U-780		PED	May 09, 2025
	7153856*PED	Oct 28, 2020			PED	Jun 21, 2026
	7491725	Mar 28, 2026	DS DP			
	7491725*PED	Sep 28, 2026				
	8680103	Feb 04, 2025	DP			
	8680103*PED	Aug 04, 2025				
<u>DASATINIB - SPRYCEL</u>						
N 021986 004	6596746	Jun 28, 2020	DS DP U-748		I-791	Dec 21, 2021
	6596746	Jun 28, 2020	DS DP U-780		NPP	Nov 09, 2020
	6596746*PED	Dec 28, 2020			ODE-164	Nov 09, 2024
	7125875	Apr 13, 2020	U-779		ODE-225	Dec 21, 2025
	7125875	Apr 13, 2020	U-780		PED	May 09, 2021

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DASATINIB - SPRYCEL</u>						
N 021986 004	7125875*PED	Oct 13, 2020			PED	Jun 21, 2022
	7153856	Apr 28, 2020	U-780		PED	May 09, 2025
	7153856*PED	Oct 28, 2020			PED	Jun 21, 2026
	7491725	Mar 28, 2026	DS DP			
	7491725*PED	Sep 28, 2026				
	8680103	Feb 04, 2025	DP			
	8680103*PED	Aug 04, 2025				
<u>DASATINIB - SPRYCEL</u>						
N 021986 005	6596746	Jun 28, 2020	DS DP U-748		I-791	Dec 21, 2021
	6596746	Jun 28, 2020	DS DP U-780		NPP	Nov 09, 2020
	6596746*PED	Dec 28, 2020			ODE-164	Nov 09, 2024
	7125875	Apr 13, 2020	U-779		ODE-225	Dec 21, 2025
	7125875	Apr 13, 2020	U-780		PED	May 09, 2021
	7125875*PED	Oct 13, 2020			PED	Jun 21, 2022
	7153856	Apr 28, 2020	U-780		PED	May 09, 2025
	7153856*PED	Oct 28, 2020			PED	Jun 21, 2026
	7491725	Mar 28, 2026	DS DP			
	7491725*PED	Sep 28, 2026				
	8680103	Feb 04, 2025	DP			
	8680103*PED	Aug 04, 2025				
<u>DASATINIB - SPRYCEL</u>						
N 021986 006	6596746	Jun 28, 2020	DS DP U-748		I-791	Dec 21, 2021
	6596746	Jun 28, 2020	DS DP U-780		NPP	Nov 09, 2020
	6596746*PED	Dec 28, 2020			ODE-164	Nov 09, 2024
	7125875	Apr 13, 2020	U-779		ODE-225	Dec 21, 2025
	7125875	Apr 13, 2020	U-780		PED	May 09, 2021
	7125875*PED	Oct 13, 2020			PED	Jun 21, 2022
	7153856	Apr 28, 2020	U-780		PED	May 09, 2025
	7153856*PED	Oct 28, 2020			PED	Jun 21, 2026
	7491725	Mar 28, 2026	DS DP			
	7491725*PED	Sep 28, 2026				
	8680103	Feb 04, 2025	DP			
	8680103*PED	Aug 04, 2025				
<u>DEFERASIROX - DEFERASIROX</u>						
A 208697 002					PC	Jun 14, 2020
<u>DEFERASIROX - EXJADE</u>						
N 021882 001					M-239	Dec 12, 2021
					M-241	Jul 24, 2022
					M-263	Jul 23, 2023
					ODE-39	Jan 23, 2020
<u>DEFERASIROX - EXJADE</u>						
N 021882 002					M-239	Dec 12, 2021
					M-241	Jul 24, 2022
					M-263	Jul 23, 2023
					ODE-39	Jan 23, 2020
<u>DEFERASIROX - EXJADE</u>						
N 021882 003					M-239	Dec 12, 2021
					M-241	Jul 24, 2022
					M-263	Jul 23, 2023
					ODE-39	Jan 23, 2020
<u>DEFERASIROX - JADENU</u>						
N 206910 001	9283209	Nov 21, 2034	DS DP		M-239	Dec 12, 2021
					M-241	Jul 24, 2022
					M-263	Jul 23, 2023
					ODE-39	Jan 23, 2020
<u>DEFERASIROX - JADENU</u>						
N 206910 002	9283209	Nov 21, 2034	DS DP		M-239	Dec 12, 2021
					M-241	Jul 24, 2022
					M-263	Jul 23, 2023
					ODE-39	Jan 23, 2020

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEFERASIROX - JADENU</u>						
N 206910	003 9283209	Nov 21, 2034	DS DP		M-239 M-241 M-263 ODE-39	Dec 12, 2021 Jul 24, 2022 Jul 23, 2023 Jan 23, 2020
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968	001				M-239 M-241 M-263	Dec 12, 2021 Jul 24, 2022 Jul 23, 2023
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968	002				M-239 M-241 M-263	Dec 12, 2021 Jul 24, 2022 Jul 23, 2023
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968	003				M-239 M-241 M-263	Dec 12, 2021 Jul 24, 2022 Jul 23, 2023
<u>DEFERIPRONE - FERRIPROX</u>						
N 021825	001 7049328	Jun 28, 2021		U-735		
<u>DEFERIPRONE - FERRIPROX</u>						
N 021825	002 7049328	Jun 28, 2021		U-735		
<u>DEFERIPRONE - FERRIPROX</u>						
N 208030	001 7049328 8703156	Jun 28, 2021 Oct 29, 2029		U-735 DP U-735		
<u>DEFERIPRONE - FERRIPROX</u>						
N 208030	002 7049328 8703156	Jun 28, 2021 Oct 29, 2029		U-735 DP U-735		
<u>DEFERIPRONE - FERRIPROX</u>						
N 212269	001 10780055 7049328	Oct 25, 2038 Jun 28, 2021		DP U-735 U-735		
<u>DEFIBROTIDE SODIUM - DEFITELIO</u>						
N 208114	001				NCE ODE-112	Mar 30, 2021 Mar 30, 2023
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684	001				NCE ODE-130 ODE-252	Feb 09, 2022 Feb 09, 2024 Jun 07, 2026
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684	002				NCE ODE-130 ODE-252	Feb 09, 2022 Feb 09, 2024 Jun 07, 2026
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684	003				NCE ODE-130 ODE-252	Feb 09, 2022 Feb 09, 2024 Jun 07, 2026
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684	004				NCE ODE-130 ODE-252	Feb 09, 2022 Feb 09, 2024 Jun 07, 2026
<u>DEFLAZACORT - EMFLAZA</u>						
N 208685	001				NCE ODE-130 ODE-252	Feb 09, 2022 Feb 09, 2024 Jun 07, 2026
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201	001 10695398 10729739 5925730	Apr 27, 2032 Feb 10, 2029 May 18, 2021		U-1895 U-1978 DS DP U-943		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 001	9415085	Apr 27, 2032	U-1895			
	9579359	Feb 10, 2029	U-1978			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 002	10695398	Apr 27, 2032	U-1895			
	10729739	Feb 10, 2029	U-1978			
	5925730	May 18, 2021	DS DP U-943			
	9415085	Apr 27, 2032	U-1895			
	9579359	Feb 10, 2029	U-1978			
<u>DELAFLOXACIN MEGLUMINE - BAXDELA</u>						
N 208610 001	7728143	Nov 20, 2027	DS		I-815	Oct 24, 2022
	8252813	Oct 02, 2026	DP U-2028		NCE	Jun 19, 2022
	8273892	Aug 06, 2026	DS		GAIN	Jun 19, 2027
	8648093	Oct 07, 2025	DP U-2028			
	8871938	Sep 23, 2029	DS			
	8969569	Oct 07, 2025	DP U-2028			
	9539250	Oct 07, 2025	DS DP U-2028			
	RE46617	Dec 28, 2029	DS			
<u>DELAFLOXACIN MEGLUMINE - BAXDELA</u>						
N 208611 001	7635773	Mar 13, 2029	DP		I-815	Oct 24, 2022
	7728143	Nov 20, 2027	DS		NCE	Jun 19, 2022
	8252813	Oct 02, 2026	DP U-2028		GAIN	Jun 19, 2027
	8273892	Aug 06, 2026	DS			
	8410077	Mar 13, 2029	DP			
	8648093	Oct 07, 2025	DP U-2028			
	8871938	Sep 23, 2029	DS			
	9200088	Mar 13, 2029	DP			
	9493582	Feb 27, 2033	DP			
	9539250	Oct 07, 2025	DS DP U-2028			
	9750822	Mar 13, 2029	DP			
	RE46617	Dec 28, 2029	DS			
<u>DEOXYCHOLIC ACID - KYBELLA</u>						
N 206333 001	10500214	Mar 02, 2030	DP			
	7622130	Dec 10, 2027	U-1690			
	7754230	Dec 10, 2027	U-1690			
	8101593	Mar 02, 2030	DP			
	8242294	May 16, 2028	DS			
	8298556	Aug 03, 2025	U-1690			
	8367649	Mar 02, 2030	DP			
	8461140	Feb 21, 2028	DP			
	8546367	Feb 21, 2028	DP U-1690			
	8653058	Mar 02, 2030	DP			
	8846066	Feb 08, 2025	U-1690			
	8883770	Feb 21, 2028	DP			
	9522155	Feb 21, 2028	DP U-1940			
	9636349	Feb 21, 2028	U-1940			
	9949986	Feb 21, 2028	U-1940			
<u>DESLORATADINE - CLARINEX</u>						
N 021312 001	7618649	Dec 19, 2020	DP U-1017			
<u>DESLORATADINE - CLARINEX</u>						
N 021312 002	7618649	Dec 19, 2020	DP U-1017			
<u>DESLORATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX-D 12 HOUR</u>						
N 021313 001	6709676	Feb 18, 2021	DP U-707			
	7618649	Dec 19, 2020	DP U-1017			
	8187630	Dec 19, 2020	DP U-1017			
<u>DESLORATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX D 24 HOUR</u>						
N 021605 001	6979463	Mar 28, 2022	DP			
	7618649	Dec 19, 2020	DP U-1017			
	7820199	Mar 28, 2022	DP			
<u>DESMOPRESSIN ACETATE - NOCDURNA</u>						
N 022517 001	10307459	May 07, 2023	DP		NP	Jun 21, 2021
	7560429	Feb 02, 2024	DP U-2326			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DESMOPRESSIN ACETATE - NOCDURNA</u>						
N 022517	001	7947654	Dec 29, 2023	DP		
		8802624	Dec 29, 2023	U-2326		
		9220747	May 07, 2023	U-2326		
		9504647	May 07, 2023	DP U-2326		
		9919025	May 07, 2023	U-2326		
		9974826	Apr 13, 2030	U-2326		
<u>DESMOPRESSIN ACETATE - NOCDURNA</u>						
N 022517	002	10137167	May 21, 2029	U-2327	NP	Jun 21, 2021
		10307459	May 07, 2023	DP		
		7560429	Feb 02, 2024	DP U-2326		
		7947654	Dec 29, 2023	DP		
		8802624	Dec 29, 2023	U-2326		
		9220747	May 07, 2023	U-2326		
		9504647	May 07, 2023	DP U-2326		
		9919025	May 07, 2023	U-2326		
		9974826	Apr 13, 2030	U-2327		
<u>DESMOPRESSIN ACETATE - NOCTIVA</u>						
N 201656	001	7405203	May 06, 2023	U-1980	NP	Mar 03, 2020
		7579321	May 06, 2023	U-1980		
		7799761	Sep 26, 2024	DP		
		9539302	Jun 15, 2030	DP		
<u>DESMOPRESSIN ACETATE - NOCTIVA</u>						
N 201656	002	7405203	May 06, 2023	U-1980	NP	Mar 03, 2020
		7579321	May 06, 2023	U-1980		
		9539302	Jun 15, 2030	DP		
<u>DESONIDE - DESONATE</u>						
N 021844	001	6387383	Aug 03, 2020	DS DP U-783		
<u>DESONIDE - VERDESO</u>						
N 021978	001	8460641	Aug 13, 2027	DP U-1412		
		8962000	Aug 31, 2025	DP U-1412		
		9492384	Aug 31, 2025	DP U-1412		
<u>DESOXIMETASONE - TOPICORT</u>						
N 204141	001	8277780	Sep 01, 2028	DP U-1408		
		8715624	May 26, 2026	DP U-1408		
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992	001	6673838	Mar 01, 2022	DS U-1364	M-222	Feb 06, 2021
		6673838	Mar 01, 2022	DS U-860		
		8269040	Jul 05, 2027	DS		
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992	002	6673838	Mar 01, 2022	DS U-1364	M-222	Feb 06, 2021
		6673838	Mar 01, 2022	DS U-860		
		8269040	Jul 05, 2027	DS		
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992	003	6673838	Mar 01, 2022	DS U-1364	M-222	Feb 06, 2021
		6673838	Mar 01, 2022	DS U-860		
		8269040	Jul 05, 2027	DS		
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082	001	8524733	Mar 27, 2031	DS DP	I-751	Aug 30, 2020
		9233959	Sep 18, 2033	DP	NCE	Apr 03, 2022
		9296739	Sep 18, 2033	DP	ODE-134	Apr 03, 2024
		9550780	Sep 18, 2033	DS DP U-1846		
		9550780	Sep 18, 2033	DS DP U-1995		
		9814708	Sep 18, 2033	DP		
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082	002	8524733	Mar 27, 2031	DS DP	I-751	Aug 30, 2020
		9233959	Sep 18, 2033	DP	NCE	Apr 03, 2022
		9296739	Sep 18, 2033	DP	ODE-134	Apr 03, 2024
		9550780	Sep 18, 2033	DS DP U-1846		
		9550780	Sep 18, 2033	DS DP U-1995		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082	002	9814708	Sep 18, 2033	DP		
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082	003	8524733	Mar 27, 2031	DS DP	I-751	Aug 30, 2020
		9233959	Sep 18, 2033	DP	NCE	Apr 03, 2022
		9296739	Sep 18, 2033	DP	ODE-134	Apr 03, 2024
		9550780	Sep 18, 2033	DS DP U-1846		
		9550780	Sep 18, 2033	DS DP U-1995		
		9814708	Sep 18, 2033	DP		
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315	001	10076526	Jan 09, 2023	DP		
		10702539	Jan 09, 2023	U-1597		
		10702539	Jan 09, 2023	U-2868		
		10702539	Jan 09, 2023	U-985		
		6726918	Oct 20, 2020	DP U-1204		
		6726918	Oct 20, 2020	DP U-1205		
		6899717	Nov 01, 2023	U-1206		
		7033605	Oct 20, 2020	DP		
		7767223	Nov 28, 2021	DP		
		8034366	Jan 09, 2023	DP U-1204		
		8034366	Jan 09, 2023	DP U-1205		
		8034370	Jan 09, 2023	DP		
		8043628	Oct 20, 2020	U-1205		
		8063031	Oct 20, 2020	DP		
		8088407	Oct 20, 2020	U-1205		
		8506987	Jan 09, 2023	U-1204		
		8506987	Jan 09, 2023	U-1205		
		9012437	Oct 20, 2020	U-1205		
		9192511	Jan 09, 2023	DP		
		9283178	Oct 20, 2020	U-1205		
		9592242	Oct 20, 2020	U-1989		
		9592242	Oct 20, 2020	U-1990		
		9775849	Oct 20, 2020	U-1989		
		9775849	Oct 20, 2020	U-1990		
<u>DEXAMETHASONE - DEXTENZA</u>						
N 208742	001	8409606	May 14, 2030	DP	I-800	Jun 20, 2022
		8563027	Feb 12, 2030	U-2487	NP	Nov 30, 2021
		9254267	Sep 11, 2024	DP		
<u>DEXAMETHASONE - DEXYCU KIT</u>						
N 208912	001	10022502	Jun 22, 2034	U-2340	NP	Feb 09, 2021
		10028965	May 23, 2034	U-2340		
		10159683	May 23, 2034	DP		
		6960346	Jul 03, 2023	DP		
		7560120	Sep 05, 2022	DP		
<u>DEXAMETHASONE - HEMADY</u>						
N 211379	001	10537585	Dec 18, 2037	DP	ODE-271	Oct 03, 2026
<u>DEXAMETHASONE; TOBRAMYCIN - TOBRADEX ST</u>						
N 050818	001	7795316	Aug 03, 2028	DP U-1082		
		8101582	Dec 19, 2027	DP U-1082		
		8450287	Dec 19, 2027	DP		
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287	001	6462058	Jun 15, 2020	DS DP U-949		
		6462058	Jun 15, 2020	DS DP U-950		
		6462058	Jun 15, 2020	DS DP U-951		
		6664276	Jan 30, 2023	DS DP U-1507		
		6664276	Jan 30, 2023	DS DP U-949		
		6664276	Jan 30, 2023	DS DP U-950		
		6664276	Jan 30, 2023	DS DP U-951		
		6664276*PED	Jul 30, 2023			
		6939971	Jun 15, 2020	U-949		
		6939971	Jun 15, 2020	U-950		
		6939971	Jun 15, 2020	U-951		
		7285668	Jun 15, 2020	DS		
		7790755	Aug 02, 2026	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 001	8105626	Sep 27, 2026	DP			
	8173158	Mar 17, 2030	U-949			
	8173158	Mar 17, 2030	U-950			
	8173158	Mar 17, 2030	U-951			
	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
	8722084	Oct 15, 2023	DP			
	8722084*PED	Apr 15, 2024				
	8784885	Oct 15, 2023	DP U-1552			
	8784885	Oct 15, 2023	DP U-1553			
	8784885	Oct 15, 2023	DP U-1554			
	8784885*PED	Apr 15, 2024				
	8871273	Jan 11, 2028	DP			
	9011926	Feb 24, 2026	DP			
	9145389	Jun 15, 2020	DS DP			
	9233103	Mar 05, 2032	U-1805			
	9238029	Jan 17, 2026	DP			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 002	6462058	Jun 15, 2020	DS DP U-949			
	6462058	Jun 15, 2020	DS DP U-950			
	6462058	Jun 15, 2020	DS DP U-951			
	6664276	Jan 30, 2023	DS DP U-1507			
	6664276	Jan 30, 2023	DS DP U-949			
	6664276	Jan 30, 2023	DS DP U-950			
	6664276	Jan 30, 2023	DS DP U-951			
	6664276*PED	Jul 30, 2023				
	6939971	Jun 15, 2020	U-949			
	6939971	Jun 15, 2020	U-950			
	6939971	Jun 15, 2020	U-951			
	7285668	Jun 15, 2020	DS			
	7790755	Aug 02, 2026	DP			
	8105626	Sep 27, 2026	DP			
	8173158	Mar 17, 2030	U-949			
	8173158	Mar 17, 2030	U-950			
	8173158	Mar 17, 2030	U-951			
	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
	8722084	Oct 15, 2023	DP			
	8722084*PED	Apr 15, 2024				
	8784885	Oct 15, 2023	DP U-1552			
	8784885	Oct 15, 2023	DP U-1553			
	8784885	Oct 15, 2023	DP U-1554			
	8784885*PED	Apr 15, 2024				
	8871273	Jan 11, 2028	DP			
	9011926	Feb 24, 2026	DP			
	9145389	Jun 15, 2020	DS DP			
	9233103	Mar 05, 2032	U-1805			
	9238029	Jan 17, 2026	DP			
<u>DEXLANSOPRAZOLE - DEXILANT SOLUTAB</u>						
N 208056 001	6462058	Jun 15, 2020	DS DP U-950			
	6462058	Jun 15, 2020	DS DP U-951			
	6462058*PED	Dec 15, 2020				
	6664276	Jan 30, 2023	DS DP U-950			
	6664276	Jan 30, 2023	DS DP U-951			
	6664276*PED	Jul 30, 2023				
	6939971	Jun 15, 2020	U-950			
	6939971	Jun 15, 2020	U-951			
	6939971*PED	Dec 15, 2020				
	7285668	Jun 15, 2020	DS			
	7285668*PED	Dec 15, 2020				
	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
	8784885	Oct 15, 2023	DP			
	8784885*PED	Apr 15, 2024				
	8871273	Jan 11, 2028	DP			
	8871273*PED	Jul 11, 2028				
	9011926	Feb 24, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXLANSOPRAZOLE - DEXILANT SOLUTAB</u>						
N 208056	001	9145389	Jun 15, 2020	DS DP		
		9238029	Jan 17, 2026	DP		
		9241910	Mar 10, 2029	DP		
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038	002	10016396	Jan 04, 2032	DP		
		8242158	Jan 04, 2032	DP		
		8242158*PED	Jul 04, 2032			
		8338470	Jan 04, 2032	DP		
		8338470*PED	Jul 04, 2032			
		8455527	Jan 04, 2032		U-421	
		8455527*PED	Jul 04, 2032			
		8648106	Jan 04, 2032	DP		
		8648106*PED	Jul 04, 2032			
		9320712	Jan 04, 2032	DP		
		9320712*PED	Jul 04, 2032			
		9616049	Jan 04, 2032	DP		
		9616049*PED	Jul 04, 2032			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038	003	10016396	Jan 04, 2032	DP		
		8242158	Jan 04, 2032	DP		
		8242158*PED	Jul 04, 2032			
		8338470	Jan 04, 2032	DP		
		8338470*PED	Jul 04, 2032			
		8455527	Jan 04, 2032		U-421	
		8455527*PED	Jul 04, 2032			
		8648106	Jan 04, 2032	DP		
		8648106*PED	Jul 04, 2032			
		9320712	Jan 04, 2032	DP		
		9320712*PED	Jul 04, 2032			
		9616049	Jan 04, 2032	DP		
		9616049*PED	Jul 04, 2032			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038	004	8242158	Jan 04, 2032	DP		
		8242158*PED	Jul 04, 2032			
		8338470	Jan 04, 2032	DP		
		8338470*PED	Jul 04, 2032			
		8455527	Jan 04, 2032		U-421	
		8455527*PED	Jul 04, 2032			
		8648106	Jan 04, 2032	DP		
		8648106*PED	Jul 04, 2032			
		9320712	Jan 04, 2032	DP		
		9320712*PED	Jul 04, 2032			
		9616049	Jan 04, 2032	DP		
		9616049*PED	Jul 04, 2032			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - DEXMEDETOMIDINE HYDROCHLORIDE</u>						
N 206628	003	9649296	Apr 20, 2036	DP		
		9717796	Apr 20, 2036	DP		
<u>DEXMEDETOMIDINE HYDROCHLORIDE - DEXMEDETOMIDINE HYDROCHLORIDE</u>						
N 206628	004	9649296	Apr 20, 2036	DP		
		9717796	Apr 20, 2036	DP		
<u>DEXRAZOXANE HYDROCHLORIDE - TOTECT</u>						
N 022025	001	6727253	Mar 13, 2020		U-829	
<u>DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN - MUCINEX DM</u>						
N 021620	001	6372252	Apr 28, 2020	DP		
		6955821	Apr 28, 2020	DP	U-685	
		7838032	Apr 28, 2020	DP		
<u>DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN - MUCINEX DM</u>						
N 021620	002	6372252	Apr 28, 2020	DP		
		6955821	Apr 28, 2020	DP	U-685	
		7838032	Apr 28, 2020	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE - NUEDEXTA</u>						
N 021879	001 7659282	Aug 13, 2026	U-1093			
	8227484	Jul 17, 2023	U-1093			
<u>DIAZEPAM - VALTOCO</u>						
N 211635	001 10265402	May 11, 2025	DP		NP	Jan 10, 2023
	8895546	Mar 27, 2029	DP		ODE-279	Jan 10, 2027
	8927497	Jul 21, 2025	DP U-2727			
	9642913	May 11, 2025	DP			
	9763876	Mar 27, 2029	DP U-2727			
<u>DIAZEPAM - VALTOCO</u>						
N 211635	002 10265402	May 11, 2025	DP		NP	Jan 10, 2023
	8895546	Mar 27, 2029	DP		ODE-279	Jan 10, 2027
	8927497	Jul 21, 2025	DP U-2727			
	9642913	May 11, 2025	DP			
	9763876	Mar 27, 2029	DP U-2727			
<u>DIAZEPAM - VALTOCO</u>						
N 211635	003 10265402	May 11, 2025	DP		NP	Jan 10, 2023
	8895546	Mar 27, 2029	DP		ODE-279	Jan 10, 2027
	8927497	Jul 21, 2025	DP U-2727			
	9642913	May 11, 2025	DP			
	9763876	Mar 27, 2029	DP U-2727			
<u>DIAZOXIDE - DIAZOXIDE</u>						
A 211050	001				CGT	Jun 17, 2020
<u>DICHLORPHENAMIDE - KEVEYIS</u>						
N 011366	002				ODE-96	Aug 07, 2022
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592	001 8679544	Apr 23, 2030	DP			
	8999387	Apr 23, 2030	U-55			
	9017721	Apr 23, 2030	DP			
	9173854	Apr 23, 2030	DP			
	9180095	Apr 23, 2030	U-55			
	9180096	Apr 23, 2030	DP			
	9186328	Apr 23, 2030	U-55			
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592	002 8679544	Apr 23, 2030	DP			
	8999387	Apr 23, 2030	U-55			
	9017721	Apr 23, 2030	DP			
	9173854	Apr 23, 2030	DP			
	9180095	Apr 23, 2030	U-55			
	9180096	Apr 23, 2030	DP			
	9186328	Apr 23, 2030	U-55			
<u>DICLOFENAC EPOLAMINE - LICART</u>						
N 206976	001				NP	Dec 19, 2021
<u>DICLOFENAC POTASSIUM - CAMBIA</u>						
N 022165	001 7759394	Jun 16, 2026	DS DP U-436			
	8097651	Jun 16, 2026	DS DP U-436			
	8927604	Jun 16, 2026	U-436			
	9827197	Jun 16, 2026	DP			
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N 022202	001 7662858	Feb 24, 2029	U-1035			
	7884095	Feb 24, 2029	U-1111			
	7939518	Feb 24, 2029	U-980			
	8110606	Feb 24, 2029	U-980			
	8623920	Feb 24, 2029	U-1482			
	9561200	Feb 24, 2029	U-1482			
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 020947	001 8217078	Jul 10, 2029	U-1248			
	8546450	Aug 09, 2030	U-1435			
	8546450	Aug 09, 2030	U-1436			
	8618164	Jul 10, 2029	U-1477			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 020947	001 8741956	Jul 10, 2029	U-1435			
<u>DICLOFENAC SODIUM - DYLOJECT</u>						
N 022396	001 8946292	Mar 22, 2027	U-1659			
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 204623	001 8217078	Jul 10, 2029	U-1477			
	8252838	Apr 21, 2028	DP U-1489			
	8546450	Aug 09, 2030	U-1435			
	8546450	Aug 09, 2030	U-1436			
	8563613	Oct 17, 2027	DP U-1488			
	8618164	Jul 10, 2029	U-1477			
	8741956	Jul 10, 2029	U-1435			
	8871809	Oct 17, 2027	U-1614			
	9066913	Oct 17, 2027	DP U-1488			
	9101591	Oct 17, 2027	DP U-1488			
	9132110	Oct 17, 2027	U-1488			
	9168304	Oct 17, 2027	DP			
	9168305	Oct 17, 2027	U-1488			
	9220784	Oct 17, 2027	U-1488			
	9339551	Oct 17, 2027	U-1488			
	9339552	Oct 17, 2027	DP U-1488			
	9370501	Jul 10, 2029	U-1614			
	9375412	Jul 10, 2029	U-1614			
	9415029	Jul 10, 2029	U-1614			
	9539335	Oct 17, 2027	U-1614			
<u>DICYCLOMINE HYDROCHLORIDE - DICYCLOMINE HYDROCHLORIDE</u>						
A 212286	001			CGT		Nov 18, 2020
<u>DIENOGEST; DIENOGEST; DIENOGEST; ESTRADIOL VALERATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE - NATAZIA</u>						
N 022252	001 8071577	May 13, 2026	DP U-1			
	8153616	Jan 30, 2028	U-1240			
<u>DIGOXIN - DIGOXIN</u>						
A 213000	001			CGT		Apr 01, 2020
<u>DIHYDROERGOTAMINE MESYLATE - DIHYDROERGOTAMINE MESYLATE</u>						
A 212907	001			CGT		Nov 19, 2020
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N 021392	001 6923984	Feb 25, 2021	DP			
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N 021392	002 6923984	Feb 25, 2021	DP			
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N 021392	003 6923984	Feb 25, 2021	DP			
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N 021392	004 6923984	Feb 25, 2021	DP			
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N 021392	005 6923984	Feb 25, 2021	DP			
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N 021392	006 6923984	Feb 25, 2021	DP			
<u>DIMETHYL FUMARATE - DIMETHYL FUMARATE</u>						
A 210305	001			PC		Feb 14, 2021
<u>DIMETHYL FUMARATE - DIMETHYL FUMARATE</u>						
A 210305	002			PC		Feb 14, 2021
<u>DIMETHYL FUMARATE - DIMETHYL FUMARATE</u>						
A 210460	001			PC		Feb 14, 2021
<u>DIMETHYL FUMARATE - DIMETHYL FUMARATE</u>						
A 210460	002			PC		Feb 14, 2021

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DIMETHYL FUMARATE - DIMETHYL FUMARATE</u>						
A 210500	001				PC	Feb 14, 2021
<u>DIMETHYL FUMARATE - DIMETHYL FUMARATE</u>						
A 210500	002				PC	Feb 14, 2021
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063	001	7619001	Jun 20, 2020	U-1384	M-260	Feb 05, 2023
		8399514	Feb 07, 2028	U-1384		
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063	002	7619001	Jun 20, 2020	U-1384	M-260	Feb 05, 2023
		8399514	Feb 07, 2028	U-1384		
<u>DIPHENHYDRAMINE CITRATE; IBUPROFEN - ADVIL PM</u>						
N 021394	001	8263647	May 30, 2022	DP		
<u>DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN - ADVIL PM</u>						
N 021393	001	8883849	Jan 17, 2022	U-1618		
		9155718	Jan 17, 2022	DP		
<u>DIROXIMEL FUMARATE - VUMERITY</u>						
N 211855	001	10080733	Sep 20, 2033	DS DP	U-1384	
		8669281	Sep 20, 2033	DS DP		
		9090558	Sep 20, 2033		U-1384	
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934	001	10842770	Aug 04, 2031	DP	U-2998	
		8940786	Sep 30, 2033	DP	U-1789	
		9308195	Sep 30, 2033	DP		
		9763880	Sep 30, 2033		U-2558	
		9763880	Sep 30, 2033		U-2559	
		9763880	Sep 30, 2033		U-2560	
		9763880	Sep 30, 2033		U-2561	
		9763880	Sep 30, 2033		U-2562	
		9763880	Sep 30, 2033		U-2563	
		9763880	Sep 30, 2033		U-2564	
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934	002	10842770	Aug 04, 2031	DP	U-2998	
		8940786	Sep 30, 2033	DP	U-1789	
		9308195	Sep 30, 2033	DP		
		9763880	Sep 30, 2033		U-2558	
		9763880	Sep 30, 2033		U-2559	
		9763880	Sep 30, 2033		U-2560	
		9763880	Sep 30, 2033		U-2561	
		9763880	Sep 30, 2033		U-2562	
		9763880	Sep 30, 2033		U-2563	
		9763880	Sep 30, 2033		U-2564	
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934	003	10842770	Aug 04, 2031	DP	U-2998	
		8940786	Sep 30, 2033	DP	U-1789	
		9308195	Sep 30, 2033	DP		
		9763880	Sep 30, 2033		U-2558	
		9763880	Sep 30, 2033		U-2559	
		9763880	Sep 30, 2033		U-2560	
		9763880	Sep 30, 2033		U-2561	
		9763880	Sep 30, 2033		U-2562	
		9763880	Sep 30, 2033		U-2563	
		9763880	Sep 30, 2033		U-2564	
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790	001	8129385	Oct 05, 2027	DS DP	I-758	Nov 21, 2020
		9242986	Dec 08, 2029	DS DP		
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790	002	8129385	Oct 05, 2027	DS DP	I-758	Nov 21, 2020
		9242986	Dec 08, 2029	DS DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790	003	8129385	Oct 05, 2027	DS DP	I-758	Nov 21, 2020
		9242986	Dec 08, 2029	DS DP		
<u>DOLUTEGRAVIR SODIUM - TIVICAY PD</u>						
N 213983	001	8129385	Oct 05, 2027	DS DP		
		9242986	Dec 08, 2029	DS DP		
<u>DOLUTEGRAVIR SODIUM; LAMIVUDINE - DOVATO</u>						
N 211994	001	8129385	Oct 05, 2027	DS DP	I-839	Aug 06, 2023
		9242986	Dec 08, 2029	DS DP	NC	Apr 08, 2022
<u>DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE - JULUCA</u>						
N 210192	001	10426780	Jan 24, 2031	DS DP U-257	NC	Nov 21, 2020
		6838464	Feb 26, 2021	DS DP		
		7125879	Apr 21, 2025	DS DP U-257		
		8080551	Apr 11, 2023	DS DP		
		8101629	Aug 09, 2022	DP		
		8129385	Oct 05, 2027	DS DP		
		9242986	Dec 08, 2029	DS DP		
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT</u>						
N 022568	001	8481565	Oct 04, 2026	DP		
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439	001	8039009	Mar 24, 2029	U-1641		
		8039009*PED	Sep 24, 2029			
		8058291	Dec 05, 2029	U-1641		
		8168209	Nov 22, 2025	DP		
		8168209*PED	May 22, 2026			
		8173708	Nov 22, 2025	U-1641		
		8173708*PED	May 22, 2026			
		8283379	Nov 22, 2025	U-1641		
		8283379*PED	May 22, 2026			
		8293794	Nov 22, 2025	DP		
		8329752	Nov 22, 2025	DP		
		8329752*PED	May 22, 2026			
		8338485	Nov 22, 2025	DP		
		8338486	Nov 22, 2025	U-1641		
		8362085	Nov 22, 2025	U-1641		
		8362085*PED	May 22, 2026			
		8580858	Nov 22, 2025	U-1641		
		8598233	Nov 22, 2025	DP		
		8598233*PED	May 22, 2026			
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439	002	8039009	Mar 24, 2029	U-1641		
		8039009*PED	Sep 24, 2029			
		8058291	Dec 05, 2029	U-1641		
		8168209	Nov 22, 2025	DP		
		8168209*PED	May 22, 2026			
		8173708	Nov 22, 2025	U-1641		
		8173708*PED	May 22, 2026			
		8283379	Nov 22, 2025	U-1641		
		8283379*PED	May 22, 2026			
		8293794	Nov 22, 2025	DP		
		8329752	Nov 22, 2025	DP		
		8329752*PED	May 22, 2026			
		8338485	Nov 22, 2025	DP		
		8338486	Nov 22, 2025	U-1641		
		8362085	Nov 22, 2025	U-1641		
		8362085*PED	May 22, 2026			
		8580858	Nov 22, 2025	U-1641		
		8598233	Nov 22, 2025	DP		
		8598233*PED	May 22, 2026			
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439	003	8039009	Mar 24, 2029	U-1641		
		8039009*PED	Sep 24, 2029			
		8058291	Dec 05, 2029	U-1641		
		8168209	Nov 22, 2025	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439	003	8168209*PED	May 22, 2026			
		8173708	Nov 22, 2025	U-1641		
		8173708*PED	May 22, 2026			
		8283379	Nov 22, 2025	U-1641		
		8283379*PED	May 22, 2026			
		8293794	Nov 22, 2025	DP		
		8329752	Nov 22, 2025	DP		
		8329752*PED	May 22, 2026			
		8338485	Nov 22, 2025	DP		
		8338486	Nov 22, 2025	U-1641		
		8362085	Nov 22, 2025	U-1641		
		8362085*PED	May 22, 2026			
		8580858	Nov 22, 2025	U-1641		
		8598233	Nov 22, 2025	DP		
		8598233*PED	May 22, 2026			
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439	004	8039009	Mar 24, 2029	U-1641		
		8039009*PED	Sep 24, 2029			
		8058291	Dec 05, 2029	U-1641		
		8168209	Nov 22, 2025	DP		
		8168209*PED	May 22, 2026			
		8173708	Nov 22, 2025	U-1641		
		8173708*PED	May 22, 2026			
		8283379	Nov 22, 2025	U-1641		
		8283379*PED	May 22, 2026			
		8293794	Nov 22, 2025	DP		
		8329752	Nov 22, 2025	DP		
		8329752*PED	May 22, 2026			
		8338485	Nov 22, 2025	DP		
		8338486	Nov 22, 2025	U-1641		
		8362085	Nov 22, 2025	U-1641		
		8362085*PED	May 22, 2026			
		8580858	Nov 22, 2025	U-1641		
		8598233	Nov 22, 2025	DP		
		8598233*PED	May 22, 2026			
<u>DORAVIRINE - PIFELTRO</u>						
N 210806	001	8486975	Oct 07, 2031	DS DP U-2394	I-827	Sep 19, 2022
		8486975	Oct 07, 2031	DS DP U-2630	NCE	Aug 30, 2023
<u>DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE - DELSTRIGO</u>						
N 210807	001	10603282	Nov 29, 2036	DP	I-806	Sep 19, 2022
		10842751	Nov 29, 2036	DP	NCE	Aug 30, 2023
		8486975	Oct 07, 2031	DS DP U-2395		
		8486975	Oct 07, 2031	DS DP U-2629		
<u>DORIPENEM - DORIBAX</u>						
N 022106	001	8247402	Mar 30, 2021	DS DP		
<u>DORIPENEM - DORIBAX</u>						
N 022106	002	8247402	Mar 30, 2021	DS DP		
<u>DOXEPIIN HYDROCHLORIDE - SILENOR</u>						
N 022036	001	10238620	May 18, 2027	U-620		
		10548871	Apr 11, 2028	U-620		
		10653660	Jul 20, 2027	U-620		
		10653662	May 18, 2027	U-620		
		6211229	Feb 17, 2020	U-620		
		7915307	Aug 24, 2027	U-620		
		8513299	Sep 07, 2030	U-620		
		9107898	May 01, 2028	U-620		
		9486437	May 18, 2027	U-620		
		9532971	Jun 01, 2029	DP		
		9572814	Jul 20, 2027	U-620		
		9861607	May 18, 2027	U-620		
		9907780	Apr 11, 2028	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DOXEPIIN HYDROCHLORIDE - SILENOR</u>						
N 022036	002	10238620	May 18, 2027			U-620
		10548871	Apr 11, 2028			U-620
		10653660	Jul 20, 2027			U-620
		10653662	May 18, 2027			U-620
		6211229	Feb 17, 2020			U-620
		7915307	Aug 24, 2027			U-620
		8513299	Sep 07, 2030			U-620
		9107898	May 01, 2028			U-620
		9486437	May 18, 2027			U-620
		9532971	Jun 01, 2029	DP		
		9572814	Jul 20, 2027			U-620
		9861607	May 18, 2027			U-620
		9907780	Apr 11, 2028	DP		
<u>DOXYCYCLINE - ORACEA</u>						
N 050805	001	10058564	Apr 05, 2022			U-1063
		7211267	Apr 05, 2022			U-925
		7232572	Apr 05, 2022			U-925
		7749532	Dec 19, 2027	DP		U-1063
		8206740	Dec 24, 2025	DP		U-925
		8394405	Apr 07, 2024	DP		U-925
		8394406	Apr 07, 2024	DP		U-925
		8470364	Apr 07, 2024	DP		U-925
		8603506	Apr 05, 2022			U-1063
		8709478	Apr 07, 2024			U-1063
		9241946	Apr 05, 2022			U-1063
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795	001	6958161	Dec 15, 2022	DP		U-918
		8715724	Feb 03, 2028	DP		
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795	002	6958161	Dec 15, 2022	DP		U-918
		8715724	Feb 03, 2028	DP		
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795	003	6958161	Dec 15, 2022	DP		U-918
		8715724	Feb 03, 2028	DP		
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795	004	6958161	Dec 15, 2022	DP		U-918
		8715724	Feb 03, 2028	DP		
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795	005	6958161	Dec 15, 2022	DP		U-918
		8715724	Feb 03, 2028	DP		
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795	006	6958161	Dec 15, 2022	DP		U-918
		8715724	Feb 03, 2028	DP		
<u>DOXYCYCLINE HYCLATE - DORYX MPC</u>						
N 050795	007	6958161	Dec 15, 2022	DP		U-918
		8715724	Feb 03, 2028	DP		
		9295652	Oct 23, 2034	DP		U-918
		9446057	Dec 23, 2034	DP		U-918
		9511031	Oct 23, 2034	DP		
<u>DOXYCYCLINE HYCLATE - DORYX MPC</u>						
N 050795	008	6958161	Dec 15, 2022	DP		U-918
		8715724	Feb 03, 2028	DP		
		9295652	Oct 23, 2034	DP		U-918
		9446057	Dec 23, 2034	DP		U-918
		9511031	Oct 23, 2034	DP		
<u>DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE - DICLEGIS</u>						
N 021876	001	6340695	Jun 21, 2021	DP		U-1382

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE - BONJESTA</u>						
N 209661	001	9089489	Feb 18, 2033	DP	U-1382	
		9375404	Feb 18, 2033	DP	U-1382	
		9526703	Feb 18, 2033	DP	U-1382	
		9937132	Feb 18, 2033	DP	U-1382	
<u>DRONABINOL - SYNDROS</u>						
N 205525	001	10265293	Aug 06, 2028	DS	DP	
		8222292	Aug 06, 2028	DS	DP	
		9345771	Aug 06, 2028	DS	DP	
<u>DRONEDARONE HYDROCHLORIDE - MULTAQ</u>						
N 022425	001	8410167	Apr 16, 2029		U-1387	
		8410167	Apr 16, 2029		U-1388	
		8602215	Jun 30, 2031		U-1473	
		9107900	Apr 16, 2029		U-1726	
		9107900	Apr 16, 2029		U-1728	
<u>DROSPIRENONE - SLYND</u>						
N 211367	001	10179140	Jun 28, 2031		U-2553	
		10603281	Jun 08, 2031		U-2553	
		10849857	Jun 28, 2031	DP		
		9603860	Jun 28, 2031		U-2553	
<u>DROSPIRENONE; ESTRADIOL - ANGELIO</u>						
N 021355	001	8906890	Oct 22, 2031	DP		
<u>DROSPIRENONE; ETHINYL ESTRADIOL - YASMIN</u>						
N 021098	001	6787531	Aug 31, 2020	DP		
<u>DROSPIRENONE; ETHINYL ESTRADIOL - YAZ</u>						
N 021676	001	6787531	Aug 31, 2020	DP		
		6958326	Dec 20, 2021	DP		
		7163931	Dec 20, 2021		U-1	
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - BEYAZ</u>						
N 022532	001	6441168	Jul 30, 2022	DS		
		6958326	Dec 20, 2021	DP		
		7163931	Mar 03, 2022		U-1	
		8617597	Feb 08, 2030	DP		
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - SAFYRAL</u>						
N 022574	001	6441168	Apr 17, 2020	DS		
		6958326	Dec 20, 2021	DP		
		7163931	Mar 03, 2022		U-1	
		8617597	Feb 08, 2030	DP		
<u>DROXIDOPA - NORTHERA</u>						
N 203202	001				ODE-61	Feb 18, 2021
<u>DROXIDOPA - NORTHERA</u>						
N 203202	002				ODE-61	Feb 18, 2021
<u>DROXIDOPA - NORTHERA</u>						
N 203202	003				ODE-61	Feb 18, 2021
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427	001				NPP	Apr 20, 2023
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427	002				NPP	Apr 20, 2023
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427	004				NPP	Apr 20, 2023
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516	001	10413525	Apr 13, 2037	DP		
		9839626	Apr 13, 2037	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516	002	10413525	Apr 13, 2037	DP		
		9839626	Apr 13, 2037	DP		
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516	003	10413525	Apr 13, 2037	DP		
		9839626	Apr 13, 2037	DP		
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516	004	10413525	Apr 13, 2037	DP		
		9839626	Apr 13, 2037	DP		
<u>DUVELISIB - COPIKTRA</u>						
N 211155	001	8193182	Feb 13, 2030	DS	NCE	Sep 24, 2023
		9216982	Jan 05, 2029	U-2412	ODE-208	Sep 24, 2025
		9216982	Jan 05, 2029	U-2413	ODE-209	Sep 24, 2025
		9840505	Jan 10, 2032	U-2412		
		9840505	Jan 10, 2032	U-2413		
		RE46621	May 17, 2032	DS DP		
<u>DUVELISIB - COPIKTRA</u>						
N 211155	002	8193182	Feb 13, 2030	DS	NCE	Sep 24, 2023
		9216982	Jan 05, 2029	U-2412	ODE-208	Sep 24, 2025
		9216982	Jan 05, 2029	U-2413	ODE-209	Sep 24, 2025
		9840505	Jan 10, 2032	U-2412		
		9840505	Jan 10, 2032	U-2413		
		RE46621	May 17, 2032	DS DP		
<u>ECONAZOLE NITRATE - ECOZA</u>						
N 205175	001	10071054	Aug 08, 2031	DP		
<u>EDARAVONE - RADICAVA</u>						
N 209176	001	6933310	Nov 13, 2020	U-2013	NCE	May 05, 2022
					ODE-144	May 05, 2024
<u>EDARAVONE - RADICAVA</u>						
N 209176	002	6933310	Nov 13, 2020	U-2013	NCE	May 05, 2022
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316	001	7365205	Jun 12, 2023	DS	M-243	Aug 09, 2022
		9149532	Mar 28, 2028	DP	NCE	Jan 08, 2020
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316	002	7365205	Jun 12, 2023	DS	M-243	Aug 09, 2022
		9149532	Mar 28, 2028	DP	NCE	Jan 08, 2020
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316	003	7365205	Jun 12, 2023	DS	M-243	Aug 09, 2022
		9149532	Mar 28, 2028	DP	NCE	Jan 08, 2020
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N 021937	001	6642245	Nov 04, 2020	U-1170		
		6642245	Nov 04, 2020	U-750		
		6703396	Mar 09, 2021	DS DP		
		8592397	Jan 13, 2024	DP U-1170		
		8592397	Jan 13, 2024	DP U-750		
		8598185	Apr 28, 2029	DP		
		8716264	Jan 13, 2024	DP U-257		
		9018192	Jun 13, 2026	U-1170		
		9018192	Jun 13, 2026	U-750		
		9457036	Jan 13, 2024	DP U-257		
		9545414	Jun 13, 2026	DP U-1170		
		9545414	Jun 13, 2026	DP U-750		
		9744181	Jan 13, 2024	DP U-257		
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567	001	10105444	Jul 08, 2030	DP	NPP	Apr 27, 2023
		10342875	Oct 02, 2034	DP U-2720		
		10478601	Apr 25, 2035	DP U-2721		
		10512640	Jan 03, 2028	U-1969		
		10828293	Oct 02, 2034	U-2720		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567	001 10828369	Jan 03, 2028	DP			
	7214506	Oct 05, 2021	U-281			
	8039494	Jul 08, 2030	U-281			
	8486978	Oct 24, 2030	DP			
	9302009	Oct 24, 2030	DP			
	9566272	Jan 03, 2028	U-1969			
	9662394	Oct 02, 2034	DP			
	9861698	Jul 08, 2030	DP			
	9877955	Jan 03, 2028	U-1969			
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450	001 10537572	Sep 01, 2036	U-2735		NCE	Jul 23, 2023
	10682351	Sep 01, 2036	U-2850			
	6872728	Jan 25, 2021	DS DP			
	7056927	Sep 10, 2024	DS DP			
	7176211	Jul 06, 2024	U-2360			
	7179815	Mar 07, 2021	U-2360			
	7419983	Jul 06, 2024	DS DP U-2360			
	7462625	Jan 25, 2021	DS DP U-2360			
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450	002 6872728	Jan 25, 2021	DS DP		NCE	Jul 23, 2023
	7056927	Sep 10, 2024	DS DP			
	7176211	Jul 06, 2024	U-2360			
	7179815	Mar 07, 2021	U-2360			
	7419983	Jul 06, 2024	DS DP U-2360			
	7462625	Jan 25, 2021	DS DP U-2360			
<u>ELAGOLIX SODIUM, ESTRADIOL, NORETHINDRONE ACETATE; ELAGOLIX SODIUM - ORIAHNN (COPACKAGED)</u>						
N 213388	001 6872728	Jan 25, 2021	DS DP		NCE	Jul 23, 2023
	7056927	Sep 10, 2024	DS DP		NP	May 29, 2023
	7179815	Mar 07, 2021	U-2842			
	7419983	Jul 06, 2024	DS DP			
	7462625	Jan 25, 2021	DS DP U-2842			
<u>ELBASVIR; GRAZOPREXIN - ZEPATIER</u>						
N 208261	001 7973040	Jul 24, 2029	DS DP U-1813		NCE	Jan 28, 2021
	8871759	May 04, 2031	DS DP U-1813			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273	001 10022352	Apr 09, 2027	DP U-2651		NCE	Feb 12, 2023
	10081621	Mar 25, 2031	DP U-2652		NCE	Oct 21, 2024
	10239867	Apr 09, 2027	DS DP U-2653		ODE-275	Oct 21, 2026
	10646481	Aug 13, 2029	DP			
	10758534	Oct 06, 2035	DS DP U-2645			
	10793547	Dec 08, 2037	DS DP U-2645			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-2645			
	8354427	Jul 06, 2026	U-2646			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-2645			
	8598181	May 01, 2027	U-2645			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-2648			
	8754224	Dec 28, 2026	DS DP			
	9012496	Jul 15, 2033	U-2649			
	9670163	Dec 28, 2026	DP U-2650			
	9931334	Dec 28, 2026	DP U-2650			
	9974781	Apr 09, 2027	DP U-2645			
<u>ELIGLUSTAT TARTRATE - CERDELGA</u>						
N 205494	001 6916802	Apr 29, 2022	DS U-1571		ODE-73	Aug 19, 2021
	7196205	Jun 26, 2026	DS			
	7253185	Apr 29, 2022	DP			
	7615573	Apr 29, 2022	U-1571			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 001	7160870	Nov 20, 2022	DS DP U-1306		ODE-210	Nov 16, 2025
	7160870	Nov 20, 2022	DS DP U-2451		ODE-75	Aug 26, 2021
	7160870*PED	May 20, 2023			PED	Feb 26, 2022
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-2451			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-2451			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-2451			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-2451			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1306			
	8052993	Aug 01, 2027	DP U-1575			
	8052993	Aug 01, 2027	DP U-2451			
	8052993	Aug 01, 2027	DP U-930			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 002	7160870	Nov 20, 2022	DS DP U-1306		ODE-210	Nov 16, 2025
	7160870	Nov 20, 2022	DS DP U-2451		ODE-75	Aug 26, 2021
	7160870*PED	May 20, 2023			PED	Feb 26, 2022
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-2451			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-2451			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-2451			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-2451			
	7795293	May 21, 2023	U-930			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1306			
	8052994	Aug 01, 2027	DP U-2451			
	8052994	Aug 01, 2027	DP U-930			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291	002	8062665*PED	Feb 01, 2028			
		8071129	Aug 01, 2027	DP U-1714		
		8071129*PED	Feb 01, 2028			
		8828430	Aug 01, 2027	DP U-1306		
		8828430	Aug 01, 2027	DP U-2451		
		8828430*PED	Feb 01, 2028			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291	003	7160870	Nov 20, 2022	DS DP U-1306	ODE-210	Nov 16, 2025
		7160870	Nov 20, 2022	DS DP U-2451	ODE-75	Aug 26, 2021
		7160870*PED	May 20, 2023		PED	Feb 26, 2022
		7332481	May 24, 2021	U-1306		
		7332481	May 24, 2021	U-2451		
		7332481*PED	Nov 24, 2021			
		7452874	May 24, 2021	DS DP		
		7452874*PED	Nov 24, 2021			
		7473686	May 24, 2021	DS DP U-1306		
		7473686	May 24, 2021	DS DP U-2451		
		7473686*PED	Nov 24, 2021			
		7547719	Jul 13, 2025	DS DP U-1306		
		7547719	Jul 13, 2025	DS DP U-1575		
		7547719	Jul 13, 2025	DS DP U-2451		
		7547719	Jul 13, 2025	DS DP U-2452		
		7547719	Jul 13, 2025	DS DP U-930		
		7547719*PED	Jan 13, 2026			
		7790704	May 24, 2021	U-1306		
		7790704	May 24, 2021	U-2451		
		7790704*PED	Nov 24, 2021			
		7795293	May 21, 2023	U-1306		
		7795293	May 21, 2023	U-2451		
		7795293	May 21, 2023	U-930		
		7795293*PED	Nov 21, 2023			
		8052993	Aug 01, 2027	DP U-1714		
		8052993*PED	Feb 01, 2028			
		8052994	Aug 01, 2027	DP U-1714		
		8052994*PED	Feb 01, 2028			
		8062665	Aug 01, 2027	DP U-1306		
		8062665	Aug 01, 2027	DP U-2451		
		8062665	Aug 01, 2027	DP U-930		
		8062665*PED	Feb 01, 2028			
		8071129	Aug 01, 2027	DP U-1714		
		8071129*PED	Feb 01, 2028			
		8828430	Aug 01, 2027	DP U-1306		
		8828430	Aug 01, 2027	DP U-2451		
		8828430*PED	Feb 01, 2028			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291	004	7160870	Nov 20, 2022	DS DP U-1306	ODE-210	Nov 16, 2025
		7160870	Nov 20, 2022	DS DP U-2451	ODE-75	Aug 26, 2021
		7160870*PED	May 20, 2023		PED	Feb 26, 2022
		7332481	May 24, 2021	U-1306		
		7332481	May 24, 2021	U-2451		
		7332481*PED	Nov 24, 2021			
		7452874	May 24, 2021	DS DP		
		7452874*PED	Nov 24, 2021			
		7473686	May 24, 2021	DS DP U-1306		
		7473686	May 24, 2021	DS DP U-2451		
		7473686*PED	Nov 24, 2021			
		7547719	Jul 13, 2025	DS DP U-1306		
		7547719	Jul 13, 2025	DS DP U-1575		
		7547719	Jul 13, 2025	DS DP U-2451		
		7547719	Jul 13, 2025	DS DP U-2452		
		7547719*PED	Jan 13, 2026			
		7790704	May 24, 2021	U-1306		
		7790704	May 24, 2021	U-2451		
		7790704*PED	Nov 24, 2021			
		7795293	May 21, 2023	U-1306		
		7795293	May 21, 2023	U-2451		
		7795293*PED	Nov 21, 2023			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 004	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1306			
	8071129	Aug 01, 2027	DP U-2451			
	8071129	Aug 01, 2027	DP U-930			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 005	7160870	Nov 20, 2022	DS DP U-1306		ODE-210	Nov 16, 2025
	7160870	Nov 20, 2022	DS DP U-1575		ODE-75	Aug 26, 2021
	7160870	Nov 20, 2022	DS DP U-1714		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-930			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			
	7332481	May 24, 2021	U-930			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686	May 24, 2021	DS DP U-930			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-930			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-930			
	7795293*PED	Nov 21, 2023				
<u>ELTROMBOPAG OLAMINE - PROMACTA KIT</u>						
N 207027 001	7160870	Nov 20, 2022	DS DP U-1306		ODE-74	Aug 26, 2021
	7160870	Nov 20, 2022	DS DP U-1736		PED	Feb 26, 2022
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1736			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1736			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1736			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1736			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1736			
	7795293*PED	Nov 24, 2023				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA KIT</u>						
N 207027	002	7160870	Nov 20, 2022	DS DP	U-1306	
		7160870	Nov 20, 2022	DS DP	U-1736	
		7160870*PED	May 20, 2023			
		7332481	May 24, 2021		U-1306	
		7332481	May 24, 2021		U-1736	
		7332481*PED	Nov 24, 2021			
		7452874	May 24, 2021	DS DP		
		7452874*PED	Nov 24, 2021			
		7473686	May 24, 2021	DS DP	U-1306	
		7473686	May 24, 2021	DS DP	U-1736	
		7473686*PED	Nov 24, 2021			
		7547719	Jul 13, 2025	DS DP	U-1306	
		7547719	Jul 13, 2025	DS DP	U-1575	
		7547719	Jul 13, 2025	DS DP	U-1736	
		7547719	Jul 13, 2025	DS DP	U-2452	
		7547719*PED	Jan 13, 2026			
		7790704	May 24, 2021		U-1306	
		7790704	May 24, 2021		U-1736	
		7790704*PED	Nov 24, 2021			
		7795293	May 21, 2023		U-1306	
		7795293	May 21, 2023		U-1736	
		7795293*PED	Nov 21, 2023			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940	001	10188632	Mar 14, 2033	DP		NCE May 27, 2020
		10213415	Mar 14, 2025	DS	U-2152	
		7741356	Jun 24, 2026	DS DP		
		7786158	Mar 14, 2025	DS		
		8344011	Mar 14, 2025		U-1709	
		8609709	Mar 14, 2025	DS		
		8691860	Jul 07, 2028	DS	U-1709	
		8772325	Mar 14, 2025		U-1709	
		9115091	Jul 07, 2028	DS DP	U-1738	
		9205076	Mar 14, 2025		U-1709	
		9364489	Jul 07, 2028		U-1709	
		9675587	Mar 14, 2033	DP		
		9700542	Mar 14, 2025	DP		
		9789125	Jul 07, 2028	DP	U-1709	
		9789125	Jul 07, 2028	DP	U-2152	
<u>ELUXADOLINE - VIBERZI</u>						
N 206940	002	10188632	Mar 14, 2033	DP		NCE May 27, 2020
		10213415	Mar 14, 2025	DS	U-2152	
		7741356	Jun 24, 2026	DS DP		
		7786158	Mar 14, 2025	DS		
		8344011	Mar 14, 2025		U-1709	
		8609709	Mar 14, 2025	DS		
		8691860	Jul 07, 2028	DS	U-1709	
		8772325	Mar 14, 2025		U-1709	
		9115091	Jul 07, 2028	DS DP	U-1738	
		9205076	Mar 14, 2025		U-1709	
		9364489	Jul 07, 2028		U-1709	
		9675587	Mar 14, 2033	DP		
		9700542	Mar 14, 2025	DP		
		9789125	Jul 07, 2028	DP	U-1709	
		9789125	Jul 07, 2028	DP	U-2152	
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093	001	7176220	Aug 27, 2026	DS DP	U-257	
		7635704	Oct 26, 2026	DS DP	U-257	
		8981103	Oct 26, 2026	DS DP		
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093	002	7176220	Aug 27, 2026	DS DP	U-257	
		7635704	Oct 26, 2026	DS DP	U-257	
		8981103	Oct 26, 2026	DS DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629	001	10258637	Apr 03, 2034		U-2290	
		7579449	Aug 01, 2028	DS		
		7713938	Apr 15, 2027	DS DP		
		8551957	Oct 14, 2029		U-1651	
		9949997	May 17, 2034		U-2292	
		9949998	Jun 11, 2034		U-2290	
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629	002	10258637	Apr 03, 2034		U-2290	
		7579449	Aug 01, 2028	DS		
		7713938	Apr 15, 2027	DS DP		
		8551957	Oct 14, 2029		U-1651	
		9949997	May 17, 2034		U-2292	
		9949998	Jun 11, 2034		U-2290	
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073	001	10258637	Apr 03, 2034		U-2290	M-252 Mar 30, 2023
		7407955	May 02, 2025	DS DP		M-258 Jul 03, 2022
		7579449	Aug 01, 2028	DS		
		7713938	Apr 15, 2027	DS DP		
		8119648	Aug 12, 2023		U-1651	
		8178541	Aug 12, 2023	DP	U-1653	
		8178541	Aug 12, 2023	DP	U-1654	
		8551957	Oct 14, 2029	DP	U-1651	
		8673927	May 04, 2027		U-1652	Y
		8883805	Nov 26, 2025	DP		
		9173859	May 04, 2027	DP	U-1772	Y
		9949998	Jun 11, 2034		U-2290	
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073	002	10258637	Apr 03, 2034		U-2290	M-252 Mar 30, 2023
		7407955	May 02, 2025	DS DP		M-258 Jul 03, 2022
		7579449	Aug 01, 2028	DS		
		7713938	Apr 15, 2027	DS DP		
		8119648	Aug 12, 2023		U-1651	
		8178541	Aug 12, 2023	DP	U-1653	
		8178541	Aug 12, 2023	DP	U-1654	
		8551957	Oct 14, 2029	DP	U-1651	
		8673927	May 04, 2027		U-1652	Y
		8883805	Nov 26, 2025	DP		
		9173859	May 04, 2027	DP	U-1772	Y
		9949998	Jun 11, 2034		U-2290	
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614	001	10022379	Apr 02, 2029	DP	U-2732	
		10258637	Apr 03, 2034		U-2731	
		10406172	Jun 15, 2030	DP	U-2733	
		10596120	Mar 07, 2032	DP	U-2776	
		10596120	Mar 07, 2032	DP	U-2790	
		6488962	Jun 20, 2020	DP		
		7407955	May 02, 2025	DS DP		
		7579449	Aug 01, 2028	DS		
		7713938	Apr 15, 2027	DS DP		
		8119648	Aug 12, 2023		U-1652	
		8178541	Aug 12, 2023	DP	U-1652	
		8551957	Oct 14, 2029	DP	U-2730	
		8883805	Nov 26, 2025	DP		
		9155705	May 21, 2030	DP		
		9415016	Apr 02, 2029	DP		
		9949998	Jun 11, 2034		U-2731	
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614	002	10022379	Apr 02, 2029	DP	U-2732	
		10258637	Apr 03, 2034		U-2731	
		10406172	Jun 15, 2030	DP	U-2733	
		10596120	Mar 07, 2032	DP	U-2776	
		10596120	Mar 07, 2032	DP	U-2790	
		6488962	Jun 20, 2020	DP		
		7407955	May 02, 2025	DS DP		
		7579449	Aug 01, 2028	DS		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614	002	7713938	Apr 15, 2027	DS DP		
		8119648	Aug 12, 2023		U-1652	
		8178541	Aug 12, 2023	DP	U-1652	
		8551957	Oct 14, 2029	DP	U-2730	
		8883805	Nov 26, 2025	DP		
		9155705	May 21, 2030	DP		
		9415016	Apr 02, 2029	DP		
		9949998	Jun 11, 2034		U-2731	
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614	003	10022379	Apr 02, 2029	DP	U-2732	
		10258637	Apr 03, 2034		U-2731	
		10406172	Jun 15, 2030	DP	U-2733	
		10596120	Mar 07, 2032	DP	U-2776	
		10596120	Mar 07, 2032	DP	U-2790	
		6488962	Jun 20, 2020	DP		
		7407955	May 02, 2025	DS DP		
		7579449	Aug 01, 2028	DS		
		7713938	Apr 15, 2027	DS DP		
		8119648	Aug 12, 2023		U-1652	
		8178541	Aug 12, 2023	DP	U-1652	
		8551957	Oct 14, 2029	DP	U-2730	
		8883805	Nov 26, 2025	DP		
		9155705	May 21, 2030	DP		
		9415016	Apr 02, 2029	DP		
		9949998	Jun 11, 2034		U-2731	
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614	004	10022379	Apr 02, 2029	DP	U-2732	
		10258637	Apr 03, 2034		U-2731	
		10406172	Jun 15, 2030	DP	U-2733	
		10596120	Mar 07, 2032	DP	U-2776	
		10596120	Mar 07, 2032	DP	U-2790	
		6488962	Jun 20, 2020	DP		
		7407955	May 02, 2025	DS DP		
		7579449	Aug 01, 2028	DS		
		7713938	Apr 15, 2027	DS DP		
		8119648	Aug 12, 2023		U-1652	
		8178541	Aug 12, 2023	DP	U-1652	
		8551957	Oct 14, 2029	DP	U-2730	
		8883805	Nov 26, 2025	DP		
		9155705	May 21, 2030	DP		
		9415016	Apr 02, 2029	DP		
		9949998	Jun 11, 2034		U-2731	
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111	001	10258637	Apr 03, 2034		U-2290	
		10610489	Sep 30, 2030	DP		
		7579449	Aug 01, 2028	DS		
		7713938	Apr 15, 2027	DS DP		
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111	002	10258637	Apr 03, 2034		U-2290	
		10610489	Sep 30, 2030	DP		
		7579449	Aug 01, 2028	DS		
		7713938	Apr 15, 2027	DS DP		
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111	003	10258637	Apr 03, 2034		U-2290	
		10610489	Sep 30, 2030	DP		
		7579449	Aug 01, 2028	DS		
		7713938	Apr 15, 2027	DS DP		
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111	004	10258637	Apr 03, 2034		U-2290	
		10610489	Sep 30, 2030	DP		
		7579449	Aug 01, 2028	DS		
		7713938	Apr 15, 2027	DS DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658	001	10258637	Apr 03, 2034		U-2290	
		10596120	Mar 07, 2032	DP	U-2775	
		10596120	Mar 07, 2032	DP	U-2792	
		6488962	Jun 20, 2020	DP		
		7579449	Aug 01, 2028	DS		
		7713938	Apr 15, 2027	DS DP		
		9949998	Jun 11, 2034		U-2290	
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658	002	10258637	Apr 03, 2034		U-2290	
		10596120	Mar 07, 2032	DP	U-2775	
		10596120	Mar 07, 2032	DP	U-2792	
		6488962	Jun 20, 2020	DP		
		7579449	Aug 01, 2028	DS		
		7713938	Apr 15, 2027	DS DP		
		9949998	Jun 11, 2034		U-2290	
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658	003	10258637	Apr 03, 2034		U-2290	
		10596120	Mar 07, 2032	DP	U-2775	
		10596120	Mar 07, 2032	DP	U-2792	
		6488962	Jun 20, 2020	DP		
		7579449	Aug 01, 2028	DS		
		7713938	Apr 15, 2027	DS DP		
		9949998	Jun 11, 2034		U-2290	
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658	004	10258637	Apr 03, 2034		U-2290	
		10596120	Mar 07, 2032	DP	U-2775	
		10596120	Mar 07, 2032	DP	U-2792	
		6488962	Jun 20, 2020	DP		
		7579449	Aug 01, 2028	DS		
		7713938	Apr 15, 2027	DS DP		
		9949998	Jun 11, 2034		U-2290	
<u>EMTRICITABINE - EMTRICITABINE</u>						
A 091168	001					PC Feb 27, 2021
<u>EMTRICITABINE - EMTRIVA</u>						
N 021500	001	6642245	Nov 04, 2020		U-257	
		6642245	Nov 04, 2020		U-541	
		6703396	Mar 09, 2021	DS DP		
<u>EMTRICITABINE - EMTRIVA</u>						
N 021896	001	6642245	Nov 04, 2020		U-257	
		6703396	Mar 09, 2021	DS DP		
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - ODEFSEY</u>						
N 208351	001	6642245	Nov 04, 2020		U-257	M-206 Aug 21, 2020
		6642245*PED	May 04, 2021			M-207 Aug 21, 2020
		6703396	Mar 09, 2021	DS DP		NCE Nov 05, 2020
		6703396*PED	Sep 09, 2021			
		6838464	Feb 26, 2021	DS DP		
		7125879	Apr 21, 2025	DS DP	U-257	
		7390791	Apr 17, 2025	DS DP		
		7803788	Feb 02, 2022		U-257	
		8080551	Apr 11, 2023	DS DP		
		8101629	Aug 09, 2022	DP		
		8754065	Aug 15, 2032	DS DP	U-257	
		9296769	Aug 15, 2032	DS DP	U-257	
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA</u>						
N 202123	001	10857102	Jan 14, 2033	DP		
		6642245	Nov 04, 2020		U-257	
		6703396	Mar 09, 2021	DS DP		
		6838464	Feb 26, 2021	DS DP		
		7125879	Apr 21, 2025	DS DP	U-257	
		8080551	Apr 11, 2023	DS DP		
		8101629	Aug 09, 2022	DP		
		8592397	Jan 13, 2024	DP	U-257	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA</u>						
N 202123	001	8716264	Jan 13, 2024	DP	U-257	
		8841310	Dec 09, 2025	DP	U-257	
		9457036	Jan 13, 2024	DP	U-257	
		9744181	Jan 13, 2024	DP	U-257	
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215	001	6642245	Nov 04, 2020		U-1663	I-812 Oct 03, 2022
		6642245*PED	May 04, 2021			NCE Nov 05, 2020
		6703396	Mar 09, 2021	DS DP		NPP Sep 28, 2020
		6703396*PED	Sep 09, 2021			ODE-284 Sep 28, 2024
		7390791	Apr 17, 2025	DS DP		ODE-285 Sep 28, 2024
		7803788	Feb 02, 2022		U-1663	
		8754065	Aug 15, 2032	DS DP	U-1259	
		8754065	Aug 15, 2032	DS DP	U-1663	
		8754065	Aug 15, 2032	DS DP	U-257	
		9296769	Aug 15, 2032	DS DP	U-1259	
		9296769	Aug 15, 2032	DS DP	U-1663	
		9296769	Aug 15, 2032	DS DP	U-257	
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752	001	6642245	Nov 04, 2020		U-1170	
		6642245	Nov 04, 2020		U-248	
		6642245	Nov 04, 2020		U-541	
		6703396	Mar 09, 2021	DS DP		
		8592397	Jan 13, 2024	DP	U-1170	
		8592397	Jan 13, 2024	DP	U-248	
		8592397	Jan 13, 2024	DP	U-541	
		8716264	Jan 13, 2024	DP	U-257	
		9457036	Jan 13, 2024	DP	U-257	
		9744181	Jan 13, 2024	DP	U-257	
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752	002	6642245	Nov 04, 2020		U-1170	
		6642245	Nov 04, 2020		U-248	
		6642245	Nov 04, 2020		U-541	
		6642245*PED	May 04, 2021			
		6703396	Mar 09, 2021	DS DP		
		6703396*PED	Sep 09, 2021			
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752	003	6642245	Nov 04, 2020		U-1170	
		6642245	Nov 04, 2020		U-248	
		6642245	Nov 04, 2020		U-541	
		6642245*PED	May 04, 2021			
		6703396	Mar 09, 2021	DS DP		
		6703396*PED	Sep 09, 2021			
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752	004	6642245	Nov 04, 2020		U-1170	
		6642245	Nov 04, 2020		U-248	
		6642245	Nov 04, 2020		U-541	
		6642245*PED	May 04, 2021			
		6703396	Mar 09, 2021	DS DP		
		6703396*PED	Sep 09, 2021			
<u>ENALAPRIL MALEATE - EPANED KIT</u>						
N 204308	001	8568747	Nov 06, 2032	DP		
		8778366	Nov 06, 2032		U-1723	
		8778366	Nov 06, 2032		U-185	
		8778366	Nov 06, 2032		U-1892	
		8778366	Nov 06, 2032		U-3	
		8778366	Nov 06, 2032		U-71	
		9855214	Nov 06, 2032	DP		
		9968553	Nov 06, 2032		U-1723	
		9968553	Nov 06, 2032		U-185	
		9968553	Nov 06, 2032		U-1892	
		9968553	Nov 06, 2032		U-3	
		9968553	Nov 06, 2032		U-71	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ENALAPRIL MALEATE - EPANED</u>						
N 208686	001	10039745	Mar 25, 2036	DP		
		10154987	Mar 25, 2036	U-1723		
		10154987	Mar 25, 2036	U-185		
		10154987	Mar 25, 2036	U-1892		
		10154987	Mar 25, 2036	U-3		
		10154987	Mar 25, 2036	U-71		
		10772868	Mar 25, 2036	DP		
		10786482	Mar 25, 2036	DP		
		9669008	Mar 25, 2036	DP		
		9808442	Mar 25, 2036	U-1723		
		9808442	Mar 25, 2036	U-185		
		9808442	Mar 25, 2036	U-1892		
		9808442	Mar 25, 2036	U-3		
		9808442	Mar 25, 2036	U-71		
<u>ENASIDENIB MESYLATE - IDHIFA</u>						
N 209606	001	10093654	Aug 01, 2034	DS DP	U-2087	NCE Aug 01, 2022
		10294215	Jan 07, 2033	DP	U-2087	ODE-151 Aug 01, 2024
		10610125	Jun 21, 2030		U-2087	
		9512107	Jan 07, 2033	DS DP	U-2087	
		9732062	Sep 16, 2034	DS		
		9738625	Aug 01, 2034	DS		
<u>ENASIDENIB MESYLATE - IDHIFA</u>						
N 209606	002	10093654	Aug 01, 2034	DS DP	U-2087	NCE Aug 01, 2022
		10294215	Jan 07, 2033	DP	U-2087	ODE-151 Aug 01, 2024
		10610125	Jun 21, 2030		U-2087	
		9512107	Jan 07, 2033	DS DP	U-2087	
		9732062	Sep 16, 2034	DS		
		9738625	Aug 01, 2034	DS		
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496	001	10005761	Aug 27, 2030		U-2335	I-826 Apr 08, 2023
		8501758	Mar 04, 2031	DS DP		NCE Jun 27, 2023
		8541575	Feb 26, 2030	DS DP	U-2335	ODE-194 Jun 27, 2025
		8946250	Jul 23, 2029	DS DP		
		9314464	Jul 04, 2031		U-2336	
		9387208	Nov 21, 2032		DP	
		9593099	Aug 27, 2030	DS		
		9593100	Aug 27, 2030		DP	
		9763941	Nov 21, 2032		U-2335	
		9850229	Aug 27, 2030		U-2337	
		9850230	Aug 27, 2030		U-2334	
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496	002	10005761	Aug 27, 2030		U-2335	I-826 Apr 08, 2023
		10005761	Aug 27, 2030		U-2802	NCE Jun 27, 2023
		10005761	Aug 27, 2030		U-2803	ODE-194 Jun 27, 2025
		10258622	Nov 21, 2032		U-2802	
		8501758	Mar 04, 2031	DS DP		
		8541575	Feb 26, 2030	DS DP	U-2335	
		8541575	Feb 26, 2030	DS DP	U-2802	
		8541575	Feb 26, 2030	DS DP	U-2803	
		8946250	Jul 23, 2029	DS DP		
		9314464	Jul 04, 2031		U-2336	
		9314464	Jul 04, 2031		U-2802	
		9314464	Jul 04, 2031		U-2803	
		9387208	Nov 21, 2032		DP	
		9474754	Aug 05, 2033		DP U-2802	
		9593099	Aug 27, 2030	DS		
		9593100	Aug 27, 2030		DP	
		9763941	Nov 21, 2032		U-2335	
		9850229	Aug 27, 2030		U-2337	
		9850230	Aug 27, 2030		U-2334	
		9850230	Aug 27, 2030		U-2802	
		9850230	Aug 27, 2030		U-2803	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 001	10231965	Feb 17, 2035	U-2617		NCE	Aug 15, 2024
	10231965	Feb 17, 2035	U-2618		ODE-265	Aug 15, 2026
	10398693	Jul 18, 2038	DP		ODE-313	Aug 15, 2026
	10561651	Feb 19, 2035	U-2745			
	10738037	May 18, 2037	DS DP U-2946			
	8299057	Mar 01, 2029	DS DP			
	8673893	Jul 08, 2028	U-2617			
	8673893	Jul 08, 2028	U-2618			
	9029356	Jul 08, 2028	DS DP			
	9085558	Jul 08, 2028	DP			
	9085565	May 22, 2033	DS DP			
	9255087	Jul 08, 2028	U-2617			
	9255087	Jul 08, 2028	U-2618			
	9616059	Jul 08, 2028	U-2618			
	9649306	May 22, 2033	U-2617			
	9649306	May 22, 2033	U-2618			
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 002	10231965	Feb 17, 2035	U-2617		NCE	Aug 15, 2024
	10231965	Feb 17, 2035	U-2618		ODE-265	Aug 15, 2026
	10398693	Jul 18, 2038	DP		ODE-313	Aug 15, 2026
	10561651	Feb 19, 2035	U-2745			
	10738037	May 18, 2037	DS DP U-2946			
	8299057	Mar 01, 2029	DS DP			
	8673893	Jul 08, 2028	U-2617			
	8673893	Jul 08, 2028	U-2618			
	9029356	Jul 08, 2028	DS DP			
	9085558	Jul 08, 2028	DP			
	9085565	May 22, 2033	DS DP			
	9255087	Jul 08, 2028	U-2617			
	9255087	Jul 08, 2028	U-2618			
	9616059	Jul 08, 2028	U-2618			
	9649306	May 22, 2033	U-2617			
	9649306	May 22, 2033	U-2618			
<u>ENZALUTAMIDE - XTANDI</u>						
N 203415 001	7709517	Aug 13, 2027	DS DP		I-786	Jul 13, 2021
	8183274	Aug 24, 2026	U-1281		I-808	Dec 16, 2022
	8183274	Aug 24, 2026	U-1588			
	8183274	Aug 24, 2026	U-2345			
	8183274	Aug 24, 2026	U-2708			
	9126941	May 15, 2026	U-1588			
	9126941	May 15, 2026	U-2345			
	9126941	May 15, 2026	U-2708			
<u>ENZALUTAMIDE - XTANDI</u>						
N 213674 001	7709517	Aug 13, 2027	DS DP		I-786	Jul 13, 2021
	8183274	Aug 24, 2026	U-2345		I-808	Dec 16, 2022
	8183274	Aug 24, 2026	U-2708			
	9126941	May 15, 2026	U-2345			
	9126941	May 15, 2026	U-2708			
<u>ENZALUTAMIDE - XTANDI</u>						
N 213674 002	7709517	Aug 13, 2027	DS DP		I-786	Jul 13, 2021
	8183274	Aug 24, 2026	U-2345		I-808	Dec 16, 2022
	8183274	Aug 24, 2026	U-2708			
	9126941	May 15, 2026	U-2345			
	9126941	May 15, 2026	U-2708			
<u>EPHEDRINE SULFATE - EPHEDRINE SULFATE</u>						
N 213994 001	10869845	Jan 22, 2040	DP			
<u>EPINEPHRINE - EPIPEN</u>						
N 019430 001	7449012	Sep 11, 2025	DP			
	7794432	Sep 11, 2025	DP			
	8048035	Sep 11, 2025	DP			
	8870827	Sep 11, 2025	DP			
	9586010	Sep 11, 2025	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EPINEPHRINE - EPIPEN JR.</u>						
N 019430	002 7449012	Sep 11, 2025	DP			
	7794432	Sep 11, 2025	DP			
	8048035	Sep 11, 2025	DP			
	8870827	Sep 11, 2025	DP			
	9586010	Sep 11, 2025	DP			
<u>EPINEPHRINE - TWINJECT 0.3</u>						
N 020800	001 7297136	Jan 18, 2025	DP			
	7621891	Feb 04, 2025	DP			
<u>EPINEPHRINE - TWINJECT 0.15</u>						
N 020800	002 7297136	Jan 18, 2025	DP			
	7621891	Feb 04, 2025	DP			
<u>EPINEPHRINE - ADRENALIN</u>						
N 020800	003 10166334	Jan 21, 2025	DP			
	7905352	Apr 12, 2027	DP			
<u>EPINEPHRINE - ADRENALIN</u>						
N 020800	004 10166334	Jan 21, 2025	DP			
	7905352	Apr 12, 2027	DP			
<u>EPINEPHRINE - AUVI-O</u>						
N 201739	001 10314977	Nov 23, 2024	DP			
	10335549	Apr 30, 2025	DP			
	10737028	Nov 23, 2024	DP			
	7731686	Jun 01, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
	8608698	Nov 23, 2024	DP			
	8920377	Nov 23, 2024	DP			
	8926594	Mar 31, 2026	DP			
	9056170	Nov 23, 2024	DP			
	9149579	Jul 19, 2025	DP		U-1758	
	9238108	Feb 20, 2027	DP			
	9259539	Feb 01, 2026	DP			
	9278182	Feb 01, 2026	DP			
	9724471	May 23, 2027	DP		U-2092	
	9737669	Nov 23, 2024	DP			
<u>EPINEPHRINE - AUVI-O</u>						
N 201739	002 10314977	Nov 23, 2024	DP			
	10335549	Apr 30, 2025	DP			
	10688244	Dec 21, 2037	DP		U-2980	
	10737028	Nov 23, 2024	DP			
	10824938	Dec 21, 2037	DP		U-2980	
	7731686	Jun 01, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
	8608698	Nov 23, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739	002	8920377	Nov 23, 2024	DP		
		8926594	Mar 31, 2026	DP		
		9056170	Nov 23, 2024	DP		
		9149579	Jul 19, 2025		U-1758	
		9238108	Feb 20, 2027	DP		
		9259539	Feb 01, 2026	DP		
		9278182	Feb 01, 2026	DP		
		9724471	May 23, 2027	DP	U-2092	
		9737669	Nov 23, 2024	DP		
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739	003	10314977	Nov 23, 2024	DP		
		10335549	Apr 30, 2025	DP		
		10688244	Dec 21, 2037	DP	U-2980	
		10737028	Nov 23, 2024	DP		
		10824938	Dec 21, 2037	DP	U-2980	
		7731686	Jun 01, 2026	DP		
		7731690	Jan 15, 2025	DP		
		7749194	Oct 30, 2028	DP		
		7918823	Nov 23, 2024	DP		
		7947017	Mar 12, 2028	DP		
		8016788	Mar 21, 2025	DP		
		8021344	Nov 02, 2029	DP		
		8206360	Feb 27, 2027	DP		
		8226610	Apr 10, 2029	DP		
		8231573	Nov 25, 2028	DP		
		8313466	Nov 23, 2024	DP		
		8361029	Nov 23, 2024	DP		
		8425462	Nov 23, 2024	DP		
		8608698	Nov 23, 2024	DP		
		8920377	Nov 23, 2024	DP		
		8926594	Mar 31, 2026	DP		
		9056170	Nov 23, 2024	DP		
		9149579	Jul 19, 2025		U-1758	
		9238108	Feb 20, 2027	DP		
		9259539	Feb 01, 2026	DP		
		9278182	Feb 01, 2026	DP		
		9724471	May 23, 2027	DP	U-2092	
		9737669	Nov 23, 2024	DP		
		9833573	Nov 23, 2024		U-2172	
<u>EPINEPHRINE - ADRENALIN</u>						
N 204200	001	9119876	Mar 13, 2035	DP		
		9295657	Mar 13, 2035		U-1829	
<u>EPINEPHRINE - ADRENALIN</u>						
N 204640	001	10130592	Mar 13, 2035	DP		
		9119876	Mar 13, 2035	DP		
		9295657	Mar 13, 2035		U-1829	
<u>EPINEPHRINE - EPINEPHRINE</u>						
N 205029	001	10004700	Aug 14, 2034	DP	U-2325	
		10039728	Aug 14, 2034		U-1828	
		9283197	Aug 15, 2034	DP	U-1828	
		9283197	Aug 15, 2034	DP	U-1829	
		9283197	Aug 15, 2034	DP	U-1830	
<u>EPINEPHRINE - PRIMATENE MIST</u>						
N 205920	001	8367734	Jan 26, 2026	DP	NP	Nov 07, 2021
<u>EPINEPHRINE; LIDOCAINE HYDROCHLORIDE - LIDOSITE TOPICAL SYSTEM KIT</u>						
N 021504	001	6629968	Jun 30, 2020	DS DP		
		6635045	Jun 29, 2021	DS DP		
<u>EPOPROSTENOL SODIUM - VELETRI</u>						
N 022260	001	8318802	Mar 15, 2027	DP		
		8598227	Feb 02, 2027			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EPOPROSTENOL SODIUM - VELETRI</u>						
N 022260	002	8318802	Mar 15, 2027	DP		
		8598227	Feb 02, 2027			
<u>ERAVACYCLINE DIHYDROCHLORIDE - XERAVA</u>						
N 211109	001	8796245	Aug 07, 2029	U-2380	NCE	Aug 27, 2023
		8906887	Dec 28, 2030	DP	GAIN	Aug 27, 2028
<u>ERDAFITINIB - BALVERSA</u>						
N 212018	001	8895601	May 22, 2031	DS DP	NCE	Apr 12, 2024
		9464071	Apr 28, 2031	U-2518		
		9902714	Mar 26, 2035	DP		
<u>ERDAFITINIB - BALVERSA</u>						
N 212018	002	8895601	May 22, 2031	DS DP	NCE	Apr 12, 2024
		9464071	Apr 28, 2031	U-2518		
		9902714	Mar 26, 2035	DP		
<u>ERDAFITINIB - BALVERSA</u>						
N 212018	003	8895601	May 22, 2031	DS DP	NCE	Apr 12, 2024
		9464071	Apr 28, 2031	U-2518		
		9902714	Mar 26, 2035	DP		
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N 201532	001	6214865	Jul 20, 2023	DS	ODE-107	Jan 28, 2023
		8097648	Jan 22, 2021	U-1096		
		RE46965	Jan 08, 2027	DP		
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743	001	6900221	Nov 09, 2020	DS DP	U-1046	
		6900221	Nov 09, 2020	DS DP	U-1403	
		6900221	Nov 09, 2020	DS DP	U-659	
		6900221	Nov 09, 2020	DS DP	U-875	
		6900221*PED	May 09, 2021			
		7087613	Nov 09, 2020	U-1045		
		7087613	Nov 09, 2020	U-1403		
		7087613	Nov 09, 2020	U-659		
		7087613*PED	May 09, 2021			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743	002	6900221	Nov 09, 2020	DS DP	U-1046	
		6900221	Nov 09, 2020	DS DP	U-1403	
		6900221	Nov 09, 2020	DS DP	U-659	
		6900221	Nov 09, 2020	DS DP	U-875	
		6900221*PED	May 09, 2021			
		7087613	Nov 09, 2020	U-1045		
		7087613	Nov 09, 2020	U-1403		
		7087613	Nov 09, 2020	U-659		
		7087613*PED	May 09, 2021			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743	003	6900221	Nov 09, 2020	DS DP	U-1046	
		6900221	Nov 09, 2020	DS DP	U-1403	
		6900221	Nov 09, 2020	DS DP	U-659	
		6900221	Nov 09, 2020	DS DP	U-875	
		6900221*PED	May 09, 2021			
		7087613	Nov 09, 2020	U-1045		
		7087613	Nov 09, 2020	U-1403		
		7087613	Nov 09, 2020	U-659		
		7087613*PED	May 09, 2021			
<u>ERTUGLIFLOZIN - STEGLATRO</u>						
N 209803	001	8080580	Jul 13, 2030	DS DP	U-2214	NCE
<u>ERTUGLIFLOZIN - STEGLATRO</u>						
N 209803	002	8080580	Jul 13, 2030	DS DP	U-2214	NCE
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET</u>						
N 209806	001	8080580	Jul 13, 2030	DS DP	U-2214	NCE
		9308204	Oct 21, 2030	DP		
		9439902	Oct 21, 2030	U-2214		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET</u>						
N 209806 002	8080580	Jul 13, 2030	DS DP	U-2214	NCE	Dec 19, 2022
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030		U-2214		
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET</u>						
N 209806 003	8080580	Jul 13, 2030	DS DP	U-2214	NCE	Dec 19, 2022
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030		U-2214		
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET</u>						
N 209806 004	8080580	Jul 13, 2030	DS DP	U-2214	NCE	Dec 19, 2022
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030		U-2214		
<u>ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN</u>						
N 209805 001	6699871	Jul 26, 2022	DS DP	U-2214	NCE	Dec 19, 2022
	6699871*PED	Jan 26, 2023				
	7326708	Nov 24, 2026	DS DP	U-2214		
	7326708*PED	May 24, 2027				
	8080580	Jul 13, 2030	DS DP	U-2214		
	9308204	Oct 21, 2030	DP			
	9439901	Oct 21, 2030		U-2214		
<u>ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN</u>						
N 209805 002	6699871	Jul 26, 2022	DS DP	U-2214	NCE	Dec 19, 2022
	6699871*PED	Jan 26, 2023				
	7326708	Nov 24, 2026	DS DP	U-2214		
	7326708*PED	May 24, 2027				
	8080580	Jul 13, 2030	DS DP	U-2214		
	9308204	Oct 21, 2030	DP			
	9439901	Oct 21, 2030		U-2214		
<u>ERYTHROMYCIN ETHYLSUCCINATE - ERYTHROMYCIN ETHYLSUCCINATE</u>						
A 211991 001					CGT	May 09, 2020
<u>ERYTHROMYCIN ETHYLSUCCINATE - ERYTHROMYCIN ETHYLSUCCINATE</u>						
A 211991 002					CGT	May 09, 2020
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N 021323 001	6916941	Aug 12, 2022	DS DP			
	7420069	Aug 12, 2022		DP		
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N 021323 002	6916941	Aug 12, 2022	DS DP			
	7420069	Aug 12, 2022		DP		
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N 021323 003	6916941	Aug 12, 2022	DS DP			
	7420069	Aug 12, 2022		DP		
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001	8785500	Jul 09, 2031		U-2502	I-840	Jul 31, 2023
	9592207	Mar 20, 2027		U-2502	NCE*	Mar 05, 2024
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	10675287	May 06, 2025		U-2041		
	10675287	May 06, 2025		U-2831		
	10695354	May 06, 2025		U-2501		
	10695354	May 06, 2025		U-2831		
	10702536	May 06, 2025		U-2501		
	5753646	Jun 27, 2021	DS DP	U-2041		
	8372431	Apr 17, 2030		DP		
	9206135	Apr 21, 2026	DS			
	9566244	Oct 23, 2028		DP		
	9643929	Apr 21, 2026		DP		
	9750747	Aug 24, 2032		U-2041		
	9750747	Aug 24, 2032		U-2121		
	9763954	Sep 13, 2028		U-2123		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	10675287	May 06, 2025	U-2041			
	10675287	May 06, 2025	U-2831			
	10695354	May 06, 2025	U-2501			
	10695354	May 06, 2025	U-2831			
	10702536	May 06, 2025	U-2501			
	5753646	Jun 27, 2021	DS DP U-2041			
	8372431	Apr 17, 2030	DP			
	9206135	Apr 21, 2026	DS			
	9566244	Oct 23, 2028	DP			
	9643929	Apr 21, 2026	DP			
	9750747	Aug 24, 2032	U-2041			
	9750747	Aug 24, 2032	U-2121			
	9763954	Sep 13, 2028	U-2123			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 003	10675287	May 06, 2025	U-2041			
	10675287	May 06, 2025	U-2831			
	10695354	May 06, 2025	U-2501			
	10695354	May 06, 2025	U-2831			
	10702536	May 06, 2025	U-2501			
	5753646	Jun 27, 2021	DS DP U-2041			
	8372431	Apr 17, 2030	DP			
	9206135	Apr 21, 2026	DS			
	9566244	Oct 23, 2028	DP			
	9643929	Apr 21, 2026	DP			
	9750747	Aug 24, 2032	U-2041			
	9750747	Aug 24, 2032	U-2121			
	9763954	Sep 13, 2028	U-2123			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	10675287	May 06, 2025	U-2041			
	10675287	May 06, 2025	U-2831			
	10695354	May 06, 2025	U-2501			
	10695354	May 06, 2025	U-2831			
	10702536	May 06, 2025	U-2501			
	5753646	Jun 27, 2021	DS DP U-2041			
	8372431	Apr 17, 2030	DP			
	9206135	Apr 21, 2026	DS			
	9566244	Oct 23, 2028	DP			
	9643929	Apr 21, 2026	DP			
	9750747	Aug 24, 2032	U-2041			
	9750747	Aug 24, 2032	U-2121			
	9763954	Sep 13, 2028	U-2123			
<u>ESMOLOL HYDROCHLORIDE - BREVIBLOC IN PLASTIC CONTAINER</u>						
N 019386 004	6310094	Jan 12, 2021				
	6528540	Jan 12, 2021				
<u>ESMOLOL HYDROCHLORIDE - BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER</u>						
N 019386 005	6310094	Jan 12, 2021				
	6528540	Jan 12, 2021				
<u>ESMOLOL HYDROCHLORIDE - BREVIBLOC</u>						
N 019386 006	6310094	Jan 12, 2021				
	6528540	Jan 12, 2021				
<u>ESMOLOL HYDROCHLORIDE - BREVIBLOC</u>						
N 019386 007	6310094	Jan 12, 2021				
	6528540	Jan 12, 2021				
<u>ESMOLOL HYDROCHLORIDE - ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER</u>						
N 205703 001	6310094	Jan 12, 2021	DP			
	6528540	Jan 12, 2021	DP			
	8829054	Mar 15, 2033	DP			
	8835505	Mar 15, 2033	DP			
<u>ESMOLOL HYDROCHLORIDE - ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER</u>						
N 205703 002	6310094	Jan 12, 2021	DP			
	6528540	Jan 12, 2021	DP			
	8829054	Mar 15, 2033	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESMOLOL HYDROCHLORIDE - ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER</u>						
N 205703	002	8835505	Mar 15, 2033	DP		
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR</u>						
N 204655	001	6428810*PED	May 03, 2020			
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR</u>						
N 207920	001	6428810*PED	May 03, 2020			
<u>ESOMEPRAZOLE MAGNESIUM - ESOMEPRAZOLE MAGNESIUM</u>						
N 214278	001	10076494	Dec 08, 2036	DP		
		10835488	Dec 08, 2036	DP		
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511	001	6926907	Feb 28, 2023	DP U-1052	NPP	Jul 06, 2020
		8557285	May 31, 2022	DP		
		8852636	May 31, 2022	DP U-1052		
		8858996	May 31, 2022	DP U-1052		
		8945621	Oct 17, 2031	U-1661		
		9161920	May 31, 2022	U-1760		
		9198888	May 31, 2022	U-1781		
		9220698	Mar 10, 2031	U-1781		
		9345695	May 31, 2022	DP		
		9393208	Sep 03, 2029	U-1781		
		9707181	May 31, 2022	DP		
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511	002	6926907	Feb 28, 2023	DP U-1052	NPP	Jul 06, 2020
		8557285	May 31, 2022	DP		
		8852636	May 31, 2022	DP U-1052		
		8858996	May 31, 2022	DP U-1052		
		8945621	Oct 17, 2031	U-1661		
		9161920	May 31, 2022	U-1760		
		9198888	May 31, 2022	U-1781		
		9345695	May 31, 2022	DP		
		9393208	Sep 03, 2029	U-1781		
		9707181	May 31, 2022	DP		
<u>ESTRADIOL - VAGIFEM</u>						
N 020908	002	7018992	Sep 17, 2022	U-1023		
<u>ESTRADIOL - ELESTRIN</u>						
N 021813	001	7198801	Jun 25, 2022	DP		
		7470433	Aug 03, 2021	DP		
<u>ESTRADIOL - EVAMIST</u>						
N 022014	001	6978945	Jul 31, 2022	DP		
<u>ESTRADIOL - MINIVELLE</u>						
N 203752	001	6841716	Apr 27, 2020	DP		
		8231906	Jul 04, 2030	DS DP		
		9730900	Jul 10, 2028		U-2086	
		9833419	Jul 10, 2028	DP		
<u>ESTRADIOL - MINIVELLE</u>						
N 203752	002	6841716	Apr 27, 2020	DP		
		8231906	Jul 04, 2030	DS DP		
		9730900	Jul 10, 2028		U-2086	
		9833419	Jul 10, 2028	DP		
<u>ESTRADIOL - MINIVELLE</u>						
N 203752	003	6841716	Apr 27, 2020	DP		
		8231906	Jul 04, 2030	DS DP		
		9730900	Jul 10, 2028		U-2086	
		9833419	Jul 10, 2028	DP		
<u>ESTRADIOL - MINIVELLE</u>						
N 203752	004	6841716	Apr 27, 2020	DP		
		8231906	Jul 04, 2030	DS DP		
		9730900	Jul 10, 2028		U-2086	
		9833419	Jul 10, 2028	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESTRADIOL - MINIVELLE</u>						
N 203752	005	6841716				
		8231906				
		9724310				
		9730900				
		9833419				
			Apr 27, 2020	DP		
			Jul 04, 2030	DS DP		
			Jul 10, 2028	DS DP		
			Jul 10, 2028	DP	U-2086	
			Jul 10, 2028	DP		
<u>ESTRADIOL - IMVEXXY</u>						
N 208564	001	10258630				
		10258630				
		10398708				
		10398708				
		10471072				
		10471072				
		10537581				
		10537581				
		10568891				
		10568891				
		10668082				
		10668082				
		10806697				
		10835487				
		10835487				
		9180091				
		9180091				
		9289382				
			Dec 20, 2033		NP	May 29, 2021
			Dec 20, 2033	U-2316		
			Dec 20, 2033	U-2317		
			Dec 20, 2033	U-2317		
			Dec 20, 2033	U-2614		
			Jun 18, 2033	U-2316		
			Jun 18, 2033	U-2317		
			Nov 21, 2032	DP U-2316		
			Nov 21, 2032	DP U-2317		
			Jun 18, 2033	U-2316		
			Jun 18, 2033	U-2317		
			Jun 18, 2033	U-2316		
			Jun 18, 2033	U-2317		
			Nov 21, 2032	DP		
			Nov 21, 2032	U-2316		
			Nov 21, 2032	U-2317		
			Dec 20, 2033	DP U-2316		
			Dec 20, 2033	DP U-2317		
			Nov 21, 2032	DP		
<u>ESTRADIOL - IMVEXXY</u>						
N 208564	002	10258630				
		10258630				
		10398708				
		10398708				
		10471072				
		10471072				
		10537581				
		10537581				
		10568891				
		10568891				
		10668082				
		10668082				
		10806697				
		10835487				
		10835487				
		9180091				
		9180091				
		9289382				
			Dec 20, 2033		NP	May 29, 2021
			Dec 20, 2033	U-2316		
			Dec 20, 2033	U-2317		
			Dec 20, 2033	U-2317		
			Dec 20, 2033	U-2614		
			Jun 18, 2033	U-2316		
			Jun 18, 2033	U-2317		
			Nov 21, 2032	DP U-2316		
			Nov 21, 2032	DP U-2317		
			Jun 18, 2033	U-2316		
			Jun 18, 2033	U-2317		
			Jun 18, 2033	U-2316		
			Jun 18, 2033	U-2317		
			Nov 21, 2032	DP		
			Nov 21, 2032	U-2316		
			Nov 21, 2032	U-2317		
			Dec 20, 2033	DP U-2316		
			Dec 20, 2033	DP U-2317		
			Nov 21, 2032	DP		
<u>ESTRADIOL ACETATE - FEMTRACE</u>						
N 021633	001	6962908				
		7572779				
		7799771				
			Dec 21, 2021	DP		
			Oct 02, 2025	U-904		
			Dec 21, 2021	DP		
<u>ESTRADIOL ACETATE - FEMTRACE</u>						
N 021633	002	6962908				
		7572779				
		7799771				
			Dec 21, 2021	DP		
			Oct 02, 2025	U-904		
			Dec 21, 2021	DP		
<u>ESTRADIOL ACETATE - FEMTRACE</u>						
N 021633	003	6962908				
		7572779				
		7799771				
			Dec 21, 2021	DP		
			Oct 02, 2025	U-904		
			Dec 21, 2021	DP		
<u>ESTRADIOL; ESTRADIOL; NORGESTIMATE - PREFEST</u>						
N 021040	001	6747019				
		7320970				
			Mar 20, 2020	U-311		
			Mar 30, 2020	DP U-844		
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132	001	10052386				
		10206932				
		10639375				
		10675288				
			Nov 21, 2032	DP	NP	Oct 28, 2021
			Nov 21, 2032	U-2439		
			Nov 21, 2032	DP		
			Nov 21, 2032	U-2439		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132	001	10806740	Nov 21, 2032	DP	U-2439	
		8633178	Nov 21, 2032	DP		
		8846648	Nov 21, 2032		U-2439	
		8846649	Nov 21, 2032	DP	U-2439	
		8987237	Nov 21, 2032	DP		
		8993548	Nov 21, 2032	DP		
		8993549	Nov 21, 2032	DP		
		9006222	Nov 21, 2032	DP	U-2439	
		9114145	Nov 21, 2032		U-2439	
		9114146	Nov 21, 2032	DP	U-2439	
		9301920	Nov 21, 2032	DP	U-2439	
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVA</u>						
N 021443	001	6660726	Mar 08, 2021	DS DP	U-904	
		6660726	Mar 08, 2021	DS DP	U-905	
		6855703	Feb 12, 2021	DS DP	U-904	
		6855703	Feb 12, 2021	DS DP	U-905	
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVA</u>						
N 021443	002	6660726	Mar 08, 2021	DS DP	U-904	
		6660726	Mar 08, 2021	DS DP	U-905	
		6855703	Feb 12, 2021	DS DP	U-904	
		6855703	Feb 12, 2021	DS DP	U-905	
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVA</u>						
N 021443	003	6660726	Mar 08, 2021	DS DP	U-904	
		6660726	Mar 08, 2021	DS DP	U-905	
		6855703	Feb 12, 2021	DS DP	U-904	
		6855703	Feb 12, 2021	DS DP	U-905	
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVA</u>						
N 021443	004	6660726	Mar 08, 2021	DS DP	U-904	
		6660726	Mar 08, 2021	DS DP	U-905	
		6855703	Feb 12, 2021	DS DP	U-904	
		6855703	Feb 12, 2021	DS DP	U-905	
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVA</u>						
N 021443	005	6660726	Mar 08, 2021	DS DP	U-904	
		6660726	Mar 08, 2021	DS DP	U-905	
		6855703	Feb 12, 2021	DS DP	U-904	
		6855703	Feb 12, 2021	DS DP	U-905	
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325	001	10344765	Jun 27, 2034	DP		NCE Feb 07, 2022
		8377880	Jul 29, 2030	DS DP		
		8999932	Feb 07, 2031	DS DP	U-2014	
		9278995	Jul 29, 2030	DS		
		9701712	Jul 29, 2030	DS DP	U-2014	
		9820938	Jun 27, 2034	DP		
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325	002	10344765	Jun 27, 2034	DP		NCE Feb 07, 2022
		8377880	Jul 29, 2030	DS DP		
		8999932	Feb 07, 2031	DS DP	U-2014	
		9278995	Jul 29, 2030	DS		
		9701712	Jul 29, 2030	DS DP	U-2014	
		9820938	Jun 27, 2034	DP		
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325	003	10344765	Jun 27, 2034	DP		NCE Feb 07, 2022
		8377880	Jul 29, 2030	DS DP		
		8999932	Feb 07, 2031	DS DP	U-2014	
		9278995	Jul 29, 2030	DS		
		9701712	Jul 29, 2030	DS DP	U-2014	
		9820938	Jun 27, 2034	DP		
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488	001	10337003	Mar 14, 2034		U-1918	NCE Sep 19, 2021
		10364431	Mar 14, 2034		U-1918	ODE-122 Sep 19, 2023
		10364431	Mar 14, 2034		U-1919	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488	001	10533174	May 04, 2021	DP		
		10781451	Jun 28, 2025	DS DP		
		8486907	Jun 28, 2025		U-1904	Y
		9018368	Jun 28, 2025	DS DP		
		9243245	Oct 27, 2028	DS	U-2097	
		9243245	Oct 27, 2028	DS	U-2098	
		9416361	May 04, 2021	DS		
		9506058	Mar 14, 2034		U-1918	
		9506058	Mar 14, 2034		U-1919	
		RE47751	Jun 28, 2025		U-1918	
		RE47751	Jun 28, 2025		U-2664	
		RE47751	Jun 28, 2025		U-2673	
		RE47751	Jun 28, 2025		U-2674	
		RE47769	Jun 28, 2025	DP		
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488	002	10337003	Mar 14, 2034		U-1918	NCE
		10364431	Mar 14, 2034		U-1918	ODE-122
		10364431	Mar 14, 2034		U-1919	
		10533174	May 04, 2021	DP		
		10781451	Jun 28, 2025	DS DP		
		8486907	Jun 28, 2025		U-1904	Y
		9018368	Jun 28, 2025	DS DP		
		9243245	Oct 27, 2028	DS	U-2097	
		9243245	Oct 27, 2028	DS	U-2098	
		9416361	May 04, 2021	DS		
		9506058	Mar 14, 2034		U-1918	
		9506058	Mar 14, 2034		U-1919	
		RE47751	Jun 28, 2025		U-1918	
		RE47751	Jun 28, 2025		U-2664	
		RE47751	Jun 28, 2025		U-2673	
		RE47751	Jun 28, 2025		U-2674	
		RE47769	Jun 28, 2025	DP		
<u>ETHINYL ESTRADIOL; ETHINYL ESTRADIOL; LEVONORGESTREL - SEASONIQUE</u>						
N 021840	001	7320969	Jan 30, 2024		U-828	
		7615545	Jun 15, 2023		U-1	
		7855190	Dec 05, 2028		U-1	
		7858605	Jun 23, 2023	DP		
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - PREVEN EMERGENCY CONTRACEPTIVE KIT</u>						
N 020946	001	6156742	Dec 05, 2020		U-374	
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - LOSEASONIQUE</u>						
N 022262	001	7615545	Jun 15, 2023		U-1	
		7855190	Dec 05, 2028		U-1	
		7858605	Jun 23, 2023	DP		
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - TWIRLA</u>						
N 204017	001	7045145	Mar 14, 2021	DP	U-2751	NP
		7384650	Mar 14, 2021	DP		
		8221784	Mar 14, 2021	DP		
		8221785	Mar 14, 2021	DP		
		8246978	Aug 26, 2028	DP		
		8747888	Jul 10, 2028	DP		
		8883196	Nov 22, 2020	DP	U-2751	
		9050348	Jul 10, 2028	DP		
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - QUARTETTE</u>						
N 204061	001	8415332	Mar 11, 2029	DP		
		8450299	Oct 07, 2025		U-1	
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - BALCOLTRA</u>						
N 208612	001	6716814	Aug 16, 2021	DS DP		
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LO LOESTRIN FE</u>						
N 022501	001	7704984	Feb 02, 2029		U-1090	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - TAYTULLA</u>						
N 204426	001 6652880	Mar 29, 2020	DP			
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LO MINASTRIN FE</u>						
N 204654	001 7704984	Feb 02, 2029	U-1			
<u>ETHINYL ESTRADIOL; SEGESTERONE ACETATE - ANNOVERA</u>						
N 209627	001 10632066	Feb 01, 2039	U-2786		NCE	Aug 10, 2023
	10632066	Feb 01, 2039	U-2787			
	10765628	Feb 01, 2039	U-2786			
	10765628	Feb 01, 2039	U-2787			
	10780047	Feb 01, 2039	U-2786			
	10780047	Feb 01, 2039	U-2787			
<u>ETHIODIZED OIL - LIPIODOL</u>						
N 009190	001				ODE-64	Apr 04, 2021
<u>ETONOGESTREL - IMPLANON</u>						
N 021529	001 9757552	Jul 28, 2030	DP U-1			
<u>ETONOGESTREL - NEXPLANON</u>						
N 021529	002 10821277	May 31, 2027	DP			
	8722037	Sep 28, 2027	DP			
	8888745	Aug 28, 2026	DP			
	9757552	Jul 28, 2030	DP U-1			
<u>ETRAVIRINE - INTELENCE</u>						
N 022187	001 6878717*PED	May 05, 2020			NPP	Jul 16, 2021
	7037917	Dec 13, 2020	DS DP U-1016		PED	Jan 16, 2022
	7037917	Dec 13, 2020	DS DP U-1237			
	7037917	Dec 13, 2020	DS DP U-2354			
	7037917	Dec 13, 2020	DS DP U-256			
	7037917*PED	Jun 13, 2021				
	8003789*PED	May 01, 2020				
<u>ETRAVIRINE - INTELENCE</u>						
N 022187	002 6878717*PED	May 05, 2020			NPP	Jul 16, 2021
	7037917	Dec 13, 2020	DS DP U-1016		PED	Jan 16, 2022
	7037917	Dec 13, 2020	DS DP U-1237			
	7037917	Dec 13, 2020	DS DP U-2354			
	7037917	Dec 13, 2020	DS DP U-256			
	7037917*PED	Jun 13, 2021				
	8003789*PED	May 01, 2020				
<u>ETRAVIRINE - INTELENCE</u>						
N 022187	003 6878717*PED	May 05, 2020			NPP	Jul 16, 2021
	7037917	Dec 13, 2020	DS DP U-1237		PED	Jan 16, 2022
	7037917	Dec 13, 2020	DS DP U-2354			
	7037917*PED	Jun 13, 2021				
	8003789*PED	May 01, 2020				
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560	001 5665772*PED	Mar 09, 2020				
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560	002 5665772*PED	Mar 09, 2020				
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560	003 5665772*PED	Mar 09, 2020				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334	001 8410131	Nov 01, 2025	U-1368		ODE-108	Feb 26, 2023
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
	8778962	Feb 18, 2022	U-1541			
	8778962*PED	Aug 18, 2022				
	9006224	Jul 01, 2028	U-1681			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - AFINITOR</u>						
N 022334	002	8410131				
		8410131	Nov 01, 2025	U-1368	ODE-108	Feb 26, 2023
		8410131*PED	May 01, 2026			
		8436010	Feb 22, 2022	U-1396		
		8436010*PED	Aug 22, 2022			
		8778962	Feb 18, 2022	U-1541		
		8778962*PED	Aug 18, 2022			
		9006224	Jul 01, 2028	U-1681		
<u>EVEROLIMUS - AFINITOR</u>						
N 022334	003	8410131				
		8410131	Nov 01, 2025	U-1368	ODE-108	Feb 26, 2023
		8410131*PED	May 01, 2026			
		8436010	Feb 22, 2022	U-1396		
		8436010*PED	Aug 22, 2022			
		8778962	Feb 18, 2022	U-1541		
		8778962*PED	Aug 18, 2022			
		9006224	Jul 01, 2028	U-1681		
<u>EVEROLIMUS - AFINITOR</u>						
N 022334	004	8410131				
		8410131	Nov 01, 2025	U-1368	ODE-108	Feb 26, 2023
		8410131*PED	May 01, 2026			
		8436010	Feb 22, 2022	U-1396		
		8436010*PED	Aug 22, 2022			
		8778962	Feb 18, 2022	U-1541		
		8778962*PED	Aug 18, 2022			
		9006224	Jul 01, 2028	U-1681		
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985	001	8617598				
		8617598	Sep 27, 2022	DP	I-773	Apr 10, 2021
		8617598*PED	Mar 27, 2023		ODE-169	Apr 10, 2025
		8778962	Feb 18, 2022	U-1541		
		8778962	Feb 18, 2022	U-2280		
		8778962*PED	Aug 18, 2022			
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985	002	8617598				
		8617598	Sep 27, 2022	DP	I-773	Apr 10, 2021
		8617598*PED	Mar 27, 2023		ODE-169	Apr 10, 2025
		8778962	Feb 18, 2022	U-1541		
		8778962	Feb 18, 2022	U-2280		
		8778962*PED	Aug 18, 2022			
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985	003	8617598				
		8617598	Sep 27, 2022	DP	I-773	Apr 10, 2021
		8617598*PED	Mar 27, 2023		ODE-169	Apr 10, 2025
		8778962	Feb 18, 2022	U-1541		
		8778962	Feb 18, 2022	U-2280		
		8778962*PED	Aug 18, 2022			
<u>EXENATIDE - BYDUREON BCISE</u>						
N 209210	001	6414126				
		6414126	Oct 04, 2020	U-2588	NP	Oct 20, 2020
		6479065	Aug 10, 2020	DP		
		6515117	Oct 04, 2025	DS DP	U-2588	
		6667061	May 25, 2020	DP		
		6824822	Oct 09, 2022	DP		
		6872700	Jan 14, 2020	U-2589		
		6872700	Jan 14, 2020	U-2590		
		6872700	Jan 14, 2020	U-2591		
		6936590	Oct 04, 2020	U-2588		
		7223440	Aug 31, 2021	DP		
		7456254	Jun 30, 2025	DP	U-2588	
		7456254	Jun 30, 2025	DP	U-2589	
		7456254	Jun 30, 2025	DP	U-2590	
		7456254	Jun 30, 2025	DP	U-2592	
		7563871	Apr 15, 2024	DP		
		7612176	Apr 13, 2025	DP	U-2589	
		7612176	Apr 13, 2025	DP	U-2590	
		7612176	Apr 13, 2025	DP	U-2592	
		8329648	Aug 18, 2026	U-2588		
		8329648	Aug 18, 2026	U-2589		
		8329648	Aug 18, 2026	U-2590		
		8329648	Aug 18, 2026	U-2593		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE - BYDUREON BCISE</u>						
N 209210 001	8329648	Aug 18, 2026	U-2594			
	8329648	Aug 18, 2026	U-2595			
	8329648	Aug 18, 2026	U-2596			
	8361972	Mar 21, 2028	U-2588			
	8431685	Apr 13, 2025	DP U-2589			
	8431685	Apr 13, 2025	DP U-2590			
	8431685	Apr 13, 2025	DP U-2597			
	8431685	Apr 13, 2025	DP U-2598			
	8461105	Apr 13, 2025	DP U-2589			
	8461105	Apr 13, 2025	DP U-2590			
	8461105	Apr 13, 2025	DP U-2597			
	8461105	Apr 13, 2025	DP U-2598			
	8501698	Jun 20, 2027	U-2588			
	8895033	Oct 04, 2030	DP U-2589			
	8895033	Oct 04, 2030	DP U-2590			
	8895033	Oct 04, 2030	DP U-2597			
	8895033	Oct 04, 2030	DP U-2600			
	8895033	Oct 04, 2030	DP U-2601			
	8895033	Oct 04, 2030	DP U-2602			
	8906851	Aug 18, 2026	U-2589			
	8906851	Aug 18, 2026	U-2590			
	8906851	Aug 18, 2026	U-2593			
	8906851	Aug 18, 2026	U-2597			
	9198925	Oct 04, 2020	U-2588			
	9238076	Apr 15, 2024	DP U-2589			
	9238076	Apr 15, 2024	DP U-2590			
	9238076	Apr 15, 2024	DP U-2597			
	9238076	Apr 15, 2024	DP U-2599			
	9884092	Aug 18, 2026	U-2589			
	9884092	Aug 18, 2026	U-2590			
	9884092	Aug 18, 2026	U-2593			
	9884092	Aug 18, 2026	U-2594			
	9884092	Aug 18, 2026	U-2595			
	9884092	Aug 18, 2026	U-2596			
	9884092	Aug 18, 2026	U-2597			
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N 021773 001	6872700	Jan 14, 2020	U-654			
	6902744	Jan 14, 2020	DP			
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N 021773 002	6872700	Jan 14, 2020	U-654			
	6902744	Jan 14, 2020	DP			
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	6414126	Oct 04, 2020	DS DP U-2588		M-212	Oct 20, 2020
	6479065	Aug 10, 2020	DP		M-224	Apr 02, 2021
	6495164	May 25, 2020	DP			
	6515117	Oct 04, 2025	DS DP U-2588			
	6667061	May 25, 2020	DP			
	6824822	Oct 09, 2022	DP			
	6872700	Jan 14, 2020	U-2588			
	6872700	Jan 14, 2020	U-2589			
	6872700	Jan 14, 2020	U-2590			
	6872700	Jan 14, 2020	U-2591			
	6936590	Oct 04, 2020	U-2588			
	7223440	Aug 31, 2021	DP			
	7456254	Jun 30, 2025	DP U-2588			
	7456254	Jun 30, 2025	DP U-2589			
	7456254	Jun 30, 2025	DP U-2590			
	7456254	Jun 30, 2025	DP U-2592			
	7563871	Apr 15, 2024	DP			
	7612176	Apr 13, 2025	DP U-2588			
	7612176	Apr 13, 2025	DP U-2589			
	7612176	Apr 13, 2025	DP U-2590			
	7612176	Apr 13, 2025	DP U-2592			
	8329648	Aug 18, 2026	U-2588			
	8329648	Aug 18, 2026	U-2589			
	8329648	Aug 18, 2026	U-2590			
	8329648	Aug 18, 2026	U-2593			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	8329648	Aug 18, 2026	U-2594			
	8329648	Aug 18, 2026	U-2595			
	8329648	Aug 18, 2026	U-2596			
	8361972	Mar 21, 2028	U-2588			
	8431685	Apr 13, 2025	DP U-2588			
	8431685	Apr 13, 2025	DP U-2589			
	8431685	Apr 13, 2025	DP U-2590			
	8431685	Apr 13, 2025	DP U-2598			
	8461105	Apr 13, 2025	DP U-2588			
	8461105	Apr 13, 2025	DP U-2589			
	8461105	Apr 13, 2025	DP U-2590			
	8461105	Apr 13, 2025	DP U-2598			
	8501698	Jun 20, 2027	DP U-2588			
	8906851	Aug 18, 2026	U-2588			
	8906851	Aug 18, 2026	U-2589			
	8906851	Aug 18, 2026	U-2590			
	8906851	Aug 18, 2026	U-2593			
	9198925	Oct 04, 2020	U-2588			
	9238076	Apr 15, 2024	DP U-2588			
	9238076	Apr 15, 2024	DP U-2589			
	9238076	Apr 15, 2024	DP U-2590			
	9238076	Apr 15, 2024	DP U-2599			
	9884092	Aug 18, 2026	U-2588			
	9884092	Aug 18, 2026	U-2589			
	9884092	Aug 18, 2026	U-2590			
	9884092	Aug 18, 2026	U-2593			
	9884092	Aug 18, 2026	U-2594			
	9884092	Aug 18, 2026	U-2595			
	9884092	Aug 18, 2026	U-2596			
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	6414126	Oct 04, 2020	DS DP U-2588		M-224	Apr 02, 2021
	6479065	Aug 10, 2020	DP			
	6495164	May 25, 2020	DP			
	6515117	Oct 04, 2025	DS DP U-2588			
	6667061	May 25, 2020	DP			
	6824822	Oct 09, 2022	DP			
	6872700	Jan 14, 2020	U-2588			
	6872700	Jan 14, 2020	U-2589			
	6872700	Jan 14, 2020	U-2590			
	6872700	Jan 14, 2020	U-2591			
	6936590	Oct 04, 2020	U-2588			
	7223440	Aug 31, 2021	DP			
	7456254	Jun 30, 2025	DP U-2588			
	7456254	Jun 30, 2025	DP U-2589			
	7456254	Jun 30, 2025	DP U-2590			
	7456254	Jun 30, 2025	DP U-2592			
	7563871	Apr 15, 2024	DP			
	7612176	Apr 13, 2025	DP U-2588			
	7612176	Apr 13, 2025	DP U-2589			
	7612176	Apr 13, 2025	DP U-2590			
	7612176	Apr 13, 2025	DP U-2592			
	8216180	Jan 12, 2028	DP			
	8329648	Aug 18, 2026	U-2588			
	8329648	Aug 18, 2026	U-2589			
	8329648	Aug 18, 2026	U-2590			
	8329648	Aug 18, 2026	U-2593			
	8329648	Aug 18, 2026	U-2594			
	8329648	Aug 18, 2026	U-2595			
	8329648	Aug 18, 2026	U-2596			
	8361972	Mar 21, 2028	U-2588			
	8431685	Apr 13, 2025	DP U-2588			
	8431685	Apr 13, 2025	DP U-2589			
	8431685	Apr 13, 2025	DP U-2590			
	8431685	Apr 13, 2025	DP U-2598			
	8439864	Mar 25, 2028	DP			
	8461105	Apr 13, 2025	DP U-2588			
	8461105	Apr 13, 2025	DP U-2589			
	8461105	Apr 13, 2025	DP U-2590			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200	002	8461105	Apr 13, 2025	DP	U-2598	
		8501698	Jun 20, 2027	DP	U-2588	
		8690837	May 19, 2029	DP		
		8721615	Jan 18, 2030	DP		
		8758292	Nov 12, 2027	DP		
		8827963	Feb 04, 2029	DP		
		8906851	Aug 18, 2026		U-2588	
		8906851	Aug 18, 2026		U-2589	
		8906851	Aug 18, 2026		U-2590	
		8906851	Aug 18, 2026		U-2593	
		8998876	Jan 07, 2030	DP		
		9198925	Oct 04, 2020		U-2588	
		9238076	Apr 15, 2024	DP	U-2588	
		9238076	Apr 15, 2024	DP	U-2589	
		9238076	Apr 15, 2024	DP	U-2590	
		9238076	Apr 15, 2024	DP	U-2599	
		9320853	Mar 25, 2028	DP		
		9884092	Aug 18, 2026		U-2588	
		9884092	Aug 18, 2026		U-2589	
		9884092	Aug 18, 2026		U-2590	
		9884092	Aug 18, 2026		U-2593	
		9884092	Aug 18, 2026		U-2594	
		9884092	Aug 18, 2026		U-2595	
		9884092	Aug 18, 2026		U-2596	
<u>EZETIMIBE - ZETIA</u>						
N 021445	001	7030106	Jan 25, 2022	DP		
		7612058	Oct 30, 2025		U-1027	
		7612058	Oct 30, 2025		U-1173	
		7612058*PED	Apr 30, 2026			
<u>FAMOTIDINE - PEPCID AC</u>						
N 020801	002	6814978	Aug 26, 2021	DP		
<u>FAMOTIDINE; IBUPROFEN - DUEXIS</u>						
N 022519	001	8067033	Jul 18, 2026	DP		
		8067451	Jul 18, 2026	DP	U-1196	
		8309127	Jul 18, 2026	DP		
		8318202	Jul 18, 2026	DP		
		8449910	Jul 18, 2026	DP		
		8501228	Jul 18, 2026		U-1196	
<u>FEBUXOSTAT - ULORIC</u>						
N 021856	001	7361676	Mar 08, 2024	DP		
		8372872	Sep 08, 2031		U-1346	
		9107912	Sep 08, 2031		U-1346	
<u>FEBUXOSTAT - ULORIC</u>						
N 021856	002	7361676	Mar 08, 2024	DP		
		8372872	Sep 08, 2031		U-1346	
		9107912	Sep 08, 2031		U-1346	
<u>FEDRATINIB HYDROCHLORIDE - INREBIC</u>						
N 212327	001	10391094	Jun 04, 2032	DP	U-2607	
		7528143	Dec 16, 2026	DS		
		7825246	Dec 16, 2026	DS		
		8138199	Jun 30, 2028		U-2607	
<u>FENFLURAMINE HYDROCHLORIDE - FINTEPLA</u>						
N 212102	001	10452815	Oct 22, 2039		U-2859	
		10478441	May 03, 2033		U-2860	
		10478442	May 03, 2033		U-2860	
		10603290	Aug 02, 2037		U-2861	
		9549909	May 03, 2033		U-2858	
		9603814	May 03, 2033		U-2858	
		9603815	May 03, 2033		U-2858	
		9610260	May 03, 2033		U-2858	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FENOFIBRATE - TRIGLIDE</u>						
N 021350	001 6696084	Sep 11, 2021	DS DP U-680			
<u>FENOFIBRATE - TRIGLIDE</u>						
N 021350	002 6696084	Sep 11, 2021	DS DP U-680			
<u>FENOFIBRATE - TRICOR</u>						
N 021656	001 6375986	Sep 21, 2020	DP U-615			
	7276249	Feb 21, 2023	DP			
	7320802	Feb 21, 2023	U-847			
<u>FENOFIBRATE - TRICOR</u>						
N 021656	002 6375986	Sep 21, 2020	DP U-615			
	7276249	Feb 21, 2023	DP			
	7320802	Feb 21, 2023	U-847			
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695	001 7101574	Aug 20, 2020	DS DP			
	7863331	Aug 08, 2020	U-1106			
	7863331	Aug 08, 2020	U-1107			
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695	003 7101574	Aug 20, 2020	DS DP			
	7863331	Aug 08, 2020	U-1106			
	7863331	Aug 08, 2020	U-1107			
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695	004 8026281	Apr 22, 2025	U-1447			
	8026281	Apr 22, 2025	U-1448			
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695	005 8026281	Apr 22, 2025	U-1447			
	8026281	Apr 22, 2025	U-1448			
	9314447	May 31, 2033	DP U-1447			
	9314447	May 31, 2033	DP U-1448			
<u>FENOFIBRATE - FENOGLIDE</u>						
N 022118	001 7658944	Dec 09, 2024	DP			
	8124125	Oct 01, 2024	DP U-1234			
	8481078	Oct 01, 2024	DP U-1416			
	9173847	Oct 01, 2024	DP			
<u>FENOFIBRATE - FENOGLIDE</u>						
N 022118	002 7658944	Dec 09, 2024	DP			
	8124125	Oct 01, 2024	DP U-1234			
	8481078	Oct 01, 2024	DP U-1416			
	9173847	Oct 01, 2024	DP			
<u>FENOFIBRIC ACID - FIBRICOR</u>						
N 022418	001 7569612	Aug 20, 2027	U-1000			
	7741373	Aug 20, 2027	U-1059			
	7741374	Aug 20, 2027	U-1060			
	7741374	Aug 20, 2027	U-1061			
	7915247	Aug 20, 2027	U-1000			
	7915247	Aug 20, 2027	U-1059			
	7915247	Aug 20, 2027	U-1061			
<u>FENOFIBRIC ACID - FIBRICOR</u>						
N 022418	002 7569612	Aug 20, 2027	U-1000			
	7741373	Aug 20, 2027	U-1059			
	7741374	Aug 20, 2027	U-1060			
	7741374	Aug 20, 2027	U-1061			
	7915247	Aug 20, 2027	U-1000			
	7915247	Aug 20, 2027	U-1059			
	7915247	Aug 20, 2027	U-1061			
<u>FENTANYL - SUBSYS</u>						
N 202788	001 10016403	Jan 25, 2027	DP			
	10610523	Jan 25, 2027	DP			
	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL - SUBSYS</u>						
N 202788	001	8835459	Jan 25, 2027	DP		
		8835460	Jan 25, 2027	DP	U-55	
		9241935	Jan 25, 2027	DP		
		9289387	Jan 25, 2027	DP	U-55	
		9642797	Jan 25, 2027	DP	U-55	
		9642844	Jan 25, 2027	DP		
<u>FENTANYL - SUBSYS</u>						
N 202788	002	10016403	Jan 25, 2027	DP		
		10610523	Jan 25, 2027	DP		
		8486972	Apr 27, 2030	DP		
		8486973	Apr 27, 2030		U-55	
		8835460	Jan 25, 2027	DP	U-55	
		9241935	Jan 25, 2027	DP		
		9289387	Jan 25, 2027	DP	U-55	
		9642797	Jan 25, 2027	DP	U-55	
		9642844	Jan 25, 2027	DP		
<u>FENTANYL - SUBSYS</u>						
N 202788	003	10016403	Jan 25, 2027	DP		
		10610523	Jan 25, 2027	DP		
		8486972	Apr 27, 2030	DP		
		8486973	Apr 27, 2030		U-55	
		8835459	Jan 25, 2027	DP		
		8835460	Jan 25, 2027	DP	U-55	
		9241935	Jan 25, 2027	DP		
		9289387	Jan 25, 2027	DP	U-55	
		9642797	Jan 25, 2027	DP	U-55	
		9642844	Jan 25, 2027	DP		
<u>FENTANYL - SUBSYS</u>						
N 202788	004	10016403	Jan 25, 2027	DP		
		10610523	Jan 25, 2027	DP		
		8486972	Apr 27, 2030	DP		
		8486973	Apr 27, 2030		U-55	
		8835459	Jan 25, 2027	DP		
		8835460	Jan 25, 2027	DP	U-55	
		9241935	Jan 25, 2027	DP		
		9289387	Jan 25, 2027	DP	U-55	
		9642797	Jan 25, 2027	DP	U-55	
		9642844	Jan 25, 2027	DP		
<u>FENTANYL - SUBSYS</u>						
N 202788	005	10016403	Jan 25, 2027	DP		
		10610523	Jan 25, 2027	DP		
		8486972	Apr 27, 2030	DP		
		8486973	Apr 27, 2030		U-55	
		8835460	Jan 25, 2027	DP	U-55	
		9241935	Jan 25, 2027	DP		
		9289387	Jan 25, 2027	DP	U-55	
		9642797	Jan 25, 2027	DP	U-55	
		9642844	Jan 25, 2027	DP		
<u>FENTANYL - SUBSYS</u>						
N 202788	006	10016403	Jan 25, 2027	DP		
		10610523	Jan 25, 2027	DP		
		8486972	Apr 27, 2030	DP		
		8486973	Apr 27, 2030		U-55	
		8835459	Jan 25, 2027	DP		
		8835460	Jan 25, 2027	DP	U-55	
		9241935	Jan 25, 2027	DP		
		9289387	Jan 25, 2027	DP	U-55	
		9642797	Jan 25, 2027	DP	U-55	
		9642844	Jan 25, 2027	DP		
<u>FENTANYL - SUBSYS</u>						
N 202788	007	10016403	Jan 25, 2027	DP		
		10610523	Jan 25, 2027	DP		
		8486972	Apr 27, 2030	DP		
		8486973	Apr 27, 2030		U-55	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL - SUBSYS</u>						
N 202788	007	8835459	Jan 25, 2027	DP		
		8835460	Jan 25, 2027	DP U-55		
		9241935	Jan 25, 2027	DP		
		9289387	Jan 25, 2027	DP U-55		
		9642797	Jan 25, 2027	DP U-55		
		9642844	Jan 25, 2027	DP		
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947	001	7862832	Jun 15, 2028	DP		
		7862833	Jun 15, 2028	DP		
		8092832	Dec 30, 2024	DP		
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947	002	7862832	Jun 15, 2028	DP		
		7862833	Jun 15, 2028	DP		
		8092832	Dec 30, 2024	DP		
		8119158	Dec 30, 2024	DP		
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947	003	7862832	Jun 15, 2028	DP		
		7862833	Jun 15, 2028	DP		
		8092832	Dec 30, 2024	DP		
		8119158	Dec 30, 2024	DP		
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947	004	7862832	Jun 15, 2028	DP		
		7862833	Jun 15, 2028	DP		
		8092832	Dec 30, 2024	DP		
		8119158	Dec 30, 2024	DP		
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947	005	7862832	Jun 15, 2028	DP		
		7862833	Jun 15, 2028	DP		
		8092832	Dec 30, 2024	DP		
		8119158	Dec 30, 2024	DP		
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266	001	7579019	Jan 22, 2020		U-767	
		9597288	Jul 23, 2027	DP	U-767	
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266	002	7579019	Jan 22, 2020		U-767	
		9597288	Jul 23, 2027	DP	U-767	
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266	003	7579019	Jan 22, 2020		U-767	
		9597288	Jul 23, 2027	DP	U-767	
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266	004	7579019	Jan 22, 2020		U-767	
		9597288	Jul 23, 2027	DP	U-767	
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266	005	7579019	Jan 22, 2020		U-767	
		9597288	Jul 23, 2027	DP	U-767	
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569	001	8216604	Oct 03, 2024		U-767	
		8889176	Jan 16, 2024		U-767	
		9078814	Jan 08, 2024	DP		
		9731869	Jan 26, 2032	DP		
		9814705	Jan 08, 2024	DP		
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569	002	8216604	Oct 03, 2024		U-767	
		8889176	Jan 16, 2024		U-767	
		9078814	Jan 08, 2024	DP		
		9731869	Jan 26, 2032	DP		
		9814705	Jan 08, 2024	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569	003	9731869	Jan 26, 2032	DP		
		9814705	Jan 08, 2024	DP		
<u>FENTANYL HYDROCHLORIDE - IONSYS</u>						
N 021338	001	6881208	Apr 19, 2022		U-736	
		6975902	Apr 01, 2024	DP		
		8301238	Sep 30, 2031	DP		
		8428708	May 21, 2032		U-736	
		8428709	Jun 11, 2032	DP	U-736	
		8781571	Mar 31, 2032	DP	U-736	
		9095706	Feb 03, 2033	DP		
		9364656	Sep 30, 2031		U-736	
		9731121	Oct 17, 2031	DP		
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565	001	10519252	Oct 20, 2023	DS	U-2709	
		10519252	Oct 20, 2023	DS	U-2710	
		10519252	Oct 20, 2023	DS	U-2711	
		10519252	Oct 20, 2023	DS	U-2712	
		7612109	Feb 05, 2024	DS DP		
		7754702	Feb 15, 2028	DP	U-1432	
		7754702	Feb 15, 2028	DP	U-2555	
		7754702	Feb 15, 2028	DP	U-2556	
		7754702	Feb 15, 2028	DP	U-2557	
		8895612	Jan 08, 2027	DP	U-1620	
		9376505	Oct 20, 2023	DS DP		
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874	001	10300039	Jul 21, 2030		U-2549	
		5753706	Feb 03, 2022	DP	U-1577	
		7767851	Feb 18, 2024	DS DP		
		8093423	Apr 21, 2026		U-1577	
		8299298	Feb 18, 2024	DP		
		8338642	Feb 18, 2024	DS DP	U-1577	
		8609896	Feb 18, 2024	DP		
		8754257	Feb 18, 2024	DP		
		8754258	Feb 18, 2024	DP		
		8846976	Feb 18, 2024		U-1577	
		8901349	Feb 18, 2024		U-1577	
		9050316	Feb 18, 2024		U-1577	
		9328133	Feb 18, 2024	DS DP	U-1577	
		9387191	Jul 21, 2030	DP		
		9757416	Feb 18, 2024	DS DP	U-1577	
<u>FERRIC DERISOMALTOSE - MONOFERRIC</u>						
N 208171	001	10414831	Mar 25, 2029	DS DP		
		8815301	Aug 14, 2029	DS DP	U-2734	
<u>FERRIC DERISOMALTOSE - MONOFERRIC</u>						
N 208171	002	10414831	Mar 25, 2029	DS DP		
		8815301	Aug 14, 2029	DS DP	U-2734	
<u>FERRIC DERISOMALTOSE - MONOFERRIC</u>						
N 208171	003	10414831	Mar 25, 2029	DS DP		
		8815301	Aug 14, 2029	DS DP	U-2734	
<u>FERRIC MALTOL - ACCRUFER</u>						
N 212320	001	10179120	Jan 06, 2035		U-2603	
		9248148	Mar 29, 2031		U-2603	
		9802973	Oct 23, 2035	DS DP	U-2603	
<u>FERRIC PYROPHOSPHATE CITRATE - TRIFERIC</u>						
N 206317	001	7816404	Apr 17, 2029	DP	U-1656	
<u>FERRIC PYROPHOSPHATE CITRATE - TRIFERIC</u>						
N 208551	001	7816404	Apr 17, 2029		U-1656	
		7857977	Sep 08, 2027		U-1656	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FERRIC PYROPHOSPHATE CITRATE - TRIFERIC AVNU</u>						
N 212860	001 7816404	Apr 17, 2029	DS U-2801			
<u>FERUMOXYTOL - FERAHEME</u>						
N 022180	001 6599498	Jun 30, 2023	DS DP		I-767	Feb 02, 2021
	7553479	Mar 08, 2020	DS DP			
	7871597	Mar 08, 2020	DS DP			
	8501158	Mar 08, 2020			U-1422	
	8591864	Mar 08, 2020	DP			
	8926947	Mar 08, 2020	DS DP			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N 022030	001 6858650	Jul 03, 2022	DS U-913			
	7807715	Jun 07, 2027	DP U-913			
	8088398	Jun 07, 2027	DP U-913			
	8501723	Jun 07, 2027	DP			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N 022030	002 6858650	Jul 03, 2022	DS U-913			
	7807715	Jun 07, 2027	DP U-913			
	8088398	Jun 07, 2027	DP U-913			
	8501723	Jun 07, 2027	DP			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N 021909	002 6723348	Nov 26, 2021	DP U-1466			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N 021909	003 6723348	Nov 26, 2021	DP			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N 201373	001 8933097	Aug 02, 2030	DP			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N 201373	002 8933097	Aug 02, 2030	DP			
<u>FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION</u>						
N 021704	002 6613357	Dec 25, 2020	DP U-1159			
<u>FIDAXOMICIN - DIFICID</u>						
N 201699	001 7378508	Jul 31, 2027	DS DP		NPP	Jan 24, 2023
	7863249	Jul 31, 2027	DS DP		PED	Jul 24, 2023
	7906489	Mar 04, 2027				
	7906489	Mar 04, 2027			U-2741	
	7906489*PED	Sep 04, 2027			U-319	
	8586551	Jul 15, 2023	DS DP			
	8586551*PED	Jan 15, 2024				
	8859510	Jul 31, 2027			U-2741	
	8859510	Jul 31, 2027			U-319	
	8859510*PED	Jan 31, 2028				
<u>FIDAXOMICIN - DIFICID</u>						
N 213138	001 7378508	Jul 31, 2027	DS DP		NP	Jan 24, 2023
	7378508*PED	Jan 31, 2028			PED	Jul 24, 2023
	7863249	Jul 31, 2027	DP			
	7863249*PED	Jan 31, 2028				
	7906489	Mar 04, 2027			U-2741	
	7906489*PED	Sep 04, 2027				
	8586551	Jul 23, 2023	DS DP			
	8586551*PED	Jan 23, 2024				
	8859510	Jul 31, 2027			U-2741	
	8859510*PED	Jan 31, 2028				
	9808530	May 28, 2034	DP			
	9808530*PED	Nov 28, 2034				
<u>FINAFLOXACIN - XTORO</u>						
N 206307	001 8536167	Aug 08, 2031			U-1679	
	9119859	Jul 02, 2030			U-1679	
	9504691	Nov 21, 2033	DP		U-1679	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FINGOLIMOD HYDROCHLORIDE - GILENYA</u>						
N 022527 001	10543179	Dec 25, 2027	U-2719		NPP	May 11, 2021
	8324283	Mar 29, 2026	DP		PED	Nov 11, 2021
	8324283*PED	Sep 29, 2026				
	9187405	Jun 25, 2027	U-2613			
	9187405*PED	Dec 25, 2027				
<u>FINGOLIMOD HYDROCHLORIDE - GILENYA</u>						
N 022527 002	9592208	Mar 30, 2032	DP U-2315		NS	May 11, 2021
	9592208*PED	Sep 30, 2032			PED	Nov 11, 2021
<u>FISH OIL TRIGLYCERIDES - OMEGAVEN</u>						
N 210589 001	10350186	Nov 05, 2024	U-2585		NCE	Jul 27, 2023
	9566260	Jul 11, 2025	DP U-2366		ODE-202	Jul 27, 2025
	9629821	Jul 11, 2025	DP U-2367			
<u>FISH OIL TRIGLYCERIDES - OMEGAVEN</u>						
N 210589 002	10350186	Nov 05, 2024	U-2585		NCE	Jul 27, 2023
	9566260	Jul 11, 2025	DP U-2366		ODE-202	Jul 27, 2025
	9629821	Jul 11, 2025	DP U-2367			
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u>						
N 207648 001					NCE	Jul 13, 2021
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u>						
N 207648 002					NCE	Jul 13, 2021
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u>						
N 207648 003					NCE	Jul 13, 2021
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u>						
N 207648 004					NCE	Jul 13, 2021
<u>FLIBANSERIN - ADDYI</u>						
N 022526 001	7151103	May 09, 2023	U-1734		NCE	Aug 18, 2020
	7420057	Aug 01, 2022	DS DP			
	8227471	May 09, 2023	U-1734			
	9468639	Oct 16, 2022	U-1734			
<u>FLORBETABEN F-18 - NEURACEQ</u>						
N 204677 001	7807135	Mar 18, 2029	DS DP U-1497			
<u>FLORBETAPIR F-18 - AMYVID</u>						
N 202008 001	7687052	Apr 30, 2027	DS DP			
	8506929	Apr 30, 2027	DS DP U-1423			
<u>FLORBETAPIR F-18 - AMYVID</u>						
N 202008 002	7687052	Apr 30, 2027	DS DP			
	8506929	Apr 30, 2027	DS DP U-1423			
<u>FLORBETAPIR F-18 - AMYVID</u>						
N 202008 003	7687052	Apr 30, 2027	DS DP			
	8506929	Apr 30, 2027	DS DP U-1423			
<u>FLORTAUCIPIR F-18 - TAUVID</u>						
N 212123 001	8932557	May 19, 2029	DS		NCE	May 28, 2025
<u>FLORTAUCIPIR F-18 - TAUVID</u>						
N 212123 002	8932557	May 19, 2029	DS		NCE	May 28, 2025
<u>FLUCICLOVINE F-18 - AXUMIN</u>						
N 208054 001	10010632	Nov 28, 2026	DP		NCE	May 27, 2021
	10124079	Dec 30, 2035	U-2450			
	10716868	Dec 30, 2035	U-2450			
	5808146	Nov 09, 2020	DS			
	9387266	Nov 28, 2026	U-1879			
<u>FLUDARABINE PHOSPHATE - OFORTA</u>						
N 022273 001	7148207	Dec 20, 2022	DP U-944			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUOCINOLONE ACETONIDE - ILUVIEN</u>						
N 201923	001	6375972	Apr 26, 2020	DP U-1597		
		8871241	Aug 12, 2027	DP		
<u>FLUOCINOLONE ACETONIDE - YUTIQ</u>						
N 210331	001	6375972	Apr 26, 2020	DP U-708	NP	Nov 12, 2021
		8574613	Apr 26, 2020	DP		
		8574659	Apr 26, 2020	DP		
		8871241	Aug 12, 2027	DP		
		9192579	Apr 26, 2020	DP		
		9849085	Apr 26, 2020	U-708		
<u>FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN - TRI-LUMA</u>						
N 021112	001	7915243	Sep 08, 2023	DP		
		7939516	Sep 08, 2023	DP		
		8247395	Oct 25, 2022	DP		
		8653053	Oct 25, 2022	DP		
<u>FLUOCINONIDE - VANOS</u>						
N 021758	001	6765001	Dec 21, 2021	DP		
		7220424	Jan 07, 2023	U-861		
		7794738	Sep 11, 2022	U-1084		
		8232264	Mar 09, 2023	DP		
<u>FLUORODOPA F-18 - FLUORODOPA F18</u>						
N 200655	001				NCE W	Oct 10, 2024 Oct 10, 2024
<u>FLUOROESTRADIOL F-18 - CERIANNA</u>						
N 212155	001				NCE	May 20, 2025
<u>FLUOROURACIL - CARAC</u>						
N 020985	001	6670335	Jun 02, 2021	DP U-68		
<u>FLUOROURACIL - TOLAK</u>						
N 022259	001	7169401	Jul 18, 2023	DP		
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137	001	7270800	Sep 03, 2025	DS DP U-336		
		7351401	Jan 24, 2023	DS DP U-336		
		8236282	May 21, 2024	DS DP		
		8691185	Jan 24, 2023	U-336		
		8916131	Sep 16, 2028	DP		
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137	002	7270800	Sep 03, 2025	DS DP U-336		
		7351401	Jan 24, 2023	DS DP U-336		
		8236282	May 21, 2024	DS DP		
		8691185	Jan 24, 2023	U-336		
		8916131	Sep 16, 2028	DP		
<u>FLUTICASONE FUROATE - FLONASE SENSIMIST ALLERGY RELIEF</u>						
N 022051	002	6858596	Aug 03, 2021	DP U-1890		
		7101866	Aug 03, 2021	DS DP U-1890		
		7541350	Aug 03, 2021	DP U-1890		
		8062264	Apr 05, 2026	DP		
		8147461	Oct 15, 2028	DP		
		8347879	Jul 15, 2028	DP		
		8752543	Apr 05, 2026	DP		
		9320862	Nov 06, 2024	DP		
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625	001	7101866	Aug 03, 2021	DS DP U-1559	NPP	May 17, 2021
		7629335	Aug 03, 2021	DP		
		8113199	Oct 23, 2027	DP		
		8161968	Feb 05, 2028	DP		
		8201556	Feb 05, 2029	DP		
		8534281	Mar 08, 2030	DP		
		8746242	Oct 11, 2030	DP		
		9333310	Oct 02, 2027	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625	002	7101866	Aug 03, 2021	DS DP U-1559		
		7629335	Aug 03, 2021	DP		
		8113199	Oct 23, 2027	DP		
		8161968	Feb 05, 2028	DP		
		8201556	Feb 05, 2029	DP		
		8534281	Mar 08, 2030	DP		
		8746242	Oct 11, 2030	DP		
		9333310	Oct 02, 2027	DP		
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625	003	7101866	Aug 03, 2021	DS DP U-2349	NS	May 17, 2021
		7629335	Aug 03, 2021	DP		
		8113199	Oct 23, 2027	DP		
		8161968	Feb 05, 2028	DP		
		8201556	Feb 05, 2029	DP		
		8534281	Mar 08, 2030	DP		
		8746242	Oct 11, 2030	DP		
		9333310	Oct 02, 2027	DP		
<u>FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - TRELEGY ELLIPTA</u>						
N 209482	001	6537983	Aug 03, 2021	DP U-2125	I-775	Apr 24, 2021
		6759398	Aug 03, 2021	DP U-2125	I-843	Sep 09, 2023
		6878698	Aug 03, 2021	U-2134		
		7101866	Aug 03, 2021	DS DP U-2126		
		7101866	Aug 03, 2021	DS DP U-2953		
		7439393	May 21, 2025	DS DP U-2127		
		7439393	May 21, 2025	DS DP U-2957		
		7488827	Dec 18, 2027	DS DP		
		7498440	Apr 27, 2025	DS DP		
		7629335	Aug 03, 2021	DP		
		7776895	Sep 11, 2022	DP		
		8113199	Oct 23, 2027	DP		
		8161968	Feb 05, 2028	DP		
		8183257	Jul 27, 2025	U-2128		
		8183257	Jul 27, 2025	U-2129		
		8309572	Apr 27, 2025	U-2129		
		8511304	Jun 14, 2027	DP U-2954		
		8534281	Mar 08, 2030	DP		
		8746242	Oct 11, 2030	DP		
		9333310	Oct 02, 2027	DP		
		9750726	Nov 29, 2030	DP		
		RE44874	Mar 23, 2023	DS DP U-2127		
		RE44874	Mar 23, 2023	DS DP U-2955		
<u>FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - TRELEGY ELLIPTA</u>						
N 209482	002	6537983	Aug 03, 2021	DP U-2125	NS	Sep 09, 2023
		6759398	Aug 03, 2021	DP U-2125		
		7101866	Aug 03, 2021	DS DP U-2953		
		7439393	May 21, 2025	DS DP U-2957		
		7488827	Dec 18, 2027	DS DP		
		7498440	Apr 27, 2025	DS DP		
		7629335	Aug 03, 2021	DP		
		7776895	Sep 11, 2022	DP		
		8113199	Oct 23, 2027	DP		
		8161968	Feb 05, 2028	DP		
		8183257	Jul 27, 2025	U-2129		
		8309572	Apr 27, 2025	U-2129		
		8511304	Jun 14, 2027	DP U-2954		
		8534281	Mar 08, 2030	DP		
		8746242	Oct 11, 2030	DP		
		9333310	Oct 02, 2027	DP		
		9750726	Nov 29, 2030	DP		
		RE44874	Mar 23, 2023	DS DP U-2955		
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275	001	6537983	Aug 03, 2021	DP U-1401	M-202	May 15, 2020
		6537983	Aug 03, 2021	DP U-1691		
		6759398	Aug 03, 2021	DP U-1401		
		6759398	Aug 03, 2021	DP U-1691		
		6878698	Aug 03, 2021	U-1401		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275	001	7101866	Aug 03, 2021	DS DP U-1401		
		7101866	Aug 03, 2021	DS DP U-1691		
		7439393	May 21, 2025	DS DP U-1401		
		7439393	May 21, 2025	DS DP U-1691		
		7439393	May 21, 2025	DS DP U-2099		
		7439393	May 21, 2025	DS DP U-2100		
		7629335	Aug 03, 2021	DP		
		7776895	Sep 11, 2022	DP		
		8113199	Oct 23, 2027	DP		
		8161968	Feb 05, 2028	DP		
		8511304	Jun 14, 2027	DP U-1424		
		8511304	Jun 14, 2027	DP U-1691		
		8534281	Mar 08, 2030	DP		
		8746242	Oct 11, 2030	DP		
		9333310	Oct 02, 2027	DP		
		RE44874	Mar 23, 2023	DS DP U-1548		
		RE44874	Mar 23, 2023	DS DP U-1691		
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275	002	6537983	Aug 03, 2021	DP U-1691	M-202	May 15, 2020
		6759398	Aug 03, 2021	DP U-1691		
		7101866	Aug 03, 2021	DS DP U-1691		
		7439393	May 21, 2025	DS DP U-1691		
		7439393	May 21, 2025	DS DP U-2099		
		7439393	May 21, 2025	DS DP U-2100		
		7629335	Aug 03, 2021	DP		
		7776895	Sep 11, 2022	DP		
		8113199	Oct 23, 2027	DP		
		8161968	Feb 05, 2028	DP		
		8511304	Jun 14, 2027	DP U-1691		
		8534281	Mar 08, 2030	DP		
		8746242	Oct 11, 2030	DP		
		9333310	Oct 02, 2027	DP		
		RE44874	Mar 23, 2023	DS DP U-1691		
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433	001	7500444	Feb 26, 2026	DP		
		7500444*PED	Aug 26, 2026			
		7832351	Jun 19, 2023	DP		
		9861771	Oct 11, 2020	DP		
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433	002	6743413	Jun 01, 2021	U-581	Y	
		7500444	Feb 26, 2026	DP		
		7500444*PED	Aug 26, 2026			
		7832351	Jun 19, 2023	DP		
		9861771	Oct 11, 2020	DP		
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433	003	7500444	Feb 26, 2026	DP		
		7500444*PED	Aug 26, 2026			
		7832351	Jun 19, 2023	DP		
		9861771	Oct 11, 2020	DP		
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798	001	10022510	May 18, 2031	DP	NP	Jan 27, 2020
		10124131	May 18, 2031	DP		
		10195375	Feb 14, 2031	DP		
		10561808	Jan 01, 2032	DP		
		10765820	May 19, 2025	DP		
		6701917	Jun 23, 2021	DP		
		6718972	Jun 23, 2021	DP		
		6748947	Jun 23, 2021	DP		
		6871646	Jun 23, 2021	DP		
		7540282	May 06, 2023	DP		
		8006690	Jun 23, 2021	DP		
		8651103	Mar 26, 2028	DP		
		8714149	Feb 25, 2032	DP		
		8978966	Jan 13, 2032	DP		
		9216260	Jun 28, 2031	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798	001	9463288	May 19, 2025	DP		
		9616024	Sep 01, 2024	DP		
		9731087	May 18, 2031	DP		
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798	002	10022510	May 18, 2031	DP	NP	Jan 27, 2020
		10124131	May 18, 2031	DP		
		10195375	Feb 14, 2031	DP		
		10561808	Jan 01, 2032	DP		
		10765820	May 19, 2025	DP		
		6701917	Jun 23, 2021	DP		
		6718972	Jun 23, 2021	DP		
		6748947	Jun 23, 2021	DP		
		6871646	Jun 23, 2021	DP		
		7540282	May 06, 2023	DP		
		8006690	Jun 23, 2021	DP		
		8651103	Mar 26, 2028	DP		
		8714149	Feb 25, 2032	DP		
		8978966	Jan 13, 2032	DP		
		9216260	Jun 28, 2031	DP		
		9463288	May 19, 2025	DP		
		9616024	Sep 01, 2024	DP		
		9731087	May 18, 2031	DP		
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798	003	10022510	May 18, 2031	DP	NP	Jan 27, 2020
		10124131	May 18, 2031	DP		
		10195375	Feb 14, 2031	DP		
		10561808	Jan 01, 2032	DP		
		10765820	May 19, 2025	DP		
		6701917	Jun 23, 2021	DP		
		6718972	Jun 23, 2021	DP		
		6748947	Jun 23, 2021	DP		
		6871646	Jun 23, 2021	DP		
		7540282	May 06, 2023	DP		
		8006690	Jun 23, 2021	DP		
		8651103	Mar 26, 2028	DP		
		8714149	Feb 25, 2032	DP		
		8978966	Jan 13, 2032	DP		
		9216260	Jun 28, 2031	DP		
		9463288	May 19, 2025	DP		
		9616024	Sep 01, 2024	DP		
		9731087	May 18, 2031	DP		
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798	004	10022510	May 18, 2031	DP		
		10124131	May 18, 2031	DP		
		10195375	Feb 14, 2031	DP		
		10561808	Jan 01, 2032	DP		
		10569034	Aug 16, 2036	DP		
		10765820	May 19, 2025	DP		
		6701917	Jun 23, 2021	DP		
		6718972	Jun 23, 2021	DP		
		6748947	Jun 23, 2021	DP		
		6871646	Jun 23, 2021	DP		
		7540282	May 06, 2023	DP		
		8006690	Jun 23, 2021	DP		
		8651103	Mar 26, 2028	DP		
		8714149	Feb 25, 2032	DP		
		8978966	Jan 13, 2032	DP		
		9216260	Jun 28, 2031	DP		
		9463288	May 19, 2025	DP		
		9616024	Sep 01, 2024	DP		
		9731087	May 18, 2031	DP		
		9782550	Aug 28, 2035	DP		
		9782551	Aug 28, 2035	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 005	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	10195375	Feb 14, 2031	DP			
	10561808	Jan 01, 2032	DP			
	10569034	Aug 16, 2036	DP			
	10765820	May 19, 2025	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 006	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	10195375	Feb 14, 2031	DP			
	10561808	Jan 01, 2032	DP			
	10569034	Aug 16, 2036	DP			
	10765820	May 19, 2025	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022 001	10076614	Oct 20, 2034	DP		NP	Sep 18, 2020
	10076615	Jul 30, 2029	DP	U-2133		
	10124132	Mar 06, 2027	DP	U-2133		
	10179216	Jul 08, 2033	DP	U-2133		
	10252010	Feb 07, 2031	DP			
	10300229	Jul 07, 2035	DP	U-2133		
	10478574	Nov 04, 2033		U-2133		
	6715485	Nov 03, 2020	DP			
	7975690	Dec 29, 2025		U-2133		
	8327844	Oct 08, 2023		U-2133		
	8522778	May 11, 2022	DP			
	8550073	Oct 22, 2029	DP			
	8555878	Mar 20, 2020	DP			
	8978647	Dec 06, 2030	DP			
	9072857	Apr 10, 2021	DP			
	9468727	Jul 30, 2020	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 100/50</u>						
N 021077 001					M-214	Dec 20, 2020
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 250/50</u>						
N 021077 002					M-214	Dec 20, 2020

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 500/50</u>						
N 021077	003				M-214	Dec 20, 2020
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254	001	7500444	Feb 26, 2026	DP		
		7500444*PED	Aug 26, 2026			
		7832351	Jun 19, 2023	DP		
		9861771	Oct 11, 2020	DP		
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254	002	7500444	Feb 26, 2026	DP		
		7500444*PED	Aug 26, 2026			
		7832351	Jun 19, 2023	DP		
		9861771	Oct 11, 2020	DP		
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254	003	7500444	Feb 26, 2026	DP		
		7500444*PED	Aug 26, 2026			
		7832351	Jun 19, 2023	DP		
		9861771	Oct 11, 2020	DP		
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799	001	10022510	May 18, 2031	DP	NP	Jan 27, 2020
		10124131	May 18, 2031	DP		
		10195375	Feb 14, 2031	DP		
		10561808	Jan 01, 2032	DP		
		10765820	May 19, 2025	DP		
		6701917	Jun 23, 2021	DP		
		6718972	Jun 23, 2021	DP		
		6748947	Jun 23, 2021	DP		
		6871646	Jun 23, 2021	DP		
		7540282	May 06, 2023	DP		
		8006690	Jun 23, 2021	DP		
		8651103	Mar 26, 2028	DP		
		8714149	Feb 25, 2032	DP		
		8978966	Jan 13, 2032	DP		
		9066957	Oct 06, 2034	DP U-645		
		9216260	Jun 28, 2031	DP		
		9415008	Oct 06, 2034	DP U-645		
		9463288	May 19, 2025	DP		
		9616024	Sep 01, 2024	DP		
		9731087	May 18, 2031	DP		
		9987229	Sep 01, 2024	DP		
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799	002	10022510	May 18, 2031	DP	NP	Jan 27, 2020
		10124131	May 18, 2031	DP		
		10195375	Feb 14, 2031	DP		
		10561808	Jan 01, 2032	DP		
		10765820	May 19, 2025	DP		
		6701917	Jun 23, 2021	DP		
		6718972	Jun 23, 2021	DP		
		6748947	Jun 23, 2021	DP		
		6871646	Jun 23, 2021	DP		
		7540282	May 06, 2023	DP		
		8006690	Jun 23, 2021	DP		
		8651103	Mar 26, 2028	DP		
		8714149	Feb 25, 2032	DP		
		8978966	Jan 13, 2032	DP		
		9066957	Oct 06, 2034	DP U-645		
		9216260	Jun 28, 2031	DP		
		9463288	May 19, 2025	DP		
		9616024	Sep 01, 2024	DP		
		9731087	May 18, 2031	DP		
		9987229	Sep 01, 2024	DP		
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799	003	10022510	May 18, 2031	DP	NP	Jan 27, 2020
		10124131	May 18, 2031	DP		
		10195375	Feb 14, 2031	DP		
		10561808	Jan 01, 2032	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003	10765820	May 19, 2025	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP	U-645		
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
	9987229	Sep 01, 2024	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 004	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	10195375	Feb 14, 2031	DP			
	10561808	Jan 01, 2032	DP			
	10569034	Aug 16, 2036	DP			
	10765820	May 19, 2025	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP	U-645		
	9216260	Jun 28, 2031	DP			
	9415008	Oct 06, 2034	DP	U-645		
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
	9987229	Sep 01, 2024	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 005	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	10195375	Feb 14, 2031	DP			
	10561808	Jan 01, 2032	DP			
	10569034	Aug 16, 2036	DP			
	10765820	May 19, 2025	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP	U-645		
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
	9987229	Sep 01, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799	006	10022510	May 18, 2031	DP		
		10124131	May 18, 2031	DP		
		10195375	Feb 14, 2031	DP		
		10561808	Jan 01, 2032	DP		
		10569034	Aug 16, 2036	DP		
		10765820	May 19, 2025	DP		
		6701917	Jun 23, 2021	DP		
		6718972	Jun 23, 2021	DP		
		6748947	Jun 23, 2021	DP		
		6871646	Jun 23, 2021	DP		
		7540282	May 06, 2023	DP		
		8006690	Jun 23, 2021	DP		
		8651103	Mar 26, 2028	DP		
		8714149	Feb 25, 2032	DP		
		8978966	Jan 13, 2032	DP		
		9066957	Oct 06, 2034	DP U-645		
		9216260	Jun 28, 2031	DP		
		9463288	May 19, 2025	DP		
		9616024	Sep 01, 2024	DP		
		9731087	May 18, 2031	DP		
		9782550	Aug 28, 2035	DP		
		9782551	Aug 28, 2035	DP		
		9987229	Sep 01, 2024	DP		
<u>FLUVASTATIN SODIUM - LESCOL XL</u>						
N 021192	001	6242003	Apr 13, 2020			
<u>FLUVOXAMINE MALEATE - LUVOX CR</u>						
N 022033	001	7465462	May 10, 2020	DP U-929		
<u>FLUVOXAMINE MALEATE - LUVOX CR</u>						
N 022033	002	7465462	May 10, 2020	DP U-929		
<u>FOMEPIZOLE - ANTIZOL</u>						
N 020696	001	7553863	Jun 30, 2027	DS DP		
<u>FORMOTEROL FUMARATE - FORADIL</u>						
N 020831	001	6887459	Nov 28, 2020		U-762	
<u>FORMOTEROL FUMARATE - PERFOROMIST</u>						
N 022007	001	6667344	Jun 22, 2021	DP		
		6814953	Jun 22, 2021	DP U-813		
		7348362	Jun 22, 2021	DP		
		7462645	Jun 22, 2021	DP U-813		
		8623922	Jun 22, 2021	DP		
		9730890	Jun 22, 2021	DP		
<u>FORMOTEROL FUMARATE; GLYCOPYRROLATE - BEVESPI AEROSPHERE</u>						
N 208294	001	10716753	May 28, 2030	DP U-2889		
		8324266	May 28, 2030	U-2889		
		8703806	May 28, 2030	U-2889		
		8808713	May 28, 2030	DP U-2889		
		8815258	Mar 17, 2031	U-2889		
		9415009	May 28, 2030	U-2889		
		9463161	May 28, 2030	DP U-2889		
<u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u>						
N 022518	001	7067502	May 21, 2020	DP U-1068	M-214	Dec 20, 2020
		7067502*PED	Nov 21, 2020		PED	Jun 20, 2021
		7566705	May 21, 2020	DP U-1068		
		7566705*PED	Nov 21, 2020			
<u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u>						
N 022518	002	7067502	May 21, 2020	DP U-1068	M-214	Dec 20, 2020
		7067502*PED	Nov 21, 2020		PED	Jun 20, 2021
		7566705	May 21, 2020	DP U-1068		
		7566705*PED	Nov 21, 2020			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u>						
N 022518	003				NS PED	Aug 12, 2022 Feb 12, 2023
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N 022023	001				NPP PED	Apr 03, 2021 Oct 03, 2021
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N 022023	002				NPP PED	Apr 03, 2021 Oct 03, 2021
<u>FOSFOMYCIN TROMETHAMINE - FOSFOMYCIN TROMETHAMINE</u>						
A 212548	001				CGT	Apr 04, 2021
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493	001	10208073	May 23, 2032	U-2301	NCE	Apr 19, 2023
		10624911	Jun 02, 2037	DP		
		10717721	May 23, 2032	DS		
		10828297	Dec 17, 2030	U-2301		
		8426450	May 23, 2032	DS DP		
		8895586	May 23, 2032	U-2301		
		9186357	Nov 18, 2030	U-2301		
		9403772	May 23, 2032	DS U-2301		
		9908907	May 23, 2032	DS DP		
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493	002	10208073	May 23, 2032	U-2301	NCE	Apr 19, 2023
		10624911	Jun 02, 2037	DP		
		10717721	May 23, 2032	DS		
		10828297	Dec 17, 2030	U-2301		
		8426450	May 23, 2032	DS DP		
		8895586	May 23, 2032	U-2301		
		9186357	Nov 18, 2030	U-2301		
		9403772	May 23, 2032	DS U-2301		
		9908907	May 23, 2032	DS DP		
<u>FOSPHENYTOIN SODIUM - SESQUIENT</u>						
N 210864	001	7635773	Mar 13, 2029	DP		
		8410077	Mar 13, 2029	DP		
		9200088	Mar 13, 2029	DP		
		9493582	Feb 27, 2033	DP		
		9750822	Mar 13, 2029	DP		
<u>FOSPHENYTOIN SODIUM - SESQUIENT</u>						
N 210864	002	7635773	Mar 13, 2029	DP		
		8410077	Mar 13, 2029	DP		
		9200088	Mar 13, 2029	DP		
		9493582	Feb 27, 2033	DP		
		9750822	Mar 13, 2029	DP		
<u>FOSPROPOFOL DISODIUM - LUSEDRA</u>						
N 022244	001	6204257	Jul 01, 2022	DS DP U-945		
<u>FOSTAMATINIB DISODIUM - TAVALISSE</u>						
N 209299	001	7449458	Sep 04, 2026	DS	NCE	Apr 17, 2023
		7538108	Mar 28, 2026	DS U-2294	ODE-174	Apr 17, 2025
		7989448	Jun 12, 2026	DS U-2294		
		8163902	Jun 17, 2026	DS U-2294		
		8211889	Jan 19, 2026	DS		
		8263122	Nov 24, 2030	DP		
		8445485	Jun 17, 2026	DP		
		8652492	Nov 06, 2028	DP		
		8771648	Jul 27, 2032	DP		
		8912170	Jun 17, 2026	U-2294		
		8951504	Jul 27, 2032	U-2294		
		9266912	Jan 19, 2026	U-2294		
		9283238	Jun 17, 2026	U-2294		
		9737554	Jan 19, 2026	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FOSTAMATINIB DISODIUM - TAVALISSE</u>						
N 209299	002 7449458	Sep 04, 2026	DS		NCE	Apr 17, 2023
	7538108	Mar 28, 2026	DS	U-2294	ODE-174	Apr 17, 2025
	7989448	Jun 12, 2026	DS	U-2294		
	8163902	Jun 17, 2026	DS	U-2294		
	8211889	Jan 19, 2026	DS			
	8263122	Nov 24, 2030		DP		
	8445485	Jun 17, 2026		DP		
	8652492	Nov 06, 2028		DP		
	8771648	Jul 27, 2032		DP		
	8912170	Jun 17, 2026		U-2294		
	8951504	Jul 27, 2032		U-2294		
	9266912	Jan 19, 2026		U-2294		
	9283238	Jun 17, 2026		U-2294		
	9737554	Jan 19, 2026		DP		
<u>FOSTEMSAVIR TROMETHAMINE - RUKOBIA</u>						
N 212950	001 7745625	Nov 19, 2027	DS		NCE	Jul 02, 2025
	8168615	Feb 25, 2025		DP		
	8461333	Feb 25, 2025	DS			
<u>FULVESTRANT - FASLODEX</u>						
N 021344	001 6774122	Jan 09, 2021		U-1826	I-749	Aug 25, 2020
	6774122	Jan 09, 2021		U-2108		
	6774122	Jan 09, 2021		U-2163		
	6774122	Jan 09, 2021		U-2504		
	6774122	Jan 09, 2021		U-596		
	6774122*PED	Jul 09, 2021				
	7456160	Jan 09, 2021		U-1826		
	7456160	Jan 09, 2021		U-2108		
	7456160	Jan 09, 2021		U-2163		
	7456160	Jan 09, 2021		U-2504		
	7456160	Jan 09, 2021		U-596		
	7456160*PED	Jul 09, 2021				
	8329680	Jan 09, 2021		U-1826		
	8329680	Jan 09, 2021		U-2108		
	8329680	Jan 09, 2021		U-2163		
	8329680	Jan 09, 2021		U-2504		
	8329680	Jan 09, 2021		U-596		
	8329680*PED	Jul 09, 2021				
	8466139	Jan 09, 2021		U-1826		
	8466139	Jan 09, 2021		U-2108		
	8466139	Jan 09, 2021		U-2163		
	8466139	Jan 09, 2021		U-2504		
	8466139	Jan 09, 2021		U-596		
	8466139*PED	Jul 09, 2021				
<u>FULVESTRANT - FULVESTRANT</u>						
N 210326	001 10188663	Feb 14, 2034		DP U-2540		
	9271990	May 17, 2034		DP U-2540		
	9833459	Feb 14, 2034		DP U-2540		
<u>GABAPENTIN - NEURONTIN</u>						
N 021129	001 7256216	May 28, 2022		DP		
<u>GABAPENTIN - GRALISE</u>						
N 022544	001 6488962	Jun 20, 2020		DP		
	6723340	Oct 25, 2021		DP		
	7438927	Feb 26, 2024		U-1114		
	7731989	Oct 25, 2022		DP		
	8192756	Oct 25, 2022		DP U-1114		
	8252332	Oct 25, 2022		DP U-1114		
	8333992	Oct 25, 2022		DP U-1114		
<u>GABAPENTIN - GRALISE</u>						
N 022544	002 6488962	Jun 20, 2020		DP		
	6723340	Oct 25, 2021		DP		
	7438927	Feb 26, 2024		U-1114		
	7731989	Oct 25, 2022		DP		
	8192756	Oct 25, 2022		DP U-1114		
	8252332	Oct 25, 2022		DP U-1114		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GABAPENTIN - GRALISE</u>						
N 022544	002 8333992	Oct 25, 2022	DP U-1114			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N 022399	001 6818787	Apr 06, 2025	DS DP			
	8026279	Nov 10, 2026	DS DP			
	8048917	Nov 06, 2022	DS DP	U-1247		
	8114909	Apr 11, 2026		U-1231		
	8686034	Jan 24, 2025		U-1231		
	8686034	Jan 24, 2025		U-1247		
	8795725	Jun 10, 2029	DP	U-1231		
	8795725	Jun 10, 2029	DP	U-1247		
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N 022399	002 6818787	Apr 06, 2025	DS DP			
	8026279	Nov 10, 2026	DS DP			
	8048917	Nov 06, 2022	DS DP	U-1247		
	8114909	Apr 11, 2026		U-1231		
	8686034	Jan 24, 2025		U-1231		
	8686034	Jan 24, 2025		U-1247		
	8795725	Jun 10, 2029	DP	U-1231		
	8795725	Jun 10, 2029	DP	U-1247		
<u>GADOBUTROL - GDAVIST</u>						
N 201277	001				I-801	Jul 12, 2022
<u>GADOBUTROL - GDAVIST</u>						
N 201277	002				I-801	Jul 12, 2022
<u>GADOBUTROL - GDAVIST</u>						
N 201277	003				I-801	Jul 12, 2022
<u>GADOBUTROL - GDAVIST</u>						
N 201277	004				I-801	Jul 12, 2022
<u>GADOBUTROL - GDAVIST</u>						
N 201277	005				I-801	Jul 12, 2022
<u>GADOBUTROL - GDAVIST</u>						
N 201277	006 5980864	Nov 09, 2021	DS DP	U-1119	I-801	Jul 12, 2022
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N 021711	001 6676929	May 04, 2020	DP			
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N 021711	002 6676929	May 04, 2020	DP			
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781	001				NPP	Aug 25, 2020
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781	002				NPP	Aug 25, 2020
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781	003				NPP	Aug 25, 2020
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781	004				NPP	Aug 25, 2020
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781	005				NPP	Aug 25, 2020
<u>GADOXETATE DISODIUM - EOVI</u>						
N 022090	001 6039931	Nov 13, 2021		U-1239		
<u>GADOXETATE DISODIUM - EOVI</u>						
N 022090	002 6039931	Nov 13, 2021		U-1239		
<u>GALLIUM DOTATATE GA-68 - NETSPOT</u>						
N 208547	001 9375498	Aug 10, 2032	DP		NCE ODE-120	Jun 01, 2021 Jun 01, 2023

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GALLIUM DOTATOC GA-68 - GALLIUM DOTATOC GA 68</u>						
N 210828	001				NCE W	Aug 21, 2024 Aug 21, 2024
<u>GANCICLOVIR - GANZYK-RTU</u>						
N 209347	001	9486530	Sep 02, 2034	DP		
<u>GATIFLOXACIN - ZYMAR</u>						
N 021493	001	6333045*PED	Feb 20, 2020			
<u>GEFITINIB - IRESSA</u>						
N 206995	001				ODE-95	Jul 13, 2022
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313	001	9241948	Jul 01, 2033	DP		
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313	002	9241948	Jul 01, 2033	DP		
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313	003	9241948	Jul 01, 2033	DP		
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313	004	9241948	Jul 01, 2033	DP		
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313	005	9241948	Jul 01, 2033	DP		
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313	006	9241948	Jul 01, 2033	DP		
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313	007	9241948	Jul 01, 2033	DP		
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313	008	9241948	Jul 01, 2033	DP		
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313	009	9241948	Jul 01, 2033	DP		
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313	010	9241948	Jul 01, 2033	DP		
<u>GILTERITINIB FUMARATE - XOSPATA</u>						
N 211349	001	10786500	Jul 01, 2036	DP	NCE	Nov 28, 2023
		8969336	Jan 27, 2031	DS DP	ODE-222	Nov 28, 2025
		9487491	Jul 28, 2030	U-2456		
<u>GIVOSIRAN SODIUM - GIVLAARI</u>						
N 212194	001	10119143	Oct 03, 2034	DS DP U-2672	NCE	Nov 20, 2024
		10125364	Mar 15, 2033	DS DP U-2672	ODE-273	Nov 20, 2026
		10131907	Aug 24, 2028	DS DP U-2672		
		10273477	Mar 08, 2024	DS		
		8106022	Dec 12, 2029	DS DP U-2672		
		8546143	Jan 09, 2022	DS U-2672		
		8828956	Dec 04, 2028	DS DP U-2672		
		9133461	May 14, 2033	DS DP U-2672		
		9150605	Aug 28, 2025	DS DP		
		9631193	Mar 15, 2033	U-2672		
		9708610	Jan 01, 2024	DS DP U-2672		
		9708615	Mar 08, 2024	DS		
<u>GLASDEGIB MALEATE - DAURISMO</u>						
N 210656	001	10414748	Apr 13, 2036	DS DP	NCE	Nov 21, 2023
		8148401	Jan 30, 2031	DS DP	ODE-224	Nov 21, 2025
		8431597	Jun 29, 2028	DP		
<u>GLASDEGIB MALEATE - DAURISMO</u>						
N 210656	002	10414748	Apr 13, 2036	DS DP	NCE	Nov 21, 2023
		8148401	Jan 30, 2031	DS DP	ODE-224	Nov 21, 2025
		8431597	Jun 29, 2028	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 209394	001	10028937	Jun 10, 2030	U-2141	D-175	Sep 26, 2022
		10028937	Jun 10, 2030	U-2532	M-230	Aug 06, 2021
		10039754	Jun 10, 2030	U-2141	M-259	Apr 10, 2023
		10039754	Jun 10, 2030	U-2532	NCE	Aug 03, 2022
		10286029	Mar 14, 2034	U-2532	NPP	Apr 30, 2022
		8648037	Jan 19, 2032	DS DP U-2141	ODE-232	Apr 30, 2026
		8648037	Jan 19, 2032	DS DP U-2532	ODE-233	Apr 30, 2026
		8937150	May 18, 2032	DS DP		
		9321807	Jun 05, 2035	DS		
		9586978	Jun 10, 2030	U-2141		
		9586978	Jun 10, 2030	U-2532		
<u>GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT</u>						
N 021925	001	7700128	Jan 30, 2027	DP		
		8071130	Jun 08, 2028	DP		
<u>GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT</u>						
N 021925	002	7700128	Jan 30, 2027	DP		
		8071130	Jun 08, 2028	DP		
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700	001	7358366	Apr 19, 2020	DS	Y	
		7358366*PED	Oct 19, 2020			
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700	002	7358366	Apr 19, 2020	DS	Y	
		7358366*PED	Oct 19, 2020			
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700	003	7358366	Apr 19, 2020	DS	Y	
		7358366*PED	Oct 19, 2020			
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700	004	7358366	Apr 19, 2020	DS	Y	
		7358366*PED	Oct 19, 2020			
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700	005	7358366	Apr 19, 2020	DS	Y	
		7358366*PED	Oct 19, 2020			
<u>GLUCAGON - BAOSIMI</u>						
N 210134	001	10213487	Feb 16, 2036	DP U-2604	NP	Jul 24, 2022
		10765602	Sep 23, 2039	DP		
		6938798	Jan 03, 2022	DP		
<u>GLUCAGON - GVOKE PFS</u>						
N 212097	001	9649364	Apr 22, 2036	DP U-2742	NP	Sep 10, 2022
<u>GLUCAGON - GVOKE PFS</u>						
N 212097	002	9649364	Apr 22, 2036	DP U-2742	NP	Sep 10, 2022
<u>GLUCAGON - GVOKE HYPOPEN</u>						
N 212097	003	9649364	Apr 22, 2036	DP U-2742	NP	Sep 10, 2022
<u>GLUCAGON - GVOKE HYPOPEN</u>						
N 212097	004	9649364	Apr 22, 2036	DP U-2742	NP	Sep 10, 2022
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284	001	10045958	Sep 22, 2030	U-1816	NPP	Apr 28, 2020
		10045959	Sep 22, 2030	U-1816	ODE-157	Apr 28, 2024
		10183002	Sep 22, 2030	U-1816	ODE-42	Feb 01, 2020
		10183003	Sep 22, 2030	U-1816		
		10183004	Sep 22, 2030	U-1816		
		10183005	Sep 22, 2030	U-1816		
		10183006	Sep 22, 2030	U-1816		
		10668040	Sep 22, 2030	U-1816		
		8404215	Mar 09, 2032	U-1383		
		8642012	Sep 22, 2030	U-1383		
		9095559	Mar 09, 2032	U-1383		
		9254278	Mar 09, 2032	U-1816		
		9326966	Mar 09, 2032	U-1816		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284	001	9561197	Sep 22, 2030	U-1383		
		9962359	Sep 22, 2030	U-1816		
		9999608	Sep 22, 2030	U-1816		
<u>GLYCOPYRROLATE - CUVPOSA</u>						
N 022571	001	7638552	Aug 20, 2023	U-1076		
		7816396	Aug 20, 2023	U-1076		
<u>GLYCOPYRROLATE - SEEBRI</u>						
N 207923	001	7229607	Apr 09, 2021	U-1773		
		7736670	Jun 27, 2021	DP		
		8029768	Apr 09, 2021	U-1773		
		8048451	Jun 27, 2021	DP		
		8182838	Oct 20, 2028	DP		
		8303991	Jun 27, 2021	DP		
		8435567	Jun 27, 2021	DP		
		8479730	Oct 11, 2028	DP		
		8580306	Jun 27, 2021	DP		
		8956661	Jun 27, 2021	DP		
		9931304	Jun 27, 2021	DP		
		9962338	Jun 27, 2021	DP		
<u>GLYCOPYRROLATE - LONHALA MAGNAIR KIT</u>						
N 208437	001	10376661	Sep 14, 2035	DP	NP	Dec 05, 2020
		10688518	Nov 12, 2036	DP		
		10744277	Dec 07, 2036	DP	U-2941	
		6962151	Oct 27, 2020	DP		
		7316067	Sep 06, 2022	DP		
		7458372	Nov 18, 2024	DP		
		7931212	Nov 25, 2025	DP		
		8511581	Nov 08, 2023	DP		
		9168556	Sep 01, 2032	DP		
		9265900	Dec 07, 2028	DP		
		9604018	May 16, 2033	DP		
		9789270	Oct 30, 2030	DP		
<u>GLYCOPYRROLATE; INDACATEROL MALEATE - UTIBRON</u>						
N 207930	001	6878721	Feb 25, 2025	DS DP	U-1773	
		7229607	Apr 09, 2021		U-1773	
		7736670	Jun 27, 2021	DP		
		7820694	Jun 02, 2020	DP	U-1773	
		8029768	Apr 09, 2021		U-1773	
		8048451	Jun 27, 2021	DP		
		8067437	Jun 02, 2020		U-1773	
		8182838	Oct 20, 2028	DP		
		8283362	Jun 02, 2020	DP	U-1773	
		8303991	Jun 27, 2021	DP		
		8435567	Jun 27, 2021	DP		
		8479730	Oct 11, 2028	DP		
		8580306	Jun 27, 2021	DP		
		8658673	Jun 02, 2020	DP	U-1773	
		8796307	Jun 02, 2020	DP		
		8956661	Jun 27, 2021	DP		
		9931304	Jun 27, 2021	DP		
		9962338	Jun 27, 2021	DP		
<u>GLYCOPYRRONIUM TOSYLATE - QBREXZA</u>						
N 210361	001	10004717	Feb 28, 2033	DP	U-2398	
		10052267	Oct 17, 2028	DP	U-2398	
		10543192	Feb 28, 2033	DP		
		10548875	Feb 28, 2033	DS DP	U-2398	
		6433003	Apr 10, 2020		U-2398	
		8618160	Dec 10, 2029	DP	U-2398	
		8859610	Feb 28, 2033	DP	U-2398	
		9259414	Feb 28, 2033		U-2398	
		9744105	Jul 18, 2030	DP	U-2398	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GOLODIRSEN - VYONDYS 53</u>						
N 211970	001	10227590	Jun 28, 2025	DS DP	NCE	Dec 12, 2024
		10266827	Jun 28, 2025		ODE-280	Dec 12, 2026
		10421966	Jun 28, 2025	DS DP		
		10533174	May 04, 2021	DP		
		9024007	Jun 28, 2025	DS DP		
		9416361	May 04, 2021	DS		
		9994851	Jun 28, 2025	DS DP		
		RE47691	Jun 28, 2025	DP		
<u>GOSERELIN ACETATE - ZOLADEX</u>						
N 019726	001	7118552	Apr 13, 2022	DP		
		7220247	Apr 09, 2022	DP		
		7500964	Feb 26, 2021	DP		
<u>GOSERELIN ACETATE - ZOLADEX</u>						
N 020578	001	7118552	Apr 13, 2022	DP		
		7220247	Apr 09, 2022	DP		
		7500964	Feb 26, 2021	DP		
<u>GRANISETRON - SANCUSO</u>						
N 022198	001	7608282	Jan 22, 2025	DP U-1011		
<u>GRANISETRON - SUSTOL</u>						
N 022445	001	10357570	Sep 28, 2024		U-2253	
		6613355	Jun 28, 2021	DP		
		6790458	May 11, 2021	DP		
		8252304	Sep 28, 2024	DP		
		8252305	Sep 28, 2024		U-1891	
		8715710	Sep 28, 2024	DP		
		9913910	Sep 28, 2024		U-2253	
<u>GUAIFENESIN - MUCINEX</u>						
N 021282	001	6372252	Apr 28, 2020		U-489	
		6955821	Apr 28, 2020	DP	U-489	
		7838032	Apr 28, 2020	DP		
<u>GUAIFENESIN - MUCINEX</u>						
N 021282	002	6372252	Apr 28, 2020		U-489	
		6955821	Apr 28, 2020	DP	U-489	
		7838032	Apr 28, 2020	DP		
<u>GUAIFENESIN; HYDROCODONE BITARTRATE - OBREDON</u>						
N 205474	001	10105324	Nov 13, 2035	DS DP	U-2023	
		9549907	Nov 13, 2035	DS DP	U-2023	
		9808431	Nov 13, 2035	DS DP	U-2023	
<u>GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE - MUCINEX D</u>						
N 021585	001	6372252	Apr 28, 2020	DP		
		6955821	Apr 28, 2020	DP	U-686	
		7838032	Apr 28, 2020	DP		
<u>GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE - MUCINEX D</u>						
N 021585	002	6372252	Apr 28, 2020	DP		
		6955821	Apr 28, 2020	DP	U-686	
		7838032	Apr 28, 2020	DP		
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037	001	6287599	Dec 20, 2020	DP		
		6287599*PED	Jun 20, 2021			
		6811794	Jul 04, 2022	DP	U-494	
		6811794*PED	Jan 04, 2023			
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037	002	6287599	Dec 20, 2020	DP		
		6287599*PED	Jun 20, 2021			
		6811794	Jul 04, 2022	DP	U-494	
		6811794*PED	Jan 04, 2023			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037	003	6287599	Dec 20, 2020	DP		
		6287599*PED	Jun 20, 2021			
		6811794	Jul 04, 2022	DP U-494		
		6811794*PED	Jan 04, 2023			
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037	004	6287599	Dec 20, 2020	DP		
		6287599*PED	Jun 20, 2021			
		6811794	Jul 04, 2022	DP U-494		
		6811794*PED	Jan 04, 2023			
<u>HALOBETASOL PROPIONATE - ULTRAVATE</u>						
N 208183	001	8962028	Jun 19, 2033	DP U-1775	NPP	Aug 31, 2023
<u>HALOBETASOL PROPIONATE - BRYHALI</u>						
N 209355	001	10478502	Nov 02, 2031	DP U-2625	NP	Nov 06, 2021
		6517847	Aug 03, 2020	DP		
		8809307	Nov 02, 2031	DP		
<u>HALOBETASOL PROPIONATE - LEXETTE</u>						
N 210566	001	10857159	Nov 30, 2036	DP	NDF	May 24, 2021
<u>HALOBETASOL PROPIONATE; TAZAROTENE - DUOBRII</u>						
N 209354	001	10251895	Jun 06, 2036	DP	NP	Apr 25, 2022
		10426787	Jun 06, 2036	U-2625		
		10478502	Nov 02, 2031	DP U-2625		
		6517847	Aug 03, 2020	DP		
		8809307	Nov 02, 2031	DP		
<u>HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT</u>						
N 022555	001	10556010	Dec 19, 2036	U-2250	M-220	Feb 15, 2021
		7348361	Nov 06, 2020	DP U-1087		
		7348361	Nov 06, 2020	DP U-2250		
<u>HISTRELIN ACETATE - SUPPRELIN LA</u>						
N 022058	001	8062652	Jun 16, 2026	U-1197		
<u>HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE - BIDIL</u>						
N 020727	001	6465463	Sep 08, 2020	U-71		
		6784177	Sep 08, 2020	U-71		
<u>HYDROCHLOROTHIAZIDE; TELMISARTAN - MICARDIS HCT</u>						
N 021162	001	6358986	Jan 10, 2020			
<u>HYDROCHLOROTHIAZIDE; TELMISARTAN - MICARDIS HCT</u>						
N 021162	002	6358986	Jan 10, 2020			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880	001	10028946	Jul 25, 2033	U-1810		
		10092559	Sep 12, 2034	U-55		
		10322120	Jul 25, 2033	DP		
		10456393	Jul 25, 2033	U-1810		
		10722511	Jul 25, 2033	U-1810		
		9132096	Sep 12, 2034	DP		
		9265760	Jul 25, 2033	U-1810		
		9326982	Jul 25, 2033	U-1810		
		9333201	Jul 25, 2033	U-1810		
		9339499	Jul 25, 2033	U-1810		
		9421200	Jul 25, 2033	U-1810		
		9433619	Jul 25, 2033	U-1810		
		9452163	Sep 12, 2034	U-55		
		9486451	Sep 12, 2034	U-55		
		9610286	Jul 25, 2033	U-1810		
		9713611	Sep 12, 2034	DP U-55		
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880	002	10028946	Jul 25, 2033	U-1810		
		10092559	Sep 12, 2034	U-55		
		10322120	Jul 25, 2033	DP		
		10456393	Jul 25, 2033	U-1810		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880	002	10722511	Jul 25, 2033		U-1810	
		9132096	Sep 12, 2034	DP		
		9265760	Jul 25, 2033		U-1810	
		9326982	Jul 25, 2033		U-1810	
		9333201	Jul 25, 2033		U-1810	
		9339499	Jul 25, 2033		U-1810	
		9421200	Jul 25, 2033		U-1810	
		9433619	Jul 25, 2033		U-1810	
		9452163	Sep 12, 2034		U-55	
		9486451	Sep 12, 2034		U-55	
		9610286	Jul 25, 2033		U-1810	
		9713611	Sep 12, 2034	DP	U-55	
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880	003	10028946	Jul 25, 2033		U-1810	
		10092559	Sep 12, 2034		U-55	
		10322120	Jul 25, 2033	DP		
		10456393	Jul 25, 2033		U-1810	
		10722511	Jul 25, 2033		U-1810	
		9132096	Sep 12, 2034	DP		
		9265760	Jul 25, 2033		U-1810	
		9326982	Jul 25, 2033		U-1810	
		9333201	Jul 25, 2033		U-1810	
		9339499	Jul 25, 2033		U-1810	
		9421200	Jul 25, 2033		U-1810	
		9433619	Jul 25, 2033		U-1810	
		9452163	Sep 12, 2034		U-55	
		9486451	Sep 12, 2034		U-55	
		9610286	Jul 25, 2033		U-1810	
		9713611	Sep 12, 2034	DP	U-55	
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880	004	10028946	Jul 25, 2033		U-1810	
		10092559	Sep 12, 2034		U-55	
		10322120	Jul 25, 2033	DP		
		10456393	Jul 25, 2033		U-1810	
		10722511	Jul 25, 2033		U-1810	
		9132096	Sep 12, 2034	DP		
		9265760	Jul 25, 2033		U-1810	
		9326982	Jul 25, 2033		U-1810	
		9333201	Jul 25, 2033		U-1810	
		9339499	Jul 25, 2033		U-1810	
		9421200	Jul 25, 2033		U-1810	
		9433619	Jul 25, 2033		U-1810	
		9452163	Sep 12, 2034		U-55	
		9486451	Sep 12, 2034		U-55	
		9610286	Jul 25, 2033		U-1810	
		9713611	Sep 12, 2034	DP	U-55	
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880	005	10028946	Jul 25, 2033		U-1810	
		10092559	Sep 12, 2034		U-55	
		10322120	Jul 25, 2033	DP		
		10456393	Jul 25, 2033		U-1810	
		10722511	Jul 25, 2033		U-1810	
		9132096	Sep 12, 2034	DP		
		9265760	Jul 25, 2033		U-1810	
		9326982	Jul 25, 2033		U-1810	
		9333201	Jul 25, 2033		U-1810	
		9339499	Jul 25, 2033		U-1810	
		9421200	Jul 25, 2033		U-1810	
		9433619	Jul 25, 2033		U-1810	
		9452163	Sep 12, 2034		U-55	
		9486451	Sep 12, 2034		U-55	
		9610286	Jul 25, 2033		U-1810	
		9713611	Sep 12, 2034	DP	U-55	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880	006	10028946	Jul 25, 2033		U-1810	
		10092559	Sep 12, 2034		U-55	
		10322120	Jul 25, 2033	DP		
		10456393	Jul 25, 2033		U-1810	
		10722511	Jul 25, 2033		U-1810	
		9132096	Sep 12, 2034	DP		
		9265760	Jul 25, 2033		U-1810	
		9326982	Jul 25, 2033		U-1810	
		9333201	Jul 25, 2033		U-1810	
		9339499	Jul 25, 2033		U-1810	
		9421200	Jul 25, 2033		U-1810	
		9433619	Jul 25, 2033		U-1810	
		9452163	Sep 12, 2034		U-55	
		9486451	Sep 12, 2034		U-55	
		9610286	Jul 25, 2033		U-1810	
		9713611	Sep 12, 2034	DP	U-55	
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627	001	10130591	Nov 20, 2023	DP	U-1819	
		10369109	Jun 16, 2023	DP		
		6733783	Oct 30, 2021	DP	U-1556	
		8309060	Nov 20, 2023	DP	U-1556	
		8361499	Oct 30, 2021	DP		
		8529948	Aug 06, 2022	DP		
		8551520	Oct 30, 2021	DP		
		8647667	Oct 30, 2021	DP		
		8808740	Dec 21, 2031	DP	U-1556	
		9023401	Oct 30, 2020	DP		
		9056052	Oct 30, 2020	DP		
		9060940	Oct 30, 2020		U-1556	
		9084816	Aug 24, 2027	DP		
		9095614	Aug 24, 2027		U-1556	
		9095615	Aug 24, 2027	DP		
		9198863	Oct 30, 2020	DP		
		9205056	Oct 30, 2020	DP		
		9289391	Oct 30, 2020	DP		
		9486412	Aug 24, 2027	DP		
		9486413	Aug 24, 2027	DP		
		9492389	Aug 24, 2027	DP		
		9492390	Aug 24, 2027		U-1556	
		9492391	Aug 24, 2027		U-1556	
		9517236	Oct 30, 2020	DP		
		9545380	Aug 24, 2027		U-1556	
		9572779	Dec 21, 2031	DP		
		9572804	Oct 30, 2020	DP		
		9669023	Oct 30, 2020	DP		
		9669024	Oct 30, 2020	DP		
		9675610	Jun 16, 2023	DP		
		9675611	Oct 30, 2020		U-1556	
		9682077	Oct 30, 2020		U-1556	
		9750703	Dec 21, 2031	DP		
		9763933	Aug 24, 2027	DP		
		9770416	Aug 24, 2027	DP		
		9775809	Aug 24, 2027	DP		
		9861584	Dec 21, 2031	DP		
		9872837	Dec 21, 2031	DP		
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627	002	10130591	Nov 20, 2023	DP	U-1819	
		10369109	Jun 16, 2023	DP		
		6733783	Oct 30, 2021	DP	U-1556	
		8309060	Nov 20, 2023	DP	U-1556	
		8361499	Oct 30, 2021	DP		
		8529948	Aug 06, 2022	DP		
		8551520	Oct 30, 2021	DP		
		8647667	Oct 30, 2021	DP		
		8808740	Dec 21, 2031	DP	U-1556	
		9023401	Oct 30, 2020	DP		
		9056052	Oct 30, 2020	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627	002	9060940	Oct 30, 2020		U-1556	
		9084816	Aug 24, 2027	DP		
		9095614	Aug 24, 2027		U-1556	
		9095615	Aug 24, 2027	DP		
		9198863	Oct 30, 2020	DP		
		9205056	Oct 30, 2020	DP		
		9289391	Oct 30, 2020	DP		
		9486412	Aug 24, 2027	DP		
		9486413	Aug 24, 2027	DP		
		9492389	Aug 24, 2027	DP		
		9492390	Aug 24, 2027		U-1556	
		9492391	Aug 24, 2027		U-1556	
		9517236	Oct 30, 2020	DP		
		9545380	Aug 24, 2027		U-1556	
		9572779	Dec 21, 2031	DP		
		9572804	Oct 30, 2020	DP		
		9669023	Oct 30, 2020	DP		
		9669024	Oct 30, 2020	DP		
		9675610	Jun 16, 2023	DP		
		9675611	Oct 30, 2020		U-1556	
		9682077	Oct 30, 2020		U-1556	
		9750703	Dec 21, 2031	DP		
		9763933	Aug 24, 2027	DP		
		9770416	Aug 24, 2027	DP		
		9775809	Aug 24, 2027	DP		
		9861584	Dec 21, 2031	DP		
		9872837	Dec 21, 2031	DP		
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627	003	10130591	Nov 20, 2023	DP	U-1819	
		10369109	Jun 16, 2023	DP		
		6733783	Oct 30, 2021	DP	U-1556	
		8309060	Nov 20, 2023	DP	U-1556	
		8361499	Oct 30, 2021	DP		
		8529948	Aug 06, 2022	DP		
		8551520	Oct 30, 2021	DP		
		8647667	Oct 30, 2021	DP		
		8808740	Dec 21, 2031	DP	U-1556	
		9023401	Oct 30, 2020	DP		
		9056052	Oct 30, 2020	DP		
		9060940	Oct 30, 2020		U-1556	
		9084816	Aug 24, 2027	DP		
		9095614	Aug 24, 2027		U-1556	
		9095615	Aug 24, 2027	DP		
		9198863	Oct 30, 2020	DP		
		9205056	Oct 30, 2020	DP		
		9289391	Oct 30, 2020	DP		
		9486412	Aug 24, 2027	DP		
		9486413	Aug 24, 2027	DP		
		9492389	Aug 24, 2027	DP		
		9492390	Aug 24, 2027		U-1556	
		9492391	Aug 24, 2027		U-1556	
		9517236	Oct 30, 2020	DP		
		9545380	Aug 24, 2027		U-1556	
		9572779	Dec 21, 2031	DP		
		9572804	Oct 30, 2020	DP		
		9669023	Oct 30, 2020	DP		
		9669024	Oct 30, 2020	DP		
		9675610	Jun 16, 2023	DP		
		9675611	Oct 30, 2020		U-1556	
		9682077	Oct 30, 2020		U-1556	
		9750703	Dec 21, 2031	DP		
		9763933	Aug 24, 2027	DP		
		9770416	Aug 24, 2027	DP		
		9775809	Aug 24, 2027	DP		
		9861584	Dec 21, 2031	DP		
		9872837	Dec 21, 2031	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 004	10130591	Nov 20, 2023	DP U-1819			
	10369109	Jun 16, 2023	DP			
	6733783	Oct 30, 2021	DP U-1556			
	8309060	Nov 20, 2023	DP U-1556			
	8361499	Oct 30, 2021	DP			
	8529948	Aug 06, 2022	DP			
	8551520	Oct 30, 2021	DP			
	8647667	Oct 30, 2021	DP			
	8808740	Dec 21, 2031	DP U-1556			
	9023401	Oct 30, 2020	DP			
	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020	U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027	U-1556			
	9492391	Aug 24, 2027	U-1556			
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020	U-1556			
	9682077	Oct 30, 2020	U-1556			
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
	9861584	Dec 21, 2031	DP			
	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 005	10130591	Nov 20, 2023	DP U-1819			
	10369109	Jun 16, 2023	DP			
	6733783	Oct 30, 2021	DP U-1556			
	8309060	Nov 20, 2023	DP U-1556			
	8361499	Oct 30, 2021	DP			
	8529948	Aug 06, 2022	DP			
	8551520	Oct 30, 2021	DP			
	8647667	Oct 30, 2021	DP			
	8808740	Dec 21, 2031	DP U-1556			
	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020	U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027	U-1556			
	9492391	Aug 24, 2027	U-1556			
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627	005	9675611	Oct 30, 2020		U-1556	
		9682077	Oct 30, 2020		U-1556	
		9750703	Dec 21, 2031	DP		
		9763933	Aug 24, 2027	DP		
		9770416	Aug 24, 2027	DP		
		9775809	Aug 24, 2027	DP		
		9861584	Dec 21, 2031	DP		
		9872837	Dec 21, 2031	DP		
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627	006	10130591	Nov 20, 2023	DP	U-1819	
		10369109	Jun 16, 2023	DP		
		6733783	Oct 30, 2021	DP	U-1556	
		8309060	Nov 20, 2023	DP	U-1556	
		8361499	Oct 30, 2021	DP		
		8529948	Aug 06, 2022	DP		
		8551520	Oct 30, 2021	DP		
		8647667	Oct 30, 2021	DP		
		8808740	Dec 21, 2031	DP	U-1556	
		9056052	Oct 30, 2020	DP		
		9060940	Oct 30, 2020		U-1556	
		9084816	Aug 24, 2027	DP		
		9095614	Aug 24, 2027		U-1556	
		9095615	Aug 24, 2027	DP		
		9198863	Oct 30, 2020	DP		
		9205056	Oct 30, 2020	DP		
		9289391	Oct 30, 2020	DP		
		9486412	Aug 24, 2027	DP		
		9486413	Aug 24, 2027	DP		
		9492389	Aug 24, 2027	DP		
		9492390	Aug 24, 2027		U-1556	
		9492391	Aug 24, 2027		U-1556	
		9517236	Oct 30, 2020	DP		
		9545380	Aug 24, 2027		U-1556	
		9572779	Dec 21, 2031	DP		
		9572804	Oct 30, 2020	DP		
		9669023	Oct 30, 2020	DP		
		9669024	Oct 30, 2020	DP		
		9675610	Jun 16, 2023	DP		
		9675611	Oct 30, 2020		U-1556	
		9682077	Oct 30, 2020		U-1556	
		9750703	Dec 21, 2031	DP		
		9763933	Aug 24, 2027	DP		
		9770416	Aug 24, 2027	DP		
		9775809	Aug 24, 2027	DP		
		9861584	Dec 21, 2031	DP		
		9872837	Dec 21, 2031	DP		
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627	007	10130591	Nov 20, 2023	DP	U-1819	
		10369109	Jun 16, 2023	DP		
		6733783	Oct 30, 2021	DP	U-1556	
		8309060	Nov 20, 2023	DP	U-1556	
		8361499	Oct 30, 2021	DP		
		8529948	Aug 06, 2022	DP		
		8551520	Oct 30, 2021	DP		
		8647667	Oct 30, 2021	DP		
		8808740	Dec 21, 2031	DP	U-1556	
		9056052	Oct 30, 2020	DP		
		9060940	Oct 30, 2020		U-1556	
		9084816	Aug 24, 2027	DP		
		9095614	Aug 24, 2027		U-1556	
		9095615	Aug 24, 2027	DP		
		9198863	Oct 30, 2020	DP		
		9205056	Oct 30, 2020	DP		
		9289391	Oct 30, 2020	DP		
		9486412	Aug 24, 2027	DP		
		9486413	Aug 24, 2027	DP		
		9492389	Aug 24, 2027	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627	007	9492390	Aug 24, 2027	U-1556		
		9492391	Aug 24, 2027	U-1556		
		9517236	Oct 30, 2020	DP		
		9545380	Aug 24, 2027	U-1556		
		9572779	Dec 21, 2031	DP		
		9572804	Oct 30, 2020	DP		
		9669023	Oct 30, 2020	DP		
		9669024	Oct 30, 2020	DP		
		9675610	Jun 16, 2023	DP		
		9675611	Oct 30, 2020	U-1556		
		9682077	Oct 30, 2020	U-1556		
		9750703	Dec 21, 2031	DP		
		9763933	Aug 24, 2027	DP		
		9770416	Aug 24, 2027	DP		
		9775809	Aug 24, 2027	DP		
		9861584	Dec 21, 2031	DP		
		9872837	Dec 21, 2031	DP		
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975	001	8445018	Jul 31, 2029	DP		
		9216176	Sep 13, 2027	DP		
		9572803	Sep 13, 2027	DP		
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975	002	8445018	Jul 31, 2029	DP		
		9216176	Sep 13, 2027	DP		
		9572803	Sep 13, 2027	DP		
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975	003	8445018	Jul 31, 2029	DP		
		9216176	Sep 13, 2027	DP		
		9572803	Sep 13, 2027	DP		
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975	004	8445018	Jul 31, 2029	DP		
		9216176	Sep 13, 2027	DP		
		9572803	Sep 13, 2027	DP		
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975	005	8445018	Jul 31, 2029	DP		
		9216176	Sep 13, 2027	DP		
		9572803	Sep 13, 2027	DP		
<u>HYDROCORTISONE BUTYRATE - LOCOID</u>						
N 022076	001	7378405	Dec 19, 2026	DP		
		7981877	Jan 23, 2025	DP		
<u>HYDROGEN PEROXIDE - ESKATA</u>						
N 209305	001	10098910	Apr 21, 2035	DP U-2205	NP	Dec 14, 2020
		10493103	Apr 21, 2035	DP		
		10729720	Apr 21, 2035	DP		
		7381427	Jun 08, 2022	U-2205		
		9675639	Jul 04, 2035	DP U-2205		
		9980983	Apr 21, 2035	U-2205		
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP</u>						
N 019034	001	6589960	Nov 09, 2020	DP		
		9248229	Mar 12, 2034	DP		
		9731082	Apr 23, 2032	DP		
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP</u>						
N 019034	002	6589960	Nov 09, 2020	DP		
		9248229	Mar 12, 2034	DP		
		9731082	Apr 23, 2032	DP		
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034	003	6589960	Nov 09, 2020	DS DP		
		9248229	Mar 12, 2034	DP		
		9731082	Apr 23, 2032	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034	004	6589960	Nov 09, 2020	DS DP		
		9248229	Mar 12, 2034	DP		
		9731082	Apr 23, 2032	DP		
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034	005	6589960	Nov 09, 2020	DS DP		
		9248229	Mar 12, 2034	DP		
		9731082	Apr 23, 2032	DP		
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019891	001	6589960	Nov 09, 2020	DS DP		
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019892	001	6589960	Nov 09, 2020	DS DP		
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019892	002	6589960	Nov 09, 2020	DS DP		
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019892	003	6589960	Nov 09, 2020	DS DP		
<u>HYDROMORPHONE HYDROCHLORIDE - PALLADONE</u>						
N 021044	001	6589960	Nov 09, 2020	DP		
<u>HYDROMORPHONE HYDROCHLORIDE - PALLADONE</u>						
N 021044	002	6589960	Nov 09, 2020	DP		
<u>HYDROMORPHONE HYDROCHLORIDE - PALLADONE</u>						
N 021044	003	6589960	Nov 09, 2020	DP		
<u>HYDROMORPHONE HYDROCHLORIDE - PALLADONE</u>						
N 021044	004	6589960	Nov 09, 2020	DP		
<u>HYDROXYPROGESTERONE CAPROATE - MAKENA (AUTOINJECTOR)</u>						
N 021945	004	10471075	May 02, 2036		U-2236	
		8021335	Oct 04, 2026	DP		
		8562564	Jan 24, 2026	DP		
		9180259	Jan 24, 2026	DP		
		9533102	Jan 24, 2026	DP		
		9629959	Jan 24, 2026	DP		
		9789257	Feb 11, 2034	DP		
		9844558	May 02, 2036		U-2236	
<u>HYDROXYUREA - SIKLOS</u>						
N 208843	001				NP	Dec 21, 2020
					ODE-177	Dec 21, 2024
<u>HYDROXYUREA - SIKLOS</u>						
N 208843	002				NP	Dec 21, 2020
					ODE-177	Dec 21, 2024
<u>IBANDRONATE SODIUM - BONIVA</u>						
N 021455	002	7192938	May 06, 2023		U-798	
		7410957	May 06, 2023		U-887	
		7718634	May 06, 2023		U-642	
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552	001	10004746	Jun 03, 2031		U-1684	
		10004746	Jun 03, 2031		U-1946	
		10004746	Jun 03, 2031		U-2241	
		10004746	Jun 03, 2031		U-2242	
		10016435	Jun 03, 2031		U-1650	
		10106548	Jun 03, 2033	DS DP	ODE-117	May 06, 2023
		10125140	Jun 03, 2033	DS DP	ODE-128	Jan 18, 2024
		10294231	Jun 03, 2033	DP	ODE-152	Aug 02, 2024
		10294232	Jun 03, 2033	DP	ODE-55	Nov 13, 2020
		10463668	Oct 24, 2034		U-2654	
		10478439	Jun 03, 2031		U-1456	
		10478439	Jun 03, 2031		U-1650	
		10478439	Jun 03, 2031		U-1684	
		10478439	Jun 03, 2031		U-1946	
					D-176	Aug 24, 2021
					I-741	Jan 18, 2020
					I-753	Aug 02, 2020
					M-236	Jan 25, 2022
					ODE-109	Mar 04, 2023
					ODE-117	May 06, 2023
					ODE-128	Jan 18, 2024
					ODE-152	Aug 02, 2024
					ODE-55	Nov 13, 2020
					ODE-60	Feb 12, 2021
					ODE-72	Jul 28, 2021
					ODE-86	Jan 29, 2022

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	10478439	Jun 03, 2031	U-1947			
	10478439	Jun 03, 2031	U-2241			
	10478439	Jun 03, 2031	U-2242			
	10478439	Jun 03, 2031	U-2665			
	10653696	Jun 03, 2031	U-1456			
	10695350	Oct 24, 2034	U-2846			
	10751342	Jun 03, 2031	U-1491			
	10751342	Jun 03, 2031	U-1946			
	10751342	Jun 03, 2031	U-2943			
	10751342	Jun 03, 2031	U-2944			
	10752634	Jun 03, 2033	DP			
	7514444	Dec 28, 2026	DS DP			
	8008309	Nov 13, 2027	DS DP			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1650			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2219			
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026	U-1491			
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031	U-1456			
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031	U-1683			
	8999999	Jun 03, 2031	U-1684			
	9125889	Jun 03, 2031	U-1745			
	9181257	Dec 28, 2026	DS DP			
	9296753	Oct 30, 2033	DS DP			
	9540382	Aug 18, 2033	U-1456			
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1684			
	9540382	Aug 18, 2033	U-1946			
	9540382	Aug 18, 2033	U-1947			
	9713617	Jun 03, 2033	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-2150			
	9795604	Oct 24, 2034	U-2969			
	9795604	Oct 24, 2034	U-2970			
	9801881	Jun 03, 2031	U-1491			
	9801883	Jun 03, 2031	U-2159			
	9814721	Jun 03, 2031	U-1947			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	10004746	Jun 03, 2031	U-1684		D-176	Aug 24, 2021
	10004746	Jun 03, 2031	U-1946		M-236	Jan 25, 2022
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10016435	Jun 03, 2031	U-1650			
	10106548	Jun 03, 2033	DS DP			
	10125140	Jun 03, 2033	DS DP			
	10294231	Jun 03, 2033	DP			
	10294232	Jun 03, 2033	DP			
	10463668	Oct 24, 2034	U-2654			
	10478439	Jun 03, 2031	U-1456			
	10478439	Jun 03, 2031	U-1650			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	10478439	Jun 03, 2031				
	10478439	Jun 03, 2031				
	10478439	Jun 03, 2031				
	10478439	Jun 03, 2031				
	10478439	Jun 03, 2031				
	10478439	Jun 03, 2031				
	10653696	Jun 03, 2031				
	10695350	Oct 24, 2034				
	10751342	Jun 03, 2031				
	10751342	Jun 03, 2031				
	10751342	Jun 03, 2031				
	10751342	Jun 03, 2031				
	7514444	Dec 28, 2026	DS DP			
	8008309	Nov 13, 2027	DS DP			
	8476284	Dec 28, 2026			U-1456	
	8476284	Dec 28, 2026			U-1650	
	8476284	Dec 28, 2026			U-1946	
	8476284	Dec 28, 2026			U-1947	
	8497277	Dec 28, 2026			U-1456	
	8497277	Dec 28, 2026			U-1491	
	8497277	Dec 28, 2026			U-1650	
	8497277	Dec 28, 2026			U-1946	
	8497277	Dec 28, 2026			U-1947	
	8563563	Apr 26, 2027			U-1491	
	8563563	Apr 26, 2027			U-1650	
	8563563	Apr 26, 2027			U-1946	
	8563563	Apr 26, 2027			U-2219	
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026			U-1491	
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031			U-1456	
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026			U-1456	
	8952015	Dec 28, 2026			U-1491	
	8952015	Dec 28, 2026			U-1650	
	8952015	Dec 28, 2026			U-1946	
	8952015	Dec 28, 2026			U-1947	
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031			U-1491	
	8999999	Jun 03, 2031			U-1946	
	8999999	Jun 03, 2031			U-2228	
	9125889	Jun 03, 2031			U-1650	
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9540382	Aug 18, 2033			U-1456	
	9540382	Aug 18, 2033			U-1491	
	9540382	Aug 18, 2033			U-1650	
	9540382	Aug 18, 2033			U-1946	
	9540382	Aug 18, 2033			U-1947	
	9713617	Jun 03, 2033	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034			U-2969	
	9795604	Oct 24, 2034			U-2970	
	9801881	Jun 03, 2031			U-1491	
	9801883	Jun 03, 2031			U-2159	
	9814721	Jun 03, 2031			U-1947	
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	10004746	Jun 03, 2031			D-176	Aug 24, 2021
	10004746	Jun 03, 2031			M-236	Jan 25, 2022
	10004746	Jun 03, 2031				
	10004746	Jun 03, 2031				
	10010507	Mar 03, 2036	DP			
	10016435	Jun 03, 2031			U-1650	
	10106548	Jun 03, 2033	DS DP			
	10125140	Jun 03, 2033	DS DP			
	10213386	Mar 03, 2036	DP			
	10463668	Oct 24, 2034			U-2654	
	10478439	Jun 03, 2031			U-1456	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	10478439	Jun 03, 2031	U-1650			
	10478439	Jun 03, 2031	U-1684			
	10478439	Jun 03, 2031	U-1946			
	10478439	Jun 03, 2031	U-1947			
	10478439	Jun 03, 2031	U-2241			
	10478439	Jun 03, 2031	U-2242			
	10478439	Jun 03, 2031	U-2665			
	10653696	Jun 03, 2031	U-1456			
	10695350	Oct 24, 2034	U-2846			
	10751342	Jun 03, 2031	U-1491			
	10751342	Jun 03, 2031	U-1946			
	10751342	Jun 03, 2031	U-2943			
	10751342	Jun 03, 2031	U-2944			
	10752634	Jun 03, 2033	DP			
	10828259	Mar 03, 2036	DP			
	7514444	Dec 28, 2026	DS DP			
	8008309	Nov 13, 2027	DS DP			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1650			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2241			
	8563563	Apr 26, 2027	U-2242			
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031	U-1456			
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2241			
	8999999	Jun 03, 2031	U-2242			
	9125889	Jun 03, 2031	U-1650			
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9655857	Mar 03, 2036	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-2969			
	9795604	Oct 24, 2034	U-2970			
	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9814721	Jun 03, 2031	U-1947			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	10004746	Jun 03, 2031	U-1684		D-176	Aug 24, 2021
	10004746	Jun 03, 2031	U-1946		M-236	Jan 25, 2022
	10004746	Jun 03, 2031	U-2241			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	10004746	Jun 03, 2031			U-2242	
	10010507	Mar 03, 2036		DP		
	10016435	Jun 03, 2031			U-1650	
	10106548	Jun 03, 2033	DS DP			
	10125140	Jun 03, 2033	DS DP			
	10213386	Mar 03, 2036		DP		
	10463668	Oct 24, 2034			U-2654	
	10478439	Jun 03, 2031			U-1456	
	10478439	Jun 03, 2031			U-1650	
	10478439	Jun 03, 2031			U-1684	
	10478439	Jun 03, 2031			U-1946	
	10478439	Jun 03, 2031			U-1947	
	10478439	Jun 03, 2031			U-2241	
	10478439	Jun 03, 2031			U-2242	
	10478439	Jun 03, 2031			U-2665	
	10653696	Jun 03, 2031			U-1456	
	10695350	Oct 24, 2034			U-2846	
	10751342	Jun 03, 2031			U-1491	
	10751342	Jun 03, 2031			U-1946	
	10751342	Jun 03, 2031			U-2943	
	10751342	Jun 03, 2031			U-2944	
	10828259	Mar 03, 2036		DP		
	7514444	Dec 28, 2026	DS DP			
	8008309	Nov 13, 2027	DS DP			
	8476284	Dec 28, 2026			U-1456	
	8476284	Dec 28, 2026			U-1650	
	8476284	Dec 28, 2026			U-1946	
	8476284	Dec 28, 2026			U-1947	
	8476284	Dec 28, 2026			U-2241	
	8497277	Dec 28, 2026			U-1456	
	8497277	Dec 28, 2026			U-1491	
	8497277	Dec 28, 2026			U-1650	
	8497277	Dec 28, 2026			U-1946	
	8497277	Dec 28, 2026			U-1947	
	8497277	Dec 28, 2026			U-2241	
	8497277	Dec 28, 2026			U-2242	
	8563563	Apr 26, 2027			U-1491	
	8563563	Apr 26, 2027			U-1650	
	8563563	Apr 26, 2027			U-1946	
	8563563	Apr 26, 2027			U-2241	
	8563563	Apr 26, 2027			U-2242	
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026			U-1491	
	8703780	Dec 28, 2026			U-2242	
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031			U-1456	
	8754091	Dec 28, 2026		DP		
	8952015	Dec 28, 2026			U-1456	
	8952015	Dec 28, 2026			U-1491	
	8952015	Dec 28, 2026			U-1650	
	8952015	Dec 28, 2026			U-1946	
	8952015	Dec 28, 2026			U-1947	
	8952015	Dec 28, 2026			U-2241	
	8952015	Dec 28, 2026			U-2242	
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031			U-1491	
	8999999	Jun 03, 2031			U-1946	
	8999999	Jun 03, 2031			U-2241	
	8999999	Jun 03, 2031			U-2242	
	9125889	Jun 03, 2031			U-1650	
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9655857	Mar 03, 2036		DP		
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034			U-2969	
	9795604	Oct 24, 2034			U-2970	
	9801881	Jun 03, 2031			U-1491	
	9801881	Jun 03, 2031			U-2242	
	9801883	Jun 03, 2031			U-2159	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563	002	9801883	Jun 03, 2031			
		9814721	Jun 03, 2031			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563	003	10004746	Jun 03, 2031		D-176	Aug 24, 2021
		10004746	Jun 03, 2031		M-236	Jan 25, 2022
		10004746	Jun 03, 2031			
		10004746	Jun 03, 2031			
		10010507	Mar 03, 2036	DP		
		10016435	Jun 03, 2031		U-1650	
		10106548	Jun 03, 2033	DS DP		
		10125140	Jun 03, 2033	DS DP		
		10213386	Mar 03, 2036	DP		
		10463668	Oct 24, 2034		U-2654	
		10478439	Jun 03, 2031		U-1456	
		10478439	Jun 03, 2031		U-1650	
		10478439	Jun 03, 2031		U-1684	
		10478439	Jun 03, 2031		U-1946	
		10478439	Jun 03, 2031		U-1947	
		10478439	Jun 03, 2031		U-2241	
		10478439	Jun 03, 2031		U-2242	
		10478439	Jun 03, 2031		U-2665	
		10653696	Jun 03, 2031		U-1456	
		10695350	Oct 24, 2034		U-2846	
		10751342	Jun 03, 2031		U-1491	
		10751342	Jun 03, 2031		U-1946	
		10751342	Jun 03, 2031		U-2943	
		10751342	Jun 03, 2031		U-2944	
		10828259	Mar 03, 2036	DP		
		7514444	Dec 28, 2026	DS DP		
		8008309	Nov 13, 2027	DS DP		
		8476284	Dec 28, 2026		U-1456	
		8476284	Dec 28, 2026		U-1650	
		8476284	Dec 28, 2026		U-1946	
		8476284	Dec 28, 2026		U-1947	
		8476284	Dec 28, 2026		U-2241	
		8497277	Dec 28, 2026		U-1456	
		8497277	Dec 28, 2026		U-1491	
		8497277	Dec 28, 2026		U-1650	
		8497277	Dec 28, 2026		U-1946	
		8497277	Dec 28, 2026		U-1947	
		8497277	Dec 28, 2026		U-2241	
		8497277	Dec 28, 2026		U-2242	
		8563563	Apr 26, 2027		U-1491	
		8563563	Apr 26, 2027		U-1650	
		8563563	Apr 26, 2027		U-1946	
		8563563	Apr 26, 2027		U-2241	
		8563563	Apr 26, 2027		U-2242	
		8697711	Dec 28, 2026	DS DP		
		8703780	Dec 28, 2026		U-1491	
		8703780	Dec 28, 2026		U-2242	
		8735403	Dec 28, 2026	DS DP		
		8754090	Jun 03, 2031		U-1456	
		8754091	Dec 28, 2026	DP		
		8952015	Dec 28, 2026		U-1456	
		8952015	Dec 28, 2026		U-1491	
		8952015	Dec 28, 2026		U-1650	
		8952015	Dec 28, 2026		U-1946	
		8952015	Dec 28, 2026		U-1947	
		8952015	Dec 28, 2026		U-2241	
		8952015	Dec 28, 2026		U-2242	
		8957079	Dec 28, 2026	DS DP		
		8999999	Jun 03, 2031		U-1491	
		8999999	Jun 03, 2031		U-1946	
		8999999	Jun 03, 2031		U-2241	
		8999999	Jun 03, 2031		U-2242	
		9125889	Jun 03, 2031		U-1650	
		9181257	Dec 28, 2026	DS		
		9296753	Oct 30, 2033	DS		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	9655857	Mar 03, 2036	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034		U-2969		
	9795604	Oct 24, 2034		U-2970		
	9801881	Jun 03, 2031		U-1491		
	9801881	Jun 03, 2031		U-2242		
	9801883	Jun 03, 2031		U-2159		
	9801883	Jun 03, 2031		U-2243		
	9814721	Jun 03, 2031		U-1947		
	<u>IBRUTINIB - IMBRUVICA</u>					
N 210563 004	10004746	Jun 03, 2031		U-1684	D-176	Aug 24, 2021
	10004746	Jun 03, 2031		U-1946	M-236	Jan 25, 2022
	10004746	Jun 03, 2031		U-2241		
	10004746	Jun 03, 2031		U-2242		
	10010507	Mar 03, 2036	DP			
	10016435	Jun 03, 2031		U-1650		
	10106548	Jun 03, 2033	DS DP			
	10125140	Jun 03, 2033	DS DP			
	10213386	Mar 03, 2036	DP			
	10463668	Oct 24, 2034		U-2654		
	10478439	Jun 03, 2031		U-1456		
	10478439	Jun 03, 2031		U-1650		
	10478439	Jun 03, 2031		U-1684		
	10478439	Jun 03, 2031		U-1946		
	10478439	Jun 03, 2031		U-1947		
	10478439	Jun 03, 2031		U-2241		
	10478439	Jun 03, 2031		U-2242		
	10478439	Jun 03, 2031		U-2665		
	10653696	Jun 03, 2031		U-1456		
	10695350	Oct 24, 2034		U-2846		
	10751342	Jun 03, 2031		U-1491		
	10751342	Jun 03, 2031		U-1946		
	10751342	Jun 03, 2031		U-2943		
	10751342	Jun 03, 2031		U-2944		
	10828259	Mar 03, 2036	DP			
	7514444	Dec 28, 2026	DS DP			
	8008309	Nov 13, 2027	DS DP			
	8476284	Dec 28, 2026		U-1456		
	8476284	Dec 28, 2026		U-1650		
	8476284	Dec 28, 2026		U-1946		
	8476284	Dec 28, 2026		U-1947		
	8476284	Dec 28, 2026		U-2241		
	8497277	Dec 28, 2026		U-1456		
	8497277	Dec 28, 2026		U-1491		
	8497277	Dec 28, 2026		U-1650		
	8497277	Dec 28, 2026		U-1946		
	8497277	Dec 28, 2026		U-1947		
	8497277	Dec 28, 2026		U-2241		
	8497277	Dec 28, 2026		U-2242		
	8563563	Apr 26, 2027		U-1491		
	8563563	Apr 26, 2027		U-1650		
	8563563	Apr 26, 2027		U-1946		
	8563563	Apr 26, 2027		U-2241		
	8563563	Apr 26, 2027		U-2242		
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026		U-1491		
	8703780	Dec 28, 2026		U-2242		
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031		U-1456		
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026		U-1456		
	8952015	Dec 28, 2026		U-1491		
8952015	Dec 28, 2026		U-1650			
8952015	Dec 28, 2026		U-1946			
8952015	Dec 28, 2026		U-1947			
8952015	Dec 28, 2026		U-2241			
8952015	Dec 28, 2026		U-2242			
8957079	Dec 28, 2026	DS DP				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563	004	8999999	Jun 03, 2031	U-1491		
		8999999	Jun 03, 2031	U-1946		
		8999999	Jun 03, 2031	U-2241		
		8999999	Jun 03, 2031	U-2242		
		9125889	Jun 03, 2031	U-1650		
		9181257	Dec 28, 2026	DS		
		9296753	Oct 30, 2033	DS		
		9655857	Mar 03, 2036	DP		
		9725455	Jun 03, 2033	DS		
		9795604	Oct 24, 2034	U-2969		
		9795604	Oct 24, 2034	U-2970		
		9801881	Jun 03, 2031	U-1491		
		9801881	Jun 03, 2031	U-2242		
		9801883	Jun 03, 2031	U-2159		
		9801883	Jun 03, 2031	U-2243		
		9814721	Jun 03, 2031	U-1947		
<u>IBUPROFEN - CHILDREN'S ADVIL-FLAVORED</u>						
N 020589	002	10238640	May 25, 2024	DP		
<u>IBUPROFEN - CALDOLOR</u>						
N 022348	001	6727286	Nov 27, 2021	DP U-981		
<u>IBUPROFEN - CALDOLOR</u>						
N 022348	002	6727286	Nov 27, 2021	DP U-981		
		8735452	Sep 30, 2029	U-981		
		8871810	Sep 30, 2029	U-981		
		9012508	Sep 14, 2030	U-981		
		9114068	Sep 30, 2029	U-1735		
		9138404	Sep 30, 2029	U-1756		
		9295639	Sep 30, 2029	U-1756		
		9649284	Sep 30, 2029	U-2018		
<u>IBUPROFEN - CALDOLOR</u>						
N 022348	003	8735452	Sep 30, 2029	U-981		
		8871810	Sep 30, 2029	U-981		
		9012508	Sep 14, 2030	U-981		
		9072661	Mar 16, 2032	U-2264		
		9072710	Mar 16, 2032	U-2266		
<u>IBUPROFEN LYSINE - NEOPROFEN</u>						
N 021903	001	6342530	Nov 14, 2020	DP U-1127		
		6342530	Nov 14, 2020	DP U-794		
		6344479	Mar 20, 2021	DS DP U-794	Y	
		8415337	Mar 02, 2032	DS DP		
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057	001	10010517	Apr 29, 2030	U-2690	I-819	Dec 13, 2022
		10265287	Apr 29, 2030	U-2700		
		10278935	Jun 28, 2033	U-2701		
		10278936	Jun 28, 2033	U-2702		
		10278937	Jun 28, 2033	U-2703		
		10383840	Jun 28, 2033	U-2704		
		10555924	Jun 28, 2033	U-2743		
		10555925	Jun 28, 2033	U-2744		
		10568861	Jun 28, 2033	U-2756		
		10576054	Jun 28, 2033	U-2762		
		10668042	Jun 28, 2033	U-2841		
		10786478	Jun 28, 2033	U-2959		
		10786478	Jun 28, 2033	U-2960		
		10792267	Apr 29, 2030	U-2961		
		10792270	Jun 28, 2033	U-2962		
		10842766	Apr 29, 2030	U-2997		
		10842768	Jun 15, 2030	U-2688		
		8188146	Jan 27, 2020	DS DP		
		8293727	Feb 09, 2030	U-1287		
		8293728	Feb 09, 2030	U-1287		
		8298554	Apr 29, 2030	DP		
		8314086	Feb 09, 2030	U-1287		
		8318715	Feb 09, 2030	U-1287		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001	8357677	Feb 09, 2030	U-1287			
	8367652	Feb 09, 2030	U-1287			
	8377920	Feb 09, 2030	U-1287			
	8399446	Feb 09, 2030	U-1287			
	8410086	Jun 15, 2030	U-2688			
	8415335	Feb 09, 2030	U-1287			
	8426399	Feb 09, 2030	U-1287			
	8431560	Feb 09, 2030	U-1287			
	8440650	Feb 09, 2030	U-1287			
	8445003	Apr 29, 2030	U-1287			
	8445013	Apr 29, 2030	U-1287			
	8454994	Apr 29, 2030	U-2689			
	8455472	Jun 15, 2030	U-2690			
	8501225	Apr 29, 2030	U-1287			
	8518929	Feb 09, 2030	U-1287			
	8524698	Feb 09, 2030	U-1287			
	8546372	Feb 09, 2030	U-1287			
	8551521	Apr 29, 2030	U-1287			
	8563608	Apr 29, 2030	U-1287			
	8617593	Apr 29, 2030	U-1478			
	8617593	Apr 29, 2030	U-2691			
	8617594	Apr 29, 2030	U-1287			
	8618166	Apr 29, 2030	U-2689			
	8623406	Apr 29, 2030	U-1478			
	8623406	Apr 29, 2030	U-2692			
	8642077	Apr 29, 2030	U-2693			
	8669245	Jun 15, 2030	U-2694			
	8680144	Feb 09, 2030	U-2695			
	8691871	Apr 29, 2030	U-2689			
	8703185	Apr 29, 2030	U-2691			
	8709475	Apr 29, 2030	U-2689			
	8710041	Jun 15, 2030	U-2690			
	9198892	Sep 25, 2027	U-2706			
	9603826	Jun 28, 2033	U-2696			
	9610272	Jun 28, 2033	U-2697			
	9623001	Jun 28, 2033	U-2698			
	9693984	Jun 28, 2033	U-2697			
	9693985	Jun 28, 2033	U-2696			
	9693986	Jun 28, 2033	U-2698			
	9700537	May 31, 2027	U-2707			
	9918954	Jun 28, 2033	U-2699			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002	10010517	Apr 29, 2030	U-2690		I-819	Dec 13, 2022
	10265287	Apr 29, 2030	U-2700			
	10278935	Jun 28, 2033	U-2701			
	10278936	Jun 28, 2033	U-2702			
	10278937	Jun 28, 2033	U-2703			
	10383840	Jun 28, 2033	U-2704			
	10555924	Jun 28, 2033	U-2743			
	10555925	Jun 28, 2033	U-2744			
	10568861	Jun 28, 2033	U-2756			
	10576054	Jun 28, 2033	U-2762			
	10668042	Jun 28, 2033	U-2841			
	10786478	Jun 28, 2033	U-2959			
	10786478	Jun 28, 2033	U-2960			
	10792267	Apr 29, 2030	U-2961			
	10792270	Jun 28, 2033	U-2962			
	10842766	Apr 29, 2030	U-2997			
	10842768	Jun 15, 2030	U-2688			
	8188146	Jan 27, 2020	DS DP			
	8293727	Feb 09, 2030	U-1287			
	8293728	Feb 09, 2030	U-1287			
	8298554	Apr 29, 2030	DP			
	8314086	Feb 09, 2030	U-1287			
	8318715	Feb 09, 2030	U-1287			
	8357677	Feb 09, 2030	U-1287			
	8367652	Feb 09, 2030	U-1287			
	8377920	Feb 09, 2030	U-1287			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002	8399446	Feb 09, 2030	U-1287			
	8410086	Jun 15, 2030	U-2688			
	8415335	Feb 09, 2030	U-1287			
	8426399	Feb 09, 2030	U-1287			
	8440650	Feb 09, 2030	U-1287			
	8445003	Apr 29, 2030	U-1287			
	8445013	Apr 29, 2030	U-1287			
	8454994	Apr 29, 2030	U-2689			
	8501225	Apr 29, 2030	U-1287			
	8518929	Feb 09, 2030	U-1287			
	8524698	Feb 09, 2030	U-1287			
	8546372	Feb 09, 2030	U-1287			
	8551521	Apr 29, 2030	U-1287			
	8563608	Apr 29, 2030	U-1287			
	8617593	Apr 29, 2030	U-1287			
	8617593	Apr 29, 2030	U-2691			
	8617594	Apr 29, 2030	U-1287			
	8623406	Apr 29, 2030	U-1287			
	8623406	Apr 29, 2030	U-2692			
	8642077	Apr 29, 2030	U-2693			
	8669245	Jun 15, 2030	U-2694			
	8680144	Feb 09, 2030	U-2695			
	8691871	Apr 29, 2030	U-2689			
	8703185	Apr 29, 2030	U-2691			
	8709475	Apr 29, 2030	U-2689			
	8710041	Jun 15, 2030	U-2690			
	9198892	Sep 25, 2027	U-2706			
	9603826	Jun 28, 2033	U-2696			
	9610272	Jun 28, 2033	U-2697			
	9623001	Jun 28, 2033	U-2698			
	9693984	Jun 28, 2033	U-2697			
	9693985	Jun 28, 2033	U-2696			
	9693986	Jun 28, 2033	U-2698			
	9700537	May 31, 2027	U-2707			
	9918954	Jun 28, 2033	U-2699			
<u>IDELALISIB - ZYDELIG</u>						
N 205858 001	10730879	Mar 05, 2033	DS DP		ODE-70	Jul 23, 2021
	6800620	Apr 24, 2021	DS U-1560		ODE-71	Jul 23, 2021
	6949535	Apr 24, 2021	DS U-1560			
	8138195	Apr 24, 2021	DS DP U-1549			
	8492389	Apr 24, 2021	DS DP			
	8637533	Apr 24, 2021	DS DP			
	8865730	Mar 05, 2033	DS DP U-1615			
	8980901	May 12, 2025	U-1678			
	9149477	May 12, 2025	U-1757			
	9469643	Sep 02, 2033	DS			
	9492449	Mar 11, 2030	U-1914			
	RE44599	Jul 21, 2025	U-1558			
	RE44599	Jul 21, 2025	U-1615			
	RE44638	Aug 05, 2025	DS DP			
<u>IDELALISIB - ZYDELIG</u>						
N 205858 002	10730879	Mar 05, 2033	DS DP		ODE-70	Jul 23, 2021
	6800620	Apr 24, 2021	DS U-1560		ODE-71	Jul 23, 2021
	6949535	Apr 24, 2021	DS U-1560			
	8138195	Apr 24, 2021	DS DP U-1549			
	8492389	Apr 24, 2021	DS DP			
	8637533	Apr 24, 2021	DS DP			
	8865730	Mar 05, 2033	DS DP U-1615			
	8980901	May 12, 2025	U-1678			
	9149477	May 12, 2025	U-1757			
	9469643	Sep 02, 2033	DS			
	9492449	Mar 11, 2030	U-1914			
	RE44599	Jul 21, 2025	U-1558			
	RE44599	Jul 21, 2025	U-1615			
	RE44638	Aug 05, 2025	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ILOPERIDONE - FANAPT</u>						
N 022192	001	8586610	Nov 02, 2027	U-1625		
		8652776	Aug 31, 2030	U-1685		
		8999638	Oct 28, 2030	U-1674		
		9072742	Jan 16, 2031	U-1674		
		9074254	Dec 28, 2031	U-1674		
		9074255	Dec 17, 2030	U-1674		
		9074256	Feb 10, 2031	U-1674		
		9138432	Sep 30, 2025	U-1737		
		9157121	Apr 05, 2030	U-1674		
<u>ILOPERIDONE - FANAPT</u>						
N 022192	002	8586610	Nov 02, 2027	U-1625		
		8652776	Aug 31, 2030	U-1685		
		8999638	Oct 28, 2030	U-1674		
		9072742	Jan 16, 2031	U-1674		
		9074254	Dec 28, 2031	U-1674		
		9074255	Dec 17, 2030	U-1674		
		9074256	Feb 10, 2031	U-1674		
		9138432	Sep 30, 2025	U-1737		
		9157121	Apr 05, 2030	U-1674		
<u>ILOPERIDONE - FANAPT</u>						
N 022192	003	8586610	Nov 02, 2027	U-1625		
		8652776	Aug 31, 2030	U-1685		
		8999638	Oct 28, 2030	U-1674		
		9072742	Jan 16, 2031	U-1674		
		9074254	Dec 28, 2031	U-1674		
		9074255	Dec 17, 2030	U-1674		
		9074256	Feb 10, 2031	U-1674		
		9138432	Sep 30, 2025	U-1737		
		9157121	Apr 05, 2030	U-1674		
<u>ILOPERIDONE - FANAPT</u>						
N 022192	004	8586610	Nov 02, 2027	U-1625		
		8652776	Aug 31, 2030	U-1685		
		8999638	Oct 28, 2030	U-1674		
		9072742	Jan 16, 2031	U-1674		
		9074254	Dec 28, 2031	U-1674		
		9074255	Dec 17, 2030	U-1674		
		9074256	Feb 10, 2031	U-1674		
		9138432	Sep 30, 2025	U-1737		
		9157121	Apr 05, 2030	U-1674		
<u>ILOPERIDONE - FANAPT</u>						
N 022192	005	8586610	Nov 02, 2027	U-1625		
		8652776	Aug 31, 2030	U-1685		
		8999638	Oct 28, 2030	U-1674		
		9072742	Jan 16, 2031	U-1674		
		9074254	Dec 28, 2031	U-1674		
		9074255	Dec 17, 2030	U-1674		
		9074256	Feb 10, 2031	U-1674		
		9138432	Sep 30, 2025	U-1737		
		9157121	Apr 05, 2030	U-1674		
<u>ILOPERIDONE - FANAPT</u>						
N 022192	006	8586610	Nov 02, 2027	U-1625		
		8652776	Aug 31, 2030	U-1685		
		8999638	Oct 28, 2030	U-1674		
		9072742	Jan 16, 2031	U-1674		
		9074254	Dec 28, 2031	U-1674		
		9074255	Dec 17, 2030	U-1674		
		9074256	Feb 10, 2031	U-1674		
		9138432	Sep 30, 2025	U-1737		
		9157121	Apr 05, 2030	U-1674		
<u>ILOPERIDONE - FANAPT</u>						
N 022192	007	8586610	Nov 02, 2027	U-1625		
		8652776	Aug 31, 2030	U-1685		
		8999638	Oct 28, 2030	U-1674		
		9072742	Jan 16, 2031	U-1674		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ILOPERIDONE - FANAPT</u>						
N 022192	007	9074254	Dec 28, 2031	U-1674		
		9074255	Dec 17, 2030	U-1674		
		9074256	Feb 10, 2031	U-1674		
		9138432	Sep 30, 2025	U-1737		
		9157121	Apr 05, 2030	U-1674		
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335	001	6958335	Dec 19, 2021	U-791		
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335	002	6958335	Dec 19, 2021	U-791		
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588	001	6958335	Dec 19, 2021	U-1883	ODE-40	Jan 25, 2020
		6958335	Dec 19, 2021	U-791		
		6958335*PED	Jun 19, 2022			
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588	002	6958335	Dec 19, 2021	U-1883	ODE-40	Jan 25, 2020
		6958335	Dec 19, 2021	U-791		
		6958335*PED	Jun 19, 2022			
<u>IMIQUIMOD - ALDARA</u>						
N 020723	001	7696159	Apr 01, 2024	DS U-1047		
		7696159	Apr 01, 2024	DS U-1048		
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483	001	10238644	Dec 11, 2029	U-68		
		10238645	Aug 18, 2029	U-1455		
		10238645	Aug 18, 2029	U-172		
		8236816	Dec 11, 2029	U-68		
		8299109	Dec 11, 2029	U-68		
		8598196	Aug 18, 2029	U-1455		
		8598196	Aug 18, 2029	U-172		
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483	002	8222270	Dec 11, 2029	U-68		
<u>INDACATEROL MALEATE - ARCAPTA NEOHALER</u>						
N 022383	001	6878721	Feb 25, 2025	DS DP U-1168		
		8067437	Jun 02, 2020	U-1168		
		8479730	Oct 11, 2028	DP		
		8658673	Jun 02, 2020	DS DP U-1168		
		8796307	Jun 02, 2020	DS DP		
<u>INDINAVIR SULFATE - CRIXIVAN</u>						
N 020685	001	6689761	Feb 10, 2021	U-554		
<u>INDINAVIR SULFATE - CRIXIVAN</u>						
N 020685	003	6689761	Feb 10, 2021	U-554		
<u>INDINAVIR SULFATE - CRIXIVAN</u>						
N 020685	005	6689761	Feb 10, 2021	U-554		
<u>INDINAVIR SULFATE - CRIXIVAN</u>						
N 020685	006	6689761	Feb 10, 2021	U-554		
<u>INDOCYANINE GREEN - SPY AGENT GREEN KIT</u>						
N 211580	001	10631746	Aug 04, 2035	DP U-2815	NP	Nov 21, 2021
		6915154	Aug 01, 2021	U-2460		
		7881777	Sep 22, 2021	U-2461		
		8185176	Jun 04, 2028	U-2462		
		8406860	Apr 09, 2029	U-2463		
		8647605	Feb 11, 2029	U-2464		
		8647605	Feb 11, 2029	U-2468		
		8892190	Aug 11, 2020	U-2465		
		9421280	Nov 24, 2025	U-2466		
		9421280	Nov 24, 2025	U-2467		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768	001	8734847	Apr 23, 2030	DP		
		8992982	Apr 23, 2030	DP		
		9089471	Apr 23, 2030		U-55	
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768	002	8734847	Apr 23, 2030	DP		
		8992982	Apr 23, 2030	DP		
		9089471	Apr 23, 2030		U-55	
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833	001	7410656	Oct 10, 2020		U-1222	
		8278292	Jul 06, 2027	DP		
		8372827	Dec 18, 2026	DP		
		8372828	Dec 18, 2026	DP		
		8377919	Dec 18, 2026	DP		
		8536163	Dec 18, 2026		U-1440	
		8716271	Dec 18, 2026		U-1440	
		8735375	Dec 18, 2026		U-1440	
		9789078	May 15, 2033		U-2138	
		9820959	Dec 18, 2026	DP	U-1440	
		9833428	Dec 18, 2026	DP		
		9833429	Dec 18, 2026	DP		
		9861603	Dec 18, 2026		U-1440	
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833	002	7410656	Oct 10, 2020		U-1222	
		8278292	Jul 06, 2027	DP		
		8372827	Dec 18, 2026	DP		
		8372828	Dec 18, 2026	DP		
		8377919	Dec 18, 2026	DP		
		8536163	Dec 18, 2026		U-1440	
		8716271	Dec 18, 2026		U-1440	
		8735375	Dec 18, 2026		U-1440	
		9820959	Dec 18, 2026	DP	U-1440	
		9833428	Dec 18, 2026	DP		
		9833429	Dec 18, 2026	DP		
		9861603	Dec 18, 2026		U-1440	
<u>INOTERSEN SODIUM - TEGSEDI</u>						
N 211172	001	7015315	Mar 21, 2023	DS		NCE Oct 05, 2023
		7101993	Sep 05, 2023	DS		ODE-212 Oct 05, 2025
		8101743	Apr 01, 2025	DS DP		
		8697860	Apr 29, 2031	DP		
		9061044	Apr 29, 2031	DS		
		9399774	Apr 29, 2031		U-2430	
<u>IOBENGUANE I-131 - AZEDRA</u>						
N 209607	001				NP	Jul 30, 2021
					ODE-204	Jul 30, 2025
<u>IODIXANOL - VISIPAQUE 320</u>						
N 020351	002				I-752	Apr 05, 2020
<u>IODIXANOL - VISIPAQUE 320</u>						
N 020808	002				I-752	Apr 05, 2020
<u>IPRATROPIUM BROMIDE - ATROVENT HFA</u>						
N 021527	001	6739333	May 26, 2020	DP		
		6983743	May 26, 2020	DP		
		8474447	Jan 17, 2030	DP		
<u>IRINOTECAN HYDROCHLORIDE - CAMPTOSAR</u>						
N 020571	001	6403569	Apr 28, 2020		U-449	
		6794370	May 01, 2020		U-606	
<u>IRINOTECAN HYDROCHLORIDE - CAMPTOSAR</u>						
N 020571	002	6403569	Apr 28, 2020		U-449	
		6794370	May 01, 2020		U-606	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793 001	10456360	Oct 15, 2036	DP		ODE-99	Oct 22, 2022
	10722508	May 02, 2025	DS DP			
	8147867	Aug 29, 2028	DS DP			
	8329213	May 02, 2025	DS DP			
	8703181	May 02, 2025		U-1434		
	8992970	May 02, 2025	DS DP			
	9339497	Jun 12, 2033		U-1848		
	9364473	Jun 12, 2033		U-1856		
	9452162	Jun 12, 2033		U-1899		
	9492442	Jun 12, 2033		U-1848		
	9492442	Jun 12, 2033		U-1899		
	9492442	Jun 12, 2033		U-1917		
	9717724	Jun 12, 2033		U-1848		
	9717724	Jun 12, 2033		U-2091		
	9724303	May 02, 2025	DS DP			
	9730891	May 02, 2025		U-1848		
	9782349	May 02, 2025	DS DP			
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500 001	6812238	Oct 31, 2025	DS		NCE	Mar 06, 2020
	7459561	Oct 31, 2020	DS		ODE-305	Mar 06, 2022
					ODE-90	Mar 06, 2022
					GAIN	Mar 06, 2025
					GAIN	Mar 06, 2027
					GAIN	Mar 06, 2027
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207501 001	6812238	Oct 31, 2025	DS		NCE	Mar 06, 2020
	7459561	Oct 31, 2020	DS		ODE-305	Mar 06, 2022
					ODE-90	Mar 06, 2022
					GAIN	Mar 06, 2025
					GAIN	Mar 06, 2027
					GAIN	Mar 06, 2027
<u>ISOPROPYL ALCOHOL - ZURAGARD</u>						
N 210872 001					NP	Apr 26, 2022
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 001	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021		U-1347		
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 002	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021		U-1347		
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 003	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021		U-1347		
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 004	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021		U-1347		
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 005	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021		U-1347		
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951	005	9089534	Sep 21, 2021	DP		
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951	006	7435427	Sep 21, 2021	DP		
		8367102	Sep 21, 2021	DP	U-1347	
		8952064	Sep 21, 2021	DP		
		9078925	Sep 21, 2021	DP		
		9089534	Sep 21, 2021	DP		
<u>ISOTRETINOIN - ABSORICA LD</u>						
N 211913	001	9700535	Aug 04, 2035	DP		
		9750711	May 29, 2035	DP		
<u>ISOTRETINOIN - ABSORICA LD</u>						
N 211913	002	9700535	Aug 04, 2035	DP		
		9750711	May 29, 2035	DP		
<u>ISOTRETINOIN - ABSORICA LD</u>						
N 211913	003	9700535	Aug 04, 2035	DP		
		9750711	May 29, 2035	DP		
<u>ISOTRETINOIN - ABSORICA LD</u>						
N 211913	004	9700535	Aug 04, 2035	DP		
		9750711	May 29, 2035	DP		
<u>ISOTRETINOIN - ABSORICA LD</u>						
N 211913	005	9700535	Aug 04, 2035	DP		
		9750711	May 29, 2035	DP		
<u>ISOTRETINOIN - ABSORICA LD</u>						
N 211913	006	9700535	Aug 04, 2035	DP		
		9750711	May 29, 2035	DP		
<u>ISTRADEFYLLINE - NOURIANZ</u>						
N 022075	001	7541363	Nov 13, 2024	DS DP		NCE Aug 27, 2024
		7727993	Jan 28, 2023	DP	U-2623	
		7727994	Jan 18, 2023	DP	U-2623	
		8318201	Sep 05, 2027	DP		
<u>ISTRADEFYLLINE - NOURIANZ</u>						
N 022075	002	7541363	Nov 13, 2024	DS DP		NCE Aug 27, 2024
		7727993	Jan 28, 2023	DP	U-2623	
		7727994	Jan 18, 2023	DP	U-2623	
		8318201	Sep 05, 2027	DP		
<u>ITRACONAZOLE - ONMEL</u>						
N 022484	001	8486456	Oct 03, 2028	DP	U-1054	
<u>ITRACONAZOLE - TOLSURA</u>						
N 208901	001	10463740	Jun 21, 2033	DP	U-2453	
		10806792	Jun 21, 2033	DP		
		8771739	Jul 25, 2023	DP		
		8921374	Jun 21, 2033	DP		
		9272046	Jun 21, 2033	DP		
		9713642	Jun 21, 2033	DP	U-2453	
<u>IVABRADINE - CORLANOR</u>						
N 209964	001	7361649	Feb 22, 2026	DS DP	U-1694	NCE Apr 15, 2020
		7361650	Feb 22, 2026	DS DP	U-1694	NP Apr 22, 2022
		7867996	Feb 22, 2026	DS DP	U-1694	ODE-234 Apr 22, 2026
		7879842	Feb 22, 2026	DS DP	U-1694	PED Oct 15, 2020
						PED Oct 22, 2022
						PED Oct 22, 2026
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143	001	7361649	Feb 22, 2026	DS DP	U-1694	NCE Apr 15, 2020
		7361649*PED	Aug 22, 2026			PED Oct 15, 2020
		7361650	Feb 22, 2026	DS DP	U-1694	
		7361650*PED	Aug 22, 2026			
		7867996	Feb 22, 2026	DS DP	U-1694	
		7867996*PED	Aug 22, 2026			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE	
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>							
N 206143 001	7879842	Feb 22, 2026	DS DP U-1694				
	7879842*PED	Aug 22, 2026					
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>							
N 206143 002	7361649	Feb 22, 2026	DS DP U-1694		NCE	Apr 15, 2020	
	7361649*PED	Aug 22, 2026			PED	Oct 15, 2020	
	7361650	Feb 22, 2026	DS DP U-1694				
	7361650*PED	Aug 22, 2026					
	7867996	Feb 22, 2026	DS DP U-1694				
	7867996*PED	Aug 22, 2026					
	7879842	Feb 22, 2026	DS DP U-1694				
	7879842*PED	Aug 22, 2026					
<u>IVACAFTOR - KALYDECO</u>							
N 203188 001	10646481	Aug 13, 2029		DP	NPP	Jul 31, 2020	
	7495103	May 20, 2027	DS DP		ODE-186	Feb 21, 2021	
	8324242	Aug 05, 2027		U-1311	ODE-187	Dec 29, 2021	
	8324242	Aug 05, 2027		U-1906	ODE-189	Jul 31, 2024	
	8354427	Jul 06, 2026		U-1311	ODE-190	May 17, 2024	
	8354427	Jul 06, 2026		U-1905	ODE-199	Aug 15, 2025	
	8410274	Dec 28, 2026		DP			
	8629162	Jun 24, 2025		U-2234			
	8754224	Dec 28, 2026	DS DP				
	9670163	Dec 28, 2026		DP U-1311			
<u>IVACAFTOR - KALYDECO</u>							
N 207925 001	10272046	Feb 27, 2033		DP U-2531	NPP	Jul 31, 2020	
	10646481	Aug 13, 2029		DP	NPP	Apr 29, 2022	
	7495103	May 20, 2027	DS DP		ODE-188	Mar 17, 2022	
	8324242	Aug 05, 2027		U-1311	ODE-189	Jul 31, 2024	
	8324242	Aug 05, 2027		U-1906	ODE-190	May 17, 2024	
	8324242	Aug 05, 2027		U-2527	ODE-199	Aug 15, 2025	
	8354427	Jul 06, 2026		U-1311	ODE-236	Apr 29, 2026	
	8354427	Jul 06, 2026		U-1905			
	8354427	Jul 06, 2026		U-2528			
	8410274	Dec 28, 2026		DP			
	8629162	Jun 24, 2025		U-2234			
	8629162	Jun 24, 2025		U-2529			
	8754224	Dec 28, 2026	DS DP				
	8883206	Feb 27, 2033		DP			
	9670163	Dec 28, 2026		DP U-1311			
	9670163	Dec 28, 2026		DP U-2530			
<u>IVACAFTOR - KALYDECO</u>							
N 207925 002	10272046	Feb 27, 2033		DP U-2531	NPP	Jul 31, 2020	
	10646481	Aug 13, 2029		DP	NPP	Apr 29, 2022	
	7495103	May 20, 2027	DS DP		ODE-188	Mar 17, 2022	
	8324242	Aug 05, 2027		U-1311	ODE-189	Jul 31, 2024	
	8324242	Aug 05, 2027		U-1906	ODE-190	May 17, 2024	
	8324242	Aug 05, 2027		U-2527	ODE-199	Aug 15, 2025	
	8354427	Jul 06, 2026		U-1311	ODE-236	Apr 29, 2026	
	8354427	Jul 06, 2026		U-1905			
	8354427	Jul 06, 2026		U-2528			
	8410274	Dec 28, 2026		DP			
	8629162	Jun 24, 2025		U-2234			
	8629162	Jun 24, 2025		U-2529			
	8754224	Dec 28, 2026	DS DP				
	8883206	Feb 27, 2033		DP			
	9670163	Dec 28, 2026		DP U-1311			
	9670163	Dec 28, 2026		DP U-2530			
<u>IVACAFTOR - KALYDECO</u>							
N 207925 003	10272046	Feb 27, 2033		DP U-2967	NPP	Jul 31, 2020	
	10646481	Aug 13, 2029		DP	NPP	Apr 29, 2022	
	7495103	May 20, 2027	DS DP		ODE-188	Mar 17, 2022	
	8324242	Aug 05, 2027		U-1311	ODE-189	Jul 31, 2024	
	8324242	Aug 05, 2027		U-1906	ODE-190	May 17, 2024	
	8324242	Aug 05, 2027		U-2963	ODE-199	Aug 15, 2025	
	8354427	Jul 06, 2026		U-1311	ODE-236	Apr 29, 2026	
	8354427	Jul 06, 2026		U-1905			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR - KALYDECO</u>						
N 207925	003	8354427	Jul 06, 2026	U-2964		
		8410274	Dec 28, 2026	DP		
		8629162	Jun 24, 2025	U-2234		
		8629162	Jun 24, 2025	U-2965		
		8754224	Dec 28, 2026	DS DP		
		8883206	Feb 27, 2033	DP		
		9670163	Dec 28, 2026	DP	U-1311	
		9670163	Dec 28, 2026	DP	U-2966	
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491	001	10022352	Apr 09, 2027	DP	U-2343	NCE Feb 12, 2023
		10022352	Apr 09, 2027	DP	U-2573	NPP Jun 21, 2022
		10058546	Jul 15, 2033	U-2399		ODE-173 Feb 12, 2025
		10058546	Jul 15, 2033	U-2572		ODE-247 Jun 21, 2026
		10081621	Mar 25, 2031	DP	U-2420	
		10081621	Mar 25, 2031	DP	U-2571	
		10206877	Apr 14, 2035	DP	U-2498	
		10206877	Apr 14, 2035	DP	U-2570	
		10239867	Apr 09, 2027	DS DP	U-2512	
		10239867	Apr 09, 2027	DS DP	U-2569	
		10646481	Aug 13, 2029	DP		
		7495103	May 20, 2027	DS DP		
		7645789	May 01, 2027	DS DP		
		7776905	Jun 03, 2027	DS DP		
		8324242	Aug 05, 2027	U-2246		
		8410274	Dec 28, 2026	DP		
		8415387	Nov 12, 2027	U-2246		
		8598181	May 01, 2027	U-2246		
		8623905	May 01, 2027	DS DP		
		8629162	Jun 24, 2025	U-2247		
		8754224	Dec 28, 2026	DS DP		
		9012496	Jul 15, 2033	U-2248		
		9670163	Dec 28, 2026	DP	U-2246	
		9931334	Dec 28, 2026	DP	U-2275	
		9931334	Dec 28, 2026	DP	U-2575	
		9974781	Apr 09, 2027	DP	U-2318	
		9974781	Apr 09, 2027	DP	U-2574	
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491	002	10022352	Apr 09, 2027	DP	U-2343	NCE Feb 12, 2023
		10022352	Apr 09, 2027	DP	U-2573	NPP Jun 21, 2022
		10058546	Jul 15, 2033	U-2399		ODE-173 Feb 12, 2025
		10058546	Jul 15, 2033	U-2572		ODE-247 Jun 21, 2026
		10081621	Mar 25, 2031	DP	U-2420	
		10081621	Mar 25, 2031	DP	U-2571	
		10206877	Apr 14, 2035	DP	U-2498	
		10206877	Apr 14, 2035	DP	U-2570	
		10239867	Apr 09, 2027	DS DP	U-2512	
		10239867	Apr 09, 2027	DS DP	U-2569	
		10646481	Aug 13, 2029	DP		
		7495103	May 20, 2027	DS DP		
		7645789	May 01, 2027	DS DP		
		7776905	Jun 03, 2027	DS DP		
		8324242	Aug 05, 2027	U-2246		
		8410274	Dec 28, 2026	DP		
		8415387	Nov 12, 2027	U-2246		
		8598181	May 01, 2027	U-2246		
		8623905	May 01, 2027	DS DP		
		8629162	Jun 24, 2025	U-2247		
		8754224	Dec 28, 2026	DS DP		
		9012496	Jul 15, 2033	U-2248		
		9670163	Dec 28, 2026	DP	U-2246	
		9931334	Dec 28, 2026	DP	U-2275	
		9931334	Dec 28, 2026	DP	U-2575	
		9974781	Apr 09, 2027	DP	U-2318	
		9974781	Apr 09, 2027	DP	U-2574	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	10076513	Dec 04, 2028	DP U-2411		M-218	Jan 25, 2021
	10597384	Dec 04, 2028	DS DP U-2777		NCE	Jul 02, 2020
	10646481	Aug 13, 2029	DP		ODE-123	Sep 28, 2023
	7495103	May 20, 2027	DS DP		ODE-93	Jul 02, 2022
	7973038	Nov 08, 2026	U-1973			
	8324242	Aug 05, 2027	U-1311			
	8324242	Aug 05, 2027	U-1911			
	8410274	Dec 28, 2026	DP			
	8507534	Sep 20, 2030	DS DP			
	8653103	Dec 04, 2028	DP			
	8716338	Sep 20, 2030	DP U-1718			
	8716338	Sep 20, 2030	DP U-1910			
	8741933	Nov 08, 2026	U-1717			
	8741933	Nov 08, 2026	U-1909			
	8754224	Dec 28, 2026	DS DP			
	8846718	Dec 04, 2028	U-1717			
	8846718	Dec 04, 2028	U-1908			
	8993600	Dec 11, 2030	DP			
	9150552	Dec 04, 2028	U-1908			
	9192606	Sep 29, 2029	DP U-1912			
	9216969	Nov 08, 2026	DS DP			
	9670163	Dec 28, 2026	DP U-1911			
	9931334	Dec 28, 2026	DP U-2276			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002	10597384	Dec 04, 2028	DS DP U-2777		M-218	Jan 25, 2021
	10646481	Aug 13, 2029	DP		NCE	Jul 02, 2020
	7495103	May 20, 2027	DS DP		ODE-123	Sep 28, 2023
	7973038	Nov 08, 2026	U-1973		ODE-93	Jul 02, 2022
	8324242	Aug 05, 2027	U-1911			
	8410274	Dec 28, 2026	DP			
	8507534	Sep 20, 2030	DS DP			
	8653103	Dec 04, 2028	DP			
	8716338	Sep 20, 2030	DP U-1910			
	8741933	Nov 08, 2026	U-1909			
	8754224	Dec 28, 2026	DS DP			
	8846718	Dec 04, 2028	U-1908			
	8993600	Dec 11, 2030	DP			
	9150552	Dec 04, 2028	U-1908			
	9192606	Sep 29, 2029	DP U-1912			
	9216969	Nov 08, 2026	DP			
	9670163	Dec 28, 2026	DP U-1911			
	9931334	Dec 28, 2026	DP U-2276			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 001	10597384	Dec 04, 2028	DS DP U-2778		NCE	Jul 02, 2020
	10646481	Aug 13, 2029	DP		NP	Aug 07, 2021
	7495103	May 20, 2027	DS DP		ODE-195	Aug 07, 2025
	7973038	Nov 08, 2026	U-2374			
	8324242	Aug 05, 2027	U-2374			
	8410274	Dec 28, 2026	DP			
	8507534	Sep 20, 2030	DS DP			
	8653103	Dec 04, 2028	DP			
	8716338	Sep 20, 2030	DP U-2396			
	8741933	Nov 08, 2026	U-2374			
	8754224	Dec 28, 2026	DS DP			
	8846718	Dec 04, 2028	U-2375			
	8993600	Dec 11, 2030	DP			
	9150552	Dec 04, 2028	U-2375			
	9192606	Sep 29, 2029	DP U-2397			
	9216969	Nov 08, 2026	DP			
	9670163	Dec 28, 2026	DP U-2376			
	9931334	Dec 28, 2026	DP U-2376			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 002	10597384	Dec 04, 2028	DS DP U-2778		NCE	Jul 02, 2020
	10646481	Aug 13, 2029	DP		NP	Aug 07, 2021
	7495103	May 20, 2027	DS DP		ODE-195	Aug 07, 2025
	7973038	Nov 08, 2026	U-2374			
	8324242	Aug 05, 2027	U-2374			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358	002 8410274	Dec 28, 2026	DP			
	8507534	Sep 20, 2030	DS DP			
	8653103	Dec 04, 2028	DP			
	8716338	Sep 20, 2030	DP	U-2396		
	8741933	Nov 08, 2026		U-2374		
	8754224	Dec 28, 2026	DS DP			
	8846718	Dec 04, 2028		U-2375		
	8993600	Dec 11, 2030	DP			
	9150552	Dec 04, 2028		U-2375		
	9192606	Sep 29, 2029	DP	U-2397		
	9216969	Nov 08, 2026	DP			
	9670163	Dec 28, 2026	DP	U-2376		
	9931334	Dec 28, 2026	DP	U-2376		
<u>IVERMECTIN - IVERMECTIN</u>						
A 210019	001				PC	Apr 11, 2020
<u>IVERMECTIN - SKLICE</u>						
N 202736	001 8791153	Oct 12, 2027	DP	Y		
	8927595	Oct 12, 2027		U-1782	Y	
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255	001 10206939	Mar 13, 2034		U-1631		
	7550440	Apr 22, 2024	DP	U-1631		
	8080530	Apr 22, 2024	DP	U-1631		
	8093219	Apr 22, 2024	DP	U-1631		
	8415311	Apr 22, 2024	DP	U-1631		
	8470788	Apr 22, 2024	DP	U-1631		
	8815816	Apr 22, 2024	DP	U-1631		
	9089587	Mar 13, 2034		U-1631		
	9233117	Mar 13, 2034		U-1631		
	9233118	Mar 13, 2034		U-1631		
	9782425	Mar 13, 2034		U-1631		
<u>IVOSIDENIB - TIBSOVO</u>						
N 211192	001 10449184	Mar 13, 2035	DP		I-816	May 02, 2022
	10610125	Jun 21, 2030		U-2784	NCE	Jul 20, 2023
	10610125	Jun 21, 2030		U-2785	ODE-203	Jul 20, 2025
	10799490	Mar 13, 2035	DP	U-2981	ODE-242	May 02, 2026
	10799490	Mar 13, 2035	DP	U-2982		
	9474779	Aug 19, 2033	DS DP	U-2350		
	9474779	Aug 19, 2033	DS DP	U-2533		
	9474779	Aug 19, 2033	DS DP	U-2534		
	9850277	Jan 18, 2033	DS DP	U-2350		
	9850277	Jan 18, 2033	DS DP	U-2533		
	9850277	Jan 18, 2033	DS DP	U-2534		
	9968595	Mar 13, 2035	DP	U-2351		
	9968595	Mar 13, 2035	DP	U-2533		
	9968595	Mar 13, 2035	DP	U-2534		
<u>IXABEPILONE - IXEMPRA KIT</u>						
N 022065	001 6670384	Jan 23, 2022	DP	U-959		
	6670384	Jan 23, 2022	DP	U-960		
	7022330	Jan 23, 2022	DP	U-958		
	7312237	Aug 21, 2024		U-965		
	RE41393	Feb 08, 2022		U-961		
	RE41911	Sep 28, 2020	DS DP	U-961		
<u>IXABEPILONE - IXEMPRA KIT</u>						
N 022065	002 6670384	Jan 23, 2022	DP	U-959		
	6670384	Jan 23, 2022	DP	U-960		
	7022330	Jan 23, 2022	DP	U-958		
	7312237	Aug 21, 2024		U-965		
	RE41393	Feb 08, 2022		U-961		
	RE41911	Sep 28, 2020	DS DP	U-961		
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462	001 7442830	Nov 20, 2029	DS DP	U-2434	NCE	Nov 20, 2020
	7687662	Aug 06, 2027	DS DP		ODE-103	Nov 20, 2022
	8003819	Aug 06, 2027	DS DP	U-2434		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462	001	8530694	Aug 06, 2027	DS DP	U-2434	
		8546608	Aug 12, 2024	DS		
		8859504	Jun 16, 2029	DS DP		
		8871745	Aug 06, 2027		U-2434	
		9175017	Jun 16, 2029		U-2434	
		9233115	Aug 12, 2024		U-2434	
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462	002	7442830	Nov 20, 2029	DS DP	U-2434	NCE Nov 20, 2020
		7687662	Aug 06, 2027	DS DP		ODE-103 Nov 20, 2022
		8003819	Aug 06, 2027	DS DP	U-2434	
		8530694	Aug 06, 2027	DS DP	U-2434	
		8546608	Aug 12, 2024	DS		
		8859504	Jun 16, 2029	DS DP		
		8871745	Aug 06, 2027		U-2434	
		9175017	Jun 16, 2029		U-2434	
		9233115	Aug 12, 2024		U-2434	
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462	003	7442830	Nov 20, 2029	DS DP	U-2434	NCE Nov 20, 2020
		7687662	Aug 06, 2027	DS DP		ODE-103 Nov 20, 2022
		8003819	Aug 06, 2027	DS DP	U-2434	
		8530694	Aug 06, 2027	DS DP	U-2434	
		8546608	Aug 12, 2024	DS		
		8859504	Jun 16, 2029	DS DP		
		8871745	Aug 06, 2027		U-2434	
		9175017	Jun 16, 2029		U-2434	
		9233115	Aug 12, 2024		U-2434	
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528	001	8008338	May 24, 2027	DS DP	U-1181	
		8207215	May 28, 2024		U-1251	
		8377982	May 28, 2024		U-1363	
		8377982*PED	Nov 28, 2024			
		8541463	May 28, 2024		U-1441	
		8541463*PED	Nov 28, 2024			
		8648107	May 28, 2024	DP		
		8906950	May 28, 2024		U-1626	
		8946281	May 28, 2024		U-1662	
		9216167	May 28, 2024		U-1800	
<u>KETOROLAC TROMETHAMINE - ACUVAIL</u>						
N 022427	001	7842714	Aug 15, 2029	DS DP		
		8512717	Mar 07, 2028	DP		
		8992952	Aug 05, 2024	DP		
		9192571	Mar 07, 2028	DP		
<u>KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - Omidria</u>						
N 205388	001	8173707	Jul 30, 2023		U-1518	NPP Dec 08, 2020
		8173707*PED	Jan 30, 2024			PED Jun 08, 2021
		8586633	Jul 30, 2023	DP		
		8586633*PED	Jan 30, 2024			
		9066856	Oct 23, 2033	DP		
		9066856*PED	Apr 23, 2034			
		9278101	Jul 30, 2023		U-1518	
		9278101*PED	Jan 30, 2024			
		9399040	Jul 30, 2023	DP		
		9399040*PED	Jan 30, 2024			
		9486406	Oct 23, 2033	DP		
		9486406*PED	Apr 23, 2034			
		9855246	Oct 23, 2033	DP		
<u>L-GLUTAMINE - ENDARI</u>						
N 208587	001					I-748 Jul 07, 2020
						ODE-150 Jul 07, 2024
<u>LACOSAMIDE - VIMPAT</u>						
N 022253	001	RE38551	Mar 17, 2022	DS DP	U-1567	NPP Nov 03, 2020
		RE38551	Mar 17, 2022	DS DP	U-2140	
		RE38551	Mar 17, 2022	DS DP	U-2989	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LACOSAMIDE - VIMPAT</u>						
N 022253	001	RE38551	Mar 17, 2022	DS DP U-2990		
		RE38551	Mar 17, 2022	DS DP U-2999		
<u>LACOSAMIDE - VIMPAT</u>						
N 022253	002	RE38551	Mar 17, 2022	DS DP U-1567	NPP	Nov 03, 2020
		RE38551	Mar 17, 2022	DS DP U-2140		
		RE38551	Mar 17, 2022	DS DP U-2989		
		RE38551	Mar 17, 2022	DS DP U-2990		
		RE38551	Mar 17, 2022	DS DP U-2999		
<u>LACOSAMIDE - VIMPAT</u>						
N 022253	003	RE38551	Mar 17, 2022	DS DP U-1567	NPP	Nov 03, 2020
		RE38551	Mar 17, 2022	DS DP U-2140		
		RE38551	Mar 17, 2022	DS DP U-2989		
		RE38551	Mar 17, 2022	DS DP U-2990		
		RE38551	Mar 17, 2022	DS DP U-2999		
<u>LACOSAMIDE - VIMPAT</u>						
N 022253	004	RE38551	Mar 17, 2022	DS DP U-1567	NPP	Nov 03, 2020
		RE38551	Mar 17, 2022	DS DP U-2140		
		RE38551	Mar 17, 2022	DS DP U-2989		
		RE38551	Mar 17, 2022	DS DP U-2990		
		RE38551	Mar 17, 2022	DS DP U-2999		
<u>LACOSAMIDE - VIMPAT</u>						
N 022254	001	RE38551	Mar 17, 2022	DS DP U-1565	M-217	Nov 03, 2020
		RE38551	Mar 17, 2022	DS DP U-1568		
		RE38551	Mar 17, 2022	DS DP U-2989		
		RE38551	Mar 17, 2022	DS DP U-2990		
		RE38551	Mar 17, 2022	DS DP U-2999		
<u>LACOSAMIDE - VIMPAT</u>						
N 022255	001	RE38551	Mar 17, 2022	DS DP U-1567	NPP	Nov 03, 2020
		RE38551	Mar 17, 2022	DS DP U-2140		
		RE38551	Mar 17, 2022	DS DP U-2989		
		RE38551	Mar 17, 2022	DS DP U-2990		
		RE38551	Mar 17, 2022	DS DP U-2999		
<u>LACTITOL - PIZENSY</u>						
N 211281	001	10806743	May 12, 2037	U-1516	NCE	Feb 12, 2025
<u>LAMIVUDINE; RALTEGRAVIR POTASSIUM - DUTREBIS</u>						
N 206510	001	7169780	Oct 03, 2023	DS DP		
		7169780*PED	Apr 03, 2024			
		7217713	Oct 21, 2022	U-1663		
		7217713*PED	Apr 21, 2023			
		7435734	Oct 21, 2022	U-1663		
		7435734*PED	Apr 21, 2023			
		7754731	Mar 11, 2029	DS DP U-1663		
		7754731*PED	Sep 11, 2029			
		7820660	Apr 25, 2023	DS		
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115	001	8637512	Jun 14, 2028	DP		
		9144547	Sep 22, 2023	DP		
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115	002	8637512	Jun 14, 2028	DP		
		9144547	Sep 22, 2023	DP		
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115	003	8637512	Jun 14, 2028	DP		
		9144547	Sep 22, 2023	DP		
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115	004	8637512	Jun 14, 2028	DP		
		9144547	Sep 22, 2023	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115	005	8637512	Jun 14, 2028	DP		
		9144547	Sep 22, 2023	DP		
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115	006	8637512	Jun 14, 2028	DP		
		9144547	Sep 22, 2023	DP		
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251	001	7919115	Jan 04, 2029	DS DP		
		8840925	Jul 02, 2028	DP U-1596		
		9339504	Jul 02, 2028	DP U-1596		
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251	004	7919115	Jan 04, 2029	DS DP		
		8840925	Jul 02, 2028	DP U-1596		
		9339504	Jul 02, 2028	DP U-1596		
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N 022074	001	5595760	Mar 08, 2020	DP U-831	I-754	Sep 15, 2020
					ODE-156	Sep 15, 2024
					ODE-82	Dec 16, 2021
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N 022074	002	5595760	Mar 08, 2020	DP U-831	I-754	Sep 15, 2020
					ODE-156	Sep 15, 2024
					ODE-82	Dec 16, 2021
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N 022074	003	5595760	Mar 08, 2020	DP U-831	I-754	Sep 15, 2020
					ODE-156	Sep 15, 2024
					ODE-82	Dec 16, 2021
<u>LANSOPRAZOLE - PREVACID IV</u>						
N 021566	001	7396841	Aug 17, 2021	DP U-947		
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 021468	001	7381428	Aug 26, 2024		U-890	
		7465465	Aug 26, 2024	DP		
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 021468	002	7381428	Aug 26, 2024		U-890	
		7465465	Aug 26, 2024	DP		
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 021468	003	7381428	Aug 26, 2024		U-890	
		7465465	Aug 26, 2024	DP		
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 021468	004	7381428	Aug 26, 2024		U-890	
		7465465	Aug 26, 2024	DP		
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 204734	001	7465465	Aug 26, 2024	DP		
		8980327	Dec 01, 2030	DP		
		9023397	Dec 01, 2030	DP		
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 204734	002	7465465	Aug 26, 2024	DP		
		8980327	Dec 01, 2030	DP		
		9023397	Dec 01, 2030	DP		
<u>LAPATINIB DITOSYLATE - TYKERB</u>						
N 022059	001	6713485	Sep 29, 2020	DS DP U-1429	M-235	Dec 06, 2021
		6713485	Sep 29, 2020	DS DP U-800		
		7157466	Nov 19, 2021	DS DP		
		8821927	Sep 18, 2029	DS DP		
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861	001	10005783	Oct 21, 2029		NCE	Nov 26, 2023
		10047097	Oct 21, 2029		ODE-215	Nov 26, 2025
		10172861	Nov 16, 2035	DS DP	ODE-220	Nov 26, 2025

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861	001	10285993	Nov 16, 2035	U-2470	ODE-221	Nov 26, 2025
		10774085	Oct 21, 2029	U-2470		
		10813936	Nov 16, 2035	U-2987		
		8513263	Dec 23, 2029	DS DP		
		8865698	Oct 21, 2029	U-2469		
		9127013	Oct 21, 2029	DS DP		
		9447104	Oct 21, 2029	U-2470		
		9676783	Oct 21, 2029	U-2469		
		9782414	Nov 16, 2035	U-2475		
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861	002	10005783	Oct 21, 2029	U-2472	NCE	Nov 26, 2023
		10047097	Oct 21, 2029	U-2474	ODE-215	Nov 26, 2025
		10172861	Nov 16, 2035	DS DP	ODE-220	Nov 26, 2025
		10285993	Nov 16, 2035	U-2470	ODE-221	Nov 26, 2025
		10774085	Oct 21, 2029	U-2470		
		10813936	Nov 16, 2035	U-2987		
		8513263	Dec 23, 2029	DS DP		
		8865698	Oct 21, 2029	U-2469		
		9127013	Oct 21, 2029	DS DP		
		9447104	Oct 21, 2029	U-2470		
		9676783	Oct 21, 2029	U-2469		
		9782414	Nov 16, 2035	U-2475		
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 211710	001	10005783	Oct 21, 2029	U-2472	NCE	Nov 26, 2023
		10045991	Apr 04, 2037	U-2473	ODE-215	Nov 26, 2025
		10047097	Oct 21, 2029	U-2474	ODE-220	Nov 26, 2025
		10137127	Apr 04, 2037	DP	ODE-221	Nov 26, 2025
		10172861	Nov 16, 2035	DS		
		10668072	Apr 04, 2037	DP		
		10774085	Oct 21, 2029	U-2470		
		8513263	Dec 23, 2029	DS DP		
		8865698	Oct 21, 2029	U-2469		
		9127013	Oct 21, 2029	DS DP		
		9447104	Oct 21, 2029	U-2470		
		9676783	Oct 21, 2029	U-2469		
		9782414	Nov 16, 2035	U-2471		
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280	001	7423050	Apr 06, 2025	DS DP U-1719	NCE	Jan 31, 2025
		8748459	Mar 27, 2023	U-1719		
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280	002	7423050	Apr 06, 2025	DS DP U-1719	NCE	Jan 31, 2025
		8748459	Mar 27, 2023	U-1719		
<u>LATANOPROST - XELPROS</u>						
N 206185	001	9539262	Oct 15, 2028	U-2400		
		9629852	Sep 12, 2029	DP		
<u>LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN</u>						
N 208259	001	10174017	Jan 27, 2030	DS DP U-1524	NC	Mar 12, 2022
		10532993	Jul 11, 2026	U-1524	NCE	Dec 18, 2022
		10588901	Mar 14, 2034	DS DP U-1524		
		10654844	Jan 27, 2030	DS DP U-1524		
		8394826	Nov 10, 2030	DS DP U-1524		
		8450344	Jul 11, 2026	DS DP U-1524		
		9096569	Jul 11, 2026	DS DP U-1524		
		9415043	Mar 14, 2034	DS		
		9931336	Mar 14, 2034	DS DP U-1524		
		9993470	Mar 14, 2034	DS DP U-1524		
<u>LATANOPROSTENE BUNOD - VYZULTA</u>						
N 207795	001	7273946	Oct 03, 2025	DS DP U-2144		
		7629345	Jan 05, 2025	DP U-2144		
		7910767	Jan 05, 2025	DS DP U-2144		
		8058467	Jan 05, 2025	DS U-2144		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001	10039779	Jan 30, 2034	DS DP U-2369		D-177	Nov 15, 2022
	10039779	Jan 30, 2034	DS DP U-2370		NPP	Apr 07, 2020
	10039779*PED	Jul 30, 2034			ODE-136	Apr 07, 2024
	10456414	Sep 14, 2032		DP	PED	Oct 07, 2024
	7964580	Mar 26, 2029	DS DP U-1470			
	7964580*PED	Sep 26, 2029				
	8088368	May 12, 2030	DS DP			
	8088368*PED	Nov 12, 2030				
	8273341	May 12, 2030		U-1470		
	8273341*PED	Nov 12, 2030				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028			U-1470	
	8735372*PED	Sep 21, 2028				
	8822430	May 12, 2030	DS DP U-1470			
	8822430*PED	Nov 12, 2030				
	8841278	May 12, 2030		DP U-1470		
	8841278*PED	Nov 12, 2030				
	8889159	Mar 26, 2029		DP U-1470		
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9393256	Sep 14, 2032			U-1470	
	9393256*PED	Mar 14, 2033				
	9511056	May 12, 2030		DP U-1470		
	9511056*PED	Nov 12, 2030				
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 002	10039779	Jan 30, 2034	DS DP U-1470		D-177	Nov 15, 2022
	10039779*PED	Jul 30, 2034				
	10456414	Sep 14, 2032		DP		
	7964580	Mar 26, 2029	DS DP U-1470			
	7964580*PED	Sep 26, 2029				
	8088368	May 12, 2030	DS DP			
	8088368*PED	Nov 12, 2030				
	8273341	May 12, 2030		U-1470		
	8273341*PED	Nov 12, 2030				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028			U-1470	
	8735372*PED	Sep 21, 2028				
	8822430	May 12, 2030	DS DP U-1470			
	8822430*PED	Nov 12, 2030				
	8841278	May 12, 2030		DP U-1470		
	8841278*PED	Nov 12, 2030				
	8889159	Mar 26, 2029		DP U-1470		
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9393256	Sep 14, 2032			U-1470	
	9393256*PED	Mar 14, 2033				
	9511056	May 12, 2030		U-1470		
	9511056*PED	Nov 12, 2030				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 212477 001	10456414	Sep 14, 2032	DP		D-177	Nov 15, 2022
	7964580	Mar 26, 2029	DS DP U-1470		ODE-262	Aug 28, 2026
	7964580*PED	Sep 26, 2029			ODE-263	Aug 28, 2026
	8088368	May 12, 2030	DS DP		ODE-264	Aug 28, 2026
	8088368*PED	Nov 12, 2030				
	8273341	May 12, 2030		U-1470		
	8273341*PED	Nov 12, 2030				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028		U-1470		
	8735372*PED	Sep 21, 2028				
	8822430	May 12, 2030	DS DP U-1470			
	8822430*PED	Nov 12, 2030				
	8841278	May 12, 2030	DP U-1470			
	8841278*PED	Nov 12, 2030				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9393256	Sep 14, 2032		U-1470		
	9393256*PED	Mar 14, 2033				
	9511056	May 12, 2030		U-1470		
	9511056*PED	Nov 12, 2030				
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 212477 002	10456414	Sep 14, 2032	DP		D-177	Nov 15, 2022
	7964580	Mar 26, 2029	DS DP U-1470		ODE-262	Aug 28, 2026
	7964580*PED	Sep 26, 2029			ODE-263	Aug 28, 2026
	8088368	May 12, 2030	DS DP		ODE-264	Aug 28, 2026
	8088368*PED	Nov 12, 2030				
	8273341	May 12, 2030		U-1470		
	8273341*PED	Nov 12, 2030				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028		U-1470		
	8735372*PED	Sep 21, 2028				
	8822430	May 12, 2030	DS DP U-1470			
	8822430*PED	Nov 12, 2030				
	8841278	May 12, 2030	DP U-1470			
	8841278*PED	Nov 12, 2030				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9393256	Sep 14, 2032		U-1470		
	9393256*PED	Mar 14, 2033				
	9511056	May 12, 2030		U-1470		
	9511056*PED	Nov 12, 2030				
<u>LEFAMULIN ACETATE - XENLETA</u>						
N 211672 001	6753445	Jul 09, 2021	DS DP U-2619		NCE	Aug 19, 2024
	8071643	Jan 16, 2029	DS DP		GAIN	Aug 19, 2029
	8153689	Mar 19, 2028	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEFAMULIN ACETATE - XENLETA</u>						
N 211672	001 9120727	May 23, 2031	DS DP			
<u>LEFAMULIN ACETATE - XENLETA</u>						
N 211673	001 6753445	Jul 09, 2021	DS DP U-2619		NCE	Aug 19, 2024
	8071643	Jan 16, 2029	DS DP		GAIN	Aug 19, 2029
	8153689	Mar 19, 2028	DS DP			
<u>LEMBOREXANT - DAYVIGO</u>						
N 212028	001 10188652	Oct 21, 2035		DP U-2791		
	8268848	Sep 20, 2031	DS DP	U-2791	NCE	Apr 07, 2025
<u>LEMBOREXANT - DAYVIGO</u>						
N 212028	002 10188652	Oct 21, 2035		DP U-2791		
	8268848	Sep 20, 2031	DS DP	U-2791	NCE	Apr 07, 2025
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880	001 6315720	Oct 23, 2020		U-1210	I-796	May 28, 2022
	6561977	Oct 23, 2020		U-1210	I-797	May 28, 2022
	6755784	Oct 23, 2020		U-1210	ODE-131	Feb 22, 2024
	7189740	Apr 11, 2023		U-1982	ODE-241	May 28, 2026
	7465800	Apr 27, 2027	DS DP		ODE-245	May 28, 2026
	7468363	Oct 07, 2023		U-1983	ODE-49	Jun 05, 2020
	7468363	Oct 07, 2023		U-2550	ODE-88	Feb 17, 2022
	7468363	Oct 07, 2023		U-2551		
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023		U-1984		
	8315886	Oct 23, 2020		U-1249		
	8404717	Apr 11, 2023		U-1982		
	8492406	Oct 07, 2023		U-2550		
	8530498	May 15, 2023		U-1984		
	8626531	Oct 23, 2020		U-1210		
	8648095	May 15, 2023		U-1984		
	8741929	Mar 08, 2028		U-1983		
	9056120	Apr 11, 2023		U-1982		
	9101621	May 15, 2023		U-1985		
	9101622	May 15, 2023		U-1986		
	9155730	May 15, 2023		U-2550		
	9393238	May 15, 2023		U-2550		
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880	002 6315720	Oct 23, 2020		U-1210	I-796	May 28, 2022
	6561977	Oct 23, 2020		U-1210	I-797	May 28, 2022
	6755784	Oct 23, 2020		U-1210	ODE-131	Feb 22, 2024
	7189740	Apr 11, 2023		U-1982	ODE-241	May 28, 2026
	7465800	Apr 27, 2027	DS DP		ODE-245	May 28, 2026
	7468363	Oct 07, 2023		U-1983	ODE-49	Jun 05, 2020
	7468363	Oct 07, 2023		U-2550	ODE-88	Feb 17, 2022
	7468363	Oct 07, 2023		U-2551		
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023		U-1984		
	8315886	Oct 23, 2020		U-1249		
	8404717	Apr 11, 2023		U-1982		
	8492406	Oct 07, 2023		U-2550		
	8530498	May 15, 2023		U-1984		
	8626531	Oct 23, 2020		U-1210		
	8648095	May 15, 2023		U-1984		
	8741929	Mar 08, 2028		U-1983		
	9056120	Apr 11, 2023		U-1982		
	9101621	May 15, 2023		U-1985		
	9101622	May 15, 2023		U-1986		
	9155730	May 15, 2023		U-2550		
	9393238	May 15, 2023		U-2550		
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880	003 6315720	Oct 23, 2020		U-1210	I-796	May 28, 2022
	6561977	Oct 23, 2020		U-1210	I-797	May 28, 2022
	6755784	Oct 23, 2020		U-1210	ODE-131	Feb 22, 2024
	7189740	Apr 11, 2023		U-1982	ODE-241	May 28, 2026
	7465800	Apr 27, 2027	DS DP		ODE-245	May 28, 2026
	7468363	Oct 07, 2023		U-1983	ODE-49	Jun 05, 2020

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLMID</u>						
N 021880 003	7468363	Oct 07, 2023	U-2550		ODE-88	Feb 17, 2022
	7468363	Oct 07, 2023	U-2551			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1984			
	8315886	Oct 23, 2020	U-1249			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
<u>LENALIDOMIDE - REVLMID</u>						
N 021880 004	6315720	Oct 23, 2020	U-1210		I-796	May 28, 2022
	6561977	Oct 23, 2020	U-1210		I-797	May 28, 2022
	6755784	Oct 23, 2020	U-1210		ODE-131	Feb 22, 2024
	7189740	Apr 11, 2023	U-1982		ODE-241	May 28, 2026
	7465800	Apr 27, 2027	DS DP		ODE-245	May 28, 2026
	7468363	Oct 07, 2023	U-1983		ODE-49	Jun 05, 2020
	7468363	Oct 07, 2023	U-2550		ODE-88	Feb 17, 2022
	7468363	Oct 07, 2023	U-2551			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1984			
	8315886	Oct 23, 2020	U-1249			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
<u>LENALIDOMIDE - REVLMID</u>						
N 021880 005	6315720	Oct 23, 2020	U-1210		I-796	May 28, 2022
	6561977	Oct 23, 2020	U-1210		I-797	May 28, 2022
	6755784	Oct 23, 2020	U-1210		ODE-131	Feb 22, 2024
	7189740	Apr 11, 2023	U-1982		ODE-241	May 28, 2026
	7465800	Apr 27, 2027	DS DP		ODE-245	May 28, 2026
	7468363	Oct 07, 2023	U-1983		ODE-49	Jun 05, 2020
	7468363	Oct 07, 2023	U-2550		ODE-88	Feb 17, 2022
	7468363	Oct 07, 2023	U-2551			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1984			
	8315886	Oct 23, 2020	U-1249			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
<u>LENALIDOMIDE - REVLMID</u>						
N 021880 006	6315720	Oct 23, 2020	U-1210		I-796	May 28, 2022
	6561977	Oct 23, 2020	U-1210		I-797	May 28, 2022
	6755784	Oct 23, 2020	U-1210		ODE-131	Feb 22, 2024
	7189740	Apr 11, 2023	U-1982		ODE-241	May 28, 2026

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880	006	7465800	Apr 27, 2027	DS DP	ODE-245	May 28, 2026
		7468363	Oct 07, 2023	U-1983	ODE-49	Jun 05, 2020
		7468363	Oct 07, 2023	U-2550	ODE-88	Feb 17, 2022
		7468363	Oct 07, 2023	U-2551		
		7855217	Nov 24, 2024	DS DP		
		7968569	Oct 07, 2023	U-1984		
		8315886	Oct 23, 2020	U-1249		
		8404717	Apr 11, 2023	U-1982		
		8492406	Oct 07, 2023	U-2550		
		8530498	May 15, 2023	U-1984		
		8626531	Oct 23, 2020	U-1210		
		8648095	May 15, 2023	U-1984		
		8741929	Mar 08, 2028	U-1983		
		9056120	Apr 11, 2023	U-1982		
		9101621	May 15, 2023	U-1985		
		9101622	May 15, 2023	U-1986		
		9155730	May 15, 2023	U-2550		
		9393238	May 15, 2023	U-2550		
<u>LENAVATINIB MESYLATE - LENVIMA</u>						
N 206947	001	10259791	Aug 26, 2035	DS	I-787	Aug 15, 2021
		10407393	Aug 26, 2035	DS	I-807	Sep 17, 2022
		7253286	Oct 19, 2021	DS DP	NCE	Feb 13, 2020
		7612208	Sep 19, 2026	DS DP	ODE-196	Aug 15, 2025
		9006256	Jul 27, 2027	U-1695	ODE-87	Feb 13, 2022
<u>LENAVATINIB MESYLATE - LENVIMA</u>						
N 206947	002	10259791	Aug 26, 2035	DS	I-787	Aug 15, 2021
		10407393	Aug 26, 2035	DS	I-807	Sep 17, 2022
		7253286	Oct 19, 2021	DS DP	NCE	Feb 13, 2020
		7612208	Sep 19, 2026	DS DP	ODE-196	Aug 15, 2025
		9006256	Jul 27, 2027	U-1695	ODE-87	Feb 13, 2022
<u>LESINURAD - ZURAMPIC</u>						
N 207988	001	10183012	Nov 26, 2028		U-2311	NCE
		8003681	Aug 25, 2025	DS		Dec 22, 2020
		8084483	Aug 17, 2029		U-1801	
		8283369	Nov 26, 2028		U-1802	
		8283369	Nov 26, 2028		U-1804	
		8357713	Nov 26, 2028	DP	U-1801	
		8357713	Nov 26, 2028	DP	U-1802	
		8357713	Nov 26, 2028	DP	U-1803	
		8546436	Feb 29, 2032	DS DP		
		8546437	Apr 29, 2029		U-1803	
		9216179	Aug 01, 2031		U-1806	
		9956205	Dec 28, 2031		U-2311	
<u>LETERMOVIR - PREVMIS</u>						
N 209939	001	8513255	May 22, 2024	DS DP	NCE	Nov 08, 2022
		RE46791	May 22, 2024	DS DP	ODE-165	Nov 08, 2024
<u>LETERMOVIR - PREVMIS</u>						
N 209939	002	8513255	May 22, 2024	DS DP	NCE	Nov 08, 2022
		RE46791	May 22, 2024	DS DP	ODE-165	Nov 08, 2024
<u>LETERMOVIR - PREVMIS</u>						
N 209940	001	10603384	Feb 28, 2033	DP	NCE	Nov 08, 2022
		8513255	May 22, 2024	DS DP	ODE-165	Nov 08, 2024
		RE46791	May 22, 2024	DS DP		
<u>LETERMOVIR - PREVMIS</u>						
N 209940	002	10603384	Feb 28, 2033	DP	NCE	Nov 08, 2022
		8513255	May 22, 2024	DS DP	ODE-165	Nov 08, 2024
		RE46791	May 22, 2024	DS DP		
<u>LETROZOLE; RIBOCICLIB SUCCINATE - KISOALI FEMARA CO-PACK (COPACKAGED)</u>						
N 209935	001	10799506	Apr 14, 2036	DP	NCE	Mar 13, 2022
		8324225	Jun 17, 2028	DS DP		
		8415355	Feb 19, 2031	DS DP		
		8685980	May 25, 2030	DS DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LETROZOLE; RIBOCICLIB SUCCINATE - KISQALI FEMARA CO-PACK (COPACKAGED)</u>						
N 209935	001	8962630	Dec 09, 2029	U-2505		
		9193732	Nov 09, 2031	DS DP		
		9416136	Aug 20, 2029	U-2505		
		9868739	Nov 09, 2031	U-2505		
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N 020517	003	8815801	Jun 28, 2022	DP		
		8921326	Feb 05, 2031	DP	U-1666	
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021343	001	6626870	Mar 27, 2020	DP		
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021379	001	6626870	Mar 27, 2020	DP		
		8470359	Oct 15, 2023	DS DP	U-621	
		8840916	Nov 13, 2020	DP		
		9539333	Nov 13, 2020	DS DP	U-621	
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021488	001	6626870	Mar 27, 2020	DP		
		8470359	Oct 15, 2023	DS DP	U-621	
		8840916	Nov 13, 2020	DP		
		9539333	Nov 13, 2020	DS DP	U-621	
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021731	001	6626870	Mar 27, 2020	DP		
		8470359	Oct 15, 2023	DS DP	U-621	
		8840916	Nov 13, 2020	DP		
		9539333	Nov 13, 2020	DS DP	U-621	
		9914802	Nov 13, 2020	DS DP	U-1666	
<u>LEUPROLIDE ACETATE - LUTRATE DEPOT KIT</u>						
N 205054	001	9789064	Dec 15, 2020	DP		
<u>LEUPROLIDE ACETATE - FENSOLVI KIT</u>						
N 213150	001	8470359	Oct 15, 2023	DS DP	U-2940	I-829
		9539333	Nov 13, 2020	DS DP		May 01, 2023
		9914802	Nov 13, 2020	DS DP	U-2940	
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837	001	6451289	Mar 21, 2021			
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837	002	6451289	Mar 21, 2021			
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837	003	6451289	Mar 21, 2021			
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837	004	6451289	Mar 21, 2021	DP		
<u>LEVALBUTEROL TARTRATE - XOPENEX HFA</u>						
N 021730	001	7256310	Oct 08, 2024	DS DP	U-636	
		8765153	Dec 08, 2023	DP		
<u>LEVETIRACETAM - KEPPRA</u>						
N 021035	001	8802142	Jun 07, 2031	DP		
		8802142*PED	Dec 07, 2031			
<u>LEVETIRACETAM - KEPPRA</u>						
N 021035	002	8802142	Jun 07, 2031	DP		
		8802142*PED	Dec 07, 2031			
<u>LEVETIRACETAM - KEPPRA</u>						
N 021035	003	8802142	Jun 07, 2031	DP		
		8802142*PED	Dec 07, 2031			
<u>LEVETIRACETAM - KEPPRA</u>						
N 021035	004	8802142	Jun 07, 2031	DP		
		8802142*PED	Dec 07, 2031			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVETIRACETAM - KEPPRA XR</u>						
N 022285	001 7858122	Sep 17, 2028	DP			
<u>LEVETIRACETAM - KEPPRA XR</u>						
N 022285	002 7858122	Sep 17, 2028	DP			
<u>LEVETIRACETAM - ELEPSIA XR</u>						
N 204417	001 8163306	Sep 03, 2027	DP			
	8425938	Feb 22, 2026	DP			
	8431156	Oct 31, 2027	DP			
	8470367	Oct 31, 2027	DP			
	8535717	Feb 22, 2026	DP			
<u>LEVETIRACETAM - ELEPSIA XR</u>						
N 204417	002 8163306	Sep 03, 2027	DP			
	8425938	Feb 22, 2026	DP			
	8431156	Oct 31, 2027	DP			
	8470367	Oct 31, 2027	DP			
	8535717	Feb 22, 2026	DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958	001 9339489	Mar 14, 2034	DP	U-1850		
	9669009	Mar 14, 2034		U-1850		
	9669009	Mar 14, 2034		U-2021		
	9669009	Mar 14, 2034		U-2022		
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958	002 9339489	Mar 14, 2034	DP	U-1850		
	9669009	Mar 14, 2034		U-1850		
	9669009	Mar 14, 2034		U-2021		
	9669009	Mar 14, 2034		U-2022		
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958	003 9339489	Mar 14, 2034	DP	U-1850		
	9669009	Mar 14, 2034		U-1850		
	9669009	Mar 14, 2034		U-2021		
	9669009	Mar 14, 2034		U-2022		
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958	004 9339489	Mar 14, 2034	DP	U-1850		
	9669009	Mar 14, 2034		U-1850		
	9669009	Mar 14, 2034		U-2021		
	9669009	Mar 14, 2034		U-2022		
<u>LEVOCARNITINE - LEVOCARNITINE</u>						
A 211676	001				CGT	Apr 13, 2020
<u>LEVOCARNITINE - LEVOCARNITINE SF</u>						
A 211676	002				CGT	Apr 13, 2020
<u>LEVOCARNITINE - CARNITOR</u>						
N 020182	001 6335369	Jan 18, 2021		U-433		
	6429230	Jan 18, 2021		U-433		
	6696493	Jan 18, 2021		U-433		
<u>LEVOCETIRIZINE DIHYDROCHLORIDE - XYZAL ALLERGY 24HR</u>						
N 209090	001 8633194	Oct 16, 2027	DP			
<u>LEVODOPA - INBRIJA</u>						
N 209184	001 6514482	Sep 19, 2020	DP	U-2484	NP	Dec 21, 2021
	6613308	Sep 19, 2020		U-2484		
	6858199	Nov 04, 2021		U-2485		
	6921528	Jun 19, 2020		U-2485		
	6979437	Sep 19, 2020		U-2484		
	7146978	Apr 16, 2021		U-2486		
	7182961	Feb 22, 2024	DP			
	7384649	Nov 20, 2022	DP			
	7556798	Nov 04, 2021		U-2485		
	8404276	Mar 19, 2023		U-2484		
	8545878	Nov 16, 2032	DP			
	8586093	Mar 19, 2023		U-2484		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVODOPA - INBRIJA</u>						
N 209184	001	8628754	Jun 19, 2020		U-2485	
		8685442	Nov 16, 2032	DP		
		8945612	Nov 16, 2032	DP		
		9155699	Mar 19, 2023	DP		
		9393210	Nov 16, 2032	DP		
		RE43711	Feb 03, 2029		U-2484	
<u>LEVOFLOXACIN - LEVAQUIN</u>						
N 021721	001	6806256	Feb 26, 2022	DP		
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N 020140	001	6500829	Mar 07, 2022	DS DP		
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N 020140	002	6500829	Mar 07, 2022	DS DP		
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N 020140	003	6500829	Mar 07, 2022	DS DP		
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168	001	8481598	Mar 02, 2031		U-839	M-249 Oct 07, 2022
		8865937	May 23, 2032	DS DP		
		RE43879	Jan 11, 2026		U-839	
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168	002	8481598	Mar 02, 2031		U-839	M-249 Oct 07, 2022
		8865937	May 23, 2032	DS DP		
		RE43879	Jan 11, 2026		U-839	
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168	003	8481598	Mar 02, 2031		U-839	M-249 Oct 07, 2022
		8865937	May 23, 2032	DS DP		
		RE43879	Jan 11, 2026		U-839	
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168	004	8481598	Mar 02, 2031		U-839	M-249 Oct 07, 2022
		8865937	May 23, 2032	DS DP		
		RE43879	Jan 11, 2026		U-839	
<u>LEVONORGESTREL - MIRENA</u>						
N 021225	001	10561524	Sep 16, 2029		U-2948	D-181 Aug 20, 2023
		9615965	Sep 16, 2029	DP	U-2003	
		9668912	Apr 01, 2031	DP		
<u>LEVONORGESTREL - SKYLA</u>						
N 203159	001	10561524	Sep 16, 2029		U-2948	
		7252839	Nov 13, 2023	DP		
		9615965	Sep 16, 2029	DP	U-2003	
		9668912	Apr 01, 2031	DP		
<u>LEVONORGESTREL - LILETTA</u>						
N 206229	001	10028858	Mar 22, 2034	DP	U-2348	
<u>LEVONORGESTREL - KYLEENA</u>						
N 208224	001	10561524	Sep 16, 2029		U-2948	
		7252839	Nov 13, 2023	DP		
		9615965	Sep 16, 2029	DP	U-2003	
		9668912	Apr 01, 2031	DP		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301	001	6555581	Feb 15, 2022			
		7067148	Feb 15, 2022	DP		
		7101569	Oct 02, 2023		U-759	
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301	002	6555581	Feb 15, 2022			
		7067148	Feb 15, 2022	DP		
		7101569	Oct 02, 2023		U-759	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 003	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023			U-759	
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 004	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023			U-759	
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 005	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023			U-759	
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 006	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023			U-759	
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 007	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023			U-759	
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 008	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023			U-759	
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 009	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023			U-759	
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 010	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023			U-759	
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 011	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023			U-759	
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 012	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023			U-759	
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 001	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 002	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 003	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 004	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 005	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 006	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 007	6399101	Mar 30, 2020				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342	008 6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342	009 6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342	010 6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342	011 6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924	002 7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924	003 7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924	004 7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924	005 7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924	006 7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924	007 7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924	008 7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924	009 7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924	010 7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924	011 7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924	012 7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924	013 7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231	001 9006289	Oct 03, 2032	DP			
	9168238	Aug 29, 2032	DP			
	9168239	Aug 29, 2032	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231	002 9006289	Oct 03, 2032	DP			
	9168238	Aug 29, 2032	DP			
	9168239	Aug 29, 2032	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231	003	9006289	Oct 03, 2032	DP		
		9168238	Aug 29, 2032	DP		
		9168239	Aug 29, 2032	DP		
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977	001	10537538	Feb 28, 2037	DP		
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977	002	10537538	Feb 28, 2037	DP		
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977	003	10537538	Feb 28, 2037	DP		
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977	004	10537538	Feb 28, 2037	DP		
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977	005	10537538	Feb 28, 2037	DP		
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977	006	10537538	Feb 28, 2037	DP		
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977	007	10537538	Feb 28, 2037	DP		
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977	008	10537538	Feb 28, 2037	DP		
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977	009	10537538	Feb 28, 2037	DP		
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977	010	10537538	Feb 28, 2037	DP		
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977	011	10537538	Feb 28, 2037	DP		
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977	012	10537538	Feb 28, 2037	DP		
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 210632	001	10398669	Dec 01, 2036	DP		
		9782376	Dec 01, 2036	DP		
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 210632	002	10398669	Dec 01, 2036	DP		
		9782376	Dec 01, 2036	DP		
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 210632	003	10398669	Dec 01, 2036	DP		
		9782376	Dec 01, 2036	DP		
<u>LEVOTHYROXINE SODIUM - THYQUIDITY</u>						
N 214047	001	9050307	Aug 06, 2031	DP		
<u>LIDOCAINE - ZTLIDO</u>						
N 207962	001	10765640	May 10, 2031	DP	NP	Feb 28, 2021
		10765749	May 10, 2031	DP		
		9283174	May 10, 2031	DP		
		9925264	May 10, 2031	DP	U-2267	
		9931403	May 10, 2031	DP		
<u>LIDOCAINE HYDROCHLORIDE - ZINGO</u>						
N 022114	001	8540665	Oct 22, 2029	U-1438		
		9358338	Apr 27, 2035	U-1870		
		9370622	Sep 28, 2035	U-1870		
<u>LIDOCAINE HYDROCHLORIDE - AKTEN</u>						
N 022221	001	8759401	Jul 24, 2026	DP	U-1523	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LIDOCAINE; TETRACAINE - SYNERA</u>						
N 021623	001 6465709	Jul 07, 2020	DP			
<u>LIDOCAINE; TETRACAINE - PLIAGLIS</u>						
N 021717	001 10350180	Jan 14, 2031	DP			
	10603293	Jan 14, 2031	DP			
	10751305	Jan 14, 2031	DP			
<u>LIFITEGRAST - XIIDRA</u>						
N 208073	001 10124000	Nov 05, 2024		U-1900	NCE	Jul 11, 2021
	7314938	Mar 10, 2025	DS DP			
	7745460	Nov 05, 2024	DS DP	U-1880		
	7790743	Nov 05, 2024		U-1880		
	7928122	Nov 05, 2024	DS DP			
	8084047	May 17, 2026	DS DP			
	8168655	May 09, 2029		U-1880		
	8367701	Apr 15, 2029	DP	U-1880		
	8592450	May 17, 2026		U-1880		
	8927574	Nov 12, 2030	DP			
	9085553	Jul 25, 2033	DP			
	9216174	Nov 05, 2024	DP			
	9353088	Oct 21, 2030	DP			
	9447077	Apr 15, 2029		U-1900		
	9890141	Oct 21, 2030	DS			
<u>LINACLOTIDE - LINZESS</u>						
N 202811	001 7304036	Aug 30, 2026	DS DP	U-1278		
	7304036	Aug 30, 2026	DS DP	U-1516		
	7371727	Jan 28, 2024	DS			
	7704947	Jan 28, 2024	DS DP			
	7745409	Jan 28, 2024	DS DP			
	8080526	Jan 28, 2024	DS DP			
	8110553	Jan 28, 2024		U-1278		
	8748573	Oct 30, 2031		U-1515		
	8748573	Oct 30, 2031		U-1516		
	8802628	Oct 30, 2031	DP			
	8933030	Feb 17, 2031	DP			
	9708371	Aug 16, 2033	DP	U-1515		
	9708371	Aug 16, 2033	DP	U-1516		
<u>LINACLOTIDE - LINZESS</u>						
N 202811	002 7304036	Aug 30, 2026	DS DP	U-1278		
	7304036	Aug 30, 2026	DS DP	U-1516		
	7371727	Jan 28, 2024	DS			
	7704947	Jan 28, 2024	DS DP			
	7745409	Jan 28, 2024	DS DP			
	8080526	Jan 28, 2024	DS DP			
	8110553	Jan 28, 2024		U-1278		
	8748573	Oct 30, 2031		U-1515		
	8748573	Oct 30, 2031		U-1516		
	8802628	Oct 30, 2031	DP			
	8933030	Feb 17, 2031	DP			
	9708371	Aug 16, 2033	DP	U-1515		
<u>LINACLOTIDE - LINZESS</u>						
N 202811	003 10675325	Aug 11, 2031	DP		NS	Jan 25, 2020
	10702576	Aug 11, 2031		U-1516		
	7304036	Aug 30, 2026	DS DP	U-1516		
	7371727	Jan 28, 2024	DS			
	7704947	Jan 28, 2024	DS DP			
	7745409	Jan 28, 2024	DS DP			
	8080526	Jan 28, 2024	DS DP			
	8110553	Jan 28, 2024		U-1516		
	8933030	Feb 17, 2031	DP	U-1516		
	9708371	Aug 16, 2033	DP	U-1516		
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280	001 10034877	Aug 05, 2029		U-2347	M-252	Mar 30, 2023
	7407955	May 02, 2025	DS DP		M-258	Jul 03, 2022
	8119648	Aug 12, 2023		U-1270		
	8119648	Aug 12, 2023		U-774		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280	001	8178541	Aug 12, 2023	U-1244		
		8178541	Aug 12, 2023	U-1245		
		8178541	Aug 12, 2023	U-1270		
		8178541	Aug 12, 2023	U-775		
		8673927	May 04, 2027	U-1503	Y	
		8846695	Jun 04, 2030	U-1503	Y	
		8853156	Mar 05, 2031	U-1642		
		8883805	Nov 26, 2025	DP		
		9486526	Aug 05, 2029	U-1915		
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281	001	10022379	Apr 02, 2029	U-2339		M-252 Mar 30, 2023
		7407955	May 02, 2025	DS DP		M-258 Jul 03, 2022
		8119648	Aug 12, 2023	U-802		
		8178541	Aug 12, 2023	DP U-775		
		8673927	May 04, 2027	U-1503	Y	
		8846695	Jun 04, 2030	U-1503		
		8883805	Nov 26, 2025	DP		
		9155705	May 21, 2030	DP		
		9415016	Apr 02, 2029	DP		
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281	002	10022379	Apr 02, 2029	U-2339		M-252 Mar 30, 2023
		7407955	May 02, 2025	DS DP		M-258 Jul 03, 2022
		8119648	Aug 12, 2023	U-802		
		8178541	Aug 12, 2023	DP U-775		
		8673927	May 04, 2027	U-1503	Y	
		8846695	Jun 04, 2030	U-1503		
		8883805	Nov 26, 2025	DP		
		9155705	May 21, 2030	DP		
		9415016	Apr 02, 2029	DP		
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281	003	10022379	Apr 02, 2029	U-2339		M-252 Mar 30, 2023
		7407955	May 02, 2025	DS DP		M-258 Jul 03, 2022
		8119648	Aug 12, 2023	U-802		
		8178541	Aug 12, 2023	DP U-775		
		8673927	May 04, 2027	U-1503	Y	
		8846695	Jun 04, 2030	U-1503	Y	
		8883805	Nov 26, 2025	DP		
		9155705	May 21, 2030	DP		
		9415016	Apr 02, 2029	DP		
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026	001	10022379	Apr 02, 2029	U-2339		M-252 Mar 30, 2023
		6488962	Jun 20, 2020	DP		M-258 Jul 03, 2022
		7407955	May 02, 2025	DS DP		
		8119648	Aug 12, 2023	U-802		
		8178541	Aug 12, 2023	DP U-1853		
		8673927	May 04, 2027	U-1503	Y	
		8883805	Nov 26, 2025	DP		
		9155705	May 21, 2030	DP		
		9173859	May 04, 2027	DP U-1503	Y	
		9415016	Apr 02, 2029	DP		
		9555001	Mar 06, 2033	DP U-1967		
		9555001	Mar 06, 2033	DP U-1968		
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026	002	10022379	Apr 02, 2029	U-2339		M-252 Mar 30, 2023
		6488962	Jun 20, 2020	DP		M-258 Jul 03, 2022
		7407955	May 02, 2025	DS DP		
		8119648	Aug 12, 2023	U-802		
		8178541	Aug 12, 2023	DP U-1853		
		8673927	May 04, 2027	U-1503	Y	
		8883805	Nov 26, 2025	DP		
		9155705	May 21, 2030	DP		
		9173859	May 04, 2027	DP U-1503	Y	
		9415016	Apr 02, 2029	DP		
		9555001	Mar 06, 2033	DP U-1967		
		9555001	Mar 06, 2033	DP U-1968		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	10022379	Apr 02, 2029	U-2339		M-252	Mar 30, 2023
	6488962	Jun 20, 2020	DP		M-258	Jul 03, 2022
	7407955	May 02, 2025	DS DP			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-1853			
	8673927	May 04, 2027	U-1503	Y		
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP U-1503	Y		
	9415016	Apr 02, 2029	DP			
	9555001	Mar 06, 2033	DP U-1967			
	9555001	Mar 06, 2033	DP U-1968			
<u>LINEZOLID - ZYVOX</u>						
N 021130 001	6514529	Mar 15, 2021	DP			
	6559305	Jan 29, 2021	DS			
<u>LINEZOLID - ZYVOX</u>						
N 021130 002	6514529	Mar 15, 2021	DP			
	6559305	Jan 29, 2021	DS			
<u>LINEZOLID - ZYVOX</u>						
N 021131 001	6559305	Jan 29, 2021	DS			
<u>LINEZOLID - ZYVOX</u>						
N 021131 002	6559305	Jan 29, 2021	DS			
	6559305*PED	Jul 29, 2021				
<u>LINEZOLID - ZYVOX</u>						
N 021131 003	6559305	Jan 29, 2021	DS			
	6559305*PED	Jul 29, 2021				
<u>LINEZOLID - ZYVOX</u>						
N 021132 001	6559305	Jan 29, 2021	DS			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	6268343	Aug 22, 2022	DS DP U-968		I-750	Aug 25, 2020
	6268343*PED	Feb 22, 2023			NPP	Jun 17, 2022
	7762994	May 23, 2024	DP		PED	Dec 17, 2022
	7762994*PED	Nov 23, 2024				
	8114833	Aug 13, 2025	DS DP			
	8114833*PED	Feb 13, 2026				
	8579869	Jun 30, 2023	DP			
	8579869*PED	Dec 30, 2023				
	8846618	Jun 27, 2022	DP			
	8846618*PED	Dec 27, 2022				
	9265893	Sep 23, 2032	DP			
	9265893*PED	Mar 23, 2033				
	9968659	Jan 09, 2037	U-2313			
	9968659*PED	Jul 09, 2037				
	RE41956	Jan 21, 2021	DP			
	RE41956*PED	Jul 21, 2021				
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	10220155	Jul 17, 2026	DP			
	10220155*PED	Jan 17, 2027				
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	6268343	Aug 22, 2022	DS DP U-1255			
	6268343*PED	Feb 22, 2023				
	6899699	Jan 01, 2022	DP			
	6899699*PED	Jul 01, 2022				
	7762994	May 23, 2024	DP			
	7762994*PED	Nov 23, 2024				
	8114833	Aug 13, 2025	DP			
	8114833*PED	Feb 13, 2026				
	8579869	Jun 30, 2023	DP			
	8579869*PED	Dec 30, 2023				
	8672898	Jan 02, 2022	DP			
	8672898*PED	Jul 02, 2022				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321	001	8684969	Oct 20, 2025	DP		
		8684969*PED	Apr 20, 2026			
		8846618	Jun 27, 2022	DP		
		8846618*PED	Dec 27, 2022			
		8920383	Jul 17, 2026	DP		
		8920383*PED	Jan 17, 2027			
		9108002	Jan 26, 2026	DP		
		9108002*PED	Jul 26, 2026			
		9132239	Feb 01, 2032	DP		
		9132239*PED	Aug 01, 2032			
		9457154	Sep 27, 2027	DP		
		9457154*PED	Mar 27, 2028			
		9486588	Jan 02, 2022	DP		
		9486588*PED	Jul 02, 2022			
		9616180	Jan 20, 2026	DP		
		9616180*PED	Jul 20, 2026			
		9687611	Feb 27, 2027	DP		
		9687611*PED	Aug 27, 2027			
		9775953	Jul 17, 2026	DP		
		9775953*PED	Jan 17, 2027			
		9861757	Jan 20, 2026	DP		
		9861757*PED	Jul 20, 2026			
		9968659	Jan 09, 2037		U-2438	
		9968659*PED	Jul 09, 2037			
		RE46363	Aug 03, 2026	DP		
		RE46363*PED	Feb 03, 2027			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977	001	7105486	Feb 24, 2023		U-727	
		7223735	Feb 24, 2023	DP		
		7655630	Feb 24, 2023	DS		
		7659253	Feb 24, 2023	DS DP	U-727	
		7659254	Feb 24, 2023		U-1034	
		7662787	Feb 24, 2023	DS		
		7662788	Feb 24, 2023		U-727	
		7671030	Feb 24, 2023	DP	U-727	
		7671031	Feb 24, 2023		U-727	
		7674774	Feb 24, 2023	DP	U-842	
		7678770	Feb 24, 2023		U-842	
		7678771	Feb 24, 2023	DP	U-842	
		7687466	Feb 24, 2023	DP		
		7687467	Feb 24, 2023	DP	U-842	
		7700561	Feb 24, 2023	DP		
		7713936	Feb 24, 2023		U-727	
		7718619	Feb 24, 2023	DP	U-842	
		7723305	Feb 24, 2023	DP	U-842	
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977	002	7105486	Feb 24, 2023		U-727	
		7223735	Feb 24, 2023	DP		
		7655630	Feb 24, 2023	DS		
		7659253	Feb 24, 2023	DS DP	U-727	
		7659254	Feb 24, 2023		U-1034	
		7662787	Feb 24, 2023	DS		
		7662788	Feb 24, 2023		U-727	
		7671030	Feb 24, 2023	DP	U-727	
		7671031	Feb 24, 2023		U-727	
		7674774	Feb 24, 2023	DP	U-842	
		7678770	Feb 24, 2023		U-842	
		7678771	Feb 24, 2023	DP	U-842	
		7687466	Feb 24, 2023	DP		
		7687467	Feb 24, 2023	DP	U-842	
		7700561	Feb 24, 2023	DP		
		7713936	Feb 24, 2023		U-727	
		7718619	Feb 24, 2023	DP	U-842	
		7723305	Feb 24, 2023	DP	U-842	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 003	7105486	Feb 24, 2023	U-727			
	7223735	Feb 24, 2023	DP			
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP	U-727		
	7659254	Feb 24, 2023		U-1034		
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023		U-727		
	7671030	Feb 24, 2023	DP	U-727		
	7671031	Feb 24, 2023		U-727		
	7674774	Feb 24, 2023	DP	U-842		
	7678770	Feb 24, 2023		U-842		
	7678771	Feb 24, 2023	DP	U-842		
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP	U-842		
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023		U-727		
	7718619	Feb 24, 2023	DP	U-842		
	7723305	Feb 24, 2023	DP	U-842		
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 004	7105486	Feb 24, 2023	U-727			
	7105486	Feb 24, 2023		U-842		
	7223735	Feb 24, 2023	DP			
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP	U-727		
	7659254	Feb 24, 2023		U-1034		
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023		U-727		
	7671030	Feb 24, 2023	DP	U-727		
	7671031	Feb 24, 2023		U-727		
	7674774	Feb 24, 2023	DP	U-842		
	7678770	Feb 24, 2023		U-842		
	7678771	Feb 24, 2023	DP	U-842		
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP	U-842		
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023		U-727		
	7718619	Feb 24, 2023	DP	U-842		
	7723305	Feb 24, 2023	DP	U-842		
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 005	7105486	Feb 24, 2023	U-842			
	7223735	Feb 24, 2023	DP			
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP	U-727		
	7659254	Feb 24, 2023		U-1034		
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023		U-727		
	7671030	Feb 24, 2023	DP	U-727		
	7671031	Feb 24, 2023		U-727		
	7674774	Feb 24, 2023	DP	U-842		
	7678770	Feb 24, 2023		U-842		
	7678771	Feb 24, 2023	DP	U-842		
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP	U-842		
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023		U-727		
	7718619	Feb 24, 2023	DP	U-842		
	7723305	Feb 24, 2023	DP	U-842		
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 006	7105486	Feb 24, 2023	U-727			
	7105486	Feb 24, 2023		U-842		
	7223735	Feb 24, 2023	DP			
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP	U-727		
	7659254	Feb 24, 2023		U-1034		
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023		U-727		
	7671030	Feb 24, 2023	DP	U-727		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977	006	7671031	Feb 24, 2023			U-727
		7674774	Feb 24, 2023	DP		U-842
		7678770	Feb 24, 2023			U-842
		7678771	Feb 24, 2023	DP		U-842
		7687466	Feb 24, 2023	DP		
		7687467	Feb 24, 2023	DP		U-842
		7700561	Feb 24, 2023	DP		
		7713936	Feb 24, 2023			U-727
		7718619	Feb 24, 2023	DP		U-842
		7723305	Feb 24, 2023	DP		U-842
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977	007	7223735	Feb 24, 2023	DP		
		7655630	Feb 24, 2023	DS		
		7659253	Feb 24, 2023	DS	DP	U-727
		7659254	Feb 24, 2023			U-1034
		7662787	Feb 24, 2023	DS		
		7662788	Feb 24, 2023			U-727
		7671030	Feb 24, 2023	DP		U-727
		7671031	Feb 24, 2023			U-727
		7674774	Feb 24, 2023	DP		U-842
		7678770	Feb 24, 2023			U-842
		7678771	Feb 24, 2023	DP		
		7687466	Feb 24, 2023	DP		
		7687467	Feb 24, 2023	DP		U-842
		7700561	Feb 24, 2023	DP		
		7713936	Feb 24, 2023			U-727
		7718619	Feb 24, 2023	DP		U-842
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510	001	7105486	Feb 24, 2023			U-727
		7223735	Feb 24, 2023	DP		
		7655630	Feb 24, 2023	DS	DP	
		7659253	Feb 24, 2023	DS	DP	U-727
		7659254	Feb 24, 2023			U-727
		7662787	Feb 24, 2023	DS		
		7662788	Feb 24, 2023			U-727
		7671030	Feb 24, 2023	DP		U-727
		7671031	Feb 24, 2023			U-727
		7674774	Feb 24, 2023	DP		U-727
		7678770	Feb 24, 2023			U-727
		7678771	Feb 24, 2023	DP		U-727
		7687466	Feb 24, 2023	DP		
		7687467	Feb 24, 2023	DP		U-727
		7713936	Feb 24, 2023			U-727
		7718619	Feb 24, 2023	DP		U-727
		7723305	Feb 24, 2023	DP		U-727
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510	002	7105486	Feb 24, 2023			U-727
		7223735	Feb 24, 2023	DP		
		7655630	Feb 24, 2023	DS	DP	
		7659253	Feb 24, 2023	DS	DP	U-727
		7659254	Feb 24, 2023			U-727
		7662787	Feb 24, 2023	DS		
		7662788	Feb 24, 2023			U-727
		7671030	Feb 24, 2023	DP		U-727
		7671031	Feb 24, 2023			U-727
		7674774	Feb 24, 2023	DP		U-727
		7678770	Feb 24, 2023			U-727
		7678771	Feb 24, 2023	DP		U-727
		7687466	Feb 24, 2023	DP		
		7687467	Feb 24, 2023	DP		U-727
		7713936	Feb 24, 2023			U-727
		7718619	Feb 24, 2023	DP		U-727
		7723305	Feb 24, 2023	DP		U-727

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 003	7105486	Feb 24, 2023				U-727
	7223735	Feb 24, 2023				DP
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP			U-727
	7659254	Feb 24, 2023				U-727
	7662787	Feb 24, 2023		DS		
	7662788	Feb 24, 2023				U-727
	7671030	Feb 24, 2023	DP			U-727
	7671031	Feb 24, 2023				U-727
	7674774	Feb 24, 2023	DP			U-727
	7678770	Feb 24, 2023				U-727
	7678771	Feb 24, 2023		DP		U-727
	7687466	Feb 24, 2023		DP		
	7687467	Feb 24, 2023		DP		U-727
	7713936	Feb 24, 2023				U-727
	7718619	Feb 24, 2023		DP		U-727
	7723305	Feb 24, 2023		DP		U-727
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 004	7105486	Feb 24, 2023				U-727
	7223735	Feb 24, 2023				DP
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP			U-727
	7659254	Feb 24, 2023				U-727
	7662787	Feb 24, 2023		DS		
	7662788	Feb 24, 2023				U-727
	7671030	Feb 24, 2023	DP			U-727
	7671031	Feb 24, 2023				U-727
	7674774	Feb 24, 2023	DP			U-727
	7678770	Feb 24, 2023				U-727
	7678771	Feb 24, 2023		DP		U-727
	7687466	Feb 24, 2023		DP		
	7687467	Feb 24, 2023		DP		U-727
	7713936	Feb 24, 2023				U-727
	7718619	Feb 24, 2023		DP		U-727
	7723305	Feb 24, 2023		DP		U-727
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 005	7105486	Feb 24, 2023				U-727
	7223735	Feb 24, 2023				DP
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP			U-727
	7659254	Feb 24, 2023				U-727
	7662787	Feb 24, 2023		DS		
	7662788	Feb 24, 2023				U-727
	7671030	Feb 24, 2023	DP			U-727
	7671031	Feb 24, 2023				U-727
	7674774	Feb 24, 2023	DP			U-727
	7678770	Feb 24, 2023				U-727
	7678771	Feb 24, 2023		DP		U-727
	7687466	Feb 24, 2023		DP		
	7687467	Feb 24, 2023		DP		U-727
	7713936	Feb 24, 2023				U-727
	7718619	Feb 24, 2023		DP		U-727
	7723305	Feb 24, 2023		DP		U-727
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 006	7105486	Feb 24, 2023				U-727
	7223735	Feb 24, 2023				DP
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP			U-727
	7659254	Feb 24, 2023				U-727
	7662787	Feb 24, 2023		DS		
	7662788	Feb 24, 2023				U-727
	7671030	Feb 24, 2023	DP			U-727
	7671031	Feb 24, 2023				U-727
	7674774	Feb 24, 2023	DP			U-727
	7678770	Feb 24, 2023				U-727
	7678771	Feb 24, 2023		DP		U-727
	7687466	Feb 24, 2023		DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510	006	7687467	Feb 24, 2023	DP	U-727	
		7713936	Feb 24, 2023		U-727	
		7718619	Feb 24, 2023	DP	U-727	
		7723305	Feb 24, 2023	DP	U-727	
<u>LISINAPRIL - OBRELIS</u>						
N 208401	001	10039800	Nov 06, 2035		U-1723	
		10039800	Nov 06, 2035		U-185	
		10039800	Nov 06, 2035		U-1864	
		10039800	Nov 06, 2035		U-1991	
		10039800	Nov 06, 2035		U-3	
		10039800	Nov 06, 2035		U-71	
		10039800	Nov 06, 2035		U-8	
		10265370	Nov 06, 2035	DP		
		10406199	Nov 06, 2035		U-1723	
		10406199	Nov 06, 2035		U-185	
		10406199	Nov 06, 2035		U-1864	
		10406199	Nov 06, 2035		U-1991	
		10406199	Nov 06, 2035		U-3	
		10406199	Nov 06, 2035		U-71	
		10406199	Nov 06, 2035		U-8	
		9463183	Nov 06, 2035	DP		
		9616096	Nov 06, 2035		U-1723	
		9616096	Nov 06, 2035		U-185	
		9616096	Nov 06, 2035		U-1864	
		9616096	Nov 06, 2035		U-1991	
		9616096	Nov 06, 2035		U-3	
		9616096	Nov 06, 2035		U-71	
		9616096	Nov 06, 2035		U-8	
		9814751	Nov 06, 2035	DP		
<u>LOFEXIDINE HYDROCHLORIDE - LUCEMYRA</u>						
N 209229	001				NCE	May 16, 2023
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858	001	10016404	Mar 07, 2025		U-1316	
		10555938	Mar 07, 2025		U-1316	
		5712279	Feb 21, 2020	DS DP	U-1317	
		7932268	Aug 19, 2027		U-1316	
		8618135	Mar 07, 2025		U-1316	
		9265758	Mar 07, 2025		U-1316	
		9364470	Mar 07, 2025		U-1851	
		9433617	Mar 07, 2025		U-1316	
		9861622	Mar 07, 2025		U-1316	
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858	002	10016404	Mar 07, 2025		U-1316	
		10555938	Mar 07, 2025		U-1316	
		5712279	Feb 21, 2020	DS DP	U-1317	
		7932268	Aug 19, 2027		U-1316	
		8618135	Mar 07, 2025		U-1316	
		9265758	Mar 07, 2025		U-1316	
		9364470	Mar 07, 2025		U-1851	
		9433617	Mar 07, 2025		U-1316	
		9861622	Mar 07, 2025		U-1316	
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858	003	10016404	Mar 07, 2025		U-1316	
		10555938	Mar 07, 2025		U-1316	
		5712279	Feb 21, 2020	DS DP	U-1317	
		7932268	Aug 19, 2027		U-1316	
		8618135	Mar 07, 2025		U-1316	
		9265758	Mar 07, 2025		U-1316	
		9364470	Mar 07, 2025		U-1851	
		9433617	Mar 07, 2025		U-1316	
		9861622	Mar 07, 2025		U-1316	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858	004	10016404	Mar 07, 2025		U-1316	
		10555938	Mar 07, 2025		U-1316	
		5712279	Feb 21, 2020	DS DP	U-1317	
		7932268	Aug 19, 2027		U-1316	
		8618135	Mar 07, 2025		U-1316	
		9265758	Mar 07, 2025		U-1316	
		9364470	Mar 07, 2025		U-1851	
		9433617	Mar 07, 2025		U-1316	
		9861622	Mar 07, 2025		U-1316	
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858	005	10016404	Mar 07, 2025		U-1316	
		10555938	Mar 07, 2025		U-1316	
		5712279	Feb 21, 2020	DS DP	U-1317	
		7932268	Aug 19, 2027		U-1316	
		8618135	Mar 07, 2025		U-1316	
		9265758	Mar 07, 2025		U-1316	
		9364470	Mar 07, 2025		U-1851	
		9433617	Mar 07, 2025		U-1316	
		9861622	Mar 07, 2025		U-1316	
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858	006	10016404	Mar 07, 2025		U-1316	
		10555938	Mar 07, 2025		U-1316	
		5712279	Feb 21, 2020	DS DP	U-1317	
		7932268	Aug 19, 2027		U-1316	
		8618135	Mar 07, 2025		U-1316	
		9265758	Mar 07, 2025		U-1316	
		9364470	Mar 07, 2025		U-1851	
		9433617	Mar 07, 2025		U-1316	
		9861622	Mar 07, 2025		U-1316	
<u>LONAFARNIB - ZOKINVY</u>						
N 213969	001				NCE	Nov 20, 2025
<u>LONAFARNIB - ZOKINVY</u>						
N 213969	002				NCE	Nov 20, 2025
<u>LOPERAMIDE HYDROCHLORIDE - IMODIUM A-D EZ CHEWS</u>						
N 020448	001	6814978	Aug 26, 2021	DP		
<u>LORCASERIN HYDROCHLORIDE - BELVIO</u>						
N 022529	001	6953787	Apr 10, 2023	DS DP	U-1252	
		6953787	Apr 10, 2023	DS DP	U-1253	
		6953787	Apr 10, 2023	DS DP	U-1254	
		6953787	Apr 10, 2023	DS DP	U-1255	
		7514422	Apr 10, 2023		U-1252	
		7514422	Apr 10, 2023		U-1253	
		7514422	Apr 10, 2023		U-1254	
		7514422	Apr 10, 2023		U-1255	
		7977329	Apr 10, 2023	DS DP	U-1252	
		7977329	Apr 10, 2023	DS DP	U-1253	
		7977329	Apr 10, 2023	DS DP	U-1254	
		7977329	Apr 10, 2023	DS DP	U-1255	
		8168624	Apr 18, 2029	DS DP		
		8207158	Apr 10, 2023		U-1252	
		8207158	Apr 10, 2023		U-1253	
		8207158	Apr 10, 2023		U-1254	
		8207158	Apr 10, 2023		U-1255	
		8273734	Apr 10, 2023		U-1254	
		8273734	Apr 10, 2023		U-1255	
		8367657	Apr 10, 2023	DS DP	U-1252	
		8367657	Apr 10, 2023	DS DP	U-1253	
		8367657	Apr 10, 2023	DS DP	U-1254	
		8367657	Apr 10, 2023	DS DP	U-1255	
		8546379	Apr 10, 2023	DS DP	U-1252	
		8546379	Apr 10, 2023	DS DP	U-1253	
		8546379	Apr 10, 2023	DS DP	U-1254	
		8546379	Apr 10, 2023	DS DP	U-1255	
		8575149	Apr 10, 2023		U-1452	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LORCASERIN HYDROCHLORIDE - BELVIO</u>						
N 022529	001	8697686	Dec 20, 2025	DS DP		
		8946207	Jun 16, 2024	DP		
		8980881	Dec 20, 2025		U-1252	
		8980881	Dec 20, 2025		U-1253	
		8980881	Dec 20, 2025		U-1254	
		8980881	Dec 20, 2025		U-1255	
		8999970	Feb 07, 2033		U-1688	
		8999970	Feb 07, 2033		U-1689	
		8999970	Feb 07, 2033		U-1692	
		9169213	Dec 06, 2032		U-1762	
		9169213	Dec 06, 2032		U-1763	
		9169213	Dec 06, 2032		U-1764	
		9169213	Dec 06, 2032		U-1765	
		9770455	Aug 31, 2031		U-2110	
<u>LORCASERIN HYDROCHLORIDE - BELVIO XR</u>						
N 208524	001	10226471	Aug 31, 2031	DP		
		10463676	Aug 31, 2031		U-2661	
		6953787	Apr 10, 2023	DS DP	U-1252	
		6953787	Apr 10, 2023	DS DP	U-1253	
		6953787	Apr 10, 2023	DS DP	U-1254	
		6953787	Apr 10, 2023	DS DP	U-1255	
		7514422	Apr 10, 2023		U-1252	
		7514422	Apr 10, 2023		U-1253	
		7514422	Apr 10, 2023		U-1254	
		7514422	Apr 10, 2023		U-1255	
		7977329	Apr 10, 2023	DS DP	U-1252	
		7977329	Apr 10, 2023	DS DP	U-1253	
		7977329	Apr 10, 2023	DS DP	U-1254	
		7977329	Apr 10, 2023	DS DP	U-1255	
		8168624	Apr 18, 2029	DS DP		
		8207158	Apr 10, 2023		U-1252	
		8207158	Apr 10, 2023		U-1253	
		8207158	Apr 10, 2023		U-1254	
		8207158	Apr 10, 2023		U-1255	
		8273734	Apr 10, 2023		U-1254	
		8273734	Apr 10, 2023		U-1255	
		8367657	Apr 10, 2023	DS DP	U-1252	
		8367657	Apr 10, 2023	DS DP	U-1253	
		8367657	Apr 10, 2023	DS DP	U-1254	
		8367657	Apr 10, 2023	DS DP	U-1255	
		8546379	Apr 10, 2023	DS DP	U-1252	
		8546379	Apr 10, 2023	DS DP	U-1253	
		8546379	Apr 10, 2023	DS DP	U-1254	
		8546379	Apr 10, 2023	DS DP	U-1255	
		8575149	Apr 10, 2023		U-1452	
		8697686	Dec 20, 2025	DS DP		
		8946207	Jun 16, 2024	DP		
		8980881	Dec 20, 2025		U-1252	
		8980881	Dec 20, 2025		U-1253	
		8980881	Dec 20, 2025		U-1254	
		8980881	Dec 20, 2025		U-1255	
		8999970	Feb 07, 2033		U-1688	
		8999970	Feb 07, 2033		U-1689	
		8999970	Feb 07, 2033		U-1692	
		9169213	Dec 06, 2032		U-1884	
		9169213	Dec 06, 2032		U-1885	
		9169213	Dec 06, 2032		U-1886	
		9169213	Dec 06, 2032		U-1887	
		9770455	Aug 31, 2031		U-2110	
<u>LORLATINIB - LORBRENA</u>						
N 210868	001	10420749	Jul 27, 2036	DS DP	U-2633	NCE Nov 02, 2023
		8680111	Mar 05, 2033	DS DP		ODE-217 Nov 02, 2025
						ODE-218 Nov 02, 2025
						ODE-219 Nov 02, 2025

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LORLATINIB - LORBRENA</u>						
N 210868	002	10420749	Jul 27, 2036	DS DP U-2633	NCE	Nov 02, 2023
		8680111	Mar 05, 2033	DS DP	ODE-217	Nov 02, 2025
					ODE-218	Nov 02, 2025
					ODE-219	Nov 02, 2025
<u>LOTEPREDNOL ETABONATE - LOTEMAX</u>						
N 202872	001				M-229	Jul 20, 2021
<u>LOTEPREDNOL ETABONATE - LOTEMAX SM</u>						
N 208219	001	10596107	Dec 23, 2036	DP U-2764	NS	Feb 22, 2022
<u>LOTEPREDNOL ETABONATE - INVELTYS</u>						
N 210565	001	10058511	May 03, 2033	DP U-2492	NP	Aug 22, 2021
		10646437	May 03, 2033	DP		
		10688045	May 03, 2033	DP		
		10864219	May 03, 2033	U-3011		
		9056057	May 03, 2033	DP U-2491		
		9393213	May 03, 2033	DP		
		9532955	May 03, 2033	U-2491		
		9737491	May 03, 2033	U-2492		
		9827191	May 03, 2033	DP U-2493		
<u>LOTEPREDNOL ETABONATE - EYSUVIS</u>						
N 210933	001	10058511	May 03, 2033	DP U-2492	NP	Oct 26, 2023
		10646436	May 03, 2033	DP		
		10688045	May 03, 2033	DP		
		10857096	May 03, 2033	U-2985		
		9056057	May 03, 2033	DP U-2491		
		9393213	May 03, 2033	DP		
		9532955	May 03, 2033	U-2491		
		9737491	May 03, 2033	U-2492		
		9827191	May 03, 2033	DP U-2985		
<u>LOXAPINE - ADASUVE</u>						
N 022549	001	6716416	May 20, 2022	DP		
		7052679	Oct 26, 2021	DP		
		7078020	Oct 26, 2021	DP U-1375		
		7090830	Oct 26, 2021	DP		
		7458374	Aug 18, 2024	DP		
		7537009	Oct 28, 2024	DP		
		7585493	Oct 26, 2021	DP		
		7601337	Oct 26, 2021	DP		
		8074644	Jul 25, 2022	DP		
		8173107	Oct 26, 2021	DP		
		8235037	Oct 26, 2021	DP		
		8387612	Oct 23, 2026	DP		
		8955512	Oct 26, 2021	DP		
		8991387	May 21, 2024	DP		
		9370629	May 20, 2024	DP		
		9439907	Oct 26, 2021	DP		
		9440034	Oct 26, 2021	DP		
		9687487	Oct 26, 2021	DS DP		
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908	001	6414016	Sep 05, 2020	U-1392	M-225	Apr 26, 2021
		6414016	Sep 05, 2020	U-717		
		6583174	Oct 16, 2020	DP		
		6982283	Dec 04, 2022	U-1391		
		7064148	Aug 30, 2022	U-1404		
		7064148	Aug 30, 2022	U-739		
		7417067	Oct 16, 2020	DP		
		8026393	Oct 25, 2027	DP		
		8071613	Sep 05, 2020	U-1203		
		8071613	Sep 05, 2020	U-1393		
		8088934	May 18, 2021	DS		
		8097649	Oct 16, 2020	DP		
		8097653	Nov 14, 2022	U-1214		
		8097653	Nov 14, 2022	U-1394		
		8114890	Sep 05, 2020	DP		
		8338639	Jan 23, 2027	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908	001	8389542	Nov 14, 2022	DP U-1345		
		8389542	Nov 14, 2022	DP U-1395		
		8748481	Sep 01, 2025	U-1520		
		8779187	Jan 23, 2027	DP		
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908	002	6414016	Sep 05, 2020	U-874	M-225	Apr 26, 2021
		6583174	Oct 16, 2020	DP		
		7064148	Aug 30, 2022	U-739		
		7064148	Aug 30, 2022	U-873		
		7417067	Oct 16, 2020	DP		
		7795312	Sep 17, 2024	U-1085		
		8026393	Oct 25, 2027	DP		
		8071613	Sep 05, 2020	U-1202		
		8088934	May 18, 2021	DS		
		8097649	Oct 16, 2020	DP		
		8114890	Sep 05, 2020	DP		
		8338639	Jan 23, 2027	DP		
		8748481	Sep 01, 2025	U-1519		
		8779187	Jan 23, 2027	DP		
<u>LULICONAZOLE - LUZU</u>						
N 204153	001	5900488	Jan 18, 2020	DS DP	NPP	Feb 20, 2021
		8980931	Apr 28, 2034	DP		
		9012484	Sep 06, 2033	DS DP U-540		
		9199977	Sep 06, 2033	DS DP		
		9453006	Sep 06, 2033	DS		
<u>LUMASIRAN SODIUM - OXLUMO</u>						
N 214103	001	10131907	Aug 24, 2028	DS DP U-2995	NCE	Nov 23, 2025
		10435692	Dec 26, 2034	U-2995		
		10465195	Dec 26, 2034	DS DP U-2995		
		10478500	Oct 09, 2035	DS DP U-2995		
		10487330	Dec 26, 2034	DS DP U-2995		
		10612024	Aug 14, 2035	DS DP U-2995		
		10612027	Aug 14, 2035	DS DP U-2995		
		8106022	Dec 12, 2029	DS DP U-2995		
		8828956	Dec 04, 2028	DS DP U-2995		
		9828606	Dec 26, 2034	DS DP		
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500	001	10464938	Mar 12, 2028	DP	NCE	Dec 20, 2024
		10695345	Aug 30, 2039	DP U-543		
		7183282	Jun 15, 2020	DS DP		
		8598119	Dec 28, 2029	U-543		
		8648077	Dec 01, 2029	DS DP		
		9199995	Mar 12, 2029	U-2713		
		9586960	Mar 12, 2029	DS DP		
		9616061	May 27, 2029	DP		
		9956227	Dec 03, 2034	U-2714		
		RE39680	Jun 15, 2020	DS DP U-543		
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603	001	8729085	May 26, 2026	DP	M-195	Jan 27, 2020
		8729085*PED	Nov 26, 2026		NPP	Jan 27, 2020
		8883794	May 26, 2026	DP	NPP	Mar 05, 2021
		8883794*PED	Nov 26, 2026		PED	Jul 27, 2020
		9174975	Feb 20, 2024	U-1770	PED	Jul 27, 2020
		9174975*PED	Aug 20, 2024			
		9259423	May 23, 2031	U-1822		
		9259423*PED	Nov 23, 2031			
		9555027	May 26, 2026	DP U-543		
		9815827	Feb 20, 2024	U-2166		
		9815827	Feb 20, 2024	U-543		
		9827242	May 23, 2031	U-2199		
		9827242	May 23, 2031	U-2201		
		9907794	May 26, 2026	DP		
		RE45573	Jun 23, 2025	DS		
		RE45573*PED	Dec 23, 2025			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603	002	8729085	May 26, 2026	DP	NPP	Jan 27, 2020
		8729085*PED	Nov 26, 2026		NPP	Mar 05, 2021
		8883794	May 26, 2026	DP	PED	Jul 27, 2020
		8883794*PED	Nov 26, 2026			
		9174975	Feb 20, 2024	U-1770		
		9174975*PED	Aug 20, 2024			
		9259423	May 23, 2031	U-1822		
		9259423*PED	Nov 23, 2031			
		9555027	May 26, 2026	DP U-543		
		9815827	Feb 20, 2024	U-2166		
		9815827	Feb 20, 2024	U-543		
		9827242	May 23, 2031	U-2199		
		9827242	May 23, 2031	U-2201		
		9907794	May 26, 2026	DP		
		RE45573	Jun 23, 2025	DS		
		RE45573*PED	Dec 23, 2025			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603	003	8729085	May 26, 2026	DP	M-195	Jan 27, 2020
		8729085*PED	Nov 26, 2026		NPP	Jan 27, 2020
		8883794	May 26, 2026	DP	NPP	Mar 05, 2021
		8883794*PED	Nov 26, 2026		PED	Jul 27, 2020
		9174975	Feb 20, 2024	U-1770	PED	Jul 27, 2020
		9174975*PED	Aug 20, 2024			
		9259423	May 23, 2031	U-1822		
		9259423*PED	Nov 23, 2031			
		9555027	May 26, 2026	DP U-543		
		9815827	Feb 20, 2024	U-2166		
		9815827	Feb 20, 2024	U-543		
		9827242	May 23, 2031	U-2199		
		9827242	May 23, 2031	U-2201		
		9907794	May 26, 2026	DP		
		RE45573	Jun 23, 2025	DS		
		RE45573*PED	Dec 23, 2025			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603	004	8729085	May 26, 2026	DP		
		8729085*PED	Nov 26, 2026			
		8883794	May 26, 2026	DP		
		8883794*PED	Nov 26, 2026			
		9174975	Feb 20, 2024	U-1770		
		9174975*PED	Aug 20, 2024			
		9259423	May 23, 2031	U-1822		
		9259423*PED	Nov 23, 2031			
		9555027	May 26, 2026	DP U-543		
		9815827	Feb 20, 2024	U-2166		
		9815827	Feb 20, 2024	U-543		
		9827242	May 23, 2031	U-2199		
		9827242	May 23, 2031	U-2201		
		9907794	May 26, 2026	DP		
		RE45573	Jun 23, 2025	DS		
		RE45573*PED	Dec 23, 2025			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603	005	8729085	May 26, 2026	DP	M-195	Jan 27, 2020
		8729085*PED	Nov 26, 2026		NPP	Jan 27, 2020
		8883794	May 26, 2026	DP	NPP	Mar 05, 2021
		8883794*PED	Nov 26, 2026		PED	Jul 27, 2020
		9174975	Feb 20, 2024	U-1770	PED	Jul 27, 2020
		9174975*PED	Aug 20, 2024			
		9259423	May 23, 2031	U-1822		
		9259423*PED	Nov 23, 2031			
		9555027	May 26, 2026	DP U-543		
		9815827	Feb 20, 2024	U-2166		
		9815827	Feb 20, 2024	U-543		
		9827242	May 23, 2031	U-2199		
		9827242	May 23, 2031	U-2201		
		9907794	May 26, 2026	DP		
		RE45573	Jun 23, 2025	DS		
		RE45573*PED	Dec 23, 2025			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603	005	8729085	May 26, 2026	DP	M-195	Jan 27, 2020
		8729085*PED	Nov 26, 2026		NPP	Jan 27, 2020
		8883794	May 26, 2026	DP	NPP	Mar 05, 2021
		8883794*PED	Nov 26, 2026		PED	Jul 27, 2020
		9174975	Feb 20, 2024	U-1770	PED	Jul 27, 2020
		9174975*PED	Aug 20, 2024			
		9259423	May 23, 2031	U-1822		
		9259423*PED	Nov 23, 2031			
		9555027	May 26, 2026	DP U-543		
		9815827	Feb 20, 2024	U-2166		
		9815827	Feb 20, 2024	U-543		
		9827242	May 23, 2031	U-2199		
		9827242	May 23, 2031	U-2201		
		9907794	May 26, 2026	DP		
		RE45573	Jun 23, 2025	DS		
		RE45573*PED	Dec 23, 2025			
<u>LURBINECTEDIN - ZEPZELCA</u>						
N 213702	001	7763615	Dec 13, 2024	DS DP U-2836	NCE ODE-304	Jun 15, 2025 Jun 15, 2027
<u>LUSUTROMBOPAG - MULPLETA</u>						
N 210923	001	7601746	Sep 05, 2024	DS DP U-2344	NCE	Jul 31, 2023
		8530668	Jan 21, 2030	DS DP		
		8889722	Jul 29, 2028	DS DP		
		9427402	Sep 29, 2031	DP		
<u>LUTETIUM DOTATATE LU-177 - LUTATHERA</u>						
N 208700	001	10596276	Jul 25, 2038	DP	NCE	Jan 26, 2023
		10596278	Jul 25, 2038	DP	ODE-166	Jan 26, 2025
<u>MACIMORELIN ACETATE - MACRILEN</u>						
N 205598	001	6861409	Aug 01, 2022	DS DP U-2220	NCE	Dec 20, 2022
		8192719	Oct 12, 2027	U-2220	ODE-170	Dec 20, 2024
<u>MACITENTAN - OPSUMIT</u>						
N 204410	001	7094781	Dec 05, 2025	DS DP	ODE-54	Oct 18, 2020
		8268847	Apr 18, 2029	U-1446		
		8367685	Oct 04, 2028	DP U-1445		
		9265762	May 29, 2027	DP U-1820		
<u>MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE - NORMOCARB HF 25</u>						
N 021910	001	7300674	Mar 04, 2023	DP U-785		
<u>MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE - SUTAB (COPACKAGED)</u>						
N 213135	001	10143656	Aug 04, 2037	DP	NP	Nov 10, 2023
<u>MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE - SUPREP BOWEL PREP KIT</u>						
N 022372	001	6946149	Mar 07, 2023	DP U-837	ODE-315	Aug 05, 2027
<u>MALATHION - OVIDE</u>						
N 018613	001	7560445	Feb 01, 2027	DS DP U-986		
		7977324	Aug 14, 2026	DP		
<u>MARAVIROC - SELZENTRY</u>						
N 022128	001	6667314	Aug 06, 2021	DS DP U-824		
		6667314*PED	Feb 06, 2022			
		7368460	Nov 25, 2022	U-824		
		7368460*PED	May 25, 2023			
		7576097	May 25, 2021	DS		
		7576097*PED	Nov 25, 2021			
<u>MARAVIROC - SELZENTRY</u>						
N 022128	002	6667314	Aug 06, 2021	DS DP U-824		
		6667314*PED	Feb 06, 2022			
		7368460	Nov 25, 2022	U-824		
		7368460*PED	May 25, 2023			
		7576097	May 25, 2021	DS		
		7576097*PED	Nov 25, 2021			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MARAVIROC - SELZENTRY</u>						
N 022128	003	6667314	Aug 06, 2021	DS DP	U-824	
		6667314*PED	Feb 06, 2022			
		7368460	Nov 25, 2022		U-824	
		7368460*PED	May 25, 2023			
		7576097	May 25, 2021	DS		
		7576097*PED	Nov 25, 2021			
<u>MARAVIROC - SELZENTRY</u>						
N 022128	004	6667314	Aug 06, 2021	DS DP	U-824	
		6667314*PED	Feb 06, 2022			
		7368460	Nov 25, 2022		U-824	
		7368460*PED	May 25, 2023			
		7576097	May 25, 2021	DS		
		7576097*PED	Nov 25, 2021			
<u>MARAVIROC - SELZENTRY</u>						
N 208984	001	6667314	Aug 06, 2021	DS DP	U-824	NPP Oct 30, 2023
		6667314*PED	Feb 06, 2022			PED Apr 30, 2024
		7368460	Nov 25, 2022		U-824	
		7368460*PED	May 25, 2023			
		7576097	May 25, 2021	DS		
		7576097*PED	Nov 25, 2021			
<u>MECHLORETHAMINE HYDROCHLORIDE - VALCHLOR</u>						
N 202317	001	7838564	Mar 07, 2026	DP		ODE-51 Aug 23, 2020
		7872050	Jul 08, 2029		U-1427	
		8450375	Mar 07, 2026	DP		
		8501818	Mar 07, 2026	DP		
		8501819	Mar 07, 2026		U-1427	
		9382191	Mar 07, 2026	DP		
<u>MEDROXYPROGESTERONE ACETATE - DEPO-SUBO PROVERA 104</u>						
N 021583	001	6495534	May 15, 2020	DP		
<u>MEGESTROL ACETATE - MEGACE ES</u>						
N 021778	001	6592903	Sep 21, 2020	DP		
		7101576	Apr 22, 2024		U-755	
		9040088	Apr 22, 2024		U-755	
		9101540	Apr 22, 2024	DP	U-755	
		9101549	Apr 22, 2024		U-755	
		9107827	Apr 22, 2024		U-755	
<u>MELOXICAM - VIVLODEX</u>						
N 207233	001	9526734	Mar 31, 2033	DP		
		9649318	Mar 31, 2035	DP		
		9808468	Mar 31, 2035		U-2160	
		9808468	Mar 31, 2035		U-2165	
<u>MELOXICAM - VIVLODEX</u>						
N 207233	002	9526734	Mar 31, 2033	DP		
		9649318	Mar 31, 2035	DP		
		9808468	Mar 31, 2035		U-2160	
		9808468	Mar 31, 2035		U-2165	
<u>MELOXICAM - ANJESO</u>						
N 210583	001	10463673	Feb 24, 2024	DP	U-2750	NP Feb 20, 2023
		10471067	Feb 24, 2024	DP	U-2750	
		10709713	May 26, 2030		U-2750	
		8512727	Dec 25, 2022	DP	U-2750	
		9974746	May 26, 2030	DP		
<u>MELOXICAM - OMIIZ ODT</u>						
N 211210	001	8545879	Aug 31, 2030	DP		
<u>MELOXICAM - OMIIZ ODT</u>						
N 211210	002	8545879	Aug 31, 2030	DP		
<u>MELPHALAN HYDROCHLORIDE - EVOMELA</u>						
N 207155	001	10040872	Jan 30, 2034	DP		ODE-110 Mar 10, 2023
		10864183	May 28, 2030	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MELPHALAN HYDROCHLORIDE - EVOMELA</u>						
N 207155	001	8410077	Mar 13, 2029	DP		
		9200088	Mar 13, 2029	DP		
		9493582	Feb 27, 2033	DP		
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525	001	8039009	Mar 24, 2029		U-539	
		8039009*PED	Sep 24, 2029			
		8168209	Nov 22, 2025	DP		
		8168209*PED	May 22, 2026			
		8173708	Nov 22, 2025		U-539	
		8173708*PED	May 22, 2026			
		8283379	Nov 22, 2025		U-539	
		8283379*PED	May 22, 2026			
		8329752	Nov 22, 2025	DP		
		8329752*PED	May 22, 2026			
		8362085	Nov 22, 2025		U-539	
		8362085*PED	May 22, 2026			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525	002	8039009	Mar 24, 2029		U-539	
		8039009*PED	Sep 24, 2029			
		8168209	Nov 22, 2025	DP		
		8168209*PED	May 22, 2026			
		8173708	Nov 22, 2025		U-539	
		8173708*PED	May 22, 2026			
		8283379	Nov 22, 2025		U-539	
		8283379*PED	May 22, 2026			
		8329752	Nov 22, 2025	DP		
		8329752*PED	May 22, 2026			
		8362085	Nov 22, 2025		U-539	
		8362085*PED	May 22, 2026			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525	003	8039009	Mar 24, 2029		U-539	
		8039009*PED	Sep 24, 2029			
		8168209	Nov 22, 2025	DP		
		8168209*PED	May 22, 2026			
		8173708	Nov 22, 2025		U-539	
		8173708*PED	May 22, 2026			
		8283379	Nov 22, 2025		U-539	
		8283379*PED	May 22, 2026			
		8329752	Nov 22, 2025	DP		
		8329752*PED	May 22, 2026			
		8362085	Nov 22, 2025		U-539	
		8362085*PED	May 22, 2026			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525	004	8039009	Mar 24, 2029		U-539	
		8039009*PED	Sep 24, 2029			
		8168209	Nov 22, 2025	DP		
		8168209*PED	May 22, 2026			
		8173708	Nov 22, 2025		U-539	
		8173708*PED	May 22, 2026			
		8283379	Nov 22, 2025		U-539	
		8283379*PED	May 22, 2026			
		8329752	Nov 22, 2025	DP		
		8329752*PED	May 22, 2026			
		8362085	Nov 22, 2025		U-539	
		8362085*PED	May 22, 2026			
		8598233	Nov 22, 2025	DP		
		8598233*PED	May 22, 2026			
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029	001	8809615	Jan 03, 2030	DP		
		9233184	Aug 01, 2027	DP		
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029	002	8809615	Jan 03, 2030	DP		
		9233184	Aug 01, 2027	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MEQUINOL; TRETINOIN - SOLAGE</u>						
N 020922	001 6353029	Aug 24, 2020				
<u>MERCAPTOPURINE - PURIXAN</u>						
N 205919	001				ODE-65	Apr 28, 2021
<u>MEROPENEM; VABORBACTAM - VABOMERE</u>						
N 209776	001 10172874	Aug 08, 2031	DP			
	10183034	Aug 08, 2031		U-2490		
	10561675	Aug 08, 2031		U-2490		
	8680136	Aug 17, 2031	DS DP			
	9694025	Aug 08, 2031		U-2120		
<u>MESALAMINE - SFROWASA</u>						
N 019618	002 7645801	Jul 24, 2027	DS DP			
<u>MESALAMINE - CANASA</u>						
N 021252	002 8217083	Jun 06, 2028	DP			
	8436051	Jun 06, 2028	DP			
<u>MESALAMINE - ASACOL HD</u>						
N 021830	001 6893662	Nov 15, 2021	DP	U-141		
	8580302	Nov 15, 2021	DP			
	9089492	Nov 15, 2021	DP			
<u>MESALAMINE - LIALDA</u>						
N 022000	001 6773720	Jun 08, 2020	DP		NPP	Jun 26, 2023
<u>MESALAMINE - APRISO</u>						
N 022301	001 8865688	May 01, 2030		U-1310		
<u>MESALAMINE - DELZICOL</u>						
N 204412	001 6649180	Apr 13, 2020	DP			
<u>METAXALONE - SKELAXIN</u>						
N 013217	003 7122566	Feb 06, 2026		U-915		
	7714006	Dec 03, 2021		U-1050		
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N 021574	001 6790459	Mar 17, 2021		U-604		
	6866866	Mar 17, 2021	DP			
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N 021574	002 6790459	Mar 17, 2021		U-604		
	6866866	Mar 17, 2021	DP			
<u>METFORMIN HYDROCHLORIDE - RIOMET</u>						
N 021591	001 6890957	Aug 07, 2021	DP			
<u>METFORMIN HYDROCHLORIDE - GLUMETZA</u>						
N 021748	001 6488962	Jun 20, 2020	DS DP			
	6723340	Oct 25, 2021	DS DP			
<u>METFORMIN HYDROCHLORIDE - GLUMETZA</u>						
N 021748	002 7780987	Mar 23, 2025	DS DP			
	8323692	Mar 30, 2023	DP			
<u>METFORMIN HYDROCHLORIDE - RIOMET ER</u>						
N 212595	001 9962336	May 01, 2035	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842	001 9101660	Jan 22, 2027	DP			
	9320714	Feb 03, 2029	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842	002 9101660	Jan 22, 2027	DP			
	9320714	Feb 03, 2029	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024	001 6790459	Mar 17, 2021		U-974		
	6866866	Mar 17, 2021	DP			
	7785627	Jul 31, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024	001	7959946	Jul 31, 2026	DP		
		8470368	Sep 19, 2023	DP		
		8668931	Sep 19, 2023	DP		
		9060941	Sep 19, 2023	DP		
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024	002	6790459	Mar 17, 2021		U-974	
		6866866	Mar 17, 2021	DP		
		7785627	Jul 31, 2026	DP		
		7959946	Jul 31, 2026	DP		
		8470368	Sep 19, 2023	DP		
		8668931	Sep 19, 2023	DP		
		9060941	Sep 19, 2023	DP		
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N 021410	001	8236345	Oct 07, 2022	DP		
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N 021410	002	8236345	Oct 07, 2022	DP		
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N 021410	003	8236345	Oct 07, 2022	DP		
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N 021410	004	8236345	Oct 07, 2022	DP		
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N 021410	005	8236345	Oct 07, 2022	DP		
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678	001	8628799	Jul 13, 2025	DP	M-198	Feb 27, 2020
		9339472	Jul 13, 2025	DP		
		RE44186	Jul 31, 2023	DS DP U-1097		
		RE44186	Jul 31, 2023	DS DP U-1838		
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678	002	8628799	Jul 13, 2025	DP	M-198	Feb 27, 2020
		9339472	Jul 13, 2025	DP		
		RE44186	Jul 31, 2023	DS DP U-1097		
		RE44186	Jul 31, 2023	DS DP U-1838		
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678	003	8628799	Jul 13, 2025	DP	M-198	Feb 27, 2020
		9339472	Jul 13, 2025	DP		
		RE44186	Jul 31, 2023	DS DP U-1097		
		RE44186	Jul 31, 2023	DS DP U-1838		
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044	001	6699871	Jul 26, 2022	DS DP U-802	M-244	Aug 12, 2022
		6699871*PED	Jan 26, 2023		PED	Feb 12, 2023
		7125873	Jul 26, 2022	DP U-1036		
		7125873	Jul 26, 2022	DP U-1038		
		7125873	Jul 26, 2022	DP U-803		
		7125873*PED	Jan 26, 2023			
		7326708	Nov 24, 2026	DS DP U-802		
		7326708*PED	May 24, 2027			
		8414921	Jul 21, 2028	DP U-1036		
		8414921*PED	Jan 21, 2029			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044	002	6699871	Jul 26, 2022	DS DP U-802	M-244	Aug 12, 2022
		6699871*PED	Jan 26, 2023		PED	Feb 12, 2023
		7125873	Jul 26, 2022	DP U-1036		
		7125873	Jul 26, 2022	DP U-1038		
		7125873	Jul 26, 2022	DP U-803		
		7125873*PED	Jan 26, 2023			
		7326708	Nov 24, 2026	DS DP U-802		
		7326708*PED	May 24, 2027			
		8414921	Jul 21, 2028	DP U-1036		
		8414921*PED	Jan 21, 2029			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270	001	6699871	Jul 26, 2022	DS DP U-1227	M-244	Aug 12, 2022
		6699871*PED	Jan 26, 2023		PED	Feb 12, 2023
		7125873	Jul 26, 2022	DP U-1227		
		7125873*PED	Jan 26, 2023			
		7326708	Nov 24, 2026	DS DP U-1227		
		7326708*PED	May 24, 2027			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270	002	6699871	Jul 26, 2022	DS DP U-1227	M-244	Aug 12, 2022
		6699871*PED	Jan 26, 2023		PED	Feb 12, 2023
		7125873	Jul 26, 2022	DP U-1227		
		7125873*PED	Jan 26, 2023			
		7326708	Nov 24, 2026	DS DP U-1227		
		7326708*PED	May 24, 2027			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270	003	6699871	Jul 26, 2022	DS DP U-1227	M-244	Aug 12, 2022
		6699871*PED	Jan 26, 2023		PED	Feb 12, 2023
		7125873	Jul 26, 2022	DP U-1227		
		7125873*PED	Jan 26, 2023			
		7326708	Nov 24, 2026	DS DP U-1227		
		7326708*PED	May 24, 2027			
<u>METHOTREXATE - OTREXUP</u>						
N 204824	001	10709844	Mar 10, 2029	DP		
		6746429	Apr 12, 2020	DP		
		8021335	Oct 04, 2026	DP		
		8480631	Mar 19, 2030	DP U-1442		
		8562564	Jan 24, 2026	DP		
		8579865	Mar 19, 2030	DP U-1442		
		8814834	May 27, 2031	DP		
		8945063	Mar 19, 2030	DP U-1442		
		9421333	Mar 19, 2030	DP U-1442		
		9533102	Jan 24, 2026	DP		
		9629959	Jan 24, 2026	DP		
		9867949	Mar 10, 2029	DP		
<u>METHOTREXATE - OTREXUP</u>						
N 204824	002	10709844	Mar 10, 2029	DP		
		6746429	Apr 12, 2020	DP		
		8021335	Oct 04, 2026	DP		
		8480631	Mar 19, 2030	DP U-1442		
		8562564	Jan 24, 2026	DP		
		8579865	Mar 19, 2030	DP U-1442		
		8814834	May 27, 2031	DP		
		8945063	Mar 19, 2030	DP U-1442		
		9421333	Mar 19, 2030	DP U-1442		
		9533102	Jan 24, 2026	DP		
		9629959	Jan 24, 2026	DP		
		9867949	Mar 10, 2029	DP		
<u>METHOTREXATE - OTREXUP</u>						
N 204824	003	10709844	Mar 10, 2029	DP		
		6746429	Apr 12, 2020	DP		
		8021335	Oct 04, 2026	DP		
		8480631	Mar 19, 2030	DP U-1442		
		8562564	Jan 24, 2026	DP		
		8579865	Mar 19, 2030	DP U-1442		
		8814834	May 27, 2031	DP		
		8945063	Mar 19, 2030	DP U-1442		
		9421333	Mar 19, 2030	DP U-1442		
		9533102	Jan 24, 2026	DP		
		9629959	Jan 24, 2026	DP		
		9867949	Mar 10, 2029	DP		
<u>METHOTREXATE - OTREXUP</u>						
N 204824	004	10709844	Mar 10, 2029	DP		
		6746429	Apr 12, 2020	DP		
		8021335	Oct 04, 2026	DP		
		8480631	Mar 19, 2030	DP U-1442		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHOTREXATE - OTREXUP</u>						
N 204824	004	8562564	Jan 24, 2026	DP		
		8579865	Mar 19, 2030	DP U-1442		
		8814834	May 27, 2031	DP		
		8945063	Mar 19, 2030	DP U-1442		
		9421333	Mar 19, 2030	DP U-1442		
		9533102	Jan 24, 2026	DP		
		9629959	Jan 24, 2026	DP		
		9867949	Mar 10, 2029	DP		
<u>METHOTREXATE - OTREXUP</u>						
N 204824	005	10709844	Mar 10, 2029	DP		
		6746429	Apr 12, 2020	DP		
		8021335	Oct 04, 2026	DP		
		8480631	Mar 19, 2030	DP U-1442		
		8562564	Jan 24, 2026	DP		
		8579865	Mar 19, 2030	DP U-1442		
		8814834	May 27, 2031	DP		
		8945063	Mar 19, 2030	DP U-1442		
		9421333	Mar 19, 2030	DP U-1442		
		9533102	Jan 24, 2026	DP		
		9629959	Jan 24, 2026	DP		
		9867949	Mar 10, 2029	DP		
<u>METHOTREXATE - OTREXUP</u>						
N 204824	006	10709844	Mar 10, 2029	DP		
		6746429	Apr 12, 2020	DP		
		8021335	Oct 04, 2026	DP		
		8480631	Mar 19, 2030	DP U-1442		
		8562564	Jan 24, 2026	DP		
		8579865	Mar 19, 2030	DP U-1442		
		8814834	May 27, 2031	DP		
		8945063	Mar 19, 2030	DP U-1442		
		9421333	Mar 19, 2030	DP U-1442		
		9533102	Jan 24, 2026	DP		
		9629959	Jan 24, 2026	DP		
		9867949	Mar 10, 2029	DP		
<u>METHOTREXATE - OTREXUP</u>						
N 204824	007	10709844	Mar 10, 2029	DP		
		6746429	Apr 12, 2020	DP		
		8021335	Oct 04, 2026	DP		
		8480631	Mar 19, 2030	DP U-1442		
		8562564	Jan 24, 2026	DP		
		8579865	Mar 19, 2030	DP U-1442		
		8814834	May 27, 2031	DP		
		8945063	Mar 19, 2030	DP U-1442		
		9421333	Mar 19, 2030	DP U-1442		
		9533102	Jan 24, 2026	DP		
		9629959	Jan 24, 2026	DP		
		9867949	Mar 10, 2029	DP		
<u>METHOTREXATE - OTREXUP</u>						
N 204824	008	10709844	Mar 10, 2029	DP		
		6746429	Apr 12, 2020	DP		
		8021335	Oct 04, 2026	DP		
		8480631	Mar 19, 2030	DP U-1442		
		8562564	Jan 24, 2026	DP		
		8579865	Mar 19, 2030	DP U-1442		
		8814834	May 27, 2031	DP		
		8945063	Mar 19, 2030	DP U-1442		
		9421333	Mar 19, 2030	DP U-1442		
		9533102	Jan 24, 2026	DP		
		9629959	Jan 24, 2026	DP		
		9867949	Mar 10, 2029	DP		
<u>METHOTREXATE - RASUVQ</u>						
N 205776	001	8664231	Jun 01, 2029	U-1442		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHOTREXATE - RASUVO</u>						
N 205776	002	8664231	Jun 01, 2029	U-1442		
<u>METHOTREXATE - RASUVO</u>						
N 205776	003	8664231	Jun 01, 2029	U-1442		
<u>METHOTREXATE - RASUVO</u>						
N 205776	004	8664231	Jun 01, 2029	U-1442		
<u>METHOTREXATE - RASUVO</u>						
N 205776	005	8664231	Jun 01, 2029	U-1442		
<u>METHOTREXATE - RASUVO</u>						
N 205776	006	8664231	Jun 01, 2029	U-1442		
<u>METHOTREXATE - RASUVO</u>						
N 205776	007	8664231	Jun 01, 2029	U-1442		
<u>METHOTREXATE - RASUVO</u>						
N 205776	008	8664231	Jun 01, 2029	U-1442		
<u>METHOTREXATE - RASUVO</u>						
N 205776	009	8664231	Jun 01, 2029	U-1442		
<u>METHOTREXATE - RASUVO</u>						
N 205776	010	8664231	Jun 01, 2029	U-1442		
<u>METHOTREXATE SODIUM - XATMEP</u>						
N 208400	001	10231927	Jan 02, 2033	U-1349	ODE-137	Apr 25, 2024
		10231927	Jan 02, 2033	U-1699	ODE-138	Apr 25, 2024
		10610485	Jan 02, 2033	DP		
		9259427	Jan 02, 2033	DP		
		9855215	Jan 02, 2033	DP		
<u>METHYLENE BLUE - PROVAYBLUE</u>						
N 204630	001				ODE-113	Apr 08, 2023
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964	001	10376584	Apr 08, 2024	DP U-1185		
		8247425	Dec 31, 2030	U-1185		
		8420663	Sep 30, 2029	U-1185		
		8552025	Apr 08, 2024	DP		
		8822490	Sep 30, 2029	DP U-1185		
		9180125	Sep 30, 2029	DP U-1185		
		9492445	Sep 30, 2029	DP U-1185		
		9669096	Apr 08, 2024	DP		
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964	002	10376584	Apr 08, 2024	DP U-1185		
		8247425	Dec 31, 2030	U-1185		
		8420663	Sep 30, 2029	U-1185		
		8552025	Apr 08, 2024	DP		
		8822490	Sep 30, 2029	DP U-1185		
		9180125	Sep 30, 2029	DP U-1185		
		9492445	Sep 30, 2029	DP U-1185		
		9669096	Apr 08, 2024	DP		
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964	003	10376584	Apr 08, 2024	DP U-1185		
		8247425	Dec 31, 2030	U-1185		
		8420663	Sep 30, 2029	U-1185		
		8552025	Apr 08, 2024	DP		
		8822490	Sep 30, 2029	DP U-1185		
		9180125	Sep 30, 2029	DP U-1185		
		9492445	Sep 30, 2029	DP U-1185		
		9669096	Apr 08, 2024	DP		
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 208271	001	10307417	Mar 10, 2031	DP		
		10376505	Mar 10, 2031	DP		
		8420663	Sep 30, 2029	U-1185		
		8524276	Mar 10, 2031	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 208271	001	8956651	Mar 10, 2031	DP		
		9180125	Sep 30, 2029	DP U-1185		
		9314461	Mar 10, 2031	DP		
		9492445	Sep 30, 2029	DP U-1185		
		9724343	Sep 30, 2029	DP U-1185		
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514	001	8632802	Oct 07, 2025	DP		
		9034370	Oct 07, 2025	DP		
		9668981	Oct 07, 2025		U-2024	
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514	002	8632802	Oct 07, 2025	DP		
		9034370	Oct 07, 2025	DP		
		9668981	Oct 07, 2025		U-2024	
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514	003	8632802	Oct 07, 2025	DP		
		9034370	Oct 07, 2025	DP		
		9668981	Oct 07, 2025		U-2024	
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514	004	8632802	Oct 07, 2025	DP		
		9034370	Oct 07, 2025	DP		
		9668981	Oct 07, 2025		U-2024	
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489	001	8840924	Jun 05, 2026	DP	NP	Jun 19, 2020
		9072680	Jun 28, 2032	DP		
		9089496	Jun 28, 2032	DP		
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489	002	8840924	Jun 05, 2026	DP	NP	Jun 19, 2020
		9072680	Jun 28, 2032	DP		
		9089496	Jun 28, 2032	DP		
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489	003	8840924	Jun 05, 2026	DP	NP	Jun 19, 2020
		9072680	Jun 28, 2032	DP		
		9089496	Jun 28, 2032	DP		
<u>METHYLPHENIDATE HYDROCHLORIDE - METADATE CD</u>						
N 021259	001	6344215	Oct 27, 2020	DP		
<u>METHYLPHENIDATE HYDROCHLORIDE - METADATE CD</u>						
N 021259	002	6344215	Oct 27, 2020	DP		
<u>METHYLPHENIDATE HYDROCHLORIDE - METADATE CD</u>						
N 021259	003	6344215	Oct 27, 2020	DP		
<u>METHYLPHENIDATE HYDROCHLORIDE - METADATE CD</u>						
N 021259	004	6344215	Oct 27, 2020	DP		
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLIN</u>						
N 021419	001	7691880	Oct 07, 2024	DP		
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLIN</u>						
N 021419	002	7691880	Oct 07, 2024	DP		
<u>METHYLPHENIDATE HYDROCHLORIDE - OUILIVANT XR</u>						
N 202100	001	8062667	Mar 29, 2029	DP		
		8287903	Feb 15, 2031	DP		
		8465765	Feb 15, 2031	DP U-1415		
		8563033	Feb 15, 2031	DP U-1415		
		8778390	Feb 15, 2031	DP U-1543		
		8956649	Feb 15, 2031	DP U-1665		
		9040083	Feb 15, 2031	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831	001	10039719*PED	Jun 16, 2020			
		6419960*PED	Jun 16, 2020			
		7083808*PED	Jun 16, 2020			
		7247318*PED	Jun 16, 2020			
		7438930*PED	Jun 16, 2020			
		8580310*PED	Jun 16, 2020			
		9066869*PED	Jun 16, 2020			
		9801823*PED	Jun 16, 2020			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831	002	10039719*PED	Jun 16, 2020			
		6419960*PED	Jun 16, 2020			
		7083808*PED	Jun 16, 2020			
		7247318*PED	Jun 16, 2020			
		7438930*PED	Jun 16, 2020			
		8580310*PED	Jun 16, 2020			
		9066869*PED	Jun 16, 2020			
		9801823*PED	Jun 16, 2020			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831	003	10039719*PED	Jun 16, 2020			
		6419960*PED	Jun 16, 2020			
		7083808*PED	Jun 16, 2020			
		7247318*PED	Jun 16, 2020			
		7438930*PED	Jun 16, 2020			
		8580310*PED	Jun 16, 2020			
		9066869*PED	Jun 16, 2020			
		9801823*PED	Jun 16, 2020			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831	004	10039719*PED	Jun 16, 2020			
		6419960*PED	Jun 16, 2020			
		7083808*PED	Jun 16, 2020			
		7247318*PED	Jun 16, 2020			
		7438930*PED	Jun 16, 2020			
		8580310*PED	Jun 16, 2020			
		9066869*PED	Jun 16, 2020			
		9801823*PED	Jun 16, 2020			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831	005	10039719*PED	Jun 16, 2020			
		6419960*PED	Jun 16, 2020			
		7083808*PED	Jun 16, 2020			
		7247318*PED	Jun 16, 2020			
		7438930*PED	Jun 16, 2020			
		8580310*PED	Jun 16, 2020			
		9066869*PED	Jun 16, 2020			
		9801823*PED	Jun 16, 2020			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831	006	10039719*PED	Jun 16, 2020			
		6419960*PED	Jun 16, 2020			
		7083808*PED	Jun 16, 2020			
		7247318*PED	Jun 16, 2020			
		7438930*PED	Jun 16, 2020			
		8580310*PED	Jun 16, 2020			
		9066869*PED	Jun 16, 2020			
		9801823*PED	Jun 16, 2020			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831	007	10039719*PED	Jun 16, 2020			
		6419960*PED	Jun 16, 2020			
		7083808*PED	Jun 16, 2020			
		7247318*PED	Jun 16, 2020			
		7438930*PED	Jun 16, 2020			
		8580310*PED	Jun 16, 2020			
		9066869*PED	Jun 16, 2020			
		9801823*PED	Jun 16, 2020			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960	001	10857143	Aug 14, 2033	DP U-2993		
		8202537	Mar 15, 2027	DP		
		8287903	Feb 15, 2031	DP		
		8999386	Aug 14, 2033	DP		
		9295642	Aug 14, 2033	DP U-1827		
		9545399	Aug 14, 2033	DP U-1827		
		9844544	Aug 14, 2033	DP U-2203		
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960	002	10857143	Aug 14, 2033	DP U-2993		
		8202537	Mar 15, 2027	DP		
		8287903	Feb 15, 2031	DP		
		8999386	Aug 14, 2033	DP		
		9295642	Aug 14, 2033	DP U-1827		
		9545399	Aug 14, 2033	DP U-1827		
		9844544	Aug 14, 2033	DP U-2203		
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960	003	10857143	Aug 14, 2033	DP U-2993		
		8202537	Mar 15, 2027	DP		
		8287903	Feb 15, 2031	DP		
		8999386	Aug 14, 2033	DP		
		9295642	Aug 14, 2033	DP U-1827		
		9545399	Aug 14, 2033	DP U-1827		
		9844544	Aug 14, 2033	DP U-2203		
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311	001	10182995	Mar 23, 2032	DP	NP	Aug 08, 2021
		10292937	Mar 23, 2032	U-2357		
		10617651	Mar 23, 2032	U-2357		
		8916588	Mar 23, 2032	U-2357		
		8927010	Mar 23, 2032	DP		
		9023389	Mar 23, 2032	DP		
		9028868	Mar 23, 2032	U-2357		
		9034902	Mar 23, 2032	U-2357		
		9283214	Mar 23, 2032	DP		
		9498447	Mar 23, 2032	DP		
		9603809	Mar 23, 2032	U-2357		
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311	002	10182995	Mar 23, 2032	DP	NP	Aug 08, 2021
		10292937	Mar 23, 2032	U-2357		
		10617651	Mar 23, 2032	U-2357		
		8916588	Mar 23, 2032	U-2357		
		8927010	Mar 23, 2032	DP		
		9023389	Mar 23, 2032	DP		
		9028868	Mar 23, 2032	U-2357		
		9034902	Mar 23, 2032	U-2357		
		9283214	Mar 23, 2032	DP		
		9498447	Mar 23, 2032	DP		
		9603809	Mar 23, 2032	U-2357		
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311	003	10182995	Mar 23, 2032	DP	NP	Aug 08, 2021
		10292937	Mar 23, 2032	U-2357		
		10617651	Mar 23, 2032	U-2357		
		8916588	Mar 23, 2032	U-2357		
		8927010	Mar 23, 2032	DP		
		9023389	Mar 23, 2032	DP		
		9028868	Mar 23, 2032	U-2357		
		9034902	Mar 23, 2032	U-2357		
		9283214	Mar 23, 2032	DP		
		9498447	Mar 23, 2032	DP		
		9603809	Mar 23, 2032	U-2357		
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311	004	10182995	Mar 23, 2032	DP	NP	Aug 08, 2021
		10292937	Mar 23, 2032	U-2357		
		10617651	Mar 23, 2032	U-2357		
		8916588	Mar 23, 2032	U-2357		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311	004	8927010	Mar 23, 2032	DP		
		9023389	Mar 23, 2032	DP		
		9028868	Mar 23, 2032		U-2357	
		9034902	Mar 23, 2032		U-2357	
		9283214	Mar 23, 2032	DP		
		9498447	Mar 23, 2032	DP		
		9603809	Mar 23, 2032		U-2357	
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311	005	10182995	Mar 23, 2032	DP		Aug 08, 2021
		10292937	Mar 23, 2032		U-2357	
		10617651	Mar 23, 2032		U-2357	
		8916588	Mar 23, 2032		U-2357	
		8927010	Mar 23, 2032	DP		
		9023389	Mar 23, 2032	DP		
		9028868	Mar 23, 2032		U-2357	
		9034902	Mar 23, 2032		U-2357	
		9283214	Mar 23, 2032	DP		
		9498447	Mar 23, 2032	DP		
		9603809	Mar 23, 2032		U-2357	
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038	001	10111839	Oct 30, 2035		U-2357	Feb 27, 2022
		10292938	Oct 30, 2035	DP		
		10292939	Oct 30, 2035	DP	U-2357	
		10449159	Oct 30, 2035		U-2357	
		10500162	Oct 30, 2035		U-2357	
		10507186	Oct 30, 2035	DP		
		10512612	Oct 30, 2035	DP		
		10512613	Oct 30, 2035		U-2357	
		10568841	Oct 30, 2035	DP	U-2357	
		10688060	Oct 30, 2035	DP		
		10722473	Nov 19, 2038		U-2357	
		9974752	Oct 30, 2035	DP		
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038	002	10111839	Oct 30, 2035		U-2357	Feb 27, 2022
		10292938	Oct 30, 2035	DP		
		10292939	Oct 30, 2035	DP	U-2357	
		10449159	Oct 30, 2035		U-2357	
		10500162	Oct 30, 2035		U-2357	
		10507186	Oct 30, 2035	DP		
		10512612	Oct 30, 2035	DP		
		10512613	Oct 30, 2035		U-2357	
		10568841	Oct 30, 2035	DP	U-2357	
		10688060	Oct 30, 2035	DP		
		10722473	Nov 19, 2038		U-2357	
		9974752	Oct 30, 2035	DP		
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038	003	10111839	Oct 30, 2035		U-2357	Feb 27, 2022
		10292938	Oct 30, 2035	DP		
		10292939	Oct 30, 2035	DP	U-2357	
		10449159	Oct 30, 2035		U-2357	
		10500162	Oct 30, 2035		U-2357	
		10507186	Oct 30, 2035	DP		
		10512612	Oct 30, 2035	DP		
		10512613	Oct 30, 2035		U-2357	
		10568841	Oct 30, 2035	DP	U-2357	
		10688060	Oct 30, 2035	DP		
		10722473	Nov 19, 2038		U-2357	
		9974752	Oct 30, 2035	DP		
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038	004	10111839	Oct 30, 2035		U-2357	Feb 27, 2022
		10292938	Oct 30, 2035	DP		
		10292939	Oct 30, 2035	DP	U-2357	
		10449159	Oct 30, 2035		U-2357	
		10500162	Oct 30, 2035		U-2357	
		10507186	Oct 30, 2035	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038	004	10512612	Oct 30, 2035	DP		
		10512613	Oct 30, 2035	U-2357		
		10568841	Oct 30, 2035	DP U-2357		
		10688060	Oct 30, 2035	DP		
		10722473	Nov 19, 2038	U-2357		
		9974752	Oct 30, 2035	DP		
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038	005	10111839	Oct 30, 2035	U-2357	NP	Feb 27, 2022
		10292938	Oct 30, 2035	DP		
		10292939	Oct 30, 2035	DP U-2357		
		10449159	Oct 30, 2035	U-2357		
		10500162	Oct 30, 2035	U-2357		
		10507186	Oct 30, 2035	DP		
		10512612	Oct 30, 2035	DP		
		10512613	Oct 30, 2035	U-2357		
		10568841	Oct 30, 2035	DP U-2357		
		10688060	Oct 30, 2035	DP		
		10722473	Nov 19, 2038	U-2357		
		9974752	Oct 30, 2035	DP		
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038	006	10111839	Oct 30, 2035	U-2357	NP	Feb 27, 2022
		10292938	Oct 30, 2035	DP		
		10292939	Oct 30, 2035	DP U-2357		
		10449159	Oct 30, 2035	U-2357		
		10500162	Oct 30, 2035	U-2357		
		10507186	Oct 30, 2035	DP		
		10512612	Oct 30, 2035	DP		
		10512613	Oct 30, 2035	U-2357		
		10568841	Oct 30, 2035	DP U-2357		
		10688060	Oct 30, 2035	DP		
		10722473	Nov 19, 2038	U-2357		
		9974752	Oct 30, 2035	DP		
<u>METOCLOPRAMIDE HYDROCHLORIDE - GIMOTI</u>						
N 209388	001	6770262	Mar 29, 2021	U-2843		
		8334281	May 16, 2030	DP U-2843		
<u>METOPROLOL SUCCINATE - KAPSPARGO SPRINKLE</u>						
N 210428	001	9504655	Jul 09, 2035	DP		
		9700530	Jul 09, 2035	DP		
<u>METOPROLOL SUCCINATE - KAPSPARGO SPRINKLE</u>						
N 210428	002	9504655	Jul 09, 2035	DP		
		9700530	Jul 09, 2035	DP		
<u>METOPROLOL SUCCINATE - KAPSPARGO SPRINKLE</u>						
N 210428	003	9504655	Jul 09, 2035	DP		
		9700530	Jul 09, 2035	DP		
<u>METOPROLOL SUCCINATE - KAPSPARGO SPRINKLE</u>						
N 210428	004	9504655	Jul 09, 2035	DP		
		9700530	Jul 09, 2035	DP		
<u>METRONIDAZOLE - METROGEL</u>						
N 021789	001	6881726	Feb 21, 2022	DP U-743		
		7348317	Feb 21, 2022	DP U-743		
<u>METRONIDAZOLE - VANDAZOLE</u>						
N 021806	001	7456207	Sep 22, 2024	DP		
<u>METRONIDAZOLE - NUVESSA</u>						
N 205223	001	10238634	Jun 28, 2032	DP		
		10596155	Jun 28, 2032	DP		
		7893097	Feb 19, 2028	DP		
		8658678	Jun 27, 2028	U-1682		
		8877792	Feb 02, 2028	DP		
		8946276	Jun 28, 2032	U-1664		
		9198858	Jun 28, 2032	U-1664		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METRONIDAZOLE - NUVESSA</u>						
N 205223	001	10238634	Jun 28, 2032	DP		
		10596155	Jun 28, 2032	DP		
		7893097	Feb 19, 2028	DP		
		8658678	Jun 27, 2028	U-1682		
		8877792	Feb 02, 2028	DP		
		8946276	Jun 28, 2032	U-1664		
		9198858	Jun 28, 2032	U-1664		
<u>METYROSINE - METYROSINE</u>						
A 213734	001				CGT	Jan 20, 2021
<u>MEXILETINE HYDROCHLORIDE - MEXILETINE HYDROCHLORIDE</u>						
A 213500	001				CGT	Jan 18, 2021
<u>MEXILETINE HYDROCHLORIDE - MEXILETINE HYDROCHLORIDE</u>						
A 213500	002				CGT	Jan 18, 2021
<u>MEXILETINE HYDROCHLORIDE - MEXILETINE HYDROCHLORIDE</u>						
A 213500	003				CGT	Jan 18, 2021
<u>MICAFUNGIN SODIUM - MICAFUNGIN SODIUM</u>						
A 207344	001				PC	Nov 04, 2020
<u>MICAFUNGIN SODIUM - MICAFUNGIN SODIUM</u>						
A 207344	002				PC	Nov 07, 2020
<u>MICAFUNGIN SODIUM - MYCAMINE</u>						
N 021506	002	6774104	Jan 08, 2021	DP U-650	I-821	Dec 20, 2022
		6774104	Jan 08, 2021	DP U-845	PED	Jun 20, 2023
		6774104*PED	Jul 08, 2021			
<u>MICAFUNGIN SODIUM - MYCAMINE</u>						
N 021506	003	6774104	Jan 08, 2021	DP U-650	I-821	Dec 20, 2022
		6774104	Jan 08, 2021	DP U-845	PED	Jun 20, 2023
		6774104*PED	Jul 08, 2021			
<u>MICONAZOLE - ORAVIG</u>						
N 022404	001	6916485	Sep 11, 2022	DP U-1051		
		7651698	Sep 11, 2022	U-1051		
		8518442	Sep 11, 2022	DP		
<u>MICONAZOLE NITRATE; MICONAZOLE NITRATE - MONISTAT 1 COMBINATION PACK</u>						
N 021308	001	6153635	Nov 28, 2020			Y
<u>MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE - VUSION</u>						
N 021026	001	8147852	Mar 30, 2028	U-1426		
<u>MIDAZOLAM - NAYZILAM</u>						
N 211321	001	8217033	Jan 18, 2028	DP U-2526	NP	May 21, 2022
		8809322	Jan 18, 2028	DP	ODE-243	May 17, 2026
		9289432	Jan 18, 2028	DP U-2526		
		9687495	Jan 18, 2028	DP U-2526		
<u>MIDAZOLAM HYDROCHLORIDE - SEIZALAM</u>						
N 209566	001				ODE-207	Sep 14, 2025
<u>MIDOSTAURIN - RYDAPT</u>						
N 207997	001	7973031	Oct 17, 2024	U-2007	NCE	Apr 28, 2022
		8222244	Oct 29, 2022	U-2007	ODE-140	Apr 28, 2024
		8575146	Dec 02, 2030	U-2008	ODE-141	Apr 28, 2024
<u>MIFEPRISTONE - KORLYM</u>						
N 202107	001	10006924	Aug 12, 2036	U-1643		
		10151763	Jan 18, 2037	U-1643		
		10166242	Apr 20, 2036	U-1643		
		10166243	Apr 20, 2036	U-1643		
		10195214	Jun 19, 2037	U-1643		
		10231983	Aug 22, 2038	U-1643		
		10314850	Aug 22, 2038	U-1643		
		10495650	Aug 12, 2036	U-1643		
		10500216	Mar 05, 2033	U-1643		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MIFEPRISTONE - KORLYM</u>						
N 202107	001	10660904	Apr 20, 2036	U-1643		
		10780097	Aug 22, 2038	U-1643		
		10842800	Jun 19, 2037	U-1643		
		10842801	Nov 15, 2032	U-1643		
		8921348	Aug 27, 2028	U-1643		
		9829495	Aug 15, 2036	U-1643		
		9943526	Apr 20, 2036	U-1643		
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623	001	10076514	Mar 15, 2037	U-2371	NCE	Aug 10, 2023
		10251873	May 30, 2038	U-2371	ODE-205	Aug 10, 2025
		10383864	May 16, 2027	U-2371		
		10406143	May 16, 2027	U-2371		
		10471053	May 30, 2038	U-2371		
		10525045	Apr 28, 2028	U-2371		
		10792278	May 30, 2038	U-2371		
		10792279	May 30, 2038	U-2371		
		10799491	May 30, 2038	U-2371		
		10806727	May 30, 2038	U-2371		
		10813921	Feb 12, 2029	U-2371		
		10849889	May 30, 2038	U-2371		
		10849890	May 30, 2038	U-2371		
		10857141	May 30, 2038	U-2371		
		10857142	May 30, 2038	U-2371		
		8592362	Feb 12, 2029	U-2371		
		9000011	May 16, 2027	U-2371		
		9095584	Feb 12, 2029	U-2371		
		9480682	May 16, 2027	U-2371		
		9987263	May 16, 2027	U-2371		
		9999618	Apr 28, 2028	U-2372		
		9999618	Apr 28, 2028	U-2373		
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N 022256	001	6602911	Jan 14, 2023	U-882		
		6992110	Nov 05, 2021	U-882		
		7888342	Nov 05, 2021	U-882		
		7994220	Sep 19, 2029	U-819		
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N 022256	002	6602911	Jan 14, 2023	U-882		
		6992110	Nov 05, 2021	U-882		
		7888342	Nov 05, 2021	U-882		
		7994220	Sep 19, 2029	U-819		
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N 022256	003	6602911	Jan 14, 2023	U-882		
		6992110	Nov 05, 2021	U-882		
		7888342	Nov 05, 2021	U-882		
		7994220	Sep 19, 2029	U-819		
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N 022256	004	6602911	Jan 14, 2023	U-882		
		6992110	Nov 05, 2021	U-882		
		7888342	Nov 05, 2021	U-882		
		7994220	Sep 19, 2029	U-819		
<u>MILTEFOSINE - IMPAVIDO</u>						
N 204684	001				ODE-63	Mar 19, 2021
<u>MINOCYCLINE HYDROCHLORIDE - MINOCIN</u>						
N 050444	001	9084802	May 12, 2031	U-282		
		9278105	May 12, 2031	U-282		
<u>MINOCYCLINE HYDROCHLORIDE - ARESTIN</u>						
N 050781	001	6682348	Mar 29, 2022	DP		
		7699609	Mar 29, 2022	DP		
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808	001	7790705	Jun 24, 2025	U-1078		
		7919483	Mar 07, 2027	U-1078		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808	001	8252776	Jun 24, 2025			U-124
		8268804	Jun 24, 2025			U-1078
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808	002	7541347	Apr 02, 2027			U-917
		7544373	Apr 02, 2027	DP		
		7790705	Jun 24, 2025			U-1078
		7919483	Mar 07, 2027			U-1078
		8252776	Jun 24, 2025			U-124
		8268804	Jun 24, 2025			U-1078
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808	003	7790705	Jun 24, 2025			U-1078
		7919483	Mar 07, 2027			U-1078
		8252776	Jun 24, 2025			U-124
		8268804	Jun 24, 2025			U-1078
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808	004	7790705	Jun 24, 2025			U-1078
		7919483	Mar 07, 2027			U-1078
		8252776	Jun 24, 2025			U-124
		8268804	Jun 24, 2025			U-1078
		9192615	Nov 17, 2031	DP		
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808	005	7790705	Jun 24, 2025			U-1078
		7919483	Mar 07, 2027			U-1078
		8252776	Jun 24, 2025			U-124
		8268804	Jun 24, 2025			U-1078
		9192615	Nov 17, 2031	DP		
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808	006	7790705	Jun 24, 2025			U-1078
		7919483	Mar 07, 2027			U-1078
		8252776	Jun 24, 2025			U-124
		8268804	Jun 24, 2025			U-1078
		8722650	Jun 24, 2025			U-1078
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808	007	7790705	Jun 24, 2025			U-1078
		7919483	Mar 07, 2027			U-1078
		8252776	Jun 24, 2025			U-124
		8268804	Jun 24, 2025			U-1078
		8722650	Jun 24, 2025			U-1078
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808	008	7790705	Jun 24, 2025			U-1078
		7919483	Mar 07, 2027			U-1078
		8252776	Jun 24, 2025			U-124
		8268804	Jun 24, 2025			U-1078
		8722650	Jun 24, 2025			U-1078
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N 201922	001	7541347	Apr 02, 2027			U-917
		7544373	Apr 02, 2027	DP		
		7790705	Jun 24, 2025			U-124
		7919483	Mar 07, 2027			U-124
		8252776	Jun 24, 2025			U-124
		8268804	Jun 24, 2025			U-124
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N 201922	003	7541347	Apr 02, 2027			U-917
		7544373	Apr 02, 2027	DP		
		7790705	Jun 24, 2025			U-124
		7919483	Mar 07, 2027			U-124
		8252776	Jun 24, 2025			U-124
		8268804	Jun 24, 2025			U-124

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N 201922	005	7541347	Apr 02, 2027		U-917	
		7544373	Apr 02, 2027	DP		
		7790705	Jun 24, 2025		U-124	
		7919483	Mar 07, 2027		U-124	
		8252776	Jun 24, 2025		U-124	
		8268804	Jun 24, 2025		U-124	
<u>MINOCYCLINE HYDROCHLORIDE - AMZEEQ</u>						
N 212379	001	10086080	Oct 01, 2030		U-2647	
		10137200	Oct 01, 2030		U-2647	
		10213512	Oct 01, 2030	DP	U-2647	
		10265404	Oct 01, 2030	DP		
		10398641	Sep 08, 2037		U-2647	
		10517882	Oct 01, 2030		U-2647	
		10821187	Oct 01, 2030		U-2647	
		10849847	Sep 08, 2037		U-2647	
		8865139	Oct 01, 2030	DP	U-2647	
		8945516	Oct 01, 2030	DP		
		8992896	Oct 01, 2030	DP	U-2647	
		9675700	Oct 01, 2030	DP	U-2647	
<u>MINOCYCLINE HYDROCHLORIDE - ZILXI</u>						
N 213690	001	10213512	Oct 01, 2030	DP	U-1631	
		10265404	Oct 01, 2030	DP		
		10322186	Oct 01, 2030		U-1631	
		8865139	Oct 01, 2030	DP	U-1631	
		8945516	Oct 01, 2030	DP		
		8992896	Oct 01, 2030	DP	U-1631	
		9675700	Oct 01, 2030	DP	U-1631	
<u>MIPOMERSEN SODIUM - KYNAMRO</u>						
N 203568	001	7015315	Mar 21, 2023	DS		ODE-41
		7101993	Sep 05, 2023	DS		Jan 29, 2020
		7407943	Aug 01, 2021		U-1353	
		7511131	Jan 29, 2027	DS		
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611	001	10842780	Sep 28, 2029	DP	U-2996	I-777
		6346532	Mar 27, 2022	DS	DP	Apr 27, 2021
		6562375	Aug 01, 2020		DP	
		7342117	Nov 04, 2023	DS		
		7982049	Nov 04, 2023		DP	
		8772315	Oct 30, 2028		U-2300	
		8835474	Nov 04, 2023		U-1527	
		RE44872	Nov 04, 2023		U-1527	
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611	002	10842780	Sep 28, 2029	DP	U-2996	I-777
		6346532	Mar 27, 2022	DS	DP	Apr 27, 2021
		6562375	Aug 01, 2020		DP	
		7342117	Nov 04, 2023	DS		
		7982049	Nov 04, 2023		DP	
		8772315	Oct 30, 2028		U-2300	
		8835474	Nov 04, 2023		U-1527	
		RE44872	Nov 04, 2023		U-1527	
<u>MITOMYCIN - MITOSOL</u>						
N 022572	001	7806265	Feb 01, 2029	DP		
		8186511	Jul 19, 2026	DP		
		9205075	Jul 19, 2026	DP		
		9539241	Jan 02, 2028	DS	DP	U-2095
		9649428	May 21, 2029		U-2095	
<u>MITOMYCIN - JELMYTO</u>						
N 211728	001	9040074	Jan 20, 2031	DP		NP
		9950069	Jan 20, 2031	DP		ODE-289
						Apr 15, 2023
						Apr 15, 2027
<u>MODAFINIL - PROVIGIL</u>						
N 020717	001	7297346	Nov 29, 2023	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MODAFINIL - PROVIGIL</u>						
N 020717	002 7297346	Nov 29, 2023	DP			
<u>MOMETASONE FUROATE - ASMANEX HFA</u>						
N 205641	003				NS PED	Aug 12, 2022 Feb 12, 2023
<u>MOMETASONE FUROATE - SINUVA</u>						
N 209310	001 10232152	Nov 24, 2034	DP U-2272		NP	Dec 08, 2020
	10357640	Oct 03, 2031	U-2272			
	10406332	Mar 13, 2034	DP			
	7544192	Nov 29, 2026	U-2272			
	7662141	Mar 12, 2024	U-2272			
	7713255	Mar 12, 2024	U-2272			
	7951130	Mar 12, 2024	U-2272			
	7951131	Mar 12, 2024	U-2272			
	7951133	Mar 12, 2024	U-2272			
	8025635	Jun 12, 2027	DP U-2272			
	8109918	Mar 12, 2024	U-2272			
	8763222	Feb 08, 2032	DP			
	9585681	Apr 04, 2026	U-2272			
<u>MONOMETHYL FUMARATE - BAFIERTAM</u>						
N 210296	001 10098863	Feb 27, 2035	DP U-1384			
	10105335	Feb 27, 2035	DP			
	10105336	Feb 27, 2035	DP U-1384			
	10105337	Feb 27, 2035	DP			
	9326947	Feb 27, 2035	DP			
	9326965	Feb 27, 2035	U-1384			
	9511043	Feb 27, 2035	U-1384			
	9517209	Feb 27, 2035	DP			
	9566259	Feb 27, 2035	DP			
	9636318	Feb 27, 2035	U-1384			
	9636319	Feb 27, 2035	DP			
	9814691	Feb 27, 2035	U-1384			
	9814692	Feb 27, 2035	U-1384			
	9820960	Feb 27, 2035	DP			
	9820961	Feb 27, 2035	DP U-1384			
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N 021409	001 8007830	Oct 24, 2022	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223	001 9072781	Mar 12, 2034	DP			
	9192608	Mar 12, 2034	U-43			
	9192608	Mar 12, 2034	U-55			
	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223	002 9072781	Mar 12, 2034	DP			
	9192608	Mar 12, 2034	U-43			
	9192608	Mar 12, 2034	U-55			
	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223	003 9072781	Mar 12, 2034	DP			
	9192608	Mar 12, 2034	U-43			
	9192608	Mar 12, 2034	U-55			
	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223	004 9072781	Mar 12, 2034	DP			
	9192608	Mar 12, 2034	U-43			
	9192608	Mar 12, 2034	U-55			
	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223	005 9072781	Mar 12, 2034	DP			
	9192608	Mar 12, 2034	U-43			
	9192608	Mar 12, 2034	U-55			
	9248229	Mar 12, 2034	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223	005	9072781	Mar 12, 2034	DP		
		9192608	Mar 12, 2034	U-43		
		9192608	Mar 12, 2034	U-55		
		9248229	Mar 12, 2034	DP		
<u>MORPHINE SULFATE - MORPHABOND ER</u>						
N 206544	001	10314788	Aug 12, 2028	DP		
		7955619	Aug 12, 2028	DP		
<u>MORPHINE SULFATE - MORPHABOND ER</u>						
N 206544	002	10314788	Aug 12, 2028	DP		
		7955619	Aug 12, 2028	DP		
<u>MORPHINE SULFATE - MORPHABOND ER</u>						
N 206544	003	10314788	Aug 12, 2028	DP		
		7955619	Aug 12, 2028	DP		
<u>MORPHINE SULFATE - MORPHABOND ER</u>						
N 206544	004	10314788	Aug 12, 2028	DP		
		7955619	Aug 12, 2028	DP		
<u>MORPHINE SULFATE - ARYMO ER</u>						
N 208603	001	9044402	Jul 01, 2033	DP	U-1556	
		9549899	Jul 01, 2033	DP	U-1556	
<u>MORPHINE SULFATE - ARYMO ER</u>						
N 208603	002	9044402	Jul 01, 2033	DP	U-1556	
		9549899	Jul 01, 2033	DP	U-1556	
<u>MORPHINE SULFATE - ARYMO ER</u>						
N 208603	003	9044402	Jul 01, 2033	DP	U-1556	
		9549899	Jul 01, 2033	DP	U-1556	
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321	001	7682633	Jun 19, 2027		U-1510	
		7682634	Jun 19, 2027	DP		
		7815934	Dec 12, 2027	DP		
		8158156	Jun 19, 2027		U-1510	
		8623418	Nov 07, 2029		U-1640	
		8685443	Jul 03, 2025		U-1508	
		8685444	Jul 03, 2025	DP		
		8846104	Jun 19, 2027	DP		
		8877247	Jun 19, 2027	DP		
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321	002	7682633	Jun 19, 2027		U-1510	
		7682634	Jun 19, 2027	DP		
		7815934	Dec 12, 2027	DP		
		8158156	Jun 19, 2027		U-1510	
		8623418	Nov 07, 2029		U-1640	
		8685443	Jul 03, 2025		U-1508	
		8685444	Jul 03, 2025	DP		
		8846104	Jun 19, 2027	DP		
		8877247	Jun 19, 2027	DP		
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321	003	7682633	Jun 19, 2027		U-1510	
		7682634	Jun 19, 2027	DP		
		7815934	Dec 12, 2027	DP		
		8158156	Jun 19, 2027		U-1510	
		8623418	Nov 07, 2029		U-1640	
		8685443	Jul 03, 2025		U-1508	
		8685444	Jul 03, 2025	DP		
		8846104	Jun 19, 2027	DP		
		8877247	Jun 19, 2027	DP		
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321	004	7682633	Jun 19, 2027		U-1510	
		7682634	Jun 19, 2027	DP		
		7815934	Dec 12, 2027	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 004	8158156	Jun 19, 2027	U-1510			
	8623418	Nov 07, 2029	U-1640			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 005	7682633	Jun 19, 2027	U-1510			
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027	U-1510			
	8623418	Nov 07, 2029	U-1640			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 006	7682633	Jun 19, 2027	U-1510			
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027	U-1510			
	8623418	Nov 07, 2029	U-1640			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
<u>MOXIDECTIN - MOXIDECTIN</u>						
N 210867 001					NCE ODE-193	Jun 13, 2023 Jun 13, 2025
<u>MOXIFLOXACIN HYDROCHLORIDE - AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER</u>						
N 021277 001	6548079	Jul 25, 2020	DP U-298			
<u>MOXIFLOXACIN HYDROCHLORIDE - MOXEZA</u>						
N 022428 001	8450311	May 29, 2029	DP			
	9114168	May 29, 2029	DP			
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N 204286 001	10166205	Jan 31, 2033	DP			
	10166206	Jan 31, 2033	DP			
	10695303	Jan 31, 2033	DP			
	10729667	Jan 31, 2033	DP			
	8778365	Jan 31, 2033	DP			
	9161914	Jan 31, 2033	U-540			
<u>NALDEMEDINE TOSYLATE - SYMPROIC</u>						
N 208854 001	9108975	Nov 11, 2031	DS DP		NCE	Mar 23, 2022
	RE46365	Jan 11, 2028	DS DP			
	RE46375	Oct 05, 2026	DS DP U-1185			
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760 001	7056500	Jun 29, 2024	DP U-1185			
	7662365	Oct 18, 2022	DS DP			
	7786133	Dec 19, 2027	DS DP			
	8067431	Dec 16, 2024	U-1185			
	8617530	Oct 18, 2022	U-1185			
	9012469	Apr 02, 2032	DS DP			
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760 002	7056500	Jun 29, 2024	DP U-1185			
	7662365	Oct 18, 2022	DS DP			
	7786133	Dec 19, 2027	DS DP			
	8067431	Dec 16, 2024	U-1185			
	8617530	Oct 18, 2022	U-1185			
	9012469	Apr 02, 2032	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NALOXONE HYDROCHLORIDE - NALOXONE HYDROCHLORIDE</u>						
A 213209	001				CGT	Sep 14, 2020
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787	001	10143972	May 24, 2031	U-2476		
		10220158	Mar 20, 2035	DP U-2500		
		10314977	Nov 23, 2024	DP		
		10322239	Feb 28, 2031	U-1907		
		10335549	Apr 30, 2025	DP		
		10737028	Nov 23, 2024	DP		
		7731686	Jun 10, 2026	DP		
		7731690	Jan 15, 2025	DP		
		7749194	Oct 30, 2028	DP		
		7918823	Nov 23, 2024	DP		
		7947017	Mar 12, 2028	DP		
		8016788	Mar 21, 2025	DP		
		8021344	Nov 02, 2029	DP		
		8206360	Feb 27, 2027	DP		
		8226610	Apr 10, 2029	DP		
		8231573	Nov 25, 2028	DP		
		8313466	Nov 23, 2024	DP		
		8361029	Nov 23, 2024	DP		
		8425462	Nov 23, 2024	DP		
		8608698	Nov 23, 2024	DP		
		8627816	Feb 04, 2032	DP		
		8926594	Mar 31, 2026	DP		
		8939943	Feb 28, 2031	DP		
		9022022	Feb 28, 2031	DP		
		9056170	Nov 23, 2024	DP		
		9238108	Feb 20, 2027	DP		
		9278182	Feb 01, 2026	DP		
		9474869	Feb 28, 2031	DP U-1907		
		9517307	Jul 18, 2034	DP U-1925		
		9724471	May 23, 2027	DP U-2092		
		9737669	Nov 23, 2024	DP		
<u>NALOXONE HYDROCHLORIDE - NARCAN</u>						
N 208411	001	10085937	Mar 16, 2035	U-1903		
		9211253	Mar 16, 2035	DP		
		9468747	Mar 16, 2035	DP U-1903		
		9561177	Mar 16, 2035	DP U-1903		
		9629965	Mar 16, 2035	DP U-1903		
		9775838	Mar 16, 2035	U-1903		
<u>NALOXONE HYDROCHLORIDE - NARCAN</u>						
N 208411	002	9480644	Mar 16, 2035	DP U-1903		
		9707226	Mar 16, 2035	DP U-1903		
<u>NALOXONE HYDROCHLORIDE - EVZIO (AUTOINJECTOR)</u>						
N 209862	001	10143792	May 24, 2031	U-2476		
		10220158	Mar 20, 2035	DP U-2500		
		10314977	Nov 23, 2024	DP		
		10322239	Feb 28, 2031	U-1907		
		10335549	Apr 30, 2025	DP		
		10737028	Nov 23, 2024	DP		
		7731686	Jun 01, 2026	DP		
		7731690	Jan 15, 2025	DP		
		7749194	Oct 30, 2028	DP		
		7918823	Nov 23, 2024	DP		
		7947017	Mar 12, 2028	DP		
		8016788	Mar 21, 2025	DP		
		8021344	Nov 02, 2029	DP		
		8206360	Feb 27, 2027	DP		
		8226610	Apr 10, 2029	DP		
		8231573	Nov 25, 2028	DP		
		8313466	Nov 23, 2024	DP		
		8361029	Nov 23, 2024	DP		
		8425462	Nov 23, 2024	DP		
		8608698	Nov 23, 2024	DP		
		8627816	Feb 04, 2032	DP		
		8926594	Mar 31, 2026	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NALOXONE HYDROCHLORIDE - EVZIO (AUTOINJECTOR)</u>						
N 209862	001	8939943	Feb 28, 2031	DP		
		9022022	Feb 28, 2031	DP		
		9056170	Nov 23, 2024	DP		
		9238108	Feb 20, 2027	DP		
		9278182	Feb 01, 2026	DP		
		9474869	Feb 28, 2031	DP	U-1907	
		9517307	Jul 18, 2034	DP	U-1925	
		9724471	May 23, 2027	DP	U-2092	
		9737669	Nov 23, 2024	DP		
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777	001	8846090	Apr 04, 2023	DP		
		8846091	Apr 04, 2023	DP		
		8969369	May 10, 2022	DP	U-1556	
		9056051	May 10, 2022	DP	U-1556	
		9073933	Mar 30, 2025	DS		
		9084729	May 10, 2022	DP	U-1556	
		9161937	May 10, 2022	DP	U-1556	
		9168252	May 10, 2022	DP	U-1556	
		9283216	May 10, 2022	DP	U-1819	
		9283221	May 10, 2022	DP	U-1819	
		9345701	May 10, 2022	DP	U-1819	
		9511066	May 10, 2022		U-1921	
		9522919	Mar 30, 2025	DS	DP	
		9555000	Apr 04, 2023	DP	U-1556	
		9907793	Apr 04, 2023	DP	U-1556	
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777	002	8846090	Apr 04, 2023	DP		
		8846091	Apr 04, 2023	DP		
		8969369	May 10, 2022	DP	U-1556	
		9056051	May 10, 2022	DP	U-1556	
		9073933	Mar 30, 2025	DS		
		9084729	May 10, 2022	DP	U-1556	
		9161937	May 10, 2022	DP	U-1556	
		9168252	May 10, 2022	DP	U-1556	
		9283216	May 10, 2022	DP	U-1819	
		9283221	May 10, 2022	DP	U-1819	
		9345701	May 10, 2022	DP	U-1819	
		9511066	May 10, 2022		U-1921	
		9522919	Mar 30, 2025	DS	DP	
		9555000	Apr 04, 2023	DP	U-1556	
		9907793	Apr 04, 2023	DP	U-1556	
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777	003	8846090	Apr 04, 2023	DP		
		8846091	Apr 04, 2023	DP		
		8969369	May 10, 2022	DP	U-1556	
		9056051	May 10, 2022	DP	U-1556	
		9073933	Mar 30, 2025	DS		
		9084729	May 10, 2022	DP	U-1556	
		9161937	May 10, 2022	DP	U-1556	
		9168252	May 10, 2022	DP	U-1556	
		9283216	May 10, 2022	DP	U-1819	
		9283221	May 10, 2022	DP	U-1819	
		9345701	May 10, 2022	DP	U-1819	
		9511066	May 10, 2022		U-1921	
		9522919	Mar 30, 2025	DS	DP	
<u>NALTREXONE - VIVITROL</u>						
N 021897	001	6264987	May 19, 2020	DP		
		6379704	May 19, 2020	DP		
		6495164	May 25, 2020	DP		
		6534092	May 19, 2020	DP		
		6667061	May 25, 2020	DP		
		7799345	May 25, 2020	DP		
		7919499	Oct 15, 2029		U-1123	
		7919499	Oct 15, 2029		U-1124	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621	001	7815934 8685443	Dec 12, 2027 Jul 03, 2025	DP U-1508		
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621	002	7815934 8685443	Dec 12, 2027 Jul 03, 2025	DP U-1508		
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621	003	7815934 8685443	Dec 12, 2027 Jul 03, 2025	DP U-1508		
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621	004	7815934 8685443	Dec 12, 2027 Jul 03, 2025	DP U-1508		
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621	005	7815934 8685443	Dec 12, 2027 Jul 03, 2025	DP U-1508		
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621	006	7815934 8685443	Dec 12, 2027 Jul 03, 2025	DP U-1508		
<u>NAPROXEN SODIUM - NAPROXEN SODIUM</u>						
N 021920	001	10022344	Mar 03, 2026	DP U-1731		
		10022344	Mar 03, 2026	DP U-1732		
		10028925	Mar 03, 2026	DP U-1731		
		10028925	Mar 03, 2026	DP U-1732		
		9693978	Mar 03, 2026	DP		
		9693979	Mar 03, 2026	DP		
<u>NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET</u>						
N 021926	001	7332183	Oct 02, 2025	DP U-867		
		7332183*PED	Apr 02, 2026			
<u>NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET</u>						
N 021926	002	7332183	Oct 02, 2025	DP U-1719		
		7332183*PED	Apr 02, 2026			
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N 021742	002	6545040	Dec 17, 2021	DP U-3		
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N 021742	003	6545040	Dec 17, 2021	DP U-3		
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N 021742	004	6545040	Dec 17, 2021	DP U-3		
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N 021742	005	6545040	Dec 17, 2021	DP U-3		
<u>NEBIVOLOL HYDROCHLORIDE; VALSARTAN - BYVALSON</u>						
N 206302	001	7803838	Aug 29, 2026	DP		
		7838552	Oct 04, 2027	U-185		
<u>NEPAFENAC - NEVANAC</u>						
N 021862	001	7834059	Jan 31, 2027	U-1095		
		8071648	Dec 02, 2025	DP		
		8324281	Dec 02, 2025	DP		
<u>NEPAFENAC - ILEVRO</u>						
N 203491	001	7947295	Jun 08, 2024	DP		
		8921337	Mar 31, 2032	DP		
		9662398	Dec 01, 2030	DP		
<u>NERATINIB MALEATE - NERLYNX</u>						
N 208051	001	10035788	Oct 15, 2028	U-2043	I-823	Feb 25, 2023
		7399865	Dec 29, 2025	DS DP	NCE	Jul 17, 2022
		7982043	Oct 08, 2025	U-2043		
		8518446	Nov 20, 2030	DP U-2043		
		8790708	Nov 05, 2030	DP U-2043		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NERATINIB MALEATE - NERLYNX</u>						
N 208051	001	9139558	Oct 15, 2028	U-2043		
		9211291	Mar 24, 2030	U-2043		
		9630946	Oct 15, 2028	U-2043		
<u>NETARSUDIL MESYLATE - RHOPRESSA</u>						
N 208254	001	10174017	Jan 27, 2030	DS DP U-1524	NCE	Dec 18, 2022
		10532993	Jul 11, 2026	U-1524		
		10588901	Mar 14, 2034	DS DP U-1524		
		10654844	Jan 27, 2030	DS DP U-1524		
		8394826	Nov 10, 2030	DS DP U-1524		
		8450344	Jul 11, 2026	DS DP U-1524		
		9096569	Jul 11, 2026	DS DP U-1524		
		9415043	Mar 14, 2034	DS		
		9931336	Mar 14, 2034	DS DP U-1524		
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718	001	10233154	Sep 25, 2035	DS		
		10676440	Sep 25, 2035	DS DP		
		10828297	Dec 17, 2030	U-2293		
		6297375	Mar 17, 2023	DS		
		8623826	Nov 18, 2030	U-2293		
		8951969	Nov 18, 2030	DP		
		9186357	Nov 18, 2030	U-2293		
		9271975	Sep 09, 2031	U-2293		
		9943515	Nov 18, 2030	U-2293		
		9951016	Sep 25, 2035	DS DP		
<u>NEVIRAPINE - VIRAMUNE XR</u>						
N 201152	001	8460704	Mar 12, 2029	U-1409		
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734	002	10758616	Apr 18, 2027	DP		
		7612102	Dec 26, 2027	DP		
		7659291	Apr 18, 2027	U-1029		
		8455524	Apr 18, 2027	U-1029		
		9364564	Dec 26, 2027	DP		
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734	003	10758616	Apr 18, 2027	DP		
		7612102	Dec 26, 2027	DP		
		7659291	Apr 18, 2027	U-1029		
		8455524	Apr 18, 2027	U-1029		
		9364564	Dec 26, 2027	DP		
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734	004	10758616	Apr 18, 2027	DP		
		7612102	Dec 26, 2027	DP		
		7659291	Apr 18, 2027	U-1029		
		8455524	Apr 18, 2027	U-1029		
		9364564	Dec 26, 2027	DP		
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734	005	7612102	Dec 26, 2027	DP		
		7659291	Apr 18, 2027	U-1029		
		8455524	Apr 18, 2027	U-1029		
		9364564	Dec 26, 2027	DP		
<u>NICOTINE - NICODERM CO</u>						
N 020165	004	8075911	May 22, 2021	DP		
		8663680	Feb 13, 2020	DP		
		8999379	Feb 13, 2020	U-1686		
<u>NICOTINE - NICODERM CO</u>						
N 020165	005	8075911	May 22, 2021	DP		
		8663680	Feb 13, 2020	DP		
		8999379	Feb 13, 2020	U-1686		
<u>NICOTINE - NICODERM CO</u>						
N 020165	006	8075911	May 22, 2021	DP		
		8663680	Feb 13, 2020	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NICOTINE - NICODERM CO</u>						
N 020165	006	8999379	Feb 13, 2020	U-1686		
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 018612	002	8323683	Apr 30, 2028			
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 020066	002	8323683	Apr 30, 2028	DP		
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360	001	8501164	Jun 14, 2029	DP		
		8940772	Apr 30, 2029	DP		
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360	002	8501164	Jun 14, 2029	DP		
		8940772	Apr 30, 2029	DP		
<u>NIFURTIMOX - LAMPIT</u>						
N 213464	001				NCE	Aug 06, 2025
<u>NIFURTIMOX - LAMPIT</u>						
N 213464	002				NCE	Aug 06, 2025
<u>NILOTINIB HYDROCHLORIDE - TASIGNA</u>						
N 022068	001	7169791	Jul 04, 2023	DS DP U-836	D-170	Dec 22, 2020
		7169791*PED	Jan 04, 2024		NPP	Mar 22, 2021
		8163904	Aug 23, 2028	DS DP	ODE-171	Mar 22, 2025
		8163904*PED	Feb 23, 2029		ODE-172	Mar 22, 2025
		8293756	Sep 25, 2027	DP	PED	Jun 22, 2021
		8293756*PED	Mar 25, 2028		PED	Sep 22, 2021
		8389537	Jul 18, 2026	DS DP U-1374	PED	Sep 22, 2025
		8389537*PED	Jan 18, 2027		PED	Sep 22, 2025
		8415363	Jul 18, 2026	DS DP U-1407		
		8415363*PED	Jan 18, 2027			
		8501760	Jul 18, 2026	DS DP		
		8501760*PED	Jan 18, 2027			
		9061029	Apr 07, 2032	DP U-1374		
		9061029*PED	Oct 07, 2032			
<u>NILOTINIB HYDROCHLORIDE - TASIGNA</u>						
N 022068	002	7169791	Jul 04, 2023	DS DP U-836	D-170	Dec 22, 2020
		7169791*PED	Jan 04, 2024		NPP	Mar 22, 2021
		8163904	Aug 23, 2028	DS DP	ODE-171	Mar 22, 2025
		8163904*PED	Feb 23, 2029		ODE-172	Mar 22, 2025
		8293756	Sep 25, 2027	DP	PED	Jun 22, 2021
		8293756*PED	Mar 25, 2028		PED	Sep 22, 2021
		8389537	Jul 18, 2026	DS DP U-1374	PED	Sep 22, 2025
		8389537*PED	Jan 18, 2027		PED	Sep 22, 2025
		8415363	Jul 18, 2026	DS DP U-1407		
		8415363*PED	Jan 18, 2027			
		8501760	Jul 18, 2026	DS DP		
		8501760*PED	Jan 18, 2027			
		9061029	Apr 07, 2032	DP U-1374		
		9061029*PED	Oct 07, 2032			
<u>NILOTINIB HYDROCHLORIDE - TASIGNA</u>						
N 022068	003	7169791	Jul 04, 2023	DS DP U-836	NPP	Mar 22, 2021
		7169791*PED	Jan 04, 2024		ODE-171	Mar 22, 2025
		8163904	Aug 23, 2028	DS DP	ODE-172	Mar 22, 2025
		8163904*PED	Feb 23, 2029		PED	Sep 22, 2021
		8293756	Sep 25, 2027	DP	PED	Sep 22, 2025
		8293756*PED	Mar 25, 2028		PED	Sep 22, 2025
		8389537	Jul 18, 2026	DS DP U-1374		
		8389537*PED	Jan 18, 2027			
		8415363	Jul 18, 2026	DS DP U-1407		
		8415363*PED	Jan 18, 2027			
		8501760	Jul 18, 2026	DS DP		
		8501760*PED	Jan 18, 2027			
		9061029	Apr 07, 2032	DS DP U-1374		
		9061029*PED	Oct 07, 2032			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NIMODIPINE - NYMALIZE</u>						
N 203340	001				ODE-46	May 10, 2020
<u>NIMODIPINE - NYMALIZE</u>						
N 203340	002	10342787	Apr 16, 2038	DP U-2804		
		10576070	Apr 16, 2038	DP U-2804		
		7070581	Jun 23, 2023	DP		
		8517997	May 14, 2024	DP		
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832	001	10105323	Jun 04, 2029	DP	I-805	Sep 06, 2022
		10154990	Dec 20, 2025	U-2620	I-825	Mar 09, 2023
		6762180	Oct 01, 2025	DS DP	ODE-261	Sep 06, 2026
		7119093	Feb 21, 2024	DS DP	ODE-77	Oct 15, 2021
		9907756	Jun 07, 2029	DP		
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832	002	10105323	Jun 04, 2029	DP	I-805	Sep 06, 2022
		10154990	Dec 20, 2025	U-2620	I-825	Mar 09, 2023
		6762180	Oct 01, 2025	DS DP	ODE-261	Sep 06, 2026
		7119093	Feb 21, 2024	DS DP	ODE-77	Oct 15, 2021
		9907756	Jun 07, 2029	DP		
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 208447	001	8071579	Aug 12, 2027	U-2655	I-813	Oct 23, 2022
		8071623	Mar 22, 2030	DS DP	I-814	Oct 23, 2022
		8143241	Aug 12, 2027	U-2655	I-833	Apr 29, 2023
		8436185	Apr 24, 2029	DS	NCE	Mar 27, 2022
		8859562	Aug 04, 2031	U-2655	ODE-133	Mar 27, 2024
					ODE-277	Oct 23, 2026
					ODE-278	Oct 23, 2026
					ODE-295	Apr 29, 2027
<u>NITISINONE - ORFADIN</u>						
N 021232	001				D-169	Sep 01, 2020
<u>NITISINONE - ORFADIN</u>						
N 021232	002				D-169	Sep 01, 2020
<u>NITISINONE - ORFADIN</u>						
N 021232	003				D-169	Sep 01, 2020
<u>NITISINONE - ORFADIN</u>						
N 021232	004				D-169	Sep 01, 2020
<u>NITISINONE - ORFADIN</u>						
N 206356	001	9301932	Feb 28, 2033	DP U-1836	D-169	Sep 01, 2020
<u>NITISINONE - NITYR</u>						
N 209449	001	10328029	Jan 05, 2035	DP U-1836		
<u>NITISINONE - NITYR</u>						
N 209449	002	10328029	Jan 05, 2035	DP U-1836		
<u>NITISINONE - NITYR</u>						
N 209449	003	10328029	Jan 05, 2035	DP U-1836		
<u>NITRIC OXIDE - INOMAX</u>						
N 020845	002	8282966	Jun 30, 2029	U-1286		
		8291904	Jan 06, 2031	DP U-1226		
		8293284	Jun 30, 2029	U-1286		
		8431163	Jun 30, 2029	U-1286		
		8431163*PED	Dec 30, 2029			
		8573209	Jan 06, 2031	DP		
		8573209*PED	Jul 06, 2031			
		8573210	Jan 06, 2031	DP U-1453		
		8573210*PED	Jul 06, 2031			
		8776794	Jan 06, 2031	DP U-1226		
		8776794*PED	Jul 06, 2031			
		8776795	Jan 06, 2031	DP U-1226		
		8776795*PED	Jul 06, 2031			
		8795741	Jun 30, 2029	U-1286		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NITRIC OXIDE - INOMAX</u>						
N 020845	002	8795741*PED	Dec 30, 2029			
		8846112	Jun 30, 2029	U-1286		
		8846112*PED	Dec 30, 2029			
<u>NITRIC OXIDE - INOMAX</u>						
N 020845	003	8282966	Jun 30, 2029	U-1286		
		8291904	Jan 06, 2031	DP U-1226		
		8293284	Jun 30, 2029	U-1286		
		8431163	Jun 30, 2029	U-1286		
		8431163*PED	Dec 30, 2029			
		8573209	Jan 06, 2031	DP		
		8573209*PED	Jul 06, 2031			
		8573210	Jan 06, 2031	DP U-1453		
		8573210*PED	Jul 06, 2031			
		8776794	Jan 06, 2031	DP U-1226		
		8776794*PED	Jul 06, 2031			
		8776795	Jan 06, 2031	DP U-1226		
		8776795*PED	Jul 06, 2031			
		8795741	Jun 30, 2029	U-1286		
		8795741*PED	Dec 30, 2029			
		8846112	Jun 30, 2029	U-1286		
		8846112*PED	Dec 30, 2029			
		9265911	Jan 06, 2031	DP U-1824		
		9265911*PED	Jul 06, 2031			
		9279794	Feb 19, 2034	DP U-1823		
		9279794*PED	Aug 19, 2034			
		9295802	Jan 06, 2031	DP U-1226		
		9295802*PED	Jul 06, 2031			
		9408993	Jan 06, 2031	DP U-1824		
		9408993*PED	Jul 06, 2031			
		9770570	May 03, 2036	U-2148		
		9770570*PED	Nov 03, 2036			
<u>NITRIC OXIDE - GENOSYL</u>						
N 202860	001	10213572	Feb 12, 2036	DP		
		10737051	Oct 20, 2035	DP		
		6758214	Feb 23, 2022	DP		
		7560076	Apr 21, 2027	DP		
		7618594	Oct 17, 2026	DP		
		9604028	Aug 13, 2029	U-2793		
<u>NITROGLYCERIN - NITROLINGUAL PUMPSPRAY</u>						
N 018705	002	7872049	Mar 12, 2029	DP U-2223		
<u>NITROGLYCERIN - GONITRO</u>						
N 208424	001	9101592	Mar 11, 2032	DP		
<u>NIZATIDINE - AXID</u>						
N 021494	001	6930119	Jul 17, 2022	DP		
<u>NUSINERSEN SODIUM - SPINRAZA</u>						
N 209531	001	10266822	Dec 05, 2025	U-1942	M-226	May 14, 2021
		10266822	Dec 05, 2025	U-1943	NCE	Dec 23, 2021
		10266822	Dec 05, 2025	U-1944	ODE-127	Dec 23, 2023
		10436802	Sep 11, 2035	U-1941		
		10436802	Sep 11, 2035	U-1942		
		10436802	Sep 11, 2035	U-1943		
		10436802	Sep 11, 2035	U-1944		
		10436802	Sep 11, 2035	U-2093		
		10436802	Sep 11, 2035	U-2094		
		7101993	Sep 05, 2023	DS		
		7838657	Jul 11, 2027	DS		
		8110560	Dec 05, 2025	U-1942		
		8110560	Dec 05, 2025	U-1943		
		8110560	Dec 05, 2025	U-1944		
		8361977	May 27, 2030	DS DP		
		8980853	Nov 24, 2030	U-1941		
		9717750	Jun 17, 2030	U-1942		
		9717750	Jun 17, 2030	U-1943		
		9717750	Jun 17, 2030	U-2093		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NUSINERSEN SODIUM - SPINRAZA</u>						
N 209531	001	9717750				
		9926559	Jun 17, 2030	U-2094		
			Jan 09, 2034	U-1943		
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999	001	10047117	Sep 06, 2033		NCE	May 27, 2021
		10052337	Apr 26, 2036	DP	ODE-119	May 27, 2023
		10174073	Jun 17, 2033	DS		
		10751349	Apr 26, 2036	DP		
		10758549	Apr 26, 2036		U-2945	
		7138390	Nov 16, 2022	DS DP		
		8058267	Feb 21, 2022		U-1854	
		8377916	Feb 21, 2022		U-1854	
		9238673	Jun 17, 2033	DP		
		RE48286	Nov 16, 2022	DS DP		
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999	002	10047117	Sep 06, 2033		NCE	May 27, 2021
		10052337	Apr 26, 2036	DP	ODE-119	May 27, 2023
		10174073	Jun 17, 2033	DS		
		10751349	Apr 26, 2036	DP		
		10758549	Apr 26, 2036		U-2945	
		7138390	Nov 16, 2022	DS DP		
		8058267	Feb 21, 2022		U-1854	
		8377916	Feb 21, 2022		U-1854	
		9238673	Jun 17, 2033	DP		
		RE48286	Nov 16, 2022	DS DP		
<u>OCTREOTIDE ACETATE - MYCAPSSA</u>						
N 208232	001	10238709	Feb 03, 2036		NP	Jun 26, 2023
		10695397	Feb 03, 2036			
		8329198	Sep 17, 2029	DP		
		8535695	Sep 17, 2029		U-2857	
		9265812	Sep 17, 2029	DP		
		9566246	Sep 17, 2029	DP		
<u>OCTREOTIDE ACETATE - BYNFEZIA PEN</u>						
N 213224	001	10342850	May 15, 2038	DP		
<u>OLAPARIB - LYNPARZA</u>						
N 206162	001	7151102	Apr 29, 2022	DS DP	ODE-83	Dec 19, 2021
		7449464	Oct 11, 2024	DS DP		
		7981889	Oct 11, 2024	DS DP		
		8143241	Aug 12, 2027		U-1634	
		8247416	Sep 24, 2028	DS		
		8859562	Aug 04, 2031		U-1634	
		8912187	Mar 12, 2024		U-1634	
<u>OLAPARIB - LYNPARZA</u>						
N 208558	001	7151102	Apr 29, 2022	DS DP	I-762	Jan 12, 2021
		7449464	Oct 11, 2024	DS DP	I-776	Dec 19, 2021
		7981889	Oct 11, 2024	DS DP	I-818	Dec 27, 2022
		8071579	Aug 12, 2027		U-2480	May 08, 2023
		8071579	Aug 12, 2027		U-2819	May 19, 2023
		8071579	Aug 12, 2027		U-2820	Aug 17, 2020
		8071579	Aug 12, 2027		U-2821	Aug 17, 2024
		8071579	Aug 12, 2027		U-2822	Aug 17, 2024
		8071579	Aug 12, 2027		U-2823	Dec 19, 2025
		8071579	Aug 12, 2027		U-2824	Dec 27, 2026
		8071579	Aug 12, 2027		U-2832	May 08, 2027
		8071579	Aug 12, 2027		U-2833	Dec 19, 2021
		8143241	Aug 12, 2027		U-2101	
		8143241	Aug 12, 2027		U-2103	
		8143241	Aug 12, 2027		U-2480	
		8143241	Aug 12, 2027		U-2481	
		8143241	Aug 12, 2027		U-2482	
		8143241	Aug 12, 2027		U-2483	
		8143241	Aug 12, 2027		U-2716	
		8143241	Aug 12, 2027		U-2819	
		8143241	Aug 12, 2027		U-2820	
		8143241	Aug 12, 2027		U-2821	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	8143241	Aug 12, 2027	U-2822			
	8143241	Aug 12, 2027	U-2823			
	8143241	Aug 12, 2027	U-2824			
	8143241	Aug 12, 2027	U-2832			
	8143241	Aug 12, 2027	U-2833			
	8475842	Dec 31, 2029		DP		
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8859562	Aug 04, 2031	U-2716			
	8859562	Aug 04, 2031	U-2819			
	8859562	Aug 04, 2031	U-2820			
	8859562	Aug 04, 2031	U-2821			
	8859562	Aug 04, 2031	U-2822			
	8859562	Aug 04, 2031	U-2823			
	8859562	Aug 04, 2031	U-2824			
	8859562	Aug 04, 2031	U-2832			
	8912187	Mar 12, 2024	U-2101			
	8912187	Mar 12, 2024	U-2480			
	8912187	Mar 12, 2024	U-2481			
	8912187	Mar 12, 2024	U-2482			
	8912187	Mar 12, 2024	U-2483			
	8912187	Mar 12, 2024	U-2819			
	8912187	Mar 12, 2024	U-2820			
	8912187	Mar 12, 2024	U-2821			
	8912187	Mar 12, 2024	U-2822			
	8912187	Mar 12, 2024	U-2823			
	8912187	Mar 12, 2024	U-2824			
	9169235	Mar 12, 2024	U-2832			
	9169235	Mar 12, 2024	U-2833			
	9566276	Mar 12, 2024	U-2716			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	7151102	Apr 29, 2022		DS DP	I-762	Jan 12, 2021
	7449464	Oct 11, 2024		DS DP	I-776	Dec 19, 2021
	7981889	Oct 11, 2024		DS DP	I-818	Dec 27, 2022
	8071579	Aug 12, 2027	U-2480		I-831	May 08, 2023
	8071579	Aug 12, 2027	U-2819		I-832	May 19, 2023
	8071579	Aug 12, 2027	U-2820		NP	Aug 17, 2020
	8071579	Aug 12, 2027	U-2821		ODE-180	Aug 17, 2024
	8071579	Aug 12, 2027	U-2823		ODE-181	Aug 17, 2024
	8071579	Aug 12, 2027	U-2824		ODE-226	Dec 19, 2025
	8071579	Aug 12, 2027	U-2832		ODE-283	Dec 27, 2026
	8071579	Aug 12, 2027	U-2833		ODE-306	May 08, 2027
	8143241	Aug 12, 2027	U-2101		ODE-83	Dec 19, 2021
	8143241	Aug 12, 2027	U-2103			
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2481			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8143241	Aug 12, 2027	U-2716			
	8143241	Aug 12, 2027	U-2819			
	8143241	Aug 12, 2027	U-2820			
	8143241	Aug 12, 2027	U-2821			
	8143241	Aug 12, 2027	U-2822			
	8143241	Aug 12, 2027	U-2823			
	8143241	Aug 12, 2027	U-2824			
	8143241	Aug 12, 2027	U-2832			
	8143241	Aug 12, 2027	U-2833			
	8475842	Dec 31, 2029		DP		
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8859562	Aug 04, 2031	U-2716			
	8859562	Aug 04, 2031	U-2819			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OLAPARIB - LYNPARZA</u>						
N 208558	002	8859562	Aug 04, 2031	U-2820		
		8859562	Aug 04, 2031	U-2821		
		8859562	Aug 04, 2031	U-2822		
		8859562	Aug 04, 2031	U-2823		
		8859562	Aug 04, 2031	U-2824		
		8859562	Aug 04, 2031	U-2832		
		8912187	Mar 12, 2024	U-2101		
		8912187	Mar 12, 2024	U-2480		
		8912187	Mar 12, 2024	U-2481		
		8912187	Mar 12, 2024	U-2482		
		8912187	Mar 12, 2024	U-2483		
		8912187	Mar 12, 2024	U-2819		
		8912187	Mar 12, 2024	U-2820		
		8912187	Mar 12, 2024	U-2821		
		8912187	Mar 12, 2024	U-2822		
		8912187	Mar 12, 2024	U-2823		
		8912187	Mar 12, 2024	U-2824		
		9169235	Mar 12, 2024	U-2832		
		9169235	Mar 12, 2024	U-2833		
		9566276	Mar 12, 2024	U-2716		
<u>OLICERIDINE - OLINVYK</u>						
N 210730	001	8835488	Mar 23, 2032	DS DP	U-2986	
		9309234	Mar 23, 2032	DS DP	U-2986	
		9642842	Mar 23, 2032	DP	U-2986	
<u>OLICERIDINE - OLINVYK</u>						
N 210730	002	8835488	Mar 23, 2032	DS DP	U-2986	
		9309234	Mar 23, 2032	DS DP	U-2986	
		9642842	Mar 23, 2032	DP	U-2986	
<u>OLICERIDINE - OLINVYK</u>						
N 210730	003	8835488	Mar 23, 2032	DS DP	U-2986	
		9309234	Mar 23, 2032	DS DP	U-2986	
		9642842	Mar 23, 2032	DP	U-2986	
<u>OLODATEROL HYDROCHLORIDE - STRIVERDI RESPIMAT</u>						
N 203108	001	6988496	Feb 23, 2020	DP	U-1547	
		7056916	Dec 07, 2023	DS DP		
		7220742	May 12, 2025	DS DP	U-1547	
		7284474	Aug 26, 2024	DP		
		7396341	Oct 10, 2026	DP	U-1547	
		7491719	Nov 10, 2023	DS DP		
		7727984	Jan 19, 2027	DS		
		7786111	Nov 10, 2023	DP		
		7837235	Mar 13, 2028	DP		
		7896264	May 26, 2025	DP		
		7988001	Aug 04, 2021	DP		
		8034809	May 12, 2025		U-1547	
		8044046	Nov 10, 2023		U-1547	
		8733341	Oct 16, 2030	DP		
		9027967	Mar 31, 2027	DP		
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756	001	6988496	Feb 23, 2020	DP		
		6988496*PED	Aug 23, 2020		M-233	Oct 05, 2021
		7056916	Dec 07, 2023	DS DP		
		7220742	May 12, 2025	DS DP	U-1703	
		7284474	Aug 26, 2024	DP		
		7284474*PED	Feb 26, 2025			
		7396341	Oct 10, 2026	DP		
		7396341*PED	Apr 10, 2027			
		7491719	Nov 10, 2023	DS DP		
		7727984	Jan 19, 2027	DS		
		7786111	Nov 10, 2023	DP		
		7837235	Mar 13, 2028	DP		
		7837235*PED	Sep 13, 2028			
		7896264	May 26, 2025	DP		
		7988001	Aug 04, 2021	DP		
		8034809	May 12, 2025		U-1702	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756 001	8044046	Nov 10, 2023	U-1702			
	8733341	Oct 16, 2030	DP			
	9027967	Mar 31, 2027	DP			
<u>OLOPATADINE HYDROCHLORIDE - PATANASE</u>						
N 021861 001	7977376	Feb 02, 2023	DP			
	8399508	Sep 17, 2022	U-726			
	8399508*PED	Mar 17, 2023				
<u>OLOPATADINE HYDROCHLORIDE - PATADAY ONCE DAILY RELIEF</u>						
N 206276 001	8791154	May 19, 2032	DP U-1680			
	9533053	May 19, 2032	DP			
<u>OMACETAXINE MEPESUCCINATE - SYNRIBO</u>						
N 203585 001	6987103	Oct 26, 2026	U-1300			
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209816 001	10111890	Aug 03, 2037	U-2444		NCE	Oct 02, 2023
	10124014	Mar 05, 2029	U-2449		GAIN	Oct 02, 2028
	10383884	Oct 31, 2037	U-2576			
	10835542	Oct 31, 2037	U-2576			
	7326696	Sep 24, 2023	DS			
	7553828	Jun 02, 2023	DS			
	8383610	Sep 23, 2030	DS			
	9265740	Mar 05, 2029	U-1569			
	9314475	Mar 18, 2031	DP			
	9365500	Jun 29, 2021	U-1569			
	9365500	Jun 29, 2021	U-2576			
	9724358	Mar 05, 2029	U-1569			
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209817 001	10124014	Mar 05, 2029	U-2449		NCE	Oct 02, 2023
	10383884	Oct 31, 2037	U-2576		GAIN	Oct 02, 2028
	10835542	Oct 31, 2037	U-2576			
	7326696	Sep 24, 2023	DS			
	7553828	Jun 02, 2023	DS			
	9265740	Mar 05, 2029	DP			
	9365500	Jun 29, 2021	U-1569			
	9365500	Jun 29, 2021	U-2576			
	9724358	Mar 05, 2029	U-1569			
<u>OMBITASVIR; PARITAPREVIR; RITONAVIR - TECHNIVIE</u>						
N 207931 001	7148359*PED	Jan 19, 2020				
	7364752	Nov 10, 2020	DP			
	7364752*PED	May 10, 2021				
	8268349	Aug 25, 2024	DP			
	8268349*PED	Feb 25, 2025				
	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
	8420596	Apr 10, 2031	DS DP			
	8420596*PED	Oct 10, 2031				
	8642538	Sep 10, 2029	DS DP U-1638			
	8686026	Jun 09, 2031	DP			
	8691938	Apr 13, 2032	DS DP			
	9006387	Jun 10, 2030	U-1687			
	9044480	Apr 10, 2031	U-1638			
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	10117844	Jan 04, 2033	U-2447			
	5792795	May 13, 2020	DP			
	5948818	May 13, 2020	DP			
	7960370	Dec 20, 2026	DP			
	8383678	Feb 07, 2025	DP U-1511			
	9012501	Feb 07, 2025	DP U-1511			
	9050308	Jan 04, 2033	U-1511			
	9050309	Jan 04, 2033	DS			
	9132112	Feb 07, 2025	DP U-1511			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OMEPRAZOLE - OMEPRAZOLE</u>						
N 022032	001 9023391	Aug 16, 2025	DP			
<u>OMEPRAZOLE - OMEPRAZOLE</u>						
N 209400	001 10076494	Dec 08, 2036	DP			
	10835488	Dec 08, 2036	DP			
<u>ONDANSETRON - ZUPLENZ</u>						
N 022524	001 8580830	Nov 23, 2029	DP			
	9095577	Jul 13, 2030	DP			
<u>ONDANSETRON - ZUPLENZ</u>						
N 022524	002 8580830	Nov 23, 2029	DP			
	9095577	Jul 13, 2030	DP			
<u>OPICAPONE - ONGENTYS</u>						
N 212489	001 10071085	Mar 31, 2030	DP		NCE	Apr 24, 2025
	10357468	May 27, 2035		U-2812		
	10583130	Mar 31, 2030		U-2811		
	8168793	Apr 02, 2029	DS DP	U-2811		
	8524746	Jul 14, 2029		U-2811		
	8907099	May 12, 2027	DS			
	9550759	Jul 26, 2026		U-2811		
	9550759	Jul 26, 2026		U-2817		
	9550759	Jul 26, 2026		U-2818		
	9630955	Dec 12, 2032	DS DP	U-2811		
	9745290	Oct 10, 2027	DP	U-2811		
<u>OPICAPONE - ONGENTYS</u>						
N 212489	002 10071085	Mar 31, 2030	DP		NCE	Apr 24, 2025
	10357468	May 27, 2035		U-2812		
	10583130	Mar 31, 2030		U-2811		
	8168793	Apr 02, 2029	DS DP	U-2811		
	8524746	Jul 14, 2029		U-2811		
	8907099	May 12, 2027	DS			
	9550759	Jul 26, 2026		U-2811		
	9550759	Jul 26, 2026		U-2817		
	9550759	Jul 26, 2026		U-2818		
	9630955	Dec 12, 2032	DS DP	U-2811		
	9745290	Oct 10, 2027	DP	U-2811		
<u>ORITAVANCIN DIPHOSPHATE - ORBACTIV</u>						
N 206334	001 5840684	Nov 24, 2020	DS DP	U-1569	NCE	Aug 06, 2019
	8420592	Aug 29, 2029		U-1570	GAIN	Aug 06, 2024
	9649352	Jul 16, 2035	DP			
	9682061	Apr 26, 2030		U-1569		
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087	001				M-251	Aug 02, 2022
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087	002				M-251	Aug 02, 2022
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087	003				M-251	Aug 02, 2022
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021246	001				M-251	Aug 02, 2022
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021246	002				M-251	Aug 02, 2022
<u>OSILODROSTAT PHOSPHATE - ISTURISA</u>						
N 212801	001 10143680	Jul 06, 2035	DP		NCE	Mar 06, 2025
	10709691	Oct 12, 2035		U-2770	ODE-286	Mar 06, 2027
	8314097	Mar 27, 2029	DS DP			
	8609862	Jan 13, 2031		U-2770		
	8835646	Aug 23, 2026	DS DP			
	9434754	Jan 13, 2031	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OSILODROSTAT PHOSPHATE - ISTURISA</u>						
N 212801	002	10143680	Jul 06, 2035	DP	NCE	Mar 06, 2025
		10709691	Oct 12, 2035	U-2770	ODE-286	Mar 06, 2027
		8314097	Mar 27, 2029	DS DP		
		8609862	Jan 13, 2031	U-2770		
		8835646	Aug 23, 2026	DS DP		
		9434754	Jan 13, 2031	DS		
<u>OSILODROSTAT PHOSPHATE - ISTURISA</u>						
N 212801	003	10143680	Jul 06, 2035	DP	NCE	Mar 06, 2025
		10709691	Oct 12, 2035	U-2770	ODE-286	Mar 06, 2027
		8314097	Mar 27, 2029	DS DP		
		8609862	Jan 13, 2031	U-2770		
		8835646	Aug 23, 2026	DS DP		
		9434754	Jan 13, 2031	DS		
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065	001	10183020	Jan 02, 2035	DP U-1777	I-774	Apr 18, 2021
		10183020	Jan 02, 2035	DP U-2289	NCE	Nov 13, 2020
		8946235	Aug 08, 2032	DS DP U-1777	ODE-102	Nov 13, 2022
		8946235	Aug 08, 2032	DS DP U-2289	ODE-176	Apr 18, 2025
		9732058	Jul 25, 2032	DS DP U-1777		
		9732058	Jul 25, 2032	DS DP U-2289		
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065	002	10183020	Jan 02, 2035	DP U-1777	I-774	Apr 18, 2021
		10183020	Jan 02, 2035	DP U-2289	NCE	Nov 13, 2020
		8946235	Aug 08, 2032	DS DP U-1777	ODE-102	Nov 13, 2022
		8946235	Aug 08, 2032	DS DP U-2289	ODE-176	Apr 18, 2025
		9732058	Jul 25, 2032	DS DP U-1777		
		9732058	Jul 25, 2032	DS DP U-2289		
<u>OSPEMIFENE - OSPHENA</u>						
N 203505	001	6245819	Jul 21, 2025	U-1370	I-793	Jan 25, 2022
		6245819	Jul 21, 2025	U-905		
		8236861	Aug 11, 2026	U-1369		
		8236861	Aug 11, 2026	U-1370		
		8236861	Aug 11, 2026	U-905		
		8470890	Feb 13, 2024	U-1369		
		8470890	Feb 13, 2024	U-1370		
		8470890	Feb 13, 2024	U-905		
		8642079	Jul 09, 2028	DP		
		8772353	Feb 13, 2024	U-1369		
		8772353	Feb 13, 2024	U-1370		
		8772353	Feb 13, 2024	U-905		
		9241915	Feb 13, 2024	U-1369		
		9241915	Feb 13, 2024	U-1370		
		9241915	Feb 13, 2024	U-905		
		9566252	Jul 21, 2020	U-1370		
		9855224	Feb 13, 2024	U-1369		
		9855224	Feb 13, 2024	U-1370		
		9855224	Feb 13, 2024	U-905		
<u>OXCARBAZEPINE - TRILEPTAL</u>						
N 021285	001	8119148	Dec 19, 2020	DP U-724		
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810	001	10220042	Apr 13, 2027	U-2501		
		7722898	Apr 13, 2027	DP		
		7910131	Apr 13, 2027	U-2041		
		8617600	Apr 13, 2027	DP		
		8821930	Apr 13, 2027	DP		
		9119791	Apr 13, 2027	U-2041		
		9351975	Apr 13, 2027	DP		
		9370525	Apr 13, 2027	DP		
		9855278	Apr 13, 2027	DP		
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810	002	10220042	Apr 13, 2027	U-2501		
		7722898	Apr 13, 2027	DP		
		7910131	Apr 13, 2027	U-2041		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810	002	8617600	Apr 13, 2027	DP		
		8821930	Apr 13, 2027	DP		
		9119791	Apr 13, 2027	DP	U-2041	
		9351975	Apr 13, 2027	DP		
		9370525	Apr 13, 2027	DP		
		9855278	Apr 13, 2027	DP		
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810	003	10220042	Apr 13, 2027		U-2501	
		7722898	Apr 13, 2027	DP		
		7910131	Apr 13, 2027	DP	U-2041	
		8617600	Apr 13, 2027	DP		
		8821930	Apr 13, 2027	DP		
		9119791	Apr 13, 2027	DP	U-2041	
		9351975	Apr 13, 2027	DP		
		9370525	Apr 13, 2027	DP		
		9855278	Apr 13, 2027	DP		
<u>OXYBUTYNYNIN - OXYTROL</u>						
N 021351	002	6743441	Apr 26, 2020	DP	U-318	
		7081249	Apr 26, 2020	DP	U-318	
		7081250	Apr 26, 2020	DP	U-318	
		7081251	Apr 26, 2020	DP	U-318	
		7081252	Apr 26, 2020	DP	U-318	
		7179483	Apr 26, 2020	DS DP	U-318	
<u>OXYBUTYNYNIN - OXYTROL FOR WOMEN</u>						
N 202211	001	6743441	Apr 26, 2020	DP	U-1329	
		7081249	Apr 26, 2020	DP	U-1329	
		7081250	Apr 26, 2020	DP	U-1329	
		7081251	Apr 26, 2020	DP	U-1329	
		7081252	Apr 26, 2020	DP	U-1329	
		7179483	Apr 26, 2020		U-1329	
<u>OXYBUTYNYNIN - GELNIOUE 3%</u>						
N 202513	001	7029694	Apr 26, 2020	DP	U-318	
		7179483	Apr 26, 2020		U-318	
		7198801	Jun 25, 2022	DP		
		8241662	Apr 26, 2020		U-318	
<u>OXYBUTYNYNIN CHLORIDE - GELNIOUE</u>						
N 022204	001	10272061	Apr 26, 2020		U-2525	
		10449173	Nov 06, 2029	DP	U-2637	
		7029694	Apr 26, 2020	DP	U-318	
		7179483	Apr 26, 2020		U-318	
		8241662	Apr 26, 2020		U-318	
		8920392	Mar 26, 2031		U-1644	
		9259388	Nov 06, 2029		U-1644	
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090	001	10004729	Dec 10, 2030	DP	U-1556	
		10188644	Sep 02, 2036	DP	U-1556	
		10525052	Jul 07, 2023	DP	U-1556	
		10525053	Jul 07, 2023	DP		
		10646485	Sep 02, 2036	DP	U-1556	
		10668060	Dec 10, 2030	DP	U-1556	
		7399488	Mar 24, 2025	DP		
		7771707	Mar 24, 2025	DP		
		8449909	Mar 24, 2025	DP		
		8557291	Mar 21, 2025	DP		
		8758813	Jun 10, 2025		U-1556	
		8840928	Jul 07, 2023	DP	U-1556	
		9044398	Jul 07, 2023	DP		
		9248195	Jul 07, 2023		U-1556	
		9592200	Jul 07, 2023	DP		
		9682075	Dec 10, 2030	DP	U-1556	
		9737530	Sep 02, 2036	DP	U-1556	
		9763883	Jul 07, 2023	DP		
		9968598	Sep 02, 2036	DP	U-1556	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090	002	10004729	Dec 10, 2030	DP U-1556		
		10188644	Sep 02, 2036	DP U-1556		
		10525052	Jul 07, 2023	DP U-1556		
		10525053	Jul 07, 2023	DP		
		10646485	Sep 02, 2036	DP U-1556		
		10668060	Dec 10, 2030	DP U-1556		
		7399488	Mar 24, 2025	DP		
		7771707	Mar 24, 2025	DP		
		8449909	Mar 24, 2025	DP		
		8557291	Mar 21, 2025	DP		
		8758813	Jun 10, 2025	U-1556		
		8840928	Jul 07, 2023	DP U-1556		
		9044398	Jul 07, 2023	DP		
		9248195	Jul 07, 2023	U-1556		
		9592200	Jul 07, 2023	DP		
		9682075	Dec 10, 2030	DP U-1556		
		9737530	Sep 02, 2036	DP U-1556		
		9763883	Jul 07, 2023	DP		
		9968598	Sep 02, 2036	DP U-1556		
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090	003	10004729	Dec 10, 2030	DP U-1556		
		10188644	Sep 02, 2036	DP U-1556		
		10525052	Jul 07, 2023	DP U-1556		
		10525053	Jul 07, 2023	DP		
		10646485	Sep 02, 2036	DP U-1556		
		10668060	Dec 10, 2030	DP U-1556		
		7399488	Mar 24, 2025	DP		
		7771707	Mar 24, 2025	DP		
		8449909	Mar 24, 2025	DP		
		8557291	Mar 21, 2025	DP		
		8758813	Jun 10, 2025	U-1556		
		8840928	Jul 07, 2023	DP U-1556		
		9044398	Jul 07, 2023	DP		
		9248195	Jul 07, 2023	U-1556		
		9592200	Jul 07, 2023	DP		
		9682075	Dec 10, 2030	DP U-1556		
		9737530	Sep 02, 2036	DP U-1556		
		9763883	Jul 07, 2023	DP		
		9968598	Sep 02, 2036	DP U-1556		
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090	004	10004729	Dec 10, 2030	DP U-1556		
		10188644	Sep 02, 2036	DP U-1556		
		10525052	Jul 07, 2023	DP U-1556		
		10525053	Jul 07, 2023	DP		
		10646485	Sep 02, 2036	DP U-1556		
		10668060	Dec 10, 2030	DP U-1556		
		7399488	Mar 24, 2025	DP		
		7771707	Mar 24, 2025	DP		
		8449909	Mar 24, 2025	DP		
		8557291	Mar 21, 2025	DP		
		8758813	Jun 10, 2025	U-1556		
		8840928	Jul 07, 2023	DP U-1556		
		9044398	Jul 07, 2023	DP		
		9248195	Jul 07, 2023	U-1556		
		9592200	Jul 07, 2023	DP		
		9682075	Dec 10, 2030	DP U-1556		
		9737530	Sep 02, 2036	DP U-1556		
		9763883	Jul 07, 2023	DP		
		9968598	Sep 02, 2036	DP U-1556		
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090	005	10004729	Dec 10, 2030	DP U-1556		
		10188644	Sep 02, 2036	DP U-1556		
		10525052	Jul 07, 2023	DP U-1556		
		10525053	Jul 07, 2023	DP		
		10646485	Sep 02, 2036	DP U-1556		
		10668060	Dec 10, 2030	DP U-1556		
		7399488	Mar 24, 2025	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090	005	7771707	Mar 24, 2025	DP		
		8449909	Mar 24, 2025	DP		
		8557291	Mar 21, 2025	DP		
		8758813	Jun 10, 2025		U-1556	
		8840928	Jul 07, 2023	DP	U-1556	
		9044398	Jul 07, 2023	DP		
		9248195	Jul 07, 2023		U-1556	
		9592200	Jul 07, 2023	DP		
		9682075	Dec 10, 2030	DP	U-1556	
		9737530	Sep 02, 2036	DP	U-1556	
		9763883	Jul 07, 2023	DP		
		9968598	Sep 02, 2036	DP	U-1556	
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272	001	10130591	Nov 20, 2023	DP	U-1819	
		10369109	Jun 16, 2023	DP		
		10407434	Mar 30, 2025	DS		
		10675278	Nov 20, 2023	DP		
		10696684	Mar 30, 2025	DS		
		7674799	Mar 30, 2025	DP		Y
		7674800	Mar 30, 2025	DS		Y
		7683072	Mar 30, 2025	DS		Y
		7776314	Apr 19, 2025	DP		Y
		8309060	Nov 20, 2023	DP	U-1556	
		8808741	Aug 24, 2027		U-1556	
		8894987	Mar 29, 2030	DP		
		8894988	Aug 24, 2027	DP		
		9073933	Mar 30, 2025	DS		
		9492389	Aug 24, 2027	DP		
		9492391	Aug 24, 2027		U-1556	
		9492392	Aug 24, 2027	DP		
		9492393	Aug 24, 2027		U-1556	
		9522919	Mar 30, 2025	DS	DP	
		9675610	Jun 16, 2023	DP		
		9763933	Aug 24, 2027	DP		
		9770416	Aug 24, 2027	DP		
		9775808	Aug 24, 2027	DP		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272	002	10130591	Nov 20, 2023	DP	U-1819	
		10369109	Jun 16, 2023	DP		
		10407434	Mar 30, 2025	DS		
		10675278	Nov 20, 2023	DP		
		10696684	Mar 30, 2025	DS		
		7674799	Mar 30, 2025	DP		Y
		7674800	Mar 30, 2025	DS		Y
		7683072	Mar 30, 2025	DS		Y
		7776314	Apr 19, 2025	DP		Y
		8309060	Nov 20, 2023	DP	U-1556	
		8808741	Aug 24, 2027		U-1556	
		8894987	Mar 29, 2030	DP		
		8894988	Aug 24, 2027	DP		
		9073933	Mar 30, 2025	DS		
		9492389	Aug 24, 2027	DP		
		9492391	Aug 24, 2027		U-1556	
		9492392	Aug 24, 2027	DP		
		9492393	Aug 24, 2027		U-1556	
		9522919	Mar 30, 2025	DS	DP	
		9675610	Jun 16, 2023	DP		
		9763933	Aug 24, 2027	DP		
		9770416	Aug 24, 2027	DP		
		9775808	Aug 24, 2027	DP		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272	003	10130591	Nov 20, 2023	DP	U-1819	
		10369109	Jun 16, 2023	DP		
		10407434	Mar 30, 2025	DS		
		10675278	Nov 20, 2023	DP		
		10696684	Mar 30, 2025	DS		
		7674799	Mar 30, 2025	DP		Y

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272	003	7674800	Mar 30, 2025	DS		Y
		7683072	Mar 30, 2025	DS		Y
		7776314	Apr 19, 2025	DP		Y
		8309060	Nov 20, 2023	DP U-1556		
		8808741	Aug 24, 2027	U-1556		
		8894987	Mar 29, 2030	DP		
		8894988	Aug 24, 2027	DP		
		9073933	Mar 30, 2025	DS		
		9492389	Aug 24, 2027	DP		
		9492391	Aug 24, 2027	U-1556		
		9492392	Aug 24, 2027	DP		
		9492393	Aug 24, 2027	U-1556		
		9522919	Mar 30, 2025	DS DP		
		9675610	Jun 16, 2023	DP		
		9763933	Aug 24, 2027	DP		
		9770416	Aug 24, 2027	DP		
		9775808	Aug 24, 2027	DP		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272	004	10130591	Nov 20, 2023	DP U-1819		
		10369109	Jun 16, 2023	DP		
		10407434	Mar 30, 2025	DS		
		10675278	Nov 20, 2023	DP		
		10696684	Mar 30, 2025	DS		
		8309060	Nov 20, 2023	DP U-1556		
		8808741	Aug 24, 2027	U-1556		
		8894987	Mar 29, 2030	DP		
		8894988	Aug 24, 2027	DP		
		9073933	Mar 30, 2025	DS		
		9492389	Aug 24, 2027	DP		
		9492391	Aug 24, 2027	U-1556		
		9492392	Aug 24, 2027	DP		
		9492393	Aug 24, 2027	U-1556		
		9522919	Mar 30, 2025	DS DP		
		9675610	Jun 16, 2023	DP		
		9763933	Aug 24, 2027	DP		
		9770416	Aug 24, 2027	DP		
		9775808	Aug 24, 2027	DP		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272	005	10130591	Nov 20, 2023	DP U-1819		
		10369109	Jun 16, 2023	DP		
		10407434	Mar 30, 2025	DS		
		10675278	Nov 20, 2023	DP		
		10696684	Mar 30, 2025	DS		
		7776314	Apr 19, 2025	DP		Y
		8309060	Nov 20, 2023	DP U-1556		
		8808741	Aug 24, 2027	U-1556		
		8894988	Aug 24, 2027	DP		
		9073933	Mar 30, 2025	DS		
		9492389	Aug 24, 2027	DP		
		9492391	Aug 24, 2027	U-1556		
		9492392	Aug 24, 2027	DP		
		9492393	Aug 24, 2027	U-1556		
		9522919	Mar 30, 2025	DS DP		
		9675610	Jun 16, 2023	DP		
		9763933	Aug 24, 2027	DP		
		9770416	Aug 24, 2027	DP		
		9775808	Aug 24, 2027	DP		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272	006	10130591	Nov 20, 2023	DP U-1819		
		10369109	Jun 16, 2023	DP		
		10407434	Mar 30, 2025	DS		
		10675278	Nov 20, 2023	DP		
		10696684	Mar 30, 2025	DS		
		8309060	Nov 20, 2023	DP U-1556		
		8808741	Aug 24, 2027	U-1556		
		8894988	Aug 24, 2027	DP		
		9073933	Mar 30, 2025	DS		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272	006	9492389	Aug 24, 2027	DP		
		9492391	Aug 24, 2027	U-1556		
		9492392	Aug 24, 2027	DP		
		9492393	Aug 24, 2027	U-1556		
		9522919	Mar 30, 2025	DS DP		
		9675610	Jun 16, 2023	DP		
		9763933	Aug 24, 2027	DP		
		9770416	Aug 24, 2027	DP		
		9775808	Aug 24, 2027	DP		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272	007	10130591	Nov 20, 2023	DP	U-1819	
		10369109	Jun 16, 2023	DP		
		10407434	Mar 30, 2025	DS		
		10675278	Nov 20, 2023	DP		
		10696684	Mar 30, 2025	DS		
		8309060	Nov 20, 2023	DP	U-1556	
		8808741	Aug 24, 2027	U-1556		
		8894988	Aug 24, 2027	DP		
		9073933	Mar 30, 2025	DS		
		9492389	Aug 24, 2027	DP		
		9492391	Aug 24, 2027	U-1556		
		9492392	Aug 24, 2027	DP		
		9492393	Aug 24, 2027	U-1556		
		9522919	Mar 30, 2025	DS DP		
		9675610	Jun 16, 2023	DP		
		9763933	Aug 24, 2027	DP		
		9770416	Aug 24, 2027	DP		
		9775808	Aug 24, 2027	DP		
<u>OXYCODONE HYDROCHLORIDE - OXAYDO</u>						
N 202080	001	7201920	Mar 16, 2025	DP		
		7510726	Nov 26, 2023	DP		
		7981439	Nov 26, 2023	DP		
		8409616	Nov 26, 2023	DP		
		8637540	Nov 26, 2023	DP		
		9492443	May 26, 2024	DP		
<u>OXYCODONE HYDROCHLORIDE - OXAYDO</u>						
N 202080	002	7201920	Mar 16, 2025	DP		
		7510726	Nov 26, 2023	DP		
		7981439	Nov 26, 2023	DP		
		8409616	Nov 26, 2023	DP		
		8637540	Nov 26, 2023	DP		
		9492443	May 26, 2024	DP		
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777	001	10314788	Aug 12, 2028	DP	NP	Apr 20, 2020
		7955619	Aug 12, 2028	DP		
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777	002	10314788	Aug 12, 2028	DP	NP	Apr 20, 2020
		7955619	Aug 12, 2028	DP		
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777	003	10314788	Aug 12, 2028	DP	NP	Apr 20, 2020
		7955619	Aug 12, 2028	DP		
<u>OXYMETAZOLINE HYDROCHLORIDE - RHOFAD</u>						
N 208552	001	10335391	Jun 11, 2035	U-2567	NP	Jan 18, 2020
		10751325	Jun 11, 2035	U-2921		
		7812049	May 02, 2028	U-1959		
		8420688	Aug 02, 2024	U-1959		
		8815929	Jan 22, 2024	U-1959		
		8883838	Dec 01, 2031	DP		
		9974773	Jun 11, 2035	U-2306		
<u>OXYMETAZOLINE HYDROCHLORIDE - UPNEEQ</u>						
N 212520	001	10799481	Dec 16, 2039	U-2849	NP	Jul 08, 2023
		10814001	Dec 16, 2039	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYMETAZOLINE HYDROCHLORIDE - UPNEEQ</u>						
N 212520	001	8357714	Aug 26, 2031	U-2849		
		9867808	Aug 26, 2031	U-2849		
<u>OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE - KOVANAZE</u>						
N 208032	001	6413499	Mar 20, 2020	U-1876		
		8580282	Apr 02, 2030	DP U-1876		
		9308191	Apr 02, 2030	DP U-1876		
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610	001	7276250	Feb 04, 2023	DP U-826		
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610	002	7276250	Feb 04, 2023	DP U-826		
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610	003	7276250	Feb 04, 2023	DP U-826		
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610	004	7276250	Feb 04, 2023	DP U-826		
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610	005	7276250	Feb 04, 2023	DP U-826		
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610	006	7276250	Feb 04, 2023	DP U-826		
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610	007	7276250	Feb 04, 2023	DP U-826		
<u>OXYMORPHONE HYDROCHLORIDE - OPANA</u>						
N 021611	001				M-14	Oct 25, 2022
<u>OXYMORPHONE HYDROCHLORIDE - OPANA</u>						
N 021611	002				M-14	Oct 25, 2022
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655	001	7851482	Jul 10, 2029	DS		
		8075872	Nov 20, 2023	DP		
		8114383	Aug 08, 2024	DP		
		8192722	Sep 15, 2025	DP		
		8309060	Nov 20, 2023	DP		
		8309122	Feb 04, 2023	DP		
		8329216	Feb 04, 2023	DP		
		8808737	Jun 21, 2027		U-1598	
		8871779	Nov 22, 2029	DS		
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655	002	7851482	Jul 10, 2029	DS		
		8075872	Nov 20, 2023	DP		
		8114383	Aug 08, 2024	DP		
		8192722	Sep 15, 2025	DP		
		8309060	Nov 20, 2023	DP		
		8309122	Feb 04, 2023	DP		
		8329216	Feb 04, 2023	DP		
		8808737	Jun 21, 2027		U-1598	
		8871779	Nov 22, 2029	DS		
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655	003	7851482	Jul 10, 2029	DS		
		8075872	Nov 20, 2023	DP		
		8114383	Aug 08, 2024	DP		
		8192722	Sep 15, 2025	DP		
		8309060	Nov 20, 2023	DP		
		8309122	Feb 04, 2023	DP		
		8329216	Feb 04, 2023	DP		
		8808737	Jun 21, 2027		U-1598	
		8871779	Nov 22, 2029	DS		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 004	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027		U-1598		
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 005	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027		U-1598		
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 006	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027		U-1598		
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 007	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027		U-1598		
	8871779	Nov 22, 2029	DS			
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 001	8481573	May 14, 2029	DS DP	U-2774	NCE	Mar 25, 2025
	8796318	May 14, 2029	DS DP			
	9382217	May 14, 2029		U-2774		
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 002	8481573	May 14, 2029	DS DP	U-2774	NCE	Mar 25, 2025
	8796318	May 14, 2029	DS DP			
	9382217	May 14, 2029		U-2774		
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 003	8481573	May 14, 2029	DS DP	U-2774	NCE	Mar 25, 2025
	8796318	May 14, 2029	DS DP			
	9382217	May 14, 2029		U-2774		
<u>OZENOXACIN - XEPI</u>						
N 208945 001	6335447	Apr 06, 2021	DS		NCE	Dec 11, 2022
	9180200	Jan 29, 2032	DP	U-805		
	9399014	Dec 15, 2029		U-805		
<u>PACLITAXEL - ABRAXANE</u>						
N 021660 001	7758891	Feb 21, 2026		U-1434	M-14	Dec 06, 2022
	7758891*PED	Aug 21, 2026			ODE-52	Sep 06, 2020
	7820788	Oct 27, 2024	DP	U-1092	PED	Mar 06, 2021
	7820788	Oct 27, 2024	DP	U-1290	PED	Jun 06, 2023
	7820788	Oct 27, 2024	DP	U-1434		
	7820788*PED	Apr 27, 2025				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PACLITAXEL - ABRAXANE</u>						
N 021660	001	7923536	Dec 09, 2023	U-1117		
		7923536	Dec 09, 2023	U-1290		
		7923536	Dec 09, 2023	U-1434		
		7923536*PED	Jun 09, 2024			
		8034375	Aug 13, 2026	U-1290		
		8138229	Dec 09, 2023	DP U-1092		
		8138229	Dec 09, 2023	DP U-1290		
		8138229	Dec 09, 2023	DP U-1434		
		8138229*PED	Jun 09, 2024			
		8268348	Feb 21, 2026	U-1290		
		8314156	Dec 09, 2023	U-1290		
		8314156	Dec 09, 2023	U-1434		
		8314156*PED	Jun 09, 2024			
		8853260	Oct 10, 2020	DP U-1092		
		8853260	Oct 10, 2020	DP U-1290		
		8853260	Oct 10, 2020	DP U-1434		
		8853260*PED	Apr 10, 2021			
		9101543	Feb 21, 2026	U-1434		
		9101543*PED	Aug 21, 2026			
		9393318	Mar 04, 2032	U-1290		
		9393318*PED	Sep 04, 2032			
		9511046	Jan 12, 2034	U-1434		
		9511046*PED	Jul 12, 2034			
		9597409	Mar 04, 2032	U-1290		
		9597409*PED	Sep 04, 2032			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103	001	10723730	Feb 08, 2034	DS DP	NCE	Feb 03, 2020
		6936612	Jan 16, 2023	DS DP		
		7208489	Jan 16, 2023	DS DP	Y	
		7456168	Jan 16, 2023	U-1998		
		7456168	Jan 16, 2023	U-2515		
		RE47739	Jan 16, 2023	DS DP		
<u>PALBOCICLIB - IBRANCE</u>						
N 207103	002	10723730	Feb 08, 2034	DS DP	NCE	Feb 03, 2020
		6936612	Jan 16, 2023	DS DP		
		7208489	Jan 16, 2023	DS DP	Y	
		7456168	Jan 16, 2023	U-1998		
		7456168	Jan 16, 2023	U-2515		
		RE47739	Jan 16, 2023	DS DP		
<u>PALBOCICLIB - IBRANCE</u>						
N 207103	003	10723730	Feb 08, 2034	DS DP	NCE	Feb 03, 2020
		6936612	Jan 16, 2023	DS DP		
		7208489	Jan 16, 2023	DS DP	Y	
		7456168	Jan 16, 2023	U-1998		
		7456168	Jan 16, 2023	U-2515		
		RE47739	Jan 16, 2023	DS DP		
<u>PALBOCICLIB - IBRANCE</u>						
N 212436	001	10723730	Feb 08, 2034	DS DP	NCE	Feb 03, 2020
		6936612	Jan 16, 2023	DS DP		
		7456168	Jan 16, 2023	U-2515		
		RE47739	Jan 16, 2023	DS DP		
<u>PALBOCICLIB - IBRANCE</u>						
N 212436	002	10723730	Feb 08, 2034	DS DP	NCE	Feb 03, 2020
		6936612	Jan 16, 2023	DS DP		
		7456168	Jan 16, 2023	U-2515		
		RE47739	Jan 16, 2023	DS DP		
<u>PALBOCICLIB - IBRANCE</u>						
N 212436	003	10723730	Feb 08, 2034	DS DP	NCE	Feb 03, 2020
		6936612	Jan 16, 2023	DS DP		
		7456168	Jan 16, 2023	U-2515		
		RE47739	Jan 16, 2023	DS DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 001	9439906	Jan 26, 2031	U-1901		M-215	Dec 20, 2020
	9439906	Jan 26, 2031	U-2757			
	9439906	Jan 26, 2031	U-2758			
	9439906	Jan 26, 2031	U-543			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 002	9439906	Jan 26, 2031	U-1901		M-215	Dec 20, 2020
	9439906	Jan 26, 2031	U-2757			
	9439906	Jan 26, 2031	U-2758			
	9439906	Jan 26, 2031	U-543			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 003	9439906	Jan 26, 2031	U-1901		M-215	Dec 20, 2020
	9439906	Jan 26, 2031	U-2757			
	9439906	Jan 26, 2031	U-2758			
	9439906	Jan 26, 2031	U-543			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 004	9439906	Jan 26, 2031	U-1901		M-215	Dec 20, 2020
	9439906	Jan 26, 2031	U-2757			
	9439906	Jan 26, 2031	U-2758			
	9439906	Jan 26, 2031	U-543			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 005	9439906	Jan 26, 2031	U-1901		M-215	Dec 20, 2020
	9439906	Jan 26, 2031	U-2757			
	9439906	Jan 26, 2031	U-2758			
	9439906	Jan 26, 2031	U-543			
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 001	10143693	Apr 05, 2036	U-2457			
	10143693	Apr 05, 2036	U-2458			
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 002	10143693	Apr 05, 2036	U-2457			
	10143693	Apr 05, 2036	U-2458			
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 003	10143693	Apr 05, 2036	U-2457			
	10143693	Apr 05, 2036	U-2458			
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 004	10143693	Apr 05, 2036	U-2457			
	10143693	Apr 05, 2036	U-2458			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 001	7947724	Jan 30, 2024	DP			
	7947724*PED	Jul 30, 2024				
	7947725	Jan 30, 2024	DP			
	7947725*PED	Jul 30, 2024				
	7960424	Jan 30, 2024	DP			
	7960424*PED	Jul 30, 2024				
	8518981	Jan 30, 2024	DP			
	8518981*PED	Jul 30, 2024				
	8598218	Jan 30, 2024	DP			
	8598218*PED	Jul 30, 2024				
	8598219	Jan 30, 2024	DP			
	8598219*PED	Jul 30, 2024				
	8729094	Jan 30, 2024	DP U-528			
	8729094*PED	Jul 30, 2024				
	9066980	Jan 30, 2024	DP U-528			
	9066980*PED	Jul 30, 2024				
	9125905	Jan 30, 2024	DP			
	9125905*PED	Jul 30, 2024				
	9173942	Jan 30, 2024	DP			
	9173942*PED	Jul 30, 2024				
	9439854	Jan 30, 2024	DP			
	9439854*PED	Jul 30, 2024				
	9457020	Jan 30, 2024	DP			
	9457020*PED	Jul 30, 2024				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372	001	9457021	Jan 30, 2024	DP		
		9457021*PED	Jul 30, 2024			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372	002	7947724	Jan 30, 2024	DP		
		7947724*PED	Jul 30, 2024			
		7947725	Jan 30, 2024	DP		
		7947725*PED	Jul 30, 2024			
		7960424	Jan 30, 2024	DP		
		7960424*PED	Jul 30, 2024			
		8518981	Jan 30, 2024	DP		
		8518981*PED	Jul 30, 2024			
		8598218	Jan 30, 2024	DP		
		8598218*PED	Jul 30, 2024			
		9173942	Jan 30, 2024	DP		
		9173942*PED	Jul 30, 2024			
		9439854	Jan 30, 2024	DP		
		9439854*PED	Jul 30, 2024			
		9457020	Jan 30, 2024	DP		
		9457020*PED	Jul 30, 2024			
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353	001	6552065	Aug 31, 2021	DS DP	NCE	Feb 23, 2020
		6833384	Sep 30, 2021	DS DP U-1669	ODE-89	Feb 23, 2022
		7067551	Aug 31, 2021	U-1669		
		7989494	Jan 17, 2028	DS DP		
		8883842	Jun 13, 2028	U-1669		
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353	002	6552065	Aug 31, 2021	DS DP	NCE	Feb 23, 2020
		6833384	Sep 30, 2021	DS DP U-1669	ODE-89	Feb 23, 2022
		7067551	Aug 31, 2021	U-1669		
		7989494	Jan 17, 2028	DS DP		
		8883842	Jun 13, 2028	U-1669		
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353	003	6552065	Aug 31, 2021	DS DP	NCE	Feb 23, 2020
		6833384	Sep 30, 2021	DS DP U-1669	ODE-89	Feb 23, 2022
		7067551	Aug 31, 2021	U-1669		
		7989494	Jan 17, 2028	DS DP		
		8883842	Jun 13, 2028	U-1669		
<u>PANTOPRAZOLE SODIUM - PANTOPRAZOLE SODIUM</u>						
A 213725	001				PC	Feb 09, 2021
<u>PANTOPRAZOLE SODIUM - PROTONIX IV</u>						
N 020988	001	6780881	Nov 17, 2021	DP		
		7351723	Nov 17, 2021	DP		
		8754108	Nov 17, 2021	DP		
		8754108*PED	May 17, 2022			
<u>PANTOPRAZOLE SODIUM - PROTONIX</u>						
N 022020	001	7544370	Jun 07, 2026	DP		
		7550153	Sep 30, 2024	U-859		
		7553498	Sep 30, 2024	U-859		
		7838027	Sep 30, 2024	DP U-859		
<u>PARICALCITOL - ZEMPLAR</u>						
N 021606	001				ODE-125	Oct 18, 2023
<u>PARICALCITOL - ZEMPLAR</u>						
N 021606	002				ODE-125	Oct 18, 2023
<u>PARICALCITOL - ZEMPLAR</u>						
N 021606	003				ODE-125	Oct 18, 2023
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299	001	7598271	May 04, 2025	DS		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299	002	7598271	May 04, 2025	DS		
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299	003	7598271	May 04, 2025	DS		
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299	004	7598271	May 04, 2025	DS		
<u>PAROXETINE MESYLATE - BRISDELLE</u>						
N 204516	001	7598271	May 04, 2025	DS		
		8658663	Apr 06, 2029	DS DP	U-904	
		8946251	Aug 04, 2026	DS DP	U-904	
		9393237	Aug 04, 2026		U-904	
<u>PASIREOTIDE DIASPARTATE - SIGNIFOR</u>						
N 200677	001	7473761	Dec 14, 2026	DS DP		
		8299209	Dec 27, 2025	DS DP		
<u>PASIREOTIDE DIASPARTATE - SIGNIFOR</u>						
N 200677	002	7473761	Dec 14, 2026	DS DP		
		8299209	Dec 27, 2025	DS DP		
<u>PASIREOTIDE DIASPARTATE - SIGNIFOR</u>						
N 200677	003	7473761	Dec 14, 2026	DS DP		
		8299209	Dec 27, 2025	DS DP		
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT</u>						
N 203255	001	7473761	Dec 14, 2026	DS DP		I-785 Jun 29, 2021
		7759308	Oct 25, 2026	DP		ODE-268 Jun 29, 2025
		8822637	Aug 06, 2023	U-1629		ODE-81 Dec 15, 2021
		9351923	May 23, 2028	DP		
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT</u>						
N 203255	002	7473761	Dec 14, 2026	DS DP		I-785 Jun 29, 2021
		7759308	Oct 25, 2026	DP		ODE-268 Jun 29, 2025
		8822637	Aug 06, 2023	U-1629		ODE-81 Dec 15, 2021
		9351923	May 23, 2028	DP		
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT</u>						
N 203255	003	7473761	Dec 14, 2026	DS DP		I-785 Jun 29, 2021
		7759308	Oct 25, 2026	DP		ODE-268 Jun 29, 2025
		8822637	Aug 06, 2023	U-1629		ODE-81 Dec 15, 2021
		9351923	May 23, 2028	DP		
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT</u>						
N 203255	004	7473761	Dec 14, 2026	DS DP		I-785 Jun 29, 2021
		7759308	Oct 25, 2026	DP		ODE-268 Jun 29, 2025
		9351923	May 23, 2028	DP		
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT</u>						
N 203255	005	7473761	Dec 14, 2026	DS DP		I-785 Jun 29, 2021
		7759308	Oct 25, 2026	DP		ODE-268 Jun 29, 2025
		9351923	May 23, 2028	DP		
<u>PATIROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739	001	10485821	Mar 30, 2024		U-1766	NCE Oct 21, 2020
		7556799	Feb 27, 2025		U-1766	
		8147873	Jun 20, 2028	DP		
		8216560	Mar 14, 2027		U-1766	
		8282913	May 29, 2027	DP		
		8287847	Mar 30, 2024		U-1766	
		8337824	May 29, 2030	DS	U-1766	
		8475780	Mar 30, 2024		U-1766	
		8778324	Mar 30, 2024		U-1766	
		8889115	Mar 30, 2024		U-1766	
		9492476	Oct 08, 2033		U-1766	
		9925212	Oct 08, 2033		U-1766	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PATIOMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739	002	10485821	Mar 30, 2024	U-1766	NCE	Oct 21, 2020
		7556799	Feb 27, 2025	U-1766		
		8147873	Jun 20, 2028	DP		
		8216560	Mar 14, 2027	U-1766		
		8282913	May 29, 2027	DP		
		8287847	Mar 30, 2024	U-1766		
		8337824	May 29, 2030	DS U-1766		
		8475780	Mar 30, 2024	U-1766		
		8778324	Mar 30, 2024	U-1766		
		8889115	Mar 30, 2024	U-1766		
		9492476	Oct 08, 2033	U-1766		
		9925212	Oct 08, 2033	U-1766		
<u>PATIOMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739	003	10485821	Mar 30, 2024	U-1766	NCE	Oct 21, 2020
		7556799	Feb 27, 2025	U-1766		
		8147873	Jun 20, 2028	DP		
		8216560	Mar 14, 2027	U-1766		
		8282913	May 29, 2027	DP		
		8287847	Mar 30, 2024	U-1766		
		8337824	May 29, 2030	DS U-1766		
		8475780	Mar 30, 2024	U-1766		
		8778324	Mar 30, 2024	U-1766		
		8889115	Mar 30, 2024	U-1766		
		9492476	Oct 08, 2033	U-1766		
		9925212	Oct 08, 2033	U-1766		
<u>PATISIRAN SODIUM - ONPATRO</u>						
N 210922	001	8058069	Apr 15, 2029	DP	NCE	Aug 10, 2023
		8158601	Nov 10, 2030	DP U-2378	ODE-197	Aug 10, 2025
		8168775	Oct 20, 2029	DS DP U-2378		
		8334373	May 27, 2025	DS DP		
		8362231	Mar 30, 2021	DS DP		
		8372968	Mar 30, 2021	DS DP		
		8492359	Apr 15, 2029	DP		
		8552171	Mar 30, 2021	DS DP		
		8642076	Oct 03, 2027	DP		
		8741866	Oct 20, 2029	U-2378		
		8778902	Mar 30, 2021	U-2378		
		8802644	Oct 21, 2030	DP U-2378		
		8822668	Apr 15, 2029	DP U-2378		
		8895718	Mar 30, 2021	DS DP		
		8895721	Mar 30, 2021	DS DP		
		9193753	Mar 30, 2021	U-2378		
		9234196	Oct 20, 2029	DP U-2378		
		9364435	Apr 15, 2029	DP U-2378		
		9567582	Mar 30, 2021	DS DP		
		9943538	Nov 04, 2023	DP		
		9943539	Nov 04, 2023	DP		
<u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u>						
N 022465	001	7105530	Oct 19, 2023	DS DP		
		7262203	Dec 19, 2021	DS DP		
		8114885	Dec 19, 2021	DS DP		
<u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u>						
N 022465	002	7105530	Oct 19, 2023	DS DP		
		7262203	Dec 19, 2021	DS DP		
		8114885	Dec 19, 2021	DS DP		
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799	001	7084245	May 12, 2024	DS DP U-1238		
		7414105	May 12, 2024	DS DP U-1238		
		7528104	May 12, 2024	DS DP		
		7550433	Jun 02, 2026	U-1238		
		7919118	May 12, 2024	DS DP		
		7919461	Jun 02, 2026	U-1238		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799 002	7084245	May 12, 2024	DS DP U-1238			
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026			U-1238	
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026			U-1238	
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799 003	7084245	May 12, 2024	DS DP U-1238			
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026			U-1238	
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026			U-1238	
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799 004	7084245	May 12, 2024	DS DP U-1238			
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026			U-1238	
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026			U-1238	
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799 005	7084245	May 12, 2024	DS DP U-1238			
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026			U-1238	
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026			U-1238	
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799 006	7084245	May 12, 2024	DS DP U-1238			
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026			U-1238	
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026			U-1238	
<u>PEGINESATIDE ACETATE - OMONTYS</u>						
N 202799 007	7084245	May 12, 2024	DS DP U-1238			
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026			U-1238	
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026			U-1238	
<u>PEGINESATIDE ACETATE - OMONTYS</u>						
N 202799 008	7084245	May 12, 2024	DS DP U-1238			
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026			U-1238	
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026			U-1238	
<u>PEMETREXED - PEMFEXY</u>						
N 209472 001	7772209	May 24, 2022			U-2728	
	7772209	May 24, 2022			U-2729	
	9604990	Oct 28, 2035	DS			
<u>PEMETREXED DISODIUM - ALIMTA</u>						
N 021462 001	7772209	Nov 24, 2021			U-1296	
<u>PEMETREXED DISODIUM - ALIMTA</u>						
N 021462 002	7772209	Nov 24, 2021			U-1296	
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 001	10131667	Jun 12, 2033			U-2809	
	9611267	Jan 30, 2035	DS DP			
					NCE	Apr 17, 2025
					ODE-292	Apr 17, 2027

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 002	10131667	Jun 12, 2033		U-2809	NCE	Apr 17, 2025
	9611267	Jan 30, 2035	DS DP		ODE-292	Apr 17, 2027
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 003	10131667	Jun 12, 2033		U-2809	NCE	Apr 17, 2025
	9611267	Jan 30, 2035	DS DP		ODE-292	Apr 17, 2027
<u>PENCICLOVIR - DENAVIR</u>						
N 020629 001	6579981	Jun 17, 2020		U-501		
<u>PERAMIVIR - RAPIVAB</u>						
N 206426 001	10391075	Feb 12, 2027		U-2622	NPP	Sep 20, 2020
	6562861	Dec 16, 2023	DS			
	8778997	May 07, 2027		U-1627		
	8778997	May 07, 2027		U-2622		
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 001	6949571	Jun 08, 2021	DS DP	U-106		
	6949571	Jun 08, 2021	DS DP	U-2088		
	6949571	Jun 08, 2021	DS DP	U-2089		
	6949571	Jun 08, 2021	DS DP	U-2428		
	6949571	Jun 08, 2021	DS DP	U-2429		
	8772497	Jul 01, 2026	DS			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002	6949571	Jun 08, 2021	DS DP	U-106		
	6949571	Jun 08, 2021	DS DP	U-2088		
	6949571	Jun 08, 2021	DS DP	U-2089		
	6949571	Jun 08, 2021	DS DP	U-2428		
	6949571	Jun 08, 2021	DS DP	U-2429		
	8772497	Jul 01, 2026	DS			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 003	6949571	Jun 08, 2021	DS DP	U-106		
	6949571	Jun 08, 2021	DS DP	U-2088		
	6949571	Jun 08, 2021	DS DP	U-2089		
	6949571	Jun 08, 2021	DS DP	U-2428		
	6949571	Jun 08, 2021	DS DP	U-2429		
	8772497	Jul 01, 2026	DS			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 004	6949571	Jun 08, 2021	DS DP	U-106		
	6949571	Jun 08, 2021	DS DP	U-2088		
	6949571	Jun 08, 2021	DS DP	U-2089		
	6949571	Jun 08, 2021	DS DP	U-2428		
	6949571	Jun 08, 2021	DS DP	U-2429		
	8772497	Jul 01, 2026	DS			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 005	6949571	Jun 08, 2021	DS DP	U-106		
	6949571	Jun 08, 2021	DS DP	U-2088		
	6949571	Jun 08, 2021	DS DP	U-2089		
	6949571	Jun 08, 2021	DS DP	U-2428		
	6949571	Jun 08, 2021	DS DP	U-2429		
	8772497	Jul 01, 2026	DS			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006	6949571	Jun 08, 2021	DS DP	U-106		
	6949571	Jun 08, 2021	DS DP	U-2088		
	6949571	Jun 08, 2021	DS DP	U-2089		
	6949571	Jun 08, 2021	DS DP	U-2428		
	6949571	Jun 08, 2021	DS DP	U-2429		
	8772497	Jul 01, 2026	DS			
<u>PERAMPANEL - FYCOMPA</u>						
N 208277 001	6949571	Jun 08, 2021	DS DP	U-106		
	6949571	Jun 08, 2021	DS DP	U-2088		
	6949571	Jun 08, 2021	DS DP	U-2089		
	6949571	Jun 08, 2021	DS DP	U-2428		
	6949571	Jun 08, 2021	DS DP	U-2429		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PERAMPANEL - FYCOMPA</u>						
N 208277	001	8772497	Jul 01, 2026	DS		
<u>PERFLUTREN - DEFINITY</u>						
N 021064	001	10583207	Dec 28, 2035		U-665	
		10583208	Mar 16, 2037		U-665	
		10588988	May 04, 2037		U-665	
		9789210	Mar 16, 2037		U-665	
<u>PERFLUTREN - DEFINITY RT</u>						
N 021064	002	10022460	Dec 28, 2035	DS DP		
		10583207	Dec 28, 2035		U-665	
		10583208	Mar 16, 2037		U-665	
		10588988	May 04, 2037		U-665	
		9789210	Mar 16, 2037		U-665	
<u>PEXIDARTINIB HYDROCHLORIDE - TURALIO</u>						
N 211810	001	10189833	May 05, 2036		U-2606	
		10435404	Jul 24, 2038	DP		NCE Aug 02, 2024
		10730876	May 05, 2036	DS		ODE-250 Aug 02, 2026
		7893075	Oct 13, 2028	DS		
		8404700	Nov 21, 2027	DS		
		8461169	Apr 19, 2028		U-2606	
		8722702	Nov 21, 2027	DS		
		9169250	Nov 21, 2027	DS		
		9358235	Jun 08, 2033		U-2606	
		9802932	May 05, 2036	DS		
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N 202088	001	8440170	Mar 14, 2029	DP		
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N 202088	002	8440170	Mar 14, 2029	DP		
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N 202088	003	8440170	Mar 14, 2029	DP		
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMIA</u>						
N 022580	001	7056890	Jun 14, 2020	DP	U-1262	
		7553818	Jun 14, 2020		U-1262	
		7659256	Jun 14, 2020	DP	U-1262	
		7674776	Jun 14, 2020	DP	U-1262	
		8580298	May 15, 2029	DP		
		8580299	Jun 14, 2029		U-1262	
		8895057	Jun 09, 2028		U-1262	
		8895058	Jun 09, 2028	DP		
		9011905	Jun 09, 2028	DP		
		9011906	Jun 09, 2028		U-1262	
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMIA</u>						
N 022580	002	7056890	Jun 14, 2020	DP	U-1262	
		7553818	Jun 14, 2020		U-1262	
		7659256	Jun 14, 2020	DP	U-1262	
		7674776	Jun 14, 2020	DP	U-1262	
		8580298	May 15, 2029	DP		
		8580299	Jun 14, 2029		U-1262	
		8895057	Jun 09, 2028		U-1262	
		8895058	Jun 09, 2028	DP		
		9011905	Jun 09, 2028	DP		
		9011906	Jun 09, 2028		U-1262	
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMIA</u>						
N 022580	003	7056890	Jun 14, 2020	DP	U-1262	
		7553818	Jun 14, 2020		U-1262	
		7659256	Jun 14, 2020	DP	U-1262	
		7674776	Jun 14, 2020	DP	U-1262	
		8580298	May 15, 2029	DP		
		8580299	Jun 14, 2029		U-1262	
		8895057	Jun 09, 2028		U-1262	
		8895058	Jun 09, 2028	DP		
		9011905	Jun 09, 2028	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580	003	9011906	Jun 09, 2028	U-1262		
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580	004	7056890	Jun 14, 2020	DP U-1262		
		7553818	Jun 14, 2020	U-1262		
		7659256	Jun 14, 2020	DP U-1262		
		7674776	Jun 14, 2020	DP U-1262		
		8580298	May 15, 2029	DP		
		8580299	Jun 14, 2029	U-1262		
		8895057	Jun 09, 2028	U-1262		
		8895058	Jun 09, 2028	DP		
		9011905	Jun 09, 2028	DP		
		9011906	Jun 09, 2028	U-1262		
<u>PHENTOLAMINE MESYLATE - ORAVERSE</u>						
N 022159	001	6764678	May 11, 2021	U-967		
		6872390	May 11, 2021	DP		
		7229630	Jun 20, 2023	DP		
		7569230	Oct 17, 2023	U-967		
		7575757	Apr 21, 2025	DP		
<u>PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE</u>						
N 203510	001	8859623	Nov 14, 2033	U-1594		
<u>PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE</u>						
N 203510	002	8859623	Nov 14, 2033	U-1594		
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318	001	10028944	Jan 15, 2024	U-1974	NCE	Apr 29, 2021
		6756393	Mar 06, 2021	DS DP		
		6815458	Mar 06, 2021	DS DP	U-1843	
		7115634	Oct 06, 2021	DS DP		
		7601740	Jun 17, 2027	DS DP		
		7659285	Aug 24, 2026	U-1844		
		7732615	Jun 03, 2028	DS DP		
		7858789	Dec 13, 2020	DS DP		
		7923564	Sep 26, 2025	DS DP		
		8110574	Dec 13, 2020	DS DP		
		8618130	Jan 15, 2024	U-1845		
		8921393	Jan 15, 2024	U-1846		
		9296694	Mar 06, 2021	DS DP		
		9566271	Jan 15, 2024	U-1974		
		9765053	Jul 27, 2022	U-1974		
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318	002	10028944	Jan 15, 2024	U-1974	NCE	Apr 29, 2021
		10517860	Mar 23, 2037	U-1974		
		6756393	Mar 06, 2021	DS DP		
		6815458	Mar 06, 2021	DS DP	U-1843	
		7115634	Oct 06, 2021	DS DP		
		7601740	Jun 17, 2027	DS DP		
		7659285	Aug 24, 2026	U-1844		
		7732615	Jun 03, 2028	DS DP		
		7858789	Dec 13, 2020	DS DP		
		7923564	Sep 26, 2025	DS DP		
		8110574	Dec 13, 2020	DS DP		
		8618130	Jan 15, 2024	U-1845		
		8921393	Jan 15, 2024	U-1846		
		9296694	Mar 06, 2021	DS DP		
		9566271	Jan 15, 2024	U-1974		
		9765053	Jul 27, 2022	U-1974		
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 210793	001	10028944	Jan 15, 2024	U-1974	NCE	Apr 29, 2021
		10449185	Aug 27, 2038	DP		
		10646480	Aug 27, 2038	DP		
		10849891	Aug 27, 2038	DP U-1974		
		6756393	Mar 06, 2021	DS DP		
		6815458	Mar 06, 2021	DS DP	U-1843	
		7115634	Oct 06, 2021	DS DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 210793	001	7601740	Jun 17, 2027	DS DP		
		7659285	Aug 24, 2026		U-1844	
		7732615	Jun 03, 2028	DS DP		
		7858789	Dec 13, 2020	DS DP		
		7923564	Sep 26, 2025	DS DP		
		8110574	Dec 13, 2020	DS DP		
		8618130	Jan 15, 2024		U-1845	
		8921393	Jan 15, 2024		U-1846	
		9296694	Mar 06, 2021	DS DP		
		9566271	Jan 15, 2024		U-1974	
		9765053	Jul 27, 2022		U-1974	
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N 050684	001	6900184	Apr 14, 2023	DP	U-282	
		7915229	Apr 14, 2023	DP		
		8133883	Apr 14, 2023	DP	U-282	
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N 050684	002	6900184	Apr 14, 2023	DP	U-282	
		7915229	Apr 14, 2023	DP		
		8133883	Apr 14, 2023	DP	U-282	
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N 050684	003	6900184	Apr 14, 2023	DP	U-282	
		7915229	Apr 14, 2023	DP		
		8133883	Apr 14, 2023	DP	U-282	
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N 050684	004	6900184	Apr 14, 2023	DP	U-282	
		7915229	Apr 14, 2023	DP		
		8133883	Apr 14, 2023	DP	U-282	
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N 050750	001	6900184	Apr 14, 2023	DP	U-282	
		7915229	Apr 14, 2023	DP		
		8133883	Apr 14, 2023	DP	U-282	
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N 050750	002	6900184	Apr 14, 2023	DP	U-282	
		7915229	Apr 14, 2023	DP		
		8133883	Apr 14, 2023	DP	U-282	
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N 050750	003	6900184	Apr 14, 2023	DP	U-282	
		7915229	Apr 14, 2023	DP		
		8133883	Apr 14, 2023	DP	U-282	
<u>PIRFENIDONE - ESBRIET</u>						
N 022535	001	7566729	Apr 22, 2029		U-1600	
		7635707	Apr 22, 2029		U-1609	
		7696236	Dec 18, 2027		U-1601	
		7767225	Sep 22, 2026	DP	U-1602	
		7767700	Dec 18, 2027		U-1601	
		7816383	Jan 08, 2030		U-1603	
		7910610	Jan 08, 2030		U-1604	
		7988994	Sep 22, 2026	DP	U-1602	
		8013002	Jan 08, 2030		U-1603	
		8084475	Jan 08, 2030		U-1605	
		8318780	Jan 08, 2030		U-1606	
		8383150	Sep 22, 2026	DP	U-2361	
		8420674	Dec 18, 2027	DP	U-1608	
		8592462	Apr 22, 2029		U-1609	
		8609701	Apr 22, 2029		U-1610	
		8648098	Jan 08, 2030		U-1611	
		8753679	Sep 22, 2026	DP	U-1602	
		8754109	Jan 08, 2030		U-1612	
		8778947	Aug 30, 2033		U-1613	

ODE-77 Oct 15, 2021

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PIRFENIDONE - ESBRIET</u>						
N 208780	001	10188637				
		Mar 28, 2037		DP	ODE-77	Oct 15, 2021
		7566729	Apr 22, 2029	U-2077		
		7566729	Apr 22, 2029	U-2078		
		7635707	Apr 22, 2029	U-2072		
		7635707	Apr 22, 2029	U-2073		
		7635707	Apr 22, 2029	U-2074		
		7635707	Apr 22, 2029	U-2075		
		7635707	Apr 22, 2029	U-2076		
		7635707	Apr 22, 2029	U-2083		
		7767700	Dec 18, 2027	U-2080		
		7816383	Jan 08, 2030	U-2042		
		7816383	Jan 08, 2030	U-2050		
		7910610	Jan 08, 2030	U-2048		
		7910610	Jan 08, 2030	U-2049		
		8013002	Jan 08, 2030	U-2047		
		8013002	Jan 08, 2030	U-2082		
		8084475	Jan 08, 2030	U-2052		
		8084475	Jan 08, 2030	U-2054		
		8318780	Jan 08, 2030	U-2046		
		8318780	Jan 08, 2030	U-2081		
		8383150	Sep 22, 2026	DP U-2361		
		8420674	Dec 18, 2027	U-2079		
		8592462	Apr 22, 2029	U-2055		
		8592462	Apr 22, 2029	U-2056		
		8592462	Apr 22, 2029	U-2057		
		8592462	Apr 22, 2029	U-2058		
		8592462	Apr 22, 2029	U-2059		
		8592462	Apr 22, 2029	U-2060		
		8592462	Apr 22, 2029	U-2061		
		8592462	Apr 22, 2029	U-2062		
		8592462	Apr 22, 2029	U-2063		
		8609701	Apr 22, 2029	U-2064		
		8609701	Apr 22, 2029	U-2065		
		8609701	Apr 22, 2029	U-2066		
		8609701	Apr 22, 2029	U-2067		
		8609701	Apr 22, 2029	U-2068		
		8609701	Apr 22, 2029	U-2069		
		8609701	Apr 22, 2029	U-2070		
		8648098	Jan 08, 2030	U-2051		
		8648098	Jan 08, 2030	U-2052		
		8754109	Jan 08, 2030	U-2053		
		8778947	Aug 30, 2033	U-2044		
		8778947	Aug 30, 2033	U-2045		
		9561217	Jan 25, 2022	DP		
<u>PIRFENIDONE - ESBRIET</u>						
N 208780	002	10188637				
		Mar 28, 2037		DP	ODE-77	Oct 15, 2021
		7566729	Apr 22, 2029	U-2269		
		7566729	Apr 22, 2029	U-2270		
		7635707	Apr 22, 2029	U-2072		
		7635707	Apr 22, 2029	U-2073		
		7635707	Apr 22, 2029	U-2074		
		7635707	Apr 22, 2029	U-2075		
		7635707	Apr 22, 2029	U-2076		
		7635707	Apr 22, 2029	U-2083		
		7767700	Dec 18, 2027	U-2080		
		7816383	Jan 08, 2030	U-2042		
		7816383	Jan 08, 2030	U-2050		
		7910610	Jan 08, 2030	U-2048		
		7910610	Jan 08, 2030	U-2049		
		8013002	Jan 08, 2030	U-2047		
		8013002	Jan 08, 2030	U-2082		
		8084475	Jan 08, 2030	U-2054		
		8084475	Jan 08, 2030	U-2268		
		8318780	Jan 08, 2030	U-2046		
		8318780	Jan 08, 2030	U-2081		
		8383150	Sep 22, 2026	DP U-2361		
		8420674	Dec 18, 2027	U-2079		
		8592462	Apr 22, 2029	U-2055		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 002	8592462	Apr 22, 2029	U-2056			
	8592462	Apr 22, 2029	U-2057			
	8592462	Apr 22, 2029	U-2058			
	8592462	Apr 22, 2029	U-2059			
	8592462	Apr 22, 2029	U-2060			
	8592462	Apr 22, 2029	U-2061			
	8592462	Apr 22, 2029	U-2062			
	8592462	Apr 22, 2029	U-2063			
	8609701	Apr 22, 2029	U-2064			
	8609701	Apr 22, 2029	U-2065			
	8609701	Apr 22, 2029	U-2066			
	8609701	Apr 22, 2029	U-2067			
	8609701	Apr 22, 2029	U-2068			
	8609701	Apr 22, 2029	U-2069			
	8609701	Apr 22, 2029	U-2070			
	8648098	Jan 08, 2030	U-2051			
	8648098	Jan 08, 2030	U-2052			
	8754109	Jan 08, 2030	U-2053			
	8778947	Aug 30, 2033	U-2044			
	8778947	Aug 30, 2033	U-2045			
	9561217	Jan 25, 2022	DP			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 003	10188637	Mar 28, 2037	DP		ODE-77	Oct 15, 2021
	7566729	Apr 22, 2029	U-2077			
	7566729	Apr 22, 2029	U-2078			
	7635707	Apr 22, 2029	U-2072			
	7635707	Apr 22, 2029	U-2073			
	7635707	Apr 22, 2029	U-2074			
	7635707	Apr 22, 2029	U-2075			
	7635707	Apr 22, 2029	U-2076			
	7635707	Apr 22, 2029	U-2083			
	7767700	Dec 18, 2027	U-2080			
	7816383	Jan 08, 2030	U-2042			
	7816383	Jan 08, 2030	U-2050			
	7910610	Jan 08, 2030	U-2048			
	7910610	Jan 08, 2030	U-2049			
	8013002	Jan 08, 2030	U-2047			
	8013002	Jan 08, 2030	U-2082			
	8084475	Jan 08, 2030	U-2052			
	8084475	Jan 08, 2030	U-2054			
	8318780	Jan 08, 2030	U-2046			
	8318780	Jan 08, 2030	U-2081			
	8383150	Sep 22, 2026	DP U-2361			
	8420674	Dec 18, 2027	U-2079			
	8592462	Apr 22, 2029	U-2055			
	8592462	Apr 22, 2029	U-2056			
	8592462	Apr 22, 2029	U-2057			
	8592462	Apr 22, 2029	U-2058			
	8592462	Apr 22, 2029	U-2059			
	8592462	Apr 22, 2029	U-2060			
	8592462	Apr 22, 2029	U-2061			
	8592462	Apr 22, 2029	U-2062			
	8592462	Apr 22, 2029	U-2063			
	8609701	Apr 22, 2029	U-2064			
	8609701	Apr 22, 2029	U-2065			
	8609701	Apr 22, 2029	U-2066			
	8609701	Apr 22, 2029	U-2067			
	8609701	Apr 22, 2029	U-2068			
	8609701	Apr 22, 2029	U-2069			
	8609701	Apr 22, 2029	U-2070			
	8648098	Jan 08, 2030	U-2051			
	8648098	Jan 08, 2030	U-2052			
	8754109	Jan 08, 2030	U-2053			
	8778947	Aug 30, 2033	U-2044			
	8778947	Aug 30, 2033	U-2045			
	9561217	Jan 25, 2022	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 001	5856336	Dec 25, 2020	DS U-998		NPP	May 16, 2022
	5856336*PED	Jun 25, 2021			PED	Nov 16, 2022
	7022713	Feb 19, 2024		U-998		
	7022713*PED	Aug 19, 2024				
	8557993	Feb 02, 2024	DP			
	8557993*PED	Aug 02, 2024				
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 002	5856336	Dec 25, 2020	DS U-998		NPP	May 16, 2022
	5856336*PED	Jun 25, 2021			PED	Nov 16, 2022
	7022713	Feb 19, 2024		U-998		
	7022713*PED	Aug 19, 2024				
	8557993	Feb 02, 2024	DP			
	8557993*PED	Aug 02, 2024				
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 003	5856336	Dec 25, 2020	DS U-998		NPP	May 16, 2022
	5856336*PED	Jun 25, 2021			PED	Nov 16, 2022
	7022713	Feb 19, 2024		U-998		
	7022713*PED	Aug 19, 2024				
	8557993	Feb 02, 2024	DP			
	8557993*PED	Aug 02, 2024				
<u>PITAVASTATIN MAGNESIUM - ZYPITAMAG</u>						
N 208379 001	8829186	Jan 19, 2031	DS DP			
<u>PITAVASTATIN MAGNESIUM - ZYPITAMAG</u>						
N 208379 002	8829186	Jan 19, 2031	DS DP			
<u>PITAVASTATIN MAGNESIUM - ZYPITAMAG</u>						
N 208379 003	8829186	Jan 19, 2031	DS DP			
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 001	7169928	Feb 02, 2020	DS DP		I-846	Oct 13, 2023
	7910605	Sep 23, 2022		U-1101	NCE	Aug 14, 2024
	7910605	Sep 23, 2022		U-1102	ODE-255	Aug 14, 2026
	8207197	Feb 25, 2029	DS DP			
	8354430	Feb 06, 2026		U-1101		
	8354430	Feb 06, 2026		U-1102		
	8486947	Sep 26, 2029		U-1101		
	8486947	Sep 26, 2029		U-1102		
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 002	7169928	Feb 02, 2020	DS DP		I-846	Oct 13, 2023
	7910605	Sep 23, 2022		U-1101	NCE	Aug 14, 2024
	7910605	Sep 23, 2022		U-1102	ODE-255	Aug 14, 2026
	8207197	Feb 25, 2029	DS DP			
	8354430	Feb 06, 2026		U-1101		
	8354430	Feb 06, 2026		U-1102		
	8486947	Sep 26, 2029		U-1101		
	8486947	Sep 26, 2029		U-1102		
<u>PLAZOMICIN SULFATE - ZEMDRI</u>						
N 210303 001	8383596	Jun 02, 2031	DS U-2328		NCE	Jun 25, 2023
	8822424	Nov 21, 2028		DP	GAIN	Jun 25, 2028
	9266919	Nov 21, 2028		U-2328		
	9688711	Nov 21, 2028	DS	U-2328		
<u>PLECANATIDE - TRULANCE</u>						
N 208745 001	10011637	Jun 05, 2034	DS		I-764	Jan 24, 2021
	7041786	Jan 30, 2028	DS		NCE	Jan 19, 2022
	7799897	Jun 09, 2022	DS			
	8637451	Mar 28, 2022		U-1964		
	9610321	Sep 15, 2031		U-1999		
	9610321	Sep 15, 2031		U-2230		
	9616097	Aug 20, 2032	DP			
	9919024	Sep 15, 2031		U-1999		
	9919024	Sep 15, 2031		U-2230		
	9925231	Sep 15, 2031	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PLERIXAFOR - MOZOBIL</u>						
N 022311	001	6987102	Jul 22, 2023	U-936		
		7897590	Jul 22, 2023	U-936		
<u>POLIDOCANOL - VARITHENA</u>						
N 205098	001	6572873	May 26, 2020	U-1461		
		6846412	Jul 19, 2022	DP		
		6942165	May 26, 2020	DP		
		7025290	May 26, 2020	DP	U-1461	
		7357336	May 26, 2020	U-1461		
		7604185	May 26, 2020	DS DP	U-1462	
		7731986	Nov 17, 2024	DS DP	U-1463	
		7814943	Nov 19, 2027	DP	U-1461	
		7842282	May 26, 2020	U-1461		
		7842283	May 26, 2020	DP		
		8122917	Sep 09, 2024	DP		
		8323677	May 26, 2020	DS		
		8734833	May 26, 2020	DS DP		
		9480652	May 12, 2032	DP		
<u>POMALIDOMIDE - POMALYST</u>						
N 204026	001	10555939	May 19, 2030	DP	ODE-296	May 14, 2027
		10555939*PED	Nov 19, 2030		ODE-297	May 14, 2027
		6315720	Oct 23, 2020	U-1361	ODE-43	Feb 08, 2020
		6561977	Oct 23, 2020	U-1361	PED	Nov 14, 2027
		6755784	Oct 23, 2020	U-1361	PED	Nov 14, 2027
		8198262	Jun 17, 2025	U-1360		
		8198262	Jun 17, 2025	U-2254		
		8198262*PED	Dec 17, 2025			
		8315886	Oct 23, 2020	U-1361		
		8626531	Oct 23, 2020	U-1361		
		8673939	May 15, 2023	U-1360		
		8673939	May 15, 2023	U-2254		
		8673939*PED	Nov 15, 2023			
		8735428	May 15, 2023	U-1360		
		8735428	May 15, 2023	U-2254		
		8735428*PED	Nov 15, 2023			
		8828427	Jun 21, 2031	DS DP		
		8828427*PED	Dec 21, 2031			
		9993467	May 19, 2030	DP		
		9993467*PED	Nov 19, 2030			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026	002	10555939	May 19, 2030	DP	ODE-296	May 14, 2027
		10555939*PED	Nov 19, 2030		ODE-297	May 14, 2027
		6315720	Oct 23, 2020	U-1361	ODE-43	Feb 08, 2020
		6561977	Oct 23, 2020	U-1361	PED	Nov 14, 2027
		6755784	Oct 23, 2020	U-1361	PED	Nov 14, 2027
		8198262	Jun 17, 2025	U-1360		
		8198262	Jun 17, 2025	U-2254		
		8198262*PED	Dec 17, 2025			
		8315886	Oct 23, 2020	U-1361		
		8626531	Oct 23, 2020	U-1361		
		8673939	May 15, 2023	U-1360		
		8673939	May 15, 2023	U-2254		
		8673939*PED	Nov 15, 2023			
		8735428	May 15, 2023	U-1360		
		8735428	May 15, 2023	U-2254		
		8735428*PED	Nov 15, 2023			
		8828427	Jun 21, 2031	DS DP		
		8828427*PED	Dec 21, 2031			
		9993467	May 19, 2030	DP		
		9993467*PED	Nov 19, 2030			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026	003	10555939	May 19, 2030	DP	ODE-296	May 14, 2027
		10555939*PED	Nov 19, 2030		ODE-297	May 14, 2027
		6315720	Oct 23, 2020	U-1361	ODE-43	Feb 08, 2020
		6561977	Oct 23, 2020	U-1361	PED	Nov 14, 2027
		6755784	Oct 23, 2020	U-1361	PED	Nov 14, 2027
		8198262	Jun 17, 2025	U-1360		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003	8198262	Jun 17, 2025	U-2254			
	8198262*PED	Dec 17, 2025				
	8315886	Oct 23, 2020	U-1361			
	8626531	Oct 23, 2020	U-1361			
	8673939	May 15, 2023	U-1360			
	8673939	May 15, 2023	U-2254			
	8673939*PED	Nov 15, 2023				
	8735428	May 15, 2023	U-1360			
	8735428	May 15, 2023	U-2254			
	8735428*PED	Nov 15, 2023				
	8828427	Jun 21, 2031	DS DP			
	8828427*PED	Dec 21, 2031				
	9993467	May 19, 2030	DP			
	9993467*PED	Nov 19, 2030				
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004	10555939	May 19, 2030	DP		ODE-296	May 14, 2027
	10555939*PED	Nov 19, 2030			ODE-297	May 14, 2027
	6315720	Oct 23, 2020	U-1361		ODE-43	Feb 08, 2020
	6561977	Oct 23, 2020	U-1361		PED	Nov 14, 2027
	6755784	Oct 23, 2020	U-1361		PED	Nov 14, 2027
	8198262	Jun 17, 2025	U-1360			
	8198262	Jun 17, 2025	U-2254			
	8198262*PED	Dec 17, 2025				
	8315886	Oct 23, 2020	U-1361			
	8626531	Oct 23, 2020	U-1361			
	8673939	May 15, 2023	U-1360			
	8673939	May 15, 2023	U-2254			
	8673939*PED	Nov 15, 2023				
	8735428	May 15, 2023	U-1360			
	8735428	May 15, 2023	U-2254			
	8735428*PED	Nov 15, 2023				
	8828427	Jun 21, 2031	DS DP			
	8828427*PED	Dec 21, 2031				
	9993467	May 19, 2030	DP			
	9993467*PED	Nov 19, 2030				
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001	8114874	Dec 22, 2026	DS DP			
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
	9029533	Dec 22, 2026	U-836			
	9493470	Dec 12, 2033	DS DP U-1700			
	9493470	Dec 12, 2033	DS DP U-1948			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002	8114874	Dec 22, 2026	DS DP			
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
	9029533	Dec 22, 2026	U-836			
	9493470	Dec 12, 2033	DS DP U-1700			
	9493470	Dec 12, 2033	DS DP U-1948			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 003	8114874	Dec 22, 2026	DS DP			
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
	9029533	Dec 22, 2026	U-836			
	9493470	Dec 12, 2033	DS DP U-1700			
	9493470	Dec 12, 2033	DS DP U-1948			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>POSACONAZOLE - NOXAFIL</u>						
N 022003	001 8263600	Apr 01, 2022	DP			
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596	001 10117951	Mar 13, 2029	DP			
	8410077	Mar 13, 2029	DP			
	9023790	Jul 04, 2031	DP		U-1698	
	9358297	Jun 24, 2031	DP		U-1454	
	9493582	Feb 27, 2033	DP			
	9750822	Mar 13, 2029	DP			
<u>POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC - POTASSIUM PHOSPHATES</u>						
N 212121	001 10632150	Apr 19, 2039	DP		U-2789	
<u>PRALATREXATE - FOLOTYN</u>						
N 022468	001 6028071	Jul 16, 2022	DS DP		U-1004	
	7622470	May 31, 2025			U-1015	
	8299078	May 31, 2025			U-1004	
<u>PRALATREXATE - FOLOTYN</u>						
N 022468	002 6028071	Jul 16, 2022	DS DP		U-1004	
	7622470	May 31, 2025			U-1015	
	8299078	May 31, 2025			U-1004	
<u>PRALSETINIB - GAVRETO</u>						
N 213721	001 10030005	Nov 01, 2036	DS DP		U-2827	
	10030005	Nov 01, 2036	DS DP		U-2952	
	10030005	Nov 01, 2036	DS DP		U-3002	
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421	001 7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP		U-219	
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421	002 7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP		U-219	
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421	003 7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP		U-219	
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421	004 7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP		U-219	
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421	005 7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP		U-219	
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421	006 7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP		U-219	
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421	007 7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP		U-219	
<u>PRASTERONE - INTRAROSA</u>						
N 208470	001 8268806	Mar 19, 2031	DP			
	8629129	Aug 07, 2028	DP			
	8957054	Aug 07, 2028			U-1922	
<u>PREDNISOLONE ACETATE - FLO-PRED</u>						
N 022067	001 7799331	Oct 11, 2028	DP		U-1068	
	7799331	Oct 11, 2028	DP		U-139	
<u>PREDNISOLONE ACETATE - FLO-PRED</u>						
N 022067	002 7799331	Oct 11, 2028	DP		U-1068	
	7799331	Oct 11, 2028	DP		U-139	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PREDNISONE - RAYOS</u>						
N 202020	001	6488960	Mar 14, 2020	DP U-1267		
		6677326	Mar 14, 2020	DP U-1268		
		8309124	Apr 23, 2024	U-1292		
		8394407	Apr 23, 2024	DP U-1362		
		9040085	Apr 23, 2024	U-1362		
		9186332	Apr 23, 2024	U-1362		
		9504699	Aug 03, 2027	U-1362		
<u>PREDNISONE - RAYOS</u>						
N 202020	002	6488960	Mar 14, 2020	DP U-1267		
		6677326	Mar 14, 2020	DP U-1268		
		8309124	Apr 23, 2024			
		8394407	Apr 23, 2024	DP U-1362		
		9040085	Apr 23, 2024	U-1362		
		9186332	Apr 23, 2024	U-1362		
		9504699	Aug 03, 2027	U-1362		
<u>PREDNISONE - RAYOS</u>						
N 202020	003	8168218	Jan 07, 2028	DP U-1269		
		8309124	Apr 23, 2024	U-1292		
		8394407	Apr 23, 2024	DP U-1362		
		9040085	Apr 23, 2024	U-1362		
		9186332	Apr 23, 2024	U-1362		
		9504699	Aug 03, 2027	U-1362		
<u>PREGABALIN - LYRICA</u>						
N 021446	001				NPP	May 03, 2021
					NPP	May 23, 2022
					PED	Nov 03, 2021
					PED	Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446	002				NPP	May 03, 2021
					NPP	May 23, 2022
					PED	Nov 03, 2021
					PED	Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446	003				NPP	May 03, 2021
					NPP	May 23, 2022
					PED	Nov 03, 2021
					PED	Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446	004				NPP	May 03, 2021
					NPP	May 23, 2022
					PED	Nov 03, 2021
					PED	Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446	005				NPP	May 03, 2021
					NPP	May 23, 2022
					PED	Nov 03, 2021
					PED	Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446	006				NPP	May 03, 2021
					NPP	May 23, 2022
					PED	Nov 03, 2021
					PED	Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446	007				NPP	May 03, 2021
					NPP	May 23, 2022
					PED	Nov 03, 2021
					PED	Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446	008				NPP	May 03, 2021
					NPP	May 23, 2022

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PREGABALIN - LYRICA</u>						
N 021446	008				PED	Nov 03, 2021
					PED	Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 022488	001				NPP	May 03, 2021
					NPP	May 23, 2022
					PED	Nov 03, 2021
					PED	Nov 23, 2022
<u>PREGABALIN - LYRICA CR</u>						
N 209501	001	10022447	Nov 02, 2026	U-2136	NP	Oct 11, 2020
		10022447	Nov 02, 2026	U-2137	PED	Apr 11, 2021
		10022447*PED	May 02, 2027			
		8945620	Nov 02, 2026	DP U-2136		
		8945620	Nov 02, 2026	DP U-2137		
		8945620*PED	May 02, 2027			
		9144559	Nov 02, 2026	DP		
		9144559*PED	May 02, 2027			
<u>PREGABALIN - LYRICA CR</u>						
N 209501	002	10022447	Nov 02, 2026	U-2136	NP	Oct 11, 2020
		10022447	Nov 02, 2026	U-2137	PED	Apr 11, 2021
		10022447*PED	May 02, 2027			
		8945620	Nov 02, 2026	DP U-2136		
		8945620	Nov 02, 2026	DP U-2137		
		8945620*PED	May 02, 2027			
		9144559	Nov 02, 2026	DP		
		9144559*PED	May 02, 2027			
<u>PREGABALIN - LYRICA CR</u>						
N 209501	003	10022447	Nov 02, 2026	U-2136	NP	Oct 11, 2020
		10022447	Nov 02, 2026	U-2137	PED	Apr 11, 2021
		10022447*PED	May 02, 2027			
		8945620	Nov 02, 2026	DP U-2136		
		8945620	Nov 02, 2026	DP U-2137		
		8945620*PED	May 02, 2027			
		9144559	Nov 02, 2026	DP		
		9144559*PED	May 02, 2027			
<u>PRETOMANID - PRETOMANID</u>						
N 212862	001				NCE	Aug 14, 2024
					ODE-253	Aug 14, 2026
					GAIN	Aug 14, 2029
<u>PROGESTERONE - MILPROSA</u>						
N 201110	001	10537584	Feb 03, 2029	DP	NP	Apr 29, 2023
		10548904	Feb 03, 2029	U-2810		
		8580293	Jan 21, 2030	U-2810		
<u>PROPOFOL - DIPRIVAN</u>						
N 019627	002	8476010	Dec 01, 2024	DS DP		
		8476010*PED	Jun 01, 2025			
<u>PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL</u>						
N 021438	001	6500454	Oct 04, 2021	DP		
<u>PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL</u>						
N 021438	002	6500454	Oct 04, 2021	DP		
<u>PROPRANOLOL HYDROCHLORIDE - HEMANGEOL</u>						
N 205410	001	8338489	Oct 16, 2028	U-1496	ODE-62	Mar 14, 2021
		8987262	Oct 16, 2028	U-1988		
<u>PRUCALOPRIDE SUCCINATE - MOTEGRITY</u>						
N 210166	001				NCE	Dec 14, 2023
<u>PRUCALOPRIDE SUCCINATE - MOTEGRITY</u>						
N 210166	002				NCE	Dec 14, 2023

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>QUAZEPAM - DORAL</u>						
N 018708	001 7608616	Jun 03, 2028	U-1012			
<u>QUAZEPAM - DORAL</u>						
N 018708	003 7608616	Jun 03, 2028	U-1012			
<u>RADIUM RA-223 DICHLORIDE - XOFIGO</u>						
N 203971	001 6635234	Nov 17, 2022	U-2271			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 022145	001 7169780	Oct 03, 2023	DS DP		D-167	May 26, 2020
	7169780*PED	Apr 03, 2024			NPP	Nov 22, 2020
	7217713	Oct 21, 2022	U-257		PED	Nov 26, 2020
	7217713*PED	Apr 21, 2023			PED	May 22, 2021
	7435734	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-900			
	7435734*PED	Apr 21, 2023				
	7754731	Mar 11, 2029	DS DP U-257			
	7754731*PED	Sep 11, 2029				
<u>RALTEGRAVIR POTASSIUM - ISENTRESS HD</u>						
N 022145	002 10772888	Mar 30, 2032	U-1663		NPP	Nov 22, 2020
	7169780	Oct 03, 2023	DS DP		NS	May 26, 2020
	7169780*PED	Apr 03, 2024			PED	Nov 26, 2020
	7217713	Oct 21, 2022	U-257		PED	May 22, 2021
	7217713*PED	Apr 21, 2023				
	7435734	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-900			
	7435734*PED	Apr 21, 2023				
	7754731	Mar 11, 2029	DS DP U-257			
	7754731*PED	Sep 11, 2029				
	9649311	Oct 21, 2030	DP			
	9649311*PED	Apr 21, 2031				
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 203045	001 7169780	Oct 03, 2023	DS DP		NPP	Nov 22, 2020
	7169780*PED	Apr 03, 2024			PED	May 22, 2021
	7217713	Oct 21, 2022	U-257			
	7217713*PED	Apr 21, 2023				
	7435734	Oct 21, 2022	U-257			
	7435734*PED	Apr 21, 2023				
	7754731	Mar 11, 2029	DS DP U-257			
	7754731*PED	Sep 11, 2029				
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 203045	002 7169780	Oct 03, 2023	DS DP		NPP	Nov 22, 2020
	7169780*PED	Apr 03, 2024			PED	May 22, 2021
	7217713	Oct 21, 2022	U-257			
	7217713*PED	Apr 21, 2023				
	7435734	Oct 21, 2022	U-257			
	7435734*PED	Apr 21, 2023				
	7754731	Mar 11, 2029	DS DP U-257			
	7754731*PED	Sep 11, 2029				
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 205786	001 7169780	Oct 03, 2023	DS DP		NPP	Nov 22, 2020
	7169780*PED	Apr 03, 2024			PED	May 22, 2021
	7217713	Oct 21, 2022	U-257			
	7217713*PED	Apr 21, 2023				
	7435734	Oct 21, 2022	U-257			
	7435734*PED	Apr 21, 2023				
	7754731	Mar 11, 2029	DS DP U-257			
	7754731*PED	Sep 11, 2029				
<u>RAMELTEON - ROZEREM</u>						
N 021782	001 10098866	Nov 16, 2021	DP U-2433			
<u>RAMIPRIL - ALTACE</u>						
N 019901	001 7368469	Aug 30, 2020	U-871			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RAMIPRIL - ALTACE</u>						
N 019901	002	7368469	Aug 30, 2020	U-871		
<u>RAMIPRIL - ALTACE</u>						
N 019901	003	7368469	Aug 30, 2020	U-871		
<u>RAMIPRIL - ALTACE</u>						
N 019901	004	7368469	Aug 30, 2020	U-871		
<u>RAMIPRIL - ALTACE</u>						
N 022021	001	7368469	Aug 30, 2020	U-871		
<u>RAMIPRIL - ALTACE</u>						
N 022021	002	7368469	Aug 30, 2020	U-871		
<u>RAMIPRIL - ALTACE</u>						
N 022021	003	7368469	Aug 30, 2020	U-871		
<u>RAMIPRIL - ALTACE</u>						
N 022021	004	7368469	Aug 30, 2020	U-871		
<u>RASAGILINE MESYLATE - AZILECT</u>						
N 021641	001	7572834	Dec 05, 2026	DP		
		7815942	Aug 27, 2027	DS DP	U-219	
<u>RASAGILINE MESYLATE - AZILECT</u>						
N 021641	002	7572834	Dec 05, 2026	DP		
		7815942	Aug 27, 2027	DS DP	U-219	
<u>REGADENOSON - LEXISCAN</u>						
N 022161	001	6403567	Apr 10, 2022	DS DP	U-869	
		8106183	Feb 02, 2027	DS		M-194
		RE47301	Feb 02, 2027	DP		Jan 17, 2020
<u>REGORAFENIB - STIVARGA</u>						
N 203085	001	7351834	Jun 28, 2022	DS		
		8637553	Feb 16, 2031	DS DP	I-744	Apr 27, 2020
		8680124	Jun 02, 2030		ODE-139	Apr 27, 2024
		9458107	Apr 08, 2031	DP	ODE-44	Feb 25, 2020
		9957232	Jul 09, 2032	DS		
<u>REMDESIVIR - VEKLURY</u>						
N 214787	001	10065958	Sep 16, 2031	DS		
		10675296	Jul 10, 2038	DP	NCE	Oct 22, 2025
		10695361	Sep 16, 2036		U-2984	
		8008264	Sep 06, 2029	DS DP		
		8318682	Apr 22, 2029	DS DP		
		9724360	Oct 29, 2035	DS DP		
		9949994	Oct 29, 2035	DS		
		RE46762	Apr 22, 2029	DS DP		
<u>REMDESIVIR - VEKLURY</u>						
N 214787	002	10065958	Sep 16, 2031	DS		
		10675296	Jul 10, 2038	DP	NCE	Oct 22, 2025
		10695361	Sep 16, 2036		U-2984	
		8008264	Sep 06, 2029	DS DP		
		8318682	Apr 22, 2029	DS DP		
		9724360	Oct 29, 2035	DS DP		
		9949994	Oct 29, 2035	DS		
		RE46762	Apr 22, 2029	DS DP		
<u>REMIMAZOLAM BESYLATE - BYFAVO</u>						
N 212295	001	10052334	Nov 07, 2031		U-2968	
		10195210	Nov 07, 2031		U-2968	
		10342800	Nov 07, 2031		U-2968	
		10472365	Jul 10, 2027		U-2968	
		10722522	Nov 07, 2031		U-2968	
		9561236	Apr 30, 2033		U-2968	
		9737547	Nov 07, 2031		U-2968	
		9777007	Jul 10, 2027	DP		
		9827251	Nov 07, 2031		U-2968	
		9914738	Jul 10, 2027	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>REMIMAZOLAM BESYLATE - BYFAVO</u>						
N 212295	001	10052334	Nov 07, 2031	U-2968	NCE	Jul 02, 2025
		10195210	Nov 07, 2031	U-2968		
		10342800	Nov 07, 2031	U-2968		
		10472365	Jul 10, 2027	U-2968		
		10722522	Nov 07, 2031	U-2968		
		9561236	Apr 30, 2033	U-2968		
		9737547	Nov 07, 2031	U-2968		
		9777007	Jul 10, 2027	DP		
		9827251	Nov 07, 2031	U-2968		
		9914738	Jul 10, 2027	DP		
<u>RETAPAMULIN - ALTABAX</u>						
N 022055	001	7875630	Feb 14, 2027	DS		
		8207191	Aug 30, 2024	U-805		
		RE43390	Apr 12, 2021	DS DP	U-805	
<u>REVEFENACIN - YUPELRI</u>						
N 210598	001	10106503	Mar 10, 2025	U-2440	NCE	Nov 09, 2023
		10343995	Mar 10, 2025	U-2440		
		10550081	Jul 14, 2030	DS		
		7288657	Dec 23, 2025	DS		
		7491736	Mar 10, 2025	U-2440		
		7521041	Mar 10, 2025	U-2440		
		7550595	Mar 10, 2025	DP		
		7585879	Mar 10, 2025	DS DP	U-2440	
		7910608	Mar 10, 2025	DS DP		
		8034946	Mar 10, 2025	DP		
		8053448	Mar 10, 2025	U-2440		
		8273894	Mar 10, 2025	DP		
		8541451	Aug 25, 2031	DS		
		9765028	Jul 14, 2030	DS		
<u>RIBAVIRIN - REBETOL</u>						
N 021546	001	6790837	Apr 05, 2023	DP		
<u>RIBOCICLIB SUCCINATE - KISOALI</u>						
N 209092	001	10799506	Apr 14, 2036	DP	I-783	Jul 18, 2021
		8324225	Jun 17, 2028	DS DP	I-784	Jul 18, 2021
		8415355	Feb 19, 2031	DS DP	NCE	Mar 13, 2022
		8685980	May 25, 2030	DS DP		
		8962630	Dec 09, 2029	U-1981		
		8962630	Dec 09, 2029	U-2355		
		8962630	Dec 09, 2029	U-2356		
		9193732	Nov 09, 2031	DS DP		
		9416136	Aug 20, 2029	U-1981		
		9416136	Aug 20, 2029	U-2355		
		9416136	Aug 20, 2029	U-2356		
		9868739	Nov 09, 2031	U-1981		
		9868739	Nov 09, 2031	U-2355		
		9868739	Nov 09, 2031	U-2356		
<u>RIBOFLAVIN 5'-PHOSPHATE SODIUM - PHOTREXA</u>						
N 203324	001				ODE-116	Apr 15, 2023
					ODE-121	Jul 15, 2023
<u>RIBOFLAVIN 5'-PHOSPHATE SODIUM - PHOTREXA VISCOUS IN DEXTRAN 20%</u>						
N 203324	002				ODE-116	Apr 15, 2023
					ODE-121	Jul 15, 2023
<u>RIFAMYCIN SODIUM - AEMCOLO</u>						
N 210910	001	8263120	May 03, 2025	DP		
		8486446	May 03, 2025	DP		
		8529945	May 03, 2025	DP		
		8741948	May 03, 2025	DP	U-2448	
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361	001	10703763	Feb 27, 2026	U-1708		
		10703763	Feb 27, 2026	U-2847		
		10703763	Feb 27, 2026	U-2848		
		7045620	Jun 19, 2024	DS DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361	001 7612199	Jun 19, 2024	DS DP			
	7902206	Jun 19, 2024	DS DP			
	7906542	Jun 01, 2025	DS DP			
	7928115	Jul 24, 2029		U-1121		
	8158644	Jun 19, 2024	DP			
	8158781	Jun 19, 2024	DS			
	8193196	Sep 02, 2027	DS DP			
	8518949	Feb 27, 2026	DP			
	8741904	Feb 27, 2026	DS	U-1526		
	8835452	Jun 19, 2024	DS DP			
	8853231	Jun 19, 2024	DP			
	9271968	Feb 27, 2026	DP			
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554	001 10314828	Jul 24, 2029		U-1481		
	10335397	Jul 24, 2029		U-2579		
	10456384	Feb 26, 2029		U-2643		
	10456384	Feb 26, 2029		U-2644		
	10703763	Feb 27, 2026		U-1708		
	10703763	Feb 27, 2026		U-2847		
	10703763	Feb 27, 2026		U-2848		
	10709694	Jul 24, 2029		U-2579		
	10765667	Feb 26, 2029		U-2643		
	10765667	Feb 26, 2029		U-2644		
	7045620	Jun 19, 2024	DS			
	7612199	Jun 19, 2024	DS DP			
	7902206	Jun 19, 2024	DS DP			
	7906542	Jun 01, 2025	DS DP			
	7915275	Feb 23, 2025		U-1707		
	7915275	Feb 23, 2025		U-1708		
	8158644	Jun 19, 2024	DP			
	8158781	Jun 19, 2024	DS			
	8193196	Sep 02, 2027	DS DP	U-1707		
	8193196	Sep 02, 2027	DS DP	U-1708		
	8309569	Jul 18, 2029		U-1707		
	8309569	Jul 18, 2029		U-1708		
	8518949	Feb 27, 2026	DP			
	8642573	Oct 02, 2029		U-1481		
	8741904	Feb 27, 2026	DS	U-1526		
	8741904	Feb 27, 2026	DS	U-1707		
	8741904	Feb 27, 2026	DS	U-1708		
	8829017	Jul 24, 2029		U-1562		
	8835452	Jun 19, 2024	DS DP			
	8853231	Jun 19, 2024	DP			
	8946252	Jul 24, 2029		U-1481		
	8969398	Oct 02, 2029		U-1481		
	9271968	Feb 27, 2026	DP			
	9421195	Jul 24, 2029		U-1481		
	9629828	Jul 24, 2029		U-1994		
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022	001 6838464	Feb 26, 2021	DS DP		M-223	Feb 01, 2021
	7125879	Apr 21, 2025	DS DP	U-1153		
	7125879	Apr 21, 2025	DS DP	U-1307		
	7125879	Apr 21, 2025	DS DP	U-1740		
	7638522	Apr 14, 2023	DP			
	8080551	Apr 11, 2023	DS DP			
	8101629	Aug 09, 2022	DP			
<u>RILUZOLE - TIGLUTIK KIT</u>						
N 209080	001 8765150	Mar 12, 2029	DP	U-2401		
<u>RILUZOLE - EXSERVAN</u>						
N 212640	001 8603514	Apr 03, 2024	DP			
	8765167	Feb 20, 2024	DP			
<u>RIMEGEPANT SULFATE - NURTEC ODT</u>						
N 212728	001 8314117	Feb 22, 2031	DS DP	U-2718	NCE	Feb 27, 2025
	8759372	Feb 25, 2033	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 001	10662188	Feb 18, 2034	DS DP U-2834		ODE-53	Oct 08, 2020
	10662188	Feb 18, 2034	DS DP U-2835			
	7173037	Dec 04, 2026	DS DP			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 002	10662188	Feb 18, 2034	DS DP U-2834		ODE-53	Oct 08, 2020
	10662188	Feb 18, 2034	DS DP U-2835			
	7173037	Dec 04, 2026	DS DP			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 003	10662188	Feb 18, 2034	DS DP U-2834		ODE-53	Oct 08, 2020
	10662188	Feb 18, 2034	DS DP U-2835			
	7173037	Dec 04, 2026	DS DP			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 004	10662188	Feb 18, 2034	DS DP U-2834		ODE-53	Oct 08, 2020
	10662188	Feb 18, 2034	DS DP U-2835			
	7173037	Dec 04, 2026	DS DP			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 005	10662188	Feb 18, 2034	DS DP U-2834		ODE-53	Oct 08, 2020
	10662188	Feb 18, 2034	DS DP U-2835			
	7173037	Dec 04, 2026	DS DP			
<u>RIPRETINIB - QINLOCK</u>						
N 213973 001	8188113	Jul 27, 2030	DS DP		NCE	May 15, 2025
	8461179	Jun 07, 2032	DS DP		ODE-298	May 15, 2027
	8940756	Jun 07, 2032	U-2829			
<u>RISDIPLAM - EVRYSDI</u>						
N 213535 001	9586955	Feb 08, 2033	DS DP		NCE	Aug 07, 2025
	9969754	May 11, 2035	DS DP U-1943			
<u>RISEDRONATE SODIUM - ACTONEL</u>						
N 020835 005	7192938	May 06, 2023		U-353		
	7718634	May 06, 2023		U-662		
<u>RISEDRONATE SODIUM - ATELVIA</u>						
N 022560 001	7645459	Jan 09, 2028	DP U-662			
	7645460	Jan 09, 2028	DP U-662			
	8246989	Jan 16, 2026	DP			
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
N 021346 001	6667061	May 25, 2020	DP			
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
N 021346 002	6667061	May 25, 2020	DP			
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
N 021346 003	6667061	May 25, 2020	DP			
<u>RISPERIDONE - PERSERIS KIT</u>						
N 210655 001	10010612	Feb 13, 2028	DP		NP	Jul 27, 2021
	10058554	Sep 26, 2026	U-2363			
	10376590	Feb 13, 2028	U-2608			
	10406160	Jun 26, 2026	DP U-2608			
	9180197	Feb 13, 2028	DP			
	9186413	Feb 13, 2028	U-543			
	9597402	Sep 26, 2026	DP			
<u>RISPERIDONE - PERSERIS KIT</u>						
N 210655 002	10010612	Feb 13, 2028	DP		NP	Jul 27, 2021
	10058554	Sep 26, 2026	U-2363			
	10376590	Feb 13, 2028	U-2608			
	10406160	Jun 26, 2026	DP U-2608			
	9180197	Feb 13, 2028	DP			
	9186413	Feb 13, 2028	U-543			
	9597402	Sep 26, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	7157456	Aug 28, 2024	DS DP U-1301		D-168	Oct 27, 2020
	7157456	Aug 28, 2024	DS DP U-1302		I-810	Oct 11, 2022
	7585860	Dec 11, 2020	DS			
	7592339	Dec 11, 2020		U-1167		
	7592339	Dec 11, 2020		U-1200		
	7592339	Dec 11, 2020		U-1301		
	7592339	Dec 11, 2020		U-1302		
	7592339	Dec 11, 2020		U-1303		
	7592339	Dec 11, 2020		U-2142		
	7592339	Dec 11, 2020		U-2640		
	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-2142			
	9415053	Nov 13, 2024	DP U-2640			
	9539218	Feb 17, 2034		U-1957		
	9539218	Feb 17, 2034		U-2143		
	9539218	Feb 17, 2034		U-2641		
<u>RIVAROXABAN - XARELTO</u>						
N 022406 002	7157456	Aug 28, 2024	DS DP U-1301		I-810	Oct 11, 2022
	7157456	Aug 28, 2024	DS DP U-1302			
	7585860	Dec 11, 2020	DS			
	7592339	Dec 11, 2020		U-1167		
	7592339	Dec 11, 2020		U-1200		
	7592339	Dec 11, 2020		U-1301		
	7592339	Dec 11, 2020		U-1302		
	7592339	Dec 11, 2020		U-1303		
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9539218	Feb 17, 2034		U-1953		
<u>RIVAROXABAN - XARELTO</u>						
N 022406 003	7157456	Aug 28, 2024	DS DP U-1301		I-810	Oct 11, 2022
	7157456	Aug 28, 2024	DS DP U-1302			
	7585860	Dec 11, 2020	DS			
	7592339	Dec 11, 2020		U-1167		
	7592339	Dec 11, 2020		U-1200		
	7592339	Dec 11, 2020		U-1301		
	7592339	Dec 11, 2020		U-1302		
	7592339	Dec 11, 2020		U-1303		
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9539218	Feb 17, 2034		U-1953		
	9539218	Feb 17, 2034		U-1954		
	9539218	Feb 17, 2034		U-1955		
<u>RIVAROXABAN - XARELTO</u>						
N 022406 004	10828310	Jan 31, 2039		U-2994	I-810	Oct 11, 2022
	7157456	Aug 28, 2024	DS DP		I-824	Oct 11, 2021
	7585860	Dec 11, 2020	DS			
	7592339	Dec 11, 2020		U-2435		
	9415053	Nov 13, 2024	DP	U-2435		
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 001	5712298	Jan 27, 2020	DS DP U-1115		D-171	Jan 23, 2021
	8431154	Feb 19, 2023		DP	M-208	Aug 31, 2020
	8536206	Mar 08, 2024		U-1115		
	8604064	Mar 08, 2024		U-1115		
	8618142	Mar 08, 2024		DP		
	9468598	Feb 19, 2023		DP		
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 002	5712298	Jan 27, 2020	DS DP U-1115		NS	Jan 23, 2021
	8431154	Feb 19, 2023		DP		
	8536206	Mar 08, 2024		U-1115		
	8604064	Mar 08, 2024		U-1115		
	8618142	Mar 08, 2024		DP		
	9468598	Feb 19, 2023		DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ROLAPITANT HYDROCHLORIDE - VARUBI</u>						
N 206500	001	7049320	Dec 08, 2023	DS DP U-1741	NCE	Sep 01, 2020
		7563801	Apr 04, 2027	DP		
		7981905	Apr 04, 2027	U-1741		
		8178550	Apr 04, 2027	DS DP		
		8361500	Oct 09, 2029	DP		
		8404702	Apr 04, 2027	U-1741		
		8470842	Jan 18, 2029	U-1741		
		8796299	Dec 17, 2022	U-1741		
<u>ROLAPITANT HYDROCHLORIDE - VARUBI</u>						
N 208399	001	7049320	Dec 08, 2023	DS DP U-1741	NCE	Sep 01, 2020
		7981905	Apr 04, 2027	U-1741		
		8178550	Apr 04, 2027	DS DP		
		8404702	Apr 04, 2027	U-1741		
		8470842	Jan 18, 2029	U-1741		
		8796299	Dec 17, 2022	U-1741		
		9101615	Jul 14, 2032	U-1741		
<u>ROMIDEPSIN - ISTODAX</u>						
N 022393	001	7608280	Aug 22, 2021	DS		
		7611724	Aug 22, 2021	DS		
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008	001	7927624	Dec 02, 2021	DP U-20	M-203	Mar 23, 2020
		8303986	Apr 12, 2021	DP		
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008	002	7927624	Dec 02, 2021	DP U-20	M-203	Mar 23, 2020
		8303986	Apr 12, 2021	DP		
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008	003	7927624	Dec 02, 2021	DP U-20	M-203	Mar 23, 2020
		8303986	Apr 12, 2021	DP		
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008	004	7927624	Dec 02, 2021	DP U-20	M-203	Mar 23, 2020
		8303986	Apr 12, 2021	DP		
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008	005	7927624	Dec 02, 2021	DP U-20	M-203	Mar 23, 2020
		8303986	Apr 12, 2021	DP		
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008	006	7927624	Dec 02, 2021	DP U-20	M-203	Mar 23, 2020
		8303986	Apr 12, 2021	DP		
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533	006	7828787	Oct 18, 2025	DP		
		7857802	Nov 28, 2026	DP		
		8118802	May 18, 2023	DP		
		8162915	May 23, 2024	DP		
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533	007	7828787	Oct 18, 2025	DP		
		7857802	Nov 28, 2026	DP		
		8118802	May 18, 2023	DP		
		8162915	May 23, 2024	DP		
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N 021071	002	7358366	Apr 19, 2020	DS	Y	
		7358366*PED	Oct 19, 2020			
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N 021071	003	7358366	Apr 19, 2020	DS	Y	
		7358366*PED	Oct 19, 2020			
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N 021071	004	7358366	Apr 19, 2020	DS	Y	
		7358366*PED	Oct 19, 2020			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 002	6316460	Aug 04, 2020	DP		ODE-118	May 27, 2023
	6858618	Dec 17, 2021	U-1032			
	6858618	Dec 17, 2021	U-1807			
	6858618	Dec 17, 2021	U-618			
	6858618*PED	Jun 17, 2022				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 003	6316460	Aug 04, 2020	DP		ODE-118	May 27, 2023
	6858618	Dec 17, 2021	U-1032			
	6858618	Dec 17, 2021	U-1807			
	6858618	Dec 17, 2021	U-618			
	6858618*PED	Jun 17, 2022				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 004	6316460	Aug 04, 2020	DP		ODE-118	May 27, 2023
	6858618	Dec 17, 2021	U-1032			
	6858618	Dec 17, 2021	U-1807			
	6858618	Dec 17, 2021	U-618			
	6858618*PED	Jun 17, 2022				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 005	6316460	Aug 04, 2020	DP		ODE-118	May 27, 2023
	6858618	Dec 17, 2021	U-618			
<u>ROSUVASTATIN CALCIUM - EZALLOR SPRINKLE</u>						
N 208647 001	10413543	Feb 12, 2036	DP			
<u>ROSUVASTATIN CALCIUM - EZALLOR SPRINKLE</u>						
N 208647 002	10413543	Feb 12, 2036	DP			
<u>ROSUVASTATIN CALCIUM - EZALLOR SPRINKLE</u>						
N 208647 003	10413543	Feb 12, 2036	DP			
<u>ROSUVASTATIN CALCIUM - EZALLOR SPRINKLE</u>						
N 208647 004	10413543	Feb 12, 2036	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 001	10130589	Dec 22, 2030	DP			
	10350174	Dec 22, 2030	DP			
	6699498	Nov 27, 2020	DP			
	6884434	Mar 30, 2021	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
	9925150	Mar 01, 2032	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 002	10130589	Dec 22, 2030	DP			
	10350174	Dec 22, 2030	DP			
	6699498	Nov 27, 2020	DP			
	6884434	Mar 30, 2021	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
	9925150	Mar 01, 2032	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 003	10130589	Dec 22, 2030	DP			
	10350174	Dec 22, 2030	DP			
	6699498	Nov 27, 2020	DP			
	6884434	Mar 30, 2021	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
	9925150	Mar 01, 2032	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 004	10130589	Dec 22, 2030	DP			
	10350174	Dec 22, 2030	DP			
	6699498	Nov 27, 2020	DP			
	6884434	Mar 30, 2021	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
	9925150	Mar 01, 2032	DP			
	<u>ROTIGOTINE - NEUPRO</u>					
N 021829 005	10130589	Dec 22, 2030	DP			
	10350174	Dec 22, 2030	DP			
	6699498	Nov 27, 2020	DP			
	6884434	Mar 30, 2021	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
	9925150	Mar 01, 2032	DP			
	<u>ROTIGOTINE - NEUPRO</u>					
N 021829 006	10130589	Dec 22, 2030	DP			
	10350174	Dec 22, 2030	DP			
	6699498	Nov 27, 2020	DP			
	6884434	Mar 30, 2021	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
	9925150	Mar 01, 2032	DP			
	<u>RUCAPARIB CAMSYLATE - RUBRACA</u>					
N 209115 001	10130636	Aug 17, 2035		U-2012	I-772	Apr 06, 2021
	10130636	Aug 17, 2035		U-2101	I-830	May 15, 2023
	10130636	Aug 17, 2035		U-2273	NCE	Dec 19, 2021
	10130636	Aug 17, 2035		U-2830	ODE-126	Dec 19, 2023
	10278974	Feb 10, 2031	DP		ODE-168	Apr 06, 2025
	6495541	Nov 22, 2023	DS DP			
	7351701	Jul 23, 2024		U-2012		
	7351701	Jul 23, 2024		U-2273		
	7351701	Jul 23, 2024		U-2830		
	7531530	Jul 23, 2024		U-2012		
	7531530	Jul 23, 2024		U-2273		
	7531530	Jul 23, 2024		U-2830		
	8071579	Aug 12, 2027		U-2012		
	8071579	Aug 12, 2027		U-2273		
	8071579	Aug 12, 2027		U-2830		
	8143241	Aug 12, 2027		U-2012		
	8143241	Aug 12, 2027		U-2273		
	8143241	Aug 12, 2027		U-2830		
	8754072	Feb 10, 2031	DS DP			
	8859562	Aug 04, 2031		U-2012		
	8859562	Aug 04, 2031		U-2273		
	8859562	Aug 04, 2031		U-2830		
	9045487	Feb 10, 2031	DS DP			
	9861638	Feb 10, 2031		U-2012		
9861638	Feb 10, 2031		U-2273			
9987285	Aug 17, 2035		DP			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 002	10130636	Aug 17, 2035		U-2012	I-772	Apr 06, 2021
	10130636	Aug 17, 2035		U-2101	I-830	May 15, 2023
	10130636	Aug 17, 2035		U-2273	NCE	Dec 19, 2021
	10130636	Aug 17, 2035		U-2830	ODE-126	Dec 19, 2023
	10278974	Feb 10, 2031	DP		ODE-168	Apr 06, 2025
	6495541	Nov 22, 2023	DS DP			
	7351701	Jul 23, 2024		U-2012		
	7351701	Jul 23, 2024		U-2273		
	7351701	Jul 23, 2024		U-2830		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115	002	7531530	Jul 23, 2024	U-2012		
		7531530	Jul 23, 2024	U-2273		
		7531530	Jul 23, 2024	U-2830		
		8071579	Aug 12, 2027	U-2012		
		8071579	Aug 12, 2027	U-2273		
		8071579	Aug 12, 2027	U-2830		
		8143241	Aug 12, 2027	U-2012		
		8143241	Aug 12, 2027	U-2273		
		8143241	Aug 12, 2027	U-2830		
		8754072	Feb 10, 2031	DS DP		
		8859562	Aug 04, 2031	U-2012		
		8859562	Aug 04, 2031	U-2273		
		8859562	Aug 04, 2031	U-2830		
		9045487	Feb 10, 2031	DS DP		
		9861638	Feb 10, 2031	U-2012		
		9861638	Feb 10, 2031	U-2273		
		9987285	Aug 17, 2035	DP		
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115	003	10130636	Aug 17, 2035	U-2012	I-772	Apr 06, 2021
		10130636	Aug 17, 2035	U-2101	I-830	May 15, 2023
		10130636	Aug 17, 2035	U-2273	NCE	Dec 19, 2021
		10130636	Aug 17, 2035	U-2830	ODE-126	Dec 19, 2023
		10278974	Feb 10, 2031	DP	ODE-168	Apr 06, 2025
		6495541	Nov 22, 2023	DS DP		
		7351701	Jul 23, 2024	U-2012		
		7351701	Jul 23, 2024	U-2273		
		7351701	Jul 23, 2024	U-2830		
		7531530	Jul 23, 2024	U-2012		
		7531530	Jul 23, 2024	U-2273		
		7531530	Jul 23, 2024	U-2830		
		8071579	Aug 12, 2027	U-2012		
		8071579	Aug 12, 2027	U-2273		
		8071579	Aug 12, 2027	U-2830		
		8143241	Aug 12, 2027	U-2012		
		8143241	Aug 12, 2027	U-2273		
		8143241	Aug 12, 2027	U-2830		
		8754072	Feb 10, 2031	DS DP		
		8859562	Aug 04, 2031	U-2012		
		8859562	Aug 04, 2031	U-2273		
		8859562	Aug 04, 2031	U-2830		
		9045487	Feb 10, 2031	DS DP		
		9861638	Feb 10, 2031	U-2012		
		9861638	Feb 10, 2031	U-2273		
		9987285	Aug 17, 2035	DP		
<u>RUFINAMIDE - BANZEL</u>						
N 021911	001	6740669	Nov 14, 2022	DS DP		
		6740669*PED	May 14, 2023			
<u>RUFINAMIDE - BANZEL</u>						
N 021911	002	6740669	Nov 14, 2022	DS DP		
		6740669*PED	May 14, 2023			
<u>RUFINAMIDE - BANZEL</u>						
N 021911	003	6740669	Nov 14, 2022	DS DP		
		6740669*PED	May 14, 2023			
<u>RUFINAMIDE - BANZEL</u>						
N 201367	001	6740669	Nov 14, 2022	DS DP		
		6740669*PED	May 14, 2023			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192	001	10016429	Jun 12, 2028	U-2536	I-799	May 24, 2022
		7598257	Dec 24, 2027	DS DP	ODE-238	May 24, 2026
		7598257	Dec 24, 2027	DS DP	ODE-79	Dec 04, 2021
		8415362	Dec 24, 2027	DS DP		
		8722693	Jun 12, 2028	DS DP		
		8822481	Jun 12, 2028	U-1573		
		8829013	Jun 12, 2028	U-1201		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192	001	8829013				
		9079912				
		9079912				
		9814722				
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192	002	10016429				
		7598257				
		7598257				
		8415362				
		8722693				
		8822481				
		8829013				
		8829013				
		9079912				
		9079912				
		9814722				
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192	003	10016429				
		7598257				
		7598257				
		8415362				
		8722693				
		8822481				
		8829013				
		8829013				
		9079912				
		9079912				
		9814722				
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192	004	10016429				
		7598257				
		7598257				
		8415362				
		8722693				
		8822481				
		8829013				
		8829013				
		9079912				
		9079912				
		9814722				
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192	005	10016429				
		7598257				
		7598257				
		8415362				
		8722693				
		8822481				
		8829013				
		8829013				
		9079912				
		9079912				
		9814722				
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620	001	7468390				
		7468390*PED				
		8101659				
		8101659*PED				
		8404744				
		8404744*PED				
		8796331				
		8796331*PED				
		8877938				
		8877938*PED				
		9388134				
		9388134*PED				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 001	7468390	Nov 27, 2023	DP		NCE	Jul 07, 2020
	7468390*PED	May 27, 2024			NPP	Oct 01, 2022
	8101659	Jan 14, 2023	DP		PED	Jan 07, 2021
	8101659*PED	Jul 14, 2023			PED	Apr 01, 2023
	8404744	Jan 14, 2023	DP			
	8404744*PED	Jul 14, 2023				
	8796331	Jan 14, 2023		U-1723		
	8796331*PED	Jul 14, 2023				
	8877938	May 27, 2027	DS DP			
	8877938*PED	Nov 27, 2027				
	9388134	Nov 08, 2026		U-1723		
	9388134*PED	May 08, 2027				
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 002	7468390	Nov 27, 2023	DP		NCE	Jul 07, 2020
	7468390*PED	May 27, 2024			NPP	Oct 01, 2022
	8101659	Jan 14, 2023	DP		PED	Jan 07, 2021
	8101659*PED	Jul 14, 2023			PED	Apr 01, 2023
	8404744	Jan 14, 2023	DP			
	8404744*PED	Jul 14, 2023				
	8796331	Jan 14, 2023		U-1723		
	8796331*PED	Jul 14, 2023				
	8877938	May 27, 2027	DS DP			
	8877938*PED	Nov 27, 2027				
	9388134	Nov 08, 2026		U-1723		
	9388134*PED	May 08, 2027				
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 003	7468390	Nov 27, 2023	DP		NCE	Jul 07, 2020
	7468390*PED	May 27, 2024			NPP	Oct 01, 2022
	8101659	Jan 14, 2023	DP		PED	Jan 07, 2021
	8101659*PED	Jul 14, 2023			PED	Apr 01, 2023
	8404744	Jan 14, 2023	DP			
	8404744*PED	Jul 14, 2023				
	8796331	Jan 14, 2023		U-1723		
	8796331*PED	Jul 14, 2023				
	8877938	May 27, 2027	DS DP			
	8877938*PED	Nov 27, 2027				
	9388134	Nov 08, 2026		U-1723		
	9388134*PED	May 08, 2027				
<u>SAFINAMIDE MESYLATE - XADAGO</u>						
N 207145 001	8076515	Dec 10, 2028	DS DP	U-1993	NCE	Mar 21, 2022
	8278485	Jun 08, 2027	DS	U-1993		
	8283380	Sep 01, 2027		U-1993		
<u>SAFINAMIDE MESYLATE - XADAGO</u>						
N 207145 002	8076515	Dec 10, 2028	DS DP	U-1993	NCE	Mar 21, 2022
	8278485	Jun 08, 2027	DS	U-1993		
	8283380	Sep 01, 2027		U-1993		
<u>SAPROPTERIN DIHYDROCHLORIDE - SAPROPTERIN DIHYDROCHLORIDE</u>						
A 207200 001					PC	Mar 30, 2021
<u>SAPROPTERIN DIHYDROCHLORIDE - SAPROPTERIN DIHYDROCHLORIDE</u>						
A 207207 001					PC	Mar 30, 2021
<u>SAPROPTERIN DIHYDROCHLORIDE - SAPROPTERIN DIHYDROCHLORIDE</u>						
A 210027 001					PC	Mar 30, 2021
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 022181 001	7566462	Nov 16, 2025	DP			
	7566462*PED	May 16, 2026				
	7566714	Nov 17, 2024		U-989		
	7566714*PED	May 17, 2025				
	7612073	Nov 17, 2024		U-1010		
	7612073*PED	May 17, 2025				
	7727987	Nov 17, 2024	DP			
	7727987*PED	May 17, 2025				
	7947681	Nov 17, 2024		U-1156	Y	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 022181	001	7947681*PED	May 17, 2025			
		8003126	Nov 16, 2025			
		8003126*PED	May 16, 2026			
		8067416	Nov 17, 2024		U-989	
		8067416*PED	May 17, 2025			
		8318745	Nov 17, 2024	DP		
		8318745*PED	May 17, 2025			
		9433624	Nov 17, 2024		U-1589	
		RE43797	Nov 17, 2024		U-1156	
		RE43797*PED	May 17, 2025			
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 205065	001	7566714	Nov 17, 2024		U-1589	
		7566714*PED	May 17, 2025			
		7612073	Nov 17, 2024		U-1010	
		7612073*PED	May 17, 2025			
		8067416	Nov 17, 2024		U-1589	
		8067416*PED	May 17, 2025			
		9216178	Nov 01, 2032	DP		
		9433624	Nov 17, 2024		U-1589	
		RE43797	Nov 17, 2024		U-1590	
		RE43797*PED	May 17, 2025			
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 205065	002	7566714	Nov 17, 2024		U-1589	
		7566714*PED	May 17, 2025			
		7612073	Nov 17, 2024		U-1010	
		7612073*PED	May 17, 2025			
		8067416	Nov 17, 2024		U-1589	
		8067416*PED	May 17, 2025			
		9216178	Nov 01, 2032	DP		
		9433624	Nov 17, 2024		U-1589	
		RE43797	Nov 17, 2024		U-1590	
		RE43797*PED	May 17, 2025			
<u>SARECYCLINE HYDROCHLORIDE - SEYSARA</u>						
N 209521	001	8318706	May 01, 2031	DS DP	U-2405	NCE Oct 01, 2023
		8513223	Dec 07, 2029		U-2406	
		9255068	Feb 09, 2033	DS DP	U-2407	
		9255068	Feb 09, 2033	DS DP	U-2408	
		9481639	Aug 10, 2028		U-2409	
<u>SARECYCLINE HYDROCHLORIDE - SEYSARA</u>						
N 209521	002	8318706	May 01, 2031	DS DP	U-2405	NCE Oct 01, 2023
		8513223	Dec 07, 2029		U-2406	
		9255068	Feb 09, 2033	DS DP	U-2407	
		9255068	Feb 09, 2033	DS DP	U-2408	
		9481639	Aug 10, 2028		U-2409	
<u>SARECYCLINE HYDROCHLORIDE - SEYSARA</u>						
N 209521	003	8318706	May 01, 2031	DS DP	U-2405	NCE Oct 01, 2023
		8513223	Dec 07, 2029		U-2406	
		9255068	Feb 09, 2033	DS DP	U-2407	
		9255068	Feb 09, 2033	DS DP	U-2408	
		9481639	Aug 10, 2028		U-2409	
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350	001	7951400	Nov 30, 2028		DP	M-198 Feb 27, 2020
		RE44186	Jul 31, 2023	DS DP	U-1837	
		RE44186	Jul 31, 2023	DS DP	U-995	
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350	002	7951400	Nov 30, 2028		DP	M-198 Feb 27, 2020
		RE44186	Jul 31, 2023	DS DP	U-1837	
		RE44186	Jul 31, 2023	DS DP	U-995	
<u>SECNIDAZOLE - SOLOSEC</u>						
N 209363	001	10335390	Sep 04, 2035		U-2583	NCE Sep 15, 2022
		10682338	Sep 04, 2035		U-2583	GAIN Sep 15, 2027
		10849884	Sep 04, 2035	DP	U-2583	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SECNIDAZOLE - SOLOSEC</u>						
N 209363	001 10857133	Sep 04, 2035	DP U-2583			
<u>SELENIOUS ACID - SELENIOUS ACID</u>						
N 209379	001				NCE	Apr 30, 2024
<u>SELEXIPAG - UPTRAVI</u>						
N 207947	001 10821108	Dec 01, 2036	DP U-2992		NCE	Dec 21, 2020
	10828298	Dec 01, 2036	DP U-2991		ODE-106	Dec 21, 2022
	7205302	Apr 04, 2023	DS DP U-1797			
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947	002 10821108	Dec 01, 2036	DP U-2992		NCE	Dec 21, 2020
	10828298	Dec 01, 2036	DP U-2991		ODE-106	Dec 21, 2022
	7205302	Apr 04, 2023	DS DP U-1797			
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947	003 10821108	Dec 01, 2036	DP U-2992		NCE	Dec 21, 2020
	10828298	Dec 01, 2036	DP U-2991		ODE-106	Dec 21, 2022
	7205302	Apr 04, 2023	DS DP U-1797			
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947	004 10821108	Dec 01, 2036	DP U-2992		NCE	Dec 21, 2020
	10828298	Dec 01, 2036	DP U-2991		ODE-106	Dec 21, 2022
	7205302	Apr 04, 2023	DS DP U-1797			
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947	005 10821108	Dec 01, 2036	DP U-2992		NCE	Dec 21, 2020
	10828298	Dec 01, 2036	DP U-2991		ODE-106	Dec 21, 2022
	7205302	Apr 04, 2023	DS DP U-1797			
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947	006 10821108	Dec 01, 2036	DP U-2992		NCE	Dec 21, 2020
	10828298	Dec 01, 2036	DP U-2991		ODE-106	Dec 21, 2022
	7205302	Apr 04, 2023	DS DP U-1797			
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947	007 10821108	Dec 01, 2036	DP U-2992		NCE	Dec 21, 2020
	10828298	Dec 01, 2036	DP U-2991		ODE-106	Dec 21, 2022
	7205302	Apr 04, 2023	DS DP U-1797			
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947	008 10821108	Dec 01, 2036	DP U-2992		NCE	Dec 21, 2020
	10828298	Dec 01, 2036	DP U-2991		ODE-106	Dec 21, 2022
	7205302	Apr 04, 2023	DS DP U-1797			
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SELINEXOR - XPOVIO</u>						
N 212306 001	10519139	Aug 14, 2035	DS DP U-2584		I-837	Jun 22, 2023
	10519139	Aug 14, 2035	DS DP U-2855		NCE	Jul 03, 2024
	10544108	Jul 26, 2032	U-2584		ODE-257	Jul 03, 2026
	8999996	Sep 15, 2032	DS DP		ODE-310	Jun 22, 2027
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-2855			
	9714226	Jul 26, 2032	DS DP			
<u>SELPERCATINIB - RETEVMO</u>						
N 213246 001	10112942	Oct 10, 2037	DS DP		NCE	May 08, 2025
	10137124	Oct 10, 2037	U-2826		ODE-301	May 08, 2027
	10137124	Oct 10, 2037	U-2827		ODE-302	May 08, 2027
	10137124	Oct 10, 2037	U-2828		ODE-303	May 08, 2027
	10172851	Oct 10, 2037	U-2826			
	10172851	Oct 10, 2037	U-2827			
	10172851	Oct 10, 2037	U-2828			
	10584124	Oct 10, 2038	DS U-2826			
	10584124	Oct 10, 2038	DS U-2827			
	10584124	Oct 10, 2038	DS U-2828			
	10786489	Oct 10, 2038	DP U-2971			
	10786489	Oct 10, 2038	DP U-2972			
	10786489	Oct 10, 2038	DP U-2973			
	10786489	Oct 10, 2038	DP U-2974			
	10786489	Oct 10, 2038	DP U-2975			
	10786489	Oct 10, 2038	DP U-2976			
	10786489	Oct 10, 2038	DP U-2977			
<u>SELPERCATINIB - RETEVMO</u>						
N 213246 002	10112942	Oct 10, 2037	DS DP		NCE	May 08, 2025
	10137124	Oct 10, 2037	U-2826		ODE-301	May 08, 2027
	10137124	Oct 10, 2037	U-2827		ODE-302	May 08, 2027
	10137124	Oct 10, 2037	U-2828		ODE-303	May 08, 2027
	10172851	Oct 10, 2037	U-2826			
	10172851	Oct 10, 2037	U-2827			
	10172851	Oct 10, 2037	U-2828			
	10584124	Oct 10, 2038	DS U-2826			
	10584124	Oct 10, 2038	DS U-2827			
	10584124	Oct 10, 2038	DS U-2828			
	10786489	Oct 10, 2038	DP U-2971			
	10786489	Oct 10, 2038	DP U-2972			
	10786489	Oct 10, 2038	DP U-2973			
	10786489	Oct 10, 2038	DP U-2974			
	10786489	Oct 10, 2038	DP U-2975			
	10786489	Oct 10, 2038	DP U-2976			
	10786489	Oct 10, 2038	DP U-2977			
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 001	7425637	Apr 11, 2024	DS		NCE	Apr 10, 2025
	8178693	Mar 13, 2023	DS DP		ODE-288	Apr 10, 2027
	9156795	Dec 12, 2026	DS DP			
	9562017	Dec 12, 2026	DS U-2800			
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 002	7425637	Apr 11, 2024	DS		NCE	Apr 10, 2025
	8178693	Mar 13, 2023	DS DP		ODE-288	Apr 10, 2027
	9156795	Dec 12, 2026	DS DP			
	9562017	Dec 12, 2026	DS U-2800			
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 001	10220155	Jul 17, 2026	DP		I-822	Jan 16, 2023
	10335462	Jun 21, 2033	U-2580		NCE	Dec 05, 2022
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	6899699	Jan 02, 2022	DP			
	7762994	May 23, 2024	DP			
	8114833	Aug 13, 2025	DP			
	8129343	Jan 29, 2029	DS DP U-2202			
	8536122	Mar 20, 2026	DS DP U-2202			
	8579869	Jun 30, 2023	DP			
	8672898	Jan 02, 2022	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637	001	8684969	Oct 20, 2025	DP		
		8920383	Jul 17, 2026	DP		
		9108002	Jan 20, 2026	DP		
		9132239	Feb 01, 2032	DP		
		9457154	Sep 27, 2027	DP		
		9486588	Jan 02, 2022	DP		
		9616180	Jan 20, 2026	DP		
		9687611	Feb 27, 2027	DP		
		9775953	Jul 17, 2026	DP		
		9861757	Jan 20, 2026	DP		
		RE46363	Aug 03, 2026	DP		
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637	002	10220155	Jul 17, 2026	DP	I-822	Jan 16, 2023
		10335462	Jun 21, 2033	U-2580	NCE	Dec 05, 2022
		10357616	Jan 20, 2026	DP		
		10376652	Jan 20, 2026	DP		
		6899699	Jan 02, 2022	DP		
		7762994	May 23, 2024	DP		
		8114833	Aug 13, 2025	DP		
		8129343	Jan 29, 2029	DS DP U-2202		
		8536122	Mar 20, 2026	DS DP U-2202		
		8579869	Jun 30, 2023	DP		
		8672898	Jan 02, 2022	DP		
		8684969	Oct 20, 2025	DP		
		8920383	Jul 17, 2026	DP		
		9108002	Jan 20, 2026	DP		
		9132239	Feb 01, 2032	DP		
		9457154	Sep 29, 2027	DP		
		9486588	Jan 02, 2022	DP		
		9616180	Jan 20, 2026	DP		
		9687611	Feb 27, 2027	DP		
		9775953	Jul 17, 2026	DP		
		9861757	Jan 20, 2026	DP		
		RE46363	Aug 03, 2026	DP		
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051	001	10086047	Dec 16, 2031	DP	M-252	Jan 16, 2023
		10278923	May 02, 2034	U-2628	NCE	Dec 05, 2022
		8129343	Jan 29, 2029	DS DP U-2628	NP	Sep 20, 2022
		8536122	Mar 20, 2026	DS DP U-2628		
		9278123	Dec 16, 2031	DP U-2628		
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051	002	10086047	Dec 16, 2031	DP	M-252	Jan 16, 2023
		10278923	May 02, 2034	U-2628	NCE	Dec 05, 2022
		8129343	Jan 29, 2029	DS DP U-2628	NP	Sep 20, 2022
		8536122	Mar 20, 2026	DS DP U-2628		
		9278123	Dec 16, 2031	DP U-2628		
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051	003	10086047	Dec 16, 2031	DP	M-252	Jan 16, 2023
		10278923	May 02, 2034	U-2628	NCE	Dec 05, 2022
		8129343	Jan 29, 2029	DS DP U-2628	NP	Sep 20, 2022
		8536122	Mar 20, 2026	DS DP U-2628		
		9278123	Dec 16, 2031	DP U-2628		
<u>SERTRALINE HYDROCHLORIDE - ZOLOFT</u>						
N 020990	001	7067555*PED	Apr 11, 2020			
<u>SETMELANOTIDE ACETATE - IMCIVREE</u>						
N 213793	001	8039435	Oct 13, 2027	DS DP	NCE	Nov 25, 2025
		9458195	Oct 13, 2027	DS DP		
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022127	001	7985418	Oct 27, 2025	DP		
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022318	001	9095509	Dec 06, 2030	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022318	002 9095509	Dec 06, 2030	DP			
<u>SEVELAMER HYDROCHLORIDE - RENAGEL</u>						
N 021179	001 6733780	Oct 18, 2020	DP			
<u>SEVELAMER HYDROCHLORIDE - RENAGEL</u>						
N 021179	002 6733780	Oct 18, 2020	DP			
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123	001 7671032	May 19, 2025	DS DP			
	8148399	Sep 05, 2029	DS DP	U-1467		
	8349869	Jul 28, 2026	DS DP	U-1467		
	8741926	Jul 28, 2026	DS	U-1467		
	8754106	Jul 28, 2026	DS	U-1467		
	9040562	Jul 28, 2026	DS DP	U-1467		
	9353103	Jul 28, 2026		U-1467		
	9623022	Jul 28, 2026		U-1467		
	9856265	Jul 28, 2026	DS DP	U-1467		
<u>SIMVASTATIN - FLOLIPID</u>						
N 206679	001 10300041	Apr 26, 2027	DP			
	9597289	Feb 23, 2030	DP			
<u>SIMVASTATIN - FLOLIPID</u>						
N 206679	002 10300041	Apr 26, 2027	DP			
	9597289	Feb 23, 2030	DP			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343	001 6699871	Jul 26, 2022	DS DP	U-1188		
	6699871*PED	Jan 26, 2023				
	7125873	Jul 26, 2022	DP	U-1189		
	7125873	Jul 26, 2022	DP	U-1190		
	7125873	Jul 26, 2022	DP	U-1192		
	7125873	Jul 26, 2022	DP	U-1193		
	7125873*PED	Jan 26, 2023				
	7326708	Apr 11, 2026	DS DP	U-1188		
	7326708*PED	Oct 11, 2026				
	8168637	Jun 26, 2022	DP	U-1188		
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343	002 6699871	Jul 26, 2022	DS DP	U-1188		
	6699871*PED	Jan 26, 2023				
	7125873	Jul 26, 2022	DP	U-1189		
	7125873	Jul 26, 2022	DP	U-1190		
	7125873	Jul 26, 2022	DP	U-1192		
	7125873	Jul 26, 2022	DP	U-1193		
	7125873*PED	Jan 26, 2023				
	7326708	Apr 11, 2026	DS DP	U-1188		
	7326708*PED	Oct 11, 2026				
	8168637	Jun 26, 2022	DP	U-1188		
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343	003 6699871	Jul 26, 2022	DS DP	U-1188		
	6699871*PED	Jan 26, 2023				
	7125873	Jul 26, 2022	DP	U-1189		
	7125873	Jul 26, 2022	DP	U-1190		
	7125873	Jul 26, 2022	DP	U-1192		
	7125873	Jul 26, 2022	DP	U-1193		
	7125873*PED	Jan 26, 2023				
	7326708	Apr 11, 2026	DS DP	U-1188		
	7326708*PED	Oct 11, 2026				
	8168637	Jun 26, 2022	DP	U-1188		
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343	004 6699871	Jul 26, 2022	DS DP	U-1188		
	6699871*PED	Jan 26, 2023				
	7125873	Jul 26, 2022	DP	U-1189		
	7125873	Jul 26, 2022	DP	U-1190		
	7125873	Jul 26, 2022	DP	U-1192		
	7125873	Jul 26, 2022	DP	U-1193		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343 004	7125873*PED	Jan 26, 2023				
	7326708	Apr 11, 2026	DS DP U-1188			
	7326708*PED	Oct 11, 2026				
	8168637	Jun 26, 2022	DP U-1188			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343 005	6699871	Jul 26, 2022	DS DP U-1188			
	6699871*PED	Jan 26, 2023				
	7125873	Jul 26, 2022	DP U-1189			
	7125873	Jul 26, 2022	DP U-1190			
	7125873	Jul 26, 2022	DP U-1192			
	7125873	Jul 26, 2022	DP U-1193			
	7125873*PED	Jan 26, 2023				
	7326708	Apr 11, 2026	DS DP U-1188			
	7326708*PED	Oct 11, 2026				
	8168637	Jun 26, 2022	DP U-1188			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343 006	6699871	Jul 26, 2022	DS DP U-1188			
	6699871*PED	Jan 26, 2023				
	7125873	Jul 26, 2022	DP U-1189			
	7125873	Jul 26, 2022	DP U-1190			
	7125873	Jul 26, 2022	DP U-1192			
	7125873	Jul 26, 2022	DP U-1193			
	7125873*PED	Jan 26, 2023				
	7326708	Apr 11, 2026	DS DP U-1188			
	7326708*PED	Oct 11, 2026				
	8168637	Jun 26, 2022	DP U-1188			
<u>SINCALIDE - KINEVAC</u>						
N 017697 001	6803046	Aug 16, 2022	DP			
<u>SINECATECHINS - VEREGEN</u>						
N 021902 001	10434059	Nov 18, 2022	DP U-172			
	5795911	Oct 31, 2020	U-172			
	7858662	Oct 02, 2026	DP U-172			
	9770406	Jul 12, 2025	DP U-172			
<u>SIPONIMOD FUMARIC ACID - MAYZENT</u>						
N 209884 001	7939519	May 19, 2024	DS DP		NCE	Mar 26, 2024
	8492441	Nov 30, 2030	U-2511			
<u>SIPONIMOD FUMARIC ACID - MAYZENT</u>						
N 209884 002	7939519	May 19, 2024	DS DP		NCE	Mar 26, 2024
	8492441	Nov 30, 2030	U-2511			
<u>SIROLIMUS - RAPAMUNE</u>						
N 021083 001					ODE-92	May 28, 2022
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 001					ODE-92	May 28, 2022
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 002					ODE-92	May 28, 2022
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 003					ODE-92	May 28, 2022
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 004					ODE-92	May 28, 2022
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 001	6699871	Jul 26, 2022	DS DP U-774		M-244	Aug 12, 2022
	7125873	Jul 26, 2022	U-1036		PED	Feb 12, 2023
	7125873	Jul 26, 2022	U-1037			
	7125873	Jul 26, 2022	U-1038			
	7125873	Jul 26, 2022	U-775			
	7326708	Nov 24, 2026	DS DP U-802			
	7326708*PED	May 24, 2027				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 002	6699871	Jul 26, 2022	DS DP U-774		M-244	Aug 12, 2022
	7125873	Jul 26, 2022	U-1036		PED	Feb 12, 2023
	7125873	Jul 26, 2022	U-1037			
	7125873	Jul 26, 2022	U-1038			
	7125873	Jul 26, 2022	U-775			
	7326708	Nov 24, 2026	DS DP U-802			
	7326708*PED	May 24, 2027				
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 003	6699871	Jul 26, 2022	DS DP U-774		M-244	Aug 12, 2022
	7125873	Jul 26, 2022	U-1036		PED	Feb 12, 2023
	7125873	Jul 26, 2022	U-1037			
	7125873	Jul 26, 2022	U-1038			
	7125873	Jul 26, 2022	U-775			
	7326708	Nov 24, 2026	DS DP U-802			
	7326708*PED	May 24, 2027				
<u>SODIUM NITRITE - SODIUM NITRITE</u>						
N 203922 001	8568793	Dec 24, 2031	DS DP			
<u>SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOLE</u>						
N 201444 001	8496973	Mar 29, 2031	DS DP U-1419			
	8568793	Dec 24, 2031	DS DP			
	9345724	Mar 29, 2031	DS DP U-2015			
	9585912	Mar 29, 2031	DS DP			
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	10213400	Mar 15, 2033		U-2499	NPP	Oct 26, 2021
	6780889	Jul 04, 2020	DP		ODE-231	Oct 26, 2025
	6780889*PED	Jan 04, 2021			PED	Apr 26, 2022
	7262219	Jul 04, 2020	DP		PED	Apr 26, 2026
	7262219*PED	Jan 04, 2021				
	7668730	Jun 16, 2024	U-1110	Y		
	7668730*PED	Dec 16, 2024				
	7851506*PED	Jun 22, 2020				
	8263650*PED	Jun 22, 2020				
	8324275*PED	Jun 22, 2020				
	8731963	Dec 17, 2022	U-1110			
	8731963*PED	Jun 17, 2023				
	8772306	Mar 15, 2033	U-1532			
	8772306*PED	Sep 15, 2033				
	8859619*PED	Jun 22, 2020				
	8952062*PED	Jun 22, 2020				
	9050302	Mar 15, 2033	U-1532			
	9050302*PED	Sep 15, 2033				
	9486426	Mar 15, 2033	U-1532			
	9486426*PED	Sep 15, 2033				
	9539330*PED	Jun 22, 2020				
<u>SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE - OSMOPREP</u>						
N 021892 001	7687075	Jun 22, 2028	DS DP			
<u>SODIUM THIOSULFATE - SODIUM THIOSULFATE</u>						
N 203923 001	8496973	Mar 29, 2031	DS DP U-1419			
	9345724	Mar 29, 2031	DS DP U-2015			
	9585912	Mar 29, 2031	DS DP			
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078 001	10300087	Oct 14, 2035	DS	U-2312	M-261	Apr 24, 2023
	10335432	Feb 10, 2032		U-2312	NCE	May 18, 2023
	10398730	Feb 10, 2032		U-2312		
	10413569	Feb 10, 2032	DS			
	10695365	Oct 22, 2033	DS			
	8802152	Apr 19, 2032	DS			
	8808750	Feb 10, 2032		U-2312		
	8877255	Oct 22, 2033	DS			
	9592253	Oct 14, 2035	DS	U-2312		
	9844567	Feb 10, 2032		U-2312		
	9861658	Feb 10, 2032		U-2312		
	9913860	Oct 22, 2033	DS	U-2312		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078	001	10300087	Oct 14, 2035	DS	U-2312	M-261
		10335432	Feb 10, 2032		U-2312	NCE
		10398730	Feb 10, 2032		U-2312	
		10413569	Feb 10, 2032	DS		
		10695365	Oct 22, 2033	DS		
		8802152	Apr 19, 2032	DS		
		8808750	Feb 10, 2032		U-2312	
		8877255	Oct 22, 2033	DS		
		9592253	Oct 14, 2035	DS	U-2312	
		9844567	Feb 10, 2032		U-2312	
		9861658	Feb 10, 2032		U-2312	
		9913860	Oct 22, 2033	DS	U-2312	
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078	002	10300087	Oct 14, 2035	DS	U-2312	M-261
		10398730	Feb 10, 2032		U-2312	NCE
		10413569	Feb 10, 2032	DS		
		10695365	Oct 22, 2033	DS		
		8802152	Apr 19, 2032	DS		
		8808750	Feb 10, 2032		U-2312	
		8877255	Oct 22, 2033	DS		
		9592253	Oct 14, 2035	DS	U-2312	
		9844567	Feb 10, 2032		U-2312	
		9861658	Feb 10, 2032		U-2312	
		9913860	Oct 22, 2033	DS	U-2312	
<u>SOFOSEBUVIR - SOVALDI</u>						
N 204671	001	7964580	Mar 26, 2029	DS DP	U-1470	NPP
		7964580*PED	Sep 26, 2029			ODE-135
		8334270	Mar 21, 2028	DS DP	U-1470	PED
		8334270*PED	Sep 21, 2028			
		8580765	Mar 21, 2028	DS DP	U-1470	
		8580765*PED	Sep 21, 2028			
		8618076	Dec 11, 2030	DS DP	U-1470	
		8618076*PED	Jun 11, 2031			
		8633309	Mar 26, 2029	DS DP	U-1470	
		8633309*PED	Sep 26, 2029			
		8889159	Mar 26, 2029		DP U-1470	
		8889159*PED	Sep 26, 2029			
		9085573	Mar 21, 2028	DS DP	U-1470	
		9085573*PED	Sep 21, 2028			
		9284342	Sep 13, 2030	DS DP	U-1470	
		9284342*PED	Mar 13, 2031			
		9549941	Mar 26, 2029		U-1958	
		9549941*PED	Sep 26, 2029			
<u>SOFOSEBUVIR - SOVALDI</u>						
N 204671	002	7964580	Mar 26, 2029	DS DP	U-1470	
		7964580*PED	Sep 26, 2029			
		8334270	Mar 21, 2028	DS DP	U-1470	
		8334270*PED	Sep 21, 2028			
		8580765	Mar 21, 2028	DS DP	U-1470	
		8580765*PED	Sep 21, 2028			
		8618076	Dec 11, 2030	DS DP	U-1470	
		8618076*PED	Jun 11, 2031			
		8633309	Mar 26, 2029	DS DP	U-1470	
		8633309*PED	Sep 26, 2029			
		8889159	Mar 26, 2029		DP U-1470	
		8889159*PED	Sep 26, 2029			
		9085573	Mar 21, 2028	DS DP	U-1470	
		9085573*PED	Sep 21, 2028			
		9284342	Sep 13, 2030	DS DP	U-1470	
		9284342*PED	Mar 13, 2031			
<u>SOFOSEBUVIR - SOVALDI</u>						
N 212480	001	7964580	Mar 26, 2029	DS DP	U-1470	ODE-258
		7964580*PED	Sep 26, 2029			
		8334270	Mar 21, 2028	DS DP	U-1470	
		8334270*PED	Sep 21, 2028			
		8580765	Mar 21, 2028	DS DP	U-1470	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SOFOSBUVIR - SOVALDI</u>						
N 212480	001	8580765*PED	Sep 21, 2028			
		8618076	Dec 11, 2030	DS DP U-1470		
		8618076*PED	Jun 11, 2031			
		8633309	Mar 26, 2029	DS DP U-1470		
		8633309*PED	Sep 26, 2029			
		8889159	Mar 26, 2029	DP U-1470		
		8889159*PED	Sep 26, 2029			
		9085573	Mar 21, 2028	DS DP U-1470		
		9085573*PED	Sep 21, 2028			
		9284342	Sep 13, 2030	DS DP U-1470		
		9284342*PED	Mar 13, 2031			
<u>SOFOSBUVIR - SOVALDI</u>						
N 212480	002	7964580	Mar 26, 2029	DS DP U-1470	ODE-258	Aug 28, 2026
		7964580*PED	Sep 26, 2029			
		8334270	Mar 21, 2028	DS DP U-1470		
		8334270*PED	Sep 21, 2028			
		8580765	Mar 21, 2028	DS DP U-1470		
		8580765*PED	Sep 21, 2028			
		8618076	Dec 11, 2030	DS DP U-1470		
		8618076*PED	Jun 11, 2031			
		8633309	Mar 26, 2029	DS DP U-1470		
		8633309*PED	Sep 26, 2029			
		8889159	Mar 26, 2029	DP U-1470		
		8889159*PED	Sep 26, 2029			
		9085573	Mar 21, 2028	DS DP U-1470		
		9085573*PED	Sep 21, 2028			
		9284342	Sep 13, 2030	DS DP U-1470		
		9284342*PED	Mar 13, 2031			
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341	001	10086011	Jan 30, 2034	U-1470	D-177	Nov 15, 2022
		7964580	Mar 26, 2029	DS DP U-1470	M-264	Jul 14, 2023
		7964580*PED	Sep 26, 2029		NCE	Jun 28, 2021
		8334270	Mar 21, 2028	DS DP U-1470	NPP	Aug 01, 2020
		8334270*PED	Sep 21, 2028		NPP	Mar 19, 2023
		8575135	Nov 16, 2032	DS DP U-1470	ODE-293	Mar 19, 2027
		8580765	Mar 21, 2028	DS DP U-1470		
		8580765*PED	Sep 21, 2028			
		8618076	Dec 11, 2030	DS DP U-1470		
		8618076*PED	Jun 11, 2031			
		8633309	Mar 26, 2029	DS DP U-1470		
		8633309*PED	Sep 26, 2029			
		8735372	Mar 21, 2028	U-1470		
		8889159	Mar 26, 2029	DP U-1470		
		8889159*PED	Sep 26, 2029			
		8921341	Nov 16, 2032	DS DP U-1470		
		8940718	Nov 16, 2032	DS DP U-1470		
		9085573	Mar 21, 2028	DS DP U-1470		
		9085573*PED	Sep 21, 2028			
		9284342	Sep 13, 2030	DS DP U-1470		
		9284342*PED	Mar 13, 2031			
		9757406	Jan 30, 2034	DP		
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341	002	10086011	Jan 30, 2034	U-1470	M-264	Jul 14, 2023
		7964580	Mar 26, 2029	DS DP U-1470	NS	Mar 19, 2023
		8334270	Mar 21, 2028	DS DP U-1470	ODE-293	Mar 19, 2027
		8575135	Nov 16, 2032	DS DP U-1470		
		8580765	Mar 21, 2028	DS DP U-1470		
		8618076	Dec 11, 2030	DS DP U-1470		
		8633309	Mar 26, 2029	DS DP U-1470		
		8735372	Mar 21, 2028	U-1470		
		8889159	Mar 26, 2029	DP U-1470		
		8921341	Nov 16, 2032	DS DP U-1470		
		8940718	Nov 16, 2032	DS DP U-1470		
		9085573	Mar 21, 2028	DS DP U-1470		
		9284342	Sep 13, 2030	DS DP U-1470		
		9757406	Jan 30, 2034	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI</u>						
N 209195 001	7964580	Mar 26, 2029	DS DP U-2039		NCE	Jul 18, 2022
	7964580	Mar 26, 2029	DS DP U-2040			
	7964580*PED	Sep 26, 2029				
	8334270	Mar 21, 2028	DS DP U-2039			
	8334270	Mar 21, 2028	DS DP U-2040			
	8334270*PED	Sep 21, 2028				
	8575135	Nov 05, 2033	DS DP U-2039			
	8575135	Nov 05, 2033	DS DP U-2040			
	8580765	Mar 21, 2028	DS DP U-2039			
	8580765	Mar 21, 2028	DS DP U-2040			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-2039			
	8618076	Dec 11, 2030	DS DP U-2040			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-2039			
	8633309	Mar 26, 2029	DS DP U-2040			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	DS DP U-2039			
	8735372	Mar 21, 2028	DS DP U-2040			
	8889159	Mar 26, 2029	DS DP U-2039			
	8889159	Mar 26, 2029	DS DP U-2040			
	8889159*PED	Sep 26, 2029				
	8921341	Nov 16, 2032	DS DP U-2039			
	8921341	Nov 16, 2032	DS DP U-2040			
	8940718	Nov 16, 2032	DS DP U-2039			
	8940718	Nov 16, 2032	DS DP U-2040			
	9085573	Mar 21, 2028	DS DP U-2039			
	9085573	Mar 21, 2028	DS DP U-2040			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-2039			
	9284342	Sep 13, 2030	DS DP U-2040			
	9284342*PED	Mar 13, 2031				
	9296782	Jul 17, 2034	DS DP			
	9585906	Mar 21, 2028	DS DP U-2039			
	9585906	Mar 21, 2028	DS DP U-2040			
	9868745	Nov 16, 2032	DS DP			
<u>SOLIFENACIN SUCCINATE - VESICARE LS</u>						
N 209529 001					NP	May 26, 2023
					PED	Nov 26, 2023
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 001	10195151	Sep 05, 2037	DP		NCE	Jun 17, 2024
	10351517	Jun 07, 2026	U-2548		ODE-254	Jun 17, 2026
	10512609	Sep 05, 2037	U-2548			
	8440715	Aug 25, 2027	U-2548			
	8877806	Jun 07, 2026	U-2548			
	9604917	Jun 07, 2026	U-2548			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 002	10195151	Sep 05, 2037	DP		NCE	Jun 17, 2024
	10351517	Jun 07, 2026	U-2548		ODE-254	Jun 17, 2026
	10512609	Sep 05, 2037	U-2548			
	8440715	Aug 25, 2027	U-2548			
	8877806	Jun 07, 2026	U-2548			
	9604917	Jun 07, 2026	U-2548			
<u>SONIDEGIB PHOSPHATE - ODOMZO</u>						
N 205266 001	8063043	Sep 15, 2029	DS DP		NCE	Jul 24, 2020
	8178563	Jul 24, 2029	DS U-1722			
<u>SORAFENIB TOSYLATE - NEXAVAR</u>						
N 021923 001	7235576	Jan 12, 2020	DS DP		ODE-56	Nov 22, 2020
	7351834	Jan 12, 2020	DS			
	7897623	Jan 12, 2020	DP			
	8124630	Jan 12, 2020	U-1459			
	8618141	Feb 11, 2023	U-1480			
	8841330	Jan 12, 2020	U-1696			
	8877933	Dec 24, 2027	DS DP U-1624			
	9737488	Sep 10, 2028	DP U-1480			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SORAFENIB TOSYLATE - NEXAVAR</u>						
N 021923	001 9737488	Sep 10, 2028	DP U-1696			
	9737488	Sep 10, 2028	DP U-2107			
<u>SOTALOL HYDROCHLORIDE - SOTALOL HYDROCHLORIDE</u>						
N 022306	001 10512620	Aug 18, 2038	U-2769			
<u>SOTALOL HYDROCHLORIDE - SOTYLIZE</u>						
N 205108	001 10206895	Apr 01, 2034	DP U-2096			
	10206895	Apr 01, 2034	DP U-2494			
	9724297	Aug 31, 2035	DP U-2096			
<u>SPINOSAD - NATROBA</u>						
N 022408	001 6063771	Jul 25, 2023	DP U-1670			
	7030095	Jul 02, 2021	DP U-1105			
<u>SPIRONOLACTONE - CAROSPIR</u>						
N 209478	001 10493083	Oct 28, 2036	DP			
	10624906	Oct 28, 2036	DP			
	10660907	Oct 28, 2036	DP			
	9757394	Oct 28, 2036	DP U-2109			
<u>STAVUDINE - ZERIT XR</u>						
N 021453	001 7135465	Feb 18, 2023	DP U-167			
<u>STAVUDINE - ZERIT XR</u>						
N 021453	002 7135465	Feb 18, 2023	DP U-167			
<u>STAVUDINE - ZERIT XR</u>						
N 021453	003 7135465	Feb 18, 2023	DP U-167			
<u>STAVUDINE - ZERIT XR</u>						
N 021453	004 7135465	Feb 18, 2023	DP U-167			
<u>STIRIPENTOL - DIACOMIT</u>						
N 206709	001				NCE ODE-198	Aug 20, 2023 Aug 20, 2025
<u>STIRIPENTOL - DIACOMIT</u>						
N 206709	002				NCE ODE-198	Aug 20, 2023 Aug 20, 2025
<u>STIRIPENTOL - DIACOMIT</u>						
N 207223	001				NCE ODE-198	Aug 20, 2023 Aug 20, 2025
<u>STIRIPENTOL - DIACOMIT</u>						
N 207223	002				NCE ODE-198	Aug 20, 2023 Aug 20, 2025
<u>SUCROFERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109	001 10624855	Nov 26, 2034	DP			
	10682376	Nov 13, 2028	DP			
	10695367	Nov 13, 2028	DP			
	6174442	Jun 12, 2020	DS U-1468			
	9561251	Jan 23, 2030	DP U-1468			
<u>SUFENTANIL CITRATE - DSUVIA</u>						
N 209128	001 10245228	Jan 05, 2027	DP U-1351		NP	Nov 02, 2021
	10342762	Jan 05, 2027	DP			
	10507180	Jan 05, 2027	DP U-1351			
	8202535	Oct 22, 2030	U-1351			
	8226978	Jan 05, 2027	DP U-1351			
	8231900	Jan 05, 2027	DP			
	8252328	Jan 05, 2027	DP			
	8252329	Jan 05, 2027	DP			
	8535714	Jan 05, 2027	DP U-1351			
	8574189	Mar 16, 2030	DP			
	8778393	Jan 05, 2027	U-1351			
	8778394	Jan 05, 2027	U-1351			
	8865211	Jan 05, 2027	U-1351			
	8865743	Oct 22, 2030	U-1351			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SUFENTANIL CITRATE - DSUVIA</u>						
N 209128	001 8945592	Jul 29, 2031	DP			
	9320710	Jan 05, 2027	U-1351			
	9744129	Jan 05, 2027	DP			
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225	001 6949527	Jan 27, 2021	U-1795		M-262	Jun 09, 2023
	7265099	Aug 07, 2020	U-1795		NCE	Dec 15, 2020
	RE44733	Jan 27, 2026	DS DP U-1794			
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225	002 6949527	Jan 27, 2021	U-1795		M-262	Jun 09, 2023
	7265099	Aug 07, 2020	U-1795		NCE	Dec 15, 2020
	RE44733	Jan 27, 2026	DS DP U-1794			
<u>SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES - LUMASON</u>						
N 203684	001 10232061	Jul 06, 2038	DP		NPP	Nov 13, 2022
	10335502	Jul 06, 2038	DP			
<u>SUMATRIPTAN - TOSYMRA</u>						
N 210884	001 10603305	Jun 16, 2030	DP U-1719			
	8268791	May 09, 2026	DP			
	8440631	May 09, 2026	DP U-1719			
	9211282	Jul 19, 2031	DP U-1719			
	9283280	May 09, 2026	DP			
	9610280	Jun 16, 2030	DP U-1719			
	9974770	Jun 16, 2030	DP U-1719			
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N 022239	001 7776007	Nov 22, 2026	DP			
	7901385	Jul 31, 2026	DP			
	8118771	Aug 10, 2023	DP			
	8241243	Aug 10, 2023	DP			
	8241244	Nov 21, 2022	DP			
	8267903	Mar 18, 2023	DP			
	8287489	Dec 06, 2024	DP			
	8343130	Oct 18, 2022	DP			
	8491524	Nov 21, 2022	DP			
<u>SUMATRIPTAN SUCCINATE - ALSUMA</u>						
N 022377	001 7811254	Aug 26, 2027	DP U-1083			
<u>SUMATRIPTAN SUCCINATE - ZECUITY</u>						
N 202278	001 6745071	Feb 21, 2023	DP			
	7973058	Apr 12, 2027	U-1328			
	8155737	Apr 12, 2027	U-1328			
	8366600	Apr 21, 2029	U-1327			
	8470853	Apr 12, 2027	U-1328			
	8597272	Apr 12, 2027	DP			
	8983594	Nov 19, 2030	DP U-1328			
	9272137	Sep 07, 2027	DP			
	9327114	Oct 08, 2032	DP U-1328			
	9427578	Apr 12, 2027	DP U-1328			
<u>SUMATRIPTAN SUCCINATE - ONZETRA XSAIL</u>						
N 206099	001 10076614	Oct 20, 2034	DP			
	10076615	Jul 30, 2029	U-2010			
	10076615	Jul 30, 2029	U-2011			
	10076615	Jul 30, 2029	U-2404			
	10124132	Mar 06, 2027	DP U-1719			
	10124132	Mar 06, 2027	DP U-2010			
	10124132	Mar 06, 2027	DP U-2011			
	10398859	Dec 19, 2027	DP			
	10478574	Nov 04, 2033	U-2404			
	10722667	Dec 30, 2028	DP			
	6715485	Mar 03, 2020	DP			
	7975690	Aug 18, 2025	DP U-1809			
	8047202	Jul 02, 2023	DP			
	8327844	Oct 03, 2023	U-1809			
	8550073	Oct 22, 2029	DP			
	8555877	Mar 03, 2020	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SUMATRIPTAN SUCCINATE - ONZETRA XSAIL</u>						
N 206099	001	8590530	Sep 15, 2025	DP U-1809		
		8875704	Apr 07, 2028	DP U-1809		
		8899229	Aug 18, 2030	DP		
		8978647	Dec 06, 2030	DP		
		9108015	Sep 15, 2025	DP		
		9119932	Apr 23, 2024	DP		
		9649456	Oct 21, 2030	DP U-1719		
		9649456	Oct 21, 2030	DP U-2010		
		9649456	Oct 21, 2030	DP U-2011		
<u>SUMATRIPTAN SUCCINATE - ZEMBRACE SYMTOUCH</u>						
N 208223	001	10537554	Jan 29, 2036	U-72		
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938	001	6573293	Feb 15, 2021	DS DP U-1154	I-755	Nov 16, 2020
		6573293	Feb 15, 2021	DS DP U-2171	PED	May 16, 2021
		6573293*PED	Aug 15, 2021			
		7125905	Feb 15, 2021	DS DP		
		7125905*PED	Aug 15, 2021			
		7211600	Dec 22, 2020	U-883		
		7211600*PED	Jun 22, 2021			
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938	002	6573293	Feb 15, 2021	DS DP U-1154	I-755	Nov 16, 2020
		6573293	Feb 15, 2021	DS DP U-2171	PED	May 16, 2021
		6573293*PED	Aug 15, 2021			
		7125905	Feb 15, 2021	DS DP		
		7125905*PED	Aug 15, 2021			
		7211600	Dec 22, 2020	U-883		
		7211600*PED	Jun 22, 2021			
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938	003	6573293	Feb 15, 2021	DS DP U-1154	I-755	Nov 16, 2020
		6573293	Feb 15, 2021	DS DP U-2171	PED	May 16, 2021
		6573293*PED	Aug 15, 2021			
		7125905	Feb 15, 2021	DS DP		
		7125905*PED	Aug 15, 2021			
		7211600	Dec 22, 2020	U-883		
		7211600*PED	Jun 22, 2021			
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938	004	6573293	Feb 15, 2021	DS DP U-1154	I-755	Nov 16, 2020
		6573293	Feb 15, 2021	DS DP U-2171	PED	May 16, 2021
		6573293*PED	Aug 15, 2021			
		7125905	Feb 15, 2021	DS DP		
		7125905*PED	Aug 15, 2021			
		7211600	Dec 22, 2020	U-883		
		7211600*PED	Jun 22, 2021			
<u>SUVOREXANT - BELSOMRA</u>						
N 204569	001	10098892	May 29, 2033	DP	M-253	Jan 29, 2023
		7951797	Nov 20, 2029	DS DP U-620		
<u>SUVOREXANT - BELSOMRA</u>						
N 204569	002	10098892	May 29, 2033	DP	M-253	Jan 29, 2023
		7951797	Nov 20, 2029	DS DP U-620		
<u>SUVOREXANT - BELSOMRA</u>						
N 204569	003	10098892	May 29, 2033	DP	M-253	Jan 29, 2023
		7951797	Nov 20, 2029	DS DP U-620		
<u>SUVOREXANT - BELSOMRA</u>						
N 204569	004	10098892	May 29, 2033	DP	M-253	Jan 29, 2023
		7951797	Nov 20, 2029	DS DP U-620		
<u>TACROLIMUS - PROGRAF</u>						
N 050708	001				ODE-294	May 24, 2025

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TACROLIMUS - PROGRAF</u>						
N 050708	002				ODE-294	May 24, 2025
<u>TACROLIMUS - PROGRAF</u>						
N 050708	003				ODE-294	May 24, 2025
<u>TACROLIMUS - PROGRAF</u>						
N 050709	001				ODE-294	May 24, 2025
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406	001	10166190	May 30, 2028	DP	ODE-94	Jul 10, 2022
		10548880	Aug 30, 2024	U-2677		
		10548880	Aug 30, 2024	U-2678		
		10864199	May 30, 2028	U-2677		
		10864199	May 30, 2028	U-2678		
		7994214	Aug 30, 2024	DP		
		8486993	Aug 30, 2024	DP U-1752		
		8586084	Aug 30, 2024	U-1752		
		8591946	Aug 30, 2024	DP		
		8617599	Aug 30, 2024	DP		
		8623410	Aug 30, 2024	DP		
		8623411	Aug 30, 2024	U-1752		
		8664239	Aug 30, 2028	U-1752		
		8664239	Aug 30, 2028	U-2677		
		8664239	Aug 30, 2028	U-2678		
		8685998	Aug 30, 2028	DP U-1752		
		8685998	Aug 30, 2028	DP U-2677		
		8685998	Aug 30, 2028	DP U-2678		
		8889185	Aug 30, 2024	U-1752		
		8889186	Aug 30, 2024	U-1752		
		9161907	Aug 30, 2024	DP U-1752		
		9549918	May 30, 2028	DP		
		9757362	Aug 30, 2024	DP		
		9763920	Aug 30, 2024	DP		
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406	002	10166190	May 30, 2028	DP	ODE-94	Jul 10, 2022
		10548880	Aug 30, 2024	U-2677		
		10548880	Aug 30, 2024	U-2678		
		10864199	May 30, 2028	U-2677		
		10864199	May 30, 2028	U-2678		
		7994214	Aug 30, 2024	DP		
		8486993	Aug 30, 2024	DP U-1752		
		8586084	Aug 30, 2024	U-1752		
		8591946	Aug 30, 2024	DP		
		8617599	Aug 30, 2024	DP		
		8623410	Aug 30, 2024	DP		
		8623411	Aug 30, 2024	U-1752		
		8664239	Aug 30, 2028	U-1752		
		8664239	Aug 30, 2028	U-2677		
		8664239	Aug 30, 2028	U-2678		
		8685998	Aug 30, 2028	DP U-1752		
		8685998	Aug 30, 2028	DP U-2677		
		8685998	Aug 30, 2028	DP U-2678		
		8889185	Aug 30, 2024	U-1752		
		8889186	Aug 30, 2024	U-1752		
		9161907	Aug 30, 2024	DP U-1752		
		9549918	May 30, 2028	DP		
		9757362	Aug 30, 2024	DP		
		9763920	Aug 30, 2024	DP		
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406	003	10166190	May 30, 2028	DP	ODE-94	Jul 10, 2022
		10548880	Aug 30, 2024	U-2677		
		10548880	Aug 30, 2024	U-2678		
		10864199	May 30, 2028	U-2677		
		10864199	May 30, 2028	U-2678		
		7994214	Aug 30, 2024	DP		
		8486993	Aug 30, 2024	DP U-1752		
		8586084	Aug 30, 2024	U-1752		
		8591946	Aug 30, 2024	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TACROLIMUS - ENVARSUS XR</u>						
N 206406	003	8617599	Aug 30, 2024	DP		
		8623410	Aug 30, 2024	DP		
		8623411	Aug 30, 2024	U-1752		
		8664239	Aug 30, 2028	U-1752		
		8664239	Aug 30, 2028	U-2677		
		8664239	Aug 30, 2028	U-2678		
		8685998	Aug 30, 2028	DP U-1752		
		8685998	Aug 30, 2028	DP U-2677		
		8685998	Aug 30, 2028	DP U-2678		
		8889185	Aug 30, 2024	U-1752		
		8889186	Aug 30, 2024	U-1752		
		9161907	Aug 30, 2024	DP U-1752		
		9549918	May 30, 2028	DP		
		9757362	Aug 30, 2024	DP		
		9763920	Aug 30, 2024	DP		
<u>TACROLIMUS - PROGRAF</u>						
N 210115	001				ODE-269	May 24, 2025
<u>TACROLIMUS - PROGRAF</u>						
N 210115	002				ODE-269	May 24, 2025
<u>TADALAFIL - CIALIS</u>						
N 021368	001	6943166	Apr 26, 2020	U-1184	M-219	Feb 15, 2021
		6943166	Apr 26, 2020	U-155	PED	Aug 15, 2021
		6943166	Apr 26, 2020	U-614		
		6943166*PED	Oct 26, 2020			
<u>TADALAFIL - CIALIS</u>						
N 021368	002	6943166	Apr 26, 2020	U-155	M-219	Feb 15, 2021
		6943166	Apr 26, 2020	U-614	PED	Aug 15, 2021
		6943166*PED	Oct 26, 2020			
<u>TADALAFIL - CIALIS</u>						
N 021368	003	6943166	Apr 26, 2020	U-614	M-219	Feb 15, 2021
		6943166*PED	Oct 26, 2020		PED	Aug 15, 2021
<u>TADALAFIL - CIALIS</u>						
N 021368	004	6943166	Apr 26, 2020	U-155	M-219	Feb 15, 2021
		6943166*PED	Oct 26, 2020		PED	Aug 15, 2021
<u>TAFAMIDIS - VYNDAMAX</u>						
N 212161	001	7214695	Apr 27, 2024	DS DP	NCE	May 03, 2024
		7214696	Dec 19, 2023	U-2524	ODE-237	May 03, 2026
		9770441	Aug 31, 2035	DS DP U-2524		
<u>TAFAMIDIS MEGLUMINE - VYNDAOEL</u>						
N 211996	001	7214695	Apr 27, 2024	DS DP	NCE	May 03, 2024
		7214696	Dec 19, 2023	U-2524	ODE-237	May 03, 2026
		8168663	Dec 19, 2023	DS DP		
		8653119	Jan 28, 2024	U-2524		
<u>TAFENOQUINE SUCCINATE - ARAKODA</u>						
N 210607	001	10342791	Dec 02, 2035	U-2582	NCE NP	Jul 20, 2023 Aug 08, 2021
<u>TAFENOQUINE SUCCINATE - KRINTAFEL</u>						
N 210795	001				NCE ODE-201	Jul 20, 2023 Jul 20, 2025
<u>TAFLUPROST - ZIOPTAN</u>						
N 202514	001	5886035	Dec 18, 2022	DS DP U-778		
		9999593	May 28, 2029	DP		
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 211651	001	10189837	Oct 20, 2031	DS DP	NCE	Oct 16, 2023
		8012976	Oct 19, 2029	DS DP		
		8420650	Jul 27, 2029	DS DP		
		8735392	Oct 20, 2031	DS DP		
		9820985	Jul 27, 2029	U-2437		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 211651	002	10189837	Oct 20, 2031	DS DP	NCE	Oct 16, 2023
		8012976	Oct 19, 2029	DS DP		
		8420650	Jul 27, 2029	DS DP		
		8735392	Oct 20, 2031	DS DP		
		9820985	Jul 27, 2029	U-2437		
<u>TALC - STERITALC</u>						
N 205555	001				ODE-143	May 01, 2024
					ODE-191	May 01, 2024
<u>TALC - STERITALC</u>						
N 205555	002				ODE-143	May 01, 2024
					ODE-191	May 01, 2024
<u>TALC - STERITALC</u>						
N 205555	003				ODE-143	May 01, 2024
					ODE-191	May 01, 2024
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 022304	001	7994364	Jun 27, 2025	DS DP U-931		
		RE39593	Aug 05, 2022	DS DP U-931		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 022304	002	7994364	Jun 27, 2025	DS DP U-931		
		RE39593	Aug 05, 2022	DS DP U-931		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 022304	003	7994364	Jun 27, 2025	DS DP U-931		
		RE39593	Aug 05, 2022	DS DP U-931		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533	001	7994364	Jun 27, 2025	DS DP U-1178		
		7994364	Jun 27, 2025	DS DP U-1276		
		8075872	Nov 20, 2023	DP		
		8114383	Oct 10, 2024	DP	Y	
		8309060	Nov 20, 2023	DP U-1178		
		8309060	Nov 20, 2023	DP U-1276		
		8420056	Nov 20, 2023	DP		
		8536130	Sep 22, 2028	U-1276		
		RE39593	Aug 05, 2022	DS DP U-1178		
		RE39593	Aug 05, 2022	DS DP U-1276		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533	002	7994364	Jun 27, 2025	DS DP U-1178		
		7994364	Jun 27, 2025	DS DP U-1276		
		8075872	Nov 20, 2023	DP		
		8114383	Oct 10, 2024	DP	Y	
		8309060	Nov 20, 2023	DP U-1178		
		8309060	Nov 20, 2023	DP U-1276		
		8420056	Nov 20, 2023	DP		
		8536130	Sep 22, 2028	U-1276		
		RE39593	Aug 05, 2022	DS DP U-1178		
		RE39593	Aug 05, 2022	DS DP U-1276		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533	003	7994364	Jun 27, 2025	DS DP U-1178		
		7994364	Jun 27, 2025	DS DP U-1276		
		8075872	Nov 20, 2023	DP		
		8114383	Oct 10, 2024	DP	Y	
		8309060	Nov 20, 2023	DP U-1178		
		8309060	Nov 20, 2023	DP U-1276		
		8420056	Nov 20, 2023	DP		
		8536130	Sep 22, 2028	U-1276		
		RE39593	Aug 05, 2022	DS DP U-1178		
		RE39593	Aug 05, 2022	DS DP U-1276		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533	004	7994364	Jun 27, 2025	DS DP U-1178		
		7994364	Jun 27, 2025	DS DP U-1276		
		8075872	Nov 20, 2023	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533	004	8114383	Oct 10, 2024	DP	Y	
		8309060	Nov 20, 2023	DP U-1178		
		8309060	Nov 20, 2023	DP U-1276		
		8420056	Nov 20, 2023	DP		
		8536130	Sep 22, 2028	U-1276		
		RE39593	Aug 05, 2022	DS DP U-1178		
		RE39593	Aug 05, 2022	DS DP U-1276		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533	005	7994364	Jun 27, 2025	DS DP U-1178		
		7994364	Jun 27, 2025	DS DP U-1276		
		8075872	Nov 20, 2023	DP		
		8114383	Oct 10, 2024	DP	Y	
		8309060	Nov 20, 2023	DP U-1178		
		8309060	Nov 20, 2023	DP U-1276		
		8420056	Nov 20, 2023	DP		
		8536130	Sep 22, 2028	U-1276		
		RE39593	Aug 05, 2022	DS DP U-1178		
		RE39593	Aug 05, 2022	DS DP U-1276		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 203794	001	7994364	Jun 27, 2025	DS DP U-1289		
		RE39593	Aug 05, 2022	DS DP U-1289		
<u>TASIMELTEON - HETLIOZ</u>						
N 205677	001	10071977	Feb 12, 2035	DS DP	ODE-59	Jan 31, 2021
		10149829	Jan 25, 2033	U-2477		
		10149829	Jan 25, 2033	U-3006		
		10179119	Aug 29, 2035	U-3003		
		10376487	Jul 27, 2035	U-2615		
		10376487	Jul 27, 2035	U-3007		
		10449176	Jan 25, 2033	U-2149		
		10610510	Jan 25, 2033	U-2805		
		10610510	Jan 25, 2033	U-3009		
		10610511	Oct 10, 2034	U-2615		
		10610511	Oct 10, 2034	U-2806		
		10610511	Oct 10, 2034	U-3007		
		10829465	Feb 12, 2035	DS DP		
		5856529	Dec 09, 2022	DS DP U-2149		
		5856529	Dec 09, 2022	DS DP U-3003		
		9060995	Jan 25, 2033	U-1710		
		9539234	Jan 25, 2033	U-1934		
		9539234	Jan 25, 2033	U-3004		
		9549913	Jan 25, 2033	U-1486		
		9730910	May 17, 2034	U-2085		
		9730910	May 17, 2034	U-3005		
		9855241	Jan 25, 2033	U-2149		
		RE46604	Jan 25, 2033	U-2147		
<u>TASIMELTEON - HETLIOZ LO</u>						
N 214517	001	10071977	Feb 12, 2035	DS DP		
		10149829	Jan 25, 2033	U-3006		
		10179119	Aug 29, 2035	U-3003		
		10376487	Jul 27, 2035	U-3007		
		10610510	Jan 25, 2033	U-3009		
		10610511	Oct 10, 2034	U-3007		
		10829465	Feb 12, 2035	DS DP		
		5856529	Dec 09, 2022	DS DP U-3003		
		9539234	Jan 25, 2033	U-3004		
		9730910	May 17, 2034	U-3005		
<u>TAVABOROLE - TAVABOROLE</u>						
A 211297	001				PC	Apr 17, 2021
<u>TAVABOROLE - TAVABOROLE</u>						
A 212188	001				PC	Apr 17, 2021
<u>TAVABOROLE - KERYDIN</u>						
N 204427	001	7582621	May 26, 2027	U-2016	Y	
		7582621*PED	Nov 26, 2027			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TAVABOROLE - KERYDIN</u>						
N 204427	001 9549938	Feb 16, 2026	U-1951			
	9549938*PED	Aug 16, 2026				
	9566289	Feb 16, 2026	DP			
	9566289*PED	Aug 16, 2026				
	9566290	Feb 16, 2026	U-1970			
	9566290*PED	Aug 16, 2026				
	9572823	Feb 16, 2026	U-1970			
	9572823*PED	Aug 16, 2026				
<u>TAZAROTENE - FABIOR</u>						
N 202428	001 10568859	Feb 24, 2030	DP U-2760			
	10688071	Feb 24, 2030	DP U-2760			
	8808716	Feb 24, 2030	DP			
<u>TAZAROTENE - ARAZLO</u>						
N 211882	001 6517847	Aug 03, 2020	DP U-2368		NP	Dec 18, 2022
<u>TAZEMETOSTAT HYDROBROMIDE - TAZVERIK</u>						
N 211723	001 10155002	Apr 13, 2032	U-2736		I-835	Jun 18, 2023
	10245269	Apr 11, 2033	U-2737		I-836	Jun 18, 2023
	10245269	Apr 11, 2033	U-2851		NCE	Jan 23, 2025
	10245269	Apr 11, 2033	U-2854		ODE-299	Jan 23, 2027
	10369155	Oct 16, 2035	U-2736		ODE-314	Jun 18, 2027
	10369155	Oct 16, 2035	U-2852			
	10369155	Oct 16, 2035	U-2853			
	10420775	Apr 13, 2032	U-2736			
	10420775	Apr 13, 2032	U-2852			
	10420775	Apr 13, 2032	U-2853			
	10786511	Dec 11, 2035	DP			
	10821113	Apr 11, 2033	DS DP			
	8410088	Apr 13, 2032	DS DP			
	8691507	Sep 12, 2031	U-2852			
	8765732	Apr 13, 2032	U-2852			
	8765732	Apr 13, 2032	U-2853			
	8895245	Sep 12, 2031	U-2852			
	9090562	Apr 13, 2032	DS DP			
	9175331	Sep 12, 2031	U-2852			
	9333217	Sep 12, 2031	U-2852			
	9334527	Sep 12, 2031	U-2852			
	9394283	Apr 11, 2033	DS DP U-2852			
	9394283	Apr 11, 2033	DS DP U-2853			
	9522152	Apr 13, 2032	U-2738			
	9549931	Apr 13, 2032	U-2736			
	9549931	Apr 13, 2032	U-2852			
	9549931	Apr 13, 2032	U-2853			
	9688665	Aug 22, 2034	U-2736			
	9855275	Apr 13, 2032	U-2736			
	9872862	Apr 11, 2033	U-2738			
	9889138	Oct 16, 2035	U-2736			
	9889138	Oct 16, 2035	U-2852			
	9889138	Oct 16, 2035	U-2853			
	9949999	Sep 12, 2031	U-2851			
<u>TECHNETIUM TC-99M TETROFOSMIN KIT - MYOVIEW 30ML</u>						
N 020372	002 9549999	Mar 10, 2030	DP			
<u>TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT</u>						
N 202207	001 6409990	May 12, 2025	DS		ODE-67	Jun 13, 2021
	9439985	Sep 27, 2033	DS DP			
<u>TECOVIRIMAT - TPOXX</u>						
N 208627	001 7737168	May 03, 2027	U-2346		NCE	Jul 13, 2023
	8039504	Jul 23, 2027	DP		ODE-200	Jul 13, 2025
	8124643	Jun 18, 2024	DS DP			
	8530509	Jun 18, 2024	DP			
	8802714	Jun 18, 2024	U-2346			
	9339466	Mar 23, 2031	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205435 001	10065947	Feb 03, 2030	DP		NCE	Jun 20, 2019
	10442829	Feb 03, 2030	DS		NPP	Jun 19, 2023
	7816379	Jun 20, 2028	DS DP U-2507		GAIN	Jun 20, 2024
	8420676	Feb 23, 2028	DS DP U-282			
	8426389	Dec 31, 2030	DS DP U-282			
	9624250	Feb 03, 2030	DS DP U-2507			
	9988406	Feb 03, 2030	DP			
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205436 001	10065947	Feb 03, 2030	DP		NCE	Jun 20, 2019
	10442829	Feb 03, 2030	DS		NPP	Jun 19, 2023
	7816379	Jun 20, 2028	DS DP U-2507		GAIN	Jun 20, 2024
	8420676	Feb 23, 2028	DS DP U-282			
	8426389	Dec 31, 2030	DS DP U-282			
	9624250	Feb 03, 2030	DS DP U-2507			
	9988406	Feb 03, 2030	DP			
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	5789379	Apr 14, 2020	DS DP U-1320		ODE-240	May 16, 2026
	5789379*PED	Oct 14, 2020				
	7056886	Sep 18, 2022	DP U-1320			
	7056886*PED	Mar 18, 2023				
	7847061	Nov 01, 2025	U-1320			
	7847061*PED	May 01, 2026				
	9060992	Nov 01, 2025	U-1320			
	9060992*PED	May 01, 2026				
	9539310	Nov 01, 2025	U-1320			
	9539310*PED	May 01, 2026				
	9545434	Nov 01, 2025	U-1320			
	9545434*PED	May 01, 2026				
	9545435	Nov 01, 2025	U-1320			
	9545435*PED	May 01, 2026				
	9555079	Nov 01, 2025	U-1320			
	9555079*PED	May 01, 2026				
	9572867	Nov 01, 2025	U-1320			
	9572867*PED	May 01, 2026				
	9592273	Nov 01, 2025	U-1320			
	9592273*PED	May 01, 2026				
	9592274	Nov 01, 2025	U-1320			
	9592274*PED	May 01, 2026				
	9968655	Nov 01, 2025	U-2308			
	9968655*PED	May 01, 2026				
	9968656	Nov 01, 2025	U-2308			
	9968656*PED	May 01, 2026				
	9968658	Nov 01, 2025	U-1320			
	9968658*PED	May 01, 2026				
	9974835	Nov 01, 2025	U-1320			
	9974835*PED	May 01, 2026				
	9974837	Nov 01, 2025	U-1320			
	9974837*PED	May 01, 2026				
	9981014	Nov 01, 2025	U-1320			
	9981014*PED	May 01, 2026				
	9981016	Nov 01, 2025	U-1320			
	9981016*PED	May 01, 2026				
	9987334	Nov 01, 2025	U-1320			
	9987334*PED	May 01, 2026				
	9987335	Nov 01, 2025	U-1320			
	9987335*PED	May 01, 2026				
	9993528	Nov 01, 2025	U-1320			
	9993528*PED	May 01, 2026				
<u>TELAPREVIR - INCIVEK</u>						
N 201917 001	7820671	Feb 25, 2025	DS DP			
	8431615	May 30, 2028	U-1398			
	8529882	Aug 31, 2021	U-1398			
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N 022110 001	6635618	Sep 11, 2023	DS DP U-728			
	6858584	Aug 24, 2022	DP			
	6872701	Jun 05, 2021	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N 022110	001	7008923	May 06, 2021		U-1005	
		7208471	May 01, 2021	DS DP		
		7351691	May 01, 2021	DS DP	U-728	
		7531623	Jan 01, 2027	DS		
		7544364	May 01, 2021	DP		
		7700550	May 01, 2021		U-282	
		8101575	May 01, 2021	DP		
		8158580	May 01, 2021	DP		
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N 022110	002	6635618	Sep 11, 2023	DS DP	U-728	
		6858584	Aug 24, 2022	DP		
		6872701	Jun 05, 2021	DP		
		7008923	May 06, 2021		U-1005	
		7208471	May 01, 2021	DS DP		
		7351691	May 01, 2021	DS DP	U-728	
		7531623	Jan 01, 2027	DS		
		7544364	May 01, 2021	DP		
		7700550	May 01, 2021		U-282	
		8101575	May 01, 2021	DP		
		8158580	May 01, 2021	DP		
<u>TELBIVUDINE - TYZEKA</u>						
N 022011	001	6569837	Oct 25, 2020		U-782	
		6569837	Oct 25, 2020		U-999	
		7589079	Sep 11, 2023	DS DP	U-999	
		7858594	Sep 11, 2023	DS DP	U-999	
<u>TELBIVUDINE - TYZEKA</u>						
N 022154	001	6569837	Oct 25, 2020		U-999	
		7858594	Sep 11, 2023	DS DP	U-999	
<u>TELMISARTAN - MICARDIS</u>						
N 020850	001	6358986	Jan 10, 2020			
<u>TELMISARTAN - MICARDIS</u>						
N 020850	002	6358986	Jan 10, 2020			
		7998953	Jun 06, 2020		U-1177	
		8003679	Oct 06, 2022		U-1176	
<u>TELMISARTAN - MICARDIS</u>						
N 020850	003	6358986	Jan 10, 2020			
<u>TELOTTRISTAT ETIPRATE - XERMELO</u>						
N 208794	001	7553840	Dec 11, 2027	DS		NCE Feb 28, 2022
		7709493	Dec 11, 2027	DS	U-1979	ODE-132 Feb 28, 2024
		7968559	Dec 11, 2027		U-1979	
		8193204	Feb 27, 2031	DS		
		8653094	Dec 19, 2028		U-1979	
<u>TEMOZOLOMIDE - TEMODAR</u>						
N 022277	001	6987108	Sep 08, 2023	DP		
		7786118	Feb 21, 2023	DP		
		8623868	Feb 21, 2023	DP		
<u>TEMSIROLIMUS - TORISEL</u>						
N 022088	001	8026276	Jan 20, 2026	DP		
		8299116	Jul 25, 2023	DP		
		8455539	Jul 25, 2023	DP		
		8455539*PED	Jan 25, 2024			
		8722700	Jul 25, 2023	DP		
		8722700*PED	Jan 25, 2024			
		8791097	May 10, 2032		U-1550	
		8791097	May 10, 2032		U-1551	
		8791097*PED	Nov 10, 2032			
<u>TENAPANOR HYDROCHLORIDE - IBSRELA</u>						
N 211801	001	8541448	Dec 30, 2029	DS DP		NCE Sep 12, 2024
		8969377	Dec 30, 2029	DS DP		
		9006281	May 02, 2030		U-2626	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TENAPANOR HYDROCHLORIDE - IBSRELA</u>						
N 211801	001 9408840	Dec 30, 2029		U-2626		
<u>TENOFOVIR ALAFENAMIDE FUMARATE - VEMLIDY</u>						
N 208464	001 7390791	Apr 17, 2025	DS DP		M-255	Feb 04, 2023
	7803788	Feb 02, 2022		U-999	M-266	Aug 22, 2023
	8754065	Aug 15, 2032	DS DP	U-999	NCE	Nov 05, 2020
	9296769	Aug 15, 2032	DS DP	U-999		
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356	001				NPP	Dec 11, 2021
					PED	Jun 11, 2022
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356	002				NPP	Dec 11, 2021
					PED	Jun 11, 2022
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356	003				NPP	Dec 11, 2021
					PED	Jun 11, 2022
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356	004				NPP	Dec 11, 2021
					PED	Jun 11, 2022
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 022577	001				NPP	Dec 11, 2021
					PED	Jun 11, 2022
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N 202992	001 6794410	Sep 12, 2026		U-1285		
	8802735	Sep 14, 2030	DP			
	9186346	Feb 04, 2034		U-1786		
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N 202992	002 6794410	Sep 12, 2026		U-1285		
	8802735	Sep 14, 2030	DP			
	9186346	Feb 04, 2034		U-1786		
<u>TERIPARATIDE - FORTEO</u>						
N 021318	001 7517334	Mar 25, 2025		DP		
<u>TERIPARATIDE - FORTEO</u>						
N 021318	002 7517334	Mar 25, 2025		DP		
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015	001 6503894	Aug 30, 2020		U-490		
	9125816	Aug 30, 2020		U-490		
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020		U-490		
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015	002 6503894	Aug 30, 2020		U-490		
	9125816	Aug 30, 2020		U-490		
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020		U-490		
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015	003 6503894	Aug 30, 2020		U-490		
	9125816	Aug 30, 2020		U-490		
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020		U-490		
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - TESTIM</u>						
N 021454	001 7320968	Jan 18, 2025		U-843		
	7608605	Apr 21, 2023		U-1009		
	7608606	Apr 21, 2023		U-1009		
	7608607	Apr 21, 2023		U-1009		
	7608608	Apr 21, 2023		U-1009		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE - TESTIM</u>						
N 021454	001	7608609	Apr 21, 2023			U-1009
		7608610	Apr 21, 2023			U-1009
		7935690	Apr 21, 2023			U-1009
		8063029	Apr 21, 2023			U-843
		8178518	Apr 21, 2023			DP
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309	001	6503894	Aug 30, 2020			U-1103
		6503894*PED	Mar 02, 2021			
		8466136	Oct 12, 2026			DP
		8466137	Oct 12, 2026			U-1103
		8466138	Oct 12, 2026			U-1103
		8486925	Oct 12, 2026			DP
		8729057	Oct 12, 2026			DP
		8741881	Oct 12, 2026			U-1103
		8754070	Oct 12, 2026			DP
		8759329	Oct 12, 2026			DP
		9125816	Aug 30, 2020			U-1103
		9125816*PED	Mar 02, 2021			
		9132089	Aug 30, 2020			U-1103
		9132089*PED	Mar 02, 2021			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309	002	6503894	Aug 30, 2020			U-1103
		6503894*PED	Mar 02, 2021			
		8466136	Oct 12, 2026			DP
		8466137	Oct 12, 2026			U-1103
		8466138	Oct 12, 2026			U-1103
		8486925	Oct 12, 2026			DP
		8729057	Oct 12, 2026			DP
		8741881	Oct 12, 2026			U-1103
		8754070	Oct 12, 2026			DP
		8759329	Oct 12, 2026			DP
		9125816	Aug 30, 2020			U-1103
		9125816*PED	Mar 02, 2021			
		9132089	Aug 30, 2020			U-1103
		9132089*PED	Mar 02, 2021			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309	003	6503894	Aug 30, 2020			U-1103
		6503894*PED	Mar 02, 2021			
		8466136	Oct 12, 2026			DP
		8466137	Oct 12, 2026			U-1103
		8466138	Oct 12, 2026			U-1103
		8486925	Oct 12, 2026			DP
		8729057	Oct 12, 2026			DP
		8741881	Oct 12, 2026			U-1103
		8754070	Oct 12, 2026			DP
		8759329	Oct 12, 2026			DP
		9125816	Aug 30, 2020			U-1103
		9125816*PED	Mar 02, 2021			
		9132089	Aug 30, 2020			U-1103
		9132089*PED	Mar 02, 2021			
<u>TESTOSTERONE - AXIRON</u>						
N 022504	001	8419307	Feb 26, 2027			U-1386
		8435944	Sep 27, 2027			U-1390
		8784878	Jul 13, 2023			DP U-1545
		8807861	Feb 26, 2027			DP U-1563
		8993520	Jun 02, 2026			U-1390
		9180194	Jun 02, 2026			U-1390
		9289586	Feb 26, 2027			U-1390
<u>TESTOSTERONE - VOGELXO</u>						
N 204399	002	8785426	Feb 11, 2034			DP U-1531
		9295675	Feb 11, 2034			DP U-1531
		9662340	Feb 11, 2034			DP U-1531

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE - VOGELXO</u>						
N 204399	003	8785426	Feb 11, 2034	DP U-1531		
		9295675	Feb 11, 2034	DP U-1531		
		9662340	Feb 11, 2034	DP U-1531		
<u>TESTOSTERONE - NATESTO</u>						
N 205488	001	8574622	Feb 04, 2024	DP		
		8784869	Feb 04, 2024	DP		
		8784882	Feb 04, 2024	DP U-1557		
		8877230	Feb 04, 2024	U-1616		
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863	001	10238662	Feb 19, 2035	DP U-2418	NP	Sep 28, 2021
		10279131	Jul 31, 2031	DP		
		10357609	Aug 21, 2031	DP		
		10478560	Jan 24, 2026	DP		
		10646495	Aug 30, 2038	DP		
		10821072	Jun 04, 2033	DP U-2418		
		8021335	Oct 04, 2026	DP		
		8562564	Jan 24, 2026	DP		
		9180259	Jan 24, 2026	DP		
		9533102	Jan 24, 2026	DP		
		9629959	Jan 24, 2026	DP		
		9744302	Nov 19, 2035	DP		
		9950125	Sep 04, 2036	DP U-2418		
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863	002	10238662	Feb 19, 2035	DP U-2418	NP	Sep 28, 2021
		10279131	Jul 31, 2031	DP		
		10357609	Aug 21, 2031	DP		
		10478560	Jan 24, 2026	DP		
		10646495	Aug 30, 2038	DP		
		10821072	Jun 04, 2033	DP U-2418		
		8021335	Oct 04, 2026	DP		
		8562564	Jan 24, 2026	DP		
		9180259	Jan 24, 2026	DP		
		9533102	Jan 24, 2026	DP		
		9629959	Jan 24, 2026	DP		
		9744302	Nov 19, 2035	DP		
		9950125	Sep 04, 2036	DP U-2418		
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863	003	10238662	Feb 19, 2035	DP U-2418	NP	Sep 28, 2021
		10279131	Jul 31, 2031	DP		
		10357609	Aug 21, 2031	DP		
		10478560	Jan 24, 2026	DP		
		10646495	Aug 30, 2038	DP		
		10821072	Jun 04, 2033	DP U-2418		
		8021335	Oct 04, 2026	DP		
		8562564	Jan 24, 2026	DP		
		9180259	Jan 24, 2026	DP		
		9533102	Jan 24, 2026	DP		
		9629959	Jan 24, 2026	DP		
		9744302	Nov 19, 2035	DP		
		9950125	Sep 04, 2036	DP U-2418		
<u>TESTOSTERONE UNDECANOATE - AVEED</u>						
N 022219	001	7718640	Mar 14, 2027	DP		
		8338395	May 08, 2027	U-1500		
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089	001	10543219	Apr 12, 2030	U-2506	NP	Mar 27, 2022
		10617696	Apr 12, 2030	DS DP		
		8241664	Mar 29, 2029	DP U-2506		
		8492369	Dec 20, 2030	DP U-2506		
		8778916	Apr 12, 2030	DP		
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089	002	10543219	Apr 12, 2030	U-2506	NP	Mar 27, 2022
		10617696	Apr 12, 2030	DS DP		
		8241664	Mar 29, 2029	DP U-2506		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089	002	8492369	Dec 20, 2030	DP	U-2506	
		8778916	Apr 12, 2030	DP		
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089	003	10543219	Apr 12, 2030		U-2506	NP
		10617696	Apr 12, 2030	DS DP		Mar 27, 2022
		8241664	Mar 29, 2029	DP	U-2506	
		8492369	Dec 20, 2030	DP	U-2506	
		8778916	Apr 12, 2030	DP		
<u>THALIDOMIDE - THALOMID</u>						
N 020785	001	6315720	Oct 23, 2020		U-442	
		6315720	Oct 23, 2020		U-731	
		6561977	Oct 23, 2020		U-371	
		6561977	Oct 23, 2020		U-731	
		6755784	Oct 23, 2020		U-371	
		6755784	Oct 23, 2020		U-731	
		6869399	Oct 23, 2020		U-371	
		6869399	Oct 23, 2020		U-731	
		6869399	Oct 23, 2020		U-732	
		6869399	Oct 23, 2020		U-733	
		7141018	Oct 23, 2020		U-371	
		7141018	Oct 23, 2020		U-731	
		7141018	Oct 23, 2020		U-732	
		7141018	Oct 23, 2020		U-733	
		7230012	Dec 09, 2023	DP		
		7959566	Oct 23, 2020		U-1155	
		8315886	Oct 23, 2020		U-1249	
		8626531	Oct 23, 2020		U-1465	
<u>THALIDOMIDE - THALOMID</u>						
N 020785	002	6315720	Oct 23, 2020		U-442	
		6315720	Oct 23, 2020		U-731	
		6561977	Oct 23, 2020		U-371	
		6561977	Oct 23, 2020		U-731	
		6755784	Oct 23, 2020		U-371	
		6755784	Oct 23, 2020		U-731	
		6869399	Oct 23, 2020		U-371	
		6869399	Oct 23, 2020		U-731	
		6869399	Oct 23, 2020		U-732	
		6869399	Oct 23, 2020		U-733	
		7141018	Oct 23, 2020		U-371	
		7141018	Oct 23, 2020		U-731	
		7141018	Oct 23, 2020		U-732	
		7141018	Oct 23, 2020		U-733	
		7230012	Dec 09, 2023	DP		
		7959566	Oct 23, 2020		U-1155	
		8315886	Oct 23, 2020		U-1249	
		8626531	Oct 23, 2020		U-1465	
<u>THALIDOMIDE - THALOMID</u>						
N 020785	003	6315720	Oct 23, 2020		U-442	
		6315720	Oct 23, 2020		U-731	
		6561977	Oct 23, 2020		U-371	
		6561977	Oct 23, 2020		U-731	
		6755784	Oct 23, 2020		U-371	
		6755784	Oct 23, 2020		U-731	
		6869399	Oct 23, 2020		U-371	
		6869399	Oct 23, 2020		U-731	
		6869399	Oct 23, 2020		U-732	
		6869399	Oct 23, 2020		U-733	
		7141018	Oct 23, 2020		U-371	
		7141018	Oct 23, 2020		U-731	
		7141018	Oct 23, 2020		U-732	
		7141018	Oct 23, 2020		U-733	
		7230012	Dec 09, 2023	DP		
		7959566	Oct 23, 2020		U-1155	
		8315886	Oct 23, 2020		U-1249	
		8626531	Oct 23, 2020		U-1465	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>THALIDOMIDE - THALOMID</u>						
N 020785	004	6315720	Oct 23, 2020	U-731		
		6561977	Oct 23, 2020	U-731		
		6755784	Oct 23, 2020	U-731		
		6869399	Oct 23, 2020	U-731		
		7141018	Oct 23, 2020	U-731		
		7959566	Oct 23, 2020	U-1155		
		8315886	Oct 23, 2020	U-1249		
		8626531	Oct 23, 2020	U-1465		
<u>THIOTEPA - TEPADINA</u>						
N 208264	001				I-747 ODE-129	Jan 26, 2020 Jan 26, 2024
<u>THIOTEPA - TEPADINA</u>						
N 208264	002				I-747 ODE-129	Jan 26, 2020 Jan 26, 2024
<u>TICAGRELOR - BRILINTA</u>						
N 022433	001	10300065	Jan 27, 2036	U-2541	I-848	Nov 05, 2023
		10300065	Jan 27, 2036	U-2542		
		7265124	Jul 09, 2021	DS DP U-1171		
		7265124	Jul 09, 2021	DS DP U-1860		
		7265124	Jul 09, 2021	DS DP U-1868		
		7265124	Jul 09, 2021	DS DP U-1869		
		8425934	Apr 17, 2030	DP		
		RE46276	Oct 30, 2024	DS DP U-1935		
		RE46276	Oct 30, 2024	DS DP U-1936		
		RE46276	Oct 30, 2024	DS DP U-1937		
		RE46276	Oct 30, 2024	DS DP U-1938		
		RE46276	Oct 30, 2024	DS DP U-2838		
		RE46276	Oct 30, 2024	DS DP U-2839		
<u>TICAGRELOR - BRILINTA</u>						
N 022433	002	10300065	Jan 27, 2036	U-2541	I-848	Nov 05, 2023
		10300065	Jan 27, 2036	U-2542		
		7265124	Jul 09, 2021	DS DP U-1171		
		7265124	Jul 09, 2021	DS DP U-1860		
		7265124	Jul 09, 2021	DS DP U-1868		
		7265124	Jul 09, 2021	DS DP U-1869		
		8425934	Apr 17, 2030	DP		
		RE46276	Oct 30, 2024	DS DP U-1935		
		RE46276	Oct 30, 2024	DS DP U-1936		
		RE46276	Oct 30, 2024	DS DP U-1937		
		RE46276	Oct 30, 2024	DS DP U-1938		
		RE46276	Oct 30, 2024	DS DP U-2838		
		RE46276	Oct 30, 2024	DS DP U-2839		
<u>TIGECYCLINE - TYGACIL</u>						
N 021821	001	10588975	Mar 13, 2026	DP		
		7879828	Feb 05, 2029	DP		
		8372995	Oct 08, 2030	DP		
		8975242	Oct 24, 2028	DP		
		9254328	Mar 13, 2026	DP		
		9694078	Mar 13, 2026	DP		
<u>TIGECYCLINE - TIGECYCLINE</u>						
N 211158	001	9855335	Apr 07, 2033	DP		
<u>TIMOLOL MALEATE - TIMOLOL MALEATE</u>						
A 212942	001				CGT	May 24, 2021
<u>TIMOLOL MALEATE - TIMOLOL MALEATE</u>						
A 212942	002				CGT	May 24, 2021
<u>TIOPRONIN - THIOLA</u>						
N 019569	001				ODE-267	Jun 28, 2026
<u>TIOTROPIUM BROMIDE - SPIRIVA</u>						
N 021395	001	6777423	Sep 24, 2021	DS DP		
		6777423*PED	Mar 24, 2022			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TIOTROPIUM BROMIDE - SPIRIVA</u>						
N 021395	001	6908928	Sep 24, 2021	DS DP U-566		
		6908928	Sep 24, 2021	DS DP U-762		
		6908928*PED	Mar 24, 2022			
		7070800	Jan 22, 2022	DP U-566		
		7070800*PED	Jul 22, 2022			
		7309707	Sep 24, 2021	DS DP		
		7309707*PED	Mar 24, 2022			
		7642268	Sep 24, 2021	DS DP		
		7642268*PED	Mar 24, 2022			
		7694676	Mar 12, 2027	DP		
		7694676*PED	Sep 12, 2027			
		8022082	Jan 19, 2026	DP U-1186		
		8022082*PED	Jul 19, 2026			
		9010323	Apr 19, 2030	DP		
		RE38912	Oct 11, 2021	DP		
		RE38912*PED	Apr 11, 2022			
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936	001	6988496	Feb 23, 2020	DP	NPP	Feb 15, 2020
		6988496*PED	Aug 23, 2020		PED	Aug 15, 2020
		7284474	Aug 26, 2024	DP		
		7284474*PED	Feb 26, 2025			
		7396341	Oct 10, 2026	DP		
		7396341*PED	Apr 10, 2027			
		7837235	Mar 13, 2028	DP		
		7837235*PED	Sep 13, 2028			
		7896264	May 26, 2025	DP		
		7896264*PED	Nov 26, 2025			
		7988001	Aug 04, 2021	DP		
		7988001*PED	Feb 04, 2022			
		8733341	Oct 16, 2030	DP		
		8733341*PED	Apr 16, 2031			
		9027967	Mar 31, 2027	DP		
		9027967*PED	Oct 01, 2027			
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936	002	6988496	Feb 23, 2020	DP	NPP	Feb 15, 2020
		6988496*PED	Aug 23, 2020		PED	Aug 15, 2020
		7284474	Aug 26, 2024	DP		
		7284474*PED	Feb 26, 2025			
		7396341	Oct 10, 2026	DP		
		7396341*PED	Apr 10, 2027			
		7837235	Mar 13, 2028	DP		
		7837235*PED	Sep 13, 2028			
		7896264	May 26, 2025	DP		
		7896264*PED	Nov 26, 2025			
		7988001	Aug 04, 2021	DP		
		7988001*PED	Feb 04, 2022			
		8733341	Oct 16, 2030	DP		
		8733341*PED	Apr 16, 2031			
		9027967	Mar 31, 2027	DP		
		9027967*PED	Oct 01, 2027			
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURE</u>						
N 207981	001	10456399	Feb 03, 2037		I-794	Feb 22, 2022
		10457666	Jun 17, 2034	DS DP	NCE	Sep 22, 2020
		6479500	Mar 16, 2020		U-1751	Feb 22, 2026
		9527833	Jun 17, 2034	DS DP	ODE-229	
		RE46284	Dec 16, 2026		U-1751	
		RE46284	Dec 16, 2026		U-2503	
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURE</u>						
N 207981	002	10456399	Feb 03, 2037		I-794	Feb 22, 2022
		10457666	Jun 17, 2034	DS DP	NCE	Sep 22, 2020
		6479500	Mar 16, 2020		U-1751	Feb 22, 2026
		9527833	Jun 17, 2034	DS DP	ODE-229	
		RE46284	Dec 16, 2026		U-1751	
		RE46284	Dec 16, 2026		U-2503	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020912	001 6770660	May 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020912	002 6770660	May 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913	001 6770660	May 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913	002 6770660	May 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913	003 6770660	May 01, 2023	U-1444			
<u>TOBRAMYCIN - TOBI PODHALER</u>						
N 201688	001 10207066	Nov 04, 2030	DP U-909			
	7368102	Dec 19, 2022	DP U-909			
	7442388	May 10, 2020	DP			
	7516741	Jan 11, 2024	DP			
	7559325	Oct 27, 2025	DP			
	8069851	Sep 24, 2024	DP			
	8349294	May 10, 2020	DP			
	8664187	Jun 20, 2025	U-909			
	8715623	Dec 19, 2022	DP U-909			
	8869794	Sep 12, 2028	DP U-909			
	9421166	Dec 19, 2022	DP U-909			
	RE47526	Apr 09, 2024	DP			
<u>TOBRAMYCIN - BETHKIS</u>						
N 201820	001 6987094	Sep 22, 2022	DP			
	7696178	Sep 22, 2022	DP			
	7939502	Jun 14, 2022	U-1324			
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214	001 6956041	Dec 08, 2020	DP		I-761	Dec 14, 2020
	6965027	Mar 25, 2023	DS		I-780	May 30, 2021
	7091208	Dec 08, 2020	U-247		NPP	Sep 25, 2023
	7265221	Dec 08, 2020	DS			
	7301023	Dec 08, 2020	DS			
	7842699	Dec 08, 2020	U-2322			
	RE41783	Dec 08, 2025	DS			
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214	002 6956041	Dec 08, 2020	DP		I-780	May 30, 2021
	6965027	Mar 25, 2023	DS			
	7265221	Dec 08, 2020	DS			
	7301023	Dec 08, 2020	DS			
	7842699	Dec 08, 2020	U-2322			
	RE41783	Dec 08, 2025	DS			
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246	001 6956041	Dec 08, 2020	DP		I-761	Dec 14, 2020
	6965027	Mar 25, 2023	DS			
	7091208	Dec 08, 2020	U-247			
	7265221	Dec 08, 2020	DS			
	7301023	Dec 08, 2020	DS			
	7842699	Dec 08, 2020	U-2322			
	9937181	Mar 14, 2034	DP			
	RE41783	Dec 08, 2025	DS			
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246	002 10639309	Mar 14, 2034	DP			
	6956041	Dec 08, 2020	DP			
	6965027	Mar 25, 2023	DS			
	7265221	Dec 08, 2020	DS			
	7301023	Dec 08, 2020	DS			
	7842699	Dec 08, 2020	U-2322			
	RE41783	Dec 08, 2025	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TOFACITINIB CITRATE - Xeljanz</u>						
N 213082	001 6956041	Dec 08, 2020	DP		NP	Sep 25, 2023
	7265221	Dec 08, 2020	DS			
	7301023	Dec 08, 2020	DS			
	RE41783	Dec 08, 2025	DS			
<u>TOLTERODINE TARTRATE - DETROL LA</u>						
N 021228	001 6911217*PED	May 11, 2020				
<u>TOLTERODINE TARTRATE - DETROL LA</u>						
N 021228	002 6911217*PED	May 11, 2020				
<u>TOLVAPTAN - SAMSCA</u>						
N 022275	001 5753677	May 19, 2020		U-978		
	8501730	Sep 01, 2026	DS			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275	002 5753677	May 19, 2020		U-978		
	8501730	Sep 01, 2026	DS			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275	003 5753677	May 19, 2020		U-978		
	8501730	Sep 01, 2026	DS			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441	001 5753677	May 19, 2020		U-2307	I-779	Apr 23, 2021
	8501730	Sep 01, 2026	DS		ODE-178	Apr 23, 2025
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441	002 5753677	May 19, 2020		U-2307	I-779	Apr 23, 2021
	8501730	Sep 01, 2026	DS		ODE-178	Apr 23, 2025
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441	003 5753677	May 19, 2020		U-2307	I-779	Apr 23, 2021
	8501730	Sep 01, 2026	DS		ODE-178	Apr 23, 2025
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441	004 5753677	May 19, 2020		U-2307	I-779	Apr 23, 2021
	8501730	Sep 01, 2026	DS		ODE-178	Apr 23, 2025
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441	005 5753677	May 19, 2020		U-2307	I-779	Apr 23, 2021
	8501730	Sep 01, 2026	DS		ODE-178	Apr 23, 2025
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635	001 10314790	Nov 16, 2027	DP	U-1675		
	10314790	Nov 16, 2027	DP	U-1992		
	8298576	Apr 04, 2028	DP	U-106		
	8298576	Apr 04, 2028	DP	U-1992		
	8298580	Nov 16, 2027	DP	U-106		
	8298580	Nov 16, 2027	DP	U-1992		
	8663683	Nov 16, 2027	DP	U-106		
	8663683	Nov 16, 2027	DP	U-1992		
	8877248	Nov 16, 2027	DP	U-106		
	8877248	Nov 16, 2027	DP	U-1992		
	8889191	Nov 16, 2027		U-106		
	8889191	Nov 16, 2027		U-1992		
	8992989	Nov 16, 2027	DP	U-1675		
	8992989	Nov 16, 2027	DP	U-1992		
	9549940	Nov 16, 2027	DP	U-1675		
	9549940	Nov 16, 2027	DP	U-1992		
	9555004	Nov 16, 2027	DP	U-1675		
	9555004	Nov 16, 2027	DP	U-1992		
	9622983	Nov 16, 2027	DP	U-1675		
	9622983	Nov 16, 2027	DP	U-1992		
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635	002 10314790	Nov 16, 2027	DP	U-1675		
	10314790	Nov 16, 2027	DP	U-1992		
	8298576	Apr 04, 2028	DP	U-106		
	8298576	Apr 04, 2028	DP	U-1992		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635	002	8298580	Nov 16, 2027	DP U-106		
		8298580	Nov 16, 2027	DP U-1992		
		8663683	Nov 16, 2027	DP U-106		
		8663683	Nov 16, 2027	DP U-1992		
		8877248	Nov 16, 2027	DP U-106		
		8877248	Nov 16, 2027	DP U-1992		
		8889191	Nov 16, 2027	U-106		
		8889191	Nov 16, 2027	U-1992		
		8992989	Nov 16, 2027	DP U-1675		
		8992989	Nov 16, 2027	DP U-1992		
		9549940	Nov 16, 2027	DP U-1675		
		9549940	Nov 16, 2027	DP U-1992		
		9555004	Nov 16, 2027	DP U-1675		
		9555004	Nov 16, 2027	DP U-1992		
		9622983	Nov 16, 2027	DP U-1675		
		9622983	Nov 16, 2027	DP U-1992		
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635	003	10314790	Nov 16, 2027	DP U-1675		
		10314790	Nov 16, 2027	DP U-1992		
		8298576	Apr 04, 2028	DP U-106		
		8298576	Apr 04, 2028	DP U-1992		
		8298580	Nov 16, 2027	DP U-106		
		8298580	Nov 16, 2027	DP U-1992		
		8663683	Nov 16, 2027	DP U-106		
		8663683	Nov 16, 2027	DP U-1992		
		8877248	Nov 16, 2027	DP U-106		
		8877248	Nov 16, 2027	DP U-1992		
		8889191	Nov 16, 2027	U-106		
		8889191	Nov 16, 2027	U-1992		
		8992989	Nov 16, 2027	DP U-1675		
		8992989	Nov 16, 2027	DP U-1992		
		9549940	Nov 16, 2027	DP U-1675		
		9549940	Nov 16, 2027	DP U-1992		
		9555004	Nov 16, 2027	DP U-1675		
		9555004	Nov 16, 2027	DP U-1992		
		9622983	Nov 16, 2027	DP U-1675		
		9622983	Nov 16, 2027	DP U-1992		
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635	004	10314790	Nov 16, 2027	DP U-1675		
		10314790	Nov 16, 2027	DP U-1992		
		8298576	Apr 04, 2028	DP U-106		
		8298576	Apr 04, 2028	DP U-1992		
		8298580	Nov 16, 2027	DP U-106		
		8298580	Nov 16, 2027	DP U-1992		
		8663683	Nov 16, 2027	DP U-106		
		8663683	Nov 16, 2027	DP U-1992		
		8877248	Nov 16, 2027	DP U-106		
		8877248	Nov 16, 2027	DP U-1992		
		8889191	Nov 16, 2027	U-106		
		8889191	Nov 16, 2027	U-1992		
		8992989	Nov 16, 2027	DP U-1675		
		8992989	Nov 16, 2027	DP U-1992		
		9549940	Nov 16, 2027	DP U-1675		
		9549940	Nov 16, 2027	DP U-1992		
		9555004	Nov 16, 2027	DP U-1675		
		9555004	Nov 16, 2027	DP U-1992		
		9622983	Nov 16, 2027	DP U-1675		
		9622983	Nov 16, 2027	DP U-1992		
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122	001	10363224	Mar 19, 2033	U-766		
		8652527	Mar 19, 2033	DP		
		8889190	Mar 19, 2033	DP		
		9101545	Mar 19, 2033	DP		
		9555005	Mar 19, 2033	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122	002	10363224	Mar 19, 2033		U-766	
		8652527	Mar 19, 2033	DP		
		8889190	Mar 19, 2033	DP		
		9101545	Mar 19, 2033	DP		
		9555005	Mar 19, 2033	DP		
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122	003	10363224	Mar 19, 2033		U-766	
		8652527	Mar 19, 2033	DP		
		8889190	Mar 19, 2033	DP		
		9101545	Mar 19, 2033	DP		
		9555005	Mar 19, 2033	DP		
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122	004	10363224	Mar 19, 2033		U-766	
		8652527	Mar 19, 2033	DP		
		8889190	Mar 19, 2033	DP		
		9101545	Mar 19, 2033	DP		
		9555005	Mar 19, 2033	DP		
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122	005	10363224	Mar 19, 2033		U-766	
		8652527	Mar 19, 2033	DP		
		8889190	Mar 19, 2033	DP		
		9101545	Mar 19, 2033	DP		
		9555005	Mar 19, 2033	DP		
<u>TOPOTECAN HYDROCHLORIDE - HYCAMTIN</u>						
N 020981	001	8158645	Dec 10, 2024	DP		
<u>TOPOTECAN HYDROCHLORIDE - HYCAMTIN</u>						
N 020981	002	8158645	Dec 10, 2024	DP		
<u>TRABECTEDIN - YONDELIS</u>						
N 207953	001	8895557	Jan 07, 2028	DP	M-232	Jun 29, 2021
		8895557*PED	Jul 07, 2028		NCE	Oct 23, 2020
					ODE-100	Oct 23, 2022
					PED	Apr 23, 2021
					PED	Dec 29, 2021
					PED	Apr 23, 2023
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
N 021745	001	6607748	Jun 29, 2020	DP		
		7988998	Oct 27, 2023	DP		
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
N 021745	002	6607748	Jun 29, 2020	DP		
		7988998	Oct 27, 2023	DP		
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
N 021745	003	6607748	Jun 29, 2020	DP		
		7988998	Oct 27, 2023	DP		
<u>TRAMADOL HYDROCHLORIDE - CONZIP</u>						
N 022370	001	7858118	Apr 11, 2022	DP	U-1104	
<u>TRAMADOL HYDROCHLORIDE - CONZIP</u>						
N 022370	002	7858118	Apr 11, 2022	DP	U-1104	
<u>TRAMADOL HYDROCHLORIDE - CONZIP</u>						
N 022370	003	7858118	Apr 11, 2022	DP	U-1104	
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114	001	7378423	May 29, 2027	DS DP	I-745	Jun 22, 2020
		8580304	Jan 28, 2032	DP	I-778	Apr 30, 2021
		8703781	Oct 15, 2030	DS DP	U-1712	May 04, 2021
		8703781	Oct 15, 2030	DS DP	U-2020	Oct 06, 2022
		8703781	Oct 15, 2030	DS DP	U-2037	Jun 22, 2024
		8703781	Oct 15, 2030	DS DP	U-2302	Apr 30, 2025
		8703781	Oct 15, 2030	DS DP	U-2305	May 04, 2025
		8835443	Jun 10, 2025	U-1581	ODE-48	May 29, 2020

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114	001	8835443	Jun 10, 2025	U-1582	ODE-57	Jan 08, 2021
		8835443	Jun 10, 2025	U-2020		
		8835443	Jun 10, 2025	U-2037		
		8835443	Jun 10, 2025	U-2302		
		8835443	Jun 10, 2025	U-2305		
		8952018	Oct 15, 2030	U-2020		
		9155706	Jan 28, 2032	DP		
		9271941	Jan 28, 2032	DP		
		9399021	Jan 28, 2032	DP		
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114	002	7378423	May 29, 2027	DS DP	I-745	Jun 22, 2020
		8580304	Jan 28, 2032	DP	I-778	Apr 30, 2021
		8703781	Oct 15, 2030	DS DP U-1712	I-781	May 04, 2021
		8703781	Oct 15, 2030	DS DP U-2020	M-246	Oct 06, 2022
		8703781	Oct 15, 2030	DS DP U-2037	ODE-148	Jun 22, 2024
		8703781	Oct 15, 2030	DS DP U-2302	ODE-182	Apr 30, 2025
		8703781	Oct 15, 2030	DS DP U-2305	ODE-183	May 04, 2025
		8835443	Jun 10, 2025	U-1581	ODE-48	May 29, 2020
		8835443	Jun 10, 2025	U-1582	ODE-57	Jan 08, 2021
		8835443	Jun 10, 2025	U-2020		
		8835443	Jun 10, 2025	U-2037		
		8835443	Jun 10, 2025	U-2302		
		8835443	Jun 10, 2025	U-2305		
		8952018	Oct 15, 2030	U-2020		
		9155706	Jan 28, 2032	DP		
		9271941	Jan 28, 2032	DP		
		9399021	Jan 28, 2032	DP		
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114	003	7378423	May 29, 2027	DS DP	I-745	Jun 22, 2020
		8580304	Jan 28, 2032	DP	I-778	Apr 30, 2021
		8703781	Oct 15, 2030	DS DP U-1712	I-781	May 04, 2021
		8703781	Oct 15, 2030	DS DP U-2020	M-246	Oct 06, 2022
		8703781	Oct 15, 2030	DS DP U-2037	ODE-148	Jun 22, 2024
		8703781	Oct 15, 2030	DS DP U-2302	ODE-182	Apr 30, 2025
		8703781	Oct 15, 2030	DS DP U-2305	ODE-183	May 04, 2025
		8835443	Jun 10, 2025	U-1581	ODE-48	May 29, 2020
		8835443	Jun 10, 2025	U-1582	ODE-57	Jan 08, 2021
		8835443	Jun 10, 2025	U-2020		
		8835443	Jun 10, 2025	U-2037		
		8835443	Jun 10, 2025	U-2302		
		8835443	Jun 10, 2025	U-2305		
		8952018	Oct 15, 2030	U-2020		
		9155706	Jan 28, 2032	DP		
		9271941	Jan 28, 2032	DP		
		9399021	Jan 28, 2032	DP		
<u>TRANEXAMIC ACID - LYSTEDA</u>						
N 022430	001	7947739	Mar 04, 2025	DP		
		8022106	Mar 04, 2025	U-1182		
		8273795	Mar 04, 2025	U-1182		
		8487005	Mar 04, 2025	DP U-1182		
		8791160	Mar 04, 2025	DP U-1182		
		8809394	Mar 04, 2025	DP U-1182		
		8957113	Mar 04, 2025	DP U-1182		
		9060939	Mar 04, 2025	DP		
<u>TRAVOPROST - TRAVATAN Z</u>						
N 021994	001	8268299	Oct 13, 2029	DP		
		8323630	Sep 20, 2027	DP		
		8388941	Sep 20, 2027	DP		
<u>TRAVOPROST - IZBA</u>						
N 204822	001	8178582	Oct 10, 2029	DP		
		8722735	Oct 10, 2029	DP		
		8754123	May 19, 2029	DP		
		9144561	Mar 13, 2029	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207	001	8133893	Mar 13, 2029	DS DP		
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207	002	8133893	Mar 13, 2029	DS DP		
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207	003	8133893	Mar 13, 2029	DS DP		
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207	004	8133893	Mar 13, 2029	DS DP		
<u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u>						
N 022411	001	6607748	Jun 29, 2020	DP		
		7829120	Mar 27, 2027	DP	U-796	
		8133893	Mar 13, 2029	DS DP		
<u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u>						
N 022411	002	6607748	Jun 29, 2020	DP		
		7829120	Mar 27, 2027	DP	U-796	
		8133893	Mar 13, 2029	DS DP		
<u>TREPROSTINIL - REMODULIN</u>						
N 021272	001	10076505	Dec 16, 2024	DP		
		10695308	Dec 16, 2024		U-2845	
		7999007	Mar 29, 2029	DP	U-1437	
		8653137	Sep 05, 2028		U-1437	
		8658694	Sep 05, 2028		U-1437	
		9199908	May 24, 2024		U-1771	
		9593066	Dec 15, 2028	DS		
		9604901	Dec 15, 2028	DS		
		9713599	Dec 16, 2024		U-2036	
<u>TREPROSTINIL - REMODULIN</u>						
N 021272	002	10076505	Dec 16, 2024	DP		
		10695308	Dec 16, 2024		U-2845	
		7999007	Mar 29, 2029	DP	U-1437	
		8653137	Sep 05, 2028		U-1437	
		8658694	Sep 05, 2028		U-1437	
		9199908	May 24, 2024		U-1771	
		9593066	Dec 15, 2028	DS		
		9604901	Dec 15, 2028	DS		
		9713599	Dec 16, 2024		U-2036	
<u>TREPROSTINIL - REMODULIN</u>						
N 021272	003	10076505	Dec 16, 2024	DP		
		10695308	Dec 16, 2024		U-2845	
		7999007	Mar 29, 2029	DP	U-1437	
		8653137	Sep 05, 2028		U-1437	
		8658694	Sep 05, 2028		U-1437	
		9199908	May 24, 2024		U-1771	
		9593066	Dec 15, 2028	DS		
		9604901	Dec 15, 2028	DS		
		9713599	Dec 16, 2024		U-2036	
<u>TREPROSTINIL - REMODULIN</u>						
N 021272	004	10076505	Dec 16, 2024	DP		
		10695308	Dec 16, 2024		U-2845	
		7999007	Mar 29, 2029	DP	U-1437	
		8653137	Sep 05, 2028		U-1437	
		8658694	Sep 05, 2028		U-1437	
		9199908	May 24, 2024		U-1771	
		9593066	Dec 15, 2028	DS		
		9604901	Dec 15, 2028	DS		
		9713599	Dec 16, 2024		U-2036	
<u>TREPROSTINIL - TYVASO</u>						
N 022387	001	10376525	May 14, 2027		U-1849	
		10716793	May 14, 2027		U-1849	
		8497393	Dec 15, 2028	DS		
		9339507	Mar 10, 2028	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL - TYVASO</u>						
N 022387	001	9358240	May 05, 2028		U-1849	
		9593066	Dec 15, 2028	DS		
		9604901	Dec 15, 2028	DS		
<u>TREPROSTINIL - REMODULIN</u>						
N 208276	001	10076505	Dec 16, 2024	DP		
		9593066	Dec 15, 2028	DS		
		9604901	Dec 15, 2028	DS		
		9713599	Dec 16, 2024		U-2036	
<u>TREPROSTINIL - REMODULIN</u>						
N 208276	002	10076505	Dec 16, 2024	DP		
		9593066	Dec 15, 2028	DS		
		9604901	Dec 15, 2028	DS		
		9713599	Dec 16, 2024		U-2036	
<u>TREPROSTINIL - REMODULIN</u>						
N 208276	003	10076505	Dec 16, 2024	DP		
		9593066	Dec 15, 2028	DS		
		9604901	Dec 15, 2028	DS		
		9713599	Dec 16, 2024		U-2036	
<u>TREPROSTINIL - REMODULIN</u>						
N 208276	004	10076505	Dec 16, 2024	DP		
		9593066	Dec 15, 2028	DS		
		9604901	Dec 15, 2028	DS		
		9713599	Dec 16, 2024		U-2036	
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496	001	7417070	Jul 30, 2026	DS		I-820 Oct 18, 2022
		7544713	Jul 14, 2024		U-1475	ODE-272 Oct 18, 2026
		8252839	May 24, 2024	DP		ODE-308 Dec 20, 2020
		8349892	Jan 22, 2031	DP		
		8410169	Feb 13, 2030	DP		
		8747897	Aug 11, 2031	DP	U-2724	
		8747897	Aug 11, 2031	DP	U-2725	
		9050311	May 24, 2024	DS DP		
		9278901	May 24, 2024		U-1475	
		9393203	Apr 27, 2026	DP	U-1877	
		9422223	May 24, 2024	DP		
		9593066	Dec 15, 2028	DS		
		9604901	Dec 15, 2028	DS		
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496	002	7417070	Jul 30, 2026	DS		I-820 Oct 18, 2022
		7544713	Jul 14, 2024		U-1475	ODE-272 Oct 18, 2026
		8252839	May 24, 2024	DP		ODE-308 Dec 20, 2020
		8349892	Jan 22, 2031	DP		
		8410169	Feb 13, 2030	DP		
		8497393	Dec 15, 2028	DS		Y
		8747897	Aug 11, 2031	DP	U-2724	
		8747897	Aug 11, 2031	DP	U-2725	
		9050311	May 24, 2024	DS DP		
		9278901	May 24, 2024		U-1475	
		9393203	Apr 27, 2026	DP	U-1877	
		9422223	May 24, 2024	DP		
		9593066	Dec 15, 2028	DS		
		9604901	Dec 15, 2028	DS		
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496	003	7417070	Jul 30, 2026	DS		I-820 Oct 18, 2022
		7544713	Jul 14, 2024		U-1475	ODE-272 Oct 18, 2026
		8252839	May 24, 2024	DP		ODE-308 Dec 20, 2020
		8349892	Jan 22, 2031	DP		
		8410169	Feb 13, 2030	DP		
		8497393	Dec 15, 2028	DS		Y
		8747897	Aug 11, 2031	DP	U-2724	
		8747897	Aug 11, 2031	DP	U-2725	
		9050311	May 24, 2024	DS DP		
		9278901	May 24, 2024		U-1475	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496	003	9393203	Apr 27, 2026	DP U-1877		
		9422223	May 24, 2024	DP		
		9593066	Dec 15, 2028	DS		
		9604901	Dec 15, 2028	DS		
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496	004	7417070	Jul 30, 2026	DS	I-820	Oct 18, 2022
		7544713	Jul 14, 2024	U-1475	ODE-272	Oct 18, 2026
		8252839	May 24, 2024	DP	ODE-308	Dec 20, 2020
		8349892	Jan 22, 2031	DP		
		8410169	Feb 13, 2030	DP		
		8497393	Dec 15, 2028	DS	Y	
		8747897	Aug 11, 2031	DP U-2724		
		8747897	Aug 11, 2031	DP U-2725		
		9050311	May 24, 2024	DS DP		
		9278901	May 24, 2024	U-1475		
		9393203	Apr 27, 2026	DP U-1877		
		9422223	May 24, 2024	DP		
		9593066	Dec 15, 2028	DS		
		9604901	Dec 15, 2028	DS		
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496	005	7417070	Jul 30, 2026	DS	I-820	Oct 18, 2022
		7544713	Jul 14, 2024	U-1475	ODE-272	Oct 18, 2026
		8252839	May 24, 2024	DP	ODE-308	Dec 20, 2020
		8349892	Jan 22, 2031	DP		
		8410169	Feb 13, 2030	DP		
		8747897	Aug 11, 2031	DP U-2724		
		8747897	Aug 11, 2031	DP U-2725		
		9050311	May 24, 2024	DS DP		
		9278901	May 24, 2024	U-1475		
		9393203	Apr 27, 2026	DP U-1877		
		9422223	May 24, 2024	DP		
		9593066	Dec 15, 2028	DS		
		9604901	Dec 15, 2028	DS		
<u>TRETINOIN - RENOVA</u>						
N 021108	001	6531141	Mar 07, 2020			
<u>TRETINOIN - ALTRENO</u>						
N 209353	001	10653656	Aug 22, 2038	DP U-2368	NDF	Aug 23, 2021
		6517847	Aug 03, 2020	DP U-2368		
<u>TRIAMCINOLONE ACETONIDE - TRIAMCINOLONE ACETONIDE</u>						
A 212384	001				CGT	May 30, 2020
<u>TRIAMCINOLONE ACETONIDE - TRIESENCE</u>						
N 022048	001	6395294	Jan 13, 2020	DP U-846		
		8128960	Dec 17, 2029	DP		
		8211880	Mar 10, 2029	U-1257		
		8211880	Mar 10, 2029	U-1258		
<u>TRIAMCINOLONE ACETONIDE - ZILRETTA</u>						
N 208845	001	8828440	Aug 04, 2031	DP	NP	Oct 06, 2020
		9555048	Aug 04, 2031	U-2151		
<u>TRICLABENDAZOLE - EGATEN</u>						
N 208711	001				NCE	Feb 13, 2024
					ODE-228	Feb 13, 2026
<u>TRIFAROTENE - AKLIEF</u>						
N 211527	001	7807708	Oct 01, 2026	DS DP	NCE	Oct 04, 2024
		8227507	Dec 21, 2025	U-818		
		8470871	Dec 21, 2025	U-2639		
		9084778	May 30, 2033	DP U-134		
<u>TRihePTANOIN - DOJOLVI</u>						
N 213687	001	8697748	Oct 03, 2025	DP	NCE	Jun 30, 2025
		9186344	Jul 01, 2025	DP	ODE-311	Jun 30, 2027

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TRIPTORELIN PAMOATE - TRELSTAR</u>						
N 022437	001 10166181	Jun 30, 2029	DP			
<u>TRIPTORELIN PAMOATE - TRIPTODUR KIT</u>						
N 208956	001 10166181	Jun 30, 2029	DP		NP ODE-149	Jun 29, 2020 Jun 29, 2024
<u>TUCATINIB - TUKYSA</u>						
N 213411	001 7452895	Nov 16, 2024	DS DP U-2788		NCE	Apr 17, 2025
	8648087	Apr 12, 2031	DS DP		ODE-309	Apr 17, 2027
	9457093	Oct 12, 2032	DP U-2788			
	9693989	May 09, 2027	DP U-2788			
<u>TUCATINIB - TUKYSA</u>						
N 213411	002 7452895	Nov 16, 2024	DS DP U-2788		NCE	Apr 17, 2025
	8648087	Apr 12, 2031	DS DP		ODE-309	Apr 17, 2027
	9457093	Oct 12, 2032	DP U-2788			
	9693989	May 09, 2027	DP U-2788			
<u>UBROGEPANT - UBRELVY</u>						
N 211765	001 10117836	Jan 30, 2035	DP		NCE	Dec 23, 2024
	8754096	Jul 19, 2032	DS DP U-2717			
	8912210	Nov 10, 2031	DS DP			
	9499545	Nov 10, 2031	DS DP U-2718			
	9833448	Nov 10, 2031	U-2718			
<u>UBROGEPANT - UBRELVY</u>						
N 211765	002 10117836	Jan 30, 2035	DP		NCE	Dec 23, 2024
	8754096	Jul 19, 2032	DS DP U-2717			
	8912210	Nov 10, 2031	DS DP			
	9499545	Nov 10, 2031	DS DP U-2718			
	9833448	Nov 10, 2031	U-2718			
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474	001 10159681	Apr 13, 2030	U-2510			
	10772897	Apr 13, 2030	U-2958			
	8426392	Jun 12, 2030	U-1389			
	8512745	Jun 02, 2030	DP			
	8735380	Feb 20, 2029	DP			
	8962603	Jun 12, 2030	U-1657			
	9283233	Apr 13, 2030	U-1821			
	9844510	Dec 08, 2028	DP			
<u>UMECRIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382	001 7488827	Dec 18, 2027	DS DP		M-245	Jun 09, 2022
	7498440	Apr 27, 2025	DS DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8183257	Jul 27, 2025	U-1476			
	8201556	Feb 05, 2029	DP			
	8309572	Apr 27, 2025	U-1476			
	8534281	Mar 08, 2030	DP			
	8746242	Oct 11, 2030	DP			
	9333310	Oct 02, 2027	DP			
<u>UMECRIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975	001 7439393	May 21, 2025	DS DP U-1476		M-245	Jun 09, 2022
	7488827	Dec 18, 2027	DS DP			
	7498440	Apr 27, 2025	DS DP			
	7776895	Sep 11, 2022	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8183257	Jul 27, 2025	U-1476			
	8309572	Apr 27, 2025	U-1476			
	8511304	Jun 14, 2027	DP U-1476			
	8534281	Mar 08, 2030	DP			
	8746242	Oct 11, 2030	DP			
	9333310	Oct 02, 2027	DP			
	9750726	Nov 29, 2030	DP			
	RE44874	Mar 23, 2023	DS DP U-1476			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>UNOPROSTONE ISOPROPYL - RESCULA</u>						
N 021214	001 6458836	Jul 09, 2021	U-1315			
	6458836	Jul 09, 2021	U-333			
<u>UPADACITINIB - RINVOO</u>						
N 211675	001 10519164	Oct 17, 2036	DP		NCE	Aug 16, 2024
	10597400	Oct 17, 2036	U-2616			
	8962629	Jan 15, 2031	DS U-2616			
	9951080	Oct 17, 2036	DS DP			
	9963459	Oct 17, 2036	DP			
	RE47221	Dec 01, 2030	DS			
<u>URIDINE TRIACETATE - VISTOGARD</u>						
N 208159	001 6258795	Jul 10, 2023	DP		NCE	Sep 04, 2020
	7776838	Aug 17, 2027	U-1791		ODE-104	Dec 11, 2022
<u>URIDINE TRIACETATE - XURIDEN</u>						
N 208169	001 6258795	Jul 10, 2023	DP		NCE	Sep 04, 2020
					ODE-98	Sep 04, 2022
<u>VALBENZAZINE TOSYLATE - INGREZZA</u>						
N 209241	001 10065952	Oct 28, 2036	DS DP U-1995		NCE	Apr 11, 2022
	10844058	Oct 28, 2036	DS DP U-1995			
	10851103	Oct 28, 2036	DS DP U-1995			
	10851104	Oct 28, 2036	DS U-1995			
	10857137	Oct 10, 2037	U-1995			
	10857148	Oct 10, 2037	U-1995			
	8039627	Oct 06, 2029	DS DP			
	8357697	Nov 08, 2027	U-1995			
<u>VALBENZAZINE TOSYLATE - INGREZZA</u>						
N 209241	002 10065952	Oct 28, 2036	DS DP U-1995		NCE	Apr 11, 2022
	10844058	Oct 28, 2036	DS DP U-1995			
	10851103	Oct 28, 2036	DS DP U-1995			
	10851104	Oct 28, 2036	DS U-1995			
	10857137	Oct 10, 2037	U-1995			
	10857148	Oct 10, 2037	U-1995			
	8039627	Oct 06, 2029	DS DP			
	8357697	Nov 08, 2027	U-1995			
<u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u>						
N 022257	001 8889109	Dec 11, 2027	DP			
	9642911	Dec 11, 2027	DP			
<u>VANCOMYCIN HYDROCHLORIDE - FIRVANO KIT</u>						
N 208910	001 10493028	Mar 13, 2035	DP			
	10688046	Mar 13, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - FIRVANO KIT</u>						
N 208910	002 10493028	Mar 13, 2035	DP			
	10688046	Mar 13, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962	001 10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
	10849956	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962	002 10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
	10849956	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962	003 10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
	10849956	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962	004 10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
	10849956	Nov 06, 2035	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962	005	10039804	Nov 06, 2035	DP U-282		
		10188697	Nov 06, 2035	DP U-282		
		10849956	Nov 06, 2035	DP		
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962	006	10039804	Nov 06, 2035	DP U-282		
		10188697	Nov 06, 2035	DP U-282		
		10849956	Nov 06, 2035	DP		
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962	007	10039804	Nov 06, 2035	DP U-282		
		10188697	Nov 06, 2035	DP U-282		
		10849956	Nov 06, 2035	DP		
<u>VANDETANIB - CAPRELSA</u>						
N 022405	001	7173038	Aug 14, 2021	DS DP		
		8067427	Aug 08, 2028	DP		
		8642608	Feb 06, 2022		U-1490	
		RE42353	Jun 27, 2022	DS DP		
<u>VANDETANIB - CAPRELSA</u>						
N 022405	002	7173038	Aug 14, 2021	DS DP		
		8067427	Aug 08, 2028	DP		
		8642608	Feb 06, 2022		U-1490	
		RE42353	Jun 27, 2022	DS DP		
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N 021400	001	8273876	Jul 23, 2027		U-1288	
		8841446	Jul 03, 2023	DP		
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N 021400	002	8273876	Jul 23, 2027		U-1288	
		8841446	Jul 03, 2023	DP		
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N 021400	003	8273876	Jul 23, 2027		U-1288	
		8841446	Jul 03, 2023	DP		
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N 021400	004	8273876	Jul 23, 2027		U-1288	
		8841446	Jul 03, 2023	DP		
<u>VARDENAFIL HYDROCHLORIDE - STAXYN</u>						
N 200179	001	8613950	Dec 23, 2028	DP		
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928	001	6410550	May 10, 2020	DS DP U-56	M-237	Feb 22, 2022
		6410550*PED	Nov 10, 2020		PED	Aug 22, 2022
		6890927	May 06, 2022	DS DP U-56		
		6890927*PED	Nov 06, 2022			
		7265119	Aug 03, 2022	DS DP U-56		
		7265119*PED	Feb 03, 2023			
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928	002	6410550	May 10, 2020	DS DP U-56	M-237	Feb 22, 2022
		6410550*PED	Nov 10, 2020		PED	Aug 22, 2022
		6890927	May 06, 2022	DS DP U-56		
		6890927*PED	Nov 06, 2022			
		7265119	Aug 03, 2022	DS DP U-56		
		7265119*PED	Feb 03, 2023			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485	001	9375478	Jan 30, 2035		U-1857	
		9687526	Jan 30, 2035		U-1857	
		9744209	Jan 30, 2035		U-1857	
		9744239	Jan 30, 2035		U-1857	
		9750785	Jan 30, 2035	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485	002	9375478	Jan 30, 2035	U-1857		
		9687526	Jan 30, 2035	U-1857		
		9744209	Jan 30, 2035	U-1857		
		9744239	Jan 30, 2035	U-1857		
		9750785	Jan 30, 2035	DP		
		9937223	Jan 30, 2035	U-1857		
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485	003	10010575	Jan 30, 2035	U-1857		
		9919026	Jan 30, 2035	DP		
		9925233	Jan 30, 2035	U-1857		
		9925234	Jan 30, 2035	U-1857		
		9962422	Jan 30, 2035	U-1857		
		9968649	Jan 30, 2035	U-1857		
		9974827	Jan 30, 2035	U-1857		
		9981006	Jan 30, 2035	U-1857		
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485	004	10010575	Jan 30, 2035	U-1857		
		9919026	Jan 30, 2035	DP		
		9925233	Jan 30, 2035	U-1857		
		9925234	Jan 30, 2035	U-1857		
		9962422	Jan 30, 2035	U-1857		
		9968649	Jan 30, 2035	U-1857		
		9974827	Jan 30, 2035	U-1857		
		9981006	Jan 30, 2035	U-1857		
<u>VEMURAFENIB - ZELBORAF</u>						
N 202429	001	7504509	Oct 22, 2026	DS DP	I-757	Nov 06, 2020
		7863288	Jun 20, 2029	DS DP	ODE-158	Nov 06, 2024
		8143271	Jun 21, 2026	DS DP		
		8470818	Aug 02, 2026		U-1418	
		8470818	Aug 02, 2026		U-2164	
		8741920	Jul 27, 2030	DS DP		
		9447089	Jun 06, 2032	DP		
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573	001	10730873	Nov 21, 2031	DS	I-782	Jun 08, 2021
		8546399	Jun 27, 2031	DS DP	I-789	Nov 21, 2021
		8722657	Jan 29, 2032	DS	I-795	May 15, 2022
		9174982	May 26, 2030		M-228	Jun 08, 2021
		9174982	May 26, 2030		M-265	Oct 16, 2023
		9174982	May 26, 2030		NCE	Apr 11, 2021
		9174982	May 26, 2030		ODE-114	Apr 11, 2023
		9539251	Sep 06, 2033		ODE-185	Jun 08, 2025
					ODE-211	Nov 21, 2025
					ODE-239	May 15, 2026
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573	002	10730873	Nov 21, 2031	DS	I-782	Jun 08, 2021
		8546399	Jun 27, 2031	DS DP	I-789	Nov 21, 2021
		8722657	Jan 29, 2032	DS	I-795	May 15, 2022
		9174982	May 26, 2030		M-228	Jun 08, 2021
		9174982	May 26, 2030		M-265	Oct 16, 2023
		9174982	May 26, 2030		NCE	Apr 11, 2021
		9174982	May 26, 2030		ODE-114	Apr 11, 2023
		9539251	Sep 06, 2033		ODE-185	Jun 08, 2025
					ODE-211	Nov 21, 2025
					ODE-239	May 15, 2026
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573	003	10730873	Nov 21, 2031	DS	I-782	Jun 08, 2021
		8546399	Jun 27, 2031	DS DP	I-789	Nov 21, 2021
		8722657	Jan 29, 2032	DS	I-795	May 15, 2022
		9174982	May 26, 2030		M-228	Jun 08, 2021
		9174982	May 26, 2030		M-265	Oct 16, 2023
		9174982	May 26, 2030		NCE	Apr 11, 2021
		9174982	May 26, 2030		ODE-114	Apr 11, 2023
		9539251	Sep 06, 2033		ODE-185	Jun 08, 2025
					ODE-211	Nov 21, 2025

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573	003				ODE-239	May 15, 2026
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567	001	7834020	Jun 05, 2022	DS DP U-839	M-254	Jan 31, 2023
		7834020*PED	Dec 05, 2022		PED	Jul 31, 2023
		8193195	Jun 05, 2022	U-839		
		8193195*PED	Dec 05, 2022			
		8236804	Jun 05, 2022	U-839		
		8236804*PED	Dec 05, 2022			
		8673921	Jun 05, 2022	DS DP		
		8673921*PED	Dec 05, 2022			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567	002	7834020	Jun 05, 2022	DS DP U-839	M-254	Jan 31, 2023
		7834020*PED	Dec 05, 2022		PED	Jul 31, 2023
		8193195	Jun 05, 2022	U-839		
		8193195*PED	Dec 05, 2022			
		8236804	Jun 05, 2022	U-839		
		8236804*PED	Dec 05, 2022			
		8673921	Jun 05, 2022	DS DP		
		8673921*PED	Dec 05, 2022			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567	003	7834020	Jun 05, 2022	DS DP U-839	M-254	Jan 31, 2023
		7834020*PED	Dec 05, 2022		PED	Jul 31, 2023
		8193195	Jun 05, 2022	U-839		
		8193195*PED	Dec 05, 2022			
		8236804	Jun 05, 2022	U-839		
		8236804*PED	Dec 05, 2022			
		8673921	Jun 05, 2022	DS DP		
		8673921*PED	Dec 05, 2022			
<u>VILTOLARSEN - VILTEPSO</u>						
N 212154	001	9079934	Aug 31, 2031	DS DP	NCE	Aug 12, 2025
<u>VINCRISTINE SULFATE - MARQIBO KIT</u>						
N 202497	001	6723338	Mar 31, 2020	U-1271		
		7247316	Sep 25, 2020	DP		
		7887836	Mar 31, 2020	U-1271		
<u>VISMODEGIB - ERIVEDGE</u>						
N 203388	001	7888364	Nov 11, 2028	DS DP		
		9278961	Dec 15, 2028	U-1825		
<u>VORAPAXAR SULFATE - ZONTIVITY</u>						
N 204886	001	7235567	Jun 13, 2021	DS DP		
		7304078	Apr 06, 2024	DS DP U-1512		
		7713999	May 30, 2024	DS DP U-2291		
<u>VORICONAZOLE - VFEND</u>						
N 021266	001				NPP	Jan 29, 2022
<u>VORICONAZOLE - VFEND</u>						
N 021266	002				NPP	Jan 29, 2022
<u>VORICONAZOLE - VFEND</u>						
N 021267	001				NPP	Jan 29, 2022
<u>VORICONAZOLE - VFEND</u>						
N 021630	001				NPP	Jan 29, 2022
<u>VORINOSTAT - ZOLINZA</u>						
N 021991	001	7399787	Feb 09, 2025	U-892		
		7456219	Mar 11, 2027	DS		
		7652069	Mar 04, 2023	DP		
		7732490	Mar 04, 2023	U-892		
		7851509	Feb 21, 2024	DP U-892		
		8067472	Mar 04, 2023	U-892		
		8093295	May 16, 2026	DP		
		8101663	Mar 04, 2023	U-892		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VORINOSTAT - ZOLINZA</u>						
N 021991	001	8450372				
		Mar 18, 2028		U-892		
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447	001	7144884				
		Jun 17, 2026	DS DP	U-1439	M-227	May 02, 2021
		8476279		DP U-1439	M-234	Oct 19, 2021
		8722684		Jun 30, 2031 DS DP	M-267	Nov 13, 2023
		8969355		Jun 15, 2027	U-1668	
		9125908		Jun 15, 2027	U-2309	
		9125909		Jun 15, 2027	U-2309	
		9125910		Jun 15, 2027	U-2309	
		9227946		Jun 15, 2027	U-1668	
		9278096		Mar 21, 2032	U-2436	
		9861630		Jun 15, 2027	U-1668	
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447	002	7144884				
		Jun 17, 2026	DS DP	U-1439	M-227	May 02, 2021
		8476279		Oct 02, 2022 DP U-1439	M-234	Oct 19, 2021
		8722684		Jun 30, 2031 DS DP	M-267	Nov 13, 2023
		8969355		Jun 15, 2027	U-1668	
		9125908		Jun 15, 2027	U-2309	
		9125909		Jun 15, 2027	U-2309	
		9125910		Jun 15, 2027	U-2309	
		9227946		Jun 15, 2027	U-1668	
		9278096		Mar 21, 2032	U-2436	
		9861630		Jun 15, 2027	U-1668	
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447	003	7144884				
		Jun 17, 2026	DS DP	U-1439	M-227	May 02, 2021
		8476279		Oct 02, 2022 DP U-1439	M-234	Oct 19, 2021
		8722684		Jun 30, 2031 DS DP	M-267	Nov 13, 2023
		8969355		Jun 15, 2027	U-1668	
		9125908		Jun 15, 2027	U-2309	
		9125909		Jun 15, 2027	U-2309	
		9125910		Jun 15, 2027	U-2309	
		9227946		Jun 15, 2027	U-1668	
		9278096		Mar 21, 2032	U-2436	
		9861630		Jun 15, 2027	U-1668	
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447	004	7144884				
		Jun 17, 2026	DS DP	U-1439	M-227	May 02, 2021
		8476279		Oct 02, 2022 DP U-1439	M-234	Oct 19, 2021
		8722684		Jun 30, 2031 DS DP	M-267	Nov 13, 2023
		8969355		Jun 15, 2027	U-1668	
		9125908		Jun 15, 2027	U-2309	
		9125909		Jun 15, 2027	U-2309	
		9125910		Jun 15, 2027	U-2309	
		9227946		Jun 15, 2027	U-1668	
		9278096		Mar 21, 2032	U-2436	
		9861630		Jun 15, 2027	U-1668	
<u>VOXELOTOR - OXBRYTA</u>						
N 213137	001	10017491				
		Dec 28, 2032		DP	NCE	Nov 25, 2024
		10034879		Dec 28, 2032 DS DP	ODE-281	Nov 25, 2026
		10493035		Oct 12, 2037 DP		
		10722502		Feb 06, 2035 DP		
		10806733		Dec 28, 2032 DS		
		9018210		Dec 28, 2032 DS DP		
		9248199		Jan 29, 2034	U-2676	
		9248199		Jan 29, 2034	U-2715	
		9447071		Feb 06, 2035 DS DP		
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 213217	001	9447106				
		Apr 22, 2034	DS DP	U-2145	NCE	Nov 14, 2024
					ODE-276	Nov 14, 2026
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060	001	8653033				
		Oct 01, 2024		U-48		
		8653033		Oct 01, 2024	U-55	
		8765680		Oct 01, 2024	U-48	
		8765680		Oct 01, 2024	U-55	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060	001	9707270	Oct 01, 2024		U-2084	
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060	002	8653033	Oct 01, 2024		U-48	
		8653033	Oct 01, 2024		U-55	
		8765680	Oct 01, 2024		U-48	
		8765680	Oct 01, 2024		U-55	
		9707270	Oct 01, 2024		U-2084	
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060	003	8653033	Oct 01, 2024		U-48	
		8653033	Oct 01, 2024		U-55	
		8765680	Oct 01, 2024		U-48	
		8765680	Oct 01, 2024		U-55	
		9707270	Oct 01, 2024		U-2084	
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060	004	8653033	Oct 01, 2024		U-48	
		8653033	Oct 01, 2024		U-55	
		8765680	Oct 01, 2024		U-48	
		8765680	Oct 01, 2024		U-55	
		9707270	Oct 01, 2024		U-2084	
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 021483	001	7175855	May 18, 2020		DP	
<u>ZOLEDRONIC ACID - ZOMETA</u>						
N 021223	002	8324189	May 29, 2025		U-1308	
		8324189	May 29, 2025		U-1309	
		8324189	May 29, 2025		U-53	
<u>ZOLEDRONIC ACID - ZOMETA</u>						
N 021223	003	7932241	Feb 05, 2028		DP	
		8324189	May 29, 2025		U-1308	
		8324189	May 29, 2025		U-1309	
		8324189	May 29, 2025		U-53	
<u>ZOLEDRONIC ACID - RECLAST</u>						
N 021817	001	7932241	Feb 05, 2028		DP	
		8052987	Oct 27, 2023		U-1199	
<u>ZOLMITRIPTAN - ZOMIG</u>						
N 021450	003	6750237	Nov 28, 2020		DP	
		6750237*PED	May 28, 2021			
		7220767	Nov 28, 2020		DP	
		7220767*PED	May 28, 2021			
<u>ZOLMITRIPTAN - ZOMIG</u>						
N 021450	004	6750237	Nov 28, 2020		DP	
		7220767	Nov 28, 2020		DP	
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997	001	9265720	Feb 25, 2031		U-674	
		9597281	Apr 06, 2027		U-674	
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997	002	9265720	Feb 25, 2031		U-674	
		9597281	Apr 06, 2027		U-674	
<u>ZOLPIDEM TARTRATE - ZOLPIMIST</u>						
N 022196	001	8236285	Aug 07, 2032	DS DP	U-70	
<u>ZOLPIDEM TARTRATE - INTERMEZZO</u>						
N 022328	001	7658945	Apr 15, 2027		DP U-1194	
		7682628	Feb 16, 2025		U-1194	
		8242131	Aug 20, 2029		U-1266	
		8252809	Feb 16, 2025		DP	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ZOLPIDEM TARTRATE - INTERMEZZO</u>						
N 022328 002	7658945	Apr 15, 2027	DP U-1194			
	7682628	Feb 16, 2025	U-1194			
	8242131	Aug 20, 2029	U-1266			
	8252809	Feb 16, 2025	DP			

PATENT AND EXCLUSIVITY TERMS**PATENT & EXCLUSIVITY ABBREVIATIONS**

CGT	COMPETITIVE GENERIC THERAPY
D	NEW DOSING SCHEDULE (SEE INDIVIDUAL REFERENCES)
GAIN	GAIN EXCLUSIVITY
I	NEW INDICATION (SEE INDIVIDUAL REFERENCES)
M	MISCELLANEOUS EXCLUSIVITY CODES (SEE INDIVIDUAL REFERENCES)
NC	NEW COMBINATION
NCE	NEW CHEMICAL ENTITY
NCE*	NEW CHEMICAL ENTITY (AN ENANTIOMER OF PREVIOUSLY APPROVED RACEMIC MIXTURE. SEE SECTION 505(U) OF THE FEDERAL FOOD AND DRUG COSMETIC ACT).
NDF	NEW DOSAGE FORM
NE	NEW ESTER OR SALT OF AN ACTIVE INGREDIENT
NP	NEW PRODUCT
NP*	NEW PRODUCT (MINT FLAVORED)
NPP	NEW PATIENT POPULATION
NR	NEW ROUTE
NS	NEW STRENGTH
ODE	ORPHAN DRUG EXCLUSIVITY (SEE INDIVIDUAL REFERENCES)
PC	PATENT CHALLENGE
PED	PEDIATRIC EXCLUSIVITY
RTO	RX TO OTC SWITCH OR OTC USE
RTO*	OTC USE FOR WOMEN AGES 15 AND 16
RTO**	OTC USE FOR WOMEN 14 AND BELOW
U	PATENT USE CODE (SEE INDIVIDUAL REFERENCES)
W	EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR - SEE SECTION 1.8 OF ORANGE BOOK PREFACE WAIVED EXCLUSIVITY

EXCLUSIVITY DOSING SCHEDULE

D-1	ONCE A DAY APPLICATION
D-2	ONCE DAILY DOSING
D-3	SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE
D-4	SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE
D-5	TEN DAYS/ELEVEN DAYS DOSING SCHEDULE
D-6	SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE
D-7	BID DOSING
D-8	INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING
D-9	NARCOTIC OVERDOSE IN ADULTS
D-10	NARCOTIC OVERDOSE IN CHILDREN
D-11	POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN
D-12	BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE DUODENAL ULCER
D-13	INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION
D-14	BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
D-15	SINGLE DAILY DOSE OF 25MG/37.5MG
D-16	CONTINUOUS INTRAVENOUS INFUSION
D-17	400MG EVERY 12 HOURS FOR THREE DAYS FOR UNCOMPLICATED URINARY TRACT INFECTIONS
D-18	LOWER RECOMMENDED STARTING DOSE GUIDELINES
D-19	BOLUS DOSING GUIDELINES
D-20	SINGLE 32MG DOSE
D-21	ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL
D-22	REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE
D-23	INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN
D-24	FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M ² OR 175MG/M ² INTRAVENOUSLY OVER THREE HOURS EVERY THREE WEEKS
D-25	ADDITIONAL DOSAGE REGIMEN EQUAL TO HALF THE ORIGINAL DOSING REGIMEN

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY DOSING SCHEDULE**

- D-26 ONCE WEEKLY APPLICATION
- D-27 BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATE EMETOGENIC CANCER CHEMOTHERAPY
- D-28 USE OF ISOVUE-370 IN EXCRETORY UROGRAPHY AT EQUIVALENT GRAMS OF IODINE TO THE CURRENTLY APPROVED ISOVUE-250 AND ISOVUE-300
- D-29 INCREASE OF CUMULATIVE DOSE TO 0.3MMOL/KG FOR MRI OF CNS IN ADULTS
- D-30 5000 IU DOSE FOR PROPHYLAXIS AGAINST DEEP VEIN THROMBOSIS
- D-31 CHANGE IN RECOMMENDED TOTAL DAILY DOSE TO 80MG (40MG BID)
- D-32 REMOVAL OF THE RESTRICTIONS LIMITING TREATMENT TO TWO CONSECUTIVE WEEKS AND TO SMALL AREAS
- D-33 ONCE DAILY DOSING FOR PLAQUE PSORIASIS
- D-34 EVERY FOUR MONTHS DOSAGE REGIMEN
- D-35 FOR A ONE WEEK DOSING OF INTERDIGITAL TINEA PEDIS
- D-36 FOR A SINGLE 2MG DOSE AS AN ALTERNATIVE TO THE 1MG DOSE GIVEN TWICE DAILY
- D-37 DOSING REGIMEN FOR ADMINISTRATION EITHER ONCE DAILY (QD) OR TWICE DAILY (BID)
- D-38 CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION
- D-39 CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM ".1/2 TO 1 HOUR BEFORE EATING" TO ".. RIGHT BEFORE EATING OR UP TO 60MIN BEFORE CONSUMING..."
- D-40 ONCE-A-DAY DOSING REGIMEN
- D-41 DRUG MAY BE DOSED RIGHT BEFORE A MEAL OR ANY TIME UP TO 30MIN BEFORE EATING OR DRINKING FOOD AND BEVERAGES THAT WOULD BE EXPECTED TO CAUSE SYMPTOMS
- D-42 TEN DAY DOSING REGIMEN FOR TRIPLE THERAPY, PREVACID IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN, FOR THE ERADICATION OF H.PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE
- D-43 INITIATION OF TREATMENT WITH 900MG/DAY BY DELETION OF THE REQUIREMENT TO TITRATE TO 900MG/DAY OVER A 3-DAY PERIOD
- D-44 IN A CLINICAL TRIAL, FEWER DISCONTINUATIONS DUE TO ADVERSE EVENTS, ESPECIALLY DIZZINESS AND VERTIGO, WERE OBSERVED WHEN TITRATING THE DOSE IN INCREMENTS OF 50MG/DAY EVERY 3 DAYS UNTIL AN EFFECTIVE DOSE (NOT EXCEEDING 400MG/DAY) WAS REACHED
- D-45 ONCE DAILY DOSING FOR MAINTENANCE ONLY
- D-46 NEW DOSING REGIMEN OF 80MG DAILY
- D-47 PREVENTION OF HEARTBURN SYMPTOMS WHEN ADMINISTERED FROM 15 MINUTES UP TO, BUT NOT INCLUDING, 1 HOUR PRIOR TO A PROVOCATIVE MEAL
- D-48 ADMINISTRATION OF CISATRACURIUM A NEUROMUSCULAR BLOCKING AGENT AT DOSES OF 3 AND 4X THE ED95 OF CISATRACURIUM FOLLOWING INDUCTION WITH THIOPIENTAL
- D-49 PEDIATRIC DOSING GUIDELINES
- D-50 INFORMATION FOR USE OF CORVERT IN POST-CARDIAC SURGERY PATIENTS
- D-51 OPTIONAL STARTING DOSE OF 40MG/DAY
- D-52 ALTERNATE DOSING REGIMEN OF 1250MG TWICE DAILY
- D-53 USE IN PEDIATRIC PATIENTS FROM 1 MONTH TO 16 YEARS OF AGE
- D-54 USE OF ZYBAN FOR MAINTENANCE THERAPY. TREATMENT UP TO 6 MONTHS WAS SHOWN EFFICACIOUS
- D-55 ADDITION OF A HIGHER DOSE OF NUTROPIN FOR PUBERTAL PATIENTS (PUBERTAL DOSE LESS THAN OR EQUAL TO 0.7MG/KG/WEEK)
- D-56 ADDITION OF POSTPRANDIAL DOSING
- D-57 3-HOUR INFUSION OF TAXOL GIVEN EVERY THREE WEEKS AT A DOSE OF 175MG/M2 FOLLOWED BY CISPLATIN AT A DOSE OF 75MG/M2 FOR THE FIRST-LINE TREATMENT OF ADVANCED OVARIAN CANCER
- D-58 CHANGE IN DOSING INTERVAL TO ONCE-DAILY ADMINISTRATION
- D-59 REDUCTION OF ELEVATED LDL-C IN A NEW, HIGHER STRENGTH TABLET, 0.8MG, AND FOR EXTENSION OF THE DOSAGE RANGE TO 0.8MG DAILY

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY DOSING SCHEDULE**

- D-60 ADDITION OF A POST-OPERATIVE DOSING REGIMEN
- D-61 ONCE WEEKLY DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
- D-62 ONCE WEEKLY DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- D-63 TO ALLOW A TITRATION DOSING REGIMEN USING A 25MG DOSE
- D-64 INCREASING DOSAGE FOR NERVE BLOCK ANESTHESIA USING NAROPIN 7.5MG/ML AND FOR EXTENDING THE DURATION OF TREATMENT FOR POSTOPERATIVE ANALGESIA USING NAROPIN 2MG/ML
- D-65 CHANGE DOSING AND ADMINISTRATION TO INDICATE MAINTENANCE OF WEIGHT LOSS OVER AN 18 MONTH PERIOD THUS EXTENDING THE USE OF THIS DRUG FROM ONE TO TWO YEARS
- D-66 DOSING RECOMMENDATIONS FOR PATIENTS UNDERGOING PCI
- D-67 SHORTER TREATMENT COURSE OF THREE DAYS IN THE TREATMENT OF RECURRENT EPISODES OF GENITAL HERPES
- D-68 CHANGE OF ADMIN RATE FOR INFUSION OF AREDIA FOR TREATMENT OF MODERATE AND SEVERE HYPERCALCEMIA OF MALIGNANCY FROM 24 HOURS TO 2 HOURS UP TO BUT NOT INCLUDING 24 HOURS
- D-69 SHORTENED DOSING REGIMEN TO 5 DAYS FOR THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS
- D-70 80MG ONCE DAILY DOSING REGIMEN
- D-71 EIGHT WEEK DOSING REGIMEN
- D-72 INFORMATION REGARDING INCREASED RATE OF INFUSION FOR DEPACON
- D-73 ONCE A WEEK DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
- D-74 ONCE A WEEK DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- D-75 INTERMITTENT DOSING REGIMEN, STARTING DAILY DOSE 14 DAYS PRIOR TO THE ANTICIPATED ONSET OF MENSTRUATION THROUGH THE FIRST FULL DAY OF MENSES AND REPEATING WITH EACH NEW CYCLE
- D-76 FOR USE ON AN "AS NEEDED" OR PRN BASIS FOR THE MANAGEMENT OF NASAL SYMPTOMS IN PATIENTS FOR WHOM THE DRUG IS INDICATED
- D-77 ADDITION OF 20MG AND 40MG DAILY AS OPTIONAL STARTING DOSES WITH 40MG INTENDED FOR PATIENTS WHO REQUIRE A LARGE REDUCTION IN LDL-C (MORE THAN 45%)
- D-78 USE OF FLEXERIL 5MG FOR THE RELIEF OF MUSCLE SPASM ASSOCIATED WITH ACUTE, PAINFUL, MUSCULOSKELETAL CONDITIONS
- D-79 NEW LOWER STARTING DOSE FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS AND/OR MODERATE TO SEVERE SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED W/ THE MENOPAUSE
- D-80 CHANGE OF DOSING SCHEDULE FOR LANTUS FROM ONCE DAILY AT BEDTIME TO FLEXIBLE DAILY DOSING
- D-81 NEW LOWER STARTING DOSE FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPORSIS
- D-82 USE OF PREMARIN 0.3 MG AND 0.45 MG FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- D-83 750 MG, ONCE DAILY FOR 5 DAYS FOR COMMUNITY ACQUIRED PNEUMONIA (CAP)
- D-84 ONCE-A-DAY DOSING OF FLOXACIN OTIC FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS (AGES 6 MO & OLDER) W/ OTITIS EXTERNA CAUSED BY SUSCEPTIBLE STRAINS OF E.COLI, P.AERUGINOSA AND S.AUREUS
- D-85 LOWER RECOMMENDED STARTING DOSE GUIDELINES FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE
- D-86 FOR USE IN SELECT EXTERNAL INSULIN PUMPS
- D-87 ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
- D-88 NEW DOSING RANGE OF 200-400MG PER DAY IN TWO DIVIDED DOSES FOR ADULTS WITH PARTIAL SEIZURES
- D-89 USE OF REYATAZ 300 MG/RITONAVIR 100 MG ONCE DAILY FOR TREATMENT IN HIV-INFECTED ANTIRETROVIRAL-EXPERIENCED PATIENTS
- D-90 ADDITION OF DAYTIME ADMINISTRATION TO TREAT VULVOVAGINAL CANDIDIASIS
- D-91 ALTERNATE INTERMITTENT DOSING REGIMEN

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY DOSING SCHEDULE**

D-92	ALTERNATIVE DOSAGE OF 1000MG ONCE DAILY AT BEDTIME
D-93	ALTERNATE TWO OR THREE TIMES DAILY DOSING REGIMENS
D-94	NEW MAXIMUM DOSAGE OF 72 MG/DAY IN ADOLESCENTS 13-17 YEARS OF AGE WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
D-95	BROADENED INITIAL STARTING DOSE FOR HYPERTENSION FROM 50 MG TO 100 MG TO 25 MG TO 100 MG DOSE RANGE
D-96	ONCE-MONTHLY TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH BONIVA (IBANDRONATE SODIUM) 150 MG TABLETS
D-97	PED CANCER PT POPULATION EXPANDED TO INCLUDE PTS 6 MOS UP TO BUT NOT INCLUDING 4 YRS AND DOSING INSTRUCTIONS TO ADMIN 30 MIN BEFORE CHEMO WITH SECOND AND THIRD DOSES 4 & 8 HOURS AFTER FIRST DOSE
D-98	DOSING FOR PED SURGICAL PTS EXPANDED TO INCLUDE PTS 1 MONTH UP TO BUT NOT INCLUDING 2 YEARS OF AGE
D-99	ONCE DAILY ADMINISTRATION FOR THE TREATMENT OF HIV INFECTION IN THERAPY NAIVE ADULT PATIENTS
D-100	750 MG ONCE DAILY FOR FIVE DAYS FOR THE TREATMENT OF ACUTE BACTERIAL SINUSITIS
D-101	ONCE DAILY IN CHRONIC IDIOPATHIC URTICARIA FOR ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER
D-102	NEW DOSING REGIMEN OF ONE SPRAY TWICE DAILY FOR SEASONAL ALLERGIC RHINITIS IN PATIENTS 12 YRS OF AGE AND OLDER
D-103	NEW DOSING RECOMMENDATION FOR THE TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT PATIENTS, SPECIFICALLY A REDUCTION IN COURSE OF THERAPY FROM FAMCICLOVIR 125 MG TWICE-A-DAY FOR 5 DAYS TO 1000 MG TWICE-A-DAY FOR 1 DAY.
D-104	0.5MG/0.1MG FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE IN WOMEN WHO HAVE A UTERUS
D-105	USE OF ACTONEL 75MG TWO CONSECUTIVE DAYS PER MONTH FOR THE PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
D-106	FIVE DAY TREATMENT OF SELECTED SUSCEPTIBLE STRAINS OF STREPTOCOCCUS PNEUMONIAE, HAEMOPHILUS INFLUENZA, MYCOPLASMA PNEUMONIAE, AND CHLAMYDIA PNEUMONIAE FOR COMMUNITY-ACQUIRED PNEUMONIA
D-107	PROVIDES FOR THE COMBINATION TABLET OF 70MG ALENDRONATE AND 5600 IU OF VITAMIN D3 FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
D-108	TREATMENT OF COMPLICATED URINARY TRACT INFECTION AND ACUTE PYELONEPHRITIS WITH LEVAQUIN 750MG ONCE DAILY FOR FIVE DAYS
D-109	PROVIDE FOR THE USE OF A LOWER DOSE FOR THE TREATMENT OF ADULTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB MESYLATE
D-110	TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGED 13-17
D-111	PROVIDES FOR ONCE DAILY USE OF CIALIS, 2.5 MG AND 5 MG, FOR THE TREATMENT OF ERECTILE DYSFUNCTION
D-112	PROVIDES FOR PEDIATRIC PUMP USE
D-113	ONCE DAILY DOSING REGIMEN FOR PATIENTS WHO BECOME CONSTIPATED ON TWICE DAILY REGIMEN
D-114	NEW DOSING RECOMMENDATIONS FOR USE OF SIROLIMUS IN COMBINATION WITH CYCLOSPORINE FOR THE PROPHYLAXIS OF REJECTION IN HIGH-RISK RENAL TRANSPLANT RECIPIENTS
D-115	STARTING DOSE OF 15MG/DAY FOR MONOTHERAPY IN ACUTE TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED
D-116	ALTERNATIVE DOSING REGIMEN ATAZANAVIR SULFATE CO-ADMINISTERED WITH RITONAVIR FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT NAIVE PATIENTS
D-117	50 MG TABLET FOR INITIATION OF DOSE TITRATION FOR BIPOLAR DISORDER
D-118	TWO 400MG TABLETS ONCE DAILY, CO-ADMINISTERED WITH 100MG RITONAVIR
D-119	DOSING RECOMMENDATIONS FOR HIV INFECTED PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OF AGE
D-120	DOSING REGIMEN ADJUSTMENTS
D-121	CHANGE TO REMOVE 20 MG MAXIMUM DOSAGE RESTRICTION

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY DOSING SCHEDULE**

D-122	USE OF VAGIFEM 10 MCG FOR THE TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE
D-123	ALTERNATIVE DOSING REGIMEN DOSE OF 20 MG/METER SQUARE BY CONTINUOUS INTRAVENOUS INFUSION OVER 1 HOUR REPEATED DAILY FOR 5 DAYS
D-124	ONCE DAILY DOSING REGIMEN IN ADULT PATIENTS WITH LESS THAN THREE LOPINAVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS
D-125	EXTEND CURRENT DOSING REGIMEN TO 900MG (2-450MG TABLETS) ONCE A DAY WITHIN 10 DAYS OF TRANSPLANTATION UNTIL 200 DAYS POST-TRANSPLANTATION FOR THE PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN ADULT KIDNEY TRANSPLANT PATIENTS AT HIGH RISK.
D-126	CHANGE DOSAGE REGIMEN FROM 250MG TO 500MG
D-127	DOSING REGIMEN FOR ADULT PATIENTS WITH CHRONIC HEPATITIS B (CHB) AND DECOMPENSATED LIVER DISEASE
D-128	SINGLE IV DOSE OF FOSAPREPITANT 150MG, DOSED CONCOMITANTLY WITH 5HT3 RECEPTOR ANTAGONIST & CORTICOSTEROID, FOR PREVENTION OF ACUTE & DELAYED NAUSEA & VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY EMETOGENIC CANCER CHEMO
D-129	800/100 MG DARUNAVIR/RITONAVIR, ONCE DAILY, IN TREATMENT-EXPERIENCED HIV-1 INFECTED PATIENTS WITH NO DARUNAVIR RESISTANCE ASSOCIATED SUBSTITUTIONS
D-130	DOSING RECOMMENDATIONS FOR TREATMENT OF HIV-1 INFECTION DURING PREGNANCY BASED ON DATA FROM STUDY AI424-182, A STUDY OF ATAZANAVIR/RITONAVIR IN COMBINATION WITH ZIDOVUDINE/LAMIVUDINE IN HIV INFECTED PREGNANT WOMEN
D-131	EVERY 6 TO 8 WEEKS FOR THE 120MG STRENGTH FOR PATIENTS WHO ARE CONTROLLED ON SOMATULINE DEPOT 60MG OR 90MG
D-132	45MG FOR 6 MONTH ADMINISTRATION
D-133	NEW EFFICACY DATA AND DOSING REGIMEN FOR PREGNANCY IN NORMAL OVULATORY WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION AS PART OF AN IVF OR INTRACYTOPLASMIC SPERM INJECTION (ICSI) CYCLE
D-134	INCREASING MAXIMUM DOSING OF PATIENTS WITH SCHIZOPHRENIA TO 160 MG/DAY
D-135	UPDATE LABELING WITH ONCE DAILY DOSING IN HIV-1 INFECTED, TREATMENT-NAIVE PEDIATRIC PATIENTS 12 TO LESS THAN 18 YEARS OF AGE
D-136	ALTERNATE DOSING REGIMEN FOR UNCOMPLICATED URETHRAL OR ENDOCERVICAL INFECTION CAUSED BY CHLAMYDIA TRACHOMATIS, ADMINISTER 200 MG BY MOUTH ONCE-A-DAY FOR 7 DAYS
D-137	NEW LOWER DOSING REGIMEN FOR REVATIO IN THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (WHO GROUP 1) IN ADULTS
D-138	80 MG DOSING REGIMEN FOR THE RISK REDUCTION OF REBLEEDING OF GASTRIC AND DUODENAL ULCERS IN THE FIRST 72 HOURS FOLLOWING THERAPEUTIC ENDOSCOPY IN ADULTS
D-139	ADDITIONAL INFORMATION ADDED TO THE DOSING AND ADMINISTRATION SECTION OF THE LABELING REGARDING THE ADMINISTRATION OF BRAVELLE AND MENOPUR IN THE SAME SYRINGE TO OVULATORY WOMEN AS PART OF AN ART CYCLE
D-140	REVISED DOSING SCHEDULE TO ADMINISTER AVANAFIL 15 MINUTES PRIOR TO SEXUAL ACTIVITY
D-141	DOSING INFORMATION IN PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA
D-142	DOSE MODIFICATION GUIDELINES FOR BORTEZOMIB WHEN GIVEN IN COMBINATION WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE
D-143	INITIATION OF VIMPAT THERAPY WITH A LOADING DOSE OF 200MG
D-144	LOWER LIMIT OF 15 MINUTES FOR THE INFUSION DURATION
D-145	UPDATES TO THE DOSAGE AND ADMINISTRATION SECTION OF THE LABELING TO REFLECT THE RESULTS OF TWO SHORT TERM STUDIES EVALUATING THE SAFETY AND EFFICACY OF INTUNIV IN CHILDREN AND ADOLESCENTS AGES 6 TO 17 WITH ADHD.
D-146	CHANGE IN TARGET DOSING TO 20MG TO 40MG ORALLY ONCE DAILY
D-147	ONCE DAILY DOSING IN PEDIATRIC PATIENTS 3 MONTHS OF AGE AND OLDER IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION
D-148	EXTENDED THE DURATION OF THE DOSING REGIMEN FROM 100 DAYS TO 200 DAYS POST-TRANSPLANTATION FOR THE PREVENTION OF CMV DISEASE IN PEDIATRIC KIDNEY TRANSPLANT
D-149	DOSING INFORMATION ADDED TO THE LABELING REGARDING PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH ITP

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY DOSING SCHEDULE**

- D-150 1600MG DAILY FOR PATIENTS ON ADJUNCTIVE THERAPY WHO DID NOT ACHIEVE A SATISFACTORY RESPONSE ON 1200MG DAILY DOSE
- D-151 DOSING RECOMMENDATIONS FOR THE TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS CO-INFECTED WITH HIV-1
- D-152 DOSING RECOMMENDATIONS AS NECESSARY FOR FEVER AND PAIN FOR AGES 6MO TO LESS THAN 12 YEARS AND 12 TO 17 YEARS.
- D-153 IN COMBINATION WITH RIBAVIRIN FOR 12 WEEKS, FOR THE TREATMENT OF GENOTYPE 1, CHRONIC HEPATITIS C TREATMENT EXPERIENCED PATIENTS WITH COMPENSATED CIRRHOSIS BASED UPON THE RESULTS OF THE SIRIUS STUDY
- D-154 ADDITION OF A 1500MG-SINGLE-DOSE REGIMEN FOR THE TREATMENT OF ADULT PATIENTS WITH ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSI)
- D-155 SINGLE IV DOSE OF FOSAPREPITANT 150MG DOSED CONCOMITANTLY WITH 5HT3 RECEPTOR ANTAGONIST & CORTICOSTEROID FOR PREVENTION OF DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF MODERATELY EMETOGENIC CANCER CHEMOTHERAPY
- D-156 DOSING INFORMATION ADDED TO THE LABELING PROVIDING INFORMATION ON TRANSITIONING FROM SUBCUTANEOUS OR INTRAVENOUS ROUTES OF ADMINISTRATION OF TREPROSTINIL
- D-157 UPDATED INFORMATION ADDED TO THE DOSAGE AND ADMINISTRATION SECTION OF THE LABELING PROVIDING DOSAGE RECOMMENDATIONS FOR INTERRUPTIONS AND DISCONTINUATION OF THERAPY
- D-158 REVISED DOSING TO EXPAND PATIENT POPULATION TO INCLUDE LIVER TRANSPLANT RECIPIENTS WITH GENOTYPE 1 HCV INFECTION
- D-159 REVISED DOSING TO EXPAND PATIENT POPULATION TO INCLUDE LIVER TRANSPLANT RECIPIENTS WITH GENOTYPE 4 HCV INFECTION
- D-160 REVISED DOSING TO EXPAND PATIENT POPULATION TO INCLUDE PATIENTS WITH DECOMPENSATED CIRRHOSIS WITH GENOTYPE 1 HCV INFECTION
- D-161 DOSAGE RECOMMENDATIONS ADDED TO INCLUDE TREATMENT OF HCV GENOTYPE 3 SUBJECTS CO-INFECTED WITH HIV-1
- D-162 DOSING TO INCLUDE PATIENTS WITH CHRONIC HCV GENOTYPE 1 INFECTION WITH COMPENSATED (CHILD-PUGH A) OR DECOMPENSATED (CHILD-PUGH B OR C) CIRRHOSIS AND TREATMENT OF CHRONIC HCV GENOTYPE 3 INFECTION IN SUBJECTS WITH DECOMPENSATED (CHILD-PUGH B OR C) CIRRHOSIS
- D-163 DOSING TO INCLUDE PATIENTS WITH CHRONIC HCV GENOTYPE 1A INFECTION WITH COMPENSATED (CHILD-PUGH A) CIRRHOSIS AND GENOTYPE 1B WITH OR WITHOUT COMPENSATED (CHILD-PUGH A) CIRRHOSIS
- D-164 UPDATES TO THE DOSAGE AND ADMINISTRATION, DOSE MODIFICATIONS SECTION OF THE LABELING
- D-165 DOSING RECOMMENDATION ADDED TO THE LABELING FOR IMBRUVICA USE IN COMBINATION WITH BENDAMUSTINE AND RITUXIMAB FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LEUKEMIA (SLL)
- D-166 BROADEN INITIAL STARTING DOSE FOR BIPOLAR I DISORDER TO 5-10MG TWICE DAILY
- D-167 ADDITION OF 1200 MG ONCE DAILY DOSING FOR TREATMENT-NAIVE PATIENTS OR PATIENTS WHO ARE VIROLOGICALLY SUPPRESSED ON AN INITIAL REGIMEN OF RALTEGRAVIR FILM-COATED TABLETS 400 MG TWICE DAILY
- D-168 NEW DOSING REGIMEN OF 10 MG ONCE DAILY FOR THE REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND/OR PULMONARY EMBOLISM (PE) IN PATIENTS AT CONTINUED RISK FOR DVT AND/OR PE AFTER COMPLETION OF INITIAL TREATMENT LASTING AT LEAST 6 MONTHS
- D-169 ONCE-DAILY DOSING FOR PATIENTS 5 YEARS OF AGE AND OLDER WHO HAVE UNDETECTABLE SERUM AND URINE SUCCINYLACETONE CONCENTRATIONS AFTER A MINIMUM OF 4 WEEKS ON A STABLE DOSAGE OF NITISINONE
- D-170 TO ALLOW WITHDRAWAL THERAPY OF PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE WHO HAVE ACHIEVED A SUSTAINED MOLECULAR RESPONSE ON NILOTINIB THERAPY FOR A MINIMUM OF ONE YEAR PRIOR TO DISCONTINUATION
- D-171 REVISED DOSING TO INCLUDE UP-TITRATION AS A STRATEGY TO IMPROVE TOLERABILITY AND THEREBY REDUCE TREATMENT DISCONTINUATION FOR ROFLUMILAST MAINTENANCE DOSAGE OF 500 MCG DAILY
- D-172 ADDITION OF A ONCE WEEKLY DOSING REGIMEN FOR CARFILZOMIB IN COMBINATION WITH DEXAMETHASONE FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY DOSING SCHEDULE**

	RECEIVED ONE TO THREE LINES OF THERAPY
D-173	DOSING RECOMMENDATION FOR THE USE OF ELVITEGRAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR ALAFENAMIDE FIXED DOSE COMBINATION IN HIV-1 INFECTED ADULT PATIENTS WITH END-STAGE-RENAL DISEASE WHO ARE RECEIVING CHRONIC HEMODIALYSIS
D-174	MODIFICATIONS TO THE EXISTING DOSING REGIMEN TO ALLOW FOR TREATMENT INTERRUPTIONS OF UP TO 8 WEEKS FOR INTOLERABLE ADVERSE REACTIONS
D-175	EIGHT-WEEK DOSING REGIMEN FOR THE TREATMENT OF GENOTYPES 1, 2, 3, 4, 5, AND 6, CHRONIC HEPATITIS C VIRUS INFECTION IN TREATMENT-NAIVE SUBJECTS WITH COMPENSATED CIRRHOSIS BASED ON THE RESULTS FROM THE EXPEDITION-8 STUDY
D-176	IBRUTINIB IN COMBINATION WITH RITUXIMAB
D-177	INFORMATION ADDED TO THE DOSING SECTION IN REGARD TO THE TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION IN PATIENTS WITH SEVERE RENAL IMPAIRMENT INCLUDING PATIENTS WITH END STAGE RENAL DISEASE ON DIALYSIS
D-181	DOSING REGIMEN EXTENDING THE CONTRACEPTION USE FROM 5 YEARS TO UP TO 6 YEARS

EXCLUSIVITY INDICATION

I-1	DYSMENORRHEA
I-2	CHOLANGIOPANCREATOGRAPHY
I-3	INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY
I-4	PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY)
I-5	HYSTEOSALPINGOGRAPHY
I-6	TREATMENT OF JUVENILE ARTHRITIS
I-7	BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN
I-8	ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY
I-9	PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
I-10	PREVENTION OF POSTOPERATIVE DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY
I-11	RELIEF OF MILD TO MODERATE PAIN
I-12	TREATMENT OF CUTANEOUS CANDIDIASIS
I-13	URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI
I-14	SEBORRHEIC DERMATITIS
I-15	PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT
I-16	STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS PARTICIPATING IN AN IN VITRO FERTILIZATION PROGRAM
I-17	MANAGEMENT OF CONGESTIVE HEART FAILURE
I-18	ENDOSCOPIC RETROGRADE PANCREATOGRAPHY
I-19	HERNIOGRAPHY
I-20	KNEE ARTHROGRAPHY
I-21	HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR
I-22	RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA
I-23	SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
I-24	TREATMENT OF RHEUMATOID ARTHRITIS
I-25	ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS
I-26	TREATMENT OF LIVER FLUKES

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

I-27	ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE
I-28	SELECTIVE ADULT VISCERAL ARTERIOGRAPHY
I-29	METASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO OOPHORECTOMY OR OVARIAN IRRADIATION
I-30	TREATMENT OF TINEA PEDIS
I-31	CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED TISSUES
I-32	PEDIATRIC MYELOGRAPHY
I-33	ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN
I-34	ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT
I-35	PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING
I-36	ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS
I-37	RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS
I-38	CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER)
I-39	TREATMENT OF ACUTE MYOCARDIAL INFARCTION
I-40	PRIMARY NOCTURNAL ENURESIS
I-41	MIGRAINE HEADACHE PROPHYLAXIS
I-42	HERPES ZOSTER
I-43	HERPES SIMPLEX ENCEPHALITIS
I-44	MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY
I-45	ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS
I-46	USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING
I-47	TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE
I-48	PEDIATRIC ANGIOCARDIOGRAPHY
I-49	TREATMENT OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI
I-50	FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER
I-51	TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS
I-52	PEDIATRIC EXCRETORY UROGRAPHY
I-53	TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA
I-54	RENAL CONCENTRATION CAPACITY TEST
I-55	HYPERTENSION
I-56	EROSIVE GASTROESOPHAGEAL REFLUX DISEASE
I-57	SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER
I-58	INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS
I-59	ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSION AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE
I-60	SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE
I-61	FEMALE ANDROGENETIC ALOPECIA
I-62	PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-63	ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION
I-64	PREVENTION OF SUPRAVENTRICULAR TACHYCARDIAS
I-65	PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

I-66	UNCOMPLICATED GONORRHEA
I-67	TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER
I-68	CENTRAL PRECOCIOUS PUBERTY
I-69	SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY
I-70	USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER
I-71	VARICELLA INFECTIONS (CHICKENPOX)
I-72	PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE
I-73	INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES
I-74	INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY
I-75	TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSIVE ESOPHAGITIS
I-76	PREVENTION OF OSTEOPOROSIS
I-77	DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM
I-78	CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY UROGRAPHY
I-79	MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM
I-80	DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE
I-81	PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL CANDIDIASIS
I-82	TREATMENT OF TRAVELERS' DIARRHEA
I-83	ANGIOCARDIOGRAPHY, CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY IN CHILDREN
I-84	INTRAOPERATIVE AND POSTOPERATIVE TACHYCARDIA AND/OR HYPERTENSION
I-85	TREATMENT OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS
I-86	TREATMENT OF SECONDARY CARNITINE DEFICIENCY
I-87	RENAL IMAGING AGENT FOR USE IN CHILDREN
I-88	MANAGEMENT OF ENDOMETRIOSIS
I-89	EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE
I-90	INTENSIVE CARE UNIT SEDATION
I-91	MONOTHERAPY USE FOR HYPERTENSION
I-92	ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE
I-93	PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS
I-94	USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY [EXCLUDING THE HEART]
I-95	TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
I-96	TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
I-97	ORAL OR RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE GASTROINTESTINAL TRACT
I-98	TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE ASSOCIATED WITH CHRONIC RENAL INSUFFICIENCY
I-99	PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER
I-100	TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY
I-101	TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY
I-102	TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER
I-103	PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

CARINII PNEUMONIA

- I-104 TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATIENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY
- I-105 TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY
- I-106 TREATMENT OF ACROMEGALY
- I-107 VAGINAL CANDIDIASIS
- I-108 EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION
- I-109 TYPHOID FEVER
- I-110 PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIOTHERAPY
- I-111 TREATMENT OF PAGET'S DISEASE OF BONE
- I-112 MANAGEMENT OF MODERATE TO SEVERE PAIN
- I-113 TREATMENT OF PROSTATITIS
- I-114 USE IN CHILDREN TO VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE BRAIN (INTRACRANIAL LESIONS), SPINE, AND ASSOCIATED TISSUE
- I-115 USE IN MRI IN ADULTS TO VISUALIZE LESIONS IN THE HEAD AND NECK
- I-116 MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS
- I-117 TO SLOW THE PROGRESSION FO CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE
- I-118 PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM FOLLOWING KNEE REPLACEMENT SURGERY
- I-119 TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY
- I-120 MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS
- I-121 EXPANDED PATIENT POPULATION -- USE IN ICU PATIENTS
- I-122 PSORIASIS OF THE SCALP
- I-123 RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER
- I-124 LEUKOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE
- I-125 EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES
- I-126 ADJUNCT TO THALLIUM- 201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY
- I-127 TREATMENT OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED PATIENTS
- I-128 IN PT W/ CH DISEASE AND HYPERCHOLESTEROLEMIA: REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH; REDUCE RISK NON-FATAL MI; REDUCE RISK UNDERGOING MYOCARDIAL REVASCULARIZATION PROCEDURES; REDUCTION ELEVATED TOTAL AND LDL CHOL LEVELS...
- I-129 TREATMENT OF ALCOHOL DEPENDENCE
- I-130 MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS
- I-131 PERIPHERAL ARTERIOGRAPHY
- I-132 TREATMENT OF MANIC PHASE OF BIPOLAR DISORDER
- I-133 MANAGEMENT OF CHRONIC STABLE ANGINA
- I-134 HEART FAILURE POST MYOCARDIAL INFARCTION
- I-135 BONE METASTASES ASSOCIATED WITH MULTIPLE MYELOMA
- I-136 IDIOPATHIC CHRONIC URTICARIA
- I-137 PREVENTION OF METAL-INDUCED HEART BURN, ACID INDIGESTION, AND SOUR STOMACH WHEN TAKEN 30 MINUTES PRIOR TO CONSUMING FOOD OR BEVERAGES
- I-138 TREATMENT OF ACUTE RECURRENT GENITAL HERPES
- I-139 PALLIATIVE TREATMENT OF ADVANCED BREAST CANCER IN PRE- AND PERIMENOPAUSAL WOMEN

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

I-140	PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN INDIVIDUALS WITH HIV INFECTION AT RISK FOR DEVELOPING CMV DISEASE
I-141	TREATMENT OF HEMODYNAMICALLY STABLE PATIENTS WITHIN 24 HOURS OF ACUTE MYOCARDIAL INFARCTION TO IMPROVE SURVIVAL
I-142	LOCALIZE MYOCARDIAL ISCHEMIA (REVERSIBLE DEFECT) AND INFARCTION (NON-REVERSIBLE DEFECTS) IN EVALUATING MYOCARDIAL FUNCTION
I-143	EPISODIC TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT ADULTS
I-144	ENHANCEMENT OF MRI OF THE ADULT BODY INTERNAL ORGANS
I-145	0.1MMOL/KG AS A SINGLE INTRAVENOUS BOLUS FOR MRI OF THE CNS IN CHILDREN
I-146	CONTRAST ENHANCEMENT AND FACILITATION OF VISUALIZATION OF EXTRACRANIAL HEAD AND NECK LESIONS
I-147	PREVENTION OF GALLSTONE FORMATION IN OBESE PATIENTS EXPERIENCING RAPID WEIGHT LOSS
I-148	TREATMENT OF ACUTE PNEUMOCYSTIS CARINI PNEUMONIA (PCP) IN HIV-INFECTED PATIENTS WHOSE ALVEOLAR-ARTERIAL OXYGEN DIFFERENCE (AaDO ₂) IS LESS THAN OR EQUAL TO 55 TORR
I-149	TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER
I-150	TREATMENT OF OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER
I-151	PREVENTION OF AND PREVENTION OF FURTHER POSTOPERATIVE NAUSEA AND VOMITING IN PEDIATRIC PATIENTS RECEIVING GENERAL ANESTHESIA
I-152	SLOWING THE PROGRESSION OF CORONARY ATHEROSCLEROSIS AND REDUCING THE RISK OF ACUTE CORONARY EVENTS
I-153	MANAGEMENT OF SEVERE SPASTICITY [ENCOMPASSES SPINAL AND CEREBRAL ORIGIN]
I-154	PATIENT POPULATION ALTERED TO INCLUDE PEDIATRIC USE
I-155	TREATMENT OF ONYCHOMYCOSIS DUE TO DERMATOPHYTES (TINEA UNGUIUM) OF THE TOENAIL WITH OR WITHOUT FINGERNAIL INVOLVEMENT
I-156	ADDITIONAL DATA REGARDING THE SAFE USE OF NORVASC IN PATIENTS WITH HEART FAILURE
I-157	TREATMENT OF ACUTE UNCOMPLICATED CYSTITIS IN FEMALES
I-158	TREATMENT OF OSTEOLYTIC BONE METASTASES OF BREAST CANCER
I-159	FOR HYPERCHOLESTEROLEMIC PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE REDUCE THE RISK OF MYOCARDIAL INFARCTION, REVASCULARIZATION, AND DEATH DUE TO CARDIOVASCULAR CAUSES WITH NO INCREASE IN DEATH FROM NON-CARDIOVASCULAR CAUSES
I-160	TREATMENT OF BACTERIAL CORNEAL ULCERS
I-161	TREATMENT OF ADULT-ONSET OR CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENCY
I-162	FOR USE IN PATIENTS 6-11 YEARS OF AGE
I-163	TREATMENT OF PHOTOPHOBIA
I-164	CHRONIC BACTERIAL PROSTATITIS
I-165	MANAGEMENT OF ADULTS WITH ACTIVE, CLASSIC AND DEFINITIVE RHEUMATOID ARTHRITIS WHO HAVE HAD INSUFFICIENT THERAPEUTIC RESPONSE TO OR ARE INTOLERANT OF AN ADEQUATE TRIAL OF FULL DOSES OF ONE OR MORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
I-166	TREATMENT OF BULIMIA
I-167	COMPLICATED INTRA-ABDOMINAL INFECTIONS (USED IN COMBINATION WITH METRONIDAZOLE) CAUSED BY MIXED AEROBIC/ANAEROBIC PATHOGENS
I-168	MANAGEMENT OF LOCALLY CONFINED STAGE B2-C METASTATIC CARCINOMA OF THE PROSTATE (IN COMBINATION WITH LHRH AGONISTS)
I-169	USE IN COMBINATION WITH CORTICOSTEROIDS AS INITIAL CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH PAIN RELATED TO ADVANCED HORMONE-REFRACTORY PROSTATE CANCER
I-170	PROPHYLACTIC USE DURING HEAD LICE EPIDEMICS
I-171	RELIEF OF SYMPTOMS OF THE COMMON COLD
I-172	TREATMENT OF INITIAL EPISODE OF GENITAL HERPES
I-173	PREOPERATIVELY FOR THE PREVENTION OF INFECTION IN TRANSRECTAL PROSTATE BIOPSY

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

I-174	PELVIC INFLAMMATORY DISEASE
I-175	TREATMENT OF TINEA CORPORIS AND TINEA CRURIS
I-176	TREATMENT OF POSTOPERATIVE INFLAMMATION IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION
I-177	TX OF MODERATE ACNE VULGARIS IN FEMALES, GREATER OR EQUAL TO 15YRS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, DESIRE CONTRACEPTION, HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS
I-178	TREATMENT OF ONYCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN
I-179	NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE
I-180	TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE)
I-181	TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION
I-182	TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME
I-183	MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11
I-184	TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2MG/DAY (MAXIMUM OF 4MG)
I-185	PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
I-186	TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE)
I-187	PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-188	TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS
I-189	TREATMENT OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS
I-190	PLANAR IMAGING AS A SECOND LINE DIAGNOSTIC DRUG AFTER MAMMOGRAPHY TO ASSIST IN THE EVALUATION OF BREAST LESIONS IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE BREAST MASS
I-191	ENDOMETRIAL THINNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR DYSFUNCTIONAL UTERINE BLEEDING
I-192	THE PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS AND A NEW DOSAGE REGIMEN, 40MG ONCE DAILY, FOR THIS INDICATION
I-193	TREATMENT OF PANIC DISORDER IN A RECOMMENDED DOSE RANGE OF 50 TO 200MG/DAY
I-194	CONGESTIVE HEART FAILURE
I-195	FOR USE OF LANSOPRAZOLE IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF DUODENAL ULCER
I-196	ACUTE TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
I-197	MAINTENANCE OF HEALING OF DUODENAL ULCER
I-198	FOR THE USE OF LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF A DUODENAL ULCER
I-199	MONOTHERAPY AND COMBINATION THERAPY WITH SULFONYLUREA IN THE TREATMENT OF TYPE II DIABETES
I-200	TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR
I-201	EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS
I-202	SECOND-LINE TREATMENT OF AIDS-RELATED KAPOSI'S SARCOMA
I-203	MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS
I-204	USE IN PEDIATRIC PATIENTS BETWEEN THE AGES OF 6 AND 11 FOR THE TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS
I-205	INITIAL ANTICONVULSANT TREATMENT OF STATUS EPILEPTICUS
I-206	TREATMENT OF EDEMA ASSOCIATED WITH CHRONIC RENAL FAILURE

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

- I-207 FOR THE SUPPRESSION OF RECURRENT EPISODES OF GENITAL HERPES IN IMMUNOCOMPETENT ADULTS
- I-208 TREATMENT OF OBSESSIVE COMPULSIVE DISORDER IN THE PEDIATRIC POPULATION
- I-209 PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (PSVT)
- I-210 TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL AND LDL CHOLESTEROL TO TARGET LEVELS
- I-211 FOR USE IN PEDIATRIC POPULATION
- I-212 TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN'S SYNDROME
- I-213 TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY
- I-214 TREATMENT OF OSTEOPOROSIS
- I-215 PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS
- I-216 FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
- I-217 PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY
- I-218 USE OF LIPITOR AS AN ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON TYPE IV)
- I-219 USE OF LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET
- I-220 TREATMENT OF EPISODIC- HEARTBURN, ACID INDIGESTION AND SOUR STOMACH
- I-221 TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY
- I-222 PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN
- I-223 USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH ALLERGIC AND NONALLERGIC-PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS
- I-224 FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS
- I-225 USE IN PATIENTS WITH PREVIOUS MI AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT MI, MYOCARDIAL REVASCLARIZATION, AND CEREBROVASCULAR DISEASE EVENTS
- I-226 FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN
- I-227 SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESOPHAGEAL REFLUX DISEASE (GERD)
- I-228 PREVENTION OF MEAL INDUCED HEARTBURN AT A DOSE OF 75MG TAKEN 30-60MIN PRIOR TO A MEAL
- I-229 PRILOSEC (OMEPRAZOLE), AMOXICILLIN, AND CLARITHROMYCIN FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE
- I-230 IN COMBINATION WITH CIS-PLATIN, FOR THE FIRST LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR RADIATION
- I-231 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY
- I-232 TREATMENT OF RECURRENT MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-AFFECTED PATIENTS AT A DOSE OF 500MG TWICE DAILY
- I-233 PROPHYLACTIC USE TO REDUCE PERIOPERATIVE BLOOD LOSS AND THE NEED FOR BLOOD TRANSFUSION IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS IN THE COURSE OF CORONARY ARTERY BYPASS GRAFT SURGERY
- I-234 FOR USE IN COMBINATION WITH CISPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED (STAGE IIIA OR IIIB) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

- I-235 PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 12 YEARS OF AGE AND OLDER
- I-236 PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
- I-237 MAINTENANCE TREATMENT OF ASTHMA AND PREVENTION OF BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
- I-238 ADJUNCTIVE TREATMENT OF LENNOX-GASTAUT SYNDROME IN PEDIATRIC AND ADULT PATIENTS
- I-239 TREATMENT OF PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
- I-240 MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM AND RESULTANT METABOLIC BONE DISEASE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL FAILURE (CCR 15 TO 55ML/MIN) NOT YET ON DIALYSIS
- I-241 USE IN PHOTODYNAMIC THERAPY (PDT) FOR REDUCTION OF OBSTRUCTION AND PALLIATION OF SYMPTOMS IN PATIENTS WITH COMPLETELY OR PARTIALLY OBSTRUCTING ENDOBRONCHIAL NONSMALL CELL LUNG CANCER
- I-242 TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE AND IN THE TREATMENT OF VULVAR AND VAGINAL ATROPHY IN WOMEN WITH AN INTACT UTERUS
- I-243 USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH THE COMMON COLD IN CHILDREN AGE 5 TO 11 YEARS
- I-244 REDUCE THE INCIDENCE OF BREAST CANCER IN WOMEN AT HIGH RISK FOR BREAST CANCER
- I-245 TREATMENT OF ACUTE SINUSITIS
- I-246 TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS
- I-247 USE IN CONVERSION TO MONOTHERAPY IN ADULTS WITH PARTIAL SEIZURES WHO ARE RECEIVING TREATMENT WITH A SINGLE ENZYME-INDUCING ANTIEPILEPTIC DRUG
- I-248 INPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITH/WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIUM AND OUTPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIUM
- I-249 TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH COMPENSATED LIVER DISEASE PREVIOUSLY UNTREATED WITH ALPHA INTERFERON THERAPY
- I-250 PRIMARY PREVENTION OF CORONARY HEART DISEASE IN PATIENTS WITHOUT SYMPATOMATIC CARDIOVASCULAR DISEASE WHO HAVE AVERAGE TO MODERATELY ELEVATED TOTAL-C AND LDL-C AND BELOW AVERAGE HDL-C
- I-251 TREATMENT OF GENERALIZED ANXIETY DISORDER
- I-252 NEW COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS METFORMIN
- I-253 COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS INSULIN
- I-254 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS (LOSS OF BONE MASS)
- I-255 PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP)
- I-256 USE IN TREATMENT OF SMALL CELL LUNG CANCER SENSITIVE DISEASE AFTER FAILURE OF FIRST-LINE CHEMOTHERAPY
- I-257 TREATMENT OF CHRONIC HEPATITIS B ASSOCIATED WITH EVIDENCE OF HEPATITIS B VIRAL REPLICATION AND ACTIVE LIVER INFLAMMATION
- I-258 FOR PERENNIAL NONALLERGIC RHINITIS FOR AGES 4 AND ABOVE
- I-259 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY
- I-260 EXPANDED PEDIATRIC USE IN CHILDREN YOUNGER THAN ONE MONTH OF AGE TO BIRTH (WITH A GESTATIONAL AGE OF 37 WEEKS OR GREATER)
- I-261 TREATMENT OF SOCIAL ANXIETY DISORDER
- I-262 TREATMENT OR PREVENTION OF BRONCHOSPASM WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE AND FOR THE PREVENTION OF EXERCISE INDUCED BRONCHOSPASM IN CHILDREN AGES 4-12
- I-263 TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION FOR THE PREVENTION OF ISCHEMIC COMPLICATIONS IN PATIENTS ON CONCURRENT ASPIRIN THERAPY
- I-264 PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIATION, INCLUDING TOTAL BODY IRRADIATION (TBI) AND FRACTIONATED ABDOMINAL RADIATION

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

I-265	TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 6 YEARS AND OLDER
I-266	USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS AGES 2-16 YEARS WITH PARTIAL ONSET SEIZURES
I-267	USE IN PEDIATRIC PATIENTS 3 MONTHS OLD AND OLDER - FOR CORTICOSTEROID-RESPONSIVE DERMATOSES
I-268	PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 7-11 YEARS OF AGE
I-269	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING CISPLATIN
I-270	ADJUVANT TREATMENT OF NODE-POSITIVE BREAST CANCER ADMINISTERED SEQUENTIALLY TO STANDARD DOXORUBICIN-CONTAINING COMBINATION CHEMOTHERAPY
I-271	TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
I-272	TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN MEN AND WOMEN RECEIVING GLUCOCORTICOID IN A DAILY DOSE EQUIVALENT TO 7.5MG OR GREATER OF PREDNISONE AND WHO HAVE LOW BONE MINERAL DENSITY
I-273	ADJUNCT TO DIET TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NON FAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB)
I-274	USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
I-275	USE IN COMBINATION WITH METFORMIN AND SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES
I-276	USE OF REZULIN IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH TYPE 2 DIABETES
I-277	TREATMENT OF TYPE III HYPERLIPOPROTEINEMIA
I-278	TREATMENT OF PATIENTS WITH ISOLATED HYPERTRIGLYCERIDEMIA (FREDERICKSON TYPE IV)
I-279	TREATMENT OF POST-TRAUMATIC STRESS DISORDER
I-280	USE OF CARNITOR INJECTION FOR THE PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS
I-281	INCREASING HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NONFAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB)
I-282	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY
I-283	TO REDUCE THE INCIDENCE OF MODERATE TO SEVERE XEROSTOMIA IN PATIENTS UNDERGOING POST-OPERATIVE RADIATION TREATMENT FOR HEAD AND NECK CANCER, WHERE THE RADIATION PORT INCLUDES A SUBSTANTIAL PORTION OF THE PAROTID GLANDS
I-284	TO REDUCE THE NUMBER OF ADENOMATOUS COLORECTAL POLYPS IN FAMILIAL ADENOMATOUS POLYPOSIS PATIENTS AS AN ADJUNCT TO USUAL CARE
I-285	TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN ADULTS AND CHILDREN 3 YEARS OF AGE AND OLDER
I-286	TREATMENT OF PATIENTS WITH FREDERICKSON TYPE III
I-287	USE OF PRAVASTATIN IN PATIENTS WITH EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH
I-288	CHANGES IN SEVERAL SECTIONS OF THE INSERT TO INCORPORATE STATEMENTS CONCERNING THE USE OF HIGH DOSES OF LISINAPRIL TO REDUCE THE RISK OF THE COMBINED OUTCOMES OF MORTALITY AND HOSPITALIZATION IN PATIENTS WITH CONGESTIVE HEART FAILURE
I-289	USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHEN DIET AND EXERCISE WITH EITHER SINGLE AGENT DOES NOT ACHIEVE ADEQUATE GLYCEMIC CONTROL
I-290	PREVENTION OF CORTICOSTEROID-INDUCED OSTEOPOROSIS
I-291	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
I-292	TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-293	TREATMENT OF CORTICOSTEROID-INDUCED OSTEOPOROSIS
I-294	TREATMENT OF UNCOMPLICATED ACUTE ILLNESS DUE TO INFLUENZA A AND B IN PEDIATRIC PATIENTS 7 YEARS AND OLDER WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 2 DAYS

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

I-295 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR WOMEN WITH AN INTACT UTERUS

I-296 LONG-TERM INTRAVENOUS TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH THE SCLERODERMA SPECTRUM OF DISEASE IN NYHA CLASS III AND CLASS IV PATIENTS WHO DO NOT RESPOND TO CONVENTIONAL THERAPY

I-297 SHORT-TERM TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER

I-298 TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IIA AND IIB HYPERLIPOPROTEINEMIA

I-299 USE OF CAMPTOSAR AS A COMPONENT OF FIRST-LINE THERAPY IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR PATIENTS WITH METASTATIC CARCINOMA OF THE COLON OR RECTUM

I-300 PROPHYLAXIS FOR ASTHMA IN CHILDREN 2-5 YEARS OF AGE

I-301 TREATMENT OF SIGNS AND SYMPTOMS OF ALLERGIC CONJUNCTIVITIS

I-302 TREATMENT OF PEDIATRIC PATIENTS WITH PRADER-WILLI SYNDROME

I-303 INCREASING HDL-CHOLESTEROL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIAS

I-304 TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IV

I-305 TREATMENT OF LEVOFLOXACIN SUSCEPTIBLE STRAINS OF PENICILLIN-RESISTANT STREPTOCOCCUS PNEUMONIAE IN PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA

I-306 INDUCTION OF SPERMATOGENESIS IN MEN WITH PRIMARY AND SECONDARY HYPOGONADOTROPIC HYPOGONADISM IN WHOM THE CAUSE OF INFERTILITY IS NOT DUE TO PRIMARY TESTICULAR FAILURE

I-307 NEW COMBINATION USE OF METFORMIN AND INSULIN IN TYPE 2 DIABETES

I-308 TREATMENT OF PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS WHO RESPONDED INADEQUATELY TO SALICYLATES OR OTHER NSAIDS

I-309 USE OF ACTONEL 35MG ONCE A WEEK TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS

I-310 REDUCTION IN RISK OF MYOCARDIAL INFARCTION, STROKE, AND DEATH FROM CARDIOVASCULAR CAUSES

I-311 ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS AGE 3 TO 12 YEARS

I-312 FIRST LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER

I-313 EXTENSION OF INDICATION TO PROVIDE FOR MAINTENANCE OF RESPONSE

I-314 TOPICAL ANESTHETIC FOR SUPERFICIAL MINOR SURGERY OF GENITAL MUCOUS MEMBRANES AND AS AN ADJUNCT FOR LOCAL INFILTRATION ANESTHESIA IN GENITAL MUCOUS MEMBRANES

I-315 THROMBOPROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS

I-316 TREATMENT OF NSAID-ASSOCIATED GASTRIC ULCER PATIENTS WHO CONTINUE NSAID USE AND REDUCING RISK OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS WITH HISTORY OF DOCUMENTED GASTRIC ULCER WHO REQUIRE USE OF AN NSAID

I-317 PROPHYLAXIS OF INFLUENZA IN ADULTS AND ADOLESCENTS 13 YEARS AND OLDER

I-318 FIRSTLINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER

I-319 USE FOR SUSPECTED OR CONFIRMED METHANOL POISONING, EITHER ALONE OR IN COMBINATION WITH HEMODIALYSIS

I-320 TREATMENT OF TYPE 2 DIABETES IN PEDIATRIC PATIENTS (AGES 10-16 YEARS)

I-321 JUVENILE RHEUMATOID ARTHRITIS

I-322 USE OF DIPRIVAN IN PATIENTS 3 MONTHS TO 16 YEARS

I-323 COLORECTAL CANCER

I-324 REDUCING NEUROLOGIC DISABILITY AND/OR FREQUENCY OF CLINICAL RELAPSES IN PATIENTS WITH SECONDARY (CHRONIC) PROGRESSIVE, PROGRESSIVE RELAPSING, OR WORSENING RELAPSING-REMITTING MULTIPLE SCLEROSIS

I-325 PREVENTION OF RELAPSE AND RECURRENCE OF DEPRESSION

I-326 GENERALIZED ANXIETY DISORDER

I-327 SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

PATIENTS 5 YEARS AND OLDER

I-328 PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 5-6 YEARS OF AGE

I-329 UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS

I-330 MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS AND CONTROL OF DAYTIME AND NIGHTTIME HEARTBURN SYMPTOMS IN PATIENTS WITH GERD

I-331 TREATMENT OF MODERATE ACNE VULGARIS

I-332 EMPIRIC THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH SUSPECTED FUNGAL INFECTIONS (EFTN)

I-333 TOPICAL TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR DUE TO MALASSEZIA FURFUR (FORMERLY PITYROSPORUM ORBICULARE)

I-334 LONG-TERM TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE WHO FAIL TO MANIFEST CATCH-UP GROWTH BY TWO YEARS OF AGE

I-335 ADJUNCTIVE THERAPY IN PATIENTS TWO YEARS AND OLDER WITH SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME

I-336 EXPANSION OF INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH PREDOMINATELY CLASSIC SUBFOVEAL CHOROIDAL NEOVASCULARIZATION DUE TO PATHOLOGIC MYOPIA OR PRESUMED OCULAR HISTOPLASMOISIS

I-337 PATHOLOGICAL HYPERSECRETION ASSOCIATED WITH ZOLLINGER-ELLISON SNYDROME

I-338 MANAGEMENT OF ACUTE PAIN IN ADULTS AND TREATMENT OF PRIMARY DYSMENORRHEA

I-339 TREATMENT OF HEPATITIS B IN PEDIATRIC PATIENTS AGES 2-17 YEARS

I-340 ATOPIC DERMATITIS IN PEDIATRIC PATIENTS AGES 2-5

I-341 BREAST CANCER COMBINATION THERAPY

I-342 USE OF FORADIL FOR LONG-TERM, TWICE DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHO-CONSTRICTION IN PATIENTS WITH COPD INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA

I-343 USE OF COREG FOR SEVERE HEART FAILURE

I-344 ACNE VULGARIS

I-345 TREATMENT OF POSTTRAUMATIC STRESS DISORDER

I-346 TREATMENT OF SYMPTOMATIC GASTRO ESOPHAGEAL REFLUX DISEASE (GERD)

I-347 TREATMENT OR PREVENTION OF BRONCHOSPASM IN CHILDREN 6 YEARS OF AGE AND OLDER WITH OBSTRUCTIVE AIRWAY DISEASE

I-348 LONG-TERM, TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD (INCLUDING EMPHYSEMA AND CHRONIC BRONCHITIS)

I-349 ACUTE CORONARY SYNDROME

I-350 TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND GIRLS AT LEAST ONE YEAR POSTMENARCHAL, AGES 10 TO 17 YEARS, WITH A RECOMMENDED DOSING RANGE OF 10 TO 40MG ONCE DAILY

I-351 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR ALL STRENGTHS

I-352 ANTICOAGULANT IN PATIENTS WITH OR AT RISK FOR HEPARIN-INDUCED THROMBOCYTOPENIA UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI)

I-353 TREATMENT OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS

I-354 MANAGEMENT OF POST HERPETIC NEURALGIA

I-355 PREMENSTRUAL DYSPHORIC DISORDER

I-356 TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS, INCLUDING ZOLLINGER-ELLISON SYNDROME

I-357 TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS

I-358 TREATMENT OF PANIC DISORDER

I-359 TREATMENT OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH MENOPAUSE

I-360 TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN CHILDREN AGES TWO UP TO AGE THREE

I-361 TREATMENT OF MULTIPLE MYELOMA AND DOCUMENTED BONE METASTASES FROM SOLID TUMORS, IN CONJUNCTION WITH STANDARD ANTINEOPLASTIC THERAPY. PROSTATE CANCER SHOULD HAVE

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

- PROGRESSED AFTER TREATMENT WITH AT LEAST ONE HORMONAL THERAPY
- I-362 TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA
- I-363 ADJUVANT TREATMENT OF POST MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER
- I-364 TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
- I-365 TREATMENT OF HEART FAILURE (NYHA CLASS II-IV) IN PATIENTS WHO ARE INTOLERANT TO AN ACE INHIBITOR
- I-366 PREVENTION OF RELAPSE FOLLOWING LONG-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER
- I-367 COMBINATION THERAPY WITH THIAZOLIDINEDIONE TO LOWER BLOOD GLUCOSE IN PTS WHOSE HYPERGLYCEMIA CANNOT BE CONTROLLED BY DIET/EXERCISE PLUS MONOTHERAPY WITH ANY OF THE FOLLOWING AGENTS: METFORMIN, SULFONYLUREAS, REPAGLINIDE, OR THIAZOLIDINEDIONES
- I-368 USE OF GLUCOVANCE WITH A THIAZOLIDINEDIONE WHEN GLYCEMIC CONTROL IS NOT OBTAINED WITH GLUCOVANCE ALONE
- I-369 PREVENTION AND TREATMENT OF POSTOPERATIVE NAUSEA AND VOMITING
- I-370 TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN CHILDREN, AGES 8-13 YEARS, WITH RECOMMENDED DOSE OF 20MG ONCE DAILY AND IN ADOLESCENTS, AGES 14-18 WITH A RECOMMENDED DOSE OF 40MG ONCE DAILY
- I-371 HELICOBACTER PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
- I-372 NOSOCOMIAL PNEUMONIA
- I-373 TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY
- I-374 SHORT TERM TOPICAL TREATMENT OF MILD TO MODERATE PLAQUE-TYPE PSORIASIS OF NON SCALP REGIONS
- I-375 FIRST LINE THERAPY FOR THE REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION
- I-376 TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (CML)
- I-377 USE OF BRAVELLE FOR MULTIPLE FOLLICULAR DEVELOPMENT (CONTROLLED OVARIAN STIMULATION) DURING ASSISTED REPRODUCTIVE TECHNOLOGY CYCLES IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED PITUITARY SUPPRESSION
- I-378 RELIEF OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER
- I-379 USE TAXOTERE IN COMBINATION WITH CISPLATIN FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE NOT PREVIOUSLY RECEIVED CHEMOTHERAPY FOR THIS CONDITION
- I-380 TO TREAT PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER AT RISK FOR EMERGENT SUICIDAL BEHAVIOR
- I-381 TREATMENT OF COLD SORES (HERPES LABIALIS) IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER
- I-382 FOR NEWLY-DIAGNOSED HIGH GRADE MALIGNANT GLIOMA PATIENTS AS AN ADJUNCT TO SURGERY AND RADIATION
- I-383 TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY
- I-384 USE IN COMBINATION WITH INSULIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS
- I-385 MODIFICATION OF THE INDICATION FOR COMMUNITY ACQUIRED PNEUMONIA TO ADD "INCLUDING PENICILLIN-RESISTANT STRAINS, MIC PENICILLIN>=2MCG/ML" TO STREPTOCOCCUS PNEUMONIAE
- I-386 RAPAMUNE (SIROLIMUS) WITHIN AN IMMUNOSUPPRESSIVE REGIMEN THAT WOULD ALLOW FOR THE WITHDRAWAL OF CYCLOSPORINE 2 TO 4 MONTHS AFTER RENAL TRANSPLANTATION IN PATIENTS CONSIDERED AT LOW TO MODERATE IMMUNOLOGIC RISK FOR RENAL TRANSPLANT REJECTION
- I-387 ADJUNCTIVE THERAPY OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS GREATER THAN OR EQUAL TO 2 YEARS OF AGE
- I-388 TREATMENT OF PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
- I-389 SUPPRESSION OF RECURRENT GENITAL HERPES IN HIV-INFECTED INDIVIDUALS

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

- I-390 USE IN PTS AT HIGH RISK CORONARY EVENTS DUE TO EXISTING CORONARY HEART DISEASE, DIABETES, PERIPHERAL VESSEL DISEASE, STROKE HISTORY, OTHER CV DISEASE TO REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH, REDUCE NONFATAL MI & STROKE.....
- I-391 ABLATION OF HIGH-GRADE DYSPLASIA IN BARRETT'S ESOPHAGUS PATIENTS WHO DO NOT UNDERGO ESOPHAGECTOMY
- I-392 TX OF PED PATIENTS W/PH+ CHRONIC PHASE CML DISEASE RECURRENCE AFTER STEM CELL TRANSPLANT OR RESISTANCE TO INTERFERON ALPHA THERAPY. NO CONTROLLED TRIALS DEMONSTRATING A CLINICAL BENEFIT SUCH AS IMPROVEMENT IN DISEASE RELATED SX OR INCREASED SURVIVAL
- I-393 CHRONIC BACTERIAL PROSTATITIS
- I-394 USE IN PATIENTS WITH CORONARY HEART DISEASE TO REDUCE THE RISK OF UNDERGOING CORONARY REVASCULARIZATION PROCEDURES
- I-395 TO IMPROVE PHYSICAL FUNCTION
- I-396 EXPANDED INDICATION TO INCLUDE THE ASSESSMENT OF VENTRICULAR FUNCTION IN SUBJECTS BEING EVALUATED FOR HEART DISEASE AND/OR VENTRICULAR FUNCTION
- I-397 EXTENDED PROPHYLAXIS IN PATIENTS UNDERGOING HIP FRACTURE SURGERY
- I-398 IDIOPATHIC SHORT STATURE
- I-399 TREATMENT OF CANDIDEMIA AND THE FOLLOWING CANDIDA INFECTIONS: INTRA-ABDOMINAL ABSCESSSES, PERITONITIS AND PLEURAL SPACE INFECTIONS
- I-400 USE OF OLANZAPINE IN COMBINATION WITH LITHIUM OR VALPROATE FOR THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR DISORDER
- I-401 LONGER-TERM EFFICACY OF ARIPIPRAZOLE IN THE TREATMENT OF SCHIZOPHRENIA
- I-402 DIABETIC FOOT INFECTIONS WITHOUT CONCOMITANT OSTEOMYELITIS
- I-403 USE OF VALTREX IN COMBINATION WITH SAFER SEX PRACTICES FOR THE REDUCTION OF THE RISK OF TRANSMISSION OF GENITAL HERPES DURING SUPPRESSIVE THERAPY OF THE SOURCE PARTNER IN A HETEROSEXUAL COUPLE
- I-404 MAINTENANCE TREATMENT OF BIPOLAR I DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES (DEPRESSION, MANIA, HYPOMANIA, MIXED EPISODES) IN PATIENTS TREATED FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY
- I-405 TREATMENT OF PREMENSTRUAL DYSPHORIC DISORDER (PMDD) USING AN INTERMITTENT DOSING REGIMEN
- I-406 PREVENTION OF CYTOMEGALOVIRUS DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)
- I-407 IMPROVE SURVIVAL OF STABLE PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (EJECTION FRACTION<=40%) AND CLINICAL EVIDENCE OF CONGESTIVE HEART FAILURE AFTER AN ACUTE MYOCARDIAL INFARCTION
- I-408 STIMULATION OF PANCREATIC SECRETIONS TO FACILITATE THE IDENTIFICATION OF THE AMPULLA OF VATER AND ACCESSORY PAPILLA DURING ENDOSCOPIC RETROGRADE CHOLANGIO-PANCREATOGRAPHY (ERCP)
- I-409 ESOPHAGEAL CANDIDIASIS
- I-410 USE OF ADVAIR DISKUS 250/50 FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) ASSOCIATED WITH CHRONIC BRONCHITIS
- I-411 EXPANDED INDICATION FOR USE IN COMBINATION WITH ANTIDIABETIC DRUGS IN THE THIAZOLIDINEDIONE CLASS
- I-412 MONOTHERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
- I-413 ADJUNCTIVE THERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
- I-414 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM (PE) IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS
- I-415 SEVERE HYPERTENSION WHEN THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY
- I-416 THE USE OF CIPRO XR FOR COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

- I-417 USE IN THE LONG TERM TREATMENT OF BIPOLAR I DISORDER
- I-418 ADJUNCTIVE THERAPY W/ MOOD STABILIZERS (LITHIUM OR DIVALPROEX) IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDERS
- I-419 MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
- I-420 TOPICAL TREATMENT OF CLINICALLY TYPICAL, NONHYPERKERATOTIC, NONHYPERTROPHIC ACTINIC KERATOSES ON THE FACE OR SCALP IN IMMUNOCOMPETENT ADULTS
- I-421 TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND PYELONEPHRITIS DUE TO E.COLI FOR PED PATIENTS (1-17) NOT AS FIRST CHOICE
- I-422 INDICATED FOR THE IN-HOSPITAL SHORT-TERM (UP TO 4 HOURS) REDUCTION IN BLOOD PRESSURE IN PEDIATRIC PATIENTS
- I-423 ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
- I-424 MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL INSUFFICIENCY NOT YET ON DIALYSIS
- I-425 ELOXATIN IN COMBINATION WITH INFUSIONAL 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) FOR THE TREATMENT OF PATIENTS PREVIOUSLY UNTREATED FOR ADVANCED COLORECTAL CANCER
- I-426 TREATMENT OF ACUTE PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
- I-427 TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
- I-428 FOR USE IN COMBINATION WITH PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR ANTHRACYCLINE CONTAINING ADJUVANT CHEMOTHERAPY UNLESS ANTHRACYCLINES WERE CLINICALLY CONTRAINDICATED
- I-429 FOR USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER
- I-430 FOR USE IN THE RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS
- I-431 NOSOCOMIAL PNEUMONIA AND COMMUNITY-ACQUIRED PNEUMONIA CAUSED BY STREPTOCOCCUS PNEUMONIAE INDICATION EXPANDED TO INCLUDE MULTI-DRUG RESISTANT STRAINS
- I-432 TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA CAUSED BY MULTI-DRUG RESISTANT STREPTOCOCCUS PNEUMONIAE
- I-433 TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA IN IMMUNOCOMPETENT ADULTS, WITH A MAXIMUM TUMOR DIAMETER OF 2.0CM, LOCATED ON THE TRUNK (EXCLUDING ANOGENITAL SKIN), NECK, OR EXTREMITIES (EXCLUDING HANDS AND FEET)
- I-434 PREVENTION OF CARDIOVASCULAR DISEASE IN ADULT PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE, BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE TO REDUCE RISK OF MI AND RISK FOR REVASCULARIZATION PROCEDURES AND ANGINA
- I-435 CHRONIC IDIOPATHIC CONSTIPATION
- I-436 FOR USE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR THE ADJUVANT TREATMENT OF PATIENTS WITH OPERABLE NODE-POSITIVE BREAST CANCER
- I-437 TREATMENT OF ACUTE MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER
- I-438 EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS
- I-439 USED TO TREAT ADULTS WITH GROWTH HORMONE DEFICIENCY
- I-440 FOR THE REPLACEMENT OF ENDOGENOUS GROWTH HORMONE IN ADULTS WITH GROWTH HORMONE DEFICIENCY
- I-441 USE COMBINATION WITH INFUSIONAL 5-FU/LV FOR ADJUVANT TREATMENT STAGE III COLON CANCER PTS WHO HAVE UNDERGONE COMPLETE RESECTION PRIMARY TUMOR-BASED ON IMPROVEMENT IN DISEASE FREE SURVIVAL, NO DEMONSTRATED BENEFIT OVERALL SURVIVAL AFTER 4YRS
- I-442 USED FOR CANDIDEMIA IN NONNEUTROPENIC PATIENTS AND THE FOLLOWING CANDIDA INFECTIONS: DISSEMINATED INFECTIONS IN SKIN & INFECTIONS IN ABDOMEN, KIDNEY, BLADDER WALL, AND WOUNDS
- I-443 TREATMENT OF NASAL POLYPS IN PATIENTS 18 YEARS OF AGE AND OLDER
- I-444 USE OF PROTONIX IV FOR INJECTION AS STAND ALONE THERAPY FOR THE SHORT-TERM

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

- TREATMENT OF PATIENTS HAVING GASTROESOPHAGEAL REFLUX (GERD) WITH A HISTORY OF EROSIIVE ESOPHAGITIS
- I-445 TO IMPROVE (COMPARED TO 4.25% DEXTROSE) LONG-DWELL ULTRAFILTRATION AND CLEARANCE OF CREATININE AND UREA NITROGEN IN PATIENTS WITH HIGH AVERAGE OR GREATER TRANSPORT CHARACTERISTICS, AS DEFINED USING THE PERITONEAL EQUILIBRATION TEST (PET)
- I-446 EXTENDED ADJUVANT TREATMENT OF EARLY BREAST CANCER IN POSTMENOPAUSAL WOMEN WHO HAVE RECEIVED 5 YRS ADJUVANT TAMOXIFEN THERAPY-EFFECTIVENESS BASED ON AN ANALYSIS OF DISEASE FREE SURVIVAL IN PATIENTS TREATED FOR A MEDIAN 24 MONTHS
- I-447 USE OF COPEGUS (RIBAVIRIN) FOR TREATMENT OF CHRONIC HEPATITIS C IN ADULT PATIENTS COINFECTED WITH HIV IN COMBINATION WITH PEGASYS (PEGINTERFERON ALFA-2A)
- I-448 TREATMENT OF HEART FAILURE (NYHA CLASS II-IV AND EJECTION FRACTION <=40%) TO REDUCE THE RISK OF DEATH FROM CARDIOVASCULAR CAUSES AND TO REDUCE HOSPITALIZATIONS FOR HEART FAILURE
- I-449 TO IMPROVE WAKEFULNESS IN TWO NEW PATIENT POPULATIONS WITH EXCESSIVE SLEEPINESS: THOSE WITH OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME AND THOSE WITH SHIFT WORK SLEEP DISORDER
- I-450 TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED HIGH GRADE GLIOMAS CONCOMITANTLY WITH RADIOTHERAPY AND THEN AS ADJUVANT TREATMENT
- I-451 MANAGEMENT OF ENDOMETRIOSIS ASSOCIATED PAIN
- I-452 EXPANDED INDICATION TO INCLUDE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY
- I-453 USE IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN WHEN DIET, EXERCISE AND BOTH AGENTS DO NOT RESULT IN ADEQUATE GLYCEMIC CONTROL (TRIPLE THERAPY)
- I-454 MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON FOR UP TO 3 MONTHS
- I-455 MODIFIED HEART FAILURE INDICATION TO INCLUDE TREATMENT OF HEART FAILURE IN PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (NYHA CLASS II-IV; EJECTION FRACTION LESS THAN OR EQUAL TO 40%)
- I-456 TO REDUCE CARDIOVASCULAR DEATH AND TO REDUCE HEART FAILURE HOSPITALIZATIONS. INCLUDES ADDITIONAL INFORMATION ON THE ADDED EFFECT ON THESE OUTCOMES WHEN USED WITH AN ACE INHIBITOR
- I-457 TREATMENT OF PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS
- I-458 USE OF BIVALIRUDIN FOR INJECTION WITH PROVISIONAL USE OF GLYCOPROTEIN IIB/IIIA INHIBITOR (GPI) AS LISTED IN THE CLINICAL TRIALS REPLACE-2 SECTION FOR USE AS AN ANTICOAGULANT IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI)
- I-459 NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) PATIENTS RECEIVING OR NOT RECEIVING AN ERYTHROPOIETIN
- I-460 TREATMENT OF DIARRHEA CAUSED BY CRYPTOSPORIDIUM PARVUM IN NON-HIV INFECTED PATIENTS 12 YEARS OF AGE AND OLDER
- I-461 USE AS A SINGLE AGENT FOR ADJUVANT TREATMENT IN PATIENTS WITH DUKES' C COLON CANCER WHO HAVE UNDERGONE COMPLETE RESECTION OF THE PRIMARY TUMOR WHEN TREATMENT WITH FLUOROPYRIMIDINE THERAPY ALONE IS PREFERRED
- I-462 LONG TERM TREATMENT OF IDIOPATHIC SHORT STATURE
- I-463 TREATMENT OF PATIENTS POST MYOCARDIAL INFARCTION
- I-464 TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME
- I-465 PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 6 MONTHS OF AGE AND OLDER
- I-466 FOR RELIEF OF THE SIGNS AND SYMPTOMS OF ANKYLOSING SPONDYLITIS
- I-467 USE OF TOPIRAMATE AS INITIAL MONOTHERAPY IN PATIENTS 10 YEARS OF AGE AND OLDER WITH PARTIAL ONSET OR PRIMARY GENERALIZED TONIC CLONIC SEIZURES
- I-468 USE IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE TO REDUCE THE RISK OF CARDIOVASCULAR MORTALITY OR NON-FATAL MYOCARDIAL INFARCTION
- I-469 RELIEF OF THE SIGNS AND SYMPTOMS OF PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS IN PATIENTS 2 YEARS OF AGE AND OLDER
- I-470 DIABETIC PERIPHERAL NEUROPATHIC PAIN

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

- I-471 INDICATED TO REDUCE THE RISK OF MYOCARDIAL INFARCTION AND STROKE IN PATIENTS WITH TYPE 2 DIABETES AND WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE
- I-472 USE IN PATIENTS WITH ANGIOGRAPHICALLY DOCUMENTED CORONARY ARTERY DISEASE
- I-473 USE IN COMBINATION WITH GEMCITABINE FOR THE FIRST LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER
- I-474 TREATMENT OF IRON DEFICIENCY ANEMIA IN PERITONEAL DIALYSIS DEPENDANT CHRONIC KIDNEY DISEASE IN PATIENTS RECEIVING AN ERYTHROPOIETIN
- I-475 PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF MODERATELY EMETOGENIC CANCER CHEMOTHERAPY
- I-476 TREATMENT OF DIABETIC FOOT INFECTIONS WITHOUT OSTEOMYELITIS
- I-477 TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS, ESCHERICHIA COLI, KLEBSIELLA PNEUMONIAE, OR ENTEROBACTER CLOACAE
- I-478 FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN CHILDREN WITH EPILEPSY AGED 2-4 YEARS
- I-479 TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS CAUSED BY E.COLI, B. FRAGILIS, S.ANGINOSUS, S.CONSTELLATUS, E. FAECALIS, P. MIRABILIS, C. PERFRINGENS, B. THETAIOAOMICRON OR PEPTOSTREPTOCOCCUS SPECIES
- I-480 PROPHYLAXIS OF INFLUENZA FOR PATIENTS BETWEEN 1-12 YEARS OF AGE
- I-481 INDICATED FOR THE ADJUVANT TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER
- I-482 TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH OR WITHOUT PSYCHOTIC FEATURES
- I-483 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- I-484 FOR THE RISK REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS
- I-485 TREATMENT OF POSTOPERATIVE INFLAMMATION AND REDUCTION OF OCULAR PAIN IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION
- I-486 ANGIOMAX IS INDICATED FOR PATIENTS WITH, OR AT RISK OF, HIT/HITTS UNDERGOING PCI
- I-487 INDICATED FOR THE RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YRS OF AGE OR OLDER
- I-488 MAINTENANCE THERAPY IN BIPOLAR I DISORDER
- I-489 FOR USE IN PEDIATRIC PATIENTS WITH TYPE I DIABETES
- I-490 FOR USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE TREATMENT OF PATIENTS WITH ADVANCED GASTRIC ADENOCARCINOMA, INCLUDING ADENOCARCINOMA OF GASTROESOPHAGEAL JUNCTION, WHO HAVE NOT RECEIVED PRIOR CHEMOTHERAPY FOR ADVANCED DISEASE
- I-491 INFLUENZA PROPHYLAXIS
- I-492 MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC OR MIXED EPISODES IN BIPOLAR I DISORDER, WITH OR WITHOUT PSYCHOTIC FEATURES
- I-493 ADMINISTERED IN COMBINATION WITH FENOFIBRATE, AS ADJUNCTIVE THERAPY TO DIET FOR THE REDUCTION OF ELEVATED TOTAL-C, LDL-C, APO B, AND NON-HDL-C IN PATIENTS WITH MIXED HYPERLIPIDEMIA
- I-494 CLINICAL DATA IN SUPPORT OF AVANDAMET AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH DUAL ROSIGLITAZONE AND METFORMIN THERAPY IS APPROPRIATE
- I-495 ADJUVANT TX OF POSTMENOPAUSAL WOMEN WITH ESTROGEN-RECEPTOR POSITIVE EARLY BREAST CANCER WHO HAVE RECEIVED 2 TO 3 YRS OF TAMOXIFEN AND ARE SWITCHED TO AROMASIN FOR COMPLETION OF A TOTAL OF 5 CONSECUTIVE YRS OF ADJUVANT HORMONAL THERAPY
- I-496 LONG TERM TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME IN PATIENTS WHO HAVE OPEN EPIPHYSES
- I-497 PREVENTION OF SEASONAL MAJOR DEPRESSIVE EPISODES IN PATIENTS WITH SEASONAL AFFECTIVE DISORDER
- I-498 PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
- I-499 USE OF GEMZAR IN COMBINATION WITH CARBOPLATIN FOR THE TREATMENT OF PATIENTS WITH ADVANCED OVARIAN CANCER THAT HAS RELAPSED AT LEAST 6 MONTHS AFTER COMPLETION OF

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

PLATINUM-BASED THERAPY

- I-500 FOR USE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
- I-501 TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN IMMUNOCOMPETENT PATIENTS WITH A SINGLE DOSE OF FAMCICLOVIR 1500 MG.
- I-502 FOR PTS WITH ST-SEGMENT ELEVATION ACUTE MYOCARDIAL INFARCTION, PLAVIX TO REDUCE RATE OF DEATH FROM ANY CAUSE AND THE RATE OF A COMBINED ENDPOINT OF DEATH, REINFARCTION OR STROKE. NOT KNOWN TO PERTAIN TO PTS WHO RECEIVE PRIMARY ANGIOPLASTY
- I-503 TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER
- I-504 TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME
- I-505 TREATMENT OF STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA), INCLUDING THOSE WITH RIGHT SIDED INFECTIVE ENDOCARDITIS, CAUSED BY METHICILLIN-SUSCEPTIBLE AND METHICILLIN-RESISTANT ISOLATES
- I-506 ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 12 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY
- I-507 ADJUNCT TO DIET TO REDUCE TOTAL-C, LDL-C AND APO B LEVELS IN ADOLESCENT BOYS AND GIRLS WHO ARE AT LEAST ONE YEAR POST-MENARCHE, 10-16 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
- I-508 PREMENSTRUAL DYSPHONIC DISORDER
- I-509 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
- I-510 ADULT DERMATOFIBROSARCOMA PROTUBERANS (DFSP)
- I-511 ADULT MYELODYSPLASTIC SYNDROME/MYELOPROLIFERATIVE DISEASES (MDS/MDP)
- I-512 ADULT PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) MONOTHERAPY
- I-513 ADULT AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM)
- I-514 ADULT HYPEREOSINOPHILIC SYNDROME/CHRONIC EOSINOPHILIC LEUKEMIA (HES/CEL)
- I-515 PROPHYLAXIS OF SURGICAL SITE INFECTION FOLLOWING ELECTIVE COLORECTAL SURGERY
- I-516 PRIMARY GENERALIZED TONIC CLONIC SEIZURES IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER
- I-517 TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEG SYNDROME (RLS)
- I-518 TREATMENT OF SHORT STATURE OR GROWTH FAILURE IN CHILDREN WITH SHOX (SHORT STATURE HOMEBOX CONTAINING GENE) DEFICIENCY WHOSE EPIPHYSES ARE NOT CLOSED
- I-519 USE OF TAXOTERE (DOCETAXEL) INJECTION CONCENTRATE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
- I-520 USE OF EXENATIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE USING A THIAZOLIDINEDIONE ALONE OR IN COMBINATION WITH METFORMIN BUT HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL
- I-521 TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 YEAR PRIOR THERAPY
- I-522 TREATMENT OF MODERATE ACNE VULGARIS IN WOMEN AT LEAST 14 YRS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, AND HAVE ACHIEVED MENARCHE, IF THE PATIENT DESIRES AN ORAL CONTRACEPTIVE FOR BIRTH CONTROL.
- I-523 USE IN ADULT PATIENTS WITH CLINICALLY EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF NONFATAL MYOCARDIAL INFARCTION, FATAL AND NONFATAL STROKE, ANGINA, REVASCULARIZATION PROCEDURES AND HOSPITALIZATION FOR CONGESTIVE HEART FAILURE
- I-524 GENERALIZED ANXIETY DISORDER (GAD)
- I-525 USE OF 0.5MG/0.1MG FOR PREVENTION OF POST-MENOPAUSAL OSTEOPOROSIS
- I-526 TREATMENT OF HYPONATREMIA IN HOSPITALIZED PATIENTS
- I-527 ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY
- I-528 TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH MENOPAUSE

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

I-529 TREATMENT OF DEMENTIA OF THE ALZHEIMER'S TYPE IN PATIENTS WITH SEVERE ALZHEIMER'S DISEASE

I-530 PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION IN PATIENTS 15 YEARS OF AGE AND OLDER

I-531 MAINTENANCE TREATMENT OF SCHIZOPHRENIA

I-532 TREATMENT OF BACTERIAL VAGINOSIS IN NON-PREGNANT FEMALES

I-533 ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI)

I-534 EXTENDED TREATMENT OF SYMPTOMATIC VENOUS THROMBOEMBOLISM (VTE) AND/OR PULMONARY EMBOLISM TO REDUCE THE RECURRENCE OF VTE IN PATIENTS WITH CANCER

I-535 MANAGEMENT OF FIBROMYALGIA

I-536 FOR THE TREATMENT OF SHORT STATURE IN CHILDREN WITH NOONAN SYNDROME

I-537 LONG TERM TREATMENT OF PANIC DISORDER

I-538 SHORT TERM TREATMENT OF PANIC DISORDER

I-539 REDUCTION IN RISK OF INVASIVE BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS OR AT HIGH RISK FOR INVASIVE BREAST CANCER

I-540 TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGES 13-17

I-541 TREATMENT OF BIPOLAR I DISORDER IN CHILDREN AGES 10-12 AND ADOLESCENTS AGES 13-17

I-542 EXPANSION OF PATIENT POPULATION FOR HEAD AND NECK CANCER FROM "INOPERABLE" PATIENTS TO ALL PATIENTS

I-543 USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)

I-544 ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 16 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY

I-545 ADJUNCTIVE TREATMENT TO TREAT PATIENTS WITH MAJOR DEPRESSIVE DISORDER

I-546 TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA

I-547 ADJUNCTIVE THERAPY TO DIET TO SLOW THE PROGRESSION OF ARTEROSCLEROSIS IN ADULT PATIENTS AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL-C AND LDL-C TO TARGET LEVELS

I-548 SEASONAL ALLERGIC RHINITIS IN PATIENTS 6 THROUGH LESS THAN 12 YEARS OF AGE

I-549 USE OF AVALIDE TABLETS AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS

I-550 TREATMENT OF HYPERTENSION IN PEDIATRIC PATIENTS 6-16 YEARS OF AGE

I-551 TREATMENT OF SHORT STATURE IN CHILDREN WITH TURNER'S SYNDROME

I-552 ADJUNCTIVE TREATMENT FOR RADIOIODINE ABLATION OF THYROID TISSUE REMNANTS IN PATIENTS WHO HAVE UNDERGONE THYROIDECTOMY FOR WELL-DIFFERENTIATED THYROID CANCER AND WHO DO NOT HAVE EVIDENCE OF METASTATIC THYROID CANCER

I-553 FOR USE AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS

I-554 TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESES

I-555 TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN PEDIATRIC PATIENTS AGED 10-17 YEARS

I-556 PREVENTION OF POST OPERATIVE NAUSEA AND VOMITING FOR UP TO 24 HOURS FOLLOWING SURGERY

I-557 USE OF AMITIZA (LUBIPROSTONE) 8 MCG TWICE DAILY FOR TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN WOMEN GREATER THAN OR EQUAL TO 18 YEARS OLD

I-558 MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION AND REDUCING EXACERBATIONS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA

I-559 ADJUNCTIVE THERAPY ADDED TO LITHIUM OR VALPROATE IN SHORT TERM TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED

I-560 MAINTENANCE TREATMENT FOR BIPOLAR I DISORDER, AS ADJUNCTIVE THERAPY TO LITHIUM OR DIVALPROEX

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

I-561	LONG-TERM TREATMENT OF SOCIAL ANXIETY DISORDER
I-562	MAINTENANCE TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS
I-563	ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SIEZURES IN ADULTS AND CHILDREN 16 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY
I-564	TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA
I-565	USE OF DUTASTERIDE IN COMBINATION WITH TAMSULOSIN FOR THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA (BPH)
I-566	MANAGEMENT OF FIBROMYALGIA
I-567	INITIAL THERAPY IN PATIENTS LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS
I-568	USE OF APTIVUS, CO-ADMINISTERED W/RITONAVIR, FOR COMBINATION ANTIRETROVIRAL TREATMENT OF HIV-1 INFECTED PED (AGE 2-18 YRS) PATIENTS WHO ARE TREATMENT-EXPERIENCED AND INFECTED W/HIV-1 STRAINS RESISTANT TO MORE THAN ONE PROTEASE INHIBITOR
I-569	TREATMENT OF CHRONIC HEPATITIS B
I-570	TREATMENT OF CHICKEN POX IN IMMUNOCOMPETENT PEDIATRIC PATIENTS 2 TO <18 YEARS OF AGE
I-571	NON-SMALL CELL LUNG CANCER IN COMBINATION WITH CISPLATIN AND AS SINGLE AGENT FOR NONSQAUMOUS NON-SMALL CELL LUNG CANCER
I-572	TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE (SGA) WITH NO CATCH-UP BY AGE 2-4 YRS.
I-573	TO TREAT PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDRICKSON TYPE III HYPERLIPOPROTEINEMIA) AS AN ADJUNCT TO DIET
I-574	MONOTHERAPY IN THE TREATMENT OF BIPOLAR DEPRESSION
I-575	MONOTHERAPY IN THE TREATMENT OF BIPOLAR MANIA
I-576	ADJUNCTIVE THERAPY IN THE TREATMENT OF BIPOLAR MANIA
I-577	SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES
I-578	EXPANSION OF INDICATION TO INCLUDE TREATMENT OF HIV IN TREATMENT NAIVE ADULTS
I-579	TREATMENT OF MODERATE TO SEVERE DYSpareunia, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO MENOPAUSE AND NEW TWICE WEEKLY DOSING REGIMEN FOR THIS INDICATION
I-580	INDOLENT B-CELL NON-HODGKINS LYMPHOMA (NHL) THAT HAS PROGRESSED DURING OR WITHIN SIX MONTHS OF TREATMENT WITH RITUXIMAB OR A RITUXIMAB CONTAINING REGIMEN
I-581	TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
I-582	TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
I-583	ADJUVANT TREATMENT OF ADULT PATIENTS FOLLOWING COMPLETE GROSS RESECTION OF KIT (CD117) POSITIVE GASTROINTESTINAL STROMAL TUMORS (GIST)
I-584	TREATMENT AND PREVENTION OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN PATIENTS EXPECTED TO BE ON GLUCOCORTICIDS FOR AT LEAST 12 MONTHS
I-585	TREATMENT OF SHORT STATURE IN PEDIATRIC PATIENTS SMALL FOR GESTATIONAL AGE WHO DO NOT MANIFEST CATCH UP GROWTH BY AGE 2 TO 4 YEARS
I-586	COMMUNITY ACQUIRED BACTERIAL PNEUMONIA
I-587	ADDITIONAL PATHOGENS TO COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS INDICATION
I-588	ADDITIONAL PATHOGENS TO COMPLICATED INTRA-ABDOMINAL INFECTIONS INDICATION
I-589	TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH OLANZAPINE
I-590	ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH OLANZAPINE)
I-591	TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH FLUOXETINE
I-592	ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH FLUOXETINE)

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

I-593 TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD)

I-594 INDICATION EXPANDED TO INCLUDE PATIENTS WHO HAVE EXPERIENCED A FIRST CLINICAL EPISODE AND HAVE MRI FEATURES CONSISTENT WITH MULTIPLE SCLEROSIS

I-595 PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

I-596 USE AS ADJUNCTIVE THERAPY WITH LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER

I-597 MONOTHERAPY FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER

I-598 TREATMENT OF PULMONARY ARTERIAL HYPERTENSION INDICATION EXPANDED TO INCLUDE DELAY IN CLINICAL WORSENING

I-599 PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 5 IN PATIENTS ON HEMODIALYSIS OR PERITONEAL DIALYSIS

I-600 FOR USE AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS

I-601 MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OR METASTATIC NONSMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST LINE CHEMOTHERAPY

I-602 TREATMENT OF MEN AND WOMEN WITH OSTEOPOROSIS ASSOCIATED WITH SUSTAINED SYSTEMIC GLUCOCORTICOID THERAPY AT HIGH RISK FOR FRACTURE

I-603 GOUT FLARES

I-604 PREVENTION OF CMV DISEASE IN KIDNEY AND HEART TRANSPLANT PATIENTS 4 MONTHS TO 16 YEARS AT HIGH RISK

I-605 ADJUNCT TO MOOD STABILIZERS AND/OR ANTIDEPRESSANTS FOR SCHIZOAFFECTIVE DISORDER

I-606 TREATMENT OF SCHIZOAFFECTIVE DISORDER AS MONOTHERAPY

I-607 INDICATION EXPANDED TO INCLUDE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (WHO GROUP I) IN PATIENTS WITH CLASS II SYMPTOMS

I-608 REDUCE LDL-C LEVELS IN BOYS AND POSTMENARCHAL GIRLS, 10 TO 17 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA AS MONOTHERAPY OR IN COMBINATION WITH A STATIN AFTER FAILING AN ADEQUATE TRIAL OF DIET THERAPY

I-610 TREATMENT OF HEAVY MENSTRUAL BLEEDING FOR WOMEN WHO CHOOSE TO USE INTRAUTERINE CONTRACEPTION AS THEIR METHOD OF CONTRACEPTION

I-611 TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND POSTMENARCHAL GIRLS, AGES 10 TO 17 YEARS, WITH A RECOMMENDATION DOSING RANGE OF 5 TO 20 MG ONCE DAILY

I-612 MICARDIS 80 MG FOR REDUCTION OF THE RISK OF MYOCARDIAL INFARCTION, STROKE, OR DEATH FROM CARDIOVASCULAR CAUSES IN PATIENTS 55 YEARS OF AGE OR OLDER AT HIGH RISK OF DEVELOPING MAJOR CARDIOVASCULAR EVENTS WHO ARE UNABLE TO TAKE ACE INHIBITORS

I-613 MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE TO LESS THAN 18 YEARS OF AGE

I-614 SHORT TERM TREATMENT OF EROSIIVE ESOPHAGITIS ASSOCIATED WITH GERD IN PEDIATRIC PATIENTS AGES FIVE YEARS AND OLDER

I-615 MAINTENANCE TREATMENT OF BIPOLAR DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE

I-616 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER IN PEDIATRIC PATIENTS AGES 6-17 YEARS OF AGE

I-617 MAINTENANCE OF GENERALIZED ANXIETY DISORDER (GAD)

I-618 ADJUNCTIVE THERAPY IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)

I-619 INTRAVENOUS CONTRAST ENHANCED COMPUTER TOMOGRAPHY OF THE HEAD AND BODY

I-620 FOR USE IN COMBINATION WITH LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER THAT OVEREXPRESSES THE HER2 RECEPTOR FOR WHOM HORMONAL THERAPY IS INDICATED

I-621 PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE, BASED ON THE RESULTS OF JUSTIFICATION FOR THE USE OF STATINS IN PRIMARY PREVENTION; AN INTERVENTION TRIAL EVALUATING ROSUVASTATIN (JUPITER)

I-622 ADJUNCTIVE THERAPY FOR PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN PATIENTS THIRTEEN YEARS OF AGE AND OLDER

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

I-623 TREATMENT OF SIGNS AND SYMPTOMS OF ADVANCED IDIOPATHIC PARKINSON'S DISEASE

I-624 MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST-LINE CHEMOTHERAPY

I-625 PANCREATIC INSUFFICIENCY DUE TO CHRONIC PANCREATITIS AND PANCREATECTOMY

I-626 RELIEF OF NASAL CONGESTION ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER

I-627 TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH & CML) IN CHRONIC PHASE.

I-628 MAINTENANCE TREATMENT OF SCHIZOPHRENIA IN ADULTS

I-629 ADJUNCTIVE THERAPY WITH EITHER LITHIUM OR VALPROATE FOR THE ACUTE TREATMENT OF MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER

I-630 TREATMENT OF PATIENTS WITH SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) ASSOCIATED WITH TUBEROUS SCLEROSIS (TS) WHO REQUIRE THERAPEUTIC INTERVENTION BUT ARE NOT CANDIDATES FOR CURATIVE SURGICAL RESECTION.

I-631 PREVENTION OF RELAPSE TO OPIOID DEPENDENCE FOLLOWING OPIOID DETOXIFICATION

I-632 MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN

I-633 MAINTENANCE TREATMENT OF BIPOLAR I DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE

I-634 TREATMENT OF SEVERE HYPERCALCEMIA IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM WHO ARE UNABLE TO UNDERGO PARATHYROIDECTOMY

I-635 ADJUNCTIVE TREATMENT WITH LONG-ACTING ORAL PSYCHOSTIMULANTS FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)

I-636 TREATMENT OF EXTERNAL GENITAL AND PERIANAL WARTS/CONDYLOMA ACUMINATA IN PATIENTS 12 YEARS OR OLDER

I-637 USE IN COMBINATION CHEMOTHERAPY WITH 5-FLUOROURACIL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED METASTATIC COLORECTAL CANCER

I-638 FOR PATIENTS WITH PROGRESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC.

I-639 TREATMENT OF PROGRESSIVE, WELL-DIFFERENTIATED PANCREATIC NEUROENDOCRINE TUMORS IN PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC DISEASE

I-640 MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS

I-641 TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)

I-642 TREATMENT OF ERECTILE DYSFUNCTION (ED) AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)

I-643 REDUCE THE RISK OF STROKE AND SYSTEMIC EMBOLISM IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION.

I-644 MONOTHERAPY IN PATIENTS 13 YEARS OF AGE AND OLDER WITH PARTIAL SEIZURES WHO ARE RECEIVING THERAPY WITH A SINGLE ANTIEPILEPTIC DRUG (AED)

I-645 MAINTENANCE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS

I-646 SIGNS AND SYMPTOMS OF ADVANCED PARKINSON'S DISEASE (APD)

I-647 SIGNS AND SYMPTOMS OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS)

I-648 TREATMENT OF HEAVY MENSTRUAL BLEEDING IN WOMEN WITHOUT ORGANIC PATHOLOGY WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION

I-649 TREATMENT OF PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA (STS) WHO HAVE RECEIVED PRIOR CHEMOTHERAPY

I-650 TREATMENT OF ADULTS WITH RENAL ANGIOMYOLIPOMA AND TUBEROUS SCLEROSIS COMPLEX (TSC), NOT REQUIRING IMMEDIATE SURGERY

I-651 MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH SPINAL CORD INJURY

I-652 MANAGEMENT OF POSTHERPETIC NEURALGIA

I-653 TREATMENT OF ENDOGENOUS ANTERIOR UVEITIS

I-654 MAGNETIC RESONANCE ANGIOGRAPHY (MRA) TO EVALUATE ADULTS WITH KNOWN OR SUSPECTED RENAL OR AORTO-ILIO-FEMORAL OCCLUSIVE VASCULAR DISEASE

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

- I-655 TREATMENT OF POSTMENOPAUSAL WOMEN WITH ADVANCED HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER (ADVANCED HR+BC) IN COMBINATION WITH EXEMESTANE, AFTER FAILURE OF TREATMENT WITH LETROZOLE OR ANASTROZOLE
- I-656 MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY (DPN) IN ADULTS WHEN A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME
- I-657 PLAQUE PSORIASIS OF THE SCALP
- I-658 FIRST-LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER, IN COMBINATION WITH CARBOPLATIN, IN PATIENTS WHO ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION THERAPY
- I-659 PLAQUE PSORIASIS OF THE BODY
- I-660 TREATMENT OF DEEP VEIN THROMBOSIS
- I-661 TREATMENT OF PULMONARY EMBOLISM
- I-662 REDUCTION IN RISK FOR DEEP VEIN THROMBOSIS AND THE REDUCTION IN RISK FOR PULMONARY EMBOLISM
- I-663 IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
- I-664 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
- I-665 TREATMENT OF CHRONIC IRON OVERLOAD IN PATIENTS 10 YRS OF AGE AND OLDER WITH (NTDT) SYNDROMES AND WITH A (LIC) OF AT LEAST 5 MG OF IRON PER GRAM OF LIVER DRY WEIGHT (MG FE/G DW) AND SERUM FERRITIN GREATER THAN 300MCG/L
- I-666 TREATMENT OF PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL) IN COMBINATION WITH CHEMOTHERAPY
- I-667 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) WHO HAVE BEEN PREVIOUSLY TREATED WITH IMATINIB MESYLATE AND SUNITINIB MALATE
- I-668 PROPHYLAXIS OF ALLOGRAFT REJECTION IN ADULT PATIENTS RECEIVING A LIVER TRANSPLANT
- I-669 SCINTIGRAPHIC ASSESSMENT OF SYMPATHETIC INNERVATION OF THE MYOCARDIUM BY MEASUREMENT OF THE HEART TO MEDIASTINUM (H/M) RATIO OF RADIOACTIVITY UPTAKE IN PATIENTS WITH NYHA CLASS II OR CLASS III HEART FAILURE AND LVEF LESS THAN 35%
- I-670 TREATMENT OF OPIOID-INDUCED CONSTIPATION (OIC) IN ADULTS WITH CHRONIC, NON-CANCER PAIN
- I-671 FIRSTLINE TREATMENT OF PATIENTS WITH METASTATIC NON- SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21(L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
- I-672 USE IN PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB
- I-673 TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA/VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) CAUSED BY SUSCEPTIBLE ISOLATES OF S. AUREUS (INCLUDING METHICILLIN-SUSCEPTIBLE AND RESISTANT ISOLATES) WHEN ALTERNATIVE TREATMENTS ARE NOT SUITABLE
- I-674 TREATMENT OF PATIENTS WITH DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER (BIPOLAR DEPRESSION) AS MONOTHERAPY AND AS ADJUNCTIVE THERAPY WITH LITHIUM OR VALPROATE
- I-675 MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER
- I-676 FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC ADENOCARCINOMA OF THE PANCREAS, IN COMBINATION WITH GEMCITABINE
- I-677 TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, DIFFERENTIATED THYROID CARCINOMA (DTC) THAT IS REFRACTORY TO RADIOACTIVE IODINE TREATMENT
- I-678 TRAMETINIB, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
- I-679 RISK REDUCTION OF REBLEEDING OF GASTRIC OR DUODENAL ULCERS FOLLOWING THERAPEUTIC ENDOSCOPY IN ADULTS

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

I-680	TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
I-681	PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT) WHICH MAY LEAD TO PULMONARY EMBOLISM (PE), IN ADULT PATIENTS WHO HAVE UNDERGONE HIP OR KNEE REPLACEMENT
I-682	TREATMENT OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM (PE) IN PATIENTS WHO HAVE BEEN TREATED WITH A PARENTERAL ANTICOAGULANT FOR 5-10 DAYS
I-683	TO REDUCE THE RISK OF RECURRENCE OF DVT AND PE IN PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED
I-684	PREVENTION OF ACUTE NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING HIGHLY EMETOGENIC CANCER CHEMOTHERAPY IN PEDIATRIC PATIENTS AGED 1 MONTH TO LESS THAN 17 YEARS
I-685	EXPANDED INDICATION OF RASAGILINE AS AN ADD-ON THERAPY TO STABLE DOSES OF DOPAMINE AGONISTS IN THE TREATMENT OF EARLY PARKINSON'S DISEASE
I-686	INDICATED FOR THE TREATMENT OF DIABETIC MACULAR EDEMA IN PATIENTS WHO ARE PSEUDOPHAKIC OR ARE PHAKIC AND SCHEDULED FOR CATARACT SURGERY
I-687	GUIDING SENTINEL LYMPH NODE BIOPSY, USING A HAND-HELD GAMMA COUNTER IN PATIENTS WITH CLINICALLY NODE NEGATIVE SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY
I-688	GADAVIST IS INDICATED WITH MRI TO DETECT THE PRESENCE AND EXTENT OF MALIGNANT BREAST DISEASE
I-689	TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION
I-690	INDICATED FOR THE TREATMENT OF DEEP VEIN THROMBOSIS (DVT)
I-691	INDICATED TO REDUCE THE RISK OF RECURRENT DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM (PE) FOLLOWING INITIAL THERAPY
I-692	INDICATED FOR MANAGEMENT OF OSTEOARTHRITIS PAIN.
I-693	TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC)
I-694	TREATMENT OF PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS WHO ARE CANDIDATES FOR PHOTOTHERAPY OR SYSTEMIC THERAPY
I-695	REVISED INDICATION FOR BORTEZOMIB IN THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA
I-696	USE AS MONOTHERAPY IN THE TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS WITH EPILEPSY AGE 17 YEARS AND OLDER
I-697	FOR USE IN COMBINATION WITH SOFOSBUVIR FOR THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1 INFECTION
I-698	SCHIZOAFFECTIVE DISORDER AS MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS
I-699	FOR TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
I-700	TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S DISORDER (6-18 YEARS)
I-701	FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, WELL-OR MODERATELY-DIFFERENTIATED, LOCALLY ADVANCED OR METASTATIC GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (GEP-NETS) TO IMPROVE PROGRESSION FREE SURVIVAL
I-702	FOR THE TREATMENT OF PATIENTS WITH WALDENSTROM MACROGLOBULINEMIA
I-703	MODERATE TO SEVERE BINGE EATING DISORDER (BED)
I-704	EXPANDED INDICATION TO INCLUDE PATIENTS WHO ARE VIROLOGICALLY-SUPPRESSED (HIV-1 RNA <50 COPIES/ML) ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS WITH NO HISTORY OF TREATMENT FAILURE IN ORDER TO REPLACE THEIR CURRENT REGIMEN
I-705	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 6 YEARS AND OLDER WHO HAVE AN R117H MUTATION IN THE CFTR GENE
I-706	EXPANDED INDICATION FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA
I-707	POMALYST, IN COMBINATION WITH DEXAMETHASONE, IS INDICATED FOR PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 2 PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY
I-708	DAILY TREATMENT OF ASTHMA IN PATIENTS AGED 18 YEARS AND OLDER
I-709	TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

- I-710 ADJUNCTIVE THERAPY FOR THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC (PG TC) SEIZURES IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE OR OLDER.
- I-711 INCLUSION OF PEDIATRIC PATIENTS AGES 6 YRS AND OLDER FOR THE TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC ITP WHO HAVE HAD AN INSUFFICIENT RESPONSE TO CORTICOSTEROIDS, IMMUNOGLOBULINS, OR SPLENECTOMY.
- I-712 EXPANDED INDICATION FOR USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE PRIOR LINES OF THERAPY
- I-713 REVISIONS TO THE LABELING TO PERMIT THE USE OF ZUBSOLV AS INITIAL ("INDUCTION") TREATMENT OF OPIOID DEPENDENCE
- I-714 EXTENDS THE 2011 APPROVAL OF BRILINTA FOR USE BEGINNING WITH ACS TO USE BEGINNING MORE REMOTE FROM MYOCARDIAL INFARCTION
- I-715 FOR THE ADDITION OF THE INDICATION FOR MONOTHERAPY TREATMENT IN PARTIAL-ONSET SEIZURES IN ADULTS.
- I-716 REVISED INDICATION TO INCLUDE LANGUAGE ABOUT THE BENEFITS OF USING LETAIRIS IN COMBINATION WITH TADALAFIL TO REDUCE THE RISK OF DISEASE PROGRESSION AND HOSPITALIZATION FOR WORSENING PAH AND TO IMPROVE EXERCISE ABILITY, BASED ON THE AMBITION STUDY
- I-717 EXPANDED INDICATION TO INCLUDE THE TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 4
- I-718 EXPANDED INDICATION TO INCLUDE SUBJECTS INFECTED WITH CHRONIC HEPATITIS C, GENOTYPE 6 VIRUS INFECTION BASED UPON THE RESULTS OF THE ELECTRON- 2 STUDY
- I-719 EXPANDED INDICATION TO INCLUDE THE TREATMENT OF SUBJECTS WITH GENOTYPE 5 CHRONIC HEPATITIS C VIRUS INFECTION BASED ON THE RESULTS FROM STUDY GS-US-337-119.
- I-720 EXPANDED INDICATION TO INCLUDE TREATMENT OF GENOTYPE 4, CHRONIC HEPATITIS C VIRUS INFECTION BASED UPON THE RESULTS FROM STUDIES ION-4 AND GS-US-337-119.
- I-721 TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA WHO HAVE RECEIVED A PRIOR ANTHRACYCLINE-CONTAINING REGIMEN.
- I-722 REVISED INDICATION FOR USE IN COMBINATION WITH DEXAMETHASONE OR WITH LENALIDOMIDE PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY.
- I-723 AS A SINGLE AGENT FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE OR MORE LINES OF THERAPY
- I-724 TREATMENT OF ADULT PATIENTS WITH PROGRESSIVE, WELL DIFFERENTIATED, NON-FUNCTIONAL NEUROENDOCRINE TUMORS (NET) OF GI OR LUNG ORIGIN WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC DISEASE
- I-725 TREATMENT OF HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER IN COMBINATION THERAPY WITH PALBOCICLIB AND FULVESTRANT IN WOMEN WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY.
- I-726 EXPANSION OF THE PATIENT POPULATION TO INCLUDE PATIENTS WITH RECURRENCE OF HEPATITIS C VIRUS (HCV) GENOTYPE 1 OR 3 AFTER LIVER TRANSPLANTATION
- I-727 EXPANSION OF THE INDICATION TO INCLUDE TREATMENT OF SUBJECTS WITH GENOTYPE-1 CHRONIC HEPATITIS C VIRUS INFECTION, INCLUDING SUBJECTS WHO ARE CO-INFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS (HIV-1) BASED ON THE RESULTS FROM THE ALLY-2 CLINICAL TRIAL
- I-728 EXPANDED INDICATION FOR USE IN ULTRASONOGRAPHY OF THE LIVER FOR CHARACTERIZATION OF FOCAL LIVER LESIONS IN ADULT AND PEDIATRIC PATIENTS
- I-729 PROVIDES FOR THE FRONTLINE INDICATION FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
- I-730 NEW INDICATION FOR THE TREATMENT OF PATIENTS WITH METASTATIC, SQUAMOUS, NON-SMALL CELL LUNG CANCER PROGRESSING AFTER PLATINUM-BASED CHEMOTHERAPY
- I-731 FOR USE IN MAGNETIC RESONANCE ANGIOGRAPHY IN ADULT AND PEDIATRIC PATIENTS (INCLUDING TERM NEONATES) TO EVALUATE KNOWN OR SUSPECTED SUPRA-AORTIC OR RENAL ARTERY DISEASE
- I-732 TREATMENT OF PEDIATRIC PATIENTS 7 TO 17 YEARS OF AGE WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA TO REDUCE LDL-C, TOTAL C, NONHDL-C AND APOB AS AN ADJUNCT TO DIET, EITHER ALONE OR WITH OTHER LIPID-LOWERING TREATMENTS
- I-733 USE OF CANAGLIFLOZIN FOR INITIAL THERAPY IN COMBINATION WITH METFORMIN
- I-734 EXPANDED INDICATION FOR THE USE OF LENVIMA IN COMBINATION WITH EVEROLIMUS FOR THE TREATMENT OF PATIENTS WITH ADVANCED RCC FOLLOWING ONE PRIOR ANTI-ANGIOGENIC

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

THERAPY.

- I-735 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH BOTH CANAGLIFLOZIN AND METFORMIN IS APPROPRIATE
- I-736 REVISED INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH SMALL LYMPHOCYTIC LEUKEMIA (SLL)
- I-737 REVISED INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH SMALL LYMPHOCYTIC LEUKEMIA (SLL) WITH 17P DELETION
- I-738 REVISIONS TO THE INDICATIONS AND USAGE SECTION WITH RESPECT TO COMPLICATED INTRA-ABDOMINAL INFECTIONS
- I-739 TO REDUCE THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE
- I-740 EXPANDED INDICATION FOR THE TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 6 YEARS AND OLDER TO INCLUDE THE G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, OR S549R MUTATION IN THE CFTR GENE
- I-741 TREATMENT OF PATIENTS WITH MARGINAL ZONE LYMPHOMA (MZL) WHO REQUIRE SYSTEMIC THERAPY AND HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED THERAPY
- I-742 TREATMENT OF NODAL MARGINAL ZONE LYMPHOMA
- I-743 INFORMATION ADDED TO THE LABELING FOR THE ADDITION OF THE TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 4 (GT4) INFECTED PATIENTS WITH COMPENSATED CIRRHOSIS BASED ON RESULTS FROM STUDY M11-665
- I-744 TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WHO HAVE BEEN PREVIOUSLY TREATED WITH SORAFENIB
- I-745 MEKINIST, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST.
- I-746 NEW INDICATION OF MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER IN ADULTS
- I-747 FOR REDUCING THE RISK OF GRAFT REJECTION WHEN USED WITH HIGH-DOSE BUSULFAN AND CYCLOPHOSPHAMIDE AS A PREPARATIVE REGIMEN FOR ALLOGENEIC HEMATOPOIETIC PROGENITOR (STEM) CELL TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH CLASS 3 BETA-THALASSEMIA
- I-748 TO REDUCE THE ACUTE COMPLICATIONS OF SICKLE CELL DISEASE IN ADULT AND PEDIATRIC PATIENTS FIVE YEARS OF AGE AND OLDER
- I-749 MONOTHERAPY FOR THE TREATMENT OF HORMONE RECEPTOR (HR) POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE, ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN NOT PREVIOUSLY TREATED WITH ENDOCRINE THERAPY
- I-750 REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE
- I-751 TREATMENT OF TARDIVE DYSKINESIA
- I-752 CORONARY COMPUTED TOMOGRAPHY ANGIOGRAPHY (CCTA) TO ASSIST DIAGNOSTIC EVALUATION OF PATIENTS WITH SUSPECTED CORONARY ARTERY DISEASE
- I-753 TREATMENT OF ADULT PATIENTS WITH CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
- I-754 TO REDUCE THE FREQUENCY OF SHORT-ACTING SOMATOSTATIN ANALOG RESCUE THERAPY WHEN USED FOR THE TREATMENT OF ADULTS WITH CARCINOID SYNDROME
- I-755 ADJUVANT TREATMENT OF ADULT PATIENTS AT HIGH RISK OF RECURRENT RENAL CELL CARCINOMA (RCC) FOLLOWING NEPHRECTOMY
- I-756 EXPANDED THE APPROVED INDICATION BY REMOVING THE RESTRICTION FOR USE ONLY IN PATIENTS WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB
- I-757 TREATMENT OF PATIENTS WITH ERDHEIM-CHESTER DISEASE WITH BRAF V600 MUTATION
- I-758 FOR USE WITH RILPIVIRINE AS A COMPLETE REGIMEN TO REPLACE THE CURRENT ARV REGIMEN IN VIROLOGICALLY SUPPRESSED PATIENTS ON A STABLE ARV REGIMEN FOR AT LEAST 6 MONTHS WITH NO HISTORY OF TX FAILURE OR KNOWN SUBSTITUTIONS ASSOC. WITH RESISTANCE TO EITHER ARV
- I-759 TREATMENT OF ADULT PATIENTS WITH NEWLY-DIAGNOSED CHRONIC PHASE (CP) PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA (PH+CML)

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

- I-760 FOR THE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA
- I-761 TREATMENT OF ADULT PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO METHOTREXATE OR OTHER NON-BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS
- I-762 TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA-MUTATED, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE METASTATIC BREAST CANCER WHO HAVE BEEN TREATED WITH CHEMOTHERAPY IN THE NEOADJUVANT, ADJUVANT OR METASTATIC SETTING
- I-763 TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS HAVE NON-RESISTANT EPIDERMAL GROWTH FACTOR RECEPTOR MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
- I-764 TREATMENT IN ADULT PATIENTS FOR IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C)
- I-765 ABIRATERONE ACETATE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC HIGH-RISK CASTRATION-SENSITIVE PROSTATE CANCER
- I-766 TREATMENT OF MINIMALLY TO MODERATELY THICK ACTINIC KERATOSIS OF THE UPPER EXTREMITIES IN CONJUNCTION WITH A BLUE LIGHT PHOTODYNAMIC THERAPY ILLUMINATOR
- I-767 TREATMENT OF IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON
- I-768 IN COMBINATION WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
- I-769 TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
- I-770 TREATMENT OF ACUTE OTITIS EXTERNA IN PATIENTS 6 MONTHS OF AGE AND OLDER DUE TO PSEUDOMONAS AERUGINOSA AND STAPHYLOCOCCUS AUREUS
- I-771 REVISION OF THE INDICATION SECTION OF THE PACKAGE INSERT REGARDING AN INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK TO PRODUCE POSTSURGICAL REGIONAL ANALGESIA
- I-772 FOR THE MAINTENANCE TREATMENT OF ADULT PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
- I-773 FOR THE ADJUNCTIVE TREATMENT OF ADULT AND PEDIATRIC PATIENTS AGE 2 YEARS AND OLDER WITH TUBEROUS SCLEROSIS COMPLEX (TSC)-ASSOCIATED PARTIAL-ONSET SEIZURES
- I-774 TO ALLOW FOR FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS, AS DETECTED BY AN FDA APPROVED TEST
- I-775 REVISED INDICATION FOR FIXED-DOSE COMBINATION OF FLUTICASONE FUROATE, UMECLIDINIUM, AND VILANTEROL TO TREAT AIRFLOW OBSTRUCTION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND TO REDUCE COPD EXACERBATIONS IN PTS WITH HISTORY OF EXACERBATIONS
- I-776 FIRSTLINE MAINTENANCE TX IN PTS W/ DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE, SOMATIC BRCA-MUTATED ADVANCED EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CA WHO ARE IN COMPLETE OR PARTIAL RESPONSE TO FIRSTLINE PLATINUM-BASED CHEMOTHERAPY
- I-777 CO-ADMINISTRATION THERAPY OF MIRABEGRON WITH SOLIFENACIN SUCCINATE FOR TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY
- I-778 DABRAFENIB IN COMBINATION WITH TRAMETINIB FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION
- I-779 USE OF TOLVAPTAN TO SLOW KIDNEY FUNCTION DECLINE IN ADULTS AT RISK OF RAPIDLY PROGRESSING AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
- I-780 TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC)
- I-781 DABRAFENIB IN COMBINATION WITH TRAMETINIB FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ANAPLASTIC THYROID CANCER (ATC) WITH BRAF V600E MUTATION AND WITH NO SATISFACTORY LOCOREGIONAL TREATMENT OPTIONS

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

- I-782 REVISIONS TO INDICATION FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
- I-783 EXPANDED INDICATION TO INCLUDE RIBOCICLIB WITH AN AROMATASE INHIBITOR IN PRE/PERIMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER, AS INITIAL ENDOCRINE-BASED THERAPY
- I-784 RIBOCICLIB WITH FULVESTRANT FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER, AS INITIAL ENDOCRINE BASED THERAPY OR FOLLOWING DISEASE PROGRESSION ON ENDOCRINE THERAPY
- I-785 TREATMENT OF PATIENTS WITH CUSHING'S DISEASE FOR WHOM PITUITARY SURGERY IS NOT AN OPTION OR HAS NOT BEEN CURATIVE
- I-786 TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
- I-787 FIRST-LINE TREATMENT OF PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC)
- I-788 NEW INDICATION FOR CANAGLIFLOZIN TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NONFATAL MYOCARDIAL INFARCTION AND NONFATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE (CVD)
- I-789 VENETOCLAX IN COMBO WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE FOR THE TX OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
- I-790 USE OF FERRIC CITRATE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WITH CKD NOT ON DIALYSIS
- I-791 TREATMENT OF PEDIATRIC PATIENTS ONE YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY
- I-792 TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA WHO HAVE BEEN PREVIOUSLY TREATED WITH SORAFENIB
- I-793 TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO MENOPAUSE
- I-794 TREATMENT OF ADULT PATIENTS WITH METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA PREVIOUSLY TREATED WITH AT LEAST TWO PRIOR LINES OF CHEMOTHERAPY, AND IF APPROPRIATE, HER2/NEU-TARGETED THERAPY
- I-795 VENETOCLAX IN COMBINATION WITH OBINUTUZUMAB IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA
- I-796 USED IN COMBINATION WITH A RITUXIMAB PRODUCT, ARE INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED FOLLICULAR LYMPHOMA (FL)
- I-797 USED IN COMBINATION WITH A RITUXIMAB PRODUCT, ARE INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMA (MZL)
- I-798 TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER (BIPOLAR DEPRESSION)
- I-799 TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
- I-800 TREATMENT OF OCULAR INFLAMMATION FOLLOWING OPHTHALMIC SURGERY
- I-801 USE IN CARDIAC MRI TO ASSESS MYOCARDIAL PERFUSION (STRESS, REST) AND LATE GADOLINIUM ENHANCEMENT IN ADULT PATIENTS WITH KNOWN OR SUSPECTED CORONARY ARTERY DISEASE (CAD)
- I-802 TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT
- I-803 TREATMENT OF ADULT PATIENTS WITH ORAL ULCERS ASSOCIATED WITH BEHCETS DISEASE
- I-804 EXPANDED INDICATION FOR USE AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
- I-805 SLOW THE RATE OF DECLINE IN PULMONARY FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE
- I-806 EXPANDED INDICATION FOR PTS WHO ARE VIROLOGICALLY SUPPRESSED (HIV-1 RNA LESS THAN 50 COPIES/ML) ON A STABLE ARV REGIMEN WITH NO HX OF TX FAILURE AND NO KNOWN SUBSTITUTIONS ASSOCIATED W RESISTANCE TO DORAVIRINE, LAMIVUDINE OR TENOFOVIR

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

DISOPROXIL FUMARATE

- I-807 TREATMENT OF ADVANCED ENDOMETRIAL CARCINOMA THAT IS NOT MICROSATELLITE INSTABILITY-HIGH OR MISMATCH REPAIR DEFICIENT, WHO HAVE DISEASE PROGRESSION FOLLOWING PRIOR SYSTEMIC THERAPY AND ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION
- I-808 TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC)
- I-809 TO REDUCE THE RISK OF END-STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND DIABETIC NEPHROPATHY WITH ALBUMINURIA > 300 MG/DAY
- I-810 PROPHYLAXIS OF VENOUS THROMBOEMBOLISM IN ACUTELY ILL MEDICAL PATIENTS AT RISK FOR THROMBOEMBOLIC COMPLICATIONS NOT AT HIGH RISK OF BLEEDING
- I-811 TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 12 YEARS OF AGE OR OLDER, WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 48 HOURS AND ARE AT HIGH RISK OF DEVELOPING INFLUENZA-RELATED COMPLICATIONS
- I-812 FOR USE IN AT RISK ADULTS AND ADOLESCENTS WEIGHING AT LEAST 35 KG FOR PRE-EXPOSURE PROPHYLAXIS TO REDUCE THE RISK OF HIV-1 INFECTION FROM SEXUAL ACQUISITION, EXCLUDING INDIVIDUALS AT RISK FROM RECEPTIVE VAGINAL SEX
- I-813 TX OF ADULT PTS W/ ADV OVARIAN FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER TREATED W/ >=3 PRIOR CHEMO REGIMENS & ASSOCIATED W/ HRD DEFICIENCY POSITIVE STATUS DEFINED BY A DELETERIOUS OR SUSPECTED DELETERIOUS BRCA MUTATION
- I-814 TX OF ADV OVARIAN FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER TREATED W/ >=3 PRIOR CHEMO REGIMENS & ASSOCIATED W/ HRD DEFICIENCY DEFINED BY POSITIVE STATUS GENOMIC INSTABILITY & WHO HAVE PROGRESSED >6MO AFTER RESPONSE TO LAST PLATINUM-BASED CHEMO
- I-815 TREATMENT OF COMMUNITY ACQUIRED BACTERIAL PNEUMONIA (CABP) CAUSED BY DESIGNATED SUSCEPTIBLE BACTERIA IN ADULTS
- I-816 TREATMENT OF ADULT PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WHO ARE >= 75 YEARS OLD OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
- I-817 TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
- I-818 MAINTENANCE TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GBRCA METASTATIC PANCREATIC ADENOCARCINOMA WHOSE DISEASE HAS NOT PROGRESSED ON AT LEAST 16 WEEKS OF A FIRST-LINE PLATINUM-BASED CHEMOTHERAPY REGIMEN
- I-819 ADJUNCT TO MAX TOLERATED STATIN TX TO REDUCE RISK OF MI, STROKE, CORONARY REVASCULARIZATION, & UNSTABLE ANGINA REQUIRING HOSPITALIZATION IN ADULTS W/ ELEVATED TG LEVELS & ESTABLISHED CV DISEASE OR DIABETES MELLITUS & 2+ RISK FACTORS FOR CV DISEASE
- I-820 INDICATED FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1) TO DELAY DISEASE PROGRESSION
- I-821 TREATMENT OF CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESSSES WITHOUT MENINGOENCEPHALITIS AND/OR OCULAR DISSEMINATION IN PEDIATRIC PATIENTS YOUNGER THAN 4 MONTHS OF AGE
- I-822 REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NON-FATAL MYOCARDIAL INFARCTION OR NON-FATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE
- I-823 USE IN COMBINATION WITH CAPECITABINE, FOR THE TREATMENT OF ADULT PATIENTS WITH ADVANCED OR METASTATIC HER2-POSITIVE BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR ANTI-HER2 BASED REGIMENS IN THE METASTATIC SETTING
- I-824 RIVAROXBAN IN COMBINATION WITH ASPIRIN, IS INDICATED TO REDUCE THE RISK OF MAJOR CV EVENTS (CV DEATH, MI, AND STROKE) IN PATIENTS WITH CHRONIC CORONARY ARTERY DISEASE (CAD) OR PERIPHERAL ARTERY DISEASE (PAD)
- I-825 TREATMENT FOR CHRONIC FIBROSING INTERSTITIAL LUNG DISEASES WITH A PROGRESSIVE PHENOTYPE
- I-826 ENCORAFENIB, IN COMBINATION WITH CETUXIMAB, FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC COLORECTAL CANCER WITH A BRAF V600E MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, AFTER PRIOR THERAPY
- I-827 EXPANDED INDICATION FOR PATIENTS WHO ARE VIROLOGICALLY SUPPRESSED (HIV-1 RNA

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

- LESS THAN 50 COPIES/ML) ON A STABLE ARV REGIMEN WITH NO HISTORY OF TREATMENT FAILURE AND NO KNOWN SUBSTITUTIONS ASSOCIATED WITH RESISTANCE TO DORAVIRINE
- I-828 INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH CUSHING'S DISEASE FOR WHOM PITUITARY SURGERY IS NOT AN OPTION OR HAS NOT BEEN CURATIVE
- I-829 TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH CENTRAL PRECOCIOUS PUBERTY (CPP)
- I-830 TREATMENT OF ADULT PATIENTS WITH A DELETERIOUS BRCA MUTATION (GERMLINE AND/OR SOMATIC)-ASSOCIATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE BEEN TREATED WITH ANDROGEN RECEPTOR-DIRECTED THERAPY AND A TAXANE-BASED CHEMOTHERAPY
- I-831 W/BEVACIZUMAB FOR MAINTENANCE TX OF ADULTS W/ADV. EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CA IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM-BASED CHEMO & CA ASSOCIATED W/ HOMOLOGOUS RECOMBINATION DEFICIENCY POSITIVE STATUS
- I-832 TX OF ADULT PTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE OR SOMATIC HOMOLOGOUS RECOMBINATION REPAIR GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE PROGRESSED FOLLOWING PRIOR TREATMENT WITH ENZALUTAMIDE OR ABIRATERONE
- I-833 MAINTENANCE TREATMENT OF ADULT PATIENTS WITH ADVANCED EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM-BASED CHEMOTHERAPY
- I-834 TO REDUCE THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH HEART FAILURE (NYHA CLASS II-IV) WITH REDUCED EJECTION FRACTION
- I-835 TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) WHOSE TUMORS ARE POSITIVE FOR AN EZH2 MUTATION AS DETECTED BY AN FDA-APPROVED TEST AND WHO HAVE RECEIVED AT LEAST 2 PRIOR SYSTEMIC THERAPIES
- I-836 TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS
- I-837 TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), NOT OTHERWISE SPECIFIED, INCLUDING DLBCL ARISING FROM FOLLICULAR LYMPHOMA, AFTER AT LEAST 2 LINES OF SYSTEMIC THERAPY
- I-838 TREATMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY (DPN) OF THE FEET
- I-839 TO REPLACE THE CURRENT ANTIRETROVIRAL REGIMEN IN THOSE WHO ARE VIROLOGICALLY SUPPRESSED (HIV-1 RNA LESS THAN 50 COPIES PER ML) ON A STABLE ANTIRETROVIRAL REGIMEN WITH NO HISTORY OF TREATMENT FAILURE
- I-840 TREATMENT OF SYMPTOMS IN ADULTS WITH MAJOR DEPRESSIVE DISORDER (MDD) WITH ACUTE SUICIDAL IDEATION OR BEHAVIOR.
- I-841 TO REDUCE THE RISK OF HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE OR MULTIPLE CARDIOVASCULAR RISK FACTORS
- I-842 TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY IN COMBINATION WITH DARATUMUMAB AND DEXAMETHASONE
- I-843 MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS AGED 18 YEARS AND OLDER
- I-844 INDICATED IN PATIENTS 18 YEARS OF AGE AND OLDER FOR THE TREATMENT OF HOSPITAL ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) CAUSED BY THE FOLLOWING SUSCEPTIBLE GRAM-NEGATIVE MICROORGANISMS: ACINETOBACTER BAUMANNII COMPLEX, ESCHERICHIA COLI, ENTEROBACTER CLOACAE COMPLEX, KLEBSIELLA PNEUMONIAE, PSEUDOMONAS AERUGINOSA, AND SERRATIA MARCESCENS
- I-845 TREATMENT OF ADULT PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) AS DETECTED BY AN FDA-APPROVED TEST
- I-846 TREATMENT OF CATAPLEXY IN ADULT PATIENTS WITH NACROLEPSY
- I-847 EXPANDED INDICATION OF THE TREATMENT OF ADULT PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) AS DETECTED BY AN FDA-APPROVED TEST
- I-848 REDUCE THE RISK OF STROKE IN PATIENTS WITH ACUTE ISCHEMIC STROKE (NIH STROKE SCALE SCORE <=5) OR HIGH-RISK TRANSIENT ISCHEMIC ATTACK (TIA)

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY MISCELLANEOUS**

- M-1 INFORMATION REGARDING SUPERIORITY CLAIM OVER RANITIDINE FOR DAY AND NIGHT HEARTBURN ADDED TO CLINICAL STUDIES SECTION
- M-2 APPROVAL FOR ADDITION TO CLINICAL PHARMACOLOGY SECTION OF THE LABEL REGARDING (1) IMPROVEMENT IN BONE MINERAL DENSITY IN CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENT PATIENTS AND (2) INCREASES IN SERUM ALKALINE PHOSPHATASE
- M-3 ADDITION OF EFFICACY AND SAFETY INFORMATION IN WHICH FOSAMAX WAS USED CONCOMITANTLY WITH ESTROGEN ALONE OR WITH ESTROGEN PLUS PROGESTIN
- M-4 CHANGES TO PEDIATRIC USE SECTION TO PROVIDE INFORMATION REGARDING SAFETY AND EFFICACY IN PEDIATRIC PATIENTS AS YOUNG AS 2 YEARS OLD
- M-5 INFORMATION REGARDING EFFECTS IN PATIENTS WITH ASTHMA ON CONCOMITANT INHALED CORTICOSTEROIDS IN CLINICAL PHARMACOLOGY SECTION
- M-6 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH GLUCOPHAGE/GLYBURIDE COMBINATION ADDED TO CLINICAL PHARMACOLOGY AND DOSING AND ADMINISTRATION
- M-7 CLINICAL PHARMACOLOGY IN PEDIATRIC PATIENTS; DOSAGE AND ADMINISTRATION INFORMATION
- M-8 ADDITIONAL INFORMATION FOR THE USE OF SONATA CAPSULES FOR UP TO 5 WEEKS (35 NIGHTS) OF TREATMENT IN A CONTROLLED TRIAL SETTING
- M-9 ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING OF TEXT AND TWO TABLES CONTAINING INFORMATION FOR THE PRESCRIBING PHYSICIAN ON BLOOD PRESSURE, HEART RATE, AND HEART RATE VARIABILITY
- M-10 INFORMATION REGARDING MAINTENANCE OF AN ANTIDEPRESSANT EFFECT UP TO 1 YEAR OF DOSING
- M-11 USE FOR LONG-TERM TREATMENT OF POSTTRAUMATIC STRESS DISORDER
- M-12 NEW LANGUAGE FOR PEDIATRIC USE
- M-13 INFORMATION FROM PEDIATRIC STUDIES ADDED TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION
- M-14 ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION
- M-15 LONGER TERM EFFICACY INFORMATION FOR RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA
- M-16 CHANGE IN WORDING OF THE PEDIATRIC SECTION OF THE PACKAGE INSERT
- M-17 INFORMATION REGARDING USE OF ULTANE IN PEDIATRIC PATIENTS WITH CONGENITAL HEART DISEASE
- M-18 INFORMATION DENOTING THE EFFICACY OF REMERON IN MAINTAINING A RESPONSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)
- M-19 INFORMATION REGARDING USE IN PEDIATRIC PATIENTS TWO YEARS OF AGE AND OLDER
- M-20 LABELING REVISIONS RELATED TO MCCUNE ALBRIGHT SYNDROME
- M-21 COMPARISON DATA ON THE ANTIHYPERTENSIVE EFFECTS OF ATACAND AND COZAAR
- M-22 CHANGE IN TIME TO ONSET OF ACTION
- M-23 INFORMATION REGARDING ELIMINATION ADDED TO CLINICAL PHARMACOLOGY, STUDY RESULTS IN PATIENTS WITH HEPATIC AND RENAL IMPAIRMENT
- M-24 INFORMATION ON RESULTS OF A LONG TERM LONGITUDINAL GROWTH STUDY AND PEDIATRIC SAFETY INFORMATION
- M-25 ADDITIONAL SAFETY AND PHARMACOKINETICS INFORMATION IN CHILDREN 6 MONTHS TO LESS THAN 6 YEARS OF AGE ADDED TO PACKAGE INSERT
- M-26 INCORPORATION OF INFORMATION CONTAINED IN THE PEG-INTRON PACKAGE INSERT INTO THE REBETOL PACKAGE INSERT AND MEDGUIDE-PEG-INTRON WAS APPROVED FOR USE IN COMBINATION WITH REBETOL FOR TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION ON 8/7/01
- M-27 INFORMATION DESCRIBING ASPIRIN ENDOSCOPY STUDY AND THE MAXIMUM RECOMMENDED DOSE FOR PATIENTS WITH MODERATE HEPATIC INSUFFICIENCY
- M-28 INFORMATION FROM A STUDY IN PEDIATRIC PATIENTS IN ASSOCIATION WITH A NEUROLOGICAL CONDITION
- M-29 LABELING CHANGES TO PROVIDE INFORMATION IN THE MANAGEMENT OF OBESITY IN ADOLESCENTS AGED 12 TO 16 YEARS
- M-30 CHANGES TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION SECTIONS OF LABELING CONCERNING USE OF LOTENSIN IN PEDIATRIC PATIENTS WITH

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY MISCELLANEOUS**

HYPERTENSION

- M-31 INFORMATION FOR USE IN PEDIATRIC PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 5 (END-STAGE RENAL DISEASE)
- M-32 ADDITIONAL LANGUAGE TO CLINICAL PHARMACOLOGY AND CLINICAL STUDIES
- M-33 INFORMATION FOR USE OF ADVAIR DISKUS 100/50 IN CHILDREN 4 TO 11 YEARS OF AGE WITH ASTHMA
- M-34 EXPANDED INFORMATION TO PEDIATRIC USE SUBSECTION OF LABELING IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
- M-35 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH ACTOS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, OR INSULIN ADDED TO CLINICAL PHARMACOLOGY
- M-36 ADDITION OF INFORMATION TO CLINICAL STUDIES REGARDING PREVENTION OF CARDIOVASCULAR DISEASE
- M-37 INFORMATION ADDED TO THE LABELING THAT DETAILS INFORMATION RELATIVE TO STUDIES DONE IN PEDIATRIC POPULATIONS IN THE CLINICAL PHARMACOLOGY AND PEDIATRIC USE SUBSECTIONS
- M-38 SAFETY AND IOP-LOWERING EFFECTS OF TRUSOPT HAVE BEEN DEMONSTRATED IN PEDIATRIC PATIENTS IN A 3 MONTH, MULTI-CENTER DOUBLE MASKED ACTIVE-TREATMENT-CONTROLLED TRIAL
- M-39 FOR LABELING CHANGES BASED ON RESULTS OF THE SPD422-202 CLINICAL STUDY REPORT (CSR) SUBMITTED IN RESPONSE TO THE WRITTEN REQUEST
- M-40 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES PERFORMED IN PEDIATRIC PATIENTS WITH LEUKEMIA ADDED TO PRECAUTIONS
- M-41 REVISION TO THE PEDIATRIC USE PRECAUTIONS OF THE PRESCRIBING INFORMATION TO INCORPORATE THE RESULTS FROM THE CAPPS-169 STUDY ENTITLED "THE EFFECT OF ORTHO TRICYCLEN ON BONE MINERAL DENSITY IN PEDIATRIC SUBJECTS WITH ANOREXIA NERVOSA"
- M-42 ADDITION OF A GERIATRIC USE SUBSECTION TO THE PRECAUTIONS SECTION OF THE PACKAGE INSERT AND GERIATRIC DOSING INFORMATION
- M-43 INCLUSION OF RESULTS OF STUDY "PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY AND PILOT EFFICACY OF ILOPROST AS ADD ON THERAPY WITH BOSENTAN IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION"
- M-44 CLINICAL INFORMATION ADDED TO THE PEDIATRIC USE SUBSECTION OF PRECAUTIONS REGARDING THE USE OF NOVLOG IN ADOLESCENTS WITH TYPE I DIABETES AGE 6 TO 18
- M-45 INFORMATION ADDED TO CLINICAL TRIALS SECTION OF LABELING, "EFFECTS OF HUMATROPE TREATMENT IN ADULTS WITH GROWTH HORMONE DEFICIENCY"
- M-46 PROVISION OF RESULTS OF STUDY AND PROPOSED REVISIONS TO PACKAGE INSERT SEE SECTION ON CARDIAC ELECTROPHYSIOLOGY
- M-47 PROVIDES FOR USE OF ANTARA WITHOUT REGARD TO MEALS
- M-48 CHANGES TO THE LABELING DESCRIBING THE RESULTS OF A STUDY OF THE USE OF NOVLOG MIX 70/30 WITH ORAL ANTIDIABETIC AGENTS IN PATIENTS WITH TYPE 2 DIABETES
- M-49 CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING EFFECT OF SINGULAIR ON GROWTH RATES IN PREPUBERTAL CHILDREN
- M-50 NEW INFO TO THE CLINICAL STUDIES, ADULT GROWTH HORMONE DEFICIENCY (GHD) SUBSECTION OF THE NUTROPIN AQ PACKAGE INSERT DESCRIBING THE EFFECTS OF SOMATROPIN ON VISCERAL ADIPOSE TISSUE IN THE ADULT GROWTH HORMONE DEFICIENT PATIENT POPULATION
- M-51 INFORMATION ADDED TO LABELING REGARDING OSTEOGENESIS IMPERFECTA STUDY
- M-52 INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY/CLINICAL STUDIES SECTION REGARDING THE USE OF RISEDRONATE ADMINISTERED ONCE A WEEK IN THE PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
- M-53 FOR LABELING CHANGES TO THE QUALITY OF LIFE (QOL) STATEMENT IN THE APPROVED PACKAGE INSERT
- M-54 INFORMATION FROM PEDIATRIC STUDIES ADDED TO LABEL
- M-55 INFORMATION ON RESULTS OF A STUDY OF THE USE OF SANDOSTATIN LAR DEPOT IN PEDIATRIC PATIENTS WITH HYPOTHALAMIC OBESITY.
- M-56 INFORMATION ADDED TO CLINICAL TRIAL SECTION WITH INFORMATION ON "GEMINI" TRIAL
- M-57 CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING THE PHARMACOKINETICS OF EZETIMIBE IN ASIAN SUBJECTS

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY MISCELLANEOUS**

- M-58 CHANGES TO THE CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, VYTORIN SUBSECTION OF THE PACKAGE INSERT TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR AN ATORVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PRMTRS
- M-59 RESULTS OF THE T20-310 STUDY WHICH EVALUATED THE PHARMACOKINETICS, SAFETY, AND ANTIVIRAL ACTIVITY OF FUZEON IN TREATMENT EXPERIENCED PEDIATRIC SUBJECTS AND ADOLESCENTS WAS ADDED TO THE PEDIATRIC SUBSECTION OF PRECAUTIONS
- M-60 CHANGES TO CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR A ROSUVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PARAMETERS IN PATIENTS WTH HYPERCHOLESTEROLEMIA
- M-61 REVISIONS TO LABELING BASED ON DATA SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
- M-62 CLINICAL INFORMATION FROM ONE CLINICAL STUDY INVESTIGATING THE USE OF AVANDAMET PLUS INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL WITH PREVIOUS ANTI-DIABETIC THERAPIES
- M-63 DETAILED INFORMATION ON AN INCONCLUSIVE PEDIATRIC STUDY
- M-64 CHANGES TO CLINICAL PHARMACOLOGY DETAILING STUDY RESULTS
- M-65 ADDITION OF INFORMATION TO LABEL TO INCLUDE INFORMATION REGARDING USE IN PATIENTS WITH HIV-ASSOCIATED ADIPOSE REDISTRIBUTION SYNDROME (HARS)
- M-66 USE IN SPECIFIC POPULATIONS - PATIENTS WITH CONCOMITANT ILLNESS SUBSECTION OF THE LABELING REGARDING USE OF STRATTERA IN PATIENTS WITH ADHD WHO HAVE COMORBID TIC DISORDER
- M-67 INDICATION EXPANDED TO INCLUDE PATIENTS ON PERITONEAL DIALYSIS
- M-68 DESCRIPTION OF RESULTS OF STUDY OF INITIAL THERAPY IN COMBINATION WITH METFORMIN WHEN DIET AND EXERCISE DO NOT PROVIDE GLYCEMIC CONTROL
- M-69 RESULTS OF STUDY OF COMBINATION THERAPY AND NON-INFERIORITY STUDY
- M-70 PROVISION OF INFORMATION OF THE RESULTS OF A PHASE 2 RANDOMIZED TRIAL OF SPRYCEL 70MG TWICE DAILY OR IMATINIB 800MG DAILY
- M-71 REVISIONS TO PROVIDE FOR RESULTS OF MAINTENANCE DATA IN ADULT PATIENTS WITH MAJOR DEPRESSIVE DISORDER
- M-72 INFORMATION ABOUT USE OF INSPRA (EPLERENONE) FOR HYPERTENSION IN PEDIATRIC PATIENTS
- M-73 NEW INFORMATION ADDED REGARDING THE TUMOR SHRINKING POTENTIAL OF SANDOSTATIN LAR DEPOT INJECTION ON GH - SECRETING PITUITARY ADENOMAS
- M-74 REVISIONS TO CLINICAL STUDIES - CHILDREN AND ADOLESCENTS BASED ON CLINICAL TRIAL DATA TO SUPPORT A DURATION OF ACTION CLAIM UP TO 12 HOURS
- M-75 PROVISION FOR USE OF ARGATROBAN IN CERTAIN PEDIATRIC PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) OR HEPARIN-INDUCED THROMBOCYTOPENIA WITH THROMBOSIS (HITTS)
- M-76 REMOVAL OF SCREEN REQUIREMENT IN PTS WITH G6PD DEFICIENCY PRIOR TO INITIATING ACZONE TREATMENT; REMOVAL OF BLOOD COUNT & RETICULOCYTE MONITORING DURING TREATMENT IN G6PD DEFICIENT PTS AND IN PATIENTS WITH HISTORY OF ANEMIA
- M-77 USE IN COMBINATION WITH THE NEW AKTILITE CL128 LAMP FOR THE TREATMENT OF THIN AND MODERATELY THICK, NON-HYPERKERATOTIC, NON-PIGMENTED ACTINIC KERATOSES OF THE FACE AND SCALP IN IMMUNOCOMPETENT PATIENTS
- M-78 CLINICAL TRIAL INFO ON USE OF STRATTERA IN PATIENTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) AND COMORBID ANXIETY DISORDER WITHOUT CAUSING WORSENING OF ANXIETY
- M-79 LABELING REVISIONS RELATED TO SMOKING AND ERLOTINIB EXPOSURE
- M-80 ADDITIONAL TIME POINT OF 30 MINUTES (0.5 HOUR) IN CHILDREN AGED 6-12 YEARS WITH A DIAGNOSIS OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD)
- M-81 ADDITIONAL INFO FOR PEDIATRIC USE FOR CASODEX (STUDIED IN COMBINATION WITH ARIMIDEX) IN THE PEDIATRIC POPULATION, SPECIFICALLY BOYS WITH FAMILIAL MALE-LIMITED PRECOCIOUS PUBERTY (TESTOTOXICOSIS)
- M-82 LABELING REVISIONS RELATED TO CLINICAL STUDIES
- M-83 ADDITIONAL INFORMATION ADDED TO LABELING REGARDING ESTABLISHMENT OF EFFICACY IN ADDITIONAL CLINICAL TRIALS AND ONE MAINTENANCE TRIAL

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY MISCELLANEOUS**

- M-84 STUDY INFORMATION ADDED TO LABEL REGARDING BONE MINERAL DENSITY
- M-85 INFORMATION ADDED TO LABELING REGARDING USE OF PREVACID IN PATIENTS LESS THAN 1 YEAR WITH SYMPTOMATIC GERD
- M-86 LABELING CHANGES SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST FOR INFANTS AGES BIRTH TO 11 MONTH INCLUSIVE REFLECTING LACK OF EFFICACY FOR GERD INDICATION FOR THIS PATIENT POPULATION
- M-87 INCLUSION OF RESULTS FROM TWO DRUG INTERACTION STUDIES WITH LIPITOR AND CRESTOR IN CLINICAL PHARMACOLOGY SECTION
- M-88 ADDITION OF INFORMATION REGARDING ABUSE POTENTIAL OF CONCERTA VERSUS IMMEDIATE-RELEASE METHYLPHENIDATE
- M-89 PROVIDES FOR REVISIONS TO MULTIPLE SECTIONS OF THE PACKAGE INSERT TO REFLECT RESULTS OF CLINICAL TRIALS 205.235 (UPLIFT) AND 205.266 (VA STUDY) IN SUPPORT OF EXACERBATION CLAIM
- M-90 LABELING CHANGES BASED ON DATA FROM CLINICAL STUDIES NV20235 AND NV20236 STUDIES OF SEASONAL PROPHYLAXIS OF INFLUENZA IN IMMUNOCOMPROMISED PATIENTS AND CHILDREN AGES 1-12
- M-91 UPDATED LABELING BASED UPON STUDY: A SINGLE-DOSE, SINGLE-BLIND, PLACEBO-AND MOXIFLOXACIN-CONTROLLED 2-PERIOD, RANDOMIZED, CROSSOVER, 3RD PERIOD SEQUENTIAL STUDY OF SIDE EFFECTS OF TEMSIROLIMUS ON CARDIAC REPOLARIZATION IN HEALTHY SUBJECTS
- M-92 UPDATES TO THE PACKAGE INSERT BASED UPON THE TRIAL ENTITLED "A PHASE I PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF TEMSIROLIMUS IN PATIENTS WITH ADVANCED MALIGNANCIES AND NORMAL AND IMPAIRED LIVER FUNCTION"
- M-93 EXPANSION OF LABELING TO INCLUDE INFORMATION ON SAFETY AND EFFICACY OF CREON IN PATIENTS AGES 7 YEARS THROUGH 11 YEARS WITH PANCREATIC EXOCRINE INSUFFICIENCY DUE TO CYSTIC FIBROSIS
- M-94 INFO ADDED TO LABEL RELATED TO NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA IC CHRONIC PHASE
- M-95 INFORMATION FOR TREATMENT OF CHRONIC HEPATITIS B (CHB) IN ADULT PATIENTS WITH DECOMPENSATED LIVER DISEASE BASED ON DATA FROM CLINICAL TRIAL GS-US-174-0108
- M-96 UPDATED INFORMATION IN THE CLINICAL STUDIES SECTION RELATED TO THE LOSS AND RECOVERY OF BONE MINERAL DENSITY IN ADOLESCENT GIRLS DURING AND FOLLOWING THE USE OF DEPO-PROVERA CONTRACEPTIVE INJECTION
- M-97 LABELING CHANGES IN RESPONSE TO PEDIATRIC STUDIES - NOT INDICATED FOR USE IN PEDIATRIC POPULATION
- M-98 NEW INFORMATION FROM A STUDY WHICH EVALUATED THE SAFETY AND EFFICACY OF FAMVIR IN TREATING RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT BLACK/AFRICAN AMERICAN SUBJECTS.
- M-99 ADDITION OF FINDINGS FROM A SINGLE PEDIATRIC CLINICAL TRIAL (P04292) OF NASONEX NASAL SPRAY IN THE TREATMENT OF NASAL POLYPS IN PATIENTS 6 TO <18 YEARS OF AGE TO THE PACKAGE INSERT.
- M-100 INFORMATION ADDED TO LABEL BASED UPON COMPLETED CLINICAL TRIAL REPORTS
- M-101 INCLUSION OF DATA FROM AN ADDITIONAL 19 SUBJECTS WITH HYPERCALCEMIA FROM PARATHYROID CARCINOMA TO THE INFORMATION CURRENTLY PRESENTED IN THE LABEL
- M-102 INFORMATION FROM PEDIATRIC STUDY REPORT ML16633, "INTRAVENOUS GRANISETRON (KYTRIL) IN THE PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING (PONV) IN PEDIATRIC SUBJECTS UNDERGOING TONSILLECTOMY OR ADENOTONSILLECTOMY."
- M-103 SAFETY, EFFICACY AND PHARMACOKINETIC INFO FOR FASLODEX IN THE PEDIATRIC POPULATION, SPECIFICALLY FOR GIRLS WITH PROGRESSIVE PRECOCIOUS PUBERTY ASSOCIATED WITH MCCUNE-ALBRIGHT SYNDROME ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING
- M-104 INFORMATION ADDED TO DOSING AND ADMINISTRATION REGARDING A 26 WEEK STUDY
- M-105 NEW LANGUAGE ADDED TO CLINICAL STUDIES REGARDING USE IN SMOKERS WITH CARDIOVASCULAR DISEASE, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND USE ACCORDING TO AN ALTERNATIVE SET OF DIRECTIONS FOR SETTING A QUIT DATE
- M-106 ADDITION OF THE T1-WEIGHTED GD-ENHANCED LESION EFFICACY VARIABLE IN THE CLINICAL STUDIES SECTION 14 OF THE PACKAGE INSERT
- M-107 INFORMATION TO THE CLINICAL STUDIES SECTION OF THE LUPRON DEPOT-PED 1-MONTH BASED UPON THE PHASE 3/4 COMPLETED CLINICAL STUDY REPORT FOR STUDY M90-516

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY MISCELLANEOUS**

- ENTITLED "STUDY OF LUPRON DEPOT IN THE TREATMENT OF CENTRAL PRECOCIOUS PUBERTY".
- M-108 CHANGES ARE BASED ON RESULTS FROM STUDY CV181057
- M-109 CHANGES TO THE PACKAGE INSERT TO REFLECT THE RESULTS OF THE STUDY OF HEART AND RENAL PROTECTION (SHARP) TRIAL
- M-110 CHANGES TO THE PACKAGE INSERT TO REFLECT THE RESULTS OF THE STUDY OF HEART AND RENAL PROTECTION (SHARP) TRIAL
- M-111 LABELING CHANGES BASED ON STUDY HW80-EW-GWCI ENTITLED A PLACEBO AND POSITIVE CONTROLLED STUDY OF THE ELECTROPHYSIOLOGICAL EFFECTS OF A SINGLE 10 MCG DOSE OF EXENATIDE ON THE 12 LEAD ELECTROCARDIOGRAM QT INTERVAL IN HEALTHY SUBJECTS
- M-112 REVISIONS TO THE PEDIATRIC USE SECTION OF THE PACKAGE INSERT TO ADD INFORMATION FROM A PEDIATRIC STUDY IN PATIENTS AGED 12 YEARS TO LESS THAN 18 YEARS OF AGE WITH RECURRENT HERPES LABIALIS
- M-113 LABELING CHANGES BASED ON STUDY H80-US-GWCO ENTITLED A RANDOMIZED TRIAL COMPARING EXENATIDE WITH PLACEBO IN SUBJECTS WITH TYPE 2 DIABETES ON INSULIN GLARGINE WITH OR WITHOUT ORAL ANTIHYPERGLYCEMIC MEDICATIONS
- M-114 CHANGES IN SECTION 14 OF THE PACKAGE INSERT TO INCLUDE DATA FROM THE SWITCHMRK STUDIES (SWITCH OF SUPPRESSED SUBJECTS FROM LOPINAVIR/RITONAVIR TO RALTEGRAVIR)
- M-115 REVISIONS TO THE PI BASED ON RESULTS FROM STUDY NN2211-1842, ENTITLED THE EFFECT OF INSULIN DETEMIR IN COMBINATION WITH LIRAGLUTIDE AND METFORMIN COMPARED TO LIRAGLUTIDE AND METFORMIN IN SUBJECTS WITH TYPE 2 DIABETES
- M-116 LABELING CHANGES BASED ON RESULTS FROM CLINICAL STUDY 01-06-TL-OPIMET-008
- M-117 ADDITION OF RESULTS OF PEDIATRIC TRIAL TO LABEL
- M-118 LABELING CHANGES BASED UPON SAFETY AND EFFICACY RESULTS FROM TRIAL 1218.36
- M-119 LABELING CHANGES REGARDING MISSED DOSES
- M-120 CHANGES TO CLINICAL TRIALS DETAILING STUDY RESULTS
- M-121 LABELING CHANGES BASED UPON SAFETY AND EFFICACY RESULTS FROM TRIAL 1218.43
- M-122 LABELING CHANGES TO INCLUDE THE RESULTS OF THE PARAMOUNT TRIAL
- M-123 UPDATED RESULTS OF OVERALL SURVIVAL FROM 'CONFIRM' STUDY
- M-124 LONG TERM SAFETY AND EFFICACY DATA FROM STUDY CLDT600A2303 FOR SUBJECTS PREVIOUSLY ENROLLED IN THE ORIGINAL TWO YEAR GLOBE (NV-02B-007/CLDT600A2302) AND NV02B-015 STUDIES WHO CONTINUED TELBIVUDINE TREATMENT FOR UP TO 208 WEEKS
- M-125 LABELING CHANGES TO INCLUDE LACK OF EFFICACY IN CHILDREN 6 MONTHS TO 4 YEARS OF AGE
- M-126 UPDATES TO THE CLINICAL STUDIES SECTION 14, OF THE PACKAGE INSERT (PI), WITH THE RESULTS OF CLINICAL TRIAL P06086
- M-127 REVISIONS TO THE PEDIATRIC USE SECTION OF THE PACKAGE INSERT TO REFLECT THE RESULTS FROM CLINICAL STUDY C-10-004
- M-128 CLINICAL TRIAL STUDY RESULTS
- M-129 RESULTS OF A CLINICAL STUDY REPORT WHICH ASSESSES THE SAFETY AND EFFICACY IN CHILDREN AGES 6 TO 12 YEARS OF AGE
- M-130 ADDITION OF INFORMATION ON LONG-TERM TREATMENT WITH VPRIV IN THE CLINICAL TRIALS SECTION OF THE PACKAGE INSERT
- M-131 INFORMATION FROM STUDIES CONDUCTED IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED NON-DISSEMINATED DIFFUSED INTRINSIC BRAINSTEM GLIOMAS
- M-132 REVISIONS TO THE CLINICAL TRIALS SECTION IN THE INOMAX LABEL TO REFLECT RESULTS FROM THE PEDIATRIC STUDY REPORTS
- M-133 INFORMATION ADDED TO THE LABELING REGARDING THE ADDITION OF SILDENAFIL TO BOSENTAN THERAPY
- M-134 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES PERFORMED WITH SAXAGLIPTIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA ADDED TO THE LABELING
- M-135 ADDITION OF INFORMATION TO THE CLINICAL STUDIES - RADIOGRAPHIC RESPONSE SECTION OF THE PACKAGE INSERT
- M-136 ADDITIONAL INFORMATION ADDED TO THE USE IN SPECIFIC POPULATIONS SECTION OF THE LABELING REGARDING POST-OPERATIVE NAUSEA AND VOMITING STUDIES IN PEDIATRIC PATIENTS

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY MISCELLANEOUS**

- M-137 LABELING REVISIONS RESULTING FROM A MAINTENANCE TRIAL IN PEDIATRIC PATIENTS WITH IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
- M-138 INFORMATION ADDED TO THE 8.4 PEDIATRIC USE SECTION ON THE USE OF MEMANTINE IN CHILDREN AGES 6-12 YEARS WITH AUTISM SPECTRUM DISORDER
- M-139 INFORMATION ADDED TO THE DOSING AND ADMINISTRATION SECTION OF THE PACKAGE INSERT REGARDING RETREATMENT WITH VELCADE FOR PATIENTS WITH MULTIPLE MYELOMA
- M-140 INFORMATION ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING REGARDING USE OF LATISSE IN PATIENTS WHO WERE POST-CHEMOTHERAPY OR HAD ALOPECIA AREATA, AND ADOLESCENTS WHO HAD HYPERTRICHOSIS WITH NO ASSOCIATED MEDICAL CONDITION
- M-141 REVISIONS TO THE PEDIATRIC USE SECTION OF THE LABELING TO INCORPORATE STUDY RESULTS FOR TREATMENT OF MAJOR DEPRESSIVE DISORDER IN ADOLESCENTS (AGES 12-17)
- M-142 ADDITIONS TO THE LABELING DESCRIBING RESULTS FROM STUDY H6P-MC-HDAY
- M-143 INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN PATIENTS WITH CURRENT OR PAST HISTORY OF MAJOR DEPRESSIVE DISORDER
- M-144 INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN PATIENTS WHO HAD BEEN PREVIOUSLY TREATED WITH VARENICLINE
- M-145 ADDITION OF INFORMATION ABOUT LONG-TERM TREATMENT OF PULMONARY ARTERIAL HYPERTENSION TO THE CLINICAL STUDIES SECTION OF THE LABELING
- M-146 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION ON INITIAL COMBINATION THERAPY WITH LINAGLIPTIN AND METFORMIN VS. LINAGLIPTIN MONOTHERAPY IN TREATMENT NAIVE PATIENTS
- M-147 OTC USE FOR TEMPORARY RELIEF OF OCULAR SYMPTOMS DUE TO HAY FEVER OR OTHER UPPER RESPIRATORY ALLERGIES
- M-148 LABELING CHANGES BASED ON STUDY H80-EW-GWDM
- M-149 INFORMATION ADDED TO THE LABELING REGARDING MAINTENANCE MONOTHERAPY FOR ADHD
- M-150 ADDITION OF THE RESULTS OF A CONTROLLED CLINICAL STUDY TREATING ADULT PATIENTS WITH SCHIZOPHRENIA EXPERIENCING AN ACUTE RELAPSE
- M-151 REVISIONS TO THE LABELING BASED ON THE OUTCOMES OF PEDIATRIC STUDIES CONDUCTED TO ASSESS THE SAFETY AND EFFICACY OF XOPENEX IN SUBJECTS LESS THAN 6 YEARS OF AGE
- M-152 INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY SECTION OF THE LABELING REGARDING A SAFETY STUDY IN PEDIATRIC SUBJECTS AGES 6 MONTHS TO 4 YEARS OF AGE WITH AN ACTIVE HEAD LICE INFESTATION
- M-153 ADDITION OF INFORMATION REGARDING THE INTRANASAL ABUSE POTENTIAL OF OXYCONTIN
- M-154 UPDATE TO THE LABELING TO REFLECT THE RESULTS OF A LONG-TERM MAINTENANCE TREATMENT STUDY OF ADHD IN CHILDREN AND ADOLESCENTS AGES 6-17.
- M-155 ADDITION OF CLINICAL FINDINGS FROM AN OBSERVATIONAL STUDY IN A PEDIATRIC AGE GROUP GREATER THAN 2 MONTHS TO 18 YEARS IN SECTION 8.4 PEDIATRIC USE OF THE PACKAGE INSERT
- M-156 UPDATE TO THE LABELING WITH INFORMATION REGARDING A CLINICAL TRIAL IN CHILDREN LESS THAN 4 YEARS OF AGE.
- M-157 INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF DAPAGLIFLOZIN 10MG ONCE DAILY IN PATIENTS WITH TYPE 2 DIABETES WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A BACKGROUND COMBINATION OF METFORMIN AND SULFONYLUREA
- M-158 UPDATES TO THE LABELING TO REFLECT SAFETY RESULTS FROM CLINICAL TRIALS IN SCHIZOPHRENIA ADOLESCENT PATIENTS AGED 12 TO 17 YEARS
- M-159 ADDITION OF PED SAFETY INFORMATION DERIVED FROM A MAINTENANCE TREATMENT STUDY OF BIPOLAR 1 DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES IN PATIENTS (> THAN OR = TO 13 YRS OF AGE) TREATED FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY
- M-160 UPDATED LABELING WITH DATA FROM A RANDOMIZED, DOUBLE-BLIND ACTIVE-CONTROLLED STUDY COMPARING EMPAGLIFLOZIN TO GLIMEPIRIDE IN PATIENTS WITH TYPE 2 DIABETES AND INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN TREATMENT
- M-161 UPDATED LABELING WITH DATA FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF EMPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND INSUFFICIENT GLYCEMIC CONTROL ON A MULTIPLE DAILY INJECTION INSULIN REGIMEN

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY MISCELLANEOUS**

ALONE OR WITH METFORMIN

- M-162 INCLUSION OF EFFICACY AND SAFETY DATA TO THE PRESCRIBING INFORMATION OF BYDUREON BASED ON STUDY GWDE
- M-163 INFORMATION ADDED TO THE LABELING REGARDING PREVIOUSLY UNTREATED ALK-POSITIVE METASTATIC NON SMALL CELL LUNG CANCER (NSCLC)
- M-164 REVISES THE CLINICAL TRIALS SECTION OF THE PRESCRIBING INFORMATION TO INCORPORATE THE RESULTS FROM STUDY E7273-G000-401 ENTITLED "PHASE IV RANDOMIZED STUDY OF TWO DOSE LEVELS OF TARGRETIN CAPSULES IN SUBJECTS WITH REFRACTORY CUTANEOUS T-CELL LYMPHOMA"
- M-165 PROVIDES FOR UPDATES TO THE PEDIATRIC USE SECTION BASED ON THE PEDIATRIC STUDY REPORT ENTITLED, "A PHASE II PILOT TRIAL OF BORTEZOMIB IN COMBINATION WITH INTENSIVE RE-INDUCTION THERAPY IN CHILDREN WITH RELAPSED ACUTE LYMPHOBLASTIC LYMPHOMA (LL) "
- M-166 UPDATE TO LABELING WITH WEEK 48 RESULTS FROM VIKING-4 IN ANTIRETROVIRAL THERAPY (ART) - EXPERIENCED INTEGRASE STRAND TRANSFER INHIBITOR (INSTI) - RESISTANT SUBJECTS
- M-167 APPROVED FOR REVISIONS TO THE LABELING BASED ON THE CLINICAL STUDY ENTITLED "BRONCHOPULMONARY DYSPLASIA (BPD) IN PRETERM INFANTS REQUIRING MECHANICAL VENTILATION OR POSITIVE PRESSURE SUPPORT ON DAYS 5 TO 14 AFTER BIRTH".
- M-168 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION OF THE LABELING REGARDING THE RE-NOVATE AND RE-NOVATE LL STUDIES (PROPHYLAXIS OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM FOLLOWING HIP REPLACEMENT SURGERY)
- M-169 UPDATES TO LABELING DESCRIBING RESPONSE TO A REPEAT COURSE OF PICATO GEL 0.015% ON THE FACE OR SCALP IF AN INCOMPLETE RESPONSE IS OBSERVED AT A FOLLOW-UP EXAMINATION.
- M-170 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION REGARDING USE FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
- M-171 UPDATES TO LABELING WITH RESULTS TO THE TIGER CLINICAL TRIAL
- M-172 UPDATES TO THE CLINICAL TRIALS SECTION OF THE LABELING TO INCLUDE RESULTS OF STUDIES PERFORMED TO EVALUATE THE BENEFIT OF ADDING INCRUSE ELLIPTA TO PATIENTS WHO ARE ON BACKGROUND THERAPY WITH BREO ELLIPTA AND ADVAIR DISKUS
- M-173 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION OF THE LABELING DESCRIBING THE EFFECTS OF STIOLTO RESPIMAT ON COPD PATIENTS
- M-174 INFORMATION ADDED TO CLINICAL STUDIES SECTION OF THE LABELING REGARDING INITIAL COMBINATION THERAPY OF EMPAGLIFLOZIN WITH METFORMIN
- M-175 INFORMATION ADDED TO THE LABELING DESCRIBING SAVOR, A PHASE IV TRIAL EVALUATING THE EFFECT OF SAXAGLIPTIN ON THE INCIDENCE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION OR ISCHAEMIC STROKE IN PATIENTS WITH TYPE 2 DIABETES
- M-176 INFORMATION ADDED TO THE LABELING DESCRIBING TRIAL NN2211-3916, A TRIAL EVALUATING THE SAFETY AND EFFICACY OF LIRAGLUTIDE IN SUBJECTS WITH TYPE 2 DIABETES AND MODERATE RENAL IMPAIRMENT
- M-177 INFORMATION ADDED TO THE LABELING DESCRIBING EXAMINE, A TRIAL EVALUATING CARDIOVASCULAR ISCHEMIC RISKS ASSOCIATED WITH ALOGLIPTIN USE IN PATIENTS WITH TYPE 2 DIABETES AT HIGH RISK OF ISCHEMIC CARDIOVASCULAR DISEASE
- M-178 INFORMATION ADDED TO THE LABELING REGARDING MAINTENANCE OF REMISSION IN CROHN'S DISEASE IN PEDIATRIC PATIENTS
- M-179 UPDATES TO THE PRODUCT LABELING WITH STUDY REPORTS FROM THE OPTIMIST-1 AND OPTIMIST-2 CLINICAL TRIALS
- M-180 INFORMATION ADDED TO THE LABELING REGARDING THE ADDITION OF MAINTENANCE TREATMENT IN PATIENTS WITH SCHIZOPHRENIA
- M-181 UPDATE TO THE DOSAGE AND ADMINISTRATION, PATIENT SELECTION (2.1), SECTION OF THE PACKAGE INSERT TO INCLUDE THE USE OF AN FDA-APPROVED PLASMA TEST FOR THE IDENTIFICATION OF EGFR EXON 19 DELETION OR EXON 21 (L858R) SUBSTITUTION MUTATIONS
- M-182 UPDATES TO THE PRODUCT LABELING BASED ON THE RESULTS OF STUDY H7T-MC-TADO TITLED, "A PHASE 3 DOUBLE-BLIND, RANDOMIZED, MULTICENTER, EFFICACY AND SAFETY STUDY OF PRASUGREL COMPARED TO PLACEBO IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE"

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY MISCELLANEOUS**

- M-183 CHANGES TO THE DOSAGE AND ADMINISTRATION AND CLINICAL STUDIES SECTIONS OF THE LABELING TO SUPPORT THE REDUCE-TO-QUIT PARADIGM
- M-184 UPDATES MADE TO THE LABELING TO INCLUDE INFORMATION FROM STUDY MO25743 ON THE ANTI-TUMOR ACTIVITY OF VEMURAFENIB IN THE TREATMENT OF PATIENTS WITH BRAF V600E MUTATION-POSITIVE MELANOMA WITH BRAIN METASTASES
- M-185 UPDATES TO THE LABELING TO INCLUDE RESULTS OF A TRIAL TO EVALUATE THE SAFETY OF MOXIFLOXACIN IN PEDIATRIC PATIENTS WITH COMPLICATED INTRA-ABDOMINAL INFECTIONS
- M-186 UPDATES TO THE PRODUCT INFORMATION REGARDING MAINTENANCE TREATMENT OF SCHIZOPHRENIA IN ADULTS BASED UPON THE RESULTS FROM STUDY 331-10-232
- M-187 ADDITION OF CLINICAL INFORMATION OBTAINED FROM A PEDIATRIC TRIAL TO SECTION 8.4 OF THE LABELING
- M-188 PROVIDES FOR DATA SUPPORTING THE SAFETY AND EFFECTIVENESS FOR THE MAINTENANCE TREATMENT OF MODERATE TO SEVERE BINGE EATING DISORDER (BED)
- M-189 LABELING DESCRIBING THE EXPECTED REDUCTION OF ABUSE OF SINGLE-ENTITY MORPHINE BY THE INTRANASAL ROUTE OF ADMINISTRATION DUE TO PHYSICOCHEMICAL PROPERTIES
- M-190 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION OF THE LABELING REGARDING THE LACK OF EFFICACY OF TARCEVA IN MAINTENANCE TREATMENT OF PATIENTS WITHOUT EGFR MUTATIONS
- M-191 ADDITION OF DATA BASED ON PEDIATRIC STUDIES TO FULFILL THE POSTMARKETING REQUIREMENT 1857-2
- M-192 PROVIDES FOR DATA EVALUATING THE NEUROPSYCHIATRIC SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN SUBJECTS WITH AND WITHOUT A HISTORY OF PSYCHIATRIC DISORDERS
- M-193 INFORMATION ADDED TO THE LABELING REGARDING A 15-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED FLEXIBLE-DOSE SAFETY AND EFFICACY STUDY OF PREGABALIN IN ADOLESCENTS (12 THROUGH 17 YEARS OLD) WITH FIBROMYALGIA
- M-194 INFORMATION ADDED TO THE LABELING REGARDING USE OF REGADENOSON ADMINISTRATION FOLLOWING AN INADEQUATE EXERCISE STRESS TEST AS COMPARED TO REGADENOSON ALONE
- M-195 REVISIONS TO THE PEDIATRIC USE SECTION OF THE LABELING REFLECTING LACK OF EFFICACY FOR IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER IN PEDIATRIC PATIENTS AGES 6-17
- M-196 REVISIONS TO THE PACKAGE INSERT BASED ON DATA FROM A RANDOMIZED, PLACEBO CONTROLLED, MULTICENTER STUDY OF INTRAVENOUS ACETAMINOPHEN FOR THE TREATMENT OF ACUTE PAIN IN PEDIATRIC PATIENTS TO FULFILL THE POST-MARKETING REQUIREMENT 1704-1
- M-197 NEW CLINICAL DATA ADDED TO THE PRESCRIBING INFORMATION REGARDING CANAGLIFLOZIN ADD-ON COMBINATION THERAPY WITH METFORMIN AND A DIPEPTIDYL-PEPTIDASE-4 INHIBITOR
- M-198 PACKAGE INSERT UPDATED WITH RESULTS FROM STUDY CV181168, A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, PHASE 3 TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF SAXAGLIPTIN ADDED TO DAPAGLIFLOZIN AND METFORMIN
- M-199 INFORMATION ADDED TO LABELING REGARDING THE TREATMENT OF PATIENTS WITH ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAD NOT RECEIVED PRIOR SYSTEMIC THERAPY FOR METASTATIC DISEASE.
- M-200 CLINICAL INFORMATION ADDED TO THE USE IN SPECIFIC POPULATIONS SECTION OF THE LABELING.
- M-201 REVISIONS TO THE PACKAGE INSERT BASED ON DATA FROM AN OPEN LABEL, MULTI-CENTER STUDY OF CABAZITAXEL IN PEDIATRIC PATIENTS WITH REFRACTORY SOLID TUMORS INCLUDING TUMORS OF THE CENTRAL NERVOUS SYSTEM.
- M-202 INCLUSION OF DATA FROM THE SUMMIT STUDY FOR BREO ELLIPTA (FLUTICASONE FUROATE/VILANTEROL TRIFENATATE) INHALATION POWDER IN THE PACKAGE INSERT.
- M-203 PROVIDES FOR REVISIONS TO THE PACKAGE INSERT TO REFLECT RESULTS OF TWO POSTMARKETING REQUIREMENT STUDIES ROP111662 AND ROP111569
- M-204 CLINICAL INFORMATION ADDED TO THE PACKAGE INSERT REGARDING USE OF ATORVASTATIN IN CHILDREN AND ADOLESCENTS AGES 10-17 WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH)
- M-205 INFORMATION ADDED TO THE LABELING REGARDING RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES ON PATIENTS WITH SEVERE RENAL IMPAIRMENT
- M-206 INFORMATION ADDED TO LABELING REGARDING 48 WEEK EFFICACY, RESISTANCE AND SAFETY

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY MISCELLANEOUS**

- DATA ON VIROLOGICALLY SUPPRESSED HIV-1 INFECTED ADULTS SWITCHING FROM COMPLERA TO ODEFSEY
- M-207 INFORMATION ADDED TO LABELING REGARDING 48 WEEK EFFICACY, RESISTANCE AND SAFETY DATA ON VIROLOGICALLY SUPPRESSED HIV-1 INFECTED ADULTS SWITCHING FROM ATRIPLA TO ODEFSEY
- M-208 INFORMATION ADDED TO THE LABELING TO INCLUDE RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY IN PATIENTS WITH SEVERE COPD ASSOCIATED WITH CHRONIC BRONCHITIS AND A HISTORY OF EXACERBATIONS
- M-209 INFORMATION ADDED TO THE LABELING REGARDING CABAZITAXEL AT 20 MG/M2 BASED ON THE RESULTS OF THE PROSELICA STUDY
- M-210 INFORMATION ADDED TO LABELING TO SUPPORT THE USE OF SYMBICORT TO REDUCE EXACERBATIONS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
- M-211 PROVIDES FOR LABELING CHANGES REGARDING THE USE OF DAPTOMYCIN IN THE PEDIATRIC POPULATION FOR STAPHYLOCOCCUS AUREUS BACTEREMIA (SAB) BASED ON RESULTS OF A TRIAL IN PEDIATRIC PATIENTS 1 TO 17 YEARS OF AGE
- M-212 INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF DAPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A BACKGROUND COMBINATION OF METFORMIN AND EXENATIDE EXTENDED RELEASE
- M-213 INFORMATION ADDED TO THE LABELING TO INCLUDE THE EFFICACY AND SAFETY OF CARIPRAZINE RELATIVE TO PLACEBO IN THE PREVENTION OF RELAPSE OF SYMPTOMS IN PATIENTS WITH SCHIZOPHRENIA
- M-214 INFORMATION ADDED TO THE CLINICAL TRIALS SECTION OF THE LABELING REGARDING A POSTMARKETING SAFETY AND EFFICACY STUDY EVALUATING THE RISK OF SERIOUS ASTHMA-RELATED EVENTS
- M-215 INFORMATION ADDED TO THE LABELING REGARDING THE COMPARISON OF PALIPERIDONE PALMITATE COMPARED WITH ORAL ANTIPSYCHOTIC TREATMENT IN DELAYING TIME TO TREATMENT FAILURE IN ADULTS WITH SCHIZOPHRENIA WHO HAVE BEEN INCARCERATED
- M-216 UPDATE THE PRESCRIBING INFORMATION AND PATIENT LABELING WITH FINDINGS FROM STUDY RP103-08 CONDUCTED IN TREATMENT-NAIVE NEPHROPATHIC CYSTINOSIS PATIENTS TO EXPAND THE INDICATED POPULATION TO PATIENTS 1 YEAR AND OLDER
- M-217 INCORPORATION OF THE LABELING REVISIONS PROVIDED FOR IN NDA 022253/S-039 AND NDA 022255/S-022 INTO THE LACOSAMIDE INJECTION LABELING
- M-218 ADDITIONAL INFORMATION ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING REGARDING A NEW CLINICAL TRIAL IN PATIENTS AGED 6 THROUGH 11 YEARS (TRIAL 4)
- M-219 INFORMATION ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING REGARDING A NEW CLINICAL TRIAL IN PATIENTS 7 TO 14 YEARS OF AGE WITH DUCHENNE MUSCULAR DYSTROPHY
- M-220 ADDITIONAL INFORMATION ADDED TO THE LABELING FROM STUDY PC B308/13 REGARDING THE USE OF BLUE LIGHT CYSTOSCOPY WITH CYSVIEW AS AN ADJUNCT TO WHITE LIGHT CYSTOSCOPY
- M-221 DRUG FACTS LABELING CHANGES UNDER THE DIRECTIONS HEADING TO REVISE THE STATED PREPARATION TIME OF A DRY SITE FROM 120 SECONDS SCRUBBING AND 90 SECONDS DRYING TO 30 SECONDS SCRUBBING AND 30 SECONDS DRYING
- M-222 ADDITION OF DATA BASED ON THE ASSESSMENT OF SAFETY AND EFFICACY IN PEDIATRIC PATIENTS WITH MAJOR DEPRESSIVE DISORDER TO FULFILL POSTMARKETING STUDY REQUIREMENT 1229-1
- M-223 INFORMATION ADDED TO SECTION 8.1 OF THE LABELING REGARDING PREGNANT PATIENTS WHO ARE ALREADY ON A STABLE RILPIVIRINE REGIMEN PRIOR TO PREGNANCY AND WHO ARE VIROLOGICALLY SUPPRESSED (HIV-1 RNA LESS THAN 50 COPIES/ML)
- M-224 INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF EXENATIDE EXTENDED RELEASE AS ADD-ON IN PATIENTS WITH TYPE 2 DIABETES WHO HAVE INADEQUATE GLYCEMIC CONTROL ON BASAL INSULIN GLARGINE WITH OR WITHOUT METFORMIN
- M-225 REVISIONS TO SECTION 8.4 OF THE PRESCRIBING INFORMATION TO INCLUDE A SAFETY AND EFFICACY STUDY IN PEDIATRIC PATIENTS AGES ≥ 6 YEARS TO < 18 YEARS WITH CHRONIC IDIOPATHIC CONSTIPATION
- M-226 CHANGES TO THE LABELING BASED ON RESULTS FROM A CONTROLLED CLINICAL TRIAL IN PATIENTS WITH LATER-ONSET SPINAL MUSCULAR ATROPHY
- M-227 ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING WITH THE SUBSECTION ENTITLED DIGIT SYMBOL SUBSTITUTION TEST IN MAJOR DEPRESSIVE DISORDER
- M-228 INFORMATION ADDED TO THE PACKAGE INSERT REGARDING THE REVISION OF THE MONOTHERAPY INDICATION OF VENETOCLAX

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY MISCELLANEOUS**

- M-229 REVISED LABELING TO INCORPORATE THE PEDIATRIC USE OF LOTEPIREDNOL ETABONATE GEL IN PATIENTS FOR THE TREATMENT OF POSTOPERATIVE INFLAMMATION FOLLOWING OCULAR SURGERY
- M-230 REVISIONS TO THE GLECAPREVIR/PIBRENTASVIR COMBINATION PRODUCT PRESCRIBING INFORMATION TO INCLUDE SAFETY AND EFFICACY DATA FROM THE HCV/HIV-1 COINFECTION STUDY M14-730 AND FROM THE LIVER AND RENAL TRANSPLANT STUDY M13-596
- M-231 REVISIONS TO THE USE IN SPECIFIC POPULATIONS SECTION (SECTION 8.3) OF THE PACKAGE INSERT WITH THE RESULTS OF CLINICAL TRIAL WV25651, CONDUCTED TO EVALUATE THE EFFECT OF VALGANCYCLOVIR ON SPERMATOGENESIS AND TO FULFILL PMR 1670-3
- M-232 INFORMATION ADDED TO SECTION 8.4 OF THE LABELING TO DESCRIBE THE RESULTS FROM PEDIATRIC STUDIES
- M-233 INFORMATION ADDED TO THE LABELING TO DESCRIBE FIXED-DOSE COMBINATION OF TIOTROPIUM BROMIDE AND OLODATEROL TO INCLUDE REDUCTION OF COPD EXACERBATIONS
- M-234 UPDATE TO THE PRESCRIBING INFORMATION FOR VORTIOXETINE ON TREATMENT-EMERGENT SEXUAL DYSFUNCTION COMPARING VORTIOXETINE AND SSRIS
- M-235 INFORMATION ADDED TO SECTION 14 OF THE LABELING TO DESCRIBE STUDY LAP016A2307 TO FULFILL POSTMARKETING STUDY REQUIREMENT 1586-1
- M-236 INFORMATION ADDED TO THE PRESCRIBING INFORMATION TO INCLUDE EFFICACY AND SAFETY DATA FROM A STUDY IN PATIENTS WITH TREATMENT NAIVE CLL/SLL TREATED WITH IBRUTINIB IN COMBINATION WITH OBINUTUZUMAB OR CHLORAMBUCIL IN COMBINATION WITH OBINUTUZUMAB
- M-237 INFORMATION ADDED TO LABELING TO DESCRIBE A STUDY TO EVALUATE THE SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN ADOLESCENT SMOKERS
- M-238 INFORMATION ADDED TO THE PRESCRIBING INFORMATION TO REFLECT THAT NO DOSE ADJUSTMENT IS NEEDED FOR PATIENTS WITH AN ESTIMATED GLOMERULAR FILTRATION RATE (EGFR) OF 45 ML/MIN/1.73 M² OR GREATER AS SUPPORTED BY CLINICAL STUDY REPORT
- M-239 INFORMATION ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING REGARDING A TRIAL CONDUCTED IN TREATMENT NAIVE PEDIATRIC PATIENTS, AGES 2 YEARS TO < 18 YEARS WITH TRANSFUSIONAL IRON OVERLOAD
- M-240 INFORMATION ADDED TO LABELING REGARDING A RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE CARDIOVASCULAR OUTCOMES AFTER TREATMENT WITH EXENATIDE ONCE WEEKLY IN PATIENTS WITH TYPE 2 DIABETES MELLITES
- M-241 INFORMATION ADDED TO THE LABELING FOR SAFETY & EFFICACY STUDY ENTITLED, A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED CLINICAL TRIAL OF DEFERASIROX IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (LOW/INT-1 RISK) & TRANSFUSIONAL IRON OVERLOAD
- M-242 INFORMATION ADDED TO THE LABELING REGARDING THE EFFICACY AND SAFETY OF INSULIN DEGLUDEC/LIRAGLUTIDE VS INSULIN GLARGINE IN PTS W/ TYPE 2 DIABETES INADEQUATELY CONTROLLED ON SGLT2I WITH OR WITHOUT ORAL ANTIDIABETIC THERAPIES
- M-243 INFORMATION ADDED TO LABELING FROM PROSPECTIVE, RANDOMIZED, OPEN-LABEL, BLIND EVALUATOR (PROBE) STUDY EVALUATING THE EFFICACY AND SAFETY OF LOW MOLECULAR WEIGHT HEPARIN/EDOXABAN VERSUS DALTEPARIN IN VENOUS THROMBOEMBOLISM ASSOCIATED WITH CANCER
- M-244 INFORMATION ADDED TO THE LABELING REGARDING EFFICACY AND SAFETY OF THE CONTINUATION OF SITAGLIPTIN COMPARED WITH THE WITHDRAWAL OF SITAGLIPTIN DURING INITIATION AND TITRATION OF INSULIN GLARGINE IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS
- M-245 ADDITIONAL INFORMATION ADDED TO THE LABELING BASED ON SAFETY AND EFFICACY DATA FROM THE IMPACT TRIAL
- M-246 ADDITION OF STUDY BRf117277, A NON-RANDOMIZED, OPEN-LABEL, MULTI-CENTER, MULTI-COHORT TRIAL OF DABRAFENIB PLUS TRAMETINIB IN SUBJECTS WITH BRAF MUTATION-POSITIVE MELANOMA THAT HAS METASTASIZED TO THE BRAIN
- M-247 REVISIONS TO THE LABELING REGARDING CONTINUOUS SUBCUTANEOUS INSULIN INFUSION AS A CONDITION OF USE FOR INSULIN ASPART
- M-248 INFORMATION ADDED TO THE LABELING TO DESCRIBE A TRIAL EVALUATING A LOWER DOSE THAN THOSE APPROVED FOR PEDIATRIC PATIENTS 13 TO 17 YEARS OF AGE
- M-249 INFORMATION ADDED TO THE LABELING TO DESCRIBE STUDY LVM-MD-15 TO FULFILL POSTMARKETING COMMITMENT 1943-4
- M-250 REVISIONS TO THE PEDIATRIC USE SECTION TO INCLUDE AN OPEN-LABEL CLINICAL TRIAL TO FULFILL PMR 1655-1

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY MISCELLANEOUS**

M-251	INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING INFLUENZA VIRUS RESISTANCE TO OSELTAMIVIR IN IMMUNOCOMPROMISED PATIENTS
M-252	ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME
M-253	INFORMATION ADDED TO THE LABELING TO DESCRIBE STUDY P061, A RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-SITE, DOUBLE-BLIND STUDY TO EVALUATE SAFETY AND EFFICACY OF SUVOREXANT FOR THE TREATMENT OF INSOMNIA IN SUBJECTS WITH ALZHEIMERS DISEASE
M-254	INFORMATION ADDED TO THE LABELING REGARDING PEDIATRIC PATIENTS AGES 7 TO 17 YEARS OF AGE WITH MAJOR DEPRESSIVE DISORDER
M-255	INFORMATION ADDED TO THE LABELING TO DESCRIBE STUDY GS-US-320-4018 IN VIROLOGICALLY SUPPRESSED ADULTS W/ CHRONIC HEP B INFECTION WHO SWITCHED FROM TENOFOVIR DISOPROXIL FUMARATE TO TENOFOVIR ALAFENAMIDE
M-256	INFORMATION ADDED TO THE CLINICAL STUDIES SECTION TO FULFILL A POST-MARKETING REQUIREMENT
M-257	INFORMATION ADDED TO THE CLINICAL STUDIES SECTION OF THE LABELING REGARDING THE USE OF PLAQUE PSORIASIS OF THE SCALP
M-258	INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINA TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4
M-259	INFORMATION ADDED TO THE LABELING REGARDING SAFETY AND EFFICACY IN SUBJECTS WITH HCV SUBTYPE 3B INFECTION
M-260	INFORMATION ADDED TO THE LABELING DESCRIBING A RANDOMIZED, OPEN-LABEL STUDY THAT EXAMINED THE CONCOMITANT USE OF DIMETHYL FUMARATE AND SEVERAL NON-LIVE VACCINES IN ADULTS 27-55 YEARS OF AGE WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS
M-261	ADDITIONAL INFORMATION ADDED TO THE LABELING REGARDING THE USE IN PATIENTS ON CHRONIC HEMODIALYSIS
M-262	REVISIONS TO THE USE IN SPECIFIC POPULATIONS SECTION OF THE PACKAGE INSERT TO INCLUDE THE RESULT OF STUDY P146 TO FULFILL THE REQUIREMENTS OF PMR 3003-4
M-263	REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY ICL670E2419 (THETIS TRIAL) TO SUPPORT PMR 3342-2 AND 3342-3
M-264	INFORMATION ADDED TO THE LABELING DESCRIBING A PHASE 2, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY/EFFICACY OF SOFOSBUVIR/VELPATASVIR IN SUBJECTS WITH CHRONIC HCV INFECTION WHO HAVE RECEIVED A LIVER TRANSPLANT
M-265	REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY M15-656 (VIALE-A) AND M16-043 (VIALE-C) TO SUPPORT PMR 3545-1 AND PMR 3545-2
M-266	INFORMATION ADDED TO THE LABELING TO DESCRIBE STUDY GS-US-320-4035 IN VIROLOGICALLY SUPPRESSED ADULTS W/ CHRONIC HEP B INFECTION WHO SWITCHED FROM TENOFOVIR DISOPROXIL FUMARATE TO TENOFOVIR ALFAENAMIDE
M-267	INFORMATION ADDED TO THE LABELING REGARDING THE RESULT OF STUDY LUAA21004-402

ORPHAN DRUG EXCLUSIVITY

ODE-1	TO REDUCE CHRONIC DROOLING IN PATIENTS AGED 3 - 16 WITH NEUROLOGIC CONDITIONS ASSOCIATED WITH PROBLEM DROOLING (E.G. CEREBRAL PALSY)
ODE-2	FOR TREATMENT OF NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE
ODE-3	TO TREAT INFANTILE SPASMS
ODE-4	TREATMENT OF PATIENTS WITH SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) ASSOCIATED WITH TUBEROUS SCLEROSIS WHO REQUIRE THERAPEUTIC INTERVENTION BUT ARE NOT CANDIDATES FOR CURATIVE SURGICAL RESECTION
ODE-5	FOR SEQUENTIAL USE FOR THE TREATMENT OF CYANIDE POISONING THAT IS JUDGED TO BE LIFE-THREATENING
ODE-6	FOR THE MANAGEMENT OF POSTHERPETIC NEURALGIA
ODE-7	TO REDUCE THE RISK OF PRETERM BIRTH IN WOMEN WITH SINGLETON PREGNANCY WHO HAVE A HISTORY OF SINGLETON SPONTANEOUS PRETERM BIRTH
ODE-8	TREATMENT OF SEVERE HYPERCALCEMIA IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM WHO ARE UNABLE TO UNDERGO PARATHYROIDECTOMY

PATENT AND EXCLUSIVITY TERMS**ORPHAN DRUG EXCLUSIVITY**

- ODE-9 TREATMENT OF ASYMPTOMATIC OR PROGRESSIVE MEDULLARY THYROID CANCER IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC DISEASE
- ODE-10 FOR USE IN COMBINATION CHEMOTHERAPY WITH 5-FLUOROURACIL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED METASTATIC COLORECTAL CANCER
- ODE-11 TREATMENT OF PROGRESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) IN PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC DISEASE
- ODE-12 TREATMENT OF PERIPHERAL T-CELL LYMPHOMA (PTCL) IN PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
- ODE-13 TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA WITH THE BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST
- ODE-14 TREATMENT OF ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA IN ADULTS 18 YEARS OF AGE AND OLDER
- ODE-15 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) THAT IS ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE AS DETECTED BY AN FDA APPROVED TEST
- ODE-16 TREATMENT OF PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD DUE TO THALASSEMIA SYNDROMES WHEN CURRENT CHELATION THERAPY IS INADEQUATE
- ODE-17 ADJUNCTIVE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME IN PATIENTS 2 YEARS OF AGE OR OLDER
- ODE-18 ADJUNCTIVE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME INPATIENTS 2 YEARS OF AGE OR OLDER
- ODE-19 TREATMENT OF PATIENTS WITH INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS, INCLUDING PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
- ODE-20 TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6 YEARS AND OLDER WHO HAVE A G551D MUTATION IN THE CFTR GENE.
- ODE-21 AN ADJUNCT TO AB EXTERNO GLAUCOMA SURGERY
- ODE-22 FOR THE CONTROL OF HYPERGLYCEMIA SECONDARY TO HYPERCORTISOLISM IN ADULT PATIENTS WITH ENDOGENOUS CUSHING'S SYNDROME WHO HAVE TYPE 2 DIABETES MELLITUS OR GLUCOSE INTOLERANCE AND HAVE FAILED SURGERY OR ARE NOT CANDIDATES FOR SURGERY
- ODE-23 ADVANCED SOFT TISSUE SARCOMA (STS) WHO HAVE RECEIVED PRIOR CHEMOTHERAPY
- ODE-24 TREATMENT OF ADULTS WITH RENAL ANGIOMYOLIPOMA AND TUBEROUS SCLEROSIS COMPLEX (TSC) NOT REQUIRING IMMEDIATE SURGERY
- ODE-25 MANAGEMENT OF POSTHERPETIC NEURALGIA IN ADULTS.
- ODE-26 TREATMENT OF ENDOGENOUS ANTERIOR UVEITIS
- ODE-27 TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY
- ODE-28 TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE (PH-) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN SECOND OR GREATER RELAPSE OR WHOSE DISEASE HAS PROGRESSED FOLLOWING TWO OR MORE ANTI-LEUKEMIA THERAPIES
- ODE-29 LOCALIZATION OF LYMPH NODES DRAINING A PRIMARY TUMOR IN PATIENTS WITH MELANOMA WHEN USED WITH A HAND-HELD GAMMA COUNTER
- ODE-30 TREATMENT OF ADULT PATIENTS WITH CHRONIC, ACCELERATED OR BLAST PHASE PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOGENOUS LEUKEMIA (CML) WITH RESISTANCE, OR INTOLERANCE TO PRIOR THERAPY
- ODE-31 TREATMENT OF CORNEAL CYSTINE CRYSTAL ACCUMULATION IN PATIENTS WITH CYSTINOSIS
- ODE-32 TREATMENT OF ADULT PATIENTS WITH CHRONIC OR ACCELERATED PHASE CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE AND/OR INTOLERANCE TO TWO OR MORE TYROSINE KINASE INHIBITORS (TKI)
- ODE-33 TREATMENT OF PROGRESSIVE, METASTATIC MEDULLARY THYROID CANCER (MTC)
- ODE-34 TREATMENT OF ADULT PATIENTS WITH CUSHING'S DISEASE FOR WHOM PITUITARY SURGERY IS NOT AN OPTION OR HAS NOT BEEN CURATIVE
- ODE-35 TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL) THAT IS RESISTANT OR INTOLERANT TO PRIOR TYROSINE KINASE INHIBITOR THERAPY.

PATENT AND EXCLUSIVITY TERMS**ORPHAN DRUG EXCLUSIVITY**

- ODE-36 ADJUNCT TO A LOW-FAT DIET AND OTHER LIPID-LOWERING TREATMENTS, INCLUDING LDL APHERESIS WHERE AVAILABLE, TO REDUCE LDL-C, TC, APOLIPOPROTEIN B, & NON-HDL-C IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
- ODE-37 TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME (SBS) WHO ARE DEPENDENT ON PARENTERAL SUPPORT
- ODE-38 PART OF COMBINATION THERAPY IN ADULTS (GREATER THAN OR EQUAL TO 18 YEARS) WITH PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS (MDR-TB)
- ODE-39 TREATMENT OF CHRONIC IRON OVERLOAD IN PATIENTS 10 YRS. & OLDER WITH NON-TRANSFUSION DEPENDENT THALASSEMIA (NTDT) SYNDROMES AND WITH A LIVER IRON CONCENTRATION OF AT LEAST 5 MG OF IRON PER GRAM OF LIVER DRY WEIGHT & SERUM FERRITIN GREATER THAN 300 MCG/L.
- ODE-40 TREATMENT OF PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL) IN COMBINATION WITH CHEMOTHERAPY, APPROVED UNDER NDA #21588/S-037
- ODE-41 ADJUNCT TO LIPID-LOWERING MEDICATIONS AND DIET TO REDUCE LDL-C, APOLIPOPROTEIN B (APO B), TOTAL CHOLESTEROL (TC), AND NON-HIGH DENSITY LIPOPROTEIN-CHOLESTEROL (NON-HDL-C) IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
- ODE-42 USE AS A NITROGEN-BINDING ADJUNCTIVE THERAPY FOR CHRONIC MGMT OF ADULT AND PEDIATRIC PATIENTS AT LEAST 2 YRS WITH UREA CYCLE DISORDERS THAT CANNOT BE MANAGED BY DIETARY PROTEIN RESTRICTION AND/OR AMINO ACID SUPPLEMENTATION ALONE
- ODE-43 TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING LENALIDOMIDE AND BORTEZOMIB AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY.
- ODE-44 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) WHO HAVE BEEN PREVIOUSLY TREATED WITH IMATINIB MESYLATE AND SUNITINIB MALATE.
- ODE-45 MANAGEMENT OF NEPHROPATHIC CYSTINOSIS IN ADULTS AND CHILDREN AGES 6 YEARS AND OLDER.
- ODE-46 IMPROVEMENT OF NEUROLOGICAL OUTCOME BY REDUCING THE INCIDENCE AND SEVERITY OF ISCHEMIC DEFICITS IN ADULT PATIENTS WITH SUBARACHNOID HEMORRHAGE FROM RUPTURED INTRACRANIAL BERRY ANEURYSMS REGARDLESS OF THEIR POST-ICTUS NEUROLOGICAL CONDITION
- ODE-47 TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E MUTATION AS DETECTED BY AN FDA APPROVED TEST.
- ODE-48 TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA APPROVED TEST
- ODE-49 TREATMENT OF MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB
- ODE-50 FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST.
- ODE-51 TOPICAL TREATMENT OF STAGE 1A AND 1B MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO HAVE RECEIVED PRIOR SKIN-DIRECTED THERAPY
- ODE-52 TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS AS FIRST-LINE TREATMENT, IN COMBINATION WITH GEMCITABINE.
- ODE-53 TREATMENT OF ADULTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) WHO GROUP 1, TO IMPROVE EXERCISE CAPACITY, WHO FUNCTIONAL CLASS AND TO DELAY CLINICAL WORSENING.
- ODE-54 TX OF PAH TO DELAY DISEASE PROGRESSION. DISEASE PROGRESSION INCLUDED: DEATH, INITIATION OF IV OR SC PROSTANOIDS, OR CLINICAL WORSENING OF PAH (DECREASED 6-MINUTE WALK DISTANCE, WORSENERD PAH SYMPTOMS AND NEED FOR ADDITIONAL PAH TREATMENT).
- ODE-55 TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
- ODE-56 TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, DIFFERENTIATED THYROID CARCINOMA (DCT) THAT IS REFRACTORY TO RADIOACTIVE IODINE TREATMENT.
- ODE-57 TRAMETINIB IN COMBO WITH DABRAFENIB FOR TX. OF PTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST. THIS INDICATION IS BASED ON THE DEMONSTRATION OF DURABLE RESPONSE

PATENT AND EXCLUSIVITY TERMS**ORPHAN DRUG EXCLUSIVITY**

RATE

- ODE-58 DABRAFENIB IN COMBO WITH TRAMETINIB FOR TX. OF PTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST. THIS INDICATION IS BASED ON THE DEMONSTRATION OF DURABLE RESPONSE RATE
- ODE-59 TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER
- ODE-60 TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
- ODE-61 TREATMENT OF NEUROGENIC SYMPTOMATIC ORTHOSTATIC HYPOTENSION IN PATIENTS WITH PRIMARY AUTONOMIC FAILURE, DOPAMINE-BETA-HYDROXYLASE DEFICIENCY, AND NONDIABETIC AUTONOMIC NEUROPATHY
- ODE-62 TREATMENT OF PROLIFERATING INFANTILE HEMANGIOMA REQUIRING SYSTEMIC THERAPY.
- ODE-63 TREATMENT OF VISCERAL LEISHMANIASIS DUE TO LEISHMANIA DONOVANI; CUTANEOUS LEISHMANIASIS DUE TO LEISHMANIA BRAZILIENSIS, LEISHMANIA GUYANENSIS, AND LEISHMANIA PANAMENSIS; AND MUCOSAL LEISHMANIASIS DUE TO LEISHMANIA BRAZILIENSIS.
- ODE-64 SELECTIVE HEPATIC INTRA-ARTERIAL USE FOR IMAGING TUMORS IN ADULTS WITH KNOWN HEPATOCELLULAR CARCINOMA (HCC)
- ODE-65 TREATMENT OF PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AS PART OF A COMBINATION REGIMEN.
- ODE-66 TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB.
- ODE-67 GUIDING SENTINEL LYMPH NODE BIOPSY, USING A HAND-HELD GAMMA COUNTER IN PATIENTS WITH CLINICALLY NODE NEGATIVE SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY
- ODE-68 TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA
- ODE-69 TREATMENT OF MALIGNANT HYPERTHERMIA IN CONJUNCTION WITH APPROPRIATE SUPPORTIVE MEASURES AND FOR THE PREVENTION OF MALIGNANT HYPERTHERMIA IN PATIENTS AT HIGH RISK
- ODE-70 RELAPSED CLL, IN COMBO. WITH RITUXIMAB, IN PATIENTS FOR WHOM RITUXIMAB ALONE WOULD BE CONSIDERED APPROPRIATE THERAPY DUE TO OTHER CO-MORBIDITIES; AND RELAPSED SLL IN PATIENTS WHO HAVE RECEIVED AT LEAST 2 PRIOR SYSTEMIC THERAPIES
- ODE-71 RELAPSED FOLLICULAR B-CELL NON-HODGKIN LYMPHOMA (FL) IN PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR SYSTEMIC THERAPIES
- ODE-72 TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION WHO HAVE NOT RECEIVED AT LEAST ONE PRIOR THERAPY
- ODE-73 LONG-TERM TREATMENT OF ADULT PATIENTS WITH GAUCHER DISEASE TYPE 1 WHO ARE CYP2D6 EXTENSIVE METABOLIZERS (EMS), INTERMEDIATE METABOLIZERS (IMS), OR POOR METABOLIZERS (PMS) AS DETECTED BY AN FDA-CLEARED TEST.
- ODE-74 TREATMENT OF PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
- ODE-75 TREATMENT OF PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY.
- ODE-76 TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE NOT RECEIVED AT LEAST 1 PRIOR THERAPY
- ODE-77 TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
- ODE-78 TREATMENT OF HYPERCALCEMIA IN ADULT PATIENTS WITH PRIMARY HYPERPARATHYROIDISM FOR WHOM PARATHYROIDECTOMY WOULD BE INDICATED ON THE BASIS OF SERUM CALCIUM LEVELS, BUT WHO ARE UNABLE TO UNDERGO PARATHYROIDECTOMY.
- ODE-79 TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
- ODE-80 TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S
- ODE-81 TREATMENT OF PATIENTS WITH ACROMEGALY WHO HAVE HAD AN INADEQUATE RESPONSE TO SURGERY AND/OR FOR WHOM SURGERY IS NOT AN OPTION
- ODE-82 TREATMENT OF PATIENTS WITH UNRESECTABLE, WELL- OR MODERATELY-DIFFERENTIATED LOCALLY ADVANCED OR METASTATIC GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS TO IMPROVE PROGRESSION-FREE SURVIVAL
- ODE-83 USE OF AS MONOTHERAPY FOR PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA MUTATED (AS DETECTED BY AN FDA-APPROVED TEST) ADVANCED OVARIAN

PATENT AND EXCLUSIVITY TERMS**ORPHAN DRUG EXCLUSIVITY**

- CANCER WHO HAVE BEEN TREATED WITH THREE OR MORE PRIOR LINES OF CHEMOTHERAPY
- ODE-84 TREATMENT OF MOTOR FLUCTUATIONS IN PATIENTS WITH ADVANCED PARKINSON'S DISEASE
- ODE-85 AS A REPLACEMENT SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT) AND IN CASE OF DRUG POISONING WHEN CRRT IS USED TO REMOVE DIALYZABLE SUBSTANCES
- ODE-86 TREATMENT OF PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA
- ODE-87 TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, RADIOACTIVE IODINE REFRACTORY DIFFERENTIATED THYROID CANCER
- ODE-88 FOR USE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE NOT RECEIVED AT LEAST ONE PRIOR THERAPY (FIRST LINE TREATMENT)
- ODE-89 TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 2 PRIOR REGIMENS, INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT
- ODE-90 TREATMENT OF INVASIVE MUCORMYCOSIS IN PATIENTS 18 YEARS OF AGE AND OLDER
- ODE-91 TREATMENT OF BILE ACID SYNTHESIS DISORDERS DUE TO SINGLE ENZYME DEFECTS
- ODE-92 TREATMENT OF LYMPHANGIOLEIOMYOMATOSIS (LAM)
- ODE-93 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 12 YEARS AND OLDER WHO ARE HOMOZYGOUS FOR F508DEL MUTATION IN THE CFTR GENE
- ODE-94 PROPHYLAXIS OF ORGAN REJECTION IN KIDNEY TRANSPLANT PATIENTS CONVERTED FROM TACROLIMUS IMMEDIATE-RELEASE FORMULATIONS IN COMBINATION WITH OTHER IMMUNOSUPPRESSANTS
- ODE-95 FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
- ODE-96 TREATMENT OF PRIMARY HYPERKALEMIC PERIODIC PARALYSIS, PRIMARY HYPOKALEMIC PERIOD PARALYSIS, AND RELATED VARIANTS
- ODE-97 TO EXPAND THE INDICATION TO PEDIATRIC PATIENTS 2-6 YEARS OF AGE WITH NEPHROPATHIC CYSTINOSIS
- ODE-98 TREATMENT OF HEREDITARY OROTIC ACIDURIA
- ODE-99 FOR USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN, FOR THE TREATMENT OF PATIENTS WITH METASTATIC ADENOCARCINOMA OF THE PANCREAS THAT HAS PROGRESSED FOLLOWING GEMCITABINE-BASED THERAPY
- ODE-100 FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA OR LEIOMYOSARCOMA WHO RECEIVED A PRIOR ANTHRACYCLINE-CONTAINING REGIMEN
- ODE-101 FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATION, IN COMBINATION WITH VEMURAFENIB. COTELLIC IS NOT INDICATED FOR TREATMENT OF PATIENTS WITH WILD-TYPE BRAF MELANOMA
- ODE-102 FOR TREATMENT OF PATIENTS WITH METASTATIC EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) T790M MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC), AS DETECTED BY AN FDA-APPROVED TEST, WHO HAVE PROGRESSED ON OR AFTER EGFR TKI THERAPY
- ODE-103 USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
- ODE-104 EMERGENCY TX OF PTS FOLLOWING A FU OR CAPECITABINE OD, OR WHO EXHIBIT EARLY-ONSET, SEVERE OR LIFE-THREATENING TOXICITY AFFECTING THE CARDIAC SYSTEM OR CNS, AND/OR EARLY-ONSET, UNUSUALLY SEVERE AR W/IN 96 HRS FOLLOWING THE END OF FU OR CAPECITABINE ADMIN.
- ODE-105 TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB
- ODE-106 FOR USE OF UPTRAVI (SELEXIPAG) TABLETS, 200, 400, 600, 800, 1000, 1200, 1400, AND 1600 MCG FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH, WHO GROUP I) TO REDUCE THE RISKS OF DISEASE PROGRESSION AND HOSPITALIZATION FOR PAH
- ODE-107 TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA WHO HAVE RECEIVED A PRIOR ANTHRACYCLINE-CONTAINING REGIMEN
- ODE-108 TREATMENT OF ADULT PATIENTS WITH PROGRESSIVE, WELL-DIFFERENTIATED, NON-FUNCTIONAL, NEUROENDOCRINE TUMORS (NET) OF GASTROINTESTINAL (GI) OR LUNG ORIGIN, (EXCLUDING PANCREATIC) WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC DISEASE

PATENT AND EXCLUSIVITY TERMS**ORPHAN DRUG EXCLUSIVITY**

- ODE-109 INDICATED FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WITHOUT 17P DELETION WHO HAVE NOT RECEIVED AT LEAST ONE PRIOR THERAPY (FIRST LINE THERAPY)
- ODE-110 FOR HIGH-DOSE CONDITIONING TREATMENT PRIOR TO HEMATOPOIETIC PROGENITOR (STEM) CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA
- ODE-111 TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS ARE ROS-1 POSITIVE.
- ODE-112 FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH HEPATIC VENO-OCCLUSIVE DISEASE (VOD), ALSO KNOWN AS SINUSOIDAL OBSTRUCTION SYNDROME (SOS), WITH RENAL OR PULMONARY DYSFUNCTION FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT).
- ODE-113 FOR TREATMENT OF PEDIATRIC AND ADULT PATIENTS WITH ACQUIRED METHEMOGLOBINEMIA.
- ODE-114 TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION, AS DETECTED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
- ODE-115 TREATMENT OF PATIENTS WITH METASTATIC, SQUAMOUS, NON-SMALL CELL LUNG CANCER PROGRESSING AFTER PLATINUM-BASED CHEMOTHERAPY
- ODE-116 TREATMENT OF PROGRESSIVE KERATOCONUS
- ODE-117 FOR TREATMENT OF PATIENTS WITH SMALL LYMPHOCYTIC LYMPHOMA (SLL)
- ODE-118 AN ADJUNCT TO DIET TO REDUCE LDL-C, TOTAL-C, NONHDL-C AND APOB IN CHILDREN AND ADOLESCENTS 7 TO 17 YEARS OF AGE WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, EITHER ALONE OR WITH OTHER LIPID-LOWERING TREATMENTS (E.G., LDL APHERESIS)
- ODE-119 TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) IN COMBINATION WITH URSODEOXYCHOLIC ACID (UDCA) IN ADULTS WITH AN INADEQUATE RESPONSE TO UDCA, OR AS MONOTHERAPY IN ADULTS UNABLE TO TOLERATE UDCA
- ODE-120 FOR USE AFTER RADIOLABELING WITH GA 68, WITH POSITRON EMISSION TOMOGRAPHY (PET) FOR LOCALIZATION OF SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS (NETS) IN ADULT AND PEDIATRIC PATIENTS.
- ODE-121 TREATMENT OF CORNEAL ECTASIA FOLLOWING REFRACTIVE SURGERY
- ODE-122 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
- ODE-123 TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6-11 YEAR OLD WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE
- ODE-124 REPLACEMENT THERAPY FOR ORAL CARBAMAZEPINE FORMULATIONS, WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE, IN ADULTS WITH THE FOLLOWING SEIZURE TYPES: PARTIAL WITH COMPLEX SYMPTOMOLOGY, GENERALIZED CLONIC-TONIC, AND MIXED
- ODE-125 INDICATED IN PEDIATRIC PATIENTS 10 YEARS AND OLDER FOR THE PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGES 3 AND 4 AND CKD STAGE 5 IN PATIENTS ON HEMODIALYSIS OR PERITONEAL DIALYSIS
- ODE-126 AS MONOTHERAPY FOR THE TREATMENT OF PATIENTS WITH DELETERIOUS BRCA MUTATION (GERMLINE AND/OR SOMATIC) ASSOCIATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH TWO OR MORE CHEMOTHERAPIES
- ODE-127 TREATMENT OF SPINAL MUSCULAR ATROPHY IN PEDIATRIC AND ADULT PATIENTS
- ODE-128 TREATMENT OF PATIENTS WITH MARGINAL ZONE LYMPHOMA (MZL) WHO REQUIRE SYSTEMIC THERAPY AND HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED THERAPY
- ODE-129 INDICATED FOR REDUCING THE RISK OF GRAFT REJECTION WHEN USED IN CONJUNCTION WITH HIGH-DOSE BUSULFAN & CYCLOPHOSPHAMIDE AS A PREPARATIVE REGIMEN FOR ALLOGENIC HEMATOPOIETIC PROGENITOR CELL TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH CLASS 3 BETA-THALASSEMIA
- ODE-130 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY IN PATIENTS 5 YEARS OF AGE AND OLDER
- ODE-131 TREATMENT OF MULTIPLE MYELOMA (MM), AS MAINTENANCE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTO-HSCT)
- ODE-132 TREATMENT OF CARCINOID SYNDROME DIARRHEA IN COMBINATION WITH SOMATOSTATIN ANALOG (SSA) THERAPY IN ADULTS INADEQUATELY CONTROLLED BY SSA THERAPY
- ODE-133 INDICATED FOR MAINTENANCE TREATMENT OF ADULT PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY

PATENT AND EXCLUSIVITY TERMS**ORPHAN DRUG EXCLUSIVITY**

- ODE-134 TREATMENT OF CHOREA ASSOCIATED WITH HUNTINGTON'S DISEASE
- ODE-135 TREATMENT OF CHRONIC HCV GENOTYPE 2 OR 3 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER OR WEIGHING AT LEAST 35 KG WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS FOR USE IN COMBINATION WITH RIBAVIRIN
- ODE-136 TREATMENT OF PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER OR WEIGHING AT LEAST 35 KG WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1, 4, 5, OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS
- ODE-137 TREATMENT OF OLIGOARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PERSISTENT OLIGOARTHRITIS, PSORIATIC JUVENILE IDIOPATHIC ARTHRITIS, ENTHESITIS-RELATED ARTHRITIS, OR UNDIFFERENTIATED ARTHRITIS) & POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS IN CHILDREN 0-16 YRS
- ODE-138 TREATMENT OF PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AS A COMPONENT OF A COMBINATION CHEMOTHERAPY MAINTENANCE REGIMEN
- ODE-139 TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC OR LIVER CANCER) WHO HAVE BEEN PREVIOUSLY TREATED WITH THE DRUG SORAFENIB.
- ODE-140 TREATMENT OF ADULT PATIENTS WITH AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM), SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGICAL NEOPLASM (SM-AHN), OR MAST CELL LEUKEMIA (MCL)
- ODE-141 TREATMENT OF ADULT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) THAT IS FLT3 MUTATION-POSITIVE AS DETECTED BY AN FDA APPROVED TEST, IN COMBINATION WITH STANDARD CYTARABINE AND DAUNORUBICIN INDUCTION AND CYTARABINE CONSOLIDATION
- ODE-142 TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB
- ODE-143 TO DECREASE THE RECURRENCE OF PNEUMOTHORAX IN ADULTS
- ODE-144 TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
- ODE-145 TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS ARE ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE AS DETECTED BY AN FDA-APPROVED TEST
- ODE-146 OPTICAL IMAGING AGENT INDICATED IN PATIENTS WITH GLIOMA (SUSPECTED WORLD HEALTH ORGANIZATION GRADES III OR IV ON PREOPERATIVE IMAGING) AS AN ADJUNCT FOR THE VISUALIZATION OF MALIGNANT TISSUE DURING SURGERY
- ODE-147 DABRAFENIB IN COMBINATION WITH TRAMETINIB, FOR THE TX. OF PTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST
- ODE-148 TRAMETINIB IN COMBINATION WITH DABRAFENIB, FOR THE TX. OF PTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST
- ODE-149 TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH CENTRAL PRECOCIOUS PUBERTY
- ODE-150 TO REDUCE THE ACUTE COMPLICATIONS OF SICKLE CELL DISEASE IN ADULT AND PEDIATRIC PATIENTS 5 YEARS OF AGE AND OLDER.
- ODE-151 TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA WITH AN ISOCITRATE DEHYDROGENASE-2 (IDH2) MUTATION AS DETECTED BY AN FDA-APPROVED TEST
- ODE-152 TREATMENT OF ADULT PATIENTS WITH CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD)
- ODE-153 TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
- ODE-154 FOR USE IN CHILDREN AGES 2 TO 12 YEARS OLD WITH CHAGAS DISEASE
- ODE-155 TREATMENT OF ADULT PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR SYSTEMIC THERAPIES
- ODE-156 TREATMENT OF ADULTS WITH CARCINOID SYNDROME; WHEN USED, IT REDUCES THE FREQUENCY OF SHORT-ACTING SOMATOSTATIN ANALOG RESCUE THERAPY
- ODE-157 FOR USE AS A NITROGEN-BINDING AGENT FOR CHRONIC MANAGEMENT OF PEDIATRIC PATIENTS ≥ 2 MONTHS AND < 2 YEARS OF AGE WITH UREA CYCLE DISORDERS (UCDS) WHO CANNOT BE MANAGED BY DIETARY PROTEIN RESTRICTION AND/OR AMINO ACID SUPPLEMENTATION ALONE
- ODE-158 TREATMENT OF PATIENTS WITH ERDHEIM-CHESTER DISEASE WITH BRAF V600 MUTATION

PATENT AND EXCLUSIVITY TERMS**ORPHAN DRUG EXCLUSIVITY**

- ODE-159 FOR TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK) POSITIVE, METASTATIC NON-SMALL-CELL LUNG CANCER (NSCLC) AS DETECTED BY AN FDA APPROVED TEST, EXCLUDING PATIENTS WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB
- ODE-160 FOR TREATMENT OF SCURVY IN ADULT AND PEDIATRIC PATIENTS AGE 5 MONTHS AND OLDER FOR WHOM ORAL ADMINISTRATION IS NOT POSSIBLE, INSUFFICIENT OR CONTRAINDICATED
- ODE-161 TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1) IN PEDIATRIC PATIENTS AGED 3 YRS AND OLDER WITH IDIOPATHIC OR CONGENITAL PAH TO IMPROVE PULMONARY VASCULAR RESISTANCE (PVR), WHICH IS EXPECTED TO RESULT IN AN IMPROVEMENT IN EXERCISE ABILITY
- ODE-162 TREATMENT OF NEPHROPATHIC CYSTINOSIS IN PEDIATRIC PATIENTS 1 YEAR OF AGE TO LESS THAN 2 YEARS OF AGE
- ODE-163 TREATMENT OF ADULT PATIENTS WITH NEWLY-DIAGNOSED CHRONIC PHASE (CP) PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA (PH+ CML)
- ODE-164 TREATMENT OF PEDIATRIC PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE
- ODE-165 PROPHYLAXIS OF CYTOMEGALOVIRUS (CMV) INFECTION AND DISEASE IN ADULT CMV-SEROPOSITIVE RECIPIENTS [R+] OF AN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)
- ODE-166 TREATMENT OF SOMATOSTATIN RECEPTOR-POSITIVE GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (GEP-NETS) INCLUDING FOREGUT, MIDGUT, AND HINDGUT NEUROENDOCRINE TUMORS IN ADULTS
- ODE-167 ARSENIC TRIOXIDE FOR USE IN COMBINATION WITH TRETINOIN FOR TREATMENT OF ADULTS WITH NEWLY-DIAGNOSED LOW-RISK ACUTE PROMYELOCYTIC LEUKEMIA (APL) WHOSE APL IS CHARACTERIZED BY THE PRESENCE OF THE T(15;17) TRANSLOCATION OR PML/RAR-ALPHA GENE EXPRESSION
- ODE-168 FOR THE MAINTENANCE TREATMENT OF ADULT PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
- ODE-169 FOR THE ADJUNCTIVE TREATMENT OF ADULT AND PEDIATRIC PATIENTS AGED 2 YEARS AND OLDER WITH TUBEROUS SCLEROSIS COMPLEX (TSC)-ASSOCIATED PARTIAL-ONSET SEIZURES
- ODE-170 FOR THE DIAGNOSIS OF ADULT GROWTH HORMONE DEFICIENCY (AGHD)
- ODE-171 TREATMENT OF PEDIATRIC PATIENTS GREATER THAN OR EQUAL TO 1 YEAR OF AGE WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML) IN CHRONIC PHASE
- ODE-172 TREATMENT OF PEDIATRIC PATIENTS GREATER THAN OR EQUAL TO 1 YEAR OF AGE WITH CHRONIC PHASE PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA WITH RESISTANCE OR INTOLERANCE TO PRIOR TYROSINE-KINASE INHIBITOR THERAPY
- ODE-173 TREATMENT OF PATIENTS WITH CYSTIC FIBROSIS AGED 12 YEARS AND OLDER WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR WHO HAVE AT LEAST ONE MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE RESPONSIVE TO TEZACAFTOR/IVACAFTOR
- ODE-174 FOR THE TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT
- ODE-175 TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
- ODE-176 INDICATED FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST
- ODE-177 TO REDUCE THE FREQUENCY OF PAINFUL CRISES AND TO REDUCE THE NEED FOR BLOOD TRANSFUSIONS IN PEDIATRIC PATIENTS, 2 YEARS OF AGE AND OLDER, WITH SICKLE CELL ANEMIA WITH RECURRENT MODERATE TO SEVERE PAINFUL CRISIS
- ODE-178 INDICATED TO SLOW KIDNEY FUNCTION DECLINE IN ADULTS AT RISK OF RAPIDLY PROGRESSING AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
- ODE-179 TREATMENT OF PATIENTS WITH CLL AND TREATMENT OF PATIENTS WITH INDOLENT B-CELL NHL THAT HAS PROGRESSED DURING OR WITHIN SIX MONTHS OF TREATMENT WITH RITUXIMAB OR A RITUXIMAB CONTAINING REGIMEN
- ODE-180 MAINTENANCE TREATMENT OF ADULT PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER, WHO ARE IN A COMPLETE OR PARTIAL

PATENT AND EXCLUSIVITY TERMS**ORPHAN DRUG EXCLUSIVITY**

RESPONSE TO PLATINUM-BASED CHEMOTHERAPY

- ODE-181 TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA-MUTATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH THREE OR MORE PRIOR LINES OF CHEMOTHERAPY
- ODE-182 TRAMETINIB IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION
- ODE-183 TRAMETINIB AND DABRAFENIB IN COMBINATION, FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ANAPLASTIC THYROID CANCER (ATC) WITH BRAF V600E MUTATION AND WITH NO SATISFACTORY LOCOREGIONAL TREATMENT OPTIONS
- ODE-184 INDICATED IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF PEDIATRIC PATIENTS WITH HIV-1 INFECTION
- ODE-185 INDICATED FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
- ODE-186 TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6 YEARS AND OLDER WHO HAVE ONE OF THE FOLLOWING MUTATIONS IN THE CFTR GENE: G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, OR S549R
- ODE-187 TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6 YEARS AND OLDER WHO HAVE AN R117H MUTATION IN THE CFTR GENE
- ODE-188 TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGES 2 TO LESS THAN 6 YEARS WHO HAVE ONE OF THE FOLLOWING MUTATIONS IN THE CFTR GENE: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, AND R117H
- ODE-189 TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 2 YEARS AND OLDER WHO HAVE ONE OF THE FOLLOWING MUTATIONS IN THE CFTR GENE: 711+3A-G, E831X, 2789+5G-A, 3272-26A-G, AND 3849+10KBC-T
- ODE-190 TX OF CF IN PTS 2 YRS AND OLDER WHO HAVE ONE OF THE FOLLOWING MUTATIONS IN THE CFTR GENE: E56K, P67L, R74W, D110E, D110H, R117C, E193K, L206W, R347H, R352Q, A455E, D579G, S945L, S977F, F1052V, K1060T, A1067T, G1069R, R1070Q, R1070W, F1074L, D1152H, D1270N
- ODE-191 TO DECREASE THE RECURRENCE OF MALIGNANT PLEURAL EFFUSIONS IN SYMPTOMATIC PATIENTS FOLLOWING MAXIMAL DRAINAGE OF THE PLEURAL EFFUSION
- ODE-192 INDICATED TO INDUCE CONTROLLED CARDIAC SEPTAL INFRACTION TO IMPROVE EXERCISE CAPACITY IN ADULTS WITH SYMPTOMATIC HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY WHO ARE NOT CANDIDATES FOR SURGICAL MYECTOMY
- ODE-193 INDICATED FOR THE TREATMENT OF ONCHOCERCIASIS DUE TO ONCHOCERCA VOLVULUS IN PATIENTS AGED 12 YEARS AND OLDER
- ODE-194 ENCORAFENIB IS INDICATED IN COMBINATION WITH BINIMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH A BRAF V600E OR V600K MUTATION, AS DETECTED BY AN FDA-APPROVED TEST
- ODE-195 FOR THE TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 2 THROUGH 5 YEARS OLD WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE
- ODE-196 INDICATED FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC)
- ODE-197 INDICATED FOR THE TREATMENT OF THE POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS IN ADULTS
- ODE-198 INDICATED FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME (DS) IN PATIENTS 2 YEARS OF AGE AND OLDER TAKING CLOBAZAM
- ODE-199 THE TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 12 MONTHS AND OLDER WHO HAVE ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR POTENTIATION BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
- ODE-200 INDICATED FOR THE TREATMENT OF HUMAN SMALLPOX DISEASE CAUSED BY VARIOLA VIRUS IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 13 KG
- ODE-201 INDICATED FOR THE RADICAL CURE (PREVENTION OF RELAPSE) OF PLASMODIUM VIVAX MALARIA IN PATIENTS AGED 16 YEARS AND OLDER WHO ARE RECEIVING APPROPRIATE ANTIMALARIAL THERAPY FOR ACUTE P. VIVAX INFECTION
- ODE-202 INDICATED AS A SOURCE OF CALORIES AND FATTY ACIDS IN PEDIATRIC PATIENTS WITH PARENTERAL NUTRITION-ASSOCIATED CHOLESTASIS (PNAC)

PATENT AND EXCLUSIVITY TERMS**ORPHAN DRUG EXCLUSIVITY**

- ODE-203 INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH A SUSCEPTIBLE ISOCITRATE DEHYDROGENASE-1 (IDH1) MUTATION AS DETECTED BY AN FDA-APPROVED TEST
- ODE-204 TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER WITH IOBENGUANE SCAN POSITIVE, UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC PHEOCHROMOCYTOMA OR PARAGANGLIOMA WHO REQUIRE SYSTEMIC ANTICANCER THERAPY
- ODE-205 INDICATED FOR THE TREATMENT OF ADULTS WITH A CONFIRMED DIAGNOSIS OF FABRY DISEASE AND AN AMENABLE GALACTOSIDASE ALPHA GENE (GLA) VARIANT BASED ON IN VITRO ASSAY DATA
- ODE-206 FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
- ODE-207 TREATMENT OF STATUS EPILEPTICUS IN ADULTS
- ODE-208 TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) AFTER AT LEAST TWO PRIOR THERAPIES
- ODE-209 TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL) AFTER AT LEAST TWO PRIOR SYSTEMIC THERAPIES
- ODE-210 INDICATED IN COMBINATION WITH STANDARD IMMUNOSUPPRESSIVE THERAPY FOR THE FIRST-LINE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS AND OLDER WITH SEVERE APLASTIC ANEMIA
- ODE-211 INDICATED IN COMBO WITH AZACITIDINE, OR DECITABINE, OR LOW-DOSE CYTARABINE FOR THE TX OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
- ODE-212 INDICATED FOR THE TREATMENT OF THE POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS IN ADULTS
- ODE-213 INDICATED FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR (EGFR) EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
- ODE-214 TX OF MAC LUNG DISEASE IN ADULTS WITH LIMITED OR NO ALTERNATIVE TX OPTIONS AS PART OF A COMBO ANTIBACTERIAL DRUG REGIMEN WHO DO NOT ACHIEVE NEGATIVE SPUTUM CULTURES AFTER A MINIMUM OF 6 CONSECUTIVE MONTHS OF A MULTIDRUG BACKGROUND REGIMEN THERAPY
- ODE-215 INDICATED FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH SOLID TUMORS THAT HAVE A NEUROTROPHIC RECEPTOR TYROSINE KINASE (NTRK) GENE FUSION WITHOUT A KNOWN ACQUIRED RESISTANCE MUTATION
- ODE-216 INDICATED FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME (LGS) OR DRAVET SYNDROME (DS) IN PATIENTS 2 YEARS OF AGE AND OLDER
- ODE-217 INDICATED FOR THE TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE DISEASE HAS PROGRESSED ON CRIZOTINIB AND AT LEAST ONE OTHER ALK INHIBITOR FOR METASTATIC DISEASE
- ODE-218 INDICATED FOR THE TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE DISEASE HAS PROGRESSED ON ALECTINIB AS THE FIRST ALK INHIBITOR THERAPY FOR METASTATIC DISEASE
- ODE-219 INDICATED FOR THE TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE DISEASE HAS PROGRESSED ON CERITINIB AS THE FIRST ALK INHIBITOR THERAPY FOR METASTATIC DISEASE
- ODE-220 INDICATED FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH SOLID TUMORS THAT ARE METASTATIC OR WHERE SURGICAL RESECTION IS LIKELY TO RESULT IN SEVERE MORBIDITY
- ODE-221 INDICATED FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH SOLID TUMORS THAT HAVE NO SATISFACTORY ALTERNATIVE TREATMENTS OR THAT HAVE PROGRESSED FOLLOWING TREATMENT
- ODE-222 INDICATED FOR THE TREATMENT OF ADULT PATIENTS WHO HAVE RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH A FMS-LIKE TYROSINE KINASE 3 (FLT3) MUTATION AS DETECTED BY AN FDA-APPROVED TEST

PATENT AND EXCLUSIVITY TERMS**ORPHAN DRUG EXCLUSIVITY**

- ODE-223 INDICATED FOR THE TREATMENT OF LAMBERT-EATON MYASTHENIC SYNDROME (LEMS) IN ADULTS
- ODE-224 INDICATED, IN COMBINATION WITH LOW-DOSE CYTARABINE, FOR THE TREATMENT OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) IN ADULT PATIENTS WHO ARE \geq 75 YEARS OLD OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
- ODE-225 INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY
- ODE-226 MAINTENANCE TREATMENT OF ADULTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE OR SOMATIC BRCA-MUTATED ADVANCED EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM-BASED CHEMOTHERAPY
- ODE-227 INDICATED FOR TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WHO HAVE BEEN PREVIOUSLY TREATED WITH SORAFENIB
- ODE-228 INDICATED FOR THE TREATMENT OF FASCIOLIASIS IN PATIENTS 6 YEARS OF AGE AND OLDER
- ODE-229 TREATMENT OF ADULT PATIENTS WITH METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA PREVIOUSLY TREATED WITH AT LEAST TWO PRIOR LINES OF CHEMOTHERAPY, AND IF APPROPRIATE, HER2/NEU-TARGETED THERAPY
- ODE-230 FIRST-LINE TREATMENT OF METASTATIC NONSMALL CELL LUNG CANCER WHOSE TUMORS HAVE NON-RESISTANT EPIDERMAL GROWTH FACTOR MUTATIONS OTHER THAN EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
- ODE-231 INDICATED FOR THE TREATMENT OF CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS (EDS) IN PEDIATRIC PATIENTS 7 YEARS OF AGE AND OLDER WITH NARCOLEPSY
- ODE-232 TREATMENT OF PEDIATRIC PATIENTS 12 YEARS AND OLDER OR WEIGHING AT LEAST 45 KG WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1,2,3,4,5 OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS (CHILD-PUGH A)
- ODE-233 TREATMENT OF PEDIATRIC PATIENTS 12 YEARS AND OLDER OR WEIGHING AT LEAST 45 KG WITH HCV GENOTYPE 1 INFECTION, WHO PREVIOUSLY HAVE BEEN TREATED WITH A REGIMEN CONTAINING AN HCV NS5A INHIBITOR OR AN NS3/4A PROTEASE INHIBITOR (PI), BUT NOT BOTH
- ODE-234 INDICATED FOR THE TREATMENT OF STABLE SYMPTOMATIC HEART FAILURE DUE TO DILATED CARDIOMYOPATHY (DCM) IN PEDIATRIC PATIENTS AGED 6 MONTHS AND OLDER, WHO ARE IN SINUS RHYTHM WITH AN ELEVATED HEART RATE
- ODE-235 INDICATED FOR THE TREATMENT OF ACUTE HERPETIC KERATITIS (DENDRITIC ULCERS) IN PATIENTS WITH HERPES SIMPLEX (HSV-1 AND HSV-2) VIRUS
- ODE-236 TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6 MONTHS TO LESS THAN 12 MONTHS WHO HAVE ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR POTENTIATION BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
- ODE-237 TREATMENT OF THE CARDIOMYOPATHY OF WILD TYPE OR HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR-CM) IN ADULTS TO REDUCE CARDIOVASCULAR MORTALITY AND CARDIOVASCULAR-RELATED HOSPITALIZATION
- ODE-238 TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
- ODE-239 TREATMENT OF PREVIOUSLY UNTREATED ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
- ODE-240 TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH SHORT BOWEL SYNDROME (SBS) WHO ARE DEPENDENT ON PARENTERAL SUPPORT
- ODE-241 INDICATED IN COMBINATION WITH A RITUXIMAB PRODUCT FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED FOLLICULAR LYMPHOMA (FL)
- ODE-242 TX OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA WITH A SUSCEPTIBLE ISOCITRATE DEHYDROGENASE-1 MUTATION AS DETECTED BY AN FDA-APPROVED TEST IN ADULT PTS WHO ARE \geq 75 YRS OLD OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
- ODE-243 ACUTE TREATMENT OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY (I.E., SEIZURE CLUSTERS, ACUTE REPETITIVE SEIZURES) THAT ARE DISTINCT FROM A PATIENT'S USUAL SEIZURE PATTERN IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER
- ODE-244 TREATMENT OF LAMBERT-EATON MYASTHENIC SYNDROME (LEMS) IN PATIENTS 6 TO LESS THAN 17 YEARS OF AGE

PATENT AND EXCLUSIVITY TERMS**ORPHAN DRUG EXCLUSIVITY**

- ODE-245 INDICATED IN COMBINATION WITH A RITUXIMAB PRODUCT FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMA (MZL)
- ODE-246 TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT
- ODE-247 TX OF PTS W/ CYSTIC FIBROSIS (CF) AGE 6 TO <12 YRS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR W/ AT LEAST 1 MUTATION IN CF TRANSMEMBRANE CONDUCTANCE REGULATORY GENE RESPONSIVE TO TEZACAFTOR/IVACAFTOR BASED ON IN VITRO DATA AND/OR CLINICAL EVIDENCE
- ODE-248 TREATMENT OF ADULT PATIENTS WITH ORAL ULCERS ASSOCIATED WITH BEHCETS DISEASE
- ODE-249 TREATMENT OF PATIENTS WITH CYSTIC FIBROSIS (CF) AGE 6 YEARS TO LESS THAN 12 YEARS WHO ARE HOMOZYGOUS FOR F508DEL MUTATION OR WHO HAVE AT LEAST ONE MUTATION IN THE CF TRANSMEMBRANE CONDUCTANCE REGULATOR GENE THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR
- ODE-250 INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH SYMPTOMATIC TENOSYNOVIAL GIANT CELL TUMOR (TGCT) ASSOCIATED WITH SEVERE MORBIDITY OR FUNCTIONAL LIMITATIONS AND NOT AMENABLE TO IMPROVEMENT WITH SURGERY
- ODE-251 INDICATED AS PART OF COMBINATION THERAPY IN THE TREATMENT OF PEDIATRIC PATIENTS (12 TO LESS THAN 18 YEARS OF AGE AND WEIGHING AT LEAST 30 KG) WITH PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS
- ODE-252 TREATMENT OF DUCHENE MUSCULAR DYSTROPHY IN PATIENTS 2 YEARS OF AGE TO LESS THAN 5 YEARS OF AGE
- ODE-253 INDICATED AS PART OF A COMBINATION REGIMEN WITH BEDAQUILINE AND LINEZOLID FOR THE TREATMENT OF ADULTS WITH PULMONARY EXTENSIVELY DRUG RESISTANT (XDR) OR TREATMENT-INTOLERANT OR NONRESPONSIVE MULTIDRUG-RESISTANT (MDR) TUBERCULOSIS (TB)
- ODE-254 INDICATED TO IMPROVE WAKEFULNESS IN ADULT PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY
- ODE-255 INDICATED FOR THE TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS (EDS) IN ADULT PATIENTS WITH NARCOLEPSY
- ODE-256 FOR HIV-1 INFECTION IN PEDIATRIC PTS AT LEAST 25 KG W/ NO ANTIRETROVIRAL (ARV) TX HX OR TO REPLACE CURRENT ARV REGIMEN FOR VIROLOGICALLY-SUPPRESSED ON STABLE ARV W/ NO HX TX FAILURE AND NO KNOWN SUBSTITUTIONS ASSOCIATED W/ RESISTANCE TO BIC, FTC, OR TAF
- ODE-257 IN COMBO W/ DEXAMETHASONE FOR ADULTS W/ RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO RECEIVED AT LEAST 4 PRIOR THERAPIES AND REFRACTORY TO AT LEAST 2 PROTEASOME INHIBITORS, AT LEAST 2 IMMUNOMODULATORY AGENTS, AND AN ANTI-CD38 MONOCLONAL ANTIBODY
- ODE-258 FOR THE TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 2 OR 3 INFECTION IN PEDIATRIC PATIENTS BETWEEN 3 YEARS OF AGE AND 12 YEARS OF AGE OR WEIGHING 35 KG WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS FOR USE IN COMBINATION WITH RIBAVIRIN
- ODE-259 INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK PRIMARY OR SECONDARY (POST-POLYCYTHEMIA VERA OR POST-ESSENTIAL THROMBOCYTHEMIA) MYELOFIBROSIS (MF)
- ODE-260 INDICATED TO INCREASE SYSTEMIC EXPOSURE OF ATAZANAVIR IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS IN THE TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS WEIGHING AT LEAST 35 KG
- ODE-261 INDICATED TO SLOW THE RATE OF DECLINE IN PULMONARY FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD)
- ODE-262 TREATMENT OF PEDIATRIC PATIENTS BETWEEN 3 YEARS OF AGE AND 12 YEARS OF AGE OR WEIGHING 35 KG WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 4, 5, OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS
- ODE-263 TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER WITH CHRONIC HCV GENOTYPE 1 INFECTION WITH DECOMPENSATED CIRRHOSIS, FOR USE IN COMBINATION WITH RIBAVIRIN
- ODE-264 TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER WITH CHRONIC HCV GENOTYPE 1 OR 4 INFECTION WHO ARE LIVER TRANSPLANT RECIPIENTS WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS, FOR USE IN COMBINATION WITH RIBAVIRIN
- ODE-265 INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS ARE ROS1-POSITIVE

PATENT AND EXCLUSIVITY TERMS**ORPHAN DRUG EXCLUSIVITY**

- ODE-266 ADULT & PED \geq 12YRS OLD W/ SOLID TUMORS THAT HAVE NTRK W/O KNOWN ACQUIRED RESISTANCE MUTATION, ARE METASTATIC OR WHERE SURGICAL RESECTION IS LIKELY TO RESULT IN SEVERE MORBIDITY & HAVE EITHER PROGRESSED FOLLOWING TX OR HAVE NO SATISFACTORY ALTERNATIVE TX
- ODE-267 INDICATED IN COMBINATION WITH HIGH FLUID INTAKE, ALKALI, AND DIET MODIFICATION, FOR THE PREVENTION OF CYSTINE STONE FORMATION IN PEDIATRIC PATIENTS 20KG TO 9 YEARS OF AGE W/SEVERE HOMOZYGOUS CYSTINURIA, WHO ARE NOT RESPONSIVE TO THESE MEASURES ALONE
- ODE-268 INDICATED FOR TREATMENT OF PATIENTS WITH CUSHING'S DISEASE FOR WHOM PITUITARY SURGERY IS NOT AN OPTION OR HAS NOT BEEN CURATIVE
- ODE-269 PROPHYLAXIS OF ORGAN REJECTION IN PEDIATRIC PATIENTS RECEIVING ALLOGENEIC KIDNEY TRANSPLANT, LIVER TRANSPLANTS, AND HEART TRANSPLANT, IN COMBINATION WITH OTHER IMMUNOSUPPRESSANTS
- ODE-270 INDICATED TO INCREASE PAIN FREE LIGHT EXPOSURE IN ADULT PATIENTS WITH A HISTORY OF PHOTOTOXIC REACTIONS FROM ERYTHROPOIETIC PROTOPORPHYRIA (EPP)
- ODE-271 INDICATED IN COMBINATION WITH OTHER ANTI-MYELOMA PRODUCTS FOR THE TREATMENT OF ADULTS WITH MULTIPLE MYELOMA (MM)
- ODE-272 INDICATED FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1) TO DELAY DISEASE PROGRESSION
- ODE-273 INDICATED FOR THE TREATMENT OF ADULTS WITH ACUTE HEPATIC PORPHYRIA (AHP)
- ODE-274 INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
- ODE-275 INDICATED FOR THE TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE
- ODE-276 INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
- ODE-277 TX OF ADULTS W/ ADV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER TREATED W/ \geq 3 PRIOR CHEMO REGIMENS & CANCER ASSOCIATED W/ HRD+ STATUS DEFINED BY A DELETERIOUS OR SUSPECTED DELETERIOUS BRCA MUTATION
- ODE-278 TX OF ADULTS W/ ADV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER TREATED W/ \geq 3 PRIOR CHEMO REGIMENS & CANCER ASSOCIATED W/ HRD+ STATUS DEFINED BY GENOMIC INSTABILITY & PROGRESSED $>$ 6 MONTHS AFTER RESPONSE TO THE LAST PLATINUM-BASED CHEMOTHERAPY
- ODE-279 INDICATED FOR THE ACUTE TX OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY (I.E. SEIZURE CLUSTERS, ACUTE REPETITIVE SEIZURES) THAT ARE DISTINCT FROM A PATIENT'S USUAL SEIZURE PATTERN IN PATIENTS WITH EPILEPSY 6 YEARS OF AGE AND OLDER
- ODE-280 INDICATED FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 53 SKIPPING
- ODE-281 INDICATED FOR THE TREATMENT OF SICKLE CELL DISEASE (SCD) IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
- ODE-282 INDICATED TO SELECTIVELY STAIN THE INTERNAL LIMITING MEMBRANE (ILM)
- ODE-283 MAINTENANCE TX OF ADULTS W/ DELETERIOUS OR SUSPECTED DELETERIOUS GBRCA METASTATIC PANCREATIC ADENOCARCINOMA WHOSE DZ HAS NOT PROGRESSED ON \geq 16WKS OF 1ST LINE PLATINUM BASED CHEMO REGIMEN. SELECT PTS FOR THERAPY BASED ON APPROVED COMPANION DIAGNOSTIC
- ODE-284 IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS, FOR THE TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS UNDER 12 YEARS OF AGE WEIGHING AT LEAST 35KG
- ODE-285 IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS OTHER THAN PROTEASE INHIBITORS THAT REQUIRE A CYP3A INHIBITOR, FOR THE TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS UNDER 12 YEARS OF AGE WEIGHING AT LEAST 25KG AND LESS THAN 35KG
- ODE-286 INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH CUSHING'S DISEASE FOR WHOM PITUITARY SURGERY IS NOT AN OPTION OR HAS NOT BEEN CURATIVE
- ODE-287 TREATMENT OF ADULTS WITH NEWLY DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC)
- ODE-288 INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC, INOPERABLE PLEXIFORM NEUROFIBROMAS (PN)

PATENT AND EXCLUSIVITY TERMS**ORPHAN DRUG EXCLUSIVITY**

- ODE-289 INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH LOW-GRADE UPPER TRACT UROTHELIAL CANCER (LG-UTUC)
- ODE-290 INDICATED FOR THE INITIAL TREATMENT OF SEVERE MALARIA IN ADULT AND PEDIATRIC PATIENTS TO ALWAYS BE FOLLOWED BY A COMPLETE TREATMENT COURSE OF AN APPROPRIATE ORAL ANTIMALARIAL REGIMEN
- ODE-291 INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE A MUTATION THAT LEADS TO MESENCHYMAL-EPITHELIAL TRANSITION (MET) EXON 14 SKIPPING AS DETECTED BY AN FDA-APPROVED TEST
- ODE-292 INDICATED FOR THE TREATMENT OF ADULTS WITH PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) FUSION OR OTHER REARRANGEMENT AS DETECTED BY AN FDA-APPROVED TEST
- ODE-293 TX OF PED PTS 6 YRS OF AGE & OLDER OR WEIGHING AT LEAST 17 KG WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION: WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS; OR WITH DECOMPENSATED CIRRHOSIS FOR USE IN COMBINATION WITH RIBAVIRIN
- ODE-294 PROPHYLAXIS OF ORGAN REJECTION IN PEDIATRIC PATIENTS RECEIVING ALLOGENEIC KIDNEY OR HEART TRANSPLANTS, IN COMBINATION WITH OTHER IMMUNOSUPPRESSANTS
- ODE-295 INDICATED FOR THE MAINTENANCE TREATMENT OF ADULT PATIENTS WITH ADVANCED EPITHELIAL OVARIAN CANCER WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM-BASED CHEMOTHERAPY
- ODE-296 INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH AIDS-RELATED KAPOSI SARCOMA (KS) AFTER FAILURE OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART)
- ODE-297 FOR THE TREATMENT OF KAPOSI SARCOMA (KS) IN ADULT PATIENTS WHO ARE HIV-NEGATIVE
- ODE-298 INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR (GIST) WHO HAVE RECEIVED PRIOR TREATMENT WITH 3 OR MORE KINASE INHIBITORS, INCLUDING IMATINIB
- ODE-299 INDICATED FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS AGED 16 YEARS AND OLDER WITH METASTATIC OR LOCALLY ADVANCED EPITHELIOD SARCOMA NOT ELIGIBLE FOR COMPLETE RESECTION
- ODE-300 FOR THE TREATMENT OF ADULT PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) AS DETECTED BY AN FDA-APPROVED TEST, NOT INCLUDING PATIENTS WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB
- ODE-301 INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
- ODE-302 INDICATED FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET-MUTANT MEDULLARY THYROID CANCER (MTC) WHO REQUIRE SYSTEMIC THERAPY
- ODE-303 ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY (IF RADIOACTIVE IODINE IS APPROPRIATE)
- ODE-304 INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC SMALL CELL LUNG CANCER (SCLC) WITH DISEASE PROGRESSION ON OR AFTER PLATINUM-BASED CHEMOTHERAPY
- ODE-305 TREATMENT OF INVASIVE ASPERGILLOSIS
- ODE-306 W/ BEVACIZUMAB FOR MAINT TX OF ADULTS W/ ADV EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CA IN COMPLETE OR PARTIAL RESPONSE TO 1ST LINE PT BASED CHEMO & WHOSE CA IS ASSOC W/ HOMOLOGOUS RECOMB DEF + STATUS DEFINED BY GENOMIC INSTABILITY
- ODE-307 INDICATED AS PART OF COMBINATION THERAPY IN THE TREATMENT OF PEDIATRIC PATIENTS 5 YEARS AND OLDER TO LESS THAN 12 YEARS OF AGE AND WEIGHING AT LEAST 15 KG WITH PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS (MDR-TB)
- ODE-308 TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1) TO IMPROVE EXERCISE CAPACITY
- ODE-309 INDICATED FOR USE IN COMBINATION WITH TRASTUZUMAB AND CAPECITABINE FOR TREATMENT OF ADULT PATIENTS WITH METASTATIC HER2-POSITIVE BREAST CANCER AND BRAIN METASTASES, WHO HAVE RECEIVED ONE OR MORE PRIOR ANTI-HER2-BASED REGIMENS IN THE METASTIC SETTING
- ODE-310 INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), NOT OTHERWISE SPECIFIED, INCLUDING DLBCL

PATENT AND EXCLUSIVITY TERMS**ORPHAN DRUG EXCLUSIVITY**

- ARISING FROM FOLLICULAR LYMPHOMA, AFTER AT LEAST 2 LINES OF SYSTEMIC THERAPY
- ODE-311 INDICATED AS A SOURCE OF CALORIES AND FATTY ACIDS FOR THE TREATMENT OF PEDIATRIC AND ADULT PATIENTS WITH MOLECULARLY CONFIRMED LONG-CHAIN FATTY ACID OXIDATION DISORDERS (LC-FAOD)
- ODE-312 INDICATED FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME IN PATIENTS 2 YEARS OF AGE AND OLDER
- ODE-313 INDICATED FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH SOLID TUMORS THAT HAVE A NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) GENE FUSION WITHOUT A KNOWN ACQUIRED RESISTENCE MUTATION, ARE METASTATIC OR WHERE SURGICAL RESECTION IS LIKELY TO RESULT IN SEVERE MORBIDITY, AND HAVE EITHER PROGRESSED FOLLOWING TREATMENT OR HAVE NO SATISFACTORY ALTERNATIVE THERAPY
- ODE-314 INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA WHOSE TUMORS ARE POSITIVE FOR AN EZH2 MUTATION AS DETECTED BY AN FDA-APPROVED TEST AND WHO HAVE RECEIVED AT LEAST 2 PRIOR SYSTEMIC THERAPIES, AND FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS
- ODE-315 FOR CLEANSING OF THE COLON AS A PREPARATION FOR COLONOSCOPY IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
- ODE-316 TREATMENT OF ADULT PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS), INCLUDING PREVIOUSLY TREATED AND UNTREATED, DE NOVO AND SECONDARY MDS WITH THE FOLLOWING FRENCH-AMERICAN-BRITISH SUBTYPES (REFRACTORY ANEMIA, REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS, REFRACTORY ANEMIA WITH EXCESS BLASTS, AND CHRONIC MYELOMONOCYTIC LEUKEMIA [CMML]) AND INTERMEDIATE-1, INTERMEDIATE-2, AND HIGH-RISK INTERNATIONAL PROGNOSTIC SCORING SYSTEM GROUPS.
- ODE-317 FOR USE WITH POSITRON EMISSION TOMOGRAPHY (PET) FOR LOCALIZATION OF SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS (NETS) IN ADULT PATIENTS
- ODE-318 TREATMENT OF ADULT PATIENTS WITH METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) AS DETECTED BY AN FDA APPROVED TEST

PATENT USE

- U-1 PREVENTION OF PREGNANCY
- U-2 TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA
- U-3 TREATMENT OF HYPERTENSION
- U-4 PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS
- U-5 METHOD OF PRODUCING BRONCHODILATION
- U-6 METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS
- U-7 INCREASING CARDIAC CONTRACTILITY
- U-8 ACUTE MYOCARDIAL INFARCTION
- U-9 CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT
- U-10 DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALAMIC MALFUNCTIONS OR LESIONS IN HUMANS
- U-11 TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS
- U-12 METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION
- U-13 A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT
- U-14 ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES
- U-15 METHOD OF LOWERING INTRAOCULAR PRESSURE
- U-16 USE IN LUNG SCANNING PROCEDURES
- U-17 TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS
- U-18 METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS
- U-19 TREATMENT OF INFLAMMATION
- U-20 A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-21 TREATMENT OF HUMANS SUFFERING UNDESIRE UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS
- U-22 METHOD OF COMBATTING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS
- U-23 METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE
- U-24 METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST
- U-25 REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS
- U-26 REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF
- U-27 DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF
- U-28 CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY
- U-29 CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY
- U-30 CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY
- U-31 INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY
- U-32 PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN
- U-33 TREATING VIRAL INFECTIONS IN A MAMMAL
- U-34 TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL
- U-35 TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION
- U-36 METHODS OF TREATING BACTERIAL ILLNESSES
- U-37 METHOD OF TREATING GASTROINTESTINAL DISEASE
- U-38 TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA
- U-39 ANGINA PECTORIS
- U-40 METHOD OF TREATMENT OF BURNS
- U-41 METHOD OF TREATING CARDIAC ARRHYTHMIAS
- U-42 ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES' STAGE C COLON CANCER
- U-43 MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA
- U-44 RELIEF OF NAUSEA AND VOMITING
- U-45 TREATMENT OF INFLAMMATION AND ANALGESIA
- U-46 TREATMENT OF PANIC DISORDER
- U-47 STIMULATION OF THE RELEASE OF GROWTH HORMONE
- U-48 ANALGESIA
- U-49 SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA
- U-50 USE IN TREATING INFLAMMATORY DERMATOSES
- U-51 BLOOD POOL IMAGING, INCLUDING CARDIAC FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING
- U-52 TREATMENT OF ADULT AND PEDIATRIC PATIENTS(OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION
- U-53 HYPERCALCEMIA OF MALIGNANCY
- U-54 REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS
- U-55 TREATMENT OF PAIN
- U-56 AID TO SMOKING CESSATION
- U-57 OPHTHALMIC USE OF NORFLOXACIN
- U-58 METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES
- U-59 METHOD OF TREATING HYPERCHOLESTEROLEMIA
- U-60 NASAL ADMINISTRATION OF BUTORPHANOL

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-61 CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD

U-62 CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY

U-63 ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE

U-64 TREATMENT OF VIRAL INFECTIONS

U-65 METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV

U-66 TRIPHASIC REGIMEN

U-67 METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL

U-68 TREATMENT OF ACTINIC KERATOSIS

U-69 TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS

U-70 TREATMENT OF TRANSIENT INSOMNIA

U-71 METHOD OF TREATMENT OF HEART FAILURE

U-72 TREATMENT OF MIGRAINE

U-73 METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES

U-74 METHOD OF PROVIDING HYPNOTIC EFFECT

U-75 RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS

U-76 USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM

U-77 TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS

U-78 ULCERATIVE COLITIS

U-79 SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURN DUE TO GERD

U-80 METHOD OF TREATING OCULAR BACTERIAL INFECTIONS

U-81 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS

U-82 TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE

U-83 TREATMENT OF SEIZURES

U-84 A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS

U-85 NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS

U-86 METHOD OF TREATING CERTAIN FORMS OF EPILEPSY

U-87 METHOD FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS

U-88 TREATMENT OF MODERATE PLAQUE PSORIASIS

U-89 TREATMENT OR PROPHYLAXIS OF EMESIS

U-90 TREATMENT OF PSYCHOTIC DISORDERS

U-91 ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS

U-92 TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATY

U-93 USE AS AN ANTIHISTAMINE/DECONGESTANT

U-94 TREATMENT-ADULTS W/ ADVANCED HIV, INTOLERANT OF APPROVED THERAPIES, INTOLERANT OF APPROVED THERAPIES W/PROVEN BENEFIT OR HAVE EXPERIENCED CLINICAL/IMMUNOLOGICAL DETERIORATION WHILE RECEIVING..OR FOR WHOM SUCH THERAPIES-CONTRAINDICATED

U-95 SHORT TERM MANAGEMENT OF MODERATE PRURITIS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS

U-96 METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS

U-97 A METHOD OF TREATING A PATIENT IN NEED OF MEMORY ENHANCEMENT

U-98 A METHOD OF INDUCING REGRESSION OF LEUKEMIA CELL GROWTH IN A MAMMAL

U-99 METHOD OF PROVIDING POTASSIUM TO A SUBJECT IN NEED OF POTASSIUM

U-100 METHOD OF TREATING OCULAR INFLAMMATION

U-101 ADJUNCT TO CONVENTIONAL CT OR MRI IMAGING IN THE LOCALIZATION OF STROKE IN PATIENTS IN WHOM STROKE HAS ALREADY BEEN DIAGNOSED

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-102 METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN

U-103 TREATMENT OF OCULAR HYPERTENSION

U-104 TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE

U-105 EMESIS

U-106 TREATMENT OF EPILEPSY

U-107 TREATMENT OF HYPERTENSION AND ANGINA PECTORIS

U-108 SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD AND PATHOLOGIAL HYPERSECRETORY CONDITIONS AND MAINTENANCE HEALING OF EROSIIVE ESOPHAGITIS

U-109 ADJUNCT DIET IN THE TX OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PTS W/PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SAT FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE

U-110 USE AS A RETRIEVABLE PESSARY

U-111 DIABETES

U-112 CONTRACEPTION

U-113 METHOD OF CONDUCTING RADIOLOGICAL EXAMINATION OF A PATIENT BY ADMINISTERING TO SAID PATIENT A RADIOPAQUE AMOUNT OF IOPROMIDE

U-114 USE FOR INHIBITING BONE RESORPTION

U-115 USE OF VASODILATORS TO EFFECT AND ENHANCE AN ERECTION (AND THUS TREAT ERECTILE DYSFUNCTION), BY INJECTION INTO THE PENIS

U-116 METHOD OF MYOCARDIAL IMAGING

U-117 TREATMENT OF OCULAR ALLERGIC RESPONSE IN HUMAN EYES

U-118 METHOD OF LOWERING BLOOD SUGAR LEVEL

U-119 TREATMENT OF NASAL HYPERSECRETION

U-120 CONTROLLING OR PREVENTING POST-OPERATIVE INTRAOCULAR PRESSURE RISES ASSOCIATED WITH OPHTHALMIC LASER SURGICAL PROCEDURES

U-121 METHOD OF TREATING CONDITIONS MEDIATED THROUGH HISTAMINE H2-RECEPTORS

U-122 A THERAPEUTIC METHOD FOR CONTROLLING THROMBOSIS

U-123 METHOD FOR CONTROLLING THROMBOSIS AND DECREASING BLOOD HYPERCOAGULATION AND HEMORRHAGING RISKS

U-124 TREATMENT OF ACNE

U-125 TREATMENT NEUROGENERATIVE DISEASES

U-126 TREATMENT OF GASTRITIS

U-127 METHOD OF PRODUCING NEUROMUSCULAR BLOCKADE

U-128 METHOD FOR TREATMENT OF TUMORS

U-129 METHOD TO DESTROY OR IMPAIR TARGET CELLS

U-130 MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS

U-131 PHOTODAMAGED SKIN

U-132 INHIBITING HIV PROTEASE

U-133 MANAGEMENT OF OBESITY INCLUDING WEIGHT LOSS AND MAINTENANCE IN PATIENTS ON A REDUCED-CALORIE DIET

U-134 TREATMENT OF ACNE VULGARIS

U-135 ANTITUMOR AGENT

U-136 PROCESS FOR WASTE NITROGEN REMOVAL

U-137 METHOD OF TREATING BACTERIAL VAGINOSIS

U-138 TREATMENT OF ALLERGIC RHINITIS

U-139 TREATMENT OF ALLERGIC REACTIONS

U-140 USE OF NORVIR TO INHIBIT HIV PROTEASE OR TO INHIBIT AN HIV INFECTION

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-141 TREATMENT OF ULCERATIVE COLITIS

U-142 METHOD OF TREATING ALLERGIC REACTIONS IN A MAMMAL BY USING THIS ACTIVE METABOLITE

U-143 BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES AS CONTRAST AGENTS FOR MR IMAGING

U-144 BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC MATERIALS FOR USE IN CLINICAL APPLICATIONS

U-145 BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC PARTICLES FOR USE AS NUCLEAR MAGNETIC RESONANCE IMAGING AGENTS

U-146 METHOD OF TREATING SUSCEPTIBLE NEOPLASMS IN MAMMALS

U-147 DETECTION OF GASTROINTESTINAL DISORDERS AND THE SUBSEQUENT BREATH COLLECTION AND MEASUREMENT OF $^{13}\text{CO}_2$

U-148 DEVICE FOR COLLECTING A BREATH SAMPLE

U-149 METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS, ACUTE MANIA OR MILD ANXIETY STATES

U-150 METHOD OF USE FOR CONTROLLING HYPERGLYCEMIA BY ADMINISTRATION OF THIS SUSTAINED RELEASE DOSAGE FORM OF GLIPIZIDE

U-151 RELIEF OF SYMPTOMS OF THE COMMON COLD

U-152 METHOD OF TREATING ANXIETY RELATED DISORDERS INCLUDING OBSESSIVE COMPULSIVE DISORDER

U-153 TREATMENT OF INITIAL EPISODE GENITAL HERPES

U-154 METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER

U-155 TREATMENT OF ERECTILE DYSFUNCTION

U-156 METHOD OF PROVIDING ANESTHESIA

U-157 TREATMENT OF A HUMAN SUFFERING FROM VITAMIN B12 DEFICIENCY

U-158 ANGINA

U-159 TREATMENT OF INTERSTITIAL CYSTITIS

U-160 TREATMENT OF BACTERIAL INFECTIOUS DISEASE

U-161 METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT

U-162 METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA

U-163 METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS

U-164 METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS

U-165 TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA

U-166 TREATMENT OF H.PYLORI-ASSOCIATED DUODENAL ULCER

U-167 METHOD FOR TREATING HIV-1 INFECTION

U-168 METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA

U-169 METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING

U-170 METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT

U-171 METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT

U-172 TREATMENT OF GENITAL WARTS

U-173 ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES

U-174 USE AS AN ANTIHISTAMINE AGENT

U-175 METHOD OF TREATING MALIGNANT TUMORS

U-176 METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES

U-177 FUNGICIDE

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-178 FACILITATED ADHERENCE OF AGENTS TO SKIN

U-179 ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT

U-180 TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER 6 MONTHS OF AGE) WITH ADVANCED HIV INFECTION

U-181 PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST

U-182 USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION

U-183 TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION

U-184 TREATING ALLERGIC EYE DISEASES IN HUMANS

U-185 METHOD OF TREATING HYPERTENSION

U-186 METHOD FOR TREATING GI DISORDERS CAUSED BY H. PYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT

U-187 THERAPEUTIC TREATMENT OF CALCIFIC TUMORS

U-188 TREATMENT OF H.PYLORI ASSOCIATED DUODENAL ULCER

U-189 ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE

U-190 USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR

U-191 METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN

U-192 USE IN TREATING ALLERGIC REACTIONS

U-193 PSORIASIS

U-194 TREATING ANGINA PECTORIS AND HIGH BLOOD PRESSURE

U-195 METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOPE OR NITROGEN LABELED CARBON

U-196 TREATMENT OF METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS

U-197 USE IN COMBINATION WITH CERTAIN LHRH ANALOGUES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER

U-198 TREATMENT METASTATIC CARCINOMA OF OVARY AFTER 1ST LINE FAILURE OR SUBSEQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND 2ND LINE TREATMENT OF AIDS RELATED KAPOSI'S SARCOMA

U-199 METHOD OF TREATING INFECTIOUS UPPER GI TRACT DISORDERS CAUSED BY CAMPYLOBACTER PYLORIDIS INFECTION COMPRISING ADMINISTRATION OF A BISMUTH AGENT AND AN ANTIMICROBIAL AGENT

U-200 METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF A BISMUTH-CONTAINING AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT

U-201 METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF CAMPYLOBACTER-INHIBITING ANTIMICROBIAL AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT

U-202 METHOD OF TREATING PEPTIC ULCER DISEASE CAUSED BY CAMPYLOBACTER PYLORIDIS COMPRISING ORAL ADMINISTRATION OF 50 TO 5,000MG BISMUTH DAILY FOR 3-56 DAYS

U-203 TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY

U-204 USE OF TAXOL IN COMBINATION WITH G-CSF FOR TREATMENT OF PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA

U-205 METHOD FOR TREATING HEARTBURN

U-206 METHOD OF USING FSH ALONE, WITHOUT THE PRESENCE OF EXOGENEOUS LH, IN IN VITRO FERTILIZATION

U-207 USE AS NASAL SPRAY

U-208 VAGINAL ADMINISTRATION USING SPECIFIED FORMULATION

U-209 VAGINAL ADMINISTRATION OF PROGESTERONE USING SPECIFIED FORMULATION

U-210 METHOD OF TREATING CONGESTIVE HEART FAILURE

U-211 USE IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION

U-212 METHOD OF TREATMENT OF PARKINSON'S DISEASE

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-213 METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA AND METHOD FOR TREATING HYPERLIPIDEMIA

U-214 USE AS A BLOOD GLUCOSE-LOWERING AGENT

U-215 TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS

U-216 TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C BY ADMINISTERING AN AGONIST OF LH-RH AND FLUTAMIDE

U-217 METHOD OF PRODUCING ANESTHESIA

U-218 METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT

U-219 TREATMENT OF PARKINSON'S DISEASE

U-220 METHOD OF DIAGNOSIS

U-221 SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION

U-222 METHOD OF TREATING PAGET'S DISEASE USING ACTONEL

U-223 TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS

U-224 CONTROLLING INTRAOCULAR PRESSURE

U-225 METHOD FOR DELIVERY

U-226 METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE

U-227 NASAL ADMINISTRATION

U-228 ASTHMA

U-229 CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE)

U-230 PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS

U-231 USE IN PARKINSON'S DISEASE

U-232 METHOD OF TREATING MIGRAINE

U-233 DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE

U-234 METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS

U-235 METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE

U-236 TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3.0MG/DAY

U-237 METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS

U-238 IMAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST IS ENHANCED....

U-239 TREATING OR CONTROLLING OCULAR INFLAMMATION WHICH COMPRISES TOPICALLY ADMINISTERING TO AFFECTED EYE A COMPOSITION COMPRISING AN NSAID, A POLYMERIC QUATERNARY AMMONIUM COMPOUND AND BORIC ACID

U-240 TREATMENT OF ACUTE MIGRAINE ATTACKS

U-241 FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR DUODENAL ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORT-TERM TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS

U-242 USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION

U-243 TOPICAL ADMINISTRATION

U-244 PLATELET AGGREGATION INHIBITORS

U-245 TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS

U-246 PHOSPHATE BINDING

U-247 TREATMENT OF RHEUMATOID ARTHRITIS

U-248 TREATMENT OF HIV

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-249 METHOD OF TREATING ALLERGIC OR NON-ALLERGIC RHINITIS IN PATIENTS BY ADMINISTERING AEROSOLIZED PARTICLES OF MOMETASONE FUROATE

U-250 TREATMENT OF HEPATITIS B INFECTION

U-251 USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES

U-252 METHOD OF TREATING A HUMAN SUBJECT HAVING GAUCHER'S DISEASE

U-253 ORAL TRANSMUCOSAL USE

U-254 USE OF AGGRASTAT IN COMBINATION WITH HEPARIN

U-255 IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY

U-256 TREATMENT OF HIV INFECTION IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS

U-257 TREATMENT OF HIV INFECTION

U-258 TREATMENT OF NEURODEGENERATIVE DISEASES

U-259 TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION DRUG SUBSTANCE

U-260 REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION

U-261 TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING FINASTERIDE

U-262 TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE

U-263 METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN

U-264 METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN

U-265 USE AS LAXATIVE

U-266 RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS; RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS; MANAGEMENT OF ACUTE PAIN IN ADULTS; TREATMENT OF PRIMARY DYSMENORRHEA; ACUTE TREATMENT OF MIGRAINE ATTACKS IN ADULTS

U-267 PREVENTING HEARTBURN EPISODES FOLLOWING INGESTION OF HEARTBURN-INDUCING FOOD/BEVERAGE, COMPRISING ADMIN TO PT, 30 MIN PRIOR TO CONSUMPTION BY THE PT THE FOOD/BEVERAGE, A COMPOSITION COMPRISING 10MG FAMOTIDINE

U-268 ACROMEGALY

U-269 EXCESS GH-SECRETION OR GASTRO-INTESTINAL DISORDERS

U-270 METHOD OF IMPROVING THE TIME FOR ADMINISTRATION OR THE TIME BETWEEN CHANGES OF GIVING SETS FOR THE DRUG PRODUCT

U-271 METHOD OF TREATING TUMORS

U-272 METHOD OF TREATING CARCINOMA

U-273 CUTANEOUS T-CELL LYMPHOMA

U-274 ZANAMIVIR FOR INHALATION

U-275 METHOD OF USE OF THE DRUG SUBSTANCE

U-276 METHOD OF USE OF LEVOBUPIVACAINE

U-277 NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING)

U-278 METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT

U-279 METHOD OF USE OF THE APPROVED PRODUCT

U-280 TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE

U-281 ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS

U-282 METHOD OF TREATING BACTERIAL INFECTIONS

U-283 METHOD FOR TREATING MENOPAUSAL SYMPTOMS IN A POSTMENOPAUSAL FEMALE

U-284 MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

WITH MENOPAUSE, AND VULVAR AND VAGINAL ATROPHY) AND OSTEOPOROSIS

U-285 DEPRESSION AND SOCIAL ANXIETY DISORDER/SOCIAL PHOBIA

U-286 DEPRESSION

U-287 TREATMENT OR PREVENTION OF OSTEOPOROSIS

U-288 THERAPY OF INFLUENZA

U-289 TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP

U-290 INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS)

U-291 INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH CYCLOSPORIN

U-292 INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH AZATHIOPRINE

U-293 INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH A CORTICOSTEROID

U-294 TREATMENT OF HYPERPIGMENTARY DISORDERS

U-295 TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS

U-296 TREATING MIGRAINE PAIN AND ONE OR MORE OF A CLUSTER OF SYMPTOMS CHARACTERISTIC OF A MIGRAINE ATTACK SYMPTOMS BEING SELECTED FROM PHOTOPHOBIA, PHONOPHOBIA NAUSEA AND FUNCTIONAL DISABILITY

U-297 PREVENTION OR TREATMENT OF REVERSIBLE VASOCONSTRICTION BY THE INHALATION OF NITRIC OXIDE WITH AN OXYGEN CONTAINING GAS

U-298 METHOD OF COMBATING BACTERIA IN A PATIENT

U-299 TREATMENT OF ADENOMATOUS POLYPS

U-300 INDICATED FOR THE REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA

U-301 USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS AND BIGUANIDES IN THE TREATMENT OF TYPE II DIABETES

U-302 TO REDUCE THE RISK OF STROKE IN PATIENTS WHO HAVE HAD TRANSIENT ISCHEMIA OF THE BRAIN OR COMPLETED ISCHEMIC STROKE DUE TO THROMBOSIS

U-303 METHOD OF USE PATENT-PRODUCT APPROVED FOR TREATMENT OF OSTEOPOROSIS, PAGET'S DISEASE, PREVENTION AND TREATMENT OF GLUCOCORTICOID INDUCED OSTEOPOROSIS

U-304 A METHOD OF TREATMENT OF A CONDITION INVOLVING AN ANTIBODY ANTIGEN REACTION

U-305 METHODS FOR USING THE DRUG PRODUCT

U-306 TREATMENT OF POST-MENOPAUSAL UROGENITAL SYMPTOMS ASSOCIATED WITH ESTROGEN DEFICIENCY

U-307 CLAIMS AN OLANZAPINE POLYMORPH USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES, EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA

U-308 CLAIMS A SOLID ORAL FORMULATION INCLUDING TABLETS AND GRANULES OF OLANZAPINE USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES, EMPLOYING OLANZAPINE AS PER THE INDICATIONS OF THIS NDA

U-309 TREATING SJOEGREN SYNDROME

U-310 TREATMENT OF XEROSTOMIA

U-311 HORMONE REPLACEMENT

U-312 PANIC DISORDER, OBSESSIVE-COMPULSIVE DISORDER, POSTTRAUMATIC STRESS DISORDER

U-313 TREATMENT OF CONGESTIVE HEART FAILURE

U-314 METHOD FOR TREATING HYPERPARATHYROIDISM WHICH COMPRISES SUPPRESSING PARATHYROID ACTIVITY

U-315 METHOD FOR ADMINISTERING DRUG TO GASTROINTESTINAL TRACT

U-316 METHOD OF TREATING A SUBJECT SUFFERING FROM PROSTATE CANCER

U-317 METHOD OF USING TROGLITAZONE TO TREAT PATIENTS HAVING INSULIN RESISTANCE

U-318 TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-319 TREATMENT OF MICROBIAL INFECTIONS

U-320 INHIBITING OR ELIMINATING ACUTE MYELOID LEUKEMIA

U-321 REDUCTION OF ELEVATED IPTH LEVELS IN THE MGT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS UNDERGONG CHRONIC RENAL DIALYSIS

U-322 TREATMENT OF ALZHEIMER'S DEMENTIA

U-323 USE AS A BILE ACID SEQUESTRANT

U-324 METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN, SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS OR ACUTE MANIA EMPLOYING OLANZAPINE

U-325 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS, INCLUDING "BIPOLAR DISORDER NOS" EMPLOYING OLANZAPINE

U-326 METHOD OF TREATING SCHIZOPHRENIA AND BIPOLAR DISORDER

U-327 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED PSYCHOTIC CONDITONS EMPLOYING OLANZAPINE

U-328 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS INCLUDING "A PSYCHOTIC CONDITION" EMPLOYING AN OLANZAPINE POLYMORPH

U-329 USE OF AVANDIA AS MONOTHERAPY, IN COMBINATION WITH METFORMIN, AND IN COMBINATION WITH SULFONYLUREAS TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

U-330 TREATMENT OF NAUSEA AND VOMITING

U-331 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

U-332 TREATMENT OR PREVENTION OF BRONCHOSPASM

U-333 METHOD OF TREATING OCULAR HYPERTENSION

U-334 TREATMENT OF EXCESSIVE FEMALE FACIAL HAIR

U-335 USE OF PRAVASTATIN SODIUM FOR SECONDARY PREVENTION OF CORONARY EVENTS IN MEN AND WOMEN WHO HAVE HAD A MYOCARDIAL INFARCTION AND HAVE NORMAL CHOLESTEROL LEVELS

U-336 DIAGNOSTIC RADIOIMAGING

U-337 USE OF CARDIOLITE/MIRALUMA KIT FOR THE PREPARATION OF TC99M SESTAMIBI

U-338 METHODS FOR TREATING DISTURBANCES OF MOOD, DISTURBANCES OF APPETITE, DEPRESSED MOOD, OR CARBOHYDRATE CRAVING ALL ASSOCIATED WITH PREMENSTRUAL SYNDROME

U-339 PREVENTION OF CARDIO-TOXICITY CAUSED BY THE ADMINISTRATION OF DOXORUBICIN

U-340 THE LONG TERM TREATMENT OF GROWTH FAILURE DUE TO LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION IN CHILDREN

U-341 METHOD FOR ENHANCING THE TREATMENT OF ... LATE LUTEAL PHASE DYSPHORIC DISORDER

U-342 METHOD FOR TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER

U-343 REDUCTION OF INTESTINAL GAS, CRAMPING AND ANORECTAL IRRITATION

U-344 METHOD FOR INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH ANOTHER HIV PROTEASE INHIBITOR

U-345 RITONAVIR AND ANOTHER HIV PROTEASE INHIBITOR FOR CONCOMITANT ADMINISTRATION FOR THE TREATMENT OF AN HIV INFECTION

U-346 METHOD FOR INHIBITING CYTOCHROME P450 MONOOXYGENASE WITH RITONAVIR AND A METHOD FOR IMPROVING THE PHARMACOKINETICS OF A DRUG THAT IS METABOLIZED BY CYTOCHROME P450 MONOOXYGENASE BY ADMIN THE DRUG AND RITONAVIR

U-347 METHOD OF USE IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS

U-348 METHOD OF USE FOR INHIBITING HIV INFECTION

U-349 METHOD OF USE WHICH IS SUBJECT OF THE APPLICATION

U-350 PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR CONCOMITANT ADMIN WITH A REVERSE TRANSCRIPTASE INHIBITOR

U-351 INHIBITING PROTEASE WITH LOPINAVIR AND INHIBITING AN HIV INFECTION WITH LOPINAVIR

U-352 INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH A REVERSE TRANSCRIPTASE INHIBITOR

U-353 PREVENTION AND TREATMENT OF OSTEOPOROSIS

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-354 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-355 METHOD OF ASSISTING PERSON TO QUIT SMOKING...TRANSDERMALLY ADMIN NICOTINE VIA..PATCH ADHERED TO SKIN AT DOSING RATE APPROX SAME AS ABSORBED FROM SMOKING
- U-356 DELIVERING A MEDICINAL AEROSOL FORMULATION USING CFC-FREE PROPELLANT 134A.
- U-357 USE OF THE DRUG PRODUCT IN PHOTODYNAMIC THERAPEUTIC PROTOCOLS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND RELATED CONDITIONS INVOLVING UNWANTED NEOVASCULATURE IN THE EYE
- U-358 DEPRESSION, OBSESSIVE COMPULSIVE DISORDER, PANIC DISORDER AND SOCIAL ANXIETY DISORDER
- U-359 METHOD OF USE OF VISICOL
- U-360 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS INCLUDING MENTAL DISORDERS EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011
- U-361 MANAGEMENT OF ANXIETY DISORDERS AND THE SHORT-TERM RELIEF OF THE SYMPTOMS OF ANXIETY
- U-362 USE OF APPROVED FORMULATIONS TO TREAT ALL APPROVED DISEASE INDICATIONS
- U-363 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS THAT RELATE TO THE USE OF A PSYCHOACTIVE SUBSTANCE EMPLOYING OLANZAPINE AS PER THE INDICATION THE SUBJECT MATTER OF SUPPLEMENT 011
- U-364 TREATING A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ANY NUMBER OF LISTED CONDITIONS INCLUDING PSYCHOSIS, EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011
- U-365 METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN OUR EXTENDED, CONTROLLED RELEASE FORMULATION
- U-366 METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN A DELAYED RELEASE FORMULATION
- U-367 TREATMENT OF CARDIOVASCULAR DISORDERS
- U-368 HEARTBURN
- U-369 METHOD OF CONTROLLING AND LOWERING INTRAOCULAR PRESSURE
- U-370 INTRAVAGINAL TREATMENT OF VAGINAL INFECTIONS WITH BUFFERED METRONIDAZOLE COMPOSITIONS
- U-371 APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.)
- U-372 METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GI TRACT OF AN ANIMAL, WHICH METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO THE ANIMAL...
- U-373 GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING "PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OF GERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
- U-374 KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX
- U-375 METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C
- U-376 TREATMENT OF INFLUENZA
- U-377 METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS
- U-378 METHOD FOR TREATING INCONTINENCE
- U-379 METHOD OF TREATING ONYCHOMYCOSIS
- U-380 COMBINATIONS OF TAXOL (PACLITAXEL) AND CISPLATIN WHICH ARE SUITABLE FOR THE TREATMENT OF OVARIAN AND NON-SMALL CELL LUNG CARCINOMAS
- U-381 TREATMENT OF HYPERPHOSPHATEMIA
- U-382 METHOD OF STABILIZING PROSTAGLANDIN
- U-383 METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-384 TREATMENT OF CMV RETINITIS

U-385 TREATMENT OF PEPTIC ULCERS

U-386 TREATMENT OF PATIENTS SUFFERING FROM A LATE ASTHMATIC REACTION OR LATE PHASE ASTHMA

U-387 TREATMENT OF PATIENTS WITH RESPIRATORY DISORDERS

U-388 SMOKING CESSATION AID APPLIED TO THE SKIN

U-389 SMOKING CESSATION AID APPLIED TO THE SKIN ON WAKING AND REMOVED PRIOR TO SLEEP AFTER ABOUT 16 HOURS

U-390 METHOD OF USING THE DRUG TO TREAT NEUROIMMUNOLOGIC DISEASES (INCLUDING MULTIPLE SCLEROSIS)

U-391 USE OF CASODEX IN COMBINATION WITH LHRH AGONISTS FOR THE TREATMENT OF PROSTATE CANCER

U-392 TREATMENT OF PATIENTS FOR INFLAMMATION

U-393 MANAGEMENT OF INCONTINENCE, MGT OF HORMONE REPLACEMENT THERAPY, TREATMENT OF INVOLUNTARY INCONTINENCE, MGT OVERACTIVE BLADDER AND INCREASING COMPLIANCE IN SUCH PT

U-394 METHOD OF USE OF ALPHAGAN

U-395 METHOD OF USE OF ALPHAGAN P

U-396 METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION

U-397 METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION WITHOUT AN INCREASE IN NAUSEA

U-398 TREATMENT OF GENERALIZED ANXIETY DISORDER

U-399 IN-THE-EYE USE OF CHLORINE DIOXIDE CONTAINING COMPOSITIONS

U-400 USE OF RIBAVIRIN TO INCREASE TYPE 1 CYTOKINE RESPONSE AND SUPPRESS TYPE 2 CYTOKINE RESPONSE TO LYMPHOCYTES, INCLUDING METHODS THAT TAKE ADVANTAGE OF SUCH MODULATION TO TREAT INFECTIONS AND INFESTATIONS

U-401 USE OF LOPINAVIR IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS FOR TREATING HIV INFECTION AND IN COMBO WITH OTHER HIV PROTEASE INHIBITORS

U-402 TREATMENT OF ACTINIC KERATOSES

U-403 ANTI-ALLERGIC FOR VARIOUS ALLERGIC DISEASES

U-404 TREATMENT OF ALLERGIC CONJUNCTIVITIS

U-405 FOR WOMEN WITH SEVERE DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS)

U-406 METHOD OF USE OF ATOVAQUONE AND PROGUANIL

U-407 METHOD OF TREATING OTOPATHY

U-408 FOR INDUCING OVULATION IN CONJUNCTION WITH A GONADOTROPIN RELEASING FACTOR ANTAGONIST AND RECRUITING OOCYTES FOR IN-VITRO FERTILIZATION

U-409 METHOD OF TREATING INFLAMMATION USING DRUG SUBSTANCE

U-410 METHOD OF REDUCING AMOUNT OF RESPECTIVE ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (INCLUDING PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER

U-411 METHOD OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN PREPARATION

U-412 TREATMENT OF TYPE 2 DIABETES

U-413 USE OF THE ACTIVE INGREDIENT FOR INHIBITING THE BIOSYNTHESIS OF CHOLESTEROL AND TREATMENT OF ATHEROSCLEROSIS

U-414 A METHOD OF TREATING GLYCOMETABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE

U-415 A METHOD FOR REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS

U-416 A METHOD FOR REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS
- U-417 COMBINATION USE OF AD-4833 WITH A BIGUANIDE
- U-418 A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
- U-419 A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE
- U-420 METHOD OF TREATMENT OF TYPE II DIABETES
- U-421 USE FOR SEDATION
- U-422 METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT HYPERACTIVITY DISORDER
- U-423 METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER, OR AIDS RELATED DEMENTIA
- U-424 FOR ONCE DAILY, BOLUS ADMINISTRATION TO A PATIENT IN ORDER TO ENGENDER TREATMENT FOR A NERVOUS DISORDER FOR SUBSTANTIALLY AN ENTIRE DAY ON A CHRONIC BASIS
- U-425 METHOD OF REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMIN TO A DIABETIC BY ADMIN A CHEMICAL COMPOUND HAVING FORMULA (INCL PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
- U-426 PREVENTION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION
- U-427 METHOD OF TREATING ALLERGIC REACTIONS IN MAMMALS
- U-428 METHOD OF TREATING ALLERGY IN A MAMMAL USING THIS ACTIVE METABOLITE
- U-429 METHOD OF USING DESLORATADINE TO TREAT ALLERGIC RHINITIS
- U-430 METHOD OF TREATING A DIABETIC BY ADMINISTERING AN INSULIN SENSITIZER IN COMBINATION WITH AN INSULIN SECRETION ENHANCER, AND A DRUG PRODUCT COMPRISING AN INSULIN SENSITIZER AND AN INSULIN SECRETION ENHANCER
- U-431 POSTTRAUMATIC STRESS DISORDER
- U-432 REDUCTION OF ATHEROSCLEROTIC EVENTS (MYOCARDIAL INFARCTION, STROKE, AND VASCULAR DEATH) IN PATIENTS WITH ATHEROSCLEROSIS DOCUMENTED BY RECENT STROKE, RECENT MYOCARDIAL INFARCTION OR ESTABLISHED PERIPHERAL ARTERIAL DISEASE
- U-433 USE OF LEVOCARNITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS
- U-434 CONTROLLED SYMPTOMS OF DIARRHEA, BLOATING PRESSURE AND CRAMPS, COMMONLY REFERRED TO AS GAS
- U-435 A TITRATION DOSING REGIMEN FOR THE TREATMENT OF PAIN USING AN INITIAL DOSE OF ABOUT 25MG
- U-436 ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
- U-437 METHOD OF USE EQUAL TO PROCESS OF PREPARATION
- U-438 TREATMENT/PREVENTION OF NEURODEGENERATIVE DISEASE
- U-439 TREATMENT OF OBESITY
- U-440 METHOD FOR TRANSDERMAL ADMINISTRATION OF A DRUG THROUGH NON-SCROTAL SKIN USING A TRANSDERMAL DRUG DELIVERY DEVICE CONTAINING THE DRUG AND HAVING AN ADHESIVE SURFACE
- U-441 METHOD OF TREATING MS BY ADMINISTERING COPAXONE
- U-442 METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURRENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG
- U-443 MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME
- U-444 TREATMENT OF MIGRAINE
- U-445 USE AS AN ANTIMYCOTIC AGENT
- U-446 TOPICAL TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA
- U-447 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-448 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-449 USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER WHERE THE DOSE OF LEUCOVORIN IS AT LEAST 200MG PER SQUARE METER
- U-450 INTERMEDIATE REL NICOTINIC ACID FORMULATIONS HAVING UNIQUE URINARY METAB PROFILES RESULTING FROM ABSORPTION PROFILES OF NICOTINIC ACID FROM THE INTERMEDIATE NICOTINIC ACID FORMULATIONS, SUITABLE FOR TX HYPERLIPIDEMIA FOLLOWING QD DOSING
- U-451 TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER
- U-452 USE OF LANSOPRAZOLE FOR COMBATING DISEASES CAUSED BY THE GENUS CAMPYLOBACTER (C.PYLORI=H.PYLORI)
- U-453 TREATMENT OF PLATELET ASSOCIATED ISCHEMIC DISORDERS
- U-454 METHOD OF TX A PT SUSPECTED OF HAVING HEPATITIS C BY ADMIN, IN COMBINATION, A CONJUGATE COMPRISING PEG 12000 & INTERFERON ALFA-2B IN AN AMT OF FROM 0.5MCG/KG TO 2MCG/KG, ONCE WEEKLY, AND RIBAVIRIN
- U-455 TREATMENT OF PULMONARY HYPERTENSION WITH UT-15
- U-456 METHOD OF DECREASING THE PRODUCTION OF A-BETA USING A COMPOSITION WHICH DECREASES BLOOD CHOLESTEROL IN PATIENTS AT RISK OF OR EXHIBITING SYMPTOMS OF ALZHEIMER'S DISEASE
- U-457 METHOD OF TREATING A VAGINAL FUNGAL INFECTION IN A FEMALE HUMAN
- U-458 METHOD OF USE OF IMAGENT
- U-459 TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER
- U-460 METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING SERTRALINE
- U-461 METHOD OF TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER (PMDD) USING SERTRALINE
- U-462 SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND ADULT RHEUMATOID ARTHRITIS AND TREATMENT OF PRIMARY DYSMENORRHEA
- U-463 VENOGRAPHY
- U-464 PERIPHERAL ARTERIOGRAPHY
- U-465 CT IMAGING OF THE HEAD
- U-466 TREATMENT OF IRRITABLE BOWEL SYNDROME
- U-467 USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR FOR TREATING HYPERTENSION
- U-468 METHOD OF USING FEXOFENADINE HCL IN TREATING ALLERGIC RHINITIS
- U-469 TREATMENT OF GASTROESOPHAGEAL REFLEX DISEASE (GERD) AND ERADICATION OF H.PYLORI TO REDUCE RISK OF DUODENAL ULCER RECURRENCE
- U-470 THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION
- U-471 METHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS
- U-472 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING METHYLPHENIDATE BI-MODAL RELEASE PROFILE EXTENDED-RELEASE CAPSULES
- U-473 TO REDUCE PLASMA CHOLESTEROL LEVELS IN A MAMMAL
- U-474 TO REDUCE PLASMA CHOLESTEROL LEVELS BY ADMIN EZETIMIBE IN COMBO WITH CHOLESTEROL BIOSYNTHESIS INHIB SELECTED FROM GROUP CONSISTING OF HMG COA REDUCTASE INHIBITORS INCL SIMVASTATIN
- U-475 TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY
- U-476 METHOD OF TREATING ANDROGEN RESPONSIVE/MEDIATED CONDITION IN MAMMAL BY ADMIN A SAFE, EFFECTIVE AMOUNT OF DUTASTERIDE OR PHARMACEUTICALLY ACCEPTABLE DERIVATIVE THEREOF..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY
- U-477 METHOD OF INHIBITING 5 ALPHA TESTOSTERONE REDUCTASE ENZYME WITH DUTASTERIDE OR ITS DERIVATIVE AND TREATING ANDROGEN RESPONSIVE/MEDIATED DISEASE INCLUDING BENIGN PROSTATIC HYPERPLASIA

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-478 METHOD OF TREATING HEPATITIS C VIRAL INFECTION BY CONTINUOUS PARENTERAL ADMINISTRATION OF INTERFERON ALPHA 2-10 MILLION IU WEEKLY, SUBCUTANEOUSLY, INJECTION OF POLYMER-INTERFERON ALPHA CONJUGATE-POLYMER IS PEG-INTERFERON IS ALPHA 2B
- U-479 METHOD OF USING PEG-INTRON/REBETOL COMBINATION THERAPY AND INTRON/REBETOL COMBINATION THERAPY
- U-480 CONTRAST AGENT FOR MRI
- U-481 DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID-LIKE ACTIVITY
- U-482 METHOD OF IN VITRO FERTILIZATION THERAPY INCLUDING MEANS FOR INDUCING OVULATION....
- U-483 METHOD FOR THE ADMINISTRATION OF DRUGS USING THAT COMPOUND
- U-484 METHOD OF TREATING A SKIN DISEASE WITH A CORTICOSTEROID-CONTAINING PHARMACEUTICAL COMPOSITION
- U-485 METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA)
- U-486 EXTERNAL PREPARATION FOR APPLICATION TO THE SKIN CONTAINING LIDOCAINE-DRUG RETAINING LAYER PLACED ON SUPPORT AND COMPRISES ADHESIVE GEL BASE 1-10% BY WEIGHT OF LIDOCAINE
- U-487 METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA)
- U-488 METHOD FOR REDUCING THE PAIN ASSOCIATED WITH HERPES-ZOSTER AND POST-HERPETIC NEURALGIA
- U-489 EXPECTORANT
- U-490 TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
- U-491 METHOD OF DELIVERING A DRUG TO THE LUNG
- U-492 METHOD FOR THE TREATMENT OF SKIN, SUFFERING FROM A CONDITION SELECTED FROM A GROUP CONSISTING OF NONACNE INFLAMMATORY DERMATOSES... COMPRISING APPLYING TO AFFECTED AREA. A THERAPEUTICALLY EFFECTIVE AMT AZELAIC ACID
- U-493 TREATMENT OF TYPE 2 DIABETES MELLITUS
- U-494 TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER
- U-495 PERITONEAL DIALYSIS SOLUTION
- U-496 METHOD FOR TREATING CHRONIC RENAL FAILURE
- U-497 RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS
- U-498 INTRA-ARTERIAL AND INTRAVENOUS USES OF ULTRAVIST
- U-499 METHOD OF USING REBETOL CAPSULES IN COMBINATION WITH A CONJUGATE COMPRISING POLYETHYLENE GLYCOL (PEG) AND AN ALPHA INTERFERON, INCLUDING, FOR EXAMPLE, PEG-INTRON POWDER FOR INJECTION
- U-500 USE AS AN ANTIHYPERTENSIVE AGENT
- U-501 TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS
- U-502 PITYRIASIS VERSICOLOR
- U-503 GENERATOR MUST BE USED WITH INFUSION SYSTEM SPECIFICALLY LABELED FOR USE WITH GENERATOR
- U-504 TINEA PEDIS, TINEA CRURIS, TINEA CORPORIS
- U-505 ULTRASOUND CONTRAST AGENT
- U-506 PHARM PRODUCT CONTAINER 1ST CHAMBER IS DISPOSED AQUEOUS DILUENT SOL 2ND CHAMBER PHARM ACTIVE AGENT COMPRISING ACETYLCHOLINE, BUFFER IN 1ST CHAM IS SUFFICIENT TO BUFFER PH OF MIXED SOL RESULTING MIXTURE OF AQUEOUS DILUENT SOL & PHARM ACTIVE..
- U-507 ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE
- U-508 METHOD OF RELEASING 17-BETA OESTRADIOL PRECURSOR IN A SUBSTANTIALLY ZERO ORDER PATTERN FOR AT LEAST THREE WEEKS
- U-509 TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-510 TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (STAGE IA AND IB) WHO HAVE REFRACTORY OR PERSISTENT DISEASE AFTER OTHER THERAPIES OR WHO HAVE NOT TOLERATED OTHER THERAPIES
- U-511 USE OF QUINOLONE COMPOUNDS AGAINST ANAEROBIC PATHOGENIC BACTERIA
- U-512 USE OF QUINOLONE COMPOUNDS AGAINST ATYPICAL UPPER RESPIRATORY PATHOGENIC BACTERIA
- U-513 METHODS OF USE OF ANTIMICROBIAL COMPOUNDS AGAINST PATHOGENIC MYCOPLASMA BACTERIA
- U-514 PREVENTION OF OVULATION IN A WOMAN
- U-515 TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON THE LAST THERAPY
- U-516 METHOD OF TREATING A PSYCHOTIC DISEASE
- U-517 STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS
- U-518 OBSESSIVE COMPULSIVE DISORDER
- U-519 POST OPERATIVE NAUSEA AND VOMITING
- U-520 PREMENOPAUSAL OSTEOPOROSIS
- U-521 METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTRON A (INTERFERON ALPHA-2 B RECOMBINANT) INJECTION TO TREAT PATIENTS WITH CHRONIC HEPATITIS C
- U-522 TREATMENT OF CMV RETINITIS BY INTRAVITREAL ADMIN OF A PHOSPHOROTHIOATE OLIGONUCLEOTIDE CAPABLE OF HYBRIDIZING WITH CMV MRNA
- U-523 METHOD OF TREATING INFECTION BY CRYPTOSPORIDIUM PARVUM IN AN IMMUNOCOMPROMISED MAMMAL
- U-524 METHOD OF TREATING DIARRHEA
- U-525 METHOD OF TREATING PARASITIC INFECTIONS
- U-526 METHOD OF PROVIDING CONTROLLED RELEASE OF A TREATING AGENT USING A CONTROLLED RELEASE COMPOSITION
- U-527 METHOD OF DELIVERING AN ACTIVE INGREDIENT USING A PROGRESSIVE HYDRATION BIOADHESIVE
- U-528 PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING
- U-529 ONCE DAILY TREATMENT OF ASTHMA WITH NEBULIZED BUDESONIDE
- U-530 TREATMENT OF HERPES ZOSTER, TREATMENT OF GENITAL HERPES, TREATMENT OF COLD SORES, SUPPRESSION OF GENITAL HERPES IN IMMUNOCOPETENT AND HIV-INFECTED INDIVIDUALS, REDUCTION OF RISK OF HETEROSEXUAL TRANSMISSION OF GENITAL HERPES
- U-531 TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION. MAY BE USED ALONE OR GIVEN WITH OTHER CLASSES OF ANTIHYPERTENSIVES, ESPECIALLY THIAZIDE DERIVATIVES
- U-532 TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD IN PATIENTS REQUIRING MORE THAN ONE BRONCHO DILATOR
- U-533 ERECTILE DYSFUNCTION
- U-534 HUMALOG IS AN INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS FOR THE CONTROL OF HYPERGLYCEMIA
- U-535 TREATMENT OF SOCIAL ANXIETY DISORDER
- U-536 CONTRAST AGENT FOR MAGNETIC RESONACE IMAGING
- U-537 TREATMENT OF CONDITIONS RELATED TO HYPERALDOSTERONISM SUCH AS HYPERTENSION AND CARDIAC INSUFFICIENCY, WITH EPLERENONE
- U-538 FIRST LINE TREATMENT OF SEVERE HYPERTENSION, IN PATIENTS WITH HYPERTENSION SEVERE ENOUGH THAT THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY IN THESE PATIENTS
- U-539 TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
- U-540 TREATMENT OF FUNGAL INFECTIONS
- U-541 METHOD OF TREATMENT OF ADULTS INFECTED WITH HIV-1
- U-542 METHOD OF TREATING PATIENT WITH TYPE 2 DIABETES BY ONCE DAILY ADMINISTRATION
- U-543 TREATMENT OF SCHIZOPHRENIA
- U-544 TREATMENT OF OVERACTIVE BLADDER. TREATMENT OF URINARY INCONTINENCE.

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-545 METHOD FOR THE PREVENTION AND/OR TREATMENT OF THROMBOTIC EPISODES, SUCH AS MYOCARDIAL INFARCTION, IN A HUMAN PATIENT AND METHOD FOR THE PREVENTION OF VENOUS THROMBOSIS IN A POSTOPERATIVE HUMAN PATIENT
- U-546 USE OF REPAGLINIDE IN COMBINATION WITH METFORMIN TO LOWER BLOOD GLUCOSE
- U-547 MAINTENANCE MONOTHERAPY FOR BIPOLAR DISORDER
- U-548 A METHOD OF REDUCING FLUSH IN AN INDIVIDUAL BEING TREATED FOR A LIPIDEMIC DISORDER AND EFFECTIVELY TREATING THE LIPIDEMIC DISORDER
- U-549 USE IN THE TREATMENT OF MEN WITH ADVANCED SYMPTOMATIC PROSTATE CANCER
- U-550 TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA
- U-551 METHOD FOR REDUCING TOXICITY OF ALIMTA TREATED PATIENTS BY ADMINISTERING FOLIC ACID
- U-552 TREATMENT OF HYPERTENSION AND HYPERLIPIDEMIA WITH A SINGLE COMPOSITION
- U-553 MANAGEMENT OF PAIN AND DISCOMFORT ASSOCIATED WITH PERIDONTAL SCALING AND ROOT PLANNING PROCEDURES BY APPLICATION OF AN EUTECTIC MIXTURE OF LOCAL ANESTHETICS TO PERIDONTAL POCKETS
- U-554 TREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS
- U-555 TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS
- U-556 USE AS ADJUNCT DIAGNOSTIC FOR SERUM THYROGLOBULIN (TG) TESTING
- U-557 NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
- U-558 INDICATED FOR THE RELIEF OF BRONCHOSPASM IN PATIENTS 2-12 YEARS OF AGE WITH ASTHMA (REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE)
- U-559 METHOD OF DECREASING OR REDUCING PARATHYROID HORMONE LEVEL; METHOD OF MODULATING PARATHYROID HORMONE SECRETION;METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF REDUCING SERUM IONIZED CALCIUM LEVEL
- U-560 METHOD OF DECREASING PARATHYROID HORMONE LEVEL;METHOD OF TREATING HYPERPARATHYROIDISM
- U-561 COSOPT IS INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION WHO ARE INSUFFICIENTLY RESPONSIVE TO BETA BLOCKERS
- U-562 TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA
- U-563 MARINOL IS INDICATED FOR, INTER ALIA, ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS
- U-564 TREATMENT OF HIV IN CONCOMITANT THERAPY
- U-565 TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS, AND CHRONIC URTICARIA
- U-566 FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
- U-567 METHOD OF TREATING INFERTILITY
- U-568 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION
- U-569 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THEREAFTER AN OVULATORY INDUCING AMOUNT OF HCG IS ADMINISTERED
- U-570 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THE DAILY AMOUNT OF FSH IS ABOUT 5-10 IU/KG
- U-571 TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA AND BIPOLAR I MANIA
- U-572 INTENSIVE CARE UNIT SEDATION
- U-573 TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)
- U-574 PROPHYLAXIS AND TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND TREATMENT OF THE NASAL SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
- U-575 LOTEMAX OPHTHALMIC SUSPENSION IS INDICATED FOR THE TREATMENT OF STEROID RESPONSIVE CONDITIONS OF THE PALPEBRAL BULBAR CONJUNCTIVA, CORNEA AND ANTERIOR

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

SEGMENT OF THE GLOBE.

- U-576 ALREX OPHTHALMIC SUSPENSION IS INDICATED FOR THE TEMPORARY RELIEF OF THE SIGNS AND SYMPTOMS OF SEASONAL ALLERGIC CONJUNCTIVITIS.
- U-577 TREATMENT OF BENIGN PROSTATIC HYPERPLASIA WITH FINASTERIDE IN COMBINATION WITH DOXAZOSIN
- U-578 TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA, ACUTE EXACERBATION OF CHRONIC BRONCHITIS, AND ACUTE BACTERIAL SINUSITIS CAUSED BY SUSCEPTIBLE STRAINS OF DESIGNATED MICROORGANISMS IN PATIENTS 18 YEARS AND OLDER.
- U-579 TREATMENT OF EPILEPSY AND/OR MIGRAINE.
- U-580 TREATMENT OF DISORDERS OF THE SEROTONERGIC SYSTEM SUCH AS DEPRESSION AND ANXIETY-RELATED DISORDERS
- U-581 METHOD OF TREATING A CONDITION CAPABLE OF TREATMENT BY INHALATION, E.G. ASTHMA, COMPRISING ADMINISTRATION OF A FORMULATION CLAIMED IN US PATENT NO. 6743413
- U-582 METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6253762
- U-583 METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING TO A PATIENT BY INHALATION, A METERED AEROSOL DOSE OF A DRUG FORMULATION FROM THE METERED DOSE INHALER SYSTEM CLAIMED IN US 6546928
- U-584 SINGLE-DOSE ADMINISTRATION BY THE EPIDURAL ROUTE, AT THE LUMBAR LEVEL, FOR THE TREATMENT OF PAIN FOLLOWING MAJOR SURGERY
- U-585 TO PROMOTE WEIGHT GAIN AFTER WEIGHT LOSS IN CERTAIN TYPES OF PATIENTS
- U-586 AN INTERMEDIATE RELEASE NICOTINIC ACID FORMULATION SUITABLE FOR ORAL ADMINISTRATION ONCE-A-DAY AS A SINGLE DOSE FOR TREATING HYPERLIPIDEMIA WITHOUT CAUSING DRUG-INDUCED HEPATOTOXICITY OR ELEVATIONS IN URIC ACID OR GLUCOSE OR BOTH
- U-587 USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR (AND OPTIONALLY A DIURETIC) FOR TREATING CONGESTIVE HEART FAILURE AND HYPERTENSION
- U-588 SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS
- U-589 METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN U.S. PATENT NO. 6131966
- U-590 METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING TO A PATIENT BY ORAL OR NASAL INHALATION A DRUG FORMULATION BY USING THE METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6532955
- U-591 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING A DOSAGE FORM WHICH PROVIDES ONCE-DAILY ORAL ADMINISTRATION OF A PHENIDATE DRUG
- U-592 TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
- U-593 TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
- U-594 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- U-595 35 MG ORALLY ONCE A WEEK FOR PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN; 35 MG ORALLY ONCE A WEEK FOR TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
- U-596 TREATMENT OF HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY
- U-597 FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT HIGH RISK FOR FRACTURE
- U-598 PROPHYLACTIC TREATMENT OF MIGRAINE
- U-599 METHOD FOR TREATING ALLERGIC CONJUNCTIVITIS
- U-600 A METHOD OF TREATING A PATIENT IN NEED OF OPHTHALMIC ANTIMICROBIAL THERAPY WITH LEVOFLOXACIN
- U-601 TREATMENT OF BIPOLAR DISORDER
- U-602 SIGNS AND SYMPTOMS OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS IN ADULTS, AND/OR

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS, ACUTE PAIN IN ADULTS; PRIMARY DYSMENORRHEA; AND/OR ACUTE MIGRAINE ATTACKS IN ADULTS
- U-603 METHOD OF TREATING INFECTIONS COMPRISING ORALLY ADMINISTERING AN EFFECTIVE AMOUNT OF THE FDA APPROVED ORAL SUSPENSION
- U-604 METHOD OF LOWERING BLOOD GLUCOSE BY ONCE DAILY ADMINISTRATION
- U-605 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD); ALTHOUGH THE MECHANISM OF THE ANTIDEPRESSANT ACTION OF DULOXETINE IN HUMANS IS UNKNOWN, IT IS BELIEVED TO BE RELATED TO ITS POTENTIATION OF SERATONERGIC AND NORADRENERGIC ACTIVITY IN THE CNS
- U-606 USE OF IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER
- U-607 CANCIDAS IS INDICATED FOR EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS.
- U-608 USE OF QUINOLONE COMPOUNDS AGAINST PNEUMOCOCCAL PATHOGENIC BACTERIA
- U-609 USE OF QUINOLONE COMPOUNDS AGAINST QUINOLONE-RESISTANT PNEUMOCOCCAL PATHOGENIC BACTERIA
- U-610 ATROVENT HFA (IPRATROPIUM BROMIDE HFA) INHALATION AEROSOL IS INDICATED AS A BRONCHODILATOR FOR MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA.
- U-611 METHOD OF USING DESLORATADINE TO TREAT SEASONAL AND PERENNIAL ALLERGIC RHINITIS, PRURITIS, AND CHRONIC IDIOPATHIC URTICARIA IN PATIENTS 2 YEARS OF AGE AND OLDER
- U-612 TREATMENT OF SEASONAL ALLERGY SYMPTOMS WITH NASAL CONGESTION IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER
- U-613 REDUCTION OF SERUM PHOSPHATE
- U-614 TREATMENT OF SEXUAL DYSFUNCTION
- U-615 ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TOTAL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)
- U-616 MANAGEMENT OF PERSISTENT, MODERATE TO SEVERE PAIN IN PATIENTS REQUIRING CONTINUOUS, AROUND-THE-CLOCK ANALGESIA WITH A HIGH POTENCY OPIOID FOR AN EXTENDED PERIOD OF TIME GENERALLY WEEKS TO MONTHS OR LONGER
- U-617 TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)
- U-618 USE OF ROSUVASTATIN CALCIUM TO REDUCE ELEVATED TOTAL-C, LDL-C, APOB, NONHDL-C OR TG LEVELS; TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA; AND TO SLOW THE PROGRESSION OF ATHEROSCLEROSIS.
- U-619 TREATMENT OF MALIGNANT NEOPLASM
- U-620 TREATMENT OF INSOMNIA
- U-621 METHOD OF TREATING CANCER
- U-622 TREATMENT OF VEGF MEDIATED OCULAR DISEASE.
- U-623 SHORT TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
- U-624 REDUCTION OF RISK OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS
- U-625 ALLERGIC RHINITIS OR NASAL POLYPS
- U-626 CLOLAR IS INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 TO 21 YEARS OLD WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA AFTER AT LEAST TWO PRIOR REGIMENS
- U-627 TREATMENT OF PATIENTS USING EXTENDED-RELEASE CARBAMAZEPINE
- U-628 USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA, AND IN COMBINATION WITH METFORMIN AND A SULFONYLUREA TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
- U-629 METHOD OF INDUCING A HYPNOTIC OR SEDATIVE EFFECT IN A HUMAN BY ADMINISTERING ESZOPICLONE
- U-630 TREATING URINARY INCONTINENCE BY ADMINISTERING AN EXTENDED-RELEASE FORM OF DARIFENACIN
- U-631 TREATING A DISEASE OF ALTERED MOTILITY OR TONE OF SMOOTH MUSCLE BY ADMINISTERING A MUSCARINIC RECEPTOR ANTAGONIZING AMOUNT OF DARIFENACIN

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-632 METHOD OF TREATMENT OF CANCER BY ADMINISTERING PARTICLES OF PACLITAXEL THAT HAVE A PROTEIN COATING

U-633 METHOD FOR TREATMENT OF TUMORS BY ADMINISTERING PACLITAXEL AT A DOSE IN THE RANGE OF ABOUT 30MG/METER SQUARE TO ABOUT 100MG/METER SQUARE IN A PHARMACEUTICALLY ACCEPTABLE FORMULATION THAT DOES NOT CONTAIN CREMOPHOR

U-634 METHOD FOR DELIVERY OF A BIOLOGIC (INCLUDING ANTINEOPLASTIC AGENTS) BY ADMINISTERING TO A PATIENT AN EFFECTIVE AMOUNT OF A BIOLOGIC AS A SOLID OR LIQUID WITH A POLYMERIC BIOCOMPATIBLE MATERIAL

U-635 TREATMENT OF GERD, MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS AND RISK REDUCTION OF NSAID ASSOCIATED GASTRIC ULCERS

U-636 TREATMENT OR PREVENTION OF BRONCHOSPASM OR ASTHMATIC SYMPTOMS

U-637 TREATMENT OF DIABETES WITH AN AMYLIN AGONIST

U-638 TREATMENT OF DIABETES WITH AN AMYLIN AGONIST, INCLUDING WITH INSULIN

U-639 TREATMENT OF A MAMMAL HAVING A NEED OF OR REDUCED ABILITY TO PRODUCE INSULIN WITH AN INSULIN AND AN AMYLIN SUCH AS PRAMLINTIDE

U-640 USE OF AN AMYLIN AGONIST TO REDUCE GASTRIC MOTILITY AND TREAT POST PRANDIAL HYPERGYLCEMIA

U-641 USE OF AN AMYLIN AGONIST HAVING SPECIFIED BINDING ACTIVITY TO REDUCE GASTRIC MOTILITY, INCLUDING USE THROUGH PARENTERAL ADMINISTRATION

U-642 TREATMENT AND PREVENTION OF OSTEOPOROSIS

U-643 THE SHORT TERM TREATMENT (UP TO 10 DAYS) IN PTS HAVING GASTROESOPHAGEAL REFLUX DISEASE (GERD) AS AN ALTERNATIVE TO ORAL THERAPY IN PTS WHEN THERAPY WITH NEXIUM CAPSULES IS NOT POSSIBLE OR APPROPRIATE

U-644 TREATMENT OF SEASONAL ALLERGIC RHINITIS

U-645 TREATMENT OF ASTHMA

U-646 METHOD OF TREATING OTITIS

U-647 TREATMENT OF OSTEOPOROSIS IN POST MENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS

U-648 THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN

U-649 A METHOD FOR TREATING A TUMOR DISEASE

U-650 TREATMENT OF ESOPHAGEAL CANDIDIASIS AND PROPHYLAXIS OF CANDIDA INFECTIONS IN HSCT PATIENTS

U-651 TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL)

U-652 TREATMENT OF CARDIAC ARRHYTHMIA

U-653 STIMULATING INSULIN RELEASE BY ADMINISTERING EXENATIDE

U-654 LOWERING PLASMA GLUCAGON IN A SUBJECT IN NEED THEREOF, INCLUDING ONE WITH TYPE 2 DIABETES, BY ADMINISTERING AN EXENDIN OR ANALOG, SUCH AS EXENDIN-4

U-655 TREATMENT OF MILD TO MODERATE ACTIVE CHROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON AND THE MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR ASCENDING COLON FOR UP TO 3 MONTHS

U-656 REDUCING GASTRIC MOTILITY OR DELAYING GASTRIC EMPTYING BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4

U-657 PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

U-658 TREATMENT OF ADVANCED HORMONE-DEPENDENT BREAST CANCER

U-659 TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) AFTER FAILURE OF AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN

U-660 TREATMENT OF HYPERTENSION AND TREATMENT OF HEART FAILURE

U-661 TREATMENT OF SEIZURE DISORDER

U-662 TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

U-663 THE TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS

U-664 TREATMENT OF CONDITIONS FOR WHICH AN ALDOSTERONE RECEPTOR BLOCKER IS INDICATED, SUCH AS HYPERTENSION, HEART FAILURE, AND POST-MYOCARDIAL INFARCTION

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-665 METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING

U-666 METHOD OF TREATING ADHD

U-667 MANAGEMENT OF INCONTINENCE; METHOD FOR TREATING INCONTINENCE

U-668 LEVEMIR IS A LONG-ACTING BASAL INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS

U-669 INDICATION OF TYPE II DIABETES

U-670 TREATMENT OF HIV-1 INFECTION BY THE CO-ADMINISTRATION OF TIPRANA VIR AND RITONA VIR.

U-671 PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 3 AND 4

U-672 TREATMENT OF INFLAMMATION OR AN INFLAMMATION-ASSOCIATED DISORDER

U-673 METHOD OF TREATMENT WITH ONCE-DAILY DOSES OF 625MG/5ML

U-674 METHOD OF TREATING INSOMNIA CHARACTERIZED BY DIFFICULTY WITH SLEEP ONSET

U-675 PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA; RELIEF OF SYMPTOMS OF ALLERGIC RHINITIS

U-676 METHOD OF TREATING ATTENTION DEFICIT DISORDER USING ORAL ADMINISTRATION OF A BI-MODAL OR PULSATILE RELEASE COMPOSITION

U-677 A METHOD OF TREATING DISEASE AMENABLE TO TREATMENT WITH A PHENIDATE DRUG BY ONCE DAILY ORAL ADMINISTRATION OF AN EXTENDED RELEASE DOSAGE FORM

U-678 METHOD OF TREATING ATTENTION DEFICIT DISORDER AND/OR ATTENTION DEFICIT HYPERACTIVITY DISORDER

U-679 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN

U-680 A METHOD OF TREATING DYSLIPIDEMIA AND DYSLIPOPROTEINEMIA USING A DOSAGE FORM THAT CAN PROVIDE AN EFFECTIVE AMOUNT OF FENOFIBRATE TO A PATIENT IN A FASTED STATE WHICH IS AT LEAST 90% OF THE AUC AMOUNT PROVIDED BY THE DOSAGE FORM

U-681 TREATMENT OF PRIMARY IGF-1 DEFICIENCY

U-682 NON-BENZODIAZEPINE HYPNOTIC AGENT INDICATED FOR TREATMENT OF INSOMNIA, CHARACTERIZED BY DIFFICULTIES WITH SLEEP ONSET AND/OR SLEEP MAINTENANCE

U-683 PREVENTION OR TREATMENT OF ISCHEMIC HEART DISEASE

U-684 TREATMENT OF UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER

U-685 EXPECTORANT AND COUGH SUPPRESSANT

U-686 EXPECTORANT AND NASAL DECONGESTANT

U-687 REDUCING FOOD INTAKE IN A SUBJECT WITH TYPE 2 DIABETES BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4

U-688 TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS

U-689 TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS

U-690 TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

U-691 USE AS A MONOTHERAPY, IN COMBINATION WITH A SULFONYLUREA, METFORMIN OR INSULIN OR IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

U-692 USE OF VALSARTAN TO REDUCE CARDIOVASCULAR MORTALITY IN CLINICALLY STABLE PATIENTS WITH LEFT VENTRICULAR FAILURE OR LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION

U-693 THE RECOMMENDED INITIAL DOSE OF EQUETRO IS 400MG/DAY GIVEN IN DIVIDED DOSES, TWICE DAILY. THE DOSE SHOULD BE ADJUSTED IN 200MG DAILY INCREMENTS TO ACHIEVE OPTIMAL CLINICAL RESPONSE.

U-694 LENALIDOMIDE IS AN ANALOGUE OF THALIDOMIDE. THALIDOMIDE IS A KNOWN HUMAN TERATOGEN THAT CAUSES SEVERE LIFE-THREATENING HUMAN BIRTH DEFECTS. IF LENALIDOMIDE IS TAKEN DURING PREGNANCY, IT MAY CAUSE BIRTH DEFECTS OR DEATH TO AN UNBORN BABY.

U-695 TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND T-CELL

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS

U-696 TREATMENT OF PATIENTS WITH T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS

U-697 A METHOD OF USING RINFABATE RECOMBINANT (RHIGFBP-3) WITH MECASERMIN RECOMBINANT (RHIGF-1) TO PROMOTE LINEAR GROWTH IN THE TREATMENT OF PRIMARY IGF-1 DEFICIENCY

U-698 METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATIENTS WITH EUVOLEMIC HYPONATREMIA

U-699 NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS

U-700 TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

U-701 TREATMENT OF HYPERCHOLESTEROLEMIA AND/OR HYPERTRIGLYCERIDEMIA

U-702 TOPICAL AEROSOL HAIR REGROWTH TREATMENT

U-703 TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMOR AND RENAL CELL CARCINOMA WITH SUNITINIB

U-704 METHOD OF ADMINISTERING INSULIN VIA INHALATION

U-705 TREATING CHRONIC ANGINA BY ADMINISTERING AN EXTENDED RELEASE FORM OF RANOLAZINE

U-706 TREATMENT OF BENIGN PROSTATIC HYPERPLASIA

U-707 ALLERGIC RHINITIS

U-708 TREATMENT OF CHRONIC NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE

U-709 METHOD OF COMBATING BACTERIA IN A PATIENT

U-710 A METHOD OF TREATING RESPIRATORY DISORDERS, E.G., ASTHMA, WHICH COMPRISES ADMINISTRATION BY INHALATION OF AN EFFECTIVE AMOUNT OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT NO. 5658549

U-711 ACUTE AND LONGER-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER

U-712 A METHOD OF USING A NICOTINIC ACID FORMULATION TO REDUCE ELEVATED TC, LDL-C AND TG LEVELS, AND RAISE HDL-C LEVELS IN PATIENTS WITH HYPERLIPIDEMIA

U-713 TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE

U-714 TOPICAL TREATMENT OF INTERDIGITAL TINEA PEDIS AND TINEA CORPORIS DUE TO TRICHOPHYTON RUBRUM, TRICHOPHYTON MENTAGROPHYTES OR EPIDERMOPHYTON FLOCCOSUM

U-715 FOR CLEANSING THE BOWEL IN PREPARATION FOR COLONOSCOPY, IN ADULTS 18 YEARS OF AGE OR OLDER

U-716 THE TREATMENT OR PREVENTION OF BRONCHOSPASM IN ADULTS AND CHILDREN 4 YEARS OF AGE AND OLDER WITH REVERSIBLE OBSTRUCTIVE AIRWAYS DISEASE AND THE PREVENTION OF EXERCISED-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER

U-717 METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT

U-718 TREATMENT OF FUNGAL INFECTIONS

U-719 TREATMENT OF PSYCHOSIS

U-720 TREATMENT OF NEUROLEPTIC DISEASES

U-721 TREATMENT OF INFLUENZA

U-722 PROPHYLAXIS OF INFLUENZA

U-723 PROPHYLACTIC TREATMENT OF MIGRAINE

U-724 METHOD OF TREATING SEIZURES

U-725 ALLERGIC RHINITIS AND URTICARIA

U-726 ALLERGIC RHINITIS

U-727 FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)

U-728 METHOD FOR TREATING BACTERIAL INFECTION

U-729 TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER, H. PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE

U-730 USE AS A NASAL SPRAY FOR TREATMENT OF THE SYMPTOMS OF SEASONAL ALLERGIC RHINITIS

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

AND VASOMOTOR RHINITIS

- U-731 USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
- U-732 ACUTE TREATMENT OF THE CUTANEOUS MANIFESTATIONS OF MODERATE TO SEVERE ERYTHEMA NODOSUM LEPROSUM (ENL)
- U-733 MAINTENANCE THERAPY FOR PREVENTION AND SUPPRESSION OF THE CUTANEOUS MANIFESTATIONS OF ENL RECURRENCE
- U-734 FIRST LINE THERAPY FOR TYPE 2 DIABETES MELLITUS
- U-735 METHOD OF TREATING CHRONIC IRON OVERLOAD
- U-736 METHOD FOR IONTOPHORETIC TRANSDERMAL DELIVERY OF FENTANYL HYDROCHLORIDE
- U-737 DISINFECTION OF PATIENT SKIN PRIOR TO AN INVASIVE PROCEDURE
- U-738 INDICATED FOR THE LONG-TERM, TWICE-DAILY MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE OR OLDER
- U-739 METHOD FOR TREATING CONSTIPATION BY OPENING CIC CHANNELS IN A MAMMALIAN SUBJECT
- U-740 FOR THE TREATMENT OF PATIENTS WITH PRIMARY BILIARY CIRRHOSIS
- U-741 COMBINATION THERAPY WITH CISPLATIN FOR THE TREATMENT OF LATE STAGE CERVICAL CANCER
- U-742 TWICE DAILY TOPICAL TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS.
- U-743 ONCE A DAY TOPICAL TREATMENT OF THE INFLAMMATORY LESIONS OF ROSACEA
- U-744 TREATMENT OF HIV INFECTION IN ANTIRETROVIRAL TREATMENT-EXPERIENCED ADULT PATIENTS
- U-745 TREATMENT OR PREVENTION OF EMESIS
- U-746 PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT
- U-747 PREVENTION OR TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING
- U-748 A METHOD FOR THE TREATMENT OF A PROTEIN TYROSINE KINASE-ASSOCIATED DISORDER
- U-749 METHOD OF CONTRACEPTION
- U-750 TREATMENT OF HIV-1 INFECTION IN ADULTS
- U-751 ONCE DAILY DOSING OF BUDESONIDE VIA NEBULIZER FOR THE TREATMENT OF ASTHMA
- U-752 SUNSCREEN
- U-753 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES
- U-754 USE FOR THE LONG-TERM MAINTENANCE TREATMENT OF ASTHMA
- U-755 TREATMENT OF ANOREXIA, CACHEXIA, OR AN UNEXPLAINED, SIGNIFICANT WEIGHT LOSS IN PATIENTS WITH A DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)
- U-756 ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
- U-757 USE AS A BILE ACID SEQUESTRANT FOR LOWERING CHOLESTEROL
- U-758 TREATMENT OF SYMPTOMS OF PREMENSTRUAL DYSPHORIC DISORDER
- U-759 METHOD OF USE OF ADMINISTERING LEVOTHYROXINE
- U-760 PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS AND TREATMENT OF OROPHARYNGEAL CANDIDIASIS
- U-761 TREATMENT OF SCHIZOPHRENIA INCLUDING MAINTAINING STABILITY IN PATIENTS WITH SCHIZOPHRENIA
- U-762 TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
- U-763 ADMINISTRATION OF ARIPIPRAZOLE BY INJECTION
- U-764 TREATMENT OF SCHIZOPHRENIA
- U-765 METHOD OF TREATING ALLERGIC CONJUNCTIVITIS
- U-766 TREATMENT OF SEIZURES
- U-767 MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-768 A METHOD OF REDUCING THE CAPACITY OF EXTENDED RELEASE NICOTINIC ACID TO PROVOKE A FLUSHING REACTION BY PRETREATING AN INDIVIDUAL WITH A FLUSH INHIBITING AGENT PRIOR TO THE ADMINISTRATION OF THE EXTENDED RELEASE NICOTINIC ACID
- U-769 REVLIMID (LENALIDOMIDE) IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
- U-770 LONG-TERM TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS
- U-771 METHOD FOR THE TREATMENT OF DIABETES MELLITUS, SUCH AS TYPE 1 DIABETES MELLITUS OR TYPE 2 DIABETES MELLITUS, IN A HUMAN PATIENT
- U-772 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN CHILDREN 2 TO 11 YEARS AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 MONTHS TO 11 YEARS
- U-773 PATHOLOGICAL HYPERSECRETORY CONDITIONS
- U-774 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
- U-775 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA
- U-776 TREATMENT OF CUTANEOUS MANIFESTATION IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL) WHO HAVE PROGRESSIVE, PERSISTENT OR RECURRENT DISEASE ON OR FOLLOWING TWO SYSTEMIC THERAPIES.
- U-777 DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE
- U-778 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
- U-779 A METHOD FOR TREATMENT OF A CANCER, WHEREIN THE CANCER IS CHRONIC MYELOGENOUS LEUKEMIA
- U-780 A METHOD FOR THE TREATMENT OF CANCER
- U-781 FOR TREATMENT OF ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE NAIVE TO PHARMACOLOGIC THERAPY
- U-782 TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS WITH EVIDENCE OF VIRAL REPLICATION AND EITHER EVIDENCE OF PERSISTANT ELEVATIONS IN SERUM AMINOTRANSFERASES (ALT OR AST) OR HISTOLOGICALLY ACTIVE DISEASE
- U-783 DESONATE GEL IS INDICATED FOR THE TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE AND OLDER
- U-784 TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS)
- U-785 USE AS REPLACEMENT SOLUTION, HEMOFILTRATION SOLUTION OR HEMODIAFILTRATION SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY
- U-786 PRODUCT IS APPROVED FOR THE TOPICAL TREATMENT OF TINEA PEDIS
- U-787 MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND PEDIATRIC PATIENTS SIX YEARS OF AGE OR OLDER, INCLUDING PATIENTS REQUIRING ORAL CORTICOSTEROID THERAPY FOR ASTHMA
- U-788 METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING PAROXETINE
- U-789 TREATMENT OF KNOWN OR SUSPECTED CYANIDE POISONING
- U-790 FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT RISK FOR FRACTURE. FORTEO CAN BE USED BY PEOPLE WHO HAVE HAD A FRACTURE RELATED TO OSTEOPOROSIS
- U-791 GLEEVEC IS ALSO INDICATED FOR THE TREATMENT OF PATIENTS WITH KIT (CD117) POSITIVE UNRESECTABLE AND/OR METASTATIC MALIGNANT GASTROINTESTINAL STROMAL TUMORS (GIST)
- U-792 TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS
- U-793 FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
- U-794 CLOSURE OF A CLINICALLY SIGNIFICANT PATENT DUCTUS ARTERIOSUS IN PREMATURE INFANTS WEIGHING BETWEEN 500 AND 1500G, WHO ARE NO MORE THAN 32 WEEKS GESTATIONAL AGE WHEN USUAL MEDICAL MANAGEMENT IS INEFFECTIVE
- U-795 METHOD FOR INHIBITING NOREPINEPHRINE UPTAKE

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-796 METHOD OF TREATING DEPRESSION

U-797 METHOD OF TREATING ANXIETY

U-798 TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN BY ONCE-MONTHLY ORAL ADMINISTRATION OF IBANDRONATE SODIUM MONOHYDRATE EQUIVALENT TO 150MG OF IBANDRONIC ACID

U-799 METHOD FOR INHIBITING SEROTONIN UPTAKE

U-800 TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER WHOSE TUMORS OVEREXPRESS HER2 AND WHO HAVE RECEIVED PRIOR THERAPY INCLUDING ANTHRACYCLINE, A TAXANE AND TRASTUZUMAB

U-801 METHOD OF TREATING CANCER

U-802 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR

U-803 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN

U-804 TREATMENT OF ACTINIC KERATOSES BY PHOTODYNAMIC THERAPY

U-805 TREATMENT OF IMPETIGO DUE TO STAPHYLOCOCCUS AUREUS OR STREPTOCOCCUS PYOGENES

U-806 INTRATHECAL TREATMENT OF LYMPHOMATOUS MENINGITIS

U-807 PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION

U-808 THE TREATMENT OF THE SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN PATIENTS 2 YEARS OF AGE AND OLDER

U-809 TREATMENT OF CHRONIC IDIOPATHIC URTICARIA

U-810 METHOD OF TREATMENT TO ALLEVIATE INFLAMMATION OF THE EYE

U-811 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS AND TREATMENT OF THE UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA

U-812 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS

U-813 MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

U-814 TREATMENT OF SCHIZOPHRENIA

U-815 TREATS COLD SORES/FEVER BLISTERS ON THE FACE OR LIPS. SHORTENS HEALING TIME AND DURATION OF SYMPTOMS: TINGLING, PAIN, BURNING AND/OR ITCHING

U-816 DEPRESSION, PANIC DISORDER, PREMENSTRUAL DISORDERS AND SOCIAL ANXIETY DISORDER

U-817 NASAL ADMINISTRATION OF CYANOCOBALAMIN

U-818 TOPICAL TREATMENT OF ACNE VULGARIS

U-819 MANAGEMENT OF FIBROMYALGIA

U-820 IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE SLEEPINESS ASSOCIATED WITH NARCOLEPSY, OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME, AND SHIFT WORK SLEEP DISORDER

U-821 METHOD OF INHIBITING ENTHOTHELIN RECEPTORS BY ADMINISTERING AMBRISENTAN TO A PATIENT TO TREAT PULMONARY ARTERIAL HYPERTENSION.

U-822 USE IN LIPID MANAGEMENT

U-823 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS AND FOR THE TREATMENT OF UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 TO 11 YEARS OF AGE

U-824 METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1

U-825 USE FOR PREVENTION OF BREAST CANCER

U-826 RELIEF OF MODERATE TO SEVERE PAIN

U-827 USE FOR TREATMENT OF DIABETES, PARTICULARLY TYPE 2 DIABETES

U-828 PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION

U-829 TREATMENT OF EXTRAVASATION RESULTING FROM IV ANTHRACYCLINE CHEMOTHERAPY

U-830 TREATMENT OF RELAPSED SMALL CELL LUNG CANCER

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-831 METHOD OF ADMINISTERING LANREOTIDE ACETATE

U-832 ZINGO IS INDICATED FOR THE USE ON INTACT SKIN TO PROVIDE LOCAL ANALGESIA PRIOR TO VENIPUNCTURE OR INTRAVENOUS CANNULATION.

U-833 METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.25% BY WEIGHT OF ROPIVACAINE

U-834 INVIRASE IN COMBINATION WITH RITONAVIR AND OTHER ANTIRETROVIRAL AGENTS IS INDICATED FOR THE TREATMENT OF HIV INFECTION

U-835 RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF ATOPIC DERMATITIS IN PATIENTS ONE YEAR OF AGE OR OLDER

U-836 A METHOD FOR THE TREATMENT OF LEUKEMIAS

U-837 GASTROINTESTINAL LAVAGE INDICATED FOR CLEANSING OF THE COLON AS A PREPARATION FOR COLONOSCOPY IN ADULTS

U-838 METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.5% BY WEIGHT OF ROPIVACAINE

U-839 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)

U-840 TREATMENT FOR TYPE 2 DIABETES MELLITUS

U-841 INDICATED FOR THE LONG-TERM, MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE AND OLDER

U-842 INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)

U-843 METHOD FOR ADMINISTRATION OF TESTOSTERONE

U-844 PREFEST IS INDICATED IN WOMEN WHO HAVE A UTERUS FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE; TREATMENT OF VULVAR AND VAGINAL ATROPHY; PREVENTION OF OSTEOPOROSIS

U-845 TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESES

U-846 USE FOR DELINEATION (VISUALIZATION) DURING A VITRECTOMY SURGICAL PROCEDURE

U-847 ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)

U-848 ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA

U-849 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP. DOSE IS ONE DROP OF COMBIGAN IN THE AFFECTED EYE TWICE DAILY

U-850 PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT

U-851 TREATMENT OF TYPE 2 DIABETES MELLITUS

U-852 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS

U-853 TREATMENT OR PREVENTION OF EMESIS

U-854 PREVENTION OF CMV DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)

U-855 METHOD TO INDUCE NATRIURESIS, DIURESIS AND/OR VASODILATION

U-856 SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN

U-857 INHIBITION OF TRANSPLANT REJECTION

U-858 PEDIATRIC USE AGED 1-11 YEARS, GERD AND EROSIIVE ESOPHAGITIS

U-859 EROSIIVE ESOPHAGITIS, HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME, MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS AND REDUCTION OF SYMPTOMS IN PATIENTS WITH GERD

U-860 FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION

U-861 RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-862 ADJUNCT TO DIET TO REDUCE ELEVATED TOTAL-C, LDL-C, NON-HDL-C, APO B, TG, AND LP(A) LEVELS AND TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, MIXED DYSLIPIDEMIA, AND HYPERTRIGLYCERIDEMIA
- U-863 TAKING ASPIRIN OR NON-STEROIDAL ANTI-INFLAMMATORY MEDICATIONS APPROXIMATELY 30 MINUTES BEFORE DOSING CAN MINIMIZE FLUSHING, A COMMON SIDE EFFECT OF NIACIN THERAPY
- U-864 PEDIATRIC USE AGES 1-2 YEARS, GERD AND EROSIIVE ESOPHAGITIS
- U-865 TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND A HIGH RISK FOR BONE FRACTURE BY REDUCING THE RISK OF VERTEBRAL AND NONVERTEBRAL BONE FRACTURE
- U-866 THE LABEL REFERENCES THE EFFECTS OF THE ACTIVE INGREDIENT OF REVLIMID UPON CYTOKINES
- U-867 TREATMENT OF MIGRAINE
- U-868 METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATIENTS WITH HYPERVOLEMIC HYONATREMIA
- U-869 METHOD FOR STIMULATING CORONARY VASODILATION FOR PURPOSES OF IMAGING THE HEART
- U-870 METHOD OF PRODUCING CORONARY VASODILATION WITHOUT PERIPHERAL VASODILATION
- U-871 METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH
- U-872 TWICE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA. TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS
- U-873 METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME BY OPENING CHLORIDE CHANNELS (CIC)
- U-874 METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME
- U-875 FIRST-LINE TREATMENT OF LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER, IN COMBINATION WITH GEMCITABINE
- U-876 TREATMENT OF MIGRAINE WITH OR WITHOUT AURA
- U-877 FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PEPTIC ULCER
- U-878 A METHOD FOR BINDING A PERIPHERAL OPIOID RECEPTOR
- U-879 A METHOD OF TREATING OR PREVENTING ILEUS
- U-880 ENDOMETRIN IS A PROGESTERONE INDICATED TO SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN
- U-881 TREATMENT OF NON-SMALL CELL LUNG CANCER
- U-882 MANAGEMENT OF FIBROMYALGIA (FM)
- U-883 TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB
- U-884 TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA
- U-885 TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY
- U-886 ADMINISTERING DESLORATADINE TO TREAT THE SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS, SEASONAL ALLERGIC RHINITIS, OR CHRONIC IDIOPATHIC URTICARIA
- U-887 TREATMENT AND PREVENTION OF OSTEOPOROSIS
- U-888 FEMALE HORMONE REPLACEMENT THERAPY FOR POSTMENOPAUSAL WOMEN
- U-889 MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE)
- U-890 REDUCTION OF SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE
- U-891 USE AS AN INTRAOCULAR IRRIGATING SOLUTION DURING SURGICAL PROCEDURES INVOLVING PERFUSION OF THE EYE
- U-892 TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL)
- U-893 CLEVIPREX IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INDICATED FOR THE REDUCTION OF BLOOD PRESSURE WHEN ORAL THERAPY IS NOT FEASIBLE OR NOT DESIRABLE
- U-894 TREATMENT OF COLD SORES IN PEDIATRIC PATIENTS TWELVE YEARS OF AGE AND OLDER

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-895 TREATMENT OF HIV INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS

U-896 TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN TWO YEARS OF AGE AND OLDER

U-897 METHOD OF TREATING TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES IN A ONCE-A-DAY AMOXICILLIN PRODUCT

U-898 USE OF GLUTAMINE TOGETHER WITH GROWTH HORMONE FOR THE TREATMENT OF PATIENTS WITH SHORT BOWEL SYNDROME

U-899 USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

U-900 INTEGRASE INHIBITION FOR THE TREATMENT OF HIV INFECTION

U-901 PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING

U-902 USE IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)

U-903 TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ADULT PATIENTS

U-904 TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE

U-905 TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE

U-906 PROPHYLAXIS OF ORGAN REJECTION IN KIDNEY, LIVER AND HEART ALLOGENIC TRANSPLANTS; TREATMENT OF PATIENTS WITH SEVERE ACTIVE, RHEUMATOID ARTHRITIS; TREATMENT OF ADULT, NONIMMUNOCOMPROMISED PATIENTS WITH SEVERE, RECALCITRANT, PLAQUE PSORIASIS

U-907 FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS IN SUBJECTS 18 YEARS OF AGE AND OLDER

U-908 PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS RECEIVING ALLOGENEIC RENAL TRANSPLANTS

U-909 TREATMENT OF CYSTIC FIBROSIS PATIENTS WITH PSEUDOMONAS AERUGINOSA

U-910 TREATMENT OF METASTATIC CARCINOMA OF THE OVARY AFTER FAILURE OF INITIAL OR SUBSEQUENT CHEMOTHERAPY

U-911 METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL TREATMENT IS TEMPORARILY NOT FEASIBLE

U-912 SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES

U-913 TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY

U-914 METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER

U-915 TREATMENT OF MUSCULOSKELETAL CONDITIONS

U-916 TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER

U-917 TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS

U-918 TO TREAT OR PREVENT INFECTIONS CAUSED BY SUSCEPTIBLE BACTERIA USING DELAYED-RELEASE TABLETS CONSISTING OF DOXYCYCLINE HYCLATE COATED PELLETS IN A TABLET

U-919 FOR THE TREATMENT OF DERMATITIS

U-920 STEROID-RESPONSIVE INFLAMMATORY OCULAR CONDITIONS FOR WHICH A CORTICOSTEROID IS INDICATED AND WHERE SUPERFICIAL BACTERIAL OCULAR INFECTION OR A RISK OF BACTERIAL OCULAR INFECTION EXISTS

U-921 TREATMENT OF ACNE VULGARIS

U-922 FOR THE TREATMENT OF FUNGAL INFECTIONS

U-923 METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION

U-924 TREATMENT OF MILD TO MODERATE INFECTION CAUSED BY SUSCEPTIBLE STRAINS

U-925 TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA

U-926 MGT SPECIFIC BACTERIAL INFECTIONS. TREATMENT PTS W/ COMMUNITY ACQUIRED PNEUMONIA OR BACTERIAL SINUSITIS DUE TO CONFIRMED, OR SUSPECTED B-LACTAMASE PRODUCING PATHOGENS & S. PNEUMONIAE WITH REDUCED SUSCEPTIBILITY TO PENICILLIN (MIC=2MC/ML)

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-927 METHOD FOR INCREASING TEAR PRODUCTION

U-928 TREATMENT OF BACTERIAL INFECTIOUS DISEASE

U-929 TREATMENT OF OBSESSIVE COMPULSIVE DISORDER TREATABLE WITH AN SSRI

U-930 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)

U-931 RELIEF OF MODERATE TO SEVERE ACUTE PAIN

U-932 PYLERA CAPSULES, IN COMBINATION WITH OMEPRAZOLE ARE INDICATED FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI

U-933 FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI. THE ERADICATION OF HELICOBACTER PYLORI HAS BEEN SHOWN TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE

U-934 IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELL TO THE PERIPHERAL BLOOD FOR COLLECTION AND SUBSEQUENT AUTOLOGOUS TRANSPLANTATION WITH NON-HODGKINS LYMPHOMA AND MULTIPLE MYELOMA

U-935 TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN ADULT PATIENTS, AND TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER

U-936 USE IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELLS TO PERIPHERAL BLOOD FOR COLLECTION & SUBSEQUENT AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA & MULTIPLE MYELOMA

U-937 TREATMENT OF PROSTATE CANCER

U-938 TREATMENT OF HAIR LOSS AND HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS

U-939 TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING AND STIMULATING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS

U-940 METHOD TO TREAT AIDS-RELATED KAPOSI'S SARCOMA

U-941 METHOD TO TREAT OVARIAN CANCER

U-942 METHOD TO TREAT MULTIPLE MYELOMA

U-943 GNRH ANTAGONIST INDICATED FOR TREATMENT OF PATIENTS WITH ADVANCED PROSTATE CANCER

U-944 TREATMENT OF PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

U-945 SEDATIVE-HYPNOTIC AGENT INDICATED FOR MONITORED ANESTHESIA CARE (MAC) SEDATION

U-946 TREATMENT OF BREAST CANCER

U-947 WHEN PATIENTS ARE UNABLE TO TAKE THE ORAL FORMULATIONS, PREVACID IV, FOR INJECTION IS INDICATED AS AN ALTERNATIVE FOR THE SHORT-TERM TREATMENT (UP TO 7 DAYS) OF ALL GRADES OF EROSIIVE ESOPHAGITIS

U-948 TREATMENT OF DIABETES MELLITUS

U-949 HEALING OF ALL GRADES OF EROSIIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS

U-950 MAINTAIN HEALING OF EROSIIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS

U-951 TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS

U-952 USE AS AN ANALGESIC

U-953 METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION

U-954 CHRONIC MANAGEMENT OF HYPERURICEMIA IN PATIENTS WITH GOUT. NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA

U-955 PROPHYLACTIC TREATMENT OF MIGRAINE

U-956 TREATMENT OF PATIENTS WITH H. PYLORI INFECTION AND DUODENAL ULCER DISEASE

U-957 A METHOD OF TREATING CANCER IN A PATIENT COMPRISING ADMINISTERING IXABEPILONE OR PHARMACEUTICAL COMPOSITIONS COMPRISING IXABEPILONE

U-958 METHOD OF TREATING PATIENT COMPRISING MIXING FIRST AND SECOND VIALS OF PRODUCT COMPRISING LYOPHILIZED IXABEPILONE TO PROVIDE AN EPOTHILONE ANALOG SOLUTION, DILUTING SOLUTION WITH A SUITABLE DILUENT TO PREPARE INTRAVENOUS FORMULATION FOR PT

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-959 METHOD OF TREATING CANCER, IV ADMIN, LYOPHILIZED IXABEPILONE DILUTED, EVERY WEEK OR 3 WEEKS; LYOPHILIZED IXABEPILONE WITH SOLVENT (DEHYDRATED ETHANOL) DILUTED TO CONCENTRATION OF 0.1MG/ML TO 0.9MG/ML
- U-960 METHOD OF TREATING CANCER IN A PATIENT COMPRISING INTRAVENOUSLY ADMINISTERING TO THE PATIENT IXABEPILONE DILUTED IN A PARENTERAL DILUENT
- U-961 METHOD OF TREATING BREAST CANCER BY ADMINISTERING IXABEPILONE; A METHOD OF TREATING A CANCER RESPONSIBLE TO MICROTUBULE STABILIZATION BY ADMINISTERING IXABEPILONE
- U-962 SYMBYAX IS INDICATED FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS
- U-963 PROZAC AND OLANZAPINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS
- U-964 ZYPREXA ZYDIS AND FLUOXETINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS
- U-965 USE OF IXABEPILONE IN COMBINATION WITH CAPECITABINE IN TREATMENT OF METASTASIS BREAST CANCER
- U-966 TREATMENT OF ASTHMA (MAINTENANCE AND PROPHYLACTIC THERAPY)
- U-967 A METHOD OF REVERSING SOFT-TISSUE ANESTHESIA I.E. ANESTHESIA OF THE LIP AND TONGUE, AND THE ASSOCIATED FUNCTIONAL DEFICITS RESULTING FROM AN INTRAORAL SUBMUCOSAL INJECTION OF A LOCAL ANESTHETIC
- U-968 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
- U-969 TREATMENT OF MIGRAINE
- U-970 TOPICAL TREATMENT OF LICE INFESTATIONS
- U-971 INDICATED FOR THE ACUTE TREATMENT OF ADULTS WITH SCHIZOPHRENIA
- U-972 MONOTHERAPY OR AS ADJUNCTIVE THERAPY TO LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER
- U-973 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH PIOGLITAZONE AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON PIOGLITAZONE OR METFORMIN ALONE
- U-974 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN
- U-975 TREATMENT OF PULMONARY HYPERTENSION
- U-976 IMPROVEMENT OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES
- U-977 TREATMENT OF ACUTE, UNCOMPLICATED MALARIA INFECTION DUE TO PLASMODIUM FALCIPARUM IN PATIENTS OF 5KG BODYWEIGHT AND ABOVE
- U-978 METHOD OF TREATING HYPONATREMIA
- U-979 RELIEF OF MUSCLE SPASM
- U-980 NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
- U-981 MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANTI-INFLAMMATORY, ANALGESIC, AND ANTIPYRETIC ACTIVITY
- U-982 A METHOD OF TREATING OSTEOPOROSIS
- U-983 METHOD OF TREATING OSTEOPOROSIS IN A POST-MENOPAUSAL WOMAN AT RISK FOR FRACTURE
- U-984 METHOD FOR THE TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND AT RISK FOR BONE FRACTURE
- U-985 TREATMENT OF MACULAR EDEMA FOLLOWING BRANCH RETINAL VEIN OCCLUSION (BRVO) OR CENTRAL RETINAL VEIN OCCLUSION (CRVO)
- U-986 TREATMENT OF PATIENTS INFECTED WITH PEDICULUS HUMANUS CAPITIS (HEAD LICE AND THEIR OVA) OF THE SCALP HAIR
- U-987 TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH CHRONIC KIDNEY DISEASE ON DIALYSIS
- U-988 TREATMENT OF RHINITIS COMPRISING THE NASAL APPLICATION OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT 7541350
- U-989 FOR REDUCING BLOOD PHENYLALANINE LEVELS IN A HUMAN SUFFERING FROM HYPERPHENYLALANINEMIA

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-990 TREATMENT OF PROTOZOAL INFECTION

U-991 TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISMS

U-992 REDUCTION OF THE RISK OF CARDIOVASCULAR HOSPITALIZATION

U-993 METHOD OF TREATING INFERTILITY

U-994 METHOD OF TREATMENT OF OSTEOPOROSIS WHEREIN THE OSTEOPOROSIS IS STEROID-INDUCED

U-995 METHOD FOR TREATING TYPE II DIABETES BY ADMINISTERING SAXAGLIPTIN

U-996 AN ADJUNCTIVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL (TC), LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPROTEIN B, TRIGLYCERIDES, AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIX DYSGLIPIDEMIA

U-997 TREATMENT OF MAJOR DEPRESSIVE DISORDER BY DOSING AT INTERVALS OF 24 HOURS

U-998 ADJUNCTIVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL, LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPROTEIN B, TRIGLYCERIDES AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSGLIPIDEMIA

U-999 TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS

U-1000 ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH HYPERLIPIDEMIAS

U-1001 METHOD FOR DELIVERING DRUG TO LUNG OF MAMMAL, COMPRISING ADMINISTERING DRUG PRODUCT BY INHALATION. TREATING A MAMMAL HAVING A CONDITION CAPABLE OF TREATMENT BY INHALATION, COMPRISING ADMINISTERING TO THE LUNG THE DRUG PRODUCT BY INHALATION

U-1002 METHOD OF TREATING INFLAMMATORY CONDITIONS

U-1003 A METHOD OF MYOCARDIAL PERFUSION IMAGING AND INCREASING CORONARY BLOOD FLOW

U-1004 TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA

U-1005 METHOD OF TREATING A STAPHYLOCOCCAL INFECTION

U-1006 NEW COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND ADOLESCENTS (12 YEARS OF AGE AND OLDER)

U-1007 METHOD OF TREATING GOUT FLARES

U-1008 APPLICATION OF ANTISEPTIC WITH MOISTURIZERS FOR SURGICAL AND HEALTHCARE PERSONNEL SKIN DISINFECTION

U-1009 METHOD FOR ADMINISTRATION OF TESTOSTERONE

U-1010 TO REDUCE BLOOD PHENYLALANINE LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA DUE TO TETRA HYDROBIOPTERIN RESPONSIVE PHENYLKETONURIA. KUVAN SHOULD BE TAKEN ORALLY WITH FOOD TO INCREASE ABSORPTION

U-1011 USE OF GRANISETRON TRANSDERMAL SYSTEM TO TREAT/PREVENT CHEMOTHERAPY INDUCED NAUSEA AND VOMITING

U-1012 METHOD FOR TREATING INSOMNIA WHILE REDUCING THE RISK OF AN ADVERSE DRUG INTERACTION

U-1013 METHOD OF USING RIBAVIRIN IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2B TO TREAT PATIENTS WITH CHRONIC HEPATITIS C

U-1014 METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTERFERON ALPHA-2B (PEGYLATED AND NONPEGYLATED) TO TREAT PATIENTS WITH CHRONIC HEPATITIS C

U-1015 TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA

U-1016 IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-EXPERIENCED ADULT PATIENTS, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO AN NNRTI AND OTHER ANTIRETROVIRAL AGENTS

U-1017 A METHOD OF TREATING NASAL AND NON-NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS

U-1018 TREATMENT OF PULMONARY HYPERTENSION BY INHALATION

U-1019 TREATMENT OF PULMONARY HYPERTENSION

U-1020 METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES

U-1021 SHORT-TERM TREATMENT (4-8 WEEKS) OF ACTIVE BENIGN GASTRIC ULCER

U-1022 FOR THE PREPARATION OF SKIN PRIOR TO SURGERY; HELPS REDUCE BACTERIA THAT CAN POTENTIALLY CAUSE SKIN INFECTION

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-1023 TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE

U-1024 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP

U-1025 TREATING FREQUENT HEARTBURN

U-1026 A METHOD OF TREATING HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS.

U-1027 REDUCTION OF ELEVATED PLASMA STEROL AND/OR STANOL LEVELS IN A MAMMAL

U-1028 A METHOD OF DISTRIBUTING SODIUM OXYBATE UNDER CONTROL OF A CENTRAL PHARMACY

U-1029 METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF

U-1030 IMPROVEMENT OF WALKING IN PATIENTS WITH MULTIPLE SCLEROSIS (MS)

U-1031 IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA

U-1032 USE OF ROSUVASTATIN CALCIUM FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN INDIVIDUALS WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH INCREASED RISK FACTORS

U-1033 TOPICAL TREATMENT OF ACNE VULGARIS

U-1034 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS

U-1035 NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN

U-1036 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN

U-1037 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH A PPAR-GAMMA AGONIST

U-1038 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN AND A PPAR-GAMMA AGONIST

U-1039 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN

U-1040 INHIBITION OF THROMBIN IN A PATIENT

U-1041 TREATMENT OF DISORDERS RESPONSIVE TO GROWTH HORMONE

U-1042 METHOD FOR STIMULATING CORONARY VASODILATION FOR PURPOSES OF IMAGING THE HEART

U-1043 MANAGEMENT OF MODERATE TO SEVERE PAIN

U-1044 TOPICAL TREATMENT OF SCALP PSORIASIS

U-1045 MAINTENANCE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHO HAVE NOT PROGRESSED ON 1ST-LINE TREATMENT WITH PLATINUM-BASED CHEMOTHERAPY

U-1046 MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES PLATINUM-BASED CHEMOTHERAPY

U-1047 TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA (SBCC)

U-1048 WORKS THROUGH THE INDUCTION OF INTERFERON AND OTHER CYTOKINES

U-1049 PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A RENAL TRANSPLANT

U-1050 USE OF METAXALONE FOR TREATMENT OF MUSCULOSKELETAL CONDITIONS

U-1051 TREATMENT OF OROPHARYNGEAL CANDIDIASIS

U-1052 RELIEF OF SIGNS AND SYMPTOMS OF ARTHRITIS AND RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER

U-1053 RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER

U-1054 ONYCHOMYCOSIS OF THE TOENAIL CAUSED BY TRICOPHYTON RUBRUM OR TRICHOPHYTON MENTAGROPHYTES, ONCE DAILY USE FOR 12 CONSECUTIVE WEEKS

U-1055 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH A THIAZOLIDINEDIONE (TZD) AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A TZD OR METFORMIN ALONE

U-1056 TREATMENT OF PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE

U-1057 TREATMENT OF INFLAMMATION AND PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-1058 USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

U-1059 ADJUNCTIVE THERAPY TO DIET TO PATIENTS WITH HYPERTRIGLYCERIDEMIA

U-1060 ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH ELEVATED CHOLESTEROL AND/OR LIPID LEVELS

U-1061 ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH MIXED DYSLIPIDEMIA

U-1062 ADMINISTRATION OF APPROVED PRODUCT FOR TREATMENT OF ALZHEIMER'S DISEASE

U-1063 TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA

U-1064 TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA

U-1065 METHOD OF TREATING ANDROGEN RESPONSIVE OR MEDICATED CONDITION IN A MAMMAL BY ADMINISTERING A SAFE & EFFECTIVE AMOUNT OF DUTASTERIDE OR A PHARMACEUTICALLY ACCEPTABLE SOLVATE THEREOF.. CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY

U-1066 METHOD OF TREATING AN ANDROGEN RESPONSE OR MEDIATED DISEASE IN A MAMMAL BY ADMINISTERING AN EFFECTIVE ANDROGEN RESPONSIVE OR MEDICATED DISEASE AMOUNT OF DUTASTERIDE..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERPLASIA

U-1067 TREATMENT OF CANCER

U-1068 TREATMENT OF ASTHMA

U-1069 A METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING AN EXCLUSIVE COMPUTER DATABASE IN A COMPUTER SYSTEM FOR DISTRIBUTION

U-1070 A METHOD TO CONTROL ABUSE OF A SENSITIVE DRUG BY CONTROLLING WITH A COMPUTER PROCESSOR THE DISTRIBUTION OF THE SENSITIVE DRUG VIA AN EXCLUSIVITY CENTRAL PHARMACY THAT MAINTAINS A CENTRAL DATABASE

U-1071 METHOD OF TREATING BLADDER DYSFUNCTION WITH ONCE A DAY TROSPRIUM SALT FORMULATION

U-1072 THE MANAGEMENT OF MODERATE TO SEVERE CHRONIC PAIN IN PATIENTS REQUIRING A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC FOR AN EXTENDED PERIOD OF TIME

U-1073 USE FOR THE TREATMENT OF ASTHMA AND COPD

U-1074 USE OF EXENATIDE MAY RESULT IN REDUCTION IN BODY WEIGHT

U-1075 USE FOR THE TREATMENT OF ASTHMA

U-1076 REDUCE CHRONIC SEVERE DROOLING (I.E., SIALORRHEA) IN PATIENTS WITH NEUROLOGIC CONDITIONS ASSOCIATED WITH PROBLEM DROOLING

U-1077 PRETREATMENT OF PATIENTS WITH VITAMIN B12 AND FOLIC ACID PRIOR TO PEMETREXED DISODIUM ADMINISTRATION

U-1078 TREATMENT OF ACNE

U-1079 REVLIMID (LENALIDOMIDE) IS INDICATED FOR THE TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)

U-1080 METHOD TO TREAT PULMONARY HYPERTENSION BY ADMINISTERING AMBRISENTAN TO A PATIENT

U-1081 LUMIGAN IS A PROSTAGLANDIN ANALOG INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION

U-1082 USE OF A COMBINATION OF TOBRAMYCIN AND DEXAMETHASONE TO TREAT OCULAR INFLAMMATION WHERE AN INFECTION OR RISK OF INFECTION EXISTS

U-1083 ACUTE TREATMENT OF MIGRAINE ATTACKS, WITH OR WITHOUT AURA, AND THE TREATMENT OF CLUSTER HEADACHE EPISODES

U-1084 RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER

U-1085 METHOD FOR TREATING IRRITABLE BOWEL SYNDROME AND METHOD FOR TREATING ABDOMINAL DISCOMFORT ASSOCIATED WITH IRRITABLE BOWEL SYNDROME

U-1086 TREATMENT OF AUTOIMMUNE DISEASE

U-1087 DETECTION OF NON-MUSCLE INVASIVE PAPILLARY CANCER OF THE BLADDER BY PHOTODYNAMIC CYSTOSCOPY

U-1088 RELIEF OF MUSCLE SPASM

U-1089 INHIBITION OF THROMBIN

U-1090 LO LOESTRIN FE IS INDICATED FOR THE PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-1091 ASSESSMENT OF BRONCHIAL HYPERRESPONSIVENESS IN PATIENTS 6 YEARS OF AGE OR OLDER WHO DO NOT HAVE CLINICALLY APPARENT ASTHMA

U-1092 TREATMENT OF BREAST CANCER

U-1093 TREATMENT OF PSEUDOBULBAR AFFECT

U-1094 MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN

U-1095 METHOD OF TREATING OCULAR INFLAMMATION

U-1096 TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER

U-1097 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH BOTH SAXAGLIPTIN AND METFORMIN IS APPROPRIATE

U-1098 METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA

U-1099 TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA

U-1100 REDUCTION OF EXCESS ABDOMINAL FAT IN HIV-INFECTED PATIENTS WITH LIPODYSTROPHY

U-1101 METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY

U-1102 METHOD OF TREATING CATAPLEXY IN PATIENTS WITH NARCOLEPSY

U-1103 TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE

U-1104 USE OF TRAMADOL FOR THE MANAGEMENT OF MODERATE TO MODERATELY SEVERE CHRONIC PAIN

U-1105 TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS FOUR (4) YEARS OF AGE AND OLDER

U-1106 TREATING HYPERTRIGLYCERIDEMIAS WITH REDUCTION OF FOOD EFFECT

U-1107 TREATING HYPERCHOLESTEROLEMIAS WITH REDUCTION OF FOOD EFFECT

U-1108 TREATING TYPE 2 DIABETES MELLITUS WITH EXENATIDE BY STIMULATING INSULIN RELEASE

U-1109 TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL) IN CONNECTION WITH A SPECIAL PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.)

U-1110 METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING A COMPUTER DATABASE IN A COMPUTER SYSTEM FOR DISTRIBUTION

U-1111 NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN

U-1112 METHOD OF MR IMAGING OF A MAMMAL

U-1113 TREATMENT AND PROPHYLAXIS OF INFLUENZA

U-1114 TREATMENT WITH GABAPENTIN, INCLUDING TREATMENT OF NEUROPATHIC PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH POSTHERPETIC NEURALGIA

U-1115 TREATMENT TO REDUCE THE RISK OF COPD EXACERBATIONS IN PATIENTS WITH SEVERE COPD ASSOCIATED WITH CHRONIC BRONCHITIS AND A HISTORY OF EXACERBATIONS

U-1116 METHOD OF ADMINISTERING COLCHICINE TO FAMILIAL MEDITERRANEAN FEVER PATIENTS

U-1117 TREATMENT OF BREAST CANCER

U-1118 USE FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA

U-1119 CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING

U-1120 TO REDUCE GASTROINTESTINAL SIDE EFFECTS ADMINISTER WITH A MEAL; AS STARTING DOSE ADMINISTER ONCE DAILY WITH EVENING MEAL

U-1121 METHOD OF TREATING TRAVELERS' DIARRHEA

U-1122 TREATMENT OF SECONDARILY INFECTED TRAUMATIC SKIN LESIONS DUE TO S. AUREUS AND S. PYOGENES

U-1123 TREATMENT OF ALCOHOL DEPENDENCE

U-1124 PREVENTION OF RELAPSE TO OPIOID DEPENDENCE, FOLLOWING OPIOID DETOXIFICATION

U-1125 METHOD FOR THE DETECTION OF NEUROENDOCRINE TUMORS

U-1126 USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE RECEIVED PRIOR CHEMOTHERAPY

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

CONTAINING DOCETAXEL

- U-1127 TREATMENT OF PATENT DUCTUS ARTERIOSUS
- U-1128 TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN IN ADULT PATIENTS (>=18 YEARS OF AGE) WITH COMPENSATED LIVER DISEASE
- U-1129 TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
- U-1130 SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR A NIGHT WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
- U-1131 TREATMENT OF HYPERTRIGLYDERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
- U-1132 TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-1133 SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-1134 TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-1135 TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A) AND INCREASE OF HDL-C
- U-1136 SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C
- U-1137 TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C
- U-1138 TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-1139 REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-1140 REDUCTION IN ELEVATED TC AND LDL-C BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-1141 REDUCTION IN TG BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-1142 TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
- U-1143 REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR A T NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
- U-1144 REDUCTION IN ELEVATED TC AND LDL-C BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
- U-1145 REDUCTION IN TG BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
- U-1146 REDUCTION IN TG WITH REDUCED FLUSHING BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-1147 TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C
- U-1148 REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C
- U-1149 TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
- U-1150 TRETMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION IN TOTAL-C, LDL-C, TG, LP(A), AND INCREASE OF HDL-C
- U-1151 TREATMENT OF HYPERTRIGLYCIDERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION IN TOTAL-C, LDL-C, LP(A), AND INCREASE OF HDL-C
- U-1152 CYANOCOBALAMIN ADMINISTRATION THROUGH NASAL INFUSION

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-1153 IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS, IS INDICATED FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTION IN ANTIRETROVIRAL TREATMENT-NAIVE ADULT PATIENTS, AS SET FORTH IN THE LABELING, INCLUDING I&U SECTION
- U-1154 TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMORS, RENAL CELL CARCINOMA AND ADVANCED PANCREATIC NEUROENDOCRINE TUMORS, WITH SUNITINIB
- U-1155 USE OF THALIDOMIDE IN TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL)
- U-1156 TO REDUCE BLOOD PHENYLALANINE (PHE) LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA (HPA)
- U-1157 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES IN ADULTS AND CHILDREN 2 YEARS OF AGE AND OLDER AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
- U-1158 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
- U-1159 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES, SWELLING OF THE NASAL PASSAGES AND SINUS CONGESTION AND PRESSURE IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER
- U-1160 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER AND 12 YEARS OF AGE AND OLDER
- U-1161 FOR THE TREATMENT AND PROPHYLAXIS OF GOUT FLARES & THE TREATMENT OF FAMILIAL MEDITERRANEAN FEVER
- U-1162 TREATMENT OF SEBORRHEIC DERMATITIS OF THE SCALP
- U-1163 METHOD OF TREATING THROMBOSIS
- U-1164 METHOD OF TREATING AN ARGATROBAN TREATABLE CONDITION
- U-1165 USE FOR THE TREATMENT OF MULTIPLE MYELOMA
- U-1166 A METHOD FOR TREATMENT OF GOUT FLARES DURING PROPHYLAXIS
- U-1167 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT)
- U-1168 THE LONG TERM, ONCE-DAILY MAINTENANCE BRONCHODILATOR TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
- U-1169 MANAGEMENT OF BREAKTHROUGH PAIN IN CANCER PATIENTS 18 YEARS OF AGE AND OLDER WHO ARE RECEIVING AND TOLERANT TO OPIOID THERAPY FOR THEIR UNDERLYING PERSISTENT CANCER PAIN
- U-1170 TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
- U-1171 REDUCTION OF THE RATE OF THROMBOTIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME
- U-1172 TO REDUCE ELEVATED TOTAL-C, APO B, AND NON-HDL-C IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE IN COMBINATION WITH A STATIN
- U-1173 TO REDUCE ELEVATED TOTAL-C, LDL-C, APO B AND NON-HDL-C IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE ALONE OR IN COMBINATION WITH A STATIN OR WITH FENOFIBRATE
- U-1174 ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE WATER FOR INJECTION, 0.9% SODIUM CHLORIDE INJECTION, OR FLOLAN STERILE DILUENT FOR INJECTION PRIOR TO ADMINISTRATION
- U-1175 REDUCTION OF CARDIAC TISSUE DAMAGE ASSOCIATED WITH MYOCARDIAL INFARCTION
- U-1176 TREATMENT OR PREVENTION OF STROKE
- U-1177 REDUCTION OF CARDIAC TISSUE DAMAGE ASSOCIATED WITH MYOCARDIAL INFARCTION
- U-1178 RELIEF OF MODERATE TO SEVERE CHRONIC PAIN
- U-1179 TREATMENT OF A CANCER MEDIATED BY AN ANAPLASTIC LYMPHOMA KINASE (ALK)
- U-1180 TREATMENT OF THE FOLLOWING INFECTIONS: COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED INFECTIVE ENDOCARDITIS

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-1181 A METHOD OF TREATING OR PREVENTING OCULAR PAIN IN A PATIENT

U-1182 TREATMENT OF CYCLIC HEAVY MENSTRUAL BLEEDING

U-1183 A METHOD FOR ADMINISTERING FOLLICLE STIMULATING HORMONE (FSH) FOR OVARIAN FOLLICLE OR TESTICULAR STIMULATION IN THE HUMAN

U-1184 TREATMENT OF ERECTILE DYSFUNCTION AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA

U-1185 TREATMENT OF OPIOID-INDUCED CONSTIPATION

U-1186 ADMINISTRATION OF AN INHALABLE POWDER COMPRISING TIOTROPIUM VIA DEVICE

U-1187 TREATMENT OF PATHOLOGICAL STATE BY ANTAGONIZING BRADYKININ RECEPTOR INCLUDING TREATMENT OF ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA (HAE)

U-1188 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE

U-1189 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH METFORMIN

U-1190 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH INSULIN

U-1191 METHOD OF TX TYPE 2 DM IN PTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBO WITH AN AGENT ACTING ON AN ATP-DEPENDENT CHANNEL IN BETA CELLS SUCH AS A SULFONYLUREA (INCL GLIPIZIDE, GLIMEPIRIDE & GLYBURIDE)

U-1192 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH A SULFONYLUREA (SUCH AS GLIPIZIDE, GLIMEPIRIDE AND GLYBURIDE)

U-1193 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH A PPAR-GAMMA AGONIST (SUCH AS PIOGLITAZONE AND ROSIGLITAZONE)

U-1194 METHOD FOR TREATING INSOMNIA

U-1195 PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 5, WHICH MAY RESULT IN RENAL OSTEODYSTROPHY, WHILE AVOIDING HYPERPHOSPHATEMIA

U-1196 RELIEF OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS AND TO DECREASE RISK OF DEVELOPING UPPER GASTROINTESTINAL ULCERS IN PATIENTS WHO ARE TAKING IBUPROFEN FOR THOSE INDICATIONS

U-1197 METHOD OF TREATMENT OF CHILDREN WITH CENTRAL PRECOCIOUS PUBERTY

U-1198 RECTIV IS A NITRATE VASODILATOR INDICATED FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH CHRONIC ANAL FISSURE

U-1199 TREATMENT AND PREVENTION OF POSTMENOPAUSAL OR GLUCOCORTICOID-INDUCED OSTEOPOROSIS AND TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS

U-1200 REDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM

U-1201 FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS

U-1202 METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME

U-1203 METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT

U-1204 TREATMENT OF UVEITIS

U-1205 TREATMENT OF MACULAR EDEMA

U-1206 DELIVERING AN OCULAR IMPLANT AS DESCRIBED IN THE DOSAGE AND ADMINISTRATION SECTION OF THE APPROVED LABELING OF OZURDEX

U-1207 INFANT USE AGED 1 MONTH TO LESS THAN ONE YEAR, GERD AND EROSIIVE ESOPHAGITIS

U-1208 TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS

U-1209 TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN ADULT PATIENTS, AND TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER

U-1210 USE OF REVLIMID (LENALIDOMIDE) WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO REVLIMID (LENALIDOMIDE)

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-1211 USE OF REVLIMID (LENALIDOMIDE) TO INHIBIT THE SECRETION OF PRO-INFLAMMATORY CYTOKINES, INCLUDING TUMOR NECROSIS FACTOR ALPHA

U-1212 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA AND TRANSFUSION-DEPENDENT ANEMIA IN MYELOYDYSPLASTIC SYNDROMES (MDS)

U-1213 TOPICAL TREATMENT OF SEBORRHEIC DERMATITIS IN IMMUNOCOMPETENT PATIENTS 12 YEARS OF AGE AND OLDER

U-1214 METHOD FOR RELIEVING CONSTIPATION IN A HUMAN PATIENT THAT COMPRISES ADMINISTERING TO THE PATIENT A DOSAGE UNIT COMPRISING (I) 24MCG+/- 10% OF A DRUG SUBSTANCE AND (II) A PHARMACEUTICALLY SUITABLE EXCIPIENT

U-1215 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF TRANSFUSION-DEPENDENT ANEMIA IN MYELOYDYSPLASTIC SYNDROMES (MDS)

U-1216 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA

U-1217 METHOD OF INCREASING HAIR GROWTH

U-1218 METHOD OF STIMULATING HAIR GROWTH

U-1219 METHOD OF INCREASING THE NUMBER OF HAIRS

U-1220 TREATMENT OF RENAL CELL CARCINOMA

U-1221 TO STIMULATE THE IMMUNE SYSTEM TO INDUCE T CELL PROLIFERATION

U-1222 TO INHIBIT THE PROLIFERATIVE ACTIVITY OF NEOPLASTIC CELLS

U-1223 METHOD FOR TREATING TYPE 2 DIABETES USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENATIDE

U-1224 REDUCTIONS IN BODY WEIGHT ARE OBSERVED WITH EXENATIDE

U-1225 ACCELERATING THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING PARTIAL LARGE OR SMALL BOWEL RESECTION SURGERY WITH PRIMARY ANASTOMOSIS

U-1226 A METHOD OF PROVIDING A PREDETERMINED CONCENTRATION OF NITRIC OXIDE TO A PATIENT

U-1227 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE

U-1228 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE ALONE OR IN COMBINATION WITH INSULIN

U-1229 TREATMENT OF MILDLY TO MODERATELY ACTIVE ULCERATIVE COLITIS IN MALE PATIENTS

U-1230 A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT

U-1231 TREATMENT OF MODERATE-TO-SEVERE PRIMARY RESTLESS LEG SYNDROME IN ADULTS

U-1232 USE AS ANTICOAGULANT IN PTS W/ UNSTABLE ANGINA UNDERGOING PTCA; W/ PROVISIONAL USE OF GLYCOPROTEIN IIB/IIIA INHIBITOR, AS ANTICOAGULANT IN PTS UNDERGOING PCI AND FOR PTS W/, OR AT RISK OF, HIT/HITTS UNDERGOING PCI.INTENDED FOR USE W/ASPIRIN

U-1233 TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION, ADMINISTERED WITH FOOD

U-1234 FOR REDUCING TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES, AND TREATING HYPERTRIGLYCERIDEMIA

U-1235 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION

U-1236 USE OF THALOMID (THALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA

U-1237 COMBO W/ OTHER ANTIRETROVIRALS FOR TX OF HIV-1 IN ANTIRETROVIRAL TX-EXPERIENCED PT 6 YEARS UP, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR AND OTHER ANTIRETROVIRALS

U-1238 TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE

U-1239 MAGNETIC RESONANCE IMAGING OF THE LIVER

U-1240 TREATMENT OF HEAVY MENSTRUAL BLEEDING IN WOMEN WITHOUT ORGANIC PATHOLOGY WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION

U-1241 MANAGEMENT OF MODERATE TO SEVERE PAIN BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED

U-1242 PREVENTION OF RESPIRATORY DISTRESS (RDS) IN PREMATURE INFANTS

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-1243 WITH DRY HANDS, GENTLY REMOVE THE SUPRENZA (PHENTERMINE HYDROCHLORIDE ODT) TABLET FROM THE BOTTLE. IMMEDIATELY PLACE THE SUPRENZA TABLET ON TOP OF THE TONGUE WHERE IT WILL DISSOLVE, THEN SWALLOW WITH OR WITHOUT WATER
- U-1244 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH SULFONYUREA
- U-1245 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH PIOGLITAZONE
- U-1246 SINGLE DOSE ADMINISTRATION INTO THE SURGICAL SITE TO PRODUCE POSTSURGICAL ANALGESIA
- U-1247 MANAGEMENT OF POSTHERPETIC NEURALGIA (PHN) IN ADULTS
- U-1248 USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL MEDICATION ON THE SAME KNEE
- U-1249 TREATMENT OF MALE PATIENT HAVING A DISEASE OR CONDITION RESPONSIVE TO A TERATOGENIC DRUG
- U-1250 TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY OR SPINAL CORD INJURY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA
- U-1251 A METHOD OF CONTROLLING POSTOPERATIVE OCULAR PAIN AND BURNING/STINGING IN A PATIENT
- U-1252 METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE
- U-1253 METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY
- U-1254 METHOD FOR CHRONIC WEIGHT MANAGEMENT BY CONTROLLING WEIGHT GAIN
- U-1255 METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY
- U-1256 TREATMENT OF SEBORRHEIC DERMATITIS
- U-1257 TREATMENT OF OPHTHALMIC DISORDERS
- U-1258 VISUALIZATION DURING VITRECTOMY PROCEDURES
- U-1259 PROPHYLAXIS OF HIV-1 INFECTION
- U-1260 TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY
- U-1261 REDUCTION OF THE RISK OF HOSPITALIZATION FOR ATRIAL FIBRILLATION
- U-1262 USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
- U-1263 TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) OR CHRONIC BRONCHITIS
- U-1264 TREATMENT OF A RESPIRATORY DISEASE
- U-1265 PATENTED METHOD OF USING REPAGLINIDE IN COMBINATION WITH METFORMIN AS INDICATED FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
- U-1266 METHOD OF TREATING MIDDLE-OF-THE-NIGHT INSOMNIA
- U-1267 TREATMENT OF RHEUMATOID ARTHRITIS BY DELAYED RELEASE FORMULATION OF 1MG OR 2MG OF PREDNISONE
- U-1268 TREATMENT OF PULMONARY, GASTROINTESTINAL AND/OR RHEUMATOLOGICAL DISEASES OR CONDITIONS BY USE OF DELAYED RELEASE FORMULATIONS OF 1MG OR 2MG PREDNISONE
- U-1269 TREATMENT OF RHEUMATOLOGIC, ALLERGIC, PULMONARY, GASTROINTESTINAL, DERMATOLOGIC DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 5MG PREDNISONE TABLET
- U-1270 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH INSULIN (WITH OR WITHOUT METFORMIN AND/OR PIOGLITAZONE)
- U-1271 TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE (PH-) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN SECOND OR GREATER RELAPSE OR WHOSE DISEASE HAS PROGRESSED FOLLOWING TWO OR MORE ANTI-LEUKEMIA THERAPIES
- U-1272 TREATMENT OF SIGNS AND SYMPTOMS OF PARKINSON'S DISEASE BY APPLICATION OF CLAIMED TRANSDERMAL SYSTEM
- U-1273 TREATMENT OF RESTLESS LEGS SYNDROME BY APPLICATION OF CLAIMED TRANSDERMAL

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

DELIVERY SYSTEM

- U-1274 TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY DUE TO CYSTIC FIBROSIS OR OTHER CONDITIONS
- U-1275 TREATMENT OF CHRONIC HEPATITIS B IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
- U-1276 MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
- U-1277 METHOD OF INCREASING EYELASH GROWTH INCLUDING LENGTH, THICKNESS, DARKNESS AND/OR NUMBER OF EYELASHES BY ADMINISTERING BIMATOPROST TO AN EYELID MARGIN
- U-1278 METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN ADULTS
- U-1279 TREATMENT OF HIV INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE
- U-1280 USE OF A CALCIPOTRIENE CONTAINING FOAM FOR THE TREATMENT OF PSORIASIS
- U-1281 THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE PREVIOUSLY RECEIVED DOCETAXEL
- U-1282 PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING
- U-1283 A METHOD OF TREATING CHRONIC MYELOGENOUS LEUKEMIA
- U-1284 A METHOD OF TREATING A NEOPLASM
- U-1285 TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS
- U-1286 A METHOD OF REDUCING THE RISK OF PULMONARY EDEMA IN PATIENTS IN NEED OF TREATMENT WITH INHALED NITRIC OXIDE
- U-1287 METHOD OF REDUCING TG LEVELS IN PATIENT SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA
- U-1288 TREATMENT OF ERECTILE DYSFUNCTION BY ADMINISTERING A FILM-COATED TABLET
- U-1289 MANAGEMENT OF MODERATE TO SEVERE ACUTE PAIN
- U-1290 TREATMENT OF LUNG CANCER
- U-1291 TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN PATIENTS WHOSE APL IS CHARACTERIZED BY THE PRESENCE OF THE (15;17) TRANSLOCATION OR PML/RAR-ALPHA GENE EXPRESSION
- U-1292 TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 1, 2, OR 5 MG PREDNISONE TABLET
- U-1293 A METHOD OF LOWERING INTRAOCULAR PRESSURE IN A PATIENT WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
- U-1294 METHOD OF TREATING GLAUCOMA IN A PATIENT
- U-1295 A METHOD OF TREATING A PATIENT WITH GLAUCOMA OR OCULAR HYPERTENSION
- U-1296 USE OF PEMETREXED WITH PRIOR AND/OR REPEATED VITAMIN B12 AND FOLIC ACID ADMINISTRATION
- U-1297 TREATMENT OF PULMONARY ARTERIAL HYPERTENSION BY INHIBITING ENDOTHELIN RECEPTORS
- U-1298 ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES
- U-1299 TREATMENT OF PATIENTS WITH LEUKEMIA INCLUDING CHRONIC MYELOID/MYELOGENOUS LEUKEMIA (CML)
- U-1300 TREATMENT OF PATIENTS WITH TYROSINE KINASE INHIBITOR (TKI) RESISTANT OR INTOLERANT CHRONIC MYELOID/MYELOGENOUS LEUKEMIA (CML)
- U-1301 TREATMENT OF DEEP VEIN THROMBOSIS (DVT)
- U-1302 TREATMENT OF PULMONARY EMBOLISM (PE)
- U-1303 REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM
- U-1304 USE OF ONCE-A-DAY AMOXICILLIN PRODUCT TO TREAT TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES
- U-1305 TREATMENT OF HIV-1 INFECTION IN ADULT PATIENTS, AND TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER, CO-ADMINISTERED WITH RITONAVIR (PREZISTA/RITONAVIR) AND WITH OTHER ANTIRETROVIRAL AGENTS
- U-1306 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-1307 IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-NAIVE ADULT PATIENTS WITH HIV-1 RNA LESS THAN OR EQUAL TO 100,000 AT THE START OF THERAPY

U-1308 MULTIPLE MYELOMA

U-1309 BONE METASTASES

U-1310 FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS

U-1311 METHOD OF TREATING CYSTIC FIBROSIS

U-1312 USE FOR THE TREATMENT OF HYPERGLYCEMIA

U-1313 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS

U-1314 USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

U-1315 THE LONG TERM TREATMENT OF PROPHYLACTIC MANAGEMENT OF OCULAR HYPERTENSION AND GLAUCOMA

U-1316 A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES

U-1317 TREATMENT OF HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA AND HYPERLIPOPROTEINEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

U-1318 TREATMENT OF HYPERCHOLESTEROLEMIA BY DECREASING THE AMOUNT OR ACTIVITY OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

U-1319 SYMPTOMATIC RELIEF OF NON-INFECTIOUS DIARRHEA

U-1320 TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME WHO ARE DEPENDENT ON PARENTERAL SUPPORT

U-1321 TREATMENT OF PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS

U-1322 METHOD OF REDUCING OCULAR HYPERTENSION

U-1323 REDUCING THE RISK OF STROKE

U-1324 MANAGEMENT OF CYSTIC FIBROSIS PATIENTS

U-1325 INDUCTION OF REMISSION IN PATIENTS WITH ACTIVE, MILD TO MODERATE ULCERATIVE COLITIS

U-1326 METHOD OF INDUCING CONTRACEPTION IN A FEMALE OF REPRODUCTIVE AGE WHO HAS NOT YET REACHED PREMENOPAUSE

U-1327 METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF, USING A FLOWABLE HYDROGEL FORMULATION

U-1328 METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF

U-1329 TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER

U-1330 METHODS OF TREATING LIPID METABOLISM AND GLYCOMETABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER

U-1331 METHODS OF REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER

U-1332 METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER

U-1333 METHODS OF LOWERING ELEVATED POST PRANDIAL BLOOD GLUCOSE LEVELS COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR

U-1334 METHODS OF TREATING DIABETES COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER

U-1335 METHODS OF MODIFYING GLUCOSE METABOLISM AND TREATING DIABETES COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR AND ONE OR MORE OTHER THERAPEUTIC AGENTS SUCH AS METFORMIN

U-1336 METHODS OF TREATING DIABETES COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

INHIBITOR AND METFORMIN

- U-1337 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
- U-1338 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
- U-1339 METHODS OF TREATING DIABETES COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
- U-1340 METHODS OF TREATING LIPID METABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
- U-1341 METHODS OF TREATING GLYCOMETABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
- U-1342 METHODS OF REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
- U-1343 METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
- U-1344 METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN PREPARATION
- U-1345 USE IN RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN PATIENT WITH A DOSAGE UNIT COMPRISING 24MICROG+/- 10% OF A DRUG SUBSTANCE AND A PHARMACEUTICALLY SUITABLE EXCIPIENT
- U-1346 USE OF FEBUXOSTAT FOR THE MANAGEMENT OF HYPERURICEMIA IN PATIENTS SUFFERING FROM GOUT AND, WHEN USED WITH THEOPHYLLINE WITHOUT THE NEED FOR DOSE ADJUSTMENT OF THEOPHYLLINE
- U-1347 TREATMENT OF A SKIN DISORDER
- U-1348 TREATMENT OF OSTEOARTHRITIS
- U-1349 TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS
- U-1350 TREATMENT OF ANKYLOSING SPONDYLITIS
- U-1351 TREATMENT OF ACUTE PAIN
- U-1352 TREATMENT OF PRIMARY DYSMENORRHEA
- U-1353 ADJUNCTIVE THERAPY TO LIPID-LOWERING MEDICATIONS AND DIET TO REDUCE LOW DENSITY LIPOPROTEIN-CHOLESTEROL, APOLIPOPROTEIN B, TOTAL CHOLESTEROL, AND NON-HIGH DENSITY LIPOPROTEIN CHOLESTEROL IN PTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
- U-1354 INHIBITION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN HYPERSTIMULATION WITH FSH
- U-1355 MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHOD FOR TREATING A RESPIRATORY DISEASE IN A CHILD
- U-1356 TREATMENT OF NASAL SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER. TREATMENT OF NASAL SYMPTOMS ASSOCIATED W PERENNIAL ALLERGIC RHINITIS IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER
- U-1357 TREATMENT OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHODS FOR TREATING A RESPIRATORY DISEASE IN A CHILD
- U-1358 TREATMENT OF BACTERIAL INFECTIONS IN THE NASAL PASSAGE OF ADULT PATIENTS AND HEALTH CARE WORKERS WITH METHICILLIN RESISTANT S. AUREUS
- U-1359 USE OF POMALIDOMIDE TO INHIBIT THE SECRETION OF PRO-INFLAMMATION CYTOKINES, INCLUDING TUMOR NECROSIS FACTOR ALPHA
- U-1360 USE OF POMALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA
- U-1361 USE OF POMALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO POMALIDOMIDE
- U-1362 TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED-RELEASE 1,2, OR 5MG PREDNISONE TABLET

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-1363 A METHOD OF TREATING OR PREVENTING OCULAR PAIN AND BURNING/STINGING FOLLOWING CORNEAL SURGERY
- U-1364 MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
- U-1365 PROPHYLAXIS OF ALLOGRAFT REJECTION IN ADULT PATIENTS RECEIVING A LIVER TRANSPLANT
- U-1366 TREATMENT OF INFERTILITY THROUGH INDUCTION OF OVULATION AND PREGNANCY TO ANOVULATORY INFERTILE WOMEN
- U-1367 METHOD OF ADMINISTERING FSH FOR THE TREATMENT OF INFERTILITY THROUGH INDUCTION OF OVULATION AND PREGNANCY IN ANOVULATORY INFERTILE WOMEN
- U-1368 TREATMENT OF SOLID EXCRETORY SYSTEM TUMORS; ADVANCED RENAL CELL CARCINOMA (RCC), AFTER FAILURE OF TREATMENT WITH SUNITINIB OR SORAFENIB
- U-1369 TREATMENT OF VAGINAL SYMPTOMS OF UROGENITAL ATROPHY BY ORALLY ADMINISTERING OSPEMIFENE WITH FOOD TO ENHANCE BIOAVAILABILITY OF OSPEMIFENE
- U-1370 TREATMENT OF DYSpareunia ASSOCIATED WITH MENOPAUSE
- U-1371 REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH ELEVATED INTRAOCULAR PRESSURE OR GLAUCOMA
- U-1372 ADMINISTRATION WITHOUT FOOD FOR TREATMENT OF HIV-1 INFECTION
- U-1373 METHOD OF TREATING ACETAMINOPHEN OVERDOSE WITH ACETYLCYSTEINE SOLUTIONS
- U-1374 TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML)
- U-1375 ADASUVE IS A TYPICAL ANTIPSYCHOTIC INDICATED FOR THE ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I DISORDER IN ADULTS
- U-1376 TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS
- U-1377 IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA
- U-1378 TREATMENT OF A NITROGEN METABOLISM DISORDER
- U-1379 IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS
- U-1380 IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS WHEREIN THE PATIENT HAS CARDIOVASCULAR DISEASE
- U-1381 USE OF PRASUGREL AND ASPIRIN IN PATIENTS REQUIRING THE REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS
- U-1382 TREATMENT OF NAUSEA AND VOMITING OF PREGNANCY IN WOMEN WHO DO NOT RESPOND TO CONSERVATIVE MANAGEMENT
- U-1383 DOSAGE ADJUSTMENT OF A NITROGEN SCAVENGING DRUG IN THE TREATMENT OF A UREA CYCLE DISORDER
- U-1384 METHOD OF TREATING MULTIPLE SCLEROSIS
- U-1385 METHOD OF TREATING AN AUTOIMMUNE DISEASE SELECTED FROM AUTOIMMUNE POLYARTHRITIS AND MULTIPLE SCLEROSIS BUT NOT TREATING PSORIATIC ARTHRITIS
- U-1386 A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF A PERSON IN NEED THEREOF
- U-1387 REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF WITHOUT SEVERE HEART FAILURE AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS
- U-1388 TREATMENT OF PATIENTS WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF WITHOUT SEVERE HEART FAILURE AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS
- U-1389 ELLA IS A PROGESTERONE AGONIST/ANTAGONIST EMERGENCY CONTRACEPTION INDICATED FOR THE PREVENTION OF PREGNANCY FOLLOWING UNPROTECTED INTERCOURSE OR A KNOWN OR SUSPECTED CONTRACEPTIVE FAILURE. ELLA CAN BE TAKEN WITH OR WITHOUT FOOD
- U-1390 A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF AN ADULT MALE SUBJECT IN NEED THEREOF
- U-1391 METHOD FOR TREATING OPIOID-INDUCED CONSTIPATION
- U-1392 METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN PATIENT WITH OPIOID-INDUCED CONSTIPATION

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-1393 METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION
- U-1394 METHOD FOR RELIEVING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION THAT COMPRISES ADMINISTERING TO THE PATIENT A DOSAGE UNIT COMPRISING (I) 24MICROG +/- 10% OF A DRUG SUBSTANCE AND (II) A PHARMACEUTICALLY SUITABLE EXCIPIENT
- U-1395 USE IN RELIEVING OR PREVENTING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION WITH A DOSAGE UNIT COMPRISING 24MICROG +/- 10% OF A DRUG SUBSTANCE AND A PHARMACEUTICALLY SUITABLE EXCIPIENT
- U-1396 TREATMENT OF ADVANCED HORMONE RECEPTOR POSITIVE, HER2-NEGATIVE BREAST CANCER IN COMBINATION WITH EXEMESTANE AFTER FAILURE OF TREATMENT WITH LETROZOLE OR ANASTROZOLE
- U-1397 USE AS AN ANTISEPTIC FOR THE PREPARATION OF A PATIENT'S SKIN PRIOR TO SURGERY
- U-1398 METHOD OF TREATING CHRONIC HEPATITIS C
- U-1399 MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES
- U-1400 FOR THE TREATMENT OF PRIMARY HYPERLIPIDEMIA, MIXED HYPERLIPIDEMIA OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
- U-1401 INDICATED FOR LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PTS WITH A HISTORY OF EXACERBATIONS
- U-1402 FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR INDOLENT B-CELL NON-HODGKIN LYMPHOMA (NHL)
- U-1403 FIRST-LINE TREATMENT OF METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) WITH EGFR EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
- U-1404 METHOD FOR TREATING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION BY OPENING CIC CHANNELS
- U-1405 THERAPEUTIC TREATMENT OF BONE METASTASES
- U-1406 TREATMENT OF MELANOMA
- U-1407 TREATMENT OF NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH + CML)
- U-1408 TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 18 YEARS OF AGE OR OLDER
- U-1409 TREATMENT OF HIV-1 BY ONCE DAILY ADMINISTRATION
- U-1410 TREATMENT OF CORTICOSTEROID-RESPONSIVE DERMATOSES
- U-1411 THIS DRUG IS ADMINISTERED BY SUBLINGUAL ROUTE TO HUMANS FOR MAINTENANCE TREATMENT OF OPIOID DEPENDENCE
- U-1412 TREATMENT OF ATOPIC DERMATITIS
- U-1413 ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH FLOLAN STERILE DILUENT FOR INJECTION PRIOR TO INFUSION
- U-1414 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MANTLE CELL LYMPHOMA (MCL)
- U-1415 TREATING A PATIENT HAVING A CONDITION SUSCEPTIBLE TO TREATMENT WITH METHYLPHENIDATE, SUCH AS ADHD, BY ADMINISTERING THE FORMULATION RECITED IN CLAIMS 1 OR 2
- U-1416 USE OF FENOFIBRATE FOR REDUCING ELEVATED TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES
- U-1417 USE FOR TREATMENT OF HELICOBACTER INFECTIONS
- U-1418 TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAFV600E MUTATION AS DETECTED BY AN FDA APPROVED TEST
- U-1419 TREATMENT OF ACUTE CYANIDE POISONING THAT IS JUDGED TO BE LIFE THREATENING
- U-1420 METHOD OF ONCE A DAY ADMINISTRATION
- U-1421 SUBLINGUAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE
- U-1422 METHOD OF TREATING PATIENTS NEEDING AN IRON SUPPLEMENT
- U-1423 AMYVID IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET)

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- IMAGING OF THE BRAIN TO ESTIMATE BETA-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT
- U-1424 LONG-TERM, ONCE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS
- U-1425 SUBLINGUAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE AND NALOXONE
- U-1426 USE FOR TREATMENT OF DIAPER DERMATITIS COMPLICATED BY CANDIDIASIS
- U-1427 ALKYLATING DRUG INDICATED FOR THE TOPICAL TREATMENT OF STAGE IA AND IB MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO HAVE RECEIVED PRIOR SKIN DIRECTED THERAPY
- U-1428 TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA
- U-1429 TREATMENT OF PATIENTS WITH BREAST CANCER WHOSE TUMORS OVEREXPRESS THE HER2 RECEPTOR
- U-1430 TREATMENT OF ALLERGIC RHINITIS, INCLUDING SEASONAL AND PERENNIAL ALLERGIC RHINITIS
- U-1431 METHOD OF TREATING HYPERGLYCEMIA TO IMPROVE GLYCEMIC CONTROL IN A PATIENT BY ORAL ADMIN OF ONCE A DAY OSMOTIC DOSAGE FORM OF GLIPIZIDE WITH POLYETHYLENE OXIDE, HYDROXYPROPYLMETHYLCELLULOSE, CELLULOSE ACETATE, AND SODIUM CHLORIDE
- U-1432 METHOD OF TREATMENT OF IRON-RELATED CONDITIONS WITH AT LEAST 0.6 GRAMS OF ELEMENTAL IRON VIA AN IRON CARBOHYDRATE COMPLEX
- U-1433 IMPROVEMENTS OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS
- U-1434 TREATMENT OF PANCREATIC CANCER
- U-1435 COMBINATION USE OF TOPICAL DICLOFENAC ON THE KNEE AND ADMINISTRATION OF AN ORAL NSAID.
- U-1436 USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL AGENT SELECTED FROM SUNSCREEN AND INSECT REPELLANT
- U-1437 ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE DILUENT FOR FLOLAN OR STERILE DILUENT FOR EPOPROSTENOL SODIUM PRIOR TO ADMINISTRATION
- U-1438 ZINGO INTRADERMAL INJECTION SYSTEM IS A DRUG DELIVERY SYSTEM THAT IS CAPABLE OF DELIVERING FINE DRY POWDERED LIDOCAINE HYDROCHLORIDE MONOHYDRATE FOR LOCAL ANESTHETIC ACTION
- U-1439 METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION
- U-1440 USE OF INGENOL MEBUTATE TO TREAT ACTINIC KERATOSIS
- U-1441 A METHOD OF TREATING OR REDUCING OCULAR PAIN AND BURNING/STINGING
- U-1442 SUBCUTANEOUS INJECTION OF METHOTREXATE
- U-1443 ACCELERATING THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING SURGERIES THAT INCLUDE PARTIAL BOWEL RESECTION WITH PRIMARY ANASTOMOSIS
- U-1444 A DOSING REGIMEN OF AGGRASTAT (TIROFIBAN HYDROCHLORIDE) (25MCG/KG FOLLOWED BY 0.15MCG/KG/MIN INFUSION) TO REDUCE THE RATE OF THROMBOTIC CORONARY EVENTS ASSOCIATED WITH ACUTE CORONARY SYNDROME (ACS) IN PATIENTS WITH NON-ST ELEVATION ACS
- U-1445 METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION BY ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING MACITENTAN AND A POLYSORBATE, WHEREIN THE POLYSORBATE REPRESENTS 0.1 TO 1% OF THE WEIGHT OF SAID PHARMACEUTICAL COMPOSITION
- U-1446 METHOD OF TREATING PULMONARY HYPERTENSION COMPRISING ADMINISTERING MACITENTAN IN COMBINATION WITH A COMPOUND HAVING PHOSPHODIESTERASE-5 INHIBITORY PROPERTIES
- U-1447 TREATING PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIA
- U-1448 TREATING SEVERE HYPERTRIGLYCERIDEMIA
- U-1449 METHOD OF ALLEVIATING A SKIN CONDITION
- U-1450 TREATMENT OF ALLERGIC RHINITIS SYMPTOMS
- U-1451 APPROVED INDICATIONS: APTIOM (ESLICARBAZEPINE ACETATE) IS INDICATED AS ADJUNCTIVE TREATMENT OF PARTIAL-ONSET SEIZURES AND APPROVED IN PATIENTS WITH

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

EPILEPSY. PATENT CLAIMS: IN A METHOD OF TREATING A SUBJECT AFFLICTED WITH EPILEPSY

U-1452 METHOD FOR CHRONIC WEIGHT MANAGEMENT

U-1453 A METHOD OF TREATING HYPOXIC RESPIRATORY FAILURE BY VERIFYING GAS INFORMATION OF NITRIC OXIDE PRIOR TO DELIVERY TO PATIENT

U-1454 PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS

U-1455 TREATMENT OF PERIANAL WARTS

U-1456 TREATMENT OF MANTLE CELL LYMPHOMA

U-1457 A METHOD OF PURGING A NITRIC OXIDE DELIVERY SYSTEM

U-1458 A METHOD OF REDUCING INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION

U-1459 TREATMENT OF CARCINOMA OF THE THYROID

U-1460 TREATMENT OF HERPES LABIALIS

U-1461 A METHOD OF GENERATING AN INJECTABLE FOAM OF CONTROLLED DENSITY AND BUBBLE SIZE

U-1462 A METHOD OF USING A SCLEROSING AGENT FOR THE TREATMENT OF INCOMPETENT GREAT SAPHENOUS VEINS, ACCESSORY SAPHENOUS VEINS AND VISIBLE VARICOSITIES OF THE GREAT SAPHENOUS (GSV) SYSTEM ABOVE AND BELOW THE KNEE

U-1463 A METHOD OF INTRAVENOUS INJECTION USING ULTRASOUND GUIDANCE, ADMINISTERED VIA A SINGLE CANNULA INTO THE LUMEN OF THE TARGET INCOMPETENT TRUNK VEINS OR BY DIRECT INJECTION INTO VARICOSITIES

U-1464 TREATMENT OF OPIOID DEPENDENCE/SUBLINGUAL OR BUCCAL APPLICATION

U-1465 USE OF THALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO THALIDOMIDE

U-1466 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER

U-1467 METHOD OF TREATING HEPATITIS C

U-1468 CONTROL OF PHOSPHOROUS LEVELS IN PATIENTS

U-1469 USE OF PHOSLYRA FOR REDUCTION OF SERUM PHOSPHOROUS IN PATIENTS

U-1470 FOR THE TREATMENT OF HEPATITIS C

U-1471 A METHOD FOR TREATING CARDIOVASCULAR DISEASE COMPRISING ADMINISTERING A RECONSTITUTED LYOPHILIZED PHARMACEUTICAL COMPOSITION COMPRISING EPOPROSTENOL, ARGININE AND SODIUM HYDROXIDE.

U-1472 INTENSIVE CARE UNIT SEDATION, INCLUDING SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES

U-1473 MANAGEMENT OF RISK OF DRONEDARONE/BETA-BLOCKER INTERACTION IN PATIENTS IN SINUS RYTHM WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF

U-1474 A METHOD FOR THE TREATMENT OF A PATIENT SUFFERING FROM A DISEASE TREATABLE WITH ROTIGOTINE, COMPRISING APPLYING THE CLAIMED TRANSDERMAL DELIVERY SYSTEM (TDS) TO THE SKIN OF THE PATIENT

U-1475 USE OF ORENITRAM FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1).

U-1476 INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA.

U-1477 USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL PRESCRIPTION MEDICATION ON THE SAME KNEE

U-1478 METHOD OF REDUCING TG LEVELS IN PATIENT ON STATIN THERAPY SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA

U-1479 INCREASE TEAR PRODUCTION TO TREAT PATIENTS WITH KERATOCONJUNCTIVITIS SICCA (DRY EYE).

U-1480 TREATMENT OF ADVANCED RENAL CELL CARCINOMA

U-1481 REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE

U-1482 DICLOFENAC POTASSIUM FOR RELIEF OF MILD TO MODERATE ACUTE PAIN

U-1483 INCREASE TEAR PRODUCTION IN PATIENTS WITH KERATOCONJUNCTIVITIS SICCA (DRY EYE).

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-1484 COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND CHILDREN (6 YEARS OF AGE AND OLDER)
- U-1485 TREATING A SUBJECT UNDERGOING ABDOMINAL SURGERY BY ADMINISTERING ALVIMOPAN TO ACCELERATE THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING SURGERIES THAT INCLUDE PARTIAL BOWEL RESECTION WITH PRIMARY ANASTOMOSIS
- U-1486 TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER
- U-1487 METHOD OF INCREASING EYELASH GROWTH
- U-1488 USE OF TOPICAL DICLOFENAC FOR TREATING PAIN
- U-1489 USE OF TOPICAL DICLOFENAC ON A JOINT FOR TREATING OSTEOARTHRITIS
- U-1490 FOR USE IN PATIENTS HAVING SYMPTOMATIC OR PROGRESSIVE MEDULLARY THYROID CANCER, WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC DISEASE
- U-1491 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
- U-1492 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
- U-1493 METHOD FOR PREVENTING ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS
- U-1494 SUBLINGUAL OR BUCCAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE AND NALOXONE
- U-1495 RISK REDUCTION OF REBLEEDING IN PTS FOLLOWING THERAPEUTIC ENDOSCOPY FOR ACUTE BLEEDING GASTRIC OR DUODENAL ULCERS IN ADULTS.
- U-1496 METHOD TO TREAT HEMANGIOMA.
- U-1497 NEURACEQ IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE P-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT
- U-1498 METHOD OF TREATING PATIENTS WITH GASTRIC RETENTIVE DOSAGE FORM
- U-1499 MANAGEMENT OF ACUTE PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA
- U-1500 TESTOSTERONE REPLACEMENT THERAPY IN ADULT MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE; PRIMARY HYPOGONADISM (CONGENITAL OR ACQUIRED); HYPOGONADOTROPIC HYPOGONADISM (CONGENITAL OR ACQUIRED).
- U-1501 PROPHYLAXIS OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM
- U-1502 PROPHYLAXIS OF PULMONARY EMBOLISM
- U-1503 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
- U-1504 USE OF OTEZLA (APREMILAST) FOR INHIBITING PDE4
- U-1505 USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIATIC ARTHRITIS
- U-1506 TREATMENT OF PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR (GIST), INCLUDING BUT NOT LIMITED TO PATIENTS PREVIOUSLY TREATED WITH IMATINIB AND PATIENTS WITH GIST HAVING RESISTANCE TO A KIT TYROSINE KINASE INHIBITOR
- U-1507 TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN
- U-1508 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT BY ORALLY ADMINISTERING A PLURALITY OF COMPOSITE SUBUNITS AS CLAIMED
- U-1509 TREATMENT OF FREQUENT HEARTBURN BY ADMINISTERING A GASTRIC ACID REDUCER
- U-1510 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED.
- U-1511 TREATMENT OF HYPERTRIGLYCERIDEMIA
- U-1512 REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS
- U-1513 TREATMENT OF HIV-1 INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
- U-1514 MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER BY BUCCAL OR SUBLINGUAL ADMINISTRATION OF FENTANYL
- U-1515 METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN ADULT PATIENTS.
- U-1516 METHOD OF TREATING CHRONIC IDIOPATHIC CONSTIPATION IN ADULT PATIENTS.
- U-1517 TREATMENT OF BACTERIAL INFECTIONS USING A TWO-DOSE REGIMEN OF DALBAVANCIN.

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-1518 MAINTAINING PUPIL SIZE BY PREVENTING INTRAOPERATIVE MIOSIS AND REDUCING POSTOPERATIVE OCULAR PAIN
- U-1519 METHOD FOR THE LONG TERM TREATMENT OF CHRONIC CONSTIPATION IN A HUMAN SUBJECT WITH IRRITABLE BOWEL SYNDROME
- U-1520 METHOD FOR THE LONG TERM TREATMENT OF CHRONIC CONSTIPATION IN A HUMAN SUBJECT
- U-1521 MAINTENANCE TREATMENT OF OPIOID DEPENDENCE
- U-1522 TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE
- U-1523 METHOD OF INDUCING TOPICAL ANESTHESIA IN THE EYE
- U-1524 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
- U-1525 METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY
- U-1526 THE TREATMENT OF PATIENTS WITH TRAVELERS' DIARRHEA (TD) OR THE REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE
- U-1527 FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY
- U-1528 A METHOD OF LOWERING INTRAOCULAR PRESSURE
- U-1529 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
- U-1530 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION
- U-1531 METHOD FOR TRANSDERMAL DELIVERY OF TESTOSTERONE
- U-1532 METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS AND/OR CATAPLEXY IN NARCOLEPSY PATIENTS WITH SODIUM OXYBATE WHEN DIVALPROEX SODIUM IS CONCOMITANTLY ADMINISTERED.
- U-1533 PULMONARY ADMINISTRATION OF PARTICLES COMPRISING A DIKETOPIPERAZINE AND INSULIN.
- U-1534 ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN COMPLEXED WITH A DIKETOPIPERAZINE.
- U-1535 ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN COMPLEXED WITH MICROPARTICLES OF A DIKETOPIPERAZINE.
- U-1536 ADMINISTRATION OF A COMPOSITION COMPRISING A DIKETOPIPERAZINE AND INSULIN.
- U-1537 TREATMENT OF A PATIENT HAVING DIABETES MELLITUS WITH A PRANDIAL RAPID ACTING INSULIN.
- U-1538 ADMINISTRATION OF FDKP MICROPARTICLES COMPRISING INSULIN.
- U-1539 PULMONARY ADMINISTRATION OF AN INSULIN COMPOSITION COMPRISING FDKP AT THE BEGINNING OF A MEAL TO A PATIENT ALSO BEING TREATED WITH A LONG-ACTING INSULIN.
- U-1540 BUTRANS IS A PARTIAL OPIOID AGONIST PRODUCT INDICATED FOR THE MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.
- U-1541 TREATMENT OF PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX (TSC) WHO HAVE SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) THAT REQUIRES THERAPEUTIC INTERVENTION BUT CANNOT BE CURATIVELY RESECTED.
- U-1542 FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND/OR NON-HODGKINS LYMPHOMA
- U-1543 TREATMENT OF A PATIENT BY ADMINISTERING THE FORMULATION RECITED IN CLAIM 1 OR CLAIM 23
- U-1544 TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA (PTCL).
- U-1545 A METHOD OF TRANSDERMALLY DELIVERING TESTOSTERONE
- U-1546 FOR USE IN THE TREATMENT OF MALIGNANT HYPERTHERMIA IN CONJUNCTION WITH APPROPRIATE SUPPORTIVE MEASURES AND FOR THE PREVENTION OF MALIGNANT HYPERTHERMIA IN PATIENTS AT HIGH RISK.
- U-1547 TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), CHRONIC BRONCHITIS OR EMPHYSEMA
- U-1548 FOR THE LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-1549 FOR THE TREATMENT OF PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA

U-1550 METHOD OF TREATING METASTATIC PAPILLARY RENAL CELL CARCINOMA WITH TEMSIROLIMUS.

U-1551 METHOD OF TREATING PAPILLARY RENAL CELL CARCINOMA WITH TEMSIROLIMUS, IN THE ABSENCE OF INTERFERON ALPHA.

U-1552 FOR HEALING OF ALL GRADES OF EROSION ESOPHAGITIS (EE)

U-1553 TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN

U-1554 FOR THE TREATMENT OF HEARTBURN ASSOCIATED WITH SYMPTOMATIC NON-EROSIVE GASTROESOPHAGEAL DISEASE (GERD)

U-1555 MANAGEMENT OF MODERATE TO SEVERE PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.

U-1556 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE

U-1557 A METHOD OF TESTOSTERONE REPLACEMENT THERAPY COMPRISING THE STEP OF NASALLY ADMINISTERING TO A PATIENT IN NEED OF SUCH TREATMENT AN EFFECTIVE AMOUNT OF TESTOSTERONE GEL FORMULATION.

U-1558 FOR THE TREATMENT OF PATIENTS WITH RELAPSED FOLLICULAR B-CELL NON-HODGKIN LYMPHOMA OR [RELAPSED] SMALL LYMPHOCYTIC LYMPHOMA

U-1559 INDICATED FOR THE ONCE-DAILY MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN PATIENTS AGED 12 YEARS OF AGE AND OLDER

U-1560 A METHOD OF DISRUPTING LEUKOCYTE FUNCTION, INCLUDING AS AN INHIBITOR OF PI3KDELTA KINASE

U-1561 USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIATIC ARTHRITIS

U-1562 TREATMENT OF PATIENTS WITH HEPATIC ENCEPHALOPATHY (HE)

U-1563 A METHOD OF TRANSDERMAL ADMINISTRATION OF A PHYSIOLOGICALLY ACTIVE AGENT TO A SUBJECT.

U-1564 A METHOD OF TREATING GAUCHER'S DISEASE

U-1565 METHOD OF TREATING, AS INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE

U-1566 METHOD OF TREATING, AS MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER

U-1567 METHOD OF TREATING, AS INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER

U-1568 METHOD OF TREATING, AS MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE

U-1569 TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS

U-1570 TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS USING A SINGLE DOSE

U-1571 TREATMENT OF GAUCHER DISEASE TYPE 1

U-1572 TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION.

U-1573 USE OF RUXOLITINIB (JAKAFI) FOR INHIBITING JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2.

U-1574 A METHOD OF CATALYZING THE HYDROLYSIS OF GLUCOCEREBROSIDE TO GLUCOSE AND CERAMIDE.

U-1575 PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY

U-1576 TREATMENT OF LEUKEMIA

U-1577 CONTROL OF SERUM PHOSPHOROUS LEVELS

U-1578 TREATMENT OF ACUTE OTITIS MEDIA

U-1579 USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

U-1580 USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAD RECEIVED PRIOR DOCETAXEL

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

CHEMOTHERAPY

- U-1581 IN COMBINATION WITH DABRAFENIB FOR THE TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA.
- U-1582 TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA
- U-1583 FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY
- U-1584 USE OF NALTREXONE AND BUPROPION IN A LAYERED FORMULATION FOR CHRONIC WEIGHT MANAGEMENT FOR AFFECTING WEIGHT LOSS
- U-1585 USE OF NALTREXONE AND BUPROPION BASED ON AN ESCALATING DOSE SCHEDULE
- U-1586 FOR EFFECT ON BLOOD GLUCOSE PARAMETERS IN PATIENTS WITH INSULIN RESISTANCE
- U-1587 SINGLE-DOSE INFILTRATION INTO THE SURGICAL SITE TO PRODUCE POSTSURGICAL ANALGESIA.
- U-1588 THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC).
- U-1589 METHOD OF USE FOR REDUCING BLOOD PHENYLALANINE LEVELS IN A HUMAN SUFFERING FROM HYPERPHENYLALANINEMIA
- U-1590 KUVAN IS INDICATED TO REDUCE BLOOD PHENYLALANINE LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA
- U-1591 TREATMENT OF ASTHMA IN PATIENTS AGED 12 YEARS AND OLDER
- U-1592 TO REDUCE SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE
- U-1593 MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA, AND REDUCTION OF EXACERBATIONS IN COPD PATIENTS.
- U-1594 DILATION OF THE PUPIL
- U-1595 USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIASIS
- U-1596 LAMICTAL IS AN ANTIEPILEPTIC DRUG (AED) INDICATED FOR: EPILEPSY-ADJUNCTIVE THERAPY IN PATIENTS GREATER THAN OR EQUAL TO 2 YEARS OF AGE: (1.1) PARTIAL SEIZURES PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
- U-1597 TREATMENT OF DIABETIC MACULAR EDEMA
- U-1598 METHOD OF ADMINISTRATION OF CONTROLLED RELEASE OXYMORPHONE
- U-1599 MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANTI-INFLAMMATORY, ANALGESIC, AND ANTIPYRETIC ACTIVITY
- U-1600 DOSAGE MODIFICATION FOLLOWING ELEVATED LIVER ENZYMES IN TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
- U-1601 DOSE ESCALATION OVER 14 DAYS FOR TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
- U-1602 METHOD OF ADMINISTERING PIRFENIDONE CAPSULES TO TREAT A FIBROTIC CONDITION
- U-1603 METHOD FOR ADMINISTERING PIRFENIDONE TO REDUCE DRUG INTERACTIONS WITH FLUVOXAMINE
- U-1604 METHOD FOR ADMINISTERING PIRFENIDONE TO REDUCE DRUG INTERACTIONS WITH A STRONG INHIBITOR OF CYP1A2
- U-1605 METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY DISCONTINUING SMOKING OR BY DISCONTINUING OR AVOIDING ANOTHER STRONG CYP1A2 INDUCER
- U-1606 METHOD FOR ADMINISTERING PIRFENIDONE WHILE AVOIDING OR DISCONTINUING CONCOMITANT USE OF A MODERATE TO STRONG INHIBITOR OF BOTH CYP1A2 AND ANOTHER CYP ENZYME INVOLVED IN PIRFENIDONE METABOLISM
- U-1607 METHOD OF ADMINISTERING A DOSAGE FORM THAT INCLUDES A GRANULATE FORMULATION OF PIRFENIDONE TO TREAT A FIBROTIC CONDITION
- U-1608 DOSE ESCALATION OVER 14 DAYS FOR TREATMENT OF A FIBROSIS CONDITION
- U-1609 CONTINUED DOSING OR DOSAGE MODIFICATION FOLLOWING ELEVATED LIVER ENZYMES IN TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
- U-1610 CONTINUED DOSING OR DOSAGE MODIFICATION FOLLOWING ELVATED LIVER ENZYMES IN USE OF PIRFENIDONE
- U-1611 METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY DISCONTINUING SMOKING OR BY DISCONTINUING A STRONG CYP1A2 INDUCER
- U-1612 METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY AVOIDING

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

SMOKING OR BY AVOIDING ANOTHER STRONG CYP1A2 INDUCER

U-1613 DOSAGE MODIFICATION IN TREATMENT WITH PIRFENIDONE TO REDUCE DRUG INTERACTIONS WITH CIPROFLOXACIN

U-1614 USE OF TOPICAL DICLOFENAC SODIUM FOR TREATING PAIN

U-1615 FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL

U-1616 NASAL ADMINISTRATION OF A TESTOSTERONE GEL TO A PATIENT TO TREAT THE PATIENT FOR A CONDITION ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE

U-1617 METHOD OF TREATING MEDULLARY THYROID CANCER

U-1618 A METHOD OF TREATING A PATIENT SUFFERING FROM A PAIN ASSOCIATED SLEEP DISTURBANCE COMPRISING ADMINISTERING A LIQUID COMPOSITION FORMULATED INSIDE A SOFT GEL CAPSULE, AS CLAIMED, TO THE PATIENT

U-1619 TREATMENT OF IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)

U-1620 METHOD OF TREATMENT OF IRON-RELATED CONDITIONS WITH AT LEAST 0.6 GRAMS OF ELEMENTAL IRON VIA AN IRON CARBOHYDRATE COMPLEX, WITH A SUBSTANTIALLY NON-IMMUNOGENIC CARBOHYDRATE COMPONENT, IN ABOUT 15 MINUTES OR LESS.

U-1621 PULMONARY ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN BOUND TO A COMPLEXING AGENT.

U-1622 FOR THE TREATMENT OF POLYCYTHEMIA VERA

U-1623 USE OF EXENATIDE MAY RESULT IN REDUCTION IN APPETITE.

U-1624 TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA, ADVANCED RENAL CELL CARCINOMA, OR DIFFERENTIATED THYROID CARCINOMA.

U-1625 METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING ILOPERIDONE TO A PATIENT BY REDUCING THE DOSE IN PATIENTS WHO ARE POOR METABOLIZERS OF CYP2D6

U-1626 A METHOD OF TREATING OR PREVENTING OCULAR PAIN AND BURNING

U-1627 TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN ADULTS

U-1628 METHOD OF TREATING DISORDERS WITH AN ETIOLOGY COMPRISING OR ASSOCIATED WITH EXCESS GH-SECRETION

U-1629 METHOD OF TREATING ACROMEGALY

U-1630 TREATMENT IN COMBINATION WITH A CORTICOID SUCH AS PREDNISONE OF PROSTATE CANCER PREVIOUSLY TREATED WITH DOCETAXEL

U-1631 TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.

U-1632 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA

U-1633 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA

U-1634 TREATMENT OF BRCA MUTATED OVARIAN CANCER USING PARP INHIBITOR

U-1635 USE OF RITONAVIR AS A POTENT CYP3A INHIBITOR TO INCREASE PLASMA DRUG CONCENTRATION OF PARITAPREVR AND OVERALL DRUG EXPOSURE FOR TREATMENT OF HCV INFECTION

U-1636 USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.

U-1637 TREATMENT OF HCV INFECTION USING PARITAPREVR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN.

U-1638 TREATMENT OF HCV INFECTION USING PARITAPREVR

U-1639 USE OF NALTREXONE AND BUPROPION IN EXTENDED-RELEASE FORM FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY

U-1640 TREATMENT OF MODERATE TO SEVERE CHRONIC PAIN BY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED

U-1641 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE

U-1642 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS WITH SEVERE CHRONIC RENAL IMPAIRMENT AND FOR WHOM METFORMIN THERAPY IS INAPPROPRIATE BY ADMINISTERING LINAGLIPTIN

U-1643 TREATING CUSHING'S SYNDROME

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-1644 TREATMENT OF OVERACTIVE BLADDER BY APPLICATION OF OXYBUTYNIN CHLORIDE GEL TO SKIN

U-1645 TREATMENT OF PARKINSON'S DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION

U-1646 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION

U-1647 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION

U-1648 TREATMENT OF PATIENTS WITH PARKINSON'S DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION

U-1649 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM

U-1650 TREATMENT OF WALDENSTROM'S MACROGLOBULINEMIA

U-1651 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN

U-1652 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN

U-1653 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT METFORMIN)

U-1654 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT INSULIN OR A SULFONYLUREA)

U-1655 A METHOD TO ACCELERATE THE TIME TO GASTROINTESTINAL RECOVERY BY ADMINISTERING ABOUT 12 MG OF ALVIMOPAN TO THE PATIENT FROM ABOUT 30 TO 60 MINUTES PRIOR TO SURGERY

U-1656 METHOD OF IRON ADMINISTRATION TO TREAT PATIENTS IN NEED OF IRON REPLACEMENT

U-1657 METHOD FOR PROVIDING POST COITAL CONTRACEPTION TO A WOMAN BY ADMINISTERING ABOUT 30 MG OF ULIPRISTAL ACETATE WITHIN ABOUT 120 HOURS AFTER INTERCOURSE, WHEREIN THE WOMAN IS OVERWEIGHT HAVING A BMI OF 25 TO 29.99

U-1658 TREATMENT OF ER-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER IN COMBINATION WITH LETROZOLE AS INITIAL ENDOCRINE-BASED THERAPY FOR METASTATIC DISEASE IN POSTMENOPAUSAL WOMEN

U-1659 MANAGEMENT OF PAIN

U-1660 TREATMENT OF HIV-1 INFECTION IN ADULTS WITH NO DARUNAVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS

U-1661 RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS ALSO TAKING LOW DOSE ASPIRIN

U-1662 A METHOD OF TREATING OCULAR PAIN

U-1663 TREATMENT OF HIV-1 INFECTION

U-1664 TREATMENT OF BACTERIAL VAGINOSIS WITH METRONIDAZOLE GEL

U-1665 METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER BY ADMINISTERING THE COMPOSITION OF CLAIM 1

U-1666 PALLIATIVE TREATMENT OF PROSTATE CANCER

U-1667 TREATMENT OF ALLERGIC RHINITIS, INCLUDING SEASONAL ALLERGIC RHINITIS

U-1668 METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER

U-1669 TREATMENT OF MULTIPLE MYELOMA, IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE

U-1670 NATROBA TOPICAL SUSPENSION IS A PEDICULICIDE INDICATED FOR THE TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS SIX (6) MONTHS OF AGE AND OLDER.

U-1671 TREATMENT OF OCULAR ITCHING ASSOCIATED WITH CONJUNCTIVITIS

U-1672 TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION

U-1673 TREATMENT OF COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELONEPHRITIS

U-1674 DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE

U-1675 USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-1676 METHODS FOR TREATING BACTERIAL INFECTIONS

U-1677 TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS (IPF)

U-1678 FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL

U-1679 TREATMENT OF ACUTE OTITIS EXTERNA

U-1680 TREATMENT OF OCULAR ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS

U-1681 TREATMENT OF PATIENTS WITH PROGRESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC

U-1682 TREATMENT OF BACTERIAL VAGINOSIS

U-1683 TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION

U-1684 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA

U-1685 DOSAGE MODIFICATION TO REDUCE THE RISK ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE

U-1686 A METHOD TO REDUCE WITHDRAWAL SYMPTOMS, INCLUDING NICOTINE CRAVING, ASSOCIATED WITH SMOKING CESSATION

U-1687 TREATMENT OF HCV INFECTION USING OMBITASVIR

U-1688 METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD

U-1689 METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD

U-1690 METHOD FOR REDUCTION OF SUBMENTAL FAT

U-1691 INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER

U-1692 METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD

U-1693 METHOD OF TREATING ADHD IN CHILDREN 6 YEARS OF AGE AND OLDER AND ADOLESCENTS

U-1694 A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE

U-1695 METHOD FOR TREATING THYROID CARCINOMA INCLUDING DIFFERENTIATED THYROID CANCER

U-1696 TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA

U-1697 PULMONARY ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN BOUND TO A DIKETOPIPERAZINE.

U-1698 PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS

U-1699 A METHOD FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIA

U-1700 A METHOD FOR TREATING PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA

U-1701 A METHOD FOR TREATING LEUKEMIA RESULTING FROM A MUTATION IN THE BCR-ABL KINASE DOMAIN

U-1702 TREATMENT OF COPD

U-1703 TREATMENT OF RESPIRATORY COMPLAINTS

U-1704 USE FOR TREATMENT IN PATIENTS WITH DIABETES

U-1705 USE FOR TREATMENT IN PATIENTS WITH HYPERGLYCEMIA

U-1706 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE WHEREIN THE COMBINED THERAPEUTIC EFFECT IS GREATER THAN THE ADDITIVE EFFECT OF ADMINISTERING EACH AGENT ALONE

U-1707 TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS AND SYMPTOMS THEREOF.

U-1708 TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS.

U-1709 TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE).

U-1710 TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH FLUVOXAMINE

U-1711 FOR THE TREATMENT OF PATIENTS WITH CLL, FL OR SLL

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-1712 MEKINIST IN COMBINATION WITH DABRAFENIB FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA
- U-1713 TAFINLAR IN COMBINATION WITH TRAMETINIB FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA
- U-1714 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
- U-1715 P2Y12 PLATELET INHIBITOR FOR USE AS ADJUNCT TO PERCUTANEOUS CORONARY INTERVENTION TO REDUCE RISK OF VARIOUS DISEASES/CONDITIONS IN PATIENTS NOT TREATED WITH A P2Y12 PLATELET INHIBITOR AND NOT GIVEN A GLYCOPROTEIN IIB/IIIA INHIBITOR
- U-1716 TREATMENT OF COUGH AND SYMPTOMS ASSOCIATED WITH UPPER RESPIRATORY ALLERGIES OR A COMMON COLD WITH CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE ORALLY ADMINISTERED EXTENDED RELEASE TABLETS
- U-1717 METHOD OF TREATING CYSTIC FIBROSIS IN PATIENTS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE
- U-1718 METHOD OF TREATING CYSTIC FIBROSIS IN PATIENTS WHO HAVE THE F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE.
- U-1719 ACUTE TREATMENT OF MIGRAINE
- U-1720 METHOD OF PROVIDING A THERAPEUTICALLY EFFECTIVE AND STABLE MEDIAN BLOOD PLASMA LEVEL OF LEVODOPA
- U-1721 USE OF RUXOLITINIB (JAKAFI) FOR BLOCKING SIGNAL TRANSDUCTION OF JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2
- U-1722 TREATMENT OF BASAL CELL CARCINOMA
- U-1723 TREATMENT OF HEART FAILURE
- U-1724 METHOD OF INHIBITING HEPATITIS C VIRUS
- U-1725 METHOD OF INHIBITING HEPATITIS C VIRUS WITH DAKLINZA AND AT LEAST ONE ADDITIONAL COMPOUND HAVING ANTI-HCV ACTIVITY
- U-1726 REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH CORONARY HEART DISEASE AND A HISTORY OF PAROXYSMAL OR PERSISTENT AF AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS
- U-1727 TOPICAL TREATMENT OF INFLAMMATORY PAPULES AND PUSTULES OF MILD TO MODERATE ROSACEA
- U-1728 REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH STABLE NYHA CLASS III HEART FAILURE AND A HISTORY OF PAROXYSMAL OR PERSISTENT AF AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS
- U-1729 REDUCE THE RISK OF RECURRENT DEEP VEIN THROMBOSIS (DVT)
- U-1730 REDUCE THE RISK OF RECURRENT PULMONARY EMBOLISM
- U-1731 TEMPORARY RELIEF OF MINOR ACHES AND PAINS
- U-1732 TEMPORARY REDUCTION OF FEVER
- U-1733 TREATMENT/PREVENTION OF CARDIOVASCULAR DISEASE
- U-1734 USE OF FLIBANSERIN OR A PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF TO TREAT HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD)
- U-1735 METHODS OF TREATING PAIN, INFLAMMATION AND/OR FEVER WITH INTRAVENOUS IBUPROFEN SUCH THAT MEAN ARTERIAL BLOOD PRESSURE DOES NOT INCREASE THE DOSAGE INTERVAL
- U-1736 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
- U-1737 METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING ILOPERIDONE TO A PATIENT BY REDUCING THE DOSE IN PATIENTS WHO ARE BEING TREATED WITH FLUOXETINE
- U-1738 TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE)
- U-1739 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND -THE-CLOCK, LONG-TERM OPIOID TREATMENT, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
- U-1740 IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-NAIVE PATIENTS WITH HIV-1 RNA LESS THAN OR EQUAL TO 100,000 AT THE START OF THEARPY

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-1741 PREVENTION OF DELAYED NAUSEA AND VOMITING ASSOCIATED WITH EMETOGENIC CANCER CHEMOTHERAPY

U-1742 ROLAPITANT IS APPROVED FOR THE PREVENTION OF DELAYED NAUSEA AND VOMITING (I.E., EMESIS) ASSOCIATED WITH EMETOGENIC CANCER CHEMOTHERAPY

U-1743 FOR THE PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY

U-1744 PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING

U-1745 FOR THE TREATMENT OF PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA

U-1746 MONOTHERAPY OR ADJUNCTIVE THERAPY FOR TREATMENT OF PARTIAL-ONSET SEIZURES AND APPROVED IN PATIENTS WITH EPILEPSY

U-1747 FOR CLAIMS 1-3,6-13,16-24 AND 26-32: METHOD OF TREATING ADHD

U-1748 FOR CLAIMS 1-4,6-14,16-24 AND 26-32: METHOD OF TREATING ADHD IN CHILDREN 6 YEARS OF AGE AND OLDER AND ADOLESCENTS

U-1749 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER

U-1750 TREATMENT OF SCHIZOPHRENIA AND/OR ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH CARIPRAZINE

U-1751 TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER WHO HAVE BEEN PREVIOUSLY TREATED WITH FLUOROPYRIMIDINE-, OXALIPLATIN- AND IRINOTECAN-BASED CHEMOTHERAPY, AN ANTI-VEGF BIOLOGICAL THERAPY, AND IF RAS WILD-TYPE, AN ANTI-EGFR THERAPY

U-1752 PROPHYLAXIS OF ORGAN REJECTION

U-1753 TREATMENT OF HCV INFECTION USING DASABUVIR

U-1754 FOR THE TREATMENT OF PULMONARY HYPERTENSION (PAH) IN COMBINATION WITH TADALAFIL

U-1755 FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS

U-1756 METHODS OF TREATING PAIN, INFLAMMATION AND/OR FEVER IN A CRITICALLY ILL PATIENT WITH INTRAVENOUS IBUPROFEN IN NEED THEREOF

U-1757 INHIBITION ON PI3K KINASE

U-1758 METHOD OF TREATING ALLERGIC REACTION VIA INJECTION

U-1759 METHOD OF REVERSING THE ANTICOAGULANT EFFECT OF DABIGATRAN USING IDARUCIZUMAB

U-1760 RISK-REDUCTION OF NSAID GASTRIC ULCER IN PATIENTS REQUIRING CHRONIC NSAID TREATMENT

U-1761 PLAQUE PSORIASIS

U-1762 USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT

U-1763 USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT

U-1764 USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT

U-1765 USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT

U-1766 TREATMENT OF HYPERKALEMIA

U-1767 USE OF CALCIPOTRIENE FOAM FOR THE TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS AGED 18 YEARS AND OLDER

U-1768 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN

U-1769 TREATMENT OF PAIN BY TRANSMUCOSAL DELIVERY OF BUPRENORPHINE

U-1770 TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN NEGATIVE SYMPTOMS AND/OR COGNITIVE DYSFUNCTION OF SCHIZOPHRENIA

U-1771 ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE WATER FOR INJECTION OR 0.9% SODIUM CHLORIDE INJECTION PRIOR TO ADMINISTRATION

U-1772 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-1773 LONG - TERM MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

U-1774 USE OF A LOTION CONTAINING HALOBETASOL PROPIONATE FOR THE TREATMENT OF CORTICOSTEROID-RESPONSIVE

U-1775 USE OF A LOTION CONTAINING HALOBETASOL PROPIONATE FOR THE TREATMENT OF CORTICOSTEROID-RESPONSIVE DERMATOSES INCLUDING PSORIASIS

U-1776 METHOD OF USING COBIMETINIB FOR THE TREATMENT OF MELANOMA

U-1777 TREATMENT OF PATIENTS WITH METASTATIC EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) T790M MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC), WHO HAVE PROGRESSED ON OR AFTER EGFR TKI THERAPY

U-1778 METHOD FOR TREATING MULTIPLE MYELOMA

U-1779 METHOD FOR TREATING MULTIPLE MYELOMA WITH ONE OR MORE OTHER THERAPEUTIC AGENTS

U-1780 METHOD FOR TREATING CANCER, INCLUDING MULTIPLE MYELOMA

U-1781 RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER IN PATIENTS REQUIRING NSAID TREATMENT

U-1782 FOR HEAD LICE INFESTATIONS

U-1783 METHOD OF TREATING FREQUENT HEARTBURN BY ADMINISTERING AN Eesomeprazole magnesium AS CLAIMED

U-1784 METHOD OF TREATING FREQUENT HEARTBURN BY ADMINISTERING AN Eesomeprazole magnesium trihydrate AS CLAIMED

U-1785 METHOD OF TREATING FREQUENT HEARTBURN BY ADMINISTERING AN Eesomeprazole magnesium FORMULATION AS CLAIMED

U-1786 TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS WHILE MANAGING THE RISK OF TERIFLUNOMIDE AND ROSUVASTATIN INTERACTION BY LIMITING THE ROSUVASTATIN DOSE TO NO MORE THAN 10MG AND/OR ADMINISTERING ABOUT HALF THE NORMAL DOSE

U-1787 TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY

U-1788 TREATMENT OF PATIENT HAVING DIABETES MELLITUS VIA ORAL INHALATION OF FDKP MICROPARTICLES COMPRISING INSULIN

U-1789 METHOD OF ADMINISTERING AN ETHANOL-FREE TAXANE LIQUID NANODISPERSION FORMULATION TO A SUBJECT COMBINING THE FORMULATION WITH AN AQUEOUS MEDIUM TO PROVIDE AN ETHANOL-FREE TAXANE DILUTED SOLUTION

U-1790 FOR USE IN TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR NON-HODGKIN'S LYMPHOMA

U-1791 EMERGENCY TREATMENT OF ADULT & PEDIATRIC PATIENTS FOLLOWING FLUOROURACIL OR CAPECITABINE OVERDOSE, OR WHO EXHIBIT EARLY-ONSET, SEVERE OR LIFE-THREATENING CARDIAC OR CNS TOXICITY OR UNUSUALLY SEVERE ADVERSE REACTIONS WITHIN 96 HOURS

U-1792 TREATMENT OF OTIC INFECTION OR INFLAMMATION

U-1793 TREATMENT OF PEDIATRIC PATIENTS WITH OTITIS MEDIA WITH EFFUSION UNDERGOING TYMPANOSTOMY TUBE PLACEMENT

U-1794 REVERSAL OF DRUG-INDUCED NEUROMUSCULAR BLOCK

U-1795 REVERSAL OF NEUROMUSCULAR BLOCKAGE INDUCED BY ROCURONIUM BROMIDE OR VECURONIUM BROMIDE

U-1796 TOPICAL TREATMENT OF INFLAMMATORY PAPULES AND PUSTULES OF MILD TO MODERATE ROSACEA

U-1797 METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING SELEXIPAG

U-1798 METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING SELEXIPAG IN COMBINATION WITH THE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN

U-1799 METHOD OF INCREASING GROWTH OF HAIR INCLUDING EYELASHES

U-1800 A METHOD OF TREATING OCULAR PAIN AND/OR ENHANCING OCULAR COMFORT

U-1801 REDUCTION OF SERUM URIC ACID LEVELS

U-1802 TREATMENT OF GOUT

U-1803 TREATMENT OF HYPERURICEMIA

U-1804 ACHIEVING A THERAPEUTIC BENEFIT IN A SUBJECT WITH GOUT

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-1805 USE OF DEXLANSOPRAZOLE IN PATIENTS TAKING CLOPIDOGREL WITHOUT MEANINGFUL CYP2C19 INTERACTIONS
- U-1806 COADMINISTERING WITH ALLOPURINOL TO REDUCE SERUM URIC ACID (SUA) BELOW 4 MG/DL; BELOW 6MG/DL IN PATIENTS HAVING URIC ACID DEPOSITS; AND/OR BELOW 6MG/DL WITH SUA INTRADAY CHANGE MORE THAN 50% AND/OR ADVERSE EVENT RATE LESS THAN 15%
- U-1807 TREATMENT OF PEDIATRIC PATIENTS 8 TO 17 YEARS OF AGE WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH)
- U-1808 USE OF NALTREXONE AND BUPROPION FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER
- U-1809 METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY
- U-1810 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
- U-1811 TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E MUTATIONS AFTER CONFIRMING THE PRESENCE OF BRAF V600E MUTATION
- U-1812 TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA
- U-1813 TREATMENT OF PATIENTS INFECTED WITH HEPATITIS C VIRUS
- U-1814 METHOD OF TREATING GLAUCOMA OR ELEVATED INTRAOCULAR PRESSURE
- U-1815 TREATMENT OF PARTIAL-ONSET SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY
- U-1816 TREATMENT OF A UREA CYCLE DISORDER
- U-1817 PEDIATRIC USE AGES 1 MONTH TO 2 YEARS, GERD AND EROSIIVE ESOPHAGITIS
- U-1818 TREATING HR-POS., HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER WITH PALBOCICLIB IN COMBO WITH LETROZOLE AS INITIAL ENDOCRINE BASED THERAPY IN POSTMENOPAUSAL WOMEN, OR FULVESTRANT IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
- U-1819 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
- U-1820 METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION BY ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING MACITENTAN AND A POLYSORBATE, WHEREIN THE POLYSORBATE REPRESENTS 0.1 TO 3% OF THE WEIGHT OF SAID PHARMACEUTICAL COMPOSITION
- U-1821 METHOD FOR CONTRACEPTION TO A WOMAN COMPRISING ADMINISTERING TO THE WOMAN 30MG OF ULIPRISTAL ACETATE MORE THAN 72 HOURS AND UP TO 120 HOURS AFTER AN UNPROTECTED INTERCOURSE
- U-1822 TREATMENT OF SCHIZOPHRENIA OR BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA AND/OR BIPOLAR DISORDER
- U-1823 A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT BY COMPENSATING LONG-TERM SENSITIVITY DRIFT OF ELECTROCHEMICAL GAS SENSORS USED IN SYSTEMS FOR DELIVERING THERAPEUTIC NITRIC OXIDE TO A PATIENT
- U-1824 A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT BY VERIFYING GAS INFORMATION OF NITRIC OXIDE PRIOR TO DELIVERY TO PATIENT
- U-1825 METHOD OF USING VISMODEGIB TO TREAT CANCER IN A MAMMAL
- U-1826 TREATMENT OF HR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER IN COMBINATION WITH PALBOCICLIB IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
- U-1827 A METHOD OF PROVIDING A SUBJECT WITH THERAPEUTICALLY EFFECTIVE AMOUNT OF RACEMIC METHYLPHENIDATE BY ORALLY ADMINISTERING TO SAID SUBJECT A SINGLE METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET ACCORDING TO CLAIM 1
- U-1828 INCREASING MEAN ARTERIAL BLOOD PRESSURE IN ADULT PATIENTS WITH HYPOTENSION ASSOCIATED WITH SEPTIC SHOCK
- U-1829 EMERGENCY TREATMENT OF ALLERGIC REACTIONS (TYPE I), INCLUDING ANAPHYLAXIS
- U-1830 INDUCTION AND MAINTENANCE OF MYDRIASIS DURING INTRAOCULAR SURGERY
- U-1831 METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A CRYSTALLINE FORM OF SELEXIPAG
- U-1832 IMPROVEMENT IN GLYCEMIC CONTROL IN DIABETES MELLITUS PATIENTS BY USE OF A PEN INJECTOR WITH A THREADED DRIVE SLEEVE
- U-1833 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

OR OCULAR HYPERTENSION

- U-1834 TREATMENT OF POSTOPERATIVE INFLAMMATION AND PREVENTION OF OCULAR PAIN IN PATIENTS UNDERGOING CATARACT SURGERY
- U-1835 TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION, AS DETECTED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
- U-1836 TREATMENT OF HEREDITARY TYROSINEMIA TYPE 1 (HT-1) IN COMBINATION WITH DIETARY RESTRICTION OF TYROSINE AND PHENYLALANINE
- U-1837 METHOD FOR TREATING TYPE II DIABETES MELLITUS BY ADMINISTERING SAXAGLIPTIN ALONE OR IN COMBINATION WITH INSULIN, METFORMIN, A THIAZOLIDINEDIONE, GLYBURIDE OR METFORMIN PLUS A SULFONYLUREA
- U-1838 METHOD FOR TREATING TYPE II DIABETES MELLITUS BY ADMINISTERING SAXAGLIPTIN IN COMBINATION WITH METFORMIN
- U-1839 COMPOSITION AND METHOD FOR PROVIDING A REDUCTION IN SIDE EFFECTS FOR HUMAN PATIENTS IN NEED OF ACETYLCYSTEINE THERAPY
- U-1840 TREATMENT OF HCV INFECTION USING PARITAPREVRIR, OMBITASVIR, RITONAVIR, AND DASABUVIR, WITHOUT RIBAVIRIN
- U-1841 USE IN THE LONG-TERM, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
- U-1842 METHOD OF TREATING EPILEPSY
- U-1843 TREATMENT OF PSYCHOSIS
- U-1844 TREATMENT OF PARKINSON'S DISEASE PSYCHOSIS
- U-1845 TREATMENT OF PSYCHOSIS OR A SYMPTOM THEREOF
- U-1846 TREATMENT OF A NEURODEGENERATIVE DISEASE OR A SYMPTOM THEREOF
- U-1847 METHOD OF TREATING A BACTERIAL INFECTION
- U-1848 TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN
- U-1849 METHOD OF TREATING PULMONARY HYPERTENSION BY ADMINISTERING TREPROSTINIL OR A SALT THEREOF BY INHALATION USING A DEVICE
- U-1850 METHOD OF ADMINISTERING LEVETIRACETAM
- U-1851 A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
- U-1852 METHOD OF TREATING TYPE 2 DIABETES
- U-1853 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND, OPTIONALLY, A SULFONYLUREA
- U-1854 TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC)
- U-1855 IMPROVEMENT IN GLYCEMIC CONTROL IN DIABETES MELLITUS PATIENTS
- U-1856 TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN, IN A PATIENT HOMOZYGOUS FOR THE UGT1A1*28 ALLELE
- U-1857 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
- U-1858 TREATMENT OF PLAQUE PSORIASIS
- U-1859 TREATMENT OF SCHIZOPHRENIA, ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER, ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER, AND TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
- U-1860 REDUCTION OF THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION
- U-1861 USE OF AN INHALER TO ADMINISTER DRY POWDER MEDICAMENT
- U-1862 TREATMENT OF POST-MYOCARDIAL INFARCTION
- U-1863 TREATMENT OF STROKE
- U-1864 TREATMENT OF MYOCARDIAL INFARCTION

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-1865 TREATMENT OF THROMBOTIC STROKE

U-1866 TREATMENT OF STABLE AND UNSTABLE ANGINA

U-1867 METHOD OF INHIBITING PLATELET AGGREGATION

U-1868 TREATMENT OF ARTERIAL THROMBOTIC COMPLICATIONS SELECTED FROM THE GROUP CONSISTING OF UNSTABLE ANGINA, THROMBOTIC OR EMBOLIC STROKE, TRANSIENT ISCHAEMIC ATTACKS, PERIPHERAL VASCULAR DISEASE AND MYOCARDIAL INFARCTION

U-1869 TREATMENT OF AN ARTERIAL THROMBOTIC COMPLICATION IN A PATIENT WITH CORONARY ARTERY, CEREBROVASCULAR OR PERIPHERAL VASCULAR DISEASE

U-1870 ZINGO IS A POWDER INTRADERMAL SYSTEM THAT IS CAPABLE OF DELIVERING FINE DRY POWDERED LIDOCAINE HYDROCHLORIDE MONOHYDRATE FOR LOCAL ANESTHETIC ACTION

U-1871 TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH STAGE 3 OR 4 CHRONIC KIDNEY DISEASE USING CONTROLLED RELEASE, ORAL 25-HYDROXYVITAMIN D

U-1872 USE OF SUSTAINED RELEASE 25-HYDROXYVITAMIN D IN TREATING PATIENTS HAVING 25-HYDROXYVITAMIN D INSUFFICIENCY OR DEFICIENCY

U-1873 ADMINISTRATION OF 25-HYDROXYVITAMIN D3 BY CONTROLLED RELEASE

U-1874 TREATMENT OF FREQUENT HEARTBURN BY ADMINISTERING OMEPRAZOLE ACCORDING TO CLAIMS 1-8

U-1875 TREATMENT OF FREQUENT HEARTBURN BY ADMINISTERING S-OMEPRAZOLE TRIHYDRATE ACCORDING TO CLAIMS 1-3

U-1876 METHOD OF ANESTHETIZING AT LEAST A PORTION OF THE MAXILLARY DENTAL ARCH

U-1877 METHOD OF TREATING PULMONARY HYPERTENSION BY ORALLY ADMINISTERING A FORMULATION OF A PHARMACEUTICALLY ACCEPTABLE SALT OF TREPROSTINIL

U-1878 FOR OPIOID DEPENDENCE

U-1879 METHOD OF DIAGNOSING TUMORS USING POSITRON EMISSION TOMOGRAPHY

U-1880 TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)

U-1881 IMPROVEMENT IN GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS BY USE OF A PEN INJECTOR

U-1882 MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANALGESIC AND ANTIPYRETIC ACTIVITY

U-1883 TREATMENT OF GASTROINTESTINAL STROMAL TUMORS (GIST)

U-1884 USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT

U-1885 USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT

U-1886 USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT

U-1887 USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT

U-1888 USE OF CONTROLLED RELEASE 25-HYDROXYVITAMIN D IN TREATING SECONDARY HYPERPARATHYROIDISM IN PATIENTS HAVING CHRONIC KIDNEY DISEASE

U-1889 TREATMENT OF HCV INFECTION USING DASABUVIR/OMBITASVIR/PARITAPREVIR/RITONAVIR FIXED DOSE COMBINATION

U-1890 OTC USE: ALLERGY SYMPTOM RELIEVER; TEMPORARILY RELIEVES THESE SYMPTOMS DUE TO HAY FEVER OR OTHER UPPER RESPIRATORY ALLERGIES; NASAL CONGESTION, RUNNY NOSE, SNEEZING, ITCHY NOSE, AND (ITCHY WATER EYES (AGES 12 AND UP))

U-1891 TREATMENT OR PREVENTION OF NAUSEA AND VOMITING

U-1892 METHOD OF TREATING LEFT VENTRICULAR DYSFUNCTION

U-1893 METHOD OF TREATING MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER IN PEDIATRIC PATIENTS

U-1894 COMBINATION TREATMENT WITH A GLITAZONE FOR IMPROVEMENT OF GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-1895	METHOD OF TREATING PROSTATE CANCER
U-1896	SUPPLEMENT FOR VITAMIN B12 DEFICIENCIES
U-1897	METHOD OF TREATING ACS USING ANGIOPLASTY WITH AGGRASTAT (TIROFIBAN HYDROCHLORIDE)
U-1898	METHOD OF INHIBITING PLATELET AGGREGATION WITH AGGRASTAT (TIROFIBAN HYDROCHLORIDE)
U-1899	TREATMENT OF PANCREATIC CANCER THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN
U-1900	TREATMENT OF THE SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
U-1901	TREATMENT OF SCHIZOAFFECTIVE DISORDER AS A MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS
U-1902	TREATMENT OR SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE, CARDIOVASCULAR EVENTS, OR CEREBROVASCULAR EVENTS AND RISK-REDUCTION OF ASPIRIN-ASSOCIATED GASTRIC ULCERS
U-1903	USE OF NALOXONE HYDROCHLORIDE FOR EMERGENCY TREATMENT OF KNOWN OR SUSPECTED OPIOID OVERDOSE, AS MANIFESTED BY RESPIRATORY AND/OR CENTRAL NERVOUS SYSTEM DEPRESSION.
U-1904	(I)TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY; (II)RESTORING/INCREASING FUNCTIONAL DYSTROPHIN PROTEIN; OR (III) INDUCING SKIPPING; EACH OF (I)-(III) IN PATIENTS HAVING A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
U-1905	METHOD OF TREATING A PATIENT HAVING CYSTIC FIBROSIS, THE PATIENT HAVING A R117H MUTATION IN CFTR, USING N-(5-HYDROXY-2,4-DI-TERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE
U-1906	METHOD OF TREATING A PATIENT HAVING CYSTIC FIBROSIS, SUCH AS A PATIENT HAVING A G551D MUTATION IN CFTR, USING N-(5-HYDROXY-2,4-DI-TERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE
U-1907	USE OF A DELIVERY DEVICE TO ADMINISTER A DOSE OF NALOXONE
U-1908	METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING IVACAFTOR AND FORM I LUMACAFTOR
U-1909	METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING IVACAFTOR AND LUMACAFTOR
U-1910	METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING THE DOSAGE UNIT OF CLAIM 1 OF U.S. PATENT NO. 8,716,338
U-1911	METHOD OF TREATING A PATIENT HAVING CYSTIC FIBROSIS USING IVACAFTOR AND LUMACAFTOR
U-1912	METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING A DOSAGE UNIT AS DEFINED IN CLAIM 1 OF U.S. PATENT NO. 9,192,606
U-1913	TREATMENT OF PEDIATRIC PATIENTS WITH BILATERAL OTITIS MEDIA WITH EFFUSION UNDERGOING TYMPANOSTOMY TUBE PLACEMENT
U-1914	IN COMBINATION WITH RITUXIMAB, FOR THE TREATMENT OF PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
U-1915	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS WITH SEVERE CHRONIC RENAL IMPAIRMENT AND WHO ARE INELIGIBLE FOR METFORMIN THERAPY BY ADMINISTERING LINAGLIPTIN
U-1916	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY (CINV)
U-1917	TREATMENT OF EXOCRINE PANCREATIC CANCER THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN
U-1918	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
U-1919	RESTORING AN MRNA READING FRAME TO INDUCE DYSTROPHIN PROTEIN PRODUCTION IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
U-1920	USE OF EXTENDED RELEASE ORAL 25-HYDROXYVITAMIN D3 IN TREATING SECONDARY HYPERPARATHYROIDISM IN ADULT PATIENTS HAVING CHRONIC KIDNEY DISEASE STAGE 3 OR STAGE 4
U-1921	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE BY PROVIDING AN ABUSE-DETERRENT ORAL CONTROLLED RELEASE COMBINATION DRUG PRODUCT

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-1922 INTRAVAGINAL PRASTERONE (DEHYDROEPIANDROSTERONE) AT A DAILY DOSE OF 6.5MG FOR THE TREATMENT OF DYSPAREUNIA, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO MENOPAUSE
- U-1923 IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY BASAL INSULIN OR LIXISENATIDE BY USE OF A PEN INJECTOR WITH A THREADED DRIVE SLEEVE
- U-1924 KYPROLIS IS INDICATED IN COMBINATION WITH LENALIDOMIDE PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY
- U-1925 USE OF AN AUTO INJECTOR TO ADMINISTER NALOXONE HCL
- U-1926 METHOD OF TREATING, REDUCING THE INCIDENCE OF, OR PREVENTING AN ISCHEMIC EVENT IN A PATIENT UNDERGOING PCI BY ADMINISTERING INTRAVENOUSLY 30 UG/KG BOLUS BEFORE PCI AND CONTINUOUS INFUSION OF 4 UG/KG/MIN FOR AT LEAST 2 HOURS OR THE DURATION OF THE PCI
- U-1927 TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB
- U-1928 RUBRACA IS INDICATED AS MONOTHERAPY FOR THE TREATMENT OF PATIENTS WITH DELETERIOUS BRCA MUTATION (GERMLINE AND/OR SOMATIC) ASSOCIATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH TWO OR MORE CHEMOTHERAPIES.
- U-1929 TREATMENT OF DIABETES MELLITUS WITH AN INHALED INSULIN TO IMPROVE GLYCEMIC CONTROL USING A DRY POWDER INHALATION SYSTEM COMPRISING AN INHALER, A CARTRIDGE AND A DRY POWDER MEDICAMENT COMPRISING INSULIN IN A SINGLE INHALATION
- U-1930 METHOD OF AEROSOLIZING/DEAGGLOMERATING AN INSULIN DRY POWDER FOR USE IN TREATING DIABETES MELLITUS VIA ORAL INHALATION USING AN INHALER WITH A CARTRIDGE CONTAINING THE INSULIN DRY POWDER.
- U-1931 PROPHYLAXIS OR TREATMENT OF VENOUS AND ARTERIAL THROMBOTIC DISEASE
- U-1932 METHOD OF TREATING MILD TO MODERATE ATOPIC DERMATITIS.
- U-1933 TREATMENT OF POSTOPERATIVE INFLAMMATION AND REDUCTION OF OCULAR PAIN IN PATIENTS WHO HAVE UNDERGONE CATARACT SURGERY
- U-1934 TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH A STRONG CYP1A2 INHIBITOR
- U-1935 REDUCTION OF THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN PATIENTS WITH A HISTORY OF MYOCARDIAL INFARCTION
- U-1936 TREATMENT OF MYOCARDIAL INFARCTION AND STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION
- U-1937 TREATMENT OF MYOCARDIAL INFARCTION IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION
- U-1938 TREATMENT OF STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION
- U-1939 ADMINISTRATION ONCE DAILY WITHIN TWO HOURS AFTER WAKING IN THE MORNING FOR IMPROVEMENT OF GLYCEMIC CONTROL IN A TYPE 2 DIABETES PATIENT
- U-1940 IMPROVEMENT IN THE APPEARANCE OF MODERATE TO SEVERE CONVEXITY OR FULLNESS ASSOCIATED WITH SUBMENTAL FAT IN ADULTS BY MEANS OF REDUCING SUBMENTAL FAT VOLUME AS DESCRIBED IN THE APPROVED LABELING
- U-1941 TREATMENT OF INFANTILE-ONSET SPINAL MUSCULAR ATROPHY
- U-1942 TREATMENT OF SPINAL MUSCULAR ATROPHY BY INCREASING EXON-7 INCLUSION IN SMN2 MRNA
- U-1943 TREATMENT OF SPINAL MUSCULAR ATROPHY
- U-1944 TREATMENT OF SPINAL MUSCULAR ATROPHY BY INHIBITING AN SMN2 PRE-MRNA INTRONIC SPLICING SILENCER SITE
- U-1945 IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN.
- U-1946 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
- U-1947 TREATMENT OF MARGINAL ZONE LYMPHOMA
- U-1948 A METHOD FOR TREATING CHRONIC MYELOID LEUKEMIA
- U-1949 FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-1950 TREATMENT OF PATIENTS WITH ADVANCED (METASTATIC) NON-SMALL CELL LUNG CANCER WHOSE DISEASE PROGRESSED DURING OR AFTER PLATINUM-BASED CHEMOTHERAPY
- U-1951 TREATMENT OF ONYCHOMYCOSIS OF A TOENAIL
- U-1952 FOR USE IN THE TREATMENT OF PATIENTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA
- U-1953 REDUCE THE RISK OF STROKE IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
- U-1954 TREATMENT OF DEEP VEIN THROMBOSIS WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
- U-1955 TREATMENT OF PULMONARY EMBOLISM WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
- U-1956 FOLLOWING INITIAL 6 MONTHS TREATMENT FOR DEEP VEIN THROMBOSIS (DVT) AND/OR PULMONARY EMBOLISM (PE), REDUCTION IN THE RISK OF RECURRENCE OF DVT AND OF PE WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
- U-1957 PROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM IN PATIENTS UNDERGOING KNEE OR HIP REPLACEMENT SURGERY, WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
- U-1958 FOR THE TREATMENT OF GENOTYPE 1, 2, 3 OR 4 CHRONIC HEPATITIS C VIRUS (HCV) INFECTION AS A COMPONENT OF A COMBINATION ANTIVIRAL TREATMENT REGIMEN WITH RIBAVIRIN
- U-1959 TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS WITH 1% OXYMETAZOLINE HYDROCHLORIDE CREAM
- U-1960 USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF SCHIZOPHRENIA IN ADULTS
- U-1961 USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: ACUTE MONOTHERAPY OF MANIC OR MIXED EPISODES (AGES 10 TO ADULT)
- U-1962 USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: MAINTENANCE MONOTHERAPY IN ADULTS
- U-1963 USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: AS ADJUNCTIVE TREATMENT TO LITHIUM OR VALPROATE IN ADULTS
- U-1964 ELEVATION OF INTRACELLULAR CGMP RESULTING IN INCREASED INTESTINAL FLUID AND ACCELERATED TRANSIT
- U-1965 FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) IN COMBINATION WITH TADALAFIL, WHEREIN THE WEIGHT RATIO OF AMBRISENTAN TO TADALAFIL IS ABOUT 1:2 TO ABOUT 1:3
- U-1966 USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: ACUTE MONOTHERAPY OF MANIC OR MIXED EPISODES IN PEDIATRIC PATIENTS AGE 10-17
- U-1967 METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH ONE OR MORE CONVENTIONAL ANTIHYPERGLYCEMIC AGENTS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
- U-1968 METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WHO HAVE NOT BEEN PREVIOUSLY TREATED WITH AN ANTIHYPERGLYCEMIC AGENT BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
- U-1969 TOPICAL TREATMENT OF ONYCHOMYCOSIS OF THE TOENAIL(S) DUE TO TRICHOPHYTON RUBRUM AND TRICHOPHYTON MENTAGROPHYTES
- U-1970 TREATMENT OF ONYCHOMYCOSIS OF A TOENAIL CAUSED BY TRICHOPHYTON RUBRUM OR TRICHOPHYTON MENTAGROPHYTES
- U-1971 FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
- U-1972 FOR THE TREATMENT OF PATIENTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA
- U-1973 METHOD OF TREATING CYSTIC FIBROSIS USING N-(5-HYDROXY-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE AND 3-(6-(1-2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID
- U-1974 TREATMENT OF HALLUCINATIONS AND DELUSIONS ASSOCIATED WITH PARKINSON'S DISEASE PSYCHOSIS
- U-1975 METHOD OF INCREASING EYELASH GROWTH WITH BIMATOPROST

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-1976 METHOD FOR TREATING TYPE 2 DIABETES MELLITUS (T2DM) IN PATIENTS WHO HAVE INADEQUATE CONTROL WITH DAPAGLIFLOZIN
- U-1977 METHOD FOR TREATING TYPE 2 DIABETES MELLITUS (T2DM) IN PATIENTS WHO ARE ALREADY TREATED WITH DAPAGLIFLOZIN AND SAXAGLIPTIN
- U-1978 TREATMENT OF ADVANCED PROSTATE CANCER WITH A REDUCED LIKELIHOOD OF CAUSING A GONADOTROPHIN RELEASING HORMONE AGONIST SIDE-EFFECT
- U-1979 THE TREATMENT OF CARCINOID SYNDROME DIARRHEA IN COMBINATION WITH SOMATOSTATIN ANALOG (SSA) THERAPY IN ADULTS INADEQUATELY CONTROLLED BY SSA THERAPY
- U-1980 A METHOD OF TREATING NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
- U-1981 IN COMBINATION WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY FOR TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER-2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
- U-1982 USE OF REVLIMID (LENALIDOMIDE) FOR TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA DUE TO LOW-OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES ASSOCIATED WITH A DELETION 5Q ABNORMALITY WITH OR WITHOUT ADDITIONAL CYTOGENETIC ABNORMALITIES
- U-1983 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB
- U-1984 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE
- U-1985 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, AS MAINTENANCE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTO-HSCT)
- U-1986 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE, WHEREIN THOSE PATIENTS HAVE NOT RECEIVED PREVIOUS TREATMENT FOR MULTIPLE MYELOMA
- U-1987 METHOD OF CONTROLLING GLYCEMIA IN DIABETICS BY ADMINISTERING AN INITIAL DOSE OF INSULIN-FDKP WITH A MEAL; DETERMINING BLOOD GLUCOSE LEVEL 1-2 HRS AFTER AND ADMINISTERING A SUPPLEMENTAL DOSE OF INSULIN-FDKP IF POSTPRANDIAL GLUCOSE LEVEL IS >140 MG/DL
- U-1988 METHOD TO TREAT INFANTILE HEMANGIOMA
- U-1989 INTRAVITREAL TREATMENT OF MACULAR EDEMA FOLLOWING BRANCH RETINAL VEIN OCCLUSION (BRVO) OR CENTRAL RETINAL VEIN OCCLUSION (CRVO)
- U-1990 INTRAVITREAL TREATMENT OF DIABETIC MACULAR EDEMA
- U-1991 REDUCTION OF MORTALITY IN ACUTE MYOCARDIAL INFARCTION
- U-1992 USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
- U-1993 ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON'S DISEASE EXPERIENCING "OFF" EPISODES
- U-1994 REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) IN ADULTS
- U-1995 TREATMENT OF TARDIVE DYSKINESIA
- U-1996 IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
- U-1997 IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR A PPAR-GAMMA AGONIST AND/OR SULFONYLUREA AND/OR INSULIN
- U-1998 TREATING HR-POS., HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER WITH PALBOCICLIB IN COMBO WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE BASED THERAPY IN POSTMENOPAUSAL WOMEN OR FULVESTRANT IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
- U-1999 CHRONIC IDIOPATHIC CONSTIPATION
- U-2000 MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS
- U-2001 USE FOR THE TREATMENT OF ASTHMA IN PATIENTS 6 YEARS OF AGE AND OLDER
- U-2002 USE FOR MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
- U-2003 A METHOD OF POSITIONING AN INTRAUTERINE SYSTEM BY HOLDING AN INSERTER HANDLE WITH ONE HAND, ADVANCING THE INSERTER THROUGH THE CERVIX AND INTO THE UTERUS, AND RETRACTING A SLIDER ON THE HANDLE TO RELEASE THE INTRAUTERINE SYSTEM

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-2004	REPLACEMENT THERAPY FOR ORAL CARBAMAZEPINE IN ADULTS WITH PARTIAL SEIZURES WITH COMPLEX SYMPTOMATOLOGY
U-2005	REPLACEMENT THERAPY FOR ORAL CARBAMAZEPINE IN ADULTS WITH GENERALIZED TONIC-CLONIC SEIZURES
U-2006	REPLACEMENT THERAPY FOR ORAL CARBAMAZEPINE IN ADULTS WITH MIXED SEIZURE PATTERNS THAT INCLUDE PARTIAL SEIZURES WITH COMPLEX SYMPTOMATOLOGY, GENERALIZED TONIC-CLONIC SEIZURES, OR OTHER PARTIAL OR GENERALIZED SEIZURES
U-2007	TREATMENT OF ADULT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WHO ARE FLT3 MUTATION-POSITIVE, IN COMBINATION WITH STANDARD CYTARABINE AND DAUNORUBICIN INDUCTION AND CYTARABINE CONSOLIDATION CHEMOTHERAPY
U-2008	TREATMENT OF ADULT PATIENTS WITH AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM), SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGICAL NEOPLASM (SM-AHN), OR MAST CELL LEUKEMIA (MCL)
U-2009	METHOD OF TREATING POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS AT HIGH RISK FOR FRACTURE.
U-2010	ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE
U-2011	TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY
U-2012	A METHOD FOR TREATING OVARIAN CANCER BY ADMINISTERING RUCAPARIB, WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA MUTATION
U-2013	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
U-2014	A METHOD OF TREATING SECONDARY HYPERPARATHYROIDISM (SHPT)
U-2015	SODIUM THIOSULFATE INJECTION IS INDICATED FOR SEQUENTIAL USE WITH SODIUM NITRITE FOR THE TREATMENT OF ACUTE CYANIDE POISONING
U-2016	TREATMENT FOR ONYCHOMYCOSIS THAT IS TINEA UNGUIUM
U-2017	TREATMENT OF OPIOID DEPENDENCE
U-2018	MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS IN A CRITICALLY ILL PATIENT WITH INTRAVENOUS IBUPROFEN IN NEED THEREOF
U-2019	METHOD OF DELIVERING TO A PATIENT WITH DIABETES MELLITUS IN A SINGLE INHALATION, GREATER THAN 75% OF A DRY POWDER DOSE COMPRISING INSULIN AND FUMARYL DIKETOPIPERAZINE USING A HIGH RESISTANCE TO FLOW DRY POWDER INHALER.
U-2020	MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST
U-2021	METHOD OF ADMINISTERING LEVETIRACETAM UNDER FASTED CONDITIONS
U-2022	METHOD OF ADMINISTERING LEVETIRACETAM UNDER FED CONDITIONS
U-2023	A METHOD OF INCREASING THE BIOAVAILABILITY OF GUAIFENESIN IN A SOLUTION CONTAINING 54% TO 66% BY WEIGHT OF PROPYLENE GLYCOL AND GLYCEROL, WHEREIN THE METHOD INCREASES THE CMAX BY AT LEAST 1.5 AND/OR INCREASES THE AUC (0-INF) BY AT LEAST 1.4
U-2024	METHOD FOR TRANSDERMALLY DELIVERING A DRUG TO A USER IN NEED THEREOF
U-2025	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
U-2026	TAFINLAR(R) IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST.
U-2027	TAFINLAR(R) IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST.
U-2028	TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY DESIGNATED SUSCEPTIBLE BACTERIA IN ADULTS
U-2029	PREVENTING CONDITION CHARACTERIZED BY UNDESIRED THROMBOSIS
U-2030	PROPHYLAXIS OF VENOUS THROMBOSIS
U-2031	TAFINLAR IS INDICATED AS A SINGLE AGENT FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-2032 TAFINLAR IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST.
- U-2033 MEKINIST IS INDICATED, AS A SINGLE AGENT OR IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS
- U-2034 INHIBITING COAGULATION
- U-2035 PROPHYLAXIS OF VENOUS THROMBOEMBOLISM
- U-2036 A METHOD OF TREATING PULMONARY HYPERTENSION COMPRISING PARENTERALLY ADMINISTERING A FORMULATION COMPRISING A) 0.1 TO 5% W/V OF TREPROSTINIL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND B) A CITRATE BUFFER
- U-2037 MEKINIST IS INDICATED, AS A SINGLE AGENT OR IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST
- U-2038 MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST
- U-2039 TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR
- U-2040 TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR
- U-2041 TREATMENT OF PARTIAL-ONSET SEIZURES
- U-2042 DISCONTINUING ADMINISTRATION OF FLUVOXAMINE TO AVOID DRUG INTERACTIONS WITH PIRFENIDONE AND THEN ADMINISTERING PIRFENIDONE
- U-2043 EXTENDED ADJUVANT TREATMENT OF ADULT PATIENTS WITH EARLY STAGE HER2-OVEREXPRESSED/AMPLIFIED BREAST CANCER, TO FOLLOW ADJUVANT TRASTUZUMAB BASE THERAPY
- U-2044 DOSE REDUCTION OF PIRFENIDONE BY ABOUT ONE HALF DURING CONCURRENT ADMINISTRATION OF CIPROFLOXACIN AT A DOSE OF 750 MG TWICE DAILY (1500 MG/DAY) TO REDUCE DRUG INTERACTIONS IN TREATMENT OF A FIBROTIC, INFLAMMATORY, OR AUTOIMMUNE DISORDER
- U-2045 ADMINISTRATION OF PIRFENIDONE AND AVOIDING CONCURRENT ADMINISTRATION OF CIPROFLOXACIN AT A DOSE OF 750 MG TO REDUCE DRUG INTERACTIONS IN TREATMENT OF A FIBROTIC, INFLAMMATORY, OR AUTOIMMUNE DISORDER
- U-2046 ADMINISTERING PIRFENIDONE WHILE AVOIDING CONCOMITANT USE OF A CYP1A2 INHIBITOR THAT IS A MODERATE TO STRONG INHIBITOR OF BOTH CYP1A2 AND ANOTHER CYP ENZYME SELECTED FROM CYP2C9, CYP2C19, AND CYP2D6
- U-2047 ADMINISTERING PIRFENIDONE CONCURRENTLY WITH FLUVOXAMINE, THE PIRFENIDONE AT A DOSE OF ABOUT 801 MG/DAY TO REDUCE DRUG INTERACTIONS WITH FLUVOXAMINE
- U-2048 ADMINISTERING PIRFENIDONE WHILE AVOIDING CO-ADMINISTRATION OF A STRONG CYP1A2 INHIBITOR TO AVOID DRUG INTERACTIONS WITH PIRFENIDONE
- U-2049 DISCONTINUING ADMINISTRATION OF A STRONG CYP1A2 INHIBITOR TO AVOID DRUG INTERACTIONS WITH PIRFENIDONE AND THEN ADMINISTERING PIRFENIDONE
- U-2050 ADMINISTERING PIRFENIDONE WHILE AVOIDING CO-ADMINISTRATION OF FLUVOXAMINE TO AVOID DRUG INTERACTIONS WITH PIRFENIDONE
- U-2051 DISCONTINUING SMOKING TO AVOID REDUCED PIRFENIDONE EFFICACY AND THEN ADMINISTERING PIRFENIDONE
- U-2052 DISCONTINUING ADMINISTRATION OF A STRONG CYP1A2 INDUCER TO AVOID REDUCED PIRFENIDONE EFFICACY AND THEN ADMINISTERING PIRFENIDONE
- U-2053 ADMINISTERING PIRFENIDONE WHILE AVOIDING CONCOMITANT ADMINISTRATION OF A STRONG INDUCER OF CYP1A2, INCLUDING CIGARETTE SMOKE, TO AVOID REDUCED PIRFENIDONE EFFICACY
- U-2054 ADMINISTERING PIRFENIDONE WHILE AVOIDING CONCOMITANT ADMINISTRATION OF A STRONG INDUCER OF CYP1A2 TO AVOID REDUCED PIRFENIDONE EFFICACY
- U-2055 DOSING OF AT LEAST 1600 MG/DAY FOLLOWING GRADE 2 LIVER ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF
- U-2056 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-1600 MG/DAY, FOLLOWING BY

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- ADMINISTERING AT LEAST 1600 MG/DAY IN TREATMENT OF IPF
- U-2057 DOSING 2403 MG/DAY PIRFENIDONE FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF
- U-2058 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-2400MG/DAY DOSE, FOLLOWED BY ADMINISTERING 2403MG/DAY IN TREATMENT OF IPF
- U-2059 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS OF LIVER FUNCTION ARE WITHIN NORMAL LIMITS, FOLLOWED BY FULL DAILY DOSE IN TREATMENT OF IPF
- U-2060 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS OF LIVER FUNCTION ARE WITHIN NORMAL LIMITS, THEN AT LEAST 1600MG/DAY IN TREATMENT OF IPF
- U-2061 DOSING OF AT LEAST 1600 MG/DAY FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF
- U-2062 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-1600 MG/DAY DOSE, FOLLOWED BY ADMINISTERING AT LEAST 1600 MG/DAY DOSE IN TREATMENT OF IPF
- U-2063 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS, FOLLOWED BY ADMINISTERING AT LEAST 1600 MG/DAY IN TREATMENT OF IPF
- U-2064 DOSING AT LEAST 1602 MG/DAY FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION
- U-2065 FULL DAILY DOSING FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION
- U-2066 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-2400 MG/DAY DOSE, FOLLOWED BY FULL DAILY DOSE
- U-2067 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE, FOLLOWED BY ADMINISTERING AT LEAST 1602 MG/DAY
- U-2068 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS OF LIVER FUNCTION ARE WITHIN NORMAL LIMITS, FOLLOWED BY FULL DAILY DOSE
- U-2069 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING A SUB-1600 MG/DAY DOSE, FOLLOWED BY ADMINISTERING AT LEAST 1602 MG/DAY
- U-2070 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS OF LIVER FUNCTION ARE WITHIN NORMAL LIMITS, THEN SUB-1600 MG/DAY, THEN AT LEAST 1602 MG/DAY
- U-2071 FULL DAILY DOSING FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF
- U-2072 FULL DAILY DOSING FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF
- U-2073 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS, FOLLOWED BY ADMINISTERING FULL DAILY DOSE IN TREATMENT OF IPF
- U-2074 DOSING 1602 MG/DAY PIRFENIDONE FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF
- U-2075 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS FOLLOWED BY ADMINISTERING 1602 MG/DAY IN TREATMENT OF IPF
- U-2076 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING 801 MG/DAY FOLLOWED BY ADMINISTERING 1602 MG/DAY IN TREATMENT OF IPF

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-2077 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-2400 MG/DAY DOSE THEN FULL DAY DAILY DOSE IN TREATMENT OF IPF
- U-2078 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN LIMITS, THEN SUB-2400MG/DAY DOSE, THEN FULL DAILY DOSE IN TREATMENT OF IPF
- U-2079 PIRFENIDONE DOSE ESCALATION REGIMEN FOR TREATMENT OF FIBROSIS AS 801 MG/DAY FOR DAYS 1-7 OF THE REGIMEN, 1602 MG/DAY FOR DAYS 8-14 OF THE REGIMEN, AND 2403 MG/DAY FOR AT LEAST DAY 15 OF THE REGIMEN
- U-2080 PIRFENIDONE DOSE ESCALATION REGIMEN FOR TREATMENT OF IPF AS 801 MG/DAY FOR DAYS 1-7 OF THE REGIMEN, 1602 MG/DAY FOR DAYS 8-14 OF THE REGIMEN, AND 2403 MG/DAY FOR AT LEAST DAY 15 OF THE REGIMEN
- U-2081 DISCONTINUING USE OF A CYP1A2 INHIBITOR THAT IS A MODERATE TO STRONG INHIBITOR OF BOTH CYP1A2 AND ANOTHER CYP ENZYME SELECTED FROM CYP2C9, CYP2C19, AND CYP2D6 AND THEN ADMINISTERING PIRFENIDONE
- U-2082 MODIFYING PIRFENIDONE ADMINISTRATION FROM A DOSE OF ABOUT 2400 MG/DAY DOWNWARD BY ABOUT 1600 MG/DAY WHILE CO-ADMINISTERING FLUVOXAMINE TO REDUCE DRUG INTERACTIONS WITH FLUVOXAMINE
- U-2083 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS, FOLLOWED BY 801 MG/DAY, DOSE, THEN 1602 MG/DAY IN TREATMENT OF IPF
- U-2084 TREATMENT OF SEVERE CHRONIC PAIN VIA INTRATHECAL INFUSION OF ZICONOTIDE IN PATIENTS ALSO RECEIVING MORPHINE
- U-2085 TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH RIFAMPIN
- U-2086 A METHOD FOR ADMINISTERING ESTRADIOL COMPRISING A MONOLITHIC TRANSDERMAL DRUG DELIVERY SYSTEM CONSISTING OF (I) A BACKING LAYER AND (II) A SINGLE ADHESIVE POLYMER MATRIX LAYER AS CLAIMED IN US PATENT NO. 9730900
- U-2087 TREATMENT OF RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH AN ISOCITRATE DEHYDROGENASE-2 (IDH2) MUTATION
- U-2088 TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY
- U-2089 TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY
- U-2090 FOR THE TREATMENT OF ADULTS WITH NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC)
- U-2091 TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN, IN A PATIENT NOT HOMOZYGOUS FOR THE UGT1A1*28 ALLELE
- U-2092 METHOD FOR CONFIRMING DOSE DELIVERY
- U-2093 TREATMENT OF TYPE II SPINAL MUSCULAR ATROPHY
- U-2094 TREATMENT OF TYPE III SPINAL MUSCULAR ATROPHY
- U-2095 MITOSOL IS AN ANTIMETABOLITE INDICATED AS AN ADJUNCT TO AB EXTERNO GLAUCOMA SURGERY. IT IS INTENDED FOR TOPICAL APPLICATION TO THE SITE OF GLAUCOMA FILTRATION SURGERY
- U-2096 SOTYLIZE IS INDICATED FOR THE MAINTENANCE OF NORMAL SINUS RHYTHM [DELAY IN TIME TO RECURRENCE OF ATRIAL FIBRILLATION/ATRIAL FLUTTER (AFIB/AFL)] IN PATIENTS WITH SYMPTOMATIC AFIB/AFL WHO ARE CURRENTLY IN SINUS RHYTHM
- U-2097 TREATMENT OF DMD IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
- U-2098 INCREASING PRODUCTION OF FUNCTIONAL DYSTROPHIN PROTEIN IN DMD PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
- U-2099 INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING BRONCHITIS AND/OR EMPHYSEMA
- U-2100 INDICATED FOR THE ONCE-DAILY TREATMENT OF ASTHMA IN PATIENTS 18 YEARS AND OLDER

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-2101 MAINTENANCE TREATMENT OF RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER, WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
- U-2102 TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA-MUTATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH THREE OR MORE PRIOR LINES OF CHEMOTHERAPY BASED ON AN FDA-APPROVED COMPANION DIAGNOSTIC FOR LYNPARZA
- U-2103 MAINTENANCE TREATMENT OF BRCA-MUTATED RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER, WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
- U-2104 TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE
- U-2105 TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING IMMEDIATE RELEASE LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
- U-2106 TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
- U-2107 TREATMENT OF LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, DIFFERENTIATED THYROID CARCINOMA REFRACTORY TO RADIOACTIVE IODINE TREATMENT
- U-2108 TREATMENT OF HORMONE RECEPTOR POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN NOT PREVIOUSLY TREATED WITH ENDOCRINE THERAPY
- U-2109 CAROSPIR IS INDICATED FOR TREATMENT OF NYHA CLASS III-IV HEART FAILURE AND REDUCED EJECTION FRACTION TO INCREASE SURVIVAL, MANAGE EDEMA, AND TO REDUCE THE NEED FOR HOSPITALIZATION FOR HEART FAILURE
- U-2110 METHOD FOR CHRONIC WEIGHT MANAGEMENT IN PATIENTS WITH MODERATE RENAL IMPAIRMENT WHO ARE OBESE, OR OVERWEIGHT AND HAVE AT LEAST ONE WEIGHT RELATED COMORBID CONDITION
- U-2111 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1-5 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 1-5
- U-2112 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 6 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 6
- U-2113 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 7 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 7
- U-2114 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 9 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 9
- U-2115 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 10 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 10
- U-2116 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 12 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 12
- U-2117 ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 14-15 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 14-15
- U-2118 ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 16-18 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 16-18
- U-2119 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- SECRETAGOGUE AS RECITED IN CLAIM 19 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 19
- U-2120 TREATMENT OF PATIENTS 18 YEARS OF AGE AND OLDER WITH COMPLICATED URINARY TRACT INFECTIONS CAUSED BY SUSCEPTIBLE MICROORGANISMS
- U-2121 TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ABSENCE SEIZURES
- U-2122 USE FOR REDUCING EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
- U-2123 TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS WITH EPILEPSY WHO HAVE BEEN PREVIOUSLY TREATED WITH OXCARBAZEPINE
- U-2124 TREATMENT OF ADULT PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR SYSTEMIC THERAPIES
- U-2125 THE TREATMENT OF AN INFLAMMATORY DISORDER OF THE RESPIRATORY TRACT BY ONCE-PER-DAY ADMINISTRATION OF A PHARMACEUTICAL FORMULATION COMPRISING FLUTICASONE FUROATE AND A LONG-ACTING BETA2 ADRENORECEPTOR AGONIST
- U-2126 USE OF FLUTICASONE FUROATE FOR THE TREATMENT OF AN INFLAMMATORY OR ALLERGIC CONDITIONS, INCLUDING CHRONIC OBSTRUCTIVE PULMONARY DISEASE
- U-2127 INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
- U-2128 METHOD OF INHIBITING THE BINDING OF ACETYLCHOLINE TO AN ACETYLCHOLINE RECEPTOR IN THE RESPIRATORY TRACT OF A HUMAN, COMPRISING CONTACTING THE RECEPTOR WITH AN EFFECTIVE AMOUNT OF UMECLIDINIUM, VIA INHALATION
- U-2129 METHOD OF INHIBITING THE BINDING OF ACETYLCHOLINE TO AN ACETYLCHOLINE RECEPTOR IN THE RESPIRATORY TRACT OF A HUMAN, COMPRISING CONTACTING THE RECEPTOR WITH AN EFFECTIVE AMOUNT OF UMECLIDINIUM, VIA TOPICAL APPLICATION
- U-2130 TREATMENT OF PARTIAL ONSET SEIZURES IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY
- U-2131 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION, WITH COMPARABLE EFFICACY, AND A REDUCTION IN SPECIFIED ADVERSE EVENTS, COMPARED TO BRIMONIDINE 0.2% TID
- U-2132 IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY
- U-2133 METHOD OF DELIVERING FLUTICASONE PROPIONATE TO A NASAL AIRWAY
- U-2134 THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY ONCE-PER-DAY ADMINISTRATION OF A PHARMACEUTICAL FORMULATION COMPRISING FLUTICASONE FUROATE AND A LONG-ACTING BETA2 ADRENORECEPTOR
- U-2135 AS MONOTHERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY AND PRIOR CHEMOTHERAPY IN THE METASTATIC SETTING
- U-2136 TREATMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
- U-2137 TREATMENT OF POSTHERPETIC NEURALGIA
- U-2138 TOPICAL TREATMENT OF ACTINIC KERATOSIS OF THE FACE OR SCALP USING MORE THAN ONE TREATMENT COURSE OF INGENOL MEBUTATE
- U-2139 TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE
- U-2140 METHOD OF TREATING PARTIAL ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER
- U-2141 TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6
- U-2142 REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND/OR PULMONARY EMBOLISM (PE) IN PATIENTS AT CONTINUED RISK FOR RECURRENT DVT AND/OR AFTER COMPLETION OF INITIAL TREATMENT LASTING AT LEAST 6 MONTHS
- U-2143 AFTER COMPLETION OF INITIAL TREATMENT LASTING AT LEAST 6 MONTHS, TO REDUCE THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS AND/OR PULMONARY EMBOLISM IN CERTAIN PATIENTS WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST 5 CONSECUTIVE DAYS
- U-2144 REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION
- U-2145 TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-2146 IMPROVEMENT IN GLYCEMIC CONTROL IN DIABETES MELLITUS PATIENTS BY USE OF A PEN INJECTOR WITH A ROTATING DRIVE SLEEVE

U-2147 TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY ORALLY ADMINISTERING 20MG OF TASIMELTEON ONCE DAILY BEFORE BEDTIME

U-2148 A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT BY MEASURING AND DISPLAYING AN INDICATION OF THE CALCULATED DELIVERY CONCENTRATION OF NITRIC OXIDE AS COMPARED TO THE DESIRED DELIVERY CONCENTRATION OF NITRIC OXIDE

U-2149 TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY ADMINISTERING TASIMELTEON

U-2150 TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE

U-2151 METHOD OF TREATING PAIN OR INFLAMMATION WITH AN INJECTABLE CONTROLLED OR SUSTAINED RELEASE FORMULATION OF TRIAMCINOLONE ACETONIDE

U-2152 TREATMENT OF PAIN ASSOCIATED WITH IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE)

U-2153 REDUCING FASTING PLASMA GLUCOSE IN A HUMAN IN NEED THEREOF USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4

U-2154 REDUCING FASTING PLASMA GLUCOSE IN A HUMAN IN NEED THEREOF USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4

U-2155 REDUCING BODY WEIGHT IN A HUMAN IN NEED THEREOF USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4

U-2156 REDUCING HBA1C IN A HUMAN IN NEED THEREOF USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4

U-2157 TREATING TYPE 2 DIABETES MELLITUS BY STIMULATING INSULIN RELEASE

U-2158 DECREASING GASTRIC MOTILITY OR DELAYING GASTRIC EMPTYING BY USING A SUSTAINED-RELEASE COMPOSITION

U-2159 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

U-2160 MANAGEMENT OF OSTEOARTHRITIS PAIN BY ADMINISTERING 5 MG OF MELOXICAM

U-2161 TREATMENT OF NAUSEA AND VOMITING, INCLUDING THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY OR MODERATELY EMETOGENIC CANCER CHEMOTHERAPY

U-2162 FOR CLEANSING THE LARGE INTESTINE AS A PREPARATION FOR COLONOSCOPY

U-2163 TREATMENT OF HR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER-2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER IN COMBINATION WITH PALBOCICLIB OR ABEMACICLIB IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY

U-2164 ZELBORAF IS INDICATED FOR THE TREATMENT OF PATIENTS WITH ERDHEIM-CHESTER DISEASE WITH BRAF V600 MUTATION

U-2165 MANAGEMENT OF OSTEOARTHRITIS PAIN BY ADMINISTERING 10 MG OF MELOXICAM

U-2166 TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER

U-2167 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER

U-2168 METHOD OF USING A LOGIC CIRCUIT TO STABILIZE BATTERY VOLTAGE SUPPLIED TO A SENSOR EMBEDDED WITH A TABLET AND THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER

U-2169 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT

U-2170 METHOD OF USING A RECEIVER TO RECEIVE A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT

U-2171 ADJUVANT TREATMENT OF ADULT PATIENTS AT HIGH RISK OF RECURRENT RCC FOLLOWING NEPHRECTOMY

U-2172 METHOD TO TREAT SEVERE ALLERGIC EMERGENCIES IN PATIENTS WEIGHING 7.5 TO 15 KG (16.5 TO 33 LBS)

U-2173 TREATING OPIOID DEPENDENCE BY ADMINISTERING BUPRENORPHINE

U-2174 TREATING OPIOID DEPENDENCY BY ADMINISTERING BUPRENORPHINE ONCE PER MONTH

U-2175 TREATING OPIOID DEPENDENCY BY ADMINISTERING BUPRENORPHINE ONCE MONTHLY

U-2176 TREATING OPIOID ADDICTION BY ADMINISTERING BUPRENORPHINE

U-2177 TREATING OPIOID ADDICTION BY SUBCUTANEOUS INJECTION OF BUPRENORPHINE

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-2178 TREATING OPIOID ADDICTION BY ADMINISTERING BUPRENORPHINE COMPOSITION WITH 28 DAY DOSE DURATION

U-2179 IN SITU FORMATION OF SOLID BUPRENORPHINE COMPOSITION

U-2180 TREATING ADDICTION WITH 100 MG OR 300 MG DOSE OF BUPRENORPHINE

U-2181 TREATING OPIOID DEPENDENCY BY SUBCUTANEOUSLY ADMINISTERING BUPRENORPHINE

U-2182 IMPROVEMENT OF GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS

U-2183 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 13

U-2184 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1, 13, AND 14

U-2185 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 15 AND 27

U-2186 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 15, 27, AND 28

U-2187 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 29 AND 39

U-2188 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 29, 39, AND 40

U-2189 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 41 AND 52

U-2190 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 41, 52, AND 53

U-2191 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 54 AND 64

U-2192 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 54, 64, AND 65

U-2193 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 66 AND 75

U-2194 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 66, 75, AND 76

U-2195 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 77 AND 87

U-2196 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 77, 87, AND 88

U-2197 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 89 AND 99

U-2198 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 89, 99, AND 100

U-2199 TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA

U-2200 COMBINATION TREATMENT WITH INSULIN GLARGINE WITH OR WITHOUT METFORMIN FOR IMPROVEMENT OF GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS

U-2201 TREATMENT OF BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

BIPOLAR DISORDER

- U-2202 OZEMPIC IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
- U-2203 A METHOD OF PROVIDING A SUBJECT WITH A THERAPEUTICALLY EFFECTIVE AMOUNT OF RACEMIC METHYLPHENIDATE BY ORALLY ADMINISTERING TO SAID SUBJECT A SINGLE METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET AS CLAIMED
- U-2204 TREATING PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA (APL) WHO ARE REFRACTORY TO, OR HAVE RELAPSED FROM, RETINOID AND ANTHRACYCLINE CHEMOTHERAPY, AND WHOSE APL IS CHARACTERIZED BY THE PRESENCE OF THE T(15;17) TRANSLOCATION OR PML/RAR-ALPHA GENE EXPRESSION
- U-2205 TREATMENT OF SEBORRHEIC KERATOSES THAT ARE RAISED
- U-2206 TREATING OPIOID DEPENDENCY BY ADMINISTERING BUPRENORPHINE
- U-2207 TREATING ADDICTION BY SUBCUTANEOUS INJECTION OF BUPRENORPHINE
- U-2208 TREATING ADDICTION BY ONCE PER MONTH ADMINISTRATION OF BUPRENORPHINE
- U-2209 TREATING OPIOID ADDICTION BY ADMINISTERING BUPRENORPHINE ONCE PER MONTH
- U-2210 TREATING OPIOID ADDICTION BY 100 MG OR 300 MG DOSE BUPRENORPHINE
- U-2211 TREATING OPIOID ADDICTION BY ADMINISTRATION OF BUPRENORPHINE
- U-2212 REDUCING FASTING PLASMA GLUCOSE IN A HUMAN IN NEED THEREOF IN COMBINATION WITH A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4
- U-2213 REDUCING HBA1C IN A HUMAN IN NEED THEREOF IN COMBINATION WITH A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4
- U-2214 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
- U-2215 ERTUGLIFLOZIN IN COMBINATION WITH SITAGLIPTIN AND IN FURTHER COMBINATION WITH METFORMIN AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
- U-2216 ERTUGLIFLOZIN AND SITAGLIPTIN IN COMBINATION AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
- U-2217 TREATING HIGH OUTPUT SHOCK WITH ANGIOTENSIN II BY INCREASING MEAN ARTERIAL PRESSURE IN PATIENTS TREATED WITH CATECHOLAMINES AND REDUCING CATECHOLAMINE USE
- U-2218 MAINTAINING MEAN ARTERIAL PRESSURE OF ABOUT 65 MMHG OR HIGHER WITH ANGIOTENSIN II IN SHOCK PATIENTS TREATED WITH CATECHOLAMINES AND REDUCING CATECHOLAMINE USE
- U-2219 TREATMENT OF CHRONIC SMALL LYMPHOCYTIC LEUKEMIA
- U-2220 A METHOD FOR THE DIAGNOSIS OF ADULT GROWTH HORMONE DEFICIENCY BY MEASURING THE LEVEL OF GROWTH HORMONE AFTER ORAL ADMINISTRATION OF MACIMORELIN
- U-2221 TREATING REFRACTORY HYPOTENSION WITH ABOUT 20 NG/KG/MIN ANGIOTENSIN II IN A PATIENT RECEIVING VASOPRESSOR
- U-2222 RELIEVES REDNESS OF THE EYE DUE TO MINOR EYE IRRITATIONS
- U-2223 METHOD OF TREATING ANGINA PECTORIS
- U-2224 TREATMENT OF DYSKINESIA AND INCREASING ON TIME WITHOUT TROUBLESOME DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
- U-2225 METHOD OF ADMINISTERING A LOCAL ANESTHETIC TO THE MUCOUS MEMBRANES IN PATIENTS WITH HEPATIC IMPAIRMENT
- U-2226 METHOD OF ADMINISTERING A LOCAL ANESTHETIC TO THE MUCOUS MEMBRANES IN PATIENTS WITH RENAL IMPAIRMENT
- U-2227 METHOD OF ADMINISTERING A LOCAL ANESTHETIC TO THE MUCOUS MEMBRANES IN GERIATRIC PATIENTS
- U-2228 TREATMENT OF SMALL LYMPHOCYTIC LEUKEMIA
- U-2229 IN COMBINATION WITH TRETINOIN, TREATING ADULTS AND PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH NEWLY-DIAGNOSED LOW-RISK ACUTE PROMYELOCYTIC LEUKEMIA (APL) CHARACTERIZED BY THE PRESENCE OF THE T(15;17) TRANSLOCATION OR PML/RAR-A GENE EXPRESSION
- U-2230 IRRITABLE BOWEL SYNDROME WITH CONSTIPATION
- U-2231 TREATING REFRACTORY HYPOTENSION WITH ABOUT 5 NG/KG/MIN TO ABOUT 20 NG/KG/MIN

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

ANGIOTENSIN II IN A PATIENT RECEIVING VASOPRESSOR

- U-2232 TREATMENT OF PSORIATIC ARTHRITIS USING A DOSAGE TITRATION SCHEDULE
- U-2233 TREATMENT OF PSORIATIC ARTHRITIS WITH APREMILAST USING A DOSAGE TITRATION SCHEDULE AND A SECOND ACTIVE AGENT
- U-2234 USE OF IVACAFTOR FOR TREATING CYSTIC FIBROSIS IN A PATIENT WITH A MILD TO MODERATE CF PHENOTYPE WITH AT LEAST ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
- U-2235 USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC HIGH-RISK CASTRATION-SENSITIVE PROSTATE CANCER
- U-2236 REDUCING THE RISK OF PRETERM BIRTH IN WOMEN WITH A SINGLETON PREGNANCY WHO HAVE A HISTORY OF SINGLETON SPONTANEOUS PRETERM BIRTH
- U-2237 TREATMENT OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC)
- U-2238 METHOD OF IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH DIABETES MELLITUS BY ADMINISTERING A MIXTURE OF INSULIN DEGLUDEC AND INSULIN ASPART DURING OR AROUND THE TIME OF THE LARGEST MEAL OF THE DAY
- U-2239 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION, WITH A REDUCTION IN SPECIFIED ADVERSE EVENTS, COMPARED TO BRIMONIDINE 0.2% TID
- U-2240 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION, WITH COMPARABLE EFFICACY TO BRIMONIDINE 0.2% TID
- U-2241 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
- U-2242 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
- U-2243 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
- U-2244 A METHOD OF TREATING BACTERIAL INFECTIONS IN HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) PATIENTS COMPRISING ADMINISTERING A BACTERICIDALLY EFFECTIVE AMOUNT OF AVIBACTAM SODIUM
- U-2245 A METHOD OF TREATING A BACTERIAL INFECTION IN HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) PATIENTS COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AVIBACTAM SODIUM
- U-2246 TEZACAFTOR AND IVACAFTOR FOR THE TREATMENT OF CYSTIC FIBROSIS IN PATIENTS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HAVING AT LEAST ONE CFTR GENE MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR BASED ON IN VITRO DATA AND/OR CLINICAL EVIDENCE
- U-2247 TEZACAFTOR AND IVACAFTOR FOR THE TREATMENT OF PATIENTS WITH A MILD TO MODERATE CLINICAL PHENOTYPE OF CYSTIC FIBROSIS HAVING AT LEAST ONE CFTR GENE MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR BASED ON IN VITRO DATA AND/OR CLINICAL EVIDENCE
- U-2248 TEZACAFTOR AND IVACAFTOR FOR THE TREATMENT OF CYSTIC FIBROSIS IN PATIENTS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HETEROZYGOUS FOR THE F508DEL MUTATION AND A SECOND MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR
- U-2249 MANAGEMENT OF ACUTE PAIN SEVERE ENOUGH TO REQUIRE AN OPIOID ANALGESIC AND FOR WHICH ALTERNATIVE TREATMENTS ARE INADEQUATE
- U-2250 DETECTION OF CARCINOMA IN THE BLADDER BY PHOTODYNAMIC CYSTOSCOPY
- U-2251 IN COMBINATION WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
- U-2252 THE TREATMENT OF ACUTE OTITIS EXTERNA IN PATIENTS 6 MONTHS OF AGE AND OLDER DUE TO PSEUDOMONAS AERUGINOSA AND STAPHYLOCOCCUS AUREUS
- U-2253 PROPHYLACTIC TREATMENT OF NAUSEA AND VOMITING, INCLUDING PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED CHEMOTHERAPY
- U-2254 USE OF POMALIDOMIDE WITH DEXAMETHASONE FOR PATIENTS WITH MULTIPLE MYELOMA AFTER AT LEAST TWO PRIOR THERAPIES INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR AND DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETING THE LAST THERAPY
- U-2255 TREATING SECONDARY HYPERPARATHYROIDISM IN CHRONIC KIDNEY DISEASE WITH SUSTAINED RELEASE 25-HYDROXYVITAMIN D TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

LEVEL AND THE SUSTAINED RELEASE IS OVER AT LEAST 10 HOURS

- U-2256 TREATING SECONDARY HYPERPARATHYROIDISM IN CHRONIC KIDNEY DISEASE WITH SUSTAINED RELEASE 25-HYDROXYVITAMIN D TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL AND CMAX IS REDUCED COMPARED TO BOLUS IV INJECTION AND IMMEDIATE-RELEASE, ORAL DOSING
- U-2257 TREATING SHPT IN CKD WITH SUSTAINED RELEASE CALCIFEDIOL TO REDUCE SERUM PARATHYROID HORMONE LEVEL AND CHANGE IN SERUM CONCENTRATION OF CALCIFEDIOL IN DOSE INTERVAL IS REDUCED COMPARED TO BOLUS IV INJECTION AND IMMEDIATE-RELEASE, ORAL DOSING
- U-2258 TREATING SECONDARY HYPERPARATHYROIDISM IN CKD WITH SUSTAINED RELEASE CALCIFEDIOL TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL AND CMAX24HR/C24HR IS REDUCED COMPARED TO BOLUS IV INJECTION AND IMMEDIATE-RELEASE, ORAL DOSING
- U-2259 TREATING SECONDARY HYPERPARATHYROIDISM IN CKD WITH SUSTAINED RELEASE CALCIFEDIOL TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL AND TMAX IS INCREASED COMPARED TO BOLUS IV INJECTION AND IMMEDIATE-RELEASE, ORAL DOSING
- U-2260 METHOD OF REDUCING THE RISK OF PERIPROCEDURAL MYOCARDIAL INFARCTION, AND STENT THROMBOSIS IN A PATIENT UNDERGOING PCI BY ADMINISTERING INTRAVENOUSLY 30 UG/KG BOLUS BEFORE PCI AND THEN A CONTINUOUS INFUSION
- U-2261 MODIFIED DOSING REGIMEN FOR THE MANAGEMENT OF MILD TO MODERATE PAIN OR MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS
- U-2262 MODIFIED DOSING REGIMEN FOR THE REDUCTION OF FEVER
- U-2263 MODIFIED DOSING REGIMEN FOR THE MANAGEMENT OF MODERATE TO SEVERE PAIN WITH ADJUNCTIVE OPIOID ANALGESICS
- U-2264 METHODS OF TREATING PAIN, INFLAMMATION, FEVER, PATENT DUCTUS ARTERIOSIS WITH AQUEOUS COMPOSITION
- U-2265 PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HEC AND MEC IN ADULT AND PEDIATRIC PATIENTS
- U-2266 METHODS OF MAKING AQUEOUS COMPOSITION AND TREATING PAIN, INFLAMMATION, FEVER, PATENT DUCTUS ARTERIOSIS WITH AQUEOUS COMPOSITION
- U-2267 METHOD FOR RELIEVING THE PAIN ASSOCIATED WITH POST-HERPETIC NEURALGIA
- U-2268 DISCONTINUING A STRONG CYP1A2 INDUCER TO AVOID REDUCED PIRFENIDONE EFFICACY AND THEN ADMINISTERING PIRFENIDONE
- U-2269 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-2400MG/DAY DOSE THEN FULL DAILY DOSE IN TREATMENT OF IPF
- U-2270 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS, THEN SUB-2400MG/DAY DOSE, THEN FULL DAILY DOSE IN TREATMENT OF IPF
- U-2271 THERAPEUTIC TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER, SYMPTOMATIC BONE METASTASES AND NO KNOWN VISCERAL METASTATIC DISEASE
- U-2272 TREATMENT OF NASAL POLYPS IN PATIENTS ≥ 18 YEARS OF AGE WHO HAVE HAD ETHMOID SINUS SURGERY USING A CORTICOSTEROID-ELUTING (MOMETASONE FUROATE) IMPLANT
- U-2273 A METHOD FOR TREATING EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER, WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA MUTATION
- U-2274 MAINTAINING SERUM 25-HYDROXYVITAMIN D AT A LEVEL OF AT LEAST 30 NG/ML WITH ORAL, SUSTAINED RELEASE 25-HYDROXYVITAMIN D
- U-2275 TREATING CYSTIC FIBROSIS PATIENTS AGES 12 AND OLDER, WHO ARE HOMOZYGOUS FOR F508DEL OR HAVE AT LEAST 1 CFTR GENE MUTATION RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH TEZACAFTOR AND A SOLID COMPOSITION COMPRISING AMORPHOUS (<30% CRYSTALLINE) IVACAFTOR
- U-2276 METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT AGE 6 OR OLDER HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFTOR AND A SOLID COMPOSITION COMPRISING AMORPHOUS (LESS THAN ABOUT 30% CRYSTALLINE) IVACAFTOR
- U-2277 IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY LIXISENATIDE
- U-2278 IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY LIXISENATIDE IN COMBINATION WITH METFORMIN

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-2279 IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY LIXISENATIDE IN COMBINATION WITH METFORMIN AND A SECOND ORAL ANTIDIABETIC DRUG
- U-2280 ADJUNCTIVE TREATMENT OF PATIENTS WITH TSC-ASSOCIATED PARTIAL-ONSET SEIZURES
- U-2281 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 1 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1
- U-2282 ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 2 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 2
- U-2283 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 3-7 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 3-7
- U-2284 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 8 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 8
- U-2285 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 11 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 11
- U-2286 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 14 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 14
- U-2287 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 16-19 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 16-19
- U-2288 TREATMENT OF TYPE 2 DIABETES MELLITUS WITH EXENATIDE AS AN ADD-ON TO BASIL INSULIN OR BASAL INSULIN PLUS METFORMIN THERAPY
- U-2289 TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21L858R MUTATIONS
- U-2290 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M² ≤ EGFR < 60 ML/MIN/1.73 M²) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
- U-2291 REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS IN PATIENTS WITH A HISTORY OF MYOCARDIAL INFARCTION (MI) OR WITH PERIPHERAL ARTERIAL DISEASE (PAD)
- U-2292 METHOD OF REDUCING THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
- U-2293 USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF CANCER CHEMOTHERAPY, INCLUDING, BUT NOT LIMITED TO, HIGHLY EMEETOGENIC CHEMOTHERAPY
- U-2294 TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT
- U-2295 TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER
- U-2296 TAFINLAR IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION
- U-2297 IMPROVEMENT OF GLYCEMIC CONTROL IN TYPE 2 DIABETES PATIENTS BY ADMINISTERING A STARTING DOSE OF 10 MCG FOR 14 DAYS AND INCREASING TO A MAINTENANCE DOSE OF 20 MCG ON DAY 15
- U-2298 TAFINLAR IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ANAPLASTIC THYROID CANCER (ATC)

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- WITH BRAF V600E MUTATION AND WITH NO SATISFACTORY LOCOREGIONAL TREATMENT OPTIONS
- U-2299 TAFINLAR IS INDICATED AS A SINGLE AGENT FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E MUTATION
- U-2300 USE IN COMBINATION WITH THE MUSCARINIC ANTAGONIST SOLIFENACIN SUCCINATE FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY
- U-2301 USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY EMETOGENIC CANCER CHEMOTHERAPY
- U-2302 MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION
- U-2303 MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION
- U-2304 MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION
- U-2305 MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ANAPLASTIC THYROID CANCER (ATC) WITH BRAF V600E MUTATION AND WITH NO SATISFACTORY LOCOREGIONAL TREATMENT OPTIONS
- U-2306 ONCE DAILY TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS WITH 1% OXYMETAZOLINE HYDROCHLORIDE CREAM
- U-2307 TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE
- U-2308 TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME WHO ARE DEPENDENT ON PARENTERAL SUPPORT
- U-2309 USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION
- U-2310 FOR CLEANSING OF THE COLON IN PREPARATION FOR COLONOSCOPY IN ADULTS
- U-2311 TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A XANTHINE OXIDASE INHIBITOR ALONE
- U-2312 TREATMENT OF HYPERKALEMIA IN ADULTS
- U-2313 METHOD OF REDUCING THE RISK OF CARDIOVASCULAR DEATH, NON-FATAL MYOCARDIAL INFARCTION, AND/OR NON-FATAL STROKE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE BY ADMINISTERING LIRAGLUTIDE
- U-2314 TREATMENT OF THROMBOCYTOPENIA IN AN ADULT PATIENT WITH CHRONIC LIVER DISEASE WHO IS SCHEDULED TO UNDERGO A PROCEDURE USING DOPTelet
- U-2315 TREATMENT OF MULTIPLE SCLEROSIS IN THE PEDIATRIC PATIENT POPULATION WITH 0.25 MG FINGOLIMOD
- U-2316 TREATMENT OF DYSPAREUNIA
- U-2317 TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY
- U-2318 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HAVE AT LEAST ONE CFTR GENE MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH TEZACAFTOR AND IVACAFTOR
- U-2319 KYPROLIS IS INDICATED IN COMBINATION WITH DEXAMETHASONE OR WITH LENALIDOMIDE PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY
- U-2320 KYPROLIS IS INDICATED AS A SINGLE AGENT FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE OR MORE LINES OF THERAPY
- U-2321 A METHOD OF APPLYING TRYPAN BLUE ONTO AN OUTER SURFACE OF THE ANTERIOR LENS CAPSULE TO FACILITATE REMOVAL OF THE LENS SUBSTANCE
- U-2322 TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC)
- U-2323 TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-2324 FOR SECONDARY PREVENTION OF CARDIOVASCULAR AND CEREBROVASCULAR EVENTS IN PATIENTS AT RISK OF DEVELOPING ASPIRIN-ASSOCIATED GASTRIC ULCERS
- U-2325 EMERGENCY TREATMENT OF ALLERGIC REACTIONS (TYPE 1), INCLUDING ANAPHYLAXIS; A METHOD OF TREATING ALLERGIC REACTION, ANAPHYLAXIS, ANAPHYLACTIC SHOCK, OR COMBINATION THEREOF BY AN INJECTION OF AT LEAST ONE DOSAGE OF THE INJECTABLE LIQUID PHARMACEUTICAL
- U-2326 TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
- U-2327 TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS, COMPRISING MONITORING A PATIENT'S SERUM SODIUM CONCENTRATION
- U-2328 METHOD OF USING PLAZOMICIN TO TREAT BACTERIAL INFECTIONS
- U-2329 METHOD OF ADMINISTERING A LOCAL ANESTHETIC PRIOR TO PERFORMING A DIAGNOSTIC OR SURGICAL PROCEDURE ON A SUBJECT WITH HEPATIC OR RENAL IMPAIRMENT
- U-2330 METHOD OF TREATING MELANOMA
- U-2331 INDICATED IN COMBINATION WITH ENCORAFENIB FOR THE TREATMENT OF MELANOMA
- U-2332 INDICATED IN COMBINATION WITH ENCORAFENIB FOR THE TREATMENT OF MELANOMA MEDIATED BY A B-RAF PROTEIN KINASE
- U-2333 INDICATED IN COMBINATION WITH ENCORAFENIB FOR THE TREATMENT OF MELANOMA WITH A BRAF MUTATION
- U-2334 TREATMENT OF MELANOMA WITH A BRAF MUTATION
- U-2335 TREATMENT OF MELANOMA
- U-2336 TREATMENT OF MELANOMA MEDIATED BY A B-RAF PROTEIN KINASE
- U-2337 INDICATED IN COMBINATION WITH BINIMETINIB FOR THE TREATMENT OF MELANOMA WITH A BRAF MUTATION
- U-2338 MAINTAINING MEAN ARTERIAL PRESSURE OF ABOUT 65 MMHG OR ABOVE WITH ABOUT 1 NG/KG/MIN TO ABOUT 40 NG/KG/MIN ANGIOTENSIN II IN HYPOTENSIVE PATIENTS TREATED WITH VASOPRESSIN OR A VASOPRESSIN ANALOGUE AND REDUCING VASOPRESSIN OR VASOPRESSIN ANALOGUE USE
- U-2339 USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS
- U-2340 TREATMENT OF POSTOPERATIVE INFLAMMATION
- U-2341 METHOD OF RECONSTITUTING A LYOPHILIZED LIPOSOMAL COMPOSITION FOR ADMINISTERING CYTARABINE AND DAUNORUBICIN TO TREAT ADULTS WITH NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC)
- U-2342 METHOD OF ADMINISTERING A RECONSTITUTED LIPOSOMAL COMPOSITION CONTAINING CYTARABINE AND DAUNORUBICIN TO TREAT ADULTS WITH NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC)
- U-2343 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HETEROZYGOUS FOR F508DEL AND A SECOND CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH TEZACAFTOR AND IVACAFTOR
- U-2344 TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC LIVER DISEASE WHO ARE SCHEDULED TO UNDERGO A PROCEDURE
- U-2345 TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC)
- U-2346 TREATMENT OF HUMAN SMALLPOX DISEASE CAUSED BY VARIOLA VIRUS IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 13 KG
- U-2347 TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT AND FOR WHOM METFORMIN THERAPY IS INAPPROPRIATE BY ADMINISTERING LINAGLIPTIN WITHOUT DOSE ADJUSTMENT
- U-2348 A METHOD FOR PREVENTION OF PREGNANCY
- U-2349 FOR ONCE-DAILY MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN PATIENTS AGED 5 YEARS AND OLDER
- U-2350 A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS ACUTE MYELOGENOUS LEUKEMIA (AML)
- U-2351 TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) WITH AN IDH1 MUTATION

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-2352 TREATMENT OF HIV-1 INFECTION IN ADULTS WHO HAVE NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS
- U-2353 TX OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PK ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASES IN ADULTS WHO HAVE NO PRIOR ANTIRETROVIRAL TX HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS
- U-2354 COMBINATION WITH OTHER ANTIRETROVIRALS (ATV) FOR TREATMENT OF HIV-1 IN ATV TREATMENT-EXPERIENCED PATIENTS 2 YEARS AND OLDER WITH EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR AND OTHER ATV
- U-2355 IN COMBINATION WITH AN AROMATASE INHIBITOR FOR THE TREATMENT OF PRE/PERIMENOPAUSAL OR POSTMENOPAUSAL WOMEN WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER, AS INITIAL ENDOCRINE-BASED THERAPY
- U-2356 IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER, AS INITIAL ENDOCRINE BASED THERAPY OR FOLLOWING DISEASE PROGRESSION ON ENDOCRINE THERAPY
- U-2357 METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
- U-2358 TREATMENT OF PATIENTS WITH HORMONE RECEPTOR (HR)-NEGATIVE BREAST CANCER WITH DELETERIOUS OR SUSPECTED DELETERIOUS GBRAM, HER2-NEGATIVE METASTATIC BREAST CANCER, WHO HAVE BEEN TREATED WITH CHEMOTHERAPY IN NEOADJUVANT, ADJUVANT, OR METASTATIC SETTING
- U-2359 TREATMENT OF PATIENTS WITH HORMONE RECEPTOR (HR)-POSITIVE BREAST CANCER WHO SHOULD HAVE BEEN TREATED WITH PRIOR ENDOCRINE THERAPY OR BE CONSIDERED INAPPROPRIATE FOR ENDOCRINE THERAPY
- U-2360 MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS
- U-2361 METHOD OF ADMINISTERING A GRANULATE FORMULATION OF 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE AS RECITED IN CLAIM 1, TO TREAT IDIOPATHIC PULMONARY FIBROSIS
- U-2362 TREATMENT OF HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6
- U-2363 ADMINISTRATION OF RISPERIDONE
- U-2364 TREATMENT OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE IN ADULTS WHO HAVE NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY
- U-2365 TREATMENT OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INIBITS CYTOCHROME P450 MONOOXYGENASE IN ADULTS WHO ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS
- U-2366 TREATMENT OF LIVER DISEASE THROUGH NUTRITION FOR PATIENTS UNDER THE AGE OF 12
- U-2367 USE FOR PATIENTS WITH PARENTERAL NUTRITION ASSOCIATED CHOLESTASIS OR PARENTERAL NUTRITION ASSOCIATED LIVER DISEASE
- U-2368 TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 9 YEARS OF AGE AND OLDER
- U-2369 FOR THE TREATMENT OF GENOTYPE 1, 4, 5 OR 6 CHRONIC HEPATITIS C VIRUS (HCV) INFECTION
- U-2370 FOR TREATMENT-NAIVE GENOTYPE 1 PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) INFECTION FOR A DURATION OF 8-WEEKS
- U-2371 THE TREATMENT OF FABRY PATIENTS
- U-2372 A METHOD OF REDUCING LEFT VENTRICULAR MASS INDEX (LVMI) IN A FABRY PATIENT BY ADMINISTERING MIGALASTAT
- U-2373 A METHOD OF REDUCING PODOCYTE GLOBOTRIAOSYLKERAMIDE (GL-3) IN A FABRY PATIENT BY ADMINISTERING MIGALASTAT
- U-2374 TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFOR AND IVACAFOR
- U-2375 TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFOR FORM I AND IVACAFOR
- U-2376 TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFOR AND A SOLID COMPOSITION COMPRISING AMORPHOUS AND LESS THAN ABOUT 30% CRYSTALLINE IVACAFOR
- U-2377 USE OF VITAL DYE FOR FACILITATING SURGICAL PROCEDURES FOR VITREO-RETINAL SURGERY

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-2378 TREATMENT OF POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS
- U-2379 USE IN IDENTIFICATION OF INTRAOCULAR MEMBRANES TO FACILITATE REMOVAL DURING OPHTHALMIC SURGERY
- U-2380 TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN PATIENTS 18 YEARS OF AGE AND OLDER
- U-2381 TREATMENT IN COMBINATION WITH A GNRH AGONIST OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC)
- U-2382 TREATMENT IN COMBINATION WITH A GNRH AGONIST OF HIGH RISK NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC)
- U-2383 METHOD OF CONTROLLING GLYCEMIA IN A DIABETIC PATIENT WITH DELAYED OR PROLONGED FOOD ABSORPTION BY ADMINISTERING 50 TO 75% OF A PREDETERMINED DOSE OF INSULIN-FDKP AT MEALTIME, AND ADMINISTERING REMAINDER OF DOSE 30-120 MINUTES AFTER BEGINNING OF MEAL
- U-2384 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 10
- U-2385 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1,10 AND 11
- U-2386 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 12 AND 19
- U-2387 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 12, 19 AND 20
- U-2388 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 21 AND 28
- U-2389 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 21, 28, AND 29
- U-2390 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 30 AND 41
- U-2391 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 30, 41, AND 42
- U-2392 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 43 AND 50
- U-2393 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 43, 50 AND 51
- U-2394 FOR USE IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN ADULT PATIENTS WITH NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY
- U-2395 FOR THE TREATMENT OF HIV-1 INFECTION IN ADULT PATIENTS WITH NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY
- U-2396 TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE DOSAGE UNIT COMPRISING LUMACAFOR AS RECITED IN CLAIM 1 OF US PATENT 8716338 AND IVACAFOR
- U-2397 TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE DOSAGE UNIT COMPRISING LUMACAFOR AND IVACAFOR AS RECITED IN CLAIM 1 OF US PATENT 9192606
- U-2398 TOPICAL TREATMENT OF PRIMARY AXILLARY HYPERHIDROSIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER
- U-2399 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 12 YEARS AND OLDER, WITH A F508DEL OR G551D CFTR GENE MUTATION AND A A455E, 2789+5G->A, OR 3849+10KBC->T MUTATION, COMPRISING CONCURRENT COADMINISTRATION OF THE COMPOSITIONS OF CLAIM 1 OF U.S. PATENT 10058546

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-2400 REDUCING ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION
- U-2401 A METHOD OF TREATING AMYOTROPHIC LATERAL SCLEROSIS IN A PATIENT IN NEED OF SUCH TREATMENT, SAID METHOD COMPRISING ADMINISTERING TO SAID PATIENT AN EFFECTIVE AMOUNT OF A SUSPENSION ACCORDING TO CLAIM 1
- U-2402 TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INTRAMUSCULAR INJECTION
- U-2403 TREATMENT OF PSORIASIS USING A DOSAGE TITRATION SCHEDULE
- U-2404 METHOD OF DELIVERING SUMATRIPTAN TO A NASAL CAVITY
- U-2405 A METHOD FOR TREATING A BACTERIAL INFECTION IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE
- U-2406 A METHOD FOR TREATING A PATIENT 9 YEARS OF AGE AND OLDER SUFFERING FROM AN INFLAMMATORY SKIN DISORDER OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE
- U-2407 A METHOD FOR TREATING ACNE IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE CRYSTALLINE SALT
- U-2408 A METHOD FOR TREATING A BACTERIAL INFECTION IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE CRYSTALLINE SALT
- U-2409 A METHOD FOR TREATING ACNE IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING SARECYCLINE HYDROCHLORIDE IN 60 MG, 100 MG OR 150 MG EQUIVALENT DOSES
- U-2410 TREATMENT OF ADULT PATIENTS FOR WHOM TREATMENT WITH BOTH AMLODIPINE FOR HYPERTENSION AND CELECOXIB FOR OSTEOARTHRITIS ARE APPROPRIATE
- U-2411 TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 12 YEARS OR OLDER WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE TABLET COMPRISING LUMACAFTOR AS RECITED IN CLAIM 1, 19, OR 21 OF U.S. PATENT NO. 10,076,513 AND IVACAFTOR
- U-2412 FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR SMALL LYMPHOCYTIC LEUKEMIA (SLL)
- U-2413 FOR THE TREATMENT OF PATIENTS WITH FOLLICULAR LYMPHOMA (FL)
- U-2414 TREATING MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE IN ADULTS AS PART OF A COMBINATION DRUG REGIMEN
- U-2415 TREATING MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE IN ADULTS AS PART OF A COMBINATION ANTIBACTERIAL DRUG REGIMEN
- U-2416 TREATING MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE IN ADULTS WITH CYSTIC FIBROSIS AS PART OF A COMBINATION DRUG REGIMEN
- U-2417 TREATING MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE IN NON-CYSTIC FIBROSIS ADULTS AS PART OF A COMBINATION ANTIBACTERIAL DRUG REGIMEN
- U-2418 METHOD OF ADMINISTERING TESTOSTERONE ENANTHATE SUBCUTANEOUSLY
- U-2419 METHOD OF OPERATING AN INJECTION DEVICE
- U-2420 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGES 12 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR ONE F508DEL MUTATION AND A CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,081,621
- U-2421 USE IN COMBINATION WITH CLOBAZAM FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH DRAVET SYNDROME
- U-2422 USE IN COMBINATION WITH CLOBAZAM FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH LENNOX GASTAUT SYNDROME WHO HAVE BEEN PREVIOUSLY TREATED WITH CLOBAZAM
- U-2423 USE IN COMBINATION WITH CLOBAZAM FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH DRAVET SYNDROME WHO HAVE BEEN PREVIOUSLY TREATED WITH CLOBAZAM
- U-2424 USE IN COMBINATION WITH CLOBAZAM FOR TREATMENT OF SEIZURES IN PATIENTS WITH LENNOX GASTAUT SYNDROME
- U-2425 USE FOR THE TREATMENT OF CONVULSIVE SEIZURES IN PATIENTS WITH DRAVET SYNDROME
- U-2426 USE FOR THE TREATMENT OF CONVULSIVE SEIZURES IN PATIENTS WITH LENNOX GASTAUT SYNDROME

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-2427 USE FOR THE TREATMENT OF DROP SEIZURES IN PATIENTS WITH DRAVET SYNDROME

U-2428 TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY 4 YEARS OF AGE AND OLDER

U-2429 TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER

U-2430 TREATMENT OF POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN AMYLOIDOSIS

U-2431 TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS

U-2432 LONG-TERM, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

U-2433 METHOD OF TREATING A BIOLOGICAL RHYTHM DISORDER, SUCH AS INSOMNIA

U-2434 USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY

U-2435 REDUCTION OF RISK OF MAJOR CARDIOVASCULAR EVENTS (CV DEATH, MI, AND STROKE) IN CHRONIC CAD OR PAD

U-2436 USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE TREATMENT EMERGENT SEXUAL DYSFUNCTION (TESD) INDUCED BY PRIOR SEROTONIN REUPTAKE INHIBITOR TREATMENT

U-2437 TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BREAST CANCER SUSCEPTIBILITY GENE (BRCA)-MUTATED (GBRCAM) HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER

U-2438 CARDIOVASCULAR OUTCOMES TRIAL OF LIRAGLUTIDE 1.8 MG IN PATIENTS WITH TYPE 2 DIABETES AND CARDIOVASCULAR DISEASE

U-2439 TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS

U-2440 FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

U-2441 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS

U-2442 USE FOR THE TREATMENT OF ATONIC SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME

U-2443 USE FOR THE TREATMENT OF ATONIC SEIZURES IN PATIENTS WITH DRAVET SYNDROME

U-2444 TREATMENT OF SUBJECTS HAVING BACTERIAL SKIN OR SKIN STRUCTURE INFECTION

U-2445 TREATMENT IN COMBINATION WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY

U-2446 TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY

U-2447 TREATMENT OF SEVERE HYPERTRIGLYCERIDEMIA (500 MG/DL) IN ADULT PATIENTS AS AN ADJUNCT TO DIET

U-2448 TREATMENT OF TRAVELERS' DIARRHEA CAUSED BY NON-INVASIVE STRAINS OF ESCHERICHIA COLI IN ADULTS

U-2449 TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTION

U-2450 POSITRON EMISSION TOMOGRAPHY DIAGNOSTIC AGENT IN ADULTS WITH SUSPECTED PROSTATE CANCER RECURRENCE BASED ON ELEVATED BLOOD PROSTATE SPECIFIC ANTIGEN LEVELS FOLLOWING PRIOR TREATMENT

U-2451 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)

U-2452 COMBINATION WITH IMMUNOSUPPRESSIVE THERAPY FOR FIRST-LINE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS AND OLDER WITH SEVERE APLASTIC ANEMIA

U-2453 TREATMENT OF FUNGAL INFECTIONS, INCLUDING BLASTOMYCOSIS, HISTOPLASMOSIS, AND ASPERGILLOSIS

U-2454 USE FOR THE TREATMENT OF DROP SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME

U-2455 USE IN COMBINATION WITH CLOBAZAM FOR TREATMENT OF DROP SEIZURES IN PATIENTS WITH LENNOX GASTAUT SYNDROME

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-2456 TREATMENT OF ACUTE MYELOID LEUKEMIA (AML)

U-2457 REINITIATION OF SCHIZOPHRENIA TREATMENT FOLLOWING A MISSED DOSE MORE THAN 9 MONTHS AGO

U-2458 REINITIATION OF SCHIZOPHRENIA TREATMENT FOLLOWING A MISSED DOSE 4-9 MONTHS AGO

U-2459 TREATMENT OF DYSKINESIA AND DECREASING OFF TIME IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS

U-2460 VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF CORONARY ARTERY BYPASS GRAFT IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY

U-2461 VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF CARDIOVASCULAR BYPASS GRAFT AND VASCULATURE IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY

U-2462 VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF VESSEL WITH ARTERIOVENOUS MALFORMATION IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY

U-2463 VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION IN SURGICAL FLAPS IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY

U-2464 VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF TRANSPLANTED ORGAN OR ATTACHED VESSEL IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY

U-2465 VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF VESSEL GRAFT IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY

U-2466 VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF DONOR ORGAN OR ATTACHED VESSEL IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY

U-2467 VISUALIZATION OF EXTRAHEPATIC BILIARY DUCT ATTACHED TO DONOR ORGAN IN PATIENTS 12 YEARS AND OLDER

U-2468 VISUALIZATION OF EXTRAHEPATIC BILIARY DUCT ATTACHED TO TRANSPLANTED ORGAN IN PATIENTS 12 YEARS AND OLDER

U-2469 METHOD OF TREATING CANCEROUS SOLID TUMORS

U-2470 METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION

U-2471 METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK FUSION GENE IN A PEDIATRIC PATIENT

U-2472 METHOD OF TREATING NEUROBLASTOMA, GLIOMA, THYROID, AND BREAST CANCER SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION

U-2473 METHOD OF TREATING CMN, IFS, HGG, DIPGS, PTC, SOFT TISSUE SARCOMA, AND SPINDLE CELL SARCOMA SOLID TUMORS EXHIBITING AN NTRK GENE FUSION IN A PEDIATRIC PATIENT WITH AN ORAL SOLUTION

U-2474 METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION AFTER SURGICAL RESECTION

U-2475 METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION IN A PEDIATRIC PATIENT

U-2476 USE OF A DELIVERY DEVICE TO DELIVER A DOSE OF NALOXONE

U-2477 TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH CYP1A2 STRONG INHIBITORS

U-2478 METHOD FOR THE INDUCTION OF LOCAL ANESTHESIA PRIOR TO PERFORMING A PROCEDURE ON, THROUGH, OR ADJACENT TO THE MUCOUS MEMBRANES

U-2479 METHOD OF ADMINISTERING A LOCAL ANESTHETIC TO THE MUCOUS MEMBRANES

U-2480 MAINTENANCE TREATMENT OF GBRCA- OR SBRCA-MUTATED ADVANCED EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM-BASED CHEMOTHERAPY

U-2481 TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA-MUTATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH THREE OR MORE PRIOR LINES OF CHEMOTHERAPY

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-2482 TREATMENT OF HR-NEGATIVE, HER-2 NEGATIVE, GBRCA-MUTATED METASTATIC BREAST CANCER, WHO HAVE BEEN TREATED WITH CHEMOTHERAPY IN THE NEOADJUVANT, ADJUVANT, OR METASTATIC SETTING
- U-2483 TREATMENT OF HR-POSITIVE, HER-2 NEGATIVE, GBRCA-MUTATED METASTATIC BREAST CANCER, WHO HAVE BEEN TREATED WITH CHEMOTHERAPY IN THE NEOADJUVANT, ADJUVANT, OR METASTATIC SETTING, AND WITH ENDOCRINE THERAPY OR ARE INAPPROPRIATE FOR ENDOCRINE THERAPY
- U-2484 INTERMITTENT TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSON'S DISEASE TREATED WITH CARBIDOPA/LEVODOPA BY INHALATION OF LEVODOPA POWDER PARTICLES
- U-2485 INTERMITTENT TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSON'S DISEASE TREATED WITH CARBIDOPA/LEVODOPA BY INHALATION OF LEVODOPA POWDER PARTICLES THROUGH A SINGLE BREATH ACTIVATED STEP
- U-2486 INTERMITTENT TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSON'S DISEASE WITH A POWDER INHALER
- U-2487 DEXTENZA IS APPROVED FOR THE TREATMENT OF OCULAR PAIN FOLLOWING OPHTHALMIC SURGERY
- U-2488 TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WHO HAVE BEEN PREVIOUSLY TREATED WITH SORAFENIB
- U-2489 TREATMENT OF MODERATE TO SEVERE OPIOID USE DISORDER
- U-2490 TREATMENT OF COMPLICATED URINARY TRACT INFECTION (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY THE FOLLOWING SUSCEPTIBLE MICROORGANISMS: ESCHERICHIA COLI, KLEBSIELLA PNEUMONIA, AND ENTEROBACTER CLOACAE SPECIES COMPLEX
- U-2491 A METHOD FOR DELIVERING A COMPOSITION TO A MUCUS MEMBRANE
- U-2492 A METHOD FOR DELIVERING A PHARMACEUTICAL AGENT ACROSS A MUCOSAL BARRIER
- U-2493 A METHOD FOR TREATING INFLAMMATION AND/OR OTHER DISORDERS IN AN EYE OF A PATIENT
- U-2494 INDICATED FOR THE TREATMENT OF VENTRICULAR ARRHYTHMIAS, SUCH AS SUSTAINED VENTRICULAR TACHYCARDIA, THAT IN THE JUDGEMENT OF THE PHYSICIAN ARE LIFE-THREATENING
- U-2495 VENTRICULAR FIBRILLATION
- U-2496 IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY USE OF A PEN INJECTOR WITH A THREADED DRIVE SLEEVE
- U-2497 TREATMENT OF DRUG-INDUCED EXTRAPYRAMIDAL REACTION IN ADULT PATIENTS
- U-2498 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGES 12 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR ONE F508DEL MUTATION AND A CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,206,877
- U-2499 METHOD OF REDUCING ADVERSE EFFECTS IN PATIENTS SUFFERING FROM EXCESSIVE DAYTIME SLEEPINESS AND/OR CATAPLEXY IN NARCOLEPSY WHO ARE CONCOMITANTLY ADMINISTERED SODIUM OXYBATE AND DIVALPROEX SODIUM
- U-2500 USE OF A DELIVERY DEVICE TO DELIVER A BIOEQUIVALENT DOSE OF A NALOXONE COMPOSITION VIA A NEEDLE
- U-2501 TREATMENT OF PARTIAL-ONSET SEIZURES
- U-2502 TREATMENT OF TREATMENT-RESISTANT DEPRESSION IN ADULT IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT
- U-2503 TREATMENT OF ADULTS WITH METASTATIC GASTRIC OR GJA PREVIOUSLY TREATED WITH AT LEAST TWO PRIOR LINES OF CHEMOTHERAPY THAT INCLUDED A FLUOROPYRIMIDINE, A PLATINUM, EITHER A TAXANE OR IRINOTECAN, AND IF APPROPRIATE, HER2/NEU-TARGETED THERAPY
- U-2504 TREATMENT OF HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN IN COMBINATION WITH RIBOCICLIB AS INITIAL ENDOCRINE BASED THERAPY OR FOLLOWING DISEASE PROGRESSION ON ENDOCRINE THERAPY
- U-2505 TREATMENT OF PRE/PERIMENOPAUSAL WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
- U-2506 METHOD OF TREATING TESTOSTERONE DEFICIENCY
- U-2507 METHOD OF TREATING ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI) CAUSED BY DESIGNATED SUSCEPTIBLE BACTERIA

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-2508 A METHOD OF TREATING BACTERIAL INFECTIONS IN COMPLICATED INTRA-ABDOMINAL INFECTION AND COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELONEPHRITIS, PATIENTS COMPRISING ADMINISTERING A BACTERICIDALLY EFFECTIVE AMOUNT OF AVIBACTAM SODIUM
- U-2509 A METHOD OF TREATING A BACTERIAL INFECTION IN COMPLICATED INTRA-ABDOMINAL INFECTION (CIAI) AND COMPLICATED URINARY TRACT INFECTION (CUTI), INCLUDING PYELONEPHRITIS, PATIENTS COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AVIBACTAM SODIUM
- U-2510 A METHOD FOR CONTRACEPTION COMPRISING THE STEP OF ORAL ADMINISTRATION A DOSAGE OF 20 MG TO 30 MG OF ULIPRISTAL ACETATE TO A WOMAN WITHIN 72 HOURS AND UP TO 120 HOURS AFTER AN UNPROTECTED INTERCOURSE
- U-2511 A METHOD OF TREATING MULTIPLE SCLEROSIS BY ADMINISTERING SIPONIMOD USING A TITRATION SCHEME TO REACH A MAINTENANCE DOSE
- U-2512 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HAVE AT LEAST ONE CFTR MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH AN EFFECTIVE AMOUNT OF TEZACAFTOR AND IVACAFTOR
- U-2513 MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
- U-2514 MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
- U-2515 PALBOCICLIB FOR HR-POS. HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER IN COMBO WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY IN POSTMENOPAUSAL WOMEN OR MEN, OR WITH FULVESTRANT IN PTS WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
- U-2516 A METHOD FOR REDUCING SERUM GLUCOSE LEVELS IN ADULTS WITH TYPE 2 DIABETES MELLITUS
- U-2517 A METHOD FOR REDUCING SERUM GLUCOSE LEVELS IN ADULTS WITH TYPE 2 DIABETES MELLITUS
- U-2518 TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT HAS SUSCEPTIBLE FGFR3 OR FGFR2 GENETIC ALTERATIONS AND PROGRESSED DURING OR FOLLOWING PRIOR PLATINUM-CONTAINING CHEMOTHERAPY
- U-2519 TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY BY ADMINISTERING 100 MG OF ACALABRUTINIB TWICE DAILY
- U-2520 TREATING MS WITH ORAL CLADRIBINE ACC. TO THE STEPS (I) INDUCTION PERIOD WITH ABOUT 1.7 MG/KG-3.5 MG/KG CLADRIBINE; (II) CLADRIBINE-FREE PERIOD OF ABOUT 8-10 MONTHS; (III) MAINTENANCE PERIOD WITH ABOUT 1.7 MG/KG CLADRIBINE; (IV) CLADRIBINE-FREE PERIOD
- U-2521 TREATMENT OF MS WITH A TABLET WITH AN ADMIXTURE OF (A) AN AMORPHOUS INCLUSION COMPLEX OF CLADRIBINE AND HYDROXYPROPYL-B-CYCLODEXTRIN AND (B) AMORPHOUS FREE CLADRIBINE AND CYCLODEXTRIN AS A NON-INCLUSION COMPLEX, CLADRIBINE/CYCLODEXTRIN 1:10-1:16 W/W
- U-2522 TREATING RRMS OR SPMS WITH ORAL CLADRIBINE: (I) 2-4 MONTHS INDUCTION WITH 1.7 MG/KG - 3.5 MG/KG CLADRIBINE; (II) CLADRIBINE-FREE PERIOD OF ABOUT 8-10 MONTHS; (III) 2-4 MONTHS MAINTENANCE WITH ABOUT 1.7 MG/KG CLADRIBINE; (IV) CLADRIBINE-FREE PERIOD
- U-2523 TREATMENT OF MS WITH AN ADMIXTURE OF (A) AN AMORPHOUS INCLUSION COMPLEX OF CLADRIBINE (2CDA) AND CYCLODEXTRIN AND (B) AMORPHOUS FREE 2CDA AND CYCLODEXTRIN AS A NON-INCLUSION COMPLEX, FORMULATED AS A SOLID ORAL FORM, W/O SIGN. AMOUNTS OF CRYST. 2CDA
- U-2524 TREATMENT OF THE CARDIOMYOPATHY OF WILD TYPE OR HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR-CM)
- U-2525 TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY OR URGE INCONTINENCE
- U-2526 ACUTE TREATMENT OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY (I.E., SEIZURE CLUSTERS, ACUTE REPETITIVE SEIZURES) THAT ARE DISTINCT FROM A PATIENT'S USUAL SEIZURE PATTERN IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER
- U-2527 TREATMENT OF CYSTIC FIBROSIS USING IVACAFTOR IN A PATIENT AGE 6 MONTHS TO <6 YEARS WHO HAS ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-2528 TREATMENT OF CYSTIC FIBROSIS USING IVACAFTOR IN A PATIENT AGE 6 MONTHS TO <6 YEARS WHO HAS A R117H MUTATION IN THE CFTR GENE
- U-2529 TREATMENT OF A MODERATE MILD CLINICAL PHENOTYPE OF CF USING IVACAFTOR IN A PATIENT AGE 6 MONTHS TO <6 YEARS WHO HAS ONE CFTR MUTATION RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
- U-2530 TREATMENT OF CF IN A PATIENT AGE 6 MONTHS TO < 6 YEARS WHO HAS ONE CFTR MUTATION RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA USING A SOLID COMPOSITION COMPRISING AMORPHOUS (LESS THAN ABOUT 30% CRYSTALLINE) IVACAFTOR
- U-2531 TREATMENT OF CF IN A PATIENT AGE 6 MONTHS TO <6 YEARS WHO HAS ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA USING THE COMPOSITION RECITED IN CLAIM 1 OF US 10272046
- U-2532 TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, OR 6 IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER OR WEIGHING AT LEAST 45 KG
- U-2533 A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
- U-2534 A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML)
- U-2535 USE IN COMBINATION WITH METHYLPREDNISOLONE FOR THE TREATMENT OF PATIENTS WITH PROSTATE CANCER
- U-2536 FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE
- U-2537 TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
- U-2538 TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LEUKEMIA (SLL) IN COMBINATION WITH A GA101 ANTIBODY SUCH AS OBINUTUZUMAB FOR ONE OR MORE DOSING PERIODS, WHEREIN THE CLL OR SLL IS A CD20-EXPRESSING CANCER
- U-2539 IN COMBINATION WITH FULVESTRANT FOR TREATMENT OF POSTMENOPAUSAL WOMEN, AND MEN, WITH HR-POSITIVE, HER-2-NEGATIVE, PIK3CA-MUTATED, ADVANCED OR METASTATIC BREAST CANCER
- U-2540 TREATMENT OF HORMONE RECEPTOR POSITIVE ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN
- U-2541 REDUCING THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION (MI), AND STROKE IN A PATIENT RECEIVING 75-100 MG ASPIRIN DAILY WITH A HISTORY OF MI BY ADMINISTERING 60 MG TICAGRELOR TWICE DAILY
- U-2542 REDUCING THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN A PATIENT RECEIVING 75-100 MG ASPIRIN DAILY AND HAVING OR WHO HAD ACUTE CORONARY SYNDROME BY ADMINISTERING 60 MG TICAGRELOR TWICE DAILY
- U-2543 TREATMENT OF SCHIZOPHRENIA WITH CARIPRAZINE
- U-2544 TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH CARIPRAZINE
- U-2545 TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER (BIPOLAR DEPRESSION) WITH CARIPRAZINE
- U-2546 USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
- U-2547 METHOD OF PROVIDING CONTRACEPTION IN A WOMAN HAVING A BMI OF 25 KG/M2 OR MORE WITH RESULTANT LIMITED BLEEDING EVENTS PER TREATMENT CYCLE
- U-2548 TO IMPROVE WAKEFULNESS IN ADULT PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY OR OBSTRUCTIVE SLEEP APNEA (OSA)
- U-2549 CONTROL OF SERUM PHOSPHORUS LEVELS
- U-2550 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PREVIOUSLY TREATED FOLLICULAR LYMPHOMA IN COMBINATION WITH A RITUXIMAB PRODUCT
- U-2551 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMA IN COMBINATION WITH A RITUXIMAB PRODUCT
- U-2552 METHOD OF TREATING POSTPARTUM DEPRESSION
- U-2553 PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE
- U-2554 TREATMENT OF MILD TO MODERATE ACTIVE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-2555 A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST ABOUT 0.6 G OF ELEMENTAL IRON
- U-2556 METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULTS WHO HAVE INTOLERANCE TO OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON ASSOCIATED WITH HEAVY UTERINE BLEEDING OR A GASTROINTESTINAL DISORDER BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE
- U-2557 A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST ABOUT 0.6 GRAMS OF ELEMENTAL IRON
- U-2558 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY
- U-2559 USE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR ADJUVANT TREATMENT OF PATIENTS WITH OPERABLE NODE-POSITIVE BREAST CANCER
- U-2560 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY
- U-2561 USE IN COMBINATION WITH CISPLATIN FOR TREATMENT OF UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITHOUT PRIOR CHEMOTHERAPY TREATMENT
- U-2562 TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER IN COMBINATION WITH PREDNISONE
- U-2563 TREATMENT OF ADVANCED GASTRIC ADENOCARCINOMA IN COMBINATION WITH CISPLATIN AND FLUOROURACIL IN PATIENTS THAT HAVE NOT RECEIVED PRIOR CHEMOTHERAPY
- U-2564 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK IN COMBINATION WITH CISPLATIN AND FLUOROURACIL
- U-2565 TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA
- U-2566 TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA
- U-2567 ONCE DAILY TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS WITH 1% OXYMETAZOLINE HYDROCHLORIDE CREAM, WHERE THE PATIENT EXPERIENCES NO REBOUND OR WORSENING OF FACIAL ERYTHEMA POST-TREATMENT
- U-2568 TREATMENT OF HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD)
- U-2569 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HAVE AT LEAST ONE CFTR MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH AN EFFECTIVE AMOUNT OF TEZACAFTOR AND IVACAFTOR
- U-2570 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGES 6 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR ONE F508DEL MUTATION AND A CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,206,877
- U-2571 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGES 6 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR ONE F508DEL MUTATION AND A CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,081,621
- U-2572 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 6 YEARS AND OLDER, WITH A F508DEL OR G551D CFTR GENE MUTATION AND A A455E, 2789+5G->, OR 3849+10KBC->T MUTATION, COMPRISING CONCURRENT COADMINISTRATION OF THE COMPOSITIONS OF CLAIM 1 OF U.S. PATENT 10058546
- U-2573 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HETEROZYGOUS FOR F508DEL AND A SECOND CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH TEZACAFTOR AND IVACAFTOR
- U-2574 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HAVE AT LEAST ONE CFTR GENE MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH TEZACAFTOR AND IVACAFTOR
- U-2575 TREATING CYSTIC FIBROSIS PATIENTS AGES 6 AND OLDER, WHO ARE HOMOZYGOUS FOR F508DEL OR HAVE AT LEAST 1 CFTR GENE MUTATION RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH TEZACAFTOR AND A SOLID COMPOSITION COMPRISING AMORPHOUS (<30% CRYSTALLINE) IVACAFTOR
- U-2576 TREATMENT OF COMMUNITY ACQUIRED BACTERIAL PNEUMONIA

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-2577 TREATMENT OF THROMBOCYTOPENIA IN AN ADULT PATIENT WITH CHRONIC IMMUNE THROMBOCYTOPENIA WHO HAS HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT
- U-2578 TREATMENT OF THROMBOCYTOPENIA IN AN ADULT PATIENT WITH CHRONIC LIVER DISEASE WHO IS SCHEDULED TO UNDERGO A PROCEDURE
- U-2579 REDUCTION IN A SUBJECT'S RISK OF EXPERIENCING A BREAKTHROUGH OVERT HEPATIC ENCEPHALOPATHY (HE) EPISODE
- U-2580 A METHOD OF TREATING TYPE 2 DIABETES COMPRISING ADMINISTERING SEMAGLUTIDE ONCE WEEKLY IN A AMOUNT OF 1.0 MG TO A SUBJECT IN NEED THEREOF
- U-2581 TREATING HYPOTENSION WITH ABOUT 20 NG/KG/MIN TO ABOUT 40 NG/KG/MIN ANGIOTENSIN II IN A HUMAN SUBJECT HAVING SEPTIC SHOCK
- U-2582 FOR THE ORAL PREVENTION/PROPHYLAXIS OF MALARIA IN ADULTS, COMPRISING A THREE-PHASE DOSING REGIMEN CONSISTING OF A LOADING/INITIAL DOSE, A MAINTENANCE/EXPOSURE DOSE, AND A TERMINAL/POST-EXPOSURE DOSE
- U-2583 TREATMENT OF BACTERIAL VAGINOSIS IN ADULT WOMEN
- U-2584 XPROVIO IS INDICATED IN COMBINATION WITH DEXAMETHASONE TO TREAT RELAPSED OR REFRACTORY MULTIPLE MYELOMA (REFRACTORY TO AT LEAST AN ANTI-CD38 MAB, 2 PROTEASOME INHIBITORS AND 2 IMMUNOMODULATORY AGENTS) IN ADULTS WHO RECEIVED AT LEAST 4 PRIOR THERAPIES
- U-2585 TREATMENT OF PARENTERAL NUTRITION-ASSOCIATED CHOLESTASIS IN PATIENTS UNDER THE AGE OF 12
- U-2586 TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS, INCLUDING PYELONEPHRITIS (CUTI)
- U-2587 TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI)
- U-2588 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
- U-2589 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
- U-2590 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
- U-2591 LOWERING PLASMA GLUCAGON IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING EXENATIDE AS AN ADJUNCT TO DIET AND EXERCISE
- U-2592 IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
- U-2593 IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
- U-2594 REDUCING FASTING PLASMA GLUCOSE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
- U-2595 REDUCING BODY WEIGHT IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
- U-2596 REDUCING HBA1C IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
- U-2597 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AS ADD-ON TO METFORMIN
- U-2598 IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN INJECTABLE SUSTAINED RELEASE FORMULATION OF EXENATIDE AS AN ADJUNCT TO DIET AND EXERCISE
- U-2599 IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE TO PROVIDE A RELEASE PROFILE HAVING A RATIO OF C-MAX TO C-AVG OF ABOUT 3 OR LESS

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-2600 IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A PRE-MIXED EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE

U-2601 STIMULATING INSULIN RELEASE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A PRE-MIXED EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE

U-2602 DELAYING GASTRIC EMPTYING IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A PRE-MIXED EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE

U-2603 METHOD OF TREATING IRON DEFICIENCY

U-2604 TREATMENT OF SEVERE HYPOGLYCEMIA IN PATIENTS WITH DIABETES

U-2605 TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION RESISTANT PROSTATE CANCER

U-2606 TREATMENT OF ADULT PATIENTS WITH SYMPTOMATIC TENOSYNOVIAL GIANT CELL TUMOR (TGCT) ASSOCIATED WITH SEVERE MORBIDITY OR FUNCTIONAL LIMITATIONS AND NOT AMENABLE TO IMPROVEMENT WITH SURGERY

U-2607 TREATMENT OF ADULT PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS

U-2608 METHOD OF TREATING SCHIZOPHRENIA

U-2609 A METHOD FOR INDUCING A REGIONAL ANAESTHESIA VIA INTRATHECAL ADMINISTRATION OF A PATENTED PRESERVATIVE FREE SOLUTION FOR INJECTION (WITH A SPECIFIC COMPOSITION, PH, OSMOLALITY AND DENSITY) CONTAINING 9-11 MG/ML CHLOROPROCAINE HCL

U-2610 TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS

U-2611 TREATMENT OF COMPLICATED URINARY TRACT INFECTION IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS

U-2612 TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN PATIENTS 10 YEARS OF AGE AND OLDER

U-2613 TREATMENT OF RELAPSING-REMITTING SCLEROSIS (MS)

U-2614 TREATMENT OF MODERATE TO SEVERE DYSpareunia

U-2615 TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH FOOD

U-2616 TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO METHOTREXATE

U-2617 TREATMENT OF ROS1-POSITIVE NON-SMALL CELL LUNG CANCER

U-2618 TREATMENT OF SOLID TUMORS THAT HAVE A NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) GENE FUSION

U-2619 TREATMENT OF ADULTS WITH COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA CAUSED BY SUSCEPTIBLE MICROORGANISMS

U-2620 USE OF NINTEDANIB FOR SLOWING THE RATE OF DECLINE IN PULMONARY FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD)

U-2621 MODIFIED DOSING REGIMEN FOR THE MANAGEMENT OF MILD TO MODERATE PAIN

U-2622 TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 2 YEARS AND OLDER

U-2623 A METHOD OF REDUCING OFF TIME FROM L-DOPA THERAPY, COMPRISING ADMINISTERING, TO A HUMAN PATIENT WITH PARKINSON'S DISEASE, AN EFFECTIVE AMOUNT OF ISTRADEFYLLINE, WHEREIN THE PATIENT CURRENTLY RECEIVES SAID L-DOPA THERAPY

U-2624 TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC)

U-2625 TOPICAL TREATMENT OF PLAQUE PSORIASIS IN ADULTS

U-2626 METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION BY ADMINISTERING TENAPANOR

U-2627 TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 12 YEARS AND OLDER

U-2628 METHOD OF TREATING TYPE 2 DIABETES MELLITUS

U-2629 TREATMENT OF HIV-1 INFECTION IN ADULT PATIENTS AS A REPLACEMENT THERAPY IN VIROLOGICALLY SUPPRESSED ADULTS WITH NO HISTORY OF TREATMENT FAILURE AND NO KNOWN SUBSTITUTIONS ASSOCIATED WITH RESISTANCE TO THE INDIVIDUAL COMPONENTS OF DELSTRIGO

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-2630 FOR USE IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 AS A REPLACEMENT THERAPY IN VIROLOGICALLY SUPPRESSED ADULTS WITH NO HISTORY OF TREATMENT FAILURE AND NO KNOWN SUBSTITUTIONS ASSOCIATED WITH RESISTANCE TO DORAVIRINE
- U-2631 TREATMENT OF COMPLICATED URINARY TRACT INFECTION
- U-2632 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
- U-2633 TREATMENT OF ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER, PROGRESSED ON: CRIZOTINIB + AT LEAST 1 OTHER ALK INHIBITOR FOR METASTATIC DISEASE; OR ALECTINIB, OR CERITINIB AS FIRST ALK INHIBITOR FOR METASTATIC DISEASE.
- U-2634 METHOD OF TREATMENT IN PATIENTS WITH CONCOMITANT ANGIOEDEMA
- U-2635 TREATMENT OF ACUTE URTICARIA
- U-2636 METHOD OF INCREASING PEAK PLASMA OR ONSET OF PLASMA CONCENTRATION BY INTRAVENOUS INJECTION IN INDIVIDUALS IN NEED OF TREATMENT FOR ACUTE URTICARIA
- U-2637 TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE WITH A SINGLE UNIT DOSE OF 10% OXYBUTYNIN CHLORIDE GEL
- U-2638 INCREASE PAIN-FREE LIGHT EXPOSURE IN ADULT PATIENTS WITH A HISTORY OF PHOTOTOXIC REACTIONS FROM ERYTHROPOIETIC PROTOPORPHYRIA (EPP)
- U-2639 METHOD OF ACTIVATING RARGAMMA RECEPTOR
- U-2640 PROPHYLAXIS OF VENOUS THROMBOEMBOLISM IN ACUTELY ILL MEDICAL PATIENTS AT RISK FOR THROMBOEMBOLIC COMPLICATIONS NOT AT HIGH RISK OF BLEEDING
- U-2641 PROPHYLAXIS OF VENOUS THROMBOEMBOLISM IN ACUTELY ILL MEDICAL PATIENTS AT RISK FOR THROMBOEMBOLIC COMPLICATIONS NOT AT HIGH RISK OF BLEEDING WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST 5 CONSECUTIVE DAYS
- U-2642 METHOD OF TREATING CANCER BY DETECTING A CREATININE CLEARANCE OF A PATIENT AND ADMINISTERING LONSURF
- U-2643 TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS 65 YEARS OF AGE OR OLDER AND SYMPTOMS THEREOF
- U-2644 TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS 65 YEARS OF AGE OR OLDER
- U-2645 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
- U-2646 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE ONE F508DEL MUTATION AND ONE R117H MUTATION IN THE CFTR GENE WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
- U-2647 TREATMENT OF NON-NODULAR ACNE VULGARIS
- U-2648 TREATMENT OF A MODERATE TO MILD CLINICAL PHENOTYPE OF CF IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
- U-2649 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH A COMPOSITION COMPRISING ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR; AND ANOTHER COMPOSITION COMPRISING IVACAFTOR
- U-2650 TREATMENT OF CF IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE USING A SOLID COMPOSITION COMPRISING ELEXACAFTOR, TEZACAFTOR, AMORPHOUS IVACAFTOR, AND LESS THAN ABOUT 30% CRYSTALLINE IVACAFTOR
- U-2651 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH AN EFFECTIVE AMOUNT OF A PHARMACEUTICAL COMPOSITION COMPRISING ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
- U-2652 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH A COMPOSITION ACCORDING TO CLAIM 1 OF US 10081621
- U-2653 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH AN EFFECTIVE AMOUNT OF

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR

- U-2654 TREATMENT OF REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE
- U-2655 A METHOD OF TREATMENT OF ADVANCED OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER ASSOCIATED WITH HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD) POSITIVE STATUS
- U-2656 TREATMENT OF ADULT PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
- U-2657 TREATMENT OF PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS WHO ARE CANDIDATES FOR PHOTOTHERAPY OR SYSTEMIC THERAPY
- U-2658 TREATMENT OF ADULT PATIENTS WITH ORAL ULCERS ASSOCIATED WITH BEHCET'S DISEASE
- U-2659 TREATMENT OF ADULT PATIENTS WITH ORAL ULCERS ASSOCIATED WITH BEHCET'S DISEASE USING A DOSAGE TITRATION SCHEDULE
- U-2660 TREATMENT OF H. PYLORI INFECTION IN ADULTS
- U-2661 CHRONIC WEIGHT MANAGEMENT IN ADULT PATIENTS USING AN EXTENDED RELEASE TABLET CONTAINING LORCARSERIN HYDROCHLORIDE HEMIHYDRATE
- U-2662 USE OF CALCIPOTRIENE FOAM FOR THE TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS AGED 4 YEARS AND OLDER
- U-2663 USE IN SONOHYSTEROSALPINOGRAPHY TO ASSESS FALLOPIAN TUBE PATENCY
- U-2664 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING BY INDUCING SKIPPING OF EXON 51
- U-2665 TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
- U-2666 TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
- U-2667 TREATMENT OF ADULT PATIENTS WITH SMALL LYMPHOCYTIC LEUKEMIA
- U-2668 TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA IN COMBINATION WITH OBINUTUZUMAB
- U-2669 TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED SMALL LYMPHOCYTIC LEUKEMIA IN COMBINATION WITH OBINUTUZUMAB
- U-2670 TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LEUKEMIA
- U-2671 TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LEUKEMIA IN COMBINATION WITH OBINUTUZUMAB
- U-2672 TREATMENT OF ACUTE HEPATIC PORPHYRIA
- U-2673 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING BY CORRECTING A DEFECTIVE GENE FOR DYSTROPHIN
- U-2674 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING BY RESTORING OR INCREASING FUNCTIONAL DYSTROPHIN PROTEIN PRODUCTION
- U-2675 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS HAVING A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 53 SKIPPING
- U-2676 TREATMENT OF SICKLE CELL DISEASE BY ADMINISTERING VOXELOTOR, AS RECITED IN CLAIM 1
- U-2677 PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS CONVERTED FROM TACROLIMUS IMMEDIATE-RELEASE FORMULATIONS
- U-2678 PROPHYLAXIS OF ORGAN REJECTION IN DE NOVO TRANSPLANT PATIENT
- U-2679 TREATING LOW BLOOD PRESSURE WITH ANGIOTENSIN II AT AN INITIAL RATE OF ABOUT 20 NG/KG/MIN AND TITRATING DOWN TO ACHIEVE AND/OR MAINTAIN A MAP OF ABOUT 65 MM HG OR ABOVE
- U-2680 TREATING LOW BLOOD PRESSURE WITH ANGIOTENSIN II WITH AN INITIAL RATE OF ABOUT 5 NG/KG/MIN TO ABOUT 20 NG/KG/MIN IN A SUBJECT HAVING REFRACTORY HYPOTENSION OR SEVERE HYPOTENSION
- U-2681 TREATING LOW BLOOD PRESSURE WITH ANGIOTENSIN II WITH AN INITIAL RATE OF ABOUT 5 NG/KG/MIN TO ABOUT 20 NG/KG/MIN IN A SUBJECT HAVING REFRACTORY HYPOTENSION OR SEVERE HYPOTENSION, AND TITRATING THE RATE UP
- U-2682 TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA BY ADMINISTERING 100MG OF ACALABRUTINIB TWICE DAILY

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-2683 TREATMENT OF ADULT PATIENTS WITH SMALL LYMPHOCYTIC LEUKEMIA BY ADMINISTERING 100MG OF ACALABRUTINIB TWICE DAILY
- U-2684 TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA BY ADMINISTERING 100 MG OF ACALABRUTINIB TWICE DAILY IN COMBINATION WITH OBINUTUZUMAB
- U-2685 TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED SMALL LYMPHOCYTIC LEUKEMIA BY ADMINISTERING 100 MG OF ACALABRUTINIB TWICE DAILY IN COMBINATION WITH OBINUTUZUMAB
- U-2686 TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LEUKEMIA BY ADMINISTERING 100 MG OF ACALABRUTINIB TWICE DAILY
- U-2687 TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LEUKEMIA IN COMBINATION WITH OBINUTUZUMAB BY ADMINISTERING 100 MG OF ACALABRUTINIB TWICE DAILY
- U-2688 USE OF VASCEPA TO LOWER TRIGLYCERIDES AND LDL-C IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (ABOUT 200 MG/DL TO LESS THAN ABOUT 500 MG/DL) AND ON STATIN THERAPY
- U-2689 USE OF VASCEPA TO TREAT MIXED DYSLIPIDEMIA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (\geq 150 MG/DL) AND ON STATIN THERAPY
- U-2690 USE OF VASCEPA TO LOWER TRIGLYCERIDES IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (ABOUT 200 MG/DL TO LESS THAN ABOUT 500 MG/DL) AND ON STATIN THERAPY
- U-2691 USE OF VASCEPA TO TREAT HYPERTRIGLYCERIDEMIA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (\geq 150 MG/DL) AND ON STATIN THERAPY
- U-2692 USE OF VASCEPA TO REDUCE TRIGLYCERIDES IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (\geq 150 MG/DL) AND ON STATIN THERAPY
- U-2693 USE OF VASCEPA TO REDUCE TRIGLYCERIDES IN A MIXED DYSLIPIDEMIA ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (\geq 150 MG/DL) AND ON STATIN THERAPY
- U-2694 USE OF VASCEPA TO LOWER TRIGLYCERIDES IN A MIXED DYSLIPIDEMIA ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (ABOUT 200 MG/DL TO LESS THAN ABOUT 500 MG/DL) AND ON STATIN THERAPY
- U-2695 USE OF VASCEPA TO TREAT MIXED HYPERTRIGLYCERIDEMIA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (\geq 150 MG/DL) AND ON STATIN THERAPY
- U-2696 USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF CARDIOVASCULAR DEATH, CORONARY REVASCULARIZATION, AND UNSTABLE ANGINA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS (TG \geq 150 MG/DL TO ABOUT 500 MG/DL)
- U-2697 USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF CARDIOVASCULAR DEATH AND/OR UNSTABLE ANGINA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS (TG \geq 150 MG/DL TO ABOUT 500 MG/DL)
- U-2698 USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF CARDIOVASCULAR DEATH AND/OR CORONARY REVASCULARIZATION IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS (TG \geq 150 MG/DL TO ABOUT 500 MG/DL)
- U-2699 USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A CARDIOVASCULAR EVENT (CORONARY REVASCULARIZATION, UNSTABLE ANGINA, STROKE AND/OR MYOCARDIAL INFARCTION) IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS
- U-2700 USE OF VASCEPA TO REDUCE TRIGLYCERIDES IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (ABOUT 200 MG/DL TO LESS THAN ABOUT 500 MG/DL) AND ON ROSUVASTATIN THERAPY
- U-2701 USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF CORONARY REVASCULARIZATION AND/OR UNSTABLE ANGINA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS (TG \geq 150 MG/DL TO ABOUT 500 MG/DL)
- U-2702 USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A CARDIOVASCULAR EVENT (CARDIOVASCULAR DEATH, CORONARY REVASCULARIZATION AND/OR UNSTABLE ANGINA) IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS
- U-2703 USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A CV EVENT (CV DEATH, CORONARY REVASCULARIZATION, UNSTABLE ANGINA, STROKE AND/OR MYOCARDIAL INFARCTION) IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS AND DIABETES MELLITUS
- U-2704 USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A CARDIOVASCULAR EVENT IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS AND

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

AT LEAST ONE RISK FACTOR FOR CARDIOVASCULAR DISEASE

- U-2705 METHOD OF USING CAPSAICIN IN COMBINATION WITH A GEL COMPOSITION FOR REMOVAL OF CAPSAICIN FROM A TREATMENT AREA OR UNINTENDED AREA
- U-2706 USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF ONSET AND/OR RECURRENCE OF CARDIOVASCULAR EVENTS IN A PATIENT WHO HAS ESCAPED THE UNSTABLE PERIOD AFTER CARDIOVASCULAR ANGIOPLASTY
- U-2707 USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE OCCURRENCE OF A CARDIOVASCULAR EVENT IN AN ADULT PATIENT WITH HYPERCHOLESTEROLEMIA
- U-2708 THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
- U-2709 A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE
- U-2710 A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE
- U-2711 A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE 750 MG OF ELEMENTAL IRON
- U-2712 A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE 750 MG OF ELEMENTAL IRON
- U-2713 MODULATION OF 5-HYDROXYTRYPTAMINE 2 RECEPTOR ACTIVITY IN SCHIZOPHRENIA
- U-2714 TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN RESIDUAL SYMPTOMS OF SCHIZOPHRENIA
- U-2715 TREATMENT OF SICKLE CELL DISEASE BY ADMINISTERING VOXELOTOR, AS RECITED IN CLAIM 2
- U-2716 MAINTENANCE TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GBRCA-MUTATED METASTATIC PANCREATIC ADENOCARCINOMA WHOSE DISEASE HAS NOT PROGRESSED ON AT LEAST 16 WEEKS OF A FIRST-LINE PLATINUM-BASED CHEMOTHERAPY REGIMEN
- U-2717 ACUTE TREATMENT OF MIGRAINE WITH HEADACHE, WITH OR WITHOUT AURA IN ADULTS
- U-2718 ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN ADULTS
- U-2719 TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS BY DETERMINING VARICELLA ZOSTER VIRUS (VZV) STATUS AND VACCINATING PRIOR TO COMMENCING TREATMENT
- U-2720 ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS; TOPICAL TREATMENT OF THE TOENAIL(S) DUE TO TRICHOPHYTON RUBRUM AND TRICHOPHYTON MENTAGROPHYTES
- U-2721 TOPICAL TREATMENT OF TINEA UNGUIUM BY USING AN APPLICATOR FOR APPLYING A SOLUTION FOR TREATING TINEA UNGUIUM TO AN AFFECTED PART OF A PATIENT
- U-2722 METHOD OF INTRAVENOUSLY ADMINISTERING A DILUTED CYSTEINE HYDROCHLORIDE SOLUTION TO A NEONATE IN NEED THEREOF
- U-2723 MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR 1 DISORDER
- U-2724 A METHOD OF ORAL DELIVERY OF TREPROSTINIL COMPRISING ADMINISTERING AN ORAL OSMOTIC PHARMACEUTICAL DOSAGE FORM
- U-2725 A METHOD OF TREATING PULMONARY HYPERTENSION AND PULMONARY ARTERIAL HYPERTENSION BY ADMINISTERING AN ORAL OSMOTIC PHARMACEUTICAL DOSAGE FORM
- U-2726 TREATMENT OF UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) HARBORING A PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (PDGFRA) EXON 18 MUTATION
- U-2727 NASAL ADMINISTRATION OF DIAZEPAM FOR TREATMENT OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY IN PATIENTS 6 YEARS OF AGE AND OLDER
- U-2728 USE OF PEMETREXED WITH PRIOR AND/OR REPEATED VITAMIN B12 AND FOLIC ACID ADMINISTRATION IN PATIENTS WITH NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
- U-2729 USE OF PEMETREXED WITH PRIOR AND/OR REPEATED VITAMIN B12 AND FOLIC ACID ADMINISTRATION IN PATIENTS WITH MESOTHELIOMA
- U-2730 METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
- U-2731 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
- U-2732 METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID
- U-2733 METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
- U-2734 METHOD OF TREATMENT OF IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON, WHO HAVE NON-HEMODIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE, BY ADMINISTERING FERRIC DERISOMALTOSE
- U-2735 MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS USING 150MG ELAGOLIX WHILE CO-ADMINISTERING RIFAMPIN
- U-2736 METHOD OF TREATING EPITHELIOID SARCOMA
- U-2737 METHOD OF TREATING EPITHELIOID SARCOMA BY INHIBITING ENHANCER OF ZESTE HOMOLOG 2 (EZH2)
- U-2738 METHOD OF TREATING A LUNG METASTASIS OF EPITHELIOID SARCOMA
- U-2739 INCREASING BLOOD PRESSURE WITH AN INITIAL RATE OF ABOUT 20 NG/KG/MIN ANGIOTENSIN II IN A HUMAN SUBJECT HAVING SEPTIC SHOCK, AND TITRATING THE RATE UP.
- U-2740 INCREASING BLOOD PRESSURE WITH A RATE OF ABOUT 20 NG/KG/MIN TO ABOUT 40 NG/KG/MIN ANGIOTENSIN II IN A HUMAN SUBJECT HAVING SEPTIC SHOCK
- U-2741 TREATMENT OF CLOSTRIDIODES DIFFICILE-ASSOCIATED DIARRHEA (CDAD) IN PATIENTS FROM 6 MONTHS OF AGE AND OLDER
- U-2742 TREATMENT OF SEVERE HYPOGLYCEMIA
- U-2743 USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF UNSTABLE ANGINA IN AN ADULT PATIENT WITH ESTABLISHED CARDIOVASCULAR DISEASE
- U-2744 USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF STROKE IN AN ADULT PATIENT WITH ESTABLISHED CARDIOVASCULAR DISEASE
- U-2745 TREATMENT OF NEUROBLASTOMAS THAT HAVE A NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) GENE FUSION
- U-2746 USE OF NEXLIZET AS AN ADJUNCT TO DIET AND MAXIMALLY TOLERATED STATIN THERAPY TO LOWER LDL-C IN ADULTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
- U-2747 USE OF NEXLETOL AS AN ADJUNCT TO DIET AND MAXIMALLY TOLERATED STATIN THERAPY TO LOWER LDL-C IN ADULTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
- U-2748 USE OF NEXLETOL AS AN ADJUNCT TO DIET AND MAXIMALLY TOLERATED STATIN THERAPY FOR INHIBITING CHOLESTEROL SYNTHESIS TO LOWER LDL-C IN ADULTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
- U-2749 USE OF NEXLIZET AS AN ADJUNCT TO DIET AND MAXIMALLY TOLERATED STATIN THERAPY FOR INHIBITING CHOLESTEROL SYNTHESIS TO LOWER LDL-C IN ADULTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
- U-2750 MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INTRAVENOUS INJECTION
- U-2751 A TRANSDERMAL METHOD OF CONTRACEPTION
- U-2752 METHOD OF USING L-CYSTEINE IN AN ADMIXTURE FOR TREATING PATIENTS NEEDING PARENTERAL NUTRITION
- U-2753 INCREASING SURVIVAL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PREVIOUSLY TREATED WITH DOCETAXEL BY ADMINISTERING AS A 3 WEEK CYCLE CABAZITAXEL AFTER 5 MG DEXCHLORPHENIRAMINE, 8 MG DEXAMETHASONE, AND AN H2-AGONIST
- U-2754 TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING
- U-2755 OCULAR EXAMINATION, INTRAOCULAR PRESSURE MEASUREMENT, OR REMOVAL OF FOREIGN BODIES OR SUTURES, IN ADULT AND PEDIATRIC PATIENTS REQUIRING A DISCLOSING AGENT IN COMBINATION WITH A TOPICAL OPHTHALMIC ANESTHETIC
- U-2756 USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF CARDIOVASCULAR DEATH IN AN ADULT PATIENT WITH ESTABLISHED CARDIOVASCULAR DISEASE

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-2757 DOSING REGIMEN FOR THE TREATMENT OF SCHIZOPHRENIA IN ADULTS BY ADMINISTERING TWO LOADING DOSES OF PALIPERIDONE PALMITATE FOLLOWED BY MAINTENANCE DOSE(S)
- U-2758 DOSING REGIMEN FOR THE TREATMENT OF SCHIZOAFFECTIVE DISORDER IN ADULTS AS A MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS BY ADMINISTERING TWO LOADING DOSES OF PALIPERIDONE PALMITATE FOLLOWED BY MAINTENANCE DOSE(S)
- U-2759 REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN ANGLE GLAUCOMA(OAG) OR OCULAR HYPERTENSION (OHT) WITH A BIODEGRADABLE BIMATOPROST IMPLANT
- U-2760 TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OF AGE OR OLDER
- U-2761 INTRAVENOUS SOTALOL DOSING REGIMEN FOR ACHIEVING STEADY STATE CONCENTRATION (EXPOSURE) FASTER COMPARED TO THE CONVENTIONAL ORAL DOSING IN A FACILITY THAT CAN PROVIDE ELECTROCARDIOGRAPHIC MONITORING
- U-2762 USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A MAJOR CARDIOVASCULAR EVENT IN AN ADULT PATIENT WITH DIABETES MELLITUS AND TWO OR MORE ADDITIONAL RISK FACTORS FOR CARDIOVASCULAR DISEASE
- U-2763 METHOD OF TREATING ADULTS WITH SCHIZOPHRENIA COMPRISING ADMINISTERING ASENAPINE VIA A TRANSDERMAL PATCH
- U-2764 TREATMENT OF POST-OPERATIVE INFLAMMATION AND PAIN FOLLOWING OCULAR SURGERY
- U-2765 TREATMENT OF HIV-1 INFECTION IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 40 KG WHO HAVE NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS
- U-2766 TX OF HIV1 INFECTION USING A COMPOSITION CONTAINING A PK ENHANCER THAT INHIBITS CY P450 MONOOXYGENASE IN ADULTS & PEDIATRIC PATIENTS AT LEAST 40KG HAVING NO PRIOR ARV TX HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ARV REGIMEN FOR AT LEAST 6 MO
- U-2767 TREATMENT OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PK ENHANCER THAT INHIBITS CY P450 MONOOXYGENASE IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 40KG WHO HAVE NO PRIOR ARV TREATMENT HISTORY
- U-2768 TREATMENT OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PK ENHANCER THAT INHIBITS CY P450 MONOOXYGENASE IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 40KG WHO ARE VIROLOGICALLY SUPPRESSED ON A STABLE ARV REGIMEN FOR AT LEAST 6 MONTHS
- U-2769 DOSING REGIMEN FOR INTRAVENOUS SOTALOL FOR ADMINISTRATION IN A FACILITY THAT CAN PROVIDE CONTINUOUS ELECTROCARDIOGRAPHIC MONITORING AND CARDIAC RESUSCITATION.
- U-2770 CUSHING'S DISEASE
- U-2771 TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN PATIENTS 18 YEARS OF AGE OR OLDER
- U-2772 MAINTENANCE TREATMENT OF CHRONIC PULMONARY DISEASE (COPD)
- U-2774 TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
- U-2775 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN
- U-2776 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
- U-2777 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 6 YEARS AND OLDER WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING A PHARMACEUTICAL COMPOSITION ACCORDING TO CLAIM 2 OF U.S. PATENT NO. 10,597,384, FURTHER COMPRISING IVACAFTOR
- U-2778 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 2 TO 5 YEARS OLD WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING A PHARMACEUTICAL COMPOSITION ACCORDING TO CLAIM 2 OF U.S. PATENT NO. 10,597,384, FURTHER COMPRISING IVACAFTOR
- U-2779 TREATMENT OF SPASTICITY
- U-2780 USE FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME
- U-2781 USE FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH DRAVET SYNDROME

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-2782	USE FOR REDUCING CONVULSIVE SEIZURE FREQUENCY IN PATIENTS WITH LENNOX GASTAUT SYNDROME
U-2783	USE FOR REDUCING CONVULSIVE SEIZURE FREQUENCY IN PATIENTS WITH DRAVET SYNDROME
U-2784	A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) AND WHERE THE MUTANT IDH1 HAS THE ABILITY TO CONVERT ALPHA-KETOGLUTARATE INTO 2-HYDROXYGLUTARATE (2-HG)
U-2785	A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) AND WHERE THE MUTANT IDH1 HAS THE ABILITY TO CONVERT ALPHA-KETOGLUTARATE INTO 2-HYDROXYGLUTARATE (2-HG)
U-2786	METHOD OF PREVENTING PREGNANCY BY INSERTING A VAGINAL SYSTEM CONTAINING 103 MG OF SEGESTERONE ACETATE AND 17.4 MG ETHINYL ESTRADIOL INTO A VAGINA FOR UP TO THIRTEEN 21/7-DAY (IN/OUT) CYCLES
U-2787	METHOD OF CONTRACEPTION BY INSERTING A VAGINAL SYSTEM FOR UP TO 13 21/7-DAY (IN/OUT) CYCLES, WHEREIN EFFICACY REQUIRES THE SYSTEM CANNOT BE OUT OF THE VAGINA FOR MORE THAN 2 CUMULATIVE HOURS IN ANY SUCH CYCLE WITHOUT USING ALTERNATIVE CONTRACEPTION
U-2788	TREATMENT OF BREAST CANCER INCLUDING HER2 (ERBB2)-POSITIVE OR -OVEREXPRESSING BREAST CANCER
U-2789	POTASSIUM PHOSPHATES INJECTION IS INDICATED AS A SOURCE OF PHOSPHORUS IN INTRAVENOUS FLUIDS TO CORRECT HYPOPHOSPHATEMIA IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
U-2790	TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
U-2791	TREATMENT OF ADULT PATIENTS WITH INSOMNIA, CHARACTERIZED BY DIFFICULTIES WITH SLEEP ONSET AND/OR SLEEP MAINTENANCE
U-2792	TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN
U-2793	A METHOD FOR DELIVERING NITRIC OXIDE TO A PATIENT WITH PULMONARY HYPERTENSION OR HYPOXIA
U-2794	TREATMENT OF TYPE 2 DIABETES MELLITUS WITH 100 MG CANAGLIFLOZIN PER DAY
U-2795	TREATMENT OF TYPE 2 DIABETES MELLITUS WITH 300 MG CANAGLIFLOZIN PER DAY
U-2796	REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS WITH 100 MG CANAGLIFLOZIN PER DAY
U-2797	REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS WITH 300 MG CANAGLIFLOZIN PER DAY
U-2798	REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS WITH 100 MG CANAGLIFLOZIN PER DAY
U-2799	REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS WITH 300 MG CANAGLIFLOZIN PER DAY
U-2800	TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC, INOPERABLE PLEXIFORM NEUROFIBROMAS (PN)
U-2801	METHOD OF IRON ADMINISTRATION TO TREAT PATIENTS IN NEED OF IRON REPLACEMENT THERAPY
U-2802	BRAFTOVI IS A KINASE INHIBITOR INDICATED IN COMBINATION WITH CETUXIMAB, FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC COLORECTAL CANCER (CRC) WITH A BRAF V600E MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, AFTER PRIOR THERAPY
U-2803	BRAFTOVI IS A KINASE INHIBITOR INDICATED IN COMBINATION WITH BINIMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH A BRAF V600E OR V600K MUTATION, AS DETECTED BY AN FDA- APPROVED TEST
U-2804	A METHOD FOR THE IMPROVEMENT OF NEUROLOGICAL OUTCOME BY REDUCING THE INCIDENCE AND SEVERITY OF ISCHEMIC DEFICITS IN ADULT PATIENTS WITH SUBARACHNOID HEMORRHAGE (SAH) FROM RUPTURED INTRACRANIAL BERRY ANEURYSMS
U-2805	TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY ADMINISTERING TASIMELTEON TO PATIENTS WITH A SMOKING HISTORY

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-2806 TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE ADMINISTRATION OF FOOD
- U-2807 TREATMENT OF MODERATE TO SEVERE MIGRAINE PAIN WITH PAIN FREE AT 2 HOURS POST ADMINISTRATION
- U-2808 TREATMENT OF DYSKINESIA, DECREASING OFF TIME, AND INCREASING ON TIME WITHOUT TROUBLESOME DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
- U-2809 FOR THE TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) FUSION OR OTHER REARRANGEMENT
- U-2810 METHOD OF SUPPORTING EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN
- U-2811 METHOD OF TREATING PARKINSON'S DISEASE
- U-2812 ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON'S DISEASE
- U-2813 USE FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH A MESENCHYMAL-EPITHELIAL TRANSITION (MET) EXON 14 SKIPPING MUTATION
- U-2814 A METHOD OF PROPHYLACTIC TREATMENT OF GOUT FLARES IN ADULTS COMPRISES ADMINISTERING TO A PATIENT A LIQUID COLCHICINE ORAL SOLUTION
- U-2815 MEASURING TIME-VARYING CHANGE IN BLOOD IN A TISSUE VOLUME USING MODIFIED BEER-LAMBERT LAW IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO-AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY
- U-2816 METHOD FOR TREATING INFLUENZA
- U-2817 METHOD OF INHIBITING COMT IN THE PERIPHERY
- U-2818 METHOD OF REDUCING O-METHYLATION OF L-DOPA
- U-2819 MAINTENANCE TREATMENT WITH BEVACIZUMAB OF ADV. EPITHELIAL OVARIAN CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM CHEMOTHERAPY AND HOMOLOGOUS RECOMBINATION DEFICIENCY-POSITIVE WITH A DELETERIOUS OR SUSPECTED DELETERIOUS BRCA MUTATION
- U-2820 MAINTENANCE TREATMENT WITH BEVACIZUMAB OF ADV. EPITHELIAL OVARIAN CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM CHEMOTHERAPY AND HOMOLOGOUS RECOMBINATION DEFICIENCY-POSITIVE WITH GENOMIC INSTABILITY
- U-2821 MAINTENANCE TREATMENT WITH BEVACIZUMAB OF FALLOPIAN TUBE CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM CHEMOTHERAPY AND HOMOLOGOUS RECOMBINATION DEFICIENCY-POSITIVE WITH A DELETERIOUS OR SUSPECTED DELETERIOUS BRCA MUTATION
- U-2822 MAINTENANCE TREATMENT WITH BEVACIZUMAB OF FALLOPIAN TUBE CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM CHEMOTHERAPY AND HOMOLOGOUS RECOMBINATION DEFICIENCY-POSITIVE WITH GENOMIC INSTABILITY
- U-2823 MAINTENANCE TREATMENT WITH BEVACIZUMAB OF PRIMARY PERITONEAL CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM CHEMOTHERAPY AND HOMOLOGOUS RECOMBINATION DEFICIENCY-POSITIVE WITH A DELETERIOUS OR SUSPECTED DELETERIOUS BRCA MUTATION
- U-2824 MAINTENANCE TREATMENT WITH BEVACIZUMAB OF PRIMARY PERITONEAL CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM CHEMOTHERAPY AND HOMOLOGOUS RECOMBINATION DEFICIENCY-POSITIVE WITH GENOMIC INSTABILITY
- U-2825 TREATMENT OF "OFF" EPISODES IN PATIENTS WITH PARKINSON'S DISEASE
- U-2826 TREATMENT OF ADULT PATIENTS WITH METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER
- U-2827 TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET-MUTANT MEDULLARY THYROID CANCER (MTC) WHO REQUIRE SYSTEMIC THERAPY
- U-2828 TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE REFRACTORY (IF RADIOACTIVE IODINE IS APPROPRIATE)
- U-2829 TREATMENT OF GASTROINTESTINAL STROMAL TUMORS
- U-2830 A METHOD FOR TREATING METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC),

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA-MUTATION

- U-2831 TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT WITH REFRACTORY PARTIAL-ONSET SEIZURES
- U-2832 TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE OR SOMATIC HOMOLOGOUS RECOMBINATION REPAIR GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, WHICH HAS PROGRESSED FOLLOWING PRIOR TREATMENT WITH ENZALUTAMIDE OR ABIRATERONE
- U-2833 TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE OR SOMATIC BRCA-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, WHICH HAS PROGRESSED FOLLOWING PRIOR TREATMENT WITH ENZALUTAMIDE OR ABIRATERONE
- U-2834 TREATMENT OF ADULTS WITH PERSISTENT/RECURRENT CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH), (WHO GROUP 4) AFTER SURGICAL TREATMENT, OR INOPERABLE CTEPH, TO IMPROVE EXERCISE CAPACITY AND WHO FUNCTIONAL CLASS
- U-2835 TREATMENT OF ADULTS WITH PULMONARY HYPERTENSION (PAH), (WHO GROUP 1), TO IMPROVE EXERCISE CAPACITY, WHO FUNCTIONAL CLASS AND TO DELAY CLINICAL WORSENING
- U-2836 TREATMENT OF ADULT PATIENTS WITH SMALL CELL LUNG CANCER (SCLC) WITH DISEASE PROGRESSION ON OR AFTER PLATINUM-BASED CHEMOTHERAPY.
- U-2837 TREATMENT OF ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)
- U-2838 REDUCTION OF THE RATE OF A FIRST MYOCARDIAL INFARCTION OR STROKE IN PATIENTS WITH CORONARY ARTERY DISEASE AT HIGH RISK FOR SUCH EVENTS
- U-2839 TREATMENT OF MYOCARDIAL INFARCTION OR STROKE IN PATIENTS WITH CORONARY ARTERY DISEASE AT HIGH RISK FOR SUCH EVENTS
- U-2840 TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP)
- U-2841 USE OF VASCEPA WITH HIGH INTENSITY STATIN THERAPY TO REDUCE THE RISK OF A CV EVENT IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS AND (1) ESTABLISHED CV DISEASE, OR (2) DIABETES MELLITUS AND TWO OR MORE ADDITIONAL RISK FACTORS FOR CV DISEASE
- U-2842 MANAGEMENT OF HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE LEIOMYOMAS (FIBROIDS)
- U-2843 NASAL ADMINISTRATION OF METOCLOPRAMIDE FOR TREATMENT OF DIABETIC GASTROPARESIS
- U-2844 IN COMBINATION WITH PEMBROLIZUMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA
- U-2845 A METHOD OF TREATING A HUMAN PATIENT SUFFERING FROM PULMONARY HYPERTENSION
- U-2846 TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE REFRACTORY TO SYSTEMIC THERAPY
- U-2847 REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE IN ADULTS
- U-2848 TREATMENT OF TRAVELERS' DIARRHEA (TD) CAUSED BY NONINVASIVE STRAINS OF ESCHERIA COLI IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
- U-2849 METHOD OF TREATING BLEPHAROPTOSIS
- U-2850 MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS USING 150 MG ELAGOLIX WHILE CO-ADMINISTERING KETOCONAZOLE
- U-2851 METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION BY INHIBITING EZH2
- U-2852 METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
- U-2853 METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
- U-2854 METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA BY INHIBITING EZH2
- U-2855 XPOVIO IS INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), NOT OTHERWISE SPECIFIED, INCLUDING DLBCL ARISING FROM FOLLICULAR LYMPHOMA, AFTER AT LEAST 2 LINES OF SYSTEMIC THERAPY
- U-2856 INCREASING SURVIVAL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PREVIOUSLY TREATED WITH DOCETAXEL BY ADMINISTERING 20 TO 25 MG/M2 CABAZITAXEL AFTER A PREMEDICATION REGIMEN THAT INCLUDES AN H2-ANTAGONIST
- U-2857 USE OF ORAL OCTREOTIDE FOR LONG-TERM MAINTENANCE TREATMENT IN ACROMEGALY PATIENTS WHO HAVE RESPONDED TO AND TOLERATED TREATMENT WITH OCTREOTIDE OR

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

LANREOTIDE

- U-2858 USE IN COMBINATION WITH STIRIPENTOL, VALPROATE, AND CLOBAZAM FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME
- U-2859 USE OF CARDIAC MONITORING AND RESTRICTED DISTRIBUTION OF FENFLURAMINE TO MITIGATE RISK OF CARDIOVASCULAR TOXICITY IN THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME
- U-2860 USE IN COMBINATION WITH STIRIPENTOL FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME
- U-2861 USE IN COMBINATION WITH CANNABIDIOL FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME
- U-2862 USE FOR THE TREATMENT OF FOCAL SEIZURES IN PATIENTS WITH DRAVET SYNDROME
- U-2863 TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS 6 MONTHS OF AGE AND OLDER
- U-2864 METHOD FOR INHIBITING CYTIDINE DEAMINASE BY ADMINISTERING CEDAZURIDINE
- U-2865 TREATMENT OF MYELODYSPLASTIC SYNDROME
- U-2866 TREATMENT OF CHRONIC MYELOMONOCYTIC LEUKEMIA
- U-2867 METHOD FOR INHIBITING DEGRADATION OF A CDA SUBSTRATE BY ADMINISTERING CEDAZURIDINE
- U-2868 TREATMENT OF NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE
- U-2869 IV ADMINISTRATION OF CANGRELOR BEFORE PCI AND CONTINUOUS INFUSION FOR AT LEAST 2 HOURS OR THE DURATION OF THE PCI AND, DURING OR AFTER THE CONTINUOUS INFUSION, ADMINISTRATION OF A LOADING DOSE OF TICAGRELOR OR AN EQUIVALENT THERAPY (PER LABELING)
- U-2870 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 2
- U-2871 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 2 AND 3
- U-2872 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 4 AND 5
- U-2873 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 4, 5, AND 6
- U-2874 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 7 AND 8
- U-2875 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 7, 8, AND 9
- U-2876 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 10 AND 11
- U-2877 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 10, 11, AND 12
- U-2878 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 13 AND 14
- U-2879 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 13, 14, AND 15
- U-2880 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 16 AND 17
- U-2881 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 16, 17, AND 18

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-2882 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 19 AND 20
- U-2883 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 19, 20, AND 21
- U-2884 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 22, 23, AND 24
- U-2885 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 25 AND 26
- U-2886 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 25, 26, AND 27
- U-2887 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 28 AND 29
- U-2888 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 28, 29, AND 30
- U-2889 USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
- U-2890 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 2 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1
- U-2891 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MEYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 3 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1
- U-2892 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 4 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1
- U-2893 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 5 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1
- U-2894 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 6 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1
- U-2895 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 7 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1
- U-2896 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 8 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1
- U-2897 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 1 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 1 AND 9
- U-2898 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 1 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 1 AND 10
- U-2899 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 1 AND WHEREIN THE EFFECTS ARE AS RECITED IN

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

CLAIMS 1 AND 11

U-2900	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 1 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 1 AND 13	2
U-2901	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 15 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1	2
U-2902	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 16 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1	2
U-2903	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 17 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1	2
U-2904	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1, 17 AND 18 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1	2
U-2905	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 19 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1	2
U-2906	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 22 WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 22	2
U-2907	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 22 AND 23 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 22	2
U-2908	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 22 AND 24 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 22	2
U-2909	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 22 AND 25 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 22	2
U-2910	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 26 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26	2
U-2911	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 27 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26	2
U-2912	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 28 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26	2
U-2913	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 29 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26	2
U-2914	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 30 WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26	2
U-2915	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2	2

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 31 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26
- U-2916 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 32 WHEREIN THE EFFECTS ARE AS RECITED IN SAID CLAIMS
- U-2917 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 33 WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS
- U-2918 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 34 WHEREIN THE EFFECTS ARE AS RECITED IN SAID CLAIMS
- U-2919 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 36 WHEREIN THE EFFECTS ARE AS RECITED IN SAID CLAIMS
- U-2920 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 38 AND WHEREIN THE EFFECTS ARE AS RECITED CLAIM 26
- U-2921 ONCE DAILY TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS
- U-2922 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 39 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26
- U-2923 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 40 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26
- U-2924 ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 42 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 42
- U-2925 ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 42 AND 43 WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 42
- U-2926 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 44 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44
- U-2927 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 45 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44
- U-2928 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 46 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44
- U-2929 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 47 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44
- U-2930 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 48 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44
- U-2931 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2

PATENT AND EXCLUSIVITY TERMS

ADB 161 of 164

PATENT USE

- DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 49 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44
- U-2932 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 50 WHEREIN THE EFFECTS ARE AS RECITED IN SAID CLAIMS
- U-2933 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 51 WHEREIN THE EFFECTS ARE AS RECITED IN SAID CLAIMS
- U-2934 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 52 WHEREIN THE EFFECTS ARE AS RECITED IN SAID CLAIMS
- U-2935 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 44 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 44 AND 54
- U-2936 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 56 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44
- U-2937 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 57 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44
- U-2938 TREATMENT OF CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS (EDS) IN PATIENTS 7 YEARS OF AGE AND OLDER WITH NARCOLEPSY WITH A MIXTURE OF SODIUM, POTASSIUM, MAGNESIUM, AND CALCIUM SALTS OF GHB
- U-2939 TREATMENT OF HIV INFECTION IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 40KG USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE
- U-2940 METHOD OF TREATING PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH CENTRAL PRECOCIOUS PUBERTY
- U-2941 A METHOD OF USING AN AEROSOL DELIVERY DEVICE TO AEROSOLIZE GLYCOPYRROLATE FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
- U-2942 METHOD OF TREATING ACNE VULGARIS WITH TOPICALLY APPLIED CORTEXOLONE 17A-PROPIONATE
- U-2943 TREATMENT OF RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
- U-2944 TREATMENT OF RELAPSED OR REFRACTORY SMALL LYMPHOCYTIC LYMPHOMA
- U-2945 TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) IN COMBINATION WITH URSODEOXYCHOLIC ACID (UDCA) IN ADULTS WITH AN INADEQUATE RESPONSE TO UDCA, OR AS MONOTHERAPY IN ADULTS UNABLE TO TOLERATE UDCA
- U-2946 TREATMENT OF COLORECTAL CANCER THAT HAS A NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) GENE FUSION
- U-2947 KYPROLIS IS INDICATED IN COMBINATION WITH DARATUMUMAB PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY
- U-2948 A METHOD OF POSITIONING AN INTRAUTERINE SYSTEM (IUS) BY DETERMINING A DEPTH OF THE UTERUS, HOLDING AN INSERTER HANDLE WITH ONE HAND, INSERTING THE IUS INTO THE UTERUS, AND RETRACTING A SLIDER ON THE HANDLE TO RELEASE THE IUS INTO THE UTERUS
- U-2949 A METHOD FOR INDUCING A POST-SURGICAL ANALGESIA SPARING EFFECT BY IMPLANTING AT THE SURGICAL SITE A COLLAGEN SPONGE CONTAINING BUPIVACAINE HCL WHICH PROVIDES LOCAL ANESTHESIA FOR UP TO 24 HOURS FOLLOWING IMPLANTATION
- U-2950 CONTINUED TREATMENT OF ADULTS WITH ACUTE MYELOID LEUKEMIA WHO ACHIEVED FIRST COMPLETE REMISSION (CR) OR CR WITH INCOMPLETE BLOOD COUNT RECOVERY FOLLOWING INTENSIVE INDUCTION CHEMOTHERAPY AND ARE NOT ABLE TO COMPLETE INTENSIVE CURATIVE THERAPY
- U-2951 USE OF CU-64 DOTATATE WITH POSITRON EMISSION TOMOGRAPHY (PET) FOR LOCALIZATION

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- OF SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS (NETS) IN ADULT PATIENTS
- U-2952 TREATMENT OF ADULT PATIENTS WITH METASTATIC REARRANGED DURING TRANSFECTION (RET) FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) AS DETECTED BY AN FDA APPROVED TEST
- U-2953 USE OF FLUTICASONE FUROATE FOR THE TREATMENT OF AN INFLAMMATORY OR ALLERGIC CONDITIONS, INCLUDING CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND ASTHMA
- U-2954 METHOD OF DISPENSING A COMBINATION MEDICAMENT PRODUCT FROM CLAIMED DELIVERY DEVICE, FOR EXAMPLE FOR THE TREATMENT OF ASTHMA OR COPD
- U-2955 INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA; AND ASTHMA
- U-2956 METHOD OF TREATING LAMBERT-EATON MYASTHENIC SYNDROME WITH AMIFAMPRIDINE
- U-2957 MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 18 YRS AND OLDER, OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
- U-2958 A METHOD FOR CONTRACEPTION, THE METHOD COMPRISING ADMINISTERING A TABLET COMPRISING 20 MG TO 30 MG OF ULIPRISTAL ACETATE TO A WOMAN WITHIN 120 HOURS AFTER AN UNPROTECTED INTERCOURSE
- U-2959 USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A THIRD AND FURTHER CARDIOVASCULAR EVENT IN AN ADULT PATIENT WITH ELEVATED TG LEVELS (≥ 150 MG/DL) AND ESTABLISHED CARDIOVASCULAR DISEASE
- U-2960 USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A SECOND OR FURTHER CARDIOVASCULAR (CV) EVENT IN AN ADULT PATIENT WITH ELEVATED TG LEVELS (≥ 150 MG/DL) AND DIABETES MELLITUS AND 2 OR MORE ADDITIONAL RISK FACTORS FOR CV DISEASE
- U-2961 USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF MYOCARDIAL INFARCTION, STROKE, BOTH IN AN ADULT PATIENT WITH TYPE 2 DIABETES MELLITUS
- U-2962 USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF CORONARY REVASCULARIZATION IN AN ADULT PATIENT WITH ESTABLISHED CARDIOVASCULAR DISEASE
- U-2963 TREATMENT OF CYSTIC FIBROSIS USING IVACAFTOR IN A PATIENT AGE 4 MONTHS TO <6 YEARS WHO HAS ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
- U-2964 TREATMENT OF CYSTIC FIBROSIS USING IVACAFTOR IN A PATIENT AGE 4 MONTHS TO <6 YEARS WHO HAS A R117H MUTATION IN THE CFTR GENE
- U-2965 TREATMENT OF A MODERATE TO MILD CLINICAL PHENOTYPE OF CF USING IVACAFTOR IN A PATIENT AGE 4 MONTHS TO <6 YEARS WHO HAS ONE CFTR MUTATION RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
- U-2966 TREATMENT OF CF IN A PATIENT AGE 4 MONTHS TO <6 YEARS WHO HAS ONE CFTR MUTATION RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA USING A SOLID COMPOSITION COMPRISING AMORPHOUS (LESS THAN ABOUT 30% CRYSTALLINE) IVACAFTOR
- U-2967 TREATMENT OF CF IN A PATIENT AGE 4 MONTHS TO <6 YEARS WHO HAS ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA USING THE COMPOSITION RECITED IN CLAIM 1 OF US 10272046
- U-2968 USE OF REMIMAZOLAM FOR INDUCTION AND MAINTENANCE OF PROCEDURAL SEDATION IN ADULTS UNDERGOING PROCEDURES LASTING 30 MINUTES OR LESS
- U-2969 TREATMENT OF ADULT PATIENTS WITH CYCLOSPORIN-RESISTANT, STEROID-DEPENDENT/REFRACTORY, OR STEROID RESISTANT CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
- U-2970 TREATMENT OF ADULT PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
- U-2971 THE TREATMENT OF ADULT PATIENTS WITH METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
- U-2972 THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET-MUTANT MEDULLARY THYROID CANCER (MTC) WHO REQUIRE SYSTEMIC THERAPY
- U-2973 TREATING ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY, WHEREIN THE CANCER IS PAPILLARY THYROID CANCER

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-2974 TREATING ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY, WHEREIN THE CANCER IS MEDULLARY THYROID CANCER
- U-2975 TREATING ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY, WHEREIN THE CANCER IS DIFFERENTIATED THYROID CANCER
- U-2976 TREATING ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY, WHEREIN THE CANCER IS RECURRENT THYROID CANCER
- U-2977 TREATING ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE REFRACTORY DIFFERENTIATED THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND ARE RADIOACTIVE IODINE-REFRACTORY
- U-2978 TREATMENT OF HIV-1 INFECTION IN ADULT OR PEDIATRIC PATIENTS (≥ 40 KG) WITH < 50 COPIES/ML HIV-1 RNA AFTER ≥ 6 MONTHS ON PRIOR ANTIRETROVIRAL REGIMEN AND NO KNOWN DARUNAVIR OR TENOFOVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS
- U-2979 METHOD COMPRISING IV ADMINISTRATION OF CANGRELOR BEFORE PCI THEN CONTINUOUS INFUSION FOR AT LEAST 2 HOURS OR THE DURATION OF PCI AND, DURING OR AFTER CONTINUOUS INFUSION, ADMINISTRATION OF A LOADING DOSE OF TICAGRELOR, OR AN EQUIVALENT METHOD
- U-2980 METHOD OF TREATING AN ALLERGIC REACTION USING AN AUTO-INJECTOR
- U-2981 A METHOD OF TREATING ACUTE MYELOGENOUS LEUKEMIA (AML) IN A SUBJECT BY ADMINISTERING A PHARMACEUTICAL COMPOSITION WHERE THE AML IS CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 AND THE AML IS NEWLY DIAGNOSED
- U-2982 A METHOD OF TREATING ACUTE MYELOGENOUS LEUKEMIA (AML) IN A SUBJECT BY ADMINISTERING A PHARMACEUTICAL COMPOSITION WHERE THE AML IS CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 AND WHERE THE AML IS RELAPSED/REFRACTORY
- U-2983 TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INJECTION
- U-2984 TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (AT LEAST 12 YEARS OF AGE AND 40 KG) REQUIRING HOSPITALIZATION
- U-2985 A METHOD FOR TREATING DRY EYE IN A PATIENT
- U-2986 MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION
- U-2987 METHOD OF TREATING LUNG CANCER, UNDIFFERENTIATED SARCOMA, OR COLORECTAL CANCER THAT EXHIBITS AN NTRK GENE FUSION
- U-2988 REDUCTION OF THE RISK OF STROKE IN PATIENTS WITH ACUTE ISCHEMIC STROKE OR HIGH-RISK TRANSIENT ISCHEMIC ATTACK
- U-2989 METHOD OF USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER
- U-2990 METHOD OF USE FOR TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER
- U-2991 METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A TABLET CONTAINING SELEXIPAG
- U-2992 METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A SOLID PREPARATION CONTAINING SELEXIPAG
- U-2993 A METHOD FOR TREATING A SUBJECT HAVING ADHD, SAID METHOD COMPRISING ORALLY ADMINISTERING TO SAID SUBJECT A RACEMIC METHYLPHENIDATE CHEWABLE TABLET AS CLAIMED
- U-2994 REDUCTION OF RISK OF MYOCARDIAL INFARCTION, STROKE OR CARDIOVASCULAR DEATH IN A PATIENT WITH CHRONIC CAD OR PAD BY ADMINISTERING CLINICALLY PROVEN EFFECTIVE AMOUNTS THAT ARE 2.5 MG RIVAROXABAN TWICE DAILY AND 75-100 MG ASPIRIN DAILY
- U-2995 TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1)
- U-2996 ADMINISTRATION OF AN EXTENDED RELEASE TABLET FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY
- U-2997 USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF STROKE IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDES AND ATRIAL FIBRILLATION

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-2998 METHOD OF ADMINISTERING DOCETAXEL TO A SUBJECT COMBINING THE DOCETAXEL PRO-EMULSION FORMULATION WITH AN AQUEOUS MEDIUM TO PRODUCE DOCETAXEL EMULSION

U-2999 METHOD OF USE OF TREATING, AS AN INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY IN PARTIAL ONSET SEIZURE PATIENTS WITH EPILEPSY AGED 17 YEARS OR OLDER

U-3000 METHOD FOR POST-EXPOSURE PROPHYLAXIS OF INFLUENZA

U-3001 PROCEDURES IN ADULT AND PEDIATRIC PATIENTS REQUIRING A DISCLOSING AGENT IN COMBINATION WITH A TOPICAL OPHTHALMIC ANESTHETIC.

U-3002 TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY (IF RADIOACTIVE IODINE IS APPROPRIATE)

U-3003 TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY ADMINISTERING TASIMELTEON

U-3004 TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH A STRONG CYP1A2 INHIBITOR

U-3005 TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE USE OF TASIMELTEON WITH RIFAMPIN

U-3006 TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH CYP1A2 STRONG INHIBITORS

U-3007 TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH FOOD

U-3008 TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY ADMINISTERING TASIMELTEON TO PATIENTS WITH A SMOKING HISTORY

U-3009 TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY ADMINISTERING TASIMELTEON TO PATIENTS WITH A SMOKING HISTORY

U-3010 PROPHYLAXIS TO PREVENT ATTACKS OF HEREDITARY ANGIOEDEMA (HAE) IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER

U-3011 A METHOD FOR TREATING OCULAR INFLAMMATION

U-3012 TREATMENT IN COMBINATION WITH ANDROGEN DEPRIVATION THERAPY OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) THAT IMPROVES METASTASIS FREE SURVIVAL

U-3013 TREATMENT IN COMBINATION WITH ORCHIECTOMY OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC)

U-3014 METHOD FOR THE INDUCTION OF LOCAL ANESTHESIA OF THE MUCOUS MEMBRANES